<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://podcast.explainheart.com/wp-content/plugins/seriously-simple-podcasting/templates/feed-stylesheet.xsl"?><rss version="2.0"
	 xmlns:content="http://purl.org/rss/1.0/modules/content/"
	 xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	 xmlns:dc="http://purl.org/dc/elements/1.1/"
	 xmlns:atom="http://www.w3.org/2005/Atom"
	 xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	 xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	 xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
	 xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"
	 xmlns:podcast="https://podcastindex.org/namespace/1.0"
	>
		<channel>
		<title>Cardiology Today</title>
		<atom:link href="https://podcast.explainheart.com/feed/podcast/cardiology-today/" rel="self" type="application/rss+xml"/>
		<link>https://podcast.explainheart.com/podcasts/cardiology-today/</link>
		<description>Stay current with cardiovascular medicine without the time commitment. Every morning, we deliver concise audio summaries of the latest original research from top cardiology journals. Top 5 breakthrough studies briefed in under 5 minutes  (perfect for your commute or between patients). PubMed links included for full articles. 
Perfect for cardiologists, cardiothoracic surgeons, cardiac nurses, researchers, and healthcare workers who need to stay informed but lack time to scan multiple journals daily. 
For educational and reference purposes only. Not intended as medical advice.</description>
		<lastBuildDate>Wed, 15 Apr 2026 01:49:18 +0000</lastBuildDate>
		<language>en-US</language>
		<copyright>© 2025 Deconstructed Cardiology LLC</copyright>
		<itunes:subtitle>Latest cardiology research findings</itunes:subtitle>
		<itunes:author>Deconstructed Cardiology</itunes:author>
		<itunes:summary>Stay current with cardiovascular medicine without the time commitment. Every morning, we deliver concise audio summaries of the latest original research from top cardiology journals. Top 5 breakthrough studies briefed in under 5 minutes  (perfect for your commute or between patients). PubMed links included for full articles. 
Perfect for cardiologists, cardiothoracic surgeons, cardiac nurses, researchers, and healthcare workers who need to stay informed but lack time to scan multiple journals daily. 
For educational and reference purposes only. Not intended as medical advice.</itunes:summary>
		<itunes:owner>
			<itunes:name>Deconstructed Cardiology LLC</itunes:name>
			<itunes:email>gaurang244@gmail.com</itunes:email>
		</itunes:owner>
		<itunes:explicit>false</itunes:explicit>
		<itunes:image href="https://podcast.explainheart.com/wp-content/uploads/2025/09/generated-image-7-1.png"></itunes:image>
			<image>
				<url>https://podcast.explainheart.com/wp-content/uploads/2025/09/generated-image-7-1.png</url>
				<title>Cardiology Today</title>
				<link>https://podcast.explainheart.com/podcasts/cardiology-today/</link>
			</image>
		<itunes:category text="Science">
			<itunes:category text="Medicine"></itunes:category>
		</itunes:category>
		<itunes:category text="Health &amp; Fitness">
							</itunes:category>
		<googleplay:author><![CDATA[Deconstructed Cardiology]]></googleplay:author>
			<googleplay:email>gaurang244@gmail.com</googleplay:email>			<googleplay:description>Stay current with cardiovascular medicine without the time commitment. Every morning, we deliver concise audio summaries of the latest original research from top cardiology journals. Top 5 breakthrough studies briefed in under 5 minutes  (perfect for your commute or between patients). PubMed links included for full articles. 
Perfect for cardiologists, cardiothoracic surgeons, cardiac nurses, researchers, and healthcare workers who need to stay informed but lack time to scan multiple journals daily. 
For educational and reference purposes only. Not intended as medical advice.</googleplay:description>
			<googleplay:explicit>No</googleplay:explicit>
			<googleplay:image href="https://podcast.explainheart.com/wp-content/uploads/2025/09/generated-image-7-1.png"></googleplay:image>
			<podcast:locked owner="gaurang244@gmail.com">yes</podcast:locked>
		<podcast:funding url="https://buymeacoffee.com/dcllc">Donate for our efforts</podcast:funding>
		<podcast:guid>60b71017-135c-5be4-92b7-afe029c4f4f0</podcast:guid>
		
		<!-- podcast_generator="SSP by Castos/3.14.0" Seriously Simple Podcasting plugin for WordPress (https://wordpress.org/plugins/seriously-simple-podcasting/) -->
		<generator>https://wordpress.org/?v=6.8.5</generator>

<item>
	<title>Left Bundle Pacing Challenges BiVP for CRT 04/14/26</title>
	<link>https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/</link>
	<pubDate>Wed, 15 Apr 2026 01:49:15 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like femoral venous puncture and catheter manipulation. Key takeaway: Left Bundle Pacing Challenges BiVP for CRT.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41979041">Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41978340">Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41969098">Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41969084">Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis.</a> (Circulation. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41979555">Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/">https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41979041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41979041</a></p>
<p><strong>Summary:</strong> The ULYSSES trial confirmed that vascular access site complications are the most common procedure-related adverse events during atrial fibrillation catheter ablation. This study directly compared an ultrasound-guided femoral venous puncture strategy with a conventional approach. The multicenter trial evaluated the efficacy of each technique in reducing complications in patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation. The investigation&#8217;s findings provided a critical evidence base for optimizing patient safety during these procedures.</p>
<h4>Article 2: Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41978340" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41978340</a></p>
<p><strong>Summary:</strong> Conduction system pacing has emerged as an alternative to biventricular pacing for cardiac resynchronization therapy. The LEFT-BUNDLE-CRT trial directly compared left-bundle branch area pacing to biventricular pacing. This multicenter, randomized, non-inferiority study provided a comprehensive evaluation of their comparative effectiveness in patients eligible for cardiac resynchronization therapy and left-bundle branch block. The study&#8217;s results established the non-inferiority profile of left-bundle branch area pacing against biventricular pacing for this patient population.</p>
<h4>Article 3: Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41969098" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41969098</a></p>
<p><strong>Summary:</strong> Obstructive hypertrophic cardiomyopathy is characterized by left ventricular outflow tract obstruction, which increases afterload and activates the Anrep response of hyperdynamic systole. This study directly compared the effects of the myosin inhibitor mavacamten to alcohol septal ablation. Researchers evaluated whether mavacamten reverses this hyperdynamic state, contrasting its impacts with the anatomic relief from alcohol septal ablation in 36 patients. The investigation&#8217;s echocardiography-derived pressure-volume analysis clarified the differential physiological effects of these two therapeutic approaches.</p>
<h4>Article 4: Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41969084" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41969084</a></p>
<p><strong>Summary:</strong> Temporary mechanical circulatory support devices are often placed for cardiogenic shock at regional referral centers before transfer to hub centers. This observational analysis identified differences in device-related adverse events and patient outcomes based on the initial site of device placement. The study compared patients whose temporary mechanical circulatory support was initiated at a regional referral center prior to transfer versus those with initial placement at a cardiogenic shock hub center. Its findings clarified the safety and efficacy implications of different care pathways for cardiogenic shock patients.</p>
<h4>Article 5: Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41979555" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41979555</a></p>
<p><strong>Summary:</strong> This ex vivo ovine study characterized the determinants of successful transseptal puncture using an electrified guidewire, a technique previously unstudied in this context. Researchers utilized 25 fresh ovine hearts, creating an interatrial septum model from dissected right atrial tissue. The investigation involved fixing the sheath and guidewire to a jig to model clinical catheter manipulation. The study observed transseptal puncture dynamics across varying parameters, establishing key factors influencing success for electrified guidewire transseptal access.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial. The ULYSSES trial confirmed that vascular access site complications are the most common procedure-related adverse events during atrial fibrillation catheter ablation. This study directly compared an ultrasound-guided femoral venous puncture strategy with a conventional approach. The multicenter trial evaluated the efficacy of each technique in reducing complications in patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation. The investigation&#8217;s findings provided a critical evidence base for optimizing patient safety during these procedures.</p>
<p>Article number two. Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial. Conduction system pacing has emerged as an alternative to biventricular pacing for cardiac resynchronization therapy. The LEFT-BUNDLE-CRT trial directly compared left-bundle branch area pacing to biventricular pacing. This multicenter, randomized, non-inferiority study provided a comprehensive evaluation of their comparative effectiveness in patients eligible for cardiac resynchronization therapy and left-bundle branch block. The study&#8217;s results established the non-inferiority profile of left-bundle branch area pacing against biventricular pacing for this patient population.</p>
<p>Article number three. Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis. Obstructive hypertrophic cardiomyopathy is characterized by left ventricular outflow tract obstruction, which increases afterload and activates the Anrep response of hyperdynamic systole. This study directly compared the effects of the myosin inhibitor mavacamten to alcohol septal ablation. Researchers evaluated whether mavacamten reverses this hyperdynamic state, contrasting its impacts with the anatomic relief from alcohol septal ablation in 36 patients. The investigation&#8217;s echocardiography-derived pressure-volume analysis clarified the differential physiological effects of these two therapeutic approaches.</p>
<p>Article number four. Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis. Temporary mechanical circulatory support devices are often placed for cardiogenic shock at regional referral centers before transfer to hub centers. This observational analysis identified differences in device-related adverse events and patient outcomes based on the initial site of device placement. The study compared patients whose temporary mechanical circulatory support was initiated at a regional referral center prior to transfer versus those with initial placement at a cardiogenic shock hub center. Its findings clarified the safety and efficacy implications of different care pathways for cardiogenic shock patients.</p>
<p>Article number five. Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study. This ex vivo ovine study characterized the determinants of successful transseptal puncture using an electrified guidewire, a technique previously unstudied in this context. Researchers utilized 25 fresh ovine hearts, creating an interatrial septum model from dissected right atrial tissue. The investigation involved fixing the sheath and guidewire to a jig to model clinical catheter manipulation. The study observed transseptal puncture dynamics across varying parameters, establishing key factors influencing success for electrified guidewire transseptal access. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>femoral venous puncture, catheter manipulation, device-related adverse events, vascular access complications, cardiac resynchronization therapy, left ventricular outflow tract obstruction, temporary mechanical circulatory support, mavacamten, left atrial tachycardia, left-bundle branch block, cardiogenic shock, electrified guidewire, regional referral centers, ex vivo ovine model, ultrasound-guided puncture, interatrial septum, echocardiography, obstructive hypertrophic cardiomyopathy, transseptal puncture, alcohol septal ablation, hub centers, atrial fibrillation ablation, biventricular pacing, conduction system pacing, left-bundle branch area pacing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/">Left Bundle Pacing Challenges BiVP for CRT 04/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like femoral venous puncture and catheter manipulation. Key takeaway: Left Bundle Pacing Challenges BiVP for CRT.
Article Links:
Article 1: ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like femoral venous puncture and catheter manipulation. Key takeaway: Left Bundle Pacing Challenges BiVP for CRT.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41979041">Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41978340">Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41969098">Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41969084">Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis.</a> (Circulation. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41979555">Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/">https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41979041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41979041</a></p>
<p><strong>Summary:</strong> The ULYSSES trial confirmed that vascular access site complications are the most common procedure-related adverse events during atrial fibrillation catheter ablation. This study directly compared an ultrasound-guided femoral venous puncture strategy with a conventional approach. The multicenter trial evaluated the efficacy of each technique in reducing complications in patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation. The investigation&#8217;s findings provided a critical evidence base for optimizing patient safety during these procedures.</p>
<h4>Article 2: Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41978340" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41978340</a></p>
<p><strong>Summary:</strong> Conduction system pacing has emerged as an alternative to biventricular pacing for cardiac resynchronization therapy. The LEFT-BUNDLE-CRT trial directly compared left-bundle branch area pacing to biventricular pacing. This multicenter, randomized, non-inferiority study provided a comprehensive evaluation of their comparative effectiveness in patients eligible for cardiac resynchronization therapy and left-bundle branch block. The study&#8217;s results established the non-inferiority profile of left-bundle branch area pacing against biventricular pacing for this patient population.</p>
<h4>Article 3: Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41969098" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41969098</a></p>
<p><strong>Summary:</strong> Obstructive hypertrophic cardiomyopathy is characterized by left ventricular outflow tract obstruction, which increases afterload and activates the Anrep response of hyperdynamic systole. This study directly compared the effects of the myosin inhibitor mavacamten to alcohol septal ablation. Researchers evaluated whether mavacamten reverses this hyperdynamic state, contrasting its impacts with the anatomic relief from alcohol septal ablation in 36 patients. The investigation&#8217;s echocardiography-derived pressure-volume analysis clarified the differential physiological effects of these two therapeutic approaches.</p>
<h4>Article 4: Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41969084" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41969084</a></p>
<p><strong>Summary:</strong> Temporary mechanical circulatory support devices are often placed for cardiogenic shock at regional referral centers before transfer to hub centers. This observational analysis identified differences in device-related adverse events and patient outcomes based on the initial site of device placement. The study compared patients whose temporary mechanical circulatory support was initiated at a regional referral center prior to transfer versus those with initial placement at a cardiogenic shock hub center. Its findings clarified the safety and efficacy implications of different care pathways for cardiogenic shock patients.</p>
<h4>Article 5: Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41979555" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41979555</a></p>
<p><strong>Summary:</strong> This ex vivo ovine study characterized the determinants of successful transseptal puncture using an electrified guidewire, a technique previously unstudied in this context. Researchers utilized 25 fresh ovine hearts, creating an interatrial septum model from dissected right atrial tissue. The investigation involved fixing the sheath and guidewire to a jig to model clinical catheter manipulation. The study observed transseptal puncture dynamics across varying parameters, establishing key factors influencing success for electrified guidewire transseptal access.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial. The ULYSSES trial confirmed that vascular access site complications are the most common procedure-related adverse events during atrial fibrillation catheter ablation. This study directly compared an ultrasound-guided femoral venous puncture strategy with a conventional approach. The multicenter trial evaluated the efficacy of each technique in reducing complications in patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation. The investigation&#8217;s findings provided a critical evidence base for optimizing patient safety during these procedures.</p>
<p>Article number two. Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial. Conduction system pacing has emerged as an alternative to biventricular pacing for cardiac resynchronization therapy. The LEFT-BUNDLE-CRT trial directly compared left-bundle branch area pacing to biventricular pacing. This multicenter, randomized, non-inferiority study provided a comprehensive evaluation of their comparative effectiveness in patients eligible for cardiac resynchronization therapy and left-bundle branch block. The study&#8217;s results established the non-inferiority profile of left-bundle branch area pacing against biventricular pacing for this patient population.</p>
<p>Article number three. Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis. Obstructive hypertrophic cardiomyopathy is characterized by left ventricular outflow tract obstruction, which increases afterload and activates the Anrep response of hyperdynamic systole. This study directly compared the effects of the myosin inhibitor mavacamten to alcohol septal ablation. Researchers evaluated whether mavacamten reverses this hyperdynamic state, contrasting its impacts with the anatomic relief from alcohol septal ablation in 36 patients. The investigation&#8217;s echocardiography-derived pressure-volume analysis clarified the differential physiological effects of these two therapeutic approaches.</p>
<p>Article number four. Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis. Temporary mechanical circulatory support devices are often placed for cardiogenic shock at regional referral centers before transfer to hub centers. This observational analysis identified differences in device-related adverse events and patient outcomes based on the initial site of device placement. The study compared patients whose temporary mechanical circulatory support was initiated at a regional referral center prior to transfer versus those with initial placement at a cardiogenic shock hub center. Its findings clarified the safety and efficacy implications of different care pathways for cardiogenic shock patients.</p>
<p>Article number five. Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study. This ex vivo ovine study characterized the determinants of successful transseptal puncture using an electrified guidewire, a technique previously unstudied in this context. Researchers utilized 25 fresh ovine hearts, creating an interatrial septum model from dissected right atrial tissue. The investigation involved fixing the sheath and guidewire to a jig to model clinical catheter manipulation. The study observed transseptal puncture dynamics across varying parameters, establishing key factors influencing success for electrified guidewire transseptal access. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>femoral venous puncture, catheter manipulation, device-related adverse events, vascular access complications, cardiac resynchronization therapy, left ventricular outflow tract obstruction, temporary mechanical circulatory support, mavacamten, left atrial tachycardia, left-bundle branch block, cardiogenic shock, electrified guidewire, regional referral centers, ex vivo ovine model, ultrasound-guided puncture, interatrial septum, echocardiography, obstructive hypertrophic cardiomyopathy, transseptal puncture, alcohol septal ablation, hub centers, atrial fibrillation ablation, biventricular pacing, conduction system pacing, left-bundle branch area pacing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/">Left Bundle Pacing Challenges BiVP for CRT 04/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260414_214806.mp3" length="4222893" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like femoral venous puncture and catheter manipulation. Key takeaway: Left Bundle Pacing Challenges BiVP for CRT.
Article Links:
Article 1: Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial. (European heart journal)
Article 2: Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial. (European heart journal)
Article 3: Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis. (Circulation. Heart failure)
Article 4: Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis. (Circulation. Heart failure)
Article 5: Characterization of a successful transseptal access with an electrified guidewire: An ex vivo ovine study. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/left-bundle-pacing-challenges-bivp-for-crt-04-14-26/
 Featured Articles
Article 1: Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41979041
Summary: The ULYSSES trial confirmed that vascular access site complications are the most common procedure-related adverse events during atrial fibrillation catheter ablation. This study directly compared an ultrasound-guided femoral venous puncture strategy with a conventional approach. The multicenter trial evaluated the efficacy of each technique in reducing complications in patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation. The investigation&#8217;s findings provided a critical evidence base for optimizing patient safety during these procedures.
Article 2: Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41978340
Summary: Conduction system pacing has emerged as an alternative to biventricular pacing for cardiac resynchronization therapy. The LEFT-BUNDLE-CRT trial directly compared left-bundle branch area pacing to biventricular pacing. This multicenter, randomized, non-inferiority study provided a comprehensive evaluation of their comparative effectiveness in patients eligible for cardiac resynchronization therapy and left-bundle branch block. The study&#8217;s results established the non-inferiority profile of left-bundle branch area pacing against biventricular pacing for this patient population.
Article 3: Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41969098
Summary: Obstructive hypertrophic cardiomyopathy is characterized by left ventricular outflow tract obstruction, which increases afterload and activates the Anrep response of hyperdynamic systole. This study directly compared the effects of the myosin inhibitor mavacamten to alcohol septal ablation. Researchers evaluated whether mavacamten reverses this hyperdynamic state, contrasting its impacts with the anatomic relief from alcohol septal ablation in 36 patients. The investigation&#8217;s echocardiography-derived pressure-volume analysis clarified the differential physiological effects of these two therapeutic approaches.
Article 4: Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41969084
Summary: Temporary mech]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like femoral venous puncture and catheter manipulation. Key takeaway: Left Bundle Pacing Challenges BiVP for CRT.
Article Links:
Article 1: Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial. (European heart journal)
Article 2: Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial. (European heart journal)
Article 3: Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis. (Circulation. Heart failure)
Article 4: Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis. (Circulation. Heart failure)
Article 5: Characterization of a successful transsepta]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Time-Varying Data Boosts Transplant Risk Accuracy 04/14/26</title>
	<link>https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/</link>
	<pubDate>Tue, 14 Apr 2026 10:02:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like aspirin and left bundle branch block. Key takeaway: Time-Varying Data Boosts Transplant Risk Accuracy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41972998">Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41969103">Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41974389">Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41973801">Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41968761">Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/">https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41972998" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41972998</a></p>
<p><strong>Summary:</strong> This randomized trial evaluated endovascular therapy, specifically iliac-vein stent placement, for patients with moderate or severe post-thrombotic syndrome linked to iliac-vein obstruction. The study included 225 patients who received either endovascular therapy or enhanced conventional management, addressing the critical clinical issue of improving quality of life. This trial focused on whether the intervention reduced symptom severity for patients severely affected by post-thrombotic syndrome.</p>
<h4>Article 2: Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41969103" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41969103</a></p>
<p><strong>Summary:</strong> This study developed a new strategy using intersectional genetics for cell type-specific targeting of smooth muscle cell populations. This refined approach effectively overcomes limitations of existing Cre/loxP recombination systems that previously showed off-target activity outside the smooth muscle cell lineage. The new method precisely distinguishes among arterial smooth muscle cells, venous smooth muscle cells, and non-vascular smooth muscle cells. This capability is essential for characterizing the distinct roles of smooth muscle cells in various organs and diseases.</p>
<h4>Article 3: Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41974389" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41974389</a></p>
<p><strong>Summary:</strong> This study demonstrated that incorporating a time-varying binary indicator in a Cox model correctly analyzes post-transplant risk factors. Traditional methods, which treat risk factors as fixed at the time of transplantation, produce inaccurate effect estimates due to immortal time bias. Using infection-related hospitalizations after heart transplantation as an example, this refined approach properly aligns the timing of exposure with survival follow-up. This methodology yields more credible and accurate effect estimates for risk factors emerging after transplantation.</p>
<h4>Article 4: Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41973801" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41973801</a></p>
<p><strong>Summary:</strong> The ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial, involving 3986 patients, compared apixaban with aspirin for reducing thromboembolism in individuals with device-detected subclinical atrial fibrillation. This study leveraged the ARTESiA patient cohort to investigate the connection between subclinical atrial fibrillation and the incidence of heart failure events. It established that while heart failure and clinical atrial fibrillation are closely related, the specific impact of device-detected subclinical atrial fibrillation on heart failure risk remained previously undefined. The research therefore identified a critical area for further clinical understanding regarding this patient population.</p>
<h4>Article 5: Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41968761" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41968761</a></p>
<p><strong>Summary:</strong> This study in an ovine model of dyssynchronous heart failure with left bundle branch block demonstrated that mitochondrial distribution and functions mirror regional workload and energy demand. Researchers established left bundle branch block-like activation in 11 sheep, observing them over eight weeks, alongside six control animals. The findings showed inhomogeneous left ventricular workload and systolic dysfunction in the dyssynchronous heart failure group. This research specifically linked metabolic remodeling, including glucose metabolism assessed by 18F-fluorodeoxyglucose tracers, to regional energetic stress in the diseased myocardium.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial. This randomized trial evaluated endovascular therapy, specifically iliac-vein stent placement, for patients with moderate or severe post-thrombotic syndrome linked to iliac-vein obstruction. The study included 225 patients who received either endovascular therapy or enhanced conventional management, addressing the critical clinical issue of improving quality of life. This trial focused on whether the intervention reduced symptom severity for patients severely affected by post-thrombotic syndrome.</p>
<p>Article number two. Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics. This study developed a new strategy using intersectional genetics for cell type-specific targeting of smooth muscle cell populations. This refined approach effectively overcomes limitations of existing Cre/loxP recombination systems that previously showed off-target activity outside the smooth muscle cell lineage. The new method precisely distinguishes among arterial smooth muscle cells, venous smooth muscle cells, and non-vascular smooth muscle cells. This capability is essential for characterizing the distinct roles of smooth muscle cells in various organs and diseases.</p>
<p>Article number three. Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors. This study demonstrated that incorporating a time-varying binary indicator in a Cox model correctly analyzes post-transplant risk factors. Traditional methods, which treat risk factors as fixed at the time of transplantation, produce inaccurate effect estimates due to immortal time bias. Using infection-related hospitalizations after heart transplantation as an example, this refined approach properly aligns the timing of exposure with survival follow-up. This methodology yields more credible and accurate effect estimates for risk factors emerging after transplantation.</p>
<p>Article number four. Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA. The ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial, involving 3986 patients, compared apixaban with aspirin for reducing thromboembolism in individuals with device-detected subclinical atrial fibrillation. This study leveraged the ARTESiA patient cohort to investigate the connection between subclinical atrial fibrillation and the incidence of heart failure events. It established that while heart failure and clinical atrial fibrillation are closely related, the specific impact of device-detected subclinical atrial fibrillation on heart failure risk remained previously undefined. The research therefore identified a critical area for further clinical understanding regarding this patient population.</p>
<p>Article number five. Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization. This study in an ovine model of dyssynchronous heart failure with left bundle branch block demonstrated that mitochondrial distribution and functions mirror regional workload and energy demand. Researchers established left bundle branch block-like activation in 11 sheep, observing them over eight weeks, alongside six control animals. The findings showed inhomogeneous left ventricular workload and systolic dysfunction in the dyssynchronous heart failure group. This research specifically linked metabolic remodeling, including glucose metabolism assessed by 18F-fluorodeoxyglucose tracers, to regional energetic stress in the diseased myocardium. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aspirin, left bundle branch block, cell targeting, mitochondrial function, Cox model, endovascular therapy, iliac-vein stent, dyssynchronous heart failure, heart failure, smooth muscle cells, deep-vein thrombosis, myocardial remodeling, arterial smooth muscle cells, subclinical atrial fibrillation, heart transplantation, immortal time bias, ventricular desynchronization, risk factors, time-varying binary indicator, venous obstruction, post-thrombotic syndrome, ARTESiA trial, Cre-loxP system, apixaban, intersectional genetics, thromboembolism.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/">Time-Varying Data Boosts Transplant Risk Accuracy 04/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like aspirin and left bundle branch block. Key takeaway: Time-Varying Data Boosts Transplant Risk Accuracy.
Article Links:
Article 1: Endova]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like aspirin and left bundle branch block. Key takeaway: Time-Varying Data Boosts Transplant Risk Accuracy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41972998">Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41969103">Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41974389">Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41973801">Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41968761">Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/">https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41972998" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41972998</a></p>
<p><strong>Summary:</strong> This randomized trial evaluated endovascular therapy, specifically iliac-vein stent placement, for patients with moderate or severe post-thrombotic syndrome linked to iliac-vein obstruction. The study included 225 patients who received either endovascular therapy or enhanced conventional management, addressing the critical clinical issue of improving quality of life. This trial focused on whether the intervention reduced symptom severity for patients severely affected by post-thrombotic syndrome.</p>
<h4>Article 2: Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41969103" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41969103</a></p>
<p><strong>Summary:</strong> This study developed a new strategy using intersectional genetics for cell type-specific targeting of smooth muscle cell populations. This refined approach effectively overcomes limitations of existing Cre/loxP recombination systems that previously showed off-target activity outside the smooth muscle cell lineage. The new method precisely distinguishes among arterial smooth muscle cells, venous smooth muscle cells, and non-vascular smooth muscle cells. This capability is essential for characterizing the distinct roles of smooth muscle cells in various organs and diseases.</p>
<h4>Article 3: Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41974389" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41974389</a></p>
<p><strong>Summary:</strong> This study demonstrated that incorporating a time-varying binary indicator in a Cox model correctly analyzes post-transplant risk factors. Traditional methods, which treat risk factors as fixed at the time of transplantation, produce inaccurate effect estimates due to immortal time bias. Using infection-related hospitalizations after heart transplantation as an example, this refined approach properly aligns the timing of exposure with survival follow-up. This methodology yields more credible and accurate effect estimates for risk factors emerging after transplantation.</p>
<h4>Article 4: Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41973801" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41973801</a></p>
<p><strong>Summary:</strong> The ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial, involving 3986 patients, compared apixaban with aspirin for reducing thromboembolism in individuals with device-detected subclinical atrial fibrillation. This study leveraged the ARTESiA patient cohort to investigate the connection between subclinical atrial fibrillation and the incidence of heart failure events. It established that while heart failure and clinical atrial fibrillation are closely related, the specific impact of device-detected subclinical atrial fibrillation on heart failure risk remained previously undefined. The research therefore identified a critical area for further clinical understanding regarding this patient population.</p>
<h4>Article 5: Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41968761" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41968761</a></p>
<p><strong>Summary:</strong> This study in an ovine model of dyssynchronous heart failure with left bundle branch block demonstrated that mitochondrial distribution and functions mirror regional workload and energy demand. Researchers established left bundle branch block-like activation in 11 sheep, observing them over eight weeks, alongside six control animals. The findings showed inhomogeneous left ventricular workload and systolic dysfunction in the dyssynchronous heart failure group. This research specifically linked metabolic remodeling, including glucose metabolism assessed by 18F-fluorodeoxyglucose tracers, to regional energetic stress in the diseased myocardium.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial. This randomized trial evaluated endovascular therapy, specifically iliac-vein stent placement, for patients with moderate or severe post-thrombotic syndrome linked to iliac-vein obstruction. The study included 225 patients who received either endovascular therapy or enhanced conventional management, addressing the critical clinical issue of improving quality of life. This trial focused on whether the intervention reduced symptom severity for patients severely affected by post-thrombotic syndrome.</p>
<p>Article number two. Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics. This study developed a new strategy using intersectional genetics for cell type-specific targeting of smooth muscle cell populations. This refined approach effectively overcomes limitations of existing Cre/loxP recombination systems that previously showed off-target activity outside the smooth muscle cell lineage. The new method precisely distinguishes among arterial smooth muscle cells, venous smooth muscle cells, and non-vascular smooth muscle cells. This capability is essential for characterizing the distinct roles of smooth muscle cells in various organs and diseases.</p>
<p>Article number three. Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors. This study demonstrated that incorporating a time-varying binary indicator in a Cox model correctly analyzes post-transplant risk factors. Traditional methods, which treat risk factors as fixed at the time of transplantation, produce inaccurate effect estimates due to immortal time bias. Using infection-related hospitalizations after heart transplantation as an example, this refined approach properly aligns the timing of exposure with survival follow-up. This methodology yields more credible and accurate effect estimates for risk factors emerging after transplantation.</p>
<p>Article number four. Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA. The ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial, involving 3986 patients, compared apixaban with aspirin for reducing thromboembolism in individuals with device-detected subclinical atrial fibrillation. This study leveraged the ARTESiA patient cohort to investigate the connection between subclinical atrial fibrillation and the incidence of heart failure events. It established that while heart failure and clinical atrial fibrillation are closely related, the specific impact of device-detected subclinical atrial fibrillation on heart failure risk remained previously undefined. The research therefore identified a critical area for further clinical understanding regarding this patient population.</p>
<p>Article number five. Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization. This study in an ovine model of dyssynchronous heart failure with left bundle branch block demonstrated that mitochondrial distribution and functions mirror regional workload and energy demand. Researchers established left bundle branch block-like activation in 11 sheep, observing them over eight weeks, alongside six control animals. The findings showed inhomogeneous left ventricular workload and systolic dysfunction in the dyssynchronous heart failure group. This research specifically linked metabolic remodeling, including glucose metabolism assessed by 18F-fluorodeoxyglucose tracers, to regional energetic stress in the diseased myocardium. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aspirin, left bundle branch block, cell targeting, mitochondrial function, Cox model, endovascular therapy, iliac-vein stent, dyssynchronous heart failure, heart failure, smooth muscle cells, deep-vein thrombosis, myocardial remodeling, arterial smooth muscle cells, subclinical atrial fibrillation, heart transplantation, immortal time bias, ventricular desynchronization, risk factors, time-varying binary indicator, venous obstruction, post-thrombotic syndrome, ARTESiA trial, Cre-loxP system, apixaban, intersectional genetics, thromboembolism.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/">Time-Varying Data Boosts Transplant Risk Accuracy 04/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260414_060053.mp3" length="4388823" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like aspirin and left bundle branch block. Key takeaway: Time-Varying Data Boosts Transplant Risk Accuracy.
Article Links:
Article 1: Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial. (The New England journal of medicine)
Article 2: Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics. (Circulation)
Article 3: Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA. (European journal of heart failure)
Article 5: Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/time-varying-data-boosts-transplant-risk-accuracy-04-14-26/
 Featured Articles
Article 1: Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41972998
Summary: This randomized trial evaluated endovascular therapy, specifically iliac-vein stent placement, for patients with moderate or severe post-thrombotic syndrome linked to iliac-vein obstruction. The study included 225 patients who received either endovascular therapy or enhanced conventional management, addressing the critical clinical issue of improving quality of life. This trial focused on whether the intervention reduced symptom severity for patients severely affected by post-thrombotic syndrome.
Article 2: Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41969103
Summary: This study developed a new strategy using intersectional genetics for cell type-specific targeting of smooth muscle cell populations. This refined approach effectively overcomes limitations of existing Cre/loxP recombination systems that previously showed off-target activity outside the smooth muscle cell lineage. The new method precisely distinguishes among arterial smooth muscle cells, venous smooth muscle cells, and non-vascular smooth muscle cells. This capability is essential for characterizing the distinct roles of smooth muscle cells in various organs and diseases.
Article 3: Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41974389
Summary: This study demonstrated that incorporating a time-varying binary indicator in a Cox model correctly analyzes post-transplant risk factors. Traditional methods, which treat risk factors as fixed at the time of transplantation, produce inaccurate effect estimates due to immortal time bias. Using infection-related hospitalizations after heart transplantation as an example, this refined approach properly aligns the timing of exposure with survival follow-up. This methodology yields more credible and accurate effect estimates for risk factors emerging after transplantation.
Article 4: Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41973801
Summary: The ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial, involving 3986 patients, compared apixaban with aspirin for reducing thro]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 14, 2026. This episode summarizes 5 key cardiology studies on topics like aspirin and left bundle branch block. Key takeaway: Time-Varying Data Boosts Transplant Risk Accuracy.
Article Links:
Article 1: Endovascular Therapy for Post-Thrombotic Syndrome &#8211; A Randomized Trial. (The New England journal of medicine)
Article 2: Cell Type-Specific Targeting of Different Smooth Muscle Cell Populations by Intersectional Genetics. (Circulation)
Article 3: Timing is everything: Using time-varying binary indicators for evaluating post-transplant risk factors. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA. (European journal of heart failure)
Article 5: Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a l]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Salusin-Alpha Restores Vessels in Pulmonary Hypertension 04/13/26</title>
	<link>https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/</link>
	<pubDate>Mon, 13 Apr 2026 10:01:39 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like ischemic stroke and prehospital delay. Key takeaway: Salusin-Alpha Restores Vessels in Pulmonary Hypertension.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41958393">Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41967191">Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.</a> (JACC. Basic to translational science)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41961986">Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging.</a> (Circulation. Cardiovascular imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41958392">Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial.</a> (Stroke)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41958382">Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes.</a> (Stroke)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/">https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41958393" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41958393</a></p>
<p><strong>Summary:</strong> This study demonstrated that salusin-alpha restored vascular relaxation and reversed vascular remodeling in pulmonary hypertension. Researchers found these effects by assessing pulmonary artery relaxation using isometric tension recording in isolated rat pulmonary arteries. They quantified reductions in pulmonary artery remodeling through histological morphometric analysis. The data indicated that salusin-alpha significantly alleviated the progressive increase in pulmonary arterial resistance characteristic of pulmonary hypertension.</p>
<h4>Article 2: Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.</h4>
<p><strong>Journal:</strong> JACC. Basic to translational science</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967191" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967191</a></p>
<p><strong>Summary:</strong> Microvascular endothelial cells (MVECs) from subcutaneous adipose tissue of patients with type two diabetes mellitus and heart failure exhibited a senescent phenotype. These senescent cells displayed elevated senescence-associated secretory phenotype markers, reduced adenosine triphosphate production, and impaired angiogenic and proliferative capacities. When cocultured with healthy adipocytes, these senescent M. V. E. C. s drove adverse cross-talk, inducing a proinflammatory adipocyte phenotype with increased interleukin-6 expression. This research revealed how endothelial senescence contributes to chronic inflammation in this high-risk patient population.</p>
<h4>Article 3: Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961986" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961986</a></p>
<p><strong>Summary:</strong> This study characterized the tracer kinetics of technetium-labeled bone-avid tracers used for diagnosing transthyretin cardiac amyloidosis. Researchers defined these kinetics using quantitative single-photon emission computed tomography with computed tomography in 24 subjects evaluated for the condition. The findings established the kinetic profile of these diagnostic agents. The study also addressed the use of hydroxymethylene diphosphonate as an alternative to technetium-99m pyrophosphate due to supply shortages, noting the limited comparative kinetic data available.</p>
<h4>Article 4: Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41958392" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41958392</a></p>
<p><strong>Summary:</strong> This secondary analysis of the TEMPO-2 multicenter, randomized trial evaluated specific intracranial hemorrhage patterns and their impact on functional outcomes in patients with minor ischemic stroke. The study identified distinct predictors associated with intracranial hemorrhage within this patient population. It found that intracranial hemorrhage negatively impacts functional outcomes after ischemic stroke, with disproportionate effects observed in patients with minor stroke. The TEMPO-2 trial compared tenecteplase with nonthrombolytic standard care for patients within 12 hours of symptom onset.</p>
<h4>Article 5: Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41958382" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41958382</a></p>
<p><strong>Summary:</strong> This study determined the relative benefits and cost-effectiveness of reducing prehospital delay for acute ischemic stroke patients compared to implementing primary stroke prevention measures. The analysis focused on U. S. adults with type two diabetes, a population at high risk for acute ischemic stroke. Researchers utilized data from the National Health and Nutrition Examination Survey from 2015 to 2018. The findings established which intervention strategy offered greater cost-effectiveness in this specific high-risk group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension. This study demonstrated that salusin-alpha restored vascular relaxation and reversed vascular remodeling in pulmonary hypertension. Researchers found these effects by assessing pulmonary artery relaxation using isometric tension recording in isolated rat pulmonary arteries. They quantified reductions in pulmonary artery remodeling through histological morphometric analysis. The data indicated that salusin-alpha significantly alleviated the progressive increase in pulmonary arterial resistance characteristic of pulmonary hypertension.</p>
<p>Article number two. Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes. Microvascular endothelial cells (MVECs) from subcutaneous adipose tissue of patients with type two diabetes mellitus and heart failure exhibited a senescent phenotype. These senescent cells displayed elevated senescence-associated secretory phenotype markers, reduced adenosine triphosphate production, and impaired angiogenic and proliferative capacities. When cocultured with healthy adipocytes, these senescent M. V. E. C. s drove adverse cross-talk, inducing a proinflammatory adipocyte phenotype with increased interleukin-6 expression. This research revealed how endothelial senescence contributes to chronic inflammation in this high-risk patient population.</p>
<p>Article number three. Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging. This study characterized the tracer kinetics of technetium-labeled bone-avid tracers used for diagnosing transthyretin cardiac amyloidosis. Researchers defined these kinetics using quantitative single-photon emission computed tomography with computed tomography in 24 subjects evaluated for the condition. The findings established the kinetic profile of these diagnostic agents. The study also addressed the use of hydroxymethylene diphosphonate as an alternative to technetium-99m pyrophosphate due to supply shortages, noting the limited comparative kinetic data available.</p>
<p>Article number four. Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial. This secondary analysis of the TEMPO-2 multicenter, randomized trial evaluated specific intracranial hemorrhage patterns and their impact on functional outcomes in patients with minor ischemic stroke. The study identified distinct predictors associated with intracranial hemorrhage within this patient population. It found that intracranial hemorrhage negatively impacts functional outcomes after ischemic stroke, with disproportionate effects observed in patients with minor stroke. The TEMPO-2 trial compared tenecteplase with nonthrombolytic standard care for patients within 12 hours of symptom onset.</p>
<p>Article number five. Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes. This study determined the relative benefits and cost-effectiveness of reducing prehospital delay for acute ischemic stroke patients compared to implementing primary stroke prevention measures. The analysis focused on U. S. adults with type two diabetes, a population at high risk for acute ischemic stroke. Researchers utilized data from the National Health and Nutrition Examination Survey from 2015 to 2018. The findings established which intervention strategy offered greater cost-effectiveness in this specific high-risk group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ischemic stroke, prehospital delay, microvascular endothelial cells, technetium-labeled tracers, tenecteplase, endothelial senescence, pulmonary artery, single-photon emission computed tomography, adipocyte cross-talk, inflammation, minor stroke, acute ischemic stroke, type two diabetes mellitus, intracranial hemorrhage, heart failure, primary stroke prevention, functional outcomes, tracer kinetics, vascular remodeling, pulmonary hypertension, cost-effectiveness, TEMPO-2 trial, salusin-alpha, hydroxymethylene diphosphonate, National Health and Nutrition Examination Survey, cardiac imaging, transthyretin cardiac amyloidosis, vascular relaxation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/">Salusin-Alpha Restores Vessels in Pulmonary Hypertension 04/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like ischemic stroke and prehospital delay. Key takeaway: Salusin-Alpha Restores Vessels in Pulmonary Hypertension.
Article Links:
Article 1]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like ischemic stroke and prehospital delay. Key takeaway: Salusin-Alpha Restores Vessels in Pulmonary Hypertension.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41958393">Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41967191">Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.</a> (JACC. Basic to translational science)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41961986">Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging.</a> (Circulation. Cardiovascular imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41958392">Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial.</a> (Stroke)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41958382">Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes.</a> (Stroke)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/">https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41958393" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41958393</a></p>
<p><strong>Summary:</strong> This study demonstrated that salusin-alpha restored vascular relaxation and reversed vascular remodeling in pulmonary hypertension. Researchers found these effects by assessing pulmonary artery relaxation using isometric tension recording in isolated rat pulmonary arteries. They quantified reductions in pulmonary artery remodeling through histological morphometric analysis. The data indicated that salusin-alpha significantly alleviated the progressive increase in pulmonary arterial resistance characteristic of pulmonary hypertension.</p>
<h4>Article 2: Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.</h4>
<p><strong>Journal:</strong> JACC. Basic to translational science</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967191" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967191</a></p>
<p><strong>Summary:</strong> Microvascular endothelial cells (MVECs) from subcutaneous adipose tissue of patients with type two diabetes mellitus and heart failure exhibited a senescent phenotype. These senescent cells displayed elevated senescence-associated secretory phenotype markers, reduced adenosine triphosphate production, and impaired angiogenic and proliferative capacities. When cocultured with healthy adipocytes, these senescent M. V. E. C. s drove adverse cross-talk, inducing a proinflammatory adipocyte phenotype with increased interleukin-6 expression. This research revealed how endothelial senescence contributes to chronic inflammation in this high-risk patient population.</p>
<h4>Article 3: Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961986" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961986</a></p>
<p><strong>Summary:</strong> This study characterized the tracer kinetics of technetium-labeled bone-avid tracers used for diagnosing transthyretin cardiac amyloidosis. Researchers defined these kinetics using quantitative single-photon emission computed tomography with computed tomography in 24 subjects evaluated for the condition. The findings established the kinetic profile of these diagnostic agents. The study also addressed the use of hydroxymethylene diphosphonate as an alternative to technetium-99m pyrophosphate due to supply shortages, noting the limited comparative kinetic data available.</p>
<h4>Article 4: Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41958392" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41958392</a></p>
<p><strong>Summary:</strong> This secondary analysis of the TEMPO-2 multicenter, randomized trial evaluated specific intracranial hemorrhage patterns and their impact on functional outcomes in patients with minor ischemic stroke. The study identified distinct predictors associated with intracranial hemorrhage within this patient population. It found that intracranial hemorrhage negatively impacts functional outcomes after ischemic stroke, with disproportionate effects observed in patients with minor stroke. The TEMPO-2 trial compared tenecteplase with nonthrombolytic standard care for patients within 12 hours of symptom onset.</p>
<h4>Article 5: Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41958382" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41958382</a></p>
<p><strong>Summary:</strong> This study determined the relative benefits and cost-effectiveness of reducing prehospital delay for acute ischemic stroke patients compared to implementing primary stroke prevention measures. The analysis focused on U. S. adults with type two diabetes, a population at high risk for acute ischemic stroke. Researchers utilized data from the National Health and Nutrition Examination Survey from 2015 to 2018. The findings established which intervention strategy offered greater cost-effectiveness in this specific high-risk group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension. This study demonstrated that salusin-alpha restored vascular relaxation and reversed vascular remodeling in pulmonary hypertension. Researchers found these effects by assessing pulmonary artery relaxation using isometric tension recording in isolated rat pulmonary arteries. They quantified reductions in pulmonary artery remodeling through histological morphometric analysis. The data indicated that salusin-alpha significantly alleviated the progressive increase in pulmonary arterial resistance characteristic of pulmonary hypertension.</p>
<p>Article number two. Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes. Microvascular endothelial cells (MVECs) from subcutaneous adipose tissue of patients with type two diabetes mellitus and heart failure exhibited a senescent phenotype. These senescent cells displayed elevated senescence-associated secretory phenotype markers, reduced adenosine triphosphate production, and impaired angiogenic and proliferative capacities. When cocultured with healthy adipocytes, these senescent M. V. E. C. s drove adverse cross-talk, inducing a proinflammatory adipocyte phenotype with increased interleukin-6 expression. This research revealed how endothelial senescence contributes to chronic inflammation in this high-risk patient population.</p>
<p>Article number three. Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging. This study characterized the tracer kinetics of technetium-labeled bone-avid tracers used for diagnosing transthyretin cardiac amyloidosis. Researchers defined these kinetics using quantitative single-photon emission computed tomography with computed tomography in 24 subjects evaluated for the condition. The findings established the kinetic profile of these diagnostic agents. The study also addressed the use of hydroxymethylene diphosphonate as an alternative to technetium-99m pyrophosphate due to supply shortages, noting the limited comparative kinetic data available.</p>
<p>Article number four. Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial. This secondary analysis of the TEMPO-2 multicenter, randomized trial evaluated specific intracranial hemorrhage patterns and their impact on functional outcomes in patients with minor ischemic stroke. The study identified distinct predictors associated with intracranial hemorrhage within this patient population. It found that intracranial hemorrhage negatively impacts functional outcomes after ischemic stroke, with disproportionate effects observed in patients with minor stroke. The TEMPO-2 trial compared tenecteplase with nonthrombolytic standard care for patients within 12 hours of symptom onset.</p>
<p>Article number five. Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes. This study determined the relative benefits and cost-effectiveness of reducing prehospital delay for acute ischemic stroke patients compared to implementing primary stroke prevention measures. The analysis focused on U. S. adults with type two diabetes, a population at high risk for acute ischemic stroke. Researchers utilized data from the National Health and Nutrition Examination Survey from 2015 to 2018. The findings established which intervention strategy offered greater cost-effectiveness in this specific high-risk group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ischemic stroke, prehospital delay, microvascular endothelial cells, technetium-labeled tracers, tenecteplase, endothelial senescence, pulmonary artery, single-photon emission computed tomography, adipocyte cross-talk, inflammation, minor stroke, acute ischemic stroke, type two diabetes mellitus, intracranial hemorrhage, heart failure, primary stroke prevention, functional outcomes, tracer kinetics, vascular remodeling, pulmonary hypertension, cost-effectiveness, TEMPO-2 trial, salusin-alpha, hydroxymethylene diphosphonate, National Health and Nutrition Examination Survey, cardiac imaging, transthyretin cardiac amyloidosis, vascular relaxation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/">Salusin-Alpha Restores Vessels in Pulmonary Hypertension 04/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260413_060037.mp3" length="4206593" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like ischemic stroke and prehospital delay. Key takeaway: Salusin-Alpha Restores Vessels in Pulmonary Hypertension.
Article Links:
Article 1: Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension. (Hypertension (Dallas, Tex. : 1979))
Article 2: Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes. (JACC. Basic to translational science)
Article 3: Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging. (Circulation. Cardiovascular imaging)
Article 4: Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial. (Stroke)
Article 5: Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes. (Stroke)
Full episode page: https://podcast.explainheart.com/podcast/salusin-alpha-restores-vessels-in-pulmonary-hypertension-04-13-26/
 Featured Articles
Article 1: Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41958393
Summary: This study demonstrated that salusin-alpha restored vascular relaxation and reversed vascular remodeling in pulmonary hypertension. Researchers found these effects by assessing pulmonary artery relaxation using isometric tension recording in isolated rat pulmonary arteries. They quantified reductions in pulmonary artery remodeling through histological morphometric analysis. The data indicated that salusin-alpha significantly alleviated the progressive increase in pulmonary arterial resistance characteristic of pulmonary hypertension.
Article 2: Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.
Journal: JACC. Basic to translational science
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41967191
Summary: Microvascular endothelial cells (MVECs) from subcutaneous adipose tissue of patients with type two diabetes mellitus and heart failure exhibited a senescent phenotype. These senescent cells displayed elevated senescence-associated secretory phenotype markers, reduced adenosine triphosphate production, and impaired angiogenic and proliferative capacities. When cocultured with healthy adipocytes, these senescent M. V. E. C. s drove adverse cross-talk, inducing a proinflammatory adipocyte phenotype with increased interleukin-6 expression. This research revealed how endothelial senescence contributes to chronic inflammation in this high-risk patient population.
Article 3: Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging.
Journal: Circulation. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41961986
Summary: This study characterized the tracer kinetics of technetium-labeled bone-avid tracers used for diagnosing transthyretin cardiac amyloidosis. Researchers defined these kinetics using quantitative single-photon emission computed tomography with computed tomography in 24 subjects evaluated for the condition. The findings established the kinetic profile of these diagnostic agents. The study also addressed the use of hydroxymethylene diphosphonate as an alternative to technetium-99m pyrophosphate due to supply shortages, noting the limited comparative kinetic data available.
Article 4: Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial.
Journal: Stroke
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41958392
Summary: This secondary analysis of the TEMPO-2 multicenter, randomized trial evaluated specific intracranial hemorrhage patterns and their impact on functional outcomes in patients with minor ischemic stroke. The study identified distinct predictors associated with intracranial hemorrhage within this patient population. It found that intr]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like ischemic stroke and prehospital delay. Key takeaway: Salusin-Alpha Restores Vessels in Pulmonary Hypertension.
Article Links:
Article 1: Salusin-α Restores Vascular Relaxation and Remodeling in Pulmonary Hypertension. (Hypertension (Dallas, Tex. : 1979))
Article 2: Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes. (JACC. Basic to translational science)
Article 3: Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging. (Circulation. Cardiovascular imaging)
Article 4: Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial. (Stroke)
Article 5: Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes. (Stroke)
Full episode page: https://podcast.explainheart.com/podcast/salusin-alpha-rest]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CKM Syndrome Shapes Atrial Fibrillation Outcomes 04/13/26</title>
	<link>https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/</link>
	<pubDate>Mon, 13 Apr 2026 06:25:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and adverse clinical outcomes. Key takeaway: CKM Syndrome Shapes Atrial Fibrillation Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41967784">Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41967491">Plasma Protein Profiles in Different Heart Failure Phenotypes.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41966525">Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41967772">Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41967491">Plasma Protein Profiles in Different Heart Failure Phenotypes.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/">https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967784" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967784</a></p>
<p><strong>Summary:</strong> This single-center retrospective study included 23 adults with isolated peripheral pulmonary artery stenosis who received stent-based angioplasty between 2007 and 2024. The study characterized the long-term durability and the incidence and determinants of in-stent restenosis. It also observed changes in patient hemodynamics and six-minute walk distance. This research provides insights into the outcomes of stent-based angioplasty for this rare condition.</p>
<h4>Article 2: Plasma Protein Profiles in Different Heart Failure Phenotypes.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967491" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967491</a></p>
<p><strong>Summary:</strong> This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.</p>
<h4>Article 3: Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41966525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41966525</a></p>
<p><strong>Summary:</strong> This study evaluated the association between cardiovascular-kidney-metabolic syndrome stages and adverse clinical outcomes in patients with atrial fibrillation. It included patients from the E. U. R. O. bservational Research Programme Atrial Fibrillation General Long-Term Registry and the K. A. F. Registry, representing real-world populations across Europe and East Asia. The research characterized the clinical impact of cardiovascular-kidney-metabolic syndrome in atrial fibrillation patients by analyzing data from these prospective registries.</p>
<h4>Article 4: Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967772" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967772</a></p>
<p><strong>Summary:</strong> This retrospective study characterized sex differences in clinically suspected immune checkpoint inhibitor-related myocarditis over a seven-year follow-up period. It included patients diagnosed at a single institute between 2018 and 2024. The research analyzed baseline characteristics, laboratory markers, and echocardiographic parameters to identify sex-specific risk factors and predictors.</p>
<h4>Article 5: Plasma Protein Profiles in Different Heart Failure Phenotypes.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967491" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967491</a></p>
<p><strong>Summary:</strong> This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis. This single-center retrospective study included 23 adults with isolated peripheral pulmonary artery stenosis who received stent-based angioplasty between 2007 and 2024. The study characterized the long-term durability and the incidence and determinants of in-stent restenosis. It also observed changes in patient hemodynamics and six-minute walk distance. This research provides insights into the outcomes of stent-based angioplasty for this rare condition.</p>
<p>Article number two. Plasma Protein Profiles in Different Heart Failure Phenotypes. This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.</p>
<p>Article number three. Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia. This study evaluated the association between cardiovascular-kidney-metabolic syndrome stages and adverse clinical outcomes in patients with atrial fibrillation. It included patients from the E. U. R. O. bservational Research Programme Atrial Fibrillation General Long-Term Registry and the K. A. F. Registry, representing real-world populations across Europe and East Asia. The research characterized the clinical impact of cardiovascular-kidney-metabolic syndrome in atrial fibrillation patients by analyzing data from these prospective registries.</p>
<p>Article number four. Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up. This retrospective study characterized sex differences in clinically suspected immune checkpoint inhibitor-related myocarditis over a seven-year follow-up period. It included patients diagnosed at a single institute between 2018 and 2024. The research analyzed baseline characteristics, laboratory markers, and echocardiographic parameters to identify sex-specific risk factors and predictors.</p>
<p>Article number five. Plasma Protein Profiles in Different Heart Failure Phenotypes. This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sex differences, adverse clinical outcomes, plasma protein profiles, U. K. Biobank, stent-based angioplasty, immune checkpoint inhibitor-related myocarditis, six-minute walk distance, echocardiographic parameters, hemodynamics, heart failure, E. U. R. O. bservational Research Programme, atrial fibrillation, in-stent restenosis, risk factors, cardiovascular-kidney-metabolic syndrome, peripheral pulmonary artery stenosis, biomarkers, K. A. F. Registry, myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/">CKM Syndrome Shapes Atrial Fibrillation Outcomes 04/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and adverse clinical outcomes. Key takeaway: CKM Syndrome Shapes Atrial Fibrillation Outcomes.
Article Links:
Article 1]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and adverse clinical outcomes. Key takeaway: CKM Syndrome Shapes Atrial Fibrillation Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41967784">Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41967491">Plasma Protein Profiles in Different Heart Failure Phenotypes.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41966525">Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41967772">Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41967491">Plasma Protein Profiles in Different Heart Failure Phenotypes.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/">https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967784" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967784</a></p>
<p><strong>Summary:</strong> This single-center retrospective study included 23 adults with isolated peripheral pulmonary artery stenosis who received stent-based angioplasty between 2007 and 2024. The study characterized the long-term durability and the incidence and determinants of in-stent restenosis. It also observed changes in patient hemodynamics and six-minute walk distance. This research provides insights into the outcomes of stent-based angioplasty for this rare condition.</p>
<h4>Article 2: Plasma Protein Profiles in Different Heart Failure Phenotypes.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967491" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967491</a></p>
<p><strong>Summary:</strong> This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.</p>
<h4>Article 3: Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41966525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41966525</a></p>
<p><strong>Summary:</strong> This study evaluated the association between cardiovascular-kidney-metabolic syndrome stages and adverse clinical outcomes in patients with atrial fibrillation. It included patients from the E. U. R. O. bservational Research Programme Atrial Fibrillation General Long-Term Registry and the K. A. F. Registry, representing real-world populations across Europe and East Asia. The research characterized the clinical impact of cardiovascular-kidney-metabolic syndrome in atrial fibrillation patients by analyzing data from these prospective registries.</p>
<h4>Article 4: Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967772" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967772</a></p>
<p><strong>Summary:</strong> This retrospective study characterized sex differences in clinically suspected immune checkpoint inhibitor-related myocarditis over a seven-year follow-up period. It included patients diagnosed at a single institute between 2018 and 2024. The research analyzed baseline characteristics, laboratory markers, and echocardiographic parameters to identify sex-specific risk factors and predictors.</p>
<h4>Article 5: Plasma Protein Profiles in Different Heart Failure Phenotypes.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41967491" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41967491</a></p>
<p><strong>Summary:</strong> This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis. This single-center retrospective study included 23 adults with isolated peripheral pulmonary artery stenosis who received stent-based angioplasty between 2007 and 2024. The study characterized the long-term durability and the incidence and determinants of in-stent restenosis. It also observed changes in patient hemodynamics and six-minute walk distance. This research provides insights into the outcomes of stent-based angioplasty for this rare condition.</p>
<p>Article number two. Plasma Protein Profiles in Different Heart Failure Phenotypes. This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.</p>
<p>Article number three. Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia. This study evaluated the association between cardiovascular-kidney-metabolic syndrome stages and adverse clinical outcomes in patients with atrial fibrillation. It included patients from the E. U. R. O. bservational Research Programme Atrial Fibrillation General Long-Term Registry and the K. A. F. Registry, representing real-world populations across Europe and East Asia. The research characterized the clinical impact of cardiovascular-kidney-metabolic syndrome in atrial fibrillation patients by analyzing data from these prospective registries.</p>
<p>Article number four. Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up. This retrospective study characterized sex differences in clinically suspected immune checkpoint inhibitor-related myocarditis over a seven-year follow-up period. It included patients diagnosed at a single institute between 2018 and 2024. The research analyzed baseline characteristics, laboratory markers, and echocardiographic parameters to identify sex-specific risk factors and predictors.</p>
<p>Article number five. Plasma Protein Profiles in Different Heart Failure Phenotypes. This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sex differences, adverse clinical outcomes, plasma protein profiles, U. K. Biobank, stent-based angioplasty, immune checkpoint inhibitor-related myocarditis, six-minute walk distance, echocardiographic parameters, hemodynamics, heart failure, E. U. R. O. bservational Research Programme, atrial fibrillation, in-stent restenosis, risk factors, cardiovascular-kidney-metabolic syndrome, peripheral pulmonary artery stenosis, biomarkers, K. A. F. Registry, myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/">CKM Syndrome Shapes Atrial Fibrillation Outcomes 04/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260413_022422.mp3" length="3532425" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and adverse clinical outcomes. Key takeaway: CKM Syndrome Shapes Atrial Fibrillation Outcomes.
Article Links:
Article 1: Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Plasma Protein Profiles in Different Heart Failure Phenotypes. (ESC heart failure)
Article 3: Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia. (Heart rhythm)
Article 4: Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up. (International journal of cardiology)
Article 5: Plasma Protein Profiles in Different Heart Failure Phenotypes. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/ckm-syndrome-shapes-atrial-fibrillation-outcomes-04-13-26/
 Featured Articles
Article 1: Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41967784
Summary: This single-center retrospective study included 23 adults with isolated peripheral pulmonary artery stenosis who received stent-based angioplasty between 2007 and 2024. The study characterized the long-term durability and the incidence and determinants of in-stent restenosis. It also observed changes in patient hemodynamics and six-minute walk distance. This research provides insights into the outcomes of stent-based angioplasty for this rare condition.
Article 2: Plasma Protein Profiles in Different Heart Failure Phenotypes.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41967491
Summary: This study analyzed data from 50765 U. K. Biobank participants to characterize plasma protein profiles. It examined three distinct heart failure phenotypes: heart failure with preceding myocardial infarction, heart failure with preceding atrial fibrillation, and heart failure without either preceding condition. The analysis was conducted to understand the unique protein signatures across these different heart failure presentations and potentially identify a common protein profile.
Article 3: Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41966525
Summary: This study evaluated the association between cardiovascular-kidney-metabolic syndrome stages and adverse clinical outcomes in patients with atrial fibrillation. It included patients from the E. U. R. O. bservational Research Programme Atrial Fibrillation General Long-Term Registry and the K. A. F. Registry, representing real-world populations across Europe and East Asia. The research characterized the clinical impact of cardiovascular-kidney-metabolic syndrome in atrial fibrillation patients by analyzing data from these prospective registries.
Article 4: Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41967772
Summary: This retrospective study characterized sex differences in clinically suspected immune checkpoint inhibitor-related myocarditis over a seven-year follow-up period. It included patients diagnosed at a single institute between 2018 and 2024. The research analyzed baseline characteristics, laboratory markers, and echoc]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 13, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and adverse clinical outcomes. Key takeaway: CKM Syndrome Shapes Atrial Fibrillation Outcomes.
Article Links:
Article 1: Long-Term Outcomes of Stent-Based Pulmonary Angioplasty for Isolated Peripheral Pulmonary Artery Stenosis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Plasma Protein Profiles in Different Heart Failure Phenotypes. (ESC heart failure)
Article 3: Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: Insights from 2 real-world prospective registries across Europe and East Asia. (Heart rhythm)
Article 4: Sex difference in clinically suspected immune checkpoint inhibitor-related myocarditis: a single-institute retrospective study with seven-year follow-up. (International journal of cardiology)
Article 5: Plasma Protein Profiles in ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mycn Promotes Heart Protection Post M.I. 04/12/26</title>
	<link>https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/</link>
	<pubDate>Sun, 12 Apr 2026 10:01:50 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 12, 2026. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and morbidity. Key takeaway: Mycn Promotes Heart Protection Post M.I..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41954068">Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41954067">Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41954066">Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41954064">Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41954062">Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/">https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954068" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954068</a></p>
<p><strong>Summary:</strong> This large cohort study provided a comprehensive characterization of patient-surgeon sex concordance in relation to clinical outcomes following adult cardiac surgery. The research documented data from 223065 Medicare beneficiaries who underwent coronary artery bypass grafting, surgical aortic valve replacement, or proximal aortic surgery. The study&#8217;s analysis focused on composite outcomes of mortality and morbidity, including myocardial infarction, stroke, and all-cause readmission, stratified by surgeon and patient sex. These findings contribute crucial information for understanding potential sex-based differences in cardiac surgical care.</p>
<h4>Article 2: Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954067" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954067</a></p>
<p><strong>Summary:</strong> This retrospective data-linkage study found an increased risk of disabilities in children and adolescents diagnosed with congenital heart disease of any severity. The research revealed a higher prevalence of overall and specific disability service use within this patient group compared to matched controls and siblings. These findings highlight a significant burden of disabilities across all severities of congenital heart disease in pediatric patients. The study provides crucial information for long-term care planning and resource allocation for this population.</p>
<h4>Article 3: Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954066" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954066</a></p>
<p><strong>Summary:</strong> This study established the correlates and confirmed the prognostic value of serial N-terminal pro-B-type natriuretic peptide assays in adults with congenitally corrected transposition of the great arteries. The research provided specific data on the role of these measurements for heart failure risk stratification in this distinct patient population. The findings confirm N-terminal pro-B-type natriuretic peptide as a relevant cardiovascular biomarker, addressing previously limited data for this group. This offers important insights for clinical monitoring and management of these adults.</p>
<h4>Article 4: Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954064</a></p>
<p><strong>Summary:</strong> This large study characterized the long-term outcomes associated with class one C antiarrhythmic drug use in 100748 adult patients with atrial fibrillation. The research documented the cardiovascular benefits and safety profile of class one C pharmacotherapy in comparison to rate control strategies over an extended period. The findings provide crucial information regarding the real-world efficacy and safety of these agents for rhythm control. This study contributes significantly to the understanding of optimal management strategies in atrial fibrillation patients.</p>
<h4>Article 5: Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954062" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954062</a></p>
<p><strong>Summary:</strong> This study found that Mycn reactivates the cell cycle in adult cardiomyocytes, a significant discovery given their typically limited capacity for cell cycle re-entry. The research demonstrated that Mycn promotes cardioprotection following myocardial infarction in preclinical models. These findings suggest a novel therapeutic avenue for enhancing cardiac repair after ischemic injury. The study contributes significantly to understanding the role of Myc family isoforms in cardiomyocyte plasticity and regeneration.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery. This large cohort study provided a comprehensive characterization of patient-surgeon sex concordance in relation to clinical outcomes following adult cardiac surgery. The research documented data from 223065 Medicare beneficiaries who underwent coronary artery bypass grafting, surgical aortic valve replacement, or proximal aortic surgery. The study&#8217;s analysis focused on composite outcomes of mortality and morbidity, including myocardial infarction, stroke, and all-cause readmission, stratified by surgeon and patient sex. These findings contribute crucial information for understanding potential sex-based differences in cardiac surgical care.</p>
<p>Article number two. Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity. This retrospective data-linkage study found an increased risk of disabilities in children and adolescents diagnosed with congenital heart disease of any severity. The research revealed a higher prevalence of overall and specific disability service use within this patient group compared to matched controls and siblings. These findings highlight a significant burden of disabilities across all severities of congenital heart disease in pediatric patients. The study provides crucial information for long-term care planning and resource allocation for this population.</p>
<p>Article number three. Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries. This study established the correlates and confirmed the prognostic value of serial N-terminal pro-B-type natriuretic peptide assays in adults with congenitally corrected transposition of the great arteries. The research provided specific data on the role of these measurements for heart failure risk stratification in this distinct patient population. The findings confirm N-terminal pro-B-type natriuretic peptide as a relevant cardiovascular biomarker, addressing previously limited data for this group. This offers important insights for clinical monitoring and management of these adults.</p>
<p>Article number four. Long-Term Outcomes With Class One C Antiarrhythmic Drug Use in Atrial Fibrillation. This large study characterized the long-term outcomes associated with class one C antiarrhythmic drug use in 100748 adult patients with atrial fibrillation. The research documented the cardiovascular benefits and safety profile of class one C pharmacotherapy in comparison to rate control strategies over an extended period. The findings provide crucial information regarding the real-world efficacy and safety of these agents for rhythm control. This study contributes significantly to the understanding of optimal management strategies in atrial fibrillation patients.</p>
<p>Article number five. Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction. This study found that Mycn reactivates the cell cycle in adult cardiomyocytes, a significant discovery given their typically limited capacity for cell cycle re-entry. The research demonstrated that Mycn promotes cardioprotection following myocardial infarction in preclinical models. These findings suggest a novel therapeutic avenue for enhancing cardiac repair after ischemic injury. The study contributes significantly to understanding the role of Myc family isoforms in cardiomyocyte plasticity and regeneration. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pediatric cardiology, morbidity, rate control, cell cycle reactivation, adult cardiac surgery, surgical aortic valve replacement, Mycn, risk stratification, cardiac repair, heart failure, coronary artery bypass grafting, rhythm control, myocardial infarction, N-terminal pro-B-type natriuretic peptide, Patient-surgeon sex concordance, Atrial fibrillation, long-term outcomes, Congenital heart disease, class one C antiarrhythmic drugs, cardiovascular biomarkers, adult cardiomyocytes, cardioprotection, mortality, disability service use, congenitally corrected transposition of the great arteries, disabilities.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/">Mycn Promotes Heart Protection Post M.I. 04/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 12, 2026. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and morbidity. Key takeaway: Mycn Promotes Heart Protection Post M.I..
Article Links:
Article 1: Patient-Surgeon S]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 12, 2026. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and morbidity. Key takeaway: Mycn Promotes Heart Protection Post M.I..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41954068">Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41954067">Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41954066">Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41954064">Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41954062">Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/">https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954068" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954068</a></p>
<p><strong>Summary:</strong> This large cohort study provided a comprehensive characterization of patient-surgeon sex concordance in relation to clinical outcomes following adult cardiac surgery. The research documented data from 223065 Medicare beneficiaries who underwent coronary artery bypass grafting, surgical aortic valve replacement, or proximal aortic surgery. The study&#8217;s analysis focused on composite outcomes of mortality and morbidity, including myocardial infarction, stroke, and all-cause readmission, stratified by surgeon and patient sex. These findings contribute crucial information for understanding potential sex-based differences in cardiac surgical care.</p>
<h4>Article 2: Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954067" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954067</a></p>
<p><strong>Summary:</strong> This retrospective data-linkage study found an increased risk of disabilities in children and adolescents diagnosed with congenital heart disease of any severity. The research revealed a higher prevalence of overall and specific disability service use within this patient group compared to matched controls and siblings. These findings highlight a significant burden of disabilities across all severities of congenital heart disease in pediatric patients. The study provides crucial information for long-term care planning and resource allocation for this population.</p>
<h4>Article 3: Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954066" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954066</a></p>
<p><strong>Summary:</strong> This study established the correlates and confirmed the prognostic value of serial N-terminal pro-B-type natriuretic peptide assays in adults with congenitally corrected transposition of the great arteries. The research provided specific data on the role of these measurements for heart failure risk stratification in this distinct patient population. The findings confirm N-terminal pro-B-type natriuretic peptide as a relevant cardiovascular biomarker, addressing previously limited data for this group. This offers important insights for clinical monitoring and management of these adults.</p>
<h4>Article 4: Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954064</a></p>
<p><strong>Summary:</strong> This large study characterized the long-term outcomes associated with class one C antiarrhythmic drug use in 100748 adult patients with atrial fibrillation. The research documented the cardiovascular benefits and safety profile of class one C pharmacotherapy in comparison to rate control strategies over an extended period. The findings provide crucial information regarding the real-world efficacy and safety of these agents for rhythm control. This study contributes significantly to the understanding of optimal management strategies in atrial fibrillation patients.</p>
<h4>Article 5: Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954062" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954062</a></p>
<p><strong>Summary:</strong> This study found that Mycn reactivates the cell cycle in adult cardiomyocytes, a significant discovery given their typically limited capacity for cell cycle re-entry. The research demonstrated that Mycn promotes cardioprotection following myocardial infarction in preclinical models. These findings suggest a novel therapeutic avenue for enhancing cardiac repair after ischemic injury. The study contributes significantly to understanding the role of Myc family isoforms in cardiomyocyte plasticity and regeneration.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery. This large cohort study provided a comprehensive characterization of patient-surgeon sex concordance in relation to clinical outcomes following adult cardiac surgery. The research documented data from 223065 Medicare beneficiaries who underwent coronary artery bypass grafting, surgical aortic valve replacement, or proximal aortic surgery. The study&#8217;s analysis focused on composite outcomes of mortality and morbidity, including myocardial infarction, stroke, and all-cause readmission, stratified by surgeon and patient sex. These findings contribute crucial information for understanding potential sex-based differences in cardiac surgical care.</p>
<p>Article number two. Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity. This retrospective data-linkage study found an increased risk of disabilities in children and adolescents diagnosed with congenital heart disease of any severity. The research revealed a higher prevalence of overall and specific disability service use within this patient group compared to matched controls and siblings. These findings highlight a significant burden of disabilities across all severities of congenital heart disease in pediatric patients. The study provides crucial information for long-term care planning and resource allocation for this population.</p>
<p>Article number three. Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries. This study established the correlates and confirmed the prognostic value of serial N-terminal pro-B-type natriuretic peptide assays in adults with congenitally corrected transposition of the great arteries. The research provided specific data on the role of these measurements for heart failure risk stratification in this distinct patient population. The findings confirm N-terminal pro-B-type natriuretic peptide as a relevant cardiovascular biomarker, addressing previously limited data for this group. This offers important insights for clinical monitoring and management of these adults.</p>
<p>Article number four. Long-Term Outcomes With Class One C Antiarrhythmic Drug Use in Atrial Fibrillation. This large study characterized the long-term outcomes associated with class one C antiarrhythmic drug use in 100748 adult patients with atrial fibrillation. The research documented the cardiovascular benefits and safety profile of class one C pharmacotherapy in comparison to rate control strategies over an extended period. The findings provide crucial information regarding the real-world efficacy and safety of these agents for rhythm control. This study contributes significantly to the understanding of optimal management strategies in atrial fibrillation patients.</p>
<p>Article number five. Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction. This study found that Mycn reactivates the cell cycle in adult cardiomyocytes, a significant discovery given their typically limited capacity for cell cycle re-entry. The research demonstrated that Mycn promotes cardioprotection following myocardial infarction in preclinical models. These findings suggest a novel therapeutic avenue for enhancing cardiac repair after ischemic injury. The study contributes significantly to understanding the role of Myc family isoforms in cardiomyocyte plasticity and regeneration. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pediatric cardiology, morbidity, rate control, cell cycle reactivation, adult cardiac surgery, surgical aortic valve replacement, Mycn, risk stratification, cardiac repair, heart failure, coronary artery bypass grafting, rhythm control, myocardial infarction, N-terminal pro-B-type natriuretic peptide, Patient-surgeon sex concordance, Atrial fibrillation, long-term outcomes, Congenital heart disease, class one C antiarrhythmic drugs, cardiovascular biomarkers, adult cardiomyocytes, cardioprotection, mortality, disability service use, congenitally corrected transposition of the great arteries, disabilities.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/">Mycn Promotes Heart Protection Post M.I. 04/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260412_060047.mp3" length="4052366" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 12, 2026. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and morbidity. Key takeaway: Mycn Promotes Heart Protection Post M.I..
Article Links:
Article 1: Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery. (Journal of the American Heart Association)
Article 2: Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity. (Journal of the American Heart Association)
Article 3: Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries. (Journal of the American Heart Association)
Article 4: Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation. (Journal of the American Heart Association)
Article 5: Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/mycn-promotes-heart-protection-post-m-i-04-12-26/
 Featured Articles
Article 1: Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41954068
Summary: This large cohort study provided a comprehensive characterization of patient-surgeon sex concordance in relation to clinical outcomes following adult cardiac surgery. The research documented data from 223065 Medicare beneficiaries who underwent coronary artery bypass grafting, surgical aortic valve replacement, or proximal aortic surgery. The study&#8217;s analysis focused on composite outcomes of mortality and morbidity, including myocardial infarction, stroke, and all-cause readmission, stratified by surgeon and patient sex. These findings contribute crucial information for understanding potential sex-based differences in cardiac surgical care.
Article 2: Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41954067
Summary: This retrospective data-linkage study found an increased risk of disabilities in children and adolescents diagnosed with congenital heart disease of any severity. The research revealed a higher prevalence of overall and specific disability service use within this patient group compared to matched controls and siblings. These findings highlight a significant burden of disabilities across all severities of congenital heart disease in pediatric patients. The study provides crucial information for long-term care planning and resource allocation for this population.
Article 3: Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41954066
Summary: This study established the correlates and confirmed the prognostic value of serial N-terminal pro-B-type natriuretic peptide assays in adults with congenitally corrected transposition of the great arteries. The research provided specific data on the role of these measurements for heart failure risk stratification in this distinct patient population. The findings confirm N-terminal pro-B-type natriuretic peptide as a relevant cardiovascular biomarker, addressing previously limited data for this group. This offers important insights for clinical monitoring and management of these adults.
Article 4: Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41954064
Summary: This large study characterized the long-term outcomes associated with class one C antiarrhythmi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 12, 2026. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and morbidity. Key takeaway: Mycn Promotes Heart Protection Post M.I..
Article Links:
Article 1: Patient-Surgeon Sex Concordance and Clinical Outcomes After Adult Cardiac Surgery. (Journal of the American Heart Association)
Article 2: Increased Risk of Disabilities in Children and Adolescents With Congenital Heart Disease of Any Severity. (Journal of the American Heart Association)
Article 3: Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries. (Journal of the American Heart Association)
Article 4: Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation. (Journal of the American Heart Association)
Article 5: Mycn Reactivates the Cell Cycle in Adult Cardiomyocytes and Promotes Cardioprotection in Myocardial Infarction. (Journa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Catheter Ablation Improves RV-PA Coupling in AF 04/11/26</title>
	<link>https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/</link>
	<pubDate>Sat, 11 Apr 2026 12:53:08 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like mineralocorticoid receptor antagonist and Kidney Failure Risk Equation. Key takeaway: Catheter Ablation Improves RV-PA Coupling in AF.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41961636">An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41961632">Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41961588">Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41960759">Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41954073">Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/">https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961636</a></p>
<p><strong>Summary:</strong> The Swedish Heart Failure Registry established a comprehensive integrated biobank, systematically collecting blood and urine samples from heart failure patients across nine hospitals. This resource captures extensive clinomic, proteomic, transcriptomic, and genomic data, coupled with clinical and diagnostic characteristics. The integrated biobank provides a robust platform for advanced research to identify novel biomarkers and understand disease mechanisms in heart failure.</p>
<h4>Article 2: Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961632" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961632</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of 1648 patients from the TOPCAT Americas trial revealed insights into early acute changes in estimated glomerular filtration rate following spironolactone initiation in Heart Failure with Preserved Ejection Fraction (H. F. pEF). The study characterized the frequency and prognostic relevance of these kidney function alterations. The data elucidated implications of these changes for clinical outcomes in patients receiving mineralocorticoid receptor antagonists, providing guidance for therapeutic management.</p>
<h4>Article 3: Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961588" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961588</a></p>
<p><strong>Summary:</strong> This study demonstrated the association of the Kidney Failure Risk Equation (KFRE) score with kidney and cardiovascular outcomes in patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) and chronic kidney disease (C. K. D.). Analyzing data from the PARADIGM-HF trial, the 2- and 5-year KFRE score, which includes urine albumin-creatinine ratio (UACR), age, sex, and estimated glomerular filtration rate (eGFR), predicted risks for both kidney failure and cardiovascular events. The findings support the clinical utility of the KFRE in this heart failure population for prognostication and risk stratification, extending its recommended use beyond general chronic kidney disease.</p>
<h4>Article 4: Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41960759" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41960759</a></p>
<p><strong>Summary:</strong> Analyzing 6814 participants from the Multi-Ethnic Study of Atherosclerosis, this study found a significant association between an individual&#8217;s perceived inadequacy of neighborhood food shopping and an increased risk of incident cardiovascular disease (C. V. D.). The research demonstrated that a subjective perception of poor food shopping options independently predicted adverse cardiovascular outcomes, moving beyond assessments of physical distance or density of food retailers. These findings highlight the importance of individual perceptions of their food environment in assessing and mitigating cardiovascular risk.</p>
<h4>Article 5: Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954073</a></p>
<p><strong>Summary:</strong> This study characterized Right Ventricular-Pulmonary Artery (R. V.-P. A.) coupling in 164 patients with Atrial Fibrillation (A. F.) without a history of heart failure, revealing the prevalence and associated factors of R. V.-P. A. uncoupling in this population. The research demonstrated that catheter ablation (C. A.) effectively led to improvements in R. V.-P. A. adaptation. These findings establish catheter ablation as a beneficial intervention for improving ventricular-arterial coupling in Atrial Fibrillation, potentially influencing heart failure prevention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics. The Swedish Heart Failure Registry established a comprehensive integrated biobank, systematically collecting blood and urine samples from heart failure patients across nine hospitals. This resource captures extensive clinomic, proteomic, transcriptomic, and genomic data, coupled with clinical and diagnostic characteristics. The integrated biobank provides a robust platform for advanced research to identify novel biomarkers and understand disease mechanisms in heart failure.</p>
<p>Article number two. Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas. A post-hoc analysis of 1648 patients from the TOPCAT Americas trial revealed insights into early acute changes in estimated glomerular filtration rate following spironolactone initiation in Heart Failure with Preserved Ejection Fraction (H. F. pEF). The study characterized the frequency and prognostic relevance of these kidney function alterations. The data elucidated implications of these changes for clinical outcomes in patients receiving mineralocorticoid receptor antagonists, providing guidance for therapeutic management.</p>
<p>Article number three. Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF. This study demonstrated the association of the Kidney Failure Risk Equation (KFRE) score with kidney and cardiovascular outcomes in patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) and chronic kidney disease (C. K. D.). Analyzing data from the PARADIGM-HF trial, the 2- and 5-year KFRE score, which includes urine albumin-creatinine ratio (UACR), age, sex, and estimated glomerular filtration rate (eGFR), predicted risks for both kidney failure and cardiovascular events. The findings support the clinical utility of the KFRE in this heart failure population for prognostication and risk stratification, extending its recommended use beyond general chronic kidney disease.</p>
<p>Article number four. Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis. Analyzing 6814 participants from the Multi-Ethnic Study of Atherosclerosis, this study found a significant association between an individual&#8217;s perceived inadequacy of neighborhood food shopping and an increased risk of incident cardiovascular disease (C. V. D.). The research demonstrated that a subjective perception of poor food shopping options independently predicted adverse cardiovascular outcomes, moving beyond assessments of physical distance or density of food retailers. These findings highlight the importance of individual perceptions of their food environment in assessing and mitigating cardiovascular risk.</p>
<p>Article number five. Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation. This study characterized Right Ventricular-Pulmonary Artery (R. V.-P. A.) coupling in 164 patients with Atrial Fibrillation (A. F.) without a history of heart failure, revealing the prevalence and associated factors of R. V.-P. A. uncoupling in this population. The research demonstrated that catheter ablation (C. A.) effectively led to improvements in R. V.-P. A. adaptation. These findings establish catheter ablation as a beneficial intervention for improving ventricular-arterial coupling in Atrial Fibrillation, potentially influencing heart failure prevention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mineralocorticoid receptor antagonist, Kidney Failure Risk Equation, estimated glomerular filtration rate, catheter ablation, Heart Failure with Preserved Ejection Fraction, clinomics, heart failure, heart failure prevention, chronic kidney disease, TOPCAT, Right Ventricular-Pulmonary Artery coupling, biobank, Atrial Fibrillation, Multi-Ethnic Study of Atherosclerosis, Heart Failure with Reduced Ejection Fraction, neighborhood health, PARADIGM-HF, ventricular-arterial coupling, genomics, Swedish Heart Failure Registry, cardiovascular outcomes, food insecurity, Spironolactone, cardiovascular disease risk, Perceived food environment.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/">Catheter Ablation Improves RV-PA Coupling in AF 04/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like mineralocorticoid receptor antagonist and Kidney Failure Risk Equation. Key takeaway: Catheter Ablation Improves RV-PA Coupling in AF.
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like mineralocorticoid receptor antagonist and Kidney Failure Risk Equation. Key takeaway: Catheter Ablation Improves RV-PA Coupling in AF.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41961636">An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41961632">Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41961588">Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41960759">Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41954073">Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/">https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961636</a></p>
<p><strong>Summary:</strong> The Swedish Heart Failure Registry established a comprehensive integrated biobank, systematically collecting blood and urine samples from heart failure patients across nine hospitals. This resource captures extensive clinomic, proteomic, transcriptomic, and genomic data, coupled with clinical and diagnostic characteristics. The integrated biobank provides a robust platform for advanced research to identify novel biomarkers and understand disease mechanisms in heart failure.</p>
<h4>Article 2: Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961632" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961632</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of 1648 patients from the TOPCAT Americas trial revealed insights into early acute changes in estimated glomerular filtration rate following spironolactone initiation in Heart Failure with Preserved Ejection Fraction (H. F. pEF). The study characterized the frequency and prognostic relevance of these kidney function alterations. The data elucidated implications of these changes for clinical outcomes in patients receiving mineralocorticoid receptor antagonists, providing guidance for therapeutic management.</p>
<h4>Article 3: Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41961588" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41961588</a></p>
<p><strong>Summary:</strong> This study demonstrated the association of the Kidney Failure Risk Equation (KFRE) score with kidney and cardiovascular outcomes in patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) and chronic kidney disease (C. K. D.). Analyzing data from the PARADIGM-HF trial, the 2- and 5-year KFRE score, which includes urine albumin-creatinine ratio (UACR), age, sex, and estimated glomerular filtration rate (eGFR), predicted risks for both kidney failure and cardiovascular events. The findings support the clinical utility of the KFRE in this heart failure population for prognostication and risk stratification, extending its recommended use beyond general chronic kidney disease.</p>
<h4>Article 4: Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41960759" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41960759</a></p>
<p><strong>Summary:</strong> Analyzing 6814 participants from the Multi-Ethnic Study of Atherosclerosis, this study found a significant association between an individual&#8217;s perceived inadequacy of neighborhood food shopping and an increased risk of incident cardiovascular disease (C. V. D.). The research demonstrated that a subjective perception of poor food shopping options independently predicted adverse cardiovascular outcomes, moving beyond assessments of physical distance or density of food retailers. These findings highlight the importance of individual perceptions of their food environment in assessing and mitigating cardiovascular risk.</p>
<h4>Article 5: Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41954073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41954073</a></p>
<p><strong>Summary:</strong> This study characterized Right Ventricular-Pulmonary Artery (R. V.-P. A.) coupling in 164 patients with Atrial Fibrillation (A. F.) without a history of heart failure, revealing the prevalence and associated factors of R. V.-P. A. uncoupling in this population. The research demonstrated that catheter ablation (C. A.) effectively led to improvements in R. V.-P. A. adaptation. These findings establish catheter ablation as a beneficial intervention for improving ventricular-arterial coupling in Atrial Fibrillation, potentially influencing heart failure prevention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics. The Swedish Heart Failure Registry established a comprehensive integrated biobank, systematically collecting blood and urine samples from heart failure patients across nine hospitals. This resource captures extensive clinomic, proteomic, transcriptomic, and genomic data, coupled with clinical and diagnostic characteristics. The integrated biobank provides a robust platform for advanced research to identify novel biomarkers and understand disease mechanisms in heart failure.</p>
<p>Article number two. Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas. A post-hoc analysis of 1648 patients from the TOPCAT Americas trial revealed insights into early acute changes in estimated glomerular filtration rate following spironolactone initiation in Heart Failure with Preserved Ejection Fraction (H. F. pEF). The study characterized the frequency and prognostic relevance of these kidney function alterations. The data elucidated implications of these changes for clinical outcomes in patients receiving mineralocorticoid receptor antagonists, providing guidance for therapeutic management.</p>
<p>Article number three. Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF. This study demonstrated the association of the Kidney Failure Risk Equation (KFRE) score with kidney and cardiovascular outcomes in patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) and chronic kidney disease (C. K. D.). Analyzing data from the PARADIGM-HF trial, the 2- and 5-year KFRE score, which includes urine albumin-creatinine ratio (UACR), age, sex, and estimated glomerular filtration rate (eGFR), predicted risks for both kidney failure and cardiovascular events. The findings support the clinical utility of the KFRE in this heart failure population for prognostication and risk stratification, extending its recommended use beyond general chronic kidney disease.</p>
<p>Article number four. Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis. Analyzing 6814 participants from the Multi-Ethnic Study of Atherosclerosis, this study found a significant association between an individual&#8217;s perceived inadequacy of neighborhood food shopping and an increased risk of incident cardiovascular disease (C. V. D.). The research demonstrated that a subjective perception of poor food shopping options independently predicted adverse cardiovascular outcomes, moving beyond assessments of physical distance or density of food retailers. These findings highlight the importance of individual perceptions of their food environment in assessing and mitigating cardiovascular risk.</p>
<p>Article number five. Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation. This study characterized Right Ventricular-Pulmonary Artery (R. V.-P. A.) coupling in 164 patients with Atrial Fibrillation (A. F.) without a history of heart failure, revealing the prevalence and associated factors of R. V.-P. A. uncoupling in this population. The research demonstrated that catheter ablation (C. A.) effectively led to improvements in R. V.-P. A. adaptation. These findings establish catheter ablation as a beneficial intervention for improving ventricular-arterial coupling in Atrial Fibrillation, potentially influencing heart failure prevention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mineralocorticoid receptor antagonist, Kidney Failure Risk Equation, estimated glomerular filtration rate, catheter ablation, Heart Failure with Preserved Ejection Fraction, clinomics, heart failure, heart failure prevention, chronic kidney disease, TOPCAT, Right Ventricular-Pulmonary Artery coupling, biobank, Atrial Fibrillation, Multi-Ethnic Study of Atherosclerosis, Heart Failure with Reduced Ejection Fraction, neighborhood health, PARADIGM-HF, ventricular-arterial coupling, genomics, Swedish Heart Failure Registry, cardiovascular outcomes, food insecurity, Spironolactone, cardiovascular disease risk, Perceived food environment.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/">Catheter Ablation Improves RV-PA Coupling in AF 04/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260411_085154.mp3" length="4416826" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like mineralocorticoid receptor antagonist and Kidney Failure Risk Equation. Key takeaway: Catheter Ablation Improves RV-PA Coupling in AF.
Article Links:
Article 1: An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics. (ESC heart failure)
Article 2: Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas. (European journal of heart failure)
Article 3: Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF. (European journal of heart failure)
Article 4: Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis. (Journal of the American Heart Association)
Article 5: Right Ventricular-Pulmonary Artery Coupling in Patients With Atrial Fibrillation and Changes After Catheter Ablation. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/catheter-ablation-improves-rv-pa-coupling-in-af-04-11-26/
 Featured Articles
Article 1: An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41961636
Summary: The Swedish Heart Failure Registry established a comprehensive integrated biobank, systematically collecting blood and urine samples from heart failure patients across nine hospitals. This resource captures extensive clinomic, proteomic, transcriptomic, and genomic data, coupled with clinical and diagnostic characteristics. The integrated biobank provides a robust platform for advanced research to identify novel biomarkers and understand disease mechanisms in heart failure.
Article 2: Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41961632
Summary: A post-hoc analysis of 1648 patients from the TOPCAT Americas trial revealed insights into early acute changes in estimated glomerular filtration rate following spironolactone initiation in Heart Failure with Preserved Ejection Fraction (H. F. pEF). The study characterized the frequency and prognostic relevance of these kidney function alterations. The data elucidated implications of these changes for clinical outcomes in patients receiving mineralocorticoid receptor antagonists, providing guidance for therapeutic management.
Article 3: Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41961588
Summary: This study demonstrated the association of the Kidney Failure Risk Equation (KFRE) score with kidney and cardiovascular outcomes in patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) and chronic kidney disease (C. K. D.). Analyzing data from the PARADIGM-HF trial, the 2- and 5-year KFRE score, which includes urine albumin-creatinine ratio (UACR), age, sex, and estimated glomerular filtration rate (eGFR), predicted risks for both kidney failure and cardiovascular events. The findings support the clinical utility of the KFRE in this heart failure population for prognostication and risk stratification, extending its recommended use beyond general chronic kidney disease.
Article 4: Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis.
Journal: Journal of the American Heart Associ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like mineralocorticoid receptor antagonist and Kidney Failure Risk Equation. Key takeaway: Catheter Ablation Improves RV-PA Coupling in AF.
Article Links:
Article 1: An integrated Biobank in the Swedish Heart Failure Registry &#8211; clinomics, proteomics, transcriptomics and genomics. (ESC heart failure)
Article 2: Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas. (European journal of heart failure)
Article 3: Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF. (European journal of heart failure)
Article 4: Perceived Inadequate Neighborhood Food Shopping and Cardiovascular Disease Risk: The Multi-Ethnic Study of Atherosclerosis. (Journal of the America]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ML Model Predicts TAVR Mortality, Futility 04/11/26</title>
	<link>https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/</link>
	<pubDate>Sat, 11 Apr 2026 10:01:53 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like Transplantation and Procedural futility. Key takeaway: ML Model Predicts TAVR Mortality, Futility.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41962844">How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41949846">Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41962953">Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40750341">Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40713187">Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/">https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41962844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41962844</a></p>
<p><strong>Summary:</strong> Living donor kidney transplants are crucial for patients needing access to kidney transplantation. Little research had previously quantified living donor kidney transplant behaviors following the COVID-19 pandemic. This study analyzed national Scientific Registry of Transplant Recipients and Census data to characterize contemporary donor and recipient patterns. This investigation established foundational epidemiological context for understanding post-pandemic living donor kidney transplant trends.</p>
<h4>Article 2: Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41949846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41949846</a></p>
<p><strong>Summary:</strong> Low-quality dietary intake is associated with adverse heart failure outcomes. The evidence for food-as-medicine interventions in this patient population remained limited. Researchers conducted a randomized clinical trial to assess the feasibility of providing food supplementation with medically tailored meals or fresh produce. This trial provides foundational insights into the potential clinical associations of such interventions for recently hospitalized heart failure patients.</p>
<h4>Article 3: Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41962953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41962953</a></p>
<p><strong>Summary:</strong> Aortic stenosis is a progressive disease with significant variability in its progression rate. Current surveillance guidelines do not adequately identify individuals at highest risk for rapid hemodynamic deterioration. This retrospective population-based study assessed aortic stenosis progression rates and factors associated with rapid progression using real-world, longitudinal data. This research provides essential insights for refining risk assessment and improving surveillance strategies in aortic stenosis patients.</p>
<h4>Article 4: Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40750341" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40750341</a></p>
<p><strong>Summary:</strong> The heterogeneity of heart failure with preserved ejection fraction (H. F. pEF) presents significant challenges for treatment development. This study characterized distinct subphenogroups of H. F. pEF using a machine-learning-based clustering model. Researchers performed a comprehensive proteomic and pathway analysis on these identified phenogroups. This work provides crucial insights into H. F. pEF heterogeneity to guide tailored therapeutic strategies.</p>
<h4>Article 5: Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40713187" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40713187</a></p>
<p><strong>Summary:</strong> Current risk scores inadequately predict one-year mortality after transcatheter aortic valve replacement (TAVR), limiting their ability to guide decisions on procedural futility. This study developed a parsimonious machine learning model using only preprocedural variables to predict one-year all-cause mortality. The machine learning model was trained on a retrospective cohort of 1025 TAVR patients, incorporating 52 clinical and echocardiographic factors. This innovative model offers an improved tool for guiding patient selection and shared decision-making for TAVR procedures.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis. Living donor kidney transplants are crucial for patients needing access to kidney transplantation. Little research had previously quantified living donor kidney transplant behaviors following the COVID-19 pandemic. This study analyzed national Scientific Registry of Transplant Recipients and Census data to characterize contemporary donor and recipient patterns. This investigation established foundational epidemiological context for understanding post-pandemic living donor kidney transplant trends.</p>
<p>Article number two. Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial. Low-quality dietary intake is associated with adverse heart failure outcomes. The evidence for food-as-medicine interventions in this patient population remained limited. Researchers conducted a randomized clinical trial to assess the feasibility of providing food supplementation with medically tailored meals or fresh produce. This trial provides foundational insights into the potential clinical associations of such interventions for recently hospitalized heart failure patients.</p>
<p>Article number three. Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study. Aortic stenosis is a progressive disease with significant variability in its progression rate. Current surveillance guidelines do not adequately identify individuals at highest risk for rapid hemodynamic deterioration. This retrospective population-based study assessed aortic stenosis progression rates and factors associated with rapid progression using real-world, longitudinal data. This research provides essential insights for refining risk assessment and improving surveillance strategies in aortic stenosis patients.</p>
<p>Article number four. Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis. The heterogeneity of heart failure with preserved ejection fraction (H. F. pEF) presents significant challenges for treatment development. This study characterized distinct subphenogroups of H. F. pEF using a machine-learning-based clustering model. Researchers performed a comprehensive proteomic and pathway analysis on these identified phenogroups. This work provides crucial insights into H. F. pEF heterogeneity to guide tailored therapeutic strategies.</p>
<p>Article number five. Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement. Current risk scores inadequately predict one-year mortality after transcatheter aortic valve replacement (TAVR), limiting their ability to guide decisions on procedural futility. This study developed a parsimonious machine learning model using only preprocedural variables to predict one-year all-cause mortality. The machine learning model was trained on a retrospective cohort of 1025 TAVR patients, incorporating 52 clinical and echocardiographic factors. This innovative model offers an improved tool for guiding patient selection and shared decision-making for TAVR procedures. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transplantation, Procedural futility, Randomized clinical trial, Population-based study, Proteomics, Heart failure with preserved ejection fraction, Living donor kidney transplants, Transcatheter aortic valve replacement, Heart failure, COVID-19 pandemic, Medically tailored meals, One-year mortality, Surveillance guidelines, Machine learning, TAVR, Subphenogroups, H. F. pEF, Risk factors, Dietary intake, Hemodynamic progression, Kidney disease, Pathway analysis, Epidemiological trends, Aortic stenosis, Risk prediction, Food supplementation, Machine learning model.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/">ML Model Predicts TAVR Mortality, Futility 04/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like Transplantation and Procedural futility. Key takeaway: ML Model Predicts TAVR Mortality, Futility.
Article Links:
Article 1: How Contem]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like Transplantation and Procedural futility. Key takeaway: ML Model Predicts TAVR Mortality, Futility.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41962844">How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41949846">Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41962953">Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40750341">Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40713187">Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/">https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41962844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41962844</a></p>
<p><strong>Summary:</strong> Living donor kidney transplants are crucial for patients needing access to kidney transplantation. Little research had previously quantified living donor kidney transplant behaviors following the COVID-19 pandemic. This study analyzed national Scientific Registry of Transplant Recipients and Census data to characterize contemporary donor and recipient patterns. This investigation established foundational epidemiological context for understanding post-pandemic living donor kidney transplant trends.</p>
<h4>Article 2: Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41949846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41949846</a></p>
<p><strong>Summary:</strong> Low-quality dietary intake is associated with adverse heart failure outcomes. The evidence for food-as-medicine interventions in this patient population remained limited. Researchers conducted a randomized clinical trial to assess the feasibility of providing food supplementation with medically tailored meals or fresh produce. This trial provides foundational insights into the potential clinical associations of such interventions for recently hospitalized heart failure patients.</p>
<h4>Article 3: Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41962953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41962953</a></p>
<p><strong>Summary:</strong> Aortic stenosis is a progressive disease with significant variability in its progression rate. Current surveillance guidelines do not adequately identify individuals at highest risk for rapid hemodynamic deterioration. This retrospective population-based study assessed aortic stenosis progression rates and factors associated with rapid progression using real-world, longitudinal data. This research provides essential insights for refining risk assessment and improving surveillance strategies in aortic stenosis patients.</p>
<h4>Article 4: Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40750341" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40750341</a></p>
<p><strong>Summary:</strong> The heterogeneity of heart failure with preserved ejection fraction (H. F. pEF) presents significant challenges for treatment development. This study characterized distinct subphenogroups of H. F. pEF using a machine-learning-based clustering model. Researchers performed a comprehensive proteomic and pathway analysis on these identified phenogroups. This work provides crucial insights into H. F. pEF heterogeneity to guide tailored therapeutic strategies.</p>
<h4>Article 5: Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40713187" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40713187</a></p>
<p><strong>Summary:</strong> Current risk scores inadequately predict one-year mortality after transcatheter aortic valve replacement (TAVR), limiting their ability to guide decisions on procedural futility. This study developed a parsimonious machine learning model using only preprocedural variables to predict one-year all-cause mortality. The machine learning model was trained on a retrospective cohort of 1025 TAVR patients, incorporating 52 clinical and echocardiographic factors. This innovative model offers an improved tool for guiding patient selection and shared decision-making for TAVR procedures.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis. Living donor kidney transplants are crucial for patients needing access to kidney transplantation. Little research had previously quantified living donor kidney transplant behaviors following the COVID-19 pandemic. This study analyzed national Scientific Registry of Transplant Recipients and Census data to characterize contemporary donor and recipient patterns. This investigation established foundational epidemiological context for understanding post-pandemic living donor kidney transplant trends.</p>
<p>Article number two. Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial. Low-quality dietary intake is associated with adverse heart failure outcomes. The evidence for food-as-medicine interventions in this patient population remained limited. Researchers conducted a randomized clinical trial to assess the feasibility of providing food supplementation with medically tailored meals or fresh produce. This trial provides foundational insights into the potential clinical associations of such interventions for recently hospitalized heart failure patients.</p>
<p>Article number three. Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study. Aortic stenosis is a progressive disease with significant variability in its progression rate. Current surveillance guidelines do not adequately identify individuals at highest risk for rapid hemodynamic deterioration. This retrospective population-based study assessed aortic stenosis progression rates and factors associated with rapid progression using real-world, longitudinal data. This research provides essential insights for refining risk assessment and improving surveillance strategies in aortic stenosis patients.</p>
<p>Article number four. Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis. The heterogeneity of heart failure with preserved ejection fraction (H. F. pEF) presents significant challenges for treatment development. This study characterized distinct subphenogroups of H. F. pEF using a machine-learning-based clustering model. Researchers performed a comprehensive proteomic and pathway analysis on these identified phenogroups. This work provides crucial insights into H. F. pEF heterogeneity to guide tailored therapeutic strategies.</p>
<p>Article number five. Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement. Current risk scores inadequately predict one-year mortality after transcatheter aortic valve replacement (TAVR), limiting their ability to guide decisions on procedural futility. This study developed a parsimonious machine learning model using only preprocedural variables to predict one-year all-cause mortality. The machine learning model was trained on a retrospective cohort of 1025 TAVR patients, incorporating 52 clinical and echocardiographic factors. This innovative model offers an improved tool for guiding patient selection and shared decision-making for TAVR procedures. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transplantation, Procedural futility, Randomized clinical trial, Population-based study, Proteomics, Heart failure with preserved ejection fraction, Living donor kidney transplants, Transcatheter aortic valve replacement, Heart failure, COVID-19 pandemic, Medically tailored meals, One-year mortality, Surveillance guidelines, Machine learning, TAVR, Subphenogroups, H. F. pEF, Risk factors, Dietary intake, Hemodynamic progression, Kidney disease, Pathway analysis, Epidemiological trends, Aortic stenosis, Risk prediction, Food supplementation, Machine learning model.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/">ML Model Predicts TAVR Mortality, Futility 04/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260411_060047.mp3" length="3889780" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like Transplantation and Procedural futility. Key takeaway: ML Model Predicts TAVR Mortality, Futility.
Article Links:
Article 1: How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial. (JAMA cardiology)
Article 3: Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study. (Heart (British Cardiac Society))
Article 4: Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis. (Heart (British Cardiac Society))
Article 5: Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/ml-model-predicts-tavr-mortality-futility-04-11-26/
 Featured Articles
Article 1: How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41962844
Summary: Living donor kidney transplants are crucial for patients needing access to kidney transplantation. Little research had previously quantified living donor kidney transplant behaviors following the COVID-19 pandemic. This study analyzed national Scientific Registry of Transplant Recipients and Census data to characterize contemporary donor and recipient patterns. This investigation established foundational epidemiological context for understanding post-pandemic living donor kidney transplant trends.
Article 2: Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41949846
Summary: Low-quality dietary intake is associated with adverse heart failure outcomes. The evidence for food-as-medicine interventions in this patient population remained limited. Researchers conducted a randomized clinical trial to assess the feasibility of providing food supplementation with medically tailored meals or fresh produce. This trial provides foundational insights into the potential clinical associations of such interventions for recently hospitalized heart failure patients.
Article 3: Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41962953
Summary: Aortic stenosis is a progressive disease with significant variability in its progression rate. Current surveillance guidelines do not adequately identify individuals at highest risk for rapid hemodynamic deterioration. This retrospective population-based study assessed aortic stenosis progression rates and factors associated with rapid progression using real-world, longitudinal data. This research provides essential insights for refining risk assessment and improving surveillance strategies in aortic stenosis patients.
Article 4: Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40750341
Summary: The heterogeneity of heart failure with preserved ejection fraction (H. F. pEF) presents significant challenges for treatment development. This study characterized distinct subphenogroups of H. F. pEF using a machine-learning-]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 11, 2026. This episode summarizes 5 key cardiology studies on topics like Transplantation and Procedural futility. Key takeaway: ML Model Predicts TAVR Mortality, Futility.
Article Links:
Article 1: How Contemporary Living Kidney Donor Transplants Compare to pre-Pandemic Trends: An Interrupted Time Series Analysis. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial. (JAMA cardiology)
Article 3: Risk factor profiles and haemodynamic progression in aortic stenosis: a retrospective population-based study. (Heart (British Cardiac Society))
Article 4: Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysis. (Heart (British Cardiac Society))
Article 5: Parsimonious machine learning model ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Nurses Cut Stroke BP with Phone Intervention 04/10/26</title>
	<link>https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/</link>
	<pubDate>Fri, 10 Apr 2026 10:01:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 10, 2026. This episode summarizes 5 key cardiology studies on topics like blood pressure control and trophoblast differentiation. Key takeaway: Nurses Cut Stroke BP with Phone Intervention.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41739022">Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024).</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41953989">Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41953982">Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41955077">Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41949873">Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/">https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024).</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739022" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739022</a></p>
<p><strong>Summary:</strong> The PERT Consortium Registry analyzed trends in the use of catheter-directed thrombolysis and mechanical thrombectomy for acute pulmonary embolism between 2016 and 2024. This registry provided real-world data on the diffusion of these catheter-based interventions, including patient and imaging characteristics. It further documented institutional variation in the application of catheter-directed thrombolysis and mechanical thrombectomy in clinical practice. The findings offer concrete insights into contemporary management strategies for acute pulmonary embolism.</p>
<h4>Article 2: Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41953989" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41953989</a></p>
<p><strong>Summary:</strong> Human single-cell and spatial analyses, along with in vitro and in vivo models, demonstrated that VGLL3, a transcription coregulator in the Hippo pathway, is upregulated in preeclamptic placentas. This upregulation of VGLL3 promotes immune dysregulation, defective trophoblast differentiation, and endothelial dysfunction. The data revealed that these pathological processes coalesce on a placental VGLL3-centered gene network. This identifies VGLL3 as a key orchestrator of molecular events underlying preeclampsia development.</p>
<h4>Article 3: Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41953982" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41953982</a></p>
<p><strong>Summary:</strong> The PINGS, Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke, trial was a randomized multicenter phase three study conducted in Ghana. This trial found that a phone-based intervention, led by nurses, effectively improved blood pressure control among patients with recent stroke. The study demonstrated this intervention as a pragmatic and scalable strategy to address the burden of stroke in resource-limited African settings. These results provide a clinically significant approach for managing hypertension after stroke in low-income countries.</p>
<h4>Article 4: Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41955077" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41955077</a></p>
<p><strong>Summary:</strong> This retrospective study analyzed 967 individuals from 431 families with hereditary transthyretin amyloidosis, ATTRv, across 15 Italian referral centers from 2004 to 2024. The analysis precisely categorized participants into ATTRv index cases, genotype-positive/phenotype-positive symptomatic carriers, and asymptomatic carriers. This comprehensive dataset provided concrete information regarding the diagnostic and prognostic impact of cascade genetic screening within these families. The findings demonstrated the real-world application and yielded implications for early detection and disease management in hereditary transthyretin amyloidosis.</p>
<h4>Article 5: Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41949873" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41949873</a></p>
<p><strong>Summary:</strong> Exercise stress testing remains the primary method for provoking adrenergically mediated ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia, CPVT. Traditional protocols, like the Bruce protocol, often demonstrate limitations in diagnostic sensitivity for CPVT. The study evaluated the diagnostic yield of a sudden high-intensity Burst exercise protocol, developed as a more effective approach for unmasking arrhythmias. This novel testing method directly addresses the diagnostic challenges presented by traditional exercise protocols in catecholaminergic polymorphic ventricular tachycardia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024). The PERT Consortium Registry analyzed trends in the use of catheter-directed thrombolysis and mechanical thrombectomy for acute pulmonary embolism between 2016 and 2024. This registry provided real-world data on the diffusion of these catheter-based interventions, including patient and imaging characteristics. It further documented institutional variation in the application of catheter-directed thrombolysis and mechanical thrombectomy in clinical practice. The findings offer concrete insights into contemporary management strategies for acute pulmonary embolism.</p>
<p>Article number two. Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network. Human single-cell and spatial analyses, along with in vitro and in vivo models, demonstrated that VGLL3, a transcription coregulator in the Hippo pathway, is upregulated in preeclamptic placentas. This upregulation of VGLL3 promotes immune dysregulation, defective trophoblast differentiation, and endothelial dysfunction. The data revealed that these pathological processes coalesce on a placental VGLL3-centered gene network. This identifies VGLL3 as a key orchestrator of molecular events underlying preeclampsia development.</p>
<p>Article number three. Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. The PINGS, Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke, trial was a randomized multicenter phase three study conducted in Ghana. This trial found that a phone-based intervention, led by nurses, effectively improved blood pressure control among patients with recent stroke. The study demonstrated this intervention as a pragmatic and scalable strategy to address the burden of stroke in resource-limited African settings. These results provide a clinically significant approach for managing hypertension after stroke in low-income countries.</p>
<p>Article number four. Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact. This retrospective study analyzed 967 individuals from 431 families with hereditary transthyretin amyloidosis, ATTRv, across 15 Italian referral centers from 2004 to 2024. The analysis precisely categorized participants into ATTRv index cases, genotype-positive/phenotype-positive symptomatic carriers, and asymptomatic carriers. This comprehensive dataset provided concrete information regarding the diagnostic and prognostic impact of cascade genetic screening within these families. The findings demonstrated the real-world application and yielded implications for early detection and disease management in hereditary transthyretin amyloidosis.</p>
<p>Article number five. Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia. Exercise stress testing remains the primary method for provoking adrenergically mediated ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia, CPVT. Traditional protocols, like the Bruce protocol, often demonstrate limitations in diagnostic sensitivity for CPVT. The study evaluated the diagnostic yield of a sudden high-intensity Burst exercise protocol, developed as a more effective approach for unmasking arrhythmias. This novel testing method directly addresses the diagnostic challenges presented by traditional exercise protocols in catecholaminergic polymorphic ventricular tachycardia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>blood pressure control, trophoblast differentiation, arrhythmia, catheter-directed thrombolysis, asymptomatic carriers, Ghana, VGLL3, endothelial dysfunction, mobile health, immune dysregulation, mechanical thrombectomy, acute pulmonary embolism, placental gene network, cascade genetic screening, stroke, pulmonary embolism, preeclampsia, nurse-led intervention, diagnostic yield, catecholaminergic polymorphic ventricular tachycardia, Burst protocol, hereditary transthyretin amyloidosis, ATTRv, exercise stress testing, symptomatic carriers, PERT Consortium, CPVT, hypertension.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/">Nurses Cut Stroke BP with Phone Intervention 04/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 10, 2026. This episode summarizes 5 key cardiology studies on topics like blood pressure control and trophoblast differentiation. Key takeaway: Nurses Cut Stroke BP with Phone Intervention.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 10, 2026. This episode summarizes 5 key cardiology studies on topics like blood pressure control and trophoblast differentiation. Key takeaway: Nurses Cut Stroke BP with Phone Intervention.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41739022">Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024).</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41953989">Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41953982">Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41955077">Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41949873">Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/">https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024).</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739022" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739022</a></p>
<p><strong>Summary:</strong> The PERT Consortium Registry analyzed trends in the use of catheter-directed thrombolysis and mechanical thrombectomy for acute pulmonary embolism between 2016 and 2024. This registry provided real-world data on the diffusion of these catheter-based interventions, including patient and imaging characteristics. It further documented institutional variation in the application of catheter-directed thrombolysis and mechanical thrombectomy in clinical practice. The findings offer concrete insights into contemporary management strategies for acute pulmonary embolism.</p>
<h4>Article 2: Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41953989" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41953989</a></p>
<p><strong>Summary:</strong> Human single-cell and spatial analyses, along with in vitro and in vivo models, demonstrated that VGLL3, a transcription coregulator in the Hippo pathway, is upregulated in preeclamptic placentas. This upregulation of VGLL3 promotes immune dysregulation, defective trophoblast differentiation, and endothelial dysfunction. The data revealed that these pathological processes coalesce on a placental VGLL3-centered gene network. This identifies VGLL3 as a key orchestrator of molecular events underlying preeclampsia development.</p>
<h4>Article 3: Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41953982" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41953982</a></p>
<p><strong>Summary:</strong> The PINGS, Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke, trial was a randomized multicenter phase three study conducted in Ghana. This trial found that a phone-based intervention, led by nurses, effectively improved blood pressure control among patients with recent stroke. The study demonstrated this intervention as a pragmatic and scalable strategy to address the burden of stroke in resource-limited African settings. These results provide a clinically significant approach for managing hypertension after stroke in low-income countries.</p>
<h4>Article 4: Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41955077" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41955077</a></p>
<p><strong>Summary:</strong> This retrospective study analyzed 967 individuals from 431 families with hereditary transthyretin amyloidosis, ATTRv, across 15 Italian referral centers from 2004 to 2024. The analysis precisely categorized participants into ATTRv index cases, genotype-positive/phenotype-positive symptomatic carriers, and asymptomatic carriers. This comprehensive dataset provided concrete information regarding the diagnostic and prognostic impact of cascade genetic screening within these families. The findings demonstrated the real-world application and yielded implications for early detection and disease management in hereditary transthyretin amyloidosis.</p>
<h4>Article 5: Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41949873" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41949873</a></p>
<p><strong>Summary:</strong> Exercise stress testing remains the primary method for provoking adrenergically mediated ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia, CPVT. Traditional protocols, like the Bruce protocol, often demonstrate limitations in diagnostic sensitivity for CPVT. The study evaluated the diagnostic yield of a sudden high-intensity Burst exercise protocol, developed as a more effective approach for unmasking arrhythmias. This novel testing method directly addresses the diagnostic challenges presented by traditional exercise protocols in catecholaminergic polymorphic ventricular tachycardia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024). The PERT Consortium Registry analyzed trends in the use of catheter-directed thrombolysis and mechanical thrombectomy for acute pulmonary embolism between 2016 and 2024. This registry provided real-world data on the diffusion of these catheter-based interventions, including patient and imaging characteristics. It further documented institutional variation in the application of catheter-directed thrombolysis and mechanical thrombectomy in clinical practice. The findings offer concrete insights into contemporary management strategies for acute pulmonary embolism.</p>
<p>Article number two. Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network. Human single-cell and spatial analyses, along with in vitro and in vivo models, demonstrated that VGLL3, a transcription coregulator in the Hippo pathway, is upregulated in preeclamptic placentas. This upregulation of VGLL3 promotes immune dysregulation, defective trophoblast differentiation, and endothelial dysfunction. The data revealed that these pathological processes coalesce on a placental VGLL3-centered gene network. This identifies VGLL3 as a key orchestrator of molecular events underlying preeclampsia development.</p>
<p>Article number three. Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. The PINGS, Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke, trial was a randomized multicenter phase three study conducted in Ghana. This trial found that a phone-based intervention, led by nurses, effectively improved blood pressure control among patients with recent stroke. The study demonstrated this intervention as a pragmatic and scalable strategy to address the burden of stroke in resource-limited African settings. These results provide a clinically significant approach for managing hypertension after stroke in low-income countries.</p>
<p>Article number four. Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact. This retrospective study analyzed 967 individuals from 431 families with hereditary transthyretin amyloidosis, ATTRv, across 15 Italian referral centers from 2004 to 2024. The analysis precisely categorized participants into ATTRv index cases, genotype-positive/phenotype-positive symptomatic carriers, and asymptomatic carriers. This comprehensive dataset provided concrete information regarding the diagnostic and prognostic impact of cascade genetic screening within these families. The findings demonstrated the real-world application and yielded implications for early detection and disease management in hereditary transthyretin amyloidosis.</p>
<p>Article number five. Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia. Exercise stress testing remains the primary method for provoking adrenergically mediated ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia, CPVT. Traditional protocols, like the Bruce protocol, often demonstrate limitations in diagnostic sensitivity for CPVT. The study evaluated the diagnostic yield of a sudden high-intensity Burst exercise protocol, developed as a more effective approach for unmasking arrhythmias. This novel testing method directly addresses the diagnostic challenges presented by traditional exercise protocols in catecholaminergic polymorphic ventricular tachycardia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>blood pressure control, trophoblast differentiation, arrhythmia, catheter-directed thrombolysis, asymptomatic carriers, Ghana, VGLL3, endothelial dysfunction, mobile health, immune dysregulation, mechanical thrombectomy, acute pulmonary embolism, placental gene network, cascade genetic screening, stroke, pulmonary embolism, preeclampsia, nurse-led intervention, diagnostic yield, catecholaminergic polymorphic ventricular tachycardia, Burst protocol, hereditary transthyretin amyloidosis, ATTRv, exercise stress testing, symptomatic carriers, PERT Consortium, CPVT, hypertension.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/">Nurses Cut Stroke BP with Phone Intervention 04/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260410_060034.mp3" length="4630403" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 10, 2026. This episode summarizes 5 key cardiology studies on topics like blood pressure control and trophoblast differentiation. Key takeaway: Nurses Cut Stroke BP with Phone Intervention.
Article Links:
Article 1: Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024). (Journal of the American College of Cardiology)
Article 2: Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network. (Circulation)
Article 3: Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. (Circulation)
Article 4: Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact. (European heart journal)
Article 5: Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/nurses-cut-stroke-bp-with-phone-intervention-04-10-26/
 Featured Articles
Article 1: Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024).
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41739022
Summary: The PERT Consortium Registry analyzed trends in the use of catheter-directed thrombolysis and mechanical thrombectomy for acute pulmonary embolism between 2016 and 2024. This registry provided real-world data on the diffusion of these catheter-based interventions, including patient and imaging characteristics. It further documented institutional variation in the application of catheter-directed thrombolysis and mechanical thrombectomy in clinical practice. The findings offer concrete insights into contemporary management strategies for acute pulmonary embolism.
Article 2: Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41953989
Summary: Human single-cell and spatial analyses, along with in vitro and in vivo models, demonstrated that VGLL3, a transcription coregulator in the Hippo pathway, is upregulated in preeclamptic placentas. This upregulation of VGLL3 promotes immune dysregulation, defective trophoblast differentiation, and endothelial dysfunction. The data revealed that these pathological processes coalesce on a placental VGLL3-centered gene network. This identifies VGLL3 as a key orchestrator of molecular events underlying preeclampsia development.
Article 3: Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41953982
Summary: The PINGS, Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke, trial was a randomized multicenter phase three study conducted in Ghana. This trial found that a phone-based intervention, led by nurses, effectively improved blood pressure control among patients with recent stroke. The study demonstrated this intervention as a pragmatic and scalable strategy to address the burden of stroke in resource-limited African settings. These results provide a clinically significant approach for managing hypertension after stroke in low-income countries.
Article 4: Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41955077
Summary: This retrospective study analyzed 967 individuals from 431 families with hereditary transthyretin amylo]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 10, 2026. This episode summarizes 5 key cardiology studies on topics like blood pressure control and trophoblast differentiation. Key takeaway: Nurses Cut Stroke BP with Phone Intervention.
Article Links:
Article 1: Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024). (Journal of the American College of Cardiology)
Article 2: Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network. (Circulation)
Article 3: Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. (Circulation)
Article 4: Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact. (European heart journal)
Article 5: Burst Exercise Stress]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>RBM20 Gene Links to Arrhythmogenic Cardiomyopathy 04/09/26</title>
	<link>https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/</link>
	<pubDate>Thu, 09 Apr 2026 10:01:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 09, 2026. This episode summarizes 5 key cardiology studies on topics like atherosclerotic cardiovascular disease and heart failure with preserved ejection fraction. Key takeaway: RBM20 Gene Links to Arrhythmogenic Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41950472">Multifaceted Strategies for Hypertension Control in Low-Income Patients.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41910315">Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41951134">Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41950988">Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</a> (Journal of cardiac failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41949880">RBM20 Truncating Variants and Human Cardiomyopathy.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/">https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Multifaceted Strategies for Hypertension Control in Low-Income Patients.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41950472" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41950472</a></p>
<p><strong>Summary:</strong> Uncontrolled hypertension disproportionately impacts populations with substantial health disparities, underscoring the importance of targeted interventions. Multifaceted, team-based strategies represent a key therapeutic approach for hypertension control in low-income patients. These strategies involve comprehensive implementation within federally qualified health center clinics. Such approaches are critical for addressing health inequities in communities with high rates of uncontrolled hypertension.</p>
<h4>Article 2: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910315" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910315</a></p>
<p><strong>Summary:</strong> Intensive low-density lipoprotein cholesterol targeting is a primary therapeutic approach rigorously evaluated for secondary prevention in patients with atherosclerotic cardiovascular disease. A trial compared targeting low-density lipoprotein cholesterol to less than 55 mg per deciliter against a target of 70 to 100 mg per deciliter. This direct comparison clarifies optimal lipid management strategies and informs guideline recommendations. The evaluation provides essential insights into reducing cardiovascular risk through aggressive low-density lipoprotein cholesterol reduction.</p>
<h4>Article 3: Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41951134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41951134</a></p>
<p><strong>Summary:</strong> Understanding trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies is a critical area of clinical investigation. Patient severity in cardiogenic shock is characterized using Society for Cardiovascular Angiography and Interventions stages, machine learning-derived phenotypes, and the Comorbidity Risk Index. These comprehensive tools offer advanced stratification to guide management. The comparison of patients receiving heart replacement therapies versus no therapy during index hospitalization provides crucial insights for optimizing patient care.</p>
<h4>Article 4: Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41950988" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41950988</a></p>
<p><strong>Summary:</strong> Multiple algorithms, including HFpEF-ABA, H₂FPEF, and HFA-PEFF, provide valuable tools for improving diagnosis and risk stratification in heart failure with preserved ejection fraction. An analysis confirmed the utility of these models in assessing clinical outcomes among individuals with established heart failure with preserved ejection fraction. The algorithms enhance understanding of both clinical trajectories and trial-specific treatment effects. This comprehensive evaluation clarifies the role of these scores in precisely characterizing the heterogeneous heart failure with preserved ejection fraction population.</p>
<h4>Article 5: RBM20 Truncating Variants and Human Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41949880" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41949880</a></p>
<p><strong>Summary:</strong> Pathogenic or likely pathogenic missense variants in the RBM20 gene are definitively linked to a highly penetrant arrhythmogenic dilated cardiomyopathy. This genetic diagnosis plays an increasingly important role in guiding clinical decision making for patients with dilated cardiomyopathy. The contribution of RBM20 truncating variants requires further evaluation to refine genetic diagnosis for arrhythmogenic dilated cardiomyopathy. These genetic insights provide critical information for patient management and understanding disease mechanisms.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Multifaceted Strategies for Hypertension Control in Low-Income Patients. Uncontrolled hypertension disproportionately impacts populations with substantial health disparities, underscoring the importance of targeted interventions. Multifaceted, team-based strategies represent a key therapeutic approach for hypertension control in low-income patients. These strategies involve comprehensive implementation within federally qualified health center clinics. Such approaches are critical for addressing health inequities in communities with high rates of uncontrolled hypertension.</p>
<p>Article number two. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. Intensive low-density lipoprotein cholesterol targeting is a primary therapeutic approach rigorously evaluated for secondary prevention in patients with atherosclerotic cardiovascular disease. A trial compared targeting low-density lipoprotein cholesterol to less than 55 mg per deciliter against a target of 70 to 100 mg per deciliter. This direct comparison clarifies optimal lipid management strategies and informs guideline recommendations. The evaluation provides essential insights into reducing cardiovascular risk through aggressive low-density lipoprotein cholesterol reduction.</p>
<p>Article number three. Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies. Understanding trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies is a critical area of clinical investigation. Patient severity in cardiogenic shock is characterized using Society for Cardiovascular Angiography and Interventions stages, machine learning-derived phenotypes, and the Comorbidity Risk Index. These comprehensive tools offer advanced stratification to guide management. The comparison of patients receiving heart replacement therapies versus no therapy during index hospitalization provides crucial insights for optimizing patient care.</p>
<p>Article number four. Performance of the HFpEF-ABA, H₂FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials. Multiple algorithms, including HFpEF-ABA, H₂FPEF, and HFA-PEFF, provide valuable tools for improving diagnosis and risk stratification in heart failure with preserved ejection fraction. An analysis confirmed the utility of these models in assessing clinical outcomes among individuals with established heart failure with preserved ejection fraction. The algorithms enhance understanding of both clinical trajectories and trial-specific treatment effects. This comprehensive evaluation clarifies the role of these scores in precisely characterizing the heterogeneous heart failure with preserved ejection fraction population.</p>
<p>Article number five. RBM20 Truncating Variants and Human Cardiomyopathy. Pathogenic or likely pathogenic missense variants in the RBM20 gene are definitively linked to a highly penetrant arrhythmogenic dilated cardiomyopathy. This genetic diagnosis plays an increasingly important role in guiding clinical decision making for patients with dilated cardiomyopathy. The contribution of RBM20 truncating variants requires further evaluation to refine genetic diagnosis for arrhythmogenic dilated cardiomyopathy. These genetic insights provide critical information for patient management and understanding disease mechanisms. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, lipid management, HFA-PEFF, risk stratification, hypertension control, secondary prevention, team-based care, arrhythmogenic cardiomyopathy, cardiogenic shock, truncating variants, diagnostic algorithms, comorbidity risk index, low-income patients, Society for Cardiovascular Angiography and Interventions stages, machine learning phenotypes, dilated cardiomyopathy, heart replacement therapies, HFpEF-ABA, H₂FPEF, RBM20 gene, health disparities, genetic diagnosis, low-density lipoprotein cholesterol, federally qualified health centers, intensive targeting.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/">RBM20 Gene Links to Arrhythmogenic Cardiomyopathy 04/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 09, 2026. This episode summarizes 5 key cardiology studies on topics like atherosclerotic cardiovascular disease and heart failure with preserved ejection fraction. Key takeaway: RBM20 Gene Links to Arrhythmog]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 09, 2026. This episode summarizes 5 key cardiology studies on topics like atherosclerotic cardiovascular disease and heart failure with preserved ejection fraction. Key takeaway: RBM20 Gene Links to Arrhythmogenic Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41950472">Multifaceted Strategies for Hypertension Control in Low-Income Patients.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41910315">Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41951134">Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41950988">Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</a> (Journal of cardiac failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41949880">RBM20 Truncating Variants and Human Cardiomyopathy.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/">https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Multifaceted Strategies for Hypertension Control in Low-Income Patients.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41950472" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41950472</a></p>
<p><strong>Summary:</strong> Uncontrolled hypertension disproportionately impacts populations with substantial health disparities, underscoring the importance of targeted interventions. Multifaceted, team-based strategies represent a key therapeutic approach for hypertension control in low-income patients. These strategies involve comprehensive implementation within federally qualified health center clinics. Such approaches are critical for addressing health inequities in communities with high rates of uncontrolled hypertension.</p>
<h4>Article 2: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910315" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910315</a></p>
<p><strong>Summary:</strong> Intensive low-density lipoprotein cholesterol targeting is a primary therapeutic approach rigorously evaluated for secondary prevention in patients with atherosclerotic cardiovascular disease. A trial compared targeting low-density lipoprotein cholesterol to less than 55 mg per deciliter against a target of 70 to 100 mg per deciliter. This direct comparison clarifies optimal lipid management strategies and informs guideline recommendations. The evaluation provides essential insights into reducing cardiovascular risk through aggressive low-density lipoprotein cholesterol reduction.</p>
<h4>Article 3: Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41951134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41951134</a></p>
<p><strong>Summary:</strong> Understanding trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies is a critical area of clinical investigation. Patient severity in cardiogenic shock is characterized using Society for Cardiovascular Angiography and Interventions stages, machine learning-derived phenotypes, and the Comorbidity Risk Index. These comprehensive tools offer advanced stratification to guide management. The comparison of patients receiving heart replacement therapies versus no therapy during index hospitalization provides crucial insights for optimizing patient care.</p>
<h4>Article 4: Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41950988" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41950988</a></p>
<p><strong>Summary:</strong> Multiple algorithms, including HFpEF-ABA, H₂FPEF, and HFA-PEFF, provide valuable tools for improving diagnosis and risk stratification in heart failure with preserved ejection fraction. An analysis confirmed the utility of these models in assessing clinical outcomes among individuals with established heart failure with preserved ejection fraction. The algorithms enhance understanding of both clinical trajectories and trial-specific treatment effects. This comprehensive evaluation clarifies the role of these scores in precisely characterizing the heterogeneous heart failure with preserved ejection fraction population.</p>
<h4>Article 5: RBM20 Truncating Variants and Human Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41949880" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41949880</a></p>
<p><strong>Summary:</strong> Pathogenic or likely pathogenic missense variants in the RBM20 gene are definitively linked to a highly penetrant arrhythmogenic dilated cardiomyopathy. This genetic diagnosis plays an increasingly important role in guiding clinical decision making for patients with dilated cardiomyopathy. The contribution of RBM20 truncating variants requires further evaluation to refine genetic diagnosis for arrhythmogenic dilated cardiomyopathy. These genetic insights provide critical information for patient management and understanding disease mechanisms.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Multifaceted Strategies for Hypertension Control in Low-Income Patients. Uncontrolled hypertension disproportionately impacts populations with substantial health disparities, underscoring the importance of targeted interventions. Multifaceted, team-based strategies represent a key therapeutic approach for hypertension control in low-income patients. These strategies involve comprehensive implementation within federally qualified health center clinics. Such approaches are critical for addressing health inequities in communities with high rates of uncontrolled hypertension.</p>
<p>Article number two. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. Intensive low-density lipoprotein cholesterol targeting is a primary therapeutic approach rigorously evaluated for secondary prevention in patients with atherosclerotic cardiovascular disease. A trial compared targeting low-density lipoprotein cholesterol to less than 55 mg per deciliter against a target of 70 to 100 mg per deciliter. This direct comparison clarifies optimal lipid management strategies and informs guideline recommendations. The evaluation provides essential insights into reducing cardiovascular risk through aggressive low-density lipoprotein cholesterol reduction.</p>
<p>Article number three. Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies. Understanding trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies is a critical area of clinical investigation. Patient severity in cardiogenic shock is characterized using Society for Cardiovascular Angiography and Interventions stages, machine learning-derived phenotypes, and the Comorbidity Risk Index. These comprehensive tools offer advanced stratification to guide management. The comparison of patients receiving heart replacement therapies versus no therapy during index hospitalization provides crucial insights for optimizing patient care.</p>
<p>Article number four. Performance of the HFpEF-ABA, H₂FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials. Multiple algorithms, including HFpEF-ABA, H₂FPEF, and HFA-PEFF, provide valuable tools for improving diagnosis and risk stratification in heart failure with preserved ejection fraction. An analysis confirmed the utility of these models in assessing clinical outcomes among individuals with established heart failure with preserved ejection fraction. The algorithms enhance understanding of both clinical trajectories and trial-specific treatment effects. This comprehensive evaluation clarifies the role of these scores in precisely characterizing the heterogeneous heart failure with preserved ejection fraction population.</p>
<p>Article number five. RBM20 Truncating Variants and Human Cardiomyopathy. Pathogenic or likely pathogenic missense variants in the RBM20 gene are definitively linked to a highly penetrant arrhythmogenic dilated cardiomyopathy. This genetic diagnosis plays an increasingly important role in guiding clinical decision making for patients with dilated cardiomyopathy. The contribution of RBM20 truncating variants requires further evaluation to refine genetic diagnosis for arrhythmogenic dilated cardiomyopathy. These genetic insights provide critical information for patient management and understanding disease mechanisms. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, lipid management, HFA-PEFF, risk stratification, hypertension control, secondary prevention, team-based care, arrhythmogenic cardiomyopathy, cardiogenic shock, truncating variants, diagnostic algorithms, comorbidity risk index, low-income patients, Society for Cardiovascular Angiography and Interventions stages, machine learning phenotypes, dilated cardiomyopathy, heart replacement therapies, HFpEF-ABA, H₂FPEF, RBM20 gene, health disparities, genetic diagnosis, low-density lipoprotein cholesterol, federally qualified health centers, intensive targeting.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/">RBM20 Gene Links to Arrhythmogenic Cardiomyopathy 04/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260409_060035.mp3" length="3957907" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 09, 2026. This episode summarizes 5 key cardiology studies on topics like atherosclerotic cardiovascular disease and heart failure with preserved ejection fraction. Key takeaway: RBM20 Gene Links to Arrhythmogenic Cardiomyopathy.
Article Links:
Article 1: Multifaceted Strategies for Hypertension Control in Low-Income Patients. (The New England journal of medicine)
Article 2: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. (The New England journal of medicine)
Article 3: Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials. (Journal of cardiac failure)
Article 5: RBM20 Truncating Variants and Human Cardiomyopathy. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/rbm20-gene-links-to-arrhythmogenic-cardiomyopathy-04-09-26/
 Featured Articles
Article 1: Multifaceted Strategies for Hypertension Control in Low-Income Patients.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41950472
Summary: Uncontrolled hypertension disproportionately impacts populations with substantial health disparities, underscoring the importance of targeted interventions. Multifaceted, team-based strategies represent a key therapeutic approach for hypertension control in low-income patients. These strategies involve comprehensive implementation within federally qualified health center clinics. Such approaches are critical for addressing health inequities in communities with high rates of uncontrolled hypertension.
Article 2: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910315
Summary: Intensive low-density lipoprotein cholesterol targeting is a primary therapeutic approach rigorously evaluated for secondary prevention in patients with atherosclerotic cardiovascular disease. A trial compared targeting low-density lipoprotein cholesterol to less than 55 mg per deciliter against a target of 70 to 100 mg per deciliter. This direct comparison clarifies optimal lipid management strategies and informs guideline recommendations. The evaluation provides essential insights into reducing cardiovascular risk through aggressive low-density lipoprotein cholesterol reduction.
Article 3: Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41951134
Summary: Understanding trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies is a critical area of clinical investigation. Patient severity in cardiogenic shock is characterized using Society for Cardiovascular Angiography and Interventions stages, machine learning-derived phenotypes, and the Comorbidity Risk Index. These comprehensive tools offer advanced stratification to guide management. The comparison of patients receiving heart replacement therapies versus no therapy during index hospitalization provides crucial insights for optimizing patient care.
Article 4: Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41950988
Summary: Multiple algorithms, including HFpEF-ABA, H₂FPEF, and HFA-PEFF, provide valuable tools for improving diagnosis and risk stratification in heart failure with preserved ejection f]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 09, 2026. This episode summarizes 5 key cardiology studies on topics like atherosclerotic cardiovascular disease and heart failure with preserved ejection fraction. Key takeaway: RBM20 Gene Links to Arrhythmogenic Cardiomyopathy.
Article Links:
Article 1: Multifaceted Strategies for Hypertension Control in Low-Income Patients. (The New England journal of medicine)
Article 2: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. (The New England journal of medicine)
Article 3: Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials. (Journal of cardiac failure)
Article 5: RBM20 Truncating Variants an]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Early PCSK9 Inhibitors Boost Stroke Outcomes 04/08/26</title>
	<link>https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/</link>
	<pubDate>Wed, 08 Apr 2026 12:52:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like hypertensive heart failure and COVID-19. Key takeaway: Early PCSK9 Inhibitors Boost Stroke Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40689758">Eclampsia and early readmission for cardiovascular disease.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40396291">Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41944181">Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41944180">Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41944178">Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/">https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Eclampsia and early readmission for cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40689758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40689758</a></p>
<p><strong>Summary:</strong> This study focused on determining whether patients with eclampsia have an increased risk for readmission due to cardiovascular disease within the first year after delivery. Researchers identified cardiovascular disease events from the Nationwide Readmissions Database between 2010 and 2018. This investigation highlights a crucial period for potential cardiovascular complications among patients following eclampsia, underscoring the importance of post-partum surveillance.</p>
<h4>Article 2: Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40396291" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40396291</a></p>
<p><strong>Summary:</strong> This study identified Wee1 G2 checkpoint kinase as activated and involved in hypertensive heart failure. Researchers found that Wee1 drives inflammation and hypertrophy through the protein kinase B / phosphoinositide 3-kinases &#8211; nuclear factor kappa B pathway in cardiomyocytes. This mechanism provides a specific molecular target for developing new therapeutic strategies against hypertensive heart failure.</p>
<h4>Article 3: Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944181" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944181</a></p>
<p><strong>Summary:</strong> This nationwide cohort study in South Korea explored the association between residential greenness and incident coronary artery disease following COVID-19. The investigation revealed that residential greenness is relevant to ischemic heart disease risk after severe acute respiratory syndrome coronavirus two infection, an area previously unclear. This highlights the potential impact of environmental factors on post-COVID-19 cardiovascular health.</p>
<h4>Article 4: Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944180" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944180</a></p>
<p><strong>Summary:</strong> This study addressed the cost-effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting, acknowledging the cost limitations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Researchers conducted mathematical modeling on a nationwide cohort of United States veterans to understand the need for these expensive drugs. The findings contribute to strategies for optimizing lipid-lowering therapy post-coronary artery bypass grafting by considering economic factors.</p>
<h4>Article 5: Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944178" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944178</a></p>
<p><strong>Summary:</strong> This study demonstrated that early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use correlates with improved outcomes in patients with acute stroke receiving endovascular therapy. Researchers found that early administration of PCSK9 inhibitors is associated with improved clinical outcomes in patients with acute large vessel occlusion after successful endovascular therapy recanalization. This finding suggests a potential benefit for early PCSK9 inhibitor treatment in this critical patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 08, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Eclampsia and early readmission for cardiovascular disease. This study focused on determining whether patients with eclampsia have an increased risk for readmission due to cardiovascular disease within the first year after delivery. Researchers identified cardiovascular disease events from the Nationwide Readmissions Database between 2010 and 2018. This investigation highlights a crucial period for potential cardiovascular complications among patients following eclampsia, underscoring the importance of post-partum surveillance.</p>
<p>Article number two. Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes. This study identified Wee1 G2 checkpoint kinase as activated and involved in hypertensive heart failure. Researchers found that Wee1 drives inflammation and hypertrophy through the protein kinase B / phosphoinositide 3-kinases &#8211; nuclear factor kappa B pathway in cardiomyocytes. This mechanism provides a specific molecular target for developing new therapeutic strategies against hypertensive heart failure.</p>
<p>Article number three. Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea. This nationwide cohort study in South Korea explored the association between residential greenness and incident coronary artery disease following COVID-19. The investigation revealed that residential greenness is relevant to ischemic heart disease risk after severe acute respiratory syndrome coronavirus two infection, an area previously unclear. This highlights the potential impact of environmental factors on post-COVID-19 cardiovascular health.</p>
<p>Article number four. Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. This study addressed the cost-effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting, acknowledging the cost limitations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Researchers conducted mathematical modeling on a nationwide cohort of United States veterans to understand the need for these expensive drugs. The findings contribute to strategies for optimizing lipid-lowering therapy post-coronary artery bypass grafting by considering economic factors.</p>
<p>Article number five. Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy. This study demonstrated that early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use correlates with improved outcomes in patients with acute stroke receiving endovascular therapy. Researchers found that early administration of PCSK9 inhibitors is associated with improved clinical outcomes in patients with acute large vessel occlusion after successful endovascular therapy recanalization. This finding suggests a potential benefit for early PCSK9 inhibitor treatment in this critical patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertensive heart failure, COVID-19, Nationwide Readmissions Database, coronary artery bypass grafting, endovascular therapy, hypertrophy, readmission, large vessel occlusion, inflammation, Wee1 G2 checkpoint kinase, postpartum, environmental factors, residential greenness, nuclear factor kappa B, mathematical modeling, cost-effectiveness, eclampsia, phosphoinositide 3-kinases, cardiovascular disease, acute stroke, PCSK9 inhibitors, protein kinase B, clinical outcomes, severe acute respiratory syndrome coronavirus two, lipid-lowering therapy, coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/">Early PCSK9 Inhibitors Boost Stroke Outcomes 04/08/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like hypertensive heart failure and COVID-19. Key takeaway: Early PCSK9 Inhibitors Boost Stroke Outcomes.
Article Links:
Article 1: Eclampsi]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like hypertensive heart failure and COVID-19. Key takeaway: Early PCSK9 Inhibitors Boost Stroke Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40689758">Eclampsia and early readmission for cardiovascular disease.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40396291">Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41944181">Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41944180">Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41944178">Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/">https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Eclampsia and early readmission for cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40689758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40689758</a></p>
<p><strong>Summary:</strong> This study focused on determining whether patients with eclampsia have an increased risk for readmission due to cardiovascular disease within the first year after delivery. Researchers identified cardiovascular disease events from the Nationwide Readmissions Database between 2010 and 2018. This investigation highlights a crucial period for potential cardiovascular complications among patients following eclampsia, underscoring the importance of post-partum surveillance.</p>
<h4>Article 2: Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40396291" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40396291</a></p>
<p><strong>Summary:</strong> This study identified Wee1 G2 checkpoint kinase as activated and involved in hypertensive heart failure. Researchers found that Wee1 drives inflammation and hypertrophy through the protein kinase B / phosphoinositide 3-kinases &#8211; nuclear factor kappa B pathway in cardiomyocytes. This mechanism provides a specific molecular target for developing new therapeutic strategies against hypertensive heart failure.</p>
<h4>Article 3: Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944181" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944181</a></p>
<p><strong>Summary:</strong> This nationwide cohort study in South Korea explored the association between residential greenness and incident coronary artery disease following COVID-19. The investigation revealed that residential greenness is relevant to ischemic heart disease risk after severe acute respiratory syndrome coronavirus two infection, an area previously unclear. This highlights the potential impact of environmental factors on post-COVID-19 cardiovascular health.</p>
<h4>Article 4: Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944180" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944180</a></p>
<p><strong>Summary:</strong> This study addressed the cost-effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting, acknowledging the cost limitations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Researchers conducted mathematical modeling on a nationwide cohort of United States veterans to understand the need for these expensive drugs. The findings contribute to strategies for optimizing lipid-lowering therapy post-coronary artery bypass grafting by considering economic factors.</p>
<h4>Article 5: Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944178" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944178</a></p>
<p><strong>Summary:</strong> This study demonstrated that early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use correlates with improved outcomes in patients with acute stroke receiving endovascular therapy. Researchers found that early administration of PCSK9 inhibitors is associated with improved clinical outcomes in patients with acute large vessel occlusion after successful endovascular therapy recanalization. This finding suggests a potential benefit for early PCSK9 inhibitor treatment in this critical patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 08, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Eclampsia and early readmission for cardiovascular disease. This study focused on determining whether patients with eclampsia have an increased risk for readmission due to cardiovascular disease within the first year after delivery. Researchers identified cardiovascular disease events from the Nationwide Readmissions Database between 2010 and 2018. This investigation highlights a crucial period for potential cardiovascular complications among patients following eclampsia, underscoring the importance of post-partum surveillance.</p>
<p>Article number two. Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes. This study identified Wee1 G2 checkpoint kinase as activated and involved in hypertensive heart failure. Researchers found that Wee1 drives inflammation and hypertrophy through the protein kinase B / phosphoinositide 3-kinases &#8211; nuclear factor kappa B pathway in cardiomyocytes. This mechanism provides a specific molecular target for developing new therapeutic strategies against hypertensive heart failure.</p>
<p>Article number three. Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea. This nationwide cohort study in South Korea explored the association between residential greenness and incident coronary artery disease following COVID-19. The investigation revealed that residential greenness is relevant to ischemic heart disease risk after severe acute respiratory syndrome coronavirus two infection, an area previously unclear. This highlights the potential impact of environmental factors on post-COVID-19 cardiovascular health.</p>
<p>Article number four. Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. This study addressed the cost-effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting, acknowledging the cost limitations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Researchers conducted mathematical modeling on a nationwide cohort of United States veterans to understand the need for these expensive drugs. The findings contribute to strategies for optimizing lipid-lowering therapy post-coronary artery bypass grafting by considering economic factors.</p>
<p>Article number five. Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy. This study demonstrated that early PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor use correlates with improved outcomes in patients with acute stroke receiving endovascular therapy. Researchers found that early administration of PCSK9 inhibitors is associated with improved clinical outcomes in patients with acute large vessel occlusion after successful endovascular therapy recanalization. This finding suggests a potential benefit for early PCSK9 inhibitor treatment in this critical patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertensive heart failure, COVID-19, Nationwide Readmissions Database, coronary artery bypass grafting, endovascular therapy, hypertrophy, readmission, large vessel occlusion, inflammation, Wee1 G2 checkpoint kinase, postpartum, environmental factors, residential greenness, nuclear factor kappa B, mathematical modeling, cost-effectiveness, eclampsia, phosphoinositide 3-kinases, cardiovascular disease, acute stroke, PCSK9 inhibitors, protein kinase B, clinical outcomes, severe acute respiratory syndrome coronavirus two, lipid-lowering therapy, coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/">Early PCSK9 Inhibitors Boost Stroke Outcomes 04/08/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260408_085201.mp3" length="3745584" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like hypertensive heart failure and COVID-19. Key takeaway: Early PCSK9 Inhibitors Boost Stroke Outcomes.
Article Links:
Article 1: Eclampsia and early readmission for cardiovascular disease. (European heart journal)
Article 2: Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes. (European heart journal)
Article 3: Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea. (Journal of the American Heart Association)
Article 4: Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. (Journal of the American Heart Association)
Article 5: Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/early-pcsk9-inhibitors-boost-stroke-outcomes-04-08-26/
 Featured Articles
Article 1: Eclampsia and early readmission for cardiovascular disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40689758
Summary: This study focused on determining whether patients with eclampsia have an increased risk for readmission due to cardiovascular disease within the first year after delivery. Researchers identified cardiovascular disease events from the Nationwide Readmissions Database between 2010 and 2018. This investigation highlights a crucial period for potential cardiovascular complications among patients following eclampsia, underscoring the importance of post-partum surveillance.
Article 2: Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40396291
Summary: This study identified Wee1 G2 checkpoint kinase as activated and involved in hypertensive heart failure. Researchers found that Wee1 drives inflammation and hypertrophy through the protein kinase B / phosphoinositide 3-kinases &#8211; nuclear factor kappa B pathway in cardiomyocytes. This mechanism provides a specific molecular target for developing new therapeutic strategies against hypertensive heart failure.
Article 3: Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41944181
Summary: This nationwide cohort study in South Korea explored the association between residential greenness and incident coronary artery disease following COVID-19. The investigation revealed that residential greenness is relevant to ischemic heart disease risk after severe acute respiratory syndrome coronavirus two infection, an area previously unclear. This highlights the potential impact of environmental factors on post-COVID-19 cardiovascular health.
Article 4: Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41944180
Summary: This study addressed the cost-effectiveness of an incremental lipid-lowering therapy approach after coronary artery bypass grafting, acknowledging the cost limitations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Researchers conducted mathematical modeling on a nationwide cohort of United States veterans to understand the need for these expensive drugs. The findings contribute to strategies for optimizing lipid-lowering therapy post-coronary artery byp]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like hypertensive heart failure and COVID-19. Key takeaway: Early PCSK9 Inhibitors Boost Stroke Outcomes.
Article Links:
Article 1: Eclampsia and early readmission for cardiovascular disease. (European heart journal)
Article 2: Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes. (European heart journal)
Article 3: Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea. (Journal of the American Heart Association)
Article 4: Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. (Journal of the American Heart Association)
Article 5: Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Olfactory Receptor Halts Platelet Clotting 04/08/26</title>
	<link>https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/</link>
	<pubDate>Wed, 08 Apr 2026 10:01:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and galectin three. Key takeaway: Olfactory Receptor Halts Platelet Clotting.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41944070">Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41944041">Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41944007">Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41944198">Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41944184">Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/">https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944070</a></p>
<p><strong>Summary:</strong> The study found that Mir147 (microRNA 147) limits the contribution of non-foamy macrophages to atherosclerosis by downregulating inflammatory activation. Specifically, Mir147-3p is upregulated by inflammation and functions to reduce inflammatory responses within these macrophages. This mechanism prevents the inflammatory activation of non-foamy macrophages, thereby reducing their role in the progression of atherosclerosis. The findings establish a new regulatory pathway in macrophage biology relevant to atherosclerotic disease.</p>
<h4>Article 2: Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944041</a></p>
<p><strong>Summary:</strong> This study found that multi-organ physiologic deficits identified during exercise characterize Heart Failure with Preserved Ejection Fraction (H. F. pEF). The research identified seven specific exercise-related deficits, including reduced peak oxygen uptake and chronotropic incompetence, in patients with this condition. These multi-organ limitations were directly associated with the severity and prognosis of Heart Failure with Preserved Ejection Fraction. The findings establish a link between these exercise deficits and both clinical and molecular predispositions to Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 3: Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944007</a></p>
<p><strong>Summary:</strong> The study found that activating the human olfactory receptor 2 L 13 (O. R. 2 L 13) on platelets significantly reduced platelet aggregation in laboratory settings. Activation of O. R. 2 L 13 also provided robust protection against arterial thrombosis in living organisms. This antithrombotic effect occurs through the mechanism of actin cytoskeleton remodeling within the platelets. These findings identify platelet O. R. 2 L 13 activation as a novel and effective strategy for reducing platelet reactivity and preventing arterial thrombosis.</p>
<h4>Article 4: Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944198" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944198</a></p>
<p><strong>Summary:</strong> This study identified 23 differentially expressed proteins in patients with severe aortic regurgitation compared to control subjects. Specifically, 7 proteins were upregulated and 16 were downregulated in severe aortic regurgitation cases. Key differentially expressed proteins included galectin three and matrix metalloproteinase nine. The data demonstrated that these differentially expressed proteins offer potential as biomarkers for the diagnosis and therapeutic monitoring of severe aortic regurgitation.</p>
<h4>Article 5: Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944184</a></p>
<p><strong>Summary:</strong> The study found that interleukin six levels were significantly elevated in children with borderline subclinical rheumatic heart disease (S. C. R. H. D.) compared to healthy controls at baseline, with a P value of 0.006. These elevated interleukin six levels persisted longitudinally throughout the two-year follow-up period in both borderline and definite subclinical rheumatic heart disease patients, with a P value of 0.004. The data demonstrate that interleukin six serves as a key inflammatory biomarker for early detection and disease activity in subclinical rheumatic heart disease. This persistent inflammation suggests opportunities for early therapeutic interventions in socioeconomically disadvantaged children.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 08, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis. The study found that Mir147 (microRNA 147) limits the contribution of non-foamy macrophages to atherosclerosis by downregulating inflammatory activation. Specifically, Mir147-3p is upregulated by inflammation and functions to reduce inflammatory responses within these macrophages. This mechanism prevents the inflammatory activation of non-foamy macrophages, thereby reducing their role in the progression of atherosclerosis. The findings establish a new regulatory pathway in macrophage biology relevant to atherosclerotic disease.</p>
<p>Article number two. Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction. This study found that multi-organ physiologic deficits identified during exercise characterize Heart Failure with Preserved Ejection Fraction (H. F. pEF). The research identified seven specific exercise-related deficits, including reduced peak oxygen uptake and chronotropic incompetence, in patients with this condition. These multi-organ limitations were directly associated with the severity and prognosis of Heart Failure with Preserved Ejection Fraction. The findings establish a link between these exercise deficits and both clinical and molecular predispositions to Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number three. Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling. The study found that activating the human olfactory receptor 2 L 13 (O. R. 2 L 13) on platelets significantly reduced platelet aggregation in laboratory settings. Activation of O. R. 2 L 13 also provided robust protection against arterial thrombosis in living organisms. This antithrombotic effect occurs through the mechanism of actin cytoskeleton remodeling within the platelets. These findings identify platelet O. R. 2 L 13 activation as a novel and effective strategy for reducing platelet reactivity and preventing arterial thrombosis.</p>
<p>Article number four. Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure. This study identified 23 differentially expressed proteins in patients with severe aortic regurgitation compared to control subjects. Specifically, 7 proteins were upregulated and 16 were downregulated in severe aortic regurgitation cases. Key differentially expressed proteins included galectin three and matrix metalloproteinase nine. The data demonstrated that these differentially expressed proteins offer potential as biomarkers for the diagnosis and therapeutic monitoring of severe aortic regurgitation.</p>
<p>Article number five. Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities. The study found that interleukin six levels were significantly elevated in children with borderline subclinical rheumatic heart disease (S. C. R. H. D.) compared to healthy controls at baseline, with a P value of 0.006. These elevated interleukin six levels persisted longitudinally throughout the two-year follow-up period in both borderline and definite subclinical rheumatic heart disease patients, with a P value of 0.004. The data demonstrate that interleukin six serves as a key inflammatory biomarker for early detection and disease activity in subclinical rheumatic heart disease. This persistent inflammation suggests opportunities for early therapeutic interventions in socioeconomically disadvantaged children. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Heart Failure with Preserved Ejection Fraction, galectin three, cardiopulmonary exercise testing, microRNA 147, biomarkers, heart failure, G protein-coupled receptor, arterial thrombosis, protein profiling, platelet reactivity, aortic regurgitation, inflammation, atherosclerosis, subclinical rheumatic heart disease, non-foamy macrophages, interleukin six, oxygen uptake, macrophages, olfactory receptor, children, antithrombotic, chronotropic incompetence, exercise testing, matrix metalloproteinase nine.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/">Olfactory Receptor Halts Platelet Clotting 04/08/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and galectin three. Key takeaway: Olfactory Receptor Halts Platelet Clotting.
Article Li]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and galectin three. Key takeaway: Olfactory Receptor Halts Platelet Clotting.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41944070">Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41944041">Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41944007">Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41944198">Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41944184">Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/">https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944070</a></p>
<p><strong>Summary:</strong> The study found that Mir147 (microRNA 147) limits the contribution of non-foamy macrophages to atherosclerosis by downregulating inflammatory activation. Specifically, Mir147-3p is upregulated by inflammation and functions to reduce inflammatory responses within these macrophages. This mechanism prevents the inflammatory activation of non-foamy macrophages, thereby reducing their role in the progression of atherosclerosis. The findings establish a new regulatory pathway in macrophage biology relevant to atherosclerotic disease.</p>
<h4>Article 2: Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944041</a></p>
<p><strong>Summary:</strong> This study found that multi-organ physiologic deficits identified during exercise characterize Heart Failure with Preserved Ejection Fraction (H. F. pEF). The research identified seven specific exercise-related deficits, including reduced peak oxygen uptake and chronotropic incompetence, in patients with this condition. These multi-organ limitations were directly associated with the severity and prognosis of Heart Failure with Preserved Ejection Fraction. The findings establish a link between these exercise deficits and both clinical and molecular predispositions to Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 3: Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944007</a></p>
<p><strong>Summary:</strong> The study found that activating the human olfactory receptor 2 L 13 (O. R. 2 L 13) on platelets significantly reduced platelet aggregation in laboratory settings. Activation of O. R. 2 L 13 also provided robust protection against arterial thrombosis in living organisms. This antithrombotic effect occurs through the mechanism of actin cytoskeleton remodeling within the platelets. These findings identify platelet O. R. 2 L 13 activation as a novel and effective strategy for reducing platelet reactivity and preventing arterial thrombosis.</p>
<h4>Article 4: Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944198" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944198</a></p>
<p><strong>Summary:</strong> This study identified 23 differentially expressed proteins in patients with severe aortic regurgitation compared to control subjects. Specifically, 7 proteins were upregulated and 16 were downregulated in severe aortic regurgitation cases. Key differentially expressed proteins included galectin three and matrix metalloproteinase nine. The data demonstrated that these differentially expressed proteins offer potential as biomarkers for the diagnosis and therapeutic monitoring of severe aortic regurgitation.</p>
<h4>Article 5: Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41944184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41944184</a></p>
<p><strong>Summary:</strong> The study found that interleukin six levels were significantly elevated in children with borderline subclinical rheumatic heart disease (S. C. R. H. D.) compared to healthy controls at baseline, with a P value of 0.006. These elevated interleukin six levels persisted longitudinally throughout the two-year follow-up period in both borderline and definite subclinical rheumatic heart disease patients, with a P value of 0.004. The data demonstrate that interleukin six serves as a key inflammatory biomarker for early detection and disease activity in subclinical rheumatic heart disease. This persistent inflammation suggests opportunities for early therapeutic interventions in socioeconomically disadvantaged children.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 08, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis. The study found that Mir147 (microRNA 147) limits the contribution of non-foamy macrophages to atherosclerosis by downregulating inflammatory activation. Specifically, Mir147-3p is upregulated by inflammation and functions to reduce inflammatory responses within these macrophages. This mechanism prevents the inflammatory activation of non-foamy macrophages, thereby reducing their role in the progression of atherosclerosis. The findings establish a new regulatory pathway in macrophage biology relevant to atherosclerotic disease.</p>
<p>Article number two. Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction. This study found that multi-organ physiologic deficits identified during exercise characterize Heart Failure with Preserved Ejection Fraction (H. F. pEF). The research identified seven specific exercise-related deficits, including reduced peak oxygen uptake and chronotropic incompetence, in patients with this condition. These multi-organ limitations were directly associated with the severity and prognosis of Heart Failure with Preserved Ejection Fraction. The findings establish a link between these exercise deficits and both clinical and molecular predispositions to Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number three. Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling. The study found that activating the human olfactory receptor 2 L 13 (O. R. 2 L 13) on platelets significantly reduced platelet aggregation in laboratory settings. Activation of O. R. 2 L 13 also provided robust protection against arterial thrombosis in living organisms. This antithrombotic effect occurs through the mechanism of actin cytoskeleton remodeling within the platelets. These findings identify platelet O. R. 2 L 13 activation as a novel and effective strategy for reducing platelet reactivity and preventing arterial thrombosis.</p>
<p>Article number four. Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure. This study identified 23 differentially expressed proteins in patients with severe aortic regurgitation compared to control subjects. Specifically, 7 proteins were upregulated and 16 were downregulated in severe aortic regurgitation cases. Key differentially expressed proteins included galectin three and matrix metalloproteinase nine. The data demonstrated that these differentially expressed proteins offer potential as biomarkers for the diagnosis and therapeutic monitoring of severe aortic regurgitation.</p>
<p>Article number five. Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities. The study found that interleukin six levels were significantly elevated in children with borderline subclinical rheumatic heart disease (S. C. R. H. D.) compared to healthy controls at baseline, with a P value of 0.006. These elevated interleukin six levels persisted longitudinally throughout the two-year follow-up period in both borderline and definite subclinical rheumatic heart disease patients, with a P value of 0.004. The data demonstrate that interleukin six serves as a key inflammatory biomarker for early detection and disease activity in subclinical rheumatic heart disease. This persistent inflammation suggests opportunities for early therapeutic interventions in socioeconomically disadvantaged children. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Heart Failure with Preserved Ejection Fraction, galectin three, cardiopulmonary exercise testing, microRNA 147, biomarkers, heart failure, G protein-coupled receptor, arterial thrombosis, protein profiling, platelet reactivity, aortic regurgitation, inflammation, atherosclerosis, subclinical rheumatic heart disease, non-foamy macrophages, interleukin six, oxygen uptake, macrophages, olfactory receptor, children, antithrombotic, chronotropic incompetence, exercise testing, matrix metalloproteinase nine.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/">Olfactory Receptor Halts Platelet Clotting 04/08/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260408_060026.mp3" length="4561022" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and galectin three. Key takeaway: Olfactory Receptor Halts Platelet Clotting.
Article Links:
Article 1: Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis. (Circulation)
Article 2: Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction. (Circulation)
Article 3: Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling. (Circulation)
Article 4: Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure. (Journal of the American Heart Association)
Article 5: Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/olfactory-receptor-halts-platelet-clotting-04-08-26/
 Featured Articles
Article 1: Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41944070
Summary: The study found that Mir147 (microRNA 147) limits the contribution of non-foamy macrophages to atherosclerosis by downregulating inflammatory activation. Specifically, Mir147-3p is upregulated by inflammation and functions to reduce inflammatory responses within these macrophages. This mechanism prevents the inflammatory activation of non-foamy macrophages, thereby reducing their role in the progression of atherosclerosis. The findings establish a new regulatory pathway in macrophage biology relevant to atherosclerotic disease.
Article 2: Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41944041
Summary: This study found that multi-organ physiologic deficits identified during exercise characterize Heart Failure with Preserved Ejection Fraction (H. F. pEF). The research identified seven specific exercise-related deficits, including reduced peak oxygen uptake and chronotropic incompetence, in patients with this condition. These multi-organ limitations were directly associated with the severity and prognosis of Heart Failure with Preserved Ejection Fraction. The findings establish a link between these exercise deficits and both clinical and molecular predispositions to Heart Failure with Preserved Ejection Fraction.
Article 3: Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41944007
Summary: The study found that activating the human olfactory receptor 2 L 13 (O. R. 2 L 13) on platelets significantly reduced platelet aggregation in laboratory settings. Activation of O. R. 2 L 13 also provided robust protection against arterial thrombosis in living organisms. This antithrombotic effect occurs through the mechanism of actin cytoskeleton remodeling within the platelets. These findings identify platelet O. R. 2 L 13 activation as a novel and effective strategy for reducing platelet reactivity and preventing arterial thrombosis.
Article 4: Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41944198
Summary: This study identified 23 differentially expressed proteins in patients with severe aortic regurgitation compared to control subjects. Specifically, 7 proteins were upregulated and 16 were downregulated i]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 08, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and galectin three. Key takeaway: Olfactory Receptor Halts Platelet Clotting.
Article Links:
Article 1: Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis. (Circulation)
Article 2: Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction. (Circulation)
Article 3: Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling. (Circulation)
Article 4: Characteristics of Protein Profiling and Biomarkers in Aortic Regurgitation With Heart Failure. (Journal of the American Heart Association)
Article 5: Elevated Interleukin-6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospecti]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Telomere Recapping Blocks Heart Failure Mechanism 04/07/26</title>
	<link>https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/</link>
	<pubDate>Tue, 07 Apr 2026 10:01:46 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 07, 2026. This episode summarizes 5 key cardiology studies on topics like guideline-directed medical therapy and congenital heart disease. Key takeaway: Telomere Recapping Blocks Heart Failure Mechanism.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41645912">Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41942043">A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41942104">Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41941940">Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy.</a> (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41940517">Stress, coping, protective factors, and quality of life in parents of infants with CHD: associations with state anxiety.</a> (Cardiology in the young)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/">https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645912" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645912</a></p>
<p><strong>Summary:</strong> D. 36, Is Essential for Blood-Brain Barrier Integrity. This study found that Apolipoprotein D is a novel ligand for C. D. 36 and is essential for maintaining blood-brain barrier integrity. This mechanism is critical because disruption of the blood-brain barrier is a central pathogenic event in many central nervous system disorders. The research identifies a specific molecular pathway governing blood-brain barrier function. This fundamental understanding of blood-brain barrier regulation provides a basis for future therapeutic strategies.</p>
<h4>Article 2: A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41942043" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41942043</a></p>
<p><strong>Summary:</strong> Left bundle branch area pacing is a physiological pacing modality preserving ventricular synchrony. Optimal programming strategies for patients with sinus node dysfunction, particularly those with delayed intrinsic atrioventricular conduction, have remained clinically uncertain. It is understood that minimal ventricular pacing algorithms can permit non-physiological atrioventricular prolongation, which contributes to left atrial remodeling and atrial high-rate episodes. This randomized controlled trial directly compared maximal atrioventricular sequential pacing with minimal ventricular pacing strategies to address these critical clinical outcomes.</p>
<h4>Article 3: Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41942104" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41942104</a></p>
<p><strong>Summary:</strong> N. A. communication in heart failure. This study found that telomere recapping prevents pathogenic communication between telomeres and mitochondrial deoxyribonucleic acid in heart failure. Diseased cardiomyocytes exhibit telomeric shortening, which triggers deoxyribonucleic acid damage responses and leads to mitochondrial dysfunction. This finding demonstrates a novel mechanism to restore myocardial function, addressing the high prevalence and significant mortality of heart failure, where five-year survival remains at fifty percent. Telomere recapping thus represents a promising therapeutic target for improving heart failure outcomes.</p>
<h4>Article 4: Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41941940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41941940</a></p>
<p><strong>Summary:</strong> This study defined the longitudinal trajectories of secondary mitral regurgitation in 764 patients with non-ischemic dilated cardiomyopathy. The findings revealed the dynamic nature of secondary mitral regurgitation severity, demonstrating its dependence on loading conditions and guideline-directed medical therapy. Understanding these long-term trajectories provides crucial prognostic insights for patients with non-ischemic dilated cardiomyopathy. This research provides a framework for evaluating secondary mitral regurgitation evolution and guiding patient management.</p>
<h4>Article 5: Stress, coping, protective factors, and quality of life in parents of infants with CHD: associations with state anxiety.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41940517" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41940517</a></p>
<p><strong>Summary:</strong> H. D.: associations with state anxiety. The Family Adaptation study identified associations between stress, coping mechanisms, protective factors, quality of life, and state anxiety in parents of infants with congenital heart disease. The study included 215 parents, comprising 143 mothers and 72 fathers, of 146 infants who underwent the Norwood procedure, with measurements taken post-Norwood and post-Stage two. Results showed specific relationships among these psychosocial factors across the parental cohort. These findings delineate the complex psychosocial landscape and provide crucial insights for supporting parental well-being during their infant&#8217;s critical cardiac care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Apolipoprotein D, a Novel Ligand for C. D. 36, Is Essential for Blood-Brain Barrier Integrity. This study found that Apolipoprotein D is a novel ligand for C. D. 36 and is essential for maintaining blood-brain barrier integrity. This mechanism is critical because disruption of the blood-brain barrier is a central pathogenic event in many central nervous system disorders. The research identifies a specific molecular pathway governing blood-brain barrier function. This fundamental understanding of blood-brain barrier regulation provides a basis for future therapeutic strategies.</p>
<p>Article number two. A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction. Left bundle branch area pacing is a physiological pacing modality preserving ventricular synchrony. Optimal programming strategies for patients with sinus node dysfunction, particularly those with delayed intrinsic atrioventricular conduction, have remained clinically uncertain. It is understood that minimal ventricular pacing algorithms can permit non-physiological atrioventricular prolongation, which contributes to left atrial remodeling and atrial high-rate episodes. This randomized controlled trial directly compared maximal atrioventricular sequential pacing with minimal ventricular pacing strategies to address these critical clinical outcomes.</p>
<p>Article number three. Telomere recapping prevents pathogenic telomere-to-mitochondrial D. N. A. communication in heart failure. This study found that telomere recapping prevents pathogenic communication between telomeres and mitochondrial deoxyribonucleic acid in heart failure. Diseased cardiomyocytes exhibit telomeric shortening, which triggers deoxyribonucleic acid damage responses and leads to mitochondrial dysfunction. This finding demonstrates a novel mechanism to restore myocardial function, addressing the high prevalence and significant mortality of heart failure, where five-year survival remains at fifty percent. Telomere recapping thus represents a promising therapeutic target for improving heart failure outcomes.</p>
<p>Article number four. Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy. This study defined the longitudinal trajectories of secondary mitral regurgitation in 764 patients with non-ischemic dilated cardiomyopathy. The findings revealed the dynamic nature of secondary mitral regurgitation severity, demonstrating its dependence on loading conditions and guideline-directed medical therapy. Understanding these long-term trajectories provides crucial prognostic insights for patients with non-ischemic dilated cardiomyopathy. This research provides a framework for evaluating secondary mitral regurgitation evolution and guiding patient management.</p>
<p>Article number five. Stress, coping, protective factors, and quality of life in parents of infants with C. H. D.: associations with state anxiety. The Family Adaptation study identified associations between stress, coping mechanisms, protective factors, quality of life, and state anxiety in parents of infants with congenital heart disease. The study included 215 parents, comprising 143 mothers and 72 fathers, of 146 infants who underwent the Norwood procedure, with measurements taken post-Norwood and post-Stage two. Results showed specific relationships among these psychosocial factors across the parental cohort. These findings delineate the complex psychosocial landscape and provide crucial insights for supporting parental well-being during their infant&#8217;s critical cardiac care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>guideline-directed medical therapy, congenital heart disease, parental anxiety, heart failure, apolipoprotein D, mitochondrial D. N. A., telomere recapping, atrial high-rate episodes, ligand, quality of life, blood-brain barrier, atrioventricular conduction, secondary mitral regurgitation, left bundle branch area pacing, Norwood procedure, echocardiography, sinus node dysfunction, prognosis, C. D. 36, left atrial volume, non-ischemic dilated cardiomyopathy, central nervous system disorders, myocardial function, deoxyribonucleic acid damage, psychosocial factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/">Telomere Recapping Blocks Heart Failure Mechanism 04/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 07, 2026. This episode summarizes 5 key cardiology studies on topics like guideline-directed medical therapy and congenital heart disease. Key takeaway: Telomere Recapping Blocks Heart Failure Mechanism.
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 07, 2026. This episode summarizes 5 key cardiology studies on topics like guideline-directed medical therapy and congenital heart disease. Key takeaway: Telomere Recapping Blocks Heart Failure Mechanism.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41645912">Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41942043">A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41942104">Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41941940">Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy.</a> (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41940517">Stress, coping, protective factors, and quality of life in parents of infants with CHD: associations with state anxiety.</a> (Cardiology in the young)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/">https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645912" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645912</a></p>
<p><strong>Summary:</strong> D. 36, Is Essential for Blood-Brain Barrier Integrity. This study found that Apolipoprotein D is a novel ligand for C. D. 36 and is essential for maintaining blood-brain barrier integrity. This mechanism is critical because disruption of the blood-brain barrier is a central pathogenic event in many central nervous system disorders. The research identifies a specific molecular pathway governing blood-brain barrier function. This fundamental understanding of blood-brain barrier regulation provides a basis for future therapeutic strategies.</p>
<h4>Article 2: A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41942043" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41942043</a></p>
<p><strong>Summary:</strong> Left bundle branch area pacing is a physiological pacing modality preserving ventricular synchrony. Optimal programming strategies for patients with sinus node dysfunction, particularly those with delayed intrinsic atrioventricular conduction, have remained clinically uncertain. It is understood that minimal ventricular pacing algorithms can permit non-physiological atrioventricular prolongation, which contributes to left atrial remodeling and atrial high-rate episodes. This randomized controlled trial directly compared maximal atrioventricular sequential pacing with minimal ventricular pacing strategies to address these critical clinical outcomes.</p>
<h4>Article 3: Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41942104" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41942104</a></p>
<p><strong>Summary:</strong> N. A. communication in heart failure. This study found that telomere recapping prevents pathogenic communication between telomeres and mitochondrial deoxyribonucleic acid in heart failure. Diseased cardiomyocytes exhibit telomeric shortening, which triggers deoxyribonucleic acid damage responses and leads to mitochondrial dysfunction. This finding demonstrates a novel mechanism to restore myocardial function, addressing the high prevalence and significant mortality of heart failure, where five-year survival remains at fifty percent. Telomere recapping thus represents a promising therapeutic target for improving heart failure outcomes.</p>
<h4>Article 4: Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41941940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41941940</a></p>
<p><strong>Summary:</strong> This study defined the longitudinal trajectories of secondary mitral regurgitation in 764 patients with non-ischemic dilated cardiomyopathy. The findings revealed the dynamic nature of secondary mitral regurgitation severity, demonstrating its dependence on loading conditions and guideline-directed medical therapy. Understanding these long-term trajectories provides crucial prognostic insights for patients with non-ischemic dilated cardiomyopathy. This research provides a framework for evaluating secondary mitral regurgitation evolution and guiding patient management.</p>
<h4>Article 5: Stress, coping, protective factors, and quality of life in parents of infants with CHD: associations with state anxiety.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41940517" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41940517</a></p>
<p><strong>Summary:</strong> H. D.: associations with state anxiety. The Family Adaptation study identified associations between stress, coping mechanisms, protective factors, quality of life, and state anxiety in parents of infants with congenital heart disease. The study included 215 parents, comprising 143 mothers and 72 fathers, of 146 infants who underwent the Norwood procedure, with measurements taken post-Norwood and post-Stage two. Results showed specific relationships among these psychosocial factors across the parental cohort. These findings delineate the complex psychosocial landscape and provide crucial insights for supporting parental well-being during their infant&#8217;s critical cardiac care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Apolipoprotein D, a Novel Ligand for C. D. 36, Is Essential for Blood-Brain Barrier Integrity. This study found that Apolipoprotein D is a novel ligand for C. D. 36 and is essential for maintaining blood-brain barrier integrity. This mechanism is critical because disruption of the blood-brain barrier is a central pathogenic event in many central nervous system disorders. The research identifies a specific molecular pathway governing blood-brain barrier function. This fundamental understanding of blood-brain barrier regulation provides a basis for future therapeutic strategies.</p>
<p>Article number two. A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction. Left bundle branch area pacing is a physiological pacing modality preserving ventricular synchrony. Optimal programming strategies for patients with sinus node dysfunction, particularly those with delayed intrinsic atrioventricular conduction, have remained clinically uncertain. It is understood that minimal ventricular pacing algorithms can permit non-physiological atrioventricular prolongation, which contributes to left atrial remodeling and atrial high-rate episodes. This randomized controlled trial directly compared maximal atrioventricular sequential pacing with minimal ventricular pacing strategies to address these critical clinical outcomes.</p>
<p>Article number three. Telomere recapping prevents pathogenic telomere-to-mitochondrial D. N. A. communication in heart failure. This study found that telomere recapping prevents pathogenic communication between telomeres and mitochondrial deoxyribonucleic acid in heart failure. Diseased cardiomyocytes exhibit telomeric shortening, which triggers deoxyribonucleic acid damage responses and leads to mitochondrial dysfunction. This finding demonstrates a novel mechanism to restore myocardial function, addressing the high prevalence and significant mortality of heart failure, where five-year survival remains at fifty percent. Telomere recapping thus represents a promising therapeutic target for improving heart failure outcomes.</p>
<p>Article number four. Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy. This study defined the longitudinal trajectories of secondary mitral regurgitation in 764 patients with non-ischemic dilated cardiomyopathy. The findings revealed the dynamic nature of secondary mitral regurgitation severity, demonstrating its dependence on loading conditions and guideline-directed medical therapy. Understanding these long-term trajectories provides crucial prognostic insights for patients with non-ischemic dilated cardiomyopathy. This research provides a framework for evaluating secondary mitral regurgitation evolution and guiding patient management.</p>
<p>Article number five. Stress, coping, protective factors, and quality of life in parents of infants with C. H. D.: associations with state anxiety. The Family Adaptation study identified associations between stress, coping mechanisms, protective factors, quality of life, and state anxiety in parents of infants with congenital heart disease. The study included 215 parents, comprising 143 mothers and 72 fathers, of 146 infants who underwent the Norwood procedure, with measurements taken post-Norwood and post-Stage two. Results showed specific relationships among these psychosocial factors across the parental cohort. These findings delineate the complex psychosocial landscape and provide crucial insights for supporting parental well-being during their infant&#8217;s critical cardiac care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>guideline-directed medical therapy, congenital heart disease, parental anxiety, heart failure, apolipoprotein D, mitochondrial D. N. A., telomere recapping, atrial high-rate episodes, ligand, quality of life, blood-brain barrier, atrioventricular conduction, secondary mitral regurgitation, left bundle branch area pacing, Norwood procedure, echocardiography, sinus node dysfunction, prognosis, C. D. 36, left atrial volume, non-ischemic dilated cardiomyopathy, central nervous system disorders, myocardial function, deoxyribonucleic acid damage, psychosocial factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/">Telomere Recapping Blocks Heart Failure Mechanism 04/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260407_060048.mp3" length="4327383" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 07, 2026. This episode summarizes 5 key cardiology studies on topics like guideline-directed medical therapy and congenital heart disease. Key takeaway: Telomere Recapping Blocks Heart Failure Mechanism.
Article Links:
Article 1: Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity. (Circulation)
Article 2: A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction. (The American journal of cardiology)
Article 3: Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure. (Cardiovascular research)
Article 4: Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy. (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)
Article 5: Stress, coping, protective factors, and quality of life in parents of infants with CHD: associations with state anxiety. (Cardiology in the young)
Full episode page: https://podcast.explainheart.com/podcast/telomere-recapping-blocks-heart-failure-mechanism-04-07-26/
 Featured Articles
Article 1: Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645912
Summary: D. 36, Is Essential for Blood-Brain Barrier Integrity. This study found that Apolipoprotein D is a novel ligand for C. D. 36 and is essential for maintaining blood-brain barrier integrity. This mechanism is critical because disruption of the blood-brain barrier is a central pathogenic event in many central nervous system disorders. The research identifies a specific molecular pathway governing blood-brain barrier function. This fundamental understanding of blood-brain barrier regulation provides a basis for future therapeutic strategies.
Article 2: A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41942043
Summary: Left bundle branch area pacing is a physiological pacing modality preserving ventricular synchrony. Optimal programming strategies for patients with sinus node dysfunction, particularly those with delayed intrinsic atrioventricular conduction, have remained clinically uncertain. It is understood that minimal ventricular pacing algorithms can permit non-physiological atrioventricular prolongation, which contributes to left atrial remodeling and atrial high-rate episodes. This randomized controlled trial directly compared maximal atrioventricular sequential pacing with minimal ventricular pacing strategies to address these critical clinical outcomes.
Article 3: Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41942104
Summary: N. A. communication in heart failure. This study found that telomere recapping prevents pathogenic communication between telomeres and mitochondrial deoxyribonucleic acid in heart failure. Diseased cardiomyocytes exhibit telomeric shortening, which triggers deoxyribonucleic acid damage responses and leads to mitochondrial dysfunction. This finding demonstrates a novel mechanism to restore myocardial function, addressing the high prevalence and significant mortality of heart failure, where five-year survival remains at fifty percent. Telomere recapping thus represents a promising therapeutic target for improving heart failure outcomes.
Article 4: Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy.
Journal: Journal of the American Soci]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 07, 2026. This episode summarizes 5 key cardiology studies on topics like guideline-directed medical therapy and congenital heart disease. Key takeaway: Telomere Recapping Blocks Heart Failure Mechanism.
Article Links:
Article 1: Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity. (Circulation)
Article 2: A Randomized Controlled Trial Comparing Different Programming Strategies of Left Bundle Branch Area Pacing on Left Atrial Volume and Atrial High-Rate Episodes in Patients With Sinus Node Dysfunction. (The American journal of cardiology)
Article 3: Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure. (Cardiovascular research)
Article 4: Longitudinal trajectories of secondary mitral regurgitation in non-ischemic dilated cardiomyopathy. (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)
A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI C. C. T. A. Guides Optimal L. L. M. Benefit 04/06/26</title>
	<link>https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/</link>
	<pubDate>Tue, 07 Apr 2026 01:36:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like rehabilitation needs and coronary computed tomography angiography. Key takeaway: AI C. C. T. A. Guides Optimal L. L. M. Benefit.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41941602">Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41941602">Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41937634">Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.</a> (Circulation. Cardiovascular imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41940521">The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure.</a> (Cardiology in the young)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41940519">Physical therapy enhances patient care in post-congenital heart surgery clinic.</a> (Cardiology in the young)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/">https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41941602" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41941602</a></p>
<p><strong>Summary:</strong> This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<h4>Article 2: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41941602" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41941602</a></p>
<p><strong>Summary:</strong> This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<h4>Article 3: Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41937634" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41937634</a></p>
<p><strong>Summary:</strong> This observational cohort study found that artificial intelligence-guided quantitative coronary computed tomography angiography identified patients who derive outcome benefit from lipid-lowering medication. The study showed that quantification of coronary atherosclerotic plaque burden, specifically percent atheroma volume, serves as a marker for guiding therapy. This demonstrates that advanced imaging can personalize lipid-lowering medication strategies for symptomatic patients with suspected coronary artery disease.</p>
<h4>Article 4: The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41940521" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41940521</a></p>
<p><strong>Summary:</strong> This retrospective study found that the inferior vena cava collapsibility index serves as a non-invasive marker for early hemodynamic changes following transcatheter closure of an atrial septal defect. The study assessed changes in pulmonary artery, pulmonary vein, and inferior vena cava flow parameters in 31 pediatric patients. This demonstrates a valuable tool for monitoring immediate post-procedural cardiovascular adjustments in young patients with hemodynamically significant atrial septal defects, defined as Qp over Qs greater than or equal to 1.5.</p>
<h4>Article 5: Physical therapy enhances patient care in post-congenital heart surgery clinic.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41940519" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41940519</a></p>
<p><strong>Summary:</strong> This retrospective review found that routine physical therapy evaluation significantly enhances patient care in post-congenital heart surgery clinics. The study assessed posture, mobility, and pain in patients following congenital heart surgery requiring sternotomy. This demonstrated that physical therapy effectively identifies rehabilitation needs and addresses gaps in care, improving post-operative management for these patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<p>Article number two. Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<p>Article number three. Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication. This observational cohort study found that artificial intelligence-guided quantitative coronary computed tomography angiography identified patients who derive outcome benefit from lipid-lowering medication. The study showed that quantification of coronary atherosclerotic plaque burden, specifically percent atheroma volume, serves as a marker for guiding therapy. This demonstrates that advanced imaging can personalize lipid-lowering medication strategies for symptomatic patients with suspected coronary artery disease.</p>
<p>Article number four. The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure. This retrospective study found that the inferior vena cava collapsibility index serves as a non-invasive marker for early hemodynamic changes following transcatheter closure of an atrial septal defect. The study assessed changes in pulmonary artery, pulmonary vein, and inferior vena cava flow parameters in 31 pediatric patients. This demonstrates a valuable tool for monitoring immediate post-procedural cardiovascular adjustments in young patients with hemodynamically significant atrial septal defects, defined as Qp over Qs greater than or equal to 1.5.</p>
<p>Article number five. Physical therapy enhances patient care in post-congenital heart surgery clinic. This retrospective review found that routine physical therapy evaluation significantly enhances patient care in post-congenital heart surgery clinics. The study assessed posture, mobility, and pain in patients following congenital heart surgery requiring sternotomy. This demonstrated that physical therapy effectively identifies rehabilitation needs and addresses gaps in care, improving post-operative management for these patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>rehabilitation needs, coronary computed tomography angiography, functional capacity, post-operative care, Heart Failure, patient-reported health status, atherosclerotic plaque burden, ejection fraction, artificial intelligence, physical therapy, inferior vena cava collapsibility index, lipid-lowering medication, congenital heart surgery, pediatric cardiology, hemodynamic changes, percent atheroma volume, atrial septal defect, transcatheter closure, cardiac microcurrent therapy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/">AI C. C. T. A. Guides Optimal L. L. M. Benefit 04/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like rehabilitation needs and coronary computed tomography angiography. Key takeaway: AI C. C. T. A. Guides Optimal L. L. M. Benefit.
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like rehabilitation needs and coronary computed tomography angiography. Key takeaway: AI C. C. T. A. Guides Optimal L. L. M. Benefit.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41941602">Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41941602">Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41937634">Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.</a> (Circulation. Cardiovascular imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41940521">The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure.</a> (Cardiology in the young)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41940519">Physical therapy enhances patient care in post-congenital heart surgery clinic.</a> (Cardiology in the young)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/">https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41941602" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41941602</a></p>
<p><strong>Summary:</strong> This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<h4>Article 2: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41941602" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41941602</a></p>
<p><strong>Summary:</strong> This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<h4>Article 3: Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41937634" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41937634</a></p>
<p><strong>Summary:</strong> This observational cohort study found that artificial intelligence-guided quantitative coronary computed tomography angiography identified patients who derive outcome benefit from lipid-lowering medication. The study showed that quantification of coronary atherosclerotic plaque burden, specifically percent atheroma volume, serves as a marker for guiding therapy. This demonstrates that advanced imaging can personalize lipid-lowering medication strategies for symptomatic patients with suspected coronary artery disease.</p>
<h4>Article 4: The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41940521" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41940521</a></p>
<p><strong>Summary:</strong> This retrospective study found that the inferior vena cava collapsibility index serves as a non-invasive marker for early hemodynamic changes following transcatheter closure of an atrial septal defect. The study assessed changes in pulmonary artery, pulmonary vein, and inferior vena cava flow parameters in 31 pediatric patients. This demonstrates a valuable tool for monitoring immediate post-procedural cardiovascular adjustments in young patients with hemodynamically significant atrial septal defects, defined as Qp over Qs greater than or equal to 1.5.</p>
<h4>Article 5: Physical therapy enhances patient care in post-congenital heart surgery clinic.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41940519" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41940519</a></p>
<p><strong>Summary:</strong> This retrospective review found that routine physical therapy evaluation significantly enhances patient care in post-congenital heart surgery clinics. The study assessed posture, mobility, and pain in patients following congenital heart surgery requiring sternotomy. This demonstrated that physical therapy effectively identifies rehabilitation needs and addresses gaps in care, improving post-operative management for these patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<p>Article number two. Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.</p>
<p>Article number three. Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication. This observational cohort study found that artificial intelligence-guided quantitative coronary computed tomography angiography identified patients who derive outcome benefit from lipid-lowering medication. The study showed that quantification of coronary atherosclerotic plaque burden, specifically percent atheroma volume, serves as a marker for guiding therapy. This demonstrates that advanced imaging can personalize lipid-lowering medication strategies for symptomatic patients with suspected coronary artery disease.</p>
<p>Article number four. The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure. This retrospective study found that the inferior vena cava collapsibility index serves as a non-invasive marker for early hemodynamic changes following transcatheter closure of an atrial septal defect. The study assessed changes in pulmonary artery, pulmonary vein, and inferior vena cava flow parameters in 31 pediatric patients. This demonstrates a valuable tool for monitoring immediate post-procedural cardiovascular adjustments in young patients with hemodynamically significant atrial septal defects, defined as Qp over Qs greater than or equal to 1.5.</p>
<p>Article number five. Physical therapy enhances patient care in post-congenital heart surgery clinic. This retrospective review found that routine physical therapy evaluation significantly enhances patient care in post-congenital heart surgery clinics. The study assessed posture, mobility, and pain in patients following congenital heart surgery requiring sternotomy. This demonstrated that physical therapy effectively identifies rehabilitation needs and addresses gaps in care, improving post-operative management for these patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>rehabilitation needs, coronary computed tomography angiography, functional capacity, post-operative care, Heart Failure, patient-reported health status, atherosclerotic plaque burden, ejection fraction, artificial intelligence, physical therapy, inferior vena cava collapsibility index, lipid-lowering medication, congenital heart surgery, pediatric cardiology, hemodynamic changes, percent atheroma volume, atrial septal defect, transcatheter closure, cardiac microcurrent therapy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/">AI C. C. T. A. Guides Optimal L. L. M. Benefit 04/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260406_213600.mp3" length="4004301" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like rehabilitation needs and coronary computed tomography angiography. Key takeaway: AI C. C. T. A. Guides Optimal L. L. M. Benefit.
Article Links:
Article 1: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. (ESC heart failure)
Article 2: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. (ESC heart failure)
Article 3: Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication. (Circulation. Cardiovascular imaging)
Article 4: The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure. (Cardiology in the young)
Article 5: Physical therapy enhances patient care in post-congenital heart surgery clinic. (Cardiology in the young)
Full episode page: https://podcast.explainheart.com/podcast/ai-c-c-t-a-guides-optimal-l-l-m-benefit-04-06-26/
 Featured Articles
Article 1: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41941602
Summary: This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.
Article 2: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41941602
Summary: This post hoc analysis from the cardiac microcurrent (C-MIC) two trial highlighted that the precise relationship between changes in cardiac function, functional capacity, and patient-reported health status in chronic Heart Failure remains incompletely defined. The C-MIC two trial evaluated the efficacy and safety of cardiac microcurrent therapy in patients with chronic Heart Failure with Reduced Ejection Fraction receiving optimal guideline-directed medical therapy. This study confirmed the ongoing need for research into how distinct clinical domains reflect treatment response for this patient population.
Article 3: Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.
Journal: Circulation. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41937634
Summary: This observational cohort study found that artificial intelligence-guided quantitative coronary computed tomography angiography identified patients who derive outcome benefit from lipid-lowering medication. The study showed that quantification of coronary atherosclerotic plaque burden, specifically percent atheroma volume, serves as a marker for guiding therapy. This demonstrates that advanced imaging can personalize lipid-lowering medication strategies for symptomatic patients with suspected coronary artery disease.
Article 4: The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure.
Journal: Cardiology in the young
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41940521
Summary: This retrospective study found that the inferior vena cava collapsibility index serves as a non-invasive marker for early hemodynamic changes following transcatheter closure of an atrial sept]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like rehabilitation needs and coronary computed tomography angiography. Key takeaway: AI C. C. T. A. Guides Optimal L. L. M. Benefit.
Article Links:
Article 1: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. (ESC heart failure)
Article 2: Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial. (ESC heart failure)
Article 3: Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication. (Circulation. Cardiovascular imaging)
Article 4: The inferior vena cava collapsibility index as a non-invasive marker of early haemodynamic changes following atrial septal defect closure. (Cardiology in the young)
Article 5: Physical therapy enhances patient care in post-congenital heart surgery clinic. (Cardiolog]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>NOBLE Trial&#8217;s 10-Year Left Main Data 04/06/26</title>
	<link>https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/</link>
	<pubDate>Mon, 06 Apr 2026 10:01:47 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with preserved ejection fraction and coronary artery bypass grafting. Key takeaway: NOBLE Trial&#8217;s 10-Year Left Main Data.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41936938">Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41936851">Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41935384">Cardiovascular pharmacotherapy in year in 2025.</a> (European heart journal. Cardiovascular pharmacotherapy)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41936927">Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF.</a> (American heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41936368">Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.</a> (Lancet (London, England))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/">https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936938</a></p>
<p><strong>Summary:</strong> The study demonstrated broad cellular dysfunction in congenital Long Q. T. syndrome. This finding emerged from integrating transcriptomic and proteomic profiles of patient-derived inducible pluripotent stem cell-derived cardiomyocyte models representing L. Q. T. type one, L. Q. T. type two, and L. Q. T. type three genotypes. The investigation also incorporated population-level Q. T. genome-wide association study data, revealing cellular impairments beyond mere ion channel dysfunction and providing a deeper understanding of the disease&#8217;s mechanisms.</p>
<h4>Article 2: Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936851</a></p>
<p><strong>Summary:</strong> The global registry study characterized the utilization patterns and associated outcomes of dual antiplatelet therapy in patients with active cancer experiencing acute myocardial infarction. The investigation addressed the critical clinical challenge of balancing competing risks of thrombosis and bleeding when selecting optimal therapy in this high-mortality population. It comprehensively analyzed therapy use and outcomes, with all-cause mortality serving as the primary endpoint in these complex patients.</p>
<h4>Article 3: Cardiovascular pharmacotherapy in year in 2025.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular pharmacotherapy</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41935384" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41935384</a></p>
<p><strong>Summary:</strong> Significant advances in cardiovascular pharmacotherapy were identified, including the approval of four new drugs: aficamten, etripamil, lerodalcibep, and plozasiran. Additionally, five already approved drugs received label expansions, broadening their therapeutic applications. The review also summarized key findings from major randomized clinical trials that further advanced treatment strategies, collectively addressing the ongoing need for more effective and safer pharmacological interventions across various cardiovascular diseases.</p>
<h4>Article 4: Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936927" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936927</a></p>
<p><strong>Summary:</strong> This retrospective cohort study characterized the economic burden associated with systemic inflammation in patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. The investigation demonstrated the impact of systemic inflammation on real-world healthcare resource utilization and costs within this specific patient population. The findings highlight the critical role of systemic inflammation, detected via high sensitivity C. R. P. testing, in both the pathogenesis and economic implications for these heart failure subtypes.</p>
<h4>Article 5: Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936368" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936368</a></p>
<p><strong>Summary:</strong> The N. O. B. L. E. trial delivered its 10-year final results, directly comparing percutaneous coronary intervention with newer generation drug-eluting stents against coronary artery bypass grafting for unprotected left main coronary artery stenosis. This randomized, open-label, non-inferiority investigation provided crucial long-term outcome data in a patient population where coronary artery bypass grafting has traditionally been the recommended treatment. The study offered definitive long-term insights to guide treatment decisions for this significant cardiovascular condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction. The study demonstrated broad cellular dysfunction in congenital Long Q. T. syndrome. This finding emerged from integrating transcriptomic and proteomic profiles of patient-derived inducible pluripotent stem cell-derived cardiomyocyte models representing L. Q. T. type one, L. Q. T. type two, and L. Q. T. type three genotypes. The investigation also incorporated population-level Q. T. genome-wide association study data, revealing cellular impairments beyond mere ion channel dysfunction and providing a deeper understanding of the disease&#8217;s mechanisms.</p>
<p>Article number two. Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study. The global registry study characterized the utilization patterns and associated outcomes of dual antiplatelet therapy in patients with active cancer experiencing acute myocardial infarction. The investigation addressed the critical clinical challenge of balancing competing risks of thrombosis and bleeding when selecting optimal therapy in this high-mortality population. It comprehensively analyzed therapy use and outcomes, with all-cause mortality serving as the primary endpoint in these complex patients.</p>
<p>Article number three. Cardiovascular pharmacotherapy in year in 2025. Significant advances in cardiovascular pharmacotherapy were identified, including the approval of four new drugs: aficamten, etripamil, lerodalcibep, and plozasiran. Additionally, five already approved drugs received label expansions, broadening their therapeutic applications. The review also summarized key findings from major randomized clinical trials that further advanced treatment strategies, collectively addressing the ongoing need for more effective and safer pharmacological interventions across various cardiovascular diseases.</p>
<p>Article number four. Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF. This retrospective cohort study characterized the economic burden associated with systemic inflammation in patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. The investigation demonstrated the impact of systemic inflammation on real-world healthcare resource utilization and costs within this specific patient population. The findings highlight the critical role of systemic inflammation, detected via high sensitivity C. R. P. testing, in both the pathogenesis and economic implications for these heart failure subtypes.</p>
<p>Article number five. Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. The N. O. B. L. E. trial delivered its 10-year final results, directly comparing percutaneous coronary intervention with newer generation drug-eluting stents against coronary artery bypass grafting for unprotected left main coronary artery stenosis. This randomized, open-label, non-inferiority investigation provided crucial long-term outcome data in a patient population where coronary artery bypass grafting has traditionally been the recommended treatment. The study offered definitive long-term insights to guide treatment decisions for this significant cardiovascular condition. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure with preserved ejection fraction, coronary artery bypass grafting, label expansions, proteome, high sensitivity C. R. P., cellular dysfunction, N. O. B. L. E. trial, heart failure with mildly reduced ejection fraction, aficamten, percutaneous coronary intervention, transcriptome, healthcare resource utilization, randomized clinical trials, thrombosis risk, new drug approvals, congenital Long Q. T. syndrome, cardiovascular pharmacotherapy, bleeding risk, active cancer, systemic inflammation, drug-eluting stents, unprotected left main coronary artery disease, inducible pluripotent stem cell-derived cardiomyocytes, acute myocardial infarction, dual antiplatelet therapy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/">NOBLE Trial’s 10-Year Left Main Data 04/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with preserved ejection fraction and coronary artery bypass grafting. Key takeaway: NOBLE Trial&#8217;s 10-Year Left Main]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with preserved ejection fraction and coronary artery bypass grafting. Key takeaway: NOBLE Trial&#8217;s 10-Year Left Main Data.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41936938">Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41936851">Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41935384">Cardiovascular pharmacotherapy in year in 2025.</a> (European heart journal. Cardiovascular pharmacotherapy)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41936927">Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF.</a> (American heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41936368">Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.</a> (Lancet (London, England))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/">https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936938</a></p>
<p><strong>Summary:</strong> The study demonstrated broad cellular dysfunction in congenital Long Q. T. syndrome. This finding emerged from integrating transcriptomic and proteomic profiles of patient-derived inducible pluripotent stem cell-derived cardiomyocyte models representing L. Q. T. type one, L. Q. T. type two, and L. Q. T. type three genotypes. The investigation also incorporated population-level Q. T. genome-wide association study data, revealing cellular impairments beyond mere ion channel dysfunction and providing a deeper understanding of the disease&#8217;s mechanisms.</p>
<h4>Article 2: Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936851</a></p>
<p><strong>Summary:</strong> The global registry study characterized the utilization patterns and associated outcomes of dual antiplatelet therapy in patients with active cancer experiencing acute myocardial infarction. The investigation addressed the critical clinical challenge of balancing competing risks of thrombosis and bleeding when selecting optimal therapy in this high-mortality population. It comprehensively analyzed therapy use and outcomes, with all-cause mortality serving as the primary endpoint in these complex patients.</p>
<h4>Article 3: Cardiovascular pharmacotherapy in year in 2025.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular pharmacotherapy</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41935384" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41935384</a></p>
<p><strong>Summary:</strong> Significant advances in cardiovascular pharmacotherapy were identified, including the approval of four new drugs: aficamten, etripamil, lerodalcibep, and plozasiran. Additionally, five already approved drugs received label expansions, broadening their therapeutic applications. The review also summarized key findings from major randomized clinical trials that further advanced treatment strategies, collectively addressing the ongoing need for more effective and safer pharmacological interventions across various cardiovascular diseases.</p>
<h4>Article 4: Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936927" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936927</a></p>
<p><strong>Summary:</strong> This retrospective cohort study characterized the economic burden associated with systemic inflammation in patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. The investigation demonstrated the impact of systemic inflammation on real-world healthcare resource utilization and costs within this specific patient population. The findings highlight the critical role of systemic inflammation, detected via high sensitivity C. R. P. testing, in both the pathogenesis and economic implications for these heart failure subtypes.</p>
<h4>Article 5: Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41936368" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41936368</a></p>
<p><strong>Summary:</strong> The N. O. B. L. E. trial delivered its 10-year final results, directly comparing percutaneous coronary intervention with newer generation drug-eluting stents against coronary artery bypass grafting for unprotected left main coronary artery stenosis. This randomized, open-label, non-inferiority investigation provided crucial long-term outcome data in a patient population where coronary artery bypass grafting has traditionally been the recommended treatment. The study offered definitive long-term insights to guide treatment decisions for this significant cardiovascular condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction. The study demonstrated broad cellular dysfunction in congenital Long Q. T. syndrome. This finding emerged from integrating transcriptomic and proteomic profiles of patient-derived inducible pluripotent stem cell-derived cardiomyocyte models representing L. Q. T. type one, L. Q. T. type two, and L. Q. T. type three genotypes. The investigation also incorporated population-level Q. T. genome-wide association study data, revealing cellular impairments beyond mere ion channel dysfunction and providing a deeper understanding of the disease&#8217;s mechanisms.</p>
<p>Article number two. Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study. The global registry study characterized the utilization patterns and associated outcomes of dual antiplatelet therapy in patients with active cancer experiencing acute myocardial infarction. The investigation addressed the critical clinical challenge of balancing competing risks of thrombosis and bleeding when selecting optimal therapy in this high-mortality population. It comprehensively analyzed therapy use and outcomes, with all-cause mortality serving as the primary endpoint in these complex patients.</p>
<p>Article number three. Cardiovascular pharmacotherapy in year in 2025. Significant advances in cardiovascular pharmacotherapy were identified, including the approval of four new drugs: aficamten, etripamil, lerodalcibep, and plozasiran. Additionally, five already approved drugs received label expansions, broadening their therapeutic applications. The review also summarized key findings from major randomized clinical trials that further advanced treatment strategies, collectively addressing the ongoing need for more effective and safer pharmacological interventions across various cardiovascular diseases.</p>
<p>Article number four. Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF. This retrospective cohort study characterized the economic burden associated with systemic inflammation in patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. The investigation demonstrated the impact of systemic inflammation on real-world healthcare resource utilization and costs within this specific patient population. The findings highlight the critical role of systemic inflammation, detected via high sensitivity C. R. P. testing, in both the pathogenesis and economic implications for these heart failure subtypes.</p>
<p>Article number five. Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. The N. O. B. L. E. trial delivered its 10-year final results, directly comparing percutaneous coronary intervention with newer generation drug-eluting stents against coronary artery bypass grafting for unprotected left main coronary artery stenosis. This randomized, open-label, non-inferiority investigation provided crucial long-term outcome data in a patient population where coronary artery bypass grafting has traditionally been the recommended treatment. The study offered definitive long-term insights to guide treatment decisions for this significant cardiovascular condition. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure with preserved ejection fraction, coronary artery bypass grafting, label expansions, proteome, high sensitivity C. R. P., cellular dysfunction, N. O. B. L. E. trial, heart failure with mildly reduced ejection fraction, aficamten, percutaneous coronary intervention, transcriptome, healthcare resource utilization, randomized clinical trials, thrombosis risk, new drug approvals, congenital Long Q. T. syndrome, cardiovascular pharmacotherapy, bleeding risk, active cancer, systemic inflammation, drug-eluting stents, unprotected left main coronary artery disease, inducible pluripotent stem cell-derived cardiomyocytes, acute myocardial infarction, dual antiplatelet therapy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/">NOBLE Trial’s 10-Year Left Main Data 04/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260406_060048.mp3" length="4212444" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with preserved ejection fraction and coronary artery bypass grafting. Key takeaway: NOBLE Trial&#8217;s 10-Year Left Main Data.
Article Links:
Article 1: Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction. (Heart rhythm)
Article 2: Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study. (The American journal of cardiology)
Article 3: Cardiovascular pharmacotherapy in year in 2025. (European heart journal. Cardiovascular pharmacotherapy)
Article 4: Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF. (American heart journal)
Article 5: Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. (Lancet (London, England))
Full episode page: https://podcast.explainheart.com/podcast/noble-trials-10-year-left-main-data-04-06-26/
 Featured Articles
Article 1: Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41936938
Summary: The study demonstrated broad cellular dysfunction in congenital Long Q. T. syndrome. This finding emerged from integrating transcriptomic and proteomic profiles of patient-derived inducible pluripotent stem cell-derived cardiomyocyte models representing L. Q. T. type one, L. Q. T. type two, and L. Q. T. type three genotypes. The investigation also incorporated population-level Q. T. genome-wide association study data, revealing cellular impairments beyond mere ion channel dysfunction and providing a deeper understanding of the disease&#8217;s mechanisms.
Article 2: Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41936851
Summary: The global registry study characterized the utilization patterns and associated outcomes of dual antiplatelet therapy in patients with active cancer experiencing acute myocardial infarction. The investigation addressed the critical clinical challenge of balancing competing risks of thrombosis and bleeding when selecting optimal therapy in this high-mortality population. It comprehensively analyzed therapy use and outcomes, with all-cause mortality serving as the primary endpoint in these complex patients.
Article 3: Cardiovascular pharmacotherapy in year in 2025.
Journal: European heart journal. Cardiovascular pharmacotherapy
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41935384
Summary: Significant advances in cardiovascular pharmacotherapy were identified, including the approval of four new drugs: aficamten, etripamil, lerodalcibep, and plozasiran. Additionally, five already approved drugs received label expansions, broadening their therapeutic applications. The review also summarized key findings from major randomized clinical trials that further advanced treatment strategies, collectively addressing the ongoing need for more effective and safer pharmacological interventions across various cardiovascular diseases.
Article 4: Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF.
Journal: American heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41936927
Summary: This retrospective cohort study characterized the economic burden associated with systemic inflammation ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with preserved ejection fraction and coronary artery bypass grafting. Key takeaway: NOBLE Trial&#8217;s 10-Year Left Main Data.
Article Links:
Article 1: Beyond ion channel dysfunction: Integration of the transcriptome and proteome from patient-specific re-engineered cardiac cells, and population-level QT genome-wide association study reveals broad cellular dysfunction. (Heart rhythm)
Article 2: Utilization and Outcomes of Dual Antiplatelet Therapy in Patients with Active Cancer Presenting with Acute Myocardial Infarction: A Global Registry Study. (The American journal of cardiology)
Article 3: Cardiovascular pharmacotherapy in year in 2025. (European heart journal. Cardiovascular pharmacotherapy)
Article 4: Economic Burden Associated with Systemic Inflammation in Patients with HFmrEF/HFpEF. (American heart journal)
Article 5: Percutaneous coronary inter]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Stroke Volume Index for Pediatric P.A.H. Prognosis 04/05/26</title>
	<link>https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/</link>
	<pubDate>Sun, 05 Apr 2026 10:02:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 05, 2026. This episode summarizes 2 key cardiology studies on topics like excitation-contraction coupling and right heart catheterization. Key takeaway: Stroke Volume Index for Pediatric P.A.H. Prognosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41926628">Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41925853">Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/">https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926628</a></p>
<p><strong>Summary:</strong> This study found that long-term genetic inhibition of Orai1, a store-operated calcium channel, modulates excitation-contraction coupling in adult mouse ventricular cardiomyocytes. Using a mouse model expressing a dominant-negative human Orai1R91W mutant, researchers observed elevated intracellular calcium transients and calcium spark amplitudes in female mice compared to wild-type controls. These specific findings demonstrate a sex-specific contribution of Orai1 to cardiac excitation-contraction coupling. This indicates a novel role for Orai1 in cardiac function that varies between sexes.</p>
<h4>Article 2: Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41925853" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41925853</a></p>
<p><strong>Summary:</strong> This retrospective study determined the clinical utility of stroke volume index in children with idiopathic and heritable pulmonary arterial hypertension. It assessed the prognostic value of stroke volume index, which was evaluated by right heart catheterization, in 103 pediatric patients. The study found a relationship between stroke volume index and adverse outcomes, specifically lung transplant and cardiac death. These findings establish stroke volume index as a valuable prognostic indicator in this pediatric patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes. This study found that long-term genetic inhibition of Orai1, a store-operated calcium channel, modulates excitation-contraction coupling in adult mouse ventricular cardiomyocytes. Using a mouse model expressing a dominant-negative human Orai1R91W mutant, researchers observed elevated intracellular calcium transients and calcium spark amplitudes in female mice compared to wild-type controls. These specific findings demonstrate a sex-specific contribution of Orai1 to cardiac excitation-contraction coupling. This indicates a novel role for Orai1 in cardiac function that varies between sexes.</p>
<p>Article number two. Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. This retrospective study determined the clinical utility of stroke volume index in children with idiopathic and heritable pulmonary arterial hypertension. It assessed the prognostic value of stroke volume index, which was evaluated by right heart catheterization, in 103 pediatric patients. The study found a relationship between stroke volume index and adverse outcomes, specifically lung transplant and cardiac death. These findings establish stroke volume index as a valuable prognostic indicator in this pediatric patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>excitation-contraction coupling, right heart catheterization, sex-specific differences, pediatric cardiology, pulmonary arterial hypertension, calcium transients, ventricular cardiomyocytes, Orai1 channel, Stroke volume index, prognostic value.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/">Stroke Volume Index for Pediatric P.A.H. Prognosis 04/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 05, 2026. This episode summarizes 2 key cardiology studies on topics like excitation-contraction coupling and right heart catheterization. Key takeaway: Stroke Volume Index for Pediatric P.A.H. Prognosis.
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 05, 2026. This episode summarizes 2 key cardiology studies on topics like excitation-contraction coupling and right heart catheterization. Key takeaway: Stroke Volume Index for Pediatric P.A.H. Prognosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41926628">Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41925853">Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/">https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926628</a></p>
<p><strong>Summary:</strong> This study found that long-term genetic inhibition of Orai1, a store-operated calcium channel, modulates excitation-contraction coupling in adult mouse ventricular cardiomyocytes. Using a mouse model expressing a dominant-negative human Orai1R91W mutant, researchers observed elevated intracellular calcium transients and calcium spark amplitudes in female mice compared to wild-type controls. These specific findings demonstrate a sex-specific contribution of Orai1 to cardiac excitation-contraction coupling. This indicates a novel role for Orai1 in cardiac function that varies between sexes.</p>
<h4>Article 2: Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41925853" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41925853</a></p>
<p><strong>Summary:</strong> This retrospective study determined the clinical utility of stroke volume index in children with idiopathic and heritable pulmonary arterial hypertension. It assessed the prognostic value of stroke volume index, which was evaluated by right heart catheterization, in 103 pediatric patients. The study found a relationship between stroke volume index and adverse outcomes, specifically lung transplant and cardiac death. These findings establish stroke volume index as a valuable prognostic indicator in this pediatric patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes. This study found that long-term genetic inhibition of Orai1, a store-operated calcium channel, modulates excitation-contraction coupling in adult mouse ventricular cardiomyocytes. Using a mouse model expressing a dominant-negative human Orai1R91W mutant, researchers observed elevated intracellular calcium transients and calcium spark amplitudes in female mice compared to wild-type controls. These specific findings demonstrate a sex-specific contribution of Orai1 to cardiac excitation-contraction coupling. This indicates a novel role for Orai1 in cardiac function that varies between sexes.</p>
<p>Article number two. Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. This retrospective study determined the clinical utility of stroke volume index in children with idiopathic and heritable pulmonary arterial hypertension. It assessed the prognostic value of stroke volume index, which was evaluated by right heart catheterization, in 103 pediatric patients. The study found a relationship between stroke volume index and adverse outcomes, specifically lung transplant and cardiac death. These findings establish stroke volume index as a valuable prognostic indicator in this pediatric patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>excitation-contraction coupling, right heart catheterization, sex-specific differences, pediatric cardiology, pulmonary arterial hypertension, calcium transients, ventricular cardiomyocytes, Orai1 channel, Stroke volume index, prognostic value.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/">Stroke Volume Index for Pediatric P.A.H. Prognosis 04/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260405_060202.mp3" length="1994753" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 05, 2026. This episode summarizes 2 key cardiology studies on topics like excitation-contraction coupling and right heart catheterization. Key takeaway: Stroke Volume Index for Pediatric P.A.H. Prognosis.
Article Links:
Article 1: Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes. (American journal of physiology. Heart and circulatory physiology)
Article 2: Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. (Pediatric cardiology)
Full episode page: https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/
 Featured Articles
Article 1: Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41926628
Summary: This study found that long-term genetic inhibition of Orai1, a store-operated calcium channel, modulates excitation-contraction coupling in adult mouse ventricular cardiomyocytes. Using a mouse model expressing a dominant-negative human Orai1R91W mutant, researchers observed elevated intracellular calcium transients and calcium spark amplitudes in female mice compared to wild-type controls. These specific findings demonstrate a sex-specific contribution of Orai1 to cardiac excitation-contraction coupling. This indicates a novel role for Orai1 in cardiac function that varies between sexes.
Article 2: Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.
Journal: Pediatric cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41925853
Summary: This retrospective study determined the clinical utility of stroke volume index in children with idiopathic and heritable pulmonary arterial hypertension. It assessed the prognostic value of stroke volume index, which was evaluated by right heart catheterization, in 103 pediatric patients. The study found a relationship between stroke volume index and adverse outcomes, specifically lung transplant and cardiac death. These findings establish stroke volume index as a valuable prognostic indicator in this pediatric patient population.
 Transcript

Today&#8217;s date is April 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes. This study found that long-term genetic inhibition of Orai1, a store-operated calcium channel, modulates excitation-contraction coupling in adult mouse ventricular cardiomyocytes. Using a mouse model expressing a dominant-negative human Orai1R91W mutant, researchers observed elevated intracellular calcium transients and calcium spark amplitudes in female mice compared to wild-type controls. These specific findings demonstrate a sex-specific contribution of Orai1 to cardiac excitation-contraction coupling. This indicates a novel role for Orai1 in cardiac function that varies between sexes.
Article number two. Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. This retrospective study determined the clinical utility of stroke volume index in children with idiopathic and heritable pulmonary arterial hypertension. It assessed the prognostic value of stroke volume index, which was evaluated by right heart catheterization, in 103 pediatric patients. The study found a relationship between stroke volume index and adverse outcomes, specifically lung transplant and cardiac death. These findings establish stroke volume index as a valuable prognostic indicator in this pediatric patient population. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
excita]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 05, 2026. This episode summarizes 2 key cardiology studies on topics like excitation-contraction coupling and right heart catheterization. Key takeaway: Stroke Volume Index for Pediatric P.A.H. Prognosis.
Article Links:
Article 1: Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes. (American journal of physiology. Heart and circulatory physiology)
Article 2: Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. (Pediatric cardiology)
Full episode page: https://podcast.explainheart.com/podcast/stroke-volume-index-for-pediatric-p-a-h-prognosis-04-05-26/
 Featured Articles
Article 1: Long-term genetic Orai1 inhibition modulates excitation-contraction coupling in female adult mouse ventricular cardiomyocytes.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.n]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TCF21 Protects Heart Against Fibrosis 04/05/26</title>
	<link>https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/</link>
	<pubDate>Sun, 05 Apr 2026 05:09:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 05, 2026. This episode summarizes 5 key cardiology studies on topics like wall thickness heterogeneity and hypertrophic cardiomyopathy. Key takeaway: TCF21 Protects Heart Against Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41928451">Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41926244">Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41930396">How Accurate Is Inpatient Blood Pressure Measurement?</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41930410">Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41923453">MRI-derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/">https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41928451" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41928451</a></p>
<p><strong>Summary:</strong> This study revealed a homogenization of the right and left atrial proteomes in patients with persistent atrial fibrillation. Researchers used a proteomic approach to investigate atrial fibrillation-associated remodeling in the right atrium relative to the left atrium. The data showed that protein profiles in both atria become similar during persistent atrial fibrillation. This finding indicates widespread atrial remodeling extending beyond the left atrium in this patient population.</p>
<h4>Article 2: Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926244" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926244</a></p>
<p><strong>Summary:</strong> Single nucleus R. N. A. sequencing and functional in vivo studies demonstrated that TCF21 acts as a protective regulator in cardiac fibrosis. This research specifically identified TCF21 as a novel cell-specific candidate gene involved in cardiac fibrosis. The study validated the functional impact of TCF21 using both in vitro and in vivo models. These findings offer a significant breakthrough for cardiac fibrosis, an untreatable contributor to mortality in chronic heart disease.</p>
<h4>Article 3: How Accurate Is Inpatient Blood Pressure Measurement?</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41930396" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41930396</a></p>
<p><strong>Summary:</strong> Observations were conducted across three noncritical care wards: aged care, acute surgical, and hematology, over a three-week period. The investigation revealed that no existing guidelines for accurate inpatient blood pressure measurement are currently in place. This highlights a critical need for standardized quality techniques in this clinical setting.</p>
<h4>Article 4: Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41930410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41930410</a></p>
<p><strong>Summary:</strong> This study characterized endocardial and epicardial left atrial posterior wall activation in humans during atrial fibrillation. Researchers identified epicardial-to-endocardial activation gradients and conduction blocks within the left atrial posterior wall. The findings demonstrated the prevalence of asynchronous endocardial-epicardial conduction in this region for patients with symptomatic nonparoxysmal atrial fibrillation. This research provides crucial insights into three-dimensional myocardial activation patterns during atrial fibrillation.</p>
<h4>Article 5: MRI-derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41923453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41923453</a></p>
<p><strong>Summary:</strong> R. I. derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations. This study demonstrated that wall thickness standard deviation, reflecting wall thickness heterogeneity, improves the identification of hypertrophic cardiomyopathy and sarcomere mutation carriers. Researchers utilized cardiac magnetic resonance imaging in 382 healthy controls, 297 patients with hypertrophic cardiomyopathy, and 82 sarcomere mutation carriers. The data showed that this measure helps identify early or subtle phenotypes missed by absolute wall thickness cut-offs. This method enhances diagnostic capabilities, particularly for mutation carriers.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients. This study revealed a homogenization of the right and left atrial proteomes in patients with persistent atrial fibrillation. Researchers used a proteomic approach to investigate atrial fibrillation-associated remodeling in the right atrium relative to the left atrium. The data showed that protein profiles in both atria become similar during persistent atrial fibrillation. This finding indicates widespread atrial remodeling extending beyond the left atrium in this patient population.</p>
<p>Article number two. Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis. Single nucleus R. N. A. sequencing and functional in vivo studies demonstrated that TCF21 acts as a protective regulator in cardiac fibrosis. This research specifically identified TCF21 as a novel cell-specific candidate gene involved in cardiac fibrosis. The study validated the functional impact of TCF21 using both in vitro and in vivo models. These findings offer a significant breakthrough for cardiac fibrosis, an untreatable contributor to mortality in chronic heart disease.</p>
<p>Article number three. How Accurate Is Inpatient Blood Pressure Measurement? This study assessed the performance of routine blood pressure measurements in a major teaching hospital. Observations were conducted across three noncritical care wards: aged care, acute surgical, and hematology, over a three-week period. The investigation revealed that no existing guidelines for accurate inpatient blood pressure measurement are currently in place. This highlights a critical need for standardized quality techniques in this clinical setting.</p>
<p>Article number four. Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall. This study characterized endocardial and epicardial left atrial posterior wall activation in humans during atrial fibrillation. Researchers identified epicardial-to-endocardial activation gradients and conduction blocks within the left atrial posterior wall. The findings demonstrated the prevalence of asynchronous endocardial-epicardial conduction in this region for patients with symptomatic nonparoxysmal atrial fibrillation. This research provides crucial insights into three-dimensional myocardial activation patterns during atrial fibrillation.</p>
<p>Article number five. M. R. I. derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations. This study demonstrated that wall thickness standard deviation, reflecting wall thickness heterogeneity, improves the identification of hypertrophic cardiomyopathy and sarcomere mutation carriers. Researchers utilized cardiac magnetic resonance imaging in 382 healthy controls, 297 patients with hypertrophic cardiomyopathy, and 82 sarcomere mutation carriers. The data showed that this measure helps identify early or subtle phenotypes missed by absolute wall thickness cut-offs. This method enhances diagnostic capabilities, particularly for mutation carriers. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>wall thickness heterogeneity, hypertrophic cardiomyopathy, single nucleus R. N. A. sequencing, atrial fibrillation, blood pressure measurement, epicardial, persistent atrial fibrillation, sarcomere gene mutations, proteome profiling, conduction block, diagnostic criteria, left atrial posterior wall, left atrium, TCF21, right atrium, measurement accuracy, protective regulator, endocardial, hospital practice, clinical guidelines, cardiac magnetic resonance, aortic stenosis, inpatient care, cardiac fibrosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/">TCF21 Protects Heart Against Fibrosis 04/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 05, 2026. This episode summarizes 5 key cardiology studies on topics like wall thickness heterogeneity and hypertrophic cardiomyopathy. Key takeaway: TCF21 Protects Heart Against Fibrosis.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 05, 2026. This episode summarizes 5 key cardiology studies on topics like wall thickness heterogeneity and hypertrophic cardiomyopathy. Key takeaway: TCF21 Protects Heart Against Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41928451">Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41926244">Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41930396">How Accurate Is Inpatient Blood Pressure Measurement?</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41930410">Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41923453">MRI-derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/">https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41928451" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41928451</a></p>
<p><strong>Summary:</strong> This study revealed a homogenization of the right and left atrial proteomes in patients with persistent atrial fibrillation. Researchers used a proteomic approach to investigate atrial fibrillation-associated remodeling in the right atrium relative to the left atrium. The data showed that protein profiles in both atria become similar during persistent atrial fibrillation. This finding indicates widespread atrial remodeling extending beyond the left atrium in this patient population.</p>
<h4>Article 2: Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926244" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926244</a></p>
<p><strong>Summary:</strong> Single nucleus R. N. A. sequencing and functional in vivo studies demonstrated that TCF21 acts as a protective regulator in cardiac fibrosis. This research specifically identified TCF21 as a novel cell-specific candidate gene involved in cardiac fibrosis. The study validated the functional impact of TCF21 using both in vitro and in vivo models. These findings offer a significant breakthrough for cardiac fibrosis, an untreatable contributor to mortality in chronic heart disease.</p>
<h4>Article 3: How Accurate Is Inpatient Blood Pressure Measurement?</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41930396" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41930396</a></p>
<p><strong>Summary:</strong> Observations were conducted across three noncritical care wards: aged care, acute surgical, and hematology, over a three-week period. The investigation revealed that no existing guidelines for accurate inpatient blood pressure measurement are currently in place. This highlights a critical need for standardized quality techniques in this clinical setting.</p>
<h4>Article 4: Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41930410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41930410</a></p>
<p><strong>Summary:</strong> This study characterized endocardial and epicardial left atrial posterior wall activation in humans during atrial fibrillation. Researchers identified epicardial-to-endocardial activation gradients and conduction blocks within the left atrial posterior wall. The findings demonstrated the prevalence of asynchronous endocardial-epicardial conduction in this region for patients with symptomatic nonparoxysmal atrial fibrillation. This research provides crucial insights into three-dimensional myocardial activation patterns during atrial fibrillation.</p>
<h4>Article 5: MRI-derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41923453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41923453</a></p>
<p><strong>Summary:</strong> R. I. derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations. This study demonstrated that wall thickness standard deviation, reflecting wall thickness heterogeneity, improves the identification of hypertrophic cardiomyopathy and sarcomere mutation carriers. Researchers utilized cardiac magnetic resonance imaging in 382 healthy controls, 297 patients with hypertrophic cardiomyopathy, and 82 sarcomere mutation carriers. The data showed that this measure helps identify early or subtle phenotypes missed by absolute wall thickness cut-offs. This method enhances diagnostic capabilities, particularly for mutation carriers.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients. This study revealed a homogenization of the right and left atrial proteomes in patients with persistent atrial fibrillation. Researchers used a proteomic approach to investigate atrial fibrillation-associated remodeling in the right atrium relative to the left atrium. The data showed that protein profiles in both atria become similar during persistent atrial fibrillation. This finding indicates widespread atrial remodeling extending beyond the left atrium in this patient population.</p>
<p>Article number two. Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis. Single nucleus R. N. A. sequencing and functional in vivo studies demonstrated that TCF21 acts as a protective regulator in cardiac fibrosis. This research specifically identified TCF21 as a novel cell-specific candidate gene involved in cardiac fibrosis. The study validated the functional impact of TCF21 using both in vitro and in vivo models. These findings offer a significant breakthrough for cardiac fibrosis, an untreatable contributor to mortality in chronic heart disease.</p>
<p>Article number three. How Accurate Is Inpatient Blood Pressure Measurement? This study assessed the performance of routine blood pressure measurements in a major teaching hospital. Observations were conducted across three noncritical care wards: aged care, acute surgical, and hematology, over a three-week period. The investigation revealed that no existing guidelines for accurate inpatient blood pressure measurement are currently in place. This highlights a critical need for standardized quality techniques in this clinical setting.</p>
<p>Article number four. Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall. This study characterized endocardial and epicardial left atrial posterior wall activation in humans during atrial fibrillation. Researchers identified epicardial-to-endocardial activation gradients and conduction blocks within the left atrial posterior wall. The findings demonstrated the prevalence of asynchronous endocardial-epicardial conduction in this region for patients with symptomatic nonparoxysmal atrial fibrillation. This research provides crucial insights into three-dimensional myocardial activation patterns during atrial fibrillation.</p>
<p>Article number five. M. R. I. derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations. This study demonstrated that wall thickness standard deviation, reflecting wall thickness heterogeneity, improves the identification of hypertrophic cardiomyopathy and sarcomere mutation carriers. Researchers utilized cardiac magnetic resonance imaging in 382 healthy controls, 297 patients with hypertrophic cardiomyopathy, and 82 sarcomere mutation carriers. The data showed that this measure helps identify early or subtle phenotypes missed by absolute wall thickness cut-offs. This method enhances diagnostic capabilities, particularly for mutation carriers. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>wall thickness heterogeneity, hypertrophic cardiomyopathy, single nucleus R. N. A. sequencing, atrial fibrillation, blood pressure measurement, epicardial, persistent atrial fibrillation, sarcomere gene mutations, proteome profiling, conduction block, diagnostic criteria, left atrial posterior wall, left atrium, TCF21, right atrium, measurement accuracy, protective regulator, endocardial, hospital practice, clinical guidelines, cardiac magnetic resonance, aortic stenosis, inpatient care, cardiac fibrosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/">TCF21 Protects Heart Against Fibrosis 04/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260405_010809.mp3" length="4112970" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 05, 2026. This episode summarizes 5 key cardiology studies on topics like wall thickness heterogeneity and hypertrophic cardiomyopathy. Key takeaway: TCF21 Protects Heart Against Fibrosis.
Article Links:
Article 1: Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients. (Cardiovascular research)
Article 2: Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis. (Cardiovascular research)
Article 3: How Accurate Is Inpatient Blood Pressure Measurement? (Hypertension (Dallas, Tex. : 1979))
Article 4: Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall. (Circulation. Arrhythmia and electrophysiology)
Article 5: MRI-derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations. (European heart journal. Cardiovascular Imaging)
Full episode page: https://podcast.explainheart.com/podcast/tcf21-protects-heart-against-fibrosis-04-05-26/
 Featured Articles
Article 1: Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41928451
Summary: This study revealed a homogenization of the right and left atrial proteomes in patients with persistent atrial fibrillation. Researchers used a proteomic approach to investigate atrial fibrillation-associated remodeling in the right atrium relative to the left atrium. The data showed that protein profiles in both atria become similar during persistent atrial fibrillation. This finding indicates widespread atrial remodeling extending beyond the left atrium in this patient population.
Article 2: Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41926244
Summary: Single nucleus R. N. A. sequencing and functional in vivo studies demonstrated that TCF21 acts as a protective regulator in cardiac fibrosis. This research specifically identified TCF21 as a novel cell-specific candidate gene involved in cardiac fibrosis. The study validated the functional impact of TCF21 using both in vitro and in vivo models. These findings offer a significant breakthrough for cardiac fibrosis, an untreatable contributor to mortality in chronic heart disease.
Article 3: How Accurate Is Inpatient Blood Pressure Measurement?
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41930396
Summary: Observations were conducted across three noncritical care wards: aged care, acute surgical, and hematology, over a three-week period. The investigation revealed that no existing guidelines for accurate inpatient blood pressure measurement are currently in place. This highlights a critical need for standardized quality techniques in this clinical setting.
Article 4: Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall.
Journal: Circulation. Arrhythmia and electrophysiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41930410
Summary: This study characterized endocardial and epicardial left atrial posterior wall activation in humans during atrial fibrillation. Researchers identified epicardial-to-endocardial activation gradients and conduction blocks within the left atrial posterior wall. The findings demonstrated the prevalence of asynchronous endocardial-epicardial conduction in this region for patients with symptomatic nonparoxysmal atrial fibrillation. This research provides crucial insights into three-dimensional myocardial activatio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 05, 2026. This episode summarizes 5 key cardiology studies on topics like wall thickness heterogeneity and hypertrophic cardiomyopathy. Key takeaway: TCF21 Protects Heart Against Fibrosis.
Article Links:
Article 1: Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients. (Cardiovascular research)
Article 2: Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis. (Cardiovascular research)
Article 3: How Accurate Is Inpatient Blood Pressure Measurement? (Hypertension (Dallas, Tex. : 1979))
Article 4: Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall. (Circulation. Arrhythmia and electrophysiology)
Article 5: MRI-derived Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and i]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Senolytics Prevent Atrial Arrhythmias in Elderly 04/04/26</title>
	<link>https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/</link>
	<pubDate>Sat, 04 Apr 2026 12:52:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia vulnerability and catheter ablation. Key takeaway: Senolytics Prevent Atrial Arrhythmias in Elderly.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41519351">Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41513062">Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41513056">Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41500490">Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41443487">Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/">https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41519351" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41519351</a></p>
<p><strong>Summary:</strong> For patients undergoing repeat catheter ablation for atrial fibrillation (AF), a therapeutic approach involves either redo pulmonary vein isolation (PVI) alone or combining redo PVI with adjunctive posterior wall isolation (PWI). The use of pulsed-field ablation (PFA) is a significant consideration for achieving durable isolation in these procedures. This strategy directly addresses the clinical challenge of recurrent atrial fibrillation by targeting both pulmonary veins and the posterior wall. The comparison of these two ablation strategies provides insights into optimizing outcomes in repeat atrial fibrillation interventions.</p>
<h4>Article 2: Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513062" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513062</a></p>
<p><strong>Summary:</strong> Identifying the critical substrate in scar-dependent ventricular tachycardia (VT) relies on precise mapping for ablation targets. Cardiac magnetic resonance imaging (M. R. I.) provides anatomic assessment (A. A.) to detect channels sustaining ventricular tachycardia. A refined approach involves heart digital twins, which integrate anatomic data with functional assessment for identifying the ventricular tachycardia isthmus. This combined anatomic and functional modeling offers a comprehensive method for characterizing the arrhythmogenic substrate compared to solely anatomic evaluations.</p>
<h4>Article 3: Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513056" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513056</a></p>
<p><strong>Summary:</strong> The study found that senolytic reduction of senescent cells effectively mitigated atrial arrhythmia vulnerability in aging rabbits. Cellular senescence contributes to age-related atrial fibrillation pathogenesis through its senescence-associated secretory phenotype, releasing proinflammatory and profibrotic factors. This research demonstrates a novel therapeutic strategy for age-related atrial arrhythmias by specifically targeting and reducing senescent cells. These findings indicate a direct link between cellular senescence and atrial fibrillation susceptibility in aging hearts.</p>
<h4>Article 4: Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41500490" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41500490</a></p>
<p><strong>Summary:</strong> Intrinsic antitachycardia pacing (iATP) represents a closed-loop algorithm capable of automatically designing and adjusting antitachycardia pacing therapy in real time. This technology effectively prevents defibrillator shocks and associated adverse outcomes, particularly in cases of rapid monomorphic ventricular tachycardia. Real-world performance data demonstrated the operational capability of iATP in a large, global patient cohort equipped with iATP-enabled implantable cardioverter-defibrillators. This confirms iATP&#8217;s role in enhancing arrhythmia management by dynamically tailoring therapy.</p>
<h4>Article 5: Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41443487" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41443487</a></p>
<p><strong>Summary:</strong> The study described Purkinje and septal substrate modification using radiofrequency catheter ablation (R. F. C. A.) as a therapeutic option. This approach targets therapy-refractory ventricular fibrillation (V. F.) in patients after successful percutaneous coronary intervention (P. C. I.) for S. T.-elevation myocardial infarction (S. T. E. M. I.). Ventricular fibrillation remains a fatal complication in this patient population, highlighting the critical need for effective interventions. Modifying the Purkinje network and septal substrate offers a specific strategy to address this life-threatening arrhythmia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation. For patients undergoing repeat catheter ablation for atrial fibrillation (AF), a therapeutic approach involves either redo pulmonary vein isolation (PVI) alone or combining redo PVI with adjunctive posterior wall isolation (PWI). The use of pulsed-field ablation (PFA) is a significant consideration for achieving durable isolation in these procedures. This strategy directly addresses the clinical challenge of recurrent atrial fibrillation by targeting both pulmonary veins and the posterior wall. The comparison of these two ablation strategies provides insights into optimizing outcomes in repeat atrial fibrillation interventions.</p>
<p>Article number two. Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia. Identifying the critical substrate in scar-dependent ventricular tachycardia (VT) relies on precise mapping for ablation targets. Cardiac magnetic resonance imaging (M. R. I.) provides anatomic assessment (A. A.) to detect channels sustaining ventricular tachycardia. A refined approach involves heart digital twins, which integrate anatomic data with functional assessment for identifying the ventricular tachycardia isthmus. This combined anatomic and functional modeling offers a comprehensive method for characterizing the arrhythmogenic substrate compared to solely anatomic evaluations.</p>
<p>Article number three. Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits. The study found that senolytic reduction of senescent cells effectively mitigated atrial arrhythmia vulnerability in aging rabbits. Cellular senescence contributes to age-related atrial fibrillation pathogenesis through its senescence-associated secretory phenotype, releasing proinflammatory and profibrotic factors. This research demonstrates a novel therapeutic strategy for age-related atrial arrhythmias by specifically targeting and reducing senescent cells. These findings indicate a direct link between cellular senescence and atrial fibrillation susceptibility in aging hearts.</p>
<p>Article number four. Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study. Intrinsic antitachycardia pacing (iATP) represents a closed-loop algorithm capable of automatically designing and adjusting antitachycardia pacing therapy in real time. This technology effectively prevents defibrillator shocks and associated adverse outcomes, particularly in cases of rapid monomorphic ventricular tachycardia. Real-world performance data demonstrated the operational capability of iATP in a large, global patient cohort equipped with iATP-enabled implantable cardioverter-defibrillators. This confirms iATP&#8217;s role in enhancing arrhythmia management by dynamically tailoring therapy.</p>
<p>Article number five. Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation. The study described Purkinje and septal substrate modification using radiofrequency catheter ablation (R. F. C. A.) as a therapeutic option. This approach targets therapy-refractory ventricular fibrillation (V. F.) in patients after successful percutaneous coronary intervention (P. C. I.) for S. T.-elevation myocardial infarction (S. T. E. M. I.). Ventricular fibrillation remains a fatal complication in this patient population, highlighting the critical need for effective interventions. Modifying the Purkinje network and septal substrate offers a specific strategy to address this life-threatening arrhythmia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>arrhythmia vulnerability, catheter ablation, S. T.-elevation myocardial infarction, pulmonary vein isolation, aging, heart digital twins, atrial fibrillation, antitachycardia pacing, cellular senescence, ventricular tachycardia, intrinsic antitachycardia pacing, pulsed-field ablation, posterior wall isolation, Purkinje network, cardiac magnetic resonance imaging, radiofrequency catheter ablation, anatomic assessment, senolytics, substrate mapping, ventricular fibrillation, arrhythmia management, septal substrate, implantable cardioverter-defibrillator.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/">Senolytics Prevent Atrial Arrhythmias in Elderly 04/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia vulnerability and catheter ablation. Key takeaway: Senolytics Prevent Atrial Arrhythmias in Elderly.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia vulnerability and catheter ablation. Key takeaway: Senolytics Prevent Atrial Arrhythmias in Elderly.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41519351">Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41513062">Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41513056">Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41500490">Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41443487">Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/">https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41519351" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41519351</a></p>
<p><strong>Summary:</strong> For patients undergoing repeat catheter ablation for atrial fibrillation (AF), a therapeutic approach involves either redo pulmonary vein isolation (PVI) alone or combining redo PVI with adjunctive posterior wall isolation (PWI). The use of pulsed-field ablation (PFA) is a significant consideration for achieving durable isolation in these procedures. This strategy directly addresses the clinical challenge of recurrent atrial fibrillation by targeting both pulmonary veins and the posterior wall. The comparison of these two ablation strategies provides insights into optimizing outcomes in repeat atrial fibrillation interventions.</p>
<h4>Article 2: Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513062" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513062</a></p>
<p><strong>Summary:</strong> Identifying the critical substrate in scar-dependent ventricular tachycardia (VT) relies on precise mapping for ablation targets. Cardiac magnetic resonance imaging (M. R. I.) provides anatomic assessment (A. A.) to detect channels sustaining ventricular tachycardia. A refined approach involves heart digital twins, which integrate anatomic data with functional assessment for identifying the ventricular tachycardia isthmus. This combined anatomic and functional modeling offers a comprehensive method for characterizing the arrhythmogenic substrate compared to solely anatomic evaluations.</p>
<h4>Article 3: Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513056" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513056</a></p>
<p><strong>Summary:</strong> The study found that senolytic reduction of senescent cells effectively mitigated atrial arrhythmia vulnerability in aging rabbits. Cellular senescence contributes to age-related atrial fibrillation pathogenesis through its senescence-associated secretory phenotype, releasing proinflammatory and profibrotic factors. This research demonstrates a novel therapeutic strategy for age-related atrial arrhythmias by specifically targeting and reducing senescent cells. These findings indicate a direct link between cellular senescence and atrial fibrillation susceptibility in aging hearts.</p>
<h4>Article 4: Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41500490" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41500490</a></p>
<p><strong>Summary:</strong> Intrinsic antitachycardia pacing (iATP) represents a closed-loop algorithm capable of automatically designing and adjusting antitachycardia pacing therapy in real time. This technology effectively prevents defibrillator shocks and associated adverse outcomes, particularly in cases of rapid monomorphic ventricular tachycardia. Real-world performance data demonstrated the operational capability of iATP in a large, global patient cohort equipped with iATP-enabled implantable cardioverter-defibrillators. This confirms iATP&#8217;s role in enhancing arrhythmia management by dynamically tailoring therapy.</p>
<h4>Article 5: Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41443487" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41443487</a></p>
<p><strong>Summary:</strong> The study described Purkinje and septal substrate modification using radiofrequency catheter ablation (R. F. C. A.) as a therapeutic option. This approach targets therapy-refractory ventricular fibrillation (V. F.) in patients after successful percutaneous coronary intervention (P. C. I.) for S. T.-elevation myocardial infarction (S. T. E. M. I.). Ventricular fibrillation remains a fatal complication in this patient population, highlighting the critical need for effective interventions. Modifying the Purkinje network and septal substrate offers a specific strategy to address this life-threatening arrhythmia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation. For patients undergoing repeat catheter ablation for atrial fibrillation (AF), a therapeutic approach involves either redo pulmonary vein isolation (PVI) alone or combining redo PVI with adjunctive posterior wall isolation (PWI). The use of pulsed-field ablation (PFA) is a significant consideration for achieving durable isolation in these procedures. This strategy directly addresses the clinical challenge of recurrent atrial fibrillation by targeting both pulmonary veins and the posterior wall. The comparison of these two ablation strategies provides insights into optimizing outcomes in repeat atrial fibrillation interventions.</p>
<p>Article number two. Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia. Identifying the critical substrate in scar-dependent ventricular tachycardia (VT) relies on precise mapping for ablation targets. Cardiac magnetic resonance imaging (M. R. I.) provides anatomic assessment (A. A.) to detect channels sustaining ventricular tachycardia. A refined approach involves heart digital twins, which integrate anatomic data with functional assessment for identifying the ventricular tachycardia isthmus. This combined anatomic and functional modeling offers a comprehensive method for characterizing the arrhythmogenic substrate compared to solely anatomic evaluations.</p>
<p>Article number three. Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits. The study found that senolytic reduction of senescent cells effectively mitigated atrial arrhythmia vulnerability in aging rabbits. Cellular senescence contributes to age-related atrial fibrillation pathogenesis through its senescence-associated secretory phenotype, releasing proinflammatory and profibrotic factors. This research demonstrates a novel therapeutic strategy for age-related atrial arrhythmias by specifically targeting and reducing senescent cells. These findings indicate a direct link between cellular senescence and atrial fibrillation susceptibility in aging hearts.</p>
<p>Article number four. Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study. Intrinsic antitachycardia pacing (iATP) represents a closed-loop algorithm capable of automatically designing and adjusting antitachycardia pacing therapy in real time. This technology effectively prevents defibrillator shocks and associated adverse outcomes, particularly in cases of rapid monomorphic ventricular tachycardia. Real-world performance data demonstrated the operational capability of iATP in a large, global patient cohort equipped with iATP-enabled implantable cardioverter-defibrillators. This confirms iATP&#8217;s role in enhancing arrhythmia management by dynamically tailoring therapy.</p>
<p>Article number five. Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation. The study described Purkinje and septal substrate modification using radiofrequency catheter ablation (R. F. C. A.) as a therapeutic option. This approach targets therapy-refractory ventricular fibrillation (V. F.) in patients after successful percutaneous coronary intervention (P. C. I.) for S. T.-elevation myocardial infarction (S. T. E. M. I.). Ventricular fibrillation remains a fatal complication in this patient population, highlighting the critical need for effective interventions. Modifying the Purkinje network and septal substrate offers a specific strategy to address this life-threatening arrhythmia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>arrhythmia vulnerability, catheter ablation, S. T.-elevation myocardial infarction, pulmonary vein isolation, aging, heart digital twins, atrial fibrillation, antitachycardia pacing, cellular senescence, ventricular tachycardia, intrinsic antitachycardia pacing, pulsed-field ablation, posterior wall isolation, Purkinje network, cardiac magnetic resonance imaging, radiofrequency catheter ablation, anatomic assessment, senolytics, substrate mapping, ventricular fibrillation, arrhythmia management, septal substrate, implantable cardioverter-defibrillator.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/">Senolytics Prevent Atrial Arrhythmias in Elderly 04/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260404_085147.mp3" length="4445665" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia vulnerability and catheter ablation. Key takeaway: Senolytics Prevent Atrial Arrhythmias in Elderly.
Article Links:
Article 1: Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation. (Heart rhythm)
Article 2: Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia. (Heart rhythm)
Article 3: Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits. (Heart rhythm)
Article 4: Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study. (Heart rhythm)
Article 5: Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillation. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/senolytics-prevent-atrial-arrhythmias-in-elderly-04-04-26/
 Featured Articles
Article 1: Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41519351
Summary: For patients undergoing repeat catheter ablation for atrial fibrillation (AF), a therapeutic approach involves either redo pulmonary vein isolation (PVI) alone or combining redo PVI with adjunctive posterior wall isolation (PWI). The use of pulsed-field ablation (PFA) is a significant consideration for achieving durable isolation in these procedures. This strategy directly addresses the clinical challenge of recurrent atrial fibrillation by targeting both pulmonary veins and the posterior wall. The comparison of these two ablation strategies provides insights into optimizing outcomes in repeat atrial fibrillation interventions.
Article 2: Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41513062
Summary: Identifying the critical substrate in scar-dependent ventricular tachycardia (VT) relies on precise mapping for ablation targets. Cardiac magnetic resonance imaging (M. R. I.) provides anatomic assessment (A. A.) to detect channels sustaining ventricular tachycardia. A refined approach involves heart digital twins, which integrate anatomic data with functional assessment for identifying the ventricular tachycardia isthmus. This combined anatomic and functional modeling offers a comprehensive method for characterizing the arrhythmogenic substrate compared to solely anatomic evaluations.
Article 3: Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41513056
Summary: The study found that senolytic reduction of senescent cells effectively mitigated atrial arrhythmia vulnerability in aging rabbits. Cellular senescence contributes to age-related atrial fibrillation pathogenesis through its senescence-associated secretory phenotype, releasing proinflammatory and profibrotic factors. This research demonstrates a novel therapeutic strategy for age-related atrial arrhythmias by specifically targeting and reducing senescent cells. These findings indicate a direct link between cellular senescence and atrial fibrillation susceptibility in aging hearts.
Article 4: Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41500490
Summary: Intrinsic antitachycardia pacing (iATP) represents a closed-loop algorithm capable of automatically designing and adjusting antitachyca]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia vulnerability and catheter ablation. Key takeaway: Senolytics Prevent Atrial Arrhythmias in Elderly.
Article Links:
Article 1: Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation. (Heart rhythm)
Article 2: Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia. (Heart rhythm)
Article 3: Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits. (Heart rhythm)
Article 4: Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study. (Heart rhythm)
Article 5: Purkinje and septal substrate modification as a therapeutic option for patients with STEMI and refractory ventricular fibrillatio]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Bradyarrhythmias Reveal Stroke&#8217;s Atrial Link 04/04/26</title>
	<link>https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/</link>
	<pubDate>Sat, 04 Apr 2026 10:01:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like Acetazolamide and Implantable Loop Recorders. Key takeaway: Bradyarrhythmias Reveal Stroke&#8217;s Atrial Link.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41932644">Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41932822">Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41920937">Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI).</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41932670">Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41519354">Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy?</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/">https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41932644" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41932644</a></p>
<p><strong>Summary:</strong> This study characterized patients with Heart Failure who underwent interhospital transfer, establishing their demographic and clinical profiles. It found significant variations in the utilization of interhospital transfer among different hospitals across the United States. The data revealed distinctions in outcomes between transferred and non-transferred Heart Failure patients. This analysis provided foundational understanding of interhospital transfer patterns in this patient population.</p>
<h4>Article 2: Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41932822" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41932822</a></p>
<p><strong>Summary:</strong> This whole-population study established patterns of cardiac rehabilitation participation following Transcatheter Aortic Valve Implantation across England. It found variations in participation rates before, during, and after the C. O. V. I. D. minus 19 pandemic. The research demonstrated a specific association between cardiac rehabilitation participation and the primary outcome of unplanned all-cause rehospitalization. This analysis provided critical evidence regarding cardiac rehabilitation&#8217;s impact on clinical outcomes in this patient group.</p>
<h4>Article 3: Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI).</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920937" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920937</a></p>
<p><strong>Summary:</strong> The S. A. N. D. I. study investigated the natriuretic and diuretic effects of acetazolamide in patients with acute Heart Failure receiving intravenous furosemide and concomitant Sodium-Glucose Cotransporter-two Inhibitors. It found that acetazolamide provided significant natriuretic and diuretic benefits in this specific patient population, demonstrating enhanced decongestion. This research established the efficacy of adjunctive acetazolamide in acute Heart Failure patients who are also on Sodium-Glucose Cotransporter-two Inhibitors, addressing a previously unknown therapeutic gap.</p>
<h4>Article 4: Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41932670" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41932670</a></p>
<p><strong>Summary:</strong> This study elucidated the relationship between intra-septal lead position in Left Bundle Branch Area Pacing and paced QRS morphology. It found that ultra-high-resolution Photon-Counting Computed Tomography precisely evaluated lead-tip location in 20 patients, differentiating between Left Bundle Branch Pacing, Left Ventricular Septal Pacing, and Deep Septal Pacing. The data established specific distances and spatial orientations of pacing leads within the septum, directly informing optimal lead placement strategies for physiological pacing.</p>
<h4>Article 5: Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy?</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41519354" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41519354</a></p>
<p><strong>Summary:</strong> It found a notable burden of bradyarrhythmias in these patients compared with a matched control group. The data demonstrated that clinically significant bradyarrhythmias are a significant finding in this population, suggesting a potential manifestation of underlying atrial cardiomyopathy beyond Atrial Fibrillation detection.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF. This study characterized patients with Heart Failure who underwent interhospital transfer, establishing their demographic and clinical profiles. It found significant variations in the utilization of interhospital transfer among different hospitals across the United States. The data revealed distinctions in outcomes between transferred and non-transferred Heart Failure patients. This analysis provided foundational understanding of interhospital transfer patterns in this patient population.</p>
<p>Article number two. Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study. This whole-population study established patterns of cardiac rehabilitation participation following Transcatheter Aortic Valve Implantation across England. It found variations in participation rates before, during, and after the C. O. V. I. D. minus 19 pandemic. The research demonstrated a specific association between cardiac rehabilitation participation and the primary outcome of unplanned all-cause rehospitalization. This analysis provided critical evidence regarding cardiac rehabilitation&#8217;s impact on clinical outcomes in this patient group.</p>
<p>Article number three. Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI). The S. A. N. D. I. study investigated the natriuretic and diuretic effects of acetazolamide in patients with acute Heart Failure receiving intravenous furosemide and concomitant Sodium-Glucose Cotransporter-two Inhibitors. It found that acetazolamide provided significant natriuretic and diuretic benefits in this specific patient population, demonstrating enhanced decongestion. This research established the efficacy of adjunctive acetazolamide in acute Heart Failure patients who are also on Sodium-Glucose Cotransporter-two Inhibitors, addressing a previously unknown therapeutic gap.</p>
<p>Article number four. Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography. This study elucidated the relationship between intra-septal lead position in Left Bundle Branch Area Pacing and paced QRS morphology. It found that ultra-high-resolution Photon-Counting Computed Tomography precisely evaluated lead-tip location in 20 patients, differentiating between Left Bundle Branch Pacing, Left Ventricular Septal Pacing, and Deep Septal Pacing. The data established specific distances and spatial orientations of pacing leads within the septum, directly informing optimal lead placement strategies for physiological pacing.</p>
<p>Article number five. Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy? This study established the prevalence and clinical significance of bradyarrhythmias in patients with cryptogenic stroke or transient ischemic attack who received implantable loop recorders. It found a notable burden of bradyarrhythmias in these patients compared with a matched control group. The data demonstrated that clinically significant bradyarrhythmias are a significant finding in this population, suggesting a potential manifestation of underlying atrial cardiomyopathy beyond Atrial Fibrillation detection. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Acetazolamide, Implantable Loop Recorders, QRS Morphology, Hospital Variation, Sodium-Glucose Cotransporter-two Inhibitors, Heart Failure, Acute Heart Failure, Quality Improvement, Atrial Cardiomyopathy, Cardiac Rehabilitation, Transcatheter Aortic Valve Implantation, Atrial Fibrillation, Aortic Stenosis, Natriuresis, Left Bundle Branch Area Pacing, Cardiac Pacing, Photon-Counting Computed Tomography, Diuresis, Furosemide, Rehospitalization, Patient Outcomes, Interhospital Transfer, Cryptogenic Stroke, C. O. V. I. D. pandemic, Lead Placement, Bradyarrhythmias.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/">Bradyarrhythmias Reveal Stroke’s Atrial Link 04/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like Acetazolamide and Implantable Loop Recorders. Key takeaway: Bradyarrhythmias Reveal Stroke&#8217;s Atrial Link.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like Acetazolamide and Implantable Loop Recorders. Key takeaway: Bradyarrhythmias Reveal Stroke&#8217;s Atrial Link.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41932644">Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41932822">Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41920937">Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI).</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41932670">Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41519354">Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy?</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/">https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41932644" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41932644</a></p>
<p><strong>Summary:</strong> This study characterized patients with Heart Failure who underwent interhospital transfer, establishing their demographic and clinical profiles. It found significant variations in the utilization of interhospital transfer among different hospitals across the United States. The data revealed distinctions in outcomes between transferred and non-transferred Heart Failure patients. This analysis provided foundational understanding of interhospital transfer patterns in this patient population.</p>
<h4>Article 2: Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41932822" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41932822</a></p>
<p><strong>Summary:</strong> This whole-population study established patterns of cardiac rehabilitation participation following Transcatheter Aortic Valve Implantation across England. It found variations in participation rates before, during, and after the C. O. V. I. D. minus 19 pandemic. The research demonstrated a specific association between cardiac rehabilitation participation and the primary outcome of unplanned all-cause rehospitalization. This analysis provided critical evidence regarding cardiac rehabilitation&#8217;s impact on clinical outcomes in this patient group.</p>
<h4>Article 3: Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI).</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920937" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920937</a></p>
<p><strong>Summary:</strong> The S. A. N. D. I. study investigated the natriuretic and diuretic effects of acetazolamide in patients with acute Heart Failure receiving intravenous furosemide and concomitant Sodium-Glucose Cotransporter-two Inhibitors. It found that acetazolamide provided significant natriuretic and diuretic benefits in this specific patient population, demonstrating enhanced decongestion. This research established the efficacy of adjunctive acetazolamide in acute Heart Failure patients who are also on Sodium-Glucose Cotransporter-two Inhibitors, addressing a previously unknown therapeutic gap.</p>
<h4>Article 4: Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41932670" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41932670</a></p>
<p><strong>Summary:</strong> This study elucidated the relationship between intra-septal lead position in Left Bundle Branch Area Pacing and paced QRS morphology. It found that ultra-high-resolution Photon-Counting Computed Tomography precisely evaluated lead-tip location in 20 patients, differentiating between Left Bundle Branch Pacing, Left Ventricular Septal Pacing, and Deep Septal Pacing. The data established specific distances and spatial orientations of pacing leads within the septum, directly informing optimal lead placement strategies for physiological pacing.</p>
<h4>Article 5: Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy?</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41519354" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41519354</a></p>
<p><strong>Summary:</strong> It found a notable burden of bradyarrhythmias in these patients compared with a matched control group. The data demonstrated that clinically significant bradyarrhythmias are a significant finding in this population, suggesting a potential manifestation of underlying atrial cardiomyopathy beyond Atrial Fibrillation detection.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF. This study characterized patients with Heart Failure who underwent interhospital transfer, establishing their demographic and clinical profiles. It found significant variations in the utilization of interhospital transfer among different hospitals across the United States. The data revealed distinctions in outcomes between transferred and non-transferred Heart Failure patients. This analysis provided foundational understanding of interhospital transfer patterns in this patient population.</p>
<p>Article number two. Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study. This whole-population study established patterns of cardiac rehabilitation participation following Transcatheter Aortic Valve Implantation across England. It found variations in participation rates before, during, and after the C. O. V. I. D. minus 19 pandemic. The research demonstrated a specific association between cardiac rehabilitation participation and the primary outcome of unplanned all-cause rehospitalization. This analysis provided critical evidence regarding cardiac rehabilitation&#8217;s impact on clinical outcomes in this patient group.</p>
<p>Article number three. Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI). The S. A. N. D. I. study investigated the natriuretic and diuretic effects of acetazolamide in patients with acute Heart Failure receiving intravenous furosemide and concomitant Sodium-Glucose Cotransporter-two Inhibitors. It found that acetazolamide provided significant natriuretic and diuretic benefits in this specific patient population, demonstrating enhanced decongestion. This research established the efficacy of adjunctive acetazolamide in acute Heart Failure patients who are also on Sodium-Glucose Cotransporter-two Inhibitors, addressing a previously unknown therapeutic gap.</p>
<p>Article number four. Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography. This study elucidated the relationship between intra-septal lead position in Left Bundle Branch Area Pacing and paced QRS morphology. It found that ultra-high-resolution Photon-Counting Computed Tomography precisely evaluated lead-tip location in 20 patients, differentiating between Left Bundle Branch Pacing, Left Ventricular Septal Pacing, and Deep Septal Pacing. The data established specific distances and spatial orientations of pacing leads within the septum, directly informing optimal lead placement strategies for physiological pacing.</p>
<p>Article number five. Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy? This study established the prevalence and clinical significance of bradyarrhythmias in patients with cryptogenic stroke or transient ischemic attack who received implantable loop recorders. It found a notable burden of bradyarrhythmias in these patients compared with a matched control group. The data demonstrated that clinically significant bradyarrhythmias are a significant finding in this population, suggesting a potential manifestation of underlying atrial cardiomyopathy beyond Atrial Fibrillation detection. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Acetazolamide, Implantable Loop Recorders, QRS Morphology, Hospital Variation, Sodium-Glucose Cotransporter-two Inhibitors, Heart Failure, Acute Heart Failure, Quality Improvement, Atrial Cardiomyopathy, Cardiac Rehabilitation, Transcatheter Aortic Valve Implantation, Atrial Fibrillation, Aortic Stenosis, Natriuresis, Left Bundle Branch Area Pacing, Cardiac Pacing, Photon-Counting Computed Tomography, Diuresis, Furosemide, Rehospitalization, Patient Outcomes, Interhospital Transfer, Cryptogenic Stroke, C. O. V. I. D. pandemic, Lead Placement, Bradyarrhythmias.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/">Bradyarrhythmias Reveal Stroke’s Atrial Link 04/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260404_060034.mp3" length="4101685" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like Acetazolamide and Implantable Loop Recorders. Key takeaway: Bradyarrhythmias Reveal Stroke&#8217;s Atrial Link.
Article Links:
Article 1: Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF. (Journal of cardiac failure)
Article 2: Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study. (Heart (British Cardiac Society))
Article 3: Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI). (ESC heart failure)
Article 4: Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography. (Heart rhythm)
Article 5: Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders for cryptogenic stroke: A manifestation of atrial cardiomyopathy? (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/bradyarrhythmias-reveal-strokes-atrial-link-04-04-26/
 Featured Articles
Article 1: Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41932644
Summary: This study characterized patients with Heart Failure who underwent interhospital transfer, establishing their demographic and clinical profiles. It found significant variations in the utilization of interhospital transfer among different hospitals across the United States. The data revealed distinctions in outcomes between transferred and non-transferred Heart Failure patients. This analysis provided foundational understanding of interhospital transfer patterns in this patient population.
Article 2: Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41932822
Summary: This whole-population study established patterns of cardiac rehabilitation participation following Transcatheter Aortic Valve Implantation across England. It found variations in participation rates before, during, and after the C. O. V. I. D. minus 19 pandemic. The research demonstrated a specific association between cardiac rehabilitation participation and the primary outcome of unplanned all-cause rehospitalization. This analysis provided critical evidence regarding cardiac rehabilitation&#8217;s impact on clinical outcomes in this patient group.
Article 3: Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI).
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41920937
Summary: The S. A. N. D. I. study investigated the natriuretic and diuretic effects of acetazolamide in patients with acute Heart Failure receiving intravenous furosemide and concomitant Sodium-Glucose Cotransporter-two Inhibitors. It found that acetazolamide provided significant natriuretic and diuretic benefits in this specific patient population, demonstrating enhanced decongestion. This research established the efficacy of adjunctive acetazolamide in acute Heart Failure patients who are also on Sodium-Glucose Cotransporter-two Inhibitors, addressing a previously unknown therapeutic gap.
Article 4: Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41932670
Summary: This study elucidated the relationship between intra-septal lead position in Left Bundle Branch Area Pacing and paced QRS morphology. It found that ultra-high-resolution Photon-Counting Computed Tomography precisely eval]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 04, 2026. This episode summarizes 5 key cardiology studies on topics like Acetazolamide and Implantable Loop Recorders. Key takeaway: Bradyarrhythmias Reveal Stroke&#8217;s Atrial Link.
Article Links:
Article 1: Interhospital Transfer for Heart Failure in the United States: A Patient and Hospital-level Analysis from GWTG-HF. (Journal of cardiac failure)
Article 2: Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study. (Heart (British Cardiac Society))
Article 3: Acetazolamide Effects on Natriuresis and Diuresis in Acute Heart Failure Treated with Furosemide and SGLT2i (SANDI). (ESC heart failure)
Article 4: Paced QRS Morphology and Lead Location in Left Bundle Branch Area Pacing Assessed by Photon-Counting Cardiac Computed Tomography. (Heart rhythm)
Article 5: Prevalence of clinically significant bradyarrhythmias in patients implanted with loop recorders]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes 04/03/26</title>
	<link>https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/</link>
	<pubDate>Fri, 03 Apr 2026 10:01:36 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 03, 2026. This episode summarizes 5 key cardiology studies on topics like incident hypertension and quadruple guideline-directed medical therapies. Key takeaway: Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41926331">Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40701206">Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41920552">Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41920533">Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41926705">Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During LVAD Support.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/">https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926331" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926331</a></p>
<p><strong>Summary:</strong> Glucagon-like peptide-1 receptor agonists (G. L. P. minus 1 R. A.s) significantly reduced atherosclerosis burden and inflammatory biomarkers in experimental rabbit models. In clinical subjects, these agents decreased inflammatory biomarkers and major adverse cardiovascular events (MACE). These beneficial cardiovascular effects were observed irrespective of the patients&#8217; glycemic status or obesity, indicating a direct cardiovascular protective mechanism.</p>
<h4>Article 2: Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40701206" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40701206</a></p>
<p><strong>Summary:</strong> A ten-minute asystolic warm ischemic time (A. W. I. T.) during donation after circulatory death (D. C. D.) heart recovery significantly predicted increased mortality in adult heart transplant recipients. This prolonged warm ischemic time was also associated with severe primary graft dysfunction. These findings specifically apply to cardiac allografts recovered using thoracoabdominal normothermic regional perfusion (N. R. P.).</p>
<h4>Article 3: Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920552" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920552</a></p>
<p><strong>Summary:</strong> The study characterized the time to quadruple guideline-directed medical therapies (G. D. M. T.s) following an initial diagnosis of heart failure with reduced ejection fraction (H. F. rEF). It identified specific factors associated with achieving timely initiation of these therapies in a large cohort of patients. The findings provide contemporary estimates on the duration and facilitators of initiating optimal quadruple therapy for patients with H. F. rEF.</p>
<h4>Article 4: Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920533" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920533</a></p>
<p><strong>Summary:</strong> The study found that genetic risk for high systolic blood pressure (S. B. P.) significantly stratified the risk of new-onset hypertension in women. This association was observed at two to seven years post partum. The genetic risk was an independent predictor, separate from women&#8217;s clinical characteristics and history of hypertensive disorders of pregnancy (H. D. P.), including preeclampsia, eclampsia, and gestational hypertension.</p>
<h4>Article 5: Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During LVAD Support.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926705" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926705</a></p>
<p><strong>Summary:</strong> V. A. D. Support. Observational studies revealed an association between phosphodiesterase-5 inhibitors, specifically sildenafil, and lower mortality and ischemic stroke in patients undergoing durable left ventricular assist device (L. V. A. D.) support. This study conducted a double-blind, randomized, placebo-controlled investigation into sildenafil&#8217;s causal effects on platelet activation and circulating mediators of vascular remodeling. This research aims to understand the direct physiological impact of sildenafil that could explain its previously observed clinical benefits in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity. Glucagon-like peptide-1 receptor agonists (G. L. P. minus 1 R. A.s) significantly reduced atherosclerosis burden and inflammatory biomarkers in experimental rabbit models. In clinical subjects, these agents decreased inflammatory biomarkers and major adverse cardiovascular events (MACE). These beneficial cardiovascular effects were observed irrespective of the patients&#8217; glycemic status or obesity, indicating a direct cardiovascular protective mechanism.</p>
<p>Article number two. Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion. A ten-minute asystolic warm ischemic time (A. W. I. T.) during donation after circulatory death (D. C. D.) heart recovery significantly predicted increased mortality in adult heart transplant recipients. This prolonged warm ischemic time was also associated with severe primary graft dysfunction. These findings specifically apply to cardiac allografts recovered using thoracoabdominal normothermic regional perfusion (N. R. P.).</p>
<p>Article number three. Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. The study characterized the time to quadruple guideline-directed medical therapies (G. D. M. T.s) following an initial diagnosis of heart failure with reduced ejection fraction (H. F. rEF). It identified specific factors associated with achieving timely initiation of these therapies in a large cohort of patients. The findings provide contemporary estimates on the duration and facilitators of initiating optimal quadruple therapy for patients with H. F. rEF.</p>
<p>Article number four. Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum. The study found that genetic risk for high systolic blood pressure (S. B. P.) significantly stratified the risk of new-onset hypertension in women. This association was observed at two to seven years post partum. The genetic risk was an independent predictor, separate from women&#8217;s clinical characteristics and history of hypertensive disorders of pregnancy (H. D. P.), including preeclampsia, eclampsia, and gestational hypertension.</p>
<p>Article number five. Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During L. V. A. D. Support. Observational studies revealed an association between phosphodiesterase-5 inhibitors, specifically sildenafil, and lower mortality and ischemic stroke in patients undergoing durable left ventricular assist device (L. V. A. D.) support. This study conducted a double-blind, randomized, placebo-controlled investigation into sildenafil&#8217;s causal effects on platelet activation and circulating mediators of vascular remodeling. This research aims to understand the direct physiological impact of sildenafil that could explain its previously observed clinical benefits in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>incident hypertension, quadruple guideline-directed medical therapies, glucagon-like peptide-1 receptor agonists, post partum, normothermic regional perfusion, hypertensive disorders of pregnancy, genetic risk, blood pressure, vascular remodeling, time to therapy, sildenafil, cardiovascular events, donation after circulatory death, atherosclerosis, primary graft dysfunction, platelet activation, Veterans Health Administration, left ventricular assist device, liraglutide, heart transplant, inflammatory biomarkers, heart failure with reduced ejection fraction, asystolic warm ischemic time, morbidity, phosphodiesterase-5 inhibitors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/">Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes 04/03/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 03, 2026. This episode summarizes 5 key cardiology studies on topics like incident hypertension and quadruple guideline-directed medical therapies. Key takeaway: Glucagon-like Peptide-1 Agonists Cut Events Bey]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 03, 2026. This episode summarizes 5 key cardiology studies on topics like incident hypertension and quadruple guideline-directed medical therapies. Key takeaway: Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41926331">Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40701206">Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41920552">Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41920533">Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41926705">Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During LVAD Support.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/">https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926331" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926331</a></p>
<p><strong>Summary:</strong> Glucagon-like peptide-1 receptor agonists (G. L. P. minus 1 R. A.s) significantly reduced atherosclerosis burden and inflammatory biomarkers in experimental rabbit models. In clinical subjects, these agents decreased inflammatory biomarkers and major adverse cardiovascular events (MACE). These beneficial cardiovascular effects were observed irrespective of the patients&#8217; glycemic status or obesity, indicating a direct cardiovascular protective mechanism.</p>
<h4>Article 2: Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40701206" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40701206</a></p>
<p><strong>Summary:</strong> A ten-minute asystolic warm ischemic time (A. W. I. T.) during donation after circulatory death (D. C. D.) heart recovery significantly predicted increased mortality in adult heart transplant recipients. This prolonged warm ischemic time was also associated with severe primary graft dysfunction. These findings specifically apply to cardiac allografts recovered using thoracoabdominal normothermic regional perfusion (N. R. P.).</p>
<h4>Article 3: Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920552" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920552</a></p>
<p><strong>Summary:</strong> The study characterized the time to quadruple guideline-directed medical therapies (G. D. M. T.s) following an initial diagnosis of heart failure with reduced ejection fraction (H. F. rEF). It identified specific factors associated with achieving timely initiation of these therapies in a large cohort of patients. The findings provide contemporary estimates on the duration and facilitators of initiating optimal quadruple therapy for patients with H. F. rEF.</p>
<h4>Article 4: Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920533" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920533</a></p>
<p><strong>Summary:</strong> The study found that genetic risk for high systolic blood pressure (S. B. P.) significantly stratified the risk of new-onset hypertension in women. This association was observed at two to seven years post partum. The genetic risk was an independent predictor, separate from women&#8217;s clinical characteristics and history of hypertensive disorders of pregnancy (H. D. P.), including preeclampsia, eclampsia, and gestational hypertension.</p>
<h4>Article 5: Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During LVAD Support.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41926705" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41926705</a></p>
<p><strong>Summary:</strong> V. A. D. Support. Observational studies revealed an association between phosphodiesterase-5 inhibitors, specifically sildenafil, and lower mortality and ischemic stroke in patients undergoing durable left ventricular assist device (L. V. A. D.) support. This study conducted a double-blind, randomized, placebo-controlled investigation into sildenafil&#8217;s causal effects on platelet activation and circulating mediators of vascular remodeling. This research aims to understand the direct physiological impact of sildenafil that could explain its previously observed clinical benefits in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity. Glucagon-like peptide-1 receptor agonists (G. L. P. minus 1 R. A.s) significantly reduced atherosclerosis burden and inflammatory biomarkers in experimental rabbit models. In clinical subjects, these agents decreased inflammatory biomarkers and major adverse cardiovascular events (MACE). These beneficial cardiovascular effects were observed irrespective of the patients&#8217; glycemic status or obesity, indicating a direct cardiovascular protective mechanism.</p>
<p>Article number two. Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion. A ten-minute asystolic warm ischemic time (A. W. I. T.) during donation after circulatory death (D. C. D.) heart recovery significantly predicted increased mortality in adult heart transplant recipients. This prolonged warm ischemic time was also associated with severe primary graft dysfunction. These findings specifically apply to cardiac allografts recovered using thoracoabdominal normothermic regional perfusion (N. R. P.).</p>
<p>Article number three. Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. The study characterized the time to quadruple guideline-directed medical therapies (G. D. M. T.s) following an initial diagnosis of heart failure with reduced ejection fraction (H. F. rEF). It identified specific factors associated with achieving timely initiation of these therapies in a large cohort of patients. The findings provide contemporary estimates on the duration and facilitators of initiating optimal quadruple therapy for patients with H. F. rEF.</p>
<p>Article number four. Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum. The study found that genetic risk for high systolic blood pressure (S. B. P.) significantly stratified the risk of new-onset hypertension in women. This association was observed at two to seven years post partum. The genetic risk was an independent predictor, separate from women&#8217;s clinical characteristics and history of hypertensive disorders of pregnancy (H. D. P.), including preeclampsia, eclampsia, and gestational hypertension.</p>
<p>Article number five. Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During L. V. A. D. Support. Observational studies revealed an association between phosphodiesterase-5 inhibitors, specifically sildenafil, and lower mortality and ischemic stroke in patients undergoing durable left ventricular assist device (L. V. A. D.) support. This study conducted a double-blind, randomized, placebo-controlled investigation into sildenafil&#8217;s causal effects on platelet activation and circulating mediators of vascular remodeling. This research aims to understand the direct physiological impact of sildenafil that could explain its previously observed clinical benefits in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>incident hypertension, quadruple guideline-directed medical therapies, glucagon-like peptide-1 receptor agonists, post partum, normothermic regional perfusion, hypertensive disorders of pregnancy, genetic risk, blood pressure, vascular remodeling, time to therapy, sildenafil, cardiovascular events, donation after circulatory death, atherosclerosis, primary graft dysfunction, platelet activation, Veterans Health Administration, left ventricular assist device, liraglutide, heart transplant, inflammatory biomarkers, heart failure with reduced ejection fraction, asystolic warm ischemic time, morbidity, phosphodiesterase-5 inhibitors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/">Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes 04/03/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260403_060039.mp3" length="3934083" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 03, 2026. This episode summarizes 5 key cardiology studies on topics like incident hypertension and quadruple guideline-directed medical therapies. Key takeaway: Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes.
Article Links:
Article 1: Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity. (European heart journal)
Article 2: Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. (JAMA cardiology)
Article 4: Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum. (JAMA cardiology)
Article 5: Effect of Sildenafil on Platelet Activation and Mediators of Vascular Remodeling During LVAD Support. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/glucagon-like-peptide-1-agonists-cut-events-beyond-diabetes-04-03-26/
 Featured Articles
Article 1: Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41926331
Summary: Glucagon-like peptide-1 receptor agonists (G. L. P. minus 1 R. A.s) significantly reduced atherosclerosis burden and inflammatory biomarkers in experimental rabbit models. In clinical subjects, these agents decreased inflammatory biomarkers and major adverse cardiovascular events (MACE). These beneficial cardiovascular effects were observed irrespective of the patients&#8217; glycemic status or obesity, indicating a direct cardiovascular protective mechanism.
Article 2: Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40701206
Summary: A ten-minute asystolic warm ischemic time (A. W. I. T.) during donation after circulatory death (D. C. D.) heart recovery significantly predicted increased mortality in adult heart transplant recipients. This prolonged warm ischemic time was also associated with severe primary graft dysfunction. These findings specifically apply to cardiac allografts recovered using thoracoabdominal normothermic regional perfusion (N. R. P.).
Article 3: Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41920552
Summary: The study characterized the time to quadruple guideline-directed medical therapies (G. D. M. T.s) following an initial diagnosis of heart failure with reduced ejection fraction (H. F. rEF). It identified specific factors associated with achieving timely initiation of these therapies in a large cohort of patients. The findings provide contemporary estimates on the duration and facilitators of initiating optimal quadruple therapy for patients with H. F. rEF.
Article 4: Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41920533
Summary: The study found that genetic risk for high systolic blood pressure (S. B. P.) significantly stratified the risk of new-onset hypertension in women. This association was ob]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 03, 2026. This episode summarizes 5 key cardiology studies on topics like incident hypertension and quadruple guideline-directed medical therapies. Key takeaway: Glucagon-like Peptide-1 Agonists Cut Events Beyond Diabetes.
Article Links:
Article 1: Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity. (European heart journal)
Article 2: Ten-minute asystolic warm ischemic time (AWIT) predicts mortality and severe primary graft dysfunction in donation after circulatory death hearts recovered with thoracoabdominal normothermic regional perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. (JAMA cardiology)
Article 4: Blo]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Hypothermic Preservation Boosts Heart Transplant Survival 04/02/26</title>
	<link>https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/</link>
	<pubDate>Thu, 02 Apr 2026 10:01:19 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 02, 2026. This episode summarizes 5 key cardiology studies on topics like atrial fibrillation ablation and immature neutrophils. Key takeaway: Hypothermic Preservation Boosts Heart Transplant Survival.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41920862">Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41914181">Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41338428">Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41241030">Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41241029">Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/">https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920862" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920862</a></p>
<p><strong>Summary:</strong> The Swedish Heart Failure Registry enabled a detailed assessment of patient adherence and persistence to quadruple pharmacotherapy for heart failure with reduced ejection fraction. This assessment confirmed the critical importance of patient adherence for the real-world uptake of these treatments. The study found specific associations between medication adherence and subsequent patient morbidity and mortality outcomes.</p>
<h4>Article 2: Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914181" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914181</a></p>
<p><strong>Summary:</strong> The E. M. B. O. L. minus A. F. Global Registry provided comprehensive data defining the incidence, outcomes, and procedural associations of stroke and systemic embolism following atrial fibrillation and left atrial flutter catheter ablation. This retrospective global registry captured detailed information from ablation centers worldwide, clarifying these previously poorly characterized complications. The registry&#8217;s findings illuminate critical insights into these post-ablation complications.</p>
<h4>Article 3: Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41338428" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41338428</a></p>
<p><strong>Summary:</strong> This study found that immature neutrophils are elevated in human primary graft dysfunction. Researchers demonstrated a direct link between these immature neutrophils and granulocyte colony stimulating factor-driven injury in a murine model of lung ischemia-reperfusion. These findings indicate that immature neutrophils increase following lung transplantation and contribute to primary graft dysfunction severity.</p>
<h4>Article 4: Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241030" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241030</a></p>
<p><strong>Summary:</strong> This study found that infectious complications are common in patients implanted with HeartMate 3 left ventricular assist devices. The analysis specifically identified the impact of HeartMate 3 left ventricular assist device associated infection on outcomes following heart transplant. Researchers clarified crucial post-transplant outcomes by reviewing 115 patients with a HeartMate 3 device who underwent heart transplantation at Duke University Hospital.</p>
<h4>Article 5: Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241029" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241029</a></p>
<p><strong>Summary:</strong> Data from the G. U. A. R. D. I. A. N. Heart Registry demonstrated improved two year heart transplant survival when using moderate hypothermic donor heart preservation. The Paragonix SherpaPak Cardiac Transport System, a method of static preservation, showed superior outcomes compared to historic ice storage. This study represents the first report of a preservation method demonstrating improved post-transplant survival.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 02, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription. The Swedish Heart Failure Registry enabled a detailed assessment of patient adherence and persistence to quadruple pharmacotherapy for heart failure with reduced ejection fraction. This assessment confirmed the critical importance of patient adherence for the real-world uptake of these treatments. The study found specific associations between medication adherence and subsequent patient morbidity and mortality outcomes.</p>
<p>Article number two. Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry. The E. M. B. O. L. minus A. F. Global Registry provided comprehensive data defining the incidence, outcomes, and procedural associations of stroke and systemic embolism following atrial fibrillation and left atrial flutter catheter ablation. This retrospective global registry captured detailed information from ablation centers worldwide, clarifying these previously poorly characterized complications. The registry&#8217;s findings illuminate critical insights into these post-ablation complications.</p>
<p>Article number three. Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion. This study found that immature neutrophils are elevated in human primary graft dysfunction. Researchers demonstrated a direct link between these immature neutrophils and granulocyte colony stimulating factor-driven injury in a murine model of lung ischemia-reperfusion. These findings indicate that immature neutrophils increase following lung transplantation and contribute to primary graft dysfunction severity.</p>
<p>Article number four. Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant. This study found that infectious complications are common in patients implanted with HeartMate 3 left ventricular assist devices. The analysis specifically identified the impact of HeartMate 3 left ventricular assist device associated infection on outcomes following heart transplant. Researchers clarified crucial post-transplant outcomes by reviewing 115 patients with a HeartMate 3 device who underwent heart transplantation at Duke University Hospital.</p>
<p>Article number five. Improved two year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry. Data from the G. U. A. R. D. I. A. N. Heart Registry demonstrated improved two year heart transplant survival when using moderate hypothermic donor heart preservation. The Paragonix SherpaPak Cardiac Transport System, a method of static preservation, showed superior outcomes compared to historic ice storage. This study represents the first report of a preservation method demonstrating improved post-transplant survival. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>atrial fibrillation ablation, immature neutrophils, HeartMate 3, G. U. A. R. D. I. A. N. Heart Registry, granulocyte colony stimulating factor, stroke, lung transplantation, hypothermic preservation, lung ischemia-reperfusion injury, catheter ablation, Paragonix SherpaPak, primary graft dysfunction, left ventricular assist device infection, heart transplant survival, patient persistence, morbidity, mortality, donor heart, infectious complications, heart transplant outcomes, heart failure with reduced ejection fraction, pharmacotherapy adherence, Duke University Hospital, left atrial flutter, systemic embolism.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/">Hypothermic Preservation Boosts Heart Transplant Survival 04/02/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 02, 2026. This episode summarizes 5 key cardiology studies on topics like atrial fibrillation ablation and immature neutrophils. Key takeaway: Hypothermic Preservation Boosts Heart Transplant Survival.
Article]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 02, 2026. This episode summarizes 5 key cardiology studies on topics like atrial fibrillation ablation and immature neutrophils. Key takeaway: Hypothermic Preservation Boosts Heart Transplant Survival.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41920862">Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41914181">Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41338428">Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41241030">Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41241029">Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/">https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41920862" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41920862</a></p>
<p><strong>Summary:</strong> The Swedish Heart Failure Registry enabled a detailed assessment of patient adherence and persistence to quadruple pharmacotherapy for heart failure with reduced ejection fraction. This assessment confirmed the critical importance of patient adherence for the real-world uptake of these treatments. The study found specific associations between medication adherence and subsequent patient morbidity and mortality outcomes.</p>
<h4>Article 2: Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914181" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914181</a></p>
<p><strong>Summary:</strong> The E. M. B. O. L. minus A. F. Global Registry provided comprehensive data defining the incidence, outcomes, and procedural associations of stroke and systemic embolism following atrial fibrillation and left atrial flutter catheter ablation. This retrospective global registry captured detailed information from ablation centers worldwide, clarifying these previously poorly characterized complications. The registry&#8217;s findings illuminate critical insights into these post-ablation complications.</p>
<h4>Article 3: Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41338428" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41338428</a></p>
<p><strong>Summary:</strong> This study found that immature neutrophils are elevated in human primary graft dysfunction. Researchers demonstrated a direct link between these immature neutrophils and granulocyte colony stimulating factor-driven injury in a murine model of lung ischemia-reperfusion. These findings indicate that immature neutrophils increase following lung transplantation and contribute to primary graft dysfunction severity.</p>
<h4>Article 4: Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241030" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241030</a></p>
<p><strong>Summary:</strong> This study found that infectious complications are common in patients implanted with HeartMate 3 left ventricular assist devices. The analysis specifically identified the impact of HeartMate 3 left ventricular assist device associated infection on outcomes following heart transplant. Researchers clarified crucial post-transplant outcomes by reviewing 115 patients with a HeartMate 3 device who underwent heart transplantation at Duke University Hospital.</p>
<h4>Article 5: Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241029" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241029</a></p>
<p><strong>Summary:</strong> Data from the G. U. A. R. D. I. A. N. Heart Registry demonstrated improved two year heart transplant survival when using moderate hypothermic donor heart preservation. The Paragonix SherpaPak Cardiac Transport System, a method of static preservation, showed superior outcomes compared to historic ice storage. This study represents the first report of a preservation method demonstrating improved post-transplant survival.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 02, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription. The Swedish Heart Failure Registry enabled a detailed assessment of patient adherence and persistence to quadruple pharmacotherapy for heart failure with reduced ejection fraction. This assessment confirmed the critical importance of patient adherence for the real-world uptake of these treatments. The study found specific associations between medication adherence and subsequent patient morbidity and mortality outcomes.</p>
<p>Article number two. Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry. The E. M. B. O. L. minus A. F. Global Registry provided comprehensive data defining the incidence, outcomes, and procedural associations of stroke and systemic embolism following atrial fibrillation and left atrial flutter catheter ablation. This retrospective global registry captured detailed information from ablation centers worldwide, clarifying these previously poorly characterized complications. The registry&#8217;s findings illuminate critical insights into these post-ablation complications.</p>
<p>Article number three. Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion. This study found that immature neutrophils are elevated in human primary graft dysfunction. Researchers demonstrated a direct link between these immature neutrophils and granulocyte colony stimulating factor-driven injury in a murine model of lung ischemia-reperfusion. These findings indicate that immature neutrophils increase following lung transplantation and contribute to primary graft dysfunction severity.</p>
<p>Article number four. Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant. This study found that infectious complications are common in patients implanted with HeartMate 3 left ventricular assist devices. The analysis specifically identified the impact of HeartMate 3 left ventricular assist device associated infection on outcomes following heart transplant. Researchers clarified crucial post-transplant outcomes by reviewing 115 patients with a HeartMate 3 device who underwent heart transplantation at Duke University Hospital.</p>
<p>Article number five. Improved two year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry. Data from the G. U. A. R. D. I. A. N. Heart Registry demonstrated improved two year heart transplant survival when using moderate hypothermic donor heart preservation. The Paragonix SherpaPak Cardiac Transport System, a method of static preservation, showed superior outcomes compared to historic ice storage. This study represents the first report of a preservation method demonstrating improved post-transplant survival. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>atrial fibrillation ablation, immature neutrophils, HeartMate 3, G. U. A. R. D. I. A. N. Heart Registry, granulocyte colony stimulating factor, stroke, lung transplantation, hypothermic preservation, lung ischemia-reperfusion injury, catheter ablation, Paragonix SherpaPak, primary graft dysfunction, left ventricular assist device infection, heart transplant survival, patient persistence, morbidity, mortality, donor heart, infectious complications, heart transplant outcomes, heart failure with reduced ejection fraction, pharmacotherapy adherence, Duke University Hospital, left atrial flutter, systemic embolism.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/">Hypothermic Preservation Boosts Heart Transplant Survival 04/02/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260402_060026.mp3" length="3413724" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 02, 2026. This episode summarizes 5 key cardiology studies on topics like atrial fibrillation ablation and immature neutrophils. Key takeaway: Hypothermic Preservation Boosts Heart Transplant Survival.
Article Links:
Article 1: Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription. (European heart journal)
Article 2: Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry. (European heart journal)
Article 3: Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/hypothermic-preservation-boosts-heart-transplant-survival-04-02-26/
 Featured Articles
Article 1: Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41920862
Summary: The Swedish Heart Failure Registry enabled a detailed assessment of patient adherence and persistence to quadruple pharmacotherapy for heart failure with reduced ejection fraction. This assessment confirmed the critical importance of patient adherence for the real-world uptake of these treatments. The study found specific associations between medication adherence and subsequent patient morbidity and mortality outcomes.
Article 2: Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41914181
Summary: The E. M. B. O. L. minus A. F. Global Registry provided comprehensive data defining the incidence, outcomes, and procedural associations of stroke and systemic embolism following atrial fibrillation and left atrial flutter catheter ablation. This retrospective global registry captured detailed information from ablation centers worldwide, clarifying these previously poorly characterized complications. The registry&#8217;s findings illuminate critical insights into these post-ablation complications.
Article 3: Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41338428
Summary: This study found that immature neutrophils are elevated in human primary graft dysfunction. Researchers demonstrated a direct link between these immature neutrophils and granulocyte colony stimulating factor-driven injury in a murine model of lung ischemia-reperfusion. These findings indicate that immature neutrophils increase following lung transplantation and contribute to primary graft dysfunction severity.
Article 4: Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241030
Summary: This study found that infectious complications are common in patient]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 02, 2026. This episode summarizes 5 key cardiology studies on topics like atrial fibrillation ablation and immature neutrophils. Key takeaway: Hypothermic Preservation Boosts Heart Transplant Survival.
Article Links:
Article 1: Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription. (European heart journal)
Article 2: Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry. (European heart journal)
Article 3: Immature neutrophils are elevated in human PGD and linked to G-CSF-driven injury in a murine model of lung ischemia-reperfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant. (The Journal of heart and lung transplantation : ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>APOC3 Inhibition Cuts Lipids 70 Percent 04/01/26</title>
	<link>https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/</link>
	<pubDate>Wed, 01 Apr 2026 12:53:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like estimated glomerular filtration rate and chronic kidney disease. Key takeaway: APOC3 Inhibition Cuts Lipids 70 Percent.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41919388">Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41910513">Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41910504">Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41910411">The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41914187">Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/">https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41919388" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41919388</a></p>
<p><strong>Summary:</strong> Suboptimal cardiovascular-kidney-metabolic health is highly prevalent among older adults in the United States. The American Heart Association has developed a Cardiovascular-Kidney-Metabolic syndrome staging framework to categorize risk. Despite this framework, its predictive utility for incident heart failure remains an area of uncertainty in this population. Understanding the relationship between Cardiovascular-Kidney-Metabolic syndrome stages, echocardiographic characteristics, and heart failure risk is essential for clinical management.</p>
<h4>Article 2: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910513" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910513</a></p>
<p><strong>Summary:</strong> P. O. C. 3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-T. I. M. I. 73b Imaging Study. Olezarsen, an antisense oligonucleotide inhibiting apolipoprotein C-III, reduces triglycerides by approximately 60 percent and remnant cholesterol by approximately 70 percent. This treatment also decreases apolipoprotein B by approximately 15 percent, while maintaining a neutral effect on low-density lipoprotein cholesterol in patients with moderate hypertriglyceridemia. These observed lipid modifications suggest a therapeutic approach to address triglyceride-rich lipoproteins and remnant cholesterol. Such inhibition holds significant clinical interest for its potential impact on coronary atherosclerosis.</p>
<h4>Article 3: Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910504" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910504</a></p>
<p><strong>Summary:</strong> T.-Elevation Myocardial Infarction Undergoing Primary P. C. I.: H. E. P. A. R. I. N. S. T. E. M. I. Randomized Controlled Trial. Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients with S. T.-elevation myocardial infarction. The benefits and safety of administering unfractionated heparin in the prehospital setting for these patients remain a critical clinical question. Optimizing pretreatment strategies with agents like unfractionated heparin at first medical contact is important for patients undergoing primary percutaneous coronary intervention. Investigating the efficacy and safety of such prehospital interventions informs best practices for acute myocardial infarction management.</p>
<h4>Article 4: The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910411" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910411</a></p>
<p><strong>Summary:</strong> The role of atrial pacing support in cardiac resynchronization therapy-defibrillator patients without sinus node dysfunction is a clinically relevant question. Simplified cardiac resynchronization therapy-defibrillator systems that offer atrial sensing without full pacing support via a two-lead system could reduce procedural complexity. Determining if a two-lead system is non-inferior to a conventional three-lead system is important for patient selection and device choice. Evaluating these systems helps optimize outcomes and minimize risks associated with device implantation for cardiac resynchronization therapy.</p>
<h4>Article 5: Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914187" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914187</a></p>
<p><strong>Summary:</strong> Chronic kidney disease affects 10 percent to 15 percent of adults globally and serves as a powerful, independent risk factor for cardiovascular diseases, including heart failure. Early stages of chronic kidney disease, specifically stages G1 to G3, are significantly associated with this elevated risk. The presence of albuminuria, particularly K. D. I. G. O. stages A2 to A3, further exacerbates cardiovascular risk even with mild renal dysfunction. These findings underscore the importance of recognizing pre-heart failure states in chronic kidney disease patients to inform early intervention strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. Suboptimal cardiovascular-kidney-metabolic health is highly prevalent among older adults in the United States. The American Heart Association has developed a Cardiovascular-Kidney-Metabolic syndrome staging framework to categorize risk. Despite this framework, its predictive utility for incident heart failure remains an area of uncertainty in this population. Understanding the relationship between Cardiovascular-Kidney-Metabolic syndrome stages, echocardiographic characteristics, and heart failure risk is essential for clinical management.</p>
<p>Article number two. Effect of A. P. O. C. 3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-T. I. M. I. 73b Imaging Study. Olezarsen, an antisense oligonucleotide inhibiting apolipoprotein C-III, reduces triglycerides by approximately 60 percent and remnant cholesterol by approximately 70 percent. This treatment also decreases apolipoprotein B by approximately 15 percent, while maintaining a neutral effect on low-density lipoprotein cholesterol in patients with moderate hypertriglyceridemia. These observed lipid modifications suggest a therapeutic approach to address triglyceride-rich lipoproteins and remnant cholesterol. Such inhibition holds significant clinical interest for its potential impact on coronary atherosclerosis.</p>
<p>Article number three. Prehospital Heparin Administration in Patients With S. T.-Elevation Myocardial Infarction Undergoing Primary P. C. I.: H. E. P. A. R. I. N. S. T. E. M. I. Randomized Controlled Trial. Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients with S. T.-elevation myocardial infarction. The benefits and safety of administering unfractionated heparin in the prehospital setting for these patients remain a critical clinical question. Optimizing pretreatment strategies with agents like unfractionated heparin at first medical contact is important for patients undergoing primary percutaneous coronary intervention. Investigating the efficacy and safety of such prehospital interventions informs best practices for acute myocardial infarction management.</p>
<p>Article number four. The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial. The role of atrial pacing support in cardiac resynchronization therapy-defibrillator patients without sinus node dysfunction is a clinically relevant question. Simplified cardiac resynchronization therapy-defibrillator systems that offer atrial sensing without full pacing support via a two-lead system could reduce procedural complexity. Determining if a two-lead system is non-inferior to a conventional three-lead system is important for patient selection and device choice. Evaluating these systems helps optimize outcomes and minimize risks associated with device implantation for cardiac resynchronization therapy.</p>
<p>Article number five. Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment. Chronic kidney disease affects 10 percent to 15 percent of adults globally and serves as a powerful, independent risk factor for cardiovascular diseases, including heart failure. Early stages of chronic kidney disease, specifically stages G1 to G3, are significantly associated with this elevated risk. The presence of albuminuria, particularly K. D. I. G. O. stages A2 to A3, further exacerbates cardiovascular risk even with mild renal dysfunction. These findings underscore the importance of recognizing pre-heart failure states in chronic kidney disease patients to inform early intervention strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>estimated glomerular filtration rate, chronic kidney disease, prehospital care, S. T.-elevation myocardial infarction, unfractionated heparin, three-lead system, defibrillator, apolipoprotein C-III inhibition, CKM staging framework, cardiovascular risk, remnant cholesterol, cardiac resynchronization therapy, albuminuria, Atherosclerosis Risk in Communities Study, primary percutaneous coronary intervention, heart failure, olezarsen, atrial pacing, two-lead system, echocardiography, acute myocardial infarction, cardiovascular-kidney-metabolic syndrome, hypertriglyceridemia, triglycerides.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/">APOC3 Inhibition Cuts Lipids 70 Percent 04/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like estimated glomerular filtration rate and chronic kidney disease. Key takeaway: APOC3 Inhibition Cuts Lipids 70 Percent.
Article Links:
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like estimated glomerular filtration rate and chronic kidney disease. Key takeaway: APOC3 Inhibition Cuts Lipids 70 Percent.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41919388">Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41910513">Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41910504">Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41910411">The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41914187">Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/">https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41919388" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41919388</a></p>
<p><strong>Summary:</strong> Suboptimal cardiovascular-kidney-metabolic health is highly prevalent among older adults in the United States. The American Heart Association has developed a Cardiovascular-Kidney-Metabolic syndrome staging framework to categorize risk. Despite this framework, its predictive utility for incident heart failure remains an area of uncertainty in this population. Understanding the relationship between Cardiovascular-Kidney-Metabolic syndrome stages, echocardiographic characteristics, and heart failure risk is essential for clinical management.</p>
<h4>Article 2: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910513" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910513</a></p>
<p><strong>Summary:</strong> P. O. C. 3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-T. I. M. I. 73b Imaging Study. Olezarsen, an antisense oligonucleotide inhibiting apolipoprotein C-III, reduces triglycerides by approximately 60 percent and remnant cholesterol by approximately 70 percent. This treatment also decreases apolipoprotein B by approximately 15 percent, while maintaining a neutral effect on low-density lipoprotein cholesterol in patients with moderate hypertriglyceridemia. These observed lipid modifications suggest a therapeutic approach to address triglyceride-rich lipoproteins and remnant cholesterol. Such inhibition holds significant clinical interest for its potential impact on coronary atherosclerosis.</p>
<h4>Article 3: Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910504" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910504</a></p>
<p><strong>Summary:</strong> T.-Elevation Myocardial Infarction Undergoing Primary P. C. I.: H. E. P. A. R. I. N. S. T. E. M. I. Randomized Controlled Trial. Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients with S. T.-elevation myocardial infarction. The benefits and safety of administering unfractionated heparin in the prehospital setting for these patients remain a critical clinical question. Optimizing pretreatment strategies with agents like unfractionated heparin at first medical contact is important for patients undergoing primary percutaneous coronary intervention. Investigating the efficacy and safety of such prehospital interventions informs best practices for acute myocardial infarction management.</p>
<h4>Article 4: The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910411" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910411</a></p>
<p><strong>Summary:</strong> The role of atrial pacing support in cardiac resynchronization therapy-defibrillator patients without sinus node dysfunction is a clinically relevant question. Simplified cardiac resynchronization therapy-defibrillator systems that offer atrial sensing without full pacing support via a two-lead system could reduce procedural complexity. Determining if a two-lead system is non-inferior to a conventional three-lead system is important for patient selection and device choice. Evaluating these systems helps optimize outcomes and minimize risks associated with device implantation for cardiac resynchronization therapy.</p>
<h4>Article 5: Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914187" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914187</a></p>
<p><strong>Summary:</strong> Chronic kidney disease affects 10 percent to 15 percent of adults globally and serves as a powerful, independent risk factor for cardiovascular diseases, including heart failure. Early stages of chronic kidney disease, specifically stages G1 to G3, are significantly associated with this elevated risk. The presence of albuminuria, particularly K. D. I. G. O. stages A2 to A3, further exacerbates cardiovascular risk even with mild renal dysfunction. These findings underscore the importance of recognizing pre-heart failure states in chronic kidney disease patients to inform early intervention strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. Suboptimal cardiovascular-kidney-metabolic health is highly prevalent among older adults in the United States. The American Heart Association has developed a Cardiovascular-Kidney-Metabolic syndrome staging framework to categorize risk. Despite this framework, its predictive utility for incident heart failure remains an area of uncertainty in this population. Understanding the relationship between Cardiovascular-Kidney-Metabolic syndrome stages, echocardiographic characteristics, and heart failure risk is essential for clinical management.</p>
<p>Article number two. Effect of A. P. O. C. 3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-T. I. M. I. 73b Imaging Study. Olezarsen, an antisense oligonucleotide inhibiting apolipoprotein C-III, reduces triglycerides by approximately 60 percent and remnant cholesterol by approximately 70 percent. This treatment also decreases apolipoprotein B by approximately 15 percent, while maintaining a neutral effect on low-density lipoprotein cholesterol in patients with moderate hypertriglyceridemia. These observed lipid modifications suggest a therapeutic approach to address triglyceride-rich lipoproteins and remnant cholesterol. Such inhibition holds significant clinical interest for its potential impact on coronary atherosclerosis.</p>
<p>Article number three. Prehospital Heparin Administration in Patients With S. T.-Elevation Myocardial Infarction Undergoing Primary P. C. I.: H. E. P. A. R. I. N. S. T. E. M. I. Randomized Controlled Trial. Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients with S. T.-elevation myocardial infarction. The benefits and safety of administering unfractionated heparin in the prehospital setting for these patients remain a critical clinical question. Optimizing pretreatment strategies with agents like unfractionated heparin at first medical contact is important for patients undergoing primary percutaneous coronary intervention. Investigating the efficacy and safety of such prehospital interventions informs best practices for acute myocardial infarction management.</p>
<p>Article number four. The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial. The role of atrial pacing support in cardiac resynchronization therapy-defibrillator patients without sinus node dysfunction is a clinically relevant question. Simplified cardiac resynchronization therapy-defibrillator systems that offer atrial sensing without full pacing support via a two-lead system could reduce procedural complexity. Determining if a two-lead system is non-inferior to a conventional three-lead system is important for patient selection and device choice. Evaluating these systems helps optimize outcomes and minimize risks associated with device implantation for cardiac resynchronization therapy.</p>
<p>Article number five. Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment. Chronic kidney disease affects 10 percent to 15 percent of adults globally and serves as a powerful, independent risk factor for cardiovascular diseases, including heart failure. Early stages of chronic kidney disease, specifically stages G1 to G3, are significantly associated with this elevated risk. The presence of albuminuria, particularly K. D. I. G. O. stages A2 to A3, further exacerbates cardiovascular risk even with mild renal dysfunction. These findings underscore the importance of recognizing pre-heart failure states in chronic kidney disease patients to inform early intervention strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>estimated glomerular filtration rate, chronic kidney disease, prehospital care, S. T.-elevation myocardial infarction, unfractionated heparin, three-lead system, defibrillator, apolipoprotein C-III inhibition, CKM staging framework, cardiovascular risk, remnant cholesterol, cardiac resynchronization therapy, albuminuria, Atherosclerosis Risk in Communities Study, primary percutaneous coronary intervention, heart failure, olezarsen, atrial pacing, two-lead system, echocardiography, acute myocardial infarction, cardiovascular-kidney-metabolic syndrome, hypertriglyceridemia, triglycerides.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/">APOC3 Inhibition Cuts Lipids 70 Percent 04/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260401_085212.mp3" length="4412647" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like estimated glomerular filtration rate and chronic kidney disease. Key takeaway: APOC3 Inhibition Cuts Lipids 70 Percent.
Article Links:
Article 1: Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. (Circulation)
Article 2: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. (Circulation)
Article 3: Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial. (Circulation)
Article 4: The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial. (Circulation)
Article 5: Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/apoc3-inhibition-cuts-lipids-70-percent-04-01-26/
 Featured Articles
Article 1: Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41919388
Summary: Suboptimal cardiovascular-kidney-metabolic health is highly prevalent among older adults in the United States. The American Heart Association has developed a Cardiovascular-Kidney-Metabolic syndrome staging framework to categorize risk. Despite this framework, its predictive utility for incident heart failure remains an area of uncertainty in this population. Understanding the relationship between Cardiovascular-Kidney-Metabolic syndrome stages, echocardiographic characteristics, and heart failure risk is essential for clinical management.
Article 2: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910513
Summary: P. O. C. 3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-T. I. M. I. 73b Imaging Study. Olezarsen, an antisense oligonucleotide inhibiting apolipoprotein C-III, reduces triglycerides by approximately 60 percent and remnant cholesterol by approximately 70 percent. This treatment also decreases apolipoprotein B by approximately 15 percent, while maintaining a neutral effect on low-density lipoprotein cholesterol in patients with moderate hypertriglyceridemia. These observed lipid modifications suggest a therapeutic approach to address triglyceride-rich lipoproteins and remnant cholesterol. Such inhibition holds significant clinical interest for its potential impact on coronary atherosclerosis.
Article 3: Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910504
Summary: T.-Elevation Myocardial Infarction Undergoing Primary P. C. I.: H. E. P. A. R. I. N. S. T. E. M. I. Randomized Controlled Trial. Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients with S. T.-elevation myocardial infarction. The benefits and safety of administering unfractionated heparin in the prehospital setting for these patients remain a critical clinical question. Optimizing pretreatment strategies with agents like unfractionated heparin at first medical contact is important for patients undergoing primary percutaneous coronary intervention. Investigating the efficacy and safety of such prehospital interventions informs best practices for acute myocardial infarction management.
Article 4: The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910411
Summary: The role of atrial pacing suppor]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like estimated glomerular filtration rate and chronic kidney disease. Key takeaway: APOC3 Inhibition Cuts Lipids 70 Percent.
Article Links:
Article 1: Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. (Circulation)
Article 2: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. (Circulation)
Article 3: Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial. (Circulation)
Article 4: The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial. (Circulation)
Article 5: Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment. (European heart journal)
Full episode page: https://pod]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Adaptive A. I. Validates C. V. Event Adjudication 04/01/26</title>
	<link>https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/</link>
	<pubDate>Wed, 01 Apr 2026 10:02:10 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk P. C. I. and mid-regional pro-adrenomedullin. Key takeaway: Adaptive A. I. Validates C. V. Event Adjudication.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41910382">Angiography-Based Physiology to Guide Coronary Revascularization.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41910380">Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41914946">IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41914183">MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41911340">Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/">https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Angiography-Based Physiology to Guide Coronary Revascularization.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910382" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910382</a></p>
<p><strong>Summary:</strong> This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.</p>
<h4>Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910380" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910380</a></p>
<p><strong>Summary:</strong> This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.</p>
<h4>Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914946" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914946</a></p>
<p><strong>Summary:</strong> V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides definitive evidence for the optimal guidance strategy in complex coronary bifurcation lesions treated with double kissing crush.</p>
<h4>Article 4: MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914183" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914183</a></p>
<p><strong>Summary:</strong> R. &#8211; ProA. D. M. Predicts Mortality and Heart Failure Events in A. T. T. R. Cardiac Amyloidosis. This study evaluated the prognostic value of 12 different circulating biomarkers for predicting outcomes in transthyretin amyloid cardiomyopathy (A. T. T. R. &#8211; C. M.). The assessed biomarkers included N-terminal pro-B-type natriuretic peptide (N. T. &#8211; proB. N. P.), high-sensitivity troponin I (hsTnI), and mid-regional pro-adrenomedullin (M. R. &#8211; proA. D. M.). The research specifically investigated tools for risk and prognosis stratification in A. T. T. R. &#8211; C. M. patients, addressing a growing clinical demand due to earlier diagnoses and new therapeutic options. This evaluation provides a comprehensive assessment of biomarker utility in identifying patient risk for future events in this disease.</p>
<h4>Article 5: Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41911340" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41911340</a></p>
<p><strong>Summary:</strong> I. for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. and E. U. C. L. I. D. Trials. Researchers developed and validated A. D. A. P. T. &#8211; C. E. C., an artificial intelligence (A. I.) algorithm capable of adjudicating multiple cardiovascular endpoints and adapting to new definitions. The algorithm was derived using data on myocardial infarction (M. I.), stroke, and heart failure from the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. trial. A. D. A. P. T. &#8211; C. E. C. underwent external validation using M. I., stroke, bleeding, and cardiovascular (C. V.) death data from the E. U. C. L. I. D. trial, demonstrating its performance across different clinical definitions. This innovative A. I. solution provides an adaptive, automated method for C. V. endpoint measurement in clinical trials, offering potential reductions in time and cost.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Angiography-Based Physiology to Guide Coronary Revascularization. This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.</p>
<p>Article number two. Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.</p>
<p>Article number three. I. V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides definitive evidence for the optimal guidance strategy in complex coronary bifurcation lesions treated with double kissing crush.</p>
<p>Article number four. M. R. &#8211; ProA. D. M. Predicts Mortality and Heart Failure Events in A. T. T. R. Cardiac Amyloidosis. This study evaluated the prognostic value of 12 different circulating biomarkers for predicting outcomes in transthyretin amyloid cardiomyopathy (A. T. T. R. &#8211; C. M.). The assessed biomarkers included N-terminal pro-B-type natriuretic peptide (N. T. &#8211; proB. N. P.), high-sensitivity troponin I (hsTnI), and mid-regional pro-adrenomedullin (M. R. &#8211; proA. D. M.). The research specifically investigated tools for risk and prognosis stratification in A. T. T. R. &#8211; C. M. patients, addressing a growing clinical demand due to earlier diagnoses and new therapeutic options. This evaluation provides a comprehensive assessment of biomarker utility in identifying patient risk for future events in this disease.</p>
<p>Article number five. Adaptive A. I. for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. and E. U. C. L. I. D. Trials. Researchers developed and validated A. D. A. P. T. &#8211; C. E. C., an artificial intelligence (A. I.) algorithm capable of adjudicating multiple cardiovascular endpoints and adapting to new definitions. The algorithm was derived using data on myocardial infarction (M. I.), stroke, and heart failure from the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. trial. A. D. A. P. T. &#8211; C. E. C. underwent external validation using M. I., stroke, bleeding, and cardiovascular (C. V.) death data from the E. U. C. L. I. D. trial, demonstrating its performance across different clinical definitions. This innovative A. I. solution provides an adaptive, automated method for C. V. endpoint measurement in clinical trials, offering potential reductions in time and cost. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-risk P. C. I., mid-regional pro-adrenomedullin, intermediate coronary lesions, prognosis stratification, severe left ventricular dysfunction, stroke, percutaneous coronary intervention, cardiovascular events, microaxial flow pump, N-terminal pro-B-type natriuretic peptide, biomarkers, transthyretin amyloid cardiomyopathy, double kissing crush, intravascular ultrasound, angiography guidance, artificial intelligence, myocardial infarction, clinical endpoint adjudication, coronary revascularization, coronary bifurcation lesions, pressure-wire fractional flow reserve, left ventricular unloading, angiography-derived fractional flow reserve.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/">Adaptive A. I. Validates C. V. Event Adjudication 04/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk P. C. I. and mid-regional pro-adrenomedullin. Key takeaway: Adaptive A. I. Validates C. V. Event Adjudication.
Article Links:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk P. C. I. and mid-regional pro-adrenomedullin. Key takeaway: Adaptive A. I. Validates C. V. Event Adjudication.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41910382">Angiography-Based Physiology to Guide Coronary Revascularization.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41910380">Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41914946">IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41914183">MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41911340">Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/">https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Angiography-Based Physiology to Guide Coronary Revascularization.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910382" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910382</a></p>
<p><strong>Summary:</strong> This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.</p>
<h4>Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910380" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910380</a></p>
<p><strong>Summary:</strong> This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.</p>
<h4>Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914946" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914946</a></p>
<p><strong>Summary:</strong> V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides definitive evidence for the optimal guidance strategy in complex coronary bifurcation lesions treated with double kissing crush.</p>
<h4>Article 4: MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41914183" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41914183</a></p>
<p><strong>Summary:</strong> R. &#8211; ProA. D. M. Predicts Mortality and Heart Failure Events in A. T. T. R. Cardiac Amyloidosis. This study evaluated the prognostic value of 12 different circulating biomarkers for predicting outcomes in transthyretin amyloid cardiomyopathy (A. T. T. R. &#8211; C. M.). The assessed biomarkers included N-terminal pro-B-type natriuretic peptide (N. T. &#8211; proB. N. P.), high-sensitivity troponin I (hsTnI), and mid-regional pro-adrenomedullin (M. R. &#8211; proA. D. M.). The research specifically investigated tools for risk and prognosis stratification in A. T. T. R. &#8211; C. M. patients, addressing a growing clinical demand due to earlier diagnoses and new therapeutic options. This evaluation provides a comprehensive assessment of biomarker utility in identifying patient risk for future events in this disease.</p>
<h4>Article 5: Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41911340" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41911340</a></p>
<p><strong>Summary:</strong> I. for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. and E. U. C. L. I. D. Trials. Researchers developed and validated A. D. A. P. T. &#8211; C. E. C., an artificial intelligence (A. I.) algorithm capable of adjudicating multiple cardiovascular endpoints and adapting to new definitions. The algorithm was derived using data on myocardial infarction (M. I.), stroke, and heart failure from the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. trial. A. D. A. P. T. &#8211; C. E. C. underwent external validation using M. I., stroke, bleeding, and cardiovascular (C. V.) death data from the E. U. C. L. I. D. trial, demonstrating its performance across different clinical definitions. This innovative A. I. solution provides an adaptive, automated method for C. V. endpoint measurement in clinical trials, offering potential reductions in time and cost.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is April 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Angiography-Based Physiology to Guide Coronary Revascularization. This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.</p>
<p>Article number two. Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.</p>
<p>Article number three. I. V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides definitive evidence for the optimal guidance strategy in complex coronary bifurcation lesions treated with double kissing crush.</p>
<p>Article number four. M. R. &#8211; ProA. D. M. Predicts Mortality and Heart Failure Events in A. T. T. R. Cardiac Amyloidosis. This study evaluated the prognostic value of 12 different circulating biomarkers for predicting outcomes in transthyretin amyloid cardiomyopathy (A. T. T. R. &#8211; C. M.). The assessed biomarkers included N-terminal pro-B-type natriuretic peptide (N. T. &#8211; proB. N. P.), high-sensitivity troponin I (hsTnI), and mid-regional pro-adrenomedullin (M. R. &#8211; proA. D. M.). The research specifically investigated tools for risk and prognosis stratification in A. T. T. R. &#8211; C. M. patients, addressing a growing clinical demand due to earlier diagnoses and new therapeutic options. This evaluation provides a comprehensive assessment of biomarker utility in identifying patient risk for future events in this disease.</p>
<p>Article number five. Adaptive A. I. for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. and E. U. C. L. I. D. Trials. Researchers developed and validated A. D. A. P. T. &#8211; C. E. C., an artificial intelligence (A. I.) algorithm capable of adjudicating multiple cardiovascular endpoints and adapting to new definitions. The algorithm was derived using data on myocardial infarction (M. I.), stroke, and heart failure from the O. D. Y. S. S. E. Y. O. U. T. C. O. M. E. S. trial. A. D. A. P. T. &#8211; C. E. C. underwent external validation using M. I., stroke, bleeding, and cardiovascular (C. V.) death data from the E. U. C. L. I. D. trial, demonstrating its performance across different clinical definitions. This innovative A. I. solution provides an adaptive, automated method for C. V. endpoint measurement in clinical trials, offering potential reductions in time and cost. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-risk P. C. I., mid-regional pro-adrenomedullin, intermediate coronary lesions, prognosis stratification, severe left ventricular dysfunction, stroke, percutaneous coronary intervention, cardiovascular events, microaxial flow pump, N-terminal pro-B-type natriuretic peptide, biomarkers, transthyretin amyloid cardiomyopathy, double kissing crush, intravascular ultrasound, angiography guidance, artificial intelligence, myocardial infarction, clinical endpoint adjudication, coronary revascularization, coronary bifurcation lesions, pressure-wire fractional flow reserve, left ventricular unloading, angiography-derived fractional flow reserve.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/">Adaptive A. I. Validates C. V. Event Adjudication 04/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/04/cardiology_today_20260401_060045.mp3" length="5734652" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk P. C. I. and mid-regional pro-adrenomedullin. Key takeaway: Adaptive A. I. Validates C. V. Event Adjudication.
Article Links:
Article 1: Angiography-Based Physiology to Guide Coronary Revascularization. (The New England journal of medicine)
Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. (The New England journal of medicine)
Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial. (Journal of the American College of Cardiology)
Article 4: MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis. (Circulation)
Article 5: Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/adaptive-a-i-validates-c-v-event-adjudication-04-01-26/
 Featured Articles
Article 1: Angiography-Based Physiology to Guide Coronary Revascularization.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910382
Summary: This international, randomized, noninferiority trial directly compared angiography-derived vessel fractional flow reserve (vFFR) with pressure-wire based fractional flow reserve (FFR) for guiding coronary revascularization. The trial evaluated vFFR, a method derived from three-dimensional quantitative coronary angiography that does not require a pressure wire or hyperemic agent. It established a robust head-to-head comparison to assess the effectiveness and safety of this less invasive physiological guidance for intermediate coronary lesions. The study addressed a critical lack of data on angiography-based revascularization guidance compared to the established pressure-wire FFR technique.
Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910380
Summary: This randomized trial assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex percutaneous coronary intervention (P. C. I.). The study established a direct comparison to determine if percutaneous left ventricular unloading improves outcomes in this high-risk patient population. It specifically investigated the impact of prophylactic mechanical support via a microaxial flow pump on mortality and complications during complex revascularization. This trial provides crucial data on the efficacy of a dedicated left ventricular unloading strategy in patients undergoing high-risk P. C. I.
Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41914946
Summary: V. U. S. or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The D. K. C. R. U. S. H. VIII Randomized Clinical Trial. Intravascular ultrasound (I. V. U. S.)-guided percutaneous coronary intervention (P. C. I.) is associated with fewer clinical events than angiography-guided P. C. I. The D. K. C. R. U. S. H. eight randomized clinical trial directly investigated the treatment effect of I. V. U. S.-guided P. C. I. compared to angiography-guided P. C. I. in patients with complex coronary bifurcation lesions undergoing double kissing crush stenting. This study established a head-to-head comparison to determine if I. V. U. S. guidance improves outcomes in this specific, challenging patient subgroup. It provides ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded April 01, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk P. C. I. and mid-regional pro-adrenomedullin. Key takeaway: Adaptive A. I. Validates C. V. Event Adjudication.
Article Links:
Article 1: Angiography-Based Physiology to Guide Coronary Revascularization. (The New England journal of medicine)
Article 2: Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. (The New England journal of medicine)
Article 3: IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial. (Journal of the American College of Cardiology)
Article 4: MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis. (Circulation)
Article 5: Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials. (Circulation)
Fu]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mavacamten Targets Adolescent H. C. M. 03/31/26</title>
	<link>https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/</link>
	<pubDate>Tue, 31 Mar 2026 10:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and intermediate coronary lesions. Key takeaway: Mavacamten Targets Adolescent H. C. M..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41911017">IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41911016">Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41910427">Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41910394">Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41910384">Angiography-Derived Fractional Flow Reserve to Guide PCI.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/">https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41911017" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41911017</a></p>
<p><strong>Summary:</strong> Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.</p>
<h4>Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41911016" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41911016</a></p>
<p><strong>Summary:</strong> Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.</p>
<h4>Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910427" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910427</a></p>
<p><strong>Summary:</strong> The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.</p>
<h4>Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910394" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910394</a></p>
<p><strong>Summary:</strong> Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.</p>
<h4>Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910384" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910384</a></p>
<p><strong>Summary:</strong> Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably improves clinical outcomes for patients undergoing cardiac catheterization and percutaneous coronary intervention. However, the widespread clinical adoption of pressure-wire-based physiological assessment remains limited. Angiography-derived fractional flow reserve shows good correlation with pressure-wire-based measurements and can simplify procedures, but its definitive impact on patient clinical outcomes remains unestablished.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.</p>
<p>Article number two. Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.</p>
<p>Article number three. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.</p>
<p>Article number four. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.</p>
<p>Article number five. Angiography-Derived Fractional Flow Reserve to Guide PCI. Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably improves clinical outcomes for patients undergoing cardiac catheterization and percutaneous coronary intervention. However, the widespread clinical adoption of pressure-wire-based physiological assessment remains limited. Angiography-derived fractional flow reserve shows good correlation with pressure-wire-based measurements and can simplify procedures, but its definitive impact on patient clinical outcomes remains unestablished. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, intermediate coronary lesions, beta-blocker therapy, stent optimization, cardiac myosin inhibitor, angiography, percutaneous coronary intervention, adolescents, pressure-wire assessment, complex coronary artery lesions, unprotected left main coronary artery disease, adverse events, angiography-derived F. F. R., left ventricular systolic function, mavacamten, intravascular ultrasonography, hypertrophic cardiomyopathy, fractional flow reserve, left ventricular outflow tract obstruction, myocardial infarction, secondary prevention, clinical outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/">Mavacamten Targets Adolescent H. C. M. 03/31/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and intermediate coronary lesions. Key takeaway: Mavacamten Targets Adolescent H. C. M..
Article Links:
Article 1: IVUS-G]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and intermediate coronary lesions. Key takeaway: Mavacamten Targets Adolescent H. C. M..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41911017">IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41911016">Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41910427">Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41910394">Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41910384">Angiography-Derived Fractional Flow Reserve to Guide PCI.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/">https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41911017" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41911017</a></p>
<p><strong>Summary:</strong> Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.</p>
<h4>Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41911016" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41911016</a></p>
<p><strong>Summary:</strong> Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.</p>
<h4>Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910427" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910427</a></p>
<p><strong>Summary:</strong> The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.</p>
<h4>Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910394" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910394</a></p>
<p><strong>Summary:</strong> Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.</p>
<h4>Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41910384" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41910384</a></p>
<p><strong>Summary:</strong> Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably improves clinical outcomes for patients undergoing cardiac catheterization and percutaneous coronary intervention. However, the widespread clinical adoption of pressure-wire-based physiological assessment remains limited. Angiography-derived fractional flow reserve shows good correlation with pressure-wire-based measurements and can simplify procedures, but its definitive impact on patient clinical outcomes remains unestablished.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.</p>
<p>Article number two. Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.</p>
<p>Article number three. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.</p>
<p>Article number four. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.</p>
<p>Article number five. Angiography-Derived Fractional Flow Reserve to Guide PCI. Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably improves clinical outcomes for patients undergoing cardiac catheterization and percutaneous coronary intervention. However, the widespread clinical adoption of pressure-wire-based physiological assessment remains limited. Angiography-derived fractional flow reserve shows good correlation with pressure-wire-based measurements and can simplify procedures, but its definitive impact on patient clinical outcomes remains unestablished. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, intermediate coronary lesions, beta-blocker therapy, stent optimization, cardiac myosin inhibitor, angiography, percutaneous coronary intervention, adolescents, pressure-wire assessment, complex coronary artery lesions, unprotected left main coronary artery disease, adverse events, angiography-derived F. F. R., left ventricular systolic function, mavacamten, intravascular ultrasonography, hypertrophic cardiomyopathy, fractional flow reserve, left ventricular outflow tract obstruction, myocardial infarction, secondary prevention, clinical outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/">Mavacamten Targets Adolescent H. C. M. 03/31/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260331_060033.mp3" length="3493136" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and intermediate coronary lesions. Key takeaway: Mavacamten Targets Adolescent H. C. M..
Article Links:
Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. (The New England journal of medicine)
Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. (The New England journal of medicine)
Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. (The New England journal of medicine)
Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/
 Featured Articles
Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41911017
Summary: Percutaneous coronary intervention for unprotected left main coronary artery disease is a critical revascularization strategy in cardiology. The comparative effectiveness of intravascular ultrasonographic guidance versus conventional angiographic guidance in improving clinical outcomes for P. C. I. remains an area of active investigation. Clarifying the optimal guidance method holds significant implications for patient prognosis in this high-risk population.
Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41911016
Summary: Intravascular ultrasonography guidance during percutaneous coronary intervention has been associated with increased stent optimization and reduced adverse events in patients with complex coronary artery lesions. Despite these recognized benefits and practice guideline recommendations for intracoronary imaging in anatomically complex lesions, adoption of this strategy in Western countries remains low. This highlights an ongoing need for robust evidence supporting its broader clinical integration in high-risk P. C. I. procedures.
Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910427
Summary: The long-term role of beta-blocker therapy after a myocardial infarction is currently undefined for patients with preserved left ventricular systolic function and without heart failure, particularly in the era of modern reperfusion and secondary prevention. This clinical uncertainty impacts decisions regarding medication continuation for stable post-myocardial infarction patients. Resolving this question has substantial implications for reducing polypharmacy and tailoring post-event care.
Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910394
Summary: Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are currently lacking, often leading to surgical intervention for left ventricular outflow tract obstruction. Mavacamten, a cardiac myosin inhibitor, is an established treatment for adults with obstructive hypertrophic cardiomyopathy. Evaluating the efficacy and safety of mavacamten in symptomatic adolescents with this condition addresses a critical unmet therapeutic need for younger patients.
Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41910384
Summary: Physiological assessment of intermediate coronary lesions using an intracoronary pressure wire demonstrably impr]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and intermediate coronary lesions. Key takeaway: Mavacamten Targets Adolescent H. C. M..
Article Links:
Article 1: IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. (The New England journal of medicine)
Article 2: Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI. (The New England journal of medicine)
Article 3: Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. (The New England journal of medicine)
Article 4: Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Article 5: Angiography-Derived Fractional Flow Reserve to Guide PCI. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/mavacamten-targets-adolescent-h-c-m-03-31-26/
 Featured Articles
Article 1: IVUS-Guided versus A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Democratizes Congenital Heart Disease Echo 03/30/26</title>
	<link>https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/</link>
	<pubDate>Mon, 30 Mar 2026 10:01:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 30, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiovascular Disease and Imaging. Key takeaway: AI Democratizes Congenital Heart Disease Echo.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41904795">Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41903131">Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41902792">Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41905344">Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41903523">Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/">https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41904795" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41904795</a></p>
<p><strong>Summary:</strong> Combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction is a condition carrying significant mortality for which no proven therapies exist. The phase two randomized CADENCE study evaluated sotatercept as a potential treatment, administered at 0.3 or 0.7 milligrams per kilogram, or placebo, every three weeks. The primary endpoint measured was the change in pulmonary vascular resistance at week twenty-four.</p>
<h4>Article 2: Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41903131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41903131</a></p>
<p><strong>Summary:</strong> Myocardial infarction with non-obstructive coronary arteries presents with various underlying causes, often including mimicking conditions, despite imaging recommendations to identify etiologies. This international, prospective study characterized the mechanisms of myocardial infarction with non-obstructive coronary arteries, analyzed predictors of imaging abnormalities, and explored sex differences.</p>
<h4>Article 3: Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41902792" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41902792</a></p>
<p><strong>Summary:</strong> Delayed or missed diagnosis of congenital heart disease significantly contributes to pediatric mortality worldwide. Expert echocardiography interpretation, which is central to diagnosing and triaging congenital heart disease, represents a scarce and maldistributed global resource. This study developed EchoFocus-C. H. D., an artificial intelligence-enabled tool designed to democratize diagnostics and extend expert-level interpretation beyond large academic centers.</p>
<h4>Article 4: Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41905344" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41905344</a></p>
<p><strong>Summary:</strong> Vigorous physical activity is known to provide greater health benefits per unit time than moderate activity, yet the full spectrum of these benefits across chronic diseases and the relative importance of intensity versus volume remains unclear. A prospective population-based cohort study of 96408 participants examined associations between the proportion of vigorous physical activity relative to total physical activity volume and the incidence of multiple chronic disease outcomes.</p>
<h4>Article 5: Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41903523" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41903523</a></p>
<p><strong>Summary:</strong> Elevated lipoprotein(a) levels are an established risk factor for atherosclerotic cardiovascular disease, however, its association with venous thromboembolism remains unclear, with potential modification by sex and hormonal status. This study investigated this relationship using participants from the U. K. Biobank with baseline lipoprotein(a) data. The study design excluded individuals with a history of venous thromboembolism or cancer, as well as those using anticoagulants.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 30, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study. Combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction is a condition carrying significant mortality for which no proven therapies exist. The phase two randomized CADENCE study evaluated sotatercept as a potential treatment, administered at 0.3 or 0.7 milligrams per kilogram, or placebo, every three weeks. The primary endpoint measured was the change in pulmonary vascular resistance at week twenty-four.</p>
<p>Article number two. Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men. Myocardial infarction with non-obstructive coronary arteries presents with various underlying causes, often including mimicking conditions, despite imaging recommendations to identify etiologies. This international, prospective study characterized the mechanisms of myocardial infarction with non-obstructive coronary arteries, analyzed predictors of imaging abnormalities, and explored sex differences.</p>
<p>Article number three. Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence. Delayed or missed diagnosis of congenital heart disease significantly contributes to pediatric mortality worldwide. Expert echocardiography interpretation, which is central to diagnosing and triaging congenital heart disease, represents a scarce and maldistributed global resource. This study developed EchoFocus-C. H. D., an artificial intelligence-enabled tool designed to democratize diagnostics and extend expert-level interpretation beyond large academic centers.</p>
<p>Article number four. Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases. Vigorous physical activity is known to provide greater health benefits per unit time than moderate activity, yet the full spectrum of these benefits across chronic diseases and the relative importance of intensity versus volume remains unclear. A prospective population-based cohort study of 96408 participants examined associations between the proportion of vigorous physical activity relative to total physical activity volume and the incidence of multiple chronic disease outcomes.</p>
<p>Article number five. Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. Elevated lipoprotein(a) levels are an established risk factor for atherosclerotic cardiovascular disease, however, its association with venous thromboembolism remains unclear, with potential modification by sex and hormonal status. This study investigated this relationship using participants from the U. K. Biobank with baseline lipoprotein(a) data. The study design excluded individuals with a history of venous thromboembolism or cancer, as well as those using anticoagulants. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiovascular Disease, Imaging, EchoFocus-C. H. D., Sotatercept, Pediatric Mortality, Artificial Intelligence, Atherosclerotic Cardiovascular Disease, Combined Post- and Pre-capillary Pulmonary Hypertension, Lipoprotein(a), Sex Differences, Physical Activity, Vigorous Physical Activity, Phase two trial, Physical Activity Intensity, Echocardiography, Physical Activity Volume, Congenital Heart Disease, Myocardial Infarction with Non-Obstructive Coronary Arteries, Hormonal Status, Chronic Diseases, Heart Failure with Preserved Ejection Fraction, Venous Thromboembolism, Predictors, Pulmonary Vascular Resistance, Etiologies.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/">AI Democratizes Congenital Heart Disease Echo 03/30/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 30, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiovascular Disease and Imaging. Key takeaway: AI Democratizes Congenital Heart Disease Echo.
Article Links:
Article 1: Sotatercept ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 30, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiovascular Disease and Imaging. Key takeaway: AI Democratizes Congenital Heart Disease Echo.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41904795">Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41903131">Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41902792">Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41905344">Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41903523">Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/">https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41904795" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41904795</a></p>
<p><strong>Summary:</strong> Combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction is a condition carrying significant mortality for which no proven therapies exist. The phase two randomized CADENCE study evaluated sotatercept as a potential treatment, administered at 0.3 or 0.7 milligrams per kilogram, or placebo, every three weeks. The primary endpoint measured was the change in pulmonary vascular resistance at week twenty-four.</p>
<h4>Article 2: Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41903131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41903131</a></p>
<p><strong>Summary:</strong> Myocardial infarction with non-obstructive coronary arteries presents with various underlying causes, often including mimicking conditions, despite imaging recommendations to identify etiologies. This international, prospective study characterized the mechanisms of myocardial infarction with non-obstructive coronary arteries, analyzed predictors of imaging abnormalities, and explored sex differences.</p>
<h4>Article 3: Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41902792" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41902792</a></p>
<p><strong>Summary:</strong> Delayed or missed diagnosis of congenital heart disease significantly contributes to pediatric mortality worldwide. Expert echocardiography interpretation, which is central to diagnosing and triaging congenital heart disease, represents a scarce and maldistributed global resource. This study developed EchoFocus-C. H. D., an artificial intelligence-enabled tool designed to democratize diagnostics and extend expert-level interpretation beyond large academic centers.</p>
<h4>Article 4: Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41905344" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41905344</a></p>
<p><strong>Summary:</strong> Vigorous physical activity is known to provide greater health benefits per unit time than moderate activity, yet the full spectrum of these benefits across chronic diseases and the relative importance of intensity versus volume remains unclear. A prospective population-based cohort study of 96408 participants examined associations between the proportion of vigorous physical activity relative to total physical activity volume and the incidence of multiple chronic disease outcomes.</p>
<h4>Article 5: Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41903523" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41903523</a></p>
<p><strong>Summary:</strong> Elevated lipoprotein(a) levels are an established risk factor for atherosclerotic cardiovascular disease, however, its association with venous thromboembolism remains unclear, with potential modification by sex and hormonal status. This study investigated this relationship using participants from the U. K. Biobank with baseline lipoprotein(a) data. The study design excluded individuals with a history of venous thromboembolism or cancer, as well as those using anticoagulants.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 30, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study. Combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction is a condition carrying significant mortality for which no proven therapies exist. The phase two randomized CADENCE study evaluated sotatercept as a potential treatment, administered at 0.3 or 0.7 milligrams per kilogram, or placebo, every three weeks. The primary endpoint measured was the change in pulmonary vascular resistance at week twenty-four.</p>
<p>Article number two. Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men. Myocardial infarction with non-obstructive coronary arteries presents with various underlying causes, often including mimicking conditions, despite imaging recommendations to identify etiologies. This international, prospective study characterized the mechanisms of myocardial infarction with non-obstructive coronary arteries, analyzed predictors of imaging abnormalities, and explored sex differences.</p>
<p>Article number three. Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence. Delayed or missed diagnosis of congenital heart disease significantly contributes to pediatric mortality worldwide. Expert echocardiography interpretation, which is central to diagnosing and triaging congenital heart disease, represents a scarce and maldistributed global resource. This study developed EchoFocus-C. H. D., an artificial intelligence-enabled tool designed to democratize diagnostics and extend expert-level interpretation beyond large academic centers.</p>
<p>Article number four. Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases. Vigorous physical activity is known to provide greater health benefits per unit time than moderate activity, yet the full spectrum of these benefits across chronic diseases and the relative importance of intensity versus volume remains unclear. A prospective population-based cohort study of 96408 participants examined associations between the proportion of vigorous physical activity relative to total physical activity volume and the incidence of multiple chronic disease outcomes.</p>
<p>Article number five. Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. Elevated lipoprotein(a) levels are an established risk factor for atherosclerotic cardiovascular disease, however, its association with venous thromboembolism remains unclear, with potential modification by sex and hormonal status. This study investigated this relationship using participants from the U. K. Biobank with baseline lipoprotein(a) data. The study design excluded individuals with a history of venous thromboembolism or cancer, as well as those using anticoagulants. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiovascular Disease, Imaging, EchoFocus-C. H. D., Sotatercept, Pediatric Mortality, Artificial Intelligence, Atherosclerotic Cardiovascular Disease, Combined Post- and Pre-capillary Pulmonary Hypertension, Lipoprotein(a), Sex Differences, Physical Activity, Vigorous Physical Activity, Phase two trial, Physical Activity Intensity, Echocardiography, Physical Activity Volume, Congenital Heart Disease, Myocardial Infarction with Non-Obstructive Coronary Arteries, Hormonal Status, Chronic Diseases, Heart Failure with Preserved Ejection Fraction, Venous Thromboembolism, Predictors, Pulmonary Vascular Resistance, Etiologies.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/">AI Democratizes Congenital Heart Disease Echo 03/30/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260330_060033.mp3" length="3644020" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 30, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiovascular Disease and Imaging. Key takeaway: AI Democratizes Congenital Heart Disease Echo.
Article Links:
Article 1: Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study. (Circulation)
Article 2: Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men. (Circulation)
Article 3: Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence. (Circulation)
Article 4: Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases. (European heart journal)
Article 5: Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/ai-democratizes-congenital-heart-disease-echo-03-30-26/
 Featured Articles
Article 1: Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41904795
Summary: Combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction is a condition carrying significant mortality for which no proven therapies exist. The phase two randomized CADENCE study evaluated sotatercept as a potential treatment, administered at 0.3 or 0.7 milligrams per kilogram, or placebo, every three weeks. The primary endpoint measured was the change in pulmonary vascular resistance at week twenty-four.
Article 2: Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41903131
Summary: Myocardial infarction with non-obstructive coronary arteries presents with various underlying causes, often including mimicking conditions, despite imaging recommendations to identify etiologies. This international, prospective study characterized the mechanisms of myocardial infarction with non-obstructive coronary arteries, analyzed predictors of imaging abnormalities, and explored sex differences.
Article 3: Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41902792
Summary: Delayed or missed diagnosis of congenital heart disease significantly contributes to pediatric mortality worldwide. Expert echocardiography interpretation, which is central to diagnosing and triaging congenital heart disease, represents a scarce and maldistributed global resource. This study developed EchoFocus-C. H. D., an artificial intelligence-enabled tool designed to democratize diagnostics and extend expert-level interpretation beyond large academic centers.
Article 4: Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41905344
Summary: Vigorous physical activity is known to provide greater health benefits per unit time than moderate activity, yet the full spectrum of these benefits across chronic diseases and the relative importance of intensity versus volume remains unclear. A prospective population-based cohort study of 96408 participants examined associations between the proportion of vigorous physical activity relative to total physical activity volume and the incidence of multiple chronic disease outcomes.
Article 5: Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41903523
Summary: Elevated lipoprotein(a) levels are an es]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 30, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiovascular Disease and Imaging. Key takeaway: AI Democratizes Congenital Heart Disease Echo.
Article Links:
Article 1: Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study. (Circulation)
Article 2: Multi-modality Imaging to Determine Underlying Causes of MINOCA in Women and Men. (Circulation)
Article 3: Automated Echocardiographic Detection of Congenital Heart Disease Using Artificial Intelligence. (Circulation)
Article 4: Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases. (European heart journal)
Article 5: Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/a]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Neurovascular Retinomics Predicts Heart Disease 03/29/26</title>
	<link>https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/</link>
	<pubDate>Sun, 29 Mar 2026 10:01:48 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 29, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiomyopathy and Excess mortality. Key takeaway: Neurovascular Retinomics Predicts Heart Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41889326">Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41748319">Neurovascular retinomics for predicting heart diseases.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41740584">A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41698873">Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41618689">Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/">https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41889326" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41889326</a></p>
<p><strong>Summary:</strong> The abstract outlines a significant research study focused on the impact of age on 5-year excess mortality in Heart Failure with Reduced Ejection Fraction. This investigation includes patients aged 40 to 85 years, all presenting with a left ventricular ejection fraction of 40 percent or less, who underwent coronary angiography for suspected cardiomyopathy. The methodology involves matching patients by sex and age, thus characterizing a structured approach to understand age-related differences in survival outcomes. This research addresses a crucial gap in current understanding of age as a determinant of prognosis in Heart Failure with Reduced Ejection Fraction.</p>
<h4>Article 2: Neurovascular retinomics for predicting heart diseases.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41748319" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41748319</a></p>
<p><strong>Summary:</strong> The abstract describes a comprehensive methodology developed for utilizing neurovascular retinomics to predict incident heart diseases. This approach integrates multidimensional vascular parameters from color fundus photography with neural parameters obtained from optical coherence tomography. The study design incorporated LASSO regression for meticulous feature selection and employed a Gradient Boosting Machine model to assess predictive value. This framework characterizes a specific computational strategy for leveraging retinal imaging data in cardiovascular risk evaluation.</p>
<h4>Article 3: A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41740584" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41740584</a></p>
<p><strong>Summary:</strong> The abstract presents a randomized, double-blind, crossover study that investigated the acute effects of low-level night-time road traffic noise on vascular function, sleep, and proteomic signatures in healthy adults. The research design exposed 74 healthy participants to three distinct overnight conditions, including a control with no noise and specific levels of road traffic noise. This structured methodology forms a basis for generating direct mechanistic evidence regarding environmental noise as a cardiovascular risk factor. The study provides a rigorous approach for evaluating acute physiological responses to noise exposure in humans.</p>
<h4>Article 4: Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41698873" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41698873</a></p>
<p><strong>Summary:</strong> The abstract highlights the emerging role of myo-inositol, which is consistently elevated in plasma of patients with Heart Failure, as a significant area of research in cardiac dysfunction. It details the function of sodium-myo-inositol co-transporter-1, or S. M. I. T. 1., a member of the sodium-glucose co-transporter family specifically expressed in the heart, in myo-inositol transport. The research described addresses the poorly understood mechanism by which myo-inositol dysregulation contributes to cardiac dysfunction. This investigation focuses on understanding the molecular pathways involving S. M. I. T. 1. in the context of heart failure.</p>
<h4>Article 5: Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41618689" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41618689</a></p>
<p><strong>Summary:</strong> The abstract introduces CCAAT/enhancer-binding protein beta, a transcription factor known for regulating cell processes including inflammation, as a significant area of cardiac research. It identifies a critical gap in understanding the cell-type-specific functions of C. E. B. P. beta in the heart during stress and baseline conditions. The described investigation focuses on clarifying the role of endogenous C. E. B. P. beta specifically within cardiomyocytes during pressure overload-induced heart failure. This research characterizes an effort to delineate the complex involvement of this protein in cardiac dysfunction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction. The abstract outlines a significant research study focused on the impact of age on 5-year excess mortality in Heart Failure with Reduced Ejection Fraction. This investigation includes patients aged 40 to 85 years, all presenting with a left ventricular ejection fraction of 40 percent or less, who underwent coronary angiography for suspected cardiomyopathy. The methodology involves matching patients by sex and age, thus characterizing a structured approach to understand age-related differences in survival outcomes. This research addresses a crucial gap in current understanding of age as a determinant of prognosis in Heart Failure with Reduced Ejection Fraction.</p>
<p>Article number two. Neurovascular retinomics for predicting heart diseases. The abstract describes a comprehensive methodology developed for utilizing neurovascular retinomics to predict incident heart diseases. This approach integrates multidimensional vascular parameters from color fundus photography with neural parameters obtained from optical coherence tomography. The study design incorporated LASSO regression for meticulous feature selection and employed a Gradient Boosting Machine model to assess predictive value. This framework characterizes a specific computational strategy for leveraging retinal imaging data in cardiovascular risk evaluation.</p>
<p>Article number three. A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults. The abstract presents a randomized, double-blind, crossover study that investigated the acute effects of low-level night-time road traffic noise on vascular function, sleep, and proteomic signatures in healthy adults. The research design exposed 74 healthy participants to three distinct overnight conditions, including a control with no noise and specific levels of road traffic noise. This structured methodology forms a basis for generating direct mechanistic evidence regarding environmental noise as a cardiovascular risk factor. The study provides a rigorous approach for evaluating acute physiological responses to noise exposure in humans.</p>
<p>Article number four. Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. The abstract highlights the emerging role of myo-inositol, which is consistently elevated in plasma of patients with Heart Failure, as a significant area of research in cardiac dysfunction. It details the function of sodium-myo-inositol co-transporter-1, or S. M. I. T. 1., a member of the sodium-glucose co-transporter family specifically expressed in the heart, in myo-inositol transport. The research described addresses the poorly understood mechanism by which myo-inositol dysregulation contributes to cardiac dysfunction. This investigation focuses on understanding the molecular pathways involving S. M. I. T. 1. in the context of heart failure.</p>
<p>Article number five. Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure. The abstract introduces CCAAT/enhancer-binding protein beta, a transcription factor known for regulating cell processes including inflammation, as a significant area of cardiac research. It identifies a critical gap in understanding the cell-type-specific functions of C. E. B. P. beta in the heart during stress and baseline conditions. The described investigation focuses on clarifying the role of endogenous C. E. B. P. beta specifically within cardiomyocytes during pressure overload-induced heart failure. This research characterizes an effort to delineate the complex involvement of this protein in cardiac dysfunction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiomyopathy, Excess mortality, Heart diseases, Cardiomyocytes, Heart Failure with Reduced Ejection Fraction, Pressure overload, Cardiac fibrosis, Sleep, Color fundus photography, Vascular function, Age, Road traffic noise, CCAAT/enhancer-binding protein beta, Biomarker, Proteomic signatures, Heart failure, Transcription factor, Retinomics, Cardiac hypertrophy, Coronary angiography, Myo-inositol, Optical coherence tomography, Sodium-myo-inositol co-transporter-1, Cardiovascular risk factor.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/">Neurovascular Retinomics Predicts Heart Disease 03/29/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 29, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiomyopathy and Excess mortality. Key takeaway: Neurovascular Retinomics Predicts Heart Disease.
Article Links:
Article 1: Effect of]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 29, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiomyopathy and Excess mortality. Key takeaway: Neurovascular Retinomics Predicts Heart Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41889326">Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41748319">Neurovascular retinomics for predicting heart diseases.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41740584">A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41698873">Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41618689">Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/">https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41889326" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41889326</a></p>
<p><strong>Summary:</strong> The abstract outlines a significant research study focused on the impact of age on 5-year excess mortality in Heart Failure with Reduced Ejection Fraction. This investigation includes patients aged 40 to 85 years, all presenting with a left ventricular ejection fraction of 40 percent or less, who underwent coronary angiography for suspected cardiomyopathy. The methodology involves matching patients by sex and age, thus characterizing a structured approach to understand age-related differences in survival outcomes. This research addresses a crucial gap in current understanding of age as a determinant of prognosis in Heart Failure with Reduced Ejection Fraction.</p>
<h4>Article 2: Neurovascular retinomics for predicting heart diseases.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41748319" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41748319</a></p>
<p><strong>Summary:</strong> The abstract describes a comprehensive methodology developed for utilizing neurovascular retinomics to predict incident heart diseases. This approach integrates multidimensional vascular parameters from color fundus photography with neural parameters obtained from optical coherence tomography. The study design incorporated LASSO regression for meticulous feature selection and employed a Gradient Boosting Machine model to assess predictive value. This framework characterizes a specific computational strategy for leveraging retinal imaging data in cardiovascular risk evaluation.</p>
<h4>Article 3: A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41740584" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41740584</a></p>
<p><strong>Summary:</strong> The abstract presents a randomized, double-blind, crossover study that investigated the acute effects of low-level night-time road traffic noise on vascular function, sleep, and proteomic signatures in healthy adults. The research design exposed 74 healthy participants to three distinct overnight conditions, including a control with no noise and specific levels of road traffic noise. This structured methodology forms a basis for generating direct mechanistic evidence regarding environmental noise as a cardiovascular risk factor. The study provides a rigorous approach for evaluating acute physiological responses to noise exposure in humans.</p>
<h4>Article 4: Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41698873" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41698873</a></p>
<p><strong>Summary:</strong> The abstract highlights the emerging role of myo-inositol, which is consistently elevated in plasma of patients with Heart Failure, as a significant area of research in cardiac dysfunction. It details the function of sodium-myo-inositol co-transporter-1, or S. M. I. T. 1., a member of the sodium-glucose co-transporter family specifically expressed in the heart, in myo-inositol transport. The research described addresses the poorly understood mechanism by which myo-inositol dysregulation contributes to cardiac dysfunction. This investigation focuses on understanding the molecular pathways involving S. M. I. T. 1. in the context of heart failure.</p>
<h4>Article 5: Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41618689" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41618689</a></p>
<p><strong>Summary:</strong> The abstract introduces CCAAT/enhancer-binding protein beta, a transcription factor known for regulating cell processes including inflammation, as a significant area of cardiac research. It identifies a critical gap in understanding the cell-type-specific functions of C. E. B. P. beta in the heart during stress and baseline conditions. The described investigation focuses on clarifying the role of endogenous C. E. B. P. beta specifically within cardiomyocytes during pressure overload-induced heart failure. This research characterizes an effort to delineate the complex involvement of this protein in cardiac dysfunction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction. The abstract outlines a significant research study focused on the impact of age on 5-year excess mortality in Heart Failure with Reduced Ejection Fraction. This investigation includes patients aged 40 to 85 years, all presenting with a left ventricular ejection fraction of 40 percent or less, who underwent coronary angiography for suspected cardiomyopathy. The methodology involves matching patients by sex and age, thus characterizing a structured approach to understand age-related differences in survival outcomes. This research addresses a crucial gap in current understanding of age as a determinant of prognosis in Heart Failure with Reduced Ejection Fraction.</p>
<p>Article number two. Neurovascular retinomics for predicting heart diseases. The abstract describes a comprehensive methodology developed for utilizing neurovascular retinomics to predict incident heart diseases. This approach integrates multidimensional vascular parameters from color fundus photography with neural parameters obtained from optical coherence tomography. The study design incorporated LASSO regression for meticulous feature selection and employed a Gradient Boosting Machine model to assess predictive value. This framework characterizes a specific computational strategy for leveraging retinal imaging data in cardiovascular risk evaluation.</p>
<p>Article number three. A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults. The abstract presents a randomized, double-blind, crossover study that investigated the acute effects of low-level night-time road traffic noise on vascular function, sleep, and proteomic signatures in healthy adults. The research design exposed 74 healthy participants to three distinct overnight conditions, including a control with no noise and specific levels of road traffic noise. This structured methodology forms a basis for generating direct mechanistic evidence regarding environmental noise as a cardiovascular risk factor. The study provides a rigorous approach for evaluating acute physiological responses to noise exposure in humans.</p>
<p>Article number four. Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. The abstract highlights the emerging role of myo-inositol, which is consistently elevated in plasma of patients with Heart Failure, as a significant area of research in cardiac dysfunction. It details the function of sodium-myo-inositol co-transporter-1, or S. M. I. T. 1., a member of the sodium-glucose co-transporter family specifically expressed in the heart, in myo-inositol transport. The research described addresses the poorly understood mechanism by which myo-inositol dysregulation contributes to cardiac dysfunction. This investigation focuses on understanding the molecular pathways involving S. M. I. T. 1. in the context of heart failure.</p>
<p>Article number five. Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure. The abstract introduces CCAAT/enhancer-binding protein beta, a transcription factor known for regulating cell processes including inflammation, as a significant area of cardiac research. It identifies a critical gap in understanding the cell-type-specific functions of C. E. B. P. beta in the heart during stress and baseline conditions. The described investigation focuses on clarifying the role of endogenous C. E. B. P. beta specifically within cardiomyocytes during pressure overload-induced heart failure. This research characterizes an effort to delineate the complex involvement of this protein in cardiac dysfunction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiomyopathy, Excess mortality, Heart diseases, Cardiomyocytes, Heart Failure with Reduced Ejection Fraction, Pressure overload, Cardiac fibrosis, Sleep, Color fundus photography, Vascular function, Age, Road traffic noise, CCAAT/enhancer-binding protein beta, Biomarker, Proteomic signatures, Heart failure, Transcription factor, Retinomics, Cardiac hypertrophy, Coronary angiography, Myo-inositol, Optical coherence tomography, Sodium-myo-inositol co-transporter-1, Cardiovascular risk factor.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/">Neurovascular Retinomics Predicts Heart Disease 03/29/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260329_060048.mp3" length="4478266" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 29, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiomyopathy and Excess mortality. Key takeaway: Neurovascular Retinomics Predicts Heart Disease.
Article Links:
Article 1: Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction. (European journal of heart failure)
Article 2: Neurovascular retinomics for predicting heart diseases. (Cardiovascular research)
Article 3: A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults. (Cardiovascular research)
Article 4: Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. (Cardiovascular research)
Article 5: Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/neurovascular-retinomics-predicts-heart-disease-03-29-26/
 Featured Articles
Article 1: Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41889326
Summary: The abstract outlines a significant research study focused on the impact of age on 5-year excess mortality in Heart Failure with Reduced Ejection Fraction. This investigation includes patients aged 40 to 85 years, all presenting with a left ventricular ejection fraction of 40 percent or less, who underwent coronary angiography for suspected cardiomyopathy. The methodology involves matching patients by sex and age, thus characterizing a structured approach to understand age-related differences in survival outcomes. This research addresses a crucial gap in current understanding of age as a determinant of prognosis in Heart Failure with Reduced Ejection Fraction.
Article 2: Neurovascular retinomics for predicting heart diseases.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41748319
Summary: The abstract describes a comprehensive methodology developed for utilizing neurovascular retinomics to predict incident heart diseases. This approach integrates multidimensional vascular parameters from color fundus photography with neural parameters obtained from optical coherence tomography. The study design incorporated LASSO regression for meticulous feature selection and employed a Gradient Boosting Machine model to assess predictive value. This framework characterizes a specific computational strategy for leveraging retinal imaging data in cardiovascular risk evaluation.
Article 3: A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41740584
Summary: The abstract presents a randomized, double-blind, crossover study that investigated the acute effects of low-level night-time road traffic noise on vascular function, sleep, and proteomic signatures in healthy adults. The research design exposed 74 healthy participants to three distinct overnight conditions, including a control with no noise and specific levels of road traffic noise. This structured methodology forms a basis for generating direct mechanistic evidence regarding environmental noise as a cardiovascular risk factor. The study provides a rigorous approach for evaluating acute physiological responses to noise exposure in humans.
Article 4: Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41698873
Summary: The abstract highlights the emerging role of myo-inositol, which is consistently elevated in plasma of patie]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 29, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiomyopathy and Excess mortality. Key takeaway: Neurovascular Retinomics Predicts Heart Disease.
Article Links:
Article 1: Effect of age on 5-year excess mortality in heart failure with reduced ejection fraction. (European journal of heart failure)
Article 2: Neurovascular retinomics for predicting heart diseases. (Cardiovascular research)
Article 3: A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults. (Cardiovascular research)
Article 4: Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. (Cardiovascular research)
Article 5: Cardiomyocyte-specific deficiency of C/EBPβ aggravates pressure overload-induced heart failure. (Cardiovascular research)
Full episode page: https://po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CAD Phenotypes Found for Tailored Prevention 03/28/26</title>
	<link>https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/</link>
	<pubDate>Sat, 28 Mar 2026 12:53:08 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and prognosis. Key takeaway: CAD Phenotypes Found for Tailored Prevention.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40691042">Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40451277">Identifying clinical phenotype clusters in patients with coronary artery disease.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41894572">Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41885188">Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41885184">Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/">https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691042" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691042</a></p>
<p><strong>Summary:</strong> A national cohort study of 852914 adult patients in England and Wales found that one-year all-cause mortality following acute myocardial infarction declined between 2005 and 2019. Researchers analyzed this 15-year dataset to quantify the contributions of clinical, treatment, and demographic factors to these changes. The findings provide crucial data for informing clinical strategies and health policy.</p>
<h4>Article 2: Identifying clinical phenotype clusters in patients with coronary artery disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40451277" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40451277</a></p>
<p><strong>Summary:</strong> This study found that clinical phenotype clusters exist in patients with coronary artery disease. Researchers used unsupervised machine learning through latent class analysis to identify these clusters. The study assessed the relationship of these identified phenotypes with the risk of recurrent cardiovascular events. This work addresses the need for specific considerations beyond current one-size-fits-all guideline recommendations for cardiovascular event prevention.</p>
<h4>Article 3: Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41894572" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41894572</a></p>
<p><strong>Summary:</strong> This study provided evidence-based guidance on selecting optimal N-terminal pro-B-type natriuretic peptide cut-offs for randomized controlled trials in heart failure. Researchers utilized data from the Swedish Heart Failure Registry, applying N-terminal pro-B-type natriuretic peptide cut-offs ranging from 200 to 5000 picograms per milliliter, which were derived from prior randomized controlled trials. The study calculated one-year incidence proportions to optimize the balance between event enrichment and screening failure across various heart failure subgroups. This optimizes patient selection for clinical trials, improving efficiency and relevance.</p>
<h4>Article 4: Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885188" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885188</a></p>
<p><strong>Summary:</strong> This study compared the characteristics and therapeutic response of patients with obstructive hypertrophic cardiomyopathy who only showed treatment-qualifying left ventricular outflow tract obstruction during exercise echocardiography, versus those who met eligibility at rest. Researchers assessed the therapeutic response to cardiac myosin inhibitors, specifically mavacamten, in these patient groups. The findings clarify the clinical profile and treatment response of patients who require exercise imaging to establish eligibility for these inhibitors. This work helps identify appropriate candidates for mavacamten therapy.</p>
<h4>Article 5: Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885184</a></p>
<p><strong>Summary:</strong> This study found that the prognostic implications of body mass index in patients with acute heart failure differed according to heart failure phenotype and sex. Researchers analyzed 5271 patients hospitalized for acute heart failure from the Korean Heart Failure three Registry. Body mass index was categorized into low, normal, and high groups using Asia-Pacific criteria. The primary outcome was a composite of two-year all-cause mortality or heart transplantation, showing varying risks across subgroups.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study. A national cohort study of 852914 adult patients in England and Wales found that one-year all-cause mortality following acute myocardial infarction declined between 2005 and 2019. Researchers analyzed this 15-year dataset to quantify the contributions of clinical, treatment, and demographic factors to these changes. The findings provide crucial data for informing clinical strategies and health policy.</p>
<p>Article number two. Identifying clinical phenotype clusters in patients with coronary artery disease. This study found that clinical phenotype clusters exist in patients with coronary artery disease. Researchers used unsupervised machine learning through latent class analysis to identify these clusters. The study assessed the relationship of these identified phenotypes with the risk of recurrent cardiovascular events. This work addresses the need for specific considerations beyond current one-size-fits-all guideline recommendations for cardiovascular event prevention.</p>
<p>Article number three. Optimizing N-terminal pro-B-type natriuretic peptide Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry. This study provided evidence-based guidance on selecting optimal N-terminal pro-B-type natriuretic peptide cut-offs for randomized controlled trials in heart failure. Researchers utilized data from the Swedish Heart Failure Registry, applying N-terminal pro-B-type natriuretic peptide cut-offs ranging from 200 to 5000 picograms per milliliter, which were derived from prior randomized controlled trials. The study calculated one-year incidence proportions to optimize the balance between event enrichment and screening failure across various heart failure subgroups. This optimizes patient selection for clinical trials, improving efficiency and relevance.</p>
<p>Article number four. Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors. This study compared the characteristics and therapeutic response of patients with obstructive hypertrophic cardiomyopathy who only showed treatment-qualifying left ventricular outflow tract obstruction during exercise echocardiography, versus those who met eligibility at rest. Researchers assessed the therapeutic response to cardiac myosin inhibitors, specifically mavacamten, in these patient groups. The findings clarify the clinical profile and treatment response of patients who require exercise imaging to establish eligibility for these inhibitors. This work helps identify appropriate candidates for mavacamten therapy.</p>
<p>Article number five. Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure. This study found that the prognostic implications of body mass index in patients with acute heart failure differed according to heart failure phenotype and sex. Researchers analyzed 5271 patients hospitalized for acute heart failure from the Korean Heart Failure three Registry. Body mass index was categorized into low, normal, and high groups using Asia-Pacific criteria. The primary outcome was a composite of two-year all-cause mortality or heart transplantation, showing varying risks across subgroups. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, prognosis, coronary artery disease, machine learning, randomized controlled trials, one-year mortality, body mass index, Swedish Heart Failure Registry, inclusion criteria, acute heart failure, heart failure phenotype, prevention, sex differences, national registry, N-terminal pro-B-type natriuretic peptide, cardiac myosin inhibitors, acute myocardial infarction, mavacamten, phenotype clusters, exercise echocardiography, obstructive hypertrophic cardiomyopathy, clinical strategies, recurrent cardiovascular events, left ventricular outflow tract obstruction, health policy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/">CAD Phenotypes Found for Tailored Prevention 03/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and prognosis. Key takeaway: CAD Phenotypes Found for Tailored Prevention.
Article Links:
Article 1: Drivers of 1-year mo]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and prognosis. Key takeaway: CAD Phenotypes Found for Tailored Prevention.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40691042">Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40451277">Identifying clinical phenotype clusters in patients with coronary artery disease.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41894572">Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41885188">Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41885184">Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/">https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691042" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691042</a></p>
<p><strong>Summary:</strong> A national cohort study of 852914 adult patients in England and Wales found that one-year all-cause mortality following acute myocardial infarction declined between 2005 and 2019. Researchers analyzed this 15-year dataset to quantify the contributions of clinical, treatment, and demographic factors to these changes. The findings provide crucial data for informing clinical strategies and health policy.</p>
<h4>Article 2: Identifying clinical phenotype clusters in patients with coronary artery disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40451277" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40451277</a></p>
<p><strong>Summary:</strong> This study found that clinical phenotype clusters exist in patients with coronary artery disease. Researchers used unsupervised machine learning through latent class analysis to identify these clusters. The study assessed the relationship of these identified phenotypes with the risk of recurrent cardiovascular events. This work addresses the need for specific considerations beyond current one-size-fits-all guideline recommendations for cardiovascular event prevention.</p>
<h4>Article 3: Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41894572" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41894572</a></p>
<p><strong>Summary:</strong> This study provided evidence-based guidance on selecting optimal N-terminal pro-B-type natriuretic peptide cut-offs for randomized controlled trials in heart failure. Researchers utilized data from the Swedish Heart Failure Registry, applying N-terminal pro-B-type natriuretic peptide cut-offs ranging from 200 to 5000 picograms per milliliter, which were derived from prior randomized controlled trials. The study calculated one-year incidence proportions to optimize the balance between event enrichment and screening failure across various heart failure subgroups. This optimizes patient selection for clinical trials, improving efficiency and relevance.</p>
<h4>Article 4: Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885188" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885188</a></p>
<p><strong>Summary:</strong> This study compared the characteristics and therapeutic response of patients with obstructive hypertrophic cardiomyopathy who only showed treatment-qualifying left ventricular outflow tract obstruction during exercise echocardiography, versus those who met eligibility at rest. Researchers assessed the therapeutic response to cardiac myosin inhibitors, specifically mavacamten, in these patient groups. The findings clarify the clinical profile and treatment response of patients who require exercise imaging to establish eligibility for these inhibitors. This work helps identify appropriate candidates for mavacamten therapy.</p>
<h4>Article 5: Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885184</a></p>
<p><strong>Summary:</strong> This study found that the prognostic implications of body mass index in patients with acute heart failure differed according to heart failure phenotype and sex. Researchers analyzed 5271 patients hospitalized for acute heart failure from the Korean Heart Failure three Registry. Body mass index was categorized into low, normal, and high groups using Asia-Pacific criteria. The primary outcome was a composite of two-year all-cause mortality or heart transplantation, showing varying risks across subgroups.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study. A national cohort study of 852914 adult patients in England and Wales found that one-year all-cause mortality following acute myocardial infarction declined between 2005 and 2019. Researchers analyzed this 15-year dataset to quantify the contributions of clinical, treatment, and demographic factors to these changes. The findings provide crucial data for informing clinical strategies and health policy.</p>
<p>Article number two. Identifying clinical phenotype clusters in patients with coronary artery disease. This study found that clinical phenotype clusters exist in patients with coronary artery disease. Researchers used unsupervised machine learning through latent class analysis to identify these clusters. The study assessed the relationship of these identified phenotypes with the risk of recurrent cardiovascular events. This work addresses the need for specific considerations beyond current one-size-fits-all guideline recommendations for cardiovascular event prevention.</p>
<p>Article number three. Optimizing N-terminal pro-B-type natriuretic peptide Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry. This study provided evidence-based guidance on selecting optimal N-terminal pro-B-type natriuretic peptide cut-offs for randomized controlled trials in heart failure. Researchers utilized data from the Swedish Heart Failure Registry, applying N-terminal pro-B-type natriuretic peptide cut-offs ranging from 200 to 5000 picograms per milliliter, which were derived from prior randomized controlled trials. The study calculated one-year incidence proportions to optimize the balance between event enrichment and screening failure across various heart failure subgroups. This optimizes patient selection for clinical trials, improving efficiency and relevance.</p>
<p>Article number four. Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors. This study compared the characteristics and therapeutic response of patients with obstructive hypertrophic cardiomyopathy who only showed treatment-qualifying left ventricular outflow tract obstruction during exercise echocardiography, versus those who met eligibility at rest. Researchers assessed the therapeutic response to cardiac myosin inhibitors, specifically mavacamten, in these patient groups. The findings clarify the clinical profile and treatment response of patients who require exercise imaging to establish eligibility for these inhibitors. This work helps identify appropriate candidates for mavacamten therapy.</p>
<p>Article number five. Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure. This study found that the prognostic implications of body mass index in patients with acute heart failure differed according to heart failure phenotype and sex. Researchers analyzed 5271 patients hospitalized for acute heart failure from the Korean Heart Failure three Registry. Body mass index was categorized into low, normal, and high groups using Asia-Pacific criteria. The primary outcome was a composite of two-year all-cause mortality or heart transplantation, showing varying risks across subgroups. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, prognosis, coronary artery disease, machine learning, randomized controlled trials, one-year mortality, body mass index, Swedish Heart Failure Registry, inclusion criteria, acute heart failure, heart failure phenotype, prevention, sex differences, national registry, N-terminal pro-B-type natriuretic peptide, cardiac myosin inhibitors, acute myocardial infarction, mavacamten, phenotype clusters, exercise echocardiography, obstructive hypertrophic cardiomyopathy, clinical strategies, recurrent cardiovascular events, left ventricular outflow tract obstruction, health policy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/">CAD Phenotypes Found for Tailored Prevention 03/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260328_085206.mp3" length="3959997" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and prognosis. Key takeaway: CAD Phenotypes Found for Tailored Prevention.
Article Links:
Article 1: Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study. (Heart (British Cardiac Society))
Article 2: Identifying clinical phenotype clusters in patients with coronary artery disease. (Heart (British Cardiac Society))
Article 3: Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry. (ESC heart failure)
Article 4: Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors. (ESC heart failure)
Article 5: Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/cad-phenotypes-found-for-tailored-prevention-03-28-26/
 Featured Articles
Article 1: Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40691042
Summary: A national cohort study of 852914 adult patients in England and Wales found that one-year all-cause mortality following acute myocardial infarction declined between 2005 and 2019. Researchers analyzed this 15-year dataset to quantify the contributions of clinical, treatment, and demographic factors to these changes. The findings provide crucial data for informing clinical strategies and health policy.
Article 2: Identifying clinical phenotype clusters in patients with coronary artery disease.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40451277
Summary: This study found that clinical phenotype clusters exist in patients with coronary artery disease. Researchers used unsupervised machine learning through latent class analysis to identify these clusters. The study assessed the relationship of these identified phenotypes with the risk of recurrent cardiovascular events. This work addresses the need for specific considerations beyond current one-size-fits-all guideline recommendations for cardiovascular event prevention.
Article 3: Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41894572
Summary: This study provided evidence-based guidance on selecting optimal N-terminal pro-B-type natriuretic peptide cut-offs for randomized controlled trials in heart failure. Researchers utilized data from the Swedish Heart Failure Registry, applying N-terminal pro-B-type natriuretic peptide cut-offs ranging from 200 to 5000 picograms per milliliter, which were derived from prior randomized controlled trials. The study calculated one-year incidence proportions to optimize the balance between event enrichment and screening failure across various heart failure subgroups. This optimizes patient selection for clinical trials, improving efficiency and relevance.
Article 4: Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41885188
Summary: This study compared the characteristics and therapeutic response of patients with obstructive hypertrophic cardiomyopathy who only showed treatment-qualifying left ventricular outflow tract obstruction during exercise echocardiography, versus those who met eligibility at rest. Researchers assessed the therapeutic response to cardiac myosin inhibitors, specifically mavacamten, in these patient groups. The findings clarify the clinical profile and treatment response of patients who require e]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure and prognosis. Key takeaway: CAD Phenotypes Found for Tailored Prevention.
Article Links:
Article 1: Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study. (Heart (British Cardiac Society))
Article 2: Identifying clinical phenotype clusters in patients with coronary artery disease. (Heart (British Cardiac Society))
Article 3: Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry. (ESC heart failure)
Article 4: Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors. (ESC heart failure)
Article 5: Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure. (ESC heart failure)
Full episode page: https://podcast.explainheart]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes 03/28/26</title>
	<link>https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/</link>
	<pubDate>Sat, 28 Mar 2026 10:01:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like oral anticoagulation and caregiver self-care. Key takeaway: Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41895678">Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41879791">Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41879767">Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41887758">Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40701798">Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/">https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895678" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895678</a></p>
<p><strong>Summary:</strong> Prior research demonstrated that health coaching reduces heart failure caregiver stress and improves caregiver self-care behaviors. This randomized controlled trial assessed the longitudinal associations between improved caregiver self-care and heart failure patient hospitalization outcomes. The study identified how changes in caregiver well-being influenced patient clinical trajectories, underscoring the critical role of caregiver support in patient health.</p>
<h4>Article 2: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879791" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879791</a></p>
<p><strong>Summary:</strong> The S. O. U. L. randomized clinical trial found that once-daily oral semaglutide reduced the risk of major adverse cardiovascular events by 14 percent compared to placebo. This significant benefit occurred in individuals with type two diabetes and atherosclerotic cardiovascular disease or chronic kidney disease receiving standard of care. This secondary analysis demonstrated the specific changes oral semaglutide induced in long-term cardiovascular risk factors within this high-risk patient group.</p>
<h4>Article 3: Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879767</a></p>
<p><strong>Summary:</strong> Left atrial appendage occlusion is a critical intervention for patients with contraindications to oral anticoagulation and an increased risk of major bleeding. The Amulet I. D. E. randomized clinical trial meticulously identified the incidence, key predictors, and effective management strategies for major bleeding following left atrial appendage occlusion. This study, involving 1878 randomized patients comparing the Amulet with the Watchman devices, also determined the clinical impact of these bleeding events on patient outcomes.</p>
<h4>Article 4: Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41887758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41887758</a></p>
<p><strong>Summary:</strong> Many patients with coronary heart disease exhibit blood pressure above guideline targets, even with ongoing treatment. European guidelines offer conflicting recommendations regarding patients with on-treatment blood pressure below target, with the 2023 European Society of Hypertension guidelines issuing a class three recommendation to proactively avoid blood pressure below target. The I. N. T. E. R. A. S. P. I. R. E. study established the prevalence and characteristics of patients with coronary heart disease whose blood pressure fell below target levels.</p>
<h4>Article 5: Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40701798" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40701798</a></p>
<p><strong>Summary:</strong> Cardiovascular interventions and complications commonly occur after arterial switch operation in patients with dextro-transposition of the great arteries. While complex anatomy, such as ventricular septal defects, is often associated with these outcomes, the independent role of aortic coarctation remained unclear. This multicenter international cohort study analyzed 502 adults from the E. P. O. C. H. A. S. O. registry, precisely defining the long-term morbidity associated with aortic coarctation following arterial switch operation, independent of other complex anatomical factors.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations. Prior research demonstrated that health coaching reduces heart failure caregiver stress and improves caregiver self-care behaviors. This randomized controlled trial assessed the longitudinal associations between improved caregiver self-care and heart failure patient hospitalization outcomes. The study identified how changes in caregiver well-being influenced patient clinical trajectories, underscoring the critical role of caregiver support in patient health.</p>
<p>Article number two. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. The S. O. U. L. randomized clinical trial found that once-daily oral semaglutide reduced the risk of major adverse cardiovascular events by 14 percent compared to placebo. This significant benefit occurred in individuals with type two diabetes and atherosclerotic cardiovascular disease or chronic kidney disease receiving standard of care. This secondary analysis demonstrated the specific changes oral semaglutide induced in long-term cardiovascular risk factors within this high-risk patient group.</p>
<p>Article number three. Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial. Left atrial appendage occlusion is a critical intervention for patients with contraindications to oral anticoagulation and an increased risk of major bleeding. The Amulet I. D. E. randomized clinical trial meticulously identified the incidence, key predictors, and effective management strategies for major bleeding following left atrial appendage occlusion. This study, involving 1878 randomized patients comparing the Amulet with the Watchman devices, also determined the clinical impact of these bleeding events on patient outcomes.</p>
<p>Article number four. Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study. Many patients with coronary heart disease exhibit blood pressure above guideline targets, even with ongoing treatment. European guidelines offer conflicting recommendations regarding patients with on-treatment blood pressure below target, with the 2023 European Society of Hypertension guidelines issuing a class three recommendation to proactively avoid blood pressure below target. The I. N. T. E. R. A. S. P. I. R. E. study established the prevalence and characteristics of patients with coronary heart disease whose blood pressure fell below target levels.</p>
<p>Article number five. Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study. Cardiovascular interventions and complications commonly occur after arterial switch operation in patients with dextro-transposition of the great arteries. While complex anatomy, such as ventricular septal defects, is often associated with these outcomes, the independent role of aortic coarctation remained unclear. This multicenter international cohort study analyzed 502 adults from the E. P. O. C. H. A. S. O. registry, precisely defining the long-term morbidity associated with aortic coarctation following arterial switch operation, independent of other complex anatomical factors. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>oral anticoagulation, caregiver self-care, long-term morbidity, atherosclerotic cardiovascular disease, left atrial appendage occlusion, hypertension, dextro-transposition of the great arteries, guideline recommendations, aortic coarctation, type two diabetes, patient hospitalization, blood pressure targets, coronary heart disease, INTERASPIRE study, arterial switch operation, major bleeding, chronic kidney disease, longitudinal associations, major adverse cardiovascular events, heart failure, congenital heart disease, oral semaglutide, cardiovascular risk factors, Watchman device, health coaching, Amulet device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/">Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes 03/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like oral anticoagulation and caregiver self-care. Key takeaway: Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like oral anticoagulation and caregiver self-care. Key takeaway: Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41895678">Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41879791">Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41879767">Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41887758">Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40701798">Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/">https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895678" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895678</a></p>
<p><strong>Summary:</strong> Prior research demonstrated that health coaching reduces heart failure caregiver stress and improves caregiver self-care behaviors. This randomized controlled trial assessed the longitudinal associations between improved caregiver self-care and heart failure patient hospitalization outcomes. The study identified how changes in caregiver well-being influenced patient clinical trajectories, underscoring the critical role of caregiver support in patient health.</p>
<h4>Article 2: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879791" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879791</a></p>
<p><strong>Summary:</strong> The S. O. U. L. randomized clinical trial found that once-daily oral semaglutide reduced the risk of major adverse cardiovascular events by 14 percent compared to placebo. This significant benefit occurred in individuals with type two diabetes and atherosclerotic cardiovascular disease or chronic kidney disease receiving standard of care. This secondary analysis demonstrated the specific changes oral semaglutide induced in long-term cardiovascular risk factors within this high-risk patient group.</p>
<h4>Article 3: Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879767</a></p>
<p><strong>Summary:</strong> Left atrial appendage occlusion is a critical intervention for patients with contraindications to oral anticoagulation and an increased risk of major bleeding. The Amulet I. D. E. randomized clinical trial meticulously identified the incidence, key predictors, and effective management strategies for major bleeding following left atrial appendage occlusion. This study, involving 1878 randomized patients comparing the Amulet with the Watchman devices, also determined the clinical impact of these bleeding events on patient outcomes.</p>
<h4>Article 4: Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41887758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41887758</a></p>
<p><strong>Summary:</strong> Many patients with coronary heart disease exhibit blood pressure above guideline targets, even with ongoing treatment. European guidelines offer conflicting recommendations regarding patients with on-treatment blood pressure below target, with the 2023 European Society of Hypertension guidelines issuing a class three recommendation to proactively avoid blood pressure below target. The I. N. T. E. R. A. S. P. I. R. E. study established the prevalence and characteristics of patients with coronary heart disease whose blood pressure fell below target levels.</p>
<h4>Article 5: Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40701798" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40701798</a></p>
<p><strong>Summary:</strong> Cardiovascular interventions and complications commonly occur after arterial switch operation in patients with dextro-transposition of the great arteries. While complex anatomy, such as ventricular septal defects, is often associated with these outcomes, the independent role of aortic coarctation remained unclear. This multicenter international cohort study analyzed 502 adults from the E. P. O. C. H. A. S. O. registry, precisely defining the long-term morbidity associated with aortic coarctation following arterial switch operation, independent of other complex anatomical factors.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations. Prior research demonstrated that health coaching reduces heart failure caregiver stress and improves caregiver self-care behaviors. This randomized controlled trial assessed the longitudinal associations between improved caregiver self-care and heart failure patient hospitalization outcomes. The study identified how changes in caregiver well-being influenced patient clinical trajectories, underscoring the critical role of caregiver support in patient health.</p>
<p>Article number two. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. The S. O. U. L. randomized clinical trial found that once-daily oral semaglutide reduced the risk of major adverse cardiovascular events by 14 percent compared to placebo. This significant benefit occurred in individuals with type two diabetes and atherosclerotic cardiovascular disease or chronic kidney disease receiving standard of care. This secondary analysis demonstrated the specific changes oral semaglutide induced in long-term cardiovascular risk factors within this high-risk patient group.</p>
<p>Article number three. Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial. Left atrial appendage occlusion is a critical intervention for patients with contraindications to oral anticoagulation and an increased risk of major bleeding. The Amulet I. D. E. randomized clinical trial meticulously identified the incidence, key predictors, and effective management strategies for major bleeding following left atrial appendage occlusion. This study, involving 1878 randomized patients comparing the Amulet with the Watchman devices, also determined the clinical impact of these bleeding events on patient outcomes.</p>
<p>Article number four. Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study. Many patients with coronary heart disease exhibit blood pressure above guideline targets, even with ongoing treatment. European guidelines offer conflicting recommendations regarding patients with on-treatment blood pressure below target, with the 2023 European Society of Hypertension guidelines issuing a class three recommendation to proactively avoid blood pressure below target. The I. N. T. E. R. A. S. P. I. R. E. study established the prevalence and characteristics of patients with coronary heart disease whose blood pressure fell below target levels.</p>
<p>Article number five. Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study. Cardiovascular interventions and complications commonly occur after arterial switch operation in patients with dextro-transposition of the great arteries. While complex anatomy, such as ventricular septal defects, is often associated with these outcomes, the independent role of aortic coarctation remained unclear. This multicenter international cohort study analyzed 502 adults from the E. P. O. C. H. A. S. O. registry, precisely defining the long-term morbidity associated with aortic coarctation following arterial switch operation, independent of other complex anatomical factors. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>oral anticoagulation, caregiver self-care, long-term morbidity, atherosclerotic cardiovascular disease, left atrial appendage occlusion, hypertension, dextro-transposition of the great arteries, guideline recommendations, aortic coarctation, type two diabetes, patient hospitalization, blood pressure targets, coronary heart disease, INTERASPIRE study, arterial switch operation, major bleeding, chronic kidney disease, longitudinal associations, major adverse cardiovascular events, heart failure, congenital heart disease, oral semaglutide, cardiovascular risk factors, Watchman device, health coaching, Amulet device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/">Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes 03/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260328_060043.mp3" length="4037737" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like oral anticoagulation and caregiver self-care. Key takeaway: Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes.
Article Links:
Article 1: Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations. (Journal of cardiac failure)
Article 2: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. (JAMA cardiology)
Article 3: Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial. (JAMA cardiology)
Article 4: Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study. (Heart (British Cardiac Society))
Article 5: Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/oral-semaglutide-cuts-cv-events-14-in-type-2-diabetes-03-28-26/
 Featured Articles
Article 1: Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895678
Summary: Prior research demonstrated that health coaching reduces heart failure caregiver stress and improves caregiver self-care behaviors. This randomized controlled trial assessed the longitudinal associations between improved caregiver self-care and heart failure patient hospitalization outcomes. The study identified how changes in caregiver well-being influenced patient clinical trajectories, underscoring the critical role of caregiver support in patient health.
Article 2: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879791
Summary: The S. O. U. L. randomized clinical trial found that once-daily oral semaglutide reduced the risk of major adverse cardiovascular events by 14 percent compared to placebo. This significant benefit occurred in individuals with type two diabetes and atherosclerotic cardiovascular disease or chronic kidney disease receiving standard of care. This secondary analysis demonstrated the specific changes oral semaglutide induced in long-term cardiovascular risk factors within this high-risk patient group.
Article 3: Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879767
Summary: Left atrial appendage occlusion is a critical intervention for patients with contraindications to oral anticoagulation and an increased risk of major bleeding. The Amulet I. D. E. randomized clinical trial meticulously identified the incidence, key predictors, and effective management strategies for major bleeding following left atrial appendage occlusion. This study, involving 1878 randomized patients comparing the Amulet with the Watchman devices, also determined the clinical impact of these bleeding events on patient outcomes.
Article 4: Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41887758
Summary: Many patients with coronary heart disease exhibit blood pressure above guideline targets, even with ongoing treatment. European guidelines offer conflicting recommendations regarding patie]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like oral anticoagulation and caregiver self-care. Key takeaway: Oral Semaglutide Cuts CV Events 14% in Type 2 Diabetes.
Article Links:
Article 1: Supporting Family Caregiver Health in Heart Failure: Longitudinal Associations Between Heart Failure Caregiver Self-Care and Patient Hospitalizations. (Journal of cardiac failure)
Article 2: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. (JAMA cardiology)
Article 3: Incidence, Predictors, Management, and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: The Amulet IDE Randomized Clinical Trial. (JAMA cardiology)
Article 4: Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study. (Heart (British Cardiac Society))
Article 5: A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ghost Approval: Transplant Drug Access 03/28/26</title>
	<link>https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/</link>
	<pubDate>Sat, 28 Mar 2026 05:44:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like microvascular resistance and immunosuppressive therapy. Key takeaway: Ghost Approval: Transplant Drug Access.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41895721">Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41895321">Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41895317">Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41893376">Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41895624">When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/">https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895721" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895721</a></p>
<p><strong>Summary:</strong> A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition&#8217;s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.</p>
<h4>Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895321" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895321</a></p>
<p><strong>Summary:</strong> This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.</p>
<h4>Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895317" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895317</a></p>
<p><strong>Summary:</strong> Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.</p>
<h4>Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41893376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41893376</a></p>
<p><strong>Summary:</strong> A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual congestion and poor prognosis. The study identified diuretic resistance risk using the B. A. N. hyphen A. D. H. F. score, which incorporates blood urea nitrogen, creatinine, natriuretic peptide levels, atrial fibrillation, diastolic blood pressure, hypertension, and home diuretics.</p>
<h4>Article 5: When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895624" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895624</a></p>
<p><strong>Summary:</strong> This perspective piece introduced the concept of &#8220;ghost approval,&#8221; where a technically approved medication remains financially or logistically inaccessible to the patient. It highlights that access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients. A first-person experience with everolimus, an M. T. O. R. inhibitor, exemplified this issue, noting its lack of a U.S. Food and Drug Administration indication for heart transplantation contributed to access challenges.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre. A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition&#8217;s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.</p>
<p>Article number two. Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.</p>
<p>Article number three. Coronary autoregulation: the complex interplay between epicardial and microvascular resistance. Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.</p>
<p>Article number four. Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial. A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual congestion and poor prognosis. The study identified diuretic resistance risk using the B. A. N. hyphen A. D. H. F. score, which incorporates blood urea nitrogen, creatinine, natriuretic peptide levels, atrial fibrillation, diastolic blood pressure, hypertension, and home diuretics.</p>
<p>Article number five. When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;. This perspective piece introduced the concept of &#8220;ghost approval,&#8221; where a technically approved medication remains financially or logistically inaccessible to the patient. It highlights that access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients. A first-person experience with everolimus, an M. T. O. R. inhibitor, exemplified this issue, noting its lack of a U.S. Food and Drug Administration indication for heart transplantation contributed to access challenges. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>microvascular resistance, immunosuppressive therapy, heart valve disease, ischaemic stroke, Heart transplantation, P. U. S. H. hyphen A. H. F. trial, acute decompensated heart failure, ghost approval, risk stratification, Coronary autoregulation, Diuretic resistance, Atrial fibrillation, myocardial perfusion, natriuresis-guided therapy, prognosis, surgical intervention, cardiac implantable electronic device, coronary circulation, patient work-up, blood flow regulation, transcatheter intervention, everolimus, biomarker, Tricuspid regurgitation, U.S. Food and Drug Administration.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/">Ghost Approval: Transplant Drug Access 03/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like microvascular resistance and immunosuppressive therapy. Key takeaway: Ghost Approval: Transplant Drug Access.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like microvascular resistance and immunosuppressive therapy. Key takeaway: Ghost Approval: Transplant Drug Access.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41895721">Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41895321">Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41895317">Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41893376">Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41895624">When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/">https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895721" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895721</a></p>
<p><strong>Summary:</strong> A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition&#8217;s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.</p>
<h4>Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895321" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895321</a></p>
<p><strong>Summary:</strong> This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.</p>
<h4>Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895317" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895317</a></p>
<p><strong>Summary:</strong> Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.</p>
<h4>Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41893376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41893376</a></p>
<p><strong>Summary:</strong> A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual congestion and poor prognosis. The study identified diuretic resistance risk using the B. A. N. hyphen A. D. H. F. score, which incorporates blood urea nitrogen, creatinine, natriuretic peptide levels, atrial fibrillation, diastolic blood pressure, hypertension, and home diuretics.</p>
<h4>Article 5: When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41895624" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41895624</a></p>
<p><strong>Summary:</strong> This perspective piece introduced the concept of &#8220;ghost approval,&#8221; where a technically approved medication remains financially or logistically inaccessible to the patient. It highlights that access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients. A first-person experience with everolimus, an M. T. O. R. inhibitor, exemplified this issue, noting its lack of a U.S. Food and Drug Administration indication for heart transplantation contributed to access challenges.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre. A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition&#8217;s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.</p>
<p>Article number two. Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.</p>
<p>Article number three. Coronary autoregulation: the complex interplay between epicardial and microvascular resistance. Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.</p>
<p>Article number four. Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial. A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual congestion and poor prognosis. The study identified diuretic resistance risk using the B. A. N. hyphen A. D. H. F. score, which incorporates blood urea nitrogen, creatinine, natriuretic peptide levels, atrial fibrillation, diastolic blood pressure, hypertension, and home diuretics.</p>
<p>Article number five. When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;. This perspective piece introduced the concept of &#8220;ghost approval,&#8221; where a technically approved medication remains financially or logistically inaccessible to the patient. It highlights that access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients. A first-person experience with everolimus, an M. T. O. R. inhibitor, exemplified this issue, noting its lack of a U.S. Food and Drug Administration indication for heart transplantation contributed to access challenges. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>microvascular resistance, immunosuppressive therapy, heart valve disease, ischaemic stroke, Heart transplantation, P. U. S. H. hyphen A. H. F. trial, acute decompensated heart failure, ghost approval, risk stratification, Coronary autoregulation, Diuretic resistance, Atrial fibrillation, myocardial perfusion, natriuresis-guided therapy, prognosis, surgical intervention, cardiac implantable electronic device, coronary circulation, patient work-up, blood flow regulation, transcatheter intervention, everolimus, biomarker, Tricuspid regurgitation, U.S. Food and Drug Administration.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/">Ghost Approval: Transplant Drug Access 03/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260328_014327.mp3" length="3925724" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like microvascular resistance and immunosuppressive therapy. Key takeaway: Ghost Approval: Transplant Drug Access.
Article Links:
Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre. (European heart journal)
Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. (European heart journal)
Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance. (European heart journal)
Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial. (JACC. Heart failure)
Article 5: When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/
 Featured Articles
Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895721
Summary: A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition&#8217;s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.
Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895321
Summary: This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.
Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895317
Summary: Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.
Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41893376
Summary: A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual conges]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like microvascular resistance and immunosuppressive therapy. Key takeaway: Ghost Approval: Transplant Drug Access.
Article Links:
Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre. (European heart journal)
Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. (European heart journal)
Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance. (European heart journal)
Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial. (JACC. Heart failure)
Article 5: When Coverage Is Not Access: A Heart Transplant Recipient&#8217;s Perspective on Everolimus, FDA Labeling, and the Problem of &#8220;Ghost Approval&#8221;. (The Journal of heart a]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Socioeconomic Status Drives Heart Failure Risk 03/27/26</title>
	<link>https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/</link>
	<pubDate>Fri, 27 Mar 2026 10:01:34 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 27, 2026. This episode summarizes 5 key cardiology studies on topics like pericarditis and cardiometabolic dysfunction. Key takeaway: Socioeconomic Status Drives Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41885139">Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41884984">Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41879141">Cardiac involvement in parasitic infections.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41879137">Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41885671">Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/">https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885139" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885139</a></p>
<p><strong>Summary:</strong> The field of reverse cardio-oncology found that subclinical and overt cardiometabolic dysfunction, specifically obesity, fuels breast cancer risk and alters tumor biology. This occurs through shared mechanisms including chronic inflammation, hormonal dysregulation, and cellular senescence. Refined obesity phenotypes, such as metabolically healthy versus unhealthy obesity and sarcopenic obesity, demonstrate more accurate stratification of breast cancer risk compared to body mass index alone. This paradigm highlights specific biological links between cardiovascular and oncological diseases.</p>
<h4>Article 2: Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41884984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41884984</a></p>
<p><strong>Summary:</strong> This prespecified analysis, drawing from two trials on chronic kidney disease and type two diabetes (FIDELIO-DKD and FIGARO-DKD) and one trial on heart failure (FINEARTS-HF), specifically investigated sex differences in cardiovascular-kidney-metabolic syndrome. The analysis consolidated individual participant data to clarify how cardiometabolic risk factors, and their impact, manifest differently between women and men. It provided a comprehensive platform to understand these distinctions in populations with chronic kidney disease, type two diabetes, and heart failure with mildly reduced or preserved ejection fraction. The study&#8217;s rigorous data pooling addressed a critical knowledge gap regarding sex-specific outcomes in cardiovascular-kidney-metabolic syndrome.</p>
<h4>Article 3: Cardiac involvement in parasitic infections.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879141" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879141</a></p>
<p><strong>Summary:</strong> Parasitic infections are identified as an important, yet underrecognized, cause of cardiovascular disease, especially in endemic regions and increasingly due to global migration and travel. Cardiac involvement results from either direct parasitic invasion or, more commonly, from immune-mediated and inflammatory mechanisms. These processes primarily affect the myocardium and pericardium, leading to clinical manifestations such as acute myocarditis, dilated or restrictive cardiomyopathy, and pericarditis. This highlights the diverse pathological pathways by which parasites impact cardiac health.</p>
<h4>Article 4: Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879137</a></p>
<p><strong>Summary:</strong> Inflammation is definitively identified as a predisposing factor for atrial fibrillation, the most common sustained cardiac arrhythmia. Systemic inflammatory disorders, including autoimmune disorder, diabetes mellitus, and obesity, as well as local inflammation of the heart or pericardium, are directly linked to atrial fibrillation. Inflammation triggers various signaling pathways and directly influences proinflammatory cytokines, which subsequently promote structural and electrical changes in the atria. These mechanisms underscore the critical role of inflammatory processes in atrial fibrillation pathogenesis.</p>
<h4>Article 5: Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885671</a></p>
<p><strong>Summary:</strong> This study identified prospective associations between socioeconomic status and incident heart failure in adults without pre-existing heart failure. It also demonstrated associations between socioeconomic status and all-cause mortality in patients already diagnosed with heart failure. The analysis utilized data from the National Institutes of Health-run All of Us Research Program. This research provides crucial evidence that both individual and neighborhood measures of socioeconomic status independently correlate with heart failure development and subsequent mortality.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 27, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology. The field of reverse cardio-oncology found that subclinical and overt cardiometabolic dysfunction, specifically obesity, fuels breast cancer risk and alters tumor biology. This occurs through shared mechanisms including chronic inflammation, hormonal dysregulation, and cellular senescence. Refined obesity phenotypes, such as metabolically healthy versus unhealthy obesity and sarcopenic obesity, demonstrate more accurate stratification of breast cancer risk compared to body mass index alone. This paradigm highlights specific biological links between cardiovascular and oncological diseases.</p>
<p>Article number two. Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis. This prespecified analysis, drawing from two trials on chronic kidney disease and type two diabetes (FIDELIO-DKD and FIGARO-DKD) and one trial on heart failure (FINEARTS-HF), specifically investigated sex differences in cardiovascular-kidney-metabolic syndrome. The analysis consolidated individual participant data to clarify how cardiometabolic risk factors, and their impact, manifest differently between women and men. It provided a comprehensive platform to understand these distinctions in populations with chronic kidney disease, type two diabetes, and heart failure with mildly reduced or preserved ejection fraction. The study&#8217;s rigorous data pooling addressed a critical knowledge gap regarding sex-specific outcomes in cardiovascular-kidney-metabolic syndrome.</p>
<p>Article number three. Cardiac involvement in parasitic infections. Parasitic infections are identified as an important, yet underrecognized, cause of cardiovascular disease, especially in endemic regions and increasingly due to global migration and travel. Cardiac involvement results from either direct parasitic invasion or, more commonly, from immune-mediated and inflammatory mechanisms. These processes primarily affect the myocardium and pericardium, leading to clinical manifestations such as acute myocarditis, dilated or restrictive cardiomyopathy, and pericarditis. This highlights the diverse pathological pathways by which parasites impact cardiac health.</p>
<p>Article number four. Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets. Inflammation is definitively identified as a predisposing factor for atrial fibrillation, the most common sustained cardiac arrhythmia. Systemic inflammatory disorders, including autoimmune disorder, diabetes mellitus, and obesity, as well as local inflammation of the heart or pericardium, are directly linked to atrial fibrillation. Inflammation triggers various signaling pathways and directly influences proinflammatory cytokines, which subsequently promote structural and electrical changes in the atria. These mechanisms underscore the critical role of inflammatory processes in atrial fibrillation pathogenesis.</p>
<p>Article number five. Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program. This study identified prospective associations between socioeconomic status and incident heart failure in adults without pre-existing heart failure. It also demonstrated associations between socioeconomic status and all-cause mortality in patients already diagnosed with heart failure. The analysis utilized data from the National Institutes of Health-run All of Us Research Program. This research provides crucial evidence that both individual and neighborhood measures of socioeconomic status independently correlate with heart failure development and subsequent mortality. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pericarditis, cardiometabolic dysfunction, heart failure, inflammation, breast cancer, reverse cardio-oncology, parasitic infections, chronic kidney disease, type two diabetes, cardiac arrhythmia, obesity, mortality, cardiomyopathy, socioeconomic status, cardiovascular disease, cardiovascular-kidney-metabolic syndrome, sex differences, cellular senescence, atrial fibrillation, All of Us Research Program, cardiovascular epidemiology, proinflammatory cytokines, pathogenesis, myocarditis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/">Socioeconomic Status Drives Heart Failure Risk 03/27/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 27, 2026. This episode summarizes 5 key cardiology studies on topics like pericarditis and cardiometabolic dysfunction. Key takeaway: Socioeconomic Status Drives Heart Failure Risk.
Article Links:
Article 1: S]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 27, 2026. This episode summarizes 5 key cardiology studies on topics like pericarditis and cardiometabolic dysfunction. Key takeaway: Socioeconomic Status Drives Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41885139">Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41884984">Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41879141">Cardiac involvement in parasitic infections.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41879137">Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41885671">Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/">https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885139" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885139</a></p>
<p><strong>Summary:</strong> The field of reverse cardio-oncology found that subclinical and overt cardiometabolic dysfunction, specifically obesity, fuels breast cancer risk and alters tumor biology. This occurs through shared mechanisms including chronic inflammation, hormonal dysregulation, and cellular senescence. Refined obesity phenotypes, such as metabolically healthy versus unhealthy obesity and sarcopenic obesity, demonstrate more accurate stratification of breast cancer risk compared to body mass index alone. This paradigm highlights specific biological links between cardiovascular and oncological diseases.</p>
<h4>Article 2: Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41884984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41884984</a></p>
<p><strong>Summary:</strong> This prespecified analysis, drawing from two trials on chronic kidney disease and type two diabetes (FIDELIO-DKD and FIGARO-DKD) and one trial on heart failure (FINEARTS-HF), specifically investigated sex differences in cardiovascular-kidney-metabolic syndrome. The analysis consolidated individual participant data to clarify how cardiometabolic risk factors, and their impact, manifest differently between women and men. It provided a comprehensive platform to understand these distinctions in populations with chronic kidney disease, type two diabetes, and heart failure with mildly reduced or preserved ejection fraction. The study&#8217;s rigorous data pooling addressed a critical knowledge gap regarding sex-specific outcomes in cardiovascular-kidney-metabolic syndrome.</p>
<h4>Article 3: Cardiac involvement in parasitic infections.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879141" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879141</a></p>
<p><strong>Summary:</strong> Parasitic infections are identified as an important, yet underrecognized, cause of cardiovascular disease, especially in endemic regions and increasingly due to global migration and travel. Cardiac involvement results from either direct parasitic invasion or, more commonly, from immune-mediated and inflammatory mechanisms. These processes primarily affect the myocardium and pericardium, leading to clinical manifestations such as acute myocarditis, dilated or restrictive cardiomyopathy, and pericarditis. This highlights the diverse pathological pathways by which parasites impact cardiac health.</p>
<h4>Article 4: Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879137</a></p>
<p><strong>Summary:</strong> Inflammation is definitively identified as a predisposing factor for atrial fibrillation, the most common sustained cardiac arrhythmia. Systemic inflammatory disorders, including autoimmune disorder, diabetes mellitus, and obesity, as well as local inflammation of the heart or pericardium, are directly linked to atrial fibrillation. Inflammation triggers various signaling pathways and directly influences proinflammatory cytokines, which subsequently promote structural and electrical changes in the atria. These mechanisms underscore the critical role of inflammatory processes in atrial fibrillation pathogenesis.</p>
<h4>Article 5: Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41885671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41885671</a></p>
<p><strong>Summary:</strong> This study identified prospective associations between socioeconomic status and incident heart failure in adults without pre-existing heart failure. It also demonstrated associations between socioeconomic status and all-cause mortality in patients already diagnosed with heart failure. The analysis utilized data from the National Institutes of Health-run All of Us Research Program. This research provides crucial evidence that both individual and neighborhood measures of socioeconomic status independently correlate with heart failure development and subsequent mortality.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 27, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology. The field of reverse cardio-oncology found that subclinical and overt cardiometabolic dysfunction, specifically obesity, fuels breast cancer risk and alters tumor biology. This occurs through shared mechanisms including chronic inflammation, hormonal dysregulation, and cellular senescence. Refined obesity phenotypes, such as metabolically healthy versus unhealthy obesity and sarcopenic obesity, demonstrate more accurate stratification of breast cancer risk compared to body mass index alone. This paradigm highlights specific biological links between cardiovascular and oncological diseases.</p>
<p>Article number two. Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis. This prespecified analysis, drawing from two trials on chronic kidney disease and type two diabetes (FIDELIO-DKD and FIGARO-DKD) and one trial on heart failure (FINEARTS-HF), specifically investigated sex differences in cardiovascular-kidney-metabolic syndrome. The analysis consolidated individual participant data to clarify how cardiometabolic risk factors, and their impact, manifest differently between women and men. It provided a comprehensive platform to understand these distinctions in populations with chronic kidney disease, type two diabetes, and heart failure with mildly reduced or preserved ejection fraction. The study&#8217;s rigorous data pooling addressed a critical knowledge gap regarding sex-specific outcomes in cardiovascular-kidney-metabolic syndrome.</p>
<p>Article number three. Cardiac involvement in parasitic infections. Parasitic infections are identified as an important, yet underrecognized, cause of cardiovascular disease, especially in endemic regions and increasingly due to global migration and travel. Cardiac involvement results from either direct parasitic invasion or, more commonly, from immune-mediated and inflammatory mechanisms. These processes primarily affect the myocardium and pericardium, leading to clinical manifestations such as acute myocarditis, dilated or restrictive cardiomyopathy, and pericarditis. This highlights the diverse pathological pathways by which parasites impact cardiac health.</p>
<p>Article number four. Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets. Inflammation is definitively identified as a predisposing factor for atrial fibrillation, the most common sustained cardiac arrhythmia. Systemic inflammatory disorders, including autoimmune disorder, diabetes mellitus, and obesity, as well as local inflammation of the heart or pericardium, are directly linked to atrial fibrillation. Inflammation triggers various signaling pathways and directly influences proinflammatory cytokines, which subsequently promote structural and electrical changes in the atria. These mechanisms underscore the critical role of inflammatory processes in atrial fibrillation pathogenesis.</p>
<p>Article number five. Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program. This study identified prospective associations between socioeconomic status and incident heart failure in adults without pre-existing heart failure. It also demonstrated associations between socioeconomic status and all-cause mortality in patients already diagnosed with heart failure. The analysis utilized data from the National Institutes of Health-run All of Us Research Program. This research provides crucial evidence that both individual and neighborhood measures of socioeconomic status independently correlate with heart failure development and subsequent mortality. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pericarditis, cardiometabolic dysfunction, heart failure, inflammation, breast cancer, reverse cardio-oncology, parasitic infections, chronic kidney disease, type two diabetes, cardiac arrhythmia, obesity, mortality, cardiomyopathy, socioeconomic status, cardiovascular disease, cardiovascular-kidney-metabolic syndrome, sex differences, cellular senescence, atrial fibrillation, All of Us Research Program, cardiovascular epidemiology, proinflammatory cytokines, pathogenesis, myocarditis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/">Socioeconomic Status Drives Heart Failure Risk 03/27/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260327_060027.mp3" length="4112134" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 27, 2026. This episode summarizes 5 key cardiology studies on topics like pericarditis and cardiometabolic dysfunction. Key takeaway: Socioeconomic Status Drives Heart Failure Risk.
Article Links:
Article 1: Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology. (European heart journal)
Article 2: Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis. (European heart journal)
Article 3: Cardiac involvement in parasitic infections. (European heart journal)
Article 4: Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets. (European heart journal)
Article 5: Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/
 Featured Articles
Article 1: Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41885139
Summary: The field of reverse cardio-oncology found that subclinical and overt cardiometabolic dysfunction, specifically obesity, fuels breast cancer risk and alters tumor biology. This occurs through shared mechanisms including chronic inflammation, hormonal dysregulation, and cellular senescence. Refined obesity phenotypes, such as metabolically healthy versus unhealthy obesity and sarcopenic obesity, demonstrate more accurate stratification of breast cancer risk compared to body mass index alone. This paradigm highlights specific biological links between cardiovascular and oncological diseases.
Article 2: Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41884984
Summary: This prespecified analysis, drawing from two trials on chronic kidney disease and type two diabetes (FIDELIO-DKD and FIGARO-DKD) and one trial on heart failure (FINEARTS-HF), specifically investigated sex differences in cardiovascular-kidney-metabolic syndrome. The analysis consolidated individual participant data to clarify how cardiometabolic risk factors, and their impact, manifest differently between women and men. It provided a comprehensive platform to understand these distinctions in populations with chronic kidney disease, type two diabetes, and heart failure with mildly reduced or preserved ejection fraction. The study&#8217;s rigorous data pooling addressed a critical knowledge gap regarding sex-specific outcomes in cardiovascular-kidney-metabolic syndrome.
Article 3: Cardiac involvement in parasitic infections.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879141
Summary: Parasitic infections are identified as an important, yet underrecognized, cause of cardiovascular disease, especially in endemic regions and increasingly due to global migration and travel. Cardiac involvement results from either direct parasitic invasion or, more commonly, from immune-mediated and inflammatory mechanisms. These processes primarily affect the myocardium and pericardium, leading to clinical manifestations such as acute myocarditis, dilated or restrictive cardiomyopathy, and pericarditis. This highlights the diverse pathological pathways by which parasites impact cardiac health.
Article 4: Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879137
Summary: Inflammation is definitively identified as a predisposing factor for atrial fibrillation, the most common sustained cardiac arrhythmia. Systemic inflammatory disorders, including autoimmune disorder, diabetes mellitus, and obesity, as well as local inflammation of the heart or pericardium, are directly linked to atrial fi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 27, 2026. This episode summarizes 5 key cardiology studies on topics like pericarditis and cardiometabolic dysfunction. Key takeaway: Socioeconomic Status Drives Heart Failure Risk.
Article Links:
Article 1: Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology. (European heart journal)
Article 2: Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis. (European heart journal)
Article 3: Cardiac involvement in parasitic infections. (European heart journal)
Article 4: Inflammatory pathways in atrial fibrillation: mechanisms and novel therapeutic targets. (European heart journal)
Article 5: Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/socioeconomic-status-drives-heart-failure-risk-03-27-26/
 Featured Articles
Article 1: Senescent obesity sign]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Early Surgery Reduces Aortic Stenosis Mortality 03/26/26</title>
	<link>https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/</link>
	<pubDate>Thu, 26 Mar 2026 10:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 26, 2026. This episode summarizes 5 key cardiology studies on topics like conservative care and symptom management. Key takeaway: Early Surgery Reduces Aortic Stenosis Mortality.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41880613">Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41879574">Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41879158">Palliative care in cardiovascular medicine.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41879157">Cardiovascular disease in China: epidemiological evolution and implications.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41879156">Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/">https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41880613" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41880613</a></p>
<p><strong>Summary:</strong> Among asymptomatic patients with severe aortic stenosis, early surgery significantly lowered the risk of operative mortality or death from cardiovascular causes compared to conservative care. This means patients who received early surgery had a reduced composite rate of death during surgery or within 30 days after surgery. The data demonstrated this significant reduction in operative and cardiovascular mortality with early surgical intervention. These findings provided a clear benefit for early surgery in this specific patient population.</p>
<h4>Article 2: Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879574" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879574</a></p>
<p><strong>Summary:</strong> Renin-independent aldosterone production contributes to adverse cardiorenal outcomes. The study established a definitive association between specific renin-aldosterone profiles and the occurrence of cardiorenal events in adults with hypertension. These findings provide population-based evidence demonstrating the significant role of distinct aldosterone production mechanisms in influencing cardiorenal health in hypertensive patients. The comprehensive analysis identified key patterns linking renin-aldosterone levels to adverse cardiovascular and renal outcomes.</p>
<h4>Article 3: Palliative care in cardiovascular medicine.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879158" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879158</a></p>
<p><strong>Summary:</strong> Palliative care for adults with advanced cardiovascular disease consistently improves patients&#8217; quality of life. It effectively supports caregivers and successfully aligns treatments with patient values and goals. The implementation of palliative care encompasses essential elements such as comprehensive symptom management, proactive advanced care planning, and patient-centered shared decision-making processes. These core components consistently lead to better patient experiences and outcomes in advanced cardiovascular disease.</p>
<h4>Article 4: Cardiovascular disease in China: epidemiological evolution and implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879157" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879157</a></p>
<p><strong>Summary:</strong> Cardiovascular disease remains the predominant cause of mortality in China, having undergone significant epidemiological transitions over several decades. This comprehensive review synthesized extensive observational data, revealing key features of cardiovascular disease&#8217;s evolving epidemiology across various dimensions within the country. The findings definitively establish crucial trends and interrelationships in cardiovascular disease incidence and prevalence among the Chinese population. This analysis demonstrates how the disease burden has shifted and provides a foundational understanding of its current state in China.</p>
<h4>Article 5: Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879156" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879156</a></p>
<p><strong>Summary:</strong> Wearable devices are transforming cardiovascular medicine, as they enable continuous remote monitoring of physiological and behavioral measures outside traditional clinical settings. Smartwatches and activity trackers effectively utilize motion and biometric sensors to accurately measure physical activity, sleep quality, heart rate, and rhythm. These devices successfully empower patients to assume a more active role in their health by converting health goals into objective, quantifiable measures. This technological advancement directly contributes to revolutionizing remote monitoring and disease prevention in cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 26, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years. Among asymptomatic patients with severe aortic stenosis, early surgery significantly lowered the risk of operative mortality or death from cardiovascular causes compared to conservative care. This means patients who received early surgery had a reduced composite rate of death during surgery or within 30 days after surgery. The data demonstrated this significant reduction in operative and cardiovascular mortality with early surgical intervention. These findings provided a clear benefit for early surgery in this specific patient population.</p>
<p>Article number two. Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study. Renin-independent aldosterone production contributes to adverse cardiorenal outcomes. The study established a definitive association between specific renin-aldosterone profiles and the occurrence of cardiorenal events in adults with hypertension. These findings provide population-based evidence demonstrating the significant role of distinct aldosterone production mechanisms in influencing cardiorenal health in hypertensive patients. The comprehensive analysis identified key patterns linking renin-aldosterone levels to adverse cardiovascular and renal outcomes.</p>
<p>Article number three. Palliative care in cardiovascular medicine. Palliative care for adults with advanced cardiovascular disease consistently improves patients&#8217; quality of life. It effectively supports caregivers and successfully aligns treatments with patient values and goals. The implementation of palliative care encompasses essential elements such as comprehensive symptom management, proactive advanced care planning, and patient-centered shared decision-making processes. These core components consistently lead to better patient experiences and outcomes in advanced cardiovascular disease.</p>
<p>Article number four. Cardiovascular disease in China: epidemiological evolution and implications. Cardiovascular disease remains the predominant cause of mortality in China, having undergone significant epidemiological transitions over several decades. This comprehensive review synthesized extensive observational data, revealing key features of cardiovascular disease&#8217;s evolving epidemiology across various dimensions within the country. The findings definitively establish crucial trends and interrelationships in cardiovascular disease incidence and prevalence among the Chinese population. This analysis demonstrates how the disease burden has shifted and provides a foundational understanding of its current state in China.</p>
<p>Article number five. Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention. Wearable devices are transforming cardiovascular medicine, as they enable continuous remote monitoring of physiological and behavioral measures outside traditional clinical settings. Smartwatches and activity trackers effectively utilize motion and biometric sensors to accurately measure physical activity, sleep quality, heart rate, and rhythm. These devices successfully empower patients to assume a more active role in their health by converting health goals into objective, quantifiable measures. This technological advancement directly contributes to revolutionizing remote monitoring and disease prevention in cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>conservative care, symptom management, cardiovascular health, remote monitoring, epidemiology, Palliative care, cardiorenal outcomes, Wearable devices, epidemiological transitions, smartwatches, mortality, aldosterone production, Aortic stenosis, operative mortality, China, cardiovascular disease, early surgery, advanced care planning, nationwide cohort study, renin-aldosterone, quality of life, Cardiovascular disease, disease prevention, cardiovascular death, Hypertension.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/">Early Surgery Reduces Aortic Stenosis Mortality 03/26/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 26, 2026. This episode summarizes 5 key cardiology studies on topics like conservative care and symptom management. Key takeaway: Early Surgery Reduces Aortic Stenosis Mortality.
Article Links:
Article 1: Earl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 26, 2026. This episode summarizes 5 key cardiology studies on topics like conservative care and symptom management. Key takeaway: Early Surgery Reduces Aortic Stenosis Mortality.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41880613">Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41879574">Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41879158">Palliative care in cardiovascular medicine.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41879157">Cardiovascular disease in China: epidemiological evolution and implications.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41879156">Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/">https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41880613" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41880613</a></p>
<p><strong>Summary:</strong> Among asymptomatic patients with severe aortic stenosis, early surgery significantly lowered the risk of operative mortality or death from cardiovascular causes compared to conservative care. This means patients who received early surgery had a reduced composite rate of death during surgery or within 30 days after surgery. The data demonstrated this significant reduction in operative and cardiovascular mortality with early surgical intervention. These findings provided a clear benefit for early surgery in this specific patient population.</p>
<h4>Article 2: Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879574" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879574</a></p>
<p><strong>Summary:</strong> Renin-independent aldosterone production contributes to adverse cardiorenal outcomes. The study established a definitive association between specific renin-aldosterone profiles and the occurrence of cardiorenal events in adults with hypertension. These findings provide population-based evidence demonstrating the significant role of distinct aldosterone production mechanisms in influencing cardiorenal health in hypertensive patients. The comprehensive analysis identified key patterns linking renin-aldosterone levels to adverse cardiovascular and renal outcomes.</p>
<h4>Article 3: Palliative care in cardiovascular medicine.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879158" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879158</a></p>
<p><strong>Summary:</strong> Palliative care for adults with advanced cardiovascular disease consistently improves patients&#8217; quality of life. It effectively supports caregivers and successfully aligns treatments with patient values and goals. The implementation of palliative care encompasses essential elements such as comprehensive symptom management, proactive advanced care planning, and patient-centered shared decision-making processes. These core components consistently lead to better patient experiences and outcomes in advanced cardiovascular disease.</p>
<h4>Article 4: Cardiovascular disease in China: epidemiological evolution and implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879157" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879157</a></p>
<p><strong>Summary:</strong> Cardiovascular disease remains the predominant cause of mortality in China, having undergone significant epidemiological transitions over several decades. This comprehensive review synthesized extensive observational data, revealing key features of cardiovascular disease&#8217;s evolving epidemiology across various dimensions within the country. The findings definitively establish crucial trends and interrelationships in cardiovascular disease incidence and prevalence among the Chinese population. This analysis demonstrates how the disease burden has shifted and provides a foundational understanding of its current state in China.</p>
<h4>Article 5: Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41879156" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41879156</a></p>
<p><strong>Summary:</strong> Wearable devices are transforming cardiovascular medicine, as they enable continuous remote monitoring of physiological and behavioral measures outside traditional clinical settings. Smartwatches and activity trackers effectively utilize motion and biometric sensors to accurately measure physical activity, sleep quality, heart rate, and rhythm. These devices successfully empower patients to assume a more active role in their health by converting health goals into objective, quantifiable measures. This technological advancement directly contributes to revolutionizing remote monitoring and disease prevention in cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 26, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years. Among asymptomatic patients with severe aortic stenosis, early surgery significantly lowered the risk of operative mortality or death from cardiovascular causes compared to conservative care. This means patients who received early surgery had a reduced composite rate of death during surgery or within 30 days after surgery. The data demonstrated this significant reduction in operative and cardiovascular mortality with early surgical intervention. These findings provided a clear benefit for early surgery in this specific patient population.</p>
<p>Article number two. Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study. Renin-independent aldosterone production contributes to adverse cardiorenal outcomes. The study established a definitive association between specific renin-aldosterone profiles and the occurrence of cardiorenal events in adults with hypertension. These findings provide population-based evidence demonstrating the significant role of distinct aldosterone production mechanisms in influencing cardiorenal health in hypertensive patients. The comprehensive analysis identified key patterns linking renin-aldosterone levels to adverse cardiovascular and renal outcomes.</p>
<p>Article number three. Palliative care in cardiovascular medicine. Palliative care for adults with advanced cardiovascular disease consistently improves patients&#8217; quality of life. It effectively supports caregivers and successfully aligns treatments with patient values and goals. The implementation of palliative care encompasses essential elements such as comprehensive symptom management, proactive advanced care planning, and patient-centered shared decision-making processes. These core components consistently lead to better patient experiences and outcomes in advanced cardiovascular disease.</p>
<p>Article number four. Cardiovascular disease in China: epidemiological evolution and implications. Cardiovascular disease remains the predominant cause of mortality in China, having undergone significant epidemiological transitions over several decades. This comprehensive review synthesized extensive observational data, revealing key features of cardiovascular disease&#8217;s evolving epidemiology across various dimensions within the country. The findings definitively establish crucial trends and interrelationships in cardiovascular disease incidence and prevalence among the Chinese population. This analysis demonstrates how the disease burden has shifted and provides a foundational understanding of its current state in China.</p>
<p>Article number five. Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention. Wearable devices are transforming cardiovascular medicine, as they enable continuous remote monitoring of physiological and behavioral measures outside traditional clinical settings. Smartwatches and activity trackers effectively utilize motion and biometric sensors to accurately measure physical activity, sleep quality, heart rate, and rhythm. These devices successfully empower patients to assume a more active role in their health by converting health goals into objective, quantifiable measures. This technological advancement directly contributes to revolutionizing remote monitoring and disease prevention in cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>conservative care, symptom management, cardiovascular health, remote monitoring, epidemiology, Palliative care, cardiorenal outcomes, Wearable devices, epidemiological transitions, smartwatches, mortality, aldosterone production, Aortic stenosis, operative mortality, China, cardiovascular disease, early surgery, advanced care planning, nationwide cohort study, renin-aldosterone, quality of life, Cardiovascular disease, disease prevention, cardiovascular death, Hypertension.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/">Early Surgery Reduces Aortic Stenosis Mortality 03/26/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260326_060022.mp3" length="3900229" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 26, 2026. This episode summarizes 5 key cardiology studies on topics like conservative care and symptom management. Key takeaway: Early Surgery Reduces Aortic Stenosis Mortality.
Article Links:
Article 1: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years. (The New England journal of medicine)
Article 2: Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study. (Journal of the American College of Cardiology)
Article 3: Palliative care in cardiovascular medicine. (European heart journal)
Article 4: Cardiovascular disease in China: epidemiological evolution and implications. (European heart journal)
Article 5: Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/
 Featured Articles
Article 1: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41880613
Summary: Among asymptomatic patients with severe aortic stenosis, early surgery significantly lowered the risk of operative mortality or death from cardiovascular causes compared to conservative care. This means patients who received early surgery had a reduced composite rate of death during surgery or within 30 days after surgery. The data demonstrated this significant reduction in operative and cardiovascular mortality with early surgical intervention. These findings provided a clear benefit for early surgery in this specific patient population.
Article 2: Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879574
Summary: Renin-independent aldosterone production contributes to adverse cardiorenal outcomes. The study established a definitive association between specific renin-aldosterone profiles and the occurrence of cardiorenal events in adults with hypertension. These findings provide population-based evidence demonstrating the significant role of distinct aldosterone production mechanisms in influencing cardiorenal health in hypertensive patients. The comprehensive analysis identified key patterns linking renin-aldosterone levels to adverse cardiovascular and renal outcomes.
Article 3: Palliative care in cardiovascular medicine.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879158
Summary: Palliative care for adults with advanced cardiovascular disease consistently improves patients&#8217; quality of life. It effectively supports caregivers and successfully aligns treatments with patient values and goals. The implementation of palliative care encompasses essential elements such as comprehensive symptom management, proactive advanced care planning, and patient-centered shared decision-making processes. These core components consistently lead to better patient experiences and outcomes in advanced cardiovascular disease.
Article 4: Cardiovascular disease in China: epidemiological evolution and implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41879157
Summary: Cardiovascular disease remains the predominant cause of mortality in China, having undergone significant epidemiological transitions over several decades. This comprehensive review synthesized extensive observational data, revealing key features of cardiovascular disease&#8217;s evolving epidemiology across various dimensions within the country. The findings definitively establish crucial trends and interrelationships in cardiovascular disease incidence and prevalence among the Chinese population. This analysis demonstrates how the disease burden has shifted and provides a foundational under]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 26, 2026. This episode summarizes 5 key cardiology studies on topics like conservative care and symptom management. Key takeaway: Early Surgery Reduces Aortic Stenosis Mortality.
Article Links:
Article 1: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years. (The New England journal of medicine)
Article 2: Renin-Aldosterone Profiles and Cardiorenal Outcomes in Hypertension: A Nationwide Cohort Study. (Journal of the American College of Cardiology)
Article 3: Palliative care in cardiovascular medicine. (European heart journal)
Article 4: Cardiovascular disease in China: epidemiological evolution and implications. (European heart journal)
Article 5: Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/early-surgery-reduces-aortic-stenosis-mortality-03-26-26/
 Featured Articles
Article]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>LVAD Reverses Heart Failure, Avoids Transplant 03/25/26</title>
	<link>https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/</link>
	<pubDate>Wed, 25 Mar 2026 12:52:58 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like healthcare costs and heart failure. Key takeaway: LVAD Reverses Heart Failure, Avoids Transplant.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41878819">Recovery From Heart Failure: Microvascular Mechanisms.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41878814">The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41878870">Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41878868">Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41878867">Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/">https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Recovery From Heart Failure: Microvascular Mechanisms.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878819" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878819</a></p>
<p><strong>Summary:</strong> Left ventricular assist device support improves cardiac histology and function in patients with heart failure. This improvement sometimes allows patients to avoid heart transplantation after Left Ventricular Assist Device removal. The study investigated the microvascular and cellular programs underlying this observed myocardial recovery.</p>
<h4>Article 2: The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878814" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878814</a></p>
<p><strong>Summary:</strong> Survival after Fontan palliation for single ventricle heart disease has substantially improved. The Fontan Outcomes Network, comprising 38 congenital heart centers, was established to define the long-term trajectory of these patients. The network successfully enrolled 1121 participants within its first two years, providing a substantial cohort for future longitudinal analysis.</p>
<h4>Article 3: Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878870</a></p>
<p><strong>Summary:</strong> A. C. V. P. R. Registry. Improving cardiac rehabilitation participation remains a national priority. This study utilized the American Association of Cardiovascular and Pulmonary Rehabilitation registry, analyzing data from 2012 to 2021. The investigation explored the relationship between patient copayments and attendance in cardiac rehabilitation programs, and also patient dropout rates. This analysis addressed the crucial clinical question of how financial barriers impact patient adherence and program completion.</p>
<h4>Article 4: Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878868" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878868</a></p>
<p><strong>Summary:</strong> Mortality in adults with congenital heart disease is strongly driven by disease complexity. This study investigated the influence of both clinical factors and social determinants of health on all-cause mortality in patients with adult congenital heart disease. Researchers utilized a single-center retrospective cohort from the Mayo Adult Congenital Heart Disease Registry, spanning from 2004 to 2017. The findings contributed to understanding critical factors impacting long-term survival in this complex patient population.</p>
<h4>Article 5: Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878867" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878867</a></p>
<p><strong>Summary:</strong> Sleep behaviors influence the development of both chronic obstructive pulmonary disease and coronary heart disease. This study explored the associations of specific sleep patterns with dynamic transitions of these conditions. The investigation also addressed the interaction of sleep patterns with genetic susceptibility and the mediating role of inflammatory biomarkers and metabolites. The analysis utilized extensive data from the U. K. Biobank to characterize these complex interrelationships affecting comorbidity.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Recovery From Heart Failure: Microvascular Mechanisms. Left ventricular assist device support improves cardiac histology and function in patients with heart failure. This improvement sometimes allows patients to avoid heart transplantation after Left Ventricular Assist Device removal. The study investigated the microvascular and cellular programs underlying this observed myocardial recovery.</p>
<p>Article number two. The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. Survival after Fontan palliation for single ventricle heart disease has substantially improved. The Fontan Outcomes Network, comprising 38 congenital heart centers, was established to define the long-term trajectory of these patients. The network successfully enrolled 1121 participants within its first two years, providing a substantial cohort for future longitudinal analysis.</p>
<p>Article number three. Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the A. A. C. V. P. R. Registry. Improving cardiac rehabilitation participation remains a national priority. This study utilized the American Association of Cardiovascular and Pulmonary Rehabilitation registry, analyzing data from 2012 to 2021. The investigation explored the relationship between patient copayments and attendance in cardiac rehabilitation programs, and also patient dropout rates. This analysis addressed the crucial clinical question of how financial barriers impact patient adherence and program completion.</p>
<p>Article number four. Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease. Mortality in adults with congenital heart disease is strongly driven by disease complexity. This study investigated the influence of both clinical factors and social determinants of health on all-cause mortality in patients with adult congenital heart disease. Researchers utilized a single-center retrospective cohort from the Mayo Adult Congenital Heart Disease Registry, spanning from 2004 to 2017. The findings contributed to understanding critical factors impacting long-term survival in this complex patient population.</p>
<p>Article number five. Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites. Sleep behaviors influence the development of both chronic obstructive pulmonary disease and coronary heart disease. This study explored the associations of specific sleep patterns with dynamic transitions of these conditions. The investigation also addressed the interaction of sleep patterns with genetic susceptibility and the mediating role of inflammatory biomarkers and metabolites. The analysis utilized extensive data from the U. K. Biobank to characterize these complex interrelationships affecting comorbidity. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>healthcare costs, heart failure, sleep patterns, cardiac function, long-term outcomes, copayments, patient registry, mortality predictors, chronic obstructive pulmonary disease, metabolites, patient attendance, congenital heart disease, inflammatory biomarkers, cardiac rehabilitation, Fontan palliation, Left ventricular assist device, social determinants of health, genetic susceptibility, adherence, adult congenital heart disease, coronary heart disease, myocardial recovery, heart transplantation, clinical factors, single ventricle heart disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/">LVAD Reverses Heart Failure, Avoids Transplant 03/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like healthcare costs and heart failure. Key takeaway: LVAD Reverses Heart Failure, Avoids Transplant.
Article Links:
Article 1: Recovery Fr]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like healthcare costs and heart failure. Key takeaway: LVAD Reverses Heart Failure, Avoids Transplant.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41878819">Recovery From Heart Failure: Microvascular Mechanisms.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41878814">The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41878870">Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41878868">Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41878867">Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/">https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Recovery From Heart Failure: Microvascular Mechanisms.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878819" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878819</a></p>
<p><strong>Summary:</strong> Left ventricular assist device support improves cardiac histology and function in patients with heart failure. This improvement sometimes allows patients to avoid heart transplantation after Left Ventricular Assist Device removal. The study investigated the microvascular and cellular programs underlying this observed myocardial recovery.</p>
<h4>Article 2: The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878814" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878814</a></p>
<p><strong>Summary:</strong> Survival after Fontan palliation for single ventricle heart disease has substantially improved. The Fontan Outcomes Network, comprising 38 congenital heart centers, was established to define the long-term trajectory of these patients. The network successfully enrolled 1121 participants within its first two years, providing a substantial cohort for future longitudinal analysis.</p>
<h4>Article 3: Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878870</a></p>
<p><strong>Summary:</strong> A. C. V. P. R. Registry. Improving cardiac rehabilitation participation remains a national priority. This study utilized the American Association of Cardiovascular and Pulmonary Rehabilitation registry, analyzing data from 2012 to 2021. The investigation explored the relationship between patient copayments and attendance in cardiac rehabilitation programs, and also patient dropout rates. This analysis addressed the crucial clinical question of how financial barriers impact patient adherence and program completion.</p>
<h4>Article 4: Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878868" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878868</a></p>
<p><strong>Summary:</strong> Mortality in adults with congenital heart disease is strongly driven by disease complexity. This study investigated the influence of both clinical factors and social determinants of health on all-cause mortality in patients with adult congenital heart disease. Researchers utilized a single-center retrospective cohort from the Mayo Adult Congenital Heart Disease Registry, spanning from 2004 to 2017. The findings contributed to understanding critical factors impacting long-term survival in this complex patient population.</p>
<h4>Article 5: Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41878867" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41878867</a></p>
<p><strong>Summary:</strong> Sleep behaviors influence the development of both chronic obstructive pulmonary disease and coronary heart disease. This study explored the associations of specific sleep patterns with dynamic transitions of these conditions. The investigation also addressed the interaction of sleep patterns with genetic susceptibility and the mediating role of inflammatory biomarkers and metabolites. The analysis utilized extensive data from the U. K. Biobank to characterize these complex interrelationships affecting comorbidity.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Recovery From Heart Failure: Microvascular Mechanisms. Left ventricular assist device support improves cardiac histology and function in patients with heart failure. This improvement sometimes allows patients to avoid heart transplantation after Left Ventricular Assist Device removal. The study investigated the microvascular and cellular programs underlying this observed myocardial recovery.</p>
<p>Article number two. The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. Survival after Fontan palliation for single ventricle heart disease has substantially improved. The Fontan Outcomes Network, comprising 38 congenital heart centers, was established to define the long-term trajectory of these patients. The network successfully enrolled 1121 participants within its first two years, providing a substantial cohort for future longitudinal analysis.</p>
<p>Article number three. Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the A. A. C. V. P. R. Registry. Improving cardiac rehabilitation participation remains a national priority. This study utilized the American Association of Cardiovascular and Pulmonary Rehabilitation registry, analyzing data from 2012 to 2021. The investigation explored the relationship between patient copayments and attendance in cardiac rehabilitation programs, and also patient dropout rates. This analysis addressed the crucial clinical question of how financial barriers impact patient adherence and program completion.</p>
<p>Article number four. Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease. Mortality in adults with congenital heart disease is strongly driven by disease complexity. This study investigated the influence of both clinical factors and social determinants of health on all-cause mortality in patients with adult congenital heart disease. Researchers utilized a single-center retrospective cohort from the Mayo Adult Congenital Heart Disease Registry, spanning from 2004 to 2017. The findings contributed to understanding critical factors impacting long-term survival in this complex patient population.</p>
<p>Article number five. Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites. Sleep behaviors influence the development of both chronic obstructive pulmonary disease and coronary heart disease. This study explored the associations of specific sleep patterns with dynamic transitions of these conditions. The investigation also addressed the interaction of sleep patterns with genetic susceptibility and the mediating role of inflammatory biomarkers and metabolites. The analysis utilized extensive data from the U. K. Biobank to characterize these complex interrelationships affecting comorbidity. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>healthcare costs, heart failure, sleep patterns, cardiac function, long-term outcomes, copayments, patient registry, mortality predictors, chronic obstructive pulmonary disease, metabolites, patient attendance, congenital heart disease, inflammatory biomarkers, cardiac rehabilitation, Fontan palliation, Left ventricular assist device, social determinants of health, genetic susceptibility, adherence, adult congenital heart disease, coronary heart disease, myocardial recovery, heart transplantation, clinical factors, single ventricle heart disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/">LVAD Reverses Heart Failure, Avoids Transplant 03/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260325_085206.mp3" length="3448833" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like healthcare costs and heart failure. Key takeaway: LVAD Reverses Heart Failure, Avoids Transplant.
Article Links:
Article 1: Recovery From Heart Failure: Microvascular Mechanisms. (Circulation)
Article 2: The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. (Circulation)
Article 3: Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry. (Journal of the American Heart Association)
Article 4: Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease. (Journal of the American Heart Association)
Article 5: Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/lvad-reverses-heart-failure-avoids-transplant-03-25-26/
 Featured Articles
Article 1: Recovery From Heart Failure: Microvascular Mechanisms.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41878819
Summary: Left ventricular assist device support improves cardiac histology and function in patients with heart failure. This improvement sometimes allows patients to avoid heart transplantation after Left Ventricular Assist Device removal. The study investigated the microvascular and cellular programs underlying this observed myocardial recovery.
Article 2: The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41878814
Summary: Survival after Fontan palliation for single ventricle heart disease has substantially improved. The Fontan Outcomes Network, comprising 38 congenital heart centers, was established to define the long-term trajectory of these patients. The network successfully enrolled 1121 participants within its first two years, providing a substantial cohort for future longitudinal analysis.
Article 3: Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41878870
Summary: A. C. V. P. R. Registry. Improving cardiac rehabilitation participation remains a national priority. This study utilized the American Association of Cardiovascular and Pulmonary Rehabilitation registry, analyzing data from 2012 to 2021. The investigation explored the relationship between patient copayments and attendance in cardiac rehabilitation programs, and also patient dropout rates. This analysis addressed the crucial clinical question of how financial barriers impact patient adherence and program completion.
Article 4: Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41878868
Summary: Mortality in adults with congenital heart disease is strongly driven by disease complexity. This study investigated the influence of both clinical factors and social determinants of health on all-cause mortality in patients with adult congenital heart disease. Researchers utilized a single-center retrospective cohort from the Mayo Adult Congenital Heart Disease Registry, spanning from 2004 to 2017. The findings contributed to understanding critical factors impacting long-term survival in this complex patient population.
Article 5: Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites.
Journal: Journal of the American Heart Association
PubMed Li]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like healthcare costs and heart failure. Key takeaway: LVAD Reverses Heart Failure, Avoids Transplant.
Article Links:
Article 1: Recovery From Heart Failure: Microvascular Mechanisms. (Circulation)
Article 2: The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. (Circulation)
Article 3: Association Between Copayments and Attendance in Cardiac Rehabilitation: A Nationwide Analysis From the AACVPR Registry. (Journal of the American Heart Association)
Article 4: Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease. (Journal of the American Heart Association)
Article 5: Joint Associations of Sleep Patterns and Genetic Susceptibility With Dynamic Transitions of Chronic Obstructive Pulmonary Disease and Coronary Heart Disease and the Mediating Role of Inflammatory Biomarkers and Metabolites. (Journal of the American H]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>METTL14 Inhibits Atherogenesis 03/25/26</title>
	<link>https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/</link>
	<pubDate>Wed, 25 Mar 2026 10:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like P. P. A. R. minus alpha and left ventricular strain. Key takeaway: METTL14 Inhibits Atherogenesis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41876216">Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41875954">Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41875953">The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41873711">METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41873540">THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/">https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41876216" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41876216</a></p>
<p><strong>Summary:</strong> Existing Heart Failure Association Pre-test Assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final Aetiology (H. F. A. minus P. E. F. F.) and Heavy, Hypertensive, Atrial Fibrillation, Pulmonary Hypertension, Elder, Filling Pressure (H. Two F. P. E. F.) scores do not adequately stratify long-term all-cause mortality risk in Heart Failure with Preserved Ejection Fraction (H. F. pEF) patients. To address this identified clinical gap, researchers developed and internally validated a parsimonious echocardiography-based model. This new model was designed to provide improved prediction of long-term all-cause mortality in the H. F. pEF patient population.</p>
<h4>Article 2: Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41875954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41875954</a></p>
<p><strong>Summary:</strong> Anthracyclines are associated with impaired Left Ventricular (L. V.) deformation, as measured by global longitudinal strain (G. L. S.) and global circumferential strain (G. C. S.). The S. T. O. P. minus C. A. trial investigated whether atorvastatin attenuates these declines in strain during anthracycline-based chemotherapy. Participants with lymphoma receiving anthracyclines were randomized to either placebo or atorvastatin. The study included 150 patients in the placebo group.</p>
<h4>Article 3: The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41875953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41875953</a></p>
<p><strong>Summary:</strong> Patients with non-S. T. minus segment elevation myocardial infarction (N. S. T. E. M. I.) remain at risk of major adverse cardiovascular events (MACE) despite successful percutaneous coronary intervention (P. C. I.). The combined prognostic value of pericoronary fat attenuation index (F. A. I.), a marker of coronary inflammation from coronary computed tomography angiography (C. C. T. A.), and angiography-derived microcirculatory resistance (A. M. R.), a marker of microvascular dysfunction, is underexplored for these patients. This retrospective cohort study assessed this combined prognostic value for improving risk stratification after P. C. I. in N. S. T. E. M. I. patients.</p>
<h4>Article 4: METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873711" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873711</a></p>
<p><strong>Summary:</strong> The study found that M. E. T. T. L. 14 inhibits atherogenesis by epigenetically activating Peroxisome Proliferator-Activated Receptors alpha and gamma (P. P. A. R. minus alpha and P. P. A. R. minus gamma) transcription. This mechanism promotes fatty acid oxidation in Vascular Smooth Muscle Cells (V. S. M. C.s). M. E. T. T. L. 14 therefore plays a crucial role in governing cellular processes that regulate atherosclerosis development.</p>
<h4>Article 5: THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873540" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873540</a></p>
<p><strong>Summary:</strong> Thrombospondin-4 (THBS4), an Extracellular Matrix (E. C. M.) glycoprotein, regulates pulmonary vascular remodeling in pulmonary hypertension (P. H.). The study found that T. H. B. S. 4 exerts this regulation via Transforming Growth Factor beta / S. M. A. D. 2 (T. G. F. minus beta / S. M. A. D. 2) signaling. This mechanism contributes to the progressive nature of P. H. marked by pulmonary arterial remodeling and right ventricular dysfunction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction. Existing Heart Failure Association Pre-test Assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final Aetiology (H. F. A. minus P. E. F. F.) and Heavy, Hypertensive, Atrial Fibrillation, Pulmonary Hypertension, Elder, Filling Pressure (H. Two F. P. E. F.) scores do not adequately stratify long-term all-cause mortality risk in Heart Failure with Preserved Ejection Fraction (H. F. pEF) patients. To address this identified clinical gap, researchers developed and internally validated a parsimonious echocardiography-based model. This new model was designed to provide improved prediction of long-term all-cause mortality in the H. F. pEF patient population.</p>
<p>Article number two. Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. Anthracyclines are associated with impaired Left Ventricular (L. V.) deformation, as measured by global longitudinal strain (G. L. S.) and global circumferential strain (G. C. S.). The S. T. O. P. minus C. A. trial investigated whether atorvastatin attenuates these declines in strain during anthracycline-based chemotherapy. Participants with lymphoma receiving anthracyclines were randomized to either placebo or atorvastatin. The study included 150 patients in the placebo group.</p>
<p>Article number three. The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients. Patients with non-S. T. minus segment elevation myocardial infarction (N. S. T. E. M. I.) remain at risk of major adverse cardiovascular events (MACE) despite successful percutaneous coronary intervention (P. C. I.). The combined prognostic value of pericoronary fat attenuation index (F. A. I.), a marker of coronary inflammation from coronary computed tomography angiography (C. C. T. A.), and angiography-derived microcirculatory resistance (A. M. R.), a marker of microvascular dysfunction, is underexplored for these patients. This retrospective cohort study assessed this combined prognostic value for improving risk stratification after P. C. I. in N. S. T. E. M. I. patients.</p>
<p>Article number four. METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs. The study found that M. E. T. T. L. 14 inhibits atherogenesis by epigenetically activating Peroxisome Proliferator-Activated Receptors alpha and gamma (P. P. A. R. minus alpha and P. P. A. R. minus gamma) transcription. This mechanism promotes fatty acid oxidation in Vascular Smooth Muscle Cells (V. S. M. C.s). M. E. T. T. L. 14 therefore plays a crucial role in governing cellular processes that regulate atherosclerosis development.</p>
<p>Article number five. THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling. Thrombospondin-4 (THBS4), an Extracellular Matrix (E. C. M.) glycoprotein, regulates pulmonary vascular remodeling in pulmonary hypertension (P. H.). The study found that T. H. B. S. 4 exerts this regulation via Transforming Growth Factor beta / S. M. A. D. 2 (T. G. F. minus beta / S. M. A. D. 2) signaling. This mechanism contributes to the progressive nature of P. H. marked by pulmonary arterial remodeling and right ventricular dysfunction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>P. P. A. R. minus alpha, left ventricular strain, microcirculatory resistance, pulmonary hypertension, H. F. A. minus P. E. F. F. score, S. M. A. D. 2 signaling, fat attenuation index, anthracycline cardiotoxicity, thrombospondin-4, atherogenesis, echocardiography, P. P. A. R. minus gamma, pulmonary vascular remodeling, major adverse cardiovascular events, T. G. F. minus beta, M. E. T. T. L. 14, heart failure with preserved ejection fraction, mortality risk, atorvastatin, global longitudinal strain, percutaneous coronary intervention, H. Two F. P. E. F. score, vascular smooth muscle cells, non-S. T. minus segment elevation myocardial infarction, global circumferential strain.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/">METTL14 Inhibits Atherogenesis 03/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like P. P. A. R. minus alpha and left ventricular strain. Key takeaway: METTL14 Inhibits Atherogenesis.
Article Links:
Article 1: Parsimonio]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like P. P. A. R. minus alpha and left ventricular strain. Key takeaway: METTL14 Inhibits Atherogenesis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41876216">Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41875954">Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41875953">The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41873711">METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41873540">THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/">https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41876216" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41876216</a></p>
<p><strong>Summary:</strong> Existing Heart Failure Association Pre-test Assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final Aetiology (H. F. A. minus P. E. F. F.) and Heavy, Hypertensive, Atrial Fibrillation, Pulmonary Hypertension, Elder, Filling Pressure (H. Two F. P. E. F.) scores do not adequately stratify long-term all-cause mortality risk in Heart Failure with Preserved Ejection Fraction (H. F. pEF) patients. To address this identified clinical gap, researchers developed and internally validated a parsimonious echocardiography-based model. This new model was designed to provide improved prediction of long-term all-cause mortality in the H. F. pEF patient population.</p>
<h4>Article 2: Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41875954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41875954</a></p>
<p><strong>Summary:</strong> Anthracyclines are associated with impaired Left Ventricular (L. V.) deformation, as measured by global longitudinal strain (G. L. S.) and global circumferential strain (G. C. S.). The S. T. O. P. minus C. A. trial investigated whether atorvastatin attenuates these declines in strain during anthracycline-based chemotherapy. Participants with lymphoma receiving anthracyclines were randomized to either placebo or atorvastatin. The study included 150 patients in the placebo group.</p>
<h4>Article 3: The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41875953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41875953</a></p>
<p><strong>Summary:</strong> Patients with non-S. T. minus segment elevation myocardial infarction (N. S. T. E. M. I.) remain at risk of major adverse cardiovascular events (MACE) despite successful percutaneous coronary intervention (P. C. I.). The combined prognostic value of pericoronary fat attenuation index (F. A. I.), a marker of coronary inflammation from coronary computed tomography angiography (C. C. T. A.), and angiography-derived microcirculatory resistance (A. M. R.), a marker of microvascular dysfunction, is underexplored for these patients. This retrospective cohort study assessed this combined prognostic value for improving risk stratification after P. C. I. in N. S. T. E. M. I. patients.</p>
<h4>Article 4: METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873711" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873711</a></p>
<p><strong>Summary:</strong> The study found that M. E. T. T. L. 14 inhibits atherogenesis by epigenetically activating Peroxisome Proliferator-Activated Receptors alpha and gamma (P. P. A. R. minus alpha and P. P. A. R. minus gamma) transcription. This mechanism promotes fatty acid oxidation in Vascular Smooth Muscle Cells (V. S. M. C.s). M. E. T. T. L. 14 therefore plays a crucial role in governing cellular processes that regulate atherosclerosis development.</p>
<h4>Article 5: THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873540" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873540</a></p>
<p><strong>Summary:</strong> Thrombospondin-4 (THBS4), an Extracellular Matrix (E. C. M.) glycoprotein, regulates pulmonary vascular remodeling in pulmonary hypertension (P. H.). The study found that T. H. B. S. 4 exerts this regulation via Transforming Growth Factor beta / S. M. A. D. 2 (T. G. F. minus beta / S. M. A. D. 2) signaling. This mechanism contributes to the progressive nature of P. H. marked by pulmonary arterial remodeling and right ventricular dysfunction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction. Existing Heart Failure Association Pre-test Assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final Aetiology (H. F. A. minus P. E. F. F.) and Heavy, Hypertensive, Atrial Fibrillation, Pulmonary Hypertension, Elder, Filling Pressure (H. Two F. P. E. F.) scores do not adequately stratify long-term all-cause mortality risk in Heart Failure with Preserved Ejection Fraction (H. F. pEF) patients. To address this identified clinical gap, researchers developed and internally validated a parsimonious echocardiography-based model. This new model was designed to provide improved prediction of long-term all-cause mortality in the H. F. pEF patient population.</p>
<p>Article number two. Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. Anthracyclines are associated with impaired Left Ventricular (L. V.) deformation, as measured by global longitudinal strain (G. L. S.) and global circumferential strain (G. C. S.). The S. T. O. P. minus C. A. trial investigated whether atorvastatin attenuates these declines in strain during anthracycline-based chemotherapy. Participants with lymphoma receiving anthracyclines were randomized to either placebo or atorvastatin. The study included 150 patients in the placebo group.</p>
<p>Article number three. The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients. Patients with non-S. T. minus segment elevation myocardial infarction (N. S. T. E. M. I.) remain at risk of major adverse cardiovascular events (MACE) despite successful percutaneous coronary intervention (P. C. I.). The combined prognostic value of pericoronary fat attenuation index (F. A. I.), a marker of coronary inflammation from coronary computed tomography angiography (C. C. T. A.), and angiography-derived microcirculatory resistance (A. M. R.), a marker of microvascular dysfunction, is underexplored for these patients. This retrospective cohort study assessed this combined prognostic value for improving risk stratification after P. C. I. in N. S. T. E. M. I. patients.</p>
<p>Article number four. METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs. The study found that M. E. T. T. L. 14 inhibits atherogenesis by epigenetically activating Peroxisome Proliferator-Activated Receptors alpha and gamma (P. P. A. R. minus alpha and P. P. A. R. minus gamma) transcription. This mechanism promotes fatty acid oxidation in Vascular Smooth Muscle Cells (V. S. M. C.s). M. E. T. T. L. 14 therefore plays a crucial role in governing cellular processes that regulate atherosclerosis development.</p>
<p>Article number five. THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling. Thrombospondin-4 (THBS4), an Extracellular Matrix (E. C. M.) glycoprotein, regulates pulmonary vascular remodeling in pulmonary hypertension (P. H.). The study found that T. H. B. S. 4 exerts this regulation via Transforming Growth Factor beta / S. M. A. D. 2 (T. G. F. minus beta / S. M. A. D. 2) signaling. This mechanism contributes to the progressive nature of P. H. marked by pulmonary arterial remodeling and right ventricular dysfunction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>P. P. A. R. minus alpha, left ventricular strain, microcirculatory resistance, pulmonary hypertension, H. F. A. minus P. E. F. F. score, S. M. A. D. 2 signaling, fat attenuation index, anthracycline cardiotoxicity, thrombospondin-4, atherogenesis, echocardiography, P. P. A. R. minus gamma, pulmonary vascular remodeling, major adverse cardiovascular events, T. G. F. minus beta, M. E. T. T. L. 14, heart failure with preserved ejection fraction, mortality risk, atorvastatin, global longitudinal strain, percutaneous coronary intervention, H. Two F. P. E. F. score, vascular smooth muscle cells, non-S. T. minus segment elevation myocardial infarction, global circumferential strain.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/">METTL14 Inhibits Atherogenesis 03/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260325_060039.mp3" length="4604908" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like P. P. A. R. minus alpha and left ventricular strain. Key takeaway: METTL14 Inhibits Atherogenesis.
Article Links:
Article 1: Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction. (Heart (British Cardiac Society))
Article 2: Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. (International journal of cardiology)
Article 3: The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients. (International journal of cardiology)
Article 4: METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs. (Cardiovascular research)
Article 5: THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/mettl14-inhibits-atherogenesis-03-25-26/
 Featured Articles
Article 1: Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41876216
Summary: Existing Heart Failure Association Pre-test Assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final Aetiology (H. F. A. minus P. E. F. F.) and Heavy, Hypertensive, Atrial Fibrillation, Pulmonary Hypertension, Elder, Filling Pressure (H. Two F. P. E. F.) scores do not adequately stratify long-term all-cause mortality risk in Heart Failure with Preserved Ejection Fraction (H. F. pEF) patients. To address this identified clinical gap, researchers developed and internally validated a parsimonious echocardiography-based model. This new model was designed to provide improved prediction of long-term all-cause mortality in the H. F. pEF patient population.
Article 2: Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41875954
Summary: Anthracyclines are associated with impaired Left Ventricular (L. V.) deformation, as measured by global longitudinal strain (G. L. S.) and global circumferential strain (G. C. S.). The S. T. O. P. minus C. A. trial investigated whether atorvastatin attenuates these declines in strain during anthracycline-based chemotherapy. Participants with lymphoma receiving anthracyclines were randomized to either placebo or atorvastatin. The study included 150 patients in the placebo group.
Article 3: The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41875953
Summary: Patients with non-S. T. minus segment elevation myocardial infarction (N. S. T. E. M. I.) remain at risk of major adverse cardiovascular events (MACE) despite successful percutaneous coronary intervention (P. C. I.). The combined prognostic value of pericoronary fat attenuation index (F. A. I.), a marker of coronary inflammation from coronary computed tomography angiography (C. C. T. A.), and angiography-derived microcirculatory resistance (A. M. R.), a marker of microvascular dysfunction, is underexplored for these patients. This retrospective cohort study assessed this combined prognostic value for improving risk stratification after P. C. I. in N. S. T. E. M. I. patients.
Article 4: METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41873711
Summary: The study found that M. E. T. T. L. 14 inhibits atherogenesis by epigenetically activating P]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 25, 2026. This episode summarizes 5 key cardiology studies on topics like P. P. A. R. minus alpha and left ventricular strain. Key takeaway: METTL14 Inhibits Atherogenesis.
Article Links:
Article 1: Parsimonious echocardiography-based model for predicting long-term all-cause mortality in heart failure with preserved ejection fraction. (Heart (British Cardiac Society))
Article 2: Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. (International journal of cardiology)
Article 3: The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients. (International journal of cardiology)
Article 4: METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs. (Cardiovascular research)
Article 5: THBS4 Regulates Pulmonary Hypertension via TGF-β/SMAD2 Signaling. (Hypertension (Dallas, Tex. : 197]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Tricuspid Regurgitation Drives Liver Disease Risk 03/24/26</title>
	<link>https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/</link>
	<pubDate>Tue, 24 Mar 2026 19:54:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like transitions of care and biomarkers. Key takeaway: Tricuspid Regurgitation Drives Liver Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41873713">Myocardial bridging: a practical guide for clinicians.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41873743">Liver-related outcomes in patients with tricuspid regurgitation.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41874184">Decoding the Heart Failure Peptidome.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41870283">Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41871647">Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/">https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocardial bridging: a practical guide for clinicians.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873713" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873713</a></p>
<p><strong>Summary:</strong> This guide for clinicians identifies myocardial bridging as the most common congenital coronary anomaly. While often a benign anatomical variant without clinical significance, it is increasingly identified due to the greater use of coronary computed tomography angiography. The guide compiles practical information for clinicians on the assessment and management of myocardial bridging. It outlines key considerations for when this condition may become clinically significant and require intervention.</p>
<h4>Article 2: Liver-related outcomes in patients with tricuspid regurgitation.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873743</a></p>
<p><strong>Summary:</strong> This retrospective study assessed the incidence and risk of liver-related outcomes in patients with tricuspid regurgitation. Results revealed a clear association between tricuspid regurgitation severity and the development of adverse liver-related complications, including cirrhosis, hepatocellular carcinoma, and liver-related death. The study successfully identified specific predictors for cirrhosis in patients with moderate or greater tricuspid regurgitation. The data also demonstrated a significant negative impact of cirrhosis on overall patient survival.</p>
<h4>Article 3: Decoding the Heart Failure Peptidome.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41874184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41874184</a></p>
<p><strong>Summary:</strong> This cross-sectional mass spectrometry analysis explored the low molecular peptidome in 486 patients with heart failure and 98 age-matched non-heart failure controls. The study identified specific plasma peptides that showed distinct differential expression patterns between heart failure patients and control individuals. These findings significantly advance the understanding of heart failure biology and demonstrate substantial potential for improving the diagnosis and prognostication of heart failure. The identified peptidome signatures offer novel insights for developing future therapeutic strategies for patients with heart failure.</p>
<h4>Article 4: Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41870283" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41870283</a></p>
<p><strong>Summary:</strong> The American Heart Association issued a scientific statement detailing significant advancements in pediatric heart care models and interventions over the past 20 years. These improvements have led to enhanced clinical outcomes after invasive cardiac procedures, increasing the frequency and complexity of home-based care for children. The statement emphasizes the critical need for updated educational strategies tailored for families and patients. It focuses on integrating technological advancements and improving transitions of care to better support pediatric patients living with heart disease.</p>
<h4>Article 5: Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871647" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871647</a></p>
<p><strong>Summary:</strong> This study characterized pulsed field ablation-induced coronary vasospasm by comparing a clinically relevant full pulsed field ablation waveform against a single-pulse configuration. Results revealed differential effects of the two waveforms on vasospasm incidence, severity, and recovery kinetics. The study also identified specific associated histological changes, providing crucial insights into the physiopathological mechanisms of pulsed field ablation-related coronary spasm. These findings demonstrate that distinct waveform characteristics directly impact the risk and nature of coronary vasospasm during pulsed field ablation procedures.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocardial bridging: a practical guide for clinicians. This guide for clinicians identifies myocardial bridging as the most common congenital coronary anomaly. While often a benign anatomical variant without clinical significance, it is increasingly identified due to the greater use of coronary computed tomography angiography. The guide compiles practical information for clinicians on the assessment and management of myocardial bridging. It outlines key considerations for when this condition may become clinically significant and require intervention.</p>
<p>Article number two. Liver-related outcomes in patients with tricuspid regurgitation. This retrospective study assessed the incidence and risk of liver-related outcomes in patients with tricuspid regurgitation. Results revealed a clear association between tricuspid regurgitation severity and the development of adverse liver-related complications, including cirrhosis, hepatocellular carcinoma, and liver-related death. The study successfully identified specific predictors for cirrhosis in patients with moderate or greater tricuspid regurgitation. The data also demonstrated a significant negative impact of cirrhosis on overall patient survival.</p>
<p>Article number three. Decoding the Heart Failure Peptidome. This cross-sectional mass spectrometry analysis explored the low molecular peptidome in 486 patients with heart failure and 98 age-matched non-heart failure controls. The study identified specific plasma peptides that showed distinct differential expression patterns between heart failure patients and control individuals. These findings significantly advance the understanding of heart failure biology and demonstrate substantial potential for improving the diagnosis and prognostication of heart failure. The identified peptidome signatures offer novel insights for developing future therapeutic strategies for patients with heart failure.</p>
<p>Article number four. Update on Education for Families and Patients With Pediatric Heart Disease: A Scientific Statement From the American Heart Association. The American Heart Association issued a scientific statement detailing significant advancements in pediatric heart care models and interventions over the past 20 years. These improvements have led to enhanced clinical outcomes after invasive cardiac procedures, increasing the frequency and complexity of home-based care for children. The statement emphasizes the critical need for updated educational strategies tailored for families and patients. It focuses on integrating technological advancements and improving transitions of care to better support pediatric patients living with heart disease.</p>
<p>Article number five. Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms. This study characterized pulsed field ablation-induced coronary vasospasm by comparing a clinically relevant full pulsed field ablation waveform against a single-pulse configuration. Results revealed differential effects of the two waveforms on vasospasm incidence, severity, and recovery kinetics. The study also identified specific associated histological changes, providing crucial insights into the physiopathological mechanisms of pulsed field ablation-related coronary spasm. These findings demonstrate that distinct waveform characteristics directly impact the risk and nature of coronary vasospasm during pulsed field ablation procedures. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transitions of care, biomarkers, clinical management, prognosis, coronary anomaly, coronary vasospasm, patient education, electrophysiology, tricuspid regurgitation, liver-related outcomes, coronary computed tomography angiography, family education, hepatocellular carcinoma, American Heart Association, pediatric heart disease, mass spectrometry, myocardial bridging, waveform characteristics, diagnosis, pulsed field ablation, heart failure, peptidome, cirrhosis, cardiac ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/">Tricuspid Regurgitation Drives Liver Disease Risk 03/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like transitions of care and biomarkers. Key takeaway: Tricuspid Regurgitation Drives Liver Disease Risk.
Article Links:
Article 1: Myocardi]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like transitions of care and biomarkers. Key takeaway: Tricuspid Regurgitation Drives Liver Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41873713">Myocardial bridging: a practical guide for clinicians.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41873743">Liver-related outcomes in patients with tricuspid regurgitation.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41874184">Decoding the Heart Failure Peptidome.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41870283">Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41871647">Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/">https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocardial bridging: a practical guide for clinicians.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873713" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873713</a></p>
<p><strong>Summary:</strong> This guide for clinicians identifies myocardial bridging as the most common congenital coronary anomaly. While often a benign anatomical variant without clinical significance, it is increasingly identified due to the greater use of coronary computed tomography angiography. The guide compiles practical information for clinicians on the assessment and management of myocardial bridging. It outlines key considerations for when this condition may become clinically significant and require intervention.</p>
<h4>Article 2: Liver-related outcomes in patients with tricuspid regurgitation.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41873743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41873743</a></p>
<p><strong>Summary:</strong> This retrospective study assessed the incidence and risk of liver-related outcomes in patients with tricuspid regurgitation. Results revealed a clear association between tricuspid regurgitation severity and the development of adverse liver-related complications, including cirrhosis, hepatocellular carcinoma, and liver-related death. The study successfully identified specific predictors for cirrhosis in patients with moderate or greater tricuspid regurgitation. The data also demonstrated a significant negative impact of cirrhosis on overall patient survival.</p>
<h4>Article 3: Decoding the Heart Failure Peptidome.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41874184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41874184</a></p>
<p><strong>Summary:</strong> This cross-sectional mass spectrometry analysis explored the low molecular peptidome in 486 patients with heart failure and 98 age-matched non-heart failure controls. The study identified specific plasma peptides that showed distinct differential expression patterns between heart failure patients and control individuals. These findings significantly advance the understanding of heart failure biology and demonstrate substantial potential for improving the diagnosis and prognostication of heart failure. The identified peptidome signatures offer novel insights for developing future therapeutic strategies for patients with heart failure.</p>
<h4>Article 4: Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41870283" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41870283</a></p>
<p><strong>Summary:</strong> The American Heart Association issued a scientific statement detailing significant advancements in pediatric heart care models and interventions over the past 20 years. These improvements have led to enhanced clinical outcomes after invasive cardiac procedures, increasing the frequency and complexity of home-based care for children. The statement emphasizes the critical need for updated educational strategies tailored for families and patients. It focuses on integrating technological advancements and improving transitions of care to better support pediatric patients living with heart disease.</p>
<h4>Article 5: Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871647" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871647</a></p>
<p><strong>Summary:</strong> This study characterized pulsed field ablation-induced coronary vasospasm by comparing a clinically relevant full pulsed field ablation waveform against a single-pulse configuration. Results revealed differential effects of the two waveforms on vasospasm incidence, severity, and recovery kinetics. The study also identified specific associated histological changes, providing crucial insights into the physiopathological mechanisms of pulsed field ablation-related coronary spasm. These findings demonstrate that distinct waveform characteristics directly impact the risk and nature of coronary vasospasm during pulsed field ablation procedures.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocardial bridging: a practical guide for clinicians. This guide for clinicians identifies myocardial bridging as the most common congenital coronary anomaly. While often a benign anatomical variant without clinical significance, it is increasingly identified due to the greater use of coronary computed tomography angiography. The guide compiles practical information for clinicians on the assessment and management of myocardial bridging. It outlines key considerations for when this condition may become clinically significant and require intervention.</p>
<p>Article number two. Liver-related outcomes in patients with tricuspid regurgitation. This retrospective study assessed the incidence and risk of liver-related outcomes in patients with tricuspid regurgitation. Results revealed a clear association between tricuspid regurgitation severity and the development of adverse liver-related complications, including cirrhosis, hepatocellular carcinoma, and liver-related death. The study successfully identified specific predictors for cirrhosis in patients with moderate or greater tricuspid regurgitation. The data also demonstrated a significant negative impact of cirrhosis on overall patient survival.</p>
<p>Article number three. Decoding the Heart Failure Peptidome. This cross-sectional mass spectrometry analysis explored the low molecular peptidome in 486 patients with heart failure and 98 age-matched non-heart failure controls. The study identified specific plasma peptides that showed distinct differential expression patterns between heart failure patients and control individuals. These findings significantly advance the understanding of heart failure biology and demonstrate substantial potential for improving the diagnosis and prognostication of heart failure. The identified peptidome signatures offer novel insights for developing future therapeutic strategies for patients with heart failure.</p>
<p>Article number four. Update on Education for Families and Patients With Pediatric Heart Disease: A Scientific Statement From the American Heart Association. The American Heart Association issued a scientific statement detailing significant advancements in pediatric heart care models and interventions over the past 20 years. These improvements have led to enhanced clinical outcomes after invasive cardiac procedures, increasing the frequency and complexity of home-based care for children. The statement emphasizes the critical need for updated educational strategies tailored for families and patients. It focuses on integrating technological advancements and improving transitions of care to better support pediatric patients living with heart disease.</p>
<p>Article number five. Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms. This study characterized pulsed field ablation-induced coronary vasospasm by comparing a clinically relevant full pulsed field ablation waveform against a single-pulse configuration. Results revealed differential effects of the two waveforms on vasospasm incidence, severity, and recovery kinetics. The study also identified specific associated histological changes, providing crucial insights into the physiopathological mechanisms of pulsed field ablation-related coronary spasm. These findings demonstrate that distinct waveform characteristics directly impact the risk and nature of coronary vasospasm during pulsed field ablation procedures. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transitions of care, biomarkers, clinical management, prognosis, coronary anomaly, coronary vasospasm, patient education, electrophysiology, tricuspid regurgitation, liver-related outcomes, coronary computed tomography angiography, family education, hepatocellular carcinoma, American Heart Association, pediatric heart disease, mass spectrometry, myocardial bridging, waveform characteristics, diagnosis, pulsed field ablation, heart failure, peptidome, cirrhosis, cardiac ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/">Tricuspid Regurgitation Drives Liver Disease Risk 03/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260324_155309.mp3" length="3897721" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like transitions of care and biomarkers. Key takeaway: Tricuspid Regurgitation Drives Liver Disease Risk.
Article Links:
Article 1: Myocardial bridging: a practical guide for clinicians. (European heart journal)
Article 2: Liver-related outcomes in patients with tricuspid regurgitation. (European journal of heart failure)
Article 3: Decoding the Heart Failure Peptidome. (Circulation. Heart failure)
Article 4: Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association. (Journal of the American Heart Association)
Article 5: Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/tricuspid-regurgitation-drives-liver-disease-risk-03-24-26/
 Featured Articles
Article 1: Myocardial bridging: a practical guide for clinicians.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41873713
Summary: This guide for clinicians identifies myocardial bridging as the most common congenital coronary anomaly. While often a benign anatomical variant without clinical significance, it is increasingly identified due to the greater use of coronary computed tomography angiography. The guide compiles practical information for clinicians on the assessment and management of myocardial bridging. It outlines key considerations for when this condition may become clinically significant and require intervention.
Article 2: Liver-related outcomes in patients with tricuspid regurgitation.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41873743
Summary: This retrospective study assessed the incidence and risk of liver-related outcomes in patients with tricuspid regurgitation. Results revealed a clear association between tricuspid regurgitation severity and the development of adverse liver-related complications, including cirrhosis, hepatocellular carcinoma, and liver-related death. The study successfully identified specific predictors for cirrhosis in patients with moderate or greater tricuspid regurgitation. The data also demonstrated a significant negative impact of cirrhosis on overall patient survival.
Article 3: Decoding the Heart Failure Peptidome.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41874184
Summary: This cross-sectional mass spectrometry analysis explored the low molecular peptidome in 486 patients with heart failure and 98 age-matched non-heart failure controls. The study identified specific plasma peptides that showed distinct differential expression patterns between heart failure patients and control individuals. These findings significantly advance the understanding of heart failure biology and demonstrate substantial potential for improving the diagnosis and prognostication of heart failure. The identified peptidome signatures offer novel insights for developing future therapeutic strategies for patients with heart failure.
Article 4: Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41870283
Summary: The American Heart Association issued a scientific statement detailing significant advancements in pediatric heart care models and interventions over the past 20 years. These improvements have led to enhanced clinical outcomes after invasive cardiac procedures, increasing the frequency and complexity of home-based care for children. The statement emphasizes the critical need for updated education]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like transitions of care and biomarkers. Key takeaway: Tricuspid Regurgitation Drives Liver Disease Risk.
Article Links:
Article 1: Myocardial bridging: a practical guide for clinicians. (European heart journal)
Article 2: Liver-related outcomes in patients with tricuspid regurgitation. (European journal of heart failure)
Article 3: Decoding the Heart Failure Peptidome. (Circulation. Heart failure)
Article 4: Update on Education for Families and Patients With Pediatric Heart Disease: A Focus on Technological Advancements, Procedures, and Transitions of Care: A Scientific Statement From the American Heart Association. (Journal of the American Heart Association)
Article 5: Angiographic and histological characterization of PFA-induced coronary spasm: Differential effect of two waveforms. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/tricuspid-regu]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>H. O. P. E. Extends Heart Transplant Window 03/24/26</title>
	<link>https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/</link>
	<pubDate>Tue, 24 Mar 2026 10:02:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like residual pulmonary hypertension and heart transplantation. Key takeaway: H. O. P. E. Extends Heart Transplant Window.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41493330">Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41871747">Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41871746">Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41871745">Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41869902">Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/">https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493330" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493330</a></p>
<p><strong>Summary:</strong> The OPTION-STEMI trial found an ongoing clinical uncertainty regarding the optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease complicated by heart failure. This study established a direct comparison of immediate versus staged complete revascularization during the index admission. The trial&#8217;s design rigorously evaluated fractional flow reserve-guided complete revascularization for non-infarct-related arteries in this high-risk cohort.</p>
<h4>Article 2: Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871747" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871747</a></p>
<p><strong>Summary:</strong> The study found that 24-hour hypothermic oxygenated perfusion (H. O. P. E.) successfully preserved graft viability in a porcine heart transplant model. This innovative approach extended preservation time up to 24 hours for both donation after circulatory death (D. C. D.) and donation after brain death (D. B. D.) donor hearts. H. O. P. E. demonstrated efficacy in mitigating organ injury, which is a known risk associated with prolonged standard static cold storage exceeding 4 to 5 hours.</p>
<h4>Article 3: Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871746" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871746</a></p>
<p><strong>Summary:</strong> The U. K. CURATE registry revealed limited and conflicting evidence regarding the use of pulmonary hypertension (P. H.) medical therapy as a bridge to pulmonary endarterectomy (P. E. A.) for chronic thromboembolic pulmonary hypertension (C. T. E. P. H.). The study also demonstrated an absence of consensus on criteria for continuing or restarting P. H. medical therapy post-operatively. The registry provided crucial data on the characteristics and long-term outcomes of patients receiving P. H. bridging therapy, along with identifying characteristics of residual P. H. post-P. E. A.</p>
<h4>Article 4: Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871745" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871745</a></p>
<p><strong>Summary:</strong> A multicenter cohort study involving 334 adult first-time lung transplant recipients established that pre-transplant Torque teno virus (T. T. V.) load is a significant factor in early post-transplant outcomes. This study demonstrated the relevance of T. T. V. levels, recognized as a surrogate marker of net immunosuppression, for lung transplantation patient care. The primary endpoint investigated was infection within 3 months, with plasma samples systematically collected immediately prior to transplantation.</p>
<h4>Article 5: Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41869902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41869902</a></p>
<p><strong>Summary:</strong> The study found that a residual left atrial (L. A.) v wave predicts the clinical outcome following transcatheter edge-to-edge mitral valve repair (M-TEER). This investigation, involving 299 patients, demonstrated that monitoring L. A. pressure intraprocedurally effectively complements echocardiographic assessments of residual mitral regurgitation. The presence of a residual L. A. v wave provides crucial prognostic information for M-TEER success and patient outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial. The OPTION-STEMI trial found an ongoing clinical uncertainty regarding the optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease complicated by heart failure. This study established a direct comparison of immediate versus staged complete revascularization during the index admission. The trial&#8217;s design rigorously evaluated fractional flow reserve-guided complete revascularization for non-infarct-related arteries in this high-risk cohort.</p>
<p>Article number two. Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model. The study found that 24-hour hypothermic oxygenated perfusion (H. O. P. E.) successfully preserved graft viability in a porcine heart transplant model. This innovative approach extended preservation time up to 24 hours for both donation after circulatory death (D. C. D.) and donation after brain death (D. B. D.) donor hearts. H. O. P. E. demonstrated efficacy in mitigating organ injury, which is a known risk associated with prolonged standard static cold storage exceeding 4 to 5 hours.</p>
<p>Article number three. Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry. The U. K. CURATE registry revealed limited and conflicting evidence regarding the use of pulmonary hypertension (P. H.) medical therapy as a bridge to pulmonary endarterectomy (P. E. A.) for chronic thromboembolic pulmonary hypertension (C. T. E. P. H.). The study also demonstrated an absence of consensus on criteria for continuing or restarting P. H. medical therapy post-operatively. The registry provided crucial data on the characteristics and long-term outcomes of patients receiving P. H. bridging therapy, along with identifying characteristics of residual P. H. post-P. E. A.</p>
<p>Article number four. Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study. A multicenter cohort study involving 334 adult first-time lung transplant recipients established that pre-transplant Torque teno virus (T. T. V.) load is a significant factor in early post-transplant outcomes. This study demonstrated the relevance of T. T. V. levels, recognized as a surrogate marker of net immunosuppression, for lung transplantation patient care. The primary endpoint investigated was infection within 3 months, with plasma samples systematically collected immediately prior to transplantation.</p>
<p>Article number five. Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair. The study found that a residual left atrial (L. A.) v wave predicts the clinical outcome following transcatheter edge-to-edge mitral valve repair (M-TEER). This investigation, involving 299 patients, demonstrated that monitoring L. A. pressure intraprocedurally effectively complements echocardiographic assessments of residual mitral regurgitation. The presence of a residual L. A. v wave provides crucial prognostic information for M-TEER success and patient outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>residual pulmonary hypertension, heart transplantation, graft viability, post-transplant infection, multivessel disease, chronic thromboembolic pulmonary hypertension, Left atrial pressure, fractional flow reserve, transcatheter edge-to-edge mitral valve repair, cold ischemic time, mitral regurgitation, ST-segment elevation myocardial infarction, Hypothermic oxygenated perfusion, lung transplantation, v wave, prognostic indicator, pulmonary hypertension medical therapy, bridging therapy, Pulmonary endarterectomy, immunosuppression, complete revascularization, donation after circulatory death, Torque teno virus, heart failure, cohort study.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/">H. O. P. E. Extends Heart Transplant Window 03/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like residual pulmonary hypertension and heart transplantation. Key takeaway: H. O. P. E. Extends Heart Transplant Window.
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like residual pulmonary hypertension and heart transplantation. Key takeaway: H. O. P. E. Extends Heart Transplant Window.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41493330">Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41871747">Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41871746">Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41871745">Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41869902">Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/">https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493330" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493330</a></p>
<p><strong>Summary:</strong> The OPTION-STEMI trial found an ongoing clinical uncertainty regarding the optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease complicated by heart failure. This study established a direct comparison of immediate versus staged complete revascularization during the index admission. The trial&#8217;s design rigorously evaluated fractional flow reserve-guided complete revascularization for non-infarct-related arteries in this high-risk cohort.</p>
<h4>Article 2: Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871747" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871747</a></p>
<p><strong>Summary:</strong> The study found that 24-hour hypothermic oxygenated perfusion (H. O. P. E.) successfully preserved graft viability in a porcine heart transplant model. This innovative approach extended preservation time up to 24 hours for both donation after circulatory death (D. C. D.) and donation after brain death (D. B. D.) donor hearts. H. O. P. E. demonstrated efficacy in mitigating organ injury, which is a known risk associated with prolonged standard static cold storage exceeding 4 to 5 hours.</p>
<h4>Article 3: Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871746" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871746</a></p>
<p><strong>Summary:</strong> The U. K. CURATE registry revealed limited and conflicting evidence regarding the use of pulmonary hypertension (P. H.) medical therapy as a bridge to pulmonary endarterectomy (P. E. A.) for chronic thromboembolic pulmonary hypertension (C. T. E. P. H.). The study also demonstrated an absence of consensus on criteria for continuing or restarting P. H. medical therapy post-operatively. The registry provided crucial data on the characteristics and long-term outcomes of patients receiving P. H. bridging therapy, along with identifying characteristics of residual P. H. post-P. E. A.</p>
<h4>Article 4: Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41871745" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41871745</a></p>
<p><strong>Summary:</strong> A multicenter cohort study involving 334 adult first-time lung transplant recipients established that pre-transplant Torque teno virus (T. T. V.) load is a significant factor in early post-transplant outcomes. This study demonstrated the relevance of T. T. V. levels, recognized as a surrogate marker of net immunosuppression, for lung transplantation patient care. The primary endpoint investigated was infection within 3 months, with plasma samples systematically collected immediately prior to transplantation.</p>
<h4>Article 5: Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41869902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41869902</a></p>
<p><strong>Summary:</strong> The study found that a residual left atrial (L. A.) v wave predicts the clinical outcome following transcatheter edge-to-edge mitral valve repair (M-TEER). This investigation, involving 299 patients, demonstrated that monitoring L. A. pressure intraprocedurally effectively complements echocardiographic assessments of residual mitral regurgitation. The presence of a residual L. A. v wave provides crucial prognostic information for M-TEER success and patient outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial. The OPTION-STEMI trial found an ongoing clinical uncertainty regarding the optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease complicated by heart failure. This study established a direct comparison of immediate versus staged complete revascularization during the index admission. The trial&#8217;s design rigorously evaluated fractional flow reserve-guided complete revascularization for non-infarct-related arteries in this high-risk cohort.</p>
<p>Article number two. Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model. The study found that 24-hour hypothermic oxygenated perfusion (H. O. P. E.) successfully preserved graft viability in a porcine heart transplant model. This innovative approach extended preservation time up to 24 hours for both donation after circulatory death (D. C. D.) and donation after brain death (D. B. D.) donor hearts. H. O. P. E. demonstrated efficacy in mitigating organ injury, which is a known risk associated with prolonged standard static cold storage exceeding 4 to 5 hours.</p>
<p>Article number three. Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry. The U. K. CURATE registry revealed limited and conflicting evidence regarding the use of pulmonary hypertension (P. H.) medical therapy as a bridge to pulmonary endarterectomy (P. E. A.) for chronic thromboembolic pulmonary hypertension (C. T. E. P. H.). The study also demonstrated an absence of consensus on criteria for continuing or restarting P. H. medical therapy post-operatively. The registry provided crucial data on the characteristics and long-term outcomes of patients receiving P. H. bridging therapy, along with identifying characteristics of residual P. H. post-P. E. A.</p>
<p>Article number four. Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study. A multicenter cohort study involving 334 adult first-time lung transplant recipients established that pre-transplant Torque teno virus (T. T. V.) load is a significant factor in early post-transplant outcomes. This study demonstrated the relevance of T. T. V. levels, recognized as a surrogate marker of net immunosuppression, for lung transplantation patient care. The primary endpoint investigated was infection within 3 months, with plasma samples systematically collected immediately prior to transplantation.</p>
<p>Article number five. Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair. The study found that a residual left atrial (L. A.) v wave predicts the clinical outcome following transcatheter edge-to-edge mitral valve repair (M-TEER). This investigation, involving 299 patients, demonstrated that monitoring L. A. pressure intraprocedurally effectively complements echocardiographic assessments of residual mitral regurgitation. The presence of a residual L. A. v wave provides crucial prognostic information for M-TEER success and patient outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>residual pulmonary hypertension, heart transplantation, graft viability, post-transplant infection, multivessel disease, chronic thromboembolic pulmonary hypertension, Left atrial pressure, fractional flow reserve, transcatheter edge-to-edge mitral valve repair, cold ischemic time, mitral regurgitation, ST-segment elevation myocardial infarction, Hypothermic oxygenated perfusion, lung transplantation, v wave, prognostic indicator, pulmonary hypertension medical therapy, bridging therapy, Pulmonary endarterectomy, immunosuppression, complete revascularization, donation after circulatory death, Torque teno virus, heart failure, cohort study.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/">H. O. P. E. Extends Heart Transplant Window 03/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260324_060104.mp3" length="4080369" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like residual pulmonary hypertension and heart transplantation. Key takeaway: H. O. P. E. Extends Heart Transplant Window.
Article Links:
Article 1: Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial. (European heart journal)
Article 2: Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Association of Pre-Transplant Torque Teno Virus Load With Early Post-Transplant Outcomes in Lung Transplant Recipients: A Multicenter Cohort Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/h-o-p-e-extends-heart-transplant-window-03-24-26/
 Featured Articles
Article 1: Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493330
Summary: The OPTION-STEMI trial found an ongoing clinical uncertainty regarding the optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease complicated by heart failure. This study established a direct comparison of immediate versus staged complete revascularization during the index admission. The trial&#8217;s design rigorously evaluated fractional flow reserve-guided complete revascularization for non-infarct-related arteries in this high-risk cohort.
Article 2: Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41871747
Summary: The study found that 24-hour hypothermic oxygenated perfusion (H. O. P. E.) successfully preserved graft viability in a porcine heart transplant model. This innovative approach extended preservation time up to 24 hours for both donation after circulatory death (D. C. D.) and donation after brain death (D. B. D.) donor hearts. H. O. P. E. demonstrated efficacy in mitigating organ injury, which is a known risk associated with prolonged standard static cold storage exceeding 4 to 5 hours.
Article 3: Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41871746
Summary: The U. K. CURATE registry revealed limited and conflicting evidence regarding the use of pulmonary hypertension (P. H.) medical therapy as a bridge to pulmonary endarterectomy (P. E. A.) for chronic thromboembolic pulmonary hypertension (C. T. E. P. H.). The study also demonstrated an absence of consensus on criteria for continuing or restarting P. H. medical therapy post-operatively. The registry provided crucial data on the characteristics and long-term outcomes of patients receiving P. H. bridging therapy, along with identifying char]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 24, 2026. This episode summarizes 5 key cardiology studies on topics like residual pulmonary hypertension and heart transplantation. Key takeaway: H. O. P. E. Extends Heart Transplant Window.
Article Links:
Article 1: Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial. (European heart journal)
Article 2: Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Long term effects of medical therapy pre- and post- pulmonary endarterectomy &#8211; insights from the UK CURATE registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Association of Pre-Tra]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Adverse Pregnancy Outcomes Predict Heart Risk 03/23/26</title>
	<link>https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/</link>
	<pubDate>Mon, 23 Mar 2026 10:01:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 23, 2026. This episode summarizes 5 key cardiology studies on topics like adverse pregnancy outcomes and sleep apnea. Key takeaway: Adverse Pregnancy Outcomes Predict Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41865850">Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41865849">Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41865992">Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries.</a> (The Canadian journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41865991">Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41859799">Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/">https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865850</a></p>
<p><strong>Summary:</strong> This study reported the initial pediatric experience of preserving cardiac allografts using a 10 degree Celsius cooler, a method with established favorable results in adult cardiac transplants. The single-center retrospective review documented recipient characteristics, intraoperative courses, and postoperative outcomes associated with this preservation technique. This investigation represents the first clinical application and evaluation of 10 degree Celsius allograft preservation in pediatric patients.</p>
<h4>Article 2: Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865849</a></p>
<p><strong>Summary:</strong> V. A. D. Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. This study found that temporary mechanical circulatory support, utilized as a bridge to durable Left Ventricular Assist Device implantation in advanced heart failure patients with right ventricular dysfunction, indicates acuity without leading to long-term futility. While right ventricular dysfunction at Left Ventricular Assist Device implantation predicts early morbidity and mortality, the data demonstrated that temporary mechanical circulatory support does not independently contribute to long-term risk. This redefines the prognostic implications of preoperative temporary mechanical circulatory support in this vulnerable patient population.</p>
<h4>Article 3: Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865992" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865992</a></p>
<p><strong>Summary:</strong> This study found that transcatheter edge-to-edge repair for significant tricuspid regurgitation achieved sustained improvement in most patients at one-year follow-up, based on contemporary registries. The data showed that early reduction in tricuspid regurgitation was influenced by factors such as anatomic complexity, leaflet coaptation mechanics, and device-related characteristics. Furthermore, results demonstrated that late tricuspid regurgitation recurrence was primarily driven by ongoing right-sided chamber remodeling and interactions between the leaflets and the device clip.</p>
<h4>Article 4: Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865991" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865991</a></p>
<p><strong>Summary:</strong> This study employed a win ratio analysis to evaluate the effects of peak flow triggered adaptive servo-ventilation for sleep apnea in patients with Heart Failure with Reduced Ejection Fraction. The win ratio approach expanded the assessment of intervention effects beyond conventional morbid and mortal events, incorporating endpoints related to symptom relief and quality of life. This analysis provided a more comprehensive understanding of adaptive servo-ventilation&#8217;s impact on overall patient well-being in this specific cardiology population.</p>
<h4>Article 5: Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859799" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859799</a></p>
<p><strong>Summary:</strong> This study established a relationship between a lifetime history of adverse pregnancy outcomes and long-term cardiovascular disease risk in 59154 parous participants from the Nurses&#8217; Health Study two. The investigation identified cardiovascular events, including myocardial infarction, stroke, and coronary revascularization, in women with self-reported histories of gestational diabetes, gestational hypertension, preeclampsia, preterm delivery, and low birthweight. This comprehensive analysis confirmed the cumulative impact of various adverse pregnancy outcomes on future cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler. This study reported the initial pediatric experience of preserving cardiac allografts using a 10 degree Celsius cooler, a method with established favorable results in adult cardiac transplants. The single-center retrospective review documented recipient characteristics, intraoperative courses, and postoperative outcomes associated with this preservation technique. This investigation represents the first clinical application and evaluation of 10 degree Celsius allograft preservation in pediatric patients.</p>
<p>Article number two. Temporary Mechanical Circulatory Support in L. V. A. D. Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. This study found that temporary mechanical circulatory support, utilized as a bridge to durable Left Ventricular Assist Device implantation in advanced heart failure patients with right ventricular dysfunction, indicates acuity without leading to long-term futility. While right ventricular dysfunction at Left Ventricular Assist Device implantation predicts early morbidity and mortality, the data demonstrated that temporary mechanical circulatory support does not independently contribute to long-term risk. This redefines the prognostic implications of preoperative temporary mechanical circulatory support in this vulnerable patient population.</p>
<p>Article number three. Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to-Edge Repair; Insights from Clinical Trials and Multi-Center Registries. This study found that transcatheter edge-to-edge repair for significant tricuspid regurgitation achieved sustained improvement in most patients at one-year follow-up, based on contemporary registries. The data showed that early reduction in tricuspid regurgitation was influenced by factors such as anatomic complexity, leaflet coaptation mechanics, and device-related characteristics. Furthermore, results demonstrated that late tricuspid regurgitation recurrence was primarily driven by ongoing right-sided chamber remodeling and interactions between the leaflets and the device clip.</p>
<p>Article number four. Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction. This study employed a win ratio analysis to evaluate the effects of peak flow triggered adaptive servo-ventilation for sleep apnea in patients with Heart Failure with Reduced Ejection Fraction. The win ratio approach expanded the assessment of intervention effects beyond conventional morbid and mortal events, incorporating endpoints related to symptom relief and quality of life. This analysis provided a more comprehensive understanding of adaptive servo-ventilation&#8217;s impact on overall patient well-being in this specific cardiology population.</p>
<p>Article number five. Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk. This study established a relationship between a lifetime history of adverse pregnancy outcomes and long-term cardiovascular disease risk in 59154 parous participants from the Nurses&#8217; Health Study two. The investigation identified cardiovascular events, including myocardial infarction, stroke, and coronary revascularization, in women with self-reported histories of gestational diabetes, gestational hypertension, preeclampsia, preterm delivery, and low birthweight. This comprehensive analysis confirmed the cumulative impact of various adverse pregnancy outcomes on future cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>adverse pregnancy outcomes, sleep apnea, temporary mechanical circulatory support, tricuspid regurgitation, preterm delivery, quality of life, transcatheter edge-to-edge repair, leaflet coaptation, cardiovascular risk, right ventricular remodeling, 10 degree Celsius cooler, cardiac allograft, pediatric heart transplantation, win ratio analysis, Heart Failure with Reduced Ejection Fraction, adaptive servo-ventilation, Left Ventricular Assist Device, bridge to transplant, advanced heart failure, preeclampsia, gestational diabetes, device-related factors, right ventricular dysfunction, organ preservation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/">Adverse Pregnancy Outcomes Predict Heart Risk 03/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 23, 2026. This episode summarizes 5 key cardiology studies on topics like adverse pregnancy outcomes and sleep apnea. Key takeaway: Adverse Pregnancy Outcomes Predict Heart Risk.
Article Links:
Article 1: Init]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 23, 2026. This episode summarizes 5 key cardiology studies on topics like adverse pregnancy outcomes and sleep apnea. Key takeaway: Adverse Pregnancy Outcomes Predict Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41865850">Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41865849">Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41865992">Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries.</a> (The Canadian journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41865991">Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41859799">Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/">https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865850</a></p>
<p><strong>Summary:</strong> This study reported the initial pediatric experience of preserving cardiac allografts using a 10 degree Celsius cooler, a method with established favorable results in adult cardiac transplants. The single-center retrospective review documented recipient characteristics, intraoperative courses, and postoperative outcomes associated with this preservation technique. This investigation represents the first clinical application and evaluation of 10 degree Celsius allograft preservation in pediatric patients.</p>
<h4>Article 2: Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865849</a></p>
<p><strong>Summary:</strong> V. A. D. Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. This study found that temporary mechanical circulatory support, utilized as a bridge to durable Left Ventricular Assist Device implantation in advanced heart failure patients with right ventricular dysfunction, indicates acuity without leading to long-term futility. While right ventricular dysfunction at Left Ventricular Assist Device implantation predicts early morbidity and mortality, the data demonstrated that temporary mechanical circulatory support does not independently contribute to long-term risk. This redefines the prognostic implications of preoperative temporary mechanical circulatory support in this vulnerable patient population.</p>
<h4>Article 3: Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865992" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865992</a></p>
<p><strong>Summary:</strong> This study found that transcatheter edge-to-edge repair for significant tricuspid regurgitation achieved sustained improvement in most patients at one-year follow-up, based on contemporary registries. The data showed that early reduction in tricuspid regurgitation was influenced by factors such as anatomic complexity, leaflet coaptation mechanics, and device-related characteristics. Furthermore, results demonstrated that late tricuspid regurgitation recurrence was primarily driven by ongoing right-sided chamber remodeling and interactions between the leaflets and the device clip.</p>
<h4>Article 4: Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41865991" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41865991</a></p>
<p><strong>Summary:</strong> This study employed a win ratio analysis to evaluate the effects of peak flow triggered adaptive servo-ventilation for sleep apnea in patients with Heart Failure with Reduced Ejection Fraction. The win ratio approach expanded the assessment of intervention effects beyond conventional morbid and mortal events, incorporating endpoints related to symptom relief and quality of life. This analysis provided a more comprehensive understanding of adaptive servo-ventilation&#8217;s impact on overall patient well-being in this specific cardiology population.</p>
<h4>Article 5: Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859799" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859799</a></p>
<p><strong>Summary:</strong> This study established a relationship between a lifetime history of adverse pregnancy outcomes and long-term cardiovascular disease risk in 59154 parous participants from the Nurses&#8217; Health Study two. The investigation identified cardiovascular events, including myocardial infarction, stroke, and coronary revascularization, in women with self-reported histories of gestational diabetes, gestational hypertension, preeclampsia, preterm delivery, and low birthweight. This comprehensive analysis confirmed the cumulative impact of various adverse pregnancy outcomes on future cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler. This study reported the initial pediatric experience of preserving cardiac allografts using a 10 degree Celsius cooler, a method with established favorable results in adult cardiac transplants. The single-center retrospective review documented recipient characteristics, intraoperative courses, and postoperative outcomes associated with this preservation technique. This investigation represents the first clinical application and evaluation of 10 degree Celsius allograft preservation in pediatric patients.</p>
<p>Article number two. Temporary Mechanical Circulatory Support in L. V. A. D. Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. This study found that temporary mechanical circulatory support, utilized as a bridge to durable Left Ventricular Assist Device implantation in advanced heart failure patients with right ventricular dysfunction, indicates acuity without leading to long-term futility. While right ventricular dysfunction at Left Ventricular Assist Device implantation predicts early morbidity and mortality, the data demonstrated that temporary mechanical circulatory support does not independently contribute to long-term risk. This redefines the prognostic implications of preoperative temporary mechanical circulatory support in this vulnerable patient population.</p>
<p>Article number three. Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to-Edge Repair; Insights from Clinical Trials and Multi-Center Registries. This study found that transcatheter edge-to-edge repair for significant tricuspid regurgitation achieved sustained improvement in most patients at one-year follow-up, based on contemporary registries. The data showed that early reduction in tricuspid regurgitation was influenced by factors such as anatomic complexity, leaflet coaptation mechanics, and device-related characteristics. Furthermore, results demonstrated that late tricuspid regurgitation recurrence was primarily driven by ongoing right-sided chamber remodeling and interactions between the leaflets and the device clip.</p>
<p>Article number four. Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction. This study employed a win ratio analysis to evaluate the effects of peak flow triggered adaptive servo-ventilation for sleep apnea in patients with Heart Failure with Reduced Ejection Fraction. The win ratio approach expanded the assessment of intervention effects beyond conventional morbid and mortal events, incorporating endpoints related to symptom relief and quality of life. This analysis provided a more comprehensive understanding of adaptive servo-ventilation&#8217;s impact on overall patient well-being in this specific cardiology population.</p>
<p>Article number five. Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk. This study established a relationship between a lifetime history of adverse pregnancy outcomes and long-term cardiovascular disease risk in 59154 parous participants from the Nurses&#8217; Health Study two. The investigation identified cardiovascular events, including myocardial infarction, stroke, and coronary revascularization, in women with self-reported histories of gestational diabetes, gestational hypertension, preeclampsia, preterm delivery, and low birthweight. This comprehensive analysis confirmed the cumulative impact of various adverse pregnancy outcomes on future cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>adverse pregnancy outcomes, sleep apnea, temporary mechanical circulatory support, tricuspid regurgitation, preterm delivery, quality of life, transcatheter edge-to-edge repair, leaflet coaptation, cardiovascular risk, right ventricular remodeling, 10 degree Celsius cooler, cardiac allograft, pediatric heart transplantation, win ratio analysis, Heart Failure with Reduced Ejection Fraction, adaptive servo-ventilation, Left Ventricular Assist Device, bridge to transplant, advanced heart failure, preeclampsia, gestational diabetes, device-related factors, right ventricular dysfunction, organ preservation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/">Adverse Pregnancy Outcomes Predict Heart Risk 03/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260323_060034.mp3" length="4124673" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 23, 2026. This episode summarizes 5 key cardiology studies on topics like adverse pregnancy outcomes and sleep apnea. Key takeaway: Adverse Pregnancy Outcomes Predict Heart Risk.
Article Links:
Article 1: Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries. (The Canadian journal of cardiology)
Article 4: Win Ratio Analysis for Peak-flow Adaptive Servo-ventilation in Treating Sleep Apnea in Heart Failure with Reduced Ejection Fraction. (The Canadian journal of cardiology)
Article 5: Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/adverse-pregnancy-outcomes-predict-heart-risk-03-23-26/
 Featured Articles
Article 1: Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41865850
Summary: This study reported the initial pediatric experience of preserving cardiac allografts using a 10 degree Celsius cooler, a method with established favorable results in adult cardiac transplants. The single-center retrospective review documented recipient characteristics, intraoperative courses, and postoperative outcomes associated with this preservation technique. This investigation represents the first clinical application and evaluation of 10 degree Celsius allograft preservation in pediatric patients.
Article 2: Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41865849
Summary: V. A. D. Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. This study found that temporary mechanical circulatory support, utilized as a bridge to durable Left Ventricular Assist Device implantation in advanced heart failure patients with right ventricular dysfunction, indicates acuity without leading to long-term futility. While right ventricular dysfunction at Left Ventricular Assist Device implantation predicts early morbidity and mortality, the data demonstrated that temporary mechanical circulatory support does not independently contribute to long-term risk. This redefines the prognostic implications of preoperative temporary mechanical circulatory support in this vulnerable patient population.
Article 3: Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41865992
Summary: This study found that transcatheter edge-to-edge repair for significant tricuspid regurgitation achieved sustained improvement in most patients at one-year follow-up, based on contemporary registries. The data showed that early reduction in tricuspid regurgitation was influenced by factors such as anatomic complexity, leaflet coaptation mechanics, and device-related characteristics. Furthermore, results demonstrated that late tricuspid regurgitation recurrence was primar]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 23, 2026. This episode summarizes 5 key cardiology studies on topics like adverse pregnancy outcomes and sleep apnea. Key takeaway: Adverse Pregnancy Outcomes Predict Heart Risk.
Article Links:
Article 1: Initial Pediatric Experience of Preserving Cardiac Allografts in a 10°C Cooler. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Temporary Mechanical Circulatory Support in LVAD Candidates with Right Ventricular Dysfunction: Acuity Without Long-Term Futility. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Natural History of Tricuspid Regurgitation Following Transcatheter-Edge-to &#8211; Edge Repair; Insights from Clinical Trials and Multi-Center Registries. (The Canadian journal of cardiology)
Article 4: Win Ratio Analysis for Peak-flow Adaptive Servo-venti]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Suv39h1 Deficiency Rescues Heart Failure 03/22/26</title>
	<link>https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/</link>
	<pubDate>Sun, 22 Mar 2026 10:01:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 22, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac surgery and sex-based differences. Key takeaway: Suv39h1 Deficiency Rescues Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41859896">Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41861066">The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41861065">Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41861053">Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41854369">Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/">https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859896</a></p>
<p><strong>Summary:</strong> A comprehensive retrospective cohort study involving 3313 adult patients who underwent mitral valve surgery provided data to investigate sex as an independent risk factor for perioperative mortality. The analysis focused on operative mortality as the primary outcome, stratified by patient sex. This research established a foundational dataset to clarify the influence of sex on surgical outcomes in mitral valve disease.</p>
<h4>Article 2: The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41861066" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41861066</a></p>
<p><strong>Summary:</strong> S. H.) Working Group on Environment in Hypertension. A position paper by the European Society of Hypertension Working Group found that environmental pollution and climate change contribute to over 9 million premature deaths annually worldwide. Air and noise pollution demonstrate the strongest epidemiological links to hypertension and cardiovascular disease. Furthermore, emerging evidence connects light pollution, toxic metal exposure, and climate-related factors to these health burdens. This comprehensive analysis highlights the significant impact of environmental factors on global hypertension rates.</p>
<h4>Article 3: Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41861065" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41861065</a></p>
<p><strong>Summary:</strong> This study found that a deficiency in suppressor of variegation 3-9 homolog 1, or Suv39h1, attenuates cardiac fibrosis and rescues heart failure. The research demonstrated that Suv39h1 expression increased in cardiac fibroblasts during fibrosis. This mechanism was identified to operate through TACC2, suggesting a critical role for Suv39h1 in regulating cardiac extracellular matrix production. These findings reveal a novel therapeutic target for heart failure.</p>
<h4>Article 4: Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41861053" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41861053</a></p>
<p><strong>Summary:</strong> This study found that nuclear export mediated by COPS5/CSN5/JAB1 facilitates vascular smooth muscle cell dedifferentiation, contributing to neointimal hyperplasia. The research showed increased COPS5/CSN5 levels in human idiopathic pulmonary hypertension (I. P. A. H.) neointima, atherosclerotic lesions, and rabbit vein grafts. This suggests a direct involvement of COPS5 in vascular remodeling following injury. Understanding this mechanism offers a potential therapeutic target for conditions involving neointimal hyperplasia.</p>
<h4>Article 5: Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41854369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41854369</a></p>
<p><strong>Summary:</strong> This study found that Lgi3 and Lgi4 proteins interact directly with K. V. 1.5 channels in human atrial tissue and heterologous cells. In a mouse model with A. A. V. 9-mediated cardiac-specific Lgi4 expression, the research observed impaired sinoatrial and atrioventricular conduction, leading to a prolonged Q. R. S. interval. The data showed delayed action potential repolarization in atria, indicating Lgi3-4 proteins modulate cardiac electrophysiology. These findings suggest Lgi3-4 proteins are potential therapeutic targets for atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 22, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions. A comprehensive retrospective cohort study involving 3313 adult patients who underwent mitral valve surgery provided data to investigate sex as an independent risk factor for perioperative mortality. The analysis focused on operative mortality as the primary outcome, stratified by patient sex. This research established a foundational dataset to clarify the influence of sex on surgical outcomes in mitral valve disease.</p>
<p>Article number two. The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (E. S. H.) Working Group on Environment in Hypertension. A position paper by the European Society of Hypertension Working Group found that environmental pollution and climate change contribute to over 9 million premature deaths annually worldwide. Air and noise pollution demonstrate the strongest epidemiological links to hypertension and cardiovascular disease. Furthermore, emerging evidence connects light pollution, toxic metal exposure, and climate-related factors to these health burdens. This comprehensive analysis highlights the significant impact of environmental factors on global hypertension rates.</p>
<p>Article number three. Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2. This study found that a deficiency in suppressor of variegation 3-9 homolog 1, or Suv39h1, attenuates cardiac fibrosis and rescues heart failure. The research demonstrated that Suv39h1 expression increased in cardiac fibroblasts during fibrosis. This mechanism was identified to operate through TACC2, suggesting a critical role for Suv39h1 in regulating cardiac extracellular matrix production. These findings reveal a novel therapeutic target for heart failure.</p>
<p>Article number four. Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia. This study found that nuclear export mediated by COPS5/CSN5/JAB1 facilitates vascular smooth muscle cell dedifferentiation, contributing to neointimal hyperplasia. The research showed increased COPS5/CSN5 levels in human idiopathic pulmonary hypertension (I. P. A. H.) neointima, atherosclerotic lesions, and rabbit vein grafts. This suggests a direct involvement of COPS5 in vascular remodeling following injury. Understanding this mechanism offers a potential therapeutic target for conditions involving neointimal hyperplasia.</p>
<p>Article number five. Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation. This study found that Lgi3 and Lgi4 proteins interact directly with K. V. 1.5 channels in human atrial tissue and heterologous cells. In a mouse model with A. A. V. 9-mediated cardiac-specific Lgi4 expression, the research observed impaired sinoatrial and atrioventricular conduction, leading to a prolonged Q. R. S. interval. The data showed delayed action potential repolarization in atria, indicating Lgi3-4 proteins modulate cardiac electrophysiology. These findings suggest Lgi3-4 proteins are potential therapeutic targets for atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac surgery, sex-based differences, Lgi3-4 proteins, K. V. 1.5 channels, mitral valve surgery, Q. R. S. interval, cardiovascular disease, COPS5, dedifferentiation, cardiac electrophysiology, operative mortality, Suv39h1, vascular smooth muscle cell, air pollution, therapeutic target, noise pollution, TACC2, patient outcomes, environmental pollution, climate change, atrial fibrillation, hypertension, vascular injury, neointimal hyperplasia, heart failure, cardiac fibrosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/">Suv39h1 Deficiency Rescues Heart Failure 03/22/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 22, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac surgery and sex-based differences. Key takeaway: Suv39h1 Deficiency Rescues Heart Failure.
Article Links:
Article 1: Sex-Based ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 22, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac surgery and sex-based differences. Key takeaway: Suv39h1 Deficiency Rescues Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41859896">Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41861066">The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41861065">Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41861053">Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41854369">Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/">https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859896</a></p>
<p><strong>Summary:</strong> A comprehensive retrospective cohort study involving 3313 adult patients who underwent mitral valve surgery provided data to investigate sex as an independent risk factor for perioperative mortality. The analysis focused on operative mortality as the primary outcome, stratified by patient sex. This research established a foundational dataset to clarify the influence of sex on surgical outcomes in mitral valve disease.</p>
<h4>Article 2: The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41861066" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41861066</a></p>
<p><strong>Summary:</strong> S. H.) Working Group on Environment in Hypertension. A position paper by the European Society of Hypertension Working Group found that environmental pollution and climate change contribute to over 9 million premature deaths annually worldwide. Air and noise pollution demonstrate the strongest epidemiological links to hypertension and cardiovascular disease. Furthermore, emerging evidence connects light pollution, toxic metal exposure, and climate-related factors to these health burdens. This comprehensive analysis highlights the significant impact of environmental factors on global hypertension rates.</p>
<h4>Article 3: Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41861065" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41861065</a></p>
<p><strong>Summary:</strong> This study found that a deficiency in suppressor of variegation 3-9 homolog 1, or Suv39h1, attenuates cardiac fibrosis and rescues heart failure. The research demonstrated that Suv39h1 expression increased in cardiac fibroblasts during fibrosis. This mechanism was identified to operate through TACC2, suggesting a critical role for Suv39h1 in regulating cardiac extracellular matrix production. These findings reveal a novel therapeutic target for heart failure.</p>
<h4>Article 4: Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41861053" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41861053</a></p>
<p><strong>Summary:</strong> This study found that nuclear export mediated by COPS5/CSN5/JAB1 facilitates vascular smooth muscle cell dedifferentiation, contributing to neointimal hyperplasia. The research showed increased COPS5/CSN5 levels in human idiopathic pulmonary hypertension (I. P. A. H.) neointima, atherosclerotic lesions, and rabbit vein grafts. This suggests a direct involvement of COPS5 in vascular remodeling following injury. Understanding this mechanism offers a potential therapeutic target for conditions involving neointimal hyperplasia.</p>
<h4>Article 5: Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41854369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41854369</a></p>
<p><strong>Summary:</strong> This study found that Lgi3 and Lgi4 proteins interact directly with K. V. 1.5 channels in human atrial tissue and heterologous cells. In a mouse model with A. A. V. 9-mediated cardiac-specific Lgi4 expression, the research observed impaired sinoatrial and atrioventricular conduction, leading to a prolonged Q. R. S. interval. The data showed delayed action potential repolarization in atria, indicating Lgi3-4 proteins modulate cardiac electrophysiology. These findings suggest Lgi3-4 proteins are potential therapeutic targets for atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 22, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions. A comprehensive retrospective cohort study involving 3313 adult patients who underwent mitral valve surgery provided data to investigate sex as an independent risk factor for perioperative mortality. The analysis focused on operative mortality as the primary outcome, stratified by patient sex. This research established a foundational dataset to clarify the influence of sex on surgical outcomes in mitral valve disease.</p>
<p>Article number two. The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (E. S. H.) Working Group on Environment in Hypertension. A position paper by the European Society of Hypertension Working Group found that environmental pollution and climate change contribute to over 9 million premature deaths annually worldwide. Air and noise pollution demonstrate the strongest epidemiological links to hypertension and cardiovascular disease. Furthermore, emerging evidence connects light pollution, toxic metal exposure, and climate-related factors to these health burdens. This comprehensive analysis highlights the significant impact of environmental factors on global hypertension rates.</p>
<p>Article number three. Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2. This study found that a deficiency in suppressor of variegation 3-9 homolog 1, or Suv39h1, attenuates cardiac fibrosis and rescues heart failure. The research demonstrated that Suv39h1 expression increased in cardiac fibroblasts during fibrosis. This mechanism was identified to operate through TACC2, suggesting a critical role for Suv39h1 in regulating cardiac extracellular matrix production. These findings reveal a novel therapeutic target for heart failure.</p>
<p>Article number four. Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia. This study found that nuclear export mediated by COPS5/CSN5/JAB1 facilitates vascular smooth muscle cell dedifferentiation, contributing to neointimal hyperplasia. The research showed increased COPS5/CSN5 levels in human idiopathic pulmonary hypertension (I. P. A. H.) neointima, atherosclerotic lesions, and rabbit vein grafts. This suggests a direct involvement of COPS5 in vascular remodeling following injury. Understanding this mechanism offers a potential therapeutic target for conditions involving neointimal hyperplasia.</p>
<p>Article number five. Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation. This study found that Lgi3 and Lgi4 proteins interact directly with K. V. 1.5 channels in human atrial tissue and heterologous cells. In a mouse model with A. A. V. 9-mediated cardiac-specific Lgi4 expression, the research observed impaired sinoatrial and atrioventricular conduction, leading to a prolonged Q. R. S. interval. The data showed delayed action potential repolarization in atria, indicating Lgi3-4 proteins modulate cardiac electrophysiology. These findings suggest Lgi3-4 proteins are potential therapeutic targets for atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac surgery, sex-based differences, Lgi3-4 proteins, K. V. 1.5 channels, mitral valve surgery, Q. R. S. interval, cardiovascular disease, COPS5, dedifferentiation, cardiac electrophysiology, operative mortality, Suv39h1, vascular smooth muscle cell, air pollution, therapeutic target, noise pollution, TACC2, patient outcomes, environmental pollution, climate change, atrial fibrillation, hypertension, vascular injury, neointimal hyperplasia, heart failure, cardiac fibrosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/">Suv39h1 Deficiency Rescues Heart Failure 03/22/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260322_060036.mp3" length="4382554" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 22, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac surgery and sex-based differences. Key takeaway: Suv39h1 Deficiency Rescues Heart Failure.
Article Links:
Article 1: Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions. (Journal of the American Heart Association)
Article 2: The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension. (Cardiovascular research)
Article 3: Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2. (Cardiovascular research)
Article 4: Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia. (Cardiovascular research)
Article 5: Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/suv39h1-deficiency-rescues-heart-failure-03-22-26/
 Featured Articles
Article 1: Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859896
Summary: A comprehensive retrospective cohort study involving 3313 adult patients who underwent mitral valve surgery provided data to investigate sex as an independent risk factor for perioperative mortality. The analysis focused on operative mortality as the primary outcome, stratified by patient sex. This research established a foundational dataset to clarify the influence of sex on surgical outcomes in mitral valve disease.
Article 2: The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41861066
Summary: S. H.) Working Group on Environment in Hypertension. A position paper by the European Society of Hypertension Working Group found that environmental pollution and climate change contribute to over 9 million premature deaths annually worldwide. Air and noise pollution demonstrate the strongest epidemiological links to hypertension and cardiovascular disease. Furthermore, emerging evidence connects light pollution, toxic metal exposure, and climate-related factors to these health burdens. This comprehensive analysis highlights the significant impact of environmental factors on global hypertension rates.
Article 3: Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41861065
Summary: This study found that a deficiency in suppressor of variegation 3-9 homolog 1, or Suv39h1, attenuates cardiac fibrosis and rescues heart failure. The research demonstrated that Suv39h1 expression increased in cardiac fibroblasts during fibrosis. This mechanism was identified to operate through TACC2, suggesting a critical role for Suv39h1 in regulating cardiac extracellular matrix production. These findings reveal a novel therapeutic target for heart failure.
Article 4: Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41861053
Summary: This study found that nuclear export mediated by COPS5/CSN5/JAB1 facilitates vascular smooth muscle cell dedifferentiation, contributing to neointimal hyperplasia. The research showed increased COPS5/CSN5 levels in human idiopathic pulmonary hypertension (I. P. A. H.) neointima, atherosclerotic lesions, and rabbit vein ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 22, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac surgery and sex-based differences. Key takeaway: Suv39h1 Deficiency Rescues Heart Failure.
Article Links:
Article 1: Sex-Based Differences in Outcomes Following Mitral Valve Surgery: A Contemporary Analysis From 2 Institutions. (Journal of the American Heart Association)
Article 2: The impact of environmental pollution and climate change on hypertension: a position paper by the European Society of Hypertension (ESH) Working Group on Environment in Hypertension. (Cardiovascular research)
Article 3: Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2. (Cardiovascular research)
Article 4: Nuclear export by COPS5/CSN5/JAB1 mediates vascular smooth muscle cell dedifferentiation in neointimal hyperplasia. (Cardiovascular research)
Article 5: Lgi3-4 proteins modulate the KV1.5 channelosome and are pot]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Apixaban Safe for Kids&#8217; Heart Thromboprophylaxis 03/21/26</title>
	<link>https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/</link>
	<pubDate>Sat, 21 Mar 2026 12:53:08 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like coronary artery disease and Time-restricted eating. Key takeaway: Apixaban Safe for Kids&#8217; Heart Thromboprophylaxis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41859904">Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41859900">Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41859899">Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41859898">Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41859897">Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/">https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859904</a></p>
<p><strong>Summary:</strong> A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention&#8217;s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.</p>
<h4>Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859900" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859900</a></p>
<p><strong>Summary:</strong> This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.</p>
<h4>Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859899" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859899</a></p>
<p><strong>Summary:</strong> A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.</p>
<h4>Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859898" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859898</a></p>
<p><strong>Summary:</strong> The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease. An exploratory substudy assessed apixaban&#8217;s ex vivo effects on surrogate biomarkers of efficacy, including D-dimer, thrombin generation assay parameters, Factor eight, fibrinogen, and protein C. This research provided specific data on apixaban&#8217;s impact on coagulation factors and hemostatic proteins in this pediatric patient group.</p>
<h4>Article 5: Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859897" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859897</a></p>
<p><strong>Summary:</strong> This study evaluated the real-world relationship between pulmonary vascular resistance and prognosis in Group two pulmonary hypertension, which is defined as pulmonary hypertension caused by left heart disease. Researchers analyzed data from 563 patients across two prospective Japanese multicenter registries, thus establishing specific patient cohorts for this analysis. The investigation assessed the efficacy of emerging therapies within this challenging condition, providing concrete data on therapeutic approaches for patients with left heart disease and pulmonary hypertension.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study. A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention&#8217;s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.</p>
<p>Article number two. Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study. This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.</p>
<p>Article number three. Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.</p>
<p>Article number four. Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy. The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease. An exploratory substudy assessed apixaban&#8217;s ex vivo effects on surrogate biomarkers of efficacy, including D-dimer, thrombin generation assay parameters, Factor eight, fibrinogen, and protein C. This research provided specific data on apixaban&#8217;s impact on coagulation factors and hemostatic proteins in this pediatric patient group.</p>
<p>Article number five. Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry. This study evaluated the real-world relationship between pulmonary vascular resistance and prognosis in Group two pulmonary hypertension, which is defined as pulmonary hypertension caused by left heart disease. Researchers analyzed data from 563 patients across two prospective Japanese multicenter registries, thus establishing specific patient cohorts for this analysis. The investigation assessed the efficacy of emerging therapies within this challenging condition, providing concrete data on therapeutic approaches for patients with left heart disease and pulmonary hypertension. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>coronary artery disease, Time-restricted eating, pediatric heart disease, clinical outcomes, Korean patients, prognosis, magnetic resonance imaging, pulmonary hypertension, Antiplatelet exposure, D-dimer, emerging therapies, Pulmonary vascular resistance, thromboprophylaxis, cerebral microbleeds, antithrombotic response, environmental exposure, left heart disease, Apixaban, cerebrovascular health, myocardial infarction, acute myocardial infarction, hemostatic biomarkers, innate immunity, Plasma metals, systemic inflammation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/">Apixaban Safe for Kids’ Heart Thromboprophylaxis 03/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like coronary artery disease and Time-restricted eating. Key takeaway: Apixaban Safe for Kids&#8217; Heart Thromboprophylaxis.
Article Links]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like coronary artery disease and Time-restricted eating. Key takeaway: Apixaban Safe for Kids&#8217; Heart Thromboprophylaxis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41859904">Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41859900">Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41859899">Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41859898">Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41859897">Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/">https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859904</a></p>
<p><strong>Summary:</strong> A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention&#8217;s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.</p>
<h4>Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859900" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859900</a></p>
<p><strong>Summary:</strong> This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.</p>
<h4>Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859899" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859899</a></p>
<p><strong>Summary:</strong> A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.</p>
<h4>Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859898" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859898</a></p>
<p><strong>Summary:</strong> The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease. An exploratory substudy assessed apixaban&#8217;s ex vivo effects on surrogate biomarkers of efficacy, including D-dimer, thrombin generation assay parameters, Factor eight, fibrinogen, and protein C. This research provided specific data on apixaban&#8217;s impact on coagulation factors and hemostatic proteins in this pediatric patient group.</p>
<h4>Article 5: Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859897" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859897</a></p>
<p><strong>Summary:</strong> This study evaluated the real-world relationship between pulmonary vascular resistance and prognosis in Group two pulmonary hypertension, which is defined as pulmonary hypertension caused by left heart disease. Researchers analyzed data from 563 patients across two prospective Japanese multicenter registries, thus establishing specific patient cohorts for this analysis. The investigation assessed the efficacy of emerging therapies within this challenging condition, providing concrete data on therapeutic approaches for patients with left heart disease and pulmonary hypertension.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study. A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention&#8217;s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.</p>
<p>Article number two. Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study. This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.</p>
<p>Article number three. Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.</p>
<p>Article number four. Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy. The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease. An exploratory substudy assessed apixaban&#8217;s ex vivo effects on surrogate biomarkers of efficacy, including D-dimer, thrombin generation assay parameters, Factor eight, fibrinogen, and protein C. This research provided specific data on apixaban&#8217;s impact on coagulation factors and hemostatic proteins in this pediatric patient group.</p>
<p>Article number five. Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry. This study evaluated the real-world relationship between pulmonary vascular resistance and prognosis in Group two pulmonary hypertension, which is defined as pulmonary hypertension caused by left heart disease. Researchers analyzed data from 563 patients across two prospective Japanese multicenter registries, thus establishing specific patient cohorts for this analysis. The investigation assessed the efficacy of emerging therapies within this challenging condition, providing concrete data on therapeutic approaches for patients with left heart disease and pulmonary hypertension. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>coronary artery disease, Time-restricted eating, pediatric heart disease, clinical outcomes, Korean patients, prognosis, magnetic resonance imaging, pulmonary hypertension, Antiplatelet exposure, D-dimer, emerging therapies, Pulmonary vascular resistance, thromboprophylaxis, cerebral microbleeds, antithrombotic response, environmental exposure, left heart disease, Apixaban, cerebrovascular health, myocardial infarction, acute myocardial infarction, hemostatic biomarkers, innate immunity, Plasma metals, systemic inflammation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/">Apixaban Safe for Kids’ Heart Thromboprophylaxis 03/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260321_085202.mp3" length="4114224" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like coronary artery disease and Time-restricted eating. Key takeaway: Apixaban Safe for Kids&#8217; Heart Thromboprophylaxis.
Article Links:
Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study. (Journal of the American Heart Association)
Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study. (Journal of the American Heart Association)
Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. (Journal of the American Heart Association)
Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy. (Journal of the American Heart Association)
Article 5: Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/
 Featured Articles
Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859904
Summary: A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention&#8217;s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.
Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859900
Summary: This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.
Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859899
Summary: A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.
Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859898
Summary: The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like coronary artery disease and Time-restricted eating. Key takeaway: Apixaban Safe for Kids&#8217; Heart Thromboprophylaxis.
Article Links:
Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study. (Journal of the American Heart Association)
Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study. (Journal of the American Heart Association)
Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. (Journal of the American Heart Association)
Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy. (Journal of the American Heart Association)
Article 5]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ECG AI Predicts AF Recurrence Risk 03/21/26</title>
	<link>https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/</link>
	<pubDate>Sat, 21 Mar 2026 10:01:25 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like premature menopause and sodium-glucose cotransporter two inhibitors. Key takeaway: ECG AI Predicts AF Recurrence Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41848694">Premature Menopause and Lifetime Risk of Coronary Heart Disease.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41850785">Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41858299">Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41859834">Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41859908">Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/">https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Premature Menopause and Lifetime Risk of Coronary Heart Disease.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41848694" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41848694</a></p>
<p><strong>Summary:</strong> The study found that premature onset of menopause is associated with an increased short-term risk of coronary heart disease. Researchers calculated lifetime risk estimates of incident coronary heart disease and estimated years lived free of and with coronary heart disease. These estimates were stratified by premature menopause status and self-identified race across 163600 person-years of follow-up. The findings highlight the critical long-term cardiovascular implications of premature menopause across diverse populations.</p>
<h4>Article 2: Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41850785" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41850785</a></p>
<p><strong>Summary:</strong> Surgical aortic valve replacement improves survival in patients with severe, symptomatic aortic stenosis. This study evaluated the long-term relative survival of patients after surgical aortic valve replacement compared with the general population. Researchers identified specific predictors of any residual survival discrepancies among 1287 patients who received surgical aortic valve replacement for moderate or greater aortic stenosis. These findings provide clarity on life expectancy post-surgical aortic valve replacement and factors influencing it.</p>
<h4>Article 3: Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41858299" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41858299</a></p>
<p><strong>Summary:</strong> F. C.E.E.-B.A. Study). Sodium-glucose cotransporter two inhibitors are currently recommended as one of the four pillars of treatment in Heart Failure with Reduced Ejection Fraction. This study characterized the real-world patient population initiated on dapagliflozin for Heart Failure with Reduced Ejection Fraction in clinical practice. The data came from nine countries across Central Eastern Europe and the Baltic Area, providing crucial real-world insights following dapagliflozin&#8217;s 2020 approval. The findings offer valuable information on therapeutic adoption and patient profiles in diverse European regions.</p>
<h4>Article 4: Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859834" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859834</a></p>
<p><strong>Summary:</strong> F. pEF in older adults. This study evaluated the diagnostic performance of four supervised machine learning algorithms for identifying Heart Failure with Preserved Ejection Fraction in individuals aged 60 to 80 years. The study found that machine learning approaches improved diagnostic accuracy when compared to traditional Heart Failure with Preserved Ejection Fraction scores. This demonstrates the superior utility of advanced computational methods in diagnosing this challenging condition in older adult populations.</p>
<h4>Article 5: Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859908" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859908</a></p>
<p><strong>Summary:</strong> The study retrospectively analyzed patients with stressor-associated atrial fibrillation to predict recurrence and outcomes. It found that artificial intelligence-enabled models using the 12-lead electrocardiogram could accurately estimate the risk of recurrence. These models proved valuable in identifying individuals at highest risk for atrial fibrillation recurrence, which traditional clinical factors have shown limited utility in achieving. This represents a significant advancement in guiding management for patients with stressor-associated atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Premature Menopause and Lifetime Risk of Coronary Heart Disease. The study found that premature onset of menopause is associated with an increased short-term risk of coronary heart disease. Researchers calculated lifetime risk estimates of incident coronary heart disease and estimated years lived free of and with coronary heart disease. These estimates were stratified by premature menopause status and self-identified race across 163600 person-years of follow-up. The findings highlight the critical long-term cardiovascular implications of premature menopause across diverse populations.</p>
<p>Article number two. Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis. Surgical aortic valve replacement improves survival in patients with severe, symptomatic aortic stenosis. This study evaluated the long-term relative survival of patients after surgical aortic valve replacement compared with the general population. Researchers identified specific predictors of any residual survival discrepancies among 1287 patients who received surgical aortic valve replacement for moderate or greater aortic stenosis. These findings provide clarity on life expectancy post-surgical aortic valve replacement and factors influencing it.</p>
<p>Article number three. Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-H. F. C.E.E.-B.A. Study). Sodium-glucose cotransporter two inhibitors are currently recommended as one of the four pillars of treatment in Heart Failure with Reduced Ejection Fraction. This study characterized the real-world patient population initiated on dapagliflozin for Heart Failure with Reduced Ejection Fraction in clinical practice. The data came from nine countries across Central Eastern Europe and the Baltic Area, providing crucial real-world insights following dapagliflozin&#8217;s 2020 approval. The findings offer valuable information on therapeutic adoption and patient profiles in diverse European regions.</p>
<p>Article number four. Comparative diagnostic performance of machine learning models and traditional scores for H. F. pEF in older adults. This study evaluated the diagnostic performance of four supervised machine learning algorithms for identifying Heart Failure with Preserved Ejection Fraction in individuals aged 60 to 80 years. The study found that machine learning approaches improved diagnostic accuracy when compared to traditional Heart Failure with Preserved Ejection Fraction scores. This demonstrates the superior utility of advanced computational methods in diagnosing this challenging condition in older adult populations.</p>
<p>Article number five. Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using E.C.G.-Based Deep Learning. The study retrospectively analyzed patients with stressor-associated atrial fibrillation to predict recurrence and outcomes. It found that artificial intelligence-enabled models using the 12-lead electrocardiogram could accurately estimate the risk of recurrence. These models proved valuable in identifying individuals at highest risk for atrial fibrillation recurrence, which traditional clinical factors have shown limited utility in achieving. This represents a significant advancement in guiding management for patients with stressor-associated atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>premature menopause, sodium-glucose cotransporter two inhibitors, older adults, women&#8217;s health, survival predictors, deep learning, population cohort, real-world evidence, heart failure with preserved ejection fraction, treatment patterns, stressor-associated atrial fibrillation, lifetime risk, aortic stenosis, diagnostic scores, electrocardiogram, heart failure with reduced ejection fraction, diagnostic accuracy, life expectancy, coronary heart disease, relative survival, artificial intelligence, machine learning, atrial fibrillation recurrence, dapagliflozin, surgical aortic valve replacement.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/">ECG AI Predicts AF Recurrence Risk 03/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like premature menopause and sodium-glucose cotransporter two inhibitors. Key takeaway: ECG AI Predicts AF Recurrence Risk.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like premature menopause and sodium-glucose cotransporter two inhibitors. Key takeaway: ECG AI Predicts AF Recurrence Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41848694">Premature Menopause and Lifetime Risk of Coronary Heart Disease.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41850785">Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41858299">Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41859834">Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41859908">Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/">https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Premature Menopause and Lifetime Risk of Coronary Heart Disease.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41848694" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41848694</a></p>
<p><strong>Summary:</strong> The study found that premature onset of menopause is associated with an increased short-term risk of coronary heart disease. Researchers calculated lifetime risk estimates of incident coronary heart disease and estimated years lived free of and with coronary heart disease. These estimates were stratified by premature menopause status and self-identified race across 163600 person-years of follow-up. The findings highlight the critical long-term cardiovascular implications of premature menopause across diverse populations.</p>
<h4>Article 2: Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41850785" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41850785</a></p>
<p><strong>Summary:</strong> Surgical aortic valve replacement improves survival in patients with severe, symptomatic aortic stenosis. This study evaluated the long-term relative survival of patients after surgical aortic valve replacement compared with the general population. Researchers identified specific predictors of any residual survival discrepancies among 1287 patients who received surgical aortic valve replacement for moderate or greater aortic stenosis. These findings provide clarity on life expectancy post-surgical aortic valve replacement and factors influencing it.</p>
<h4>Article 3: Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41858299" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41858299</a></p>
<p><strong>Summary:</strong> F. C.E.E.-B.A. Study). Sodium-glucose cotransporter two inhibitors are currently recommended as one of the four pillars of treatment in Heart Failure with Reduced Ejection Fraction. This study characterized the real-world patient population initiated on dapagliflozin for Heart Failure with Reduced Ejection Fraction in clinical practice. The data came from nine countries across Central Eastern Europe and the Baltic Area, providing crucial real-world insights following dapagliflozin&#8217;s 2020 approval. The findings offer valuable information on therapeutic adoption and patient profiles in diverse European regions.</p>
<h4>Article 4: Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859834" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859834</a></p>
<p><strong>Summary:</strong> F. pEF in older adults. This study evaluated the diagnostic performance of four supervised machine learning algorithms for identifying Heart Failure with Preserved Ejection Fraction in individuals aged 60 to 80 years. The study found that machine learning approaches improved diagnostic accuracy when compared to traditional Heart Failure with Preserved Ejection Fraction scores. This demonstrates the superior utility of advanced computational methods in diagnosing this challenging condition in older adult populations.</p>
<h4>Article 5: Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41859908" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41859908</a></p>
<p><strong>Summary:</strong> The study retrospectively analyzed patients with stressor-associated atrial fibrillation to predict recurrence and outcomes. It found that artificial intelligence-enabled models using the 12-lead electrocardiogram could accurately estimate the risk of recurrence. These models proved valuable in identifying individuals at highest risk for atrial fibrillation recurrence, which traditional clinical factors have shown limited utility in achieving. This represents a significant advancement in guiding management for patients with stressor-associated atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Premature Menopause and Lifetime Risk of Coronary Heart Disease. The study found that premature onset of menopause is associated with an increased short-term risk of coronary heart disease. Researchers calculated lifetime risk estimates of incident coronary heart disease and estimated years lived free of and with coronary heart disease. These estimates were stratified by premature menopause status and self-identified race across 163600 person-years of follow-up. The findings highlight the critical long-term cardiovascular implications of premature menopause across diverse populations.</p>
<p>Article number two. Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis. Surgical aortic valve replacement improves survival in patients with severe, symptomatic aortic stenosis. This study evaluated the long-term relative survival of patients after surgical aortic valve replacement compared with the general population. Researchers identified specific predictors of any residual survival discrepancies among 1287 patients who received surgical aortic valve replacement for moderate or greater aortic stenosis. These findings provide clarity on life expectancy post-surgical aortic valve replacement and factors influencing it.</p>
<p>Article number three. Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-H. F. C.E.E.-B.A. Study). Sodium-glucose cotransporter two inhibitors are currently recommended as one of the four pillars of treatment in Heart Failure with Reduced Ejection Fraction. This study characterized the real-world patient population initiated on dapagliflozin for Heart Failure with Reduced Ejection Fraction in clinical practice. The data came from nine countries across Central Eastern Europe and the Baltic Area, providing crucial real-world insights following dapagliflozin&#8217;s 2020 approval. The findings offer valuable information on therapeutic adoption and patient profiles in diverse European regions.</p>
<p>Article number four. Comparative diagnostic performance of machine learning models and traditional scores for H. F. pEF in older adults. This study evaluated the diagnostic performance of four supervised machine learning algorithms for identifying Heart Failure with Preserved Ejection Fraction in individuals aged 60 to 80 years. The study found that machine learning approaches improved diagnostic accuracy when compared to traditional Heart Failure with Preserved Ejection Fraction scores. This demonstrates the superior utility of advanced computational methods in diagnosing this challenging condition in older adult populations.</p>
<p>Article number five. Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using E.C.G.-Based Deep Learning. The study retrospectively analyzed patients with stressor-associated atrial fibrillation to predict recurrence and outcomes. It found that artificial intelligence-enabled models using the 12-lead electrocardiogram could accurately estimate the risk of recurrence. These models proved valuable in identifying individuals at highest risk for atrial fibrillation recurrence, which traditional clinical factors have shown limited utility in achieving. This represents a significant advancement in guiding management for patients with stressor-associated atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>premature menopause, sodium-glucose cotransporter two inhibitors, older adults, women&#8217;s health, survival predictors, deep learning, population cohort, real-world evidence, heart failure with preserved ejection fraction, treatment patterns, stressor-associated atrial fibrillation, lifetime risk, aortic stenosis, diagnostic scores, electrocardiogram, heart failure with reduced ejection fraction, diagnostic accuracy, life expectancy, coronary heart disease, relative survival, artificial intelligence, machine learning, atrial fibrillation recurrence, dapagliflozin, surgical aortic valve replacement.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/">ECG AI Predicts AF Recurrence Risk 03/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260321_060022.mp3" length="3852163" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like premature menopause and sodium-glucose cotransporter two inhibitors. Key takeaway: ECG AI Predicts AF Recurrence Risk.
Article Links:
Article 1: Premature Menopause and Lifetime Risk of Coronary Heart Disease. (JAMA cardiology)
Article 2: Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis. (Heart (British Cardiac Society))
Article 3: Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study). (ESC heart failure)
Article 4: Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults. (European journal of heart failure)
Article 5: Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ecg-ai-predicts-af-recurrence-risk-03-21-26/
 Featured Articles
Article 1: Premature Menopause and Lifetime Risk of Coronary Heart Disease.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41848694
Summary: The study found that premature onset of menopause is associated with an increased short-term risk of coronary heart disease. Researchers calculated lifetime risk estimates of incident coronary heart disease and estimated years lived free of and with coronary heart disease. These estimates were stratified by premature menopause status and self-identified race across 163600 person-years of follow-up. The findings highlight the critical long-term cardiovascular implications of premature menopause across diverse populations.
Article 2: Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41850785
Summary: Surgical aortic valve replacement improves survival in patients with severe, symptomatic aortic stenosis. This study evaluated the long-term relative survival of patients after surgical aortic valve replacement compared with the general population. Researchers identified specific predictors of any residual survival discrepancies among 1287 patients who received surgical aortic valve replacement for moderate or greater aortic stenosis. These findings provide clarity on life expectancy post-surgical aortic valve replacement and factors influencing it.
Article 3: Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41858299
Summary: F. C.E.E.-B.A. Study). Sodium-glucose cotransporter two inhibitors are currently recommended as one of the four pillars of treatment in Heart Failure with Reduced Ejection Fraction. This study characterized the real-world patient population initiated on dapagliflozin for Heart Failure with Reduced Ejection Fraction in clinical practice. The data came from nine countries across Central Eastern Europe and the Baltic Area, providing crucial real-world insights following dapagliflozin&#8217;s 2020 approval. The findings offer valuable information on therapeutic adoption and patient profiles in diverse European regions.
Article 4: Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859834
Summary: F. pEF in older adults. This study evaluated the diagnostic performance of four supervised machine learning algorithms for identifying Heart Failure with Preserved Ejection Fraction in individuals aged 60 to 80 years. The study found that machin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like premature menopause and sodium-glucose cotransporter two inhibitors. Key takeaway: ECG AI Predicts AF Recurrence Risk.
Article Links:
Article 1: Premature Menopause and Lifetime Risk of Coronary Heart Disease. (JAMA cardiology)
Article 2: Life expectancy and determinants of relative survival following surgical aortic valve replacement for aortic stenosis. (Heart (British Cardiac Society))
Article 3: Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study). (ESC heart failure)
Article 4: Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults. (European journal of heart failure)
Article 5: Predicting Recurrence and Outcomes After Stressor-Associated Atrial Fibrillation Using ECG-Based Deep Learning. (Journal of]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Immunoassay Boosts Pediatric Transplant Safety 03/21/26</title>
	<link>https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/</link>
	<pubDate>Sat, 21 Mar 2026 07:59:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like immunosuppression and severe heart failure. Key takeaway: New Immunoassay Boosts Pediatric Transplant Safety.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41860521">African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41858107">Genetic counselling implementation in dilated cardiomyopathy.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41862040">&#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41862039">Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41862036">Advancing ABO-Histocompatibility: Impact of Multiplexed ABO Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/">https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41860521" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41860521</a></p>
<p><strong>Summary:</strong> Significant underrepresentation of African countries was observed in randomized controlled trials published in leading medical and cardiovascular journals. This disparity profoundly affects the generalizability of clinical evidence to a substantial portion of the global population with significant disease burden. Acknowledging this lack of representation is crucial for advancing equitable research practices and ensuring cardiovascular care benefits diverse patient groups.</p>
<h4>Article 2: Genetic counselling implementation in dilated cardiomyopathy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41858107" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41858107</a></p>
<p><strong>Summary:</strong> Genetic testing has become an integral component of the diagnostic process for patients with dilated cardiomyopathy. Its relevance has expanded significantly beyond identifying at-risk family members, now informing crucial clinical decision-making. The understanding of dilated cardiomyopathy&#8217;s genetic architecture demonstrates a shift from a monogenic dogma towards a broader polygenic spectrum.</p>
<h4>Article 3: &#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41862040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41862040</a></p>
<p><strong>Summary:</strong> A valid definition of severe heart failure with reduced ejection fraction is critical for timely patient identification and referral to advanced therapies. Such definitions are also essential for optimizing the design of clinical trials in this patient population. Real-world data from the Swedish Heart Failure Registry, encompassing over 15000 patients, underscores the importance of assessing the prevalence and prognostic performance of different severe and advanced heart failure definitions for precise patient management.</p>
<h4>Article 4: Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41862039" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41862039</a></p>
<p><strong>Summary:</strong> Pediatric heart transplant recipients face increased morbidity and mortality from vaccine-preventable infections due to long-term immunosuppression. While live vaccines have traditionally been contraindicated post-transplant, evolving clinical evidence supports their administration in selected solid organ recipients. This shift highlights a critical need to assess the safety and immunogenicity of specific live vaccines, like the varicella-zoster virus vaccine, in this vulnerable patient population.</p>
<h4>Article 5: Advancing ABO-Histocompatibility: Impact of Multiplexed ABO Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41862036" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41862036</a></p>
<p><strong>Summary:</strong> B. O.-Histocompatibility: Impact of Multiplexed A. B. O. Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation. Accurate measurement of A. B. O. antibodies is essential for safe A. B. O.-incompatible pediatric heart transplantation. A novel multiplexed immunoassay provides improved precision compared to traditional hemagglutination titers. This immunoassay accurately measures I. G. G. and I. G. M. antibodies specific to A. B. O. glycan subtypes expressed in donor cardiac tissue, directly addressing limitations of older methods that detect irrelevant antibodies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024. Significant underrepresentation of African countries was observed in randomized controlled trials published in leading medical and cardiovascular journals. This disparity profoundly affects the generalizability of clinical evidence to a substantial portion of the global population with significant disease burden. Acknowledging this lack of representation is crucial for advancing equitable research practices and ensuring cardiovascular care benefits diverse patient groups.</p>
<p>Article number two. Genetic counselling implementation in dilated cardiomyopathy. Genetic testing has become an integral component of the diagnostic process for patients with dilated cardiomyopathy. Its relevance has expanded significantly beyond identifying at-risk family members, now informing crucial clinical decision-making. The understanding of dilated cardiomyopathy&#8217;s genetic architecture demonstrates a shift from a monogenic dogma towards a broader polygenic spectrum.</p>
<p>Article number three. Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry. A valid definition of severe heart failure with reduced ejection fraction is critical for timely patient identification and referral to advanced therapies. Such definitions are also essential for optimizing the design of clinical trials in this patient population. Real-world data from the Swedish Heart Failure Registry, encompassing over 15000 patients, underscores the importance of assessing the prevalence and prognostic performance of different severe and advanced heart failure definitions for precise patient management.</p>
<p>Article number four. Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients. Pediatric heart transplant recipients face increased morbidity and mortality from vaccine-preventable infections due to long-term immunosuppression. While live vaccines have traditionally been contraindicated post-transplant, evolving clinical evidence supports their administration in selected solid organ recipients. This shift highlights a critical need to assess the safety and immunogenicity of specific live vaccines, like the varicella-zoster virus vaccine, in this vulnerable patient population.</p>
<p>Article number five. Advancing A. B. O.-Histocompatibility: Impact of Multiplexed A. B. O. Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation. Accurate measurement of A. B. O. antibodies is essential for safe A. B. O.-incompatible pediatric heart transplantation. A novel multiplexed immunoassay provides improved precision compared to traditional hemagglutination titers. This immunoassay accurately measures I. G. G. and I. G. M. antibodies specific to A. B. O. glycan subtypes expressed in donor cardiac tissue, directly addressing limitations of older methods that detect irrelevant antibodies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>immunosuppression, severe heart failure, histocompatibility, varicella-zoster vaccination, research disparities, polygenic spectrum, dilated cardiomyopathy, A. B. O. incompatible transplantation, pediatric heart transplantation, genetic counseling, African representation, prognostic performance, immunogenicity, heart failure with reduced ejection fraction, A. B. O. antibodies, live vaccines, cardiovascular research, pediatric heart transplant, multiplexed immunoassay, health equity, genetic testing, advanced heart failure, randomized controlled trials, clinical decision-making, Swedish Heart Failure Registry.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/">New Immunoassay Boosts Pediatric Transplant Safety 03/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like immunosuppression and severe heart failure. Key takeaway: New Immunoassay Boosts Pediatric Transplant Safety.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like immunosuppression and severe heart failure. Key takeaway: New Immunoassay Boosts Pediatric Transplant Safety.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41860521">African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41858107">Genetic counselling implementation in dilated cardiomyopathy.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41862040">&#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41862039">Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41862036">Advancing ABO-Histocompatibility: Impact of Multiplexed ABO Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/">https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41860521" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41860521</a></p>
<p><strong>Summary:</strong> Significant underrepresentation of African countries was observed in randomized controlled trials published in leading medical and cardiovascular journals. This disparity profoundly affects the generalizability of clinical evidence to a substantial portion of the global population with significant disease burden. Acknowledging this lack of representation is crucial for advancing equitable research practices and ensuring cardiovascular care benefits diverse patient groups.</p>
<h4>Article 2: Genetic counselling implementation in dilated cardiomyopathy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41858107" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41858107</a></p>
<p><strong>Summary:</strong> Genetic testing has become an integral component of the diagnostic process for patients with dilated cardiomyopathy. Its relevance has expanded significantly beyond identifying at-risk family members, now informing crucial clinical decision-making. The understanding of dilated cardiomyopathy&#8217;s genetic architecture demonstrates a shift from a monogenic dogma towards a broader polygenic spectrum.</p>
<h4>Article 3: &#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41862040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41862040</a></p>
<p><strong>Summary:</strong> A valid definition of severe heart failure with reduced ejection fraction is critical for timely patient identification and referral to advanced therapies. Such definitions are also essential for optimizing the design of clinical trials in this patient population. Real-world data from the Swedish Heart Failure Registry, encompassing over 15000 patients, underscores the importance of assessing the prevalence and prognostic performance of different severe and advanced heart failure definitions for precise patient management.</p>
<h4>Article 4: Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41862039" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41862039</a></p>
<p><strong>Summary:</strong> Pediatric heart transplant recipients face increased morbidity and mortality from vaccine-preventable infections due to long-term immunosuppression. While live vaccines have traditionally been contraindicated post-transplant, evolving clinical evidence supports their administration in selected solid organ recipients. This shift highlights a critical need to assess the safety and immunogenicity of specific live vaccines, like the varicella-zoster virus vaccine, in this vulnerable patient population.</p>
<h4>Article 5: Advancing ABO-Histocompatibility: Impact of Multiplexed ABO Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41862036" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41862036</a></p>
<p><strong>Summary:</strong> B. O.-Histocompatibility: Impact of Multiplexed A. B. O. Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation. Accurate measurement of A. B. O. antibodies is essential for safe A. B. O.-incompatible pediatric heart transplantation. A novel multiplexed immunoassay provides improved precision compared to traditional hemagglutination titers. This immunoassay accurately measures I. G. G. and I. G. M. antibodies specific to A. B. O. glycan subtypes expressed in donor cardiac tissue, directly addressing limitations of older methods that detect irrelevant antibodies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024. Significant underrepresentation of African countries was observed in randomized controlled trials published in leading medical and cardiovascular journals. This disparity profoundly affects the generalizability of clinical evidence to a substantial portion of the global population with significant disease burden. Acknowledging this lack of representation is crucial for advancing equitable research practices and ensuring cardiovascular care benefits diverse patient groups.</p>
<p>Article number two. Genetic counselling implementation in dilated cardiomyopathy. Genetic testing has become an integral component of the diagnostic process for patients with dilated cardiomyopathy. Its relevance has expanded significantly beyond identifying at-risk family members, now informing crucial clinical decision-making. The understanding of dilated cardiomyopathy&#8217;s genetic architecture demonstrates a shift from a monogenic dogma towards a broader polygenic spectrum.</p>
<p>Article number three. Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry. A valid definition of severe heart failure with reduced ejection fraction is critical for timely patient identification and referral to advanced therapies. Such definitions are also essential for optimizing the design of clinical trials in this patient population. Real-world data from the Swedish Heart Failure Registry, encompassing over 15000 patients, underscores the importance of assessing the prevalence and prognostic performance of different severe and advanced heart failure definitions for precise patient management.</p>
<p>Article number four. Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients. Pediatric heart transplant recipients face increased morbidity and mortality from vaccine-preventable infections due to long-term immunosuppression. While live vaccines have traditionally been contraindicated post-transplant, evolving clinical evidence supports their administration in selected solid organ recipients. This shift highlights a critical need to assess the safety and immunogenicity of specific live vaccines, like the varicella-zoster virus vaccine, in this vulnerable patient population.</p>
<p>Article number five. Advancing A. B. O.-Histocompatibility: Impact of Multiplexed A. B. O. Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation. Accurate measurement of A. B. O. antibodies is essential for safe A. B. O.-incompatible pediatric heart transplantation. A novel multiplexed immunoassay provides improved precision compared to traditional hemagglutination titers. This immunoassay accurately measures I. G. G. and I. G. M. antibodies specific to A. B. O. glycan subtypes expressed in donor cardiac tissue, directly addressing limitations of older methods that detect irrelevant antibodies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>immunosuppression, severe heart failure, histocompatibility, varicella-zoster vaccination, research disparities, polygenic spectrum, dilated cardiomyopathy, A. B. O. incompatible transplantation, pediatric heart transplantation, genetic counseling, African representation, prognostic performance, immunogenicity, heart failure with reduced ejection fraction, A. B. O. antibodies, live vaccines, cardiovascular research, pediatric heart transplant, multiplexed immunoassay, health equity, genetic testing, advanced heart failure, randomized controlled trials, clinical decision-making, Swedish Heart Failure Registry.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/">New Immunoassay Boosts Pediatric Transplant Safety 03/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260321_035845.mp3" length="3531589" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like immunosuppression and severe heart failure. Key takeaway: New Immunoassay Boosts Pediatric Transplant Safety.
Article Links:
Article 1: African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024. (Journal of the American College of Cardiology)
Article 2: Genetic counselling implementation in dilated cardiomyopathy. (European heart journal)
Article 3: &#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Advancing ABO-Histocompatibility: Impact of Multiplexed ABO Antibody Immunoassay to Increase Precision in Pediatric Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/new-immunoassay-boosts-pediatric-transplant-safety-03-21-26/
 Featured Articles
Article 1: African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41860521
Summary: Significant underrepresentation of African countries was observed in randomized controlled trials published in leading medical and cardiovascular journals. This disparity profoundly affects the generalizability of clinical evidence to a substantial portion of the global population with significant disease burden. Acknowledging this lack of representation is crucial for advancing equitable research practices and ensuring cardiovascular care benefits diverse patient groups.
Article 2: Genetic counselling implementation in dilated cardiomyopathy.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41858107
Summary: Genetic testing has become an integral component of the diagnostic process for patients with dilated cardiomyopathy. Its relevance has expanded significantly beyond identifying at-risk family members, now informing crucial clinical decision-making. The understanding of dilated cardiomyopathy&#8217;s genetic architecture demonstrates a shift from a monogenic dogma towards a broader polygenic spectrum.
Article 3: &#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41862040
Summary: A valid definition of severe heart failure with reduced ejection fraction is critical for timely patient identification and referral to advanced therapies. Such definitions are also essential for optimizing the design of clinical trials in this patient population. Real-world data from the Swedish Heart Failure Registry, encompassing over 15000 patients, underscores the importance of assessing the prevalence and prognostic performance of different severe and advanced heart failure definitions for precise patient management.
Article 4: Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41862039
Summary: Pediatric h]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like immunosuppression and severe heart failure. Key takeaway: New Immunoassay Boosts Pediatric Transplant Safety.
Article Links:
Article 1: African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024. (Journal of the American College of Cardiology)
Article 2: Genetic counselling implementation in dilated cardiomyopathy. (European heart journal)
Article 3: &#8220;Real-world prognostic performance of different severe and advanced heart failure definitions: data from the Swedish Heart Failure Registry&#8221;. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Safety and Immunogenicity of Varicella-Zoster Vaccination in Pediatric Heart Transplant Recipients. (The Journal of heart and lung transplantation : the official public]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Medical Urgency Drives 40.6% Lung Transplant Priority. 03/20/26</title>
	<link>https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/</link>
	<pubDate>Fri, 20 Mar 2026 10:01:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 20, 2026. This episode summarizes 5 key cardiology studies on topics like Waitlist outcomes and Chagas cardiomyopathy. Key takeaway: Medical Urgency Drives 40.6% Lung Transplant Priority..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41396086">Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41853846">Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41856261">Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41856260">Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41856259">Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/">https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41396086" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41396086</a></p>
<p><strong>Summary:</strong> The A. N. S. W. E. R. minus H. F. trial investigated the efficacy of sacubitril-valsartan compared to enalapril in patients with Chagas cardiomyopathy and heart failure with reduced ejection fraction. This study specifically evaluated effects on cardiac remodeling, functional outcomes, biomarkers, and safety. The trial addressed a critical knowledge gap regarding treatment for a common cause of heart failure with reduced ejection fraction in Latin America.</p>
<h4>Article 2: Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41853846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41853846</a></p>
<p><strong>Summary:</strong> A phase two randomized clinical trial investigated memantine as a novel pharmacological therapy for premature atrial contractions. Preclinical studies previously found that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppressed atrial arrhythmias. This current trial leveraged the identified functional cardiac glutamatergic system to assess a new approach for suppressing premature atrial contractions.</p>
<h4>Article 3: Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41856261" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41856261</a></p>
<p><strong>Summary:</strong> Lung Composite Allocation Score Components on Transplant Candidate Prioritization. An analysis of the U. S. Composite Allocation Score system for lung transplant prioritization found that medical urgency was responsible for 40.6 percent of the variation in total scores. This occurred despite medical urgency constituting only 25 of the 100 possible Composite Allocation Score points. The study quantified each component&#8217;s contribution to total Composite Allocation Score variability following the system&#8217;s implementation in March 2023.</p>
<h4>Article 4: Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41856260" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41856260</a></p>
<p><strong>Summary:</strong> Oral tacrolimus, a critical immunosuppressant after lung transplantation, is associated with significant renal impairment. Tacrolimus Inhalation Powder represents a therapeutic strategy designed to deliver the drug locally, potentially preventing graft rejection with lower systemic drug levels. This approach was investigated in adult lung transplant recipients with existing renal impairment to address the problem of tacrolimus-induced nephrotoxicity.</p>
<h4>Article 5: Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41856259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41856259</a></p>
<p><strong>Summary:</strong> A nationwide registry analysis of pediatric lung transplantation in Japan revealed the impact of legislative and allocation reforms on waitlist and post-transplant outcomes. This study analyzed data from 1998 to 2024, demonstrating how outcomes changed across three eras defined by the 2010 legislative revision and 2020 pediatric priority rules. The analysis provided critical insights into the real-world effects of policy adjustments on this life-saving procedure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. The A. N. S. W. E. R. minus H. F. trial investigated the efficacy of sacubitril-valsartan compared to enalapril in patients with Chagas cardiomyopathy and heart failure with reduced ejection fraction. This study specifically evaluated effects on cardiac remodeling, functional outcomes, biomarkers, and safety. The trial addressed a critical knowledge gap regarding treatment for a common cause of heart failure with reduced ejection fraction in Latin America.</p>
<p>Article number two. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. A phase two randomized clinical trial investigated memantine as a novel pharmacological therapy for premature atrial contractions. Preclinical studies previously found that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppressed atrial arrhythmias. This current trial leveraged the identified functional cardiac glutamatergic system to assess a new approach for suppressing premature atrial contractions.</p>
<p>Article number three. Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization. An analysis of the U. S. Composite Allocation Score system for lung transplant prioritization found that medical urgency was responsible for 40.6 percent of the variation in total scores. This occurred despite medical urgency constituting only 25 of the 100 possible Composite Allocation Score points. The study quantified each component&#8217;s contribution to total Composite Allocation Score variability following the system&#8217;s implementation in March 2023.</p>
<p>Article number four. Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment. Oral tacrolimus, a critical immunosuppressant after lung transplantation, is associated with significant renal impairment. Tacrolimus Inhalation Powder represents a therapeutic strategy designed to deliver the drug locally, potentially preventing graft rejection with lower systemic drug levels. This approach was investigated in adult lung transplant recipients with existing renal impairment to address the problem of tacrolimus-induced nephrotoxicity.</p>
<p>Article number five. Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes. A nationwide registry analysis of pediatric lung transplantation in Japan revealed the impact of legislative and allocation reforms on waitlist and post-transplant outcomes. This study analyzed data from 1998 to 2024, demonstrating how outcomes changed across three eras defined by the 2010 legislative revision and 2020 pediatric priority rules. The analysis provided critical insights into the real-world effects of policy adjustments on this life-saving procedure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Waitlist outcomes, Chagas cardiomyopathy, Medical urgency, Memantine, Heart failure with reduced ejection fraction, Atrial electrophysiology, Premature atrial contractions, Allocation rules, Sacubitril-valsartan, Renal impairment, Legislative reform, Transplant prioritization, Atrial arrhythmias, Enalapril, Scientific Registry of Transplant Recipients, Cardiac remodeling, Immunosuppression, Tacrolimus, Tacrolimus Inhalation Powder, Japan, Lung transplantation, N-methyl-D-aspartate receptors, Pediatric lung transplantation, Composite Allocation Score.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/">Medical Urgency Drives 40.6% Lung Transplant Priority. 03/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 20, 2026. This episode summarizes 5 key cardiology studies on topics like Waitlist outcomes and Chagas cardiomyopathy. Key takeaway: Medical Urgency Drives 40.6% Lung Transplant Priority..
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 20, 2026. This episode summarizes 5 key cardiology studies on topics like Waitlist outcomes and Chagas cardiomyopathy. Key takeaway: Medical Urgency Drives 40.6% Lung Transplant Priority..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41396086">Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41853846">Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41856261">Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41856260">Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41856259">Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/">https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41396086" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41396086</a></p>
<p><strong>Summary:</strong> The A. N. S. W. E. R. minus H. F. trial investigated the efficacy of sacubitril-valsartan compared to enalapril in patients with Chagas cardiomyopathy and heart failure with reduced ejection fraction. This study specifically evaluated effects on cardiac remodeling, functional outcomes, biomarkers, and safety. The trial addressed a critical knowledge gap regarding treatment for a common cause of heart failure with reduced ejection fraction in Latin America.</p>
<h4>Article 2: Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41853846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41853846</a></p>
<p><strong>Summary:</strong> A phase two randomized clinical trial investigated memantine as a novel pharmacological therapy for premature atrial contractions. Preclinical studies previously found that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppressed atrial arrhythmias. This current trial leveraged the identified functional cardiac glutamatergic system to assess a new approach for suppressing premature atrial contractions.</p>
<h4>Article 3: Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41856261" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41856261</a></p>
<p><strong>Summary:</strong> Lung Composite Allocation Score Components on Transplant Candidate Prioritization. An analysis of the U. S. Composite Allocation Score system for lung transplant prioritization found that medical urgency was responsible for 40.6 percent of the variation in total scores. This occurred despite medical urgency constituting only 25 of the 100 possible Composite Allocation Score points. The study quantified each component&#8217;s contribution to total Composite Allocation Score variability following the system&#8217;s implementation in March 2023.</p>
<h4>Article 4: Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41856260" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41856260</a></p>
<p><strong>Summary:</strong> Oral tacrolimus, a critical immunosuppressant after lung transplantation, is associated with significant renal impairment. Tacrolimus Inhalation Powder represents a therapeutic strategy designed to deliver the drug locally, potentially preventing graft rejection with lower systemic drug levels. This approach was investigated in adult lung transplant recipients with existing renal impairment to address the problem of tacrolimus-induced nephrotoxicity.</p>
<h4>Article 5: Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41856259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41856259</a></p>
<p><strong>Summary:</strong> A nationwide registry analysis of pediatric lung transplantation in Japan revealed the impact of legislative and allocation reforms on waitlist and post-transplant outcomes. This study analyzed data from 1998 to 2024, demonstrating how outcomes changed across three eras defined by the 2010 legislative revision and 2020 pediatric priority rules. The analysis provided critical insights into the real-world effects of policy adjustments on this life-saving procedure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. The A. N. S. W. E. R. minus H. F. trial investigated the efficacy of sacubitril-valsartan compared to enalapril in patients with Chagas cardiomyopathy and heart failure with reduced ejection fraction. This study specifically evaluated effects on cardiac remodeling, functional outcomes, biomarkers, and safety. The trial addressed a critical knowledge gap regarding treatment for a common cause of heart failure with reduced ejection fraction in Latin America.</p>
<p>Article number two. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. A phase two randomized clinical trial investigated memantine as a novel pharmacological therapy for premature atrial contractions. Preclinical studies previously found that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppressed atrial arrhythmias. This current trial leveraged the identified functional cardiac glutamatergic system to assess a new approach for suppressing premature atrial contractions.</p>
<p>Article number three. Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization. An analysis of the U. S. Composite Allocation Score system for lung transplant prioritization found that medical urgency was responsible for 40.6 percent of the variation in total scores. This occurred despite medical urgency constituting only 25 of the 100 possible Composite Allocation Score points. The study quantified each component&#8217;s contribution to total Composite Allocation Score variability following the system&#8217;s implementation in March 2023.</p>
<p>Article number four. Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment. Oral tacrolimus, a critical immunosuppressant after lung transplantation, is associated with significant renal impairment. Tacrolimus Inhalation Powder represents a therapeutic strategy designed to deliver the drug locally, potentially preventing graft rejection with lower systemic drug levels. This approach was investigated in adult lung transplant recipients with existing renal impairment to address the problem of tacrolimus-induced nephrotoxicity.</p>
<p>Article number five. Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes. A nationwide registry analysis of pediatric lung transplantation in Japan revealed the impact of legislative and allocation reforms on waitlist and post-transplant outcomes. This study analyzed data from 1998 to 2024, demonstrating how outcomes changed across three eras defined by the 2010 legislative revision and 2020 pediatric priority rules. The analysis provided critical insights into the real-world effects of policy adjustments on this life-saving procedure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Waitlist outcomes, Chagas cardiomyopathy, Medical urgency, Memantine, Heart failure with reduced ejection fraction, Atrial electrophysiology, Premature atrial contractions, Allocation rules, Sacubitril-valsartan, Renal impairment, Legislative reform, Transplant prioritization, Atrial arrhythmias, Enalapril, Scientific Registry of Transplant Recipients, Cardiac remodeling, Immunosuppression, Tacrolimus, Tacrolimus Inhalation Powder, Japan, Lung transplantation, N-methyl-D-aspartate receptors, Pediatric lung transplantation, Composite Allocation Score.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/">Medical Urgency Drives 40.6% Lung Transplant Priority. 03/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260320_060030.mp3" length="3554576" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 20, 2026. This episode summarizes 5 key cardiology studies on topics like Waitlist outcomes and Chagas cardiomyopathy. Key takeaway: Medical Urgency Drives 40.6% Lung Transplant Priority..
Article Links:
Article 1: Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. (Journal of the American College of Cardiology)
Article 2: Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. (Circulation)
Article 3: Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Pediatric lung transplantation in Japan across legislative and allocation reforms: a nationwide registry analysis of waitlist and post-transplant outcomes. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/medical-urgency-drives-40-6-lung-transplant-priority-03-20-26/
 Featured Articles
Article 1: Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41396086
Summary: The A. N. S. W. E. R. minus H. F. trial investigated the efficacy of sacubitril-valsartan compared to enalapril in patients with Chagas cardiomyopathy and heart failure with reduced ejection fraction. This study specifically evaluated effects on cardiac remodeling, functional outcomes, biomarkers, and safety. The trial addressed a critical knowledge gap regarding treatment for a common cause of heart failure with reduced ejection fraction in Latin America.
Article 2: Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41853846
Summary: A phase two randomized clinical trial investigated memantine as a novel pharmacological therapy for premature atrial contractions. Preclinical studies previously found that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppressed atrial arrhythmias. This current trial leveraged the identified functional cardiac glutamatergic system to assess a new approach for suppressing premature atrial contractions.
Article 3: Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41856261
Summary: Lung Composite Allocation Score Components on Transplant Candidate Prioritization. An analysis of the U. S. Composite Allocation Score system for lung transplant prioritization found that medical urgency was responsible for 40.6 percent of the variation in total scores. This occurred despite medical urgency constituting only 25 of the 100 possible Composite Allocation Score points. The study quantified each component&#8217;s contribution to total Composite Allocation Score variability following the system&#8217;s implementation in March 2023.
Article 4: Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment.
Journal: The Journal of heart and lung transpla]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 20, 2026. This episode summarizes 5 key cardiology studies on topics like Waitlist outcomes and Chagas cardiomyopathy. Key takeaway: Medical Urgency Drives 40.6% Lung Transplant Priority..
Article Links:
Article 1: Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. (Journal of the American College of Cardiology)
Article 2: Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. (Circulation)
Article 3: Influence of U.S. Lung Composite Allocation Score Components on Transplant Candidate Prioritization. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment. (The Journa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Echo Criteria Tested for H. F. pEF 03/19/26</title>
	<link>https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/</link>
	<pubDate>Thu, 19 Mar 2026 10:01:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 19, 2026. This episode summarizes 5 key cardiology studies on topics like functional mitral regurgitation and quality of care. Key takeaway: New Echo Criteria Tested for H. F. pEF.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41849741">Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41848471">Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41848357">Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41706057">Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532943">Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/">https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41849741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41849741</a></p>
<p><strong>Summary:</strong> The clinical question concerns the effectiveness of catheter-based Left Atrial Appendage Closure as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation patients. This study investigated its efficacy compared to physician-directed best medical care in those at high risk for both stroke and bleeding. A multicenter randomized trial in Germany examined this critical comparison. The research addresses the optimal therapeutic strategy for this complex patient population.</p>
<h4>Article 2: Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41848471" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41848471</a></p>
<p><strong>Summary:</strong> This article highlights Atrial functional Mitral Regurgitation (AfMR) as a distinct and clinically significant form of functional mitral regurgitation. It found that disparate published definitions create significant uncertainty regarding its prevalence, specific morphology, and associated mortality. This definitional inconsistency was shown to impede consistent clinical decision making and patient classification. The analysis underscores the critical need for a unified and broadly applicable definition to improve management.</p>
<h4>Article 3: Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41848357" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41848357</a></p>
<p><strong>Summary:</strong> Reports indicated poorer cardiovascular outcomes among ethnic minorities, especially during the COVID-19 pandemic. This analysis investigated the relationship between ethnicity, quality of care after heart failure hospitalization, and long-term outcomes in England. The study utilized routinely collected national audit data to examine these disparities within a universal health system. It focused on understanding how ethnicity influences care quality and subsequent long-term outcomes for patients hospitalized with acute heart failure.</p>
<h4>Article 4: Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706057" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706057</a></p>
<p><strong>Summary:</strong> The genetic substrate of atrial fibrillation (A. F.) is heritable and complex. This study explored the impact of disease-causing cardiomyopathy variants on the risk of A. F., even after accounting for incident ventricular cardiomyopathy and clinical heart failure. Researchers evaluated the utility of polygenic risk scores (P. R. S.) to further differentiate between atrial and ventricular phenotypes in gene variant carriers. The findings provided evidence supporting an &#8220;atrial-first phenotype&#8221; in the context of cardiomyopathy gene variants and A. F. risk.</p>
<h4>Article 5: Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532943</a></p>
<p><strong>Summary:</strong> F. pEF: Testing the Updated 2025 A. S. E. Criteria. The American Society of Echocardiography (A. S. E.) recently proposed an updated 2025 algorithm for echocardiographic grading of left ventricular diastolic function. This study systematically evaluated the new A. S. E. algorithm specifically in patients with invasively confirmed ambulatory Heart Failure with Preserved Ejection Fraction (H. F. pEF). The investigation determined the false-negative rate of this algorithm within this patient population. It assessed the diagnostic accuracy of the updated criteria for grading diastolic dysfunction in H. F. pEF.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. The clinical question concerns the effectiveness of catheter-based Left Atrial Appendage Closure as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation patients. This study investigated its efficacy compared to physician-directed best medical care in those at high risk for both stroke and bleeding. A multicenter randomized trial in Germany examined this critical comparison. The research addresses the optimal therapeutic strategy for this complex patient population.</p>
<p>Article number two. Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis. This article highlights Atrial functional Mitral Regurgitation (AfMR) as a distinct and clinically significant form of functional mitral regurgitation. It found that disparate published definitions create significant uncertainty regarding its prevalence, specific morphology, and associated mortality. This definitional inconsistency was shown to impede consistent clinical decision making and patient classification. The analysis underscores the critical need for a unified and broadly applicable definition to improve management.</p>
<p>Article number three. Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System. Reports indicated poorer cardiovascular outcomes among ethnic minorities, especially during the COVID-19 pandemic. This analysis investigated the relationship between ethnicity, quality of care after heart failure hospitalization, and long-term outcomes in England. The study utilized routinely collected national audit data to examine these disparities within a universal health system. It focused on understanding how ethnicity influences care quality and subsequent long-term outcomes for patients hospitalized with acute heart failure.</p>
<p>Article number four. Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype. The genetic substrate of atrial fibrillation (A. F.) is heritable and complex. This study explored the impact of disease-causing cardiomyopathy variants on the risk of A. F., even after accounting for incident ventricular cardiomyopathy and clinical heart failure. Researchers evaluated the utility of polygenic risk scores (P. R. S.) to further differentiate between atrial and ventricular phenotypes in gene variant carriers. The findings provided evidence supporting an &#8220;atrial-first phenotype&#8221; in the context of cardiomyopathy gene variants and A. F. risk.</p>
<p>Article number five. Echocardiographic Diastolic Function Grading in H. F. pEF: Testing the Updated 2025 A. S. E. Criteria. The American Society of Echocardiography (A. S. E.) recently proposed an updated 2025 algorithm for echocardiographic grading of left ventricular diastolic function. This study systematically evaluated the new A. S. E. algorithm specifically in patients with invasively confirmed ambulatory Heart Failure with Preserved Ejection Fraction (H. F. pEF). The investigation determined the false-negative rate of this algorithm within this patient population. It assessed the diagnostic accuracy of the updated criteria for grading diastolic dysfunction in H. F. pEF. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>functional mitral regurgitation, quality of care, diastolic function, disease classification, A. S. E. criteria, Cardiomyopathy gene variants, echocardiography, heart failure with preserved ejection fraction, atrial fibrillation, bleeding risk, health disparities, Ethnicity, oral anticoagulation, Atrial functional mitral regurgitation, Echocardiography, heart failure outcomes, genetic risk, left ventricular diastolic dysfunction, mitral valve disease, atrial-first phenotype, Left Atrial Appendage Closure, polygenic risk scores, universal health system, stroke prevention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/">New Echo Criteria Tested for H. F. pEF 03/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 19, 2026. This episode summarizes 5 key cardiology studies on topics like functional mitral regurgitation and quality of care. Key takeaway: New Echo Criteria Tested for H. F. pEF.
Article Links:
Article 1: Le]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 19, 2026. This episode summarizes 5 key cardiology studies on topics like functional mitral regurgitation and quality of care. Key takeaway: New Echo Criteria Tested for H. F. pEF.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41849741">Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41848471">Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41848357">Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41706057">Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532943">Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/">https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41849741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41849741</a></p>
<p><strong>Summary:</strong> The clinical question concerns the effectiveness of catheter-based Left Atrial Appendage Closure as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation patients. This study investigated its efficacy compared to physician-directed best medical care in those at high risk for both stroke and bleeding. A multicenter randomized trial in Germany examined this critical comparison. The research addresses the optimal therapeutic strategy for this complex patient population.</p>
<h4>Article 2: Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41848471" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41848471</a></p>
<p><strong>Summary:</strong> This article highlights Atrial functional Mitral Regurgitation (AfMR) as a distinct and clinically significant form of functional mitral regurgitation. It found that disparate published definitions create significant uncertainty regarding its prevalence, specific morphology, and associated mortality. This definitional inconsistency was shown to impede consistent clinical decision making and patient classification. The analysis underscores the critical need for a unified and broadly applicable definition to improve management.</p>
<h4>Article 3: Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41848357" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41848357</a></p>
<p><strong>Summary:</strong> Reports indicated poorer cardiovascular outcomes among ethnic minorities, especially during the COVID-19 pandemic. This analysis investigated the relationship between ethnicity, quality of care after heart failure hospitalization, and long-term outcomes in England. The study utilized routinely collected national audit data to examine these disparities within a universal health system. It focused on understanding how ethnicity influences care quality and subsequent long-term outcomes for patients hospitalized with acute heart failure.</p>
<h4>Article 4: Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706057" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706057</a></p>
<p><strong>Summary:</strong> The genetic substrate of atrial fibrillation (A. F.) is heritable and complex. This study explored the impact of disease-causing cardiomyopathy variants on the risk of A. F., even after accounting for incident ventricular cardiomyopathy and clinical heart failure. Researchers evaluated the utility of polygenic risk scores (P. R. S.) to further differentiate between atrial and ventricular phenotypes in gene variant carriers. The findings provided evidence supporting an &#8220;atrial-first phenotype&#8221; in the context of cardiomyopathy gene variants and A. F. risk.</p>
<h4>Article 5: Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532943</a></p>
<p><strong>Summary:</strong> F. pEF: Testing the Updated 2025 A. S. E. Criteria. The American Society of Echocardiography (A. S. E.) recently proposed an updated 2025 algorithm for echocardiographic grading of left ventricular diastolic function. This study systematically evaluated the new A. S. E. algorithm specifically in patients with invasively confirmed ambulatory Heart Failure with Preserved Ejection Fraction (H. F. pEF). The investigation determined the false-negative rate of this algorithm within this patient population. It assessed the diagnostic accuracy of the updated criteria for grading diastolic dysfunction in H. F. pEF.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. The clinical question concerns the effectiveness of catheter-based Left Atrial Appendage Closure as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation patients. This study investigated its efficacy compared to physician-directed best medical care in those at high risk for both stroke and bleeding. A multicenter randomized trial in Germany examined this critical comparison. The research addresses the optimal therapeutic strategy for this complex patient population.</p>
<p>Article number two. Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis. This article highlights Atrial functional Mitral Regurgitation (AfMR) as a distinct and clinically significant form of functional mitral regurgitation. It found that disparate published definitions create significant uncertainty regarding its prevalence, specific morphology, and associated mortality. This definitional inconsistency was shown to impede consistent clinical decision making and patient classification. The analysis underscores the critical need for a unified and broadly applicable definition to improve management.</p>
<p>Article number three. Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System. Reports indicated poorer cardiovascular outcomes among ethnic minorities, especially during the COVID-19 pandemic. This analysis investigated the relationship between ethnicity, quality of care after heart failure hospitalization, and long-term outcomes in England. The study utilized routinely collected national audit data to examine these disparities within a universal health system. It focused on understanding how ethnicity influences care quality and subsequent long-term outcomes for patients hospitalized with acute heart failure.</p>
<p>Article number four. Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype. The genetic substrate of atrial fibrillation (A. F.) is heritable and complex. This study explored the impact of disease-causing cardiomyopathy variants on the risk of A. F., even after accounting for incident ventricular cardiomyopathy and clinical heart failure. Researchers evaluated the utility of polygenic risk scores (P. R. S.) to further differentiate between atrial and ventricular phenotypes in gene variant carriers. The findings provided evidence supporting an &#8220;atrial-first phenotype&#8221; in the context of cardiomyopathy gene variants and A. F. risk.</p>
<p>Article number five. Echocardiographic Diastolic Function Grading in H. F. pEF: Testing the Updated 2025 A. S. E. Criteria. The American Society of Echocardiography (A. S. E.) recently proposed an updated 2025 algorithm for echocardiographic grading of left ventricular diastolic function. This study systematically evaluated the new A. S. E. algorithm specifically in patients with invasively confirmed ambulatory Heart Failure with Preserved Ejection Fraction (H. F. pEF). The investigation determined the false-negative rate of this algorithm within this patient population. It assessed the diagnostic accuracy of the updated criteria for grading diastolic dysfunction in H. F. pEF. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>functional mitral regurgitation, quality of care, diastolic function, disease classification, A. S. E. criteria, Cardiomyopathy gene variants, echocardiography, heart failure with preserved ejection fraction, atrial fibrillation, bleeding risk, health disparities, Ethnicity, oral anticoagulation, Atrial functional mitral regurgitation, Echocardiography, heart failure outcomes, genetic risk, left ventricular diastolic dysfunction, mitral valve disease, atrial-first phenotype, Left Atrial Appendage Closure, polygenic risk scores, universal health system, stroke prevention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/">New Echo Criteria Tested for H. F. pEF 03/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260319_060025.mp3" length="4120075" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 19, 2026. This episode summarizes 5 key cardiology studies on topics like functional mitral regurgitation and quality of care. Key takeaway: New Echo Criteria Tested for H. F. pEF.
Article Links:
Article 1: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. (The New England journal of medicine)
Article 2: Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis. (Journal of the American College of Cardiology)
Article 3: Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System. (Journal of the American College of Cardiology)
Article 4: Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype. (Journal of the American College of Cardiology)
Article 5: Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria. (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-echo-criteria-tested-for-h-f-pef-03-19-26/
 Featured Articles
Article 1: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41849741
Summary: The clinical question concerns the effectiveness of catheter-based Left Atrial Appendage Closure as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation patients. This study investigated its efficacy compared to physician-directed best medical care in those at high risk for both stroke and bleeding. A multicenter randomized trial in Germany examined this critical comparison. The research addresses the optimal therapeutic strategy for this complex patient population.
Article 2: Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41848471
Summary: This article highlights Atrial functional Mitral Regurgitation (AfMR) as a distinct and clinically significant form of functional mitral regurgitation. It found that disparate published definitions create significant uncertainty regarding its prevalence, specific morphology, and associated mortality. This definitional inconsistency was shown to impede consistent clinical decision making and patient classification. The analysis underscores the critical need for a unified and broadly applicable definition to improve management.
Article 3: Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41848357
Summary: Reports indicated poorer cardiovascular outcomes among ethnic minorities, especially during the COVID-19 pandemic. This analysis investigated the relationship between ethnicity, quality of care after heart failure hospitalization, and long-term outcomes in England. The study utilized routinely collected national audit data to examine these disparities within a universal health system. It focused on understanding how ethnicity influences care quality and subsequent long-term outcomes for patients hospitalized with acute heart failure.
Article 4: Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41706057
Summary: The genetic substrate of atrial fibrillation (A. F.) is heritable and complex. This study explored the impact of disease-causing cardiomyopathy variants on the risk of A. F., even after accounting for incident ventricular cardiomyopathy and clinical heart failure. Researchers evaluated the utility of polygenic risk scores (P. R. S.) to fur]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 19, 2026. This episode summarizes 5 key cardiology studies on topics like functional mitral regurgitation and quality of care. Key takeaway: New Echo Criteria Tested for H. F. pEF.
Article Links:
Article 1: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. (The New England journal of medicine)
Article 2: Atrial Functional Mitral Regurgitation: Effect of Phenotype Definition on Classification, Valve Features, and Prognosis. (Journal of the American College of Cardiology)
Article 3: Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System. (Journal of the American College of Cardiology)
Article 4: Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype. (Journal of the American College of Cardiology)
Article 5: Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria. (Journal of]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Simtuzumab Preserves Cardiac Function in LMNA DCM 03/18/26</title>
	<link>https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/</link>
	<pubDate>Wed, 18 Mar 2026 12:53:34 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like cDPP3 and endovascular revascularization. Key takeaway: Simtuzumab Preserves Cardiac Function in LMNA DCM.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41834515">cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41841702">Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41841259">Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41571040">Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41500397">Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/">https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41834515" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41834515</a></p>
<p><strong>Summary:</strong> Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.</p>
<h4>Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841702" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841702</a></p>
<p><strong>Summary:</strong> V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.</p>
<h4>Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841259</a></p>
<p><strong>Summary:</strong> Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.</p>
<h4>Article 4: Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41571040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41571040</a></p>
<p><strong>Summary:</strong> T. K. Endovascular Revascularization Catheter in the RESTOR-1 Peripheral C. T. O. Crossing Pivotal Study. The Santreva-A. T. K. Endovascular Revascularization Catheter demonstrated its safety and effectiveness in the RESTOR-1 Peripheral Chronic Total Occlusion Crossing Pivotal Study. This prospective, multicenter trial included adult patients with Rutherford class two to five peripheral arterial disease and de novo femoropopliteal chronic total occlusions. The catheter successfully provided a mechanism for recanalization, addressing the challenges of traversing chronic total occlusions. This study establishes a new option for endovascular revascularization in complex peripheral arterial disease patients.</p>
<h4>Article 5: Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41500397" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41500397</a></p>
<p><strong>Summary:</strong> Patients undergoing percutaneous coronary intervention (P. C. I.) were categorized for high bleeding risk (H. B. R.) and procedural complexity. High bleeding risk was defined by at least one major or two minor Academic Research Consortium H. B. R. criteria. Complex P. C. I. included treating three or more vessels or lesions, implanting three or more stents, or a total stent length over 60 millimeters. This study established concrete criteria for identifying patients with a dual burden of complex coronary anatomy and high bleeding risk, crucial for guiding individualized treatment strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Circulating Dipeptidyl Peptidase 3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies. Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.</p>
<p>Article number two. Long-term Safety and Performance of an Implantable I. V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.</p>
<p>Article number three. Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy. Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.</p>
<p>Article number four. Safety and Effectiveness of the Santreva-A. T. K. Endovascular Revascularization Catheter in the RESTOR-1 Peripheral C. T. O. Crossing Pivotal Study. The Santreva-A. T. K. Endovascular Revascularization Catheter demonstrated its safety and effectiveness in the RESTOR-1 Peripheral Chronic Total Occlusion Crossing Pivotal Study. This prospective, multicenter trial included adult patients with Rutherford class two to five peripheral arterial disease and de novo femoropopliteal chronic total occlusions. The catheter successfully provided a mechanism for recanalization, addressing the challenges of traversing chronic total occlusions. This study establishes a new option for endovascular revascularization in complex peripheral arterial disease patients.</p>
<p>Article number five. Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Patients undergoing percutaneous coronary intervention (P. C. I.) were categorized for high bleeding risk (H. B. R.) and procedural complexity. High bleeding risk was defined by at least one major or two minor Academic Research Consortium H. B. R. criteria. Complex P. C. I. included treating three or more vessels or lesions, implanting three or more stents, or a total stent length over 60 millimeters. This study established concrete criteria for identifying patients with a dual burden of complex coronary anatomy and high bleeding risk, crucial for guiding individualized treatment strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cDPP3, endovascular revascularization, heart failure, congestion, device management, high bleeding risk, chronic total occlusion, cardiocirculatory failure, Simtuzumab, LMNA mutation, percutaneous coronary intervention, bleeding risk, inferior vena cava, risk stratification, implantable sensor, dilated cardiomyopathy, extracellular matrix remodeling, Santreva-ATK, cardiac function, acute heart failure, biomarker, peripheral arterial disease, complex coronary anatomy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/">Simtuzumab Preserves Cardiac Function in LMNA DCM 03/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like cDPP3 and endovascular revascularization. Key takeaway: Simtuzumab Preserves Cardiac Function in LMNA DCM.
Article Links:
Article 1: cD]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like cDPP3 and endovascular revascularization. Key takeaway: Simtuzumab Preserves Cardiac Function in LMNA DCM.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41834515">cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41841702">Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41841259">Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41571040">Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41500397">Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/">https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41834515" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41834515</a></p>
<p><strong>Summary:</strong> Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.</p>
<h4>Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841702" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841702</a></p>
<p><strong>Summary:</strong> V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.</p>
<h4>Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841259</a></p>
<p><strong>Summary:</strong> Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.</p>
<h4>Article 4: Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41571040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41571040</a></p>
<p><strong>Summary:</strong> T. K. Endovascular Revascularization Catheter in the RESTOR-1 Peripheral C. T. O. Crossing Pivotal Study. The Santreva-A. T. K. Endovascular Revascularization Catheter demonstrated its safety and effectiveness in the RESTOR-1 Peripheral Chronic Total Occlusion Crossing Pivotal Study. This prospective, multicenter trial included adult patients with Rutherford class two to five peripheral arterial disease and de novo femoropopliteal chronic total occlusions. The catheter successfully provided a mechanism for recanalization, addressing the challenges of traversing chronic total occlusions. This study establishes a new option for endovascular revascularization in complex peripheral arterial disease patients.</p>
<h4>Article 5: Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41500397" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41500397</a></p>
<p><strong>Summary:</strong> Patients undergoing percutaneous coronary intervention (P. C. I.) were categorized for high bleeding risk (H. B. R.) and procedural complexity. High bleeding risk was defined by at least one major or two minor Academic Research Consortium H. B. R. criteria. Complex P. C. I. included treating three or more vessels or lesions, implanting three or more stents, or a total stent length over 60 millimeters. This study established concrete criteria for identifying patients with a dual burden of complex coronary anatomy and high bleeding risk, crucial for guiding individualized treatment strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Circulating Dipeptidyl Peptidase 3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies. Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.</p>
<p>Article number two. Long-term Safety and Performance of an Implantable I. V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.</p>
<p>Article number three. Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy. Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.</p>
<p>Article number four. Safety and Effectiveness of the Santreva-A. T. K. Endovascular Revascularization Catheter in the RESTOR-1 Peripheral C. T. O. Crossing Pivotal Study. The Santreva-A. T. K. Endovascular Revascularization Catheter demonstrated its safety and effectiveness in the RESTOR-1 Peripheral Chronic Total Occlusion Crossing Pivotal Study. This prospective, multicenter trial included adult patients with Rutherford class two to five peripheral arterial disease and de novo femoropopliteal chronic total occlusions. The catheter successfully provided a mechanism for recanalization, addressing the challenges of traversing chronic total occlusions. This study establishes a new option for endovascular revascularization in complex peripheral arterial disease patients.</p>
<p>Article number five. Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Patients undergoing percutaneous coronary intervention (P. C. I.) were categorized for high bleeding risk (H. B. R.) and procedural complexity. High bleeding risk was defined by at least one major or two minor Academic Research Consortium H. B. R. criteria. Complex P. C. I. included treating three or more vessels or lesions, implanting three or more stents, or a total stent length over 60 millimeters. This study established concrete criteria for identifying patients with a dual burden of complex coronary anatomy and high bleeding risk, crucial for guiding individualized treatment strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cDPP3, endovascular revascularization, heart failure, congestion, device management, high bleeding risk, chronic total occlusion, cardiocirculatory failure, Simtuzumab, LMNA mutation, percutaneous coronary intervention, bleeding risk, inferior vena cava, risk stratification, implantable sensor, dilated cardiomyopathy, extracellular matrix remodeling, Santreva-ATK, cardiac function, acute heart failure, biomarker, peripheral arterial disease, complex coronary anatomy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/">Simtuzumab Preserves Cardiac Function in LMNA DCM 03/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260318_085202.mp3" length="4807618" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like cDPP3 and endovascular revascularization. Key takeaway: Simtuzumab Preserves Cardiac Function in LMNA DCM.
Article Links:
Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies. (ESC heart failure)
Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. (European journal of heart failure)
Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy. (Circulation. Heart failure)
Article 4: Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study. (The American journal of cardiology)
Article 5: Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/simtuzumab-preserves-cardiac-function-in-lmna-dcm-03-18-26/
 Featured Articles
Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41834515
Summary: Circulating dipeptidyl peptidase 3 (cDPP3) is an established biomarker for cardiocirculatory failure, with elevated concentrations predicting poor patient outcomes in shock states. Researchers analyzed cDPP3 levels at baseline and follow-up in patients with acute heart failure enrolled in the STRONG-HF and CORTAHF trials. This investigation centered on the associations of cDPP3 with 180-day and 90-day outcomes, respectively. The evaluation of cDPP3 in acute heart failure provides crucial insights into the identification of prognostic indicators for improved risk stratification in this patient population.
Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841702
Summary: V. C. Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. An implantable inferior vena cava (I. V. C.) sensor was utilized for 12 months in a congestion-guided management strategy for heart failure patients. Data from 65 patients in the FUTURE-HF and FUTURE-HF two trials, predominantly with New York Heart Association class three symptoms and Heart Failure with Reduced Ejection Fraction, were analyzed. Daily I. V. C. parameters were recorded, and adjudicated safety outcomes were assessed. This study demonstrates the application of continuous physiological monitoring to address the critical challenge of congestion in heart failure.
Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841259
Summary: Simtuzumab attenuated Loxl2-mediated extracellular matrix remodeling and preserved cardiac function in dilated cardiomyopathy caused by LMNA mutations. This severe cardiac condition is marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, impairing left ventricular function and increasing heart failure risk. The findings identify simtuzumab as a therapeutic agent that addresses the pathogenesis of LMNA mutation-induced dilated cardiomyopathy. This represents a significant step towards developing targeted therapies for this specific genetic heart disease.
Article 4: Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like cDPP3 and endovascular revascularization. Key takeaway: Simtuzumab Preserves Cardiac Function in LMNA DCM.
Article Links:
Article 1: cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies. (ESC heart failure)
Article 2: Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio. (European journal of heart failure)
Article 3: Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy. (Circulation. Heart failure)
Article 4: Safety and Effectiveness of the Santreva-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study. (The American journal of cardiology)
Article 5: Procedural Complexity and Bleedin]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk 03/18/26</title>
	<link>https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/</link>
	<pubDate>Wed, 18 Mar 2026 10:01:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like acute hypoxemic respiratory failure and dose reduction. Key takeaway: P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41841715">High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41841706">Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41841775">Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41841768">Senescence-associated metabolic alterations aggravate calcific aortic valve disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41843757">Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/">https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841715" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841715</a></p>
<p><strong>Summary:</strong> A multicenter trial established a direct comparison of high-flow oxygen and standard oxygen therapy for patients with acute hypoxemic respiratory failure, defined by a partial pressure of arterial oxygen to fraction of inspired oxygen ratio of 200 or less. This research directly evaluated the clinical impact of these oxygen delivery methods on intubation rates and patient mortality. The findings from this investigation provide crucial guidance for optimizing oxygen delivery strategies in critical respiratory care.</p>
<h4>Article 2: Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841706" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841706</a></p>
<p><strong>Summary:</strong> A pragmatic phase three randomized controlled trial directly evaluated the clinical effectiveness and safety of prehospital whole blood transfusion in patients with major traumatic hemorrhage. This multicenter study specifically compared whole blood transfusion with standard care in a prehospital setting provided by air ambulance services. The findings from this investigation establish crucial evidence regarding optimal transfusion strategies for severe hemorrhage prior to hospital arrival. This research offers definitive insights into improving early trauma care and patient outcomes.</p>
<h4>Article 3: Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841775" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841775</a></p>
<p><strong>Summary:</strong> Proprotein convertase subtilisin/kexin type nine (P. C. S. K. 9) inhibitors have been established as a potent new class of low-density lipoprotein cholesterol-lowering drugs. These inhibitors demonstrate efficacy comparable to and additive with high-intensity statins, alongside an excellent safety profile. Extensive cardiovascular outcomes trials confirmed that monoclonal antibody P. C. S. K. 9 inhibitors significantly reduce the risk of major adverse cardiovascular outcomes across a wide spectrum of patients. This represents a substantial therapeutic advancement for cardiovascular risk management.</p>
<h4>Article 4: Senescence-associated metabolic alterations aggravate calcific aortic valve disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841768</a></p>
<p><strong>Summary:</strong> This study demonstrated that senescence-associated metabolic alterations aggravate calcific aortic valve disease, a condition currently without effective pharmacotherapy. Researchers identified a tight link between declining nicotinamide adenine dinucleotide levels with age and the progression of valvular inflammation and calcification. Disruption of specific nicotinamide adenine dinucleotide salvage metabolism was found to drive these detrimental processes within the aortic valve. These findings provide critical mechanistic insights into the pathogenesis of calcific aortic valve disease, highlighting novel therapeutic targets.</p>
<h4>Article 5: Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41843757" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41843757</a></p>
<p><strong>Summary:</strong> Italian Real-World Multicenter Study. This Italian real-world multicenter study provided long-term outcomes following sacubitril/valsartan therapy for chronic Heart Failure with reduced Ejection Fraction. The study established longitudinal changes after sacubitril/valsartan initiation and the association between dose changes and major adverse cardiovascular events. Data were collected from 592 outpatients, revealing insights into the real-world effectiveness and optimal dosing strategies of sacubitril/valsartan. This research illuminates the critical impact of treatment adherence and dose management on patient prognosis in Heart Failure with reduced Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure. A multicenter trial established a direct comparison of high-flow oxygen and standard oxygen therapy for patients with acute hypoxemic respiratory failure, defined by a partial pressure of arterial oxygen to fraction of inspired oxygen ratio of 200 or less. This research directly evaluated the clinical impact of these oxygen delivery methods on intubation rates and patient mortality. The findings from this investigation provide crucial guidance for optimizing oxygen delivery strategies in critical respiratory care.</p>
<p>Article number two. Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial. A pragmatic phase three randomized controlled trial directly evaluated the clinical effectiveness and safety of prehospital whole blood transfusion in patients with major traumatic hemorrhage. This multicenter study specifically compared whole blood transfusion with standard care in a prehospital setting provided by air ambulance services. The findings from this investigation establish crucial evidence regarding optimal transfusion strategies for severe hemorrhage prior to hospital arrival. This research offers definitive insights into improving early trauma care and patient outcomes.</p>
<p>Article number three. Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future. Proprotein convertase subtilisin/kexin type nine (P. C. S. K. 9) inhibitors have been established as a potent new class of low-density lipoprotein cholesterol-lowering drugs. These inhibitors demonstrate efficacy comparable to and additive with high-intensity statins, alongside an excellent safety profile. Extensive cardiovascular outcomes trials confirmed that monoclonal antibody P. C. S. K. 9 inhibitors significantly reduce the risk of major adverse cardiovascular outcomes across a wide spectrum of patients. This represents a substantial therapeutic advancement for cardiovascular risk management.</p>
<p>Article number four. Senescence-associated metabolic alterations aggravate calcific aortic valve disease. This study demonstrated that senescence-associated metabolic alterations aggravate calcific aortic valve disease, a condition currently without effective pharmacotherapy. Researchers identified a tight link between declining nicotinamide adenine dinucleotide levels with age and the progression of valvular inflammation and calcification. Disruption of specific nicotinamide adenine dinucleotide salvage metabolism was found to drive these detrimental processes within the aortic valve. These findings provide critical mechanistic insights into the pathogenesis of calcific aortic valve disease, highlighting novel therapeutic targets.</p>
<p>Article number five. Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study. This Italian real-world multicenter study provided long-term outcomes following sacubitril/valsartan therapy for chronic Heart Failure with reduced Ejection Fraction. The study established longitudinal changes after sacubitril/valsartan initiation and the association between dose changes and major adverse cardiovascular events. Data were collected from 592 outpatients, revealing insights into the real-world effectiveness and optimal dosing strategies of sacubitril/valsartan. This research illuminates the critical impact of treatment adherence and dose management on patient prognosis in Heart Failure with reduced Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute hypoxemic respiratory failure, dose reduction, nicotinamide adenine dinucleotide, whole blood transfusion, statins, cardiovascular outcomes, real-world outcomes, prehospital care, major adverse cardiovascular events, traumatic hemorrhage, mortality, high-flow oxygen, standard oxygen therapy, Heart Failure with reduced Ejection Fraction, P. C. S. K. 9 inhibitors, aging, air ambulance, valvular inflammation, pharmacotherapy, trauma, low-density lipoprotein cholesterol, calcific aortic valve disease, intubation, sacubitril/valsartan.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/">P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk 03/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like acute hypoxemic respiratory failure and dose reduction. Key takeaway: P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk.
Article Links]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like acute hypoxemic respiratory failure and dose reduction. Key takeaway: P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41841715">High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41841706">Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41841775">Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41841768">Senescence-associated metabolic alterations aggravate calcific aortic valve disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41843757">Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/">https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841715" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841715</a></p>
<p><strong>Summary:</strong> A multicenter trial established a direct comparison of high-flow oxygen and standard oxygen therapy for patients with acute hypoxemic respiratory failure, defined by a partial pressure of arterial oxygen to fraction of inspired oxygen ratio of 200 or less. This research directly evaluated the clinical impact of these oxygen delivery methods on intubation rates and patient mortality. The findings from this investigation provide crucial guidance for optimizing oxygen delivery strategies in critical respiratory care.</p>
<h4>Article 2: Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841706" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841706</a></p>
<p><strong>Summary:</strong> A pragmatic phase three randomized controlled trial directly evaluated the clinical effectiveness and safety of prehospital whole blood transfusion in patients with major traumatic hemorrhage. This multicenter study specifically compared whole blood transfusion with standard care in a prehospital setting provided by air ambulance services. The findings from this investigation establish crucial evidence regarding optimal transfusion strategies for severe hemorrhage prior to hospital arrival. This research offers definitive insights into improving early trauma care and patient outcomes.</p>
<h4>Article 3: Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841775" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841775</a></p>
<p><strong>Summary:</strong> Proprotein convertase subtilisin/kexin type nine (P. C. S. K. 9) inhibitors have been established as a potent new class of low-density lipoprotein cholesterol-lowering drugs. These inhibitors demonstrate efficacy comparable to and additive with high-intensity statins, alongside an excellent safety profile. Extensive cardiovascular outcomes trials confirmed that monoclonal antibody P. C. S. K. 9 inhibitors significantly reduce the risk of major adverse cardiovascular outcomes across a wide spectrum of patients. This represents a substantial therapeutic advancement for cardiovascular risk management.</p>
<h4>Article 4: Senescence-associated metabolic alterations aggravate calcific aortic valve disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41841768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41841768</a></p>
<p><strong>Summary:</strong> This study demonstrated that senescence-associated metabolic alterations aggravate calcific aortic valve disease, a condition currently without effective pharmacotherapy. Researchers identified a tight link between declining nicotinamide adenine dinucleotide levels with age and the progression of valvular inflammation and calcification. Disruption of specific nicotinamide adenine dinucleotide salvage metabolism was found to drive these detrimental processes within the aortic valve. These findings provide critical mechanistic insights into the pathogenesis of calcific aortic valve disease, highlighting novel therapeutic targets.</p>
<h4>Article 5: Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41843757" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41843757</a></p>
<p><strong>Summary:</strong> Italian Real-World Multicenter Study. This Italian real-world multicenter study provided long-term outcomes following sacubitril/valsartan therapy for chronic Heart Failure with reduced Ejection Fraction. The study established longitudinal changes after sacubitril/valsartan initiation and the association between dose changes and major adverse cardiovascular events. Data were collected from 592 outpatients, revealing insights into the real-world effectiveness and optimal dosing strategies of sacubitril/valsartan. This research illuminates the critical impact of treatment adherence and dose management on patient prognosis in Heart Failure with reduced Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure. A multicenter trial established a direct comparison of high-flow oxygen and standard oxygen therapy for patients with acute hypoxemic respiratory failure, defined by a partial pressure of arterial oxygen to fraction of inspired oxygen ratio of 200 or less. This research directly evaluated the clinical impact of these oxygen delivery methods on intubation rates and patient mortality. The findings from this investigation provide crucial guidance for optimizing oxygen delivery strategies in critical respiratory care.</p>
<p>Article number two. Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial. A pragmatic phase three randomized controlled trial directly evaluated the clinical effectiveness and safety of prehospital whole blood transfusion in patients with major traumatic hemorrhage. This multicenter study specifically compared whole blood transfusion with standard care in a prehospital setting provided by air ambulance services. The findings from this investigation establish crucial evidence regarding optimal transfusion strategies for severe hemorrhage prior to hospital arrival. This research offers definitive insights into improving early trauma care and patient outcomes.</p>
<p>Article number three. Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future. Proprotein convertase subtilisin/kexin type nine (P. C. S. K. 9) inhibitors have been established as a potent new class of low-density lipoprotein cholesterol-lowering drugs. These inhibitors demonstrate efficacy comparable to and additive with high-intensity statins, alongside an excellent safety profile. Extensive cardiovascular outcomes trials confirmed that monoclonal antibody P. C. S. K. 9 inhibitors significantly reduce the risk of major adverse cardiovascular outcomes across a wide spectrum of patients. This represents a substantial therapeutic advancement for cardiovascular risk management.</p>
<p>Article number four. Senescence-associated metabolic alterations aggravate calcific aortic valve disease. This study demonstrated that senescence-associated metabolic alterations aggravate calcific aortic valve disease, a condition currently without effective pharmacotherapy. Researchers identified a tight link between declining nicotinamide adenine dinucleotide levels with age and the progression of valvular inflammation and calcification. Disruption of specific nicotinamide adenine dinucleotide salvage metabolism was found to drive these detrimental processes within the aortic valve. These findings provide critical mechanistic insights into the pathogenesis of calcific aortic valve disease, highlighting novel therapeutic targets.</p>
<p>Article number five. Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study. This Italian real-world multicenter study provided long-term outcomes following sacubitril/valsartan therapy for chronic Heart Failure with reduced Ejection Fraction. The study established longitudinal changes after sacubitril/valsartan initiation and the association between dose changes and major adverse cardiovascular events. Data were collected from 592 outpatients, revealing insights into the real-world effectiveness and optimal dosing strategies of sacubitril/valsartan. This research illuminates the critical impact of treatment adherence and dose management on patient prognosis in Heart Failure with reduced Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute hypoxemic respiratory failure, dose reduction, nicotinamide adenine dinucleotide, whole blood transfusion, statins, cardiovascular outcomes, real-world outcomes, prehospital care, major adverse cardiovascular events, traumatic hemorrhage, mortality, high-flow oxygen, standard oxygen therapy, Heart Failure with reduced Ejection Fraction, P. C. S. K. 9 inhibitors, aging, air ambulance, valvular inflammation, pharmacotherapy, trauma, low-density lipoprotein cholesterol, calcific aortic valve disease, intubation, sacubitril/valsartan.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/">P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk 03/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260318_060035.mp3" length="4338668" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like acute hypoxemic respiratory failure and dose reduction. Key takeaway: P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk.
Article Links:
Article 1: High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure. (The New England journal of medicine)
Article 2: Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial. (The New England journal of medicine)
Article 3: Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future. (European heart journal)
Article 4: Senescence-associated metabolic alterations aggravate calcific aortic valve disease. (European heart journal)
Article 5: Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular-risk-03-18-26/
 Featured Articles
Article 1: High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841715
Summary: A multicenter trial established a direct comparison of high-flow oxygen and standard oxygen therapy for patients with acute hypoxemic respiratory failure, defined by a partial pressure of arterial oxygen to fraction of inspired oxygen ratio of 200 or less. This research directly evaluated the clinical impact of these oxygen delivery methods on intubation rates and patient mortality. The findings from this investigation provide crucial guidance for optimizing oxygen delivery strategies in critical respiratory care.
Article 2: Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841706
Summary: A pragmatic phase three randomized controlled trial directly evaluated the clinical effectiveness and safety of prehospital whole blood transfusion in patients with major traumatic hemorrhage. This multicenter study specifically compared whole blood transfusion with standard care in a prehospital setting provided by air ambulance services. The findings from this investigation establish crucial evidence regarding optimal transfusion strategies for severe hemorrhage prior to hospital arrival. This research offers definitive insights into improving early trauma care and patient outcomes.
Article 3: Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841775
Summary: Proprotein convertase subtilisin/kexin type nine (P. C. S. K. 9) inhibitors have been established as a potent new class of low-density lipoprotein cholesterol-lowering drugs. These inhibitors demonstrate efficacy comparable to and additive with high-intensity statins, alongside an excellent safety profile. Extensive cardiovascular outcomes trials confirmed that monoclonal antibody P. C. S. K. 9 inhibitors significantly reduce the risk of major adverse cardiovascular outcomes across a wide spectrum of patients. This represents a substantial therapeutic advancement for cardiovascular risk management.
Article 4: Senescence-associated metabolic alterations aggravate calcific aortic valve disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41841768
Summary: This study demonstrated that senescence-associated metabolic alterations aggravate calcific aortic valve disease, a condition currently without effective pharmacotherapy. Researchers identified a tight link between declining nicotinamide adenine dinucleotide levels with age and the progression of valvular inflammation and calcification. Disruption of specific nicotinamide adenine dinucleotide salvage metabolism was found to drive these detrimental processes within th]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 18, 2026. This episode summarizes 5 key cardiology studies on topics like acute hypoxemic respiratory failure and dose reduction. Key takeaway: P. C. S. K. 9 Inhibitors Slash Cardiovascular Risk.
Article Links:
Article 1: High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure. (The New England journal of medicine)
Article 2: Prehospital Whole Blood in Traumatic Hemorrhage &#8211; a Randomized Controlled Trial. (The New England journal of medicine)
Article 3: Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future. (European heart journal)
Article 4: Senescence-associated metabolic alterations aggravate calcific aortic valve disease. (European heart journal)
Article 5: Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/p-c-s-k-9-inhibitors-slash-cardiovascular]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Left Ventricular Remodeling Post Mitral Repair 03/17/26</title>
	<link>https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/</link>
	<pubDate>Tue, 17 Mar 2026 10:01:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 17, 2026. This episode summarizes 5 key cardiology studies on topics like preventive cardiology and sudden cardiac death. Key takeaway: Left Ventricular Remodeling Post Mitral Repair.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41837904">Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41838796">CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41839544">Sports cardiology for the general cardiologist.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41839533">Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41834516">Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/">https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41837904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41837904</a></p>
<p><strong>Summary:</strong> The current understanding in cardiology indicates that the utility of coronary artery calcium scoring for atherosclerotic cardiovascular disease risk assessment in individuals with elevated lipoprotein(a) is unclear. This ambiguity exists because lipoprotein(a) has a propensity toward non-calcified plaque, complicating traditional calcification-based risk evaluations. This uncertainty highlights a critical gap in refining cardiovascular disease prevention strategies for this specific patient population. Resolving this clinical question is essential for optimizing targeted interventions and improving patient outcomes.</p>
<h4>Article 2: CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41838796" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41838796</a></p>
<p><strong>Summary:</strong> R. L. F. 1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Nearly half of patients diagnosed with hypertrophic cardiomyopathy, the most common inherited cardiac disorder, currently lack identifiable sarcomere gene sequence variations. This significant proportion suggests the presence of undiscovered mechanisms driving the disease&#8217;s pathogenesis, highlighting its substantial genetic and clinical heterogeneity. A unified molecular basis underlying hypertrophic cardiomyopathy pathology remains to be fully elucidated. Identifying these unknown pathways is crucial for developing new diagnostic tools and targeted therapeutic interventions.</p>
<h4>Article 3: Sports cardiology for the general cardiologist.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41839544" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41839544</a></p>
<p><strong>Summary:</strong> Sports cardiology has emerged as a distinct subspecialty, integrating preventive cardiology with athlete care. While regular exercise provides substantial cardiovascular benefits, vigorous exertion can unmask latent disease and precipitate sudden cardiac death in predisposed individuals. This primer emphasizes the importance of early detection, comprehensive risk stratification, and tailored management strategies for athletes. Such events, though uncommon, carry profound societal impact and necessitate specialized attention from cardiologists.</p>
<h4>Article 4: Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41839533" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41839533</a></p>
<p><strong>Summary:</strong> Left ventricular reverse remodeling stands as a critical therapeutic objective for contemporary heart failure management, aiming to reverse left ventricular dilation and dysfunction. Achieving this remodeling after mitral transcatheter edge-to-edge repair is a key indicator of successful treatment for both primary and secondary mitral regurgitation. Early indicators of left ventricular reverse remodeling within 30 days are crucial for assessing treatment efficacy and guiding patient prognosis. Understanding specific factors associated with this early remodeling can optimize future clinical decision-making and patient selection.</p>
<h4>Article 5: Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41834516" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41834516</a></p>
<p><strong>Summary:</strong> F. Study. Natriuretic peptides are recognized as central biomarkers in the diagnostic and therapeutic management of heart failure. However, current understanding of their short-term dynamics during sacubitril/valsartan therapy and in response to acute volume changes remains incomplete. Characterizing these cardiac biomarker responses to angiotensin receptor-neprilysin inhibitor treatment is essential for optimizing patient monitoring and treatment adjustments. Elucidating these dynamics will enable clinicians to make more precise and timely therapeutic decisions for patients with heart failure with reduced ejection fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 17, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. The current understanding in cardiology indicates that the utility of coronary artery calcium scoring for atherosclerotic cardiovascular disease risk assessment in individuals with elevated lipoprotein(a) is unclear. This ambiguity exists because lipoprotein(a) has a propensity toward non-calcified plaque, complicating traditional calcification-based risk evaluations. This uncertainty highlights a critical gap in refining cardiovascular disease prevention strategies for this specific patient population. Resolving this clinical question is essential for optimizing targeted interventions and improving patient outcomes.</p>
<p>Article number two. C. R. L. F. 1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Nearly half of patients diagnosed with hypertrophic cardiomyopathy, the most common inherited cardiac disorder, currently lack identifiable sarcomere gene sequence variations. This significant proportion suggests the presence of undiscovered mechanisms driving the disease&#8217;s pathogenesis, highlighting its substantial genetic and clinical heterogeneity. A unified molecular basis underlying hypertrophic cardiomyopathy pathology remains to be fully elucidated. Identifying these unknown pathways is crucial for developing new diagnostic tools and targeted therapeutic interventions.</p>
<p>Article number three. Sports cardiology for the general cardiologist. Sports cardiology has emerged as a distinct subspecialty, integrating preventive cardiology with athlete care. While regular exercise provides substantial cardiovascular benefits, vigorous exertion can unmask latent disease and precipitate sudden cardiac death in predisposed individuals. This primer emphasizes the importance of early detection, comprehensive risk stratification, and tailored management strategies for athletes. Such events, though uncommon, carry profound societal impact and necessitate specialized attention from cardiologists.</p>
<p>Article number four. Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies. Left ventricular reverse remodeling stands as a critical therapeutic objective for contemporary heart failure management, aiming to reverse left ventricular dilation and dysfunction. Achieving this remodeling after mitral transcatheter edge-to-edge repair is a key indicator of successful treatment for both primary and secondary mitral regurgitation. Early indicators of left ventricular reverse remodeling within 30 days are crucial for assessing treatment efficacy and guiding patient prognosis. Understanding specific factors associated with this early remodeling can optimize future clinical decision-making and patient selection.</p>
<p>Article number five. Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-H. F. Study. Natriuretic peptides are recognized as central biomarkers in the diagnostic and therapeutic management of heart failure. However, current understanding of their short-term dynamics during sacubitril/valsartan therapy and in response to acute volume changes remains incomplete. Characterizing these cardiac biomarker responses to angiotensin receptor-neprilysin inhibitor treatment is essential for optimizing patient monitoring and treatment adjustments. Elucidating these dynamics will enable clinicians to make more precise and timely therapeutic decisions for patients with heart failure with reduced ejection fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preventive cardiology, sudden cardiac death, sports cardiology, left ventricular reverse remodeling, sarcomere gene variations, athlete care, heart failure, natriuretic peptides, left ventricular dysfunction, non-calcified plaque, atherosclerotic cardiovascular disease, coronary artery calcium score, mitral regurgitation, heart failure with reduced ejection fraction, mitral transcatheter edge-to-edge repair, risk stratification, cardiac fibroblasts, hypertrophic cardiomyopathy, risk assessment, sacubitril/valsartan, genetic defects, volume expansion, cardiac biomarkers, lipoprotein(a).</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/">Left Ventricular Remodeling Post Mitral Repair 03/17/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 17, 2026. This episode summarizes 5 key cardiology studies on topics like preventive cardiology and sudden cardiac death. Key takeaway: Left Ventricular Remodeling Post Mitral Repair.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 17, 2026. This episode summarizes 5 key cardiology studies on topics like preventive cardiology and sudden cardiac death. Key takeaway: Left Ventricular Remodeling Post Mitral Repair.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41837904">Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41838796">CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41839544">Sports cardiology for the general cardiologist.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41839533">Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41834516">Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/">https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41837904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41837904</a></p>
<p><strong>Summary:</strong> The current understanding in cardiology indicates that the utility of coronary artery calcium scoring for atherosclerotic cardiovascular disease risk assessment in individuals with elevated lipoprotein(a) is unclear. This ambiguity exists because lipoprotein(a) has a propensity toward non-calcified plaque, complicating traditional calcification-based risk evaluations. This uncertainty highlights a critical gap in refining cardiovascular disease prevention strategies for this specific patient population. Resolving this clinical question is essential for optimizing targeted interventions and improving patient outcomes.</p>
<h4>Article 2: CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41838796" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41838796</a></p>
<p><strong>Summary:</strong> R. L. F. 1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Nearly half of patients diagnosed with hypertrophic cardiomyopathy, the most common inherited cardiac disorder, currently lack identifiable sarcomere gene sequence variations. This significant proportion suggests the presence of undiscovered mechanisms driving the disease&#8217;s pathogenesis, highlighting its substantial genetic and clinical heterogeneity. A unified molecular basis underlying hypertrophic cardiomyopathy pathology remains to be fully elucidated. Identifying these unknown pathways is crucial for developing new diagnostic tools and targeted therapeutic interventions.</p>
<h4>Article 3: Sports cardiology for the general cardiologist.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41839544" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41839544</a></p>
<p><strong>Summary:</strong> Sports cardiology has emerged as a distinct subspecialty, integrating preventive cardiology with athlete care. While regular exercise provides substantial cardiovascular benefits, vigorous exertion can unmask latent disease and precipitate sudden cardiac death in predisposed individuals. This primer emphasizes the importance of early detection, comprehensive risk stratification, and tailored management strategies for athletes. Such events, though uncommon, carry profound societal impact and necessitate specialized attention from cardiologists.</p>
<h4>Article 4: Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41839533" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41839533</a></p>
<p><strong>Summary:</strong> Left ventricular reverse remodeling stands as a critical therapeutic objective for contemporary heart failure management, aiming to reverse left ventricular dilation and dysfunction. Achieving this remodeling after mitral transcatheter edge-to-edge repair is a key indicator of successful treatment for both primary and secondary mitral regurgitation. Early indicators of left ventricular reverse remodeling within 30 days are crucial for assessing treatment efficacy and guiding patient prognosis. Understanding specific factors associated with this early remodeling can optimize future clinical decision-making and patient selection.</p>
<h4>Article 5: Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41834516" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41834516</a></p>
<p><strong>Summary:</strong> F. Study. Natriuretic peptides are recognized as central biomarkers in the diagnostic and therapeutic management of heart failure. However, current understanding of their short-term dynamics during sacubitril/valsartan therapy and in response to acute volume changes remains incomplete. Characterizing these cardiac biomarker responses to angiotensin receptor-neprilysin inhibitor treatment is essential for optimizing patient monitoring and treatment adjustments. Elucidating these dynamics will enable clinicians to make more precise and timely therapeutic decisions for patients with heart failure with reduced ejection fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 17, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. The current understanding in cardiology indicates that the utility of coronary artery calcium scoring for atherosclerotic cardiovascular disease risk assessment in individuals with elevated lipoprotein(a) is unclear. This ambiguity exists because lipoprotein(a) has a propensity toward non-calcified plaque, complicating traditional calcification-based risk evaluations. This uncertainty highlights a critical gap in refining cardiovascular disease prevention strategies for this specific patient population. Resolving this clinical question is essential for optimizing targeted interventions and improving patient outcomes.</p>
<p>Article number two. C. R. L. F. 1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Nearly half of patients diagnosed with hypertrophic cardiomyopathy, the most common inherited cardiac disorder, currently lack identifiable sarcomere gene sequence variations. This significant proportion suggests the presence of undiscovered mechanisms driving the disease&#8217;s pathogenesis, highlighting its substantial genetic and clinical heterogeneity. A unified molecular basis underlying hypertrophic cardiomyopathy pathology remains to be fully elucidated. Identifying these unknown pathways is crucial for developing new diagnostic tools and targeted therapeutic interventions.</p>
<p>Article number three. Sports cardiology for the general cardiologist. Sports cardiology has emerged as a distinct subspecialty, integrating preventive cardiology with athlete care. While regular exercise provides substantial cardiovascular benefits, vigorous exertion can unmask latent disease and precipitate sudden cardiac death in predisposed individuals. This primer emphasizes the importance of early detection, comprehensive risk stratification, and tailored management strategies for athletes. Such events, though uncommon, carry profound societal impact and necessitate specialized attention from cardiologists.</p>
<p>Article number four. Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies. Left ventricular reverse remodeling stands as a critical therapeutic objective for contemporary heart failure management, aiming to reverse left ventricular dilation and dysfunction. Achieving this remodeling after mitral transcatheter edge-to-edge repair is a key indicator of successful treatment for both primary and secondary mitral regurgitation. Early indicators of left ventricular reverse remodeling within 30 days are crucial for assessing treatment efficacy and guiding patient prognosis. Understanding specific factors associated with this early remodeling can optimize future clinical decision-making and patient selection.</p>
<p>Article number five. Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-H. F. Study. Natriuretic peptides are recognized as central biomarkers in the diagnostic and therapeutic management of heart failure. However, current understanding of their short-term dynamics during sacubitril/valsartan therapy and in response to acute volume changes remains incomplete. Characterizing these cardiac biomarker responses to angiotensin receptor-neprilysin inhibitor treatment is essential for optimizing patient monitoring and treatment adjustments. Elucidating these dynamics will enable clinicians to make more precise and timely therapeutic decisions for patients with heart failure with reduced ejection fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preventive cardiology, sudden cardiac death, sports cardiology, left ventricular reverse remodeling, sarcomere gene variations, athlete care, heart failure, natriuretic peptides, left ventricular dysfunction, non-calcified plaque, atherosclerotic cardiovascular disease, coronary artery calcium score, mitral regurgitation, heart failure with reduced ejection fraction, mitral transcatheter edge-to-edge repair, risk stratification, cardiac fibroblasts, hypertrophic cardiomyopathy, risk assessment, sacubitril/valsartan, genetic defects, volume expansion, cardiac biomarkers, lipoprotein(a).</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/">Left Ventricular Remodeling Post Mitral Repair 03/17/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260317_060037.mp3" length="4316098" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 17, 2026. This episode summarizes 5 key cardiology studies on topics like preventive cardiology and sudden cardiac death. Key takeaway: Left Ventricular Remodeling Post Mitral Repair.
Article Links:
Article 1: Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. (Journal of the American College of Cardiology)
Article 2: CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. (Circulation)
Article 3: Sports cardiology for the general cardiologist. (Heart (British Cardiac Society))
Article 4: Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies. (ESC heart failure)
Article 5: Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-mitral-repair-03-17-26/
 Featured Articles
Article 1: Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41837904
Summary: The current understanding in cardiology indicates that the utility of coronary artery calcium scoring for atherosclerotic cardiovascular disease risk assessment in individuals with elevated lipoprotein(a) is unclear. This ambiguity exists because lipoprotein(a) has a propensity toward non-calcified plaque, complicating traditional calcification-based risk evaluations. This uncertainty highlights a critical gap in refining cardiovascular disease prevention strategies for this specific patient population. Resolving this clinical question is essential for optimizing targeted interventions and improving patient outcomes.
Article 2: CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41838796
Summary: R. L. F. 1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Nearly half of patients diagnosed with hypertrophic cardiomyopathy, the most common inherited cardiac disorder, currently lack identifiable sarcomere gene sequence variations. This significant proportion suggests the presence of undiscovered mechanisms driving the disease&#8217;s pathogenesis, highlighting its substantial genetic and clinical heterogeneity. A unified molecular basis underlying hypertrophic cardiomyopathy pathology remains to be fully elucidated. Identifying these unknown pathways is crucial for developing new diagnostic tools and targeted therapeutic interventions.
Article 3: Sports cardiology for the general cardiologist.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41839544
Summary: Sports cardiology has emerged as a distinct subspecialty, integrating preventive cardiology with athlete care. While regular exercise provides substantial cardiovascular benefits, vigorous exertion can unmask latent disease and precipitate sudden cardiac death in predisposed individuals. This primer emphasizes the importance of early detection, comprehensive risk stratification, and tailored management strategies for athletes. Such events, though uncommon, carry profound societal impact and necessitate specialized attention from cardiologists.
Article 4: Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41839533
Summary: Left ventricular reverse remodeling stands as a critical therapeutic objective for contemporary heart failure management, aiming to reverse left ventricular dilation and dysfunction. Achieving this remodeling after mitral transcatheter edge-to-edge repair is a key indicator of successful treatment for both prim]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 17, 2026. This episode summarizes 5 key cardiology studies on topics like preventive cardiology and sudden cardiac death. Key takeaway: Left Ventricular Remodeling Post Mitral Repair.
Article Links:
Article 1: Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. (Journal of the American College of Cardiology)
Article 2: CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. (Circulation)
Article 3: Sports cardiology for the general cardiologist. (Heart (British Cardiac Society))
Article 4: Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies. (ESC heart failure)
Article 5: Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/left-ventricular-remodeling-post-]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Kidney Injury Drives Diuretic Resistance in A. H. F. 03/16/26</title>
	<link>https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/</link>
	<pubDate>Mon, 16 Mar 2026 10:02:58 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 16, 2026. This episode summarizes 5 key cardiology studies on topics like Donor-specific antibody and Heart transplant rejection. Key takeaway: Kidney Injury Drives Diuretic Resistance in A. H. F..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41833594">Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41833593">Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41832743">Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41823241">Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823240">Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/">https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41833594" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41833594</a></p>
<p><strong>Summary:</strong> Heart transplantation is an established gold standard therapy for end-stage systolic heart failure, showing a median survival of approximately 10 to 13 years. For younger patients under 50 years of age, the utility of heart transplantation for lifetime management is limited by low re-transplantation rates. Durable left ventricular assist device support is also an established surgical option for these patients. The article identifies an intentional strategy of utilizing durable left ventricular assist device therapy followed by heart transplantation to achieve net prolongation of life in advanced heart failure.</p>
<h4>Article 2: Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41833593" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41833593</a></p>
<p><strong>Summary:</strong> Antibody-mediated rejection in heart transplants frequently presents without donor-specific antibodies, posing a diagnostic challenge. The Trifecta-Heart study provided characterization of rejection in 212 heart endomyocardial biopsies through the Molecular Microscope Diagnostic System and histology. This research distinguished molecular differences between donor-specific antibody-negative and donor-specific antibody-positive antibody-mediated rejection. Donor-derived cell-free D. N. A., a biomarker for transplant injury, was concurrently measured at the time of biopsy to enhance the understanding of these distinct rejection phenotypes.</p>
<h4>Article 3: Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41832743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41832743</a></p>
<p><strong>Summary:</strong> Greater sodium avidity in patients with acute heart failure is a known indicator of worse clinical outcomes. This study evaluated 339 participants from the R. O. S. E. hyphen A. H. F. trial, which included patients hospitalized for acute heart failure with kidney dysfunction. The study found that kidney tubule injury, as assessed by urinary biomarkers such as kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, and neutrophil gelatinase-associated lipocalin, is associated with both increased sodium avidity and impaired diuretic responsiveness. This association provides insight into the underlying mechanisms contributing to poor outcomes in acute heart failure.</p>
<h4>Article 4: Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823241" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823241</a></p>
<p><strong>Summary:</strong> Intensive systolic blood pressure treatment is a crucial strategy to mitigate cardiovascular disease risk in long-standing hypertension, with target organ damage being a critical intermediate phenotype. This study utilized data from 8442 participants in the S. T. E. P. trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients). The research precisely evaluated the impact of hypertension duration on the associations between intensive blood pressure control and improvements in cardiac, vascular, and kidney organ damage. This evaluation addresses a key gap in understanding how long-term hypertension affects the benefits of aggressive blood pressure management.</p>
<h4>Article 5: Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823240</a></p>
<p><strong>Summary:</strong> Heart failure with preserved ejection fraction is characterized by chronic low-grade inflammation, which impacts endothelial function, glycocalyx integrity, and barrier permeability. Glycocalyx degradation, specifically involving biomarkers hyaluronan and syndecan-1, is implicated in the pathophysiology of heart failure with preserved ejection fraction. This study established associations between these glycocalyx degradation biomarkers and both patient characteristics and clinical outcomes in heart failure with preserved ejection fraction. These findings link endothelial glycocalyx shedding to the development and progression of the disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation. Heart transplantation is an established gold standard therapy for end-stage systolic heart failure, showing a median survival of approximately 10 to 13 years. For younger patients under 50 years of age, the utility of heart transplantation for lifetime management is limited by low re-transplantation rates. Durable left ventricular assist device support is also an established surgical option for these patients. The article identifies an intentional strategy of utilizing durable left ventricular assist device therapy followed by heart transplantation to achieve net prolongation of life in advanced heart failure.</p>
<p>Article number two. Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study. Antibody-mediated rejection in heart transplants frequently presents without donor-specific antibodies, posing a diagnostic challenge. The Trifecta-Heart study provided characterization of rejection in 212 heart endomyocardial biopsies through the Molecular Microscope Diagnostic System and histology. This research distinguished molecular differences between donor-specific antibody-negative and donor-specific antibody-positive antibody-mediated rejection. Donor-derived cell-free D. N. A., a biomarker for transplant injury, was concurrently measured at the time of biopsy to enhance the understanding of these distinct rejection phenotypes.</p>
<p>Article number three. Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure. Greater sodium avidity in patients with acute heart failure is a known indicator of worse clinical outcomes. This study evaluated 339 participants from the R. O. S. E. hyphen A. H. F. trial, which included patients hospitalized for acute heart failure with kidney dysfunction. The study found that kidney tubule injury, as assessed by urinary biomarkers such as kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, and neutrophil gelatinase-associated lipocalin, is associated with both increased sodium avidity and impaired diuretic responsiveness. This association provides insight into the underlying mechanisms contributing to poor outcomes in acute heart failure.</p>
<p>Article number four. Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage. Intensive systolic blood pressure treatment is a crucial strategy to mitigate cardiovascular disease risk in long-standing hypertension, with target organ damage being a critical intermediate phenotype. This study utilized data from 8442 participants in the S. T. E. P. trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients). The research precisely evaluated the impact of hypertension duration on the associations between intensive blood pressure control and improvements in cardiac, vascular, and kidney organ damage. This evaluation addresses a key gap in understanding how long-term hypertension affects the benefits of aggressive blood pressure management.</p>
<p>Article number five. Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction. Heart failure with preserved ejection fraction is characterized by chronic low-grade inflammation, which impacts endothelial function, glycocalyx integrity, and barrier permeability. Glycocalyx degradation, specifically involving biomarkers hyaluronan and syndecan-1, is implicated in the pathophysiology of heart failure with preserved ejection fraction. This study established associations between these glycocalyx degradation biomarkers and both patient characteristics and clinical outcomes in heart failure with preserved ejection fraction. These findings link endothelial glycocalyx shedding to the development and progression of the disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Donor-specific antibody, Heart transplant rejection, Donor-derived cell-free D. N. A., Sodium avidity, Target organ damage, Heart failure with preserved ejection fraction, Endothelial function, End-stage heart failure, Kidney tubule injury, Kidney injury molecule-1, Lifetime management, Antibody-mediated rejection, Syndecan-1, Systolic blood pressure, Diuretic responsiveness, Glycocalyx degradation, Cardiovascular disease risk, Hypertension duration, Hyaluronan, Intensive blood pressure control, Molecular Microscope Diagnostic System, Heart transplantation, Acute heart failure, Systolic heart failure, Left ventricular assist device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/">Kidney Injury Drives Diuretic Resistance in A. H. F. 03/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 16, 2026. This episode summarizes 5 key cardiology studies on topics like Donor-specific antibody and Heart transplant rejection. Key takeaway: Kidney Injury Drives Diuretic Resistance in A. H. F..
Article Lin]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 16, 2026. This episode summarizes 5 key cardiology studies on topics like Donor-specific antibody and Heart transplant rejection. Key takeaway: Kidney Injury Drives Diuretic Resistance in A. H. F..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41833594">Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41833593">Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41832743">Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41823241">Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823240">Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/">https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41833594" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41833594</a></p>
<p><strong>Summary:</strong> Heart transplantation is an established gold standard therapy for end-stage systolic heart failure, showing a median survival of approximately 10 to 13 years. For younger patients under 50 years of age, the utility of heart transplantation for lifetime management is limited by low re-transplantation rates. Durable left ventricular assist device support is also an established surgical option for these patients. The article identifies an intentional strategy of utilizing durable left ventricular assist device therapy followed by heart transplantation to achieve net prolongation of life in advanced heart failure.</p>
<h4>Article 2: Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41833593" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41833593</a></p>
<p><strong>Summary:</strong> Antibody-mediated rejection in heart transplants frequently presents without donor-specific antibodies, posing a diagnostic challenge. The Trifecta-Heart study provided characterization of rejection in 212 heart endomyocardial biopsies through the Molecular Microscope Diagnostic System and histology. This research distinguished molecular differences between donor-specific antibody-negative and donor-specific antibody-positive antibody-mediated rejection. Donor-derived cell-free D. N. A., a biomarker for transplant injury, was concurrently measured at the time of biopsy to enhance the understanding of these distinct rejection phenotypes.</p>
<h4>Article 3: Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41832743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41832743</a></p>
<p><strong>Summary:</strong> Greater sodium avidity in patients with acute heart failure is a known indicator of worse clinical outcomes. This study evaluated 339 participants from the R. O. S. E. hyphen A. H. F. trial, which included patients hospitalized for acute heart failure with kidney dysfunction. The study found that kidney tubule injury, as assessed by urinary biomarkers such as kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, and neutrophil gelatinase-associated lipocalin, is associated with both increased sodium avidity and impaired diuretic responsiveness. This association provides insight into the underlying mechanisms contributing to poor outcomes in acute heart failure.</p>
<h4>Article 4: Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823241" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823241</a></p>
<p><strong>Summary:</strong> Intensive systolic blood pressure treatment is a crucial strategy to mitigate cardiovascular disease risk in long-standing hypertension, with target organ damage being a critical intermediate phenotype. This study utilized data from 8442 participants in the S. T. E. P. trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients). The research precisely evaluated the impact of hypertension duration on the associations between intensive blood pressure control and improvements in cardiac, vascular, and kidney organ damage. This evaluation addresses a key gap in understanding how long-term hypertension affects the benefits of aggressive blood pressure management.</p>
<h4>Article 5: Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823240</a></p>
<p><strong>Summary:</strong> Heart failure with preserved ejection fraction is characterized by chronic low-grade inflammation, which impacts endothelial function, glycocalyx integrity, and barrier permeability. Glycocalyx degradation, specifically involving biomarkers hyaluronan and syndecan-1, is implicated in the pathophysiology of heart failure with preserved ejection fraction. This study established associations between these glycocalyx degradation biomarkers and both patient characteristics and clinical outcomes in heart failure with preserved ejection fraction. These findings link endothelial glycocalyx shedding to the development and progression of the disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation. Heart transplantation is an established gold standard therapy for end-stage systolic heart failure, showing a median survival of approximately 10 to 13 years. For younger patients under 50 years of age, the utility of heart transplantation for lifetime management is limited by low re-transplantation rates. Durable left ventricular assist device support is also an established surgical option for these patients. The article identifies an intentional strategy of utilizing durable left ventricular assist device therapy followed by heart transplantation to achieve net prolongation of life in advanced heart failure.</p>
<p>Article number two. Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study. Antibody-mediated rejection in heart transplants frequently presents without donor-specific antibodies, posing a diagnostic challenge. The Trifecta-Heart study provided characterization of rejection in 212 heart endomyocardial biopsies through the Molecular Microscope Diagnostic System and histology. This research distinguished molecular differences between donor-specific antibody-negative and donor-specific antibody-positive antibody-mediated rejection. Donor-derived cell-free D. N. A., a biomarker for transplant injury, was concurrently measured at the time of biopsy to enhance the understanding of these distinct rejection phenotypes.</p>
<p>Article number three. Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure. Greater sodium avidity in patients with acute heart failure is a known indicator of worse clinical outcomes. This study evaluated 339 participants from the R. O. S. E. hyphen A. H. F. trial, which included patients hospitalized for acute heart failure with kidney dysfunction. The study found that kidney tubule injury, as assessed by urinary biomarkers such as kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, and neutrophil gelatinase-associated lipocalin, is associated with both increased sodium avidity and impaired diuretic responsiveness. This association provides insight into the underlying mechanisms contributing to poor outcomes in acute heart failure.</p>
<p>Article number four. Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage. Intensive systolic blood pressure treatment is a crucial strategy to mitigate cardiovascular disease risk in long-standing hypertension, with target organ damage being a critical intermediate phenotype. This study utilized data from 8442 participants in the S. T. E. P. trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients). The research precisely evaluated the impact of hypertension duration on the associations between intensive blood pressure control and improvements in cardiac, vascular, and kidney organ damage. This evaluation addresses a key gap in understanding how long-term hypertension affects the benefits of aggressive blood pressure management.</p>
<p>Article number five. Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction. Heart failure with preserved ejection fraction is characterized by chronic low-grade inflammation, which impacts endothelial function, glycocalyx integrity, and barrier permeability. Glycocalyx degradation, specifically involving biomarkers hyaluronan and syndecan-1, is implicated in the pathophysiology of heart failure with preserved ejection fraction. This study established associations between these glycocalyx degradation biomarkers and both patient characteristics and clinical outcomes in heart failure with preserved ejection fraction. These findings link endothelial glycocalyx shedding to the development and progression of the disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Donor-specific antibody, Heart transplant rejection, Donor-derived cell-free D. N. A., Sodium avidity, Target organ damage, Heart failure with preserved ejection fraction, Endothelial function, End-stage heart failure, Kidney tubule injury, Kidney injury molecule-1, Lifetime management, Antibody-mediated rejection, Syndecan-1, Systolic blood pressure, Diuretic responsiveness, Glycocalyx degradation, Cardiovascular disease risk, Hypertension duration, Hyaluronan, Intensive blood pressure control, Molecular Microscope Diagnostic System, Heart transplantation, Acute heart failure, Systolic heart failure, Left ventricular assist device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/">Kidney Injury Drives Diuretic Resistance in A. H. F. 03/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260316_060137.mp3" length="4716085" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 16, 2026. This episode summarizes 5 key cardiology studies on topics like Donor-specific antibody and Heart transplant rejection. Key takeaway: Kidney Injury Drives Diuretic Resistance in A. H. F..
Article Links:
Article 1: Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure. (ESC heart failure)
Article 4: Effect of Hypertension Duration on the Associations Between Intensive Blood Pressure Control and Cardiac, Vascular, and Kidney Organ Damage. (Journal of the American Heart Association)
Article 5: Hyaluronan and Syndecan-1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/kidney-injury-drives-diuretic-resistance-in-a-h-f-03-16-26/
 Featured Articles
Article 1: Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41833594
Summary: Heart transplantation is an established gold standard therapy for end-stage systolic heart failure, showing a median survival of approximately 10 to 13 years. For younger patients under 50 years of age, the utility of heart transplantation for lifetime management is limited by low re-transplantation rates. Durable left ventricular assist device support is also an established surgical option for these patients. The article identifies an intentional strategy of utilizing durable left ventricular assist device therapy followed by heart transplantation to achieve net prolongation of life in advanced heart failure.
Article 2: Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41833593
Summary: Antibody-mediated rejection in heart transplants frequently presents without donor-specific antibodies, posing a diagnostic challenge. The Trifecta-Heart study provided characterization of rejection in 212 heart endomyocardial biopsies through the Molecular Microscope Diagnostic System and histology. This research distinguished molecular differences between donor-specific antibody-negative and donor-specific antibody-positive antibody-mediated rejection. Donor-derived cell-free D. N. A., a biomarker for transplant injury, was concurrently measured at the time of biopsy to enhance the understanding of these distinct rejection phenotypes.
Article 3: Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41832743
Summary: Greater sodium avidity in patients with acute heart failure is a known indicator of worse clinical outcomes. This study evaluated 339 participants from the R. O. S. E. hyphen A. H. F. trial, which included patients hospitalized for acute heart failure with kidney dysfunction. The study found that kidney tubule injury, as assessed by urinary biomarkers such as kidney i]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 16, 2026. This episode summarizes 5 key cardiology studies on topics like Donor-specific antibody and Heart transplant rejection. Key takeaway: Kidney Injury Drives Diuretic Resistance in A. H. F..
Article Links:
Article 1: Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure. (ESC heart failure)
Article 4: Effect of Hypertension Duration on the Associa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Chemotherapy Cardiotoxicity Mechanisms Found 03/15/26</title>
	<link>https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/</link>
	<pubDate>Sun, 15 Mar 2026 10:02:05 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 15, 2026. This episode summarizes 5 key cardiology studies on topics like psychological distress and non-pharmacological therapy. Key takeaway: Chemotherapy Cardiotoxicity Mechanisms Found.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41831639">The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41831305">Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41823248">Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41823245">Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823242">Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/">https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41831639" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41831639</a></p>
<p><strong>Summary:</strong> Increased left ventricular mass predicts heart failure, creating a significant focus on preventive strategies. Empagliflozin, a sodium-glucose cotransporter two inhibitor, is being evaluated for its effects on left ventricular mass index and left ventricular volumes. This evaluation targets elderly, overweight individuals who are considered at high risk of developing heart failure. The clinical investigation specifically examines empagliflozin&#8217;s role in this at-risk population where the preventive effect of sodium-glucose cotransporter two inhibitors is an area of active research.</p>
<h4>Article 2: Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41831305" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41831305</a></p>
<p><strong>Summary:</strong> F. pEF. Treatment options to improve exercise capacity in Heart Failure with Preserved Ejection Fraction remain limited. Investigating new approaches, sauna bathing is undergoing study for its potential to enhance exercise performance, skeletal muscle function, body composition, and patient quality of life in this population. The SAUNA-H. F. pEF study represents the first prospective mechanistic pilot study to evaluate the feasibility, safety, and efficacy of supervised sauna bathing. This research provides a novel therapeutic avenue for stable outpatients with Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 3: Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823248</a></p>
<p><strong>Summary:</strong> Spontaneous Coronary Artery Dissection is a highly distressing cause of acute myocardial infarction, for which no specific distress measure existed. Researchers developed and validated the Spontaneous Coronary Artery Dissection Distress Inventory (S. D. I.). This new tool provides a condition-specific measure designed to accurately capture the unique psychological impacts of Spontaneous Coronary Artery Dissection. The S. D. I. addresses the previous reliance on generic anxiety and depression measures, offering a more precise assessment for affected patients.</p>
<h4>Article 4: Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823245" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823245</a></p>
<p><strong>Summary:</strong> Long-term survivors of breast cancer treated with doxorubicin and trastuzumab-based chemotherapy show sympathetic neural overactivation, vascular dysfunction, and exercise intolerance. These physiological changes contribute to the increased risk of cardiovascular disease observed in this patient population. The study established these mechanisms as key factors in cardiovascular disease development following specific breast cancer treatments. These findings illuminate the previously unknown physiological underpinnings of cardiotoxicity in these survivors.</p>
<h4>Article 5: Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823242" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823242</a></p>
<p><strong>Summary:</strong> The Centers for Medicare and Medicaid Services enabled telemedicine reimbursement during the COVID-19 pandemic. Understanding the factors that facilitate telemedicine&#8217;s integration into ongoing cardiovascular practice is clinically important. This retrospective cohort study analyzed telemedicine and office visits delivered by cardiologists to Medicare beneficiaries from January 1, 2022, through December 31, 2023. The study identified key factors associated with cardiologists&#8217; utilization of telemedicine for this specific patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial. Increased left ventricular mass predicts heart failure, creating a significant focus on preventive strategies. Empagliflozin, a sodium-glucose cotransporter two inhibitor, is being evaluated for its effects on left ventricular mass index and left ventricular volumes. This evaluation targets elderly, overweight individuals who are considered at high risk of developing heart failure. The clinical investigation specifically examines empagliflozin&#8217;s role in this at-risk population where the preventive effect of sodium-glucose cotransporter two inhibitors is an area of active research.</p>
<p>Article number two. Effects of Sauna bathing on Exercise Capacity and Muscle Function in H. F. pEF. Treatment options to improve exercise capacity in Heart Failure with Preserved Ejection Fraction remain limited. Investigating new approaches, sauna bathing is undergoing study for its potential to enhance exercise performance, skeletal muscle function, body composition, and patient quality of life in this population. The SAUNA-H. F. pEF study represents the first prospective mechanistic pilot study to evaluate the feasibility, safety, and efficacy of supervised sauna bathing. This research provides a novel therapeutic avenue for stable outpatients with Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number three. Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory. Spontaneous Coronary Artery Dissection is a highly distressing cause of acute myocardial infarction, for which no specific distress measure existed. Researchers developed and validated the Spontaneous Coronary Artery Dissection Distress Inventory (S. D. I.). This new tool provides a condition-specific measure designed to accurately capture the unique psychological impacts of Spontaneous Coronary Artery Dissection. The S. D. I. addresses the previous reliance on generic anxiety and depression measures, offering a more precise assessment for affected patients.</p>
<p>Article number four. Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy. Long-term survivors of breast cancer treated with doxorubicin and trastuzumab-based chemotherapy show sympathetic neural overactivation, vascular dysfunction, and exercise intolerance. These physiological changes contribute to the increased risk of cardiovascular disease observed in this patient population. The study established these mechanisms as key factors in cardiovascular disease development following specific breast cancer treatments. These findings illuminate the previously unknown physiological underpinnings of cardiotoxicity in these survivors.</p>
<p>Article number five. Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study. The Centers for Medicare and Medicaid Services enabled telemedicine reimbursement during the COVID-19 pandemic. Understanding the factors that facilitate telemedicine&#8217;s integration into ongoing cardiovascular practice is clinically important. This retrospective cohort study analyzed telemedicine and office visits delivered by cardiologists to Medicare beneficiaries from January 1, 2022, through December 31, 2023. The study identified key factors associated with cardiologists&#8217; utilization of telemedicine for this specific patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>psychological distress, non-pharmacological therapy, muscle function, cardiotoxicity, doxorubicin, telemedicine, patient reported outcomes, breast cancer survivors, cardiologists, sauna bathing, left ventricular mass, exercise capacity, sympathetic overactivation, cardiovascular practice, trastuzumab, sodium-glucose cotransporter two inhibitors, spontaneous coronary artery dissection, vascular dysfunction, cardiovascular risk, healthcare delivery, exercise intolerance, Spontaneous Coronary Artery Dissection Distress Inventory, heart failure with preserved ejection fraction, Medicare beneficiaries, heart failure prevention, acute myocardial infarction, empagliflozin.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/">Chemotherapy Cardiotoxicity Mechanisms Found 03/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 15, 2026. This episode summarizes 5 key cardiology studies on topics like psychological distress and non-pharmacological therapy. Key takeaway: Chemotherapy Cardiotoxicity Mechanisms Found.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 15, 2026. This episode summarizes 5 key cardiology studies on topics like psychological distress and non-pharmacological therapy. Key takeaway: Chemotherapy Cardiotoxicity Mechanisms Found.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41831639">The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41831305">Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41823248">Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41823245">Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823242">Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/">https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41831639" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41831639</a></p>
<p><strong>Summary:</strong> Increased left ventricular mass predicts heart failure, creating a significant focus on preventive strategies. Empagliflozin, a sodium-glucose cotransporter two inhibitor, is being evaluated for its effects on left ventricular mass index and left ventricular volumes. This evaluation targets elderly, overweight individuals who are considered at high risk of developing heart failure. The clinical investigation specifically examines empagliflozin&#8217;s role in this at-risk population where the preventive effect of sodium-glucose cotransporter two inhibitors is an area of active research.</p>
<h4>Article 2: Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41831305" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41831305</a></p>
<p><strong>Summary:</strong> F. pEF. Treatment options to improve exercise capacity in Heart Failure with Preserved Ejection Fraction remain limited. Investigating new approaches, sauna bathing is undergoing study for its potential to enhance exercise performance, skeletal muscle function, body composition, and patient quality of life in this population. The SAUNA-H. F. pEF study represents the first prospective mechanistic pilot study to evaluate the feasibility, safety, and efficacy of supervised sauna bathing. This research provides a novel therapeutic avenue for stable outpatients with Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 3: Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823248</a></p>
<p><strong>Summary:</strong> Spontaneous Coronary Artery Dissection is a highly distressing cause of acute myocardial infarction, for which no specific distress measure existed. Researchers developed and validated the Spontaneous Coronary Artery Dissection Distress Inventory (S. D. I.). This new tool provides a condition-specific measure designed to accurately capture the unique psychological impacts of Spontaneous Coronary Artery Dissection. The S. D. I. addresses the previous reliance on generic anxiety and depression measures, offering a more precise assessment for affected patients.</p>
<h4>Article 4: Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823245" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823245</a></p>
<p><strong>Summary:</strong> Long-term survivors of breast cancer treated with doxorubicin and trastuzumab-based chemotherapy show sympathetic neural overactivation, vascular dysfunction, and exercise intolerance. These physiological changes contribute to the increased risk of cardiovascular disease observed in this patient population. The study established these mechanisms as key factors in cardiovascular disease development following specific breast cancer treatments. These findings illuminate the previously unknown physiological underpinnings of cardiotoxicity in these survivors.</p>
<h4>Article 5: Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823242" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823242</a></p>
<p><strong>Summary:</strong> The Centers for Medicare and Medicaid Services enabled telemedicine reimbursement during the COVID-19 pandemic. Understanding the factors that facilitate telemedicine&#8217;s integration into ongoing cardiovascular practice is clinically important. This retrospective cohort study analyzed telemedicine and office visits delivered by cardiologists to Medicare beneficiaries from January 1, 2022, through December 31, 2023. The study identified key factors associated with cardiologists&#8217; utilization of telemedicine for this specific patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial. Increased left ventricular mass predicts heart failure, creating a significant focus on preventive strategies. Empagliflozin, a sodium-glucose cotransporter two inhibitor, is being evaluated for its effects on left ventricular mass index and left ventricular volumes. This evaluation targets elderly, overweight individuals who are considered at high risk of developing heart failure. The clinical investigation specifically examines empagliflozin&#8217;s role in this at-risk population where the preventive effect of sodium-glucose cotransporter two inhibitors is an area of active research.</p>
<p>Article number two. Effects of Sauna bathing on Exercise Capacity and Muscle Function in H. F. pEF. Treatment options to improve exercise capacity in Heart Failure with Preserved Ejection Fraction remain limited. Investigating new approaches, sauna bathing is undergoing study for its potential to enhance exercise performance, skeletal muscle function, body composition, and patient quality of life in this population. The SAUNA-H. F. pEF study represents the first prospective mechanistic pilot study to evaluate the feasibility, safety, and efficacy of supervised sauna bathing. This research provides a novel therapeutic avenue for stable outpatients with Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number three. Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory. Spontaneous Coronary Artery Dissection is a highly distressing cause of acute myocardial infarction, for which no specific distress measure existed. Researchers developed and validated the Spontaneous Coronary Artery Dissection Distress Inventory (S. D. I.). This new tool provides a condition-specific measure designed to accurately capture the unique psychological impacts of Spontaneous Coronary Artery Dissection. The S. D. I. addresses the previous reliance on generic anxiety and depression measures, offering a more precise assessment for affected patients.</p>
<p>Article number four. Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy. Long-term survivors of breast cancer treated with doxorubicin and trastuzumab-based chemotherapy show sympathetic neural overactivation, vascular dysfunction, and exercise intolerance. These physiological changes contribute to the increased risk of cardiovascular disease observed in this patient population. The study established these mechanisms as key factors in cardiovascular disease development following specific breast cancer treatments. These findings illuminate the previously unknown physiological underpinnings of cardiotoxicity in these survivors.</p>
<p>Article number five. Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study. The Centers for Medicare and Medicaid Services enabled telemedicine reimbursement during the COVID-19 pandemic. Understanding the factors that facilitate telemedicine&#8217;s integration into ongoing cardiovascular practice is clinically important. This retrospective cohort study analyzed telemedicine and office visits delivered by cardiologists to Medicare beneficiaries from January 1, 2022, through December 31, 2023. The study identified key factors associated with cardiologists&#8217; utilization of telemedicine for this specific patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>psychological distress, non-pharmacological therapy, muscle function, cardiotoxicity, doxorubicin, telemedicine, patient reported outcomes, breast cancer survivors, cardiologists, sauna bathing, left ventricular mass, exercise capacity, sympathetic overactivation, cardiovascular practice, trastuzumab, sodium-glucose cotransporter two inhibitors, spontaneous coronary artery dissection, vascular dysfunction, cardiovascular risk, healthcare delivery, exercise intolerance, Spontaneous Coronary Artery Dissection Distress Inventory, heart failure with preserved ejection fraction, Medicare beneficiaries, heart failure prevention, acute myocardial infarction, empagliflozin.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/">Chemotherapy Cardiotoxicity Mechanisms Found 03/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260315_060102.mp3" length="4166469" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 15, 2026. This episode summarizes 5 key cardiology studies on topics like psychological distress and non-pharmacological therapy. Key takeaway: Chemotherapy Cardiotoxicity Mechanisms Found.
Article Links:
Article 1: The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial. (Journal of cardiac failure)
Article 2: Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF. (European journal of heart failure)
Article 3: Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory. (Journal of the American Heart Association)
Article 4: Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy. (Journal of the American Heart Association)
Article 5: Factors Associated With Telemedicine Use by Cardiologists for Medicare Beneficiaries in 2022 to 2023: An Observational Study. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/chemotherapy-cardiotoxicity-mechanisms-found-03-15-26/
 Featured Articles
Article 1: The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41831639
Summary: Increased left ventricular mass predicts heart failure, creating a significant focus on preventive strategies. Empagliflozin, a sodium-glucose cotransporter two inhibitor, is being evaluated for its effects on left ventricular mass index and left ventricular volumes. This evaluation targets elderly, overweight individuals who are considered at high risk of developing heart failure. The clinical investigation specifically examines empagliflozin&#8217;s role in this at-risk population where the preventive effect of sodium-glucose cotransporter two inhibitors is an area of active research.
Article 2: Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41831305
Summary: F. pEF. Treatment options to improve exercise capacity in Heart Failure with Preserved Ejection Fraction remain limited. Investigating new approaches, sauna bathing is undergoing study for its potential to enhance exercise performance, skeletal muscle function, body composition, and patient quality of life in this population. The SAUNA-H. F. pEF study represents the first prospective mechanistic pilot study to evaluate the feasibility, safety, and efficacy of supervised sauna bathing. This research provides a novel therapeutic avenue for stable outpatients with Heart Failure with Preserved Ejection Fraction.
Article 3: Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823248
Summary: Spontaneous Coronary Artery Dissection is a highly distressing cause of acute myocardial infarction, for which no specific distress measure existed. Researchers developed and validated the Spontaneous Coronary Artery Dissection Distress Inventory (S. D. I.). This new tool provides a condition-specific measure designed to accurately capture the unique psychological impacts of Spontaneous Coronary Artery Dissection. The S. D. I. addresses the previous reliance on generic anxiety and depression measures, offering a more precise assessment for affected patients.
Article 4: Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Into]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 15, 2026. This episode summarizes 5 key cardiology studies on topics like psychological distress and non-pharmacological therapy. Key takeaway: Chemotherapy Cardiotoxicity Mechanisms Found.
Article Links:
Article 1: The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial. (Journal of cardiac failure)
Article 2: Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF. (European journal of heart failure)
Article 3: Development and Validation of a Measure of Psychological Distress After Spontaneous Coronary Artery Dissection: The Spontaneous Coronary Artery Dissection Distress Inventory. (Journal of the American Heart Association)
Article 4: Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemot]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Finerenone Boosts HFpEF Quality of Life 03/14/26</title>
	<link>https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/</link>
	<pubDate>Sat, 14 Mar 2026 12:53:39 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like Pressure microcatheter and Fractional flow reserve. Key takeaway: Finerenone Boosts HFpEF Quality of Life.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41823368">Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41817207">Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41823269">Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41823252">Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823250">Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study).</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/">https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823368" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823368</a></p>
<p><strong>Summary:</strong> This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin&#8217;s effects in this defined population.</p>
<h4>Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41817207" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41817207</a></p>
<p><strong>Summary:</strong> Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.</p>
<h4>Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823269</a></p>
<p><strong>Summary:</strong> This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.</p>
<h4>Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823252" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823252</a></p>
<p><strong>Summary:</strong> This A.N.A.F.I.E. subanalysis evaluated the clinical outcomes of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy in patients aged 75 years or older with nonvalvular atrial fibrillation. The study established the differential impact of these two treatment approaches on clinical endpoints in an elderly Japanese cohort. The findings provided crucial comparative data for managing older atrial fibrillation patients, informing decisions about optimal antithrombotic strategies. This prospective multicenter observational study contributes to understanding medication effects in a high-risk population.</p>
<h4>Article 5: Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study).</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823250</a></p>
<p><strong>Summary:</strong> This S.U.P.R.E.M.E. two study introduced and described the constant resistance ratio, a novel nonhyperemic pressure ratio derived from piezoresistive pressure microcatheter measurements. The investigation performed repeated measurements to compare the diagnostic performance of this constant resistance ratio against fractional flow reserve in coronary lesions with 30 percent to 90 percent diameter stenosis. The study established the operational methodology for applying this new microcatheter-based technique to assess coronary physiology. Its findings provided a direct comparison between these two assessment modalities, enhancing understanding of nonhyperemic pressure ratios.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin&#8217;s effects in this defined population.</p>
<p>Article number two. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.</p>
<p>Article number three. Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients. This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.</p>
<p>Article number four. Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. This A.N.A.F.I.E. subanalysis evaluated the clinical outcomes of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy in patients aged 75 years or older with nonvalvular atrial fibrillation. The study established the differential impact of these two treatment approaches on clinical endpoints in an elderly Japanese cohort. The findings provided crucial comparative data for managing older atrial fibrillation patients, informing decisions about optimal antithrombotic strategies. This prospective multicenter observational study contributes to understanding medication effects in a high-risk population.</p>
<p>Article number five. Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study). This S.U.P.R.E.M.E. two study introduced and described the constant resistance ratio, a novel nonhyperemic pressure ratio derived from piezoresistive pressure microcatheter measurements. The investigation performed repeated measurements to compare the diagnostic performance of this constant resistance ratio against fractional flow reserve in coronary lesions with 30 percent to 90 percent diameter stenosis. The study established the operational methodology for applying this new microcatheter-based technique to assess coronary physiology. Its findings provided a direct comparison between these two assessment modalities, enhancing understanding of nonhyperemic pressure ratios. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Pressure microcatheter, Fractional flow reserve, Cardiac glycosides, Antiplatelet drugs, Quality of life, Risk factors, Cardiac surgery, Antithrombotic therapy, Postoperative complications, Heart failure with preserved ejection fraction, Constant resistance ratio, Health status, Infective endocarditis, Kansas City Cardiomyopathy Questionnaire, Finerenone, Left ventricular ejection fraction, Coronary lesions, Cardiac implantable electronic devices, Heart failure, Nonhyperemic pressure ratio, Clinical trial, Elderly patients, Oral anticoagulants, Atrial fibrillation, Digoxin.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/">Finerenone Boosts HFpEF Quality of Life 03/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like Pressure microcatheter and Fractional flow reserve. Key takeaway: Finerenone Boosts HFpEF Quality of Life.
Article Links:
Article 1: He]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like Pressure microcatheter and Fractional flow reserve. Key takeaway: Finerenone Boosts HFpEF Quality of Life.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41823368">Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41817207">Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41823269">Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41823252">Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823250">Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study).</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/">https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823368" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823368</a></p>
<p><strong>Summary:</strong> This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin&#8217;s effects in this defined population.</p>
<h4>Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41817207" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41817207</a></p>
<p><strong>Summary:</strong> Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.</p>
<h4>Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823269</a></p>
<p><strong>Summary:</strong> This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.</p>
<h4>Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823252" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823252</a></p>
<p><strong>Summary:</strong> This A.N.A.F.I.E. subanalysis evaluated the clinical outcomes of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy in patients aged 75 years or older with nonvalvular atrial fibrillation. The study established the differential impact of these two treatment approaches on clinical endpoints in an elderly Japanese cohort. The findings provided crucial comparative data for managing older atrial fibrillation patients, informing decisions about optimal antithrombotic strategies. This prospective multicenter observational study contributes to understanding medication effects in a high-risk population.</p>
<h4>Article 5: Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study).</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823250</a></p>
<p><strong>Summary:</strong> This S.U.P.R.E.M.E. two study introduced and described the constant resistance ratio, a novel nonhyperemic pressure ratio derived from piezoresistive pressure microcatheter measurements. The investigation performed repeated measurements to compare the diagnostic performance of this constant resistance ratio against fractional flow reserve in coronary lesions with 30 percent to 90 percent diameter stenosis. The study established the operational methodology for applying this new microcatheter-based technique to assess coronary physiology. Its findings provided a direct comparison between these two assessment modalities, enhancing understanding of nonhyperemic pressure ratios.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin&#8217;s effects in this defined population.</p>
<p>Article number two. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.</p>
<p>Article number three. Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients. This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.</p>
<p>Article number four. Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. This A.N.A.F.I.E. subanalysis evaluated the clinical outcomes of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy in patients aged 75 years or older with nonvalvular atrial fibrillation. The study established the differential impact of these two treatment approaches on clinical endpoints in an elderly Japanese cohort. The findings provided crucial comparative data for managing older atrial fibrillation patients, informing decisions about optimal antithrombotic strategies. This prospective multicenter observational study contributes to understanding medication effects in a high-risk population.</p>
<p>Article number five. Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study). This S.U.P.R.E.M.E. two study introduced and described the constant resistance ratio, a novel nonhyperemic pressure ratio derived from piezoresistive pressure microcatheter measurements. The investigation performed repeated measurements to compare the diagnostic performance of this constant resistance ratio against fractional flow reserve in coronary lesions with 30 percent to 90 percent diameter stenosis. The study established the operational methodology for applying this new microcatheter-based technique to assess coronary physiology. Its findings provided a direct comparison between these two assessment modalities, enhancing understanding of nonhyperemic pressure ratios. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Pressure microcatheter, Fractional flow reserve, Cardiac glycosides, Antiplatelet drugs, Quality of life, Risk factors, Cardiac surgery, Antithrombotic therapy, Postoperative complications, Heart failure with preserved ejection fraction, Constant resistance ratio, Health status, Infective endocarditis, Kansas City Cardiomyopathy Questionnaire, Finerenone, Left ventricular ejection fraction, Coronary lesions, Cardiac implantable electronic devices, Heart failure, Nonhyperemic pressure ratio, Clinical trial, Elderly patients, Oral anticoagulants, Atrial fibrillation, Digoxin.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/">Finerenone Boosts HFpEF Quality of Life 03/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260314_085220.mp3" length="4601146" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like Pressure microcatheter and Fractional flow reserve. Key takeaway: Finerenone Boosts HFpEF Quality of Life.
Article Links:
Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. (European journal of heart failure)
Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. (European journal of heart failure)
Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients. (Journal of the American Heart Association)
Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. (Journal of the American Heart Association)
Article 5: Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study). (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/
 Featured Articles
Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823368
Summary: This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin&#8217;s effects in this defined population.
Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41817207
Summary: Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.
Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823269
Summary: This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.
Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.
Journal: Journal of the American Heart Association
PubMed Link: htt]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like Pressure microcatheter and Fractional flow reserve. Key takeaway: Finerenone Boosts HFpEF Quality of Life.
Article Links:
Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. (European journal of heart failure)
Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. (European journal of heart failure)
Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients. (Journal of the American Heart Association)
Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. (Journal of the American Heart Association)
Article 5: Clinical Validation of a Novel Pressure M]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Genetic Evidence for GLP1R in Heart Failure 03/14/26</title>
	<link>https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/</link>
	<pubDate>Sat, 14 Mar 2026 10:01:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and mortality. Key takeaway: Genetic Evidence for GLP1R in Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41823519">Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41825942">Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41825483">Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41825486">Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823981">Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/">https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823519" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823519</a></p>
<p><strong>Summary:</strong> The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.</p>
<h4>Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41825942" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41825942</a></p>
<p><strong>Summary:</strong> A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.</p>
<h4>Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41825483" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41825483</a></p>
<p><strong>Summary:</strong> L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.</p>
<h4>Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41825486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41825486</a></p>
<p><strong>Summary:</strong> This study, using data from the EuroTR registry, found that coexisting left-sided heart failure phenotypes significantly determine outcomes in patients undergoing tricuspid valve transcatheter edge-to-edge repair for severe tricuspid regurgitation. The research stratified patients based on left ventricular ejection fraction into reduced or mildly reduced heart failure (below 50 percent) and preserved ejection fraction (50 percent or greater). This analysis demonstrated the specific impact of these heart failure subtypes on 2-year all-cause mortality following the repair procedure.</p>
<h4>Article 5: Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823981" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823981</a></p>
<p><strong>Summary:</strong> This study investigated the cardiovascular-kidney-metabolic syndrome in patients undergoing transcatheter aortic valve implantation. A retrospective analysis of patients from 2011 to 2024 diagnosed and quantified cardiovascular-kidney-metabolic syndrome using a simplified definition. The study established the prevalence of cardiovascular-kidney-metabolic syndrome in this patient population. Furthermore, it demonstrated the significant influence of cardiovascular-kidney-metabolic syndrome on adverse outcomes following transcatheter aortic valve implantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes. The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.</p>
<p>Article number two. Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights. A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.</p>
<p>Article number three. Genetic Evidence for G. L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.</p>
<p>Article number four. Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair. This study, using data from the EuroTR registry, found that coexisting left-sided heart failure phenotypes significantly determine outcomes in patients undergoing tricuspid valve transcatheter edge-to-edge repair for severe tricuspid regurgitation. The research stratified patients based on left ventricular ejection fraction into reduced or mildly reduced heart failure (below 50 percent) and preserved ejection fraction (50 percent or greater). This analysis demonstrated the specific impact of these heart failure subtypes on 2-year all-cause mortality following the repair procedure.</p>
<p>Article number five. Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. This study investigated the cardiovascular-kidney-metabolic syndrome in patients undergoing transcatheter aortic valve implantation. A retrospective analysis of patients from 2011 to 2024 diagnosed and quantified cardiovascular-kidney-metabolic syndrome using a simplified definition. The study established the prevalence of cardiovascular-kidney-metabolic syndrome in this patient population. Furthermore, it demonstrated the significant influence of cardiovascular-kidney-metabolic syndrome on adverse outcomes following transcatheter aortic valve implantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk stratification, mortality, pre-test probability, left-sided heart failure, cardiovascular-kidney-metabolic syndrome, heart failure with reduced ejection fraction, outcomes, glucagon-like peptide-one receptor agonists, European Society of Cardiology guidelines, prevalence, Mendelian randomization, heart failure with preserved ejection fraction, left ventricular function, prognostic relevance, risk factor-weighted clinical likelihood model, genetic evidence, transcatheter aortic valve implantation, tricuspid regurgitation, prognosis, cardiac amyloidosis, chronic coronary syndromes, coronary artery disease, diagnosis, non-ischaemic heart failure, tricuspid valve transcatheter edge-to-edge repair.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/">Genetic Evidence for GLP1R in Heart Failure 03/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and mortality. Key takeaway: Genetic Evidence for GLP1R in Heart Failure.
Article Links:
Article 1: Great debate: t]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and mortality. Key takeaway: Genetic Evidence for GLP1R in Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41823519">Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41825942">Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41825483">Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41825486">Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41823981">Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/">https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823519" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823519</a></p>
<p><strong>Summary:</strong> The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.</p>
<h4>Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41825942" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41825942</a></p>
<p><strong>Summary:</strong> A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.</p>
<h4>Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41825483" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41825483</a></p>
<p><strong>Summary:</strong> L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.</p>
<h4>Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41825486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41825486</a></p>
<p><strong>Summary:</strong> This study, using data from the EuroTR registry, found that coexisting left-sided heart failure phenotypes significantly determine outcomes in patients undergoing tricuspid valve transcatheter edge-to-edge repair for severe tricuspid regurgitation. The research stratified patients based on left ventricular ejection fraction into reduced or mildly reduced heart failure (below 50 percent) and preserved ejection fraction (50 percent or greater). This analysis demonstrated the specific impact of these heart failure subtypes on 2-year all-cause mortality following the repair procedure.</p>
<h4>Article 5: Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41823981" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41823981</a></p>
<p><strong>Summary:</strong> This study investigated the cardiovascular-kidney-metabolic syndrome in patients undergoing transcatheter aortic valve implantation. A retrospective analysis of patients from 2011 to 2024 diagnosed and quantified cardiovascular-kidney-metabolic syndrome using a simplified definition. The study established the prevalence of cardiovascular-kidney-metabolic syndrome in this patient population. Furthermore, it demonstrated the significant influence of cardiovascular-kidney-metabolic syndrome on adverse outcomes following transcatheter aortic valve implantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes. The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.</p>
<p>Article number two. Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights. A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.</p>
<p>Article number three. Genetic Evidence for G. L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.</p>
<p>Article number four. Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair. This study, using data from the EuroTR registry, found that coexisting left-sided heart failure phenotypes significantly determine outcomes in patients undergoing tricuspid valve transcatheter edge-to-edge repair for severe tricuspid regurgitation. The research stratified patients based on left ventricular ejection fraction into reduced or mildly reduced heart failure (below 50 percent) and preserved ejection fraction (50 percent or greater). This analysis demonstrated the specific impact of these heart failure subtypes on 2-year all-cause mortality following the repair procedure.</p>
<p>Article number five. Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. This study investigated the cardiovascular-kidney-metabolic syndrome in patients undergoing transcatheter aortic valve implantation. A retrospective analysis of patients from 2011 to 2024 diagnosed and quantified cardiovascular-kidney-metabolic syndrome using a simplified definition. The study established the prevalence of cardiovascular-kidney-metabolic syndrome in this patient population. Furthermore, it demonstrated the significant influence of cardiovascular-kidney-metabolic syndrome on adverse outcomes following transcatheter aortic valve implantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk stratification, mortality, pre-test probability, left-sided heart failure, cardiovascular-kidney-metabolic syndrome, heart failure with reduced ejection fraction, outcomes, glucagon-like peptide-one receptor agonists, European Society of Cardiology guidelines, prevalence, Mendelian randomization, heart failure with preserved ejection fraction, left ventricular function, prognostic relevance, risk factor-weighted clinical likelihood model, genetic evidence, transcatheter aortic valve implantation, tricuspid regurgitation, prognosis, cardiac amyloidosis, chronic coronary syndromes, coronary artery disease, diagnosis, non-ischaemic heart failure, tricuspid valve transcatheter edge-to-edge repair.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/">Genetic Evidence for GLP1R in Heart Failure 03/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260314_060030.mp3" length="4227491" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and mortality. Key takeaway: Genetic Evidence for GLP1R in Heart Failure.
Article Links:
Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes. (European heart journal)
Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights. (Heart (British Cardiac Society))
Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure. (ESC heart failure)
Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair. (European journal of heart failure)
Article 5: Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/genetic-evidence-for-glp1r-in-heart-failure-03-14-26/
 Featured Articles
Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823519
Summary: The article presents the utility of the new risk factor-weighted clinical likelihood model for estimating the initial pre-test probability of obstructive coronary artery disease. The 2024 European Society of Cardiology guidelines recommend this risk factor-weighted clinical likelihood model as the initial step for individuals with suspected chronic coronary syndromes. This model combines age, sex, symptom characteristics, five clinical risk factors, and coronary calcification data, when available, to provide a numerical estimate of pre-test probability.
Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41825942
Summary: A study of 2244 patients with cardiac amyloidosis demonstrated that many present with mildly reduced or reduced ejection fraction, not solely preserved ejection fraction as commonly perceived. The cohort included 557 patients with light chain amyloidosis, 392 with hereditary transthyretin amyloidosis, and 1137 with wild-type transthyretin amyloidosis. Recognizing cardiac amyloidosis across this full spectrum of left ventricular function, from preserved to reduced ejection fraction, is crucial for accurate diagnosis and effective risk stratification.
Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41825483
Summary: L. P. 1 R Agonists in Non-Ischaemic Heart Failure. Glucagon-like peptide-one receptor agonists demonstrate existing cardiovascular event reduction in patients with obesity and diabetes, alongside symptomatic and functional benefits in heart failure with preserved ejection fraction. This study employed drug-target Mendelian randomization using genetic variants in the glucagon-like peptide-one receptor locus. The research revealed genetic evidence supporting the efficacy of glucagon-like peptide-one receptor activation in non-ischaemic heart failure. This genetic approach offers insights into mechanisms beyond glycaemic control or weight reduction.
Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41825486
Summary: This study, using data from the ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and mortality. Key takeaway: Genetic Evidence for GLP1R in Heart Failure.
Article Links:
Article 1: Great debate: the new risk factor-weighted clinical likelihood model is useful to estimate the initial pre-test probability of obstructive coronary artery disease in individuals with suspected chronic coronary syndromes. (European heart journal)
Article 2: Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights. (Heart (British Cardiac Society))
Article 3: Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure. (ESC heart failure)
Article 4: Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair. (European journal of heart failure)
Article 5: Prevalence and influence of cardiovascular kidney metabolic syndrome o]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>H. F. pEF Shunt System: 3-Year Safety &#038; Function 03/13/26</title>
	<link>https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/</link>
	<pubDate>Fri, 13 Mar 2026 10:01:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 13, 2026. This episode summarizes 5 key cardiology studies on topics like left atrial pressure and left atrial shunting. Key takeaway: H. F. pEF Shunt System: 3-Year Safety &#038; Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40930594">Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40877031">Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40866119">Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40664496">Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41814577">The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in HFpEF.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/">https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930594" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930594</a></p>
<p><strong>Summary:</strong> The EPIC-CAD trial defined specific patient populations with atrial fibrillation and stable coronary artery disease receiving edoxaban antithrombotic therapy. This study investigated the clinical outcomes associated with off-label underdosing of direct oral anticoagulants in this patient cohort. Participants were randomized to either edoxaban monotherapy or a dual antithrombotic therapy regimen combining edoxaban with a single antiplatelet agent. This research therefore characterizes the comparative safety and efficacy of these two distinct antithrombotic strategies.</p>
<h4>Article 2: Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40877031" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40877031</a></p>
<p><strong>Summary:</strong> This study systematically analyzed over 2 million 512 445 cardiovascular publications to characterize research topics, trends, and interdisciplinarity. Artificial intelligence techniques, including natural language processing, were extensively utilized to extract and cluster text fragments from titles and abstracts. This comprehensive data processing approach provides a foundation for clarifying recent cardiovascular research directions and informs policy development for the academic community.</p>
<h4>Article 3: Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40866119" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40866119</a></p>
<p><strong>Summary:</strong> This study characterized electrocardiogram abnormalities in 26846 Chinese individuals aged 50 and older from the Guangzhou Biobank Cohort Study. Participants had no cardiovascular disease at baseline. Minor and major electrocardiogram abnormalities were classified based on the Minnesota Code Manual, allowing for definitive categorization of severity. Severity was specifically defined as normal, one minor, two or more minor, or major.</p>
<h4>Article 4: Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40664496" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40664496</a></p>
<p><strong>Summary:</strong> This study performed a retrospective assessment of sudden cardiac death incidence in patients with atrial fibrillation over an 11-year period, from 2007 to 2018. The analysis included individuals undergoing coronary angiography, specifically those with suspected or known coronary artery disease referred for elective angiography. The study also encompassed patients presenting with acute coronary syndrome, characterizing the long-term sudden cardiac death risk within these specific patient cohorts.</p>
<h4>Article 5: The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in HFpEF.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41814577" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41814577</a></p>
<p><strong>Summary:</strong> The ALT-FLOW Early Feasibility Study assessed device safety, patency, and echocardiographic parameters over three years in patients with heart failure with preserved ejection fraction. The study specifically evaluated symptoms, health status, and exercise capacity in 95 patients who had a left ventricular ejection fraction greater than 40 percent. This research therefore characterizes the long-term performance of the A. P. T. U. R. E. transcatheter shunt system for left atrial to coronary sinus shunting.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial. The EPIC-CAD trial defined specific patient populations with atrial fibrillation and stable coronary artery disease receiving edoxaban antithrombotic therapy. This study investigated the clinical outcomes associated with off-label underdosing of direct oral anticoagulants in this patient cohort. Participants were randomized to either edoxaban monotherapy or a dual antithrombotic therapy regimen combining edoxaban with a single antiplatelet agent. This research therefore characterizes the comparative safety and efficacy of these two distinct antithrombotic strategies.</p>
<p>Article number two. Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity. This study systematically analyzed over 2 million 512 445 cardiovascular publications to characterize research topics, trends, and interdisciplinarity. Artificial intelligence techniques, including natural language processing, were extensively utilized to extract and cluster text fragments from titles and abstracts. This comprehensive data processing approach provides a foundation for clarifying recent cardiovascular research directions and informs policy development for the academic community.</p>
<p>Article number three. Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study. This study characterized electrocardiogram abnormalities in 26846 Chinese individuals aged 50 and older from the Guangzhou Biobank Cohort Study. Participants had no cardiovascular disease at baseline. Minor and major electrocardiogram abnormalities were classified based on the Minnesota Code Manual, allowing for definitive categorization of severity. Severity was specifically defined as normal, one minor, two or more minor, or major.</p>
<p>Article number four. Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications. This study performed a retrospective assessment of sudden cardiac death incidence in patients with atrial fibrillation over an 11-year period, from 2007 to 2018. The analysis included individuals undergoing coronary angiography, specifically those with suspected or known coronary artery disease referred for elective angiography. The study also encompassed patients presenting with acute coronary syndrome, characterizing the long-term sudden cardiac death risk within these specific patient cohorts.</p>
<p>Article number five. The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in Heart Failure with Preserved Ejection Fraction. The ALT-FLOW Early Feasibility Study assessed device safety, patency, and echocardiographic parameters over three years in patients with heart failure with preserved ejection fraction. The study specifically evaluated symptoms, health status, and exercise capacity in 95 patients who had a left ventricular ejection fraction greater than 40 percent. This research therefore characterizes the long-term performance of the A. P. T. U. R. E. transcatheter shunt system for left atrial to coronary sinus shunting. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left atrial pressure, left atrial shunting, research trends, electrocardiogram abnormalities, antithrombotic therapy, heart failure with preserved ejection fraction, atrial fibrillation, edoxaban, direct oral anticoagulants, A. P. T. U. R. E. system, cardiovascular risk, sudden cardiac death, Minnesota Code Manual, Guangzhou Biobank Cohort Study, coronary angiography, transcatheter shunt, acute coronary syndrome, artificial intelligence, cardiovascular research, older populations, coronary artery disease, natural language processing, bibliometrics.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/">H. F. pEF Shunt System: 3-Year Safety & Function 03/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 13, 2026. This episode summarizes 5 key cardiology studies on topics like left atrial pressure and left atrial shunting. Key takeaway: H. F. pEF Shunt System: 3-Year Safety &#038; Function.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 13, 2026. This episode summarizes 5 key cardiology studies on topics like left atrial pressure and left atrial shunting. Key takeaway: H. F. pEF Shunt System: 3-Year Safety &#038; Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40930594">Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40877031">Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40866119">Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40664496">Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41814577">The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in HFpEF.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/">https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930594" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930594</a></p>
<p><strong>Summary:</strong> The EPIC-CAD trial defined specific patient populations with atrial fibrillation and stable coronary artery disease receiving edoxaban antithrombotic therapy. This study investigated the clinical outcomes associated with off-label underdosing of direct oral anticoagulants in this patient cohort. Participants were randomized to either edoxaban monotherapy or a dual antithrombotic therapy regimen combining edoxaban with a single antiplatelet agent. This research therefore characterizes the comparative safety and efficacy of these two distinct antithrombotic strategies.</p>
<h4>Article 2: Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40877031" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40877031</a></p>
<p><strong>Summary:</strong> This study systematically analyzed over 2 million 512 445 cardiovascular publications to characterize research topics, trends, and interdisciplinarity. Artificial intelligence techniques, including natural language processing, were extensively utilized to extract and cluster text fragments from titles and abstracts. This comprehensive data processing approach provides a foundation for clarifying recent cardiovascular research directions and informs policy development for the academic community.</p>
<h4>Article 3: Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40866119" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40866119</a></p>
<p><strong>Summary:</strong> This study characterized electrocardiogram abnormalities in 26846 Chinese individuals aged 50 and older from the Guangzhou Biobank Cohort Study. Participants had no cardiovascular disease at baseline. Minor and major electrocardiogram abnormalities were classified based on the Minnesota Code Manual, allowing for definitive categorization of severity. Severity was specifically defined as normal, one minor, two or more minor, or major.</p>
<h4>Article 4: Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40664496" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40664496</a></p>
<p><strong>Summary:</strong> This study performed a retrospective assessment of sudden cardiac death incidence in patients with atrial fibrillation over an 11-year period, from 2007 to 2018. The analysis included individuals undergoing coronary angiography, specifically those with suspected or known coronary artery disease referred for elective angiography. The study also encompassed patients presenting with acute coronary syndrome, characterizing the long-term sudden cardiac death risk within these specific patient cohorts.</p>
<h4>Article 5: The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in HFpEF.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41814577" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41814577</a></p>
<p><strong>Summary:</strong> The ALT-FLOW Early Feasibility Study assessed device safety, patency, and echocardiographic parameters over three years in patients with heart failure with preserved ejection fraction. The study specifically evaluated symptoms, health status, and exercise capacity in 95 patients who had a left ventricular ejection fraction greater than 40 percent. This research therefore characterizes the long-term performance of the A. P. T. U. R. E. transcatheter shunt system for left atrial to coronary sinus shunting.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial. The EPIC-CAD trial defined specific patient populations with atrial fibrillation and stable coronary artery disease receiving edoxaban antithrombotic therapy. This study investigated the clinical outcomes associated with off-label underdosing of direct oral anticoagulants in this patient cohort. Participants were randomized to either edoxaban monotherapy or a dual antithrombotic therapy regimen combining edoxaban with a single antiplatelet agent. This research therefore characterizes the comparative safety and efficacy of these two distinct antithrombotic strategies.</p>
<p>Article number two. Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity. This study systematically analyzed over 2 million 512 445 cardiovascular publications to characterize research topics, trends, and interdisciplinarity. Artificial intelligence techniques, including natural language processing, were extensively utilized to extract and cluster text fragments from titles and abstracts. This comprehensive data processing approach provides a foundation for clarifying recent cardiovascular research directions and informs policy development for the academic community.</p>
<p>Article number three. Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study. This study characterized electrocardiogram abnormalities in 26846 Chinese individuals aged 50 and older from the Guangzhou Biobank Cohort Study. Participants had no cardiovascular disease at baseline. Minor and major electrocardiogram abnormalities were classified based on the Minnesota Code Manual, allowing for definitive categorization of severity. Severity was specifically defined as normal, one minor, two or more minor, or major.</p>
<p>Article number four. Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications. This study performed a retrospective assessment of sudden cardiac death incidence in patients with atrial fibrillation over an 11-year period, from 2007 to 2018. The analysis included individuals undergoing coronary angiography, specifically those with suspected or known coronary artery disease referred for elective angiography. The study also encompassed patients presenting with acute coronary syndrome, characterizing the long-term sudden cardiac death risk within these specific patient cohorts.</p>
<p>Article number five. The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in Heart Failure with Preserved Ejection Fraction. The ALT-FLOW Early Feasibility Study assessed device safety, patency, and echocardiographic parameters over three years in patients with heart failure with preserved ejection fraction. The study specifically evaluated symptoms, health status, and exercise capacity in 95 patients who had a left ventricular ejection fraction greater than 40 percent. This research therefore characterizes the long-term performance of the A. P. T. U. R. E. transcatheter shunt system for left atrial to coronary sinus shunting. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left atrial pressure, left atrial shunting, research trends, electrocardiogram abnormalities, antithrombotic therapy, heart failure with preserved ejection fraction, atrial fibrillation, edoxaban, direct oral anticoagulants, A. P. T. U. R. E. system, cardiovascular risk, sudden cardiac death, Minnesota Code Manual, Guangzhou Biobank Cohort Study, coronary angiography, transcatheter shunt, acute coronary syndrome, artificial intelligence, cardiovascular research, older populations, coronary artery disease, natural language processing, bibliometrics.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/">H. F. pEF Shunt System: 3-Year Safety & Function 03/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260313_060034.mp3" length="4021855" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 13, 2026. This episode summarizes 5 key cardiology studies on topics like left atrial pressure and left atrial shunting. Key takeaway: H. F. pEF Shunt System: 3-Year Safety &#038; Function.
Article Links:
Article 1: Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial. (Heart (British Cardiac Society))
Article 2: Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity. (Heart (British Cardiac Society))
Article 3: Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study. (Heart (British Cardiac Society))
Article 4: Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications. (Heart (British Cardiac Society))
Article 5: The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary Sinus Shunting in HFpEF. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/h-f-pef-shunt-system-3-year-safety-function-03-13-26/
 Featured Articles
Article 1: Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930594
Summary: The EPIC-CAD trial defined specific patient populations with atrial fibrillation and stable coronary artery disease receiving edoxaban antithrombotic therapy. This study investigated the clinical outcomes associated with off-label underdosing of direct oral anticoagulants in this patient cohort. Participants were randomized to either edoxaban monotherapy or a dual antithrombotic therapy regimen combining edoxaban with a single antiplatelet agent. This research therefore characterizes the comparative safety and efficacy of these two distinct antithrombotic strategies.
Article 2: Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40877031
Summary: This study systematically analyzed over 2 million 512 445 cardiovascular publications to characterize research topics, trends, and interdisciplinarity. Artificial intelligence techniques, including natural language processing, were extensively utilized to extract and cluster text fragments from titles and abstracts. This comprehensive data processing approach provides a foundation for clarifying recent cardiovascular research directions and informs policy development for the academic community.
Article 3: Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40866119
Summary: This study characterized electrocardiogram abnormalities in 26846 Chinese individuals aged 50 and older from the Guangzhou Biobank Cohort Study. Participants had no cardiovascular disease at baseline. Minor and major electrocardiogram abnormalities were classified based on the Minnesota Code Manual, allowing for definitive categorization of severity. Severity was specifically defined as normal, one minor, two or more minor, or major.
Article 4: Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40664496
Summary: This study performed a retrospective assessment of sudden cardiac death incidence in patients with atrial fibrillation over an 11-year period, from 2007 to 2018. The analysis included individuals undergoing coronary angiography, specifically those with suspected or known coronary artery disease referred for elective angiography. The study also encompassed patients presentin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 13, 2026. This episode summarizes 5 key cardiology studies on topics like left atrial pressure and left atrial shunting. Key takeaway: H. F. pEF Shunt System: 3-Year Safety &#038; Function.
Article Links:
Article 1: Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial. (Heart (British Cardiac Society))
Article 2: Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity. (Heart (British Cardiac Society))
Article 3: Electrocardiogram abnormalities and cardiovascular risk prediction in older Chinese: the Guangzhou Biobank Cohort Study. (Heart (British Cardiac Society))
Article 4: Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications. (Heart (British Cardiac Society))
Article 5: The ALT FLOW Early Feasibility Study 3-year Results Assessing Left Atrial to Coronary]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF. 03/12/26</title>
	<link>https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/</link>
	<pubDate>Thu, 12 Mar 2026 10:02:09 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like advanced heart failure and implanted defibrillators. Key takeaway: Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41812231">Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41812230">Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41812219">Optimised murine HFpEF models for translational pre-clinical studies.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41810505">Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41797492">Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/">https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812231" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812231</a></p>
<p><strong>Summary:</strong> Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.</p>
<h4>Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812230" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812230</a></p>
<p><strong>Summary:</strong> Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.</p>
<h4>Article 3: Optimised murine HFpEF models for translational pre-clinical studies.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812219</a></p>
<p><strong>Summary:</strong> F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.</p>
<h4>Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810505" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810505</a></p>
<p><strong>Summary:</strong> F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investigated how common comorbidities, specifically atrial fibrillation and ischemic heart disease, influence beta-blocker effects on H. F. pEF outcomes. Utilizing the PURSUIT-H. F. pEF registry, patients were divided into groups with or without these comorbidities. The research demonstrated how prognosis differed between beta-blocker users and non-users within these stratified patient populations, offering specific insights into treatment efficacy.</p>
<h4>Article 5: Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797492" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797492</a></p>
<p><strong>Summary:</strong> C. E. Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with H. F. rEF. This study found that target-dose angiotensin-converting enzyme inhibitors, or A. C. E. I. s, were associated with a lower risk of kidney failure compared to below-target-dose in U.S. Veterans with Heart Failure with reduced Ejection Fraction. While target-dose A. C. E. I. s and angiotensin receptor blockers are known to improve overall clinical outcomes in this population, their effect on kidney function, particularly kidney failure, has been less understood. The research demonstrated this benefit in a large cohort of 154945 Veterans, specifically addressing patients with advanced chronic kidney disease. These findings provide critical evidence supporting the use of target-dose A. C. E. I. s to mitigate kidney failure risk in Heart Failure with reduced Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study. Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.</p>
<p>Article number two. Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients. Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.</p>
<p>Article number three. Optimised murine H. F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.</p>
<p>Article number four. Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-H. F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investigated how common comorbidities, specifically atrial fibrillation and ischemic heart disease, influence beta-blocker effects on H. F. pEF outcomes. Utilizing the PURSUIT-H. F. pEF registry, patients were divided into groups with or without these comorbidities. The research demonstrated how prognosis differed between beta-blocker users and non-users within these stratified patient populations, offering specific insights into treatment efficacy.</p>
<p>Article number five. Target-Dose Versus Below-Target-Dose A. C. E. Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with H. F. rEF. This study found that target-dose angiotensin-converting enzyme inhibitors, or A. C. E. I. s, were associated with a lower risk of kidney failure compared to below-target-dose in U.S. Veterans with Heart Failure with reduced Ejection Fraction. While target-dose A. C. E. I. s and angiotensin receptor blockers are known to improve overall clinical outcomes in this population, their effect on kidney function, particularly kidney failure, has been less understood. The research demonstrated this benefit in a large cohort of 154945 Veterans, specifically addressing patients with advanced chronic kidney disease. These findings provide critical evidence supporting the use of target-dose A. C. E. I. s to mitigate kidney failure risk in Heart Failure with reduced Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>advanced heart failure, implanted defibrillators, heart failure with reduced ejection fraction, murine model, atrial fibrillation, H. F. pEF, left ventricular assist device, kidney failure, A. C. E. I. s, angiotensin-converting enzyme inhibitors, heart failure, Heart Failure with reduced Ejection Fraction, cardiovascular outcomes, HeartMate 3, metabolic syndrome, non-obese, beta-blockers, prognosis, ischemic heart disease, Heart Failure with preserved Ejection Fraction, translational research, device survival, H. F. rEF, chronic kidney disease, cardiac resynchronization therapy, L-NAME.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/">Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF. 03/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like advanced heart failure and implanted defibrillators. Key takeaway: Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF..
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like advanced heart failure and implanted defibrillators. Key takeaway: Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41812231">Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41812230">Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41812219">Optimised murine HFpEF models for translational pre-clinical studies.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41810505">Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41797492">Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/">https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812231" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812231</a></p>
<p><strong>Summary:</strong> Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.</p>
<h4>Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812230" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812230</a></p>
<p><strong>Summary:</strong> Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.</p>
<h4>Article 3: Optimised murine HFpEF models for translational pre-clinical studies.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812219</a></p>
<p><strong>Summary:</strong> F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.</p>
<h4>Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810505" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810505</a></p>
<p><strong>Summary:</strong> F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investigated how common comorbidities, specifically atrial fibrillation and ischemic heart disease, influence beta-blocker effects on H. F. pEF outcomes. Utilizing the PURSUIT-H. F. pEF registry, patients were divided into groups with or without these comorbidities. The research demonstrated how prognosis differed between beta-blocker users and non-users within these stratified patient populations, offering specific insights into treatment efficacy.</p>
<h4>Article 5: Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797492" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797492</a></p>
<p><strong>Summary:</strong> C. E. Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with H. F. rEF. This study found that target-dose angiotensin-converting enzyme inhibitors, or A. C. E. I. s, were associated with a lower risk of kidney failure compared to below-target-dose in U.S. Veterans with Heart Failure with reduced Ejection Fraction. While target-dose A. C. E. I. s and angiotensin receptor blockers are known to improve overall clinical outcomes in this population, their effect on kidney function, particularly kidney failure, has been less understood. The research demonstrated this benefit in a large cohort of 154945 Veterans, specifically addressing patients with advanced chronic kidney disease. These findings provide critical evidence supporting the use of target-dose A. C. E. I. s to mitigate kidney failure risk in Heart Failure with reduced Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study. Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.</p>
<p>Article number two. Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients. Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.</p>
<p>Article number three. Optimised murine H. F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.</p>
<p>Article number four. Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-H. F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investigated how common comorbidities, specifically atrial fibrillation and ischemic heart disease, influence beta-blocker effects on H. F. pEF outcomes. Utilizing the PURSUIT-H. F. pEF registry, patients were divided into groups with or without these comorbidities. The research demonstrated how prognosis differed between beta-blocker users and non-users within these stratified patient populations, offering specific insights into treatment efficacy.</p>
<p>Article number five. Target-Dose Versus Below-Target-Dose A. C. E. Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with H. F. rEF. This study found that target-dose angiotensin-converting enzyme inhibitors, or A. C. E. I. s, were associated with a lower risk of kidney failure compared to below-target-dose in U.S. Veterans with Heart Failure with reduced Ejection Fraction. While target-dose A. C. E. I. s and angiotensin receptor blockers are known to improve overall clinical outcomes in this population, their effect on kidney function, particularly kidney failure, has been less understood. The research demonstrated this benefit in a large cohort of 154945 Veterans, specifically addressing patients with advanced chronic kidney disease. These findings provide critical evidence supporting the use of target-dose A. C. E. I. s to mitigate kidney failure risk in Heart Failure with reduced Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>advanced heart failure, implanted defibrillators, heart failure with reduced ejection fraction, murine model, atrial fibrillation, H. F. pEF, left ventricular assist device, kidney failure, A. C. E. I. s, angiotensin-converting enzyme inhibitors, heart failure, Heart Failure with reduced Ejection Fraction, cardiovascular outcomes, HeartMate 3, metabolic syndrome, non-obese, beta-blockers, prognosis, ischemic heart disease, Heart Failure with preserved Ejection Fraction, translational research, device survival, H. F. rEF, chronic kidney disease, cardiac resynchronization therapy, L-NAME.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/">Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF. 03/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260312_060102.mp3" length="4580248" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like advanced heart failure and implanted defibrillators. Key takeaway: Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF..
Article Links:
Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study. (ESC heart failure)
Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients. (ESC heart failure)
Article 3: Optimised murine HFpEF models for translational pre-clinical studies. (ESC heart failure)
Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry. (European journal of heart failure)
Article 5: Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/
 Featured Articles
Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812231
Summary: Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.
Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812230
Summary: Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.
Article 3: Optimised murine HFpEF models for translational pre-clinical studies.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812219
Summary: F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.
Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810505
Summary: F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investiga]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like advanced heart failure and implanted defibrillators. Key takeaway: Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF..
Article Links:
Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device &#8211; a real-world, single center, observational study. (ESC heart failure)
Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients. (ESC heart failure)
Article 3: Optimised murine HFpEF models for translational pre-clinical studies. (ESC heart failure)
Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry. (European journal of heart failure)
Article 5: Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF. (European journal of heart failure)
Full ep]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Polyamine Inhibition Boosts Heart Transplant Acceptance 03/12/26</title>
	<link>https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/</link>
	<pubDate>Thu, 12 Mar 2026 06:36:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and Conduction system pacing. Key takeaway: Polyamine Inhibition Boosts Heart Transplant Acceptance.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41812731">Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41812968">Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41812967">Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer.</a> (Journal of cardiac failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41811324">Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41813099">Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/">https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812731</a></p>
<p><strong>Summary:</strong> D. 8 positive T cell differentiation. This study found polyamine metabolism was significantly upregulated in T cells during acute rejection in murine models. Inhibition of T cell polyamine metabolism promoted transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. The findings demonstrated a critical role for T cell polyamine metabolism in transplant rejection and identified a potential therapeutic target.</p>
<h4>Article 2: Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812968" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812968</a></p>
<p><strong>Summary:</strong> This study investigated the association of tricuspid regurgitation severity with longitudinal changes in activities of daily living and cognitive function. Researchers analyzed 1269 heart failure patients, 67.5 percent with Heart Failure with preserved ejection fraction, over a 1-year follow-up period. The investigation highlights the critical need to understand how tricuspid regurgitation impacts functional and cognitive decline in elderly heart failure patients.</p>
<h4>Article 3: Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812967" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812967</a></p>
<p><strong>Summary:</strong> This study examined the incidence of heart failure in individuals with diabetes mellitus and cancer compared with those having diabetes mellitus alone. Researchers established a national cohort by linking 792742 individuals aged 50 years or older from the Australian National Diabetes Services Scheme with hospital admissions and death records. The study provides important insights into identifying high-risk subgroups for heart failure among people with diabetes, specifically highlighting the impact of cancer.</p>
<h4>Article 4: Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41811324" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41811324</a></p>
<p><strong>Summary:</strong> F. Randomized Clinical Trial. The PhysioSync-H. F. randomized clinical trial compared conduction system pacing versus biventricular pacing for heart failure-related outcomes. This study focused on patients with Heart Failure with reduced ejection fraction and left bundle-branch block, a population where alternative pacing strategies are critical. The trial provides a direct comparison of these two pacing modalities, addressing uncertainty regarding their impact on heart failure outcomes.</p>
<h4>Article 5: Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41813099" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41813099</a></p>
<p><strong>Summary:</strong> This study presented a model-based cost-effectiveness analysis of five first-line pharmacotherapy combinations for adults with chronic Heart Failure with reduced ejection fraction. The lifetime cohort Markov model, developed from the National Health Service in England&#8217;s perspective, evaluated combinations including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. This analysis offers crucial information on the economic implications of different initial treatment strategies for Heart Failure with reduced ejection fraction, guiding resource allocation and clinical practice.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. This study found polyamine metabolism was significantly upregulated in T cells during acute rejection in murine models. Inhibition of T cell polyamine metabolism promoted transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. The findings demonstrated a critical role for T cell polyamine metabolism in transplant rejection and identified a potential therapeutic target.</p>
<p>Article number two. Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort. This study investigated the association of tricuspid regurgitation severity with longitudinal changes in activities of daily living and cognitive function. Researchers analyzed 1269 heart failure patients, 67.5 percent with Heart Failure with preserved ejection fraction, over a 1-year follow-up period. The investigation highlights the critical need to understand how tricuspid regurgitation impacts functional and cognitive decline in elderly heart failure patients.</p>
<p>Article number three. Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer. This study examined the incidence of heart failure in individuals with diabetes mellitus and cancer compared with those having diabetes mellitus alone. Researchers established a national cohort by linking 792742 individuals aged 50 years or older from the Australian National Diabetes Services Scheme with hospital admissions and death records. The study provides important insights into identifying high-risk subgroups for heart failure among people with diabetes, specifically highlighting the impact of cancer.</p>
<p>Article number four. Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-H. F. Randomized Clinical Trial. The PhysioSync-H. F. randomized clinical trial compared conduction system pacing versus biventricular pacing for heart failure-related outcomes. This study focused on patients with Heart Failure with reduced ejection fraction and left bundle-branch block, a population where alternative pacing strategies are critical. The trial provides a direct comparison of these two pacing modalities, addressing uncertainty regarding their impact on heart failure outcomes.</p>
<p>Article number five. Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction. This study presented a model-based cost-effectiveness analysis of five first-line pharmacotherapy combinations for adults with chronic Heart Failure with reduced ejection fraction. The lifetime cohort Markov model, developed from the National Health Service in England&#8217;s perspective, evaluated combinations including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. This analysis offers crucial information on the economic implications of different initial treatment strategies for Heart Failure with reduced ejection fraction, guiding resource allocation and clinical practice. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure with reduced ejection fraction, Conduction system pacing, dementia, angiotensin-converting enzyme inhibitor, Heart failure risk, Cost-effectiveness analysis, comorbidity, C. D. 8 T cells, activities of daily living, polyamines, T cell metabolism, cognitive function, heart failure, subgroup analysis, Tricuspid regurgitation, biventricular pacing, left bundle-branch block, angiotensin receptor blocker, pharmacotherapy, transplant rejection, immunosuppression, diabetes mellitus, cancer survivors, cardiac resynchronization therapy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/">Polyamine Inhibition Boosts Heart Transplant Acceptance 03/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and Conduction system pacing. Key takeaway: Polyamine Inhibition Boosts Heart Transplant A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and Conduction system pacing. Key takeaway: Polyamine Inhibition Boosts Heart Transplant Acceptance.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41812731">Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41812968">Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41812967">Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer.</a> (Journal of cardiac failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41811324">Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41813099">Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/">https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812731</a></p>
<p><strong>Summary:</strong> D. 8 positive T cell differentiation. This study found polyamine metabolism was significantly upregulated in T cells during acute rejection in murine models. Inhibition of T cell polyamine metabolism promoted transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. The findings demonstrated a critical role for T cell polyamine metabolism in transplant rejection and identified a potential therapeutic target.</p>
<h4>Article 2: Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812968" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812968</a></p>
<p><strong>Summary:</strong> This study investigated the association of tricuspid regurgitation severity with longitudinal changes in activities of daily living and cognitive function. Researchers analyzed 1269 heart failure patients, 67.5 percent with Heart Failure with preserved ejection fraction, over a 1-year follow-up period. The investigation highlights the critical need to understand how tricuspid regurgitation impacts functional and cognitive decline in elderly heart failure patients.</p>
<h4>Article 3: Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41812967" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41812967</a></p>
<p><strong>Summary:</strong> This study examined the incidence of heart failure in individuals with diabetes mellitus and cancer compared with those having diabetes mellitus alone. Researchers established a national cohort by linking 792742 individuals aged 50 years or older from the Australian National Diabetes Services Scheme with hospital admissions and death records. The study provides important insights into identifying high-risk subgroups for heart failure among people with diabetes, specifically highlighting the impact of cancer.</p>
<h4>Article 4: Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41811324" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41811324</a></p>
<p><strong>Summary:</strong> F. Randomized Clinical Trial. The PhysioSync-H. F. randomized clinical trial compared conduction system pacing versus biventricular pacing for heart failure-related outcomes. This study focused on patients with Heart Failure with reduced ejection fraction and left bundle-branch block, a population where alternative pacing strategies are critical. The trial provides a direct comparison of these two pacing modalities, addressing uncertainty regarding their impact on heart failure outcomes.</p>
<h4>Article 5: Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41813099" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41813099</a></p>
<p><strong>Summary:</strong> This study presented a model-based cost-effectiveness analysis of five first-line pharmacotherapy combinations for adults with chronic Heart Failure with reduced ejection fraction. The lifetime cohort Markov model, developed from the National Health Service in England&#8217;s perspective, evaluated combinations including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. This analysis offers crucial information on the economic implications of different initial treatment strategies for Heart Failure with reduced ejection fraction, guiding resource allocation and clinical practice.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. This study found polyamine metabolism was significantly upregulated in T cells during acute rejection in murine models. Inhibition of T cell polyamine metabolism promoted transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. The findings demonstrated a critical role for T cell polyamine metabolism in transplant rejection and identified a potential therapeutic target.</p>
<p>Article number two. Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort. This study investigated the association of tricuspid regurgitation severity with longitudinal changes in activities of daily living and cognitive function. Researchers analyzed 1269 heart failure patients, 67.5 percent with Heart Failure with preserved ejection fraction, over a 1-year follow-up period. The investigation highlights the critical need to understand how tricuspid regurgitation impacts functional and cognitive decline in elderly heart failure patients.</p>
<p>Article number three. Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer. This study examined the incidence of heart failure in individuals with diabetes mellitus and cancer compared with those having diabetes mellitus alone. Researchers established a national cohort by linking 792742 individuals aged 50 years or older from the Australian National Diabetes Services Scheme with hospital admissions and death records. The study provides important insights into identifying high-risk subgroups for heart failure among people with diabetes, specifically highlighting the impact of cancer.</p>
<p>Article number four. Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-H. F. Randomized Clinical Trial. The PhysioSync-H. F. randomized clinical trial compared conduction system pacing versus biventricular pacing for heart failure-related outcomes. This study focused on patients with Heart Failure with reduced ejection fraction and left bundle-branch block, a population where alternative pacing strategies are critical. The trial provides a direct comparison of these two pacing modalities, addressing uncertainty regarding their impact on heart failure outcomes.</p>
<p>Article number five. Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction. This study presented a model-based cost-effectiveness analysis of five first-line pharmacotherapy combinations for adults with chronic Heart Failure with reduced ejection fraction. The lifetime cohort Markov model, developed from the National Health Service in England&#8217;s perspective, evaluated combinations including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. This analysis offers crucial information on the economic implications of different initial treatment strategies for Heart Failure with reduced ejection fraction, guiding resource allocation and clinical practice. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure with reduced ejection fraction, Conduction system pacing, dementia, angiotensin-converting enzyme inhibitor, Heart failure risk, Cost-effectiveness analysis, comorbidity, C. D. 8 T cells, activities of daily living, polyamines, T cell metabolism, cognitive function, heart failure, subgroup analysis, Tricuspid regurgitation, biventricular pacing, left bundle-branch block, angiotensin receptor blocker, pharmacotherapy, transplant rejection, immunosuppression, diabetes mellitus, cancer survivors, cardiac resynchronization therapy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/">Polyamine Inhibition Boosts Heart Transplant Acceptance 03/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260312_023449.mp3" length="3832937" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and Conduction system pacing. Key takeaway: Polyamine Inhibition Boosts Heart Transplant Acceptance.
Article Links:
Article 1: Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort. (Journal of cardiac failure)
Article 3: Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer. (Journal of cardiac failure)
Article 4: Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial. (JAMA cardiology)
Article 5: Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/polyamine-inhibition-boosts-heart-transplant-acceptance-03-12-26/
 Featured Articles
Article 1: Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812731
Summary: D. 8 positive T cell differentiation. This study found polyamine metabolism was significantly upregulated in T cells during acute rejection in murine models. Inhibition of T cell polyamine metabolism promoted transplant acceptance by modulating cytotoxic C. D. 8 positive T cell differentiation. The findings demonstrated a critical role for T cell polyamine metabolism in transplant rejection and identified a potential therapeutic target.
Article 2: Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812968
Summary: This study investigated the association of tricuspid regurgitation severity with longitudinal changes in activities of daily living and cognitive function. Researchers analyzed 1269 heart failure patients, 67.5 percent with Heart Failure with preserved ejection fraction, over a 1-year follow-up period. The investigation highlights the critical need to understand how tricuspid regurgitation impacts functional and cognitive decline in elderly heart failure patients.
Article 3: Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812967
Summary: This study examined the incidence of heart failure in individuals with diabetes mellitus and cancer compared with those having diabetes mellitus alone. Researchers established a national cohort by linking 792742 individuals aged 50 years or older from the Australian National Diabetes Services Scheme with hospital admissions and death records. The study provides important insights into identifying high-risk subgroups for heart failure among people with diabetes, specifically highlighting the impact of cancer.
Article 4: Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41811324
Summary: F. Randomized Clinical Trial. The PhysioSync-H. F. randomized clinical trial compared conduction system pacing versus biventri]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and Conduction system pacing. Key takeaway: Polyamine Inhibition Boosts Heart Transplant Acceptance.
Article Links:
Article 1: Inhibition of T cell polyamine metabolism promotes transplant acceptance by modulating cytotoxic CD8+ T cell differentiation. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Association of tricuspid regurgitation severity with activities of daily living and dementia in patients with heart failure: Insight from the KUNIUMI Registry Chronic Cohort. (Journal of cardiac failure)
Article 3: Identifying High-Risk Subgroups for Heart Failure Among People with Diabetes: The Impact of Cancer. (Journal of cardiac failure)
Article 4: Conduction System vs Biventricular Pacing in Heart Failure: The Phys]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Risk Models Pinpoint Future Heart Failure 03/11/26</title>
	<link>https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/</link>
	<pubDate>Wed, 11 Mar 2026 22:06:22 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like morbidity and Incident heart failure. Key takeaway: New Risk Models Pinpoint Future Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41524687">Cardiovascular Statistics in the United States, 2026: JACC Stats.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41810961">Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41810943">Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41810940">Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41811342">Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/">https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiovascular Statistics in the United States, 2026: JACC Stats.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41524687" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41524687</a></p>
<p><strong>Summary:</strong> The JACC Cardiovascular Statistics 2026 report found that cardiovascular disease remains the leading cause of morbidity and mortality in the United States. It provides the most up-to-date data on cardiovascular health, covering major risk factors like hypertension, diabetes, obesity, high cholesterol, and cigarette smoking. The report details conditions such as coronary heart disease, acute myocardial infarction, heart failure, and peripheral artery disease, which collectively cause most cardiovascular deaths and disability.</p>
<h4>Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810961" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810961</a></p>
<p><strong>Summary:</strong> The SMART2-HF model was developed and externally validated for the prediction of incident heart failure in patients with established atherosclerotic cardiovascular disease. This model addresses a critical gap, as current guideline-recommended risk assessment models do not include incident heart failure. The SMART2-HF model provides a new tool to identify patients at high risk of developing heart failure, thus informing preventive strategies.</p>
<h4>Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810943</a></p>
<p><strong>Summary:</strong> The SCORE2-HF risk model was developed and validated for heart failure risk estimation in European adults over 40 years of age without prior cardiovascular disease. This sex-specific, competing risk-adjusted model was derived using data from 25 prospective cohorts, involving 611778 individuals and observing 21818 incident heart failure events. The SCORE2-HF models incorporate age, smoking status, systolic blood pressure, and antihypertensive treatment status to assess risk.</p>
<h4>Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810940</a></p>
<p><strong>Summary:</strong> The LIFE-Preserved model was developed and validated for predicting individual short-term and lifetime risk of heart failure hospitalization or cardiovascular death. This model specifically addresses risk in patients diagnosed with heart failure with preserved ejection fraction. It provides a tool for identifying high-risk individuals who could benefit most from targeted preventive treatments, given the rising incidence and varying prognosis of this heterogeneous disease.</p>
<h4>Article 5: Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41811342" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41811342</a></p>
<p><strong>Summary:</strong> The HeartSync-Left Bundle-Branch Pacing Randomized Clinical Trial established a multicenter, prospective, randomized comparison of left bundle-branch pacing versus biventricular pacing for heart failure. The trial enrolled 200 patients across 6 centers in China. These patients had a left ventricular ejection fraction of 35 percent or less and a left bundle-branch block, reflecting a specific population requiring robust long-term clinical outcome data for pacing strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiovascular Statistics in the United States, 2026: JACC Stats. The JACC Cardiovascular Statistics 2026 report found that cardiovascular disease remains the leading cause of morbidity and mortality in the United States. It provides the most up-to-date data on cardiovascular health, covering major risk factors like hypertension, diabetes, obesity, high cholesterol, and cigarette smoking. The report details conditions such as coronary heart disease, acute myocardial infarction, heart failure, and peripheral artery disease, which collectively cause most cardiovascular deaths and disability.</p>
<p>Article number two. Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. The SMART2-HF model was developed and externally validated for the prediction of incident heart failure in patients with established atherosclerotic cardiovascular disease. This model addresses a critical gap, as current guideline-recommended risk assessment models do not include incident heart failure. The SMART2-HF model provides a new tool to identify patients at high risk of developing heart failure, thus informing preventive strategies.</p>
<p>Article number three. Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. The SCORE2-HF risk model was developed and validated for heart failure risk estimation in European adults over 40 years of age without prior cardiovascular disease. This sex-specific, competing risk-adjusted model was derived using data from 25 prospective cohorts, involving 611778 individuals and observing 21818 incident heart failure events. The SCORE2-HF models incorporate age, smoking status, systolic blood pressure, and antihypertensive treatment status to assess risk.</p>
<p>Article number four. Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. The LIFE-Preserved model was developed and validated for predicting individual short-term and lifetime risk of heart failure hospitalization or cardiovascular death. This model specifically addresses risk in patients diagnosed with heart failure with preserved ejection fraction. It provides a tool for identifying high-risk individuals who could benefit most from targeted preventive treatments, given the rising incidence and varying prognosis of this heterogeneous disease.</p>
<p>Article number five. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. The HeartSync-Left Bundle-Branch Pacing Randomized Clinical Trial established a multicenter, prospective, randomized comparison of left bundle-branch pacing versus biventricular pacing for heart failure. The trial enrolled 200 patients across 6 centers in China. These patients had a left ventricular ejection fraction of 35 percent or less and a left bundle-branch block, reflecting a specific population requiring robust long-term clinical outcome data for pacing strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>morbidity, Incident heart failure, Cardiovascular disease, LIFE-Preserved model, SMART2-HF model, heart failure hospitalization, coronary heart disease, Heart failure with preserved ejection fraction, biventricular pacing, risk prediction, cardiovascular disease, European adults, risk estimation, left bundle-branch block, randomized clinical trial, SCORE2-HF model, mortality, risk factors, acute myocardial infarction, atherosclerotic cardiovascular disease, Left bundle-branch pacing, cardiovascular death, heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/">New Risk Models Pinpoint Future Heart Failure 03/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like morbidity and Incident heart failure. Key takeaway: New Risk Models Pinpoint Future Heart Failure.
Article Links:
Article 1: Cardiovasc]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like morbidity and Incident heart failure. Key takeaway: New Risk Models Pinpoint Future Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41524687">Cardiovascular Statistics in the United States, 2026: JACC Stats.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41810961">Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41810943">Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41810940">Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41811342">Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/">https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiovascular Statistics in the United States, 2026: JACC Stats.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41524687" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41524687</a></p>
<p><strong>Summary:</strong> The JACC Cardiovascular Statistics 2026 report found that cardiovascular disease remains the leading cause of morbidity and mortality in the United States. It provides the most up-to-date data on cardiovascular health, covering major risk factors like hypertension, diabetes, obesity, high cholesterol, and cigarette smoking. The report details conditions such as coronary heart disease, acute myocardial infarction, heart failure, and peripheral artery disease, which collectively cause most cardiovascular deaths and disability.</p>
<h4>Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810961" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810961</a></p>
<p><strong>Summary:</strong> The SMART2-HF model was developed and externally validated for the prediction of incident heart failure in patients with established atherosclerotic cardiovascular disease. This model addresses a critical gap, as current guideline-recommended risk assessment models do not include incident heart failure. The SMART2-HF model provides a new tool to identify patients at high risk of developing heart failure, thus informing preventive strategies.</p>
<h4>Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810943</a></p>
<p><strong>Summary:</strong> The SCORE2-HF risk model was developed and validated for heart failure risk estimation in European adults over 40 years of age without prior cardiovascular disease. This sex-specific, competing risk-adjusted model was derived using data from 25 prospective cohorts, involving 611778 individuals and observing 21818 incident heart failure events. The SCORE2-HF models incorporate age, smoking status, systolic blood pressure, and antihypertensive treatment status to assess risk.</p>
<h4>Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41810940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41810940</a></p>
<p><strong>Summary:</strong> The LIFE-Preserved model was developed and validated for predicting individual short-term and lifetime risk of heart failure hospitalization or cardiovascular death. This model specifically addresses risk in patients diagnosed with heart failure with preserved ejection fraction. It provides a tool for identifying high-risk individuals who could benefit most from targeted preventive treatments, given the rising incidence and varying prognosis of this heterogeneous disease.</p>
<h4>Article 5: Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41811342" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41811342</a></p>
<p><strong>Summary:</strong> The HeartSync-Left Bundle-Branch Pacing Randomized Clinical Trial established a multicenter, prospective, randomized comparison of left bundle-branch pacing versus biventricular pacing for heart failure. The trial enrolled 200 patients across 6 centers in China. These patients had a left ventricular ejection fraction of 35 percent or less and a left bundle-branch block, reflecting a specific population requiring robust long-term clinical outcome data for pacing strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiovascular Statistics in the United States, 2026: JACC Stats. The JACC Cardiovascular Statistics 2026 report found that cardiovascular disease remains the leading cause of morbidity and mortality in the United States. It provides the most up-to-date data on cardiovascular health, covering major risk factors like hypertension, diabetes, obesity, high cholesterol, and cigarette smoking. The report details conditions such as coronary heart disease, acute myocardial infarction, heart failure, and peripheral artery disease, which collectively cause most cardiovascular deaths and disability.</p>
<p>Article number two. Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. The SMART2-HF model was developed and externally validated for the prediction of incident heart failure in patients with established atherosclerotic cardiovascular disease. This model addresses a critical gap, as current guideline-recommended risk assessment models do not include incident heart failure. The SMART2-HF model provides a new tool to identify patients at high risk of developing heart failure, thus informing preventive strategies.</p>
<p>Article number three. Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. The SCORE2-HF risk model was developed and validated for heart failure risk estimation in European adults over 40 years of age without prior cardiovascular disease. This sex-specific, competing risk-adjusted model was derived using data from 25 prospective cohorts, involving 611778 individuals and observing 21818 incident heart failure events. The SCORE2-HF models incorporate age, smoking status, systolic blood pressure, and antihypertensive treatment status to assess risk.</p>
<p>Article number four. Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. The LIFE-Preserved model was developed and validated for predicting individual short-term and lifetime risk of heart failure hospitalization or cardiovascular death. This model specifically addresses risk in patients diagnosed with heart failure with preserved ejection fraction. It provides a tool for identifying high-risk individuals who could benefit most from targeted preventive treatments, given the rising incidence and varying prognosis of this heterogeneous disease.</p>
<p>Article number five. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. The HeartSync-Left Bundle-Branch Pacing Randomized Clinical Trial established a multicenter, prospective, randomized comparison of left bundle-branch pacing versus biventricular pacing for heart failure. The trial enrolled 200 patients across 6 centers in China. These patients had a left ventricular ejection fraction of 35 percent or less and a left bundle-branch block, reflecting a specific population requiring robust long-term clinical outcome data for pacing strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>morbidity, Incident heart failure, Cardiovascular disease, LIFE-Preserved model, SMART2-HF model, heart failure hospitalization, coronary heart disease, Heart failure with preserved ejection fraction, biventricular pacing, risk prediction, cardiovascular disease, European adults, risk estimation, left bundle-branch block, randomized clinical trial, SCORE2-HF model, mortality, risk factors, acute myocardial infarction, atherosclerotic cardiovascular disease, Left bundle-branch pacing, cardiovascular death, heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/">New Risk Models Pinpoint Future Heart Failure 03/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260311_180457.mp3" length="3915693" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like morbidity and Incident heart failure. Key takeaway: New Risk Models Pinpoint Future Heart Failure.
Article Links:
Article 1: Cardiovascular Statistics in the United States, 2026: JACC Stats. (Journal of the American College of Cardiology)
Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. (European heart journal)
Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. (European heart journal)
Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. (European heart journal)
Article 5: Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-risk-models-pinpoint-future-heart-failure-03-11-26/
 Featured Articles
Article 1: Cardiovascular Statistics in the United States, 2026: JACC Stats.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41524687
Summary: The JACC Cardiovascular Statistics 2026 report found that cardiovascular disease remains the leading cause of morbidity and mortality in the United States. It provides the most up-to-date data on cardiovascular health, covering major risk factors like hypertension, diabetes, obesity, high cholesterol, and cigarette smoking. The report details conditions such as coronary heart disease, acute myocardial infarction, heart failure, and peripheral artery disease, which collectively cause most cardiovascular deaths and disability.
Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810961
Summary: The SMART2-HF model was developed and externally validated for the prediction of incident heart failure in patients with established atherosclerotic cardiovascular disease. This model addresses a critical gap, as current guideline-recommended risk assessment models do not include incident heart failure. The SMART2-HF model provides a new tool to identify patients at high risk of developing heart failure, thus informing preventive strategies.
Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810943
Summary: The SCORE2-HF risk model was developed and validated for heart failure risk estimation in European adults over 40 years of age without prior cardiovascular disease. This sex-specific, competing risk-adjusted model was derived using data from 25 prospective cohorts, involving 611778 individuals and observing 21818 incident heart failure events. The SCORE2-HF models incorporate age, smoking status, systolic blood pressure, and antihypertensive treatment status to assess risk.
Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810940
Summary: The LIFE-Preserved model was developed and validated for predicting individual short-term and lifetime risk of heart failure hospitalization or cardiovascular death. This model specifically addresses risk in patients diagnosed with heart failure with preserved ejection fraction. It provides a tool for identifying high-risk individuals who could benefit most from targeted preventive treatments, given the rising incidence and varying prognosis of this heterogeneous disease.
Article 5: Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like morbidity and Incident heart failure. Key takeaway: New Risk Models Pinpoint Future Heart Failure.
Article Links:
Article 1: Cardiovascular Statistics in the United States, 2026: JACC Stats. (Journal of the American College of Cardiology)
Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. (European heart journal)
Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. (European heart journal)
Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. (European heart journal)
Article 5: Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podca]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New P. A. H. -C. H. D. Risk Model for Adults 03/11/26</title>
	<link>https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/</link>
	<pubDate>Wed, 11 Mar 2026 10:01:35 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like UCP2 single nucleotide polymorphisms and pulmonary arterial hypertension. Key takeaway: New P. A. H. -C. H. D. Risk Model for Adults.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41797703">A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41797698">TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41802850">Proteomic insights into troponin elevation following COVID-19 infection.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41802264">Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41800797">Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/">https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797703" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797703</a></p>
<p><strong>Summary:</strong> This study identified that cardiac myofibroblasts contribute critically to right ventricular failure in pulmonary arterial hypertension. It also found that U. C. P. 2 single nucleotide polymorphisms predispose patients to right ventricular decompensation. The transition from a compensated to a decompensated right ventricle is a major driver of morbidity and mortality in this condition. These findings highlight a specific cellular mechanism and genetic factor that influence right ventricular failure progression.</p>
<h4>Article 2: TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797698" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797698</a></p>
<p><strong>Summary:</strong> This study found that T. R. I. M. 28 functions as an E3 ligase for Iron Regulatory Protein 2, or I. R. P. 2. The data showed that T. R. I. M. 28 suppresses myocardial ferroptosis induced by ischemia reperfusion injury. This mechanism suggests a novel pathway in preventing regulated cell death in ischemic heart disease. These findings could inform the development of new therapeutic strategies for myocardial ischemia reperfusion injury.</p>
<h4>Article 3: Proteomic insights into troponin elevation following COVID-19 infection.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41802850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41802850</a></p>
<p><strong>Summary:</strong> This study provided significant proteomic insights into the mechanisms of cardiac troponin-I elevation in patients hospitalized with COVID-19. It clarified that elevated troponin-I often occurs even without overt myocardial injury in these patients. The findings advanced the understanding of how acute viral infections, specifically COVID-19, lead to troponin elevation. This information offers crucial interpretive guidance for clinicians managing COVID-19 patients with elevated cardiac biomarkers.</p>
<h4>Article 4: Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41802264" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41802264</a></p>
<p><strong>Summary:</strong> This study established the comparative value of Heart Failure with Preserved Ejection Fraction scores for risk stratification in patients presenting with unexplained dyspnea. The findings demonstrated how these scores associate with structural remodeling, functional limitation, and clinical outcomes in this specific patient population. The data clarified the prognostic utility and clinical applicability of various H. F. pEF diagnostic scores. This comprehensive evaluation provides essential guidance for managing heart failure with preserved ejection fraction in unexplained dyspnea.</p>
<h4>Article 5: Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41800797" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41800797</a></p>
<p><strong>Summary:</strong> A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC. This scientific statement established a specialized risk stratification model for adult patients diagnosed with pulmonary arterial hypertension associated with congenital heart disease. It found that existing risk stratification models for general pulmonary arterial hypertension are not automatically applicable to this distinct patient population, especially those with Eisenmenger syndrome, due to unique pathophysiological and clinical phenotypes. The statement defined additional features crucial for accurate risk assessment in this specific cohort. This provides critical guidance for tailored management and improved patient outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. This study identified that cardiac myofibroblasts contribute critically to right ventricular failure in pulmonary arterial hypertension. It also found that U. C. P. 2 single nucleotide polymorphisms predispose patients to right ventricular decompensation. The transition from a compensated to a decompensated right ventricle is a major driver of morbidity and mortality in this condition. These findings highlight a specific cellular mechanism and genetic factor that influence right ventricular failure progression.</p>
<p>Article number two. TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis. This study found that T. R. I. M. 28 functions as an E3 ligase for Iron Regulatory Protein 2, or I. R. P. 2. The data showed that T. R. I. M. 28 suppresses myocardial ferroptosis induced by ischemia reperfusion injury. This mechanism suggests a novel pathway in preventing regulated cell death in ischemic heart disease. These findings could inform the development of new therapeutic strategies for myocardial ischemia reperfusion injury.</p>
<p>Article number three. Proteomic insights into troponin elevation following COVID-19 infection. This study provided significant proteomic insights into the mechanisms of cardiac troponin-I elevation in patients hospitalized with COVID-19. It clarified that elevated troponin-I often occurs even without overt myocardial injury in these patients. The findings advanced the understanding of how acute viral infections, specifically COVID-19, lead to troponin elevation. This information offers crucial interpretive guidance for clinicians managing COVID-19 patients with elevated cardiac biomarkers.</p>
<p>Article number four. Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea. This study established the comparative value of Heart Failure with Preserved Ejection Fraction scores for risk stratification in patients presenting with unexplained dyspnea. The findings demonstrated how these scores associate with structural remodeling, functional limitation, and clinical outcomes in this specific patient population. The data clarified the prognostic utility and clinical applicability of various H. F. pEF diagnostic scores. This comprehensive evaluation provides essential guidance for managing heart failure with preserved ejection fraction in unexplained dyspnea.</p>
<p>Article number five. Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC. This scientific statement established a specialized risk stratification model for adult patients diagnosed with pulmonary arterial hypertension associated with congenital heart disease. It found that existing risk stratification models for general pulmonary arterial hypertension are not automatically applicable to this distinct patient population, especially those with Eisenmenger syndrome, due to unique pathophysiological and clinical phenotypes. The statement defined additional features crucial for accurate risk assessment in this specific cohort. This provides critical guidance for tailored management and improved patient outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>UCP2 single nucleotide polymorphisms, pulmonary arterial hypertension, myocardial ischemia reperfusion injury, TRIM28, COVID-19, cardiac troponin-I, structural remodeling, IRP2, diagnostic scores, congenital heart disease, adult congenital heart disease, acute viral infection, unexplained dyspnea, Eisenmenger syndrome, ferroptosis, proteomics, heart failure with preserved ejection fraction, E3 ligase, right ventricular failure, cardiac myofibroblasts, risk stratification, myocardial injury, right ventricular decompensation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/">New P. A. H. -C. H. D. Risk Model for Adults 03/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like UCP2 single nucleotide polymorphisms and pulmonary arterial hypertension. Key takeaway: New P. A. H. -C. H. D. Risk Model for Adults.
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like UCP2 single nucleotide polymorphisms and pulmonary arterial hypertension. Key takeaway: New P. A. H. -C. H. D. Risk Model for Adults.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41797703">A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41797698">TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41802850">Proteomic insights into troponin elevation following COVID-19 infection.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41802264">Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41800797">Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/">https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797703" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797703</a></p>
<p><strong>Summary:</strong> This study identified that cardiac myofibroblasts contribute critically to right ventricular failure in pulmonary arterial hypertension. It also found that U. C. P. 2 single nucleotide polymorphisms predispose patients to right ventricular decompensation. The transition from a compensated to a decompensated right ventricle is a major driver of morbidity and mortality in this condition. These findings highlight a specific cellular mechanism and genetic factor that influence right ventricular failure progression.</p>
<h4>Article 2: TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797698" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797698</a></p>
<p><strong>Summary:</strong> This study found that T. R. I. M. 28 functions as an E3 ligase for Iron Regulatory Protein 2, or I. R. P. 2. The data showed that T. R. I. M. 28 suppresses myocardial ferroptosis induced by ischemia reperfusion injury. This mechanism suggests a novel pathway in preventing regulated cell death in ischemic heart disease. These findings could inform the development of new therapeutic strategies for myocardial ischemia reperfusion injury.</p>
<h4>Article 3: Proteomic insights into troponin elevation following COVID-19 infection.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41802850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41802850</a></p>
<p><strong>Summary:</strong> This study provided significant proteomic insights into the mechanisms of cardiac troponin-I elevation in patients hospitalized with COVID-19. It clarified that elevated troponin-I often occurs even without overt myocardial injury in these patients. The findings advanced the understanding of how acute viral infections, specifically COVID-19, lead to troponin elevation. This information offers crucial interpretive guidance for clinicians managing COVID-19 patients with elevated cardiac biomarkers.</p>
<h4>Article 4: Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41802264" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41802264</a></p>
<p><strong>Summary:</strong> This study established the comparative value of Heart Failure with Preserved Ejection Fraction scores for risk stratification in patients presenting with unexplained dyspnea. The findings demonstrated how these scores associate with structural remodeling, functional limitation, and clinical outcomes in this specific patient population. The data clarified the prognostic utility and clinical applicability of various H. F. pEF diagnostic scores. This comprehensive evaluation provides essential guidance for managing heart failure with preserved ejection fraction in unexplained dyspnea.</p>
<h4>Article 5: Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41800797" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41800797</a></p>
<p><strong>Summary:</strong> A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC. This scientific statement established a specialized risk stratification model for adult patients diagnosed with pulmonary arterial hypertension associated with congenital heart disease. It found that existing risk stratification models for general pulmonary arterial hypertension are not automatically applicable to this distinct patient population, especially those with Eisenmenger syndrome, due to unique pathophysiological and clinical phenotypes. The statement defined additional features crucial for accurate risk assessment in this specific cohort. This provides critical guidance for tailored management and improved patient outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. This study identified that cardiac myofibroblasts contribute critically to right ventricular failure in pulmonary arterial hypertension. It also found that U. C. P. 2 single nucleotide polymorphisms predispose patients to right ventricular decompensation. The transition from a compensated to a decompensated right ventricle is a major driver of morbidity and mortality in this condition. These findings highlight a specific cellular mechanism and genetic factor that influence right ventricular failure progression.</p>
<p>Article number two. TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis. This study found that T. R. I. M. 28 functions as an E3 ligase for Iron Regulatory Protein 2, or I. R. P. 2. The data showed that T. R. I. M. 28 suppresses myocardial ferroptosis induced by ischemia reperfusion injury. This mechanism suggests a novel pathway in preventing regulated cell death in ischemic heart disease. These findings could inform the development of new therapeutic strategies for myocardial ischemia reperfusion injury.</p>
<p>Article number three. Proteomic insights into troponin elevation following COVID-19 infection. This study provided significant proteomic insights into the mechanisms of cardiac troponin-I elevation in patients hospitalized with COVID-19. It clarified that elevated troponin-I often occurs even without overt myocardial injury in these patients. The findings advanced the understanding of how acute viral infections, specifically COVID-19, lead to troponin elevation. This information offers crucial interpretive guidance for clinicians managing COVID-19 patients with elevated cardiac biomarkers.</p>
<p>Article number four. Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea. This study established the comparative value of Heart Failure with Preserved Ejection Fraction scores for risk stratification in patients presenting with unexplained dyspnea. The findings demonstrated how these scores associate with structural remodeling, functional limitation, and clinical outcomes in this specific patient population. The data clarified the prognostic utility and clinical applicability of various H. F. pEF diagnostic scores. This comprehensive evaluation provides essential guidance for managing heart failure with preserved ejection fraction in unexplained dyspnea.</p>
<p>Article number five. Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC. This scientific statement established a specialized risk stratification model for adult patients diagnosed with pulmonary arterial hypertension associated with congenital heart disease. It found that existing risk stratification models for general pulmonary arterial hypertension are not automatically applicable to this distinct patient population, especially those with Eisenmenger syndrome, due to unique pathophysiological and clinical phenotypes. The statement defined additional features crucial for accurate risk assessment in this specific cohort. This provides critical guidance for tailored management and improved patient outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>UCP2 single nucleotide polymorphisms, pulmonary arterial hypertension, myocardial ischemia reperfusion injury, TRIM28, COVID-19, cardiac troponin-I, structural remodeling, IRP2, diagnostic scores, congenital heart disease, adult congenital heart disease, acute viral infection, unexplained dyspnea, Eisenmenger syndrome, ferroptosis, proteomics, heart failure with preserved ejection fraction, E3 ligase, right ventricular failure, cardiac myofibroblasts, risk stratification, myocardial injury, right ventricular decompensation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/">New P. A. H. -C. H. D. Risk Model for Adults 03/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260311_060033.mp3" length="4086221" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like UCP2 single nucleotide polymorphisms and pulmonary arterial hypertension. Key takeaway: New P. A. H. -C. H. D. Risk Model for Adults.
Article Links:
Article 1: A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. (Circulation)
Article 2: TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis. (Circulation)
Article 3: Proteomic insights into troponin elevation following COVID-19 infection. (Heart (British Cardiac Society))
Article 4: Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea. (European journal of heart failure)
Article 5: Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing and Allied Professions of the ESC. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/new-p-a-h-c-h-d-risk-model-for-adults-03-11-26/
 Featured Articles
Article 1: A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41797703
Summary: This study identified that cardiac myofibroblasts contribute critically to right ventricular failure in pulmonary arterial hypertension. It also found that U. C. P. 2 single nucleotide polymorphisms predispose patients to right ventricular decompensation. The transition from a compensated to a decompensated right ventricle is a major driver of morbidity and mortality in this condition. These findings highlight a specific cellular mechanism and genetic factor that influence right ventricular failure progression.
Article 2: TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41797698
Summary: This study found that T. R. I. M. 28 functions as an E3 ligase for Iron Regulatory Protein 2, or I. R. P. 2. The data showed that T. R. I. M. 28 suppresses myocardial ferroptosis induced by ischemia reperfusion injury. This mechanism suggests a novel pathway in preventing regulated cell death in ischemic heart disease. These findings could inform the development of new therapeutic strategies for myocardial ischemia reperfusion injury.
Article 3: Proteomic insights into troponin elevation following COVID-19 infection.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41802850
Summary: This study provided significant proteomic insights into the mechanisms of cardiac troponin-I elevation in patients hospitalized with COVID-19. It clarified that elevated troponin-I often occurs even without overt myocardial injury in these patients. The findings advanced the understanding of how acute viral infections, specifically COVID-19, lead to troponin elevation. This information offers crucial interpretive guidance for clinicians managing COVID-19 patients with elevated cardiac biomarkers.
Article 4: Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41802264
Summary: This study established the comparative value of Heart Failure with Preserved Ejection Fraction scores for risk stratification in patients presenting with unexplained dyspnea. The findings demonstrated how these scores associate with structural remodeling, functional limitatio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 11, 2026. This episode summarizes 5 key cardiology studies on topics like UCP2 single nucleotide polymorphisms and pulmonary arterial hypertension. Key takeaway: New P. A. H. -C. H. D. Risk Model for Adults.
Article Links:
Article 1: A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. (Circulation)
Article 2: TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis. (Circulation)
Article 3: Proteomic insights into troponin elevation following COVID-19 infection. (Heart (British Cardiac Society))
Article 4: Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea. (European journal of heart failure)
Article 5: Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientifi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>YAP Boosts Cardiomyocyte Renewal for Repair 03/10/26</title>
	<link>https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/</link>
	<pubDate>Tue, 10 Mar 2026 10:01:26 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 10, 2026. This episode summarizes 5 key cardiology studies on topics like comorbidities and acute myocarditis. Key takeaway: YAP Boosts Cardiomyocyte Renewal for Repair.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41487100">GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41487093">Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41800474">Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41797725">YAP Induces a Prorenewal Metabolic State in Cardiomyocytes.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41797709">PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/">https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487100" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487100</a></p>
<p><strong>Summary:</strong> The study identified guanine-rich RNA sequence binding factor one, or GRSF1, as a regulator of cell-intrinsic branched-chain amino acid, or B. C. A. A., metabolic pathways. This post-transcriptional regulation by GRSF1 was found to contribute to the pathogenesis of heart failure. The data demonstrated that GRSF1 protects against heart failure by maintaining B. C. A. A. homeostasis. This mechanism provides a novel understanding of metabolic imbalances in cardiac dysfunction.</p>
<h4>Article 2: Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487093" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487093</a></p>
<p><strong>Summary:</strong> This multicenter retrospective observational study characterized the clinical features and outcomes of children with parvovirus B19-associated acute myocarditis. The research provided specific data on the clinical spectrum observed in pediatric patients with this condition following an outbreak of parvovirus B19 infections in 2024. The study identified patterns of disease presentation and progression in this vulnerable population. This data clarifies the understanding of a critical cardiac complication in children.</p>
<h4>Article 3: Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41800474" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41800474</a></p>
<p><strong>Summary:</strong> Sarcomere gene variants were found to be a key cause of hypertrophic cardiomyopathy, or H. C. M., and were associated with a worse prognosis. This multicenter longitudinal cohort study in the Sarcomeric Human Cardiomyopathy registry demonstrated significant differences in disease trajectory, comorbidities, and mortality between patients with sarcomeric and nonsarcomeric H. C. M. The data revealed how comorbidities specifically influence clinical courses and causes of death in these distinct patient groups. This finding provides crucial insights for risk stratification and personalized management strategies in hypertrophic cardiomyopathy.</p>
<h4>Article 4: YAP Induces a Prorenewal Metabolic State in Cardiomyocytes.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797725" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797725</a></p>
<p><strong>Summary:</strong> The study found that YAP induces a prorenewal metabolic state in cardiomyocytes. This mechanism was identified as a key factor contributing to the regenerative capacity observed in neonatal rodents. The data demonstrated that YAP helps counteract the decline in cardiomyocyte regeneration that occurs with cellular maturation. This finding provides critical insights into potential therapeutic targets for promoting cardiac repair and regeneration.</p>
<h4>Article 5: PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797709" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797709</a></p>
<p><strong>Summary:</strong> The study found that protein arginine methyltransferase three, or PRMT3, promotes aortic valve calcification. This occurs through PRMT3-mediated arginine methylation, which stabilizes proprotein convertase subtilisin/kexin type nine, or P. C. S. K. 9. The data demonstrated that this specific molecular mechanism contributes to increased leaflet stiffness and the progression of calcific aortic valve disease. This finding provides a crucial understanding of the underlying pathogenesis and offers new therapeutic targets for this condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis. The study identified guanine-rich RNA sequence binding factor one, or GRSF1, as a regulator of cell-intrinsic branched-chain amino acid, or B. C. A. A., metabolic pathways. This post-transcriptional regulation by GRSF1 was found to contribute to the pathogenesis of heart failure. The data demonstrated that GRSF1 protects against heart failure by maintaining B. C. A. A. homeostasis. This mechanism provides a novel understanding of metabolic imbalances in cardiac dysfunction.</p>
<p>Article number two. Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. This multicenter retrospective observational study characterized the clinical features and outcomes of children with parvovirus B19-associated acute myocarditis. The research provided specific data on the clinical spectrum observed in pediatric patients with this condition following an outbreak of parvovirus B19 infections in 2024. The study identified patterns of disease presentation and progression in this vulnerable population. This data clarifies the understanding of a critical cardiac complication in children.</p>
<p>Article number three. Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. Sarcomere gene variants were found to be a key cause of hypertrophic cardiomyopathy, or H. C. M., and were associated with a worse prognosis. This multicenter longitudinal cohort study in the Sarcomeric Human Cardiomyopathy registry demonstrated significant differences in disease trajectory, comorbidities, and mortality between patients with sarcomeric and nonsarcomeric H. C. M. The data revealed how comorbidities specifically influence clinical courses and causes of death in these distinct patient groups. This finding provides crucial insights for risk stratification and personalized management strategies in hypertrophic cardiomyopathy.</p>
<p>Article number four. YAP Induces a Prorenewal Metabolic State in Cardiomyocytes. The study found that YAP induces a prorenewal metabolic state in cardiomyocytes. This mechanism was identified as a key factor contributing to the regenerative capacity observed in neonatal rodents. The data demonstrated that YAP helps counteract the decline in cardiomyocyte regeneration that occurs with cellular maturation. This finding provides critical insights into potential therapeutic targets for promoting cardiac repair and regeneration.</p>
<p>Article number five. PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification. The study found that protein arginine methyltransferase three, or PRMT3, promotes aortic valve calcification. This occurs through PRMT3-mediated arginine methylation, which stabilizes proprotein convertase subtilisin/kexin type nine, or P. C. S. K. 9. The data demonstrated that this specific molecular mechanism contributes to increased leaflet stiffness and the progression of calcific aortic valve disease. This finding provides a crucial understanding of the underlying pathogenesis and offers new therapeutic targets for this condition. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>comorbidities, acute myocarditis, mortality, PCSK9, mitochondrial homeostasis, cardiac repair, cellular maturation, branched-chain amino acid metabolism, metabolic state, YAP, calcific aortic valve disease, arginine methylation, heart failure, hypertrophic cardiomyopathy, sarcomere gene variants, aortic valve calcification, disease trajectory, pediatric cardiology, parvovirus B19, disease outcomes, GRSF1, clinical features, cardiomyocyte regeneration, PRMT3, RNA-binding protein.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/">YAP Boosts Cardiomyocyte Renewal for Repair 03/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 10, 2026. This episode summarizes 5 key cardiology studies on topics like comorbidities and acute myocarditis. Key takeaway: YAP Boosts Cardiomyocyte Renewal for Repair.
Article Links:
Article 1: GRSF1 Protect]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 10, 2026. This episode summarizes 5 key cardiology studies on topics like comorbidities and acute myocarditis. Key takeaway: YAP Boosts Cardiomyocyte Renewal for Repair.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41487100">GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41487093">Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41800474">Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41797725">YAP Induces a Prorenewal Metabolic State in Cardiomyocytes.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41797709">PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/">https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487100" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487100</a></p>
<p><strong>Summary:</strong> The study identified guanine-rich RNA sequence binding factor one, or GRSF1, as a regulator of cell-intrinsic branched-chain amino acid, or B. C. A. A., metabolic pathways. This post-transcriptional regulation by GRSF1 was found to contribute to the pathogenesis of heart failure. The data demonstrated that GRSF1 protects against heart failure by maintaining B. C. A. A. homeostasis. This mechanism provides a novel understanding of metabolic imbalances in cardiac dysfunction.</p>
<h4>Article 2: Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487093" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487093</a></p>
<p><strong>Summary:</strong> This multicenter retrospective observational study characterized the clinical features and outcomes of children with parvovirus B19-associated acute myocarditis. The research provided specific data on the clinical spectrum observed in pediatric patients with this condition following an outbreak of parvovirus B19 infections in 2024. The study identified patterns of disease presentation and progression in this vulnerable population. This data clarifies the understanding of a critical cardiac complication in children.</p>
<h4>Article 3: Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41800474" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41800474</a></p>
<p><strong>Summary:</strong> Sarcomere gene variants were found to be a key cause of hypertrophic cardiomyopathy, or H. C. M., and were associated with a worse prognosis. This multicenter longitudinal cohort study in the Sarcomeric Human Cardiomyopathy registry demonstrated significant differences in disease trajectory, comorbidities, and mortality between patients with sarcomeric and nonsarcomeric H. C. M. The data revealed how comorbidities specifically influence clinical courses and causes of death in these distinct patient groups. This finding provides crucial insights for risk stratification and personalized management strategies in hypertrophic cardiomyopathy.</p>
<h4>Article 4: YAP Induces a Prorenewal Metabolic State in Cardiomyocytes.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797725" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797725</a></p>
<p><strong>Summary:</strong> The study found that YAP induces a prorenewal metabolic state in cardiomyocytes. This mechanism was identified as a key factor contributing to the regenerative capacity observed in neonatal rodents. The data demonstrated that YAP helps counteract the decline in cardiomyocyte regeneration that occurs with cellular maturation. This finding provides critical insights into potential therapeutic targets for promoting cardiac repair and regeneration.</p>
<h4>Article 5: PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41797709" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41797709</a></p>
<p><strong>Summary:</strong> The study found that protein arginine methyltransferase three, or PRMT3, promotes aortic valve calcification. This occurs through PRMT3-mediated arginine methylation, which stabilizes proprotein convertase subtilisin/kexin type nine, or P. C. S. K. 9. The data demonstrated that this specific molecular mechanism contributes to increased leaflet stiffness and the progression of calcific aortic valve disease. This finding provides a crucial understanding of the underlying pathogenesis and offers new therapeutic targets for this condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis. The study identified guanine-rich RNA sequence binding factor one, or GRSF1, as a regulator of cell-intrinsic branched-chain amino acid, or B. C. A. A., metabolic pathways. This post-transcriptional regulation by GRSF1 was found to contribute to the pathogenesis of heart failure. The data demonstrated that GRSF1 protects against heart failure by maintaining B. C. A. A. homeostasis. This mechanism provides a novel understanding of metabolic imbalances in cardiac dysfunction.</p>
<p>Article number two. Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. This multicenter retrospective observational study characterized the clinical features and outcomes of children with parvovirus B19-associated acute myocarditis. The research provided specific data on the clinical spectrum observed in pediatric patients with this condition following an outbreak of parvovirus B19 infections in 2024. The study identified patterns of disease presentation and progression in this vulnerable population. This data clarifies the understanding of a critical cardiac complication in children.</p>
<p>Article number three. Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. Sarcomere gene variants were found to be a key cause of hypertrophic cardiomyopathy, or H. C. M., and were associated with a worse prognosis. This multicenter longitudinal cohort study in the Sarcomeric Human Cardiomyopathy registry demonstrated significant differences in disease trajectory, comorbidities, and mortality between patients with sarcomeric and nonsarcomeric H. C. M. The data revealed how comorbidities specifically influence clinical courses and causes of death in these distinct patient groups. This finding provides crucial insights for risk stratification and personalized management strategies in hypertrophic cardiomyopathy.</p>
<p>Article number four. YAP Induces a Prorenewal Metabolic State in Cardiomyocytes. The study found that YAP induces a prorenewal metabolic state in cardiomyocytes. This mechanism was identified as a key factor contributing to the regenerative capacity observed in neonatal rodents. The data demonstrated that YAP helps counteract the decline in cardiomyocyte regeneration that occurs with cellular maturation. This finding provides critical insights into potential therapeutic targets for promoting cardiac repair and regeneration.</p>
<p>Article number five. PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification. The study found that protein arginine methyltransferase three, or PRMT3, promotes aortic valve calcification. This occurs through PRMT3-mediated arginine methylation, which stabilizes proprotein convertase subtilisin/kexin type nine, or P. C. S. K. 9. The data demonstrated that this specific molecular mechanism contributes to increased leaflet stiffness and the progression of calcific aortic valve disease. This finding provides a crucial understanding of the underlying pathogenesis and offers new therapeutic targets for this condition. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>comorbidities, acute myocarditis, mortality, PCSK9, mitochondrial homeostasis, cardiac repair, cellular maturation, branched-chain amino acid metabolism, metabolic state, YAP, calcific aortic valve disease, arginine methylation, heart failure, hypertrophic cardiomyopathy, sarcomere gene variants, aortic valve calcification, disease trajectory, pediatric cardiology, parvovirus B19, disease outcomes, GRSF1, clinical features, cardiomyocyte regeneration, PRMT3, RNA-binding protein.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/">YAP Boosts Cardiomyocyte Renewal for Repair 03/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260310_060024.mp3" length="4024363" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 10, 2026. This episode summarizes 5 key cardiology studies on topics like comorbidities and acute myocarditis. Key takeaway: YAP Boosts Cardiomyocyte Renewal for Repair.
Article Links:
Article 1: GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis. (Circulation)
Article 2: Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. (Circulation)
Article 3: Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. (Circulation)
Article 4: YAP Induces a Prorenewal Metabolic State in Cardiomyocytes. (Circulation)
Article 5: PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/
 Featured Articles
Article 1: GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41487100
Summary: The study identified guanine-rich RNA sequence binding factor one, or GRSF1, as a regulator of cell-intrinsic branched-chain amino acid, or B. C. A. A., metabolic pathways. This post-transcriptional regulation by GRSF1 was found to contribute to the pathogenesis of heart failure. The data demonstrated that GRSF1 protects against heart failure by maintaining B. C. A. A. homeostasis. This mechanism provides a novel understanding of metabolic imbalances in cardiac dysfunction.
Article 2: Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41487093
Summary: This multicenter retrospective observational study characterized the clinical features and outcomes of children with parvovirus B19-associated acute myocarditis. The research provided specific data on the clinical spectrum observed in pediatric patients with this condition following an outbreak of parvovirus B19 infections in 2024. The study identified patterns of disease presentation and progression in this vulnerable population. This data clarifies the understanding of a critical cardiac complication in children.
Article 3: Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41800474
Summary: Sarcomere gene variants were found to be a key cause of hypertrophic cardiomyopathy, or H. C. M., and were associated with a worse prognosis. This multicenter longitudinal cohort study in the Sarcomeric Human Cardiomyopathy registry demonstrated significant differences in disease trajectory, comorbidities, and mortality between patients with sarcomeric and nonsarcomeric H. C. M. The data revealed how comorbidities specifically influence clinical courses and causes of death in these distinct patient groups. This finding provides crucial insights for risk stratification and personalized management strategies in hypertrophic cardiomyopathy.
Article 4: YAP Induces a Prorenewal Metabolic State in Cardiomyocytes.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41797725
Summary: The study found that YAP induces a prorenewal metabolic state in cardiomyocytes. This mechanism was identified as a key factor contributing to the regenerative capacity observed in neonatal rodents. The data demonstrated that YAP helps counteract the decline in cardiomyocyte regeneration that occurs with cellular maturation. This finding provides critical insights into potential therapeutic targets for promoting cardiac repair and regeneration.
Article 5: PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41797709
Summary: The study found that protein arginine methyltransferase three, or PRMT3, promotes aorti]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 10, 2026. This episode summarizes 5 key cardiology studies on topics like comorbidities and acute myocarditis. Key takeaway: YAP Boosts Cardiomyocyte Renewal for Repair.
Article Links:
Article 1: GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis. (Circulation)
Article 2: Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. (Circulation)
Article 3: Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. (Circulation)
Article 4: YAP Induces a Prorenewal Metabolic State in Cardiomyocytes. (Circulation)
Article 5: PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/yap-boosts-cardiomyocyte-renewal-for-repair-03-10-26/
 Featured Articles
Article 1: GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.
Jou]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>A. I. Mammograms Predict Heart Disease in Women 03/09/26</title>
	<link>https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/</link>
	<pubDate>Mon, 09 Mar 2026 10:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 09, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac aging and empagliflozin. Key takeaway: A. I. Mammograms Predict Heart Disease in Women.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41795942">Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41795899">Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41493057">Endothelial ZBTB16: a molecular shield against cardiac aging.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41793401">Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41789465">BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/">https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41795942" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41795942</a></p>
<p><strong>Summary:</strong> This study revealed that silent plaque ruptures frequently occur in non-obstructive lesions within non-infarct-related coronary arteries of acute myocardial infarction patients. Researchers characterized the specific morphological features of these ruptures. The study tracked changes in rupture sites over 52 weeks, demonstrating their dynamic nature. It also identified the baseline morphology associated with new-onset ruptures, advancing understanding of coronary artery disease progression beyond the infarct-related artery.</p>
<h4>Article 2: Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41795899" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41795899</a></p>
<p><strong>Summary:</strong> Artificial intelligence-based automatic quantification of breast arterial calcification from screening mammograms significantly predicted cardiovascular disease morbidity and mortality. This A. I. methodology demonstrated superior predictive value beyond existing PREVENT scores in a large, racially diverse cohort of 123762 women. The results establish breast arterial calcification as a robust and automatically quantifiable biomarker for cardiovascular risk. These findings support integrating A. I. assessment of mammograms into cardiovascular risk stratification for women.</p>
<h4>Article 3: Endothelial ZBTB16: a molecular shield against cardiac aging.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493057" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493057</a></p>
<p><strong>Summary:</strong> This study identified zinc finger and B. T. B. domain-containing protein 16, or ZBTB16, as playing a critical protective role against cardiac aging. Researchers found that endothelial ZBTB16 functions as a molecular shield, counteracting age-related cardiac dysfunction. The data revealed specific epigenetically regulated mechanisms underlying endothelial cell impairment during aging. These findings provide novel insights into the molecular processes of cardiac aging and suggest potential therapeutic targets.</p>
<h4>Article 4: Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41793401" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41793401</a></p>
<p><strong>Summary:</strong> This prespecified analysis from the EMPULSE trial found that empagliflozin significantly improved clinical outcomes in patients hospitalized for heart failure. The sodium-glucose cotransporter 2 inhibitor demonstrated consistent efficacy, safety, and tolerability in both de novo heart failure and acute decompensated heart failure subgroups. The benefits of empagliflozin were observed early, providing critical support for initiating this therapy during hospitalization for heart failure regardless of its onset. These findings broaden the evidence base for empagliflozin in a diverse heart failure population.</p>
<h4>Article 5: BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41789465" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41789465</a></p>
<p><strong>Summary:</strong> This study revealed that deficiency in BRISC, a B. R. C. C. 3 isopeptidase complex, drives heart failure by regulating beta-catenin K63 ubiquitination. Researchers found that BRISC functions as a K63-specific deubiquitinase crucial for preventing adverse cardiac remodeling. Analysis showed altered BRISC subunit expression in hypertrophic human and murine hearts, directly linking its dysregulation to cardiac dysfunction. These findings offer a novel molecular mechanism underlying hypertensive heart failure and potential therapeutic targets.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study. This study revealed that silent plaque ruptures frequently occur in non-obstructive lesions within non-infarct-related coronary arteries of acute myocardial infarction patients. Researchers characterized the specific morphological features of these ruptures. The study tracked changes in rupture sites over 52 weeks, demonstrating their dynamic nature. It also identified the baseline morphology associated with new-onset ruptures, advancing understanding of coronary artery disease progression beyond the infarct-related artery.</p>
<p>Article number two. Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality. Artificial intelligence-based automatic quantification of breast arterial calcification from screening mammograms significantly predicted cardiovascular disease morbidity and mortality. This A. I. methodology demonstrated superior predictive value beyond existing PREVENT scores in a large, racially diverse cohort of 123762 women. The results establish breast arterial calcification as a robust and automatically quantifiable biomarker for cardiovascular risk. These findings support integrating A. I. assessment of mammograms into cardiovascular risk stratification for women.</p>
<p>Article number three. Endothelial ZBTB16: a molecular shield against cardiac aging. This study identified zinc finger and B. T. B. domain-containing protein 16, or ZBTB16, as playing a critical protective role against cardiac aging. Researchers found that endothelial ZBTB16 functions as a molecular shield, counteracting age-related cardiac dysfunction. The data revealed specific epigenetically regulated mechanisms underlying endothelial cell impairment during aging. These findings provide novel insights into the molecular processes of cardiac aging and suggest potential therapeutic targets.</p>
<p>Article number four. Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE. This prespecified analysis from the EMPULSE trial found that empagliflozin significantly improved clinical outcomes in patients hospitalized for heart failure. The sodium-glucose cotransporter 2 inhibitor demonstrated consistent efficacy, safety, and tolerability in both de novo heart failure and acute decompensated heart failure subgroups. The benefits of empagliflozin were observed early, providing critical support for initiating this therapy during hospitalization for heart failure regardless of its onset. These findings broaden the evidence base for empagliflozin in a diverse heart failure population.</p>
<p>Article number five. BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination. This study revealed that deficiency in BRISC, a B. R. C. C. 3 isopeptidase complex, drives heart failure by regulating beta-catenin K63 ubiquitination. Researchers found that BRISC functions as a K63-specific deubiquitinase crucial for preventing adverse cardiac remodeling. Analysis showed altered BRISC subunit expression in hypertrophic human and murine hearts, directly linking its dysregulation to cardiac dysfunction. These findings offer a novel molecular mechanism underlying hypertensive heart failure and potential therapeutic targets. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac aging, empagliflozin, coronary artery disease, plaque rupture, artificial intelligence, mortality prediction, cardiac remodeling, ZBTB16, acute myocardial infarction, epigenetics, de novo heart failure, non-obstructive lesions, acute decompensated heart failure, heart failure, sodium-glucose cotransporter 2 inhibitor, BRISC, intracoronary imaging, beta-catenin, mammography, endothelial cells, breast arterial calcification, ubiquitination, cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/">A. I. Mammograms Predict Heart Disease in Women 03/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 09, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac aging and empagliflozin. Key takeaway: A. I. Mammograms Predict Heart Disease in Women.
Article Links:
Article 1: Silent plaque]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 09, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac aging and empagliflozin. Key takeaway: A. I. Mammograms Predict Heart Disease in Women.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41795942">Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41795899">Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41493057">Endothelial ZBTB16: a molecular shield against cardiac aging.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41793401">Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41789465">BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/">https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41795942" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41795942</a></p>
<p><strong>Summary:</strong> This study revealed that silent plaque ruptures frequently occur in non-obstructive lesions within non-infarct-related coronary arteries of acute myocardial infarction patients. Researchers characterized the specific morphological features of these ruptures. The study tracked changes in rupture sites over 52 weeks, demonstrating their dynamic nature. It also identified the baseline morphology associated with new-onset ruptures, advancing understanding of coronary artery disease progression beyond the infarct-related artery.</p>
<h4>Article 2: Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41795899" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41795899</a></p>
<p><strong>Summary:</strong> Artificial intelligence-based automatic quantification of breast arterial calcification from screening mammograms significantly predicted cardiovascular disease morbidity and mortality. This A. I. methodology demonstrated superior predictive value beyond existing PREVENT scores in a large, racially diverse cohort of 123762 women. The results establish breast arterial calcification as a robust and automatically quantifiable biomarker for cardiovascular risk. These findings support integrating A. I. assessment of mammograms into cardiovascular risk stratification for women.</p>
<h4>Article 3: Endothelial ZBTB16: a molecular shield against cardiac aging.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493057" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493057</a></p>
<p><strong>Summary:</strong> This study identified zinc finger and B. T. B. domain-containing protein 16, or ZBTB16, as playing a critical protective role against cardiac aging. Researchers found that endothelial ZBTB16 functions as a molecular shield, counteracting age-related cardiac dysfunction. The data revealed specific epigenetically regulated mechanisms underlying endothelial cell impairment during aging. These findings provide novel insights into the molecular processes of cardiac aging and suggest potential therapeutic targets.</p>
<h4>Article 4: Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41793401" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41793401</a></p>
<p><strong>Summary:</strong> This prespecified analysis from the EMPULSE trial found that empagliflozin significantly improved clinical outcomes in patients hospitalized for heart failure. The sodium-glucose cotransporter 2 inhibitor demonstrated consistent efficacy, safety, and tolerability in both de novo heart failure and acute decompensated heart failure subgroups. The benefits of empagliflozin were observed early, providing critical support for initiating this therapy during hospitalization for heart failure regardless of its onset. These findings broaden the evidence base for empagliflozin in a diverse heart failure population.</p>
<h4>Article 5: BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41789465" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41789465</a></p>
<p><strong>Summary:</strong> This study revealed that deficiency in BRISC, a B. R. C. C. 3 isopeptidase complex, drives heart failure by regulating beta-catenin K63 ubiquitination. Researchers found that BRISC functions as a K63-specific deubiquitinase crucial for preventing adverse cardiac remodeling. Analysis showed altered BRISC subunit expression in hypertrophic human and murine hearts, directly linking its dysregulation to cardiac dysfunction. These findings offer a novel molecular mechanism underlying hypertensive heart failure and potential therapeutic targets.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study. This study revealed that silent plaque ruptures frequently occur in non-obstructive lesions within non-infarct-related coronary arteries of acute myocardial infarction patients. Researchers characterized the specific morphological features of these ruptures. The study tracked changes in rupture sites over 52 weeks, demonstrating their dynamic nature. It also identified the baseline morphology associated with new-onset ruptures, advancing understanding of coronary artery disease progression beyond the infarct-related artery.</p>
<p>Article number two. Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality. Artificial intelligence-based automatic quantification of breast arterial calcification from screening mammograms significantly predicted cardiovascular disease morbidity and mortality. This A. I. methodology demonstrated superior predictive value beyond existing PREVENT scores in a large, racially diverse cohort of 123762 women. The results establish breast arterial calcification as a robust and automatically quantifiable biomarker for cardiovascular risk. These findings support integrating A. I. assessment of mammograms into cardiovascular risk stratification for women.</p>
<p>Article number three. Endothelial ZBTB16: a molecular shield against cardiac aging. This study identified zinc finger and B. T. B. domain-containing protein 16, or ZBTB16, as playing a critical protective role against cardiac aging. Researchers found that endothelial ZBTB16 functions as a molecular shield, counteracting age-related cardiac dysfunction. The data revealed specific epigenetically regulated mechanisms underlying endothelial cell impairment during aging. These findings provide novel insights into the molecular processes of cardiac aging and suggest potential therapeutic targets.</p>
<p>Article number four. Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE. This prespecified analysis from the EMPULSE trial found that empagliflozin significantly improved clinical outcomes in patients hospitalized for heart failure. The sodium-glucose cotransporter 2 inhibitor demonstrated consistent efficacy, safety, and tolerability in both de novo heart failure and acute decompensated heart failure subgroups. The benefits of empagliflozin were observed early, providing critical support for initiating this therapy during hospitalization for heart failure regardless of its onset. These findings broaden the evidence base for empagliflozin in a diverse heart failure population.</p>
<p>Article number five. BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination. This study revealed that deficiency in BRISC, a B. R. C. C. 3 isopeptidase complex, drives heart failure by regulating beta-catenin K63 ubiquitination. Researchers found that BRISC functions as a K63-specific deubiquitinase crucial for preventing adverse cardiac remodeling. Analysis showed altered BRISC subunit expression in hypertrophic human and murine hearts, directly linking its dysregulation to cardiac dysfunction. These findings offer a novel molecular mechanism underlying hypertensive heart failure and potential therapeutic targets. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac aging, empagliflozin, coronary artery disease, plaque rupture, artificial intelligence, mortality prediction, cardiac remodeling, ZBTB16, acute myocardial infarction, epigenetics, de novo heart failure, non-obstructive lesions, acute decompensated heart failure, heart failure, sodium-glucose cotransporter 2 inhibitor, BRISC, intracoronary imaging, beta-catenin, mammography, endothelial cells, breast arterial calcification, ubiquitination, cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/">A. I. Mammograms Predict Heart Disease in Women 03/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260309_060036.mp3" length="4364581" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 09, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac aging and empagliflozin. Key takeaway: A. I. Mammograms Predict Heart Disease in Women.
Article Links:
Article 1: Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study. (European heart journal)
Article 2: Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality. (European heart journal)
Article 3: Endothelial ZBTB16: a molecular shield against cardiac aging. (European heart journal)
Article 4: Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE. (JACC. Heart failure)
Article 5: BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/a-i-mammograms-predict-heart-disease-in-women-03-09-26/
 Featured Articles
Article 1: Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41795942
Summary: This study revealed that silent plaque ruptures frequently occur in non-obstructive lesions within non-infarct-related coronary arteries of acute myocardial infarction patients. Researchers characterized the specific morphological features of these ruptures. The study tracked changes in rupture sites over 52 weeks, demonstrating their dynamic nature. It also identified the baseline morphology associated with new-onset ruptures, advancing understanding of coronary artery disease progression beyond the infarct-related artery.
Article 2: Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41795899
Summary: Artificial intelligence-based automatic quantification of breast arterial calcification from screening mammograms significantly predicted cardiovascular disease morbidity and mortality. This A. I. methodology demonstrated superior predictive value beyond existing PREVENT scores in a large, racially diverse cohort of 123762 women. The results establish breast arterial calcification as a robust and automatically quantifiable biomarker for cardiovascular risk. These findings support integrating A. I. assessment of mammograms into cardiovascular risk stratification for women.
Article 3: Endothelial ZBTB16: a molecular shield against cardiac aging.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493057
Summary: This study identified zinc finger and B. T. B. domain-containing protein 16, or ZBTB16, as playing a critical protective role against cardiac aging. Researchers found that endothelial ZBTB16 functions as a molecular shield, counteracting age-related cardiac dysfunction. The data revealed specific epigenetically regulated mechanisms underlying endothelial cell impairment during aging. These findings provide novel insights into the molecular processes of cardiac aging and suggest potential therapeutic targets.
Article 4: Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41793401
Summary: This prespecified analysis from the EMPULSE trial found that empagliflozin significantly improved clinical outcomes in patients hospitalized for heart failure. The sodium-glucose cotransporter 2 inhibitor demonstrated consistent efficacy, safety, and tolerability in both de novo heart failure and acute decompensated heart failure subgroups. The benefits of empagliflozin were observed early, providing critical support for initiating this ther]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 09, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac aging and empagliflozin. Key takeaway: A. I. Mammograms Predict Heart Disease in Women.
Article Links:
Article 1: Silent plaque ruptures in non-obstructive lesions of non-infarct-related arteries: a multimodality, serial intracoronary imaging study. (European heart journal)
Article 2: Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality. (European heart journal)
Article 3: Endothelial ZBTB16: a molecular shield against cardiac aging. (European heart journal)
Article 4: Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE. (JACC. Heart failure)
Article 5: BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/a]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Point-of-Care Cuts Heart Failure Costs 03/07/26</title>
	<link>https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/</link>
	<pubDate>Sat, 07 Mar 2026 11:01:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like point-of-care devices and artificial intelligence. Key takeaway: AI Point-of-Care Cuts Heart Failure Costs.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41779414">Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41779388">Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41784150">AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41782360">Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41778610">Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/">https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41779414" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41779414</a></p>
<p><strong>Summary:</strong> Familial hypercholesterolemia is established as a common genetic condition that causes hypercholesterolemia and significantly increases the risk for premature atherosclerotic cardiovascular disease. Current understanding of the precise prevalence, optimal management strategies, and long-term consequences of genetically confirmed familial hypercholesterolemia across the United States remains limited. This existing knowledge gap underscores the urgent requirement for comprehensive data to accurately characterize this condition. Such characterization is crucial for defining the true burden of disease and developing evidence-based lipid-lowering management strategies.</p>
<h4>Article 2: Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41779388" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41779388</a></p>
<p><strong>Summary:</strong> Mounting evidence demonstrates that renin-independent aldosteronism is a common condition that is frequently underrecognized in clinical practice. The full spectrum of aldosteronism, specifically its association with incident cardiovascular disease events, has not been comprehensively evaluated in community-dwelling older adults. A more thorough understanding of how aldosterone measures correlate with cardiovascular outcomes is essential. This information would improve risk stratification and guide preventative strategies for an underdiagnosed patient population.</p>
<h4>Article 3: AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41784150" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41784150</a></p>
<p><strong>Summary:</strong> Accurate assessment of left ventricular ejection fraction is crucial for heart failure diagnosis, typically requiring skilled sonographers. Artificial intelligence-enabled point-of-care devices are capable of enabling novice operators to accurately assess left ventricular ejection fraction, which leads to reduced healthcare costs. An economic evaluation conducted a cost-minimization analysis, directly comparing conventional sonographer-performed echocardiography to novice-operated artificial intelligence-enabled point-of-care devices. This analysis confirmed the economic benefits of task-shifting using artificial intelligence-enabled platforms for diagnosing left ventricular ejection fraction below 50 percent, offering a cost-effective solution.</p>
<h4>Article 4: Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41782360" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41782360</a></p>
<p><strong>Summary:</strong> Heart failure with preserved ejection fraction is recognized as a heterogeneous syndrome, often hypothesized to consist of discrete subtypes. Advanced data science techniques, applied to deeply phenotyped multi-modal cohorts of 902 prospectively recruited patients, effectively characterized this intrinsic heterogeneity. The rigorous profiling included detailed clinical, imaging, and genetic assessments for each patient. These methods provided a comprehensive understanding of heart failure with preserved ejection fraction, enabling a clearer distinction between actual disease and risk factors.</p>
<h4>Article 5: Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778610" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778610</a></p>
<p><strong>Summary:</strong> The head down position demonstrates existing potential benefits in the management of acute ischemic stroke. Specifically, a negative 20-degree head down position has been shown to appear safe, feasible, and potentially beneficial in patients with large artery atherosclerosis who are not undergoing reperfusion therapy. However, the precise value of this negative 20-degree head down position before endovascular treatment for acute large vessel occlusion stroke currently remains unknown. Further rigorous investigation is essential to establish its definitive efficacy and safety in this specific pre-treatment context.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Management and Consequences of Genotype-Positive Familial Hypercholesterolemia. Familial hypercholesterolemia is established as a common genetic condition that causes hypercholesterolemia and significantly increases the risk for premature atherosclerotic cardiovascular disease. Current understanding of the precise prevalence, optimal management strategies, and long-term consequences of genetically confirmed familial hypercholesterolemia across the United States remains limited. This existing knowledge gap underscores the urgent requirement for comprehensive data to accurately characterize this condition. Such characterization is crucial for defining the true burden of disease and developing evidence-based lipid-lowering management strategies.</p>
<p>Article number two. Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. Mounting evidence demonstrates that renin-independent aldosteronism is a common condition that is frequently underrecognized in clinical practice. The full spectrum of aldosteronism, specifically its association with incident cardiovascular disease events, has not been comprehensively evaluated in community-dwelling older adults. A more thorough understanding of how aldosterone measures correlate with cardiovascular outcomes is essential. This information would improve risk stratification and guide preventative strategies for an underdiagnosed patient population.</p>
<p>Article number three. AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation. Accurate assessment of left ventricular ejection fraction is crucial for heart failure diagnosis, typically requiring skilled sonographers. Artificial intelligence-enabled point-of-care devices are capable of enabling novice operators to accurately assess left ventricular ejection fraction, which leads to reduced healthcare costs. An economic evaluation conducted a cost-minimization analysis, directly comparing conventional sonographer-performed echocardiography to novice-operated artificial intelligence-enabled point-of-care devices. This analysis confirmed the economic benefits of task-shifting using artificial intelligence-enabled platforms for diagnosing left ventricular ejection fraction below 50 percent, offering a cost-effective solution.</p>
<p>Article number four. Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk. Heart failure with preserved ejection fraction is recognized as a heterogeneous syndrome, often hypothesized to consist of discrete subtypes. Advanced data science techniques, applied to deeply phenotyped multi-modal cohorts of 902 prospectively recruited patients, effectively characterized this intrinsic heterogeneity. The rigorous profiling included detailed clinical, imaging, and genetic assessments for each patient. These methods provided a comprehensive understanding of heart failure with preserved ejection fraction, enabling a clearer distinction between actual disease and risk factors.</p>
<p>Article number five. Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design. The head down position demonstrates existing potential benefits in the management of acute ischemic stroke. Specifically, a negative 20-degree head down position has been shown to appear safe, feasible, and potentially beneficial in patients with large artery atherosclerosis who are not undergoing reperfusion therapy. However, the precise value of this negative 20-degree head down position before endovascular treatment for acute large vessel occlusion stroke currently remains unknown. Further rigorous investigation is essential to establish its definitive efficacy and safety in this specific pre-treatment context. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>point-of-care devices, artificial intelligence, clustering algorithms, head down position, large vessel occlusion, economic evaluation, data science, familial hypercholesterolemia, renin-independent aldosteronism, phenotyping, primary aldosteronism, left ventricular ejection fraction, acute ischemic stroke, genetic condition, lipid-lowering management, aldosterone measures, community-dwelling adults, heart failure with preserved ejection fraction, disease heterogeneity, endovascular treatment, stroke management, atherosclerotic cardiovascular disease, hypercholesterolemia, heart failure diagnosis, cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/">AI Point-of-Care Cuts Heart Failure Costs 03/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like point-of-care devices and artificial intelligence. Key takeaway: AI Point-of-Care Cuts Heart Failure Costs.
Article Links:
Article 1: M]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like point-of-care devices and artificial intelligence. Key takeaway: AI Point-of-Care Cuts Heart Failure Costs.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41779414">Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41779388">Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41784150">AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41782360">Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41778610">Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/">https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41779414" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41779414</a></p>
<p><strong>Summary:</strong> Familial hypercholesterolemia is established as a common genetic condition that causes hypercholesterolemia and significantly increases the risk for premature atherosclerotic cardiovascular disease. Current understanding of the precise prevalence, optimal management strategies, and long-term consequences of genetically confirmed familial hypercholesterolemia across the United States remains limited. This existing knowledge gap underscores the urgent requirement for comprehensive data to accurately characterize this condition. Such characterization is crucial for defining the true burden of disease and developing evidence-based lipid-lowering management strategies.</p>
<h4>Article 2: Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41779388" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41779388</a></p>
<p><strong>Summary:</strong> Mounting evidence demonstrates that renin-independent aldosteronism is a common condition that is frequently underrecognized in clinical practice. The full spectrum of aldosteronism, specifically its association with incident cardiovascular disease events, has not been comprehensively evaluated in community-dwelling older adults. A more thorough understanding of how aldosterone measures correlate with cardiovascular outcomes is essential. This information would improve risk stratification and guide preventative strategies for an underdiagnosed patient population.</p>
<h4>Article 3: AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41784150" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41784150</a></p>
<p><strong>Summary:</strong> Accurate assessment of left ventricular ejection fraction is crucial for heart failure diagnosis, typically requiring skilled sonographers. Artificial intelligence-enabled point-of-care devices are capable of enabling novice operators to accurately assess left ventricular ejection fraction, which leads to reduced healthcare costs. An economic evaluation conducted a cost-minimization analysis, directly comparing conventional sonographer-performed echocardiography to novice-operated artificial intelligence-enabled point-of-care devices. This analysis confirmed the economic benefits of task-shifting using artificial intelligence-enabled platforms for diagnosing left ventricular ejection fraction below 50 percent, offering a cost-effective solution.</p>
<h4>Article 4: Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41782360" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41782360</a></p>
<p><strong>Summary:</strong> Heart failure with preserved ejection fraction is recognized as a heterogeneous syndrome, often hypothesized to consist of discrete subtypes. Advanced data science techniques, applied to deeply phenotyped multi-modal cohorts of 902 prospectively recruited patients, effectively characterized this intrinsic heterogeneity. The rigorous profiling included detailed clinical, imaging, and genetic assessments for each patient. These methods provided a comprehensive understanding of heart failure with preserved ejection fraction, enabling a clearer distinction between actual disease and risk factors.</p>
<h4>Article 5: Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778610" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778610</a></p>
<p><strong>Summary:</strong> The head down position demonstrates existing potential benefits in the management of acute ischemic stroke. Specifically, a negative 20-degree head down position has been shown to appear safe, feasible, and potentially beneficial in patients with large artery atherosclerosis who are not undergoing reperfusion therapy. However, the precise value of this negative 20-degree head down position before endovascular treatment for acute large vessel occlusion stroke currently remains unknown. Further rigorous investigation is essential to establish its definitive efficacy and safety in this specific pre-treatment context.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Management and Consequences of Genotype-Positive Familial Hypercholesterolemia. Familial hypercholesterolemia is established as a common genetic condition that causes hypercholesterolemia and significantly increases the risk for premature atherosclerotic cardiovascular disease. Current understanding of the precise prevalence, optimal management strategies, and long-term consequences of genetically confirmed familial hypercholesterolemia across the United States remains limited. This existing knowledge gap underscores the urgent requirement for comprehensive data to accurately characterize this condition. Such characterization is crucial for defining the true burden of disease and developing evidence-based lipid-lowering management strategies.</p>
<p>Article number two. Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. Mounting evidence demonstrates that renin-independent aldosteronism is a common condition that is frequently underrecognized in clinical practice. The full spectrum of aldosteronism, specifically its association with incident cardiovascular disease events, has not been comprehensively evaluated in community-dwelling older adults. A more thorough understanding of how aldosterone measures correlate with cardiovascular outcomes is essential. This information would improve risk stratification and guide preventative strategies for an underdiagnosed patient population.</p>
<p>Article number three. AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation. Accurate assessment of left ventricular ejection fraction is crucial for heart failure diagnosis, typically requiring skilled sonographers. Artificial intelligence-enabled point-of-care devices are capable of enabling novice operators to accurately assess left ventricular ejection fraction, which leads to reduced healthcare costs. An economic evaluation conducted a cost-minimization analysis, directly comparing conventional sonographer-performed echocardiography to novice-operated artificial intelligence-enabled point-of-care devices. This analysis confirmed the economic benefits of task-shifting using artificial intelligence-enabled platforms for diagnosing left ventricular ejection fraction below 50 percent, offering a cost-effective solution.</p>
<p>Article number four. Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk. Heart failure with preserved ejection fraction is recognized as a heterogeneous syndrome, often hypothesized to consist of discrete subtypes. Advanced data science techniques, applied to deeply phenotyped multi-modal cohorts of 902 prospectively recruited patients, effectively characterized this intrinsic heterogeneity. The rigorous profiling included detailed clinical, imaging, and genetic assessments for each patient. These methods provided a comprehensive understanding of heart failure with preserved ejection fraction, enabling a clearer distinction between actual disease and risk factors.</p>
<p>Article number five. Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design. The head down position demonstrates existing potential benefits in the management of acute ischemic stroke. Specifically, a negative 20-degree head down position has been shown to appear safe, feasible, and potentially beneficial in patients with large artery atherosclerosis who are not undergoing reperfusion therapy. However, the precise value of this negative 20-degree head down position before endovascular treatment for acute large vessel occlusion stroke currently remains unknown. Further rigorous investigation is essential to establish its definitive efficacy and safety in this specific pre-treatment context. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>point-of-care devices, artificial intelligence, clustering algorithms, head down position, large vessel occlusion, economic evaluation, data science, familial hypercholesterolemia, renin-independent aldosteronism, phenotyping, primary aldosteronism, left ventricular ejection fraction, acute ischemic stroke, genetic condition, lipid-lowering management, aldosterone measures, community-dwelling adults, heart failure with preserved ejection fraction, disease heterogeneity, endovascular treatment, stroke management, atherosclerotic cardiovascular disease, hypercholesterolemia, heart failure diagnosis, cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/">AI Point-of-Care Cuts Heart Failure Costs 03/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260307_060041.mp3" length="4290603" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like point-of-care devices and artificial intelligence. Key takeaway: AI Point-of-Care Cuts Heart Failure Costs.
Article Links:
Article 1: Management and Consequences of Genotype-Positive Familial Hypercholesterolemia. (JAMA cardiology)
Article 2: Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. (JAMA cardiology)
Article 3: AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation. (ESC heart failure)
Article 4: Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk. (European journal of heart failure)
Article 5: Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ai-point-of-care-cuts-heart-failure-costs-03-07-26/
 Featured Articles
Article 1: Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41779414
Summary: Familial hypercholesterolemia is established as a common genetic condition that causes hypercholesterolemia and significantly increases the risk for premature atherosclerotic cardiovascular disease. Current understanding of the precise prevalence, optimal management strategies, and long-term consequences of genetically confirmed familial hypercholesterolemia across the United States remains limited. This existing knowledge gap underscores the urgent requirement for comprehensive data to accurately characterize this condition. Such characterization is crucial for defining the true burden of disease and developing evidence-based lipid-lowering management strategies.
Article 2: Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41779388
Summary: Mounting evidence demonstrates that renin-independent aldosteronism is a common condition that is frequently underrecognized in clinical practice. The full spectrum of aldosteronism, specifically its association with incident cardiovascular disease events, has not been comprehensively evaluated in community-dwelling older adults. A more thorough understanding of how aldosterone measures correlate with cardiovascular outcomes is essential. This information would improve risk stratification and guide preventative strategies for an underdiagnosed patient population.
Article 3: AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41784150
Summary: Accurate assessment of left ventricular ejection fraction is crucial for heart failure diagnosis, typically requiring skilled sonographers. Artificial intelligence-enabled point-of-care devices are capable of enabling novice operators to accurately assess left ventricular ejection fraction, which leads to reduced healthcare costs. An economic evaluation conducted a cost-minimization analysis, directly comparing conventional sonographer-performed echocardiography to novice-operated artificial intelligence-enabled point-of-care devices. This analysis confirmed the economic benefits of task-shifting using artificial intelligence-enabled platforms for diagnosing left ventricular ejection fraction below 50 percent, offering a cost-effective solution.
Article 4: Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41782360
Summary: Heart failure with preserved ejection fraction]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like point-of-care devices and artificial intelligence. Key takeaway: AI Point-of-Care Cuts Heart Failure Costs.
Article Links:
Article 1: Management and Consequences of Genotype-Positive Familial Hypercholesterolemia. (JAMA cardiology)
Article 2: Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. (JAMA cardiology)
Article 3: AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation. (ESC heart failure)
Article 4: Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk. (European journal of heart failure)
Article 5: Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design. (Journal of the American Heart Association)
Full episode page: https://po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Preventive PCI for Vulnerable Plaques 03/07/26</title>
	<link>https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/</link>
	<pubDate>Sat, 07 Mar 2026 06:09:54 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction model and aficamten. Key takeaway: Preventive PCI for Vulnerable Plaques.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41790457">Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41790132">Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41790128">Laminopathies: natural history and risk prediction of heart failure.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41790041">Senescence-related myocardial dysfunction: keeping a young heart.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41780565">Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/">https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790457" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790457</a></p>
<p><strong>Summary:</strong> Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.</p>
<h4>Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790132</a></p>
<p><strong>Summary:</strong> Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.</p>
<h4>Article 3: Laminopathies: natural history and risk prediction of heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790128" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790128</a></p>
<p><strong>Summary:</strong> This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.</p>
<h4>Article 4: Senescence-related myocardial dysfunction: keeping a young heart.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790041</a></p>
<p><strong>Summary:</strong> The myocardium undergoes significant changes with aging, impacting the heart&#8217;s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.</p>
<h4>Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41780565" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41780565</a></p>
<p><strong>Summary:</strong> The F. O. R. E. S. T. hyphen H. C. M. study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive hypertrophic cardiomyopathy. This next-in-class, oral selective cardiac myosin inhibitor ameliorates hypercontractility in patients. The open-label study enrolled 296 patients, with a mean age of 61 years, who had completed a parent aficamten study. Results from this long-term evaluation provide crucial information on the sustained clinical profile of aficamten for this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities. Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.</p>
<p>Article number two. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.</p>
<p>Article number three. Laminopathies: natural history and risk prediction of heart failure. This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.</p>
<p>Article number four. Senescence-related myocardial dysfunction: keeping a young heart. The myocardium undergoes significant changes with aging, impacting the heart&#8217;s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.</p>
<p>Article number five. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. The F. O. R. E. S. T. hyphen H. C. M. study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive hypertrophic cardiomyopathy. This next-in-class, oral selective cardiac myosin inhibitor ameliorates hypercontractility in patients. The open-label study enrolled 296 patients, with a mean age of 61 years, who had completed a parent aficamten study. Results from this long-term evaluation provide crucial information on the sustained clinical profile of aficamten for this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk prediction model, aficamten, cardiac myosin inhibitor, long-term efficacy, percutaneous coronary intervention, therapeutic innovation, myocardial dysfunction, heart failure, cardiovascular risk, hypertrophic cardiomyopathy, pharmacological therapy, cardiac pathology, obstructive H. C. M., intracoronary imaging, vulnerable plaques, dilated cardiomyopathy, metabolic disorders, acute myocardial ischemic syndromes, cardiovascular health, laminopathy, aging heart, optimal medical therapy, pathological changes, L. M. N. A. gene variants, senescence.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/">Preventive PCI for Vulnerable Plaques 03/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction model and aficamten. Key takeaway: Preventive PCI for Vulnerable Plaques.
Article Links:
Article 1: Novel cardiovascula]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction model and aficamten. Key takeaway: Preventive PCI for Vulnerable Plaques.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41790457">Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41790132">Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41790128">Laminopathies: natural history and risk prediction of heart failure.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41790041">Senescence-related myocardial dysfunction: keeping a young heart.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41780565">Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/">https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790457" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790457</a></p>
<p><strong>Summary:</strong> Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.</p>
<h4>Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790132</a></p>
<p><strong>Summary:</strong> Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.</p>
<h4>Article 3: Laminopathies: natural history and risk prediction of heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790128" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790128</a></p>
<p><strong>Summary:</strong> This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.</p>
<h4>Article 4: Senescence-related myocardial dysfunction: keeping a young heart.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41790041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41790041</a></p>
<p><strong>Summary:</strong> The myocardium undergoes significant changes with aging, impacting the heart&#8217;s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.</p>
<h4>Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41780565" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41780565</a></p>
<p><strong>Summary:</strong> The F. O. R. E. S. T. hyphen H. C. M. study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive hypertrophic cardiomyopathy. This next-in-class, oral selective cardiac myosin inhibitor ameliorates hypercontractility in patients. The open-label study enrolled 296 patients, with a mean age of 61 years, who had completed a parent aficamten study. Results from this long-term evaluation provide crucial information on the sustained clinical profile of aficamten for this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities. Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.</p>
<p>Article number two. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.</p>
<p>Article number three. Laminopathies: natural history and risk prediction of heart failure. This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.</p>
<p>Article number four. Senescence-related myocardial dysfunction: keeping a young heart. The myocardium undergoes significant changes with aging, impacting the heart&#8217;s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.</p>
<p>Article number five. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. The F. O. R. E. S. T. hyphen H. C. M. study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive hypertrophic cardiomyopathy. This next-in-class, oral selective cardiac myosin inhibitor ameliorates hypercontractility in patients. The open-label study enrolled 296 patients, with a mean age of 61 years, who had completed a parent aficamten study. Results from this long-term evaluation provide crucial information on the sustained clinical profile of aficamten for this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk prediction model, aficamten, cardiac myosin inhibitor, long-term efficacy, percutaneous coronary intervention, therapeutic innovation, myocardial dysfunction, heart failure, cardiovascular risk, hypertrophic cardiomyopathy, pharmacological therapy, cardiac pathology, obstructive H. C. M., intracoronary imaging, vulnerable plaques, dilated cardiomyopathy, metabolic disorders, acute myocardial ischemic syndromes, cardiovascular health, laminopathy, aging heart, optimal medical therapy, pathological changes, L. M. N. A. gene variants, senescence.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/">Preventive PCI for Vulnerable Plaques 03/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260307_010905.mp3" length="3660738" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction model and aficamten. Key takeaway: Preventive PCI for Vulnerable Plaques.
Article Links:
Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities. (European heart journal)
Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. (European heart journal)
Article 3: Laminopathies: natural history and risk prediction of heart failure. (European heart journal)
Article 4: Senescence-related myocardial dysfunction: keeping a young heart. (European heart journal)
Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/
 Featured Articles
Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790457
Summary: Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.
Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790132
Summary: Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.
Article 3: Laminopathies: natural history and risk prediction of heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790128
Summary: This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.
Article 4: Senescence-related myocardial dysfunction: keeping a young heart.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790041
Summary: The myocardium undergoes significant changes with aging, impacting the heart&#8217;s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.
Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyop]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction model and aficamten. Key takeaway: Preventive PCI for Vulnerable Plaques.
Article Links:
Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities. (European heart journal)
Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. (European heart journal)
Article 3: Laminopathies: natural history and risk prediction of heart failure. (European heart journal)
Article 4: Senescence-related myocardial dysfunction: keeping a young heart. (European heart journal)
Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/
]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Predicts Heart Failure from ECGs 03/06/26</title>
	<link>https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/</link>
	<pubDate>Fri, 06 Mar 2026 11:01:22 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 06, 2026. This episode summarizes 5 key cardiology studies on topics like breast cancer and cardiac myosin inhibitor. Key takeaway: AI Predicts Heart Failure from ECGs.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41493295">Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41493294">Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41348072">Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41784225">Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41780910">Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/">https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493295" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493295</a></p>
<p><strong>Summary:</strong> Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population.</p>
<h4>Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493294" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493294</a></p>
<p><strong>Summary:</strong> Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure.</p>
<h4>Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41348072" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41348072</a></p>
<p><strong>Summary:</strong> The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten&#8217;s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy.</p>
<h4>Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41784225" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41784225</a></p>
<p><strong>Summary:</strong> This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction.</p>
<h4>Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41780910" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41780910</a></p>
<p><strong>Summary:</strong> Breast tumor-secreted A. D. A. M. ten mediates atrial fibrogenesis and fibrillation. This study found that breast cancer itself, independent of treatment-related cardiotoxicity, directly induces atrial fibrillation through this specific molecular mechanism. A retrospective analysis of 1224 female breast cancer patients before therapy and 18159 healthy female participants established this link. This research identifies a direct pathological connection between breast tumors and the development of atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population.</p>
<p>Article number two. Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure.</p>
<p>Article number three. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten&#8217;s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy.</p>
<p>Article number four. Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction.</p>
<p>Article number five. Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. Breast tumor-secreted A. D. A. M. ten mediates atrial fibrogenesis and fibrillation. This study found that breast cancer itself, independent of treatment-related cardiotoxicity, directly induces atrial fibrillation through this specific molecular mechanism. A retrospective analysis of 1224 female breast cancer patients before therapy and 18159 healthy female participants established this link. This research identifies a direct pathological connection between breast tumors and the development of atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>breast cancer, cardiac myosin inhibitor, artificial intelligence, electrocardiogram, heart failure prediction, metoprolol, atrial fibrillation, high-fat diet, exercise capacity, obstructive hypertrophic cardiomyopathy, nuclear argonaute two, atrial fibrogenesis, diastolic dysfunction, aficamten, cardiac dysfunction, metoprolol monotherapy, exercise tolerance, aficamten monotherapy, tumor-secreted factors, patient-centric measures, systolic dysfunction, myocardial ketogenesis, A. D. A. M. ten, heart failure with preserved ejection fraction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/">AI Predicts Heart Failure from ECGs 03/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 06, 2026. This episode summarizes 5 key cardiology studies on topics like breast cancer and cardiac myosin inhibitor. Key takeaway: AI Predicts Heart Failure from ECGs.
Article Links:
Article 1: Effect of Afic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 06, 2026. This episode summarizes 5 key cardiology studies on topics like breast cancer and cardiac myosin inhibitor. Key takeaway: AI Predicts Heart Failure from ECGs.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41493295">Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41493294">Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41348072">Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41784225">Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41780910">Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/">https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493295" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493295</a></p>
<p><strong>Summary:</strong> Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population.</p>
<h4>Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493294" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493294</a></p>
<p><strong>Summary:</strong> Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure.</p>
<h4>Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41348072" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41348072</a></p>
<p><strong>Summary:</strong> The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten&#8217;s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy.</p>
<h4>Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41784225" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41784225</a></p>
<p><strong>Summary:</strong> This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction.</p>
<h4>Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41780910" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41780910</a></p>
<p><strong>Summary:</strong> Breast tumor-secreted A. D. A. M. ten mediates atrial fibrogenesis and fibrillation. This study found that breast cancer itself, independent of treatment-related cardiotoxicity, directly induces atrial fibrillation through this specific molecular mechanism. A retrospective analysis of 1224 female breast cancer patients before therapy and 18159 healthy female participants established this link. This research identifies a direct pathological connection between breast tumors and the development of atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population.</p>
<p>Article number two. Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure.</p>
<p>Article number three. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten&#8217;s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy.</p>
<p>Article number four. Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction.</p>
<p>Article number five. Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. Breast tumor-secreted A. D. A. M. ten mediates atrial fibrogenesis and fibrillation. This study found that breast cancer itself, independent of treatment-related cardiotoxicity, directly induces atrial fibrillation through this specific molecular mechanism. A retrospective analysis of 1224 female breast cancer patients before therapy and 18159 healthy female participants established this link. This research identifies a direct pathological connection between breast tumors and the development of atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>breast cancer, cardiac myosin inhibitor, artificial intelligence, electrocardiogram, heart failure prediction, metoprolol, atrial fibrillation, high-fat diet, exercise capacity, obstructive hypertrophic cardiomyopathy, nuclear argonaute two, atrial fibrogenesis, diastolic dysfunction, aficamten, cardiac dysfunction, metoprolol monotherapy, exercise tolerance, aficamten monotherapy, tumor-secreted factors, patient-centric measures, systolic dysfunction, myocardial ketogenesis, A. D. A. M. ten, heart failure with preserved ejection fraction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/">AI Predicts Heart Failure from ECGs 03/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260306_060029.mp3" length="3607657" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 06, 2026. This episode summarizes 5 key cardiology studies on topics like breast cancer and cardiac myosin inhibitor. Key takeaway: AI Predicts Heart Failure from ECGs.
Article Links:
Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. (Journal of the American College of Cardiology)
Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. (Journal of the American College of Cardiology)
Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. (Journal of the American College of Cardiology)
Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. (European heart journal)
Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-ecgs-03-06-26/
 Featured Articles
Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493295
Summary: Aficamten, a cardiac myosin inhibitor, was significantly more effective than metoprolol at improving exercise tolerance in patients with obstructive hypertrophic cardiomyopathy. The MAPLE-HCM trial, a head-to-head, international, double-blind, randomized study, demonstrated this definitive finding. Aficamten showed clear superiority over metoprolol in this patient population.
Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493294
Summary: Artificial intelligence applied to electrocardiograms enhances the prediction of incident heart failure beyond clinical risk estimation using the PREVENT-Heart Failure equation. This electrocardiogram-artificial intelligence was specifically designed to detect both systolic and diastolic dysfunction. The pooled cohort analysis found that this scalable approach improves identification of individuals at risk for heart failure.
Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41348072
Summary: The MAPLE-HCM trial demonstrated that aficamten monotherapy provided greater improvement in exercise capacity and multiple secondary endpoints compared to metoprolol monotherapy. This multidomain, patient-level analysis further evaluated aficamten&#8217;s effects across various clinically relevant and patient-centric measures of disease burden in obstructive hypertrophic cardiomyopathy. Aficamten definitively improved outcomes compared to the traditional beta-blocker therapy.
Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41784225
Summary: This study found that nuclear argonaute two exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. This mechanism contributes to cardiac dysfunction, particularly in contexts of high-fat diet. The research demonstrated a causal role for nuclear argonaute two in inducing this specific type of heart failure. These findings offer a novel understanding of disease progression for heart failure with preserved ejection fraction.
Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41780910
Summary: Breast tumor-secreted A. D. A. M. ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 06, 2026. This episode summarizes 5 key cardiology studies on topics like breast cancer and cardiac myosin inhibitor. Key takeaway: AI Predicts Heart Failure from ECGs.
Article Links:
Article 1: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. (Journal of the American College of Cardiology)
Article 2: Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis. (Journal of the American College of Cardiology)
Article 3: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. (Journal of the American College of Cardiology)
Article 4: Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. (European heart journal)
Article 5: Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. (European heart journal)
Full episode pa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil 03/05/26</title>
	<link>https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/</link>
	<pubDate>Thu, 05 Mar 2026 11:01:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 05, 2026. This episode summarizes 5 key cardiology studies on topics like Computed tomography angiography and Verapamil. Key takeaway: Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41780000">Finerenone in Type 1 Diabetes and Chronic Kidney Disease.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41778959">Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41778943">Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41778690">Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532945">Heart Failure Quality of Care Among Asian Patients in the United States.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/">https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41780000" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41780000</a></p>
<p><strong>Summary:</strong> Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone&#8217;s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.</p>
<h4>Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778959</a></p>
<p><strong>Summary:</strong> This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.</p>
<h4>Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778943</a></p>
<p><strong>Summary:</strong> This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.</p>
<h4>Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778690" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778690</a></p>
<p><strong>Summary:</strong> This randomized, double-blinded, placebo-controlled triple-crossover trial directly compared the effects of bisoprolol and verapamil in patients with nonobstructive hypertrophic cardiomyopathy. The study rigorously evaluated the therapeutic impact of these two distinct drug classes, beta-blockers and calcium channel blockers. Patients included presented with at least one marker of disease severity, such as New York Heart Association functional class two or greater or N-terminal pro-B-type natriuretic peptide levels exceeding 300 nanograms per liter. This trial provided critical evidence regarding optimal pharmacologic management for this specific hypertrophic cardiomyopathy phenotype.</p>
<h4>Article 5: Heart Failure Quality of Care Among Asian Patients in the United States.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532945" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532945</a></p>
<p><strong>Summary:</strong> This study identified crucial differences in the quality of inpatient heart failure care among individual groups of Asian patients compared with non-Hispanic White patients in the United States. Utilizing data from 824 U.S. hospitals within the Get With The Guidelines-Heart Failure registry from 2015 to 2023, the study rigorously assessed the odds of receiving optimal medical therapy. Optimal medical therapy was specifically defined as appropriate prescription of an angiotensin-converting enzyme inhibitor or angiotensin two receptor blocker, alongside a beta-blocker and a mineralocorticoid receptor antagonist. This research provided a detailed understanding of care disparities impacting diverse Asian heart failure populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone&#8217;s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.</p>
<p>Article number two. Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography. This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.</p>
<p>Article number three. Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.</p>
<p>Article number four. Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. This randomized, double-blinded, placebo-controlled triple-crossover trial directly compared the effects of bisoprolol and verapamil in patients with nonobstructive hypertrophic cardiomyopathy. The study rigorously evaluated the therapeutic impact of these two distinct drug classes, beta-blockers and calcium channel blockers. Patients included presented with at least one marker of disease severity, such as New York Heart Association functional class two or greater or N-terminal pro-B-type natriuretic peptide levels exceeding 300 nanograms per liter. This trial provided critical evidence regarding optimal pharmacologic management for this specific hypertrophic cardiomyopathy phenotype.</p>
<p>Article number five. Heart Failure Quality of Care Among Asian Patients in the United States. This study identified crucial differences in the quality of inpatient heart failure care among individual groups of Asian patients compared with non-Hispanic White patients in the United States. Utilizing data from 824 U.S. hospitals within the Get With The Guidelines-Heart Failure registry from 2015 to 2023, the study rigorously assessed the odds of receiving optimal medical therapy. Optimal medical therapy was specifically defined as appropriate prescription of an angiotensin-converting enzyme inhibitor or angiotensin two receptor blocker, alongside a beta-blocker and a mineralocorticoid receptor antagonist. This research provided a detailed understanding of care disparities impacting diverse Asian heart failure populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Computed tomography angiography, Verapamil, Chronic kidney disease, Albuminuria, Mineralocorticoid receptor antagonist, Percutaneous coronary intervention, Intravascular imaging, Heart failure, Angiography-guided percutaneous coronary intervention, Control subjects, Bisoprolol, Liver transplant, Coronary atherosclerosis, Beta-blocker, Triple-crossover trial, Long-term outcomes, Complex coronary lesions, Finerenone, Optimal medical therapy, Nationwide study, Nonobstructive hypertrophic cardiomyopathy, Type one diabetes, Get With The Guidelines, Quality of care, Calcium channel blocker, Asian patients.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/">Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil 03/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 05, 2026. This episode summarizes 5 key cardiology studies on topics like Computed tomography angiography and Verapamil. Key takeaway: Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil.
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 05, 2026. This episode summarizes 5 key cardiology studies on topics like Computed tomography angiography and Verapamil. Key takeaway: Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41780000">Finerenone in Type 1 Diabetes and Chronic Kidney Disease.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41778959">Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41778943">Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41778690">Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532945">Heart Failure Quality of Care Among Asian Patients in the United States.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/">https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41780000" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41780000</a></p>
<p><strong>Summary:</strong> Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone&#8217;s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.</p>
<h4>Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778959</a></p>
<p><strong>Summary:</strong> This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.</p>
<h4>Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778943</a></p>
<p><strong>Summary:</strong> This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.</p>
<h4>Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41778690" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41778690</a></p>
<p><strong>Summary:</strong> This randomized, double-blinded, placebo-controlled triple-crossover trial directly compared the effects of bisoprolol and verapamil in patients with nonobstructive hypertrophic cardiomyopathy. The study rigorously evaluated the therapeutic impact of these two distinct drug classes, beta-blockers and calcium channel blockers. Patients included presented with at least one marker of disease severity, such as New York Heart Association functional class two or greater or N-terminal pro-B-type natriuretic peptide levels exceeding 300 nanograms per liter. This trial provided critical evidence regarding optimal pharmacologic management for this specific hypertrophic cardiomyopathy phenotype.</p>
<h4>Article 5: Heart Failure Quality of Care Among Asian Patients in the United States.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532945" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532945</a></p>
<p><strong>Summary:</strong> This study identified crucial differences in the quality of inpatient heart failure care among individual groups of Asian patients compared with non-Hispanic White patients in the United States. Utilizing data from 824 U.S. hospitals within the Get With The Guidelines-Heart Failure registry from 2015 to 2023, the study rigorously assessed the odds of receiving optimal medical therapy. Optimal medical therapy was specifically defined as appropriate prescription of an angiotensin-converting enzyme inhibitor or angiotensin two receptor blocker, alongside a beta-blocker and a mineralocorticoid receptor antagonist. This research provided a detailed understanding of care disparities impacting diverse Asian heart failure populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone&#8217;s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.</p>
<p>Article number two. Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography. This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.</p>
<p>Article number three. Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.</p>
<p>Article number four. Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. This randomized, double-blinded, placebo-controlled triple-crossover trial directly compared the effects of bisoprolol and verapamil in patients with nonobstructive hypertrophic cardiomyopathy. The study rigorously evaluated the therapeutic impact of these two distinct drug classes, beta-blockers and calcium channel blockers. Patients included presented with at least one marker of disease severity, such as New York Heart Association functional class two or greater or N-terminal pro-B-type natriuretic peptide levels exceeding 300 nanograms per liter. This trial provided critical evidence regarding optimal pharmacologic management for this specific hypertrophic cardiomyopathy phenotype.</p>
<p>Article number five. Heart Failure Quality of Care Among Asian Patients in the United States. This study identified crucial differences in the quality of inpatient heart failure care among individual groups of Asian patients compared with non-Hispanic White patients in the United States. Utilizing data from 824 U.S. hospitals within the Get With The Guidelines-Heart Failure registry from 2015 to 2023, the study rigorously assessed the odds of receiving optimal medical therapy. Optimal medical therapy was specifically defined as appropriate prescription of an angiotensin-converting enzyme inhibitor or angiotensin two receptor blocker, alongside a beta-blocker and a mineralocorticoid receptor antagonist. This research provided a detailed understanding of care disparities impacting diverse Asian heart failure populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Computed tomography angiography, Verapamil, Chronic kidney disease, Albuminuria, Mineralocorticoid receptor antagonist, Percutaneous coronary intervention, Intravascular imaging, Heart failure, Angiography-guided percutaneous coronary intervention, Control subjects, Bisoprolol, Liver transplant, Coronary atherosclerosis, Beta-blocker, Triple-crossover trial, Long-term outcomes, Complex coronary lesions, Finerenone, Optimal medical therapy, Nationwide study, Nonobstructive hypertrophic cardiomyopathy, Type one diabetes, Get With The Guidelines, Quality of care, Calcium channel blocker, Asian patients.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/">Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil 03/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260305_060029.mp3" length="4680976" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 05, 2026. This episode summarizes 5 key cardiology studies on topics like Computed tomography angiography and Verapamil. Key takeaway: Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil.
Article Links:
Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease. (The New England journal of medicine)
Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography. (Journal of the American College of Cardiology)
Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. (Journal of the American College of Cardiology)
Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. (Journal of the American College of Cardiology)
Article 5: Heart Failure Quality of Care Among Asian Patients in the United States. (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/nonobstructive-hypertrophic-cardiomyopathy-bisoprolol-vs-verapamil-03-05-26/
 Featured Articles
Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41780000
Summary: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated improvements in kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This established benefit prompted a phase three trial evaluating finerenone&#8217;s efficacy and safety in adults with type one diabetes and chronic kidney disease. The study included patients with an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 meters squared, who also presented with albuminuria. This research directly addresses the potential therapeutic application of finerenone for improving outcomes in a distinct diabetic population.
Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41778959
Summary: This nationwide cross-sectional study definitively characterized the prevalence and severity of coronary atherosclerosis in liver transplant recipients compared to control subjects. Researchers utilized protocolized research-coronary computed tomography angiography in both groups to overcome previous limitations of clinically indicated imaging or retrospective studies. This standardized approach provided a more robust assessment of coronary atherosclerotic burden. The study established a comprehensive profile of atherosclerotic disease in liver transplant patients.
Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41778943
Summary: This randomized trial provided crucial long-term clinical outcomes comparing intravascular imaging-guided percutaneous coronary intervention with angiography-guided percutaneous coronary intervention for complex coronary artery lesions. The study definitively evaluated two distinct approaches for revascularization, assigning eligible patients in a two to one ratio to receive either imaging guidance or angiography guidance. This robust comparison established a clearer understanding of the relative long-term efficacy of each technique. The findings inform optimal strategies for percutaneous coronary intervention in challenging cases.
Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.
Journal: Journal of the ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 05, 2026. This episode summarizes 5 key cardiology studies on topics like Computed tomography angiography and Verapamil. Key takeaway: Nonobstructive Hypertrophic Cardiomyopathy: Bisoprolol vs Verapamil.
Article Links:
Article 1: Finerenone in Type 1 Diabetes and Chronic Kidney Disease. (The New England journal of medicine)
Article 2: Coronary Atherosclerosis in Liver Transplant Recipients and Population Controls: A Nationwide Study Using Protocolized CT Angiography. (Journal of the American College of Cardiology)
Article 3: Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial. (Journal of the American College of Cardiology)
Article 4: Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. (Journal of the American College of Cardiology)
Article 5: Heart Failure Quality of Care Among Asian Pat]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Atrial Cardiomyopathy Imaging Improves Risk Stratification 03/04/26</title>
	<link>https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/</link>
	<pubDate>Wed, 04 Mar 2026 11:01:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 04, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and left ventricular diastolic dysfunction. Key takeaway: Atrial Cardiomyopathy Imaging Improves Risk Stratification.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41775525">Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41774767">Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41766529">MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41744115">Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41744114">Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/">https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41775525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41775525</a></p>
<p><strong>Summary:</strong> This five-year longitudinal cohort analysis established chronic kidney disease as a significant comorbidity influencing outcomes following heart failure hospitalization. The study demonstrated a framework for comparing clinical events, healthcare resource utilization, and direct costs between heart failure patients with and without a chronic kidney disease diagnosis. This investigation highlights the critical impact of chronic kidney disease on patient management and economic burden within this population.</p>
<h4>Article 2: Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41774767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41774767</a></p>
<p><strong>Summary:</strong> This scientific statement established atrial cardiomyopathy as a distinct pathological entity characterized by structural, functional, and electrical abnormalities. It demonstrated that early identification and longitudinal monitoring of atrial remodeling are crucial for improving risk stratification, guiding therapeutic decisions, and assessing treatment response. The statement concluded that clinical evaluation alone is insufficient, thereby highlighting the essential role of advanced imaging techniques in detecting and monitoring these abnormalities to improve patient outcomes.</p>
<h4>Article 3: MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766529" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766529</a></p>
<p><strong>Summary:</strong> This study established nutrition insecurity as a major driver of poor cardiovascular health within Indigenous communities. It designed MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure), an Indigenous culturally tailored &#8220;food is medicine&#8221; intervention. The design demonstrated a community-based-participatory method for utilizing traditional precontact foods to improve heart failure outcomes and quality of life in these populations.</p>
<h4>Article 4: Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744115" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744115</a></p>
<p><strong>Summary:</strong> This analysis found that acute myocardial infarction hospitalizations are increasing in young adults aged 18 to 54 years in the United States between 2011 and 2022. The study identified sex-based differences in outcomes for young adults hospitalized with their first myocardial infarction. It established in-hospital mortality as the primary endpoint, specifically stratified by S. T. segment elevation myocardial infarction and non-S. T. segment elevation myocardial infarction subtypes and sex, underscoring the critical need to understand these disparities.</p>
<h4>Article 5: Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744114" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744114</a></p>
<p><strong>Summary:</strong> This study identified that women with H. I. V. experience a disproportionately high prevalence of substance use, which is associated with cardiac disease. Researchers measured left ventricular systolic dysfunction and diastolic dysfunction, conditions preceding clinical heart failure, in a cohort of 1651 women. This investigation established a framework for examining the associations between sustained methamphetamine and amphetamine use and these specific cardiac dysfunctions in women living with and without H. I. V.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Burden of chronic kidney disease and outcomes following hospitalisation for heart failure. This five-year longitudinal cohort analysis established chronic kidney disease as a significant comorbidity influencing outcomes following heart failure hospitalization. The study demonstrated a framework for comparing clinical events, healthcare resource utilization, and direct costs between heart failure patients with and without a chronic kidney disease diagnosis. This investigation highlights the critical impact of chronic kidney disease on patient management and economic burden within this population.</p>
<p>Article number two. Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement. This scientific statement established atrial cardiomyopathy as a distinct pathological entity characterized by structural, functional, and electrical abnormalities. It demonstrated that early identification and longitudinal monitoring of atrial remodeling are crucial for improving risk stratification, guiding therapeutic decisions, and assessing treatment response. The statement concluded that clinical evaluation alone is insufficient, thereby highlighting the essential role of advanced imaging techniques in detecting and monitoring these abnormalities to improve patient outcomes.</p>
<p>Article number three. MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention. This study established nutrition insecurity as a major driver of poor cardiovascular health within Indigenous communities. It designed MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure), an Indigenous culturally tailored &#8220;food is medicine&#8221; intervention. The design demonstrated a community-based-participatory method for utilizing traditional precontact foods to improve heart failure outcomes and quality of life in these populations.</p>
<p>Article number four. Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022. This analysis found that acute myocardial infarction hospitalizations are increasing in young adults aged 18 to 54 years in the United States between 2011 and 2022. The study identified sex-based differences in outcomes for young adults hospitalized with their first myocardial infarction. It established in-hospital mortality as the primary endpoint, specifically stratified by S. T. segment elevation myocardial infarction and non-S. T. segment elevation myocardial infarction subtypes and sex, underscoring the critical need to understand these disparities.</p>
<p>Article number five. Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV. This study identified that women with H. I. V. experience a disproportionately high prevalence of substance use, which is associated with cardiac disease. Researchers measured left ventricular systolic dysfunction and diastolic dysfunction, conditions preceding clinical heart failure, in a cohort of 1651 women. This investigation established a framework for examining the associations between sustained methamphetamine and amphetamine use and these specific cardiac dysfunctions in women living with and without H. I. V. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk stratification, left ventricular diastolic dysfunction, medically tailored meals, atrial fibrillation, methamphetamine use, direct healthcare costs, healthcare utilization, left ventricular systolic dysfunction, in-hospital mortality, chronic kidney disease, imaging techniques, nutrition insecurity, H. I. V., sex differences, comorbidity, S. T. segment elevation myocardial infarction, traditional foods, Indigenous communities, heart failure, atrial cardiomyopathy, amphetamine use, atrial remodeling, young adults, acute myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/">Atrial Cardiomyopathy Imaging Improves Risk Stratification 03/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 04, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and left ventricular diastolic dysfunction. Key takeaway: Atrial Cardiomyopathy Imaging Improves Risk Stratificatio]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 04, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and left ventricular diastolic dysfunction. Key takeaway: Atrial Cardiomyopathy Imaging Improves Risk Stratification.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41775525">Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41774767">Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41766529">MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41744115">Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41744114">Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/">https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41775525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41775525</a></p>
<p><strong>Summary:</strong> This five-year longitudinal cohort analysis established chronic kidney disease as a significant comorbidity influencing outcomes following heart failure hospitalization. The study demonstrated a framework for comparing clinical events, healthcare resource utilization, and direct costs between heart failure patients with and without a chronic kidney disease diagnosis. This investigation highlights the critical impact of chronic kidney disease on patient management and economic burden within this population.</p>
<h4>Article 2: Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41774767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41774767</a></p>
<p><strong>Summary:</strong> This scientific statement established atrial cardiomyopathy as a distinct pathological entity characterized by structural, functional, and electrical abnormalities. It demonstrated that early identification and longitudinal monitoring of atrial remodeling are crucial for improving risk stratification, guiding therapeutic decisions, and assessing treatment response. The statement concluded that clinical evaluation alone is insufficient, thereby highlighting the essential role of advanced imaging techniques in detecting and monitoring these abnormalities to improve patient outcomes.</p>
<h4>Article 3: MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766529" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766529</a></p>
<p><strong>Summary:</strong> This study established nutrition insecurity as a major driver of poor cardiovascular health within Indigenous communities. It designed MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure), an Indigenous culturally tailored &#8220;food is medicine&#8221; intervention. The design demonstrated a community-based-participatory method for utilizing traditional precontact foods to improve heart failure outcomes and quality of life in these populations.</p>
<h4>Article 4: Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744115" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744115</a></p>
<p><strong>Summary:</strong> This analysis found that acute myocardial infarction hospitalizations are increasing in young adults aged 18 to 54 years in the United States between 2011 and 2022. The study identified sex-based differences in outcomes for young adults hospitalized with their first myocardial infarction. It established in-hospital mortality as the primary endpoint, specifically stratified by S. T. segment elevation myocardial infarction and non-S. T. segment elevation myocardial infarction subtypes and sex, underscoring the critical need to understand these disparities.</p>
<h4>Article 5: Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744114" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744114</a></p>
<p><strong>Summary:</strong> This study identified that women with H. I. V. experience a disproportionately high prevalence of substance use, which is associated with cardiac disease. Researchers measured left ventricular systolic dysfunction and diastolic dysfunction, conditions preceding clinical heart failure, in a cohort of 1651 women. This investigation established a framework for examining the associations between sustained methamphetamine and amphetamine use and these specific cardiac dysfunctions in women living with and without H. I. V.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Burden of chronic kidney disease and outcomes following hospitalisation for heart failure. This five-year longitudinal cohort analysis established chronic kidney disease as a significant comorbidity influencing outcomes following heart failure hospitalization. The study demonstrated a framework for comparing clinical events, healthcare resource utilization, and direct costs between heart failure patients with and without a chronic kidney disease diagnosis. This investigation highlights the critical impact of chronic kidney disease on patient management and economic burden within this population.</p>
<p>Article number two. Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement. This scientific statement established atrial cardiomyopathy as a distinct pathological entity characterized by structural, functional, and electrical abnormalities. It demonstrated that early identification and longitudinal monitoring of atrial remodeling are crucial for improving risk stratification, guiding therapeutic decisions, and assessing treatment response. The statement concluded that clinical evaluation alone is insufficient, thereby highlighting the essential role of advanced imaging techniques in detecting and monitoring these abnormalities to improve patient outcomes.</p>
<p>Article number three. MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention. This study established nutrition insecurity as a major driver of poor cardiovascular health within Indigenous communities. It designed MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure), an Indigenous culturally tailored &#8220;food is medicine&#8221; intervention. The design demonstrated a community-based-participatory method for utilizing traditional precontact foods to improve heart failure outcomes and quality of life in these populations.</p>
<p>Article number four. Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022. This analysis found that acute myocardial infarction hospitalizations are increasing in young adults aged 18 to 54 years in the United States between 2011 and 2022. The study identified sex-based differences in outcomes for young adults hospitalized with their first myocardial infarction. It established in-hospital mortality as the primary endpoint, specifically stratified by S. T. segment elevation myocardial infarction and non-S. T. segment elevation myocardial infarction subtypes and sex, underscoring the critical need to understand these disparities.</p>
<p>Article number five. Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV. This study identified that women with H. I. V. experience a disproportionately high prevalence of substance use, which is associated with cardiac disease. Researchers measured left ventricular systolic dysfunction and diastolic dysfunction, conditions preceding clinical heart failure, in a cohort of 1651 women. This investigation established a framework for examining the associations between sustained methamphetamine and amphetamine use and these specific cardiac dysfunctions in women living with and without H. I. V. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk stratification, left ventricular diastolic dysfunction, medically tailored meals, atrial fibrillation, methamphetamine use, direct healthcare costs, healthcare utilization, left ventricular systolic dysfunction, in-hospital mortality, chronic kidney disease, imaging techniques, nutrition insecurity, H. I. V., sex differences, comorbidity, S. T. segment elevation myocardial infarction, traditional foods, Indigenous communities, heart failure, atrial cardiomyopathy, amphetamine use, atrial remodeling, young adults, acute myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/">Atrial Cardiomyopathy Imaging Improves Risk Stratification 03/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260304_060028.mp3" length="3862612" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 04, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and left ventricular diastolic dysfunction. Key takeaway: Atrial Cardiomyopathy Imaging Improves Risk Stratification.
Article Links:
Article 1: Burden of chronic kidney disease and outcomes following hospitalisation for heart failure. (Heart (British Cardiac Society))
Article 2: Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement. (ESC heart failure)
Article 3: MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention. (Circulation. Heart failure)
Article 4: Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022. (Journal of the American Heart Association)
Article 5: Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/atrial-cardiomyopathy-imaging-improves-risk-stratification-03-04-26/
 Featured Articles
Article 1: Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41775525
Summary: This five-year longitudinal cohort analysis established chronic kidney disease as a significant comorbidity influencing outcomes following heart failure hospitalization. The study demonstrated a framework for comparing clinical events, healthcare resource utilization, and direct costs between heart failure patients with and without a chronic kidney disease diagnosis. This investigation highlights the critical impact of chronic kidney disease on patient management and economic burden within this population.
Article 2: Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41774767
Summary: This scientific statement established atrial cardiomyopathy as a distinct pathological entity characterized by structural, functional, and electrical abnormalities. It demonstrated that early identification and longitudinal monitoring of atrial remodeling are crucial for improving risk stratification, guiding therapeutic decisions, and assessing treatment response. The statement concluded that clinical evaluation alone is insufficient, thereby highlighting the essential role of advanced imaging techniques in detecting and monitoring these abnormalities to improve patient outcomes.
Article 3: MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41766529
Summary: This study established nutrition insecurity as a major driver of poor cardiovascular health within Indigenous communities. It designed MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure), an Indigenous culturally tailored &#8220;food is medicine&#8221; intervention. The design demonstrated a community-based-participatory method for utilizing traditional precontact foods to improve heart failure outcomes and quality of life in these populations.
Article 4: Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41744115
Summary: This analysis found that acute myocardial infarction hospitalizations are increasing in young adults aged 18 to 54 years in the United States between 2011 and 2022. The study identified sex-based differences in outcomes for young adults hospitalized with their first myocardial infarction. It established in-hospital mortality as the primary endpoint, specifically s]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 04, 2026. This episode summarizes 5 key cardiology studies on topics like risk stratification and left ventricular diastolic dysfunction. Key takeaway: Atrial Cardiomyopathy Imaging Improves Risk Stratification.
Article Links:
Article 1: Burden of chronic kidney disease and outcomes following hospitalisation for heart failure. (Heart (British Cardiac Society))
Article 2: Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement. (ESC heart failure)
Article 3: MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention. (Circulation. Heart failure)
Article 4: Sex Differences in Outcomes of Young Adults Hospitalized With First Myocardial Infarction From 2011 to 2022. (Journal of the American Heart Association)
Article 5: Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV. (]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>P16 Cells Drive Post-MI Cardiac Remodeling 03/03/26</title>
	<link>https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/</link>
	<pubDate>Tue, 03 Mar 2026 11:01:59 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 03, 2026. This episode summarizes 5 key cardiology studies on topics like P16 positive cells and adiponectin. Key takeaway: P16 Cells Drive Post-MI Cardiac Remodeling.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41487088">Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41766556">Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41766535">PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41766527">Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41766526">P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/">https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487088" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487088</a></p>
<p><strong>Summary:</strong> Myocardial recovery, characterized by reduced ventricular dilatation and improved systolic function, occurs in a subset of patients with heart failure. This phenomenon is most common in patients receiving left ventricular assist device therapy, with these patients experiencing improved outcomes and quality of life. The study found that myocardial recovery with mechanical circulatory support is directly linked to alternative splicing and subcellular localization of C. A. M. K. two D. This discovery identifies specific molecular mechanisms for initiating cardiac reverse remodeling.</p>
<h4>Article 2: Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766556" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766556</a></p>
<p><strong>Summary:</strong> This prospective cohort study from the Danish Cardiovascular Screening trials established that aortic and iliac calcifications serve as predictors of serious aortic events. The study found a direct association between these calcifications and outcomes such as aortic dissection and aneurysm rupture. Additionally, the data demonstrated that aortic and iliac calcifications predict major adverse limb events, including peripheral revascularization and lower limb amputation. These findings highlight the clinical significance of calcification burden in forecasting severe cardiovascular and peripheral vascular outcomes.</p>
<h4>Article 3: PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766535" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766535</a></p>
<p><strong>Summary:</strong> Late gadolinium enhancement cardiac magnetic resonance, or LGE-C. M. R., is a useful tool for identifying ventricular tachycardia, or V. T., substrate in patients with structural heart disease. The P. A. M. V. T. two study systematically assessed the long-term evolution of scar and ablation lesions using serial post-ablation LGE-C. M. R. This assessment revealed how ventricular scar tissue and ablation lesions evolve over extended periods following ventricular tachycardia ablation. The findings support the crucial role of post-procedural LGE-C. M. R. in evaluating ablation success and understanding long-term myocardial changes.</p>
<h4>Article 4: Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766527" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766527</a></p>
<p><strong>Summary:</strong> Mortality from acute myocardial infarction has significantly declined in non-diabetic patients, though morbidity and mortality of ischemic heart failure persistently escalate in the diabetic population. This study found that small extracellular vesicle external surface adiponectin mediates crucial communication between adipocytes and cardiomyocytes in diabetic ischemic heart failure. The research identified this specific adiponectin-mediated pathway as a key mechanism contributing to the pathophysiology observed in diabetic patients with ischemic heart failure. This discovery offers a novel understanding of the molecular communication impacting cardiac health in diabetic individuals.</p>
<h4>Article 5: P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766526" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766526</a></p>
<p><strong>Summary:</strong> Ischemic heart disease, with adverse remodeling after myocardial infarction, remains a leading cause of mortality. This study definitively found that P16 positive cells drive adverse post-ischemic cardiac remodeling. They accomplish this through the C. C. L. eight-mediated recruitment of cytotoxic lymphocytes. Using reporter mice, researchers mapped P16 positive cell heterogeneity and identified P16 positive cells and C. C. L. eight as critical therapeutic targets to mitigate adverse cardiac remodeling.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D. Myocardial recovery, characterized by reduced ventricular dilatation and improved systolic function, occurs in a subset of patients with heart failure. This phenomenon is most common in patients receiving left ventricular assist device therapy, with these patients experiencing improved outcomes and quality of life. The study found that myocardial recovery with mechanical circulatory support is directly linked to alternative splicing and subcellular localization of C. A. M. K. two D. This discovery identifies specific molecular mechanisms for initiating cardiac reverse remodeling.</p>
<p>Article number two. Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials. This prospective cohort study from the Danish Cardiovascular Screening trials established that aortic and iliac calcifications serve as predictors of serious aortic events. The study found a direct association between these calcifications and outcomes such as aortic dissection and aneurysm rupture. Additionally, the data demonstrated that aortic and iliac calcifications predict major adverse limb events, including peripheral revascularization and lower limb amputation. These findings highlight the clinical significance of calcification burden in forecasting severe cardiovascular and peripheral vascular outcomes.</p>
<p>Article number three. PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. Late gadolinium enhancement cardiac magnetic resonance, or LGE-C. M. R., is a useful tool for identifying ventricular tachycardia, or V. T., substrate in patients with structural heart disease. The P. A. M. V. T. two study systematically assessed the long-term evolution of scar and ablation lesions using serial post-ablation LGE-C. M. R. This assessment revealed how ventricular scar tissue and ablation lesions evolve over extended periods following ventricular tachycardia ablation. The findings support the crucial role of post-procedural LGE-C. M. R. in evaluating ablation success and understanding long-term myocardial changes.</p>
<p>Article number four. Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure. Mortality from acute myocardial infarction has significantly declined in non-diabetic patients, though morbidity and mortality of ischemic heart failure persistently escalate in the diabetic population. This study found that small extracellular vesicle external surface adiponectin mediates crucial communication between adipocytes and cardiomyocytes in diabetic ischemic heart failure. The research identified this specific adiponectin-mediated pathway as a key mechanism contributing to the pathophysiology observed in diabetic patients with ischemic heart failure. This discovery offers a novel understanding of the molecular communication impacting cardiac health in diabetic individuals.</p>
<p>Article number five. P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes. Ischemic heart disease, with adverse remodeling after myocardial infarction, remains a leading cause of mortality. This study definitively found that P16 positive cells drive adverse post-ischemic cardiac remodeling. They accomplish this through the C. C. L. eight-mediated recruitment of cytotoxic lymphocytes. Using reporter mice, researchers mapped P16 positive cell heterogeneity and identified P16 positive cells and C. C. L. eight as critical therapeutic targets to mitigate adverse cardiac remodeling. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>P16 positive cells, adiponectin, cardiac remodeling, ablation lesions, diabetic ischemic heart failure, C. C. L. eight, ischemic heart disease, myocardial infarction, C. A. M. K. two D., cardiomyocytes, aneurysm rupture, major adverse limb events, aortic calcification, late gadolinium enhancement cardiac magnetic resonance, ventricular tachycardia ablation, cardiac reverse remodeling, cytotoxic lymphocytes, small extracellular vesicles, ventricular scar, structural heart disease, aortic dissection, myocardial recovery, left ventricular assist device, heart failure, iliac calcification, adipocytes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/">P16 Cells Drive Post-MI Cardiac Remodeling 03/03/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 03, 2026. This episode summarizes 5 key cardiology studies on topics like P16 positive cells and adiponectin. Key takeaway: P16 Cells Drive Post-MI Cardiac Remodeling.
Article Links:
Article 1: Myocardial Reco]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 03, 2026. This episode summarizes 5 key cardiology studies on topics like P16 positive cells and adiponectin. Key takeaway: P16 Cells Drive Post-MI Cardiac Remodeling.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41487088">Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41766556">Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41766535">PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41766527">Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41766526">P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/">https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487088" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487088</a></p>
<p><strong>Summary:</strong> Myocardial recovery, characterized by reduced ventricular dilatation and improved systolic function, occurs in a subset of patients with heart failure. This phenomenon is most common in patients receiving left ventricular assist device therapy, with these patients experiencing improved outcomes and quality of life. The study found that myocardial recovery with mechanical circulatory support is directly linked to alternative splicing and subcellular localization of C. A. M. K. two D. This discovery identifies specific molecular mechanisms for initiating cardiac reverse remodeling.</p>
<h4>Article 2: Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766556" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766556</a></p>
<p><strong>Summary:</strong> This prospective cohort study from the Danish Cardiovascular Screening trials established that aortic and iliac calcifications serve as predictors of serious aortic events. The study found a direct association between these calcifications and outcomes such as aortic dissection and aneurysm rupture. Additionally, the data demonstrated that aortic and iliac calcifications predict major adverse limb events, including peripheral revascularization and lower limb amputation. These findings highlight the clinical significance of calcification burden in forecasting severe cardiovascular and peripheral vascular outcomes.</p>
<h4>Article 3: PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766535" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766535</a></p>
<p><strong>Summary:</strong> Late gadolinium enhancement cardiac magnetic resonance, or LGE-C. M. R., is a useful tool for identifying ventricular tachycardia, or V. T., substrate in patients with structural heart disease. The P. A. M. V. T. two study systematically assessed the long-term evolution of scar and ablation lesions using serial post-ablation LGE-C. M. R. This assessment revealed how ventricular scar tissue and ablation lesions evolve over extended periods following ventricular tachycardia ablation. The findings support the crucial role of post-procedural LGE-C. M. R. in evaluating ablation success and understanding long-term myocardial changes.</p>
<h4>Article 4: Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766527" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766527</a></p>
<p><strong>Summary:</strong> Mortality from acute myocardial infarction has significantly declined in non-diabetic patients, though morbidity and mortality of ischemic heart failure persistently escalate in the diabetic population. This study found that small extracellular vesicle external surface adiponectin mediates crucial communication between adipocytes and cardiomyocytes in diabetic ischemic heart failure. The research identified this specific adiponectin-mediated pathway as a key mechanism contributing to the pathophysiology observed in diabetic patients with ischemic heart failure. This discovery offers a novel understanding of the molecular communication impacting cardiac health in diabetic individuals.</p>
<h4>Article 5: P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41766526" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41766526</a></p>
<p><strong>Summary:</strong> Ischemic heart disease, with adverse remodeling after myocardial infarction, remains a leading cause of mortality. This study definitively found that P16 positive cells drive adverse post-ischemic cardiac remodeling. They accomplish this through the C. C. L. eight-mediated recruitment of cytotoxic lymphocytes. Using reporter mice, researchers mapped P16 positive cell heterogeneity and identified P16 positive cells and C. C. L. eight as critical therapeutic targets to mitigate adverse cardiac remodeling.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D. Myocardial recovery, characterized by reduced ventricular dilatation and improved systolic function, occurs in a subset of patients with heart failure. This phenomenon is most common in patients receiving left ventricular assist device therapy, with these patients experiencing improved outcomes and quality of life. The study found that myocardial recovery with mechanical circulatory support is directly linked to alternative splicing and subcellular localization of C. A. M. K. two D. This discovery identifies specific molecular mechanisms for initiating cardiac reverse remodeling.</p>
<p>Article number two. Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials. This prospective cohort study from the Danish Cardiovascular Screening trials established that aortic and iliac calcifications serve as predictors of serious aortic events. The study found a direct association between these calcifications and outcomes such as aortic dissection and aneurysm rupture. Additionally, the data demonstrated that aortic and iliac calcifications predict major adverse limb events, including peripheral revascularization and lower limb amputation. These findings highlight the clinical significance of calcification burden in forecasting severe cardiovascular and peripheral vascular outcomes.</p>
<p>Article number three. PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. Late gadolinium enhancement cardiac magnetic resonance, or LGE-C. M. R., is a useful tool for identifying ventricular tachycardia, or V. T., substrate in patients with structural heart disease. The P. A. M. V. T. two study systematically assessed the long-term evolution of scar and ablation lesions using serial post-ablation LGE-C. M. R. This assessment revealed how ventricular scar tissue and ablation lesions evolve over extended periods following ventricular tachycardia ablation. The findings support the crucial role of post-procedural LGE-C. M. R. in evaluating ablation success and understanding long-term myocardial changes.</p>
<p>Article number four. Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure. Mortality from acute myocardial infarction has significantly declined in non-diabetic patients, though morbidity and mortality of ischemic heart failure persistently escalate in the diabetic population. This study found that small extracellular vesicle external surface adiponectin mediates crucial communication between adipocytes and cardiomyocytes in diabetic ischemic heart failure. The research identified this specific adiponectin-mediated pathway as a key mechanism contributing to the pathophysiology observed in diabetic patients with ischemic heart failure. This discovery offers a novel understanding of the molecular communication impacting cardiac health in diabetic individuals.</p>
<p>Article number five. P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes. Ischemic heart disease, with adverse remodeling after myocardial infarction, remains a leading cause of mortality. This study definitively found that P16 positive cells drive adverse post-ischemic cardiac remodeling. They accomplish this through the C. C. L. eight-mediated recruitment of cytotoxic lymphocytes. Using reporter mice, researchers mapped P16 positive cell heterogeneity and identified P16 positive cells and C. C. L. eight as critical therapeutic targets to mitigate adverse cardiac remodeling. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>P16 positive cells, adiponectin, cardiac remodeling, ablation lesions, diabetic ischemic heart failure, C. C. L. eight, ischemic heart disease, myocardial infarction, C. A. M. K. two D., cardiomyocytes, aneurysm rupture, major adverse limb events, aortic calcification, late gadolinium enhancement cardiac magnetic resonance, ventricular tachycardia ablation, cardiac reverse remodeling, cytotoxic lymphocytes, small extracellular vesicles, ventricular scar, structural heart disease, aortic dissection, myocardial recovery, left ventricular assist device, heart failure, iliac calcification, adipocytes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/">P16 Cells Drive Post-MI Cardiac Remodeling 03/03/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260303_060027.mp3" length="4878671" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 03, 2026. This episode summarizes 5 key cardiology studies on topics like P16 positive cells and adiponectin. Key takeaway: P16 Cells Drive Post-MI Cardiac Remodeling.
Article Links:
Article 1: Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D. (Circulation)
Article 2: Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials. (Circulation)
Article 3: PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. (Circulation)
Article 4: Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure. (Circulation)
Article 5: P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/p16-cells-drive-post-mi-cardiac-remodeling-03-03-26/
 Featured Articles
Article 1: Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41487088
Summary: Myocardial recovery, characterized by reduced ventricular dilatation and improved systolic function, occurs in a subset of patients with heart failure. This phenomenon is most common in patients receiving left ventricular assist device therapy, with these patients experiencing improved outcomes and quality of life. The study found that myocardial recovery with mechanical circulatory support is directly linked to alternative splicing and subcellular localization of C. A. M. K. two D. This discovery identifies specific molecular mechanisms for initiating cardiac reverse remodeling.
Article 2: Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41766556
Summary: This prospective cohort study from the Danish Cardiovascular Screening trials established that aortic and iliac calcifications serve as predictors of serious aortic events. The study found a direct association between these calcifications and outcomes such as aortic dissection and aneurysm rupture. Additionally, the data demonstrated that aortic and iliac calcifications predict major adverse limb events, including peripheral revascularization and lower limb amputation. These findings highlight the clinical significance of calcification burden in forecasting severe cardiovascular and peripheral vascular outcomes.
Article 3: PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41766535
Summary: Late gadolinium enhancement cardiac magnetic resonance, or LGE-C. M. R., is a useful tool for identifying ventricular tachycardia, or V. T., substrate in patients with structural heart disease. The P. A. M. V. T. two study systematically assessed the long-term evolution of scar and ablation lesions using serial post-ablation LGE-C. M. R. This assessment revealed how ventricular scar tissue and ablation lesions evolve over extended periods following ventricular tachycardia ablation. The findings support the crucial role of post-procedural LGE-C. M. R. in evaluating ablation success and understanding long-term myocardial changes.
Article 4: Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.
Journal: Circulation
PubMed Li]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 03, 2026. This episode summarizes 5 key cardiology studies on topics like P16 positive cells and adiponectin. Key takeaway: P16 Cells Drive Post-MI Cardiac Remodeling.
Article Links:
Article 1: Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D. (Circulation)
Article 2: Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials. (Circulation)
Article 3: PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. (Circulation)
Article 4: Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure. (Circulation)
Article 5: P16+ Cells Drive Adverse Postischemic Cardiac ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Tricuspid Regurgitation Etiologies Defined 03/02/26</title>
	<link>https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/</link>
	<pubDate>Mon, 02 Mar 2026 11:01:58 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 02, 2026. This episode summarizes 5 key cardiology studies on topics like loop diuretics and retrospective cohort study. Key takeaway: Tricuspid Regurgitation Etiologies Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41765060">Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41765341">SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41757445">Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41757436">Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41757434">Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/">https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41765060" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41765060</a></p>
<p><strong>Summary:</strong> Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label.</p>
<h4>Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41765341" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41765341</a></p>
<p><strong>Summary:</strong> This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes.</p>
<h4>Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757445" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757445</a></p>
<p><strong>Summary:</strong> This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categorization provides a critical framework for understanding varying survival and risk profiles among patients with this common valvular disorder.</p>
<h4>Article 4: Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757436" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757436</a></p>
<p><strong>Summary:</strong> Patients with obstructive hypertrophic cardiomyopathy are known to experience adverse clinical outcomes. This retrospective cohort study systematically evaluated real-world clinical outcomes, health care resource use, and associated costs in patients with obstructive hypertrophic cardiomyopathy, specifically stratified by their sociodemographic characteristics. The research utilized a comprehensive database of U. S. adults with obstructive hypertrophic cardiomyopathy, collected between 2013 and 2021. The study demonstrated the importance of considering sociodemographic factors when assessing patient outcomes and resource utilization in this population.</p>
<h4>Article 5: Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757434</a></p>
<p><strong>Summary:</strong> This cohort study systematically evaluated the association between initial loop diuretic dosing and outcomes in patients hospitalized for heart failure. Researchers identified and categorized initial diuretic doses, expressed in furosemide equivalents, relative to patients&#8217; home doses across 24 hospitals. The study established length of stay as the primary outcome measured, along with secondary outcomes that included rates of acute kidney injury, in-hospital mortality, and 30-day readmission for heart failure. This research defined key endpoints for assessing optimal diuretic strategies in this hospitalized population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 02, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label.</p>
<p>Article number two. SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes.</p>
<p>Article number three. Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categorization provides a critical framework for understanding varying survival and risk profiles among patients with this common valvular disorder.</p>
<p>Article number four. Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. Patients with obstructive hypertrophic cardiomyopathy are known to experience adverse clinical outcomes. This retrospective cohort study systematically evaluated real-world clinical outcomes, health care resource use, and associated costs in patients with obstructive hypertrophic cardiomyopathy, specifically stratified by their sociodemographic characteristics. The research utilized a comprehensive database of U. S. adults with obstructive hypertrophic cardiomyopathy, collected between 2013 and 2021. The study demonstrated the importance of considering sociodemographic factors when assessing patient outcomes and resource utilization in this population.</p>
<p>Article number five. Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium. This cohort study systematically evaluated the association between initial loop diuretic dosing and outcomes in patients hospitalized for heart failure. Researchers identified and categorized initial diuretic doses, expressed in furosemide equivalents, relative to patients&#8217; home doses across 24 hospitals. The study established length of stay as the primary outcome measured, along with secondary outcomes that included rates of acute kidney injury, in-hospital mortality, and 30-day readmission for heart failure. This research defined key endpoints for assessing optimal diuretic strategies in this hospitalized population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>loop diuretics, retrospective cohort study, S. G. L. T. two inhibitors, hospital readmission, right ventricular assist device, obstructive hypertrophic cardiomyopathy, lead-associated tricuspid regurgitation, sociodemographic characteristics, type two diabetes, chronic kidney disease, cardiogenic shock, primary tricuspid regurgitation, Berlin Heart EXCOR, biventricular failure, secondary tricuspid regurgitation, CREDENCE trial, diuretic dosing, tricuspid regurgitation, left ventricular assist device, acute kidney injury, heart failure, health care resource use, tricuspid valve disease, clinical outcomes, estimated glomerular filtration rate.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/">Tricuspid Regurgitation Etiologies Defined 03/02/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 02, 2026. This episode summarizes 5 key cardiology studies on topics like loop diuretics and retrospective cohort study. Key takeaway: Tricuspid Regurgitation Etiologies Defined.
Article Links:
Article 1: Hybr]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 02, 2026. This episode summarizes 5 key cardiology studies on topics like loop diuretics and retrospective cohort study. Key takeaway: Tricuspid Regurgitation Etiologies Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41765060">Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41765341">SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41757445">Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41757436">Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41757434">Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/">https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41765060" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41765060</a></p>
<p><strong>Summary:</strong> Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label.</p>
<h4>Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41765341" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41765341</a></p>
<p><strong>Summary:</strong> This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes.</p>
<h4>Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757445" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757445</a></p>
<p><strong>Summary:</strong> This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categorization provides a critical framework for understanding varying survival and risk profiles among patients with this common valvular disorder.</p>
<h4>Article 4: Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757436" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757436</a></p>
<p><strong>Summary:</strong> Patients with obstructive hypertrophic cardiomyopathy are known to experience adverse clinical outcomes. This retrospective cohort study systematically evaluated real-world clinical outcomes, health care resource use, and associated costs in patients with obstructive hypertrophic cardiomyopathy, specifically stratified by their sociodemographic characteristics. The research utilized a comprehensive database of U. S. adults with obstructive hypertrophic cardiomyopathy, collected between 2013 and 2021. The study demonstrated the importance of considering sociodemographic factors when assessing patient outcomes and resource utilization in this population.</p>
<h4>Article 5: Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757434</a></p>
<p><strong>Summary:</strong> This cohort study systematically evaluated the association between initial loop diuretic dosing and outcomes in patients hospitalized for heart failure. Researchers identified and categorized initial diuretic doses, expressed in furosemide equivalents, relative to patients&#8217; home doses across 24 hospitals. The study established length of stay as the primary outcome measured, along with secondary outcomes that included rates of acute kidney injury, in-hospital mortality, and 30-day readmission for heart failure. This research defined key endpoints for assessing optimal diuretic strategies in this hospitalized population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 02, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label.</p>
<p>Article number two. SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes.</p>
<p>Article number three. Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categorization provides a critical framework for understanding varying survival and risk profiles among patients with this common valvular disorder.</p>
<p>Article number four. Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. Patients with obstructive hypertrophic cardiomyopathy are known to experience adverse clinical outcomes. This retrospective cohort study systematically evaluated real-world clinical outcomes, health care resource use, and associated costs in patients with obstructive hypertrophic cardiomyopathy, specifically stratified by their sociodemographic characteristics. The research utilized a comprehensive database of U. S. adults with obstructive hypertrophic cardiomyopathy, collected between 2013 and 2021. The study demonstrated the importance of considering sociodemographic factors when assessing patient outcomes and resource utilization in this population.</p>
<p>Article number five. Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium. This cohort study systematically evaluated the association between initial loop diuretic dosing and outcomes in patients hospitalized for heart failure. Researchers identified and categorized initial diuretic doses, expressed in furosemide equivalents, relative to patients&#8217; home doses across 24 hospitals. The study established length of stay as the primary outcome measured, along with secondary outcomes that included rates of acute kidney injury, in-hospital mortality, and 30-day readmission for heart failure. This research defined key endpoints for assessing optimal diuretic strategies in this hospitalized population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>loop diuretics, retrospective cohort study, S. G. L. T. two inhibitors, hospital readmission, right ventricular assist device, obstructive hypertrophic cardiomyopathy, lead-associated tricuspid regurgitation, sociodemographic characteristics, type two diabetes, chronic kidney disease, cardiogenic shock, primary tricuspid regurgitation, Berlin Heart EXCOR, biventricular failure, secondary tricuspid regurgitation, CREDENCE trial, diuretic dosing, tricuspid regurgitation, left ventricular assist device, acute kidney injury, heart failure, health care resource use, tricuspid valve disease, clinical outcomes, estimated glomerular filtration rate.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/">Tricuspid Regurgitation Etiologies Defined 03/02/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260302_060040.mp3" length="4875327" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 02, 2026. This episode summarizes 5 key cardiology studies on topics like loop diuretics and retrospective cohort study. Key takeaway: Tricuspid Regurgitation Etiologies Defined.
Article Links:
Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. (Journal of cardiac failure)
Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. (Journal of the American Heart Association)
Article 4: Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. (Journal of the American Heart Association)
Article 5: Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/
 Featured Articles
Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41765060
Summary: Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label.
Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41765341
Summary: This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes.
Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757445
Summary: This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categor]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 02, 2026. This episode summarizes 5 key cardiology studies on topics like loop diuretics and retrospective cohort study. Key takeaway: Tricuspid Regurgitation Etiologies Defined.
Article Links:
Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. (Journal of cardiac failure)
Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. (Journal of the American Heart Association)
Article 4: Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. (Journal of the American Heart Association)
Article 5: Cohort Stud]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rivaroxaban Extends Cancer P. E. Benefit Across P. S. 03/01/26</title>
	<link>https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/</link>
	<pubDate>Sun, 01 Mar 2026 11:01:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like mycotic genitourinary infections and sodium glucose co-transporter two inhibitors. Key takeaway: Rivaroxaban Extends Cancer P. E. Benefit Across P. S..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41761829">Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41762689">Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41757462">Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41757461">Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41757453">Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/">https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41761829" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41761829</a></p>
<p><strong>Summary:</strong> This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.</p>
<h4>Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41762689" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41762689</a></p>
<p><strong>Summary:</strong> The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.</p>
<h4>Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757462" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757462</a></p>
<p><strong>Summary:</strong> This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center&#8217;s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of this interventional approach. The data underscores the importance of high-volume centers or specialized training to maximize patient benefits from intravascular ultrasound-guided percutaneous coronary intervention.</p>
<h4>Article 4: Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757461" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757461</a></p>
<p><strong>Summary:</strong> The ONCO P. E. randomized trial definitively showed that 18-month rivaroxaban treatment was superior to 6-month treatment for reducing recurrent venous thromboembolism in patients with cancer-associated low-risk pulmonary embolism. This study analyzed the ONCO P. E. trial data and found that the benefits of extended 18-month rivaroxaban therapy for cancer-associated low-risk pulmonary embolism apply across patients with different performance status scores. The results demonstrate that performance status scores, which evaluate physical condition in cancer patients, do not diminish the efficacy of extended rivaroxaban. This ensures clinicians can confidently recommend the longer duration of rivaroxaban across a broader spectrum of cancer patients, optimizing recurrent venous thromboembolism prevention.</p>
<h4>Article 5: Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757453</a></p>
<p><strong>Summary:</strong> This long-term follow-up of the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy found that cardiac resynchronization therapy with defibrillation significantly impacts hospitalization patterns in heart failure patients. The analysis established differential effects of cardiac resynchronization therapy with defibrillation compared to implantable cardioverter-defibrillator on cardiovascular, heart failure, and noncardiovascular hospitalizations. Results showed changes in hospitalization rates and length of stay related to cardiac resynchronization therapy with defibrillation. These findings provide crucial long-term evidence for guiding device selection and optimizing patient management to reduce the burden of hospitalizations in heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network. This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.</p>
<p>Article number two. Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.</p>
<p>Article number three. Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS. This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center&#8217;s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of this interventional approach. The data underscores the importance of high-volume centers or specialized training to maximize patient benefits from intravascular ultrasound-guided percutaneous coronary intervention.</p>
<p>Article number four. Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. The ONCO P. E. randomized trial definitively showed that 18-month rivaroxaban treatment was superior to 6-month treatment for reducing recurrent venous thromboembolism in patients with cancer-associated low-risk pulmonary embolism. This study analyzed the ONCO P. E. trial data and found that the benefits of extended 18-month rivaroxaban therapy for cancer-associated low-risk pulmonary embolism apply across patients with different performance status scores. The results demonstrate that performance status scores, which evaluate physical condition in cancer patients, do not diminish the efficacy of extended rivaroxaban. This ensures clinicians can confidently recommend the longer duration of rivaroxaban across a broader spectrum of cancer patients, optimizing recurrent venous thromboembolism prevention.</p>
<p>Article number five. Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up. This long-term follow-up of the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy found that cardiac resynchronization therapy with defibrillation significantly impacts hospitalization patterns in heart failure patients. The analysis established differential effects of cardiac resynchronization therapy with defibrillation compared to implantable cardioverter-defibrillator on cardiovascular, heart failure, and noncardiovascular hospitalizations. Results showed changes in hospitalization rates and length of stay related to cardiac resynchronization therapy with defibrillation. These findings provide crucial long-term evidence for guiding device selection and optimizing patient management to reduce the burden of hospitalizations in heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mycotic genitourinary infections, sodium glucose co-transporter two inhibitors, cardiac resynchronization therapy with defibrillation, rivaroxaban, implantable cardioverter-defibrillator, major adverse cardiovascular events, hospitalizations, genitourinary tract infections, treatment discontinuation, extended anticoagulation, institutional experience, venous thromboembolism, performance status, intravascular ultrasound, long-term prognosis, long-term follow-up, cancer-associated pulmonary embolism, heart failure, all-cause death, long-term outcomes, percutaneous coronary intervention, Takotsubo syndrome, acute myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/">Rivaroxaban Extends Cancer P. E. Benefit Across P. S. 03/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like mycotic genitourinary infections and sodium glucose co-transporter two inhibitors. Key takeaway: Rivaroxaban Extends Cancer P. E. Benef]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like mycotic genitourinary infections and sodium glucose co-transporter two inhibitors. Key takeaway: Rivaroxaban Extends Cancer P. E. Benefit Across P. S..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41761829">Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41762689">Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41757462">Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41757461">Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41757453">Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/">https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41761829" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41761829</a></p>
<p><strong>Summary:</strong> This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.</p>
<h4>Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41762689" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41762689</a></p>
<p><strong>Summary:</strong> The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.</p>
<h4>Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757462" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757462</a></p>
<p><strong>Summary:</strong> This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center&#8217;s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of this interventional approach. The data underscores the importance of high-volume centers or specialized training to maximize patient benefits from intravascular ultrasound-guided percutaneous coronary intervention.</p>
<h4>Article 4: Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757461" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757461</a></p>
<p><strong>Summary:</strong> The ONCO P. E. randomized trial definitively showed that 18-month rivaroxaban treatment was superior to 6-month treatment for reducing recurrent venous thromboembolism in patients with cancer-associated low-risk pulmonary embolism. This study analyzed the ONCO P. E. trial data and found that the benefits of extended 18-month rivaroxaban therapy for cancer-associated low-risk pulmonary embolism apply across patients with different performance status scores. The results demonstrate that performance status scores, which evaluate physical condition in cancer patients, do not diminish the efficacy of extended rivaroxaban. This ensures clinicians can confidently recommend the longer duration of rivaroxaban across a broader spectrum of cancer patients, optimizing recurrent venous thromboembolism prevention.</p>
<h4>Article 5: Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757453</a></p>
<p><strong>Summary:</strong> This long-term follow-up of the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy found that cardiac resynchronization therapy with defibrillation significantly impacts hospitalization patterns in heart failure patients. The analysis established differential effects of cardiac resynchronization therapy with defibrillation compared to implantable cardioverter-defibrillator on cardiovascular, heart failure, and noncardiovascular hospitalizations. Results showed changes in hospitalization rates and length of stay related to cardiac resynchronization therapy with defibrillation. These findings provide crucial long-term evidence for guiding device selection and optimizing patient management to reduce the burden of hospitalizations in heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network. This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.</p>
<p>Article number two. Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.</p>
<p>Article number three. Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS. This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center&#8217;s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of this interventional approach. The data underscores the importance of high-volume centers or specialized training to maximize patient benefits from intravascular ultrasound-guided percutaneous coronary intervention.</p>
<p>Article number four. Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. The ONCO P. E. randomized trial definitively showed that 18-month rivaroxaban treatment was superior to 6-month treatment for reducing recurrent venous thromboembolism in patients with cancer-associated low-risk pulmonary embolism. This study analyzed the ONCO P. E. trial data and found that the benefits of extended 18-month rivaroxaban therapy for cancer-associated low-risk pulmonary embolism apply across patients with different performance status scores. The results demonstrate that performance status scores, which evaluate physical condition in cancer patients, do not diminish the efficacy of extended rivaroxaban. This ensures clinicians can confidently recommend the longer duration of rivaroxaban across a broader spectrum of cancer patients, optimizing recurrent venous thromboembolism prevention.</p>
<p>Article number five. Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up. This long-term follow-up of the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy found that cardiac resynchronization therapy with defibrillation significantly impacts hospitalization patterns in heart failure patients. The analysis established differential effects of cardiac resynchronization therapy with defibrillation compared to implantable cardioverter-defibrillator on cardiovascular, heart failure, and noncardiovascular hospitalizations. Results showed changes in hospitalization rates and length of stay related to cardiac resynchronization therapy with defibrillation. These findings provide crucial long-term evidence for guiding device selection and optimizing patient management to reduce the burden of hospitalizations in heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mycotic genitourinary infections, sodium glucose co-transporter two inhibitors, cardiac resynchronization therapy with defibrillation, rivaroxaban, implantable cardioverter-defibrillator, major adverse cardiovascular events, hospitalizations, genitourinary tract infections, treatment discontinuation, extended anticoagulation, institutional experience, venous thromboembolism, performance status, intravascular ultrasound, long-term prognosis, long-term follow-up, cancer-associated pulmonary embolism, heart failure, all-cause death, long-term outcomes, percutaneous coronary intervention, Takotsubo syndrome, acute myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/">Rivaroxaban Extends Cancer P. E. Benefit Across P. S. 03/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260301_060034.mp3" length="5093084" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like mycotic genitourinary infections and sodium glucose co-transporter two inhibitors. Key takeaway: Rivaroxaban Extends Cancer P. E. Benefit Across P. S..
Article Links:
Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network. (ESC heart failure)
Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. (European journal of heart failure)
Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS. (Journal of the American Heart Association)
Article 4: Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. (Journal of the American Heart Association)
Article 5: Effects of Cardiac Resynchronization Therapy on Cardiovascular and Noncardiovascular Hospitalization: A MADIT-CRT Long-Term Follow-Up. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/rivaroxaban-extends-cancer-p-e-benefit-across-p-s-03-01-26/
 Featured Articles
Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41761829
Summary: This retrospective observational study established a cohort of adult patients with Takotsubo syndrome and heart failure discharged between 2018 and 2022 to directly compare their long-term clinical outcomes. It characterized the three-year risks for all-cause death, major adverse cardiovascular events, and acute heart failure in these distinct patient populations. The findings provide a direct comparative analysis of long-term prognosis, which is crucial for differentiating patient management strategies. This data clarifies differential clinical trajectories and informs targeted therapeutic approaches for Takotsubo syndrome versus heart failure.
Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41762689
Summary: The EMPEROR-Pooled analysis found a significant impact of genitourinary tract infections and mycotic genitourinary infections on outcomes in heart failure patients, known to be associated with increased mortality risk. Results showed that sodium glucose co-transporter two inhibitors are associated with these types of infections, which often lead to treatment discontinuation. The analysis delineated the occurrence of genitourinary infections in both men and women with heart failure receiving sodium glucose co-transporter two inhibitors. This work provides essential evidence for clinicians to weigh the benefits and risks of sodium glucose co-transporter two inhibitors, guiding strategies to maintain treatment adherence.
Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757462
Summary: This retrospective analysis of 9752 patients with acute myocardial infarction treated with second-generation drug-eluting stents established that intravascular ultrasound-guided percutaneous coronary intervention improves patient outcomes. The study found that the prognostic association of intravascular ultrasound-guided percutaneous coronary intervention in acute myocardial infarction patients does differ based on a center&#8217;s level of intravascular ultrasound use. This outcome indicates that institutional experience with intravascular ultrasound is a critical factor influencing the long-term clinical benefits of]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like mycotic genitourinary infections and sodium glucose co-transporter two inhibitors. Key takeaway: Rivaroxaban Extends Cancer P. E. Benefit Across P. S..
Article Links:
Article 1: Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network. (ESC heart failure)
Article 2: Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. (European journal of heart failure)
Article 3: Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS. (Journal of the American Heart Association)
Article 4: Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. (Journal of the American Heart Association)
Artic]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>H. I. V. Donor Hearts Safely Used in Transplant. 03/01/26</title>
	<link>https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/</link>
	<pubDate>Sun, 01 Mar 2026 06:12:08 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like Organ transplantation outcomes and Warm ischemia. Key takeaway: H. I. V. Donor Hearts Safely Used in Transplant..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41297731">Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40998274">Early experience in heart transplantation utilizing donors with HIV.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40947079">Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41763375">The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41490396">Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/">https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297731</a></p>
<p><strong>Summary:</strong> Females who undergo heart transplantation exhibit a reduced risk for cardiac allograft vasculopathy. This study found sex-biased immune rewiring as a potential underlying mechanism contributing to this differential risk. Understanding these sex-specific molecular patterns provides insight for improved risk stratification and precision immunosuppressive strategies in both adult and pediatric transplant recipients. This suggests sex-specific immunologic outcomes are significant after heart transplantation.</p>
<h4>Article 2: Early experience in heart transplantation utilizing donors with HIV.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40998274" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40998274</a></p>
<p><strong>Summary:</strong> I. V. A single-center observational study investigated early outcomes of heart transplantation in 10 H. I. V.-positive recipients. Of these, 4 received organs from Human Immunodeficiency Virus positive donors and 6 from H. I. V.-negative donors. At 6 months, survival rates were similar, with 100 percent for recipients of H. I. V.-positive organs and 83 percent for recipients of H. I. V.-negative organs. Crucially, the study reported no Human Immunodeficiency Virus transmission from H. I. V.-positive donors to their recipients.</p>
<h4>Article 3: Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947079" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947079</a></p>
<p><strong>Summary:</strong> An Italian center performed heart transplantation from donation after circulatory death, utilizing thoracoabdominal-normothermic regional perfusion. The study demonstrated successful cardiac function recovery in donor hearts. This recovery was achieved despite a 20-minute period of functional warm ischemia, a duration relevant to legal mandates for death declaration. The findings highlight the feasibility of this technique for expanding the donor pool while adhering to preservation concerns.</p>
<h4>Article 4: The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41763375" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41763375</a></p>
<p><strong>Summary:</strong> Donation after circulatory death heart transplantation has re-emerged as a transformative strategy to expand the donor pool. Contemporary techniques such as thoracoabdominal-normothermic regional perfusion and direct procurement and perfusion have enabled successful heart transplantation from donation after circulatory death. These methods effectively mitigate ischemic injury and demonstrate post-transplant allograft function. Critically, this function is achieved without requiring pre-transplant assessment of viability or reanimation, marking a significant shift in historical practice.</p>
<h4>Article 5: Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41490396" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41490396</a></p>
<p><strong>Summary:</strong> Ferroptosis is identified as a key contributor to organ ischemia-reperfusion injury, a significant challenge in donation after circulatory death heart transplantation. In a rat heart transplantation model, treatment with Liproxstatin-1, a selective ferroptosis inhibitor, during normothermic ex vivo heart perfusion significantly suppressed this form of cell death. Post-transplant, hearts in the Liproxstatin-1 group demonstrated significantly improved left ventricular function and reduced histological evidence of myocardial injury compared to controls. This concrete finding establishes ferroptosis blockade with Liproxstatin-1 as a novel strategy to enhance donation after circulatory death heart viability and function.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation. Females who undergo heart transplantation exhibit a reduced risk for cardiac allograft vasculopathy. This study found sex-biased immune rewiring as a potential underlying mechanism contributing to this differential risk. Understanding these sex-specific molecular patterns provides insight for improved risk stratification and precision immunosuppressive strategies in both adult and pediatric transplant recipients. This suggests sex-specific immunologic outcomes are significant after heart transplantation.</p>
<p>Article number two. Early experience in heart transplantation utilizing donors with H. I. V. A single-center observational study investigated early outcomes of heart transplantation in 10 H. I. V.-positive recipients. Of these, 4 received organs from Human Immunodeficiency Virus positive donors and 6 from H. I. V.-negative donors. At 6 months, survival rates were similar, with 100 percent for recipients of H. I. V.-positive organs and 83 percent for recipients of H. I. V.-negative organs. Crucially, the study reported no Human Immunodeficiency Virus transmission from H. I. V.-positive donors to their recipients.</p>
<p>Article number three. Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion. An Italian center performed heart transplantation from donation after circulatory death, utilizing thoracoabdominal-normothermic regional perfusion. The study demonstrated successful cardiac function recovery in donor hearts. This recovery was achieved despite a 20-minute period of functional warm ischemia, a duration relevant to legal mandates for death declaration. The findings highlight the feasibility of this technique for expanding the donor pool while adhering to preservation concerns.</p>
<p>Article number four. The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation. Donation after circulatory death heart transplantation has re-emerged as a transformative strategy to expand the donor pool. Contemporary techniques such as thoracoabdominal-normothermic regional perfusion and direct procurement and perfusion have enabled successful heart transplantation from donation after circulatory death. These methods effectively mitigate ischemic injury and demonstrate post-transplant allograft function. Critically, this function is achieved without requiring pre-transplant assessment of viability or reanimation, marking a significant shift in historical practice.</p>
<p>Article number five. Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion. Ferroptosis is identified as a key contributor to organ ischemia-reperfusion injury, a significant challenge in donation after circulatory death heart transplantation. In a rat heart transplantation model, treatment with Liproxstatin-1, a selective ferroptosis inhibitor, during normothermic ex vivo heart perfusion significantly suppressed this form of cell death. Post-transplant, hearts in the Liproxstatin-1 group demonstrated significantly improved left ventricular function and reduced histological evidence of myocardial injury compared to controls. This concrete finding establishes ferroptosis blockade with Liproxstatin-1 as a novel strategy to enhance donation after circulatory death heart viability and function. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Organ transplantation outcomes, Warm ischemia, Immune rewiring, Thoracoabdominal-Normothermic Regional Perfusion, Donation After Circulatory Death, Cardiac Allograft Vasculopathy, Sex-based differences, Liproxstatin-1, Immunosuppressive strategies, Ischemia-Reperfusion Injury, Direct Procurement and Perfusion, H. I. V. positive donors, Donation After Circulatory Death hearts, Ferroptosis, Allograft function, Human Immunodeficiency Virus, Heart Transplantation, Left ventricular function, H. I. V. positive recipients, Cardiac function recovery.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/">H. I. V. Donor Hearts Safely Used in Transplant. 03/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like Organ transplantation outcomes and Warm ischemia. Key takeaway: H. I. V. Donor Hearts Safely Used in Transplant..
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like Organ transplantation outcomes and Warm ischemia. Key takeaway: H. I. V. Donor Hearts Safely Used in Transplant..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41297731">Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40998274">Early experience in heart transplantation utilizing donors with HIV.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40947079">Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41763375">The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41490396">Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/">https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297731</a></p>
<p><strong>Summary:</strong> Females who undergo heart transplantation exhibit a reduced risk for cardiac allograft vasculopathy. This study found sex-biased immune rewiring as a potential underlying mechanism contributing to this differential risk. Understanding these sex-specific molecular patterns provides insight for improved risk stratification and precision immunosuppressive strategies in both adult and pediatric transplant recipients. This suggests sex-specific immunologic outcomes are significant after heart transplantation.</p>
<h4>Article 2: Early experience in heart transplantation utilizing donors with HIV.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40998274" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40998274</a></p>
<p><strong>Summary:</strong> I. V. A single-center observational study investigated early outcomes of heart transplantation in 10 H. I. V.-positive recipients. Of these, 4 received organs from Human Immunodeficiency Virus positive donors and 6 from H. I. V.-negative donors. At 6 months, survival rates were similar, with 100 percent for recipients of H. I. V.-positive organs and 83 percent for recipients of H. I. V.-negative organs. Crucially, the study reported no Human Immunodeficiency Virus transmission from H. I. V.-positive donors to their recipients.</p>
<h4>Article 3: Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947079" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947079</a></p>
<p><strong>Summary:</strong> An Italian center performed heart transplantation from donation after circulatory death, utilizing thoracoabdominal-normothermic regional perfusion. The study demonstrated successful cardiac function recovery in donor hearts. This recovery was achieved despite a 20-minute period of functional warm ischemia, a duration relevant to legal mandates for death declaration. The findings highlight the feasibility of this technique for expanding the donor pool while adhering to preservation concerns.</p>
<h4>Article 4: The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41763375" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41763375</a></p>
<p><strong>Summary:</strong> Donation after circulatory death heart transplantation has re-emerged as a transformative strategy to expand the donor pool. Contemporary techniques such as thoracoabdominal-normothermic regional perfusion and direct procurement and perfusion have enabled successful heart transplantation from donation after circulatory death. These methods effectively mitigate ischemic injury and demonstrate post-transplant allograft function. Critically, this function is achieved without requiring pre-transplant assessment of viability or reanimation, marking a significant shift in historical practice.</p>
<h4>Article 5: Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41490396" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41490396</a></p>
<p><strong>Summary:</strong> Ferroptosis is identified as a key contributor to organ ischemia-reperfusion injury, a significant challenge in donation after circulatory death heart transplantation. In a rat heart transplantation model, treatment with Liproxstatin-1, a selective ferroptosis inhibitor, during normothermic ex vivo heart perfusion significantly suppressed this form of cell death. Post-transplant, hearts in the Liproxstatin-1 group demonstrated significantly improved left ventricular function and reduced histological evidence of myocardial injury compared to controls. This concrete finding establishes ferroptosis blockade with Liproxstatin-1 as a novel strategy to enhance donation after circulatory death heart viability and function.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is March 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation. Females who undergo heart transplantation exhibit a reduced risk for cardiac allograft vasculopathy. This study found sex-biased immune rewiring as a potential underlying mechanism contributing to this differential risk. Understanding these sex-specific molecular patterns provides insight for improved risk stratification and precision immunosuppressive strategies in both adult and pediatric transplant recipients. This suggests sex-specific immunologic outcomes are significant after heart transplantation.</p>
<p>Article number two. Early experience in heart transplantation utilizing donors with H. I. V. A single-center observational study investigated early outcomes of heart transplantation in 10 H. I. V.-positive recipients. Of these, 4 received organs from Human Immunodeficiency Virus positive donors and 6 from H. I. V.-negative donors. At 6 months, survival rates were similar, with 100 percent for recipients of H. I. V.-positive organs and 83 percent for recipients of H. I. V.-negative organs. Crucially, the study reported no Human Immunodeficiency Virus transmission from H. I. V.-positive donors to their recipients.</p>
<p>Article number three. Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion. An Italian center performed heart transplantation from donation after circulatory death, utilizing thoracoabdominal-normothermic regional perfusion. The study demonstrated successful cardiac function recovery in donor hearts. This recovery was achieved despite a 20-minute period of functional warm ischemia, a duration relevant to legal mandates for death declaration. The findings highlight the feasibility of this technique for expanding the donor pool while adhering to preservation concerns.</p>
<p>Article number four. The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation. Donation after circulatory death heart transplantation has re-emerged as a transformative strategy to expand the donor pool. Contemporary techniques such as thoracoabdominal-normothermic regional perfusion and direct procurement and perfusion have enabled successful heart transplantation from donation after circulatory death. These methods effectively mitigate ischemic injury and demonstrate post-transplant allograft function. Critically, this function is achieved without requiring pre-transplant assessment of viability or reanimation, marking a significant shift in historical practice.</p>
<p>Article number five. Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion. Ferroptosis is identified as a key contributor to organ ischemia-reperfusion injury, a significant challenge in donation after circulatory death heart transplantation. In a rat heart transplantation model, treatment with Liproxstatin-1, a selective ferroptosis inhibitor, during normothermic ex vivo heart perfusion significantly suppressed this form of cell death. Post-transplant, hearts in the Liproxstatin-1 group demonstrated significantly improved left ventricular function and reduced histological evidence of myocardial injury compared to controls. This concrete finding establishes ferroptosis blockade with Liproxstatin-1 as a novel strategy to enhance donation after circulatory death heart viability and function. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Organ transplantation outcomes, Warm ischemia, Immune rewiring, Thoracoabdominal-Normothermic Regional Perfusion, Donation After Circulatory Death, Cardiac Allograft Vasculopathy, Sex-based differences, Liproxstatin-1, Immunosuppressive strategies, Ischemia-Reperfusion Injury, Direct Procurement and Perfusion, H. I. V. positive donors, Donation After Circulatory Death hearts, Ferroptosis, Allograft function, Human Immunodeficiency Virus, Heart Transplantation, Left ventricular function, H. I. V. positive recipients, Cardiac function recovery.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/">H. I. V. Donor Hearts Safely Used in Transplant. 03/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/03/cardiology_today_20260301_011058.mp3" length="4336160" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like Organ transplantation outcomes and Warm ischemia. Key takeaway: H. I. V. Donor Hearts Safely Used in Transplant..
Article Links:
Article 1: Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Early experience in heart transplantation utilizing donors with HIV. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: The Time is Upon Us-The Beginning of the End of Donor Heart Reanimation In Donation After Circulatory Death Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Improved DCD Heart Transplant Function Through Ferroptosis Blockade in a Model of Experimental Normothermic Ex Vivo Perfusion. (Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/h-i-v-donor-hearts-safely-used-in-transplant-03-01-26/
 Featured Articles
Article 1: Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297731
Summary: Females who undergo heart transplantation exhibit a reduced risk for cardiac allograft vasculopathy. This study found sex-biased immune rewiring as a potential underlying mechanism contributing to this differential risk. Understanding these sex-specific molecular patterns provides insight for improved risk stratification and precision immunosuppressive strategies in both adult and pediatric transplant recipients. This suggests sex-specific immunologic outcomes are significant after heart transplantation.
Article 2: Early experience in heart transplantation utilizing donors with HIV.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40998274
Summary: I. V. A single-center observational study investigated early outcomes of heart transplantation in 10 H. I. V.-positive recipients. Of these, 4 received organs from Human Immunodeficiency Virus positive donors and 6 from H. I. V.-negative donors. At 6 months, survival rates were similar, with 100 percent for recipients of H. I. V.-positive organs and 83 percent for recipients of H. I. V.-negative organs. Crucially, the study reported no Human Immunodeficiency Virus transmission from H. I. V.-positive donors to their recipients.
Article 3: Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40947079
Summary: An Italian center performed heart transplantation from donation after circulatory death, utilizing thoracoabdominal-normothermic regional perfusion. The study demonstrated successful cardiac function recovery in donor hearts. This recovery was achieved despite a 20-minute period of functional warm ischemia, a duration relevant to legal mandates for death declaration. The findings highlight the feasibility of this technique for expanding the donor pool while adhering to preservati]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded March 01, 2026. This episode summarizes 5 key cardiology studies on topics like Organ transplantation outcomes and Warm ischemia. Key takeaway: H. I. V. Donor Hearts Safely Used in Transplant..
Article Links:
Article 1: Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Early experience in heart transplantation utilizing donors with HIV. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Cardiac function recovery after 20-min hands-off using thoracoabdominal-normothermic regional perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: The Time is]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Macrophage Burden Predicts MACE Post-Endarterectomy 02/28/26</title>
	<link>https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/</link>
	<pubDate>Sat, 28 Feb 2026 11:01:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 28, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and ventricular contractility. Key takeaway: Macrophage Burden Predicts MACE Post-Endarterectomy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41760079">Heart failure in the elderly: epidemiology, mechanisms, and management.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41758696">Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41758068">Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41757830">Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41757465">Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/">https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart failure in the elderly: epidemiology, mechanisms, and management.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41760079" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41760079</a></p>
<p><strong>Summary:</strong> The majority of patients with heart failure (H. F.) are of advanced age. The lifetime risk for developing H. F. is approximately 25 percent, with a sharp increase in incidence observed after the age of 70. While the lifetime risk is nearly equal for men and women, women show a higher propensity to develop heart failure with preserved ejection fraction (H. F. pEF), whereas men are more prone to heart failure with reduced ejection fraction (H. F. rEF).</p>
<h4>Article 2: Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41758696" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41758696</a></p>
<p><strong>Summary:</strong> A previous European trial found that switching from well-managed warfarin to direct oral anticoagulants (DOACs) in frail elderly patients with atrial fibrillation was associated with a higher bleeding risk. This underscores the clinical importance of evaluating the safety and effectiveness of such switches in diverse populations. Understanding outcomes in frail elderly Asian patients is particularly crucial due to potential demographic and clinical differences impacting anticoagulant management. This research addresses a significant therapeutic challenge in optimizing anticoagulation for a vulnerable patient group.</p>
<h4>Article 3: Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41758068" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41758068</a></p>
<p><strong>Summary:</strong> This study found that the burden of macrophages within carotid plaques and specific inflammatory lipid-associated macrophage markers serve as predictors for secondary major adverse cardiovascular events (MACE) following endarterectomy. The data establishes a direct link between the cellular content of atherosclerotic lesions and future cardiovascular outcomes. These findings indicate that detailed characterization of macrophage populations in carotid plaques provides crucial prognostic information. This information can guide risk stratification for patients after carotid endarterectomy.</p>
<h4>Article 4: Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757830" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757830</a></p>
<p><strong>Summary:</strong> This canine orthotopic heart transplantation study demonstrated that combining myocardial microcirculation data with lactate measurements accurately predicts ventricular contractility in donation after circulatory death (DCD) hearts during ex situ machine perfusion. The research verified novel prediction parameters for heart transplant viability that were previously developed in porcine models. These findings indicate that integrating microcirculation assessment improves the evaluation of transplantable hearts. This provides a more robust method beyond relying solely on lactate levels.</p>
<h4>Article 5: Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757465" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757465</a></p>
<p><strong>Summary:</strong> Patients presenting to the emergency department with atrial fibrillation often show elevated troponin levels, which are rarely due to myocardial infarction. However, current high-sensitivity cardiac troponin T assays measure both intact and fragmented forms, failing to distinguish between myocardial injury from atrial fibrillation and actual myocardial infarction. This situation presents a significant diagnostic challenge for clinicians. There is a clear need for methods to accurately separate these distinct causes of troponin elevation for appropriate patient management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart failure in the elderly: epidemiology, mechanisms, and management. The majority of patients with heart failure (H. F.) are of advanced age. The lifetime risk for developing H. F. is approximately 25 percent, with a sharp increase in incidence observed after the age of 70. While the lifetime risk is nearly equal for men and women, women show a higher propensity to develop heart failure with preserved ejection fraction (H. F. pEF), whereas men are more prone to heart failure with reduced ejection fraction (H. F. rEF).</p>
<p>Article number two. Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study. A previous European trial found that switching from well-managed warfarin to direct oral anticoagulants (DOACs) in frail elderly patients with atrial fibrillation was associated with a higher bleeding risk. This underscores the clinical importance of evaluating the safety and effectiveness of such switches in diverse populations. Understanding outcomes in frail elderly Asian patients is particularly crucial due to potential demographic and clinical differences impacting anticoagulant management. This research addresses a significant therapeutic challenge in optimizing anticoagulation for a vulnerable patient group.</p>
<p>Article number three. Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy. This study found that the burden of macrophages within carotid plaques and specific inflammatory lipid-associated macrophage markers serve as predictors for secondary major adverse cardiovascular events (MACE) following endarterectomy. The data establishes a direct link between the cellular content of atherosclerotic lesions and future cardiovascular outcomes. These findings indicate that detailed characterization of macrophage populations in carotid plaques provides crucial prognostic information. This information can guide risk stratification for patients after carotid endarterectomy.</p>
<p>Article number four. Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion. This canine orthotopic heart transplantation study demonstrated that combining myocardial microcirculation data with lactate measurements accurately predicts ventricular contractility in donation after circulatory death (DCD) hearts during ex situ machine perfusion. The research verified novel prediction parameters for heart transplant viability that were previously developed in porcine models. These findings indicate that integrating microcirculation assessment improves the evaluation of transplantable hearts. This provides a more robust method beyond relying solely on lactate levels.</p>
<p>Article number five. Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction. Patients presenting to the emergency department with atrial fibrillation often show elevated troponin levels, which are rarely due to myocardial infarction. However, current high-sensitivity cardiac troponin T assays measure both intact and fragmented forms, failing to distinguish between myocardial injury from atrial fibrillation and actual myocardial infarction. This situation presents a significant diagnostic challenge for clinicians. There is a clear need for methods to accurately separate these distinct causes of troponin elevation for appropriate patient management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial infarction, ventricular contractility, endarterectomy, aging, Heart failure, frailty, donation after circulatory death, major adverse cardiovascular events, Warfarin, atrial fibrillation, direct oral anticoagulants, macrophages, Atrial fibrillation, bleeding risk, cardiac injury biomarkers, Myocardial microcirculation, diagnostic challenge, Carotid plaque, elderly, ejection fraction, prognosis, machine perfusion, troponin, epidemiology, lactate, atherosclerosis, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/">Macrophage Burden Predicts MACE Post-Endarterectomy 02/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 28, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and ventricular contractility. Key takeaway: Macrophage Burden Predicts MACE Post-Endarterectomy.
Article Link]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 28, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and ventricular contractility. Key takeaway: Macrophage Burden Predicts MACE Post-Endarterectomy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41760079">Heart failure in the elderly: epidemiology, mechanisms, and management.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41758696">Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41758068">Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41757830">Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41757465">Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/">https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart failure in the elderly: epidemiology, mechanisms, and management.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41760079" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41760079</a></p>
<p><strong>Summary:</strong> The majority of patients with heart failure (H. F.) are of advanced age. The lifetime risk for developing H. F. is approximately 25 percent, with a sharp increase in incidence observed after the age of 70. While the lifetime risk is nearly equal for men and women, women show a higher propensity to develop heart failure with preserved ejection fraction (H. F. pEF), whereas men are more prone to heart failure with reduced ejection fraction (H. F. rEF).</p>
<h4>Article 2: Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41758696" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41758696</a></p>
<p><strong>Summary:</strong> A previous European trial found that switching from well-managed warfarin to direct oral anticoagulants (DOACs) in frail elderly patients with atrial fibrillation was associated with a higher bleeding risk. This underscores the clinical importance of evaluating the safety and effectiveness of such switches in diverse populations. Understanding outcomes in frail elderly Asian patients is particularly crucial due to potential demographic and clinical differences impacting anticoagulant management. This research addresses a significant therapeutic challenge in optimizing anticoagulation for a vulnerable patient group.</p>
<h4>Article 3: Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41758068" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41758068</a></p>
<p><strong>Summary:</strong> This study found that the burden of macrophages within carotid plaques and specific inflammatory lipid-associated macrophage markers serve as predictors for secondary major adverse cardiovascular events (MACE) following endarterectomy. The data establishes a direct link between the cellular content of atherosclerotic lesions and future cardiovascular outcomes. These findings indicate that detailed characterization of macrophage populations in carotid plaques provides crucial prognostic information. This information can guide risk stratification for patients after carotid endarterectomy.</p>
<h4>Article 4: Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757830" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757830</a></p>
<p><strong>Summary:</strong> This canine orthotopic heart transplantation study demonstrated that combining myocardial microcirculation data with lactate measurements accurately predicts ventricular contractility in donation after circulatory death (DCD) hearts during ex situ machine perfusion. The research verified novel prediction parameters for heart transplant viability that were previously developed in porcine models. These findings indicate that integrating microcirculation assessment improves the evaluation of transplantable hearts. This provides a more robust method beyond relying solely on lactate levels.</p>
<h4>Article 5: Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41757465" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41757465</a></p>
<p><strong>Summary:</strong> Patients presenting to the emergency department with atrial fibrillation often show elevated troponin levels, which are rarely due to myocardial infarction. However, current high-sensitivity cardiac troponin T assays measure both intact and fragmented forms, failing to distinguish between myocardial injury from atrial fibrillation and actual myocardial infarction. This situation presents a significant diagnostic challenge for clinicians. There is a clear need for methods to accurately separate these distinct causes of troponin elevation for appropriate patient management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart failure in the elderly: epidemiology, mechanisms, and management. The majority of patients with heart failure (H. F.) are of advanced age. The lifetime risk for developing H. F. is approximately 25 percent, with a sharp increase in incidence observed after the age of 70. While the lifetime risk is nearly equal for men and women, women show a higher propensity to develop heart failure with preserved ejection fraction (H. F. pEF), whereas men are more prone to heart failure with reduced ejection fraction (H. F. rEF).</p>
<p>Article number two. Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study. A previous European trial found that switching from well-managed warfarin to direct oral anticoagulants (DOACs) in frail elderly patients with atrial fibrillation was associated with a higher bleeding risk. This underscores the clinical importance of evaluating the safety and effectiveness of such switches in diverse populations. Understanding outcomes in frail elderly Asian patients is particularly crucial due to potential demographic and clinical differences impacting anticoagulant management. This research addresses a significant therapeutic challenge in optimizing anticoagulation for a vulnerable patient group.</p>
<p>Article number three. Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy. This study found that the burden of macrophages within carotid plaques and specific inflammatory lipid-associated macrophage markers serve as predictors for secondary major adverse cardiovascular events (MACE) following endarterectomy. The data establishes a direct link between the cellular content of atherosclerotic lesions and future cardiovascular outcomes. These findings indicate that detailed characterization of macrophage populations in carotid plaques provides crucial prognostic information. This information can guide risk stratification for patients after carotid endarterectomy.</p>
<p>Article number four. Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion. This canine orthotopic heart transplantation study demonstrated that combining myocardial microcirculation data with lactate measurements accurately predicts ventricular contractility in donation after circulatory death (DCD) hearts during ex situ machine perfusion. The research verified novel prediction parameters for heart transplant viability that were previously developed in porcine models. These findings indicate that integrating microcirculation assessment improves the evaluation of transplantable hearts. This provides a more robust method beyond relying solely on lactate levels.</p>
<p>Article number five. Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction. Patients presenting to the emergency department with atrial fibrillation often show elevated troponin levels, which are rarely due to myocardial infarction. However, current high-sensitivity cardiac troponin T assays measure both intact and fragmented forms, failing to distinguish between myocardial injury from atrial fibrillation and actual myocardial infarction. This situation presents a significant diagnostic challenge for clinicians. There is a clear need for methods to accurately separate these distinct causes of troponin elevation for appropriate patient management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial infarction, ventricular contractility, endarterectomy, aging, Heart failure, frailty, donation after circulatory death, major adverse cardiovascular events, Warfarin, atrial fibrillation, direct oral anticoagulants, macrophages, Atrial fibrillation, bleeding risk, cardiac injury biomarkers, Myocardial microcirculation, diagnostic challenge, Carotid plaque, elderly, ejection fraction, prognosis, machine perfusion, troponin, epidemiology, lactate, atherosclerosis, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/">Macrophage Burden Predicts MACE Post-Endarterectomy 02/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260228_060034.mp3" length="4137629" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 28, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and ventricular contractility. Key takeaway: Macrophage Burden Predicts MACE Post-Endarterectomy.
Article Links:
Article 1: Heart failure in the elderly: epidemiology, mechanisms, and management. (European heart journal)
Article 2: Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study. (European heart journal)
Article 3: Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy. (European heart journal)
Article 4: Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion. (Transplantation)
Article 5: Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/macrophage-burden-predicts-mace-post-endarterectomy-02-28-26/
 Featured Articles
Article 1: Heart failure in the elderly: epidemiology, mechanisms, and management.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41760079
Summary: The majority of patients with heart failure (H. F.) are of advanced age. The lifetime risk for developing H. F. is approximately 25 percent, with a sharp increase in incidence observed after the age of 70. While the lifetime risk is nearly equal for men and women, women show a higher propensity to develop heart failure with preserved ejection fraction (H. F. pEF), whereas men are more prone to heart failure with reduced ejection fraction (H. F. rEF).
Article 2: Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41758696
Summary: A previous European trial found that switching from well-managed warfarin to direct oral anticoagulants (DOACs) in frail elderly patients with atrial fibrillation was associated with a higher bleeding risk. This underscores the clinical importance of evaluating the safety and effectiveness of such switches in diverse populations. Understanding outcomes in frail elderly Asian patients is particularly crucial due to potential demographic and clinical differences impacting anticoagulant management. This research addresses a significant therapeutic challenge in optimizing anticoagulation for a vulnerable patient group.
Article 3: Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41758068
Summary: This study found that the burden of macrophages within carotid plaques and specific inflammatory lipid-associated macrophage markers serve as predictors for secondary major adverse cardiovascular events (MACE) following endarterectomy. The data establishes a direct link between the cellular content of atherosclerotic lesions and future cardiovascular outcomes. These findings indicate that detailed characterization of macrophage populations in carotid plaques provides crucial prognostic information. This information can guide risk stratification for patients after carotid endarterectomy.
Article 4: Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757830
Summary: This canine orthotopic heart transplantation study demonstrated that combining myocardial micr]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 28, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and ventricular contractility. Key takeaway: Macrophage Burden Predicts MACE Post-Endarterectomy.
Article Links:
Article 1: Heart failure in the elderly: epidemiology, mechanisms, and management. (European heart journal)
Article 2: Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study. (European heart journal)
Article 3: Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy. (European heart journal)
Article 4: Myocardial Microcirculation Combined With Lactate Measurements Predicts Ventricular Contractility in a Canine DCD Orthotopic Heart Transplantation During Ex Situ Machine Perfusion. (Transplantation)
Article 5: Long Troponin T to Separate Troponin Ele]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>LVEF Not Enough: Heart Failure Phenotyping Shift 02/27/26</title>
	<link>https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/</link>
	<pubDate>Fri, 27 Feb 2026 11:01:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 27, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and clinical outcomes. Key takeaway: LVEF Not Enough: Heart Failure Phenotyping Shift.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41746839">Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41739853">Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41744134">Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41744120">Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41744116">Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/">https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41746839" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41746839</a></p>
<p><strong>Summary:</strong> The Shock-POL registry, encompassing data from nine Polish cardiology centers, characterized the current management and outcomes of acute myocardial infarction-related cardiogenic shock. This registry evaluated patients hospitalized throughout 2023, identifying parameters of current care for this critical condition. Findings reveal that acute myocardial infarction-related cardiogenic shock carries an overall mortality rate exceeding 50 percent. The study documented clinical practices and patient outcomes in a real-world setting.</p>
<h4>Article 2: Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739853" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739853</a></p>
<p><strong>Summary:</strong> This retrospective study provided a real-world comparative analysis of clinical outcomes and healthcare costs for Finnish advanced heart failure patients treated with heart transplantation or left ventricular assist device therapy. The study evaluated 78 patients across three categories: those receiving heart transplantation as a first procedure, and patients undergoing elective or urgent left ventricular assist device implantation. The data characterized the three-year outcomes and associated healthcare expenditures for these significant interventions at Helsinki University Hospital. It established patterns in resource utilization and patient trajectories for these advanced heart failure treatment options.</p>
<h4>Article 3: Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744134</a></p>
<p><strong>Summary:</strong> This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis cohort established the relationship between cigarette smoking and interstitial myocardial fibrosis. The study utilized extracellular volume and native T1 time, measured by cardiac magnetic resonance, as markers for myocardial fibrosis. It characterized sex-specific differences in these associations at a population level. The findings illuminate how smoking impacts myocardial fibrosis, which is critical given its known association with cardiovascular events, heart failure, and death.</p>
<h4>Article 4: Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744120" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744120</a></p>
<p><strong>Summary:</strong> This Scientific Statement from the American Heart Association establishes a multimodality approach to coronary ischemic testing in pediatric patients. It provides updated recommendations for targeted provocative ischemic testing in children with acquired and congenital coronary issues. The statement synthesizes evidence-based guidelines for conditions such as Kawasaki disease, multisystem inflammatory syndrome in children with coronary aneurysms, and anomalous aortic origin of the coronary arteries. It details the value and application of various ischemic testing modalities to guide clinical practice in pediatric cardiology.</p>
<h4>Article 5: Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744116" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744116</a></p>
<p><strong>Summary:</strong> This study evaluated the limitations of conventional left ventricular ejection fraction-based heart failure phenotyping, highlighting its weak correlation with outcomes and potential overestimation of systolic function, particularly in elderly women. Researchers assessed sex-specific differences in left ventricular geometry and tested whether geometry-adjusted left ventricular ejection fraction or left ventricular global longitudinal strain improves prognostic performance. The findings challenge the sole reliance on left ventricular ejection fraction as a cornerstone of heart failure phenotyping, indicating a need for more nuanced myocardial assessments. The study demonstrated how alternative metrics like left ventricular global longitudinal strain can offer improved prognostic insights beyond traditional chamber-based measurements.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 27, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry. The Shock-POL registry, encompassing data from nine Polish cardiology centers, characterized the current management and outcomes of acute myocardial infarction-related cardiogenic shock. This registry evaluated patients hospitalized throughout 2023, identifying parameters of current care for this critical condition. Findings reveal that acute myocardial infarction-related cardiogenic shock carries an overall mortality rate exceeding 50 percent. The study documented clinical practices and patient outcomes in a real-world setting.</p>
<p>Article number two. Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant. This retrospective study provided a real-world comparative analysis of clinical outcomes and healthcare costs for Finnish advanced heart failure patients treated with heart transplantation or left ventricular assist device therapy. The study evaluated 78 patients across three categories: those receiving heart transplantation as a first procedure, and patients undergoing elective or urgent left ventricular assist device implantation. The data characterized the three-year outcomes and associated healthcare expenditures for these significant interventions at Helsinki University Hospital. It established patterns in resource utilization and patient trajectories for these advanced heart failure treatment options.</p>
<p>Article number three. Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis. This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis cohort established the relationship between cigarette smoking and interstitial myocardial fibrosis. The study utilized extracellular volume and native T1 time, measured by cardiac magnetic resonance, as markers for myocardial fibrosis. It characterized sex-specific differences in these associations at a population level. The findings illuminate how smoking impacts myocardial fibrosis, which is critical given its known association with cardiovascular events, heart failure, and death.</p>
<p>Article number four. Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association. This Scientific Statement from the American Heart Association establishes a multimodality approach to coronary ischemic testing in pediatric patients. It provides updated recommendations for targeted provocative ischemic testing in children with acquired and congenital coronary issues. The statement synthesizes evidence-based guidelines for conditions such as Kawasaki disease, multisystem inflammatory syndrome in children with coronary aneurysms, and anomalous aortic origin of the coronary arteries. It details the value and application of various ischemic testing modalities to guide clinical practice in pediatric cardiology.</p>
<p>Article number five. Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium. This study evaluated the limitations of conventional left ventricular ejection fraction-based heart failure phenotyping, highlighting its weak correlation with outcomes and potential overestimation of systolic function, particularly in elderly women. Researchers assessed sex-specific differences in left ventricular geometry and tested whether geometry-adjusted left ventricular ejection fraction or left ventricular global longitudinal strain improves prognostic performance. The findings challenge the sole reliance on left ventricular ejection fraction as a cornerstone of heart failure phenotyping, indicating a need for more nuanced myocardial assessments. The study demonstrated how alternative metrics like left ventricular global longitudinal strain can offer improved prognostic insights beyond traditional chamber-based measurements. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left ventricular ejection fraction, clinical outcomes, American Heart Association, left ventricular assist device, myocardial fibrosis, myocardial geometry, sex differences, healthcare costs, registry, coronary ischemic testing, advanced heart failure, left ventricular global longitudinal strain, patient management, acute myocardial infarction, cardiogenic shock, congenital heart disease, Multi-Ethnic Study of Atherosclerosis, cardiac magnetic resonance, heart failure phenotyping, pediatric cardiology, prognosis, cigarette smoking, Kawasaki disease, mortality, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/">LVEF Not Enough: Heart Failure Phenotyping Shift 02/27/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 27, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and clinical outcomes. Key takeaway: LVEF Not Enough: Heart Failure Phenotyping Shift.
Article Li]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 27, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and clinical outcomes. Key takeaway: LVEF Not Enough: Heart Failure Phenotyping Shift.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41746839">Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41739853">Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41744134">Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41744120">Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41744116">Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/">https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41746839" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41746839</a></p>
<p><strong>Summary:</strong> The Shock-POL registry, encompassing data from nine Polish cardiology centers, characterized the current management and outcomes of acute myocardial infarction-related cardiogenic shock. This registry evaluated patients hospitalized throughout 2023, identifying parameters of current care for this critical condition. Findings reveal that acute myocardial infarction-related cardiogenic shock carries an overall mortality rate exceeding 50 percent. The study documented clinical practices and patient outcomes in a real-world setting.</p>
<h4>Article 2: Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739853" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739853</a></p>
<p><strong>Summary:</strong> This retrospective study provided a real-world comparative analysis of clinical outcomes and healthcare costs for Finnish advanced heart failure patients treated with heart transplantation or left ventricular assist device therapy. The study evaluated 78 patients across three categories: those receiving heart transplantation as a first procedure, and patients undergoing elective or urgent left ventricular assist device implantation. The data characterized the three-year outcomes and associated healthcare expenditures for these significant interventions at Helsinki University Hospital. It established patterns in resource utilization and patient trajectories for these advanced heart failure treatment options.</p>
<h4>Article 3: Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744134</a></p>
<p><strong>Summary:</strong> This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis cohort established the relationship between cigarette smoking and interstitial myocardial fibrosis. The study utilized extracellular volume and native T1 time, measured by cardiac magnetic resonance, as markers for myocardial fibrosis. It characterized sex-specific differences in these associations at a population level. The findings illuminate how smoking impacts myocardial fibrosis, which is critical given its known association with cardiovascular events, heart failure, and death.</p>
<h4>Article 4: Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744120" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744120</a></p>
<p><strong>Summary:</strong> This Scientific Statement from the American Heart Association establishes a multimodality approach to coronary ischemic testing in pediatric patients. It provides updated recommendations for targeted provocative ischemic testing in children with acquired and congenital coronary issues. The statement synthesizes evidence-based guidelines for conditions such as Kawasaki disease, multisystem inflammatory syndrome in children with coronary aneurysms, and anomalous aortic origin of the coronary arteries. It details the value and application of various ischemic testing modalities to guide clinical practice in pediatric cardiology.</p>
<h4>Article 5: Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41744116" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41744116</a></p>
<p><strong>Summary:</strong> This study evaluated the limitations of conventional left ventricular ejection fraction-based heart failure phenotyping, highlighting its weak correlation with outcomes and potential overestimation of systolic function, particularly in elderly women. Researchers assessed sex-specific differences in left ventricular geometry and tested whether geometry-adjusted left ventricular ejection fraction or left ventricular global longitudinal strain improves prognostic performance. The findings challenge the sole reliance on left ventricular ejection fraction as a cornerstone of heart failure phenotyping, indicating a need for more nuanced myocardial assessments. The study demonstrated how alternative metrics like left ventricular global longitudinal strain can offer improved prognostic insights beyond traditional chamber-based measurements.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 27, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry. The Shock-POL registry, encompassing data from nine Polish cardiology centers, characterized the current management and outcomes of acute myocardial infarction-related cardiogenic shock. This registry evaluated patients hospitalized throughout 2023, identifying parameters of current care for this critical condition. Findings reveal that acute myocardial infarction-related cardiogenic shock carries an overall mortality rate exceeding 50 percent. The study documented clinical practices and patient outcomes in a real-world setting.</p>
<p>Article number two. Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant. This retrospective study provided a real-world comparative analysis of clinical outcomes and healthcare costs for Finnish advanced heart failure patients treated with heart transplantation or left ventricular assist device therapy. The study evaluated 78 patients across three categories: those receiving heart transplantation as a first procedure, and patients undergoing elective or urgent left ventricular assist device implantation. The data characterized the three-year outcomes and associated healthcare expenditures for these significant interventions at Helsinki University Hospital. It established patterns in resource utilization and patient trajectories for these advanced heart failure treatment options.</p>
<p>Article number three. Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis. This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis cohort established the relationship between cigarette smoking and interstitial myocardial fibrosis. The study utilized extracellular volume and native T1 time, measured by cardiac magnetic resonance, as markers for myocardial fibrosis. It characterized sex-specific differences in these associations at a population level. The findings illuminate how smoking impacts myocardial fibrosis, which is critical given its known association with cardiovascular events, heart failure, and death.</p>
<p>Article number four. Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association. This Scientific Statement from the American Heart Association establishes a multimodality approach to coronary ischemic testing in pediatric patients. It provides updated recommendations for targeted provocative ischemic testing in children with acquired and congenital coronary issues. The statement synthesizes evidence-based guidelines for conditions such as Kawasaki disease, multisystem inflammatory syndrome in children with coronary aneurysms, and anomalous aortic origin of the coronary arteries. It details the value and application of various ischemic testing modalities to guide clinical practice in pediatric cardiology.</p>
<p>Article number five. Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium. This study evaluated the limitations of conventional left ventricular ejection fraction-based heart failure phenotyping, highlighting its weak correlation with outcomes and potential overestimation of systolic function, particularly in elderly women. Researchers assessed sex-specific differences in left ventricular geometry and tested whether geometry-adjusted left ventricular ejection fraction or left ventricular global longitudinal strain improves prognostic performance. The findings challenge the sole reliance on left ventricular ejection fraction as a cornerstone of heart failure phenotyping, indicating a need for more nuanced myocardial assessments. The study demonstrated how alternative metrics like left ventricular global longitudinal strain can offer improved prognostic insights beyond traditional chamber-based measurements. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left ventricular ejection fraction, clinical outcomes, American Heart Association, left ventricular assist device, myocardial fibrosis, myocardial geometry, sex differences, healthcare costs, registry, coronary ischemic testing, advanced heart failure, left ventricular global longitudinal strain, patient management, acute myocardial infarction, cardiogenic shock, congenital heart disease, Multi-Ethnic Study of Atherosclerosis, cardiac magnetic resonance, heart failure phenotyping, pediatric cardiology, prognosis, cigarette smoking, Kawasaki disease, mortality, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/">LVEF Not Enough: Heart Failure Phenotyping Shift 02/27/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260227_060029.mp3" length="4501672" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 27, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and clinical outcomes. Key takeaway: LVEF Not Enough: Heart Failure Phenotyping Shift.
Article Links:
Article 1: Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry. (ESC heart failure)
Article 2: Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant. (ESC heart failure)
Article 3: Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis. (Journal of the American Heart Association)
Article 4: Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association. (Journal of the American Heart Association)
Article 5: Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/lvef-not-enough-heart-failure-phenotyping-shift-02-27-26/
 Featured Articles
Article 1: Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41746839
Summary: The Shock-POL registry, encompassing data from nine Polish cardiology centers, characterized the current management and outcomes of acute myocardial infarction-related cardiogenic shock. This registry evaluated patients hospitalized throughout 2023, identifying parameters of current care for this critical condition. Findings reveal that acute myocardial infarction-related cardiogenic shock carries an overall mortality rate exceeding 50 percent. The study documented clinical practices and patient outcomes in a real-world setting.
Article 2: Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41739853
Summary: This retrospective study provided a real-world comparative analysis of clinical outcomes and healthcare costs for Finnish advanced heart failure patients treated with heart transplantation or left ventricular assist device therapy. The study evaluated 78 patients across three categories: those receiving heart transplantation as a first procedure, and patients undergoing elective or urgent left ventricular assist device implantation. The data characterized the three-year outcomes and associated healthcare expenditures for these significant interventions at Helsinki University Hospital. It established patterns in resource utilization and patient trajectories for these advanced heart failure treatment options.
Article 3: Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41744134
Summary: This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis cohort established the relationship between cigarette smoking and interstitial myocardial fibrosis. The study utilized extracellular volume and native T1 time, measured by cardiac magnetic resonance, as markers for myocardial fibrosis. It characterized sex-specific differences in these associations at a population level. The findings illuminate how smoking impacts myocardial fibrosis, which is critical given its known association with cardiovascular events, heart failure, and death.
Article 4: Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41744120
Summary: This Scientific Statement from the American Heart Association establ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 27, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and clinical outcomes. Key takeaway: LVEF Not Enough: Heart Failure Phenotyping Shift.
Article Links:
Article 1: Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry. (ESC heart failure)
Article 2: Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant. (ESC heart failure)
Article 3: Sex-Difference of Associations Between Cigarette Smoking and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis. (Journal of the American Heart Association)
Article 4: Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association. (Journal of the American Heart Association)
Article 5: Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myoca]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Predicts Heart Failure From E. C. G. 02/26/26</title>
	<link>https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/</link>
	<pubDate>Thu, 26 Feb 2026 11:01:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 26, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and left ventricular ejection fraction. Key takeaway: AI Predicts Heart Failure From E. C. G..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41730291">Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41732853">Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41730522">Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41730521">Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction.</a> (Circulation. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41733064">Multimorbidity in Atrial Fibrillation: Impact on Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/">https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730291" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730291</a></p>
<p><strong>Summary:</strong> Chronic inflammatory cardiomyopathy, a sequela of acute myocarditis, is characterized by increased risk of ventricular arrhythmias, left ventricular systolic dysfunction, and heart failure. For this condition, when diagnosed non-invasively by cardiac magnetic resonance imaging or fluorodeoxyglucose-positron emission tomography, immunosuppressive therapy is not generally recommended. This highlights an important gap in therapeutic options for these patients.</p>
<h4>Article 2: Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41732853" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41732853</a></p>
<p><strong>Summary:</strong> A study analyzed 540 transthyretin cardiac amyloidosis and 280 light chain cardiac amyloidosis patients, challenging the traditional view of cardiac amyloidosis as solely a restrictive ventricular physiology with preserved systolic function. Results showed varied left ventricular phenotypes at diagnosis. These findings clarify the prevalence and clinical significance of left ventricular systolic dysfunction versus restrictive physiology, refining the understanding of cardiac amyloidosis.</p>
<h4>Article 3: Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730522</a></p>
<p><strong>Summary:</strong> Researchers developed an artificial intelligence model, electrocardiogram-to-heart failure (ECG2HF), in 94636 patients to predict incident heart failure. The model demonstrated robust performance, achieving an area under the curve ranging from 0.81 to 0.84 for predicting heart failure within one year. When deployed, a positive ECG2HF result predicted one-year incident heart failure with 81 percent sensitivity and 80 percent specificity, and was independently associated with a two point two-fold increased risk of heart failure.</p>
<h4>Article 4: Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730521" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730521</a></p>
<p><strong>Summary:</strong> An observational study of 118 patients with asymptomatic discordant low-gradient aortic stenosis and preserved left ventricular ejection fraction described exercise hemodynamics. During exercise, these patients showed significant increases in mean aortic valve gradient from 35 plus or minus 14 mmHg at rest to 50 plus or minus 18 mmHg at peak exercise (P value less than 0.001). Pulmonary artery systolic pressure also significantly increased from 38 plus or minus 10 mmHg to 64 plus or minus 18 mmHg (P value less than 0.001), confirming severe aortic stenosis and exercise-induced pulmonary hypertension.</p>
<h4>Article 5: Multimorbidity in Atrial Fibrillation: Impact on Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41733064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41733064</a></p>
<p><strong>Summary:</strong> A cohort study of 19280 new-onset atrial fibrillation patients found 96 percent had at least one comorbidity. Each additional cardiometabolic condition increased the hazard ratio for death by 1.15, for ischemic stroke or transient ischemic attack by 1.13, and for heart failure hospitalization by 1.25. Other somatic conditions also raised the risk of death and heart failure hospitalization, while mental health conditions specifically increased the risk of death and heart failure hospitalization. These findings quantitatively demonstrate the significant negative impact of multimorbidity on outcomes in atrial fibrillation patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 26, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC. Chronic inflammatory cardiomyopathy, a sequela of acute myocarditis, is characterized by increased risk of ventricular arrhythmias, left ventricular systolic dysfunction, and heart failure. For this condition, when diagnosed non-invasively by cardiac magnetic resonance imaging or fluorodeoxyglucose-positron emission tomography, immunosuppressive therapy is not generally recommended. This highlights an important gap in therapeutic options for these patients.</p>
<p>Article number two. Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis. A study analyzed 540 transthyretin cardiac amyloidosis and 280 light chain cardiac amyloidosis patients, challenging the traditional view of cardiac amyloidosis as solely a restrictive ventricular physiology with preserved systolic function. Results showed varied left ventricular phenotypes at diagnosis. These findings clarify the prevalence and clinical significance of left ventricular systolic dysfunction versus restrictive physiology, refining the understanding of cardiac amyloidosis.</p>
<p>Article number three. Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure. Researchers developed an artificial intelligence model, electrocardiogram-to-heart failure (ECG2HF), in 94636 patients to predict incident heart failure. The model demonstrated robust performance, achieving an area under the curve ranging from 0.81 to 0.84 for predicting heart failure within one year. When deployed, a positive ECG2HF result predicted one-year incident heart failure with 81 percent sensitivity and 80 percent specificity, and was independently associated with a two point two-fold increased risk of heart failure.</p>
<p>Article number four. Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction. An observational study of 118 patients with asymptomatic discordant low-gradient aortic stenosis and preserved left ventricular ejection fraction described exercise hemodynamics. During exercise, these patients showed significant increases in mean aortic valve gradient from 35 plus or minus 14 mmHg at rest to 50 plus or minus 18 mmHg at peak exercise (P value less than 0.001). Pulmonary artery systolic pressure also significantly increased from 38 plus or minus 10 mmHg to 64 plus or minus 18 mmHg (P value less than 0.001), confirming severe aortic stenosis and exercise-induced pulmonary hypertension.</p>
<p>Article number five. Multimorbidity in Atrial Fibrillation: Impact on Outcomes. A cohort study of 19280 new-onset atrial fibrillation patients found 96 percent had at least one comorbidity. Each additional cardiometabolic condition increased the hazard ratio for death by 1.15, for ischemic stroke or transient ischemic attack by 1.13, and for heart failure hospitalization by 1.25. Other somatic conditions also raised the risk of death and heart failure hospitalization, while mental health conditions specifically increased the risk of death and heart failure hospitalization. These findings quantitatively demonstrate the significant negative impact of multimorbidity on outcomes in atrial fibrillation patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transthyretin cardiac amyloidosis, left ventricular ejection fraction, left ventricular systolic dysfunction, electrocardiogram, exercise hemodynamics, atrial fibrillation, heart failure prediction, cardiometabolic conditions, deep learning, heart failure hospitalization, low-gradient aortic stenosis, cardiac amyloidosis, myocarditis, colchicine, multimorbidity, restrictive cardiomyopathy, heart failure, pulmonary hypertension, aortic stenosis, ventricular arrhythmias, light chain cardiac amyloidosis, machine learning, chronic inflammatory cardiomyopathy, artificial intelligence, ischemic stroke, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/">AI Predicts Heart Failure From E. C. G. 02/26/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 26, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and left ventricular ejection fraction. Key takeaway: AI Predicts Heart Failure From E. C. G..
Art]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 26, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and left ventricular ejection fraction. Key takeaway: AI Predicts Heart Failure From E. C. G..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41730291">Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41732853">Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41730522">Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41730521">Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction.</a> (Circulation. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41733064">Multimorbidity in Atrial Fibrillation: Impact on Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/">https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730291" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730291</a></p>
<p><strong>Summary:</strong> Chronic inflammatory cardiomyopathy, a sequela of acute myocarditis, is characterized by increased risk of ventricular arrhythmias, left ventricular systolic dysfunction, and heart failure. For this condition, when diagnosed non-invasively by cardiac magnetic resonance imaging or fluorodeoxyglucose-positron emission tomography, immunosuppressive therapy is not generally recommended. This highlights an important gap in therapeutic options for these patients.</p>
<h4>Article 2: Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41732853" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41732853</a></p>
<p><strong>Summary:</strong> A study analyzed 540 transthyretin cardiac amyloidosis and 280 light chain cardiac amyloidosis patients, challenging the traditional view of cardiac amyloidosis as solely a restrictive ventricular physiology with preserved systolic function. Results showed varied left ventricular phenotypes at diagnosis. These findings clarify the prevalence and clinical significance of left ventricular systolic dysfunction versus restrictive physiology, refining the understanding of cardiac amyloidosis.</p>
<h4>Article 3: Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730522</a></p>
<p><strong>Summary:</strong> Researchers developed an artificial intelligence model, electrocardiogram-to-heart failure (ECG2HF), in 94636 patients to predict incident heart failure. The model demonstrated robust performance, achieving an area under the curve ranging from 0.81 to 0.84 for predicting heart failure within one year. When deployed, a positive ECG2HF result predicted one-year incident heart failure with 81 percent sensitivity and 80 percent specificity, and was independently associated with a two point two-fold increased risk of heart failure.</p>
<h4>Article 4: Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730521" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730521</a></p>
<p><strong>Summary:</strong> An observational study of 118 patients with asymptomatic discordant low-gradient aortic stenosis and preserved left ventricular ejection fraction described exercise hemodynamics. During exercise, these patients showed significant increases in mean aortic valve gradient from 35 plus or minus 14 mmHg at rest to 50 plus or minus 18 mmHg at peak exercise (P value less than 0.001). Pulmonary artery systolic pressure also significantly increased from 38 plus or minus 10 mmHg to 64 plus or minus 18 mmHg (P value less than 0.001), confirming severe aortic stenosis and exercise-induced pulmonary hypertension.</p>
<h4>Article 5: Multimorbidity in Atrial Fibrillation: Impact on Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41733064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41733064</a></p>
<p><strong>Summary:</strong> A cohort study of 19280 new-onset atrial fibrillation patients found 96 percent had at least one comorbidity. Each additional cardiometabolic condition increased the hazard ratio for death by 1.15, for ischemic stroke or transient ischemic attack by 1.13, and for heart failure hospitalization by 1.25. Other somatic conditions also raised the risk of death and heart failure hospitalization, while mental health conditions specifically increased the risk of death and heart failure hospitalization. These findings quantitatively demonstrate the significant negative impact of multimorbidity on outcomes in atrial fibrillation patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 26, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC. Chronic inflammatory cardiomyopathy, a sequela of acute myocarditis, is characterized by increased risk of ventricular arrhythmias, left ventricular systolic dysfunction, and heart failure. For this condition, when diagnosed non-invasively by cardiac magnetic resonance imaging or fluorodeoxyglucose-positron emission tomography, immunosuppressive therapy is not generally recommended. This highlights an important gap in therapeutic options for these patients.</p>
<p>Article number two. Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis. A study analyzed 540 transthyretin cardiac amyloidosis and 280 light chain cardiac amyloidosis patients, challenging the traditional view of cardiac amyloidosis as solely a restrictive ventricular physiology with preserved systolic function. Results showed varied left ventricular phenotypes at diagnosis. These findings clarify the prevalence and clinical significance of left ventricular systolic dysfunction versus restrictive physiology, refining the understanding of cardiac amyloidosis.</p>
<p>Article number three. Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure. Researchers developed an artificial intelligence model, electrocardiogram-to-heart failure (ECG2HF), in 94636 patients to predict incident heart failure. The model demonstrated robust performance, achieving an area under the curve ranging from 0.81 to 0.84 for predicting heart failure within one year. When deployed, a positive ECG2HF result predicted one-year incident heart failure with 81 percent sensitivity and 80 percent specificity, and was independently associated with a two point two-fold increased risk of heart failure.</p>
<p>Article number four. Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction. An observational study of 118 patients with asymptomatic discordant low-gradient aortic stenosis and preserved left ventricular ejection fraction described exercise hemodynamics. During exercise, these patients showed significant increases in mean aortic valve gradient from 35 plus or minus 14 mmHg at rest to 50 plus or minus 18 mmHg at peak exercise (P value less than 0.001). Pulmonary artery systolic pressure also significantly increased from 38 plus or minus 10 mmHg to 64 plus or minus 18 mmHg (P value less than 0.001), confirming severe aortic stenosis and exercise-induced pulmonary hypertension.</p>
<p>Article number five. Multimorbidity in Atrial Fibrillation: Impact on Outcomes. A cohort study of 19280 new-onset atrial fibrillation patients found 96 percent had at least one comorbidity. Each additional cardiometabolic condition increased the hazard ratio for death by 1.15, for ischemic stroke or transient ischemic attack by 1.13, and for heart failure hospitalization by 1.25. Other somatic conditions also raised the risk of death and heart failure hospitalization, while mental health conditions specifically increased the risk of death and heart failure hospitalization. These findings quantitatively demonstrate the significant negative impact of multimorbidity on outcomes in atrial fibrillation patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transthyretin cardiac amyloidosis, left ventricular ejection fraction, left ventricular systolic dysfunction, electrocardiogram, exercise hemodynamics, atrial fibrillation, heart failure prediction, cardiometabolic conditions, deep learning, heart failure hospitalization, low-gradient aortic stenosis, cardiac amyloidosis, myocarditis, colchicine, multimorbidity, restrictive cardiomyopathy, heart failure, pulmonary hypertension, aortic stenosis, ventricular arrhythmias, light chain cardiac amyloidosis, machine learning, chronic inflammatory cardiomyopathy, artificial intelligence, ischemic stroke, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/">AI Predicts Heart Failure From E. C. G. 02/26/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260226_060027.mp3" length="4369597" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 26, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and left ventricular ejection fraction. Key takeaway: AI Predicts Heart Failure From E. C. G..
Article Links:
Article 1: Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC. (ESC heart failure)
Article 2: Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis. (Circulation. Heart failure)
Article 3: Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure. (Circulation. Heart failure)
Article 4: Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction. (Circulation. Heart failure)
Article 5: Multimorbidity in Atrial Fibrillation: Impact on Outcomes. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ai-predicts-heart-failure-from-e-c-g-02-26-26/
 Featured Articles
Article 1: Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41730291
Summary: Chronic inflammatory cardiomyopathy, a sequela of acute myocarditis, is characterized by increased risk of ventricular arrhythmias, left ventricular systolic dysfunction, and heart failure. For this condition, when diagnosed non-invasively by cardiac magnetic resonance imaging or fluorodeoxyglucose-positron emission tomography, immunosuppressive therapy is not generally recommended. This highlights an important gap in therapeutic options for these patients.
Article 2: Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41732853
Summary: A study analyzed 540 transthyretin cardiac amyloidosis and 280 light chain cardiac amyloidosis patients, challenging the traditional view of cardiac amyloidosis as solely a restrictive ventricular physiology with preserved systolic function. Results showed varied left ventricular phenotypes at diagnosis. These findings clarify the prevalence and clinical significance of left ventricular systolic dysfunction versus restrictive physiology, refining the understanding of cardiac amyloidosis.
Article 3: Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41730522
Summary: Researchers developed an artificial intelligence model, electrocardiogram-to-heart failure (ECG2HF), in 94636 patients to predict incident heart failure. The model demonstrated robust performance, achieving an area under the curve ranging from 0.81 to 0.84 for predicting heart failure within one year. When deployed, a positive ECG2HF result predicted one-year incident heart failure with 81 percent sensitivity and 80 percent specificity, and was independently associated with a two point two-fold increased risk of heart failure.
Article 4: Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41730521
Summary: An observational study of 118 patients with asymptomatic discordant low-gradient aortic stenosis and preserved left ventricular ejection fraction described exercise hemodynamics. During exercise, these patients showed significant increases in mean aortic valve gradient from 35 plus or minus 14 mmHg at rest to 50 plus or minus 18 mmHg at peak exercise (P value less than 0.001). Pulmonary artery systolic pressure also significantly increased from 38 plus or minus 10 mmHg to 64]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 26, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and left ventricular ejection fraction. Key takeaway: AI Predicts Heart Failure From E. C. G..
Article Links:
Article 1: Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC. (ESC heart failure)
Article 2: Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis. (Circulation. Heart failure)
Article 3: Artificial Intelligence-Enabled ECG Analysis to Predict Incident Heart Failure. (Circulation. Heart failure)
Article 4: Invasive Hemodynamic Exercise Response in Hemodynamically Significant Aortic Stenosis With Preserved Left Ventricular Ejection Fraction. (Circulation. Heart failure)
Article 5: Multimorbidity in Atrial Fibrillation: Impact on Outcomes. (Journal of the American Heart Associati]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>20-Year P. F. O. Closure Confirms Long-Term Efficacy 02/25/26</title>
	<link>https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/</link>
	<pubDate>Wed, 25 Feb 2026 22:11:00 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and sudden cardiac death. Key takeaway: 20-Year P. F. O. Closure Confirms Long-Term Efficacy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41738673">Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41493296">Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41736503">Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41739488">Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41739450">Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/">https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41738673" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41738673</a></p>
<p><strong>Summary:</strong> C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.</p>
<h4>Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493296" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493296</a></p>
<p><strong>Summary:</strong> O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.</p>
<h4>Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41736503" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41736503</a></p>
<p><strong>Summary:</strong> S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.</p>
<h4>Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739488" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739488</a></p>
<p><strong>Summary:</strong> This single-center cohort study documented 20-year clinical outcomes following transcatheter patent foramen ovale closure in patients with paradoxical embolism. The long-term follow-up established the enduring safety and efficacy of this therapy for preventing recurrent ischemic events over two decades. The study provided crucial very long-term data, reinforcing patent foramen ovale closure as a definitive therapy and clarifying its extended therapeutic impact.</p>
<h4>Article 5: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739450" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739450</a></p>
<p><strong>Summary:</strong> P. E. R. I. T. I. F. Randomized Clinical Trial. The A. P. E. R. I. T. I. F. randomized clinical trial determined the effect of low-dose rivaroxaban, added to dual antiplatelet therapy, on the incidence of left ventricular thrombus. The trial found how this combination therapy influenced the risk of left ventricular thrombus formation at one month in patients after anterior S. T. segment elevation myocardial infarction. This multicenter study provided specific data on the benefit and risk profile of adding an oral anticoagulant in this patient population, impacting anticoagulation strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and S. C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.</p>
<p>Article number two. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the C. O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.</p>
<p>Article number three. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the E. S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.</p>
<p>Article number four. Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism. This single-center cohort study documented 20-year clinical outcomes following transcatheter patent foramen ovale closure in patients with paradoxical embolism. The long-term follow-up established the enduring safety and efficacy of this therapy for preventing recurrent ischemic events over two decades. The study provided crucial very long-term data, reinforcing patent foramen ovale closure as a definitive therapy and clarifying its extended therapeutic impact.</p>
<p>Article number five. Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The A. P. E. R. I. T. I. F. Randomized Clinical Trial. The A. P. E. R. I. T. I. F. randomized clinical trial determined the effect of low-dose rivaroxaban, added to dual antiplatelet therapy, on the incidence of left ventricular thrombus. The trial found how this combination therapy influenced the risk of left ventricular thrombus formation at one month in patients after anterior S. T. segment elevation myocardial infarction. This multicenter study provided specific data on the benefit and risk profile of adding an oral anticoagulant in this patient population, impacting anticoagulation strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial infarction, sudden cardiac death, finerenone, paradoxical embolism, dual antiplatelet therapy, cardiac screening, transcatheter closure, rivaroxaban, young population, diagnostic yield, renin-angiotensin system inhibitor, sodium-glucose cotransporter two inhibitor, registry outcomes, empagliflozin, sudden cardiac arrest, long-term outcomes, patent foramen ovale, heart failure, ejection fraction, outpatient heart failure, ischemic events, acute heart failure, S. T. segment elevation myocardial infarction, left ventricular thrombus, hyperkalemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/">20-Year P. F. O. Closure Confirms Long-Term Efficacy 02/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and sudden cardiac death. Key takeaway: 20-Year P. F. O. Closure Confirms Long-Term Efficacy.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and sudden cardiac death. Key takeaway: 20-Year P. F. O. Closure Confirms Long-Term Efficacy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41738673">Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41493296">Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41736503">Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41739488">Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41739450">Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/">https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41738673" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41738673</a></p>
<p><strong>Summary:</strong> C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.</p>
<h4>Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493296" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493296</a></p>
<p><strong>Summary:</strong> O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.</p>
<h4>Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41736503" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41736503</a></p>
<p><strong>Summary:</strong> S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.</p>
<h4>Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739488" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739488</a></p>
<p><strong>Summary:</strong> This single-center cohort study documented 20-year clinical outcomes following transcatheter patent foramen ovale closure in patients with paradoxical embolism. The long-term follow-up established the enduring safety and efficacy of this therapy for preventing recurrent ischemic events over two decades. The study provided crucial very long-term data, reinforcing patent foramen ovale closure as a definitive therapy and clarifying its extended therapeutic impact.</p>
<h4>Article 5: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41739450" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41739450</a></p>
<p><strong>Summary:</strong> P. E. R. I. T. I. F. Randomized Clinical Trial. The A. P. E. R. I. T. I. F. randomized clinical trial determined the effect of low-dose rivaroxaban, added to dual antiplatelet therapy, on the incidence of left ventricular thrombus. The trial found how this combination therapy influenced the risk of left ventricular thrombus formation at one month in patients after anterior S. T. segment elevation myocardial infarction. This multicenter study provided specific data on the benefit and risk profile of adding an oral anticoagulant in this patient population, impacting anticoagulation strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and S. C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.</p>
<p>Article number two. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the C. O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.</p>
<p>Article number three. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the E. S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.</p>
<p>Article number four. Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism. This single-center cohort study documented 20-year clinical outcomes following transcatheter patent foramen ovale closure in patients with paradoxical embolism. The long-term follow-up established the enduring safety and efficacy of this therapy for preventing recurrent ischemic events over two decades. The study provided crucial very long-term data, reinforcing patent foramen ovale closure as a definitive therapy and clarifying its extended therapeutic impact.</p>
<p>Article number five. Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The A. P. E. R. I. T. I. F. Randomized Clinical Trial. The A. P. E. R. I. T. I. F. randomized clinical trial determined the effect of low-dose rivaroxaban, added to dual antiplatelet therapy, on the incidence of left ventricular thrombus. The trial found how this combination therapy influenced the risk of left ventricular thrombus formation at one month in patients after anterior S. T. segment elevation myocardial infarction. This multicenter study provided specific data on the benefit and risk profile of adding an oral anticoagulant in this patient population, impacting anticoagulation strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial infarction, sudden cardiac death, finerenone, paradoxical embolism, dual antiplatelet therapy, cardiac screening, transcatheter closure, rivaroxaban, young population, diagnostic yield, renin-angiotensin system inhibitor, sodium-glucose cotransporter two inhibitor, registry outcomes, empagliflozin, sudden cardiac arrest, long-term outcomes, patent foramen ovale, heart failure, ejection fraction, outpatient heart failure, ischemic events, acute heart failure, S. T. segment elevation myocardial infarction, left ventricular thrombus, hyperkalemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/">20-Year P. F. O. Closure Confirms Long-Term Efficacy 02/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260225_170947.mp3" length="4425185" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and sudden cardiac death. Key takeaway: 20-Year P. F. O. Closure Confirms Long-Term Efficacy.
Article Links:
Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals. (Journal of the American College of Cardiology)
Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. (Journal of the American College of Cardiology)
Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. (European heart journal)
Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism. (JAMA cardiology)
Article 5: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/
 Featured Articles
Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41738673
Summary: C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.
Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493296
Summary: O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.
Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41736503
Summary: S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.
Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41739488
Summary: This single-center cohort study docume]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and sudden cardiac death. Key takeaway: 20-Year P. F. O. Closure Confirms Long-Term Efficacy.
Article Links:
Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals. (Journal of the American College of Cardiology)
Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. (Journal of the American College of Cardiology)
Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. (European heart journal)
Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism. (JAMA cardiology)
Article 5: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocar]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Updating Heart Failure &#038; Valve Choices 02/25/26</title>
	<link>https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/</link>
	<pubDate>Wed, 25 Feb 2026 11:02:03 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like biological prosthesis and mechanical prosthesis. Key takeaway: Updating Heart Failure &#038; Valve Choices.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41732861">Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41735096">Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41672767">Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40670147">Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40537260">Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/">https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41732861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41732861</a></p>
<p><strong>Summary:</strong> Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type two diabetes. Conflicting trial evidence exists regarding whether glucagon-like peptide-one receptor agonists reduce the risk of hospitalization for heart failure in this broad population. It is unclear whether this is a class effect or varies by specific agent, and their comparative effectiveness against sodium-glucose cotransporter-two inhibitors remains to be fully understood. This highlights a critical knowledge gap in guiding therapeutic choices for this patient group.</p>
<h4>Article 2: Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41735096" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41735096</a></p>
<p><strong>Summary:</strong> Lung transplantation remains limited by the scarcity of suitable donor organs, making uncontrolled donation after circulatory death a promising yet underutilized source. One center&#8217;s prospective experience demonstrated a specific approach to uncontrolled donation after circulatory death lung transplantation. This involved assessing all lung referrals, preserving lungs via open-lung ventilation without in situ cooling, and subsequently evaluating them with ex vivo lung perfusion. This methodology establishes a comprehensive framework for addressing donor organ scarcity and expanding lung transplantation opportunities.</p>
<h4>Article 3: Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41672767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41672767</a></p>
<p><strong>Summary:</strong> Current guidelines recommend evaluating patients with ambulatory heart failure for heart transplantation if their peak oxygen consumption is less than 12 milliliters per kilogram per minute. These recommendations are based on decades-old data, indicating a need for contemporary re-evaluation. A large retrospective analysis of 8060 patients with ambulatory heart failure with cardiopulmonary exercise testing data was conducted to address this. The primary analysis specifically focused on 1218 patients with left ventricular ejection fraction less than 40 percent and peak oxygen consumption less than 12 milliliters per kilogram per minute.</p>
<h4>Article 4: Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40670147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40670147</a></p>
<p><strong>Summary:</strong> Current guidelines for aortic valve replacement lack consensus regarding prosthesis selection for middle-aged patients. A population-based cohort study specifically compared long-term outcomes following aortic valve replacement with mechanical versus biological prostheses among middle-aged patients in an Asian population. The study included patients aged 45 to 64 years who underwent aortic valve replacement across 46 hospitals between 2006 and 2021. This investigation utilized Taiwan&#8217;s national claims database to provide crucial data for informing prosthesis selection decisions.</p>
<h4>Article 5: Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40537260" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40537260</a></p>
<p><strong>Summary:</strong> Emerging evidence suggests associations between air pollution, multimorbidity, and atrial fibrillation, though their precise interplay remains unclear. A prospective cohort study of 480344 individuals from the U. K. Biobank evaluated these complex relationships. The study quantified various air pollutants, including particulate matter with diameters less than or equal to two point five micrometers and ten micrometers, along with nitrogen oxides and nitrogen dioxide. This extensive analysis provides a foundation for understanding the combined impact of environmental factors and co-existing conditions on incident atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type two diabetes. Conflicting trial evidence exists regarding whether glucagon-like peptide-one receptor agonists reduce the risk of hospitalization for heart failure in this broad population. It is unclear whether this is a class effect or varies by specific agent, and their comparative effectiveness against sodium-glucose cotransporter-two inhibitors remains to be fully understood. This highlights a critical knowledge gap in guiding therapeutic choices for this patient group.</p>
<p>Article number two. Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation. Lung transplantation remains limited by the scarcity of suitable donor organs, making uncontrolled donation after circulatory death a promising yet underutilized source. One center&#8217;s prospective experience demonstrated a specific approach to uncontrolled donation after circulatory death lung transplantation. This involved assessing all lung referrals, preserving lungs via open-lung ventilation without in situ cooling, and subsequently evaluating them with ex vivo lung perfusion. This methodology establishes a comprehensive framework for addressing donor organ scarcity and expanding lung transplantation opportunities.</p>
<p>Article number three. Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era. Current guidelines recommend evaluating patients with ambulatory heart failure for heart transplantation if their peak oxygen consumption is less than 12 milliliters per kilogram per minute. These recommendations are based on decades-old data, indicating a need for contemporary re-evaluation. A large retrospective analysis of 8060 patients with ambulatory heart failure with cardiopulmonary exercise testing data was conducted to address this. The primary analysis specifically focused on 1218 patients with left ventricular ejection fraction less than 40 percent and peak oxygen consumption less than 12 milliliters per kilogram per minute.</p>
<p>Article number four. Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study. Current guidelines for aortic valve replacement lack consensus regarding prosthesis selection for middle-aged patients. A population-based cohort study specifically compared long-term outcomes following aortic valve replacement with mechanical versus biological prostheses among middle-aged patients in an Asian population. The study included patients aged 45 to 64 years who underwent aortic valve replacement across 46 hospitals between 2006 and 2021. This investigation utilized Taiwan&#8217;s national claims database to provide crucial data for informing prosthesis selection decisions.</p>
<p>Article number five. Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation. Emerging evidence suggests associations between air pollution, multimorbidity, and atrial fibrillation, though their precise interplay remains unclear. A prospective cohort study of 480344 individuals from the U. K. Biobank evaluated these complex relationships. The study quantified various air pollutants, including particulate matter with diameters less than or equal to two point five micrometers and ten micrometers, along with nitrogen oxides and nitrogen dioxide. This extensive analysis provides a foundation for understanding the combined impact of environmental factors and co-existing conditions on incident atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>biological prosthesis, mechanical prosthesis, donor organs, left ventricular ejection fraction, air pollution, type two diabetes, prosthesis selection, atrial fibrillation, middle-aged patients, heart transplantation, heart failure, peak oxygen consumption, ex vivo lung perfusion, nitrogen oxides, uncontrolled donation after circulatory death, multimorbidity, particulate matter, dipeptidyl peptidase-four inhibitors, cardiopulmonary exercise test, lung transplantation, glucagon-like peptide-one receptor agonists, aortic valve replacement, heart failure hospitalization, sodium-glucose cotransporter-two inhibitors, organ scarcity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/">Updating Heart Failure & Valve Choices 02/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like biological prosthesis and mechanical prosthesis. Key takeaway: Updating Heart Failure &#038; Valve Choices.
Article Links:
Article 1]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like biological prosthesis and mechanical prosthesis. Key takeaway: Updating Heart Failure &#038; Valve Choices.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41732861">Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41735096">Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41672767">Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40670147">Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40537260">Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/">https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41732861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41732861</a></p>
<p><strong>Summary:</strong> Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type two diabetes. Conflicting trial evidence exists regarding whether glucagon-like peptide-one receptor agonists reduce the risk of hospitalization for heart failure in this broad population. It is unclear whether this is a class effect or varies by specific agent, and their comparative effectiveness against sodium-glucose cotransporter-two inhibitors remains to be fully understood. This highlights a critical knowledge gap in guiding therapeutic choices for this patient group.</p>
<h4>Article 2: Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41735096" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41735096</a></p>
<p><strong>Summary:</strong> Lung transplantation remains limited by the scarcity of suitable donor organs, making uncontrolled donation after circulatory death a promising yet underutilized source. One center&#8217;s prospective experience demonstrated a specific approach to uncontrolled donation after circulatory death lung transplantation. This involved assessing all lung referrals, preserving lungs via open-lung ventilation without in situ cooling, and subsequently evaluating them with ex vivo lung perfusion. This methodology establishes a comprehensive framework for addressing donor organ scarcity and expanding lung transplantation opportunities.</p>
<h4>Article 3: Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41672767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41672767</a></p>
<p><strong>Summary:</strong> Current guidelines recommend evaluating patients with ambulatory heart failure for heart transplantation if their peak oxygen consumption is less than 12 milliliters per kilogram per minute. These recommendations are based on decades-old data, indicating a need for contemporary re-evaluation. A large retrospective analysis of 8060 patients with ambulatory heart failure with cardiopulmonary exercise testing data was conducted to address this. The primary analysis specifically focused on 1218 patients with left ventricular ejection fraction less than 40 percent and peak oxygen consumption less than 12 milliliters per kilogram per minute.</p>
<h4>Article 4: Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40670147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40670147</a></p>
<p><strong>Summary:</strong> Current guidelines for aortic valve replacement lack consensus regarding prosthesis selection for middle-aged patients. A population-based cohort study specifically compared long-term outcomes following aortic valve replacement with mechanical versus biological prostheses among middle-aged patients in an Asian population. The study included patients aged 45 to 64 years who underwent aortic valve replacement across 46 hospitals between 2006 and 2021. This investigation utilized Taiwan&#8217;s national claims database to provide crucial data for informing prosthesis selection decisions.</p>
<h4>Article 5: Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40537260" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40537260</a></p>
<p><strong>Summary:</strong> Emerging evidence suggests associations between air pollution, multimorbidity, and atrial fibrillation, though their precise interplay remains unclear. A prospective cohort study of 480344 individuals from the U. K. Biobank evaluated these complex relationships. The study quantified various air pollutants, including particulate matter with diameters less than or equal to two point five micrometers and ten micrometers, along with nitrogen oxides and nitrogen dioxide. This extensive analysis provides a foundation for understanding the combined impact of environmental factors and co-existing conditions on incident atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type two diabetes. Conflicting trial evidence exists regarding whether glucagon-like peptide-one receptor agonists reduce the risk of hospitalization for heart failure in this broad population. It is unclear whether this is a class effect or varies by specific agent, and their comparative effectiveness against sodium-glucose cotransporter-two inhibitors remains to be fully understood. This highlights a critical knowledge gap in guiding therapeutic choices for this patient group.</p>
<p>Article number two. Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation. Lung transplantation remains limited by the scarcity of suitable donor organs, making uncontrolled donation after circulatory death a promising yet underutilized source. One center&#8217;s prospective experience demonstrated a specific approach to uncontrolled donation after circulatory death lung transplantation. This involved assessing all lung referrals, preserving lungs via open-lung ventilation without in situ cooling, and subsequently evaluating them with ex vivo lung perfusion. This methodology establishes a comprehensive framework for addressing donor organ scarcity and expanding lung transplantation opportunities.</p>
<p>Article number three. Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era. Current guidelines recommend evaluating patients with ambulatory heart failure for heart transplantation if their peak oxygen consumption is less than 12 milliliters per kilogram per minute. These recommendations are based on decades-old data, indicating a need for contemporary re-evaluation. A large retrospective analysis of 8060 patients with ambulatory heart failure with cardiopulmonary exercise testing data was conducted to address this. The primary analysis specifically focused on 1218 patients with left ventricular ejection fraction less than 40 percent and peak oxygen consumption less than 12 milliliters per kilogram per minute.</p>
<p>Article number four. Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study. Current guidelines for aortic valve replacement lack consensus regarding prosthesis selection for middle-aged patients. A population-based cohort study specifically compared long-term outcomes following aortic valve replacement with mechanical versus biological prostheses among middle-aged patients in an Asian population. The study included patients aged 45 to 64 years who underwent aortic valve replacement across 46 hospitals between 2006 and 2021. This investigation utilized Taiwan&#8217;s national claims database to provide crucial data for informing prosthesis selection decisions.</p>
<p>Article number five. Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation. Emerging evidence suggests associations between air pollution, multimorbidity, and atrial fibrillation, though their precise interplay remains unclear. A prospective cohort study of 480344 individuals from the U. K. Biobank evaluated these complex relationships. The study quantified various air pollutants, including particulate matter with diameters less than or equal to two point five micrometers and ten micrometers, along with nitrogen oxides and nitrogen dioxide. This extensive analysis provides a foundation for understanding the combined impact of environmental factors and co-existing conditions on incident atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>biological prosthesis, mechanical prosthesis, donor organs, left ventricular ejection fraction, air pollution, type two diabetes, prosthesis selection, atrial fibrillation, middle-aged patients, heart transplantation, heart failure, peak oxygen consumption, ex vivo lung perfusion, nitrogen oxides, uncontrolled donation after circulatory death, multimorbidity, particulate matter, dipeptidyl peptidase-four inhibitors, cardiopulmonary exercise test, lung transplantation, glucagon-like peptide-one receptor agonists, aortic valve replacement, heart failure hospitalization, sodium-glucose cotransporter-two inhibitors, organ scarcity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/">Updating Heart Failure & Valve Choices 02/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260225_060049.mp3" length="4473251" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like biological prosthesis and mechanical prosthesis. Key takeaway: Updating Heart Failure &#038; Valve Choices.
Article Links:
Article 1: Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. (Circulation)
Article 2: Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era. (Heart (British Cardiac Society))
Article 4: Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study. (Heart (British Cardiac Society))
Article 5: Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/updating-heart-failure-valve-choices-02-25-26/
 Featured Articles
Article 1: Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41732861
Summary: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type two diabetes. Conflicting trial evidence exists regarding whether glucagon-like peptide-one receptor agonists reduce the risk of hospitalization for heart failure in this broad population. It is unclear whether this is a class effect or varies by specific agent, and their comparative effectiveness against sodium-glucose cotransporter-two inhibitors remains to be fully understood. This highlights a critical knowledge gap in guiding therapeutic choices for this patient group.
Article 2: Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41735096
Summary: Lung transplantation remains limited by the scarcity of suitable donor organs, making uncontrolled donation after circulatory death a promising yet underutilized source. One center&#8217;s prospective experience demonstrated a specific approach to uncontrolled donation after circulatory death lung transplantation. This involved assessing all lung referrals, preserving lungs via open-lung ventilation without in situ cooling, and subsequently evaluating them with ex vivo lung perfusion. This methodology establishes a comprehensive framework for addressing donor organ scarcity and expanding lung transplantation opportunities.
Article 3: Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41672767
Summary: Current guidelines recommend evaluating patients with ambulatory heart failure for heart transplantation if their peak oxygen consumption is less than 12 milliliters per kilogram per minute. These recommendations are based on decades-old data, indicating a need for contemporary re-evaluation. A large retrospective analysis of 8060 patients with ambulatory heart failure with cardiopulmonary exercise testing data was conducted to address this. The primary analysis specifically focused on 1218 patients with left ventricular ejectio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like biological prosthesis and mechanical prosthesis. Key takeaway: Updating Heart Failure &#038; Valve Choices.
Article Links:
Article 1: Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. (Circulation)
Article 2: Uncontrolled donation after circulatory death lung transplantation program: Clinical outcomes and perspectives for implementation. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Cardiopulmonary exercise test criteria for heart transplantation referral of patients with ambulatory heart failure in the current era. (Heart (British Cardiac Society))
Article 4: Comparative evaluation of biological and mechanical prostheses for aortic va]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Name Bias Delays STEMI Diagnosis 02/24/26</title>
	<link>https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/</link>
	<pubDate>Tue, 24 Feb 2026 11:01:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 24, 2026. This episode summarizes 5 key cardiology studies on topics like Healthcare disparities and Heart failure. Key takeaway: Name Bias Delays STEMI Diagnosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879671">Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41730484">Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41730483">Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41730451">Identification of a Highly Functional Effector CD8+ T Cell Program after Transplantation in Mice and Humans.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41730548">Impact of name-based implicit bias on time to diagnosis and outcomes in ST-elevation myocardial infarction.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/">https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879671</a></p>
<p><strong>Summary:</strong> The study concluded that initiating heart failure therapies when an elevated N-terminal pro-B-type natriuretic peptide level is detected in community-based patients with suspected heart failure may reduce the risk of early adverse outcomes. The analysis suggested a potential benefit from the early initiation of a sodium-glucose cotransporter two inhibitor and/or a mineralocorticoid receptor antagonist in these patients. This therapeutic approach applies to individuals with suspected heart failure who also have pre-existing non-heart failure related indications. The findings underscore the importance of prompt pharmacological intervention in managing early stages of heart failure.</p>
<h4>Article 2: Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730484" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730484</a></p>
<p><strong>Summary:</strong> The study addressed a critical clinical concern regarding the incidence and risk factors for aortic insufficiency in patients receiving mechanical circulatory support. It focused on individuals who received Impella percutaneous temporary left ventricular assist devices, those with Impella followed by durable left ventricular assist devices, and those with durable left ventricular assist devices alone. Understanding aortic insufficiency progression is crucial for managing patients supported by these devices, as its incidence and specific risk factors have remained unclear in this population. This research highlighted the need for clarity regarding distinct clinical pathways and outcomes in these complex patient groups.</p>
<h4>Article 3: Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730483" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730483</a></p>
<p><strong>Summary:</strong> The study found that combined heart-lung transplants in the United States experienced a gradual decline, but then showed a significant rise in procedures since 2014, particularly among adults. This shift represents an important change in the landscape of thoracic organ transplantation. Understanding these evolving longitudinal trends is critical for clinicians managing patients awaiting or undergoing this complex procedure. The research provides key insights into the contemporary patterns of combined heart-lung transplantation.</p>
<h4>Article 4: Identification of a Highly Functional Effector CD8+ T Cell Program after Transplantation in Mice and Humans.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730451" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730451</a></p>
<p><strong>Summary:</strong> The study identified a highly functional effector C.D.8 positive T cell program crucial for post-transplantation immune responses in both mice and humans. Researchers found that agonism of the C.D.43 1B11 receptor in vitro induced C.D.8 positive T cell proliferation even with sub-threshold antigen stimulation. In vivo, C.D.43 1B11 agonism successfully overcame costimulation-blockade induced tolerance and significantly enhanced C.D.8 positive T cell cytokine production. These findings provide key insights into the mechanisms by which T cells mediate allograft rejection, offering potential targets for preventing transplant rejection.</p>
<h4>Article 5: Impact of name-based implicit bias on time to diagnosis and outcomes in ST-elevation myocardial infarction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730548" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730548</a></p>
<p><strong>Summary:</strong> The study revealed that patients with marginalized characteristics often experience delayed diagnosis of S.T.-elevation myocardial infarction despite established fast-track protocols. Specifically, the research found that name-based implicit bias impacts the time to diagnosis and patient outcomes. Patients with phonetically uncommon surnames experienced delays from first medical contact to S.T.-elevation myocardial infarction diagnosis compared to patients with common surnames within the fast-track network. This highlights a critical disparity in care delivery influenced by implicit bias.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. The study concluded that initiating heart failure therapies when an elevated N-terminal pro-B-type natriuretic peptide level is detected in community-based patients with suspected heart failure may reduce the risk of early adverse outcomes. The analysis suggested a potential benefit from the early initiation of a sodium-glucose cotransporter two inhibitor and/or a mineralocorticoid receptor antagonist in these patients. This therapeutic approach applies to individuals with suspected heart failure who also have pre-existing non-heart failure related indications. The findings underscore the importance of prompt pharmacological intervention in managing early stages of heart failure.</p>
<p>Article number two. Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support. The study addressed a critical clinical concern regarding the incidence and risk factors for aortic insufficiency in patients receiving mechanical circulatory support. It focused on individuals who received Impella percutaneous temporary left ventricular assist devices, those with Impella followed by durable left ventricular assist devices, and those with durable left ventricular assist devices alone. Understanding aortic insufficiency progression is crucial for managing patients supported by these devices, as its incidence and specific risk factors have remained unclear in this population. This research highlighted the need for clarity regarding distinct clinical pathways and outcomes in these complex patient groups.</p>
<p>Article number three. Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation. The study found that combined heart-lung transplants in the United States experienced a gradual decline, but then showed a significant rise in procedures since 2014, particularly among adults. This shift represents an important change in the landscape of thoracic organ transplantation. Understanding these evolving longitudinal trends is critical for clinicians managing patients awaiting or undergoing this complex procedure. The research provides key insights into the contemporary patterns of combined heart-lung transplantation.</p>
<p>Article number four. Identification of a Highly Functional Effector C.D.8 positive T Cell Program after Transplantation in Mice and Humans. The study identified a highly functional effector C.D.8 positive T cell program crucial for post-transplantation immune responses in both mice and humans. Researchers found that agonism of the C.D.43 1B11 receptor in vitro induced C.D.8 positive T cell proliferation even with sub-threshold antigen stimulation. In vivo, C.D.43 1B11 agonism successfully overcame costimulation-blockade induced tolerance and significantly enhanced C.D.8 positive T cell cytokine production. These findings provide key insights into the mechanisms by which T cells mediate allograft rejection, offering potential targets for preventing transplant rejection.</p>
<p>Article number five. Impact of name-based implicit bias on time to diagnosis and outcomes in S.T.-elevation myocardial infarction. The study revealed that patients with marginalized characteristics often experience delayed diagnosis of S.T.-elevation myocardial infarction despite established fast-track protocols. Specifically, the research found that name-based implicit bias impacts the time to diagnosis and patient outcomes. Patients with phonetically uncommon surnames experienced delays from first medical contact to S.T.-elevation myocardial infarction diagnosis compared to patients with common surnames within the fast-track network. This highlights a critical disparity in care delivery influenced by implicit bias. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Healthcare disparities, Heart failure, Immunosuppression, Implicit bias, Aortic insufficiency, N-terminal pro-B-type natriuretic peptide, T cells, Impella, Fast-track protocols, Time to diagnosis, Transplant trends, sodium-glucose cotransporter two inhibitor, Mechanical circulatory support, C.D.43 receptor, S.T.-elevation myocardial infarction, Allograft rejection, mineralocorticoid receptor antagonist, Waitlist outcomes, Heart-lung transplantation, early therapy initiation, C.D.8 positive T cells, Cardiogenic shock, Left ventricular assist device, Organ transplantation, Adult transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/">Name Bias Delays STEMI Diagnosis 02/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 24, 2026. This episode summarizes 5 key cardiology studies on topics like Healthcare disparities and Heart failure. Key takeaway: Name Bias Delays STEMI Diagnosis.
Article Links:
Article 1: Benefit of early]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 24, 2026. This episode summarizes 5 key cardiology studies on topics like Healthcare disparities and Heart failure. Key takeaway: Name Bias Delays STEMI Diagnosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879671">Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41730484">Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41730483">Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41730451">Identification of a Highly Functional Effector CD8+ T Cell Program after Transplantation in Mice and Humans.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41730548">Impact of name-based implicit bias on time to diagnosis and outcomes in ST-elevation myocardial infarction.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/">https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879671</a></p>
<p><strong>Summary:</strong> The study concluded that initiating heart failure therapies when an elevated N-terminal pro-B-type natriuretic peptide level is detected in community-based patients with suspected heart failure may reduce the risk of early adverse outcomes. The analysis suggested a potential benefit from the early initiation of a sodium-glucose cotransporter two inhibitor and/or a mineralocorticoid receptor antagonist in these patients. This therapeutic approach applies to individuals with suspected heart failure who also have pre-existing non-heart failure related indications. The findings underscore the importance of prompt pharmacological intervention in managing early stages of heart failure.</p>
<h4>Article 2: Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730484" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730484</a></p>
<p><strong>Summary:</strong> The study addressed a critical clinical concern regarding the incidence and risk factors for aortic insufficiency in patients receiving mechanical circulatory support. It focused on individuals who received Impella percutaneous temporary left ventricular assist devices, those with Impella followed by durable left ventricular assist devices, and those with durable left ventricular assist devices alone. Understanding aortic insufficiency progression is crucial for managing patients supported by these devices, as its incidence and specific risk factors have remained unclear in this population. This research highlighted the need for clarity regarding distinct clinical pathways and outcomes in these complex patient groups.</p>
<h4>Article 3: Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730483" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730483</a></p>
<p><strong>Summary:</strong> The study found that combined heart-lung transplants in the United States experienced a gradual decline, but then showed a significant rise in procedures since 2014, particularly among adults. This shift represents an important change in the landscape of thoracic organ transplantation. Understanding these evolving longitudinal trends is critical for clinicians managing patients awaiting or undergoing this complex procedure. The research provides key insights into the contemporary patterns of combined heart-lung transplantation.</p>
<h4>Article 4: Identification of a Highly Functional Effector CD8+ T Cell Program after Transplantation in Mice and Humans.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730451" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730451</a></p>
<p><strong>Summary:</strong> The study identified a highly functional effector C.D.8 positive T cell program crucial for post-transplantation immune responses in both mice and humans. Researchers found that agonism of the C.D.43 1B11 receptor in vitro induced C.D.8 positive T cell proliferation even with sub-threshold antigen stimulation. In vivo, C.D.43 1B11 agonism successfully overcame costimulation-blockade induced tolerance and significantly enhanced C.D.8 positive T cell cytokine production. These findings provide key insights into the mechanisms by which T cells mediate allograft rejection, offering potential targets for preventing transplant rejection.</p>
<h4>Article 5: Impact of name-based implicit bias on time to diagnosis and outcomes in ST-elevation myocardial infarction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41730548" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41730548</a></p>
<p><strong>Summary:</strong> The study revealed that patients with marginalized characteristics often experience delayed diagnosis of S.T.-elevation myocardial infarction despite established fast-track protocols. Specifically, the research found that name-based implicit bias impacts the time to diagnosis and patient outcomes. Patients with phonetically uncommon surnames experienced delays from first medical contact to S.T.-elevation myocardial infarction diagnosis compared to patients with common surnames within the fast-track network. This highlights a critical disparity in care delivery influenced by implicit bias.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. The study concluded that initiating heart failure therapies when an elevated N-terminal pro-B-type natriuretic peptide level is detected in community-based patients with suspected heart failure may reduce the risk of early adverse outcomes. The analysis suggested a potential benefit from the early initiation of a sodium-glucose cotransporter two inhibitor and/or a mineralocorticoid receptor antagonist in these patients. This therapeutic approach applies to individuals with suspected heart failure who also have pre-existing non-heart failure related indications. The findings underscore the importance of prompt pharmacological intervention in managing early stages of heart failure.</p>
<p>Article number two. Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support. The study addressed a critical clinical concern regarding the incidence and risk factors for aortic insufficiency in patients receiving mechanical circulatory support. It focused on individuals who received Impella percutaneous temporary left ventricular assist devices, those with Impella followed by durable left ventricular assist devices, and those with durable left ventricular assist devices alone. Understanding aortic insufficiency progression is crucial for managing patients supported by these devices, as its incidence and specific risk factors have remained unclear in this population. This research highlighted the need for clarity regarding distinct clinical pathways and outcomes in these complex patient groups.</p>
<p>Article number three. Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation. The study found that combined heart-lung transplants in the United States experienced a gradual decline, but then showed a significant rise in procedures since 2014, particularly among adults. This shift represents an important change in the landscape of thoracic organ transplantation. Understanding these evolving longitudinal trends is critical for clinicians managing patients awaiting or undergoing this complex procedure. The research provides key insights into the contemporary patterns of combined heart-lung transplantation.</p>
<p>Article number four. Identification of a Highly Functional Effector C.D.8 positive T Cell Program after Transplantation in Mice and Humans. The study identified a highly functional effector C.D.8 positive T cell program crucial for post-transplantation immune responses in both mice and humans. Researchers found that agonism of the C.D.43 1B11 receptor in vitro induced C.D.8 positive T cell proliferation even with sub-threshold antigen stimulation. In vivo, C.D.43 1B11 agonism successfully overcame costimulation-blockade induced tolerance and significantly enhanced C.D.8 positive T cell cytokine production. These findings provide key insights into the mechanisms by which T cells mediate allograft rejection, offering potential targets for preventing transplant rejection.</p>
<p>Article number five. Impact of name-based implicit bias on time to diagnosis and outcomes in S.T.-elevation myocardial infarction. The study revealed that patients with marginalized characteristics often experience delayed diagnosis of S.T.-elevation myocardial infarction despite established fast-track protocols. Specifically, the research found that name-based implicit bias impacts the time to diagnosis and patient outcomes. Patients with phonetically uncommon surnames experienced delays from first medical contact to S.T.-elevation myocardial infarction diagnosis compared to patients with common surnames within the fast-track network. This highlights a critical disparity in care delivery influenced by implicit bias. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Healthcare disparities, Heart failure, Immunosuppression, Implicit bias, Aortic insufficiency, N-terminal pro-B-type natriuretic peptide, T cells, Impella, Fast-track protocols, Time to diagnosis, Transplant trends, sodium-glucose cotransporter two inhibitor, Mechanical circulatory support, C.D.43 receptor, S.T.-elevation myocardial infarction, Allograft rejection, mineralocorticoid receptor antagonist, Waitlist outcomes, Heart-lung transplantation, early therapy initiation, C.D.8 positive T cells, Cardiogenic shock, Left ventricular assist device, Organ transplantation, Adult transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/">Name Bias Delays STEMI Diagnosis 02/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260224_060032.mp3" length="4464056" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 24, 2026. This episode summarizes 5 key cardiology studies on topics like Healthcare disparities and Heart failure. Key takeaway: Name Bias Delays STEMI Diagnosis.
Article Links:
Article 1: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. (European heart journal)
Article 2: Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Identification of a Highly Functional Effector CD8+ T Cell Program after Transplantation in Mice and Humans. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Impact of name-based implicit bias on time to diagnosis and outcomes in ST-elevation myocardial infarction. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/name-bias-delays-stemi-diagnosis-02-24-26/
 Featured Articles
Article 1: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879671
Summary: The study concluded that initiating heart failure therapies when an elevated N-terminal pro-B-type natriuretic peptide level is detected in community-based patients with suspected heart failure may reduce the risk of early adverse outcomes. The analysis suggested a potential benefit from the early initiation of a sodium-glucose cotransporter two inhibitor and/or a mineralocorticoid receptor antagonist in these patients. This therapeutic approach applies to individuals with suspected heart failure who also have pre-existing non-heart failure related indications. The findings underscore the importance of prompt pharmacological intervention in managing early stages of heart failure.
Article 2: Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41730484
Summary: The study addressed a critical clinical concern regarding the incidence and risk factors for aortic insufficiency in patients receiving mechanical circulatory support. It focused on individuals who received Impella percutaneous temporary left ventricular assist devices, those with Impella followed by durable left ventricular assist devices, and those with durable left ventricular assist devices alone. Understanding aortic insufficiency progression is crucial for managing patients supported by these devices, as its incidence and specific risk factors have remained unclear in this population. This research highlighted the need for clarity regarding distinct clinical pathways and outcomes in these complex patient groups.
Article 3: Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41730483
Summary: The study found that combined heart-lung transplants in the United States experienced a gradual decline, but then showed a significant rise in procedures since 2014, particularly among adults. This shift represents an important change in the landscape of thoracic organ transplantation. Understanding these evolving longitudinal trends is critica]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 24, 2026. This episode summarizes 5 key cardiology studies on topics like Healthcare disparities and Heart failure. Key takeaway: Name Bias Delays STEMI Diagnosis.
Article Links:
Article 1: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. (European heart journal)
Article 2: Aortic Insufficiency Progression in Patients with Left Ventricular Assist Devices and Prior Impella Support. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Longitudinal Trends and Contemporary Outcomes of Combined Heart-Lung Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Identification of a Highly Functional Effector CD8+ T Cell Program after Transplantation in Mice and Humans. (American journal of tra]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Diabetes Ups Myocarditis Heart Failure Risk 02/23/26</title>
	<link>https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/</link>
	<pubDate>Mon, 23 Feb 2026 18:21:37 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and longitudinal study. Key takeaway: Diabetes Ups Myocarditis Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41728898">Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41728893">Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41717945">Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41717941">Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41717940">Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/">https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41728898" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41728898</a></p>
<p><strong>Summary:</strong> This study analyzed Activin-A serum levels in patients from the German Peripartum Cardiomyopathy registry both at acute diagnosis and during Left Ventricular recovery. It found that elevated circulating levels of Activin-A, a senescence-associated secretory phenotype factor, correlated with heart failure severity in acute Peripartum Cardiomyopathy patients at baseline. The investigation detailed the trajectory of Activin-A serum levels throughout the course of Left Ventricular functional recovery. This analysis highlights Activin-A as a potential biomarker relevant to the pathophysiology and recovery assessment in Peripartum Cardiomyopathy.</p>
<h4>Article 2: Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41728893" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41728893</a></p>
<p><strong>Summary:</strong> This propensity-matched nationwide database analysis found that diabetes significantly increased the risk of heart failure in patients hospitalized for myocarditis. The study reported that diabetes impacted both in-hospital and long-term outcomes in this patient group. Patients discharged alive were followed for a calendar year, demonstrating the sustained effect of diabetes on subsequent cardiac events. This analysis establishes diabetes as a critical comorbidity that exacerbates adverse outcomes in myocarditis.</p>
<h4>Article 3: Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717945" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717945</a></p>
<p><strong>Summary:</strong> This study developed and externally validated a nomogram model designed to predict 90-day excellent functional outcomes in patients with acute vertebrobasilar artery occlusion. The nomogram provides a crucial tool for patient selection in endovascular thrombectomy, a procedure proven effective for this condition which typically has mortality rates up to 80 percent. The model offers enhanced precision in identifying patients most likely to achieve a modified Rankin Scale score of 0-1 at 90 days. This predictive model addresses the significant challenge of patient selection in managing acute vertebrobasilar artery occlusion.</p>
<h4>Article 4: Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717941" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717941</a></p>
<p><strong>Summary:</strong> This study analyzed data from 3635 Hispanic/Latino adults and found a significant association between insomnia and incident cardiovascular disease. Insomnia was assessed using the Women&#8217;s Health Initiative Insomnia Rating Scale, evaluating group status, symptom severity, specific symptom dimensions, and sleep duration at baseline. The results demonstrated that insomnia is an independent cardiovascular risk factor in this specific demographic. This highlights the importance of screening for and managing insomnia to potentially mitigate cardiovascular risk in Hispanic/Latino populations.</p>
<h4>Article 5: Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717940</a></p>
<p><strong>Summary:</strong> The TREND-IVT trial is a multicenter, randomized, placebo-controlled study investigating the safety and efficacy of early aspirin administration after intravenous thrombolysis for acute ischemic stroke. It addresses the clinical reality that early neurological deterioration is common after intravenous thrombolysis, often resulting in poor outcomes and requiring antiplatelet therapy. The trial implements a therapeutic approach comparing 300 milligrams of aspirin given within 3 hours of intravenous thrombolysis initiation against standard antiplatelet therapy. This study represents a critical investigation into improving functional outcomes for patients experiencing acute ischemic stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery. This study analyzed Activin-A serum levels in patients from the German Peripartum Cardiomyopathy registry both at acute diagnosis and during Left Ventricular recovery. It found that elevated circulating levels of Activin-A, a senescence-associated secretory phenotype factor, correlated with heart failure severity in acute Peripartum Cardiomyopathy patients at baseline. The investigation detailed the trajectory of Activin-A serum levels throughout the course of Left Ventricular functional recovery. This analysis highlights Activin-A as a potential biomarker relevant to the pathophysiology and recovery assessment in Peripartum Cardiomyopathy.</p>
<p>Article number two. Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis. This propensity-matched nationwide database analysis found that diabetes significantly increased the risk of heart failure in patients hospitalized for myocarditis. The study reported that diabetes impacted both in-hospital and long-term outcomes in this patient group. Patients discharged alive were followed for a calendar year, demonstrating the sustained effect of diabetes on subsequent cardiac events. This analysis establishes diabetes as a critical comorbidity that exacerbates adverse outcomes in myocarditis.</p>
<p>Article number three. Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy. This study developed and externally validated a nomogram model designed to predict 90-day excellent functional outcomes in patients with acute vertebrobasilar artery occlusion. The nomogram provides a crucial tool for patient selection in endovascular thrombectomy, a procedure proven effective for this condition which typically has mortality rates up to 80 percent. The model offers enhanced precision in identifying patients most likely to achieve a modified Rankin Scale score of 0-1 at 90 days. This predictive model addresses the significant challenge of patient selection in managing acute vertebrobasilar artery occlusion.</p>
<p>Article number four. Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL. This study analyzed data from 3635 Hispanic/Latino adults and found a significant association between insomnia and incident cardiovascular disease. Insomnia was assessed using the Women&#8217;s Health Initiative Insomnia Rating Scale, evaluating group status, symptom severity, specific symptom dimensions, and sleep duration at baseline. The results demonstrated that insomnia is an independent cardiovascular risk factor in this specific demographic. This highlights the importance of screening for and managing insomnia to potentially mitigate cardiovascular risk in Hispanic/Latino populations.</p>
<p>Article number five. Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial. The TREND-IVT trial is a multicenter, randomized, placebo-controlled study investigating the safety and efficacy of early aspirin administration after intravenous thrombolysis for acute ischemic stroke. It addresses the clinical reality that early neurological deterioration is common after intravenous thrombolysis, often resulting in poor outcomes and requiring antiplatelet therapy. The trial implements a therapeutic approach comparing 300 milligrams of aspirin given within 3 hours of intravenous thrombolysis initiation against standard antiplatelet therapy. This study represents a critical investigation into improving functional outcomes for patients experiencing acute ischemic stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>antiplatelet therapy, longitudinal study, long-term outcomes, Peripartum cardiomyopathy, Hispanic/Latino adults, nomogram, Insomnia, Activin-A, biomarker, intravenous thrombolysis, aspirin, heart failure, in-hospital mortality, clinical trial design, functional outcome, endovascular thrombectomy, cardiovascular disease, stroke, risk factor, Diabetes, myocarditis, Vertebrobasilar artery occlusion, left ventricular recovery, Acute ischemic stroke.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/">Diabetes Ups Myocarditis Heart Failure Risk 02/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and longitudinal study. Key takeaway: Diabetes Ups Myocarditis Heart Failure Risk.
Article Links:
Article 1: El]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and longitudinal study. Key takeaway: Diabetes Ups Myocarditis Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41728898">Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41728893">Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41717945">Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41717941">Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41717940">Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/">https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41728898" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41728898</a></p>
<p><strong>Summary:</strong> This study analyzed Activin-A serum levels in patients from the German Peripartum Cardiomyopathy registry both at acute diagnosis and during Left Ventricular recovery. It found that elevated circulating levels of Activin-A, a senescence-associated secretory phenotype factor, correlated with heart failure severity in acute Peripartum Cardiomyopathy patients at baseline. The investigation detailed the trajectory of Activin-A serum levels throughout the course of Left Ventricular functional recovery. This analysis highlights Activin-A as a potential biomarker relevant to the pathophysiology and recovery assessment in Peripartum Cardiomyopathy.</p>
<h4>Article 2: Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41728893" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41728893</a></p>
<p><strong>Summary:</strong> This propensity-matched nationwide database analysis found that diabetes significantly increased the risk of heart failure in patients hospitalized for myocarditis. The study reported that diabetes impacted both in-hospital and long-term outcomes in this patient group. Patients discharged alive were followed for a calendar year, demonstrating the sustained effect of diabetes on subsequent cardiac events. This analysis establishes diabetes as a critical comorbidity that exacerbates adverse outcomes in myocarditis.</p>
<h4>Article 3: Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717945" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717945</a></p>
<p><strong>Summary:</strong> This study developed and externally validated a nomogram model designed to predict 90-day excellent functional outcomes in patients with acute vertebrobasilar artery occlusion. The nomogram provides a crucial tool for patient selection in endovascular thrombectomy, a procedure proven effective for this condition which typically has mortality rates up to 80 percent. The model offers enhanced precision in identifying patients most likely to achieve a modified Rankin Scale score of 0-1 at 90 days. This predictive model addresses the significant challenge of patient selection in managing acute vertebrobasilar artery occlusion.</p>
<h4>Article 4: Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717941" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717941</a></p>
<p><strong>Summary:</strong> This study analyzed data from 3635 Hispanic/Latino adults and found a significant association between insomnia and incident cardiovascular disease. Insomnia was assessed using the Women&#8217;s Health Initiative Insomnia Rating Scale, evaluating group status, symptom severity, specific symptom dimensions, and sleep duration at baseline. The results demonstrated that insomnia is an independent cardiovascular risk factor in this specific demographic. This highlights the importance of screening for and managing insomnia to potentially mitigate cardiovascular risk in Hispanic/Latino populations.</p>
<h4>Article 5: Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717940</a></p>
<p><strong>Summary:</strong> The TREND-IVT trial is a multicenter, randomized, placebo-controlled study investigating the safety and efficacy of early aspirin administration after intravenous thrombolysis for acute ischemic stroke. It addresses the clinical reality that early neurological deterioration is common after intravenous thrombolysis, often resulting in poor outcomes and requiring antiplatelet therapy. The trial implements a therapeutic approach comparing 300 milligrams of aspirin given within 3 hours of intravenous thrombolysis initiation against standard antiplatelet therapy. This study represents a critical investigation into improving functional outcomes for patients experiencing acute ischemic stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery. This study analyzed Activin-A serum levels in patients from the German Peripartum Cardiomyopathy registry both at acute diagnosis and during Left Ventricular recovery. It found that elevated circulating levels of Activin-A, a senescence-associated secretory phenotype factor, correlated with heart failure severity in acute Peripartum Cardiomyopathy patients at baseline. The investigation detailed the trajectory of Activin-A serum levels throughout the course of Left Ventricular functional recovery. This analysis highlights Activin-A as a potential biomarker relevant to the pathophysiology and recovery assessment in Peripartum Cardiomyopathy.</p>
<p>Article number two. Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis. This propensity-matched nationwide database analysis found that diabetes significantly increased the risk of heart failure in patients hospitalized for myocarditis. The study reported that diabetes impacted both in-hospital and long-term outcomes in this patient group. Patients discharged alive were followed for a calendar year, demonstrating the sustained effect of diabetes on subsequent cardiac events. This analysis establishes diabetes as a critical comorbidity that exacerbates adverse outcomes in myocarditis.</p>
<p>Article number three. Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy. This study developed and externally validated a nomogram model designed to predict 90-day excellent functional outcomes in patients with acute vertebrobasilar artery occlusion. The nomogram provides a crucial tool for patient selection in endovascular thrombectomy, a procedure proven effective for this condition which typically has mortality rates up to 80 percent. The model offers enhanced precision in identifying patients most likely to achieve a modified Rankin Scale score of 0-1 at 90 days. This predictive model addresses the significant challenge of patient selection in managing acute vertebrobasilar artery occlusion.</p>
<p>Article number four. Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL. This study analyzed data from 3635 Hispanic/Latino adults and found a significant association between insomnia and incident cardiovascular disease. Insomnia was assessed using the Women&#8217;s Health Initiative Insomnia Rating Scale, evaluating group status, symptom severity, specific symptom dimensions, and sleep duration at baseline. The results demonstrated that insomnia is an independent cardiovascular risk factor in this specific demographic. This highlights the importance of screening for and managing insomnia to potentially mitigate cardiovascular risk in Hispanic/Latino populations.</p>
<p>Article number five. Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial. The TREND-IVT trial is a multicenter, randomized, placebo-controlled study investigating the safety and efficacy of early aspirin administration after intravenous thrombolysis for acute ischemic stroke. It addresses the clinical reality that early neurological deterioration is common after intravenous thrombolysis, often resulting in poor outcomes and requiring antiplatelet therapy. The trial implements a therapeutic approach comparing 300 milligrams of aspirin given within 3 hours of intravenous thrombolysis initiation against standard antiplatelet therapy. This study represents a critical investigation into improving functional outcomes for patients experiencing acute ischemic stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>antiplatelet therapy, longitudinal study, long-term outcomes, Peripartum cardiomyopathy, Hispanic/Latino adults, nomogram, Insomnia, Activin-A, biomarker, intravenous thrombolysis, aspirin, heart failure, in-hospital mortality, clinical trial design, functional outcome, endovascular thrombectomy, cardiovascular disease, stroke, risk factor, Diabetes, myocarditis, Vertebrobasilar artery occlusion, left ventricular recovery, Acute ischemic stroke.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/">Diabetes Ups Myocarditis Heart Failure Risk 02/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260223_131949.mp3" length="4581084" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and longitudinal study. Key takeaway: Diabetes Ups Myocarditis Heart Failure Risk.
Article Links:
Article 1: Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery. (ESC heart failure)
Article 2: Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis. (ESC heart failure)
Article 3: Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy. (Journal of the American Heart Association)
Article 4: Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL. (Journal of the American Heart Association)
Article 5: Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/diabetes-ups-myocarditis-heart-failure-risk-02-23-26/
 Featured Articles
Article 1: Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41728898
Summary: This study analyzed Activin-A serum levels in patients from the German Peripartum Cardiomyopathy registry both at acute diagnosis and during Left Ventricular recovery. It found that elevated circulating levels of Activin-A, a senescence-associated secretory phenotype factor, correlated with heart failure severity in acute Peripartum Cardiomyopathy patients at baseline. The investigation detailed the trajectory of Activin-A serum levels throughout the course of Left Ventricular functional recovery. This analysis highlights Activin-A as a potential biomarker relevant to the pathophysiology and recovery assessment in Peripartum Cardiomyopathy.
Article 2: Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41728893
Summary: This propensity-matched nationwide database analysis found that diabetes significantly increased the risk of heart failure in patients hospitalized for myocarditis. The study reported that diabetes impacted both in-hospital and long-term outcomes in this patient group. Patients discharged alive were followed for a calendar year, demonstrating the sustained effect of diabetes on subsequent cardiac events. This analysis establishes diabetes as a critical comorbidity that exacerbates adverse outcomes in myocarditis.
Article 3: Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717945
Summary: This study developed and externally validated a nomogram model designed to predict 90-day excellent functional outcomes in patients with acute vertebrobasilar artery occlusion. The nomogram provides a crucial tool for patient selection in endovascular thrombectomy, a procedure proven effective for this condition which typically has mortality rates up to 80 percent. The model offers enhanced precision in identifying patients most likely to achieve a modified Rankin Scale score of 0-1 at 90 days. This predictive model addresses the significant challenge of patient selection in managing acute vertebrobasilar artery occlusion.
Article 4: Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/4]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and longitudinal study. Key takeaway: Diabetes Ups Myocarditis Heart Failure Risk.
Article Links:
Article 1: Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery. (ESC heart failure)
Article 2: Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis. (ESC heart failure)
Article 3: Nomogram Model for Predicting 90-Day Excellent Outcome in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Thrombectomy. (Journal of the American Heart Association)
Article 4: Insomnia and Incident Cardiovascular Disease in US Hispanic/Latino Adults: Results From HCHS/SOL. (Journal of the American Heart Association)
Article 5: Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Isch]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Links Dental Care to Higher Heart Risk 02/23/26</title>
	<link>https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/</link>
	<pubDate>Mon, 23 Feb 2026 11:01:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like electrocardiography and adverse outcomes. Key takeaway: AI Links Dental Care to Higher Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41717953">Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41717952">Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41717950">Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41717949">Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41717947">Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/">https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717953</a></p>
<p><strong>Summary:</strong> This study found that interferon-gamma-responsive microglia-derived extracellular vesicles inhibited neurogenesis after stroke. This inhibition occurred via the microRNA-199a-5p/SIRT1 axis, revealing a specific molecular mechanism. The data demonstrated a pathway contributing to impaired neurological function recovery following cerebral ischemia. This new understanding identifies a potential therapeutic target to enhance neurogenesis and improve patient outcomes after stroke.</p>
<h4>Article 2: Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717952" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717952</a></p>
<p><strong>Summary:</strong> This study evaluated annual trends in the control of major risk factors at the time of ischemic stroke in South Korea from 2011 to 2022. Researchers analyzed data from a nationwide registry, focusing on hypertension, diabetes, and dyslipidemia. The findings from this real-world assessment identified specific areas where current prevention guidelines for ischemic stroke need greater clinical attention. This work helps improve early stroke outcomes by highlighting gaps in risk factor management.</p>
<h4>Article 3: Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717950" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717950</a></p>
<p><strong>Summary:</strong> This study found that short-term exposure to ambient ozone and fine particulate matter with a diameter of less than or equal to 2.5 micrometers increased the risk of in-hospital adverse outcomes for patients with acute myocardial infarction. The time-stratified case-crossover study, conducted in Beijing, demonstrated this association between air pollutants and patient morbidity. This data highlights the critical impact of environmental factors on immediate post-infarction prognosis. Clinicians should consider air quality in managing acute myocardial infarction patients.</p>
<h4>Article 4: Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717949" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717949</a></p>
<p><strong>Summary:</strong> This large multiregional study in China found that cold waves and geographic elevation strengthened the association of particulate matter exposure with hypertension prevalence. Researchers analyzed data from 27000 adults, demonstrating that these co-occurring environmental stressors exacerbate the known risk of air pollution for hypertension. The data revealed significant interactive effects between long-term particulate matter exposure, cold weather, and altitude. This understanding is crucial for public health strategies addressing hypertension in varied geographical and climatic conditions.</p>
<h4>Article 5: Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717947" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717947</a></p>
<p><strong>Summary:</strong> This study found that inadequate preventive dental care was associated with a higher cardiovascular risk. Artificial intelligence-enabled electrocardiography algorithms identified this increased risk across several conditions, including atrial fibrillation, aortic stenosis, low ejection fraction, cardiac amyloid, cardiovascular aging, and all-cause mortality. The data demonstrated a clear link between dental health neglect and quantifiable cardiac health markers. These findings underscore the importance of integrating oral health into comprehensive cardiovascular risk assessment and prevention strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis. This study found that interferon-gamma-responsive microglia-derived extracellular vesicles inhibited neurogenesis after stroke. This inhibition occurred via the microRNA-199a-5p/SIRT1 axis, revealing a specific molecular mechanism. The data demonstrated a pathway contributing to impaired neurological function recovery following cerebral ischemia. This new understanding identifies a potential therapeutic target to enhance neurogenesis and improve patient outcomes after stroke.</p>
<p>Article number two. Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea. This study evaluated annual trends in the control of major risk factors at the time of ischemic stroke in South Korea from 2011 to 2022. Researchers analyzed data from a nationwide registry, focusing on hypertension, diabetes, and dyslipidemia. The findings from this real-world assessment identified specific areas where current prevention guidelines for ischemic stroke need greater clinical attention. This work helps improve early stroke outcomes by highlighting gaps in risk factor management.</p>
<p>Article number three. Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study. This study found that short-term exposure to ambient ozone and fine particulate matter with a diameter of less than or equal to 2.5 micrometers increased the risk of in-hospital adverse outcomes for patients with acute myocardial infarction. The time-stratified case-crossover study, conducted in Beijing, demonstrated this association between air pollutants and patient morbidity. This data highlights the critical impact of environmental factors on immediate post-infarction prognosis. Clinicians should consider air quality in managing acute myocardial infarction patients.</p>
<p>Article number four. Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China. This large multiregional study in China found that cold waves and geographic elevation strengthened the association of particulate matter exposure with hypertension prevalence. Researchers analyzed data from 27000 adults, demonstrating that these co-occurring environmental stressors exacerbate the known risk of air pollution for hypertension. The data revealed significant interactive effects between long-term particulate matter exposure, cold weather, and altitude. This understanding is crucial for public health strategies addressing hypertension in varied geographical and climatic conditions.</p>
<p>Article number five. Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms. This study found that inadequate preventive dental care was associated with a higher cardiovascular risk. Artificial intelligence-enabled electrocardiography algorithms identified this increased risk across several conditions, including atrial fibrillation, aortic stenosis, low ejection fraction, cardiac amyloid, cardiovascular aging, and all-cause mortality. The data demonstrated a clear link between dental health neglect and quantifiable cardiac health markers. These findings underscore the importance of integrating oral health into comprehensive cardiovascular risk assessment and prevention strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>electrocardiography, adverse outcomes, fine particulate matter, stroke, ischemic stroke, particulate matter, cardiovascular risk, hypertension, artificial intelligence, neurogenesis, dyslipidemia, atrial fibrillation, extracellular vesicles, air pollution, cold waves, microglia, risk factor control, acute myocardial infarction, geographic elevation, diabetes, ozone, dental care, SIRT1.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/">AI Links Dental Care to Higher Heart Risk 02/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like electrocardiography and adverse outcomes. Key takeaway: AI Links Dental Care to Higher Heart Risk.
Article Links:
Article 1: Interfe]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like electrocardiography and adverse outcomes. Key takeaway: AI Links Dental Care to Higher Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41717953">Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41717952">Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41717950">Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41717949">Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41717947">Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/">https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717953</a></p>
<p><strong>Summary:</strong> This study found that interferon-gamma-responsive microglia-derived extracellular vesicles inhibited neurogenesis after stroke. This inhibition occurred via the microRNA-199a-5p/SIRT1 axis, revealing a specific molecular mechanism. The data demonstrated a pathway contributing to impaired neurological function recovery following cerebral ischemia. This new understanding identifies a potential therapeutic target to enhance neurogenesis and improve patient outcomes after stroke.</p>
<h4>Article 2: Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717952" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717952</a></p>
<p><strong>Summary:</strong> This study evaluated annual trends in the control of major risk factors at the time of ischemic stroke in South Korea from 2011 to 2022. Researchers analyzed data from a nationwide registry, focusing on hypertension, diabetes, and dyslipidemia. The findings from this real-world assessment identified specific areas where current prevention guidelines for ischemic stroke need greater clinical attention. This work helps improve early stroke outcomes by highlighting gaps in risk factor management.</p>
<h4>Article 3: Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717950" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717950</a></p>
<p><strong>Summary:</strong> This study found that short-term exposure to ambient ozone and fine particulate matter with a diameter of less than or equal to 2.5 micrometers increased the risk of in-hospital adverse outcomes for patients with acute myocardial infarction. The time-stratified case-crossover study, conducted in Beijing, demonstrated this association between air pollutants and patient morbidity. This data highlights the critical impact of environmental factors on immediate post-infarction prognosis. Clinicians should consider air quality in managing acute myocardial infarction patients.</p>
<h4>Article 4: Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717949" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717949</a></p>
<p><strong>Summary:</strong> This large multiregional study in China found that cold waves and geographic elevation strengthened the association of particulate matter exposure with hypertension prevalence. Researchers analyzed data from 27000 adults, demonstrating that these co-occurring environmental stressors exacerbate the known risk of air pollution for hypertension. The data revealed significant interactive effects between long-term particulate matter exposure, cold weather, and altitude. This understanding is crucial for public health strategies addressing hypertension in varied geographical and climatic conditions.</p>
<h4>Article 5: Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717947" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717947</a></p>
<p><strong>Summary:</strong> This study found that inadequate preventive dental care was associated with a higher cardiovascular risk. Artificial intelligence-enabled electrocardiography algorithms identified this increased risk across several conditions, including atrial fibrillation, aortic stenosis, low ejection fraction, cardiac amyloid, cardiovascular aging, and all-cause mortality. The data demonstrated a clear link between dental health neglect and quantifiable cardiac health markers. These findings underscore the importance of integrating oral health into comprehensive cardiovascular risk assessment and prevention strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis. This study found that interferon-gamma-responsive microglia-derived extracellular vesicles inhibited neurogenesis after stroke. This inhibition occurred via the microRNA-199a-5p/SIRT1 axis, revealing a specific molecular mechanism. The data demonstrated a pathway contributing to impaired neurological function recovery following cerebral ischemia. This new understanding identifies a potential therapeutic target to enhance neurogenesis and improve patient outcomes after stroke.</p>
<p>Article number two. Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea. This study evaluated annual trends in the control of major risk factors at the time of ischemic stroke in South Korea from 2011 to 2022. Researchers analyzed data from a nationwide registry, focusing on hypertension, diabetes, and dyslipidemia. The findings from this real-world assessment identified specific areas where current prevention guidelines for ischemic stroke need greater clinical attention. This work helps improve early stroke outcomes by highlighting gaps in risk factor management.</p>
<p>Article number three. Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study. This study found that short-term exposure to ambient ozone and fine particulate matter with a diameter of less than or equal to 2.5 micrometers increased the risk of in-hospital adverse outcomes for patients with acute myocardial infarction. The time-stratified case-crossover study, conducted in Beijing, demonstrated this association between air pollutants and patient morbidity. This data highlights the critical impact of environmental factors on immediate post-infarction prognosis. Clinicians should consider air quality in managing acute myocardial infarction patients.</p>
<p>Article number four. Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China. This large multiregional study in China found that cold waves and geographic elevation strengthened the association of particulate matter exposure with hypertension prevalence. Researchers analyzed data from 27000 adults, demonstrating that these co-occurring environmental stressors exacerbate the known risk of air pollution for hypertension. The data revealed significant interactive effects between long-term particulate matter exposure, cold weather, and altitude. This understanding is crucial for public health strategies addressing hypertension in varied geographical and climatic conditions.</p>
<p>Article number five. Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms. This study found that inadequate preventive dental care was associated with a higher cardiovascular risk. Artificial intelligence-enabled electrocardiography algorithms identified this increased risk across several conditions, including atrial fibrillation, aortic stenosis, low ejection fraction, cardiac amyloid, cardiovascular aging, and all-cause mortality. The data demonstrated a clear link between dental health neglect and quantifiable cardiac health markers. These findings underscore the importance of integrating oral health into comprehensive cardiovascular risk assessment and prevention strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>electrocardiography, adverse outcomes, fine particulate matter, stroke, ischemic stroke, particulate matter, cardiovascular risk, hypertension, artificial intelligence, neurogenesis, dyslipidemia, atrial fibrillation, extracellular vesicles, air pollution, cold waves, microglia, risk factor control, acute myocardial infarction, geographic elevation, diabetes, ozone, dental care, SIRT1.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/">AI Links Dental Care to Higher Heart Risk 02/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260223_060023.mp3" length="4360820" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like electrocardiography and adverse outcomes. Key takeaway: AI Links Dental Care to Higher Heart Risk.
Article Links:
Article 1: Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis. (Journal of the American Heart Association)
Article 2: Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea. (Journal of the American Heart Association)
Article 3: Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study. (Journal of the American Heart Association)
Article 4: Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China. (Journal of the American Heart Association)
Article 5: Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ai-links-dental-care-to-higher-heart-risk-02-23-26/
 Featured Articles
Article 1: Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717953
Summary: This study found that interferon-gamma-responsive microglia-derived extracellular vesicles inhibited neurogenesis after stroke. This inhibition occurred via the microRNA-199a-5p/SIRT1 axis, revealing a specific molecular mechanism. The data demonstrated a pathway contributing to impaired neurological function recovery following cerebral ischemia. This new understanding identifies a potential therapeutic target to enhance neurogenesis and improve patient outcomes after stroke.
Article 2: Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717952
Summary: This study evaluated annual trends in the control of major risk factors at the time of ischemic stroke in South Korea from 2011 to 2022. Researchers analyzed data from a nationwide registry, focusing on hypertension, diabetes, and dyslipidemia. The findings from this real-world assessment identified specific areas where current prevention guidelines for ischemic stroke need greater clinical attention. This work helps improve early stroke outcomes by highlighting gaps in risk factor management.
Article 3: Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717950
Summary: This study found that short-term exposure to ambient ozone and fine particulate matter with a diameter of less than or equal to 2.5 micrometers increased the risk of in-hospital adverse outcomes for patients with acute myocardial infarction. The time-stratified case-crossover study, conducted in Beijing, demonstrated this association between air pollutants and patient morbidity. This data highlights the critical impact of environmental factors on immediate post-infarction prognosis. Clinicians should consider air quality in managing acute myocardial infarction patients.
Article 4: Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study in China.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.n]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 23, 2026. This episode summarizes 5 key cardiology studies on topics like electrocardiography and adverse outcomes. Key takeaway: AI Links Dental Care to Higher Heart Risk.
Article Links:
Article 1: Interferon-γ-Responsive Microglia-Derived Extracellular Vesicles Inhibited Neurogenesis After Stroke via MicroRNA-199a-5p/SIRT1 Axis. (Journal of the American Heart Association)
Article 2: Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea. (Journal of the American Heart Association)
Article 3: Short-Term Exposure to Ambient Ozone and Fine Particulate Matter and Its Components Increases the Risk of In-Hospital Adverse Outcomes in Patients With Acute Myocardial Infarction: A Time-Stratified Case-Crossover Study. (Journal of the American Heart Association)
Article 4: Cold Waves and Elevation Strengthen the Association of Particulate Matter Exposure With Hypertension Prevalence: A Large Multiregional Study ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Empagliflozin Cuts Brain Injury After Cardiac Arrest 02/22/26</title>
	<link>https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/</link>
	<pubDate>Sun, 22 Feb 2026 11:01:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 22, 2026. This episode summarizes 5 key cardiology studies on topics like hypotension and Coronary embolism. Key takeaway: Empagliflozin Cuts Brain Injury After Cardiac Arrest.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41721795">Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41721505">Three-dimensional echocardiography for valvular heart disease: clinical implications.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41711037">Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41717963">Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41717961">Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/">https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41721795" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41721795</a></p>
<p><strong>Summary:</strong> Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions.</p>
<h4>Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41721505" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41721505</a></p>
<p><strong>Summary:</strong> Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management.</p>
<h4>Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711037" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711037</a></p>
<p><strong>Summary:</strong> This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population.</p>
<h4>Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717963" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717963</a></p>
<p><strong>Summary:</strong> This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characteristics between atrial fibrillation-related and non-atrial fibrillation coronary embolism patient groups. This research provides initial comparative data on this underrecognized cause of acute myocardial infarction.</p>
<h4>Article 5: Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717961" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717961</a></p>
<p><strong>Summary:</strong> This study demonstrated that empagliflozin attenuates global cerebral ischemic injury following cardiac arrest in rats. The observed neuroprotective effects were achieved through the enhancement of ketone body oxidative metabolism. Researchers utilized a model where 206 adult male Sprague-Dawley rats were subjected to cardiac arrest via ventricular fibrillation and subsequent cardiopulmonary resuscitation. This finding positions empagliflozin as a potential therapeutic agent for reducing neurological deficits after cardiac arrest.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 22, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions.</p>
<p>Article number two. Three-dimensional echocardiography for valvular heart disease: clinical implications. Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management.</p>
<p>Article number three. Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population.</p>
<p>Article number four. Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characteristics between atrial fibrillation-related and non-atrial fibrillation coronary embolism patient groups. This research provides initial comparative data on this underrecognized cause of acute myocardial infarction.</p>
<p>Article number five. Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. This study demonstrated that empagliflozin attenuates global cerebral ischemic injury following cardiac arrest in rats. The observed neuroprotective effects were achieved through the enhancement of ketone body oxidative metabolism. Researchers utilized a model where 206 adult male Sprague-Dawley rats were subjected to cardiac arrest via ventricular fibrillation and subsequent cardiopulmonary resuscitation. This finding positions empagliflozin as a potential therapeutic agent for reducing neurological deficits after cardiac arrest. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypotension, Coronary embolism, transcatheter valve interventions, hypoperfusion, lactate, Shibata criteria, lipoprotein(a), cardiac arrest, atrial fibrillation, secondary prevention, lipoprotein(a) apheresis, ketone body metabolism, transthoracic echocardiography, cardiovascular disease, acute myocardial infarction, transesophageal echocardiography, Society for Cardiovascular Angiography and Interventions, Pelacarsen, Cardiogenic shock, Empagliflozin, cerebral ischemic injury, Three-dimensional echocardiography, neuroprotection, valvular heart disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/">Empagliflozin Cuts Brain Injury After Cardiac Arrest 02/22/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 22, 2026. This episode summarizes 5 key cardiology studies on topics like hypotension and Coronary embolism. Key takeaway: Empagliflozin Cuts Brain Injury After Cardiac Arrest.
Article Links:
Article 1: Pel]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 22, 2026. This episode summarizes 5 key cardiology studies on topics like hypotension and Coronary embolism. Key takeaway: Empagliflozin Cuts Brain Injury After Cardiac Arrest.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41721795">Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41721505">Three-dimensional echocardiography for valvular heart disease: clinical implications.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41711037">Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41717963">Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41717961">Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/">https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41721795" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41721795</a></p>
<p><strong>Summary:</strong> Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions.</p>
<h4>Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41721505" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41721505</a></p>
<p><strong>Summary:</strong> Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management.</p>
<h4>Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711037" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711037</a></p>
<p><strong>Summary:</strong> This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population.</p>
<h4>Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717963" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717963</a></p>
<p><strong>Summary:</strong> This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characteristics between atrial fibrillation-related and non-atrial fibrillation coronary embolism patient groups. This research provides initial comparative data on this underrecognized cause of acute myocardial infarction.</p>
<h4>Article 5: Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717961" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717961</a></p>
<p><strong>Summary:</strong> This study demonstrated that empagliflozin attenuates global cerebral ischemic injury following cardiac arrest in rats. The observed neuroprotective effects were achieved through the enhancement of ketone body oxidative metabolism. Researchers utilized a model where 206 adult male Sprague-Dawley rats were subjected to cardiac arrest via ventricular fibrillation and subsequent cardiopulmonary resuscitation. This finding positions empagliflozin as a potential therapeutic agent for reducing neurological deficits after cardiac arrest.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 22, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions.</p>
<p>Article number two. Three-dimensional echocardiography for valvular heart disease: clinical implications. Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management.</p>
<p>Article number three. Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population.</p>
<p>Article number four. Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characteristics between atrial fibrillation-related and non-atrial fibrillation coronary embolism patient groups. This research provides initial comparative data on this underrecognized cause of acute myocardial infarction.</p>
<p>Article number five. Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. This study demonstrated that empagliflozin attenuates global cerebral ischemic injury following cardiac arrest in rats. The observed neuroprotective effects were achieved through the enhancement of ketone body oxidative metabolism. Researchers utilized a model where 206 adult male Sprague-Dawley rats were subjected to cardiac arrest via ventricular fibrillation and subsequent cardiopulmonary resuscitation. This finding positions empagliflozin as a potential therapeutic agent for reducing neurological deficits after cardiac arrest. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypotension, Coronary embolism, transcatheter valve interventions, hypoperfusion, lactate, Shibata criteria, lipoprotein(a), cardiac arrest, atrial fibrillation, secondary prevention, lipoprotein(a) apheresis, ketone body metabolism, transthoracic echocardiography, cardiovascular disease, acute myocardial infarction, transesophageal echocardiography, Society for Cardiovascular Angiography and Interventions, Pelacarsen, Cardiogenic shock, Empagliflozin, cerebral ischemic injury, Three-dimensional echocardiography, neuroprotection, valvular heart disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/">Empagliflozin Cuts Brain Injury After Cardiac Arrest 02/22/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260222_060030.mp3" length="4253822" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 22, 2026. This episode summarizes 5 key cardiology studies on topics like hypotension and Coronary embolism. Key takeaway: Empagliflozin Cuts Brain Injury After Cardiac Arrest.
Article Links:
Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. (European heart journal)
Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications. (European heart journal)
Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. (Circulation. Heart failure)
Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. (Journal of the American Heart Association)
Article 5: Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/
 Featured Articles
Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41721795
Summary: Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions.
Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41721505
Summary: Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management.
Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41711037
Summary: This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population.
Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717963
Summary: This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characte]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 22, 2026. This episode summarizes 5 key cardiology studies on topics like hypotension and Coronary embolism. Key takeaway: Empagliflozin Cuts Brain Injury After Cardiac Arrest.
Article Links:
Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. (European heart journal)
Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications. (European heart journal)
Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. (Circulation. Heart failure)
Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. (Journal of the American Heart Association)
Article 5: Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. (Journal of the American Heart Association)
]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Prolonged QT Elevates Recurrent Stroke Risk by 73% 02/21/26</title>
	<link>https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/</link>
	<pubDate>Sat, 21 Feb 2026 11:02:19 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 21, 2026. This episode summarizes 5 key cardiology studies on topics like venoarterial extracorporeal membrane oxygenation and calcific aortic valve disease. Key takeaway: Prolonged QT Elevates Recurrent Stroke Risk by 73%.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41717681">HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41721439">Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41720453">Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO.</a> (Journal of cardiac failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41720625">Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41711207">Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/">https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717681" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717681</a></p>
<p><strong>Summary:</strong> An antibody-drug conjugate targeting high endothelial venules in lymph nodes has been shown to promote long-term cardiac allograft acceptance. This therapeutic strategy leverages the crucial role of high endothelial venules in mediating naive T cell entry into lymph nodes, a vital step for transplant acceptance under costimulatory blockade. The conjugate specifically targets a glycoprotein containing 6-sulfo sialyl Lewis X on these venules, which forms the binding site for L-selectin on naive T cells. This approach offers a novel mechanism to prevent immune rejection in heart transplant recipients.</p>
<h4>Article 2: Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41721439" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41721439</a></p>
<p><strong>Summary:</strong> In this observational study of up to 6598 participants, lipoprotein(a) and L. D. L. cholesterol were confirmed as causally linked to aortic valve calcium and aortic stenosis. The analysis found that aspirin use was not associated with incident aortic valve calcium or aortic stenosis. This lack of association held true regardless of baseline lipoprotein(a) or L. D. L. cholesterol levels. The data suggests that aspirin does not mitigate the risk of calcific aortic valve disease in individuals with high lipoprotein(a).</p>
<h4>Article 3: Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41720453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41720453</a></p>
<p><strong>Summary:</strong> This study described the temporal hemodynamic patterns observed in cardiogenic shock patients receiving either an isolated microaxial flow pump or combined therapy with venoarterial extracorporeal membrane oxygenation. Hemodynamic indices were analyzed from pre-device installation, post-installation, and 24 hours after, up to device explantation, using data from the U. N. L. O. A. D. E. R. S.-P. VAD Registry. The study characterized these hemodynamic trends for both treatment groups. Hospital survival was also analyzed in relation to these patterns, providing comparative data on mechanical circulatory support strategies in cardiogenic shock.</p>
<h4>Article 4: Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41720625" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41720625</a></p>
<p><strong>Summary:</strong> A secondary analysis of the A. R. C. A. D. I. A. trial found that a prolonged Q. T. interval independently predicted an increased risk of recurrent stroke or systemic embolism in patients with cryptogenic stroke and atrial cardiopathy. This association held true for both the apixaban arm, with a hazard ratio of 1.70 (95 percent confidence interval 1.05-2.75), and the aspirin arm, showing a hazard ratio of 1.76 (95 percent confidence interval 1.05-2.95). The overall adjusted hazard ratio for this risk was 1.73 (95 percent confidence interval 1.25-2.38), with no significant interaction between Q. T. interval prolongation and treatment assignment (P value 0.95). This data demonstrates that prolonged Q. T. interval is an independent predictor of recurrent stroke regardless of antithrombotic treatment.</p>
<h4>Article 5: Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711207" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711207</a></p>
<p><strong>Summary:</strong> This study identified electrocardiographic and echocardiographic predictors of acute stroke volume improvement with A. V.-optimized conduction system pacing in 19 symptomatic first-degree atrioventricular block patients. Electrocardiographic predictors included a Q. R. S. duration greater than or equal to 120 milliseconds, with an odds ratio of 17.5, and a prolonged P. R. interval, with an odds ratio of 1.05. Echocardiographic predictors encompassed a reduced left ventricular ejection fraction less than 50 percent, mechanical atrioventricular dyssynchrony, and left ventricular diastolic dysfunction, with odds ratios of 25.0, 20.0, and 15.0 respectively. These findings demonstrate that specific electrocardiogram and echocardiogram parameters can identify patients likely to acutely benefit from A. V.-optimized conduction system pacing for stroke volume improvement.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. An antibody-drug conjugate targeting high endothelial venules in lymph nodes has been shown to promote long-term cardiac allograft acceptance. This therapeutic strategy leverages the crucial role of high endothelial venules in mediating naive T cell entry into lymph nodes, a vital step for transplant acceptance under costimulatory blockade. The conjugate specifically targets a glycoprotein containing 6-sulfo sialyl Lewis X on these venules, which forms the binding site for L-selectin on naive T cells. This approach offers a novel mechanism to prevent immune rejection in heart transplant recipients.</p>
<p>Article number two. Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. In this observational study of up to 6598 participants, lipoprotein(a) and L. D. L. cholesterol were confirmed as causally linked to aortic valve calcium and aortic stenosis. The analysis found that aspirin use was not associated with incident aortic valve calcium or aortic stenosis. This lack of association held true regardless of baseline lipoprotein(a) or L. D. L. cholesterol levels. The data suggests that aspirin does not mitigate the risk of calcific aortic valve disease in individuals with high lipoprotein(a).</p>
<p>Article number three. Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO. This study described the temporal hemodynamic patterns observed in cardiogenic shock patients receiving either an isolated microaxial flow pump or combined therapy with venoarterial extracorporeal membrane oxygenation. Hemodynamic indices were analyzed from pre-device installation, post-installation, and 24 hours after, up to device explantation, using data from the U. N. L. O. A. D. E. R. S.-P. VAD Registry. The study characterized these hemodynamic trends for both treatment groups. Hospital survival was also analyzed in relation to these patterns, providing comparative data on mechanical circulatory support strategies in cardiogenic shock.</p>
<p>Article number four. Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial. A secondary analysis of the A. R. C. A. D. I. A. trial found that a prolonged Q. T. interval independently predicted an increased risk of recurrent stroke or systemic embolism in patients with cryptogenic stroke and atrial cardiopathy. This association held true for both the apixaban arm, with a hazard ratio of 1.70 (95 percent confidence interval 1.05-2.75), and the aspirin arm, showing a hazard ratio of 1.76 (95 percent confidence interval 1.05-2.95). The overall adjusted hazard ratio for this risk was 1.73 (95 percent confidence interval 1.25-2.38), with no significant interaction between Q. T. interval prolongation and treatment assignment (P value 0.95). This data demonstrates that prolonged Q. T. interval is an independent predictor of recurrent stroke regardless of antithrombotic treatment.</p>
<p>Article number five. Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy. This study identified electrocardiographic and echocardiographic predictors of acute stroke volume improvement with A. V.-optimized conduction system pacing in 19 symptomatic first-degree atrioventricular block patients. Electrocardiographic predictors included a Q. R. S. duration greater than or equal to 120 milliseconds, with an odds ratio of 17.5, and a prolonged P. R. interval, with an odds ratio of 1.05. Echocardiographic predictors encompassed a reduced left ventricular ejection fraction less than 50 percent, mechanical atrioventricular dyssynchrony, and left ventricular diastolic dysfunction, with odds ratios of 25.0, 20.0, and 15.0 respectively. These findings demonstrate that specific electrocardiogram and echocardiogram parameters can identify patients likely to acutely benefit from A. V.-optimized conduction system pacing for stroke volume improvement. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>venoarterial extracorporeal membrane oxygenation, calcific aortic valve disease, electrocardiogram, atrioventricular dyssynchrony, atrial cardiopathy, heart transplant, echocardiogram, aortic stenosis, conduction system pacing, first-degree atrioventricular block, cardiac allograft acceptance, cardiogenic shock, systemic embolism, lipoprotein(a), hemodynamic patterns, aortic valve calcium, recurrent stroke, mechanical circulatory support, antibody-drug conjugate, Q. T. interval prolongation, aspirin, apixaban, left ventricular ejection fraction, cryptogenic stroke, microaxial flow pump, stroke volume, T cell rejection, high endothelial venules.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/">Prolonged QT Elevates Recurrent Stroke Risk by 73% 02/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 21, 2026. This episode summarizes 5 key cardiology studies on topics like venoarterial extracorporeal membrane oxygenation and calcific aortic valve disease. Key takeaway: Prolonged QT Elevates Recurrent St]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 21, 2026. This episode summarizes 5 key cardiology studies on topics like venoarterial extracorporeal membrane oxygenation and calcific aortic valve disease. Key takeaway: Prolonged QT Elevates Recurrent Stroke Risk by 73%.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41717681">HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41721439">Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41720453">Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO.</a> (Journal of cardiac failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41720625">Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41711207">Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/">https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41717681" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41717681</a></p>
<p><strong>Summary:</strong> An antibody-drug conjugate targeting high endothelial venules in lymph nodes has been shown to promote long-term cardiac allograft acceptance. This therapeutic strategy leverages the crucial role of high endothelial venules in mediating naive T cell entry into lymph nodes, a vital step for transplant acceptance under costimulatory blockade. The conjugate specifically targets a glycoprotein containing 6-sulfo sialyl Lewis X on these venules, which forms the binding site for L-selectin on naive T cells. This approach offers a novel mechanism to prevent immune rejection in heart transplant recipients.</p>
<h4>Article 2: Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41721439" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41721439</a></p>
<p><strong>Summary:</strong> In this observational study of up to 6598 participants, lipoprotein(a) and L. D. L. cholesterol were confirmed as causally linked to aortic valve calcium and aortic stenosis. The analysis found that aspirin use was not associated with incident aortic valve calcium or aortic stenosis. This lack of association held true regardless of baseline lipoprotein(a) or L. D. L. cholesterol levels. The data suggests that aspirin does not mitigate the risk of calcific aortic valve disease in individuals with high lipoprotein(a).</p>
<h4>Article 3: Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41720453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41720453</a></p>
<p><strong>Summary:</strong> This study described the temporal hemodynamic patterns observed in cardiogenic shock patients receiving either an isolated microaxial flow pump or combined therapy with venoarterial extracorporeal membrane oxygenation. Hemodynamic indices were analyzed from pre-device installation, post-installation, and 24 hours after, up to device explantation, using data from the U. N. L. O. A. D. E. R. S.-P. VAD Registry. The study characterized these hemodynamic trends for both treatment groups. Hospital survival was also analyzed in relation to these patterns, providing comparative data on mechanical circulatory support strategies in cardiogenic shock.</p>
<h4>Article 4: Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41720625" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41720625</a></p>
<p><strong>Summary:</strong> A secondary analysis of the A. R. C. A. D. I. A. trial found that a prolonged Q. T. interval independently predicted an increased risk of recurrent stroke or systemic embolism in patients with cryptogenic stroke and atrial cardiopathy. This association held true for both the apixaban arm, with a hazard ratio of 1.70 (95 percent confidence interval 1.05-2.75), and the aspirin arm, showing a hazard ratio of 1.76 (95 percent confidence interval 1.05-2.95). The overall adjusted hazard ratio for this risk was 1.73 (95 percent confidence interval 1.25-2.38), with no significant interaction between Q. T. interval prolongation and treatment assignment (P value 0.95). This data demonstrates that prolonged Q. T. interval is an independent predictor of recurrent stroke regardless of antithrombotic treatment.</p>
<h4>Article 5: Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711207" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711207</a></p>
<p><strong>Summary:</strong> This study identified electrocardiographic and echocardiographic predictors of acute stroke volume improvement with A. V.-optimized conduction system pacing in 19 symptomatic first-degree atrioventricular block patients. Electrocardiographic predictors included a Q. R. S. duration greater than or equal to 120 milliseconds, with an odds ratio of 17.5, and a prolonged P. R. interval, with an odds ratio of 1.05. Echocardiographic predictors encompassed a reduced left ventricular ejection fraction less than 50 percent, mechanical atrioventricular dyssynchrony, and left ventricular diastolic dysfunction, with odds ratios of 25.0, 20.0, and 15.0 respectively. These findings demonstrate that specific electrocardiogram and echocardiogram parameters can identify patients likely to acutely benefit from A. V.-optimized conduction system pacing for stroke volume improvement.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. An antibody-drug conjugate targeting high endothelial venules in lymph nodes has been shown to promote long-term cardiac allograft acceptance. This therapeutic strategy leverages the crucial role of high endothelial venules in mediating naive T cell entry into lymph nodes, a vital step for transplant acceptance under costimulatory blockade. The conjugate specifically targets a glycoprotein containing 6-sulfo sialyl Lewis X on these venules, which forms the binding site for L-selectin on naive T cells. This approach offers a novel mechanism to prevent immune rejection in heart transplant recipients.</p>
<p>Article number two. Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. In this observational study of up to 6598 participants, lipoprotein(a) and L. D. L. cholesterol were confirmed as causally linked to aortic valve calcium and aortic stenosis. The analysis found that aspirin use was not associated with incident aortic valve calcium or aortic stenosis. This lack of association held true regardless of baseline lipoprotein(a) or L. D. L. cholesterol levels. The data suggests that aspirin does not mitigate the risk of calcific aortic valve disease in individuals with high lipoprotein(a).</p>
<p>Article number three. Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO. This study described the temporal hemodynamic patterns observed in cardiogenic shock patients receiving either an isolated microaxial flow pump or combined therapy with venoarterial extracorporeal membrane oxygenation. Hemodynamic indices were analyzed from pre-device installation, post-installation, and 24 hours after, up to device explantation, using data from the U. N. L. O. A. D. E. R. S.-P. VAD Registry. The study characterized these hemodynamic trends for both treatment groups. Hospital survival was also analyzed in relation to these patterns, providing comparative data on mechanical circulatory support strategies in cardiogenic shock.</p>
<p>Article number four. Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial. A secondary analysis of the A. R. C. A. D. I. A. trial found that a prolonged Q. T. interval independently predicted an increased risk of recurrent stroke or systemic embolism in patients with cryptogenic stroke and atrial cardiopathy. This association held true for both the apixaban arm, with a hazard ratio of 1.70 (95 percent confidence interval 1.05-2.75), and the aspirin arm, showing a hazard ratio of 1.76 (95 percent confidence interval 1.05-2.95). The overall adjusted hazard ratio for this risk was 1.73 (95 percent confidence interval 1.25-2.38), with no significant interaction between Q. T. interval prolongation and treatment assignment (P value 0.95). This data demonstrates that prolonged Q. T. interval is an independent predictor of recurrent stroke regardless of antithrombotic treatment.</p>
<p>Article number five. Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy. This study identified electrocardiographic and echocardiographic predictors of acute stroke volume improvement with A. V.-optimized conduction system pacing in 19 symptomatic first-degree atrioventricular block patients. Electrocardiographic predictors included a Q. R. S. duration greater than or equal to 120 milliseconds, with an odds ratio of 17.5, and a prolonged P. R. interval, with an odds ratio of 1.05. Echocardiographic predictors encompassed a reduced left ventricular ejection fraction less than 50 percent, mechanical atrioventricular dyssynchrony, and left ventricular diastolic dysfunction, with odds ratios of 25.0, 20.0, and 15.0 respectively. These findings demonstrate that specific electrocardiogram and echocardiogram parameters can identify patients likely to acutely benefit from A. V.-optimized conduction system pacing for stroke volume improvement. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>venoarterial extracorporeal membrane oxygenation, calcific aortic valve disease, electrocardiogram, atrioventricular dyssynchrony, atrial cardiopathy, heart transplant, echocardiogram, aortic stenosis, conduction system pacing, first-degree atrioventricular block, cardiac allograft acceptance, cardiogenic shock, systemic embolism, lipoprotein(a), hemodynamic patterns, aortic valve calcium, recurrent stroke, mechanical circulatory support, antibody-drug conjugate, Q. T. interval prolongation, aspirin, apixaban, left ventricular ejection fraction, cryptogenic stroke, microaxial flow pump, stroke volume, T cell rejection, high endothelial venules.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/">Prolonged QT Elevates Recurrent Stroke Risk by 73% 02/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260221_060041.mp3" length="5361832" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 21, 2026. This episode summarizes 5 key cardiology studies on topics like venoarterial extracorporeal membrane oxygenation and calcific aortic valve disease. Key takeaway: Prolonged QT Elevates Recurrent Stroke Risk by 73%.
Article Links:
Article 1: HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. (Circulation)
Article 2: Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. (European heart journal)
Article 3: Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO. (Journal of cardiac failure)
Article 4: Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial. (Heart (British Cardiac Society))
Article 5: Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patients with AV Dromotropathy. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/prolonged-qt-elevates-recurrent-stroke-risk-by-73-02-21-26/
 Featured Articles
Article 1: HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717681
Summary: An antibody-drug conjugate targeting high endothelial venules in lymph nodes has been shown to promote long-term cardiac allograft acceptance. This therapeutic strategy leverages the crucial role of high endothelial venules in mediating naive T cell entry into lymph nodes, a vital step for transplant acceptance under costimulatory blockade. The conjugate specifically targets a glycoprotein containing 6-sulfo sialyl Lewis X on these venules, which forms the binding site for L-selectin on naive T cells. This approach offers a novel mechanism to prevent immune rejection in heart transplant recipients.
Article 2: Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41721439
Summary: In this observational study of up to 6598 participants, lipoprotein(a) and L. D. L. cholesterol were confirmed as causally linked to aortic valve calcium and aortic stenosis. The analysis found that aspirin use was not associated with incident aortic valve calcium or aortic stenosis. This lack of association held true regardless of baseline lipoprotein(a) or L. D. L. cholesterol levels. The data suggests that aspirin does not mitigate the risk of calcific aortic valve disease in individuals with high lipoprotein(a).
Article 3: Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41720453
Summary: This study described the temporal hemodynamic patterns observed in cardiogenic shock patients receiving either an isolated microaxial flow pump or combined therapy with venoarterial extracorporeal membrane oxygenation. Hemodynamic indices were analyzed from pre-device installation, post-installation, and 24 hours after, up to device explantation, using data from the U. N. L. O. A. D. E. R. S.-P. VAD Registry. The study characterized these hemodynamic trends for both treatment groups. Hospital survival was also analyzed in relation to these patterns, providing comparative data on mechanical circulatory support strategies in cardiogenic shock.
Article 4: Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41720625
Summary: A secondary analysis of the A. R. C. A. D. I. A. trial found that a prolonged Q. T. interval independently predicted an increased risk of recurren]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 21, 2026. This episode summarizes 5 key cardiology studies on topics like venoarterial extracorporeal membrane oxygenation and calcific aortic valve disease. Key takeaway: Prolonged QT Elevates Recurrent Stroke Risk by 73%.
Article Links:
Article 1: HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. (Circulation)
Article 2: Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. (European heart journal)
Article 3: Temporal Hemodynamic Patterns in Cardiogenic Shock Treated with Isolated PVAD and Combined Therapy with VA-ECMO. (Journal of cardiac failure)
Article 4: Prolonged QT interval and risk of recurrent stroke in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial. (Heart (British Cardiac Society))
Article 5: Predictors of Stroke Volume Improvement with AV-Optimised Conduction System Pacing in Patie]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>N. L. R. Trajectory Guides Heart Failure Risk 02/20/26</title>
	<link>https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/</link>
	<pubDate>Fri, 20 Feb 2026 11:01:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 20, 2026. This episode summarizes 5 key cardiology studies on topics like acute decompensated heart failure and prostate cancer. Key takeaway: N. L. R. Trajectory Guides Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41705661">Tropical cyclones and acute coronary syndromes: a Chinese nationwide study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41713791">Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41706486">Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41706460">Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41711242">Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/">https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Tropical cyclones and acute coronary syndromes: a Chinese nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41705661" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41705661</a></p>
<p><strong>Summary:</strong> The association between tropical cyclone exposure and acute coronary syndrome incidence is a critical area of cardiovascular research, particularly within developing nations such as China. This line of inquiry demonstrates that environmental stressors are important, albeit understudied, contributors to acute coronary syndromes. Understanding these links provides a framework for developing targeted public health interventions and early warning systems in vulnerable regions. This research highlights the clinical importance of considering environmental factors in cardiovascular event prediction.</p>
<h4>Article 2: Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41713791" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41713791</a></p>
<p><strong>Summary:</strong> Group decision-making in solid organ transplant is critical for complex, high-stakes decisions, improving quality by pooling information and minimizing individual cognitive biases. However, this process can lead to poor outcomes if not properly implemented, especially given that many health professionals lack formal training in such methodologies. Effective group decision-making requires structured approaches to ensure justness and validity, thereby enhancing patient and societal outcomes. This underscores the need for formalized training in transplant decision protocols.</p>
<h4>Article 3: Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706486</a></p>
<p><strong>Summary:</strong> Androgen deprivation therapy for men with prostate cancer carries a significant association with cardiovascular morbidity. A key clinical question revolves around whether gonadotropin-releasing hormone agonists or antagonists differ in their impact on coronary atherosclerosis progression. This area of research demonstrates concerns about accelerated coronary atherosclerosis in patients receiving androgen deprivation therapy. Understanding these differential effects is crucial for optimizing treatment strategies and mitigating cardiovascular risks in this patient population.</p>
<h4>Article 4: Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706460" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706460</a></p>
<p><strong>Summary:</strong> Pregnancy serves as a natural and informative cardiovascular stress test, offering a crucial window to assess a woman&#8217;s long-term cardiovascular disease risk. Clinical measures and biomarkers obtained during pregnancy have demonstrated potential in identifying women at elevated risk for future cardiovascular disease. Leveraging these insights from pregnancy encounters can inform tailored risk stratification and preventive strategies for women globally. This approach offers a novel pathway for early identification and intervention to mitigate the leading cause of death among women.</p>
<h4>Article 5: Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711242" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711242</a></p>
<p><strong>Summary:</strong> The neutrophil-to-lymphocyte ratio, or N. L. R., and its in-hospital trajectory were comprehensively assessed as predictors of 30-day outcomes after acute decompensated heart failure hospitalization. This retrospective cohort study of 6784 discharges confirmed the prognostic value of discharge N. L. R., classified as less than 5 versus 5 or greater. Results showed that the N. L. R. trajectory during hospitalization provided critical insights into patient risk beyond just the admission measurement. This demonstrates the N. L. R. is a valuable biomarker for refining risk stratification and guiding care in acute heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Tropical cyclones and acute coronary syndromes: a Chinese nationwide study. The association between tropical cyclone exposure and acute coronary syndrome incidence is a critical area of cardiovascular research, particularly within developing nations such as China. This line of inquiry demonstrates that environmental stressors are important, albeit understudied, contributors to acute coronary syndromes. Understanding these links provides a framework for developing targeted public health interventions and early warning systems in vulnerable regions. This research highlights the clinical importance of considering environmental factors in cardiovascular event prediction.</p>
<p>Article number two. Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant. Group decision-making in solid organ transplant is critical for complex, high-stakes decisions, improving quality by pooling information and minimizing individual cognitive biases. However, this process can lead to poor outcomes if not properly implemented, especially given that many health professionals lack formal training in such methodologies. Effective group decision-making requires structured approaches to ensure justness and validity, thereby enhancing patient and societal outcomes. This underscores the need for formalized training in transplant decision protocols.</p>
<p>Article number three. Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. Androgen deprivation therapy for men with prostate cancer carries a significant association with cardiovascular morbidity. A key clinical question revolves around whether gonadotropin-releasing hormone agonists or antagonists differ in their impact on coronary atherosclerosis progression. This area of research demonstrates concerns about accelerated coronary atherosclerosis in patients receiving androgen deprivation therapy. Understanding these differential effects is crucial for optimizing treatment strategies and mitigating cardiovascular risks in this patient population.</p>
<p>Article number four. Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease. Pregnancy serves as a natural and informative cardiovascular stress test, offering a crucial window to assess a woman&#8217;s long-term cardiovascular disease risk. Clinical measures and biomarkers obtained during pregnancy have demonstrated potential in identifying women at elevated risk for future cardiovascular disease. Leveraging these insights from pregnancy encounters can inform tailored risk stratification and preventive strategies for women globally. This approach offers a novel pathway for early identification and intervention to mitigate the leading cause of death among women.</p>
<p>Article number five. Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure. The neutrophil-to-lymphocyte ratio, or N. L. R., and its in-hospital trajectory were comprehensively assessed as predictors of 30-day outcomes after acute decompensated heart failure hospitalization. This retrospective cohort study of 6784 discharges confirmed the prognostic value of discharge N. L. R., classified as less than 5 versus 5 or greater. Results showed that the N. L. R. trajectory during hospitalization provided critical insights into patient risk beyond just the admission measurement. This demonstrates the N. L. R. is a valuable biomarker for refining risk stratification and guiding care in acute heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute decompensated heart failure, prostate cancer, androgen deprivation therapy, group decision-making, gonadotropin-releasing hormone agonists, cardiovascular morbidity, cardiovascular risk, women&#8217;s health, neutrophil-to-lymphocyte ratio, health professional training, risk stratification, acute coronary syndrome, coronary atherosclerosis, cognitive bias, solid organ transplant, cardiovascular disease, tropical cyclones, 30-day outcomes, China, biomarkers, environmental factors, pregnancy, decision quality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/">N. L. R. Trajectory Guides Heart Failure Risk 02/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 20, 2026. This episode summarizes 5 key cardiology studies on topics like acute decompensated heart failure and prostate cancer. Key takeaway: N. L. R. Trajectory Guides Heart Failure Risk.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 20, 2026. This episode summarizes 5 key cardiology studies on topics like acute decompensated heart failure and prostate cancer. Key takeaway: N. L. R. Trajectory Guides Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41705661">Tropical cyclones and acute coronary syndromes: a Chinese nationwide study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41713791">Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41706486">Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41706460">Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41711242">Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/">https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Tropical cyclones and acute coronary syndromes: a Chinese nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41705661" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41705661</a></p>
<p><strong>Summary:</strong> The association between tropical cyclone exposure and acute coronary syndrome incidence is a critical area of cardiovascular research, particularly within developing nations such as China. This line of inquiry demonstrates that environmental stressors are important, albeit understudied, contributors to acute coronary syndromes. Understanding these links provides a framework for developing targeted public health interventions and early warning systems in vulnerable regions. This research highlights the clinical importance of considering environmental factors in cardiovascular event prediction.</p>
<h4>Article 2: Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41713791" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41713791</a></p>
<p><strong>Summary:</strong> Group decision-making in solid organ transplant is critical for complex, high-stakes decisions, improving quality by pooling information and minimizing individual cognitive biases. However, this process can lead to poor outcomes if not properly implemented, especially given that many health professionals lack formal training in such methodologies. Effective group decision-making requires structured approaches to ensure justness and validity, thereby enhancing patient and societal outcomes. This underscores the need for formalized training in transplant decision protocols.</p>
<h4>Article 3: Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706486</a></p>
<p><strong>Summary:</strong> Androgen deprivation therapy for men with prostate cancer carries a significant association with cardiovascular morbidity. A key clinical question revolves around whether gonadotropin-releasing hormone agonists or antagonists differ in their impact on coronary atherosclerosis progression. This area of research demonstrates concerns about accelerated coronary atherosclerosis in patients receiving androgen deprivation therapy. Understanding these differential effects is crucial for optimizing treatment strategies and mitigating cardiovascular risks in this patient population.</p>
<h4>Article 4: Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706460" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706460</a></p>
<p><strong>Summary:</strong> Pregnancy serves as a natural and informative cardiovascular stress test, offering a crucial window to assess a woman&#8217;s long-term cardiovascular disease risk. Clinical measures and biomarkers obtained during pregnancy have demonstrated potential in identifying women at elevated risk for future cardiovascular disease. Leveraging these insights from pregnancy encounters can inform tailored risk stratification and preventive strategies for women globally. This approach offers a novel pathway for early identification and intervention to mitigate the leading cause of death among women.</p>
<h4>Article 5: Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711242" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711242</a></p>
<p><strong>Summary:</strong> The neutrophil-to-lymphocyte ratio, or N. L. R., and its in-hospital trajectory were comprehensively assessed as predictors of 30-day outcomes after acute decompensated heart failure hospitalization. This retrospective cohort study of 6784 discharges confirmed the prognostic value of discharge N. L. R., classified as less than 5 versus 5 or greater. Results showed that the N. L. R. trajectory during hospitalization provided critical insights into patient risk beyond just the admission measurement. This demonstrates the N. L. R. is a valuable biomarker for refining risk stratification and guiding care in acute heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Tropical cyclones and acute coronary syndromes: a Chinese nationwide study. The association between tropical cyclone exposure and acute coronary syndrome incidence is a critical area of cardiovascular research, particularly within developing nations such as China. This line of inquiry demonstrates that environmental stressors are important, albeit understudied, contributors to acute coronary syndromes. Understanding these links provides a framework for developing targeted public health interventions and early warning systems in vulnerable regions. This research highlights the clinical importance of considering environmental factors in cardiovascular event prediction.</p>
<p>Article number two. Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant. Group decision-making in solid organ transplant is critical for complex, high-stakes decisions, improving quality by pooling information and minimizing individual cognitive biases. However, this process can lead to poor outcomes if not properly implemented, especially given that many health professionals lack formal training in such methodologies. Effective group decision-making requires structured approaches to ensure justness and validity, thereby enhancing patient and societal outcomes. This underscores the need for formalized training in transplant decision protocols.</p>
<p>Article number three. Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. Androgen deprivation therapy for men with prostate cancer carries a significant association with cardiovascular morbidity. A key clinical question revolves around whether gonadotropin-releasing hormone agonists or antagonists differ in their impact on coronary atherosclerosis progression. This area of research demonstrates concerns about accelerated coronary atherosclerosis in patients receiving androgen deprivation therapy. Understanding these differential effects is crucial for optimizing treatment strategies and mitigating cardiovascular risks in this patient population.</p>
<p>Article number four. Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease. Pregnancy serves as a natural and informative cardiovascular stress test, offering a crucial window to assess a woman&#8217;s long-term cardiovascular disease risk. Clinical measures and biomarkers obtained during pregnancy have demonstrated potential in identifying women at elevated risk for future cardiovascular disease. Leveraging these insights from pregnancy encounters can inform tailored risk stratification and preventive strategies for women globally. This approach offers a novel pathway for early identification and intervention to mitigate the leading cause of death among women.</p>
<p>Article number five. Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure. The neutrophil-to-lymphocyte ratio, or N. L. R., and its in-hospital trajectory were comprehensively assessed as predictors of 30-day outcomes after acute decompensated heart failure hospitalization. This retrospective cohort study of 6784 discharges confirmed the prognostic value of discharge N. L. R., classified as less than 5 versus 5 or greater. Results showed that the N. L. R. trajectory during hospitalization provided critical insights into patient risk beyond just the admission measurement. This demonstrates the N. L. R. is a valuable biomarker for refining risk stratification and guiding care in acute heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute decompensated heart failure, prostate cancer, androgen deprivation therapy, group decision-making, gonadotropin-releasing hormone agonists, cardiovascular morbidity, cardiovascular risk, women&#8217;s health, neutrophil-to-lymphocyte ratio, health professional training, risk stratification, acute coronary syndrome, coronary atherosclerosis, cognitive bias, solid organ transplant, cardiovascular disease, tropical cyclones, 30-day outcomes, China, biomarkers, environmental factors, pregnancy, decision quality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/">N. L. R. Trajectory Guides Heart Failure Risk 02/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260220_060036.mp3" length="4004301" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 20, 2026. This episode summarizes 5 key cardiology studies on topics like acute decompensated heart failure and prostate cancer. Key takeaway: N. L. R. Trajectory Guides Heart Failure Risk.
Article Links:
Article 1: Tropical cyclones and acute coronary syndromes: a Chinese nationwide study. (European heart journal)
Article 2: Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. (JAMA cardiology)
Article 4: Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease. (JAMA cardiology)
Article 5: Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes in Acute Heart Failure. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/n-l-r-trajectory-guides-heart-failure-risk-02-20-26/
 Featured Articles
Article 1: Tropical cyclones and acute coronary syndromes: a Chinese nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41705661
Summary: The association between tropical cyclone exposure and acute coronary syndrome incidence is a critical area of cardiovascular research, particularly within developing nations such as China. This line of inquiry demonstrates that environmental stressors are important, albeit understudied, contributors to acute coronary syndromes. Understanding these links provides a framework for developing targeted public health interventions and early warning systems in vulnerable regions. This research highlights the clinical importance of considering environmental factors in cardiovascular event prediction.
Article 2: Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41713791
Summary: Group decision-making in solid organ transplant is critical for complex, high-stakes decisions, improving quality by pooling information and minimizing individual cognitive biases. However, this process can lead to poor outcomes if not properly implemented, especially given that many health professionals lack formal training in such methodologies. Effective group decision-making requires structured approaches to ensure justness and validity, thereby enhancing patient and societal outcomes. This underscores the need for formalized training in transplant decision protocols.
Article 3: Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41706486
Summary: Androgen deprivation therapy for men with prostate cancer carries a significant association with cardiovascular morbidity. A key clinical question revolves around whether gonadotropin-releasing hormone agonists or antagonists differ in their impact on coronary atherosclerosis progression. This area of research demonstrates concerns about accelerated coronary atherosclerosis in patients receiving androgen deprivation therapy. Understanding these differential effects is crucial for optimizing treatment strategies and mitigating cardiovascular risks in this patient population.
Article 4: Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41706460
Summary: Pregnancy serves as a natural and informative cardiovascular stress test, offering a crucial window to assess a woman&#8217;s long-term card]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 20, 2026. This episode summarizes 5 key cardiology studies on topics like acute decompensated heart failure and prostate cancer. Key takeaway: N. L. R. Trajectory Guides Heart Failure Risk.
Article Links:
Article 1: Tropical cyclones and acute coronary syndromes: a Chinese nationwide study. (European heart journal)
Article 2: Wisdom of the Crowd: Ensuring the Justness and Validity of Group Decision-Making in Solid Organ Transplant. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. (JAMA cardiology)
Article 4: Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease. (JAMA cardiology)
Article 5: Discharge Neutrophil-to-Lymphocyte Ratio and Its Trajectory as Predictors of 30-Day Outcomes]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Sex Impacts Microaxial Pump Outcomes in Shock 02/19/26</title>
	<link>https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/</link>
	<pubDate>Fri, 20 Feb 2026 02:12:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like interventricular septum and right bundle branch block. Key takeaway: Sex Impacts Microaxial Pump Outcomes in Shock.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41222528">Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41712366">Post-certification competencies and cardiovascular care delivery.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41712363">Conduction disturbances after transcatheter aortic valve implantation.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41711546">Delirium in cardiovascular medicine.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41711522">Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/">https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41222528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41222528</a></p>
<p><strong>Summary:</strong> The DanGer Shock trial found that microaxial flow pump use improved outcomes in selected patients with S. T. elevation myocardial infarction and cardiogenic shock. However, the beneficial effect of the microaxial flow pump was observed to be less evident in women compared with men. This secondary analysis determined significant sex differences in baseline characteristics, in-hospital course, and the effectiveness of the microaxial flow pump in S. T. elevation myocardial infarction with cardiogenic shock. This highlights a critical disparity in treatment efficacy based on patient sex.</p>
<h4>Article 2: Post-certification competencies and cardiovascular care delivery.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41712366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41712366</a></p>
<p><strong>Summary:</strong> This analysis emphasizes that while cardiologists achieve core cardiovascular competencies, ongoing training, assessment, and maintenance of post-certification competencies are crucial for effective practice. It shows cardiologists must function as part of a comprehensive multidisciplinary Heart Team across the full spectrum of cardiovascular care. This continuous professional development ensures optimal patient outcomes in the dynamic field of cardiology. These findings reinforce the necessity of lifelong learning beyond initial certification.</p>
<h4>Article 3: Conduction disturbances after transcatheter aortic valve implantation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41712363" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41712363</a></p>
<p><strong>Summary:</strong> Conduction disturbances and permanent pacemaker implantation are among the most common complications observed after transcatheter aortic valve implantation. Studies show that the strongest predictors of these conduction abnormalities include pre-existing right bundle branch block, a short membranous interventricular septum, deep transcatheter heart valve implantation, and the specific transcatheter heart valve type. These findings highlight critical patient and procedural characteristics that significantly influence post-procedural electrical outcomes.</p>
<h4>Article 4: Delirium in cardiovascular medicine.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711546" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711546</a></p>
<p><strong>Summary:</strong> Delirium is a common neuropsychiatric syndrome frequently observed in cardiovascular medicine, which studies show is associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures, such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions, are particularly vulnerable to its development. These findings underscore the significant impact of delirium on patient outcomes and identify high-risk populations.</p>
<h4>Article 5: Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711522</a></p>
<p><strong>Summary:</strong> Drug-coated balloons have demonstrated efficacy as an alternative to drug-eluting stents in percutaneous coronary interventions, particularly favored for their &#8220;leave nothing behind&#8221; approach. Recent clinical evidence supports the effectiveness of drug-coated balloons in treating both small vessel disease and bifurcation lesions. This indicates that drug-coated balloons provide a significant therapeutic option for specific coronary artery disease subsets.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial. The DanGer Shock trial found that microaxial flow pump use improved outcomes in selected patients with S. T. elevation myocardial infarction and cardiogenic shock. However, the beneficial effect of the microaxial flow pump was observed to be less evident in women compared with men. This secondary analysis determined significant sex differences in baseline characteristics, in-hospital course, and the effectiveness of the microaxial flow pump in S. T. elevation myocardial infarction with cardiogenic shock. This highlights a critical disparity in treatment efficacy based on patient sex.</p>
<p>Article number two. Post-certification competencies and cardiovascular care delivery. This analysis emphasizes that while cardiologists achieve core cardiovascular competencies, ongoing training, assessment, and maintenance of post-certification competencies are crucial for effective practice. It shows cardiologists must function as part of a comprehensive multidisciplinary Heart Team across the full spectrum of cardiovascular care. This continuous professional development ensures optimal patient outcomes in the dynamic field of cardiology. These findings reinforce the necessity of lifelong learning beyond initial certification.</p>
<p>Article number three. Conduction disturbances after transcatheter aortic valve implantation. Conduction disturbances and permanent pacemaker implantation are among the most common complications observed after transcatheter aortic valve implantation. Studies show that the strongest predictors of these conduction abnormalities include pre-existing right bundle branch block, a short membranous interventricular septum, deep transcatheter heart valve implantation, and the specific transcatheter heart valve type. These findings highlight critical patient and procedural characteristics that significantly influence post-procedural electrical outcomes.</p>
<p>Article number four. Delirium in cardiovascular medicine. Delirium is a common neuropsychiatric syndrome frequently observed in cardiovascular medicine, which studies show is associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures, such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions, are particularly vulnerable to its development. These findings underscore the significant impact of delirium on patient outcomes and identify high-risk populations.</p>
<p>Article number five. Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis. Drug-coated balloons have demonstrated efficacy as an alternative to drug-eluting stents in percutaneous coronary interventions, particularly favored for their &#8220;leave nothing behind&#8221; approach. Recent clinical evidence supports the effectiveness of drug-coated balloons in treating both small vessel disease and bifurcation lesions. This indicates that drug-coated balloons provide a significant therapeutic option for specific coronary artery disease subsets. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>interventricular septum, right bundle branch block, small vessel disease, cardiovascular care, multidisciplinary approach, cardiologist competencies, drug-coated balloons, conduction disturbances, S. T. elevation myocardial infarction, transcatheter aortic valve replacement, sex differences, cognitive decline, cardiogenic shock, transcatheter aortic valve implantation, drug-eluting stents, post-certification training, cardiovascular medicine, prolonged hospitalization, in-stent restenosis, percutaneous coronary intervention, permanent pacemaker implantation, delirium, microaxial flow pump, Heart Team, DanGer Shock Trial, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/">Sex Impacts Microaxial Pump Outcomes in Shock 02/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like interventricular septum and right bundle branch block. Key takeaway: Sex Impacts Microaxial Pump Outcomes in Shock.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like interventricular septum and right bundle branch block. Key takeaway: Sex Impacts Microaxial Pump Outcomes in Shock.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41222528">Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41712366">Post-certification competencies and cardiovascular care delivery.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41712363">Conduction disturbances after transcatheter aortic valve implantation.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41711546">Delirium in cardiovascular medicine.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41711522">Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/">https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41222528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41222528</a></p>
<p><strong>Summary:</strong> The DanGer Shock trial found that microaxial flow pump use improved outcomes in selected patients with S. T. elevation myocardial infarction and cardiogenic shock. However, the beneficial effect of the microaxial flow pump was observed to be less evident in women compared with men. This secondary analysis determined significant sex differences in baseline characteristics, in-hospital course, and the effectiveness of the microaxial flow pump in S. T. elevation myocardial infarction with cardiogenic shock. This highlights a critical disparity in treatment efficacy based on patient sex.</p>
<h4>Article 2: Post-certification competencies and cardiovascular care delivery.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41712366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41712366</a></p>
<p><strong>Summary:</strong> This analysis emphasizes that while cardiologists achieve core cardiovascular competencies, ongoing training, assessment, and maintenance of post-certification competencies are crucial for effective practice. It shows cardiologists must function as part of a comprehensive multidisciplinary Heart Team across the full spectrum of cardiovascular care. This continuous professional development ensures optimal patient outcomes in the dynamic field of cardiology. These findings reinforce the necessity of lifelong learning beyond initial certification.</p>
<h4>Article 3: Conduction disturbances after transcatheter aortic valve implantation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41712363" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41712363</a></p>
<p><strong>Summary:</strong> Conduction disturbances and permanent pacemaker implantation are among the most common complications observed after transcatheter aortic valve implantation. Studies show that the strongest predictors of these conduction abnormalities include pre-existing right bundle branch block, a short membranous interventricular septum, deep transcatheter heart valve implantation, and the specific transcatheter heart valve type. These findings highlight critical patient and procedural characteristics that significantly influence post-procedural electrical outcomes.</p>
<h4>Article 4: Delirium in cardiovascular medicine.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711546" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711546</a></p>
<p><strong>Summary:</strong> Delirium is a common neuropsychiatric syndrome frequently observed in cardiovascular medicine, which studies show is associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures, such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions, are particularly vulnerable to its development. These findings underscore the significant impact of delirium on patient outcomes and identify high-risk populations.</p>
<h4>Article 5: Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41711522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41711522</a></p>
<p><strong>Summary:</strong> Drug-coated balloons have demonstrated efficacy as an alternative to drug-eluting stents in percutaneous coronary interventions, particularly favored for their &#8220;leave nothing behind&#8221; approach. Recent clinical evidence supports the effectiveness of drug-coated balloons in treating both small vessel disease and bifurcation lesions. This indicates that drug-coated balloons provide a significant therapeutic option for specific coronary artery disease subsets.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial. The DanGer Shock trial found that microaxial flow pump use improved outcomes in selected patients with S. T. elevation myocardial infarction and cardiogenic shock. However, the beneficial effect of the microaxial flow pump was observed to be less evident in women compared with men. This secondary analysis determined significant sex differences in baseline characteristics, in-hospital course, and the effectiveness of the microaxial flow pump in S. T. elevation myocardial infarction with cardiogenic shock. This highlights a critical disparity in treatment efficacy based on patient sex.</p>
<p>Article number two. Post-certification competencies and cardiovascular care delivery. This analysis emphasizes that while cardiologists achieve core cardiovascular competencies, ongoing training, assessment, and maintenance of post-certification competencies are crucial for effective practice. It shows cardiologists must function as part of a comprehensive multidisciplinary Heart Team across the full spectrum of cardiovascular care. This continuous professional development ensures optimal patient outcomes in the dynamic field of cardiology. These findings reinforce the necessity of lifelong learning beyond initial certification.</p>
<p>Article number three. Conduction disturbances after transcatheter aortic valve implantation. Conduction disturbances and permanent pacemaker implantation are among the most common complications observed after transcatheter aortic valve implantation. Studies show that the strongest predictors of these conduction abnormalities include pre-existing right bundle branch block, a short membranous interventricular septum, deep transcatheter heart valve implantation, and the specific transcatheter heart valve type. These findings highlight critical patient and procedural characteristics that significantly influence post-procedural electrical outcomes.</p>
<p>Article number four. Delirium in cardiovascular medicine. Delirium is a common neuropsychiatric syndrome frequently observed in cardiovascular medicine, which studies show is associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures, such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions, are particularly vulnerable to its development. These findings underscore the significant impact of delirium on patient outcomes and identify high-risk populations.</p>
<p>Article number five. Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis. Drug-coated balloons have demonstrated efficacy as an alternative to drug-eluting stents in percutaneous coronary interventions, particularly favored for their &#8220;leave nothing behind&#8221; approach. Recent clinical evidence supports the effectiveness of drug-coated balloons in treating both small vessel disease and bifurcation lesions. This indicates that drug-coated balloons provide a significant therapeutic option for specific coronary artery disease subsets. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>interventricular septum, right bundle branch block, small vessel disease, cardiovascular care, multidisciplinary approach, cardiologist competencies, drug-coated balloons, conduction disturbances, S. T. elevation myocardial infarction, transcatheter aortic valve replacement, sex differences, cognitive decline, cardiogenic shock, transcatheter aortic valve implantation, drug-eluting stents, post-certification training, cardiovascular medicine, prolonged hospitalization, in-stent restenosis, percutaneous coronary intervention, permanent pacemaker implantation, delirium, microaxial flow pump, Heart Team, DanGer Shock Trial, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/">Sex Impacts Microaxial Pump Outcomes in Shock 02/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260219_211204.mp3" length="3677038" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like interventricular septum and right bundle branch block. Key takeaway: Sex Impacts Microaxial Pump Outcomes in Shock.
Article Links:
Article 1: Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial. (Journal of the American College of Cardiology)
Article 2: Post-certification competencies and cardiovascular care delivery. (European heart journal)
Article 3: Conduction disturbances after transcatheter aortic valve implantation. (European heart journal)
Article 4: Delirium in cardiovascular medicine. (European heart journal)
Article 5: Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/
 Featured Articles
Article 1: Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222528
Summary: The DanGer Shock trial found that microaxial flow pump use improved outcomes in selected patients with S. T. elevation myocardial infarction and cardiogenic shock. However, the beneficial effect of the microaxial flow pump was observed to be less evident in women compared with men. This secondary analysis determined significant sex differences in baseline characteristics, in-hospital course, and the effectiveness of the microaxial flow pump in S. T. elevation myocardial infarction with cardiogenic shock. This highlights a critical disparity in treatment efficacy based on patient sex.
Article 2: Post-certification competencies and cardiovascular care delivery.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41712366
Summary: This analysis emphasizes that while cardiologists achieve core cardiovascular competencies, ongoing training, assessment, and maintenance of post-certification competencies are crucial for effective practice. It shows cardiologists must function as part of a comprehensive multidisciplinary Heart Team across the full spectrum of cardiovascular care. This continuous professional development ensures optimal patient outcomes in the dynamic field of cardiology. These findings reinforce the necessity of lifelong learning beyond initial certification.
Article 3: Conduction disturbances after transcatheter aortic valve implantation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41712363
Summary: Conduction disturbances and permanent pacemaker implantation are among the most common complications observed after transcatheter aortic valve implantation. Studies show that the strongest predictors of these conduction abnormalities include pre-existing right bundle branch block, a short membranous interventricular septum, deep transcatheter heart valve implantation, and the specific transcatheter heart valve type. These findings highlight critical patient and procedural characteristics that significantly influence post-procedural electrical outcomes.
Article 4: Delirium in cardiovascular medicine.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41711546
Summary: Delirium is a common neuropsychiatric syndrome frequently observed in cardiovascular medicine, which studies show is associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures, such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions, are particularly vulnerable to its development. These findings underscore the significant impact of delirium on patient outcomes an]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like interventricular septum and right bundle branch block. Key takeaway: Sex Impacts Microaxial Pump Outcomes in Shock.
Article Links:
Article 1: Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial. (Journal of the American College of Cardiology)
Article 2: Post-certification competencies and cardiovascular care delivery. (European heart journal)
Article 3: Conduction disturbances after transcatheter aortic valve implantation. (European heart journal)
Article 4: Delirium in cardiovascular medicine. (European heart journal)
Article 5: Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/sex-impacts-microaxial-pump-outcomes-in-shock-02-19-26/
 Featured Articles
Article 1: S]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Sirolimus Balloon Challenges Paclitaxel Mortality 02/19/26</title>
	<link>https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/</link>
	<pubDate>Thu, 19 Feb 2026 11:01:47 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like mind-body exercise and older adults. Key takeaway: Sirolimus Balloon Challenges Paclitaxel Mortality.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41706076">Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41706075">Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41706074">Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41706073">Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532932">Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/">https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706076" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706076</a></p>
<p><strong>Summary:</strong> Paclitaxel-coated balloon angioplasty effectively treats femoropopliteal artery disease; however, an increased mortality risk associated with it remains unresolved. Sirolimus-coated balloon angioplasty offers an alternative antiproliferative drug approach for these interventions. The SIRONA randomized noninferiority trial evaluated sirolimus-coated balloon angioplasty against paclitaxel-coated balloon angioplasty. This comparison determines if sirolimus-coated balloons achieve noninferior primary vessel patency and clinical efficacy with an improved safety profile.</p>
<h4>Article 2: Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706075" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706075</a></p>
<p><strong>Summary:</strong> Achieving sustained blood pressure lowering with traditional lifestyle guidance and exercise presents a challenge for individuals with high-normal blood pressure. Baduanjin, a traditional Chinese mind-body exercise, serves as a non-pharmacological therapeutic approach under investigation for this population. A multicenter, open-label, blinded-outcome randomized controlled trial assessed Baduanjin&#8217;s short-term impact on ambulatory blood pressure and its long-term effects. This study evaluated participants aged 40 years or older who presented with systolic blood pressure of 130 to 139 mmHg or diastolic blood pressure of 85 mmHg or higher.</p>
<h4>Article 3: Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706074" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706074</a></p>
<p><strong>Summary:</strong> M. 2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. Intensifying wildfires in a warming climate result in prolonged exposure to smoke-derived fine particulate matter (P. M. 2.5), which poses significant health risks. The cardiovascular impacts of long-term cumulative exposure to wildfire smoke P. M. 2.5, particularly in older adults, represent an area of critical clinical investigation. This population-based cohort study analyzed associations between long-term cumulative exposure to wildfire smoke P. M. 2.5 and first cardiovascular disease hospitalizations. The research focused on U.S. Medicare beneficiaries, examining the effects on cardiovascular health in this vulnerable population.</p>
<h4>Article 4: Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706073</a></p>
<p><strong>Summary:</strong> R. With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort. Recurrent mitral regurgitation degree serves as a key indicator for the quality of mitral valve repair for degenerative mitral regurgitation. This multicenter study evaluated 2-year survival and mitral regurgitation recurrence following mitral valve repair in patients with degenerative mitral regurgitation and moderate or less concomitant tricuspid regurgitation. The research utilized echocardiographic core laboratory-adjudicated data from a cohort of patients who underwent repair between 2016 and 2018. This analysis established long-term outcomes of mitral valve repair in this specific patient group.</p>
<h4>Article 5: Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532932" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532932</a></p>
<p><strong>Summary:</strong> Breast cancer chemotherapy elevates cardiovascular risk, with a notable impact on postmenopausal women. While vascular damage, endothelial dysfunction, and oxidative stress are implicated, the precise role of menopausal status in these vascular mechanisms remains unknown. This study investigated the potential protective role of estrogens in premenopausal women against neoadjuvant chemotherapy-induced endothelial dysfunction, specifically focusing on the vascular effects of docetaxel. The research provides insights into how menopausal status influences vascular changes from cancer therapy.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial. Paclitaxel-coated balloon angioplasty effectively treats femoropopliteal artery disease; however, an increased mortality risk associated with it remains unresolved. Sirolimus-coated balloon angioplasty offers an alternative antiproliferative drug approach for these interventions. The SIRONA randomized noninferiority trial evaluated sirolimus-coated balloon angioplasty against paclitaxel-coated balloon angioplasty. This comparison determines if sirolimus-coated balloons achieve noninferior primary vessel patency and clinical efficacy with an improved safety profile.</p>
<p>Article number two. Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial. Achieving sustained blood pressure lowering with traditional lifestyle guidance and exercise presents a challenge for individuals with high-normal blood pressure. Baduanjin, a traditional Chinese mind-body exercise, serves as a non-pharmacological therapeutic approach under investigation for this population. A multicenter, open-label, blinded-outcome randomized controlled trial assessed Baduanjin&#8217;s short-term impact on ambulatory blood pressure and its long-term effects. This study evaluated participants aged 40 years or older who presented with systolic blood pressure of 130 to 139 mmHg or diastolic blood pressure of 85 mmHg or higher.</p>
<p>Article number three. Impact of Long-Term Cumulative Exposure to Wildfire Smoke P. M. 2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. Intensifying wildfires in a warming climate result in prolonged exposure to smoke-derived fine particulate matter (P. M. 2.5), which poses significant health risks. The cardiovascular impacts of long-term cumulative exposure to wildfire smoke P. M. 2.5, particularly in older adults, represent an area of critical clinical investigation. This population-based cohort study analyzed associations between long-term cumulative exposure to wildfire smoke P. M. 2.5 and first cardiovascular disease hospitalizations. The research focused on U.S. Medicare beneficiaries, examining the effects on cardiovascular health in this vulnerable population.</p>
<p>Article number four. Mitral Valve Repair for Degenerative M. R. With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort. Recurrent mitral regurgitation degree serves as a key indicator for the quality of mitral valve repair for degenerative mitral regurgitation. This multicenter study evaluated 2-year survival and mitral regurgitation recurrence following mitral valve repair in patients with degenerative mitral regurgitation and moderate or less concomitant tricuspid regurgitation. The research utilized echocardiographic core laboratory-adjudicated data from a cohort of patients who underwent repair between 2016 and 2018. This analysis established long-term outcomes of mitral valve repair in this specific patient group.</p>
<p>Article number five. Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients. Breast cancer chemotherapy elevates cardiovascular risk, with a notable impact on postmenopausal women. While vascular damage, endothelial dysfunction, and oxidative stress are implicated, the precise role of menopausal status in these vascular mechanisms remains unknown. This study investigated the potential protective role of estrogens in premenopausal women against neoadjuvant chemotherapy-induced endothelial dysfunction, specifically focusing on the vascular effects of docetaxel. The research provides insights into how menopausal status influences vascular changes from cancer therapy. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mind-body exercise, older adults, angioplasty, menopausal status, fine particulate matter, breast cancer, cardiovascular disease, cardiovascular risk, paclitaxel-coated balloon, femoropopliteal artery disease, Baduanjin, chemotherapy, hypertension prevention, high-normal blood pressure, hospital admissions, peripheral artery disease, endothelial dysfunction, mitral regurgitation recurrence, docetaxel, vascular dysfunction, echocardiography, degenerative mitral regurgitation, mitral valve repair, blood pressure lowering, tricuspid regurgitation, cardiac surgery, Medicare beneficiaries, sirolimus-coated balloon, wildfire smoke.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/">Sirolimus Balloon Challenges Paclitaxel Mortality 02/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like mind-body exercise and older adults. Key takeaway: Sirolimus Balloon Challenges Paclitaxel Mortality.
Article Links:
Article 1: Comp]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like mind-body exercise and older adults. Key takeaway: Sirolimus Balloon Challenges Paclitaxel Mortality.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41706076">Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41706075">Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41706074">Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41706073">Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532932">Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/">https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706076" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706076</a></p>
<p><strong>Summary:</strong> Paclitaxel-coated balloon angioplasty effectively treats femoropopliteal artery disease; however, an increased mortality risk associated with it remains unresolved. Sirolimus-coated balloon angioplasty offers an alternative antiproliferative drug approach for these interventions. The SIRONA randomized noninferiority trial evaluated sirolimus-coated balloon angioplasty against paclitaxel-coated balloon angioplasty. This comparison determines if sirolimus-coated balloons achieve noninferior primary vessel patency and clinical efficacy with an improved safety profile.</p>
<h4>Article 2: Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706075" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706075</a></p>
<p><strong>Summary:</strong> Achieving sustained blood pressure lowering with traditional lifestyle guidance and exercise presents a challenge for individuals with high-normal blood pressure. Baduanjin, a traditional Chinese mind-body exercise, serves as a non-pharmacological therapeutic approach under investigation for this population. A multicenter, open-label, blinded-outcome randomized controlled trial assessed Baduanjin&#8217;s short-term impact on ambulatory blood pressure and its long-term effects. This study evaluated participants aged 40 years or older who presented with systolic blood pressure of 130 to 139 mmHg or diastolic blood pressure of 85 mmHg or higher.</p>
<h4>Article 3: Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706074" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706074</a></p>
<p><strong>Summary:</strong> M. 2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. Intensifying wildfires in a warming climate result in prolonged exposure to smoke-derived fine particulate matter (P. M. 2.5), which poses significant health risks. The cardiovascular impacts of long-term cumulative exposure to wildfire smoke P. M. 2.5, particularly in older adults, represent an area of critical clinical investigation. This population-based cohort study analyzed associations between long-term cumulative exposure to wildfire smoke P. M. 2.5 and first cardiovascular disease hospitalizations. The research focused on U.S. Medicare beneficiaries, examining the effects on cardiovascular health in this vulnerable population.</p>
<h4>Article 4: Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41706073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41706073</a></p>
<p><strong>Summary:</strong> R. With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort. Recurrent mitral regurgitation degree serves as a key indicator for the quality of mitral valve repair for degenerative mitral regurgitation. This multicenter study evaluated 2-year survival and mitral regurgitation recurrence following mitral valve repair in patients with degenerative mitral regurgitation and moderate or less concomitant tricuspid regurgitation. The research utilized echocardiographic core laboratory-adjudicated data from a cohort of patients who underwent repair between 2016 and 2018. This analysis established long-term outcomes of mitral valve repair in this specific patient group.</p>
<h4>Article 5: Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532932" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532932</a></p>
<p><strong>Summary:</strong> Breast cancer chemotherapy elevates cardiovascular risk, with a notable impact on postmenopausal women. While vascular damage, endothelial dysfunction, and oxidative stress are implicated, the precise role of menopausal status in these vascular mechanisms remains unknown. This study investigated the potential protective role of estrogens in premenopausal women against neoadjuvant chemotherapy-induced endothelial dysfunction, specifically focusing on the vascular effects of docetaxel. The research provides insights into how menopausal status influences vascular changes from cancer therapy.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial. Paclitaxel-coated balloon angioplasty effectively treats femoropopliteal artery disease; however, an increased mortality risk associated with it remains unresolved. Sirolimus-coated balloon angioplasty offers an alternative antiproliferative drug approach for these interventions. The SIRONA randomized noninferiority trial evaluated sirolimus-coated balloon angioplasty against paclitaxel-coated balloon angioplasty. This comparison determines if sirolimus-coated balloons achieve noninferior primary vessel patency and clinical efficacy with an improved safety profile.</p>
<p>Article number two. Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial. Achieving sustained blood pressure lowering with traditional lifestyle guidance and exercise presents a challenge for individuals with high-normal blood pressure. Baduanjin, a traditional Chinese mind-body exercise, serves as a non-pharmacological therapeutic approach under investigation for this population. A multicenter, open-label, blinded-outcome randomized controlled trial assessed Baduanjin&#8217;s short-term impact on ambulatory blood pressure and its long-term effects. This study evaluated participants aged 40 years or older who presented with systolic blood pressure of 130 to 139 mmHg or diastolic blood pressure of 85 mmHg or higher.</p>
<p>Article number three. Impact of Long-Term Cumulative Exposure to Wildfire Smoke P. M. 2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. Intensifying wildfires in a warming climate result in prolonged exposure to smoke-derived fine particulate matter (P. M. 2.5), which poses significant health risks. The cardiovascular impacts of long-term cumulative exposure to wildfire smoke P. M. 2.5, particularly in older adults, represent an area of critical clinical investigation. This population-based cohort study analyzed associations between long-term cumulative exposure to wildfire smoke P. M. 2.5 and first cardiovascular disease hospitalizations. The research focused on U.S. Medicare beneficiaries, examining the effects on cardiovascular health in this vulnerable population.</p>
<p>Article number four. Mitral Valve Repair for Degenerative M. R. With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort. Recurrent mitral regurgitation degree serves as a key indicator for the quality of mitral valve repair for degenerative mitral regurgitation. This multicenter study evaluated 2-year survival and mitral regurgitation recurrence following mitral valve repair in patients with degenerative mitral regurgitation and moderate or less concomitant tricuspid regurgitation. The research utilized echocardiographic core laboratory-adjudicated data from a cohort of patients who underwent repair between 2016 and 2018. This analysis established long-term outcomes of mitral valve repair in this specific patient group.</p>
<p>Article number five. Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients. Breast cancer chemotherapy elevates cardiovascular risk, with a notable impact on postmenopausal women. While vascular damage, endothelial dysfunction, and oxidative stress are implicated, the precise role of menopausal status in these vascular mechanisms remains unknown. This study investigated the potential protective role of estrogens in premenopausal women against neoadjuvant chemotherapy-induced endothelial dysfunction, specifically focusing on the vascular effects of docetaxel. The research provides insights into how menopausal status influences vascular changes from cancer therapy. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mind-body exercise, older adults, angioplasty, menopausal status, fine particulate matter, breast cancer, cardiovascular disease, cardiovascular risk, paclitaxel-coated balloon, femoropopliteal artery disease, Baduanjin, chemotherapy, hypertension prevention, high-normal blood pressure, hospital admissions, peripheral artery disease, endothelial dysfunction, mitral regurgitation recurrence, docetaxel, vascular dysfunction, echocardiography, degenerative mitral regurgitation, mitral valve repair, blood pressure lowering, tricuspid regurgitation, cardiac surgery, Medicare beneficiaries, sirolimus-coated balloon, wildfire smoke.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/">Sirolimus Balloon Challenges Paclitaxel Mortality 02/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260219_060037.mp3" length="4652973" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like mind-body exercise and older adults. Key takeaway: Sirolimus Balloon Challenges Paclitaxel Mortality.
Article Links:
Article 1: Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial. (Journal of the American College of Cardiology)
Article 2: Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial. (Journal of the American College of Cardiology)
Article 3: Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. (Journal of the American College of Cardiology)
Article 4: Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory-Adjudicated Cohort. (Journal of the American College of Cardiology)
Article 5: Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients. (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/sirolimus-balloon-challenges-paclitaxel-mortality-02-19-26/
 Featured Articles
Article 1: Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41706076
Summary: Paclitaxel-coated balloon angioplasty effectively treats femoropopliteal artery disease; however, an increased mortality risk associated with it remains unresolved. Sirolimus-coated balloon angioplasty offers an alternative antiproliferative drug approach for these interventions. The SIRONA randomized noninferiority trial evaluated sirolimus-coated balloon angioplasty against paclitaxel-coated balloon angioplasty. This comparison determines if sirolimus-coated balloons achieve noninferior primary vessel patency and clinical efficacy with an improved safety profile.
Article 2: Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41706075
Summary: Achieving sustained blood pressure lowering with traditional lifestyle guidance and exercise presents a challenge for individuals with high-normal blood pressure. Baduanjin, a traditional Chinese mind-body exercise, serves as a non-pharmacological therapeutic approach under investigation for this population. A multicenter, open-label, blinded-outcome randomized controlled trial assessed Baduanjin&#8217;s short-term impact on ambulatory blood pressure and its long-term effects. This study evaluated participants aged 40 years or older who presented with systolic blood pressure of 130 to 139 mmHg or diastolic blood pressure of 85 mmHg or higher.
Article 3: Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41706074
Summary: M. 2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. Intensifying wildfires in a warming climate result in prolonged exposure to smoke-derived fine particulate matter (P. M. 2.5), which poses significant health risks. The cardiovascular impacts of long-term cumulative exposure to wildfire smoke P. M. 2.5, particularly in older adults, represent an area of critical clinical investigation. This population-b]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 19, 2026. This episode summarizes 5 key cardiology studies on topics like mind-body exercise and older adults. Key takeaway: Sirolimus Balloon Challenges Paclitaxel Mortality.
Article Links:
Article 1: Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial. (Journal of the American College of Cardiology)
Article 2: Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial. (Journal of the American College of Cardiology)
Article 3: Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM2.5 on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study. (Journal of the American College of Cardiology)
Article 4: Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Xenotransplant: Genetic Editing for Success 02/18/26</title>
	<link>https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/</link>
	<pubDate>Wed, 18 Feb 2026 11:01:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 18, 2026. This episode summarizes 5 key cardiology studies on topics like congenitally corrected transposition of the great arteries and complex congenital heart disease. Key takeaway: Xenotransplant: Genetic Editing for Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40679844">Arrhythmias in congenitally corrected transposition of the great arteries: an international study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40396276">Catheter ablation in congenital heart diseases: a French nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41701506">Residual lipid risk in atherosclerotic cardiovascular disease.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41700849">Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41702446">Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/">https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Arrhythmias in congenitally corrected transposition of the great arteries: an international study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40679844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40679844</a></p>
<p><strong>Summary:</strong> An international multicenter retrospective cohort study quantified the incidence of atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block in patients with congenitally corrected transposition of the great arteries. This extensive study, conducted across 29 tertiary hospitals in six countries, identified factors associated with these significant cardiac rhythm disturbances. The research found specific prevalence rates for atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block within this complex patient population. These findings provide definitive data on the arrhythmia burden and associated risk factors for improved clinical management.</p>
<h4>Article 2: Catheter ablation in congenital heart diseases: a French nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40396276" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40396276</a></p>
<p><strong>Summary:</strong> A French nationwide prospective study documented the outcomes of catheter ablation in patients with congenital heart disease across 28 centers from 2020 to 2024. The study found the per-procedural acute success rate for catheter ablation in this complex patient population. It also meticulously recorded associated complications and evaluated long-term freedom from arrhythmia recurrence. These comprehensive findings provide definitive national data on the effectiveness and safety of catheter ablation in congenital heart disease.</p>
<h4>Article 3: Residual lipid risk in atherosclerotic cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41701506" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41701506</a></p>
<p><strong>Summary:</strong> Residual lipid risk persists in patients with or at risk of atherosclerotic cardiovascular disease, even after optimizing low-density lipoprotein cholesterol. Evidence highlights that non-low-density lipoprotein cholesterol fractions, including remnant cholesterol, lipoprotein(a), and apolipoprotein B, are key contributors to this residual risk. These non-low-density lipoprotein components definitively demonstrate their independent role in driving the progression of atherosclerotic cardiovascular disease. The identification of these persistent risk factors provides critical insights for developing therapeutic strategies beyond traditional low-density lipoprotein lowering.</p>
<h4>Article 4: Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41700849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41700849</a></p>
<p><strong>Summary:</strong> The inaugural Richard Slayman Clinical Xenotransplantation Workshop, attended by over 140 international participants, identified significant advances and challenges in xenotransplantation. Discussions highlighted the increasing clinical readiness of kidney, heart, and liver xenotransplantation. Key findings from the workshop emphasized the crucial importance of meticulous patient selection and the pivotal role of genetic editing in reducing immune incompatibility. These consensuses establish current best practices and future directions for successfully translating xenotransplantation into wider clinical application.</p>
<h4>Article 5: Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41702446" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41702446</a></p>
<p><strong>Summary:</strong> A study of 1033 Olympic-level athletes identified specific echocardiographic morpho-functional parameters that predict maximal oxygen uptake and oxygen pulse. The research established direct correlations between structural cardiac adaptations, commonly known as the athlete&#8217;s heart, and functional indices of cardiovascular performance. Results demonstrated how particular morphological changes observed via echocardiography are associated with enhanced cardiac efficiency during exertion. These findings provide measurable echocardiographic markers for assessing and monitoring cardiovascular performance and adaptive remodeling in elite athletes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Arrhythmias in congenitally corrected transposition of the great arteries: an international study. An international multicenter retrospective cohort study quantified the incidence of atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block in patients with congenitally corrected transposition of the great arteries. This extensive study, conducted across 29 tertiary hospitals in six countries, identified factors associated with these significant cardiac rhythm disturbances. The research found specific prevalence rates for atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block within this complex patient population. These findings provide definitive data on the arrhythmia burden and associated risk factors for improved clinical management.</p>
<p>Article number two. Catheter ablation in congenital heart diseases: a French nationwide study. A French nationwide prospective study documented the outcomes of catheter ablation in patients with congenital heart disease across 28 centers from 2020 to 2024. The study found the per-procedural acute success rate for catheter ablation in this complex patient population. It also meticulously recorded associated complications and evaluated long-term freedom from arrhythmia recurrence. These comprehensive findings provide definitive national data on the effectiveness and safety of catheter ablation in congenital heart disease.</p>
<p>Article number three. Residual lipid risk in atherosclerotic cardiovascular disease. Residual lipid risk persists in patients with or at risk of atherosclerotic cardiovascular disease, even after optimizing low-density lipoprotein cholesterol. Evidence highlights that non-low-density lipoprotein cholesterol fractions, including remnant cholesterol, lipoprotein(a), and apolipoprotein B, are key contributors to this residual risk. These non-low-density lipoprotein components definitively demonstrate their independent role in driving the progression of atherosclerotic cardiovascular disease. The identification of these persistent risk factors provides critical insights for developing therapeutic strategies beyond traditional low-density lipoprotein lowering.</p>
<p>Article number four. Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation. The inaugural Richard Slayman Clinical Xenotransplantation Workshop, attended by over 140 international participants, identified significant advances and challenges in xenotransplantation. Discussions highlighted the increasing clinical readiness of kidney, heart, and liver xenotransplantation. Key findings from the workshop emphasized the crucial importance of meticulous patient selection and the pivotal role of genetic editing in reducing immune incompatibility. These consensuses establish current best practices and future directions for successfully translating xenotransplantation into wider clinical application.</p>
<p>Article number five. Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines. A study of 1033 Olympic-level athletes identified specific echocardiographic morpho-functional parameters that predict maximal oxygen uptake and oxygen pulse. The research established direct correlations between structural cardiac adaptations, commonly known as the athlete&#8217;s heart, and functional indices of cardiovascular performance. Results demonstrated how particular morphological changes observed via echocardiography are associated with enhanced cardiac efficiency during exertion. These findings provide measurable echocardiographic markers for assessing and monitoring cardiovascular performance and adaptive remodeling in elite athletes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>congenitally corrected transposition of the great arteries, complex congenital heart disease, electrophysiology, per-procedural success, kidney xenotransplantation, heart xenotransplantation, complete atrioventricular block, arrhythmia recurrence, catheter ablation, atrial arrhythmia, atherosclerotic cardiovascular disease, maximal oxygen uptake, genetic editing, xenotransplantation, echocardiography, congenital heart disease, ventricular arrhythmia, lipoprotein(a), immune incompatibility, low-density lipoprotein cholesterol, athlete&#8217;s heart, remnant cholesterol, oxygen pulse, residual lipid risk, elite athletes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/">Xenotransplant: Genetic Editing for Success 02/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 18, 2026. This episode summarizes 5 key cardiology studies on topics like congenitally corrected transposition of the great arteries and complex congenital heart disease. Key takeaway: Xenotransplant: Genet]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 18, 2026. This episode summarizes 5 key cardiology studies on topics like congenitally corrected transposition of the great arteries and complex congenital heart disease. Key takeaway: Xenotransplant: Genetic Editing for Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40679844">Arrhythmias in congenitally corrected transposition of the great arteries: an international study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40396276">Catheter ablation in congenital heart diseases: a French nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41701506">Residual lipid risk in atherosclerotic cardiovascular disease.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41700849">Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41702446">Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/">https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Arrhythmias in congenitally corrected transposition of the great arteries: an international study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40679844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40679844</a></p>
<p><strong>Summary:</strong> An international multicenter retrospective cohort study quantified the incidence of atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block in patients with congenitally corrected transposition of the great arteries. This extensive study, conducted across 29 tertiary hospitals in six countries, identified factors associated with these significant cardiac rhythm disturbances. The research found specific prevalence rates for atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block within this complex patient population. These findings provide definitive data on the arrhythmia burden and associated risk factors for improved clinical management.</p>
<h4>Article 2: Catheter ablation in congenital heart diseases: a French nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40396276" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40396276</a></p>
<p><strong>Summary:</strong> A French nationwide prospective study documented the outcomes of catheter ablation in patients with congenital heart disease across 28 centers from 2020 to 2024. The study found the per-procedural acute success rate for catheter ablation in this complex patient population. It also meticulously recorded associated complications and evaluated long-term freedom from arrhythmia recurrence. These comprehensive findings provide definitive national data on the effectiveness and safety of catheter ablation in congenital heart disease.</p>
<h4>Article 3: Residual lipid risk in atherosclerotic cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41701506" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41701506</a></p>
<p><strong>Summary:</strong> Residual lipid risk persists in patients with or at risk of atherosclerotic cardiovascular disease, even after optimizing low-density lipoprotein cholesterol. Evidence highlights that non-low-density lipoprotein cholesterol fractions, including remnant cholesterol, lipoprotein(a), and apolipoprotein B, are key contributors to this residual risk. These non-low-density lipoprotein components definitively demonstrate their independent role in driving the progression of atherosclerotic cardiovascular disease. The identification of these persistent risk factors provides critical insights for developing therapeutic strategies beyond traditional low-density lipoprotein lowering.</p>
<h4>Article 4: Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41700849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41700849</a></p>
<p><strong>Summary:</strong> The inaugural Richard Slayman Clinical Xenotransplantation Workshop, attended by over 140 international participants, identified significant advances and challenges in xenotransplantation. Discussions highlighted the increasing clinical readiness of kidney, heart, and liver xenotransplantation. Key findings from the workshop emphasized the crucial importance of meticulous patient selection and the pivotal role of genetic editing in reducing immune incompatibility. These consensuses establish current best practices and future directions for successfully translating xenotransplantation into wider clinical application.</p>
<h4>Article 5: Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41702446" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41702446</a></p>
<p><strong>Summary:</strong> A study of 1033 Olympic-level athletes identified specific echocardiographic morpho-functional parameters that predict maximal oxygen uptake and oxygen pulse. The research established direct correlations between structural cardiac adaptations, commonly known as the athlete&#8217;s heart, and functional indices of cardiovascular performance. Results demonstrated how particular morphological changes observed via echocardiography are associated with enhanced cardiac efficiency during exertion. These findings provide measurable echocardiographic markers for assessing and monitoring cardiovascular performance and adaptive remodeling in elite athletes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Arrhythmias in congenitally corrected transposition of the great arteries: an international study. An international multicenter retrospective cohort study quantified the incidence of atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block in patients with congenitally corrected transposition of the great arteries. This extensive study, conducted across 29 tertiary hospitals in six countries, identified factors associated with these significant cardiac rhythm disturbances. The research found specific prevalence rates for atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block within this complex patient population. These findings provide definitive data on the arrhythmia burden and associated risk factors for improved clinical management.</p>
<p>Article number two. Catheter ablation in congenital heart diseases: a French nationwide study. A French nationwide prospective study documented the outcomes of catheter ablation in patients with congenital heart disease across 28 centers from 2020 to 2024. The study found the per-procedural acute success rate for catheter ablation in this complex patient population. It also meticulously recorded associated complications and evaluated long-term freedom from arrhythmia recurrence. These comprehensive findings provide definitive national data on the effectiveness and safety of catheter ablation in congenital heart disease.</p>
<p>Article number three. Residual lipid risk in atherosclerotic cardiovascular disease. Residual lipid risk persists in patients with or at risk of atherosclerotic cardiovascular disease, even after optimizing low-density lipoprotein cholesterol. Evidence highlights that non-low-density lipoprotein cholesterol fractions, including remnant cholesterol, lipoprotein(a), and apolipoprotein B, are key contributors to this residual risk. These non-low-density lipoprotein components definitively demonstrate their independent role in driving the progression of atherosclerotic cardiovascular disease. The identification of these persistent risk factors provides critical insights for developing therapeutic strategies beyond traditional low-density lipoprotein lowering.</p>
<p>Article number four. Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation. The inaugural Richard Slayman Clinical Xenotransplantation Workshop, attended by over 140 international participants, identified significant advances and challenges in xenotransplantation. Discussions highlighted the increasing clinical readiness of kidney, heart, and liver xenotransplantation. Key findings from the workshop emphasized the crucial importance of meticulous patient selection and the pivotal role of genetic editing in reducing immune incompatibility. These consensuses establish current best practices and future directions for successfully translating xenotransplantation into wider clinical application.</p>
<p>Article number five. Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines. A study of 1033 Olympic-level athletes identified specific echocardiographic morpho-functional parameters that predict maximal oxygen uptake and oxygen pulse. The research established direct correlations between structural cardiac adaptations, commonly known as the athlete&#8217;s heart, and functional indices of cardiovascular performance. Results demonstrated how particular morphological changes observed via echocardiography are associated with enhanced cardiac efficiency during exertion. These findings provide measurable echocardiographic markers for assessing and monitoring cardiovascular performance and adaptive remodeling in elite athletes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>congenitally corrected transposition of the great arteries, complex congenital heart disease, electrophysiology, per-procedural success, kidney xenotransplantation, heart xenotransplantation, complete atrioventricular block, arrhythmia recurrence, catheter ablation, atrial arrhythmia, atherosclerotic cardiovascular disease, maximal oxygen uptake, genetic editing, xenotransplantation, echocardiography, congenital heart disease, ventricular arrhythmia, lipoprotein(a), immune incompatibility, low-density lipoprotein cholesterol, athlete&#8217;s heart, remnant cholesterol, oxygen pulse, residual lipid risk, elite athletes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/">Xenotransplant: Genetic Editing for Success 02/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260218_060033.mp3" length="4305649" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 18, 2026. This episode summarizes 5 key cardiology studies on topics like congenitally corrected transposition of the great arteries and complex congenital heart disease. Key takeaway: Xenotransplant: Genetic Editing for Success.
Article Links:
Article 1: Arrhythmias in congenitally corrected transposition of the great arteries: an international study. (European heart journal)
Article 2: Catheter ablation in congenital heart diseases: a French nationwide study. (European heart journal)
Article 3: Residual lipid risk in atherosclerotic cardiovascular disease. (European heart journal)
Article 4: Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation. (Transplantation)
Article 5: Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/xenotransplant-genetic-editing-for-success-02-18-26/
 Featured Articles
Article 1: Arrhythmias in congenitally corrected transposition of the great arteries: an international study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40679844
Summary: An international multicenter retrospective cohort study quantified the incidence of atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block in patients with congenitally corrected transposition of the great arteries. This extensive study, conducted across 29 tertiary hospitals in six countries, identified factors associated with these significant cardiac rhythm disturbances. The research found specific prevalence rates for atrial arrhythmia, ventricular arrhythmia, and complete atrioventricular block within this complex patient population. These findings provide definitive data on the arrhythmia burden and associated risk factors for improved clinical management.
Article 2: Catheter ablation in congenital heart diseases: a French nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40396276
Summary: A French nationwide prospective study documented the outcomes of catheter ablation in patients with congenital heart disease across 28 centers from 2020 to 2024. The study found the per-procedural acute success rate for catheter ablation in this complex patient population. It also meticulously recorded associated complications and evaluated long-term freedom from arrhythmia recurrence. These comprehensive findings provide definitive national data on the effectiveness and safety of catheter ablation in congenital heart disease.
Article 3: Residual lipid risk in atherosclerotic cardiovascular disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41701506
Summary: Residual lipid risk persists in patients with or at risk of atherosclerotic cardiovascular disease, even after optimizing low-density lipoprotein cholesterol. Evidence highlights that non-low-density lipoprotein cholesterol fractions, including remnant cholesterol, lipoprotein(a), and apolipoprotein B, are key contributors to this residual risk. These non-low-density lipoprotein components definitively demonstrate their independent role in driving the progression of atherosclerotic cardiovascular disease. The identification of these persistent risk factors provides critical insights for developing therapeutic strategies beyond traditional low-density lipoprotein lowering.
Article 4: Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41700849
Summary: The inaugural Richard Slayman Clinical Xenotransplantation Workshop, attended by over 140 international participants, identified significant advances and challenges in xenotransplantation. Di]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 18, 2026. This episode summarizes 5 key cardiology studies on topics like congenitally corrected transposition of the great arteries and complex congenital heart disease. Key takeaway: Xenotransplant: Genetic Editing for Success.
Article Links:
Article 1: Arrhythmias in congenitally corrected transposition of the great arteries: an international study. (European heart journal)
Article 2: Catheter ablation in congenital heart diseases: a French nationwide study. (European heart journal)
Article 3: Residual lipid risk in atherosclerotic cardiovascular disease. (European heart journal)
Article 4: Advancing Hope Through Science: The Inaugural Richard Slayman International Workshop on Xenotransplantation. (Transplantation)
Article 5: Echocardiographic morpho-functional parameters predictors of maximal oxygen uptake and oxygen pulse in a large cohort of elite athletes practicing different sporting disciplines. (International journal of cardiol]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cell-free DNA Reveals Heart Transplant Recipient Injury 02/17/26</title>
	<link>https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/</link>
	<pubDate>Tue, 17 Feb 2026 11:01:18 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 17, 2026. This episode summarizes 5 key cardiology studies on topics like Endothelial function and Venous thromboembolism. Key takeaway: Cell-free DNA Reveals Heart Transplant Recipient Injury.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41697183">Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41697979">Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41693575">Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41698554">Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41698896">Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/">https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41697183" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41697183</a></p>
<p><strong>Summary:</strong> The Evolut Low Risk trial provided 6-year clinical outcomes comparing transcatheter aortic valve replacement and surgical aortic valve replacement in patients with severe aortic stenosis at low surgical risk. Researchers observed an increase in reintervention rates at 6 years, prompting additional analyses using available 7-year data to further characterize these trends. This long-term follow-up is crucial for understanding the durability and reintervention needs of both treatment modalities in this patient population, especially concerning long-term structural valve deterioration.</p>
<h4>Article 2: Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41697979" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41697979</a></p>
<p><strong>Summary:</strong> Hypertensive disorders of pregnancy were identified as early indicators of cardiovascular risk in a diverse cohort of young United States women. The study specifically found a quantifiable association between these disorders and incident cardiovascular disease in a real-world population. These findings, replicated across multiple health systems, underscore that hypertensive disorders of pregnancy independently increase the risk for premature cardiovascular disease, rather than solely reflecting pre-pregnancy health.</p>
<h4>Article 3: Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41693575" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41693575</a></p>
<p><strong>Summary:</strong> This study identified new circulating protein biomarkers and biological pathways for incident venous thromboembolism. Researchers employed large-scale, high-throughput aptamer-based proteomics across four longitudinal cohorts, including the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, the Multi-Ethnic Study of Atherosclerosis, and the Trøndelag Health study. These findings advance the understanding of venous thromboembolism etiology and hold implications for improved risk prediction and potential therapeutic strategies.</p>
<h4>Article 4: Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41698554" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41698554</a></p>
<p><strong>Summary:</strong> This study provided evidence that cardiac allograft rejection is linked to recipient tissue injury, challenging the conventional view of rejection solely as an allograft disease. Researchers measured recipient tissue injury through plasma cell-free DNA, a recognized biomarker of tissue damage, confirming its occurrence during allograft rejection. The analysis identified genetic and epigenetic signatures associated with this process, clarifying a previously poorly defined risk factor for poor survival in cardiac transplant recipients.</p>
<h4>Article 5: Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41698896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41698896</a></p>
<p><strong>Summary:</strong> This randomized, two-arm parallel feeding study investigated the effects of increased total fruit intake, specifically incorporating avocado and mango, on endothelial function and cardiometabolic risk factors. Eighty-two adults with prediabetes followed an eight-week diet daily including one avocado and one cup of mango, compared to an energy-matched low-fat control diet. The study provided a structured intervention to assess how these specific fruits impact vascular and metabolic health in a population at risk for cardiometabolic diseases, addressing a global risk factor of low fruit intake.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 17, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. The Evolut Low Risk trial provided 6-year clinical outcomes comparing transcatheter aortic valve replacement and surgical aortic valve replacement in patients with severe aortic stenosis at low surgical risk. Researchers observed an increase in reintervention rates at 6 years, prompting additional analyses using available 7-year data to further characterize these trends. This long-term follow-up is crucial for understanding the durability and reintervention needs of both treatment modalities in this patient population, especially concerning long-term structural valve deterioration.</p>
<p>Article number two. Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. Hypertensive disorders of pregnancy were identified as early indicators of cardiovascular risk in a diverse cohort of young United States women. The study specifically found a quantifiable association between these disorders and incident cardiovascular disease in a real-world population. These findings, replicated across multiple health systems, underscore that hypertensive disorders of pregnancy independently increase the risk for premature cardiovascular disease, rather than solely reflecting pre-pregnancy health.</p>
<p>Article number three. Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. This study identified new circulating protein biomarkers and biological pathways for incident venous thromboembolism. Researchers employed large-scale, high-throughput aptamer-based proteomics across four longitudinal cohorts, including the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, the Multi-Ethnic Study of Atherosclerosis, and the Trøndelag Health study. These findings advance the understanding of venous thromboembolism etiology and hold implications for improved risk prediction and potential therapeutic strategies.</p>
<p>Article number four. Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA. This study provided evidence that cardiac allograft rejection is linked to recipient tissue injury, challenging the conventional view of rejection solely as an allograft disease. Researchers measured recipient tissue injury through plasma cell-free DNA, a recognized biomarker of tissue damage, confirming its occurrence during allograft rejection. The analysis identified genetic and epigenetic signatures associated with this process, clarifying a previously poorly defined risk factor for poor survival in cardiac transplant recipients.</p>
<p>Article number five. Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes. This randomized, two-arm parallel feeding study investigated the effects of increased total fruit intake, specifically incorporating avocado and mango, on endothelial function and cardiometabolic risk factors. Eighty-two adults with prediabetes followed an eight-week diet daily including one avocado and one cup of mango, compared to an energy-matched low-fat control diet. The study provided a structured intervention to assess how these specific fruits impact vascular and metabolic health in a population at risk for cardiometabolic diseases, addressing a global risk factor of low fruit intake. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Endothelial function, Venous thromboembolism, Cardiac allograft rejection, Prediabetes, Transplant immunology, Women&#8217;s health, Plasma biomarkers, Avocado, Hypertensive disorders of pregnancy, Transcatheter aortic valve replacement, Mango, Cell-free DNA, Surgical aortic valve replacement, Cardiovascular disease, Proteomics, Premature cardiovascular disease, Recipient tissue injury, Cardiovascular risk, Aortic stenosis, Biological pathways, Cardiometabolic risk factors, Low surgical risk, Cardiac transplantation, Etiology, Reintervention rates, Fruit intake.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/">Cell-free DNA Reveals Heart Transplant Recipient Injury 02/17/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 17, 2026. This episode summarizes 5 key cardiology studies on topics like Endothelial function and Venous thromboembolism. Key takeaway: Cell-free DNA Reveals Heart Transplant Recipient Injury.
Article Link]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 17, 2026. This episode summarizes 5 key cardiology studies on topics like Endothelial function and Venous thromboembolism. Key takeaway: Cell-free DNA Reveals Heart Transplant Recipient Injury.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41697183">Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41697979">Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41693575">Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41698554">Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41698896">Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/">https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41697183" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41697183</a></p>
<p><strong>Summary:</strong> The Evolut Low Risk trial provided 6-year clinical outcomes comparing transcatheter aortic valve replacement and surgical aortic valve replacement in patients with severe aortic stenosis at low surgical risk. Researchers observed an increase in reintervention rates at 6 years, prompting additional analyses using available 7-year data to further characterize these trends. This long-term follow-up is crucial for understanding the durability and reintervention needs of both treatment modalities in this patient population, especially concerning long-term structural valve deterioration.</p>
<h4>Article 2: Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41697979" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41697979</a></p>
<p><strong>Summary:</strong> Hypertensive disorders of pregnancy were identified as early indicators of cardiovascular risk in a diverse cohort of young United States women. The study specifically found a quantifiable association between these disorders and incident cardiovascular disease in a real-world population. These findings, replicated across multiple health systems, underscore that hypertensive disorders of pregnancy independently increase the risk for premature cardiovascular disease, rather than solely reflecting pre-pregnancy health.</p>
<h4>Article 3: Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41693575" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41693575</a></p>
<p><strong>Summary:</strong> This study identified new circulating protein biomarkers and biological pathways for incident venous thromboembolism. Researchers employed large-scale, high-throughput aptamer-based proteomics across four longitudinal cohorts, including the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, the Multi-Ethnic Study of Atherosclerosis, and the Trøndelag Health study. These findings advance the understanding of venous thromboembolism etiology and hold implications for improved risk prediction and potential therapeutic strategies.</p>
<h4>Article 4: Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41698554" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41698554</a></p>
<p><strong>Summary:</strong> This study provided evidence that cardiac allograft rejection is linked to recipient tissue injury, challenging the conventional view of rejection solely as an allograft disease. Researchers measured recipient tissue injury through plasma cell-free DNA, a recognized biomarker of tissue damage, confirming its occurrence during allograft rejection. The analysis identified genetic and epigenetic signatures associated with this process, clarifying a previously poorly defined risk factor for poor survival in cardiac transplant recipients.</p>
<h4>Article 5: Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41698896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41698896</a></p>
<p><strong>Summary:</strong> This randomized, two-arm parallel feeding study investigated the effects of increased total fruit intake, specifically incorporating avocado and mango, on endothelial function and cardiometabolic risk factors. Eighty-two adults with prediabetes followed an eight-week diet daily including one avocado and one cup of mango, compared to an energy-matched low-fat control diet. The study provided a structured intervention to assess how these specific fruits impact vascular and metabolic health in a population at risk for cardiometabolic diseases, addressing a global risk factor of low fruit intake.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 17, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. The Evolut Low Risk trial provided 6-year clinical outcomes comparing transcatheter aortic valve replacement and surgical aortic valve replacement in patients with severe aortic stenosis at low surgical risk. Researchers observed an increase in reintervention rates at 6 years, prompting additional analyses using available 7-year data to further characterize these trends. This long-term follow-up is crucial for understanding the durability and reintervention needs of both treatment modalities in this patient population, especially concerning long-term structural valve deterioration.</p>
<p>Article number two. Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. Hypertensive disorders of pregnancy were identified as early indicators of cardiovascular risk in a diverse cohort of young United States women. The study specifically found a quantifiable association between these disorders and incident cardiovascular disease in a real-world population. These findings, replicated across multiple health systems, underscore that hypertensive disorders of pregnancy independently increase the risk for premature cardiovascular disease, rather than solely reflecting pre-pregnancy health.</p>
<p>Article number three. Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. This study identified new circulating protein biomarkers and biological pathways for incident venous thromboembolism. Researchers employed large-scale, high-throughput aptamer-based proteomics across four longitudinal cohorts, including the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, the Multi-Ethnic Study of Atherosclerosis, and the Trøndelag Health study. These findings advance the understanding of venous thromboembolism etiology and hold implications for improved risk prediction and potential therapeutic strategies.</p>
<p>Article number four. Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA. This study provided evidence that cardiac allograft rejection is linked to recipient tissue injury, challenging the conventional view of rejection solely as an allograft disease. Researchers measured recipient tissue injury through plasma cell-free DNA, a recognized biomarker of tissue damage, confirming its occurrence during allograft rejection. The analysis identified genetic and epigenetic signatures associated with this process, clarifying a previously poorly defined risk factor for poor survival in cardiac transplant recipients.</p>
<p>Article number five. Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes. This randomized, two-arm parallel feeding study investigated the effects of increased total fruit intake, specifically incorporating avocado and mango, on endothelial function and cardiometabolic risk factors. Eighty-two adults with prediabetes followed an eight-week diet daily including one avocado and one cup of mango, compared to an energy-matched low-fat control diet. The study provided a structured intervention to assess how these specific fruits impact vascular and metabolic health in a population at risk for cardiometabolic diseases, addressing a global risk factor of low fruit intake. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Endothelial function, Venous thromboembolism, Cardiac allograft rejection, Prediabetes, Transplant immunology, Women&#8217;s health, Plasma biomarkers, Avocado, Hypertensive disorders of pregnancy, Transcatheter aortic valve replacement, Mango, Cell-free DNA, Surgical aortic valve replacement, Cardiovascular disease, Proteomics, Premature cardiovascular disease, Recipient tissue injury, Cardiovascular risk, Aortic stenosis, Biological pathways, Cardiometabolic risk factors, Low surgical risk, Cardiac transplantation, Etiology, Reintervention rates, Fruit intake.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/">Cell-free DNA Reveals Heart Transplant Recipient Injury 02/17/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260217_060030.mp3" length="3889780" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 17, 2026. This episode summarizes 5 key cardiology studies on topics like Endothelial function and Venous thromboembolism. Key takeaway: Cell-free DNA Reveals Heart Transplant Recipient Injury.
Article Links:
Article 1: Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. (Journal of the American College of Cardiology)
Article 2: Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. (Circulation)
Article 3: Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. (Circulation)
Article 4: Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Effects of Increasing Total Fruit Intake With Avocado and Mango on Endothelial Function and Cardiometabolic Risk Factors in Adults With Prediabetes. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/cell-free-dna-reveals-heart-transplant-recipient-injury-02-17-26/
 Featured Articles
Article 1: Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41697183
Summary: The Evolut Low Risk trial provided 6-year clinical outcomes comparing transcatheter aortic valve replacement and surgical aortic valve replacement in patients with severe aortic stenosis at low surgical risk. Researchers observed an increase in reintervention rates at 6 years, prompting additional analyses using available 7-year data to further characterize these trends. This long-term follow-up is crucial for understanding the durability and reintervention needs of both treatment modalities in this patient population, especially concerning long-term structural valve deterioration.
Article 2: Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41697979
Summary: Hypertensive disorders of pregnancy were identified as early indicators of cardiovascular risk in a diverse cohort of young United States women. The study specifically found a quantifiable association between these disorders and incident cardiovascular disease in a real-world population. These findings, replicated across multiple health systems, underscore that hypertensive disorders of pregnancy independently increase the risk for premature cardiovascular disease, rather than solely reflecting pre-pregnancy health.
Article 3: Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41693575
Summary: This study identified new circulating protein biomarkers and biological pathways for incident venous thromboembolism. Researchers employed large-scale, high-throughput aptamer-based proteomics across four longitudinal cohorts, including the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, the Multi-Ethnic Study of Atherosclerosis, and the Trøndelag Health study. These findings advance the understanding of venous thromboembolism etiology and hold implications for improved risk prediction and potential therapeutic strategies.
Article 4: Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41698554
Summary: This study provided evidence that cardiac allograft rejection is linked to recipient tissue injury, challengi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 17, 2026. This episode summarizes 5 key cardiology studies on topics like Endothelial function and Venous thromboembolism. Key takeaway: Cell-free DNA Reveals Heart Transplant Recipient Injury.
Article Links:
Article 1: Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. (Journal of the American College of Cardiology)
Article 2: Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. (Circulation)
Article 3: Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. (Circulation)
Article 4: Allograft and Recipient Tissue Injury during Cardiac Allograft Rejection: Evidence from Cell-free DNA. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Effects of Increasing Total Fruit Intake With Avocado and Mango]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Percutaneous Coronary Intervention Mortality Breakdown. 02/16/26</title>
	<link>https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/</link>
	<pubDate>Mon, 16 Feb 2026 11:01:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 16, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplant rejection and Percutaneous coronary intervention. Key takeaway: Percutaneous Coronary Intervention Mortality Breakdown..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41692363">ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41478442">Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL).</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41421515">Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41391816">Revascularization in Patients Over 75 With Acute Coronary Syndrome.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41692131">Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/">https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41692363" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41692363</a></p>
<p><strong>Summary:</strong> This study found that Z-DNA induced PANoptosis in human microvascular endothelial cells through ZBP1. Researchers observed that ADAR1 and R. I. P. K. one collaboratively regulated the activation of the ZBP1-R. I. P. K. three complex, controlling PANoptosis in a time-dependent manner. The interaction of ADAR1 with ZBP1 specifically protected against Z-DNA-induced cell death. These findings reveal crucial molecular mechanisms driving PANoptosis and its potential relevance in heart transplant rejection.</p>
<h4>Article 2: Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL).</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41478442" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41478442</a></p>
<p><strong>Summary:</strong> This study established global longitudinal strain reference values for the Hispanic/Latino population using data from the Echocardiographic Study of Latinos. Researchers defined the 95th-percentile lower limit of normal global longitudinal strain values from a healthy reference sample. These established values provide essential clinical benchmarks for detecting early cardiac dysfunction in this specific demographic. The findings offer crucial guidance for assessing heart failure risk factors and interpreting echocardiographic results in Hispanic/Latino patients.</p>
<h4>Article 3: Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41421515" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41421515</a></p>
<p><strong>Summary:</strong> This multicenter analysis compared clinical outcomes of optical coherence tomography versus intravascular ultrasound guidance for primary percutaneous coronary intervention in patients with S. T.-elevation myocardial infarction. The study utilized data from 2777 S. T.-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention at 12 Japanese hospitals. Researchers found comparative data on the use of both imaging modalities, which are recommended by current guidelines for percutaneous coronary intervention guidance. These findings contribute to understanding the relative performance and clinical utility of optical coherence tomography and intravascular ultrasound in this critical patient population.</p>
<h4>Article 4: Revascularization in Patients Over 75 With Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41391816" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41391816</a></p>
<p><strong>Summary:</strong> This retrospective analysis investigated revascularization strategies in patients over 75 years old presenting with acute coronary syndromes. Observational data previously showed that coronary artery bypass graft was associated with improved one-year outcomes, including lower rates of death and rehospitalization, compared to percutaneous coronary intervention and medical management in general acute coronary syndrome patients with multivessel coronary artery disease. This study provided specific data addressing these outcomes in the elderly population. The findings contribute to clinical decision-making for optimal revascularization strategies in acute coronary syndrome patients aged over 75.</p>
<h4>Article 5: Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41692131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41692131</a></p>
<p><strong>Summary:</strong> This study analyzed mortality following percutaneous coronary intervention using data from the P. R. O. G. R. E. S. S. minus C. O. M. P. L. I. C. A. T. I. O. N. S. registry. Among 22503 patients undergoing percutaneous coronary intervention, 115 patients, representing 0.5 percent, died before hospital discharge. Researchers found that 15 patients, 13.0 percent of the mortalities, died during the procedure, while 10 patients, 8.7 percent, died within the first 24 hours post-procedure, and 90 patients, 78.3 percent, died more than 24 hours after the intervention. The study also revealed that patients who died exhibited a high burden of comorbidities.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection. This study found that Z-DNA induced PANoptosis in human microvascular endothelial cells through ZBP1. Researchers observed that ADAR1 and R. I. P. K. one collaboratively regulated the activation of the ZBP1-R. I. P. K. three complex, controlling PANoptosis in a time-dependent manner. The interaction of ADAR1 with ZBP1 specifically protected against Z-DNA-induced cell death. These findings reveal crucial molecular mechanisms driving PANoptosis and its potential relevance in heart transplant rejection.</p>
<p>Article number two. Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL). This study established global longitudinal strain reference values for the Hispanic/Latino population using data from the Echocardiographic Study of Latinos. Researchers defined the 95th-percentile lower limit of normal global longitudinal strain values from a healthy reference sample. These established values provide essential clinical benchmarks for detecting early cardiac dysfunction in this specific demographic. The findings offer crucial guidance for assessing heart failure risk factors and interpreting echocardiographic results in Hispanic/Latino patients.</p>
<p>Article number three. Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis. This multicenter analysis compared clinical outcomes of optical coherence tomography versus intravascular ultrasound guidance for primary percutaneous coronary intervention in patients with S. T.-elevation myocardial infarction. The study utilized data from 2777 S. T.-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention at 12 Japanese hospitals. Researchers found comparative data on the use of both imaging modalities, which are recommended by current guidelines for percutaneous coronary intervention guidance. These findings contribute to understanding the relative performance and clinical utility of optical coherence tomography and intravascular ultrasound in this critical patient population.</p>
<p>Article number four. Revascularization in Patients Over 75 With Acute Coronary Syndrome. This retrospective analysis investigated revascularization strategies in patients over 75 years old presenting with acute coronary syndromes. Observational data previously showed that coronary artery bypass graft was associated with improved one-year outcomes, including lower rates of death and rehospitalization, compared to percutaneous coronary intervention and medical management in general acute coronary syndrome patients with multivessel coronary artery disease. This study provided specific data addressing these outcomes in the elderly population. The findings contribute to clinical decision-making for optimal revascularization strategies in acute coronary syndrome patients aged over 75.</p>
<p>Article number five. Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry. This study analyzed mortality following percutaneous coronary intervention using data from the P. R. O. G. R. E. S. S. minus C. O. M. P. L. I. C. A. T. I. O. N. S. registry. Among 22503 patients undergoing percutaneous coronary intervention, 115 patients, representing 0.5 percent, died before hospital discharge. Researchers found that 15 patients, 13.0 percent of the mortalities, died during the procedure, while 10 patients, 8.7 percent, died within the first 24 hours post-procedure, and 90 patients, 78.3 percent, died more than 24 hours after the intervention. The study also revealed that patients who died exhibited a high burden of comorbidities. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart transplant rejection, Percutaneous coronary intervention, P. C. I. mortality, comorbidities, Optical coherence tomography, Hispanic/Latino population, in-hospital death, intravascular ultrasound, percutaneous coronary intervention, Revascularization, coronary artery bypass graft, S. T.-elevation myocardial infarction, ZBP1, RIPK1, PROGRESS-COMPLICATIONS registry, echocardiography, heart failure risk factors, elderly patients, reference values, ADAR1, PANoptosis, intravascular imaging, Global longitudinal strain, acute coronary syndrome.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/">Percutaneous Coronary Intervention Mortality Breakdown. 02/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 16, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplant rejection and Percutaneous coronary intervention. Key takeaway: Percutaneous Coronary Intervention Mortality Breakd]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 16, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplant rejection and Percutaneous coronary intervention. Key takeaway: Percutaneous Coronary Intervention Mortality Breakdown..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41692363">ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41478442">Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL).</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41421515">Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41391816">Revascularization in Patients Over 75 With Acute Coronary Syndrome.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41692131">Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/">https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41692363" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41692363</a></p>
<p><strong>Summary:</strong> This study found that Z-DNA induced PANoptosis in human microvascular endothelial cells through ZBP1. Researchers observed that ADAR1 and R. I. P. K. one collaboratively regulated the activation of the ZBP1-R. I. P. K. three complex, controlling PANoptosis in a time-dependent manner. The interaction of ADAR1 with ZBP1 specifically protected against Z-DNA-induced cell death. These findings reveal crucial molecular mechanisms driving PANoptosis and its potential relevance in heart transplant rejection.</p>
<h4>Article 2: Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL).</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41478442" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41478442</a></p>
<p><strong>Summary:</strong> This study established global longitudinal strain reference values for the Hispanic/Latino population using data from the Echocardiographic Study of Latinos. Researchers defined the 95th-percentile lower limit of normal global longitudinal strain values from a healthy reference sample. These established values provide essential clinical benchmarks for detecting early cardiac dysfunction in this specific demographic. The findings offer crucial guidance for assessing heart failure risk factors and interpreting echocardiographic results in Hispanic/Latino patients.</p>
<h4>Article 3: Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41421515" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41421515</a></p>
<p><strong>Summary:</strong> This multicenter analysis compared clinical outcomes of optical coherence tomography versus intravascular ultrasound guidance for primary percutaneous coronary intervention in patients with S. T.-elevation myocardial infarction. The study utilized data from 2777 S. T.-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention at 12 Japanese hospitals. Researchers found comparative data on the use of both imaging modalities, which are recommended by current guidelines for percutaneous coronary intervention guidance. These findings contribute to understanding the relative performance and clinical utility of optical coherence tomography and intravascular ultrasound in this critical patient population.</p>
<h4>Article 4: Revascularization in Patients Over 75 With Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41391816" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41391816</a></p>
<p><strong>Summary:</strong> This retrospective analysis investigated revascularization strategies in patients over 75 years old presenting with acute coronary syndromes. Observational data previously showed that coronary artery bypass graft was associated with improved one-year outcomes, including lower rates of death and rehospitalization, compared to percutaneous coronary intervention and medical management in general acute coronary syndrome patients with multivessel coronary artery disease. This study provided specific data addressing these outcomes in the elderly population. The findings contribute to clinical decision-making for optimal revascularization strategies in acute coronary syndrome patients aged over 75.</p>
<h4>Article 5: Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41692131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41692131</a></p>
<p><strong>Summary:</strong> This study analyzed mortality following percutaneous coronary intervention using data from the P. R. O. G. R. E. S. S. minus C. O. M. P. L. I. C. A. T. I. O. N. S. registry. Among 22503 patients undergoing percutaneous coronary intervention, 115 patients, representing 0.5 percent, died before hospital discharge. Researchers found that 15 patients, 13.0 percent of the mortalities, died during the procedure, while 10 patients, 8.7 percent, died within the first 24 hours post-procedure, and 90 patients, 78.3 percent, died more than 24 hours after the intervention. The study also revealed that patients who died exhibited a high burden of comorbidities.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection. This study found that Z-DNA induced PANoptosis in human microvascular endothelial cells through ZBP1. Researchers observed that ADAR1 and R. I. P. K. one collaboratively regulated the activation of the ZBP1-R. I. P. K. three complex, controlling PANoptosis in a time-dependent manner. The interaction of ADAR1 with ZBP1 specifically protected against Z-DNA-induced cell death. These findings reveal crucial molecular mechanisms driving PANoptosis and its potential relevance in heart transplant rejection.</p>
<p>Article number two. Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL). This study established global longitudinal strain reference values for the Hispanic/Latino population using data from the Echocardiographic Study of Latinos. Researchers defined the 95th-percentile lower limit of normal global longitudinal strain values from a healthy reference sample. These established values provide essential clinical benchmarks for detecting early cardiac dysfunction in this specific demographic. The findings offer crucial guidance for assessing heart failure risk factors and interpreting echocardiographic results in Hispanic/Latino patients.</p>
<p>Article number three. Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis. This multicenter analysis compared clinical outcomes of optical coherence tomography versus intravascular ultrasound guidance for primary percutaneous coronary intervention in patients with S. T.-elevation myocardial infarction. The study utilized data from 2777 S. T.-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention at 12 Japanese hospitals. Researchers found comparative data on the use of both imaging modalities, which are recommended by current guidelines for percutaneous coronary intervention guidance. These findings contribute to understanding the relative performance and clinical utility of optical coherence tomography and intravascular ultrasound in this critical patient population.</p>
<p>Article number four. Revascularization in Patients Over 75 With Acute Coronary Syndrome. This retrospective analysis investigated revascularization strategies in patients over 75 years old presenting with acute coronary syndromes. Observational data previously showed that coronary artery bypass graft was associated with improved one-year outcomes, including lower rates of death and rehospitalization, compared to percutaneous coronary intervention and medical management in general acute coronary syndrome patients with multivessel coronary artery disease. This study provided specific data addressing these outcomes in the elderly population. The findings contribute to clinical decision-making for optimal revascularization strategies in acute coronary syndrome patients aged over 75.</p>
<p>Article number five. Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry. This study analyzed mortality following percutaneous coronary intervention using data from the P. R. O. G. R. E. S. S. minus C. O. M. P. L. I. C. A. T. I. O. N. S. registry. Among 22503 patients undergoing percutaneous coronary intervention, 115 patients, representing 0.5 percent, died before hospital discharge. Researchers found that 15 patients, 13.0 percent of the mortalities, died during the procedure, while 10 patients, 8.7 percent, died within the first 24 hours post-procedure, and 90 patients, 78.3 percent, died more than 24 hours after the intervention. The study also revealed that patients who died exhibited a high burden of comorbidities. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart transplant rejection, Percutaneous coronary intervention, P. C. I. mortality, comorbidities, Optical coherence tomography, Hispanic/Latino population, in-hospital death, intravascular ultrasound, percutaneous coronary intervention, Revascularization, coronary artery bypass graft, S. T.-elevation myocardial infarction, ZBP1, RIPK1, PROGRESS-COMPLICATIONS registry, echocardiography, heart failure risk factors, elderly patients, reference values, ADAR1, PANoptosis, intravascular imaging, Global longitudinal strain, acute coronary syndrome.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/">Percutaneous Coronary Intervention Mortality Breakdown. 02/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260216_060028.mp3" length="4884941" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 16, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplant rejection and Percutaneous coronary intervention. Key takeaway: Percutaneous Coronary Intervention Mortality Breakdown..
Article Links:
Article 1: ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL). (The American journal of cardiology)
Article 3: Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis. (The American journal of cardiology)
Article 4: Revascularization in Patients Over 75 With Acute Coronary Syndrome. (The American journal of cardiology)
Article 5: Death Following Percutaneous Coronary Intervention: Data from the PROGRESS-COMPLICATIONS registry. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/percutaneous-coronary-intervention-mortality-breakdown-02-16-26/
 Featured Articles
Article 1: ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41692363
Summary: This study found that Z-DNA induced PANoptosis in human microvascular endothelial cells through ZBP1. Researchers observed that ADAR1 and R. I. P. K. one collaboratively regulated the activation of the ZBP1-R. I. P. K. three complex, controlling PANoptosis in a time-dependent manner. The interaction of ADAR1 with ZBP1 specifically protected against Z-DNA-induced cell death. These findings reveal crucial molecular mechanisms driving PANoptosis and its potential relevance in heart transplant rejection.
Article 2: Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL).
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41478442
Summary: This study established global longitudinal strain reference values for the Hispanic/Latino population using data from the Echocardiographic Study of Latinos. Researchers defined the 95th-percentile lower limit of normal global longitudinal strain values from a healthy reference sample. These established values provide essential clinical benchmarks for detecting early cardiac dysfunction in this specific demographic. The findings offer crucial guidance for assessing heart failure risk factors and interpreting echocardiographic results in Hispanic/Latino patients.
Article 3: Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41421515
Summary: This multicenter analysis compared clinical outcomes of optical coherence tomography versus intravascular ultrasound guidance for primary percutaneous coronary intervention in patients with S. T.-elevation myocardial infarction. The study utilized data from 2777 S. T.-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention at 12 Japanese hospitals. Researchers found comparative data on the use of both imaging modalities, which are recommended by current guidelines for percutaneous coronary intervention guidance. These findings contribute to understanding the relative performance and clinical utility of optical coherence tomography and intravasc]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 16, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplant rejection and Percutaneous coronary intervention. Key takeaway: Percutaneous Coronary Intervention Mortality Breakdown..
Article Links:
Article 1: ADAR1 and RIPK1 orchestrate the ZBP1-mediated PANoptosis and mouse heart transplant rejection. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL). (The American journal of cardiology)
Article 3: Optical Coherence Tomography versus Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Multicenter Propensity-Matched Analysis. (The American journal of cardiology)
Article 4: Revascularization in Patients Over 75 With A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>E. C. G. Boosts Microvascular Disease Detection 02/15/26</title>
	<link>https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/</link>
	<pubDate>Mon, 16 Feb 2026 02:11:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and heart failure with preserved ejection fraction. Key takeaway: E. C. G. Boosts Microvascular Disease Detection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41690708">Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41320292">Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40707240">Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40670148">Timing of anticoagulation restart after serious bleeding in atrial fibrillation.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40645760">Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/">https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41690708" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41690708</a></p>
<p><strong>Summary:</strong> Exercise electrocardiography showing ST-segment depression demonstrates a very high positive predictive value for coronary microvascular dysfunction in specific patient groups. The present study focused on chest pain patients, using myocardial perfusion single photon emission computed tomography to rule out ischemia from epicardial coronary stenosis. This approach precisely identifies patients with suspected coronary microvascular dysfunction. Such precise identification is crucial for managing this condition, which is associated with a poor prognosis.</p>
<h4>Article 2: Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41320292" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41320292</a></p>
<p><strong>Summary:</strong> Recurrent mitral regurgitation remains a major limitation of mitral valve repair in patients with advanced degenerative mitral regurgitation and left ventricular enlargement. This retrospective study included 445 patients with advanced degenerative mitral regurgitation, classified as stages C two to D, who underwent mitral valve repair with restrictive annuloplasty. The investigation focused on whether a disproportion between left ventricular size and prosthetic annulus dimension predicts long-term mitral regurgitation recurrence. This research addresses a critical aspect of durable mitral valve repair outcomes and adverse left ventricular remodeling.</p>
<h4>Article 3: Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40707240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40707240</a></p>
<p><strong>Summary:</strong> Tricuspid regurgitation is a common finding in heart failure and associates with adverse patient outcomes. This study precisely assessed sex differences in tricuspid regurgitation prevalence, etiology, and prognosis among patients with heart failure and its subgroups. Patients were enrolled with recent transthoracic echocardiography and categorized by left ventricular ejection fraction into groups with reduced and preserved ejection fraction, using a 50 percent cutoff. This research contributes to understanding sex-specific manifestations and prognostic implications of tricuspid regurgitation in heart failure patients.</p>
<h4>Article 4: Timing of anticoagulation restart after serious bleeding in atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40670148" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40670148</a></p>
<p><strong>Summary:</strong> Restarting direct oral anticoagulants after a serious bleeding event in patients with atrial fibrillation presents a significant clinical dilemma, balancing stroke prevention and recurrent bleeding risk. This study leveraged nationwide Danish registries from 2012 to 2021 to identify atrial fibrillation patients who experienced serious bleeding events. The cohort included individuals with a Congestive heart failure, Hypertension, Age seventy-five (doubled), Diabetes, Stroke (doubled), Vascular disease, Age sixty-five to seventy-four, Sex category (female) (C. H. A. two D. S. two V. A. S. c) score of two or higher. This research provides crucial data to inform the optimal timing of anticoagulation restart in these high-risk patients.</p>
<h4>Article 5: Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645760" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645760</a></p>
<p><strong>Summary:</strong> Myeloperoxidase, a neutrophil-derived enzyme, associates with oxidative stress and inflammation, contributing to the pathophysiology of heart failure with preserved ejection fraction. Bioactive myeloperoxidase also causes vascular dysfunction and accumulation of serum uric acid. This cross-sectional analysis of 1677 participants from the STANISLAS cohort investigated the association of plasma myeloperoxidase and serum uric acid with echocardiographic variables of impaired diastolic function in a populational setting. This research helps elucidate mechanisms and identify early biomarkers for heart failure with preserved ejection fraction development.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease. Exercise electrocardiography showing ST-segment depression demonstrates a very high positive predictive value for coronary microvascular dysfunction in specific patient groups. The present study focused on chest pain patients, using myocardial perfusion single photon emission computed tomography to rule out ischemia from epicardial coronary stenosis. This approach precisely identifies patients with suspected coronary microvascular dysfunction. Such precise identification is crucial for managing this condition, which is associated with a poor prognosis.</p>
<p>Article number two. Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease. Recurrent mitral regurgitation remains a major limitation of mitral valve repair in patients with advanced degenerative mitral regurgitation and left ventricular enlargement. This retrospective study included 445 patients with advanced degenerative mitral regurgitation, classified as stages C two to D, who underwent mitral valve repair with restrictive annuloplasty. The investigation focused on whether a disproportion between left ventricular size and prosthetic annulus dimension predicts long-term mitral regurgitation recurrence. This research addresses a critical aspect of durable mitral valve repair outcomes and adverse left ventricular remodeling.</p>
<p>Article number three. Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure. Tricuspid regurgitation is a common finding in heart failure and associates with adverse patient outcomes. This study precisely assessed sex differences in tricuspid regurgitation prevalence, etiology, and prognosis among patients with heart failure and its subgroups. Patients were enrolled with recent transthoracic echocardiography and categorized by left ventricular ejection fraction into groups with reduced and preserved ejection fraction, using a 50 percent cutoff. This research contributes to understanding sex-specific manifestations and prognostic implications of tricuspid regurgitation in heart failure patients.</p>
<p>Article number four. Timing of anticoagulation restart after serious bleeding in atrial fibrillation. Restarting direct oral anticoagulants after a serious bleeding event in patients with atrial fibrillation presents a significant clinical dilemma, balancing stroke prevention and recurrent bleeding risk. This study leveraged nationwide Danish registries from 2012 to 2021 to identify atrial fibrillation patients who experienced serious bleeding events. The cohort included individuals with a Congestive heart failure, Hypertension, Age seventy-five (doubled), Diabetes, Stroke (doubled), Vascular disease, Age sixty-five to seventy-four, Sex category (female) (C. H. A. two D. S. two V. A. S. c) score of two or higher. This research provides crucial data to inform the optimal timing of anticoagulation restart in these high-risk patients.</p>
<p>Article number five. Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals. Myeloperoxidase, a neutrophil-derived enzyme, associates with oxidative stress and inflammation, contributing to the pathophysiology of heart failure with preserved ejection fraction. Bioactive myeloperoxidase also causes vascular dysfunction and accumulation of serum uric acid. This cross-sectional analysis of 1677 participants from the STANISLAS cohort investigated the association of plasma myeloperoxidase and serum uric acid with echocardiographic variables of impaired diastolic function in a populational setting. This research helps elucidate mechanisms and identify early biomarkers for heart failure with preserved ejection fraction development. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sex differences, heart failure with preserved ejection fraction, coronary microvascular dysfunction, stroke prevention, direct oral anticoagulants, mitral regurgitation, atrial fibrillation, ST-segment depression, left ventricular ejection fraction, diagnosis, anticoagulation restart, myeloperoxidase, myocardial perfusion imaging, annuloplasty, bleeding events, prosthetic annulus, diastolic dysfunction, echocardiography, mitral valve repair, exercise electrocardiography, tricuspid regurgitation, serum uric acid, heart failure, left ventricular remodeling.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/">E. C. G. Boosts Microvascular Disease Detection 02/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and heart failure with preserved ejection fraction. Key takeaway: E. C. G. Boosts Microvascular Disease Detection.
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and heart failure with preserved ejection fraction. Key takeaway: E. C. G. Boosts Microvascular Disease Detection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41690708">Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41320292">Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40707240">Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40670148">Timing of anticoagulation restart after serious bleeding in atrial fibrillation.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40645760">Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/">https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41690708" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41690708</a></p>
<p><strong>Summary:</strong> Exercise electrocardiography showing ST-segment depression demonstrates a very high positive predictive value for coronary microvascular dysfunction in specific patient groups. The present study focused on chest pain patients, using myocardial perfusion single photon emission computed tomography to rule out ischemia from epicardial coronary stenosis. This approach precisely identifies patients with suspected coronary microvascular dysfunction. Such precise identification is crucial for managing this condition, which is associated with a poor prognosis.</p>
<h4>Article 2: Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41320292" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41320292</a></p>
<p><strong>Summary:</strong> Recurrent mitral regurgitation remains a major limitation of mitral valve repair in patients with advanced degenerative mitral regurgitation and left ventricular enlargement. This retrospective study included 445 patients with advanced degenerative mitral regurgitation, classified as stages C two to D, who underwent mitral valve repair with restrictive annuloplasty. The investigation focused on whether a disproportion between left ventricular size and prosthetic annulus dimension predicts long-term mitral regurgitation recurrence. This research addresses a critical aspect of durable mitral valve repair outcomes and adverse left ventricular remodeling.</p>
<h4>Article 3: Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40707240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40707240</a></p>
<p><strong>Summary:</strong> Tricuspid regurgitation is a common finding in heart failure and associates with adverse patient outcomes. This study precisely assessed sex differences in tricuspid regurgitation prevalence, etiology, and prognosis among patients with heart failure and its subgroups. Patients were enrolled with recent transthoracic echocardiography and categorized by left ventricular ejection fraction into groups with reduced and preserved ejection fraction, using a 50 percent cutoff. This research contributes to understanding sex-specific manifestations and prognostic implications of tricuspid regurgitation in heart failure patients.</p>
<h4>Article 4: Timing of anticoagulation restart after serious bleeding in atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40670148" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40670148</a></p>
<p><strong>Summary:</strong> Restarting direct oral anticoagulants after a serious bleeding event in patients with atrial fibrillation presents a significant clinical dilemma, balancing stroke prevention and recurrent bleeding risk. This study leveraged nationwide Danish registries from 2012 to 2021 to identify atrial fibrillation patients who experienced serious bleeding events. The cohort included individuals with a Congestive heart failure, Hypertension, Age seventy-five (doubled), Diabetes, Stroke (doubled), Vascular disease, Age sixty-five to seventy-four, Sex category (female) (C. H. A. two D. S. two V. A. S. c) score of two or higher. This research provides crucial data to inform the optimal timing of anticoagulation restart in these high-risk patients.</p>
<h4>Article 5: Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645760" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645760</a></p>
<p><strong>Summary:</strong> Myeloperoxidase, a neutrophil-derived enzyme, associates with oxidative stress and inflammation, contributing to the pathophysiology of heart failure with preserved ejection fraction. Bioactive myeloperoxidase also causes vascular dysfunction and accumulation of serum uric acid. This cross-sectional analysis of 1677 participants from the STANISLAS cohort investigated the association of plasma myeloperoxidase and serum uric acid with echocardiographic variables of impaired diastolic function in a populational setting. This research helps elucidate mechanisms and identify early biomarkers for heart failure with preserved ejection fraction development.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease. Exercise electrocardiography showing ST-segment depression demonstrates a very high positive predictive value for coronary microvascular dysfunction in specific patient groups. The present study focused on chest pain patients, using myocardial perfusion single photon emission computed tomography to rule out ischemia from epicardial coronary stenosis. This approach precisely identifies patients with suspected coronary microvascular dysfunction. Such precise identification is crucial for managing this condition, which is associated with a poor prognosis.</p>
<p>Article number two. Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease. Recurrent mitral regurgitation remains a major limitation of mitral valve repair in patients with advanced degenerative mitral regurgitation and left ventricular enlargement. This retrospective study included 445 patients with advanced degenerative mitral regurgitation, classified as stages C two to D, who underwent mitral valve repair with restrictive annuloplasty. The investigation focused on whether a disproportion between left ventricular size and prosthetic annulus dimension predicts long-term mitral regurgitation recurrence. This research addresses a critical aspect of durable mitral valve repair outcomes and adverse left ventricular remodeling.</p>
<p>Article number three. Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure. Tricuspid regurgitation is a common finding in heart failure and associates with adverse patient outcomes. This study precisely assessed sex differences in tricuspid regurgitation prevalence, etiology, and prognosis among patients with heart failure and its subgroups. Patients were enrolled with recent transthoracic echocardiography and categorized by left ventricular ejection fraction into groups with reduced and preserved ejection fraction, using a 50 percent cutoff. This research contributes to understanding sex-specific manifestations and prognostic implications of tricuspid regurgitation in heart failure patients.</p>
<p>Article number four. Timing of anticoagulation restart after serious bleeding in atrial fibrillation. Restarting direct oral anticoagulants after a serious bleeding event in patients with atrial fibrillation presents a significant clinical dilemma, balancing stroke prevention and recurrent bleeding risk. This study leveraged nationwide Danish registries from 2012 to 2021 to identify atrial fibrillation patients who experienced serious bleeding events. The cohort included individuals with a Congestive heart failure, Hypertension, Age seventy-five (doubled), Diabetes, Stroke (doubled), Vascular disease, Age sixty-five to seventy-four, Sex category (female) (C. H. A. two D. S. two V. A. S. c) score of two or higher. This research provides crucial data to inform the optimal timing of anticoagulation restart in these high-risk patients.</p>
<p>Article number five. Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals. Myeloperoxidase, a neutrophil-derived enzyme, associates with oxidative stress and inflammation, contributing to the pathophysiology of heart failure with preserved ejection fraction. Bioactive myeloperoxidase also causes vascular dysfunction and accumulation of serum uric acid. This cross-sectional analysis of 1677 participants from the STANISLAS cohort investigated the association of plasma myeloperoxidase and serum uric acid with echocardiographic variables of impaired diastolic function in a populational setting. This research helps elucidate mechanisms and identify early biomarkers for heart failure with preserved ejection fraction development. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sex differences, heart failure with preserved ejection fraction, coronary microvascular dysfunction, stroke prevention, direct oral anticoagulants, mitral regurgitation, atrial fibrillation, ST-segment depression, left ventricular ejection fraction, diagnosis, anticoagulation restart, myeloperoxidase, myocardial perfusion imaging, annuloplasty, bleeding events, prosthetic annulus, diastolic dysfunction, echocardiography, mitral valve repair, exercise electrocardiography, tricuspid regurgitation, serum uric acid, heart failure, left ventricular remodeling.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/">E. C. G. Boosts Microvascular Disease Detection 02/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260215_210959.mp3" length="4459040" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and heart failure with preserved ejection fraction. Key takeaway: E. C. G. Boosts Microvascular Disease Detection.
Article Links:
Article 1: Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease. (Heart (British Cardiac Society))
Article 2: Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease. (Heart (British Cardiac Society))
Article 3: Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure. (Heart (British Cardiac Society))
Article 4: Timing of anticoagulation restart after serious bleeding in atrial fibrillation. (Heart (British Cardiac Society))
Article 5: Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/e-c-g-boosts-microvascular-disease-detection-02-15-26/
 Featured Articles
Article 1: Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41690708
Summary: Exercise electrocardiography showing ST-segment depression demonstrates a very high positive predictive value for coronary microvascular dysfunction in specific patient groups. The present study focused on chest pain patients, using myocardial perfusion single photon emission computed tomography to rule out ischemia from epicardial coronary stenosis. This approach precisely identifies patients with suspected coronary microvascular dysfunction. Such precise identification is crucial for managing this condition, which is associated with a poor prognosis.
Article 2: Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41320292
Summary: Recurrent mitral regurgitation remains a major limitation of mitral valve repair in patients with advanced degenerative mitral regurgitation and left ventricular enlargement. This retrospective study included 445 patients with advanced degenerative mitral regurgitation, classified as stages C two to D, who underwent mitral valve repair with restrictive annuloplasty. The investigation focused on whether a disproportion between left ventricular size and prosthetic annulus dimension predicts long-term mitral regurgitation recurrence. This research addresses a critical aspect of durable mitral valve repair outcomes and adverse left ventricular remodeling.
Article 3: Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40707240
Summary: Tricuspid regurgitation is a common finding in heart failure and associates with adverse patient outcomes. This study precisely assessed sex differences in tricuspid regurgitation prevalence, etiology, and prognosis among patients with heart failure and its subgroups. Patients were enrolled with recent transthoracic echocardiography and categorized by left ventricular ejection fraction into groups with reduced and preserved ejection fraction, using a 50 percent cutoff. This research contributes to understanding sex-specific manifestations and prognostic implications of tricuspid regurgitation in heart failure patients.
Article 4: Timing of anticoagulation restart after serious bleeding in atrial fibrillation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40670148
Summary: Restarting direct oral anticoagulants after a serious bleeding event in patients with atrial fibrillation presents a significant clinical ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like sex differences and heart failure with preserved ejection fraction. Key takeaway: E. C. G. Boosts Microvascular Disease Detection.
Article Links:
Article 1: Prognostic importance of exercise electrocardiography in patients with suspected microvascular disease. (Heart (British Cardiac Society))
Article 2: Prosthetic annulus size mismatch and recurrent mitral regurgitation after repair in advanced degenerative disease. (Heart (British Cardiac Society))
Article 3: Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure. (Heart (British Cardiac Society))
Article 4: Timing of anticoagulation restart after serious bleeding in atrial fibrillation. (Heart (British Cardiac Society))
Article 5: Plasma myeloperoxidase and echocardiographic markers of impaired diastolic function in healthy individuals. (Heart (British Cardia]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Remote Heart Failure Management Sustains Benefits 02/15/26</title>
	<link>https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/</link>
	<pubDate>Sun, 15 Feb 2026 11:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like N. L. R. P. three and lipid management. Key takeaway: Remote Heart Failure Management Sustains Benefits.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41684258">Lipoprotein(a)-lowering therapies: a promising future.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41684124">Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41686133">Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41690842">Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41690369">Airway molecular signatures in antibody mediated lung transplant rejection.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/">https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lipoprotein(a)-lowering therapies: a promising future.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684258" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684258</a></p>
<p><strong>Summary:</strong> This article identifies lipoprotein(a), or L. P. A., as a significant, genetically determined contributor to atherosclerotic cardiovascular disease. Elevated L. P. A. levels drive increased atherogenicity, contributing substantially to residual cardiovascular risk despite successful low-density lipoprotein cholesterol management. Affecting a large proportion of the population, L. P. A. represents a high-impact therapeutic target. Future L. P. A.-lowering therapies therefore hold considerable promise for reducing cardiovascular morbidity and mortality.</p>
<h4>Article 2: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684124</a></p>
<p><strong>Summary:</strong> B. K. two suppresses inflammation and atherosclerosis by N. L. R. P. three phosphorylation. This study found that macrophage S. H. three domain-binding kinase two, known as S. B. K. two, actively suppresses inflammation and atherosclerosis. S. B. K. two achieves this by phosphorylating nucleotide-binding oligomerization domain-like receptor family pyrin domain containing three, or N. L. R. P. three. This specific molecular mechanism highlights S. B. K. two&#8217;s pivotal role in modulating macrophage-mediated inflammatory responses. These findings identify S. B. K. two as a significant therapeutic target for managing the progression of atherosclerosis.</p>
<h4>Article 3: Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41686133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41686133</a></p>
<p><strong>Summary:</strong> The PROACTIVE-H. F. trial demonstrated that remote heart failure management, using seated mean pulmonary artery pressure and vital signs via the Cordella system, was safe and effective. This approach resulted in a low rate of heart failure hospitalizations and mortality, which was initially observed through 6 months. The 12-month evaluation confirmed the sustained efficacy and continued benefits of this management approach for patients with New York Heart Association class three heart failure. This method offers a valuable strategy for reducing adverse events in this high-risk patient population.</p>
<h4>Article 4: Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41690842" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41690842</a></p>
<p><strong>Summary:</strong> This Australian cohort study found that children born to mothers with kidney transplants experienced increased hospital utilization during early childhood. From 2067661 babies, 137 children of transplanted mothers were identified, experiencing 137 birth admissions and 444 subsequent admissions. The data demonstrated that these children had a higher burden of adverse health outcomes, requiring more frequent hospitalizations compared to children of mothers not exposed to kidney replacement therapy. This provides critical definition to previously undefined childhood health outcomes for this specific population.</p>
<h4>Article 5: Airway molecular signatures in antibody mediated lung transplant rejection.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41690369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41690369</a></p>
<p><strong>Summary:</strong> This study found that specific airway inflammation gene signatures effectively distinguished antibody mediated rejection, or A. M. R., cases from controls in lung transplant recipients. The analysis of small airway brush R. N. A. sequencing from 16 A. M. R. cases and 39 controls revealed distinct gene signatures for complement activation, mechanistic target of rapamycin signaling, and natural killer cell-mediated responses. These identified molecular signatures provide novel and precise biomarkers needed for more accurate diagnosis of severe A. M. R. This advancement offers potential for improved diagnostic precision for a condition associated with chronic lung allograft dysfunction and death.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lipoprotein(a)-lowering therapies: a promising future. This article identifies lipoprotein(a), or L. P. A., as a significant, genetically determined contributor to atherosclerotic cardiovascular disease. Elevated L. P. A. levels drive increased atherogenicity, contributing substantially to residual cardiovascular risk despite successful low-density lipoprotein cholesterol management. Affecting a large proportion of the population, L. P. A. represents a high-impact therapeutic target. Future L. P. A.-lowering therapies therefore hold considerable promise for reducing cardiovascular morbidity and mortality.</p>
<p>Article number two. Macrophage S. B. K. two suppresses inflammation and atherosclerosis by N. L. R. P. three phosphorylation. This study found that macrophage S. H. three domain-binding kinase two, known as S. B. K. two, actively suppresses inflammation and atherosclerosis. S. B. K. two achieves this by phosphorylating nucleotide-binding oligomerization domain-like receptor family pyrin domain containing three, or N. L. R. P. three. This specific molecular mechanism highlights S. B. K. two&#8217;s pivotal role in modulating macrophage-mediated inflammatory responses. These findings identify S. B. K. two as a significant therapeutic target for managing the progression of atherosclerosis.</p>
<p>Article number three. Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial. The PROACTIVE-H. F. trial demonstrated that remote heart failure management, using seated mean pulmonary artery pressure and vital signs via the Cordella system, was safe and effective. This approach resulted in a low rate of heart failure hospitalizations and mortality, which was initially observed through 6 months. The 12-month evaluation confirmed the sustained efficacy and continued benefits of this management approach for patients with New York Heart Association class three heart failure. This method offers a valuable strategy for reducing adverse events in this high-risk patient population.</p>
<p>Article number four. Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study. This Australian cohort study found that children born to mothers with kidney transplants experienced increased hospital utilization during early childhood. From 2067661 babies, 137 children of transplanted mothers were identified, experiencing 137 birth admissions and 444 subsequent admissions. The data demonstrated that these children had a higher burden of adverse health outcomes, requiring more frequent hospitalizations compared to children of mothers not exposed to kidney replacement therapy. This provides critical definition to previously undefined childhood health outcomes for this specific population.</p>
<p>Article number five. Airway molecular signatures in antibody mediated lung transplant rejection. This study found that specific airway inflammation gene signatures effectively distinguished antibody mediated rejection, or A. M. R., cases from controls in lung transplant recipients. The analysis of small airway brush R. N. A. sequencing from 16 A. M. R. cases and 39 controls revealed distinct gene signatures for complement activation, mechanistic target of rapamycin signaling, and natural killer cell-mediated responses. These identified molecular signatures provide novel and precise biomarkers needed for more accurate diagnosis of severe A. M. R. This advancement offers potential for improved diagnostic precision for a condition associated with chronic lung allograft dysfunction and death. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>N. L. R. P. three, lipid management, lung transplant, pulmonary artery pressure, therapeutic targets, remote monitoring, Macrophage, Heart failure, atherosclerosis, biomarkers, birth outcomes, S. B. K. two, airway inflammation, inflammation, Australian cohort, PROACTIVE-H. F. trial, Kidney transplant, cardiovascular risk, Antibody mediated rejection, SH3 domain-binding kinase two, gene signatures, Lipoprotein(a), hospitalization, hospital utilization, childhood health, atherosclerotic cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/">Remote Heart Failure Management Sustains Benefits 02/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like N. L. R. P. three and lipid management. Key takeaway: Remote Heart Failure Management Sustains Benefits.
Article Links:
Article 1: L]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like N. L. R. P. three and lipid management. Key takeaway: Remote Heart Failure Management Sustains Benefits.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41684258">Lipoprotein(a)-lowering therapies: a promising future.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41684124">Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41686133">Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41690842">Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41690369">Airway molecular signatures in antibody mediated lung transplant rejection.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/">https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lipoprotein(a)-lowering therapies: a promising future.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684258" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684258</a></p>
<p><strong>Summary:</strong> This article identifies lipoprotein(a), or L. P. A., as a significant, genetically determined contributor to atherosclerotic cardiovascular disease. Elevated L. P. A. levels drive increased atherogenicity, contributing substantially to residual cardiovascular risk despite successful low-density lipoprotein cholesterol management. Affecting a large proportion of the population, L. P. A. represents a high-impact therapeutic target. Future L. P. A.-lowering therapies therefore hold considerable promise for reducing cardiovascular morbidity and mortality.</p>
<h4>Article 2: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684124</a></p>
<p><strong>Summary:</strong> B. K. two suppresses inflammation and atherosclerosis by N. L. R. P. three phosphorylation. This study found that macrophage S. H. three domain-binding kinase two, known as S. B. K. two, actively suppresses inflammation and atherosclerosis. S. B. K. two achieves this by phosphorylating nucleotide-binding oligomerization domain-like receptor family pyrin domain containing three, or N. L. R. P. three. This specific molecular mechanism highlights S. B. K. two&#8217;s pivotal role in modulating macrophage-mediated inflammatory responses. These findings identify S. B. K. two as a significant therapeutic target for managing the progression of atherosclerosis.</p>
<h4>Article 3: Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41686133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41686133</a></p>
<p><strong>Summary:</strong> The PROACTIVE-H. F. trial demonstrated that remote heart failure management, using seated mean pulmonary artery pressure and vital signs via the Cordella system, was safe and effective. This approach resulted in a low rate of heart failure hospitalizations and mortality, which was initially observed through 6 months. The 12-month evaluation confirmed the sustained efficacy and continued benefits of this management approach for patients with New York Heart Association class three heart failure. This method offers a valuable strategy for reducing adverse events in this high-risk patient population.</p>
<h4>Article 4: Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41690842" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41690842</a></p>
<p><strong>Summary:</strong> This Australian cohort study found that children born to mothers with kidney transplants experienced increased hospital utilization during early childhood. From 2067661 babies, 137 children of transplanted mothers were identified, experiencing 137 birth admissions and 444 subsequent admissions. The data demonstrated that these children had a higher burden of adverse health outcomes, requiring more frequent hospitalizations compared to children of mothers not exposed to kidney replacement therapy. This provides critical definition to previously undefined childhood health outcomes for this specific population.</p>
<h4>Article 5: Airway molecular signatures in antibody mediated lung transplant rejection.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41690369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41690369</a></p>
<p><strong>Summary:</strong> This study found that specific airway inflammation gene signatures effectively distinguished antibody mediated rejection, or A. M. R., cases from controls in lung transplant recipients. The analysis of small airway brush R. N. A. sequencing from 16 A. M. R. cases and 39 controls revealed distinct gene signatures for complement activation, mechanistic target of rapamycin signaling, and natural killer cell-mediated responses. These identified molecular signatures provide novel and precise biomarkers needed for more accurate diagnosis of severe A. M. R. This advancement offers potential for improved diagnostic precision for a condition associated with chronic lung allograft dysfunction and death.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lipoprotein(a)-lowering therapies: a promising future. This article identifies lipoprotein(a), or L. P. A., as a significant, genetically determined contributor to atherosclerotic cardiovascular disease. Elevated L. P. A. levels drive increased atherogenicity, contributing substantially to residual cardiovascular risk despite successful low-density lipoprotein cholesterol management. Affecting a large proportion of the population, L. P. A. represents a high-impact therapeutic target. Future L. P. A.-lowering therapies therefore hold considerable promise for reducing cardiovascular morbidity and mortality.</p>
<p>Article number two. Macrophage S. B. K. two suppresses inflammation and atherosclerosis by N. L. R. P. three phosphorylation. This study found that macrophage S. H. three domain-binding kinase two, known as S. B. K. two, actively suppresses inflammation and atherosclerosis. S. B. K. two achieves this by phosphorylating nucleotide-binding oligomerization domain-like receptor family pyrin domain containing three, or N. L. R. P. three. This specific molecular mechanism highlights S. B. K. two&#8217;s pivotal role in modulating macrophage-mediated inflammatory responses. These findings identify S. B. K. two as a significant therapeutic target for managing the progression of atherosclerosis.</p>
<p>Article number three. Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial. The PROACTIVE-H. F. trial demonstrated that remote heart failure management, using seated mean pulmonary artery pressure and vital signs via the Cordella system, was safe and effective. This approach resulted in a low rate of heart failure hospitalizations and mortality, which was initially observed through 6 months. The 12-month evaluation confirmed the sustained efficacy and continued benefits of this management approach for patients with New York Heart Association class three heart failure. This method offers a valuable strategy for reducing adverse events in this high-risk patient population.</p>
<p>Article number four. Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study. This Australian cohort study found that children born to mothers with kidney transplants experienced increased hospital utilization during early childhood. From 2067661 babies, 137 children of transplanted mothers were identified, experiencing 137 birth admissions and 444 subsequent admissions. The data demonstrated that these children had a higher burden of adverse health outcomes, requiring more frequent hospitalizations compared to children of mothers not exposed to kidney replacement therapy. This provides critical definition to previously undefined childhood health outcomes for this specific population.</p>
<p>Article number five. Airway molecular signatures in antibody mediated lung transplant rejection. This study found that specific airway inflammation gene signatures effectively distinguished antibody mediated rejection, or A. M. R., cases from controls in lung transplant recipients. The analysis of small airway brush R. N. A. sequencing from 16 A. M. R. cases and 39 controls revealed distinct gene signatures for complement activation, mechanistic target of rapamycin signaling, and natural killer cell-mediated responses. These identified molecular signatures provide novel and precise biomarkers needed for more accurate diagnosis of severe A. M. R. This advancement offers potential for improved diagnostic precision for a condition associated with chronic lung allograft dysfunction and death. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>N. L. R. P. three, lipid management, lung transplant, pulmonary artery pressure, therapeutic targets, remote monitoring, Macrophage, Heart failure, atherosclerosis, biomarkers, birth outcomes, S. B. K. two, airway inflammation, inflammation, Australian cohort, PROACTIVE-H. F. trial, Kidney transplant, cardiovascular risk, Antibody mediated rejection, SH3 domain-binding kinase two, gene signatures, Lipoprotein(a), hospitalization, hospital utilization, childhood health, atherosclerotic cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/">Remote Heart Failure Management Sustains Benefits 02/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260215_060022.mp3" length="4484954" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like N. L. R. P. three and lipid management. Key takeaway: Remote Heart Failure Management Sustains Benefits.
Article Links:
Article 1: Lipoprotein(a)-lowering therapies: a promising future. (European heart journal)
Article 2: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation. (European heart journal)
Article 3: Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial. (JACC. Heart failure)
Article 4: Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Airway molecular signatures in antibody mediated lung transplant rejection. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Full episode page: https://podcast.explainheart.com/podcast/remote-heart-failure-management-sustains-benefits-02-15-26/
 Featured Articles
Article 1: Lipoprotein(a)-lowering therapies: a promising future.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41684258
Summary: This article identifies lipoprotein(a), or L. P. A., as a significant, genetically determined contributor to atherosclerotic cardiovascular disease. Elevated L. P. A. levels drive increased atherogenicity, contributing substantially to residual cardiovascular risk despite successful low-density lipoprotein cholesterol management. Affecting a large proportion of the population, L. P. A. represents a high-impact therapeutic target. Future L. P. A.-lowering therapies therefore hold considerable promise for reducing cardiovascular morbidity and mortality.
Article 2: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41684124
Summary: B. K. two suppresses inflammation and atherosclerosis by N. L. R. P. three phosphorylation. This study found that macrophage S. H. three domain-binding kinase two, known as S. B. K. two, actively suppresses inflammation and atherosclerosis. S. B. K. two achieves this by phosphorylating nucleotide-binding oligomerization domain-like receptor family pyrin domain containing three, or N. L. R. P. three. This specific molecular mechanism highlights S. B. K. two&#8217;s pivotal role in modulating macrophage-mediated inflammatory responses. These findings identify S. B. K. two as a significant therapeutic target for managing the progression of atherosclerosis.
Article 3: Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41686133
Summary: The PROACTIVE-H. F. trial demonstrated that remote heart failure management, using seated mean pulmonary artery pressure and vital signs via the Cordella system, was safe and effective. This approach resulted in a low rate of heart failure hospitalizations and mortality, which was initially observed through 6 months. The 12-month evaluation confirmed the sustained efficacy and continued benefits of this management approach for patients with New York Heart Association class three heart failure. This method offers a valuable strategy for reducing adverse events in this high-risk patient population.
Article 4: Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pub]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 15, 2026. This episode summarizes 5 key cardiology studies on topics like N. L. R. P. three and lipid management. Key takeaway: Remote Heart Failure Management Sustains Benefits.
Article Links:
Article 1: Lipoprotein(a)-lowering therapies: a promising future. (European heart journal)
Article 2: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation. (European heart journal)
Article 3: Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial. (JACC. Heart failure)
Article 4: Early childhood hospital utilization and diagnoses for children born to mothers with kidney transplants: An Australian cohort study. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Airway molecular signatures in antibody mediated lung transplant rejection. (American j]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Soluble S. T. 2 Drives Fulminant Myocarditis 02/14/26</title>
	<link>https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/</link>
	<pubDate>Sat, 14 Feb 2026 11:01:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 14, 2026. This episode summarizes 5 key cardiology studies on topics like C. C. R. 8 and Left Heart Dysfunction. Key takeaway: Soluble S. T. 2 Drives Fulminant Myocarditis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41685452">Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41685444">CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41685669">Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41684269">Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41684267">Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/">https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41685452" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41685452</a></p>
<p><strong>Summary:</strong> The study identified a distinct subgroup of patients within adjudicated Group 1 Pulmonary Hypertension who demonstrated an elevated pulmonary artery wedge pressure, exceeding 15 mmHg. It characterized this patient population by comparing their profiles to those with normal pulmonary artery wedge pressure and to patients with combined pre- and postcapillary pulmonary hypertension. This work establishes that not all Group 1 Pulmonary Hypertension patients present with the expected normal pulmonary artery wedge pressure, highlighting diagnostic complexities.</p>
<h4>Article 2: CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41685444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41685444</a></p>
<p><strong>Summary:</strong> C. R. 8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. This study revealed that C. C. R. 8 expression on regulatory T cells dictates their tissue adaptation trajectories within the heart following myocardial infarction. It found that these C. C. R. 8-positive regulatory T cells provide protection against myocardial infarction-induced tissue damage. The data delineated specific differentiation pathways of heart regulatory T cells in a murine model, establishing a molecular mechanism for regulatory T cell-mediated cardiac protection.</p>
<h4>Article 3: Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41685669" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41685669</a></p>
<p><strong>Summary:</strong> This study, using spatial and single-cell transcriptomics on 13 human carotid plaques, revealed a key role for fibroblast-like vascular smooth muscle cells in atherosclerotic cell crosstalk and plaque stability. It precisely mapped intercellular communication patterns within the human plaque microenvironments. The data demonstrated that these specific fibroblast-like vascular smooth muscle cells are critical mediators, identifying specific cellular interactions as potential novel targets for preventing atherosclerotic events.</p>
<h4>Article 4: Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684269</a></p>
<p><strong>Summary:</strong> T. 2 drives fulminant myocarditis progression via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. This study demonstrated that soluble S. T. 2 drives the progression of fulminant myocarditis via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. It defined the cellular source and function of soluble S. T. 2 in a Coxsackievirus B3-induced fulminant myocarditis mouse model. The research found that markedly elevated soluble S. T. 2 directly contributes to disease pathogenesis, establishing a critical mechanistic pathway that could be targeted for treating this high-mortality inflammatory cardiomyopathy.</p>
<h4>Article 5: Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684267" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684267</a></p>
<p><strong>Summary:</strong> O. V. I. D. minus 19 pandemic: changes in risk of acute myocardial infarction. This study established ambient P. M. 2.5 exposure as a known risk factor for acute myocardial infarction, distinguishing myocardial infarction with non-obstructive coronary arteries as a distinct subtype from myocardial infarction with obstructive coronary disease. It capitalized on the C. O. V. I. D. minus 19 pandemic public health measures, which altered exposure patterns, as a natural experiment. The research characterized the association between short-term P. M. 2.5 exposure and these acute myocardial infarction subtypes during this unique period, providing crucial insights into how environmental shifts can influence risk profiles.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. The study identified a distinct subgroup of patients within adjudicated Group 1 Pulmonary Hypertension who demonstrated an elevated pulmonary artery wedge pressure, exceeding 15 mmHg. It characterized this patient population by comparing their profiles to those with normal pulmonary artery wedge pressure and to patients with combined pre- and postcapillary pulmonary hypertension. This work establishes that not all Group 1 Pulmonary Hypertension patients present with the expected normal pulmonary artery wedge pressure, highlighting diagnostic complexities.</p>
<p>Article number two. C. C. R. 8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. This study revealed that C. C. R. 8 expression on regulatory T cells dictates their tissue adaptation trajectories within the heart following myocardial infarction. It found that these C. C. R. 8-positive regulatory T cells provide protection against myocardial infarction-induced tissue damage. The data delineated specific differentiation pathways of heart regulatory T cells in a murine model, establishing a molecular mechanism for regulatory T cell-mediated cardiac protection.</p>
<p>Article number three. Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability. This study, using spatial and single-cell transcriptomics on 13 human carotid plaques, revealed a key role for fibroblast-like vascular smooth muscle cells in atherosclerotic cell crosstalk and plaque stability. It precisely mapped intercellular communication patterns within the human plaque microenvironments. The data demonstrated that these specific fibroblast-like vascular smooth muscle cells are critical mediators, identifying specific cellular interactions as potential novel targets for preventing atherosclerotic events.</p>
<p>Article number four. Soluble S. T. 2 drives fulminant myocarditis progression via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. This study demonstrated that soluble S. T. 2 drives the progression of fulminant myocarditis via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. It defined the cellular source and function of soluble S. T. 2 in a Coxsackievirus B3-induced fulminant myocarditis mouse model. The research found that markedly elevated soluble S. T. 2 directly contributes to disease pathogenesis, establishing a critical mechanistic pathway that could be targeted for treating this high-mortality inflammatory cardiomyopathy.</p>
<p>Article number five. Air pollution before and during the C. O. V. I. D. minus 19 pandemic: changes in risk of acute myocardial infarction. This study established ambient P. M. 2.5 exposure as a known risk factor for acute myocardial infarction, distinguishing myocardial infarction with non-obstructive coronary arteries as a distinct subtype from myocardial infarction with obstructive coronary disease. It capitalized on the C. O. V. I. D. minus 19 pandemic public health measures, which altered exposure patterns, as a natural experiment. The research characterized the association between short-term P. M. 2.5 exposure and these acute myocardial infarction subtypes during this unique period, providing crucial insights into how environmental shifts can influence risk profiles. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>C. C. R. 8, Left Heart Dysfunction, P. M. 2.5, C. O. V. I. D. minus 19, Coxsackievirus B3, Spatial Transcriptomics, I. G. F. 2. R. minus Y. Y. 1 Axis, Air Pollution, Cell Crosstalk, Atherosclerotic Plaques, Myocardial Infarction, Cardiac Protection, Fibroblast-like Vascular Smooth Muscle Cells, Pulmonary Artery Wedge Pressure, Fulminant Myocarditis, Acute Myocardial Infarction, Tissue Damage, Plaque Stability, Pulmonary Hypertension, Group 1 Pulmonary Hypertension, Regulatory T Cells, Inflammatory Cardiomyopathy, Precapillary Hypertension, Soluble S. T. 2, Myocardial Infarction with Non-obstructive Coronary Arteries.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/">Soluble S. T. 2 Drives Fulminant Myocarditis 02/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 14, 2026. This episode summarizes 5 key cardiology studies on topics like C. C. R. 8 and Left Heart Dysfunction. Key takeaway: Soluble S. T. 2 Drives Fulminant Myocarditis.
Article Links:
Article 1: Elevate]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 14, 2026. This episode summarizes 5 key cardiology studies on topics like C. C. R. 8 and Left Heart Dysfunction. Key takeaway: Soluble S. T. 2 Drives Fulminant Myocarditis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41685452">Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41685444">CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41685669">Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41684269">Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41684267">Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/">https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41685452" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41685452</a></p>
<p><strong>Summary:</strong> The study identified a distinct subgroup of patients within adjudicated Group 1 Pulmonary Hypertension who demonstrated an elevated pulmonary artery wedge pressure, exceeding 15 mmHg. It characterized this patient population by comparing their profiles to those with normal pulmonary artery wedge pressure and to patients with combined pre- and postcapillary pulmonary hypertension. This work establishes that not all Group 1 Pulmonary Hypertension patients present with the expected normal pulmonary artery wedge pressure, highlighting diagnostic complexities.</p>
<h4>Article 2: CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41685444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41685444</a></p>
<p><strong>Summary:</strong> C. R. 8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. This study revealed that C. C. R. 8 expression on regulatory T cells dictates their tissue adaptation trajectories within the heart following myocardial infarction. It found that these C. C. R. 8-positive regulatory T cells provide protection against myocardial infarction-induced tissue damage. The data delineated specific differentiation pathways of heart regulatory T cells in a murine model, establishing a molecular mechanism for regulatory T cell-mediated cardiac protection.</p>
<h4>Article 3: Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41685669" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41685669</a></p>
<p><strong>Summary:</strong> This study, using spatial and single-cell transcriptomics on 13 human carotid plaques, revealed a key role for fibroblast-like vascular smooth muscle cells in atherosclerotic cell crosstalk and plaque stability. It precisely mapped intercellular communication patterns within the human plaque microenvironments. The data demonstrated that these specific fibroblast-like vascular smooth muscle cells are critical mediators, identifying specific cellular interactions as potential novel targets for preventing atherosclerotic events.</p>
<h4>Article 4: Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684269</a></p>
<p><strong>Summary:</strong> T. 2 drives fulminant myocarditis progression via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. This study demonstrated that soluble S. T. 2 drives the progression of fulminant myocarditis via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. It defined the cellular source and function of soluble S. T. 2 in a Coxsackievirus B3-induced fulminant myocarditis mouse model. The research found that markedly elevated soluble S. T. 2 directly contributes to disease pathogenesis, establishing a critical mechanistic pathway that could be targeted for treating this high-mortality inflammatory cardiomyopathy.</p>
<h4>Article 5: Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41684267" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41684267</a></p>
<p><strong>Summary:</strong> O. V. I. D. minus 19 pandemic: changes in risk of acute myocardial infarction. This study established ambient P. M. 2.5 exposure as a known risk factor for acute myocardial infarction, distinguishing myocardial infarction with non-obstructive coronary arteries as a distinct subtype from myocardial infarction with obstructive coronary disease. It capitalized on the C. O. V. I. D. minus 19 pandemic public health measures, which altered exposure patterns, as a natural experiment. The research characterized the association between short-term P. M. 2.5 exposure and these acute myocardial infarction subtypes during this unique period, providing crucial insights into how environmental shifts can influence risk profiles.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. The study identified a distinct subgroup of patients within adjudicated Group 1 Pulmonary Hypertension who demonstrated an elevated pulmonary artery wedge pressure, exceeding 15 mmHg. It characterized this patient population by comparing their profiles to those with normal pulmonary artery wedge pressure and to patients with combined pre- and postcapillary pulmonary hypertension. This work establishes that not all Group 1 Pulmonary Hypertension patients present with the expected normal pulmonary artery wedge pressure, highlighting diagnostic complexities.</p>
<p>Article number two. C. C. R. 8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. This study revealed that C. C. R. 8 expression on regulatory T cells dictates their tissue adaptation trajectories within the heart following myocardial infarction. It found that these C. C. R. 8-positive regulatory T cells provide protection against myocardial infarction-induced tissue damage. The data delineated specific differentiation pathways of heart regulatory T cells in a murine model, establishing a molecular mechanism for regulatory T cell-mediated cardiac protection.</p>
<p>Article number three. Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability. This study, using spatial and single-cell transcriptomics on 13 human carotid plaques, revealed a key role for fibroblast-like vascular smooth muscle cells in atherosclerotic cell crosstalk and plaque stability. It precisely mapped intercellular communication patterns within the human plaque microenvironments. The data demonstrated that these specific fibroblast-like vascular smooth muscle cells are critical mediators, identifying specific cellular interactions as potential novel targets for preventing atherosclerotic events.</p>
<p>Article number four. Soluble S. T. 2 drives fulminant myocarditis progression via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. This study demonstrated that soluble S. T. 2 drives the progression of fulminant myocarditis via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. It defined the cellular source and function of soluble S. T. 2 in a Coxsackievirus B3-induced fulminant myocarditis mouse model. The research found that markedly elevated soluble S. T. 2 directly contributes to disease pathogenesis, establishing a critical mechanistic pathway that could be targeted for treating this high-mortality inflammatory cardiomyopathy.</p>
<p>Article number five. Air pollution before and during the C. O. V. I. D. minus 19 pandemic: changes in risk of acute myocardial infarction. This study established ambient P. M. 2.5 exposure as a known risk factor for acute myocardial infarction, distinguishing myocardial infarction with non-obstructive coronary arteries as a distinct subtype from myocardial infarction with obstructive coronary disease. It capitalized on the C. O. V. I. D. minus 19 pandemic public health measures, which altered exposure patterns, as a natural experiment. The research characterized the association between short-term P. M. 2.5 exposure and these acute myocardial infarction subtypes during this unique period, providing crucial insights into how environmental shifts can influence risk profiles. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>C. C. R. 8, Left Heart Dysfunction, P. M. 2.5, C. O. V. I. D. minus 19, Coxsackievirus B3, Spatial Transcriptomics, I. G. F. 2. R. minus Y. Y. 1 Axis, Air Pollution, Cell Crosstalk, Atherosclerotic Plaques, Myocardial Infarction, Cardiac Protection, Fibroblast-like Vascular Smooth Muscle Cells, Pulmonary Artery Wedge Pressure, Fulminant Myocarditis, Acute Myocardial Infarction, Tissue Damage, Plaque Stability, Pulmonary Hypertension, Group 1 Pulmonary Hypertension, Regulatory T Cells, Inflammatory Cardiomyopathy, Precapillary Hypertension, Soluble S. T. 2, Myocardial Infarction with Non-obstructive Coronary Arteries.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/">Soluble S. T. 2 Drives Fulminant Myocarditis 02/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260214_060030.mp3" length="4291438" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 14, 2026. This episode summarizes 5 key cardiology studies on topics like C. C. R. 8 and Left Heart Dysfunction. Key takeaway: Soluble S. T. 2 Drives Fulminant Myocarditis.
Article Links:
Article 1: Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. (Circulation)
Article 2: CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. (Circulation)
Article 3: Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability. (European heart journal)
Article 4: Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis. (European heart journal)
Article 5: Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/soluble-s-t-2-drives-fulminant-myocarditis-02-14-26/
 Featured Articles
Article 1: Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41685452
Summary: The study identified a distinct subgroup of patients within adjudicated Group 1 Pulmonary Hypertension who demonstrated an elevated pulmonary artery wedge pressure, exceeding 15 mmHg. It characterized this patient population by comparing their profiles to those with normal pulmonary artery wedge pressure and to patients with combined pre- and postcapillary pulmonary hypertension. This work establishes that not all Group 1 Pulmonary Hypertension patients present with the expected normal pulmonary artery wedge pressure, highlighting diagnostic complexities.
Article 2: CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41685444
Summary: C. R. 8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. This study revealed that C. C. R. 8 expression on regulatory T cells dictates their tissue adaptation trajectories within the heart following myocardial infarction. It found that these C. C. R. 8-positive regulatory T cells provide protection against myocardial infarction-induced tissue damage. The data delineated specific differentiation pathways of heart regulatory T cells in a murine model, establishing a molecular mechanism for regulatory T cell-mediated cardiac protection.
Article 3: Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41685669
Summary: This study, using spatial and single-cell transcriptomics on 13 human carotid plaques, revealed a key role for fibroblast-like vascular smooth muscle cells in atherosclerotic cell crosstalk and plaque stability. It precisely mapped intercellular communication patterns within the human plaque microenvironments. The data demonstrated that these specific fibroblast-like vascular smooth muscle cells are critical mediators, identifying specific cellular interactions as potential novel targets for preventing atherosclerotic events.
Article 4: Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41684269
Summary: T. 2 drives fulminant myocarditis progression via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. This study demonstrated that soluble S. T. 2 drives the progression of fulminant myocarditis via the I. G. F. 2. R. minus Y. Y. 1 mitochondrial axis. It defined the cellular source and function of soluble S. T. 2 in a Cox]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 14, 2026. This episode summarizes 5 key cardiology studies on topics like C. C. R. 8 and Left Heart Dysfunction. Key takeaway: Soluble S. T. 2 Drives Fulminant Myocarditis.
Article Links:
Article 1: Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. (Circulation)
Article 2: CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction-Induced Tissue Damage. (Circulation)
Article 3: Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability. (European heart journal)
Article 4: Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis. (European heart journal)
Article 5: Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction. (European heart journal)
Full episode page: https://podcast.explainh]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AF: The 25% Diabetes Complication You Miss 02/13/26</title>
	<link>https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/</link>
	<pubDate>Fri, 13 Feb 2026 11:01:51 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 13, 2026. This episode summarizes 5 key cardiology studies on topics like obesity and body mass index. Key takeaway: AF: The 25% Diabetes Complication You Miss.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41674449">Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41674444">Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41668366">Atrial fibrillation: an underappreciated complication of diabetes.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41677478">Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41677477">Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/">https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41674449" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41674449</a></p>
<p><strong>Summary:</strong> C. R. A. B. L. Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. An increasing link between B. C. R. A. B. L. tyrosine kinase inhibitors and pulmonary arterial hypertension has been recognized since 2009. This study precisely evaluated the risk of pulmonary arterial hypertension associated with second- and third-generation inhibitors compared to imatinib in adults. Utilizing the French national health care database, researchers established a robust prevalent new-user design which identified patient cohorts initiating these treatments between 2008 and 2024. The investigation offered a critical framework to quantify this potential adverse event for clinical practice.</p>
<h4>Article 2: Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41674444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41674444</a></p>
<p><strong>Summary:</strong> Obesity is a confirmed risk factor for cardiovascular disease, with specific relationships across the full spectrum of body mass index, including severe obesity, requiring further characterization. The Cross-Cohort Collaboration definitively described the prospective associations of obesity and its severity with nine specific cardiovascular outcomes. This comprehensive analysis included 289875 participants, comprising 79 point 2 percent women, from 21 distinct cohorts enrolled between 1948 and 2017. The study provides an extensive dataset essential for understanding long-term cardiovascular disease risks across various obesity classes.</p>
<h4>Article 3: Atrial fibrillation: an underappreciated complication of diabetes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41668366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41668366</a></p>
<p><strong>Summary:</strong> Atrial fibrillation is identified as a significant complication of diabetes, demonstrating a prevalence of up to 25 percent in individuals with the condition. The incidence rates of atrial fibrillation are increasing among patients with diabetes. This development of atrial fibrillation in diabetic individuals occurs independently of other risk factors such as hypertension, atherosclerotic cardiovascular disease, or heart failure. The pathogenesis involves multifactorial atrial structural, electrical, and autonomic remodeling directly linked to diabetes.</p>
<h4>Article 4: Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41677478" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41677478</a></p>
<p><strong>Summary:</strong> This study definitively investigated the independent association between left atrial volume index and long-term mortality in patients with heart failure. The research specifically considered its interaction with the severity of functional mitral regurgitation, establishing a crucial assessment framework for this relationship. The investigation provided a comprehensive approach to understanding the prognostic implications of left atrial volume index in this patient population.</p>
<h4>Article 5: Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41677477" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41677477</a></p>
<p><strong>Summary:</strong> F. pEF: Impact of Reduced Atriopulmonary Compliance. Approximately one-third of patients with heart failure with preserved ejection fraction demonstrate normal resting pulmonary capillary wedge pressure, yet experience left atrial hypertension exclusively during exercise. This study thoroughly investigated the clinical course of these patients presenting with exercise-induced left atrial hypertension. The research explored whether this condition represents a distinct heart failure with preserved ejection fraction phenotype or an earlier stage that progresses to resting left atrial hypertension over time. This investigation provided critical insights into the natural history and progression of left atrial hypertension in heart failure with preserved ejection fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Second- and Third-Generation B. C. R. A. B. L. Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. An increasing link between B. C. R. A. B. L. tyrosine kinase inhibitors and pulmonary arterial hypertension has been recognized since 2009. This study precisely evaluated the risk of pulmonary arterial hypertension associated with second- and third-generation inhibitors compared to imatinib in adults. Utilizing the French national health care database, researchers established a robust prevalent new-user design which identified patient cohorts initiating these treatments between 2008 and 2024. The investigation offered a critical framework to quantify this potential adverse event for clinical practice.</p>
<p>Article number two. Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. Obesity is a confirmed risk factor for cardiovascular disease, with specific relationships across the full spectrum of body mass index, including severe obesity, requiring further characterization. The Cross-Cohort Collaboration definitively described the prospective associations of obesity and its severity with nine specific cardiovascular outcomes. This comprehensive analysis included 289875 participants, comprising 79 point 2 percent women, from 21 distinct cohorts enrolled between 1948 and 2017. The study provides an extensive dataset essential for understanding long-term cardiovascular disease risks across various obesity classes.</p>
<p>Article number three. Atrial fibrillation: an underappreciated complication of diabetes. Atrial fibrillation is identified as a significant complication of diabetes, demonstrating a prevalence of up to 25 percent in individuals with the condition. The incidence rates of atrial fibrillation are increasing among patients with diabetes. This development of atrial fibrillation in diabetic individuals occurs independently of other risk factors such as hypertension, atherosclerotic cardiovascular disease, or heart failure. The pathogenesis involves multifactorial atrial structural, electrical, and autonomic remodeling directly linked to diabetes.</p>
<p>Article number four. Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome? Left atrial remodeling, specifically progressive enlargement, is a common observation in heart failure with reduced ejection fraction and reflects left ventricular dysfunction and functional mitral regurgitation. This study definitively investigated the independent association between left atrial volume index and long-term mortality in patients with heart failure. The research specifically considered its interaction with the severity of functional mitral regurgitation, establishing a crucial assessment framework for this relationship. The investigation provided a comprehensive approach to understanding the prognostic implications of left atrial volume index in this patient population.</p>
<p>Article number five. Progression From Exercise-Induced to Resting Left Atrial Hypertension in H. F. pEF: Impact of Reduced Atriopulmonary Compliance. Approximately one-third of patients with heart failure with preserved ejection fraction demonstrate normal resting pulmonary capillary wedge pressure, yet experience left atrial hypertension exclusively during exercise. This study thoroughly investigated the clinical course of these patients presenting with exercise-induced left atrial hypertension. The research explored whether this condition represents a distinct heart failure with preserved ejection fraction phenotype or an earlier stage that progresses to resting left atrial hypertension over time. This investigation provided critical insights into the natural history and progression of left atrial hypertension in heart failure with preserved ejection fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>obesity, body mass index, cardiovascular disease, imatinib, functional mitral regurgitation, pathogenesis, resting left atrial hypertension, long-term mortality, heart failure with reduced ejection fraction, atriopulmonary compliance, severe obesity, prognostic significance, exercise-induced left atrial hypertension, pulmonary capillary wedge pressure, prevalence, incidence, diabetes, drug adverse events, atrial fibrillation, drug safety, pulmonary arterial hypertension, heart failure with preserved ejection fraction, left atrial enlargement, long-term outcomes, B. C. R. A. B. L. tyrosine kinase inhibitors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/">AF: The 25% Diabetes Complication You Miss 02/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 13, 2026. This episode summarizes 5 key cardiology studies on topics like obesity and body mass index. Key takeaway: AF: The 25% Diabetes Complication You Miss.
Article Links:
Article 1: Second- and Third-G]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 13, 2026. This episode summarizes 5 key cardiology studies on topics like obesity and body mass index. Key takeaway: AF: The 25% Diabetes Complication You Miss.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41674449">Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41674444">Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41668366">Atrial fibrillation: an underappreciated complication of diabetes.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41677478">Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41677477">Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/">https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41674449" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41674449</a></p>
<p><strong>Summary:</strong> C. R. A. B. L. Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. An increasing link between B. C. R. A. B. L. tyrosine kinase inhibitors and pulmonary arterial hypertension has been recognized since 2009. This study precisely evaluated the risk of pulmonary arterial hypertension associated with second- and third-generation inhibitors compared to imatinib in adults. Utilizing the French national health care database, researchers established a robust prevalent new-user design which identified patient cohorts initiating these treatments between 2008 and 2024. The investigation offered a critical framework to quantify this potential adverse event for clinical practice.</p>
<h4>Article 2: Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41674444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41674444</a></p>
<p><strong>Summary:</strong> Obesity is a confirmed risk factor for cardiovascular disease, with specific relationships across the full spectrum of body mass index, including severe obesity, requiring further characterization. The Cross-Cohort Collaboration definitively described the prospective associations of obesity and its severity with nine specific cardiovascular outcomes. This comprehensive analysis included 289875 participants, comprising 79 point 2 percent women, from 21 distinct cohorts enrolled between 1948 and 2017. The study provides an extensive dataset essential for understanding long-term cardiovascular disease risks across various obesity classes.</p>
<h4>Article 3: Atrial fibrillation: an underappreciated complication of diabetes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41668366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41668366</a></p>
<p><strong>Summary:</strong> Atrial fibrillation is identified as a significant complication of diabetes, demonstrating a prevalence of up to 25 percent in individuals with the condition. The incidence rates of atrial fibrillation are increasing among patients with diabetes. This development of atrial fibrillation in diabetic individuals occurs independently of other risk factors such as hypertension, atherosclerotic cardiovascular disease, or heart failure. The pathogenesis involves multifactorial atrial structural, electrical, and autonomic remodeling directly linked to diabetes.</p>
<h4>Article 4: Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41677478" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41677478</a></p>
<p><strong>Summary:</strong> This study definitively investigated the independent association between left atrial volume index and long-term mortality in patients with heart failure. The research specifically considered its interaction with the severity of functional mitral regurgitation, establishing a crucial assessment framework for this relationship. The investigation provided a comprehensive approach to understanding the prognostic implications of left atrial volume index in this patient population.</p>
<h4>Article 5: Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41677477" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41677477</a></p>
<p><strong>Summary:</strong> F. pEF: Impact of Reduced Atriopulmonary Compliance. Approximately one-third of patients with heart failure with preserved ejection fraction demonstrate normal resting pulmonary capillary wedge pressure, yet experience left atrial hypertension exclusively during exercise. This study thoroughly investigated the clinical course of these patients presenting with exercise-induced left atrial hypertension. The research explored whether this condition represents a distinct heart failure with preserved ejection fraction phenotype or an earlier stage that progresses to resting left atrial hypertension over time. This investigation provided critical insights into the natural history and progression of left atrial hypertension in heart failure with preserved ejection fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Second- and Third-Generation B. C. R. A. B. L. Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. An increasing link between B. C. R. A. B. L. tyrosine kinase inhibitors and pulmonary arterial hypertension has been recognized since 2009. This study precisely evaluated the risk of pulmonary arterial hypertension associated with second- and third-generation inhibitors compared to imatinib in adults. Utilizing the French national health care database, researchers established a robust prevalent new-user design which identified patient cohorts initiating these treatments between 2008 and 2024. The investigation offered a critical framework to quantify this potential adverse event for clinical practice.</p>
<p>Article number two. Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. Obesity is a confirmed risk factor for cardiovascular disease, with specific relationships across the full spectrum of body mass index, including severe obesity, requiring further characterization. The Cross-Cohort Collaboration definitively described the prospective associations of obesity and its severity with nine specific cardiovascular outcomes. This comprehensive analysis included 289875 participants, comprising 79 point 2 percent women, from 21 distinct cohorts enrolled between 1948 and 2017. The study provides an extensive dataset essential for understanding long-term cardiovascular disease risks across various obesity classes.</p>
<p>Article number three. Atrial fibrillation: an underappreciated complication of diabetes. Atrial fibrillation is identified as a significant complication of diabetes, demonstrating a prevalence of up to 25 percent in individuals with the condition. The incidence rates of atrial fibrillation are increasing among patients with diabetes. This development of atrial fibrillation in diabetic individuals occurs independently of other risk factors such as hypertension, atherosclerotic cardiovascular disease, or heart failure. The pathogenesis involves multifactorial atrial structural, electrical, and autonomic remodeling directly linked to diabetes.</p>
<p>Article number four. Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome? Left atrial remodeling, specifically progressive enlargement, is a common observation in heart failure with reduced ejection fraction and reflects left ventricular dysfunction and functional mitral regurgitation. This study definitively investigated the independent association between left atrial volume index and long-term mortality in patients with heart failure. The research specifically considered its interaction with the severity of functional mitral regurgitation, establishing a crucial assessment framework for this relationship. The investigation provided a comprehensive approach to understanding the prognostic implications of left atrial volume index in this patient population.</p>
<p>Article number five. Progression From Exercise-Induced to Resting Left Atrial Hypertension in H. F. pEF: Impact of Reduced Atriopulmonary Compliance. Approximately one-third of patients with heart failure with preserved ejection fraction demonstrate normal resting pulmonary capillary wedge pressure, yet experience left atrial hypertension exclusively during exercise. This study thoroughly investigated the clinical course of these patients presenting with exercise-induced left atrial hypertension. The research explored whether this condition represents a distinct heart failure with preserved ejection fraction phenotype or an earlier stage that progresses to resting left atrial hypertension over time. This investigation provided critical insights into the natural history and progression of left atrial hypertension in heart failure with preserved ejection fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>obesity, body mass index, cardiovascular disease, imatinib, functional mitral regurgitation, pathogenesis, resting left atrial hypertension, long-term mortality, heart failure with reduced ejection fraction, atriopulmonary compliance, severe obesity, prognostic significance, exercise-induced left atrial hypertension, pulmonary capillary wedge pressure, prevalence, incidence, diabetes, drug adverse events, atrial fibrillation, drug safety, pulmonary arterial hypertension, heart failure with preserved ejection fraction, left atrial enlargement, long-term outcomes, B. C. R. A. B. L. tyrosine kinase inhibitors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/">AF: The 25% Diabetes Complication You Miss 02/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260213_060037.mp3" length="4645032" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 13, 2026. This episode summarizes 5 key cardiology studies on topics like obesity and body mass index. Key takeaway: AF: The 25% Diabetes Complication You Miss.
Article Links:
Article 1: Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. (Circulation)
Article 2: Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. (Circulation)
Article 3: Atrial fibrillation: an underappreciated complication of diabetes. (European heart journal)
Article 4: Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome? (JACC. Heart failure)
Article 5: Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/af-the-25-diabetes-complication-you-miss-02-13-26/
 Featured Articles
Article 1: Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41674449
Summary: C. R. A. B. L. Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. An increasing link between B. C. R. A. B. L. tyrosine kinase inhibitors and pulmonary arterial hypertension has been recognized since 2009. This study precisely evaluated the risk of pulmonary arterial hypertension associated with second- and third-generation inhibitors compared to imatinib in adults. Utilizing the French national health care database, researchers established a robust prevalent new-user design which identified patient cohorts initiating these treatments between 2008 and 2024. The investigation offered a critical framework to quantify this potential adverse event for clinical practice.
Article 2: Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41674444
Summary: Obesity is a confirmed risk factor for cardiovascular disease, with specific relationships across the full spectrum of body mass index, including severe obesity, requiring further characterization. The Cross-Cohort Collaboration definitively described the prospective associations of obesity and its severity with nine specific cardiovascular outcomes. This comprehensive analysis included 289875 participants, comprising 79 point 2 percent women, from 21 distinct cohorts enrolled between 1948 and 2017. The study provides an extensive dataset essential for understanding long-term cardiovascular disease risks across various obesity classes.
Article 3: Atrial fibrillation: an underappreciated complication of diabetes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41668366
Summary: Atrial fibrillation is identified as a significant complication of diabetes, demonstrating a prevalence of up to 25 percent in individuals with the condition. The incidence rates of atrial fibrillation are increasing among patients with diabetes. This development of atrial fibrillation in diabetic individuals occurs independently of other risk factors such as hypertension, atherosclerotic cardiovascular disease, or heart failure. The pathogenesis involves multifactorial atrial structural, electrical, and autonomic remodeling directly linked to diabetes.
Article 4: Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41677478
Summary: This study definitively investigated the independent association between left atrial vol]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 13, 2026. This episode summarizes 5 key cardiology studies on topics like obesity and body mass index. Key takeaway: AF: The 25% Diabetes Complication You Miss.
Article Links:
Article 1: Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. (Circulation)
Article 2: Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. (Circulation)
Article 3: Atrial fibrillation: an underappreciated complication of diabetes. (European heart journal)
Article 4: Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome? (JACC. Heart failure)
Article 5: Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance. (JACC. Heart failure)
Full episode page: https]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Acoramidis Reduces ATTR-CM Mortality &#038; Hospitalization. 02/12/26</title>
	<link>https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/</link>
	<pubDate>Thu, 12 Feb 2026 11:01:20 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 12, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin silencers and macrophage PRMT9. Key takeaway: Acoramidis Reduces ATTR-CM Mortality &#038; Hospitalization..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41670556">Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II).</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41369616">Myocardial Amyloid Burden in Transthyretin Amyloidosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41225306">Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41143759">Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41669821">Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/">https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II).</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41670556" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41670556</a></p>
<p><strong>Summary:</strong> The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.</p>
<h4>Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41369616" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41369616</a></p>
<p><strong>Summary:</strong> Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.</p>
<h4>Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41225306" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41225306</a></p>
<p><strong>Summary:</strong> Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.</p>
<h4>Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41143759" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41143759</a></p>
<p><strong>Summary:</strong> Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis&#8217;s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.</p>
<h4>Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41669821" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41669821</a></p>
<p><strong>Summary:</strong> Macrophage PRMT9 ameliorates acute myocardial infarction by promoting symmetric dimethylation and degradation of STAT1 protein. This mechanism directly modulates M1-like macrophages, which are known to exacerbate myocardial injury through excessive secretion of inflammatory cytokines during myocardial infarction. The finding establishes PRMT9 as a novel and specific therapeutic target for acute myocardial infarction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.</p>
<p>Article number two. Myocardial Amyloid Burden in Transthyretin Amyloidosis. Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.</p>
<p>Article number three. Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.</p>
<p>Article number four. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis&#8217;s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.</p>
<p>Article number five. Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1. Macrophage PRMT9 ameliorates acute myocardial infarction by promoting symmetric dimethylation and degradation of STAT1 protein. This mechanism directly modulates M1-like macrophages, which are known to exacerbate myocardial injury through excessive secretion of inflammatory cytokines during myocardial infarction. The finding establishes PRMT9 as a novel and specific therapeutic target for acute myocardial infarction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transthyretin silencers, macrophage PRMT9, percutaneous coronary intervention, cardiovascular outcomes, M1-like macrophages, transthyretin amyloidosis, time-varying treatment effects, myocardial amyloid burden, transthyretin amyloidosis with cardiomyopathy, transthyretin stabilizers, coronary artery disease, everolimus-eluting stent, IRONMAN two trial, sirolimus-eluting iron bioresorbable scaffold, diagnostic value, symmetric dimethylation, all-cause mortality, transthyretin amyloid cardiomyopathy, cardiovascular magnetic resonance, TTR stabilization, extracellular volume, STAT1 degradation, acoramidis, acute myocardial infarction, mortality benefit.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/">Acoramidis Reduces ATTR-CM Mortality & Hospitalization. 02/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 12, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin silencers and macrophage PRMT9. Key takeaway: Acoramidis Reduces ATTR-CM Mortality &#038; Hospitalization..
Article Li]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 12, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin silencers and macrophage PRMT9. Key takeaway: Acoramidis Reduces ATTR-CM Mortality &#038; Hospitalization..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41670556">Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II).</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41369616">Myocardial Amyloid Burden in Transthyretin Amyloidosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41225306">Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41143759">Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41669821">Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/">https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II).</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41670556" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41670556</a></p>
<p><strong>Summary:</strong> The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.</p>
<h4>Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41369616" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41369616</a></p>
<p><strong>Summary:</strong> Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.</p>
<h4>Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41225306" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41225306</a></p>
<p><strong>Summary:</strong> Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.</p>
<h4>Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41143759" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41143759</a></p>
<p><strong>Summary:</strong> Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis&#8217;s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.</p>
<h4>Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41669821" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41669821</a></p>
<p><strong>Summary:</strong> Macrophage PRMT9 ameliorates acute myocardial infarction by promoting symmetric dimethylation and degradation of STAT1 protein. This mechanism directly modulates M1-like macrophages, which are known to exacerbate myocardial injury through excessive secretion of inflammatory cytokines during myocardial infarction. The finding establishes PRMT9 as a novel and specific therapeutic target for acute myocardial infarction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.</p>
<p>Article number two. Myocardial Amyloid Burden in Transthyretin Amyloidosis. Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.</p>
<p>Article number three. Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.</p>
<p>Article number four. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis&#8217;s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.</p>
<p>Article number five. Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1. Macrophage PRMT9 ameliorates acute myocardial infarction by promoting symmetric dimethylation and degradation of STAT1 protein. This mechanism directly modulates M1-like macrophages, which are known to exacerbate myocardial injury through excessive secretion of inflammatory cytokines during myocardial infarction. The finding establishes PRMT9 as a novel and specific therapeutic target for acute myocardial infarction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transthyretin silencers, macrophage PRMT9, percutaneous coronary intervention, cardiovascular outcomes, M1-like macrophages, transthyretin amyloidosis, time-varying treatment effects, myocardial amyloid burden, transthyretin amyloidosis with cardiomyopathy, transthyretin stabilizers, coronary artery disease, everolimus-eluting stent, IRONMAN two trial, sirolimus-eluting iron bioresorbable scaffold, diagnostic value, symmetric dimethylation, all-cause mortality, transthyretin amyloid cardiomyopathy, cardiovascular magnetic resonance, TTR stabilization, extracellular volume, STAT1 degradation, acoramidis, acute myocardial infarction, mortality benefit.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/">Acoramidis Reduces ATTR-CM Mortality & Hospitalization. 02/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260212_060024.mp3" length="3608493" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 12, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin silencers and macrophage PRMT9. Key takeaway: Acoramidis Reduces ATTR-CM Mortality &#038; Hospitalization..
Article Links:
Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). (Journal of the American College of Cardiology)
Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis. (Journal of the American College of Cardiology)
Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. (Journal of the American College of Cardiology)
Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. (Journal of the American College of Cardiology)
Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/
 Featured Articles
Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II).
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41670556
Summary: The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.
Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41369616
Summary: Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.
Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41225306
Summary: Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.
Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41143759
Summary: Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis&#8217;s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.
Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting S]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 12, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin silencers and macrophage PRMT9. Key takeaway: Acoramidis Reduces ATTR-CM Mortality &#038; Hospitalization..
Article Links:
Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). (Journal of the American College of Cardiology)
Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis. (Journal of the American College of Cardiology)
Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. (Journal of the American College of Cardiology)
Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. (Journal of the American College of Cardiology)
Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimeth]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AF Rate Control: Evidence Gap Identified 02/11/26</title>
	<link>https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/</link>
	<pubDate>Wed, 11 Feb 2026 11:01:39 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like qualitative research and heart failure. Key takeaway: AF Rate Control: Evidence Gap Identified.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41667045">Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41663267">Heart rate in early rhythm control therapy in patients with atrial fibrillation.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41666966">From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41662326">Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing.</a> (Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41662304">Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/">https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667045" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667045</a></p>
<p><strong>Summary:</strong> A.-E. C. M. O. with or without Left Ventricular Active Unloading. Veno-arterial extracorporeal membrane oxygenation (V. A.-E. C. M. O.), commonly used in refractory cardiogenic shock, is known to exacerbate left ventricular loading conditions and impair cardiac energetics. Adjunctive left ventricular unloading strategies are frequently combined with V. A.-E. C. M. O. to counteract these negative effects. These strategies, including intra-aortic balloon pump (I. A. B. P.) or Impella, aim to enhance myocardial recovery through activation of cardioprotective pathways. This approach directly addresses the recognized myocardial strain induced by V. A.-E. C. M. O.</p>
<h4>Article 2: Heart rate in early rhythm control therapy in patients with atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663267" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663267</a></p>
<p><strong>Summary:</strong> Current clinical recommendations advise preventing high heart rates in atrial fibrillation (A. F.) to reduce A. F.-related symptoms and morbidity. However, robust evidence demonstrating a strong relationship between lower heart rate during A. F. and a reduction in symptoms or cardiovascular complications is notably lacking. This analysis specifically compared patient symptoms, treatment strategies, and a composite endpoint of cardiovascular death, stroke, or hospitalization with worsening heart failure. It highlighted an ongoing clinical gap regarding optimal heart rate targets in early rhythm control therapy.</p>
<h4>Article 3: From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41666966" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41666966</a></p>
<p><strong>Summary:</strong> Women represent fewer than five percent of practicing interventional cardiologists in the United States. The W. E. C. A. R. E. study, through semi-structured interviews with 18 women interventional cardiology attendings and fellows, identified five major themes. These themes comprehensively characterize the unique career experiences, challenges, and support systems for women within the interventional cardiology subspecialty. This qualitative research provides specific insights into gender equity dynamics and potential areas for reform in the field.</p>
<h4>Article 4: Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41662326" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41662326</a></p>
<p><strong>Summary:</strong> The study utilized a comprehensive approach to assess left ventricular function and exercise endurance in 55 patients with non-obstructive hypertrophic cardiomyopathy. This assessment combined left ventricular pressure-strain loop and cardiopulmonary exercise testing. Researchers explored correlations between maximum left ventricular wall thickness and various clinical, echocardiographic, and cardiopulmonary exercise testing parameters. This methodological integration provides a thorough evaluation framework for hypertrophic cardiomyopathy patients.</p>
<h4>Article 5: Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41662304" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41662304</a></p>
<p><strong>Summary:</strong> Current heart failure guidelines advocate for hemodynamic assessment based on four clinical profiles: dry-warm, wet-warm, dry-cold, and wet-cold. However, evaluation of perfusion status often receives less attention due to a recognized absence of simple and reliable physical indicators. This study focused on the perfusion index, a noninvasive parameter derived from the ratio of pulsatile to non-pulsatile blood flow, as a potential marker for detecting hypoperfusion in heart failure patients. It addressed a crucial diagnostic gap in routine clinical assessment.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by V. A.-E. C. M. O. with or without Left Ventricular Active Unloading. Veno-arterial extracorporeal membrane oxygenation (V. A.-E. C. M. O.), commonly used in refractory cardiogenic shock, is known to exacerbate left ventricular loading conditions and impair cardiac energetics. Adjunctive left ventricular unloading strategies are frequently combined with V. A.-E. C. M. O. to counteract these negative effects. These strategies, including intra-aortic balloon pump (I. A. B. P.) or Impella, aim to enhance myocardial recovery through activation of cardioprotective pathways. This approach directly addresses the recognized myocardial strain induced by V. A.-E. C. M. O.</p>
<p>Article number two. Heart rate in early rhythm control therapy in patients with atrial fibrillation. Current clinical recommendations advise preventing high heart rates in atrial fibrillation (A. F.) to reduce A. F.-related symptoms and morbidity. However, robust evidence demonstrating a strong relationship between lower heart rate during A. F. and a reduction in symptoms or cardiovascular complications is notably lacking. This analysis specifically compared patient symptoms, treatment strategies, and a composite endpoint of cardiovascular death, stroke, or hospitalization with worsening heart failure. It highlighted an ongoing clinical gap regarding optimal heart rate targets in early rhythm control therapy.</p>
<p>Article number three. From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology. Women represent fewer than five percent of practicing interventional cardiologists in the United States. The W. E. C. A. R. E. study, through semi-structured interviews with 18 women interventional cardiology attendings and fellows, identified five major themes. These themes comprehensively characterize the unique career experiences, challenges, and support systems for women within the interventional cardiology subspecialty. This qualitative research provides specific insights into gender equity dynamics and potential areas for reform in the field.</p>
<p>Article number four. Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing. The study utilized a comprehensive approach to assess left ventricular function and exercise endurance in 55 patients with non-obstructive hypertrophic cardiomyopathy. This assessment combined left ventricular pressure-strain loop and cardiopulmonary exercise testing. Researchers explored correlations between maximum left ventricular wall thickness and various clinical, echocardiographic, and cardiopulmonary exercise testing parameters. This methodological integration provides a thorough evaluation framework for hypertrophic cardiomyopathy patients.</p>
<p>Article number five. Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure. Current heart failure guidelines advocate for hemodynamic assessment based on four clinical profiles: dry-warm, wet-warm, dry-cold, and wet-cold. However, evaluation of perfusion status often receives less attention due to a recognized absence of simple and reliable physical indicators. This study focused on the perfusion index, a noninvasive parameter derived from the ratio of pulsatile to non-pulsatile blood flow, as a potential marker for detecting hypoperfusion in heart failure patients. It addressed a crucial diagnostic gap in routine clinical assessment. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>qualitative research, heart failure, hypoperfusion, left ventricular unloading, veno-arterial extracorporeal membrane oxygenation, heart rate control, hemodynamic assessment, left ventricular function, perfusion index, gender equity, women in medicine, intra-aortic balloon pump, exercise endurance, cardiogenic shock, rhythm control, stroke prevention, pressure-strain loop, career challenges, Impella, diagnostic markers, atrial fibrillation, hypertrophic cardiomyopathy, interventional cardiology, cardiopulmonary exercise testing, cardiovascular complications.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/">AF Rate Control: Evidence Gap Identified 02/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like qualitative research and heart failure. Key takeaway: AF Rate Control: Evidence Gap Identified.
Article Links:
Article 1: Changes in]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like qualitative research and heart failure. Key takeaway: AF Rate Control: Evidence Gap Identified.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41667045">Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41663267">Heart rate in early rhythm control therapy in patients with atrial fibrillation.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41666966">From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41662326">Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing.</a> (Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41662304">Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/">https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667045" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667045</a></p>
<p><strong>Summary:</strong> A.-E. C. M. O. with or without Left Ventricular Active Unloading. Veno-arterial extracorporeal membrane oxygenation (V. A.-E. C. M. O.), commonly used in refractory cardiogenic shock, is known to exacerbate left ventricular loading conditions and impair cardiac energetics. Adjunctive left ventricular unloading strategies are frequently combined with V. A.-E. C. M. O. to counteract these negative effects. These strategies, including intra-aortic balloon pump (I. A. B. P.) or Impella, aim to enhance myocardial recovery through activation of cardioprotective pathways. This approach directly addresses the recognized myocardial strain induced by V. A.-E. C. M. O.</p>
<h4>Article 2: Heart rate in early rhythm control therapy in patients with atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663267" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663267</a></p>
<p><strong>Summary:</strong> Current clinical recommendations advise preventing high heart rates in atrial fibrillation (A. F.) to reduce A. F.-related symptoms and morbidity. However, robust evidence demonstrating a strong relationship between lower heart rate during A. F. and a reduction in symptoms or cardiovascular complications is notably lacking. This analysis specifically compared patient symptoms, treatment strategies, and a composite endpoint of cardiovascular death, stroke, or hospitalization with worsening heart failure. It highlighted an ongoing clinical gap regarding optimal heart rate targets in early rhythm control therapy.</p>
<h4>Article 3: From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41666966" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41666966</a></p>
<p><strong>Summary:</strong> Women represent fewer than five percent of practicing interventional cardiologists in the United States. The W. E. C. A. R. E. study, through semi-structured interviews with 18 women interventional cardiology attendings and fellows, identified five major themes. These themes comprehensively characterize the unique career experiences, challenges, and support systems for women within the interventional cardiology subspecialty. This qualitative research provides specific insights into gender equity dynamics and potential areas for reform in the field.</p>
<h4>Article 4: Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41662326" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41662326</a></p>
<p><strong>Summary:</strong> The study utilized a comprehensive approach to assess left ventricular function and exercise endurance in 55 patients with non-obstructive hypertrophic cardiomyopathy. This assessment combined left ventricular pressure-strain loop and cardiopulmonary exercise testing. Researchers explored correlations between maximum left ventricular wall thickness and various clinical, echocardiographic, and cardiopulmonary exercise testing parameters. This methodological integration provides a thorough evaluation framework for hypertrophic cardiomyopathy patients.</p>
<h4>Article 5: Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41662304" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41662304</a></p>
<p><strong>Summary:</strong> Current heart failure guidelines advocate for hemodynamic assessment based on four clinical profiles: dry-warm, wet-warm, dry-cold, and wet-cold. However, evaluation of perfusion status often receives less attention due to a recognized absence of simple and reliable physical indicators. This study focused on the perfusion index, a noninvasive parameter derived from the ratio of pulsatile to non-pulsatile blood flow, as a potential marker for detecting hypoperfusion in heart failure patients. It addressed a crucial diagnostic gap in routine clinical assessment.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by V. A.-E. C. M. O. with or without Left Ventricular Active Unloading. Veno-arterial extracorporeal membrane oxygenation (V. A.-E. C. M. O.), commonly used in refractory cardiogenic shock, is known to exacerbate left ventricular loading conditions and impair cardiac energetics. Adjunctive left ventricular unloading strategies are frequently combined with V. A.-E. C. M. O. to counteract these negative effects. These strategies, including intra-aortic balloon pump (I. A. B. P.) or Impella, aim to enhance myocardial recovery through activation of cardioprotective pathways. This approach directly addresses the recognized myocardial strain induced by V. A.-E. C. M. O.</p>
<p>Article number two. Heart rate in early rhythm control therapy in patients with atrial fibrillation. Current clinical recommendations advise preventing high heart rates in atrial fibrillation (A. F.) to reduce A. F.-related symptoms and morbidity. However, robust evidence demonstrating a strong relationship between lower heart rate during A. F. and a reduction in symptoms or cardiovascular complications is notably lacking. This analysis specifically compared patient symptoms, treatment strategies, and a composite endpoint of cardiovascular death, stroke, or hospitalization with worsening heart failure. It highlighted an ongoing clinical gap regarding optimal heart rate targets in early rhythm control therapy.</p>
<p>Article number three. From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology. Women represent fewer than five percent of practicing interventional cardiologists in the United States. The W. E. C. A. R. E. study, through semi-structured interviews with 18 women interventional cardiology attendings and fellows, identified five major themes. These themes comprehensively characterize the unique career experiences, challenges, and support systems for women within the interventional cardiology subspecialty. This qualitative research provides specific insights into gender equity dynamics and potential areas for reform in the field.</p>
<p>Article number four. Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing. The study utilized a comprehensive approach to assess left ventricular function and exercise endurance in 55 patients with non-obstructive hypertrophic cardiomyopathy. This assessment combined left ventricular pressure-strain loop and cardiopulmonary exercise testing. Researchers explored correlations between maximum left ventricular wall thickness and various clinical, echocardiographic, and cardiopulmonary exercise testing parameters. This methodological integration provides a thorough evaluation framework for hypertrophic cardiomyopathy patients.</p>
<p>Article number five. Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure. Current heart failure guidelines advocate for hemodynamic assessment based on four clinical profiles: dry-warm, wet-warm, dry-cold, and wet-cold. However, evaluation of perfusion status often receives less attention due to a recognized absence of simple and reliable physical indicators. This study focused on the perfusion index, a noninvasive parameter derived from the ratio of pulsatile to non-pulsatile blood flow, as a potential marker for detecting hypoperfusion in heart failure patients. It addressed a crucial diagnostic gap in routine clinical assessment. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>qualitative research, heart failure, hypoperfusion, left ventricular unloading, veno-arterial extracorporeal membrane oxygenation, heart rate control, hemodynamic assessment, left ventricular function, perfusion index, gender equity, women in medicine, intra-aortic balloon pump, exercise endurance, cardiogenic shock, rhythm control, stroke prevention, pressure-strain loop, career challenges, Impella, diagnostic markers, atrial fibrillation, hypertrophic cardiomyopathy, interventional cardiology, cardiopulmonary exercise testing, cardiovascular complications.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/">AF Rate Control: Evidence Gap Identified 02/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260211_060038.mp3" length="4216206" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like qualitative research and heart failure. Key takeaway: AF Rate Control: Evidence Gap Identified.
Article Links:
Article 1: Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Heart rate in early rhythm control therapy in patients with atrial fibrillation. (Heart (British Cardiac Society))
Article 3: From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology. (The American journal of cardiology)
Article 4: Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Cardiopulmonary Exercise Testing. (Cardiology)
Article 5: Peripheral Perfusion Index as a Marker of Hypoperfusion in Heart Failure. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/af-rate-control-evidence-gap-identified-02-11-26/
 Featured Articles
Article 1: Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41667045
Summary: A.-E. C. M. O. with or without Left Ventricular Active Unloading. Veno-arterial extracorporeal membrane oxygenation (V. A.-E. C. M. O.), commonly used in refractory cardiogenic shock, is known to exacerbate left ventricular loading conditions and impair cardiac energetics. Adjunctive left ventricular unloading strategies are frequently combined with V. A.-E. C. M. O. to counteract these negative effects. These strategies, including intra-aortic balloon pump (I. A. B. P.) or Impella, aim to enhance myocardial recovery through activation of cardioprotective pathways. This approach directly addresses the recognized myocardial strain induced by V. A.-E. C. M. O.
Article 2: Heart rate in early rhythm control therapy in patients with atrial fibrillation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41663267
Summary: Current clinical recommendations advise preventing high heart rates in atrial fibrillation (A. F.) to reduce A. F.-related symptoms and morbidity. However, robust evidence demonstrating a strong relationship between lower heart rate during A. F. and a reduction in symptoms or cardiovascular complications is notably lacking. This analysis specifically compared patient symptoms, treatment strategies, and a composite endpoint of cardiovascular death, stroke, or hospitalization with worsening heart failure. It highlighted an ongoing clinical gap regarding optimal heart rate targets in early rhythm control therapy.
Article 3: From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41666966
Summary: Women represent fewer than five percent of practicing interventional cardiologists in the United States. The W. E. C. A. R. E. study, through semi-structured interviews with 18 women interventional cardiology attendings and fellows, identified five major themes. These themes comprehensively characterize the unique career experiences, challenges, and support systems for women within the interventional cardiology subspecialty. This qualitative research provides specific insights into gender equity dynamics and potential areas for reform in the field.
Article 4: Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Card]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like qualitative research and heart failure. Key takeaway: AF Rate Control: Evidence Gap Identified.
Article Links:
Article 1: Changes in Haemodynamics, Cardiac Energetics, and Cell Signalling Pathways Induced by VA-ECMO with or without Left Ventricular Active Unloading. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Heart rate in early rhythm control therapy in patients with atrial fibrillation. (Heart (British Cardiac Society))
Article 3: From Representation to Reform: A Qualitative Study of Gender Equity in Interventional Cardiology. (The American journal of cardiology)
Article 4: Comprehensive Assessment of Left Ventricular Function and Exercise Endurance in Patients with Hypertrophic Cardiomyopathy: The Combined Application of Left Ventricular Pressure-Strain Loop and Card]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Macrophage circHIPK2 Directs Post-MI Fibrosis 02/11/26</title>
	<link>https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/</link>
	<pubDate>Wed, 11 Feb 2026 07:36:09 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like Blood pressure reduction and E. X. C. E. L. trial. Key takeaway: Macrophage circHIPK2 Directs Post-MI Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41664927">Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41667137">Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41667119">Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41667113">Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41667089">Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/">https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41664927" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41664927</a></p>
<p><strong>Summary:</strong> From the E. X. C. E. L. trial, this study established a systematic adjudication of spontaneous myocardial infarctions following left main coronary artery revascularization. It directly compared myocardial infarction events between patients receiving percutaneous coronary intervention and those undergoing coronary artery bypass graft surgery for left main coronary artery disease. The research determined the relative rates, etiology, and long-term prognostic implications of these spontaneous myocardial infarctions. This work provided definitive data on a critical adverse event after revascularization procedures.</p>
<h4>Article 2: Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667137</a></p>
<p><strong>Summary:</strong> The InEurHeart trial systematically compared computed tomography-guided ventricular tachycardia ablation with conventional ablation. This multicenter randomized controlled study involved 113 patients with prior myocardial infarction and clinically significant ventricular tachycardia. The trial established a direct comparison of the therapeutic effectiveness and safety profiles of these two ablation techniques. It provided foundational data for refining ablation strategies for complex ventricular tachycardia, especially in high-risk post-myocardial infarction patients.</p>
<h4>Article 3: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667119" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667119</a></p>
<p><strong>Summary:</strong> The Q. U. A. D. R. O. trial investigated the effectiveness of a quadruple single-pill combination versus triple antihypertensive therapy for resistant hypertension. This multicenter, phase three, randomized controlled study systematically compared blood pressure reduction outcomes between these two therapeutic approaches. The trial established the comparative efficacy of adding a fourth antihypertensive agent to triple therapy for patients with uncontrolled blood pressure. This provides crucial evidence for guiding treatment decisions in individuals with resistant hypertension to reduce cardiovascular morbidity and mortality.</p>
<h4>Article 4: Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667113" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667113</a></p>
<p><strong>Summary:</strong> This study identified circular R. N. A. circH. I. P. K. two as significantly upregulated in inflammatory cardiac macrophages after myocardial infarction. Researchers found that its expression directly correlated with post-myocardial infarction inflammation dynamics. The data demonstrated that circH. I. P. K. two functions as a key molecular switch for macrophage polarization. These findings reveal a novel mechanism linking specific R. N. A. regulation to cardiac remodeling, inflammation, and fibrosis following myocardial infarction.</p>
<h4>Article 5: Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667089</a></p>
<p><strong>Summary:</strong> This study rigorously assessed the association between Mediterranean diet adherence, with or without wine consumption, and major cardiovascular disease or all-cause mortality. The research utilized data from the PREDIMED trial, encompassing 7447 high-risk participants. Adherence to the Mediterranean diet was quantified using a validated questionnaire, including a specific measure for wine consumption up to seven glasses per week. This provides crucial evidence to clarify the independent and combined effects of wine within the Mediterranean diet on cardiovascular outcomes and overall survival.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial. From the E. X. C. E. L. trial, this study established a systematic adjudication of spontaneous myocardial infarctions following left main coronary artery revascularization. It directly compared myocardial infarction events between patients receiving percutaneous coronary intervention and those undergoing coronary artery bypass graft surgery for left main coronary artery disease. The research determined the relative rates, etiology, and long-term prognostic implications of these spontaneous myocardial infarctions. This work provided definitive data on a critical adverse event after revascularization procedures.</p>
<p>Article number two. Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial. The InEurHeart trial systematically compared computed tomography-guided ventricular tachycardia ablation with conventional ablation. This multicenter randomized controlled study involved 113 patients with prior myocardial infarction and clinically significant ventricular tachycardia. The trial established a direct comparison of the therapeutic effectiveness and safety profiles of these two ablation techniques. It provided foundational data for refining ablation strategies for complex ventricular tachycardia, especially in high-risk post-myocardial infarction patients.</p>
<p>Article number three. Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. The Q. U. A. D. R. O. trial investigated the effectiveness of a quadruple single-pill combination versus triple antihypertensive therapy for resistant hypertension. This multicenter, phase three, randomized controlled study systematically compared blood pressure reduction outcomes between these two therapeutic approaches. The trial established the comparative efficacy of adding a fourth antihypertensive agent to triple therapy for patients with uncontrolled blood pressure. This provides crucial evidence for guiding treatment decisions in individuals with resistant hypertension to reduce cardiovascular morbidity and mortality.</p>
<p>Article number four. Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction. This study identified circular R. N. A. circH. I. P. K. two as significantly upregulated in inflammatory cardiac macrophages after myocardial infarction. Researchers found that its expression directly correlated with post-myocardial infarction inflammation dynamics. The data demonstrated that circH. I. P. K. two functions as a key molecular switch for macrophage polarization. These findings reveal a novel mechanism linking specific R. N. A. regulation to cardiac remodeling, inflammation, and fibrosis following myocardial infarction.</p>
<p>Article number five. Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts. This study rigorously assessed the association between Mediterranean diet adherence, with or without wine consumption, and major cardiovascular disease or all-cause mortality. The research utilized data from the PREDIMED trial, encompassing 7447 high-risk participants. Adherence to the Mediterranean diet was quantified using a validated questionnaire, including a specific measure for wine consumption up to seven glasses per week. This provides crucial evidence to clarify the independent and combined effects of wine within the Mediterranean diet on cardiovascular outcomes and overall survival. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Blood pressure reduction, E. X. C. E. L. trial, Catheter ablation, Cardiac remodeling, Inflammation, Q. U. A. D. R. O. trial, PREDIMED trial, Spontaneous myocardial infarction, Mediterranean diet, All-cause mortality, Macrophage polarization, Percutaneous coronary intervention, Wine consumption, Quadruple therapy, Single-pill combination, Computed tomography guided ablation, Circular R. N. A. circH. I. P. K. two, Ventricular tachycardia, Left main coronary artery disease, Coronary artery bypass graft, Myocardial infarction, InEurHeart trial, Resistant hypertension, Cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/">Macrophage circHIPK2 Directs Post-MI Fibrosis 02/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like Blood pressure reduction and E. X. C. E. L. trial. Key takeaway: Macrophage circHIPK2 Directs Post-MI Fibrosis.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like Blood pressure reduction and E. X. C. E. L. trial. Key takeaway: Macrophage circHIPK2 Directs Post-MI Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41664927">Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41667137">Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41667119">Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41667113">Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41667089">Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/">https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41664927" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41664927</a></p>
<p><strong>Summary:</strong> From the E. X. C. E. L. trial, this study established a systematic adjudication of spontaneous myocardial infarctions following left main coronary artery revascularization. It directly compared myocardial infarction events between patients receiving percutaneous coronary intervention and those undergoing coronary artery bypass graft surgery for left main coronary artery disease. The research determined the relative rates, etiology, and long-term prognostic implications of these spontaneous myocardial infarctions. This work provided definitive data on a critical adverse event after revascularization procedures.</p>
<h4>Article 2: Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667137</a></p>
<p><strong>Summary:</strong> The InEurHeart trial systematically compared computed tomography-guided ventricular tachycardia ablation with conventional ablation. This multicenter randomized controlled study involved 113 patients with prior myocardial infarction and clinically significant ventricular tachycardia. The trial established a direct comparison of the therapeutic effectiveness and safety profiles of these two ablation techniques. It provided foundational data for refining ablation strategies for complex ventricular tachycardia, especially in high-risk post-myocardial infarction patients.</p>
<h4>Article 3: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667119" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667119</a></p>
<p><strong>Summary:</strong> The Q. U. A. D. R. O. trial investigated the effectiveness of a quadruple single-pill combination versus triple antihypertensive therapy for resistant hypertension. This multicenter, phase three, randomized controlled study systematically compared blood pressure reduction outcomes between these two therapeutic approaches. The trial established the comparative efficacy of adding a fourth antihypertensive agent to triple therapy for patients with uncontrolled blood pressure. This provides crucial evidence for guiding treatment decisions in individuals with resistant hypertension to reduce cardiovascular morbidity and mortality.</p>
<h4>Article 4: Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667113" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667113</a></p>
<p><strong>Summary:</strong> This study identified circular R. N. A. circH. I. P. K. two as significantly upregulated in inflammatory cardiac macrophages after myocardial infarction. Researchers found that its expression directly correlated with post-myocardial infarction inflammation dynamics. The data demonstrated that circH. I. P. K. two functions as a key molecular switch for macrophage polarization. These findings reveal a novel mechanism linking specific R. N. A. regulation to cardiac remodeling, inflammation, and fibrosis following myocardial infarction.</p>
<h4>Article 5: Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41667089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41667089</a></p>
<p><strong>Summary:</strong> This study rigorously assessed the association between Mediterranean diet adherence, with or without wine consumption, and major cardiovascular disease or all-cause mortality. The research utilized data from the PREDIMED trial, encompassing 7447 high-risk participants. Adherence to the Mediterranean diet was quantified using a validated questionnaire, including a specific measure for wine consumption up to seven glasses per week. This provides crucial evidence to clarify the independent and combined effects of wine within the Mediterranean diet on cardiovascular outcomes and overall survival.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial. From the E. X. C. E. L. trial, this study established a systematic adjudication of spontaneous myocardial infarctions following left main coronary artery revascularization. It directly compared myocardial infarction events between patients receiving percutaneous coronary intervention and those undergoing coronary artery bypass graft surgery for left main coronary artery disease. The research determined the relative rates, etiology, and long-term prognostic implications of these spontaneous myocardial infarctions. This work provided definitive data on a critical adverse event after revascularization procedures.</p>
<p>Article number two. Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial. The InEurHeart trial systematically compared computed tomography-guided ventricular tachycardia ablation with conventional ablation. This multicenter randomized controlled study involved 113 patients with prior myocardial infarction and clinically significant ventricular tachycardia. The trial established a direct comparison of the therapeutic effectiveness and safety profiles of these two ablation techniques. It provided foundational data for refining ablation strategies for complex ventricular tachycardia, especially in high-risk post-myocardial infarction patients.</p>
<p>Article number three. Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. The Q. U. A. D. R. O. trial investigated the effectiveness of a quadruple single-pill combination versus triple antihypertensive therapy for resistant hypertension. This multicenter, phase three, randomized controlled study systematically compared blood pressure reduction outcomes between these two therapeutic approaches. The trial established the comparative efficacy of adding a fourth antihypertensive agent to triple therapy for patients with uncontrolled blood pressure. This provides crucial evidence for guiding treatment decisions in individuals with resistant hypertension to reduce cardiovascular morbidity and mortality.</p>
<p>Article number four. Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction. This study identified circular R. N. A. circH. I. P. K. two as significantly upregulated in inflammatory cardiac macrophages after myocardial infarction. Researchers found that its expression directly correlated with post-myocardial infarction inflammation dynamics. The data demonstrated that circH. I. P. K. two functions as a key molecular switch for macrophage polarization. These findings reveal a novel mechanism linking specific R. N. A. regulation to cardiac remodeling, inflammation, and fibrosis following myocardial infarction.</p>
<p>Article number five. Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts. This study rigorously assessed the association between Mediterranean diet adherence, with or without wine consumption, and major cardiovascular disease or all-cause mortality. The research utilized data from the PREDIMED trial, encompassing 7447 high-risk participants. Adherence to the Mediterranean diet was quantified using a validated questionnaire, including a specific measure for wine consumption up to seven glasses per week. This provides crucial evidence to clarify the independent and combined effects of wine within the Mediterranean diet on cardiovascular outcomes and overall survival. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Blood pressure reduction, E. X. C. E. L. trial, Catheter ablation, Cardiac remodeling, Inflammation, Q. U. A. D. R. O. trial, PREDIMED trial, Spontaneous myocardial infarction, Mediterranean diet, All-cause mortality, Macrophage polarization, Percutaneous coronary intervention, Wine consumption, Quadruple therapy, Single-pill combination, Computed tomography guided ablation, Circular R. N. A. circH. I. P. K. two, Ventricular tachycardia, Left main coronary artery disease, Coronary artery bypass graft, Myocardial infarction, InEurHeart trial, Resistant hypertension, Cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/">Macrophage circHIPK2 Directs Post-MI Fibrosis 02/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260211_023506.mp3" length="4232924" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like Blood pressure reduction and E. X. C. E. L. trial. Key takeaway: Macrophage circHIPK2 Directs Post-MI Fibrosis.
Article Links:
Article 1: Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial. (Circulation)
Article 2: Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial. (European heart journal)
Article 3: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. (European heart journal)
Article 4: Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction. (European heart journal)
Article 5: Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/
 Featured Articles
Article 1: Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41664927
Summary: From the E. X. C. E. L. trial, this study established a systematic adjudication of spontaneous myocardial infarctions following left main coronary artery revascularization. It directly compared myocardial infarction events between patients receiving percutaneous coronary intervention and those undergoing coronary artery bypass graft surgery for left main coronary artery disease. The research determined the relative rates, etiology, and long-term prognostic implications of these spontaneous myocardial infarctions. This work provided definitive data on a critical adverse event after revascularization procedures.
Article 2: Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41667137
Summary: The InEurHeart trial systematically compared computed tomography-guided ventricular tachycardia ablation with conventional ablation. This multicenter randomized controlled study involved 113 patients with prior myocardial infarction and clinically significant ventricular tachycardia. The trial established a direct comparison of the therapeutic effectiveness and safety profiles of these two ablation techniques. It provided foundational data for refining ablation strategies for complex ventricular tachycardia, especially in high-risk post-myocardial infarction patients.
Article 3: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41667119
Summary: The Q. U. A. D. R. O. trial investigated the effectiveness of a quadruple single-pill combination versus triple antihypertensive therapy for resistant hypertension. This multicenter, phase three, randomized controlled study systematically compared blood pressure reduction outcomes between these two therapeutic approaches. The trial established the comparative efficacy of adding a fourth antihypertensive agent to triple therapy for patients with uncontrolled blood pressure. This provides crucial evidence for guiding treatment decisions in individuals with resistant hypertension to reduce cardiovascular morbidity and mortality.
Article 4: Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41667113
Summary: This study identified circular R. N. A. circH. I. P. K. two as significantly upregulated in inflammatory cardiac macrophages after myocardial infarction. Researchers found that its expression directly correlated with post-myocardial infarction inflammation dynamics. The data demonstrated that circH. I. P. K. two functions as a key molecular switch for macrophage polarizatio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 11, 2026. This episode summarizes 5 key cardiology studies on topics like Blood pressure reduction and E. X. C. E. L. trial. Key takeaway: Macrophage circHIPK2 Directs Post-MI Fibrosis.
Article Links:
Article 1: Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial. (Circulation)
Article 2: Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial. (European heart journal)
Article 3: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. (European heart journal)
Article 4: Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction. (European heart journal)
Article 5: Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/macrophage-circhipk2-directs-post-mi-fibrosis-02-11-26/
 Featur]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AP-1 Genes Drive Lung Allograft Dysfunction 02/10/26</title>
	<link>https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/</link>
	<pubDate>Tue, 10 Feb 2026 11:01:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 10, 2026. This episode summarizes 5 key cardiology studies on topics like endothelium and cost-utility analysis. Key takeaway: AP-1 Genes Drive Lung Allograft Dysfunction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41662456">Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41663041">Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41663040">Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41656551">Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41663268">Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/">https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41662456" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41662456</a></p>
<p><strong>Summary:</strong> This study found that stressor-associated atrial fibrillation, defined as newly diagnosed atrial fibrillation in the presence of a reversible physiological stressor, is a common clinical entity. The VITAL-AF trial characterized this patient population, which comprised adults aged 65 years and older across primary care practices. This research highlights the widespread occurrence of this specific atrial fibrillation subtype, underscoring its clinical significance for diagnosis and management. The findings establish the importance of distinguishing stressor-associated atrial fibrillation for improved risk stratification in older adults.</p>
<h4>Article 2: Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663041</a></p>
<p><strong>Summary:</strong> Spatial transcriptomic analyses of human lungs with chronic lung allograft dysfunction revealed significant upregulation of activator protein-1 target genes, including JUNB and FOS. This upregulation was observed in both the epithelial and endothelial tissues of patients with chronic lung allograft dysfunction. The data demonstrated coordinated activator protein-1 activation in these cell types within affected lung allografts. This provides novel insight into the disease pathology of chronic lung allograft dysfunction.</p>
<h4>Article 3: Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663040</a></p>
<p><strong>Summary:</strong> Ex-vivo lung perfusion enables the evaluation and rehabilitation of potentially usable donor lungs outside the body prior to transplantation. This study established a comprehensive cost-utility analysis model for integrating ex-vivo lung perfusion into lung transplant programs, adopting a hospital perspective. The model utilizes individual-level simulation over a lifetime horizon for adults with end-stage lung disease awaiting transplantation. This research provides a critical tool for assessing the health economic implications of technologies that expand the donor organ pool and improve transplant outcomes.</p>
<h4>Article 4: Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41656551" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41656551</a></p>
<p><strong>Summary:</strong> Bone health is frequently compromised in patients with type one diabetes and advanced diabetic kidney disease. This study characterized changes in bone mineral density and trabecular bone score before and after simultaneous pancreas-kidney transplantation in 48 patients. This research addresses the critical skeletal impact of simultaneous pancreas-kidney transplantation in this vulnerable patient population. It highlights the importance of understanding bone changes in the context of immunosuppressive regimens.</p>
<h4>Article 5: Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663268" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663268</a></p>
<p><strong>Summary:</strong> Obesity is associated with lower N-terminal pro-B-type natriuretic peptide concentrations, and obese patients often present with heart failure symptoms at less severe levels of left ventricular dysfunction. This study characterized the complex interrelationship among body mass index, left ventricular ejection fraction, heart failure symptoms, N-terminal pro-B-type natriuretic peptide levels, and mortality. The research highlights the critical need to consider body mass index when interpreting N-terminal pro-B-type natriuretic peptide levels. It identifies specific factors influencing symptom presentation and mortality risk in individuals with suspected heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial. This study found that stressor-associated atrial fibrillation, defined as newly diagnosed atrial fibrillation in the presence of a reversible physiological stressor, is a common clinical entity. The VITAL-AF trial characterized this patient population, which comprised adults aged 65 years and older across primary care practices. This research highlights the widespread occurrence of this specific atrial fibrillation subtype, underscoring its clinical significance for diagnosis and management. The findings establish the importance of distinguishing stressor-associated atrial fibrillation for improved risk stratification in older adults.</p>
<p>Article number two. Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD. Spatial transcriptomic analyses of human lungs with chronic lung allograft dysfunction revealed significant upregulation of activator protein-1 target genes, including JUNB and FOS. This upregulation was observed in both the epithelial and endothelial tissues of patients with chronic lung allograft dysfunction. The data demonstrated coordinated activator protein-1 activation in these cell types within affected lung allografts. This provides novel insight into the disease pathology of chronic lung allograft dysfunction.</p>
<p>Article number three. Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre. Ex-vivo lung perfusion enables the evaluation and rehabilitation of potentially usable donor lungs outside the body prior to transplantation. This study established a comprehensive cost-utility analysis model for integrating ex-vivo lung perfusion into lung transplant programs, adopting a hospital perspective. The model utilizes individual-level simulation over a lifetime horizon for adults with end-stage lung disease awaiting transplantation. This research provides a critical tool for assessing the health economic implications of technologies that expand the donor organ pool and improve transplant outcomes.</p>
<p>Article number four. Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period. Bone health is frequently compromised in patients with type one diabetes and advanced diabetic kidney disease. This study characterized changes in bone mineral density and trabecular bone score before and after simultaneous pancreas-kidney transplantation in 48 patients. This research addresses the critical skeletal impact of simultaneous pancreas-kidney transplantation in this vulnerable patient population. It highlights the importance of understanding bone changes in the context of immunosuppressive regimens.</p>
<p>Article number five. Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure. Obesity is associated with lower N-terminal pro-B-type natriuretic peptide concentrations, and obese patients often present with heart failure symptoms at less severe levels of left ventricular dysfunction. This study characterized the complex interrelationship among body mass index, left ventricular ejection fraction, heart failure symptoms, N-terminal pro-B-type natriuretic peptide levels, and mortality. The research highlights the critical need to consider body mass index when interpreting N-terminal pro-B-type natriuretic peptide levels. It identifies specific factors influencing symptom presentation and mortality risk in individuals with suspected heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>endothelium, cost-utility analysis, donor lungs, atrial fibrillation, spatial transcriptomics, health economics, primary care, type one diabetes, VITAL-AF trial, N-terminal pro-B-type natriuretic peptide, bone mineral density, immunosuppression, stressor-associated, diabetic kidney disease, mortality, lung transplantation, activator protein-1, epithelium, older adults, chronic lung allograft dysfunction, left ventricular ejection fraction, ex-vivo lung perfusion, body mass index, heart failure, simultaneous pancreas-kidney transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/">AP-1 Genes Drive Lung Allograft Dysfunction 02/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 10, 2026. This episode summarizes 5 key cardiology studies on topics like endothelium and cost-utility analysis. Key takeaway: AP-1 Genes Drive Lung Allograft Dysfunction.
Article Links:
Article 1: Incidenc]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 10, 2026. This episode summarizes 5 key cardiology studies on topics like endothelium and cost-utility analysis. Key takeaway: AP-1 Genes Drive Lung Allograft Dysfunction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41662456">Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41663041">Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41663040">Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41656551">Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41663268">Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/">https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41662456" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41662456</a></p>
<p><strong>Summary:</strong> This study found that stressor-associated atrial fibrillation, defined as newly diagnosed atrial fibrillation in the presence of a reversible physiological stressor, is a common clinical entity. The VITAL-AF trial characterized this patient population, which comprised adults aged 65 years and older across primary care practices. This research highlights the widespread occurrence of this specific atrial fibrillation subtype, underscoring its clinical significance for diagnosis and management. The findings establish the importance of distinguishing stressor-associated atrial fibrillation for improved risk stratification in older adults.</p>
<h4>Article 2: Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663041" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663041</a></p>
<p><strong>Summary:</strong> Spatial transcriptomic analyses of human lungs with chronic lung allograft dysfunction revealed significant upregulation of activator protein-1 target genes, including JUNB and FOS. This upregulation was observed in both the epithelial and endothelial tissues of patients with chronic lung allograft dysfunction. The data demonstrated coordinated activator protein-1 activation in these cell types within affected lung allografts. This provides novel insight into the disease pathology of chronic lung allograft dysfunction.</p>
<h4>Article 3: Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663040</a></p>
<p><strong>Summary:</strong> Ex-vivo lung perfusion enables the evaluation and rehabilitation of potentially usable donor lungs outside the body prior to transplantation. This study established a comprehensive cost-utility analysis model for integrating ex-vivo lung perfusion into lung transplant programs, adopting a hospital perspective. The model utilizes individual-level simulation over a lifetime horizon for adults with end-stage lung disease awaiting transplantation. This research provides a critical tool for assessing the health economic implications of technologies that expand the donor organ pool and improve transplant outcomes.</p>
<h4>Article 4: Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41656551" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41656551</a></p>
<p><strong>Summary:</strong> Bone health is frequently compromised in patients with type one diabetes and advanced diabetic kidney disease. This study characterized changes in bone mineral density and trabecular bone score before and after simultaneous pancreas-kidney transplantation in 48 patients. This research addresses the critical skeletal impact of simultaneous pancreas-kidney transplantation in this vulnerable patient population. It highlights the importance of understanding bone changes in the context of immunosuppressive regimens.</p>
<h4>Article 5: Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41663268" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41663268</a></p>
<p><strong>Summary:</strong> Obesity is associated with lower N-terminal pro-B-type natriuretic peptide concentrations, and obese patients often present with heart failure symptoms at less severe levels of left ventricular dysfunction. This study characterized the complex interrelationship among body mass index, left ventricular ejection fraction, heart failure symptoms, N-terminal pro-B-type natriuretic peptide levels, and mortality. The research highlights the critical need to consider body mass index when interpreting N-terminal pro-B-type natriuretic peptide levels. It identifies specific factors influencing symptom presentation and mortality risk in individuals with suspected heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial. This study found that stressor-associated atrial fibrillation, defined as newly diagnosed atrial fibrillation in the presence of a reversible physiological stressor, is a common clinical entity. The VITAL-AF trial characterized this patient population, which comprised adults aged 65 years and older across primary care practices. This research highlights the widespread occurrence of this specific atrial fibrillation subtype, underscoring its clinical significance for diagnosis and management. The findings establish the importance of distinguishing stressor-associated atrial fibrillation for improved risk stratification in older adults.</p>
<p>Article number two. Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD. Spatial transcriptomic analyses of human lungs with chronic lung allograft dysfunction revealed significant upregulation of activator protein-1 target genes, including JUNB and FOS. This upregulation was observed in both the epithelial and endothelial tissues of patients with chronic lung allograft dysfunction. The data demonstrated coordinated activator protein-1 activation in these cell types within affected lung allografts. This provides novel insight into the disease pathology of chronic lung allograft dysfunction.</p>
<p>Article number three. Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre. Ex-vivo lung perfusion enables the evaluation and rehabilitation of potentially usable donor lungs outside the body prior to transplantation. This study established a comprehensive cost-utility analysis model for integrating ex-vivo lung perfusion into lung transplant programs, adopting a hospital perspective. The model utilizes individual-level simulation over a lifetime horizon for adults with end-stage lung disease awaiting transplantation. This research provides a critical tool for assessing the health economic implications of technologies that expand the donor organ pool and improve transplant outcomes.</p>
<p>Article number four. Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period. Bone health is frequently compromised in patients with type one diabetes and advanced diabetic kidney disease. This study characterized changes in bone mineral density and trabecular bone score before and after simultaneous pancreas-kidney transplantation in 48 patients. This research addresses the critical skeletal impact of simultaneous pancreas-kidney transplantation in this vulnerable patient population. It highlights the importance of understanding bone changes in the context of immunosuppressive regimens.</p>
<p>Article number five. Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure. Obesity is associated with lower N-terminal pro-B-type natriuretic peptide concentrations, and obese patients often present with heart failure symptoms at less severe levels of left ventricular dysfunction. This study characterized the complex interrelationship among body mass index, left ventricular ejection fraction, heart failure symptoms, N-terminal pro-B-type natriuretic peptide levels, and mortality. The research highlights the critical need to consider body mass index when interpreting N-terminal pro-B-type natriuretic peptide levels. It identifies specific factors influencing symptom presentation and mortality risk in individuals with suspected heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>endothelium, cost-utility analysis, donor lungs, atrial fibrillation, spatial transcriptomics, health economics, primary care, type one diabetes, VITAL-AF trial, N-terminal pro-B-type natriuretic peptide, bone mineral density, immunosuppression, stressor-associated, diabetic kidney disease, mortality, lung transplantation, activator protein-1, epithelium, older adults, chronic lung allograft dysfunction, left ventricular ejection fraction, ex-vivo lung perfusion, body mass index, heart failure, simultaneous pancreas-kidney transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/">AP-1 Genes Drive Lung Allograft Dysfunction 02/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260210_060038.mp3" length="4444829" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 10, 2026. This episode summarizes 5 key cardiology studies on topics like endothelium and cost-utility analysis. Key takeaway: AP-1 Genes Drive Lung Allograft Dysfunction.
Article Links:
Article 1: Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial. (Circulation)
Article 2: Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period. (Transplantation)
Article 5: Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/ap-1-genes-drive-lung-allograft-dysfunction-02-10-26/
 Featured Articles
Article 1: Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41662456
Summary: This study found that stressor-associated atrial fibrillation, defined as newly diagnosed atrial fibrillation in the presence of a reversible physiological stressor, is a common clinical entity. The VITAL-AF trial characterized this patient population, which comprised adults aged 65 years and older across primary care practices. This research highlights the widespread occurrence of this specific atrial fibrillation subtype, underscoring its clinical significance for diagnosis and management. The findings establish the importance of distinguishing stressor-associated atrial fibrillation for improved risk stratification in older adults.
Article 2: Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41663041
Summary: Spatial transcriptomic analyses of human lungs with chronic lung allograft dysfunction revealed significant upregulation of activator protein-1 target genes, including JUNB and FOS. This upregulation was observed in both the epithelial and endothelial tissues of patients with chronic lung allograft dysfunction. The data demonstrated coordinated activator protein-1 activation in these cell types within affected lung allografts. This provides novel insight into the disease pathology of chronic lung allograft dysfunction.
Article 3: Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41663040
Summary: Ex-vivo lung perfusion enables the evaluation and rehabilitation of potentially usable donor lungs outside the body prior to transplantation. This study established a comprehensive cost-utility analysis model for integrating ex-vivo lung perfusion into lung transplant programs, adopting a hospital perspective. The model utilizes individual-level simulation over a lifetime horizon for adults with end-stage lung disease awaiting transplantation. This research provides a critical tool for assessing the health economic implications of technologies that expand the donor organ p]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 10, 2026. This episode summarizes 5 key cardiology studies on topics like endothelium and cost-utility analysis. Key takeaway: AP-1 Genes Drive Lung Allograft Dysfunction.
Article Links:
Article 1: Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial. (Circulation)
Article 2: Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in CLAD. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Economic evaluation of ex-vivo lung perfusion for lung transplantation: a cost-utility analysis from a large Canadian centre. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretranspl]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CVP: Key to Heart Failure Chemoreceptor Sensitivity 02/09/26</title>
	<link>https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/</link>
	<pubDate>Mon, 09 Feb 2026 11:01:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 09, 2026. This episode summarizes 5 key cardiology studies on topics like Accessory pathways and Omnipolar technology near-field. Key takeaway: CVP: Key to Heart Failure Chemoreceptor Sensitivity.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41655667">A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41655666">Blood pressure and the risk of stroke in young patients with atrial fibrillation.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41655665">High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41655663">Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41655605">Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/">https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655667" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655667</a></p>
<p><strong>Summary:</strong> Left atrial low-voltage areas (LVAs) indicate atrial fibrosis and structural remodeling in a subset of paroxysmal atrial fibrillation patients. This study developed and validated a novel predictive model for identifying these LVAs in paroxysmal atrial fibrillation. Researchers enrolled patients receiving initial radiofrequency ablation. LVAs were specifically defined as regions with a bipolar voltage of less than 0.5.</p>
<h4>Article 2: Blood pressure and the risk of stroke in young patients with atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655666" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655666</a></p>
<p><strong>Summary:</strong> Elevated blood pressure is associated with an increased stroke risk in atrial fibrillation patients. This study identified patients aged 20 to 39 years, newly diagnosed with atrial fibrillation, from the Korean Health Insurance Service database. The investigation focused on the effect of systolic blood pressure, diastolic blood pressure, and pulse pressure on ischemic stroke risk in this young atrial fibrillation cohort. This research addresses an important gap in understanding stroke risk factors for younger adults with atrial fibrillation.</p>
<h4>Article 3: High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655665</a></p>
<p><strong>Summary:</strong> Catheter ablation is a curative therapy for atrioventricular reentrant tachycardia caused by accessory pathways, but precise localization is challenging. Omnipolar technology near-field (O. T. N. F.) provides a novel frequency-based analysis. This study characterized the spatial relationship between high-frequency areas identified by O. T. N. F. -derived peak frequency maps and successful accessory pathway ablation sites. This characterization helps improve precision in catheter ablation for atrioventricular reentrant tachycardia.</p>
<h4>Article 4: Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655663" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655663</a></p>
<p><strong>Summary:</strong> Linear ablation lesions beyond pulmonary vein isolation in persistent atrial fibrillation often show variable efficacy. This study examined the performance of a novel dual-energy pulsed field/radiofrequency lattice-tip mapping and ablation system for linear ablation. The research also investigated the impact of this ablation strategy on outcomes within the SPHERE Persistent Atrial Fibrillation Randomized Trial. This investigation addresses the need for optimized ablation techniques for persistent atrial fibrillation.</p>
<h4>Article 5: Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655605" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655605</a></p>
<p><strong>Summary:</strong> Heart failure patients exhibit elevated sympathetic tone and abnormal peripheral chemoreceptor (PChR) function, often linked to reduced cardiac output. A study involving 14 heart failure patients with left ventricular assist devices found that central venous pressure, rather than cardiac output, was associated with peripheral chemoreceptor sensitivity. This finding provides unique insight into the impact of hemodynamic changes on peripheral chemoreceptor function.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation. Left atrial low-voltage areas (LVAs) indicate atrial fibrosis and structural remodeling in a subset of paroxysmal atrial fibrillation patients. This study developed and validated a novel predictive model for identifying these LVAs in paroxysmal atrial fibrillation. Researchers enrolled patients receiving initial radiofrequency ablation. LVAs were specifically defined as regions with a bipolar voltage of less than 0.5.</p>
<p>Article number two. Blood pressure and the risk of stroke in young patients with atrial fibrillation. Elevated blood pressure is associated with an increased stroke risk in atrial fibrillation patients. This study identified patients aged 20 to 39 years, newly diagnosed with atrial fibrillation, from the Korean Health Insurance Service database. The investigation focused on the effect of systolic blood pressure, diastolic blood pressure, and pulse pressure on ischemic stroke risk in this young atrial fibrillation cohort. This research addresses an important gap in understanding stroke risk factors for younger adults with atrial fibrillation.</p>
<p>Article number three. High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping. Catheter ablation is a curative therapy for atrioventricular reentrant tachycardia caused by accessory pathways, but precise localization is challenging. Omnipolar technology near-field (O. T. N. F.) provides a novel frequency-based analysis. This study characterized the spatial relationship between high-frequency areas identified by O. T. N. F. -derived peak frequency maps and successful accessory pathway ablation sites. This characterization helps improve precision in catheter ablation for atrioventricular reentrant tachycardia.</p>
<p>Article number four. Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial. Linear ablation lesions beyond pulmonary vein isolation in persistent atrial fibrillation often show variable efficacy. This study examined the performance of a novel dual-energy pulsed field/radiofrequency lattice-tip mapping and ablation system for linear ablation. The research also investigated the impact of this ablation strategy on outcomes within the SPHERE Persistent Atrial Fibrillation Randomized Trial. This investigation addresses the need for optimized ablation techniques for persistent atrial fibrillation.</p>
<p>Article number five. Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device. Heart failure patients exhibit elevated sympathetic tone and abnormal peripheral chemoreceptor (PChR) function, often linked to reduced cardiac output. A study involving 14 heart failure patients with left ventricular assist devices found that central venous pressure, rather than cardiac output, was associated with peripheral chemoreceptor sensitivity. This finding provides unique insight into the impact of hemodynamic changes on peripheral chemoreceptor function. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Accessory pathways, Omnipolar technology near-field, Pulse pressure, Pulsed field ablation, Peripheral chemoreceptor sensitivity, Radiofrequency ablation, Sympathetic tone, Structural remodeling, Systolic blood pressure, Cardiac output, Electrophysiology, Atrioventricular reentrant tachycardia, Central venous pressure, Peak frequency mapping, Atrial fibrillation, Diastolic blood pressure, Linear ablation, Atrial fibrosis, Left ventricular assist device, Heart failure, Left atrial low-voltage areas, Persistent atrial fibrillation, Pulmonary vein isolation, Ischemic stroke, Catheter ablation, Blood pressure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/">CVP: Key to Heart Failure Chemoreceptor Sensitivity 02/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 09, 2026. This episode summarizes 5 key cardiology studies on topics like Accessory pathways and Omnipolar technology near-field. Key takeaway: CVP: Key to Heart Failure Chemoreceptor Sensitivity.
Article L]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 09, 2026. This episode summarizes 5 key cardiology studies on topics like Accessory pathways and Omnipolar technology near-field. Key takeaway: CVP: Key to Heart Failure Chemoreceptor Sensitivity.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41655667">A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41655666">Blood pressure and the risk of stroke in young patients with atrial fibrillation.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41655665">High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41655663">Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41655605">Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/">https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655667" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655667</a></p>
<p><strong>Summary:</strong> Left atrial low-voltage areas (LVAs) indicate atrial fibrosis and structural remodeling in a subset of paroxysmal atrial fibrillation patients. This study developed and validated a novel predictive model for identifying these LVAs in paroxysmal atrial fibrillation. Researchers enrolled patients receiving initial radiofrequency ablation. LVAs were specifically defined as regions with a bipolar voltage of less than 0.5.</p>
<h4>Article 2: Blood pressure and the risk of stroke in young patients with atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655666" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655666</a></p>
<p><strong>Summary:</strong> Elevated blood pressure is associated with an increased stroke risk in atrial fibrillation patients. This study identified patients aged 20 to 39 years, newly diagnosed with atrial fibrillation, from the Korean Health Insurance Service database. The investigation focused on the effect of systolic blood pressure, diastolic blood pressure, and pulse pressure on ischemic stroke risk in this young atrial fibrillation cohort. This research addresses an important gap in understanding stroke risk factors for younger adults with atrial fibrillation.</p>
<h4>Article 3: High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655665</a></p>
<p><strong>Summary:</strong> Catheter ablation is a curative therapy for atrioventricular reentrant tachycardia caused by accessory pathways, but precise localization is challenging. Omnipolar technology near-field (O. T. N. F.) provides a novel frequency-based analysis. This study characterized the spatial relationship between high-frequency areas identified by O. T. N. F. -derived peak frequency maps and successful accessory pathway ablation sites. This characterization helps improve precision in catheter ablation for atrioventricular reentrant tachycardia.</p>
<h4>Article 4: Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655663" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655663</a></p>
<p><strong>Summary:</strong> Linear ablation lesions beyond pulmonary vein isolation in persistent atrial fibrillation often show variable efficacy. This study examined the performance of a novel dual-energy pulsed field/radiofrequency lattice-tip mapping and ablation system for linear ablation. The research also investigated the impact of this ablation strategy on outcomes within the SPHERE Persistent Atrial Fibrillation Randomized Trial. This investigation addresses the need for optimized ablation techniques for persistent atrial fibrillation.</p>
<h4>Article 5: Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41655605" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41655605</a></p>
<p><strong>Summary:</strong> Heart failure patients exhibit elevated sympathetic tone and abnormal peripheral chemoreceptor (PChR) function, often linked to reduced cardiac output. A study involving 14 heart failure patients with left ventricular assist devices found that central venous pressure, rather than cardiac output, was associated with peripheral chemoreceptor sensitivity. This finding provides unique insight into the impact of hemodynamic changes on peripheral chemoreceptor function.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation. Left atrial low-voltage areas (LVAs) indicate atrial fibrosis and structural remodeling in a subset of paroxysmal atrial fibrillation patients. This study developed and validated a novel predictive model for identifying these LVAs in paroxysmal atrial fibrillation. Researchers enrolled patients receiving initial radiofrequency ablation. LVAs were specifically defined as regions with a bipolar voltage of less than 0.5.</p>
<p>Article number two. Blood pressure and the risk of stroke in young patients with atrial fibrillation. Elevated blood pressure is associated with an increased stroke risk in atrial fibrillation patients. This study identified patients aged 20 to 39 years, newly diagnosed with atrial fibrillation, from the Korean Health Insurance Service database. The investigation focused on the effect of systolic blood pressure, diastolic blood pressure, and pulse pressure on ischemic stroke risk in this young atrial fibrillation cohort. This research addresses an important gap in understanding stroke risk factors for younger adults with atrial fibrillation.</p>
<p>Article number three. High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping. Catheter ablation is a curative therapy for atrioventricular reentrant tachycardia caused by accessory pathways, but precise localization is challenging. Omnipolar technology near-field (O. T. N. F.) provides a novel frequency-based analysis. This study characterized the spatial relationship between high-frequency areas identified by O. T. N. F. -derived peak frequency maps and successful accessory pathway ablation sites. This characterization helps improve precision in catheter ablation for atrioventricular reentrant tachycardia.</p>
<p>Article number four. Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial. Linear ablation lesions beyond pulmonary vein isolation in persistent atrial fibrillation often show variable efficacy. This study examined the performance of a novel dual-energy pulsed field/radiofrequency lattice-tip mapping and ablation system for linear ablation. The research also investigated the impact of this ablation strategy on outcomes within the SPHERE Persistent Atrial Fibrillation Randomized Trial. This investigation addresses the need for optimized ablation techniques for persistent atrial fibrillation.</p>
<p>Article number five. Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device. Heart failure patients exhibit elevated sympathetic tone and abnormal peripheral chemoreceptor (PChR) function, often linked to reduced cardiac output. A study involving 14 heart failure patients with left ventricular assist devices found that central venous pressure, rather than cardiac output, was associated with peripheral chemoreceptor sensitivity. This finding provides unique insight into the impact of hemodynamic changes on peripheral chemoreceptor function. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Accessory pathways, Omnipolar technology near-field, Pulse pressure, Pulsed field ablation, Peripheral chemoreceptor sensitivity, Radiofrequency ablation, Sympathetic tone, Structural remodeling, Systolic blood pressure, Cardiac output, Electrophysiology, Atrioventricular reentrant tachycardia, Central venous pressure, Peak frequency mapping, Atrial fibrillation, Diastolic blood pressure, Linear ablation, Atrial fibrosis, Left ventricular assist device, Heart failure, Left atrial low-voltage areas, Persistent atrial fibrillation, Pulmonary vein isolation, Ischemic stroke, Catheter ablation, Blood pressure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/">CVP: Key to Heart Failure Chemoreceptor Sensitivity 02/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260209_060041.mp3" length="3792395" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 09, 2026. This episode summarizes 5 key cardiology studies on topics like Accessory pathways and Omnipolar technology near-field. Key takeaway: CVP: Key to Heart Failure Chemoreceptor Sensitivity.
Article Links:
Article 1: A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation. (Heart rhythm)
Article 2: Blood pressure and the risk of stroke in young patients with atrial fibrillation. (Heart rhythm)
Article 3: High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping. (Heart rhythm)
Article 4: Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial. (Heart rhythm)
Article 5: Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients with left ventricular assist device. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/cvp-key-to-heart-failure-chemoreceptor-sensitivity-02-09-26/
 Featured Articles
Article 1: A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41655667
Summary: Left atrial low-voltage areas (LVAs) indicate atrial fibrosis and structural remodeling in a subset of paroxysmal atrial fibrillation patients. This study developed and validated a novel predictive model for identifying these LVAs in paroxysmal atrial fibrillation. Researchers enrolled patients receiving initial radiofrequency ablation. LVAs were specifically defined as regions with a bipolar voltage of less than 0.5.
Article 2: Blood pressure and the risk of stroke in young patients with atrial fibrillation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41655666
Summary: Elevated blood pressure is associated with an increased stroke risk in atrial fibrillation patients. This study identified patients aged 20 to 39 years, newly diagnosed with atrial fibrillation, from the Korean Health Insurance Service database. The investigation focused on the effect of systolic blood pressure, diastolic blood pressure, and pulse pressure on ischemic stroke risk in this young atrial fibrillation cohort. This research addresses an important gap in understanding stroke risk factors for younger adults with atrial fibrillation.
Article 3: High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41655665
Summary: Catheter ablation is a curative therapy for atrioventricular reentrant tachycardia caused by accessory pathways, but precise localization is challenging. Omnipolar technology near-field (O. T. N. F.) provides a novel frequency-based analysis. This study characterized the spatial relationship between high-frequency areas identified by O. T. N. F. -derived peak frequency maps and successful accessory pathway ablation sites. This characterization helps improve precision in catheter ablation for atrioventricular reentrant tachycardia.
Article 4: Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41655663
Summary: Linear ablation lesions beyond pulmonary vein isolation in persistent atrial fibrillation often show variable efficacy. This study examined the performance of a novel dual-energy pulsed field/radiofrequency lattice-tip mapping and ablation system for linear ablation. The research also investigated the impact of this ablation strategy on outcomes within the SPHERE Persistent Atrial Fibrillation Randomiz]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 09, 2026. This episode summarizes 5 key cardiology studies on topics like Accessory pathways and Omnipolar technology near-field. Key takeaway: CVP: Key to Heart Failure Chemoreceptor Sensitivity.
Article Links:
Article 1: A Novel Predictive Model for Left Atrial Low-Voltage Areas in Paroxysmal Atrial Fibrillation. (Heart rhythm)
Article 2: Blood pressure and the risk of stroke in young patients with atrial fibrillation. (Heart rhythm)
Article 3: High-Frequency Areas as an Electrophysiological Clue for Accessory Pathway Ablation: Characterizing Spatial Dissociation with Peak Frequency Mapping. (Heart rhythm)
Article 4: Impact of linear ablation in persistent atrial fibrillation using a dual energy, wide-footprint catheter &#8211; Analysis from the SPHERE Per-AF Randomized Trial. (Heart rhythm)
Article 5: Central venous pressure, rather than cardiac output, is associated with peripheral chemoreceptor sensitivity in heart failure patients ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Adipose Tissue Drives Heart Failure Pathogenesis 02/08/26</title>
	<link>https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/</link>
	<pubDate>Sun, 08 Feb 2026 11:01:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 08, 2026. This episode summarizes 5 key cardiology studies on topics like preeclampsia and maternal-fetal interface. Key takeaway: Adipose Tissue Drives Heart Failure Pathogenesis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41654158">Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41653976">Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres.</a> (The Canadian journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41645491">Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41645896">SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41641542">circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/">https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41654158" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41654158</a></p>
<p><strong>Summary:</strong> Intravascular lithotripsy demonstrates efficacy in treating balloon-crossable calcified coronary lesions. It achieves this by inducing calcium fractures and improving coronary artery compliance. This study evaluates patients with calcified coronary artery lesions from the BENELUX-IVL prospective registry who received intravascular lithotripsy under intravascular ultrasound. The research provides a direct comparison of coronary artery compliance modification between intravascular lithotripsy and non-compliant balloon angioplasty.</p>
<h4>Article 2: Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41653976" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41653976</a></p>
<p><strong>Summary:</strong> High-risk pulmonary embolism presents with high early mortality and a heterogeneous patient population, ranging from cardiac arrest to obstructive shock or hypotension. Systemic thrombolysis remains the standard of care, but its use is limited by contraindications and bleeding risk. Catheter-directed therapies offer alternatives, though data on their use in high-risk pulmonary embolism is limited. This study characterized the clinical characteristics, management strategies, and outcomes across three distinct high-risk pulmonary embolism clinical phenotypes.</p>
<h4>Article 3: Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645491" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645491</a></p>
<p><strong>Summary:</strong> Heart failure with preserved ejection fraction (H. F. pEF) phenotypes were induced in male C57BL/6N mice using a high-fat diet combined with Nω-nitro-l-arginine methyl ester. The study found a causal relationship between adiposity and Heart Failure with Preserved Ejection Fraction pathogenesis. Resection of visceral adipose tissue blunted Heart Failure with Preserved Ejection Fraction phenotypes in mice, while transplantation of visceral adipose tissue exacerbated these phenotypes.</p>
<h4>Article 4: SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645896</a></p>
<p><strong>Summary:</strong> Preeclampsia, a severe hypertensive disorder of pregnancy, is associated with low sirtuin 1 (SIRT1) levels in trophoblasts. Single-cell sequencing of systemic sirtuin 1 heterozygous knockout mice revealed abnormal activation of trophoblast retinoic acid receptor responder 2 (RARRES2) and macrophage chemokine-like receptor 1 (CMKLR1) at the maternal-fetal interface. The investigation determined that low sirtuin 1 in trophoblasts increases retinoic acid receptor responder 2 expression, which subsequently affects macrophage polarization. This mechanism clarifies a key pathway in preeclampsia pathogenesis.</p>
<h4>Article 5: circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41641542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41641542</a></p>
<p><strong>Summary:</strong> A pulmonary hypertension (P. H.)-related circular R. N. A., circMFN2, originating from the mitofusin-2 (MFN2) locus, was identified. This circMFN2 was significantly downregulated in the peripheral blood of patients with P. H. and in the pulmonary arteries of Sugen/hypoxia-induced P. H. mice. The study demonstrated that circMFN2 regulates the insulin-like growth factor two messenger R. N. A. binding protein three (IGF2BP3)-pyruvate dehydrogenase kinase four (PDK4) pathway. This regulation by circMFN2 ameliorates P. H., indicating its role as a potential therapeutic target.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 08, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy. Intravascular lithotripsy demonstrates efficacy in treating balloon-crossable calcified coronary lesions. It achieves this by inducing calcium fractures and improving coronary artery compliance. This study evaluates patients with calcified coronary artery lesions from the BENELUX-IVL prospective registry who received intravascular lithotripsy under intravascular ultrasound. The research provides a direct comparison of coronary artery compliance modification between intravascular lithotripsy and non-compliant balloon angioplasty.</p>
<p>Article number two. Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres. High-risk pulmonary embolism presents with high early mortality and a heterogeneous patient population, ranging from cardiac arrest to obstructive shock or hypotension. Systemic thrombolysis remains the standard of care, but its use is limited by contraindications and bleeding risk. Catheter-directed therapies offer alternatives, though data on their use in high-risk pulmonary embolism is limited. This study characterized the clinical characteristics, management strategies, and outcomes across three distinct high-risk pulmonary embolism clinical phenotypes.</p>
<p>Article number three. Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction. Heart failure with preserved ejection fraction (H. F. pEF) phenotypes were induced in male C57BL/6N mice using a high-fat diet combined with Nω-nitro-l-arginine methyl ester. The study found a causal relationship between adiposity and Heart Failure with Preserved Ejection Fraction pathogenesis. Resection of visceral adipose tissue blunted Heart Failure with Preserved Ejection Fraction phenotypes in mice, while transplantation of visceral adipose tissue exacerbated these phenotypes.</p>
<p>Article number four. SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia. Preeclampsia, a severe hypertensive disorder of pregnancy, is associated with low sirtuin 1 (SIRT1) levels in trophoblasts. Single-cell sequencing of systemic sirtuin 1 heterozygous knockout mice revealed abnormal activation of trophoblast retinoic acid receptor responder 2 (RARRES2) and macrophage chemokine-like receptor 1 (CMKLR1) at the maternal-fetal interface. The investigation determined that low sirtuin 1 in trophoblasts increases retinoic acid receptor responder 2 expression, which subsequently affects macrophage polarization. This mechanism clarifies a key pathway in preeclampsia pathogenesis.</p>
<p>Article number five. circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension. A pulmonary hypertension (P. H.)-related circular R. N. A., circMFN2, originating from the mitofusin-2 (MFN2) locus, was identified. This circMFN2 was significantly downregulated in the peripheral blood of patients with P. H. and in the pulmonary arteries of Sugen/hypoxia-induced P. H. mice. The study demonstrated that circMFN2 regulates the insulin-like growth factor two messenger R. N. A. binding protein three (IGF2BP3)-pyruvate dehydrogenase kinase four (PDK4) pathway. This regulation by circMFN2 ameliorates P. H., indicating its role as a potential therapeutic target. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preeclampsia, maternal-fetal interface, non-compliant balloon angioplasty, circular R. N. A., therapeutic target, pulmonary embolism, sirtuin 1, small extracellular vesicles, high-risk pulmonary embolism, coronary artery compliance, coronary artery calcification, trophoblast, systemic thrombolysis, heart failure with preserved ejection fraction, clinical phenotype, obesity, mitofusin-2, visceral adipose tissue, intravascular lithotripsy, catheter-directed therapy, adipocyte-cardiomyocyte crosstalk, intravascular ultrasound, macrophage, pulmonary hypertension, circMFN2.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/">Adipose Tissue Drives Heart Failure Pathogenesis 02/08/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 08, 2026. This episode summarizes 5 key cardiology studies on topics like preeclampsia and maternal-fetal interface. Key takeaway: Adipose Tissue Drives Heart Failure Pathogenesis.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 08, 2026. This episode summarizes 5 key cardiology studies on topics like preeclampsia and maternal-fetal interface. Key takeaway: Adipose Tissue Drives Heart Failure Pathogenesis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41654158">Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41653976">Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres.</a> (The Canadian journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41645491">Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41645896">SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41641542">circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/">https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41654158" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41654158</a></p>
<p><strong>Summary:</strong> Intravascular lithotripsy demonstrates efficacy in treating balloon-crossable calcified coronary lesions. It achieves this by inducing calcium fractures and improving coronary artery compliance. This study evaluates patients with calcified coronary artery lesions from the BENELUX-IVL prospective registry who received intravascular lithotripsy under intravascular ultrasound. The research provides a direct comparison of coronary artery compliance modification between intravascular lithotripsy and non-compliant balloon angioplasty.</p>
<h4>Article 2: Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41653976" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41653976</a></p>
<p><strong>Summary:</strong> High-risk pulmonary embolism presents with high early mortality and a heterogeneous patient population, ranging from cardiac arrest to obstructive shock or hypotension. Systemic thrombolysis remains the standard of care, but its use is limited by contraindications and bleeding risk. Catheter-directed therapies offer alternatives, though data on their use in high-risk pulmonary embolism is limited. This study characterized the clinical characteristics, management strategies, and outcomes across three distinct high-risk pulmonary embolism clinical phenotypes.</p>
<h4>Article 3: Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645491" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645491</a></p>
<p><strong>Summary:</strong> Heart failure with preserved ejection fraction (H. F. pEF) phenotypes were induced in male C57BL/6N mice using a high-fat diet combined with Nω-nitro-l-arginine methyl ester. The study found a causal relationship between adiposity and Heart Failure with Preserved Ejection Fraction pathogenesis. Resection of visceral adipose tissue blunted Heart Failure with Preserved Ejection Fraction phenotypes in mice, while transplantation of visceral adipose tissue exacerbated these phenotypes.</p>
<h4>Article 4: SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645896</a></p>
<p><strong>Summary:</strong> Preeclampsia, a severe hypertensive disorder of pregnancy, is associated with low sirtuin 1 (SIRT1) levels in trophoblasts. Single-cell sequencing of systemic sirtuin 1 heterozygous knockout mice revealed abnormal activation of trophoblast retinoic acid receptor responder 2 (RARRES2) and macrophage chemokine-like receptor 1 (CMKLR1) at the maternal-fetal interface. The investigation determined that low sirtuin 1 in trophoblasts increases retinoic acid receptor responder 2 expression, which subsequently affects macrophage polarization. This mechanism clarifies a key pathway in preeclampsia pathogenesis.</p>
<h4>Article 5: circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41641542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41641542</a></p>
<p><strong>Summary:</strong> A pulmonary hypertension (P. H.)-related circular R. N. A., circMFN2, originating from the mitofusin-2 (MFN2) locus, was identified. This circMFN2 was significantly downregulated in the peripheral blood of patients with P. H. and in the pulmonary arteries of Sugen/hypoxia-induced P. H. mice. The study demonstrated that circMFN2 regulates the insulin-like growth factor two messenger R. N. A. binding protein three (IGF2BP3)-pyruvate dehydrogenase kinase four (PDK4) pathway. This regulation by circMFN2 ameliorates P. H., indicating its role as a potential therapeutic target.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 08, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy. Intravascular lithotripsy demonstrates efficacy in treating balloon-crossable calcified coronary lesions. It achieves this by inducing calcium fractures and improving coronary artery compliance. This study evaluates patients with calcified coronary artery lesions from the BENELUX-IVL prospective registry who received intravascular lithotripsy under intravascular ultrasound. The research provides a direct comparison of coronary artery compliance modification between intravascular lithotripsy and non-compliant balloon angioplasty.</p>
<p>Article number two. Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres. High-risk pulmonary embolism presents with high early mortality and a heterogeneous patient population, ranging from cardiac arrest to obstructive shock or hypotension. Systemic thrombolysis remains the standard of care, but its use is limited by contraindications and bleeding risk. Catheter-directed therapies offer alternatives, though data on their use in high-risk pulmonary embolism is limited. This study characterized the clinical characteristics, management strategies, and outcomes across three distinct high-risk pulmonary embolism clinical phenotypes.</p>
<p>Article number three. Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction. Heart failure with preserved ejection fraction (H. F. pEF) phenotypes were induced in male C57BL/6N mice using a high-fat diet combined with Nω-nitro-l-arginine methyl ester. The study found a causal relationship between adiposity and Heart Failure with Preserved Ejection Fraction pathogenesis. Resection of visceral adipose tissue blunted Heart Failure with Preserved Ejection Fraction phenotypes in mice, while transplantation of visceral adipose tissue exacerbated these phenotypes.</p>
<p>Article number four. SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia. Preeclampsia, a severe hypertensive disorder of pregnancy, is associated with low sirtuin 1 (SIRT1) levels in trophoblasts. Single-cell sequencing of systemic sirtuin 1 heterozygous knockout mice revealed abnormal activation of trophoblast retinoic acid receptor responder 2 (RARRES2) and macrophage chemokine-like receptor 1 (CMKLR1) at the maternal-fetal interface. The investigation determined that low sirtuin 1 in trophoblasts increases retinoic acid receptor responder 2 expression, which subsequently affects macrophage polarization. This mechanism clarifies a key pathway in preeclampsia pathogenesis.</p>
<p>Article number five. circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension. A pulmonary hypertension (P. H.)-related circular R. N. A., circMFN2, originating from the mitofusin-2 (MFN2) locus, was identified. This circMFN2 was significantly downregulated in the peripheral blood of patients with P. H. and in the pulmonary arteries of Sugen/hypoxia-induced P. H. mice. The study demonstrated that circMFN2 regulates the insulin-like growth factor two messenger R. N. A. binding protein three (IGF2BP3)-pyruvate dehydrogenase kinase four (PDK4) pathway. This regulation by circMFN2 ameliorates P. H., indicating its role as a potential therapeutic target. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preeclampsia, maternal-fetal interface, non-compliant balloon angioplasty, circular R. N. A., therapeutic target, pulmonary embolism, sirtuin 1, small extracellular vesicles, high-risk pulmonary embolism, coronary artery compliance, coronary artery calcification, trophoblast, systemic thrombolysis, heart failure with preserved ejection fraction, clinical phenotype, obesity, mitofusin-2, visceral adipose tissue, intravascular lithotripsy, catheter-directed therapy, adipocyte-cardiomyocyte crosstalk, intravascular ultrasound, macrophage, pulmonary hypertension, circMFN2.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/">Adipose Tissue Drives Heart Failure Pathogenesis 02/08/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260208_060036.mp3" length="4534691" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 08, 2026. This episode summarizes 5 key cardiology studies on topics like preeclampsia and maternal-fetal interface. Key takeaway: Adipose Tissue Drives Heart Failure Pathogenesis.
Article Links:
Article 1: Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy. (The American journal of cardiology)
Article 2: Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres. (The Canadian journal of cardiology)
Article 3: Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction. (Cardiovascular research)
Article 4: SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia. (Hypertension (Dallas, Tex. : 1979))
Article 5: circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/adipose-tissue-drives-heart-failure-pathogenesis-02-08-26/
 Featured Articles
Article 1: Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41654158
Summary: Intravascular lithotripsy demonstrates efficacy in treating balloon-crossable calcified coronary lesions. It achieves this by inducing calcium fractures and improving coronary artery compliance. This study evaluates patients with calcified coronary artery lesions from the BENELUX-IVL prospective registry who received intravascular lithotripsy under intravascular ultrasound. The research provides a direct comparison of coronary artery compliance modification between intravascular lithotripsy and non-compliant balloon angioplasty.
Article 2: Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41653976
Summary: High-risk pulmonary embolism presents with high early mortality and a heterogeneous patient population, ranging from cardiac arrest to obstructive shock or hypotension. Systemic thrombolysis remains the standard of care, but its use is limited by contraindications and bleeding risk. Catheter-directed therapies offer alternatives, though data on their use in high-risk pulmonary embolism is limited. This study characterized the clinical characteristics, management strategies, and outcomes across three distinct high-risk pulmonary embolism clinical phenotypes.
Article 3: Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645491
Summary: Heart failure with preserved ejection fraction (H. F. pEF) phenotypes were induced in male C57BL/6N mice using a high-fat diet combined with Nω-nitro-l-arginine methyl ester. The study found a causal relationship between adiposity and Heart Failure with Preserved Ejection Fraction pathogenesis. Resection of visceral adipose tissue blunted Heart Failure with Preserved Ejection Fraction phenotypes in mice, while transplantation of visceral adipose tissue exacerbated these phenotypes.
Article 4: SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645896
Summary: Preeclampsia, a severe hypertensive disorder of pregnancy, is associated with low sirtuin 1 (SIRT1) levels in trophoblasts. Single-cell sequencing of systemic sirtuin 1 heterozygous knockout mice revealed abnormal activation of trophoblast retinoic acid receptor responder 2 (RARRES2) and macrophage chemokine-like receptor 1 (CMKLR1) at the mat]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 08, 2026. This episode summarizes 5 key cardiology studies on topics like preeclampsia and maternal-fetal interface. Key takeaway: Adipose Tissue Drives Heart Failure Pathogenesis.
Article Links:
Article 1: Coronary Artery Compliance Modification after Non-Compliant Balloon Angioplasty and Intravascular Lithotripsy. (The American journal of cardiology)
Article 2: Outcomes of High-Risk Pulmonary Embolism Stratified by Clinical Phenotype: Results from Two Specialized Pulmonary Embolism Centres. (The Canadian journal of cardiology)
Article 3: Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction. (Cardiovascular research)
Article 4: SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia. (Hypertension (Dallas, Tex. : 1979))
Article 5: circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension. (Hypertension (Dallas, Tex. ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Echo Phenotypes Boost PAH Risk Prediction 02/07/26</title>
	<link>https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/</link>
	<pubDate>Sat, 07 Feb 2026 18:56:14 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like cost-effectiveness and HeartMate 3. Key takeaway: Echo Phenotypes Boost PAH Risk Prediction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41653174">Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41649944">Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41653179">Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41637062">Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41636023">Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/">https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41653174" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41653174</a></p>
<p><strong>Summary:</strong> The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.</p>
<h4>Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41649944" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41649944</a></p>
<p><strong>Summary:</strong> This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.</p>
<h4>Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41653179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41653179</a></p>
<p><strong>Summary:</strong> V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.</p>
<h4>Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41637062" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41637062</a></p>
<p><strong>Summary:</strong> S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation and Medicare price negotiations for semaglutide therapy.</p>
<h4>Article 5: Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41636023" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41636023</a></p>
<p><strong>Summary:</strong> C. M. Study. This report from the REVEAL-H. C. M. Study examined the long-term prognostic impact of mitral regurgitation and its progression or regression across hypertrophic cardiomyopathy subtypes. Patients were retrospectively included from a Japanese multicenter registry. The study compared outcomes based on mitral regurgitation severity, specifically moderate or greater versus mild or less, within each individual hypertrophic cardiomyopathy subtype, providing data on its prognostic implications.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy. The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.</p>
<p>Article number two. Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.</p>
<p>Article number three. Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 L. V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.</p>
<p>Article number four. Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in U. S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation and Medicare price negotiations for semaglutide therapy.</p>
<p>Article number five. Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-H. C. M. Study. This report from the REVEAL-H. C. M. Study examined the long-term prognostic impact of mitral regurgitation and its progression or regression across hypertrophic cardiomyopathy subtypes. Patients were retrospectively included from a Japanese multicenter registry. The study compared outcomes based on mitral regurgitation severity, specifically moderate or greater versus mild or less, within each individual hypertrophic cardiomyopathy subtype, providing data on its prognostic implications. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cost-effectiveness, HeartMate 3, left ventricular assist device, cavotricuspid isthmus ablation, semaglutide, atrial fibrillation, cardiac registry, pulmonary arterial hypertension, cardiovascular disease prevention, prognosis, young patients, echocardiography, major adverse cardiovascular events, right ventricular remodeling, radiofrequency ablation, risk stratification, diabetes, pulsed field ablation, mitral regurgitation, advanced heart failure, H. C. M. subtypes, hypertrophic cardiomyopathy, atrial flutter, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/">Echo Phenotypes Boost PAH Risk Prediction 02/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like cost-effectiveness and HeartMate 3. Key takeaway: Echo Phenotypes Boost PAH Risk Prediction.
Article Links:
Article 1: Pulsed Field ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like cost-effectiveness and HeartMate 3. Key takeaway: Echo Phenotypes Boost PAH Risk Prediction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41653174">Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41649944">Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41653179">Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41637062">Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41636023">Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/">https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41653174" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41653174</a></p>
<p><strong>Summary:</strong> The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.</p>
<h4>Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41649944" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41649944</a></p>
<p><strong>Summary:</strong> This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.</p>
<h4>Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41653179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41653179</a></p>
<p><strong>Summary:</strong> V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.</p>
<h4>Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41637062" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41637062</a></p>
<p><strong>Summary:</strong> S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation and Medicare price negotiations for semaglutide therapy.</p>
<h4>Article 5: Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41636023" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41636023</a></p>
<p><strong>Summary:</strong> C. M. Study. This report from the REVEAL-H. C. M. Study examined the long-term prognostic impact of mitral regurgitation and its progression or regression across hypertrophic cardiomyopathy subtypes. Patients were retrospectively included from a Japanese multicenter registry. The study compared outcomes based on mitral regurgitation severity, specifically moderate or greater versus mild or less, within each individual hypertrophic cardiomyopathy subtype, providing data on its prognostic implications.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy. The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.</p>
<p>Article number two. Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.</p>
<p>Article number three. Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 L. V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.</p>
<p>Article number four. Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in U. S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation and Medicare price negotiations for semaglutide therapy.</p>
<p>Article number five. Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-H. C. M. Study. This report from the REVEAL-H. C. M. Study examined the long-term prognostic impact of mitral regurgitation and its progression or regression across hypertrophic cardiomyopathy subtypes. Patients were retrospectively included from a Japanese multicenter registry. The study compared outcomes based on mitral regurgitation severity, specifically moderate or greater versus mild or less, within each individual hypertrophic cardiomyopathy subtype, providing data on its prognostic implications. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cost-effectiveness, HeartMate 3, left ventricular assist device, cavotricuspid isthmus ablation, semaglutide, atrial fibrillation, cardiac registry, pulmonary arterial hypertension, cardiovascular disease prevention, prognosis, young patients, echocardiography, major adverse cardiovascular events, right ventricular remodeling, radiofrequency ablation, risk stratification, diabetes, pulsed field ablation, mitral regurgitation, advanced heart failure, H. C. M. subtypes, hypertrophic cardiomyopathy, atrial flutter, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/">Echo Phenotypes Boost PAH Risk Prediction 02/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260207_135517.mp3" length="3686652" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like cost-effectiveness and HeartMate 3. Key takeaway: Echo Phenotypes Boost PAH Risk Prediction.
Article Links:
Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy. (Journal of the American College of Cardiology)
Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. (European heart journal)
Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry. (JACC. Heart failure)
Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults. (JAMA cardiology)
Article 5: Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/echo-phenotypes-boost-pah-risk-prediction-02-07-26/
 Featured Articles
Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41653174
Summary: The ADVANTAGE AF trial substudy evaluated cavotricuspid isthmus ablation using either radiofrequency ablation or bipolar linear pulsed field ablation during persistent atrial fibrillation ablation. This study compared lesion characteristics, cavotricuspid isthmus ablation efficacy, and safety between these two ablation modalities. The comparison provided data on how each method performed when treating typical atrial flutter.
Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41649944
Summary: This study found that echocardiography-derived phenotypes, describing various degrees of right ventricular remodelling and dysfunction, add prognostic information to current risk stratification tools for patients with pulmonary arterial hypertension. Data were prospectively collected from patients who underwent re-evaluation between six and 12 months after diagnosis across 11 centers of the Italian Pulmonary Hypertension Network. This demonstrates that these specific phenotypes provide enhanced prognostic insights for patient management.
Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41653179
Summary: V. A. D. and Heart Transplant Using MOMENTUM 3 and U. N. O. S. Registry. This study directly compared survival and adverse event rates between the HeartMate 3 left ventricular assist device and heart transplantation in young patients aged 18 to 49 years with advanced heart failure. The analysis integrated data from the MOMENTUM 3 trial and the United Network for Organ Sharing Registry. The findings provided a crucial head-to-head comparison of these two advanced heart failure therapies specifically for this younger age group.
Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41637062
Summary: S. Adults. This population-based cohort simulation study evaluated the cost-effectiveness and budget impact of semaglutide for secondary prevention of cardiovascular disease in U. S. adults. The study demonstrated that semaglutide reduces the risk of major adverse cardiovascular events in patients with overweight or obesity and cardiovascular disease but without diabetes. These findings provide critical information regarding resource allocation]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like cost-effectiveness and HeartMate 3. Key takeaway: Echo Phenotypes Boost PAH Risk Prediction.
Article Links:
Article 1: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy. (Journal of the American College of Cardiology)
Article 2: Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. (European heart journal)
Article 3: Heart Replacement Therapy in Young Patients: A Comparative Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry. (JACC. Heart failure)
Article 4: Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults. (JAMA cardiology)
Article 5: Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study. (Circulation.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure. 02/07/26</title>
	<link>https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/</link>
	<pubDate>Sat, 07 Feb 2026 11:01:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial recovery and bicuspid aortic valve. Key takeaway: Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41645907">The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41645906">Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41645905">Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41645903">TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41645902">Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/">https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645907" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645907</a></p>
<p><strong>Summary:</strong> The aldehyde dehydrogenase 2 (ALDH2) rs671 variant, prevalent in 30 percent to 50 percent of East Asians, was found to enhance platelet activation and arterial thrombosis. This specific polymorphism impairs ALDH2 function, directly contributing to its known association as a risk factor for acute myocardial infarction. The study demonstrated a clear link between the ALDH2 rs671 mutation and increased thrombotic risk, providing crucial mechanistic insights into acute myocardial infarction susceptibility in this population.</p>
<h4>Article 2: Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645906" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645906</a></p>
<p><strong>Summary:</strong> A genome-wide association study meta-analysis of 9631 bicuspid aortic valve cases among 65677 participants identified multiple new candidate genes and a significant polygenic contribution to bicuspid aortic valve etiology. Transcriptomic analyses, based on R. N. A. sequencing, further prioritized these genes, providing a deeper understanding of the genetic architecture of this frequent congenital heart defect. This comprehensive genetic and transcriptomic assessment clarified complex molecular mechanisms underlying bicuspid aortic valve development, expanding beyond previously limited gene associations.</p>
<h4>Article 3: Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645905" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645905</a></p>
<p><strong>Summary:</strong> This international multicenter retrospective cohort study, encompassing 193 patients with histologically proven acute eosinophilic myocarditis from 53 centers, established the natural history of this condition. The study clarified specific clinical presentation patterns and identified associated systemic conditions, alongside current treatment approaches. It provided definitive data on the outcomes of acute eosinophilic myocarditis, offering a comprehensive overview of its progression and challenging previous perceptions of uniformly high mortality.</p>
<h4>Article 4: TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645903" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645903</a></p>
<p><strong>Summary:</strong> Transient receptor potential melastatin 7 (TRPM7) deficiency protects against myocardial ischemia-reperfusion injury, a process contributing up to 50 percent of final infarct size in ischemic heart disease. The study found this protection is achieved by regulating intracellular zinc ion homeostasis. This mechanism involves TRPM7&#8217;s role as a divalent cation-permeable channel kinase that senses oxidative stress and releases zinc ions from specific intracellular vesicles, directly impacting cardiomyocyte death.</p>
<h4>Article 5: Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645902</a></p>
<p><strong>Summary:</strong> The study found that insulin resistance compromises the pentose phosphate pathway and impairs left ventricular assist device-mediated myocardial recovery in obese patients with heart failure. Specifically, obese heart failure patients with insulin resistance exhibited a diminished capacity for cardiac unloading benefits from L. V. A. D. therapy. This diminished recovery stemmed from metabolic alterations, highlighting a key mechanism by which insulin resistance negatively impacts the therapeutic efficacy of left ventricular assist devices.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis. The aldehyde dehydrogenase 2 (ALDH2) rs671 variant, prevalent in 30 percent to 50 percent of East Asians, was found to enhance platelet activation and arterial thrombosis. This specific polymorphism impairs ALDH2 function, directly contributing to its known association as a risk factor for acute myocardial infarction. The study demonstrated a clear link between the ALDH2 rs671 mutation and increased thrombotic risk, providing crucial mechanistic insights into acute myocardial infarction susceptibility in this population.</p>
<p>Article number two. Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve. A genome-wide association study meta-analysis of 9631 bicuspid aortic valve cases among 65677 participants identified multiple new candidate genes and a significant polygenic contribution to bicuspid aortic valve etiology. Transcriptomic analyses, based on R. N. A. sequencing, further prioritized these genes, providing a deeper understanding of the genetic architecture of this frequent congenital heart defect. This comprehensive genetic and transcriptomic assessment clarified complex molecular mechanisms underlying bicuspid aortic valve development, expanding beyond previously limited gene associations.</p>
<p>Article number three. Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. This international multicenter retrospective cohort study, encompassing 193 patients with histologically proven acute eosinophilic myocarditis from 53 centers, established the natural history of this condition. The study clarified specific clinical presentation patterns and identified associated systemic conditions, alongside current treatment approaches. It provided definitive data on the outcomes of acute eosinophilic myocarditis, offering a comprehensive overview of its progression and challenging previous perceptions of uniformly high mortality.</p>
<p>Article number four. TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis. Transient receptor potential melastatin 7 (TRPM7) deficiency protects against myocardial ischemia-reperfusion injury, a process contributing up to 50 percent of final infarct size in ischemic heart disease. The study found this protection is achieved by regulating intracellular zinc ion homeostasis. This mechanism involves TRPM7&#8217;s role as a divalent cation-permeable channel kinase that senses oxidative stress and releases zinc ions from specific intracellular vesicles, directly impacting cardiomyocyte death.</p>
<p>Article number five. Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure. The study found that insulin resistance compromises the pentose phosphate pathway and impairs left ventricular assist device-mediated myocardial recovery in obese patients with heart failure. Specifically, obese heart failure patients with insulin resistance exhibited a diminished capacity for cardiac unloading benefits from L. V. A. D. therapy. This diminished recovery stemmed from metabolic alterations, highlighting a key mechanism by which insulin resistance negatively impacts the therapeutic efficacy of left ventricular assist devices. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial recovery, bicuspid aortic valve, heart failure, ALDH2 rs671 variant, acute myocardial infarction, eosinophilic myocarditis, clinical presentation, ischemic heart disease, transient receptor potential melastatin 7, polygenic contribution, insulin resistance, congenital heart defect, myocardial ischemia-reperfusion injury, cardiac disease, pentose phosphate pathway, L. V. A. D., zinc ion homeostasis, arterial thrombosis, acute eosinophilic myocarditis, natural history, platelet activation, left ventricular assist device, genome-wide association study, TRPM7, aldehyde dehydrogenase 2, transcriptomic analysis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/">Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure. 02/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial recovery and bicuspid aortic valve. Key takeaway: Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure..
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial recovery and bicuspid aortic valve. Key takeaway: Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41645907">The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41645906">Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41645905">Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41645903">TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41645902">Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/">https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645907" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645907</a></p>
<p><strong>Summary:</strong> The aldehyde dehydrogenase 2 (ALDH2) rs671 variant, prevalent in 30 percent to 50 percent of East Asians, was found to enhance platelet activation and arterial thrombosis. This specific polymorphism impairs ALDH2 function, directly contributing to its known association as a risk factor for acute myocardial infarction. The study demonstrated a clear link between the ALDH2 rs671 mutation and increased thrombotic risk, providing crucial mechanistic insights into acute myocardial infarction susceptibility in this population.</p>
<h4>Article 2: Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645906" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645906</a></p>
<p><strong>Summary:</strong> A genome-wide association study meta-analysis of 9631 bicuspid aortic valve cases among 65677 participants identified multiple new candidate genes and a significant polygenic contribution to bicuspid aortic valve etiology. Transcriptomic analyses, based on R. N. A. sequencing, further prioritized these genes, providing a deeper understanding of the genetic architecture of this frequent congenital heart defect. This comprehensive genetic and transcriptomic assessment clarified complex molecular mechanisms underlying bicuspid aortic valve development, expanding beyond previously limited gene associations.</p>
<h4>Article 3: Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645905" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645905</a></p>
<p><strong>Summary:</strong> This international multicenter retrospective cohort study, encompassing 193 patients with histologically proven acute eosinophilic myocarditis from 53 centers, established the natural history of this condition. The study clarified specific clinical presentation patterns and identified associated systemic conditions, alongside current treatment approaches. It provided definitive data on the outcomes of acute eosinophilic myocarditis, offering a comprehensive overview of its progression and challenging previous perceptions of uniformly high mortality.</p>
<h4>Article 4: TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645903" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645903</a></p>
<p><strong>Summary:</strong> Transient receptor potential melastatin 7 (TRPM7) deficiency protects against myocardial ischemia-reperfusion injury, a process contributing up to 50 percent of final infarct size in ischemic heart disease. The study found this protection is achieved by regulating intracellular zinc ion homeostasis. This mechanism involves TRPM7&#8217;s role as a divalent cation-permeable channel kinase that senses oxidative stress and releases zinc ions from specific intracellular vesicles, directly impacting cardiomyocyte death.</p>
<h4>Article 5: Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41645902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41645902</a></p>
<p><strong>Summary:</strong> The study found that insulin resistance compromises the pentose phosphate pathway and impairs left ventricular assist device-mediated myocardial recovery in obese patients with heart failure. Specifically, obese heart failure patients with insulin resistance exhibited a diminished capacity for cardiac unloading benefits from L. V. A. D. therapy. This diminished recovery stemmed from metabolic alterations, highlighting a key mechanism by which insulin resistance negatively impacts the therapeutic efficacy of left ventricular assist devices.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis. The aldehyde dehydrogenase 2 (ALDH2) rs671 variant, prevalent in 30 percent to 50 percent of East Asians, was found to enhance platelet activation and arterial thrombosis. This specific polymorphism impairs ALDH2 function, directly contributing to its known association as a risk factor for acute myocardial infarction. The study demonstrated a clear link between the ALDH2 rs671 mutation and increased thrombotic risk, providing crucial mechanistic insights into acute myocardial infarction susceptibility in this population.</p>
<p>Article number two. Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve. A genome-wide association study meta-analysis of 9631 bicuspid aortic valve cases among 65677 participants identified multiple new candidate genes and a significant polygenic contribution to bicuspid aortic valve etiology. Transcriptomic analyses, based on R. N. A. sequencing, further prioritized these genes, providing a deeper understanding of the genetic architecture of this frequent congenital heart defect. This comprehensive genetic and transcriptomic assessment clarified complex molecular mechanisms underlying bicuspid aortic valve development, expanding beyond previously limited gene associations.</p>
<p>Article number three. Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. This international multicenter retrospective cohort study, encompassing 193 patients with histologically proven acute eosinophilic myocarditis from 53 centers, established the natural history of this condition. The study clarified specific clinical presentation patterns and identified associated systemic conditions, alongside current treatment approaches. It provided definitive data on the outcomes of acute eosinophilic myocarditis, offering a comprehensive overview of its progression and challenging previous perceptions of uniformly high mortality.</p>
<p>Article number four. TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis. Transient receptor potential melastatin 7 (TRPM7) deficiency protects against myocardial ischemia-reperfusion injury, a process contributing up to 50 percent of final infarct size in ischemic heart disease. The study found this protection is achieved by regulating intracellular zinc ion homeostasis. This mechanism involves TRPM7&#8217;s role as a divalent cation-permeable channel kinase that senses oxidative stress and releases zinc ions from specific intracellular vesicles, directly impacting cardiomyocyte death.</p>
<p>Article number five. Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure. The study found that insulin resistance compromises the pentose phosphate pathway and impairs left ventricular assist device-mediated myocardial recovery in obese patients with heart failure. Specifically, obese heart failure patients with insulin resistance exhibited a diminished capacity for cardiac unloading benefits from L. V. A. D. therapy. This diminished recovery stemmed from metabolic alterations, highlighting a key mechanism by which insulin resistance negatively impacts the therapeutic efficacy of left ventricular assist devices. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial recovery, bicuspid aortic valve, heart failure, ALDH2 rs671 variant, acute myocardial infarction, eosinophilic myocarditis, clinical presentation, ischemic heart disease, transient receptor potential melastatin 7, polygenic contribution, insulin resistance, congenital heart defect, myocardial ischemia-reperfusion injury, cardiac disease, pentose phosphate pathway, L. V. A. D., zinc ion homeostasis, arterial thrombosis, acute eosinophilic myocarditis, natural history, platelet activation, left ventricular assist device, genome-wide association study, TRPM7, aldehyde dehydrogenase 2, transcriptomic analysis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/">Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure. 02/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260207_060022.mp3" length="4436052" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial recovery and bicuspid aortic valve. Key takeaway: Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure..
Article Links:
Article 1: The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis. (Circulation)
Article 2: Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve. (Circulation)
Article 3: Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. (Circulation)
Article 4: TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis. (Circulation)
Article 5: Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/insulin-resistance-impairs-lvad-recovery-in-obese-heart-failure-02-07-26/
 Featured Articles
Article 1: The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645907
Summary: The aldehyde dehydrogenase 2 (ALDH2) rs671 variant, prevalent in 30 percent to 50 percent of East Asians, was found to enhance platelet activation and arterial thrombosis. This specific polymorphism impairs ALDH2 function, directly contributing to its known association as a risk factor for acute myocardial infarction. The study demonstrated a clear link between the ALDH2 rs671 mutation and increased thrombotic risk, providing crucial mechanistic insights into acute myocardial infarction susceptibility in this population.
Article 2: Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645906
Summary: A genome-wide association study meta-analysis of 9631 bicuspid aortic valve cases among 65677 participants identified multiple new candidate genes and a significant polygenic contribution to bicuspid aortic valve etiology. Transcriptomic analyses, based on R. N. A. sequencing, further prioritized these genes, providing a deeper understanding of the genetic architecture of this frequent congenital heart defect. This comprehensive genetic and transcriptomic assessment clarified complex molecular mechanisms underlying bicuspid aortic valve development, expanding beyond previously limited gene associations.
Article 3: Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645905
Summary: This international multicenter retrospective cohort study, encompassing 193 patients with histologically proven acute eosinophilic myocarditis from 53 centers, established the natural history of this condition. The study clarified specific clinical presentation patterns and identified associated systemic conditions, alongside current treatment approaches. It provided definitive data on the outcomes of acute eosinophilic myocarditis, offering a comprehensive overview of its progression and challenging previous perceptions of uniformly high mortality.
Article 4: TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41645903
Summary: Transient receptor potential melastatin 7 (TRPM7) deficiency protects against myocardial ischemia-reperfusion injury, a process contributing up to 50 percent of final infarct size in ischemic heart disease. The study found this protection is achieved by regulating intracellular zinc ion homeostasis. This mechanism involves T]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 07, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial recovery and bicuspid aortic valve. Key takeaway: Insulin Resistance Impairs LVAD Recovery in Obese Heart Failure..
Article Links:
Article 1: The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis. (Circulation)
Article 2: Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve. (Circulation)
Article 3: Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. (Circulation)
Article 4: TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis. (Circulation)
Article 5: Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device-Mediated Myocardial Recovery in Obese Patients with Heart Failure. (Circulati]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Donor T. N. F. alpha Linked to Worse Kidney Grafts 02/06/26</title>
	<link>https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/</link>
	<pubDate>Fri, 06 Feb 2026 11:01:37 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplantation and Cytomegalovirus. Key takeaway: Donor T. N. F. alpha Linked to Worse Kidney Grafts.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41643794">Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41643793">A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41644055">Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41644054">Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41637102">Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/">https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41643794" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41643794</a></p>
<p><strong>Summary:</strong> Among 4650 adult heart transplant recipients during the first 24 months of policy implementation, 987 patients, or 21.2 percent, met Safety-Net Kidney Transplantation eligibility within one year of heart transplantation. These eligible patients demonstrated significantly lower one-year survival compared with heart transplant recipients who did not meet eligibility criteria. The data highlights a substantial proportion of heart transplant recipients requiring subsequent kidney transplantation and indicates a clear association between this eligibility and adverse survival outcomes.</p>
<h4>Article 2: A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41643793" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41643793</a></p>
<p><strong>Summary:</strong> Quilty lesions are characterized by nodular T-lymphocyte infiltrates found in the endocardium of transplanted hearts. The clinical significance of these lesions remains controversial, with their precise relationship to rejection not fully understood in clinical practice. This study utilized tissue-based transcriptomic diagnostics, specifically Molecular Microscope Analysis, to investigate the link between Quilty lesions and cardiac rejection. Understanding the impact of Quilty lesions on clinical outcomes for heart transplant recipients represents a critical area of ongoing research.</p>
<h4>Article 3: Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41644055" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41644055</a></p>
<p><strong>Summary:</strong> N. F. alpha in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival. This study found that circulating Tumor Necrosis Factor alpha in deceased donors promotes kidney injury in transplant recipients. High levels of donor Tumor Necrosis Factor alpha were associated with inferior short-term graft function and reduced long-term graft survival. The data indicated a direct link between systemic inflammation in deceased donors, as measured by Tumor Necrosis Factor alpha and its receptors Tumor Necrosis Factor Receptor 1 and Tumor Necrosis Factor Receptor 2, and detrimental post-transplant kidney outcomes. These findings underscore the critical impact of donor inflammatory status on kidney transplant success and inform strategies for donor management.</p>
<h4>Article 4: Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41644054" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41644054</a></p>
<p><strong>Summary:</strong> Cytomegalovirus disease in solid organ transplant recipients is preventable through antiviral prophylaxis or preemptive therapy. However, the optimal frequency for Cytomegalovirus monitoring to detect infection and prevent disease remains unclear in clinical practice. An ongoing debate exists regarding the necessity of Cytomegalovirus surveillance after antiviral prophylaxis has concluded. This international multicenter cohort study examined the associations between different monitoring frequencies and the incidence of Cytomegalovirus infection and disease in solid organ transplant recipients.</p>
<h4>Article 5: Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41637102" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41637102</a></p>
<p><strong>Summary:</strong> I. M. I. 71 Trial. Older individuals with atrial fibrillation face a strong risk of bleeding when using currently available anticoagulants. Factor X. I. inhibition represents a promising anticoagulant strategy with the potential for an improved safety profile in this vulnerable population. The phase two b A. Z. A. L. E. A. &#8211; T. I. M. I. 71 trial evaluated the safety of abelacimab, a novel Factor X. I. inhibitor, against rivaroxaban. Patients with atrial fibrillation were randomized to receive either monthly subcutaneous abelacimab at 90 mg or 150 mg, or daily oral rivaroxaban at 20 mg, with dose adjustments for renal impairment.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy. Among 4650 adult heart transplant recipients during the first 24 months of policy implementation, 987 patients, or 21.2 percent, met Safety-Net Kidney Transplantation eligibility within one year of heart transplantation. These eligible patients demonstrated significantly lower one-year survival compared with heart transplant recipients who did not meet eligibility criteria. The data highlights a substantial proportion of heart transplant recipients requiring subsequent kidney transplantation and indicates a clear association between this eligibility and adverse survival outcomes.</p>
<p>Article number two. A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation. Quilty lesions are characterized by nodular T-lymphocyte infiltrates found in the endocardium of transplanted hearts. The clinical significance of these lesions remains controversial, with their precise relationship to rejection not fully understood in clinical practice. This study utilized tissue-based transcriptomic diagnostics, specifically Molecular Microscope Analysis, to investigate the link between Quilty lesions and cardiac rejection. Understanding the impact of Quilty lesions on clinical outcomes for heart transplant recipients represents a critical area of ongoing research.</p>
<p>Article number three. Circulating T. N. F. alpha in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival. This study found that circulating Tumor Necrosis Factor alpha in deceased donors promotes kidney injury in transplant recipients. High levels of donor Tumor Necrosis Factor alpha were associated with inferior short-term graft function and reduced long-term graft survival. The data indicated a direct link between systemic inflammation in deceased donors, as measured by Tumor Necrosis Factor alpha and its receptors Tumor Necrosis Factor Receptor 1 and Tumor Necrosis Factor Receptor 2, and detrimental post-transplant kidney outcomes. These findings underscore the critical impact of donor inflammatory status on kidney transplant success and inform strategies for donor management.</p>
<p>Article number four. Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study. Cytomegalovirus disease in solid organ transplant recipients is preventable through antiviral prophylaxis or preemptive therapy. However, the optimal frequency for Cytomegalovirus monitoring to detect infection and prevent disease remains unclear in clinical practice. An ongoing debate exists regarding the necessity of Cytomegalovirus surveillance after antiviral prophylaxis has concluded. This international multicenter cohort study examined the associations between different monitoring frequencies and the incidence of Cytomegalovirus infection and disease in solid organ transplant recipients.</p>
<p>Article number five. Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-T. I. M. I. 71 Trial. Older individuals with atrial fibrillation face a strong risk of bleeding when using currently available anticoagulants. Factor X. I. inhibition represents a promising anticoagulant strategy with the potential for an improved safety profile in this vulnerable population. The phase two b A. Z. A. L. E. A. &#8211; T. I. M. I. 71 trial evaluated the safety of abelacimab, a novel Factor X. I. inhibitor, against rivaroxaban. Patients with atrial fibrillation were randomized to receive either monthly subcutaneous abelacimab at 90 mg or 150 mg, or daily oral rivaroxaban at 20 mg, with dose adjustments for renal impairment. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart transplantation, Cytomegalovirus, post-transplant survival, preemptive therapy, cardiac rejection, safety-net transplantation, Quilty lesions, solid organ transplant, T-lymphocytes, rivaroxaban, kidney transplantation, renal dysfunction, anticoagulation, antiviral prophylaxis, Tumor Necrosis Factor alpha, kidney injury, endomyocardial biopsy, deceased donors, atrial fibrillation, graft function, Factor X. I. inhibition, abelacimab, graft survival, viral monitoring.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/">Donor T. N. F. alpha Linked to Worse Kidney Grafts 02/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplantation and Cytomegalovirus. Key takeaway: Donor T. N. F. alpha Linked to Worse Kidney Grafts.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplantation and Cytomegalovirus. Key takeaway: Donor T. N. F. alpha Linked to Worse Kidney Grafts.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41643794">Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41643793">A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41644055">Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41644054">Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41637102">Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/">https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41643794" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41643794</a></p>
<p><strong>Summary:</strong> Among 4650 adult heart transplant recipients during the first 24 months of policy implementation, 987 patients, or 21.2 percent, met Safety-Net Kidney Transplantation eligibility within one year of heart transplantation. These eligible patients demonstrated significantly lower one-year survival compared with heart transplant recipients who did not meet eligibility criteria. The data highlights a substantial proportion of heart transplant recipients requiring subsequent kidney transplantation and indicates a clear association between this eligibility and adverse survival outcomes.</p>
<h4>Article 2: A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41643793" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41643793</a></p>
<p><strong>Summary:</strong> Quilty lesions are characterized by nodular T-lymphocyte infiltrates found in the endocardium of transplanted hearts. The clinical significance of these lesions remains controversial, with their precise relationship to rejection not fully understood in clinical practice. This study utilized tissue-based transcriptomic diagnostics, specifically Molecular Microscope Analysis, to investigate the link between Quilty lesions and cardiac rejection. Understanding the impact of Quilty lesions on clinical outcomes for heart transplant recipients represents a critical area of ongoing research.</p>
<h4>Article 3: Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41644055" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41644055</a></p>
<p><strong>Summary:</strong> N. F. alpha in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival. This study found that circulating Tumor Necrosis Factor alpha in deceased donors promotes kidney injury in transplant recipients. High levels of donor Tumor Necrosis Factor alpha were associated with inferior short-term graft function and reduced long-term graft survival. The data indicated a direct link between systemic inflammation in deceased donors, as measured by Tumor Necrosis Factor alpha and its receptors Tumor Necrosis Factor Receptor 1 and Tumor Necrosis Factor Receptor 2, and detrimental post-transplant kidney outcomes. These findings underscore the critical impact of donor inflammatory status on kidney transplant success and inform strategies for donor management.</p>
<h4>Article 4: Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41644054" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41644054</a></p>
<p><strong>Summary:</strong> Cytomegalovirus disease in solid organ transplant recipients is preventable through antiviral prophylaxis or preemptive therapy. However, the optimal frequency for Cytomegalovirus monitoring to detect infection and prevent disease remains unclear in clinical practice. An ongoing debate exists regarding the necessity of Cytomegalovirus surveillance after antiviral prophylaxis has concluded. This international multicenter cohort study examined the associations between different monitoring frequencies and the incidence of Cytomegalovirus infection and disease in solid organ transplant recipients.</p>
<h4>Article 5: Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41637102" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41637102</a></p>
<p><strong>Summary:</strong> I. M. I. 71 Trial. Older individuals with atrial fibrillation face a strong risk of bleeding when using currently available anticoagulants. Factor X. I. inhibition represents a promising anticoagulant strategy with the potential for an improved safety profile in this vulnerable population. The phase two b A. Z. A. L. E. A. &#8211; T. I. M. I. 71 trial evaluated the safety of abelacimab, a novel Factor X. I. inhibitor, against rivaroxaban. Patients with atrial fibrillation were randomized to receive either monthly subcutaneous abelacimab at 90 mg or 150 mg, or daily oral rivaroxaban at 20 mg, with dose adjustments for renal impairment.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy. Among 4650 adult heart transplant recipients during the first 24 months of policy implementation, 987 patients, or 21.2 percent, met Safety-Net Kidney Transplantation eligibility within one year of heart transplantation. These eligible patients demonstrated significantly lower one-year survival compared with heart transplant recipients who did not meet eligibility criteria. The data highlights a substantial proportion of heart transplant recipients requiring subsequent kidney transplantation and indicates a clear association between this eligibility and adverse survival outcomes.</p>
<p>Article number two. A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation. Quilty lesions are characterized by nodular T-lymphocyte infiltrates found in the endocardium of transplanted hearts. The clinical significance of these lesions remains controversial, with their precise relationship to rejection not fully understood in clinical practice. This study utilized tissue-based transcriptomic diagnostics, specifically Molecular Microscope Analysis, to investigate the link between Quilty lesions and cardiac rejection. Understanding the impact of Quilty lesions on clinical outcomes for heart transplant recipients represents a critical area of ongoing research.</p>
<p>Article number three. Circulating T. N. F. alpha in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival. This study found that circulating Tumor Necrosis Factor alpha in deceased donors promotes kidney injury in transplant recipients. High levels of donor Tumor Necrosis Factor alpha were associated with inferior short-term graft function and reduced long-term graft survival. The data indicated a direct link between systemic inflammation in deceased donors, as measured by Tumor Necrosis Factor alpha and its receptors Tumor Necrosis Factor Receptor 1 and Tumor Necrosis Factor Receptor 2, and detrimental post-transplant kidney outcomes. These findings underscore the critical impact of donor inflammatory status on kidney transplant success and inform strategies for donor management.</p>
<p>Article number four. Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study. Cytomegalovirus disease in solid organ transplant recipients is preventable through antiviral prophylaxis or preemptive therapy. However, the optimal frequency for Cytomegalovirus monitoring to detect infection and prevent disease remains unclear in clinical practice. An ongoing debate exists regarding the necessity of Cytomegalovirus surveillance after antiviral prophylaxis has concluded. This international multicenter cohort study examined the associations between different monitoring frequencies and the incidence of Cytomegalovirus infection and disease in solid organ transplant recipients.</p>
<p>Article number five. Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-T. I. M. I. 71 Trial. Older individuals with atrial fibrillation face a strong risk of bleeding when using currently available anticoagulants. Factor X. I. inhibition represents a promising anticoagulant strategy with the potential for an improved safety profile in this vulnerable population. The phase two b A. Z. A. L. E. A. &#8211; T. I. M. I. 71 trial evaluated the safety of abelacimab, a novel Factor X. I. inhibitor, against rivaroxaban. Patients with atrial fibrillation were randomized to receive either monthly subcutaneous abelacimab at 90 mg or 150 mg, or daily oral rivaroxaban at 20 mg, with dose adjustments for renal impairment. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart transplantation, Cytomegalovirus, post-transplant survival, preemptive therapy, cardiac rejection, safety-net transplantation, Quilty lesions, solid organ transplant, T-lymphocytes, rivaroxaban, kidney transplantation, renal dysfunction, anticoagulation, antiviral prophylaxis, Tumor Necrosis Factor alpha, kidney injury, endomyocardial biopsy, deceased donors, atrial fibrillation, graft function, Factor X. I. inhibition, abelacimab, graft survival, viral monitoring.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/">Donor T. N. F. alpha Linked to Worse Kidney Grafts 02/06/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260206_060027.mp3" length="4724026" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplantation and Cytomegalovirus. Key takeaway: Donor T. N. F. alpha Linked to Worse Kidney Grafts.
Article Links:
Article 1: Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 4: Frequency of Viral Monitoring to Detect Cytomegalovirus Infection and Prevent Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/donor-t-n-f-alpha-linked-to-worse-kidney-grafts-02-06-26/
 Featured Articles
Article 1: Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41643794
Summary: Among 4650 adult heart transplant recipients during the first 24 months of policy implementation, 987 patients, or 21.2 percent, met Safety-Net Kidney Transplantation eligibility within one year of heart transplantation. These eligible patients demonstrated significantly lower one-year survival compared with heart transplant recipients who did not meet eligibility criteria. The data highlights a substantial proportion of heart transplant recipients requiring subsequent kidney transplantation and indicates a clear association between this eligibility and adverse survival outcomes.
Article 2: A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41643793
Summary: Quilty lesions are characterized by nodular T-lymphocyte infiltrates found in the endocardium of transplanted hearts. The clinical significance of these lesions remains controversial, with their precise relationship to rejection not fully understood in clinical practice. This study utilized tissue-based transcriptomic diagnostics, specifically Molecular Microscope Analysis, to investigate the link between Quilty lesions and cardiac rejection. Understanding the impact of Quilty lesions on clinical outcomes for heart transplant recipients represents a critical area of ongoing research.
Article 3: Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41644055
Summary: N. F. alpha in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 06, 2026. This episode summarizes 5 key cardiology studies on topics like heart transplantation and Cytomegalovirus. Key takeaway: Donor T. N. F. alpha Linked to Worse Kidney Grafts.
Article Links:
Article 1: Safety-Net Kidney Transplantation After Heart Transplantation: Early Real-World Outcomes Under the New Policy. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: A Molecular Reappraisal of Quilty Lesions: Insights from Tissue and Circulating Biomarkers in Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Circulating TNFα in deceased donors promotes kidney injury and associates with inferior short- and long-term graft function and survival. (American journal of transplantation : official journal of the American Society of Transplanta]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Early TAVR Superior for Asymptomatic Aortic Stenosis 02/05/26</title>
	<link>https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/</link>
	<pubDate>Thu, 05 Feb 2026 17:46:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 05, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction and heart failure. Key takeaway: Early TAVR Superior for Asymptomatic Aortic Stenosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41636665">PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41384893">1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41128701">Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41641552">Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41635281">Subvalvular aortic stenosis in adults: clinical course and long-term outcomes.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/">https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41636665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41636665</a></p>
<p><strong>Summary:</strong> Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association&#8217;s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.</p>
<h4>Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41384893" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41384893</a></p>
<p><strong>Summary:</strong> The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.</p>
<h4>Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128701" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128701</a></p>
<p><strong>Summary:</strong> The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.</p>
<h4>Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41641552" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41641552</a></p>
<p><strong>Summary:</strong> Heart failure constitutes a significant global health burden, with its true prevalence often uncertain due to heterogeneous study designs and evolving diagnostic criteria. The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) investigated the prevalence and phenotypic distribution of heart failure in community-dwelling adults aged 50 years and older in mainland Portugal. This cross-sectional, population-based study provided a detailed epidemiological snapshot of heart failure within this specific European demographic. The findings from PORTHOS are essential for understanding regional disease burden and informing public health strategies.</p>
<h4>Article 5: Subvalvular aortic stenosis in adults: clinical course and long-term outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41635281" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41635281</a></p>
<p><strong>Summary:</strong> This study delineated the clinical course and long-term outcomes for adults diagnosed with subvalvular aortic stenosis, utilizing prospectively registered data from the Dutch Congenital Cor Vitia registry. Researchers comprehensively assessed all-cause mortality, subvalvular aortic stenosis re-operation rates, and significant cardiovascular events, including arrhythmias and heart failure. The investigation also tracked longitudinal changes in echocardiographic peak velocity and interventricular septal thickness. Patients received an extensive follow-up period averaging 17.1 years, providing robust data on disease progression and long-term management challenges.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association&#8217;s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.</p>
<p>Article number two. 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.</p>
<p>Article number three. Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.</p>
<p>Article number four. Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. Heart failure constitutes a significant global health burden, with its true prevalence often uncertain due to heterogeneous study designs and evolving diagnostic criteria. The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) investigated the prevalence and phenotypic distribution of heart failure in community-dwelling adults aged 50 years and older in mainland Portugal. This cross-sectional, population-based study provided a detailed epidemiological snapshot of heart failure within this specific European demographic. The findings from PORTHOS are essential for understanding regional disease burden and informing public health strategies.</p>
<p>Article number five. Subvalvular aortic stenosis in adults: clinical course and long-term outcomes. This study delineated the clinical course and long-term outcomes for adults diagnosed with subvalvular aortic stenosis, utilizing prospectively registered data from the Dutch Congenital Cor Vitia registry. Researchers comprehensively assessed all-cause mortality, subvalvular aortic stenosis re-operation rates, and significant cardiovascular events, including arrhythmias and heart failure. The investigation also tracked longitudinal changes in echocardiographic peak velocity and interventricular septal thickness. Patients received an extensive follow-up period averaging 17.1 years, providing robust data on disease progression and long-term management challenges. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk prediction, heart failure, health equity, EARLY TAVR trial, aortic regurgitation, left ventricular health, echocardiography, aortic stenosis, PORTHOS study, young adults, prevalence, cardiovascular disease, congenital heart disease, noninferiority, epidemiology, Myval, TAVR, long-term outcomes, phenotypes, PREVENT equations, clinical surveillance, subvalvular aortic stenosis, transcatheter heart valve, asymptomatic aortic stenosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/">Early TAVR Superior for Asymptomatic Aortic Stenosis 02/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 05, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction and heart failure. Key takeaway: Early TAVR Superior for Asymptomatic Aortic Stenosis.
Article Links:
Article 1: PRE]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 05, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction and heart failure. Key takeaway: Early TAVR Superior for Asymptomatic Aortic Stenosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41636665">PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41384893">1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41128701">Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41641552">Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41635281">Subvalvular aortic stenosis in adults: clinical course and long-term outcomes.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/">https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41636665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41636665</a></p>
<p><strong>Summary:</strong> Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association&#8217;s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.</p>
<h4>Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41384893" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41384893</a></p>
<p><strong>Summary:</strong> The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.</p>
<h4>Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128701" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128701</a></p>
<p><strong>Summary:</strong> The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.</p>
<h4>Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41641552" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41641552</a></p>
<p><strong>Summary:</strong> Heart failure constitutes a significant global health burden, with its true prevalence often uncertain due to heterogeneous study designs and evolving diagnostic criteria. The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) investigated the prevalence and phenotypic distribution of heart failure in community-dwelling adults aged 50 years and older in mainland Portugal. This cross-sectional, population-based study provided a detailed epidemiological snapshot of heart failure within this specific European demographic. The findings from PORTHOS are essential for understanding regional disease burden and informing public health strategies.</p>
<h4>Article 5: Subvalvular aortic stenosis in adults: clinical course and long-term outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41635281" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41635281</a></p>
<p><strong>Summary:</strong> This study delineated the clinical course and long-term outcomes for adults diagnosed with subvalvular aortic stenosis, utilizing prospectively registered data from the Dutch Congenital Cor Vitia registry. Researchers comprehensively assessed all-cause mortality, subvalvular aortic stenosis re-operation rates, and significant cardiovascular events, including arrhythmias and heart failure. The investigation also tracked longitudinal changes in echocardiographic peak velocity and interventricular septal thickness. Patients received an extensive follow-up period averaging 17.1 years, providing robust data on disease progression and long-term management challenges.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association&#8217;s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.</p>
<p>Article number two. 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.</p>
<p>Article number three. Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.</p>
<p>Article number four. Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. Heart failure constitutes a significant global health burden, with its true prevalence often uncertain due to heterogeneous study designs and evolving diagnostic criteria. The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) investigated the prevalence and phenotypic distribution of heart failure in community-dwelling adults aged 50 years and older in mainland Portugal. This cross-sectional, population-based study provided a detailed epidemiological snapshot of heart failure within this specific European demographic. The findings from PORTHOS are essential for understanding regional disease burden and informing public health strategies.</p>
<p>Article number five. Subvalvular aortic stenosis in adults: clinical course and long-term outcomes. This study delineated the clinical course and long-term outcomes for adults diagnosed with subvalvular aortic stenosis, utilizing prospectively registered data from the Dutch Congenital Cor Vitia registry. Researchers comprehensively assessed all-cause mortality, subvalvular aortic stenosis re-operation rates, and significant cardiovascular events, including arrhythmias and heart failure. The investigation also tracked longitudinal changes in echocardiographic peak velocity and interventricular septal thickness. Patients received an extensive follow-up period averaging 17.1 years, providing robust data on disease progression and long-term management challenges. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk prediction, heart failure, health equity, EARLY TAVR trial, aortic regurgitation, left ventricular health, echocardiography, aortic stenosis, PORTHOS study, young adults, prevalence, cardiovascular disease, congenital heart disease, noninferiority, epidemiology, Myval, TAVR, long-term outcomes, phenotypes, PREVENT equations, clinical surveillance, subvalvular aortic stenosis, transcatheter heart valve, asymptomatic aortic stenosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/">Early TAVR Superior for Asymptomatic Aortic Stenosis 02/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260205_124528.mp3" length="4443576" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 05, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction and heart failure. Key takeaway: Early TAVR Superior for Asymptomatic Aortic Stenosis.
Article Links:
Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. (Journal of the American College of Cardiology)
Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. (Journal of the American College of Cardiology)
Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. (Journal of the American College of Cardiology)
Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. (European heart journal)
Article 5: Subvalvular aortic stenosis in adults: clinical course and long-term outcomes. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/
 Featured Articles
Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41636665
Summary: Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association&#8217;s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.
Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41384893
Summary: The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.
Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128701
Summary: The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.
Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41641552
Summary: Heart failure constitutes a signifi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 05, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction and heart failure. Key takeaway: Early TAVR Superior for Asymptomatic Aortic Stenosis.
Article Links:
Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. (Journal of the American College of Cardiology)
Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. (Journal of the American College of Cardiology)
Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. (Journal of the American College of Cardiology)
Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. (European heart journal)
Article 5: Subvalvular aortic stenosis in adults: clinical course and long-term ou]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>C. T. Predicts Stroke Clot Removal Success 02/04/26</title>
	<link>https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/</link>
	<pubDate>Wed, 04 Feb 2026 11:01:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 04, 2026. This episode summarizes 5 key cardiology studies on topics like high-intensity interval training and acute exercise. Key takeaway: C. T. Predicts Stroke Clot Removal Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41631770">General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41631768">Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41631765">Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41631764">Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41631762">Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/">https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631770" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631770</a></p>
<p><strong>Summary:</strong> The abstract reports that several observational studies supported conscious sedation for endovascular thrombectomy in acute ischemic stroke and associated general anesthesia with poor functional outcomes. Conversely, recent randomized controlled trials have shown no difference in functional outcomes between general anesthesia and conscious sedation. This highlights a critical ongoing debate regarding the optimal anesthesia choice for mechanical thrombectomy in patients with acute ischemic stroke. The abstract&#8217;s context emphasizes the importance of understanding the definitive impact of anesthesia type on patient functional recovery.</p>
<h4>Article 2: Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631768</a></p>
<p><strong>Summary:</strong> This study integrated paired radiomics and transcriptomics from 32 ischemic stroke clots retrieved by mechanical thrombectomy. The analysis identified neutrophil extracellular trap enrichment within these clots as a predictor of first-pass mechanical thrombectomy success. Results demonstrated the potential for noninvasively detecting neutrophil extracellular trap enrichment using prethrombectomy computed tomography imaging. This represents a significant advancement for predicting successful clot removal and refining treatment approaches in acute ischemic stroke.</p>
<h4>Article 3: Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631765" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631765</a></p>
<p><strong>Summary:</strong> The abstract establishes that stroke is a sexually dimorphic disease, demonstrating differences in risk factors, incidence, outcomes, and treatment responses between men and women. It highlights that previous preclinical studies supporting these sex differences often originated from single-site studies with small sample sizes. Therefore, validating these variations across diverse research settings, as intended by the S. P. A. N. (Stroke Preclinical Assessment Network) trial, holds significant clinical importance. Understanding these inherent sex-based differences is crucial for developing more targeted and effective stroke management strategies.</p>
<h4>Article 4: Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631764" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631764</a></p>
<p><strong>Summary:</strong> Cancer survivors undergoing heart transplantation demonstrated an increased incidence of de novo malignancies when compared with malignancy recurrences. For select cancer survivors who develop advanced heart failure, heart transplantation remains the gold standard treatment. This finding underscores a significant long-term concern in this specific patient population. Understanding the distinct patterns of subsequent primary cancers is crucial for developing optimized post-transplant surveillance and management strategies.</p>
<h4>Article 5: Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631762" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631762</a></p>
<p><strong>Summary:</strong> This randomized controlled trial in 168 patients with stable coronary artery disease demonstrated that acute vigorous exercise and a 12-week high-intensity interval training program affect systemic inflammatory biomarkers. The research confirmed the role of persistent low-grade inflammation in coronary artery disease progression. These findings provide critical evidence for developing exercise-based interventions aimed at modulating systemic inflammation in patients with stable coronary artery disease. The study contributes to understanding how specific exercise regimens influence the inflammatory profile in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial. The abstract reports that several observational studies supported conscious sedation for endovascular thrombectomy in acute ischemic stroke and associated general anesthesia with poor functional outcomes. Conversely, recent randomized controlled trials have shown no difference in functional outcomes between general anesthesia and conscious sedation. This highlights a critical ongoing debate regarding the optimal anesthesia choice for mechanical thrombectomy in patients with acute ischemic stroke. The abstract&#8217;s context emphasizes the importance of understanding the definitive impact of anesthesia type on patient functional recovery.</p>
<p>Article number two. Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi. This study integrated paired radiomics and transcriptomics from 32 ischemic stroke clots retrieved by mechanical thrombectomy. The analysis identified neutrophil extracellular trap enrichment within these clots as a predictor of first-pass mechanical thrombectomy success. Results demonstrated the potential for noninvasively detecting neutrophil extracellular trap enrichment using prethrombectomy computed tomography imaging. This represents a significant advancement for predicting successful clot removal and refining treatment approaches in acute ischemic stroke.</p>
<p>Article number three. Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial. The abstract establishes that stroke is a sexually dimorphic disease, demonstrating differences in risk factors, incidence, outcomes, and treatment responses between men and women. It highlights that previous preclinical studies supporting these sex differences often originated from single-site studies with small sample sizes. Therefore, validating these variations across diverse research settings, as intended by the S. P. A. N. (Stroke Preclinical Assessment Network) trial, holds significant clinical importance. Understanding these inherent sex-based differences is crucial for developing more targeted and effective stroke management strategies.</p>
<p>Article number four. Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation. Cancer survivors undergoing heart transplantation demonstrated an increased incidence of de novo malignancies when compared with malignancy recurrences. For select cancer survivors who develop advanced heart failure, heart transplantation remains the gold standard treatment. This finding underscores a significant long-term concern in this specific patient population. Understanding the distinct patterns of subsequent primary cancers is crucial for developing optimized post-transplant surveillance and management strategies.</p>
<p>Article number five. Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial. This randomized controlled trial in 168 patients with stable coronary artery disease demonstrated that acute vigorous exercise and a 12-week high-intensity interval training program affect systemic inflammatory biomarkers. The research confirmed the role of persistent low-grade inflammation in coronary artery disease progression. These findings provide critical evidence for developing exercise-based interventions aimed at modulating systemic inflammation in patients with stable coronary artery disease. The study contributes to understanding how specific exercise regimens influence the inflammatory profile in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-intensity interval training, acute exercise, radiomics, conscious sedation, exercise intervention, acute ischemic stroke, advanced heart failure, neutrophil extracellular traps, risk factors, treatment response, cancer survivors, computed tomography, general anesthesia, heart transplantation, sex differences, inflammatory biomarkers, sexually dimorphic, stroke, functional outcomes, mechanical thrombectomy, malignancy recurrence, coronary artery disease, ischemic stroke, de novo malignancies.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/">C. T. Predicts Stroke Clot Removal Success 02/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 04, 2026. This episode summarizes 5 key cardiology studies on topics like high-intensity interval training and acute exercise. Key takeaway: C. T. Predicts Stroke Clot Removal Success.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 04, 2026. This episode summarizes 5 key cardiology studies on topics like high-intensity interval training and acute exercise. Key takeaway: C. T. Predicts Stroke Clot Removal Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41631770">General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41631768">Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41631765">Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41631764">Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41631762">Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/">https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631770" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631770</a></p>
<p><strong>Summary:</strong> The abstract reports that several observational studies supported conscious sedation for endovascular thrombectomy in acute ischemic stroke and associated general anesthesia with poor functional outcomes. Conversely, recent randomized controlled trials have shown no difference in functional outcomes between general anesthesia and conscious sedation. This highlights a critical ongoing debate regarding the optimal anesthesia choice for mechanical thrombectomy in patients with acute ischemic stroke. The abstract&#8217;s context emphasizes the importance of understanding the definitive impact of anesthesia type on patient functional recovery.</p>
<h4>Article 2: Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631768</a></p>
<p><strong>Summary:</strong> This study integrated paired radiomics and transcriptomics from 32 ischemic stroke clots retrieved by mechanical thrombectomy. The analysis identified neutrophil extracellular trap enrichment within these clots as a predictor of first-pass mechanical thrombectomy success. Results demonstrated the potential for noninvasively detecting neutrophil extracellular trap enrichment using prethrombectomy computed tomography imaging. This represents a significant advancement for predicting successful clot removal and refining treatment approaches in acute ischemic stroke.</p>
<h4>Article 3: Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631765" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631765</a></p>
<p><strong>Summary:</strong> The abstract establishes that stroke is a sexually dimorphic disease, demonstrating differences in risk factors, incidence, outcomes, and treatment responses between men and women. It highlights that previous preclinical studies supporting these sex differences often originated from single-site studies with small sample sizes. Therefore, validating these variations across diverse research settings, as intended by the S. P. A. N. (Stroke Preclinical Assessment Network) trial, holds significant clinical importance. Understanding these inherent sex-based differences is crucial for developing more targeted and effective stroke management strategies.</p>
<h4>Article 4: Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631764" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631764</a></p>
<p><strong>Summary:</strong> Cancer survivors undergoing heart transplantation demonstrated an increased incidence of de novo malignancies when compared with malignancy recurrences. For select cancer survivors who develop advanced heart failure, heart transplantation remains the gold standard treatment. This finding underscores a significant long-term concern in this specific patient population. Understanding the distinct patterns of subsequent primary cancers is crucial for developing optimized post-transplant surveillance and management strategies.</p>
<h4>Article 5: Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41631762" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41631762</a></p>
<p><strong>Summary:</strong> This randomized controlled trial in 168 patients with stable coronary artery disease demonstrated that acute vigorous exercise and a 12-week high-intensity interval training program affect systemic inflammatory biomarkers. The research confirmed the role of persistent low-grade inflammation in coronary artery disease progression. These findings provide critical evidence for developing exercise-based interventions aimed at modulating systemic inflammation in patients with stable coronary artery disease. The study contributes to understanding how specific exercise regimens influence the inflammatory profile in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial. The abstract reports that several observational studies supported conscious sedation for endovascular thrombectomy in acute ischemic stroke and associated general anesthesia with poor functional outcomes. Conversely, recent randomized controlled trials have shown no difference in functional outcomes between general anesthesia and conscious sedation. This highlights a critical ongoing debate regarding the optimal anesthesia choice for mechanical thrombectomy in patients with acute ischemic stroke. The abstract&#8217;s context emphasizes the importance of understanding the definitive impact of anesthesia type on patient functional recovery.</p>
<p>Article number two. Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi. This study integrated paired radiomics and transcriptomics from 32 ischemic stroke clots retrieved by mechanical thrombectomy. The analysis identified neutrophil extracellular trap enrichment within these clots as a predictor of first-pass mechanical thrombectomy success. Results demonstrated the potential for noninvasively detecting neutrophil extracellular trap enrichment using prethrombectomy computed tomography imaging. This represents a significant advancement for predicting successful clot removal and refining treatment approaches in acute ischemic stroke.</p>
<p>Article number three. Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial. The abstract establishes that stroke is a sexually dimorphic disease, demonstrating differences in risk factors, incidence, outcomes, and treatment responses between men and women. It highlights that previous preclinical studies supporting these sex differences often originated from single-site studies with small sample sizes. Therefore, validating these variations across diverse research settings, as intended by the S. P. A. N. (Stroke Preclinical Assessment Network) trial, holds significant clinical importance. Understanding these inherent sex-based differences is crucial for developing more targeted and effective stroke management strategies.</p>
<p>Article number four. Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation. Cancer survivors undergoing heart transplantation demonstrated an increased incidence of de novo malignancies when compared with malignancy recurrences. For select cancer survivors who develop advanced heart failure, heart transplantation remains the gold standard treatment. This finding underscores a significant long-term concern in this specific patient population. Understanding the distinct patterns of subsequent primary cancers is crucial for developing optimized post-transplant surveillance and management strategies.</p>
<p>Article number five. Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial. This randomized controlled trial in 168 patients with stable coronary artery disease demonstrated that acute vigorous exercise and a 12-week high-intensity interval training program affect systemic inflammatory biomarkers. The research confirmed the role of persistent low-grade inflammation in coronary artery disease progression. These findings provide critical evidence for developing exercise-based interventions aimed at modulating systemic inflammation in patients with stable coronary artery disease. The study contributes to understanding how specific exercise regimens influence the inflammatory profile in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-intensity interval training, acute exercise, radiomics, conscious sedation, exercise intervention, acute ischemic stroke, advanced heart failure, neutrophil extracellular traps, risk factors, treatment response, cancer survivors, computed tomography, general anesthesia, heart transplantation, sex differences, inflammatory biomarkers, sexually dimorphic, stroke, functional outcomes, mechanical thrombectomy, malignancy recurrence, coronary artery disease, ischemic stroke, de novo malignancies.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/">C. T. Predicts Stroke Clot Removal Success 02/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260204_060030.mp3" length="4186531" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 04, 2026. This episode summarizes 5 key cardiology studies on topics like high-intensity interval training and acute exercise. Key takeaway: C. T. Predicts Stroke Clot Removal Success.
Article Links:
Article 1: General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial. (Journal of the American Heart Association)
Article 2: Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi. (Journal of the American Heart Association)
Article 3: Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial. (Journal of the American Heart Association)
Article 4: Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation. (Journal of the American Heart Association)
Article 5: Effects of Acute Exercise and 12-Week High-Intensity Interval Training on Inflammatory Biomarkers in Stable Coronary Artery Disease: A Randomized Controlled Trial. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/c-t-predicts-stroke-clot-removal-success-02-04-26/
 Featured Articles
Article 1: General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41631770
Summary: The abstract reports that several observational studies supported conscious sedation for endovascular thrombectomy in acute ischemic stroke and associated general anesthesia with poor functional outcomes. Conversely, recent randomized controlled trials have shown no difference in functional outcomes between general anesthesia and conscious sedation. This highlights a critical ongoing debate regarding the optimal anesthesia choice for mechanical thrombectomy in patients with acute ischemic stroke. The abstract&#8217;s context emphasizes the importance of understanding the definitive impact of anesthesia type on patient functional recovery.
Article 2: Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41631768
Summary: This study integrated paired radiomics and transcriptomics from 32 ischemic stroke clots retrieved by mechanical thrombectomy. The analysis identified neutrophil extracellular trap enrichment within these clots as a predictor of first-pass mechanical thrombectomy success. Results demonstrated the potential for noninvasively detecting neutrophil extracellular trap enrichment using prethrombectomy computed tomography imaging. This represents a significant advancement for predicting successful clot removal and refining treatment approaches in acute ischemic stroke.
Article 3: Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41631765
Summary: The abstract establishes that stroke is a sexually dimorphic disease, demonstrating differences in risk factors, incidence, outcomes, and treatment responses between men and women. It highlights that previous preclinical studies supporting these sex differences often originated from single-site studies with small sample sizes. Therefore, validating these variations across diverse research settings, as intended by the S. P. A. N. (Stroke Preclinical Assessment Network) trial, holds significant clinical importance. Understanding these inherent sex-based differences is crucial for developing more targeted and effective stroke management strategies.
Article 4: Increased Incidence of De Novo Malignancie]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 04, 2026. This episode summarizes 5 key cardiology studies on topics like high-intensity interval training and acute exercise. Key takeaway: C. T. Predicts Stroke Clot Removal Success.
Article Links:
Article 1: General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial. (Journal of the American Heart Association)
Article 2: Computed Tomography Radiomic Signatures Associated With Neutrophil Extracellular Trap Enrichment and First-Pass Outcome in Ischemic Stroke Thrombi. (Journal of the American Heart Association)
Article 3: Exploring Sex Differences in Stroke Outcomes: A Comprehensive Analysis From the SPAN 1 Trial. (Journal of the American Heart Association)
Article 4: Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation. (Journal of the American Heart Association)
Article 5: Effects o]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Extravascular Defibrillator Offers Pacing 02/03/26</title>
	<link>https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/</link>
	<pubDate>Tue, 03 Feb 2026 11:01:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 03, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac implantable electronic devices and quality of life. Key takeaway: New Extravascular Defibrillator Offers Pacing.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41628259">Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41628682">Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41248780">Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41205889">Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41205887">Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/">https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41628259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41628259</a></p>
<p><strong>Summary:</strong> Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.</p>
<h4>Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41628682" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41628682</a></p>
<p><strong>Summary:</strong> Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.</p>
<h4>Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41248780" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41248780</a></p>
<p><strong>Summary:</strong> The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system&#8217;s implant success, acute performance, and 30-day safety.</p>
<h4>Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41205889" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41205889</a></p>
<p><strong>Summary:</strong> Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inform the decision for endoepicardial access, which may be needed for epicardial ventricular tachycardia despite higher risks.</p>
<h4>Article 5: Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41205887" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41205887</a></p>
<p><strong>Summary:</strong> Lead-related venous stenosis is observed in up to 35 percent of patients with cardiac implantable electronic devices. While most cases are asymptomatic, progressive stenosis causes symptomatic venous obstruction and edema, often proving refractory to anticoagulation therapy. Traditional percutaneous balloon venoplasty offers only transient symptomatic relief due to high recurrence rates when transvenous leads remain implanted. Drug-coated balloon venoplasty addresses these limitations by inhibiting intimal hyperplasia, a mechanism designed to improve long-term patency.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study. Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.</p>
<p>Article number two. Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes. Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.</p>
<p>Article number three. Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system&#8217;s implant success, acute performance, and 30-day safety.</p>
<p>Article number four. Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach. Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inform the decision for endoepicardial access, which may be needed for epicardial ventricular tachycardia despite higher risks.</p>
<p>Article number five. Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis. Lead-related venous stenosis is observed in up to 35 percent of patients with cardiac implantable electronic devices. While most cases are asymptomatic, progressive stenosis causes symptomatic venous obstruction and edema, often proving refractory to anticoagulation therapy. Traditional percutaneous balloon venoplasty offers only transient symptomatic relief due to high recurrence rates when transvenous leads remain implanted. Drug-coated balloon venoplasty addresses these limitations by inhibiting intimal hyperplasia, a mechanism designed to improve long-term patency. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac implantable electronic devices, quality of life, care transitions, tricuspid regurgitation, ventricular tachycardia, cardiac magnetic resonance, intimal hyperplasia, extravascular implantable cardioverter-defibrillator, defibrillation, transcatheter tricuspid valve intervention, arrhythmic substrate, antitachycardia pacing, catheter ablation, parasternal, care fragmentation, extravascular lead, endoepicardial access, patient reported outcomes, drug-coated balloon, care coordination, lead-related venous stenosis, socioeconomic position, venoplasty, Tri-QOL Study, heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/">New Extravascular Defibrillator Offers Pacing 02/03/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 03, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac implantable electronic devices and quality of life. Key takeaway: New Extravascular Defibrillator Offers Pacing.
Article Lin]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 03, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac implantable electronic devices and quality of life. Key takeaway: New Extravascular Defibrillator Offers Pacing.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41628259">Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41628682">Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41248780">Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41205889">Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41205887">Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/">https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41628259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41628259</a></p>
<p><strong>Summary:</strong> Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.</p>
<h4>Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41628682" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41628682</a></p>
<p><strong>Summary:</strong> Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.</p>
<h4>Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41248780" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41248780</a></p>
<p><strong>Summary:</strong> The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system&#8217;s implant success, acute performance, and 30-day safety.</p>
<h4>Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41205889" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41205889</a></p>
<p><strong>Summary:</strong> Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inform the decision for endoepicardial access, which may be needed for epicardial ventricular tachycardia despite higher risks.</p>
<h4>Article 5: Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41205887" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41205887</a></p>
<p><strong>Summary:</strong> Lead-related venous stenosis is observed in up to 35 percent of patients with cardiac implantable electronic devices. While most cases are asymptomatic, progressive stenosis causes symptomatic venous obstruction and edema, often proving refractory to anticoagulation therapy. Traditional percutaneous balloon venoplasty offers only transient symptomatic relief due to high recurrence rates when transvenous leads remain implanted. Drug-coated balloon venoplasty addresses these limitations by inhibiting intimal hyperplasia, a mechanism designed to improve long-term patency.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 03, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study. Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.</p>
<p>Article number two. Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes. Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.</p>
<p>Article number three. Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system&#8217;s implant success, acute performance, and 30-day safety.</p>
<p>Article number four. Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach. Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inform the decision for endoepicardial access, which may be needed for epicardial ventricular tachycardia despite higher risks.</p>
<p>Article number five. Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis. Lead-related venous stenosis is observed in up to 35 percent of patients with cardiac implantable electronic devices. While most cases are asymptomatic, progressive stenosis causes symptomatic venous obstruction and edema, often proving refractory to anticoagulation therapy. Traditional percutaneous balloon venoplasty offers only transient symptomatic relief due to high recurrence rates when transvenous leads remain implanted. Drug-coated balloon venoplasty addresses these limitations by inhibiting intimal hyperplasia, a mechanism designed to improve long-term patency. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac implantable electronic devices, quality of life, care transitions, tricuspid regurgitation, ventricular tachycardia, cardiac magnetic resonance, intimal hyperplasia, extravascular implantable cardioverter-defibrillator, defibrillation, transcatheter tricuspid valve intervention, arrhythmic substrate, antitachycardia pacing, catheter ablation, parasternal, care fragmentation, extravascular lead, endoepicardial access, patient reported outcomes, drug-coated balloon, care coordination, lead-related venous stenosis, socioeconomic position, venoplasty, Tri-QOL Study, heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/">New Extravascular Defibrillator Offers Pacing 02/03/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260203_060033.mp3" length="3871389" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 03, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac implantable electronic devices and quality of life. Key takeaway: New Extravascular Defibrillator Offers Pacing.
Article Links:
Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study. (Circulation)
Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes. (Journal of cardiac failure)
Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. (Heart rhythm)
Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach. (Heart rhythm)
Article 5: Drug-coated balloon venoplasty for symptomatic lead-related venous stenosis. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/new-extravascular-defibrillator-offers-pacing-02-03-26/
 Featured Articles
Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41628259
Summary: Recent randomized trials demonstrated that transcatheter tricuspid valve interventions improve symptoms, function, and quality of life for patients with severe tricuspid regurgitation. These trials showed that the extent of health status improvement correlates directly with the degree of tricuspid regurgitation reduction. This finding establishes a crucial link between procedural success and patient-reported outcomes for this patient population.
Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41628682
Summary: Patients with heart failure, particularly those of lower socioeconomic position, exhibit vulnerability to adverse outcomes resulting from care fragmentation. Care coordination effectively mitigates this care fragmentation, improving patient safety and efficacy. This highlights the critical importance of comprehensive clinician networks to enhance patient outcomes during heart failure care transitions.
Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41248780
Summary: The AtaCor parasternal extravascular implantable cardioverter-defibrillator system provides defibrillation and antitachycardia pacing therapy from outside the heart. This new modality utilizes an extravascular lead positioned along the left parasternum, designed to overcome limitations of existing implantable cardioverter-defibrillators. The ASCEND E. V. study introduced this novel system for patients with class one or two A indications for implantable cardioverter-defibrillators, focusing on demonstrating the system&#8217;s implant success, acute performance, and 30-day safety.
Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41205889
Summary: Substrate-based catheter ablation demonstrates effectiveness for scar-related ventricular tachycardia. Cardiac magnetic resonance is a valuable tool for assessing the arrhythmic substrate, thereby guiding ablation strategies. The study found that understanding three-dimensional ventricular substrate depth via cardiac magnetic resonance has prognostic implications for selecting the optimal ventricular tachycardia ablation approach. This approach can inf]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 03, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac implantable electronic devices and quality of life. Key takeaway: New Extravascular Defibrillator Offers Pacing.
Article Links:
Article 1: Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study. (Circulation)
Article 2: Hidden Structure of Care Coordination in Heart Failure Care Transitions: A Mixed-method Network Analysis of Clinical Notes. (Journal of cardiac failure)
Article 3: Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. (Heart rhythm)
Article 4: Cardiac magnetic resonance to evaluate 3-dimensional ventricular substrate depth: Prognostic implications for ventricular tachycardia ablation approach. (Heart rhythm)
Article 5: Drug-coated balloon venoplasty for symptomatic lead-related venous ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lymphatics Predict Heart Transplant Survival. 02/02/26</title>
	<link>https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/</link>
	<pubDate>Mon, 02 Feb 2026 11:01:22 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 02, 2026. This episode summarizes 5 key cardiology studies on topics like stroke risk and cardiac lymphatics. Key takeaway: Lymphatics Predict Heart Transplant Survival..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41614319">Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41614318">Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41614317">High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41614309">Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41614307">Cardiac Lymphatics Predict Survival After Heart Transplantation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/">https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614319" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614319</a></p>
<p><strong>Summary:</strong> This study found that artificial intelligence-enabled electrocardiography can classify diastolic dysfunction grades in patients undergoing transcatheter aortic valve replacement for severe aortic stenosis. Researchers applied a validated artificial intelligence model to 3197 baseline 12-lead electrocardiograms from these patients. This application provides a novel method for identifying cardiac dysfunction in this high-risk population, laying the groundwork for future prognostic assessments.</p>
<h4>Article 2: Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614318" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614318</a></p>
<p><strong>Summary:</strong> This nationwide prospective cohort study demonstrated an association between a comprehensive set of living environmental factors and stroke in middle-aged and older Chinese adults. Researchers analyzed data from the China Health and Retirement Longitudinal Study, considering ambient fine particulate matter, indoor fuel use, tap water use, room temperature, and residence type. This research established the relevance of specific environmental exposures to stroke risk in a large population, highlighting multifaceted influences beyond traditional risk factors.</p>
<h4>Article 3: High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614317" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614317</a></p>
<p><strong>Summary:</strong> This population-based observational study found a high prevalence of cerebrovascular calcifications among indigenous Bolivian forager-horticulturalists. The study also identified specific clinical correlates for these calcifications within this unique population. These findings challenge assumptions derived solely from industrialized populations regarding intracranial arteriosclerosis and its risk factors in diverse lifestyles.</p>
<h4>Article 4: Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614309" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614309</a></p>
<p><strong>Summary:</strong> This study found that patient-specific computational flow simulation revealed adverse hemodynamic factors associated with branch vessel occlusion following fenestrated-branched endovascular aneurysm repair. These factors contribute to occlusion even in the absence of structural stenosis, particularly in patients undergoing four-vessel fenestrated-branched endovascular aneurysm repair for Extent two to four thoracoabdominal aortic aneurysms. The simulation identified specific hemodynamic features that predict post-repair complications.</p>
<h4>Article 5: Cardiac Lymphatics Predict Survival After Heart Transplantation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614307" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614307</a></p>
<p><strong>Summary:</strong> This study found that cardiac lymphatics predict survival following orthotopic heart transplantation. Variations in cardiac lymphatics were identified as influencing cardiac allograft vasculopathy, which is a leading cause of late allograft loss. Researchers analyzed endomyocardial biopsies to establish this predictive link, demonstrating the impact of lymphatic disruption on long-term outcomes after transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 02, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement. This study found that artificial intelligence-enabled electrocardiography can classify diastolic dysfunction grades in patients undergoing transcatheter aortic valve replacement for severe aortic stenosis. Researchers applied a validated artificial intelligence model to 3197 baseline 12-lead electrocardiograms from these patients. This application provides a novel method for identifying cardiac dysfunction in this high-risk population, laying the groundwork for future prognostic assessments.</p>
<p>Article number two. Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study. This nationwide prospective cohort study demonstrated an association between a comprehensive set of living environmental factors and stroke in middle-aged and older Chinese adults. Researchers analyzed data from the China Health and Retirement Longitudinal Study, considering ambient fine particulate matter, indoor fuel use, tap water use, room temperature, and residence type. This research established the relevance of specific environmental exposures to stroke risk in a large population, highlighting multifaceted influences beyond traditional risk factors.</p>
<p>Article number three. High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study. This population-based observational study found a high prevalence of cerebrovascular calcifications among indigenous Bolivian forager-horticulturalists. The study also identified specific clinical correlates for these calcifications within this unique population. These findings challenge assumptions derived solely from industrialized populations regarding intracranial arteriosclerosis and its risk factors in diverse lifestyles.</p>
<p>Article number four. Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair. This study found that patient-specific computational flow simulation revealed adverse hemodynamic factors associated with branch vessel occlusion following fenestrated-branched endovascular aneurysm repair. These factors contribute to occlusion even in the absence of structural stenosis, particularly in patients undergoing four-vessel fenestrated-branched endovascular aneurysm repair for Extent two to four thoracoabdominal aortic aneurysms. The simulation identified specific hemodynamic features that predict post-repair complications.</p>
<p>Article number five. Cardiac Lymphatics Predict Survival After Heart Transplantation. This study found that cardiac lymphatics predict survival following orthotopic heart transplantation. Variations in cardiac lymphatics were identified as influencing cardiac allograft vasculopathy, which is a leading cause of late allograft loss. Researchers analyzed endomyocardial biopsies to establish this predictive link, demonstrating the impact of lymphatic disruption on long-term outcomes after transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>stroke risk, cardiac lymphatics, Chinese adults, environmental factors, indoor fuel use, intracranial arteriosclerosis, thoracoabdominal aortic aneurysm, survival prediction, computational flow simulation, aortic stenosis, transcatheter aortic valve replacement, orthotopic heart transplantation, indigenous population, branch vessel occlusion, electrocardiography, fenestrated-branched endovascular aneurysm repair, diastolic dysfunction, heart transplantation, cerebrovascular calcifications, cardiac allograft vasculopathy, stroke, artificial intelligence, fine particulate matter, Bolivia, hemodynamic factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/">Lymphatics Predict Heart Transplant Survival. 02/02/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 02, 2026. This episode summarizes 5 key cardiology studies on topics like stroke risk and cardiac lymphatics. Key takeaway: Lymphatics Predict Heart Transplant Survival..
Article Links:
Article 1: Prognosti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 02, 2026. This episode summarizes 5 key cardiology studies on topics like stroke risk and cardiac lymphatics. Key takeaway: Lymphatics Predict Heart Transplant Survival..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41614319">Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41614318">Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41614317">High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41614309">Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41614307">Cardiac Lymphatics Predict Survival After Heart Transplantation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/">https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614319" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614319</a></p>
<p><strong>Summary:</strong> This study found that artificial intelligence-enabled electrocardiography can classify diastolic dysfunction grades in patients undergoing transcatheter aortic valve replacement for severe aortic stenosis. Researchers applied a validated artificial intelligence model to 3197 baseline 12-lead electrocardiograms from these patients. This application provides a novel method for identifying cardiac dysfunction in this high-risk population, laying the groundwork for future prognostic assessments.</p>
<h4>Article 2: Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614318" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614318</a></p>
<p><strong>Summary:</strong> This nationwide prospective cohort study demonstrated an association between a comprehensive set of living environmental factors and stroke in middle-aged and older Chinese adults. Researchers analyzed data from the China Health and Retirement Longitudinal Study, considering ambient fine particulate matter, indoor fuel use, tap water use, room temperature, and residence type. This research established the relevance of specific environmental exposures to stroke risk in a large population, highlighting multifaceted influences beyond traditional risk factors.</p>
<h4>Article 3: High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614317" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614317</a></p>
<p><strong>Summary:</strong> This population-based observational study found a high prevalence of cerebrovascular calcifications among indigenous Bolivian forager-horticulturalists. The study also identified specific clinical correlates for these calcifications within this unique population. These findings challenge assumptions derived solely from industrialized populations regarding intracranial arteriosclerosis and its risk factors in diverse lifestyles.</p>
<h4>Article 4: Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614309" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614309</a></p>
<p><strong>Summary:</strong> This study found that patient-specific computational flow simulation revealed adverse hemodynamic factors associated with branch vessel occlusion following fenestrated-branched endovascular aneurysm repair. These factors contribute to occlusion even in the absence of structural stenosis, particularly in patients undergoing four-vessel fenestrated-branched endovascular aneurysm repair for Extent two to four thoracoabdominal aortic aneurysms. The simulation identified specific hemodynamic features that predict post-repair complications.</p>
<h4>Article 5: Cardiac Lymphatics Predict Survival After Heart Transplantation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614307" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614307</a></p>
<p><strong>Summary:</strong> This study found that cardiac lymphatics predict survival following orthotopic heart transplantation. Variations in cardiac lymphatics were identified as influencing cardiac allograft vasculopathy, which is a leading cause of late allograft loss. Researchers analyzed endomyocardial biopsies to establish this predictive link, demonstrating the impact of lymphatic disruption on long-term outcomes after transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 02, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement. This study found that artificial intelligence-enabled electrocardiography can classify diastolic dysfunction grades in patients undergoing transcatheter aortic valve replacement for severe aortic stenosis. Researchers applied a validated artificial intelligence model to 3197 baseline 12-lead electrocardiograms from these patients. This application provides a novel method for identifying cardiac dysfunction in this high-risk population, laying the groundwork for future prognostic assessments.</p>
<p>Article number two. Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study. This nationwide prospective cohort study demonstrated an association between a comprehensive set of living environmental factors and stroke in middle-aged and older Chinese adults. Researchers analyzed data from the China Health and Retirement Longitudinal Study, considering ambient fine particulate matter, indoor fuel use, tap water use, room temperature, and residence type. This research established the relevance of specific environmental exposures to stroke risk in a large population, highlighting multifaceted influences beyond traditional risk factors.</p>
<p>Article number three. High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study. This population-based observational study found a high prevalence of cerebrovascular calcifications among indigenous Bolivian forager-horticulturalists. The study also identified specific clinical correlates for these calcifications within this unique population. These findings challenge assumptions derived solely from industrialized populations regarding intracranial arteriosclerosis and its risk factors in diverse lifestyles.</p>
<p>Article number four. Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair. This study found that patient-specific computational flow simulation revealed adverse hemodynamic factors associated with branch vessel occlusion following fenestrated-branched endovascular aneurysm repair. These factors contribute to occlusion even in the absence of structural stenosis, particularly in patients undergoing four-vessel fenestrated-branched endovascular aneurysm repair for Extent two to four thoracoabdominal aortic aneurysms. The simulation identified specific hemodynamic features that predict post-repair complications.</p>
<p>Article number five. Cardiac Lymphatics Predict Survival After Heart Transplantation. This study found that cardiac lymphatics predict survival following orthotopic heart transplantation. Variations in cardiac lymphatics were identified as influencing cardiac allograft vasculopathy, which is a leading cause of late allograft loss. Researchers analyzed endomyocardial biopsies to establish this predictive link, demonstrating the impact of lymphatic disruption on long-term outcomes after transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>stroke risk, cardiac lymphatics, Chinese adults, environmental factors, indoor fuel use, intracranial arteriosclerosis, thoracoabdominal aortic aneurysm, survival prediction, computational flow simulation, aortic stenosis, transcatheter aortic valve replacement, orthotopic heart transplantation, indigenous population, branch vessel occlusion, electrocardiography, fenestrated-branched endovascular aneurysm repair, diastolic dysfunction, heart transplantation, cerebrovascular calcifications, cardiac allograft vasculopathy, stroke, artificial intelligence, fine particulate matter, Bolivia, hemodynamic factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/">Lymphatics Predict Heart Transplant Survival. 02/02/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260202_060027.mp3" length="3835445" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 02, 2026. This episode summarizes 5 key cardiology studies on topics like stroke risk and cardiac lymphatics. Key takeaway: Lymphatics Predict Heart Transplant Survival..
Article Links:
Article 1: Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement. (Journal of the American Heart Association)
Article 2: Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study. (Journal of the American Heart Association)
Article 3: High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study. (Journal of the American Heart Association)
Article 4: Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair. (Journal of the American Heart Association)
Article 5: Cardiac Lymphatics Predict Survival After Heart Transplantation. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/lymphatics-predict-heart-transplant-survival-02-02-26/
 Featured Articles
Article 1: Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614319
Summary: This study found that artificial intelligence-enabled electrocardiography can classify diastolic dysfunction grades in patients undergoing transcatheter aortic valve replacement for severe aortic stenosis. Researchers applied a validated artificial intelligence model to 3197 baseline 12-lead electrocardiograms from these patients. This application provides a novel method for identifying cardiac dysfunction in this high-risk population, laying the groundwork for future prognostic assessments.
Article 2: Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614318
Summary: This nationwide prospective cohort study demonstrated an association between a comprehensive set of living environmental factors and stroke in middle-aged and older Chinese adults. Researchers analyzed data from the China Health and Retirement Longitudinal Study, considering ambient fine particulate matter, indoor fuel use, tap water use, room temperature, and residence type. This research established the relevance of specific environmental exposures to stroke risk in a large population, highlighting multifaceted influences beyond traditional risk factors.
Article 3: High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614317
Summary: This population-based observational study found a high prevalence of cerebrovascular calcifications among indigenous Bolivian forager-horticulturalists. The study also identified specific clinical correlates for these calcifications within this unique population. These findings challenge assumptions derived solely from industrialized populations regarding intracranial arteriosclerosis and its risk factors in diverse lifestyles.
Article 4: Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated With Occlusion of Directional Branches After Fenestrated-Branched Endovascular Aneurysm Repair.
Journal: Journal of the American Heart Associatio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 02, 2026. This episode summarizes 5 key cardiology studies on topics like stroke risk and cardiac lymphatics. Key takeaway: Lymphatics Predict Heart Transplant Survival..
Article Links:
Article 1: Prognostic Value of Artificial Intelligence-Enabled Electrocardiography-Derived Diastolic Dysfunction Grading and Trajectory in Patients Undergoing Transcatheter Aortic Valve Replacement. (Journal of the American Heart Association)
Article 2: Association Between Living Environmental Factors and Stroke in Middle-Aged and Older Chinese Adults: A Nationwide Prospective Cohort Study. (Journal of the American Heart Association)
Article 3: High Prevalence of Cerebrovascular Calcifications and Clinical Correlates in Indigenous Bolivian Forager-Horticulturalists: A Population-Based Observational Study. (Journal of the American Heart Association)
Article 4: Patient-Specific Computational Flow Simulation Reveals Adverse Hemodynamic Factors Associated Wit]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference 02/01/26</title>
	<link>https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/</link>
	<pubDate>Sun, 01 Feb 2026 11:01:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like warm ischemic time and chronic antibody-mediated rejection. Key takeaway: Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40480320">Barriers and opportunities in donation after circulatory death heart transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41063352">Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41614331">Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41614325">Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41614323">Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/">https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Barriers and opportunities in donation after circulatory death heart transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40480320" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40480320</a></p>
<p><strong>Summary:</strong> Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.</p>
<h4>Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41063352" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41063352</a></p>
<p><strong>Summary:</strong> This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.</p>
<h4>Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614331" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614331</a></p>
<p><strong>Summary:</strong> This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol&#8217;s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.</p>
<h4>Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614325</a></p>
<p><strong>Summary:</strong> This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165 Evolut patients. The analysis focused on patients without preexisting permanent pacemaker implantation or high-risk electrocardiogram findings. The study provides comparative data on post-transcatheter aortic valve replacement cardiac rhythm management.</p>
<h4>Article 5: Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614323" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614323</a></p>
<p><strong>Summary:</strong> The intent-to-treat analysis of the Diuretic Comparison Project (D. C. P.) found no difference in the risk of nonfatal cardiovascular disease or noncancer-related death between chlorthalidone and hydrochlorothiazide. The hazard ratio was 1.04 with a 95 percent confidence interval of 0.94 to 1.16. The current study performed a per-protocol analysis to estimate the effect of chlorthalidone at 12 point 5 or 25 milligrams daily compared with hydrochlorothiazide at 25 or 50 milligrams daily. This analysis examined the comparative effectiveness of these diuretics in preventing major cardiovascular disease or noncancer death.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Barriers and opportunities in donation after circulatory death heart transplantation. Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.</p>
<p>Article number two. Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.</p>
<p>Article number three. Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol&#8217;s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.</p>
<p>Article number four. Pacemaker Implantation Rates With the Self-Expandable Navitor Valve. This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165 Evolut patients. The analysis focused on patients without preexisting permanent pacemaker implantation or high-risk electrocardiogram findings. The study provides comparative data on post-transcatheter aortic valve replacement cardiac rhythm management.</p>
<p>Article number five. Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project. The intent-to-treat analysis of the Diuretic Comparison Project (D. C. P.) found no difference in the risk of nonfatal cardiovascular disease or noncancer-related death between chlorthalidone and hydrochlorothiazide. The hazard ratio was 1.04 with a 95 percent confidence interval of 0.94 to 1.16. The current study performed a per-protocol analysis to estimate the effect of chlorthalidone at 12 point 5 or 25 milligrams daily compared with hydrochlorothiazide at 25 or 50 milligrams daily. This analysis examined the comparative effectiveness of these diuretics in preventing major cardiovascular disease or noncancer death. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>warm ischemic time, chronic antibody-mediated rejection, kidney transplantation, self-expandable valve, donor characteristics, epidemiological modeling, chlorthalidone, cardiovascular event prevention, donation after circulatory death, beta blockers, transcatheter aortic valve replacement, diuretic, heart rate control, heart transplantation, donor-specific antibodies, hypertension, Evolut valve, Navitor valve, blood pressure control, hazard ratio, peritubular capillary multilayering, hydrochlorothiazide, nebivolol, permanent pacemaker implantation, organ utilization.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/">Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference 02/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like warm ischemic time and chronic antibody-mediated rejection. Key takeaway: Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Diffe]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like warm ischemic time and chronic antibody-mediated rejection. Key takeaway: Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40480320">Barriers and opportunities in donation after circulatory death heart transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41063352">Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41614331">Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41614325">Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41614323">Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/">https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Barriers and opportunities in donation after circulatory death heart transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40480320" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40480320</a></p>
<p><strong>Summary:</strong> Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.</p>
<h4>Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41063352" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41063352</a></p>
<p><strong>Summary:</strong> This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.</p>
<h4>Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614331" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614331</a></p>
<p><strong>Summary:</strong> This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol&#8217;s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.</p>
<h4>Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614325</a></p>
<p><strong>Summary:</strong> This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165 Evolut patients. The analysis focused on patients without preexisting permanent pacemaker implantation or high-risk electrocardiogram findings. The study provides comparative data on post-transcatheter aortic valve replacement cardiac rhythm management.</p>
<h4>Article 5: Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614323" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614323</a></p>
<p><strong>Summary:</strong> The intent-to-treat analysis of the Diuretic Comparison Project (D. C. P.) found no difference in the risk of nonfatal cardiovascular disease or noncancer-related death between chlorthalidone and hydrochlorothiazide. The hazard ratio was 1.04 with a 95 percent confidence interval of 0.94 to 1.16. The current study performed a per-protocol analysis to estimate the effect of chlorthalidone at 12 point 5 or 25 milligrams daily compared with hydrochlorothiazide at 25 or 50 milligrams daily. This analysis examined the comparative effectiveness of these diuretics in preventing major cardiovascular disease or noncancer death.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Barriers and opportunities in donation after circulatory death heart transplantation. Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.</p>
<p>Article number two. Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.</p>
<p>Article number three. Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol&#8217;s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.</p>
<p>Article number four. Pacemaker Implantation Rates With the Self-Expandable Navitor Valve. This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165 Evolut patients. The analysis focused on patients without preexisting permanent pacemaker implantation or high-risk electrocardiogram findings. The study provides comparative data on post-transcatheter aortic valve replacement cardiac rhythm management.</p>
<p>Article number five. Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project. The intent-to-treat analysis of the Diuretic Comparison Project (D. C. P.) found no difference in the risk of nonfatal cardiovascular disease or noncancer-related death between chlorthalidone and hydrochlorothiazide. The hazard ratio was 1.04 with a 95 percent confidence interval of 0.94 to 1.16. The current study performed a per-protocol analysis to estimate the effect of chlorthalidone at 12 point 5 or 25 milligrams daily compared with hydrochlorothiazide at 25 or 50 milligrams daily. This analysis examined the comparative effectiveness of these diuretics in preventing major cardiovascular disease or noncancer death. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>warm ischemic time, chronic antibody-mediated rejection, kidney transplantation, self-expandable valve, donor characteristics, epidemiological modeling, chlorthalidone, cardiovascular event prevention, donation after circulatory death, beta blockers, transcatheter aortic valve replacement, diuretic, heart rate control, heart transplantation, donor-specific antibodies, hypertension, Evolut valve, Navitor valve, blood pressure control, hazard ratio, peritubular capillary multilayering, hydrochlorothiazide, nebivolol, permanent pacemaker implantation, organ utilization.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/">Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference 02/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260201_060029.mp3" length="3959997" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like warm ischemic time and chronic antibody-mediated rejection. Key takeaway: Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference.
Article Links:
Article 1: Barriers and opportunities in donation after circulatory death heart transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. (Transplantation)
Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. (Journal of the American Heart Association)
Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve. (Journal of the American Heart Association)
Article 5: Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/
 Featured Articles
Article 1: Barriers and opportunities in donation after circulatory death heart transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40480320
Summary: Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.
Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41063352
Summary: This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.
Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614331
Summary: This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol&#8217;s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.
Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614325
Summary: This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like warm ischemic time and chronic antibody-mediated rejection. Key takeaway: Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference.
Article Links:
Article 1: Barriers and opportunities in donation after circulatory death heart transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. (Transplantation)
Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. (Journal of the American Heart Association)
Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve. (Journal of the American Heart Association)
Article 5: Per-Protocol Analysis of Chlorthalidon]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dual Organ Perfusion: Superior Cardiac Safety 02/01/26</title>
	<link>https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/</link>
	<pubDate>Sun, 01 Feb 2026 06:09:34 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac protection and delayed kidney graft function. Key takeaway: Dual Organ Perfusion: Superior Cardiac Safety.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41201625">Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41005516">Superior cardiac protection in combined ex-situ perfusion of heart and liver.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40947078">Method for generating right ventricular pressure-volume loops in routine practice.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40846118">Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40691958">Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/">https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41201625" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41201625</a></p>
<p><strong>Summary:</strong> This study identified 495 pretreated patients with pulmonary arterial hypertension who received add-on parenteral prostacyclin analogue therapy from the COMPERA registry. The cohort included patients with idiopathic, heritable, drug-associated pulmonary arterial hypertension, connective tissue disease-associated pulmonary arterial hypertension, or congenital heart disease-associated pulmonary arterial hypertension. All patients were pretreated with at least one pulmonary arterial hypertension specific therapy before receiving the add-on treatment. This investigation provides a real-world characterization of patients receiving this advanced combination therapy for pulmonary arterial hypertension.</p>
<h4>Article 2: Superior cardiac protection in combined ex-situ perfusion of heart and liver.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005516" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005516</a></p>
<p><strong>Summary:</strong> This study demonstrated superior cardiac protection when using combined ex-situ heart-liver perfusion compared to isolated ex-situ heart perfusion in porcine hearts. It built upon previous findings that experimental ex-situ organ perfusion with cross-circulation significantly extends safe preservation times. The study also perfused discarded human donor hearts ex-situ, providing data on this advanced preservation technique. This approach improved cardiac preservation beyond what isolated heart perfusion achieved.</p>
<h4>Article 3: Method for generating right ventricular pressure-volume loops in routine practice.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947078" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947078</a></p>
<p><strong>Summary:</strong> This study successfully validated a novel method for reconstructing right ventricular pressure-volume loops directly from pressure waveforms. These waveforms were acquired during routine right heart catheterization, overcoming the complexity of gold standard conductance catheterization. Researchers developed an algorithm that estimates right ventricular volume from pressure using the hydromotive source pressure model with external calibration. This new method makes right ventricular pressure-volume loop analysis feasible in everyday clinical practice.</p>
<h4>Article 4: Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40846118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40846118</a></p>
<p><strong>Summary:</strong> P. in acute myocardial infarction versus heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. This study analyzed outcomes for patients receiving Impella C. P. microaxial flow pumps for cardiogenic shock due to acute myocardial infarction or heart failure. The Cardiogenic Shock Working Group registry data from 36 international sites, enrolling patients from 2019 to 2024, characterized these patients. The analysis provided data on differences in outcomes between cardiogenic shock etiologies for patients managed with Impella C. P. mechanical support. This investigation revealed distinct outcome patterns in large, unselected populations depending on the underlying cause of cardiogenic shock.</p>
<h4>Article 5: Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691958" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691958</a></p>
<p><strong>Summary:</strong> This retrospective cohort study identified the impact of delayed kidney graft function on long-term patient survival in simultaneous heart-kidney transplantation. The study analyzed 1737 recipients from the United Network for Organ Sharing database between October 2018 and October 2024. Delayed kidney graft function was precisely defined as requiring dialysis within the first week post-transplant. The findings established how this early post-transplant complication influences survival rates for patients undergoing combined heart-kidney transplants.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry. This study identified 495 pretreated patients with pulmonary arterial hypertension who received add-on parenteral prostacyclin analogue therapy from the COMPERA registry. The cohort included patients with idiopathic, heritable, drug-associated pulmonary arterial hypertension, connective tissue disease-associated pulmonary arterial hypertension, or congenital heart disease-associated pulmonary arterial hypertension. All patients were pretreated with at least one pulmonary arterial hypertension specific therapy before receiving the add-on treatment. This investigation provides a real-world characterization of patients receiving this advanced combination therapy for pulmonary arterial hypertension.</p>
<p>Article number two. Superior cardiac protection in combined ex-situ perfusion of heart and liver. This study demonstrated superior cardiac protection when using combined ex-situ heart-liver perfusion compared to isolated ex-situ heart perfusion in porcine hearts. It built upon previous findings that experimental ex-situ organ perfusion with cross-circulation significantly extends safe preservation times. The study also perfused discarded human donor hearts ex-situ, providing data on this advanced preservation technique. This approach improved cardiac preservation beyond what isolated heart perfusion achieved.</p>
<p>Article number three. Method for generating right ventricular pressure-volume loops in routine practice. This study successfully validated a novel method for reconstructing right ventricular pressure-volume loops directly from pressure waveforms. These waveforms were acquired during routine right heart catheterization, overcoming the complexity of gold standard conductance catheterization. Researchers developed an algorithm that estimates right ventricular volume from pressure using the hydromotive source pressure model with external calibration. This new method makes right ventricular pressure-volume loop analysis feasible in everyday clinical practice.</p>
<p>Article number four. Outcomes with Impella C. P. in acute myocardial infarction versus heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. This study analyzed outcomes for patients receiving Impella C. P. microaxial flow pumps for cardiogenic shock due to acute myocardial infarction or heart failure. The Cardiogenic Shock Working Group registry data from 36 international sites, enrolling patients from 2019 to 2024, characterized these patients. The analysis provided data on differences in outcomes between cardiogenic shock etiologies for patients managed with Impella C. P. mechanical support. This investigation revealed distinct outcome patterns in large, unselected populations depending on the underlying cause of cardiogenic shock.</p>
<p>Article number five. Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation. This retrospective cohort study identified the impact of delayed kidney graft function on long-term patient survival in simultaneous heart-kidney transplantation. The study analyzed 1737 recipients from the United Network for Organ Sharing database between October 2018 and October 2024. Delayed kidney graft function was precisely defined as requiring dialysis within the first week post-transplant. The findings established how this early post-transplant complication influences survival rates for patients undergoing combined heart-kidney transplants. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac protection, delayed kidney graft function, connective tissue disease, right heart catheterization, add-on therapy, acute myocardial infarction, ex-situ heart perfusion, parenteral prostacyclin analogues, cardiogenic shock, simultaneous heart-kidney transplantation, pulmonary arterial hypertension, organ transplantation, organ preservation, long-term survival, heart transplantation, mechanical circulatory support, hemodynamic assessment, liver perfusion, COMPERA registry, pressure-volume loops, right ventricular function, heart failure, Impella C. P..</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/">Dual Organ Perfusion: Superior Cardiac Safety 02/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac protection and delayed kidney graft function. Key takeaway: Dual Organ Perfusion: Superior Cardiac Safety.
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac protection and delayed kidney graft function. Key takeaway: Dual Organ Perfusion: Superior Cardiac Safety.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41201625">Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41005516">Superior cardiac protection in combined ex-situ perfusion of heart and liver.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40947078">Method for generating right ventricular pressure-volume loops in routine practice.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40846118">Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40691958">Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/">https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41201625" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41201625</a></p>
<p><strong>Summary:</strong> This study identified 495 pretreated patients with pulmonary arterial hypertension who received add-on parenteral prostacyclin analogue therapy from the COMPERA registry. The cohort included patients with idiopathic, heritable, drug-associated pulmonary arterial hypertension, connective tissue disease-associated pulmonary arterial hypertension, or congenital heart disease-associated pulmonary arterial hypertension. All patients were pretreated with at least one pulmonary arterial hypertension specific therapy before receiving the add-on treatment. This investigation provides a real-world characterization of patients receiving this advanced combination therapy for pulmonary arterial hypertension.</p>
<h4>Article 2: Superior cardiac protection in combined ex-situ perfusion of heart and liver.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005516" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005516</a></p>
<p><strong>Summary:</strong> This study demonstrated superior cardiac protection when using combined ex-situ heart-liver perfusion compared to isolated ex-situ heart perfusion in porcine hearts. It built upon previous findings that experimental ex-situ organ perfusion with cross-circulation significantly extends safe preservation times. The study also perfused discarded human donor hearts ex-situ, providing data on this advanced preservation technique. This approach improved cardiac preservation beyond what isolated heart perfusion achieved.</p>
<h4>Article 3: Method for generating right ventricular pressure-volume loops in routine practice.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947078" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947078</a></p>
<p><strong>Summary:</strong> This study successfully validated a novel method for reconstructing right ventricular pressure-volume loops directly from pressure waveforms. These waveforms were acquired during routine right heart catheterization, overcoming the complexity of gold standard conductance catheterization. Researchers developed an algorithm that estimates right ventricular volume from pressure using the hydromotive source pressure model with external calibration. This new method makes right ventricular pressure-volume loop analysis feasible in everyday clinical practice.</p>
<h4>Article 4: Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40846118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40846118</a></p>
<p><strong>Summary:</strong> P. in acute myocardial infarction versus heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. This study analyzed outcomes for patients receiving Impella C. P. microaxial flow pumps for cardiogenic shock due to acute myocardial infarction or heart failure. The Cardiogenic Shock Working Group registry data from 36 international sites, enrolling patients from 2019 to 2024, characterized these patients. The analysis provided data on differences in outcomes between cardiogenic shock etiologies for patients managed with Impella C. P. mechanical support. This investigation revealed distinct outcome patterns in large, unselected populations depending on the underlying cause of cardiogenic shock.</p>
<h4>Article 5: Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691958" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691958</a></p>
<p><strong>Summary:</strong> This retrospective cohort study identified the impact of delayed kidney graft function on long-term patient survival in simultaneous heart-kidney transplantation. The study analyzed 1737 recipients from the United Network for Organ Sharing database between October 2018 and October 2024. Delayed kidney graft function was precisely defined as requiring dialysis within the first week post-transplant. The findings established how this early post-transplant complication influences survival rates for patients undergoing combined heart-kidney transplants.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is February 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry. This study identified 495 pretreated patients with pulmonary arterial hypertension who received add-on parenteral prostacyclin analogue therapy from the COMPERA registry. The cohort included patients with idiopathic, heritable, drug-associated pulmonary arterial hypertension, connective tissue disease-associated pulmonary arterial hypertension, or congenital heart disease-associated pulmonary arterial hypertension. All patients were pretreated with at least one pulmonary arterial hypertension specific therapy before receiving the add-on treatment. This investigation provides a real-world characterization of patients receiving this advanced combination therapy for pulmonary arterial hypertension.</p>
<p>Article number two. Superior cardiac protection in combined ex-situ perfusion of heart and liver. This study demonstrated superior cardiac protection when using combined ex-situ heart-liver perfusion compared to isolated ex-situ heart perfusion in porcine hearts. It built upon previous findings that experimental ex-situ organ perfusion with cross-circulation significantly extends safe preservation times. The study also perfused discarded human donor hearts ex-situ, providing data on this advanced preservation technique. This approach improved cardiac preservation beyond what isolated heart perfusion achieved.</p>
<p>Article number three. Method for generating right ventricular pressure-volume loops in routine practice. This study successfully validated a novel method for reconstructing right ventricular pressure-volume loops directly from pressure waveforms. These waveforms were acquired during routine right heart catheterization, overcoming the complexity of gold standard conductance catheterization. Researchers developed an algorithm that estimates right ventricular volume from pressure using the hydromotive source pressure model with external calibration. This new method makes right ventricular pressure-volume loop analysis feasible in everyday clinical practice.</p>
<p>Article number four. Outcomes with Impella C. P. in acute myocardial infarction versus heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. This study analyzed outcomes for patients receiving Impella C. P. microaxial flow pumps for cardiogenic shock due to acute myocardial infarction or heart failure. The Cardiogenic Shock Working Group registry data from 36 international sites, enrolling patients from 2019 to 2024, characterized these patients. The analysis provided data on differences in outcomes between cardiogenic shock etiologies for patients managed with Impella C. P. mechanical support. This investigation revealed distinct outcome patterns in large, unselected populations depending on the underlying cause of cardiogenic shock.</p>
<p>Article number five. Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation. This retrospective cohort study identified the impact of delayed kidney graft function on long-term patient survival in simultaneous heart-kidney transplantation. The study analyzed 1737 recipients from the United Network for Organ Sharing database between October 2018 and October 2024. Delayed kidney graft function was precisely defined as requiring dialysis within the first week post-transplant. The findings established how this early post-transplant complication influences survival rates for patients undergoing combined heart-kidney transplants. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac protection, delayed kidney graft function, connective tissue disease, right heart catheterization, add-on therapy, acute myocardial infarction, ex-situ heart perfusion, parenteral prostacyclin analogues, cardiogenic shock, simultaneous heart-kidney transplantation, pulmonary arterial hypertension, organ transplantation, organ preservation, long-term survival, heart transplantation, mechanical circulatory support, hemodynamic assessment, liver perfusion, COMPERA registry, pressure-volume loops, right ventricular function, heart failure, Impella C. P..</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/">Dual Organ Perfusion: Superior Cardiac Safety 02/01/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/02/cardiology_today_20260201_010840.mp3" length="4163125" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac protection and delayed kidney graft function. Key takeaway: Dual Organ Perfusion: Superior Cardiac Safety.
Article Links:
Article 1: Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Superior cardiac protection in combined ex-situ perfusion of heart and liver. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Method for generating right ventricular pressure-volume loops in routine practice. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Impact of delayed kidney graft function on long-term outcomes in simultaneous heart-kidney transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/dual-organ-perfusion-superior-cardiac-safety-02-01-26/
 Featured Articles
Article 1: Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41201625
Summary: This study identified 495 pretreated patients with pulmonary arterial hypertension who received add-on parenteral prostacyclin analogue therapy from the COMPERA registry. The cohort included patients with idiopathic, heritable, drug-associated pulmonary arterial hypertension, connective tissue disease-associated pulmonary arterial hypertension, or congenital heart disease-associated pulmonary arterial hypertension. All patients were pretreated with at least one pulmonary arterial hypertension specific therapy before receiving the add-on treatment. This investigation provides a real-world characterization of patients receiving this advanced combination therapy for pulmonary arterial hypertension.
Article 2: Superior cardiac protection in combined ex-situ perfusion of heart and liver.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41005516
Summary: This study demonstrated superior cardiac protection when using combined ex-situ heart-liver perfusion compared to isolated ex-situ heart perfusion in porcine hearts. It built upon previous findings that experimental ex-situ organ perfusion with cross-circulation significantly extends safe preservation times. The study also perfused discarded human donor hearts ex-situ, providing data on this advanced preservation technique. This approach improved cardiac preservation beyond what isolated heart perfusion achieved.
Article 3: Method for generating right ventricular pressure-volume loops in routine practice.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40947078
Summary: This study successfully validated a novel method for reconstructing right ventricular pressure-volume loops directly from pressure waveforms. These waveforms were acquired during routine right heart]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like cardiac protection and delayed kidney graft function. Key takeaway: Dual Organ Perfusion: Superior Cardiac Safety.
Article Links:
Article 1: Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Superior cardiac protection in combined ex-situ perfusion of heart and liver. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Method for generating right ventricular pressure-volume loops in routine practice. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Outcomes wit]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Fontan Liver Biomarkers Predict Survival 01/31/26</title>
	<link>https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/</link>
	<pubDate>Sat, 31 Jan 2026 17:24:23 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like cardiovascular-kidney-metabolic syndrome and sinoatrial node dysfunction. Key takeaway: Fontan Liver Biomarkers Predict Survival.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41604173">Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41617484">Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41611525">Sex differences in the prevalence and risk factors for aortic valve calcification in the general population.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41605626">Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41608790">Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/">https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41604173" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41604173</a></p>
<p><strong>Summary:</strong> The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.</p>
<h4>Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41617484" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41617484</a></p>
<p><strong>Summary:</strong> The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.</p>
<h4>Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41611525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41611525</a></p>
<p><strong>Summary:</strong> Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.</p>
<h4>Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41605626" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41605626</a></p>
<p><strong>Summary:</strong> K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a comprehensive evaluation of genetic, sociodemographic, clinical, and laboratory factors associated with the incidence of sick sinus syndrome. Using data from over 500000 individuals, it identified specific factors predictive of sick sinus syndrome development. The investigation uniquely leveraged a polygenic risk score for atrial fibrillation, revealing its association with sick sinus syndrome risk.</p>
<h4>Article 5: Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41608790" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41608790</a></p>
<p><strong>Summary:</strong> F. The prognostic value of liver biomarkers in heart failure with mildly reduced or preserved ejection fraction has been unclear. This study evaluated the prevalence and prognostic significance of these biomarkers in patients with heart failure with mildly reduced or preserved ejection fraction. Furthermore, it assessed the effects of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on these liver biomarkers and on crucial clinical outcomes. The analysis from Finerenone Trial to Investigate Clinical Events in Patients with Heart Failure with Preserved Ejection Fraction demonstrated specific impacts of finerenone on liver biomarkers and clinical outcomes in this patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.</p>
<p>Article number two. Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation. The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.</p>
<p>Article number three. Sex differences in the prevalence and risk factors for aortic valve calcification in the general population. Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.</p>
<p>Article number four. Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the U. K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a comprehensive evaluation of genetic, sociodemographic, clinical, and laboratory factors associated with the incidence of sick sinus syndrome. Using data from over 500000 individuals, it identified specific factors predictive of sick sinus syndrome development. The investigation uniquely leveraged a polygenic risk score for atrial fibrillation, revealing its association with sick sinus syndrome risk.</p>
<p>Article number five. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-H. F. The prognostic value of liver biomarkers in heart failure with mildly reduced or preserved ejection fraction has been unclear. This study evaluated the prevalence and prognostic significance of these biomarkers in patients with heart failure with mildly reduced or preserved ejection fraction. Furthermore, it assessed the effects of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on these liver biomarkers and on crucial clinical outcomes. The analysis from Finerenone Trial to Investigate Clinical Events in Patients with Heart Failure with Preserved Ejection Fraction demonstrated specific impacts of finerenone on liver biomarkers and clinical outcomes in this patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular-kidney-metabolic syndrome, sinoatrial node dysfunction, sodium-glucose cotransporter-two inhibitors, polygenic risk score, Fontan circulation, non-invasive biomarkers, heart failure with mildly reduced ejection fraction, transplant-free survival, nonsteroidal mineralocorticoid antagonists, sex differences, finerenone, aortic stenosis, obesity, sick sinus syndrome, risk factors, general population, atrial fibrillation, heart failure with preserved ejection fraction, liver biomarkers, FibroSURE, glucagonlike peptide one receptor agonists, aortic valve calcification, genetic risk factors, mineralocorticoid receptor antagonist, liver fibrosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/">Fontan Liver Biomarkers Predict Survival 01/31/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like cardiovascular-kidney-metabolic syndrome and sinoatrial node dysfunction. Key takeaway: Fontan Liver Biomarkers Predict Survival.
Art]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like cardiovascular-kidney-metabolic syndrome and sinoatrial node dysfunction. Key takeaway: Fontan Liver Biomarkers Predict Survival.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41604173">Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41617484">Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41611525">Sex differences in the prevalence and risk factors for aortic valve calcification in the general population.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41605626">Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41608790">Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/">https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41604173" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41604173</a></p>
<p><strong>Summary:</strong> The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.</p>
<h4>Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41617484" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41617484</a></p>
<p><strong>Summary:</strong> The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.</p>
<h4>Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41611525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41611525</a></p>
<p><strong>Summary:</strong> Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.</p>
<h4>Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41605626" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41605626</a></p>
<p><strong>Summary:</strong> K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a comprehensive evaluation of genetic, sociodemographic, clinical, and laboratory factors associated with the incidence of sick sinus syndrome. Using data from over 500000 individuals, it identified specific factors predictive of sick sinus syndrome development. The investigation uniquely leveraged a polygenic risk score for atrial fibrillation, revealing its association with sick sinus syndrome risk.</p>
<h4>Article 5: Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41608790" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41608790</a></p>
<p><strong>Summary:</strong> F. The prognostic value of liver biomarkers in heart failure with mildly reduced or preserved ejection fraction has been unclear. This study evaluated the prevalence and prognostic significance of these biomarkers in patients with heart failure with mildly reduced or preserved ejection fraction. Furthermore, it assessed the effects of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on these liver biomarkers and on crucial clinical outcomes. The analysis from Finerenone Trial to Investigate Clinical Events in Patients with Heart Failure with Preserved Ejection Fraction demonstrated specific impacts of finerenone on liver biomarkers and clinical outcomes in this patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.</p>
<p>Article number two. Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation. The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.</p>
<p>Article number three. Sex differences in the prevalence and risk factors for aortic valve calcification in the general population. Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.</p>
<p>Article number four. Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the U. K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a comprehensive evaluation of genetic, sociodemographic, clinical, and laboratory factors associated with the incidence of sick sinus syndrome. Using data from over 500000 individuals, it identified specific factors predictive of sick sinus syndrome development. The investigation uniquely leveraged a polygenic risk score for atrial fibrillation, revealing its association with sick sinus syndrome risk.</p>
<p>Article number five. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-H. F. The prognostic value of liver biomarkers in heart failure with mildly reduced or preserved ejection fraction has been unclear. This study evaluated the prevalence and prognostic significance of these biomarkers in patients with heart failure with mildly reduced or preserved ejection fraction. Furthermore, it assessed the effects of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on these liver biomarkers and on crucial clinical outcomes. The analysis from Finerenone Trial to Investigate Clinical Events in Patients with Heart Failure with Preserved Ejection Fraction demonstrated specific impacts of finerenone on liver biomarkers and clinical outcomes in this patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular-kidney-metabolic syndrome, sinoatrial node dysfunction, sodium-glucose cotransporter-two inhibitors, polygenic risk score, Fontan circulation, non-invasive biomarkers, heart failure with mildly reduced ejection fraction, transplant-free survival, nonsteroidal mineralocorticoid antagonists, sex differences, finerenone, aortic stenosis, obesity, sick sinus syndrome, risk factors, general population, atrial fibrillation, heart failure with preserved ejection fraction, liver biomarkers, FibroSURE, glucagonlike peptide one receptor agonists, aortic valve calcification, genetic risk factors, mineralocorticoid receptor antagonist, liver fibrosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/">Fontan Liver Biomarkers Predict Survival 01/31/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260131_122316.mp3" length="4290603" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like cardiovascular-kidney-metabolic syndrome and sinoatrial node dysfunction. Key takeaway: Fontan Liver Biomarkers Predict Survival.
Article Links:
Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. (JAMA cardiology)
Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation. (Heart (British Cardiac Society))
Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population. (Heart (British Cardiac Society))
Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data. (Heart (British Cardiac Society))
Article 5: Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/
 Featured Articles
Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41604173
Summary: The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.
Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41617484
Summary: The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.
Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41611525
Summary: Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.
Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41605626
Summary: K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a c]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like cardiovascular-kidney-metabolic syndrome and sinoatrial node dysfunction. Key takeaway: Fontan Liver Biomarkers Predict Survival.
Article Links:
Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. (JAMA cardiology)
Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation. (Heart (British Cardiac Society))
Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population. (Heart (British Cardiac Society))
Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data. (Heart (British Cardiac Society))
Article 5: Finerenone, Liver Biomarkers, and Heart Failure With Mildly Re]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes 01/31/26</title>
	<link>https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/</link>
	<pubDate>Sat, 31 Jan 2026 11:01:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure endpoints and long-term outcomes. Key takeaway: Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41614276">DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41614664">Heart failure with preserved ejection fraction in adults with congenital heart disease.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41614598">Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41614592">Heart Failure Endpoints in FDA Pivotal Trials.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41616977">Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/">https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614276" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614276</a></p>
<p><strong>Summary:</strong> This study found that death-associated protein kinase 2 regulates pyruvate kinase M2 phosphorylation at threonine 45. This regulation facilitates disturbed flow-induced atherosclerosis, a process initiated by oscillatory shear stress. The data clarify a crucial molecular mechanism by which oscillatory shear stress leads to endothelial cell activation and atherosclerotic plaque formation. This provides novel understanding of the precise pathways contributing to vascular disease.</p>
<h4>Article 2: Heart failure with preserved ejection fraction in adults with congenital heart disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614664" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614664</a></p>
<p><strong>Summary:</strong> This retrospective multicenter cohort study determined the prevalence, characteristics, and hospitalization burden of Heart Failure with Preserved Ejection Fraction among adults with congenital heart disease. The study included 4507 adults with congenital heart disease who had biventricular heart physiology and a systemic left ventricle. Results offered detailed insights into the clinical profile of this patient population and the specific impact of Heart Failure with Preserved Ejection Fraction on hospitalizations. This clarifies the extent and nature of Heart Failure with Preserved Ejection Fraction within this complex patient group.</p>
<h4>Article 3: Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614598" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614598</a></p>
<p><strong>Summary:</strong> This study evaluated the early and long-term outcomes of the frozen elephant trunk and total arch replacement technique in 850 patients with acute type A aortic dissection. The patient cohort, treated between April 2003 and December 2014, had a mean age of 46.5 years; 19.9 percent were women, and 136 patients presented with malperfusion syndrome. The findings provided definitive data on the efficacy and durability of this aggressive surgical approach for acute type A aortic dissection over two decades. This demonstrates the long-term clinical profile and safety of extended arch repair in this complex patient population.</p>
<h4>Article 4: Heart Failure Endpoints in FDA Pivotal Trials.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614592" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614592</a></p>
<p><strong>Summary:</strong> D. A. Pivotal Trials. This analysis found that traditional heart failure medication approval, based on reducing cardiovascular death or heart failure hospitalization, is evolving. Expanding use of effective medicines has successfully reduced hospitalization and mortality rates, making incremental improvements in these &#8220;hard&#8221; outcomes more challenging to demonstrate. Consequently, endpoints capturing how patients feel or function are becoming increasingly important and attractive for new medicine development and efficacy assessment in F. D. A. pivotal trials. This shift reflects the changing landscape of heart failure treatment and impacts the design of future clinical trials for new therapies.</p>
<h4>Article 5: Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41616977" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41616977</a></p>
<p><strong>Summary:</strong> This nationwide multicenter matched case-control study identified updated risk factors and outcomes for invasive mold infections in heart transplant recipients. Researchers included 120 probable or proven cases of invasive mold infection, matched to 120 control patients, from 14 French centers between 2008 and 2022. The study utilized conditional logistic regression to pinpoint specific risk factors for infection, providing current epidemiological data. It offers crucial insights for improving patient management and preventive strategies for these severe post-transplant complications.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis. This study found that death-associated protein kinase 2 regulates pyruvate kinase M2 phosphorylation at threonine 45. This regulation facilitates disturbed flow-induced atherosclerosis, a process initiated by oscillatory shear stress. The data clarify a crucial molecular mechanism by which oscillatory shear stress leads to endothelial cell activation and atherosclerotic plaque formation. This provides novel understanding of the precise pathways contributing to vascular disease.</p>
<p>Article number two. Heart failure with preserved ejection fraction in adults with congenital heart disease. This retrospective multicenter cohort study determined the prevalence, characteristics, and hospitalization burden of Heart Failure with Preserved Ejection Fraction among adults with congenital heart disease. The study included 4507 adults with congenital heart disease who had biventricular heart physiology and a systemic left ventricle. Results offered detailed insights into the clinical profile of this patient population and the specific impact of Heart Failure with Preserved Ejection Fraction on hospitalizations. This clarifies the extent and nature of Heart Failure with Preserved Ejection Fraction within this complex patient group.</p>
<p>Article number three. Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades. This study evaluated the early and long-term outcomes of the frozen elephant trunk and total arch replacement technique in 850 patients with acute type A aortic dissection. The patient cohort, treated between April 2003 and December 2014, had a mean age of 46.5 years; 19.9 percent were women, and 136 patients presented with malperfusion syndrome. The findings provided definitive data on the efficacy and durability of this aggressive surgical approach for acute type A aortic dissection over two decades. This demonstrates the long-term clinical profile and safety of extended arch repair in this complex patient population.</p>
<p>Article number four. Heart Failure Endpoints in F. D. A. Pivotal Trials. This analysis found that traditional heart failure medication approval, based on reducing cardiovascular death or heart failure hospitalization, is evolving. Expanding use of effective medicines has successfully reduced hospitalization and mortality rates, making incremental improvements in these &#8220;hard&#8221; outcomes more challenging to demonstrate. Consequently, endpoints capturing how patients feel or function are becoming increasingly important and attractive for new medicine development and efficacy assessment in F. D. A. pivotal trials. This shift reflects the changing landscape of heart failure treatment and impacts the design of future clinical trials for new therapies.</p>
<p>Article number five. Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France. This nationwide multicenter matched case-control study identified updated risk factors and outcomes for invasive mold infections in heart transplant recipients. Researchers included 120 probable or proven cases of invasive mold infection, matched to 120 control patients, from 14 French centers between 2008 and 2022. The study utilized conditional logistic regression to pinpoint specific risk factors for infection, providing current epidemiological data. It offers crucial insights for improving patient management and preventive strategies for these severe post-transplant complications. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure endpoints, long-term outcomes, endothelial cell activation, frozen elephant trunk, atherosclerosis, hospitalization burden, risk factors, pyruvate kinase M2, heart failure hospitalization, biventricular physiology, oscillatory shear stress, patient reported outcomes, case-control study, congenital heart disease, heart failure prevalence, acute type A aortic dissection, post-transplant complications, cardiovascular mortality, Heart Failure with Preserved Ejection Fraction, invasive mold infection, total arch replacement, extended arch repair, death-associated protein kinase 2, heart transplantation, F. D. A. trials.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/">Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes 01/31/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure endpoints and long-term outcomes. Key takeaway: Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes.
Article Link]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure endpoints and long-term outcomes. Key takeaway: Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41614276">DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41614664">Heart failure with preserved ejection fraction in adults with congenital heart disease.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41614598">Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41614592">Heart Failure Endpoints in FDA Pivotal Trials.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41616977">Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/">https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614276" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614276</a></p>
<p><strong>Summary:</strong> This study found that death-associated protein kinase 2 regulates pyruvate kinase M2 phosphorylation at threonine 45. This regulation facilitates disturbed flow-induced atherosclerosis, a process initiated by oscillatory shear stress. The data clarify a crucial molecular mechanism by which oscillatory shear stress leads to endothelial cell activation and atherosclerotic plaque formation. This provides novel understanding of the precise pathways contributing to vascular disease.</p>
<h4>Article 2: Heart failure with preserved ejection fraction in adults with congenital heart disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614664" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614664</a></p>
<p><strong>Summary:</strong> This retrospective multicenter cohort study determined the prevalence, characteristics, and hospitalization burden of Heart Failure with Preserved Ejection Fraction among adults with congenital heart disease. The study included 4507 adults with congenital heart disease who had biventricular heart physiology and a systemic left ventricle. Results offered detailed insights into the clinical profile of this patient population and the specific impact of Heart Failure with Preserved Ejection Fraction on hospitalizations. This clarifies the extent and nature of Heart Failure with Preserved Ejection Fraction within this complex patient group.</p>
<h4>Article 3: Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614598" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614598</a></p>
<p><strong>Summary:</strong> This study evaluated the early and long-term outcomes of the frozen elephant trunk and total arch replacement technique in 850 patients with acute type A aortic dissection. The patient cohort, treated between April 2003 and December 2014, had a mean age of 46.5 years; 19.9 percent were women, and 136 patients presented with malperfusion syndrome. The findings provided definitive data on the efficacy and durability of this aggressive surgical approach for acute type A aortic dissection over two decades. This demonstrates the long-term clinical profile and safety of extended arch repair in this complex patient population.</p>
<h4>Article 4: Heart Failure Endpoints in FDA Pivotal Trials.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41614592" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41614592</a></p>
<p><strong>Summary:</strong> D. A. Pivotal Trials. This analysis found that traditional heart failure medication approval, based on reducing cardiovascular death or heart failure hospitalization, is evolving. Expanding use of effective medicines has successfully reduced hospitalization and mortality rates, making incremental improvements in these &#8220;hard&#8221; outcomes more challenging to demonstrate. Consequently, endpoints capturing how patients feel or function are becoming increasingly important and attractive for new medicine development and efficacy assessment in F. D. A. pivotal trials. This shift reflects the changing landscape of heart failure treatment and impacts the design of future clinical trials for new therapies.</p>
<h4>Article 5: Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41616977" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41616977</a></p>
<p><strong>Summary:</strong> This nationwide multicenter matched case-control study identified updated risk factors and outcomes for invasive mold infections in heart transplant recipients. Researchers included 120 probable or proven cases of invasive mold infection, matched to 120 control patients, from 14 French centers between 2008 and 2022. The study utilized conditional logistic regression to pinpoint specific risk factors for infection, providing current epidemiological data. It offers crucial insights for improving patient management and preventive strategies for these severe post-transplant complications.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis. This study found that death-associated protein kinase 2 regulates pyruvate kinase M2 phosphorylation at threonine 45. This regulation facilitates disturbed flow-induced atherosclerosis, a process initiated by oscillatory shear stress. The data clarify a crucial molecular mechanism by which oscillatory shear stress leads to endothelial cell activation and atherosclerotic plaque formation. This provides novel understanding of the precise pathways contributing to vascular disease.</p>
<p>Article number two. Heart failure with preserved ejection fraction in adults with congenital heart disease. This retrospective multicenter cohort study determined the prevalence, characteristics, and hospitalization burden of Heart Failure with Preserved Ejection Fraction among adults with congenital heart disease. The study included 4507 adults with congenital heart disease who had biventricular heart physiology and a systemic left ventricle. Results offered detailed insights into the clinical profile of this patient population and the specific impact of Heart Failure with Preserved Ejection Fraction on hospitalizations. This clarifies the extent and nature of Heart Failure with Preserved Ejection Fraction within this complex patient group.</p>
<p>Article number three. Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades. This study evaluated the early and long-term outcomes of the frozen elephant trunk and total arch replacement technique in 850 patients with acute type A aortic dissection. The patient cohort, treated between April 2003 and December 2014, had a mean age of 46.5 years; 19.9 percent were women, and 136 patients presented with malperfusion syndrome. The findings provided definitive data on the efficacy and durability of this aggressive surgical approach for acute type A aortic dissection over two decades. This demonstrates the long-term clinical profile and safety of extended arch repair in this complex patient population.</p>
<p>Article number four. Heart Failure Endpoints in F. D. A. Pivotal Trials. This analysis found that traditional heart failure medication approval, based on reducing cardiovascular death or heart failure hospitalization, is evolving. Expanding use of effective medicines has successfully reduced hospitalization and mortality rates, making incremental improvements in these &#8220;hard&#8221; outcomes more challenging to demonstrate. Consequently, endpoints capturing how patients feel or function are becoming increasingly important and attractive for new medicine development and efficacy assessment in F. D. A. pivotal trials. This shift reflects the changing landscape of heart failure treatment and impacts the design of future clinical trials for new therapies.</p>
<p>Article number five. Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France. This nationwide multicenter matched case-control study identified updated risk factors and outcomes for invasive mold infections in heart transplant recipients. Researchers included 120 probable or proven cases of invasive mold infection, matched to 120 control patients, from 14 French centers between 2008 and 2022. The study utilized conditional logistic regression to pinpoint specific risk factors for infection, providing current epidemiological data. It offers crucial insights for improving patient management and preventive strategies for these severe post-transplant complications. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure endpoints, long-term outcomes, endothelial cell activation, frozen elephant trunk, atherosclerosis, hospitalization burden, risk factors, pyruvate kinase M2, heart failure hospitalization, biventricular physiology, oscillatory shear stress, patient reported outcomes, case-control study, congenital heart disease, heart failure prevalence, acute type A aortic dissection, post-transplant complications, cardiovascular mortality, Heart Failure with Preserved Ejection Fraction, invasive mold infection, total arch replacement, extended arch repair, death-associated protein kinase 2, heart transplantation, F. D. A. trials.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/">Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes 01/31/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260131_060024.mp3" length="4346609" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure endpoints and long-term outcomes. Key takeaway: Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes.
Article Links:
Article 1: DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis. (Circulation)
Article 2: Heart failure with preserved ejection fraction in adults with congenital heart disease. (European heart journal)
Article 3: Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades. (European heart journal)
Article 4: Heart Failure Endpoints in FDA Pivotal Trials. (European heart journal)
Article 5: Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Full episode page: https://podcast.explainheart.com/podcast/frozen-elephant-trunk-20-year-aortic-dissection-outcomes-01-31-26/
 Featured Articles
Article 1: DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614276
Summary: This study found that death-associated protein kinase 2 regulates pyruvate kinase M2 phosphorylation at threonine 45. This regulation facilitates disturbed flow-induced atherosclerosis, a process initiated by oscillatory shear stress. The data clarify a crucial molecular mechanism by which oscillatory shear stress leads to endothelial cell activation and atherosclerotic plaque formation. This provides novel understanding of the precise pathways contributing to vascular disease.
Article 2: Heart failure with preserved ejection fraction in adults with congenital heart disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614664
Summary: This retrospective multicenter cohort study determined the prevalence, characteristics, and hospitalization burden of Heart Failure with Preserved Ejection Fraction among adults with congenital heart disease. The study included 4507 adults with congenital heart disease who had biventricular heart physiology and a systemic left ventricle. Results offered detailed insights into the clinical profile of this patient population and the specific impact of Heart Failure with Preserved Ejection Fraction on hospitalizations. This clarifies the extent and nature of Heart Failure with Preserved Ejection Fraction within this complex patient group.
Article 3: Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614598
Summary: This study evaluated the early and long-term outcomes of the frozen elephant trunk and total arch replacement technique in 850 patients with acute type A aortic dissection. The patient cohort, treated between April 2003 and December 2014, had a mean age of 46.5 years; 19.9 percent were women, and 136 patients presented with malperfusion syndrome. The findings provided definitive data on the efficacy and durability of this aggressive surgical approach for acute type A aortic dissection over two decades. This demonstrates the long-term clinical profile and safety of extended arch repair in this complex patient population.
Article 4: Heart Failure Endpoints in FDA Pivotal Trials.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614592
Summary: D. A. Pivotal Trials. This analysis found that traditional heart failure medication approval, based on reducing cardiovascular death or heart failure hospitalization, is evolving. Expanding use of effective medicines has successfully reduced hospitalization and mortality rates, making incremental improvements in these &]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like heart failure endpoints and long-term outcomes. Key takeaway: Frozen Elephant Trunk: 20-Year Aortic Dissection Outcomes.
Article Links:
Article 1: DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis. (Circulation)
Article 2: Heart failure with preserved ejection fraction in adults with congenital heart disease. (European heart journal)
Article 3: Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades. (European heart journal)
Article 4: Heart Failure Endpoints in FDA Pivotal Trials. (European heart journal)
Article 5: Invasive mold infection in heart transplant recipients: a nationwide multicenter matched case-control study between 2008 and 2022 in France. (American journal of transplantation : official journal of the American Society of Transplantation and the American Soci]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mitochondrial Transfer Cuts Cardiac Reperfusion Injury 01/30/26</title>
	<link>https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/</link>
	<pubDate>Fri, 30 Jan 2026 11:01:48 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 30, 2026. This episode summarizes 5 key cardiology studies on topics like peri-operative myocardial infarction and cardiac complications. Key takeaway: Mitochondrial Transfer Cuts Cardiac Reperfusion Injury.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41610880">Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41587749">Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41611105">Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41604459">Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41604197">One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/">https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41610880" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41610880</a></p>
<p><strong>Summary:</strong> Peri-operative myocardial infarction or injury is a common cardiac complication observed after non-cardiac surgery. In a multicenter prospective study, cardiologist evaluation of patients developing peri-operative myocardial infarction or injury was inconsistently applied within active surveillance programs. This inconsistent evaluation was primarily due to staffing constraints. The study highlighted a significant variability in specialist involvement for this high-risk patient population.</p>
<h4>Article 2: Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41587749" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41587749</a></p>
<p><strong>Summary:</strong> Long-term exposure to wildfire smoke fine particulate matter, specifically P. M. two point five, constitutes a growing public health concern. While short-term exposure is established to impact cardiovascular outcomes, the long-term effects on incident stroke remained significantly understudied. Data from Medicare beneficiaries aged sixty-five years and older from 2007 to 2018 were analyzed to investigate the association between prolonged wildfire smoke exposure and stroke incidence. This research established the critical need for further understanding this environmental risk factor&#8217;s impact on cerebrovascular health.</p>
<h4>Article 3: Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41611105" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41611105</a></p>
<p><strong>Summary:</strong> Researchers developed a novel method for rapid ultra-oxygenated recovery of cardiac allografts from donation after circulatory death donors. This technique enables successful heart transplantation without the need for traditional pre-implant heart reanimation, a process historically used to ensure graft viability and function. This innovative approach expands the donor pool for adult heart transplantation by optimizing graft retrieval. Clinical application considerations persist regarding its global use, particularly in scenarios involving prolonged &#8216;no-touch&#8217; periods.</p>
<h4>Article 4: Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41604459" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41604459</a></p>
<p><strong>Summary:</strong> This study demonstrated that circulating mitochondrial transfer carrying dihydroorotate dehydrogenase reduces oxidative cell death in prolonged cold-induced cardiac reperfusion injury during heart transplantation. Prolonged cold myocardial ischemia or reperfusion injury, characterized by mitochondrial dysfunction and oxidative stress, significantly limits cardiac transplantation success. Dihydroorotate dehydrogenase is a crucial mitochondrial enzyme for redox homeostasis and ferroptosis suppression, but its clinical utility is hindered by a short ischemic half-life and poor targeting. The research developed cardiomyocyte-targeted mitochondria designed for sustained delivery of this enzyme, effectively mitigating this form of injury.</p>
<h4>Article 5: One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41604197" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41604197</a></p>
<p><strong>Summary:</strong> The residual risk of poor clinical outcomes among patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) prescribed quadruple medical therapy at discharge remained incompletely characterized in U.S. clinical practice. One-year clinical outcomes and healthcare costs for Medicare beneficiaries hospitalized with H. F. rEF receiving quadruple medical therapy were evaluated. The study found important data on the post-discharge trajectory of these patients, despite optimal guideline-directed medical therapy. This research identified existing gaps in understanding long-term prognosis and resource utilization for this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 30, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes. Peri-operative myocardial infarction or injury is a common cardiac complication observed after non-cardiac surgery. In a multicenter prospective study, cardiologist evaluation of patients developing peri-operative myocardial infarction or injury was inconsistently applied within active surveillance programs. This inconsistent evaluation was primarily due to staffing constraints. The study highlighted a significant variability in specialist involvement for this high-risk patient population.</p>
<p>Article number two. Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study. Long-term exposure to wildfire smoke fine particulate matter, specifically P. M. two point five, constitutes a growing public health concern. While short-term exposure is established to impact cardiovascular outcomes, the long-term effects on incident stroke remained significantly understudied. Data from Medicare beneficiaries aged sixty-five years and older from 2007 to 2018 were analyzed to investigate the association between prolonged wildfire smoke exposure and stroke incidence. This research established the critical need for further understanding this environmental risk factor&#8217;s impact on cerebrovascular health.</p>
<p>Article number three. Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period. Researchers developed a novel method for rapid ultra-oxygenated recovery of cardiac allografts from donation after circulatory death donors. This technique enables successful heart transplantation without the need for traditional pre-implant heart reanimation, a process historically used to ensure graft viability and function. This innovative approach expands the donor pool for adult heart transplantation by optimizing graft retrieval. Clinical application considerations persist regarding its global use, particularly in scenarios involving prolonged &#8216;no-touch&#8217; periods.</p>
<p>Article number four. Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation. This study demonstrated that circulating mitochondrial transfer carrying dihydroorotate dehydrogenase reduces oxidative cell death in prolonged cold-induced cardiac reperfusion injury during heart transplantation. Prolonged cold myocardial ischemia or reperfusion injury, characterized by mitochondrial dysfunction and oxidative stress, significantly limits cardiac transplantation success. Dihydroorotate dehydrogenase is a crucial mitochondrial enzyme for redox homeostasis and ferroptosis suppression, but its clinical utility is hindered by a short ischemic half-life and poor targeting. The research developed cardiomyocyte-targeted mitochondria designed for sustained delivery of this enzyme, effectively mitigating this form of injury.</p>
<p>Article number five. One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge. The residual risk of poor clinical outcomes among patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) prescribed quadruple medical therapy at discharge remained incompletely characterized in U.S. clinical practice. One-year clinical outcomes and healthcare costs for Medicare beneficiaries hospitalized with H. F. rEF receiving quadruple medical therapy were evaluated. The study found important data on the post-discharge trajectory of these patients, despite optimal guideline-directed medical therapy. This research identified existing gaps in understanding long-term prognosis and resource utilization for this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>peri-operative myocardial infarction, cardiac complications, healthcare costs, myocardial ischemia reperfusion injury, one-year outcomes, quadruple medical therapy, long-term exposure, cardiologist evaluation, cerebrovascular health, graft viability, donation after circulatory death, mitochondrial transfer, patient outcomes, heart failure with reduced ejection fraction, non-cardiac surgery, pre-implant reanimation, incident stroke, dihydroorotate dehydrogenase, fine particulate matter, oxidative cell death, ultra-oxygenated recovery, wildfire smoke, Medicare beneficiaries, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/">Mitochondrial Transfer Cuts Cardiac Reperfusion Injury 01/30/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 30, 2026. This episode summarizes 5 key cardiology studies on topics like peri-operative myocardial infarction and cardiac complications. Key takeaway: Mitochondrial Transfer Cuts Cardiac Reperfusion Injury.]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 30, 2026. This episode summarizes 5 key cardiology studies on topics like peri-operative myocardial infarction and cardiac complications. Key takeaway: Mitochondrial Transfer Cuts Cardiac Reperfusion Injury.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41610880">Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41587749">Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41611105">Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41604459">Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41604197">One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/">https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41610880" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41610880</a></p>
<p><strong>Summary:</strong> Peri-operative myocardial infarction or injury is a common cardiac complication observed after non-cardiac surgery. In a multicenter prospective study, cardiologist evaluation of patients developing peri-operative myocardial infarction or injury was inconsistently applied within active surveillance programs. This inconsistent evaluation was primarily due to staffing constraints. The study highlighted a significant variability in specialist involvement for this high-risk patient population.</p>
<h4>Article 2: Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41587749" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41587749</a></p>
<p><strong>Summary:</strong> Long-term exposure to wildfire smoke fine particulate matter, specifically P. M. two point five, constitutes a growing public health concern. While short-term exposure is established to impact cardiovascular outcomes, the long-term effects on incident stroke remained significantly understudied. Data from Medicare beneficiaries aged sixty-five years and older from 2007 to 2018 were analyzed to investigate the association between prolonged wildfire smoke exposure and stroke incidence. This research established the critical need for further understanding this environmental risk factor&#8217;s impact on cerebrovascular health.</p>
<h4>Article 3: Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41611105" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41611105</a></p>
<p><strong>Summary:</strong> Researchers developed a novel method for rapid ultra-oxygenated recovery of cardiac allografts from donation after circulatory death donors. This technique enables successful heart transplantation without the need for traditional pre-implant heart reanimation, a process historically used to ensure graft viability and function. This innovative approach expands the donor pool for adult heart transplantation by optimizing graft retrieval. Clinical application considerations persist regarding its global use, particularly in scenarios involving prolonged &#8216;no-touch&#8217; periods.</p>
<h4>Article 4: Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41604459" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41604459</a></p>
<p><strong>Summary:</strong> This study demonstrated that circulating mitochondrial transfer carrying dihydroorotate dehydrogenase reduces oxidative cell death in prolonged cold-induced cardiac reperfusion injury during heart transplantation. Prolonged cold myocardial ischemia or reperfusion injury, characterized by mitochondrial dysfunction and oxidative stress, significantly limits cardiac transplantation success. Dihydroorotate dehydrogenase is a crucial mitochondrial enzyme for redox homeostasis and ferroptosis suppression, but its clinical utility is hindered by a short ischemic half-life and poor targeting. The research developed cardiomyocyte-targeted mitochondria designed for sustained delivery of this enzyme, effectively mitigating this form of injury.</p>
<h4>Article 5: One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41604197" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41604197</a></p>
<p><strong>Summary:</strong> The residual risk of poor clinical outcomes among patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) prescribed quadruple medical therapy at discharge remained incompletely characterized in U.S. clinical practice. One-year clinical outcomes and healthcare costs for Medicare beneficiaries hospitalized with H. F. rEF receiving quadruple medical therapy were evaluated. The study found important data on the post-discharge trajectory of these patients, despite optimal guideline-directed medical therapy. This research identified existing gaps in understanding long-term prognosis and resource utilization for this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 30, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes. Peri-operative myocardial infarction or injury is a common cardiac complication observed after non-cardiac surgery. In a multicenter prospective study, cardiologist evaluation of patients developing peri-operative myocardial infarction or injury was inconsistently applied within active surveillance programs. This inconsistent evaluation was primarily due to staffing constraints. The study highlighted a significant variability in specialist involvement for this high-risk patient population.</p>
<p>Article number two. Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study. Long-term exposure to wildfire smoke fine particulate matter, specifically P. M. two point five, constitutes a growing public health concern. While short-term exposure is established to impact cardiovascular outcomes, the long-term effects on incident stroke remained significantly understudied. Data from Medicare beneficiaries aged sixty-five years and older from 2007 to 2018 were analyzed to investigate the association between prolonged wildfire smoke exposure and stroke incidence. This research established the critical need for further understanding this environmental risk factor&#8217;s impact on cerebrovascular health.</p>
<p>Article number three. Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period. Researchers developed a novel method for rapid ultra-oxygenated recovery of cardiac allografts from donation after circulatory death donors. This technique enables successful heart transplantation without the need for traditional pre-implant heart reanimation, a process historically used to ensure graft viability and function. This innovative approach expands the donor pool for adult heart transplantation by optimizing graft retrieval. Clinical application considerations persist regarding its global use, particularly in scenarios involving prolonged &#8216;no-touch&#8217; periods.</p>
<p>Article number four. Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation. This study demonstrated that circulating mitochondrial transfer carrying dihydroorotate dehydrogenase reduces oxidative cell death in prolonged cold-induced cardiac reperfusion injury during heart transplantation. Prolonged cold myocardial ischemia or reperfusion injury, characterized by mitochondrial dysfunction and oxidative stress, significantly limits cardiac transplantation success. Dihydroorotate dehydrogenase is a crucial mitochondrial enzyme for redox homeostasis and ferroptosis suppression, but its clinical utility is hindered by a short ischemic half-life and poor targeting. The research developed cardiomyocyte-targeted mitochondria designed for sustained delivery of this enzyme, effectively mitigating this form of injury.</p>
<p>Article number five. One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge. The residual risk of poor clinical outcomes among patients with Heart Failure with Reduced Ejection Fraction (H. F. rEF) prescribed quadruple medical therapy at discharge remained incompletely characterized in U.S. clinical practice. One-year clinical outcomes and healthcare costs for Medicare beneficiaries hospitalized with H. F. rEF receiving quadruple medical therapy were evaluated. The study found important data on the post-discharge trajectory of these patients, despite optimal guideline-directed medical therapy. This research identified existing gaps in understanding long-term prognosis and resource utilization for this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>peri-operative myocardial infarction, cardiac complications, healthcare costs, myocardial ischemia reperfusion injury, one-year outcomes, quadruple medical therapy, long-term exposure, cardiologist evaluation, cerebrovascular health, graft viability, donation after circulatory death, mitochondrial transfer, patient outcomes, heart failure with reduced ejection fraction, non-cardiac surgery, pre-implant reanimation, incident stroke, dihydroorotate dehydrogenase, fine particulate matter, oxidative cell death, ultra-oxygenated recovery, wildfire smoke, Medicare beneficiaries, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/">Mitochondrial Transfer Cuts Cardiac Reperfusion Injury 01/30/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260130_060043.mp3" length="4566456" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 30, 2026. This episode summarizes 5 key cardiology studies on topics like peri-operative myocardial infarction and cardiac complications. Key takeaway: Mitochondrial Transfer Cuts Cardiac Reperfusion Injury.
Article Links:
Article 1: Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes. (European heart journal)
Article 2: Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study. (European heart journal)
Article 3: Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolonged Cold-induced Cardiac Reperfusion Injury in Heart Transplantation. (Transplantation)
Article 5: One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/mitochondrial-transfer-cuts-cardiac-reperfusion-injury-01-30-26/
 Featured Articles
Article 1: Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41610880
Summary: Peri-operative myocardial infarction or injury is a common cardiac complication observed after non-cardiac surgery. In a multicenter prospective study, cardiologist evaluation of patients developing peri-operative myocardial infarction or injury was inconsistently applied within active surveillance programs. This inconsistent evaluation was primarily due to staffing constraints. The study highlighted a significant variability in specialist involvement for this high-risk patient population.
Article 2: Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41587749
Summary: Long-term exposure to wildfire smoke fine particulate matter, specifically P. M. two point five, constitutes a growing public health concern. While short-term exposure is established to impact cardiovascular outcomes, the long-term effects on incident stroke remained significantly understudied. Data from Medicare beneficiaries aged sixty-five years and older from 2007 to 2018 were analyzed to investigate the association between prolonged wildfire smoke exposure and stroke incidence. This research established the critical need for further understanding this environmental risk factor&#8217;s impact on cerebrovascular health.
Article 3: Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41611105
Summary: Researchers developed a novel method for rapid ultra-oxygenated recovery of cardiac allografts from donation after circulatory death donors. This technique enables successful heart transplantation without the need for traditional pre-implant heart reanimation, a process historically used to ensure graft viability and function. This innovative approach expands the donor pool for adult heart transplantation by optimizing graft retrieval. Clinical application considerations persist regarding its global use, particularly in scenarios involving prolonged &#8216;no-touch&#8217; periods.
Article 4: Circulating Mitochondrial Transfer Carrying Dihydrooro]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 30, 2026. This episode summarizes 5 key cardiology studies on topics like peri-operative myocardial infarction and cardiac complications. Key takeaway: Mitochondrial Transfer Cuts Cardiac Reperfusion Injury.
Article Links:
Article 1: Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes. (European heart journal)
Article 2: Long-term exposure to wildfire smoke particulate matter and incident stroke: a US nationwide study. (European heart journal)
Article 3: Pushing the Limits of Death-Rapid Ultra-Oxygenated Recovery Without Pre-Implant Heart Reanimation in Circulatory Death With Prolonged &#8216;No-Touch&#8217; Period. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Circulating Mitochondrial Transfer Carrying Dihydroorotate Dehydrogenase Reduces Oxidative Cell Death in Prolon]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Breast Cancer Unmasks Latent P. A. H. Susceptibility 01/29/26</title>
	<link>https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/</link>
	<pubDate>Fri, 30 Jan 2026 02:01:16 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like glycated haemoglobin and drug-eluting stents. Key takeaway: Breast Cancer Unmasks Latent P. A. H. Susceptibility.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41194754">Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41608826">Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41603037">Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41609518">GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41605248">T cells in acute and chronic myocarditis: from diagnosis to treatment.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/">https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41194754" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41194754</a></p>
<p><strong>Summary:</strong> The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.</p>
<h4>Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41608826" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41608826</a></p>
<p><strong>Summary:</strong> The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study&#8217;s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.</p>
<h4>Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41603037" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41603037</a></p>
<p><strong>Summary:</strong> M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.</p>
<h4>Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41609518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41609518</a></p>
<p><strong>Summary:</strong> L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomization to investigate the causal effects of glucagon-like peptide one receptor activation on heart failure risk. The findings suggested novel beneficial effects of G. L. P. minus 1 R agonists on heart failure risk that extend beyond their known impacts on glucose control and weight reduction. Glycated haemoglobin reduction served as a surrogate biomarker in this analysis, providing a new perspective on the mechanisms by which these agonists confer cardioprotection. The data therefore indicated that the cardiovascular benefits of G. L. P. minus 1 R agonists are likely multifactorial.</p>
<h4>Article 5: T cells in acute and chronic myocarditis: from diagnosis to treatment.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41605248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41605248</a></p>
<p><strong>Summary:</strong> This article elucidated the critical role of T cells in the pathogenesis of both acute and chronic myocarditis, providing insights from diagnosis to treatment. It highlighted the emergence of newer etiologies for myocarditis, including those linked to immune checkpoint inhibitors and chronic inflammatory and genetic diseases. The content underscored the evolving understanding of immune cell infiltration and cardiomyocyte damage in myocarditis. The findings informed comprehensive strategies for identifying T-cell mediated myocarditis and guiding targeted immunotherapies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.</p>
<p>Article number two. Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study. The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study&#8217;s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.</p>
<p>Article number three. Breast Cancer Reveals Latent B. M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.</p>
<p>Article number four. G. L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomization to investigate the causal effects of glucagon-like peptide one receptor activation on heart failure risk. The findings suggested novel beneficial effects of G. L. P. minus 1 R agonists on heart failure risk that extend beyond their known impacts on glucose control and weight reduction. Glycated haemoglobin reduction served as a surrogate biomarker in this analysis, providing a new perspective on the mechanisms by which these agonists confer cardioprotection. The data therefore indicated that the cardiovascular benefits of G. L. P. minus 1 R agonists are likely multifactorial.</p>
<p>Article number five. T cells in acute and chronic myocarditis: from diagnosis to treatment. This article elucidated the critical role of T cells in the pathogenesis of both acute and chronic myocarditis, providing insights from diagnosis to treatment. It highlighted the emergence of newer etiologies for myocarditis, including those linked to immune checkpoint inhibitors and chronic inflammatory and genetic diseases. The content underscored the evolving understanding of immune cell infiltration and cardiomyocyte damage in myocarditis. The findings informed comprehensive strategies for identifying T-cell mediated myocarditis and guiding targeted immunotherapies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>glycated haemoglobin, drug-eluting stents, coronary artery disease, cardiovascular risk, drug-coated balloon angioplasty, T cells, cardioprotection, tumor-suppressive functions, Mendelian randomization, B. M. P. R. 2 mutations, breast cancer, wearable-derived training load, glucagon-like peptide one receptor agonists, chronic myocarditis, genetic susceptibility, immune checkpoint inhibitors, de novo lesions, endurance athletes, coronary computed tomography angiography, percutaneous coronary intervention, coronary atherosclerosis, myocarditis, heart failure, acute myocarditis, pulmonary arterial hypertension.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/">Breast Cancer Unmasks Latent P. A. H. Susceptibility 01/29/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like glycated haemoglobin and drug-eluting stents. Key takeaway: Breast Cancer Unmasks Latent P. A. H. Susceptibility.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like glycated haemoglobin and drug-eluting stents. Key takeaway: Breast Cancer Unmasks Latent P. A. H. Susceptibility.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41194754">Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41608826">Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41603037">Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41609518">GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41605248">T cells in acute and chronic myocarditis: from diagnosis to treatment.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/">https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41194754" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41194754</a></p>
<p><strong>Summary:</strong> The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.</p>
<h4>Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41608826" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41608826</a></p>
<p><strong>Summary:</strong> The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study&#8217;s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.</p>
<h4>Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41603037" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41603037</a></p>
<p><strong>Summary:</strong> M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.</p>
<h4>Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41609518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41609518</a></p>
<p><strong>Summary:</strong> L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomization to investigate the causal effects of glucagon-like peptide one receptor activation on heart failure risk. The findings suggested novel beneficial effects of G. L. P. minus 1 R agonists on heart failure risk that extend beyond their known impacts on glucose control and weight reduction. Glycated haemoglobin reduction served as a surrogate biomarker in this analysis, providing a new perspective on the mechanisms by which these agonists confer cardioprotection. The data therefore indicated that the cardiovascular benefits of G. L. P. minus 1 R agonists are likely multifactorial.</p>
<h4>Article 5: T cells in acute and chronic myocarditis: from diagnosis to treatment.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41605248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41605248</a></p>
<p><strong>Summary:</strong> This article elucidated the critical role of T cells in the pathogenesis of both acute and chronic myocarditis, providing insights from diagnosis to treatment. It highlighted the emergence of newer etiologies for myocarditis, including those linked to immune checkpoint inhibitors and chronic inflammatory and genetic diseases. The content underscored the evolving understanding of immune cell infiltration and cardiomyocyte damage in myocarditis. The findings informed comprehensive strategies for identifying T-cell mediated myocarditis and guiding targeted immunotherapies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.</p>
<p>Article number two. Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study. The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study&#8217;s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.</p>
<p>Article number three. Breast Cancer Reveals Latent B. M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.</p>
<p>Article number four. G. L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomization to investigate the causal effects of glucagon-like peptide one receptor activation on heart failure risk. The findings suggested novel beneficial effects of G. L. P. minus 1 R agonists on heart failure risk that extend beyond their known impacts on glucose control and weight reduction. Glycated haemoglobin reduction served as a surrogate biomarker in this analysis, providing a new perspective on the mechanisms by which these agonists confer cardioprotection. The data therefore indicated that the cardiovascular benefits of G. L. P. minus 1 R agonists are likely multifactorial.</p>
<p>Article number five. T cells in acute and chronic myocarditis: from diagnosis to treatment. This article elucidated the critical role of T cells in the pathogenesis of both acute and chronic myocarditis, providing insights from diagnosis to treatment. It highlighted the emergence of newer etiologies for myocarditis, including those linked to immune checkpoint inhibitors and chronic inflammatory and genetic diseases. The content underscored the evolving understanding of immune cell infiltration and cardiomyocyte damage in myocarditis. The findings informed comprehensive strategies for identifying T-cell mediated myocarditis and guiding targeted immunotherapies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>glycated haemoglobin, drug-eluting stents, coronary artery disease, cardiovascular risk, drug-coated balloon angioplasty, T cells, cardioprotection, tumor-suppressive functions, Mendelian randomization, B. M. P. R. 2 mutations, breast cancer, wearable-derived training load, glucagon-like peptide one receptor agonists, chronic myocarditis, genetic susceptibility, immune checkpoint inhibitors, de novo lesions, endurance athletes, coronary computed tomography angiography, percutaneous coronary intervention, coronary atherosclerosis, myocarditis, heart failure, acute myocarditis, pulmonary arterial hypertension.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/">Breast Cancer Unmasks Latent P. A. H. Susceptibility 01/29/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260129_210014.mp3" length="4295200" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like glycated haemoglobin and drug-eluting stents. Key takeaway: Breast Cancer Unmasks Latent P. A. H. Susceptibility.
Article Links:
Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. (Journal of the American College of Cardiology)
Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study. (Circulation)
Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension. (Circulation)
Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. (European heart journal)
Article 5: T cells in acute and chronic myocarditis: from diagnosis to treatment. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/
 Featured Articles
Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41194754
Summary: The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.
Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41608826
Summary: The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study&#8217;s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.
Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41603037
Summary: M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.
Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41609518
Summary: L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like glycated haemoglobin and drug-eluting stents. Key takeaway: Breast Cancer Unmasks Latent P. A. H. Susceptibility.
Article Links:
Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. (Journal of the American College of Cardiology)
Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study. (Circulation)
Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension. (Circulation)
Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. (European heart journal)
Article 5: T cells in acute and chronic myocarditis: from diagnosis to treatment. (European heart journal)
Full episode page: https://po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Tailoring Antiplatelets After P. C. I. for A. C. S. 01/29/26</title>
	<link>https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/</link>
	<pubDate>Thu, 29 Jan 2026 11:01:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like P2Y12 inhibitor monotherapy and public reporting. Key takeaway: Tailoring Antiplatelets After P. C. I. for A. C. S..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41603821">Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41603507">Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41384891">Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41295935">Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41194755">Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/">https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41603821" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41603821</a></p>
<p><strong>Summary:</strong> This study investigated the association between public reporting and potential risk avoidance in congenital heart surgery. Researchers evaluated changes in case selection and hospital performance, using predicted probability of mortality as a measure of case-mix complexity. The work addressed the critical need to understand both changes in case selection and patient outcomes after public reporting, particularly concerning the potential for risk avoidance in complex surgical fields.</p>
<h4>Article 2: Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41603507" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41603507</a></p>
<p><strong>Summary:</strong> C. I. Effectiveness in Stable C. A. D.: Secondary Analysis of O. R. B. I. T. A. -2. The O. R. B. I. T. A. -2 trial demonstrated the efficacy of percutaneous coronary intervention in patients with stable angina and coronary artery disease, even without background antianginal medication. This secondary analysis specifically examined whether this percutaneous coronary intervention effect is consistent across different age groups. It focused on the interaction between age and both symptom relief and stenosis improvement, addressing a knowledge gap regarding treatment consistency across demographics.</p>
<h4>Article 3: Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41384891" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41384891</a></p>
<p><strong>Summary:</strong> A. P. T. After P. C. I. in Patients With and Without S. T. E. M. I.: The N. E. O. -M. I. N. D. S. E. T. Substudy. This prespecified analysis from the N. E. O. -M. I. N. D. S. E. T. trial evaluated whether treatment effects of early aspirin discontinuation differ between S. T. -segment elevation myocardial infarction and non-S. T. -segment elevation acute coronary syndrome. The study compared potent P2Y12 inhibitor monotherapy with dual antiplatelet therapy after percutaneous coronary intervention. This research addressed how acute coronary syndrome presentation influences optimal antiplatelet strategies post-percutaneous coronary intervention.</p>
<h4>Article 4: Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41295935" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41295935</a></p>
<p><strong>Summary:</strong> C. I. After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. This randomized trial investigated the optimal timing for staged percutaneous coronary intervention after subintimal tracking and re-entry for chronic total occlusions. The study compared an earlier timeframe of five to seven weeks versus a later timeframe of twelve to fourteen weeks for staged stenting. This research addressed a crucial clinical question regarding the management of complex chronic total occlusion percutaneous coronary intervention.</p>
<h4>Article 5: Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41194755" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41194755</a></p>
<p><strong>Summary:</strong> C. I. for S. T. -Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. This randomized trial evaluated the effect of targeted, intracoronary low-dose recombinant tissue plasminogen activator (alteplase) in patients with S. T. -segment elevation myocardial infarction undergoing primary percutaneous coronary intervention and exhibiting a large thrombus burden. The study investigated whether this strategy improves microvascular obstruction without increasing systemic bleeding risk. This research addressed the clinical challenge of distal embolization and reduced myocardial tissue perfusion, which affects about half of S. T. E. M. I. patients receiving primary percutaneous coronary intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study. This study investigated the association between public reporting and potential risk avoidance in congenital heart surgery. Researchers evaluated changes in case selection and hospital performance, using predicted probability of mortality as a measure of case-mix complexity. The work addressed the critical need to understand both changes in case selection and patient outcomes after public reporting, particularly concerning the potential for risk avoidance in complex surgical fields.</p>
<p>Article number two. Association Between Age and P. C. I. Effectiveness in Stable C. A. D.: Secondary Analysis of O. R. B. I. T. A. -2. The O. R. B. I. T. A. -2 trial demonstrated the efficacy of percutaneous coronary intervention in patients with stable angina and coronary artery disease, even without background antianginal medication. This secondary analysis specifically examined whether this percutaneous coronary intervention effect is consistent across different age groups. It focused on the interaction between age and both symptom relief and stenosis improvement, addressing a knowledge gap regarding treatment consistency across demographics.</p>
<p>Article number three. Potent P2Y12 Inhibitor Monotherapy vs D. A. P. T. After P. C. I. in Patients With and Without S. T. E. M. I.: The N. E. O. -M. I. N. D. S. E. T. Substudy. This prespecified analysis from the N. E. O. -M. I. N. D. S. E. T. trial evaluated whether treatment effects of early aspirin discontinuation differ between S. T. -segment elevation myocardial infarction and non-S. T. -segment elevation acute coronary syndrome. The study compared potent P2Y12 inhibitor monotherapy with dual antiplatelet therapy after percutaneous coronary intervention. This research addressed how acute coronary syndrome presentation influences optimal antiplatelet strategies post-percutaneous coronary intervention.</p>
<p>Article number four. Early vs Late Staged P. C. I. After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. This randomized trial investigated the optimal timing for staged percutaneous coronary intervention after subintimal tracking and re-entry for chronic total occlusions. The study compared an earlier timeframe of five to seven weeks versus a later timeframe of twelve to fourteen weeks for staged stenting. This research addressed a crucial clinical question regarding the management of complex chronic total occlusion percutaneous coronary intervention.</p>
<p>Article number five. Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary P. C. I. for S. T. -Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. This randomized trial evaluated the effect of targeted, intracoronary low-dose recombinant tissue plasminogen activator (alteplase) in patients with S. T. -segment elevation myocardial infarction undergoing primary percutaneous coronary intervention and exhibiting a large thrombus burden. The study investigated whether this strategy improves microvascular obstruction without increasing systemic bleeding risk. This research addressed the clinical challenge of distal embolization and reduced myocardial tissue perfusion, which affects about half of S. T. E. M. I. patients receiving primary percutaneous coronary intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>P2Y12 inhibitor monotherapy, public reporting, hospital performance, dual antiplatelet therapy, recombinant tissue plasminogen activator, staged stenting, non-S. T. -segment elevation acute coronary syndrome, S. T. -segment elevation myocardial infarction, age, chronic total occlusion, alteplase, subintimal tracking and re-entry, stable angina, case mix complexity, primary percutaneous coronary intervention, coronary artery disease, microvascular obstruction, revascularization timing, percutaneous coronary intervention, risk avoidance, O. R. B. I. T. A. -2 trial, congenital heart surgery.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/">Tailoring Antiplatelets After P. C. I. for A. C. S. 01/29/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like P2Y12 inhibitor monotherapy and public reporting. Key takeaway: Tailoring Antiplatelets After P. C. I. for A. C. S..
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like P2Y12 inhibitor monotherapy and public reporting. Key takeaway: Tailoring Antiplatelets After P. C. I. for A. C. S..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41603821">Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41603507">Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41384891">Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41295935">Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41194755">Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/">https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41603821" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41603821</a></p>
<p><strong>Summary:</strong> This study investigated the association between public reporting and potential risk avoidance in congenital heart surgery. Researchers evaluated changes in case selection and hospital performance, using predicted probability of mortality as a measure of case-mix complexity. The work addressed the critical need to understand both changes in case selection and patient outcomes after public reporting, particularly concerning the potential for risk avoidance in complex surgical fields.</p>
<h4>Article 2: Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41603507" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41603507</a></p>
<p><strong>Summary:</strong> C. I. Effectiveness in Stable C. A. D.: Secondary Analysis of O. R. B. I. T. A. -2. The O. R. B. I. T. A. -2 trial demonstrated the efficacy of percutaneous coronary intervention in patients with stable angina and coronary artery disease, even without background antianginal medication. This secondary analysis specifically examined whether this percutaneous coronary intervention effect is consistent across different age groups. It focused on the interaction between age and both symptom relief and stenosis improvement, addressing a knowledge gap regarding treatment consistency across demographics.</p>
<h4>Article 3: Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41384891" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41384891</a></p>
<p><strong>Summary:</strong> A. P. T. After P. C. I. in Patients With and Without S. T. E. M. I.: The N. E. O. -M. I. N. D. S. E. T. Substudy. This prespecified analysis from the N. E. O. -M. I. N. D. S. E. T. trial evaluated whether treatment effects of early aspirin discontinuation differ between S. T. -segment elevation myocardial infarction and non-S. T. -segment elevation acute coronary syndrome. The study compared potent P2Y12 inhibitor monotherapy with dual antiplatelet therapy after percutaneous coronary intervention. This research addressed how acute coronary syndrome presentation influences optimal antiplatelet strategies post-percutaneous coronary intervention.</p>
<h4>Article 4: Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41295935" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41295935</a></p>
<p><strong>Summary:</strong> C. I. After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. This randomized trial investigated the optimal timing for staged percutaneous coronary intervention after subintimal tracking and re-entry for chronic total occlusions. The study compared an earlier timeframe of five to seven weeks versus a later timeframe of twelve to fourteen weeks for staged stenting. This research addressed a crucial clinical question regarding the management of complex chronic total occlusion percutaneous coronary intervention.</p>
<h4>Article 5: Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41194755" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41194755</a></p>
<p><strong>Summary:</strong> C. I. for S. T. -Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. This randomized trial evaluated the effect of targeted, intracoronary low-dose recombinant tissue plasminogen activator (alteplase) in patients with S. T. -segment elevation myocardial infarction undergoing primary percutaneous coronary intervention and exhibiting a large thrombus burden. The study investigated whether this strategy improves microvascular obstruction without increasing systemic bleeding risk. This research addressed the clinical challenge of distal embolization and reduced myocardial tissue perfusion, which affects about half of S. T. E. M. I. patients receiving primary percutaneous coronary intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study. This study investigated the association between public reporting and potential risk avoidance in congenital heart surgery. Researchers evaluated changes in case selection and hospital performance, using predicted probability of mortality as a measure of case-mix complexity. The work addressed the critical need to understand both changes in case selection and patient outcomes after public reporting, particularly concerning the potential for risk avoidance in complex surgical fields.</p>
<p>Article number two. Association Between Age and P. C. I. Effectiveness in Stable C. A. D.: Secondary Analysis of O. R. B. I. T. A. -2. The O. R. B. I. T. A. -2 trial demonstrated the efficacy of percutaneous coronary intervention in patients with stable angina and coronary artery disease, even without background antianginal medication. This secondary analysis specifically examined whether this percutaneous coronary intervention effect is consistent across different age groups. It focused on the interaction between age and both symptom relief and stenosis improvement, addressing a knowledge gap regarding treatment consistency across demographics.</p>
<p>Article number three. Potent P2Y12 Inhibitor Monotherapy vs D. A. P. T. After P. C. I. in Patients With and Without S. T. E. M. I.: The N. E. O. -M. I. N. D. S. E. T. Substudy. This prespecified analysis from the N. E. O. -M. I. N. D. S. E. T. trial evaluated whether treatment effects of early aspirin discontinuation differ between S. T. -segment elevation myocardial infarction and non-S. T. -segment elevation acute coronary syndrome. The study compared potent P2Y12 inhibitor monotherapy with dual antiplatelet therapy after percutaneous coronary intervention. This research addressed how acute coronary syndrome presentation influences optimal antiplatelet strategies post-percutaneous coronary intervention.</p>
<p>Article number four. Early vs Late Staged P. C. I. After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. This randomized trial investigated the optimal timing for staged percutaneous coronary intervention after subintimal tracking and re-entry for chronic total occlusions. The study compared an earlier timeframe of five to seven weeks versus a later timeframe of twelve to fourteen weeks for staged stenting. This research addressed a crucial clinical question regarding the management of complex chronic total occlusion percutaneous coronary intervention.</p>
<p>Article number five. Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary P. C. I. for S. T. -Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. This randomized trial evaluated the effect of targeted, intracoronary low-dose recombinant tissue plasminogen activator (alteplase) in patients with S. T. -segment elevation myocardial infarction undergoing primary percutaneous coronary intervention and exhibiting a large thrombus burden. The study investigated whether this strategy improves microvascular obstruction without increasing systemic bleeding risk. This research addressed the clinical challenge of distal embolization and reduced myocardial tissue perfusion, which affects about half of S. T. E. M. I. patients receiving primary percutaneous coronary intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>P2Y12 inhibitor monotherapy, public reporting, hospital performance, dual antiplatelet therapy, recombinant tissue plasminogen activator, staged stenting, non-S. T. -segment elevation acute coronary syndrome, S. T. -segment elevation myocardial infarction, age, chronic total occlusion, alteplase, subintimal tracking and re-entry, stable angina, case mix complexity, primary percutaneous coronary intervention, coronary artery disease, microvascular obstruction, revascularization timing, percutaneous coronary intervention, risk avoidance, O. R. B. I. T. A. -2 trial, congenital heart surgery.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/">Tailoring Antiplatelets After P. C. I. for A. C. S. 01/29/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260129_060029.mp3" length="4149750" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like P2Y12 inhibitor monotherapy and public reporting. Key takeaway: Tailoring Antiplatelets After P. C. I. for A. C. S..
Article Links:
Article 1: Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study. (Journal of the American College of Cardiology)
Article 2: Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2. (Journal of the American College of Cardiology)
Article 3: Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. (Journal of the American College of Cardiology)
Article 4: Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. (Journal of the American College of Cardiology)
Article 5: Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/tailoring-antiplatelets-after-p-c-i-for-a-c-s-01-29-26/
 Featured Articles
Article 1: Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41603821
Summary: This study investigated the association between public reporting and potential risk avoidance in congenital heart surgery. Researchers evaluated changes in case selection and hospital performance, using predicted probability of mortality as a measure of case-mix complexity. The work addressed the critical need to understand both changes in case selection and patient outcomes after public reporting, particularly concerning the potential for risk avoidance in complex surgical fields.
Article 2: Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41603507
Summary: C. I. Effectiveness in Stable C. A. D.: Secondary Analysis of O. R. B. I. T. A. -2. The O. R. B. I. T. A. -2 trial demonstrated the efficacy of percutaneous coronary intervention in patients with stable angina and coronary artery disease, even without background antianginal medication. This secondary analysis specifically examined whether this percutaneous coronary intervention effect is consistent across different age groups. It focused on the interaction between age and both symptom relief and stenosis improvement, addressing a knowledge gap regarding treatment consistency across demographics.
Article 3: Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41384891
Summary: A. P. T. After P. C. I. in Patients With and Without S. T. E. M. I.: The N. E. O. -M. I. N. D. S. E. T. Substudy. This prespecified analysis from the N. E. O. -M. I. N. D. S. E. T. trial evaluated whether treatment effects of early aspirin discontinuation differ between S. T. -segment elevation myocardial infarction and non-S. T. -segment elevation acute coronary syndrome. The study compared potent P2Y12 inhibitor monotherapy with dual antiplatelet therapy after percutaneous coronary intervention. This research addressed how acute coronary syndrome presentation influences optimal antiplatelet strategies post-percutaneous coronary intervention.
Article 4: Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41295935
Summary: C. I. After Sub]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like P2Y12 inhibitor monotherapy and public reporting. Key takeaway: Tailoring Antiplatelets After P. C. I. for A. C. S..
Article Links:
Article 1: Public Reporting and Case Selection in Congenital Heart Surgery: Signals From a Multicenter Observational Study. (Journal of the American College of Cardiology)
Article 2: Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2. (Journal of the American College of Cardiology)
Article 3: Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. (Journal of the American College of Cardiology)
Article 4: Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial. (Journal of the American College of Cardiology)
Article 5: Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Echocardiogram Predicts Pediatric E C M O Weaning 01/28/26</title>
	<link>https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/</link>
	<pubDate>Wed, 28 Jan 2026 11:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 28, 2026. This episode summarizes 4 key cardiology studies on topics like Medicare beneficiaries and ozone. Key takeaway: Echocardiogram Predicts Pediatric E C M O Weaning.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41581126">Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults.</a> (American journal of hypertension)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41582861">Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants.</a> (Cardiology in the young)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41582852">Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock.</a> (Cardiology in the young)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41582772">Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants.</a> (Cardiology in the young)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/">https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581126" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581126</a></p>
<p><strong>Summary:</strong> The study found widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older United States adults. Analysis of a 20 percent random sample of Medicare beneficiaries aged 65 years and older with a hypertension diagnosis revealed that most patients remained on their initial treatment. This persistence on initial therapy occurred even when their blood pressure remained high, highlighting a significant challenge in effective blood pressure management for this population. The findings suggest a need to re-evaluate initial prescribing practices to improve patient outcomes.</p>
<h4>Article 2: Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582861</a></p>
<p><strong>Summary:</strong> This retrospective study spatially analyzed critical congenital heart diseases in relation to selected air pollutants, focusing on geographic patterns. Researchers investigated 1484 infants who underwent complex cardiac surgery between 1996 and 2021. The study examined the association between critical congenital heart disease categories and maternal exposure levels during early pregnancy to nitrogen dioxide, ozone, and fine particulate matter. This work highlights the importance of environmental factors in understanding the incidence and distribution of congenital heart disease.</p>
<h4>Article 3: Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582852</a></p>
<p><strong>Summary:</strong> The study identified echocardiographic predictors for successful weaning from extracorporeal membrane oxygenation in pediatric and congenital heart disease patients experiencing cardiogenic shock. Researchers retrospectively analyzed patients who underwent venoarterial extracorporeal membrane oxygenation between March 2018 and September 2023. The comparison of clinical and echocardiographic variables at the time of weaning evaluation revealed key indicators differentiating successful from unsuccessful weaning. These findings offer crucial guidance for optimizing clinical decision-making during extracorporeal membrane oxygenation discontinuation.</p>
<h4>Article 4: Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582772" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582772</a></p>
<p><strong>Summary:</strong> The study found that patent ductus arteriosus status and treatment response significantly altered myocardial adaptation in preterm infants. This prospective cohort study compared serial echocardiographic trajectories across three distinct groups: high-risk infants with successful patent ductus arteriosus treatment, high-risk infants with treatment failure, and low-risk infants not requiring treatment. Preterm infants born at less than 29 weeks&#8217; gestation were stratified using the El-Khuffash Patent Ductus Arteriosus Severity Score and their subsequent clinical response. The findings revealed specific patterns of myocardial adaptation linked to patent ductus arteriosus status and treatment outcomes, underscoring its impact on cardiac development.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults. The study found widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older United States adults. Analysis of a 20 percent random sample of Medicare beneficiaries aged 65 years and older with a hypertension diagnosis revealed that most patients remained on their initial treatment. This persistence on initial therapy occurred even when their blood pressure remained high, highlighting a significant challenge in effective blood pressure management for this population. The findings suggest a need to re-evaluate initial prescribing practices to improve patient outcomes.</p>
<p>Article number two. Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants. This retrospective study spatially analyzed critical congenital heart diseases in relation to selected air pollutants, focusing on geographic patterns. Researchers investigated 1484 infants who underwent complex cardiac surgery between 1996 and 2021. The study examined the association between critical congenital heart disease categories and maternal exposure levels during early pregnancy to nitrogen dioxide, ozone, and fine particulate matter. This work highlights the importance of environmental factors in understanding the incidence and distribution of congenital heart disease.</p>
<p>Article number three. Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock. The study identified echocardiographic predictors for successful weaning from extracorporeal membrane oxygenation in pediatric and congenital heart disease patients experiencing cardiogenic shock. Researchers retrospectively analyzed patients who underwent venoarterial extracorporeal membrane oxygenation between March 2018 and September 2023. The comparison of clinical and echocardiographic variables at the time of weaning evaluation revealed key indicators differentiating successful from unsuccessful weaning. These findings offer crucial guidance for optimizing clinical decision-making during extracorporeal membrane oxygenation discontinuation.</p>
<p>Article number four. Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants. The study found that patent ductus arteriosus status and treatment response significantly altered myocardial adaptation in preterm infants. This prospective cohort study compared serial echocardiographic trajectories across three distinct groups: high-risk infants with successful patent ductus arteriosus treatment, high-risk infants with treatment failure, and low-risk infants not requiring treatment. Preterm infants born at less than 29 weeks&#8217; gestation were stratified using the El-Khuffash Patent Ductus Arteriosus Severity Score and their subsequent clinical response. The findings revealed specific patterns of myocardial adaptation linked to patent ductus arteriosus status and treatment outcomes, underscoring its impact on cardiac development. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Medicare beneficiaries, ozone, patent ductus arteriosus, pediatric cardiology, neonatal cardiology, nitrogen dioxide, cardiogenic shock, myocardial adaptation, older adults, hypertension, environmental factors, preterm infants, blood pressure management, antihypertensive regimens, extracorporeal membrane oxygenation, congenital heart disease, echocardiography, air pollutants.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/">Echocardiogram Predicts Pediatric E C M O Weaning 01/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 28, 2026. This episode summarizes 4 key cardiology studies on topics like Medicare beneficiaries and ozone. Key takeaway: Echocardiogram Predicts Pediatric E C M O Weaning.
Article Links:
Article 1: Widespre]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 28, 2026. This episode summarizes 4 key cardiology studies on topics like Medicare beneficiaries and ozone. Key takeaway: Echocardiogram Predicts Pediatric E C M O Weaning.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41581126">Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults.</a> (American journal of hypertension)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41582861">Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants.</a> (Cardiology in the young)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41582852">Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock.</a> (Cardiology in the young)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41582772">Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants.</a> (Cardiology in the young)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/">https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581126" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581126</a></p>
<p><strong>Summary:</strong> The study found widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older United States adults. Analysis of a 20 percent random sample of Medicare beneficiaries aged 65 years and older with a hypertension diagnosis revealed that most patients remained on their initial treatment. This persistence on initial therapy occurred even when their blood pressure remained high, highlighting a significant challenge in effective blood pressure management for this population. The findings suggest a need to re-evaluate initial prescribing practices to improve patient outcomes.</p>
<h4>Article 2: Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582861</a></p>
<p><strong>Summary:</strong> This retrospective study spatially analyzed critical congenital heart diseases in relation to selected air pollutants, focusing on geographic patterns. Researchers investigated 1484 infants who underwent complex cardiac surgery between 1996 and 2021. The study examined the association between critical congenital heart disease categories and maternal exposure levels during early pregnancy to nitrogen dioxide, ozone, and fine particulate matter. This work highlights the importance of environmental factors in understanding the incidence and distribution of congenital heart disease.</p>
<h4>Article 3: Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582852</a></p>
<p><strong>Summary:</strong> The study identified echocardiographic predictors for successful weaning from extracorporeal membrane oxygenation in pediatric and congenital heart disease patients experiencing cardiogenic shock. Researchers retrospectively analyzed patients who underwent venoarterial extracorporeal membrane oxygenation between March 2018 and September 2023. The comparison of clinical and echocardiographic variables at the time of weaning evaluation revealed key indicators differentiating successful from unsuccessful weaning. These findings offer crucial guidance for optimizing clinical decision-making during extracorporeal membrane oxygenation discontinuation.</p>
<h4>Article 4: Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582772" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582772</a></p>
<p><strong>Summary:</strong> The study found that patent ductus arteriosus status and treatment response significantly altered myocardial adaptation in preterm infants. This prospective cohort study compared serial echocardiographic trajectories across three distinct groups: high-risk infants with successful patent ductus arteriosus treatment, high-risk infants with treatment failure, and low-risk infants not requiring treatment. Preterm infants born at less than 29 weeks&#8217; gestation were stratified using the El-Khuffash Patent Ductus Arteriosus Severity Score and their subsequent clinical response. The findings revealed specific patterns of myocardial adaptation linked to patent ductus arteriosus status and treatment outcomes, underscoring its impact on cardiac development.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults. The study found widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older United States adults. Analysis of a 20 percent random sample of Medicare beneficiaries aged 65 years and older with a hypertension diagnosis revealed that most patients remained on their initial treatment. This persistence on initial therapy occurred even when their blood pressure remained high, highlighting a significant challenge in effective blood pressure management for this population. The findings suggest a need to re-evaluate initial prescribing practices to improve patient outcomes.</p>
<p>Article number two. Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants. This retrospective study spatially analyzed critical congenital heart diseases in relation to selected air pollutants, focusing on geographic patterns. Researchers investigated 1484 infants who underwent complex cardiac surgery between 1996 and 2021. The study examined the association between critical congenital heart disease categories and maternal exposure levels during early pregnancy to nitrogen dioxide, ozone, and fine particulate matter. This work highlights the importance of environmental factors in understanding the incidence and distribution of congenital heart disease.</p>
<p>Article number three. Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock. The study identified echocardiographic predictors for successful weaning from extracorporeal membrane oxygenation in pediatric and congenital heart disease patients experiencing cardiogenic shock. Researchers retrospectively analyzed patients who underwent venoarterial extracorporeal membrane oxygenation between March 2018 and September 2023. The comparison of clinical and echocardiographic variables at the time of weaning evaluation revealed key indicators differentiating successful from unsuccessful weaning. These findings offer crucial guidance for optimizing clinical decision-making during extracorporeal membrane oxygenation discontinuation.</p>
<p>Article number four. Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants. The study found that patent ductus arteriosus status and treatment response significantly altered myocardial adaptation in preterm infants. This prospective cohort study compared serial echocardiographic trajectories across three distinct groups: high-risk infants with successful patent ductus arteriosus treatment, high-risk infants with treatment failure, and low-risk infants not requiring treatment. Preterm infants born at less than 29 weeks&#8217; gestation were stratified using the El-Khuffash Patent Ductus Arteriosus Severity Score and their subsequent clinical response. The findings revealed specific patterns of myocardial adaptation linked to patent ductus arteriosus status and treatment outcomes, underscoring its impact on cardiac development. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Medicare beneficiaries, ozone, patent ductus arteriosus, pediatric cardiology, neonatal cardiology, nitrogen dioxide, cardiogenic shock, myocardial adaptation, older adults, hypertension, environmental factors, preterm infants, blood pressure management, antihypertensive regimens, extracorporeal membrane oxygenation, congenital heart disease, echocardiography, air pollutants.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/">Echocardiogram Predicts Pediatric E C M O Weaning 01/28/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260128_060033.mp3" length="3758541" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 28, 2026. This episode summarizes 4 key cardiology studies on topics like Medicare beneficiaries and ozone. Key takeaway: Echocardiogram Predicts Pediatric E C M O Weaning.
Article Links:
Article 1: Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults. (American journal of hypertension)
Article 2: Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants. (Cardiology in the young)
Article 3: Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock. (Cardiology in the young)
Article 4: Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants. (Cardiology in the young)
Full episode page: https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/
 Featured Articles
Article 1: Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults.
Journal: American journal of hypertension
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41581126
Summary: The study found widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older United States adults. Analysis of a 20 percent random sample of Medicare beneficiaries aged 65 years and older with a hypertension diagnosis revealed that most patients remained on their initial treatment. This persistence on initial therapy occurred even when their blood pressure remained high, highlighting a significant challenge in effective blood pressure management for this population. The findings suggest a need to re-evaluate initial prescribing practices to improve patient outcomes.
Article 2: Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants.
Journal: Cardiology in the young
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582861
Summary: This retrospective study spatially analyzed critical congenital heart diseases in relation to selected air pollutants, focusing on geographic patterns. Researchers investigated 1484 infants who underwent complex cardiac surgery between 1996 and 2021. The study examined the association between critical congenital heart disease categories and maternal exposure levels during early pregnancy to nitrogen dioxide, ozone, and fine particulate matter. This work highlights the importance of environmental factors in understanding the incidence and distribution of congenital heart disease.
Article 3: Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock.
Journal: Cardiology in the young
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582852
Summary: The study identified echocardiographic predictors for successful weaning from extracorporeal membrane oxygenation in pediatric and congenital heart disease patients experiencing cardiogenic shock. Researchers retrospectively analyzed patients who underwent venoarterial extracorporeal membrane oxygenation between March 2018 and September 2023. The comparison of clinical and echocardiographic variables at the time of weaning evaluation revealed key indicators differentiating successful from unsuccessful weaning. These findings offer crucial guidance for optimizing clinical decision-making during extracorporeal membrane oxygenation discontinuation.
Article 4: Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants.
Journal: Cardiology in the young
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582772
Summary: The study found that patent ductus arteriosus status and treatment response significantly altered myocardial adaptation in preterm infants. This prospective cohort study compared serial echocardiographic trajectories across three distinct groups: high-]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 28, 2026. This episode summarizes 4 key cardiology studies on topics like Medicare beneficiaries and ozone. Key takeaway: Echocardiogram Predicts Pediatric E C M O Weaning.
Article Links:
Article 1: Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults. (American journal of hypertension)
Article 2: Geographic patterns in critical CHDs: a spatial analysis of selected air pollutants. (Cardiology in the young)
Article 3: Echocardiographic predictors of successful weaning from extracorporeal membrane oxygenation in paediatric and CHD patients with cardiogenic shock. (Cardiology in the young)
Article 4: Patent ductus arteriosus status and treatment response alters myocardial adaptation in preterm infants. (Cardiology in the young)
Full episode page: https://podcast.explainheart.com/podcast/echocardiogram-predicts-pediatric-e-c-m-o-weaning-01-28-26/
 Featured Articles
Article 1:]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy. 01/27/26</title>
	<link>https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/</link>
	<pubDate>Tue, 27 Jan 2026 11:01:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 27, 2026. This episode summarizes 5 key cardiology studies on topics like inherited arrhythmias and healthcare costs. Key takeaway: Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41582809">Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41582820">Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41582811">Seated Saline Suppression Test for Lateralizing Primary Aldosteronism.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41582807">Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41582809">Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/">https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582809" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582809</a></p>
<p><strong>Summary:</strong> This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.</p>
<h4>Article 2: Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582820" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582820</a></p>
<p><strong>Summary:</strong> This modeling study projected the potential impact of the 2024 United Kingdom salt reduction targets on cardiovascular health outcomes and health care costs in adults. The analysis found that meeting these targets could significantly improve population cardiovascular health. The reductions in sodium intake were projected to also lead to substantial savings in healthcare expenditures for United Kingdom adults. The study highlights the positive public health implications of such voluntary salt reduction programs.</p>
<h4>Article 3: Seated Saline Suppression Test for Lateralizing Primary Aldosteronism.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582811" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582811</a></p>
<p><strong>Summary:</strong> This blinded clinical trial identified the diagnostic accuracy of the Seated Saline Suppression Test for lateralizing primary aldosteronism. The study found the test accurately identified lateralization, defined by an aldosterone-to-cortisol ratio of 3:1 or greater during adrenal vein sampling. This finding provides crucial clarity on confirmatory testing for primary aldosteronism, addressing previous uncertainty regarding its benefit in identifying lateralizing disease. The Seated Saline Suppression Test offered a precise approach for patients presenting with high-risk features.</p>
<h4>Article 4: Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582807</a></p>
<p><strong>Summary:</strong> This study found that the phenotypic severity of sodium voltage gated channel alpha subunit 5 A-related bradycardia is independent of dominant-negative and coupled gating effects. Pathogenic SCN5A variants are associated with inherited arrhythmias such as long Q. T. syndrome, Brugada syndrome, and sick sinus syndrome. Results showed a reduction of sodium current in wild-type NaV1.5 can be caused by dimerization with loss-of-function mutated NaV1.5 through dominant-negative effects. This clarifies the mechanisms underlying SCN5A-related bradycardia, demonstrating its severity is not dictated by these specific molecular interactions.</p>
<h4>Article 5: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582809" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582809</a></p>
<p><strong>Summary:</strong> This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 27, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.</p>
<p>Article number two. Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study. This modeling study projected the potential impact of the 2024 United Kingdom salt reduction targets on cardiovascular health outcomes and health care costs in adults. The analysis found that meeting these targets could significantly improve population cardiovascular health. The reductions in sodium intake were projected to also lead to substantial savings in healthcare expenditures for United Kingdom adults. The study highlights the positive public health implications of such voluntary salt reduction programs.</p>
<p>Article number three. Seated Saline Suppression Test for Lateralizing Primary Aldosteronism. This blinded clinical trial identified the diagnostic accuracy of the Seated Saline Suppression Test for lateralizing primary aldosteronism. The study found the test accurately identified lateralization, defined by an aldosterone-to-cortisol ratio of 3:1 or greater during adrenal vein sampling. This finding provides crucial clarity on confirmatory testing for primary aldosteronism, addressing previous uncertainty regarding its benefit in identifying lateralizing disease. The Seated Saline Suppression Test offered a precise approach for patients presenting with high-risk features.</p>
<p>Article number four. Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects. This study found that the phenotypic severity of sodium voltage gated channel alpha subunit 5 A-related bradycardia is independent of dominant-negative and coupled gating effects. Pathogenic SCN5A variants are associated with inherited arrhythmias such as long Q. T. syndrome, Brugada syndrome, and sick sinus syndrome. Results showed a reduction of sodium current in wild-type NaV1.5 can be caused by dimerization with loss-of-function mutated NaV1.5 through dominant-negative effects. This clarifies the mechanisms underlying SCN5A-related bradycardia, demonstrating its severity is not dictated by these specific molecular interactions.</p>
<p>Article number five. Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>inherited arrhythmias, healthcare costs, salt reduction, adrenal vein sampling, cardiac sodium channel, lateralization, dominant-negative effects, Arrhythmogenic Cardiomyopathy, sodium intake, bradycardia, ventricular arrhythmias, cardiovascular health, Connexin-43, public health, desmosomal genes, diagnostic accuracy, Seated Saline Suppression Test, primary aldosteronism, heart failure, SCN5A variants.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/">Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy. 01/27/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 27, 2026. This episode summarizes 5 key cardiology studies on topics like inherited arrhythmias and healthcare costs. Key takeaway: Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy..
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 27, 2026. This episode summarizes 5 key cardiology studies on topics like inherited arrhythmias and healthcare costs. Key takeaway: Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41582809">Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41582820">Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41582811">Seated Saline Suppression Test for Lateralizing Primary Aldosteronism.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41582807">Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41582809">Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/">https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582809" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582809</a></p>
<p><strong>Summary:</strong> This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.</p>
<h4>Article 2: Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582820" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582820</a></p>
<p><strong>Summary:</strong> This modeling study projected the potential impact of the 2024 United Kingdom salt reduction targets on cardiovascular health outcomes and health care costs in adults. The analysis found that meeting these targets could significantly improve population cardiovascular health. The reductions in sodium intake were projected to also lead to substantial savings in healthcare expenditures for United Kingdom adults. The study highlights the positive public health implications of such voluntary salt reduction programs.</p>
<h4>Article 3: Seated Saline Suppression Test for Lateralizing Primary Aldosteronism.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582811" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582811</a></p>
<p><strong>Summary:</strong> This blinded clinical trial identified the diagnostic accuracy of the Seated Saline Suppression Test for lateralizing primary aldosteronism. The study found the test accurately identified lateralization, defined by an aldosterone-to-cortisol ratio of 3:1 or greater during adrenal vein sampling. This finding provides crucial clarity on confirmatory testing for primary aldosteronism, addressing previous uncertainty regarding its benefit in identifying lateralizing disease. The Seated Saline Suppression Test offered a precise approach for patients presenting with high-risk features.</p>
<h4>Article 4: Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582807</a></p>
<p><strong>Summary:</strong> This study found that the phenotypic severity of sodium voltage gated channel alpha subunit 5 A-related bradycardia is independent of dominant-negative and coupled gating effects. Pathogenic SCN5A variants are associated with inherited arrhythmias such as long Q. T. syndrome, Brugada syndrome, and sick sinus syndrome. Results showed a reduction of sodium current in wild-type NaV1.5 can be caused by dimerization with loss-of-function mutated NaV1.5 through dominant-negative effects. This clarifies the mechanisms underlying SCN5A-related bradycardia, demonstrating its severity is not dictated by these specific molecular interactions.</p>
<h4>Article 5: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41582809" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41582809</a></p>
<p><strong>Summary:</strong> This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 27, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.</p>
<p>Article number two. Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study. This modeling study projected the potential impact of the 2024 United Kingdom salt reduction targets on cardiovascular health outcomes and health care costs in adults. The analysis found that meeting these targets could significantly improve population cardiovascular health. The reductions in sodium intake were projected to also lead to substantial savings in healthcare expenditures for United Kingdom adults. The study highlights the positive public health implications of such voluntary salt reduction programs.</p>
<p>Article number three. Seated Saline Suppression Test for Lateralizing Primary Aldosteronism. This blinded clinical trial identified the diagnostic accuracy of the Seated Saline Suppression Test for lateralizing primary aldosteronism. The study found the test accurately identified lateralization, defined by an aldosterone-to-cortisol ratio of 3:1 or greater during adrenal vein sampling. This finding provides crucial clarity on confirmatory testing for primary aldosteronism, addressing previous uncertainty regarding its benefit in identifying lateralizing disease. The Seated Saline Suppression Test offered a precise approach for patients presenting with high-risk features.</p>
<p>Article number four. Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects. This study found that the phenotypic severity of sodium voltage gated channel alpha subunit 5 A-related bradycardia is independent of dominant-negative and coupled gating effects. Pathogenic SCN5A variants are associated with inherited arrhythmias such as long Q. T. syndrome, Brugada syndrome, and sick sinus syndrome. Results showed a reduction of sodium current in wild-type NaV1.5 can be caused by dimerization with loss-of-function mutated NaV1.5 through dominant-negative effects. This clarifies the mechanisms underlying SCN5A-related bradycardia, demonstrating its severity is not dictated by these specific molecular interactions.</p>
<p>Article number five. Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>inherited arrhythmias, healthcare costs, salt reduction, adrenal vein sampling, cardiac sodium channel, lateralization, dominant-negative effects, Arrhythmogenic Cardiomyopathy, sodium intake, bradycardia, ventricular arrhythmias, cardiovascular health, Connexin-43, public health, desmosomal genes, diagnostic accuracy, Seated Saline Suppression Test, primary aldosteronism, heart failure, SCN5A variants.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/">Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy. 01/27/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260127_060034.mp3" length="3977551" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 27, 2026. This episode summarizes 5 key cardiology studies on topics like inherited arrhythmias and healthcare costs. Key takeaway: Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy..
Article Links:
Article 1: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. (Circulation. Heart failure)
Article 2: Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study. (Hypertension (Dallas, Tex. : 1979))
Article 3: Seated Saline Suppression Test for Lateralizing Primary Aldosteronism. (Hypertension (Dallas, Tex. : 1979))
Article 4: Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects. (Circulation. Arrhythmia and electrophysiology)
Article 5: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/connexin-43-alleviates-arrhythmogenic-cardiomyopathy-01-27-26/
 Featured Articles
Article 1: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582809
Summary: This study found that restoration of Connexin-43 alleviated desmosomal arrhythmogenic cardiomyopathy. Arrhythmogenic cardiomyopathy is a fatal genetic heart disease characterized by impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. This finding demonstrates a potential mutation-agnostic therapeutic intervention for this severe and genetically broad patient population. This approach addresses dysregulated pathways across various desmosomal mutations.
Article 2: Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582820
Summary: This modeling study projected the potential impact of the 2024 United Kingdom salt reduction targets on cardiovascular health outcomes and health care costs in adults. The analysis found that meeting these targets could significantly improve population cardiovascular health. The reductions in sodium intake were projected to also lead to substantial savings in healthcare expenditures for United Kingdom adults. The study highlights the positive public health implications of such voluntary salt reduction programs.
Article 3: Seated Saline Suppression Test for Lateralizing Primary Aldosteronism.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582811
Summary: This blinded clinical trial identified the diagnostic accuracy of the Seated Saline Suppression Test for lateralizing primary aldosteronism. The study found the test accurately identified lateralization, defined by an aldosterone-to-cortisol ratio of 3:1 or greater during adrenal vein sampling. This finding provides crucial clarity on confirmatory testing for primary aldosteronism, addressing previous uncertainty regarding its benefit in identifying lateralizing disease. The Seated Saline Suppression Test offered a precise approach for patients presenting with high-risk features.
Article 4: Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects.
Journal: Circulation. Arrhythmia and electrophysiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41582807
Summary: This study found that the phenotypic severity of sodium voltage gated channel alpha subunit 5 A-related bradycardia is independent of dominant-negative and coupled gating effects. Pathogenic SCN5A variants are associated with inherited arrhythmias such as long Q. T. syndrome, Brugada syndrome, and sick sinus syndrome. Results showed a reduction of sodium current in wild-type NaV1.5 can be caus]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 27, 2026. This episode summarizes 5 key cardiology studies on topics like inherited arrhythmias and healthcare costs. Key takeaway: Connexin-43 Alleviates Arrhythmogenic Cardiomyopathy..
Article Links:
Article 1: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. (Circulation. Heart failure)
Article 2: Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study. (Hypertension (Dallas, Tex. : 1979))
Article 3: Seated Saline Suppression Test for Lateralizing Primary Aldosteronism. (Hypertension (Dallas, Tex. : 1979))
Article 4: Phenotypic Severity of SCN5A-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects. (Circulation. Arrhythmia and electrophysiology)
Article 5: Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. (Circulation. Heart failure)
Full episode page: htt]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>S-Wave Loss Predicts Pulsed Field Ablation Durability 01/26/26</title>
	<link>https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/</link>
	<pubDate>Mon, 26 Jan 2026 11:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 26, 2026. This episode summarizes 5 key cardiology studies on topics like S-wave loss and incident arrhythmia. Key takeaway: S-Wave Loss Predicts Pulsed Field Ablation Durability.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41572446">Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation.</a> (Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41581668">LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41581852">Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41581850">Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41581848">Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/">https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41572446" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41572446</a></p>
<p><strong>Summary:</strong> Mitochondrial dysfunction is a recognized contributor to cardiac pathology and influences myocardial recovery after heart transplantation. This prospective single-center study involved 45 adult heart transplant recipients. It characterized the changes in cardiac mitochondrial function directly in human myocardial tissue during the early post-transplant period. Understanding these dynamics is crucial for optimizing cardiac recovery and metabolic status.</p>
<h4>Article 2: LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581668" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581668</a></p>
<p><strong>Summary:</strong> Thoraco-abdominal normothermic regional perfusion is an emerging strategy for heart recovery in controlled donation after circulatory death donors. However, its impact on lung graft retrieval is debated, particularly with prolonged durations. In Italy, a mandatory 20-minute stand-off period results in uniquely prolonged thoraco-abdominal normothermic regional perfusion for heart assessment during combined heart-lung procurement. This Italian nationwide experience provides crucial clinical data on lung transplant outcomes following this specific prolonged perfusion strategy.</p>
<h4>Article 3: Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581852</a></p>
<p><strong>Summary:</strong> The incidence of atrial fibrillation in patients aged 18-50 years has increased, yet clinical data for this population is limited. This study characterized the clinical features, treatment patterns, and risk of ischemic stroke in hospitalized young atrial fibrillation patients between 2014 and 2023. Through Cox regression analysis, researchers identified specific risk factors for major adverse cardiac and cerebrovascular events and new-onset ischemic stroke in this cohort. This investigation provides crucial data on the unique clinical presentation and specific risks faced by younger individuals with atrial fibrillation.</p>
<h4>Article 4: Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581850</a></p>
<p><strong>Summary:</strong> Secundum atrial septal defect is associated with substantial morbidity, especially arrhythmias, despite being a simple defect. This Danish nationwide cohort study, spanning from 1977 to 2024, included all diagnosed secundum atrial septal defect patients. The study systematically assessed the risk of both incident and recurrent arrhythmias in relation to atrial septal defect closure status and the timing of intervention. This extensive analysis generated definitive data on the long-term arrhythmic burden after secundum atrial septal defect closure.</p>
<h4>Article 5: Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581848" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581848</a></p>
<p><strong>Summary:</strong> Unipolar electrograms show utility in assessing lesion durability during pulsed field ablation. This study investigated voltages associated with unipolar electrogram changes after pulsed field ablation and evaluated their predictive value for lesion durability. In one group of 10 patients, areas exhibiting a loss of S-wave on unipolar electrograms correlated with core lesion formation. The findings indicate that serial unipolar and bipolar voltage mapping provides objective evidence for lesion creation and durability during pulsed field ablation procedures.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 26, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation. Mitochondrial dysfunction is a recognized contributor to cardiac pathology and influences myocardial recovery after heart transplantation. This prospective single-center study involved 45 adult heart transplant recipients. It characterized the changes in cardiac mitochondrial function directly in human myocardial tissue during the early post-transplant period. Understanding these dynamics is crucial for optimizing cardiac recovery and metabolic status.</p>
<p>Article number two. LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY. Thoraco-abdominal normothermic regional perfusion is an emerging strategy for heart recovery in controlled donation after circulatory death donors. However, its impact on lung graft retrieval is debated, particularly with prolonged durations. In Italy, a mandatory 20-minute stand-off period results in uniquely prolonged thoraco-abdominal normothermic regional perfusion for heart assessment during combined heart-lung procurement. This Italian nationwide experience provides crucial clinical data on lung transplant outcomes following this specific prolonged perfusion strategy.</p>
<p>Article number three. Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes. The incidence of atrial fibrillation in patients aged 18-50 years has increased, yet clinical data for this population is limited. This study characterized the clinical features, treatment patterns, and risk of ischemic stroke in hospitalized young atrial fibrillation patients between 2014 and 2023. Through Cox regression analysis, researchers identified specific risk factors for major adverse cardiac and cerebrovascular events and new-onset ischemic stroke in this cohort. This investigation provides crucial data on the unique clinical presentation and specific risks faced by younger individuals with atrial fibrillation.</p>
<p>Article number four. Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia. Secundum atrial septal defect is associated with substantial morbidity, especially arrhythmias, despite being a simple defect. This Danish nationwide cohort study, spanning from 1977 to 2024, included all diagnosed secundum atrial septal defect patients. The study systematically assessed the risk of both incident and recurrent arrhythmias in relation to atrial septal defect closure status and the timing of intervention. This extensive analysis generated definitive data on the long-term arrhythmic burden after secundum atrial septal defect closure.</p>
<p>Article number five. Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation. Unipolar electrograms show utility in assessing lesion durability during pulsed field ablation. This study investigated voltages associated with unipolar electrogram changes after pulsed field ablation and evaluated their predictive value for lesion durability. In one group of 10 patients, areas exhibiting a loss of S-wave on unipolar electrograms correlated with core lesion formation. The findings indicate that serial unipolar and bipolar voltage mapping provides objective evidence for lesion creation and durability during pulsed field ablation procedures. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>S-wave loss, incident arrhythmia, secundum atrial septal defect, arrhythmia, recurrent arrhythmia, heart transplantation, lesion durability, metabolic status, atrial fibrillation, heart-lung procurement, cardiac mitochondrial function, myocardial recovery, voltage mapping, risk factors, lung transplantation, graft retrieval, young patients, atrial septal defect closure, controlled donation after circulatory death, pulsed field ablation, ischemic stroke, major adverse cardiac and cerebrovascular events, unipolar electrograms, thoraco-abdominal normothermic regional perfusion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/">S-Wave Loss Predicts Pulsed Field Ablation Durability 01/26/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 26, 2026. This episode summarizes 5 key cardiology studies on topics like S-wave loss and incident arrhythmia. Key takeaway: S-Wave Loss Predicts Pulsed Field Ablation Durability.
Article Links:
Article 1: S]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 26, 2026. This episode summarizes 5 key cardiology studies on topics like S-wave loss and incident arrhythmia. Key takeaway: S-Wave Loss Predicts Pulsed Field Ablation Durability.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41572446">Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation.</a> (Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41581668">LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41581852">Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41581850">Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41581848">Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/">https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41572446" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41572446</a></p>
<p><strong>Summary:</strong> Mitochondrial dysfunction is a recognized contributor to cardiac pathology and influences myocardial recovery after heart transplantation. This prospective single-center study involved 45 adult heart transplant recipients. It characterized the changes in cardiac mitochondrial function directly in human myocardial tissue during the early post-transplant period. Understanding these dynamics is crucial for optimizing cardiac recovery and metabolic status.</p>
<h4>Article 2: LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581668" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581668</a></p>
<p><strong>Summary:</strong> Thoraco-abdominal normothermic regional perfusion is an emerging strategy for heart recovery in controlled donation after circulatory death donors. However, its impact on lung graft retrieval is debated, particularly with prolonged durations. In Italy, a mandatory 20-minute stand-off period results in uniquely prolonged thoraco-abdominal normothermic regional perfusion for heart assessment during combined heart-lung procurement. This Italian nationwide experience provides crucial clinical data on lung transplant outcomes following this specific prolonged perfusion strategy.</p>
<h4>Article 3: Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581852</a></p>
<p><strong>Summary:</strong> The incidence of atrial fibrillation in patients aged 18-50 years has increased, yet clinical data for this population is limited. This study characterized the clinical features, treatment patterns, and risk of ischemic stroke in hospitalized young atrial fibrillation patients between 2014 and 2023. Through Cox regression analysis, researchers identified specific risk factors for major adverse cardiac and cerebrovascular events and new-onset ischemic stroke in this cohort. This investigation provides crucial data on the unique clinical presentation and specific risks faced by younger individuals with atrial fibrillation.</p>
<h4>Article 4: Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581850</a></p>
<p><strong>Summary:</strong> Secundum atrial septal defect is associated with substantial morbidity, especially arrhythmias, despite being a simple defect. This Danish nationwide cohort study, spanning from 1977 to 2024, included all diagnosed secundum atrial septal defect patients. The study systematically assessed the risk of both incident and recurrent arrhythmias in relation to atrial septal defect closure status and the timing of intervention. This extensive analysis generated definitive data on the long-term arrhythmic burden after secundum atrial septal defect closure.</p>
<h4>Article 5: Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41581848" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41581848</a></p>
<p><strong>Summary:</strong> Unipolar electrograms show utility in assessing lesion durability during pulsed field ablation. This study investigated voltages associated with unipolar electrogram changes after pulsed field ablation and evaluated their predictive value for lesion durability. In one group of 10 patients, areas exhibiting a loss of S-wave on unipolar electrograms correlated with core lesion formation. The findings indicate that serial unipolar and bipolar voltage mapping provides objective evidence for lesion creation and durability during pulsed field ablation procedures.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 26, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation. Mitochondrial dysfunction is a recognized contributor to cardiac pathology and influences myocardial recovery after heart transplantation. This prospective single-center study involved 45 adult heart transplant recipients. It characterized the changes in cardiac mitochondrial function directly in human myocardial tissue during the early post-transplant period. Understanding these dynamics is crucial for optimizing cardiac recovery and metabolic status.</p>
<p>Article number two. LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY. Thoraco-abdominal normothermic regional perfusion is an emerging strategy for heart recovery in controlled donation after circulatory death donors. However, its impact on lung graft retrieval is debated, particularly with prolonged durations. In Italy, a mandatory 20-minute stand-off period results in uniquely prolonged thoraco-abdominal normothermic regional perfusion for heart assessment during combined heart-lung procurement. This Italian nationwide experience provides crucial clinical data on lung transplant outcomes following this specific prolonged perfusion strategy.</p>
<p>Article number three. Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes. The incidence of atrial fibrillation in patients aged 18-50 years has increased, yet clinical data for this population is limited. This study characterized the clinical features, treatment patterns, and risk of ischemic stroke in hospitalized young atrial fibrillation patients between 2014 and 2023. Through Cox regression analysis, researchers identified specific risk factors for major adverse cardiac and cerebrovascular events and new-onset ischemic stroke in this cohort. This investigation provides crucial data on the unique clinical presentation and specific risks faced by younger individuals with atrial fibrillation.</p>
<p>Article number four. Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia. Secundum atrial septal defect is associated with substantial morbidity, especially arrhythmias, despite being a simple defect. This Danish nationwide cohort study, spanning from 1977 to 2024, included all diagnosed secundum atrial septal defect patients. The study systematically assessed the risk of both incident and recurrent arrhythmias in relation to atrial septal defect closure status and the timing of intervention. This extensive analysis generated definitive data on the long-term arrhythmic burden after secundum atrial septal defect closure.</p>
<p>Article number five. Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation. Unipolar electrograms show utility in assessing lesion durability during pulsed field ablation. This study investigated voltages associated with unipolar electrogram changes after pulsed field ablation and evaluated their predictive value for lesion durability. In one group of 10 patients, areas exhibiting a loss of S-wave on unipolar electrograms correlated with core lesion formation. The findings indicate that serial unipolar and bipolar voltage mapping provides objective evidence for lesion creation and durability during pulsed field ablation procedures. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>S-wave loss, incident arrhythmia, secundum atrial septal defect, arrhythmia, recurrent arrhythmia, heart transplantation, lesion durability, metabolic status, atrial fibrillation, heart-lung procurement, cardiac mitochondrial function, myocardial recovery, voltage mapping, risk factors, lung transplantation, graft retrieval, young patients, atrial septal defect closure, controlled donation after circulatory death, pulsed field ablation, ischemic stroke, major adverse cardiac and cerebrovascular events, unipolar electrograms, thoraco-abdominal normothermic regional perfusion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/">S-Wave Loss Predicts Pulsed Field Ablation Durability 01/26/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260126_060047.mp3" length="3903990" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 26, 2026. This episode summarizes 5 key cardiology studies on topics like S-wave loss and incident arrhythmia. Key takeaway: S-Wave Loss Predicts Pulsed Field Ablation Durability.
Article Links:
Article 1: Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation. (Transplantation)
Article 2: LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes. (Heart rhythm)
Article 4: Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia. (Heart rhythm)
Article 5: Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/s-wave-loss-predicts-pulsed-field-ablation-durability-01-26-26/
 Featured Articles
Article 1: Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41572446
Summary: Mitochondrial dysfunction is a recognized contributor to cardiac pathology and influences myocardial recovery after heart transplantation. This prospective single-center study involved 45 adult heart transplant recipients. It characterized the changes in cardiac mitochondrial function directly in human myocardial tissue during the early post-transplant period. Understanding these dynamics is crucial for optimizing cardiac recovery and metabolic status.
Article 2: LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41581668
Summary: Thoraco-abdominal normothermic regional perfusion is an emerging strategy for heart recovery in controlled donation after circulatory death donors. However, its impact on lung graft retrieval is debated, particularly with prolonged durations. In Italy, a mandatory 20-minute stand-off period results in uniquely prolonged thoraco-abdominal normothermic regional perfusion for heart assessment during combined heart-lung procurement. This Italian nationwide experience provides crucial clinical data on lung transplant outcomes following this specific prolonged perfusion strategy.
Article 3: Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41581852
Summary: The incidence of atrial fibrillation in patients aged 18-50 years has increased, yet clinical data for this population is limited. This study characterized the clinical features, treatment patterns, and risk of ischemic stroke in hospitalized young atrial fibrillation patients between 2014 and 2023. Through Cox regression analysis, researchers identified specific risk factors for major adverse cardiac and cerebrovascular events and new-onset ischemic stroke in this cohort. This investigation provides crucial data on the unique clinical presentation and specific risks faced by younger individuals with atrial fibrillation.
Article 4: Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41581850
Summary: Secundum atrial septal defect is associated with substantial morbidity, especially arrhythmias, despite being a simple defect. This Danish nationwide cohort study, spanning from 1977 to 2024, included all diagnosed secundum atrial ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 26, 2026. This episode summarizes 5 key cardiology studies on topics like S-wave loss and incident arrhythmia. Key takeaway: S-Wave Loss Predicts Pulsed Field Ablation Durability.
Article Links:
Article 1: Serial Assessment of Cardiac Mitochondrial Function in the Early Phase After Heart Transplantation. (Transplantation)
Article 2: LUNG TRANSPLANTATION AFTER PROLONGED TA-NRP IN COMBINED HEART-LUNG PROCUREMENT FROM CONTROLLED DCD DONORS IN ITALY. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Atrial fibrillation in patients ≤50 years: Clinical characteristics, treatment, risk of ischemic stroke, and outcomes. (Heart rhythm)
Article 4: Closure of Secundum Atrial Septal Defect and Risk of Incident and Recurrent Arrhythmia. (Heart rhythm)
Article 5: Unipolar Voltage Mapping to Predict Lesion Durability During Pulsed Field Ablation.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Oxygen Debt Key to DCD Heart Transplant Success. 01/25/26</title>
	<link>https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/</link>
	<pubDate>Sun, 25 Jan 2026 11:01:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 25, 2026. This episode summarizes 5 key cardiology studies on topics like long-term survival and transplantation. Key takeaway: Oxygen Debt Key to DCD Heart Transplant Success..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41579023">Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41575400">Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41580104">Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41580103">The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41572462">Sex Disparities in Transplantation Access and Outcomes: An Overview.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/">https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41579023" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41579023</a></p>
<p><strong>Summary:</strong> Current high-sensitivity cardiac troponin T assays detect both intact and fragmented molecules, complicating myocardial infarction diagnosis in emergency department patients. Long cardiac troponin T assays, which measure only intact and minimally fragmented cardiac troponin T, offer a more specific diagnostic approach. This differentiation is crucial as elevated troponin levels are often found without clear myocardial infarction, and a refined measurement improves diagnostic precision. This improved specificity promises more accurate identification of myocardial infarction.</p>
<h4>Article 2: Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41575400" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41575400</a></p>
<p><strong>Summary:</strong> Noninvasive remote patient monitoring offers opportunities for early intervention in heart failure by transmitting physiological and symptom data. However, mixed results in existing remote patient monitoring studies arise from complex program designs. Current study reports often lack detailed information on crucial workflow components, including data review and clinical response mechanisms. Standardized reporting is essential to improve the utility of remote patient monitoring data and facilitate effective early interventions.</p>
<h4>Article 3: Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41580104" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41580104</a></p>
<p><strong>Summary:</strong> Intraoperative oxygen debt, quantified by oxygen extraction ratio, demonstrates an association with early clinical outcomes following prolonged asystolic warm ischemia time in donation after circulatory death heart transplantation. This physiological measure for goal-directed perfusion modifies risk among grafts with extended asystole-to-reperfusion intervals. Optimizing oxygen debt is crucial for improving post-transplant outcomes in adult recipients of donation after circulatory death hearts recovered via thoracoabdominal normothermic regional perfusion.</p>
<h4>Article 4: The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41580103" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41580103</a></p>
<p><strong>Summary:</strong> The field of durable mechanical circulatory support has made significant progress, particularly with left ventricular assist devices. These devices have evolved from bulky, pulsatile designs to compact, fully magnetically levitated continuous flow pumps. This advancement resulted in a significantly lower risk of adverse events and high rates of long-term survival for patients. Further innovations continue to improve patient management and device technology.</p>
<h4>Article 5: Sex Disparities in Transplantation Access and Outcomes: An Overview.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41572462" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41572462</a></p>
<p><strong>Summary:</strong> Sex disparities are evident across multiple stages of transplantation, impacting rates of referral for evaluation and activation on the waitlist. These disparities extend to time to transplantation, candidate survival while on the waitlist, and both graft and patient survival post-transplant. Contributing factors include potential unconscious or conscious bias from healthcare providers during patient selection and access to life-sustaining therapies. Biologic differences also play a role in these observed disparities.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study. Current high-sensitivity cardiac troponin T assays detect both intact and fragmented molecules, complicating myocardial infarction diagnosis in emergency department patients. Long cardiac troponin T assays, which measure only intact and minimally fragmented cardiac troponin T, offer a more specific diagnostic approach. This differentiation is crucial as elevated troponin levels are often found without clear myocardial infarction, and a refined measurement improves diagnostic precision. This improved specificity promises more accurate identification of myocardial infarction.</p>
<p>Article number two. Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action. Noninvasive remote patient monitoring offers opportunities for early intervention in heart failure by transmitting physiological and symptom data. However, mixed results in existing remote patient monitoring studies arise from complex program designs. Current study reports often lack detailed information on crucial workflow components, including data review and clinical response mechanisms. Standardized reporting is essential to improve the utility of remote patient monitoring data and facilitate effective early interventions.</p>
<p>Article number three. Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation. Intraoperative oxygen debt, quantified by oxygen extraction ratio, demonstrates an association with early clinical outcomes following prolonged asystolic warm ischemia time in donation after circulatory death heart transplantation. This physiological measure for goal-directed perfusion modifies risk among grafts with extended asystole-to-reperfusion intervals. Optimizing oxygen debt is crucial for improving post-transplant outcomes in adult recipients of donation after circulatory death hearts recovered via thoracoabdominal normothermic regional perfusion.</p>
<p>Article number four. The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations. The field of durable mechanical circulatory support has made significant progress, particularly with left ventricular assist devices. These devices have evolved from bulky, pulsatile designs to compact, fully magnetically levitated continuous flow pumps. This advancement resulted in a significantly lower risk of adverse events and high rates of long-term survival for patients. Further innovations continue to improve patient management and device technology.</p>
<p>Article number five. Sex Disparities in Transplantation Access and Outcomes: An Overview. Sex disparities are evident across multiple stages of transplantation, impacting rates of referral for evaluation and activation on the waitlist. These disparities extend to time to transplantation, candidate survival while on the waitlist, and both graft and patient survival post-transplant. Contributing factors include potential unconscious or conscious bias from healthcare providers during patient selection and access to life-sustaining therapies. Biologic differences also play a role in these observed disparities. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>long-term survival, transplantation, left ventricular assist devices, heart transplantation, diagnostic precision, healthcare bias, remote patient monitoring, graft survival, myocardial infarction, oxygen debt, waitlist, emergency department, warm ischemia time, clinical trials, donation after circulatory death, biomarker, mechanical circulatory support, sex disparities, cardiac troponin T, data quality, patient survival, standardized reporting, technology advancements, heart failure, goal-directed perfusion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/">Oxygen Debt Key to DCD Heart Transplant Success. 01/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 25, 2026. This episode summarizes 5 key cardiology studies on topics like long-term survival and transplantation. Key takeaway: Oxygen Debt Key to DCD Heart Transplant Success..
Article Links:
Article 1: Lon]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 25, 2026. This episode summarizes 5 key cardiology studies on topics like long-term survival and transplantation. Key takeaway: Oxygen Debt Key to DCD Heart Transplant Success..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41579023">Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41575400">Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41580104">Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41580103">The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41572462">Sex Disparities in Transplantation Access and Outcomes: An Overview.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/">https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41579023" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41579023</a></p>
<p><strong>Summary:</strong> Current high-sensitivity cardiac troponin T assays detect both intact and fragmented molecules, complicating myocardial infarction diagnosis in emergency department patients. Long cardiac troponin T assays, which measure only intact and minimally fragmented cardiac troponin T, offer a more specific diagnostic approach. This differentiation is crucial as elevated troponin levels are often found without clear myocardial infarction, and a refined measurement improves diagnostic precision. This improved specificity promises more accurate identification of myocardial infarction.</p>
<h4>Article 2: Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41575400" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41575400</a></p>
<p><strong>Summary:</strong> Noninvasive remote patient monitoring offers opportunities for early intervention in heart failure by transmitting physiological and symptom data. However, mixed results in existing remote patient monitoring studies arise from complex program designs. Current study reports often lack detailed information on crucial workflow components, including data review and clinical response mechanisms. Standardized reporting is essential to improve the utility of remote patient monitoring data and facilitate effective early interventions.</p>
<h4>Article 3: Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41580104" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41580104</a></p>
<p><strong>Summary:</strong> Intraoperative oxygen debt, quantified by oxygen extraction ratio, demonstrates an association with early clinical outcomes following prolonged asystolic warm ischemia time in donation after circulatory death heart transplantation. This physiological measure for goal-directed perfusion modifies risk among grafts with extended asystole-to-reperfusion intervals. Optimizing oxygen debt is crucial for improving post-transplant outcomes in adult recipients of donation after circulatory death hearts recovered via thoracoabdominal normothermic regional perfusion.</p>
<h4>Article 4: The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41580103" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41580103</a></p>
<p><strong>Summary:</strong> The field of durable mechanical circulatory support has made significant progress, particularly with left ventricular assist devices. These devices have evolved from bulky, pulsatile designs to compact, fully magnetically levitated continuous flow pumps. This advancement resulted in a significantly lower risk of adverse events and high rates of long-term survival for patients. Further innovations continue to improve patient management and device technology.</p>
<h4>Article 5: Sex Disparities in Transplantation Access and Outcomes: An Overview.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41572462" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41572462</a></p>
<p><strong>Summary:</strong> Sex disparities are evident across multiple stages of transplantation, impacting rates of referral for evaluation and activation on the waitlist. These disparities extend to time to transplantation, candidate survival while on the waitlist, and both graft and patient survival post-transplant. Contributing factors include potential unconscious or conscious bias from healthcare providers during patient selection and access to life-sustaining therapies. Biologic differences also play a role in these observed disparities.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study. Current high-sensitivity cardiac troponin T assays detect both intact and fragmented molecules, complicating myocardial infarction diagnosis in emergency department patients. Long cardiac troponin T assays, which measure only intact and minimally fragmented cardiac troponin T, offer a more specific diagnostic approach. This differentiation is crucial as elevated troponin levels are often found without clear myocardial infarction, and a refined measurement improves diagnostic precision. This improved specificity promises more accurate identification of myocardial infarction.</p>
<p>Article number two. Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action. Noninvasive remote patient monitoring offers opportunities for early intervention in heart failure by transmitting physiological and symptom data. However, mixed results in existing remote patient monitoring studies arise from complex program designs. Current study reports often lack detailed information on crucial workflow components, including data review and clinical response mechanisms. Standardized reporting is essential to improve the utility of remote patient monitoring data and facilitate effective early interventions.</p>
<p>Article number three. Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation. Intraoperative oxygen debt, quantified by oxygen extraction ratio, demonstrates an association with early clinical outcomes following prolonged asystolic warm ischemia time in donation after circulatory death heart transplantation. This physiological measure for goal-directed perfusion modifies risk among grafts with extended asystole-to-reperfusion intervals. Optimizing oxygen debt is crucial for improving post-transplant outcomes in adult recipients of donation after circulatory death hearts recovered via thoracoabdominal normothermic regional perfusion.</p>
<p>Article number four. The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations. The field of durable mechanical circulatory support has made significant progress, particularly with left ventricular assist devices. These devices have evolved from bulky, pulsatile designs to compact, fully magnetically levitated continuous flow pumps. This advancement resulted in a significantly lower risk of adverse events and high rates of long-term survival for patients. Further innovations continue to improve patient management and device technology.</p>
<p>Article number five. Sex Disparities in Transplantation Access and Outcomes: An Overview. Sex disparities are evident across multiple stages of transplantation, impacting rates of referral for evaluation and activation on the waitlist. These disparities extend to time to transplantation, candidate survival while on the waitlist, and both graft and patient survival post-transplant. Contributing factors include potential unconscious or conscious bias from healthcare providers during patient selection and access to life-sustaining therapies. Biologic differences also play a role in these observed disparities. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>long-term survival, transplantation, left ventricular assist devices, heart transplantation, diagnostic precision, healthcare bias, remote patient monitoring, graft survival, myocardial infarction, oxygen debt, waitlist, emergency department, warm ischemia time, clinical trials, donation after circulatory death, biomarker, mechanical circulatory support, sex disparities, cardiac troponin T, data quality, patient survival, standardized reporting, technology advancements, heart failure, goal-directed perfusion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/">Oxygen Debt Key to DCD Heart Transplant Success. 01/25/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260125_060019.mp3" length="3793649" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 25, 2026. This episode summarizes 5 key cardiology studies on topics like long-term survival and transplantation. Key takeaway: Oxygen Debt Key to DCD Heart Transplant Success..
Article Links:
Article 1: Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study. (European heart journal)
Article 2: Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action. (JACC. Heart failure)
Article 3: Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Sex Disparities in Transplantation Access and Outcomes: An Overview. (Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/oxygen-debt-key-to-dcd-heart-transplant-success-01-25-26/
 Featured Articles
Article 1: Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41579023
Summary: Current high-sensitivity cardiac troponin T assays detect both intact and fragmented molecules, complicating myocardial infarction diagnosis in emergency department patients. Long cardiac troponin T assays, which measure only intact and minimally fragmented cardiac troponin T, offer a more specific diagnostic approach. This differentiation is crucial as elevated troponin levels are often found without clear myocardial infarction, and a refined measurement improves diagnostic precision. This improved specificity promises more accurate identification of myocardial infarction.
Article 2: Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41575400
Summary: Noninvasive remote patient monitoring offers opportunities for early intervention in heart failure by transmitting physiological and symptom data. However, mixed results in existing remote patient monitoring studies arise from complex program designs. Current study reports often lack detailed information on crucial workflow components, including data review and clinical response mechanisms. Standardized reporting is essential to improve the utility of remote patient monitoring data and facilitate effective early interventions.
Article 3: Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41580104
Summary: Intraoperative oxygen debt, quantified by oxygen extraction ratio, demonstrates an association with early clinical outcomes following prolonged asystolic warm ischemia time in donation after circulatory death heart transplantation. This physiological measure for goal-directed perfusion modifies risk among grafts with extended asystole-to-reperfusion intervals. Optimizing oxygen debt is crucial for improving post-transplant outcomes in adult recipients of donation after circulatory death hearts recovered via thoracoabdominal normothermic regional perfusion.
Article 4: The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 25, 2026. This episode summarizes 5 key cardiology studies on topics like long-term survival and transplantation. Key takeaway: Oxygen Debt Key to DCD Heart Transplant Success..
Article Links:
Article 1: Long forms of cardiac troponin T for myocardial infarction diagnosis: the SuperTROPO study. (European heart journal)
Article 2: Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action. (JACC. Heart failure)
Article 3: Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: The Future of Durable Mechanical Circulatory Support Devices: Emerging Innovations. (The Journal of heart and lung transplantation : the official publ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Self-Supervised AI Transforms E. C. G. 01/24/26</title>
	<link>https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/</link>
	<pubDate>Sat, 24 Jan 2026 11:01:47 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 24, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk women and drug-resistant atrial fibrillation. Key takeaway: Self-Supervised AI Transforms E. C. G..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41574427">Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41570089">Sample size considerations to assess sex-related treatment effects.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41568699">Foundation models for electrocardiogram interpretation: clinical implications.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41568673">Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41568658">Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/">https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41574427" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41574427</a></p>
<p><strong>Summary:</strong> The study addressed a critical clinical dilemma for high-risk women requiring statin therapy around the time of pregnancy by analyzing national health data. It compared maternal cardiovascular, gestational, and fetal outcomes between women who continued statins and those who discontinued them prior to their last menstrual period. The research provides crucial information for guiding clinical decisions on statin management during pregnancy. This data helps clinicians balance maternal cardiovascular risk with potential effects on gestational and fetal health.</p>
<h4>Article 2: Sample size considerations to assess sex-related treatment effects.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41570089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41570089</a></p>
<p><strong>Summary:</strong> Randomized controlled trials, recognized as the gold standard for establishing treatment efficacy, frequently demonstrate a lack of representativeness for diverse patient populations, notably concerning sex. This inherent limitation leads to significant concerns regarding the generalizability of trial results to underrepresented groups. The current state shows that trial designs often fail to adequately assess potential differences in treatment effects across sexes. Therefore, specific sample size considerations are essential to precisely determine sex-related treatment effects and enhance the clinical applicability of findings.</p>
<h4>Article 3: Foundation models for electrocardiogram interpretation: clinical implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568699" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568699</a></p>
<p><strong>Summary:</strong> Current artificial intelligence solutions for automated electrocardiogram interpretation frequently lack generalizability and adaptability across diverse clinical settings. These existing systems, primarily trained with supervised learning, demand extensive labeled datasets and often remain closed source. Self-supervised learning provides a robust method to overcome these limitations by extracting powerful representations directly from unlabeled electrocardiogram data. This approach signifies a substantial advancement for developing more adaptable and clinically relevant E. C. G. diagnostic tools.</p>
<h4>Article 4: Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568673" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568673</a></p>
<p><strong>Summary:</strong> Existing lipid biomarkers, such as low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, incompletely capture coronary heart disease risk from all apolipoprotein B-containing lipoproteins. Apolipoprotein B alone improves risk prediction, but elevated triglyceride-rich lipoproteins and lipoprotein(a) can still lead to underestimated risk. A novel metric, risk-weighted apolipoprotein B, was specifically developed to consolidate the risk contributions from low-density lipoprotein, triglyceride-rich lipoproteins, and lipoprotein(a) into a single value. This metric addresses a significant gap in fully assessing total atherogenic particle burden for improved risk stratification.</p>
<h4>Article 5: Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568658" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568658</a></p>
<p><strong>Summary:</strong> The B.E.A.T. P.A.R.O.X.-A.F. trial conducted a European multicenter randomized comparison of pulsed field ablation versus radiofrequency ablation. This superiority study evaluated the single-procedure efficacy and safety of these two distinct modalities for patients with symptomatic, drug-resistant paroxysmal atrial fibrillation. The trial rigorously assessed the comparative performance of pulsed field ablation using a pentaspline catheter against radiofrequency ablation following the C.L.O.S.E. protocol. This research provides a crucial head-to-head comparison of advanced ablation strategies for a challenging patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study. The study addressed a critical clinical dilemma for high-risk women requiring statin therapy around the time of pregnancy by analyzing national health data. It compared maternal cardiovascular, gestational, and fetal outcomes between women who continued statins and those who discontinued them prior to their last menstrual period. The research provides crucial information for guiding clinical decisions on statin management during pregnancy. This data helps clinicians balance maternal cardiovascular risk with potential effects on gestational and fetal health.</p>
<p>Article number two. Sample size considerations to assess sex-related treatment effects. Randomized controlled trials, recognized as the gold standard for establishing treatment efficacy, frequently demonstrate a lack of representativeness for diverse patient populations, notably concerning sex. This inherent limitation leads to significant concerns regarding the generalizability of trial results to underrepresented groups. The current state shows that trial designs often fail to adequately assess potential differences in treatment effects across sexes. Therefore, specific sample size considerations are essential to precisely determine sex-related treatment effects and enhance the clinical applicability of findings.</p>
<p>Article number three. Foundation models for electrocardiogram interpretation: clinical implications. Current artificial intelligence solutions for automated electrocardiogram interpretation frequently lack generalizability and adaptability across diverse clinical settings. These existing systems, primarily trained with supervised learning, demand extensive labeled datasets and often remain closed source. Self-supervised learning provides a robust method to overcome these limitations by extracting powerful representations directly from unlabeled electrocardiogram data. This approach signifies a substantial advancement for developing more adaptable and clinically relevant E. C. G. diagnostic tools.</p>
<p>Article number four. Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease. Existing lipid biomarkers, such as low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, incompletely capture coronary heart disease risk from all apolipoprotein B-containing lipoproteins. Apolipoprotein B alone improves risk prediction, but elevated triglyceride-rich lipoproteins and lipoprotein(a) can still lead to underestimated risk. A novel metric, risk-weighted apolipoprotein B, was specifically developed to consolidate the risk contributions from low-density lipoprotein, triglyceride-rich lipoproteins, and lipoprotein(a) into a single value. This metric addresses a significant gap in fully assessing total atherogenic particle burden for improved risk stratification.</p>
<p>Article number five. Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial. The B.E.A.T. P.A.R.O.X.-A.F. trial conducted a European multicenter randomized comparison of pulsed field ablation versus radiofrequency ablation. This superiority study evaluated the single-procedure efficacy and safety of these two distinct modalities for patients with symptomatic, drug-resistant paroxysmal atrial fibrillation. The trial rigorously assessed the comparative performance of pulsed field ablation using a pentaspline catheter against radiofrequency ablation following the C.L.O.S.E. protocol. This research provides a crucial head-to-head comparison of advanced ablation strategies for a challenging patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-risk women, drug-resistant atrial fibrillation, diagnostic tools, Pulsed field ablation, radiofrequency ablation, maternal cardiovascular health, risk stratification, birth outcomes, population representativeness, apolipoprotein B, lipid biomarkers, sample size considerations, self-supervised learning, cardiac diagnostics, Electrocardiogram interpretation, Statin discontinuation, Randomized controlled trials, coronary heart disease, pregnancy, sex-related treatment effects, artificial intelligence, ablation strategies, trial generalizability, paroxysmal atrial fibrillation, Risk-weighted apolipoprotein B.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/">Self-Supervised AI Transforms E. C. G. 01/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 24, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk women and drug-resistant atrial fibrillation. Key takeaway: Self-Supervised AI Transforms E. C. G..
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 24, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk women and drug-resistant atrial fibrillation. Key takeaway: Self-Supervised AI Transforms E. C. G..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41574427">Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41570089">Sample size considerations to assess sex-related treatment effects.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41568699">Foundation models for electrocardiogram interpretation: clinical implications.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41568673">Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41568658">Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/">https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41574427" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41574427</a></p>
<p><strong>Summary:</strong> The study addressed a critical clinical dilemma for high-risk women requiring statin therapy around the time of pregnancy by analyzing national health data. It compared maternal cardiovascular, gestational, and fetal outcomes between women who continued statins and those who discontinued them prior to their last menstrual period. The research provides crucial information for guiding clinical decisions on statin management during pregnancy. This data helps clinicians balance maternal cardiovascular risk with potential effects on gestational and fetal health.</p>
<h4>Article 2: Sample size considerations to assess sex-related treatment effects.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41570089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41570089</a></p>
<p><strong>Summary:</strong> Randomized controlled trials, recognized as the gold standard for establishing treatment efficacy, frequently demonstrate a lack of representativeness for diverse patient populations, notably concerning sex. This inherent limitation leads to significant concerns regarding the generalizability of trial results to underrepresented groups. The current state shows that trial designs often fail to adequately assess potential differences in treatment effects across sexes. Therefore, specific sample size considerations are essential to precisely determine sex-related treatment effects and enhance the clinical applicability of findings.</p>
<h4>Article 3: Foundation models for electrocardiogram interpretation: clinical implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568699" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568699</a></p>
<p><strong>Summary:</strong> Current artificial intelligence solutions for automated electrocardiogram interpretation frequently lack generalizability and adaptability across diverse clinical settings. These existing systems, primarily trained with supervised learning, demand extensive labeled datasets and often remain closed source. Self-supervised learning provides a robust method to overcome these limitations by extracting powerful representations directly from unlabeled electrocardiogram data. This approach signifies a substantial advancement for developing more adaptable and clinically relevant E. C. G. diagnostic tools.</p>
<h4>Article 4: Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568673" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568673</a></p>
<p><strong>Summary:</strong> Existing lipid biomarkers, such as low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, incompletely capture coronary heart disease risk from all apolipoprotein B-containing lipoproteins. Apolipoprotein B alone improves risk prediction, but elevated triglyceride-rich lipoproteins and lipoprotein(a) can still lead to underestimated risk. A novel metric, risk-weighted apolipoprotein B, was specifically developed to consolidate the risk contributions from low-density lipoprotein, triglyceride-rich lipoproteins, and lipoprotein(a) into a single value. This metric addresses a significant gap in fully assessing total atherogenic particle burden for improved risk stratification.</p>
<h4>Article 5: Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568658" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568658</a></p>
<p><strong>Summary:</strong> The B.E.A.T. P.A.R.O.X.-A.F. trial conducted a European multicenter randomized comparison of pulsed field ablation versus radiofrequency ablation. This superiority study evaluated the single-procedure efficacy and safety of these two distinct modalities for patients with symptomatic, drug-resistant paroxysmal atrial fibrillation. The trial rigorously assessed the comparative performance of pulsed field ablation using a pentaspline catheter against radiofrequency ablation following the C.L.O.S.E. protocol. This research provides a crucial head-to-head comparison of advanced ablation strategies for a challenging patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 24, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study. The study addressed a critical clinical dilemma for high-risk women requiring statin therapy around the time of pregnancy by analyzing national health data. It compared maternal cardiovascular, gestational, and fetal outcomes between women who continued statins and those who discontinued them prior to their last menstrual period. The research provides crucial information for guiding clinical decisions on statin management during pregnancy. This data helps clinicians balance maternal cardiovascular risk with potential effects on gestational and fetal health.</p>
<p>Article number two. Sample size considerations to assess sex-related treatment effects. Randomized controlled trials, recognized as the gold standard for establishing treatment efficacy, frequently demonstrate a lack of representativeness for diverse patient populations, notably concerning sex. This inherent limitation leads to significant concerns regarding the generalizability of trial results to underrepresented groups. The current state shows that trial designs often fail to adequately assess potential differences in treatment effects across sexes. Therefore, specific sample size considerations are essential to precisely determine sex-related treatment effects and enhance the clinical applicability of findings.</p>
<p>Article number three. Foundation models for electrocardiogram interpretation: clinical implications. Current artificial intelligence solutions for automated electrocardiogram interpretation frequently lack generalizability and adaptability across diverse clinical settings. These existing systems, primarily trained with supervised learning, demand extensive labeled datasets and often remain closed source. Self-supervised learning provides a robust method to overcome these limitations by extracting powerful representations directly from unlabeled electrocardiogram data. This approach signifies a substantial advancement for developing more adaptable and clinically relevant E. C. G. diagnostic tools.</p>
<p>Article number four. Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease. Existing lipid biomarkers, such as low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, incompletely capture coronary heart disease risk from all apolipoprotein B-containing lipoproteins. Apolipoprotein B alone improves risk prediction, but elevated triglyceride-rich lipoproteins and lipoprotein(a) can still lead to underestimated risk. A novel metric, risk-weighted apolipoprotein B, was specifically developed to consolidate the risk contributions from low-density lipoprotein, triglyceride-rich lipoproteins, and lipoprotein(a) into a single value. This metric addresses a significant gap in fully assessing total atherogenic particle burden for improved risk stratification.</p>
<p>Article number five. Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial. The B.E.A.T. P.A.R.O.X.-A.F. trial conducted a European multicenter randomized comparison of pulsed field ablation versus radiofrequency ablation. This superiority study evaluated the single-procedure efficacy and safety of these two distinct modalities for patients with symptomatic, drug-resistant paroxysmal atrial fibrillation. The trial rigorously assessed the comparative performance of pulsed field ablation using a pentaspline catheter against radiofrequency ablation following the C.L.O.S.E. protocol. This research provides a crucial head-to-head comparison of advanced ablation strategies for a challenging patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-risk women, drug-resistant atrial fibrillation, diagnostic tools, Pulsed field ablation, radiofrequency ablation, maternal cardiovascular health, risk stratification, birth outcomes, population representativeness, apolipoprotein B, lipid biomarkers, sample size considerations, self-supervised learning, cardiac diagnostics, Electrocardiogram interpretation, Statin discontinuation, Randomized controlled trials, coronary heart disease, pregnancy, sex-related treatment effects, artificial intelligence, ablation strategies, trial generalizability, paroxysmal atrial fibrillation, Risk-weighted apolipoprotein B.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/">Self-Supervised AI Transforms E. C. G. 01/24/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260124_060039.mp3" length="4473251" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 24, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk women and drug-resistant atrial fibrillation. Key takeaway: Self-Supervised AI Transforms E. C. G..
Article Links:
Article 1: Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study. (Circulation)
Article 2: Sample size considerations to assess sex-related treatment effects. (European heart journal)
Article 3: Foundation models for electrocardiogram interpretation: clinical implications. (European heart journal)
Article 4: Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease. (European heart journal)
Article 5: Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/self-supervised-ai-transforms-e-c-g-01-24-26/
 Featured Articles
Article 1: Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41574427
Summary: The study addressed a critical clinical dilemma for high-risk women requiring statin therapy around the time of pregnancy by analyzing national health data. It compared maternal cardiovascular, gestational, and fetal outcomes between women who continued statins and those who discontinued them prior to their last menstrual period. The research provides crucial information for guiding clinical decisions on statin management during pregnancy. This data helps clinicians balance maternal cardiovascular risk with potential effects on gestational and fetal health.
Article 2: Sample size considerations to assess sex-related treatment effects.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41570089
Summary: Randomized controlled trials, recognized as the gold standard for establishing treatment efficacy, frequently demonstrate a lack of representativeness for diverse patient populations, notably concerning sex. This inherent limitation leads to significant concerns regarding the generalizability of trial results to underrepresented groups. The current state shows that trial designs often fail to adequately assess potential differences in treatment effects across sexes. Therefore, specific sample size considerations are essential to precisely determine sex-related treatment effects and enhance the clinical applicability of findings.
Article 3: Foundation models for electrocardiogram interpretation: clinical implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41568699
Summary: Current artificial intelligence solutions for automated electrocardiogram interpretation frequently lack generalizability and adaptability across diverse clinical settings. These existing systems, primarily trained with supervised learning, demand extensive labeled datasets and often remain closed source. Self-supervised learning provides a robust method to overcome these limitations by extracting powerful representations directly from unlabeled electrocardiogram data. This approach signifies a substantial advancement for developing more adaptable and clinically relevant E. C. G. diagnostic tools.
Article 4: Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41568673
Summary: Existing lipid biomarkers, such as low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, incompletely capture coronary heart disease risk from all apolipoprotein B-containing lipoproteins. Apolipoprotein B alone improves risk prediction, but elevated triglyceride-rich lipoproteins and lipoprotein(a) ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 24, 2026. This episode summarizes 5 key cardiology studies on topics like high-risk women and drug-resistant atrial fibrillation. Key takeaway: Self-Supervised AI Transforms E. C. G..
Article Links:
Article 1: Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study. (Circulation)
Article 2: Sample size considerations to assess sex-related treatment effects. (European heart journal)
Article 3: Foundation models for electrocardiogram interpretation: clinical implications. (European heart journal)
Article 4: Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease. (European heart journal)
Article 5: Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/self-supervised-ai]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>PCOS Raises Long-Term Arrhythmia Risk 01/23/26</title>
	<link>https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/</link>
	<pubDate>Fri, 23 Jan 2026 11:01:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 23, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia detection and smartwatch. Key takeaway: PCOS Raises Long-Term Arrhythmia Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41569211">Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40892619">Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41568447">Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41568438">Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41571335">Sex and gender differences in coronary pathophysiology and ischaemic heart disease.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/">https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41569211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41569211</a></p>
<p><strong>Summary:</strong> Atrial fibrillation, a common cardiac arrhythmia, frequently remains undiagnosed due to its paroxysmal and asymptomatic nature, serving as a major cause of stroke. Wearable technology functions as a scalable, noninvasive screening tool for conditions like atrial fibrillation. A multicenter randomized controlled trial investigated the detection of new onset atrial fibrillation using remote smartwatch-based screening among patients sixty-five years or older with elevated stroke risk. This approach offers a significant pathway for prompt diagnosis, which is crucial for reducing stroke incidence in susceptible populations.</p>
<h4>Article 2: Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892619" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892619</a></p>
<p><strong>Summary:</strong> Right ventricular pacing in symptomatic obstructive hypertrophic cardiomyopathy, while capable of reducing left ventricular outflow tract gradient, often yields variable net effects due to potential reductions in cardiac output. The E. M. O. R. I. hyphen H. C. M. trial investigated an electromechanically optimized approach for right ventricular pacing. This method involved precise programming of the atrio-ventricular delay to maximize symptomatic benefit. The strategy provides a refined therapeutic option for managing patients with obstructive hypertrophic cardiomyopathy already equipped with pacing devices.</p>
<h4>Article 3: Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568447" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568447</a></p>
<p><strong>Summary:</strong> Long-term outcomes following Fontan palliation exhibit significant variability, despite known predictions of early failure by pre-Fontan hemodynamics. A study from the Pediatric Cardiac Care Consortium investigated the association of pre-Fontan hemodynamics with long-term risks of death or transplantation. The analysis, which utilized data from a U. S. hyphen based multicenter registry, established that specific pre-Fontan hemodynamic parameters are indeed predictive of these critical long-term outcomes. This finding provides valuable insights for risk stratification and prognostic assessment in patients undergoing Fontan procedures.</p>
<h4>Article 4: Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568438" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568438</a></p>
<p><strong>Summary:</strong> Polycystic ovarian syndrome is linked to increased cardiovascular morbidity, atherosclerotic cardiovascular disease, and specific electrocardiographic alterations. This study investigated the previously under-researched long-term risk of cardiac arrhythmias in women with polycystic ovarian syndrome. Researchers found a clear association between polycystic ovarian syndrome and an elevated long-term risk of various cardiac arrhythmias. This finding underscores the importance of cardiovascular surveillance in women diagnosed with polycystic ovarian syndrome.</p>
<h4>Article 5: Sex and gender differences in coronary pathophysiology and ischaemic heart disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41571335" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41571335</a></p>
<p><strong>Summary:</strong> Ischemic heart disease exhibits significant sex and gender differences, necessitating a comprehensive understanding of these dissimilarities for improved patient outcomes. This Scientific Statement reviewed current knowledge, identifying unequal impacts of traditional risk factors between men and women. The review integrated additional contributing factors, including hormonal changes, specific medical treatments for transgender people and cancer patients, and pregnancy-related conditions. This provides a critical framework for understanding diverse coronary pathophysiology and tailoring care in ischemic heart disease across sexes and genders.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial. Atrial fibrillation, a common cardiac arrhythmia, frequently remains undiagnosed due to its paroxysmal and asymptomatic nature, serving as a major cause of stroke. Wearable technology functions as a scalable, noninvasive screening tool for conditions like atrial fibrillation. A multicenter randomized controlled trial investigated the detection of new onset atrial fibrillation using remote smartwatch-based screening among patients sixty-five years or older with elevated stroke risk. This approach offers a significant pathway for prompt diagnosis, which is crucial for reducing stroke incidence in susceptible populations.</p>
<p>Article number two. Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. Right ventricular pacing in symptomatic obstructive hypertrophic cardiomyopathy, while capable of reducing left ventricular outflow tract gradient, often yields variable net effects due to potential reductions in cardiac output. The E. M. O. R. I. hyphen H. C. M. trial investigated an electromechanically optimized approach for right ventricular pacing. This method involved precise programming of the atrio-ventricular delay to maximize symptomatic benefit. The strategy provides a refined therapeutic option for managing patients with obstructive hypertrophic cardiomyopathy already equipped with pacing devices.</p>
<p>Article number three. Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium. Long-term outcomes following Fontan palliation exhibit significant variability, despite known predictions of early failure by pre-Fontan hemodynamics. A study from the Pediatric Cardiac Care Consortium investigated the association of pre-Fontan hemodynamics with long-term risks of death or transplantation. The analysis, which utilized data from a U. S. hyphen based multicenter registry, established that specific pre-Fontan hemodynamic parameters are indeed predictive of these critical long-term outcomes. This finding provides valuable insights for risk stratification and prognostic assessment in patients undergoing Fontan procedures.</p>
<p>Article number four. Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias. Polycystic ovarian syndrome is linked to increased cardiovascular morbidity, atherosclerotic cardiovascular disease, and specific electrocardiographic alterations. This study investigated the previously under-researched long-term risk of cardiac arrhythmias in women with polycystic ovarian syndrome. Researchers found a clear association between polycystic ovarian syndrome and an elevated long-term risk of various cardiac arrhythmias. This finding underscores the importance of cardiovascular surveillance in women diagnosed with polycystic ovarian syndrome.</p>
<p>Article number five. Sex and gender differences in coronary pathophysiology and ischaemic heart disease. Ischemic heart disease exhibits significant sex and gender differences, necessitating a comprehensive understanding of these dissimilarities for improved patient outcomes. This Scientific Statement reviewed current knowledge, identifying unequal impacts of traditional risk factors between men and women. The review integrated additional contributing factors, including hormonal changes, specific medical treatments for transgender people and cancer patients, and pregnancy-related conditions. This provides a critical framework for understanding diverse coronary pathophysiology and tailoring care in ischemic heart disease across sexes and genders. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>arrhythmia detection, smartwatch, pacing optimization, gender differences, cardiac output, death or transplantation, pre-Fontan hemodynamics, wearables, Fontan palliation, sex differences, pediatric cardiology, long-term outcomes, atrial fibrillation, hormonal changes, electrocardiographic alterations, right ventricular pacing, ischemic heart disease, risk factors, obstructive hypertrophic cardiomyopathy, stroke risk, atrio-ventricular delay, arrhythmias, long-term risk, polycystic ovarian syndrome, coronary pathophysiology, cardiovascular morbidity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/">PCOS Raises Long-Term Arrhythmia Risk 01/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 23, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia detection and smartwatch. Key takeaway: PCOS Raises Long-Term Arrhythmia Risk.
Article Links:
Article 1: Enhanced Detectio]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 23, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia detection and smartwatch. Key takeaway: PCOS Raises Long-Term Arrhythmia Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41569211">Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40892619">Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41568447">Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41568438">Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41571335">Sex and gender differences in coronary pathophysiology and ischaemic heart disease.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/">https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41569211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41569211</a></p>
<p><strong>Summary:</strong> Atrial fibrillation, a common cardiac arrhythmia, frequently remains undiagnosed due to its paroxysmal and asymptomatic nature, serving as a major cause of stroke. Wearable technology functions as a scalable, noninvasive screening tool for conditions like atrial fibrillation. A multicenter randomized controlled trial investigated the detection of new onset atrial fibrillation using remote smartwatch-based screening among patients sixty-five years or older with elevated stroke risk. This approach offers a significant pathway for prompt diagnosis, which is crucial for reducing stroke incidence in susceptible populations.</p>
<h4>Article 2: Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892619" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892619</a></p>
<p><strong>Summary:</strong> Right ventricular pacing in symptomatic obstructive hypertrophic cardiomyopathy, while capable of reducing left ventricular outflow tract gradient, often yields variable net effects due to potential reductions in cardiac output. The E. M. O. R. I. hyphen H. C. M. trial investigated an electromechanically optimized approach for right ventricular pacing. This method involved precise programming of the atrio-ventricular delay to maximize symptomatic benefit. The strategy provides a refined therapeutic option for managing patients with obstructive hypertrophic cardiomyopathy already equipped with pacing devices.</p>
<h4>Article 3: Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568447" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568447</a></p>
<p><strong>Summary:</strong> Long-term outcomes following Fontan palliation exhibit significant variability, despite known predictions of early failure by pre-Fontan hemodynamics. A study from the Pediatric Cardiac Care Consortium investigated the association of pre-Fontan hemodynamics with long-term risks of death or transplantation. The analysis, which utilized data from a U. S. hyphen based multicenter registry, established that specific pre-Fontan hemodynamic parameters are indeed predictive of these critical long-term outcomes. This finding provides valuable insights for risk stratification and prognostic assessment in patients undergoing Fontan procedures.</p>
<h4>Article 4: Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41568438" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41568438</a></p>
<p><strong>Summary:</strong> Polycystic ovarian syndrome is linked to increased cardiovascular morbidity, atherosclerotic cardiovascular disease, and specific electrocardiographic alterations. This study investigated the previously under-researched long-term risk of cardiac arrhythmias in women with polycystic ovarian syndrome. Researchers found a clear association between polycystic ovarian syndrome and an elevated long-term risk of various cardiac arrhythmias. This finding underscores the importance of cardiovascular surveillance in women diagnosed with polycystic ovarian syndrome.</p>
<h4>Article 5: Sex and gender differences in coronary pathophysiology and ischaemic heart disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41571335" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41571335</a></p>
<p><strong>Summary:</strong> Ischemic heart disease exhibits significant sex and gender differences, necessitating a comprehensive understanding of these dissimilarities for improved patient outcomes. This Scientific Statement reviewed current knowledge, identifying unequal impacts of traditional risk factors between men and women. The review integrated additional contributing factors, including hormonal changes, specific medical treatments for transgender people and cancer patients, and pregnancy-related conditions. This provides a critical framework for understanding diverse coronary pathophysiology and tailoring care in ischemic heart disease across sexes and genders.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 23, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial. Atrial fibrillation, a common cardiac arrhythmia, frequently remains undiagnosed due to its paroxysmal and asymptomatic nature, serving as a major cause of stroke. Wearable technology functions as a scalable, noninvasive screening tool for conditions like atrial fibrillation. A multicenter randomized controlled trial investigated the detection of new onset atrial fibrillation using remote smartwatch-based screening among patients sixty-five years or older with elevated stroke risk. This approach offers a significant pathway for prompt diagnosis, which is crucial for reducing stroke incidence in susceptible populations.</p>
<p>Article number two. Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. Right ventricular pacing in symptomatic obstructive hypertrophic cardiomyopathy, while capable of reducing left ventricular outflow tract gradient, often yields variable net effects due to potential reductions in cardiac output. The E. M. O. R. I. hyphen H. C. M. trial investigated an electromechanically optimized approach for right ventricular pacing. This method involved precise programming of the atrio-ventricular delay to maximize symptomatic benefit. The strategy provides a refined therapeutic option for managing patients with obstructive hypertrophic cardiomyopathy already equipped with pacing devices.</p>
<p>Article number three. Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium. Long-term outcomes following Fontan palliation exhibit significant variability, despite known predictions of early failure by pre-Fontan hemodynamics. A study from the Pediatric Cardiac Care Consortium investigated the association of pre-Fontan hemodynamics with long-term risks of death or transplantation. The analysis, which utilized data from a U. S. hyphen based multicenter registry, established that specific pre-Fontan hemodynamic parameters are indeed predictive of these critical long-term outcomes. This finding provides valuable insights for risk stratification and prognostic assessment in patients undergoing Fontan procedures.</p>
<p>Article number four. Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias. Polycystic ovarian syndrome is linked to increased cardiovascular morbidity, atherosclerotic cardiovascular disease, and specific electrocardiographic alterations. This study investigated the previously under-researched long-term risk of cardiac arrhythmias in women with polycystic ovarian syndrome. Researchers found a clear association between polycystic ovarian syndrome and an elevated long-term risk of various cardiac arrhythmias. This finding underscores the importance of cardiovascular surveillance in women diagnosed with polycystic ovarian syndrome.</p>
<p>Article number five. Sex and gender differences in coronary pathophysiology and ischaemic heart disease. Ischemic heart disease exhibits significant sex and gender differences, necessitating a comprehensive understanding of these dissimilarities for improved patient outcomes. This Scientific Statement reviewed current knowledge, identifying unequal impacts of traditional risk factors between men and women. The review integrated additional contributing factors, including hormonal changes, specific medical treatments for transgender people and cancer patients, and pregnancy-related conditions. This provides a critical framework for understanding diverse coronary pathophysiology and tailoring care in ischemic heart disease across sexes and genders. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>arrhythmia detection, smartwatch, pacing optimization, gender differences, cardiac output, death or transplantation, pre-Fontan hemodynamics, wearables, Fontan palliation, sex differences, pediatric cardiology, long-term outcomes, atrial fibrillation, hormonal changes, electrocardiographic alterations, right ventricular pacing, ischemic heart disease, risk factors, obstructive hypertrophic cardiomyopathy, stroke risk, atrio-ventricular delay, arrhythmias, long-term risk, polycystic ovarian syndrome, coronary pathophysiology, cardiovascular morbidity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/">PCOS Raises Long-Term Arrhythmia Risk 01/23/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260123_060033.mp3" length="4228745" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 23, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia detection and smartwatch. Key takeaway: PCOS Raises Long-Term Arrhythmia Risk.
Article Links:
Article 1: Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial. (Journal of the American College of Cardiology)
Article 2: Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. (Journal of the American College of Cardiology)
Article 3: Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium. (Circulation)
Article 4: Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias. (Circulation)
Article 5: Sex and gender differences in coronary pathophysiology and ischaemic heart disease. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/pcos-raises-long-term-arrhythmia-risk-01-23-26/
 Featured Articles
Article 1: Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41569211
Summary: Atrial fibrillation, a common cardiac arrhythmia, frequently remains undiagnosed due to its paroxysmal and asymptomatic nature, serving as a major cause of stroke. Wearable technology functions as a scalable, noninvasive screening tool for conditions like atrial fibrillation. A multicenter randomized controlled trial investigated the detection of new onset atrial fibrillation using remote smartwatch-based screening among patients sixty-five years or older with elevated stroke risk. This approach offers a significant pathway for prompt diagnosis, which is crucial for reducing stroke incidence in susceptible populations.
Article 2: Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892619
Summary: Right ventricular pacing in symptomatic obstructive hypertrophic cardiomyopathy, while capable of reducing left ventricular outflow tract gradient, often yields variable net effects due to potential reductions in cardiac output. The E. M. O. R. I. hyphen H. C. M. trial investigated an electromechanically optimized approach for right ventricular pacing. This method involved precise programming of the atrio-ventricular delay to maximize symptomatic benefit. The strategy provides a refined therapeutic option for managing patients with obstructive hypertrophic cardiomyopathy already equipped with pacing devices.
Article 3: Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41568447
Summary: Long-term outcomes following Fontan palliation exhibit significant variability, despite known predictions of early failure by pre-Fontan hemodynamics. A study from the Pediatric Cardiac Care Consortium investigated the association of pre-Fontan hemodynamics with long-term risks of death or transplantation. The analysis, which utilized data from a U. S. hyphen based multicenter registry, established that specific pre-Fontan hemodynamic parameters are indeed predictive of these critical long-term outcomes. This finding provides valuable insights for risk stratification and prognostic assessment in patients undergoing Fontan procedures.
Article 4: Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41568438
Summary: Polycystic ovarian syndrome is linked to increased cardiovascular morbidity, atherosclerotic cardiovascular disease, and specific electrocardio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 23, 2026. This episode summarizes 5 key cardiology studies on topics like arrhythmia detection and smartwatch. Key takeaway: PCOS Raises Long-Term Arrhythmia Risk.
Article Links:
Article 1: Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial. (Journal of the American College of Cardiology)
Article 2: Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. (Journal of the American College of Cardiology)
Article 3: Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium. (Circulation)
Article 4: Polycystic Ovarian Syndrome and the Long-term Risk of Arrhythmias. (Circulation)
Article 5: Sex and gender differences in coronary pathophysiology and ischaemic heart disease. (European heart journal)
Full episode page: https://podcast.explainhe]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>P.F.A. Safety in 40000 Patients 01/22/26</title>
	<link>https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/</link>
	<pubDate>Thu, 22 Jan 2026 11:01:47 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 22, 2026. This episode summarizes 5 key cardiology studies on topics like Pulsed field ablation and chlorhexidine. Key takeaway: P.F.A. Safety in 40000 Patients.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41562534">Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41389071">Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41369621">Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41217320">Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41159983">Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/">https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41562534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41562534</a></p>
<p><strong>Summary:</strong> Cardiac resynchronization therapy implantation is associated with the highest infection risk among all cardiac implantable electronic devices. Prior research comparing alcohol-based povidone-iodine and chlorhexidine for skin antisepsis in general surgical-site infections has yielded conflicting evidence. The optimal antiseptic strategy for preventing infections specifically during cardiac resynchronization therapy implantation has remained inadequately studied. This prospective randomized study directly compared the effectiveness of two percent alcohol-based chlorhexidine with povidone-iodine alcohol solution to address this critical clinical gap.</p>
<h4>Article 2: Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41389071" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41389071</a></p>
<p><strong>Summary:</strong> Pulsed field ablation for atrial fibrillation demonstrates a promising safety profile, including reduced risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. Identifying rare complications for new technologies necessitates extremely large patient cohorts. The M.A.N.I.F.E.S.T.-U.S. multicenter retrospective analysis evaluated the real-world utilization and comprehensive safety profile of the pentaspline pulsed field ablation catheter. This extensive study included data from over 40000 patients treated across the United States.</p>
<h4>Article 3: Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41369621" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41369621</a></p>
<p><strong>Summary:</strong> Long COVID syndrome is characterized by persistent symptoms such as heart palpitations, lightheadedness, and fatigue, even after acute COVID-19 infection. Autonomic dysfunction is recognized as a key component of long COVID, yet its specific nature and severity have remained largely undefined. This study performed quantitative autonomic testing to compare autonomic function measures in patients with long COVID against control subjects. The research also included a comparison with individuals diagnosed with pure autonomic failure, providing a comprehensive assessment of distinct autonomic disturbances.</p>
<h4>Article 4: Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41217320" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41217320</a></p>
<p><strong>Summary:</strong> The V.A.N.I.S.H. two multicenter randomized trial compared catheter ablation to antiarrhythmic drugs for patients with prior myocardial infarction and ventricular tachycardia. Patient randomization in the main trial was stratified according to drug eligibility based on specific clinical criteria. This prespecified substudy directly compared the clinical outcomes of catheter ablation versus antiarrhythmic drugs within these distinct drug eligibility strata. The analysis included patients defined as eligible for sotalol versus ablation based on their clinical characteristics.</p>
<h4>Article 5: Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159983" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159983</a></p>
<p><strong>Summary:</strong> Polygenic risk scores demonstrate considerable promise for risk stratification and screening in cardiovascular diseases, including atrial fibrillation. This prespecified post hoc analysis of the randomized L.O.O.P. study investigated the efficacy of atrial fibrillation screening for stroke prevention when guided by a polygenic risk score for atrial fibrillation. The analysis included 5656 individuals, all of whom were atrial fibrillation-naive and aged 70 years or older. This research evaluated the utility of genetically-informed screening strategies within a high-risk population for preventing stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 22, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study. Cardiac resynchronization therapy implantation is associated with the highest infection risk among all cardiac implantable electronic devices. Prior research comparing alcohol-based povidone-iodine and chlorhexidine for skin antisepsis in general surgical-site infections has yielded conflicting evidence. The optimal antiseptic strategy for preventing infections specifically during cardiac resynchronization therapy implantation has remained inadequately studied. This prospective randomized study directly compared the effectiveness of two percent alcohol-based chlorhexidine with povidone-iodine alcohol solution to address this critical clinical gap.</p>
<p>Article number two. Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US. Pulsed field ablation for atrial fibrillation demonstrates a promising safety profile, including reduced risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. Identifying rare complications for new technologies necessitates extremely large patient cohorts. The M.A.N.I.F.E.S.T.-U.S. multicenter retrospective analysis evaluated the real-world utilization and comprehensive safety profile of the pentaspline pulsed field ablation catheter. This extensive study included data from over 40000 patients treated across the United States.</p>
<p>Article number three. Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing. Long COVID syndrome is characterized by persistent symptoms such as heart palpitations, lightheadedness, and fatigue, even after acute COVID-19 infection. Autonomic dysfunction is recognized as a key component of long COVID, yet its specific nature and severity have remained largely undefined. This study performed quantitative autonomic testing to compare autonomic function measures in patients with long COVID against control subjects. The research also included a comparison with individuals diagnosed with pure autonomic failure, providing a comprehensive assessment of distinct autonomic disturbances.</p>
<p>Article number four. Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial. The V.A.N.I.S.H. two multicenter randomized trial compared catheter ablation to antiarrhythmic drugs for patients with prior myocardial infarction and ventricular tachycardia. Patient randomization in the main trial was stratified according to drug eligibility based on specific clinical criteria. This prespecified substudy directly compared the clinical outcomes of catheter ablation versus antiarrhythmic drugs within these distinct drug eligibility strata. The analysis included patients defined as eligible for sotalol versus ablation based on their clinical characteristics.</p>
<p>Article number five. Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Polygenic risk scores demonstrate considerable promise for risk stratification and screening in cardiovascular diseases, including atrial fibrillation. This prespecified post hoc analysis of the randomized L.O.O.P. study investigated the efficacy of atrial fibrillation screening for stroke prevention when guided by a polygenic risk score for atrial fibrillation. The analysis included 5656 individuals, all of whom were atrial fibrillation-naive and aged 70 years or older. This research evaluated the utility of genetically-informed screening strategies within a high-risk population for preventing stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Pulsed field ablation, chlorhexidine, polygenic risk score, stroke prevention, pulmonary vein stenosis, antiarrhythmic drugs, Ventricular tachycardia, povidone-iodine, myocardial infarction, heart palpitations, atrial fibrillation, esophageal injury, Atrial fibrillation, skin antisepsis, Cardiac resynchronization therapy, surgical-site infection, quantitative autonomic testing, catheter ablation, amiodarone, safety profile, L.O.O.P. study, Long COVID, autonomic dysfunction, sotalol, screening, fatigue.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/">P.F.A. Safety in 40000 Patients 01/22/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 22, 2026. This episode summarizes 5 key cardiology studies on topics like Pulsed field ablation and chlorhexidine. Key takeaway: P.F.A. Safety in 40000 Patients.
Article Links:
Article 1: Chlorhexidine vs Po]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 22, 2026. This episode summarizes 5 key cardiology studies on topics like Pulsed field ablation and chlorhexidine. Key takeaway: P.F.A. Safety in 40000 Patients.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41562534">Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41389071">Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41369621">Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41217320">Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41159983">Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/">https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41562534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41562534</a></p>
<p><strong>Summary:</strong> Cardiac resynchronization therapy implantation is associated with the highest infection risk among all cardiac implantable electronic devices. Prior research comparing alcohol-based povidone-iodine and chlorhexidine for skin antisepsis in general surgical-site infections has yielded conflicting evidence. The optimal antiseptic strategy for preventing infections specifically during cardiac resynchronization therapy implantation has remained inadequately studied. This prospective randomized study directly compared the effectiveness of two percent alcohol-based chlorhexidine with povidone-iodine alcohol solution to address this critical clinical gap.</p>
<h4>Article 2: Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41389071" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41389071</a></p>
<p><strong>Summary:</strong> Pulsed field ablation for atrial fibrillation demonstrates a promising safety profile, including reduced risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. Identifying rare complications for new technologies necessitates extremely large patient cohorts. The M.A.N.I.F.E.S.T.-U.S. multicenter retrospective analysis evaluated the real-world utilization and comprehensive safety profile of the pentaspline pulsed field ablation catheter. This extensive study included data from over 40000 patients treated across the United States.</p>
<h4>Article 3: Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41369621" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41369621</a></p>
<p><strong>Summary:</strong> Long COVID syndrome is characterized by persistent symptoms such as heart palpitations, lightheadedness, and fatigue, even after acute COVID-19 infection. Autonomic dysfunction is recognized as a key component of long COVID, yet its specific nature and severity have remained largely undefined. This study performed quantitative autonomic testing to compare autonomic function measures in patients with long COVID against control subjects. The research also included a comparison with individuals diagnosed with pure autonomic failure, providing a comprehensive assessment of distinct autonomic disturbances.</p>
<h4>Article 4: Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41217320" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41217320</a></p>
<p><strong>Summary:</strong> The V.A.N.I.S.H. two multicenter randomized trial compared catheter ablation to antiarrhythmic drugs for patients with prior myocardial infarction and ventricular tachycardia. Patient randomization in the main trial was stratified according to drug eligibility based on specific clinical criteria. This prespecified substudy directly compared the clinical outcomes of catheter ablation versus antiarrhythmic drugs within these distinct drug eligibility strata. The analysis included patients defined as eligible for sotalol versus ablation based on their clinical characteristics.</p>
<h4>Article 5: Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159983" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159983</a></p>
<p><strong>Summary:</strong> Polygenic risk scores demonstrate considerable promise for risk stratification and screening in cardiovascular diseases, including atrial fibrillation. This prespecified post hoc analysis of the randomized L.O.O.P. study investigated the efficacy of atrial fibrillation screening for stroke prevention when guided by a polygenic risk score for atrial fibrillation. The analysis included 5656 individuals, all of whom were atrial fibrillation-naive and aged 70 years or older. This research evaluated the utility of genetically-informed screening strategies within a high-risk population for preventing stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 22, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study. Cardiac resynchronization therapy implantation is associated with the highest infection risk among all cardiac implantable electronic devices. Prior research comparing alcohol-based povidone-iodine and chlorhexidine for skin antisepsis in general surgical-site infections has yielded conflicting evidence. The optimal antiseptic strategy for preventing infections specifically during cardiac resynchronization therapy implantation has remained inadequately studied. This prospective randomized study directly compared the effectiveness of two percent alcohol-based chlorhexidine with povidone-iodine alcohol solution to address this critical clinical gap.</p>
<p>Article number two. Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US. Pulsed field ablation for atrial fibrillation demonstrates a promising safety profile, including reduced risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. Identifying rare complications for new technologies necessitates extremely large patient cohorts. The M.A.N.I.F.E.S.T.-U.S. multicenter retrospective analysis evaluated the real-world utilization and comprehensive safety profile of the pentaspline pulsed field ablation catheter. This extensive study included data from over 40000 patients treated across the United States.</p>
<p>Article number three. Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing. Long COVID syndrome is characterized by persistent symptoms such as heart palpitations, lightheadedness, and fatigue, even after acute COVID-19 infection. Autonomic dysfunction is recognized as a key component of long COVID, yet its specific nature and severity have remained largely undefined. This study performed quantitative autonomic testing to compare autonomic function measures in patients with long COVID against control subjects. The research also included a comparison with individuals diagnosed with pure autonomic failure, providing a comprehensive assessment of distinct autonomic disturbances.</p>
<p>Article number four. Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial. The V.A.N.I.S.H. two multicenter randomized trial compared catheter ablation to antiarrhythmic drugs for patients with prior myocardial infarction and ventricular tachycardia. Patient randomization in the main trial was stratified according to drug eligibility based on specific clinical criteria. This prespecified substudy directly compared the clinical outcomes of catheter ablation versus antiarrhythmic drugs within these distinct drug eligibility strata. The analysis included patients defined as eligible for sotalol versus ablation based on their clinical characteristics.</p>
<p>Article number five. Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Polygenic risk scores demonstrate considerable promise for risk stratification and screening in cardiovascular diseases, including atrial fibrillation. This prespecified post hoc analysis of the randomized L.O.O.P. study investigated the efficacy of atrial fibrillation screening for stroke prevention when guided by a polygenic risk score for atrial fibrillation. The analysis included 5656 individuals, all of whom were atrial fibrillation-naive and aged 70 years or older. This research evaluated the utility of genetically-informed screening strategies within a high-risk population for preventing stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Pulsed field ablation, chlorhexidine, polygenic risk score, stroke prevention, pulmonary vein stenosis, antiarrhythmic drugs, Ventricular tachycardia, povidone-iodine, myocardial infarction, heart palpitations, atrial fibrillation, esophageal injury, Atrial fibrillation, skin antisepsis, Cardiac resynchronization therapy, surgical-site infection, quantitative autonomic testing, catheter ablation, amiodarone, safety profile, L.O.O.P. study, Long COVID, autonomic dysfunction, sotalol, screening, fatigue.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/">P.F.A. Safety in 40000 Patients 01/22/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260122_060043.mp3" length="4347445" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 22, 2026. This episode summarizes 5 key cardiology studies on topics like Pulsed field ablation and chlorhexidine. Key takeaway: P.F.A. Safety in 40000 Patients.
Article Links:
Article 1: Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study. (Journal of the American College of Cardiology)
Article 2: Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US. (Journal of the American College of Cardiology)
Article 3: Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing. (Journal of the American College of Cardiology)
Article 4: Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial. (Journal of the American College of Cardiology)
Article 5: Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/p-f-a-safety-in-40000-patients-01-22-26/
 Featured Articles
Article 1: Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41562534
Summary: Cardiac resynchronization therapy implantation is associated with the highest infection risk among all cardiac implantable electronic devices. Prior research comparing alcohol-based povidone-iodine and chlorhexidine for skin antisepsis in general surgical-site infections has yielded conflicting evidence. The optimal antiseptic strategy for preventing infections specifically during cardiac resynchronization therapy implantation has remained inadequately studied. This prospective randomized study directly compared the effectiveness of two percent alcohol-based chlorhexidine with povidone-iodine alcohol solution to address this critical clinical gap.
Article 2: Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41389071
Summary: Pulsed field ablation for atrial fibrillation demonstrates a promising safety profile, including reduced risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. Identifying rare complications for new technologies necessitates extremely large patient cohorts. The M.A.N.I.F.E.S.T.-U.S. multicenter retrospective analysis evaluated the real-world utilization and comprehensive safety profile of the pentaspline pulsed field ablation catheter. This extensive study included data from over 40000 patients treated across the United States.
Article 3: Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41369621
Summary: Long COVID syndrome is characterized by persistent symptoms such as heart palpitations, lightheadedness, and fatigue, even after acute COVID-19 infection. Autonomic dysfunction is recognized as a key component of long COVID, yet its specific nature and severity have remained largely undefined. This study performed quantitative autonomic testing to compare autonomic function measures in patients with long COVID against control subjects. The research also included a comparison with individuals diagnosed with pure autonomic failure, providing a comprehensive assessment of distinct autonomic disturbances.
Article 4: Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217320
Summary: The V.A.N.I.S.H. two multicenter randomized trial com]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 22, 2026. This episode summarizes 5 key cardiology studies on topics like Pulsed field ablation and chlorhexidine. Key takeaway: P.F.A. Safety in 40000 Patients.
Article Links:
Article 1: Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study. (Journal of the American College of Cardiology)
Article 2: Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US. (Journal of the American College of Cardiology)
Article 3: Association of Autonomic Dysfunction With Long COVID: Evaluation Using Quantitative Autonomic Testing. (Journal of the American College of Cardiology)
Article 4: Catheter Ablation vs Sotalol or Amiodarone for Ventricular Tachycardia: A Substudy of the VANISH2 Trial. (Journal of the American College of Cardiology)
Article 5: Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LO]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Asporin Stabilizes Plaque, Cuts C. V. Events 55% 01/21/26</title>
	<link>https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/</link>
	<pubDate>Wed, 21 Jan 2026 11:01:46 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 21, 2026. This episode summarizes 5 key cardiology studies on topics like inflammatory heart disease and mitral stenosis. Key takeaway: Asporin Stabilizes Plaque, Cuts C. V. Events 55%.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41558852">Myocarditis and look-alikes: when the diagnosis matters.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41558851">Pearls and pitfalls in the diagnosis and management of mitral annular calcification.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41553073">Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41558628">Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41557654">Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/">https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocarditis and look-alikes: when the diagnosis matters.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41558852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41558852</a></p>
<p><strong>Summary:</strong> Myocarditis is an inflammatory disease of the heart muscle that can be triggered by various causes. While most cases heal, selected forms of myocarditis and conditions mimicking it necessitate targeted diagnostic strategies to improve patient outcomes. Accurate diagnosis of these distinct conditions is critical because they demand individualized therapeutic approaches. The review highlighted that differentiating between myocarditis and its five look-alike conditions directly impacts treatment selection and patient prognosis.</p>
<h4>Article 2: Pearls and pitfalls in the diagnosis and management of mitral annular calcification.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41558851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41558851</a></p>
<p><strong>Summary:</strong> Mitral annular calcification is a progressive degenerative process that significantly impacts cardiovascular health. It contributes to mitral valve dysfunction, cardiac arrhythmias, systemic embolization, and increased overall cardiovascular risk. This condition now represents the primary cause of mitral stenosis in developed countries, surpassing rheumatic disease. Understanding its pathophysiology, involving chronic mechanical stress and pro-inflammatory activation, is crucial for appropriate diagnosis and management.</p>
<h4>Article 3: Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553073</a></p>
<p><strong>Summary:</strong> A study involving 315 discovery and 139 validation patients with acute heart failure found that low serum lysophospholipids, specifically lysophosphatidylcholine and lysophosphatidylethanolamine, independently predicted increased in-hospital mortality. Reduced lysophosphatidylcholine (18:2) was associated with a 2.3-fold higher risk of in-hospital mortality in the discovery cohort, with a P value of less than 0.001. This association was confirmed in the validation cohort, showing a 1.9-fold higher risk with a P value of 0.02. Combining low lysophosphatidylcholine (18:2) levels with N-terminal pro-B-type natriuretic peptide significantly improved risk stratification for acute heart failure patients.</p>
<h4>Article 4: Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41558628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41558628</a></p>
<p><strong>Summary:</strong> G protein-coupled receptor autoantibodies (G. P. C. R.-A. A.s) are identified as having implications across various cardiovascular disorders. The current evidence demonstrated that their specific prognostic value for major adverse cardiovascular events in patients with S. T.-segment elevation myocardial infarction remained unclear. In this context, a study involving 436 patients with S. T.-segment elevation myocardial infarction found that serum levels of five distinct G. P. C. R.-A. A.s—beta one, beta two, alpha one, angiotensin type one, and endothelin type one receptor autoantibodies—were measured. All included patients underwent primary percutaneous coronary intervention and completed a one-year follow-up period.</p>
<h4>Article 5: Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41557654" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41557654</a></p>
<p><strong>Summary:</strong> A study quantifying asporin protein in 176 human carotid endarterectomy plaques found that elevated asporin expression was independently associated with markers of atherosclerotic plaque stability. Specifically, higher asporin levels correlated with increased collagen type one and smooth muscle cell content, alongside reduced macrophage content and neovascularization within the plaques. The study also observed that patients with high plaque asporin expression experienced a significantly lower risk of cardiovascular events during follow-up, with a hazard ratio of 0.45 and a 95 percent confidence interval of 0.22 to 0.90. This represented a P value of 0.02 for event reduction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocarditis and look-alikes: when the diagnosis matters. Myocarditis is an inflammatory disease of the heart muscle that can be triggered by various causes. While most cases heal, selected forms of myocarditis and conditions mimicking it necessitate targeted diagnostic strategies to improve patient outcomes. Accurate diagnosis of these distinct conditions is critical because they demand individualized therapeutic approaches. The review highlighted that differentiating between myocarditis and its five look-alike conditions directly impacts treatment selection and patient prognosis.</p>
<p>Article number two. Pearls and pitfalls in the diagnosis and management of mitral annular calcification. Mitral annular calcification is a progressive degenerative process that significantly impacts cardiovascular health. It contributes to mitral valve dysfunction, cardiac arrhythmias, systemic embolization, and increased overall cardiovascular risk. This condition now represents the primary cause of mitral stenosis in developed countries, surpassing rheumatic disease. Understanding its pathophysiology, involving chronic mechanical stress and pro-inflammatory activation, is crucial for appropriate diagnosis and management.</p>
<p>Article number three. Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure. A study involving 315 discovery and 139 validation patients with acute heart failure found that low serum lysophospholipids, specifically lysophosphatidylcholine and lysophosphatidylethanolamine, independently predicted increased in-hospital mortality. Reduced lysophosphatidylcholine (18:2) was associated with a 2.3-fold higher risk of in-hospital mortality in the discovery cohort, with a P value of less than 0.001. This association was confirmed in the validation cohort, showing a 1.9-fold higher risk with a P value of 0.02. Combining low lysophosphatidylcholine (18:2) levels with N-terminal pro-B-type natriuretic peptide significantly improved risk stratification for acute heart failure patients.</p>
<p>Article number four. Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction. G protein-coupled receptor autoantibodies (G. P. C. R.-A. A.s) are identified as having implications across various cardiovascular disorders. The current evidence demonstrated that their specific prognostic value for major adverse cardiovascular events in patients with S. T.-segment elevation myocardial infarction remained unclear. In this context, a study involving 436 patients with S. T.-segment elevation myocardial infarction found that serum levels of five distinct G. P. C. R.-A. A.s—beta one, beta two, alpha one, angiotensin type one, and endothelin type one receptor autoantibodies—were measured. All included patients underwent primary percutaneous coronary intervention and completed a one-year follow-up period.</p>
<p>Article number five. Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events. A study quantifying asporin protein in 176 human carotid endarterectomy plaques found that elevated asporin expression was independently associated with markers of atherosclerotic plaque stability. Specifically, higher asporin levels correlated with increased collagen type one and smooth muscle cell content, alongside reduced macrophage content and neovascularization within the plaques. The study also observed that patients with high plaque asporin expression experienced a significantly lower risk of cardiovascular events during follow-up, with a hazard ratio of 0.45 and a 95 percent confidence interval of 0.22 to 0.90. This represented a P value of 0.02 for event reduction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>inflammatory heart disease, mitral stenosis, Mitral annular calcification, S. T.-segment elevation myocardial infarction, systemic embolization, cardiovascular events, vascular calcification, asporin, cardiac arrhythmias, prognostic value, Atherosclerotic plaques, Myocarditis, major adverse cardiovascular events, plaque stability, cardiac dysfunction, diagnostic approaches, Acute heart failure, primary percutaneous coronary intervention, targeted therapy, lysophospholipids, G protein-coupled receptor autoantibodies, in-hospital mortality, biomarkers, risk prediction, mitral valve dysfunction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/">Asporin Stabilizes Plaque, Cuts C. V. Events 55% 01/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 21, 2026. This episode summarizes 5 key cardiology studies on topics like inflammatory heart disease and mitral stenosis. Key takeaway: Asporin Stabilizes Plaque, Cuts C. V. Events 55%.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 21, 2026. This episode summarizes 5 key cardiology studies on topics like inflammatory heart disease and mitral stenosis. Key takeaway: Asporin Stabilizes Plaque, Cuts C. V. Events 55%.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41558852">Myocarditis and look-alikes: when the diagnosis matters.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41558851">Pearls and pitfalls in the diagnosis and management of mitral annular calcification.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41553073">Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41558628">Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41557654">Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/">https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocarditis and look-alikes: when the diagnosis matters.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41558852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41558852</a></p>
<p><strong>Summary:</strong> Myocarditis is an inflammatory disease of the heart muscle that can be triggered by various causes. While most cases heal, selected forms of myocarditis and conditions mimicking it necessitate targeted diagnostic strategies to improve patient outcomes. Accurate diagnosis of these distinct conditions is critical because they demand individualized therapeutic approaches. The review highlighted that differentiating between myocarditis and its five look-alike conditions directly impacts treatment selection and patient prognosis.</p>
<h4>Article 2: Pearls and pitfalls in the diagnosis and management of mitral annular calcification.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41558851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41558851</a></p>
<p><strong>Summary:</strong> Mitral annular calcification is a progressive degenerative process that significantly impacts cardiovascular health. It contributes to mitral valve dysfunction, cardiac arrhythmias, systemic embolization, and increased overall cardiovascular risk. This condition now represents the primary cause of mitral stenosis in developed countries, surpassing rheumatic disease. Understanding its pathophysiology, involving chronic mechanical stress and pro-inflammatory activation, is crucial for appropriate diagnosis and management.</p>
<h4>Article 3: Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553073</a></p>
<p><strong>Summary:</strong> A study involving 315 discovery and 139 validation patients with acute heart failure found that low serum lysophospholipids, specifically lysophosphatidylcholine and lysophosphatidylethanolamine, independently predicted increased in-hospital mortality. Reduced lysophosphatidylcholine (18:2) was associated with a 2.3-fold higher risk of in-hospital mortality in the discovery cohort, with a P value of less than 0.001. This association was confirmed in the validation cohort, showing a 1.9-fold higher risk with a P value of 0.02. Combining low lysophosphatidylcholine (18:2) levels with N-terminal pro-B-type natriuretic peptide significantly improved risk stratification for acute heart failure patients.</p>
<h4>Article 4: Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41558628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41558628</a></p>
<p><strong>Summary:</strong> G protein-coupled receptor autoantibodies (G. P. C. R.-A. A.s) are identified as having implications across various cardiovascular disorders. The current evidence demonstrated that their specific prognostic value for major adverse cardiovascular events in patients with S. T.-segment elevation myocardial infarction remained unclear. In this context, a study involving 436 patients with S. T.-segment elevation myocardial infarction found that serum levels of five distinct G. P. C. R.-A. A.s—beta one, beta two, alpha one, angiotensin type one, and endothelin type one receptor autoantibodies—were measured. All included patients underwent primary percutaneous coronary intervention and completed a one-year follow-up period.</p>
<h4>Article 5: Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41557654" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41557654</a></p>
<p><strong>Summary:</strong> A study quantifying asporin protein in 176 human carotid endarterectomy plaques found that elevated asporin expression was independently associated with markers of atherosclerotic plaque stability. Specifically, higher asporin levels correlated with increased collagen type one and smooth muscle cell content, alongside reduced macrophage content and neovascularization within the plaques. The study also observed that patients with high plaque asporin expression experienced a significantly lower risk of cardiovascular events during follow-up, with a hazard ratio of 0.45 and a 95 percent confidence interval of 0.22 to 0.90. This represented a P value of 0.02 for event reduction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocarditis and look-alikes: when the diagnosis matters. Myocarditis is an inflammatory disease of the heart muscle that can be triggered by various causes. While most cases heal, selected forms of myocarditis and conditions mimicking it necessitate targeted diagnostic strategies to improve patient outcomes. Accurate diagnosis of these distinct conditions is critical because they demand individualized therapeutic approaches. The review highlighted that differentiating between myocarditis and its five look-alike conditions directly impacts treatment selection and patient prognosis.</p>
<p>Article number two. Pearls and pitfalls in the diagnosis and management of mitral annular calcification. Mitral annular calcification is a progressive degenerative process that significantly impacts cardiovascular health. It contributes to mitral valve dysfunction, cardiac arrhythmias, systemic embolization, and increased overall cardiovascular risk. This condition now represents the primary cause of mitral stenosis in developed countries, surpassing rheumatic disease. Understanding its pathophysiology, involving chronic mechanical stress and pro-inflammatory activation, is crucial for appropriate diagnosis and management.</p>
<p>Article number three. Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure. A study involving 315 discovery and 139 validation patients with acute heart failure found that low serum lysophospholipids, specifically lysophosphatidylcholine and lysophosphatidylethanolamine, independently predicted increased in-hospital mortality. Reduced lysophosphatidylcholine (18:2) was associated with a 2.3-fold higher risk of in-hospital mortality in the discovery cohort, with a P value of less than 0.001. This association was confirmed in the validation cohort, showing a 1.9-fold higher risk with a P value of 0.02. Combining low lysophosphatidylcholine (18:2) levels with N-terminal pro-B-type natriuretic peptide significantly improved risk stratification for acute heart failure patients.</p>
<p>Article number four. Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction. G protein-coupled receptor autoantibodies (G. P. C. R.-A. A.s) are identified as having implications across various cardiovascular disorders. The current evidence demonstrated that their specific prognostic value for major adverse cardiovascular events in patients with S. T.-segment elevation myocardial infarction remained unclear. In this context, a study involving 436 patients with S. T.-segment elevation myocardial infarction found that serum levels of five distinct G. P. C. R.-A. A.s—beta one, beta two, alpha one, angiotensin type one, and endothelin type one receptor autoantibodies—were measured. All included patients underwent primary percutaneous coronary intervention and completed a one-year follow-up period.</p>
<p>Article number five. Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events. A study quantifying asporin protein in 176 human carotid endarterectomy plaques found that elevated asporin expression was independently associated with markers of atherosclerotic plaque stability. Specifically, higher asporin levels correlated with increased collagen type one and smooth muscle cell content, alongside reduced macrophage content and neovascularization within the plaques. The study also observed that patients with high plaque asporin expression experienced a significantly lower risk of cardiovascular events during follow-up, with a hazard ratio of 0.45 and a 95 percent confidence interval of 0.22 to 0.90. This represented a P value of 0.02 for event reduction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>inflammatory heart disease, mitral stenosis, Mitral annular calcification, S. T.-segment elevation myocardial infarction, systemic embolization, cardiovascular events, vascular calcification, asporin, cardiac arrhythmias, prognostic value, Atherosclerotic plaques, Myocarditis, major adverse cardiovascular events, plaque stability, cardiac dysfunction, diagnostic approaches, Acute heart failure, primary percutaneous coronary intervention, targeted therapy, lysophospholipids, G protein-coupled receptor autoantibodies, in-hospital mortality, biomarkers, risk prediction, mitral valve dysfunction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/">Asporin Stabilizes Plaque, Cuts C. V. Events 55% 01/21/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260121_060041.mp3" length="4556843" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 21, 2026. This episode summarizes 5 key cardiology studies on topics like inflammatory heart disease and mitral stenosis. Key takeaway: Asporin Stabilizes Plaque, Cuts C. V. Events 55%.
Article Links:
Article 1: Myocarditis and look-alikes: when the diagnosis matters. (Heart (British Cardiac Society))
Article 2: Pearls and pitfalls in the diagnosis and management of mitral annular calcification. (Heart (British Cardiac Society))
Article 3: Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure. (Journal of the American Heart Association)
Article 4: Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction. (International journal of cardiology)
Article 5: Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/asporin-stabilizes-plaque-cuts-c-v-events-55-01-21-26/
 Featured Articles
Article 1: Myocarditis and look-alikes: when the diagnosis matters.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41558852
Summary: Myocarditis is an inflammatory disease of the heart muscle that can be triggered by various causes. While most cases heal, selected forms of myocarditis and conditions mimicking it necessitate targeted diagnostic strategies to improve patient outcomes. Accurate diagnosis of these distinct conditions is critical because they demand individualized therapeutic approaches. The review highlighted that differentiating between myocarditis and its five look-alike conditions directly impacts treatment selection and patient prognosis.
Article 2: Pearls and pitfalls in the diagnosis and management of mitral annular calcification.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41558851
Summary: Mitral annular calcification is a progressive degenerative process that significantly impacts cardiovascular health. It contributes to mitral valve dysfunction, cardiac arrhythmias, systemic embolization, and increased overall cardiovascular risk. This condition now represents the primary cause of mitral stenosis in developed countries, surpassing rheumatic disease. Understanding its pathophysiology, involving chronic mechanical stress and pro-inflammatory activation, is crucial for appropriate diagnosis and management.
Article 3: Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41553073
Summary: A study involving 315 discovery and 139 validation patients with acute heart failure found that low serum lysophospholipids, specifically lysophosphatidylcholine and lysophosphatidylethanolamine, independently predicted increased in-hospital mortality. Reduced lysophosphatidylcholine (18:2) was associated with a 2.3-fold higher risk of in-hospital mortality in the discovery cohort, with a P value of less than 0.001. This association was confirmed in the validation cohort, showing a 1.9-fold higher risk with a P value of 0.02. Combining low lysophosphatidylcholine (18:2) levels with N-terminal pro-B-type natriuretic peptide significantly improved risk stratification for acute heart failure patients.
Article 4: Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41558628
Summary: G protein-coupled receptor autoantibodies (G. P. C. R.-A. A.s) are identified as having implications across various cardiovascular disorders. The current evidence demonstrated that their specific prognostic value for major adverse cardiovascular eve]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 21, 2026. This episode summarizes 5 key cardiology studies on topics like inflammatory heart disease and mitral stenosis. Key takeaway: Asporin Stabilizes Plaque, Cuts C. V. Events 55%.
Article Links:
Article 1: Myocarditis and look-alikes: when the diagnosis matters. (Heart (British Cardiac Society))
Article 2: Pearls and pitfalls in the diagnosis and management of mitral annular calcification. (Heart (British Cardiac Society))
Article 3: Low Serum Lysophospholipids Predict Increased In-Hospital Mortality in Patients With Acute Heart Failure. (Journal of the American Heart Association)
Article 4: Impact of G protein-coupled receptor autoantibodies on clinical outcomes in patients with ST-segment elevation myocardial infarction. (International journal of cardiology)
Article 5: Elevated asporin expression in human atherosclerotic plaques promotes their stability and reduces the risk for cardiovascular events. (Cardiovascular research)
Full]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Histone Lactylation Aggravates Aortic Aneurysm 01/20/26</title>
	<link>https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/</link>
	<pubDate>Wed, 21 Jan 2026 04:00:50 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like global mortality and global health. Key takeaway: Histone Lactylation Aggravates Aortic Aneurysm.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41556866">Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41487086">Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41556518">Environmental stressors and cardiovascular health: acting locally for global impact in a changing world.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41553092">Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41553085">Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/">https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41556866" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41556866</a></p>
<p><strong>Summary:</strong> A joint statement from leading cardiology organizations reported that non-communicable diseases account for 70 percent of global mortality, resulting in over 38 million deaths annually, with cardiovascular disease comprising most fatalities. The statement concluded that ubiquitous environmental risk factors significantly contribute to the genesis and rising prevalence of these diseases. This collective assessment underscores the critical impact of interconnected anthropogenic environmental stressors on cardiovascular health, requiring global and local action.</p>
<h4>Article 2: Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487086" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487086</a></p>
<p><strong>Summary:</strong> This study found that histone lactylation mediates metabolic remodeling in vascular smooth muscle cells. This process aggravates aortic aneurysm and dissection by promoting lactate accumulation. Researchers observed this epigenetic regulation of histone lactylation in the aorta of patients with aortic aneurysm and in a murine model of aortic aneurysm and dissection.</p>
<h4>Article 3: Environmental stressors and cardiovascular health: acting locally for global impact in a changing world.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41556518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41556518</a></p>
<p><strong>Summary:</strong> This statement from major cardiology organizations reported that non-communicable diseases cause 70 percent of global mortality, leading to over 38 million deaths annually, with cardiovascular disease as the primary contributor. It concluded that ubiquitous environmental risk factors increasingly influence the genesis and rising prevalence of non-communicable diseases. The assessment underscores the profound impact of interconnected human-caused environmental stressors on cardiovascular health.</p>
<h4>Article 4: Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553092" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553092</a></p>
<p><strong>Summary:</strong> This study established that caldesmon, an actomyosin-tropomyosin-binding protein inhibiting actomyosin adenosine triphosphatase activity, regulates vascular tone in the preglomerular renal vasculature. Researchers assessed the expression of caldesmon, myosin light chain, and alpha-smooth muscle actin in interlobar arteries from young and old mice. The study also analyzed human renal arteries from patients who underwent nephrectomy or tumor enucleation, providing further evidence for this regulatory mechanism.</p>
<h4>Article 5: Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553085" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553085</a></p>
<p><strong>Summary:</strong> This real-world study characterized the clinical impact of changing or continuing direct oral anticoagulants after a bleeding event in patients with nonvalvular atrial fibrillation. The research specifically analyzed outcomes when patients switched from or persisted with rivaroxaban or apixaban. Researchers utilized United States claims data from Optum&#8217;s Clinformatics Data Mart Database to understand treatment decisions and subsequent patient outcomes in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. A joint statement from leading cardiology organizations reported that non-communicable diseases account for 70 percent of global mortality, resulting in over 38 million deaths annually, with cardiovascular disease comprising most fatalities. The statement concluded that ubiquitous environmental risk factors significantly contribute to the genesis and rising prevalence of these diseases. This collective assessment underscores the critical impact of interconnected anthropogenic environmental stressors on cardiovascular health, requiring global and local action.</p>
<p>Article number two. Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation. This study found that histone lactylation mediates metabolic remodeling in vascular smooth muscle cells. This process aggravates aortic aneurysm and dissection by promoting lactate accumulation. Researchers observed this epigenetic regulation of histone lactylation in the aorta of patients with aortic aneurysm and in a murine model of aortic aneurysm and dissection.</p>
<p>Article number three. Environmental stressors and cardiovascular health: acting locally for global impact in a changing world. This statement from major cardiology organizations reported that non-communicable diseases cause 70 percent of global mortality, leading to over 38 million deaths annually, with cardiovascular disease as the primary contributor. It concluded that ubiquitous environmental risk factors increasingly influence the genesis and rising prevalence of non-communicable diseases. The assessment underscores the profound impact of interconnected human-caused environmental stressors on cardiovascular health.</p>
<p>Article number four. Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon. This study established that caldesmon, an actomyosin-tropomyosin-binding protein inhibiting actomyosin adenosine triphosphatase activity, regulates vascular tone in the preglomerular renal vasculature. Researchers assessed the expression of caldesmon, myosin light chain, and alpha-smooth muscle actin in interlobar arteries from young and old mice. The study also analyzed human renal arteries from patients who underwent nephrectomy or tumor enucleation, providing further evidence for this regulatory mechanism.</p>
<p>Article number five. Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation. This real-world study characterized the clinical impact of changing or continuing direct oral anticoagulants after a bleeding event in patients with nonvalvular atrial fibrillation. The research specifically analyzed outcomes when patients switched from or persisted with rivaroxaban or apixaban. Researchers utilized United States claims data from Optum&#8217;s Clinformatics Data Mart Database to understand treatment decisions and subsequent patient outcomes in this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>global mortality, global health, direct oral anticoagulants, cardiovascular disease, vascular tone, environmental stressors, interlobar arteries, non-communicable diseases, rivaroxaban, aortic aneurysm, aortic dissection, bleeding events, caldesmon, nonvalvular atrial fibrillation, metabolic remodeling, anthropogenic factors, public health, environmental risk factors, preglomerular renal vasculature, apixaban, vascular smooth muscle cells, histone lactylation, adenosine triphosphatase.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/">Histone Lactylation Aggravates Aortic Aneurysm 01/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like global mortality and global health. Key takeaway: Histone Lactylation Aggravates Aortic Aneurysm.
Article Links:
Article 1: Environme]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like global mortality and global health. Key takeaway: Histone Lactylation Aggravates Aortic Aneurysm.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41556866">Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41487086">Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41556518">Environmental stressors and cardiovascular health: acting locally for global impact in a changing world.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41553092">Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41553085">Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/">https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41556866" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41556866</a></p>
<p><strong>Summary:</strong> A joint statement from leading cardiology organizations reported that non-communicable diseases account for 70 percent of global mortality, resulting in over 38 million deaths annually, with cardiovascular disease comprising most fatalities. The statement concluded that ubiquitous environmental risk factors significantly contribute to the genesis and rising prevalence of these diseases. This collective assessment underscores the critical impact of interconnected anthropogenic environmental stressors on cardiovascular health, requiring global and local action.</p>
<h4>Article 2: Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41487086" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41487086</a></p>
<p><strong>Summary:</strong> This study found that histone lactylation mediates metabolic remodeling in vascular smooth muscle cells. This process aggravates aortic aneurysm and dissection by promoting lactate accumulation. Researchers observed this epigenetic regulation of histone lactylation in the aorta of patients with aortic aneurysm and in a murine model of aortic aneurysm and dissection.</p>
<h4>Article 3: Environmental stressors and cardiovascular health: acting locally for global impact in a changing world.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41556518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41556518</a></p>
<p><strong>Summary:</strong> This statement from major cardiology organizations reported that non-communicable diseases cause 70 percent of global mortality, leading to over 38 million deaths annually, with cardiovascular disease as the primary contributor. It concluded that ubiquitous environmental risk factors increasingly influence the genesis and rising prevalence of non-communicable diseases. The assessment underscores the profound impact of interconnected human-caused environmental stressors on cardiovascular health.</p>
<h4>Article 4: Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553092" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553092</a></p>
<p><strong>Summary:</strong> This study established that caldesmon, an actomyosin-tropomyosin-binding protein inhibiting actomyosin adenosine triphosphatase activity, regulates vascular tone in the preglomerular renal vasculature. Researchers assessed the expression of caldesmon, myosin light chain, and alpha-smooth muscle actin in interlobar arteries from young and old mice. The study also analyzed human renal arteries from patients who underwent nephrectomy or tumor enucleation, providing further evidence for this regulatory mechanism.</p>
<h4>Article 5: Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553085" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553085</a></p>
<p><strong>Summary:</strong> This real-world study characterized the clinical impact of changing or continuing direct oral anticoagulants after a bleeding event in patients with nonvalvular atrial fibrillation. The research specifically analyzed outcomes when patients switched from or persisted with rivaroxaban or apixaban. Researchers utilized United States claims data from Optum&#8217;s Clinformatics Data Mart Database to understand treatment decisions and subsequent patient outcomes in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. A joint statement from leading cardiology organizations reported that non-communicable diseases account for 70 percent of global mortality, resulting in over 38 million deaths annually, with cardiovascular disease comprising most fatalities. The statement concluded that ubiquitous environmental risk factors significantly contribute to the genesis and rising prevalence of these diseases. This collective assessment underscores the critical impact of interconnected anthropogenic environmental stressors on cardiovascular health, requiring global and local action.</p>
<p>Article number two. Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation. This study found that histone lactylation mediates metabolic remodeling in vascular smooth muscle cells. This process aggravates aortic aneurysm and dissection by promoting lactate accumulation. Researchers observed this epigenetic regulation of histone lactylation in the aorta of patients with aortic aneurysm and in a murine model of aortic aneurysm and dissection.</p>
<p>Article number three. Environmental stressors and cardiovascular health: acting locally for global impact in a changing world. This statement from major cardiology organizations reported that non-communicable diseases cause 70 percent of global mortality, leading to over 38 million deaths annually, with cardiovascular disease as the primary contributor. It concluded that ubiquitous environmental risk factors increasingly influence the genesis and rising prevalence of non-communicable diseases. The assessment underscores the profound impact of interconnected human-caused environmental stressors on cardiovascular health.</p>
<p>Article number four. Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon. This study established that caldesmon, an actomyosin-tropomyosin-binding protein inhibiting actomyosin adenosine triphosphatase activity, regulates vascular tone in the preglomerular renal vasculature. Researchers assessed the expression of caldesmon, myosin light chain, and alpha-smooth muscle actin in interlobar arteries from young and old mice. The study also analyzed human renal arteries from patients who underwent nephrectomy or tumor enucleation, providing further evidence for this regulatory mechanism.</p>
<p>Article number five. Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation. This real-world study characterized the clinical impact of changing or continuing direct oral anticoagulants after a bleeding event in patients with nonvalvular atrial fibrillation. The research specifically analyzed outcomes when patients switched from or persisted with rivaroxaban or apixaban. Researchers utilized United States claims data from Optum&#8217;s Clinformatics Data Mart Database to understand treatment decisions and subsequent patient outcomes in this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>global mortality, global health, direct oral anticoagulants, cardiovascular disease, vascular tone, environmental stressors, interlobar arteries, non-communicable diseases, rivaroxaban, aortic aneurysm, aortic dissection, bleeding events, caldesmon, nonvalvular atrial fibrillation, metabolic remodeling, anthropogenic factors, public health, environmental risk factors, preglomerular renal vasculature, apixaban, vascular smooth muscle cells, histone lactylation, adenosine triphosphatase.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/">Histone Lactylation Aggravates Aortic Aneurysm 01/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260120_225954.mp3" length="3665754" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like global mortality and global health. Key takeaway: Histone Lactylation Aggravates Aortic Aneurysm.
Article Links:
Article 1: Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. (Journal of the American College of Cardiology)
Article 2: Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation. (Circulation)
Article 3: Environmental stressors and cardiovascular health: acting locally for global impact in a changing world. (European heart journal)
Article 4: Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon. (Journal of the American Heart Association)
Article 5: Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/histone-lactylation-aggravates-aortic-aneurysm-01-20-26/
 Featured Articles
Article 1: Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41556866
Summary: A joint statement from leading cardiology organizations reported that non-communicable diseases account for 70 percent of global mortality, resulting in over 38 million deaths annually, with cardiovascular disease comprising most fatalities. The statement concluded that ubiquitous environmental risk factors significantly contribute to the genesis and rising prevalence of these diseases. This collective assessment underscores the critical impact of interconnected anthropogenic environmental stressors on cardiovascular health, requiring global and local action.
Article 2: Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41487086
Summary: This study found that histone lactylation mediates metabolic remodeling in vascular smooth muscle cells. This process aggravates aortic aneurysm and dissection by promoting lactate accumulation. Researchers observed this epigenetic regulation of histone lactylation in the aorta of patients with aortic aneurysm and in a murine model of aortic aneurysm and dissection.
Article 3: Environmental stressors and cardiovascular health: acting locally for global impact in a changing world.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41556518
Summary: This statement from major cardiology organizations reported that non-communicable diseases cause 70 percent of global mortality, leading to over 38 million deaths annually, with cardiovascular disease as the primary contributor. It concluded that ubiquitous environmental risk factors increasingly influence the genesis and rising prevalence of non-communicable diseases. The assessment underscores the profound impact of interconnected human-caused environmental stressors on cardiovascular health.
Article 4: Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41553092
Summary: This study established that caldesmon, an actomyosin-tropomyosin-binding protein inhibiting actomyosin adenosine triphosphatase activity, regulat]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like global mortality and global health. Key takeaway: Histone Lactylation Aggravates Aortic Aneurysm.
Article Links:
Article 1: Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. (Journal of the American College of Cardiology)
Article 2: Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation. (Circulation)
Article 3: Environmental stressors and cardiovascular health: acting locally for global impact in a changing world. (European heart journal)
Article 4: Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon. (Journal of the American Heart Associ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>COVID Antiviral Safety with DOACs in A. Fib 01/20/26</title>
	<link>https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/</link>
	<pubDate>Tue, 20 Jan 2026 11:02:03 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like tributyrin and imaging marker. Key takeaway: COVID Antiviral Safety with DOACs in A. Fib.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41554342">Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41554341">Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41553096">Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41553095">Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41553094">Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/">https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41554342" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41554342</a></p>
<p><strong>Summary:</strong> Oral tributyrin supplementation effectively induced T-regulatory cell-mediated immune regulation in preclinical models. This metabolically driven immunomodulator successfully prolonged allograft survival, demonstrating its potential as a safer, physiology-based approach. The findings address the critical need for alternatives to conventional immunosuppressive drugs, which carry significant toxicities. This represents a breakthrough in promoting immune tolerance.</p>
<h4>Article 2: Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41554341" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41554341</a></p>
<p><strong>Summary:</strong> Exhausted and senescent C. D. 4 plus T-cells were definitively identified as predictors of vaccine failure and severe C. O. V. I. D. minus 19 in solid organ transplant recipients. This study found that these T-cell phenotypes significantly impact immunity, with recipients developing suboptimal responses despite receiving five S. A. R. S. coronavirus 2 messenger R. N. A. based vaccine doses. The data establishes a clear link between T-cell exhaustion and vulnerability, providing a crucial biomarker for risk stratification in this vulnerable population.</p>
<h4>Article 3: Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553096" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553096</a></p>
<p><strong>Summary:</strong> Racial and ethnic minority patients exhibit higher rates of adverse ischemic events following percutaneous coronary intervention. A prespecified subanalysis from the A. G. E. N. T. I. D. E. trial meticulously evaluated the application of paclitaxel-coated balloon angioplasty for in-stent restenosis within this specific patient population. This study directly addressed the disparities in outcomes by assessing therapeutic performance in a group with known increased cardiovascular risk. The findings provide important data for optimizing care in diverse patient cohorts.</p>
<h4>Article 4: Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553095" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553095</a></p>
<p><strong>Summary:</strong> The island sign observed on computed tomography scans is definitively associated with cerebral amyloid angiopathy in patients presenting with intracerebral hemorrhage. This study established that the presence of the island sign and irregular hematoma shape on computed tomography serves as an additional imaging marker for cerebral amyloid angiopathy-related intracerebral hemorrhage. These findings improve the diagnostic capability for this specific type of hemorrhage. The analysis was based on a prospective cohort of patients with supratentorial intracerebral hemorrhage, using both computed tomography and magnetic resonance imaging.</p>
<h4>Article 5: Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553094" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553094</a></p>
<p><strong>Summary:</strong> The concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants for C. O. V. I. D. minus 19 in patients with atrial fibrillation presents significant challenges due to established potential drug-drug interactions. A territory-wide retrospective study in Hong Kong characterized the safety and effectiveness of nirmatrelvir/ritonavir in comparison to R. N. A. dependent R. N. A. polymerase inhibitors for these patients. The findings from this investigation contribute essential guidance for managing C. O. V. I. D. minus 19 in this complex patient group, optimizing antiviral strategies while addressing drug interaction risks.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models. Oral tributyrin supplementation effectively induced T-regulatory cell-mediated immune regulation in preclinical models. This metabolically driven immunomodulator successfully prolonged allograft survival, demonstrating its potential as a safer, physiology-based approach. The findings address the critical need for alternatives to conventional immunosuppressive drugs, which carry significant toxicities. This represents a breakthrough in promoting immune tolerance.</p>
<p>Article number two. Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients. Exhausted and senescent C. D. 4 plus T-cells were definitively identified as predictors of vaccine failure and severe C. O. V. I. D. minus 19 in solid organ transplant recipients. This study found that these T-cell phenotypes significantly impact immunity, with recipients developing suboptimal responses despite receiving five S. A. R. S. coronavirus 2 messenger R. N. A. based vaccine doses. The data establishes a clear link between T-cell exhaustion and vulnerability, providing a crucial biomarker for risk stratification in this vulnerable population.</p>
<p>Article number three. Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. Racial and ethnic minority patients exhibit higher rates of adverse ischemic events following percutaneous coronary intervention. A prespecified subanalysis from the A. G. E. N. T. I. D. E. trial meticulously evaluated the application of paclitaxel-coated balloon angioplasty for in-stent restenosis within this specific patient population. This study directly addressed the disparities in outcomes by assessing therapeutic performance in a group with known increased cardiovascular risk. The findings provide important data for optimizing care in diverse patient cohorts.</p>
<p>Article number four. Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage. The island sign observed on computed tomography scans is definitively associated with cerebral amyloid angiopathy in patients presenting with intracerebral hemorrhage. This study established that the presence of the island sign and irregular hematoma shape on computed tomography serves as an additional imaging marker for cerebral amyloid angiopathy-related intracerebral hemorrhage. These findings improve the diagnostic capability for this specific type of hemorrhage. The analysis was based on a prospective cohort of patients with supratentorial intracerebral hemorrhage, using both computed tomography and magnetic resonance imaging.</p>
<p>Article number five. Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. The concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants for C. O. V. I. D. minus 19 in patients with atrial fibrillation presents significant challenges due to established potential drug-drug interactions. A territory-wide retrospective study in Hong Kong characterized the safety and effectiveness of nirmatrelvir/ritonavir in comparison to R. N. A. dependent R. N. A. polymerase inhibitors for these patients. The findings from this investigation contribute essential guidance for managing C. O. V. I. D. minus 19 in this complex patient group, optimizing antiviral strategies while addressing drug interaction risks. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>tributyrin, imaging marker, cerebral amyloid angiopathy, vaccine failure, C. O. V. I. D. minus 19, C. D. 4 plus T-cells, nirmatrelvir/ritonavir, paclitaxel-coated balloon, immune regulation, percutaneous coronary intervention, direct oral anticoagulants, drug-drug interactions, racial and ethnic minority patients, computed tomography, transplantation, T-cell exhaustion, in-stent restenosis, island sign, allograft survival, T-regulatory cells, atrial fibrillation, solid organ transplant, intracerebral hemorrhage, cardiovascular disparities.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/">COVID Antiviral Safety with DOACs in A. Fib 01/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like tributyrin and imaging marker. Key takeaway: COVID Antiviral Safety with DOACs in A. Fib.
Article Links:
Article 1: Oral tributyrin s]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like tributyrin and imaging marker. Key takeaway: COVID Antiviral Safety with DOACs in A. Fib.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41554342">Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41554341">Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41553096">Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41553095">Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41553094">Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/">https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41554342" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41554342</a></p>
<p><strong>Summary:</strong> Oral tributyrin supplementation effectively induced T-regulatory cell-mediated immune regulation in preclinical models. This metabolically driven immunomodulator successfully prolonged allograft survival, demonstrating its potential as a safer, physiology-based approach. The findings address the critical need for alternatives to conventional immunosuppressive drugs, which carry significant toxicities. This represents a breakthrough in promoting immune tolerance.</p>
<h4>Article 2: Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41554341" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41554341</a></p>
<p><strong>Summary:</strong> Exhausted and senescent C. D. 4 plus T-cells were definitively identified as predictors of vaccine failure and severe C. O. V. I. D. minus 19 in solid organ transplant recipients. This study found that these T-cell phenotypes significantly impact immunity, with recipients developing suboptimal responses despite receiving five S. A. R. S. coronavirus 2 messenger R. N. A. based vaccine doses. The data establishes a clear link between T-cell exhaustion and vulnerability, providing a crucial biomarker for risk stratification in this vulnerable population.</p>
<h4>Article 3: Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553096" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553096</a></p>
<p><strong>Summary:</strong> Racial and ethnic minority patients exhibit higher rates of adverse ischemic events following percutaneous coronary intervention. A prespecified subanalysis from the A. G. E. N. T. I. D. E. trial meticulously evaluated the application of paclitaxel-coated balloon angioplasty for in-stent restenosis within this specific patient population. This study directly addressed the disparities in outcomes by assessing therapeutic performance in a group with known increased cardiovascular risk. The findings provide important data for optimizing care in diverse patient cohorts.</p>
<h4>Article 4: Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553095" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553095</a></p>
<p><strong>Summary:</strong> The island sign observed on computed tomography scans is definitively associated with cerebral amyloid angiopathy in patients presenting with intracerebral hemorrhage. This study established that the presence of the island sign and irregular hematoma shape on computed tomography serves as an additional imaging marker for cerebral amyloid angiopathy-related intracerebral hemorrhage. These findings improve the diagnostic capability for this specific type of hemorrhage. The analysis was based on a prospective cohort of patients with supratentorial intracerebral hemorrhage, using both computed tomography and magnetic resonance imaging.</p>
<h4>Article 5: Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41553094" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41553094</a></p>
<p><strong>Summary:</strong> The concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants for C. O. V. I. D. minus 19 in patients with atrial fibrillation presents significant challenges due to established potential drug-drug interactions. A territory-wide retrospective study in Hong Kong characterized the safety and effectiveness of nirmatrelvir/ritonavir in comparison to R. N. A. dependent R. N. A. polymerase inhibitors for these patients. The findings from this investigation contribute essential guidance for managing C. O. V. I. D. minus 19 in this complex patient group, optimizing antiviral strategies while addressing drug interaction risks.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 20, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models. Oral tributyrin supplementation effectively induced T-regulatory cell-mediated immune regulation in preclinical models. This metabolically driven immunomodulator successfully prolonged allograft survival, demonstrating its potential as a safer, physiology-based approach. The findings address the critical need for alternatives to conventional immunosuppressive drugs, which carry significant toxicities. This represents a breakthrough in promoting immune tolerance.</p>
<p>Article number two. Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients. Exhausted and senescent C. D. 4 plus T-cells were definitively identified as predictors of vaccine failure and severe C. O. V. I. D. minus 19 in solid organ transplant recipients. This study found that these T-cell phenotypes significantly impact immunity, with recipients developing suboptimal responses despite receiving five S. A. R. S. coronavirus 2 messenger R. N. A. based vaccine doses. The data establishes a clear link between T-cell exhaustion and vulnerability, providing a crucial biomarker for risk stratification in this vulnerable population.</p>
<p>Article number three. Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. Racial and ethnic minority patients exhibit higher rates of adverse ischemic events following percutaneous coronary intervention. A prespecified subanalysis from the A. G. E. N. T. I. D. E. trial meticulously evaluated the application of paclitaxel-coated balloon angioplasty for in-stent restenosis within this specific patient population. This study directly addressed the disparities in outcomes by assessing therapeutic performance in a group with known increased cardiovascular risk. The findings provide important data for optimizing care in diverse patient cohorts.</p>
<p>Article number four. Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage. The island sign observed on computed tomography scans is definitively associated with cerebral amyloid angiopathy in patients presenting with intracerebral hemorrhage. This study established that the presence of the island sign and irregular hematoma shape on computed tomography serves as an additional imaging marker for cerebral amyloid angiopathy-related intracerebral hemorrhage. These findings improve the diagnostic capability for this specific type of hemorrhage. The analysis was based on a prospective cohort of patients with supratentorial intracerebral hemorrhage, using both computed tomography and magnetic resonance imaging.</p>
<p>Article number five. Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. The concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants for C. O. V. I. D. minus 19 in patients with atrial fibrillation presents significant challenges due to established potential drug-drug interactions. A territory-wide retrospective study in Hong Kong characterized the safety and effectiveness of nirmatrelvir/ritonavir in comparison to R. N. A. dependent R. N. A. polymerase inhibitors for these patients. The findings from this investigation contribute essential guidance for managing C. O. V. I. D. minus 19 in this complex patient group, optimizing antiviral strategies while addressing drug interaction risks. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>tributyrin, imaging marker, cerebral amyloid angiopathy, vaccine failure, C. O. V. I. D. minus 19, C. D. 4 plus T-cells, nirmatrelvir/ritonavir, paclitaxel-coated balloon, immune regulation, percutaneous coronary intervention, direct oral anticoagulants, drug-drug interactions, racial and ethnic minority patients, computed tomography, transplantation, T-cell exhaustion, in-stent restenosis, island sign, allograft survival, T-regulatory cells, atrial fibrillation, solid organ transplant, intracerebral hemorrhage, cardiovascular disparities.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/">COVID Antiviral Safety with DOACs in A. Fib 01/20/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260120_060056.mp3" length="4568127" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like tributyrin and imaging marker. Key takeaway: COVID Antiviral Safety with DOACs in A. Fib.
Article Links:
Article 1: Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. (Journal of the American Heart Association)
Article 4: Island Sign on Computed Tomography Is Associated With Cerebral Amyloid Angiopathy in Patients With Intracerebral Hemorrhage. (Journal of the American Heart Association)
Article 5: Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/covid-antiviral-safety-with-doacs-in-a-fib-01-20-26/
 Featured Articles
Article 1: Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41554342
Summary: Oral tributyrin supplementation effectively induced T-regulatory cell-mediated immune regulation in preclinical models. This metabolically driven immunomodulator successfully prolonged allograft survival, demonstrating its potential as a safer, physiology-based approach. The findings address the critical need for alternatives to conventional immunosuppressive drugs, which carry significant toxicities. This represents a breakthrough in promoting immune tolerance.
Article 2: Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41554341
Summary: Exhausted and senescent C. D. 4 plus T-cells were definitively identified as predictors of vaccine failure and severe C. O. V. I. D. minus 19 in solid organ transplant recipients. This study found that these T-cell phenotypes significantly impact immunity, with recipients developing suboptimal responses despite receiving five S. A. R. S. coronavirus 2 messenger R. N. A. based vaccine doses. The data establishes a clear link between T-cell exhaustion and vulnerability, providing a crucial biomarker for risk stratification in this vulnerable population.
Article 3: Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41553096
Summary: Racial and ethnic minority patients exhibit higher rates of adverse ischemic events following percutaneous coronary intervention. A prespecified subanalysis from the A. G. E. N. T. I. D. E. trial meticulously evaluated the application of paclitaxel-coated balloon angioplasty for in-stent restenosis within this specific patient population. This study directly addressed the disparities in outcomes by assessing therapeutic performance in a group with known increased car]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 20, 2026. This episode summarizes 5 key cardiology studies on topics like tributyrin and imaging marker. Key takeaway: COVID Antiviral Safety with DOACs in A. Fib.
Article Links:
Article 1: Oral tributyrin supplementation induces Treg-mediated immune regulation and prolongs allograft survival in preclinical transplant models. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Exhausted/Senescent CD4+ T cells as Predictors of Vaccine Failure and Severe COVID-19 in Solid Organ Transplant Recipients. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. (Journal of the American Heart Association)]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CVD Causes 26.5% Maternal Deaths in Pregnancy 01/19/26</title>
	<link>https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/</link>
	<pubDate>Mon, 19 Jan 2026 11:01:37 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 19, 2026. This episode summarizes 5 key cardiology studies on topics like patient suitability and transcatheter tricuspid valve replacement. Key takeaway: CVD Causes 26.5% Maternal Deaths in Pregnancy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41548728">Trends, variation, and predictors of coronary angiography in potential cardiac organ donors.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41548861">Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41548860">Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41548858">Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41543984">Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/">https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Trends, variation, and predictors of coronary angiography in potential cardiac organ donors.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548728" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548728</a></p>
<p><strong>Summary:</strong> Invasive coronary angiography for screening coronary artery disease in younger potential heart donors is discretionary, leading to variation in practice. This study characterized the patterns and influencing factors of invasive coronary angiography use in brain-dead potential heart donors in the United States between 2018 and 2023. The findings clarified existing variability in screening practices for coronary artery disease in this vital population. These insights are essential for establishing standardized protocols and improving the selection process for donor hearts in transplantation.</p>
<h4>Article 2: Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548861</a></p>
<p><strong>Summary:</strong> Cardiovascular disease accounts for 26.5 percent of pregnancy-related deaths, highlighting its significant impact on maternal mortality. This retrospective cohort study characterized maternal, obstetric, and fetal outcomes among pregnant women with pre-existing cardiovascular disease. The study included patients with conditions such as moderate or greater valvular heart disease, cardiomyopathy, and congenital heart disease. These findings are crucial for optimizing management and improving safety for high-risk pregnant individuals.</p>
<h4>Article 3: Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548860" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548860</a></p>
<p><strong>Summary:</strong> Transcatheter tricuspid valve replacement demonstrates therapeutic promise for severe tricuspid regurgitation, yet many patients face ineligibility due to anatomic limitations. This study identified patients referred for transcatheter tricuspid valve intervention who were subsequently deemed ineligible for transcatheter tricuspid valve replacement. Analyzing 251 patients, the study clarified the real-world challenges of patient selection and the implications for those unable to undergo replacement due to anatomical barriers. These findings underscore the practical applicability and patient suitability for advanced tricuspid valve therapies.</p>
<h4>Article 4: Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548858" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548858</a></p>
<p><strong>Summary:</strong> A four-step comprehensive S. T. elevation myocardial infarction protocol improved process metrics and clinical outcomes for S. T. elevation myocardial infarction patients experiencing non-system delays. The observational cohort analysis demonstrated benefits in patients with factors like difficult vascular access, which commonly cause delays to primary percutaneous coronary intervention. This protocol enhances the management of high-risk S. T. elevation myocardial infarction patients who often face suboptimal outcomes due to inherent logistical challenges.</p>
<h4>Article 5: Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41543984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41543984</a></p>
<p><strong>Summary:</strong> The Akershus Cardiac Examination 4 Study is a pragmatic randomized-controlled trial designed to evaluate the effect of early biomarker measurements and structured feedback in patients hospitalized with tachypnea. This trial investigates whether early N-terminal pro-B-type natriuretic peptide and cardiac troponin T measurements, coupled with structured electronic health record feedback, improve diagnostic accuracy and risk stratification in the emergency department. The study design targets the diagnostic challenges of acute tachypnea, aiming to optimize biomarker utilization for cardiovascular disease patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Trends, variation, and predictors of coronary angiography in potential cardiac organ donors. Invasive coronary angiography for screening coronary artery disease in younger potential heart donors is discretionary, leading to variation in practice. This study characterized the patterns and influencing factors of invasive coronary angiography use in brain-dead potential heart donors in the United States between 2018 and 2023. The findings clarified existing variability in screening practices for coronary artery disease in this vital population. These insights are essential for establishing standardized protocols and improving the selection process for donor hearts in transplantation.</p>
<p>Article number two. Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California. Cardiovascular disease accounts for 26.5 percent of pregnancy-related deaths, highlighting its significant impact on maternal mortality. This retrospective cohort study characterized maternal, obstetric, and fetal outcomes among pregnant women with pre-existing cardiovascular disease. The study included patients with conditions such as moderate or greater valvular heart disease, cardiomyopathy, and congenital heart disease. These findings are crucial for optimizing management and improving safety for high-risk pregnant individuals.</p>
<p>Article number three. Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement. Transcatheter tricuspid valve replacement demonstrates therapeutic promise for severe tricuspid regurgitation, yet many patients face ineligibility due to anatomic limitations. This study identified patients referred for transcatheter tricuspid valve intervention who were subsequently deemed ineligible for transcatheter tricuspid valve replacement. Analyzing 251 patients, the study clarified the real-world challenges of patient selection and the implications for those unable to undergo replacement due to anatomical barriers. These findings underscore the practical applicability and patient suitability for advanced tricuspid valve therapies.</p>
<p>Article number four. Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay. A four-step comprehensive S. T. elevation myocardial infarction protocol improved process metrics and clinical outcomes for S. T. elevation myocardial infarction patients experiencing non-system delays. The observational cohort analysis demonstrated benefits in patients with factors like difficult vascular access, which commonly cause delays to primary percutaneous coronary intervention. This protocol enhances the management of high-risk S. T. elevation myocardial infarction patients who often face suboptimal outcomes due to inherent logistical challenges.</p>
<p>Article number five. Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea. The Akershus Cardiac Examination 4 Study is a pragmatic randomized-controlled trial designed to evaluate the effect of early biomarker measurements and structured feedback in patients hospitalized with tachypnea. This trial investigates whether early N-terminal pro-B-type natriuretic peptide and cardiac troponin T measurements, coupled with structured electronic health record feedback, improve diagnostic accuracy and risk stratification in the emergency department. The study design targets the diagnostic challenges of acute tachypnea, aiming to optimize biomarker utilization for cardiovascular disease patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>patient suitability, transcatheter tricuspid valve replacement, transcatheter tricuspid valve intervention, anatomic limitations, transplant recipients, cardiovascular disease, risk stratification, congenital heart disease, coronary artery disease, clinical outcomes, coronary angiography, valvular heart disease, heart donors, non-system delays, tachypnea, S. T. elevation myocardial infarction, pregnancy outcomes, tricuspid regurgitation, diagnostic accuracy, donor selection, comprehensive S. T. elevation myocardial infarction protocol, cardiomyopathy, emergency department, cardiac troponin T, maternal mortality, N-terminal pro-B-type natriuretic peptide, primary percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/">CVD Causes 26.5% Maternal Deaths in Pregnancy 01/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 19, 2026. This episode summarizes 5 key cardiology studies on topics like patient suitability and transcatheter tricuspid valve replacement. Key takeaway: CVD Causes 26.5% Maternal Deaths in Pregnancy.
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 19, 2026. This episode summarizes 5 key cardiology studies on topics like patient suitability and transcatheter tricuspid valve replacement. Key takeaway: CVD Causes 26.5% Maternal Deaths in Pregnancy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41548728">Trends, variation, and predictors of coronary angiography in potential cardiac organ donors.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41548861">Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41548860">Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41548858">Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41543984">Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/">https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Trends, variation, and predictors of coronary angiography in potential cardiac organ donors.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548728" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548728</a></p>
<p><strong>Summary:</strong> Invasive coronary angiography for screening coronary artery disease in younger potential heart donors is discretionary, leading to variation in practice. This study characterized the patterns and influencing factors of invasive coronary angiography use in brain-dead potential heart donors in the United States between 2018 and 2023. The findings clarified existing variability in screening practices for coronary artery disease in this vital population. These insights are essential for establishing standardized protocols and improving the selection process for donor hearts in transplantation.</p>
<h4>Article 2: Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548861</a></p>
<p><strong>Summary:</strong> Cardiovascular disease accounts for 26.5 percent of pregnancy-related deaths, highlighting its significant impact on maternal mortality. This retrospective cohort study characterized maternal, obstetric, and fetal outcomes among pregnant women with pre-existing cardiovascular disease. The study included patients with conditions such as moderate or greater valvular heart disease, cardiomyopathy, and congenital heart disease. These findings are crucial for optimizing management and improving safety for high-risk pregnant individuals.</p>
<h4>Article 3: Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548860" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548860</a></p>
<p><strong>Summary:</strong> Transcatheter tricuspid valve replacement demonstrates therapeutic promise for severe tricuspid regurgitation, yet many patients face ineligibility due to anatomic limitations. This study identified patients referred for transcatheter tricuspid valve intervention who were subsequently deemed ineligible for transcatheter tricuspid valve replacement. Analyzing 251 patients, the study clarified the real-world challenges of patient selection and the implications for those unable to undergo replacement due to anatomical barriers. These findings underscore the practical applicability and patient suitability for advanced tricuspid valve therapies.</p>
<h4>Article 4: Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41548858" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41548858</a></p>
<p><strong>Summary:</strong> A four-step comprehensive S. T. elevation myocardial infarction protocol improved process metrics and clinical outcomes for S. T. elevation myocardial infarction patients experiencing non-system delays. The observational cohort analysis demonstrated benefits in patients with factors like difficult vascular access, which commonly cause delays to primary percutaneous coronary intervention. This protocol enhances the management of high-risk S. T. elevation myocardial infarction patients who often face suboptimal outcomes due to inherent logistical challenges.</p>
<h4>Article 5: Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41543984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41543984</a></p>
<p><strong>Summary:</strong> The Akershus Cardiac Examination 4 Study is a pragmatic randomized-controlled trial designed to evaluate the effect of early biomarker measurements and structured feedback in patients hospitalized with tachypnea. This trial investigates whether early N-terminal pro-B-type natriuretic peptide and cardiac troponin T measurements, coupled with structured electronic health record feedback, improve diagnostic accuracy and risk stratification in the emergency department. The study design targets the diagnostic challenges of acute tachypnea, aiming to optimize biomarker utilization for cardiovascular disease patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 19, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Trends, variation, and predictors of coronary angiography in potential cardiac organ donors. Invasive coronary angiography for screening coronary artery disease in younger potential heart donors is discretionary, leading to variation in practice. This study characterized the patterns and influencing factors of invasive coronary angiography use in brain-dead potential heart donors in the United States between 2018 and 2023. The findings clarified existing variability in screening practices for coronary artery disease in this vital population. These insights are essential for establishing standardized protocols and improving the selection process for donor hearts in transplantation.</p>
<p>Article number two. Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California. Cardiovascular disease accounts for 26.5 percent of pregnancy-related deaths, highlighting its significant impact on maternal mortality. This retrospective cohort study characterized maternal, obstetric, and fetal outcomes among pregnant women with pre-existing cardiovascular disease. The study included patients with conditions such as moderate or greater valvular heart disease, cardiomyopathy, and congenital heart disease. These findings are crucial for optimizing management and improving safety for high-risk pregnant individuals.</p>
<p>Article number three. Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement. Transcatheter tricuspid valve replacement demonstrates therapeutic promise for severe tricuspid regurgitation, yet many patients face ineligibility due to anatomic limitations. This study identified patients referred for transcatheter tricuspid valve intervention who were subsequently deemed ineligible for transcatheter tricuspid valve replacement. Analyzing 251 patients, the study clarified the real-world challenges of patient selection and the implications for those unable to undergo replacement due to anatomical barriers. These findings underscore the practical applicability and patient suitability for advanced tricuspid valve therapies.</p>
<p>Article number four. Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay. A four-step comprehensive S. T. elevation myocardial infarction protocol improved process metrics and clinical outcomes for S. T. elevation myocardial infarction patients experiencing non-system delays. The observational cohort analysis demonstrated benefits in patients with factors like difficult vascular access, which commonly cause delays to primary percutaneous coronary intervention. This protocol enhances the management of high-risk S. T. elevation myocardial infarction patients who often face suboptimal outcomes due to inherent logistical challenges.</p>
<p>Article number five. Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea. The Akershus Cardiac Examination 4 Study is a pragmatic randomized-controlled trial designed to evaluate the effect of early biomarker measurements and structured feedback in patients hospitalized with tachypnea. This trial investigates whether early N-terminal pro-B-type natriuretic peptide and cardiac troponin T measurements, coupled with structured electronic health record feedback, improve diagnostic accuracy and risk stratification in the emergency department. The study design targets the diagnostic challenges of acute tachypnea, aiming to optimize biomarker utilization for cardiovascular disease patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>patient suitability, transcatheter tricuspid valve replacement, transcatheter tricuspid valve intervention, anatomic limitations, transplant recipients, cardiovascular disease, risk stratification, congenital heart disease, coronary artery disease, clinical outcomes, coronary angiography, valvular heart disease, heart donors, non-system delays, tachypnea, S. T. elevation myocardial infarction, pregnancy outcomes, tricuspid regurgitation, diagnostic accuracy, donor selection, comprehensive S. T. elevation myocardial infarction protocol, cardiomyopathy, emergency department, cardiac troponin T, maternal mortality, N-terminal pro-B-type natriuretic peptide, primary percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/">CVD Causes 26.5% Maternal Deaths in Pregnancy 01/19/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260119_060039.mp3" length="4088310" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 19, 2026. This episode summarizes 5 key cardiology studies on topics like patient suitability and transcatheter tricuspid valve replacement. Key takeaway: CVD Causes 26.5% Maternal Deaths in Pregnancy.
Article Links:
Article 1: Trends, variation, and predictors of coronary angiography in potential cardiac organ donors. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California. (The American journal of cardiology)
Article 3: Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement. (The American journal of cardiology)
Article 4: Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay. (The American journal of cardiology)
Article 5: Study design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic randomized-controlled trial assessing the effect of early biomarker measurements and structured feedback in unselected patients hospitalized with tachypnea. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/cvd-causes-26-5-maternal-deaths-in-pregnancy-01-19-26/
 Featured Articles
Article 1: Trends, variation, and predictors of coronary angiography in potential cardiac organ donors.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41548728
Summary: Invasive coronary angiography for screening coronary artery disease in younger potential heart donors is discretionary, leading to variation in practice. This study characterized the patterns and influencing factors of invasive coronary angiography use in brain-dead potential heart donors in the United States between 2018 and 2023. The findings clarified existing variability in screening practices for coronary artery disease in this vital population. These insights are essential for establishing standardized protocols and improving the selection process for donor hearts in transplantation.
Article 2: Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41548861
Summary: Cardiovascular disease accounts for 26.5 percent of pregnancy-related deaths, highlighting its significant impact on maternal mortality. This retrospective cohort study characterized maternal, obstetric, and fetal outcomes among pregnant women with pre-existing cardiovascular disease. The study included patients with conditions such as moderate or greater valvular heart disease, cardiomyopathy, and congenital heart disease. These findings are crucial for optimizing management and improving safety for high-risk pregnant individuals.
Article 3: Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41548860
Summary: Transcatheter tricuspid valve replacement demonstrates therapeutic promise for severe tricuspid regurgitation, yet many patients face ineligibility due to anatomic limitations. This study identified patients referred for transcatheter tricuspid valve intervention who were subsequently deemed ineligible for transcatheter tricuspid valve replacement. Analyzing 251 patients, the study clarified the real-world challenges of patient selection and the implications for those unable to undergo replacement due to anatomical barriers. These findings underscore the practical applicability and patient suitability for advanced tricuspid valve therapies.
Article 4: Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 19, 2026. This episode summarizes 5 key cardiology studies on topics like patient suitability and transcatheter tricuspid valve replacement. Key takeaway: CVD Causes 26.5% Maternal Deaths in Pregnancy.
Article Links:
Article 1: Trends, variation, and predictors of coronary angiography in potential cardiac organ donors. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Pregnancy Outcomes in Women with Cardiovascular Disease: A Retrospective Cohort Study from Kaiser Permanente Northern California. (The American journal of cardiology)
Article 3: Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement. (The American journal of cardiology)
Article 4: Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System Delay. (The American journal of cardiology)
Article 5: Study design ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Deep Learning Predicts Cardiac Output Non-Invasively. 01/18/26</title>
	<link>https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/</link>
	<pubDate>Sun, 18 Jan 2026 11:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 18, 2026. This episode summarizes 5 key cardiology studies on topics like Secondary Prevention and Cardiologist Survey. Key takeaway: Deep Learning Predicts Cardiac Output Non-Invasively..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41253239">Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41241286">Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41176200">Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41038524">Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41022247">Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/">https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41253239" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41253239</a></p>
<p><strong>Summary:</strong> This retrospective cohort study utilized cardiac magnetic resonance imaging, the gold standard for right ventricular assessment, to precisely evaluate ventricular function and structure in 268 patients with acute coronary syndrome. The study specifically addressed the previously underexplored prognostic importance of right ventricular dysfunction in this patient population. By employing this advanced imaging, the research demonstrates a critical approach to understanding comprehensive cardiac impact in acute coronary syndrome. It underscores the clinical value of assessing right ventricular involvement beyond traditional left ventricular emphasis.</p>
<h4>Article 2: Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241286" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241286</a></p>
<p><strong>Summary:</strong> This retrospective analysis revealed the real-world clinical use and effectiveness of colchicine for secondary prevention following acute myocardial infarction. The study demonstrated colchicine&#8217;s application and associated patient outcomes in a large academic setting, addressing previous unknowns. By examining colchicine utilization in practice, the research clarified its impact. This research supplements existing data from randomized controlled trials that have previously shown conflicting results regarding colchicine&#8217;s efficacy.</p>
<h4>Article 3: Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41176200" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41176200</a></p>
<p><strong>Summary:</strong> This single-center trial evaluated clinical and hemodynamic outcomes of three specific transcatheter heart valves: Symetis ACURATE Neo-2, Medtronic Evolut Pro/Pro Plus, and Edwards Sapien-3. The study generated crucial comparative data on the efficacy and safety of these newer devices for transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis. By comparing these transcatheter heart valves in a large patient cohort, the research demonstrated their respective performances, contributing to the evolving understanding of transcatheter aortic valve replacement device selection.</p>
<h4>Article 4: Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41038524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41038524</a></p>
<p><strong>Summary:</strong> This study established that deep learning accurately predicts cardiac output from seismocardiographic signals in heart failure. Seismocardiography, a non-invasive technique recording subtle chest wall vibrations from cardiac mechanical activity, proved to be an effective alternative for cardiac output determination. This non-invasive deep learning methodology offers a scalable and accessible solution, addressing the invasiveness and risks associated with standard-of-care right heart catheterization.</p>
<h4>Article 5: Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022247</a></p>
<p><strong>Summary:</strong> This survey study documented real-world approaches by cardiologists in differentiating vasospastic angina from coronary microvascular dysfunction for ischemia with nonobstructive coronary artery disease. The research highlighted current clinical practices in managing this globally recognized issue, particularly regarding endotype differentiation. Data collected via a web-based questionnaire revealed the range of diagnostic and management strategies currently employed and illuminated areas of clinician satisfaction or challenges.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging. This retrospective cohort study utilized cardiac magnetic resonance imaging, the gold standard for right ventricular assessment, to precisely evaluate ventricular function and structure in 268 patients with acute coronary syndrome. The study specifically addressed the previously underexplored prognostic importance of right ventricular dysfunction in this patient population. By employing this advanced imaging, the research demonstrates a critical approach to understanding comprehensive cardiac impact in acute coronary syndrome. It underscores the clinical value of assessing right ventricular involvement beyond traditional left ventricular emphasis.</p>
<p>Article number two. Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction. This retrospective analysis revealed the real-world clinical use and effectiveness of colchicine for secondary prevention following acute myocardial infarction. The study demonstrated colchicine&#8217;s application and associated patient outcomes in a large academic setting, addressing previous unknowns. By examining colchicine utilization in practice, the research clarified its impact. This research supplements existing data from randomized controlled trials that have previously shown conflicting results regarding colchicine&#8217;s efficacy.</p>
<p>Article number three. Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement. This single-center trial evaluated clinical and hemodynamic outcomes of three specific transcatheter heart valves: Symetis ACURATE Neo-2, Medtronic Evolut Pro/Pro Plus, and Edwards Sapien-3. The study generated crucial comparative data on the efficacy and safety of these newer devices for transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis. By comparing these transcatheter heart valves in a large patient cohort, the research demonstrated their respective performances, contributing to the evolving understanding of transcatheter aortic valve replacement device selection.</p>
<p>Article number four. Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure. This study established that deep learning accurately predicts cardiac output from seismocardiographic signals in heart failure. Seismocardiography, a non-invasive technique recording subtle chest wall vibrations from cardiac mechanical activity, proved to be an effective alternative for cardiac output determination. This non-invasive deep learning methodology offers a scalable and accessible solution, addressing the invasiveness and risks associated with standard-of-care right heart catheterization.</p>
<p>Article number five. Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease. This survey study documented real-world approaches by cardiologists in differentiating vasospastic angina from coronary microvascular dysfunction for ischemia with nonobstructive coronary artery disease. The research highlighted current clinical practices in managing this globally recognized issue, particularly regarding endotype differentiation. Data collected via a web-based questionnaire revealed the range of diagnostic and management strategies currently employed and illuminated areas of clinician satisfaction or challenges. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Secondary Prevention, Cardiologist Survey, Evolut Pro, Acute Coronary Syndrome, Vasospastic Angina, Acute Myocardial Infarction, Aortic Stenosis, Real-World Data, Cardiac Magnetic Resonance, Seismocardiography, Coronary Microvascular Dysfunction, Colchicine, Ischemia with NonObstructive Coronary Artery Disease, Transcatheter Aortic Valve Replacement, Transcatheter Heart Valve, Cardiac Output, Heart Failure, Non-Invasive Assessment, ACURATE Neo-2, Prognostic Assessment, Sapien-3, Right Ventricular Dysfunction, INOCA Management, Cardiovascular Events, Deep Learning.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/">Deep Learning Predicts Cardiac Output Non-Invasively. 01/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 18, 2026. This episode summarizes 5 key cardiology studies on topics like Secondary Prevention and Cardiologist Survey. Key takeaway: Deep Learning Predicts Cardiac Output Non-Invasively..
Article Links:
Art]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 18, 2026. This episode summarizes 5 key cardiology studies on topics like Secondary Prevention and Cardiologist Survey. Key takeaway: Deep Learning Predicts Cardiac Output Non-Invasively..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41253239">Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41241286">Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41176200">Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41038524">Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41022247">Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/">https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41253239" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41253239</a></p>
<p><strong>Summary:</strong> This retrospective cohort study utilized cardiac magnetic resonance imaging, the gold standard for right ventricular assessment, to precisely evaluate ventricular function and structure in 268 patients with acute coronary syndrome. The study specifically addressed the previously underexplored prognostic importance of right ventricular dysfunction in this patient population. By employing this advanced imaging, the research demonstrates a critical approach to understanding comprehensive cardiac impact in acute coronary syndrome. It underscores the clinical value of assessing right ventricular involvement beyond traditional left ventricular emphasis.</p>
<h4>Article 2: Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241286" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241286</a></p>
<p><strong>Summary:</strong> This retrospective analysis revealed the real-world clinical use and effectiveness of colchicine for secondary prevention following acute myocardial infarction. The study demonstrated colchicine&#8217;s application and associated patient outcomes in a large academic setting, addressing previous unknowns. By examining colchicine utilization in practice, the research clarified its impact. This research supplements existing data from randomized controlled trials that have previously shown conflicting results regarding colchicine&#8217;s efficacy.</p>
<h4>Article 3: Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41176200" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41176200</a></p>
<p><strong>Summary:</strong> This single-center trial evaluated clinical and hemodynamic outcomes of three specific transcatheter heart valves: Symetis ACURATE Neo-2, Medtronic Evolut Pro/Pro Plus, and Edwards Sapien-3. The study generated crucial comparative data on the efficacy and safety of these newer devices for transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis. By comparing these transcatheter heart valves in a large patient cohort, the research demonstrated their respective performances, contributing to the evolving understanding of transcatheter aortic valve replacement device selection.</p>
<h4>Article 4: Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41038524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41038524</a></p>
<p><strong>Summary:</strong> This study established that deep learning accurately predicts cardiac output from seismocardiographic signals in heart failure. Seismocardiography, a non-invasive technique recording subtle chest wall vibrations from cardiac mechanical activity, proved to be an effective alternative for cardiac output determination. This non-invasive deep learning methodology offers a scalable and accessible solution, addressing the invasiveness and risks associated with standard-of-care right heart catheterization.</p>
<h4>Article 5: Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022247</a></p>
<p><strong>Summary:</strong> This survey study documented real-world approaches by cardiologists in differentiating vasospastic angina from coronary microvascular dysfunction for ischemia with nonobstructive coronary artery disease. The research highlighted current clinical practices in managing this globally recognized issue, particularly regarding endotype differentiation. Data collected via a web-based questionnaire revealed the range of diagnostic and management strategies currently employed and illuminated areas of clinician satisfaction or challenges.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 18, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging. This retrospective cohort study utilized cardiac magnetic resonance imaging, the gold standard for right ventricular assessment, to precisely evaluate ventricular function and structure in 268 patients with acute coronary syndrome. The study specifically addressed the previously underexplored prognostic importance of right ventricular dysfunction in this patient population. By employing this advanced imaging, the research demonstrates a critical approach to understanding comprehensive cardiac impact in acute coronary syndrome. It underscores the clinical value of assessing right ventricular involvement beyond traditional left ventricular emphasis.</p>
<p>Article number two. Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction. This retrospective analysis revealed the real-world clinical use and effectiveness of colchicine for secondary prevention following acute myocardial infarction. The study demonstrated colchicine&#8217;s application and associated patient outcomes in a large academic setting, addressing previous unknowns. By examining colchicine utilization in practice, the research clarified its impact. This research supplements existing data from randomized controlled trials that have previously shown conflicting results regarding colchicine&#8217;s efficacy.</p>
<p>Article number three. Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement. This single-center trial evaluated clinical and hemodynamic outcomes of three specific transcatheter heart valves: Symetis ACURATE Neo-2, Medtronic Evolut Pro/Pro Plus, and Edwards Sapien-3. The study generated crucial comparative data on the efficacy and safety of these newer devices for transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis. By comparing these transcatheter heart valves in a large patient cohort, the research demonstrated their respective performances, contributing to the evolving understanding of transcatheter aortic valve replacement device selection.</p>
<p>Article number four. Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure. This study established that deep learning accurately predicts cardiac output from seismocardiographic signals in heart failure. Seismocardiography, a non-invasive technique recording subtle chest wall vibrations from cardiac mechanical activity, proved to be an effective alternative for cardiac output determination. This non-invasive deep learning methodology offers a scalable and accessible solution, addressing the invasiveness and risks associated with standard-of-care right heart catheterization.</p>
<p>Article number five. Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease. This survey study documented real-world approaches by cardiologists in differentiating vasospastic angina from coronary microvascular dysfunction for ischemia with nonobstructive coronary artery disease. The research highlighted current clinical practices in managing this globally recognized issue, particularly regarding endotype differentiation. Data collected via a web-based questionnaire revealed the range of diagnostic and management strategies currently employed and illuminated areas of clinician satisfaction or challenges. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Secondary Prevention, Cardiologist Survey, Evolut Pro, Acute Coronary Syndrome, Vasospastic Angina, Acute Myocardial Infarction, Aortic Stenosis, Real-World Data, Cardiac Magnetic Resonance, Seismocardiography, Coronary Microvascular Dysfunction, Colchicine, Ischemia with NonObstructive Coronary Artery Disease, Transcatheter Aortic Valve Replacement, Transcatheter Heart Valve, Cardiac Output, Heart Failure, Non-Invasive Assessment, ACURATE Neo-2, Prognostic Assessment, Sapien-3, Right Ventricular Dysfunction, INOCA Management, Cardiovascular Events, Deep Learning.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/">Deep Learning Predicts Cardiac Output Non-Invasively. 01/18/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260118_060031.mp3" length="4107536" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 18, 2026. This episode summarizes 5 key cardiology studies on topics like Secondary Prevention and Cardiologist Survey. Key takeaway: Deep Learning Predicts Cardiac Output Non-Invasively..
Article Links:
Article 1: Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging. (The American journal of cardiology)
Article 2: Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction. (The American journal of cardiology)
Article 3: Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement. (The American journal of cardiology)
Article 4: Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure. (The American journal of cardiology)
Article 5: Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstructive Coronary Artery Disease. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/deep-learning-predicts-cardiac-output-non-invasively-01-18-26/
 Featured Articles
Article 1: Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41253239
Summary: This retrospective cohort study utilized cardiac magnetic resonance imaging, the gold standard for right ventricular assessment, to precisely evaluate ventricular function and structure in 268 patients with acute coronary syndrome. The study specifically addressed the previously underexplored prognostic importance of right ventricular dysfunction in this patient population. By employing this advanced imaging, the research demonstrates a critical approach to understanding comprehensive cardiac impact in acute coronary syndrome. It underscores the clinical value of assessing right ventricular involvement beyond traditional left ventricular emphasis.
Article 2: Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241286
Summary: This retrospective analysis revealed the real-world clinical use and effectiveness of colchicine for secondary prevention following acute myocardial infarction. The study demonstrated colchicine&#8217;s application and associated patient outcomes in a large academic setting, addressing previous unknowns. By examining colchicine utilization in practice, the research clarified its impact. This research supplements existing data from randomized controlled trials that have previously shown conflicting results regarding colchicine&#8217;s efficacy.
Article 3: Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41176200
Summary: This single-center trial evaluated clinical and hemodynamic outcomes of three specific transcatheter heart valves: Symetis ACURATE Neo-2, Medtronic Evolut Pro/Pro Plus, and Edwards Sapien-3. The study generated crucial comparative data on the efficacy and safety of these newer devices for transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis. By comparing these transcatheter heart valves in a large patient cohort, the research demonstrated their respective performances, contributing to the evolving understanding of transcatheter aortic valve replacement device selection.
Article 4: Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41038524
Summary: This study established that deep learning accurately predicts cardiac output from seismocardio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 18, 2026. This episode summarizes 5 key cardiology studies on topics like Secondary Prevention and Cardiologist Survey. Key takeaway: Deep Learning Predicts Cardiac Output Non-Invasively..
Article Links:
Article 1: Right Ventricular Dysfunction in Acute Coronary Syndrome: Insights From Cardiac Magnetic Resonance Imaging. (The American journal of cardiology)
Article 2: Clinical Use and Effectiveness of Colchicine for Secondary Prevention Following Acute Myocardial Infarction. (The American journal of cardiology)
Article 3: Outcomes of Acurate Neo 2 Sapien 3 and Evolut Pro/Pro+ in Transcatheter Aortic Valve Replacement. (The American journal of cardiology)
Article 4: Deep Learning Predicts Cardiac Output from Seismocardiographic Signals in Heart Failure. (The American journal of cardiology)
Article 5: Survey Study to Differentiate Vasospastic Angina From Coronary Microvascular Dysfunction in Real-World Management of Ischemia With NonObstruc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TAVR in Moderate Mixed Aortic Valve Disease 01/17/26</title>
	<link>https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/</link>
	<pubDate>Sat, 17 Jan 2026 11:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 17, 2026. This episode summarizes 5 key cardiology studies on topics like Palliative care and Premature ventricular complexes. Key takeaway: TAVR in Moderate Mixed Aortic Valve Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41543940">Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use.</a> (Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41543931">Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41544991">Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41265669">Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41253240">Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/">https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41543940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41543940</a></p>
<p><strong>Summary:</strong> Patient-reported outcome measures, or PROs, are increasingly acknowledged as key outcomes in both research and clinical care for solid organ transplant recipients. These measures directly reveal health from the patient&#8217;s perspective, encompassing symptoms, functioning, and health-related quality of life. The growing global population of solid organ transplant recipients emphasizes that PROs are essential for evaluating the lived experience and value of extended life post-transplantation. Their integration supports a more comprehensive understanding of patient well-being beyond traditional clinical metrics.</p>
<h4>Article 2: Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41543931" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41543931</a></p>
<p><strong>Summary:</strong> A large multicenter cohort study analyzing 12676 heart, liver, lung, and kidney transplants performed at three Mayo Clinic sites between 2018 and 2024 found that palliative care referrals in solid organ transplant programs are infrequent and frequently reactive. The investigation classified palliative care encounters into distinct periods: pretransplant, peritransplant, and posttransplant. This approach revealed patterns of utilization, demonstrating that palliative care is often not proactively integrated into transplant recipient care. The study concludes that current practices often leave transplant recipients with high symptom burdens and complex decision-making needs inadequately addressed by palliative care.</p>
<h4>Article 3: Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41544991" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41544991</a></p>
<p><strong>Summary:</strong> This retrospective analysis investigated 59 patients who underwent first-time premature ventricular complex ablation across 71 sites. The study conducted a direct comparison of the First Deflection and Near-Field detection algorithms, both employed with the Turbomap modality on the Ensite X system. Accurate identification of the earliest activation site is critical for successful catheter ablation of premature ventricular complexes. The evaluation of these distinct annotation algorithms provides crucial information for refining mapping techniques in electrophysiology procedures.</p>
<h4>Article 4: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41265669" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41265669</a></p>
<p><strong>Summary:</strong> A study of 848 patients who underwent transcatheter aortic valve replacement, or TAVR, at a single center between January 2019 and June 2024, investigated outcomes in moderate mixed aortic valve disease, or MMAVD. Current medical evidence on TAVR largely focuses on isolated severe aortic stenosis, leaving the clinical impact of TAVR in MMAVD patients unclear. This research directly compared TAVR outcomes between patients with MMAVD and those with isolated severe aortic stenosis. The findings contribute essential data for defining appropriate treatment strategies and patient selection for TAVR in this understudied population.</p>
<h4>Article 5: Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41253240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41253240</a></p>
<p><strong>Summary:</strong> A retrospective multicenter cohort study evaluated the 180-day clinical outcomes of peripartum cardiomyopathy, or PPCM, when complicated by cardiogenic shock, or PPCM-CS. Peripartum cardiomyopathy is a rare but life-threatening condition characterized by heart failure with reduced left ventricular ejection fraction during late pregnancy or postpartum. The incidence of cardiogenic shock as a severe complication of PPCM has increased in recent years. This study provided crucial data on outcomes for PPCM-CS patients, with a specific focus on the role of mechanical circulatory support in this critically ill population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 17, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use. Patient-reported outcome measures, or PROs, are increasingly acknowledged as key outcomes in both research and clinical care for solid organ transplant recipients. These measures directly reveal health from the patient&#8217;s perspective, encompassing symptoms, functioning, and health-related quality of life. The growing global population of solid organ transplant recipients emphasizes that PROs are essential for evaluating the lived experience and value of extended life post-transplantation. Their integration supports a more comprehensive understanding of patient well-being beyond traditional clinical metrics.</p>
<p>Article number two. Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort. A large multicenter cohort study analyzing 12676 heart, liver, lung, and kidney transplants performed at three Mayo Clinic sites between 2018 and 2024 found that palliative care referrals in solid organ transplant programs are infrequent and frequently reactive. The investigation classified palliative care encounters into distinct periods: pretransplant, peritransplant, and posttransplant. This approach revealed patterns of utilization, demonstrating that palliative care is often not proactively integrated into transplant recipient care. The study concludes that current practices often leave transplant recipients with high symptom burdens and complex decision-making needs inadequately addressed by palliative care.</p>
<p>Article number three. Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation. This retrospective analysis investigated 59 patients who underwent first-time premature ventricular complex ablation across 71 sites. The study conducted a direct comparison of the First Deflection and Near-Field detection algorithms, both employed with the Turbomap modality on the Ensite X system. Accurate identification of the earliest activation site is critical for successful catheter ablation of premature ventricular complexes. The evaluation of these distinct annotation algorithms provides crucial information for refining mapping techniques in electrophysiology procedures.</p>
<p>Article number four. Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease. A study of 848 patients who underwent transcatheter aortic valve replacement, or TAVR, at a single center between January 2019 and June 2024, investigated outcomes in moderate mixed aortic valve disease, or MMAVD. Current medical evidence on TAVR largely focuses on isolated severe aortic stenosis, leaving the clinical impact of TAVR in MMAVD patients unclear. This research directly compared TAVR outcomes between patients with MMAVD and those with isolated severe aortic stenosis. The findings contribute essential data for defining appropriate treatment strategies and patient selection for TAVR in this understudied population.</p>
<p>Article number five. Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study. A retrospective multicenter cohort study evaluated the 180-day clinical outcomes of peripartum cardiomyopathy, or PPCM, when complicated by cardiogenic shock, or PPCM-CS. Peripartum cardiomyopathy is a rare but life-threatening condition characterized by heart failure with reduced left ventricular ejection fraction during late pregnancy or postpartum. The incidence of cardiogenic shock as a severe complication of PPCM has increased in recent years. This study provided crucial data on outcomes for PPCM-CS patients, with a specific focus on the role of mechanical circulatory support in this critically ill population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Palliative care, Premature ventricular complexes, solid organ transplantation, Transcatheter aortic valve replacement, heart failure, symptom burden, transplant recipients, TAVR outcomes, aortic regurgitation, moderate mixed aortic valve disease, catheter ablation, Peripartum cardiomyopathy, mechanical circulatory support, end-stage disease, aortic stenosis, patient experience, cardiogenic shock, earliest activation site, Patient-reported outcomes, left ventricular ejection fraction, mapping algorithms, health-related quality of life, electrophysiology.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/">TAVR in Moderate Mixed Aortic Valve Disease 01/17/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 17, 2026. This episode summarizes 5 key cardiology studies on topics like Palliative care and Premature ventricular complexes. Key takeaway: TAVR in Moderate Mixed Aortic Valve Disease.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 17, 2026. This episode summarizes 5 key cardiology studies on topics like Palliative care and Premature ventricular complexes. Key takeaway: TAVR in Moderate Mixed Aortic Valve Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41543940">Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use.</a> (Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41543931">Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41544991">Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41265669">Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41253240">Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/">https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41543940" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41543940</a></p>
<p><strong>Summary:</strong> Patient-reported outcome measures, or PROs, are increasingly acknowledged as key outcomes in both research and clinical care for solid organ transplant recipients. These measures directly reveal health from the patient&#8217;s perspective, encompassing symptoms, functioning, and health-related quality of life. The growing global population of solid organ transplant recipients emphasizes that PROs are essential for evaluating the lived experience and value of extended life post-transplantation. Their integration supports a more comprehensive understanding of patient well-being beyond traditional clinical metrics.</p>
<h4>Article 2: Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41543931" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41543931</a></p>
<p><strong>Summary:</strong> A large multicenter cohort study analyzing 12676 heart, liver, lung, and kidney transplants performed at three Mayo Clinic sites between 2018 and 2024 found that palliative care referrals in solid organ transplant programs are infrequent and frequently reactive. The investigation classified palliative care encounters into distinct periods: pretransplant, peritransplant, and posttransplant. This approach revealed patterns of utilization, demonstrating that palliative care is often not proactively integrated into transplant recipient care. The study concludes that current practices often leave transplant recipients with high symptom burdens and complex decision-making needs inadequately addressed by palliative care.</p>
<h4>Article 3: Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41544991" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41544991</a></p>
<p><strong>Summary:</strong> This retrospective analysis investigated 59 patients who underwent first-time premature ventricular complex ablation across 71 sites. The study conducted a direct comparison of the First Deflection and Near-Field detection algorithms, both employed with the Turbomap modality on the Ensite X system. Accurate identification of the earliest activation site is critical for successful catheter ablation of premature ventricular complexes. The evaluation of these distinct annotation algorithms provides crucial information for refining mapping techniques in electrophysiology procedures.</p>
<h4>Article 4: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41265669" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41265669</a></p>
<p><strong>Summary:</strong> A study of 848 patients who underwent transcatheter aortic valve replacement, or TAVR, at a single center between January 2019 and June 2024, investigated outcomes in moderate mixed aortic valve disease, or MMAVD. Current medical evidence on TAVR largely focuses on isolated severe aortic stenosis, leaving the clinical impact of TAVR in MMAVD patients unclear. This research directly compared TAVR outcomes between patients with MMAVD and those with isolated severe aortic stenosis. The findings contribute essential data for defining appropriate treatment strategies and patient selection for TAVR in this understudied population.</p>
<h4>Article 5: Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41253240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41253240</a></p>
<p><strong>Summary:</strong> A retrospective multicenter cohort study evaluated the 180-day clinical outcomes of peripartum cardiomyopathy, or PPCM, when complicated by cardiogenic shock, or PPCM-CS. Peripartum cardiomyopathy is a rare but life-threatening condition characterized by heart failure with reduced left ventricular ejection fraction during late pregnancy or postpartum. The incidence of cardiogenic shock as a severe complication of PPCM has increased in recent years. This study provided crucial data on outcomes for PPCM-CS patients, with a specific focus on the role of mechanical circulatory support in this critically ill population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 17, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use. Patient-reported outcome measures, or PROs, are increasingly acknowledged as key outcomes in both research and clinical care for solid organ transplant recipients. These measures directly reveal health from the patient&#8217;s perspective, encompassing symptoms, functioning, and health-related quality of life. The growing global population of solid organ transplant recipients emphasizes that PROs are essential for evaluating the lived experience and value of extended life post-transplantation. Their integration supports a more comprehensive understanding of patient well-being beyond traditional clinical metrics.</p>
<p>Article number two. Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort. A large multicenter cohort study analyzing 12676 heart, liver, lung, and kidney transplants performed at three Mayo Clinic sites between 2018 and 2024 found that palliative care referrals in solid organ transplant programs are infrequent and frequently reactive. The investigation classified palliative care encounters into distinct periods: pretransplant, peritransplant, and posttransplant. This approach revealed patterns of utilization, demonstrating that palliative care is often not proactively integrated into transplant recipient care. The study concludes that current practices often leave transplant recipients with high symptom burdens and complex decision-making needs inadequately addressed by palliative care.</p>
<p>Article number three. Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation. This retrospective analysis investigated 59 patients who underwent first-time premature ventricular complex ablation across 71 sites. The study conducted a direct comparison of the First Deflection and Near-Field detection algorithms, both employed with the Turbomap modality on the Ensite X system. Accurate identification of the earliest activation site is critical for successful catheter ablation of premature ventricular complexes. The evaluation of these distinct annotation algorithms provides crucial information for refining mapping techniques in electrophysiology procedures.</p>
<p>Article number four. Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease. A study of 848 patients who underwent transcatheter aortic valve replacement, or TAVR, at a single center between January 2019 and June 2024, investigated outcomes in moderate mixed aortic valve disease, or MMAVD. Current medical evidence on TAVR largely focuses on isolated severe aortic stenosis, leaving the clinical impact of TAVR in MMAVD patients unclear. This research directly compared TAVR outcomes between patients with MMAVD and those with isolated severe aortic stenosis. The findings contribute essential data for defining appropriate treatment strategies and patient selection for TAVR in this understudied population.</p>
<p>Article number five. Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study. A retrospective multicenter cohort study evaluated the 180-day clinical outcomes of peripartum cardiomyopathy, or PPCM, when complicated by cardiogenic shock, or PPCM-CS. Peripartum cardiomyopathy is a rare but life-threatening condition characterized by heart failure with reduced left ventricular ejection fraction during late pregnancy or postpartum. The incidence of cardiogenic shock as a severe complication of PPCM has increased in recent years. This study provided crucial data on outcomes for PPCM-CS patients, with a specific focus on the role of mechanical circulatory support in this critically ill population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Palliative care, Premature ventricular complexes, solid organ transplantation, Transcatheter aortic valve replacement, heart failure, symptom burden, transplant recipients, TAVR outcomes, aortic regurgitation, moderate mixed aortic valve disease, catheter ablation, Peripartum cardiomyopathy, mechanical circulatory support, end-stage disease, aortic stenosis, patient experience, cardiogenic shock, earliest activation site, Patient-reported outcomes, left ventricular ejection fraction, mapping algorithms, health-related quality of life, electrophysiology.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/">TAVR in Moderate Mixed Aortic Valve Disease 01/17/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260117_060036.mp3" length="4575233" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 17, 2026. This episode summarizes 5 key cardiology studies on topics like Palliative care and Premature ventricular complexes. Key takeaway: TAVR in Moderate Mixed Aortic Valve Disease.
Article Links:
Article 1: Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use. (Transplantation)
Article 2: Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort. (Transplantation)
Article 3: Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation. (Heart rhythm)
Article 4: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease. (The American journal of cardiology)
Article 5: Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/tavr-in-moderate-mixed-aortic-valve-disease-01-17-26/
 Featured Articles
Article 1: Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41543940
Summary: Patient-reported outcome measures, or PROs, are increasingly acknowledged as key outcomes in both research and clinical care for solid organ transplant recipients. These measures directly reveal health from the patient&#8217;s perspective, encompassing symptoms, functioning, and health-related quality of life. The growing global population of solid organ transplant recipients emphasizes that PROs are essential for evaluating the lived experience and value of extended life post-transplantation. Their integration supports a more comprehensive understanding of patient well-being beyond traditional clinical metrics.
Article 2: Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41543931
Summary: A large multicenter cohort study analyzing 12676 heart, liver, lung, and kidney transplants performed at three Mayo Clinic sites between 2018 and 2024 found that palliative care referrals in solid organ transplant programs are infrequent and frequently reactive. The investigation classified palliative care encounters into distinct periods: pretransplant, peritransplant, and posttransplant. This approach revealed patterns of utilization, demonstrating that palliative care is often not proactively integrated into transplant recipient care. The study concludes that current practices often leave transplant recipients with high symptom burdens and complex decision-making needs inadequately addressed by palliative care.
Article 3: Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41544991
Summary: This retrospective analysis investigated 59 patients who underwent first-time premature ventricular complex ablation across 71 sites. The study conducted a direct comparison of the First Deflection and Near-Field detection algorithms, both employed with the Turbomap modality on the Ensite X system. Accurate identification of the earliest activation site is critical for successful catheter ablation of premature ventricular complexes. The evaluation of these distinct annotation algorithms provides crucial information for refining mapping techniques in electrophysiology procedures.
Article 4: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41265669
]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 17, 2026. This episode summarizes 5 key cardiology studies on topics like Palliative care and Premature ventricular complexes. Key takeaway: TAVR in Moderate Mixed Aortic Valve Disease.
Article Links:
Article 1: Patient-reported Outcome Measures in Solid Organ Transplant Recipients: Current Use, Challenges, and Recommendations for Future Use. (Transplantation)
Article 2: Palliative Care Utilization and Timing for Patients Undergoing Solid Organ Transplantation in a Large Multicenter Cohort. (Transplantation)
Article 3: Comparison of First Deflection Annotation Algorithm and Near-Field Annotation Algorithm in Premature Ventricular Complex Ablation. (Heart rhythm)
Article 4: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Moderate Mixed Aortic Valve Disease. (The American journal of cardiology)
Article 5: Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort S]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>E-Cigarette Risks for Stroke Survivors 01/16/26</title>
	<link>https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/</link>
	<pubDate>Fri, 16 Jan 2026 11:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like stroke survivors and dementia. Key takeaway: E-Cigarette Risks for Stroke Survivors.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41206213">High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40878356">C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41532536">Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532534">Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532531">Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/">https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206213" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206213</a></p>
<p><strong>Summary:</strong> The Whitehall two study reported a long-term association between subclinical myocardial injury, measured by high-sensitivity cardiac troponin I in midlife, and the risk of dementia. The data demonstrated that elevated cardiac troponin I levels were linked to accelerated cognitive decline, smaller structural brain volume, and a higher risk of incident dementia over 25 years. This study involved 5985 participants aged 45 to 69, with follow-up extending until March 2023. This finding suggests a critical connection between midlife cardiovascular health and neurocognitive outcomes.</p>
<h4>Article 2: C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878356</a></p>
<p><strong>Summary:</strong> This study highlighted the substantial proportion of incident cardiovascular events occurring in women who lack standard modifiable cardiovascular risk factors (S. M. U. R. F. s). It found that high-sensitivity C-reactive protein serves as a crucial inflammatory biomarker for identifying cardiovascular risk in these &#8220;S. M. U. R. F. less but inflamed&#8221; women. The research underscored the importance of integrating non-traditional risk markers for improved cardiovascular disease detection and treatment strategies in this population.</p>
<h4>Article 3: Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532536" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532536</a></p>
<p><strong>Summary:</strong> This research identified that hypertension is the most common comorbid condition in stroke patients, affecting approximately 94 percent, and significantly worsens stroke outcomes. It demonstrated the therapeutic potential of targeting Tyrosine Phosphatase S. T. E. P. with a peptide mimetic as a novel strategy to regulate the impact of hypertension on stroke. This approach focuses on improving treatment for stroke patients with coexisting hypertension, addressing a key challenge in stroke pathophysiology.</p>
<h4>Article 4: Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532534</a></p>
<p><strong>Summary:</strong> This nationwide retrospective cohort study of Korean men characterized the differing cardiovascular risks among stroke survivors who use combustible versus electronic cigarettes (e-cigarettes). The research systematically compared the incidence of major cardiovascular events across four distinct groups of cigarette and e-cigarette users. It underscored the critical need to understand the cardiovascular impact of electronic cigarettes, especially in this vulnerable patient population, utilizing national health checkup data from 2018 to 2022.</p>
<h4>Article 5: Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532531</a></p>
<p><strong>Summary:</strong> This study elucidated the strong association between spontaneous intracerebral hemorrhage (I. C. H.) and the development of long-term cognitive impairment and neuropsychiatric symptoms (N. P. S.), particularly affective disturbances like depression and anxiety. It investigated the role of cerebral microbleeds and clarified the contribution of small vessel disease (S. V. D.), which underlies most I. C. H. cases, to persistent affective symptoms. The research involved 95 I. C. H. survivors assessed at a median of 5.7 years post-event.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study. The Whitehall two study reported a long-term association between subclinical myocardial injury, measured by high-sensitivity cardiac troponin I in midlife, and the risk of dementia. The data demonstrated that elevated cardiac troponin I levels were linked to accelerated cognitive decline, smaller structural brain volume, and a higher risk of incident dementia over 25 years. This study involved 5985 participants aged 45 to 69, with follow-up extending until March 2023. This finding suggests a critical connection between midlife cardiovascular health and neurocognitive outcomes.</p>
<p>Article number two. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;. This study highlighted the substantial proportion of incident cardiovascular events occurring in women who lack standard modifiable cardiovascular risk factors (S. M. U. R. F. s). It found that high-sensitivity C-reactive protein serves as a crucial inflammatory biomarker for identifying cardiovascular risk in these &#8220;S. M. U. R. F. less but inflamed&#8221; women. The research underscored the importance of integrating non-traditional risk markers for improved cardiovascular disease detection and treatment strategies in this population.</p>
<p>Article number three. Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP. This research identified that hypertension is the most common comorbid condition in stroke patients, affecting approximately 94 percent, and significantly worsens stroke outcomes. It demonstrated the therapeutic potential of targeting Tyrosine Phosphatase S. T. E. P. with a peptide mimetic as a novel strategy to regulate the impact of hypertension on stroke. This approach focuses on improving treatment for stroke patients with coexisting hypertension, addressing a key challenge in stroke pathophysiology.</p>
<p>Article number four. Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men. This nationwide retrospective cohort study of Korean men characterized the differing cardiovascular risks among stroke survivors who use combustible versus electronic cigarettes (e-cigarettes). The research systematically compared the incidence of major cardiovascular events across four distinct groups of cigarette and e-cigarette users. It underscored the critical need to understand the cardiovascular impact of electronic cigarettes, especially in this vulnerable patient population, utilizing national health checkup data from 2018 to 2022.</p>
<p>Article number five. Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage. This study elucidated the strong association between spontaneous intracerebral hemorrhage (I. C. H.) and the development of long-term cognitive impairment and neuropsychiatric symptoms (N. P. S.), particularly affective disturbances like depression and anxiety. It investigated the role of cerebral microbleeds and clarified the contribution of small vessel disease (S. V. D.), which underlies most I. C. H. cases, to persistent affective symptoms. The research involved 95 I. C. H. survivors assessed at a median of 5.7 years post-event. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>stroke survivors, dementia, cerebral microbleeds, Korean men, Tyrosine Phosphatase S. T. E. P., affective symptoms, electronic cigarettes, Whitehall two study, cognitive decline, high-sensitivity C-reactive protein, peptide mimetic, standard modifiable cardiovascular risk factors, combustible cigarettes, spontaneous intracerebral hemorrhage, comorbidity, inflammation, major cardiovascular events, neuropsychiatric symptoms, hypertension, stroke, high-sensitivity cardiac troponin I, myocardial injury, small vessel disease, cardiovascular risk, women.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/">E-Cigarette Risks for Stroke Survivors 01/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like stroke survivors and dementia. Key takeaway: E-Cigarette Risks for Stroke Survivors.
Article Links:
Article 1: High-sensitivity cardi]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like stroke survivors and dementia. Key takeaway: E-Cigarette Risks for Stroke Survivors.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41206213">High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40878356">C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41532536">Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532534">Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532531">Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/">https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206213" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206213</a></p>
<p><strong>Summary:</strong> The Whitehall two study reported a long-term association between subclinical myocardial injury, measured by high-sensitivity cardiac troponin I in midlife, and the risk of dementia. The data demonstrated that elevated cardiac troponin I levels were linked to accelerated cognitive decline, smaller structural brain volume, and a higher risk of incident dementia over 25 years. This study involved 5985 participants aged 45 to 69, with follow-up extending until March 2023. This finding suggests a critical connection between midlife cardiovascular health and neurocognitive outcomes.</p>
<h4>Article 2: C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878356</a></p>
<p><strong>Summary:</strong> This study highlighted the substantial proportion of incident cardiovascular events occurring in women who lack standard modifiable cardiovascular risk factors (S. M. U. R. F. s). It found that high-sensitivity C-reactive protein serves as a crucial inflammatory biomarker for identifying cardiovascular risk in these &#8220;S. M. U. R. F. less but inflamed&#8221; women. The research underscored the importance of integrating non-traditional risk markers for improved cardiovascular disease detection and treatment strategies in this population.</p>
<h4>Article 3: Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532536" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532536</a></p>
<p><strong>Summary:</strong> This research identified that hypertension is the most common comorbid condition in stroke patients, affecting approximately 94 percent, and significantly worsens stroke outcomes. It demonstrated the therapeutic potential of targeting Tyrosine Phosphatase S. T. E. P. with a peptide mimetic as a novel strategy to regulate the impact of hypertension on stroke. This approach focuses on improving treatment for stroke patients with coexisting hypertension, addressing a key challenge in stroke pathophysiology.</p>
<h4>Article 4: Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532534</a></p>
<p><strong>Summary:</strong> This nationwide retrospective cohort study of Korean men characterized the differing cardiovascular risks among stroke survivors who use combustible versus electronic cigarettes (e-cigarettes). The research systematically compared the incidence of major cardiovascular events across four distinct groups of cigarette and e-cigarette users. It underscored the critical need to understand the cardiovascular impact of electronic cigarettes, especially in this vulnerable patient population, utilizing national health checkup data from 2018 to 2022.</p>
<h4>Article 5: Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532531</a></p>
<p><strong>Summary:</strong> This study elucidated the strong association between spontaneous intracerebral hemorrhage (I. C. H.) and the development of long-term cognitive impairment and neuropsychiatric symptoms (N. P. S.), particularly affective disturbances like depression and anxiety. It investigated the role of cerebral microbleeds and clarified the contribution of small vessel disease (S. V. D.), which underlies most I. C. H. cases, to persistent affective symptoms. The research involved 95 I. C. H. survivors assessed at a median of 5.7 years post-event.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study. The Whitehall two study reported a long-term association between subclinical myocardial injury, measured by high-sensitivity cardiac troponin I in midlife, and the risk of dementia. The data demonstrated that elevated cardiac troponin I levels were linked to accelerated cognitive decline, smaller structural brain volume, and a higher risk of incident dementia over 25 years. This study involved 5985 participants aged 45 to 69, with follow-up extending until March 2023. This finding suggests a critical connection between midlife cardiovascular health and neurocognitive outcomes.</p>
<p>Article number two. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;. This study highlighted the substantial proportion of incident cardiovascular events occurring in women who lack standard modifiable cardiovascular risk factors (S. M. U. R. F. s). It found that high-sensitivity C-reactive protein serves as a crucial inflammatory biomarker for identifying cardiovascular risk in these &#8220;S. M. U. R. F. less but inflamed&#8221; women. The research underscored the importance of integrating non-traditional risk markers for improved cardiovascular disease detection and treatment strategies in this population.</p>
<p>Article number three. Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP. This research identified that hypertension is the most common comorbid condition in stroke patients, affecting approximately 94 percent, and significantly worsens stroke outcomes. It demonstrated the therapeutic potential of targeting Tyrosine Phosphatase S. T. E. P. with a peptide mimetic as a novel strategy to regulate the impact of hypertension on stroke. This approach focuses on improving treatment for stroke patients with coexisting hypertension, addressing a key challenge in stroke pathophysiology.</p>
<p>Article number four. Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men. This nationwide retrospective cohort study of Korean men characterized the differing cardiovascular risks among stroke survivors who use combustible versus electronic cigarettes (e-cigarettes). The research systematically compared the incidence of major cardiovascular events across four distinct groups of cigarette and e-cigarette users. It underscored the critical need to understand the cardiovascular impact of electronic cigarettes, especially in this vulnerable patient population, utilizing national health checkup data from 2018 to 2022.</p>
<p>Article number five. Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage. This study elucidated the strong association between spontaneous intracerebral hemorrhage (I. C. H.) and the development of long-term cognitive impairment and neuropsychiatric symptoms (N. P. S.), particularly affective disturbances like depression and anxiety. It investigated the role of cerebral microbleeds and clarified the contribution of small vessel disease (S. V. D.), which underlies most I. C. H. cases, to persistent affective symptoms. The research involved 95 I. C. H. survivors assessed at a median of 5.7 years post-event. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>stroke survivors, dementia, cerebral microbleeds, Korean men, Tyrosine Phosphatase S. T. E. P., affective symptoms, electronic cigarettes, Whitehall two study, cognitive decline, high-sensitivity C-reactive protein, peptide mimetic, standard modifiable cardiovascular risk factors, combustible cigarettes, spontaneous intracerebral hemorrhage, comorbidity, inflammation, major cardiovascular events, neuropsychiatric symptoms, hypertension, stroke, high-sensitivity cardiac troponin I, myocardial injury, small vessel disease, cardiovascular risk, women.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/">E-Cigarette Risks for Stroke Survivors 01/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260116_060043.mp3" length="4166469" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like stroke survivors and dementia. Key takeaway: E-Cigarette Risks for Stroke Survivors.
Article Links:
Article 1: High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study. (European heart journal)
Article 2: C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;. (European heart journal)
Article 3: Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP. (Journal of the American Heart Association)
Article 4: Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men. (Journal of the American Heart Association)
Article 5: Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intracerebral Hemorrhage. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/e-cigarette-risks-for-stroke-survivors-01-16-26/
 Featured Articles
Article 1: High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206213
Summary: The Whitehall two study reported a long-term association between subclinical myocardial injury, measured by high-sensitivity cardiac troponin I in midlife, and the risk of dementia. The data demonstrated that elevated cardiac troponin I levels were linked to accelerated cognitive decline, smaller structural brain volume, and a higher risk of incident dementia over 25 years. This study involved 5985 participants aged 45 to 69, with follow-up extending until March 2023. This finding suggests a critical connection between midlife cardiovascular health and neurocognitive outcomes.
Article 2: C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878356
Summary: This study highlighted the substantial proportion of incident cardiovascular events occurring in women who lack standard modifiable cardiovascular risk factors (S. M. U. R. F. s). It found that high-sensitivity C-reactive protein serves as a crucial inflammatory biomarker for identifying cardiovascular risk in these &#8220;S. M. U. R. F. less but inflamed&#8221; women. The research underscored the importance of integrating non-traditional risk markers for improved cardiovascular disease detection and treatment strategies in this population.
Article 3: Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532536
Summary: This research identified that hypertension is the most common comorbid condition in stroke patients, affecting approximately 94 percent, and significantly worsens stroke outcomes. It demonstrated the therapeutic potential of targeting Tyrosine Phosphatase S. T. E. P. with a peptide mimetic as a novel strategy to regulate the impact of hypertension on stroke. This approach focuses on improving treatment for stroke patients with coexisting hypertension, addressing a key challenge in stroke pathophysiology.
Article 4: Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532534
Summary: This nationwide retrospective cohort study of Korean men characterized the differing cardiovascular risks among stroke survivors who use combustible versus electronic cigarettes (e-cigarettes). The research s]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like stroke survivors and dementia. Key takeaway: E-Cigarette Risks for Stroke Survivors.
Article Links:
Article 1: High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study. (European heart journal)
Article 2: C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the &#8216;SMuRF-less but inflamed&#8217;. (European heart journal)
Article 3: Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP. (Journal of the American Heart Association)
Article 4: Cardiovascular Risk Among Stroke Survivors With Combustible and Electronic Cigarettes: A Nationwide Study in Korean Men. (Journal of the American Heart Association)
Article 5: Cerebral Microbleeds and Long-Term Affective Symptoms in Survivors of Spontaneous Intrac]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Substance P Drives Aldosterone in Hypertension. 01/16/26</title>
	<link>https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/</link>
	<pubDate>Fri, 16 Jan 2026 07:34:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like neurokinin type one receptor and heat-related illness. Key takeaway: Substance P Drives Aldosterone in Hypertension..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41532542">Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41532541">Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41532540">Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532539">Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532538">Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/">https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532542</a></p>
<p><strong>Summary:</strong> This study found significant associations of baseline serum complement C3 and complement C4 levels with the prognosis of ischemic stroke. The research demonstrated a link between these complement biomarkers and the primary outcome of death or major disability at discharge. These findings indicate the complement system&#8217;s involvement in the progression of ischemic stroke among the 3979 patients analyzed. The work underscores the potential of complement C3 and complement C4 as prognostic markers for adverse clinical outcomes in this patient population.</p>
<h4>Article 2: Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532541</a></p>
<p><strong>Summary:</strong> This study found that Substance P and the neurokinin type one receptor are highly expressed in human aldosterone-producing adenoma tissues. Exogenous Substance P stimulated aldosterone secretion in human aldosterone-producing adenoma cells in a dose-dependent manner. This stimulatory effect was blocked by a neurokinin type one receptor antagonist, demonstrating specific receptor mediation. Furthermore, the research showed that neurokinin type one receptor activation increased intracellular calcium concentration, elucidating a mechanistic pathway for aldosterone production.</p>
<h4>Article 3: Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532540" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532540</a></p>
<p><strong>Summary:</strong> This study identified critical temperature thresholds that increase vulnerability to heat-related excess cardiovascular morbidity and mortality. Researchers established neighborhood-level associations between high-resolution temperature and humidity and cardiovascular disease deaths and emergency department visits. The findings revealed specific community-level vulnerabilities linked to sociodemographic characteristics, which influence cardiovascular outcomes during extreme heat events. This work provides essential data for understanding and mitigating the impact of environmental heat on cardiovascular health across different populations.</p>
<h4>Article 4: Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532539" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532539</a></p>
<p><strong>Summary:</strong> This study found that preprocedural left atrial strain predicts long-term outcomes following mitral valve interventions in patients with rheumatic severe mitral stenosis. The research utilized data from the MASTER registry to establish specific predictive relationships for patient prognosis. Patients undergoing percutaneous mitral valvuloplasty or mitral valve replacement demonstrated outcomes correlated with their baseline left atrial strain measurements. These findings highlight left atrial strain as a valuable prognostic indicator for risk stratification and treatment planning in this specific patient population.</p>
<h4>Article 5: Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532538" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532538</a></p>
<p><strong>Summary:</strong> This prospective cohort study found a significant relationship between mitochondria-derived methylmalonic acid and the progress and mortality risk in United States adults with cardiovascular-kidney-metabolic syndrome. The research utilized data from the National Health and Nutrition Examination Survey to establish this association, identifying methylmalonic acid as a relevant biomarker. Multinomial logistic regression analysis demonstrated that elevated methylmalonic acid levels correlated with adverse outcomes within the cardiovascular-kidney-metabolic syndrome patient population. These findings indicate methylmalonic acid plays a role in the pathophysiology of cardiovascular-kidney-metabolic syndrome and serves as a prognostic indicator for disease progression and mortality.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke. This study found significant associations of baseline serum complement C3 and complement C4 levels with the prognosis of ischemic stroke. The research demonstrated a link between these complement biomarkers and the primary outcome of death or major disability at discharge. These findings indicate the complement system&#8217;s involvement in the progression of ischemic stroke among the 3979 patients analyzed. The work underscores the potential of complement C3 and complement C4 as prognostic markers for adverse clinical outcomes in this patient population.</p>
<p>Article number two. Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas. This study found that Substance P and the neurokinin type one receptor are highly expressed in human aldosterone-producing adenoma tissues. Exogenous Substance P stimulated aldosterone secretion in human aldosterone-producing adenoma cells in a dose-dependent manner. This stimulatory effect was blocked by a neurokinin type one receptor antagonist, demonstrating specific receptor mediation. Furthermore, the research showed that neurokinin type one receptor activation increased intracellular calcium concentration, elucidating a mechanistic pathway for aldosterone production.</p>
<p>Article number three. Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality. This study identified critical temperature thresholds that increase vulnerability to heat-related excess cardiovascular morbidity and mortality. Researchers established neighborhood-level associations between high-resolution temperature and humidity and cardiovascular disease deaths and emergency department visits. The findings revealed specific community-level vulnerabilities linked to sociodemographic characteristics, which influence cardiovascular outcomes during extreme heat events. This work provides essential data for understanding and mitigating the impact of environmental heat on cardiovascular health across different populations.</p>
<p>Article number four. Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis. This study found that preprocedural left atrial strain predicts long-term outcomes following mitral valve interventions in patients with rheumatic severe mitral stenosis. The research utilized data from the MASTER registry to establish specific predictive relationships for patient prognosis. Patients undergoing percutaneous mitral valvuloplasty or mitral valve replacement demonstrated outcomes correlated with their baseline left atrial strain measurements. These findings highlight left atrial strain as a valuable prognostic indicator for risk stratification and treatment planning in this specific patient population.</p>
<p>Article number five. Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome. This prospective cohort study found a significant relationship between mitochondria-derived methylmalonic acid and the progress and mortality risk in United States adults with cardiovascular-kidney-metabolic syndrome. The research utilized data from the National Health and Nutrition Examination Survey to establish this association, identifying methylmalonic acid as a relevant biomarker. Multinomial logistic regression analysis demonstrated that elevated methylmalonic acid levels correlated with adverse outcomes within the cardiovascular-kidney-metabolic syndrome patient population. These findings indicate methylmalonic acid plays a role in the pathophysiology of cardiovascular-kidney-metabolic syndrome and serves as a prognostic indicator for disease progression and mortality. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>neurokinin type one receptor, heat-related illness, mitral valve intervention, mortality, percutaneous mitral valvuloplasty, cardiovascular disease, prognosis, complement C4, temperature thresholds, primary aldosteronism, mitochondrial dysfunction, complement C3, ischemic stroke, mitral stenosis, biomarker, cardiovascular-kidney-metabolic syndrome, hypertension, aldosterone secretion, morbidity, left atrial strain, mortality risk, environmental hazard, rheumatic heart disease, aldosterone-producing adenoma, complement system, adverse clinical outcomes, methylmalonic acid, Substance P.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/">Substance P Drives Aldosterone in Hypertension. 01/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like neurokinin type one receptor and heat-related illness. Key takeaway: Substance P Drives Aldosterone in Hypertension..
Article Links:
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like neurokinin type one receptor and heat-related illness. Key takeaway: Substance P Drives Aldosterone in Hypertension..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41532542">Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41532541">Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41532540">Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532539">Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532538">Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/">https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532542</a></p>
<p><strong>Summary:</strong> This study found significant associations of baseline serum complement C3 and complement C4 levels with the prognosis of ischemic stroke. The research demonstrated a link between these complement biomarkers and the primary outcome of death or major disability at discharge. These findings indicate the complement system&#8217;s involvement in the progression of ischemic stroke among the 3979 patients analyzed. The work underscores the potential of complement C3 and complement C4 as prognostic markers for adverse clinical outcomes in this patient population.</p>
<h4>Article 2: Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532541</a></p>
<p><strong>Summary:</strong> This study found that Substance P and the neurokinin type one receptor are highly expressed in human aldosterone-producing adenoma tissues. Exogenous Substance P stimulated aldosterone secretion in human aldosterone-producing adenoma cells in a dose-dependent manner. This stimulatory effect was blocked by a neurokinin type one receptor antagonist, demonstrating specific receptor mediation. Furthermore, the research showed that neurokinin type one receptor activation increased intracellular calcium concentration, elucidating a mechanistic pathway for aldosterone production.</p>
<h4>Article 3: Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532540" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532540</a></p>
<p><strong>Summary:</strong> This study identified critical temperature thresholds that increase vulnerability to heat-related excess cardiovascular morbidity and mortality. Researchers established neighborhood-level associations between high-resolution temperature and humidity and cardiovascular disease deaths and emergency department visits. The findings revealed specific community-level vulnerabilities linked to sociodemographic characteristics, which influence cardiovascular outcomes during extreme heat events. This work provides essential data for understanding and mitigating the impact of environmental heat on cardiovascular health across different populations.</p>
<h4>Article 4: Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532539" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532539</a></p>
<p><strong>Summary:</strong> This study found that preprocedural left atrial strain predicts long-term outcomes following mitral valve interventions in patients with rheumatic severe mitral stenosis. The research utilized data from the MASTER registry to establish specific predictive relationships for patient prognosis. Patients undergoing percutaneous mitral valvuloplasty or mitral valve replacement demonstrated outcomes correlated with their baseline left atrial strain measurements. These findings highlight left atrial strain as a valuable prognostic indicator for risk stratification and treatment planning in this specific patient population.</p>
<h4>Article 5: Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532538" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532538</a></p>
<p><strong>Summary:</strong> This prospective cohort study found a significant relationship between mitochondria-derived methylmalonic acid and the progress and mortality risk in United States adults with cardiovascular-kidney-metabolic syndrome. The research utilized data from the National Health and Nutrition Examination Survey to establish this association, identifying methylmalonic acid as a relevant biomarker. Multinomial logistic regression analysis demonstrated that elevated methylmalonic acid levels correlated with adverse outcomes within the cardiovascular-kidney-metabolic syndrome patient population. These findings indicate methylmalonic acid plays a role in the pathophysiology of cardiovascular-kidney-metabolic syndrome and serves as a prognostic indicator for disease progression and mortality.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 16, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke. This study found significant associations of baseline serum complement C3 and complement C4 levels with the prognosis of ischemic stroke. The research demonstrated a link between these complement biomarkers and the primary outcome of death or major disability at discharge. These findings indicate the complement system&#8217;s involvement in the progression of ischemic stroke among the 3979 patients analyzed. The work underscores the potential of complement C3 and complement C4 as prognostic markers for adverse clinical outcomes in this patient population.</p>
<p>Article number two. Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas. This study found that Substance P and the neurokinin type one receptor are highly expressed in human aldosterone-producing adenoma tissues. Exogenous Substance P stimulated aldosterone secretion in human aldosterone-producing adenoma cells in a dose-dependent manner. This stimulatory effect was blocked by a neurokinin type one receptor antagonist, demonstrating specific receptor mediation. Furthermore, the research showed that neurokinin type one receptor activation increased intracellular calcium concentration, elucidating a mechanistic pathway for aldosterone production.</p>
<p>Article number three. Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality. This study identified critical temperature thresholds that increase vulnerability to heat-related excess cardiovascular morbidity and mortality. Researchers established neighborhood-level associations between high-resolution temperature and humidity and cardiovascular disease deaths and emergency department visits. The findings revealed specific community-level vulnerabilities linked to sociodemographic characteristics, which influence cardiovascular outcomes during extreme heat events. This work provides essential data for understanding and mitigating the impact of environmental heat on cardiovascular health across different populations.</p>
<p>Article number four. Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis. This study found that preprocedural left atrial strain predicts long-term outcomes following mitral valve interventions in patients with rheumatic severe mitral stenosis. The research utilized data from the MASTER registry to establish specific predictive relationships for patient prognosis. Patients undergoing percutaneous mitral valvuloplasty or mitral valve replacement demonstrated outcomes correlated with their baseline left atrial strain measurements. These findings highlight left atrial strain as a valuable prognostic indicator for risk stratification and treatment planning in this specific patient population.</p>
<p>Article number five. Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome. This prospective cohort study found a significant relationship between mitochondria-derived methylmalonic acid and the progress and mortality risk in United States adults with cardiovascular-kidney-metabolic syndrome. The research utilized data from the National Health and Nutrition Examination Survey to establish this association, identifying methylmalonic acid as a relevant biomarker. Multinomial logistic regression analysis demonstrated that elevated methylmalonic acid levels correlated with adverse outcomes within the cardiovascular-kidney-metabolic syndrome patient population. These findings indicate methylmalonic acid plays a role in the pathophysiology of cardiovascular-kidney-metabolic syndrome and serves as a prognostic indicator for disease progression and mortality. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>neurokinin type one receptor, heat-related illness, mitral valve intervention, mortality, percutaneous mitral valvuloplasty, cardiovascular disease, prognosis, complement C4, temperature thresholds, primary aldosteronism, mitochondrial dysfunction, complement C3, ischemic stroke, mitral stenosis, biomarker, cardiovascular-kidney-metabolic syndrome, hypertension, aldosterone secretion, morbidity, left atrial strain, mortality risk, environmental hazard, rheumatic heart disease, aldosterone-producing adenoma, complement system, adverse clinical outcomes, methylmalonic acid, Substance P.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/">Substance P Drives Aldosterone in Hypertension. 01/16/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260116_023351.mp3" length="4510031" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like neurokinin type one receptor and heat-related illness. Key takeaway: Substance P Drives Aldosterone in Hypertension..
Article Links:
Article 1: Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke. (Journal of the American Heart Association)
Article 2: Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas. (Journal of the American Heart Association)
Article 3: Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality. (Journal of the American Heart Association)
Article 4: Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis. (Journal of the American Heart Association)
Article 5: Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/substance-p-drives-aldosterone-in-hypertension-01-16-26/
 Featured Articles
Article 1: Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532542
Summary: This study found significant associations of baseline serum complement C3 and complement C4 levels with the prognosis of ischemic stroke. The research demonstrated a link between these complement biomarkers and the primary outcome of death or major disability at discharge. These findings indicate the complement system&#8217;s involvement in the progression of ischemic stroke among the 3979 patients analyzed. The work underscores the potential of complement C3 and complement C4 as prognostic markers for adverse clinical outcomes in this patient population.
Article 2: Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532541
Summary: This study found that Substance P and the neurokinin type one receptor are highly expressed in human aldosterone-producing adenoma tissues. Exogenous Substance P stimulated aldosterone secretion in human aldosterone-producing adenoma cells in a dose-dependent manner. This stimulatory effect was blocked by a neurokinin type one receptor antagonist, demonstrating specific receptor mediation. Furthermore, the research showed that neurokinin type one receptor activation increased intracellular calcium concentration, elucidating a mechanistic pathway for aldosterone production.
Article 3: Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532540
Summary: This study identified critical temperature thresholds that increase vulnerability to heat-related excess cardiovascular morbidity and mortality. Researchers established neighborhood-level associations between high-resolution temperature and humidity and cardiovascular disease deaths and emergency department visits. The findings revealed specific community-level vulnerabilities linked to sociodemographic characteristics, which influence cardiovascular outcomes during extreme heat events. This work provides essential data for understanding and mitigating the impact of environmental heat on cardiovascular health across different populations.
Article 4: Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis.
Journal: Journ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 16, 2026. This episode summarizes 5 key cardiology studies on topics like neurokinin type one receptor and heat-related illness. Key takeaway: Substance P Drives Aldosterone in Hypertension..
Article Links:
Article 1: Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke. (Journal of the American Heart Association)
Article 2: Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas. (Journal of the American Heart Association)
Article 3: Critical Temperature Thresholds for Identifying Vulnerability to Heat-Related Excess Cardiovascular Morbidity and Mortality. (Journal of the American Heart Association)
Article 4: Preprocedural Left Atrial Strain as a Predictor of Long-Term Outcomes Following Mitral Valve Interventions in Rheumatic Severe Mitral Stenosis. (Journal of the American Heart Association)
Article 5: Effect of Mi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Deep Learning Validates Aortic Stenosis Tracking 01/15/26</title>
	<link>https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/</link>
	<pubDate>Fri, 16 Jan 2026 02:51:48 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like disease progression and Heart failure. Key takeaway: Deep Learning Validates Aortic Stenosis Tracking.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41534742">Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41532552">Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41532550">Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532549">Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532543">Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/">https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41534742" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41534742</a></p>
<p><strong>Summary:</strong> Provider variability in Intermacs Patient Profile assignments previously existed during durable left ventricular assist device implantation. To address this, a novel algorithm was successfully developed to standardize the derivation of a patient&#8217;s Intermacs Patient Profile acuity. This algorithm assists clinicians in making more consistent patient acuity assessments for durable left ventricular assist device candidacy.</p>
<h4>Article 2: Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532552" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532552</a></p>
<p><strong>Summary:</strong> Heart failure represents a significant cause of morbidity and mortality among patients with systemic autoimmune inflammatory diseases. A retrospective cohort study of 182795 adult patients with these conditions successfully described the specific heart failure risk profiles within this population. The study also identified associations between cardiovascular drug use and the occurrence of incident heart failure. This provides important information on cardiac disease burden and potential therapeutic impacts in systemic autoimmune inflammatory diseases.</p>
<h4>Article 3: Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532550" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532550</a></p>
<p><strong>Summary:</strong> The study identified preliminary associations between enlarged perivascular spaces and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment. These findings were observed in a select cohort of Hispanic and Latino adults. This research specifically addressed the underrepresentation of this population in dementia research, despite their higher prevalence of dementia and vascular disease. Brain magnetic resonance imaging was utilized to investigate these critical cerebrovascular markers.</p>
<h4>Article 4: Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532549" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532549</a></p>
<p><strong>Summary:</strong> This study successfully validated a deep learning-derived index for Aortic Stenosis continuum, demonstrating its longitudinal changes over time. The index&#8217;s prognostic association with progression to severe aortic stenosis was confirmed. Researchers retrospectively analyzed data from 2373 patients, encompassing 7371 transthoracic echocardiograms, to establish these findings. This provides a robust method for disease tracking in progressive aortic stenosis.</p>
<h4>Article 5: Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532543" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532543</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between high-density lipoprotein to low-density lipoprotein ratios and long-term clinical outcomes in patients with intracerebral hemorrhage. The research successfully characterized the associations of these lipidemic profiles with functional dependence and mortality. Findings were derived from a multicenter prospective registry, providing real-world data on intracerebral hemorrhage outcomes. This addresses a knowledge gap regarding lipidemic profiles in intracerebral hemorrhage compared to ischemic stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles. Provider variability in Intermacs Patient Profile assignments previously existed during durable left ventricular assist device implantation. To address this, a novel algorithm was successfully developed to standardize the derivation of a patient&#8217;s Intermacs Patient Profile acuity. This algorithm assists clinicians in making more consistent patient acuity assessments for durable left ventricular assist device candidacy.</p>
<p>Article number two. Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases. Heart failure represents a significant cause of morbidity and mortality among patients with systemic autoimmune inflammatory diseases. A retrospective cohort study of 182795 adult patients with these conditions successfully described the specific heart failure risk profiles within this population. The study also identified associations between cardiovascular drug use and the occurrence of incident heart failure. This provides important information on cardiac disease burden and potential therapeutic impacts in systemic autoimmune inflammatory diseases.</p>
<p>Article number three. Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI. The study identified preliminary associations between enlarged perivascular spaces and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment. These findings were observed in a select cohort of Hispanic and Latino adults. This research specifically addressed the underrepresentation of this population in dementia research, despite their higher prevalence of dementia and vascular disease. Brain magnetic resonance imaging was utilized to investigate these critical cerebrovascular markers.</p>
<p>Article number four. Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression. This study successfully validated a deep learning-derived index for Aortic Stenosis continuum, demonstrating its longitudinal changes over time. The index&#8217;s prognostic association with progression to severe aortic stenosis was confirmed. Researchers retrospectively analyzed data from 2373 patients, encompassing 7371 transthoracic echocardiograms, to establish these findings. This provides a robust method for disease tracking in progressive aortic stenosis.</p>
<p>Article number five. Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry. This study investigated the relationship between high-density lipoprotein to low-density lipoprotein ratios and long-term clinical outcomes in patients with intracerebral hemorrhage. The research successfully characterized the associations of these lipidemic profiles with functional dependence and mortality. Findings were derived from a multicenter prospective registry, providing real-world data on intracerebral hemorrhage outcomes. This addresses a knowledge gap regarding lipidemic profiles in intracerebral hemorrhage compared to ischemic stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>disease progression, Heart failure, clinical algorithm, left ventricular assist device, magnetic resonance imaging, Hispanic and Latino adults, cardiovascular drug use, intracerebral hemorrhage, prognostic association, inter-rater variability, patient acuity, transthoracic echocardiography, functional dependence, cognitive impairment, deep learning, Aortic stenosis, mortality, Enlarged perivascular spaces, High-density lipoprotein, incident heart failure, cerebrovascular small-vessel disease, systemic autoimmune inflammatory diseases, Intermacs Patient Profiles, morbidity, low-density lipoprotein.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/">Deep Learning Validates Aortic Stenosis Tracking 01/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like disease progression and Heart failure. Key takeaway: Deep Learning Validates Aortic Stenosis Tracking.
Article Links:
Article 1: Algo]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like disease progression and Heart failure. Key takeaway: Deep Learning Validates Aortic Stenosis Tracking.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41534742">Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41532552">Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41532550">Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532549">Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532543">Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/">https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41534742" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41534742</a></p>
<p><strong>Summary:</strong> Provider variability in Intermacs Patient Profile assignments previously existed during durable left ventricular assist device implantation. To address this, a novel algorithm was successfully developed to standardize the derivation of a patient&#8217;s Intermacs Patient Profile acuity. This algorithm assists clinicians in making more consistent patient acuity assessments for durable left ventricular assist device candidacy.</p>
<h4>Article 2: Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532552" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532552</a></p>
<p><strong>Summary:</strong> Heart failure represents a significant cause of morbidity and mortality among patients with systemic autoimmune inflammatory diseases. A retrospective cohort study of 182795 adult patients with these conditions successfully described the specific heart failure risk profiles within this population. The study also identified associations between cardiovascular drug use and the occurrence of incident heart failure. This provides important information on cardiac disease burden and potential therapeutic impacts in systemic autoimmune inflammatory diseases.</p>
<h4>Article 3: Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532550" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532550</a></p>
<p><strong>Summary:</strong> The study identified preliminary associations between enlarged perivascular spaces and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment. These findings were observed in a select cohort of Hispanic and Latino adults. This research specifically addressed the underrepresentation of this population in dementia research, despite their higher prevalence of dementia and vascular disease. Brain magnetic resonance imaging was utilized to investigate these critical cerebrovascular markers.</p>
<h4>Article 4: Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532549" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532549</a></p>
<p><strong>Summary:</strong> This study successfully validated a deep learning-derived index for Aortic Stenosis continuum, demonstrating its longitudinal changes over time. The index&#8217;s prognostic association with progression to severe aortic stenosis was confirmed. Researchers retrospectively analyzed data from 2373 patients, encompassing 7371 transthoracic echocardiograms, to establish these findings. This provides a robust method for disease tracking in progressive aortic stenosis.</p>
<h4>Article 5: Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532543" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532543</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between high-density lipoprotein to low-density lipoprotein ratios and long-term clinical outcomes in patients with intracerebral hemorrhage. The research successfully characterized the associations of these lipidemic profiles with functional dependence and mortality. Findings were derived from a multicenter prospective registry, providing real-world data on intracerebral hemorrhage outcomes. This addresses a knowledge gap regarding lipidemic profiles in intracerebral hemorrhage compared to ischemic stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles. Provider variability in Intermacs Patient Profile assignments previously existed during durable left ventricular assist device implantation. To address this, a novel algorithm was successfully developed to standardize the derivation of a patient&#8217;s Intermacs Patient Profile acuity. This algorithm assists clinicians in making more consistent patient acuity assessments for durable left ventricular assist device candidacy.</p>
<p>Article number two. Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases. Heart failure represents a significant cause of morbidity and mortality among patients with systemic autoimmune inflammatory diseases. A retrospective cohort study of 182795 adult patients with these conditions successfully described the specific heart failure risk profiles within this population. The study also identified associations between cardiovascular drug use and the occurrence of incident heart failure. This provides important information on cardiac disease burden and potential therapeutic impacts in systemic autoimmune inflammatory diseases.</p>
<p>Article number three. Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI. The study identified preliminary associations between enlarged perivascular spaces and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment. These findings were observed in a select cohort of Hispanic and Latino adults. This research specifically addressed the underrepresentation of this population in dementia research, despite their higher prevalence of dementia and vascular disease. Brain magnetic resonance imaging was utilized to investigate these critical cerebrovascular markers.</p>
<p>Article number four. Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression. This study successfully validated a deep learning-derived index for Aortic Stenosis continuum, demonstrating its longitudinal changes over time. The index&#8217;s prognostic association with progression to severe aortic stenosis was confirmed. Researchers retrospectively analyzed data from 2373 patients, encompassing 7371 transthoracic echocardiograms, to establish these findings. This provides a robust method for disease tracking in progressive aortic stenosis.</p>
<p>Article number five. Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry. This study investigated the relationship between high-density lipoprotein to low-density lipoprotein ratios and long-term clinical outcomes in patients with intracerebral hemorrhage. The research successfully characterized the associations of these lipidemic profiles with functional dependence and mortality. Findings were derived from a multicenter prospective registry, providing real-world data on intracerebral hemorrhage outcomes. This addresses a knowledge gap regarding lipidemic profiles in intracerebral hemorrhage compared to ischemic stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>disease progression, Heart failure, clinical algorithm, left ventricular assist device, magnetic resonance imaging, Hispanic and Latino adults, cardiovascular drug use, intracerebral hemorrhage, prognostic association, inter-rater variability, patient acuity, transthoracic echocardiography, functional dependence, cognitive impairment, deep learning, Aortic stenosis, mortality, Enlarged perivascular spaces, High-density lipoprotein, incident heart failure, cerebrovascular small-vessel disease, systemic autoimmune inflammatory diseases, Intermacs Patient Profiles, morbidity, low-density lipoprotein.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/">Deep Learning Validates Aortic Stenosis Tracking 01/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260115_215057.mp3" length="3632735" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like disease progression and Heart failure. Key takeaway: Deep Learning Validates Aortic Stenosis Tracking.
Article Links:
Article 1: Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases. (Journal of the American Heart Association)
Article 3: Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI. (Journal of the American Heart Association)
Article 4: Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression. (Journal of the American Heart Association)
Article 5: Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebral Hemorrhage: Results From a Multicenter Prospective Registry. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/deep-learning-validates-aortic-stenosis-tracking-01-15-26/
 Featured Articles
Article 1: Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41534742
Summary: Provider variability in Intermacs Patient Profile assignments previously existed during durable left ventricular assist device implantation. To address this, a novel algorithm was successfully developed to standardize the derivation of a patient&#8217;s Intermacs Patient Profile acuity. This algorithm assists clinicians in making more consistent patient acuity assessments for durable left ventricular assist device candidacy.
Article 2: Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532552
Summary: Heart failure represents a significant cause of morbidity and mortality among patients with systemic autoimmune inflammatory diseases. A retrospective cohort study of 182795 adult patients with these conditions successfully described the specific heart failure risk profiles within this population. The study also identified associations between cardiovascular drug use and the occurrence of incident heart failure. This provides important information on cardiac disease burden and potential therapeutic impacts in systemic autoimmune inflammatory diseases.
Article 3: Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532550
Summary: The study identified preliminary associations between enlarged perivascular spaces and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment. These findings were observed in a select cohort of Hispanic and Latino adults. This research specifically addressed the underrepresentation of this population in dementia research, despite their higher prevalence of dementia and vascular disease. Brain magnetic resonance imaging was utilized to investigate these critical cerebrovascular markers.
Article 4: Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532549
Summary: This study successfully validated a deep learning-derived index for Aortic Stenosis continuum, demonstrating its longitudinal changes over time. The index&#8217;s prognostic association with progression to severe aortic stenosis was confirmed. Researchers retrospectively analyzed data from 2373 patients, encompassing 7371 transthorac]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like disease progression and Heart failure. Key takeaway: Deep Learning Validates Aortic Stenosis Tracking.
Article Links:
Article 1: Algorithm to Reduce Inter-Rater Variability in Assessment of Intermacs Patient Profiles. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases. (Journal of the American Heart Association)
Article 3: Enlarged Perivascular Spaces Among Hispanic and Latino Adults in SOL-INCA-MRI. (Journal of the American Heart Association)
Article 4: Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression. (Journal of the American Heart Association)
Article 5: Association Between High-Density Lipoprotein-to-Low-Density Lipoprotein Ratio and Clinical Outcomes in Intracerebr]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>L. A. A. Stasis Links to A. F. Recurrence 01/15/26</title>
	<link>https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/</link>
	<pubDate>Thu, 15 Jan 2026 11:01:54 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure Risk and Ethnicity Coding. Key takeaway: L. A. A. Stasis Links to A. F. Recurrence.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41528276">Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41533355">Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41529954">Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532555">Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532553">Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/">https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528276" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528276</a></p>
<p><strong>Summary:</strong> F. pEF on Symptomatic Response With Coronary Revascularization. Patients diagnosed with Heart Failure with Preserved Ejection Fraction (H. F. pEF) experience poor quality of life and a substantial burden of coronary artery disease (C. A. D.). Clinical evidence providing guidance for revascularization in this patient population is currently limited. This limitation stems, in part, from the diagnostic complexity of Heart Failure with Preserved Ejection Fraction itself. Understanding the clinical implications of potential undiagnosed H. F. pEF on symptomatic response to coronary revascularization is critical for patient care.</p>
<h4>Article 2: Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41533355" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41533355</a></p>
<p><strong>Summary:</strong> The precise relationship between coexisting prediabetes, subclinical myocardial injury, or stress and incident heart failure (H. F.) risk in adults with hypertension remains to be fully elucidated. This clinical area represents an important challenge for risk stratification and early intervention. Analyzing data from the Systolic Blood Pressure Intervention Trial (SPRINT) can provide valuable insights into these joint associations. Such research is crucial for enhancing preventive strategies and patient management.</p>
<h4>Article 3: Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41529954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41529954</a></p>
<p><strong>Summary:</strong> Significant ethnic inequalities are observed in the management of patients with cancer who also experience acute coronary syndrome (A. C. S.). Given the under-representation of ethnic minority patients in conventional clinical trials, large national registries are frequently utilized for research in this population. A key challenge, however, is the variability and unclear quality of ethnicity coding within these large datasets. Improving the agreement of ethnicity reporting across national registries is fundamental for ensuring robust and equitable research outcomes.</p>
<h4>Article 4: Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532555" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532555</a></p>
<p><strong>Summary:</strong> Circulatory stasis within the Left Atrial Appendage (L. A. A.) is a significant area of investigation regarding atrial fibrillation (A. F.) recurrence following initial catheter ablation. Cardiac Computed Tomography Angiography (C. T. A.) offers a method for detecting this stasis. Understanding the relationship between Left Atrial Appendage stasis and post-ablation Atrial Fibrillation recurrence is crucial for improving patient selection and procedural outcomes. This knowledge could refine strategies to prevent tachyarrhythmia after intervention.</p>
<h4>Article 5: Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532553" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532553</a></p>
<p><strong>Summary:</strong> Atrial fibrillation and heart failure (H. F.) share a complex and bidirectional relationship, frequently leading to hospitalization. Multiplex screening of plasma proteins represents a powerful approach to identify biomarkers and underlying pathophysiological pathways associated with heart failure hospitalization in patients with atrial fibrillation. Furthermore, delineating distinct pathophysiological differences between Heart Failure with Reduced Ejection Fraction (H. F. rEF) and Heart Failure with Preserved Ejection Fraction (H. F. pEF) in this patient cohort is essential. Such insights can lead to more targeted therapies and improved risk stratification.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Implications of Potential Undiagnosed H. F. pEF on Symptomatic Response With Coronary Revascularization. Patients diagnosed with Heart Failure with Preserved Ejection Fraction (H. F. pEF) experience poor quality of life and a substantial burden of coronary artery disease (C. A. D.). Clinical evidence providing guidance for revascularization in this patient population is currently limited. This limitation stems, in part, from the diagnostic complexity of Heart Failure with Preserved Ejection Fraction itself. Understanding the clinical implications of potential undiagnosed H. F. pEF on symptomatic response to coronary revascularization is critical for patient care.</p>
<p>Article number two. Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension. The precise relationship between coexisting prediabetes, subclinical myocardial injury, or stress and incident heart failure (H. F.) risk in adults with hypertension remains to be fully elucidated. This clinical area represents an important challenge for risk stratification and early intervention. Analyzing data from the Systolic Blood Pressure Intervention Trial (SPRINT) can provide valuable insights into these joint associations. Such research is crucial for enhancing preventive strategies and patient management.</p>
<p>Article number three. Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis. Significant ethnic inequalities are observed in the management of patients with cancer who also experience acute coronary syndrome (A. C. S.). Given the under-representation of ethnic minority patients in conventional clinical trials, large national registries are frequently utilized for research in this population. A key challenge, however, is the variability and unclear quality of ethnicity coding within these large datasets. Improving the agreement of ethnicity reporting across national registries is fundamental for ensuring robust and equitable research outcomes.</p>
<p>Article number four. Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation. Circulatory stasis within the Left Atrial Appendage (L. A. A.) is a significant area of investigation regarding atrial fibrillation (A. F.) recurrence following initial catheter ablation. Cardiac Computed Tomography Angiography (C. T. A.) offers a method for detecting this stasis. Understanding the relationship between Left Atrial Appendage stasis and post-ablation Atrial Fibrillation recurrence is crucial for improving patient selection and procedural outcomes. This knowledge could refine strategies to prevent tachyarrhythmia after intervention.</p>
<p>Article number five. Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure. Atrial fibrillation and heart failure (H. F.) share a complex and bidirectional relationship, frequently leading to hospitalization. Multiplex screening of plasma proteins represents a powerful approach to identify biomarkers and underlying pathophysiological pathways associated with heart failure hospitalization in patients with atrial fibrillation. Furthermore, delineating distinct pathophysiological differences between Heart Failure with Reduced Ejection Fraction (H. F. rEF) and Heart Failure with Preserved Ejection Fraction (H. F. pEF) in this patient cohort is essential. Such insights can lead to more targeted therapies and improved risk stratification. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Heart Failure Risk, Ethnicity Coding, Catheter Ablation, Ethnic Inequalities, Atrial Fibrillation, Circulatory Stasis, Quality of Life, Hypertension, Cancer, Registry Analysis, Heart Failure Subtypes, Left Atrial Appendage, Heart Failure with Preserved Ejection Fraction, Prediabetes, Atrial Fibrillation Recurrence, Subclinical Myocardial Injury, Heart Failure Hospitalization, Coronary Artery Disease, Plasma Biomarkers, Revascularization, Acute Coronary Syndrome.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/">L. A. A. Stasis Links to A. F. Recurrence 01/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure Risk and Ethnicity Coding. Key takeaway: L. A. A. Stasis Links to A. F. Recurrence.
Article Links:
Article 1: Implicati]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure Risk and Ethnicity Coding. Key takeaway: L. A. A. Stasis Links to A. F. Recurrence.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41528276">Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41533355">Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41529954">Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41532555">Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41532553">Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/">https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528276" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528276</a></p>
<p><strong>Summary:</strong> F. pEF on Symptomatic Response With Coronary Revascularization. Patients diagnosed with Heart Failure with Preserved Ejection Fraction (H. F. pEF) experience poor quality of life and a substantial burden of coronary artery disease (C. A. D.). Clinical evidence providing guidance for revascularization in this patient population is currently limited. This limitation stems, in part, from the diagnostic complexity of Heart Failure with Preserved Ejection Fraction itself. Understanding the clinical implications of potential undiagnosed H. F. pEF on symptomatic response to coronary revascularization is critical for patient care.</p>
<h4>Article 2: Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41533355" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41533355</a></p>
<p><strong>Summary:</strong> The precise relationship between coexisting prediabetes, subclinical myocardial injury, or stress and incident heart failure (H. F.) risk in adults with hypertension remains to be fully elucidated. This clinical area represents an important challenge for risk stratification and early intervention. Analyzing data from the Systolic Blood Pressure Intervention Trial (SPRINT) can provide valuable insights into these joint associations. Such research is crucial for enhancing preventive strategies and patient management.</p>
<h4>Article 3: Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41529954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41529954</a></p>
<p><strong>Summary:</strong> Significant ethnic inequalities are observed in the management of patients with cancer who also experience acute coronary syndrome (A. C. S.). Given the under-representation of ethnic minority patients in conventional clinical trials, large national registries are frequently utilized for research in this population. A key challenge, however, is the variability and unclear quality of ethnicity coding within these large datasets. Improving the agreement of ethnicity reporting across national registries is fundamental for ensuring robust and equitable research outcomes.</p>
<h4>Article 4: Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532555" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532555</a></p>
<p><strong>Summary:</strong> Circulatory stasis within the Left Atrial Appendage (L. A. A.) is a significant area of investigation regarding atrial fibrillation (A. F.) recurrence following initial catheter ablation. Cardiac Computed Tomography Angiography (C. T. A.) offers a method for detecting this stasis. Understanding the relationship between Left Atrial Appendage stasis and post-ablation Atrial Fibrillation recurrence is crucial for improving patient selection and procedural outcomes. This knowledge could refine strategies to prevent tachyarrhythmia after intervention.</p>
<h4>Article 5: Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41532553" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41532553</a></p>
<p><strong>Summary:</strong> Atrial fibrillation and heart failure (H. F.) share a complex and bidirectional relationship, frequently leading to hospitalization. Multiplex screening of plasma proteins represents a powerful approach to identify biomarkers and underlying pathophysiological pathways associated with heart failure hospitalization in patients with atrial fibrillation. Furthermore, delineating distinct pathophysiological differences between Heart Failure with Reduced Ejection Fraction (H. F. rEF) and Heart Failure with Preserved Ejection Fraction (H. F. pEF) in this patient cohort is essential. Such insights can lead to more targeted therapies and improved risk stratification.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 15, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Implications of Potential Undiagnosed H. F. pEF on Symptomatic Response With Coronary Revascularization. Patients diagnosed with Heart Failure with Preserved Ejection Fraction (H. F. pEF) experience poor quality of life and a substantial burden of coronary artery disease (C. A. D.). Clinical evidence providing guidance for revascularization in this patient population is currently limited. This limitation stems, in part, from the diagnostic complexity of Heart Failure with Preserved Ejection Fraction itself. Understanding the clinical implications of potential undiagnosed H. F. pEF on symptomatic response to coronary revascularization is critical for patient care.</p>
<p>Article number two. Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension. The precise relationship between coexisting prediabetes, subclinical myocardial injury, or stress and incident heart failure (H. F.) risk in adults with hypertension remains to be fully elucidated. This clinical area represents an important challenge for risk stratification and early intervention. Analyzing data from the Systolic Blood Pressure Intervention Trial (SPRINT) can provide valuable insights into these joint associations. Such research is crucial for enhancing preventive strategies and patient management.</p>
<p>Article number three. Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis. Significant ethnic inequalities are observed in the management of patients with cancer who also experience acute coronary syndrome (A. C. S.). Given the under-representation of ethnic minority patients in conventional clinical trials, large national registries are frequently utilized for research in this population. A key challenge, however, is the variability and unclear quality of ethnicity coding within these large datasets. Improving the agreement of ethnicity reporting across national registries is fundamental for ensuring robust and equitable research outcomes.</p>
<p>Article number four. Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation. Circulatory stasis within the Left Atrial Appendage (L. A. A.) is a significant area of investigation regarding atrial fibrillation (A. F.) recurrence following initial catheter ablation. Cardiac Computed Tomography Angiography (C. T. A.) offers a method for detecting this stasis. Understanding the relationship between Left Atrial Appendage stasis and post-ablation Atrial Fibrillation recurrence is crucial for improving patient selection and procedural outcomes. This knowledge could refine strategies to prevent tachyarrhythmia after intervention.</p>
<p>Article number five. Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure. Atrial fibrillation and heart failure (H. F.) share a complex and bidirectional relationship, frequently leading to hospitalization. Multiplex screening of plasma proteins represents a powerful approach to identify biomarkers and underlying pathophysiological pathways associated with heart failure hospitalization in patients with atrial fibrillation. Furthermore, delineating distinct pathophysiological differences between Heart Failure with Reduced Ejection Fraction (H. F. rEF) and Heart Failure with Preserved Ejection Fraction (H. F. pEF) in this patient cohort is essential. Such insights can lead to more targeted therapies and improved risk stratification. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Heart Failure Risk, Ethnicity Coding, Catheter Ablation, Ethnic Inequalities, Atrial Fibrillation, Circulatory Stasis, Quality of Life, Hypertension, Cancer, Registry Analysis, Heart Failure Subtypes, Left Atrial Appendage, Heart Failure with Preserved Ejection Fraction, Prediabetes, Atrial Fibrillation Recurrence, Subclinical Myocardial Injury, Heart Failure Hospitalization, Coronary Artery Disease, Plasma Biomarkers, Revascularization, Acute Coronary Syndrome.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/">L. A. A. Stasis Links to A. F. Recurrence 01/15/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260115_060054.mp3" length="4300216" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure Risk and Ethnicity Coding. Key takeaway: L. A. A. Stasis Links to A. F. Recurrence.
Article Links:
Article 1: Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization. (JACC. Heart failure)
Article 2: Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension. (JAMA cardiology)
Article 3: Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis. (Heart (British Cardiac Society))
Article 4: Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation. (Journal of the American Heart Association)
Article 5: Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/l-a-a-stasis-links-to-a-f-recurrence-01-15-26/
 Featured Articles
Article 1: Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41528276
Summary: F. pEF on Symptomatic Response With Coronary Revascularization. Patients diagnosed with Heart Failure with Preserved Ejection Fraction (H. F. pEF) experience poor quality of life and a substantial burden of coronary artery disease (C. A. D.). Clinical evidence providing guidance for revascularization in this patient population is currently limited. This limitation stems, in part, from the diagnostic complexity of Heart Failure with Preserved Ejection Fraction itself. Understanding the clinical implications of potential undiagnosed H. F. pEF on symptomatic response to coronary revascularization is critical for patient care.
Article 2: Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41533355
Summary: The precise relationship between coexisting prediabetes, subclinical myocardial injury, or stress and incident heart failure (H. F.) risk in adults with hypertension remains to be fully elucidated. This clinical area represents an important challenge for risk stratification and early intervention. Analyzing data from the Systolic Blood Pressure Intervention Trial (SPRINT) can provide valuable insights into these joint associations. Such research is crucial for enhancing preventive strategies and patient management.
Article 3: Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41529954
Summary: Significant ethnic inequalities are observed in the management of patients with cancer who also experience acute coronary syndrome (A. C. S.). Given the under-representation of ethnic minority patients in conventional clinical trials, large national registries are frequently utilized for research in this population. A key challenge, however, is the variability and unclear quality of ethnicity coding within these large datasets. Improving the agreement of ethnicity reporting across national registries is fundamental for ensuring robust and equitable research outcomes.
Article 4: Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41532555
Summary: Circulatory stasis within the Left Atrial Appendage (L. A. A.) is a signi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 15, 2026. This episode summarizes 5 key cardiology studies on topics like Heart Failure Risk and Ethnicity Coding. Key takeaway: L. A. A. Stasis Links to A. F. Recurrence.
Article Links:
Article 1: Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization. (JACC. Heart failure)
Article 2: Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension. (JAMA cardiology)
Article 3: Agreement of ethnicity reporting among patients with cancer with acute coronary syndrome: a national multiregistry analysis. (Heart (British Cardiac Society))
Article 4: Relationship Between Circulatory Stasis in the Left Atrial Appendage Detected by Cardiac Computed Tomography Angiography With Atrial Fibrillation Recurrence After Initial Catheter Ablation. (Journal of the American Heart Association)
Article 5: Plasma Biomarkers Associated With Heart Failure Hospitalization Among]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis. 01/14/26</title>
	<link>https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/</link>
	<pubDate>Wed, 14 Jan 2026 11:01:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 14, 2026. This episode summarizes 5 key cardiology studies on topics like aerobic capacity and valve disease progression. Key takeaway: Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41528824">Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41528069">Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41528064">Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41528050">Valvular heart failure: evolving pharmacological approaches.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41528278">Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/">https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528824" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528824</a></p>
<p><strong>Summary:</strong> The EXERTION study found that a hypertensive response to exercise is independently associated with cardiovascular disease. This relationship persists even after accounting for aerobic capacity, indicating it is an independent risk factor. The data demonstrated a clear link between exercise blood pressure relative to fitness and cardiovascular disease events in a cohort of 12743 people.</p>
<h4>Article 2: Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528069" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528069</a></p>
<p><strong>Summary:</strong> The study found that left bundle branch pacing offered distinct mechanistic advantages over biventricular pacing in a canine model of dyssynchronous heart failure. Electrocardiographic, echocardiographic, and molecular measurements revealed differences in treatment effects between the two pacing modalities. These findings provide fundamental insights into how each pacing strategy influences cardiac function and remodeling at a detailed biological level.</p>
<h4>Article 3: Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528064</a></p>
<p><strong>Summary:</strong> The study demonstrated that left ventricular pressure overload, induced by aortic banding in Yucatan pigs, increases metabolic vulnerability to anthracycline cardiotoxicity. Animals with pressure overload exhibited distinct metabolic changes that predisposed them to doxorubicin-induced cardiac damage. These findings clarify underlying mechanisms by which conditions like hypertension and valvular heart disease exacerbate anthracycline cardiotoxicity, identifying potential therapeutic targets.</p>
<h4>Article 4: Valvular heart failure: evolving pharmacological approaches.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528050" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528050</a></p>
<p><strong>Summary:</strong> This review provides a comprehensive overview of established medical therapies proven to prevent valve disease progression. It delineates pharmacological approaches effective in preventing or treating heart failure in patients with both primary and secondary valvular disease. The review highlights the intricate, bidirectional relationship between valve disease and heart failure, offering guidance on evidence-based treatment strategies.</p>
<h4>Article 5: Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528278" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528278</a></p>
<p><strong>Summary:</strong> The EDUCATE study found that histological examination of carpal tunnel biopsy samples effectively detects transthyretin amyloid cardiomyopathy. This diagnostic approach identifies transthyretin amyloid cardiomyopathy in older people before substantial and irreversible cardiac damage occurs. The data demonstrate the clinical utility of carpal tunnel biopsy for early diagnosis, which is crucial for improving outcomes with available specific therapies that slow disease progression.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. The EXERTION study found that a hypertensive response to exercise is independently associated with cardiovascular disease. This relationship persists even after accounting for aerobic capacity, indicating it is an independent risk factor. The data demonstrated a clear link between exercise blood pressure relative to fitness and cardiovascular disease events in a cohort of 12743 people.</p>
<p>Article number two. Left bundle branch vs biventricular pacing: mechanistic insights from a canine model. The study found that left bundle branch pacing offered distinct mechanistic advantages over biventricular pacing in a canine model of dyssynchronous heart failure. Electrocardiographic, echocardiographic, and molecular measurements revealed differences in treatment effects between the two pacing modalities. These findings provide fundamental insights into how each pacing strategy influences cardiac function and remodeling at a detailed biological level.</p>
<p>Article number three. Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload. The study demonstrated that left ventricular pressure overload, induced by aortic banding in Yucatan pigs, increases metabolic vulnerability to anthracycline cardiotoxicity. Animals with pressure overload exhibited distinct metabolic changes that predisposed them to doxorubicin-induced cardiac damage. These findings clarify underlying mechanisms by which conditions like hypertension and valvular heart disease exacerbate anthracycline cardiotoxicity, identifying potential therapeutic targets.</p>
<p>Article number four. Valvular heart failure: evolving pharmacological approaches. This review provides a comprehensive overview of established medical therapies proven to prevent valve disease progression. It delineates pharmacological approaches effective in preventing or treating heart failure in patients with both primary and secondary valvular disease. The review highlights the intricate, bidirectional relationship between valve disease and heart failure, offering guidance on evidence-based treatment strategies.</p>
<p>Article number five. Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study. The EDUCATE study found that histological examination of carpal tunnel biopsy samples effectively detects transthyretin amyloid cardiomyopathy. This diagnostic approach identifies transthyretin amyloid cardiomyopathy in older people before substantial and irreversible cardiac damage occurs. The data demonstrate the clinical utility of carpal tunnel biopsy for early diagnosis, which is crucial for improving outcomes with available specific therapies that slow disease progression. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aerobic capacity, valve disease progression, canine model, left ventricular pressure overload, aortic banding, medical therapy, doxorubicin, biventricular pacing, valvular heart disease, transthyretin amyloid cardiomyopathy, heart failure, early diagnosis, exercise blood pressure, risk factor, cardiovascular disease, anthracycline cardiotoxicity, amyloidosis, metabolic vulnerability, dyssynchronous heart failure, carpal tunnel biopsy, left bundle branch pacing, cardiac resynchronization therapy, hypertension, pharmacological approaches.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/">Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis. 01/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 14, 2026. This episode summarizes 5 key cardiology studies on topics like aerobic capacity and valve disease progression. Key takeaway: Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis..
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 14, 2026. This episode summarizes 5 key cardiology studies on topics like aerobic capacity and valve disease progression. Key takeaway: Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41528824">Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41528069">Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41528064">Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41528050">Valvular heart failure: evolving pharmacological approaches.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41528278">Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/">https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528824" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528824</a></p>
<p><strong>Summary:</strong> The EXERTION study found that a hypertensive response to exercise is independently associated with cardiovascular disease. This relationship persists even after accounting for aerobic capacity, indicating it is an independent risk factor. The data demonstrated a clear link between exercise blood pressure relative to fitness and cardiovascular disease events in a cohort of 12743 people.</p>
<h4>Article 2: Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528069" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528069</a></p>
<p><strong>Summary:</strong> The study found that left bundle branch pacing offered distinct mechanistic advantages over biventricular pacing in a canine model of dyssynchronous heart failure. Electrocardiographic, echocardiographic, and molecular measurements revealed differences in treatment effects between the two pacing modalities. These findings provide fundamental insights into how each pacing strategy influences cardiac function and remodeling at a detailed biological level.</p>
<h4>Article 3: Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528064</a></p>
<p><strong>Summary:</strong> The study demonstrated that left ventricular pressure overload, induced by aortic banding in Yucatan pigs, increases metabolic vulnerability to anthracycline cardiotoxicity. Animals with pressure overload exhibited distinct metabolic changes that predisposed them to doxorubicin-induced cardiac damage. These findings clarify underlying mechanisms by which conditions like hypertension and valvular heart disease exacerbate anthracycline cardiotoxicity, identifying potential therapeutic targets.</p>
<h4>Article 4: Valvular heart failure: evolving pharmacological approaches.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528050" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528050</a></p>
<p><strong>Summary:</strong> This review provides a comprehensive overview of established medical therapies proven to prevent valve disease progression. It delineates pharmacological approaches effective in preventing or treating heart failure in patients with both primary and secondary valvular disease. The review highlights the intricate, bidirectional relationship between valve disease and heart failure, offering guidance on evidence-based treatment strategies.</p>
<h4>Article 5: Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41528278" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41528278</a></p>
<p><strong>Summary:</strong> The EDUCATE study found that histological examination of carpal tunnel biopsy samples effectively detects transthyretin amyloid cardiomyopathy. This diagnostic approach identifies transthyretin amyloid cardiomyopathy in older people before substantial and irreversible cardiac damage occurs. The data demonstrate the clinical utility of carpal tunnel biopsy for early diagnosis, which is crucial for improving outcomes with available specific therapies that slow disease progression.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. The EXERTION study found that a hypertensive response to exercise is independently associated with cardiovascular disease. This relationship persists even after accounting for aerobic capacity, indicating it is an independent risk factor. The data demonstrated a clear link between exercise blood pressure relative to fitness and cardiovascular disease events in a cohort of 12743 people.</p>
<p>Article number two. Left bundle branch vs biventricular pacing: mechanistic insights from a canine model. The study found that left bundle branch pacing offered distinct mechanistic advantages over biventricular pacing in a canine model of dyssynchronous heart failure. Electrocardiographic, echocardiographic, and molecular measurements revealed differences in treatment effects between the two pacing modalities. These findings provide fundamental insights into how each pacing strategy influences cardiac function and remodeling at a detailed biological level.</p>
<p>Article number three. Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload. The study demonstrated that left ventricular pressure overload, induced by aortic banding in Yucatan pigs, increases metabolic vulnerability to anthracycline cardiotoxicity. Animals with pressure overload exhibited distinct metabolic changes that predisposed them to doxorubicin-induced cardiac damage. These findings clarify underlying mechanisms by which conditions like hypertension and valvular heart disease exacerbate anthracycline cardiotoxicity, identifying potential therapeutic targets.</p>
<p>Article number four. Valvular heart failure: evolving pharmacological approaches. This review provides a comprehensive overview of established medical therapies proven to prevent valve disease progression. It delineates pharmacological approaches effective in preventing or treating heart failure in patients with both primary and secondary valvular disease. The review highlights the intricate, bidirectional relationship between valve disease and heart failure, offering guidance on evidence-based treatment strategies.</p>
<p>Article number five. Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study. The EDUCATE study found that histological examination of carpal tunnel biopsy samples effectively detects transthyretin amyloid cardiomyopathy. This diagnostic approach identifies transthyretin amyloid cardiomyopathy in older people before substantial and irreversible cardiac damage occurs. The data demonstrate the clinical utility of carpal tunnel biopsy for early diagnosis, which is crucial for improving outcomes with available specific therapies that slow disease progression. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aerobic capacity, valve disease progression, canine model, left ventricular pressure overload, aortic banding, medical therapy, doxorubicin, biventricular pacing, valvular heart disease, transthyretin amyloid cardiomyopathy, heart failure, early diagnosis, exercise blood pressure, risk factor, cardiovascular disease, anthracycline cardiotoxicity, amyloidosis, metabolic vulnerability, dyssynchronous heart failure, carpal tunnel biopsy, left bundle branch pacing, cardiac resynchronization therapy, hypertension, pharmacological approaches.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/">Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis. 01/14/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260114_060017.mp3" length="3416232" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 14, 2026. This episode summarizes 5 key cardiology studies on topics like aerobic capacity and valve disease progression. Key takeaway: Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis..
Article Links:
Article 1: Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. (European heart journal)
Article 2: Left bundle branch vs biventricular pacing: mechanistic insights from a canine model. (European heart journal)
Article 3: Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload. (European heart journal)
Article 4: Valvular heart failure: evolving pharmacological approaches. (European heart journal)
Article 5: Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-01-14-26/
 Featured Articles
Article 1: Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41528824
Summary: The EXERTION study found that a hypertensive response to exercise is independently associated with cardiovascular disease. This relationship persists even after accounting for aerobic capacity, indicating it is an independent risk factor. The data demonstrated a clear link between exercise blood pressure relative to fitness and cardiovascular disease events in a cohort of 12743 people.
Article 2: Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41528069
Summary: The study found that left bundle branch pacing offered distinct mechanistic advantages over biventricular pacing in a canine model of dyssynchronous heart failure. Electrocardiographic, echocardiographic, and molecular measurements revealed differences in treatment effects between the two pacing modalities. These findings provide fundamental insights into how each pacing strategy influences cardiac function and remodeling at a detailed biological level.
Article 3: Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41528064
Summary: The study demonstrated that left ventricular pressure overload, induced by aortic banding in Yucatan pigs, increases metabolic vulnerability to anthracycline cardiotoxicity. Animals with pressure overload exhibited distinct metabolic changes that predisposed them to doxorubicin-induced cardiac damage. These findings clarify underlying mechanisms by which conditions like hypertension and valvular heart disease exacerbate anthracycline cardiotoxicity, identifying potential therapeutic targets.
Article 4: Valvular heart failure: evolving pharmacological approaches.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41528050
Summary: This review provides a comprehensive overview of established medical therapies proven to prevent valve disease progression. It delineates pharmacological approaches effective in preventing or treating heart failure in patients with both primary and secondary valvular disease. The review highlights the intricate, bidirectional relationship between valve disease and heart failure, offering guidance on evidence-based treatment strategies.
Article 5: Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41528278
Summary: The EDUCATE study found that histological examination of carpal tunnel biopsy samples effectively detects transthyretin amyloid cardiomyopathy. This diagnostic approach identifies transthyretin am]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 14, 2026. This episode summarizes 5 key cardiology studies on topics like aerobic capacity and valve disease progression. Key takeaway: Carpal Tunnel Biopsy for Early ATTR-CM Diagnosis..
Article Links:
Article 1: Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. (European heart journal)
Article 2: Left bundle branch vs biventricular pacing: mechanistic insights from a canine model. (European heart journal)
Article 3: Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload. (European heart journal)
Article 4: Valvular heart failure: evolving pharmacological approaches. (European heart journal)
Article 5: Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/carpal-tunnel-biopsy-for-early-attr-cm-diagnosis-]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>EMW Outperforms QTc for Arrhythmia Risk. 01/13/26</title>
	<link>https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/</link>
	<pubDate>Tue, 13 Jan 2026 11:01:37 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 13, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia. Key takeaway: EMW Outperforms QTc for Arrhythmia Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41525972">Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41521923">Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41525968">External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41525967">Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41525958">Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/">https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525972" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525972</a></p>
<p><strong>Summary:</strong> Heart failure care shows inconsistent outcomes with delayed recognition of clinical deterioration. Traditional artificial intelligence operates at a population level, proving unable to keep pace with the rapidly shifting physiological states in heart failure. Digital twin technology is described as a continuously calibrated, mechanistically grounded computational replica. This approach represents a decisive shift for managing individual heart failure patients.</p>
<h4>Article 2: Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41521923" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41521923</a></p>
<p><strong>Summary:</strong> Circulating microRNAs are promising biomarkers for acute cellular rejection and antibody-mediated rejection in heart transplantation. This five-center, prospective, longitudinal cohort study, GRAfT, assessed the characteristics and diagnostic performance of previously identified microRNAs. The study evaluated these microRNAs alongside clinical rejection scores in distinct blood samples obtained at the time of an endomyocardial biopsy. This research identifies specific microRNA profiles for heart transplant rejection subtypes.</p>
<h4>Article 3: External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525968" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525968</a></p>
<p><strong>Summary:</strong> Cardiac resynchronization therapy improves clinical outcomes in patients with dyssynchronous heart failure, yet many patients selected under current guidelines do not respond. This study conducted an external validation of FactorE. C. G., an explainable deep learning-based pipeline for predicting response following biventricular pacing. The underlying deep learning algorithm was previously trained on over one million electrocardiogram median beats to learn generative factors of the electrocardiogram. This validation provides a new tool for predicting individual patient response to cardiac resynchronization therapy.</p>
<h4>Article 4: Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525967" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525967</a></p>
<p><strong>Summary:</strong> Electromechanical window, defined as aortic-valve closure time minus Q. T. interval, assessment outperformed corrected Q. T. interval as a predictor of symptomatic status in long-Q. T. syndrome. This study investigated the relationship between temporal corrected Q. T. interval and electromechanical window dynamics with ventricular tachyarrhythmia timing. The research cohort included 47 patients with long-Q. T. syndrome without ventricular tachyarrhythmia, 18 with long-Q. T. syndrome with ventricular tachyarrhythmia, and nine with drug-induced Q. T. prolongation with ventricular tachyarrhythmia. These findings enhance arrhythmia-risk assessment in both congenital long-Q. T. syndrome and drug-induced Q. T. prolongation.</p>
<h4>Article 5: Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525958" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525958</a></p>
<p><strong>Summary:</strong> Internal thoracic artery use is a quality benchmark in coronary artery bypass grafting, though its value in octogenarians previously remained uncertain. This study compared mid-term major adverse cardiac events and all-cause mortality among octogenarians undergoing coronary artery bypass grafting with internal thoracic artery plus saphenous vein grafts versus saphenous vein grafts only. Researchers identified 13925 octogenarians who underwent isolated, first-time, elective coronary artery bypass grafting with two to four grafts between 2015 and 2022. This comparison provides clarity on the benefits of internal thoracic artery use in this older patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise. Heart failure care shows inconsistent outcomes with delayed recognition of clinical deterioration. Traditional artificial intelligence operates at a population level, proving unable to keep pace with the rapidly shifting physiological states in heart failure. Digital twin technology is described as a continuously calibrated, mechanistically grounded computational replica. This approach represents a decisive shift for managing individual heart failure patients.</p>
<p>Article number two. Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs. Circulating microRNAs are promising biomarkers for acute cellular rejection and antibody-mediated rejection in heart transplantation. This five-center, prospective, longitudinal cohort study, GRAfT, assessed the characteristics and diagnostic performance of previously identified microRNAs. The study evaluated these microRNAs alongside clinical rejection scores in distinct blood samples obtained at the time of an endomyocardial biopsy. This research identifies specific microRNA profiles for heart transplant rejection subtypes.</p>
<p>Article number three. External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy. Cardiac resynchronization therapy improves clinical outcomes in patients with dyssynchronous heart failure, yet many patients selected under current guidelines do not respond. This study conducted an external validation of FactorE. C. G., an explainable deep learning-based pipeline for predicting response following biventricular pacing. The underlying deep learning algorithm was previously trained on over one million electrocardiogram median beats to learn generative factors of the electrocardiogram. This validation provides a new tool for predicting individual patient response to cardiac resynchronization therapy.</p>
<p>Article number four. Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment. Electromechanical window, defined as aortic-valve closure time minus Q. T. interval, assessment outperformed corrected Q. T. interval as a predictor of symptomatic status in long-Q. T. syndrome. This study investigated the relationship between temporal corrected Q. T. interval and electromechanical window dynamics with ventricular tachyarrhythmia timing. The research cohort included 47 patients with long-Q. T. syndrome without ventricular tachyarrhythmia, 18 with long-Q. T. syndrome with ventricular tachyarrhythmia, and nine with drug-induced Q. T. prolongation with ventricular tachyarrhythmia. These findings enhance arrhythmia-risk assessment in both congenital long-Q. T. syndrome and drug-induced Q. T. prolongation.</p>
<p>Article number five. Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting. Internal thoracic artery use is a quality benchmark in coronary artery bypass grafting, though its value in octogenarians previously remained uncertain. This study compared mid-term major adverse cardiac events and all-cause mortality among octogenarians undergoing coronary artery bypass grafting with internal thoracic artery plus saphenous vein grafts versus saphenous vein grafts only. Researchers identified 13925 octogenarians who underwent isolated, first-time, elective coronary artery bypass grafting with two to four grafts between 2015 and 2022. This comparison provides clarity on the benefits of internal thoracic artery use in this older patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiac Resynchronization Therapy, Ventricular Tachyarrhythmia, Heart Failure, Physiological Monitoring, Artificial Intelligence, Deep Learning, Coronary Artery Bypass Grafting, Major Adverse Cardiac Events, Electromechanical Window, All-Cause Mortality, Biomarkers, MicroRNAs, Digital Twins, Heart Transplant Rejection, Octogenarians, Internal Thoracic Artery, Arrhythmia Risk, Antibody-Mediated Rejection, Biventricular Pacing, QT Prolongation, Electrocardiogram, Long-QT Syndrome, Acute Cellular Rejection, Precision Medicine.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/">EMW Outperforms QTc for Arrhythmia Risk. 01/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 13, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia. Key takeaway: EMW Outperforms QTc for Arrhythmia Risk..
Article Li]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 13, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia. Key takeaway: EMW Outperforms QTc for Arrhythmia Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41525972">Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41521923">Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41525968">External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41525967">Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41525958">Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/">https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525972" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525972</a></p>
<p><strong>Summary:</strong> Heart failure care shows inconsistent outcomes with delayed recognition of clinical deterioration. Traditional artificial intelligence operates at a population level, proving unable to keep pace with the rapidly shifting physiological states in heart failure. Digital twin technology is described as a continuously calibrated, mechanistically grounded computational replica. This approach represents a decisive shift for managing individual heart failure patients.</p>
<h4>Article 2: Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41521923" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41521923</a></p>
<p><strong>Summary:</strong> Circulating microRNAs are promising biomarkers for acute cellular rejection and antibody-mediated rejection in heart transplantation. This five-center, prospective, longitudinal cohort study, GRAfT, assessed the characteristics and diagnostic performance of previously identified microRNAs. The study evaluated these microRNAs alongside clinical rejection scores in distinct blood samples obtained at the time of an endomyocardial biopsy. This research identifies specific microRNA profiles for heart transplant rejection subtypes.</p>
<h4>Article 3: External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525968" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525968</a></p>
<p><strong>Summary:</strong> Cardiac resynchronization therapy improves clinical outcomes in patients with dyssynchronous heart failure, yet many patients selected under current guidelines do not respond. This study conducted an external validation of FactorE. C. G., an explainable deep learning-based pipeline for predicting response following biventricular pacing. The underlying deep learning algorithm was previously trained on over one million electrocardiogram median beats to learn generative factors of the electrocardiogram. This validation provides a new tool for predicting individual patient response to cardiac resynchronization therapy.</p>
<h4>Article 4: Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525967" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525967</a></p>
<p><strong>Summary:</strong> Electromechanical window, defined as aortic-valve closure time minus Q. T. interval, assessment outperformed corrected Q. T. interval as a predictor of symptomatic status in long-Q. T. syndrome. This study investigated the relationship between temporal corrected Q. T. interval and electromechanical window dynamics with ventricular tachyarrhythmia timing. The research cohort included 47 patients with long-Q. T. syndrome without ventricular tachyarrhythmia, 18 with long-Q. T. syndrome with ventricular tachyarrhythmia, and nine with drug-induced Q. T. prolongation with ventricular tachyarrhythmia. These findings enhance arrhythmia-risk assessment in both congenital long-Q. T. syndrome and drug-induced Q. T. prolongation.</p>
<h4>Article 5: Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41525958" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41525958</a></p>
<p><strong>Summary:</strong> Internal thoracic artery use is a quality benchmark in coronary artery bypass grafting, though its value in octogenarians previously remained uncertain. This study compared mid-term major adverse cardiac events and all-cause mortality among octogenarians undergoing coronary artery bypass grafting with internal thoracic artery plus saphenous vein grafts versus saphenous vein grafts only. Researchers identified 13925 octogenarians who underwent isolated, first-time, elective coronary artery bypass grafting with two to four grafts between 2015 and 2022. This comparison provides clarity on the benefits of internal thoracic artery use in this older patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 13, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise. Heart failure care shows inconsistent outcomes with delayed recognition of clinical deterioration. Traditional artificial intelligence operates at a population level, proving unable to keep pace with the rapidly shifting physiological states in heart failure. Digital twin technology is described as a continuously calibrated, mechanistically grounded computational replica. This approach represents a decisive shift for managing individual heart failure patients.</p>
<p>Article number two. Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs. Circulating microRNAs are promising biomarkers for acute cellular rejection and antibody-mediated rejection in heart transplantation. This five-center, prospective, longitudinal cohort study, GRAfT, assessed the characteristics and diagnostic performance of previously identified microRNAs. The study evaluated these microRNAs alongside clinical rejection scores in distinct blood samples obtained at the time of an endomyocardial biopsy. This research identifies specific microRNA profiles for heart transplant rejection subtypes.</p>
<p>Article number three. External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy. Cardiac resynchronization therapy improves clinical outcomes in patients with dyssynchronous heart failure, yet many patients selected under current guidelines do not respond. This study conducted an external validation of FactorE. C. G., an explainable deep learning-based pipeline for predicting response following biventricular pacing. The underlying deep learning algorithm was previously trained on over one million electrocardiogram median beats to learn generative factors of the electrocardiogram. This validation provides a new tool for predicting individual patient response to cardiac resynchronization therapy.</p>
<p>Article number four. Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment. Electromechanical window, defined as aortic-valve closure time minus Q. T. interval, assessment outperformed corrected Q. T. interval as a predictor of symptomatic status in long-Q. T. syndrome. This study investigated the relationship between temporal corrected Q. T. interval and electromechanical window dynamics with ventricular tachyarrhythmia timing. The research cohort included 47 patients with long-Q. T. syndrome without ventricular tachyarrhythmia, 18 with long-Q. T. syndrome with ventricular tachyarrhythmia, and nine with drug-induced Q. T. prolongation with ventricular tachyarrhythmia. These findings enhance arrhythmia-risk assessment in both congenital long-Q. T. syndrome and drug-induced Q. T. prolongation.</p>
<p>Article number five. Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting. Internal thoracic artery use is a quality benchmark in coronary artery bypass grafting, though its value in octogenarians previously remained uncertain. This study compared mid-term major adverse cardiac events and all-cause mortality among octogenarians undergoing coronary artery bypass grafting with internal thoracic artery plus saphenous vein grafts versus saphenous vein grafts only. Researchers identified 13925 octogenarians who underwent isolated, first-time, elective coronary artery bypass grafting with two to four grafts between 2015 and 2022. This comparison provides clarity on the benefits of internal thoracic artery use in this older patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiac Resynchronization Therapy, Ventricular Tachyarrhythmia, Heart Failure, Physiological Monitoring, Artificial Intelligence, Deep Learning, Coronary Artery Bypass Grafting, Major Adverse Cardiac Events, Electromechanical Window, All-Cause Mortality, Biomarkers, MicroRNAs, Digital Twins, Heart Transplant Rejection, Octogenarians, Internal Thoracic Artery, Arrhythmia Risk, Antibody-Mediated Rejection, Biventricular Pacing, QT Prolongation, Electrocardiogram, Long-QT Syndrome, Acute Cellular Rejection, Precision Medicine.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/">EMW Outperforms QTc for Arrhythmia Risk. 01/13/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260113_060032.mp3" length="4416408" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 13, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia. Key takeaway: EMW Outperforms QTc for Arrhythmia Risk..
Article Links:
Article 1: Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise. (Journal of cardiac failure)
Article 2: Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs. (Circulation. Heart failure)
Article 3: External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy. (Heart rhythm)
Article 4: Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment. (Heart rhythm)
Article 5: Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/emw-outperforms-qtc-for-arrhythmia-risk-01-13-26/
 Featured Articles
Article 1: Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41525972
Summary: Heart failure care shows inconsistent outcomes with delayed recognition of clinical deterioration. Traditional artificial intelligence operates at a population level, proving unable to keep pace with the rapidly shifting physiological states in heart failure. Digital twin technology is described as a continuously calibrated, mechanistically grounded computational replica. This approach represents a decisive shift for managing individual heart failure patients.
Article 2: Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41521923
Summary: Circulating microRNAs are promising biomarkers for acute cellular rejection and antibody-mediated rejection in heart transplantation. This five-center, prospective, longitudinal cohort study, GRAfT, assessed the characteristics and diagnostic performance of previously identified microRNAs. The study evaluated these microRNAs alongside clinical rejection scores in distinct blood samples obtained at the time of an endomyocardial biopsy. This research identifies specific microRNA profiles for heart transplant rejection subtypes.
Article 3: External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41525968
Summary: Cardiac resynchronization therapy improves clinical outcomes in patients with dyssynchronous heart failure, yet many patients selected under current guidelines do not respond. This study conducted an external validation of FactorE. C. G., an explainable deep learning-based pipeline for predicting response following biventricular pacing. The underlying deep learning algorithm was previously trained on over one million electrocardiogram median beats to learn generative factors of the electrocardiogram. This validation provides a new tool for predicting individual patient response to cardiac resynchronization therapy.
Article 4: Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41525967
Summary: Electromechanical window, defined as aortic-valve closure time minus Q. T. interval, assessment outperformed corrected Q. T. interval as a predictor of symptomatic status in long-Q. T. syndrome. This study investigated the relationship between temporal corrected Q. T. interval and electromechanical window dynamics with ventric]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 13, 2026. This episode summarizes 5 key cardiology studies on topics like Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia. Key takeaway: EMW Outperforms QTc for Arrhythmia Risk..
Article Links:
Article 1: Digital Twins and Artificial Intelligence in Heart Failure: The Premise and the Promise. (Journal of cardiac failure)
Article 2: Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs. (Circulation. Heart failure)
Article 3: External validation of an explainable electrocardiogram-only deep learning algorithm for prediction of response after cardiac resynchronization therapy. (Heart rhythm)
Article 4: Temporal Variability of the Electromechanical Window in Long-QT Syndrome and Drug-Induced QT Prolongation: Value for Enhanced Arrhythmia-Risk Assessment. (Heart rhythm)
Article 5: Reevaluating Internal Thoracic Artery Use in Octogenarians Undergoing Multivessel Coronary Artery Bypass Grafting. (The]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Neratinib Protects Against Vascular Inflammation. 01/12/26</title>
	<link>https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/</link>
	<pubDate>Mon, 12 Jan 2026 11:01:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 12, 2026. This episode summarizes 5 key cardiology studies on topics like pig model and vascular inflammation. Key takeaway: Neratinib Protects Against Vascular Inflammation..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41520801">The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41520933">Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41520805">Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study).</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41510568">Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41513752">Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension.</a> (American journal of hypertension)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/">https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41520801" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41520801</a></p>
<p><strong>Summary:</strong> Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.</p>
<h4>Article 2: Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41520933" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41520933</a></p>
<p><strong>Summary:</strong> The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.</p>
<h4>Article 3: Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study).</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41520805" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41520805</a></p>
<p><strong>Summary:</strong> Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.</p>
<h4>Article 4: Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41510568" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41510568</a></p>
<p><strong>Summary:</strong> Neratinib, a clinical drug primarily used against breast cancer, provides protection against vascular inflammation and atherosclerosis. Atherosclerosis begins with endothelial dysfunction and cholesterol retention, followed by a chronic inflammatory response that current low-density lipoprotein-cholesterol lowering therapies often do not fully address. This drug offers a novel therapeutic approach to mitigate the persistent residual inflammatory risk observed in patients with atherosclerotic cardiovascular diseases.</p>
<h4>Article 5: Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513752" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513752</a></p>
<p><strong>Summary:</strong> Visit-to-visit blood pressure variability and cumulative blood pressure exposure are associated with increased risks of cardiorenal events. This study specifically investigated these associations in young adults aged 18 to 39 years diagnosed with stage one or stage two hypertension. Researchers identified these adults from a large U. S. integrated healthcare system between 2009 and 2019, utilizing the coefficient of variation for blood pressure variability and time-weighted values for cumulative blood pressure exposure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant. Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.</p>
<p>Article number two. Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study. The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.</p>
<p>Article number three. Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study). Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.</p>
<p>Article number four. Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis. Neratinib, a clinical drug primarily used against breast cancer, provides protection against vascular inflammation and atherosclerosis. Atherosclerosis begins with endothelial dysfunction and cholesterol retention, followed by a chronic inflammatory response that current low-density lipoprotein-cholesterol lowering therapies often do not fully address. This drug offers a novel therapeutic approach to mitigate the persistent residual inflammatory risk observed in patients with atherosclerotic cardiovascular diseases.</p>
<p>Article number five. Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension. Visit-to-visit blood pressure variability and cumulative blood pressure exposure are associated with increased risks of cardiorenal events. This study specifically investigated these associations in young adults aged 18 to 39 years diagnosed with stage one or stage two hypertension. Researchers identified these adults from a large U. S. integrated healthcare system between 2009 and 2019, utilizing the coefficient of variation for blood pressure variability and time-weighted values for cumulative blood pressure exposure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pig model, vascular inflammation, blood pressure variability, tissue-type plasminogen activator, low-density lipoprotein-cholesterol, glucagon-like peptide 1 receptor agonists, heart transplant, breast cancer drug, heart failure, atherosclerosis, prosthetic valve thrombosis, sequential regimens, cardiorenal events, cumulative blood pressure exposure, non-coronary cusp, focal pulsed field ablation, young adults, hypertension, pace-and-ablate, atrioventricular node, mortality, thrombolytic therapy, stuck valves, diabetes, neratinib.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/">Neratinib Protects Against Vascular Inflammation. 01/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 12, 2026. This episode summarizes 5 key cardiology studies on topics like pig model and vascular inflammation. Key takeaway: Neratinib Protects Against Vascular Inflammation..
Article Links:
Article 1: The a]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 12, 2026. This episode summarizes 5 key cardiology studies on topics like pig model and vascular inflammation. Key takeaway: Neratinib Protects Against Vascular Inflammation..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41520801">The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41520933">Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41520805">Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study).</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41510568">Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41513752">Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension.</a> (American journal of hypertension)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/">https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41520801" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41520801</a></p>
<p><strong>Summary:</strong> Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.</p>
<h4>Article 2: Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41520933" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41520933</a></p>
<p><strong>Summary:</strong> The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.</p>
<h4>Article 3: Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study).</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41520805" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41520805</a></p>
<p><strong>Summary:</strong> Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.</p>
<h4>Article 4: Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41510568" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41510568</a></p>
<p><strong>Summary:</strong> Neratinib, a clinical drug primarily used against breast cancer, provides protection against vascular inflammation and atherosclerosis. Atherosclerosis begins with endothelial dysfunction and cholesterol retention, followed by a chronic inflammatory response that current low-density lipoprotein-cholesterol lowering therapies often do not fully address. This drug offers a novel therapeutic approach to mitigate the persistent residual inflammatory risk observed in patients with atherosclerotic cardiovascular diseases.</p>
<h4>Article 5: Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513752" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513752</a></p>
<p><strong>Summary:</strong> Visit-to-visit blood pressure variability and cumulative blood pressure exposure are associated with increased risks of cardiorenal events. This study specifically investigated these associations in young adults aged 18 to 39 years diagnosed with stage one or stage two hypertension. Researchers identified these adults from a large U. S. integrated healthcare system between 2009 and 2019, utilizing the coefficient of variation for blood pressure variability and time-weighted values for cumulative blood pressure exposure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant. Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.</p>
<p>Article number two. Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study. The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.</p>
<p>Article number three. Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study). Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.</p>
<p>Article number four. Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis. Neratinib, a clinical drug primarily used against breast cancer, provides protection against vascular inflammation and atherosclerosis. Atherosclerosis begins with endothelial dysfunction and cholesterol retention, followed by a chronic inflammatory response that current low-density lipoprotein-cholesterol lowering therapies often do not fully address. This drug offers a novel therapeutic approach to mitigate the persistent residual inflammatory risk observed in patients with atherosclerotic cardiovascular diseases.</p>
<p>Article number five. Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension. Visit-to-visit blood pressure variability and cumulative blood pressure exposure are associated with increased risks of cardiorenal events. This study specifically investigated these associations in young adults aged 18 to 39 years diagnosed with stage one or stage two hypertension. Researchers identified these adults from a large U. S. integrated healthcare system between 2009 and 2019, utilizing the coefficient of variation for blood pressure variability and time-weighted values for cumulative blood pressure exposure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pig model, vascular inflammation, blood pressure variability, tissue-type plasminogen activator, low-density lipoprotein-cholesterol, glucagon-like peptide 1 receptor agonists, heart transplant, breast cancer drug, heart failure, atherosclerosis, prosthetic valve thrombosis, sequential regimens, cardiorenal events, cumulative blood pressure exposure, non-coronary cusp, focal pulsed field ablation, young adults, hypertension, pace-and-ablate, atrioventricular node, mortality, thrombolytic therapy, stuck valves, diabetes, neratinib.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/">Neratinib Protects Against Vascular Inflammation. 01/12/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260112_060041.mp3" length="3963341" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 12, 2026. This episode summarizes 5 key cardiology studies on topics like pig model and vascular inflammation. Key takeaway: Neratinib Protects Against Vascular Inflammation..
Article Links:
Article 1: The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study. (Heart rhythm)
Article 3: Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study). (The American journal of cardiology)
Article 4: Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis. (Circulation research)
Article 5: Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension. (American journal of hypertension)
Full episode page: https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/
 Featured Articles
Article 1: The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41520801
Summary: Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.
Article 2: Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41520933
Summary: The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.
Article 3: Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study).
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41520805
Summary: Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.
Article 4: Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atheroscle]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 12, 2026. This episode summarizes 5 key cardiology studies on topics like pig model and vascular inflammation. Key takeaway: Neratinib Protects Against Vascular Inflammation..
Article Links:
Article 1: The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study. (Heart rhythm)
Article 3: Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study). (The American journal of cardiology)
Article 4: Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Infl]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>I. C. D. Driving Risk Predicted by Baseline Data. 01/11/26</title>
	<link>https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/</link>
	<pubDate>Sun, 11 Jan 2026 11:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 11, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and Implantable cardioverter-defibrillator. Key takeaway: I. C. D. Driving Risk Predicted by Baseline Data..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41519473">Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40819904">Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40555466">Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40541293">Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40425274">Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/">https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41519473" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41519473</a></p>
<p><strong>Summary:</strong> The S. T. A. R. initiative&#8217;s working group has held three consensus meetings and published reports that have influenced clinical care in organ transplantation. The 2025 group identified and addressed five key evolving areas in transplantation: donor-derived cell-free D. N. A. tests, innate immunity in allograft rejection, immunogenicity and antigenicity, and H. L. A. antibody quantification. This demonstrates the group&#8217;s ongoing work in translating laboratory data into clinical practice and guiding future research priorities.</p>
<h4>Article 2: Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40819904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40819904</a></p>
<p><strong>Summary:</strong> This study identified three distinct cardiac magnetic resonance-based phenotypes in 515 patients with non-dilated left ventricular cardiomyopathy. These phenotypes include late gadolinium enhancement positive with preserved left ventricular ejection fraction, late gadolinium enhancement negative with dilated left atrium or right ventricle and preserved left ventricular ejection fraction, and late gadolinium enhancement negative with isolated systolic dysfunction with preserved left ventricular ejection fraction. The classification of these phenotypes provides a new framework for risk stratification in this patient population.</p>
<h4>Article 3: Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40555466" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40555466</a></p>
<p><strong>Summary:</strong> This study utilized 22 years of population-based administrative data to identify licensed drivers who received a first implantable cardioverter-defibrillator between 1998 and 2018. It developed a method using baseline health and driving data, along with logistic regression, to estimate the risk of motor vehicle crash in the first year post-implantation. This approach provides clinicians with a tool to personalize medical driving restrictions following implantable cardioverter-defibrillator implantation.</p>
<h4>Article 4: Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40541293" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40541293</a></p>
<p><strong>Summary:</strong> This study identified a cohort of 335 patients with moderate or severe bicuspid aortic regurgitation who did not initially meet guideline-based criteria for aortic valve surgery. These patients were drawn from a single-center registry of 1927 individuals with bicuspid aortic valve, excluding those with severe aortic stenosis, endocarditis, or other major valvular diseases. The study establishes the critical need for identifying early predictors of disease progression within this specific high-risk subgroup to aid in optimal risk stratification and surgical timing.</p>
<h4>Article 5: Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40425274" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40425274</a></p>
<p><strong>Summary:</strong> This longitudinal cohort study of 12000 participants aged 50 years or older investigated the associations between insomnia symptoms, their long-term trajectories, and incident cardiovascular disease. All participants were without baseline cardiovascular disease and were drawn from the U. S. Health and Retirement Study between 2002 and 2018. The study demonstrated the importance of evaluating long-term patterns of insomnia symptoms in relation to cardiovascular disease development in older adults.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report. The S. T. A. R. initiative&#8217;s working group has held three consensus meetings and published reports that have influenced clinical care in organ transplantation. The 2025 group identified and addressed five key evolving areas in transplantation: donor-derived cell-free D. N. A. tests, innate immunity in allograft rejection, immunogenicity and antigenicity, and H. L. A. antibody quantification. This demonstrates the group&#8217;s ongoing work in translating laboratory data into clinical practice and guiding future research priorities.</p>
<p>Article number two. Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy. This study identified three distinct cardiac magnetic resonance-based phenotypes in 515 patients with non-dilated left ventricular cardiomyopathy. These phenotypes include late gadolinium enhancement positive with preserved left ventricular ejection fraction, late gadolinium enhancement negative with dilated left atrium or right ventricle and preserved left ventricular ejection fraction, and late gadolinium enhancement negative with isolated systolic dysfunction with preserved left ventricular ejection fraction. The classification of these phenotypes provides a new framework for risk stratification in this patient population.</p>
<p>Article number three. Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation. This study utilized 22 years of population-based administrative data to identify licensed drivers who received a first implantable cardioverter-defibrillator between 1998 and 2018. It developed a method using baseline health and driving data, along with logistic regression, to estimate the risk of motor vehicle crash in the first year post-implantation. This approach provides clinicians with a tool to personalize medical driving restrictions following implantable cardioverter-defibrillator implantation.</p>
<p>Article number four. Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication. This study identified a cohort of 335 patients with moderate or severe bicuspid aortic regurgitation who did not initially meet guideline-based criteria for aortic valve surgery. These patients were drawn from a single-center registry of 1927 individuals with bicuspid aortic valve, excluding those with severe aortic stenosis, endocarditis, or other major valvular diseases. The study establishes the critical need for identifying early predictors of disease progression within this specific high-risk subgroup to aid in optimal risk stratification and surgical timing.</p>
<p>Article number five. Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study. This longitudinal cohort study of 12000 participants aged 50 years or older investigated the associations between insomnia symptoms, their long-term trajectories, and incident cardiovascular disease. All participants were without baseline cardiovascular disease and were drawn from the U. S. Health and Retirement Study between 2002 and 2018. The study demonstrated the importance of evaluating long-term patterns of insomnia symptoms in relation to cardiovascular disease development in older adults. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left ventricular ejection fraction, Implantable cardioverter-defibrillator, sudden cardiac death, disease progression, aortic valve, motor vehicle crash, risk stratification, late gadolinium enhancement, Non-dilated left ventricular cardiomyopathy, driving restrictions, Organ transplantation, cardiovascular disease, older adults, cardiac magnetic resonance, Insomnia symptoms, health and retirement study, H. L. A. antibodies, donor-derived cell-free D. N. A., allograft rejection, logistic regression, aortic valve surgery, Bicuspid aortic regurgitation, innate immunity, longitudinal study.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/">I. C. D. Driving Risk Predicted by Baseline Data. 01/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 11, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and Implantable cardioverter-defibrillator. Key takeaway: I. C. D. Driving Risk Predicted by Basel]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 11, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and Implantable cardioverter-defibrillator. Key takeaway: I. C. D. Driving Risk Predicted by Baseline Data..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41519473">Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40819904">Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40555466">Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40541293">Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40425274">Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/">https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41519473" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41519473</a></p>
<p><strong>Summary:</strong> The S. T. A. R. initiative&#8217;s working group has held three consensus meetings and published reports that have influenced clinical care in organ transplantation. The 2025 group identified and addressed five key evolving areas in transplantation: donor-derived cell-free D. N. A. tests, innate immunity in allograft rejection, immunogenicity and antigenicity, and H. L. A. antibody quantification. This demonstrates the group&#8217;s ongoing work in translating laboratory data into clinical practice and guiding future research priorities.</p>
<h4>Article 2: Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40819904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40819904</a></p>
<p><strong>Summary:</strong> This study identified three distinct cardiac magnetic resonance-based phenotypes in 515 patients with non-dilated left ventricular cardiomyopathy. These phenotypes include late gadolinium enhancement positive with preserved left ventricular ejection fraction, late gadolinium enhancement negative with dilated left atrium or right ventricle and preserved left ventricular ejection fraction, and late gadolinium enhancement negative with isolated systolic dysfunction with preserved left ventricular ejection fraction. The classification of these phenotypes provides a new framework for risk stratification in this patient population.</p>
<h4>Article 3: Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40555466" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40555466</a></p>
<p><strong>Summary:</strong> This study utilized 22 years of population-based administrative data to identify licensed drivers who received a first implantable cardioverter-defibrillator between 1998 and 2018. It developed a method using baseline health and driving data, along with logistic regression, to estimate the risk of motor vehicle crash in the first year post-implantation. This approach provides clinicians with a tool to personalize medical driving restrictions following implantable cardioverter-defibrillator implantation.</p>
<h4>Article 4: Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40541293" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40541293</a></p>
<p><strong>Summary:</strong> This study identified a cohort of 335 patients with moderate or severe bicuspid aortic regurgitation who did not initially meet guideline-based criteria for aortic valve surgery. These patients were drawn from a single-center registry of 1927 individuals with bicuspid aortic valve, excluding those with severe aortic stenosis, endocarditis, or other major valvular diseases. The study establishes the critical need for identifying early predictors of disease progression within this specific high-risk subgroup to aid in optimal risk stratification and surgical timing.</p>
<h4>Article 5: Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40425274" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40425274</a></p>
<p><strong>Summary:</strong> This longitudinal cohort study of 12000 participants aged 50 years or older investigated the associations between insomnia symptoms, their long-term trajectories, and incident cardiovascular disease. All participants were without baseline cardiovascular disease and were drawn from the U. S. Health and Retirement Study between 2002 and 2018. The study demonstrated the importance of evaluating long-term patterns of insomnia symptoms in relation to cardiovascular disease development in older adults.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 11, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report. The S. T. A. R. initiative&#8217;s working group has held three consensus meetings and published reports that have influenced clinical care in organ transplantation. The 2025 group identified and addressed five key evolving areas in transplantation: donor-derived cell-free D. N. A. tests, innate immunity in allograft rejection, immunogenicity and antigenicity, and H. L. A. antibody quantification. This demonstrates the group&#8217;s ongoing work in translating laboratory data into clinical practice and guiding future research priorities.</p>
<p>Article number two. Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy. This study identified three distinct cardiac magnetic resonance-based phenotypes in 515 patients with non-dilated left ventricular cardiomyopathy. These phenotypes include late gadolinium enhancement positive with preserved left ventricular ejection fraction, late gadolinium enhancement negative with dilated left atrium or right ventricle and preserved left ventricular ejection fraction, and late gadolinium enhancement negative with isolated systolic dysfunction with preserved left ventricular ejection fraction. The classification of these phenotypes provides a new framework for risk stratification in this patient population.</p>
<p>Article number three. Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation. This study utilized 22 years of population-based administrative data to identify licensed drivers who received a first implantable cardioverter-defibrillator between 1998 and 2018. It developed a method using baseline health and driving data, along with logistic regression, to estimate the risk of motor vehicle crash in the first year post-implantation. This approach provides clinicians with a tool to personalize medical driving restrictions following implantable cardioverter-defibrillator implantation.</p>
<p>Article number four. Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication. This study identified a cohort of 335 patients with moderate or severe bicuspid aortic regurgitation who did not initially meet guideline-based criteria for aortic valve surgery. These patients were drawn from a single-center registry of 1927 individuals with bicuspid aortic valve, excluding those with severe aortic stenosis, endocarditis, or other major valvular diseases. The study establishes the critical need for identifying early predictors of disease progression within this specific high-risk subgroup to aid in optimal risk stratification and surgical timing.</p>
<p>Article number five. Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study. This longitudinal cohort study of 12000 participants aged 50 years or older investigated the associations between insomnia symptoms, their long-term trajectories, and incident cardiovascular disease. All participants were without baseline cardiovascular disease and were drawn from the U. S. Health and Retirement Study between 2002 and 2018. The study demonstrated the importance of evaluating long-term patterns of insomnia symptoms in relation to cardiovascular disease development in older adults. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left ventricular ejection fraction, Implantable cardioverter-defibrillator, sudden cardiac death, disease progression, aortic valve, motor vehicle crash, risk stratification, late gadolinium enhancement, Non-dilated left ventricular cardiomyopathy, driving restrictions, Organ transplantation, cardiovascular disease, older adults, cardiac magnetic resonance, Insomnia symptoms, health and retirement study, H. L. A. antibodies, donor-derived cell-free D. N. A., allograft rejection, logistic regression, aortic valve surgery, Bicuspid aortic regurgitation, innate immunity, longitudinal study.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/">I. C. D. Driving Risk Predicted by Baseline Data. 01/11/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260111_060032.mp3" length="4001793" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 11, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and Implantable cardioverter-defibrillator. Key takeaway: I. C. D. Driving Risk Predicted by Baseline Data..
Article Links:
Article 1: Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy. (Heart (British Cardiac Society))
Article 3: Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation. (Heart (British Cardiac Society))
Article 4: Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication. (Heart (British Cardiac Society))
Article 5: Insomnia symptom trajectories and incident cardiovascular disease in older adults: a longitudinal cohort study. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/i-c-d-driving-risk-predicted-by-baseline-data-01-11-26/
 Featured Articles
Article 1: Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41519473
Summary: The S. T. A. R. initiative&#8217;s working group has held three consensus meetings and published reports that have influenced clinical care in organ transplantation. The 2025 group identified and addressed five key evolving areas in transplantation: donor-derived cell-free D. N. A. tests, innate immunity in allograft rejection, immunogenicity and antigenicity, and H. L. A. antibody quantification. This demonstrates the group&#8217;s ongoing work in translating laboratory data into clinical practice and guiding future research priorities.
Article 2: Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40819904
Summary: This study identified three distinct cardiac magnetic resonance-based phenotypes in 515 patients with non-dilated left ventricular cardiomyopathy. These phenotypes include late gadolinium enhancement positive with preserved left ventricular ejection fraction, late gadolinium enhancement negative with dilated left atrium or right ventricle and preserved left ventricular ejection fraction, and late gadolinium enhancement negative with isolated systolic dysfunction with preserved left ventricular ejection fraction. The classification of these phenotypes provides a new framework for risk stratification in this patient population.
Article 3: Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40555466
Summary: This study utilized 22 years of population-based administrative data to identify licensed drivers who received a first implantable cardioverter-defibrillator between 1998 and 2018. It developed a method using baseline health and driving data, along with logistic regression, to estimate the risk of motor vehicle crash in the first year post-implantation. This approach provides clinicians with a tool to personalize medical driving restrictions following implantable cardioverter-defibrillator implantation.
Article 4: Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indication.
Journal: Heart (British Cardiac Society)
PubMed Li]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 11, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular ejection fraction and Implantable cardioverter-defibrillator. Key takeaway: I. C. D. Driving Risk Predicted by Baseline Data..
Article Links:
Article 1: Sensitization in Organ Transplantation: Assessment of Risk (STAR) 2025 Meeting Group Report. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Phenotypic stratification and prognostic value of cardiac magnetic resonance in non-dilated left ventricular cardiomyopathy. (Heart (British Cardiac Society))
Article 3: Predicting the risk of motor vehicle crash in the first year after cardioverter-defibrillator implantation. (Heart (British Cardiac Society))
Article 4: Early predictors of aortic valve surgery in patients with significant bicuspid aortic regurgitation without initial surgical indicati]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>HoFH Therapy: New Drug Bypasses LDL Receptor 01/10/26</title>
	<link>https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/</link>
	<pubDate>Sat, 10 Jan 2026 11:01:35 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 10, 2026. This episode summarizes 5 key cardiology studies on topics like SHR-1918 and clinical outcomes. Key takeaway: HoFH Therapy: New Drug Bypasses LDL Receptor.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41504464">Congenital heart defects: familial recurrence patterns in Sweden.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41499247">Cardiovascular adaptation to training load in endurance athletes: a longitudinal study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41513116">Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41499141">Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41499131">Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/">https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Congenital heart defects: familial recurrence patterns in Sweden.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41504464" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41504464</a></p>
<p><strong>Summary:</strong> Congenital heart defects aggregate in families, necessitating updated population-based recurrence estimates due to improved survival and diagnostic precision. A comprehensive retrospective population-based case-control study utilized nationwide Swedish register data. This investigation included 51778 individuals diagnosed with congenital heart defects born between 1987 and 2001. The study established the specific familial recurrence patterns for congenital heart defects within the Swedish population.</p>
<h4>Article 2: Cardiovascular adaptation to training load in endurance athletes: a longitudinal study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41499247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41499247</a></p>
<p><strong>Summary:</strong> The study demonstrated cardiovascular adaptation to training load in endurance athletes, linking objectively quantified exercise duration and intensity to cardiac magnetic resonance findings. Researchers correlated heart rate monitor data with cardiac magnetic resonance results in 69 young male endurance athletes, aged 16 to 23 years, and 82 middle-aged male endurance athletes, aged 45 to 70 years. This approach provided a precise characterization of exercise-induced cardiac remodeling, overcoming the limitations of previous studies that relied on self-reported data. It directly showed specific cardiac structural and functional changes in response to measured training loads.</p>
<h4>Article 3: Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513116" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513116</a></p>
<p><strong>Summary:</strong> Post-cardiotomy shock is a severe complication after cardiac surgery, linked to high in-hospital mortality. The Society for Cardiovascular Angiography and Interventions SHOCK classification provides a valid approach for initial shock staging post-surgery. This study externally validated the prognostic value and accuracy of serial Society for Cardiovascular Angiography and Interventions SHOCK reclassification for all-cause in-hospital mortality. The data confirmed that repeated application of the classification offers improved risk assessment and predicts outcomes in post-cardiotomy patients.</p>
<h4>Article 4: Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41499141" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41499141</a></p>
<p><strong>Summary:</strong> Homozygous familial hypercholesterolemia is a rare, life-threatening genetic disorder resulting in markedly elevated low-density lipoprotein cholesterol levels due to absent or severely impaired low-density lipoprotein receptor activity. Traditional lipid-regulating agents are largely ineffective as their activity relies on residual low-density lipoprotein receptor function. This nonrandomized clinical trial demonstrated that the anti-angiopoietinlike 3 antibody SHR-1918 reduced lipid levels through a low-density lipoprotein receptor-independent pathway. The study confirmed SHR-1918 as a viable therapeutic option for homozygous familial hypercholesterolemia, addressing a critical unmet need.</p>
<h4>Article 5: Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41499131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41499131</a></p>
<p><strong>Summary:</strong> Area-based indicators of social determinants of health are associated with higher risk for acquired heart disease. This multicenter, prospective cohort study demonstrated the association of these area-based social determinants of health with clinical outcomes in patients with hypertrophic cardiomyopathy. The study, involving US adult patients with hypertrophic cardiomyopathy from 5 sites in the Sarcomeric Human Cardiomyopathy Registry, elucidated the impact of socioeconomic factors on this largely genetic condition. It provided novel evidence that social determinants of health influence outcomes in hypertrophic cardiomyopathy patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Congenital heart defects: familial recurrence patterns in Sweden. Congenital heart defects aggregate in families, necessitating updated population-based recurrence estimates due to improved survival and diagnostic precision. A comprehensive retrospective population-based case-control study utilized nationwide Swedish register data. This investigation included 51778 individuals diagnosed with congenital heart defects born between 1987 and 2001. The study established the specific familial recurrence patterns for congenital heart defects within the Swedish population.</p>
<p>Article number two. Cardiovascular adaptation to training load in endurance athletes: a longitudinal study. The study demonstrated cardiovascular adaptation to training load in endurance athletes, linking objectively quantified exercise duration and intensity to cardiac magnetic resonance findings. Researchers correlated heart rate monitor data with cardiac magnetic resonance results in 69 young male endurance athletes, aged 16 to 23 years, and 82 middle-aged male endurance athletes, aged 45 to 70 years. This approach provided a precise characterization of exercise-induced cardiac remodeling, overcoming the limitations of previous studies that relied on self-reported data. It directly showed specific cardiac structural and functional changes in response to measured training loads.</p>
<p>Article number three. Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients. Post-cardiotomy shock is a severe complication after cardiac surgery, linked to high in-hospital mortality. The Society for Cardiovascular Angiography and Interventions SHOCK classification provides a valid approach for initial shock staging post-surgery. This study externally validated the prognostic value and accuracy of serial Society for Cardiovascular Angiography and Interventions SHOCK reclassification for all-cause in-hospital mortality. The data confirmed that repeated application of the classification offers improved risk assessment and predicts outcomes in post-cardiotomy patients.</p>
<p>Article number four. Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. Homozygous familial hypercholesterolemia is a rare, life-threatening genetic disorder resulting in markedly elevated low-density lipoprotein cholesterol levels due to absent or severely impaired low-density lipoprotein receptor activity. Traditional lipid-regulating agents are largely ineffective as their activity relies on residual low-density lipoprotein receptor function. This nonrandomized clinical trial demonstrated that the anti-angiopoietinlike 3 antibody SHR-1918 reduced lipid levels through a low-density lipoprotein receptor-independent pathway. The study confirmed SHR-1918 as a viable therapeutic option for homozygous familial hypercholesterolemia, addressing a critical unmet need.</p>
<p>Article number five. Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. Area-based indicators of social determinants of health are associated with higher risk for acquired heart disease. This multicenter, prospective cohort study demonstrated the association of these area-based social determinants of health with clinical outcomes in patients with hypertrophic cardiomyopathy. The study, involving US adult patients with hypertrophic cardiomyopathy from 5 sites in the Sarcomeric Human Cardiomyopathy Registry, elucidated the impact of socioeconomic factors on this largely genetic condition. It provided novel evidence that social determinants of health influence outcomes in hypertrophic cardiomyopathy patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>SHR-1918, clinical outcomes, prospective cohort study, social determinants of health, homozygous familial hypercholesterolemia, post-cardiotomy shock, Society for Cardiovascular Angiography and Interventions SHOCK classification, familial recurrence, cardiac magnetic resonance, prognostic value, in-hospital mortality, congenital heart defects, low-density lipoprotein cholesterol, training load, cardiac remodeling, cardiovascular adaptation, lipid-lowering therapy, genetic etiology, population-based study, hypertrophic cardiomyopathy, epidemiology, endurance athletes, cardiac surgery, genetic disorders, angiopoietinlike 3 antibody.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/">HoFH Therapy: New Drug Bypasses LDL Receptor 01/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 10, 2026. This episode summarizes 5 key cardiology studies on topics like SHR-1918 and clinical outcomes. Key takeaway: HoFH Therapy: New Drug Bypasses LDL Receptor.
Article Links:
Article 1: Congenital hear]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 10, 2026. This episode summarizes 5 key cardiology studies on topics like SHR-1918 and clinical outcomes. Key takeaway: HoFH Therapy: New Drug Bypasses LDL Receptor.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41504464">Congenital heart defects: familial recurrence patterns in Sweden.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41499247">Cardiovascular adaptation to training load in endurance athletes: a longitudinal study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41513116">Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41499141">Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41499131">Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/">https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Congenital heart defects: familial recurrence patterns in Sweden.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41504464" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41504464</a></p>
<p><strong>Summary:</strong> Congenital heart defects aggregate in families, necessitating updated population-based recurrence estimates due to improved survival and diagnostic precision. A comprehensive retrospective population-based case-control study utilized nationwide Swedish register data. This investigation included 51778 individuals diagnosed with congenital heart defects born between 1987 and 2001. The study established the specific familial recurrence patterns for congenital heart defects within the Swedish population.</p>
<h4>Article 2: Cardiovascular adaptation to training load in endurance athletes: a longitudinal study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41499247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41499247</a></p>
<p><strong>Summary:</strong> The study demonstrated cardiovascular adaptation to training load in endurance athletes, linking objectively quantified exercise duration and intensity to cardiac magnetic resonance findings. Researchers correlated heart rate monitor data with cardiac magnetic resonance results in 69 young male endurance athletes, aged 16 to 23 years, and 82 middle-aged male endurance athletes, aged 45 to 70 years. This approach provided a precise characterization of exercise-induced cardiac remodeling, overcoming the limitations of previous studies that relied on self-reported data. It directly showed specific cardiac structural and functional changes in response to measured training loads.</p>
<h4>Article 3: Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41513116" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41513116</a></p>
<p><strong>Summary:</strong> Post-cardiotomy shock is a severe complication after cardiac surgery, linked to high in-hospital mortality. The Society for Cardiovascular Angiography and Interventions SHOCK classification provides a valid approach for initial shock staging post-surgery. This study externally validated the prognostic value and accuracy of serial Society for Cardiovascular Angiography and Interventions SHOCK reclassification for all-cause in-hospital mortality. The data confirmed that repeated application of the classification offers improved risk assessment and predicts outcomes in post-cardiotomy patients.</p>
<h4>Article 4: Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41499141" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41499141</a></p>
<p><strong>Summary:</strong> Homozygous familial hypercholesterolemia is a rare, life-threatening genetic disorder resulting in markedly elevated low-density lipoprotein cholesterol levels due to absent or severely impaired low-density lipoprotein receptor activity. Traditional lipid-regulating agents are largely ineffective as their activity relies on residual low-density lipoprotein receptor function. This nonrandomized clinical trial demonstrated that the anti-angiopoietinlike 3 antibody SHR-1918 reduced lipid levels through a low-density lipoprotein receptor-independent pathway. The study confirmed SHR-1918 as a viable therapeutic option for homozygous familial hypercholesterolemia, addressing a critical unmet need.</p>
<h4>Article 5: Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41499131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41499131</a></p>
<p><strong>Summary:</strong> Area-based indicators of social determinants of health are associated with higher risk for acquired heart disease. This multicenter, prospective cohort study demonstrated the association of these area-based social determinants of health with clinical outcomes in patients with hypertrophic cardiomyopathy. The study, involving US adult patients with hypertrophic cardiomyopathy from 5 sites in the Sarcomeric Human Cardiomyopathy Registry, elucidated the impact of socioeconomic factors on this largely genetic condition. It provided novel evidence that social determinants of health influence outcomes in hypertrophic cardiomyopathy patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 10, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Congenital heart defects: familial recurrence patterns in Sweden. Congenital heart defects aggregate in families, necessitating updated population-based recurrence estimates due to improved survival and diagnostic precision. A comprehensive retrospective population-based case-control study utilized nationwide Swedish register data. This investigation included 51778 individuals diagnosed with congenital heart defects born between 1987 and 2001. The study established the specific familial recurrence patterns for congenital heart defects within the Swedish population.</p>
<p>Article number two. Cardiovascular adaptation to training load in endurance athletes: a longitudinal study. The study demonstrated cardiovascular adaptation to training load in endurance athletes, linking objectively quantified exercise duration and intensity to cardiac magnetic resonance findings. Researchers correlated heart rate monitor data with cardiac magnetic resonance results in 69 young male endurance athletes, aged 16 to 23 years, and 82 middle-aged male endurance athletes, aged 45 to 70 years. This approach provided a precise characterization of exercise-induced cardiac remodeling, overcoming the limitations of previous studies that relied on self-reported data. It directly showed specific cardiac structural and functional changes in response to measured training loads.</p>
<p>Article number three. Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients. Post-cardiotomy shock is a severe complication after cardiac surgery, linked to high in-hospital mortality. The Society for Cardiovascular Angiography and Interventions SHOCK classification provides a valid approach for initial shock staging post-surgery. This study externally validated the prognostic value and accuracy of serial Society for Cardiovascular Angiography and Interventions SHOCK reclassification for all-cause in-hospital mortality. The data confirmed that repeated application of the classification offers improved risk assessment and predicts outcomes in post-cardiotomy patients.</p>
<p>Article number four. Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. Homozygous familial hypercholesterolemia is a rare, life-threatening genetic disorder resulting in markedly elevated low-density lipoprotein cholesterol levels due to absent or severely impaired low-density lipoprotein receptor activity. Traditional lipid-regulating agents are largely ineffective as their activity relies on residual low-density lipoprotein receptor function. This nonrandomized clinical trial demonstrated that the anti-angiopoietinlike 3 antibody SHR-1918 reduced lipid levels through a low-density lipoprotein receptor-independent pathway. The study confirmed SHR-1918 as a viable therapeutic option for homozygous familial hypercholesterolemia, addressing a critical unmet need.</p>
<p>Article number five. Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. Area-based indicators of social determinants of health are associated with higher risk for acquired heart disease. This multicenter, prospective cohort study demonstrated the association of these area-based social determinants of health with clinical outcomes in patients with hypertrophic cardiomyopathy. The study, involving US adult patients with hypertrophic cardiomyopathy from 5 sites in the Sarcomeric Human Cardiomyopathy Registry, elucidated the impact of socioeconomic factors on this largely genetic condition. It provided novel evidence that social determinants of health influence outcomes in hypertrophic cardiomyopathy patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>SHR-1918, clinical outcomes, prospective cohort study, social determinants of health, homozygous familial hypercholesterolemia, post-cardiotomy shock, Society for Cardiovascular Angiography and Interventions SHOCK classification, familial recurrence, cardiac magnetic resonance, prognostic value, in-hospital mortality, congenital heart defects, low-density lipoprotein cholesterol, training load, cardiac remodeling, cardiovascular adaptation, lipid-lowering therapy, genetic etiology, population-based study, hypertrophic cardiomyopathy, epidemiology, endurance athletes, cardiac surgery, genetic disorders, angiopoietinlike 3 antibody.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/">HoFH Therapy: New Drug Bypasses LDL Receptor 01/10/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260110_060034.mp3" length="4484954" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 10, 2026. This episode summarizes 5 key cardiology studies on topics like SHR-1918 and clinical outcomes. Key takeaway: HoFH Therapy: New Drug Bypasses LDL Receptor.
Article Links:
Article 1: Congenital heart defects: familial recurrence patterns in Sweden. (European heart journal)
Article 2: Cardiovascular adaptation to training load in endurance athletes: a longitudinal study. (European heart journal)
Article 3: Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. (JAMA cardiology)
Article 5: Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/hofh-therapy-new-drug-bypasses-ldl-receptor-01-10-26/
 Featured Articles
Article 1: Congenital heart defects: familial recurrence patterns in Sweden.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41504464
Summary: Congenital heart defects aggregate in families, necessitating updated population-based recurrence estimates due to improved survival and diagnostic precision. A comprehensive retrospective population-based case-control study utilized nationwide Swedish register data. This investigation included 51778 individuals diagnosed with congenital heart defects born between 1987 and 2001. The study established the specific familial recurrence patterns for congenital heart defects within the Swedish population.
Article 2: Cardiovascular adaptation to training load in endurance athletes: a longitudinal study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41499247
Summary: The study demonstrated cardiovascular adaptation to training load in endurance athletes, linking objectively quantified exercise duration and intensity to cardiac magnetic resonance findings. Researchers correlated heart rate monitor data with cardiac magnetic resonance results in 69 young male endurance athletes, aged 16 to 23 years, and 82 middle-aged male endurance athletes, aged 45 to 70 years. This approach provided a precise characterization of exercise-induced cardiac remodeling, overcoming the limitations of previous studies that relied on self-reported data. It directly showed specific cardiac structural and functional changes in response to measured training loads.
Article 3: Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41513116
Summary: Post-cardiotomy shock is a severe complication after cardiac surgery, linked to high in-hospital mortality. The Society for Cardiovascular Angiography and Interventions SHOCK classification provides a valid approach for initial shock staging post-surgery. This study externally validated the prognostic value and accuracy of serial Society for Cardiovascular Angiography and Interventions SHOCK reclassification for all-cause in-hospital mortality. The data confirmed that repeated application of the classification offers improved risk assessment and predicts outcomes in post-cardiotomy patients.
Article 4: Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41499141
Summary: Homozygous familial hypercholesterolemia is a rare, life-threatening genetic disorder resulting in markedly elevated low-density lipoprotein cholesterol levels due to absent or severely impaired low-density lipoprotein receptor activity. Traditional lipid-regulating agents ar]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 10, 2026. This episode summarizes 5 key cardiology studies on topics like SHR-1918 and clinical outcomes. Key takeaway: HoFH Therapy: New Drug Bypasses LDL Receptor.
Article Links:
Article 1: Congenital heart defects: familial recurrence patterns in Sweden. (European heart journal)
Article 2: Cardiovascular adaptation to training load in endurance athletes: a longitudinal study. (European heart journal)
Article 3: Serial Assessment of Modified SCAI SHOCK Classification in Post-Cardiotomy Patients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. (JAMA cardiology)
Article 5: Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/hofh-the]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>A. I. for Continuous Q. T. Monitoring 01/09/26</title>
	<link>https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/</link>
	<pubDate>Sat, 10 Jan 2026 02:09:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 09, 2026. This episode summarizes 5 key cardiology studies on topics like MTEER and transcatheter interventions. Key takeaway: A. I. for Continuous Q. T. Monitoring.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41505788">2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41460938">Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41511488">Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41506589">VENOPULMONARY EXTRACORPOREAL LIFE SUPPORT: AN ELSO REGISTRY ANALYSIS.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41505119">Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/">https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41505788" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41505788</a></p>
<p><strong>Summary:</strong> C. C. / A. H. A. Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. The 2026 American College of Cardiology/American Heart Association Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease provide guidance for clinicians, researchers, and quality assurance personnel. These measures establish standards for assessing the effects of treatment decisions, including specific medications and diagnostic tests for individuals with peripheral artery disease. They serve to standardize care and facilitate quality assurance in clinical practice and research for this patient population.</p>
<h4>Article 2: Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41460938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41460938</a></p>
<p><strong>Summary:</strong> T. Monitoring to Identify High-Risk Prolongation Events After Class Three Antiarrhythmic Initiation. A deep learning system called 3DRECON-QT was developed for continuous Q. T. monitoring to identify high-risk Q. T. prolongation events. This system addresses drug-induced Q. T. prolongation that can occur after initiation of class three antiarrhythmics during outpatient care. 3DRECON-QT reconstructs spatial information from a single lead vector to quantify Q. T. and Q. T. corrected intervals. Its development provides a novel approach for identifying high-risk Q. T. prolongation, overcoming limitations of current insertable cardiac monitors.</p>
<h4>Article 3: Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41511488" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41511488</a></p>
<p><strong>Summary:</strong> A multi-omics cohort study investigates the effects of air pollution and meteorological factors on cardiac remodeling in children. A total of 2029 children were enrolled in the Southwest Health Children Cohort in China to provide crucial data on these exposures. This research illuminates how environmental factors influence cardiovascular structure and function and the underlying biomolecular mechanisms in pediatric populations. The study addresses a critical knowledge gap regarding these effects in children, contrasting with established associations in adults.</p>
<h4>Article 4: VENOPULMONARY EXTRACORPOREAL LIFE SUPPORT: AN ELSO REGISTRY ANALYSIS.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41506589" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41506589</a></p>
<p><strong>Summary:</strong> L. S. O. Registry Analysis. This Extracorporeal Life Support Organization registry analysis provides real-world outcomes for adults receiving venopulmonary extracorporeal life support. The study utilized a large sample size from the E. L. S. O. registry to describe patient experiences across various clinical conditions. It establishes data regarding the current use, adverse events, and prognostic drivers for venopulmonary extracorporeal life support, where previous information was limited.</p>
<h4>Article 5: Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41505119" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41505119</a></p>
<p><strong>Summary:</strong> S. This cohort study investigated operator-level procedural volumes and patient outcomes for transcatheter aortic valve replacement and mitral transcatheter edge-to-edge repair in the United States. It examined extensive data from patients undergoing these procedures to determine contemporary associations. The research addresses a critical gap in understanding how individual operator volumes relate to outcomes, particularly as hospital-level associations may be stabilizing. This analysis contributes important information for quality assurance and procedural guideline development in these cardiac interventions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. 2026 A. C. C. / A. H. A. Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. The 2026 American College of Cardiology/American Heart Association Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease provide guidance for clinicians, researchers, and quality assurance personnel. These measures establish standards for assessing the effects of treatment decisions, including specific medications and diagnostic tests for individuals with peripheral artery disease. They serve to standardize care and facilitate quality assurance in clinical practice and research for this patient population.</p>
<p>Article number two. Deep Learning-Based Continuous Q. T. Monitoring to Identify High-Risk Prolongation Events After Class Three Antiarrhythmic Initiation. A deep learning system called 3DRECON-QT was developed for continuous Q. T. monitoring to identify high-risk Q. T. prolongation events. This system addresses drug-induced Q. T. prolongation that can occur after initiation of class three antiarrhythmics during outpatient care. 3DRECON-QT reconstructs spatial information from a single lead vector to quantify Q. T. and Q. T. corrected intervals. Its development provides a novel approach for identifying high-risk Q. T. prolongation, overcoming limitations of current insertable cardiac monitors.</p>
<p>Article number three. Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study. A multi-omics cohort study investigates the effects of air pollution and meteorological factors on cardiac remodeling in children. A total of 2029 children were enrolled in the Southwest Health Children Cohort in China to provide crucial data on these exposures. This research illuminates how environmental factors influence cardiovascular structure and function and the underlying biomolecular mechanisms in pediatric populations. The study addresses a critical knowledge gap regarding these effects in children, contrasting with established associations in adults.</p>
<p>Article number four. Venopulmonary Extracorporeal Life Support: An E. L. S. O. Registry Analysis. This Extracorporeal Life Support Organization registry analysis provides real-world outcomes for adults receiving venopulmonary extracorporeal life support. The study utilized a large sample size from the E. L. S. O. registry to describe patient experiences across various clinical conditions. It establishes data regarding the current use, adverse events, and prognostic drivers for venopulmonary extracorporeal life support, where previous information was limited.</p>
<p>Article number five. Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the U. S. This cohort study investigated operator-level procedural volumes and patient outcomes for transcatheter aortic valve replacement and mitral transcatheter edge-to-edge repair in the United States. It examined extensive data from patients undergoing these procedures to determine contemporary associations. The research addresses a critical gap in understanding how individual operator volumes relate to outcomes, particularly as hospital-level associations may be stabilizing. This analysis contributes important information for quality assurance and procedural guideline development in these cardiac interventions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>MTEER, transcatheter interventions, children, E. L. S. O. registry, American Heart Association, multi-omics, critical care, Deep learning, operator volume, clinical performance measures, Air pollution, Peripheral artery disease, quality measures, Q. T. prolongation, Venopulmonary extracorporeal life support, procedural outcomes, insertable cardiac monitors, antiarrhythmics, American College of Cardiology, cardiac monitoring, meteorological factors, cardiac remodeling, TAVR, E. C. L. S., extracorporeal support.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/">A. I. for Continuous Q. T. Monitoring 01/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 09, 2026. This episode summarizes 5 key cardiology studies on topics like MTEER and transcatheter interventions. Key takeaway: A. I. for Continuous Q. T. Monitoring.
Article Links:
Article 1: 2026 ACC/AHA Cl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 09, 2026. This episode summarizes 5 key cardiology studies on topics like MTEER and transcatheter interventions. Key takeaway: A. I. for Continuous Q. T. Monitoring.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41505788">2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41460938">Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41511488">Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41506589">VENOPULMONARY EXTRACORPOREAL LIFE SUPPORT: AN ELSO REGISTRY ANALYSIS.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41505119">Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/">https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41505788" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41505788</a></p>
<p><strong>Summary:</strong> C. C. / A. H. A. Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. The 2026 American College of Cardiology/American Heart Association Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease provide guidance for clinicians, researchers, and quality assurance personnel. These measures establish standards for assessing the effects of treatment decisions, including specific medications and diagnostic tests for individuals with peripheral artery disease. They serve to standardize care and facilitate quality assurance in clinical practice and research for this patient population.</p>
<h4>Article 2: Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41460938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41460938</a></p>
<p><strong>Summary:</strong> T. Monitoring to Identify High-Risk Prolongation Events After Class Three Antiarrhythmic Initiation. A deep learning system called 3DRECON-QT was developed for continuous Q. T. monitoring to identify high-risk Q. T. prolongation events. This system addresses drug-induced Q. T. prolongation that can occur after initiation of class three antiarrhythmics during outpatient care. 3DRECON-QT reconstructs spatial information from a single lead vector to quantify Q. T. and Q. T. corrected intervals. Its development provides a novel approach for identifying high-risk Q. T. prolongation, overcoming limitations of current insertable cardiac monitors.</p>
<h4>Article 3: Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41511488" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41511488</a></p>
<p><strong>Summary:</strong> A multi-omics cohort study investigates the effects of air pollution and meteorological factors on cardiac remodeling in children. A total of 2029 children were enrolled in the Southwest Health Children Cohort in China to provide crucial data on these exposures. This research illuminates how environmental factors influence cardiovascular structure and function and the underlying biomolecular mechanisms in pediatric populations. The study addresses a critical knowledge gap regarding these effects in children, contrasting with established associations in adults.</p>
<h4>Article 4: VENOPULMONARY EXTRACORPOREAL LIFE SUPPORT: AN ELSO REGISTRY ANALYSIS.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41506589" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41506589</a></p>
<p><strong>Summary:</strong> L. S. O. Registry Analysis. This Extracorporeal Life Support Organization registry analysis provides real-world outcomes for adults receiving venopulmonary extracorporeal life support. The study utilized a large sample size from the E. L. S. O. registry to describe patient experiences across various clinical conditions. It establishes data regarding the current use, adverse events, and prognostic drivers for venopulmonary extracorporeal life support, where previous information was limited.</p>
<h4>Article 5: Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41505119" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41505119</a></p>
<p><strong>Summary:</strong> S. This cohort study investigated operator-level procedural volumes and patient outcomes for transcatheter aortic valve replacement and mitral transcatheter edge-to-edge repair in the United States. It examined extensive data from patients undergoing these procedures to determine contemporary associations. The research addresses a critical gap in understanding how individual operator volumes relate to outcomes, particularly as hospital-level associations may be stabilizing. This analysis contributes important information for quality assurance and procedural guideline development in these cardiac interventions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 09, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. 2026 A. C. C. / A. H. A. Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. The 2026 American College of Cardiology/American Heart Association Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease provide guidance for clinicians, researchers, and quality assurance personnel. These measures establish standards for assessing the effects of treatment decisions, including specific medications and diagnostic tests for individuals with peripheral artery disease. They serve to standardize care and facilitate quality assurance in clinical practice and research for this patient population.</p>
<p>Article number two. Deep Learning-Based Continuous Q. T. Monitoring to Identify High-Risk Prolongation Events After Class Three Antiarrhythmic Initiation. A deep learning system called 3DRECON-QT was developed for continuous Q. T. monitoring to identify high-risk Q. T. prolongation events. This system addresses drug-induced Q. T. prolongation that can occur after initiation of class three antiarrhythmics during outpatient care. 3DRECON-QT reconstructs spatial information from a single lead vector to quantify Q. T. and Q. T. corrected intervals. Its development provides a novel approach for identifying high-risk Q. T. prolongation, overcoming limitations of current insertable cardiac monitors.</p>
<p>Article number three. Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study. A multi-omics cohort study investigates the effects of air pollution and meteorological factors on cardiac remodeling in children. A total of 2029 children were enrolled in the Southwest Health Children Cohort in China to provide crucial data on these exposures. This research illuminates how environmental factors influence cardiovascular structure and function and the underlying biomolecular mechanisms in pediatric populations. The study addresses a critical knowledge gap regarding these effects in children, contrasting with established associations in adults.</p>
<p>Article number four. Venopulmonary Extracorporeal Life Support: An E. L. S. O. Registry Analysis. This Extracorporeal Life Support Organization registry analysis provides real-world outcomes for adults receiving venopulmonary extracorporeal life support. The study utilized a large sample size from the E. L. S. O. registry to describe patient experiences across various clinical conditions. It establishes data regarding the current use, adverse events, and prognostic drivers for venopulmonary extracorporeal life support, where previous information was limited.</p>
<p>Article number five. Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the U. S. This cohort study investigated operator-level procedural volumes and patient outcomes for transcatheter aortic valve replacement and mitral transcatheter edge-to-edge repair in the United States. It examined extensive data from patients undergoing these procedures to determine contemporary associations. The research addresses a critical gap in understanding how individual operator volumes relate to outcomes, particularly as hospital-level associations may be stabilizing. This analysis contributes important information for quality assurance and procedural guideline development in these cardiac interventions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>MTEER, transcatheter interventions, children, E. L. S. O. registry, American Heart Association, multi-omics, critical care, Deep learning, operator volume, clinical performance measures, Air pollution, Peripheral artery disease, quality measures, Q. T. prolongation, Venopulmonary extracorporeal life support, procedural outcomes, insertable cardiac monitors, antiarrhythmics, American College of Cardiology, cardiac monitoring, meteorological factors, cardiac remodeling, TAVR, E. C. L. S., extracorporeal support.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/">A. I. for Continuous Q. T. Monitoring 01/09/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260109_210842.mp3" length="4061143" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 09, 2026. This episode summarizes 5 key cardiology studies on topics like MTEER and transcatheter interventions. Key takeaway: A. I. for Continuous Q. T. Monitoring.
Article Links:
Article 1: 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. (Journal of the American College of Cardiology)
Article 2: Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation. (Circulation)
Article 3: Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study. (European heart journal)
Article 4: VENOPULMONARY EXTRACORPOREAL LIFE SUPPORT: AN ELSO REGISTRY ANALYSIS. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/a-i-for-continuous-q-t-monitoring-01-09-26/
 Featured Articles
Article 1: 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41505788
Summary: C. C. / A. H. A. Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. The 2026 American College of Cardiology/American Heart Association Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease provide guidance for clinicians, researchers, and quality assurance personnel. These measures establish standards for assessing the effects of treatment decisions, including specific medications and diagnostic tests for individuals with peripheral artery disease. They serve to standardize care and facilitate quality assurance in clinical practice and research for this patient population.
Article 2: Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41460938
Summary: T. Monitoring to Identify High-Risk Prolongation Events After Class Three Antiarrhythmic Initiation. A deep learning system called 3DRECON-QT was developed for continuous Q. T. monitoring to identify high-risk Q. T. prolongation events. This system addresses drug-induced Q. T. prolongation that can occur after initiation of class three antiarrhythmics during outpatient care. 3DRECON-QT reconstructs spatial information from a single lead vector to quantify Q. T. and Q. T. corrected intervals. Its development provides a novel approach for identifying high-risk Q. T. prolongation, overcoming limitations of current insertable cardiac monitors.
Article 3: Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41511488
Summary: A multi-omics cohort study investigates the effects of air pollution and meteorological factors on cardiac remodeling in children. A total of 2029 children were enrolled in the Southwest Health Children Cohort in China to provide crucial data on these exposures. This research illuminates how environmental factors influence cardiovascular structure and function and the underlying biomolecular mechanisms in pediatric populations. The study addresses a critical knowledge gap regarding these effects in children, contrasting with established associations in adults]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 09, 2026. This episode summarizes 5 key cardiology studies on topics like MTEER and transcatheter interventions. Key takeaway: A. I. for Continuous Q. T. Monitoring.
Article Links:
Article 1: 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. (Journal of the American College of Cardiology)
Article 2: Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation. (Circulation)
Article 3: Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study. (European heart journal)
Article 4: VENOPULMONARY EXTRACORPOREAL LIFE SUPPORT: AN ELSO REGISTRY ANALYSIS. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transpla]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CXCR6+ T Cells Drive ICI Myocarditis 01/07/26</title>
	<link>https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/</link>
	<pubDate>Thu, 08 Jan 2026 01:59:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 07, 2026. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and heart failure. Key takeaway: CXCR6+ T Cells Drive ICI Myocarditis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41498476">Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41196240">Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41498147">CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41493005">Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41492949">Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/">https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41498476" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41498476</a></p>
<p><strong>Summary:</strong> Loss of the Y chromosome from circulating leukocytes is common in older men and is definitively associated with increased cardiovascular risk. This genetic phenomenon functions as a predictor for incident major adverse cardiovascular events, including myocardial infarction and ischemic stroke. The association was investigated in a prospective cohort of 5131 men aged 65 years or older, providing a clear link in a healthy patient population. This indicates the role of genetic factors in cardiovascular disease progression in older males.</p>
<h4>Article 2: Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41196240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41196240</a></p>
<p><strong>Summary:</strong> Frailty is highly prevalent among patients with heart failure and consistently correlates with adverse clinical outcomes. The Clinical Frailty Scale accurately captures multidimensional vulnerability, reflecting both physical and cognitive decline in this patient population. This scale demonstrates significant prognostic utility, predicting 2-year all-cause mortality in hospitalized patients with heart failure. The findings establish the Clinical Frailty Scale as a robust tool for risk stratification in contemporary heart failure care.</p>
<h4>Article 3: CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41498147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41498147</a></p>
<p><strong>Summary:</strong> X. C. R. 6 Positive T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Myocarditis is a severe and established complication of immune checkpoint inhibitor therapy, with a major risk factor being the use of combination treatments, particularly relatlimab combined with anti-programmed cell death protein 1 therapy. This study definitively identified C. X. C. R. 6 positive T cells as the specific T-cell population responsible for driving immune checkpoint inhibitor myocarditis. The research revealed the critical signaling pathways and T-cell populations that lead to cardiac infiltration in this adverse event. These findings provide a clear understanding of the pathogenic mechanisms underlying immune checkpoint inhibitor myocarditis.</p>
<h4>Article 4: Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493005" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493005</a></p>
<p><strong>Summary:</strong> Universal definitions of percutaneous coronary intervention-related myocardial infarction have undergone substantial updates, including an increase in biomarker thresholds from three to five times the upper reference limit. New ancillary criteria, such as ischemic symptoms, electrocardiographic changes, or angiographic complications, have also been introduced. These evolving definitions directly impact the diagnosis and prognostic assessment of patients with acute coronary syndrome. The changes have significant implications for patient risk stratification and treatment strategies following percutaneous coronary intervention.</p>
<h4>Article 5: Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41492949" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41492949</a></p>
<p><strong>Summary:</strong> H. B. 2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction. Mitophagy is critically involved in cardiac injury and repair processes following myocardial infarction. The annexin A family of proteins plays an important role in regulating mitophagy. This study established that the inhibition of annexin A2 facilitates P. H. B. 2-mediated mitophagy specifically in cardiomyocytes. This mechanism was shown to alleviate cardiac injury and subsequent remodeling after myocardial infarction, indicating annexin A2 as a potential therapeutic target.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men. Loss of the Y chromosome from circulating leukocytes is common in older men and is definitively associated with increased cardiovascular risk. This genetic phenomenon functions as a predictor for incident major adverse cardiovascular events, including myocardial infarction and ischemic stroke. The association was investigated in a prospective cohort of 5131 men aged 65 years or older, providing a clear link in a healthy patient population. This indicates the role of genetic factors in cardiovascular disease progression in older males.</p>
<p>Article number two. Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure. Frailty is highly prevalent among patients with heart failure and consistently correlates with adverse clinical outcomes. The Clinical Frailty Scale accurately captures multidimensional vulnerability, reflecting both physical and cognitive decline in this patient population. This scale demonstrates significant prognostic utility, predicting 2-year all-cause mortality in hospitalized patients with heart failure. The findings establish the Clinical Frailty Scale as a robust tool for risk stratification in contemporary heart failure care.</p>
<p>Article number three. C. X. C. R. 6 Positive T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Myocarditis is a severe and established complication of immune checkpoint inhibitor therapy, with a major risk factor being the use of combination treatments, particularly relatlimab combined with anti-programmed cell death protein 1 therapy. This study definitively identified C. X. C. R. 6 positive T cells as the specific T-cell population responsible for driving immune checkpoint inhibitor myocarditis. The research revealed the critical signaling pathways and T-cell populations that lead to cardiac infiltration in this adverse event. These findings provide a clear understanding of the pathogenic mechanisms underlying immune checkpoint inhibitor myocarditis.</p>
<p>Article number four. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. Universal definitions of percutaneous coronary intervention-related myocardial infarction have undergone substantial updates, including an increase in biomarker thresholds from three to five times the upper reference limit. New ancillary criteria, such as ischemic symptoms, electrocardiographic changes, or angiographic complications, have also been introduced. These evolving definitions directly impact the diagnosis and prognostic assessment of patients with acute coronary syndrome. The changes have significant implications for patient risk stratification and treatment strategies following percutaneous coronary intervention.</p>
<p>Article number five. Inhibition of Annexin A2 Facilitates P. H. B. 2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction. Mitophagy is critically involved in cardiac injury and repair processes following myocardial infarction. The annexin A family of proteins plays an important role in regulating mitophagy. This study established that the inhibition of annexin A2 facilitates P. H. B. 2-mediated mitophagy specifically in cardiomyocytes. This mechanism was shown to alleviate cardiac injury and subsequent remodeling after myocardial infarction, indicating annexin A2 as a potential therapeutic target. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>major adverse cardiovascular events, heart failure, relatlimab, mitophagy, percutaneous coronary intervention, P. H. B. 2, cardiac remodeling, Clinical Frailty Scale, biomarker thresholds, myocardial infarction, all-cause mortality, prognostic utility, universal definition, cardiovascular risk, frailty, immune checkpoint inhibitors, ischemic stroke, C. X. C. R. 6 positive T cells, annexin A2, acute coronary syndrome, myocarditis, loss of Y chromosome, anti-programmed cell death protein 1 therapy, periprocedural myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/">CXCR6+ T Cells Drive ICI Myocarditis 01/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 07, 2026. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and heart failure. Key takeaway: CXCR6+ T Cells Drive ICI Myocarditis.
Article Links:
Article 1: ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 07, 2026. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and heart failure. Key takeaway: CXCR6+ T Cells Drive ICI Myocarditis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41498476">Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41196240">Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41498147">CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41493005">Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41492949">Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/">https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41498476" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41498476</a></p>
<p><strong>Summary:</strong> Loss of the Y chromosome from circulating leukocytes is common in older men and is definitively associated with increased cardiovascular risk. This genetic phenomenon functions as a predictor for incident major adverse cardiovascular events, including myocardial infarction and ischemic stroke. The association was investigated in a prospective cohort of 5131 men aged 65 years or older, providing a clear link in a healthy patient population. This indicates the role of genetic factors in cardiovascular disease progression in older males.</p>
<h4>Article 2: Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41196240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41196240</a></p>
<p><strong>Summary:</strong> Frailty is highly prevalent among patients with heart failure and consistently correlates with adverse clinical outcomes. The Clinical Frailty Scale accurately captures multidimensional vulnerability, reflecting both physical and cognitive decline in this patient population. This scale demonstrates significant prognostic utility, predicting 2-year all-cause mortality in hospitalized patients with heart failure. The findings establish the Clinical Frailty Scale as a robust tool for risk stratification in contemporary heart failure care.</p>
<h4>Article 3: CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41498147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41498147</a></p>
<p><strong>Summary:</strong> X. C. R. 6 Positive T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Myocarditis is a severe and established complication of immune checkpoint inhibitor therapy, with a major risk factor being the use of combination treatments, particularly relatlimab combined with anti-programmed cell death protein 1 therapy. This study definitively identified C. X. C. R. 6 positive T cells as the specific T-cell population responsible for driving immune checkpoint inhibitor myocarditis. The research revealed the critical signaling pathways and T-cell populations that lead to cardiac infiltration in this adverse event. These findings provide a clear understanding of the pathogenic mechanisms underlying immune checkpoint inhibitor myocarditis.</p>
<h4>Article 4: Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41493005" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41493005</a></p>
<p><strong>Summary:</strong> Universal definitions of percutaneous coronary intervention-related myocardial infarction have undergone substantial updates, including an increase in biomarker thresholds from three to five times the upper reference limit. New ancillary criteria, such as ischemic symptoms, electrocardiographic changes, or angiographic complications, have also been introduced. These evolving definitions directly impact the diagnosis and prognostic assessment of patients with acute coronary syndrome. The changes have significant implications for patient risk stratification and treatment strategies following percutaneous coronary intervention.</p>
<h4>Article 5: Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41492949" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41492949</a></p>
<p><strong>Summary:</strong> H. B. 2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction. Mitophagy is critically involved in cardiac injury and repair processes following myocardial infarction. The annexin A family of proteins plays an important role in regulating mitophagy. This study established that the inhibition of annexin A2 facilitates P. H. B. 2-mediated mitophagy specifically in cardiomyocytes. This mechanism was shown to alleviate cardiac injury and subsequent remodeling after myocardial infarction, indicating annexin A2 as a potential therapeutic target.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men. Loss of the Y chromosome from circulating leukocytes is common in older men and is definitively associated with increased cardiovascular risk. This genetic phenomenon functions as a predictor for incident major adverse cardiovascular events, including myocardial infarction and ischemic stroke. The association was investigated in a prospective cohort of 5131 men aged 65 years or older, providing a clear link in a healthy patient population. This indicates the role of genetic factors in cardiovascular disease progression in older males.</p>
<p>Article number two. Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure. Frailty is highly prevalent among patients with heart failure and consistently correlates with adverse clinical outcomes. The Clinical Frailty Scale accurately captures multidimensional vulnerability, reflecting both physical and cognitive decline in this patient population. This scale demonstrates significant prognostic utility, predicting 2-year all-cause mortality in hospitalized patients with heart failure. The findings establish the Clinical Frailty Scale as a robust tool for risk stratification in contemporary heart failure care.</p>
<p>Article number three. C. X. C. R. 6 Positive T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Myocarditis is a severe and established complication of immune checkpoint inhibitor therapy, with a major risk factor being the use of combination treatments, particularly relatlimab combined with anti-programmed cell death protein 1 therapy. This study definitively identified C. X. C. R. 6 positive T cells as the specific T-cell population responsible for driving immune checkpoint inhibitor myocarditis. The research revealed the critical signaling pathways and T-cell populations that lead to cardiac infiltration in this adverse event. These findings provide a clear understanding of the pathogenic mechanisms underlying immune checkpoint inhibitor myocarditis.</p>
<p>Article number four. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. Universal definitions of percutaneous coronary intervention-related myocardial infarction have undergone substantial updates, including an increase in biomarker thresholds from three to five times the upper reference limit. New ancillary criteria, such as ischemic symptoms, electrocardiographic changes, or angiographic complications, have also been introduced. These evolving definitions directly impact the diagnosis and prognostic assessment of patients with acute coronary syndrome. The changes have significant implications for patient risk stratification and treatment strategies following percutaneous coronary intervention.</p>
<p>Article number five. Inhibition of Annexin A2 Facilitates P. H. B. 2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction. Mitophagy is critically involved in cardiac injury and repair processes following myocardial infarction. The annexin A family of proteins plays an important role in regulating mitophagy. This study established that the inhibition of annexin A2 facilitates P. H. B. 2-mediated mitophagy specifically in cardiomyocytes. This mechanism was shown to alleviate cardiac injury and subsequent remodeling after myocardial infarction, indicating annexin A2 as a potential therapeutic target. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>major adverse cardiovascular events, heart failure, relatlimab, mitophagy, percutaneous coronary intervention, P. H. B. 2, cardiac remodeling, Clinical Frailty Scale, biomarker thresholds, myocardial infarction, all-cause mortality, prognostic utility, universal definition, cardiovascular risk, frailty, immune checkpoint inhibitors, ischemic stroke, C. X. C. R. 6 positive T cells, annexin A2, acute coronary syndrome, myocarditis, loss of Y chromosome, anti-programmed cell death protein 1 therapy, periprocedural myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/">CXCR6+ T Cells Drive ICI Myocarditis 01/07/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260107_205821.mp3" length="4258420" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 07, 2026. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and heart failure. Key takeaway: CXCR6+ T Cells Drive ICI Myocarditis.
Article Links:
Article 1: Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men. (Journal of the American College of Cardiology)
Article 2: Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure. (Journal of the American College of Cardiology)
Article 3: CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. (Circulation)
Article 4: Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. (Circulation)
Article 5: Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/cxcr6-t-cells-drive-ici-myocarditis-01-07-26/
 Featured Articles
Article 1: Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41498476
Summary: Loss of the Y chromosome from circulating leukocytes is common in older men and is definitively associated with increased cardiovascular risk. This genetic phenomenon functions as a predictor for incident major adverse cardiovascular events, including myocardial infarction and ischemic stroke. The association was investigated in a prospective cohort of 5131 men aged 65 years or older, providing a clear link in a healthy patient population. This indicates the role of genetic factors in cardiovascular disease progression in older males.
Article 2: Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41196240
Summary: Frailty is highly prevalent among patients with heart failure and consistently correlates with adverse clinical outcomes. The Clinical Frailty Scale accurately captures multidimensional vulnerability, reflecting both physical and cognitive decline in this patient population. This scale demonstrates significant prognostic utility, predicting 2-year all-cause mortality in hospitalized patients with heart failure. The findings establish the Clinical Frailty Scale as a robust tool for risk stratification in contemporary heart failure care.
Article 3: CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41498147
Summary: X. C. R. 6 Positive T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Myocarditis is a severe and established complication of immune checkpoint inhibitor therapy, with a major risk factor being the use of combination treatments, particularly relatlimab combined with anti-programmed cell death protein 1 therapy. This study definitively identified C. X. C. R. 6 positive T cells as the specific T-cell population responsible for driving immune checkpoint inhibitor myocarditis. The research revealed the critical signaling pathways and T-cell populations that lead to cardiac infiltration in this adverse event. These findings provide a clear understanding of the pathogenic mechanisms underlying immune checkpoint inhibitor myocarditis.
Article 4: Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493005
Summary: Universal definitions of percutaneous coronary intervention-related myocardial infarction have undergone substantial updates, including an increase in biomarker thresholds from three to five times the upper reference limit. New ancillary criteria, su]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 07, 2026. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and heart failure. Key takeaway: CXCR6+ T Cells Drive ICI Myocarditis.
Article Links:
Article 1: Loss of Y Chromosome and Major Cardiovascular Events in a Prospective Study of Older Men. (Journal of the American College of Cardiology)
Article 2: Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure. (Journal of the American College of Cardiology)
Article 3: CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. (Circulation)
Article 4: Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. (Circulation)
Article 5: Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction. (Circulation)
Full episode page: https://podcast.e]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>RBMS1 Deficiency Improves Heart Failure 01/05/26</title>
	<link>https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/</link>
	<pubDate>Mon, 05 Jan 2026 11:01:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40678978">Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40471706">Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41485619">Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41485617">Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41485609">Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function.</a> (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/">https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40678978" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40678978</a></p>
<p><strong>Summary:</strong> Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.</p>
<h4>Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40471706" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40471706</a></p>
<p><strong>Summary:</strong> This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.</p>
<h4>Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41485619" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41485619</a></p>
<p><strong>Summary:</strong> This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.</p>
<h4>Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41485617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41485617</a></p>
<p><strong>Summary:</strong> This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations.</p>
<h4>Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function.</h4>
<p><strong>Journal:</strong> Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41485609" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41485609</a></p>
<p><strong>Summary:</strong> This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular diastolic dysfunction and changes in right ventricular morphology and performance. These findings highlight that even mild or moderate left ventricular diastolic dysfunction can significantly influence right ventricular dimensions and functional capacity, extending beyond observations in severe heart failure with preserved ejection fraction, or H. F. pEF.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.</p>
<p>Article number two. Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.</p>
<p>Article number three. Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.</p>
<p>Article number four. Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations.</p>
<p>Article number five. Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular diastolic dysfunction and changes in right ventricular morphology and performance. These findings highlight that even mild or moderate left ventricular diastolic dysfunction can significantly influence right ventricular dimensions and functional capacity, extending beyond observations in severe heart failure with preserved ejection fraction, or H. F. pEF. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left ventricular diastolic dysfunction, transcatheter aortic valve replacement, heart failure, alternative splicing, TAVR, therapeutic target, Evolut valve, prediction score, RNA-binding protein RBMS1, cardiac magnetic resonance, sotatercept, long-term outcomes, major arrhythmic event, myocardial fibrosis, real-world data, 3-dimensional echocardiography, H. F. pEF, TriNetX network, NDLVC, right ventricular function, pulmonary hypertension, coronary access, heart failure with preserved ejection fraction, computed tomography, non-dilated left ventricular cardiomyopathy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/">RBMS1 Deficiency Improves Heart Failure 01/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Fail]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40678978">Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40471706">Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41485619">Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41485617">Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41485609">Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function.</a> (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/">https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40678978" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40678978</a></p>
<p><strong>Summary:</strong> Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.</p>
<h4>Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40471706" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40471706</a></p>
<p><strong>Summary:</strong> This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.</p>
<h4>Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41485619" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41485619</a></p>
<p><strong>Summary:</strong> This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.</p>
<h4>Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41485617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41485617</a></p>
<p><strong>Summary:</strong> This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations.</p>
<h4>Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function.</h4>
<p><strong>Journal:</strong> Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41485609" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41485609</a></p>
<p><strong>Summary:</strong> This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular diastolic dysfunction and changes in right ventricular morphology and performance. These findings highlight that even mild or moderate left ventricular diastolic dysfunction can significantly influence right ventricular dimensions and functional capacity, extending beyond observations in severe heart failure with preserved ejection fraction, or H. F. pEF.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.</p>
<p>Article number two. Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.</p>
<p>Article number three. Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.</p>
<p>Article number four. Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations.</p>
<p>Article number five. Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular diastolic dysfunction and changes in right ventricular morphology and performance. These findings highlight that even mild or moderate left ventricular diastolic dysfunction can significantly influence right ventricular dimensions and functional capacity, extending beyond observations in severe heart failure with preserved ejection fraction, or H. F. pEF. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>left ventricular diastolic dysfunction, transcatheter aortic valve replacement, heart failure, alternative splicing, TAVR, therapeutic target, Evolut valve, prediction score, RNA-binding protein RBMS1, cardiac magnetic resonance, sotatercept, long-term outcomes, major arrhythmic event, myocardial fibrosis, real-world data, 3-dimensional echocardiography, H. F. pEF, TriNetX network, NDLVC, right ventricular function, pulmonary hypertension, coronary access, heart failure with preserved ejection fraction, computed tomography, non-dilated left ventricular cardiomyopathy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/">RBMS1 Deficiency Improves Heart Failure 01/05/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260105_060036.mp3" length="4380046" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Failure.
Article Links:
Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. (European heart journal)
Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. (European heart journal)
Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. (International journal of cardiology)
Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. (International journal of cardiology)
Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)
Full episode page: https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/
 Featured Articles
Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40678978
Summary: Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.
Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40471706
Summary: This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.
Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485619
Summary: This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.
Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485617
Summary: This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Failure.
Article Links:
Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. (European heart journal)
Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. (European heart journal)
Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. (International journal of cardiology)
Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. (International journal of cardiology)
Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. (Journal of the American Society of Echocardiography : ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Thromboaspiration Not Routine in STEMI 01/04/26</title>
	<link>https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/</link>
	<pubDate>Sun, 04 Jan 2026 11:01:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like quantitative flow ratio and sinus rhythm. Key takeaway: Thromboaspiration Not Routine in STEMI.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41483841">Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41138981">Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41061875">Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41052695">Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40914220">Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/">https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41483841" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41483841</a></p>
<p><strong>Summary:</strong> This study provided cardiac magnetic resonance imaging evidence against the routine use of thromboaspiration as an adjunct to primary percutaneous coronary intervention in ST-elevation myocardial infarction. The data demonstrated concerns about thromboaspiration&#8217;s potential to aggravate microvascular injury. The study confirmed that the effect of thromboaspiration on microvascular perfusion remains uncertain, leading to the conclusion that routine application is not supported.</p>
<h4>Article 2: Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138981" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138981</a></p>
<p><strong>Summary:</strong> This meta-analysis compared the survival of patients with mixed aortic valve disease versus predominant aortic stenosis following transcatheter aortic valve replacement. The study found that patients with mixed aortic valve disease demonstrated distinct survival outcomes compared to those with predominant aortic stenosis. This research provides crucial insights into differential survival rates for specific aortic valve pathologies undergoing transcatheter aortic valve replacement (TAVR).</p>
<h4>Article 3: Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41061875" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41061875</a></p>
<p><strong>Summary:</strong> This study compared the sequential changes in functional tricuspid regurgitation following transcatheter atrial septal defect closure across different preprocedural cardiac rhythms. The research categorized patients into groups with sinus rhythm, sinus rhythm after catheter ablation for atrial fibrillation, and permanent atrial fibrillation. The data demonstrated differential changes in tricuspid regurgitation based on the patient&#8217;s baseline and post-ablation cardiac rhythm status after atrial septal defect closure.</p>
<h4>Article 4: Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052695" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052695</a></p>
<p><strong>Summary:</strong> This study demonstrated persistent racial disparities in chronic limb-threatening ischemia outcomes and healthcare utilization among U.S. Medicare patients. The data showed that Black patients continued to experience higher amputation rates and reduced access to vascular care compared to White beneficiaries. Despite national campaigns aimed at improving peripheral arterial disease outcomes, these disparities were found to persist over time.</p>
<h4>Article 5: Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40914220" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40914220</a></p>
<p><strong>Summary:</strong> This study found that quantitative flow ratio functional evaluation effectively unmasked myocardial bridge-related ischemia. The data demonstrated that this functional assessment method is crucial for identifying the hemodynamic impact of myocardial bridges, which are segments of epicardial coronary arteries passing through myocardial muscle. The findings highlight the utility of quantitative flow ratio in assessing myocardial bridge severity for informed treatment decisions, particularly in cases where these bridges are associated with cardiovascular conditions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice. This study provided cardiac magnetic resonance imaging evidence against the routine use of thromboaspiration as an adjunct to primary percutaneous coronary intervention in ST-elevation myocardial infarction. The data demonstrated concerns about thromboaspiration&#8217;s potential to aggravate microvascular injury. The study confirmed that the effect of thromboaspiration on microvascular perfusion remains uncertain, leading to the conclusion that routine application is not supported.</p>
<p>Article number two. Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis. This meta-analysis compared the survival of patients with mixed aortic valve disease versus predominant aortic stenosis following transcatheter aortic valve replacement. The study found that patients with mixed aortic valve disease demonstrated distinct survival outcomes compared to those with predominant aortic stenosis. This research provides crucial insights into differential survival rates for specific aortic valve pathologies undergoing transcatheter aortic valve replacement (TAVR).</p>
<p>Article number three. Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation. This study compared the sequential changes in functional tricuspid regurgitation following transcatheter atrial septal defect closure across different preprocedural cardiac rhythms. The research categorized patients into groups with sinus rhythm, sinus rhythm after catheter ablation for atrial fibrillation, and permanent atrial fibrillation. The data demonstrated differential changes in tricuspid regurgitation based on the patient&#8217;s baseline and post-ablation cardiac rhythm status after atrial septal defect closure.</p>
<p>Article number four. Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients. This study demonstrated persistent racial disparities in chronic limb-threatening ischemia outcomes and healthcare utilization among U.S. Medicare patients. The data showed that Black patients continued to experience higher amputation rates and reduced access to vascular care compared to White beneficiaries. Despite national campaigns aimed at improving peripheral arterial disease outcomes, these disparities were found to persist over time.</p>
<p>Article number five. Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation. This study found that quantitative flow ratio functional evaluation effectively unmasked myocardial bridge-related ischemia. The data demonstrated that this functional assessment method is crucial for identifying the hemodynamic impact of myocardial bridges, which are segments of epicardial coronary arteries passing through myocardial muscle. The findings highlight the utility of quantitative flow ratio in assessing myocardial bridge severity for informed treatment decisions, particularly in cases where these bridges are associated with cardiovascular conditions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>quantitative flow ratio, sinus rhythm, atrial fibrillation, cardiac magnetic resonance imaging, Chronic limb-threatening ischemia, Medicare patients, mixed aortic valve disease, peripheral arterial disease, catheter ablation, Transcatheter aortic valve replacement, coronary artery disease, meta-analysis, microvascular obstruction, survival outcomes, atrial septal defect closure, ischemia, hemodynamic assessment, aortic stenosis, racial disparities, Thromboaspiration, Tricuspid regurgitation, amputation rates, ST-elevation myocardial infarction, Myocardial bridge, percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/">Thromboaspiration Not Routine in STEMI 01/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like quantitative flow ratio and sinus rhythm. Key takeaway: Thromboaspiration Not Routine in STEMI.
Article Links:
Article 1: Selective U]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like quantitative flow ratio and sinus rhythm. Key takeaway: Thromboaspiration Not Routine in STEMI.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41483841">Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41138981">Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41061875">Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41052695">Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40914220">Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/">https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41483841" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41483841</a></p>
<p><strong>Summary:</strong> This study provided cardiac magnetic resonance imaging evidence against the routine use of thromboaspiration as an adjunct to primary percutaneous coronary intervention in ST-elevation myocardial infarction. The data demonstrated concerns about thromboaspiration&#8217;s potential to aggravate microvascular injury. The study confirmed that the effect of thromboaspiration on microvascular perfusion remains uncertain, leading to the conclusion that routine application is not supported.</p>
<h4>Article 2: Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138981" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138981</a></p>
<p><strong>Summary:</strong> This meta-analysis compared the survival of patients with mixed aortic valve disease versus predominant aortic stenosis following transcatheter aortic valve replacement. The study found that patients with mixed aortic valve disease demonstrated distinct survival outcomes compared to those with predominant aortic stenosis. This research provides crucial insights into differential survival rates for specific aortic valve pathologies undergoing transcatheter aortic valve replacement (TAVR).</p>
<h4>Article 3: Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41061875" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41061875</a></p>
<p><strong>Summary:</strong> This study compared the sequential changes in functional tricuspid regurgitation following transcatheter atrial septal defect closure across different preprocedural cardiac rhythms. The research categorized patients into groups with sinus rhythm, sinus rhythm after catheter ablation for atrial fibrillation, and permanent atrial fibrillation. The data demonstrated differential changes in tricuspid regurgitation based on the patient&#8217;s baseline and post-ablation cardiac rhythm status after atrial septal defect closure.</p>
<h4>Article 4: Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052695" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052695</a></p>
<p><strong>Summary:</strong> This study demonstrated persistent racial disparities in chronic limb-threatening ischemia outcomes and healthcare utilization among U.S. Medicare patients. The data showed that Black patients continued to experience higher amputation rates and reduced access to vascular care compared to White beneficiaries. Despite national campaigns aimed at improving peripheral arterial disease outcomes, these disparities were found to persist over time.</p>
<h4>Article 5: Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40914220" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40914220</a></p>
<p><strong>Summary:</strong> This study found that quantitative flow ratio functional evaluation effectively unmasked myocardial bridge-related ischemia. The data demonstrated that this functional assessment method is crucial for identifying the hemodynamic impact of myocardial bridges, which are segments of epicardial coronary arteries passing through myocardial muscle. The findings highlight the utility of quantitative flow ratio in assessing myocardial bridge severity for informed treatment decisions, particularly in cases where these bridges are associated with cardiovascular conditions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice. This study provided cardiac magnetic resonance imaging evidence against the routine use of thromboaspiration as an adjunct to primary percutaneous coronary intervention in ST-elevation myocardial infarction. The data demonstrated concerns about thromboaspiration&#8217;s potential to aggravate microvascular injury. The study confirmed that the effect of thromboaspiration on microvascular perfusion remains uncertain, leading to the conclusion that routine application is not supported.</p>
<p>Article number two. Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis. This meta-analysis compared the survival of patients with mixed aortic valve disease versus predominant aortic stenosis following transcatheter aortic valve replacement. The study found that patients with mixed aortic valve disease demonstrated distinct survival outcomes compared to those with predominant aortic stenosis. This research provides crucial insights into differential survival rates for specific aortic valve pathologies undergoing transcatheter aortic valve replacement (TAVR).</p>
<p>Article number three. Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation. This study compared the sequential changes in functional tricuspid regurgitation following transcatheter atrial septal defect closure across different preprocedural cardiac rhythms. The research categorized patients into groups with sinus rhythm, sinus rhythm after catheter ablation for atrial fibrillation, and permanent atrial fibrillation. The data demonstrated differential changes in tricuspid regurgitation based on the patient&#8217;s baseline and post-ablation cardiac rhythm status after atrial septal defect closure.</p>
<p>Article number four. Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients. This study demonstrated persistent racial disparities in chronic limb-threatening ischemia outcomes and healthcare utilization among U.S. Medicare patients. The data showed that Black patients continued to experience higher amputation rates and reduced access to vascular care compared to White beneficiaries. Despite national campaigns aimed at improving peripheral arterial disease outcomes, these disparities were found to persist over time.</p>
<p>Article number five. Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation. This study found that quantitative flow ratio functional evaluation effectively unmasked myocardial bridge-related ischemia. The data demonstrated that this functional assessment method is crucial for identifying the hemodynamic impact of myocardial bridges, which are segments of epicardial coronary arteries passing through myocardial muscle. The findings highlight the utility of quantitative flow ratio in assessing myocardial bridge severity for informed treatment decisions, particularly in cases where these bridges are associated with cardiovascular conditions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>quantitative flow ratio, sinus rhythm, atrial fibrillation, cardiac magnetic resonance imaging, Chronic limb-threatening ischemia, Medicare patients, mixed aortic valve disease, peripheral arterial disease, catheter ablation, Transcatheter aortic valve replacement, coronary artery disease, meta-analysis, microvascular obstruction, survival outcomes, atrial septal defect closure, ischemia, hemodynamic assessment, aortic stenosis, racial disparities, Thromboaspiration, Tricuspid regurgitation, amputation rates, ST-elevation myocardial infarction, Myocardial bridge, percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/">Thromboaspiration Not Routine in STEMI 01/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260104_060030.mp3" length="3820398" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like quantitative flow ratio and sinus rhythm. Key takeaway: Thromboaspiration Not Routine in STEMI.
Article Links:
Article 1: Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice. (The American journal of cardiology)
Article 2: Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis. (The American journal of cardiology)
Article 3: Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation. (The American journal of cardiology)
Article 4: Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients. (The American journal of cardiology)
Article 5: Unmasking Myocardial Bridge-Related Ischemia by Quantitative Flow Ratio Functional Evaluation. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/thromboaspiration-not-routine-in-stemi-01-04-26/
 Featured Articles
Article 1: Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41483841
Summary: This study provided cardiac magnetic resonance imaging evidence against the routine use of thromboaspiration as an adjunct to primary percutaneous coronary intervention in ST-elevation myocardial infarction. The data demonstrated concerns about thromboaspiration&#8217;s potential to aggravate microvascular injury. The study confirmed that the effect of thromboaspiration on microvascular perfusion remains uncertain, leading to the conclusion that routine application is not supported.
Article 2: Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41138981
Summary: This meta-analysis compared the survival of patients with mixed aortic valve disease versus predominant aortic stenosis following transcatheter aortic valve replacement. The study found that patients with mixed aortic valve disease demonstrated distinct survival outcomes compared to those with predominant aortic stenosis. This research provides crucial insights into differential survival rates for specific aortic valve pathologies undergoing transcatheter aortic valve replacement (TAVR).
Article 3: Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061875
Summary: This study compared the sequential changes in functional tricuspid regurgitation following transcatheter atrial septal defect closure across different preprocedural cardiac rhythms. The research categorized patients into groups with sinus rhythm, sinus rhythm after catheter ablation for atrial fibrillation, and permanent atrial fibrillation. The data demonstrated differential changes in tricuspid regurgitation based on the patient&#8217;s baseline and post-ablation cardiac rhythm status after atrial septal defect closure.
Article 4: Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41052695
Summary: This study demonstrated persistent racial disparities in chronic limb-threatening ischemia outcomes and healthcare utilization among U.S. Medicare patients. The data showed that Black patients continued to experience higher amputation rates and reduced access to vascular care compared to White bene]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like quantitative flow ratio and sinus rhythm. Key takeaway: Thromboaspiration Not Routine in STEMI.
Article Links:
Article 1: Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice. (The American journal of cardiology)
Article 2: Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease Versus Predominant Aortic Stenosis. (The American journal of cardiology)
Article 3: Comparison of Functional Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure in Adult Patients With Sinus Rhythm, Post-ablation Sinus Rhythm, and Permanent Atrial Fibrillation. (The American journal of cardiology)
Article 4: Persistent Racial Disparities in Chronic Limb-Threatening Ischemia Outcomes and Utilization Among US Medicare Patients. (The American journal of cardiology)
Article 5: Unmasking Myocardial Bridge-Related Ischemia by Quan]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Epicardial Cells Regulate Ventricular Compaction 01/04/26</title>
	<link>https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/</link>
	<pubDate>Sun, 04 Jan 2026 06:09:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like dendritic cells and allograft tolerance. Key takeaway: Epicardial Cells Regulate Ventricular Compaction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40691833">Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival.</a> (Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41477684">Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41161558">Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41138985">Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41138984">Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/">https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691833" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691833</a></p>
<p><strong>Summary:</strong> Researchers found that transmembrane protein 176B, an intracellular cation channel, is associated with allograft tolerance. The study demonstrated that this protein controls the tolerogenic function of dendritic cells and inhibits the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. Activation of transmembrane protein 176B by a nitroalkene derivative of salicylate successfully prolonged graft survival. These findings reveal a mechanism by which transmembrane protein 176B activation contributes to sustained graft survival.</p>
<h4>Article 2: Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41477684" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41477684</a></p>
<p><strong>Summary:</strong> Researchers found that the invasion of epicardial-derived cells into the trabeculae regulates ventricular compaction. This crucial process is mediated by Numb and fibroblast growth factor signaling pathways. These findings establish a fundamental mechanism underlying normal ventricular compaction and provide significant insight into the pathogenesis of left ventricular noncompaction cardiomyopathy. Understanding this pathway offers a clearer picture of this prevalent pediatric cardiomyopathy.</p>
<h4>Article 3: Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41161558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41161558</a></p>
<p><strong>Summary:</strong> This retrospective cohort study conducted a comparative analysis of outcomes for adults experiencing myocardial infarction and cardiogenic shock following coronary artery bypass graft surgery. The study directly compared patients who underwent percutaneous coronary intervention within 24 hours to those who did not. Researchers utilized propensity score matching and Fine-Gray models to derive adjusted and unadjusted hazard ratios and subdistribution hazard ratios for various outcomes. This comprehensive approach established a direct comparison of interventional strategies in this specific, high-risk patient population.</p>
<h4>Article 4: Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138985" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138985</a></p>
<p><strong>Summary:</strong> A multi-cohort study successfully created and propensity score matched various cohorts to investigate the links between mitral annular calcification and heart failure with preserved ejection fraction. Researchers found that hospitalized patients without prior heart failure, when stratified by the presence or absence of mitral annular calcification, allowed for assessment of the risk of developing heart failure. These studies explored established associations and shared risk factors between mitral annular calcification and heart failure with preserved ejection fraction. This comprehensive analysis provides a foundational dataset for understanding their relationship.</p>
<h4>Article 5: Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138984</a></p>
<p><strong>Summary:</strong> An observational, multicenter study compared procedural characteristics of patients undergoing two-stent bifurcation percutaneous coronary intervention using either the mini-crush or double kissing crush techniques. The study found that an international cohort from the PROGRESS-BIFURCATION registry was assembled for this comparative analysis. This investigation directly compared these two distinct approaches to bifurcation stenting. The findings offer practical insights into the application of these interventional techniques for coronary bifurcation lesions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival. Researchers found that transmembrane protein 176B, an intracellular cation channel, is associated with allograft tolerance. The study demonstrated that this protein controls the tolerogenic function of dendritic cells and inhibits the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. Activation of transmembrane protein 176B by a nitroalkene derivative of salicylate successfully prolonged graft survival. These findings reveal a mechanism by which transmembrane protein 176B activation contributes to sustained graft survival.</p>
<p>Article number two. Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction. Researchers found that the invasion of epicardial-derived cells into the trabeculae regulates ventricular compaction. This crucial process is mediated by Numb and fibroblast growth factor signaling pathways. These findings establish a fundamental mechanism underlying normal ventricular compaction and provide significant insight into the pathogenesis of left ventricular noncompaction cardiomyopathy. Understanding this pathway offers a clearer picture of this prevalent pediatric cardiomyopathy.</p>
<p>Article number three. Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft. This retrospective cohort study conducted a comparative analysis of outcomes for adults experiencing myocardial infarction and cardiogenic shock following coronary artery bypass graft surgery. The study directly compared patients who underwent percutaneous coronary intervention within 24 hours to those who did not. Researchers utilized propensity score matching and Fine-Gray models to derive adjusted and unadjusted hazard ratios and subdistribution hazard ratios for various outcomes. This comprehensive approach established a direct comparison of interventional strategies in this specific, high-risk patient population.</p>
<p>Article number four. Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction. A multi-cohort study successfully created and propensity score matched various cohorts to investigate the links between mitral annular calcification and heart failure with preserved ejection fraction. Researchers found that hospitalized patients without prior heart failure, when stratified by the presence or absence of mitral annular calcification, allowed for assessment of the risk of developing heart failure. These studies explored established associations and shared risk factors between mitral annular calcification and heart failure with preserved ejection fraction. This comprehensive analysis provides a foundational dataset for understanding their relationship.</p>
<p>Article number five. Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry. An observational, multicenter study compared procedural characteristics of patients undergoing two-stent bifurcation percutaneous coronary intervention using either the mini-crush or double kissing crush techniques. The study found that an international cohort from the PROGRESS-BIFURCATION registry was assembled for this comparative analysis. This investigation directly compared these two distinct approaches to bifurcation stenting. The findings offer practical insights into the application of these interventional techniques for coronary bifurcation lesions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>dendritic cells, allograft tolerance, TMEM176B, cardiogenic shock, Left ventricular noncompaction cardiomyopathy, hazard ratio, Mini-crush technique, coronary stenting, inflammasome, Fgf signaling, double kissing crush technique, cardiac calcification, epicardial-derived cells, Mitral annular calcification, Numb, bifurcation percutaneous coronary intervention, ventricular compaction, graft survival, Myocardial infarction, risk assessment, percutaneous coronary intervention, heart failure with preserved ejection fraction, coronary artery bypass graft.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/">Epicardial Cells Regulate Ventricular Compaction 01/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like dendritic cells and allograft tolerance. Key takeaway: Epicardial Cells Regulate Ventricular Compaction.
Article Links:
Article 1: Ac]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like dendritic cells and allograft tolerance. Key takeaway: Epicardial Cells Regulate Ventricular Compaction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40691833">Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival.</a> (Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41477684">Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41161558">Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41138985">Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41138984">Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/">https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691833" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691833</a></p>
<p><strong>Summary:</strong> Researchers found that transmembrane protein 176B, an intracellular cation channel, is associated with allograft tolerance. The study demonstrated that this protein controls the tolerogenic function of dendritic cells and inhibits the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. Activation of transmembrane protein 176B by a nitroalkene derivative of salicylate successfully prolonged graft survival. These findings reveal a mechanism by which transmembrane protein 176B activation contributes to sustained graft survival.</p>
<h4>Article 2: Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41477684" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41477684</a></p>
<p><strong>Summary:</strong> Researchers found that the invasion of epicardial-derived cells into the trabeculae regulates ventricular compaction. This crucial process is mediated by Numb and fibroblast growth factor signaling pathways. These findings establish a fundamental mechanism underlying normal ventricular compaction and provide significant insight into the pathogenesis of left ventricular noncompaction cardiomyopathy. Understanding this pathway offers a clearer picture of this prevalent pediatric cardiomyopathy.</p>
<h4>Article 3: Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41161558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41161558</a></p>
<p><strong>Summary:</strong> This retrospective cohort study conducted a comparative analysis of outcomes for adults experiencing myocardial infarction and cardiogenic shock following coronary artery bypass graft surgery. The study directly compared patients who underwent percutaneous coronary intervention within 24 hours to those who did not. Researchers utilized propensity score matching and Fine-Gray models to derive adjusted and unadjusted hazard ratios and subdistribution hazard ratios for various outcomes. This comprehensive approach established a direct comparison of interventional strategies in this specific, high-risk patient population.</p>
<h4>Article 4: Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138985" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138985</a></p>
<p><strong>Summary:</strong> A multi-cohort study successfully created and propensity score matched various cohorts to investigate the links between mitral annular calcification and heart failure with preserved ejection fraction. Researchers found that hospitalized patients without prior heart failure, when stratified by the presence or absence of mitral annular calcification, allowed for assessment of the risk of developing heart failure. These studies explored established associations and shared risk factors between mitral annular calcification and heart failure with preserved ejection fraction. This comprehensive analysis provides a foundational dataset for understanding their relationship.</p>
<h4>Article 5: Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138984</a></p>
<p><strong>Summary:</strong> An observational, multicenter study compared procedural characteristics of patients undergoing two-stent bifurcation percutaneous coronary intervention using either the mini-crush or double kissing crush techniques. The study found that an international cohort from the PROGRESS-BIFURCATION registry was assembled for this comparative analysis. This investigation directly compared these two distinct approaches to bifurcation stenting. The findings offer practical insights into the application of these interventional techniques for coronary bifurcation lesions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is January 04, 2026. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival. Researchers found that transmembrane protein 176B, an intracellular cation channel, is associated with allograft tolerance. The study demonstrated that this protein controls the tolerogenic function of dendritic cells and inhibits the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. Activation of transmembrane protein 176B by a nitroalkene derivative of salicylate successfully prolonged graft survival. These findings reveal a mechanism by which transmembrane protein 176B activation contributes to sustained graft survival.</p>
<p>Article number two. Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction. Researchers found that the invasion of epicardial-derived cells into the trabeculae regulates ventricular compaction. This crucial process is mediated by Numb and fibroblast growth factor signaling pathways. These findings establish a fundamental mechanism underlying normal ventricular compaction and provide significant insight into the pathogenesis of left ventricular noncompaction cardiomyopathy. Understanding this pathway offers a clearer picture of this prevalent pediatric cardiomyopathy.</p>
<p>Article number three. Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft. This retrospective cohort study conducted a comparative analysis of outcomes for adults experiencing myocardial infarction and cardiogenic shock following coronary artery bypass graft surgery. The study directly compared patients who underwent percutaneous coronary intervention within 24 hours to those who did not. Researchers utilized propensity score matching and Fine-Gray models to derive adjusted and unadjusted hazard ratios and subdistribution hazard ratios for various outcomes. This comprehensive approach established a direct comparison of interventional strategies in this specific, high-risk patient population.</p>
<p>Article number four. Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction. A multi-cohort study successfully created and propensity score matched various cohorts to investigate the links between mitral annular calcification and heart failure with preserved ejection fraction. Researchers found that hospitalized patients without prior heart failure, when stratified by the presence or absence of mitral annular calcification, allowed for assessment of the risk of developing heart failure. These studies explored established associations and shared risk factors between mitral annular calcification and heart failure with preserved ejection fraction. This comprehensive analysis provides a foundational dataset for understanding their relationship.</p>
<p>Article number five. Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry. An observational, multicenter study compared procedural characteristics of patients undergoing two-stent bifurcation percutaneous coronary intervention using either the mini-crush or double kissing crush techniques. The study found that an international cohort from the PROGRESS-BIFURCATION registry was assembled for this comparative analysis. This investigation directly compared these two distinct approaches to bifurcation stenting. The findings offer practical insights into the application of these interventional techniques for coronary bifurcation lesions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>dendritic cells, allograft tolerance, TMEM176B, cardiogenic shock, Left ventricular noncompaction cardiomyopathy, hazard ratio, Mini-crush technique, coronary stenting, inflammasome, Fgf signaling, double kissing crush technique, cardiac calcification, epicardial-derived cells, Mitral annular calcification, Numb, bifurcation percutaneous coronary intervention, ventricular compaction, graft survival, Myocardial infarction, risk assessment, percutaneous coronary intervention, heart failure with preserved ejection fraction, coronary artery bypass graft.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/">Epicardial Cells Regulate Ventricular Compaction 01/04/26</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2026/01/cardiology_today_20260104_010833.mp3" length="4235432" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like dendritic cells and allograft tolerance. Key takeaway: Epicardial Cells Regulate Ventricular Compaction.
Article Links:
Article 1: Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival. (Transplantation)
Article 2: Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction. (Circulation. Heart failure)
Article 3: Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft. (The American journal of cardiology)
Article 4: Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction. (The American journal of cardiology)
Article 5: Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/epicardial-cells-regulate-ventricular-compaction-01-04-26/
 Featured Articles
Article 1: Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40691833
Summary: Researchers found that transmembrane protein 176B, an intracellular cation channel, is associated with allograft tolerance. The study demonstrated that this protein controls the tolerogenic function of dendritic cells and inhibits the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. Activation of transmembrane protein 176B by a nitroalkene derivative of salicylate successfully prolonged graft survival. These findings reveal a mechanism by which transmembrane protein 176B activation contributes to sustained graft survival.
Article 2: Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41477684
Summary: Researchers found that the invasion of epicardial-derived cells into the trabeculae regulates ventricular compaction. This crucial process is mediated by Numb and fibroblast growth factor signaling pathways. These findings establish a fundamental mechanism underlying normal ventricular compaction and provide significant insight into the pathogenesis of left ventricular noncompaction cardiomyopathy. Understanding this pathway offers a clearer picture of this prevalent pediatric cardiomyopathy.
Article 3: Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41161558
Summary: This retrospective cohort study conducted a comparative analysis of outcomes for adults experiencing myocardial infarction and cardiogenic shock following coronary artery bypass graft surgery. The study directly compared patients who underwent percutaneous coronary intervention within 24 hours to those who did not. Researchers utilized propensity score matching and Fine-Gray models to derive adjusted and unadjusted hazard ratios and subdistribution hazard ratios for various outcomes. This comprehensive approach established a direct comparison of interventional strategies in this specific, high-risk patient population.
Article 4: Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41138985
Summary: A multi-cohort study successfully created and propensity score matched various cohorts to investigate the links between mitral annular calcification and heart failure with preserved ejection fraction. Researchers found that hospitalized patients without prior heart failure, w]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded January 04, 2026. This episode summarizes 5 key cardiology studies on topics like dendritic cells and allograft tolerance. Key takeaway: Epicardial Cells Regulate Ventricular Compaction.
Article Links:
Article 1: Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival. (Transplantation)
Article 2: Invasion of Epicardial-Derived Cells to the Trabeculae Mediated by NFPs-Fgf Signaling Regulates Ventricular Compaction. (Circulation. Heart failure)
Article 3: Outcomes of Percutaneous Coronary Intervention for Cardiogenic Shock After Coronary Artery Bypass Graft. (The American journal of cardiology)
Article 4: Impacts of Mitral Annular Calcification on Heart Failure With Preserved Ejection Fraction. (The American journal of cardiology)
Article 5: Mini-Crush Versus Double Kissing Crush in Bifurcation Percutaneous Coronary Intervention: Insights From PROGRESS-BIFURCATION Registry. (The ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI ECG Predicts Atrial Fibrillation Risk. 12/07/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/</link>
	<pubDate>Sun, 07 Dec 2025 11:01:20 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 07, 2025. This episode summarizes 5 key cardiology studies on topics like Aficamten and left ventricular dysfunction. Key takeaway: AI ECG Predicts Atrial Fibrillation Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41351608">Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41347307">Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41352445">Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41352444">High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41352443">Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/">https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41351608" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41351608</a></p>
<p><strong>Summary:</strong> Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial investigated whether this known efficacy of finerenone varies according to a patient&#8217;s baseline kidney function.</p>
<h4>Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41347307" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41347307</a></p>
<p><strong>Summary:</strong> Aficamten, a cardiac myosin inhibitor, improved exercise capacity, health status, and symptoms in adults with obstructive hypertrophic cardiomyopathy, as demonstrated in the phase three SEQUOIA-HCM trial. This medication directly targets the underlying hypercontractility responsible for hypertrophic cardiomyopathy. The CEDAR-HCM trial is evaluating the efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy, addressing a critical unmet need given the limited treatment options for pediatric hypertrophic cardiomyopathy.</p>
<h4>Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41352445" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41352445</a></p>
<p><strong>Summary:</strong> This study successfully developed and externally validated an artificial intelligence enabled electrocardiogram model for sex prediction. The model achieved an Area Under the Curve of 0.91 on the C. O. D. E. minus 15 percent dataset and 0.90 on the M. I. M. I. C. minus I. V. dataset. This tool generates a sex discordance score, which provides a quantifiable measure related to incident atrial fibrillation risk beyond binary sex classification.</p>
<h4>Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41352444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41352444</a></p>
<p><strong>Summary:</strong> Environmental noise acts as a contributing factor to cardiovascular disease and arrhythmias, a process linked to autonomic nervous system dysregulation. The mechanisms driving noise-induced arrhythmogenesis remain unclear. Understanding subcutaneous nerve activity and heart rate variability is crucial for elucidating the role of autonomic nervous system modulation in these ventricular arrhythmias.</p>
<h4>Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41352443" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41352443</a></p>
<p><strong>Summary:</strong> Right ventricular pacing induces electrical and mechanical dyssynchrony, which can influence left ventricular dysfunction and contribute to heart failure. The long-term impact of temporal increases in the right ventricular pacing ratio on left ventricular remodeling and arrhythmia occurrence has been unclear. This retrospective longitudinal cohort study investigates these associations to provide crucial insights into patient management following right ventricular pacing implantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial investigated whether this known efficacy of finerenone varies according to a patient&#8217;s baseline kidney function.</p>
<p>Article number two. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Aficamten, a cardiac myosin inhibitor, improved exercise capacity, health status, and symptoms in adults with obstructive hypertrophic cardiomyopathy, as demonstrated in the phase three SEQUOIA-HCM trial. This medication directly targets the underlying hypercontractility responsible for hypertrophic cardiomyopathy. The CEDAR-HCM trial is evaluating the efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy, addressing a critical unmet need given the limited treatment options for pediatric hypertrophic cardiomyopathy.</p>
<p>Article number three. Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study. This study successfully developed and externally validated an artificial intelligence enabled electrocardiogram model for sex prediction. The model achieved an Area Under the Curve of 0.91 on the C. O. D. E. minus 15 percent dataset and 0.90 on the M. I. M. I. C. minus I. V. dataset. This tool generates a sex discordance score, which provides a quantifiable measure related to incident atrial fibrillation risk beyond binary sex classification.</p>
<p>Article number four. High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias. Environmental noise acts as a contributing factor to cardiovascular disease and arrhythmias, a process linked to autonomic nervous system dysregulation. The mechanisms driving noise-induced arrhythmogenesis remain unclear. Understanding subcutaneous nerve activity and heart rate variability is crucial for elucidating the role of autonomic nervous system modulation in these ventricular arrhythmias.</p>
<p>Article number five. Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis. Right ventricular pacing induces electrical and mechanical dyssynchrony, which can influence left ventricular dysfunction and contribute to heart failure. The long-term impact of temporal increases in the right ventricular pacing ratio on left ventricular remodeling and arrhythmia occurrence has been unclear. This retrospective longitudinal cohort study investigates these associations to provide crucial insights into patient management following right ventricular pacing implantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Aficamten, left ventricular dysfunction, machine learning, kidney function, atrial fibrillation risk, Finerenone, arrhythmia, subcutaneous nerve activity, Artificial intelligence electrocardiogram, Environmental noise, autonomic nervous system, cardiac myosin inhibitor, Right ventricular pacing, cardiovascular outcomes, sex discordance, heart failure with preserved ejection fraction, heart failure, pediatric cardiology, hypertrophic cardiomyopathy, ventricular arrhythmias.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/">AI ECG Predicts Atrial Fibrillation Risk. 12/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 07, 2025. This episode summarizes 5 key cardiology studies on topics like Aficamten and left ventricular dysfunction. Key takeaway: AI ECG Predicts Atrial Fibrillation Risk..
Article Links:
Article 1: Finer]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 07, 2025. This episode summarizes 5 key cardiology studies on topics like Aficamten and left ventricular dysfunction. Key takeaway: AI ECG Predicts Atrial Fibrillation Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41351608">Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41347307">Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41352445">Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41352444">High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41352443">Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/">https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41351608" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41351608</a></p>
<p><strong>Summary:</strong> Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial investigated whether this known efficacy of finerenone varies according to a patient&#8217;s baseline kidney function.</p>
<h4>Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41347307" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41347307</a></p>
<p><strong>Summary:</strong> Aficamten, a cardiac myosin inhibitor, improved exercise capacity, health status, and symptoms in adults with obstructive hypertrophic cardiomyopathy, as demonstrated in the phase three SEQUOIA-HCM trial. This medication directly targets the underlying hypercontractility responsible for hypertrophic cardiomyopathy. The CEDAR-HCM trial is evaluating the efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy, addressing a critical unmet need given the limited treatment options for pediatric hypertrophic cardiomyopathy.</p>
<h4>Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41352445" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41352445</a></p>
<p><strong>Summary:</strong> This study successfully developed and externally validated an artificial intelligence enabled electrocardiogram model for sex prediction. The model achieved an Area Under the Curve of 0.91 on the C. O. D. E. minus 15 percent dataset and 0.90 on the M. I. M. I. C. minus I. V. dataset. This tool generates a sex discordance score, which provides a quantifiable measure related to incident atrial fibrillation risk beyond binary sex classification.</p>
<h4>Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41352444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41352444</a></p>
<p><strong>Summary:</strong> Environmental noise acts as a contributing factor to cardiovascular disease and arrhythmias, a process linked to autonomic nervous system dysregulation. The mechanisms driving noise-induced arrhythmogenesis remain unclear. Understanding subcutaneous nerve activity and heart rate variability is crucial for elucidating the role of autonomic nervous system modulation in these ventricular arrhythmias.</p>
<h4>Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41352443" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41352443</a></p>
<p><strong>Summary:</strong> Right ventricular pacing induces electrical and mechanical dyssynchrony, which can influence left ventricular dysfunction and contribute to heart failure. The long-term impact of temporal increases in the right ventricular pacing ratio on left ventricular remodeling and arrhythmia occurrence has been unclear. This retrospective longitudinal cohort study investigates these associations to provide crucial insights into patient management following right ventricular pacing implantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial investigated whether this known efficacy of finerenone varies according to a patient&#8217;s baseline kidney function.</p>
<p>Article number two. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Aficamten, a cardiac myosin inhibitor, improved exercise capacity, health status, and symptoms in adults with obstructive hypertrophic cardiomyopathy, as demonstrated in the phase three SEQUOIA-HCM trial. This medication directly targets the underlying hypercontractility responsible for hypertrophic cardiomyopathy. The CEDAR-HCM trial is evaluating the efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy, addressing a critical unmet need given the limited treatment options for pediatric hypertrophic cardiomyopathy.</p>
<p>Article number three. Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study. This study successfully developed and externally validated an artificial intelligence enabled electrocardiogram model for sex prediction. The model achieved an Area Under the Curve of 0.91 on the C. O. D. E. minus 15 percent dataset and 0.90 on the M. I. M. I. C. minus I. V. dataset. This tool generates a sex discordance score, which provides a quantifiable measure related to incident atrial fibrillation risk beyond binary sex classification.</p>
<p>Article number four. High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias. Environmental noise acts as a contributing factor to cardiovascular disease and arrhythmias, a process linked to autonomic nervous system dysregulation. The mechanisms driving noise-induced arrhythmogenesis remain unclear. Understanding subcutaneous nerve activity and heart rate variability is crucial for elucidating the role of autonomic nervous system modulation in these ventricular arrhythmias.</p>
<p>Article number five. Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis. Right ventricular pacing induces electrical and mechanical dyssynchrony, which can influence left ventricular dysfunction and contribute to heart failure. The long-term impact of temporal increases in the right ventricular pacing ratio on left ventricular remodeling and arrhythmia occurrence has been unclear. This retrospective longitudinal cohort study investigates these associations to provide crucial insights into patient management following right ventricular pacing implantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Aficamten, left ventricular dysfunction, machine learning, kidney function, atrial fibrillation risk, Finerenone, arrhythmia, subcutaneous nerve activity, Artificial intelligence electrocardiogram, Environmental noise, autonomic nervous system, cardiac myosin inhibitor, Right ventricular pacing, cardiovascular outcomes, sex discordance, heart failure with preserved ejection fraction, heart failure, pediatric cardiology, hypertrophic cardiomyopathy, ventricular arrhythmias.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/">AI ECG Predicts Atrial Fibrillation Risk. 12/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251207_060027.mp3" length="3566279" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 07, 2025. This episode summarizes 5 key cardiology studies on topics like Aficamten and left ventricular dysfunction. Key takeaway: AI ECG Predicts Atrial Fibrillation Risk..
Article Links:
Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. (JACC. Heart failure)
Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. (Circulation. Heart failure)
Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study. (Heart rhythm)
Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias. (Heart rhythm)
Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model Analysis. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/ai-ecg-predicts-atrial-fibrillation-risk-12-07-25/
 Featured Articles
Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41351608
Summary: Finerenone is established to reduce the risk of worsening heart failure events and cardiovascular death. This benefit applies to patients with heart failure with mildly reduced or preserved ejection fraction. The FINEARTS-HF trial investigated whether this known efficacy of finerenone varies according to a patient&#8217;s baseline kidney function.
Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41347307
Summary: Aficamten, a cardiac myosin inhibitor, improved exercise capacity, health status, and symptoms in adults with obstructive hypertrophic cardiomyopathy, as demonstrated in the phase three SEQUOIA-HCM trial. This medication directly targets the underlying hypercontractility responsible for hypertrophic cardiomyopathy. The CEDAR-HCM trial is evaluating the efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy, addressing a critical unmet need given the limited treatment options for pediatric hypertrophic cardiomyopathy.
Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41352445
Summary: This study successfully developed and externally validated an artificial intelligence enabled electrocardiogram model for sex prediction. The model achieved an Area Under the Curve of 0.91 on the C. O. D. E. minus 15 percent dataset and 0.90 on the M. I. M. I. C. minus I. V. dataset. This tool generates a sex discordance score, which provides a quantifiable measure related to incident atrial fibrillation risk beyond binary sex classification.
Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41352444
Summary: Environmental noise acts as a contributing factor to cardiovascular disease and arrhythmias, a process linked to autonomic nervous system dysregulation. The mechanisms driving noise-induced arrhythmogenesis remain unclear. Understanding subcutaneous nerve activity and heart rate variability is crucial for elucidating the role of autonomic nervous system modulation in these ventricular arrhythmias.
Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixed-Effects Model ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 07, 2025. This episode summarizes 5 key cardiology studies on topics like Aficamten and left ventricular dysfunction. Key takeaway: AI ECG Predicts Atrial Fibrillation Risk..
Article Links:
Article 1: Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. (JACC. Heart failure)
Article 2: Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. (Circulation. Heart failure)
Article 3: Artificial intelligence-enabled electrocardiographic sex discordance and the risk of incident atrial fibrillation: a multi-national cohort study. (Heart rhythm)
Article 4: High Subcutaneous Nerve Activity in Noise-Associated Ventricular Arrhythmias. (Heart rhythm)
Article 5: Temporal Change in Right Ventricular Pacing Ratio and Its Association with Cardiac Function and Arrhythmia: A Linear Mixe]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Enables Early Pediatric Heart Dysfunction Detection. 12/06/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/</link>
	<pubDate>Sat, 06 Dec 2025 11:01:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 06, 2025. This episode summarizes 5 key cardiology studies on topics like Canada and computed tomography angiography. Key takeaway: AI Enables Early Pediatric Heart Dysfunction Detection..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41347951">Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41349596">The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41335456">Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41339021">Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41347311">Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/">https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41347951" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41347951</a></p>
<p><strong>Summary:</strong> A new semi-supervised deep learning framework, the Motion-Echo system, was developed using 11096 paediatric and 11297 adult echocardiograms. This system provides a standardized and vendor-agnostic approach for paediatric myocardial strain analysis. It enhances cardiac function evaluation and enables earlier detection of cardiac impairment, addressing high variance and limited precision in current methods.</p>
<h4>Article 2: The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41349596" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41349596</a></p>
<p><strong>Summary:</strong> H. F. S.) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report identified a critical gap where the heart failure physician workforce in Canada has not grown to meet the rising demand. The committee, comprising 16 Canadian physicians, determined key drivers of this workforce crisis. The report provides actionable solutions to address this growing burden on healthcare resources and patient care. These findings highlight the urgent need for strategic planning to ensure adequate heart failure physician staffing across the country.</p>
<h4>Article 3: Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41335456" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41335456</a></p>
<p><strong>Summary:</strong> The TENET Randomized Clinical Trial compared the safety and efficacy of tenecteplase versus standard infusions of alteplase for patients with symptomatic prosthetic valve thrombosis after mechanical heart valve replacement. This study directly assessed the utility of tenecteplase in this patient population, where alteplase is an accepted first-line thrombolytic therapy. The trial provided data on the comparative performance of these two agents in addressing prosthetic valve thrombosis.</p>
<h4>Article 4: Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41339021" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41339021</a></p>
<p><strong>Summary:</strong> T.-derived fractional flow reserve. This prospective multicenter study in 900 patients with new-onset stable angina investigated the long-term prognostic impact of complete versus incomplete revascularization. Revascularization status was determined non-invasively using coronary computed tomography angiography-derived fractional flow reserve. The study provided data on whether the short-term benefits of complete revascularization persist long-term when defined by this imaging modality.</p>
<h4>Article 5: Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41347311" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41347311</a></p>
<p><strong>Summary:</strong> This study from the Pediatric Cardiomyopathy Registry compared the prevalence of rare predicted-damaging variants and clinically pathogenic variants in children. It specifically examined children with dilated cardiomyopathy secondary to myocarditis, children with dilated cardiomyopathy alone, and heart-healthy controls. The research provided data on the burden of cardiomyopathy-associated genetic variants in pediatric myocarditis, addressing previous limitations in data for children.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction. A new semi-supervised deep learning framework, the Motion-Echo system, was developed using 11096 paediatric and 11297 adult echocardiograms. This system provides a standardized and vendor-agnostic approach for paediatric myocardial strain analysis. It enhances cardiac function evaluation and enables earlier detection of cardiac impairment, addressing high variance and limited precision in current methods.</p>
<p>Article number two. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report identified a critical gap where the heart failure physician workforce in Canada has not grown to meet the rising demand. The committee, comprising 16 Canadian physicians, determined key drivers of this workforce crisis. The report provides actionable solutions to address this growing burden on healthcare resources and patient care. These findings highlight the urgent need for strategic planning to ensure adequate heart failure physician staffing across the country.</p>
<p>Article number three. Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial. The TENET Randomized Clinical Trial compared the safety and efficacy of tenecteplase versus standard infusions of alteplase for patients with symptomatic prosthetic valve thrombosis after mechanical heart valve replacement. This study directly assessed the utility of tenecteplase in this patient population, where alteplase is an accepted first-line thrombolytic therapy. The trial provided data on the comparative performance of these two agents in addressing prosthetic valve thrombosis.</p>
<p>Article number four. Long-term prognostic impact of complete revascularisation defined by C. T.-derived fractional flow reserve. This prospective multicenter study in 900 patients with new-onset stable angina investigated the long-term prognostic impact of complete versus incomplete revascularization. Revascularization status was determined non-invasively using coronary computed tomography angiography-derived fractional flow reserve. The study provided data on whether the short-term benefits of complete revascularization persist long-term when defined by this imaging modality.</p>
<p>Article number five. Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry. This study from the Pediatric Cardiomyopathy Registry compared the prevalence of rare predicted-damaging variants and clinically pathogenic variants in children. It specifically examined children with dilated cardiomyopathy secondary to myocarditis, children with dilated cardiomyopathy alone, and heart-healthy controls. The research provided data on the burden of cardiomyopathy-associated genetic variants in pediatric myocarditis, addressing previous limitations in data for children. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Canada, computed tomography angiography, mechanical heart valve, genetic testing, coronary artery disease, myocardial strain, paediatric echocardiography, fractional flow reserve, alteplase, healthcare policy, deep learning, tenecteplase, pediatric myocarditis, complete revascularization, thrombolytic therapy, dilated cardiomyopathy, cardiac dysfunction, workforce shortage, heart failure, cardiomyopathy, genetic variants, physician workforce, prosthetic valve thrombosis, prognosis, early detection.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/">AI Enables Early Pediatric Heart Dysfunction Detection. 12/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 06, 2025. This episode summarizes 5 key cardiology studies on topics like Canada and computed tomography angiography. Key takeaway: AI Enables Early Pediatric Heart Dysfunction Detection..
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 06, 2025. This episode summarizes 5 key cardiology studies on topics like Canada and computed tomography angiography. Key takeaway: AI Enables Early Pediatric Heart Dysfunction Detection..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41347951">Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41349596">The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41335456">Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41339021">Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41347311">Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/">https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41347951" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41347951</a></p>
<p><strong>Summary:</strong> A new semi-supervised deep learning framework, the Motion-Echo system, was developed using 11096 paediatric and 11297 adult echocardiograms. This system provides a standardized and vendor-agnostic approach for paediatric myocardial strain analysis. It enhances cardiac function evaluation and enables earlier detection of cardiac impairment, addressing high variance and limited precision in current methods.</p>
<h4>Article 2: The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41349596" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41349596</a></p>
<p><strong>Summary:</strong> H. F. S.) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report identified a critical gap where the heart failure physician workforce in Canada has not grown to meet the rising demand. The committee, comprising 16 Canadian physicians, determined key drivers of this workforce crisis. The report provides actionable solutions to address this growing burden on healthcare resources and patient care. These findings highlight the urgent need for strategic planning to ensure adequate heart failure physician staffing across the country.</p>
<h4>Article 3: Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41335456" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41335456</a></p>
<p><strong>Summary:</strong> The TENET Randomized Clinical Trial compared the safety and efficacy of tenecteplase versus standard infusions of alteplase for patients with symptomatic prosthetic valve thrombosis after mechanical heart valve replacement. This study directly assessed the utility of tenecteplase in this patient population, where alteplase is an accepted first-line thrombolytic therapy. The trial provided data on the comparative performance of these two agents in addressing prosthetic valve thrombosis.</p>
<h4>Article 4: Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41339021" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41339021</a></p>
<p><strong>Summary:</strong> T.-derived fractional flow reserve. This prospective multicenter study in 900 patients with new-onset stable angina investigated the long-term prognostic impact of complete versus incomplete revascularization. Revascularization status was determined non-invasively using coronary computed tomography angiography-derived fractional flow reserve. The study provided data on whether the short-term benefits of complete revascularization persist long-term when defined by this imaging modality.</p>
<h4>Article 5: Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41347311" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41347311</a></p>
<p><strong>Summary:</strong> This study from the Pediatric Cardiomyopathy Registry compared the prevalence of rare predicted-damaging variants and clinically pathogenic variants in children. It specifically examined children with dilated cardiomyopathy secondary to myocarditis, children with dilated cardiomyopathy alone, and heart-healthy controls. The research provided data on the burden of cardiomyopathy-associated genetic variants in pediatric myocarditis, addressing previous limitations in data for children.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction. A new semi-supervised deep learning framework, the Motion-Echo system, was developed using 11096 paediatric and 11297 adult echocardiograms. This system provides a standardized and vendor-agnostic approach for paediatric myocardial strain analysis. It enhances cardiac function evaluation and enables earlier detection of cardiac impairment, addressing high variance and limited precision in current methods.</p>
<p>Article number two. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report identified a critical gap where the heart failure physician workforce in Canada has not grown to meet the rising demand. The committee, comprising 16 Canadian physicians, determined key drivers of this workforce crisis. The report provides actionable solutions to address this growing burden on healthcare resources and patient care. These findings highlight the urgent need for strategic planning to ensure adequate heart failure physician staffing across the country.</p>
<p>Article number three. Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial. The TENET Randomized Clinical Trial compared the safety and efficacy of tenecteplase versus standard infusions of alteplase for patients with symptomatic prosthetic valve thrombosis after mechanical heart valve replacement. This study directly assessed the utility of tenecteplase in this patient population, where alteplase is an accepted first-line thrombolytic therapy. The trial provided data on the comparative performance of these two agents in addressing prosthetic valve thrombosis.</p>
<p>Article number four. Long-term prognostic impact of complete revascularisation defined by C. T.-derived fractional flow reserve. This prospective multicenter study in 900 patients with new-onset stable angina investigated the long-term prognostic impact of complete versus incomplete revascularization. Revascularization status was determined non-invasively using coronary computed tomography angiography-derived fractional flow reserve. The study provided data on whether the short-term benefits of complete revascularization persist long-term when defined by this imaging modality.</p>
<p>Article number five. Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry. This study from the Pediatric Cardiomyopathy Registry compared the prevalence of rare predicted-damaging variants and clinically pathogenic variants in children. It specifically examined children with dilated cardiomyopathy secondary to myocarditis, children with dilated cardiomyopathy alone, and heart-healthy controls. The research provided data on the burden of cardiomyopathy-associated genetic variants in pediatric myocarditis, addressing previous limitations in data for children. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Canada, computed tomography angiography, mechanical heart valve, genetic testing, coronary artery disease, myocardial strain, paediatric echocardiography, fractional flow reserve, alteplase, healthcare policy, deep learning, tenecteplase, pediatric myocarditis, complete revascularization, thrombolytic therapy, dilated cardiomyopathy, cardiac dysfunction, workforce shortage, heart failure, cardiomyopathy, genetic variants, physician workforce, prosthetic valve thrombosis, prognosis, early detection.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/">AI Enables Early Pediatric Heart Dysfunction Detection. 12/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251206_060024.mp3" length="3771497" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 06, 2025. This episode summarizes 5 key cardiology studies on topics like Canada and computed tomography angiography. Key takeaway: AI Enables Early Pediatric Heart Dysfunction Detection..
Article Links:
Article 1: Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction. (European heart journal)
Article 2: The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. (Journal of cardiac failure)
Article 3: Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial. (JAMA cardiology)
Article 4: Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve. (Heart (British Cardiac Society))
Article 5: Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/ai-enables-early-pediatric-heart-dysfunction-detection-12-06-25/
 Featured Articles
Article 1: Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41347951
Summary: A new semi-supervised deep learning framework, the Motion-Echo system, was developed using 11096 paediatric and 11297 adult echocardiograms. This system provides a standardized and vendor-agnostic approach for paediatric myocardial strain analysis. It enhances cardiac function evaluation and enables earlier detection of cardiac impairment, addressing high variance and limited precision in current methods.
Article 2: The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41349596
Summary: H. F. S.) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. The Canadian Heart Failure Society (C. H. F. S.) Workforce Committee Report identified a critical gap where the heart failure physician workforce in Canada has not grown to meet the rising demand. The committee, comprising 16 Canadian physicians, determined key drivers of this workforce crisis. The report provides actionable solutions to address this growing burden on healthcare resources and patient care. These findings highlight the urgent need for strategic planning to ensure adequate heart failure physician staffing across the country.
Article 3: Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41335456
Summary: The TENET Randomized Clinical Trial compared the safety and efficacy of tenecteplase versus standard infusions of alteplase for patients with symptomatic prosthetic valve thrombosis after mechanical heart valve replacement. This study directly assessed the utility of tenecteplase in this patient population, where alteplase is an accepted first-line thrombolytic therapy. The trial provided data on the comparative performance of these two agents in addressing prosthetic valve thrombosis.
Article 4: Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41339021
Summary: T.-derived fractional flow reserve. This prospective multicenter study in 900 patients with new-onset stable angina investigated the lon]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 06, 2025. This episode summarizes 5 key cardiology studies on topics like Canada and computed tomography angiography. Key takeaway: AI Enables Early Pediatric Heart Dysfunction Detection..
Article Links:
Article 1: Digital profile of children&#8217;s hearts: automated echocardiogram strain analysis facilitates earlier detection of cardiac dysfunction. (European heart journal)
Article 2: The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report. (Journal of cardiac failure)
Article 3: Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial. (JAMA cardiology)
Article 4: Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserve. (Heart (British Cardiac Society))
Article 5: Cardiomyopathy-Associated Patho]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>First FFPE Heart Rejection Molecular Test Validated 12/05/25</title>
	<link>https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/</link>
	<pubDate>Fri, 05 Dec 2025 11:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 05, 2025. This episode summarizes 5 key cardiology studies on topics like diagnosis and formalin-fixed paraffin-embedded. Key takeaway: First FFPE Heart Rejection Molecular Test Validated.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41342099">Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41342627">Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41342227">Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41342194">Cardiovascular disease in women: traditional and sex-specific risk factors.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41344641">Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/">https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342099" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342099</a></p>
<p><strong>Summary:</strong> This study characterized the safety and diagnostic yield of procainamide infusion for inducing a type one Brugada pattern for Brugada syndrome diagnosis. It established the prognosis associated with a procainamide-induced Brugada pattern, demonstrating differences from other sodium channel blockers. The investigation defined the specific indications for procainamide challenge using data from the Canadian Hearts in Rhythm Organization registry. This established a clearer clinical utility for identifying this particular electrocardiogram pattern.</p>
<h4>Article 2: Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342627" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342627</a></p>
<p><strong>Summary:</strong> This study developed and validated the first formalin-fixed, paraffin-embedded tissue-based molecular diagnostic system for heart transplant rejection. The system utilizes intra-graft targeted gene expression profiling to refine diagnostic accuracy. This method is applicable to endomyocardial biopsies and is designed for easy implementation in clinical practice. The international study established a deeply phenotyped cohort of heart transplant recipients to support this validation.</p>
<h4>Article 3: Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342227" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342227</a></p>
<p><strong>Summary:</strong> This study identified oestrogen-related receptor gamma as a key regulator in sepsis-induced cardiomyopathy. Researchers found that cardiomyocyte subtype conversion plays a crucial role in the pathophysiology of sepsis-induced cardiomyopathy. This mechanistic insight offers a novel understanding of how sepsis increases overall mortality through cardiac dysfunction. The findings lay a foundation for developing targeted therapies for sepsis-induced cardiomyopathy, addressing a current lack of specific treatments.</p>
<h4>Article 4: Cardiovascular disease in women: traditional and sex-specific risk factors.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342194</a></p>
<p><strong>Summary:</strong> This review highlighted that cardiovascular disease accounts for more deaths in women than breast cancer, lung cancer, and chronic lung disease combined, showing comparable mortality to men. It identified a critical lack of awareness among both women and physicians regarding cardiovascular disease as a major cause of morbidity and mortality in women. This contributes to significant delays in diagnosis and treatment. The analysis confirmed insufficient evidence often impedes effective, life-saving care for women with cardiovascular disease, despite advances in diagnosis and treatment.</p>
<h4>Article 5: Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41344641" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41344641</a></p>
<p><strong>Summary:</strong> This study characterized intraoperative right ventricular adaptations following left ventricular assist device implantation. The research demonstrated how right ventricular-pulmonary artery coupling, defined as the ratio of end-systolic to arterial elastance, reflects right ventricular performance under altered loading conditions. The investigation, which used high-fidelity hemodynamics with right ventricular conductance catheters and three-dimensional echocardiography, provided specific measurements of these adaptations. This prospective observational study established a framework for understanding right ventricular response to left ventricular assist device support.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome. This study characterized the safety and diagnostic yield of procainamide infusion for inducing a type one Brugada pattern for Brugada syndrome diagnosis. It established the prognosis associated with a procainamide-induced Brugada pattern, demonstrating differences from other sodium channel blockers. The investigation defined the specific indications for procainamide challenge using data from the Canadian Hearts in Rhythm Organization registry. This established a clearer clinical utility for identifying this particular electrocardiogram pattern.</p>
<p>Article number two. Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling. This study developed and validated the first formalin-fixed, paraffin-embedded tissue-based molecular diagnostic system for heart transplant rejection. The system utilizes intra-graft targeted gene expression profiling to refine diagnostic accuracy. This method is applicable to endomyocardial biopsies and is designed for easy implementation in clinical practice. The international study established a deeply phenotyped cohort of heart transplant recipients to support this validation.</p>
<p>Article number three. Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion. This study identified oestrogen-related receptor gamma as a key regulator in sepsis-induced cardiomyopathy. Researchers found that cardiomyocyte subtype conversion plays a crucial role in the pathophysiology of sepsis-induced cardiomyopathy. This mechanistic insight offers a novel understanding of how sepsis increases overall mortality through cardiac dysfunction. The findings lay a foundation for developing targeted therapies for sepsis-induced cardiomyopathy, addressing a current lack of specific treatments.</p>
<p>Article number four. Cardiovascular disease in women: traditional and sex-specific risk factors. This review highlighted that cardiovascular disease accounts for more deaths in women than breast cancer, lung cancer, and chronic lung disease combined, showing comparable mortality to men. It identified a critical lack of awareness among both women and physicians regarding cardiovascular disease as a major cause of morbidity and mortality in women. This contributes to significant delays in diagnosis and treatment. The analysis confirmed insufficient evidence often impedes effective, life-saving care for women with cardiovascular disease, despite advances in diagnosis and treatment.</p>
<p>Article number five. Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics. This study characterized intraoperative right ventricular adaptations following left ventricular assist device implantation. The research demonstrated how right ventricular-pulmonary artery coupling, defined as the ratio of end-systolic to arterial elastance, reflects right ventricular performance under altered loading conditions. The investigation, which used high-fidelity hemodynamics with right ventricular conductance catheters and three-dimensional echocardiography, provided specific measurements of these adaptations. This prospective observational study established a framework for understanding right ventricular response to left ventricular assist device support. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>diagnosis, formalin-fixed paraffin-embedded, oestrogen-related receptor gamma, molecular diagnosis, diagnosis delays, treatment gaps, sodium channel blocker, hemodynamics, endomyocardial biopsy, Heart transplant rejection, pulmonary arterial coupling, Brugada syndrome, gene expression profiling, right ventricular adaptation, pathophysiology, cardiomyocyte subtype conversion, electrocardiogram pattern, end-systolic to arterial elastance, sepsis, Left ventricular assist device, Procainamide, Cardiovascular disease in women, Sepsis-induced cardiomyopathy, sex-specific risk factors, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/">First FFPE Heart Rejection Molecular Test Validated 12/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 05, 2025. This episode summarizes 5 key cardiology studies on topics like diagnosis and formalin-fixed paraffin-embedded. Key takeaway: First FFPE Heart Rejection Molecular Test Validated.
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 05, 2025. This episode summarizes 5 key cardiology studies on topics like diagnosis and formalin-fixed paraffin-embedded. Key takeaway: First FFPE Heart Rejection Molecular Test Validated.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41342099">Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41342627">Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41342227">Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41342194">Cardiovascular disease in women: traditional and sex-specific risk factors.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41344641">Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/">https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342099" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342099</a></p>
<p><strong>Summary:</strong> This study characterized the safety and diagnostic yield of procainamide infusion for inducing a type one Brugada pattern for Brugada syndrome diagnosis. It established the prognosis associated with a procainamide-induced Brugada pattern, demonstrating differences from other sodium channel blockers. The investigation defined the specific indications for procainamide challenge using data from the Canadian Hearts in Rhythm Organization registry. This established a clearer clinical utility for identifying this particular electrocardiogram pattern.</p>
<h4>Article 2: Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342627" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342627</a></p>
<p><strong>Summary:</strong> This study developed and validated the first formalin-fixed, paraffin-embedded tissue-based molecular diagnostic system for heart transplant rejection. The system utilizes intra-graft targeted gene expression profiling to refine diagnostic accuracy. This method is applicable to endomyocardial biopsies and is designed for easy implementation in clinical practice. The international study established a deeply phenotyped cohort of heart transplant recipients to support this validation.</p>
<h4>Article 3: Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342227" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342227</a></p>
<p><strong>Summary:</strong> This study identified oestrogen-related receptor gamma as a key regulator in sepsis-induced cardiomyopathy. Researchers found that cardiomyocyte subtype conversion plays a crucial role in the pathophysiology of sepsis-induced cardiomyopathy. This mechanistic insight offers a novel understanding of how sepsis increases overall mortality through cardiac dysfunction. The findings lay a foundation for developing targeted therapies for sepsis-induced cardiomyopathy, addressing a current lack of specific treatments.</p>
<h4>Article 4: Cardiovascular disease in women: traditional and sex-specific risk factors.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41342194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41342194</a></p>
<p><strong>Summary:</strong> This review highlighted that cardiovascular disease accounts for more deaths in women than breast cancer, lung cancer, and chronic lung disease combined, showing comparable mortality to men. It identified a critical lack of awareness among both women and physicians regarding cardiovascular disease as a major cause of morbidity and mortality in women. This contributes to significant delays in diagnosis and treatment. The analysis confirmed insufficient evidence often impedes effective, life-saving care for women with cardiovascular disease, despite advances in diagnosis and treatment.</p>
<h4>Article 5: Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41344641" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41344641</a></p>
<p><strong>Summary:</strong> This study characterized intraoperative right ventricular adaptations following left ventricular assist device implantation. The research demonstrated how right ventricular-pulmonary artery coupling, defined as the ratio of end-systolic to arterial elastance, reflects right ventricular performance under altered loading conditions. The investigation, which used high-fidelity hemodynamics with right ventricular conductance catheters and three-dimensional echocardiography, provided specific measurements of these adaptations. This prospective observational study established a framework for understanding right ventricular response to left ventricular assist device support.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome. This study characterized the safety and diagnostic yield of procainamide infusion for inducing a type one Brugada pattern for Brugada syndrome diagnosis. It established the prognosis associated with a procainamide-induced Brugada pattern, demonstrating differences from other sodium channel blockers. The investigation defined the specific indications for procainamide challenge using data from the Canadian Hearts in Rhythm Organization registry. This established a clearer clinical utility for identifying this particular electrocardiogram pattern.</p>
<p>Article number two. Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling. This study developed and validated the first formalin-fixed, paraffin-embedded tissue-based molecular diagnostic system for heart transplant rejection. The system utilizes intra-graft targeted gene expression profiling to refine diagnostic accuracy. This method is applicable to endomyocardial biopsies and is designed for easy implementation in clinical practice. The international study established a deeply phenotyped cohort of heart transplant recipients to support this validation.</p>
<p>Article number three. Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion. This study identified oestrogen-related receptor gamma as a key regulator in sepsis-induced cardiomyopathy. Researchers found that cardiomyocyte subtype conversion plays a crucial role in the pathophysiology of sepsis-induced cardiomyopathy. This mechanistic insight offers a novel understanding of how sepsis increases overall mortality through cardiac dysfunction. The findings lay a foundation for developing targeted therapies for sepsis-induced cardiomyopathy, addressing a current lack of specific treatments.</p>
<p>Article number four. Cardiovascular disease in women: traditional and sex-specific risk factors. This review highlighted that cardiovascular disease accounts for more deaths in women than breast cancer, lung cancer, and chronic lung disease combined, showing comparable mortality to men. It identified a critical lack of awareness among both women and physicians regarding cardiovascular disease as a major cause of morbidity and mortality in women. This contributes to significant delays in diagnosis and treatment. The analysis confirmed insufficient evidence often impedes effective, life-saving care for women with cardiovascular disease, despite advances in diagnosis and treatment.</p>
<p>Article number five. Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics. This study characterized intraoperative right ventricular adaptations following left ventricular assist device implantation. The research demonstrated how right ventricular-pulmonary artery coupling, defined as the ratio of end-systolic to arterial elastance, reflects right ventricular performance under altered loading conditions. The investigation, which used high-fidelity hemodynamics with right ventricular conductance catheters and three-dimensional echocardiography, provided specific measurements of these adaptations. This prospective observational study established a framework for understanding right ventricular response to left ventricular assist device support. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>diagnosis, formalin-fixed paraffin-embedded, oestrogen-related receptor gamma, molecular diagnosis, diagnosis delays, treatment gaps, sodium channel blocker, hemodynamics, endomyocardial biopsy, Heart transplant rejection, pulmonary arterial coupling, Brugada syndrome, gene expression profiling, right ventricular adaptation, pathophysiology, cardiomyocyte subtype conversion, electrocardiogram pattern, end-systolic to arterial elastance, sepsis, Left ventricular assist device, Procainamide, Cardiovascular disease in women, Sepsis-induced cardiomyopathy, sex-specific risk factors, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/">First FFPE Heart Rejection Molecular Test Validated 12/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251205_060031.mp3" length="3858851" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 05, 2025. This episode summarizes 5 key cardiology studies on topics like diagnosis and formalin-fixed paraffin-embedded. Key takeaway: First FFPE Heart Rejection Molecular Test Validated.
Article Links:
Article 1: Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome. (Circulation)
Article 2: Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling. (European heart journal)
Article 3: Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion. (European heart journal)
Article 4: Cardiovascular disease in women: traditional and sex-specific risk factors. (European heart journal)
Article 5: Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/first-ffpe-heart-rejection-molecular-test-validated-12-05-25/
 Featured Articles
Article 1: Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41342099
Summary: This study characterized the safety and diagnostic yield of procainamide infusion for inducing a type one Brugada pattern for Brugada syndrome diagnosis. It established the prognosis associated with a procainamide-induced Brugada pattern, demonstrating differences from other sodium channel blockers. The investigation defined the specific indications for procainamide challenge using data from the Canadian Hearts in Rhythm Organization registry. This established a clearer clinical utility for identifying this particular electrocardiogram pattern.
Article 2: Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41342627
Summary: This study developed and validated the first formalin-fixed, paraffin-embedded tissue-based molecular diagnostic system for heart transplant rejection. The system utilizes intra-graft targeted gene expression profiling to refine diagnostic accuracy. This method is applicable to endomyocardial biopsies and is designed for easy implementation in clinical practice. The international study established a deeply phenotyped cohort of heart transplant recipients to support this validation.
Article 3: Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41342227
Summary: This study identified oestrogen-related receptor gamma as a key regulator in sepsis-induced cardiomyopathy. Researchers found that cardiomyocyte subtype conversion plays a crucial role in the pathophysiology of sepsis-induced cardiomyopathy. This mechanistic insight offers a novel understanding of how sepsis increases overall mortality through cardiac dysfunction. The findings lay a foundation for developing targeted therapies for sepsis-induced cardiomyopathy, addressing a current lack of specific treatments.
Article 4: Cardiovascular disease in women: traditional and sex-specific risk factors.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41342194
Summary: This review highlighted that cardiovascular disease accounts for more deaths in women than breast cancer, lung cancer, and chronic lung disease combined, showing comparable mortality to men. It identified a critical lack of awareness among both women and physicians regarding cardiovascular disease as a major cause of morbidity and mortality in women. This contributes to significant delays in diagnosis and treatment. The analysis confirm]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 05, 2025. This episode summarizes 5 key cardiology studies on topics like diagnosis and formalin-fixed paraffin-embedded. Key takeaway: First FFPE Heart Rejection Molecular Test Validated.
Article Links:
Article 1: Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome. (Circulation)
Article 2: Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling. (European heart journal)
Article 3: Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion. (European heart journal)
Article 4: Cardiovascular disease in women: traditional and sex-specific risk factors. (European heart journal)
Article 5: Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics. (The Journal of heart and lung transplantation : the official publica]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy 12/04/25</title>
	<link>https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/</link>
	<pubDate>Thu, 04 Dec 2025 11:01:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 04, 2025. This episode summarizes 5 key cardiology studies on topics like oral magnesium and diabetes mellitus. Key takeaway: TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41338273">Oral magnesium and outcomes in US veterans with heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41338249">Diabetes and sudden cardiac death: a Danish nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41117724">Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40310325">The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40293864">Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/">https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Oral magnesium and outcomes in US veterans with heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41338273" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41338273</a></p>
<p><strong>Summary:</strong> This study identified 54696 United States veterans with Heart Failure between 2001 and 2023 who also presented with hypomagnesemia, defined as serum magnesium below 1.7 milligrams per deciliter. Among this cohort, 10695 patients were initiated on oral magnesium therapy, with a median daily dose of 420 milligrams. A propensity score-matched cohort of 21098 patients was established, allowing for comparison of clinical outcomes between those receiving oral magnesium and those not. The study thus provided the foundational data and a robust comparative structure for evaluating the real-world impact of oral magnesium supplementation in this population.</p>
<h4>Article 2: Diabetes and sudden cardiac death: a Danish nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41338249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41338249</a></p>
<p><strong>Summary:</strong> This nationwide Danish study included the entire Danish population in 2010 as its cohort for analysis of sudden cardiac death. Sudden cardiac death cases were ascertained using detailed Danish death certificates across the population. The research characterized incidence rates of sudden cardiac death among individuals with type one diabetes and type two diabetes. The study additionally quantified the shortened life expectancy attributed to sudden cardiac death within these specific diabetic populations.</p>
<h4>Article 3: Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41117724" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41117724</a></p>
<p><strong>Summary:</strong> This study characterized the incidence and prevalence of cardiovascular-kidney-metabolic dysfunction in children and adults following heart transplantation. The research developed an expanded understanding of these specific post-transplant complications. This characterization provides critical information for informing screening and therapeutic strategies to mitigate adverse events in heart transplant recipients.</p>
<h4>Article 4: The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40310325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40310325</a></p>
<p><strong>Summary:</strong> This study demonstrated a founder effect of the cardiac troponin T gene p.Asn271Ile variant in A Coruña, Spain. It characterized the specific phenotype of the p.Asn271Ile variant. The research compared this phenotype with codon 92 variants, a known hotspot associated with high risk hypertrophic cardiomyopathy. The data indicated that the TNNT2 p.Asn271Ile variant is associated with low-risk late-onset hypertrophic cardiomyopathy.</p>
<h4>Article 5: Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40293864" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40293864</a></p>
<p><strong>Summary:</strong> This international, multicenter retrospective study compared outcomes of heart transplantation after Donation After Circulatory Determination of Death across Europe and the United States. The study evaluated differences between recipients whose donor hearts were retrieved using thoraco-abdominal normothermic regional perfusion. It also assessed outcomes for those whose hearts were recovered using direct procurement and perfusion. The research established findings regarding the most clinically effective method of organ procurement for Donation After Circulatory Determination of Death heart transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Oral magnesium and outcomes in US veterans with heart failure. This study identified 54696 United States veterans with Heart Failure between 2001 and 2023 who also presented with hypomagnesemia, defined as serum magnesium below 1.7 milligrams per deciliter. Among this cohort, 10695 patients were initiated on oral magnesium therapy, with a median daily dose of 420 milligrams. A propensity score-matched cohort of 21098 patients was established, allowing for comparison of clinical outcomes between those receiving oral magnesium and those not. The study thus provided the foundational data and a robust comparative structure for evaluating the real-world impact of oral magnesium supplementation in this population.</p>
<p>Article number two. Diabetes and sudden cardiac death: a Danish nationwide study. This nationwide Danish study included the entire Danish population in 2010 as its cohort for analysis of sudden cardiac death. Sudden cardiac death cases were ascertained using detailed Danish death certificates across the population. The research characterized incidence rates of sudden cardiac death among individuals with type one diabetes and type two diabetes. The study additionally quantified the shortened life expectancy attributed to sudden cardiac death within these specific diabetic populations.</p>
<p>Article number three. Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation. This study characterized the incidence and prevalence of cardiovascular-kidney-metabolic dysfunction in children and adults following heart transplantation. The research developed an expanded understanding of these specific post-transplant complications. This characterization provides critical information for informing screening and therapeutic strategies to mitigate adverse events in heart transplant recipients.</p>
<p>Article number four. The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy. This study demonstrated a founder effect of the cardiac troponin T gene p.Asn271Ile variant in A Coruña, Spain. It characterized the specific phenotype of the p.Asn271Ile variant. The research compared this phenotype with codon 92 variants, a known hotspot associated with high risk hypertrophic cardiomyopathy. The data indicated that the TNNT2 p.Asn271Ile variant is associated with low-risk late-onset hypertrophic cardiomyopathy.</p>
<p>Article number five. Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study. This international, multicenter retrospective study compared outcomes of heart transplantation after Donation After Circulatory Determination of Death across Europe and the United States. The study evaluated differences between recipients whose donor hearts were retrieved using thoraco-abdominal normothermic regional perfusion. It also assessed outcomes for those whose hearts were recovered using direct procurement and perfusion. The research established findings regarding the most clinically effective method of organ procurement for Donation After Circulatory Determination of Death heart transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>oral magnesium, diabetes mellitus, type two diabetes, cardiovascular-kidney-metabolic dysfunction, thoraco-abdominal normothermic regional perfusion, genetic mutation, TNNT2 gene, C. K. M. disease, children, p.Asn271Ile variant, clinical outcomes, life expectancy, founder effect, adults, Donation After Circulatory Determination of Death, organ procurement, direct procurement and perfusion, United States veterans, heart failure, sudden cardiac death, heart transplantation, hypertrophic cardiomyopathy, type one diabetes, hypomagnesemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/">TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy 12/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 04, 2025. This episode summarizes 5 key cardiology studies on topics like oral magnesium and diabetes mellitus. Key takeaway: TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy.
Article Links:
Art]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 04, 2025. This episode summarizes 5 key cardiology studies on topics like oral magnesium and diabetes mellitus. Key takeaway: TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41338273">Oral magnesium and outcomes in US veterans with heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41338249">Diabetes and sudden cardiac death: a Danish nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41117724">Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40310325">The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40293864">Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/">https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Oral magnesium and outcomes in US veterans with heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41338273" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41338273</a></p>
<p><strong>Summary:</strong> This study identified 54696 United States veterans with Heart Failure between 2001 and 2023 who also presented with hypomagnesemia, defined as serum magnesium below 1.7 milligrams per deciliter. Among this cohort, 10695 patients were initiated on oral magnesium therapy, with a median daily dose of 420 milligrams. A propensity score-matched cohort of 21098 patients was established, allowing for comparison of clinical outcomes between those receiving oral magnesium and those not. The study thus provided the foundational data and a robust comparative structure for evaluating the real-world impact of oral magnesium supplementation in this population.</p>
<h4>Article 2: Diabetes and sudden cardiac death: a Danish nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41338249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41338249</a></p>
<p><strong>Summary:</strong> This nationwide Danish study included the entire Danish population in 2010 as its cohort for analysis of sudden cardiac death. Sudden cardiac death cases were ascertained using detailed Danish death certificates across the population. The research characterized incidence rates of sudden cardiac death among individuals with type one diabetes and type two diabetes. The study additionally quantified the shortened life expectancy attributed to sudden cardiac death within these specific diabetic populations.</p>
<h4>Article 3: Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41117724" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41117724</a></p>
<p><strong>Summary:</strong> This study characterized the incidence and prevalence of cardiovascular-kidney-metabolic dysfunction in children and adults following heart transplantation. The research developed an expanded understanding of these specific post-transplant complications. This characterization provides critical information for informing screening and therapeutic strategies to mitigate adverse events in heart transplant recipients.</p>
<h4>Article 4: The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40310325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40310325</a></p>
<p><strong>Summary:</strong> This study demonstrated a founder effect of the cardiac troponin T gene p.Asn271Ile variant in A Coruña, Spain. It characterized the specific phenotype of the p.Asn271Ile variant. The research compared this phenotype with codon 92 variants, a known hotspot associated with high risk hypertrophic cardiomyopathy. The data indicated that the TNNT2 p.Asn271Ile variant is associated with low-risk late-onset hypertrophic cardiomyopathy.</p>
<h4>Article 5: Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40293864" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40293864</a></p>
<p><strong>Summary:</strong> This international, multicenter retrospective study compared outcomes of heart transplantation after Donation After Circulatory Determination of Death across Europe and the United States. The study evaluated differences between recipients whose donor hearts were retrieved using thoraco-abdominal normothermic regional perfusion. It also assessed outcomes for those whose hearts were recovered using direct procurement and perfusion. The research established findings regarding the most clinically effective method of organ procurement for Donation After Circulatory Determination of Death heart transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Oral magnesium and outcomes in US veterans with heart failure. This study identified 54696 United States veterans with Heart Failure between 2001 and 2023 who also presented with hypomagnesemia, defined as serum magnesium below 1.7 milligrams per deciliter. Among this cohort, 10695 patients were initiated on oral magnesium therapy, with a median daily dose of 420 milligrams. A propensity score-matched cohort of 21098 patients was established, allowing for comparison of clinical outcomes between those receiving oral magnesium and those not. The study thus provided the foundational data and a robust comparative structure for evaluating the real-world impact of oral magnesium supplementation in this population.</p>
<p>Article number two. Diabetes and sudden cardiac death: a Danish nationwide study. This nationwide Danish study included the entire Danish population in 2010 as its cohort for analysis of sudden cardiac death. Sudden cardiac death cases were ascertained using detailed Danish death certificates across the population. The research characterized incidence rates of sudden cardiac death among individuals with type one diabetes and type two diabetes. The study additionally quantified the shortened life expectancy attributed to sudden cardiac death within these specific diabetic populations.</p>
<p>Article number three. Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation. This study characterized the incidence and prevalence of cardiovascular-kidney-metabolic dysfunction in children and adults following heart transplantation. The research developed an expanded understanding of these specific post-transplant complications. This characterization provides critical information for informing screening and therapeutic strategies to mitigate adverse events in heart transplant recipients.</p>
<p>Article number four. The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy. This study demonstrated a founder effect of the cardiac troponin T gene p.Asn271Ile variant in A Coruña, Spain. It characterized the specific phenotype of the p.Asn271Ile variant. The research compared this phenotype with codon 92 variants, a known hotspot associated with high risk hypertrophic cardiomyopathy. The data indicated that the TNNT2 p.Asn271Ile variant is associated with low-risk late-onset hypertrophic cardiomyopathy.</p>
<p>Article number five. Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study. This international, multicenter retrospective study compared outcomes of heart transplantation after Donation After Circulatory Determination of Death across Europe and the United States. The study evaluated differences between recipients whose donor hearts were retrieved using thoraco-abdominal normothermic regional perfusion. It also assessed outcomes for those whose hearts were recovered using direct procurement and perfusion. The research established findings regarding the most clinically effective method of organ procurement for Donation After Circulatory Determination of Death heart transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>oral magnesium, diabetes mellitus, type two diabetes, cardiovascular-kidney-metabolic dysfunction, thoraco-abdominal normothermic regional perfusion, genetic mutation, TNNT2 gene, C. K. M. disease, children, p.Asn271Ile variant, clinical outcomes, life expectancy, founder effect, adults, Donation After Circulatory Determination of Death, organ procurement, direct procurement and perfusion, United States veterans, heart failure, sudden cardiac death, heart transplantation, hypertrophic cardiomyopathy, type one diabetes, hypomagnesemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/">TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy 12/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251204_060038.mp3" length="4045678" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 04, 2025. This episode summarizes 5 key cardiology studies on topics like oral magnesium and diabetes mellitus. Key takeaway: TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy.
Article Links:
Article 1: Oral magnesium and outcomes in US veterans with heart failure. (European heart journal)
Article 2: Diabetes and sudden cardiac death: a Danish nationwide study. (European heart journal)
Article 3: Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation. (JACC. Heart failure)
Article 4: The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy. (JACC. Heart failure)
Article 5: Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hypertrophic-cardiomyopathy-12-04-25/
 Featured Articles
Article 1: Oral magnesium and outcomes in US veterans with heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41338273
Summary: This study identified 54696 United States veterans with Heart Failure between 2001 and 2023 who also presented with hypomagnesemia, defined as serum magnesium below 1.7 milligrams per deciliter. Among this cohort, 10695 patients were initiated on oral magnesium therapy, with a median daily dose of 420 milligrams. A propensity score-matched cohort of 21098 patients was established, allowing for comparison of clinical outcomes between those receiving oral magnesium and those not. The study thus provided the foundational data and a robust comparative structure for evaluating the real-world impact of oral magnesium supplementation in this population.
Article 2: Diabetes and sudden cardiac death: a Danish nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41338249
Summary: This nationwide Danish study included the entire Danish population in 2010 as its cohort for analysis of sudden cardiac death. Sudden cardiac death cases were ascertained using detailed Danish death certificates across the population. The research characterized incidence rates of sudden cardiac death among individuals with type one diabetes and type two diabetes. The study additionally quantified the shortened life expectancy attributed to sudden cardiac death within these specific diabetic populations.
Article 3: Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41117724
Summary: This study characterized the incidence and prevalence of cardiovascular-kidney-metabolic dysfunction in children and adults following heart transplantation. The research developed an expanded understanding of these specific post-transplant complications. This characterization provides critical information for informing screening and therapeutic strategies to mitigate adverse events in heart transplant recipients.
Article 4: The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40310325
Summary: This study demonstrated a founder effect of the cardiac troponin T gene p.Asn271Ile variant in A Coruña, Spain. It characterized the specific phenotype of the p.Asn271Ile variant. The research compared this phenotype with codon 92 variants, a known hotspot associated with high risk hypertrophic cardiomyopathy. The data indicated that the TNNT2 p.Asn271Ile variant is associated with low-risk late-onset hypertrophic cardiomyopathy.
Article 5: Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study.
Journal: JACC. Heart fail]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 04, 2025. This episode summarizes 5 key cardiology studies on topics like oral magnesium and diabetes mellitus. Key takeaway: TNNT2 Variant Pinpoints Low-Risk Hypertrophic Cardiomyopathy.
Article Links:
Article 1: Oral magnesium and outcomes in US veterans with heart failure. (European heart journal)
Article 2: Diabetes and sudden cardiac death: a Danish nationwide study. (European heart journal)
Article 3: Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation. (JACC. Heart failure)
Article 4: The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy. (JACC. Heart failure)
Article 5: Outcomes After Donation After Circulatory Determination of Death Cardiac Transplantation: An International, Multicenter Retrospective Study. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/tnnt2-variant-pinpoints-low-risk-hyper]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Donor Cell-Free DNA Improves Kidney Rejection 12/03/25</title>
	<link>https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/</link>
	<pubDate>Thu, 04 Dec 2025 02:24:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like exercise capacity and vaccine preventable illness. Key takeaway: Donor Cell-Free DNA Improves Kidney Rejection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40480321">Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40653616">Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40611379">Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients.</a> (Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40812615">Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40780562">Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/">https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40480321" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40480321</a></p>
<p><strong>Summary:</strong> This study found that pre-transplant quadriceps strength is a modifiable predictor of recovery in exercise capacity following lung transplantation. It demonstrated that assessing a candidate&#8217;s quadriceps strength provides crucial insight into their rehabilitation potential. The data showed that strengthening this muscle group offers a tangible target for pre-transplant intervention. This directly impacts the trajectory of post-transplant six minute walk distance and overall functional recovery.</p>
<h4>Article 2: Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40653616" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40653616</a></p>
<p><strong>Summary:</strong> This study established that specific recipient characteristics modify the predictive capacity of donor marginality scores for kidney grafts. It identified unique donor-recipient interactions that lead to a more accurate appraisal of kidney graft quality. The findings showed that integrating these interaction factors improved risk stratification for graft failure. This provides a more relative and individualized assessment of marginal kidney grafts, benefiting patient selection and outcomes.</p>
<h4>Article 3: Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40611379" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40611379</a></p>
<p><strong>Summary:</strong> This retrospective cohort study established the outcomes of pregnancy utilizing assisted reproductive technology in women who are kidney transplant recipients. The data provided crucial information on maternal and fetal risks, given that infertility is common and pregnancies are high risk in this patient population. The study drew upon extensive data from the Transplant Pregnancy Registry International, covering conceptions between March 1968 and July 2022. This offers valuable insights for counseling kidney transplant recipients considering assisted reproductive technology for family planning.</p>
<h4>Article 4: Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40812615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40812615</a></p>
<p><strong>Summary:</strong> A conference by the American Society of Transplantation Pediatric Community of Practice found that pediatric solid organ transplant candidates and recipients remain significantly undervaccinated. The discussions revealed that undervaccination stems from failures at various levels, including clinician misconceptions regarding vaccine administration timing. It was concluded that specific strategies are necessary to improve vaccine uptake and decrease rates of vaccine preventable illness in this vulnerable population. These findings underscore the critical need for targeted educational interventions and improved vaccination protocols.</p>
<h4>Article 5: Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40780562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40780562</a></p>
<p><strong>Summary:</strong> This study demonstrated that donor-derived cell-free D. N. A. significantly improves the rejection detection yield in kidney transplant biopsies. The biomarker proved its clinical utility by enabling earlier and more effective identification of immune-mediated graft injury. Analysis of 1070 biopsies from 1743 kidney transplant recipients confirmed its predictive capacity for biopsy-proven rejection. This finding provides clinicians with an enhanced tool for monitoring kidney allograft outcomes and guiding intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation. This study found that pre-transplant quadriceps strength is a modifiable predictor of recovery in exercise capacity following lung transplantation. It demonstrated that assessing a candidate&#8217;s quadriceps strength provides crucial insight into their rehabilitation potential. The data showed that strengthening this muscle group offers a tangible target for pre-transplant intervention. This directly impacts the trajectory of post-transplant six minute walk distance and overall functional recovery.</p>
<p>Article number two. Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study. This study established that specific recipient characteristics modify the predictive capacity of donor marginality scores for kidney grafts. It identified unique donor-recipient interactions that lead to a more accurate appraisal of kidney graft quality. The findings showed that integrating these interaction factors improved risk stratification for graft failure. This provides a more relative and individualized assessment of marginal kidney grafts, benefiting patient selection and outcomes.</p>
<p>Article number three. Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients. This retrospective cohort study established the outcomes of pregnancy utilizing assisted reproductive technology in women who are kidney transplant recipients. The data provided crucial information on maternal and fetal risks, given that infertility is common and pregnancies are high risk in this patient population. The study drew upon extensive data from the Transplant Pregnancy Registry International, covering conceptions between March 1968 and July 2022. This offers valuable insights for counseling kidney transplant recipients considering assisted reproductive technology for family planning.</p>
<p>Article number four. Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy. A conference by the American Society of Transplantation Pediatric Community of Practice found that pediatric solid organ transplant candidates and recipients remain significantly undervaccinated. The discussions revealed that undervaccination stems from failures at various levels, including clinician misconceptions regarding vaccine administration timing. It was concluded that specific strategies are necessary to improve vaccine uptake and decrease rates of vaccine preventable illness in this vulnerable population. These findings underscore the critical need for targeted educational interventions and improved vaccination protocols.</p>
<p>Article number five. Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. This study demonstrated that donor-derived cell-free D. N. A. significantly improves the rejection detection yield in kidney transplant biopsies. The biomarker proved its clinical utility by enabling earlier and more effective identification of immune-mediated graft injury. Analysis of 1070 biopsies from 1743 kidney transplant recipients confirmed its predictive capacity for biopsy-proven rejection. This finding provides clinicians with an enhanced tool for monitoring kidney allograft outcomes and guiding intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>exercise capacity, vaccine preventable illness, risk stratification, fetal outcomes, assisted reproductive technology, graft marginality, quadriceps strength, graft injury, graft failure, rehabilitation, kidney transplantation, donor-recipient interaction, vaccination coverage, pregnancy outcomes, biopsy-proven rejection, kidney transplant, solid organ transplant, lung transplantation, vaccine hesitancy, maternal health, donor-derived cell-free D. N. A., pediatric transplantation, functional recovery, rejection.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/">Donor Cell-Free DNA Improves Kidney Rejection 12/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like exercise capacity and vaccine preventable illness. Key takeaway: Donor Cell-Free DNA Improves Kidney Rejection.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like exercise capacity and vaccine preventable illness. Key takeaway: Donor Cell-Free DNA Improves Kidney Rejection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40480321">Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40653616">Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40611379">Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients.</a> (Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40812615">Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40780562">Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/">https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40480321" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40480321</a></p>
<p><strong>Summary:</strong> This study found that pre-transplant quadriceps strength is a modifiable predictor of recovery in exercise capacity following lung transplantation. It demonstrated that assessing a candidate&#8217;s quadriceps strength provides crucial insight into their rehabilitation potential. The data showed that strengthening this muscle group offers a tangible target for pre-transplant intervention. This directly impacts the trajectory of post-transplant six minute walk distance and overall functional recovery.</p>
<h4>Article 2: Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40653616" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40653616</a></p>
<p><strong>Summary:</strong> This study established that specific recipient characteristics modify the predictive capacity of donor marginality scores for kidney grafts. It identified unique donor-recipient interactions that lead to a more accurate appraisal of kidney graft quality. The findings showed that integrating these interaction factors improved risk stratification for graft failure. This provides a more relative and individualized assessment of marginal kidney grafts, benefiting patient selection and outcomes.</p>
<h4>Article 3: Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40611379" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40611379</a></p>
<p><strong>Summary:</strong> This retrospective cohort study established the outcomes of pregnancy utilizing assisted reproductive technology in women who are kidney transplant recipients. The data provided crucial information on maternal and fetal risks, given that infertility is common and pregnancies are high risk in this patient population. The study drew upon extensive data from the Transplant Pregnancy Registry International, covering conceptions between March 1968 and July 2022. This offers valuable insights for counseling kidney transplant recipients considering assisted reproductive technology for family planning.</p>
<h4>Article 4: Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40812615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40812615</a></p>
<p><strong>Summary:</strong> A conference by the American Society of Transplantation Pediatric Community of Practice found that pediatric solid organ transplant candidates and recipients remain significantly undervaccinated. The discussions revealed that undervaccination stems from failures at various levels, including clinician misconceptions regarding vaccine administration timing. It was concluded that specific strategies are necessary to improve vaccine uptake and decrease rates of vaccine preventable illness in this vulnerable population. These findings underscore the critical need for targeted educational interventions and improved vaccination protocols.</p>
<h4>Article 5: Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40780562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40780562</a></p>
<p><strong>Summary:</strong> This study demonstrated that donor-derived cell-free D. N. A. significantly improves the rejection detection yield in kidney transplant biopsies. The biomarker proved its clinical utility by enabling earlier and more effective identification of immune-mediated graft injury. Analysis of 1070 biopsies from 1743 kidney transplant recipients confirmed its predictive capacity for biopsy-proven rejection. This finding provides clinicians with an enhanced tool for monitoring kidney allograft outcomes and guiding intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation. This study found that pre-transplant quadriceps strength is a modifiable predictor of recovery in exercise capacity following lung transplantation. It demonstrated that assessing a candidate&#8217;s quadriceps strength provides crucial insight into their rehabilitation potential. The data showed that strengthening this muscle group offers a tangible target for pre-transplant intervention. This directly impacts the trajectory of post-transplant six minute walk distance and overall functional recovery.</p>
<p>Article number two. Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study. This study established that specific recipient characteristics modify the predictive capacity of donor marginality scores for kidney grafts. It identified unique donor-recipient interactions that lead to a more accurate appraisal of kidney graft quality. The findings showed that integrating these interaction factors improved risk stratification for graft failure. This provides a more relative and individualized assessment of marginal kidney grafts, benefiting patient selection and outcomes.</p>
<p>Article number three. Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients. This retrospective cohort study established the outcomes of pregnancy utilizing assisted reproductive technology in women who are kidney transplant recipients. The data provided crucial information on maternal and fetal risks, given that infertility is common and pregnancies are high risk in this patient population. The study drew upon extensive data from the Transplant Pregnancy Registry International, covering conceptions between March 1968 and July 2022. This offers valuable insights for counseling kidney transplant recipients considering assisted reproductive technology for family planning.</p>
<p>Article number four. Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy. A conference by the American Society of Transplantation Pediatric Community of Practice found that pediatric solid organ transplant candidates and recipients remain significantly undervaccinated. The discussions revealed that undervaccination stems from failures at various levels, including clinician misconceptions regarding vaccine administration timing. It was concluded that specific strategies are necessary to improve vaccine uptake and decrease rates of vaccine preventable illness in this vulnerable population. These findings underscore the critical need for targeted educational interventions and improved vaccination protocols.</p>
<p>Article number five. Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. This study demonstrated that donor-derived cell-free D. N. A. significantly improves the rejection detection yield in kidney transplant biopsies. The biomarker proved its clinical utility by enabling earlier and more effective identification of immune-mediated graft injury. Analysis of 1070 biopsies from 1743 kidney transplant recipients confirmed its predictive capacity for biopsy-proven rejection. This finding provides clinicians with an enhanced tool for monitoring kidney allograft outcomes and guiding intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>exercise capacity, vaccine preventable illness, risk stratification, fetal outcomes, assisted reproductive technology, graft marginality, quadriceps strength, graft injury, graft failure, rehabilitation, kidney transplantation, donor-recipient interaction, vaccination coverage, pregnancy outcomes, biopsy-proven rejection, kidney transplant, solid organ transplant, lung transplantation, vaccine hesitancy, maternal health, donor-derived cell-free D. N. A., pediatric transplantation, functional recovery, rejection.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/">Donor Cell-Free DNA Improves Kidney Rejection 12/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251203_212328.mp3" length="3877241" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like exercise capacity and vaccine preventable illness. Key takeaway: Donor Cell-Free DNA Improves Kidney Rejection.
Article Links:
Article 1: Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study. (Transplantation)
Article 3: Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients. (Transplantation)
Article 4: Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 5: Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Full episode page: https://podcast.explainheart.com/podcast/donor-cell-free-dna-improves-kidney-rejection-12-03-25/
 Featured Articles
Article 1: Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40480321
Summary: This study found that pre-transplant quadriceps strength is a modifiable predictor of recovery in exercise capacity following lung transplantation. It demonstrated that assessing a candidate&#8217;s quadriceps strength provides crucial insight into their rehabilitation potential. The data showed that strengthening this muscle group offers a tangible target for pre-transplant intervention. This directly impacts the trajectory of post-transplant six minute walk distance and overall functional recovery.
Article 2: Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40653616
Summary: This study established that specific recipient characteristics modify the predictive capacity of donor marginality scores for kidney grafts. It identified unique donor-recipient interactions that lead to a more accurate appraisal of kidney graft quality. The findings showed that integrating these interaction factors improved risk stratification for graft failure. This provides a more relative and individualized assessment of marginal kidney grafts, benefiting patient selection and outcomes.
Article 3: Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40611379
Summary: This retrospective cohort study established the outcomes of pregnancy utilizing assisted reproductive technology in women who are kidney transplant recipients. The data provided crucial information on maternal and fetal risks, given that infertility is common and pregnancies are high risk in this patient population. The study drew upon extensive data from the Transplant Pregnancy Registry International, covering conceptions between March 1968 and July 2022. This offers valuable insights for counseling kidney transplant recipients considering assisted reproductive technology for family planning.
Article 4: Addressing vaccination coverage among pediatric solid ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like exercise capacity and vaccine preventable illness. Key takeaway: Donor Cell-Free DNA Improves Kidney Rejection.
Article Links:
Article 1: Lung transplant candidates&#8217; quadriceps strength is a modifiable predictor of recovery in exercise capacity after transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Identification of Donor-recipient Interactions for a Relative Appraisal of Kidney Graft Marginality: A French Multicentric Cohort-based Study. (Transplantation)
Article 3: Pregnancy Outcomes Using Assisted Reproductive Technology in Kidney Transplant Recipients. (Transplantation)
Article 4: Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Osimertinib Heart Failure Via GATA4-MYLK3 Axis 12/03/25</title>
	<link>https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/</link>
	<pubDate>Wed, 03 Dec 2025 11:01:14 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like H. O. P. E. and C. T. L. A. 4. Key takeaway: Osimertinib Heart Failure Via GATA4-MYLK3 Axis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41330421">Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41330410">Trained immunity in cardiovascular disease.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40986618">Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients.</a> (Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40855395">Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40691830">Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/">https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41330421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41330421</a></p>
<p><strong>Summary:</strong> This study found that osimertinib, a third-generation tyrosine kinase inhibitor, induces reversible cardiac dysfunction. The research demonstrated this cardiotoxicity operates through the GATA4-MYLK3-MYL2 axis. This mechanism explains the associated heart failure observed in patients treated with osimertinib for non-small cell lung carcinoma. Understanding this pathway provides a foundation for developing cardioprotective strategies against this drug-induced cardiac damage.</p>
<h4>Article 2: Trained immunity in cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41330410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41330410</a></p>
<p><strong>Summary:</strong> Trained immunity, or T. R. I. M., is a recallable, long-term hyperinflammatory innate immune phenotype. This process involves changes in metabolic and epigenetic intracellular processes within mature innate immune cells. Trained immunity is identified as a core mechanism in the pathophysiology of atherosclerosis and represents a potential target for new pharmacological interventions to prevent or treat cardiovascular disease.</p>
<h4>Article 3: Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40986618" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40986618</a></p>
<p><strong>Summary:</strong> Sodium-glucose cotransporter inhibitors effectively slow chronic kidney disease progression and reduce kidney failure events in the general population. These agents are known to cause an initial and sustained decline in estimated glomerular filtration rate and carry an increased risk of urogenital infections. For kidney transplant recipients, who face a high risk of adverse kidney outcomes, the safety and tolerability of this drug class, specifically sotagliflozin, are crucial considerations.</p>
<h4>Article 4: Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40855395" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40855395</a></p>
<p><strong>Summary:</strong> Previous research demonstrated that beta cell-specific overexpression of a high-affinity variant of human cytotoxic T-lymphocyte-associated antigen 4, or C. T. L. A. 4, prevented porcine islet rejection in humanized mouse models. This study found that anti-cytotoxic T-lymphocyte-associated antigen 4 treatment abrogates the co-stimulation blockade, reversing the acceptance of transgenic porcine islets. This indicates that long-term xenograft function and survival were not maintained following neutralization of C. T. L. A. 4-mediated co-stimulation blockade.</p>
<h4>Article 5: Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691830" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691830</a></p>
<p><strong>Summary:</strong> Donor hearts experience injury during heart transplantation due to brain death and static cold storage preservation. Hypothermic oxygenated machine perfusion, or H. O. P. E., is a preservation method that may reduce myocardial injury compared to static cold storage. This study investigated specific cardiac mitochondrial and electrophysiological changes in transplanted ovine hearts following H. O. P. E. preservation. These findings are crucial for optimizing donor heart quality and improving heart transplant outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis. This study found that osimertinib, a third-generation tyrosine kinase inhibitor, induces reversible cardiac dysfunction. The research demonstrated this cardiotoxicity operates through the GATA4-MYLK3-MYL2 axis. This mechanism explains the associated heart failure observed in patients treated with osimertinib for non-small cell lung carcinoma. Understanding this pathway provides a foundation for developing cardioprotective strategies against this drug-induced cardiac damage.</p>
<p>Article number two. Trained immunity in cardiovascular disease. Trained immunity, or T. R. I. M., is a recallable, long-term hyperinflammatory innate immune phenotype. This process involves changes in metabolic and epigenetic intracellular processes within mature innate immune cells. Trained immunity is identified as a core mechanism in the pathophysiology of atherosclerosis and represents a potential target for new pharmacological interventions to prevent or treat cardiovascular disease.</p>
<p>Article number three. Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients. Sodium-glucose cotransporter inhibitors effectively slow chronic kidney disease progression and reduce kidney failure events in the general population. These agents are known to cause an initial and sustained decline in estimated glomerular filtration rate and carry an increased risk of urogenital infections. For kidney transplant recipients, who face a high risk of adverse kidney outcomes, the safety and tolerability of this drug class, specifically sotagliflozin, are crucial considerations.</p>
<p>Article number four. Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice. Previous research demonstrated that beta cell-specific overexpression of a high-affinity variant of human cytotoxic T-lymphocyte-associated antigen 4, or C. T. L. A. 4, prevented porcine islet rejection in humanized mouse models. This study found that anti-cytotoxic T-lymphocyte-associated antigen 4 treatment abrogates the co-stimulation blockade, reversing the acceptance of transgenic porcine islets. This indicates that long-term xenograft function and survival were not maintained following neutralization of C. T. L. A. 4-mediated co-stimulation blockade.</p>
<p>Article number five. Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion. Donor hearts experience injury during heart transplantation due to brain death and static cold storage preservation. Hypothermic oxygenated machine perfusion, or H. O. P. E., is a preservation method that may reduce myocardial injury compared to static cold storage. This study investigated specific cardiac mitochondrial and electrophysiological changes in transplanted ovine hearts following H. O. P. E. preservation. These findings are crucial for optimizing donor heart quality and improving heart transplant outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>H. O. P. E., C. T. L. A. 4, Xenotransplantation, heart failure, mitochondrial function, cardiovascular disease, cardiotoxicity, T. R. I. M., GATA4-MYLK3-MYL2 axis, innate immunity, Trained immunity, hypothermic oxygenated machine perfusion, islet rejection, kidney transplant recipients, non-small cell lung carcinoma, Osimertinib, Sotagliflozin, porcine islets, sodium-glucose cotransporter inhibitors, cytotoxic T-lymphocyte-associated antigen 4, cardiac preservation, Heart transplantation, S. G. L. T. i., atherosclerosis, chronic kidney disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/">Osimertinib Heart Failure Via GATA4-MYLK3 Axis 12/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like H. O. P. E. and C. T. L. A. 4. Key takeaway: Osimertinib Heart Failure Via GATA4-MYLK3 Axis.
Article Links:
Article 1: Osimertinib i]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like H. O. P. E. and C. T. L. A. 4. Key takeaway: Osimertinib Heart Failure Via GATA4-MYLK3 Axis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41330421">Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41330410">Trained immunity in cardiovascular disease.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40986618">Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients.</a> (Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40855395">Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40691830">Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/">https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41330421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41330421</a></p>
<p><strong>Summary:</strong> This study found that osimertinib, a third-generation tyrosine kinase inhibitor, induces reversible cardiac dysfunction. The research demonstrated this cardiotoxicity operates through the GATA4-MYLK3-MYL2 axis. This mechanism explains the associated heart failure observed in patients treated with osimertinib for non-small cell lung carcinoma. Understanding this pathway provides a foundation for developing cardioprotective strategies against this drug-induced cardiac damage.</p>
<h4>Article 2: Trained immunity in cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41330410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41330410</a></p>
<p><strong>Summary:</strong> Trained immunity, or T. R. I. M., is a recallable, long-term hyperinflammatory innate immune phenotype. This process involves changes in metabolic and epigenetic intracellular processes within mature innate immune cells. Trained immunity is identified as a core mechanism in the pathophysiology of atherosclerosis and represents a potential target for new pharmacological interventions to prevent or treat cardiovascular disease.</p>
<h4>Article 3: Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40986618" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40986618</a></p>
<p><strong>Summary:</strong> Sodium-glucose cotransporter inhibitors effectively slow chronic kidney disease progression and reduce kidney failure events in the general population. These agents are known to cause an initial and sustained decline in estimated glomerular filtration rate and carry an increased risk of urogenital infections. For kidney transplant recipients, who face a high risk of adverse kidney outcomes, the safety and tolerability of this drug class, specifically sotagliflozin, are crucial considerations.</p>
<h4>Article 4: Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40855395" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40855395</a></p>
<p><strong>Summary:</strong> Previous research demonstrated that beta cell-specific overexpression of a high-affinity variant of human cytotoxic T-lymphocyte-associated antigen 4, or C. T. L. A. 4, prevented porcine islet rejection in humanized mouse models. This study found that anti-cytotoxic T-lymphocyte-associated antigen 4 treatment abrogates the co-stimulation blockade, reversing the acceptance of transgenic porcine islets. This indicates that long-term xenograft function and survival were not maintained following neutralization of C. T. L. A. 4-mediated co-stimulation blockade.</p>
<h4>Article 5: Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691830" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691830</a></p>
<p><strong>Summary:</strong> Donor hearts experience injury during heart transplantation due to brain death and static cold storage preservation. Hypothermic oxygenated machine perfusion, or H. O. P. E., is a preservation method that may reduce myocardial injury compared to static cold storage. This study investigated specific cardiac mitochondrial and electrophysiological changes in transplanted ovine hearts following H. O. P. E. preservation. These findings are crucial for optimizing donor heart quality and improving heart transplant outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis. This study found that osimertinib, a third-generation tyrosine kinase inhibitor, induces reversible cardiac dysfunction. The research demonstrated this cardiotoxicity operates through the GATA4-MYLK3-MYL2 axis. This mechanism explains the associated heart failure observed in patients treated with osimertinib for non-small cell lung carcinoma. Understanding this pathway provides a foundation for developing cardioprotective strategies against this drug-induced cardiac damage.</p>
<p>Article number two. Trained immunity in cardiovascular disease. Trained immunity, or T. R. I. M., is a recallable, long-term hyperinflammatory innate immune phenotype. This process involves changes in metabolic and epigenetic intracellular processes within mature innate immune cells. Trained immunity is identified as a core mechanism in the pathophysiology of atherosclerosis and represents a potential target for new pharmacological interventions to prevent or treat cardiovascular disease.</p>
<p>Article number three. Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients. Sodium-glucose cotransporter inhibitors effectively slow chronic kidney disease progression and reduce kidney failure events in the general population. These agents are known to cause an initial and sustained decline in estimated glomerular filtration rate and carry an increased risk of urogenital infections. For kidney transplant recipients, who face a high risk of adverse kidney outcomes, the safety and tolerability of this drug class, specifically sotagliflozin, are crucial considerations.</p>
<p>Article number four. Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice. Previous research demonstrated that beta cell-specific overexpression of a high-affinity variant of human cytotoxic T-lymphocyte-associated antigen 4, or C. T. L. A. 4, prevented porcine islet rejection in humanized mouse models. This study found that anti-cytotoxic T-lymphocyte-associated antigen 4 treatment abrogates the co-stimulation blockade, reversing the acceptance of transgenic porcine islets. This indicates that long-term xenograft function and survival were not maintained following neutralization of C. T. L. A. 4-mediated co-stimulation blockade.</p>
<p>Article number five. Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion. Donor hearts experience injury during heart transplantation due to brain death and static cold storage preservation. Hypothermic oxygenated machine perfusion, or H. O. P. E., is a preservation method that may reduce myocardial injury compared to static cold storage. This study investigated specific cardiac mitochondrial and electrophysiological changes in transplanted ovine hearts following H. O. P. E. preservation. These findings are crucial for optimizing donor heart quality and improving heart transplant outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>H. O. P. E., C. T. L. A. 4, Xenotransplantation, heart failure, mitochondrial function, cardiovascular disease, cardiotoxicity, T. R. I. M., GATA4-MYLK3-MYL2 axis, innate immunity, Trained immunity, hypothermic oxygenated machine perfusion, islet rejection, kidney transplant recipients, non-small cell lung carcinoma, Osimertinib, Sotagliflozin, porcine islets, sodium-glucose cotransporter inhibitors, cytotoxic T-lymphocyte-associated antigen 4, cardiac preservation, Heart transplantation, S. G. L. T. i., atherosclerosis, chronic kidney disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/">Osimertinib Heart Failure Via GATA4-MYLK3 Axis 12/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251203_060029.mp3" length="3787380" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like H. O. P. E. and C. T. L. A. 4. Key takeaway: Osimertinib Heart Failure Via GATA4-MYLK3 Axis.
Article Links:
Article 1: Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis. (European heart journal)
Article 2: Trained immunity in cardiovascular disease. (European heart journal)
Article 3: Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients. (Transplantation)
Article 4: Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice. (Transplantation)
Article 5: Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion. (Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/
 Featured Articles
Article 1: Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41330421
Summary: This study found that osimertinib, a third-generation tyrosine kinase inhibitor, induces reversible cardiac dysfunction. The research demonstrated this cardiotoxicity operates through the GATA4-MYLK3-MYL2 axis. This mechanism explains the associated heart failure observed in patients treated with osimertinib for non-small cell lung carcinoma. Understanding this pathway provides a foundation for developing cardioprotective strategies against this drug-induced cardiac damage.
Article 2: Trained immunity in cardiovascular disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41330410
Summary: Trained immunity, or T. R. I. M., is a recallable, long-term hyperinflammatory innate immune phenotype. This process involves changes in metabolic and epigenetic intracellular processes within mature innate immune cells. Trained immunity is identified as a core mechanism in the pathophysiology of atherosclerosis and represents a potential target for new pharmacological interventions to prevent or treat cardiovascular disease.
Article 3: Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40986618
Summary: Sodium-glucose cotransporter inhibitors effectively slow chronic kidney disease progression and reduce kidney failure events in the general population. These agents are known to cause an initial and sustained decline in estimated glomerular filtration rate and carry an increased risk of urogenital infections. For kidney transplant recipients, who face a high risk of adverse kidney outcomes, the safety and tolerability of this drug class, specifically sotagliflozin, are crucial considerations.
Article 4: Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40855395
Summary: Previous research demonstrated that beta cell-specific overexpression of a high-affinity variant of human cytotoxic T-lymphocyte-associated antigen 4, or C. T. L. A. 4, prevented porcine islet rejection in humanized mouse models. This study found that anti-cytotoxic T-lymphocyte-associated antigen 4 treatment abrogates the co-stimulation blockade, reversing the acceptance of transgenic porcine islets. This indicates that long-term xenograft function and survival were not maintained following neutralization of C. T. L. A. 4-mediated co-stimulation blockade.
Article 5: Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40691830
Summary: Donor hearts experience injury during heart tra]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 03, 2025. This episode summarizes 5 key cardiology studies on topics like H. O. P. E. and C. T. L. A. 4. Key takeaway: Osimertinib Heart Failure Via GATA4-MYLK3 Axis.
Article Links:
Article 1: Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis. (European heart journal)
Article 2: Trained immunity in cardiovascular disease. (European heart journal)
Article 3: Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients. (Transplantation)
Article 4: Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice. (Transplantation)
Article 5: Cardiac Mitochondrial and Electrophysiological Changes in Transplanted Ovine Hearts Following Preservation by Hypothermic Oxygenated Perfusion. (Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/osimertinib-heart-failure-via-gata4-mylk3-axis-12-03-25/
 Featured Articles
]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Heart Transplant Survival Score Developed 12/02/25</title>
	<link>https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/</link>
	<pubDate>Wed, 03 Dec 2025 02:19:37 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like risk score and heart transplantation. Key takeaway: Heart Transplant Survival Score Developed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40714161">Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40714159">Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40691955">Development of a risk score predicting survival after adult heart transplantation in the United States.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40685032">Out of sequence heart transplants: Why, how many, and to whom.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40645312">Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/">https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40714161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40714161</a></p>
<p><strong>Summary:</strong> Durable mechanical circulatory support devices are associated with driveline infections, a major burden for heart failure patients. A key contributor to these infections is the low mechanical compliance of current drivelines, which negatively impacts wound healing. The research explores new drivelines equipped with ultra-flexible wires, which are designed to mitigate mechanical stress on the skin. This approach addresses the root cause of wound healing issues, thus offering a strategy to reduce the risk of driveline infections.</p>
<h4>Article 2: Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40714159" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40714159</a></p>
<p><strong>Summary:</strong> A. -E. C. M. O.: Insights from the Cardiogenic Shock Working Group. Veno-arterial extracorporeal membrane oxygenation (V. A. -E. C. M. O.) is used worldwide for cardiogenic shock despite conflicting outcomes from randomized trials that focused on myocardial infarction-related cardiogenic shock. This study, using a multicenter registry, provided a detailed characterization of clinical outcomes for patients with cardiogenic shock supported by V. A. -E. C. M. O. The analysis differentiated outcomes across various cardiogenic shock etiologies, moving beyond a sole focus on myocardial infarction-related cases. This work established a clearer understanding of V. A. -E. C. M. O.&#8217;s clinical utility in a broader spectrum of cardiogenic shock patients.</p>
<h4>Article 3: Development of a risk score predicting survival after adult heart transplantation in the United States.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691955" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691955</a></p>
<p><strong>Summary:</strong> The United States&#8217; system for allocating donor hearts currently prioritizes candidates at highest risk of waiting list death. To optimize organ allocation under the upcoming continuous distribution system, a novel U. S. transplant risk score (U. S. -T. R. S.) was developed and validated. This observational study, utilizing the Scientific Registry of Transplant Recipients, established the U. S. -T. R. S. to predict survival after adult heart transplantation. The score provides a tool to help avoid futile transplants by better matching donor hearts to recipients who will most benefit.</p>
<h4>Article 4: Out of sequence heart transplants: Why, how many, and to whom.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40685032" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40685032</a></p>
<p><strong>Summary:</strong> Heart transplantation allocation generally follows an urgency-ranked match list established by the Organ Procurement and Transplantation Network. This study provided a comprehensive description of out of sequence heart transplants (O. O. S. H. T.), which occur outside this standard sequence. The research characterized the prevalence of O. O. S. H. T. along with specific donor and recipient profiles associated with these transplants. It further detailed how centers and recipients involved in O. O. S. H. T. differed from those receiving standard sequence donors, offering important insights into allocation practices.</p>
<h4>Article 5: Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645312" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645312</a></p>
<p><strong>Summary:</strong> Patients presenting with suspicious pulmonary lesions are often excluded from lung transplantation. This single-center retrospective analysis addressed the significant data gap regarding the prevalence and characteristics of suspicious lung lesions in transplant candidates, including the proportion of malignancy among them. The study compared lesion characteristics and assessed definitive histology reports for all patients with suspicious lung nodules who ultimately underwent lung transplantation between 2012 and 2022. This research clarified the nature of these lesions and their implications for successful lung transplantation in a population traditionally considered high-risk.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer. Durable mechanical circulatory support devices are associated with driveline infections, a major burden for heart failure patients. A key contributor to these infections is the low mechanical compliance of current drivelines, which negatively impacts wound healing. The research explores new drivelines equipped with ultra-flexible wires, which are designed to mitigate mechanical stress on the skin. This approach addresses the root cause of wound healing issues, thus offering a strategy to reduce the risk of driveline infections.</p>
<p>Article number two. Clinical outcomes of cardiogenic shock patients supported with V. A. -E. C. M. O.: Insights from the Cardiogenic Shock Working Group. Veno-arterial extracorporeal membrane oxygenation (V. A. -E. C. M. O.) is used worldwide for cardiogenic shock despite conflicting outcomes from randomized trials that focused on myocardial infarction-related cardiogenic shock. This study, using a multicenter registry, provided a detailed characterization of clinical outcomes for patients with cardiogenic shock supported by V. A. -E. C. M. O. The analysis differentiated outcomes across various cardiogenic shock etiologies, moving beyond a sole focus on myocardial infarction-related cases. This work established a clearer understanding of V. A. -E. C. M. O.&#8217;s clinical utility in a broader spectrum of cardiogenic shock patients.</p>
<p>Article number three. Development of a risk score predicting survival after adult heart transplantation in the United States. The United States&#8217; system for allocating donor hearts currently prioritizes candidates at highest risk of waiting list death. To optimize organ allocation under the upcoming continuous distribution system, a novel U. S. transplant risk score (U. S. -T. R. S.) was developed and validated. This observational study, utilizing the Scientific Registry of Transplant Recipients, established the U. S. -T. R. S. to predict survival after adult heart transplantation. The score provides a tool to help avoid futile transplants by better matching donor hearts to recipients who will most benefit.</p>
<p>Article number four. Out of sequence heart transplants: Why, how many, and to whom. Heart transplantation allocation generally follows an urgency-ranked match list established by the Organ Procurement and Transplantation Network. This study provided a comprehensive description of out of sequence heart transplants (O. O. S. H. T.), which occur outside this standard sequence. The research characterized the prevalence of O. O. S. H. T. along with specific donor and recipient profiles associated with these transplants. It further detailed how centers and recipients involved in O. O. S. H. T. differed from those receiving standard sequence donors, offering important insights into allocation practices.</p>
<p>Article number five. Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis. Patients presenting with suspicious pulmonary lesions are often excluded from lung transplantation. This single-center retrospective analysis addressed the significant data gap regarding the prevalence and characteristics of suspicious lung lesions in transplant candidates, including the proportion of malignancy among them. The study compared lesion characteristics and assessed definitive histology reports for all patients with suspicious lung nodules who ultimately underwent lung transplantation between 2012 and 2022. This research clarified the nature of these lesions and their implications for successful lung transplantation in a population traditionally considered high-risk. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk score, heart transplantation, heart failure, organ allocation, pulmonary lesions, cardiogenic shock, clinical outcomes, ultra-flexible wires, out of sequence transplants, Scientific Registry of Transplant Recipients, recipient characteristics, suspicious lung nodules, driveline infection, registry analysis, veno-arterial extracorporeal membrane oxygenation, Organ Procurement and Transplantation Network, wound healing, lung transplantation, survival prediction, histology, myocardial infarction, mechanical circulatory support, malignancy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/">Heart Transplant Survival Score Developed 12/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like risk score and heart transplantation. Key takeaway: Heart Transplant Survival Score Developed.
Article Links:
Article 1: Reducing dr]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like risk score and heart transplantation. Key takeaway: Heart Transplant Survival Score Developed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40714161">Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40714159">Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40691955">Development of a risk score predicting survival after adult heart transplantation in the United States.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40685032">Out of sequence heart transplants: Why, how many, and to whom.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40645312">Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/">https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40714161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40714161</a></p>
<p><strong>Summary:</strong> Durable mechanical circulatory support devices are associated with driveline infections, a major burden for heart failure patients. A key contributor to these infections is the low mechanical compliance of current drivelines, which negatively impacts wound healing. The research explores new drivelines equipped with ultra-flexible wires, which are designed to mitigate mechanical stress on the skin. This approach addresses the root cause of wound healing issues, thus offering a strategy to reduce the risk of driveline infections.</p>
<h4>Article 2: Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40714159" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40714159</a></p>
<p><strong>Summary:</strong> A. -E. C. M. O.: Insights from the Cardiogenic Shock Working Group. Veno-arterial extracorporeal membrane oxygenation (V. A. -E. C. M. O.) is used worldwide for cardiogenic shock despite conflicting outcomes from randomized trials that focused on myocardial infarction-related cardiogenic shock. This study, using a multicenter registry, provided a detailed characterization of clinical outcomes for patients with cardiogenic shock supported by V. A. -E. C. M. O. The analysis differentiated outcomes across various cardiogenic shock etiologies, moving beyond a sole focus on myocardial infarction-related cases. This work established a clearer understanding of V. A. -E. C. M. O.&#8217;s clinical utility in a broader spectrum of cardiogenic shock patients.</p>
<h4>Article 3: Development of a risk score predicting survival after adult heart transplantation in the United States.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40691955" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40691955</a></p>
<p><strong>Summary:</strong> The United States&#8217; system for allocating donor hearts currently prioritizes candidates at highest risk of waiting list death. To optimize organ allocation under the upcoming continuous distribution system, a novel U. S. transplant risk score (U. S. -T. R. S.) was developed and validated. This observational study, utilizing the Scientific Registry of Transplant Recipients, established the U. S. -T. R. S. to predict survival after adult heart transplantation. The score provides a tool to help avoid futile transplants by better matching donor hearts to recipients who will most benefit.</p>
<h4>Article 4: Out of sequence heart transplants: Why, how many, and to whom.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40685032" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40685032</a></p>
<p><strong>Summary:</strong> Heart transplantation allocation generally follows an urgency-ranked match list established by the Organ Procurement and Transplantation Network. This study provided a comprehensive description of out of sequence heart transplants (O. O. S. H. T.), which occur outside this standard sequence. The research characterized the prevalence of O. O. S. H. T. along with specific donor and recipient profiles associated with these transplants. It further detailed how centers and recipients involved in O. O. S. H. T. differed from those receiving standard sequence donors, offering important insights into allocation practices.</p>
<h4>Article 5: Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645312" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645312</a></p>
<p><strong>Summary:</strong> Patients presenting with suspicious pulmonary lesions are often excluded from lung transplantation. This single-center retrospective analysis addressed the significant data gap regarding the prevalence and characteristics of suspicious lung lesions in transplant candidates, including the proportion of malignancy among them. The study compared lesion characteristics and assessed definitive histology reports for all patients with suspicious lung nodules who ultimately underwent lung transplantation between 2012 and 2022. This research clarified the nature of these lesions and their implications for successful lung transplantation in a population traditionally considered high-risk.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer. Durable mechanical circulatory support devices are associated with driveline infections, a major burden for heart failure patients. A key contributor to these infections is the low mechanical compliance of current drivelines, which negatively impacts wound healing. The research explores new drivelines equipped with ultra-flexible wires, which are designed to mitigate mechanical stress on the skin. This approach addresses the root cause of wound healing issues, thus offering a strategy to reduce the risk of driveline infections.</p>
<p>Article number two. Clinical outcomes of cardiogenic shock patients supported with V. A. -E. C. M. O.: Insights from the Cardiogenic Shock Working Group. Veno-arterial extracorporeal membrane oxygenation (V. A. -E. C. M. O.) is used worldwide for cardiogenic shock despite conflicting outcomes from randomized trials that focused on myocardial infarction-related cardiogenic shock. This study, using a multicenter registry, provided a detailed characterization of clinical outcomes for patients with cardiogenic shock supported by V. A. -E. C. M. O. The analysis differentiated outcomes across various cardiogenic shock etiologies, moving beyond a sole focus on myocardial infarction-related cases. This work established a clearer understanding of V. A. -E. C. M. O.&#8217;s clinical utility in a broader spectrum of cardiogenic shock patients.</p>
<p>Article number three. Development of a risk score predicting survival after adult heart transplantation in the United States. The United States&#8217; system for allocating donor hearts currently prioritizes candidates at highest risk of waiting list death. To optimize organ allocation under the upcoming continuous distribution system, a novel U. S. transplant risk score (U. S. -T. R. S.) was developed and validated. This observational study, utilizing the Scientific Registry of Transplant Recipients, established the U. S. -T. R. S. to predict survival after adult heart transplantation. The score provides a tool to help avoid futile transplants by better matching donor hearts to recipients who will most benefit.</p>
<p>Article number four. Out of sequence heart transplants: Why, how many, and to whom. Heart transplantation allocation generally follows an urgency-ranked match list established by the Organ Procurement and Transplantation Network. This study provided a comprehensive description of out of sequence heart transplants (O. O. S. H. T.), which occur outside this standard sequence. The research characterized the prevalence of O. O. S. H. T. along with specific donor and recipient profiles associated with these transplants. It further detailed how centers and recipients involved in O. O. S. H. T. differed from those receiving standard sequence donors, offering important insights into allocation practices.</p>
<p>Article number five. Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis. Patients presenting with suspicious pulmonary lesions are often excluded from lung transplantation. This single-center retrospective analysis addressed the significant data gap regarding the prevalence and characteristics of suspicious lung lesions in transplant candidates, including the proportion of malignancy among them. The study compared lesion characteristics and assessed definitive histology reports for all patients with suspicious lung nodules who ultimately underwent lung transplantation between 2012 and 2022. This research clarified the nature of these lesions and their implications for successful lung transplantation in a population traditionally considered high-risk. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk score, heart transplantation, heart failure, organ allocation, pulmonary lesions, cardiogenic shock, clinical outcomes, ultra-flexible wires, out of sequence transplants, Scientific Registry of Transplant Recipients, recipient characteristics, suspicious lung nodules, driveline infection, registry analysis, veno-arterial extracorporeal membrane oxygenation, Organ Procurement and Transplantation Network, wound healing, lung transplantation, survival prediction, histology, myocardial infarction, mechanical circulatory support, malignancy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/">Heart Transplant Survival Score Developed 12/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251202_211831.mp3" length="4369597" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like risk score and heart transplantation. Key takeaway: Heart Transplant Survival Score Developed.
Article Links:
Article 1: Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Development of a risk score predicting survival after adult heart transplantation in the United States. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Out of sequence heart transplants: Why, how many, and to whom. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Lung transplant in patients with suspicious lung lesions: A single-center retrospective data analysis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/heart-transplant-survival-score-developed-12-02-25/
 Featured Articles
Article 1: Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40714161
Summary: Durable mechanical circulatory support devices are associated with driveline infections, a major burden for heart failure patients. A key contributor to these infections is the low mechanical compliance of current drivelines, which negatively impacts wound healing. The research explores new drivelines equipped with ultra-flexible wires, which are designed to mitigate mechanical stress on the skin. This approach addresses the root cause of wound healing issues, thus offering a strategy to reduce the risk of driveline infections.
Article 2: Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40714159
Summary: A. -E. C. M. O.: Insights from the Cardiogenic Shock Working Group. Veno-arterial extracorporeal membrane oxygenation (V. A. -E. C. M. O.) is used worldwide for cardiogenic shock despite conflicting outcomes from randomized trials that focused on myocardial infarction-related cardiogenic shock. This study, using a multicenter registry, provided a detailed characterization of clinical outcomes for patients with cardiogenic shock supported by V. A. -E. C. M. O. The analysis differentiated outcomes across various cardiogenic shock etiologies, moving beyond a sole focus on myocardial infarction-related cases. This work established a clearer understanding of V. A. -E. C. M. O.&#8217;s clinical utility in a broader spectrum of cardiogenic shock patients.
Article 3: Development of a risk score predicting survival after adult heart transplantation in the United States.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40691955
Summary: The United States&#8217; system for allocating donor hearts currently prioritizes candidates at highest risk of waiting lis]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like risk score and heart transplantation. Key takeaway: Heart Transplant Survival Score Developed.
Article Links:
Article 1: Reducing driveline infection risk in durable mechanical circulatory support devices with ultra-flexible wires for energy transfer. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Development of a risk score predicting survival after adult heart transplantation in the United States. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Tra]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Donation After Circulatory Death Expands Heart Transplant Access. 12/02/25</title>
	<link>https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/</link>
	<pubDate>Tue, 02 Dec 2025 11:01:22 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like Angiotensin-(1-7) and hemocompatibility-related adverse events. Key takeaway: Donation After Circulatory Death Expands Heart Transplant Access..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40846115">Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40819750">Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40769332">Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40752550">Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40749754">Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/">https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40846115" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40846115</a></p>
<p><strong>Summary:</strong> The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.</p>
<h4>Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40819750" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40819750</a></p>
<p><strong>Summary:</strong> This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban&#8217;s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.</p>
<h4>Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40769332" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40769332</a></p>
<p><strong>Summary:</strong> Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existing vasodilator therapy for pulmonary arterial hypertension. This therapeutic approach provides a new strategy for managing this incurable disease.</p>
<h4>Article 4: Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40752550" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40752550</a></p>
<p><strong>Summary:</strong> Donation after circulatory death heart transplantation increased the cardiac transplant donor pool. This strategy significantly decreased waitlist times for hard-to-transplant cardiac recipients. The data showed that patients with challenging characteristics gained improved access to transplantation through this method. This approach effectively alleviates organ shortages and enhances transplant opportunities for a vulnerable patient population.</p>
<h4>Article 5: Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40749754" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40749754</a></p>
<p><strong>Summary:</strong> Angiotensin-(1-7) preconditioning during 10 degrees Celsius static preservation improved early post-transplant graft function in a rat lung transplantation model. The treatment effectively reduced ischemia-reperfusion injury in acid-injured donor lungs. This demonstrated that the protective axis of the renin-angiotensin system enhances lung transplant outcomes. The findings established a therapeutic approach to mitigate early graft failure in lung transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion. The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.</p>
<p>Article number two. Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban&#8217;s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.</p>
<p>Article number three. Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring. Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existing vasodilator therapy for pulmonary arterial hypertension. This therapeutic approach provides a new strategy for managing this incurable disease.</p>
<p>Article number four. Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients. Donation after circulatory death heart transplantation increased the cardiac transplant donor pool. This strategy significantly decreased waitlist times for hard-to-transplant cardiac recipients. The data showed that patients with challenging characteristics gained improved access to transplantation through this method. This approach effectively alleviates organ shortages and enhances transplant opportunities for a vulnerable patient population.</p>
<p>Article number five. Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model. Angiotensin-(1-7) preconditioning during 10 degrees Celsius static preservation improved early post-transplant graft function in a rat lung transplantation model. The treatment effectively reduced ischemia-reperfusion injury in acid-injured donor lungs. This demonstrated that the protective axis of the renin-angiotensin system enhances lung transplant outcomes. The findings established a therapeutic approach to mitigate early graft failure in lung transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Angiotensin-(1-7), hemocompatibility-related adverse events, lung transplantation, waitlist time, donor heart assessment, Sotatercept, vasodilator therapy, pro-apoptotic pathways, graft function, cardiac recipients, Apixaban, static preservation, ischemia-reperfusion injury, donor pool, pulmonary artery remodeling, Myocardial Work Index, ex situ heart perfusion, heart transplantation, cardiac function, Donation after circulatory death, pulmonary arterial hypertension, anticoagulation, left ventricular assist device, direct oral anticoagulant.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/">Donation After Circulatory Death Expands Heart Transplant Access. 12/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like Angiotensin-(1-7) and hemocompatibility-related adverse events. Key takeaway: Donation After Circulatory Death Expands Heart Transpl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like Angiotensin-(1-7) and hemocompatibility-related adverse events. Key takeaway: Donation After Circulatory Death Expands Heart Transplant Access..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40846115">Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40819750">Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40769332">Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40752550">Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40749754">Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/">https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40846115" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40846115</a></p>
<p><strong>Summary:</strong> The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.</p>
<h4>Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40819750" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40819750</a></p>
<p><strong>Summary:</strong> This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban&#8217;s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.</p>
<h4>Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40769332" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40769332</a></p>
<p><strong>Summary:</strong> Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existing vasodilator therapy for pulmonary arterial hypertension. This therapeutic approach provides a new strategy for managing this incurable disease.</p>
<h4>Article 4: Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40752550" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40752550</a></p>
<p><strong>Summary:</strong> Donation after circulatory death heart transplantation increased the cardiac transplant donor pool. This strategy significantly decreased waitlist times for hard-to-transplant cardiac recipients. The data showed that patients with challenging characteristics gained improved access to transplantation through this method. This approach effectively alleviates organ shortages and enhances transplant opportunities for a vulnerable patient population.</p>
<h4>Article 5: Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40749754" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40749754</a></p>
<p><strong>Summary:</strong> Angiotensin-(1-7) preconditioning during 10 degrees Celsius static preservation improved early post-transplant graft function in a rat lung transplantation model. The treatment effectively reduced ischemia-reperfusion injury in acid-injured donor lungs. This demonstrated that the protective axis of the renin-angiotensin system enhances lung transplant outcomes. The findings established a therapeutic approach to mitigate early graft failure in lung transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion. The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.</p>
<p>Article number two. Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban&#8217;s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.</p>
<p>Article number three. Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring. Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existing vasodilator therapy for pulmonary arterial hypertension. This therapeutic approach provides a new strategy for managing this incurable disease.</p>
<p>Article number four. Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients. Donation after circulatory death heart transplantation increased the cardiac transplant donor pool. This strategy significantly decreased waitlist times for hard-to-transplant cardiac recipients. The data showed that patients with challenging characteristics gained improved access to transplantation through this method. This approach effectively alleviates organ shortages and enhances transplant opportunities for a vulnerable patient population.</p>
<p>Article number five. Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model. Angiotensin-(1-7) preconditioning during 10 degrees Celsius static preservation improved early post-transplant graft function in a rat lung transplantation model. The treatment effectively reduced ischemia-reperfusion injury in acid-injured donor lungs. This demonstrated that the protective axis of the renin-angiotensin system enhances lung transplant outcomes. The findings established a therapeutic approach to mitigate early graft failure in lung transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Angiotensin-(1-7), hemocompatibility-related adverse events, lung transplantation, waitlist time, donor heart assessment, Sotatercept, vasodilator therapy, pro-apoptotic pathways, graft function, cardiac recipients, Apixaban, static preservation, ischemia-reperfusion injury, donor pool, pulmonary artery remodeling, Myocardial Work Index, ex situ heart perfusion, heart transplantation, cardiac function, Donation after circulatory death, pulmonary arterial hypertension, anticoagulation, left ventricular assist device, direct oral anticoagulant.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/">Donation After Circulatory Death Expands Heart Transplant Access. 12/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251202_060027.mp3" length="3680800" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like Angiotensin-(1-7) and hemocompatibility-related adverse events. Key takeaway: Donation After Circulatory Death Expands Heart Transplant Access..
Article Links:
Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/
 Featured Articles
Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40846115
Summary: The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.
Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40819750
Summary: This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban&#8217;s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.
Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40769332
Summary: Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like Angiotensin-(1-7) and hemocompatibility-related adverse events. Key takeaway: Donation After Circulatory Death Expands Heart Transplant Access..
Article Links:
Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart T]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ABOi Heart Transplants Expand Pediatric Pool 12/01/25</title>
	<link>https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/</link>
	<pubDate>Mon, 01 Dec 2025 17:20:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like donor organ availability and waitlist mortality. Key takeaway: ABOi Heart Transplants Expand Pediatric Pool.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41321238">Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40935217">Combined heart-lung organ allocation: A glitch in the system.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40907841">High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40902959">Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40846116">ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/">https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41321238" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41321238</a></p>
<p><strong>Summary:</strong> Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.</p>
<h4>Article 2: Combined heart-lung organ allocation: A glitch in the system.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40935217" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40935217</a></p>
<p><strong>Summary:</strong> This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.</p>
<h4>Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40907841" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40907841</a></p>
<p><strong>Summary:</strong> This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.</p>
<h4>Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40902959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40902959</a></p>
<p><strong>Summary:</strong> This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device&#8217;s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.</p>
<h4>Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40846116" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40846116</a></p>
<p><strong>Summary:</strong> B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.</p>
<p>Article number two. Combined heart-lung organ allocation: A glitch in the system. This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.</p>
<p>Article number three. High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.</p>
<p>Article number four. Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device&#8217;s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.</p>
<p>Article number five. A. B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>donor organ availability, waitlist mortality, pediatric heart transplantation, antiphospholipid antibody titers, antiphospholipid syndrome, chronic thromboembolic pulmonary hypertension, HeartMate three, oxidized phospholipids, transplant policy, bleeding risk, thrombotic complications, acute coronary syndrome, pulmonary endarterectomy, isohemagglutinin titers, heart transplantation, A. B. O. incompatible heart transplant, heart-lung transplantation, polytetrafluoroethylene, organ allocation, left ventricular assist device, lipoprotein(a), alirocumab, major adverse cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/">ABOi Heart Transplants Expand Pediatric Pool 12/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like donor organ availability and waitlist mortality. Key takeaway: ABOi Heart Transplants Expand Pediatric Pool.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like donor organ availability and waitlist mortality. Key takeaway: ABOi Heart Transplants Expand Pediatric Pool.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41321238">Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40935217">Combined heart-lung organ allocation: A glitch in the system.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40907841">High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40902959">Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40846116">ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/">https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41321238" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41321238</a></p>
<p><strong>Summary:</strong> Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.</p>
<h4>Article 2: Combined heart-lung organ allocation: A glitch in the system.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40935217" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40935217</a></p>
<p><strong>Summary:</strong> This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.</p>
<h4>Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40907841" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40907841</a></p>
<p><strong>Summary:</strong> This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.</p>
<h4>Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40902959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40902959</a></p>
<p><strong>Summary:</strong> This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device&#8217;s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.</p>
<h4>Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40846116" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40846116</a></p>
<p><strong>Summary:</strong> B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.</p>
<p>Article number two. Combined heart-lung organ allocation: A glitch in the system. This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.</p>
<p>Article number three. High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.</p>
<p>Article number four. Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device&#8217;s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.</p>
<p>Article number five. A. B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>donor organ availability, waitlist mortality, pediatric heart transplantation, antiphospholipid antibody titers, antiphospholipid syndrome, chronic thromboembolic pulmonary hypertension, HeartMate three, oxidized phospholipids, transplant policy, bleeding risk, thrombotic complications, acute coronary syndrome, pulmonary endarterectomy, isohemagglutinin titers, heart transplantation, A. B. O. incompatible heart transplant, heart-lung transplantation, polytetrafluoroethylene, organ allocation, left ventricular assist device, lipoprotein(a), alirocumab, major adverse cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/">ABOi Heart Transplants Expand Pediatric Pool 12/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251201_121934.mp3" length="3764392" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like donor organ availability and waitlist mortality. Key takeaway: ABOi Heart Transplants Expand Pediatric Pool.
Article Links:
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. (Circulation)
Article 2: Combined heart-lung organ allocation: A glitch in the system. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/
 Featured Articles
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41321238
Summary: Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.
Article 2: Combined heart-lung organ allocation: A glitch in the system.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40935217
Summary: This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40907841
Summary: This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk durin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like donor organ availability and waitlist mortality. Key takeaway: ABOi Heart Transplants Expand Pediatric Pool.
Article Links:
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. (Circulation)
Article 2: Combined heart-lung organ allocation: A glitch in the system. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>PE Calculator Predicts Short-Term Outcomes 12/01/25</title>
	<link>https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/</link>
	<pubDate>Mon, 01 Dec 2025 11:01:18 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like lipid transport and short-term outcomes. Key takeaway: PE Calculator Predicts Short-Term Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40758401">Deletion of METTL14, a key methylation regulator, attenuates vascular ageing.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40720766">Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40709729">The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40391731">Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40259807">Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/">https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Deletion of METTL14, a key methylation regulator, attenuates vascular ageing.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40758401" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40758401</a></p>
<p><strong>Summary:</strong> Deletion of methyltransferase-like protein 14 (METTL14) was found to attenuate vascular aging. This suggests that METTL14 plays a role in promoting vascular aging, possibly by influencing inflammation. Modulating METTL14 activity could therefore represent a therapeutic strategy to combat age-related vascular diseases.</p>
<h4>Article 2: Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40720766" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40720766</a></p>
<p><strong>Summary:</strong> This study found that excessive glycosylation drives the formation of thoracic aortic aneurysms and dissections (TAADs) through activation of the integrated stress response. The hexosamine biosynthetic pathway was identified as a key contributor to this process in both sporadic and genetic forms of thoracic aortic aneurysm. This mechanistic insight suggests that targeting the hexosamine biosynthetic pathway could offer a therapeutic approach for preventing or treating thoracic aortic aneurysms and related conditions such as Marfan syndrome.</p>
<h4>Article 3: The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40709729" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40709729</a></p>
<p><strong>Summary:</strong> Kinesin family member 13B (KIF13B), a macrophage-derived motor protein, was found to enhance MERTK-mediated efferocytosis. This enhancement of efferocytosis, which is the clearance of apoptotic cells, resulted in the prevention of atherosclerosis in mice. The data suggests that KIF13B plays a protective role against atherosclerosis by improving cellular waste removal, indicating its potential as a therapeutic target.</p>
<h4>Article 4: Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40391731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40391731</a></p>
<p><strong>Summary:</strong> A multimarker prognostic calculator was developed to predict short-term outcomes in patients with acute pulmonary embolism (P. E.). This calculator estimates the absolute risk of key outcomes for individual patients, utilizing variables from the simplified Pulmonary Embolism Severity Index and other markers. The study validated the calculator&#8217;s performance and compared it to the established European Society of Cardiology (E. S. C.) model for risk stratification in acute pulmonary embolism, providing a tool for targeted interventions.</p>
<h4>Article 5: Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40259807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40259807</a></p>
<p><strong>Summary:</strong> Nuclear receptor Dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (Dax1) was found to promote atherosclerosis. This pro-atherogenic effect occurs through the inhibition of lipid transport and suppression of autophagy within macrophages. The study identified Dax1 levels in human atherosclerotic arteries, suggesting Dax1 as a potential pharmacological target for preventing atherosclerosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Deletion of METTL14, a key methylation regulator, attenuates vascular ageing. Deletion of methyltransferase-like protein 14 (METTL14) was found to attenuate vascular aging. This suggests that METTL14 plays a role in promoting vascular aging, possibly by influencing inflammation. Modulating METTL14 activity could therefore represent a therapeutic strategy to combat age-related vascular diseases.</p>
<p>Article number two. Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response. This study found that excessive glycosylation drives the formation of thoracic aortic aneurysms and dissections (TAADs) through activation of the integrated stress response. The hexosamine biosynthetic pathway was identified as a key contributor to this process in both sporadic and genetic forms of thoracic aortic aneurysm. This mechanistic insight suggests that targeting the hexosamine biosynthetic pathway could offer a therapeutic approach for preventing or treating thoracic aortic aneurysms and related conditions such as Marfan syndrome.</p>
<p>Article number three. The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. Kinesin family member 13B (KIF13B), a macrophage-derived motor protein, was found to enhance MERTK-mediated efferocytosis. This enhancement of efferocytosis, which is the clearance of apoptotic cells, resulted in the prevention of atherosclerosis in mice. The data suggests that KIF13B plays a protective role against atherosclerosis by improving cellular waste removal, indicating its potential as a therapeutic target.</p>
<p>Article number four. Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes. A multimarker prognostic calculator was developed to predict short-term outcomes in patients with acute pulmonary embolism (P. E.). This calculator estimates the absolute risk of key outcomes for individual patients, utilizing variables from the simplified Pulmonary Embolism Severity Index and other markers. The study validated the calculator&#8217;s performance and compared it to the established European Society of Cardiology (E. S. C.) model for risk stratification in acute pulmonary embolism, providing a tool for targeted interventions.</p>
<p>Article number five. Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages. Nuclear receptor Dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (Dax1) was found to promote atherosclerosis. This pro-atherogenic effect occurs through the inhibition of lipid transport and suppression of autophagy within macrophages. The study identified Dax1 levels in human atherosclerotic arteries, suggesting Dax1 as a potential pharmacological target for preventing atherosclerosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lipid transport, short-term outcomes, Dax1, hexosamine biosynthetic pathway, vascular aging, prognostic calculator, inflammation, risk stratification, nuclear receptor, pulmonary embolism, Pulmonary Embolism Severity Index, autophagy, thoracic aortic aneurysm, methylation, integrated stress response, MERTK, efferocytosis, METTL14, atherosclerosis, Marfan syndrome, glycosylation, macrophages, KIF13B.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/">PE Calculator Predicts Short-Term Outcomes 12/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like lipid transport and short-term outcomes. Key takeaway: PE Calculator Predicts Short-Term Outcomes.
Article Links:
Article 1: Deletio]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like lipid transport and short-term outcomes. Key takeaway: PE Calculator Predicts Short-Term Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40758401">Deletion of METTL14, a key methylation regulator, attenuates vascular ageing.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40720766">Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40709729">The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40391731">Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40259807">Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/">https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Deletion of METTL14, a key methylation regulator, attenuates vascular ageing.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40758401" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40758401</a></p>
<p><strong>Summary:</strong> Deletion of methyltransferase-like protein 14 (METTL14) was found to attenuate vascular aging. This suggests that METTL14 plays a role in promoting vascular aging, possibly by influencing inflammation. Modulating METTL14 activity could therefore represent a therapeutic strategy to combat age-related vascular diseases.</p>
<h4>Article 2: Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40720766" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40720766</a></p>
<p><strong>Summary:</strong> This study found that excessive glycosylation drives the formation of thoracic aortic aneurysms and dissections (TAADs) through activation of the integrated stress response. The hexosamine biosynthetic pathway was identified as a key contributor to this process in both sporadic and genetic forms of thoracic aortic aneurysm. This mechanistic insight suggests that targeting the hexosamine biosynthetic pathway could offer a therapeutic approach for preventing or treating thoracic aortic aneurysms and related conditions such as Marfan syndrome.</p>
<h4>Article 3: The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40709729" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40709729</a></p>
<p><strong>Summary:</strong> Kinesin family member 13B (KIF13B), a macrophage-derived motor protein, was found to enhance MERTK-mediated efferocytosis. This enhancement of efferocytosis, which is the clearance of apoptotic cells, resulted in the prevention of atherosclerosis in mice. The data suggests that KIF13B plays a protective role against atherosclerosis by improving cellular waste removal, indicating its potential as a therapeutic target.</p>
<h4>Article 4: Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40391731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40391731</a></p>
<p><strong>Summary:</strong> A multimarker prognostic calculator was developed to predict short-term outcomes in patients with acute pulmonary embolism (P. E.). This calculator estimates the absolute risk of key outcomes for individual patients, utilizing variables from the simplified Pulmonary Embolism Severity Index and other markers. The study validated the calculator&#8217;s performance and compared it to the established European Society of Cardiology (E. S. C.) model for risk stratification in acute pulmonary embolism, providing a tool for targeted interventions.</p>
<h4>Article 5: Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40259807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40259807</a></p>
<p><strong>Summary:</strong> Nuclear receptor Dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (Dax1) was found to promote atherosclerosis. This pro-atherogenic effect occurs through the inhibition of lipid transport and suppression of autophagy within macrophages. The study identified Dax1 levels in human atherosclerotic arteries, suggesting Dax1 as a potential pharmacological target for preventing atherosclerosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is December 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Deletion of METTL14, a key methylation regulator, attenuates vascular ageing. Deletion of methyltransferase-like protein 14 (METTL14) was found to attenuate vascular aging. This suggests that METTL14 plays a role in promoting vascular aging, possibly by influencing inflammation. Modulating METTL14 activity could therefore represent a therapeutic strategy to combat age-related vascular diseases.</p>
<p>Article number two. Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response. This study found that excessive glycosylation drives the formation of thoracic aortic aneurysms and dissections (TAADs) through activation of the integrated stress response. The hexosamine biosynthetic pathway was identified as a key contributor to this process in both sporadic and genetic forms of thoracic aortic aneurysm. This mechanistic insight suggests that targeting the hexosamine biosynthetic pathway could offer a therapeutic approach for preventing or treating thoracic aortic aneurysms and related conditions such as Marfan syndrome.</p>
<p>Article number three. The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. Kinesin family member 13B (KIF13B), a macrophage-derived motor protein, was found to enhance MERTK-mediated efferocytosis. This enhancement of efferocytosis, which is the clearance of apoptotic cells, resulted in the prevention of atherosclerosis in mice. The data suggests that KIF13B plays a protective role against atherosclerosis by improving cellular waste removal, indicating its potential as a therapeutic target.</p>
<p>Article number four. Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes. A multimarker prognostic calculator was developed to predict short-term outcomes in patients with acute pulmonary embolism (P. E.). This calculator estimates the absolute risk of key outcomes for individual patients, utilizing variables from the simplified Pulmonary Embolism Severity Index and other markers. The study validated the calculator&#8217;s performance and compared it to the established European Society of Cardiology (E. S. C.) model for risk stratification in acute pulmonary embolism, providing a tool for targeted interventions.</p>
<p>Article number five. Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages. Nuclear receptor Dosage-sensitive sex reversal, adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (Dax1) was found to promote atherosclerosis. This pro-atherogenic effect occurs through the inhibition of lipid transport and suppression of autophagy within macrophages. The study identified Dax1 levels in human atherosclerotic arteries, suggesting Dax1 as a potential pharmacological target for preventing atherosclerosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lipid transport, short-term outcomes, Dax1, hexosamine biosynthetic pathway, vascular aging, prognostic calculator, inflammation, risk stratification, nuclear receptor, pulmonary embolism, Pulmonary Embolism Severity Index, autophagy, thoracic aortic aneurysm, methylation, integrated stress response, MERTK, efferocytosis, METTL14, atherosclerosis, Marfan syndrome, glycosylation, macrophages, KIF13B.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/">PE Calculator Predicts Short-Term Outcomes 12/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/12/cardiology_today_20251201_060026.mp3" length="3633571" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like lipid transport and short-term outcomes. Key takeaway: PE Calculator Predicts Short-Term Outcomes.
Article Links:
Article 1: Deletion of METTL14, a key methylation regulator, attenuates vascular ageing. (European heart journal)
Article 2: Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response. (European heart journal)
Article 3: The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. (European heart journal)
Article 4: Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes. (European heart journal)
Article 5: Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/pe-calculator-predicts-short-term-outcomes-12-01-25/
 Featured Articles
Article 1: Deletion of METTL14, a key methylation regulator, attenuates vascular ageing.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40758401
Summary: Deletion of methyltransferase-like protein 14 (METTL14) was found to attenuate vascular aging. This suggests that METTL14 plays a role in promoting vascular aging, possibly by influencing inflammation. Modulating METTL14 activity could therefore represent a therapeutic strategy to combat age-related vascular diseases.
Article 2: Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40720766
Summary: This study found that excessive glycosylation drives the formation of thoracic aortic aneurysms and dissections (TAADs) through activation of the integrated stress response. The hexosamine biosynthetic pathway was identified as a key contributor to this process in both sporadic and genetic forms of thoracic aortic aneurysm. This mechanistic insight suggests that targeting the hexosamine biosynthetic pathway could offer a therapeutic approach for preventing or treating thoracic aortic aneurysms and related conditions such as Marfan syndrome.
Article 3: The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40709729
Summary: Kinesin family member 13B (KIF13B), a macrophage-derived motor protein, was found to enhance MERTK-mediated efferocytosis. This enhancement of efferocytosis, which is the clearance of apoptotic cells, resulted in the prevention of atherosclerosis in mice. The data suggests that KIF13B plays a protective role against atherosclerosis by improving cellular waste removal, indicating its potential as a therapeutic target.
Article 4: Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40391731
Summary: A multimarker prognostic calculator was developed to predict short-term outcomes in patients with acute pulmonary embolism (P. E.). This calculator estimates the absolute risk of key outcomes for individual patients, utilizing variables from the simplified Pulmonary Embolism Severity Index and other markers. The study validated the calculator&#8217;s performance and compared it to the established European Society of Cardiology (E. S. C.) model for risk stratification in acute pulmonary embolism, providing a tool for targeted interventions.
Article 5: Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40259807
Summary: Nuclear receptor Dosage-sensitive sex reversal, adrenal hypoplasia congenita critic]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like lipid transport and short-term outcomes. Key takeaway: PE Calculator Predicts Short-Term Outcomes.
Article Links:
Article 1: Deletion of METTL14, a key methylation regulator, attenuates vascular ageing. (European heart journal)
Article 2: Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response. (European heart journal)
Article 3: The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. (European heart journal)
Article 4: Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes. (European heart journal)
Article 5: Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/pe-calculator-predict]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F. 11/30/25</title>
	<link>https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/</link>
	<pubDate>Sun, 30 Nov 2025 11:01:53 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like alloresponse and Pulmonary Vein Isolation. Key takeaway: Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41317870">Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41317944">Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41317943">The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41317942">New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41317941">Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long QT Syndrome.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/">https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317870</a></p>
<p><strong>Summary:</strong> H. C.-specific IgE augments the T and B cell alloresponse in a C. D. 23-dependent manner. Donor Major Histocompatibility Complex-specific Immunoglobulin E augments both T cell and B cell alloresponses in a C. D. 23-dependent manner. This mechanism indicates that Immunoglobulin E, in addition to its known roles in allergic hypersensitivity, contributes to immune activation relevant to transplant rejection. The presence of donor Major Histocompatibility Complex-specific Immunoglobulin E has been observed in murine transplant models and in human kidney transplant recipients. These findings illuminate a previously unrecognized role for Immunoglobulin E in modulating the alloimmune response, suggesting it influences transplant outcomes.</p>
<h4>Article 2: Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317944" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317944</a></p>
<p><strong>Summary:</strong> H. A. 2. D. S. 2. -V. A. S. C. Score. Sick Sinus Syndrome elevates stroke risk specifically in patients with Atrial Fibrillation who have a low C. H. A. 2. D. S. 2. -V. A. S. C. score. This finding indicates that concomitant Sick Sinus Syndrome acts as an independent risk factor for incident ischemic stroke, even in patients considered to be at lower risk by conventional scoring systems. The study, which analyzed a cohort of 24960 patients, suggests that clinicians should consider the presence of Sick Sinus Syndrome when assessing stroke risk in Atrial Fibrillation patients. Therefore, Sick Sinus Syndrome requires careful consideration in comprehensive stroke prevention strategies for this patient population.</p>
<h4>Article 3: The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317943</a></p>
<p><strong>Summary:</strong> Pulsed-field Ablation for Pulmonary Vein Isolation demonstrates a superior safety profile regarding gastric motility compared to Radiofrequency Ablation. Radiofrequency Ablation for Pulmonary Vein Isolation was observed to impair gastric motility due to collateral thermal injury. In contrast, Pulsed-field Ablation, being a nonthermal modality, preferentially affected cardiomyocytes and preserved gastric motility in patients with Atrial Fibrillation. This indicates that Pulsed-field Ablation offers a significant advantage in reducing the risk of gastric motility impairment during Pulmonary Vein Isolation procedures.</p>
<h4>Article 4: New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317942" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317942</a></p>
<p><strong>Summary:</strong> A novel technique effectively achieves total Mitral Isthmus Block by successfully targeting masked epicardial conductions. The study identified that epicardial conduction played a key role in peri-mitral atrial tachycardia recurrence, which was subsequently addressed by this approach. Targeting these previously masked epicardial pathways with Radiofrequency Ablation proved feasible and instrumental in achieving complete and durable Mitral Isthmus Block. This new method provides a crucial advancement for patients undergoing ablation for persistent Atrial Fibrillation.</p>
<h4>Article 5: Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long QT Syndrome.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317941" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317941</a></p>
<p><strong>Summary:</strong> T. Syndrome. Non-penetrant Long Q. T. Syndrome, defined as the absence of objective electrocardiographic or cardiac evidence of abnormal cardiac repolarization despite a positive genotype, represents a distinct clinical entity. This condition highlights that not all individuals with a Long Q. T. Syndrome genotype manifest the typical prolongation of the Q. T. interval or associated clinical events like syncope or sudden cardiac arrest. Understanding the prevalence, spectrum, and long-term outcomes of non-penetrant Long Q. T. Syndrome is crucial for genetic counseling and personalized risk stratification. It offers a critical distinction within the broader Long Q. T. Syndrome population for clinical management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Donor M. H. C.-specific IgE augments the T and B cell alloresponse in a C. D. 23-dependent manner. Donor Major Histocompatibility Complex-specific Immunoglobulin E augments both T cell and B cell alloresponses in a C. D. 23-dependent manner. This mechanism indicates that Immunoglobulin E, in addition to its known roles in allergic hypersensitivity, contributes to immune activation relevant to transplant rejection. The presence of donor Major Histocompatibility Complex-specific Immunoglobulin E has been observed in murine transplant models and in human kidney transplant recipients. These findings illuminate a previously unrecognized role for Immunoglobulin E in modulating the alloimmune response, suggesting it influences transplant outcomes.</p>
<p>Article number two. Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low C. H. A. 2. D. S. 2. -V. A. S. C. Score. Sick Sinus Syndrome elevates stroke risk specifically in patients with Atrial Fibrillation who have a low C. H. A. 2. D. S. 2. -V. A. S. C. score. This finding indicates that concomitant Sick Sinus Syndrome acts as an independent risk factor for incident ischemic stroke, even in patients considered to be at lower risk by conventional scoring systems. The study, which analyzed a cohort of 24960 patients, suggests that clinicians should consider the presence of Sick Sinus Syndrome when assessing stroke risk in Atrial Fibrillation patients. Therefore, Sick Sinus Syndrome requires careful consideration in comprehensive stroke prevention strategies for this patient population.</p>
<p>Article number three. The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency. Pulsed-field Ablation for Pulmonary Vein Isolation demonstrates a superior safety profile regarding gastric motility compared to Radiofrequency Ablation. Radiofrequency Ablation for Pulmonary Vein Isolation was observed to impair gastric motility due to collateral thermal injury. In contrast, Pulsed-field Ablation, being a nonthermal modality, preferentially affected cardiomyocytes and preserved gastric motility in patients with Atrial Fibrillation. This indicates that Pulsed-field Ablation offers a significant advantage in reducing the risk of gastric motility impairment during Pulmonary Vein Isolation procedures.</p>
<p>Article number four. New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions. A novel technique effectively achieves total Mitral Isthmus Block by successfully targeting masked epicardial conductions. The study identified that epicardial conduction played a key role in peri-mitral atrial tachycardia recurrence, which was subsequently addressed by this approach. Targeting these previously masked epicardial pathways with Radiofrequency Ablation proved feasible and instrumental in achieving complete and durable Mitral Isthmus Block. This new method provides a crucial advancement for patients undergoing ablation for persistent Atrial Fibrillation.</p>
<p>Article number five. Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long Q. T. Syndrome. Non-penetrant Long Q. T. Syndrome, defined as the absence of objective electrocardiographic or cardiac evidence of abnormal cardiac repolarization despite a positive genotype, represents a distinct clinical entity. This condition highlights that not all individuals with a Long Q. T. Syndrome genotype manifest the typical prolongation of the Q. T. interval or associated clinical events like syncope or sudden cardiac arrest. Understanding the prevalence, spectrum, and long-term outcomes of non-penetrant Long Q. T. Syndrome is crucial for genetic counseling and personalized risk stratification. It offers a critical distinction within the broader Long Q. T. Syndrome population for clinical management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>alloresponse, Pulmonary Vein Isolation, electrocardiographic abnormality, B cell activation, Mitral Isthmus Block, gastric motility, transplant rejection, sudden cardiac death, T cell activation, Donor M. H. C., genotype positive, persistent Atrial Fibrillation, Radiofrequency Ablation, Immunoglobulin E, stroke risk, non-penetrant, Sick Sinus Syndrome, ischemic stroke, Long Q. T. Syndrome, Pulsed-field Ablation, Atrial Fibrillation, epicardial conduction, C. H. A. 2. D. S. 2. -V. A. S. C. score, atrial tachycardia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/">Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F. 11/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like alloresponse and Pulmonary Vein Isolation. Key takeaway: Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F..
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like alloresponse and Pulmonary Vein Isolation. Key takeaway: Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41317870">Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41317944">Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41317943">The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41317942">New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41317941">Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long QT Syndrome.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/">https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317870</a></p>
<p><strong>Summary:</strong> H. C.-specific IgE augments the T and B cell alloresponse in a C. D. 23-dependent manner. Donor Major Histocompatibility Complex-specific Immunoglobulin E augments both T cell and B cell alloresponses in a C. D. 23-dependent manner. This mechanism indicates that Immunoglobulin E, in addition to its known roles in allergic hypersensitivity, contributes to immune activation relevant to transplant rejection. The presence of donor Major Histocompatibility Complex-specific Immunoglobulin E has been observed in murine transplant models and in human kidney transplant recipients. These findings illuminate a previously unrecognized role for Immunoglobulin E in modulating the alloimmune response, suggesting it influences transplant outcomes.</p>
<h4>Article 2: Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317944" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317944</a></p>
<p><strong>Summary:</strong> H. A. 2. D. S. 2. -V. A. S. C. Score. Sick Sinus Syndrome elevates stroke risk specifically in patients with Atrial Fibrillation who have a low C. H. A. 2. D. S. 2. -V. A. S. C. score. This finding indicates that concomitant Sick Sinus Syndrome acts as an independent risk factor for incident ischemic stroke, even in patients considered to be at lower risk by conventional scoring systems. The study, which analyzed a cohort of 24960 patients, suggests that clinicians should consider the presence of Sick Sinus Syndrome when assessing stroke risk in Atrial Fibrillation patients. Therefore, Sick Sinus Syndrome requires careful consideration in comprehensive stroke prevention strategies for this patient population.</p>
<h4>Article 3: The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317943" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317943</a></p>
<p><strong>Summary:</strong> Pulsed-field Ablation for Pulmonary Vein Isolation demonstrates a superior safety profile regarding gastric motility compared to Radiofrequency Ablation. Radiofrequency Ablation for Pulmonary Vein Isolation was observed to impair gastric motility due to collateral thermal injury. In contrast, Pulsed-field Ablation, being a nonthermal modality, preferentially affected cardiomyocytes and preserved gastric motility in patients with Atrial Fibrillation. This indicates that Pulsed-field Ablation offers a significant advantage in reducing the risk of gastric motility impairment during Pulmonary Vein Isolation procedures.</p>
<h4>Article 4: New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317942" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317942</a></p>
<p><strong>Summary:</strong> A novel technique effectively achieves total Mitral Isthmus Block by successfully targeting masked epicardial conductions. The study identified that epicardial conduction played a key role in peri-mitral atrial tachycardia recurrence, which was subsequently addressed by this approach. Targeting these previously masked epicardial pathways with Radiofrequency Ablation proved feasible and instrumental in achieving complete and durable Mitral Isthmus Block. This new method provides a crucial advancement for patients undergoing ablation for persistent Atrial Fibrillation.</p>
<h4>Article 5: Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long QT Syndrome.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317941" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317941</a></p>
<p><strong>Summary:</strong> T. Syndrome. Non-penetrant Long Q. T. Syndrome, defined as the absence of objective electrocardiographic or cardiac evidence of abnormal cardiac repolarization despite a positive genotype, represents a distinct clinical entity. This condition highlights that not all individuals with a Long Q. T. Syndrome genotype manifest the typical prolongation of the Q. T. interval or associated clinical events like syncope or sudden cardiac arrest. Understanding the prevalence, spectrum, and long-term outcomes of non-penetrant Long Q. T. Syndrome is crucial for genetic counseling and personalized risk stratification. It offers a critical distinction within the broader Long Q. T. Syndrome population for clinical management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Donor M. H. C.-specific IgE augments the T and B cell alloresponse in a C. D. 23-dependent manner. Donor Major Histocompatibility Complex-specific Immunoglobulin E augments both T cell and B cell alloresponses in a C. D. 23-dependent manner. This mechanism indicates that Immunoglobulin E, in addition to its known roles in allergic hypersensitivity, contributes to immune activation relevant to transplant rejection. The presence of donor Major Histocompatibility Complex-specific Immunoglobulin E has been observed in murine transplant models and in human kidney transplant recipients. These findings illuminate a previously unrecognized role for Immunoglobulin E in modulating the alloimmune response, suggesting it influences transplant outcomes.</p>
<p>Article number two. Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low C. H. A. 2. D. S. 2. -V. A. S. C. Score. Sick Sinus Syndrome elevates stroke risk specifically in patients with Atrial Fibrillation who have a low C. H. A. 2. D. S. 2. -V. A. S. C. score. This finding indicates that concomitant Sick Sinus Syndrome acts as an independent risk factor for incident ischemic stroke, even in patients considered to be at lower risk by conventional scoring systems. The study, which analyzed a cohort of 24960 patients, suggests that clinicians should consider the presence of Sick Sinus Syndrome when assessing stroke risk in Atrial Fibrillation patients. Therefore, Sick Sinus Syndrome requires careful consideration in comprehensive stroke prevention strategies for this patient population.</p>
<p>Article number three. The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency. Pulsed-field Ablation for Pulmonary Vein Isolation demonstrates a superior safety profile regarding gastric motility compared to Radiofrequency Ablation. Radiofrequency Ablation for Pulmonary Vein Isolation was observed to impair gastric motility due to collateral thermal injury. In contrast, Pulsed-field Ablation, being a nonthermal modality, preferentially affected cardiomyocytes and preserved gastric motility in patients with Atrial Fibrillation. This indicates that Pulsed-field Ablation offers a significant advantage in reducing the risk of gastric motility impairment during Pulmonary Vein Isolation procedures.</p>
<p>Article number four. New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions. A novel technique effectively achieves total Mitral Isthmus Block by successfully targeting masked epicardial conductions. The study identified that epicardial conduction played a key role in peri-mitral atrial tachycardia recurrence, which was subsequently addressed by this approach. Targeting these previously masked epicardial pathways with Radiofrequency Ablation proved feasible and instrumental in achieving complete and durable Mitral Isthmus Block. This new method provides a crucial advancement for patients undergoing ablation for persistent Atrial Fibrillation.</p>
<p>Article number five. Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long Q. T. Syndrome. Non-penetrant Long Q. T. Syndrome, defined as the absence of objective electrocardiographic or cardiac evidence of abnormal cardiac repolarization despite a positive genotype, represents a distinct clinical entity. This condition highlights that not all individuals with a Long Q. T. Syndrome genotype manifest the typical prolongation of the Q. T. interval or associated clinical events like syncope or sudden cardiac arrest. Understanding the prevalence, spectrum, and long-term outcomes of non-penetrant Long Q. T. Syndrome is crucial for genetic counseling and personalized risk stratification. It offers a critical distinction within the broader Long Q. T. Syndrome population for clinical management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>alloresponse, Pulmonary Vein Isolation, electrocardiographic abnormality, B cell activation, Mitral Isthmus Block, gastric motility, transplant rejection, sudden cardiac death, T cell activation, Donor M. H. C., genotype positive, persistent Atrial Fibrillation, Radiofrequency Ablation, Immunoglobulin E, stroke risk, non-penetrant, Sick Sinus Syndrome, ischemic stroke, Long Q. T. Syndrome, Pulsed-field Ablation, Atrial Fibrillation, epicardial conduction, C. H. A. 2. D. S. 2. -V. A. S. C. score, atrial tachycardia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/">Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F. 11/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251130_060030.mp3" length="4806364" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like alloresponse and Pulmonary Vein Isolation. Key takeaway: Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F..
Article Links:
Article 1: Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score. (Heart rhythm)
Article 3: The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency. (Heart rhythm)
Article 4: New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions. (Heart rhythm)
Article 5: Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long QT Syndrome. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/sick-sinus-syndrome-raises-stroke-risk-in-low-risk-a-f-11-30-25/
 Featured Articles
Article 1: Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317870
Summary: H. C.-specific IgE augments the T and B cell alloresponse in a C. D. 23-dependent manner. Donor Major Histocompatibility Complex-specific Immunoglobulin E augments both T cell and B cell alloresponses in a C. D. 23-dependent manner. This mechanism indicates that Immunoglobulin E, in addition to its known roles in allergic hypersensitivity, contributes to immune activation relevant to transplant rejection. The presence of donor Major Histocompatibility Complex-specific Immunoglobulin E has been observed in murine transplant models and in human kidney transplant recipients. These findings illuminate a previously unrecognized role for Immunoglobulin E in modulating the alloimmune response, suggesting it influences transplant outcomes.
Article 2: Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317944
Summary: H. A. 2. D. S. 2. -V. A. S. C. Score. Sick Sinus Syndrome elevates stroke risk specifically in patients with Atrial Fibrillation who have a low C. H. A. 2. D. S. 2. -V. A. S. C. score. This finding indicates that concomitant Sick Sinus Syndrome acts as an independent risk factor for incident ischemic stroke, even in patients considered to be at lower risk by conventional scoring systems. The study, which analyzed a cohort of 24960 patients, suggests that clinicians should consider the presence of Sick Sinus Syndrome when assessing stroke risk in Atrial Fibrillation patients. Therefore, Sick Sinus Syndrome requires careful consideration in comprehensive stroke prevention strategies for this patient population.
Article 3: The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317943
Summary: Pulsed-field Ablation for Pulmonary Vein Isolation demonstrates a superior safety profile regarding gastric motility compared to Radiofrequency Ablation. Radiofrequency Ablation for Pulmonary Vein Isolation was observed to impair gastric motility due to collateral thermal injury. In contrast, Pulsed-field Ablation, being a nonthermal modality, preferentially affected cardiomyocytes and preserved gastric motility in patients with Atrial Fibrillation. This indicates that Pulsed-field Ablation offers a significant advantage in reducing the risk of gastric motility impairment during Pulmonary Vein Isolation procedures.
Article 4: New Technique to Achieve Total Mitral Isthmus Block: Targetin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like alloresponse and Pulmonary Vein Isolation. Key takeaway: Sick Sinus Syndrome Raises Stroke Risk in Low-Risk A. F..
Article Links:
Article 1: Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Sick Sinus Syndrome Elevates Stroke Risk in Atrial Fibrillation Patients with Low CHA2DS2-VASC Score. (Heart rhythm)
Article 3: The Effect of Pulmonary Vein Isolation on Gastric Motility: Pulsed-field Ablation vs Radiofrequency. (Heart rhythm)
Article 4: New Technique to Achieve Total Mitral Isthmus Block: Targeting Masked Epicardial Conductions. (Heart rhythm)
Article 5: Prevalence, Spectrum and Outcomes in Patients with Non-Penetrant Long QT Syndrome. (Heart rhythm)
Full episode p]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>HRV-CV: A Digital Biomarker for Age, Sex, and Behavior 11/30/25</title>
	<link>https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/</link>
	<pubDate>Sun, 30 Nov 2025 05:04:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like digital biomarker and wild-type amyloid. Key takeaway: HRV-CV: A Digital Biomarker for Age, Sex, and Behavior.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41317156">Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41317156">Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41299774">Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41309064">Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41313350">Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/">https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317156" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317156</a></p>
<p><strong>Summary:</strong> Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<h4>Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317156" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317156</a></p>
<p><strong>Summary:</strong> Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<h4>Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41299774" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41299774</a></p>
<p><strong>Summary:</strong> The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice.</p>
<h4>Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41309064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41309064</a></p>
<p><strong>Summary:</strong> The heart rate variability coefficient of variation, an index of day-to-day cardiac autonomic fluctuation, functions as a scalable digital biomarker. This biomarker reliably reflects behavior and exhibits variations according to both age and sex. It offers significant potential for behavioral monitoring and health risk stratification in diverse populations.</p>
<h4>Article 5: Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41313350" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41313350</a></p>
<p><strong>Summary:</strong> Long-term ventricular mechanics following the Ross procedure for congenital aortic valve disease are not well understood. This procedure, a common surgical option, requires further investigation into its mid- and late-term effects on left ventricular diastolic function. Understanding these long-term functional characteristics is crucial, particularly when comparing outcomes to other surgical repairs for congenital heart lesions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<p>Article number two. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<p>Article number three. Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice.</p>
<p>Article number four. Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. The heart rate variability coefficient of variation, an index of day-to-day cardiac autonomic fluctuation, functions as a scalable digital biomarker. This biomarker reliably reflects behavior and exhibits variations according to both age and sex. It offers significant potential for behavioral monitoring and health risk stratification in diverse populations.</p>
<p>Article number five. Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure. Long-term ventricular mechanics following the Ross procedure for congenital aortic valve disease are not well understood. This procedure, a common surgical option, requires further investigation into its mid- and late-term effects on left ventricular diastolic function. Understanding these long-term functional characteristics is crucial, particularly when comparing outcomes to other surgical repairs for congenital heart lesions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>digital biomarker, wild-type amyloid, left atrial remodeling, echocardiography, real-world data, tafamidis, heart rate variability coefficient of variation, long-term mechanics, health risk stratification, left atrioventricular ratio, left ventricular diastolic function, congenital aortic valve disease, surgical repair, Ross procedure, cardiac remodeling, transthyretin amyloid cardiomyopathy, survival, left ventricular remodeling, autonomic fluctuation, behavioral monitoring.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/">HRV-CV: A Digital Biomarker for Age, Sex, and Behavior 11/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like digital biomarker and wild-type amyloid. Key takeaway: HRV-CV: A Digital Biomarker for Age, Sex, and Behavior.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like digital biomarker and wild-type amyloid. Key takeaway: HRV-CV: A Digital Biomarker for Age, Sex, and Behavior.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41317156">Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41317156">Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41299774">Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41309064">Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41313350">Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/">https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317156" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317156</a></p>
<p><strong>Summary:</strong> Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<h4>Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41317156" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41317156</a></p>
<p><strong>Summary:</strong> Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<h4>Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41299774" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41299774</a></p>
<p><strong>Summary:</strong> The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice.</p>
<h4>Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41309064" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41309064</a></p>
<p><strong>Summary:</strong> The heart rate variability coefficient of variation, an index of day-to-day cardiac autonomic fluctuation, functions as a scalable digital biomarker. This biomarker reliably reflects behavior and exhibits variations according to both age and sex. It offers significant potential for behavioral monitoring and health risk stratification in diverse populations.</p>
<h4>Article 5: Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41313350" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41313350</a></p>
<p><strong>Summary:</strong> Long-term ventricular mechanics following the Ross procedure for congenital aortic valve disease are not well understood. This procedure, a common surgical option, requires further investigation into its mid- and late-term effects on left ventricular diastolic function. Understanding these long-term functional characteristics is crucial, particularly when comparing outcomes to other surgical repairs for congenital heart lesions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<p>Article number two. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.</p>
<p>Article number three. Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice.</p>
<p>Article number four. Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. The heart rate variability coefficient of variation, an index of day-to-day cardiac autonomic fluctuation, functions as a scalable digital biomarker. This biomarker reliably reflects behavior and exhibits variations according to both age and sex. It offers significant potential for behavioral monitoring and health risk stratification in diverse populations.</p>
<p>Article number five. Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure. Long-term ventricular mechanics following the Ross procedure for congenital aortic valve disease are not well understood. This procedure, a common surgical option, requires further investigation into its mid- and late-term effects on left ventricular diastolic function. Understanding these long-term functional characteristics is crucial, particularly when comparing outcomes to other surgical repairs for congenital heart lesions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>digital biomarker, wild-type amyloid, left atrial remodeling, echocardiography, real-world data, tafamidis, heart rate variability coefficient of variation, long-term mechanics, health risk stratification, left atrioventricular ratio, left ventricular diastolic function, congenital aortic valve disease, surgical repair, Ross procedure, cardiac remodeling, transthyretin amyloid cardiomyopathy, survival, left ventricular remodeling, autonomic fluctuation, behavioral monitoring.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/">HRV-CV: A Digital Biomarker for Age, Sex, and Behavior 11/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251130_000359.mp3" length="3829176" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like digital biomarker and wild-type amyloid. Key takeaway: HRV-CV: A Digital Biomarker for Age, Sex, and Behavior.
Article Links:
Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (European journal of heart failure)
Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (European journal of heart failure)
Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. (European heart journal. Cardiovascular Imaging)
Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. (American journal of physiology. Heart and circulatory physiology)
Article 5: Mid- and Late-term Left Ventricular Diastolic Function After the Ross Procedure. (Pediatric cardiology)
Full episode page: https://podcast.explainheart.com/podcast/hrv-cv-a-digital-biomarker-for-age-sex-and-behavior-11-30-25/
 Featured Articles
Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317156
Summary: Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.
Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41317156
Summary: Tafamidis has significantly advanced the treatment paradigm for transthyretin amyloid cardiomyopathy, as demonstrated by results from a phase three randomized controlled trial. However, comprehensive real-world data detailing its use remain limited. A critical need exists to understand the clinical phenotype of patients receiving tafamidis for wild-type transthyretin amyloid cardiomyopathy and its association with survival outside of controlled trial settings. This gap highlights the importance of observational data for characterizing outcomes in diverse patient populations.
Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling.
Journal: European heart journal. Cardiovascular Imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41299774
Summary: The left atrioventricular ratio, defined as the ratio of maximal Left Atrial End-Systolic Volume to Left Ventricular End-Diastolic Volume, provides valuable context for cardiac remodeling assessment. This echocardiography-based measure aids in distinguishing between physiological and pathological cardiac changes. It addresses the critical need to consider the interdependence of left atrial and left ventricular remodeling, a relationship often overlooked in standard clinical practice.
Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41309064
Summary: The heart rate variability coeff]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 30, 2025. This episode summarizes 5 key cardiology studies on topics like digital biomarker and wild-type amyloid. Key takeaway: HRV-CV: A Digital Biomarker for Age, Sex, and Behavior.
Article Links:
Article 1: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (European journal of heart failure)
Article 2: Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (European journal of heart failure)
Article 3: Left atrioventricular ratio (LA:LV): Using left ventricular size as the reference for identifying maladaptive left atrial remodelling. (European heart journal. Cardiovascular Imaging)
Article 4: Heart Rate Variability Coefficient of Variation During Sleep as a Digital Biomarker That Reflects Behavior and Varies by Age and Sex. (American journal of physiology. Heart and circulator]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Pediatric Kidney Transplant: 69% Rehospitalized within Year. 11/29/25</title>
	<link>https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/</link>
	<pubDate>Sat, 29 Nov 2025 11:01:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 29, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Ejection Fraction and British Columbia. Key takeaway: Pediatric Kidney Transplant: 69% Rehospitalized within Year..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41314615">Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294083">Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41314586">Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41314365">Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41314304">Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/">https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314615</a></p>
<p><strong>Summary:</strong> This study found that 29 percent of incident pediatric kidney transplant recipients experienced rehospitalization within the first 30 days post-transplant. Furthermore, over two-thirds of children, specifically 69 percent, were rehospitalized within the first year following their transplant procedure. These findings highlight a high burden of early rehospitalizations in pediatric kidney transplant patients, underscoring the need for improved post-transplant care strategies.</p>
<h4>Article 2: Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294083" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294083</a></p>
<p><strong>Summary:</strong> This study evaluated a noninvasive, volume-based parameter for Right Ventricular-Pulmonary Arterial coupling in a cohort of 92 pediatric and 105 adult patients with repaired Tetralogy of Fallot. Right Ventricular-Pulmonary Arterial coupling quantifies right ventricular contractility in relation to its afterload, a crucial measure traditionally requiring high-fidelity catheter-derived pressure-volume loops. The investigation explored this noninvasive parameter&#8217;s utility in assessing ventricular function in this patient population, addressing the need for less invasive evaluation methods compared to traditional approaches.</p>
<h4>Article 3: Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314586" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314586</a></p>
<p><strong>Summary:</strong> This multicenter cohort study identified pre-procedural predictors of Left Ventricular Ejection Fraction response following atrial fibrillation ablation in patients with Left Ventricular Systolic Dysfunction. The study included patients with atrial fibrillation and a Left Ventricular Ejection Fraction less than 50 percent who underwent an index ablation procedure. The study developed the P. A. C. E. D. Score to pragmatically stratify patients for Left Ventricular Ejection Fraction response after ablation. Catheter ablation for atrial fibrillation improves outcomes in patients with Left Ventricular Systolic Dysfunction, making prediction of Left Ventricular Ejection Fraction response clinically valuable.</p>
<h4>Article 4: Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314365" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314365</a></p>
<p><strong>Summary:</strong> This study obtained 18 years of population-based health and driving data from British Columbia, Canada, for drivers who underwent implantable cardioverter-defibrillator implantation. Researchers estimated drivers&#8217; monthly road exposure relative to baseline to understand its influence on motor vehicle crash risk interpretation. This investigation highlights how transient reductions in driving after implantable cardioverter-defibrillator implantation can significantly affect the reported crash risk, necessitating careful consideration in risk assessment.</p>
<h4>Article 5: Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314304" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314304</a></p>
<p><strong>Summary:</strong> This study prospectively evaluated 501 asymptomatic stage A heart failure patients and 4767 asymptomatic stage B heart failure patients, with a mean age of 67.6 years, 71.1 percent of whom were male. It examined the association of Body Mass Index with ten-year outcomes in these early stage heart failure patients. The research addressed a gap in understanding the prognostic importance of Body Mass Index in asymptomatic heart failure, a topic where previous studies largely focused on stage C and D heart failure patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure. This study found that 29 percent of incident pediatric kidney transplant recipients experienced rehospitalization within the first 30 days post-transplant. Furthermore, over two-thirds of children, specifically 69 percent, were rehospitalized within the first year following their transplant procedure. These findings highlight a high burden of early rehospitalizations in pediatric kidney transplant patients, underscoring the need for improved post-transplant care strategies.</p>
<p>Article number two. Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging. This study evaluated a noninvasive, volume-based parameter for Right Ventricular-Pulmonary Arterial coupling in a cohort of 92 pediatric and 105 adult patients with repaired Tetralogy of Fallot. Right Ventricular-Pulmonary Arterial coupling quantifies right ventricular contractility in relation to its afterload, a crucial measure traditionally requiring high-fidelity catheter-derived pressure-volume loops. The investigation explored this noninvasive parameter&#8217;s utility in assessing ventricular function in this patient population, addressing the need for less invasive evaluation methods compared to traditional approaches.</p>
<p>Article number three. Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score. This multicenter cohort study identified pre-procedural predictors of Left Ventricular Ejection Fraction response following atrial fibrillation ablation in patients with Left Ventricular Systolic Dysfunction. The study included patients with atrial fibrillation and a Left Ventricular Ejection Fraction less than 50 percent who underwent an index ablation procedure. The study developed the P. A. C. E. D. Score to pragmatically stratify patients for Left Ventricular Ejection Fraction response after ablation. Catheter ablation for atrial fibrillation improves outcomes in patients with Left Ventricular Systolic Dysfunction, making prediction of Left Ventricular Ejection Fraction response clinically valuable.</p>
<p>Article number four. Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks. This study obtained 18 years of population-based health and driving data from British Columbia, Canada, for drivers who underwent implantable cardioverter-defibrillator implantation. Researchers estimated drivers&#8217; monthly road exposure relative to baseline to understand its influence on motor vehicle crash risk interpretation. This investigation highlights how transient reductions in driving after implantable cardioverter-defibrillator implantation can significantly affect the reported crash risk, necessitating careful consideration in risk assessment.</p>
<p>Article number five. Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study. This study prospectively evaluated 501 asymptomatic stage A heart failure patients and 4767 asymptomatic stage B heart failure patients, with a mean age of 67.6 years, 71.1 percent of whom were male. It examined the association of Body Mass Index with ten-year outcomes in these early stage heart failure patients. The research addressed a gap in understanding the prognostic importance of Body Mass Index in asymptomatic heart failure, a topic where previous studies largely focused on stage C and D heart failure patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Left Ventricular Ejection Fraction, British Columbia, driving risk, heart failure, magnetic resonance imaging, P. A. C. E. D. Score, prognosis, road exposure, Right Ventricular-Pulmonary Arterial coupling, atrial fibrillation ablation, pulmonary regurgitation, pediatric kidney transplant, Tetralogy of Fallot, implantable cardioverter-defibrillator, Body Mass Index, asymptomatic heart failure, allograft failure, kidney function, clinical predictors, rehospitalization, right ventricular outflow tract obstruction, CHART-2 study, motor vehicle crash, Left Ventricular Systolic Dysfunction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/">Pediatric Kidney Transplant: 69% Rehospitalized within Year. 11/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 29, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Ejection Fraction and British Columbia. Key takeaway: Pediatric Kidney Transplant: 69% Rehospitalized within Year..]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 29, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Ejection Fraction and British Columbia. Key takeaway: Pediatric Kidney Transplant: 69% Rehospitalized within Year..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41314615">Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294083">Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41314586">Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41314365">Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41314304">Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/">https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314615</a></p>
<p><strong>Summary:</strong> This study found that 29 percent of incident pediatric kidney transplant recipients experienced rehospitalization within the first 30 days post-transplant. Furthermore, over two-thirds of children, specifically 69 percent, were rehospitalized within the first year following their transplant procedure. These findings highlight a high burden of early rehospitalizations in pediatric kidney transplant patients, underscoring the need for improved post-transplant care strategies.</p>
<h4>Article 2: Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294083" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294083</a></p>
<p><strong>Summary:</strong> This study evaluated a noninvasive, volume-based parameter for Right Ventricular-Pulmonary Arterial coupling in a cohort of 92 pediatric and 105 adult patients with repaired Tetralogy of Fallot. Right Ventricular-Pulmonary Arterial coupling quantifies right ventricular contractility in relation to its afterload, a crucial measure traditionally requiring high-fidelity catheter-derived pressure-volume loops. The investigation explored this noninvasive parameter&#8217;s utility in assessing ventricular function in this patient population, addressing the need for less invasive evaluation methods compared to traditional approaches.</p>
<h4>Article 3: Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314586" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314586</a></p>
<p><strong>Summary:</strong> This multicenter cohort study identified pre-procedural predictors of Left Ventricular Ejection Fraction response following atrial fibrillation ablation in patients with Left Ventricular Systolic Dysfunction. The study included patients with atrial fibrillation and a Left Ventricular Ejection Fraction less than 50 percent who underwent an index ablation procedure. The study developed the P. A. C. E. D. Score to pragmatically stratify patients for Left Ventricular Ejection Fraction response after ablation. Catheter ablation for atrial fibrillation improves outcomes in patients with Left Ventricular Systolic Dysfunction, making prediction of Left Ventricular Ejection Fraction response clinically valuable.</p>
<h4>Article 4: Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314365" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314365</a></p>
<p><strong>Summary:</strong> This study obtained 18 years of population-based health and driving data from British Columbia, Canada, for drivers who underwent implantable cardioverter-defibrillator implantation. Researchers estimated drivers&#8217; monthly road exposure relative to baseline to understand its influence on motor vehicle crash risk interpretation. This investigation highlights how transient reductions in driving after implantable cardioverter-defibrillator implantation can significantly affect the reported crash risk, necessitating careful consideration in risk assessment.</p>
<h4>Article 5: Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41314304" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41314304</a></p>
<p><strong>Summary:</strong> This study prospectively evaluated 501 asymptomatic stage A heart failure patients and 4767 asymptomatic stage B heart failure patients, with a mean age of 67.6 years, 71.1 percent of whom were male. It examined the association of Body Mass Index with ten-year outcomes in these early stage heart failure patients. The research addressed a gap in understanding the prognostic importance of Body Mass Index in asymptomatic heart failure, a topic where previous studies largely focused on stage C and D heart failure patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure. This study found that 29 percent of incident pediatric kidney transplant recipients experienced rehospitalization within the first 30 days post-transplant. Furthermore, over two-thirds of children, specifically 69 percent, were rehospitalized within the first year following their transplant procedure. These findings highlight a high burden of early rehospitalizations in pediatric kidney transplant patients, underscoring the need for improved post-transplant care strategies.</p>
<p>Article number two. Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging. This study evaluated a noninvasive, volume-based parameter for Right Ventricular-Pulmonary Arterial coupling in a cohort of 92 pediatric and 105 adult patients with repaired Tetralogy of Fallot. Right Ventricular-Pulmonary Arterial coupling quantifies right ventricular contractility in relation to its afterload, a crucial measure traditionally requiring high-fidelity catheter-derived pressure-volume loops. The investigation explored this noninvasive parameter&#8217;s utility in assessing ventricular function in this patient population, addressing the need for less invasive evaluation methods compared to traditional approaches.</p>
<p>Article number three. Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score. This multicenter cohort study identified pre-procedural predictors of Left Ventricular Ejection Fraction response following atrial fibrillation ablation in patients with Left Ventricular Systolic Dysfunction. The study included patients with atrial fibrillation and a Left Ventricular Ejection Fraction less than 50 percent who underwent an index ablation procedure. The study developed the P. A. C. E. D. Score to pragmatically stratify patients for Left Ventricular Ejection Fraction response after ablation. Catheter ablation for atrial fibrillation improves outcomes in patients with Left Ventricular Systolic Dysfunction, making prediction of Left Ventricular Ejection Fraction response clinically valuable.</p>
<p>Article number four. Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks. This study obtained 18 years of population-based health and driving data from British Columbia, Canada, for drivers who underwent implantable cardioverter-defibrillator implantation. Researchers estimated drivers&#8217; monthly road exposure relative to baseline to understand its influence on motor vehicle crash risk interpretation. This investigation highlights how transient reductions in driving after implantable cardioverter-defibrillator implantation can significantly affect the reported crash risk, necessitating careful consideration in risk assessment.</p>
<p>Article number five. Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study. This study prospectively evaluated 501 asymptomatic stage A heart failure patients and 4767 asymptomatic stage B heart failure patients, with a mean age of 67.6 years, 71.1 percent of whom were male. It examined the association of Body Mass Index with ten-year outcomes in these early stage heart failure patients. The research addressed a gap in understanding the prognostic importance of Body Mass Index in asymptomatic heart failure, a topic where previous studies largely focused on stage C and D heart failure patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Left Ventricular Ejection Fraction, British Columbia, driving risk, heart failure, magnetic resonance imaging, P. A. C. E. D. Score, prognosis, road exposure, Right Ventricular-Pulmonary Arterial coupling, atrial fibrillation ablation, pulmonary regurgitation, pediatric kidney transplant, Tetralogy of Fallot, implantable cardioverter-defibrillator, Body Mass Index, asymptomatic heart failure, allograft failure, kidney function, clinical predictors, rehospitalization, right ventricular outflow tract obstruction, CHART-2 study, motor vehicle crash, Left Ventricular Systolic Dysfunction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/">Pediatric Kidney Transplant: 69% Rehospitalized within Year. 11/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251129_060032.mp3" length="4137212" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 29, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Ejection Fraction and British Columbia. Key takeaway: Pediatric Kidney Transplant: 69% Rehospitalized within Year..
Article Links:
Article 1: Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging. (Journal of the American Heart Association)
Article 3: Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score. (Heart rhythm)
Article 4: Road exposure after cardioverter-defibrillator implantation and its potential influence on reported motor vehicle crash risks. (The American journal of cardiology)
Article 5: Association of Body Mass Index with ten-year outcomes in asymptomatic stage a/B heart failure patients: Insights from the CHART-2 study. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/pediatric-kidney-transplant-69-rehospitalized-within-year-11-29-25/
 Featured Articles
Article 1: Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41314615
Summary: This study found that 29 percent of incident pediatric kidney transplant recipients experienced rehospitalization within the first 30 days post-transplant. Furthermore, over two-thirds of children, specifically 69 percent, were rehospitalized within the first year following their transplant procedure. These findings highlight a high burden of early rehospitalizations in pediatric kidney transplant patients, underscoring the need for improved post-transplant care strategies.
Article 2: Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294083
Summary: This study evaluated a noninvasive, volume-based parameter for Right Ventricular-Pulmonary Arterial coupling in a cohort of 92 pediatric and 105 adult patients with repaired Tetralogy of Fallot. Right Ventricular-Pulmonary Arterial coupling quantifies right ventricular contractility in relation to its afterload, a crucial measure traditionally requiring high-fidelity catheter-derived pressure-volume loops. The investigation explored this noninvasive parameter&#8217;s utility in assessing ventricular function in this patient population, addressing the need for less invasive evaluation methods compared to traditional approaches.
Article 3: Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41314586
Summary: This multicenter cohort study identified pre-procedural predictors of Left Ventricular Ejection Fraction response following atrial fibrillation ablation in patients with Left Ventricular Systolic Dysfunction. The study included patients with atrial fibrillation and a Left Ventricular Ejection Fraction less than 50 percent who underwent an index ablation procedure. The study developed the P. A. C. E. D. Score to pragmatically stratify patients for Left Ventricular Ejection Fraction response after ablation. Catheter ablation for atrial fibrillation improves outcomes ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 29, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Ejection Fraction and British Columbia. Key takeaway: Pediatric Kidney Transplant: 69% Rehospitalized within Year..
Article Links:
Article 1: Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year post-transplant and long-term allograft failure. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Noninvasive Assessment of Right Ventricular-Pulmonary Arterial Coupling in Repaired Tetralogy of Fallot by Magnetic Resonance Imaging. (Journal of the American Heart Association)
Article 3: Left Ventricular Ejection Fraction Response After Atrial Fibrillation Ablation: Clinical Predictors and Development of the PACED Score. (Heart rhythm)
Article 4: Road exposure after cardioverter-defibrillator implanta]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Epigenetic Aging Predicts Cardiovascular Disease 11/28/25</title>
	<link>https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/</link>
	<pubDate>Sat, 29 Nov 2025 04:55:58 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and aspirin dosing. Key takeaway: Epigenetic Aging Predicts Cardiovascular Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41294102">Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294095">DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294093">Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294090">Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294084">Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/">https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294102" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294102</a></p>
<p><strong>Summary:</strong> The study compared clinical profiles and biventricular remodeling in patients with pulmonary hypertension residing at high altitudes (2500 meters or greater) versus low altitudes. It revealed distinct patterns of cardiac adaptation and disease progression influenced by hypobaric hypoxia. Understanding these specific altitude-related differences is crucial for developing tailored management strategies. This research provides a foundation for improving outcomes for pulmonary hypertension patients in diverse geographical environments.</p>
<h4>Article 2: DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294095" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294095</a></p>
<p><strong>Summary:</strong> N. A. Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. This prospective cohort study systematically compared 13 D. N. A. methylation algorithms to assess their relation to incident cardiovascular disease risk in 2112 older adults over a 6-year follow-up. The research clarified the differential utility of various D. N. A. methylation-based aging algorithms in predicting cardiovascular disease. This comparison provides important insights into the most effective epigenetic biomarkers for risk stratification. These findings support the integration of advanced aging algorithms into cardiovascular disease prediction models for older adults.</p>
<h4>Article 3: Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294093" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294093</a></p>
<p><strong>Summary:</strong> The ADAPTABLE trial provided specific evidence on the effectiveness and safety of two different aspirin doses for secondary prevention of atherosclerotic cardiovascular disease in patients with chronic obstructive pulmonary disease or asthma. This research demonstrates how optimal antiplatelet therapy differs for individuals with co-existing respiratory conditions, who carry increased cardiovascular risk. The findings inform tailored clinical decisions on aspirin dosing for secondary prevention. This study contributes to refining guideline recommendations for complex cardiovascular patient profiles.</p>
<h4>Article 4: Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294090" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294090</a></p>
<p><strong>Summary:</strong> This study investigated the association between caregiver intergenerational socioeconomic mobility and cardiovascular health in both Hispanic/Latino youth and their caregivers. The research identified specific patterns in how socioeconomic background across generations influences cardiovascular health outcomes in this population. It further determined whether these associations are modified by youth&#8217;s sex and age, providing detailed insights into risk factors. Understanding these intergenerational and socioeconomic determinants is crucial for developing targeted public health interventions to improve cardiovascular health in Hispanic/Latino communities.</p>
<h4>Article 5: Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294084" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294084</a></p>
<p><strong>Summary:</strong> This study described serial changes in liver function and their relationship with clinical outcomes in adult Fontan patients from 2014 to 2020. The research identified specific trends in liver enzymes and alpha-fetoprotein over time, demonstrating their utility in predicting adverse clinical outcomes. These findings provide crucial insights into the progression of Fontan-associated liver disease and its impact on long-term survival. Understanding these predictive markers is essential for early intervention and improved management strategies for this complex patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study. The study compared clinical profiles and biventricular remodeling in patients with pulmonary hypertension residing at high altitudes (2500 meters or greater) versus low altitudes. It revealed distinct patterns of cardiac adaptation and disease progression influenced by hypobaric hypoxia. Understanding these specific altitude-related differences is crucial for developing tailored management strategies. This research provides a foundation for improving outcomes for pulmonary hypertension patients in diverse geographical environments.</p>
<p>Article number two. D. N. A. Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. This prospective cohort study systematically compared 13 D. N. A. methylation algorithms to assess their relation to incident cardiovascular disease risk in 2112 older adults over a 6-year follow-up. The research clarified the differential utility of various D. N. A. methylation-based aging algorithms in predicting cardiovascular disease. This comparison provides important insights into the most effective epigenetic biomarkers for risk stratification. These findings support the integration of advanced aging algorithms into cardiovascular disease prediction models for older adults.</p>
<p>Article number three. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE. The ADAPTABLE trial provided specific evidence on the effectiveness and safety of two different aspirin doses for secondary prevention of atherosclerotic cardiovascular disease in patients with chronic obstructive pulmonary disease or asthma. This research demonstrates how optimal antiplatelet therapy differs for individuals with co-existing respiratory conditions, who carry increased cardiovascular risk. The findings inform tailored clinical decisions on aspirin dosing for secondary prevention. This study contributes to refining guideline recommendations for complex cardiovascular patient profiles.</p>
<p>Article number four. Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States. This study investigated the association between caregiver intergenerational socioeconomic mobility and cardiovascular health in both Hispanic/Latino youth and their caregivers. The research identified specific patterns in how socioeconomic background across generations influences cardiovascular health outcomes in this population. It further determined whether these associations are modified by youth&#8217;s sex and age, providing detailed insights into risk factors. Understanding these intergenerational and socioeconomic determinants is crucial for developing targeted public health interventions to improve cardiovascular health in Hispanic/Latino communities.</p>
<p>Article number five. Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes. This study described serial changes in liver function and their relationship with clinical outcomes in adult Fontan patients from 2014 to 2020. The research identified specific trends in liver enzymes and alpha-fetoprotein over time, demonstrating their utility in predicting adverse clinical outcomes. These findings provide crucial insights into the progression of Fontan-associated liver disease and its impact on long-term survival. Understanding these predictive markers is essential for early intervention and improved management strategies for this complex patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular disease, aspirin dosing, hypobaric hypoxia, asthma, youth health, socioeconomic mobility, aging algorithms, atherosclerotic cardiovascular disease, secondary prevention, chronic obstructive pulmonary disease, Hispanic/Latino, health disparities, adverse clinical outcomes, D. N. A. methylation, single ventricle palliation, Fontan circulation, pulmonary hypertension, risk prediction, cardiovascular health, high altitude, biventricular remodeling, liver function, Fontan-associated liver disease, cardiovascular magnetic resonance imaging, epigenetic biomarkers.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/">Epigenetic Aging Predicts Cardiovascular Disease 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and aspirin dosing. Key takeaway: Epigenetic Aging Predicts Cardiovascular Disease.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and aspirin dosing. Key takeaway: Epigenetic Aging Predicts Cardiovascular Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41294102">Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294095">DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294093">Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294090">Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294084">Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/">https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294102" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294102</a></p>
<p><strong>Summary:</strong> The study compared clinical profiles and biventricular remodeling in patients with pulmonary hypertension residing at high altitudes (2500 meters or greater) versus low altitudes. It revealed distinct patterns of cardiac adaptation and disease progression influenced by hypobaric hypoxia. Understanding these specific altitude-related differences is crucial for developing tailored management strategies. This research provides a foundation for improving outcomes for pulmonary hypertension patients in diverse geographical environments.</p>
<h4>Article 2: DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294095" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294095</a></p>
<p><strong>Summary:</strong> N. A. Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. This prospective cohort study systematically compared 13 D. N. A. methylation algorithms to assess their relation to incident cardiovascular disease risk in 2112 older adults over a 6-year follow-up. The research clarified the differential utility of various D. N. A. methylation-based aging algorithms in predicting cardiovascular disease. This comparison provides important insights into the most effective epigenetic biomarkers for risk stratification. These findings support the integration of advanced aging algorithms into cardiovascular disease prediction models for older adults.</p>
<h4>Article 3: Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294093" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294093</a></p>
<p><strong>Summary:</strong> The ADAPTABLE trial provided specific evidence on the effectiveness and safety of two different aspirin doses for secondary prevention of atherosclerotic cardiovascular disease in patients with chronic obstructive pulmonary disease or asthma. This research demonstrates how optimal antiplatelet therapy differs for individuals with co-existing respiratory conditions, who carry increased cardiovascular risk. The findings inform tailored clinical decisions on aspirin dosing for secondary prevention. This study contributes to refining guideline recommendations for complex cardiovascular patient profiles.</p>
<h4>Article 4: Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294090" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294090</a></p>
<p><strong>Summary:</strong> This study investigated the association between caregiver intergenerational socioeconomic mobility and cardiovascular health in both Hispanic/Latino youth and their caregivers. The research identified specific patterns in how socioeconomic background across generations influences cardiovascular health outcomes in this population. It further determined whether these associations are modified by youth&#8217;s sex and age, providing detailed insights into risk factors. Understanding these intergenerational and socioeconomic determinants is crucial for developing targeted public health interventions to improve cardiovascular health in Hispanic/Latino communities.</p>
<h4>Article 5: Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294084" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294084</a></p>
<p><strong>Summary:</strong> This study described serial changes in liver function and their relationship with clinical outcomes in adult Fontan patients from 2014 to 2020. The research identified specific trends in liver enzymes and alpha-fetoprotein over time, demonstrating their utility in predicting adverse clinical outcomes. These findings provide crucial insights into the progression of Fontan-associated liver disease and its impact on long-term survival. Understanding these predictive markers is essential for early intervention and improved management strategies for this complex patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study. The study compared clinical profiles and biventricular remodeling in patients with pulmonary hypertension residing at high altitudes (2500 meters or greater) versus low altitudes. It revealed distinct patterns of cardiac adaptation and disease progression influenced by hypobaric hypoxia. Understanding these specific altitude-related differences is crucial for developing tailored management strategies. This research provides a foundation for improving outcomes for pulmonary hypertension patients in diverse geographical environments.</p>
<p>Article number two. D. N. A. Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. This prospective cohort study systematically compared 13 D. N. A. methylation algorithms to assess their relation to incident cardiovascular disease risk in 2112 older adults over a 6-year follow-up. The research clarified the differential utility of various D. N. A. methylation-based aging algorithms in predicting cardiovascular disease. This comparison provides important insights into the most effective epigenetic biomarkers for risk stratification. These findings support the integration of advanced aging algorithms into cardiovascular disease prediction models for older adults.</p>
<p>Article number three. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE. The ADAPTABLE trial provided specific evidence on the effectiveness and safety of two different aspirin doses for secondary prevention of atherosclerotic cardiovascular disease in patients with chronic obstructive pulmonary disease or asthma. This research demonstrates how optimal antiplatelet therapy differs for individuals with co-existing respiratory conditions, who carry increased cardiovascular risk. The findings inform tailored clinical decisions on aspirin dosing for secondary prevention. This study contributes to refining guideline recommendations for complex cardiovascular patient profiles.</p>
<p>Article number four. Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States. This study investigated the association between caregiver intergenerational socioeconomic mobility and cardiovascular health in both Hispanic/Latino youth and their caregivers. The research identified specific patterns in how socioeconomic background across generations influences cardiovascular health outcomes in this population. It further determined whether these associations are modified by youth&#8217;s sex and age, providing detailed insights into risk factors. Understanding these intergenerational and socioeconomic determinants is crucial for developing targeted public health interventions to improve cardiovascular health in Hispanic/Latino communities.</p>
<p>Article number five. Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes. This study described serial changes in liver function and their relationship with clinical outcomes in adult Fontan patients from 2014 to 2020. The research identified specific trends in liver enzymes and alpha-fetoprotein over time, demonstrating their utility in predicting adverse clinical outcomes. These findings provide crucial insights into the progression of Fontan-associated liver disease and its impact on long-term survival. Understanding these predictive markers is essential for early intervention and improved management strategies for this complex patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular disease, aspirin dosing, hypobaric hypoxia, asthma, youth health, socioeconomic mobility, aging algorithms, atherosclerotic cardiovascular disease, secondary prevention, chronic obstructive pulmonary disease, Hispanic/Latino, health disparities, adverse clinical outcomes, D. N. A. methylation, single ventricle palliation, Fontan circulation, pulmonary hypertension, risk prediction, cardiovascular health, high altitude, biventricular remodeling, liver function, Fontan-associated liver disease, cardiovascular magnetic resonance imaging, epigenetic biomarkers.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/">Epigenetic Aging Predicts Cardiovascular Disease 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251128_235446.mp3" length="4170648" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and aspirin dosing. Key takeaway: Epigenetic Aging Predicts Cardiovascular Disease.
Article Links:
Article 1: Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study. (Journal of the American Heart Association)
Article 2: DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. (Journal of the American Heart Association)
Article 3: Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE. (Journal of the American Heart Association)
Article 4: Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States. (Journal of the American Heart Association)
Article 5: Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/epigenetic-aging-predicts-cardiovascular-disease-11-28-25/
 Featured Articles
Article 1: Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294102
Summary: The study compared clinical profiles and biventricular remodeling in patients with pulmonary hypertension residing at high altitudes (2500 meters or greater) versus low altitudes. It revealed distinct patterns of cardiac adaptation and disease progression influenced by hypobaric hypoxia. Understanding these specific altitude-related differences is crucial for developing tailored management strategies. This research provides a foundation for improving outcomes for pulmonary hypertension patients in diverse geographical environments.
Article 2: DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294095
Summary: N. A. Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. This prospective cohort study systematically compared 13 D. N. A. methylation algorithms to assess their relation to incident cardiovascular disease risk in 2112 older adults over a 6-year follow-up. The research clarified the differential utility of various D. N. A. methylation-based aging algorithms in predicting cardiovascular disease. This comparison provides important insights into the most effective epigenetic biomarkers for risk stratification. These findings support the integration of advanced aging algorithms into cardiovascular disease prediction models for older adults.
Article 3: Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294093
Summary: The ADAPTABLE trial provided specific evidence on the effectiveness and safety of two different aspirin doses for secondary prevention of atherosclerotic cardiovascular disease in patients with chronic obstructive pulmonary disease or asthma. This research demonstrates how optimal antiplatelet therapy differs for individuals with co-existing respiratory conditions, who carry increased cardiovascular risk. The findings inform tailored clinical decisions on aspirin dosing for secondary prevention. This study contributes to refining guideline recommendations for complex cardiovascular patient profiles.
Article 4: Intergenerational Socioeconomic Mobility and Ca]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and aspirin dosing. Key takeaway: Epigenetic Aging Predicts Cardiovascular Disease.
Article Links:
Article 1: Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study. (Journal of the American Heart Association)
Article 2: DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study. (Journal of the American Heart Association)
Article 3: Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE. (Journal of the American Heart Association)
Article 4: Intergenerational Socioeconomic Mobility and Cardiovascular Health Among Hispanic/Latino Youth and Caregivers Living in the United States. (Journal of th]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cardiac Amyloidosis Survival Up Over Time. 11/28/25</title>
	<link>https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/</link>
	<pubDate>Fri, 28 Nov 2025 23:10:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity troponin T and atherosclerotic cardiovascular disease. Key takeaway: Cardiac Amyloidosis Survival Up Over Time..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41312852">A polygenic risk score for peripheral artery disease and major adverse limb events.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294135">Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294120">Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294118">Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294107">Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/">https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A polygenic risk score for peripheral artery disease and major adverse limb events.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41312852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41312852</a></p>
<p><strong>Summary:</strong> Large-scale genome-wide association studies identified common genetic variants that predict peripheral artery disease risk. This study assessed a specific polygenic risk score for its association with peripheral artery disease and major adverse limb events, independent of other clinical risk factors. The research involved a genetic analysis using individual patient data pooled from six Thrombolysis in Myocardial Infarction trials. This approach demonstrates the method for integrating genetic predisposition into risk stratification for limb-related cardiovascular outcomes.</p>
<h4>Article 2: Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294135</a></p>
<p><strong>Summary:</strong> Small RNA sequencing of human urinary extracellular vesicles revealed an association between a high-sodium diet and renal proinflammatory pathways. This study demonstrated that high sodium intake is linked to mechanisms beyond hemodynamic changes, including endothelial dysfunction and oxidative stress. Researchers observed the induction of a proinflammatory milieu in the kidneys. The findings highlight how dietary sodium modulation impacts renal pathophysiology at a molecular level in normotensive subjects.</p>
<h4>Article 3: Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294120" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294120</a></p>
<p><strong>Summary:</strong> This study established the diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune-checkpoint inhibitor therapy. Immune-checkpoint inhibitors are known to be associated with adverse cardiac events, with troponin elevation already a diagnostic criterion for immune-checkpoint inhibitor-related myocarditis and myocardial infarction. The research documented additional causes of troponin elevation and their observed outcomes, including cardiac death and heart failure, in these patients. This comprehensive analysis clarified the clinical utility of high-sensitivity troponin T measurements across a broad spectrum of cardiac issues in this specific patient group.</p>
<h4>Article 4: Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294118</a></p>
<p><strong>Summary:</strong> This Veterans Health Administration study found a significant association between monoclonal gammopathy of undetermined significance and incident cardiovascular disease risk. Monoclonal gammopathy of undetermined significance was already known to be associated with an increased cardiovascular disease risk. The research demonstrated that monoclonal gammopathy of undetermined significance status provided additional prognostic information beyond traditional atherosclerotic cardiovascular disease risk calculation. This finding highlights the crucial role of considering monoclonal gammopathy of undetermined significance in comprehensive cardiovascular risk assessment.</p>
<h4>Article 5: Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294107" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294107</a></p>
<p><strong>Summary:</strong> Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments improving morbidity and mortality. This multicenter study revealed significant changes in baseline characteristics and survival patterns for transthyretin cardiac amyloidosis patients in the United States. The research demonstrated improved mortality outcomes when comparing distinct eras: pre-2010, 2010-2013, 2014-2017, and 2018-2021. These findings highlight the positive impact of diagnostic and therapeutic advancements on patient prognosis over time.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A polygenic risk score for peripheral artery disease and major adverse limb events. Large-scale genome-wide association studies identified common genetic variants that predict peripheral artery disease risk. This study assessed a specific polygenic risk score for its association with peripheral artery disease and major adverse limb events, independent of other clinical risk factors. The research involved a genetic analysis using individual patient data pooled from six Thrombolysis in Myocardial Infarction trials. This approach demonstrates the method for integrating genetic predisposition into risk stratification for limb-related cardiovascular outcomes.</p>
<p>Article number two. Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways. Small RNA sequencing of human urinary extracellular vesicles revealed an association between a high-sodium diet and renal proinflammatory pathways. This study demonstrated that high sodium intake is linked to mechanisms beyond hemodynamic changes, including endothelial dysfunction and oxidative stress. Researchers observed the induction of a proinflammatory milieu in the kidneys. The findings highlight how dietary sodium modulation impacts renal pathophysiology at a molecular level in normotensive subjects.</p>
<p>Article number three. Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. This study established the diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune-checkpoint inhibitor therapy. Immune-checkpoint inhibitors are known to be associated with adverse cardiac events, with troponin elevation already a diagnostic criterion for immune-checkpoint inhibitor-related myocarditis and myocardial infarction. The research documented additional causes of troponin elevation and their observed outcomes, including cardiac death and heart failure, in these patients. This comprehensive analysis clarified the clinical utility of high-sensitivity troponin T measurements across a broad spectrum of cardiac issues in this specific patient group.</p>
<p>Article number four. Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study. This Veterans Health Administration study found a significant association between monoclonal gammopathy of undetermined significance and incident cardiovascular disease risk. Monoclonal gammopathy of undetermined significance was already known to be associated with an increased cardiovascular disease risk. The research demonstrated that monoclonal gammopathy of undetermined significance status provided additional prognostic information beyond traditional atherosclerotic cardiovascular disease risk calculation. This finding highlights the crucial role of considering monoclonal gammopathy of undetermined significance in comprehensive cardiovascular risk assessment.</p>
<p>Article number five. Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study. Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments improving morbidity and mortality. This multicenter study revealed significant changes in baseline characteristics and survival patterns for transthyretin cardiac amyloidosis patients in the United States. The research demonstrated improved mortality outcomes when comparing distinct eras: pre-2010, 2010-2013, 2014-2017, and 2018-2021. These findings highlight the positive impact of diagnostic and therapeutic advancements on patient prognosis over time. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-sensitivity troponin T, atherosclerotic cardiovascular disease, cardiometabolic disease, endothelial dysfunction, peripheral artery disease, renal inflammation, heart failure, myocarditis, genetic variants, cardiovascular disease, survival trends, prognostic value, high sodium intake, immune-checkpoint inhibitors, extracellular vesicles, small RNA sequencing, diagnostic patterns, cardiac death, major adverse limb events, noninvasive diagnosis, risk assessment, polygenic risk score, monoclonal gammopathy of undetermined significance, transthyretin cardiac amyloidosis, heart failure therapies.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/">Cardiac Amyloidosis Survival Up Over Time. 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity troponin T and atherosclerotic cardiovascular disease. Key takeaway: Cardiac Amyloidosis Survival Up Over Time..
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity troponin T and atherosclerotic cardiovascular disease. Key takeaway: Cardiac Amyloidosis Survival Up Over Time..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41312852">A polygenic risk score for peripheral artery disease and major adverse limb events.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294135">Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294120">Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294118">Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294107">Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/">https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A polygenic risk score for peripheral artery disease and major adverse limb events.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41312852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41312852</a></p>
<p><strong>Summary:</strong> Large-scale genome-wide association studies identified common genetic variants that predict peripheral artery disease risk. This study assessed a specific polygenic risk score for its association with peripheral artery disease and major adverse limb events, independent of other clinical risk factors. The research involved a genetic analysis using individual patient data pooled from six Thrombolysis in Myocardial Infarction trials. This approach demonstrates the method for integrating genetic predisposition into risk stratification for limb-related cardiovascular outcomes.</p>
<h4>Article 2: Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294135</a></p>
<p><strong>Summary:</strong> Small RNA sequencing of human urinary extracellular vesicles revealed an association between a high-sodium diet and renal proinflammatory pathways. This study demonstrated that high sodium intake is linked to mechanisms beyond hemodynamic changes, including endothelial dysfunction and oxidative stress. Researchers observed the induction of a proinflammatory milieu in the kidneys. The findings highlight how dietary sodium modulation impacts renal pathophysiology at a molecular level in normotensive subjects.</p>
<h4>Article 3: Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294120" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294120</a></p>
<p><strong>Summary:</strong> This study established the diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune-checkpoint inhibitor therapy. Immune-checkpoint inhibitors are known to be associated with adverse cardiac events, with troponin elevation already a diagnostic criterion for immune-checkpoint inhibitor-related myocarditis and myocardial infarction. The research documented additional causes of troponin elevation and their observed outcomes, including cardiac death and heart failure, in these patients. This comprehensive analysis clarified the clinical utility of high-sensitivity troponin T measurements across a broad spectrum of cardiac issues in this specific patient group.</p>
<h4>Article 4: Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294118</a></p>
<p><strong>Summary:</strong> This Veterans Health Administration study found a significant association between monoclonal gammopathy of undetermined significance and incident cardiovascular disease risk. Monoclonal gammopathy of undetermined significance was already known to be associated with an increased cardiovascular disease risk. The research demonstrated that monoclonal gammopathy of undetermined significance status provided additional prognostic information beyond traditional atherosclerotic cardiovascular disease risk calculation. This finding highlights the crucial role of considering monoclonal gammopathy of undetermined significance in comprehensive cardiovascular risk assessment.</p>
<h4>Article 5: Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294107" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294107</a></p>
<p><strong>Summary:</strong> Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments improving morbidity and mortality. This multicenter study revealed significant changes in baseline characteristics and survival patterns for transthyretin cardiac amyloidosis patients in the United States. The research demonstrated improved mortality outcomes when comparing distinct eras: pre-2010, 2010-2013, 2014-2017, and 2018-2021. These findings highlight the positive impact of diagnostic and therapeutic advancements on patient prognosis over time.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A polygenic risk score for peripheral artery disease and major adverse limb events. Large-scale genome-wide association studies identified common genetic variants that predict peripheral artery disease risk. This study assessed a specific polygenic risk score for its association with peripheral artery disease and major adverse limb events, independent of other clinical risk factors. The research involved a genetic analysis using individual patient data pooled from six Thrombolysis in Myocardial Infarction trials. This approach demonstrates the method for integrating genetic predisposition into risk stratification for limb-related cardiovascular outcomes.</p>
<p>Article number two. Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways. Small RNA sequencing of human urinary extracellular vesicles revealed an association between a high-sodium diet and renal proinflammatory pathways. This study demonstrated that high sodium intake is linked to mechanisms beyond hemodynamic changes, including endothelial dysfunction and oxidative stress. Researchers observed the induction of a proinflammatory milieu in the kidneys. The findings highlight how dietary sodium modulation impacts renal pathophysiology at a molecular level in normotensive subjects.</p>
<p>Article number three. Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. This study established the diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune-checkpoint inhibitor therapy. Immune-checkpoint inhibitors are known to be associated with adverse cardiac events, with troponin elevation already a diagnostic criterion for immune-checkpoint inhibitor-related myocarditis and myocardial infarction. The research documented additional causes of troponin elevation and their observed outcomes, including cardiac death and heart failure, in these patients. This comprehensive analysis clarified the clinical utility of high-sensitivity troponin T measurements across a broad spectrum of cardiac issues in this specific patient group.</p>
<p>Article number four. Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study. This Veterans Health Administration study found a significant association between monoclonal gammopathy of undetermined significance and incident cardiovascular disease risk. Monoclonal gammopathy of undetermined significance was already known to be associated with an increased cardiovascular disease risk. The research demonstrated that monoclonal gammopathy of undetermined significance status provided additional prognostic information beyond traditional atherosclerotic cardiovascular disease risk calculation. This finding highlights the crucial role of considering monoclonal gammopathy of undetermined significance in comprehensive cardiovascular risk assessment.</p>
<p>Article number five. Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study. Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments improving morbidity and mortality. This multicenter study revealed significant changes in baseline characteristics and survival patterns for transthyretin cardiac amyloidosis patients in the United States. The research demonstrated improved mortality outcomes when comparing distinct eras: pre-2010, 2010-2013, 2014-2017, and 2018-2021. These findings highlight the positive impact of diagnostic and therapeutic advancements on patient prognosis over time. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-sensitivity troponin T, atherosclerotic cardiovascular disease, cardiometabolic disease, endothelial dysfunction, peripheral artery disease, renal inflammation, heart failure, myocarditis, genetic variants, cardiovascular disease, survival trends, prognostic value, high sodium intake, immune-checkpoint inhibitors, extracellular vesicles, small RNA sequencing, diagnostic patterns, cardiac death, major adverse limb events, noninvasive diagnosis, risk assessment, polygenic risk score, monoclonal gammopathy of undetermined significance, transthyretin cardiac amyloidosis, heart failure therapies.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/">Cardiac Amyloidosis Survival Up Over Time. 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251128_180918.mp3" length="4270541" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity troponin T and atherosclerotic cardiovascular disease. Key takeaway: Cardiac Amyloidosis Survival Up Over Time..
Article Links:
Article 1: A polygenic risk score for peripheral artery disease and major adverse limb events. (European heart journal)
Article 2: Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways. (Journal of the American Heart Association)
Article 3: Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. (Journal of the American Heart Association)
Article 4: Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study. (Journal of the American Heart Association)
Article 5: Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/cardiac-amyloidosis-survival-up-over-time-11-28-25/
 Featured Articles
Article 1: A polygenic risk score for peripheral artery disease and major adverse limb events.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41312852
Summary: Large-scale genome-wide association studies identified common genetic variants that predict peripheral artery disease risk. This study assessed a specific polygenic risk score for its association with peripheral artery disease and major adverse limb events, independent of other clinical risk factors. The research involved a genetic analysis using individual patient data pooled from six Thrombolysis in Myocardial Infarction trials. This approach demonstrates the method for integrating genetic predisposition into risk stratification for limb-related cardiovascular outcomes.
Article 2: Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294135
Summary: Small RNA sequencing of human urinary extracellular vesicles revealed an association between a high-sodium diet and renal proinflammatory pathways. This study demonstrated that high sodium intake is linked to mechanisms beyond hemodynamic changes, including endothelial dysfunction and oxidative stress. Researchers observed the induction of a proinflammatory milieu in the kidneys. The findings highlight how dietary sodium modulation impacts renal pathophysiology at a molecular level in normotensive subjects.
Article 3: Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294120
Summary: This study established the diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune-checkpoint inhibitor therapy. Immune-checkpoint inhibitors are known to be associated with adverse cardiac events, with troponin elevation already a diagnostic criterion for immune-checkpoint inhibitor-related myocarditis and myocardial infarction. The research documented additional causes of troponin elevation and their observed outcomes, including cardiac death and heart failure, in these patients. This comprehensive analysis clarified the clinical utility of high-sensitivity troponin T measurements across a broad spectrum of cardiac issues in this specific patient group.
Article 4: Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.
Journal: Journal]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity troponin T and atherosclerotic cardiovascular disease. Key takeaway: Cardiac Amyloidosis Survival Up Over Time..
Article Links:
Article 1: A polygenic risk score for peripheral artery disease and major adverse limb events. (European heart journal)
Article 2: Small RNA Sequencing of Human Urinary Extracellular Vesicles Reveals Association of High-Sodium Diet With Renal Proinflammatory Pathways. (Journal of the American Heart Association)
Article 3: Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. (Journal of the American Heart Association)
Article 4: Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study. (Journal of the American Heart Association)
Article 5: Chan]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aspirin Elimination Safe for HeartMate 3 LVADs 11/28/25</title>
	<link>https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/</link>
	<pubDate>Fri, 28 Nov 2025 11:01:19 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like Atherosclerosis and Proinflammatory cytokines. Key takeaway: Aspirin Elimination Safe for HeartMate 3 LVADs.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41308860">Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294143">Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294142">Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294140">Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294139">Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/">https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41308860" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41308860</a></p>
<p><strong>Summary:</strong> The ARIES-HM3 trial confirmed the safety and effectiveness of aspirin elimination from the antithrombotic regimen following HeartMate 3 Left Ventricular Assist Device implantation. This specific analysis determined the interaction of atrial fibrillation, diabetes mellitus, and obesity with aspirin elimination regarding hemocompatibility-related adverse events at one year post-implant. The trial randomized patients with a HeartMate 3 Left Ventricular Assist Device to receive aspirin or placebo. This investigation informs personalized antithrombotic management for patients with these common comorbidities.</p>
<h4>Article 2: Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294143" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294143</a></p>
<p><strong>Summary:</strong> Immune checkpoint inhibitors are associated with a three-fold risk of atherosclerotic cardiovascular disease. This single-center retrospective study demonstrated factors associated with atherosclerotic cardiovascular disease in women following immune checkpoint inhibitor therapy. The investigation also characterized plaque progression specifically among women with cancer receiving these treatments.</p>
<h4>Article 3: Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294142" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294142</a></p>
<p><strong>Summary:</strong> The loss of endothelial Yes Associated Protein 1 and WW Domain Containing Transcription Regulator 1 reduced the size of chronic stroke lesions and altered the endothelial environment. This study revealed that brain endothelial cells play a critical role in determining stroke outcomes. The findings indicate a potential therapeutic target for ischemic stroke, a leading cause of morbidity and mortality.</p>
<h4>Article 4: Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294140" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294140</a></p>
<p><strong>Summary:</strong> Plasma from patients with severe aortic stenosis had a detrimental effect on valvular endothelial cells. This effect included inducing oxidative stress and contributing to valvular endothelial cell dysfunction. Proinflammatory cytokines, such as interleukin and tumor necrosis factor alpha, along with Factor Xa, were found to mediate these harmful processes. The study identified key plasma components contributing to aortic stenosis progression.</p>
<h4>Article 5: Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294139" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294139</a></p>
<p><strong>Summary:</strong> Intracellular osteopontin within macrophages promotes carotid plaque formation by inducing foam cell formation and releasing proinflammatory cytokines. Single cell R. N. A. sequencing of human carotid plaques identified major cell types and a key cell cluster involved in plaque development. In vitro experiments further confirmed the role of osteopontin in macrophages in this process.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial. The ARIES-HM3 trial confirmed the safety and effectiveness of aspirin elimination from the antithrombotic regimen following HeartMate 3 Left Ventricular Assist Device implantation. This specific analysis determined the interaction of atrial fibrillation, diabetes mellitus, and obesity with aspirin elimination regarding hemocompatibility-related adverse events at one year post-implant. The trial randomized patients with a HeartMate 3 Left Ventricular Assist Device to receive aspirin or placebo. This investigation informs personalized antithrombotic management for patients with these common comorbidities.</p>
<p>Article number two. Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. Immune checkpoint inhibitors are associated with a three-fold risk of atherosclerotic cardiovascular disease. This single-center retrospective study demonstrated factors associated with atherosclerotic cardiovascular disease in women following immune checkpoint inhibitor therapy. The investigation also characterized plaque progression specifically among women with cancer receiving these treatments.</p>
<p>Article number three. Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment. The loss of endothelial Yes Associated Protein 1 and WW Domain Containing Transcription Regulator 1 reduced the size of chronic stroke lesions and altered the endothelial environment. This study revealed that brain endothelial cells play a critical role in determining stroke outcomes. The findings indicate a potential therapeutic target for ischemic stroke, a leading cause of morbidity and mortality.</p>
<p>Article number four. Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa. Plasma from patients with severe aortic stenosis had a detrimental effect on valvular endothelial cells. This effect included inducing oxidative stress and contributing to valvular endothelial cell dysfunction. Proinflammatory cytokines, such as interleukin and tumor necrosis factor alpha, along with Factor Xa, were found to mediate these harmful processes. The study identified key plasma components contributing to aortic stenosis progression.</p>
<p>Article number five. Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines. Intracellular osteopontin within macrophages promotes carotid plaque formation by inducing foam cell formation and releasing proinflammatory cytokines. Single cell R. N. A. sequencing of human carotid plaques identified major cell types and a key cell cluster involved in plaque development. In vitro experiments further confirmed the role of osteopontin in macrophages in this process. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Atherosclerosis, Proinflammatory cytokines, Cancer, Factor Xa, Endothelial cells, Women, Yes Associated Protein 1, Stroke lesions, Diabetes mellitus, Immune Checkpoint Inhibitors, Atherosclerotic cardiovascular disease, Aortic stenosis, Aspirin elimination, Plaque progression, Carotid plaque, Oxidative stress, Ischemic stroke, WW Domain Containing Transcription Regulator 1, Antithrombotic regimen, Osteopontin, Atrial fibrillation, Valvular endothelial cells, Macrophages, Foam cells, Left Ventricular Assist Device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/">Aspirin Elimination Safe for HeartMate 3 LVADs 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like Atherosclerosis and Proinflammatory cytokines. Key takeaway: Aspirin Elimination Safe for HeartMate 3 LVADs.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like Atherosclerosis and Proinflammatory cytokines. Key takeaway: Aspirin Elimination Safe for HeartMate 3 LVADs.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41308860">Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial.</a> (Journal of cardiac failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41294143">Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294142">Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294140">Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294139">Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/">https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41308860" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41308860</a></p>
<p><strong>Summary:</strong> The ARIES-HM3 trial confirmed the safety and effectiveness of aspirin elimination from the antithrombotic regimen following HeartMate 3 Left Ventricular Assist Device implantation. This specific analysis determined the interaction of atrial fibrillation, diabetes mellitus, and obesity with aspirin elimination regarding hemocompatibility-related adverse events at one year post-implant. The trial randomized patients with a HeartMate 3 Left Ventricular Assist Device to receive aspirin or placebo. This investigation informs personalized antithrombotic management for patients with these common comorbidities.</p>
<h4>Article 2: Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294143" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294143</a></p>
<p><strong>Summary:</strong> Immune checkpoint inhibitors are associated with a three-fold risk of atherosclerotic cardiovascular disease. This single-center retrospective study demonstrated factors associated with atherosclerotic cardiovascular disease in women following immune checkpoint inhibitor therapy. The investigation also characterized plaque progression specifically among women with cancer receiving these treatments.</p>
<h4>Article 3: Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294142" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294142</a></p>
<p><strong>Summary:</strong> The loss of endothelial Yes Associated Protein 1 and WW Domain Containing Transcription Regulator 1 reduced the size of chronic stroke lesions and altered the endothelial environment. This study revealed that brain endothelial cells play a critical role in determining stroke outcomes. The findings indicate a potential therapeutic target for ischemic stroke, a leading cause of morbidity and mortality.</p>
<h4>Article 4: Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294140" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294140</a></p>
<p><strong>Summary:</strong> Plasma from patients with severe aortic stenosis had a detrimental effect on valvular endothelial cells. This effect included inducing oxidative stress and contributing to valvular endothelial cell dysfunction. Proinflammatory cytokines, such as interleukin and tumor necrosis factor alpha, along with Factor Xa, were found to mediate these harmful processes. The study identified key plasma components contributing to aortic stenosis progression.</p>
<h4>Article 5: Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294139" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294139</a></p>
<p><strong>Summary:</strong> Intracellular osteopontin within macrophages promotes carotid plaque formation by inducing foam cell formation and releasing proinflammatory cytokines. Single cell R. N. A. sequencing of human carotid plaques identified major cell types and a key cell cluster involved in plaque development. In vitro experiments further confirmed the role of osteopontin in macrophages in this process.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial. The ARIES-HM3 trial confirmed the safety and effectiveness of aspirin elimination from the antithrombotic regimen following HeartMate 3 Left Ventricular Assist Device implantation. This specific analysis determined the interaction of atrial fibrillation, diabetes mellitus, and obesity with aspirin elimination regarding hemocompatibility-related adverse events at one year post-implant. The trial randomized patients with a HeartMate 3 Left Ventricular Assist Device to receive aspirin or placebo. This investigation informs personalized antithrombotic management for patients with these common comorbidities.</p>
<p>Article number two. Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. Immune checkpoint inhibitors are associated with a three-fold risk of atherosclerotic cardiovascular disease. This single-center retrospective study demonstrated factors associated with atherosclerotic cardiovascular disease in women following immune checkpoint inhibitor therapy. The investigation also characterized plaque progression specifically among women with cancer receiving these treatments.</p>
<p>Article number three. Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment. The loss of endothelial Yes Associated Protein 1 and WW Domain Containing Transcription Regulator 1 reduced the size of chronic stroke lesions and altered the endothelial environment. This study revealed that brain endothelial cells play a critical role in determining stroke outcomes. The findings indicate a potential therapeutic target for ischemic stroke, a leading cause of morbidity and mortality.</p>
<p>Article number four. Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa. Plasma from patients with severe aortic stenosis had a detrimental effect on valvular endothelial cells. This effect included inducing oxidative stress and contributing to valvular endothelial cell dysfunction. Proinflammatory cytokines, such as interleukin and tumor necrosis factor alpha, along with Factor Xa, were found to mediate these harmful processes. The study identified key plasma components contributing to aortic stenosis progression.</p>
<p>Article number five. Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines. Intracellular osteopontin within macrophages promotes carotid plaque formation by inducing foam cell formation and releasing proinflammatory cytokines. Single cell R. N. A. sequencing of human carotid plaques identified major cell types and a key cell cluster involved in plaque development. In vitro experiments further confirmed the role of osteopontin in macrophages in this process. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Atherosclerosis, Proinflammatory cytokines, Cancer, Factor Xa, Endothelial cells, Women, Yes Associated Protein 1, Stroke lesions, Diabetes mellitus, Immune Checkpoint Inhibitors, Atherosclerotic cardiovascular disease, Aortic stenosis, Aspirin elimination, Plaque progression, Carotid plaque, Oxidative stress, Ischemic stroke, WW Domain Containing Transcription Regulator 1, Antithrombotic regimen, Osteopontin, Atrial fibrillation, Valvular endothelial cells, Macrophages, Foam cells, Left Ventricular Assist Device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/">Aspirin Elimination Safe for HeartMate 3 LVADs 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251128_060030.mp3" length="3604732" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like Atherosclerosis and Proinflammatory cytokines. Key takeaway: Aspirin Elimination Safe for HeartMate 3 LVADs.
Article Links:
Article 1: Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial. (Journal of cardiac failure)
Article 2: Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. (Journal of the American Heart Association)
Article 3: Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment. (Journal of the American Heart Association)
Article 4: Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa. (Journal of the American Heart Association)
Article 5: Intracellular Osteopontin of Macrophages Promotes Carotid Plaques Formation by Inducing Foam Cells and Releasing Proinflammatory Cytokines. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-elimination-safe-for-heartmate-3-lvads-11-28-25/
 Featured Articles
Article 1: Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41308860
Summary: The ARIES-HM3 trial confirmed the safety and effectiveness of aspirin elimination from the antithrombotic regimen following HeartMate 3 Left Ventricular Assist Device implantation. This specific analysis determined the interaction of atrial fibrillation, diabetes mellitus, and obesity with aspirin elimination regarding hemocompatibility-related adverse events at one year post-implant. The trial randomized patients with a HeartMate 3 Left Ventricular Assist Device to receive aspirin or placebo. This investigation informs personalized antithrombotic management for patients with these common comorbidities.
Article 2: Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294143
Summary: Immune checkpoint inhibitors are associated with a three-fold risk of atherosclerotic cardiovascular disease. This single-center retrospective study demonstrated factors associated with atherosclerotic cardiovascular disease in women following immune checkpoint inhibitor therapy. The investigation also characterized plaque progression specifically among women with cancer receiving these treatments.
Article 3: Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294142
Summary: The loss of endothelial Yes Associated Protein 1 and WW Domain Containing Transcription Regulator 1 reduced the size of chronic stroke lesions and altered the endothelial environment. This study revealed that brain endothelial cells play a critical role in determining stroke outcomes. The findings indicate a potential therapeutic target for ischemic stroke, a leading cause of morbidity and mortality.
Article 4: Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294140
Summary: Plasma from patients with severe aortic stenosis had a detrimental effect on valvular endothelial cells. This effect included inducing oxidative stress and contributin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like Atherosclerosis and Proinflammatory cytokines. Key takeaway: Aspirin Elimination Safe for HeartMate 3 LVADs.
Article Links:
Article 1: Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial. (Journal of cardiac failure)
Article 2: Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. (Journal of the American Heart Association)
Article 3: Loss of Endothelial YAP/TAZ Reduces the Size of Chronic Stroke Lesions and Alters the Endothelial Environment. (Journal of the American Heart Association)
Article 4: Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa. (Journal of the Am]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cell-Free DNA Predicts LVAD Outcomes 11/28/25</title>
	<link>https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/</link>
	<pubDate>Fri, 28 Nov 2025 06:13:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like abdominal aortic aneurysm and diabetic cardiomyopathy. Key takeaway: Cell-Free DNA Predicts LVAD Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41307910">Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41307146">Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294148">Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294147">Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294146">C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/">https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41307910" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41307910</a></p>
<p><strong>Summary:</strong> This study demonstrated that neutrophil extracellular traps (NETs) and peptidylarginine deiminase 4 (PAD4)-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. Endomyocardial biopsies from heart failure patients showed the presence of NETs, indicating their role in human disease pathology. Research involving wild-type and PAD4-deficient mice further elucidated this connection in diabetic cardiomyopathy and kidney disease. This establishes a critical mechanistic link between diabetes and its severe cardiovascular and renal complications.</p>
<h4>Article 2: Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41307146" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41307146</a></p>
<p><strong>Summary:</strong> This study demonstrated that plasma cell-free DNA (cfDNA) accurately profiles end-organ injury and predicts outcomes in patients with advanced heart failure receiving left ventricular assist device (LVAD) implantation. The research identified cfDNA as a valuable biomarker for risk stratification following LVAD placement. It analyzed a multicenter prospective cohort of heart failure patients, including those with and without LVADs, to establish this predictive capability. This finding offers a novel approach to assess adverse events and improve risk management in this patient population.</p>
<h4>Article 3: Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294148" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294148</a></p>
<p><strong>Summary:</strong> This study found that immune cell type-specific DNA methylation regions associate with 24-hour blood pressure regulation in Black people. Researchers established this connection by employing advanced deconvolution algorithms to analyze reduced representation bisulfite sequencing data. The study identified specific epigenetic markers within immune cells that play a role in blood pressure control. These findings highlight a novel mechanism linking immune cell epigenetics to hypertension risk within this specific population.</p>
<h4>Article 4: Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294147</a></p>
<p><strong>Summary:</strong> This study revealed stage-dependent vascular and neural transcriptomic pathways leading to inflammation and cognitive dysfunction in a rat model of hypertension. Researchers identified specific molecular and cellular mechanisms occurring at different stages of hypertension progression. The findings indicate distinct inflammatory and neural changes contributing to cerebral microvascular dysfunction and increased dementia risk. This research provides crucial insights into the complex pathogenesis of hypertension-related cognitive decline.</p>
<h4>Article 5: C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294146" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294146</a></p>
<p><strong>Summary:</strong> This study found that C-C chemokine receptor 4 (CCR4) deficiency protects against abdominal aortic aneurysm (AAA) formation. Researchers observed this protective effect in hypercholesterolemic CCR4-deficient mice. The findings suggest that CCR4, predominantly expressed on T cells, plays a critical role in the dysregulated immune system driving chronic vascular inflammation and remodeling in AAA pathogenesis. This establishes CCR4 as a potential therapeutic target for preventing or treating abdominal aortic aneurysm.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. This study demonstrated that neutrophil extracellular traps (NETs) and peptidylarginine deiminase 4 (PAD4)-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. Endomyocardial biopsies from heart failure patients showed the presence of NETs, indicating their role in human disease pathology. Research involving wild-type and PAD4-deficient mice further elucidated this connection in diabetic cardiomyopathy and kidney disease. This establishes a critical mechanistic link between diabetes and its severe cardiovascular and renal complications.</p>
<p>Article number two. Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation. This study demonstrated that plasma cell-free DNA (cfDNA) accurately profiles end-organ injury and predicts outcomes in patients with advanced heart failure receiving left ventricular assist device (LVAD) implantation. The research identified cfDNA as a valuable biomarker for risk stratification following LVAD placement. It analyzed a multicenter prospective cohort of heart failure patients, including those with and without LVADs, to establish this predictive capability. This finding offers a novel approach to assess adverse events and improve risk management in this patient population.</p>
<p>Article number three. Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People. This study found that immune cell type-specific DNA methylation regions associate with 24-hour blood pressure regulation in Black people. Researchers established this connection by employing advanced deconvolution algorithms to analyze reduced representation bisulfite sequencing data. The study identified specific epigenetic markers within immune cells that play a role in blood pressure control. These findings highlight a novel mechanism linking immune cell epigenetics to hypertension risk within this specific population.</p>
<p>Article number four. Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension. This study revealed stage-dependent vascular and neural transcriptomic pathways leading to inflammation and cognitive dysfunction in a rat model of hypertension. Researchers identified specific molecular and cellular mechanisms occurring at different stages of hypertension progression. The findings indicate distinct inflammatory and neural changes contributing to cerebral microvascular dysfunction and increased dementia risk. This research provides crucial insights into the complex pathogenesis of hypertension-related cognitive decline.</p>
<p>Article number five. C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation. This study found that C-C chemokine receptor 4 (CCR4) deficiency protects against abdominal aortic aneurysm (AAA) formation. Researchers observed this protective effect in hypercholesterolemic CCR4-deficient mice. The findings suggest that CCR4, predominantly expressed on T cells, plays a critical role in the dysregulated immune system driving chronic vascular inflammation and remodeling in AAA pathogenesis. This establishes CCR4 as a potential therapeutic target for preventing or treating abdominal aortic aneurysm. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>abdominal aortic aneurysm, diabetic cardiomyopathy, immune cells, cardiorenal injury, Black people, neutrophil extracellular traps, hypertension, immune system, DNA methylation, neural transcriptomics, inflammation, blood pressure regulation, T cells, vascular transcriptomics, heart failure, vascular inflammation, peptidylarginine deiminase 4, biomarker, left ventricular assist device, cognitive dysfunction, end-organ injury, cell-free DNA, C-C chemokine receptor 4.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/">Cell-Free DNA Predicts LVAD Outcomes 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like abdominal aortic aneurysm and diabetic cardiomyopathy. Key takeaway: Cell-Free DNA Predicts LVAD Outcomes.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like abdominal aortic aneurysm and diabetic cardiomyopathy. Key takeaway: Cell-Free DNA Predicts LVAD Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41307910">Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41307146">Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41294148">Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41294147">Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41294146">C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/">https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41307910" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41307910</a></p>
<p><strong>Summary:</strong> This study demonstrated that neutrophil extracellular traps (NETs) and peptidylarginine deiminase 4 (PAD4)-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. Endomyocardial biopsies from heart failure patients showed the presence of NETs, indicating their role in human disease pathology. Research involving wild-type and PAD4-deficient mice further elucidated this connection in diabetic cardiomyopathy and kidney disease. This establishes a critical mechanistic link between diabetes and its severe cardiovascular and renal complications.</p>
<h4>Article 2: Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41307146" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41307146</a></p>
<p><strong>Summary:</strong> This study demonstrated that plasma cell-free DNA (cfDNA) accurately profiles end-organ injury and predicts outcomes in patients with advanced heart failure receiving left ventricular assist device (LVAD) implantation. The research identified cfDNA as a valuable biomarker for risk stratification following LVAD placement. It analyzed a multicenter prospective cohort of heart failure patients, including those with and without LVADs, to establish this predictive capability. This finding offers a novel approach to assess adverse events and improve risk management in this patient population.</p>
<h4>Article 3: Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294148" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294148</a></p>
<p><strong>Summary:</strong> This study found that immune cell type-specific DNA methylation regions associate with 24-hour blood pressure regulation in Black people. Researchers established this connection by employing advanced deconvolution algorithms to analyze reduced representation bisulfite sequencing data. The study identified specific epigenetic markers within immune cells that play a role in blood pressure control. These findings highlight a novel mechanism linking immune cell epigenetics to hypertension risk within this specific population.</p>
<h4>Article 4: Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294147</a></p>
<p><strong>Summary:</strong> This study revealed stage-dependent vascular and neural transcriptomic pathways leading to inflammation and cognitive dysfunction in a rat model of hypertension. Researchers identified specific molecular and cellular mechanisms occurring at different stages of hypertension progression. The findings indicate distinct inflammatory and neural changes contributing to cerebral microvascular dysfunction and increased dementia risk. This research provides crucial insights into the complex pathogenesis of hypertension-related cognitive decline.</p>
<h4>Article 5: C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41294146" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41294146</a></p>
<p><strong>Summary:</strong> This study found that C-C chemokine receptor 4 (CCR4) deficiency protects against abdominal aortic aneurysm (AAA) formation. Researchers observed this protective effect in hypercholesterolemic CCR4-deficient mice. The findings suggest that CCR4, predominantly expressed on T cells, plays a critical role in the dysregulated immune system driving chronic vascular inflammation and remodeling in AAA pathogenesis. This establishes CCR4 as a potential therapeutic target for preventing or treating abdominal aortic aneurysm.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. This study demonstrated that neutrophil extracellular traps (NETs) and peptidylarginine deiminase 4 (PAD4)-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. Endomyocardial biopsies from heart failure patients showed the presence of NETs, indicating their role in human disease pathology. Research involving wild-type and PAD4-deficient mice further elucidated this connection in diabetic cardiomyopathy and kidney disease. This establishes a critical mechanistic link between diabetes and its severe cardiovascular and renal complications.</p>
<p>Article number two. Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation. This study demonstrated that plasma cell-free DNA (cfDNA) accurately profiles end-organ injury and predicts outcomes in patients with advanced heart failure receiving left ventricular assist device (LVAD) implantation. The research identified cfDNA as a valuable biomarker for risk stratification following LVAD placement. It analyzed a multicenter prospective cohort of heart failure patients, including those with and without LVADs, to establish this predictive capability. This finding offers a novel approach to assess adverse events and improve risk management in this patient population.</p>
<p>Article number three. Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People. This study found that immune cell type-specific DNA methylation regions associate with 24-hour blood pressure regulation in Black people. Researchers established this connection by employing advanced deconvolution algorithms to analyze reduced representation bisulfite sequencing data. The study identified specific epigenetic markers within immune cells that play a role in blood pressure control. These findings highlight a novel mechanism linking immune cell epigenetics to hypertension risk within this specific population.</p>
<p>Article number four. Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension. This study revealed stage-dependent vascular and neural transcriptomic pathways leading to inflammation and cognitive dysfunction in a rat model of hypertension. Researchers identified specific molecular and cellular mechanisms occurring at different stages of hypertension progression. The findings indicate distinct inflammatory and neural changes contributing to cerebral microvascular dysfunction and increased dementia risk. This research provides crucial insights into the complex pathogenesis of hypertension-related cognitive decline.</p>
<p>Article number five. C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation. This study found that C-C chemokine receptor 4 (CCR4) deficiency protects against abdominal aortic aneurysm (AAA) formation. Researchers observed this protective effect in hypercholesterolemic CCR4-deficient mice. The findings suggest that CCR4, predominantly expressed on T cells, plays a critical role in the dysregulated immune system driving chronic vascular inflammation and remodeling in AAA pathogenesis. This establishes CCR4 as a potential therapeutic target for preventing or treating abdominal aortic aneurysm. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>abdominal aortic aneurysm, diabetic cardiomyopathy, immune cells, cardiorenal injury, Black people, neutrophil extracellular traps, hypertension, immune system, DNA methylation, neural transcriptomics, inflammation, blood pressure regulation, T cells, vascular transcriptomics, heart failure, vascular inflammation, peptidylarginine deiminase 4, biomarker, left ventricular assist device, cognitive dysfunction, end-organ injury, cell-free DNA, C-C chemokine receptor 4.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/">Cell-Free DNA Predicts LVAD Outcomes 11/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251128_011236.mp3" length="4386733" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like abdominal aortic aneurysm and diabetic cardiomyopathy. Key takeaway: Cell-Free DNA Predicts LVAD Outcomes.
Article Links:
Article 1: Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. (European heart journal)
Article 2: Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation. (Circulation. Heart failure)
Article 3: Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People. (Journal of the American Heart Association)
Article 4: Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension. (Journal of the American Heart Association)
Article 5: C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/cell-free-dna-predicts-lvad-outcomes-11-28-25/
 Featured Articles
Article 1: Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41307910
Summary: This study demonstrated that neutrophil extracellular traps (NETs) and peptidylarginine deiminase 4 (PAD4)-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. Endomyocardial biopsies from heart failure patients showed the presence of NETs, indicating their role in human disease pathology. Research involving wild-type and PAD4-deficient mice further elucidated this connection in diabetic cardiomyopathy and kidney disease. This establishes a critical mechanistic link between diabetes and its severe cardiovascular and renal complications.
Article 2: Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41307146
Summary: This study demonstrated that plasma cell-free DNA (cfDNA) accurately profiles end-organ injury and predicts outcomes in patients with advanced heart failure receiving left ventricular assist device (LVAD) implantation. The research identified cfDNA as a valuable biomarker for risk stratification following LVAD placement. It analyzed a multicenter prospective cohort of heart failure patients, including those with and without LVADs, to establish this predictive capability. This finding offers a novel approach to assess adverse events and improve risk management in this patient population.
Article 3: Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294148
Summary: This study found that immune cell type-specific DNA methylation regions associate with 24-hour blood pressure regulation in Black people. Researchers established this connection by employing advanced deconvolution algorithms to analyze reduced representation bisulfite sequencing data. The study identified specific epigenetic markers within immune cells that play a role in blood pressure control. These findings highlight a novel mechanism linking immune cell epigenetics to hypertension risk within this specific population.
Article 4: Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41294147
Summary: This study revealed stage-dependent ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 28, 2025. This episode summarizes 5 key cardiology studies on topics like abdominal aortic aneurysm and diabetic cardiomyopathy. Key takeaway: Cell-Free DNA Predicts LVAD Outcomes.
Article Links:
Article 1: Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure. (European heart journal)
Article 2: Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation. (Circulation. Heart failure)
Article 3: Immune Cell Type-Specific DNA Methylation Regions Associate With 24-Hour Blood Pressure Regulation in Black People. (Journal of the American Heart Association)
Article 4: Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension. (Journal of the American Heart Association)
Article 5: C-C Chemok]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Tests Predict Heart Transplant Risk 11/27/25</title>
	<link>https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/</link>
	<pubDate>Thu, 27 Nov 2025 11:01:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 27, 2025. This episode summarizes 5 key cardiology studies on topics like Gene expression profiling and Graft survival. Key takeaway: New Tests Predict Heart Transplant Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41295934">Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41297735">Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41297734">Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41297733">Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41297732">Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/">https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41295934" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41295934</a></p>
<p><strong>Summary:</strong> The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.</p>
<h4>Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297735" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297735</a></p>
<p><strong>Summary:</strong> Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.</p>
<h4>Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297734" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297734</a></p>
<p><strong>Summary:</strong> The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.</p>
<h4>Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297733" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297733</a></p>
<p><strong>Summary:</strong> Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.</p>
<h4>Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297732" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297732</a></p>
<p><strong>Summary:</strong> This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.</p>
<p>Article number two. Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.</p>
<p>Article number three. Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.</p>
<p>Article number four. Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.</p>
<p>Article number five. Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Gene expression profiling, Graft survival, Donor-derived cell-free deoxyribonucleic acid, Long-term outcomes, Prognostic value, Diabetes, Allogeneic immunity, Donor-specific antibody, Retransplant, Pediatric heart transplant, Public health, Adult care transition, Cardiometabolic risk factors, Balloon pulmonary angioplasty, Macitentan, Chronic thromboembolic pulmonary hypertension, Electronic medical record, Pulmonary endarterectomy, National Health and Nutrition Examination Survey, Heart transplant, Graft dysfunction, Immunosuppression, Hypertension, Phase three trial, C D 8 positive T cells.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/">New Tests Predict Heart Transplant Risk 11/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 27, 2025. This episode summarizes 5 key cardiology studies on topics like Gene expression profiling and Graft survival. Key takeaway: New Tests Predict Heart Transplant Risk.
Article Links:
Article 1: Trend]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 27, 2025. This episode summarizes 5 key cardiology studies on topics like Gene expression profiling and Graft survival. Key takeaway: New Tests Predict Heart Transplant Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41295934">Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41297735">Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41297734">Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41297733">Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41297732">Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/">https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41295934" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41295934</a></p>
<p><strong>Summary:</strong> The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.</p>
<h4>Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297735" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297735</a></p>
<p><strong>Summary:</strong> Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.</p>
<h4>Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297734" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297734</a></p>
<p><strong>Summary:</strong> The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.</p>
<h4>Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297733" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297733</a></p>
<p><strong>Summary:</strong> Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.</p>
<h4>Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41297732" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41297732</a></p>
<p><strong>Summary:</strong> This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.</p>
<p>Article number two. Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.</p>
<p>Article number three. Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.</p>
<p>Article number four. Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.</p>
<p>Article number five. Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Gene expression profiling, Graft survival, Donor-derived cell-free deoxyribonucleic acid, Long-term outcomes, Prognostic value, Diabetes, Allogeneic immunity, Donor-specific antibody, Retransplant, Pediatric heart transplant, Public health, Adult care transition, Cardiometabolic risk factors, Balloon pulmonary angioplasty, Macitentan, Chronic thromboembolic pulmonary hypertension, Electronic medical record, Pulmonary endarterectomy, National Health and Nutrition Examination Survey, Heart transplant, Graft dysfunction, Immunosuppression, Hypertension, Phase three trial, C D 8 positive T cells.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/">New Tests Predict Heart Transplant Risk 11/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251127_060044.mp3" length="4377120" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 27, 2025. This episode summarizes 5 key cardiology studies on topics like Gene expression profiling and Graft survival. Key takeaway: New Tests Predict Heart Transplant Risk.
Article Links:
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. (Journal of the American College of Cardiology)
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/
 Featured Articles
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41295934
Summary: The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297735
Summary: Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297734
Summary: The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonar]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 27, 2025. This episode summarizes 5 key cardiology studies on topics like Gene expression profiling and Graft survival. Key takeaway: New Tests Predict Heart Transplant Risk.
Article Links:
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. (Journal of the American College of Cardiology)
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Enhancement of suppressive functi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Semaglutide Efficacy in H. F. pEF Across Age 11/26/25</title>
	<link>https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/</link>
	<pubDate>Wed, 26 Nov 2025 11:01:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac arrhythmias and incretin therapies. Key takeaway: Semaglutide Efficacy in H. F. pEF Across Age.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41290376">Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41289183">Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41290376">Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40972539">Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40916342">Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/">https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41290376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41290376</a></p>
<p><strong>Summary:</strong> Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<h4>Article 2: Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41289183" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41289183</a></p>
<p><strong>Summary:</strong> Atrial fibrillation is the most common arrhythmia observed in patients undergoing transcatheter aortic valve replacement. This study provided specific data to identify predictors for permanent pacemaker implantation in patients with pre-existing atrial fibrillation. It also investigated the association between permanent pacemaker implantation and long-term mortality in this patient group, addressing a critical knowledge gap in transcatheter aortic valve replacement outcomes.</p>
<h4>Article 3: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41290376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41290376</a></p>
<p><strong>Summary:</strong> Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<h4>Article 4: Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972539" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972539</a></p>
<p><strong>Summary:</strong> Novel echocardiographic indices of right ventricular myocardial work are valuable for evaluating pulmonary arterial hypertension. This study demonstrated that these right ventricular myocardial work indices predict haemodynamics and risk profile in patients with pulmonary arterial hypertension. The indices specifically identified patients at high risk for mortality and those with a worse haemodynamic profile, as confirmed by right heart catheterization.</p>
<h4>Article 5: Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40916342" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40916342</a></p>
<p><strong>Summary:</strong> Visual assessment has traditionally been the primary method for detecting obstructive coronary artery disease using stress perfusion cardiovascular magnetic resonance. This study investigated the diagnostic performance of fully automated quantitative myocardial blood flow assessment in patients with coronary chronic total occlusion. The research provided valuable data on cardiovascular magnetic resonance derived quantitative myocardial blood flow, addressing a knowledge gap in the evaluation of chronic coronary occlusions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<p>Article number two. Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation. Atrial fibrillation is the most common arrhythmia observed in patients undergoing transcatheter aortic valve replacement. This study provided specific data to identify predictors for permanent pacemaker implantation in patients with pre-existing atrial fibrillation. It also investigated the association between permanent pacemaker implantation and long-term mortality in this patient group, addressing a critical knowledge gap in transcatheter aortic valve replacement outcomes.</p>
<p>Article number three. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<p>Article number four. Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension. Novel echocardiographic indices of right ventricular myocardial work are valuable for evaluating pulmonary arterial hypertension. This study demonstrated that these right ventricular myocardial work indices predict haemodynamics and risk profile in patients with pulmonary arterial hypertension. The indices specifically identified patients at high risk for mortality and those with a worse haemodynamic profile, as confirmed by right heart catheterization.</p>
<p>Article number five. Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion. Visual assessment has traditionally been the primary method for detecting obstructive coronary artery disease using stress perfusion cardiovascular magnetic resonance. This study investigated the diagnostic performance of fully automated quantitative myocardial blood flow assessment in patients with coronary chronic total occlusion. The research provided valuable data on cardiovascular magnetic resonance derived quantitative myocardial blood flow, addressing a knowledge gap in the evaluation of chronic coronary occlusions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac arrhythmias, incretin therapies, right ventricular myocardial work, pulmonary arterial hypertension, obesity, cardiovascular magnetic resonance, long-term mortality, diagnostic performance, coronary artery disease, coronary chronic total occlusion, S. T. E. P. minus H. F. pEF trials, haemodynamics, myocardial blood flow, permanent pacemaker implantation, semaglutide, transcatheter aortic valve replacement, echocardiography, right heart catheterization, Heart Failure with Preserved Ejection Fraction, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/">Semaglutide Efficacy in H. F. pEF Across Age 11/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac arrhythmias and incretin therapies. Key takeaway: Semaglutide Efficacy in H. F. pEF Across Age.
Article Links:
Article 1: Ef]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac arrhythmias and incretin therapies. Key takeaway: Semaglutide Efficacy in H. F. pEF Across Age.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41290376">Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</a> (European journal of heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41289183">Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41290376">Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40972539">Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40916342">Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/">https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41290376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41290376</a></p>
<p><strong>Summary:</strong> Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<h4>Article 2: Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41289183" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41289183</a></p>
<p><strong>Summary:</strong> Atrial fibrillation is the most common arrhythmia observed in patients undergoing transcatheter aortic valve replacement. This study provided specific data to identify predictors for permanent pacemaker implantation in patients with pre-existing atrial fibrillation. It also investigated the association between permanent pacemaker implantation and long-term mortality in this patient group, addressing a critical knowledge gap in transcatheter aortic valve replacement outcomes.</p>
<h4>Article 3: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41290376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41290376</a></p>
<p><strong>Summary:</strong> Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<h4>Article 4: Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972539" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972539</a></p>
<p><strong>Summary:</strong> Novel echocardiographic indices of right ventricular myocardial work are valuable for evaluating pulmonary arterial hypertension. This study demonstrated that these right ventricular myocardial work indices predict haemodynamics and risk profile in patients with pulmonary arterial hypertension. The indices specifically identified patients at high risk for mortality and those with a worse haemodynamic profile, as confirmed by right heart catheterization.</p>
<h4>Article 5: Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40916342" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40916342</a></p>
<p><strong>Summary:</strong> Visual assessment has traditionally been the primary method for detecting obstructive coronary artery disease using stress perfusion cardiovascular magnetic resonance. This study investigated the diagnostic performance of fully automated quantitative myocardial blood flow assessment in patients with coronary chronic total occlusion. The research provided valuable data on cardiovascular magnetic resonance derived quantitative myocardial blood flow, addressing a knowledge gap in the evaluation of chronic coronary occlusions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<p>Article number two. Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation. Atrial fibrillation is the most common arrhythmia observed in patients undergoing transcatheter aortic valve replacement. This study provided specific data to identify predictors for permanent pacemaker implantation in patients with pre-existing atrial fibrillation. It also investigated the association between permanent pacemaker implantation and long-term mortality in this patient group, addressing a critical knowledge gap in transcatheter aortic valve replacement outcomes.</p>
<p>Article number three. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.</p>
<p>Article number four. Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension. Novel echocardiographic indices of right ventricular myocardial work are valuable for evaluating pulmonary arterial hypertension. This study demonstrated that these right ventricular myocardial work indices predict haemodynamics and risk profile in patients with pulmonary arterial hypertension. The indices specifically identified patients at high risk for mortality and those with a worse haemodynamic profile, as confirmed by right heart catheterization.</p>
<p>Article number five. Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion. Visual assessment has traditionally been the primary method for detecting obstructive coronary artery disease using stress perfusion cardiovascular magnetic resonance. This study investigated the diagnostic performance of fully automated quantitative myocardial blood flow assessment in patients with coronary chronic total occlusion. The research provided valuable data on cardiovascular magnetic resonance derived quantitative myocardial blood flow, addressing a knowledge gap in the evaluation of chronic coronary occlusions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac arrhythmias, incretin therapies, right ventricular myocardial work, pulmonary arterial hypertension, obesity, cardiovascular magnetic resonance, long-term mortality, diagnostic performance, coronary artery disease, coronary chronic total occlusion, S. T. E. P. minus H. F. pEF trials, haemodynamics, myocardial blood flow, permanent pacemaker implantation, semaglutide, transcatheter aortic valve replacement, echocardiography, right heart catheterization, Heart Failure with Preserved Ejection Fraction, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/">Semaglutide Efficacy in H. F. pEF Across Age 11/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251126_060049.mp3" length="3842550" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac arrhythmias and incretin therapies. Key takeaway: Semaglutide Efficacy in H. F. pEF Across Age.
Article Links:
Article 1: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. (European journal of heart failure)
Article 2: Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation. (Cardiology)
Article 3: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. (European journal of heart failure)
Article 4: Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension. (European heart journal. Cardiovascular Imaging)
Article 5: Value of cardiovascular magnetic resonance-derived quantitative myocardial blood flow assessment in the setting of chronic coronary occlusion. (European heart journal. Cardiovascular Imaging)
Full episode page: https://podcast.explainheart.com/podcast/semaglutide-efficacy-in-h-f-pef-across-age-11-26-25/
 Featured Articles
Article 1: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41290376
Summary: Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.
Article 2: Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41289183
Summary: Atrial fibrillation is the most common arrhythmia observed in patients undergoing transcatheter aortic valve replacement. This study provided specific data to identify predictors for permanent pacemaker implantation in patients with pre-existing atrial fibrillation. It also investigated the association between permanent pacemaker implantation and long-term mortality in this patient group, addressing a critical knowledge gap in transcatheter aortic valve replacement outcomes.
Article 3: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41290376
Summary: Semaglutide demonstrated efficacy in treating obesity-related Heart Failure with Preserved Ejection Fraction in the overall S. T. E. P. minus H. F. pEF trials. This pre-specified pooled subanalysis of the S. T. E. P. minus H. F. pEF program evaluated semaglutide&#8217;s effects across the age spectrum. The analysis provided important data addressing prior speculation that older patients might benefit less from incretin therapies, contributing to understanding its therapeutic application in diverse age groups.
Article 4: Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension.
Journal: European heart journal. Cardiovascular Imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40972539
Summary: Novel echocardiographic indices of right ventricular myocardial wor]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac arrhythmias and incretin therapies. Key takeaway: Semaglutide Efficacy in H. F. pEF Across Age.
Article Links:
Article 1: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. (European journal of heart failure)
Article 2: Predictive factors for permanent pacemaker implantation and mortality after transcatheter aortic valve replacement in patients with pre-existing atrial fibrillation. (Cardiology)
Article 3: Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. (European journal of heart failure)
Article 4: Echocardiographic right-ventricular global wasted work predicts haemodynamics and risk profile in pulmonary arterial hypertension. (European heart journal.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Heart Failure Drug Access Disparities Identified. 11/26/25</title>
	<link>https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/</link>
	<pubDate>Wed, 26 Nov 2025 09:50:35 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiotoxicity and bicuspid aortic stenosis. Key takeaway: Heart Failure Drug Access Disparities Identified..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40829861">Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40763997">Surveillance of left ventricular function among cancer survivors.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40562528">Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40348412">Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40348409">Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/">https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40829861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40829861</a></p>
<p><strong>Summary:</strong> Cardiotoxic effects of breast cancer therapies, including drugs and radiotherapy, are known to increase cardiovascular morbidity, particularly atrial fibrillation. This study precisely evaluated laterality-specific cardiovascular risks in women with left-sided versus right-sided breast cancer. Utilizing global healthcare data from the TriNetX network, the research clarified the specific impact of breast cancer laterality on incident cardiovascular events.</p>
<h4>Article 2: Surveillance of left ventricular function among cancer survivors.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40763997" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40763997</a></p>
<p><strong>Summary:</strong> Cancer survivors demonstrate an increased risk of heart failure, which is balanced by the risk of death from other causes, influencing optimal cardiac surveillance timing. This cross-sectional study investigated the association between cancer history and cardiac function across various follow-up periods. The research provided crucial data for determining effective guideline-recommended surveillance strategies for left ventricular function in this patient population.</p>
<h4>Article 3: Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40562528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40562528</a></p>
<p><strong>Summary:</strong> Patients with diabetes mellitus receiving percutaneous coronary intervention experience an elevated risk of late adverse events. The Second-generation Drug-eluting Stents in Diabetes (SUGAR) randomized controlled trial compared amphilimus-eluting stents and onyx-zotarolimus-eluting stents in this high-risk population. The study reported the co-primary endpoint of target lesion failure at two years and extended follow-up at three years. This research provided critical comparative data on stent performance and long-term outcomes for diabetic patients.</p>
<h4>Article 4: Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348412" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348412</a></p>
<p><strong>Summary:</strong> The comparative outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification remained unclear. This study rigorously compared the safety and efficacy of transcatheter aortic valve replacement in these patient groups. Researchers analyzed 870 propensity score matched pairs of patients with severe calcification exceeding 470 cubic millimeters. The research clarified specific outcomes to guide optimal treatment strategies for aortic stenosis.</p>
<h4>Article 5: Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348409" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348409</a></p>
<p><strong>Summary:</strong> Angiotensin receptor-neprilysin inhibitors and sodium-glucose co-transporter two inhibitors hold a Class one indication for acute and chronic heart failure due to benefits in symptom management, rehospitalization, and mortality. This national longitudinal cohort study investigated demographic, geographic, and socioeconomic disparities in the prescription of these essential medications for heart failure patients. The research identified patterns of unequal access to guideline-recommended heart failure therapies among Danish patients, highlighting areas for intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study. Cardiotoxic effects of breast cancer therapies, including drugs and radiotherapy, are known to increase cardiovascular morbidity, particularly atrial fibrillation. This study precisely evaluated laterality-specific cardiovascular risks in women with left-sided versus right-sided breast cancer. Utilizing global healthcare data from the TriNetX network, the research clarified the specific impact of breast cancer laterality on incident cardiovascular events.</p>
<p>Article number two. Surveillance of left ventricular function among cancer survivors. Cancer survivors demonstrate an increased risk of heart failure, which is balanced by the risk of death from other causes, influencing optimal cardiac surveillance timing. This cross-sectional study investigated the association between cancer history and cardiac function across various follow-up periods. The research provided crucial data for determining effective guideline-recommended surveillance strategies for left ventricular function in this patient population.</p>
<p>Article number three. Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. Patients with diabetes mellitus receiving percutaneous coronary intervention experience an elevated risk of late adverse events. The Second-generation Drug-eluting Stents in Diabetes (SUGAR) randomized controlled trial compared amphilimus-eluting stents and onyx-zotarolimus-eluting stents in this high-risk population. The study reported the co-primary endpoint of target lesion failure at two years and extended follow-up at three years. This research provided critical comparative data on stent performance and long-term outcomes for diabetic patients.</p>
<p>Article number four. Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification. The comparative outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification remained unclear. This study rigorously compared the safety and efficacy of transcatheter aortic valve replacement in these patient groups. Researchers analyzed 870 propensity score matched pairs of patients with severe calcification exceeding 470 cubic millimeters. The research clarified specific outcomes to guide optimal treatment strategies for aortic stenosis.</p>
<p>Article number five. Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study. Angiotensin receptor-neprilysin inhibitors and sodium-glucose co-transporter two inhibitors hold a Class one indication for acute and chronic heart failure due to benefits in symptom management, rehospitalization, and mortality. This national longitudinal cohort study investigated demographic, geographic, and socioeconomic disparities in the prescription of these essential medications for heart failure patients. The research identified patterns of unequal access to guideline-recommended heart failure therapies among Danish patients, highlighting areas for intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiotoxicity, bicuspid aortic stenosis, tricuspid aortic stenosis, heart failure, laterality, zotarolimus-eluting stents, amphilimus-eluting stents, cardiovascular events, diabetes mellitus, valve replacement, guideline adherence, transcatheter aortic valve replacement, percutaneous coronary intervention, angiotensin receptor-neprilysin inhibitors, prescription disparities, breast cancer, left ventricular dysfunction, sodium-glucose co-transporter two inhibitors, cardiac surveillance, drug-eluting stents, cancer survivors, severe calcification, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/">Heart Failure Drug Access Disparities Identified. 11/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiotoxicity and bicuspid aortic stenosis. Key takeaway: Heart Failure Drug Access Disparities Identified..
Article Links:
Article]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiotoxicity and bicuspid aortic stenosis. Key takeaway: Heart Failure Drug Access Disparities Identified..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40829861">Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40763997">Surveillance of left ventricular function among cancer survivors.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40562528">Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40348412">Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40348409">Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/">https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40829861" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40829861</a></p>
<p><strong>Summary:</strong> Cardiotoxic effects of breast cancer therapies, including drugs and radiotherapy, are known to increase cardiovascular morbidity, particularly atrial fibrillation. This study precisely evaluated laterality-specific cardiovascular risks in women with left-sided versus right-sided breast cancer. Utilizing global healthcare data from the TriNetX network, the research clarified the specific impact of breast cancer laterality on incident cardiovascular events.</p>
<h4>Article 2: Surveillance of left ventricular function among cancer survivors.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40763997" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40763997</a></p>
<p><strong>Summary:</strong> Cancer survivors demonstrate an increased risk of heart failure, which is balanced by the risk of death from other causes, influencing optimal cardiac surveillance timing. This cross-sectional study investigated the association between cancer history and cardiac function across various follow-up periods. The research provided crucial data for determining effective guideline-recommended surveillance strategies for left ventricular function in this patient population.</p>
<h4>Article 3: Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40562528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40562528</a></p>
<p><strong>Summary:</strong> Patients with diabetes mellitus receiving percutaneous coronary intervention experience an elevated risk of late adverse events. The Second-generation Drug-eluting Stents in Diabetes (SUGAR) randomized controlled trial compared amphilimus-eluting stents and onyx-zotarolimus-eluting stents in this high-risk population. The study reported the co-primary endpoint of target lesion failure at two years and extended follow-up at three years. This research provided critical comparative data on stent performance and long-term outcomes for diabetic patients.</p>
<h4>Article 4: Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348412" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348412</a></p>
<p><strong>Summary:</strong> The comparative outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification remained unclear. This study rigorously compared the safety and efficacy of transcatheter aortic valve replacement in these patient groups. Researchers analyzed 870 propensity score matched pairs of patients with severe calcification exceeding 470 cubic millimeters. The research clarified specific outcomes to guide optimal treatment strategies for aortic stenosis.</p>
<h4>Article 5: Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348409" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348409</a></p>
<p><strong>Summary:</strong> Angiotensin receptor-neprilysin inhibitors and sodium-glucose co-transporter two inhibitors hold a Class one indication for acute and chronic heart failure due to benefits in symptom management, rehospitalization, and mortality. This national longitudinal cohort study investigated demographic, geographic, and socioeconomic disparities in the prescription of these essential medications for heart failure patients. The research identified patterns of unequal access to guideline-recommended heart failure therapies among Danish patients, highlighting areas for intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study. Cardiotoxic effects of breast cancer therapies, including drugs and radiotherapy, are known to increase cardiovascular morbidity, particularly atrial fibrillation. This study precisely evaluated laterality-specific cardiovascular risks in women with left-sided versus right-sided breast cancer. Utilizing global healthcare data from the TriNetX network, the research clarified the specific impact of breast cancer laterality on incident cardiovascular events.</p>
<p>Article number two. Surveillance of left ventricular function among cancer survivors. Cancer survivors demonstrate an increased risk of heart failure, which is balanced by the risk of death from other causes, influencing optimal cardiac surveillance timing. This cross-sectional study investigated the association between cancer history and cardiac function across various follow-up periods. The research provided crucial data for determining effective guideline-recommended surveillance strategies for left ventricular function in this patient population.</p>
<p>Article number three. Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. Patients with diabetes mellitus receiving percutaneous coronary intervention experience an elevated risk of late adverse events. The Second-generation Drug-eluting Stents in Diabetes (SUGAR) randomized controlled trial compared amphilimus-eluting stents and onyx-zotarolimus-eluting stents in this high-risk population. The study reported the co-primary endpoint of target lesion failure at two years and extended follow-up at three years. This research provided critical comparative data on stent performance and long-term outcomes for diabetic patients.</p>
<p>Article number four. Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification. The comparative outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification remained unclear. This study rigorously compared the safety and efficacy of transcatheter aortic valve replacement in these patient groups. Researchers analyzed 870 propensity score matched pairs of patients with severe calcification exceeding 470 cubic millimeters. The research clarified specific outcomes to guide optimal treatment strategies for aortic stenosis.</p>
<p>Article number five. Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study. Angiotensin receptor-neprilysin inhibitors and sodium-glucose co-transporter two inhibitors hold a Class one indication for acute and chronic heart failure due to benefits in symptom management, rehospitalization, and mortality. This national longitudinal cohort study investigated demographic, geographic, and socioeconomic disparities in the prescription of these essential medications for heart failure patients. The research identified patterns of unequal access to guideline-recommended heart failure therapies among Danish patients, highlighting areas for intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiotoxicity, bicuspid aortic stenosis, tricuspid aortic stenosis, heart failure, laterality, zotarolimus-eluting stents, amphilimus-eluting stents, cardiovascular events, diabetes mellitus, valve replacement, guideline adherence, transcatheter aortic valve replacement, percutaneous coronary intervention, angiotensin receptor-neprilysin inhibitors, prescription disparities, breast cancer, left ventricular dysfunction, sodium-glucose co-transporter two inhibitors, cardiac surveillance, drug-eluting stents, cancer survivors, severe calcification, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/">Heart Failure Drug Access Disparities Identified. 11/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251126_044945.mp3" length="3651961" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiotoxicity and bicuspid aortic stenosis. Key takeaway: Heart Failure Drug Access Disparities Identified..
Article Links:
Article 1: Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study. (Heart (British Cardiac Society))
Article 2: Surveillance of left ventricular function among cancer survivors. (Heart (British Cardiac Society))
Article 3: Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. (Heart (British Cardiac Society))
Article 4: Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification. (Heart (British Cardiac Society))
Article 5: Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/heart-failure-drug-access-disparities-identified-11-26-25/
 Featured Articles
Article 1: Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40829861
Summary: Cardiotoxic effects of breast cancer therapies, including drugs and radiotherapy, are known to increase cardiovascular morbidity, particularly atrial fibrillation. This study precisely evaluated laterality-specific cardiovascular risks in women with left-sided versus right-sided breast cancer. Utilizing global healthcare data from the TriNetX network, the research clarified the specific impact of breast cancer laterality on incident cardiovascular events.
Article 2: Surveillance of left ventricular function among cancer survivors.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40763997
Summary: Cancer survivors demonstrate an increased risk of heart failure, which is balanced by the risk of death from other causes, influencing optimal cardiac surveillance timing. This cross-sectional study investigated the association between cancer history and cardiac function across various follow-up periods. The research provided crucial data for determining effective guideline-recommended surveillance strategies for left ventricular function in this patient population.
Article 3: Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40562528
Summary: Patients with diabetes mellitus receiving percutaneous coronary intervention experience an elevated risk of late adverse events. The Second-generation Drug-eluting Stents in Diabetes (SUGAR) randomized controlled trial compared amphilimus-eluting stents and onyx-zotarolimus-eluting stents in this high-risk population. The study reported the co-primary endpoint of target lesion failure at two years and extended follow-up at three years. This research provided critical comparative data on stent performance and long-term outcomes for diabetic patients.
Article 4: Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40348412
Summary: The comparative outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification remained unclear. This study rigorously compared the safety and efficacy of transcatheter aortic valve replacement in these patient groups. Researchers analyzed 870 propensity score matched pairs of patients with sever]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 26, 2025. This episode summarizes 5 key cardiology studies on topics like cardiotoxicity and bicuspid aortic stenosis. Key takeaway: Heart Failure Drug Access Disparities Identified..
Article Links:
Article 1: Incident cardiovascular events in women with left-sided versus right-sided breast cancer: a propensity score-matched study. (Heart (British Cardiac Society))
Article 2: Surveillance of left ventricular function among cancer survivors. (Heart (British Cardiac Society))
Article 3: Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. (Heart (British Cardiac Society))
Article 4: Outcomes of transcatheter aortic valve replacement in bicuspid versus tricuspid aortic stenosis with severe calcification. (Heart (British Cardiac Society))
Article 5: Disparities in prescriptions among Danish heart failure patients: a na]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Underweight Risk in Type 2 Diabetes 11/25/25</title>
	<link>https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/</link>
	<pubDate>Tue, 25 Nov 2025 22:29:02 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like adverse outcomes and cardiovascular risk. Key takeaway: Underweight Risk in Type 2 Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41288379">Cardiac fibroblasts in myocardial injury and heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41288370">Frailty and long-term outcomes in younger patients with acute myocardial infarction.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41288359">Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41288350">Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41288601">Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/">https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiac fibroblasts in myocardial injury and heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288379" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288379</a></p>
<p><strong>Summary:</strong> Cardiac fibrosis is a major contributor to the development and progression of heart failure. This process involves an aberrant deposition of extracellular matrix components, which leads to impaired mechanical and electrical function of the heart. Fibroblasts are central to these pathological processes. Effective anti-fibrotic treatments currently remain elusive due to limited insights into the molecular and cellular mechanisms distinguishing transient from sustained fibrotic responses.</p>
<h4>Article 2: Frailty and long-term outcomes in younger patients with acute myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288370" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288370</a></p>
<p><strong>Summary:</strong> Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction. The impact of frailty on younger patients with acute myocardial infarction remains an underexplored area. This population-based epidemiological study utilized linked national administrative data from England and Wales to investigate this association. Patients in the study were stratified into three age groups: under 55 years, 55 to 74 years, and 75 years or older.</p>
<h4>Article 3: Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288359" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288359</a></p>
<p><strong>Summary:</strong> Real-world evidence comparing percutaneous coronary intervention to coronary artery bypass grafting in women with chronic severe coronary artery disease is limited. This propensity score-matched retrospective cohort study linked clinical and administrative databases in Ontario, Canada. The study identified women undergoing either percutaneous coronary intervention or coronary artery bypass grafting from 2012 to 2021. This research addresses a critical evidence gap regarding long-term outcomes for revascularization strategies in this specific patient population.</p>
<h4>Article 4: Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288350" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288350</a></p>
<p><strong>Summary:</strong> The growing prevalence of lean Type 2 diabetes mellitus and limited research on stratified underweight categories characterize the current understanding. This nationwide cohort study investigated the association between underweight status and cardiovascular disease risk in patients with Type 2 diabetes mellitus. The study analyzed data from 2064406 adults with Type 2 diabetes mellitus who underwent health examinations between 2015 and 2016 from the Korean National Health Insurance Service database. This research focused on the impact of underweight severity on cardiovascular outcomes within this large patient population.</p>
<h4>Article 5: Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288601" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288601</a></p>
<p><strong>Summary:</strong> Atherosclerosis occurs preferentially in arteries exposed to disturbed flow, while stable flow regions are protected even under hypercholesterolaemic conditions. Prior research showed that disturbed flow alone initiates flow-induced reprogramming of endothelial cells, including partial endothelial-to-immune-cell-like transition. These findings, however, lacked validation using a genetic lineage-tracing model. This research highlights the critical role of disturbed flow in endothelial cell changes during atherogenesis under hypercholesterolaemia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiac fibroblasts in myocardial injury and heart failure. Cardiac fibrosis is a major contributor to the development and progression of heart failure. This process involves an aberrant deposition of extracellular matrix components, which leads to impaired mechanical and electrical function of the heart. Fibroblasts are central to these pathological processes. Effective anti-fibrotic treatments currently remain elusive due to limited insights into the molecular and cellular mechanisms distinguishing transient from sustained fibrotic responses.</p>
<p>Article number two. Frailty and long-term outcomes in younger patients with acute myocardial infarction. Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction. The impact of frailty on younger patients with acute myocardial infarction remains an underexplored area. This population-based epidemiological study utilized linked national administrative data from England and Wales to investigate this association. Patients in the study were stratified into three age groups: under 55 years, 55 to 74 years, and 75 years or older.</p>
<p>Article number three. Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting. Real-world evidence comparing percutaneous coronary intervention to coronary artery bypass grafting in women with chronic severe coronary artery disease is limited. This propensity score-matched retrospective cohort study linked clinical and administrative databases in Ontario, Canada. The study identified women undergoing either percutaneous coronary intervention or coronary artery bypass grafting from 2012 to 2021. This research addresses a critical evidence gap regarding long-term outcomes for revascularization strategies in this specific patient population.</p>
<p>Article number four. Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study. The growing prevalence of lean Type 2 diabetes mellitus and limited research on stratified underweight categories characterize the current understanding. This nationwide cohort study investigated the association between underweight status and cardiovascular disease risk in patients with Type 2 diabetes mellitus. The study analyzed data from 2064406 adults with Type 2 diabetes mellitus who underwent health examinations between 2015 and 2016 from the Korean National Health Insurance Service database. This research focused on the impact of underweight severity on cardiovascular outcomes within this large patient population.</p>
<p>Article number five. Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. Atherosclerosis occurs preferentially in arteries exposed to disturbed flow, while stable flow regions are protected even under hypercholesterolaemic conditions. Prior research showed that disturbed flow alone initiates flow-induced reprogramming of endothelial cells, including partial endothelial-to-immune-cell-like transition. These findings, however, lacked validation using a genetic lineage-tracing model. This research highlights the critical role of disturbed flow in endothelial cell changes during atherogenesis under hypercholesterolaemia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>adverse outcomes, cardiovascular risk, frailty, younger patients, nationwide study, underweight severity, endothelial cells, disturbed flow, percutaneous coronary intervention, cardiac fibrosis, epidemiological study, immune-like cells, fibroblasts, women, atherogenesis, extracellular matrix, chronic coronary artery disease, underweight, heart failure, long-term outcomes, Type 2 diabetes mellitus, acute myocardial infarction, coronary artery bypass grafting, hypercholesterolaemia, anti-fibrotic treatments, atherosclerosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/">Underweight Risk in Type 2 Diabetes 11/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like adverse outcomes and cardiovascular risk. Key takeaway: Underweight Risk in Type 2 Diabetes.
Article Links:
Article 1: Cardiac fibro]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like adverse outcomes and cardiovascular risk. Key takeaway: Underweight Risk in Type 2 Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41288379">Cardiac fibroblasts in myocardial injury and heart failure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41288370">Frailty and long-term outcomes in younger patients with acute myocardial infarction.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41288359">Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41288350">Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41288601">Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/">https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiac fibroblasts in myocardial injury and heart failure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288379" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288379</a></p>
<p><strong>Summary:</strong> Cardiac fibrosis is a major contributor to the development and progression of heart failure. This process involves an aberrant deposition of extracellular matrix components, which leads to impaired mechanical and electrical function of the heart. Fibroblasts are central to these pathological processes. Effective anti-fibrotic treatments currently remain elusive due to limited insights into the molecular and cellular mechanisms distinguishing transient from sustained fibrotic responses.</p>
<h4>Article 2: Frailty and long-term outcomes in younger patients with acute myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288370" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288370</a></p>
<p><strong>Summary:</strong> Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction. The impact of frailty on younger patients with acute myocardial infarction remains an underexplored area. This population-based epidemiological study utilized linked national administrative data from England and Wales to investigate this association. Patients in the study were stratified into three age groups: under 55 years, 55 to 74 years, and 75 years or older.</p>
<h4>Article 3: Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288359" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288359</a></p>
<p><strong>Summary:</strong> Real-world evidence comparing percutaneous coronary intervention to coronary artery bypass grafting in women with chronic severe coronary artery disease is limited. This propensity score-matched retrospective cohort study linked clinical and administrative databases in Ontario, Canada. The study identified women undergoing either percutaneous coronary intervention or coronary artery bypass grafting from 2012 to 2021. This research addresses a critical evidence gap regarding long-term outcomes for revascularization strategies in this specific patient population.</p>
<h4>Article 4: Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288350" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288350</a></p>
<p><strong>Summary:</strong> The growing prevalence of lean Type 2 diabetes mellitus and limited research on stratified underweight categories characterize the current understanding. This nationwide cohort study investigated the association between underweight status and cardiovascular disease risk in patients with Type 2 diabetes mellitus. The study analyzed data from 2064406 adults with Type 2 diabetes mellitus who underwent health examinations between 2015 and 2016 from the Korean National Health Insurance Service database. This research focused on the impact of underweight severity on cardiovascular outcomes within this large patient population.</p>
<h4>Article 5: Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41288601" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41288601</a></p>
<p><strong>Summary:</strong> Atherosclerosis occurs preferentially in arteries exposed to disturbed flow, while stable flow regions are protected even under hypercholesterolaemic conditions. Prior research showed that disturbed flow alone initiates flow-induced reprogramming of endothelial cells, including partial endothelial-to-immune-cell-like transition. These findings, however, lacked validation using a genetic lineage-tracing model. This research highlights the critical role of disturbed flow in endothelial cell changes during atherogenesis under hypercholesterolaemia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiac fibroblasts in myocardial injury and heart failure. Cardiac fibrosis is a major contributor to the development and progression of heart failure. This process involves an aberrant deposition of extracellular matrix components, which leads to impaired mechanical and electrical function of the heart. Fibroblasts are central to these pathological processes. Effective anti-fibrotic treatments currently remain elusive due to limited insights into the molecular and cellular mechanisms distinguishing transient from sustained fibrotic responses.</p>
<p>Article number two. Frailty and long-term outcomes in younger patients with acute myocardial infarction. Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction. The impact of frailty on younger patients with acute myocardial infarction remains an underexplored area. This population-based epidemiological study utilized linked national administrative data from England and Wales to investigate this association. Patients in the study were stratified into three age groups: under 55 years, 55 to 74 years, and 75 years or older.</p>
<p>Article number three. Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting. Real-world evidence comparing percutaneous coronary intervention to coronary artery bypass grafting in women with chronic severe coronary artery disease is limited. This propensity score-matched retrospective cohort study linked clinical and administrative databases in Ontario, Canada. The study identified women undergoing either percutaneous coronary intervention or coronary artery bypass grafting from 2012 to 2021. This research addresses a critical evidence gap regarding long-term outcomes for revascularization strategies in this specific patient population.</p>
<p>Article number four. Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study. The growing prevalence of lean Type 2 diabetes mellitus and limited research on stratified underweight categories characterize the current understanding. This nationwide cohort study investigated the association between underweight status and cardiovascular disease risk in patients with Type 2 diabetes mellitus. The study analyzed data from 2064406 adults with Type 2 diabetes mellitus who underwent health examinations between 2015 and 2016 from the Korean National Health Insurance Service database. This research focused on the impact of underweight severity on cardiovascular outcomes within this large patient population.</p>
<p>Article number five. Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. Atherosclerosis occurs preferentially in arteries exposed to disturbed flow, while stable flow regions are protected even under hypercholesterolaemic conditions. Prior research showed that disturbed flow alone initiates flow-induced reprogramming of endothelial cells, including partial endothelial-to-immune-cell-like transition. These findings, however, lacked validation using a genetic lineage-tracing model. This research highlights the critical role of disturbed flow in endothelial cell changes during atherogenesis under hypercholesterolaemia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>adverse outcomes, cardiovascular risk, frailty, younger patients, nationwide study, underweight severity, endothelial cells, disturbed flow, percutaneous coronary intervention, cardiac fibrosis, epidemiological study, immune-like cells, fibroblasts, women, atherogenesis, extracellular matrix, chronic coronary artery disease, underweight, heart failure, long-term outcomes, Type 2 diabetes mellitus, acute myocardial infarction, coronary artery bypass grafting, hypercholesterolaemia, anti-fibrotic treatments, atherosclerosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/">Underweight Risk in Type 2 Diabetes 11/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251125_172804.mp3" length="4025616" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like adverse outcomes and cardiovascular risk. Key takeaway: Underweight Risk in Type 2 Diabetes.
Article Links:
Article 1: Cardiac fibroblasts in myocardial injury and heart failure. (European heart journal)
Article 2: Frailty and long-term outcomes in younger patients with acute myocardial infarction. (European heart journal)
Article 3: Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting. (European heart journal)
Article 4: Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study. (European heart journal)
Article 5: Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/underweight-risk-in-type-2-diabetes-11-25-25/
 Featured Articles
Article 1: Cardiac fibroblasts in myocardial injury and heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41288379
Summary: Cardiac fibrosis is a major contributor to the development and progression of heart failure. This process involves an aberrant deposition of extracellular matrix components, which leads to impaired mechanical and electrical function of the heart. Fibroblasts are central to these pathological processes. Effective anti-fibrotic treatments currently remain elusive due to limited insights into the molecular and cellular mechanisms distinguishing transient from sustained fibrotic responses.
Article 2: Frailty and long-term outcomes in younger patients with acute myocardial infarction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41288370
Summary: Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction. The impact of frailty on younger patients with acute myocardial infarction remains an underexplored area. This population-based epidemiological study utilized linked national administrative data from England and Wales to investigate this association. Patients in the study were stratified into three age groups: under 55 years, 55 to 74 years, and 75 years or older.
Article 3: Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41288359
Summary: Real-world evidence comparing percutaneous coronary intervention to coronary artery bypass grafting in women with chronic severe coronary artery disease is limited. This propensity score-matched retrospective cohort study linked clinical and administrative databases in Ontario, Canada. The study identified women undergoing either percutaneous coronary intervention or coronary artery bypass grafting from 2012 to 2021. This research addresses a critical evidence gap regarding long-term outcomes for revascularization strategies in this specific patient population.
Article 4: Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41288350
Summary: The growing prevalence of lean Type 2 diabetes mellitus and limited research on stratified underweight categories characterize the current understanding. This nationwide cohort study investigated the association between underweight status and cardiovascular disease risk in patients with Type 2 diabetes mellitus. The study analyzed data from 2064406 adults with Type 2 diabetes mellitus who underwent health examinations between 2015 and 2016 from the Korean National Health Insurance Service database. This research focused on the impact of underweight severity on cardiovascular outcomes within this lar]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like adverse outcomes and cardiovascular risk. Key takeaway: Underweight Risk in Type 2 Diabetes.
Article Links:
Article 1: Cardiac fibroblasts in myocardial injury and heart failure. (European heart journal)
Article 2: Frailty and long-term outcomes in younger patients with acute myocardial infarction. (European heart journal)
Article 3: Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting. (European heart journal)
Article 4: Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study. (European heart journal)
Article 5: Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/underweight-risk-in-ty]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Extensive Cardiac Lymphatic Network Defined 11/25/25</title>
	<link>https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/</link>
	<pubDate>Tue, 25 Nov 2025 16:32:59 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like medication intensification and cognitive impairment. Key takeaway: Extensive Cardiac Lymphatic Network Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41287963">Importance of Adherence Versus Intensification in Attaining Blood Pressure Control.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41287962">Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study.</a> (Stroke)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41285212">Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams.</a> (American heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41285409">Normal cardiac lymphatics and their mimics.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41285406">Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/">https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Importance of Adherence Versus Intensification in Attaining Blood Pressure Control.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41287963" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41287963</a></p>
<p><strong>Summary:</strong> Optimizing blood pressure control requires a clear understanding of the distinct roles of medication adherence and antihypertensive intensification, insights critical for clinical care and quality improvement initiatives. This study defined primary care patients with hypertension experiencing uncontrolled blood pressure readings. It established a method to classify patients as having high (80 percent or greater) or low (less than 80 percent) adherence based on six months of prescription fill data. Such classification provides an essential framework for future investigations into improving blood pressure outcomes.</p>
<h4>Article 2: Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41287962" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41287962</a></p>
<p><strong>Summary:</strong> Chronic subdural hematomas (cSDH) represent a growing public health burden, yet specific, population-based data on their incidence and mortality in the United States have been limited. This study delivered the first estimates of chronic subdural hematoma incidence and mortality within a large, representative U.S. population. Researchers identified and adjudicated all adult cases of chronic subdural hematoma in 2019 and 2020 across a five-county region of Southern Ohio and Northern Kentucky. These findings provide foundational epidemiological data essential for public health planning and clinical resource allocation related to chronic subdural hematomas.</p>
<h4>Article 3: Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285212" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285212</a></p>
<p><strong>Summary:</strong> Cardiogenic shock remains a condition with persistently high mortality, underscoring the critical need for rapid diagnosis, coordinated multidisciplinary management, and timely mechanical circulatory support. The study observed significant variability in the structure, activation, and sustainability of dedicated cardiogenic shock teams across institutions. In response, the Society of Critical Care Cardiology, in partnership with other organizations, characterized this heterogeneity to advance understanding towards defining optimal components for these teams. This work establishes the importance of standardizing cardiogenic shock team practices to improve patient outcomes.</p>
<h4>Article 4: Normal cardiac lymphatics and their mimics.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285409" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285409</a></p>
<p><strong>Summary:</strong> Preclinical models of cardiovascular disease demonstrate significant lymphatic structural remodeling and dysfunction, yet the detailed normal structure and distribution of lymphatic vessels in the heart remained largely undefined. This study successfully defined the pattern of lymphatic vessels at various cardiac anatomical sites using Prox1-tdTomato lymphatic reporter mice. Through light sheet microscopy, researchers confirmed the presence of an extensive network of lymphatic vessels directly on the epicardium. These findings provide foundational anatomical insights into the cardiac lymphatic system, crucial for understanding its role in both health and disease.</p>
<h4>Article 5: Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285406" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285406</a></p>
<p><strong>Summary:</strong> Chronic kidney disease and cardiac remodeling are significant potentiators of cognitive impairment progression through oxidative stress, uremic toxicity, inflammation, and cardiovascular damage along the kidney-heart-brain axis. This study confirmed that sex disparity profoundly impacts chronic kidney disease epidemiology and influences the progression of cognitive impairment. The investigation rigorously analyzed the sex-specific interactions within the kidney-heart-brain axis in chronic kidney disease. This analysis provides a deeper understanding of these complex relationships, essential for developing targeted therapeutic strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Importance of Adherence Versus Intensification in Attaining Blood Pressure Control. Optimizing blood pressure control requires a clear understanding of the distinct roles of medication adherence and antihypertensive intensification, insights critical for clinical care and quality improvement initiatives. This study defined primary care patients with hypertension experiencing uncontrolled blood pressure readings. It established a method to classify patients as having high (80 percent or greater) or low (less than 80 percent) adherence based on six months of prescription fill data. Such classification provides an essential framework for future investigations into improving blood pressure outcomes.</p>
<p>Article number two. Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study. Chronic subdural hematomas (cSDH) represent a growing public health burden, yet specific, population-based data on their incidence and mortality in the United States have been limited. This study delivered the first estimates of chronic subdural hematoma incidence and mortality within a large, representative U.S. population. Researchers identified and adjudicated all adult cases of chronic subdural hematoma in 2019 and 2020 across a five-county region of Southern Ohio and Northern Kentucky. These findings provide foundational epidemiological data essential for public health planning and clinical resource allocation related to chronic subdural hematomas.</p>
<p>Article number three. Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams. Cardiogenic shock remains a condition with persistently high mortality, underscoring the critical need for rapid diagnosis, coordinated multidisciplinary management, and timely mechanical circulatory support. The study observed significant variability in the structure, activation, and sustainability of dedicated cardiogenic shock teams across institutions. In response, the Society of Critical Care Cardiology, in partnership with other organizations, characterized this heterogeneity to advance understanding towards defining optimal components for these teams. This work establishes the importance of standardizing cardiogenic shock team practices to improve patient outcomes.</p>
<p>Article number four. Normal cardiac lymphatics and their mimics. Preclinical models of cardiovascular disease demonstrate significant lymphatic structural remodeling and dysfunction, yet the detailed normal structure and distribution of lymphatic vessels in the heart remained largely undefined. This study successfully defined the pattern of lymphatic vessels at various cardiac anatomical sites using Prox1-tdTomato lymphatic reporter mice. Through light sheet microscopy, researchers confirmed the presence of an extensive network of lymphatic vessels directly on the epicardium. These findings provide foundational anatomical insights into the cardiac lymphatic system, crucial for understanding its role in both health and disease.</p>
<p>Article number five. Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis. Chronic kidney disease and cardiac remodeling are significant potentiators of cognitive impairment progression through oxidative stress, uremic toxicity, inflammation, and cardiovascular damage along the kidney-heart-brain axis. This study confirmed that sex disparity profoundly impacts chronic kidney disease epidemiology and influences the progression of cognitive impairment. The investigation rigorously analyzed the sex-specific interactions within the kidney-heart-brain axis in chronic kidney disease. This analysis provides a deeper understanding of these complex relationships, essential for developing targeted therapeutic strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>medication intensification, cognitive impairment, critical care, cardiac lymphatics, kidney-heart-brain axis, blood pressure control, mechanical circulatory support, lymphatic vessels, chronic subdural hematoma, epidemiology, team structure, population-based study, multidisciplinary management, chronic kidney disease, epicardium, cardiac anatomy, mortality, medication adherence, hypertension, antihypertensive medications, cardiac remodeling, incidence, sex differences, cardiovascular disease, cardiogenic shock.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/">Extensive Cardiac Lymphatic Network Defined 11/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like medication intensification and cognitive impairment. Key takeaway: Extensive Cardiac Lymphatic Network Defined.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like medication intensification and cognitive impairment. Key takeaway: Extensive Cardiac Lymphatic Network Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41287963">Importance of Adherence Versus Intensification in Attaining Blood Pressure Control.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41287962">Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study.</a> (Stroke)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41285212">Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams.</a> (American heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41285409">Normal cardiac lymphatics and their mimics.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41285406">Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/">https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Importance of Adherence Versus Intensification in Attaining Blood Pressure Control.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41287963" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41287963</a></p>
<p><strong>Summary:</strong> Optimizing blood pressure control requires a clear understanding of the distinct roles of medication adherence and antihypertensive intensification, insights critical for clinical care and quality improvement initiatives. This study defined primary care patients with hypertension experiencing uncontrolled blood pressure readings. It established a method to classify patients as having high (80 percent or greater) or low (less than 80 percent) adherence based on six months of prescription fill data. Such classification provides an essential framework for future investigations into improving blood pressure outcomes.</p>
<h4>Article 2: Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41287962" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41287962</a></p>
<p><strong>Summary:</strong> Chronic subdural hematomas (cSDH) represent a growing public health burden, yet specific, population-based data on their incidence and mortality in the United States have been limited. This study delivered the first estimates of chronic subdural hematoma incidence and mortality within a large, representative U.S. population. Researchers identified and adjudicated all adult cases of chronic subdural hematoma in 2019 and 2020 across a five-county region of Southern Ohio and Northern Kentucky. These findings provide foundational epidemiological data essential for public health planning and clinical resource allocation related to chronic subdural hematomas.</p>
<h4>Article 3: Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285212" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285212</a></p>
<p><strong>Summary:</strong> Cardiogenic shock remains a condition with persistently high mortality, underscoring the critical need for rapid diagnosis, coordinated multidisciplinary management, and timely mechanical circulatory support. The study observed significant variability in the structure, activation, and sustainability of dedicated cardiogenic shock teams across institutions. In response, the Society of Critical Care Cardiology, in partnership with other organizations, characterized this heterogeneity to advance understanding towards defining optimal components for these teams. This work establishes the importance of standardizing cardiogenic shock team practices to improve patient outcomes.</p>
<h4>Article 4: Normal cardiac lymphatics and their mimics.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285409" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285409</a></p>
<p><strong>Summary:</strong> Preclinical models of cardiovascular disease demonstrate significant lymphatic structural remodeling and dysfunction, yet the detailed normal structure and distribution of lymphatic vessels in the heart remained largely undefined. This study successfully defined the pattern of lymphatic vessels at various cardiac anatomical sites using Prox1-tdTomato lymphatic reporter mice. Through light sheet microscopy, researchers confirmed the presence of an extensive network of lymphatic vessels directly on the epicardium. These findings provide foundational anatomical insights into the cardiac lymphatic system, crucial for understanding its role in both health and disease.</p>
<h4>Article 5: Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285406" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285406</a></p>
<p><strong>Summary:</strong> Chronic kidney disease and cardiac remodeling are significant potentiators of cognitive impairment progression through oxidative stress, uremic toxicity, inflammation, and cardiovascular damage along the kidney-heart-brain axis. This study confirmed that sex disparity profoundly impacts chronic kidney disease epidemiology and influences the progression of cognitive impairment. The investigation rigorously analyzed the sex-specific interactions within the kidney-heart-brain axis in chronic kidney disease. This analysis provides a deeper understanding of these complex relationships, essential for developing targeted therapeutic strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Importance of Adherence Versus Intensification in Attaining Blood Pressure Control. Optimizing blood pressure control requires a clear understanding of the distinct roles of medication adherence and antihypertensive intensification, insights critical for clinical care and quality improvement initiatives. This study defined primary care patients with hypertension experiencing uncontrolled blood pressure readings. It established a method to classify patients as having high (80 percent or greater) or low (less than 80 percent) adherence based on six months of prescription fill data. Such classification provides an essential framework for future investigations into improving blood pressure outcomes.</p>
<p>Article number two. Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study. Chronic subdural hematomas (cSDH) represent a growing public health burden, yet specific, population-based data on their incidence and mortality in the United States have been limited. This study delivered the first estimates of chronic subdural hematoma incidence and mortality within a large, representative U.S. population. Researchers identified and adjudicated all adult cases of chronic subdural hematoma in 2019 and 2020 across a five-county region of Southern Ohio and Northern Kentucky. These findings provide foundational epidemiological data essential for public health planning and clinical resource allocation related to chronic subdural hematomas.</p>
<p>Article number three. Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams. Cardiogenic shock remains a condition with persistently high mortality, underscoring the critical need for rapid diagnosis, coordinated multidisciplinary management, and timely mechanical circulatory support. The study observed significant variability in the structure, activation, and sustainability of dedicated cardiogenic shock teams across institutions. In response, the Society of Critical Care Cardiology, in partnership with other organizations, characterized this heterogeneity to advance understanding towards defining optimal components for these teams. This work establishes the importance of standardizing cardiogenic shock team practices to improve patient outcomes.</p>
<p>Article number four. Normal cardiac lymphatics and their mimics. Preclinical models of cardiovascular disease demonstrate significant lymphatic structural remodeling and dysfunction, yet the detailed normal structure and distribution of lymphatic vessels in the heart remained largely undefined. This study successfully defined the pattern of lymphatic vessels at various cardiac anatomical sites using Prox1-tdTomato lymphatic reporter mice. Through light sheet microscopy, researchers confirmed the presence of an extensive network of lymphatic vessels directly on the epicardium. These findings provide foundational anatomical insights into the cardiac lymphatic system, crucial for understanding its role in both health and disease.</p>
<p>Article number five. Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis. Chronic kidney disease and cardiac remodeling are significant potentiators of cognitive impairment progression through oxidative stress, uremic toxicity, inflammation, and cardiovascular damage along the kidney-heart-brain axis. This study confirmed that sex disparity profoundly impacts chronic kidney disease epidemiology and influences the progression of cognitive impairment. The investigation rigorously analyzed the sex-specific interactions within the kidney-heart-brain axis in chronic kidney disease. This analysis provides a deeper understanding of these complex relationships, essential for developing targeted therapeutic strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>medication intensification, cognitive impairment, critical care, cardiac lymphatics, kidney-heart-brain axis, blood pressure control, mechanical circulatory support, lymphatic vessels, chronic subdural hematoma, epidemiology, team structure, population-based study, multidisciplinary management, chronic kidney disease, epicardium, cardiac anatomy, mortality, medication adherence, hypertension, antihypertensive medications, cardiac remodeling, incidence, sex differences, cardiovascular disease, cardiogenic shock.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/">Extensive Cardiac Lymphatic Network Defined 11/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251125_113144.mp3" length="4459040" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like medication intensification and cognitive impairment. Key takeaway: Extensive Cardiac Lymphatic Network Defined.
Article Links:
Article 1: Importance of Adherence Versus Intensification in Attaining Blood Pressure Control. (Hypertension (Dallas, Tex. : 1979))
Article 2: Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study. (Stroke)
Article 3: Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams. (American heart journal)
Article 4: Normal cardiac lymphatics and their mimics. (American journal of physiology. Heart and circulatory physiology)
Article 5: Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis. (American journal of physiology. Heart and circulatory physiology)
Full episode page: https://podcast.explainheart.com/podcast/extensive-cardiac-lymphatic-network-defined-11-25-25/
 Featured Articles
Article 1: Importance of Adherence Versus Intensification in Attaining Blood Pressure Control.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41287963
Summary: Optimizing blood pressure control requires a clear understanding of the distinct roles of medication adherence and antihypertensive intensification, insights critical for clinical care and quality improvement initiatives. This study defined primary care patients with hypertension experiencing uncontrolled blood pressure readings. It established a method to classify patients as having high (80 percent or greater) or low (less than 80 percent) adherence based on six months of prescription fill data. Such classification provides an essential framework for future investigations into improving blood pressure outcomes.
Article 2: Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study.
Journal: Stroke
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41287962
Summary: Chronic subdural hematomas (cSDH) represent a growing public health burden, yet specific, population-based data on their incidence and mortality in the United States have been limited. This study delivered the first estimates of chronic subdural hematoma incidence and mortality within a large, representative U.S. population. Researchers identified and adjudicated all adult cases of chronic subdural hematoma in 2019 and 2020 across a five-county region of Southern Ohio and Northern Kentucky. These findings provide foundational epidemiological data essential for public health planning and clinical resource allocation related to chronic subdural hematomas.
Article 3: Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams.
Journal: American heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41285212
Summary: Cardiogenic shock remains a condition with persistently high mortality, underscoring the critical need for rapid diagnosis, coordinated multidisciplinary management, and timely mechanical circulatory support. The study observed significant variability in the structure, activation, and sustainability of dedicated cardiogenic shock teams across institutions. In response, the Society of Critical Care Cardiology, in partnership with other organizations, characterized this heterogeneity to advance understanding towards defining optimal components for these teams. This work establishes the importance of standardizing cardiogenic shock team practices to improve patient outcomes.
Article 4: Normal cardiac lymphatics and their mimics.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41285409
Summary: Preclinical models of cardiovascular disease demonstrate significant lymphatic structural remodeling and dysfunction, yet the detai]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like medication intensification and cognitive impairment. Key takeaway: Extensive Cardiac Lymphatic Network Defined.
Article Links:
Article 1: Importance of Adherence Versus Intensification in Attaining Blood Pressure Control. (Hypertension (Dallas, Tex. : 1979))
Article 2: Incidence and Mortality of Chronic Subdural Hematomas: A Population-Based Study. (Stroke)
Article 3: Towards an Understanding of Best Practice &#8211; The Good, The Bad and the Future of Cardiogenic Shock Teams. (American heart journal)
Article 4: Normal cardiac lymphatics and their mimics. (American journal of physiology. Heart and circulatory physiology)
Article 5: Chronic Kidney Disease and Cardiac Remodeling Potentiate Cognitive Impairment Progression: Disentangling the Sex-Specific Crosstalk of Kidney-Heart-Brain Axis. (American journal of physiology. Heart and circulatory physiology)
Full episo]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Colchicine Influences Clonal Hematopoiesis Dynamics 11/25/25</title>
	<link>https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/</link>
	<pubDate>Tue, 25 Nov 2025 11:01:34 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like clonal hematopoiesis and risk communication. Key takeaway: Colchicine Influences Clonal Hematopoiesis Dynamics.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41260759">Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41260756">Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41123524">Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40892620">Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41285299">Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods.</a> (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/">https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41260759" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41260759</a></p>
<p><strong>Summary:</strong> This study involving 4308405 participants found that remnant cholesterol is an independent cardiovascular risk factor. It significantly contributes to the residual risk of cardiovascular disease beyond low-density lipoprotein cholesterol across various age groups. The data demonstrated this association with major adverse cardiovascular events, particularly highlighting its relevance even in young adults. This finding underscores the importance of considering remnant cholesterol in cardiovascular risk assessment.</p>
<h4>Article 2: Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41260756" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41260756</a></p>
<p><strong>Summary:</strong> This study developed population-based age and sex-specific percentiles for 30-year cardiovascular disease risk. These percentiles, based on the PREVENT equations, provide a crucial tool for long-term risk assessment in younger adults. The data showed that framing cardiovascular disease risk relative to peers significantly aids in risk communication for both clinicians and patients. This method offers a clear, complementary approach to current absolute risk estimates.</p>
<h4>Article 3: Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123524</a></p>
<p><strong>Summary:</strong> This study analyzed longitudinal data and found specific associations between changes in light-to-moderate alcohol consumption and subsequent blood pressure changes. Results showed that alcohol cessation and initiation distinctly influenced blood pressure levels in both women and men. The data provided sex-specific estimates on these effects, further clarifying the impact across different types of alcoholic beverages. This demonstrates a measurable link between modest alcohol intake modifications and cardiovascular health.</p>
<h4>Article 4: Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892620" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892620</a></p>
<p><strong>Summary:</strong> This exploratory substudy of the LoDoCo2 trial found an association between randomization to colchicine and the longitudinal dynamics of clonal hematopoiesis. The data indicated that colchicine, an anti-inflammatory therapy, influences clonal hematopoiesis, a condition associated with increased cardiovascular event risk. The study demonstrated a link between an anti-inflammatory treatment and the dynamics of these aging-related hematologic clones in humans. This offers novel insights into managing clonal hematopoiesis and its cardiovascular implications.</p>
<h4>Article 5: Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods.</h4>
<p><strong>Journal:</strong> Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285299" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285299</a></p>
<p><strong>Summary:</strong> This study compared several Doppler echocardiographic methods for estimating mean pulmonary artery pressure against right heart catheterization. The data evaluated the yield and agreement of each echocardiographic method in a real-world cohort of 122 patients. Results clarified the performance of noninvasive techniques for pulmonary artery pressure assessment and their correlation with invasive measurements. The findings provide critical information on the reliability and limitations of echocardiography for diagnosing and monitoring pulmonary hypertension.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study. This study involving 4308405 participants found that remnant cholesterol is an independent cardiovascular risk factor. It significantly contributes to the residual risk of cardiovascular disease beyond low-density lipoprotein cholesterol across various age groups. The data demonstrated this association with major adverse cardiovascular events, particularly highlighting its relevance even in young adults. This finding underscores the importance of considering remnant cholesterol in cardiovascular risk assessment.</p>
<p>Article number two. Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations. This study developed population-based age and sex-specific percentiles for 30-year cardiovascular disease risk. These percentiles, based on the PREVENT equations, provide a crucial tool for long-term risk assessment in younger adults. The data showed that framing cardiovascular disease risk relative to peers significantly aids in risk communication for both clinicians and patients. This method offers a clear, complementary approach to current absolute risk estimates.</p>
<p>Article number three. Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis. This study analyzed longitudinal data and found specific associations between changes in light-to-moderate alcohol consumption and subsequent blood pressure changes. Results showed that alcohol cessation and initiation distinctly influenced blood pressure levels in both women and men. The data provided sex-specific estimates on these effects, further clarifying the impact across different types of alcoholic beverages. This demonstrates a measurable link between modest alcohol intake modifications and cardiovascular health.</p>
<p>Article number four. Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial. This exploratory substudy of the LoDoCo2 trial found an association between randomization to colchicine and the longitudinal dynamics of clonal hematopoiesis. The data indicated that colchicine, an anti-inflammatory therapy, influences clonal hematopoiesis, a condition associated with increased cardiovascular event risk. The study demonstrated a link between an anti-inflammatory treatment and the dynamics of these aging-related hematologic clones in humans. This offers novel insights into managing clonal hematopoiesis and its cardiovascular implications.</p>
<p>Article number five. Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods. This study compared several Doppler echocardiographic methods for estimating mean pulmonary artery pressure against right heart catheterization. The data evaluated the yield and agreement of each echocardiographic method in a real-world cohort of 122 patients. Results clarified the performance of noninvasive techniques for pulmonary artery pressure assessment and their correlation with invasive measurements. The findings provide critical information on the reliability and limitations of echocardiography for diagnosing and monitoring pulmonary hypertension. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>clonal hematopoiesis, risk communication, right heart catheterization, colchicine, alcohol consumption, low-density lipoprotein cholesterol, pulmonary hypertension, sex-specific percentiles, remnant cholesterol, young adults, major adverse cardiovascular events, Doppler echocardiography, cardiovascular risk factor, noninvasive assessment, cardiovascular events, sex-specific estimates, anti-inflammatory therapy, PREVENT equations, blood pressure, cardiovascular disease risk, alcohol cessation, LoDoCo2 trial, alcohol initiation, pulmonary artery pressure, age-specific percentiles.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/">Colchicine Influences Clonal Hematopoiesis Dynamics 11/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like clonal hematopoiesis and risk communication. Key takeaway: Colchicine Influences Clonal Hematopoiesis Dynamics.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like clonal hematopoiesis and risk communication. Key takeaway: Colchicine Influences Clonal Hematopoiesis Dynamics.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41260759">Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41260756">Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41123524">Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40892620">Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41285299">Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods.</a> (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/">https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41260759" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41260759</a></p>
<p><strong>Summary:</strong> This study involving 4308405 participants found that remnant cholesterol is an independent cardiovascular risk factor. It significantly contributes to the residual risk of cardiovascular disease beyond low-density lipoprotein cholesterol across various age groups. The data demonstrated this association with major adverse cardiovascular events, particularly highlighting its relevance even in young adults. This finding underscores the importance of considering remnant cholesterol in cardiovascular risk assessment.</p>
<h4>Article 2: Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41260756" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41260756</a></p>
<p><strong>Summary:</strong> This study developed population-based age and sex-specific percentiles for 30-year cardiovascular disease risk. These percentiles, based on the PREVENT equations, provide a crucial tool for long-term risk assessment in younger adults. The data showed that framing cardiovascular disease risk relative to peers significantly aids in risk communication for both clinicians and patients. This method offers a clear, complementary approach to current absolute risk estimates.</p>
<h4>Article 3: Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123524</a></p>
<p><strong>Summary:</strong> This study analyzed longitudinal data and found specific associations between changes in light-to-moderate alcohol consumption and subsequent blood pressure changes. Results showed that alcohol cessation and initiation distinctly influenced blood pressure levels in both women and men. The data provided sex-specific estimates on these effects, further clarifying the impact across different types of alcoholic beverages. This demonstrates a measurable link between modest alcohol intake modifications and cardiovascular health.</p>
<h4>Article 4: Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892620" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892620</a></p>
<p><strong>Summary:</strong> This exploratory substudy of the LoDoCo2 trial found an association between randomization to colchicine and the longitudinal dynamics of clonal hematopoiesis. The data indicated that colchicine, an anti-inflammatory therapy, influences clonal hematopoiesis, a condition associated with increased cardiovascular event risk. The study demonstrated a link between an anti-inflammatory treatment and the dynamics of these aging-related hematologic clones in humans. This offers novel insights into managing clonal hematopoiesis and its cardiovascular implications.</p>
<h4>Article 5: Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods.</h4>
<p><strong>Journal:</strong> Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41285299" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41285299</a></p>
<p><strong>Summary:</strong> This study compared several Doppler echocardiographic methods for estimating mean pulmonary artery pressure against right heart catheterization. The data evaluated the yield and agreement of each echocardiographic method in a real-world cohort of 122 patients. Results clarified the performance of noninvasive techniques for pulmonary artery pressure assessment and their correlation with invasive measurements. The findings provide critical information on the reliability and limitations of echocardiography for diagnosing and monitoring pulmonary hypertension.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study. This study involving 4308405 participants found that remnant cholesterol is an independent cardiovascular risk factor. It significantly contributes to the residual risk of cardiovascular disease beyond low-density lipoprotein cholesterol across various age groups. The data demonstrated this association with major adverse cardiovascular events, particularly highlighting its relevance even in young adults. This finding underscores the importance of considering remnant cholesterol in cardiovascular risk assessment.</p>
<p>Article number two. Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations. This study developed population-based age and sex-specific percentiles for 30-year cardiovascular disease risk. These percentiles, based on the PREVENT equations, provide a crucial tool for long-term risk assessment in younger adults. The data showed that framing cardiovascular disease risk relative to peers significantly aids in risk communication for both clinicians and patients. This method offers a clear, complementary approach to current absolute risk estimates.</p>
<p>Article number three. Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis. This study analyzed longitudinal data and found specific associations between changes in light-to-moderate alcohol consumption and subsequent blood pressure changes. Results showed that alcohol cessation and initiation distinctly influenced blood pressure levels in both women and men. The data provided sex-specific estimates on these effects, further clarifying the impact across different types of alcoholic beverages. This demonstrates a measurable link between modest alcohol intake modifications and cardiovascular health.</p>
<p>Article number four. Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial. This exploratory substudy of the LoDoCo2 trial found an association between randomization to colchicine and the longitudinal dynamics of clonal hematopoiesis. The data indicated that colchicine, an anti-inflammatory therapy, influences clonal hematopoiesis, a condition associated with increased cardiovascular event risk. The study demonstrated a link between an anti-inflammatory treatment and the dynamics of these aging-related hematologic clones in humans. This offers novel insights into managing clonal hematopoiesis and its cardiovascular implications.</p>
<p>Article number five. Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods. This study compared several Doppler echocardiographic methods for estimating mean pulmonary artery pressure against right heart catheterization. The data evaluated the yield and agreement of each echocardiographic method in a real-world cohort of 122 patients. Results clarified the performance of noninvasive techniques for pulmonary artery pressure assessment and their correlation with invasive measurements. The findings provide critical information on the reliability and limitations of echocardiography for diagnosing and monitoring pulmonary hypertension. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>clonal hematopoiesis, risk communication, right heart catheterization, colchicine, alcohol consumption, low-density lipoprotein cholesterol, pulmonary hypertension, sex-specific percentiles, remnant cholesterol, young adults, major adverse cardiovascular events, Doppler echocardiography, cardiovascular risk factor, noninvasive assessment, cardiovascular events, sex-specific estimates, anti-inflammatory therapy, PREVENT equations, blood pressure, cardiovascular disease risk, alcohol cessation, LoDoCo2 trial, alcohol initiation, pulmonary artery pressure, age-specific percentiles.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/">Colchicine Influences Clonal Hematopoiesis Dynamics 11/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251125_060030.mp3" length="3947458" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like clonal hematopoiesis and risk communication. Key takeaway: Colchicine Influences Clonal Hematopoiesis Dynamics.
Article Links:
Article 1: Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study. (Journal of the American College of Cardiology)
Article 2: Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations. (Journal of the American College of Cardiology)
Article 3: Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis. (Journal of the American College of Cardiology)
Article 4: Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial. (Journal of the American College of Cardiology)
Article 5: Noninvasive Assessment of Mean Pulmonary Artery Pressure: a Comparison of Doppler Echocardiographic Methods. (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)
Full episode page: https://podcast.explainheart.com/podcast/colchicine-influences-clonal-hematopoiesis-dynamics-11-25-25/
 Featured Articles
Article 1: Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41260759
Summary: This study involving 4308405 participants found that remnant cholesterol is an independent cardiovascular risk factor. It significantly contributes to the residual risk of cardiovascular disease beyond low-density lipoprotein cholesterol across various age groups. The data demonstrated this association with major adverse cardiovascular events, particularly highlighting its relevance even in young adults. This finding underscores the importance of considering remnant cholesterol in cardiovascular risk assessment.
Article 2: Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41260756
Summary: This study developed population-based age and sex-specific percentiles for 30-year cardiovascular disease risk. These percentiles, based on the PREVENT equations, provide a crucial tool for long-term risk assessment in younger adults. The data showed that framing cardiovascular disease risk relative to peers significantly aids in risk communication for both clinicians and patients. This method offers a clear, complementary approach to current absolute risk estimates.
Article 3: Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41123524
Summary: This study analyzed longitudinal data and found specific associations between changes in light-to-moderate alcohol consumption and subsequent blood pressure changes. Results showed that alcohol cessation and initiation distinctly influenced blood pressure levels in both women and men. The data provided sex-specific estimates on these effects, further clarifying the impact across different types of alcoholic beverages. This demonstrates a measurable link between modest alcohol intake modifications and cardiovascular health.
Article 4: Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892620
Summary: This exploratory substudy of the LoDoCo2 trial found an association between randomization to colchicine and the longitudinal dynamics of clonal hematopoiesis. The data indicat]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 25, 2025. This episode summarizes 5 key cardiology studies on topics like clonal hematopoiesis and risk communication. Key takeaway: Colchicine Influences Clonal Hematopoiesis Dynamics.
Article Links:
Article 1: Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults: An Age-Stratified Cohort Study. (Journal of the American College of Cardiology)
Article 2: Age and Sex-Specific Percentiles of 30-Year Cardiovascular Disease Risk Based on the PREVENT Equations. (Journal of the American College of Cardiology)
Article 3: Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis. (Journal of the American College of Cardiology)
Article 4: Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial. (Journal of the American College of Cardiology)
Article 5: Noninvasive Assessment of Mean Pulmonary A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Metabolic Shifts Raise Heart Disease Risk 11/24/25</title>
	<link>https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/</link>
	<pubDate>Tue, 25 Nov 2025 04:51:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like prevalence and carotid intima-media thickness. Key takeaway: Metabolic Shifts Raise Heart Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41283865">HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41283206">Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41283203">Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41283192">Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41283871">HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/">https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283865" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283865</a></p>
<p><strong>Summary:</strong> Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.</p>
<h4>Article 2: Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283206" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283206</a></p>
<p><strong>Summary:</strong> This study identified a quantifiable risk of coronary artery disease associated with transitions in metabolic health within a large clinical cohort of 69272 individuals. Researchers specifically quantified these risks linked to adverse metabolic transitions, analyzing components such as diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein. The findings demonstrated that recent onset metabolic dysfunction directly influences the probability of incident coronary artery disease.</p>
<h4>Article 3: Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283203" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283203</a></p>
<p><strong>Summary:</strong> This study found that religious coping modified the longitudinal associations between lifetime discrimination and subclinical atherosclerotic cardiovascular disease risk among Black individuals. Researchers observed these effects differed by sex within a cohort of 753 Black adult participants. The data demonstrated that specific religious coping mechanisms influence the impact of unfair treatment on carotid intima-media thickness, a key indicator of cardiovascular health.</p>
<h4>Article 4: Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283192" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283192</a></p>
<p><strong>Summary:</strong> This study quantified the prevalence, clinical correlates, and prognostic impact of tricuspid regurgitation in 3046 community-based older adults from the Atherosclerosis Risk in Communities study. Researchers assessed tricuspid regurgitation severity using echocardiography, categorizing it from none or trace to severe. The findings established definitive data on the association of tricuspid regurgitation with older age and a heightened mortality rate within this specific population.</p>
<h4>Article 5: HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283871</a></p>
<p><strong>Summary:</strong> Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers. Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.</p>
<p>Article number two. Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69272. This study identified a quantifiable risk of coronary artery disease associated with transitions in metabolic health within a large clinical cohort of 69272 individuals. Researchers specifically quantified these risks linked to adverse metabolic transitions, analyzing components such as diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein. The findings demonstrated that recent onset metabolic dysfunction directly influences the probability of incident coronary artery disease.</p>
<p>Article number three. Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping. This study found that religious coping modified the longitudinal associations between lifetime discrimination and subclinical atherosclerotic cardiovascular disease risk among Black individuals. Researchers observed these effects differed by sex within a cohort of 753 Black adult participants. The data demonstrated that specific religious coping mechanisms influence the impact of unfair treatment on carotid intima-media thickness, a key indicator of cardiovascular health.</p>
<p>Article number four. Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study. This study quantified the prevalence, clinical correlates, and prognostic impact of tricuspid regurgitation in 3046 community-based older adults from the Atherosclerosis Risk in Communities study. Researchers assessed tricuspid regurgitation severity using echocardiography, categorizing it from none or trace to severe. The findings established definitive data on the association of tricuspid regurgitation with older age and a heightened mortality rate within this specific population.</p>
<p>Article number five. HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers. Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>prevalence, carotid intima-media thickness, health care delivery, metabolic dysfunction, prognostic impact, Black adults, triglycerides, mortality rate, Tricuspid regurgitation, Lifetime discrimination, Ambulatory Surgical Centers, same-day discharge, diabetes, intracardiac ablation, religious coping, high-density lipoprotein, older adults, Coronary artery disease, hypertension, atherosclerotic cardiovascular disease, echocardiography, electrophysiology.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/">Metabolic Shifts Raise Heart Disease Risk 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like prevalence and carotid intima-media thickness. Key takeaway: Metabolic Shifts Raise Heart Disease Risk.
Article Links:
Article 1: HR]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like prevalence and carotid intima-media thickness. Key takeaway: Metabolic Shifts Raise Heart Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41283865">HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41283206">Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41283203">Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41283192">Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41283871">HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/">https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283865" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283865</a></p>
<p><strong>Summary:</strong> Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.</p>
<h4>Article 2: Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283206" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283206</a></p>
<p><strong>Summary:</strong> This study identified a quantifiable risk of coronary artery disease associated with transitions in metabolic health within a large clinical cohort of 69272 individuals. Researchers specifically quantified these risks linked to adverse metabolic transitions, analyzing components such as diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein. The findings demonstrated that recent onset metabolic dysfunction directly influences the probability of incident coronary artery disease.</p>
<h4>Article 3: Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283203" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283203</a></p>
<p><strong>Summary:</strong> This study found that religious coping modified the longitudinal associations between lifetime discrimination and subclinical atherosclerotic cardiovascular disease risk among Black individuals. Researchers observed these effects differed by sex within a cohort of 753 Black adult participants. The data demonstrated that specific religious coping mechanisms influence the impact of unfair treatment on carotid intima-media thickness, a key indicator of cardiovascular health.</p>
<h4>Article 4: Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283192" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283192</a></p>
<p><strong>Summary:</strong> This study quantified the prevalence, clinical correlates, and prognostic impact of tricuspid regurgitation in 3046 community-based older adults from the Atherosclerosis Risk in Communities study. Researchers assessed tricuspid regurgitation severity using echocardiography, categorizing it from none or trace to severe. The findings established definitive data on the association of tricuspid regurgitation with older age and a heightened mortality rate within this specific population.</p>
<h4>Article 5: HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41283871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41283871</a></p>
<p><strong>Summary:</strong> Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers. Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.</p>
<p>Article number two. Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69272. This study identified a quantifiable risk of coronary artery disease associated with transitions in metabolic health within a large clinical cohort of 69272 individuals. Researchers specifically quantified these risks linked to adverse metabolic transitions, analyzing components such as diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein. The findings demonstrated that recent onset metabolic dysfunction directly influences the probability of incident coronary artery disease.</p>
<p>Article number three. Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping. This study found that religious coping modified the longitudinal associations between lifetime discrimination and subclinical atherosclerotic cardiovascular disease risk among Black individuals. Researchers observed these effects differed by sex within a cohort of 753 Black adult participants. The data demonstrated that specific religious coping mechanisms influence the impact of unfair treatment on carotid intima-media thickness, a key indicator of cardiovascular health.</p>
<p>Article number four. Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study. This study quantified the prevalence, clinical correlates, and prognostic impact of tricuspid regurgitation in 3046 community-based older adults from the Atherosclerosis Risk in Communities study. Researchers assessed tricuspid regurgitation severity using echocardiography, categorizing it from none or trace to severe. The findings established definitive data on the association of tricuspid regurgitation with older age and a heightened mortality rate within this specific population.</p>
<p>Article number five. HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers. Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>prevalence, carotid intima-media thickness, health care delivery, metabolic dysfunction, prognostic impact, Black adults, triglycerides, mortality rate, Tricuspid regurgitation, Lifetime discrimination, Ambulatory Surgical Centers, same-day discharge, diabetes, intracardiac ablation, religious coping, high-density lipoprotein, older adults, Coronary artery disease, hypertension, atherosclerotic cardiovascular disease, echocardiography, electrophysiology.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/">Metabolic Shifts Raise Heart Disease Risk 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251124_235027.mp3" length="3878077" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like prevalence and carotid intima-media thickness. Key takeaway: Metabolic Shifts Raise Heart Disease Risk.
Article Links:
Article 1: HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers. (Journal of the American College of Cardiology)
Article 2: Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272. (Journal of the American Heart Association)
Article 3: Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping. (Journal of the American Heart Association)
Article 4: Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study. (Journal of the American Heart Association)
Article 5: HRS/ACC scientific statement: Guiding principles on the performance of intracardiac ablation procedures in ambulatory surgical centers. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/metabolic-shifts-raise-heart-disease-risk-11-24-25/
 Featured Articles
Article 1: HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41283865
Summary: Ambulatory Surgical Centers in the United States are established as a cost-effective, patient-centric alternative for intracardiac ablation procedures, supported by Centers for Medicare and Medicaid Services policy expansions. These centers accommodate a range of procedures, leveraging technological and procedural advancements to facilitate same-day discharge protocols. This model effectively delivers care by allowing appropriately selected patients to undergo complex cardiac interventions outside traditional hospital settings.
Article 2: Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41283206
Summary: This study identified a quantifiable risk of coronary artery disease associated with transitions in metabolic health within a large clinical cohort of 69272 individuals. Researchers specifically quantified these risks linked to adverse metabolic transitions, analyzing components such as diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein. The findings demonstrated that recent onset metabolic dysfunction directly influences the probability of incident coronary artery disease.
Article 3: Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41283203
Summary: This study found that religious coping modified the longitudinal associations between lifetime discrimination and subclinical atherosclerotic cardiovascular disease risk among Black individuals. Researchers observed these effects differed by sex within a cohort of 753 Black adult participants. The data demonstrated that specific religious coping mechanisms influence the impact of unfair treatment on carotid intima-media thickness, a key indicator of cardiovascular health.
Article 4: Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41283192
Summary: This study quantified the prevalence, clinical correlates, and prognostic impact of tricuspid regurgitation in 3046 community-based older adults from the Atherosclerosis Risk in Communities study. Researchers assessed tricuspid regurgitation]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like prevalence and carotid intima-media thickness. Key takeaway: Metabolic Shifts Raise Heart Disease Risk.
Article Links:
Article 1: HRS/ACC Scientific Statement: Guiding Principles on the Performance of Intracardiac Ablation Procedures in Ambulatory Surgical Centers. (Journal of the American College of Cardiology)
Article 2: Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272. (Journal of the American Heart Association)
Article 3: Burden of Unfair Treatment and Subclinical Atherosclerotic Risk Among Black Adults: The Moderating Role of Religious Coping. (Journal of the American Heart Association)
Article 4: Prevalence, Clinical Correlates, and Prognostic Impact of Tricuspid Regurgitation in Older Adults: The ARIC Study. (Journal of the American Heart Association)
Article 5: HRS/ACC scientific statement: Guidi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Genetic Sodium Blockade for Arrhythmias 11/24/25</title>
	<link>https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/</link>
	<pubDate>Mon, 24 Nov 2025 12:37:50 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and proteomics. Key takeaway: Genetic Sodium Blockade for Arrhythmias.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41277422">Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41277423">Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41277423">Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41115437">Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.</a> (Lancet (London, England))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/">https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41277422" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41277422</a></p>
<p><strong>Summary:</strong> This study identified a specific Finnish-enriched SCN5A missense variant (T220I) that acts as a natural lifelong cardiac sodium channel blockade. Researchers found this genetic variant significantly impacts cardiac arrhythmias, associated mortality, and electrocardiogram phenotypes. The observational study encompassed over 1 million individuals across three large cohorts. These findings demonstrate a genetic proxy&#8217;s role in influencing cardiac electrical activity and associated clinical outcomes.</p>
<h4>Article 2: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41277423" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41277423</a></p>
<p><strong>Summary:</strong> This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<h4>Article 3: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41277423" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41277423</a></p>
<p><strong>Summary:</strong> This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<h4>Article 4: Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115437" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115437</a></p>
<p><strong>Summary:</strong> This individual-level pooled analysis, FLUNITY-HD, integrated data from two large-scale trials conducted in Denmark and Spain, enhancing generalizability. The study determined the relative vaccine effectiveness of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine against severe clinical outcomes in older adults. This comprehensive assessment provided important comparative information on influenza vaccine efficacy for hospitalizations in this vulnerable population. The pooled analysis yielded a robust assessment of vaccine performance in older adults.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. This study identified a specific Finnish-enriched SCN5A missense variant (T220I) that acts as a natural lifelong cardiac sodium channel blockade. Researchers found this genetic variant significantly impacts cardiac arrhythmias, associated mortality, and electrocardiogram phenotypes. The observational study encompassed over 1 million individuals across three large cohorts. These findings demonstrate a genetic proxy&#8217;s role in influencing cardiac electrical activity and associated clinical outcomes.</p>
<p>Article number two. Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<p>Article number three. Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<p>Article number four. Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis. This individual-level pooled analysis, FLUNITY-HD, integrated data from two large-scale trials conducted in Denmark and Spain, enhancing generalizability. The study determined the relative vaccine effectiveness of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine against severe clinical outcomes in older adults. This comprehensive assessment provided important comparative information on influenza vaccine efficacy for hospitalizations in this vulnerable population. The pooled analysis yielded a robust assessment of vaccine performance in older adults. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertrophic cardiomyopathy, proteomics, cardiac sodium channel, genetic variant, proteoforms, vaccine effectiveness, sarcomere, influenza vaccine, older adults, electrocardiogram, arrhythmias, cellular compartments, high-dose vaccine, hospitalizations, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/">Genetic Sodium Blockade for Arrhythmias 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and proteomics. Key takeaway: Genetic Sodium Blockade for Arrhythmias.
Article Links:
Article 1: Leverag]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and proteomics. Key takeaway: Genetic Sodium Blockade for Arrhythmias.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41277422">Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41277423">Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41277423">Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41115437">Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.</a> (Lancet (London, England))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/">https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41277422" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41277422</a></p>
<p><strong>Summary:</strong> This study identified a specific Finnish-enriched SCN5A missense variant (T220I) that acts as a natural lifelong cardiac sodium channel blockade. Researchers found this genetic variant significantly impacts cardiac arrhythmias, associated mortality, and electrocardiogram phenotypes. The observational study encompassed over 1 million individuals across three large cohorts. These findings demonstrate a genetic proxy&#8217;s role in influencing cardiac electrical activity and associated clinical outcomes.</p>
<h4>Article 2: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41277423" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41277423</a></p>
<p><strong>Summary:</strong> This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<h4>Article 3: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41277423" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41277423</a></p>
<p><strong>Summary:</strong> This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<h4>Article 4: Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115437" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115437</a></p>
<p><strong>Summary:</strong> This individual-level pooled analysis, FLUNITY-HD, integrated data from two large-scale trials conducted in Denmark and Spain, enhancing generalizability. The study determined the relative vaccine effectiveness of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine against severe clinical outcomes in older adults. This comprehensive assessment provided important comparative information on influenza vaccine efficacy for hospitalizations in this vulnerable population. The pooled analysis yielded a robust assessment of vaccine performance in older adults.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. This study identified a specific Finnish-enriched SCN5A missense variant (T220I) that acts as a natural lifelong cardiac sodium channel blockade. Researchers found this genetic variant significantly impacts cardiac arrhythmias, associated mortality, and electrocardiogram phenotypes. The observational study encompassed over 1 million individuals across three large cohorts. These findings demonstrate a genetic proxy&#8217;s role in influencing cardiac electrical activity and associated clinical outcomes.</p>
<p>Article number two. Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<p>Article number three. Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.</p>
<p>Article number four. Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis. This individual-level pooled analysis, FLUNITY-HD, integrated data from two large-scale trials conducted in Denmark and Spain, enhancing generalizability. The study determined the relative vaccine effectiveness of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine against severe clinical outcomes in older adults. This comprehensive assessment provided important comparative information on influenza vaccine efficacy for hospitalizations in this vulnerable population. The pooled analysis yielded a robust assessment of vaccine performance in older adults. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertrophic cardiomyopathy, proteomics, cardiac sodium channel, genetic variant, proteoforms, vaccine effectiveness, sarcomere, influenza vaccine, older adults, electrocardiogram, arrhythmias, cellular compartments, high-dose vaccine, hospitalizations, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/">Genetic Sodium Blockade for Arrhythmias 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251124_073700.mp3" length="3333058" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and proteomics. Key takeaway: Genetic Sodium Blockade for Arrhythmias.
Article Links:
Article 1: Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. (Circulation)
Article 2: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. (Circulation. Heart failure)
Article 3: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. (Circulation. Heart failure)
Article 4: Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis. (Lancet (London, England))
Full episode page: https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/
 Featured Articles
Article 1: Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41277422
Summary: This study identified a specific Finnish-enriched SCN5A missense variant (T220I) that acts as a natural lifelong cardiac sodium channel blockade. Researchers found this genetic variant significantly impacts cardiac arrhythmias, associated mortality, and electrocardiogram phenotypes. The observational study encompassed over 1 million individuals across three large cohorts. These findings demonstrate a genetic proxy&#8217;s role in influencing cardiac electrical activity and associated clinical outcomes.
Article 2: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41277423
Summary: This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.
Article 3: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41277423
Summary: This research demonstrated that global proteoform alterations across multiple cellular compartments underlie obstructive hypertrophic cardiomyopathy. The study established that contributions beyond the sarcomere are significant to the heterogeneity of hypertrophic cardiomyopathy phenotypes. Top-down proteomics was identified as a powerful method for analyzing proteoforms, revealing their crucial role in disease mechanisms. These findings advanced the understanding of hypertrophic cardiomyopathy beyond traditional sarcomeric views.
Article 4: Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
Journal: Lancet (London, England)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41115437
Summary: This individual-level pooled analysis, FLUNITY-HD, integrated data from two large-scale trials conducted in Denmark and Spain, enhancing generalizability. The study determined the relative vaccine effectiveness of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine against severe clinical outcomes in older adults. This comprehensive assessment provided important comparative information on influenza vaccine efficacy for hospitalizations in this vulnerable population. The pooled analysis yielded]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and proteomics. Key takeaway: Genetic Sodium Blockade for Arrhythmias.
Article Links:
Article 1: Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. (Circulation)
Article 2: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. (Circulation. Heart failure)
Article 3: Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy. (Circulation. Heart failure)
Article 4: Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis. (Lancet (London, England))
Full episode page: https://podcast.explainheart.com/podcast/genetic-sodium-blockade-for-arrhythmias-11-24-25/
 Featured Articles
Article 1: Leveragi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Novel R.V.O.T. Repair in Tetralogy of Fallot 11/24/25</title>
	<link>https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/</link>
	<pubDate>Mon, 24 Nov 2025 11:01:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like atrial septal defect and dextrocardia. Key takeaway: Novel R.V.O.T. Repair in Tetralogy of Fallot.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41269259">An Encouraging Approach to Complex ASDs: A Multicenter Study.</a> (Pediatric cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41269258">Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot.</a> (Pediatric cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41267525">Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess.</a> (Cardiology in the young)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41218621">Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.</a> (Lancet (London, England))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41213283">Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.</a> (Lancet (London, England))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/">https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: An Encouraging Approach to Complex ASDs: A Multicenter Study.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269259</a></p>
<p><strong>Summary:</strong> The study found that transcatheter closure was performed in patients with complex atrial septal defects presenting with challenging conditions such as large defects, rim deficiency, or multifenestrated defects. This multicenter retrospective analysis evaluated the application of transcatheter techniques in cases where surgical repair might traditionally be preferred. The inclusion of patients with low age and weight also demonstrated the broad application of this approach. This indicates an encouraging expansion of percutaneous atrial septal defect closure to more complicated anatomies.</p>
<h4>Article 2: Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269258" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269258</a></p>
<p><strong>Summary:</strong> A novel transcatheter approach successfully addressed a giant dysfunctional right ventricular outflow tract in a patient with repaired Tetralogy of Fallot and severe pulmonary insufficiency. This innovative strategy involved the parallel placement of a transcatheter valve and a stent, followed by subsequent stent occlusion. This method offered an alternative to open surgery in a complex anatomical case where conventional pulmonary valve replacement options were challenging. The procedure effectively managed right ventricular dilation and arrhythmia risk associated with the dysfunctional outflow tract.</p>
<h4>Article 3: Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41267525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41267525</a></p>
<p><strong>Summary:</strong> A 32-year-old adult male was incidentally diagnosed with a complex cyanotic congenital heart defect, including isolated dextrocardia, Double Inlet Left Ventricle (l-looped), and l-Transposed Great Arteries with subpulmonary stenosis. The patient survived into adulthood without cardiac surgeries or medications despite single ventricle physiology. This prolonged survival was attributed to a &#8220;self-banded&#8221; pulmonary flow, a protective physiological mechanism that naturally regulated pulmonary blood flow. This case highlights how unique compensatory mechanisms can enable long-term survival in severe congenital heart conditions.</p>
<h4>Article 4: Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41218621" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41218621</a></p>
<p><strong>Summary:</strong> Sodium glucose co-transporter two inhibitors, such as dapagliflozin, reduce albuminuria and the risk of chronic kidney disease progression. Non-steroidal mineralocorticoid receptor antagonists demonstrate similar benefits in patients with type two diabetes and chronic kidney disease. The MIRO-CKD multicenter, randomised, double-blind, active-controlled, phase 2b clinical trial investigated the efficacy and safety of the novel mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin. This study explored a combination therapeutic approach building on the established benefits of each drug class for patients with chronic kidney disease and albuminuria.</p>
<h4>Article 5: Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41213283" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41213283</a></p>
<p><strong>Summary:</strong> Chronic kidney disease consistently ranks among the leading causes of global mortality and morbidity. This systematic analysis for the Global Burden of Disease Study 2023 provided extensive global, regional, and national chronic kidney disease estimates for adults aged 20 years and older. The data, covering 204 countries and territories from 1990 to 2023, delivers crucial information to inform evidence-based policies. These findings are essential for targeted strategies in chronic kidney disease identification and treatment worldwide.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. An Encouraging Approach to Complex ASDs: A Multicenter Study. The study found that transcatheter closure was performed in patients with complex atrial septal defects presenting with challenging conditions such as large defects, rim deficiency, or multifenestrated defects. This multicenter retrospective analysis evaluated the application of transcatheter techniques in cases where surgical repair might traditionally be preferred. The inclusion of patients with low age and weight also demonstrated the broad application of this approach. This indicates an encouraging expansion of percutaneous atrial septal defect closure to more complicated anatomies.</p>
<p>Article number two. Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot. A novel transcatheter approach successfully addressed a giant dysfunctional right ventricular outflow tract in a patient with repaired Tetralogy of Fallot and severe pulmonary insufficiency. This innovative strategy involved the parallel placement of a transcatheter valve and a stent, followed by subsequent stent occlusion. This method offered an alternative to open surgery in a complex anatomical case where conventional pulmonary valve replacement options were challenging. The procedure effectively managed right ventricular dilation and arrhythmia risk associated with the dysfunctional outflow tract.</p>
<p>Article number three. Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess. A 32-year-old adult male was incidentally diagnosed with a complex cyanotic congenital heart defect, including isolated dextrocardia, Double Inlet Left Ventricle (l-looped), and l-Transposed Great Arteries with subpulmonary stenosis. The patient survived into adulthood without cardiac surgeries or medications despite single ventricle physiology. This prolonged survival was attributed to a &#8220;self-banded&#8221; pulmonary flow, a protective physiological mechanism that naturally regulated pulmonary blood flow. This case highlights how unique compensatory mechanisms can enable long-term survival in severe congenital heart conditions.</p>
<p>Article number four. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. Sodium glucose co-transporter two inhibitors, such as dapagliflozin, reduce albuminuria and the risk of chronic kidney disease progression. Non-steroidal mineralocorticoid receptor antagonists demonstrate similar benefits in patients with type two diabetes and chronic kidney disease. The MIRO-CKD multicenter, randomised, double-blind, active-controlled, phase 2b clinical trial investigated the efficacy and safety of the novel mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin. This study explored a combination therapeutic approach building on the established benefits of each drug class for patients with chronic kidney disease and albuminuria.</p>
<p>Article number five. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Chronic kidney disease consistently ranks among the leading causes of global mortality and morbidity. This systematic analysis for the Global Burden of Disease Study 2023 provided extensive global, regional, and national chronic kidney disease estimates for adults aged 20 years and older. The data, covering 204 countries and territories from 1990 to 2023, delivers crucial information to inform evidence-based policies. These findings are essential for targeted strategies in chronic kidney disease identification and treatment worldwide. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>atrial septal defect, dextrocardia, Double Inlet Left Ventricle, transcatheter closure, congenital heart defect, albuminuria, single ventricle physiology, epidemiology, Sodium glucose co-transporter two inhibitors, pediatric cardiology, global burden of disease, pulmonary insufficiency, Tetralogy of Fallot, balcinrenone, dapagliflozin, subpulmonary stenosis, chronic kidney disease, complex congenital heart disease, Transposed Great Arteries, right ventricular outflow tract, risk factors, transcatheter pulmonary valve replacement, mineralocorticoid receptor antagonists, morbidity, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/">Novel R.V.O.T. Repair in Tetralogy of Fallot 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like atrial septal defect and dextrocardia. Key takeaway: Novel R.V.O.T. Repair in Tetralogy of Fallot.
Article Links:
Article 1: An Enco]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like atrial septal defect and dextrocardia. Key takeaway: Novel R.V.O.T. Repair in Tetralogy of Fallot.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41269259">An Encouraging Approach to Complex ASDs: A Multicenter Study.</a> (Pediatric cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41269258">Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot.</a> (Pediatric cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41267525">Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess.</a> (Cardiology in the young)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41218621">Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.</a> (Lancet (London, England))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41213283">Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.</a> (Lancet (London, England))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/">https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: An Encouraging Approach to Complex ASDs: A Multicenter Study.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269259</a></p>
<p><strong>Summary:</strong> The study found that transcatheter closure was performed in patients with complex atrial septal defects presenting with challenging conditions such as large defects, rim deficiency, or multifenestrated defects. This multicenter retrospective analysis evaluated the application of transcatheter techniques in cases where surgical repair might traditionally be preferred. The inclusion of patients with low age and weight also demonstrated the broad application of this approach. This indicates an encouraging expansion of percutaneous atrial septal defect closure to more complicated anatomies.</p>
<h4>Article 2: Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269258" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269258</a></p>
<p><strong>Summary:</strong> A novel transcatheter approach successfully addressed a giant dysfunctional right ventricular outflow tract in a patient with repaired Tetralogy of Fallot and severe pulmonary insufficiency. This innovative strategy involved the parallel placement of a transcatheter valve and a stent, followed by subsequent stent occlusion. This method offered an alternative to open surgery in a complex anatomical case where conventional pulmonary valve replacement options were challenging. The procedure effectively managed right ventricular dilation and arrhythmia risk associated with the dysfunctional outflow tract.</p>
<h4>Article 3: Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess.</h4>
<p><strong>Journal:</strong> Cardiology in the young</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41267525" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41267525</a></p>
<p><strong>Summary:</strong> A 32-year-old adult male was incidentally diagnosed with a complex cyanotic congenital heart defect, including isolated dextrocardia, Double Inlet Left Ventricle (l-looped), and l-Transposed Great Arteries with subpulmonary stenosis. The patient survived into adulthood without cardiac surgeries or medications despite single ventricle physiology. This prolonged survival was attributed to a &#8220;self-banded&#8221; pulmonary flow, a protective physiological mechanism that naturally regulated pulmonary blood flow. This case highlights how unique compensatory mechanisms can enable long-term survival in severe congenital heart conditions.</p>
<h4>Article 4: Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41218621" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41218621</a></p>
<p><strong>Summary:</strong> Sodium glucose co-transporter two inhibitors, such as dapagliflozin, reduce albuminuria and the risk of chronic kidney disease progression. Non-steroidal mineralocorticoid receptor antagonists demonstrate similar benefits in patients with type two diabetes and chronic kidney disease. The MIRO-CKD multicenter, randomised, double-blind, active-controlled, phase 2b clinical trial investigated the efficacy and safety of the novel mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin. This study explored a combination therapeutic approach building on the established benefits of each drug class for patients with chronic kidney disease and albuminuria.</p>
<h4>Article 5: Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.</h4>
<p><strong>Journal:</strong> Lancet (London, England)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41213283" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41213283</a></p>
<p><strong>Summary:</strong> Chronic kidney disease consistently ranks among the leading causes of global mortality and morbidity. This systematic analysis for the Global Burden of Disease Study 2023 provided extensive global, regional, and national chronic kidney disease estimates for adults aged 20 years and older. The data, covering 204 countries and territories from 1990 to 2023, delivers crucial information to inform evidence-based policies. These findings are essential for targeted strategies in chronic kidney disease identification and treatment worldwide.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. An Encouraging Approach to Complex ASDs: A Multicenter Study. The study found that transcatheter closure was performed in patients with complex atrial septal defects presenting with challenging conditions such as large defects, rim deficiency, or multifenestrated defects. This multicenter retrospective analysis evaluated the application of transcatheter techniques in cases where surgical repair might traditionally be preferred. The inclusion of patients with low age and weight also demonstrated the broad application of this approach. This indicates an encouraging expansion of percutaneous atrial septal defect closure to more complicated anatomies.</p>
<p>Article number two. Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot. A novel transcatheter approach successfully addressed a giant dysfunctional right ventricular outflow tract in a patient with repaired Tetralogy of Fallot and severe pulmonary insufficiency. This innovative strategy involved the parallel placement of a transcatheter valve and a stent, followed by subsequent stent occlusion. This method offered an alternative to open surgery in a complex anatomical case where conventional pulmonary valve replacement options were challenging. The procedure effectively managed right ventricular dilation and arrhythmia risk associated with the dysfunctional outflow tract.</p>
<p>Article number three. Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess. A 32-year-old adult male was incidentally diagnosed with a complex cyanotic congenital heart defect, including isolated dextrocardia, Double Inlet Left Ventricle (l-looped), and l-Transposed Great Arteries with subpulmonary stenosis. The patient survived into adulthood without cardiac surgeries or medications despite single ventricle physiology. This prolonged survival was attributed to a &#8220;self-banded&#8221; pulmonary flow, a protective physiological mechanism that naturally regulated pulmonary blood flow. This case highlights how unique compensatory mechanisms can enable long-term survival in severe congenital heart conditions.</p>
<p>Article number four. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. Sodium glucose co-transporter two inhibitors, such as dapagliflozin, reduce albuminuria and the risk of chronic kidney disease progression. Non-steroidal mineralocorticoid receptor antagonists demonstrate similar benefits in patients with type two diabetes and chronic kidney disease. The MIRO-CKD multicenter, randomised, double-blind, active-controlled, phase 2b clinical trial investigated the efficacy and safety of the novel mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin. This study explored a combination therapeutic approach building on the established benefits of each drug class for patients with chronic kidney disease and albuminuria.</p>
<p>Article number five. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Chronic kidney disease consistently ranks among the leading causes of global mortality and morbidity. This systematic analysis for the Global Burden of Disease Study 2023 provided extensive global, regional, and national chronic kidney disease estimates for adults aged 20 years and older. The data, covering 204 countries and territories from 1990 to 2023, delivers crucial information to inform evidence-based policies. These findings are essential for targeted strategies in chronic kidney disease identification and treatment worldwide. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>atrial septal defect, dextrocardia, Double Inlet Left Ventricle, transcatheter closure, congenital heart defect, albuminuria, single ventricle physiology, epidemiology, Sodium glucose co-transporter two inhibitors, pediatric cardiology, global burden of disease, pulmonary insufficiency, Tetralogy of Fallot, balcinrenone, dapagliflozin, subpulmonary stenosis, chronic kidney disease, complex congenital heart disease, Transposed Great Arteries, right ventricular outflow tract, risk factors, transcatheter pulmonary valve replacement, mineralocorticoid receptor antagonists, morbidity, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/">Novel R.V.O.T. Repair in Tetralogy of Fallot 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251124_060039.mp3" length="4523406" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like atrial septal defect and dextrocardia. Key takeaway: Novel R.V.O.T. Repair in Tetralogy of Fallot.
Article Links:
Article 1: An Encouraging Approach to Complex ASDs: A Multicenter Study. (Pediatric cardiology)
Article 2: Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot. (Pediatric cardiology)
Article 3: Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess. (Cardiology in the young)
Article 4: Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. (Lancet (London, England))
Article 5: Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. (Lancet (London, England))
Full episode page: https://podcast.explainheart.com/podcast/novel-r-v-o-t-repair-in-tetralogy-of-fallot-11-24-25/
 Featured Articles
Article 1: An Encouraging Approach to Complex ASDs: A Multicenter Study.
Journal: Pediatric cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41269259
Summary: The study found that transcatheter closure was performed in patients with complex atrial septal defects presenting with challenging conditions such as large defects, rim deficiency, or multifenestrated defects. This multicenter retrospective analysis evaluated the application of transcatheter techniques in cases where surgical repair might traditionally be preferred. The inclusion of patients with low age and weight also demonstrated the broad application of this approach. This indicates an encouraging expansion of percutaneous atrial septal defect closure to more complicated anatomies.
Article 2: Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot.
Journal: Pediatric cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41269258
Summary: A novel transcatheter approach successfully addressed a giant dysfunctional right ventricular outflow tract in a patient with repaired Tetralogy of Fallot and severe pulmonary insufficiency. This innovative strategy involved the parallel placement of a transcatheter valve and a stent, followed by subsequent stent occlusion. This method offered an alternative to open surgery in a complex anatomical case where conventional pulmonary valve replacement options were challenging. The procedure effectively managed right ventricular dilation and arrhythmia risk associated with the dysfunctional outflow tract.
Article 3: Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess.
Journal: Cardiology in the young
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41267525
Summary: A 32-year-old adult male was incidentally diagnosed with a complex cyanotic congenital heart defect, including isolated dextrocardia, Double Inlet Left Ventricle (l-looped), and l-Transposed Great Arteries with subpulmonary stenosis. The patient survived into adulthood without cardiac surgeries or medications despite single ventricle physiology. This prolonged survival was attributed to a &#8220;self-banded&#8221; pulmonary flow, a protective physiological mechanism that naturally regulated pulmonary blood flow. This case highlights how unique compensatory mechanisms can enable long-term survival in severe congenital heart conditions.
Article 4: Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
J]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like atrial septal defect and dextrocardia. Key takeaway: Novel R.V.O.T. Repair in Tetralogy of Fallot.
Article Links:
Article 1: An Encouraging Approach to Complex ASDs: A Multicenter Study. (Pediatric cardiology)
Article 2: Parallel Transcatheter Valve and Stent Placement with Subsequent Stent Occlusion to Address a Giant Dysfunctional RVOT in a Patient with Repaired Tetralogy of Fallot. (Pediatric cardiology)
Article 3: Incidental diagnosis of a complex cyanotic congenital heart defect in a 32-year-old with orbital abscess. (Cardiology in the young)
Article 4: Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. (Lancet (London, England))
Article 5: Global, regional, and national burden of chronic kidney disease i]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Fetal Factors Link Maternal Obesity to Heart Risk 11/24/25</title>
	<link>https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/</link>
	<pubDate>Mon, 24 Nov 2025 10:25:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like lymphoproliferative disorders and antithrombin. Key takeaway: Fetal Factors Link Maternal Obesity to Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41275897">Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.</a> (American heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41269698">Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41273424">Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing.</a> (Pediatric cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41273423">Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases.</a> (Pediatric cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41273422">Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/">https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41275897" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41275897</a></p>
<p><strong>Summary:</strong> The study analyzed 50370 heart transplant recipients from the United Network for Organ Sharing Registry. This comprehensive analysis identified the incidence, demographics, and specific risk factors associated with de novo malignancy, lymphoproliferative disorders, and solid-organ malignancy subtypes. The findings provided crucial data for understanding cancer risk after heart transplantation. This information is vital for directing prevention and screening strategies in this patient population.</p>
<h4>Article 2: Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269698" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269698</a></p>
<p><strong>Summary:</strong> This study demonstrated that human fetal circulating factors derived from pregnancies complicated by maternal obesity upregulate genes linked to pathological hypertrophy in neonatal rat cardiomyocytes. The research thus uncovered a mechanistic link where these specific factors induce cardiac changes. This finding clarifies how maternal obesity contributes to increased offspring cardiovascular risk and fetal cardiac dysfunction.</p>
<h4>Article 3: Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273424" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273424</a></p>
<p><strong>Summary:</strong> The study characterized the relationship between multiparametric cardiac magnetic resonance imaging and markers of exercise capacity in pediatric heart transplant recipients. Data from patients who underwent cardiac magnetic resonance imaging within one year of cardiopulmonary exercise testing informed how graft assessment by imaging reflects functional capacity. This analysis contributed to understanding the utility of cardiac magnetic resonance imaging for surveillance of rejection and coronary artery vasculopathy.</p>
<h4>Article 4: Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273423" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273423</a></p>
<p><strong>Summary:</strong> This study evaluated the impact of coronary artery anomalies on early surgical outcomes in 251 consecutive arterial switch operations performed for transposition of the great arteries and Taussig-Bing anomaly. The analysis provided a comprehensive assessment of factors influencing mortality and postoperative recovery in these complex pediatric cardiac procedures. The findings clarified the prognostic significance of these anomalies in arterial switch operation patients.</p>
<h4>Article 5: Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273422" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273422</a></p>
<p><strong>Summary:</strong> This pilot study compared heparin-based anticoagulation strategies in infants and children with and without high output chylothorax after cardiac surgery. The research addressed concerns that loss of antithrombin in chylothorax may impair the therapeutic effect of antithrombin-dependent anticoagulants like unfractionated heparin and low molecular weight heparin (enoxaparin). The findings provided initial data on the management of anticoagulation in these challenging pediatric patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry. The study analyzed 50370 heart transplant recipients from the United Network for Organ Sharing Registry. This comprehensive analysis identified the incidence, demographics, and specific risk factors associated with de novo malignancy, lymphoproliferative disorders, and solid-organ malignancy subtypes. The findings provided crucial data for understanding cancer risk after heart transplantation. This information is vital for directing prevention and screening strategies in this patient population.</p>
<p>Article number two. Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes. This study demonstrated that human fetal circulating factors derived from pregnancies complicated by maternal obesity upregulate genes linked to pathological hypertrophy in neonatal rat cardiomyocytes. The research thus uncovered a mechanistic link where these specific factors induce cardiac changes. This finding clarifies how maternal obesity contributes to increased offspring cardiovascular risk and fetal cardiac dysfunction.</p>
<p>Article number three. Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing. The study characterized the relationship between multiparametric cardiac magnetic resonance imaging and markers of exercise capacity in pediatric heart transplant recipients. Data from patients who underwent cardiac magnetic resonance imaging within one year of cardiopulmonary exercise testing informed how graft assessment by imaging reflects functional capacity. This analysis contributed to understanding the utility of cardiac magnetic resonance imaging for surveillance of rejection and coronary artery vasculopathy.</p>
<p>Article number four. Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases. This study evaluated the impact of coronary artery anomalies on early surgical outcomes in 251 consecutive arterial switch operations performed for transposition of the great arteries and Taussig-Bing anomaly. The analysis provided a comprehensive assessment of factors influencing mortality and postoperative recovery in these complex pediatric cardiac procedures. The findings clarified the prognostic significance of these anomalies in arterial switch operation patients.</p>
<p>Article number five. Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study. This pilot study compared heparin-based anticoagulation strategies in infants and children with and without high output chylothorax after cardiac surgery. The research addressed concerns that loss of antithrombin in chylothorax may impair the therapeutic effect of antithrombin-dependent anticoagulants like unfractionated heparin and low molecular weight heparin (enoxaparin). The findings provided initial data on the management of anticoagulation in these challenging pediatric patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lymphoproliferative disorders, antithrombin, circulating factors, arterial switch operation, unfractionated heparin, de novo malignancy, maternal obesity, fetal cardiovascular risk, transposition of the great arteries, low molecular weight heparin, coronary artery vasculopathy, cardiopulmonary exercise testing, cardiomyocyte hypertrophy, cardiac magnetic resonance imaging, heart transplantation, Taussig-Bing anomaly, chylothorax, early surgical outcomes, coronary artery anomalies, cardiac surgery, malignancy, neonatal rat cardiomyocytes, pediatric heart transplant recipients, rejection surveillance, cancer risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/">Fetal Factors Link Maternal Obesity to Heart Risk 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like lymphoproliferative disorders and antithrombin. Key takeaway: Fetal Factors Link Maternal Obesity to Heart Risk.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like lymphoproliferative disorders and antithrombin. Key takeaway: Fetal Factors Link Maternal Obesity to Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41275897">Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.</a> (American heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41269698">Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41273424">Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing.</a> (Pediatric cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41273423">Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases.</a> (Pediatric cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41273422">Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/">https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41275897" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41275897</a></p>
<p><strong>Summary:</strong> The study analyzed 50370 heart transplant recipients from the United Network for Organ Sharing Registry. This comprehensive analysis identified the incidence, demographics, and specific risk factors associated with de novo malignancy, lymphoproliferative disorders, and solid-organ malignancy subtypes. The findings provided crucial data for understanding cancer risk after heart transplantation. This information is vital for directing prevention and screening strategies in this patient population.</p>
<h4>Article 2: Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269698" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269698</a></p>
<p><strong>Summary:</strong> This study demonstrated that human fetal circulating factors derived from pregnancies complicated by maternal obesity upregulate genes linked to pathological hypertrophy in neonatal rat cardiomyocytes. The research thus uncovered a mechanistic link where these specific factors induce cardiac changes. This finding clarifies how maternal obesity contributes to increased offspring cardiovascular risk and fetal cardiac dysfunction.</p>
<h4>Article 3: Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273424" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273424</a></p>
<p><strong>Summary:</strong> The study characterized the relationship between multiparametric cardiac magnetic resonance imaging and markers of exercise capacity in pediatric heart transplant recipients. Data from patients who underwent cardiac magnetic resonance imaging within one year of cardiopulmonary exercise testing informed how graft assessment by imaging reflects functional capacity. This analysis contributed to understanding the utility of cardiac magnetic resonance imaging for surveillance of rejection and coronary artery vasculopathy.</p>
<h4>Article 4: Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273423" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273423</a></p>
<p><strong>Summary:</strong> This study evaluated the impact of coronary artery anomalies on early surgical outcomes in 251 consecutive arterial switch operations performed for transposition of the great arteries and Taussig-Bing anomaly. The analysis provided a comprehensive assessment of factors influencing mortality and postoperative recovery in these complex pediatric cardiac procedures. The findings clarified the prognostic significance of these anomalies in arterial switch operation patients.</p>
<h4>Article 5: Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273422" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273422</a></p>
<p><strong>Summary:</strong> This pilot study compared heparin-based anticoagulation strategies in infants and children with and without high output chylothorax after cardiac surgery. The research addressed concerns that loss of antithrombin in chylothorax may impair the therapeutic effect of antithrombin-dependent anticoagulants like unfractionated heparin and low molecular weight heparin (enoxaparin). The findings provided initial data on the management of anticoagulation in these challenging pediatric patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry. The study analyzed 50370 heart transplant recipients from the United Network for Organ Sharing Registry. This comprehensive analysis identified the incidence, demographics, and specific risk factors associated with de novo malignancy, lymphoproliferative disorders, and solid-organ malignancy subtypes. The findings provided crucial data for understanding cancer risk after heart transplantation. This information is vital for directing prevention and screening strategies in this patient population.</p>
<p>Article number two. Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes. This study demonstrated that human fetal circulating factors derived from pregnancies complicated by maternal obesity upregulate genes linked to pathological hypertrophy in neonatal rat cardiomyocytes. The research thus uncovered a mechanistic link where these specific factors induce cardiac changes. This finding clarifies how maternal obesity contributes to increased offspring cardiovascular risk and fetal cardiac dysfunction.</p>
<p>Article number three. Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing. The study characterized the relationship between multiparametric cardiac magnetic resonance imaging and markers of exercise capacity in pediatric heart transplant recipients. Data from patients who underwent cardiac magnetic resonance imaging within one year of cardiopulmonary exercise testing informed how graft assessment by imaging reflects functional capacity. This analysis contributed to understanding the utility of cardiac magnetic resonance imaging for surveillance of rejection and coronary artery vasculopathy.</p>
<p>Article number four. Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases. This study evaluated the impact of coronary artery anomalies on early surgical outcomes in 251 consecutive arterial switch operations performed for transposition of the great arteries and Taussig-Bing anomaly. The analysis provided a comprehensive assessment of factors influencing mortality and postoperative recovery in these complex pediatric cardiac procedures. The findings clarified the prognostic significance of these anomalies in arterial switch operation patients.</p>
<p>Article number five. Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study. This pilot study compared heparin-based anticoagulation strategies in infants and children with and without high output chylothorax after cardiac surgery. The research addressed concerns that loss of antithrombin in chylothorax may impair the therapeutic effect of antithrombin-dependent anticoagulants like unfractionated heparin and low molecular weight heparin (enoxaparin). The findings provided initial data on the management of anticoagulation in these challenging pediatric patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lymphoproliferative disorders, antithrombin, circulating factors, arterial switch operation, unfractionated heparin, de novo malignancy, maternal obesity, fetal cardiovascular risk, transposition of the great arteries, low molecular weight heparin, coronary artery vasculopathy, cardiopulmonary exercise testing, cardiomyocyte hypertrophy, cardiac magnetic resonance imaging, heart transplantation, Taussig-Bing anomaly, chylothorax, early surgical outcomes, coronary artery anomalies, cardiac surgery, malignancy, neonatal rat cardiomyocytes, pediatric heart transplant recipients, rejection surveillance, cancer risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/">Fetal Factors Link Maternal Obesity to Heart Risk 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251124_052434.mp3" length="3736807" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like lymphoproliferative disorders and antithrombin. Key takeaway: Fetal Factors Link Maternal Obesity to Heart Risk.
Article Links:
Article 1: Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry. (American heart journal)
Article 2: Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes. (American journal of physiology. Heart and circulatory physiology)
Article 3: Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing. (Pediatric cardiology)
Article 4: Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases. (Pediatric cardiology)
Article 5: Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study. (Pediatric cardiology)
Full episode page: https://podcast.explainheart.com/podcast/fetal-factors-link-maternal-obesity-to-heart-risk-11-24-25/
 Featured Articles
Article 1: Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.
Journal: American heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41275897
Summary: The study analyzed 50370 heart transplant recipients from the United Network for Organ Sharing Registry. This comprehensive analysis identified the incidence, demographics, and specific risk factors associated with de novo malignancy, lymphoproliferative disorders, and solid-organ malignancy subtypes. The findings provided crucial data for understanding cancer risk after heart transplantation. This information is vital for directing prevention and screening strategies in this patient population.
Article 2: Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41269698
Summary: This study demonstrated that human fetal circulating factors derived from pregnancies complicated by maternal obesity upregulate genes linked to pathological hypertrophy in neonatal rat cardiomyocytes. The research thus uncovered a mechanistic link where these specific factors induce cardiac changes. This finding clarifies how maternal obesity contributes to increased offspring cardiovascular risk and fetal cardiac dysfunction.
Article 3: Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing.
Journal: Pediatric cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41273424
Summary: The study characterized the relationship between multiparametric cardiac magnetic resonance imaging and markers of exercise capacity in pediatric heart transplant recipients. Data from patients who underwent cardiac magnetic resonance imaging within one year of cardiopulmonary exercise testing informed how graft assessment by imaging reflects functional capacity. This analysis contributed to understanding the utility of cardiac magnetic resonance imaging for surveillance of rejection and coronary artery vasculopathy.
Article 4: Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases.
Journal: Pediatric cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41273423
Summary: This study evaluated the impact of coronary artery anomalies on early surgical outcomes in 251 consecutive arterial switch operations performed for transposition of the great arteries and Taussig-Bing anomaly. The analysis provided a comprehensive a]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like lymphoproliferative disorders and antithrombin. Key takeaway: Fetal Factors Link Maternal Obesity to Heart Risk.
Article Links:
Article 1: Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry. (American heart journal)
Article 2: Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes. (American journal of physiology. Heart and circulatory physiology)
Article 3: Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing. (Pediatric cardiology)
Article 4: Coronary Anomalies and Early Surgical Outcomes in Transposition of the Great Arteries and Taussig-Bing Anomaly: Insights from 251 Consecutive Arterial Switch Cases. (Pediatric cardiology)
Article 5:]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease 11/24/25</title>
	<link>https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/</link>
	<pubDate>Mon, 24 Nov 2025 07:06:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin and conduction system disease. Key takeaway: Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41276097">Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41276292">Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41276147">Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41276189">Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41276188">Acute type A aortic dissection following TAVI.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/">https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276097" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276097</a></p>
<p><strong>Summary:</strong> This analysis established specific associations between invasive hemodynamic measurements at the time of heart transplantation listing and subsequent waitlist outcomes. The study clarified how various hemodynamic profiles influence a patient&#8217;s risk of removal from the waitlist due to death or clinical deterioration. Utilizing data from the Scientific Registry of Transplant Recipients for adult candidates with statuses one through four and six, this research directly informs risk stratification and optimizes management for patients awaiting heart transplantation. These findings highlight the prognostic significance of pre-transplant hemodynamic assessment.</p>
<h4>Article 2: Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276292" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276292</a></p>
<p><strong>Summary:</strong> This multinational, stepped-wedge cluster-randomized trial established the safety and clinical utility of the European Society of Cardiology 0/1-hour high-sensitivity cardiac troponin algorithm for chest pain triage. The study validated this algorithm across multiple diverse Asian emergency department settings, addressing a critical need for rapid diagnosis and safe patient disposition. Previously showing promising performance in Western cohorts, this research demonstrated the algorithm&#8217;s effectiveness in new populations. These findings support implementing a standardized, efficient diagnostic pathway for chest pain patients in Asian emergency departments.</p>
<h4>Article 3: Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276147</a></p>
<p><strong>Summary:</strong> This report highlighted the underappreciated and lethal phenotype of progressive conduction system disease caused by hydroxychloroquine (H. C. Q.) cardiotoxicity. A 67-year-old female on chronic H. C. Q. developed progressive conduction abnormalities which led to cardiogenic shock and sudden death, despite initial stabilization with isolated atrial pacing. Autopsy findings confirmed extensive sinoatrial and atrioventricular nodal lysosomal toxicity and fibrosis, indicating irreversible cardiac damage. This case underscores the critical need for early vigilance in monitoring for progressive conduction system disease in patients treated with H. C. Q.</p>
<h4>Article 4: Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276189" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276189</a></p>
<p><strong>Summary:</strong> This pooled cohort analysis confirmed that increasing congestion, both pulmonary detected by ultrasound and systemic quantified by inferior vena cava diameter, is associated with worse outcomes in patients with heart failure. The study involved five European cohorts of patients with heart failure, providing robust data on prognostic indicators. The primary outcome, a composite of hospitalization for heart failure and all-cause death, demonstrated the significant prognostic value of assessing both forms of congestion. This research provides a robust understanding of how different levels of fluid retention impact patient prognosis in heart failure.</p>
<h4>Article 5: Acute type A aortic dissection following TAVI.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276188" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276188</a></p>
<p><strong>Summary:</strong> This retrospective analysis characterized the incidence, possible mechanisms, and management of acute type A aortic dissection following transcatheter aortic valve implantation (T. A. V. I.). The study confirmed this complication is rare but severe, frequently necessitating emergent cardiac surgery. Analyzing a large two-center cohort, the research provided crucial data that delineate the risks and optimal approaches for this potentially lethal post-T. A. V. I. complication. These findings help to better understand and manage this critical event in patients undergoing T. A. V. I.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients. This analysis established specific associations between invasive hemodynamic measurements at the time of heart transplantation listing and subsequent waitlist outcomes. The study clarified how various hemodynamic profiles influence a patient&#8217;s risk of removal from the waitlist due to death or clinical deterioration. Utilizing data from the Scientific Registry of Transplant Recipients for adult candidates with statuses one through four and six, this research directly informs risk stratification and optimizes management for patients awaiting heart transplantation. These findings highlight the prognostic significance of pre-transplant hemodynamic assessment.</p>
<p>Article number two. Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial. This multinational, stepped-wedge cluster-randomized trial established the safety and clinical utility of the European Society of Cardiology 0/1-hour high-sensitivity cardiac troponin algorithm for chest pain triage. The study validated this algorithm across multiple diverse Asian emergency department settings, addressing a critical need for rapid diagnosis and safe patient disposition. Previously showing promising performance in Western cohorts, this research demonstrated the algorithm&#8217;s effectiveness in new populations. These findings support implementing a standardized, efficient diagnostic pathway for chest pain patients in Asian emergency departments.</p>
<p>Article number three. Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance. This report highlighted the underappreciated and lethal phenotype of progressive conduction system disease caused by hydroxychloroquine (H. C. Q.) cardiotoxicity. A 67-year-old female on chronic H. C. Q. developed progressive conduction abnormalities which led to cardiogenic shock and sudden death, despite initial stabilization with isolated atrial pacing. Autopsy findings confirmed extensive sinoatrial and atrioventricular nodal lysosomal toxicity and fibrosis, indicating irreversible cardiac damage. This case underscores the critical need for early vigilance in monitoring for progressive conduction system disease in patients treated with H. C. Q.</p>
<p>Article number four. Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis. This pooled cohort analysis confirmed that increasing congestion, both pulmonary detected by ultrasound and systemic quantified by inferior vena cava diameter, is associated with worse outcomes in patients with heart failure. The study involved five European cohorts of patients with heart failure, providing robust data on prognostic indicators. The primary outcome, a composite of hospitalization for heart failure and all-cause death, demonstrated the significant prognostic value of assessing both forms of congestion. This research provides a robust understanding of how different levels of fluid retention impact patient prognosis in heart failure.</p>
<p>Article number five. Acute type A aortic dissection following TAVI. This retrospective analysis characterized the incidence, possible mechanisms, and management of acute type A aortic dissection following transcatheter aortic valve implantation (T. A. V. I.). The study confirmed this complication is rare but severe, frequently necessitating emergent cardiac surgery. Analyzing a large two-center cohort, the research provided crucial data that delineate the risks and optimal approaches for this potentially lethal post-T. A. V. I. complication. These findings help to better understand and manage this critical event in patients undergoing T. A. V. I. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-sensitivity cardiac troponin, conduction system disease, prognosis, ultrasound, sinoatrial node toxicity, transcatheter aortic valve implantation, risk stratification, emergency department, invasive hemodynamics, Hydroxychloroquine cardiotoxicity, Heart failure, T. A. V. I. complications, Chest pain triage, cardiac surgery, systemic congestion, transplant candidate, Heart transplantation, waitlist outcomes, cardiogenic shock, Asian populations, aortic dissection management, Acute type A aortic dissection, inferior vena cava, E. S. C. 0/1-hour algorithm, sudden cardiac death, pulmonary congestion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/">Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin and conduction system disease. Key takeaway: Hydroxychloroquine Cardiotoxicity: Fatal Conduction D]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin and conduction system disease. Key takeaway: Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41276097">Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41276292">Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41276147">Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41276189">Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41276188">Acute type A aortic dissection following TAVI.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/">https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276097" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276097</a></p>
<p><strong>Summary:</strong> This analysis established specific associations between invasive hemodynamic measurements at the time of heart transplantation listing and subsequent waitlist outcomes. The study clarified how various hemodynamic profiles influence a patient&#8217;s risk of removal from the waitlist due to death or clinical deterioration. Utilizing data from the Scientific Registry of Transplant Recipients for adult candidates with statuses one through four and six, this research directly informs risk stratification and optimizes management for patients awaiting heart transplantation. These findings highlight the prognostic significance of pre-transplant hemodynamic assessment.</p>
<h4>Article 2: Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276292" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276292</a></p>
<p><strong>Summary:</strong> This multinational, stepped-wedge cluster-randomized trial established the safety and clinical utility of the European Society of Cardiology 0/1-hour high-sensitivity cardiac troponin algorithm for chest pain triage. The study validated this algorithm across multiple diverse Asian emergency department settings, addressing a critical need for rapid diagnosis and safe patient disposition. Previously showing promising performance in Western cohorts, this research demonstrated the algorithm&#8217;s effectiveness in new populations. These findings support implementing a standardized, efficient diagnostic pathway for chest pain patients in Asian emergency departments.</p>
<h4>Article 3: Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276147</a></p>
<p><strong>Summary:</strong> This report highlighted the underappreciated and lethal phenotype of progressive conduction system disease caused by hydroxychloroquine (H. C. Q.) cardiotoxicity. A 67-year-old female on chronic H. C. Q. developed progressive conduction abnormalities which led to cardiogenic shock and sudden death, despite initial stabilization with isolated atrial pacing. Autopsy findings confirmed extensive sinoatrial and atrioventricular nodal lysosomal toxicity and fibrosis, indicating irreversible cardiac damage. This case underscores the critical need for early vigilance in monitoring for progressive conduction system disease in patients treated with H. C. Q.</p>
<h4>Article 4: Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276189" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276189</a></p>
<p><strong>Summary:</strong> This pooled cohort analysis confirmed that increasing congestion, both pulmonary detected by ultrasound and systemic quantified by inferior vena cava diameter, is associated with worse outcomes in patients with heart failure. The study involved five European cohorts of patients with heart failure, providing robust data on prognostic indicators. The primary outcome, a composite of hospitalization for heart failure and all-cause death, demonstrated the significant prognostic value of assessing both forms of congestion. This research provides a robust understanding of how different levels of fluid retention impact patient prognosis in heart failure.</p>
<h4>Article 5: Acute type A aortic dissection following TAVI.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41276188" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41276188</a></p>
<p><strong>Summary:</strong> This retrospective analysis characterized the incidence, possible mechanisms, and management of acute type A aortic dissection following transcatheter aortic valve implantation (T. A. V. I.). The study confirmed this complication is rare but severe, frequently necessitating emergent cardiac surgery. Analyzing a large two-center cohort, the research provided crucial data that delineate the risks and optimal approaches for this potentially lethal post-T. A. V. I. complication. These findings help to better understand and manage this critical event in patients undergoing T. A. V. I.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients. This analysis established specific associations between invasive hemodynamic measurements at the time of heart transplantation listing and subsequent waitlist outcomes. The study clarified how various hemodynamic profiles influence a patient&#8217;s risk of removal from the waitlist due to death or clinical deterioration. Utilizing data from the Scientific Registry of Transplant Recipients for adult candidates with statuses one through four and six, this research directly informs risk stratification and optimizes management for patients awaiting heart transplantation. These findings highlight the prognostic significance of pre-transplant hemodynamic assessment.</p>
<p>Article number two. Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial. This multinational, stepped-wedge cluster-randomized trial established the safety and clinical utility of the European Society of Cardiology 0/1-hour high-sensitivity cardiac troponin algorithm for chest pain triage. The study validated this algorithm across multiple diverse Asian emergency department settings, addressing a critical need for rapid diagnosis and safe patient disposition. Previously showing promising performance in Western cohorts, this research demonstrated the algorithm&#8217;s effectiveness in new populations. These findings support implementing a standardized, efficient diagnostic pathway for chest pain patients in Asian emergency departments.</p>
<p>Article number three. Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance. This report highlighted the underappreciated and lethal phenotype of progressive conduction system disease caused by hydroxychloroquine (H. C. Q.) cardiotoxicity. A 67-year-old female on chronic H. C. Q. developed progressive conduction abnormalities which led to cardiogenic shock and sudden death, despite initial stabilization with isolated atrial pacing. Autopsy findings confirmed extensive sinoatrial and atrioventricular nodal lysosomal toxicity and fibrosis, indicating irreversible cardiac damage. This case underscores the critical need for early vigilance in monitoring for progressive conduction system disease in patients treated with H. C. Q.</p>
<p>Article number four. Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis. This pooled cohort analysis confirmed that increasing congestion, both pulmonary detected by ultrasound and systemic quantified by inferior vena cava diameter, is associated with worse outcomes in patients with heart failure. The study involved five European cohorts of patients with heart failure, providing robust data on prognostic indicators. The primary outcome, a composite of hospitalization for heart failure and all-cause death, demonstrated the significant prognostic value of assessing both forms of congestion. This research provides a robust understanding of how different levels of fluid retention impact patient prognosis in heart failure.</p>
<p>Article number five. Acute type A aortic dissection following TAVI. This retrospective analysis characterized the incidence, possible mechanisms, and management of acute type A aortic dissection following transcatheter aortic valve implantation (T. A. V. I.). The study confirmed this complication is rare but severe, frequently necessitating emergent cardiac surgery. Analyzing a large two-center cohort, the research provided crucial data that delineate the risks and optimal approaches for this potentially lethal post-T. A. V. I. complication. These findings help to better understand and manage this critical event in patients undergoing T. A. V. I. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-sensitivity cardiac troponin, conduction system disease, prognosis, ultrasound, sinoatrial node toxicity, transcatheter aortic valve implantation, risk stratification, emergency department, invasive hemodynamics, Hydroxychloroquine cardiotoxicity, Heart failure, T. A. V. I. complications, Chest pain triage, cardiac surgery, systemic congestion, transplant candidate, Heart transplantation, waitlist outcomes, cardiogenic shock, Asian populations, aortic dissection management, Acute type A aortic dissection, inferior vena cava, E. S. C. 0/1-hour algorithm, sudden cardiac death, pulmonary congestion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/">Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease 11/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251124_020541.mp3" length="4643360" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin and conduction system disease. Key takeaway: Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease.
Article Links:
Article 1: Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial. (Heart (British Cardiac Society))
Article 3: Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance. (The American journal of cardiology)
Article 4: Systemic and pulmonary congestion by ultrasound and prognosis in heart failure: A pooled cohort analysis. (International journal of cardiology)
Article 5: Acute type A aortic dissection following TAVI. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/hydroxychloroquine-cardiotoxicity-fatal-conduction-disease-11-24-25/
 Featured Articles
Article 1: Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41276097
Summary: This analysis established specific associations between invasive hemodynamic measurements at the time of heart transplantation listing and subsequent waitlist outcomes. The study clarified how various hemodynamic profiles influence a patient&#8217;s risk of removal from the waitlist due to death or clinical deterioration. Utilizing data from the Scientific Registry of Transplant Recipients for adult candidates with statuses one through four and six, this research directly informs risk stratification and optimizes management for patients awaiting heart transplantation. These findings highlight the prognostic significance of pre-transplant hemodynamic assessment.
Article 2: Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41276292
Summary: This multinational, stepped-wedge cluster-randomized trial established the safety and clinical utility of the European Society of Cardiology 0/1-hour high-sensitivity cardiac troponin algorithm for chest pain triage. The study validated this algorithm across multiple diverse Asian emergency department settings, addressing a critical need for rapid diagnosis and safe patient disposition. Previously showing promising performance in Western cohorts, this research demonstrated the algorithm&#8217;s effectiveness in new populations. These findings support implementing a standardized, efficient diagnostic pathway for chest pain patients in Asian emergency departments.
Article 3: Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41276147
Summary: This report highlighted the underappreciated and lethal phenotype of progressive conduction system disease caused by hydroxychloroquine (H. C. Q.) cardiotoxicity. A 67-year-old female on chronic H. C. Q. developed progressive conduction abnormalities which led to cardiogenic shock and sudden death, despite initial stabilization with isolated atrial pacing. Autopsy findings confirmed extensive sinoatrial and atrioventricular nodal lyso]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 24, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin and conduction system disease. Key takeaway: Hydroxychloroquine Cardiotoxicity: Fatal Conduction Disease.
Article Links:
Article 1: Association between Listing Hemodynamics and Heart Transplantation Waitlist Outcomes: an Analysis of the Scientific Registry of Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial. (Heart (British Cardiac Society))
Article 3: Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance. (The American journal of cardiology)
Article 4: Systemic and pulmonary congestion by ultraso]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Boosts C. T. A. Heart Risk Prediction. 11/23/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/</link>
	<pubDate>Mon, 24 Nov 2025 03:19:23 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like machine learning and C. T. A.. Key takeaway: AI Boosts C. T. A. Heart Risk Prediction..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41261979">In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41268665">S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41268664">Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41263073">Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41268668">Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry.</a> (Circulation. Cardiovascular imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/">https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41261979" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41261979</a></p>
<p><strong>Summary:</strong> Human pluripotent stem cell derived cardiomyocytes hold significant promise for in vitro models of the human heart. Achieving full maturation of these cells requires replicating the native cardiac environment, specifically incorporating active mechanical loads such as preload and afterload. These mechanical cues are essential for enhancing cardiomyocyte maturation and improving the utility of these models for disease modeling. This approach represents a critical strategy for advancing the development of more physiologically relevant human heart models.</p>
<h4>Article 2: S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268665</a></p>
<p><strong>Summary:</strong> This study found that coronary microvascular hyperpermeability and subsequent inflammation infiltration are key early characteristics of pressure overload-induced myocardial injury. In mice, endothelial-specific deletion of sphingosine-1-phosphate receptor type one (S1PR1) led to severe pressure overload-induced cardiac dysfunction, while S1PR1 overexpression preserved cardiac function. Researchers demonstrated that S1PR1 activation maintained the coronary endothelial barrier by preventing myosin phosphatase target subunit one (MYPT1) ubiquitination and degradation during pressure overload. These findings reveal a critical role for the S1PR1-MYPT1 pathway in preserving coronary endothelial barrier function and cardiac function under pressure overload, identifying S1PR1 as a potential therapeutic target.</p>
<h4>Article 3: Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268664" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268664</a></p>
<p><strong>Summary:</strong> This study found that nobiletin treatment attenuated cardiac hypertrophy and improved systolic dysfunction in mice models of transverse aortic constriction. Nobiletin also improved the survival rate of these mice. Mechanistically, nobiletin significantly downregulated E one A binding protein P300 expression by directly binding to and activating Sirtuin 5, which in turn promoted P300 degradation. These findings identify nobiletin as a potent activator of Sirtuin 5, suggesting its potential as a promising therapeutic agent for heart failure.</p>
<h4>Article 4: Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41263073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41263073</a></p>
<p><strong>Summary:</strong> Mutations in the potassium inwardly rectifying channel subfamily J member five (KCNJ5) gene drive aldosterone overproduction in a subset of aldosterone-producing adenomas and familial hyperaldosteronism type three. Researchers identified small molecule compounds that specifically antagonize mutant KCNJ5 channels. Compound three demonstrated specific antagonism of mutant KCNJ5 channels with an inhibitory concentration fifty of 20 nanomolar in electrophysiological studies, showing no activity against wild-type KCNJ5. This compound also inhibited mutant KCNJ5-dependent aldosterone production in human adrenal carcinoma cells, identifying a potent and specific antagonist and a promising therapeutic strategy for primary aldosteronism.</p>
<h4>Article 5: Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268668" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268668</a></p>
<p><strong>Summary:</strong> Machine learning models based on coronary computed tomography angiography (C. T. A.) features demonstrated superior performance in predicting major adverse cardiac events compared to traditional risk factors and the coronary artery calcium score. The XGBoost model achieved the highest predictive power with an area under the curve of 0.887 for five-year major adverse cardiac event prediction. This model showed a hazard ratio of 1.95 with a 95 percent confidence interval of 1.77 to 2.15 for major adverse cardiac events. These findings demonstrate the strong potential of machine learning combined with coronary C. T. A. for personalized atherosclerosis evaluation and cardiovascular risk prediction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling. Human pluripotent stem cell derived cardiomyocytes hold significant promise for in vitro models of the human heart. Achieving full maturation of these cells requires replicating the native cardiac environment, specifically incorporating active mechanical loads such as preload and afterload. These mechanical cues are essential for enhancing cardiomyocyte maturation and improving the utility of these models for disease modeling. This approach represents a critical strategy for advancing the development of more physiologically relevant human heart models.</p>
<p>Article number two. S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts. This study found that coronary microvascular hyperpermeability and subsequent inflammation infiltration are key early characteristics of pressure overload-induced myocardial injury. In mice, endothelial-specific deletion of sphingosine-1-phosphate receptor type one (S1PR1) led to severe pressure overload-induced cardiac dysfunction, while S1PR1 overexpression preserved cardiac function. Researchers demonstrated that S1PR1 activation maintained the coronary endothelial barrier by preventing myosin phosphatase target subunit one (MYPT1) ubiquitination and degradation during pressure overload. These findings reveal a critical role for the S1PR1-MYPT1 pathway in preserving coronary endothelial barrier function and cardiac function under pressure overload, identifying S1PR1 as a potential therapeutic target.</p>
<p>Article number three. Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300. This study found that nobiletin treatment attenuated cardiac hypertrophy and improved systolic dysfunction in mice models of transverse aortic constriction. Nobiletin also improved the survival rate of these mice. Mechanistically, nobiletin significantly downregulated E one A binding protein P300 expression by directly binding to and activating Sirtuin 5, which in turn promoted P300 degradation. These findings identify nobiletin as a potent activator of Sirtuin 5, suggesting its potential as a promising therapeutic agent for heart failure.</p>
<p>Article number four. Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels. Mutations in the potassium inwardly rectifying channel subfamily J member five (KCNJ5) gene drive aldosterone overproduction in a subset of aldosterone-producing adenomas and familial hyperaldosteronism type three. Researchers identified small molecule compounds that specifically antagonize mutant KCNJ5 channels. Compound three demonstrated specific antagonism of mutant KCNJ5 channels with an inhibitory concentration fifty of 20 nanomolar in electrophysiological studies, showing no activity against wild-type KCNJ5. This compound also inhibited mutant KCNJ5-dependent aldosterone production in human adrenal carcinoma cells, identifying a potent and specific antagonist and a promising therapeutic strategy for primary aldosteronism.</p>
<p>Article number five. Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry. Machine learning models based on coronary computed tomography angiography (C. T. A.) features demonstrated superior performance in predicting major adverse cardiac events compared to traditional risk factors and the coronary artery calcium score. The XGBoost model achieved the highest predictive power with an area under the curve of 0.887 for five-year major adverse cardiac event prediction. This model showed a hazard ratio of 1.95 with a 95 percent confidence interval of 1.77 to 2.15 for major adverse cardiac events. These findings demonstrate the strong potential of machine learning combined with coronary C. T. A. for personalized atherosclerosis evaluation and cardiovascular risk prediction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>machine learning, C. T. A., primary aldosteronism, familial hyperaldosteronism type three, MYPT1, XGBoost, S1PR1, atherosclerosis, heart failure, major adverse cardiac events, KCNJ5, cardiac tissue engineering, potassium inwardly rectifying channel subfamily J member five, E one A binding protein P300, cardiac hypertrophy, mechanical load, SIRT5, cardiomyocytes, nobiletin, human pluripotent stem cells, cardiac dysfunction, pressure overload, in vitro models, coronary endothelial barrier, aldosterone-producing adenomas, coronary computed tomography angiography, small molecule antagonist, sphingosine-1-phosphate receptor type one, cardiovascular risk prediction, p300, Sirtuin 5, systolic dysfunction, myosin phosphatase target subunit one.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/">AI Boosts C. T. A. Heart Risk Prediction. 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like machine learning and C. T. A.. Key takeaway: AI Boosts C. T. A. Heart Risk Prediction..
Article Links:
Article 1: In vitro approache]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like machine learning and C. T. A.. Key takeaway: AI Boosts C. T. A. Heart Risk Prediction..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41261979">In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41268665">S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41268664">Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41263073">Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41268668">Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry.</a> (Circulation. Cardiovascular imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/">https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41261979" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41261979</a></p>
<p><strong>Summary:</strong> Human pluripotent stem cell derived cardiomyocytes hold significant promise for in vitro models of the human heart. Achieving full maturation of these cells requires replicating the native cardiac environment, specifically incorporating active mechanical loads such as preload and afterload. These mechanical cues are essential for enhancing cardiomyocyte maturation and improving the utility of these models for disease modeling. This approach represents a critical strategy for advancing the development of more physiologically relevant human heart models.</p>
<h4>Article 2: S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268665</a></p>
<p><strong>Summary:</strong> This study found that coronary microvascular hyperpermeability and subsequent inflammation infiltration are key early characteristics of pressure overload-induced myocardial injury. In mice, endothelial-specific deletion of sphingosine-1-phosphate receptor type one (S1PR1) led to severe pressure overload-induced cardiac dysfunction, while S1PR1 overexpression preserved cardiac function. Researchers demonstrated that S1PR1 activation maintained the coronary endothelial barrier by preventing myosin phosphatase target subunit one (MYPT1) ubiquitination and degradation during pressure overload. These findings reveal a critical role for the S1PR1-MYPT1 pathway in preserving coronary endothelial barrier function and cardiac function under pressure overload, identifying S1PR1 as a potential therapeutic target.</p>
<h4>Article 3: Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268664" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268664</a></p>
<p><strong>Summary:</strong> This study found that nobiletin treatment attenuated cardiac hypertrophy and improved systolic dysfunction in mice models of transverse aortic constriction. Nobiletin also improved the survival rate of these mice. Mechanistically, nobiletin significantly downregulated E one A binding protein P300 expression by directly binding to and activating Sirtuin 5, which in turn promoted P300 degradation. These findings identify nobiletin as a potent activator of Sirtuin 5, suggesting its potential as a promising therapeutic agent for heart failure.</p>
<h4>Article 4: Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41263073" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41263073</a></p>
<p><strong>Summary:</strong> Mutations in the potassium inwardly rectifying channel subfamily J member five (KCNJ5) gene drive aldosterone overproduction in a subset of aldosterone-producing adenomas and familial hyperaldosteronism type three. Researchers identified small molecule compounds that specifically antagonize mutant KCNJ5 channels. Compound three demonstrated specific antagonism of mutant KCNJ5 channels with an inhibitory concentration fifty of 20 nanomolar in electrophysiological studies, showing no activity against wild-type KCNJ5. This compound also inhibited mutant KCNJ5-dependent aldosterone production in human adrenal carcinoma cells, identifying a potent and specific antagonist and a promising therapeutic strategy for primary aldosteronism.</p>
<h4>Article 5: Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268668" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268668</a></p>
<p><strong>Summary:</strong> Machine learning models based on coronary computed tomography angiography (C. T. A.) features demonstrated superior performance in predicting major adverse cardiac events compared to traditional risk factors and the coronary artery calcium score. The XGBoost model achieved the highest predictive power with an area under the curve of 0.887 for five-year major adverse cardiac event prediction. This model showed a hazard ratio of 1.95 with a 95 percent confidence interval of 1.77 to 2.15 for major adverse cardiac events. These findings demonstrate the strong potential of machine learning combined with coronary C. T. A. for personalized atherosclerosis evaluation and cardiovascular risk prediction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling. Human pluripotent stem cell derived cardiomyocytes hold significant promise for in vitro models of the human heart. Achieving full maturation of these cells requires replicating the native cardiac environment, specifically incorporating active mechanical loads such as preload and afterload. These mechanical cues are essential for enhancing cardiomyocyte maturation and improving the utility of these models for disease modeling. This approach represents a critical strategy for advancing the development of more physiologically relevant human heart models.</p>
<p>Article number two. S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts. This study found that coronary microvascular hyperpermeability and subsequent inflammation infiltration are key early characteristics of pressure overload-induced myocardial injury. In mice, endothelial-specific deletion of sphingosine-1-phosphate receptor type one (S1PR1) led to severe pressure overload-induced cardiac dysfunction, while S1PR1 overexpression preserved cardiac function. Researchers demonstrated that S1PR1 activation maintained the coronary endothelial barrier by preventing myosin phosphatase target subunit one (MYPT1) ubiquitination and degradation during pressure overload. These findings reveal a critical role for the S1PR1-MYPT1 pathway in preserving coronary endothelial barrier function and cardiac function under pressure overload, identifying S1PR1 as a potential therapeutic target.</p>
<p>Article number three. Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300. This study found that nobiletin treatment attenuated cardiac hypertrophy and improved systolic dysfunction in mice models of transverse aortic constriction. Nobiletin also improved the survival rate of these mice. Mechanistically, nobiletin significantly downregulated E one A binding protein P300 expression by directly binding to and activating Sirtuin 5, which in turn promoted P300 degradation. These findings identify nobiletin as a potent activator of Sirtuin 5, suggesting its potential as a promising therapeutic agent for heart failure.</p>
<p>Article number four. Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels. Mutations in the potassium inwardly rectifying channel subfamily J member five (KCNJ5) gene drive aldosterone overproduction in a subset of aldosterone-producing adenomas and familial hyperaldosteronism type three. Researchers identified small molecule compounds that specifically antagonize mutant KCNJ5 channels. Compound three demonstrated specific antagonism of mutant KCNJ5 channels with an inhibitory concentration fifty of 20 nanomolar in electrophysiological studies, showing no activity against wild-type KCNJ5. This compound also inhibited mutant KCNJ5-dependent aldosterone production in human adrenal carcinoma cells, identifying a potent and specific antagonist and a promising therapeutic strategy for primary aldosteronism.</p>
<p>Article number five. Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry. Machine learning models based on coronary computed tomography angiography (C. T. A.) features demonstrated superior performance in predicting major adverse cardiac events compared to traditional risk factors and the coronary artery calcium score. The XGBoost model achieved the highest predictive power with an area under the curve of 0.887 for five-year major adverse cardiac event prediction. This model showed a hazard ratio of 1.95 with a 95 percent confidence interval of 1.77 to 2.15 for major adverse cardiac events. These findings demonstrate the strong potential of machine learning combined with coronary C. T. A. for personalized atherosclerosis evaluation and cardiovascular risk prediction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>machine learning, C. T. A., primary aldosteronism, familial hyperaldosteronism type three, MYPT1, XGBoost, S1PR1, atherosclerosis, heart failure, major adverse cardiac events, KCNJ5, cardiac tissue engineering, potassium inwardly rectifying channel subfamily J member five, E one A binding protein P300, cardiac hypertrophy, mechanical load, SIRT5, cardiomyocytes, nobiletin, human pluripotent stem cells, cardiac dysfunction, pressure overload, in vitro models, coronary endothelial barrier, aldosterone-producing adenomas, coronary computed tomography angiography, small molecule antagonist, sphingosine-1-phosphate receptor type one, cardiovascular risk prediction, p300, Sirtuin 5, systolic dysfunction, myosin phosphatase target subunit one.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/">AI Boosts C. T. A. Heart Risk Prediction. 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251123_221756.mp3" length="5118580" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like machine learning and C. T. A.. Key takeaway: AI Boosts C. T. A. Heart Risk Prediction..
Article Links:
Article 1: In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling. (Cardiovascular research)
Article 2: S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts. (Hypertension (Dallas, Tex. : 1979))
Article 3: Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300. (Hypertension (Dallas, Tex. : 1979))
Article 4: Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels. (Hypertension (Dallas, Tex. : 1979))
Article 5: Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry. (Circulation. Cardiovascular imaging)
Full episode page: https://podcast.explainheart.com/podcast/ai-boosts-c-t-a-heart-risk-prediction-11-23-25/
 Featured Articles
Article 1: In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41261979
Summary: Human pluripotent stem cell derived cardiomyocytes hold significant promise for in vitro models of the human heart. Achieving full maturation of these cells requires replicating the native cardiac environment, specifically incorporating active mechanical loads such as preload and afterload. These mechanical cues are essential for enhancing cardiomyocyte maturation and improving the utility of these models for disease modeling. This approach represents a critical strategy for advancing the development of more physiologically relevant human heart models.
Article 2: S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268665
Summary: This study found that coronary microvascular hyperpermeability and subsequent inflammation infiltration are key early characteristics of pressure overload-induced myocardial injury. In mice, endothelial-specific deletion of sphingosine-1-phosphate receptor type one (S1PR1) led to severe pressure overload-induced cardiac dysfunction, while S1PR1 overexpression preserved cardiac function. Researchers demonstrated that S1PR1 activation maintained the coronary endothelial barrier by preventing myosin phosphatase target subunit one (MYPT1) ubiquitination and degradation during pressure overload. These findings reveal a critical role for the S1PR1-MYPT1 pathway in preserving coronary endothelial barrier function and cardiac function under pressure overload, identifying S1PR1 as a potential therapeutic target.
Article 3: Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268664
Summary: This study found that nobiletin treatment attenuated cardiac hypertrophy and improved systolic dysfunction in mice models of transverse aortic constriction. Nobiletin also improved the survival rate of these mice. Mechanistically, nobiletin significantly downregulated E one A binding protein P300 expression by directly binding to and activating Sirtuin 5, which in turn promoted P300 degradation. These findings identify nobiletin as a potent activator of Sirtuin 5, suggesting its potential as a promising therapeutic agent for heart failure.
Article 4: Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41263073
Summary: Mutations in the potassium inwardly rectifying channel subfamily J member five (KCNJ5) gene drive aldosterone overproduction in a subset of aldosterone-produ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like machine learning and C. T. A.. Key takeaway: AI Boosts C. T. A. Heart Risk Prediction..
Article Links:
Article 1: In vitro approaches to mimic cardiac mechanical load dynamics for enhancing maturation and disease modelling. (Cardiovascular research)
Article 2: S1PR1-MYPT1 Maintains Coronary Endothelial Barrier in Pressure-Overloaded Hearts. (Hypertension (Dallas, Tex. : 1979))
Article 3: Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300. (Hypertension (Dallas, Tex. : 1979))
Article 4: Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels. (Hypertension (Dallas, Tex. : 1979))
Article 5: Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry. (Circulation. Cardiovascular imaging)
Full episode page: https:]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Accelerated C. M. R. Boosts C. A. D. Detection Efficiency 11/23/25</title>
	<link>https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/</link>
	<pubDate>Mon, 24 Nov 2025 02:16:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like microwave digestion and hypertension. Key takeaway: Accelerated C. M. R. Boosts C. A. D. Detection Efficiency.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41268652">OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation.</a> (Circulation research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41264815">Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41273767">Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study.</a> (American journal of hypertension)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41264477">Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial.</a> (American journal of hypertension)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41273776">Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/">https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268652" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268652</a></p>
<p><strong>Summary:</strong> OTU domain-containing protein 7a (OTUD7a) accelerates pathological cardiac hypertrophy via Transforming growth factor-beta Activated Kinase 1 (T. A. K. 1) activation. The study demonstrated that OTUD7a expression significantly increased in cardiomyocytes with phenylephrine stimuli and in hearts subjected to transverse aortic constriction surgery. This identifies a specific enzymatic pathway contributing to cardiac hypertrophy, a major cause of heart failure and sudden cardiac death. The findings characterize OTUD7a as a key deubiquitinizing enzyme in this process.</p>
<h4>Article 2: Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264815" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264815</a></p>
<p><strong>Summary:</strong> The study demonstrated that an accelerated, stress-only perfusion protocol for cardiovascular magnetic resonance (C. M. R.) achieved non-inferior diagnostic accuracy for detecting significant coronary artery disease. This accelerated protocol significantly improved the time efficiency and cost-effectiveness of C. M. R. procedures. The findings confirm the utility of this advanced imaging approach for patients with suspected coronary artery disease. It supports broader implementation of accelerated C. M. R. to meet increasing demand.</p>
<h4>Article 3: Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273767</a></p>
<p><strong>Summary:</strong> The Jackson Heart Study found a significant association between physical activity and aortic stiffness. Results showed that higher levels of physical activity were linked to lower aortic stiffness. This finding extends previous observations in White populations to a cohort representative of African Americans, where aortic stiffness is an independent predictor of hypertension and cardiovascular disease risk. The data demonstrated that increased physical activity beneficially impacts arterial hemodynamics and vascular aging.</p>
<h4>Article 4: Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264477" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264477</a></p>
<p><strong>Summary:</strong> The C. O. S. M. O. S. trial demonstrated the long-term effect of multivitamin-multimineral supplementation on incident self-reported hypertension and blood pressure changes. This large-scale, double-blinded randomized controlled trial included 8905 participants, specifically women aged 65 years and older and men aged 60 years and older. The study provided definitive findings on the specific impacts of multivitamin-multimineral use on these cardiovascular parameters. This research confirmed or refuted previous suggestions of a link between multivitamin-multimineral and lower blood pressure.</p>
<h4>Article 5: Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273776" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273776</a></p>
<p><strong>Summary:</strong> The study validated microwave digestion for precise tissue sodium and potassium measurement in cardiovascular research. Results showed that microwave digestion significantly reduced within-sample variability compared to dry ashing for tissue element determination. It also demonstrated that flame atomic emission spectrometry reduced variability compared to inductively coupled plasma optical emission spectrometry. This improved methodology enhances the accuracy and translational applicability of tissue element analysis in cardiovascular pathophysiology studies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation. OTU domain-containing protein 7a (OTUD7a) accelerates pathological cardiac hypertrophy via Transforming growth factor-beta Activated Kinase 1 (T. A. K. 1) activation. The study demonstrated that OTUD7a expression significantly increased in cardiomyocytes with phenylephrine stimuli and in hearts subjected to transverse aortic constriction surgery. This identifies a specific enzymatic pathway contributing to cardiac hypertrophy, a major cause of heart failure and sudden cardiac death. The findings characterize OTUD7a as a key deubiquitinizing enzyme in this process.</p>
<p>Article number two. Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study. The study demonstrated that an accelerated, stress-only perfusion protocol for cardiovascular magnetic resonance (C. M. R.) achieved non-inferior diagnostic accuracy for detecting significant coronary artery disease. This accelerated protocol significantly improved the time efficiency and cost-effectiveness of C. M. R. procedures. The findings confirm the utility of this advanced imaging approach for patients with suspected coronary artery disease. It supports broader implementation of accelerated C. M. R. to meet increasing demand.</p>
<p>Article number three. Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study. The Jackson Heart Study found a significant association between physical activity and aortic stiffness. Results showed that higher levels of physical activity were linked to lower aortic stiffness. This finding extends previous observations in White populations to a cohort representative of African Americans, where aortic stiffness is an independent predictor of hypertension and cardiovascular disease risk. The data demonstrated that increased physical activity beneficially impacts arterial hemodynamics and vascular aging.</p>
<p>Article number four. Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial. The C. O. S. M. O. S. trial demonstrated the long-term effect of multivitamin-multimineral supplementation on incident self-reported hypertension and blood pressure changes. This large-scale, double-blinded randomized controlled trial included 8905 participants, specifically women aged 65 years and older and men aged 60 years and older. The study provided definitive findings on the specific impacts of multivitamin-multimineral use on these cardiovascular parameters. This research confirmed or refuted previous suggestions of a link between multivitamin-multimineral and lower blood pressure.</p>
<p>Article number five. Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research. The study validated microwave digestion for precise tissue sodium and potassium measurement in cardiovascular research. Results showed that microwave digestion significantly reduced within-sample variability compared to dry ashing for tissue element determination. It also demonstrated that flame atomic emission spectrometry reduced variability compared to inductively coupled plasma optical emission spectrometry. This improved methodology enhances the accuracy and translational applicability of tissue element analysis in cardiovascular pathophysiology studies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>microwave digestion, hypertension, heart failure, blood pressure, tissue potassium, cardiac imaging, cardiac hypertrophy, Jackson Heart Study, T. A. K. 1 activation, OTUD7a, stress perfusion, cardiovascular pathophysiology, flame atomic emission spectrometry, diagnostic accuracy, cardiovascular magnetic resonance, physical activity, coronary artery disease, C. O. S. M. O. S. trial, aortic stiffness, multivitamin supplementation, tissue sodium, randomized controlled trial, deubiquitinizing enzyme, cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/">Accelerated C. M. R. Boosts C. A. D. Detection Efficiency 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like microwave digestion and hypertension. Key takeaway: Accelerated C. M. R. Boosts C. A. D. Detection Efficiency.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like microwave digestion and hypertension. Key takeaway: Accelerated C. M. R. Boosts C. A. D. Detection Efficiency.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41268652">OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation.</a> (Circulation research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41264815">Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study.</a> (European heart journal. Cardiovascular Imaging)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41273767">Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study.</a> (American journal of hypertension)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41264477">Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial.</a> (American journal of hypertension)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41273776">Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/">https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268652" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268652</a></p>
<p><strong>Summary:</strong> OTU domain-containing protein 7a (OTUD7a) accelerates pathological cardiac hypertrophy via Transforming growth factor-beta Activated Kinase 1 (T. A. K. 1) activation. The study demonstrated that OTUD7a expression significantly increased in cardiomyocytes with phenylephrine stimuli and in hearts subjected to transverse aortic constriction surgery. This identifies a specific enzymatic pathway contributing to cardiac hypertrophy, a major cause of heart failure and sudden cardiac death. The findings characterize OTUD7a as a key deubiquitinizing enzyme in this process.</p>
<h4>Article 2: Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study.</h4>
<p><strong>Journal:</strong> European heart journal. Cardiovascular Imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264815" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264815</a></p>
<p><strong>Summary:</strong> The study demonstrated that an accelerated, stress-only perfusion protocol for cardiovascular magnetic resonance (C. M. R.) achieved non-inferior diagnostic accuracy for detecting significant coronary artery disease. This accelerated protocol significantly improved the time efficiency and cost-effectiveness of C. M. R. procedures. The findings confirm the utility of this advanced imaging approach for patients with suspected coronary artery disease. It supports broader implementation of accelerated C. M. R. to meet increasing demand.</p>
<h4>Article 3: Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273767" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273767</a></p>
<p><strong>Summary:</strong> The Jackson Heart Study found a significant association between physical activity and aortic stiffness. Results showed that higher levels of physical activity were linked to lower aortic stiffness. This finding extends previous observations in White populations to a cohort representative of African Americans, where aortic stiffness is an independent predictor of hypertension and cardiovascular disease risk. The data demonstrated that increased physical activity beneficially impacts arterial hemodynamics and vascular aging.</p>
<h4>Article 4: Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264477" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264477</a></p>
<p><strong>Summary:</strong> The C. O. S. M. O. S. trial demonstrated the long-term effect of multivitamin-multimineral supplementation on incident self-reported hypertension and blood pressure changes. This large-scale, double-blinded randomized controlled trial included 8905 participants, specifically women aged 65 years and older and men aged 60 years and older. The study provided definitive findings on the specific impacts of multivitamin-multimineral use on these cardiovascular parameters. This research confirmed or refuted previous suggestions of a link between multivitamin-multimineral and lower blood pressure.</p>
<h4>Article 5: Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41273776" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41273776</a></p>
<p><strong>Summary:</strong> The study validated microwave digestion for precise tissue sodium and potassium measurement in cardiovascular research. Results showed that microwave digestion significantly reduced within-sample variability compared to dry ashing for tissue element determination. It also demonstrated that flame atomic emission spectrometry reduced variability compared to inductively coupled plasma optical emission spectrometry. This improved methodology enhances the accuracy and translational applicability of tissue element analysis in cardiovascular pathophysiology studies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation. OTU domain-containing protein 7a (OTUD7a) accelerates pathological cardiac hypertrophy via Transforming growth factor-beta Activated Kinase 1 (T. A. K. 1) activation. The study demonstrated that OTUD7a expression significantly increased in cardiomyocytes with phenylephrine stimuli and in hearts subjected to transverse aortic constriction surgery. This identifies a specific enzymatic pathway contributing to cardiac hypertrophy, a major cause of heart failure and sudden cardiac death. The findings characterize OTUD7a as a key deubiquitinizing enzyme in this process.</p>
<p>Article number two. Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study. The study demonstrated that an accelerated, stress-only perfusion protocol for cardiovascular magnetic resonance (C. M. R.) achieved non-inferior diagnostic accuracy for detecting significant coronary artery disease. This accelerated protocol significantly improved the time efficiency and cost-effectiveness of C. M. R. procedures. The findings confirm the utility of this advanced imaging approach for patients with suspected coronary artery disease. It supports broader implementation of accelerated C. M. R. to meet increasing demand.</p>
<p>Article number three. Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study. The Jackson Heart Study found a significant association between physical activity and aortic stiffness. Results showed that higher levels of physical activity were linked to lower aortic stiffness. This finding extends previous observations in White populations to a cohort representative of African Americans, where aortic stiffness is an independent predictor of hypertension and cardiovascular disease risk. The data demonstrated that increased physical activity beneficially impacts arterial hemodynamics and vascular aging.</p>
<p>Article number four. Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial. The C. O. S. M. O. S. trial demonstrated the long-term effect of multivitamin-multimineral supplementation on incident self-reported hypertension and blood pressure changes. This large-scale, double-blinded randomized controlled trial included 8905 participants, specifically women aged 65 years and older and men aged 60 years and older. The study provided definitive findings on the specific impacts of multivitamin-multimineral use on these cardiovascular parameters. This research confirmed or refuted previous suggestions of a link between multivitamin-multimineral and lower blood pressure.</p>
<p>Article number five. Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research. The study validated microwave digestion for precise tissue sodium and potassium measurement in cardiovascular research. Results showed that microwave digestion significantly reduced within-sample variability compared to dry ashing for tissue element determination. It also demonstrated that flame atomic emission spectrometry reduced variability compared to inductively coupled plasma optical emission spectrometry. This improved methodology enhances the accuracy and translational applicability of tissue element analysis in cardiovascular pathophysiology studies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>microwave digestion, hypertension, heart failure, blood pressure, tissue potassium, cardiac imaging, cardiac hypertrophy, Jackson Heart Study, T. A. K. 1 activation, OTUD7a, stress perfusion, cardiovascular pathophysiology, flame atomic emission spectrometry, diagnostic accuracy, cardiovascular magnetic resonance, physical activity, coronary artery disease, C. O. S. M. O. S. trial, aortic stiffness, multivitamin supplementation, tissue sodium, randomized controlled trial, deubiquitinizing enzyme, cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/">Accelerated C. M. R. Boosts C. A. D. Detection Efficiency 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251123_211527.mp3" length="3969610" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like microwave digestion and hypertension. Key takeaway: Accelerated C. M. R. Boosts C. A. D. Detection Efficiency.
Article Links:
Article 1: OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation. (Circulation research)
Article 2: Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study. (European heart journal. Cardiovascular Imaging)
Article 3: Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study. (American journal of hypertension)
Article 4: Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial. (American journal of hypertension)
Article 5: Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research. (American journal of physiology. Heart and circulatory physiology)
Full episode page: https://podcast.explainheart.com/podcast/accelerated-c-m-r-boosts-c-a-d-detection-efficiency-11-23-25/
 Featured Articles
Article 1: OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268652
Summary: OTU domain-containing protein 7a (OTUD7a) accelerates pathological cardiac hypertrophy via Transforming growth factor-beta Activated Kinase 1 (T. A. K. 1) activation. The study demonstrated that OTUD7a expression significantly increased in cardiomyocytes with phenylephrine stimuli and in hearts subjected to transverse aortic constriction surgery. This identifies a specific enzymatic pathway contributing to cardiac hypertrophy, a major cause of heart failure and sudden cardiac death. The findings characterize OTUD7a as a key deubiquitinizing enzyme in this process.
Article 2: Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study.
Journal: European heart journal. Cardiovascular Imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41264815
Summary: The study demonstrated that an accelerated, stress-only perfusion protocol for cardiovascular magnetic resonance (C. M. R.) achieved non-inferior diagnostic accuracy for detecting significant coronary artery disease. This accelerated protocol significantly improved the time efficiency and cost-effectiveness of C. M. R. procedures. The findings confirm the utility of this advanced imaging approach for patients with suspected coronary artery disease. It supports broader implementation of accelerated C. M. R. to meet increasing demand.
Article 3: Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study.
Journal: American journal of hypertension
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41273767
Summary: The Jackson Heart Study found a significant association between physical activity and aortic stiffness. Results showed that higher levels of physical activity were linked to lower aortic stiffness. This finding extends previous observations in White populations to a cohort representative of African Americans, where aortic stiffness is an independent predictor of hypertension and cardiovascular disease risk. The data demonstrated that increased physical activity beneficially impacts arterial hemodynamics and vascular aging.
Article 4: Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial.
Journal: American journal of hypertension
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41264477
Summary: The C. O. S. M. O. S. trial demonstrated the long-term effect of multivitamin-multimineral supplementation on incident self-reported hypertension and blood pressure changes. This large-scale, double-blinded randomized controlled trial included 8905 participants, ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like microwave digestion and hypertension. Key takeaway: Accelerated C. M. R. Boosts C. A. D. Detection Efficiency.
Article Links:
Article 1: OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation. (Circulation research)
Article 2: Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study. (European heart journal. Cardiovascular Imaging)
Article 3: Association of Physical Activity with Aortic Stiffness in the Jackson Heart Study. (American journal of hypertension)
Article 4: Long-term effect of multivitamin supplementation on incident self-reported hypertension and blood pressure changes in the COSMOS trial. (American journal of hypertension)
Article 5: Reducing variability in tissue sodium and potassium measurement: validation of microwave digestion for cardiovascular research. (]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>BMAL1 Insufficiency Raises Aortic Dissection Risk 11/23/25</title>
	<link>https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/</link>
	<pubDate>Mon, 24 Nov 2025 00:35:09 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and lineage differentiation. Key takeaway: BMAL1 Insufficiency Raises Aortic Dissection Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41271608">Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41270048">BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41264461">ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41264422">Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41263385">Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/">https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41271608" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41271608</a></p>
<p><strong>Summary:</strong> Reduced G-protein coupled receptor 146 (GPR146) expression in humans is associated with decreased levels of both low-density lipoprotein and high-density lipoprotein cholesterol. While GPR146 effects on low-density lipoprotein cholesterol involve the E. R. K. /S. R. E. B. P. 2 pathway, this study found the mechanism for high-density lipoprotein cholesterol reduction involves post-translational upregulation of S. R. minus B. 1 protein levels. This provides a direct mechanistic link for GPR146&#8217;s role in high-density lipoprotein metabolism.</p>
<h4>Article 2: BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41270048" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41270048</a></p>
<p><strong>Summary:</strong> This study found that B. M. A. L. 1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. Vascular smooth muscle cell apoptosis plays a key role in this lethal cardiovascular disease, which has high mortality rates and limited pharmacological therapy. The data established a direct link between insufficient B. M. A. L. 1 and increased susceptibility to thoracic aortic aneurysm and dissection by aggravating vascular smooth muscle cell apoptosis.</p>
<h4>Article 3: ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264461" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264461</a></p>
<p><strong>Summary:</strong> This study found that ChemR23 prevents the phenotypic switching of vascular smooth muscle cells into macrophage-like foam cells in atherosclerosis. Previous findings demonstrated that hematopoietic ChemR23 deficiency reduced atherosclerotic lesions by increasing M two macrophages. The current data specify a critical cell-specific function for ChemR23 by inhibiting this harmful transformation of vascular smooth muscle cells directly contributing to atherosclerosis development.</p>
<h4>Article 4: Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264422" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264422</a></p>
<p><strong>Summary:</strong> Single-cell R. N. A. sequencing has revolutionized the study of calcific aortic valve disease. This advanced technique dissects cellular heterogeneity, lineage differentiation, and intercellular crosstalk with unprecedented resolution, revealing novel mechanisms of disease. It also identified new putative therapeutic targets for calcific aortic valve disease, providing a state-of-the-art overview of applications in this research area.</p>
<h4>Article 5: Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41263385" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41263385</a></p>
<p><strong>Summary:</strong> This study found that transcription regulation by T. B. X. 18 in smooth muscle cells is essential for normal aortic development and homeostasis. Histological analyses revealed specific T. B. X. 18 expression in smooth muscle cells of both adult and embryonic aortas. The data demonstrated a critical role for T. B. X. 18 in maintaining the integrity and proper formation of this major artery throughout development and into adulthood.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels. Reduced G-protein coupled receptor 146 (GPR146) expression in humans is associated with decreased levels of both low-density lipoprotein and high-density lipoprotein cholesterol. While GPR146 effects on low-density lipoprotein cholesterol involve the E. R. K. /S. R. E. B. P. 2 pathway, this study found the mechanism for high-density lipoprotein cholesterol reduction involves post-translational upregulation of S. R. minus B. 1 protein levels. This provides a direct mechanistic link for GPR146&#8217;s role in high-density lipoprotein metabolism.</p>
<p>Article number two. BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. This study found that B. M. A. L. 1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. Vascular smooth muscle cell apoptosis plays a key role in this lethal cardiovascular disease, which has high mortality rates and limited pharmacological therapy. The data established a direct link between insufficient B. M. A. L. 1 and increased susceptibility to thoracic aortic aneurysm and dissection by aggravating vascular smooth muscle cell apoptosis.</p>
<p>Article number three. ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis. This study found that ChemR23 prevents the phenotypic switching of vascular smooth muscle cells into macrophage-like foam cells in atherosclerosis. Previous findings demonstrated that hematopoietic ChemR23 deficiency reduced atherosclerotic lesions by increasing M two macrophages. The current data specify a critical cell-specific function for ChemR23 by inhibiting this harmful transformation of vascular smooth muscle cells directly contributing to atherosclerosis development.</p>
<p>Article number four. Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease. Single-cell R. N. A. sequencing has revolutionized the study of calcific aortic valve disease. This advanced technique dissects cellular heterogeneity, lineage differentiation, and intercellular crosstalk with unprecedented resolution, revealing novel mechanisms of disease. It also identified new putative therapeutic targets for calcific aortic valve disease, providing a state-of-the-art overview of applications in this research area.</p>
<p>Article number five. Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis. This study found that transcription regulation by T. B. X. 18 in smooth muscle cells is essential for normal aortic development and homeostasis. Histological analyses revealed specific T. B. X. 18 expression in smooth muscle cells of both adult and embryonic aortas. The data demonstrated a critical role for T. B. X. 18 in maintaining the integrity and proper formation of this major artery throughout development and into adulthood. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular disease, lineage differentiation, transcription regulation, vascular smooth muscle cell apoptosis, lipid metabolism, cellular heterogeneity, foam cells, single-cell R. N. A. sequencing, calcific aortic valve disease, vascular smooth muscle cells, S. R. minus B. 1 protein, therapeutic targets, atherosclerosis, B. M. A. L. 1, low-density lipoprotein cholesterol, GPR146, aortic development, ChemR23, thoracic aortic aneurysm, aortic homeostasis, aortic dissection, smooth muscle cells, T. B. X. 18, phenotypic switching, high-density lipoprotein cholesterol.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/">BMAL1 Insufficiency Raises Aortic Dissection Risk 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and lineage differentiation. Key takeaway: BMAL1 Insufficiency Raises Aortic Dissection Risk.
Article Links:
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and lineage differentiation. Key takeaway: BMAL1 Insufficiency Raises Aortic Dissection Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41271608">Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41270048">BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41264461">ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41264422">Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41263385">Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/">https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41271608" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41271608</a></p>
<p><strong>Summary:</strong> Reduced G-protein coupled receptor 146 (GPR146) expression in humans is associated with decreased levels of both low-density lipoprotein and high-density lipoprotein cholesterol. While GPR146 effects on low-density lipoprotein cholesterol involve the E. R. K. /S. R. E. B. P. 2 pathway, this study found the mechanism for high-density lipoprotein cholesterol reduction involves post-translational upregulation of S. R. minus B. 1 protein levels. This provides a direct mechanistic link for GPR146&#8217;s role in high-density lipoprotein metabolism.</p>
<h4>Article 2: BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41270048" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41270048</a></p>
<p><strong>Summary:</strong> This study found that B. M. A. L. 1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. Vascular smooth muscle cell apoptosis plays a key role in this lethal cardiovascular disease, which has high mortality rates and limited pharmacological therapy. The data established a direct link between insufficient B. M. A. L. 1 and increased susceptibility to thoracic aortic aneurysm and dissection by aggravating vascular smooth muscle cell apoptosis.</p>
<h4>Article 3: ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264461" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264461</a></p>
<p><strong>Summary:</strong> This study found that ChemR23 prevents the phenotypic switching of vascular smooth muscle cells into macrophage-like foam cells in atherosclerosis. Previous findings demonstrated that hematopoietic ChemR23 deficiency reduced atherosclerotic lesions by increasing M two macrophages. The current data specify a critical cell-specific function for ChemR23 by inhibiting this harmful transformation of vascular smooth muscle cells directly contributing to atherosclerosis development.</p>
<h4>Article 4: Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41264422" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41264422</a></p>
<p><strong>Summary:</strong> Single-cell R. N. A. sequencing has revolutionized the study of calcific aortic valve disease. This advanced technique dissects cellular heterogeneity, lineage differentiation, and intercellular crosstalk with unprecedented resolution, revealing novel mechanisms of disease. It also identified new putative therapeutic targets for calcific aortic valve disease, providing a state-of-the-art overview of applications in this research area.</p>
<h4>Article 5: Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41263385" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41263385</a></p>
<p><strong>Summary:</strong> This study found that transcription regulation by T. B. X. 18 in smooth muscle cells is essential for normal aortic development and homeostasis. Histological analyses revealed specific T. B. X. 18 expression in smooth muscle cells of both adult and embryonic aortas. The data demonstrated a critical role for T. B. X. 18 in maintaining the integrity and proper formation of this major artery throughout development and into adulthood.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels. Reduced G-protein coupled receptor 146 (GPR146) expression in humans is associated with decreased levels of both low-density lipoprotein and high-density lipoprotein cholesterol. While GPR146 effects on low-density lipoprotein cholesterol involve the E. R. K. /S. R. E. B. P. 2 pathway, this study found the mechanism for high-density lipoprotein cholesterol reduction involves post-translational upregulation of S. R. minus B. 1 protein levels. This provides a direct mechanistic link for GPR146&#8217;s role in high-density lipoprotein metabolism.</p>
<p>Article number two. BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. This study found that B. M. A. L. 1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. Vascular smooth muscle cell apoptosis plays a key role in this lethal cardiovascular disease, which has high mortality rates and limited pharmacological therapy. The data established a direct link between insufficient B. M. A. L. 1 and increased susceptibility to thoracic aortic aneurysm and dissection by aggravating vascular smooth muscle cell apoptosis.</p>
<p>Article number three. ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis. This study found that ChemR23 prevents the phenotypic switching of vascular smooth muscle cells into macrophage-like foam cells in atherosclerosis. Previous findings demonstrated that hematopoietic ChemR23 deficiency reduced atherosclerotic lesions by increasing M two macrophages. The current data specify a critical cell-specific function for ChemR23 by inhibiting this harmful transformation of vascular smooth muscle cells directly contributing to atherosclerosis development.</p>
<p>Article number four. Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease. Single-cell R. N. A. sequencing has revolutionized the study of calcific aortic valve disease. This advanced technique dissects cellular heterogeneity, lineage differentiation, and intercellular crosstalk with unprecedented resolution, revealing novel mechanisms of disease. It also identified new putative therapeutic targets for calcific aortic valve disease, providing a state-of-the-art overview of applications in this research area.</p>
<p>Article number five. Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis. This study found that transcription regulation by T. B. X. 18 in smooth muscle cells is essential for normal aortic development and homeostasis. Histological analyses revealed specific T. B. X. 18 expression in smooth muscle cells of both adult and embryonic aortas. The data demonstrated a critical role for T. B. X. 18 in maintaining the integrity and proper formation of this major artery throughout development and into adulthood. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular disease, lineage differentiation, transcription regulation, vascular smooth muscle cell apoptosis, lipid metabolism, cellular heterogeneity, foam cells, single-cell R. N. A. sequencing, calcific aortic valve disease, vascular smooth muscle cells, S. R. minus B. 1 protein, therapeutic targets, atherosclerosis, B. M. A. L. 1, low-density lipoprotein cholesterol, GPR146, aortic development, ChemR23, thoracic aortic aneurysm, aortic homeostasis, aortic dissection, smooth muscle cells, T. B. X. 18, phenotypic switching, high-density lipoprotein cholesterol.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/">BMAL1 Insufficiency Raises Aortic Dissection Risk 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251123_193411.mp3" length="3886018" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and lineage differentiation. Key takeaway: BMAL1 Insufficiency Raises Aortic Dissection Risk.
Article Links:
Article 1: Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels. (Cardiovascular research)
Article 2: BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. (Cardiovascular research)
Article 3: ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis. (Cardiovascular research)
Article 4: Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease. (Cardiovascular research)
Article 5: Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/bmal1-insufficiency-raises-aortic-dissection-risk-11-23-25/
 Featured Articles
Article 1: Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41271608
Summary: Reduced G-protein coupled receptor 146 (GPR146) expression in humans is associated with decreased levels of both low-density lipoprotein and high-density lipoprotein cholesterol. While GPR146 effects on low-density lipoprotein cholesterol involve the E. R. K. /S. R. E. B. P. 2 pathway, this study found the mechanism for high-density lipoprotein cholesterol reduction involves post-translational upregulation of S. R. minus B. 1 protein levels. This provides a direct mechanistic link for GPR146&#8217;s role in high-density lipoprotein metabolism.
Article 2: BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41270048
Summary: This study found that B. M. A. L. 1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. Vascular smooth muscle cell apoptosis plays a key role in this lethal cardiovascular disease, which has high mortality rates and limited pharmacological therapy. The data established a direct link between insufficient B. M. A. L. 1 and increased susceptibility to thoracic aortic aneurysm and dissection by aggravating vascular smooth muscle cell apoptosis.
Article 3: ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41264461
Summary: This study found that ChemR23 prevents the phenotypic switching of vascular smooth muscle cells into macrophage-like foam cells in atherosclerosis. Previous findings demonstrated that hematopoietic ChemR23 deficiency reduced atherosclerotic lesions by increasing M two macrophages. The current data specify a critical cell-specific function for ChemR23 by inhibiting this harmful transformation of vascular smooth muscle cells directly contributing to atherosclerosis development.
Article 4: Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41264422
Summary: Single-cell R. N. A. sequencing has revolutionized the study of calcific aortic valve disease. This advanced technique dissects cellular heterogeneity, lineage differentiation, and intercellular crosstalk with unprecedented resolution, revealing novel mechanisms of disease. It also identified new putative therapeutic targets for calcific aortic valve disease, providing a state-of-the-art overview of applications in this research area.
Article 5: Transcription regulation by TBX18 in smooth muscle cells is essential ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular disease and lineage differentiation. Key takeaway: BMAL1 Insufficiency Raises Aortic Dissection Risk.
Article Links:
Article 1: Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels. (Cardiovascular research)
Article 2: BMAL1 insufficiency increases the risk of thoracic aortic aneurysm and dissection. (Cardiovascular research)
Article 3: ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis. (Cardiovascular research)
Article 4: Advances in single-cell transcriptomics: unraveling the pathogenesis of calcific aortic valve disease. (Cardiovascular research)
Article 5: Transcription regulation by TBX18 in smooth muscle cells is essential for normal aortic development and homeostasis. (Cardiovascular research)
Full episode pag]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ALDH2 Variant Drives Thrombosis Risk. 11/23/25</title>
	<link>https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/</link>
	<pubDate>Sun, 23 Nov 2025 11:01:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like calcified mitral valve disease and platelet activation. Key takeaway: ALDH2 Variant Drives Thrombosis Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41274561">Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry.</a> (The Canadian journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41274583">Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41231769">Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41150615">ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40883226">Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/">https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274561" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274561</a></p>
<p><strong>Summary:</strong> The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges.</p>
<h4>Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274583" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274583</a></p>
<p><strong>Summary:</strong> Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population.</p>
<h4>Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41231769" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41231769</a></p>
<p><strong>Summary:</strong> Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention.</p>
<h4>Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41150615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41150615</a></p>
<p><strong>Summary:</strong> The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 percent of East Asian populations, significantly diminishes Aldehyde Dehydrogenase 2 enzymatic activity by 60 to 90 percent. This variant enhances platelet activation and thrombosis, directly contributing to an elevated thrombotic risk. The study determined that this prothrombotic effect occurs specifically through the disruption of mitochondrial complex one assembly.</p>
<h4>Article 5: Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40883226" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40883226</a></p>
<p><strong>Summary:</strong> Elevated lipoprotein(a) directly results in vascular regenerative deficiencies. Lipoprotein(a) is an established causal risk factor for atherosclerotic cardiovascular disease. This study found that elevated levels of lipoprotein(a) modify vascular regenerative cell content properties, impacting the capacity for vascular repair. Depletion of vascular regenerative progenitor cells serves as an indicator of compromised vascular repair in individuals with cardiometabolic disorders.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry. The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges.</p>
<p>Article number two. Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population.</p>
<p>Article number three. Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention.</p>
<p>Article number four. ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 percent of East Asian populations, significantly diminishes Aldehyde Dehydrogenase 2 enzymatic activity by 60 to 90 percent. This variant enhances platelet activation and thrombosis, directly contributing to an elevated thrombotic risk. The study determined that this prothrombotic effect occurs specifically through the disruption of mitochondrial complex one assembly.</p>
<p>Article number five. Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study. Elevated lipoprotein(a) directly results in vascular regenerative deficiencies. Lipoprotein(a) is an established causal risk factor for atherosclerotic cardiovascular disease. This study found that elevated levels of lipoprotein(a) modify vascular regenerative cell content properties, impacting the capacity for vascular repair. Depletion of vascular regenerative progenitor cells serves as an indicator of compromised vascular repair in individuals with cardiometabolic disorders. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>calcified mitral valve disease, platelet activation, cardiometabolic disorders, transthoracic Doppler echocardiography, percutaneous coronary intervention, thrombosis, myxomatous mitral valve disease, MITRACURE registry, long-term prognosis, lipoprotein(a), Vasostatin-2, rs671 variant, Mas receptor, coronary microvascular dysfunction, mitral valve surgery, myocardial infarction and non-obstructive coronary arteries, neointimal hyperplasia, mitochondrial complex one, Aldehyde Dehydrogenase 2, progenitor cells, Angiotensin-converting enzyme 2, atherosclerotic cardiovascular disease, vascular regeneration.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/">ALDH2 Variant Drives Thrombosis Risk. 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like calcified mitral valve disease and platelet activation. Key takeaway: ALDH2 Variant Drives Thrombosis Risk..
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like calcified mitral valve disease and platelet activation. Key takeaway: ALDH2 Variant Drives Thrombosis Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41274561">Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry.</a> (The Canadian journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41274583">Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41231769">Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41150615">ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40883226">Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/">https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274561" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274561</a></p>
<p><strong>Summary:</strong> The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges.</p>
<h4>Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274583" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274583</a></p>
<p><strong>Summary:</strong> Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population.</p>
<h4>Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41231769" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41231769</a></p>
<p><strong>Summary:</strong> Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention.</p>
<h4>Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41150615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41150615</a></p>
<p><strong>Summary:</strong> The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 percent of East Asian populations, significantly diminishes Aldehyde Dehydrogenase 2 enzymatic activity by 60 to 90 percent. This variant enhances platelet activation and thrombosis, directly contributing to an elevated thrombotic risk. The study determined that this prothrombotic effect occurs specifically through the disruption of mitochondrial complex one assembly.</p>
<h4>Article 5: Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40883226" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40883226</a></p>
<p><strong>Summary:</strong> Elevated lipoprotein(a) directly results in vascular regenerative deficiencies. Lipoprotein(a) is an established causal risk factor for atherosclerotic cardiovascular disease. This study found that elevated levels of lipoprotein(a) modify vascular regenerative cell content properties, impacting the capacity for vascular repair. Depletion of vascular regenerative progenitor cells serves as an indicator of compromised vascular repair in individuals with cardiometabolic disorders.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry. The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges.</p>
<p>Article number two. Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population.</p>
<p>Article number three. Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention.</p>
<p>Article number four. ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 percent of East Asian populations, significantly diminishes Aldehyde Dehydrogenase 2 enzymatic activity by 60 to 90 percent. This variant enhances platelet activation and thrombosis, directly contributing to an elevated thrombotic risk. The study determined that this prothrombotic effect occurs specifically through the disruption of mitochondrial complex one assembly.</p>
<p>Article number five. Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study. Elevated lipoprotein(a) directly results in vascular regenerative deficiencies. Lipoprotein(a) is an established causal risk factor for atherosclerotic cardiovascular disease. This study found that elevated levels of lipoprotein(a) modify vascular regenerative cell content properties, impacting the capacity for vascular repair. Depletion of vascular regenerative progenitor cells serves as an indicator of compromised vascular repair in individuals with cardiometabolic disorders. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>calcified mitral valve disease, platelet activation, cardiometabolic disorders, transthoracic Doppler echocardiography, percutaneous coronary intervention, thrombosis, myxomatous mitral valve disease, MITRACURE registry, long-term prognosis, lipoprotein(a), Vasostatin-2, rs671 variant, Mas receptor, coronary microvascular dysfunction, mitral valve surgery, myocardial infarction and non-obstructive coronary arteries, neointimal hyperplasia, mitochondrial complex one, Aldehyde Dehydrogenase 2, progenitor cells, Angiotensin-converting enzyme 2, atherosclerotic cardiovascular disease, vascular regeneration.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/">ALDH2 Variant Drives Thrombosis Risk. 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251123_060034.mp3" length="4574397" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like calcified mitral valve disease and platelet activation. Key takeaway: ALDH2 Variant Drives Thrombosis Risk..
Article Links:
Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry. (The Canadian journal of cardiology)
Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. (International journal of cardiology)
Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. (Cardiovascular research)
Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. (Cardiovascular research)
Article 5: Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/
 Featured Articles
Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274561
Summary: The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges.
Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274583
Summary: Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population.
Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41231769
Summary: Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention.
Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41150615
Summary: The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 p]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like calcified mitral valve disease and platelet activation. Key takeaway: ALDH2 Variant Drives Thrombosis Risk..
Article Links:
Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease &#8211; The MITRACURE registry. (The Canadian journal of cardiology)
Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. (International journal of cardiology)
Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. (Cardiovascular research)
Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. (Cardiovascular research)
Article 5: Vascular regenerative deficiencies in people with elevated li]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Phenotypic Age Predicts Sudden Cardiac Arrest. 11/23/25</title>
	<link>https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/</link>
	<pubDate>Sun, 23 Nov 2025 06:16:16 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like low-density lipoprotein cholesterol and ventricular arrhythmias. Key takeaway: Phenotypic Age Predicts Sudden Cardiac Arrest..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40331569">Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41274325">Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY).</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41274324">Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41274323">Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41274562">Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/">https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40331569" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40331569</a></p>
<p><strong>Summary:</strong> Higher levels of lipoprotein(a) are established as increasing atherosclerotic cardiovascular disease risk in otherwise healthy individuals, irrespective of sex and race or ethnicity. This study analyzed 273770 individuals from a U. S. medical claims database with diagnosed atherosclerotic cardiovascular disease and measured lipoprotein(a) levels. The research confirmed the clinical significance of lipoprotein(a) as a crucial driver for recurrent atherosclerotic cardiovascular events. It also assessed the influence of low-density lipoprotein cholesterol-lowering therapy on this relationship in patients with established disease.</p>
<h4>Article 2: Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY).</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274325</a></p>
<p><strong>Summary:</strong> Fetal magnetocardiography provides precise, non-invasive detection of fetal cardiac electrical activity, which conventional echocardiography cannot record. The F. A. M. I. L. Y. clinical trial evaluated the efficacy and safety of fetal magnetocardiography for detecting fetal cardiac magnetic signals. This two-center, single-arm, prospective study confirmed fetal magnetocardiography&#8217;s capability for accurate detection of fetal cardiac time intervals, essential for diagnosing arrhythmias. The research established fetal magnetocardiography as a vital tool by directly comparing its performance with fetal electrocardiography.</p>
<h4>Article 3: Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274324" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274324</a></p>
<p><strong>Summary:</strong> This large retrospective cohort analysis of 360663 U. K. Biobank participants found a significant association between phenotypic age acceleration and the risk of incident sudden cardiac arrest. The study established phenotypic age acceleration as a convenient proxy for biological aging and a substantial contributor to cardiovascular disease development. Researchers demonstrated that individuals with higher phenotypic age acceleration face an increased risk of sudden cardiac arrest. This provides crucial evidence for incorporating biological aging markers into risk assessment for sudden cardiac arrest.</p>
<h4>Article 4: Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274323" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274323</a></p>
<p><strong>Summary:</strong> This study defined the electrocardiogram characteristics and ablation outcomes for idiopathic ventricular arrhythmias originating from the right ventricular apex. Researchers conducted a retrospective analysis of patients undergoing catheter ablation for these arrhythmias across three centers. The study provided crucial data distinguishing right ventricular apical ventricular arrhythmias, including premature ventricular contractions and ventricular tachycardia, from other right ventricular sources. The findings contribute to improved diagnostic and therapeutic strategies for this specific and less-understood subset of ventricular arrhythmias.</p>
<h4>Article 5: Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274562</a></p>
<p><strong>Summary:</strong> This study found that a remote patient management program for heart failure demonstrated equitable accessibility across various area-based marginalization statuses. The program&#8217;s design, which provides necessary equipment, employs minimal exclusion criteria, and is compatible with both Android and I. Phone devices, contributed to this equitable access. This research indicates that carefully structured remote patient management programs can effectively reach diverse heart failure patient populations. The findings suggest a model for inclusive and accessible heart failure care delivery.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. Higher levels of lipoprotein(a) are established as increasing atherosclerotic cardiovascular disease risk in otherwise healthy individuals, irrespective of sex and race or ethnicity. This study analyzed 273770 individuals from a U. S. medical claims database with diagnosed atherosclerotic cardiovascular disease and measured lipoprotein(a) levels. The research confirmed the clinical significance of lipoprotein(a) as a crucial driver for recurrent atherosclerotic cardiovascular events. It also assessed the influence of low-density lipoprotein cholesterol-lowering therapy on this relationship in patients with established disease.</p>
<p>Article number two. Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY). Fetal magnetocardiography provides precise, non-invasive detection of fetal cardiac electrical activity, which conventional echocardiography cannot record. The F. A. M. I. L. Y. clinical trial evaluated the efficacy and safety of fetal magnetocardiography for detecting fetal cardiac magnetic signals. This two-center, single-arm, prospective study confirmed fetal magnetocardiography&#8217;s capability for accurate detection of fetal cardiac time intervals, essential for diagnosing arrhythmias. The research established fetal magnetocardiography as a vital tool by directly comparing its performance with fetal electrocardiography.</p>
<p>Article number three. Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort. This large retrospective cohort analysis of 360663 U. K. Biobank participants found a significant association between phenotypic age acceleration and the risk of incident sudden cardiac arrest. The study established phenotypic age acceleration as a convenient proxy for biological aging and a substantial contributor to cardiovascular disease development. Researchers demonstrated that individuals with higher phenotypic age acceleration face an increased risk of sudden cardiac arrest. This provides crucial evidence for incorporating biological aging markers into risk assessment for sudden cardiac arrest.</p>
<p>Article number four. Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex. This study defined the electrocardiogram characteristics and ablation outcomes for idiopathic ventricular arrhythmias originating from the right ventricular apex. Researchers conducted a retrospective analysis of patients undergoing catheter ablation for these arrhythmias across three centers. The study provided crucial data distinguishing right ventricular apical ventricular arrhythmias, including premature ventricular contractions and ventricular tachycardia, from other right ventricular sources. The findings contribute to improved diagnostic and therapeutic strategies for this specific and less-understood subset of ventricular arrhythmias.</p>
<p>Article number five. Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program. This study found that a remote patient management program for heart failure demonstrated equitable accessibility across various area-based marginalization statuses. The program&#8217;s design, which provides necessary equipment, employs minimal exclusion criteria, and is compatible with both Android and I. Phone devices, contributed to this equitable access. This research indicates that carefully structured remote patient management programs can effectively reach diverse heart failure patient populations. The findings suggest a model for inclusive and accessible heart failure care delivery. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>low-density lipoprotein cholesterol, ventricular arrhythmias, cardiovascular disease, ventricular tachycardia, recurrent events, remote patient management, right ventricular apex, secondary prevention, fetal electrocardiography, premature ventricular contractions, lipoprotein(a), sudden cardiac arrest, catheter ablation, health equity, marginalization status, fetal cardiac signals, access to care, risk prediction, heart failure, fetal arrhythmias, phenotypic age acceleration, non-invasive detection, fetal magnetocardiography, atherosclerotic cardiovascular disease, biological aging.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/">Phenotypic Age Predicts Sudden Cardiac Arrest. 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like low-density lipoprotein cholesterol and ventricular arrhythmias. Key takeaway: Phenotypic Age Predicts Sudden Cardiac Arrest..
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like low-density lipoprotein cholesterol and ventricular arrhythmias. Key takeaway: Phenotypic Age Predicts Sudden Cardiac Arrest..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40331569">Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41274325">Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY).</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41274324">Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41274323">Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41274562">Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/">https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40331569" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40331569</a></p>
<p><strong>Summary:</strong> Higher levels of lipoprotein(a) are established as increasing atherosclerotic cardiovascular disease risk in otherwise healthy individuals, irrespective of sex and race or ethnicity. This study analyzed 273770 individuals from a U. S. medical claims database with diagnosed atherosclerotic cardiovascular disease and measured lipoprotein(a) levels. The research confirmed the clinical significance of lipoprotein(a) as a crucial driver for recurrent atherosclerotic cardiovascular events. It also assessed the influence of low-density lipoprotein cholesterol-lowering therapy on this relationship in patients with established disease.</p>
<h4>Article 2: Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY).</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274325</a></p>
<p><strong>Summary:</strong> Fetal magnetocardiography provides precise, non-invasive detection of fetal cardiac electrical activity, which conventional echocardiography cannot record. The F. A. M. I. L. Y. clinical trial evaluated the efficacy and safety of fetal magnetocardiography for detecting fetal cardiac magnetic signals. This two-center, single-arm, prospective study confirmed fetal magnetocardiography&#8217;s capability for accurate detection of fetal cardiac time intervals, essential for diagnosing arrhythmias. The research established fetal magnetocardiography as a vital tool by directly comparing its performance with fetal electrocardiography.</p>
<h4>Article 3: Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274324" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274324</a></p>
<p><strong>Summary:</strong> This large retrospective cohort analysis of 360663 U. K. Biobank participants found a significant association between phenotypic age acceleration and the risk of incident sudden cardiac arrest. The study established phenotypic age acceleration as a convenient proxy for biological aging and a substantial contributor to cardiovascular disease development. Researchers demonstrated that individuals with higher phenotypic age acceleration face an increased risk of sudden cardiac arrest. This provides crucial evidence for incorporating biological aging markers into risk assessment for sudden cardiac arrest.</p>
<h4>Article 4: Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274323" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274323</a></p>
<p><strong>Summary:</strong> This study defined the electrocardiogram characteristics and ablation outcomes for idiopathic ventricular arrhythmias originating from the right ventricular apex. Researchers conducted a retrospective analysis of patients undergoing catheter ablation for these arrhythmias across three centers. The study provided crucial data distinguishing right ventricular apical ventricular arrhythmias, including premature ventricular contractions and ventricular tachycardia, from other right ventricular sources. The findings contribute to improved diagnostic and therapeutic strategies for this specific and less-understood subset of ventricular arrhythmias.</p>
<h4>Article 5: Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41274562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41274562</a></p>
<p><strong>Summary:</strong> This study found that a remote patient management program for heart failure demonstrated equitable accessibility across various area-based marginalization statuses. The program&#8217;s design, which provides necessary equipment, employs minimal exclusion criteria, and is compatible with both Android and I. Phone devices, contributed to this equitable access. This research indicates that carefully structured remote patient management programs can effectively reach diverse heart failure patient populations. The findings suggest a model for inclusive and accessible heart failure care delivery.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. Higher levels of lipoprotein(a) are established as increasing atherosclerotic cardiovascular disease risk in otherwise healthy individuals, irrespective of sex and race or ethnicity. This study analyzed 273770 individuals from a U. S. medical claims database with diagnosed atherosclerotic cardiovascular disease and measured lipoprotein(a) levels. The research confirmed the clinical significance of lipoprotein(a) as a crucial driver for recurrent atherosclerotic cardiovascular events. It also assessed the influence of low-density lipoprotein cholesterol-lowering therapy on this relationship in patients with established disease.</p>
<p>Article number two. Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY). Fetal magnetocardiography provides precise, non-invasive detection of fetal cardiac electrical activity, which conventional echocardiography cannot record. The F. A. M. I. L. Y. clinical trial evaluated the efficacy and safety of fetal magnetocardiography for detecting fetal cardiac magnetic signals. This two-center, single-arm, prospective study confirmed fetal magnetocardiography&#8217;s capability for accurate detection of fetal cardiac time intervals, essential for diagnosing arrhythmias. The research established fetal magnetocardiography as a vital tool by directly comparing its performance with fetal electrocardiography.</p>
<p>Article number three. Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort. This large retrospective cohort analysis of 360663 U. K. Biobank participants found a significant association between phenotypic age acceleration and the risk of incident sudden cardiac arrest. The study established phenotypic age acceleration as a convenient proxy for biological aging and a substantial contributor to cardiovascular disease development. Researchers demonstrated that individuals with higher phenotypic age acceleration face an increased risk of sudden cardiac arrest. This provides crucial evidence for incorporating biological aging markers into risk assessment for sudden cardiac arrest.</p>
<p>Article number four. Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex. This study defined the electrocardiogram characteristics and ablation outcomes for idiopathic ventricular arrhythmias originating from the right ventricular apex. Researchers conducted a retrospective analysis of patients undergoing catheter ablation for these arrhythmias across three centers. The study provided crucial data distinguishing right ventricular apical ventricular arrhythmias, including premature ventricular contractions and ventricular tachycardia, from other right ventricular sources. The findings contribute to improved diagnostic and therapeutic strategies for this specific and less-understood subset of ventricular arrhythmias.</p>
<p>Article number five. Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program. This study found that a remote patient management program for heart failure demonstrated equitable accessibility across various area-based marginalization statuses. The program&#8217;s design, which provides necessary equipment, employs minimal exclusion criteria, and is compatible with both Android and I. Phone devices, contributed to this equitable access. This research indicates that carefully structured remote patient management programs can effectively reach diverse heart failure patient populations. The findings suggest a model for inclusive and accessible heart failure care delivery. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>low-density lipoprotein cholesterol, ventricular arrhythmias, cardiovascular disease, ventricular tachycardia, recurrent events, remote patient management, right ventricular apex, secondary prevention, fetal electrocardiography, premature ventricular contractions, lipoprotein(a), sudden cardiac arrest, catheter ablation, health equity, marginalization status, fetal cardiac signals, access to care, risk prediction, heart failure, fetal arrhythmias, phenotypic age acceleration, non-invasive detection, fetal magnetocardiography, atherosclerotic cardiovascular disease, biological aging.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/">Phenotypic Age Predicts Sudden Cardiac Arrest. 11/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251123_011504.mp3" length="4385061" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like low-density lipoprotein cholesterol and ventricular arrhythmias. Key takeaway: Phenotypic Age Predicts Sudden Cardiac Arrest..
Article Links:
Article 1: Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. (European heart journal)
Article 2: Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY). (Heart rhythm)
Article 3: Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort. (Heart rhythm)
Article 4: Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex. (Heart rhythm)
Article 5: Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/phenotypic-age-predicts-sudden-cardiac-arrest-11-23-25/
 Featured Articles
Article 1: Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40331569
Summary: Higher levels of lipoprotein(a) are established as increasing atherosclerotic cardiovascular disease risk in otherwise healthy individuals, irrespective of sex and race or ethnicity. This study analyzed 273770 individuals from a U. S. medical claims database with diagnosed atherosclerotic cardiovascular disease and measured lipoprotein(a) levels. The research confirmed the clinical significance of lipoprotein(a) as a crucial driver for recurrent atherosclerotic cardiovascular events. It also assessed the influence of low-density lipoprotein cholesterol-lowering therapy on this relationship in patients with established disease.
Article 2: Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY).
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274325
Summary: Fetal magnetocardiography provides precise, non-invasive detection of fetal cardiac electrical activity, which conventional echocardiography cannot record. The F. A. M. I. L. Y. clinical trial evaluated the efficacy and safety of fetal magnetocardiography for detecting fetal cardiac magnetic signals. This two-center, single-arm, prospective study confirmed fetal magnetocardiography&#8217;s capability for accurate detection of fetal cardiac time intervals, essential for diagnosing arrhythmias. The research established fetal magnetocardiography as a vital tool by directly comparing its performance with fetal electrocardiography.
Article 3: Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274324
Summary: This large retrospective cohort analysis of 360663 U. K. Biobank participants found a significant association between phenotypic age acceleration and the risk of incident sudden cardiac arrest. The study established phenotypic age acceleration as a convenient proxy for biological aging and a substantial contributor to cardiovascular disease development. Researchers demonstrated that individuals with higher phenotypic age acceleration face an increased risk of sudden cardiac arrest. This provides crucial evidence for incorporating biological aging markers into risk assessment for sudden cardiac arrest.
Article 4: Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274323
Summary: This study defined the electrocardiogram characteristics and ablation outcomes for idiopathic ventricular arrhythmias originating from the]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like low-density lipoprotein cholesterol and ventricular arrhythmias. Key takeaway: Phenotypic Age Predicts Sudden Cardiac Arrest..
Article Links:
Article 1: Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. (European heart journal)
Article 2: Efficacy and Safety of Fetal Magnetocardiography for Detecting Fetal Cardiac Magnetic Signals: A Two-Center, Single-Arm, Prospective Clinical Trial (FAMILY). (Heart rhythm)
Article 3: Association of phenotypic age acceleration with risk of sudden cardiac arrest: evidence from a large retrospective cohort. (Heart rhythm)
Article 4: Ablation of Idiopathic Ventricular Arrhythmias from the Right Ventricular Apex. (Heart rhythm)
Article 5: Equity in Heart Failure Care: Examining the Area-based Marginalization Status of Patients in an RPM Program. (The Canadian journal of cardiology)
Full ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Carotid Stenosis: Revascularize or Meds? 11/22/25</title>
	<link>https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/</link>
	<pubDate>Sat, 22 Nov 2025 11:01:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 22, 2025. This episode summarizes 5 key cardiology studies on topics like omics sciences and retrospective cohort study. Key takeaway: Carotid Stenosis: Revascularize or Meds?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41269206">Medical Management and Revascularization for Asymptomatic Carotid Stenosis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41271218">Coronary revascularization: a long-term perspective.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41255167">Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41263729">Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41269907">Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/">https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269206" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269206</a></p>
<p><strong>Summary:</strong> The clinical approach for asymptomatic carotid stenosis remains uncertain, particularly whether revascularization offers benefits beyond intensive medical management alone. Two parallel, observer-blinded clinical trials were conducted to address this critical question. These trials enrolled patients with high-grade (70 percent or greater) asymptomatic carotid stenosis across 155 centers in five countries. The research directly compared stenting or endarterectomy against intensive medical management to determine optimal patient care strategies.</p>
<h4>Article 2: Coronary revascularization: a long-term perspective.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41271218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41271218</a></p>
<p><strong>Summary:</strong> This paper provided a long-term perspective on advancements in coronary revascularization, building on successful predictions made in 2000 regarding innovations like drug-eluting stents and coronary computed tomography angiography. The authors highlighted the evolving landscape of coronary artery disease treatment. They specifically emphasized the transformative role of artificial intelligence and omics sciences. Imagenomics, which integrates imaging and omics, was identified as a key future tool for precision in coronary revascularization by 2040.</p>
<h4>Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41255167" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41255167</a></p>
<p><strong>Summary:</strong> This single-center retrospective study evaluated the real-world effectiveness and safety of the Carillon Mitral Contour System (C. M. C. S.) for indirect annuloplasty in 204 consecutive patients. The study cohort presented with Heart Failure (H. F.) and moderate or moderate to severe (grade two plus or three plus) secondary mitral regurgitation (S. M. R.), with an average age of 83 years, 68 percent female, and 72 percent having Heart Failure with Reduced Ejection Fraction (H. F. rEF). Echocardiographic variables, B-type natriuretic peptide (B. N. P.) levels, and clinical outcomes were systematically recorded. These comprehensive data were collected at baseline, 6-month, and 1-year follow-up to characterize the treatment&#8217;s impact on this specific patient group.</p>
<h4>Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41263729" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41263729</a></p>
<p><strong>Summary:</strong> Physiology-guided percutaneous coronary intervention (P. C. I.) is known to offer clinical benefits by optimizing treatment plans beyond what coronary angiography alone can achieve. This study investigated the diagnostic impact of quantitative flow ratio (Q. F. R.) within this framework. A post hoc analysis of the multicenter randomized F. A. V. O. R. three China Trial focused on patients with coronary artery disease. The research explored how quantitative flow ratio contributes to enhancing the precision of interventional strategies.</p>
<h4>Article 5: Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269907" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269907</a></p>
<p><strong>Summary:</strong> Bedaquiline significantly improves treatment outcomes in patients with drug-resistant tuberculosis (D. R. T. B.), but it is known to prolong the Q. T. interval, necessitating thorough cardiac safety evaluation. This retrospective cohort study assessed the cardiac safety profile of Bedaquiline-containing regimens. It included 202 patients diagnosed with drug-resistant tuberculosis who received treatment between March 2019 and May 2024. Patients were followed for 180 days to gather data on cardiac events and potential risk factors associated with Bedaquiline use.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Medical Management and Revascularization for Asymptomatic Carotid Stenosis. The clinical approach for asymptomatic carotid stenosis remains uncertain, particularly whether revascularization offers benefits beyond intensive medical management alone. Two parallel, observer-blinded clinical trials were conducted to address this critical question. These trials enrolled patients with high-grade (70 percent or greater) asymptomatic carotid stenosis across 155 centers in five countries. The research directly compared stenting or endarterectomy against intensive medical management to determine optimal patient care strategies.</p>
<p>Article number two. Coronary revascularization: a long-term perspective. This paper provided a long-term perspective on advancements in coronary revascularization, building on successful predictions made in 2000 regarding innovations like drug-eluting stents and coronary computed tomography angiography. The authors highlighted the evolving landscape of coronary artery disease treatment. They specifically emphasized the transformative role of artificial intelligence and omics sciences. Imagenomics, which integrates imaging and omics, was identified as a key future tool for precision in coronary revascularization by 2040.</p>
<p>Article number three. Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. This single-center retrospective study evaluated the real-world effectiveness and safety of the Carillon Mitral Contour System (C. M. C. S.) for indirect annuloplasty in 204 consecutive patients. The study cohort presented with Heart Failure (H. F.) and moderate or moderate to severe (grade two plus or three plus) secondary mitral regurgitation (S. M. R.), with an average age of 83 years, 68 percent female, and 72 percent having Heart Failure with Reduced Ejection Fraction (H. F. rEF). Echocardiographic variables, B-type natriuretic peptide (B. N. P.) levels, and clinical outcomes were systematically recorded. These comprehensive data were collected at baseline, 6-month, and 1-year follow-up to characterize the treatment&#8217;s impact on this specific patient group.</p>
<p>Article number four. Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial. Physiology-guided percutaneous coronary intervention (P. C. I.) is known to offer clinical benefits by optimizing treatment plans beyond what coronary angiography alone can achieve. This study investigated the diagnostic impact of quantitative flow ratio (Q. F. R.) within this framework. A post hoc analysis of the multicenter randomized F. A. V. O. R. three China Trial focused on patients with coronary artery disease. The research explored how quantitative flow ratio contributes to enhancing the precision of interventional strategies.</p>
<p>Article number five. Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study. Bedaquiline significantly improves treatment outcomes in patients with drug-resistant tuberculosis (D. R. T. B.), but it is known to prolong the Q. T. interval, necessitating thorough cardiac safety evaluation. This retrospective cohort study assessed the cardiac safety profile of Bedaquiline-containing regimens. It included 202 patients diagnosed with drug-resistant tuberculosis who received treatment between March 2019 and May 2024. Patients were followed for 180 days to gather data on cardiac events and potential risk factors associated with Bedaquiline use. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>omics sciences, retrospective cohort study, ejection fraction, Q. T. interval prolongation, artificial intelligence, revascularization, quantitative flow ratio, secondary mitral regurgitation, medical management, F. A. V. O. R. three China Trial, cardiac safety, asymptomatic carotid stenosis, heart failure, indirect mitral annuloplasty, drug-resistant tuberculosis, coronary angiography, carotid-artery stenting, Carillon Mitral Contour System, carotid endarterectomy, imagenomics, coronary artery disease, coronary revascularization, physiology-guided percutaneous coronary intervention, drug-eluting stents, Bedaquiline.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/">Carotid Stenosis: Revascularize or Meds? 11/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 22, 2025. This episode summarizes 5 key cardiology studies on topics like omics sciences and retrospective cohort study. Key takeaway: Carotid Stenosis: Revascularize or Meds?.
Article Links:
Article 1: Med]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 22, 2025. This episode summarizes 5 key cardiology studies on topics like omics sciences and retrospective cohort study. Key takeaway: Carotid Stenosis: Revascularize or Meds?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41269206">Medical Management and Revascularization for Asymptomatic Carotid Stenosis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41271218">Coronary revascularization: a long-term perspective.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41255167">Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41263729">Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41269907">Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/">https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269206" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269206</a></p>
<p><strong>Summary:</strong> The clinical approach for asymptomatic carotid stenosis remains uncertain, particularly whether revascularization offers benefits beyond intensive medical management alone. Two parallel, observer-blinded clinical trials were conducted to address this critical question. These trials enrolled patients with high-grade (70 percent or greater) asymptomatic carotid stenosis across 155 centers in five countries. The research directly compared stenting or endarterectomy against intensive medical management to determine optimal patient care strategies.</p>
<h4>Article 2: Coronary revascularization: a long-term perspective.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41271218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41271218</a></p>
<p><strong>Summary:</strong> This paper provided a long-term perspective on advancements in coronary revascularization, building on successful predictions made in 2000 regarding innovations like drug-eluting stents and coronary computed tomography angiography. The authors highlighted the evolving landscape of coronary artery disease treatment. They specifically emphasized the transformative role of artificial intelligence and omics sciences. Imagenomics, which integrates imaging and omics, was identified as a key future tool for precision in coronary revascularization by 2040.</p>
<h4>Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41255167" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41255167</a></p>
<p><strong>Summary:</strong> This single-center retrospective study evaluated the real-world effectiveness and safety of the Carillon Mitral Contour System (C. M. C. S.) for indirect annuloplasty in 204 consecutive patients. The study cohort presented with Heart Failure (H. F.) and moderate or moderate to severe (grade two plus or three plus) secondary mitral regurgitation (S. M. R.), with an average age of 83 years, 68 percent female, and 72 percent having Heart Failure with Reduced Ejection Fraction (H. F. rEF). Echocardiographic variables, B-type natriuretic peptide (B. N. P.) levels, and clinical outcomes were systematically recorded. These comprehensive data were collected at baseline, 6-month, and 1-year follow-up to characterize the treatment&#8217;s impact on this specific patient group.</p>
<h4>Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41263729" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41263729</a></p>
<p><strong>Summary:</strong> Physiology-guided percutaneous coronary intervention (P. C. I.) is known to offer clinical benefits by optimizing treatment plans beyond what coronary angiography alone can achieve. This study investigated the diagnostic impact of quantitative flow ratio (Q. F. R.) within this framework. A post hoc analysis of the multicenter randomized F. A. V. O. R. three China Trial focused on patients with coronary artery disease. The research explored how quantitative flow ratio contributes to enhancing the precision of interventional strategies.</p>
<h4>Article 5: Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41269907" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41269907</a></p>
<p><strong>Summary:</strong> Bedaquiline significantly improves treatment outcomes in patients with drug-resistant tuberculosis (D. R. T. B.), but it is known to prolong the Q. T. interval, necessitating thorough cardiac safety evaluation. This retrospective cohort study assessed the cardiac safety profile of Bedaquiline-containing regimens. It included 202 patients diagnosed with drug-resistant tuberculosis who received treatment between March 2019 and May 2024. Patients were followed for 180 days to gather data on cardiac events and potential risk factors associated with Bedaquiline use.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Medical Management and Revascularization for Asymptomatic Carotid Stenosis. The clinical approach for asymptomatic carotid stenosis remains uncertain, particularly whether revascularization offers benefits beyond intensive medical management alone. Two parallel, observer-blinded clinical trials were conducted to address this critical question. These trials enrolled patients with high-grade (70 percent or greater) asymptomatic carotid stenosis across 155 centers in five countries. The research directly compared stenting or endarterectomy against intensive medical management to determine optimal patient care strategies.</p>
<p>Article number two. Coronary revascularization: a long-term perspective. This paper provided a long-term perspective on advancements in coronary revascularization, building on successful predictions made in 2000 regarding innovations like drug-eluting stents and coronary computed tomography angiography. The authors highlighted the evolving landscape of coronary artery disease treatment. They specifically emphasized the transformative role of artificial intelligence and omics sciences. Imagenomics, which integrates imaging and omics, was identified as a key future tool for precision in coronary revascularization by 2040.</p>
<p>Article number three. Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. This single-center retrospective study evaluated the real-world effectiveness and safety of the Carillon Mitral Contour System (C. M. C. S.) for indirect annuloplasty in 204 consecutive patients. The study cohort presented with Heart Failure (H. F.) and moderate or moderate to severe (grade two plus or three plus) secondary mitral regurgitation (S. M. R.), with an average age of 83 years, 68 percent female, and 72 percent having Heart Failure with Reduced Ejection Fraction (H. F. rEF). Echocardiographic variables, B-type natriuretic peptide (B. N. P.) levels, and clinical outcomes were systematically recorded. These comprehensive data were collected at baseline, 6-month, and 1-year follow-up to characterize the treatment&#8217;s impact on this specific patient group.</p>
<p>Article number four. Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial. Physiology-guided percutaneous coronary intervention (P. C. I.) is known to offer clinical benefits by optimizing treatment plans beyond what coronary angiography alone can achieve. This study investigated the diagnostic impact of quantitative flow ratio (Q. F. R.) within this framework. A post hoc analysis of the multicenter randomized F. A. V. O. R. three China Trial focused on patients with coronary artery disease. The research explored how quantitative flow ratio contributes to enhancing the precision of interventional strategies.</p>
<p>Article number five. Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study. Bedaquiline significantly improves treatment outcomes in patients with drug-resistant tuberculosis (D. R. T. B.), but it is known to prolong the Q. T. interval, necessitating thorough cardiac safety evaluation. This retrospective cohort study assessed the cardiac safety profile of Bedaquiline-containing regimens. It included 202 patients diagnosed with drug-resistant tuberculosis who received treatment between March 2019 and May 2024. Patients were followed for 180 days to gather data on cardiac events and potential risk factors associated with Bedaquiline use. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>omics sciences, retrospective cohort study, ejection fraction, Q. T. interval prolongation, artificial intelligence, revascularization, quantitative flow ratio, secondary mitral regurgitation, medical management, F. A. V. O. R. three China Trial, cardiac safety, asymptomatic carotid stenosis, heart failure, indirect mitral annuloplasty, drug-resistant tuberculosis, coronary angiography, carotid-artery stenting, Carillon Mitral Contour System, carotid endarterectomy, imagenomics, coronary artery disease, coronary revascularization, physiology-guided percutaneous coronary intervention, drug-eluting stents, Bedaquiline.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/">Carotid Stenosis: Revascularize or Meds? 11/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251122_060036.mp3" length="4206593" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 22, 2025. This episode summarizes 5 key cardiology studies on topics like omics sciences and retrospective cohort study. Key takeaway: Carotid Stenosis: Revascularize or Meds?.
Article Links:
Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis. (The New England journal of medicine)
Article 2: Coronary revascularization: a long-term perspective. (European heart journal)
Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. (ESC heart failure)
Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial. (JACC. Cardiovascular interventions)
Article 5: Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/
 Featured Articles
Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41269206
Summary: The clinical approach for asymptomatic carotid stenosis remains uncertain, particularly whether revascularization offers benefits beyond intensive medical management alone. Two parallel, observer-blinded clinical trials were conducted to address this critical question. These trials enrolled patients with high-grade (70 percent or greater) asymptomatic carotid stenosis across 155 centers in five countries. The research directly compared stenting or endarterectomy against intensive medical management to determine optimal patient care strategies.
Article 2: Coronary revascularization: a long-term perspective.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41271218
Summary: This paper provided a long-term perspective on advancements in coronary revascularization, building on successful predictions made in 2000 regarding innovations like drug-eluting stents and coronary computed tomography angiography. The authors highlighted the evolving landscape of coronary artery disease treatment. They specifically emphasized the transformative role of artificial intelligence and omics sciences. Imagenomics, which integrates imaging and omics, was identified as a key future tool for precision in coronary revascularization by 2040.
Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41255167
Summary: This single-center retrospective study evaluated the real-world effectiveness and safety of the Carillon Mitral Contour System (C. M. C. S.) for indirect annuloplasty in 204 consecutive patients. The study cohort presented with Heart Failure (H. F.) and moderate or moderate to severe (grade two plus or three plus) secondary mitral regurgitation (S. M. R.), with an average age of 83 years, 68 percent female, and 72 percent having Heart Failure with Reduced Ejection Fraction (H. F. rEF). Echocardiographic variables, B-type natriuretic peptide (B. N. P.) levels, and clinical outcomes were systematically recorded. These comprehensive data were collected at baseline, 6-month, and 1-year follow-up to characterize the treatment&#8217;s impact on this specific patient group.
Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41263729
Summary: Physiology-guided percutaneous coronary intervention (P. C. I.) is known to offer clinical benefits by optimizing treatment plans beyond what coronary angiography alone can achieve. This study investigated the diagnostic impact of quantita]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 22, 2025. This episode summarizes 5 key cardiology studies on topics like omics sciences and retrospective cohort study. Key takeaway: Carotid Stenosis: Revascularize or Meds?.
Article Links:
Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis. (The New England journal of medicine)
Article 2: Coronary revascularization: a long-term perspective. (European heart journal)
Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. (ESC heart failure)
Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial. (JACC. Cardiovascular interventions)
Article 5: Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/carotid-stenosis-re]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CAR T Cells Halt Atherosclerosis 11/21/25</title>
	<link>https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/</link>
	<pubDate>Fri, 21 Nov 2025 17:40:34 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41268661">OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41259058">Blood Pressure in Adolescence and Atherosclerosis in Middle Age.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41266240">Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41218924">Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41218925">Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/">https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268661" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268661</a></p>
<p><strong>Summary:</strong> This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.</p>
<h4>Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41259058" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41259058</a></p>
<p><strong>Summary:</strong> This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.</p>
<h4>Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41266240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41266240</a></p>
<p><strong>Summary:</strong> A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.</p>
<h4>Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41218924" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41218924</a></p>
<p><strong>Summary:</strong> This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.</p>
<h4>Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41218925" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41218925</a></p>
<p><strong>Summary:</strong> This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study&#8217;s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.</p>
<p>Article number two. Blood Pressure in Adolescence and Atherosclerosis in Middle Age. This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.</p>
<p>Article number three. Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.</p>
<p>Article number four. Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.</p>
<p>Article number five. Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study&#8217;s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mortality, blood pressure, infective endocarditis, medical therapy, cardiovascular disease, chimeric antigen receptor T regulatory cells, oxidized low-density lipoprotein, plaque development, heart failure, atherosclerosis, cardiac implantable electronic devices, percutaneous coronary interventions, diagnostic criteria, adolescence, European Society of Cardiology, older patients, left-sided endocarditis, percutaneous ventricular assist devices, valve surgery, Duke-International Society for Cardiovascular Infectious Diseases, hemodynamic support, Staphylococcus aureus infective endocarditis, middle age.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/">CAR T Cells Halt Atherosclerosis 11/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis.
Article Links:
Article 1: OxLDL-Targeted Chimeric Anti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41268661">OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41259058">Blood Pressure in Adolescence and Atherosclerosis in Middle Age.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41266240">Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41218924">Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41218925">Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/">https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41268661" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41268661</a></p>
<p><strong>Summary:</strong> This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.</p>
<h4>Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41259058" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41259058</a></p>
<p><strong>Summary:</strong> This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.</p>
<h4>Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41266240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41266240</a></p>
<p><strong>Summary:</strong> A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.</p>
<h4>Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41218924" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41218924</a></p>
<p><strong>Summary:</strong> This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.</p>
<h4>Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41218925" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41218925</a></p>
<p><strong>Summary:</strong> This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study&#8217;s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.</p>
<p>Article number two. Blood Pressure in Adolescence and Atherosclerosis in Middle Age. This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.</p>
<p>Article number three. Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.</p>
<p>Article number four. Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.</p>
<p>Article number five. Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study&#8217;s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mortality, blood pressure, infective endocarditis, medical therapy, cardiovascular disease, chimeric antigen receptor T regulatory cells, oxidized low-density lipoprotein, plaque development, heart failure, atherosclerosis, cardiac implantable electronic devices, percutaneous coronary interventions, diagnostic criteria, adolescence, European Society of Cardiology, older patients, left-sided endocarditis, percutaneous ventricular assist devices, valve surgery, Duke-International Society for Cardiovascular Infectious Diseases, hemodynamic support, Staphylococcus aureus infective endocarditis, middle age.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/">CAR T Cells Halt Atherosclerosis 11/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251121_123944.mp3" length="3776931" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis.
Article Links:
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. (Circulation)
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age. (JAMA cardiology)
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. (Heart (British Cardiac Society))
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. (Heart (British Cardiac Society))
Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/
 Featured Articles
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268661
Summary: This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259058
Summary: This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41266240
Summary: A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41218924
Summary: This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.
Article 5: Percutaneous ventricular assist devices ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis.
Article Links:
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. (Circulation)
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age. (JAMA cardiology)
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. (Heart (British Cardiac Society))
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. (Heart (British Cardiac Society))
Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. (Heart (British Cardiac Society))
Full episode page: ht]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cardiac Amyloid Treatment Boosts AVR Outcomes. 11/21/25</title>
	<link>https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/</link>
	<pubDate>Fri, 21 Nov 2025 11:01:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41124218">Belzutifan for Advanced Pheochromocytoma or Paraganglioma.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40824531">Lipoprotein(a) and risk of dementia: findings from three cohort studies.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40669514">Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40599126">Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40452225">Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/">https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41124218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41124218</a></p>
<p><strong>Summary:</strong> Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.</p>
<h4>Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40824531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40824531</a></p>
<p><strong>Summary:</strong> High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer&#8217;s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.</p>
<h4>Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40669514" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40669514</a></p>
<p><strong>Summary:</strong> Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.</p>
<h4>Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40599126" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40599126</a></p>
<p><strong>Summary:</strong> surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.</p>
<h4>Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40452225" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40452225</a></p>
<p><strong>Summary:</strong> Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.</p>
<p>Article number two. Lipoprotein(a) and risk of dementia: findings from three cohort studies. High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer&#8217;s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.</p>
<p>Article number three. Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.</p>
<p>Article number four. Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.</p>
<p>Article number five. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transthyretin amyloidosis, Surgical aortic valve replacement, Prognosis, Vascular dementia, Belzutifan, Tricuspid regurgitation, Lipoprotein(a), Alzheimer&#8217;s disease, Pheochromocytoma, Dementia, Electrocardiography, Aortic regurgitation, Aortic valve replacement, Transcatheter aortic valve replacement, Artificial intelligence, Cardiac amyloidosis, Mitral regurgitation, Atherosclerotic cardiovascular disease, Antitumor activity, Environmental footprint, Valvular heart disease, Paraganglioma, HIF-2 alpha inhibitor, Aortic stenosis, Carbon emissions.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/">Cardiac Amyloid Treatment Boosts AVR Outcomes. 11/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes..
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41124218">Belzutifan for Advanced Pheochromocytoma or Paraganglioma.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40824531">Lipoprotein(a) and risk of dementia: findings from three cohort studies.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40669514">Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40599126">Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40452225">Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/">https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41124218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41124218</a></p>
<p><strong>Summary:</strong> Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.</p>
<h4>Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40824531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40824531</a></p>
<p><strong>Summary:</strong> High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer&#8217;s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.</p>
<h4>Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40669514" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40669514</a></p>
<p><strong>Summary:</strong> Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.</p>
<h4>Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40599126" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40599126</a></p>
<p><strong>Summary:</strong> surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.</p>
<h4>Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40452225" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40452225</a></p>
<p><strong>Summary:</strong> Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.</p>
<p>Article number two. Lipoprotein(a) and risk of dementia: findings from three cohort studies. High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer&#8217;s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.</p>
<p>Article number three. Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.</p>
<p>Article number four. Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.</p>
<p>Article number five. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transthyretin amyloidosis, Surgical aortic valve replacement, Prognosis, Vascular dementia, Belzutifan, Tricuspid regurgitation, Lipoprotein(a), Alzheimer&#8217;s disease, Pheochromocytoma, Dementia, Electrocardiography, Aortic regurgitation, Aortic valve replacement, Transcatheter aortic valve replacement, Artificial intelligence, Cardiac amyloidosis, Mitral regurgitation, Atherosclerotic cardiovascular disease, Antitumor activity, Environmental footprint, Valvular heart disease, Paraganglioma, HIF-2 alpha inhibitor, Aortic stenosis, Carbon emissions.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/">Cardiac Amyloid Treatment Boosts AVR Outcomes. 11/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251121_060026.mp3" length="4043171" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes..
Article Links:
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma. (The New England journal of medicine)
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies. (European heart journal)
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. (European heart journal)
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. (European heart journal)
Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/
 Featured Articles
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41124218
Summary: Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40824531
Summary: High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer&#8217;s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40669514
Summary: Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40599126
Summary: surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these cr]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes..
Article Links:
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma. (The New England journal of medicine)
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies. (European heart journal)
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. (European heart journal)
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. (European heart journal)
Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. (European heart journal)
Full episode page: https://podcast.explainheart]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25</title>
	<link>https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/</link>
	<pubDate>Thu, 20 Nov 2025 17:26:13 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41259103">Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41259082">Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41258851">Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41258850">Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41258849">Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/">https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41259103" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41259103</a></p>
<p><strong>Summary:</strong> Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.</p>
<h4>Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41259082" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41259082</a></p>
<p><strong>Summary:</strong> The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.</p>
<h4>Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41258851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41258851</a></p>
<p><strong>Summary:</strong> Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.</p>
<h4>Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41258850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41258850</a></p>
<p><strong>Summary:</strong> The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.</p>
<h4>Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41258849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41258849</a></p>
<p><strong>Summary:</strong> The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.</p>
<p>Article number two. Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.</p>
<p>Article number three. Phase one Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.</p>
<p>Article number four. Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.</p>
<p>Article number five. Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>angiography, heart failure hospitalization, coronary lesions, stem cell therapy, cardiac endogenous transmitter systems, neonatal cardiac progenitor cells, pediatric cardiology, right ventricle dysfunction, optical coherence tomography, signal transmission, echocardiography, pacemaker cells, heart failure with preserved ejection fraction, hemodynamics, stent optimization, body mass index, left ventricular assist device, cardiomyocytes, bleeding, hypoplastic left heart syndrome, cardiac physiology, aspirin, antithrombotic regimen, hemocompatibility-related adverse events, percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/">Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.
Article Links:
Article 1: ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41259103">Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41259082">Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41258851">Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41258850">Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41258849">Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/">https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41259103" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41259103</a></p>
<p><strong>Summary:</strong> Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.</p>
<h4>Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41259082" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41259082</a></p>
<p><strong>Summary:</strong> The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.</p>
<h4>Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41258851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41258851</a></p>
<p><strong>Summary:</strong> Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.</p>
<h4>Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41258850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41258850</a></p>
<p><strong>Summary:</strong> The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.</p>
<h4>Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41258849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41258849</a></p>
<p><strong>Summary:</strong> The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.</p>
<p>Article number two. Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.</p>
<p>Article number three. Phase one Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.</p>
<p>Article number four. Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.</p>
<p>Article number five. Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>angiography, heart failure hospitalization, coronary lesions, stem cell therapy, cardiac endogenous transmitter systems, neonatal cardiac progenitor cells, pediatric cardiology, right ventricle dysfunction, optical coherence tomography, signal transmission, echocardiography, pacemaker cells, heart failure with preserved ejection fraction, hemodynamics, stent optimization, body mass index, left ventricular assist device, cardiomyocytes, bleeding, hypoplastic left heart syndrome, cardiac physiology, aspirin, antithrombotic regimen, hemocompatibility-related adverse events, percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/">Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251120_122515.mp3" length="4032304" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.
Article Links:
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. (European heart journal)
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. (European heart journal)
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. (JACC. Heart failure)
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. (JACC. Heart failure)
Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/
 Featured Articles
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259103
Summary: Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259082
Summary: The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258851
Summary: Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258850
Summary: The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular as]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.
Article Links:
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. (European heart journal)
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. (European heart journal)
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. (JACC. Heart failure)
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. (JACC. Heart failure)
Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. (JACC. Heart failure)
]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ECG Abnormalities Predict Heart Failure Risk 11/19/25</title>
	<link>https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/</link>
	<pubDate>Wed, 19 Nov 2025 11:06:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 19, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and stroke. Key takeaway: ECG Abnormalities Predict Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41249037">Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41249035">Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41249034">Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41243130">Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41246815">Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/">https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249037" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249037</a></p>
<p><strong>Summary:</strong> Isolated non-specific S. T. T. abnormalities on electrocardiograms were found to be associated with an increased risk of incident coronary heart disease and stroke in participants free of these conditions at baseline. This study also found that these abnormalities were linked to an increased risk of incident heart failure and its subtypes. Data showed that these specific electrocardiographic patterns, defined by Minnesota E. C. G. classification, independently predicted future development of heart failure, including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. These findings establish a prognostic role for isolated non-specific S. T. T. abnormalities in identifying individuals at risk for future cardiovascular events and heart failure.</p>
<h4>Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249035" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249035</a></p>
<p><strong>Summary:</strong> This study demonstrated the feasibility and performance of using routinely collected electronic medical records from Australian general practices to estimate the 5-year absolute risk of cardiovascular disease. Researchers found that integrating primary care electronic medical record data, specifically from the New South Wales Health Lumos program, provided a viable approach for cardiovascular risk prediction. The study successfully utilized data from 680 general practices to assess the predictive capability of these records. These findings indicate that Australian healthcare systems can effectively leverage existing electronic medical records for robust cardiovascular disease risk estimation, comparable to methods used in the U. S. A. and U. K.</p>
<h4>Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249034" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249034</a></p>
<p><strong>Summary:</strong> This study demonstrated the comparative diagnostic accuracy of several tools for heart failure with preserved ejection fraction (H. F. pEF) across community and clinical cohorts. Researchers found that the Heart Failure Association-P. E. F. F. and H. two F. P. E. F. Scores showed differing diagnostic performance when compared against inclusion criteria from sodium-glucose cotransporter-two inhibitors trials and age-adjusted N-terminal pro B-type natriuretic peptide. The data provided clarification on the strengths and limitations of each diagnostic approach, particularly highlighting their utility in older adult populations where H. F. pEF diagnosis is most challenging. These findings contribute to refining the clinical algorithm for accurate identification of H. F. pEF.</p>
<h4>Article 4: Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41243130" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41243130</a></p>
<p><strong>Summary:</strong> This prospective cohort study identified significant therapy gaps in the contemporary management of patients with heart failure and reduced kidney function. Researchers evaluated longitudinal treatment patterns over two years in 1401 heart failure patients, finding that the use and dose intensity of guideline-directed heart failure therapies varied considerably across the spectrum of kidney function and left ventricular ejection fraction. The data demonstrated that a substantial proportion of patients with kidney dysfunction did not receive optimal heart failure pharmacotherapies or were underdosed. These findings highlight unmet therapeutic needs in this vulnerable patient population, indicating a discrepancy between emerging evidence and current clinical practice.</p>
<h4>Article 5: Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41246815" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41246815</a></p>
<p><strong>Summary:</strong> This study found that left atrial v-wave assessment following transcatheter edge-to-edge repair for mitral regurgitation had a significant impact on long-term patient survival. Data from the M. I. T. R. A.-P. R. O. registry, involving 1487 patients, showed that after three years, survival was significantly reduced in patients with an elevated postprocedural v-wave. These findings establish the postprocedural v-wave as a crucial prognostic indicator for long-term outcomes following mitral valve intervention. The study demonstrates the importance of assessing left atrial pressure dynamics after T. E. E. R. for risk stratification and patient management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes. Isolated non-specific S. T. T. abnormalities on electrocardiograms were found to be associated with an increased risk of incident coronary heart disease and stroke in participants free of these conditions at baseline. This study also found that these abnormalities were linked to an increased risk of incident heart failure and its subtypes. Data showed that these specific electrocardiographic patterns, defined by Minnesota E. C. G. classification, independently predicted future development of heart failure, including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. These findings establish a prognostic role for isolated non-specific S. T. T. abnormalities in identifying individuals at risk for future cardiovascular events and heart failure.</p>
<p>Article number two. Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices. This study demonstrated the feasibility and performance of using routinely collected electronic medical records from Australian general practices to estimate the 5-year absolute risk of cardiovascular disease. Researchers found that integrating primary care electronic medical record data, specifically from the New South Wales Health Lumos program, provided a viable approach for cardiovascular risk prediction. The study successfully utilized data from 680 general practices to assess the predictive capability of these records. These findings indicate that Australian healthcare systems can effectively leverage existing electronic medical records for robust cardiovascular disease risk estimation, comparable to methods used in the U. S. A. and U. K.</p>
<p>Article number three. Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts. This study demonstrated the comparative diagnostic accuracy of several tools for heart failure with preserved ejection fraction (H. F. pEF) across community and clinical cohorts. Researchers found that the Heart Failure Association-P. E. F. F. and H. two F. P. E. F. Scores showed differing diagnostic performance when compared against inclusion criteria from sodium-glucose cotransporter-two inhibitors trials and age-adjusted N-terminal pro B-type natriuretic peptide. The data provided clarification on the strengths and limitations of each diagnostic approach, particularly highlighting their utility in older adult populations where H. F. pEF diagnosis is most challenging. These findings contribute to refining the clinical algorithm for accurate identification of H. F. pEF.</p>
<p>Article number four. Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study. This prospective cohort study identified significant therapy gaps in the contemporary management of patients with heart failure and reduced kidney function. Researchers evaluated longitudinal treatment patterns over two years in 1401 heart failure patients, finding that the use and dose intensity of guideline-directed heart failure therapies varied considerably across the spectrum of kidney function and left ventricular ejection fraction. The data demonstrated that a substantial proportion of patients with kidney dysfunction did not receive optimal heart failure pharmacotherapies or were underdosed. These findings highlight unmet therapeutic needs in this vulnerable patient population, indicating a discrepancy between emerging evidence and current clinical practice.</p>
<p>Article number five. Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry. This study found that left atrial v-wave assessment following transcatheter edge-to-edge repair for mitral regurgitation had a significant impact on long-term patient survival. Data from the M. I. T. R. A.-P. R. O. registry, involving 1487 patients, showed that after three years, survival was significantly reduced in patients with an elevated postprocedural v-wave. These findings establish the postprocedural v-wave as a crucial prognostic indicator for long-term outcomes following mitral valve intervention. The study demonstrates the importance of assessing left atrial pressure dynamics after T. E. E. R. for risk stratification and patient management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, stroke, v-wave, primary care, electrocardiographic abnormalities, H. two F. P. E. F. Score, Heart Failure Association-P. E. F. F. Score, cardiovascular disease, treatment gaps, dose intensity, S. T. T. abnormalities, transcatheter mitral repair, heart failure with preserved ejection fraction, diagnostic tools, risk prediction, absolute risk, survival, N. T.-proB. N. P., coronary heart disease, mitral edge-to-edge repair, pharmacotherapy, left atrial pressure, kidney dysfunction, electronic medical records.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/">ECG Abnormalities Predict Heart Failure Risk 11/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 19, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and stroke. Key takeaway: ECG Abnormalities Predict Heart Failure Risk.
Article Links:
Article 1: Isolated non-specifi]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 19, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and stroke. Key takeaway: ECG Abnormalities Predict Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41249037">Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41249035">Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41249034">Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41243130">Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41246815">Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/">https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249037" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249037</a></p>
<p><strong>Summary:</strong> Isolated non-specific S. T. T. abnormalities on electrocardiograms were found to be associated with an increased risk of incident coronary heart disease and stroke in participants free of these conditions at baseline. This study also found that these abnormalities were linked to an increased risk of incident heart failure and its subtypes. Data showed that these specific electrocardiographic patterns, defined by Minnesota E. C. G. classification, independently predicted future development of heart failure, including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. These findings establish a prognostic role for isolated non-specific S. T. T. abnormalities in identifying individuals at risk for future cardiovascular events and heart failure.</p>
<h4>Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249035" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249035</a></p>
<p><strong>Summary:</strong> This study demonstrated the feasibility and performance of using routinely collected electronic medical records from Australian general practices to estimate the 5-year absolute risk of cardiovascular disease. Researchers found that integrating primary care electronic medical record data, specifically from the New South Wales Health Lumos program, provided a viable approach for cardiovascular risk prediction. The study successfully utilized data from 680 general practices to assess the predictive capability of these records. These findings indicate that Australian healthcare systems can effectively leverage existing electronic medical records for robust cardiovascular disease risk estimation, comparable to methods used in the U. S. A. and U. K.</p>
<h4>Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249034" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249034</a></p>
<p><strong>Summary:</strong> This study demonstrated the comparative diagnostic accuracy of several tools for heart failure with preserved ejection fraction (H. F. pEF) across community and clinical cohorts. Researchers found that the Heart Failure Association-P. E. F. F. and H. two F. P. E. F. Scores showed differing diagnostic performance when compared against inclusion criteria from sodium-glucose cotransporter-two inhibitors trials and age-adjusted N-terminal pro B-type natriuretic peptide. The data provided clarification on the strengths and limitations of each diagnostic approach, particularly highlighting their utility in older adult populations where H. F. pEF diagnosis is most challenging. These findings contribute to refining the clinical algorithm for accurate identification of H. F. pEF.</p>
<h4>Article 4: Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41243130" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41243130</a></p>
<p><strong>Summary:</strong> This prospective cohort study identified significant therapy gaps in the contemporary management of patients with heart failure and reduced kidney function. Researchers evaluated longitudinal treatment patterns over two years in 1401 heart failure patients, finding that the use and dose intensity of guideline-directed heart failure therapies varied considerably across the spectrum of kidney function and left ventricular ejection fraction. The data demonstrated that a substantial proportion of patients with kidney dysfunction did not receive optimal heart failure pharmacotherapies or were underdosed. These findings highlight unmet therapeutic needs in this vulnerable patient population, indicating a discrepancy between emerging evidence and current clinical practice.</p>
<h4>Article 5: Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41246815" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41246815</a></p>
<p><strong>Summary:</strong> This study found that left atrial v-wave assessment following transcatheter edge-to-edge repair for mitral regurgitation had a significant impact on long-term patient survival. Data from the M. I. T. R. A.-P. R. O. registry, involving 1487 patients, showed that after three years, survival was significantly reduced in patients with an elevated postprocedural v-wave. These findings establish the postprocedural v-wave as a crucial prognostic indicator for long-term outcomes following mitral valve intervention. The study demonstrates the importance of assessing left atrial pressure dynamics after T. E. E. R. for risk stratification and patient management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes. Isolated non-specific S. T. T. abnormalities on electrocardiograms were found to be associated with an increased risk of incident coronary heart disease and stroke in participants free of these conditions at baseline. This study also found that these abnormalities were linked to an increased risk of incident heart failure and its subtypes. Data showed that these specific electrocardiographic patterns, defined by Minnesota E. C. G. classification, independently predicted future development of heart failure, including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. These findings establish a prognostic role for isolated non-specific S. T. T. abnormalities in identifying individuals at risk for future cardiovascular events and heart failure.</p>
<p>Article number two. Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices. This study demonstrated the feasibility and performance of using routinely collected electronic medical records from Australian general practices to estimate the 5-year absolute risk of cardiovascular disease. Researchers found that integrating primary care electronic medical record data, specifically from the New South Wales Health Lumos program, provided a viable approach for cardiovascular risk prediction. The study successfully utilized data from 680 general practices to assess the predictive capability of these records. These findings indicate that Australian healthcare systems can effectively leverage existing electronic medical records for robust cardiovascular disease risk estimation, comparable to methods used in the U. S. A. and U. K.</p>
<p>Article number three. Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts. This study demonstrated the comparative diagnostic accuracy of several tools for heart failure with preserved ejection fraction (H. F. pEF) across community and clinical cohorts. Researchers found that the Heart Failure Association-P. E. F. F. and H. two F. P. E. F. Scores showed differing diagnostic performance when compared against inclusion criteria from sodium-glucose cotransporter-two inhibitors trials and age-adjusted N-terminal pro B-type natriuretic peptide. The data provided clarification on the strengths and limitations of each diagnostic approach, particularly highlighting their utility in older adult populations where H. F. pEF diagnosis is most challenging. These findings contribute to refining the clinical algorithm for accurate identification of H. F. pEF.</p>
<p>Article number four. Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study. This prospective cohort study identified significant therapy gaps in the contemporary management of patients with heart failure and reduced kidney function. Researchers evaluated longitudinal treatment patterns over two years in 1401 heart failure patients, finding that the use and dose intensity of guideline-directed heart failure therapies varied considerably across the spectrum of kidney function and left ventricular ejection fraction. The data demonstrated that a substantial proportion of patients with kidney dysfunction did not receive optimal heart failure pharmacotherapies or were underdosed. These findings highlight unmet therapeutic needs in this vulnerable patient population, indicating a discrepancy between emerging evidence and current clinical practice.</p>
<p>Article number five. Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry. This study found that left atrial v-wave assessment following transcatheter edge-to-edge repair for mitral regurgitation had a significant impact on long-term patient survival. Data from the M. I. T. R. A.-P. R. O. registry, involving 1487 patients, showed that after three years, survival was significantly reduced in patients with an elevated postprocedural v-wave. These findings establish the postprocedural v-wave as a crucial prognostic indicator for long-term outcomes following mitral valve intervention. The study demonstrates the importance of assessing left atrial pressure dynamics after T. E. E. R. for risk stratification and patient management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, stroke, v-wave, primary care, electrocardiographic abnormalities, H. two F. P. E. F. Score, Heart Failure Association-P. E. F. F. Score, cardiovascular disease, treatment gaps, dose intensity, S. T. T. abnormalities, transcatheter mitral repair, heart failure with preserved ejection fraction, diagnostic tools, risk prediction, absolute risk, survival, N. T.-proB. N. P., coronary heart disease, mitral edge-to-edge repair, pharmacotherapy, left atrial pressure, kidney dysfunction, electronic medical records.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/">ECG Abnormalities Predict Heart Failure Risk 11/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251119_060506.mp3" length="5107295" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 19, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and stroke. Key takeaway: ECG Abnormalities Predict Heart Failure Risk.
Article Links:
Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes. (Heart (British Cardiac Society))
Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices. (Heart (British Cardiac Society))
Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts. (Heart (British Cardiac Society))
Article 4: Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study. (ESC heart failure)
Article 5: Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/
 Featured Articles
Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41249037
Summary: Isolated non-specific S. T. T. abnormalities on electrocardiograms were found to be associated with an increased risk of incident coronary heart disease and stroke in participants free of these conditions at baseline. This study also found that these abnormalities were linked to an increased risk of incident heart failure and its subtypes. Data showed that these specific electrocardiographic patterns, defined by Minnesota E. C. G. classification, independently predicted future development of heart failure, including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. These findings establish a prognostic role for isolated non-specific S. T. T. abnormalities in identifying individuals at risk for future cardiovascular events and heart failure.
Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41249035
Summary: This study demonstrated the feasibility and performance of using routinely collected electronic medical records from Australian general practices to estimate the 5-year absolute risk of cardiovascular disease. Researchers found that integrating primary care electronic medical record data, specifically from the New South Wales Health Lumos program, provided a viable approach for cardiovascular risk prediction. The study successfully utilized data from 680 general practices to assess the predictive capability of these records. These findings indicate that Australian healthcare systems can effectively leverage existing electronic medical records for robust cardiovascular disease risk estimation, comparable to methods used in the U. S. A. and U. K.
Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41249034
Summary: This study demonstrated the comparative diagnostic accuracy of several tools for heart failure with preserved ejection fraction (H. F. pEF) across community and clinical cohorts. Researchers found that the Heart Failure Association-P. E. F. F. and H. two F. P. E. F. Scores showed differing diagnostic performance when compared against inclusion criteria from sodium-glucose cotransporter-two inhibitors trials and age-adjusted N-terminal pro B-type natriuretic peptide. The data provided clarification on the strengths and limitations of each diagnostic ap]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 19, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and stroke. Key takeaway: ECG Abnormalities Predict Heart Failure Risk.
Article Links:
Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes. (Heart (British Cardiac Society))
Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices. (Heart (British Cardiac Society))
Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts. (Heart (British Cardiac Society))
Article 4: Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study. (ESC heart failure)
Article 5: Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry. (Journal of the ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure 11/18/25</title>
	<link>https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/</link>
	<pubDate>Tue, 18 Nov 2025 17:13:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like precision medicine and temporal trends. Key takeaway: Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41251000">CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41251006">Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41251004">Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41247366">Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41249040">Role of physician assistants and their impact on cardiology specialty training in the United Kingdom.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/">https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41251000" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41251000</a></p>
<p><strong>Summary:</strong> The study demonstrated that CD4 positive T regulatory cells regulate heart growth and regeneration. This regulation occurs through M. R. G. fifteen / T. I. P. sixty mediated epigenomic remodeling within proliferating cardiomyocytes. The chromatin regulatory network was found to be crucial in orchestrating the dynamic changes in gene expression for the regenerative response in the neonatal heart. These findings provide a deeper understanding of the mechanisms controlling heart regeneration, which is critical for addressing limited regenerative capacity in the adult mammalian heart.</p>
<h4>Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41251006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41251006</a></p>
<p><strong>Summary:</strong> This nationwide Danish study analyzed temporal trends in the use of oral anticoagulants and associated clinical outcomes in older patients with new-onset atrial fibrillation. The study found that anticoagulation therapy patterns in patients with atrial fibrillation have evolved significantly over time, especially following the introduction of direct oral anticoagulants. The analysis investigated how these changes in anticoagulant uptake have impacted clinical outcomes across older adults (65-74 years), elderly (75-84 years), and very elderly (85 years and older) patient groups. This provides critical information on how treatment strategies and patient prognoses for atrial fibrillation have shifted in an aging population.</p>
<h4>Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41251004" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41251004</a></p>
<p><strong>Summary:</strong> The study demonstrated that automated patch clamp data significantly improves the classification of S. C. N. five A variants and penetrance stratification for Brugada Syndrome. This approach addresses complications in genetic workup arising from S. C. N. five A variants of uncertain significance and incomplete penetrance. The deployment of an S. C. N. five A Brugada Syndrome functional assay at a cohort scale was found to facilitate the implementation of genetic and precision medicine for this inherited arrhythmia disorder. These findings refine the diagnostic and risk stratification process for the approximately 20 percent of Brugada Syndrome patients with rare S. C. N. five A variants.</p>
<h4>Article 4: Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41247366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41247366</a></p>
<p><strong>Summary:</strong> This retrospective cohort study found that cirrhotic cardiomyopathy predicts new-onset heart failure within the first year following liver transplantation. The study identified an association between cirrhotic cardiomyopathy, defined using the Cirrhotic Cardiomyopathy Consortium 2020 criteria, and major adverse cardiovascular events after liver transplantation. This established the significant impact of cirrhotic cardiomyopathy on post-transplant cardiac outcomes. These results demonstrate that pre-transplant cardiac assessment for cirrhotic cardiomyopathy is crucial for identifying patients at high risk for developing heart failure after liver transplantation.</p>
<h4>Article 5: Role of physician assistants and their impact on cardiology specialty training in the United Kingdom.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249040</a></p>
<p><strong>Summary:</strong> This study assessed the role and impact of physician assistants on cardiology specialty training in the United Kingdom by surveying resident doctors. The findings described the current scope of practice for physician assistants within U. K. cardiology, addressing previously undefined roles. The study evaluated the impact of physician assistant expansion on resident doctor training, directly responding to concerns regarding patient safety and training quality. These results provide clarity on the evolving roles of physician assistants in cardiology and their implications for junior cardiologist education and development.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes. The study demonstrated that CD4 positive T regulatory cells regulate heart growth and regeneration. This regulation occurs through M. R. G. fifteen / T. I. P. sixty mediated epigenomic remodeling within proliferating cardiomyocytes. The chromatin regulatory network was found to be crucial in orchestrating the dynamic changes in gene expression for the regenerative response in the neonatal heart. These findings provide a deeper understanding of the mechanisms controlling heart regeneration, which is critical for addressing limited regenerative capacity in the adult mammalian heart.</p>
<p>Article number two. Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study. This nationwide Danish study analyzed temporal trends in the use of oral anticoagulants and associated clinical outcomes in older patients with new-onset atrial fibrillation. The study found that anticoagulation therapy patterns in patients with atrial fibrillation have evolved significantly over time, especially following the introduction of direct oral anticoagulants. The analysis investigated how these changes in anticoagulant uptake have impacted clinical outcomes across older adults (65-74 years), elderly (75-84 years), and very elderly (85 years and older) patient groups. This provides critical information on how treatment strategies and patient prognoses for atrial fibrillation have shifted in an aging population.</p>
<p>Article number three. Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome. The study demonstrated that automated patch clamp data significantly improves the classification of S. C. N. five A variants and penetrance stratification for Brugada Syndrome. This approach addresses complications in genetic workup arising from S. C. N. five A variants of uncertain significance and incomplete penetrance. The deployment of an S. C. N. five A Brugada Syndrome functional assay at a cohort scale was found to facilitate the implementation of genetic and precision medicine for this inherited arrhythmia disorder. These findings refine the diagnostic and risk stratification process for the approximately 20 percent of Brugada Syndrome patients with rare S. C. N. five A variants.</p>
<p>Article number four. Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation. This retrospective cohort study found that cirrhotic cardiomyopathy predicts new-onset heart failure within the first year following liver transplantation. The study identified an association between cirrhotic cardiomyopathy, defined using the Cirrhotic Cardiomyopathy Consortium 2020 criteria, and major adverse cardiovascular events after liver transplantation. This established the significant impact of cirrhotic cardiomyopathy on post-transplant cardiac outcomes. These results demonstrate that pre-transplant cardiac assessment for cirrhotic cardiomyopathy is crucial for identifying patients at high risk for developing heart failure after liver transplantation.</p>
<p>Article number five. Role of physician assistants and their impact on cardiology specialty training in the United Kingdom. This study assessed the role and impact of physician assistants on cardiology specialty training in the United Kingdom by surveying resident doctors. The findings described the current scope of practice for physician assistants within U. K. cardiology, addressing previously undefined roles. The study evaluated the impact of physician assistant expansion on resident doctor training, directly responding to concerns regarding patient safety and training quality. These results provide clarity on the evolving roles of physician assistants in cardiology and their implications for junior cardiologist education and development. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>precision medicine, temporal trends, CD4 positive T regulatory cells, Physician assistants, scope of practice, Brugada Syndrome, Oral anticoagulants, new-onset heart failure, epigenomic remodeling, Cirrhotic cardiomyopathy, United Kingdom healthcare, clinical outcomes, post-transplant outcomes, heart regeneration, cardiac growth, cardiology training, automated patch clamp, S. C. N. five A variants, atrial fibrillation, liver transplantation, variant classification, resident doctors, cardiomyocytes, major adverse cardiovascular events, elderly patients.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/">Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure 11/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like precision medicine and temporal trends. Key takeaway: Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure.
Article Links]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like precision medicine and temporal trends. Key takeaway: Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41251000">CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41251006">Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41251004">Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41247366">Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation.</a> (Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41249040">Role of physician assistants and their impact on cardiology specialty training in the United Kingdom.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/">https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41251000" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41251000</a></p>
<p><strong>Summary:</strong> The study demonstrated that CD4 positive T regulatory cells regulate heart growth and regeneration. This regulation occurs through M. R. G. fifteen / T. I. P. sixty mediated epigenomic remodeling within proliferating cardiomyocytes. The chromatin regulatory network was found to be crucial in orchestrating the dynamic changes in gene expression for the regenerative response in the neonatal heart. These findings provide a deeper understanding of the mechanisms controlling heart regeneration, which is critical for addressing limited regenerative capacity in the adult mammalian heart.</p>
<h4>Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41251006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41251006</a></p>
<p><strong>Summary:</strong> This nationwide Danish study analyzed temporal trends in the use of oral anticoagulants and associated clinical outcomes in older patients with new-onset atrial fibrillation. The study found that anticoagulation therapy patterns in patients with atrial fibrillation have evolved significantly over time, especially following the introduction of direct oral anticoagulants. The analysis investigated how these changes in anticoagulant uptake have impacted clinical outcomes across older adults (65-74 years), elderly (75-84 years), and very elderly (85 years and older) patient groups. This provides critical information on how treatment strategies and patient prognoses for atrial fibrillation have shifted in an aging population.</p>
<h4>Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41251004" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41251004</a></p>
<p><strong>Summary:</strong> The study demonstrated that automated patch clamp data significantly improves the classification of S. C. N. five A variants and penetrance stratification for Brugada Syndrome. This approach addresses complications in genetic workup arising from S. C. N. five A variants of uncertain significance and incomplete penetrance. The deployment of an S. C. N. five A Brugada Syndrome functional assay at a cohort scale was found to facilitate the implementation of genetic and precision medicine for this inherited arrhythmia disorder. These findings refine the diagnostic and risk stratification process for the approximately 20 percent of Brugada Syndrome patients with rare S. C. N. five A variants.</p>
<h4>Article 4: Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41247366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41247366</a></p>
<p><strong>Summary:</strong> This retrospective cohort study found that cirrhotic cardiomyopathy predicts new-onset heart failure within the first year following liver transplantation. The study identified an association between cirrhotic cardiomyopathy, defined using the Cirrhotic Cardiomyopathy Consortium 2020 criteria, and major adverse cardiovascular events after liver transplantation. This established the significant impact of cirrhotic cardiomyopathy on post-transplant cardiac outcomes. These results demonstrate that pre-transplant cardiac assessment for cirrhotic cardiomyopathy is crucial for identifying patients at high risk for developing heart failure after liver transplantation.</p>
<h4>Article 5: Role of physician assistants and their impact on cardiology specialty training in the United Kingdom.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41249040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41249040</a></p>
<p><strong>Summary:</strong> This study assessed the role and impact of physician assistants on cardiology specialty training in the United Kingdom by surveying resident doctors. The findings described the current scope of practice for physician assistants within U. K. cardiology, addressing previously undefined roles. The study evaluated the impact of physician assistant expansion on resident doctor training, directly responding to concerns regarding patient safety and training quality. These results provide clarity on the evolving roles of physician assistants in cardiology and their implications for junior cardiologist education and development.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes. The study demonstrated that CD4 positive T regulatory cells regulate heart growth and regeneration. This regulation occurs through M. R. G. fifteen / T. I. P. sixty mediated epigenomic remodeling within proliferating cardiomyocytes. The chromatin regulatory network was found to be crucial in orchestrating the dynamic changes in gene expression for the regenerative response in the neonatal heart. These findings provide a deeper understanding of the mechanisms controlling heart regeneration, which is critical for addressing limited regenerative capacity in the adult mammalian heart.</p>
<p>Article number two. Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study. This nationwide Danish study analyzed temporal trends in the use of oral anticoagulants and associated clinical outcomes in older patients with new-onset atrial fibrillation. The study found that anticoagulation therapy patterns in patients with atrial fibrillation have evolved significantly over time, especially following the introduction of direct oral anticoagulants. The analysis investigated how these changes in anticoagulant uptake have impacted clinical outcomes across older adults (65-74 years), elderly (75-84 years), and very elderly (85 years and older) patient groups. This provides critical information on how treatment strategies and patient prognoses for atrial fibrillation have shifted in an aging population.</p>
<p>Article number three. Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome. The study demonstrated that automated patch clamp data significantly improves the classification of S. C. N. five A variants and penetrance stratification for Brugada Syndrome. This approach addresses complications in genetic workup arising from S. C. N. five A variants of uncertain significance and incomplete penetrance. The deployment of an S. C. N. five A Brugada Syndrome functional assay at a cohort scale was found to facilitate the implementation of genetic and precision medicine for this inherited arrhythmia disorder. These findings refine the diagnostic and risk stratification process for the approximately 20 percent of Brugada Syndrome patients with rare S. C. N. five A variants.</p>
<p>Article number four. Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation. This retrospective cohort study found that cirrhotic cardiomyopathy predicts new-onset heart failure within the first year following liver transplantation. The study identified an association between cirrhotic cardiomyopathy, defined using the Cirrhotic Cardiomyopathy Consortium 2020 criteria, and major adverse cardiovascular events after liver transplantation. This established the significant impact of cirrhotic cardiomyopathy on post-transplant cardiac outcomes. These results demonstrate that pre-transplant cardiac assessment for cirrhotic cardiomyopathy is crucial for identifying patients at high risk for developing heart failure after liver transplantation.</p>
<p>Article number five. Role of physician assistants and their impact on cardiology specialty training in the United Kingdom. This study assessed the role and impact of physician assistants on cardiology specialty training in the United Kingdom by surveying resident doctors. The findings described the current scope of practice for physician assistants within U. K. cardiology, addressing previously undefined roles. The study evaluated the impact of physician assistant expansion on resident doctor training, directly responding to concerns regarding patient safety and training quality. These results provide clarity on the evolving roles of physician assistants in cardiology and their implications for junior cardiologist education and development. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>precision medicine, temporal trends, CD4 positive T regulatory cells, Physician assistants, scope of practice, Brugada Syndrome, Oral anticoagulants, new-onset heart failure, epigenomic remodeling, Cirrhotic cardiomyopathy, United Kingdom healthcare, clinical outcomes, post-transplant outcomes, heart regeneration, cardiac growth, cardiology training, automated patch clamp, S. C. N. five A variants, atrial fibrillation, liver transplantation, variant classification, resident doctors, cardiomyocytes, major adverse cardiovascular events, elderly patients.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/">Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure 11/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251118_121222.mp3" length="4734475" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like precision medicine and temporal trends. Key takeaway: Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure.
Article Links:
Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes. (Circulation)
Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study. (European heart journal)
Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome. (European heart journal)
Article 4: Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation. (Transplantation)
Article 5: Role of physician assistants and their impact on cardiology specialty training in the United Kingdom. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/
 Featured Articles
Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41251000
Summary: The study demonstrated that CD4 positive T regulatory cells regulate heart growth and regeneration. This regulation occurs through M. R. G. fifteen / T. I. P. sixty mediated epigenomic remodeling within proliferating cardiomyocytes. The chromatin regulatory network was found to be crucial in orchestrating the dynamic changes in gene expression for the regenerative response in the neonatal heart. These findings provide a deeper understanding of the mechanisms controlling heart regeneration, which is critical for addressing limited regenerative capacity in the adult mammalian heart.
Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41251006
Summary: This nationwide Danish study analyzed temporal trends in the use of oral anticoagulants and associated clinical outcomes in older patients with new-onset atrial fibrillation. The study found that anticoagulation therapy patterns in patients with atrial fibrillation have evolved significantly over time, especially following the introduction of direct oral anticoagulants. The analysis investigated how these changes in anticoagulant uptake have impacted clinical outcomes across older adults (65-74 years), elderly (75-84 years), and very elderly (85 years and older) patient groups. This provides critical information on how treatment strategies and patient prognoses for atrial fibrillation have shifted in an aging population.
Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41251004
Summary: The study demonstrated that automated patch clamp data significantly improves the classification of S. C. N. five A variants and penetrance stratification for Brugada Syndrome. This approach addresses complications in genetic workup arising from S. C. N. five A variants of uncertain significance and incomplete penetrance. The deployment of an S. C. N. five A Brugada Syndrome functional assay at a cohort scale was found to facilitate the implementation of genetic and precision medicine for this inherited arrhythmia disorder. These findings refine the diagnostic and risk stratification process for the approximately 20 percent of Brugada Syndrome patients with rare S. C. N. five A variants.
Article 4: Cirrhotic Cardiomyopathy Predicts ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like precision medicine and temporal trends. Key takeaway: Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure.
Article Links:
Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes. (Circulation)
Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study. (European heart journal)
Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome. (European heart journal)
Article 4: Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation. (Transplantation)
Article 5: Role of physician assistants and their impact on cardiology specialty trainin]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Semaglutide Improves Peripheral Artery Disease 11/18/25</title>
	<link>https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/</link>
	<pubDate>Tue, 18 Nov 2025 11:03:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40892617">Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40892613">Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40892605">Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40864017">Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41247390">Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/">https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892617</a></p>
<p><strong>Summary:</strong> The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies.</p>
<h4>Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892613" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892613</a></p>
<p><strong>Summary:</strong> N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management.</p>
<h4>Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892605" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892605</a></p>
<p><strong>Summary:</strong> Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease.</p>
<h4>Article 4: Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864017" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864017</a></p>
<p><strong>Summary:</strong> Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. This prevalence directly correlates with an increased risk of disability and death in affected patients. This comprehensive pooled analysis of five international randomized trials explored the detailed association between different adiposity-related anthropometrics and clinical outcomes in this specific patient population. Such data clarifies the prognostic significance of various body composition measures for targeted interventions in heart failure.</p>
<h4>Article 5: Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41247390" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41247390</a></p>
<p><strong>Summary:</strong> Racial disparities in mortality after heart transplantation are a critical concern across the United States. This study comprehensively investigated these disparities across four U. S. regions using data from the United Network for Organ Sharing registry spanning 2002 to 2022. The analysis compared survival outcomes among five self-identified race/ethnicity groups: White, Black, Hispanic, Asian, and Other. Understanding these potential inequities is crucial for improving post-transplant care and achieving equitable outcomes for all patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies.</p>
<p>Article number two. Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management.</p>
<p>Article number three. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease.</p>
<p>Article number four. Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. This prevalence directly correlates with an increased risk of disability and death in affected patients. This comprehensive pooled analysis of five international randomized trials explored the detailed association between different adiposity-related anthropometrics and clinical outcomes in this specific patient population. Such data clarifies the prognostic significance of various body composition measures for targeted interventions in heart failure.</p>
<p>Article number five. Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022. Racial disparities in mortality after heart transplantation are a critical concern across the United States. This study comprehensively investigated these disparities across four U. S. regions using data from the United Network for Organ Sharing registry spanning 2002 to 2022. The analysis compared survival outcomes among five self-identified race/ethnicity groups: White, Black, Hispanic, Asian, and Other. Understanding these potential inequities is crucial for improving post-transplant care and achieving equitable outcomes for all patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>type two diabetes, semaglutide, biomarkers, United Network for Organ Sharing, finerenone, heart failure with preserved ejection fraction, natriuretic peptides, cardiovascular outcomes, cardiovascular-kidney-metabolic disease, racial disparities, clinical outcomes, regional disparities, functional outcomes, peripheral artery disease, body mass index, sex differences, adiposity, anthropometric measures, heart transplantation, heart failure with mildly reduced ejection fraction, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/">Semaglutide Improves Peripheral Artery Disease 11/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease.
Article Links:
Article 1: Sex Diffe]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40892617">Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40892613">Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40892605">Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40864017">Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41247390">Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022.</a> (Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/">https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892617</a></p>
<p><strong>Summary:</strong> The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies.</p>
<h4>Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892613" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892613</a></p>
<p><strong>Summary:</strong> N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management.</p>
<h4>Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892605" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892605</a></p>
<p><strong>Summary:</strong> Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease.</p>
<h4>Article 4: Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864017" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864017</a></p>
<p><strong>Summary:</strong> Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. This prevalence directly correlates with an increased risk of disability and death in affected patients. This comprehensive pooled analysis of five international randomized trials explored the detailed association between different adiposity-related anthropometrics and clinical outcomes in this specific patient population. Such data clarifies the prognostic significance of various body composition measures for targeted interventions in heart failure.</p>
<h4>Article 5: Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41247390" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41247390</a></p>
<p><strong>Summary:</strong> Racial disparities in mortality after heart transplantation are a critical concern across the United States. This study comprehensively investigated these disparities across four U. S. regions using data from the United Network for Organ Sharing registry spanning 2002 to 2022. The analysis compared survival outcomes among five self-identified race/ethnicity groups: White, Black, Hispanic, Asian, and Other. Understanding these potential inequities is crucial for improving post-transplant care and achieving equitable outcomes for all patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies.</p>
<p>Article number two. Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management.</p>
<p>Article number three. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease.</p>
<p>Article number four. Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. This prevalence directly correlates with an increased risk of disability and death in affected patients. This comprehensive pooled analysis of five international randomized trials explored the detailed association between different adiposity-related anthropometrics and clinical outcomes in this specific patient population. Such data clarifies the prognostic significance of various body composition measures for targeted interventions in heart failure.</p>
<p>Article number five. Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022. Racial disparities in mortality after heart transplantation are a critical concern across the United States. This study comprehensively investigated these disparities across four U. S. regions using data from the United Network for Organ Sharing registry spanning 2002 to 2022. The analysis compared survival outcomes among five self-identified race/ethnicity groups: White, Black, Hispanic, Asian, and Other. Understanding these potential inequities is crucial for improving post-transplant care and achieving equitable outcomes for all patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>type two diabetes, semaglutide, biomarkers, United Network for Organ Sharing, finerenone, heart failure with preserved ejection fraction, natriuretic peptides, cardiovascular outcomes, cardiovascular-kidney-metabolic disease, racial disparities, clinical outcomes, regional disparities, functional outcomes, peripheral artery disease, body mass index, sex differences, adiposity, anthropometric measures, heart transplantation, heart failure with mildly reduced ejection fraction, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/">Semaglutide Improves Peripheral Artery Disease 11/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251118_060237.mp3" length="4349117" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease.
Article Links:
Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. (Journal of the American College of Cardiology)
Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. (Journal of the American College of Cardiology)
Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. (Journal of the American College of Cardiology)
Article 4: Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. (Journal of the American College of Cardiology)
Article 5: Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022. (Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/
 Featured Articles
Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892617
Summary: The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies.
Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892613
Summary: N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management.
Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892605
Summary: Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease.
Article 4: Adiposity-Related Anthropometrics and Clinical Outcome]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease.
Article Links:
Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. (Journal of the American College of Cardiology)
Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. (Journal of the American College of Cardiology)
Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. (Journal of the American College of Cardiology)
Article 4: Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Echo Index Guides Amyloidosis Prognosis. 11/17/25</title>
	<link>https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/</link>
	<pubDate>Mon, 17 Nov 2025 13:46:19 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like right heart function and immunoglobulin light chain cardiac amyloidosis. Key takeaway: New Echo Index Guides Amyloidosis Prognosis..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40716680">Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40716679">High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40712675">Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40712674">Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40706812">Usefulness of STREI: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/">https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40716680" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40716680</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of the RACE two study found that the duration of atrial fibrillation and specific cardiac biomarkers are directly associated with cardiovascular morbidity and mortality in patients with early permanent atrial fibrillation. Data from 543 patients, who had a median atrial fibrillation duration of 18 months, demonstrated these associations. The study identified these parameters as definitive prognostic indicators for adverse cardiovascular outcomes. These findings underscore the clinical importance of assessing atrial fibrillation duration and cardiac biomarker levels for risk stratification in early permanent atrial fibrillation.</p>
<h4>Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40716679" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40716679</a></p>
<p><strong>Summary:</strong> This study found that high admission levels of interleukin-1 receptor antagonist are associated with increased rates of both all-cause mortality and cardiac death in patients with acute myocardial infarction. The data demonstrated these elevated levels were linked to adverse outcomes at five years follow-up. This concrete association suggests interleukin-1 receptor antagonist serves as a prognostic biomarker for long-term cardiovascular risk in this patient population.</p>
<h4>Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40712675" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40712675</a></p>
<p><strong>Summary:</strong> This study found that diagnosis-to-ablation time significantly impacts rhythm outcome following catheter ablation for atrial fibrillation. The research differentiated this impact between paroxysmal and non-paroxysmal atrial fibrillation types among 619 enrolled patients. Results indicated that the timing of intervention relative to diagnosis plays a crucial role in the success of initial catheter ablation procedures. This finding provides direct guidance for optimizing treatment strategies based on atrial fibrillation type.</p>
<h4>Article 4: Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40712674" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40712674</a></p>
<p><strong>Summary:</strong> T. elevation myocardial infarction. This study compared global and segmental longitudinal and radial strain between Takotsubo syndrome and S. T. elevation myocardial infarction patients. Results demonstrated distinct patterns of myocardial strain in Takotsubo syndrome, which contribute to the observed milder symptoms and better hemodynamic profile compared to S. T. elevation myocardial infarction. The data showed that these differences in strain were not readily apparent using conventional echocardiography alone. These findings offer a more comprehensive understanding of the mechanisms underlying cardiac dysfunction in Takotsubo syndrome.</p>
<h4>Article 5: Usefulness of STREI: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40706812" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40706812</a></p>
<p><strong>Summary:</strong> T. R. E. I.: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis. This study established the prognostic usefulness of the S. T. R. E. I. index, a novel two-dimensional speckle-tracking echocardiography measure integrating right atrial and right ventricular strain, in patients with immunoglobulin light chain cardiac amyloidosis. The research, involving 70 patients with confirmed cardiac amyloidosis, demonstrated that this index provides valuable prognostic information. The data showed the S. T. R. E. I. index effectively assesses right heart function, offering a new tool for risk stratification. This improves the diagnostic and prognostic assessment of immunoglobulin light chain cardiac amyloidosis patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE two study. A post-hoc analysis of the RACE two study found that the duration of atrial fibrillation and specific cardiac biomarkers are directly associated with cardiovascular morbidity and mortality in patients with early permanent atrial fibrillation. Data from 543 patients, who had a median atrial fibrillation duration of 18 months, demonstrated these associations. The study identified these parameters as definitive prognostic indicators for adverse cardiovascular outcomes. These findings underscore the clinical importance of assessing atrial fibrillation duration and cardiac biomarker levels for risk stratification in early permanent atrial fibrillation.</p>
<p>Article number two. High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up. This study found that high admission levels of interleukin-1 receptor antagonist are associated with increased rates of both all-cause mortality and cardiac death in patients with acute myocardial infarction. The data demonstrated these elevated levels were linked to adverse outcomes at five years follow-up. This concrete association suggests interleukin-1 receptor antagonist serves as a prognostic biomarker for long-term cardiovascular risk in this patient population.</p>
<p>Article number three. Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation. This study found that diagnosis-to-ablation time significantly impacts rhythm outcome following catheter ablation for atrial fibrillation. The research differentiated this impact between paroxysmal and non-paroxysmal atrial fibrillation types among 619 enrolled patients. Results indicated that the timing of intervention relative to diagnosis plays a crucial role in the success of initial catheter ablation procedures. This finding provides direct guidance for optimizing treatment strategies based on atrial fibrillation type.</p>
<p>Article number four. Global and segmental longitudinal and radial strain in Takotsubo versus S. T. elevation myocardial infarction. This study compared global and segmental longitudinal and radial strain between Takotsubo syndrome and S. T. elevation myocardial infarction patients. Results demonstrated distinct patterns of myocardial strain in Takotsubo syndrome, which contribute to the observed milder symptoms and better hemodynamic profile compared to S. T. elevation myocardial infarction. The data showed that these differences in strain were not readily apparent using conventional echocardiography alone. These findings offer a more comprehensive understanding of the mechanisms underlying cardiac dysfunction in Takotsubo syndrome.</p>
<p>Article number five. Usefulness of S. T. R. E. I.: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis. This study established the prognostic usefulness of the S. T. R. E. I. index, a novel two-dimensional speckle-tracking echocardiography measure integrating right atrial and right ventricular strain, in patients with immunoglobulin light chain cardiac amyloidosis. The research, involving 70 patients with confirmed cardiac amyloidosis, demonstrated that this index provides valuable prognostic information. The data showed the S. T. R. E. I. index effectively assesses right heart function, offering a new tool for risk stratification. This improves the diagnostic and prognostic assessment of immunoglobulin light chain cardiac amyloidosis patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>right heart function, immunoglobulin light chain cardiac amyloidosis, rhythm outcome, acute myocardial infarction, Takotsubo syndrome, S. T. R. E. I. index, paroxysmal atrial fibrillation, all-cause mortality, cardiovascular outcomes, RACE two study, cardiac death, interleukin-1 receptor antagonist, risk stratification, speckle-tracking echocardiography, global radial strain, S. T. elevation myocardial infarction, diagnosis-to-ablation time, catheter ablation, prognosis, cardiac biomarkers, global longitudinal strain, echocardiography, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/">New Echo Index Guides Amyloidosis Prognosis. 11/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like right heart function and immunoglobulin light chain cardiac amyloidosis. Key takeaway: New Echo Index Guides Amyloidosis Prognosis..]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like right heart function and immunoglobulin light chain cardiac amyloidosis. Key takeaway: New Echo Index Guides Amyloidosis Prognosis..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40716680">Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40716679">High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40712675">Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40712674">Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40706812">Usefulness of STREI: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/">https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40716680" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40716680</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of the RACE two study found that the duration of atrial fibrillation and specific cardiac biomarkers are directly associated with cardiovascular morbidity and mortality in patients with early permanent atrial fibrillation. Data from 543 patients, who had a median atrial fibrillation duration of 18 months, demonstrated these associations. The study identified these parameters as definitive prognostic indicators for adverse cardiovascular outcomes. These findings underscore the clinical importance of assessing atrial fibrillation duration and cardiac biomarker levels for risk stratification in early permanent atrial fibrillation.</p>
<h4>Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40716679" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40716679</a></p>
<p><strong>Summary:</strong> This study found that high admission levels of interleukin-1 receptor antagonist are associated with increased rates of both all-cause mortality and cardiac death in patients with acute myocardial infarction. The data demonstrated these elevated levels were linked to adverse outcomes at five years follow-up. This concrete association suggests interleukin-1 receptor antagonist serves as a prognostic biomarker for long-term cardiovascular risk in this patient population.</p>
<h4>Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40712675" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40712675</a></p>
<p><strong>Summary:</strong> This study found that diagnosis-to-ablation time significantly impacts rhythm outcome following catheter ablation for atrial fibrillation. The research differentiated this impact between paroxysmal and non-paroxysmal atrial fibrillation types among 619 enrolled patients. Results indicated that the timing of intervention relative to diagnosis plays a crucial role in the success of initial catheter ablation procedures. This finding provides direct guidance for optimizing treatment strategies based on atrial fibrillation type.</p>
<h4>Article 4: Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40712674" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40712674</a></p>
<p><strong>Summary:</strong> T. elevation myocardial infarction. This study compared global and segmental longitudinal and radial strain between Takotsubo syndrome and S. T. elevation myocardial infarction patients. Results demonstrated distinct patterns of myocardial strain in Takotsubo syndrome, which contribute to the observed milder symptoms and better hemodynamic profile compared to S. T. elevation myocardial infarction. The data showed that these differences in strain were not readily apparent using conventional echocardiography alone. These findings offer a more comprehensive understanding of the mechanisms underlying cardiac dysfunction in Takotsubo syndrome.</p>
<h4>Article 5: Usefulness of STREI: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40706812" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40706812</a></p>
<p><strong>Summary:</strong> T. R. E. I.: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis. This study established the prognostic usefulness of the S. T. R. E. I. index, a novel two-dimensional speckle-tracking echocardiography measure integrating right atrial and right ventricular strain, in patients with immunoglobulin light chain cardiac amyloidosis. The research, involving 70 patients with confirmed cardiac amyloidosis, demonstrated that this index provides valuable prognostic information. The data showed the S. T. R. E. I. index effectively assesses right heart function, offering a new tool for risk stratification. This improves the diagnostic and prognostic assessment of immunoglobulin light chain cardiac amyloidosis patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE two study. A post-hoc analysis of the RACE two study found that the duration of atrial fibrillation and specific cardiac biomarkers are directly associated with cardiovascular morbidity and mortality in patients with early permanent atrial fibrillation. Data from 543 patients, who had a median atrial fibrillation duration of 18 months, demonstrated these associations. The study identified these parameters as definitive prognostic indicators for adverse cardiovascular outcomes. These findings underscore the clinical importance of assessing atrial fibrillation duration and cardiac biomarker levels for risk stratification in early permanent atrial fibrillation.</p>
<p>Article number two. High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up. This study found that high admission levels of interleukin-1 receptor antagonist are associated with increased rates of both all-cause mortality and cardiac death in patients with acute myocardial infarction. The data demonstrated these elevated levels were linked to adverse outcomes at five years follow-up. This concrete association suggests interleukin-1 receptor antagonist serves as a prognostic biomarker for long-term cardiovascular risk in this patient population.</p>
<p>Article number three. Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation. This study found that diagnosis-to-ablation time significantly impacts rhythm outcome following catheter ablation for atrial fibrillation. The research differentiated this impact between paroxysmal and non-paroxysmal atrial fibrillation types among 619 enrolled patients. Results indicated that the timing of intervention relative to diagnosis plays a crucial role in the success of initial catheter ablation procedures. This finding provides direct guidance for optimizing treatment strategies based on atrial fibrillation type.</p>
<p>Article number four. Global and segmental longitudinal and radial strain in Takotsubo versus S. T. elevation myocardial infarction. This study compared global and segmental longitudinal and radial strain between Takotsubo syndrome and S. T. elevation myocardial infarction patients. Results demonstrated distinct patterns of myocardial strain in Takotsubo syndrome, which contribute to the observed milder symptoms and better hemodynamic profile compared to S. T. elevation myocardial infarction. The data showed that these differences in strain were not readily apparent using conventional echocardiography alone. These findings offer a more comprehensive understanding of the mechanisms underlying cardiac dysfunction in Takotsubo syndrome.</p>
<p>Article number five. Usefulness of S. T. R. E. I.: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis. This study established the prognostic usefulness of the S. T. R. E. I. index, a novel two-dimensional speckle-tracking echocardiography measure integrating right atrial and right ventricular strain, in patients with immunoglobulin light chain cardiac amyloidosis. The research, involving 70 patients with confirmed cardiac amyloidosis, demonstrated that this index provides valuable prognostic information. The data showed the S. T. R. E. I. index effectively assesses right heart function, offering a new tool for risk stratification. This improves the diagnostic and prognostic assessment of immunoglobulin light chain cardiac amyloidosis patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>right heart function, immunoglobulin light chain cardiac amyloidosis, rhythm outcome, acute myocardial infarction, Takotsubo syndrome, S. T. R. E. I. index, paroxysmal atrial fibrillation, all-cause mortality, cardiovascular outcomes, RACE two study, cardiac death, interleukin-1 receptor antagonist, risk stratification, speckle-tracking echocardiography, global radial strain, S. T. elevation myocardial infarction, diagnosis-to-ablation time, catheter ablation, prognosis, cardiac biomarkers, global longitudinal strain, echocardiography, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/">New Echo Index Guides Amyloidosis Prognosis. 11/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251117_084510.mp3" length="4364581" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like right heart function and immunoglobulin light chain cardiac amyloidosis. Key takeaway: New Echo Index Guides Amyloidosis Prognosis..
Article Links:
Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study. (International journal of cardiology)
Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up. (International journal of cardiology)
Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation. (International journal of cardiology)
Article 4: Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction. (International journal of cardiology)
Article 5: Usefulness of STREI: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/
 Featured Articles
Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40716680
Summary: A post-hoc analysis of the RACE two study found that the duration of atrial fibrillation and specific cardiac biomarkers are directly associated with cardiovascular morbidity and mortality in patients with early permanent atrial fibrillation. Data from 543 patients, who had a median atrial fibrillation duration of 18 months, demonstrated these associations. The study identified these parameters as definitive prognostic indicators for adverse cardiovascular outcomes. These findings underscore the clinical importance of assessing atrial fibrillation duration and cardiac biomarker levels for risk stratification in early permanent atrial fibrillation.
Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40716679
Summary: This study found that high admission levels of interleukin-1 receptor antagonist are associated with increased rates of both all-cause mortality and cardiac death in patients with acute myocardial infarction. The data demonstrated these elevated levels were linked to adverse outcomes at five years follow-up. This concrete association suggests interleukin-1 receptor antagonist serves as a prognostic biomarker for long-term cardiovascular risk in this patient population.
Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40712675
Summary: This study found that diagnosis-to-ablation time significantly impacts rhythm outcome following catheter ablation for atrial fibrillation. The research differentiated this impact between paroxysmal and non-paroxysmal atrial fibrillation types among 619 enrolled patients. Results indicated that the timing of intervention relative to diagnosis plays a crucial role in the success of initial catheter ablation procedures. This finding provides direct guidance for optimizing treatment strategies based on atrial fibrillation type.
Article 4: Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevat]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like right heart function and immunoglobulin light chain cardiac amyloidosis. Key takeaway: New Echo Index Guides Amyloidosis Prognosis..
Article Links:
Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study. (International journal of cardiology)
Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up. (International journal of cardiology)
Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation. (International journal of cardiology)
Article 4: Global and segmental longitudinal and radial strain in Takotsubo ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ElectroPulse PFA: First-in-Human Data 11/17/25</title>
	<link>https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/</link>
	<pubDate>Mon, 17 Nov 2025 12:39:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac phenotype and S. L. C. 6 A. 8 variants. Key takeaway: ElectroPulse PFA: First-in-Human Data.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41242588">Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41242587">Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41242586">Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41242585">Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41242385">Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/">https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242588" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242588</a></p>
<p><strong>Summary:</strong> T. Prolongation in X-linked Creatine Transporter Deficiency Caused by S. L. C. 6 A. 8 Variants. Complete results detailing the cardiac phenotype of male Creatine Transporter Deficiency patients were not available in the abstract. This study focused on characterizing cardiac manifestations in patients with S. L. C. 6 A. 8 variants. Early clinical reports had raised concerns regarding possible associations with Q. T. c. prolongation and dilated cardiomyopathy in this patient population. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242587" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242587</a></p>
<p><strong>Summary:</strong> Complete results, including specific numerical findings for the primary endpoint, were not available in the abstract. This first-in-human study evaluated mid-term outcomes of the ElectroPulse pulsed field ablation system for pulmonary vein and posterior wall isolation. The trial enrolled 60 patients with symptomatic atrial fibrillation, with two cohorts receiving either a standard or a modified ablation protocol. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242586" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242586</a></p>
<p><strong>Summary:</strong> Complete results detailing the incidence, risk factors, and outcomes of atrioventricular block following transcatheter atrial septal defect closure were not available in the abstract. The study retrospectively analyzed 1954 patients who underwent transcatheter atrial septal defect closure between 1999 and 2020 at three tertiary centers. This comprehensive analysis uniquely focused on providing detailed short-term to long-term follow-up. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242585" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242585</a></p>
<p><strong>Summary:</strong> Specific numerical findings regarding the temporal frequency pattern of premature atrial contractions before atrial fibrillation onset were not available in the abstract. This retrospective study utilized long-term monitoring data from cardiovascular implantable electronic devices. It included 101 patients from Boston Scientific devices with a mean follow-up of 5.2 years, divided into groups based on whether they developed atrial fibrillation. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 5: Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242385" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242385</a></p>
<p><strong>Summary:</strong> Specific numerical findings on the diagnostic value of electrophysiological study in new-onset left bundle branch block after transcatheter aortic valve implantation were not available in the abstract. This prospective multicenter study included 183 patients who developed new-onset left bundle branch block 24 hours or more after transcatheter aortic valve implantation. The research compared His-ventricular intervals with electrocardiogram parameters to assess diagnostic performance for risk stratification. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prominent U-waves Without Q. T. Prolongation in X-linked Creatine Transporter Deficiency Caused by S. L. C. 6 A. 8 Variants. Complete results detailing the cardiac phenotype of male Creatine Transporter Deficiency patients were not available in the abstract. This study focused on characterizing cardiac manifestations in patients with S. L. C. 6 A. 8 variants. Early clinical reports had raised concerns regarding possible associations with Q. T. c. prolongation and dilated cardiomyopathy in this patient population. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number two. Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation. Complete results, including specific numerical findings for the primary endpoint, were not available in the abstract. This first-in-human study evaluated mid-term outcomes of the ElectroPulse pulsed field ablation system for pulmonary vein and posterior wall isolation. The trial enrolled 60 patients with symptomatic atrial fibrillation, with two cohorts receiving either a standard or a modified ablation protocol. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number three. Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis. Complete results detailing the incidence, risk factors, and outcomes of atrioventricular block following transcatheter atrial septal defect closure were not available in the abstract. The study retrospectively analyzed 1954 patients who underwent transcatheter atrial septal defect closure between 1999 and 2020 at three tertiary centers. This comprehensive analysis uniquely focused on providing detailed short-term to long-term follow-up. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number four. Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset. Specific numerical findings regarding the temporal frequency pattern of premature atrial contractions before atrial fibrillation onset were not available in the abstract. This retrospective study utilized long-term monitoring data from cardiovascular implantable electronic devices. It included 101 patients from Boston Scientific devices with a mean follow-up of 5.2 years, divided into groups based on whether they developed atrial fibrillation. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number five. Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation. Specific numerical findings on the diagnostic value of electrophysiological study in new-onset left bundle branch block after transcatheter aortic valve implantation were not available in the abstract. This prospective multicenter study included 183 patients who developed new-onset left bundle branch block 24 hours or more after transcatheter aortic valve implantation. The research compared His-ventricular intervals with electrocardiogram parameters to assess diagnostic performance for risk stratification. Therefore, no definitive outcomes from this study can be reported based on the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac phenotype, S. L. C. 6 A. 8 variants, premature atrial contractions, left bundle branch block, atrial fibrillation, posterior wall isolation, transcatheter aortic valve implantation, P. A. C. frequency, pulsed field ablation, ElectroPulse system, dilated cardiomyopathy, longitudinal monitoring, electrophysiological study, transcatheter atrial septal defect closure, cardiovascular implantable electronic devices, long-term outcomes, atrial septal defect, atrioventricular block, conduction disturbances, Q. T. c. prolongation, Creatine Transporter Deficiency, His-ventricular interval, pulmonary vein isolation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/">ElectroPulse PFA: First-in-Human Data 11/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac phenotype and S. L. C. 6 A. 8 variants. Key takeaway: ElectroPulse PFA: First-in-Human Data.
Article Links:
Article 1: Promi]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac phenotype and S. L. C. 6 A. 8 variants. Key takeaway: ElectroPulse PFA: First-in-Human Data.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41242588">Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41242587">Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41242586">Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41242585">Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41242385">Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/">https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242588" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242588</a></p>
<p><strong>Summary:</strong> T. Prolongation in X-linked Creatine Transporter Deficiency Caused by S. L. C. 6 A. 8 Variants. Complete results detailing the cardiac phenotype of male Creatine Transporter Deficiency patients were not available in the abstract. This study focused on characterizing cardiac manifestations in patients with S. L. C. 6 A. 8 variants. Early clinical reports had raised concerns regarding possible associations with Q. T. c. prolongation and dilated cardiomyopathy in this patient population. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242587" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242587</a></p>
<p><strong>Summary:</strong> Complete results, including specific numerical findings for the primary endpoint, were not available in the abstract. This first-in-human study evaluated mid-term outcomes of the ElectroPulse pulsed field ablation system for pulmonary vein and posterior wall isolation. The trial enrolled 60 patients with symptomatic atrial fibrillation, with two cohorts receiving either a standard or a modified ablation protocol. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242586" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242586</a></p>
<p><strong>Summary:</strong> Complete results detailing the incidence, risk factors, and outcomes of atrioventricular block following transcatheter atrial septal defect closure were not available in the abstract. The study retrospectively analyzed 1954 patients who underwent transcatheter atrial septal defect closure between 1999 and 2020 at three tertiary centers. This comprehensive analysis uniquely focused on providing detailed short-term to long-term follow-up. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242585" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242585</a></p>
<p><strong>Summary:</strong> Specific numerical findings regarding the temporal frequency pattern of premature atrial contractions before atrial fibrillation onset were not available in the abstract. This retrospective study utilized long-term monitoring data from cardiovascular implantable electronic devices. It included 101 patients from Boston Scientific devices with a mean follow-up of 5.2 years, divided into groups based on whether they developed atrial fibrillation. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h4>Article 5: Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242385" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242385</a></p>
<p><strong>Summary:</strong> Specific numerical findings on the diagnostic value of electrophysiological study in new-onset left bundle branch block after transcatheter aortic valve implantation were not available in the abstract. This prospective multicenter study included 183 patients who developed new-onset left bundle branch block 24 hours or more after transcatheter aortic valve implantation. The research compared His-ventricular intervals with electrocardiogram parameters to assess diagnostic performance for risk stratification. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prominent U-waves Without Q. T. Prolongation in X-linked Creatine Transporter Deficiency Caused by S. L. C. 6 A. 8 Variants. Complete results detailing the cardiac phenotype of male Creatine Transporter Deficiency patients were not available in the abstract. This study focused on characterizing cardiac manifestations in patients with S. L. C. 6 A. 8 variants. Early clinical reports had raised concerns regarding possible associations with Q. T. c. prolongation and dilated cardiomyopathy in this patient population. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number two. Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation. Complete results, including specific numerical findings for the primary endpoint, were not available in the abstract. This first-in-human study evaluated mid-term outcomes of the ElectroPulse pulsed field ablation system for pulmonary vein and posterior wall isolation. The trial enrolled 60 patients with symptomatic atrial fibrillation, with two cohorts receiving either a standard or a modified ablation protocol. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number three. Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis. Complete results detailing the incidence, risk factors, and outcomes of atrioventricular block following transcatheter atrial septal defect closure were not available in the abstract. The study retrospectively analyzed 1954 patients who underwent transcatheter atrial septal defect closure between 1999 and 2020 at three tertiary centers. This comprehensive analysis uniquely focused on providing detailed short-term to long-term follow-up. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number four. Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset. Specific numerical findings regarding the temporal frequency pattern of premature atrial contractions before atrial fibrillation onset were not available in the abstract. This retrospective study utilized long-term monitoring data from cardiovascular implantable electronic devices. It included 101 patients from Boston Scientific devices with a mean follow-up of 5.2 years, divided into groups based on whether they developed atrial fibrillation. Therefore, no definitive outcomes from this study can be reported based on the abstract.</p>
<p>Article number five. Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation. Specific numerical findings on the diagnostic value of electrophysiological study in new-onset left bundle branch block after transcatheter aortic valve implantation were not available in the abstract. This prospective multicenter study included 183 patients who developed new-onset left bundle branch block 24 hours or more after transcatheter aortic valve implantation. The research compared His-ventricular intervals with electrocardiogram parameters to assess diagnostic performance for risk stratification. Therefore, no definitive outcomes from this study can be reported based on the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac phenotype, S. L. C. 6 A. 8 variants, premature atrial contractions, left bundle branch block, atrial fibrillation, posterior wall isolation, transcatheter aortic valve implantation, P. A. C. frequency, pulsed field ablation, ElectroPulse system, dilated cardiomyopathy, longitudinal monitoring, electrophysiological study, transcatheter atrial septal defect closure, cardiovascular implantable electronic devices, long-term outcomes, atrial septal defect, atrioventricular block, conduction disturbances, Q. T. c. prolongation, Creatine Transporter Deficiency, His-ventricular interval, pulmonary vein isolation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/">ElectroPulse PFA: First-in-Human Data 11/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251117_073758.mp3" length="4133450" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac phenotype and S. L. C. 6 A. 8 variants. Key takeaway: ElectroPulse PFA: First-in-Human Data.
Article Links:
Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants. (Heart rhythm)
Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation. (Heart rhythm)
Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis. (Heart rhythm)
Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset. (Heart rhythm)
Article 5: Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/
 Featured Articles
Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242588
Summary: T. Prolongation in X-linked Creatine Transporter Deficiency Caused by S. L. C. 6 A. 8 Variants. Complete results detailing the cardiac phenotype of male Creatine Transporter Deficiency patients were not available in the abstract. This study focused on characterizing cardiac manifestations in patients with S. L. C. 6 A. 8 variants. Early clinical reports had raised concerns regarding possible associations with Q. T. c. prolongation and dilated cardiomyopathy in this patient population. Therefore, no definitive outcomes from this study can be reported based on the abstract.
Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242587
Summary: Complete results, including specific numerical findings for the primary endpoint, were not available in the abstract. This first-in-human study evaluated mid-term outcomes of the ElectroPulse pulsed field ablation system for pulmonary vein and posterior wall isolation. The trial enrolled 60 patients with symptomatic atrial fibrillation, with two cohorts receiving either a standard or a modified ablation protocol. Therefore, no definitive outcomes from this study can be reported based on the abstract.
Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242586
Summary: Complete results detailing the incidence, risk factors, and outcomes of atrioventricular block following transcatheter atrial septal defect closure were not available in the abstract. The study retrospectively analyzed 1954 patients who underwent transcatheter atrial septal defect closure between 1999 and 2020 at three tertiary centers. This comprehensive analysis uniquely focused on providing detailed short-term to long-term follow-up. Therefore, no definitive outcomes from this study can be reported based on the abstract.
Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242585
Summary: Specific numerical findings regarding the temporal frequency pattern of premature atrial contractions before atrial fibrillation onset were not available in the abstract. This retrospective study utilized long-term monitoring data from cardiovascular implantable electronic devices. It included 101 patients from Boston Scientific devices with a mean follow-up of 5.2 years, divided into groups based on whether they developed atrial fibrillation. Therefore, no definitive outcome]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac phenotype and S. L. C. 6 A. 8 variants. Key takeaway: ElectroPulse PFA: First-in-Human Data.
Article Links:
Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants. (Heart rhythm)
Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation. (Heart rhythm)
Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis. (Heart rhythm)
Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset. (Heart rhythm)
Article 5: Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation. (The Canadian journal of cardiology)
Full episode page: https://podcast.exp]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Ablation Cuts Persistent AF Recurrence 11/17/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/</link>
	<pubDate>Mon, 17 Nov 2025 11:02:03 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41242357">Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41242356">Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41242355">Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41242590">Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41242589">Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/">https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242357" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242357</a></p>
<p><strong>Summary:</strong> The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.</p>
<h4>Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242356</a></p>
<p><strong>Summary:</strong> This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.</p>
<h4>Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242355" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242355</a></p>
<p><strong>Summary:</strong> This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.</p>
<h4>Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242590" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242590</a></p>
<p><strong>Summary:</strong> The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.</p>
<h4>Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242589" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242589</a></p>
<p><strong>Summary:</strong> This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.</p>
<p>Article number two. Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.</p>
<p>Article number three. Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.</p>
<p>Article number four. Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.</p>
<p>Article number five. Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>selexipag, atrial flutter, direct oral anticoagulants, prostacyclin receptor agonist, mortality, pulmonary vein isolation, electroanatomic mapping, transbronchial biopsy, recurrent arrhythmia, lung transplant, vitamin K antagonists, pulmonary arterial hypertension, atrial tachycardia, GRIPHON trial, Cox-Maze procedure, morbidity, balloon pulmonary angioplasty, baseline lung allograft dysfunction, gene expression, atrial fibrillation, artificial intelligence, persistent atrial fibrillation, pulmonary angiogram, pulmonary function, chronic thromboembolic pulmonary hypertension, catheter ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/">AI Ablation Cuts Persistent AF Recurrence 11/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence.
Article Links:
Article 1: Evaluating oral sel]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41242357">Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41242356">Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41242355">Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41242590">Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41242589">Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/">https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242357" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242357</a></p>
<p><strong>Summary:</strong> The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.</p>
<h4>Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242356</a></p>
<p><strong>Summary:</strong> This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.</p>
<h4>Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242355" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242355</a></p>
<p><strong>Summary:</strong> This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.</p>
<h4>Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242590" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242590</a></p>
<p><strong>Summary:</strong> The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.</p>
<h4>Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41242589" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41242589</a></p>
<p><strong>Summary:</strong> This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.</p>
<p>Article number two. Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.</p>
<p>Article number three. Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.</p>
<p>Article number four. Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.</p>
<p>Article number five. Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>selexipag, atrial flutter, direct oral anticoagulants, prostacyclin receptor agonist, mortality, pulmonary vein isolation, electroanatomic mapping, transbronchial biopsy, recurrent arrhythmia, lung transplant, vitamin K antagonists, pulmonary arterial hypertension, atrial tachycardia, GRIPHON trial, Cox-Maze procedure, morbidity, balloon pulmonary angioplasty, baseline lung allograft dysfunction, gene expression, atrial fibrillation, artificial intelligence, persistent atrial fibrillation, pulmonary angiogram, pulmonary function, chronic thromboembolic pulmonary hypertension, catheter ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/">AI Ablation Cuts Persistent AF Recurrence 11/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251117_060050.mp3" length="4308993" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence.
Article Links:
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. (Heart rhythm)
Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/
 Featured Articles
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242357
Summary: The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242356
Summary: This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242355
Summary: This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence.
Article Links:
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. (The Journ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Simplified DCD Heart Tx: 100 percent Graft Function. 11/16/25</title>
	<link>https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/</link>
	<pubDate>Sun, 16 Nov 2025 11:01:36 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 16, 2025. This episode summarizes 5 key cardiology studies on topics like myocardial performance score and right ventricular failure. Key takeaway: Simplified DCD Heart Tx: 100 percent Graft Function..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41241036">DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41241034">Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41241033">Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41241032">Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41241031">Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/">https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241036" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241036</a></p>
<p><strong>Summary:</strong> This study successfully performed five heart transplantations using a simplified direct procurement technique from donation after circulatory death donors. All five recipients demonstrated normal cardiac graft function after the procedure. No evidence of rejection was observed during their short-term follow-up period. The approach, which employed cold blood perfusion and preservation solution, proved to be both feasible and logistically efficient.</p>
<h4>Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241034" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241034</a></p>
<p><strong>Summary:</strong> The Trifecta-Heart study compared four tests used to assess antibody-mediated rejection in heart transplant patients: standard endomyocardial biopsy histology, endomyocardial biopsy molecular analysis using the Molecular Microscope Diagnostic System, donor-derived cell-free D. N. A., and donor-specific antibody measurements. Specific numerical results defining the relationships among these tests were not provided in the abstract. The abstract focused on the comparison of these assessment methods.</p>
<h4>Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241033" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241033</a></p>
<p><strong>Summary:</strong> Following the 2018 heart allocation policy change, status two listings for heart transplant candidates with temporary mechanical circulatory support were observed to increase, while listings for durable left ventricular assist devices decreased. The study identified adult heart transplant candidates from the Scientific Registry of Transplant Recipients. Specific numerical data detailing the low rates of inotropic support and durable left ventricular assist device placement were not included in this abstract.</p>
<h4>Article 4: Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241032" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241032</a></p>
<p><strong>Summary:</strong> This study performed 800 pressure-volume loop in silico simulations to evaluate right ventricular myocardial performance. The right ventricular myocardial performance score was precisely calculated using the formula (3 multiplied by pulmonary artery pulsatility index multiplied by right ventricular cardiac power output) divided by 2. A validation cohort comprising 223 patients was included for further assessment. Specific findings regarding the utility of the right ventricular myocardial performance score as a marker for right ventricular function and prognosis were not detailed in this abstract.</p>
<h4>Article 5: Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241031" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241031</a></p>
<p><strong>Summary:</strong> This study investigated the impact of ex-vivo heart perfusion on outcomes in donation after circulatory death heart transplantation following a prolonged agonal period. Adult isolated heart transplants reported to the United Network for Organ Sharing thoracic registry between January 2019 and April 2025 were reviewed. Ex-vivo heart perfusion was defined as the primary exposure for analysis. Concrete findings and specific numerical results demonstrating the attenuation of early post-transplant risk were not provided in the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access. This study successfully performed five heart transplantations using a simplified direct procurement technique from donation after circulatory death donors. All five recipients demonstrated normal cardiac graft function after the procedure. No evidence of rejection was observed during their short-term follow-up period. The approach, which employed cold blood perfusion and preservation solution, proved to be both feasible and logistically efficient.</p>
<p>Article number two. Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. The Trifecta-Heart study compared four tests used to assess antibody-mediated rejection in heart transplant patients: standard endomyocardial biopsy histology, endomyocardial biopsy molecular analysis using the Molecular Microscope Diagnostic System, donor-derived cell-free D. N. A., and donor-specific antibody measurements. Specific numerical results defining the relationships among these tests were not provided in the abstract. The abstract focused on the comparison of these assessment methods.</p>
<p>Article number three. Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. Following the 2018 heart allocation policy change, status two listings for heart transplant candidates with temporary mechanical circulatory support were observed to increase, while listings for durable left ventricular assist devices decreased. The study identified adult heart transplant candidates from the Scientific Registry of Transplant Recipients. Specific numerical data detailing the low rates of inotropic support and durable left ventricular assist device placement were not included in this abstract.</p>
<p>Article number four. Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score. This study performed 800 pressure-volume loop in silico simulations to evaluate right ventricular myocardial performance. The right ventricular myocardial performance score was precisely calculated using the formula (3 multiplied by pulmonary artery pulsatility index multiplied by right ventricular cardiac power output) divided by 2. A validation cohort comprising 223 patients was included for further assessment. Specific findings regarding the utility of the right ventricular myocardial performance score as a marker for right ventricular function and prognosis were not detailed in this abstract.</p>
<p>Article number five. Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation. This study investigated the impact of ex-vivo heart perfusion on outcomes in donation after circulatory death heart transplantation following a prolonged agonal period. Adult isolated heart transplants reported to the United Network for Organ Sharing thoracic registry between January 2019 and April 2025 were reviewed. Ex-vivo heart perfusion was defined as the primary exposure for analysis. Concrete findings and specific numerical results demonstrating the attenuation of early post-transplant risk were not provided in the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial performance score, right ventricular failure, hemodynamics, cold perfusion, antibody-mediated rejection, heart transplant, donor-derived cell-free D. N. A., heart transplant candidates, pressure-volume loop, left ventricular assist device, donor-specific antibody, ex-vivo heart perfusion, donation after circulatory death, direct procurement, graft function, Scientific Registry of Transplant Recipients, heart allocation policy, endomyocardial biopsy, pulmonary artery pulsatility index, heart transplantation, warm ischemic injury, temporary mechanical circulatory support, agonal period.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/">Simplified DCD Heart Tx: 100 percent Graft Function. 11/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 16, 2025. This episode summarizes 5 key cardiology studies on topics like myocardial performance score and right ventricular failure. Key takeaway: Simplified DCD Heart Tx: 100 percent Graft Function..
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 16, 2025. This episode summarizes 5 key cardiology studies on topics like myocardial performance score and right ventricular failure. Key takeaway: Simplified DCD Heart Tx: 100 percent Graft Function..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41241036">DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41241034">Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41241033">Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41241032">Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41241031">Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/">https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241036" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241036</a></p>
<p><strong>Summary:</strong> This study successfully performed five heart transplantations using a simplified direct procurement technique from donation after circulatory death donors. All five recipients demonstrated normal cardiac graft function after the procedure. No evidence of rejection was observed during their short-term follow-up period. The approach, which employed cold blood perfusion and preservation solution, proved to be both feasible and logistically efficient.</p>
<h4>Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241034" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241034</a></p>
<p><strong>Summary:</strong> The Trifecta-Heart study compared four tests used to assess antibody-mediated rejection in heart transplant patients: standard endomyocardial biopsy histology, endomyocardial biopsy molecular analysis using the Molecular Microscope Diagnostic System, donor-derived cell-free D. N. A., and donor-specific antibody measurements. Specific numerical results defining the relationships among these tests were not provided in the abstract. The abstract focused on the comparison of these assessment methods.</p>
<h4>Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241033" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241033</a></p>
<p><strong>Summary:</strong> Following the 2018 heart allocation policy change, status two listings for heart transplant candidates with temporary mechanical circulatory support were observed to increase, while listings for durable left ventricular assist devices decreased. The study identified adult heart transplant candidates from the Scientific Registry of Transplant Recipients. Specific numerical data detailing the low rates of inotropic support and durable left ventricular assist device placement were not included in this abstract.</p>
<h4>Article 4: Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241032" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241032</a></p>
<p><strong>Summary:</strong> This study performed 800 pressure-volume loop in silico simulations to evaluate right ventricular myocardial performance. The right ventricular myocardial performance score was precisely calculated using the formula (3 multiplied by pulmonary artery pulsatility index multiplied by right ventricular cardiac power output) divided by 2. A validation cohort comprising 223 patients was included for further assessment. Specific findings regarding the utility of the right ventricular myocardial performance score as a marker for right ventricular function and prognosis were not detailed in this abstract.</p>
<h4>Article 5: Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41241031" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41241031</a></p>
<p><strong>Summary:</strong> This study investigated the impact of ex-vivo heart perfusion on outcomes in donation after circulatory death heart transplantation following a prolonged agonal period. Adult isolated heart transplants reported to the United Network for Organ Sharing thoracic registry between January 2019 and April 2025 were reviewed. Ex-vivo heart perfusion was defined as the primary exposure for analysis. Concrete findings and specific numerical results demonstrating the attenuation of early post-transplant risk were not provided in the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access. This study successfully performed five heart transplantations using a simplified direct procurement technique from donation after circulatory death donors. All five recipients demonstrated normal cardiac graft function after the procedure. No evidence of rejection was observed during their short-term follow-up period. The approach, which employed cold blood perfusion and preservation solution, proved to be both feasible and logistically efficient.</p>
<p>Article number two. Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. The Trifecta-Heart study compared four tests used to assess antibody-mediated rejection in heart transplant patients: standard endomyocardial biopsy histology, endomyocardial biopsy molecular analysis using the Molecular Microscope Diagnostic System, donor-derived cell-free D. N. A., and donor-specific antibody measurements. Specific numerical results defining the relationships among these tests were not provided in the abstract. The abstract focused on the comparison of these assessment methods.</p>
<p>Article number three. Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. Following the 2018 heart allocation policy change, status two listings for heart transplant candidates with temporary mechanical circulatory support were observed to increase, while listings for durable left ventricular assist devices decreased. The study identified adult heart transplant candidates from the Scientific Registry of Transplant Recipients. Specific numerical data detailing the low rates of inotropic support and durable left ventricular assist device placement were not included in this abstract.</p>
<p>Article number four. Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score. This study performed 800 pressure-volume loop in silico simulations to evaluate right ventricular myocardial performance. The right ventricular myocardial performance score was precisely calculated using the formula (3 multiplied by pulmonary artery pulsatility index multiplied by right ventricular cardiac power output) divided by 2. A validation cohort comprising 223 patients was included for further assessment. Specific findings regarding the utility of the right ventricular myocardial performance score as a marker for right ventricular function and prognosis were not detailed in this abstract.</p>
<p>Article number five. Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation. This study investigated the impact of ex-vivo heart perfusion on outcomes in donation after circulatory death heart transplantation following a prolonged agonal period. Adult isolated heart transplants reported to the United Network for Organ Sharing thoracic registry between January 2019 and April 2025 were reviewed. Ex-vivo heart perfusion was defined as the primary exposure for analysis. Concrete findings and specific numerical results demonstrating the attenuation of early post-transplant risk were not provided in the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myocardial performance score, right ventricular failure, hemodynamics, cold perfusion, antibody-mediated rejection, heart transplant, donor-derived cell-free D. N. A., heart transplant candidates, pressure-volume loop, left ventricular assist device, donor-specific antibody, ex-vivo heart perfusion, donation after circulatory death, direct procurement, graft function, Scientific Registry of Transplant Recipients, heart allocation policy, endomyocardial biopsy, pulmonary artery pulsatility index, heart transplantation, warm ischemic injury, temporary mechanical circulatory support, agonal period.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/">Simplified DCD Heart Tx: 100 percent Graft Function. 11/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251116_060025.mp3" length="3867628" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 16, 2025. This episode summarizes 5 key cardiology studies on topics like myocardial performance score and right ventricular failure. Key takeaway: Simplified DCD Heart Tx: 100 percent Graft Function..
Article Links:
Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/
 Featured Articles
Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241036
Summary: This study successfully performed five heart transplantations using a simplified direct procurement technique from donation after circulatory death donors. All five recipients demonstrated normal cardiac graft function after the procedure. No evidence of rejection was observed during their short-term follow-up period. The approach, which employed cold blood perfusion and preservation solution, proved to be both feasible and logistically efficient.
Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241034
Summary: The Trifecta-Heart study compared four tests used to assess antibody-mediated rejection in heart transplant patients: standard endomyocardial biopsy histology, endomyocardial biopsy molecular analysis using the Molecular Microscope Diagnostic System, donor-derived cell-free D. N. A., and donor-specific antibody measurements. Specific numerical results defining the relationships among these tests were not provided in the abstract. The abstract focused on the comparison of these assessment methods.
Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241033
Summary: Following the 2018 heart allocation policy change, status two listings for heart transplant candidates with temporary mechanical circulatory support were observed to increase, while listings for durable left ventricular assist devices decreased. The study identified ad]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 16, 2025. This episode summarizes 5 key cardiology studies on topics like myocardial performance score and right ventricular failure. Key takeaway: Simplified DCD Heart Tx: 100 percent Graft Function..
Article Links:
Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. (The Journal of heart and lung transplan]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Albuminuria and Acute Heart Failure Risk 11/15/25</title>
	<link>https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/</link>
	<pubDate>Sat, 15 Nov 2025 22:58:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular systolic function and congenital heart disease. Key takeaway: Albuminuria and Acute Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41229088">Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41224248">Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41231743">Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function.</a> (Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41238115">Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41238114">Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/">https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41229088" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41229088</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This study aimed to characterize the myocardial transcriptome and proteome in patients with arrhythmogenic cardiomyopathy. Specific numerical findings on which immune and metabolic pathways were dysregulated, or the detectability of key molecules in plasma and tissue, were not provided.</p>
<h4>Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41224248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41224248</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This study evaluated if albuminuria was associated with adverse outcomes in non-diabetic individuals hospitalized with acute heart failure. Specific numerical findings regarding the association between albuminuria and patient outcomes were not provided.</p>
<h4>Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41231743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41231743</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This retrospective study aimed to stratify patients with severe secondary tricuspid regurgitation based on right ventricular fractional area change. Specific echocardiographic parameters influencing prognosis or definitive conclusions on patient stratification were not provided.</p>
<h4>Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41238115" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41238115</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This study hypothesized that endothelial transient receptor potential vanilloid 4 contributes to post-ischemic vascular hyperpermeability and myocardial injury. Specific numerical findings demonstrating the exacerbation of ischemia-reperfusion injury or the impairment of vascular integrity were not provided.</p>
<h4>Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41238114" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41238114</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This retrospective cohort study assessed the feasibility and reproducibility of echocardiogram-derived systolic function indices in adults with Fontan palliation. Specific numerical findings on the relationship between these indices and clinical outcomes were not provided.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. Complete results were not available in the abstract. This study aimed to characterize the myocardial transcriptome and proteome in patients with arrhythmogenic cardiomyopathy. Specific numerical findings on which immune and metabolic pathways were dysregulated, or the detectability of key molecules in plasma and tissue, were not provided.</p>
<p>Article number two. Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. Complete results were not available in the abstract. This study evaluated if albuminuria was associated with adverse outcomes in non-diabetic individuals hospitalized with acute heart failure. Specific numerical findings regarding the association between albuminuria and patient outcomes were not provided.</p>
<p>Article number three. Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function. Complete results were not available in the abstract. This retrospective study aimed to stratify patients with severe secondary tricuspid regurgitation based on right ventricular fractional area change. Specific echocardiographic parameters influencing prognosis or definitive conclusions on patient stratification were not provided.</p>
<p>Article number four. Activation of endothelial transient receptor potential vanilloid 4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment. Complete results were not available in the abstract. This study hypothesized that endothelial transient receptor potential vanilloid 4 contributes to post-ischemic vascular hyperpermeability and myocardial injury. Specific numerical findings demonstrating the exacerbation of ischemia-reperfusion injury or the impairment of vascular integrity were not provided.</p>
<p>Article number five. Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications. Complete results were not available in the abstract. This retrospective cohort study assessed the feasibility and reproducibility of echocardiogram-derived systolic function indices in adults with Fontan palliation. Specific numerical findings on the relationship between these indices and clinical outcomes were not provided. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ventricular systolic function, congenital heart disease, Fontan palliation, arrhythmogenic cardiomyopathy, metabolic pathways, chronic kidney disease, right ventricular systolic function, ischemia-reperfusion injury, myocardial injury, non-diabetic, acute heart failure, albuminuria, transcriptome, right ventricular fractional area change, immune pathways, proteome, feasibility, prognosis, endothelial cells, secondary tricuspid regurgitation, heart failure, echocardiography, vascular integrity, transient receptor potential vanilloid 4.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/">Albuminuria and Acute Heart Failure Risk 11/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular systolic function and congenital heart disease. Key takeaway: Albuminuria and Acute Heart Failure Risk.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular systolic function and congenital heart disease. Key takeaway: Albuminuria and Acute Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41229088">Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41224248">Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41231743">Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function.</a> (Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41238115">Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41238114">Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/">https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41229088" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41229088</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This study aimed to characterize the myocardial transcriptome and proteome in patients with arrhythmogenic cardiomyopathy. Specific numerical findings on which immune and metabolic pathways were dysregulated, or the detectability of key molecules in plasma and tissue, were not provided.</p>
<h4>Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41224248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41224248</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This study evaluated if albuminuria was associated with adverse outcomes in non-diabetic individuals hospitalized with acute heart failure. Specific numerical findings regarding the association between albuminuria and patient outcomes were not provided.</p>
<h4>Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41231743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41231743</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This retrospective study aimed to stratify patients with severe secondary tricuspid regurgitation based on right ventricular fractional area change. Specific echocardiographic parameters influencing prognosis or definitive conclusions on patient stratification were not provided.</p>
<h4>Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41238115" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41238115</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This study hypothesized that endothelial transient receptor potential vanilloid 4 contributes to post-ischemic vascular hyperpermeability and myocardial injury. Specific numerical findings demonstrating the exacerbation of ischemia-reperfusion injury or the impairment of vascular integrity were not provided.</p>
<h4>Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41238114" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41238114</a></p>
<p><strong>Summary:</strong> Complete results were not available in the abstract. This retrospective cohort study assessed the feasibility and reproducibility of echocardiogram-derived systolic function indices in adults with Fontan palliation. Specific numerical findings on the relationship between these indices and clinical outcomes were not provided.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. Complete results were not available in the abstract. This study aimed to characterize the myocardial transcriptome and proteome in patients with arrhythmogenic cardiomyopathy. Specific numerical findings on which immune and metabolic pathways were dysregulated, or the detectability of key molecules in plasma and tissue, were not provided.</p>
<p>Article number two. Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. Complete results were not available in the abstract. This study evaluated if albuminuria was associated with adverse outcomes in non-diabetic individuals hospitalized with acute heart failure. Specific numerical findings regarding the association between albuminuria and patient outcomes were not provided.</p>
<p>Article number three. Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function. Complete results were not available in the abstract. This retrospective study aimed to stratify patients with severe secondary tricuspid regurgitation based on right ventricular fractional area change. Specific echocardiographic parameters influencing prognosis or definitive conclusions on patient stratification were not provided.</p>
<p>Article number four. Activation of endothelial transient receptor potential vanilloid 4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment. Complete results were not available in the abstract. This study hypothesized that endothelial transient receptor potential vanilloid 4 contributes to post-ischemic vascular hyperpermeability and myocardial injury. Specific numerical findings demonstrating the exacerbation of ischemia-reperfusion injury or the impairment of vascular integrity were not provided.</p>
<p>Article number five. Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications. Complete results were not available in the abstract. This retrospective cohort study assessed the feasibility and reproducibility of echocardiogram-derived systolic function indices in adults with Fontan palliation. Specific numerical findings on the relationship between these indices and clinical outcomes were not provided. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ventricular systolic function, congenital heart disease, Fontan palliation, arrhythmogenic cardiomyopathy, metabolic pathways, chronic kidney disease, right ventricular systolic function, ischemia-reperfusion injury, myocardial injury, non-diabetic, acute heart failure, albuminuria, transcriptome, right ventricular fractional area change, immune pathways, proteome, feasibility, prognosis, endothelial cells, secondary tricuspid regurgitation, heart failure, echocardiography, vascular integrity, transient receptor potential vanilloid 4.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/">Albuminuria and Acute Heart Failure Risk 11/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251115_175728.mp3" length="2825656" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular systolic function and congenital heart disease. Key takeaway: Albuminuria and Acute Heart Failure Risk.
Article Links:
Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. (ESC heart failure)
Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. (ESC heart failure)
Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function. (Cardiology)
Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment. (The Canadian journal of cardiology)
Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/
 Featured Articles
Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41229088
Summary: Complete results were not available in the abstract. This study aimed to characterize the myocardial transcriptome and proteome in patients with arrhythmogenic cardiomyopathy. Specific numerical findings on which immune and metabolic pathways were dysregulated, or the detectability of key molecules in plasma and tissue, were not provided.
Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224248
Summary: Complete results were not available in the abstract. This study evaluated if albuminuria was associated with adverse outcomes in non-diabetic individuals hospitalized with acute heart failure. Specific numerical findings regarding the association between albuminuria and patient outcomes were not provided.
Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41231743
Summary: Complete results were not available in the abstract. This retrospective study aimed to stratify patients with severe secondary tricuspid regurgitation based on right ventricular fractional area change. Specific echocardiographic parameters influencing prognosis or definitive conclusions on patient stratification were not provided.
Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41238115
Summary: Complete results were not available in the abstract. This study hypothesized that endothelial transient receptor potential vanilloid 4 contributes to post-ischemic vascular hyperpermeability and myocardial injury. Specific numerical findings demonstrating the exacerbation of ischemia-reperfusion injury or the impairment of vascular integrity were not provided.
Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41238114
Summary: Complete results were not available in the abstract. This retrospective cohort study assessed the feasibility and reproducibility of echocardiogram-derived systolic function indices in adults with Fontan palliation. Specific numerical findings on the relationship between these indices and clinical outcomes were not p]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular systolic function and congenital heart disease. Key takeaway: Albuminuria and Acute Heart Failure Risk.
Article Links:
Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. (ESC heart failure)
Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. (ESC heart failure)
Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function. (Cardiology)
Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment. (The Canadian journal of cardiology)
Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Progno]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>PA-Led Heart Transplant Recovery: Safe, Effective 11/15/25</title>
	<link>https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/</link>
	<pubDate>Sat, 15 Nov 2025 11:01:39 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Heart failure. Key takeaway: PA-Led Heart Transplant Recovery: Safe, Effective.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41238023">Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40393691">Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40348411">Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40312105">Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41229332">Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/">https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41238023" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41238023</a></p>
<p><strong>Summary:</strong> This observational cohort study assessed the clinical outcomes and programmatic benefits of a physician assistant-led allograft recovery model for adult heart transplantation. Researchers compared 130 transplantations using physician assistant teams with 367 using non-physician assistant teams at a high-volume center between 2020 and 2024. The implementation of this physician assistant-led model for donor organ recovery demonstrated comparable clinical outcomes for heart transplantation recipients. This model offers significant programmatic advantages, potentially enhancing efficiency and resource utilization within heart transplantation programs.</p>
<h4>Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40393691" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40393691</a></p>
<p><strong>Summary:</strong> This subanalysis of the Low-Dose Colchicine 2 Trial aimed to investigate the effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition. Researchers performed cross-sectional computed tomography angiography studies in 151 participants with chronic coronary disease. The primary objective was to understand the underlying mechanisms by which low-dose colchicine, administered at 0.5 mg once daily, reduces the risk of major cardiovascular events. This study established a methodology to assess how colchicine may exert its beneficial anti-inflammatory actions on coronary arteries.</p>
<h4>Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348411" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348411</a></p>
<p><strong>Summary:</strong> This prospective registry study investigated the incidence, predictors, and clinical impact of late upper gastrointestinal bleeding following transcatheter aortic valve replacement. Researchers analyzed 3144 patients, stratifying them based on the occurrence of upper gastrointestinal bleeding within one year of hospital discharge. The study characterized the frequency of this complication in transcatheter aortic valve replacement patients and identified specific factors that predict its occurrence. Understanding these predictors is crucial for implementing targeted preventative strategies and improving patient safety after this cardiac procedure.</p>
<h4>Article 4: Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40312105" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40312105</a></p>
<p><strong>Summary:</strong> This study determined the incidence, predictors, and clinical outcomes of tricuspid regurgitation progression following left-sided valvular intervention. Researchers analyzed one thousand six hundred forty-four patients who underwent surgical or transcatheter treatment for aortic or mitral valve disease, excluding those with severe tricuspid regurgitation at baseline. The study defined tricuspid regurgitation progression as an increase to at least moderate or severe grade, identifying key factors influencing this critical clinical concern. This research provides essential information for risk stratification and monitoring strategies to prevent worsening tricuspid regurgitation in this patient population.</p>
<h4>Article 5: Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41229332" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41229332</a></p>
<p><strong>Summary:</strong> This study aimed to identify factors determining diuresis and natriuresis after ambulatory intravenous loop diuretic administration for worsening heart failure. Researchers analyzed patients receiving four-hour intravenous diuretic sessions, which included an initial bolus followed by a tailored continuous infusion protocol. The research focused on advanced heart failure patients with frequent hospital admissions, representing a challenging clinical population. Understanding these determinants is crucial for optimizing diuretic response in an outpatient setting, potentially reducing hospitalization rates and improving patient care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center. This observational cohort study assessed the clinical outcomes and programmatic benefits of a physician assistant-led allograft recovery model for adult heart transplantation. Researchers compared 130 transplantations using physician assistant teams with 367 using non-physician assistant teams at a high-volume center between 2020 and 2024. The implementation of this physician assistant-led model for donor organ recovery demonstrated comparable clinical outcomes for heart transplantation recipients. This model offers significant programmatic advantages, potentially enhancing efficiency and resource utilization within heart transplantation programs.</p>
<p>Article number two. Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. This subanalysis of the Low-Dose Colchicine 2 Trial aimed to investigate the effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition. Researchers performed cross-sectional computed tomography angiography studies in 151 participants with chronic coronary disease. The primary objective was to understand the underlying mechanisms by which low-dose colchicine, administered at 0.5 mg once daily, reduces the risk of major cardiovascular events. This study established a methodology to assess how colchicine may exert its beneficial anti-inflammatory actions on coronary arteries.</p>
<p>Article number three. Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. This prospective registry study investigated the incidence, predictors, and clinical impact of late upper gastrointestinal bleeding following transcatheter aortic valve replacement. Researchers analyzed 3144 patients, stratifying them based on the occurrence of upper gastrointestinal bleeding within one year of hospital discharge. The study characterized the frequency of this complication in transcatheter aortic valve replacement patients and identified specific factors that predict its occurrence. Understanding these predictors is crucial for implementing targeted preventative strategies and improving patient safety after this cardiac procedure.</p>
<p>Article number four. Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention. This study determined the incidence, predictors, and clinical outcomes of tricuspid regurgitation progression following left-sided valvular intervention. Researchers analyzed one thousand six hundred forty-four patients who underwent surgical or transcatheter treatment for aortic or mitral valve disease, excluding those with severe tricuspid regurgitation at baseline. The study defined tricuspid regurgitation progression as an increase to at least moderate or severe grade, identifying key factors influencing this critical clinical concern. This research provides essential information for risk stratification and monitoring strategies to prevent worsening tricuspid regurgitation in this patient population.</p>
<p>Article number five. Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure. This study aimed to identify factors determining diuresis and natriuresis after ambulatory intravenous loop diuretic administration for worsening heart failure. Researchers analyzed patients receiving four-hour intravenous diuretic sessions, which included an initial bolus followed by a tailored continuous infusion protocol. The research focused on advanced heart failure patients with frequent hospital admissions, representing a challenging clinical population. Understanding these determinants is crucial for optimizing diuretic response in an outpatient setting, potentially reducing hospitalization rates and improving patient care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transcatheter aortic valve replacement, Heart failure, Low-dose colchicine, allograft recovery, pericoronary inflammation, computed tomography angiography, ambulatory care, donor organ procurement, transcatheter treatment, chronic coronary disease, aortic stenosis, loop diuretics, left-sided valvular heart disease, natriuresis, diuresis, aortic valve disease, intravenous diuretics, physician assistant, coronary plaque, Tricuspid regurgitation, clinical outcomes, upper gastrointestinal bleeding, antiplatelet therapy, Heart transplantation, mitral valve disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/">PA-Led Heart Transplant Recovery: Safe, Effective 11/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Heart failure. Key takeaway: PA-Led Heart Transplant Recovery: Safe, Effective.
Article L]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Heart failure. Key takeaway: PA-Led Heart Transplant Recovery: Safe, Effective.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41238023">Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40393691">Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40348411">Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40312105">Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41229332">Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/">https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41238023" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41238023</a></p>
<p><strong>Summary:</strong> This observational cohort study assessed the clinical outcomes and programmatic benefits of a physician assistant-led allograft recovery model for adult heart transplantation. Researchers compared 130 transplantations using physician assistant teams with 367 using non-physician assistant teams at a high-volume center between 2020 and 2024. The implementation of this physician assistant-led model for donor organ recovery demonstrated comparable clinical outcomes for heart transplantation recipients. This model offers significant programmatic advantages, potentially enhancing efficiency and resource utilization within heart transplantation programs.</p>
<h4>Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40393691" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40393691</a></p>
<p><strong>Summary:</strong> This subanalysis of the Low-Dose Colchicine 2 Trial aimed to investigate the effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition. Researchers performed cross-sectional computed tomography angiography studies in 151 participants with chronic coronary disease. The primary objective was to understand the underlying mechanisms by which low-dose colchicine, administered at 0.5 mg once daily, reduces the risk of major cardiovascular events. This study established a methodology to assess how colchicine may exert its beneficial anti-inflammatory actions on coronary arteries.</p>
<h4>Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348411" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348411</a></p>
<p><strong>Summary:</strong> This prospective registry study investigated the incidence, predictors, and clinical impact of late upper gastrointestinal bleeding following transcatheter aortic valve replacement. Researchers analyzed 3144 patients, stratifying them based on the occurrence of upper gastrointestinal bleeding within one year of hospital discharge. The study characterized the frequency of this complication in transcatheter aortic valve replacement patients and identified specific factors that predict its occurrence. Understanding these predictors is crucial for implementing targeted preventative strategies and improving patient safety after this cardiac procedure.</p>
<h4>Article 4: Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40312105" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40312105</a></p>
<p><strong>Summary:</strong> This study determined the incidence, predictors, and clinical outcomes of tricuspid regurgitation progression following left-sided valvular intervention. Researchers analyzed one thousand six hundred forty-four patients who underwent surgical or transcatheter treatment for aortic or mitral valve disease, excluding those with severe tricuspid regurgitation at baseline. The study defined tricuspid regurgitation progression as an increase to at least moderate or severe grade, identifying key factors influencing this critical clinical concern. This research provides essential information for risk stratification and monitoring strategies to prevent worsening tricuspid regurgitation in this patient population.</p>
<h4>Article 5: Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41229332" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41229332</a></p>
<p><strong>Summary:</strong> This study aimed to identify factors determining diuresis and natriuresis after ambulatory intravenous loop diuretic administration for worsening heart failure. Researchers analyzed patients receiving four-hour intravenous diuretic sessions, which included an initial bolus followed by a tailored continuous infusion protocol. The research focused on advanced heart failure patients with frequent hospital admissions, representing a challenging clinical population. Understanding these determinants is crucial for optimizing diuretic response in an outpatient setting, potentially reducing hospitalization rates and improving patient care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center. This observational cohort study assessed the clinical outcomes and programmatic benefits of a physician assistant-led allograft recovery model for adult heart transplantation. Researchers compared 130 transplantations using physician assistant teams with 367 using non-physician assistant teams at a high-volume center between 2020 and 2024. The implementation of this physician assistant-led model for donor organ recovery demonstrated comparable clinical outcomes for heart transplantation recipients. This model offers significant programmatic advantages, potentially enhancing efficiency and resource utilization within heart transplantation programs.</p>
<p>Article number two. Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. This subanalysis of the Low-Dose Colchicine 2 Trial aimed to investigate the effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition. Researchers performed cross-sectional computed tomography angiography studies in 151 participants with chronic coronary disease. The primary objective was to understand the underlying mechanisms by which low-dose colchicine, administered at 0.5 mg once daily, reduces the risk of major cardiovascular events. This study established a methodology to assess how colchicine may exert its beneficial anti-inflammatory actions on coronary arteries.</p>
<p>Article number three. Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. This prospective registry study investigated the incidence, predictors, and clinical impact of late upper gastrointestinal bleeding following transcatheter aortic valve replacement. Researchers analyzed 3144 patients, stratifying them based on the occurrence of upper gastrointestinal bleeding within one year of hospital discharge. The study characterized the frequency of this complication in transcatheter aortic valve replacement patients and identified specific factors that predict its occurrence. Understanding these predictors is crucial for implementing targeted preventative strategies and improving patient safety after this cardiac procedure.</p>
<p>Article number four. Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention. This study determined the incidence, predictors, and clinical outcomes of tricuspid regurgitation progression following left-sided valvular intervention. Researchers analyzed one thousand six hundred forty-four patients who underwent surgical or transcatheter treatment for aortic or mitral valve disease, excluding those with severe tricuspid regurgitation at baseline. The study defined tricuspid regurgitation progression as an increase to at least moderate or severe grade, identifying key factors influencing this critical clinical concern. This research provides essential information for risk stratification and monitoring strategies to prevent worsening tricuspid regurgitation in this patient population.</p>
<p>Article number five. Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure. This study aimed to identify factors determining diuresis and natriuresis after ambulatory intravenous loop diuretic administration for worsening heart failure. Researchers analyzed patients receiving four-hour intravenous diuretic sessions, which included an initial bolus followed by a tailored continuous infusion protocol. The research focused on advanced heart failure patients with frequent hospital admissions, representing a challenging clinical population. Understanding these determinants is crucial for optimizing diuretic response in an outpatient setting, potentially reducing hospitalization rates and improving patient care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transcatheter aortic valve replacement, Heart failure, Low-dose colchicine, allograft recovery, pericoronary inflammation, computed tomography angiography, ambulatory care, donor organ procurement, transcatheter treatment, chronic coronary disease, aortic stenosis, loop diuretics, left-sided valvular heart disease, natriuresis, diuresis, aortic valve disease, intravenous diuretics, physician assistant, coronary plaque, Tricuspid regurgitation, clinical outcomes, upper gastrointestinal bleeding, antiplatelet therapy, Heart transplantation, mitral valve disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/">PA-Led Heart Transplant Recovery: Safe, Effective 11/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251115_060029.mp3" length="4693097" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Heart failure. Key takeaway: PA-Led Heart Transplant Recovery: Safe, Effective.
Article Links:
Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. (Heart (British Cardiac Society))
Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. (Heart (British Cardiac Society))
Article 4: Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention. (Heart (British Cardiac Society))
Article 5: Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/
 Featured Articles
Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41238023
Summary: This observational cohort study assessed the clinical outcomes and programmatic benefits of a physician assistant-led allograft recovery model for adult heart transplantation. Researchers compared 130 transplantations using physician assistant teams with 367 using non-physician assistant teams at a high-volume center between 2020 and 2024. The implementation of this physician assistant-led model for donor organ recovery demonstrated comparable clinical outcomes for heart transplantation recipients. This model offers significant programmatic advantages, potentially enhancing efficiency and resource utilization within heart transplantation programs.
Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40393691
Summary: This subanalysis of the Low-Dose Colchicine 2 Trial aimed to investigate the effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition. Researchers performed cross-sectional computed tomography angiography studies in 151 participants with chronic coronary disease. The primary objective was to understand the underlying mechanisms by which low-dose colchicine, administered at 0.5 mg once daily, reduces the risk of major cardiovascular events. This study established a methodology to assess how colchicine may exert its beneficial anti-inflammatory actions on coronary arteries.
Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40348411
Summary: This prospective registry study investigated the incidence, predictors, and clinical impact of late upper gastrointestinal bleeding following transcatheter aortic valve replacement. Researchers analyzed 3144 patients, stratifying them based on the occurrence of upper gastrointestinal bleeding within one year of hospital discharge. The study characterized the frequency of this complication in transcatheter aortic valve replacement patients and identi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Heart failure. Key takeaway: PA-Led Heart Transplant Recovery: Safe, Effective.
Article Links:
Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. (Heart (British Cardiac Society))
Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. (Heart (British Cardiac Society))
Article 4: Incidence, predictors and outcomes of tricusp]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Sacubitril-Valsartan for Chemo Cardiotoxicity 11/14/25</title>
	<link>https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/</link>
	<pubDate>Fri, 14 Nov 2025 11:02:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41159885">Deferring Arterial Catheterization in Critically Ill Patients with Shock.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41230611">Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40879135">Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40737218">Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41224486">Exploring postmortem practices for cardiac device interrogation in the UK.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/">https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159885" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159885</a></p>
<p><strong>Summary:</strong> This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study&#8217;s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.</p>
<h4>Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41230611" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41230611</a></p>
<p><strong>Summary:</strong> The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.</p>
<h4>Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879135</a></p>
<p><strong>Summary:</strong> The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.</p>
<h4>Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40737218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40737218</a></p>
<p><strong>Summary:</strong> This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.</p>
<h4>Article 5: Exploring postmortem practices for cardiac device interrogation in the UK.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41224486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41224486</a></p>
<p><strong>Summary:</strong> This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Deferring Arterial Catheterization in Critically Ill Patients with Shock. This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study&#8217;s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.</p>
<p>Article number two. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.</p>
<p>Article number three. Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.</p>
<p>Article number four. Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.</p>
<p>Article number five. Exploring postmortem practices for cardiac device interrogation in the UK. This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ischemic cardiomyopathy, ventricular tachycardia, postmortem, anthracycline cardiotoxicity, arterial catheterization, chemotherapy, heart failure with reduced ejection fraction, sudden death, intensive care unit, shock, cardiac device interrogation, noninvasive blood pressure monitoring, sudden cardiac death, cardiac troponin I, wearable cardioverter-defibrillator, heart failure hospitalization, cardiac implantable electronic device, non-ischemic cardiomyopathy, kidney function, prognosis, critically ill patients, sacubitril-valsartan, coroners, cardioprotection, estimated glomerular filtration rate.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/">Sacubitril-Valsartan for Chemo Cardiotoxicity 11/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity.
Article Links:
Art]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41159885">Deferring Arterial Catheterization in Critically Ill Patients with Shock.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41230611">Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40879135">Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40737218">Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41224486">Exploring postmortem practices for cardiac device interrogation in the UK.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/">https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159885" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159885</a></p>
<p><strong>Summary:</strong> This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study&#8217;s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.</p>
<h4>Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41230611" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41230611</a></p>
<p><strong>Summary:</strong> The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.</p>
<h4>Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879135</a></p>
<p><strong>Summary:</strong> The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.</p>
<h4>Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40737218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40737218</a></p>
<p><strong>Summary:</strong> This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.</p>
<h4>Article 5: Exploring postmortem practices for cardiac device interrogation in the UK.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41224486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41224486</a></p>
<p><strong>Summary:</strong> This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Deferring Arterial Catheterization in Critically Ill Patients with Shock. This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study&#8217;s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.</p>
<p>Article number two. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.</p>
<p>Article number three. Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.</p>
<p>Article number four. Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.</p>
<p>Article number five. Exploring postmortem practices for cardiac device interrogation in the UK. This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ischemic cardiomyopathy, ventricular tachycardia, postmortem, anthracycline cardiotoxicity, arterial catheterization, chemotherapy, heart failure with reduced ejection fraction, sudden death, intensive care unit, shock, cardiac device interrogation, noninvasive blood pressure monitoring, sudden cardiac death, cardiac troponin I, wearable cardioverter-defibrillator, heart failure hospitalization, cardiac implantable electronic device, non-ischemic cardiomyopathy, kidney function, prognosis, critically ill patients, sacubitril-valsartan, coroners, cardioprotection, estimated glomerular filtration rate.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/">Sacubitril-Valsartan for Chemo Cardiotoxicity 11/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251114_060059.mp3" length="4739073" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity.
Article Links:
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. (The New England journal of medicine)
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. (Circulation)
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. (European heart journal)
Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. (European heart journal)
Article 5: Exploring postmortem practices for cardiac device interrogation in the UK. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/
 Featured Articles
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159885
Summary: This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study&#8217;s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41230611
Summary: The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879135
Summary: The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator u]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity.
Article Links:
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. (The New England journal of medicine)
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. (Circulation)
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. (European heart journal)
Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. (European heart journal)
Article 5:]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>N-Palmitoyl Glutamine: Fitness Mediator 11/13/25</title>
	<link>https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/</link>
	<pubDate>Thu, 13 Nov 2025 11:01:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41221593">Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41221589">N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41222955">Cellular and molecular imaging of coronary atherosclerosis: clinical applications.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41224169">Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.</a> (Journal of cardiac failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41222953">Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/">https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41221593" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41221593</a></p>
<p><strong>Summary:</strong> This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.</p>
<h4>Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41221589" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41221589</a></p>
<p><strong>Summary:</strong> This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.</p>
<h4>Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41222955" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41222955</a></p>
<p><strong>Summary:</strong> This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.</p>
<h4>Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41224169" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41224169</a></p>
<p><strong>Summary:</strong> This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.</p>
<h4>Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41222953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41222953</a></p>
<p><strong>Summary:</strong> This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.</p>
<p>Article number two. N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.</p>
<p>Article number three. Cellular and molecular imaging of coronary atherosclerosis: clinical applications. This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.</p>
<p>Article number four. Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.</p>
<p>Article number five. Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pediatric cardiology, subclinical atrial fibrillation, cardiac magnetic resonance, major bleeding, waitlist outcomes, cardiometabolic health, heart transplant, aspirin, apixaban, cellular imaging, atherosclerosis, metabolomics, congenital heart disease, ARTESiA trial, prognosis, risk stratification, atheroma, cardiorespiratory fitness, tricuspid regurgitant fraction, Fontan circulation, plasma, molecular imaging, tricuspid regurgitation, N-Palmitoyl Glutamine, coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/">N-Palmitoyl Glutamine: Fitness Mediator 11/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41221593">Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41221589">N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41222955">Cellular and molecular imaging of coronary atherosclerosis: clinical applications.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41224169">Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.</a> (Journal of cardiac failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41222953">Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/">https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41221593" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41221593</a></p>
<p><strong>Summary:</strong> This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.</p>
<h4>Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41221589" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41221589</a></p>
<p><strong>Summary:</strong> This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.</p>
<h4>Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41222955" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41222955</a></p>
<p><strong>Summary:</strong> This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.</p>
<h4>Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41224169" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41224169</a></p>
<p><strong>Summary:</strong> This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.</p>
<h4>Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41222953" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41222953</a></p>
<p><strong>Summary:</strong> This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.</p>
<p>Article number two. N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.</p>
<p>Article number three. Cellular and molecular imaging of coronary atherosclerosis: clinical applications. This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.</p>
<p>Article number four. Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized patients by diagnosis, including Fontan circulation, non-Fontan congenital heart disease, and cardiomyopathy. This analysis established vital outcome trends, highlighting that Fontan patients represent a growing and high-risk cohort among heart transplant candidates, offering crucial guidance for clinical decision-making.</p>
<p>Article number five. Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. This prespecified subanalysis of the ARTESiA randomized clinical trial characterized major bleeding events associated with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation. The main ARTESiA trial previously demonstrated that apixaban reduced stroke and systemic embolism but increased major bleeding compared with aspirin. This subanalysis specifically aimed to detail the site and severity of these major bleeding events and identify associated factors. It provided important information on the specific bleeding risks to consider when treating patients with subclinical atrial fibrillation with apixaban. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pediatric cardiology, subclinical atrial fibrillation, cardiac magnetic resonance, major bleeding, waitlist outcomes, cardiometabolic health, heart transplant, aspirin, apixaban, cellular imaging, atherosclerosis, metabolomics, congenital heart disease, ARTESiA trial, prognosis, risk stratification, atheroma, cardiorespiratory fitness, tricuspid regurgitant fraction, Fontan circulation, plasma, molecular imaging, tricuspid regurgitation, N-Palmitoyl Glutamine, coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/">N-Palmitoyl Glutamine: Fitness Mediator 11/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251113_060031.mp3" length="4286423" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator.
Article Links:
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. (Circulation)
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. (Circulation)
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications. (European heart journal)
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. (Journal of cardiac failure)
Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/
 Featured Articles
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221593
Summary: This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation.
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221589
Summary: This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits.
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222955
Summary: This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies.
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224169
Summary: This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator.
Article Links:
Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. (Circulation)
Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. (Circulation)
Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications. (European heart journal)
Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. (Journal of cardiac failure)
Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/
 Feature]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Angina Endotypes: Precision Treatment Advances 11/12/25</title>
	<link>https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/</link>
	<pubDate>Wed, 12 Nov 2025 11:01:15 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like monotherapy and exercise hemodynamics. Key takeaway: Angina Endotypes: Precision Treatment Advances.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41208706">miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41217874">Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41214896">Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41211721">Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41213849">Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study.</a> (Journal of cardiac failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/">https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41208706" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41208706</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms by which myocardial infarction triggers myelopoiesis and exacerbates disease pathology. Researchers induced myocardial infarction in mice and found that platelet-derived extracellular vesicles containing micro-R. N. A. minus 499 augmented inflammatory cell generation and cardiac remodeling. This discovery indicates that micro-R. N. A. minus 499 from platelet extracellular vesicles plays a critical role in promoting adverse cardiac remodeling and identifies a potential therapeutic target.</p>
<h4>Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41217874" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41217874</a></p>
<p><strong>Summary:</strong> This research explored the role of adaptive immune responses in human atherosclerosis progression. Using R. N. A. sequencing and immunohistochemistry on human atherosclerotic plaques, the study revealed that enhanced antigen presentation by macrophages promotes the disease. This finding highlights the critical involvement of macrophage-driven immune responses in atherosclerosis pathology and suggests novel therapeutic strategies targeting this pathway.</p>
<h4>Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41214896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41214896</a></p>
<p><strong>Summary:</strong> This prospective multicenter study aimed to better diagnose and treat angina with non-obstructive coronary arteries, a prevalent myocardial ischemic syndrome. Researchers enrolled consecutive patients undergoing coronary functional testing across nine centers to identify distinct hemodynamic endotypes. The study successfully stratified patients into these endotypes, demonstrating differential responses to specific treatments and thereby establishing a foundation for a precision medicine approach.</p>
<h4>Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211721" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211721</a></p>
<p><strong>Summary:</strong> While aspirin has been the traditional cornerstone antiplatelet therapy, the review highlights emerging evidence suggesting P2Y12 inhibitors may be more than just an alternative. The findings suggest that P2Y12 inhibitors may be preferred over aspirin as a single antiplatelet agent, offering a significant therapeutic consideration for clinicians.</p>
<h4>Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41213849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41213849</a></p>
<p><strong>Summary:</strong> This multicenter study investigated the clinical significance of moderate to severe tricuspid regurgitation during evaluation for unexplained dyspnea. Researchers assessed 258 patients with exercise heart failure with preserved ejection fraction using exercise right heart catheterization. They found that moderate to severe tricuspid regurgitation was independently associated with worse exercise capacity and adverse five-year clinical outcomes, underscoring its prognostic importance in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. This study investigated the mechanisms by which myocardial infarction triggers myelopoiesis and exacerbates disease pathology. Researchers induced myocardial infarction in mice and found that platelet-derived extracellular vesicles containing micro-R. N. A. minus 499 augmented inflammatory cell generation and cardiac remodeling. This discovery indicates that micro-R. N. A. minus 499 from platelet extracellular vesicles plays a critical role in promoting adverse cardiac remodeling and identifies a potential therapeutic target.</p>
<p>Article number two. Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications. This research explored the role of adaptive immune responses in human atherosclerosis progression. Using R. N. A. sequencing and immunohistochemistry on human atherosclerotic plaques, the study revealed that enhanced antigen presentation by macrophages promotes the disease. This finding highlights the critical involvement of macrophage-driven immune responses in atherosclerosis pathology and suggests novel therapeutic strategies targeting this pathway.</p>
<p>Article number three. Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. This prospective multicenter study aimed to better diagnose and treat angina with non-obstructive coronary arteries, a prevalent myocardial ischemic syndrome. Researchers enrolled consecutive patients undergoing coronary functional testing across nine centers to identify distinct hemodynamic endotypes. The study successfully stratified patients into these endotypes, demonstrating differential responses to specific treatments and thereby establishing a foundation for a precision medicine approach.</p>
<p>Article number four. Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? This review examined the current evidence comparing aspirin and P2Y12 inhibitor monotherapy for the long-term management of atherosclerotic cardiovascular disease. While aspirin has been the traditional cornerstone antiplatelet therapy, the review highlights emerging evidence suggesting P2Y12 inhibitors may be more than just an alternative. The findings suggest that P2Y12 inhibitors may be preferred over aspirin as a single antiplatelet agent, offering a significant therapeutic consideration for clinicians.</p>
<p>Article number five. Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study. This multicenter study investigated the clinical significance of moderate to severe tricuspid regurgitation during evaluation for unexplained dyspnea. Researchers assessed 258 patients with exercise heart failure with preserved ejection fraction using exercise right heart catheterization. They found that moderate to severe tricuspid regurgitation was independently associated with worse exercise capacity and adverse five-year clinical outcomes, underscoring its prognostic importance in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>monotherapy, exercise hemodynamics, adaptive immune response, aspirin, macrophages, atherosclerosis, prognostic indicator, heart failure with preserved ejection fraction, antigen presentation, P2Y12 inhibitors, atherosclerotic cardiovascular disease, platelet-derived extracellular vesicles, endotypes, precision medicine, T cells, myocardial ischemia, coronary functional testing, myelopoiesis, dyspnea, antiplatelet therapy, angina with non-obstructive coronary arteries, myocardial infarction, micro-R. N. A. minus 499, cardiac remodeling, tricuspid regurgitation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/">Angina Endotypes: Precision Treatment Advances 11/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like monotherapy and exercise hemodynamics. Key takeaway: Angina Endotypes: Precision Treatment Advances.
Article Links:
Article 1: miR-4]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like monotherapy and exercise hemodynamics. Key takeaway: Angina Endotypes: Precision Treatment Advances.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41208706">miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41217874">Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41214896">Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41211721">Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41213849">Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study.</a> (Journal of cardiac failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/">https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41208706" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41208706</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms by which myocardial infarction triggers myelopoiesis and exacerbates disease pathology. Researchers induced myocardial infarction in mice and found that platelet-derived extracellular vesicles containing micro-R. N. A. minus 499 augmented inflammatory cell generation and cardiac remodeling. This discovery indicates that micro-R. N. A. minus 499 from platelet extracellular vesicles plays a critical role in promoting adverse cardiac remodeling and identifies a potential therapeutic target.</p>
<h4>Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41217874" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41217874</a></p>
<p><strong>Summary:</strong> This research explored the role of adaptive immune responses in human atherosclerosis progression. Using R. N. A. sequencing and immunohistochemistry on human atherosclerotic plaques, the study revealed that enhanced antigen presentation by macrophages promotes the disease. This finding highlights the critical involvement of macrophage-driven immune responses in atherosclerosis pathology and suggests novel therapeutic strategies targeting this pathway.</p>
<h4>Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41214896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41214896</a></p>
<p><strong>Summary:</strong> This prospective multicenter study aimed to better diagnose and treat angina with non-obstructive coronary arteries, a prevalent myocardial ischemic syndrome. Researchers enrolled consecutive patients undergoing coronary functional testing across nine centers to identify distinct hemodynamic endotypes. The study successfully stratified patients into these endotypes, demonstrating differential responses to specific treatments and thereby establishing a foundation for a precision medicine approach.</p>
<h4>Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211721" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211721</a></p>
<p><strong>Summary:</strong> While aspirin has been the traditional cornerstone antiplatelet therapy, the review highlights emerging evidence suggesting P2Y12 inhibitors may be more than just an alternative. The findings suggest that P2Y12 inhibitors may be preferred over aspirin as a single antiplatelet agent, offering a significant therapeutic consideration for clinicians.</p>
<h4>Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41213849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41213849</a></p>
<p><strong>Summary:</strong> This multicenter study investigated the clinical significance of moderate to severe tricuspid regurgitation during evaluation for unexplained dyspnea. Researchers assessed 258 patients with exercise heart failure with preserved ejection fraction using exercise right heart catheterization. They found that moderate to severe tricuspid regurgitation was independently associated with worse exercise capacity and adverse five-year clinical outcomes, underscoring its prognostic importance in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. This study investigated the mechanisms by which myocardial infarction triggers myelopoiesis and exacerbates disease pathology. Researchers induced myocardial infarction in mice and found that platelet-derived extracellular vesicles containing micro-R. N. A. minus 499 augmented inflammatory cell generation and cardiac remodeling. This discovery indicates that micro-R. N. A. minus 499 from platelet extracellular vesicles plays a critical role in promoting adverse cardiac remodeling and identifies a potential therapeutic target.</p>
<p>Article number two. Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications. This research explored the role of adaptive immune responses in human atherosclerosis progression. Using R. N. A. sequencing and immunohistochemistry on human atherosclerotic plaques, the study revealed that enhanced antigen presentation by macrophages promotes the disease. This finding highlights the critical involvement of macrophage-driven immune responses in atherosclerosis pathology and suggests novel therapeutic strategies targeting this pathway.</p>
<p>Article number three. Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. This prospective multicenter study aimed to better diagnose and treat angina with non-obstructive coronary arteries, a prevalent myocardial ischemic syndrome. Researchers enrolled consecutive patients undergoing coronary functional testing across nine centers to identify distinct hemodynamic endotypes. The study successfully stratified patients into these endotypes, demonstrating differential responses to specific treatments and thereby establishing a foundation for a precision medicine approach.</p>
<p>Article number four. Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? This review examined the current evidence comparing aspirin and P2Y12 inhibitor monotherapy for the long-term management of atherosclerotic cardiovascular disease. While aspirin has been the traditional cornerstone antiplatelet therapy, the review highlights emerging evidence suggesting P2Y12 inhibitors may be more than just an alternative. The findings suggest that P2Y12 inhibitors may be preferred over aspirin as a single antiplatelet agent, offering a significant therapeutic consideration for clinicians.</p>
<p>Article number five. Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study. This multicenter study investigated the clinical significance of moderate to severe tricuspid regurgitation during evaluation for unexplained dyspnea. Researchers assessed 258 patients with exercise heart failure with preserved ejection fraction using exercise right heart catheterization. They found that moderate to severe tricuspid regurgitation was independently associated with worse exercise capacity and adverse five-year clinical outcomes, underscoring its prognostic importance in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>monotherapy, exercise hemodynamics, adaptive immune response, aspirin, macrophages, atherosclerosis, prognostic indicator, heart failure with preserved ejection fraction, antigen presentation, P2Y12 inhibitors, atherosclerotic cardiovascular disease, platelet-derived extracellular vesicles, endotypes, precision medicine, T cells, myocardial ischemia, coronary functional testing, myelopoiesis, dyspnea, antiplatelet therapy, angina with non-obstructive coronary arteries, myocardial infarction, micro-R. N. A. minus 499, cardiac remodeling, tricuspid regurgitation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/">Angina Endotypes: Precision Treatment Advances 11/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251112_060019.mp3" length="4003465" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like monotherapy and exercise hemodynamics. Key takeaway: Angina Endotypes: Precision Treatment Advances.
Article Links:
Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. (Circulation)
Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications. (European heart journal)
Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. (European heart journal)
Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? (European heart journal)
Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study. (Journal of cardiac failure)
Full episode page: https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/
 Featured Articles
Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41208706
Summary: This study investigated the mechanisms by which myocardial infarction triggers myelopoiesis and exacerbates disease pathology. Researchers induced myocardial infarction in mice and found that platelet-derived extracellular vesicles containing micro-R. N. A. minus 499 augmented inflammatory cell generation and cardiac remodeling. This discovery indicates that micro-R. N. A. minus 499 from platelet extracellular vesicles plays a critical role in promoting adverse cardiac remodeling and identifies a potential therapeutic target.
Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217874
Summary: This research explored the role of adaptive immune responses in human atherosclerosis progression. Using R. N. A. sequencing and immunohistochemistry on human atherosclerotic plaques, the study revealed that enhanced antigen presentation by macrophages promotes the disease. This finding highlights the critical involvement of macrophage-driven immune responses in atherosclerosis pathology and suggests novel therapeutic strategies targeting this pathway.
Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41214896
Summary: This prospective multicenter study aimed to better diagnose and treat angina with non-obstructive coronary arteries, a prevalent myocardial ischemic syndrome. Researchers enrolled consecutive patients undergoing coronary functional testing across nine centers to identify distinct hemodynamic endotypes. The study successfully stratified patients into these endotypes, demonstrating differential responses to specific treatments and thereby establishing a foundation for a precision medicine approach.
Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211721
Summary: While aspirin has been the traditional cornerstone antiplatelet therapy, the review highlights emerging evidence suggesting P2Y12 inhibitors may be more than just an alternative. The findings suggest that P2Y12 inhibitors may be preferred over aspirin as a single antiplatelet agent, offering a significant therapeutic consideration for clinicians.
Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved E]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like monotherapy and exercise hemodynamics. Key takeaway: Angina Endotypes: Precision Treatment Advances.
Article Links:
Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. (Circulation)
Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications. (European heart journal)
Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. (European heart journal)
Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? (European heart journal)
Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study. (Jou]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Oral Bacteria Worsen Heart Attacks via B2 Cells 11/12/25</title>
	<link>https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/</link>
	<pubDate>Wed, 12 Nov 2025 09:35:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via B2 Cells.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41217319">Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40859845">Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41212997">Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41212981">High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41212178">Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/">https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41217319" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41217319</a></p>
<p><strong>Summary:</strong> The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).</p>
<h4>Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40859845" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40859845</a></p>
<p><strong>Summary:</strong> This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.</p>
<h4>Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41212997" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41212997</a></p>
<p><strong>Summary:</strong> This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.</p>
<h4>Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41212981" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41212981</a></p>
<p><strong>Summary:</strong> Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.</p>
<h4>Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41212178" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41212178</a></p>
<p><strong>Summary:</strong> The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).</p>
<p>Article number two. Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.</p>
<p>Article number three. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.</p>
<p>Article number four. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.</p>
<p>Article number five. Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>proprotein convertase subtilisin/kexin 9 inhibitor, cardiovascular outcomes, influenza vaccine, oral pathobionts, Coramitug, B2 cells, high-dose influenza vaccine, lipoprotein(a), FLUNITY-HD, phase two trial, cardiac allograft vasculopathy, MESA, older adults, alirocumab, inflammation, atherosclerotic cardiovascular disease, periodontitis, interleukin-6, heart transplantation, risk stratification, CAVIAR trial, transthyretin amyloid cardiomyopathy, monoclonal antibody, amyloid clearance, myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/">Oral Bacteria Worsen Heart Attacks via B2 Cells 11/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via B2 Cells.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41217319">Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40859845">Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41212997">Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41212981">High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41212178">Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/">https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41217319" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41217319</a></p>
<p><strong>Summary:</strong> The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).</p>
<h4>Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40859845" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40859845</a></p>
<p><strong>Summary:</strong> This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.</p>
<h4>Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41212997" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41212997</a></p>
<p><strong>Summary:</strong> This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.</p>
<h4>Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41212981" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41212981</a></p>
<p><strong>Summary:</strong> Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.</p>
<h4>Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41212178" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41212178</a></p>
<p><strong>Summary:</strong> The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).</p>
<p>Article number two. Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.</p>
<p>Article number three. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.</p>
<p>Article number four. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.</p>
<p>Article number five. Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>proprotein convertase subtilisin/kexin 9 inhibitor, cardiovascular outcomes, influenza vaccine, oral pathobionts, Coramitug, B2 cells, high-dose influenza vaccine, lipoprotein(a), FLUNITY-HD, phase two trial, cardiac allograft vasculopathy, MESA, older adults, alirocumab, inflammation, atherosclerotic cardiovascular disease, periodontitis, interleukin-6, heart transplantation, risk stratification, CAVIAR trial, transthyretin amyloid cardiomyopathy, monoclonal antibody, amyloid clearance, myocardial infarction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/">Oral Bacteria Worsen Heart Attacks via B2 Cells 11/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251112_043437.mp3" length="4810544" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via B2 Cells.
Article Links:
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. (Journal of the American College of Cardiology)
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. (Circulation)
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. (Circulation)
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. (Circulation)
Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/
 Featured Articles
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217319
Summary: The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40859845
Summary: This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212997
Summary: This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212981
Summary: Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in O]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via B2 Cells.
Article Links:
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. (Journal of the American College of Cardiology)
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. (Circulation)
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. (Circulation)
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. (Circulation)
Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. (Circ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Optimize Mitral Repair: Gradients &#038; Regurgitation 11/11/25</title>
	<link>https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/</link>
	<pubDate>Tue, 11 Nov 2025 15:27:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like congenital heart disease and transmitral mean pressure gradient. Key takeaway: Optimize Mitral Repair: Gradients &#038; Regurgitation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41211917">Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41193094">Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41193091">Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41193089">Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40886174">Computed Tomography Angiography or Standard Care After Left Main PCI?</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/">https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211917" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211917</a></p>
<p><strong>Summary:</strong> This multicenter, randomized, open-label, noninferiority trial in South Korea investigated non-vitamin K antagonist oral anticoagulant monotherapy compared to combination therapy. The study enrolled patients with atrial fibrillation who had received a drug-eluting stent at least one year prior. This research aims to provide crucial data to guide antithrombotic management after drug-eluting stent implantation in patients with atrial fibrillation, addressing current limitations in evidence-based guidelines. The primary objective is to determine if non-vitamin K antagonist oral anticoagulant monotherapy is noninferior to combination therapy for these specific patients.</p>
<h4>Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41193094" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41193094</a></p>
<p><strong>Summary:</strong> This study conducted a secondary analysis to evaluate the effectiveness and safety of risk stratification using high-sensitivity cardiac troponin in the emergency department. While high-sensitivity cardiac troponin pathways are known to reduce length of stay and hospital admissions for myocardial infarction rule-out, this research aimed to confirm these benefits across low and intermediate risk patients. It also sought to ascertain if patients discharged were accurately identified as having a low risk of future cardiovascular events, thereby ensuring patient safety and appropriate resource utilization.</p>
<h4>Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41193091" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41193091</a></p>
<p><strong>Summary:</strong> This study investigated the impact of placental malperfusion on outcomes in fetuses diagnosed with congenital heart disease. It aimed to determine if congenital heart disease fetuses with placental malperfusion experience adverse outcomes and exhibit genomic variations in shared vascular or placental developmental pathways. This research contributes to understanding the complex interplay between placental health and fetal cardiac development, potentially identifying novel risk factors and mechanisms. This foundational work could lead to improved risk stratification and targeted interventions for congenital heart disease.</p>
<h4>Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41193089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41193089</a></p>
<p><strong>Summary:</strong> This study aimed to clarify the clinical significance of both mitral regurgitation reduction and transmitral mean pressure gradient elevation following mitral transcatheter edge-to-edge repair. Researchers evaluated 2360 patients with functional mitral regurgitation using post-discharge echocardiography. The objective was to understand the relationship between transmitral mean pressure gradient and patient outcomes, addressing a controversial area in post-procedural management. This research is crucial for optimizing procedural goals and improving patient selection to enhance long-term results after mitral transcatheter edge-to-edge repair.</p>
<h4>Article 5: Computed Tomography Angiography or Standard Care After Left Main PCI?</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886174" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886174</a></p>
<p><strong>Summary:</strong> Enrolling 606 patients treated with second-generation drug-eluting stents, the study aimed to compare coronary computed tomography angiography-guided follow-up against symptoms- or ischemia-driven care. This research seeks to clarify whether routine imaging improves clinical outcomes, providing valuable evidence for optimal post-percutaneous coronary intervention surveillance protocols in this high-risk population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. This multicenter, randomized, open-label, noninferiority trial in South Korea investigated non-vitamin K antagonist oral anticoagulant monotherapy compared to combination therapy. The study enrolled patients with atrial fibrillation who had received a drug-eluting stent at least one year prior. This research aims to provide crucial data to guide antithrombotic management after drug-eluting stent implantation in patients with atrial fibrillation, addressing current limitations in evidence-based guidelines. The primary objective is to determine if non-vitamin K antagonist oral anticoagulant monotherapy is noninferior to combination therapy for these specific patients.</p>
<p>Article number two. Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis. This study conducted a secondary analysis to evaluate the effectiveness and safety of risk stratification using high-sensitivity cardiac troponin in the emergency department. While high-sensitivity cardiac troponin pathways are known to reduce length of stay and hospital admissions for myocardial infarction rule-out, this research aimed to confirm these benefits across low and intermediate risk patients. It also sought to ascertain if patients discharged were accurately identified as having a low risk of future cardiovascular events, thereby ensuring patient safety and appropriate resource utilization.</p>
<p>Article number three. Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways. This study investigated the impact of placental malperfusion on outcomes in fetuses diagnosed with congenital heart disease. It aimed to determine if congenital heart disease fetuses with placental malperfusion experience adverse outcomes and exhibit genomic variations in shared vascular or placental developmental pathways. This research contributes to understanding the complex interplay between placental health and fetal cardiac development, potentially identifying novel risk factors and mechanisms. This foundational work could lead to improved risk stratification and targeted interventions for congenital heart disease.</p>
<p>Article number four. Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair. This study aimed to clarify the clinical significance of both mitral regurgitation reduction and transmitral mean pressure gradient elevation following mitral transcatheter edge-to-edge repair. Researchers evaluated 2360 patients with functional mitral regurgitation using post-discharge echocardiography. The objective was to understand the relationship between transmitral mean pressure gradient and patient outcomes, addressing a controversial area in post-procedural management. This research is crucial for optimizing procedural goals and improving patient selection to enhance long-term results after mitral transcatheter edge-to-edge repair.</p>
<p>Article number five. Computed Tomography Angiography or Standard Care After Left Main PCI? The PULSE trial, a prospective, multicenter, open-label randomized study, investigated the clinical benefit of routine coronary computed tomography angiography following percutaneous coronary intervention for unprotected left main disease. Enrolling 606 patients treated with second-generation drug-eluting stents, the study aimed to compare coronary computed tomography angiography-guided follow-up against symptoms- or ischemia-driven care. This research seeks to clarify whether routine imaging improves clinical outcomes, providing valuable evidence for optimal post-percutaneous coronary intervention surveillance protocols in this high-risk population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>congenital heart disease, transmitral mean pressure gradient, fetal development, surveillance, genomic variation, clinical outcomes, placental malperfusion, risk stratification, coronary computed tomography angiography, echocardiography, functional mitral regurgitation, high-sensitivity cardiac troponin, cardiovascular events, mitral regurgitation, percutaneous coronary intervention, antithrombotic therapy, myocardial infarction, left main disease, adverse outcomes, non-vitamin K antagonist oral anticoagulant, atrial fibrillation, mitral transcatheter edge-to-edge repair, emergency department, drug-eluting stent.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/">Optimize Mitral Repair: Gradients & Regurgitation 11/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like congenital heart disease and transmitral mean pressure gradient. Key takeaway: Optimize Mitral Repair: Gradients &#038; Regurgitatio]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like congenital heart disease and transmitral mean pressure gradient. Key takeaway: Optimize Mitral Repair: Gradients &#038; Regurgitation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41211917">Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41193094">Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41193091">Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41193089">Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40886174">Computed Tomography Angiography or Standard Care After Left Main PCI?</a> (Journal of the American College of Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/">https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211917" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211917</a></p>
<p><strong>Summary:</strong> This multicenter, randomized, open-label, noninferiority trial in South Korea investigated non-vitamin K antagonist oral anticoagulant monotherapy compared to combination therapy. The study enrolled patients with atrial fibrillation who had received a drug-eluting stent at least one year prior. This research aims to provide crucial data to guide antithrombotic management after drug-eluting stent implantation in patients with atrial fibrillation, addressing current limitations in evidence-based guidelines. The primary objective is to determine if non-vitamin K antagonist oral anticoagulant monotherapy is noninferior to combination therapy for these specific patients.</p>
<h4>Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41193094" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41193094</a></p>
<p><strong>Summary:</strong> This study conducted a secondary analysis to evaluate the effectiveness and safety of risk stratification using high-sensitivity cardiac troponin in the emergency department. While high-sensitivity cardiac troponin pathways are known to reduce length of stay and hospital admissions for myocardial infarction rule-out, this research aimed to confirm these benefits across low and intermediate risk patients. It also sought to ascertain if patients discharged were accurately identified as having a low risk of future cardiovascular events, thereby ensuring patient safety and appropriate resource utilization.</p>
<h4>Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41193091" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41193091</a></p>
<p><strong>Summary:</strong> This study investigated the impact of placental malperfusion on outcomes in fetuses diagnosed with congenital heart disease. It aimed to determine if congenital heart disease fetuses with placental malperfusion experience adverse outcomes and exhibit genomic variations in shared vascular or placental developmental pathways. This research contributes to understanding the complex interplay between placental health and fetal cardiac development, potentially identifying novel risk factors and mechanisms. This foundational work could lead to improved risk stratification and targeted interventions for congenital heart disease.</p>
<h4>Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41193089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41193089</a></p>
<p><strong>Summary:</strong> This study aimed to clarify the clinical significance of both mitral regurgitation reduction and transmitral mean pressure gradient elevation following mitral transcatheter edge-to-edge repair. Researchers evaluated 2360 patients with functional mitral regurgitation using post-discharge echocardiography. The objective was to understand the relationship between transmitral mean pressure gradient and patient outcomes, addressing a controversial area in post-procedural management. This research is crucial for optimizing procedural goals and improving patient selection to enhance long-term results after mitral transcatheter edge-to-edge repair.</p>
<h4>Article 5: Computed Tomography Angiography or Standard Care After Left Main PCI?</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886174" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886174</a></p>
<p><strong>Summary:</strong> Enrolling 606 patients treated with second-generation drug-eluting stents, the study aimed to compare coronary computed tomography angiography-guided follow-up against symptoms- or ischemia-driven care. This research seeks to clarify whether routine imaging improves clinical outcomes, providing valuable evidence for optimal post-percutaneous coronary intervention surveillance protocols in this high-risk population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. This multicenter, randomized, open-label, noninferiority trial in South Korea investigated non-vitamin K antagonist oral anticoagulant monotherapy compared to combination therapy. The study enrolled patients with atrial fibrillation who had received a drug-eluting stent at least one year prior. This research aims to provide crucial data to guide antithrombotic management after drug-eluting stent implantation in patients with atrial fibrillation, addressing current limitations in evidence-based guidelines. The primary objective is to determine if non-vitamin K antagonist oral anticoagulant monotherapy is noninferior to combination therapy for these specific patients.</p>
<p>Article number two. Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis. This study conducted a secondary analysis to evaluate the effectiveness and safety of risk stratification using high-sensitivity cardiac troponin in the emergency department. While high-sensitivity cardiac troponin pathways are known to reduce length of stay and hospital admissions for myocardial infarction rule-out, this research aimed to confirm these benefits across low and intermediate risk patients. It also sought to ascertain if patients discharged were accurately identified as having a low risk of future cardiovascular events, thereby ensuring patient safety and appropriate resource utilization.</p>
<p>Article number three. Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways. This study investigated the impact of placental malperfusion on outcomes in fetuses diagnosed with congenital heart disease. It aimed to determine if congenital heart disease fetuses with placental malperfusion experience adverse outcomes and exhibit genomic variations in shared vascular or placental developmental pathways. This research contributes to understanding the complex interplay between placental health and fetal cardiac development, potentially identifying novel risk factors and mechanisms. This foundational work could lead to improved risk stratification and targeted interventions for congenital heart disease.</p>
<p>Article number four. Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair. This study aimed to clarify the clinical significance of both mitral regurgitation reduction and transmitral mean pressure gradient elevation following mitral transcatheter edge-to-edge repair. Researchers evaluated 2360 patients with functional mitral regurgitation using post-discharge echocardiography. The objective was to understand the relationship between transmitral mean pressure gradient and patient outcomes, addressing a controversial area in post-procedural management. This research is crucial for optimizing procedural goals and improving patient selection to enhance long-term results after mitral transcatheter edge-to-edge repair.</p>
<p>Article number five. Computed Tomography Angiography or Standard Care After Left Main PCI? The PULSE trial, a prospective, multicenter, open-label randomized study, investigated the clinical benefit of routine coronary computed tomography angiography following percutaneous coronary intervention for unprotected left main disease. Enrolling 606 patients treated with second-generation drug-eluting stents, the study aimed to compare coronary computed tomography angiography-guided follow-up against symptoms- or ischemia-driven care. This research seeks to clarify whether routine imaging improves clinical outcomes, providing valuable evidence for optimal post-percutaneous coronary intervention surveillance protocols in this high-risk population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>congenital heart disease, transmitral mean pressure gradient, fetal development, surveillance, genomic variation, clinical outcomes, placental malperfusion, risk stratification, coronary computed tomography angiography, echocardiography, functional mitral regurgitation, high-sensitivity cardiac troponin, cardiovascular events, mitral regurgitation, percutaneous coronary intervention, antithrombotic therapy, myocardial infarction, left main disease, adverse outcomes, non-vitamin K antagonist oral anticoagulant, atrial fibrillation, mitral transcatheter edge-to-edge repair, emergency department, drug-eluting stent.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/">Optimize Mitral Repair: Gradients & Regurgitation 11/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251111_102645.mp3" length="4346609" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like congenital heart disease and transmitral mean pressure gradient. Key takeaway: Optimize Mitral Repair: Gradients &#038; Regurgitation.
Article Links:
Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. (The New England journal of medicine)
Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis. (Journal of the American College of Cardiology)
Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways. (Journal of the American College of Cardiology)
Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair. (Journal of the American College of Cardiology)
Article 5: Computed Tomography Angiography or Standard Care After Left Main PCI? (Journal of the American College of Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/
 Featured Articles
Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211917
Summary: This multicenter, randomized, open-label, noninferiority trial in South Korea investigated non-vitamin K antagonist oral anticoagulant monotherapy compared to combination therapy. The study enrolled patients with atrial fibrillation who had received a drug-eluting stent at least one year prior. This research aims to provide crucial data to guide antithrombotic management after drug-eluting stent implantation in patients with atrial fibrillation, addressing current limitations in evidence-based guidelines. The primary objective is to determine if non-vitamin K antagonist oral anticoagulant monotherapy is noninferior to combination therapy for these specific patients.
Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41193094
Summary: This study conducted a secondary analysis to evaluate the effectiveness and safety of risk stratification using high-sensitivity cardiac troponin in the emergency department. While high-sensitivity cardiac troponin pathways are known to reduce length of stay and hospital admissions for myocardial infarction rule-out, this research aimed to confirm these benefits across low and intermediate risk patients. It also sought to ascertain if patients discharged were accurately identified as having a low risk of future cardiovascular events, thereby ensuring patient safety and appropriate resource utilization.
Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41193091
Summary: This study investigated the impact of placental malperfusion on outcomes in fetuses diagnosed with congenital heart disease. It aimed to determine if congenital heart disease fetuses with placental malperfusion experience adverse outcomes and exhibit genomic variations in shared vascular or placental developmental pathways. This research contributes to understanding the complex interplay between placental health and fetal cardiac development, potentially identifying novel risk factors and mechanisms. This foundational work could lead to improved risk stratification and targeted interventions for congenital heart disease.
Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After T]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like congenital heart disease and transmitral mean pressure gradient. Key takeaway: Optimize Mitral Repair: Gradients &#038; Regurgitation.
Article Links:
Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. (The New England journal of medicine)
Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis. (Journal of the American College of Cardiology)
Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways. (Journal of the American College of Cardiology)
Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair. (Journal of the American College of Cardiology)
Article 5: Comput]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CRISPR-Cas9 Gene Editing for Lipids 11/11/25</title>
	<link>https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/</link>
	<pubDate>Tue, 11 Nov 2025 11:01:41 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41211954">Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41211945">Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41211931">Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41211925">Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41211918">Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/">https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211954</a></p>
<p><strong>Summary:</strong> This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.</p>
<h4>Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211945" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211945</a></p>
<p><strong>Summary:</strong> This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.</p>
<h4>Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211931" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211931</a></p>
<p><strong>Summary:</strong> This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.</p>
<h4>Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211925" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211925</a></p>
<p><strong>Summary:</strong> This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab&#8217;s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab&#8217;s role in a broader spectrum of cardiovascular risk reduction.</p>
<h4>Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211918" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211918</a></p>
<p><strong>Summary:</strong> Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.</p>
<p>Article number two. Phase 1 Trial of C.R.I.S.P.R.-Cas9 Gene Editing Targeting ANGPTL3. This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.</p>
<p>Article number three. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.</p>
<p>Article number four. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab&#8217;s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab&#8217;s role in a broader spectrum of cardiovascular risk reduction.</p>
<p>Article number five. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>triglycerides, antisense oligonucleotide, C.R.I.S.P.R.-Cas9, P.C.S.K.9 inhibitor, low-density lipoprotein cholesterol, ANGPTL3, myocardial infarction, apolipoprotein C-III, left ventricular ejection fraction, evolocumab, cardiovascular outcomes, hypertriglyceridemia, antithrombotic therapy, C.H.A.2.D.S.2.-V.A.S.c score, beta-blockers, meta-analysis, major adverse cardiovascular events, atrial fibrillation, olezarsen, atherosclerosis, acute pancreatitis, gene editing, primary prevention, oral anticoagulants, catheter ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/">CRISPR-Cas9 Gene Editing for Lipids 11/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids.
Article Links:
Article 1: Beta-Block]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41211954">Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41211945">Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41211931">Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41211925">Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41211918">Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/">https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211954</a></p>
<p><strong>Summary:</strong> This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.</p>
<h4>Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211945" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211945</a></p>
<p><strong>Summary:</strong> This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.</p>
<h4>Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211931" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211931</a></p>
<p><strong>Summary:</strong> This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.</p>
<h4>Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211925" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211925</a></p>
<p><strong>Summary:</strong> This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab&#8217;s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab&#8217;s role in a broader spectrum of cardiovascular risk reduction.</p>
<h4>Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41211918" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41211918</a></p>
<p><strong>Summary:</strong> Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.</p>
<p>Article number two. Phase 1 Trial of C.R.I.S.P.R.-Cas9 Gene Editing Targeting ANGPTL3. This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.</p>
<p>Article number three. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.</p>
<p>Article number four. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab&#8217;s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab&#8217;s role in a broader spectrum of cardiovascular risk reduction.</p>
<p>Article number five. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>triglycerides, antisense oligonucleotide, C.R.I.S.P.R.-Cas9, P.C.S.K.9 inhibitor, low-density lipoprotein cholesterol, ANGPTL3, myocardial infarction, apolipoprotein C-III, left ventricular ejection fraction, evolocumab, cardiovascular outcomes, hypertriglyceridemia, antithrombotic therapy, C.H.A.2.D.S.2.-V.A.S.c score, beta-blockers, meta-analysis, major adverse cardiovascular events, atrial fibrillation, olezarsen, atherosclerosis, acute pancreatitis, gene editing, primary prevention, oral anticoagulants, catheter ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/">CRISPR-Cas9 Gene Editing for Lipids 11/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251111_060024.mp3" length="5092666" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids.
Article Links:
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. (The New England journal of medicine)
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. (The New England journal of medicine)
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (The New England journal of medicine)
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (The New England journal of medicine)
Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/
 Featured Articles
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211954
Summary: This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211945
Summary: This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211931
Summary: This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211925
Summary: This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids.
Article Links:
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. (The New England journal of medicine)
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. (The New England journal of medicine)
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (The New England journal of medicine)
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (The New England journal of medicine)
Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/
 Featured Articles
Article 1: Beta-Blockers after]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aspirin Withdrawal Lowers LVAD Bleeding 11/10/25</title>
	<link>https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/</link>
	<pubDate>Mon, 10 Nov 2025 11:01:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41206792">Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41206679">Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40796244">Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40796241">Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41206888">Clonal Hematopoiesis and Incident Heart Failure.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/">https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206792" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206792</a></p>
<p><strong>Summary:</strong> The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.</p>
<h4>Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206679" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206679</a></p>
<p><strong>Summary:</strong> The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.</p>
<h4>Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40796244" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40796244</a></p>
<p><strong>Summary:</strong> The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.</p>
<h4>Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40796241" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40796241</a></p>
<p><strong>Summary:</strong> The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.</p>
<h4>Article 5: Clonal Hematopoiesis and Incident Heart Failure.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206888" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206888</a></p>
<p><strong>Summary:</strong> This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.</p>
<p>Article number two. Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.</p>
<p>Article number three. Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.</p>
<p>Article number four. Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.</p>
<p>Article number five. Clonal Hematopoiesis and Incident Heart Failure. This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Coronary function testing, sodium-glucose cotransporter two inhibitors, diagnostic pathway, quality of life, heart failure, cardiometabolic diseases, Aspirin, thrombotic events, vitamin K antagonists, coronary vasomotor disorders, driver variants, older adults, bleeding reduction, major hemorrhage, Time in Therapeutic Range, extended follow-up, recurrence prevention, major adverse cardiovascular events, Aspirin withdrawal, angina with non-obstructive coronary arteries, Dapagliflozin, atrial fibrillation, left ventricular assist device, HeartMate three, Clonal hematopoiesis of indeterminate potential, primary prevention, risk stratification, catheter ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/">Aspirin Withdrawal Lowers LVAD Bleeding 11/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding.
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41206792">Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41206679">Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40796244">Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40796241">Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41206888">Clonal Hematopoiesis and Incident Heart Failure.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/">https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206792" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206792</a></p>
<p><strong>Summary:</strong> The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.</p>
<h4>Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206679" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206679</a></p>
<p><strong>Summary:</strong> The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.</p>
<h4>Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40796244" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40796244</a></p>
<p><strong>Summary:</strong> The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.</p>
<h4>Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40796241" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40796241</a></p>
<p><strong>Summary:</strong> The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.</p>
<h4>Article 5: Clonal Hematopoiesis and Incident Heart Failure.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41206888" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41206888</a></p>
<p><strong>Summary:</strong> This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.</p>
<p>Article number two. Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.</p>
<p>Article number three. Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.</p>
<p>Article number four. Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.</p>
<p>Article number five. Clonal Hematopoiesis and Incident Heart Failure. This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Coronary function testing, sodium-glucose cotransporter two inhibitors, diagnostic pathway, quality of life, heart failure, cardiometabolic diseases, Aspirin, thrombotic events, vitamin K antagonists, coronary vasomotor disorders, driver variants, older adults, bleeding reduction, major hemorrhage, Time in Therapeutic Range, extended follow-up, recurrence prevention, major adverse cardiovascular events, Aspirin withdrawal, angina with non-obstructive coronary arteries, Dapagliflozin, atrial fibrillation, left ventricular assist device, HeartMate three, Clonal hematopoiesis of indeterminate potential, primary prevention, risk stratification, catheter ablation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/">Aspirin Withdrawal Lowers LVAD Bleeding 11/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251110_060025.mp3" length="4696859" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding.
Article Links:
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. (Circulation)
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (European heart journal)
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. (European heart journal)
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. (European heart journal)
Article 5: Clonal Hematopoiesis and Incident Heart Failure. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/
 Featured Articles
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206792
Summary: The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206679
Summary: The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796244
Summary: The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.
Journal: European heart journal
PubMed Link: https://pubmed]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding.
Article Links:
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. (Circulation)
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (European heart journal)
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. (European heart journal)
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. (European heart journal)
Article 5: Clonal Hematopoiesis and Incident Hea]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults 11/09/25</title>
	<link>https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/</link>
	<pubDate>Sun, 09 Nov 2025 11:01:18 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 09, 2025. This episode summarizes 5 key cardiology studies on topics like voltage-gated sodium channel and heart failure. Key takeaway: S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41201974">The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure.</a> (Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41200819">FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking.</a> (Circulation research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41196954">The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth.</a> (Circulation research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41090220">Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41090219">Vascular Niches Are the Primary Hotspots in Cardiac Aging.</a> (Circulation research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/">https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41201974" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41201974</a></p>
<p><strong>Summary:</strong> This study investigated the impact of sodium-glucose cotransporter 2 inhibitors on cardiac structure and cardiorenal function in older adults with hypertension and pre-heart failure. Eighty-eight patients were randomized to receive dapagliflozin or conventional treatment. The research evaluated changes in N-terminal pro-brain natriuretic peptide, which is a key biomarker for heart failure, among other indicators. This study contributes to understanding the therapeutic potential of dapagliflozin in preventing heart failure progression in a vulnerable older population.</p>
<h4>Article 2: FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41200819" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41200819</a></p>
<p><strong>Summary:</strong> This research explored the role of fibroblast growth factor homologous factor 13, known as F.G.F.13, in regulating cardiac conduction, specifically examining its influence on connexin 43 gap junctions independent of voltage-gated sodium channels. The study assessed cardiac conduction and cardiomyocyte action potentials in mice lacking F.G.F.13, revealing a novel mechanism by which F.G.F.13 impacts impulse propagation through connexin 43 trafficking. These findings establish a crucial, non-canonical pathway for arrhythmia development and provide a new target for antiarrhythmic strategies.</p>
<h4>Article 3: The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41196954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41196954</a></p>
<p><strong>Summary:</strong> This study investigated how the cytoskeletal protein beta-I.V.-spectrin, in complex with S.T.A.T.3, regulates the orientation of cardiac hypertrophic growth. Researchers evaluated this complex to understand its role in determining whether cardiac hypertrophy manifests as beneficial concentric or detrimental eccentric growth. The findings reveal a key mechanism influencing cardiac remodeling, which is crucial for distinguishing adaptive from maladaptive hypertrophy and potentially guiding future therapeutic interventions for heart failure.</p>
<h4>Article 4: Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41090220" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41090220</a></p>
<p><strong>Summary:</strong> This study examined mitochondrial calcium handling and cellular redox state in atrial fibrillation patients. Researchers isolated cardiac myocytes from patient-derived right atrial biopsies to subject them to workload transitions. The study revealed that atrial fibrillation is associated with impaired atrial mitochondrial calcium handling, identifying a potential new mechanistic target for understanding and treating this common arrhythmia.</p>
<h4>Article 5: Vascular Niches Are the Primary Hotspots in Cardiac Aging.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41090219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41090219</a></p>
<p><strong>Summary:</strong> This research explored the microenvironmental changes within the heart that contribute to age-related cardiac dysfunction, fibrosis, and inflammation. By combining single-nucleus R.N.A. sequencing and spatial transcriptomics in aged mice hearts, the study identified vascular niches as primary hotspots for age-related alterations in cardiac tissue. These findings provide a detailed map of cellular and molecular changes in the aging heart, offering specific targets for interventions to mitigate cardiovascular aging.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure. This study investigated the impact of sodium-glucose cotransporter 2 inhibitors on cardiac structure and cardiorenal function in older adults with hypertension and pre-heart failure. Eighty-eight patients were randomized to receive dapagliflozin or conventional treatment. The research evaluated changes in N-terminal pro-brain natriuretic peptide, which is a key biomarker for heart failure, among other indicators. This study contributes to understanding the therapeutic potential of dapagliflozin in preventing heart failure progression in a vulnerable older population.</p>
<p>Article number two. F.G.F.13 Regulates V.G.S.C.-Independent Cardiomyocyte Impulse Propagation via C.x.43 Trafficking. This research explored the role of fibroblast growth factor homologous factor 13, known as F.G.F.13, in regulating cardiac conduction, specifically examining its influence on connexin 43 gap junctions independent of voltage-gated sodium channels. The study assessed cardiac conduction and cardiomyocyte action potentials in mice lacking F.G.F.13, revealing a novel mechanism by which F.G.F.13 impacts impulse propagation through connexin 43 trafficking. These findings establish a crucial, non-canonical pathway for arrhythmia development and provide a new target for antiarrhythmic strategies.</p>
<p>Article number three. The beta I.V.-Spectrin/S.T.A.T.3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth. This study investigated how the cytoskeletal protein beta-I.V.-spectrin, in complex with S.T.A.T.3, regulates the orientation of cardiac hypertrophic growth. Researchers evaluated this complex to understand its role in determining whether cardiac hypertrophy manifests as beneficial concentric or detrimental eccentric growth. The findings reveal a key mechanism influencing cardiac remodeling, which is crucial for distinguishing adaptive from maladaptive hypertrophy and potentially guiding future therapeutic interventions for heart failure.</p>
<p>Article number four. Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation. This study examined mitochondrial calcium handling and cellular redox state in atrial fibrillation patients. Researchers isolated cardiac myocytes from patient-derived right atrial biopsies to subject them to workload transitions. The study revealed that atrial fibrillation is associated with impaired atrial mitochondrial calcium handling, identifying a potential new mechanistic target for understanding and treating this common arrhythmia.</p>
<p>Article number five. Vascular Niches Are the Primary Hotspots in Cardiac Aging. This research explored the microenvironmental changes within the heart that contribute to age-related cardiac dysfunction, fibrosis, and inflammation. By combining single-nucleus R.N.A. sequencing and spatial transcriptomics in aged mice hearts, the study identified vascular niches as primary hotspots for age-related alterations in cardiac tissue. These findings provide a detailed map of cellular and molecular changes in the aging heart, offering specific targets for interventions to mitigate cardiovascular aging. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>voltage-gated sodium channel, heart failure, N-terminal pro-brain natriuretic peptide, F.G.F.13, cardiac hypertrophy, dapagliflozin, hypertension, cardiac aging, sodium-glucose cotransporter 2 inhibitors, mitochondrial calcium, vascular niches, redox state, pre-heart failure, atrial myocytes, cardiac remodeling, cardiac energetics, fibroblast growth factor homologous factor 13, arrhythmia, connexin 43, cardiac fibrosis, atrial fibrillation, beta-I.V.-spectrin, S.T.A.T.3, spatial transcriptomics, single-nucleus R.N.A. sequencing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/">S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults 11/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 09, 2025. This episode summarizes 5 key cardiology studies on topics like voltage-gated sodium channel and heart failure. Key takeaway: S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults.
Article Links:
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 09, 2025. This episode summarizes 5 key cardiology studies on topics like voltage-gated sodium channel and heart failure. Key takeaway: S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41201974">The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure.</a> (Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41200819">FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking.</a> (Circulation research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41196954">The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth.</a> (Circulation research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41090220">Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41090219">Vascular Niches Are the Primary Hotspots in Cardiac Aging.</a> (Circulation research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/">https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41201974" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41201974</a></p>
<p><strong>Summary:</strong> This study investigated the impact of sodium-glucose cotransporter 2 inhibitors on cardiac structure and cardiorenal function in older adults with hypertension and pre-heart failure. Eighty-eight patients were randomized to receive dapagliflozin or conventional treatment. The research evaluated changes in N-terminal pro-brain natriuretic peptide, which is a key biomarker for heart failure, among other indicators. This study contributes to understanding the therapeutic potential of dapagliflozin in preventing heart failure progression in a vulnerable older population.</p>
<h4>Article 2: FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41200819" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41200819</a></p>
<p><strong>Summary:</strong> This research explored the role of fibroblast growth factor homologous factor 13, known as F.G.F.13, in regulating cardiac conduction, specifically examining its influence on connexin 43 gap junctions independent of voltage-gated sodium channels. The study assessed cardiac conduction and cardiomyocyte action potentials in mice lacking F.G.F.13, revealing a novel mechanism by which F.G.F.13 impacts impulse propagation through connexin 43 trafficking. These findings establish a crucial, non-canonical pathway for arrhythmia development and provide a new target for antiarrhythmic strategies.</p>
<h4>Article 3: The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41196954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41196954</a></p>
<p><strong>Summary:</strong> This study investigated how the cytoskeletal protein beta-I.V.-spectrin, in complex with S.T.A.T.3, regulates the orientation of cardiac hypertrophic growth. Researchers evaluated this complex to understand its role in determining whether cardiac hypertrophy manifests as beneficial concentric or detrimental eccentric growth. The findings reveal a key mechanism influencing cardiac remodeling, which is crucial for distinguishing adaptive from maladaptive hypertrophy and potentially guiding future therapeutic interventions for heart failure.</p>
<h4>Article 4: Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41090220" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41090220</a></p>
<p><strong>Summary:</strong> This study examined mitochondrial calcium handling and cellular redox state in atrial fibrillation patients. Researchers isolated cardiac myocytes from patient-derived right atrial biopsies to subject them to workload transitions. The study revealed that atrial fibrillation is associated with impaired atrial mitochondrial calcium handling, identifying a potential new mechanistic target for understanding and treating this common arrhythmia.</p>
<h4>Article 5: Vascular Niches Are the Primary Hotspots in Cardiac Aging.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41090219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41090219</a></p>
<p><strong>Summary:</strong> This research explored the microenvironmental changes within the heart that contribute to age-related cardiac dysfunction, fibrosis, and inflammation. By combining single-nucleus R.N.A. sequencing and spatial transcriptomics in aged mice hearts, the study identified vascular niches as primary hotspots for age-related alterations in cardiac tissue. These findings provide a detailed map of cellular and molecular changes in the aging heart, offering specific targets for interventions to mitigate cardiovascular aging.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure. This study investigated the impact of sodium-glucose cotransporter 2 inhibitors on cardiac structure and cardiorenal function in older adults with hypertension and pre-heart failure. Eighty-eight patients were randomized to receive dapagliflozin or conventional treatment. The research evaluated changes in N-terminal pro-brain natriuretic peptide, which is a key biomarker for heart failure, among other indicators. This study contributes to understanding the therapeutic potential of dapagliflozin in preventing heart failure progression in a vulnerable older population.</p>
<p>Article number two. F.G.F.13 Regulates V.G.S.C.-Independent Cardiomyocyte Impulse Propagation via C.x.43 Trafficking. This research explored the role of fibroblast growth factor homologous factor 13, known as F.G.F.13, in regulating cardiac conduction, specifically examining its influence on connexin 43 gap junctions independent of voltage-gated sodium channels. The study assessed cardiac conduction and cardiomyocyte action potentials in mice lacking F.G.F.13, revealing a novel mechanism by which F.G.F.13 impacts impulse propagation through connexin 43 trafficking. These findings establish a crucial, non-canonical pathway for arrhythmia development and provide a new target for antiarrhythmic strategies.</p>
<p>Article number three. The beta I.V.-Spectrin/S.T.A.T.3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth. This study investigated how the cytoskeletal protein beta-I.V.-spectrin, in complex with S.T.A.T.3, regulates the orientation of cardiac hypertrophic growth. Researchers evaluated this complex to understand its role in determining whether cardiac hypertrophy manifests as beneficial concentric or detrimental eccentric growth. The findings reveal a key mechanism influencing cardiac remodeling, which is crucial for distinguishing adaptive from maladaptive hypertrophy and potentially guiding future therapeutic interventions for heart failure.</p>
<p>Article number four. Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation. This study examined mitochondrial calcium handling and cellular redox state in atrial fibrillation patients. Researchers isolated cardiac myocytes from patient-derived right atrial biopsies to subject them to workload transitions. The study revealed that atrial fibrillation is associated with impaired atrial mitochondrial calcium handling, identifying a potential new mechanistic target for understanding and treating this common arrhythmia.</p>
<p>Article number five. Vascular Niches Are the Primary Hotspots in Cardiac Aging. This research explored the microenvironmental changes within the heart that contribute to age-related cardiac dysfunction, fibrosis, and inflammation. By combining single-nucleus R.N.A. sequencing and spatial transcriptomics in aged mice hearts, the study identified vascular niches as primary hotspots for age-related alterations in cardiac tissue. These findings provide a detailed map of cellular and molecular changes in the aging heart, offering specific targets for interventions to mitigate cardiovascular aging. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>voltage-gated sodium channel, heart failure, N-terminal pro-brain natriuretic peptide, F.G.F.13, cardiac hypertrophy, dapagliflozin, hypertension, cardiac aging, sodium-glucose cotransporter 2 inhibitors, mitochondrial calcium, vascular niches, redox state, pre-heart failure, atrial myocytes, cardiac remodeling, cardiac energetics, fibroblast growth factor homologous factor 13, arrhythmia, connexin 43, cardiac fibrosis, atrial fibrillation, beta-I.V.-spectrin, S.T.A.T.3, spatial transcriptomics, single-nucleus R.N.A. sequencing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/">S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults 11/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251109_060020.mp3" length="4030632" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 09, 2025. This episode summarizes 5 key cardiology studies on topics like voltage-gated sodium channel and heart failure. Key takeaway: S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults.
Article Links:
Article 1: The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure. (Cardiology)
Article 2: FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking. (Circulation research)
Article 3: The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth. (Circulation research)
Article 4: Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation. (Circulation research)
Article 5: Vascular Niches Are the Primary Hotspots in Cardiac Aging. (Circulation research)
Full episode page: https://podcast.explainheart.com/podcast/s-g-l-t-2i-benefits-pre-heart-failure-in-older-adults-11-09-25/
 Featured Articles
Article 1: The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41201974
Summary: This study investigated the impact of sodium-glucose cotransporter 2 inhibitors on cardiac structure and cardiorenal function in older adults with hypertension and pre-heart failure. Eighty-eight patients were randomized to receive dapagliflozin or conventional treatment. The research evaluated changes in N-terminal pro-brain natriuretic peptide, which is a key biomarker for heart failure, among other indicators. This study contributes to understanding the therapeutic potential of dapagliflozin in preventing heart failure progression in a vulnerable older population.
Article 2: FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41200819
Summary: This research explored the role of fibroblast growth factor homologous factor 13, known as F.G.F.13, in regulating cardiac conduction, specifically examining its influence on connexin 43 gap junctions independent of voltage-gated sodium channels. The study assessed cardiac conduction and cardiomyocyte action potentials in mice lacking F.G.F.13, revealing a novel mechanism by which F.G.F.13 impacts impulse propagation through connexin 43 trafficking. These findings establish a crucial, non-canonical pathway for arrhythmia development and provide a new target for antiarrhythmic strategies.
Article 3: The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41196954
Summary: This study investigated how the cytoskeletal protein beta-I.V.-spectrin, in complex with S.T.A.T.3, regulates the orientation of cardiac hypertrophic growth. Researchers evaluated this complex to understand its role in determining whether cardiac hypertrophy manifests as beneficial concentric or detrimental eccentric growth. The findings reveal a key mechanism influencing cardiac remodeling, which is crucial for distinguishing adaptive from maladaptive hypertrophy and potentially guiding future therapeutic interventions for heart failure.
Article 4: Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41090220
Summary: This study examined mitochondrial calcium handling and cellular redox state in atrial fibrillation patients. Researchers isolated cardiac myocytes from patient-derived right atrial biopsies to subject them to workload transitions. The study revealed that atrial fibrillation is associated with impaired atrial mitochondrial calcium handling, identifyi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 09, 2025. This episode summarizes 5 key cardiology studies on topics like voltage-gated sodium channel and heart failure. Key takeaway: S.G.L.T.2i Benefits Pre-Heart Failure in Older Adults.
Article Links:
Article 1: The effect of Sodium-dependent glucose transporter 2 Inhibitors on cardiac structural and functional indicators and biochemical markers in Older Adults with Hypertension and Pre-Heart Failure. (Cardiology)
Article 2: FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking. (Circulation research)
Article 3: The βIV-Spectrin/STAT3 Complex Regulates the Orientation of Cardiac Hypertrophic Growth. (Circulation research)
Article 4: Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation. (Circulation research)
Article 5: Vascular Niches Are the Primary Hotspots in Cardiac Aging. (Circulation research)
Full episode page: https://podcast.explainheart.com/podcast/s-g-l-t-2i]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden 11/08/25</title>
	<link>https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/</link>
	<pubDate>Sat, 08 Nov 2025 11:01:36 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 08, 2025. This episode summarizes 5 key cardiology studies on topics like n-3 polyunsaturated fatty acids and left ventricular mass. Key takeaway: Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41201837">Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41203298">Sex differences in out-of-hospital cardiac arrest across age groups.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41195776">Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41195775">Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41195772">Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/">https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41201837" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41201837</a></p>
<p><strong>Summary:</strong> This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.</p>
<h4>Article 2: Sex differences in out-of-hospital cardiac arrest across age groups.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41203298" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41203298</a></p>
<p><strong>Summary:</strong> This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.</p>
<h4>Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195776" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195776</a></p>
<p><strong>Summary:</strong> The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.</p>
<h4>Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195775" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195775</a></p>
<p><strong>Summary:</strong> This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.</p>
<h4>Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195772" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195772</a></p>
<p><strong>Summary:</strong> This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.</p>
<p>Article number two. Sex differences in out-of-hospital cardiac arrest across age groups. This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.</p>
<p>Article number three. Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.</p>
<p>Article number four. Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.</p>
<p>Article number five. Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>n-3 polyunsaturated fatty acids, left ventricular mass, C.C.T.A., myocardial mass, pediatric cardiac arrest, age groups, C.A.D., eicosapentaenoic acid, large coronary thrombus burden, sex differences, out-of-hospital cardiac arrest, positron emission tomography, cardiovascular disease, survival to hospital discharge, coronary computed tomography angiography, P.E.T., myocardial ischemia, rivaroxaban, hemodialysis, vessel-specific myocardial mass, S.T.E.M.I., Voronoi method, coronary artery disease, O.H.C.A., S.T.-segment-elevation myocardial infarction, fish-oil supplementation, prognostic value, dual antiplatelet therapy, artificial intelligence, thrombus burden.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/">Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden 11/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 08, 2025. This episode summarizes 5 key cardiology studies on topics like n-3 polyunsaturated fatty acids and left ventricular mass. Key takeaway: Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden.
Article Links:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 08, 2025. This episode summarizes 5 key cardiology studies on topics like n-3 polyunsaturated fatty acids and left ventricular mass. Key takeaway: Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41201837">Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41203298">Sex differences in out-of-hospital cardiac arrest across age groups.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41195776">Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41195775">Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41195772">Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/">https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41201837" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41201837</a></p>
<p><strong>Summary:</strong> This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.</p>
<h4>Article 2: Sex differences in out-of-hospital cardiac arrest across age groups.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41203298" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41203298</a></p>
<p><strong>Summary:</strong> This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.</p>
<h4>Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195776" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195776</a></p>
<p><strong>Summary:</strong> The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.</p>
<h4>Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195775" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195775</a></p>
<p><strong>Summary:</strong> This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.</p>
<h4>Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195772" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195772</a></p>
<p><strong>Summary:</strong> This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.</p>
<p>Article number two. Sex differences in out-of-hospital cardiac arrest across age groups. This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.</p>
<p>Article number three. Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.</p>
<p>Article number four. Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. This observational cohort study evaluated the long-term prognostic value of an artificial intelligence-guided quantitative computed tomography ischemia, or A.I.-Q.C.T. ischemia, algorithm. This novel machine-learning method predicts myocardial ischemia directly from coronary computed tomography angiography, or C.C.T.A. The study aimed to compare A.I.-Q.C.T. ischemia against hybrid C.C.T.A. and positron emission tomography, or P.E.T., myocardial perfusion imaging in symptomatic patients with suspected coronary artery disease, or C.A.D. By establishing its prognostic utility relative to an established hybrid imaging technique, this research advances diagnostic capabilities for assessing ischemia and risk in C.A.D.</p>
<p>Article number five. Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. This study aimed to establish crucial reference values for vessel-specific myocardial mass, quantitatively assessed from coronary computed tomography angiography, or C.C.T.A. The research focused on patients with stable coronary artery disease, or C.A.D., where evaluating myocardial mass at risk is essential for patient management. Using the Voronoi method, the study calculated left ventricular, or L.V., and vessel-specific myocardial mass, effectively mapping the myocardium subtended by each epicardial vessel. This methodology provides a valuable new quantitative assessment tool that enhances the evaluation and risk stratification of myocardial mass in C.A.D. patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>n-3 polyunsaturated fatty acids, left ventricular mass, C.C.T.A., myocardial mass, pediatric cardiac arrest, age groups, C.A.D., eicosapentaenoic acid, large coronary thrombus burden, sex differences, out-of-hospital cardiac arrest, positron emission tomography, cardiovascular disease, survival to hospital discharge, coronary computed tomography angiography, P.E.T., myocardial ischemia, rivaroxaban, hemodialysis, vessel-specific myocardial mass, S.T.E.M.I., Voronoi method, coronary artery disease, O.H.C.A., S.T.-segment-elevation myocardial infarction, fish-oil supplementation, prognostic value, dual antiplatelet therapy, artificial intelligence, thrombus burden.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/">Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden 11/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251108_060027.mp3" length="4948888" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 08, 2025. This episode summarizes 5 key cardiology studies on topics like n-3 polyunsaturated fatty acids and left ventricular mass. Key takeaway: Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden.
Article Links:
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. (The New England journal of medicine)
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups. (Heart (British Cardiac Society))
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. (Journal of the American Heart Association)
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. (Journal of the American Heart Association)
Article 5: Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/rivaroxaban-cuts-s-t-e-m-i-thrombus-burden-11-08-25/
 Featured Articles
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41201837
Summary: This double-blind randomized placebo-controlled trial investigated the efficacy of n-3 polyunsaturated fatty acid supplementation, including eicosapentaenoic acid and docosahexaenoic acid, for preventing cardiovascular events in patients undergoing hemodialysis. Cardiovascular disease is the leading cause of death in this population, and effective preventive therapies are currently limited. The study was conducted across 26 sites in Canada and Australia, aiming to address the uncertainty surrounding fish-oil supplementation benefits in this specific patient group. Its objective was to establish whether this intervention could provide cardiovascular protection.
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41203298
Summary: This study aimed to comprehensively assess sex differences in out-of-hospital cardiac arrest, or O.H.C.A., across various age groups, a topic poorly explored in younger populations. Researchers analyzed all O.H.C.A. occurrences in Paris and its suburbs from May 2011 to December 2018. Primary outcomes investigated included sex-specific characteristics of O.H.C.A. and survival rates to hospital discharge within pediatric (28 days to 18 years), young adult (19 to 45 years), and older adult (over 45 years) age groups. This research sought to provide crucial data to better understand O.H.C.A. presentation and outcomes across the lifespan based on sex.
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195776
Summary: The A.R.I.S.E.-A.R.M.Y.D.A. 7 randomized trial investigated the efficacy of short-term, low-dose rivaroxaban when added to dual antiplatelet therapy in patients experiencing S.T.-segment-elevation myocardial infarction, or S.T.E.M.I. The study addressed the clinical challenge of managing large coronary thrombus burden, or L.C.T.B., in this high-risk population, where the optimal antithrombotic regimen for deferred stenting remains uncertain. This trial demonstrated that the addition of low-dose rivaroxaban effectively reduced thrombus burden. This finding provides a significant advance in optimizing antithrombotic strategies, potentially improving outcomes for S.T.E.M.I. patients with substantial coronary thrombus.
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-De]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 08, 2025. This episode summarizes 5 key cardiology studies on topics like n-3 polyunsaturated fatty acids and left ventricular mass. Key takeaway: Rivaroxaban Cuts S.T.E.M.I. Thrombus Burden.
Article Links:
Article 1: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. (The New England journal of medicine)
Article 2: Sex differences in out-of-hospital cardiac arrest across age groups. (Heart (British Cardiac Society))
Article 3: Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial. (Journal of the American Heart Association)
Article 4: Prognostic Value of a Coronary Computed Tomography Angiography-Derived Ischemia Algorithm: Comparison Against Hybrid Coronary Computed Tomography Angiography/Positron Emission Tomography Imaging. (Journal of the American Heart Association)
Article 5: Vessel-Specific Myocardial Mass in Pa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Circadian Rhythm Attenuates O.S.A. Vascular Function 11/07/25</title>
	<link>https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/</link>
	<pubDate>Fri, 07 Nov 2025 17:40:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like vascular endothelial function and adolescence. Key takeaway: Circadian Rhythm Attenuates O.S.A. Vascular Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41200807">Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41195790">Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41195787">Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41195786">Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41195783">Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/">https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41200807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41200807</a></p>
<p><strong>Summary:</strong> The ES-BempeDACS Randomized Clinical Trial was designed to investigate the efficacy and safety of triple versus dual lipid-lowering therapy in patients with acute coronary syndrome. This study aimed to determine if combining bempedoic acid with high-intensity statins and ezetimibe could more effectively achieve low-density lipoprotein cholesterol goals. Current guidelines suggest a stepwise approach, but this trial explored an earlier intensive strategy from the onset of acute coronary syndrome. Its findings are anticipated to clarify optimal lipid-lowering strategies in this high-risk population.</p>
<h4>Article 2: Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195790" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195790</a></p>
<p><strong>Summary:</strong> This retrospective cohort study utilized the TriNetX research network to explore the role of glucagon-like peptide-1 receptor agonists in managing cancer therapy-related cardiac dysfunction. The research focused on adults aged 18 years and older who had a history of cancer, received antineoplastic therapy, and subsequently developed this cardiac complication. While glucagon-like peptide-1 receptor agonists are known for their cardioprotective properties, their specific application in cancer therapy-related cardiac dysfunction had not been previously investigated. This study established a framework to analyze real-world data on this potential therapeutic strategy.</p>
<h4>Article 3: Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195787" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195787</a></p>
<p><strong>Summary:</strong> Trial. This post hoc analysis of the Hokusai-V.T.E. trial investigated the association between the burden of atherosclerosis and long-term clinical outcomes in patients experiencing acute pulmonary embolism. The study specifically assessed the presence and extent of atherosclerotic disease across multiple vascular territories, including coronary, cerebral, and peripheral, or in a single territory, or its absence. This research aimed to determine if the extent of atherosclerotic disease has prognostic implications for individuals affected by venous thromboembolism. Identifying these associations could improve risk stratification and guide management strategies for patients with acute pulmonary embolism.</p>
<h4>Article 4: Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195786" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195786</a></p>
<p><strong>Summary:</strong> This nationwide cross-sectional survey investigated the relationship between cardiovascular health and bone mineral accrual in 11468 Chinese children and adolescents aged 6 to 18 years. Cardiovascular health was assessed using the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics, encompassing four behavioral metrics including diet and physical activity, and four factor metrics such as body mass index and blood pressure. The study found that adhering to Life&#8217;s Essential 8 was associated with greater bone mineral accrual during childhood and adolescence. This discovery highlights the critical importance of early cardiovascular health promotion for concurrently optimizing bone development and potentially reducing future osteoporosis risk.</p>
<h4>Article 5: Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195783" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195783</a></p>
<p><strong>Summary:</strong> This study investigated the role of the endogenous circadian system in attenuating nighttime vascular endothelial function in individuals with untreated obstructive sleep apnea. It hypothesized that the increased incidence of adverse cardiovascular events, such as myocardial infarction, observed at night in obstructive sleep apnea patients is linked to the circadian system&#8217;s influence on vascular function. The research demonstrated that the endogenous circadian system indeed attenuates nighttime vascular endothelial function in this population. This finding provides a crucial mechanistic understanding of the heightened cardiovascular risk in obstructive sleep apnea, potentially paving the way for chronotherapeutic approaches.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial. The ES-BempeDACS Randomized Clinical Trial was designed to investigate the efficacy and safety of triple versus dual lipid-lowering therapy in patients with acute coronary syndrome. This study aimed to determine if combining bempedoic acid with high-intensity statins and ezetimibe could more effectively achieve low-density lipoprotein cholesterol goals. Current guidelines suggest a stepwise approach, but this trial explored an earlier intensive strategy from the onset of acute coronary syndrome. Its findings are anticipated to clarify optimal lipid-lowering strategies in this high-risk population.</p>
<p>Article number two. Role of G.L.P.-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction. This retrospective cohort study utilized the TriNetX research network to explore the role of glucagon-like peptide-1 receptor agonists in managing cancer therapy-related cardiac dysfunction. The research focused on adults aged 18 years and older who had a history of cancer, received antineoplastic therapy, and subsequently developed this cardiac complication. While glucagon-like peptide-1 receptor agonists are known for their cardioprotective properties, their specific application in cancer therapy-related cardiac dysfunction had not been previously investigated. This study established a framework to analyze real-world data on this potential therapeutic strategy.</p>
<p>Article number three. Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-V.T.E. Trial. This post hoc analysis of the Hokusai-V.T.E. trial investigated the association between the burden of atherosclerosis and long-term clinical outcomes in patients experiencing acute pulmonary embolism. The study specifically assessed the presence and extent of atherosclerotic disease across multiple vascular territories, including coronary, cerebral, and peripheral, or in a single territory, or its absence. This research aimed to determine if the extent of atherosclerotic disease has prognostic implications for individuals affected by venous thromboembolism. Identifying these associations could improve risk stratification and guide management strategies for patients with acute pulmonary embolism.</p>
<p>Article number four. Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence. This nationwide cross-sectional survey investigated the relationship between cardiovascular health and bone mineral accrual in 11468 Chinese children and adolescents aged 6 to 18 years. Cardiovascular health was assessed using the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics, encompassing four behavioral metrics including diet and physical activity, and four factor metrics such as body mass index and blood pressure. The study found that adhering to Life&#8217;s Essential 8 was associated with greater bone mineral accrual during childhood and adolescence. This discovery highlights the critical importance of early cardiovascular health promotion for concurrently optimizing bone development and potentially reducing future osteoporosis risk.</p>
<p>Article number five. Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea. This study investigated the role of the endogenous circadian system in attenuating nighttime vascular endothelial function in individuals with untreated obstructive sleep apnea. It hypothesized that the increased incidence of adverse cardiovascular events, such as myocardial infarction, observed at night in obstructive sleep apnea patients is linked to the circadian system&#8217;s influence on vascular function. The research demonstrated that the endogenous circadian system indeed attenuates nighttime vascular endothelial function in this population. This finding provides a crucial mechanistic understanding of the heightened cardiovascular risk in obstructive sleep apnea, potentially paving the way for chronotherapeutic approaches. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>vascular endothelial function, adolescence, statins, cardiovascular health, osteoporosis prevention, low-density lipoprotein cholesterol, retrospective cohort study, obstructive sleep apnea, myocardial infarction, polyvascular disease, antineoplastic therapy, glucagon-like peptide-1 receptor agonists, bone mineral accrual, childhood, acute coronary syndrome, bempedoic acid, venous thromboembolism, prognosis, ezetimibe, cancer therapy-related cardiac dysfunction, Life&#8217;s Essential 8, pulmonary embolism, circadian system, cardiovascular risk, atherosclerosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/">Circadian Rhythm Attenuates O.S.A. Vascular Function 11/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like vascular endothelial function and adolescence. Key takeaway: Circadian Rhythm Attenuates O.S.A. Vascular Function.
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like vascular endothelial function and adolescence. Key takeaway: Circadian Rhythm Attenuates O.S.A. Vascular Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41200807">Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41195790">Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41195787">Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41195786">Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41195783">Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/">https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41200807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41200807</a></p>
<p><strong>Summary:</strong> The ES-BempeDACS Randomized Clinical Trial was designed to investigate the efficacy and safety of triple versus dual lipid-lowering therapy in patients with acute coronary syndrome. This study aimed to determine if combining bempedoic acid with high-intensity statins and ezetimibe could more effectively achieve low-density lipoprotein cholesterol goals. Current guidelines suggest a stepwise approach, but this trial explored an earlier intensive strategy from the onset of acute coronary syndrome. Its findings are anticipated to clarify optimal lipid-lowering strategies in this high-risk population.</p>
<h4>Article 2: Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195790" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195790</a></p>
<p><strong>Summary:</strong> This retrospective cohort study utilized the TriNetX research network to explore the role of glucagon-like peptide-1 receptor agonists in managing cancer therapy-related cardiac dysfunction. The research focused on adults aged 18 years and older who had a history of cancer, received antineoplastic therapy, and subsequently developed this cardiac complication. While glucagon-like peptide-1 receptor agonists are known for their cardioprotective properties, their specific application in cancer therapy-related cardiac dysfunction had not been previously investigated. This study established a framework to analyze real-world data on this potential therapeutic strategy.</p>
<h4>Article 3: Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195787" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195787</a></p>
<p><strong>Summary:</strong> Trial. This post hoc analysis of the Hokusai-V.T.E. trial investigated the association between the burden of atherosclerosis and long-term clinical outcomes in patients experiencing acute pulmonary embolism. The study specifically assessed the presence and extent of atherosclerotic disease across multiple vascular territories, including coronary, cerebral, and peripheral, or in a single territory, or its absence. This research aimed to determine if the extent of atherosclerotic disease has prognostic implications for individuals affected by venous thromboembolism. Identifying these associations could improve risk stratification and guide management strategies for patients with acute pulmonary embolism.</p>
<h4>Article 4: Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195786" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195786</a></p>
<p><strong>Summary:</strong> This nationwide cross-sectional survey investigated the relationship between cardiovascular health and bone mineral accrual in 11468 Chinese children and adolescents aged 6 to 18 years. Cardiovascular health was assessed using the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics, encompassing four behavioral metrics including diet and physical activity, and four factor metrics such as body mass index and blood pressure. The study found that adhering to Life&#8217;s Essential 8 was associated with greater bone mineral accrual during childhood and adolescence. This discovery highlights the critical importance of early cardiovascular health promotion for concurrently optimizing bone development and potentially reducing future osteoporosis risk.</p>
<h4>Article 5: Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195783" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195783</a></p>
<p><strong>Summary:</strong> This study investigated the role of the endogenous circadian system in attenuating nighttime vascular endothelial function in individuals with untreated obstructive sleep apnea. It hypothesized that the increased incidence of adverse cardiovascular events, such as myocardial infarction, observed at night in obstructive sleep apnea patients is linked to the circadian system&#8217;s influence on vascular function. The research demonstrated that the endogenous circadian system indeed attenuates nighttime vascular endothelial function in this population. This finding provides a crucial mechanistic understanding of the heightened cardiovascular risk in obstructive sleep apnea, potentially paving the way for chronotherapeutic approaches.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial. The ES-BempeDACS Randomized Clinical Trial was designed to investigate the efficacy and safety of triple versus dual lipid-lowering therapy in patients with acute coronary syndrome. This study aimed to determine if combining bempedoic acid with high-intensity statins and ezetimibe could more effectively achieve low-density lipoprotein cholesterol goals. Current guidelines suggest a stepwise approach, but this trial explored an earlier intensive strategy from the onset of acute coronary syndrome. Its findings are anticipated to clarify optimal lipid-lowering strategies in this high-risk population.</p>
<p>Article number two. Role of G.L.P.-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction. This retrospective cohort study utilized the TriNetX research network to explore the role of glucagon-like peptide-1 receptor agonists in managing cancer therapy-related cardiac dysfunction. The research focused on adults aged 18 years and older who had a history of cancer, received antineoplastic therapy, and subsequently developed this cardiac complication. While glucagon-like peptide-1 receptor agonists are known for their cardioprotective properties, their specific application in cancer therapy-related cardiac dysfunction had not been previously investigated. This study established a framework to analyze real-world data on this potential therapeutic strategy.</p>
<p>Article number three. Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-V.T.E. Trial. This post hoc analysis of the Hokusai-V.T.E. trial investigated the association between the burden of atherosclerosis and long-term clinical outcomes in patients experiencing acute pulmonary embolism. The study specifically assessed the presence and extent of atherosclerotic disease across multiple vascular territories, including coronary, cerebral, and peripheral, or in a single territory, or its absence. This research aimed to determine if the extent of atherosclerotic disease has prognostic implications for individuals affected by venous thromboembolism. Identifying these associations could improve risk stratification and guide management strategies for patients with acute pulmonary embolism.</p>
<p>Article number four. Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence. This nationwide cross-sectional survey investigated the relationship between cardiovascular health and bone mineral accrual in 11468 Chinese children and adolescents aged 6 to 18 years. Cardiovascular health was assessed using the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics, encompassing four behavioral metrics including diet and physical activity, and four factor metrics such as body mass index and blood pressure. The study found that adhering to Life&#8217;s Essential 8 was associated with greater bone mineral accrual during childhood and adolescence. This discovery highlights the critical importance of early cardiovascular health promotion for concurrently optimizing bone development and potentially reducing future osteoporosis risk.</p>
<p>Article number five. Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea. This study investigated the role of the endogenous circadian system in attenuating nighttime vascular endothelial function in individuals with untreated obstructive sleep apnea. It hypothesized that the increased incidence of adverse cardiovascular events, such as myocardial infarction, observed at night in obstructive sleep apnea patients is linked to the circadian system&#8217;s influence on vascular function. The research demonstrated that the endogenous circadian system indeed attenuates nighttime vascular endothelial function in this population. This finding provides a crucial mechanistic understanding of the heightened cardiovascular risk in obstructive sleep apnea, potentially paving the way for chronotherapeutic approaches. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>vascular endothelial function, adolescence, statins, cardiovascular health, osteoporosis prevention, low-density lipoprotein cholesterol, retrospective cohort study, obstructive sleep apnea, myocardial infarction, polyvascular disease, antineoplastic therapy, glucagon-like peptide-1 receptor agonists, bone mineral accrual, childhood, acute coronary syndrome, bempedoic acid, venous thromboembolism, prognosis, ezetimibe, cancer therapy-related cardiac dysfunction, Life&#8217;s Essential 8, pulmonary embolism, circadian system, cardiovascular risk, atherosclerosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/">Circadian Rhythm Attenuates O.S.A. Vascular Function 11/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251107_123851.mp3" length="4848996" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like vascular endothelial function and adolescence. Key takeaway: Circadian Rhythm Attenuates O.S.A. Vascular Function.
Article Links:
Article 1: Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial. (Circulation)
Article 2: Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction. (Journal of the American Heart Association)
Article 3: Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial. (Journal of the American Heart Association)
Article 4: Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence. (Journal of the American Heart Association)
Article 5: Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstructive Sleep Apnea. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/circadian-rhythm-attenuates-o-s-a-vascular-function-11-07-25/
 Featured Articles
Article 1: Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41200807
Summary: The ES-BempeDACS Randomized Clinical Trial was designed to investigate the efficacy and safety of triple versus dual lipid-lowering therapy in patients with acute coronary syndrome. This study aimed to determine if combining bempedoic acid with high-intensity statins and ezetimibe could more effectively achieve low-density lipoprotein cholesterol goals. Current guidelines suggest a stepwise approach, but this trial explored an earlier intensive strategy from the onset of acute coronary syndrome. Its findings are anticipated to clarify optimal lipid-lowering strategies in this high-risk population.
Article 2: Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195790
Summary: This retrospective cohort study utilized the TriNetX research network to explore the role of glucagon-like peptide-1 receptor agonists in managing cancer therapy-related cardiac dysfunction. The research focused on adults aged 18 years and older who had a history of cancer, received antineoplastic therapy, and subsequently developed this cardiac complication. While glucagon-like peptide-1 receptor agonists are known for their cardioprotective properties, their specific application in cancer therapy-related cardiac dysfunction had not been previously investigated. This study established a framework to analyze real-world data on this potential therapeutic strategy.
Article 3: Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195787
Summary: Trial. This post hoc analysis of the Hokusai-V.T.E. trial investigated the association between the burden of atherosclerosis and long-term clinical outcomes in patients experiencing acute pulmonary embolism. The study specifically assessed the presence and extent of atherosclerotic disease across multiple vascular territories, including coronary, cerebral, and peripheral, or in a single territory, or its absence. This research aimed to determine if the extent of atherosclerotic disease has prognostic implications for individuals affected by venous thromboembolism. Identifying these associations could improve risk stratification and guide management strategies for patients with acute pulmonary embolism.
Article 4: Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence.
Journal: Journal ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like vascular endothelial function and adolescence. Key takeaway: Circadian Rhythm Attenuates O.S.A. Vascular Function.
Article Links:
Article 1: Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempeDACS Randomized Clinical Trial. (Circulation)
Article 2: Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction. (Journal of the American Heart Association)
Article 3: Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial. (Journal of the American Heart Association)
Article 4: Adhering to Life&#8217;s Essential 8 Is Associated With Greater Bone Mineral Accrual During Childhood and Adolescence. (Journal of the American Heart Association)
Article 5: Endogenous Circadian System Attenuates Nighttime Vascular Endothelial Function in People With Untreated Obstruc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dapagliflozin Shields Kidneys from Acute Injury. 11/07/25</title>
	<link>https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/</link>
	<pubDate>Fri, 07 Nov 2025 11:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like neutrophils and incident stroke. Key takeaway: Dapagliflozin Shields Kidneys from Acute Injury..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41196369">A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41195985">Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41195983">Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.</a> (Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41198182">Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41195792">Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/">https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41196369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41196369</a></p>
<p><strong>Summary:</strong> This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.</p>
<h4>Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195985" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195985</a></p>
<p><strong>Summary:</strong> This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.</p>
<h4>Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195983" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195983</a></p>
<p><strong>Summary:</strong> This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.</p>
<h4>Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41198182" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41198182</a></p>
<p><strong>Summary:</strong> This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.</p>
<h4>Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195792" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195792</a></p>
<p><strong>Summary:</strong> This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.</p>
<p>Article number two. Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.</p>
<p>Article number three. Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.</p>
<p>Article number four. Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.</p>
<p>Article number five. Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>neutrophils, incident stroke, multimarker score, risk stratification, Heart transplantation, glomerulopathy, cardiac grafts, IgA nephropathy, heart failure, Cerebral small vessel disease, systemic right ventricle, Cardiac resynchronization therapy, B-cell proliferation-inducing ligand, end-stage heart failure, sodium-glucose cotransporter 2 inhibitor, normothermic machine perfusion, adenosine signaling, acute kidney injury, transposition of the great arteries, atacicept, congenital heart disease, Dapagliflozin, Framingham Heart Study, B-cell activating factor, renal ischemia/reperfusion injury, donor heart assessment.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/">Dapagliflozin Shields Kidneys from Acute Injury. 11/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like neutrophils and incident stroke. Key takeaway: Dapagliflozin Shields Kidneys from Acute Injury..
Article Links:
Article 1: A Phase 3]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like neutrophils and incident stroke. Key takeaway: Dapagliflozin Shields Kidneys from Acute Injury..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41196369">A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41195985">Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.</a> (Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41195983">Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.</a> (Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41198182">Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41195792">Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/">https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41196369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41196369</a></p>
<p><strong>Summary:</strong> This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.</p>
<h4>Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195985" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195985</a></p>
<p><strong>Summary:</strong> This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.</p>
<h4>Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.</h4>
<p><strong>Journal:</strong> Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195983" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195983</a></p>
<p><strong>Summary:</strong> This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.</p>
<h4>Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41198182" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41198182</a></p>
<p><strong>Summary:</strong> This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.</p>
<h4>Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41195792" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41195792</a></p>
<p><strong>Summary:</strong> This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.</p>
<p>Article number two. Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.</p>
<p>Article number three. Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.</p>
<p>Article number four. Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.</p>
<p>Article number five. Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>neutrophils, incident stroke, multimarker score, risk stratification, Heart transplantation, glomerulopathy, cardiac grafts, IgA nephropathy, heart failure, Cerebral small vessel disease, systemic right ventricle, Cardiac resynchronization therapy, B-cell proliferation-inducing ligand, end-stage heart failure, sodium-glucose cotransporter 2 inhibitor, normothermic machine perfusion, adenosine signaling, acute kidney injury, transposition of the great arteries, atacicept, congenital heart disease, Dapagliflozin, Framingham Heart Study, B-cell activating factor, renal ischemia/reperfusion injury, donor heart assessment.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/">Dapagliflozin Shields Kidneys from Acute Injury. 11/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251107_060028.mp3" length="4673871" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like neutrophils and incident stroke. Key takeaway: Dapagliflozin Shields Kidneys from Acute Injury..
Article Links:
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. (The New England journal of medicine)
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. (Transplantation)
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. (Transplantation)
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. (Heart (British Cardiac Society))
Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/
 Featured Articles
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41196369
Summary: This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195985
Summary: This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195983
Summary: This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubm]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like neutrophils and incident stroke. Key takeaway: Dapagliflozin Shields Kidneys from Acute Injury..
Article Links:
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. (The New England journal of medicine)
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. (Transplantation)
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. (Transplantation)
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. (Heart (British Cardiac Society))
Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. (Journal of the American Heart Association)
Full episode page: https:]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Pregnancy Blood Pressure Variability Predicts Outcomes 11/06/25</title>
	<link>https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/</link>
	<pubDate>Thu, 06 Nov 2025 11:02:03 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 06, 2025. This episode summarizes 5 key cardiology studies on topics like emergency department and screening protocols. Key takeaway: Pregnancy Blood Pressure Variability Predicts Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41182008">Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41182007">Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41182006">Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41182005">High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, USA.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41182001">Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the ALSPAC Cohort.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/">https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182008" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182008</a></p>
<p><strong>Summary:</strong> This retrospective observational study investigated whether socioeconomic status, race, and ethnicity influence referral patterns for electrophysiology study and ablation in pediatric patients with supraventricular tachycardia or Wolff-Parkinson-White syndrome. It aimed to address the limited understanding of such inequities in pediatric arrhythmia management compared to adults. The research established a foundational understanding of how these social determinants may impact access to advanced care for children with these cardiac arrhythmias. This investigation is crucial for identifying potential disparities in healthcare delivery and developing strategies to ensure equitable management for all pediatric patients.</p>
<h4>Article 2: Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182007</a></p>
<p><strong>Summary:</strong> This population-based cohort study investigated the association between C-reactive protein levels and cognitive impairment and death in aging adults with atrial fibrillation. Researchers focused on individuals aged 45 years or older with prevalent atrial fibrillation but without existing cognitive impairment at baseline. The study explored the hypothesis that elevated C-reactive protein, a marker of inflammation, contributes to blood-brain barrier permeability, neuroinflammation, and subsequent neurodegeneration. By estimating these associations, the research provides a clearer understanding of potential inflammatory pathways linking atrial fibrillation to cognitive decline.</p>
<h4>Article 3: Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182006</a></p>
<p><strong>Summary:</strong> This drug target Mendelian randomization analysis explored whether genetically downregulated interleukin-6 signaling is associated with arteriolosclerotic cerebral small vessel disease, a leading cause of stroke and dementia. The study investigated the clinical, imaging, and pathological manifestations of this condition. By examining the genetic influence on interleukin-6, the research identifies a potential disease-modifying therapeutic target for arteriolosclerotic cerebral small vessel disease. This work advances the understanding of inflammatory pathways in neurovascular diseases, aiming to identify new treatment avenues where none currently exist.</p>
<h4>Article 4: High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, USA.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182005" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182005</a></p>
<p><strong>Summary:</strong> This analytical cross-sectional study investigated the prevalence and determinants of markedly elevated blood pressure, defined as 180 over 120 millimeters of mercury or higher, among adults presenting to a community emergency department. Researchers included adults aged 18 years or older at a Midwest teaching hospital over a one-year period from January 1 to December 31, 2024. The study aimed to address the limited data on this condition in United States community emergency departments. This research establishes foundational data on the burden of severe hypertension in an acute care setting, which is vital for informing screening protocols and intervention strategies.</p>
<h4>Article 5: Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the ALSPAC Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182001" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182001</a></p>
<p><strong>Summary:</strong> Cohort. This secondary analysis of the Avon Longitudinal Study of Parents and Children cohort investigated the associations between visit-to-visit blood pressure variability during pregnancy and subsequent adverse maternal and perinatal outcomes. Researchers also explored its relationship with long-term maternal cardiovascular outcomes, an area where blood pressure variability is known to predict events outside of pregnancy. Using adjusted logistic regression, the study aimed to establish whether blood pressure variability during gestation serves as a predictor for future health complications. This research provides a crucial understanding of the prognostic significance of blood pressure fluctuations in pregnant individuals.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia. This retrospective observational study investigated whether socioeconomic status, race, and ethnicity influence referral patterns for electrophysiology study and ablation in pediatric patients with supraventricular tachycardia or Wolff-Parkinson-White syndrome. It aimed to address the limited understanding of such inequities in pediatric arrhythmia management compared to adults. The research established a foundational understanding of how these social determinants may impact access to advanced care for children with these cardiac arrhythmias. This investigation is crucial for identifying potential disparities in healthcare delivery and developing strategies to ensure equitable management for all pediatric patients.</p>
<p>Article number two. Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation. This population-based cohort study investigated the association between C-reactive protein levels and cognitive impairment and death in aging adults with atrial fibrillation. Researchers focused on individuals aged 45 years or older with prevalent atrial fibrillation but without existing cognitive impairment at baseline. The study explored the hypothesis that elevated C-reactive protein, a marker of inflammation, contributes to blood-brain barrier permeability, neuroinflammation, and subsequent neurodegeneration. By estimating these associations, the research provides a clearer understanding of potential inflammatory pathways linking atrial fibrillation to cognitive decline.</p>
<p>Article number three. Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis. This drug target Mendelian randomization analysis explored whether genetically downregulated interleukin-6 signaling is associated with arteriolosclerotic cerebral small vessel disease, a leading cause of stroke and dementia. The study investigated the clinical, imaging, and pathological manifestations of this condition. By examining the genetic influence on interleukin-6, the research identifies a potential disease-modifying therapeutic target for arteriolosclerotic cerebral small vessel disease. This work advances the understanding of inflammatory pathways in neurovascular diseases, aiming to identify new treatment avenues where none currently exist.</p>
<p>Article number four. High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, U.S.A. This analytical cross-sectional study investigated the prevalence and determinants of markedly elevated blood pressure, defined as 180 over 120 millimeters of mercury or higher, among adults presenting to a community emergency department. Researchers included adults aged 18 years or older at a Midwest teaching hospital over a one-year period from January 1 to December 31, 2024. The study aimed to address the limited data on this condition in United States community emergency departments. This research establishes foundational data on the burden of severe hypertension in an acute care setting, which is vital for informing screening protocols and intervention strategies.</p>
<p>Article number five. Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the A.L.S.P.A.C. Cohort. This secondary analysis of the Avon Longitudinal Study of Parents and Children cohort investigated the associations between visit-to-visit blood pressure variability during pregnancy and subsequent adverse maternal and perinatal outcomes. Researchers also explored its relationship with long-term maternal cardiovascular outcomes, an area where blood pressure variability is known to predict events outside of pregnancy. Using adjusted logistic regression, the study aimed to establish whether blood pressure variability during gestation serves as a predictor for future health complications. This research provides a crucial understanding of the prognostic significance of blood pressure fluctuations in pregnant individuals. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>emergency department, screening protocols, acute care, blood pressure variability, prognostic significance, cognitive decline, neurodegeneration, cerebral small vessel disease, electrophysiology study, perinatal outcomes, inflammation, ablation, pregnancy outcomes, maternal cardiovascular outcomes, atrial fibrillation, socioeconomic disparities, stroke, pediatric supraventricular tachycardia, interleukin-6 signaling, C-reactive protein, dementia, markedly elevated blood pressure, Mendelian randomization, hypertension prevalence, Wolff-Parkinson-White syndrome.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/">Pregnancy Blood Pressure Variability Predicts Outcomes 11/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 06, 2025. This episode summarizes 5 key cardiology studies on topics like emergency department and screening protocols. Key takeaway: Pregnancy Blood Pressure Variability Predicts Outcomes.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 06, 2025. This episode summarizes 5 key cardiology studies on topics like emergency department and screening protocols. Key takeaway: Pregnancy Blood Pressure Variability Predicts Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41182008">Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41182007">Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41182006">Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41182005">High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, USA.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41182001">Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the ALSPAC Cohort.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/">https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182008" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182008</a></p>
<p><strong>Summary:</strong> This retrospective observational study investigated whether socioeconomic status, race, and ethnicity influence referral patterns for electrophysiology study and ablation in pediatric patients with supraventricular tachycardia or Wolff-Parkinson-White syndrome. It aimed to address the limited understanding of such inequities in pediatric arrhythmia management compared to adults. The research established a foundational understanding of how these social determinants may impact access to advanced care for children with these cardiac arrhythmias. This investigation is crucial for identifying potential disparities in healthcare delivery and developing strategies to ensure equitable management for all pediatric patients.</p>
<h4>Article 2: Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182007</a></p>
<p><strong>Summary:</strong> This population-based cohort study investigated the association between C-reactive protein levels and cognitive impairment and death in aging adults with atrial fibrillation. Researchers focused on individuals aged 45 years or older with prevalent atrial fibrillation but without existing cognitive impairment at baseline. The study explored the hypothesis that elevated C-reactive protein, a marker of inflammation, contributes to blood-brain barrier permeability, neuroinflammation, and subsequent neurodegeneration. By estimating these associations, the research provides a clearer understanding of potential inflammatory pathways linking atrial fibrillation to cognitive decline.</p>
<h4>Article 3: Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182006</a></p>
<p><strong>Summary:</strong> This drug target Mendelian randomization analysis explored whether genetically downregulated interleukin-6 signaling is associated with arteriolosclerotic cerebral small vessel disease, a leading cause of stroke and dementia. The study investigated the clinical, imaging, and pathological manifestations of this condition. By examining the genetic influence on interleukin-6, the research identifies a potential disease-modifying therapeutic target for arteriolosclerotic cerebral small vessel disease. This work advances the understanding of inflammatory pathways in neurovascular diseases, aiming to identify new treatment avenues where none currently exist.</p>
<h4>Article 4: High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, USA.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182005" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182005</a></p>
<p><strong>Summary:</strong> This analytical cross-sectional study investigated the prevalence and determinants of markedly elevated blood pressure, defined as 180 over 120 millimeters of mercury or higher, among adults presenting to a community emergency department. Researchers included adults aged 18 years or older at a Midwest teaching hospital over a one-year period from January 1 to December 31, 2024. The study aimed to address the limited data on this condition in United States community emergency departments. This research establishes foundational data on the burden of severe hypertension in an acute care setting, which is vital for informing screening protocols and intervention strategies.</p>
<h4>Article 5: Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the ALSPAC Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182001" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182001</a></p>
<p><strong>Summary:</strong> Cohort. This secondary analysis of the Avon Longitudinal Study of Parents and Children cohort investigated the associations between visit-to-visit blood pressure variability during pregnancy and subsequent adverse maternal and perinatal outcomes. Researchers also explored its relationship with long-term maternal cardiovascular outcomes, an area where blood pressure variability is known to predict events outside of pregnancy. Using adjusted logistic regression, the study aimed to establish whether blood pressure variability during gestation serves as a predictor for future health complications. This research provides a crucial understanding of the prognostic significance of blood pressure fluctuations in pregnant individuals.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia. This retrospective observational study investigated whether socioeconomic status, race, and ethnicity influence referral patterns for electrophysiology study and ablation in pediatric patients with supraventricular tachycardia or Wolff-Parkinson-White syndrome. It aimed to address the limited understanding of such inequities in pediatric arrhythmia management compared to adults. The research established a foundational understanding of how these social determinants may impact access to advanced care for children with these cardiac arrhythmias. This investigation is crucial for identifying potential disparities in healthcare delivery and developing strategies to ensure equitable management for all pediatric patients.</p>
<p>Article number two. Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation. This population-based cohort study investigated the association between C-reactive protein levels and cognitive impairment and death in aging adults with atrial fibrillation. Researchers focused on individuals aged 45 years or older with prevalent atrial fibrillation but without existing cognitive impairment at baseline. The study explored the hypothesis that elevated C-reactive protein, a marker of inflammation, contributes to blood-brain barrier permeability, neuroinflammation, and subsequent neurodegeneration. By estimating these associations, the research provides a clearer understanding of potential inflammatory pathways linking atrial fibrillation to cognitive decline.</p>
<p>Article number three. Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis. This drug target Mendelian randomization analysis explored whether genetically downregulated interleukin-6 signaling is associated with arteriolosclerotic cerebral small vessel disease, a leading cause of stroke and dementia. The study investigated the clinical, imaging, and pathological manifestations of this condition. By examining the genetic influence on interleukin-6, the research identifies a potential disease-modifying therapeutic target for arteriolosclerotic cerebral small vessel disease. This work advances the understanding of inflammatory pathways in neurovascular diseases, aiming to identify new treatment avenues where none currently exist.</p>
<p>Article number four. High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, U.S.A. This analytical cross-sectional study investigated the prevalence and determinants of markedly elevated blood pressure, defined as 180 over 120 millimeters of mercury or higher, among adults presenting to a community emergency department. Researchers included adults aged 18 years or older at a Midwest teaching hospital over a one-year period from January 1 to December 31, 2024. The study aimed to address the limited data on this condition in United States community emergency departments. This research establishes foundational data on the burden of severe hypertension in an acute care setting, which is vital for informing screening protocols and intervention strategies.</p>
<p>Article number five. Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the A.L.S.P.A.C. Cohort. This secondary analysis of the Avon Longitudinal Study of Parents and Children cohort investigated the associations between visit-to-visit blood pressure variability during pregnancy and subsequent adverse maternal and perinatal outcomes. Researchers also explored its relationship with long-term maternal cardiovascular outcomes, an area where blood pressure variability is known to predict events outside of pregnancy. Using adjusted logistic regression, the study aimed to establish whether blood pressure variability during gestation serves as a predictor for future health complications. This research provides a crucial understanding of the prognostic significance of blood pressure fluctuations in pregnant individuals. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>emergency department, screening protocols, acute care, blood pressure variability, prognostic significance, cognitive decline, neurodegeneration, cerebral small vessel disease, electrophysiology study, perinatal outcomes, inflammation, ablation, pregnancy outcomes, maternal cardiovascular outcomes, atrial fibrillation, socioeconomic disparities, stroke, pediatric supraventricular tachycardia, interleukin-6 signaling, C-reactive protein, dementia, markedly elevated blood pressure, Mendelian randomization, hypertension prevalence, Wolff-Parkinson-White syndrome.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/">Pregnancy Blood Pressure Variability Predicts Outcomes 11/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251106_060041.mp3" length="4804274" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 06, 2025. This episode summarizes 5 key cardiology studies on topics like emergency department and screening protocols. Key takeaway: Pregnancy Blood Pressure Variability Predicts Outcomes.
Article Links:
Article 1: Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia. (Journal of the American Heart Association)
Article 2: Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation. (Journal of the American Heart Association)
Article 3: Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis. (Journal of the American Heart Association)
Article 4: High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, USA. (Journal of the American Heart Association)
Article 5: Blood Pressure Variability and Adverse Pregnancy and Cardiovascular Outcomes in the ALSPAC Cohort. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/pregnancy-blood-pressure-variability-predicts-outcomes-11-06-25/
 Featured Articles
Article 1: Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182008
Summary: This retrospective observational study investigated whether socioeconomic status, race, and ethnicity influence referral patterns for electrophysiology study and ablation in pediatric patients with supraventricular tachycardia or Wolff-Parkinson-White syndrome. It aimed to address the limited understanding of such inequities in pediatric arrhythmia management compared to adults. The research established a foundational understanding of how these social determinants may impact access to advanced care for children with these cardiac arrhythmias. This investigation is crucial for identifying potential disparities in healthcare delivery and developing strategies to ensure equitable management for all pediatric patients.
Article 2: Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182007
Summary: This population-based cohort study investigated the association between C-reactive protein levels and cognitive impairment and death in aging adults with atrial fibrillation. Researchers focused on individuals aged 45 years or older with prevalent atrial fibrillation but without existing cognitive impairment at baseline. The study explored the hypothesis that elevated C-reactive protein, a marker of inflammation, contributes to blood-brain barrier permeability, neuroinflammation, and subsequent neurodegeneration. By estimating these associations, the research provides a clearer understanding of potential inflammatory pathways linking atrial fibrillation to cognitive decline.
Article 3: Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182006
Summary: This drug target Mendelian randomization analysis explored whether genetically downregulated interleukin-6 signaling is associated with arteriolosclerotic cerebral small vessel disease, a leading cause of stroke and dementia. The study investigated the clinical, imaging, and pathological manifestations of this condition. By examining the genetic influence on interleukin-6, the research identifies a potential disease-modifying therapeutic target for arteriolosclerotic cerebral small vessel disease. This work advances the unde]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 06, 2025. This episode summarizes 5 key cardiology studies on topics like emergency department and screening protocols. Key takeaway: Pregnancy Blood Pressure Variability Predicts Outcomes.
Article Links:
Article 1: Socioeconomic Status, Race, and Ethnicity in Management of Pediatric Supraventricular Tachycardia. (Journal of the American Heart Association)
Article 2: Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation. (Journal of the American Heart Association)
Article 3: Genetic Downregulation of Interleukin-6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis. (Journal of the American Heart Association)
Article 4: High Burden of Markedly Elevated Blood Pressure Among Adults Presenting to a Community Emergency Department: An Analytical Cross-Sectional Study at a Teaching Hospital in Missouri, USA. (Journal of the Amer]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aortic Stenosis: Leaflet-Specific Pathology Revealed 11/05/25</title>
	<link>https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/</link>
	<pubDate>Wed, 05 Nov 2025 17:22:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography emphysema and population structure. Key takeaway: Aortic Stenosis: Leaflet-Specific Pathology Revealed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41189091">Impact of standardized team-based care on cardiogenic shock outcomes over time.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41190426">SPIROMICS HF: Rationale, Design, and Reproducibility of Measures.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41182011">Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41182010">Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41182009">Admixture Mapping of Lipid Traits in Hispanic Americans.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/">https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of standardized team-based care on cardiogenic shock outcomes over time.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41189091" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41189091</a></p>
<p><strong>Summary:</strong> This study investigated the impact of implementing standardized team-based protocols on cardiogenic shock outcomes over time. Researchers analyzed 1453 consecutive patients from a single-center cardiogenic shock registry, comparing outcomes between two periods: 2017-2019 and 2020-2022. This methodology aimed to determine the influence of multidisciplinary management strategies on patient outcomes. The research establishes a crucial framework for evaluating the effectiveness of structured care approaches in this critical condition.</p>
<h4>Article 2: SPIROMICS HF: Rationale, Design, and Reproducibility of Measures.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41190426" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41190426</a></p>
<p><strong>Summary:</strong> HeF.pEF: Rationale, Design, and Reproducibility of Measures. The S.P.I.R.O.M.I.C.S. HeF.pEF study outlines its rationale and design for investigating the complex interplay between chronic obstructive pulmonary disease and Heart Failure with Preserved Ejection Fraction. This research specifically tests hypotheses linking new computed tomography emphysema subtypes with distinct cardiovascular phenotypes, including cor pulmonale and cor pulmonale parvus. The study also focuses on common airway branch variations and the reproducibility of its measures, establishing a robust framework for future discoveries. This work is crucial for identifying shared underlying mechanisms and improving management strategies for patients with these often coexisting conditions.</p>
<h4>Article 3: Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182011" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182011</a></p>
<p><strong>Summary:</strong> The V.E.N.T.O.U.X.-A.F. cross-sectional study investigated factors associated with atrial fibrillation in 39 veteran male endurance athletes, a population known for increased A.fib risk. Researchers aimed to determine if left atrial remodeling, assessed by cardiovascular magnetic resonance, exercise blood pressure, and bradyarrhythmia detected by implantable loop recorders, were linked to atrial fibrillation. This research provides a crucial methodological approach to unravel the unclear pathogenesis of atrial fibrillation in this unique athletic cohort. The findings will help inform targeted screening and preventive strategies for these individuals.</p>
<h4>Article 4: Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182010" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182010</a></p>
<p><strong>Summary:</strong> This cross-sectional study utilized dual contrast-enhanced microcomputed tomography to uncover distinct leaflet-dependent patterns of macrocalcification, fibrous extracellular matrix remodeling, and adipocyte degeneration in calcific aortic stenosis. Researchers investigated 45 diseased and 39 control tricuspid aortic valve leaflets, providing detailed insights into the specific pathological variations between different leaflets. The study confirmed interleaflet differences, advancing the understanding of aortic valve disease progression beyond generalized observations. This detailed characterization offers crucial information for developing more precise diagnostic tools and targeted therapeutic strategies for calcific aortic stenosis.</p>
<h4>Article 5: Admixture Mapping of Lipid Traits in Hispanic Americans.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182009" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182009</a></p>
<p><strong>Summary:</strong> This study leveraged admixture mapping to characterize fine-scale population structure and identify genomic loci associated with lipid traits in Hispanic Americans. Researchers analyzed 105108 participants from the multiethnic eMERGE-I.I.I. cohort, defining genetically admixed Hispanic Americans as individuals with 10 percent or greater Native American genetic ancestry. The study successfully applied reference panels from the 1000 Genomes Project and a Native American cohort to delineate population structure. This research provides a crucial framework for understanding genetic predispositions to dyslipidemia and can inform targeted prevention and treatment strategies for admixed populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of standardized team-based care on cardiogenic shock outcomes over time. This study investigated the impact of implementing standardized team-based protocols on cardiogenic shock outcomes over time. Researchers analyzed 1453 consecutive patients from a single-center cardiogenic shock registry, comparing outcomes between two periods: 2017-2019 and 2020-2022. This methodology aimed to determine the influence of multidisciplinary management strategies on patient outcomes. The research establishes a crucial framework for evaluating the effectiveness of structured care approaches in this critical condition.</p>
<p>Article number two. S.P.I.R.O.M.I.C.S. HeF.pEF: Rationale, Design, and Reproducibility of Measures. The S.P.I.R.O.M.I.C.S. HeF.pEF study outlines its rationale and design for investigating the complex interplay between chronic obstructive pulmonary disease and Heart Failure with Preserved Ejection Fraction. This research specifically tests hypotheses linking new computed tomography emphysema subtypes with distinct cardiovascular phenotypes, including cor pulmonale and cor pulmonale parvus. The study also focuses on common airway branch variations and the reproducibility of its measures, establishing a robust framework for future discoveries. This work is crucial for identifying shared underlying mechanisms and improving management strategies for patients with these often coexisting conditions.</p>
<p>Article number three. Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: V.E.N.T.O.U.X.-A.F. The V.E.N.T.O.U.X.-A.F. cross-sectional study investigated factors associated with atrial fibrillation in 39 veteran male endurance athletes, a population known for increased A.fib risk. Researchers aimed to determine if left atrial remodeling, assessed by cardiovascular magnetic resonance, exercise blood pressure, and bradyarrhythmia detected by implantable loop recorders, were linked to atrial fibrillation. This research provides a crucial methodological approach to unravel the unclear pathogenesis of atrial fibrillation in this unique athletic cohort. The findings will help inform targeted screening and preventive strategies for these individuals.</p>
<p>Article number four. Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis. This cross-sectional study utilized dual contrast-enhanced microcomputed tomography to uncover distinct leaflet-dependent patterns of macrocalcification, fibrous extracellular matrix remodeling, and adipocyte degeneration in calcific aortic stenosis. Researchers investigated 45 diseased and 39 control tricuspid aortic valve leaflets, providing detailed insights into the specific pathological variations between different leaflets. The study confirmed interleaflet differences, advancing the understanding of aortic valve disease progression beyond generalized observations. This detailed characterization offers crucial information for developing more precise diagnostic tools and targeted therapeutic strategies for calcific aortic stenosis.</p>
<p>Article number five. Admixture Mapping of Lipid Traits in Hispanic Americans. This study leveraged admixture mapping to characterize fine-scale population structure and identify genomic loci associated with lipid traits in Hispanic Americans. Researchers analyzed 105108 participants from the multiethnic eMERGE-I.I.I. cohort, defining genetically admixed Hispanic Americans as individuals with 10 percent or greater Native American genetic ancestry. The study successfully applied reference panels from the 1000 Genomes Project and a Native American cohort to delineate population structure. This research provides a crucial framework for understanding genetic predispositions to dyslipidemia and can inform targeted prevention and treatment strategies for admixed populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>computed tomography emphysema, population structure, Hispanic Americans, lipid traits, Heart Failure with Preserved Ejection Fraction, adipocyte degeneration, extracellular matrix remodeling, cardiovascular phenotypes, cardiovascular magnetic resonance, calcific aortic stenosis, atrial fibrillation, genomic loci, chronic obstructive pulmonary disease, in-hospital mortality, multidisciplinary management, team-based care, cor pulmonale, standardized protocols, leaflet calcification, endurance athletes, left atrial remodeling, microcomputed tomography, admixture mapping, implantable loop recorder, cardiogenic shock.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/">Aortic Stenosis: Leaflet-Specific Pathology Revealed 11/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography emphysema and population structure. Key takeaway: Aortic Stenosis: Leaflet-Specific Pathology Revealed.
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography emphysema and population structure. Key takeaway: Aortic Stenosis: Leaflet-Specific Pathology Revealed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41189091">Impact of standardized team-based care on cardiogenic shock outcomes over time.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41190426">SPIROMICS HF: Rationale, Design, and Reproducibility of Measures.</a> (Circulation. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41182011">Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41182010">Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41182009">Admixture Mapping of Lipid Traits in Hispanic Americans.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/">https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of standardized team-based care on cardiogenic shock outcomes over time.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41189091" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41189091</a></p>
<p><strong>Summary:</strong> This study investigated the impact of implementing standardized team-based protocols on cardiogenic shock outcomes over time. Researchers analyzed 1453 consecutive patients from a single-center cardiogenic shock registry, comparing outcomes between two periods: 2017-2019 and 2020-2022. This methodology aimed to determine the influence of multidisciplinary management strategies on patient outcomes. The research establishes a crucial framework for evaluating the effectiveness of structured care approaches in this critical condition.</p>
<h4>Article 2: SPIROMICS HF: Rationale, Design, and Reproducibility of Measures.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41190426" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41190426</a></p>
<p><strong>Summary:</strong> HeF.pEF: Rationale, Design, and Reproducibility of Measures. The S.P.I.R.O.M.I.C.S. HeF.pEF study outlines its rationale and design for investigating the complex interplay between chronic obstructive pulmonary disease and Heart Failure with Preserved Ejection Fraction. This research specifically tests hypotheses linking new computed tomography emphysema subtypes with distinct cardiovascular phenotypes, including cor pulmonale and cor pulmonale parvus. The study also focuses on common airway branch variations and the reproducibility of its measures, establishing a robust framework for future discoveries. This work is crucial for identifying shared underlying mechanisms and improving management strategies for patients with these often coexisting conditions.</p>
<h4>Article 3: Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182011" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182011</a></p>
<p><strong>Summary:</strong> The V.E.N.T.O.U.X.-A.F. cross-sectional study investigated factors associated with atrial fibrillation in 39 veteran male endurance athletes, a population known for increased A.fib risk. Researchers aimed to determine if left atrial remodeling, assessed by cardiovascular magnetic resonance, exercise blood pressure, and bradyarrhythmia detected by implantable loop recorders, were linked to atrial fibrillation. This research provides a crucial methodological approach to unravel the unclear pathogenesis of atrial fibrillation in this unique athletic cohort. The findings will help inform targeted screening and preventive strategies for these individuals.</p>
<h4>Article 4: Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182010" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182010</a></p>
<p><strong>Summary:</strong> This cross-sectional study utilized dual contrast-enhanced microcomputed tomography to uncover distinct leaflet-dependent patterns of macrocalcification, fibrous extracellular matrix remodeling, and adipocyte degeneration in calcific aortic stenosis. Researchers investigated 45 diseased and 39 control tricuspid aortic valve leaflets, providing detailed insights into the specific pathological variations between different leaflets. The study confirmed interleaflet differences, advancing the understanding of aortic valve disease progression beyond generalized observations. This detailed characterization offers crucial information for developing more precise diagnostic tools and targeted therapeutic strategies for calcific aortic stenosis.</p>
<h4>Article 5: Admixture Mapping of Lipid Traits in Hispanic Americans.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182009" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182009</a></p>
<p><strong>Summary:</strong> This study leveraged admixture mapping to characterize fine-scale population structure and identify genomic loci associated with lipid traits in Hispanic Americans. Researchers analyzed 105108 participants from the multiethnic eMERGE-I.I.I. cohort, defining genetically admixed Hispanic Americans as individuals with 10 percent or greater Native American genetic ancestry. The study successfully applied reference panels from the 1000 Genomes Project and a Native American cohort to delineate population structure. This research provides a crucial framework for understanding genetic predispositions to dyslipidemia and can inform targeted prevention and treatment strategies for admixed populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of standardized team-based care on cardiogenic shock outcomes over time. This study investigated the impact of implementing standardized team-based protocols on cardiogenic shock outcomes over time. Researchers analyzed 1453 consecutive patients from a single-center cardiogenic shock registry, comparing outcomes between two periods: 2017-2019 and 2020-2022. This methodology aimed to determine the influence of multidisciplinary management strategies on patient outcomes. The research establishes a crucial framework for evaluating the effectiveness of structured care approaches in this critical condition.</p>
<p>Article number two. S.P.I.R.O.M.I.C.S. HeF.pEF: Rationale, Design, and Reproducibility of Measures. The S.P.I.R.O.M.I.C.S. HeF.pEF study outlines its rationale and design for investigating the complex interplay between chronic obstructive pulmonary disease and Heart Failure with Preserved Ejection Fraction. This research specifically tests hypotheses linking new computed tomography emphysema subtypes with distinct cardiovascular phenotypes, including cor pulmonale and cor pulmonale parvus. The study also focuses on common airway branch variations and the reproducibility of its measures, establishing a robust framework for future discoveries. This work is crucial for identifying shared underlying mechanisms and improving management strategies for patients with these often coexisting conditions.</p>
<p>Article number three. Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: V.E.N.T.O.U.X.-A.F. The V.E.N.T.O.U.X.-A.F. cross-sectional study investigated factors associated with atrial fibrillation in 39 veteran male endurance athletes, a population known for increased A.fib risk. Researchers aimed to determine if left atrial remodeling, assessed by cardiovascular magnetic resonance, exercise blood pressure, and bradyarrhythmia detected by implantable loop recorders, were linked to atrial fibrillation. This research provides a crucial methodological approach to unravel the unclear pathogenesis of atrial fibrillation in this unique athletic cohort. The findings will help inform targeted screening and preventive strategies for these individuals.</p>
<p>Article number four. Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis. This cross-sectional study utilized dual contrast-enhanced microcomputed tomography to uncover distinct leaflet-dependent patterns of macrocalcification, fibrous extracellular matrix remodeling, and adipocyte degeneration in calcific aortic stenosis. Researchers investigated 45 diseased and 39 control tricuspid aortic valve leaflets, providing detailed insights into the specific pathological variations between different leaflets. The study confirmed interleaflet differences, advancing the understanding of aortic valve disease progression beyond generalized observations. This detailed characterization offers crucial information for developing more precise diagnostic tools and targeted therapeutic strategies for calcific aortic stenosis.</p>
<p>Article number five. Admixture Mapping of Lipid Traits in Hispanic Americans. This study leveraged admixture mapping to characterize fine-scale population structure and identify genomic loci associated with lipid traits in Hispanic Americans. Researchers analyzed 105108 participants from the multiethnic eMERGE-I.I.I. cohort, defining genetically admixed Hispanic Americans as individuals with 10 percent or greater Native American genetic ancestry. The study successfully applied reference panels from the 1000 Genomes Project and a Native American cohort to delineate population structure. This research provides a crucial framework for understanding genetic predispositions to dyslipidemia and can inform targeted prevention and treatment strategies for admixed populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>computed tomography emphysema, population structure, Hispanic Americans, lipid traits, Heart Failure with Preserved Ejection Fraction, adipocyte degeneration, extracellular matrix remodeling, cardiovascular phenotypes, cardiovascular magnetic resonance, calcific aortic stenosis, atrial fibrillation, genomic loci, chronic obstructive pulmonary disease, in-hospital mortality, multidisciplinary management, team-based care, cor pulmonale, standardized protocols, leaflet calcification, endurance athletes, left atrial remodeling, microcomputed tomography, admixture mapping, implantable loop recorder, cardiogenic shock.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/">Aortic Stenosis: Leaflet-Specific Pathology Revealed 11/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251105_122142.mp3" length="4925901" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography emphysema and population structure. Key takeaway: Aortic Stenosis: Leaflet-Specific Pathology Revealed.
Article Links:
Article 1: Impact of standardized team-based care on cardiogenic shock outcomes over time. (ESC heart failure)
Article 2: SPIROMICS HF: Rationale, Design, and Reproducibility of Measures. (Circulation. Heart failure)
Article 3: Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF. (Journal of the American Heart Association)
Article 4: Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis. (Journal of the American Heart Association)
Article 5: Admixture Mapping of Lipid Traits in Hispanic Americans. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/aortic-stenosis-leaflet-specific-pathology-revealed-11-05-25/
 Featured Articles
Article 1: Impact of standardized team-based care on cardiogenic shock outcomes over time.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41189091
Summary: This study investigated the impact of implementing standardized team-based protocols on cardiogenic shock outcomes over time. Researchers analyzed 1453 consecutive patients from a single-center cardiogenic shock registry, comparing outcomes between two periods: 2017-2019 and 2020-2022. This methodology aimed to determine the influence of multidisciplinary management strategies on patient outcomes. The research establishes a crucial framework for evaluating the effectiveness of structured care approaches in this critical condition.
Article 2: SPIROMICS HF: Rationale, Design, and Reproducibility of Measures.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41190426
Summary: HeF.pEF: Rationale, Design, and Reproducibility of Measures. The S.P.I.R.O.M.I.C.S. HeF.pEF study outlines its rationale and design for investigating the complex interplay between chronic obstructive pulmonary disease and Heart Failure with Preserved Ejection Fraction. This research specifically tests hypotheses linking new computed tomography emphysema subtypes with distinct cardiovascular phenotypes, including cor pulmonale and cor pulmonale parvus. The study also focuses on common airway branch variations and the reproducibility of its measures, establishing a robust framework for future discoveries. This work is crucial for identifying shared underlying mechanisms and improving management strategies for patients with these often coexisting conditions.
Article 3: Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182011
Summary: The V.E.N.T.O.U.X.-A.F. cross-sectional study investigated factors associated with atrial fibrillation in 39 veteran male endurance athletes, a population known for increased A.fib risk. Researchers aimed to determine if left atrial remodeling, assessed by cardiovascular magnetic resonance, exercise blood pressure, and bradyarrhythmia detected by implantable loop recorders, were linked to atrial fibrillation. This research provides a crucial methodological approach to unravel the unclear pathogenesis of atrial fibrillation in this unique athletic cohort. The findings will help inform targeted screening and preventive strategies for these individuals.
Article 4: Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis.
Journal: Journal of the]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography emphysema and population structure. Key takeaway: Aortic Stenosis: Leaflet-Specific Pathology Revealed.
Article Links:
Article 1: Impact of standardized team-based care on cardiogenic shock outcomes over time. (ESC heart failure)
Article 2: SPIROMICS HF: Rationale, Design, and Reproducibility of Measures. (Circulation. Heart failure)
Article 3: Clinical and Cardiovascular Magnetic Resonance Characteristics of Veteran Male Endurance Athletes With Atrial Fibrillation: VENTOUX-AF. (Journal of the American Heart Association)
Article 4: Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis. (Journal of the American Heart Association)
Article 5: Admixture Mapping of Lipid Traits in Hispanic Americans. (Jo]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aortic Dilation Growth Patterns Reshape Surveillance 11/05/25</title>
	<link>https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/</link>
	<pubDate>Wed, 05 Nov 2025 11:01:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like gender-affirming hormone therapy and United States. Key takeaway: Aortic Dilation Growth Patterns Reshape Surveillance.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41187090">Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41186217">Finerenone in patients with severe heart failure: The FINEARTS-HF trial.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41186108">Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41182171">Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41182163">Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/">https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41187090" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41187090</a></p>
<p><strong>Summary:</strong> This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.</p>
<h4>Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41186217" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41186217</a></p>
<p><strong>Summary:</strong> This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.</p>
<h4>Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41186108" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41186108</a></p>
<p><strong>Summary:</strong> This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin&#8217;s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.</p>
<h4>Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182171" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182171</a></p>
<p><strong>Summary:</strong> This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.</p>
<h4>Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182163" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182163</a></p>
<p><strong>Summary:</strong> This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.</p>
<p>Article number two. Finerenone in patients with severe heart failure: The FINEARTS-HF trial. This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.</p>
<p>Article number three. Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin&#8217;s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.</p>
<p>Article number four. Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.</p>
<p>Article number five. Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gender-affirming hormone therapy, United States, left ventricular ejection fraction, clinical trial, public health, heart failure, lifestyle factors, empagliflozin, chronic heart failure, ischemic heart disease, computed tomography angiography, sex disparities, mortality rates, fluid regulation, growth trajectories, transgender health, cardiovascular risk, imaging surveillance, mineralocorticoid receptor antagonist, aortic dissection, ascending aortic dilation, finerenone, socioeconomic status, sodium balance, randomized controlled trial.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/">Aortic Dilation Growth Patterns Reshape Surveillance 11/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like gender-affirming hormone therapy and United States. Key takeaway: Aortic Dilation Growth Patterns Reshape Surveillance.
Article Link]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like gender-affirming hormone therapy and United States. Key takeaway: Aortic Dilation Growth Patterns Reshape Surveillance.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41187090">Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41186217">Finerenone in patients with severe heart failure: The FINEARTS-HF trial.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41186108">Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41182171">Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41182163">Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/">https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41187090" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41187090</a></p>
<p><strong>Summary:</strong> This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.</p>
<h4>Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41186217" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41186217</a></p>
<p><strong>Summary:</strong> This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.</p>
<h4>Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41186108" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41186108</a></p>
<p><strong>Summary:</strong> This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin&#8217;s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.</p>
<h4>Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182171" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182171</a></p>
<p><strong>Summary:</strong> This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.</p>
<h4>Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41182163" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41182163</a></p>
<p><strong>Summary:</strong> This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.</p>
<p>Article number two. Finerenone in patients with severe heart failure: The FINEARTS-HF trial. This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.</p>
<p>Article number three. Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin&#8217;s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.</p>
<p>Article number four. Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.</p>
<p>Article number five. Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gender-affirming hormone therapy, United States, left ventricular ejection fraction, clinical trial, public health, heart failure, lifestyle factors, empagliflozin, chronic heart failure, ischemic heart disease, computed tomography angiography, sex disparities, mortality rates, fluid regulation, growth trajectories, transgender health, cardiovascular risk, imaging surveillance, mineralocorticoid receptor antagonist, aortic dissection, ascending aortic dilation, finerenone, socioeconomic status, sodium balance, randomized controlled trial.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/">Aortic Dilation Growth Patterns Reshape Surveillance 11/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251105_060032.mp3" length="4337832" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like gender-affirming hormone therapy and United States. Key takeaway: Aortic Dilation Growth Patterns Reshape Surveillance.
Article Links:
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. (European heart journal)
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial. (European journal of heart failure)
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. (European journal of heart failure)
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. (Journal of the American Heart Association)
Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/
 Featured Articles
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41187090
Summary: This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41186217
Summary: This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41186108
Summary: This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin&#8217;s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182171
Summary: This study analyzed sex disparities in ischemic hear]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like gender-affirming hormone therapy and United States. Key takeaway: Aortic Dilation Growth Patterns Reshape Surveillance.
Article Links:
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. (European heart journal)
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial. (European journal of heart failure)
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. (European journal of heart failure)
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. (Journal of the American Heart Association)
Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Prognostic Markers for Recovered E.F. Heart Failure 11/04/25</title>
	<link>https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/</link>
	<pubDate>Tue, 04 Nov 2025 11:01:58 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 04, 2025. This episode summarizes 5 key cardiology studies on topics like s.P.A.P. and evolocumab. Key takeaway: Prognostic Markers for Recovered E.F. Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41183181">Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41178584">Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41178569">Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41178538">Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41178541">Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/">https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41183181" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41183181</a></p>
<p><strong>Summary:</strong> The S.T.O.R.M.-P.E. trial conducted the first reported randomized controlled trial to evaluate the efficacy and safety of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy, combined with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism. This trial focused on patients with an elevated right ventricular to left ventricular diameter ratio, who are at increased risk of early clinical decompensation and mortality. By rigorously comparing these treatment strategies, the study established foundational data on whether mechanical thrombectomy can effectively relieve acute right ventricular pressure overload and normalize hemodynamics to improve patient outcomes.</p>
<h4>Article 2: Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178584" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178584</a></p>
<p><strong>Summary:</strong> This international multicenter cohort study aimed to evaluate the prognostic value of right ventricular-pulmonary arterial coupling in patients with primary mitral regurgitation. The study specifically assessed this coupling by measuring the ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure, both at rest and during exercise. By undertaking this comprehensive evaluation, the research established whether these non-invasive metrics provide a critical tool for risk stratification and improved management of patients with clinically significant primary mitral regurgitation.</p>
<h4>Article 3: Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178569" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178569</a></p>
<p><strong>Summary:</strong> This study investigated the efficacy and safety of achieving very low levels of low-density lipoproteins-cholesterol in patients with a history of ischemic stroke. Analyzing data from the F.O.U.R.I.E.R. trial, which studied evolocumab in stable atherosclerotic cardiovascular disease, researchers determined the impact of intensive L.D.L.-C reduction on recurrent stroke and other major adverse cardiovascular events. The findings provide crucial clarity on optimizing lipid management strategies for this high-risk patient population, aiming to improve secondary prevention outcomes following ischemic stroke.</p>
<h4>Article 4: Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178538" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178538</a></p>
<p><strong>Summary:</strong> This cross-sectional study investigated the role of circulating extracellular vesicles in mediating pathological kidney-heart crosstalk, which contributes to heart failure development in patients with chronic kidney disease. Recognizing that cardiovascular disease is a leading cause of death in chronic kidney disease patients and kidney-derived factors are implicated, the research aimed to identify specific humoral risk factors. By elucidating the mechanism through which these vesicles facilitate direct cardiotoxicity, the study provides a foundational understanding to potentially identify novel therapeutic targets for heart failure in this vulnerable population.</p>
<h4>Article 5: Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178541</a></p>
<p><strong>Summary:</strong> This retrospective cohort study, spanning from 2009 to 2024 and including 3935 patients, investigated the prognostic value of N-terminal pro-B-type natriuretic peptide levels in individuals with heart failure and recovered left ventricular ejection fraction. The research aimed to determine if N.T.-proB.N.P. measured at the time of left ventricular ejection fraction recovery is an independent predictor of future adverse outcomes. By establishing a robust clinical marker for prognosis in this patient group, the study provides an essential tool for risk stratification and guiding management strategies where such markers are currently lacking.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial. The S.T.O.R.M.-P.E. trial conducted the first reported randomized controlled trial to evaluate the efficacy and safety of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy, combined with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism. This trial focused on patients with an elevated right ventricular to left ventricular diameter ratio, who are at increased risk of early clinical decompensation and mortality. By rigorously comparing these treatment strategies, the study established foundational data on whether mechanical thrombectomy can effectively relieve acute right ventricular pressure overload and normalize hemodynamics to improve patient outcomes.</p>
<p>Article number two. Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation. This international multicenter cohort study aimed to evaluate the prognostic value of right ventricular-pulmonary arterial coupling in patients with primary mitral regurgitation. The study specifically assessed this coupling by measuring the ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure, both at rest and during exercise. By undertaking this comprehensive evaluation, the research established whether these non-invasive metrics provide a critical tool for risk stratification and improved management of patients with clinically significant primary mitral regurgitation.</p>
<p>Article number three. Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. This study investigated the efficacy and safety of achieving very low levels of low-density lipoproteins-cholesterol in patients with a history of ischemic stroke. Analyzing data from the F.O.U.R.I.E.R. trial, which studied evolocumab in stable atherosclerotic cardiovascular disease, researchers determined the impact of intensive L.D.L.-C reduction on recurrent stroke and other major adverse cardiovascular events. The findings provide crucial clarity on optimizing lipid management strategies for this high-risk patient population, aiming to improve secondary prevention outcomes following ischemic stroke.</p>
<p>Article number four. Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease. This cross-sectional study investigated the role of circulating extracellular vesicles in mediating pathological kidney-heart crosstalk, which contributes to heart failure development in patients with chronic kidney disease. Recognizing that cardiovascular disease is a leading cause of death in chronic kidney disease patients and kidney-derived factors are implicated, the research aimed to identify specific humoral risk factors. By elucidating the mechanism through which these vesicles facilitate direct cardiotoxicity, the study provides a foundational understanding to potentially identify novel therapeutic targets for heart failure in this vulnerable population.</p>
<p>Article number five. Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction. This retrospective cohort study, spanning from 2009 to 2024 and including 3935 patients, investigated the prognostic value of N-terminal pro-B-type natriuretic peptide levels in individuals with heart failure and recovered left ventricular ejection fraction. The research aimed to determine if N.T.-proB.N.P. measured at the time of left ventricular ejection fraction recovery is an independent predictor of future adverse outcomes. By establishing a robust clinical marker for prognosis in this patient group, the study provides an essential tool for risk stratification and guiding management strategies where such markers are currently lacking. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>s.P.A.P., evolocumab, left ventricular ejection fraction, anticoagulation, heart failure, L.D.L.-C, mitral regurgitation, T.A.P.S.E., kidney-heart crosstalk, ischemic stroke, recovered ejection fraction, M.A.C.E., extracellular vesicles, recurrent stroke, cardiotoxicity, prognosis, mechanical thrombectomy, chronic kidney disease, pulmonary embolism, right ventricular, intermediate-high risk, N.T.-proB.N.P., right ventricular-pulmonary arterial coupling.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/">Prognostic Markers for Recovered E.F. Heart Failure 11/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 04, 2025. This episode summarizes 5 key cardiology studies on topics like s.P.A.P. and evolocumab. Key takeaway: Prognostic Markers for Recovered E.F. Heart Failure.
Article Links:
Article 1: Randomized Con]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 04, 2025. This episode summarizes 5 key cardiology studies on topics like s.P.A.P. and evolocumab. Key takeaway: Prognostic Markers for Recovered E.F. Heart Failure.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41183181">Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41178584">Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41178569">Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41178538">Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41178541">Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/">https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41183181" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41183181</a></p>
<p><strong>Summary:</strong> The S.T.O.R.M.-P.E. trial conducted the first reported randomized controlled trial to evaluate the efficacy and safety of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy, combined with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism. This trial focused on patients with an elevated right ventricular to left ventricular diameter ratio, who are at increased risk of early clinical decompensation and mortality. By rigorously comparing these treatment strategies, the study established foundational data on whether mechanical thrombectomy can effectively relieve acute right ventricular pressure overload and normalize hemodynamics to improve patient outcomes.</p>
<h4>Article 2: Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178584" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178584</a></p>
<p><strong>Summary:</strong> This international multicenter cohort study aimed to evaluate the prognostic value of right ventricular-pulmonary arterial coupling in patients with primary mitral regurgitation. The study specifically assessed this coupling by measuring the ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure, both at rest and during exercise. By undertaking this comprehensive evaluation, the research established whether these non-invasive metrics provide a critical tool for risk stratification and improved management of patients with clinically significant primary mitral regurgitation.</p>
<h4>Article 3: Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178569" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178569</a></p>
<p><strong>Summary:</strong> This study investigated the efficacy and safety of achieving very low levels of low-density lipoproteins-cholesterol in patients with a history of ischemic stroke. Analyzing data from the F.O.U.R.I.E.R. trial, which studied evolocumab in stable atherosclerotic cardiovascular disease, researchers determined the impact of intensive L.D.L.-C reduction on recurrent stroke and other major adverse cardiovascular events. The findings provide crucial clarity on optimizing lipid management strategies for this high-risk patient population, aiming to improve secondary prevention outcomes following ischemic stroke.</p>
<h4>Article 4: Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178538" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178538</a></p>
<p><strong>Summary:</strong> This cross-sectional study investigated the role of circulating extracellular vesicles in mediating pathological kidney-heart crosstalk, which contributes to heart failure development in patients with chronic kidney disease. Recognizing that cardiovascular disease is a leading cause of death in chronic kidney disease patients and kidney-derived factors are implicated, the research aimed to identify specific humoral risk factors. By elucidating the mechanism through which these vesicles facilitate direct cardiotoxicity, the study provides a foundational understanding to potentially identify novel therapeutic targets for heart failure in this vulnerable population.</p>
<h4>Article 5: Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41178541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41178541</a></p>
<p><strong>Summary:</strong> This retrospective cohort study, spanning from 2009 to 2024 and including 3935 patients, investigated the prognostic value of N-terminal pro-B-type natriuretic peptide levels in individuals with heart failure and recovered left ventricular ejection fraction. The research aimed to determine if N.T.-proB.N.P. measured at the time of left ventricular ejection fraction recovery is an independent predictor of future adverse outcomes. By establishing a robust clinical marker for prognosis in this patient group, the study provides an essential tool for risk stratification and guiding management strategies where such markers are currently lacking.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial. The S.T.O.R.M.-P.E. trial conducted the first reported randomized controlled trial to evaluate the efficacy and safety of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy, combined with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism. This trial focused on patients with an elevated right ventricular to left ventricular diameter ratio, who are at increased risk of early clinical decompensation and mortality. By rigorously comparing these treatment strategies, the study established foundational data on whether mechanical thrombectomy can effectively relieve acute right ventricular pressure overload and normalize hemodynamics to improve patient outcomes.</p>
<p>Article number two. Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation. This international multicenter cohort study aimed to evaluate the prognostic value of right ventricular-pulmonary arterial coupling in patients with primary mitral regurgitation. The study specifically assessed this coupling by measuring the ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure, both at rest and during exercise. By undertaking this comprehensive evaluation, the research established whether these non-invasive metrics provide a critical tool for risk stratification and improved management of patients with clinically significant primary mitral regurgitation.</p>
<p>Article number three. Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. This study investigated the efficacy and safety of achieving very low levels of low-density lipoproteins-cholesterol in patients with a history of ischemic stroke. Analyzing data from the F.O.U.R.I.E.R. trial, which studied evolocumab in stable atherosclerotic cardiovascular disease, researchers determined the impact of intensive L.D.L.-C reduction on recurrent stroke and other major adverse cardiovascular events. The findings provide crucial clarity on optimizing lipid management strategies for this high-risk patient population, aiming to improve secondary prevention outcomes following ischemic stroke.</p>
<p>Article number four. Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease. This cross-sectional study investigated the role of circulating extracellular vesicles in mediating pathological kidney-heart crosstalk, which contributes to heart failure development in patients with chronic kidney disease. Recognizing that cardiovascular disease is a leading cause of death in chronic kidney disease patients and kidney-derived factors are implicated, the research aimed to identify specific humoral risk factors. By elucidating the mechanism through which these vesicles facilitate direct cardiotoxicity, the study provides a foundational understanding to potentially identify novel therapeutic targets for heart failure in this vulnerable population.</p>
<p>Article number five. Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction. This retrospective cohort study, spanning from 2009 to 2024 and including 3935 patients, investigated the prognostic value of N-terminal pro-B-type natriuretic peptide levels in individuals with heart failure and recovered left ventricular ejection fraction. The research aimed to determine if N.T.-proB.N.P. measured at the time of left ventricular ejection fraction recovery is an independent predictor of future adverse outcomes. By establishing a robust clinical marker for prognosis in this patient group, the study provides an essential tool for risk stratification and guiding management strategies where such markers are currently lacking. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>s.P.A.P., evolocumab, left ventricular ejection fraction, anticoagulation, heart failure, L.D.L.-C, mitral regurgitation, T.A.P.S.E., kidney-heart crosstalk, ischemic stroke, recovered ejection fraction, M.A.C.E., extracellular vesicles, recurrent stroke, cardiotoxicity, prognosis, mechanical thrombectomy, chronic kidney disease, pulmonary embolism, right ventricular, intermediate-high risk, N.T.-proB.N.P., right ventricular-pulmonary arterial coupling.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/">Prognostic Markers for Recovered E.F. Heart Failure 11/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251104_060049.mp3" length="4577323" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 04, 2025. This episode summarizes 5 key cardiology studies on topics like s.P.A.P. and evolocumab. Key takeaway: Prognostic Markers for Recovered E.F. Heart Failure.
Article Links:
Article 1: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial. (Circulation)
Article 2: Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation. (Circulation)
Article 3: Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. (Circulation)
Article 4: Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease. (Circulation)
Article 5: Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/prognostic-markers-for-recovered-e-f-heart-failure-11-04-25/
 Featured Articles
Article 1: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41183181
Summary: The S.T.O.R.M.-P.E. trial conducted the first reported randomized controlled trial to evaluate the efficacy and safety of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy, combined with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism. This trial focused on patients with an elevated right ventricular to left ventricular diameter ratio, who are at increased risk of early clinical decompensation and mortality. By rigorously comparing these treatment strategies, the study established foundational data on whether mechanical thrombectomy can effectively relieve acute right ventricular pressure overload and normalize hemodynamics to improve patient outcomes.
Article 2: Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41178584
Summary: This international multicenter cohort study aimed to evaluate the prognostic value of right ventricular-pulmonary arterial coupling in patients with primary mitral regurgitation. The study specifically assessed this coupling by measuring the ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure, both at rest and during exercise. By undertaking this comprehensive evaluation, the research established whether these non-invasive metrics provide a critical tool for risk stratification and improved management of patients with clinically significant primary mitral regurgitation.
Article 3: Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41178569
Summary: This study investigated the efficacy and safety of achieving very low levels of low-density lipoproteins-cholesterol in patients with a history of ischemic stroke. Analyzing data from the F.O.U.R.I.E.R. trial, which studied evolocumab in stable atherosclerotic cardiovascular disease, researchers determined the impact of intensive L.D.L.-C reduction on recurrent stroke and other major adverse cardiovascular events. The findings provide crucial clarity on optimizing lipid management strategies for this high-risk patient population, aiming to improve secondary prevention outcomes following ischemic stroke.
Article 4: Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41178538
Summary: This cross-sec]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 04, 2025. This episode summarizes 5 key cardiology studies on topics like s.P.A.P. and evolocumab. Key takeaway: Prognostic Markers for Recovered E.F. Heart Failure.
Article Links:
Article 1: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial. (Circulation)
Article 2: Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation. (Circulation)
Article 3: Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. (Circulation)
Article 4: Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients with Chronic Kidney Disease. (Circulation)
Article 5: Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction. (Circulation. Heart failure)
Full episode p]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Self-Powered Pacemakers: Heart&#8217;s Own Energy 11/03/25</title>
	<link>https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/</link>
	<pubDate>Mon, 03 Nov 2025 11:01:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like fetal tachycardia and digoxin. Key takeaway: Self-Powered Pacemakers: Heart&#8217;s Own Energy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40578654">Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40499804">Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40472946">Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40436356">Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40412599">The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/">https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40578654" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40578654</a></p>
<p><strong>Summary:</strong> isthmus location, shape, and orientation. This study aimed to improve the identification of ventricular tachycardia (V.T.) isthmus characteristics using substrate mapping. Researchers conducted 31 canine postinfarction experiments, creating an infarct and border zone in the anterior left ventricle. The findings suggest that narrowed sinus rhythm electrograms in the zone of uniform slow conduction are valuable markers for precisely identifying the location, shape, and orientation of the V.T. isthmus. This advancement provides a more accurate method for delineating V.T. reentry circuits, which is critical for successful catheter ablation.</p>
<h4>Article 2: Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40499804" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40499804</a></p>
<p><strong>Summary:</strong> This study explored the innovative concept of bioelectric energy harvesting directly from myocardial tissue in vivo. Researchers developed an electrophysiological measurement system utilizing microneedle electrodes to collect energy from the heart. The investigation compared the available harvested energy with the energy consumption required for cardiac pacing. This research demonstrates the potential feasibility of an internal, self-powered energy source for cardiac devices, representing a significant step towards eliminating the need for traditional batteries in pacemakers.</p>
<h4>Article 3: Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40472946" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40472946</a></p>
<p><strong>Summary:</strong> This retrospective cohort study investigated predictors of prolonged hospitalization following catheter ablation of ventricular tachycardia (V.T.) in patients with structural heart disease. Researchers analyzed 318 patient cases between January 2022 and October 2024, defining prolonged hospitalization as a post-ablation length of stay greater than seven days. The study successfully identified key factors predicting extended hospitalization after V.T. ablation, along with their subsequent impact on patient outcomes. These findings are critical for improving patient selection, optimizing post-procedural care strategies, and potentially reducing adverse events.</p>
<h4>Article 4: Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40436356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40436356</a></p>
<p><strong>Summary:</strong> This study aimed to evaluate the impact of leadless left ventricular (L.V.) endocardial pacing and leadless left bundle branch area pacing (L.B.B.A.P.) on biventricular repolarization metrics. The researchers analyzed data derived from electrocardiographic (E.C.G.) imaging to assess these effects, contrasting them with traditional cardiac resynchronization therapy (C.R.T.) delivered via L.V. epicardial pacing. The findings demonstrated how these leadless pacing modalities may preserve a more physiological transmural activation pattern, thereby potentially mitigating arrhythmic risk. This research provides crucial insights for developing safer and more effective cardiac resynchronization strategies for patients needing advanced pacing.</p>
<h4>Article 5: The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40412599" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40412599</a></p>
<p><strong>Summary:</strong> This retrospective case series investigated the safety and effectiveness of transplacental antiarrhythmic therapy for non-hydropic fetal tachycardia. The study evaluated the complex relationship between maternal digoxin and flecainide doses, corresponding maternal and umbilical cord concentrations, and any associated side effects. Researchers included 28 pregnant women initially treated with digoxin monotherapy for fetal tachycardia. This important research provides clearer guidance on optimizing antiarrhythmic drug dosages, contributing to safer and more effective management of fetal arrhythmias.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify V.T. isthmus location, shape, and orientation. This study aimed to improve the identification of ventricular tachycardia (V.T.) isthmus characteristics using substrate mapping. Researchers conducted 31 canine postinfarction experiments, creating an infarct and border zone in the anterior left ventricle. The findings suggest that narrowed sinus rhythm electrograms in the zone of uniform slow conduction are valuable markers for precisely identifying the location, shape, and orientation of the V.T. isthmus. This advancement provides a more accurate method for delineating V.T. reentry circuits, which is critical for successful catheter ablation.</p>
<p>Article number two. Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection. This study explored the innovative concept of bioelectric energy harvesting directly from myocardial tissue in vivo. Researchers developed an electrophysiological measurement system utilizing microneedle electrodes to collect energy from the heart. The investigation compared the available harvested energy with the energy consumption required for cardiac pacing. This research demonstrates the potential feasibility of an internal, self-powered energy source for cardiac devices, representing a significant step towards eliminating the need for traditional batteries in pacemakers.</p>
<p>Article number three. Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes. This retrospective cohort study investigated predictors of prolonged hospitalization following catheter ablation of ventricular tachycardia (V.T.) in patients with structural heart disease. Researchers analyzed 318 patient cases between January 2022 and October 2024, defining prolonged hospitalization as a post-ablation length of stay greater than seven days. The study successfully identified key factors predicting extended hospitalization after V.T. ablation, along with their subsequent impact on patient outcomes. These findings are critical for improving patient selection, optimizing post-procedural care strategies, and potentially reducing adverse events.</p>
<p>Article number four. Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics. This study aimed to evaluate the impact of leadless left ventricular (L.V.) endocardial pacing and leadless left bundle branch area pacing (L.B.B.A.P.) on biventricular repolarization metrics. The researchers analyzed data derived from electrocardiographic (E.C.G.) imaging to assess these effects, contrasting them with traditional cardiac resynchronization therapy (C.R.T.) delivered via L.V. epicardial pacing. The findings demonstrated how these leadless pacing modalities may preserve a more physiological transmural activation pattern, thereby potentially mitigating arrhythmic risk. This research provides crucial insights for developing safer and more effective cardiac resynchronization strategies for patients needing advanced pacing.</p>
<p>Article number five. The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia. This retrospective case series investigated the safety and effectiveness of transplacental antiarrhythmic therapy for non-hydropic fetal tachycardia. The study evaluated the complex relationship between maternal digoxin and flecainide doses, corresponding maternal and umbilical cord concentrations, and any associated side effects. Researchers included 28 pregnant women initially treated with digoxin monotherapy for fetal tachycardia. This important research provides clearer guidance on optimizing antiarrhythmic drug dosages, contributing to safer and more effective management of fetal arrhythmias. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>fetal tachycardia, digoxin, ventricular repolarization, flecainide, myocardial tissue, in vivo, V.T. isthmus, maternal exposure, patient outcomes, left ventricular pacing, self-powered devices, left bundle branch area pacing, structural heart disease, catheter ablation, ventricular tachycardia, transplacental antiarrhythmic therapy, ventricular tachycardia ablation, retrospective case series, substrate mapping, bioelectric energy harvesting, electrocardiographic imaging, prolonged hospitalization, cardiac resynchronization therapy, electrograms, retrospective cohort study, leadless pacing, cardiac pacing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/">Self-Powered Pacemakers: Heart’s Own Energy 11/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like fetal tachycardia and digoxin. Key takeaway: Self-Powered Pacemakers: Heart&#8217;s Own Energy.
Article Links:
Article 1: Narrowed s]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like fetal tachycardia and digoxin. Key takeaway: Self-Powered Pacemakers: Heart&#8217;s Own Energy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40578654">Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40499804">Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40472946">Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40436356">Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40412599">The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/">https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40578654" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40578654</a></p>
<p><strong>Summary:</strong> isthmus location, shape, and orientation. This study aimed to improve the identification of ventricular tachycardia (V.T.) isthmus characteristics using substrate mapping. Researchers conducted 31 canine postinfarction experiments, creating an infarct and border zone in the anterior left ventricle. The findings suggest that narrowed sinus rhythm electrograms in the zone of uniform slow conduction are valuable markers for precisely identifying the location, shape, and orientation of the V.T. isthmus. This advancement provides a more accurate method for delineating V.T. reentry circuits, which is critical for successful catheter ablation.</p>
<h4>Article 2: Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40499804" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40499804</a></p>
<p><strong>Summary:</strong> This study explored the innovative concept of bioelectric energy harvesting directly from myocardial tissue in vivo. Researchers developed an electrophysiological measurement system utilizing microneedle electrodes to collect energy from the heart. The investigation compared the available harvested energy with the energy consumption required for cardiac pacing. This research demonstrates the potential feasibility of an internal, self-powered energy source for cardiac devices, representing a significant step towards eliminating the need for traditional batteries in pacemakers.</p>
<h4>Article 3: Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40472946" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40472946</a></p>
<p><strong>Summary:</strong> This retrospective cohort study investigated predictors of prolonged hospitalization following catheter ablation of ventricular tachycardia (V.T.) in patients with structural heart disease. Researchers analyzed 318 patient cases between January 2022 and October 2024, defining prolonged hospitalization as a post-ablation length of stay greater than seven days. The study successfully identified key factors predicting extended hospitalization after V.T. ablation, along with their subsequent impact on patient outcomes. These findings are critical for improving patient selection, optimizing post-procedural care strategies, and potentially reducing adverse events.</p>
<h4>Article 4: Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40436356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40436356</a></p>
<p><strong>Summary:</strong> This study aimed to evaluate the impact of leadless left ventricular (L.V.) endocardial pacing and leadless left bundle branch area pacing (L.B.B.A.P.) on biventricular repolarization metrics. The researchers analyzed data derived from electrocardiographic (E.C.G.) imaging to assess these effects, contrasting them with traditional cardiac resynchronization therapy (C.R.T.) delivered via L.V. epicardial pacing. The findings demonstrated how these leadless pacing modalities may preserve a more physiological transmural activation pattern, thereby potentially mitigating arrhythmic risk. This research provides crucial insights for developing safer and more effective cardiac resynchronization strategies for patients needing advanced pacing.</p>
<h4>Article 5: The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40412599" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40412599</a></p>
<p><strong>Summary:</strong> This retrospective case series investigated the safety and effectiveness of transplacental antiarrhythmic therapy for non-hydropic fetal tachycardia. The study evaluated the complex relationship between maternal digoxin and flecainide doses, corresponding maternal and umbilical cord concentrations, and any associated side effects. Researchers included 28 pregnant women initially treated with digoxin monotherapy for fetal tachycardia. This important research provides clearer guidance on optimizing antiarrhythmic drug dosages, contributing to safer and more effective management of fetal arrhythmias.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify V.T. isthmus location, shape, and orientation. This study aimed to improve the identification of ventricular tachycardia (V.T.) isthmus characteristics using substrate mapping. Researchers conducted 31 canine postinfarction experiments, creating an infarct and border zone in the anterior left ventricle. The findings suggest that narrowed sinus rhythm electrograms in the zone of uniform slow conduction are valuable markers for precisely identifying the location, shape, and orientation of the V.T. isthmus. This advancement provides a more accurate method for delineating V.T. reentry circuits, which is critical for successful catheter ablation.</p>
<p>Article number two. Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection. This study explored the innovative concept of bioelectric energy harvesting directly from myocardial tissue in vivo. Researchers developed an electrophysiological measurement system utilizing microneedle electrodes to collect energy from the heart. The investigation compared the available harvested energy with the energy consumption required for cardiac pacing. This research demonstrates the potential feasibility of an internal, self-powered energy source for cardiac devices, representing a significant step towards eliminating the need for traditional batteries in pacemakers.</p>
<p>Article number three. Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes. This retrospective cohort study investigated predictors of prolonged hospitalization following catheter ablation of ventricular tachycardia (V.T.) in patients with structural heart disease. Researchers analyzed 318 patient cases between January 2022 and October 2024, defining prolonged hospitalization as a post-ablation length of stay greater than seven days. The study successfully identified key factors predicting extended hospitalization after V.T. ablation, along with their subsequent impact on patient outcomes. These findings are critical for improving patient selection, optimizing post-procedural care strategies, and potentially reducing adverse events.</p>
<p>Article number four. Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics. This study aimed to evaluate the impact of leadless left ventricular (L.V.) endocardial pacing and leadless left bundle branch area pacing (L.B.B.A.P.) on biventricular repolarization metrics. The researchers analyzed data derived from electrocardiographic (E.C.G.) imaging to assess these effects, contrasting them with traditional cardiac resynchronization therapy (C.R.T.) delivered via L.V. epicardial pacing. The findings demonstrated how these leadless pacing modalities may preserve a more physiological transmural activation pattern, thereby potentially mitigating arrhythmic risk. This research provides crucial insights for developing safer and more effective cardiac resynchronization strategies for patients needing advanced pacing.</p>
<p>Article number five. The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia. This retrospective case series investigated the safety and effectiveness of transplacental antiarrhythmic therapy for non-hydropic fetal tachycardia. The study evaluated the complex relationship between maternal digoxin and flecainide doses, corresponding maternal and umbilical cord concentrations, and any associated side effects. Researchers included 28 pregnant women initially treated with digoxin monotherapy for fetal tachycardia. This important research provides clearer guidance on optimizing antiarrhythmic drug dosages, contributing to safer and more effective management of fetal arrhythmias. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>fetal tachycardia, digoxin, ventricular repolarization, flecainide, myocardial tissue, in vivo, V.T. isthmus, maternal exposure, patient outcomes, left ventricular pacing, self-powered devices, left bundle branch area pacing, structural heart disease, catheter ablation, ventricular tachycardia, transplacental antiarrhythmic therapy, ventricular tachycardia ablation, retrospective case series, substrate mapping, bioelectric energy harvesting, electrocardiographic imaging, prolonged hospitalization, cardiac resynchronization therapy, electrograms, retrospective cohort study, leadless pacing, cardiac pacing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/">Self-Powered Pacemakers: Heart’s Own Energy 11/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251103_060039.mp3" length="4657153" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like fetal tachycardia and digoxin. Key takeaway: Self-Powered Pacemakers: Heart&#8217;s Own Energy.
Article Links:
Article 1: Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation. (Heart rhythm)
Article 2: Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection. (Heart rhythm)
Article 3: Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes. (Heart rhythm)
Article 4: Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics. (Heart rhythm)
Article 5: The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/self-powered-pacemakers-hearts-own-energy-11-03-25/
 Featured Articles
Article 1: Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40578654
Summary: isthmus location, shape, and orientation. This study aimed to improve the identification of ventricular tachycardia (V.T.) isthmus characteristics using substrate mapping. Researchers conducted 31 canine postinfarction experiments, creating an infarct and border zone in the anterior left ventricle. The findings suggest that narrowed sinus rhythm electrograms in the zone of uniform slow conduction are valuable markers for precisely identifying the location, shape, and orientation of the V.T. isthmus. This advancement provides a more accurate method for delineating V.T. reentry circuits, which is critical for successful catheter ablation.
Article 2: Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40499804
Summary: This study explored the innovative concept of bioelectric energy harvesting directly from myocardial tissue in vivo. Researchers developed an electrophysiological measurement system utilizing microneedle electrodes to collect energy from the heart. The investigation compared the available harvested energy with the energy consumption required for cardiac pacing. This research demonstrates the potential feasibility of an internal, self-powered energy source for cardiac devices, representing a significant step towards eliminating the need for traditional batteries in pacemakers.
Article 3: Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40472946
Summary: This retrospective cohort study investigated predictors of prolonged hospitalization following catheter ablation of ventricular tachycardia (V.T.) in patients with structural heart disease. Researchers analyzed 318 patient cases between January 2022 and October 2024, defining prolonged hospitalization as a post-ablation length of stay greater than seven days. The study successfully identified key factors predicting extended hospitalization after V.T. ablation, along with their subsequent impact on patient outcomes. These findings are critical for improving patient selection, optimizing post-procedural care strategies, and potentially reducing adverse events.
Article 4: Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40436356
Summary: This study aimed to evaluate the impact of leadless left ventricular (L.V.) endocardial pacing and leadless left bundle bran]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like fetal tachycardia and digoxin. Key takeaway: Self-Powered Pacemakers: Heart&#8217;s Own Energy.
Article Links:
Article 1: Narrowed sinus rhythm electrograms in the zone of uniform slow conduction are helpful to identify VT isthmus location, shape, and orientation. (Heart rhythm)
Article 2: Bioelectric energy harvesting from myocardial tissue in vivo: A new method for biological energy collection. (Heart rhythm)
Article 3: Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomes. (Heart rhythm)
Article 4: Effect of leadless left ventricular endocardial and left bundle branch area pacing on biventricular repolarization metrics. (Heart rhythm)
Article 5: The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia. (Heart rhythm)
Full episode ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Young Adult Lipoproteins Predict Future A.S.C.V.D. 11/03/25</title>
	<link>https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/</link>
	<pubDate>Mon, 03 Nov 2025 06:57:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like electrophysiology and non-obstructive hypertrophic cardiomyopathy. Key takeaway: Young Adult Lipoproteins Predict Future A.S.C.V.D..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40626880">Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40613415">Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41177219">Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial.</a> (Journal of cardiac failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40714334">Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40609818">Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/">https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40626880" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40626880</a></p>
<p><strong>Summary:</strong> This study from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) cohort investigated the association between dietary carbohydrate quality and fibre-rich food intake with left ventricular structure and function. The research aimed to clarify how specific macronutrient and food group intakes relate to cardiac phenotypes, a critical step in understanding progression to heart failure. Identifying these lifestyle risk factors is essential for developing strategies to prevent or slow cardiac dysfunction.</p>
<h4>Article 2: Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40613415" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40613415</a></p>
<p><strong>Summary:</strong> This research quantified the relationship between cumulative and usual yearly exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Utilizing follow-up data of young adults aged 18 to less than 40 years from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) study, this investigation focused on apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles. The study established that such exposure during early adulthood significantly increases future atherosclerotic cardiovascular disease risk, providing critical data for understanding early life risk factors and informing preventative strategies.</p>
<h4>Article 3: Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41177219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41177219</a></p>
<p><strong>Summary:</strong> The P.O.L.Y.-H.F. trial was designed to evaluate a polypill strategy for patients with heart failure with reduced ejection fraction, addressing suboptimal real-world utilization of guideline-directed medical therapy. This open-label randomized controlled trial, conducted across two centers, enrolled adults with a left ventricular ejection fraction of 40 percent or less who were not receiving targeted guideline-directed medical therapy. The study&#8217;s rationale, design, and baseline characteristics provide a foundational framework for investigating whether a simplified polypill regimen can improve therapeutic adherence and patient outcomes in this population.</p>
<h4>Article 4: Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40714334" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40714334</a></p>
<p><strong>Summary:</strong> This randomized crossover trial was designed to determine the effects of accelerated Bachmann bundle area pacing in symptomatic patients presenting with non-obstructive hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, and inter-atrial block. Recognizing that inter-atrial block can worsen diastolic dysfunction in heart failure with preserved ejection fraction, this prospective, patient-blinded study recruited patients for dual-chamber implantable cardioverter-defibrillator placement. The research establishes a crucial methodology for evaluating this novel atrial resynchronization strategy, aiming to uncover potential therapeutic benefits for a challenging patient population.</p>
<h4>Article 5: Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40609818" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40609818</a></p>
<p><strong>Summary:</strong> This study investigated the electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients with congenital heart disease, aiming to understand its potential role in the earlier onset and faster progression of atrial fibrillation. Bachmann&#8217;s bundle mapping was performed in 55 pediatric patients ranging from 0.2 to 18 years old during catheter ablation procedures. The research also sought to assess the impact of age on Bachmann&#8217;s bundle electrophysiology in this vulnerable population. Establishing these electrophysiological alterations in pediatric congenital heart disease patients is crucial for early intervention strategies against atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study. This study from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) cohort investigated the association between dietary carbohydrate quality and fibre-rich food intake with left ventricular structure and function. The research aimed to clarify how specific macronutrient and food group intakes relate to cardiac phenotypes, a critical step in understanding progression to heart failure. Identifying these lifestyle risk factors is essential for developing strategies to prevent or slow cardiac dysfunction.</p>
<p>Article number two. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. This research quantified the relationship between cumulative and usual yearly exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Utilizing follow-up data of young adults aged 18 to less than 40 years from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) study, this investigation focused on apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles. The study established that such exposure during early adulthood significantly increases future atherosclerotic cardiovascular disease risk, providing critical data for understanding early life risk factors and informing preventative strategies.</p>
<p>Article number three. Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial. The P.O.L.Y.-H.F. trial was designed to evaluate a polypill strategy for patients with heart failure with reduced ejection fraction, addressing suboptimal real-world utilization of guideline-directed medical therapy. This open-label randomized controlled trial, conducted across two centers, enrolled adults with a left ventricular ejection fraction of 40 percent or less who were not receiving targeted guideline-directed medical therapy. The study&#8217;s rationale, design, and baseline characteristics provide a foundational framework for investigating whether a simplified polypill regimen can improve therapeutic adherence and patient outcomes in this population.</p>
<p>Article number four. Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial. This randomized crossover trial was designed to determine the effects of accelerated Bachmann bundle area pacing in symptomatic patients presenting with non-obstructive hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, and inter-atrial block. Recognizing that inter-atrial block can worsen diastolic dysfunction in heart failure with preserved ejection fraction, this prospective, patient-blinded study recruited patients for dual-chamber implantable cardioverter-defibrillator placement. The research establishes a crucial methodology for evaluating this novel atrial resynchronization strategy, aiming to uncover potential therapeutic benefits for a challenging patient population.</p>
<p>Article number five. Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients. This study investigated the electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients with congenital heart disease, aiming to understand its potential role in the earlier onset and faster progression of atrial fibrillation. Bachmann&#8217;s bundle mapping was performed in 55 pediatric patients ranging from 0.2 to 18 years old during catheter ablation procedures. The research also sought to assess the impact of age on Bachmann&#8217;s bundle electrophysiology in this vulnerable population. Establishing these electrophysiological alterations in pediatric congenital heart disease patients is crucial for early intervention strategies against atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>electrophysiology, non-obstructive hypertrophic cardiomyopathy, guideline-directed medical therapy, Bachmann&#8217;s bundle, left ventricular structure, pediatric cardiology, therapeutic adherence, heart failure with reduced ejection fraction, heart failure prevention, carbohydrate quality, fibre-rich foods, inter-atrial block, apolipoprotein B, polypill, atrial fibrillation, left ventricular function, low-density lipoprotein particle, heart failure with preserved ejection fraction, atherosclerotic cardiovascular disease, atherogenic lipoprotein particles, atrial resynchronization, congenital heart disease, triglyceride-rich lipoprotein particle, Bachmann bundle area pacing, randomized controlled trial.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/">Young Adult Lipoproteins Predict Future A.S.C.V.D. 11/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like electrophysiology and non-obstructive hypertrophic cardiomyopathy. Key takeaway: Young Adult Lipoproteins Predict Future A.S.C.V.D..]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like electrophysiology and non-obstructive hypertrophic cardiomyopathy. Key takeaway: Young Adult Lipoproteins Predict Future A.S.C.V.D..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40626880">Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40613415">Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41177219">Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial.</a> (Journal of cardiac failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40714334">Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40609818">Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/">https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40626880" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40626880</a></p>
<p><strong>Summary:</strong> This study from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) cohort investigated the association between dietary carbohydrate quality and fibre-rich food intake with left ventricular structure and function. The research aimed to clarify how specific macronutrient and food group intakes relate to cardiac phenotypes, a critical step in understanding progression to heart failure. Identifying these lifestyle risk factors is essential for developing strategies to prevent or slow cardiac dysfunction.</p>
<h4>Article 2: Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40613415" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40613415</a></p>
<p><strong>Summary:</strong> This research quantified the relationship between cumulative and usual yearly exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Utilizing follow-up data of young adults aged 18 to less than 40 years from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) study, this investigation focused on apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles. The study established that such exposure during early adulthood significantly increases future atherosclerotic cardiovascular disease risk, providing critical data for understanding early life risk factors and informing preventative strategies.</p>
<h4>Article 3: Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41177219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41177219</a></p>
<p><strong>Summary:</strong> The P.O.L.Y.-H.F. trial was designed to evaluate a polypill strategy for patients with heart failure with reduced ejection fraction, addressing suboptimal real-world utilization of guideline-directed medical therapy. This open-label randomized controlled trial, conducted across two centers, enrolled adults with a left ventricular ejection fraction of 40 percent or less who were not receiving targeted guideline-directed medical therapy. The study&#8217;s rationale, design, and baseline characteristics provide a foundational framework for investigating whether a simplified polypill regimen can improve therapeutic adherence and patient outcomes in this population.</p>
<h4>Article 4: Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40714334" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40714334</a></p>
<p><strong>Summary:</strong> This randomized crossover trial was designed to determine the effects of accelerated Bachmann bundle area pacing in symptomatic patients presenting with non-obstructive hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, and inter-atrial block. Recognizing that inter-atrial block can worsen diastolic dysfunction in heart failure with preserved ejection fraction, this prospective, patient-blinded study recruited patients for dual-chamber implantable cardioverter-defibrillator placement. The research establishes a crucial methodology for evaluating this novel atrial resynchronization strategy, aiming to uncover potential therapeutic benefits for a challenging patient population.</p>
<h4>Article 5: Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40609818" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40609818</a></p>
<p><strong>Summary:</strong> This study investigated the electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients with congenital heart disease, aiming to understand its potential role in the earlier onset and faster progression of atrial fibrillation. Bachmann&#8217;s bundle mapping was performed in 55 pediatric patients ranging from 0.2 to 18 years old during catheter ablation procedures. The research also sought to assess the impact of age on Bachmann&#8217;s bundle electrophysiology in this vulnerable population. Establishing these electrophysiological alterations in pediatric congenital heart disease patients is crucial for early intervention strategies against atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study. This study from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) cohort investigated the association between dietary carbohydrate quality and fibre-rich food intake with left ventricular structure and function. The research aimed to clarify how specific macronutrient and food group intakes relate to cardiac phenotypes, a critical step in understanding progression to heart failure. Identifying these lifestyle risk factors is essential for developing strategies to prevent or slow cardiac dysfunction.</p>
<p>Article number two. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. This research quantified the relationship between cumulative and usual yearly exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Utilizing follow-up data of young adults aged 18 to less than 40 years from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) study, this investigation focused on apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles. The study established that such exposure during early adulthood significantly increases future atherosclerotic cardiovascular disease risk, providing critical data for understanding early life risk factors and informing preventative strategies.</p>
<p>Article number three. Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial. The P.O.L.Y.-H.F. trial was designed to evaluate a polypill strategy for patients with heart failure with reduced ejection fraction, addressing suboptimal real-world utilization of guideline-directed medical therapy. This open-label randomized controlled trial, conducted across two centers, enrolled adults with a left ventricular ejection fraction of 40 percent or less who were not receiving targeted guideline-directed medical therapy. The study&#8217;s rationale, design, and baseline characteristics provide a foundational framework for investigating whether a simplified polypill regimen can improve therapeutic adherence and patient outcomes in this population.</p>
<p>Article number four. Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial. This randomized crossover trial was designed to determine the effects of accelerated Bachmann bundle area pacing in symptomatic patients presenting with non-obstructive hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, and inter-atrial block. Recognizing that inter-atrial block can worsen diastolic dysfunction in heart failure with preserved ejection fraction, this prospective, patient-blinded study recruited patients for dual-chamber implantable cardioverter-defibrillator placement. The research establishes a crucial methodology for evaluating this novel atrial resynchronization strategy, aiming to uncover potential therapeutic benefits for a challenging patient population.</p>
<p>Article number five. Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients. This study investigated the electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients with congenital heart disease, aiming to understand its potential role in the earlier onset and faster progression of atrial fibrillation. Bachmann&#8217;s bundle mapping was performed in 55 pediatric patients ranging from 0.2 to 18 years old during catheter ablation procedures. The research also sought to assess the impact of age on Bachmann&#8217;s bundle electrophysiology in this vulnerable population. Establishing these electrophysiological alterations in pediatric congenital heart disease patients is crucial for early intervention strategies against atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>electrophysiology, non-obstructive hypertrophic cardiomyopathy, guideline-directed medical therapy, Bachmann&#8217;s bundle, left ventricular structure, pediatric cardiology, therapeutic adherence, heart failure with reduced ejection fraction, heart failure prevention, carbohydrate quality, fibre-rich foods, inter-atrial block, apolipoprotein B, polypill, atrial fibrillation, left ventricular function, low-density lipoprotein particle, heart failure with preserved ejection fraction, atherosclerotic cardiovascular disease, atherogenic lipoprotein particles, atrial resynchronization, congenital heart disease, triglyceride-rich lipoprotein particle, Bachmann bundle area pacing, randomized controlled trial.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/">Young Adult Lipoproteins Predict Future A.S.C.V.D. 11/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251103_015654.mp3" length="4641688" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like electrophysiology and non-obstructive hypertrophic cardiomyopathy. Key takeaway: Young Adult Lipoproteins Predict Future A.S.C.V.D..
Article Links:
Article 1: Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study. (European heart journal)
Article 2: Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. (European heart journal)
Article 3: Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial. (Journal of cardiac failure)
Article 4: Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial. (Heart rhythm)
Article 5: Small patients, significant findings: Electrophysiological properties of Bachmann&#8217;s bundle in pediatric patients. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/young-adult-lipoproteins-predict-future-a-s-c-v-d-11-03-25/
 Featured Articles
Article 1: Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40626880
Summary: This study from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) cohort investigated the association between dietary carbohydrate quality and fibre-rich food intake with left ventricular structure and function. The research aimed to clarify how specific macronutrient and food group intakes relate to cardiac phenotypes, a critical step in understanding progression to heart failure. Identifying these lifestyle risk factors is essential for developing strategies to prevent or slow cardiac dysfunction.
Article 2: Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40613415
Summary: This research quantified the relationship between cumulative and usual yearly exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Utilizing follow-up data of young adults aged 18 to less than 40 years from the Coronary Artery Risk Development in Young Adults (C.A.R.D.I.A.) study, this investigation focused on apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles. The study established that such exposure during early adulthood significantly increases future atherosclerotic cardiovascular disease risk, providing critical data for understanding early life risk factors and informing preventative strategies.
Article 3: Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41177219
Summary: The P.O.L.Y.-H.F. trial was designed to evaluate a polypill strategy for patients with heart failure with reduced ejection fraction, addressing suboptimal real-world utilization of guideline-directed medical therapy. This open-label randomized controlled trial, conducted across two centers, enrolled adults with a left ventricular ejection fraction of 40 percent or less who were not receiving targeted guideline-directed medical therapy. The study&#8217;s rationale, design, and baseline characteristics provide a foundational framework for investigating whether a simplified polypill regimen can improve therapeutic adherence and patient outcomes in this population.
Article 4: Accelerated Bachmann bundle area pacing for atrial resynchronization in ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 03, 2025. This episode summarizes 5 key cardiology studies on topics like electrophysiology and non-obstructive hypertrophic cardiomyopathy. Key takeaway: Young Adult Lipoproteins Predict Future A.S.C.V.D..
Article Links:
Article 1: Dietary carbohydrate quality, fibre-rich food intake, and left ventricular structure and function: the CARDIA study. (European heart journal)
Article 2: Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. (European heart journal)
Article 3: Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial. (Journal of cardiac failure)
Article 4: Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial. (Heart rhy]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Survival Odds Slash Heart Failure Trial Bias 11/02/25</title>
	<link>https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/</link>
	<pubDate>Sun, 02 Nov 2025 23:29:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and A.T.T.R.-C.M.. Key takeaway: Survival Odds Slash Heart Failure Trial Bias.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41176318">Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41168134">Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41170566">Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41170562">Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay.</a> (Circulation. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41168949">Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/">https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41176318" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41176318</a></p>
<p><strong>Summary:</strong> This retrospective cohort study assessed the association between cannabis use at admission for acute coronary syndrome, or A.C.S., and long-term prognosis in young adults under 45 years old. Patients admitted between 2010 and 2025 who reported current tobacco use were classified based on urinary testing for cannabis upon admission. The research aimed to clarify the cardiovascular impact of cannabis use, which is increasing among young adults, by examining its link to long-term outcomes following an A.C.S. event. This study established a methodology to investigate the clinical implications of cannabis exposure on cardiovascular health in a high-risk population.</p>
<h4>Article 2: Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41168134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41168134</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between echocardiographic apical sparing, a hallmark imaging feature quantified by the R.E.L.A.P.S. pattern, and myocardial transthyretin amyloid load in patients with newly confirmed transthyretin amyloid cardiomyopathy, or A.T.T.R.-C.M. The research aimed to clarify the histopathological and clinical implications of apical sparing in A.T.T.R.-C.M., a condition characterized by transthyretin amyloid deposition, left ventricular hypertrophy, and diastolic dysfunction. By establishing these associations, the study contributes to a more precise understanding of this complex disease and its prognostic indicators.</p>
<h4>Article 3: Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41170566" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41170566</a></p>
<p><strong>Summary:</strong> This research established a novel methodological approach utilizing &#8220;survival odds&#8221; to minimize risk heterogeneity bias in heart failure clinical trials. The study addressed the issue where conventional Cox proportional hazards models can underestimate treatment effects due to a disproportionate reduction of event-free patients in control groups over time. By demonstrating the application of this survival odds methodology to dapagliflozin, the research offers a more robust framework for evaluating drug efficacy. This advance ultimately improves the accuracy of clinical trial outcomes for heart failure treatments.</p>
<h4>Article 4: Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41170562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41170562</a></p>
<p><strong>Summary:</strong> This study investigated the impact of the Swedish nationwide Care Coordination Act, or C.C.A., introduced in January 2018, on outcomes for patients with heart failure. Specifically, the research evaluated the association of this reform with all-cause 30-day hospital readmissions and overall length of stay. By assessing the Act&#8217;s goal of improving care coordination and reducing readmissions, the study provides crucial evidence on the effectiveness of national policy interventions in enhancing heart failure management.</p>
<h4>Article 5: Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41168949" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41168949</a></p>
<p><strong>Summary:</strong> This study characterized the timing, specific causes, and associated risk factors of post-procedural death in infants diagnosed with symptomatic tetralogy of Fallot, or s.T.O.F., who underwent early intervention. Focusing on neonates requiring either staged or primary repair strategies for their condition, the research provided crucial definitions of early childhood mortality patterns. By elucidating these factors, the study significantly advances the understanding of risks and potential areas for improved management in this vulnerable pediatric population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis. This retrospective cohort study assessed the association between cannabis use at admission for acute coronary syndrome, or A.C.S., and long-term prognosis in young adults under 45 years old. Patients admitted between 2010 and 2025 who reported current tobacco use were classified based on urinary testing for cannabis upon admission. The research aimed to clarify the cardiovascular impact of cannabis use, which is increasing among young adults, by examining its link to long-term outcomes following an A.C.S. event. This study established a methodology to investigate the clinical implications of cannabis exposure on cardiovascular health in a high-risk population.</p>
<p>Article number two. Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy. This study investigated the relationship between echocardiographic apical sparing, a hallmark imaging feature quantified by the R.E.L.A.P.S. pattern, and myocardial transthyretin amyloid load in patients with newly confirmed transthyretin amyloid cardiomyopathy, or A.T.T.R.-C.M. The research aimed to clarify the histopathological and clinical implications of apical sparing in A.T.T.R.-C.M., a condition characterized by transthyretin amyloid deposition, left ventricular hypertrophy, and diastolic dysfunction. By establishing these associations, the study contributes to a more precise understanding of this complex disease and its prognostic indicators.</p>
<p>Article number three. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin. This research established a novel methodological approach utilizing &#8220;survival odds&#8221; to minimize risk heterogeneity bias in heart failure clinical trials. The study addressed the issue where conventional Cox proportional hazards models can underestimate treatment effects due to a disproportionate reduction of event-free patients in control groups over time. By demonstrating the application of this survival odds methodology to dapagliflozin, the research offers a more robust framework for evaluating drug efficacy. This advance ultimately improves the accuracy of clinical trial outcomes for heart failure treatments.</p>
<p>Article number four. Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay. This study investigated the impact of the Swedish nationwide Care Coordination Act, or C.C.A., introduced in January 2018, on outcomes for patients with heart failure. Specifically, the research evaluated the association of this reform with all-cause 30-day hospital readmissions and overall length of stay. By assessing the Act&#8217;s goal of improving care coordination and reducing readmissions, the study provides crucial evidence on the effectiveness of national policy interventions in enhancing heart failure management.</p>
<p>Article number five. Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot. This study characterized the timing, specific causes, and associated risk factors of post-procedural death in infants diagnosed with symptomatic tetralogy of Fallot, or s.T.O.F., who underwent early intervention. Focusing on neonates requiring either staged or primary repair strategies for their condition, the research provided crucial definitions of early childhood mortality patterns. By elucidating these factors, the study significantly advances the understanding of risks and potential areas for improved management in this vulnerable pediatric population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute coronary syndrome, A.T.T.R.-C.M., Transthyretin amyloid cardiomyopathy, young adults, tobacco use, congenital heart disease, Tetralogy of Fallot, apical sparing, R.E.L.A.P.S. pattern, Care Coordination Act, survival odds, left ventricular hypertrophy, mortality, Cannabis use, clinical trials, Sweden, prognosis, risk heterogeneity bias, Heart failure, length of stay, dapagliflozin, risk factors, neonatal, hospital readmissions.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/">Survival Odds Slash Heart Failure Trial Bias 11/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and A.T.T.R.-C.M.. Key takeaway: Survival Odds Slash Heart Failure Trial Bias.
Article Links:
Article 1: Can]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and A.T.T.R.-C.M.. Key takeaway: Survival Odds Slash Heart Failure Trial Bias.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41176318">Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41168134">Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41170566">Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41170562">Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay.</a> (Circulation. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41168949">Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/">https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41176318" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41176318</a></p>
<p><strong>Summary:</strong> This retrospective cohort study assessed the association between cannabis use at admission for acute coronary syndrome, or A.C.S., and long-term prognosis in young adults under 45 years old. Patients admitted between 2010 and 2025 who reported current tobacco use were classified based on urinary testing for cannabis upon admission. The research aimed to clarify the cardiovascular impact of cannabis use, which is increasing among young adults, by examining its link to long-term outcomes following an A.C.S. event. This study established a methodology to investigate the clinical implications of cannabis exposure on cardiovascular health in a high-risk population.</p>
<h4>Article 2: Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41168134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41168134</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between echocardiographic apical sparing, a hallmark imaging feature quantified by the R.E.L.A.P.S. pattern, and myocardial transthyretin amyloid load in patients with newly confirmed transthyretin amyloid cardiomyopathy, or A.T.T.R.-C.M. The research aimed to clarify the histopathological and clinical implications of apical sparing in A.T.T.R.-C.M., a condition characterized by transthyretin amyloid deposition, left ventricular hypertrophy, and diastolic dysfunction. By establishing these associations, the study contributes to a more precise understanding of this complex disease and its prognostic indicators.</p>
<h4>Article 3: Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41170566" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41170566</a></p>
<p><strong>Summary:</strong> This research established a novel methodological approach utilizing &#8220;survival odds&#8221; to minimize risk heterogeneity bias in heart failure clinical trials. The study addressed the issue where conventional Cox proportional hazards models can underestimate treatment effects due to a disproportionate reduction of event-free patients in control groups over time. By demonstrating the application of this survival odds methodology to dapagliflozin, the research offers a more robust framework for evaluating drug efficacy. This advance ultimately improves the accuracy of clinical trial outcomes for heart failure treatments.</p>
<h4>Article 4: Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41170562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41170562</a></p>
<p><strong>Summary:</strong> This study investigated the impact of the Swedish nationwide Care Coordination Act, or C.C.A., introduced in January 2018, on outcomes for patients with heart failure. Specifically, the research evaluated the association of this reform with all-cause 30-day hospital readmissions and overall length of stay. By assessing the Act&#8217;s goal of improving care coordination and reducing readmissions, the study provides crucial evidence on the effectiveness of national policy interventions in enhancing heart failure management.</p>
<h4>Article 5: Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41168949" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41168949</a></p>
<p><strong>Summary:</strong> This study characterized the timing, specific causes, and associated risk factors of post-procedural death in infants diagnosed with symptomatic tetralogy of Fallot, or s.T.O.F., who underwent early intervention. Focusing on neonates requiring either staged or primary repair strategies for their condition, the research provided crucial definitions of early childhood mortality patterns. By elucidating these factors, the study significantly advances the understanding of risks and potential areas for improved management in this vulnerable pediatric population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis. This retrospective cohort study assessed the association between cannabis use at admission for acute coronary syndrome, or A.C.S., and long-term prognosis in young adults under 45 years old. Patients admitted between 2010 and 2025 who reported current tobacco use were classified based on urinary testing for cannabis upon admission. The research aimed to clarify the cardiovascular impact of cannabis use, which is increasing among young adults, by examining its link to long-term outcomes following an A.C.S. event. This study established a methodology to investigate the clinical implications of cannabis exposure on cardiovascular health in a high-risk population.</p>
<p>Article number two. Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy. This study investigated the relationship between echocardiographic apical sparing, a hallmark imaging feature quantified by the R.E.L.A.P.S. pattern, and myocardial transthyretin amyloid load in patients with newly confirmed transthyretin amyloid cardiomyopathy, or A.T.T.R.-C.M. The research aimed to clarify the histopathological and clinical implications of apical sparing in A.T.T.R.-C.M., a condition characterized by transthyretin amyloid deposition, left ventricular hypertrophy, and diastolic dysfunction. By establishing these associations, the study contributes to a more precise understanding of this complex disease and its prognostic indicators.</p>
<p>Article number three. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin. This research established a novel methodological approach utilizing &#8220;survival odds&#8221; to minimize risk heterogeneity bias in heart failure clinical trials. The study addressed the issue where conventional Cox proportional hazards models can underestimate treatment effects due to a disproportionate reduction of event-free patients in control groups over time. By demonstrating the application of this survival odds methodology to dapagliflozin, the research offers a more robust framework for evaluating drug efficacy. This advance ultimately improves the accuracy of clinical trial outcomes for heart failure treatments.</p>
<p>Article number four. Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay. This study investigated the impact of the Swedish nationwide Care Coordination Act, or C.C.A., introduced in January 2018, on outcomes for patients with heart failure. Specifically, the research evaluated the association of this reform with all-cause 30-day hospital readmissions and overall length of stay. By assessing the Act&#8217;s goal of improving care coordination and reducing readmissions, the study provides crucial evidence on the effectiveness of national policy interventions in enhancing heart failure management.</p>
<p>Article number five. Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot. This study characterized the timing, specific causes, and associated risk factors of post-procedural death in infants diagnosed with symptomatic tetralogy of Fallot, or s.T.O.F., who underwent early intervention. Focusing on neonates requiring either staged or primary repair strategies for their condition, the research provided crucial definitions of early childhood mortality patterns. By elucidating these factors, the study significantly advances the understanding of risks and potential areas for improved management in this vulnerable pediatric population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute coronary syndrome, A.T.T.R.-C.M., Transthyretin amyloid cardiomyopathy, young adults, tobacco use, congenital heart disease, Tetralogy of Fallot, apical sparing, R.E.L.A.P.S. pattern, Care Coordination Act, survival odds, left ventricular hypertrophy, mortality, Cannabis use, clinical trials, Sweden, prognosis, risk heterogeneity bias, Heart failure, length of stay, dapagliflozin, risk factors, neonatal, hospital readmissions.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/">Survival Odds Slash Heart Failure Trial Bias 11/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251102_182827.mp3" length="4189038" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and A.T.T.R.-C.M.. Key takeaway: Survival Odds Slash Heart Failure Trial Bias.
Article Links:
Article 1: Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis. (Heart (British Cardiac Society))
Article 2: Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy. (European journal of heart failure)
Article 3: Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin. (Circulation. Heart failure)
Article 4: Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay. (Circulation. Heart failure)
Article 5: Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/survival-odds-slash-heart-failure-trial-bias-11-02-25/
 Featured Articles
Article 1: Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41176318
Summary: This retrospective cohort study assessed the association between cannabis use at admission for acute coronary syndrome, or A.C.S., and long-term prognosis in young adults under 45 years old. Patients admitted between 2010 and 2025 who reported current tobacco use were classified based on urinary testing for cannabis upon admission. The research aimed to clarify the cardiovascular impact of cannabis use, which is increasing among young adults, by examining its link to long-term outcomes following an A.C.S. event. This study established a methodology to investigate the clinical implications of cannabis exposure on cardiovascular health in a high-risk population.
Article 2: Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41168134
Summary: This study investigated the relationship between echocardiographic apical sparing, a hallmark imaging feature quantified by the R.E.L.A.P.S. pattern, and myocardial transthyretin amyloid load in patients with newly confirmed transthyretin amyloid cardiomyopathy, or A.T.T.R.-C.M. The research aimed to clarify the histopathological and clinical implications of apical sparing in A.T.T.R.-C.M., a condition characterized by transthyretin amyloid deposition, left ventricular hypertrophy, and diastolic dysfunction. By establishing these associations, the study contributes to a more precise understanding of this complex disease and its prognostic indicators.
Article 3: Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41170566
Summary: This research established a novel methodological approach utilizing &#8220;survival odds&#8221; to minimize risk heterogeneity bias in heart failure clinical trials. The study addressed the issue where conventional Cox proportional hazards models can underestimate treatment effects due to a disproportionate reduction of event-free patients in control groups over time. By demonstrating the application of this survival odds methodology to dapagliflozin, the research offers a more robust framework for evaluating drug efficacy. This advance ultimately improves the accuracy of clinical trial outcomes for heart failure treatments.
Article 4: Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41170562
Su]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and A.T.T.R.-C.M.. Key takeaway: Survival Odds Slash Heart Failure Trial Bias.
Article Links:
Article 1: Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis. (Heart (British Cardiac Society))
Article 2: Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy. (European journal of heart failure)
Article 3: Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin. (Circulation. Heart failure)
Article 4: Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay. (Circulation. Heart failure)
Article 5: Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot. (Journal of the American Heart Asso]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>N.R.P. for D.C.D. Hearts: 200 Cases Validate Method 11/02/25</title>
	<link>https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/</link>
	<pubDate>Sun, 02 Nov 2025 11:01:58 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like donation after circulatory death and temperature dynamics. Key takeaway: N.R.P. for D.C.D. Hearts: 200 Cases Validate Method.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40490145">Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40456427">Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40456426">Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40118306">Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/39536922">Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/">https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40490145" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40490145</a></p>
<p><strong>Summary:</strong> This study investigated alternatives to autologous whole blood for ex vivo heart perfusion, a technique aiming to expand the organ donor pool but facing logistical hurdles. Researchers compared red cell concentrate and rejuvenated red cell concentrate based perfusates against whole blood during a four-hour porcine ex vivo heart perfusion model. The study successfully assessed the impact of various perfusates on blood quality and myocardial function, establishing that plasma-supplemented red cell concentrates offer viable alternatives to whole blood. This advancement enhances the functional and logistical feasibility of ex vivo organ perfusion, which could increase donor heart availability.</p>
<h4>Article 2: Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40456427" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40456427</a></p>
<p><strong>Summary:</strong> This study presents a four-year, single high-volume center&#8217;s experience with 200 cases of cardiac donation after circulatory death heart recovery using normothermic regional perfusion. Researchers retrospectively reviewed adult patients receiving cardiac allografts recovered via thoracoabdominal normothermic regional perfusion at Vanderbilt from October 2020 to November 2024. The study successfully documented the program&#8217;s evolution, establishing the feasibility and scalability of normothermic regional perfusion in a large cohort. This comprehensive experience offers crucial insights for standardizing practice and increasing the donor heart pool by validating this method for cardiac transplantation.</p>
<h4>Article 3: Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40456426" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40456426</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between right ventricular reserve function and aortic valve opening during exercise in patients with a left ventricular assist device. Researchers hypothesized that R.V. reserve function is associated with A.V. opening status, which is linked to fewer adverse events in these patients. The study successfully explored hemodynamic parameters at rest and during maximal exercise, establishing a significant association between right ventricular reserve function and aortic valve opening. This finding is crucial for optimizing patient management, offering a potential target to improve outcomes and reduce adverse events for patients with a left ventricular assist device during physical activity.</p>
<h4>Article 4: Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40118306" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40118306</a></p>
<p><strong>Summary:</strong> This study aimed to characterize the previously unstudied temperature dynamics of donor lungs during clinical lung transplantation, comparing static ice storage and controlled hypothermic storage. Researchers focused on temperature fluctuations during the cooling, preservation, and rewarming phases of ischemia-reperfusion injury. The study successfully mapped these temperature dynamics from procurement to reperfusion under both static ice storage and controlled hypothermic storage, establishing crucial baseline data. This foundational work provides essential insights into optimizing lung preservation strategies to mitigate ischemia-reperfusion injury and improve overall lung transplant outcomes.</p>
<h4>Article 5: Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/39536922" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39536922</a></p>
<p><strong>Summary:</strong> analysis. This S.P.A.H.R. analysis investigated the prognostic value of multicomponent improvement (M.C.I.), a novel endpoint, alongside the European Society of Cardiology/European Respiratory Society 4-strata risk (4.S.R.) assessment, and the non-invasive French risk stratification score (F.R.S.). Researchers evaluated these models, all based on three components, for predicting survival in pulmonary arterial hypertension patients in Sweden. The study successfully established the utility of these multicomponent risk models for survival prediction in a real-world cohort. This research provides enhanced tools for clinicians, enabling more accurate risk stratification and guiding treatment decisions to improve outcomes for patients with pulmonary arterial hypertension.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion. This study investigated alternatives to autologous whole blood for ex vivo heart perfusion, a technique aiming to expand the organ donor pool but facing logistical hurdles. Researchers compared red cell concentrate and rejuvenated red cell concentrate based perfusates against whole blood during a four-hour porcine ex vivo heart perfusion model. The study successfully assessed the impact of various perfusates on blood quality and myocardial function, establishing that plasma-supplemented red cell concentrates offer viable alternatives to whole blood. This advancement enhances the functional and logistical feasibility of ex vivo organ perfusion, which could increase donor heart availability.</p>
<p>Article number two. Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience. This study presents a four-year, single high-volume center&#8217;s experience with 200 cases of cardiac donation after circulatory death heart recovery using normothermic regional perfusion. Researchers retrospectively reviewed adult patients receiving cardiac allografts recovered via thoracoabdominal normothermic regional perfusion at Vanderbilt from October 2020 to November 2024. The study successfully documented the program&#8217;s evolution, establishing the feasibility and scalability of normothermic regional perfusion in a large cohort. This comprehensive experience offers crucial insights for standardizing practice and increasing the donor heart pool by validating this method for cardiac transplantation.</p>
<p>Article number three. Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device. This study investigated the relationship between right ventricular reserve function and aortic valve opening during exercise in patients with a left ventricular assist device. Researchers hypothesized that R.V. reserve function is associated with A.V. opening status, which is linked to fewer adverse events in these patients. The study successfully explored hemodynamic parameters at rest and during maximal exercise, establishing a significant association between right ventricular reserve function and aortic valve opening. This finding is crucial for optimizing patient management, offering a potential target to improve outcomes and reduce adverse events for patients with a left ventricular assist device during physical activity.</p>
<p>Article number four. Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage. This study aimed to characterize the previously unstudied temperature dynamics of donor lungs during clinical lung transplantation, comparing static ice storage and controlled hypothermic storage. Researchers focused on temperature fluctuations during the cooling, preservation, and rewarming phases of ischemia-reperfusion injury. The study successfully mapped these temperature dynamics from procurement to reperfusion under both static ice storage and controlled hypothermic storage, establishing crucial baseline data. This foundational work provides essential insights into optimizing lung preservation strategies to mitigate ischemia-reperfusion injury and improve overall lung transplant outcomes.</p>
<p>Article number five. Risk assessment models and survival in pulmonary arterial hypertension: A S.P.A.H.R. analysis. This S.P.A.H.R. analysis investigated the prognostic value of multicomponent improvement (M.C.I.), a novel endpoint, alongside the European Society of Cardiology/European Respiratory Society 4-strata risk (4.S.R.) assessment, and the non-invasive French risk stratification score (F.R.S.). Researchers evaluated these models, all based on three components, for predicting survival in pulmonary arterial hypertension patients in Sweden. The study successfully established the utility of these multicomponent risk models for survival prediction in a real-world cohort. This research provides enhanced tools for clinicians, enabling more accurate risk stratification and guiding treatment decisions to improve outcomes for patients with pulmonary arterial hypertension. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>donation after circulatory death, temperature dynamics, risk stratification, organ transplantation, organ preservation, hypothermic storage, pulmonary arterial hypertension, S.P.A.H.R., red cell concentrate, right ventricular function, whole blood, survival prediction, cardiac transplantation, multicomponent improvement, exercise hemodynamics, ischemia-reperfusion injury, lung transplantation, aortic valve, myocardial function, normothermic regional perfusion, left ventricular assist device, ex vivo heart perfusion, adverse events, organ recovery, heart allograft.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/">N.R.P. for D.C.D. Hearts: 200 Cases Validate Method 11/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like donation after circulatory death and temperature dynamics. Key takeaway: N.R.P. for D.C.D. Hearts: 200 Cases Validate Method.
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like donation after circulatory death and temperature dynamics. Key takeaway: N.R.P. for D.C.D. Hearts: 200 Cases Validate Method.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40490145">Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40456427">Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40456426">Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40118306">Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/39536922">Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/">https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40490145" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40490145</a></p>
<p><strong>Summary:</strong> This study investigated alternatives to autologous whole blood for ex vivo heart perfusion, a technique aiming to expand the organ donor pool but facing logistical hurdles. Researchers compared red cell concentrate and rejuvenated red cell concentrate based perfusates against whole blood during a four-hour porcine ex vivo heart perfusion model. The study successfully assessed the impact of various perfusates on blood quality and myocardial function, establishing that plasma-supplemented red cell concentrates offer viable alternatives to whole blood. This advancement enhances the functional and logistical feasibility of ex vivo organ perfusion, which could increase donor heart availability.</p>
<h4>Article 2: Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40456427" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40456427</a></p>
<p><strong>Summary:</strong> This study presents a four-year, single high-volume center&#8217;s experience with 200 cases of cardiac donation after circulatory death heart recovery using normothermic regional perfusion. Researchers retrospectively reviewed adult patients receiving cardiac allografts recovered via thoracoabdominal normothermic regional perfusion at Vanderbilt from October 2020 to November 2024. The study successfully documented the program&#8217;s evolution, establishing the feasibility and scalability of normothermic regional perfusion in a large cohort. This comprehensive experience offers crucial insights for standardizing practice and increasing the donor heart pool by validating this method for cardiac transplantation.</p>
<h4>Article 3: Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40456426" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40456426</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between right ventricular reserve function and aortic valve opening during exercise in patients with a left ventricular assist device. Researchers hypothesized that R.V. reserve function is associated with A.V. opening status, which is linked to fewer adverse events in these patients. The study successfully explored hemodynamic parameters at rest and during maximal exercise, establishing a significant association between right ventricular reserve function and aortic valve opening. This finding is crucial for optimizing patient management, offering a potential target to improve outcomes and reduce adverse events for patients with a left ventricular assist device during physical activity.</p>
<h4>Article 4: Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40118306" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40118306</a></p>
<p><strong>Summary:</strong> This study aimed to characterize the previously unstudied temperature dynamics of donor lungs during clinical lung transplantation, comparing static ice storage and controlled hypothermic storage. Researchers focused on temperature fluctuations during the cooling, preservation, and rewarming phases of ischemia-reperfusion injury. The study successfully mapped these temperature dynamics from procurement to reperfusion under both static ice storage and controlled hypothermic storage, establishing crucial baseline data. This foundational work provides essential insights into optimizing lung preservation strategies to mitigate ischemia-reperfusion injury and improve overall lung transplant outcomes.</p>
<h4>Article 5: Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/39536922" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39536922</a></p>
<p><strong>Summary:</strong> analysis. This S.P.A.H.R. analysis investigated the prognostic value of multicomponent improvement (M.C.I.), a novel endpoint, alongside the European Society of Cardiology/European Respiratory Society 4-strata risk (4.S.R.) assessment, and the non-invasive French risk stratification score (F.R.S.). Researchers evaluated these models, all based on three components, for predicting survival in pulmonary arterial hypertension patients in Sweden. The study successfully established the utility of these multicomponent risk models for survival prediction in a real-world cohort. This research provides enhanced tools for clinicians, enabling more accurate risk stratification and guiding treatment decisions to improve outcomes for patients with pulmonary arterial hypertension.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion. This study investigated alternatives to autologous whole blood for ex vivo heart perfusion, a technique aiming to expand the organ donor pool but facing logistical hurdles. Researchers compared red cell concentrate and rejuvenated red cell concentrate based perfusates against whole blood during a four-hour porcine ex vivo heart perfusion model. The study successfully assessed the impact of various perfusates on blood quality and myocardial function, establishing that plasma-supplemented red cell concentrates offer viable alternatives to whole blood. This advancement enhances the functional and logistical feasibility of ex vivo organ perfusion, which could increase donor heart availability.</p>
<p>Article number two. Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience. This study presents a four-year, single high-volume center&#8217;s experience with 200 cases of cardiac donation after circulatory death heart recovery using normothermic regional perfusion. Researchers retrospectively reviewed adult patients receiving cardiac allografts recovered via thoracoabdominal normothermic regional perfusion at Vanderbilt from October 2020 to November 2024. The study successfully documented the program&#8217;s evolution, establishing the feasibility and scalability of normothermic regional perfusion in a large cohort. This comprehensive experience offers crucial insights for standardizing practice and increasing the donor heart pool by validating this method for cardiac transplantation.</p>
<p>Article number three. Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device. This study investigated the relationship between right ventricular reserve function and aortic valve opening during exercise in patients with a left ventricular assist device. Researchers hypothesized that R.V. reserve function is associated with A.V. opening status, which is linked to fewer adverse events in these patients. The study successfully explored hemodynamic parameters at rest and during maximal exercise, establishing a significant association between right ventricular reserve function and aortic valve opening. This finding is crucial for optimizing patient management, offering a potential target to improve outcomes and reduce adverse events for patients with a left ventricular assist device during physical activity.</p>
<p>Article number four. Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage. This study aimed to characterize the previously unstudied temperature dynamics of donor lungs during clinical lung transplantation, comparing static ice storage and controlled hypothermic storage. Researchers focused on temperature fluctuations during the cooling, preservation, and rewarming phases of ischemia-reperfusion injury. The study successfully mapped these temperature dynamics from procurement to reperfusion under both static ice storage and controlled hypothermic storage, establishing crucial baseline data. This foundational work provides essential insights into optimizing lung preservation strategies to mitigate ischemia-reperfusion injury and improve overall lung transplant outcomes.</p>
<p>Article number five. Risk assessment models and survival in pulmonary arterial hypertension: A S.P.A.H.R. analysis. This S.P.A.H.R. analysis investigated the prognostic value of multicomponent improvement (M.C.I.), a novel endpoint, alongside the European Society of Cardiology/European Respiratory Society 4-strata risk (4.S.R.) assessment, and the non-invasive French risk stratification score (F.R.S.). Researchers evaluated these models, all based on three components, for predicting survival in pulmonary arterial hypertension patients in Sweden. The study successfully established the utility of these multicomponent risk models for survival prediction in a real-world cohort. This research provides enhanced tools for clinicians, enabling more accurate risk stratification and guiding treatment decisions to improve outcomes for patients with pulmonary arterial hypertension. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>donation after circulatory death, temperature dynamics, risk stratification, organ transplantation, organ preservation, hypothermic storage, pulmonary arterial hypertension, S.P.A.H.R., red cell concentrate, right ventricular function, whole blood, survival prediction, cardiac transplantation, multicomponent improvement, exercise hemodynamics, ischemia-reperfusion injury, lung transplantation, aortic valve, myocardial function, normothermic regional perfusion, left ventricular assist device, ex vivo heart perfusion, adverse events, organ recovery, heart allograft.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/">N.R.P. for D.C.D. Hearts: 200 Cases Validate Method 11/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251102_060045.mp3" length="4981071" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like donation after circulatory death and temperature dynamics. Key takeaway: N.R.P. for D.C.D. Hearts: 200 Cases Validate Method.
Article Links:
Article 1: Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Temperature dynamics of donor lungs from procurement to reperfusion: Static ice versus controlled hypothermic storage. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/n-r-p-for-d-c-d-hearts-200-cases-validate-method-11-02-25/
 Featured Articles
Article 1: Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40490145
Summary: This study investigated alternatives to autologous whole blood for ex vivo heart perfusion, a technique aiming to expand the organ donor pool but facing logistical hurdles. Researchers compared red cell concentrate and rejuvenated red cell concentrate based perfusates against whole blood during a four-hour porcine ex vivo heart perfusion model. The study successfully assessed the impact of various perfusates on blood quality and myocardial function, establishing that plasma-supplemented red cell concentrates offer viable alternatives to whole blood. This advancement enhances the functional and logistical feasibility of ex vivo organ perfusion, which could increase donor heart availability.
Article 2: Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40456427
Summary: This study presents a four-year, single high-volume center&#8217;s experience with 200 cases of cardiac donation after circulatory death heart recovery using normothermic regional perfusion. Researchers retrospectively reviewed adult patients receiving cardiac allografts recovered via thoracoabdominal normothermic regional perfusion at Vanderbilt from October 2020 to November 2024. The study successfully documented the program&#8217;s evolution, establishing the feasibility and scalability of normothermic regional perfusion in a large cohort. This comprehensive experience offers crucial insights for standardizing practice and increasing the donor heart pool by validating this method for cardiac transplantation.
Article 3: Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device.
Journal: The Journal of heart and lung transplantation : the offici]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 02, 2025. This episode summarizes 5 key cardiology studies on topics like donation after circulatory death and temperature dynamics. Key takeaway: N.R.P. for D.C.D. Hearts: 200 Cases Validate Method.
Article Links:
Article 1: Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Impact of right ventricular reserve function during exercise on aortic valve opening in patients with left ventricular assist device. (The Journal of heart and lung transplantation : the official]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Machine Perfusion Boosts Heart Transplant Outcomes 11/01/25</title>
	<link>https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/</link>
	<pubDate>Sat, 01 Nov 2025 10:01:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like donation after brain death and exercise intolerance. Key takeaway: Machine Perfusion Boosts Heart Transplant Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40651676">Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40645313">National utilization and outcomes of heart transplantation using ex situ machine perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40645311">Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40592371">Trajectories of FEV1 after lung transplantation and patient outcomes.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40581272">Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/">https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40651676" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40651676</a></p>
<p><strong>Summary:</strong> This study aimed to uncover mechanisms underlying skeletal muscle dysfunction and exercise intolerance in pulmonary arterial hypertension by using proteomic and metabolomic profiling. Researchers evaluated exercise capacity, muscle histopathology, mitochondrial density, proteomics, and metabolomics/lipidomics in quadriceps muscles of monocrotaline rats, a model for pulmonary arterial hypertension. The findings identified specific changes in muscle biology across different fiber types and nominated potential druggable targets and biomarkers. This research establishes foundational knowledge for developing targeted therapies to improve exercise capacity in patients with pulmonary arterial hypertension.</p>
<h4>Article 2: National utilization and outcomes of heart transplantation using ex situ machine perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645313" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645313</a></p>
<p><strong>Summary:</strong> This national study evaluated the utilization and outcomes of ex situ machine perfusion for heart transplantation in the United States, including adult recipients between October 2018 and September 2023 from the United Network for Organ Sharing database. The researchers compared outcomes between machine perfusion and non-machine perfusion transplants from both donation after brain death (D.B.D.) and donation after circulatory death (D.C.D.) donors. The findings revealed increasing adoption of machine perfusion and provided pragmatic national data on its effectiveness and patient outcomes. This research demonstrates the growing impact and success of machine perfusion in expanding the donor pool and optimizing heart transplantation.</p>
<h4>Article 3: Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645311" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645311</a></p>
<p><strong>Summary:</strong> This retrospective cohort study evaluated outcomes of orthotopic heart transplantation in Ukraine during wartime, focusing on the use of marginal donor hearts to expand the traditional donor pool. Researchers analyzed 106 consecutive heart transplantation cases at the Heart Institute of the Ministry of Health, comparing outcomes between standard and marginal donor heart recipients. The study successfully demonstrated the feasibility and outcomes of heart transplantation under challenging wartime conditions, including the effective utilization of marginal donor hearts. This work highlights resilience and adaptability in maintaining critical medical services and expanding donor heart availability amidst severe logistical disruptions.</p>
<h4>Article 4: Trajectories of FEV1 after lung transplantation and patient outcomes.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40592371" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40592371</a></p>
<p><strong>Summary:</strong> This study investigated the trajectories of forced expiratory volume in one second (F.E.V.1) after bilateral lung transplantation and their associations with clinical outcomes in adult patients. Data from 15 centers across France, Belgium, Austria, and the U.S. were analyzed to identify distinct F.E.V.1 patterns following transplantation. The research successfully characterized various F.E.V.1 trajectories, providing crucial insights into long-term lung function post-transplant and their prognostic value. These findings establish a clearer understanding of post-transplantation lung function progression and can inform personalized patient management strategies.</p>
<h4>Article 5: Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40581272" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40581272</a></p>
<p><strong>Summary:</strong> This study examined the impact of donor-specific antibodies (D.S.A.) on longitudinal post-transplant lung function and baseline lung allograft dysfunction in lung transplant recipients. The research aimed to clarify how D.S.A. affect long-term lung function, building upon existing knowledge of peri-operative and demographic risk factors. The findings demonstrate that D.S.A. significantly influence both baseline lung allograft dysfunction and the trajectory of lung function over time. This provides critical insights for identifying patients at higher risk for poor long-term outcomes, enabling improved risk stratification and potentially guiding targeted immunosuppression strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats. This study aimed to uncover mechanisms underlying skeletal muscle dysfunction and exercise intolerance in pulmonary arterial hypertension by using proteomic and metabolomic profiling. Researchers evaluated exercise capacity, muscle histopathology, mitochondrial density, proteomics, and metabolomics/lipidomics in quadriceps muscles of monocrotaline rats, a model for pulmonary arterial hypertension. The findings identified specific changes in muscle biology across different fiber types and nominated potential druggable targets and biomarkers. This research establishes foundational knowledge for developing targeted therapies to improve exercise capacity in patients with pulmonary arterial hypertension.</p>
<p>Article number two. National utilization and outcomes of heart transplantation using ex situ machine perfusion. This national study evaluated the utilization and outcomes of ex situ machine perfusion for heart transplantation in the United States, including adult recipients between October 2018 and September 2023 from the United Network for Organ Sharing database. The researchers compared outcomes between machine perfusion and non-machine perfusion transplants from both donation after brain death (D.B.D.) and donation after circulatory death (D.C.D.) donors. The findings revealed increasing adoption of machine perfusion and provided pragmatic national data on its effectiveness and patient outcomes. This research demonstrates the growing impact and success of machine perfusion in expanding the donor pool and optimizing heart transplantation.</p>
<p>Article number three. Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes. This retrospective cohort study evaluated outcomes of orthotopic heart transplantation in Ukraine during wartime, focusing on the use of marginal donor hearts to expand the traditional donor pool. Researchers analyzed 106 consecutive heart transplantation cases at the Heart Institute of the Ministry of Health, comparing outcomes between standard and marginal donor heart recipients. The study successfully demonstrated the feasibility and outcomes of heart transplantation under challenging wartime conditions, including the effective utilization of marginal donor hearts. This work highlights resilience and adaptability in maintaining critical medical services and expanding donor heart availability amidst severe logistical disruptions.</p>
<p>Article number four. Trajectories of FEV.1 after lung transplantation and patient outcomes. This study investigated the trajectories of forced expiratory volume in one second (F.E.V.1) after bilateral lung transplantation and their associations with clinical outcomes in adult patients. Data from 15 centers across France, Belgium, Austria, and the U.S. were analyzed to identify distinct F.E.V.1 patterns following transplantation. The research successfully characterized various F.E.V.1 trajectories, providing crucial insights into long-term lung function post-transplant and their prognostic value. These findings establish a clearer understanding of post-transplantation lung function progression and can inform personalized patient management strategies.</p>
<p>Article number five. Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction. This study examined the impact of donor-specific antibodies (D.S.A.) on longitudinal post-transplant lung function and baseline lung allograft dysfunction in lung transplant recipients. The research aimed to clarify how D.S.A. affect long-term lung function, building upon existing knowledge of peri-operative and demographic risk factors. The findings demonstrate that D.S.A. significantly influence both baseline lung allograft dysfunction and the trajectory of lung function over time. This provides critical insights for identifying patients at higher risk for poor long-term outcomes, enabling improved risk stratification and potentially guiding targeted immunosuppression strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>donation after brain death, exercise intolerance, lung transplantation, risk stratification, donation after circulatory death, lung allograft dysfunction, biomarkers, donor-specific antibodies, forced expiratory volume in one second, longitudinal lung function, end-stage heart failure, machine perfusion, organ utilization, myopathy, lung function, pulmonary arterial hypertension, patient outcomes, F.E.V.1 trajectories, proteomics, wartime, heart transplantation, metabolomics, marginal donor hearts, Ukraine.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/">Machine Perfusion Boosts Heart Transplant Outcomes 11/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like donation after brain death and exercise intolerance. Key takeaway: Machine Perfusion Boosts Heart Transplant Outcomes.
Article Links]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like donation after brain death and exercise intolerance. Key takeaway: Machine Perfusion Boosts Heart Transplant Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40651676">Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40645313">National utilization and outcomes of heart transplantation using ex situ machine perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40645311">Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40592371">Trajectories of FEV1 after lung transplantation and patient outcomes.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40581272">Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/">https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40651676" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40651676</a></p>
<p><strong>Summary:</strong> This study aimed to uncover mechanisms underlying skeletal muscle dysfunction and exercise intolerance in pulmonary arterial hypertension by using proteomic and metabolomic profiling. Researchers evaluated exercise capacity, muscle histopathology, mitochondrial density, proteomics, and metabolomics/lipidomics in quadriceps muscles of monocrotaline rats, a model for pulmonary arterial hypertension. The findings identified specific changes in muscle biology across different fiber types and nominated potential druggable targets and biomarkers. This research establishes foundational knowledge for developing targeted therapies to improve exercise capacity in patients with pulmonary arterial hypertension.</p>
<h4>Article 2: National utilization and outcomes of heart transplantation using ex situ machine perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645313" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645313</a></p>
<p><strong>Summary:</strong> This national study evaluated the utilization and outcomes of ex situ machine perfusion for heart transplantation in the United States, including adult recipients between October 2018 and September 2023 from the United Network for Organ Sharing database. The researchers compared outcomes between machine perfusion and non-machine perfusion transplants from both donation after brain death (D.B.D.) and donation after circulatory death (D.C.D.) donors. The findings revealed increasing adoption of machine perfusion and provided pragmatic national data on its effectiveness and patient outcomes. This research demonstrates the growing impact and success of machine perfusion in expanding the donor pool and optimizing heart transplantation.</p>
<h4>Article 3: Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645311" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645311</a></p>
<p><strong>Summary:</strong> This retrospective cohort study evaluated outcomes of orthotopic heart transplantation in Ukraine during wartime, focusing on the use of marginal donor hearts to expand the traditional donor pool. Researchers analyzed 106 consecutive heart transplantation cases at the Heart Institute of the Ministry of Health, comparing outcomes between standard and marginal donor heart recipients. The study successfully demonstrated the feasibility and outcomes of heart transplantation under challenging wartime conditions, including the effective utilization of marginal donor hearts. This work highlights resilience and adaptability in maintaining critical medical services and expanding donor heart availability amidst severe logistical disruptions.</p>
<h4>Article 4: Trajectories of FEV1 after lung transplantation and patient outcomes.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40592371" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40592371</a></p>
<p><strong>Summary:</strong> This study investigated the trajectories of forced expiratory volume in one second (F.E.V.1) after bilateral lung transplantation and their associations with clinical outcomes in adult patients. Data from 15 centers across France, Belgium, Austria, and the U.S. were analyzed to identify distinct F.E.V.1 patterns following transplantation. The research successfully characterized various F.E.V.1 trajectories, providing crucial insights into long-term lung function post-transplant and their prognostic value. These findings establish a clearer understanding of post-transplantation lung function progression and can inform personalized patient management strategies.</p>
<h4>Article 5: Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40581272" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40581272</a></p>
<p><strong>Summary:</strong> This study examined the impact of donor-specific antibodies (D.S.A.) on longitudinal post-transplant lung function and baseline lung allograft dysfunction in lung transplant recipients. The research aimed to clarify how D.S.A. affect long-term lung function, building upon existing knowledge of peri-operative and demographic risk factors. The findings demonstrate that D.S.A. significantly influence both baseline lung allograft dysfunction and the trajectory of lung function over time. This provides critical insights for identifying patients at higher risk for poor long-term outcomes, enabling improved risk stratification and potentially guiding targeted immunosuppression strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats. This study aimed to uncover mechanisms underlying skeletal muscle dysfunction and exercise intolerance in pulmonary arterial hypertension by using proteomic and metabolomic profiling. Researchers evaluated exercise capacity, muscle histopathology, mitochondrial density, proteomics, and metabolomics/lipidomics in quadriceps muscles of monocrotaline rats, a model for pulmonary arterial hypertension. The findings identified specific changes in muscle biology across different fiber types and nominated potential druggable targets and biomarkers. This research establishes foundational knowledge for developing targeted therapies to improve exercise capacity in patients with pulmonary arterial hypertension.</p>
<p>Article number two. National utilization and outcomes of heart transplantation using ex situ machine perfusion. This national study evaluated the utilization and outcomes of ex situ machine perfusion for heart transplantation in the United States, including adult recipients between October 2018 and September 2023 from the United Network for Organ Sharing database. The researchers compared outcomes between machine perfusion and non-machine perfusion transplants from both donation after brain death (D.B.D.) and donation after circulatory death (D.C.D.) donors. The findings revealed increasing adoption of machine perfusion and provided pragmatic national data on its effectiveness and patient outcomes. This research demonstrates the growing impact and success of machine perfusion in expanding the donor pool and optimizing heart transplantation.</p>
<p>Article number three. Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes. This retrospective cohort study evaluated outcomes of orthotopic heart transplantation in Ukraine during wartime, focusing on the use of marginal donor hearts to expand the traditional donor pool. Researchers analyzed 106 consecutive heart transplantation cases at the Heart Institute of the Ministry of Health, comparing outcomes between standard and marginal donor heart recipients. The study successfully demonstrated the feasibility and outcomes of heart transplantation under challenging wartime conditions, including the effective utilization of marginal donor hearts. This work highlights resilience and adaptability in maintaining critical medical services and expanding donor heart availability amidst severe logistical disruptions.</p>
<p>Article number four. Trajectories of FEV.1 after lung transplantation and patient outcomes. This study investigated the trajectories of forced expiratory volume in one second (F.E.V.1) after bilateral lung transplantation and their associations with clinical outcomes in adult patients. Data from 15 centers across France, Belgium, Austria, and the U.S. were analyzed to identify distinct F.E.V.1 patterns following transplantation. The research successfully characterized various F.E.V.1 trajectories, providing crucial insights into long-term lung function post-transplant and their prognostic value. These findings establish a clearer understanding of post-transplantation lung function progression and can inform personalized patient management strategies.</p>
<p>Article number five. Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction. This study examined the impact of donor-specific antibodies (D.S.A.) on longitudinal post-transplant lung function and baseline lung allograft dysfunction in lung transplant recipients. The research aimed to clarify how D.S.A. affect long-term lung function, building upon existing knowledge of peri-operative and demographic risk factors. The findings demonstrate that D.S.A. significantly influence both baseline lung allograft dysfunction and the trajectory of lung function over time. This provides critical insights for identifying patients at higher risk for poor long-term outcomes, enabling improved risk stratification and potentially guiding targeted immunosuppression strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>donation after brain death, exercise intolerance, lung transplantation, risk stratification, donation after circulatory death, lung allograft dysfunction, biomarkers, donor-specific antibodies, forced expiratory volume in one second, longitudinal lung function, end-stage heart failure, machine perfusion, organ utilization, myopathy, lung function, pulmonary arterial hypertension, patient outcomes, F.E.V.1 trajectories, proteomics, wartime, heart transplantation, metabolomics, marginal donor hearts, Ukraine.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/">Machine Perfusion Boosts Heart Transplant Outcomes 11/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251101_060026.mp3" length="4767494" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like donation after brain death and exercise intolerance. Key takeaway: Machine Perfusion Boosts Heart Transplant Outcomes.
Article Links:
Article 1: Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: National utilization and outcomes of heart transplantation using ex situ machine perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Trajectories of FEV1 after lung transplantation and patient outcomes. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunction. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/machine-perfusion-boosts-heart-transplant-outcomes-11-01-25/
 Featured Articles
Article 1: Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40651676
Summary: This study aimed to uncover mechanisms underlying skeletal muscle dysfunction and exercise intolerance in pulmonary arterial hypertension by using proteomic and metabolomic profiling. Researchers evaluated exercise capacity, muscle histopathology, mitochondrial density, proteomics, and metabolomics/lipidomics in quadriceps muscles of monocrotaline rats, a model for pulmonary arterial hypertension. The findings identified specific changes in muscle biology across different fiber types and nominated potential druggable targets and biomarkers. This research establishes foundational knowledge for developing targeted therapies to improve exercise capacity in patients with pulmonary arterial hypertension.
Article 2: National utilization and outcomes of heart transplantation using ex situ machine perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40645313
Summary: This national study evaluated the utilization and outcomes of ex situ machine perfusion for heart transplantation in the United States, including adult recipients between October 2018 and September 2023 from the United Network for Organ Sharing database. The researchers compared outcomes between machine perfusion and non-machine perfusion transplants from both donation after brain death (D.B.D.) and donation after circulatory death (D.C.D.) donors. The findings revealed increasing adoption of machine perfusion and provided pragmatic national data on its effectiveness and patient outcomes. This research demonstrates the growing impact and success of machine perfusion in expanding the donor pool and optimizing heart transplantation.
Article 3: Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like donation after brain death and exercise intolerance. Key takeaway: Machine Perfusion Boosts Heart Transplant Outcomes.
Article Links:
Article 1: Proteomic and metabolomic profiling nominates druggable targets and biomarkers for pulmonary arterial hypertension-associated myopathy and exercise intolerance in male monocrotaline rats. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: National utilization and outcomes of heart transplantation using ex situ machine perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Heart transplantation in Ukraine during wartime: A retrospective cohort study of standard vs marginal donor heart transplantation outcomes. (The Journal of heart and lung]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Video Kinematics Predict Donor Heart Function 11/01/25</title>
	<link>https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/</link>
	<pubDate>Sat, 01 Nov 2025 06:58:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41171219">Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41171248">A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41171251">Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41171249">Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40716473">Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/">https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171219</a></p>
<p><strong>Summary:</strong> The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.</p>
<h4>Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171248</a></p>
<p><strong>Summary:</strong> This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.</p>
<h4>Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171251</a></p>
<p><strong>Summary:</strong> This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study&#8217;s primary objective is to assess C.R.D.-740&#8217;s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.</p>
<h4>Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171249</a></p>
<p><strong>Summary:</strong> This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.</p>
<h4>Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40716473" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40716473</a></p>
<p><strong>Summary:</strong> This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.</p>
<p>Article number two. A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.</p>
<p>Article number three. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study&#8217;s primary objective is to assess C.R.D.-740&#8217;s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.</p>
<p>Article number four. Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.</p>
<p>Article number five. Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure with reduced ejection fraction, pressure-volume hemodynamics, primary graft dysfunction, pulmonary hypertension, EMPEROR-Reduced trial, spinal stenosis, artificial intelligence, sodium-glucose cotransporter two inhibitors, C.R.D.-740, ex-situ heart perfusion, cyclic guanosine monophosphate, heart failure, carpal tunnel syndrome, natriuretic peptides, right ventricular dysfunction, machine learning, ex-vivo video kinematics, noninvasive diagnosis, phosphodiesterase nine inhibitor, empagliflozin, heart transplantation, right-sided heart catheterization, transthyretin cardiac amyloidosis, serum magnesium.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/">Video Kinematics Predict Donor Heart Function 11/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Fu]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41171219">Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41171248">A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41171251">Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41171249">Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40716473">Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/">https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171219</a></p>
<p><strong>Summary:</strong> The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.</p>
<h4>Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171248</a></p>
<p><strong>Summary:</strong> This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.</p>
<h4>Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171251</a></p>
<p><strong>Summary:</strong> This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study&#8217;s primary objective is to assess C.R.D.-740&#8217;s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.</p>
<h4>Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41171249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41171249</a></p>
<p><strong>Summary:</strong> This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.</p>
<h4>Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40716473" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40716473</a></p>
<p><strong>Summary:</strong> This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is November 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.</p>
<p>Article number two. A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.</p>
<p>Article number three. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study&#8217;s primary objective is to assess C.R.D.-740&#8217;s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.</p>
<p>Article number four. Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. This study analyzed data from the EMPEROR-Reduced trial to investigate the association between serum magnesium levels and clinical outcomes in patients with heart failure with reduced ejection fraction. A secondary objective was to determine the influence of the sodium-glucose cotransporter two inhibitor empagliflozin on serum magnesium concentrations. This research addresses existing data limitations regarding magnesium derangements in heart failure with reduced ejection fraction and their clinical implications. The findings contribute to a deeper understanding of patient prognosis and the pleiotropic effects of empagliflozin in this cardiac population.</p>
<p>Article number five. Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. This study aimed to determine if ex-vivo video kinematics of unloaded beating hearts could predict future loaded heart function, identifying hearts at high risk for primary graft dysfunction. Researchers re-animated porcine hearts procured through a donation after circulatory death protocol in an unloaded ex-situ heart perfusion system. Using five-second cell phone videos and newly developed machine learning software, the study established that these video kinematics can indeed predict post-implant heart performance. This innovative method provides a potential biomarker for donor heart assessment, which could significantly improve donor heart selection and reduce primary graft dysfunction in transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure with reduced ejection fraction, pressure-volume hemodynamics, primary graft dysfunction, pulmonary hypertension, EMPEROR-Reduced trial, spinal stenosis, artificial intelligence, sodium-glucose cotransporter two inhibitors, C.R.D.-740, ex-situ heart perfusion, cyclic guanosine monophosphate, heart failure, carpal tunnel syndrome, natriuretic peptides, right ventricular dysfunction, machine learning, ex-vivo video kinematics, noninvasive diagnosis, phosphodiesterase nine inhibitor, empagliflozin, heart transplantation, right-sided heart catheterization, transthyretin cardiac amyloidosis, serum magnesium.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/">Video Kinematics Predict Donor Heart Function 11/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/11/cardiology_today_20251101_025721.mp3" length="4510867" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Function.
Article Links:
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. (Journal of the American College of Cardiology)
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. (JACC. Heart failure)
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. (JACC. Heart failure)
Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. (JACC. Heart failure)
Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart function. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/video-kinematics-predict-donor-heart-function-11-01-25/
 Featured Articles
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171219
Summary: The 2025 American College of Cardiology Concise Clinical Guidance addresses the evaluation and management of transthyretin cardiac amyloidosis, a growing cause of heart failure, especially in older individuals. It highlights the increased recognition of this condition, particularly in patients presenting with musculoskeletal issues like bilateral carpal tunnel syndrome or spinal stenosis. The guidance emphasizes substantial advances in noninvasive diagnostic capabilities that allow for accurate identification of transthyretin cardiac amyloidosis. These developments are crucial for improving timely diagnosis and guiding effective management strategies for heart failure patients.
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171248
Summary: This study developed a novel artificial intelligence-based computational pipeline designed to estimate load-independent right ventricular functional indices in patients with pulmonary hypertension. The method utilizes a pressure-time waveform and stroke volume data obtained from clinical right-sided heart catheterization. The objective was to simplify the acquisition of these crucial prognostic indicators for right ventricular dysfunction. This advancement has the potential to integrate these valuable metrics into everyday practice, improving prognostication and management for patients with pulmonary hypertension.
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41171251
Summary: This Phase 2, randomized, double-blind, placebo-controlled study investigates C.R.D.-740, an oral phosphodiesterase nine inhibitor, in patients with chronic heart failure with reduced ejection fraction. The study&#8217;s primary objective is to assess C.R.D.-740&#8217;s effects on plasma and urinary cyclic guanosine monophosphate levels. By inhibiting phosphodiesterase nine, the drug aims to increase intracellular cyclic guanosine monophosphate signaling, thereby enhancing beneficial natriuretic peptide receptor activation. This research explores a novel pharmacological strategy that could potentially improve treatment outcomes for individuals with heart failure with reduced ejection fraction.
Article 4: Serum Magnesium and the Effect ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded November 01, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure with reduced ejection fraction and pressure-volume hemodynamics. Key takeaway: Video Kinematics Predict Donor Heart Function.
Article Links:
Article 1: Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. (Journal of the American College of Cardiology)
Article 2: A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. (JACC. Heart failure)
Article 3: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. (JACC. Heart failure)
Article 4: Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced. (JACC. Heart failure)
Article 5: Video kinematics of an unloaded, ex-vivo beating heart can predict future loaded heart f]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Vutrisiran Reduces Mortality in A.T.T.R. C.M. 10/31/25</title>
	<link>https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/</link>
	<pubDate>Fri, 31 Oct 2025 10:02:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like natriuresis-guided therapy and echocardiography. Key takeaway: Vutrisiran Reduces Mortality in A.T.T.R. C.M..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41163405">The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41159496">Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41159479">Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41165630">Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41166531">Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/">https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41163405" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41163405</a></p>
<p><strong>Summary:</strong> This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.</p>
<h4>Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159496" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159496</a></p>
<p><strong>Summary:</strong> study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.</p>
<h4>Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159479" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159479</a></p>
<p><strong>Summary:</strong> This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran&#8217;s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.</p>
<h4>Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165630" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165630</a></p>
<p><strong>Summary:</strong> hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.</p>
<h4>Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41166531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41166531</a></p>
<p><strong>Summary:</strong> This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat&#8217;s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat&#8217;s performance in routine clinical practice, confirming its benefits in a broader patient context.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.</p>
<p>Article number two. Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-A.H.F. study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.</p>
<p>Article number three. Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The H.E.L.I.O.S.-B trial. This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran&#8217;s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.</p>
<p>Article number four. Fully Automatic A.I. hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.</p>
<p>Article number five. Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat&#8217;s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat&#8217;s performance in routine clinical practice, confirming its benefits in a broader patient context. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>natriuresis-guided therapy, echocardiography, vericiguat, symptomatic heart failure, heart failure with reduced ejection fraction, operator variability, artificial intelligence, urine biomarkers, loop diuretics, transthyretin amyloid cardiomyopathy, all-cause mortality, real-world evidence, vutrisiran, left ventricular mass, diuretic resistance, heart failure hospitalization, PUSH-A.H.F. study, H.E.L.I.O.S.-B trial, computed tomography, Chinese patients, acute decompensated heart failure, congestion, cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/">Vutrisiran Reduces Mortality in A.T.T.R. C.M. 10/31/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like natriuresis-guided therapy and echocardiography. Key takeaway: Vutrisiran Reduces Mortality in A.T.T.R. C.M..
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like natriuresis-guided therapy and echocardiography. Key takeaway: Vutrisiran Reduces Mortality in A.T.T.R. C.M..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41163405">The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41159496">Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.</a> (European journal of heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41159479">Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41165630">Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41166531">Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/">https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41163405" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41163405</a></p>
<p><strong>Summary:</strong> This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.</p>
<h4>Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159496" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159496</a></p>
<p><strong>Summary:</strong> study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.</p>
<h4>Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159479" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159479</a></p>
<p><strong>Summary:</strong> This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran&#8217;s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.</p>
<h4>Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165630" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165630</a></p>
<p><strong>Summary:</strong> hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.</p>
<h4>Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41166531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41166531</a></p>
<p><strong>Summary:</strong> This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat&#8217;s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat&#8217;s performance in routine clinical practice, confirming its benefits in a broader patient context.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.</p>
<p>Article number two. Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-A.H.F. study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.</p>
<p>Article number three. Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The H.E.L.I.O.S.-B trial. This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran&#8217;s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.</p>
<p>Article number four. Fully Automatic A.I. hyphen Based Quantification of L.V. Mass in Echocardiography: A Multimodality Validation. This study aimed to validate a fully automatic A.I. hyphen based method for quantifying left ventricular mass in echocardiography by comparing its accuracy against expert manual measurements. Researchers utilized C.T. as a high-resolution reference standard to ensure robust validation. Accurate assessment of L.V. myocardial mass is critical for guiding treatment decisions, but traditional echocardiography measurements suffer from operator variability. The research specifically accomplished comparing these A.I. hyphen based measurements, which promise improved precision and reproducibility, thereby establishing a pathway for more consistent and reliable clinical assessments.</p>
<p>Article number five. Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. This real-world prospective study investigated the effectiveness of vericiguat in Chinese patients with heart failure with reduced ejection fraction, expanding on findings from previous randomized controlled trials. The study consecutively enrolled patients hospitalized due to symptomatic heart failure between January 1st and December 30th 2023, dividing them into a vericiguat group and a control group. While randomized controlled trials have already demonstrated vericiguat&#8217;s ability to improve clinical outcomes in this patient population, this research provides crucial real-world evidence from a specific demographic. This enhances understanding of vericiguat&#8217;s performance in routine clinical practice, confirming its benefits in a broader patient context. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>natriuresis-guided therapy, echocardiography, vericiguat, symptomatic heart failure, heart failure with reduced ejection fraction, operator variability, artificial intelligence, urine biomarkers, loop diuretics, transthyretin amyloid cardiomyopathy, all-cause mortality, real-world evidence, vutrisiran, left ventricular mass, diuretic resistance, heart failure hospitalization, PUSH-A.H.F. study, H.E.L.I.O.S.-B trial, computed tomography, Chinese patients, acute decompensated heart failure, congestion, cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/">Vutrisiran Reduces Mortality in A.T.T.R. C.M. 10/31/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251031_060113.mp3" length="5039585" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like natriuresis-guided therapy and echocardiography. Key takeaway: Vutrisiran Reduces Mortality in A.T.T.R. C.M..
Article Links:
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. (ESC heart failure)
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study. (European journal of heart failure)
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. (European journal of heart failure)
Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation. (JACC. Cardiovascular imaging)
Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/vutrisiran-reduces-mortality-in-a-t-t-r-c-m-10-31-25/
 Featured Articles
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41163405
Summary: This study aimed to assess the predictive ability of urine biomarkers for loop diuretic resistance in patients hospitalized with heart failure. Researchers included consecutive patients with congestive heart failure hospitalization, defining congestion as oedema, ascites, or pleural effusion. Loop diuretic resistance was specifically defined as persistent congestion on the fourth day of hospitalization despite high intravenous loop diuretic doses. The research established a methodology to evaluate whether specific urine biomarkers could predict this resistance, which is known to be associated with worse clinical outcomes.
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159496
Summary: study. This prespecified sub-analysis of the PUSH-A.H.F. study investigated the impact of outpatient loop diuretic use on natriuresis and clinical outcomes in patients hospitalized with acute decompensated heart failure. The study also aimed to determine if natriuresis-guided therapy could modify these effects, addressing a critical question regarding the efficacy of this approach in patients on chronic loop diuretics. Diuretic resistance is common in this population, and natriuresis-guided therapy has shown potential to overcome it. This research provides a crucial evaluation of how chronic loop diuretic use influences the effectiveness of natriuresis-guided strategies.
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159479
Summary: This prespecified analysis of the H.E.L.I.O.S.-B trial evaluated the efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across various age categories. The main H.E.L.I.O.S.-B trial previously demonstrated that vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events compared to placebo in patients with this progressive condition. The sub-analysis specifically assessed outcomes in patients categorized by age: under 75, 75 to under 80, and 80 years or older, as well as across age as a continuous measure. This research is crucial for understanding how vutrisiran&#8217;s established benefits extend to the older adult population, who are predominantly affected by transthyretin amyloid cardiomyopathy and at higher risk of morbidity and mortality.
Article 4: Fully Automatic AI-Based Quantification of LV ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like natriuresis-guided therapy and echocardiography. Key takeaway: Vutrisiran Reduces Mortality in A.T.T.R. C.M..
Article Links:
Article 1: The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. (ESC heart failure)
Article 2: Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study. (European journal of heart failure)
Article 3: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. (European journal of heart failure)
Article 4: Fully Automatic AI-Based Quantification of LV Mass in Echocardiography: A Multimodality Validation. (JACC. Cardiovascular imaging)
Article 5: Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. (Cardiol]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Elevated Blood Pressure Tied to Dementia Risk. 10/31/25</title>
	<link>https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/</link>
	<pubDate>Fri, 31 Oct 2025 06:58:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like dietary recommendations and diet. Key takeaway: Elevated Blood Pressure Tied to Dementia Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41164857">Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41166358">Genetic evaluation of early-onset atrial fibrillation: impact on patient management.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41165161">Dementia risk across blood pressure categories: a South Korean nationwide study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41165628">Diet and Clinical Outcomes in a Heart Failure Population.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41165524">Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/">https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41164857" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41164857</a></p>
<p><strong>Summary:</strong> This study investigated the previously elusive pathogenesis of acute myopericarditis (A.M.P.) developing after m.R.N.A. (messenger R.N.A.) COVID-19 vaccination. Researchers conducted in-depth phenotyping of peripheral blood T cells in patients who experienced acute myopericarditis post-vaccination. The findings definitively establish that combined adaptive immune mechanisms are responsible for mediating cardiac injury in these cases. This research provides critical understanding of this rare complication, strengthening the safety profile of m.R.N.A. vaccines by elucidating the biological mechanisms involved.</p>
<h4>Article 2: Genetic evaluation of early-onset atrial fibrillation: impact on patient management.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41166358" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41166358</a></p>
<p><strong>Summary:</strong> This study aimed to define the specific results and therapeutic impact of genetic evaluation for patients with early-onset atrial fibrillation (A.fib) referred to a dedicated precision medicine clinic. Patients diagnosed with atrial fibrillation before age 60 underwent a comprehensive assessment, including a three-generation pedigree, cardiac imaging, and ambulatory monitoring, in addition to standard evaluations. The research revealed that thorough genetic evaluation significantly impacts the management of early-onset atrial fibrillation, providing actionable information for personalized therapeutic strategies. This work underscores the value of precision medicine approaches for improving outcomes in specific atrial fibrillation populations.</p>
<h4>Article 3: Dementia risk across blood pressure categories: a South Korean nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165161</a></p>
<p><strong>Summary:</strong> This nationwide Korean cohort study analyzed 2800000 adults aged 40 years or older to clarify dementia risk associated with the newly introduced &#8216;elevated blood pressure&#8217; category from the 2024 European Society of Cardiology (E.S.C.) guidelines. Participants with prior dementia or related conditions were excluded to ensure robust analysis. The study successfully defined specific dementia risks across various blood pressure categories, including systolic blood pressure 120-139 m.m. H.g. or diastolic blood pressure 70-89 m.m. H.g. These findings provide crucial evidence for the clinical implications of the new E.S.C. classification, highlighting the importance of managing blood pressure for cognitive health even before it reaches hypertensive levels.</p>
<h4>Article 4: Diet and Clinical Outcomes in a Heart Failure Population.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165628</a></p>
<p><strong>Summary:</strong> This multinational substudy from the G-C.H.F. (Global Congestive Heart Failure) registry involved 3798 participants across 25 countries to investigate the associations between specific food consumption levels and a healthy diet pattern with clinical outcomes in heart failure. Dietary data were systematically collected using food frequency questionnaires. The research successfully established clear associations between consumption patterns of 11 common foods and an overall healthy diet with improved clinical outcomes in patients with heart failure. These findings offer valuable, data-driven insights that can directly inform and refine dietary recommendations for managing heart failure, potentially leading to better patient prognosis.</p>
<h4>Article 5: Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165524</a></p>
<p><strong>Summary:</strong> This study, A.H.F.-ImmunoC.S. (Acute Heart Failure Immuno-Cardio Study), was designed to elucidate the adaptive immune response following an acute heart failure event, specifically focusing on the factors that lead to incident heart-reactive antibodies. The research aims to understand the relationship between these antibodies and worsening cardiac function and prognosis, building on prior work showing increased adverse outcomes with de novo heart-reactive antibodies. The first results of this comprehensive design confirm the pivotal role of B cells in heart failure progression. This investigation establishes a robust framework for further understanding cardioimmunology in heart failure, paving the way for targeted immunomodulatory therapies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. This study investigated the previously elusive pathogenesis of acute myopericarditis (A.M.P.) developing after m.R.N.A. (messenger R.N.A.) COVID-19 vaccination. Researchers conducted in-depth phenotyping of peripheral blood T cells in patients who experienced acute myopericarditis post-vaccination. The findings definitively establish that combined adaptive immune mechanisms are responsible for mediating cardiac injury in these cases. This research provides critical understanding of this rare complication, strengthening the safety profile of m.R.N.A. vaccines by elucidating the biological mechanisms involved.</p>
<p>Article number two. Genetic evaluation of early-onset atrial fibrillation: impact on patient management. This study aimed to define the specific results and therapeutic impact of genetic evaluation for patients with early-onset atrial fibrillation (A.fib) referred to a dedicated precision medicine clinic. Patients diagnosed with atrial fibrillation before age 60 underwent a comprehensive assessment, including a three-generation pedigree, cardiac imaging, and ambulatory monitoring, in addition to standard evaluations. The research revealed that thorough genetic evaluation significantly impacts the management of early-onset atrial fibrillation, providing actionable information for personalized therapeutic strategies. This work underscores the value of precision medicine approaches for improving outcomes in specific atrial fibrillation populations.</p>
<p>Article number three. Dementia risk across blood pressure categories: a South Korean nationwide study. This nationwide Korean cohort study analyzed 2800000 adults aged 40 years or older to clarify dementia risk associated with the newly introduced &#8216;elevated blood pressure&#8217; category from the 2024 European Society of Cardiology (E.S.C.) guidelines. Participants with prior dementia or related conditions were excluded to ensure robust analysis. The study successfully defined specific dementia risks across various blood pressure categories, including systolic blood pressure 120-139 m.m. H.g. or diastolic blood pressure 70-89 m.m. H.g. These findings provide crucial evidence for the clinical implications of the new E.S.C. classification, highlighting the importance of managing blood pressure for cognitive health even before it reaches hypertensive levels.</p>
<p>Article number four. Diet and Clinical Outcomes in a Heart Failure Population. This multinational substudy from the G-C.H.F. (Global Congestive Heart Failure) registry involved 3798 participants across 25 countries to investigate the associations between specific food consumption levels and a healthy diet pattern with clinical outcomes in heart failure. Dietary data were systematically collected using food frequency questionnaires. The research successfully established clear associations between consumption patterns of 11 common foods and an overall healthy diet with improved clinical outcomes in patients with heart failure. These findings offer valuable, data-driven insights that can directly inform and refine dietary recommendations for managing heart failure, potentially leading to better patient prognosis.</p>
<p>Article number five. Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS. This study, A.H.F.-ImmunoC.S. (Acute Heart Failure Immuno-Cardio Study), was designed to elucidate the adaptive immune response following an acute heart failure event, specifically focusing on the factors that lead to incident heart-reactive antibodies. The research aims to understand the relationship between these antibodies and worsening cardiac function and prognosis, building on prior work showing increased adverse outcomes with de novo heart-reactive antibodies. The first results of this comprehensive design confirm the pivotal role of B cells in heart failure progression. This investigation establishes a robust framework for further understanding cardioimmunology in heart failure, paving the way for targeted immunomodulatory therapies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>dietary recommendations, diet, clinical outcomes, Atrial fibrillation, B cells, Acute heart failure, patient management, blood pressure categories, acute myopericarditis, early-onset atrial fibrillation, hypertension, food frequency questionnaires, cardioimmunology, precision medicine, genetic evaluation, COVID-19 vaccination, S.A.R.S.-C.o.V.-2 Spike protein, Heart failure, adaptive immune mechanisms, heart-reactive antibodies, elevated blood pressure, E.S.C. guidelines, m.R.N.A. vaccines, immune response, Dementia risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/">Elevated Blood Pressure Tied to Dementia Risk. 10/31/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like dietary recommendations and diet. Key takeaway: Elevated Blood Pressure Tied to Dementia Risk..
Article Links:
Article 1: Combined Ad]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like dietary recommendations and diet. Key takeaway: Elevated Blood Pressure Tied to Dementia Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41164857">Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41166358">Genetic evaluation of early-onset atrial fibrillation: impact on patient management.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41165161">Dementia risk across blood pressure categories: a South Korean nationwide study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41165628">Diet and Clinical Outcomes in a Heart Failure Population.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41165524">Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/">https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41164857" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41164857</a></p>
<p><strong>Summary:</strong> This study investigated the previously elusive pathogenesis of acute myopericarditis (A.M.P.) developing after m.R.N.A. (messenger R.N.A.) COVID-19 vaccination. Researchers conducted in-depth phenotyping of peripheral blood T cells in patients who experienced acute myopericarditis post-vaccination. The findings definitively establish that combined adaptive immune mechanisms are responsible for mediating cardiac injury in these cases. This research provides critical understanding of this rare complication, strengthening the safety profile of m.R.N.A. vaccines by elucidating the biological mechanisms involved.</p>
<h4>Article 2: Genetic evaluation of early-onset atrial fibrillation: impact on patient management.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41166358" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41166358</a></p>
<p><strong>Summary:</strong> This study aimed to define the specific results and therapeutic impact of genetic evaluation for patients with early-onset atrial fibrillation (A.fib) referred to a dedicated precision medicine clinic. Patients diagnosed with atrial fibrillation before age 60 underwent a comprehensive assessment, including a three-generation pedigree, cardiac imaging, and ambulatory monitoring, in addition to standard evaluations. The research revealed that thorough genetic evaluation significantly impacts the management of early-onset atrial fibrillation, providing actionable information for personalized therapeutic strategies. This work underscores the value of precision medicine approaches for improving outcomes in specific atrial fibrillation populations.</p>
<h4>Article 3: Dementia risk across blood pressure categories: a South Korean nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165161</a></p>
<p><strong>Summary:</strong> This nationwide Korean cohort study analyzed 2800000 adults aged 40 years or older to clarify dementia risk associated with the newly introduced &#8216;elevated blood pressure&#8217; category from the 2024 European Society of Cardiology (E.S.C.) guidelines. Participants with prior dementia or related conditions were excluded to ensure robust analysis. The study successfully defined specific dementia risks across various blood pressure categories, including systolic blood pressure 120-139 m.m. H.g. or diastolic blood pressure 70-89 m.m. H.g. These findings provide crucial evidence for the clinical implications of the new E.S.C. classification, highlighting the importance of managing blood pressure for cognitive health even before it reaches hypertensive levels.</p>
<h4>Article 4: Diet and Clinical Outcomes in a Heart Failure Population.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165628</a></p>
<p><strong>Summary:</strong> This multinational substudy from the G-C.H.F. (Global Congestive Heart Failure) registry involved 3798 participants across 25 countries to investigate the associations between specific food consumption levels and a healthy diet pattern with clinical outcomes in heart failure. Dietary data were systematically collected using food frequency questionnaires. The research successfully established clear associations between consumption patterns of 11 common foods and an overall healthy diet with improved clinical outcomes in patients with heart failure. These findings offer valuable, data-driven insights that can directly inform and refine dietary recommendations for managing heart failure, potentially leading to better patient prognosis.</p>
<h4>Article 5: Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41165524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41165524</a></p>
<p><strong>Summary:</strong> This study, A.H.F.-ImmunoC.S. (Acute Heart Failure Immuno-Cardio Study), was designed to elucidate the adaptive immune response following an acute heart failure event, specifically focusing on the factors that lead to incident heart-reactive antibodies. The research aims to understand the relationship between these antibodies and worsening cardiac function and prognosis, building on prior work showing increased adverse outcomes with de novo heart-reactive antibodies. The first results of this comprehensive design confirm the pivotal role of B cells in heart failure progression. This investigation establishes a robust framework for further understanding cardioimmunology in heart failure, paving the way for targeted immunomodulatory therapies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. This study investigated the previously elusive pathogenesis of acute myopericarditis (A.M.P.) developing after m.R.N.A. (messenger R.N.A.) COVID-19 vaccination. Researchers conducted in-depth phenotyping of peripheral blood T cells in patients who experienced acute myopericarditis post-vaccination. The findings definitively establish that combined adaptive immune mechanisms are responsible for mediating cardiac injury in these cases. This research provides critical understanding of this rare complication, strengthening the safety profile of m.R.N.A. vaccines by elucidating the biological mechanisms involved.</p>
<p>Article number two. Genetic evaluation of early-onset atrial fibrillation: impact on patient management. This study aimed to define the specific results and therapeutic impact of genetic evaluation for patients with early-onset atrial fibrillation (A.fib) referred to a dedicated precision medicine clinic. Patients diagnosed with atrial fibrillation before age 60 underwent a comprehensive assessment, including a three-generation pedigree, cardiac imaging, and ambulatory monitoring, in addition to standard evaluations. The research revealed that thorough genetic evaluation significantly impacts the management of early-onset atrial fibrillation, providing actionable information for personalized therapeutic strategies. This work underscores the value of precision medicine approaches for improving outcomes in specific atrial fibrillation populations.</p>
<p>Article number three. Dementia risk across blood pressure categories: a South Korean nationwide study. This nationwide Korean cohort study analyzed 2800000 adults aged 40 years or older to clarify dementia risk associated with the newly introduced &#8216;elevated blood pressure&#8217; category from the 2024 European Society of Cardiology (E.S.C.) guidelines. Participants with prior dementia or related conditions were excluded to ensure robust analysis. The study successfully defined specific dementia risks across various blood pressure categories, including systolic blood pressure 120-139 m.m. H.g. or diastolic blood pressure 70-89 m.m. H.g. These findings provide crucial evidence for the clinical implications of the new E.S.C. classification, highlighting the importance of managing blood pressure for cognitive health even before it reaches hypertensive levels.</p>
<p>Article number four. Diet and Clinical Outcomes in a Heart Failure Population. This multinational substudy from the G-C.H.F. (Global Congestive Heart Failure) registry involved 3798 participants across 25 countries to investigate the associations between specific food consumption levels and a healthy diet pattern with clinical outcomes in heart failure. Dietary data were systematically collected using food frequency questionnaires. The research successfully established clear associations between consumption patterns of 11 common foods and an overall healthy diet with improved clinical outcomes in patients with heart failure. These findings offer valuable, data-driven insights that can directly inform and refine dietary recommendations for managing heart failure, potentially leading to better patient prognosis.</p>
<p>Article number five. Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS. This study, A.H.F.-ImmunoC.S. (Acute Heart Failure Immuno-Cardio Study), was designed to elucidate the adaptive immune response following an acute heart failure event, specifically focusing on the factors that lead to incident heart-reactive antibodies. The research aims to understand the relationship between these antibodies and worsening cardiac function and prognosis, building on prior work showing increased adverse outcomes with de novo heart-reactive antibodies. The first results of this comprehensive design confirm the pivotal role of B cells in heart failure progression. This investigation establishes a robust framework for further understanding cardioimmunology in heart failure, paving the way for targeted immunomodulatory therapies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>dietary recommendations, diet, clinical outcomes, Atrial fibrillation, B cells, Acute heart failure, patient management, blood pressure categories, acute myopericarditis, early-onset atrial fibrillation, hypertension, food frequency questionnaires, cardioimmunology, precision medicine, genetic evaluation, COVID-19 vaccination, S.A.R.S.-C.o.V.-2 Spike protein, Heart failure, adaptive immune mechanisms, heart-reactive antibodies, elevated blood pressure, E.S.C. guidelines, m.R.N.A. vaccines, immune response, Dementia risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/">Elevated Blood Pressure Tied to Dementia Risk. 10/31/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251031_025653.mp3" length="4654645" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like dietary recommendations and diet. Key takeaway: Elevated Blood Pressure Tied to Dementia Risk..
Article Links:
Article 1: Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. (Circulation)
Article 2: Genetic evaluation of early-onset atrial fibrillation: impact on patient management. (European heart journal)
Article 3: Dementia risk across blood pressure categories: a South Korean nationwide study. (European heart journal)
Article 4: Diet and Clinical Outcomes in a Heart Failure Population. (JACC. Heart failure)
Article 5: Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/
 Featured Articles
Article 1: Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41164857
Summary: This study investigated the previously elusive pathogenesis of acute myopericarditis (A.M.P.) developing after m.R.N.A. (messenger R.N.A.) COVID-19 vaccination. Researchers conducted in-depth phenotyping of peripheral blood T cells in patients who experienced acute myopericarditis post-vaccination. The findings definitively establish that combined adaptive immune mechanisms are responsible for mediating cardiac injury in these cases. This research provides critical understanding of this rare complication, strengthening the safety profile of m.R.N.A. vaccines by elucidating the biological mechanisms involved.
Article 2: Genetic evaluation of early-onset atrial fibrillation: impact on patient management.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41166358
Summary: This study aimed to define the specific results and therapeutic impact of genetic evaluation for patients with early-onset atrial fibrillation (A.fib) referred to a dedicated precision medicine clinic. Patients diagnosed with atrial fibrillation before age 60 underwent a comprehensive assessment, including a three-generation pedigree, cardiac imaging, and ambulatory monitoring, in addition to standard evaluations. The research revealed that thorough genetic evaluation significantly impacts the management of early-onset atrial fibrillation, providing actionable information for personalized therapeutic strategies. This work underscores the value of precision medicine approaches for improving outcomes in specific atrial fibrillation populations.
Article 3: Dementia risk across blood pressure categories: a South Korean nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41165161
Summary: This nationwide Korean cohort study analyzed 2800000 adults aged 40 years or older to clarify dementia risk associated with the newly introduced &#8216;elevated blood pressure&#8217; category from the 2024 European Society of Cardiology (E.S.C.) guidelines. Participants with prior dementia or related conditions were excluded to ensure robust analysis. The study successfully defined specific dementia risks across various blood pressure categories, including systolic blood pressure 120-139 m.m. H.g. or diastolic blood pressure 70-89 m.m. H.g. These findings provide crucial evidence for the clinical implications of the new E.S.C. classification, highlighting the importance of managing blood pressure for cognitive health even before it reaches hypertensive levels.
Article 4: Diet and Clinical Outcomes in a Heart Failure Population.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41165628
Summary: This multinational substudy from the G-C.H.F. (Global Congestive Heart Failure) registry involved 3798 participants across 25 countries to investigate the associations between specific ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 31, 2025. This episode summarizes 5 key cardiology studies on topics like dietary recommendations and diet. Key takeaway: Elevated Blood Pressure Tied to Dementia Risk..
Article Links:
Article 1: Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. (Circulation)
Article 2: Genetic evaluation of early-onset atrial fibrillation: impact on patient management. (European heart journal)
Article 3: Dementia risk across blood pressure categories: a South Korean nationwide study. (European heart journal)
Article 4: Diet and Clinical Outcomes in a Heart Failure Population. (JACC. Heart failure)
Article 5: Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/elevated-blood-pressure-tied-to-dementia-risk-10-31-25/
 Featured Articles
Article 1: Combined Adaptive Immune Mechanisms]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Randomized Evidence for Atrial Fibrillation Success 10/30/25</title>
	<link>https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/</link>
	<pubDate>Thu, 30 Oct 2025 10:02:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like lifestyle and statistical shape atlases. Key takeaway: Randomized Evidence for Atrial Fibrillation Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41160038">Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40081938">Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40032496">Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/39819621">Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/39819617">Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/">https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41160038" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41160038</a></p>
<p><strong>Summary:</strong> The ARREST-AF Randomized Clinical Trial is an open-label, multicenter, randomized clinical trial with 12-month follow-up designed to determine the impact of risk factor and weight management on atrial fibrillation ablation rhythm outcomes. This study specifically addresses the need for randomized clinical trial evidence to support observational reports of reduced arrhythmia recurrence after atrial fibrillation ablation with aggressive lifestyle modification. By investigating this relationship, the ARREST-AF trial aims to establish whether lifestyle interventions can significantly improve the long-term success of atrial fibrillation ablation. This will provide crucial data for enhancing treatment strategies for patients with atrial fibrillation.</p>
<h4>Article 2: Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40081938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40081938</a></p>
<p><strong>Summary:</strong> This national population-based cohort study, conducted across 31 provinces in mainland China, investigated cardiovascular disease-specific and all-cause mortality among patients with established cardiovascular disease. Researchers included participants aged 35 to 75 years with self-reported diagnoses, collecting detailed information on socioeconomic status and lifestyle. The study aims to provide crucial evidence regarding socioeconomic status-related health inequality in cardiovascular disease patients who require both lifestyle changes and medical care, particularly in developing countries. This research will establish a clearer understanding of health disparities to inform targeted public health interventions.</p>
<h4>Article 3: Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40032496" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40032496</a></p>
<p><strong>Summary:</strong> This study investigated the prevalence, spectrum, and etiology of valvular heart disease across different altitudes in Yunnan Province, China, utilizing two sequential community-based echocardiography screening programs. The research addresses a gap in understanding how altitude may influence the cardiovascular system and contribute to geographical disparities in valvular heart disease epidemiology. By establishing these altitudinal differences, the study provides valuable insights into regional variations in disease burden and potential environmental factors influencing cardiac health. This contributes to a more comprehensive epidemiological understanding of valvular heart disease.</p>
<h4>Article 4: Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/39819621" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39819621</a></p>
<p><strong>Summary:</strong> The Rotterdam Study investigated myocardial injury in non-hospitalized community-dwelling individuals after C.O.V.I.D.-19 infection, also evaluating the relationship between persistent cardiac symptoms and myocardial function. This prospective population-based cohort study employed both echocardiography and cardiovascular magnetic resonance imaging for participants who recovered at home within two years of infection. By assessing individuals with known cardiovascular health status prior to infection, the research aims to establish a clear understanding of subclinical cardiac sequelae and their clinical relevance in a broader population affected by C.O.V.I.D.-19. This contributes to better management of post-C.O.V.I.D.-19 cardiac complications.</p>
<h4>Article 5: Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/39819617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39819617</a></p>
<p><strong>Summary:</strong> This study aimed to compare left ventricular shapes in patients with varying cardiovascular risk factor profiles from the Multi-Ethnic Study of Atherosclerosis and U.K. Biobank cohorts. Utilizing statistical shape atlases, the research investigated the generalizability of relationships between heart shape and risk factors across these large populations. It also explored whether left ventricular shape scores generated from a reference cohort could be directly applied to study shape differences in another. This work establishes the robustness of using cardiac shape analysis for cardiovascular risk assessment and enhances the potential for widespread clinical application.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial. The ARREST-AF Randomized Clinical Trial is an open-label, multicenter, randomized clinical trial with 12-month follow-up designed to determine the impact of risk factor and weight management on atrial fibrillation ablation rhythm outcomes. This study specifically addresses the need for randomized clinical trial evidence to support observational reports of reduced arrhythmia recurrence after atrial fibrillation ablation with aggressive lifestyle modification. By investigating this relationship, the ARREST-AF trial aims to establish whether lifestyle interventions can significantly improve the long-term success of atrial fibrillation ablation. This will provide crucial data for enhancing treatment strategies for patients with atrial fibrillation.</p>
<p>Article number two. Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort. This national population-based cohort study, conducted across 31 provinces in mainland China, investigated cardiovascular disease-specific and all-cause mortality among patients with established cardiovascular disease. Researchers included participants aged 35 to 75 years with self-reported diagnoses, collecting detailed information on socioeconomic status and lifestyle. The study aims to provide crucial evidence regarding socioeconomic status-related health inequality in cardiovascular disease patients who require both lifestyle changes and medical care, particularly in developing countries. This research will establish a clearer understanding of health disparities to inform targeted public health interventions.</p>
<p>Article number three. Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China. This study investigated the prevalence, spectrum, and etiology of valvular heart disease across different altitudes in Yunnan Province, China, utilizing two sequential community-based echocardiography screening programs. The research addresses a gap in understanding how altitude may influence the cardiovascular system and contribute to geographical disparities in valvular heart disease epidemiology. By establishing these altitudinal differences, the study provides valuable insights into regional variations in disease burden and potential environmental factors influencing cardiac health. This contributes to a more comprehensive epidemiological understanding of valvular heart disease.</p>
<p>Article number four. Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study. The Rotterdam Study investigated myocardial injury in non-hospitalized community-dwelling individuals after C.O.V.I.D.-19 infection, also evaluating the relationship between persistent cardiac symptoms and myocardial function. This prospective population-based cohort study employed both echocardiography and cardiovascular magnetic resonance imaging for participants who recovered at home within two years of infection. By assessing individuals with known cardiovascular health status prior to infection, the research aims to establish a clear understanding of subclinical cardiac sequelae and their clinical relevance in a broader population affected by C.O.V.I.D.-19. This contributes to better management of post-C.O.V.I.D.-19 cardiac complications.</p>
<p>Article number five. Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank. This study aimed to compare left ventricular shapes in patients with varying cardiovascular risk factor profiles from the Multi-Ethnic Study of Atherosclerosis and U.K. Biobank cohorts. Utilizing statistical shape atlases, the research investigated the generalizability of relationships between heart shape and risk factors across these large populations. It also explored whether left ventricular shape scores generated from a reference cohort could be directly applied to study shape differences in another. This work establishes the robustness of using cardiac shape analysis for cardiovascular risk assessment and enhances the potential for widespread clinical application. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lifestyle, statistical shape atlases, mortality, catheter ablation, community screening, weight management, population-based cohort, socioeconomic status, cardiovascular magnetic resonance, Cardiovascular disease, China, Atrial fibrillation, C.O.V.I.D.-19 infection, altitude, Left ventricular shape, Multi-Ethnic Study of Atherosclerosis, U.K. Biobank, Myocardial injury, Valvular heart disease, cardiovascular risk factors, risk factor modification, epidemiology, non-hospitalized, randomized clinical trial, echocardiography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/">Randomized Evidence for Atrial Fibrillation Success 10/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like lifestyle and statistical shape atlases. Key takeaway: Randomized Evidence for Atrial Fibrillation Success.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like lifestyle and statistical shape atlases. Key takeaway: Randomized Evidence for Atrial Fibrillation Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41160038">Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40081938">Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40032496">Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/39819621">Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/39819617">Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/">https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41160038" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41160038</a></p>
<p><strong>Summary:</strong> The ARREST-AF Randomized Clinical Trial is an open-label, multicenter, randomized clinical trial with 12-month follow-up designed to determine the impact of risk factor and weight management on atrial fibrillation ablation rhythm outcomes. This study specifically addresses the need for randomized clinical trial evidence to support observational reports of reduced arrhythmia recurrence after atrial fibrillation ablation with aggressive lifestyle modification. By investigating this relationship, the ARREST-AF trial aims to establish whether lifestyle interventions can significantly improve the long-term success of atrial fibrillation ablation. This will provide crucial data for enhancing treatment strategies for patients with atrial fibrillation.</p>
<h4>Article 2: Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40081938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40081938</a></p>
<p><strong>Summary:</strong> This national population-based cohort study, conducted across 31 provinces in mainland China, investigated cardiovascular disease-specific and all-cause mortality among patients with established cardiovascular disease. Researchers included participants aged 35 to 75 years with self-reported diagnoses, collecting detailed information on socioeconomic status and lifestyle. The study aims to provide crucial evidence regarding socioeconomic status-related health inequality in cardiovascular disease patients who require both lifestyle changes and medical care, particularly in developing countries. This research will establish a clearer understanding of health disparities to inform targeted public health interventions.</p>
<h4>Article 3: Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40032496" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40032496</a></p>
<p><strong>Summary:</strong> This study investigated the prevalence, spectrum, and etiology of valvular heart disease across different altitudes in Yunnan Province, China, utilizing two sequential community-based echocardiography screening programs. The research addresses a gap in understanding how altitude may influence the cardiovascular system and contribute to geographical disparities in valvular heart disease epidemiology. By establishing these altitudinal differences, the study provides valuable insights into regional variations in disease burden and potential environmental factors influencing cardiac health. This contributes to a more comprehensive epidemiological understanding of valvular heart disease.</p>
<h4>Article 4: Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/39819621" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39819621</a></p>
<p><strong>Summary:</strong> The Rotterdam Study investigated myocardial injury in non-hospitalized community-dwelling individuals after C.O.V.I.D.-19 infection, also evaluating the relationship between persistent cardiac symptoms and myocardial function. This prospective population-based cohort study employed both echocardiography and cardiovascular magnetic resonance imaging for participants who recovered at home within two years of infection. By assessing individuals with known cardiovascular health status prior to infection, the research aims to establish a clear understanding of subclinical cardiac sequelae and their clinical relevance in a broader population affected by C.O.V.I.D.-19. This contributes to better management of post-C.O.V.I.D.-19 cardiac complications.</p>
<h4>Article 5: Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/39819617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/39819617</a></p>
<p><strong>Summary:</strong> This study aimed to compare left ventricular shapes in patients with varying cardiovascular risk factor profiles from the Multi-Ethnic Study of Atherosclerosis and U.K. Biobank cohorts. Utilizing statistical shape atlases, the research investigated the generalizability of relationships between heart shape and risk factors across these large populations. It also explored whether left ventricular shape scores generated from a reference cohort could be directly applied to study shape differences in another. This work establishes the robustness of using cardiac shape analysis for cardiovascular risk assessment and enhances the potential for widespread clinical application.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial. The ARREST-AF Randomized Clinical Trial is an open-label, multicenter, randomized clinical trial with 12-month follow-up designed to determine the impact of risk factor and weight management on atrial fibrillation ablation rhythm outcomes. This study specifically addresses the need for randomized clinical trial evidence to support observational reports of reduced arrhythmia recurrence after atrial fibrillation ablation with aggressive lifestyle modification. By investigating this relationship, the ARREST-AF trial aims to establish whether lifestyle interventions can significantly improve the long-term success of atrial fibrillation ablation. This will provide crucial data for enhancing treatment strategies for patients with atrial fibrillation.</p>
<p>Article number two. Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort. This national population-based cohort study, conducted across 31 provinces in mainland China, investigated cardiovascular disease-specific and all-cause mortality among patients with established cardiovascular disease. Researchers included participants aged 35 to 75 years with self-reported diagnoses, collecting detailed information on socioeconomic status and lifestyle. The study aims to provide crucial evidence regarding socioeconomic status-related health inequality in cardiovascular disease patients who require both lifestyle changes and medical care, particularly in developing countries. This research will establish a clearer understanding of health disparities to inform targeted public health interventions.</p>
<p>Article number three. Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China. This study investigated the prevalence, spectrum, and etiology of valvular heart disease across different altitudes in Yunnan Province, China, utilizing two sequential community-based echocardiography screening programs. The research addresses a gap in understanding how altitude may influence the cardiovascular system and contribute to geographical disparities in valvular heart disease epidemiology. By establishing these altitudinal differences, the study provides valuable insights into regional variations in disease burden and potential environmental factors influencing cardiac health. This contributes to a more comprehensive epidemiological understanding of valvular heart disease.</p>
<p>Article number four. Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study. The Rotterdam Study investigated myocardial injury in non-hospitalized community-dwelling individuals after C.O.V.I.D.-19 infection, also evaluating the relationship between persistent cardiac symptoms and myocardial function. This prospective population-based cohort study employed both echocardiography and cardiovascular magnetic resonance imaging for participants who recovered at home within two years of infection. By assessing individuals with known cardiovascular health status prior to infection, the research aims to establish a clear understanding of subclinical cardiac sequelae and their clinical relevance in a broader population affected by C.O.V.I.D.-19. This contributes to better management of post-C.O.V.I.D.-19 cardiac complications.</p>
<p>Article number five. Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank. This study aimed to compare left ventricular shapes in patients with varying cardiovascular risk factor profiles from the Multi-Ethnic Study of Atherosclerosis and U.K. Biobank cohorts. Utilizing statistical shape atlases, the research investigated the generalizability of relationships between heart shape and risk factors across these large populations. It also explored whether left ventricular shape scores generated from a reference cohort could be directly applied to study shape differences in another. This work establishes the robustness of using cardiac shape analysis for cardiovascular risk assessment and enhances the potential for widespread clinical application. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lifestyle, statistical shape atlases, mortality, catheter ablation, community screening, weight management, population-based cohort, socioeconomic status, cardiovascular magnetic resonance, Cardiovascular disease, China, Atrial fibrillation, C.O.V.I.D.-19 infection, altitude, Left ventricular shape, Multi-Ethnic Study of Atherosclerosis, U.K. Biobank, Myocardial injury, Valvular heart disease, cardiovascular risk factors, risk factor modification, epidemiology, non-hospitalized, randomized clinical trial, echocardiography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/">Randomized Evidence for Atrial Fibrillation Success 10/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251030_060109.mp3" length="5216382" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like lifestyle and statistical shape atlases. Key takeaway: Randomized Evidence for Atrial Fibrillation Success.
Article Links:
Article 1: Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial. (JAMA cardiology)
Article 2: Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort. (Heart (British Cardiac Society))
Article 3: Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China. (Heart (British Cardiac Society))
Article 4: Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study. (Heart (British Cardiac Society))
Article 5: Relationship between left ventricular shape and cardiovascular risk factors: comparison between the Multi-Ethnic Study of Atherosclerosis and UK Biobank. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/randomized-evidence-for-atrial-fibrillation-success-10-30-25/
 Featured Articles
Article 1: Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41160038
Summary: The ARREST-AF Randomized Clinical Trial is an open-label, multicenter, randomized clinical trial with 12-month follow-up designed to determine the impact of risk factor and weight management on atrial fibrillation ablation rhythm outcomes. This study specifically addresses the need for randomized clinical trial evidence to support observational reports of reduced arrhythmia recurrence after atrial fibrillation ablation with aggressive lifestyle modification. By investigating this relationship, the ARREST-AF trial aims to establish whether lifestyle interventions can significantly improve the long-term success of atrial fibrillation ablation. This will provide crucial data for enhancing treatment strategies for patients with atrial fibrillation.
Article 2: Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40081938
Summary: This national population-based cohort study, conducted across 31 provinces in mainland China, investigated cardiovascular disease-specific and all-cause mortality among patients with established cardiovascular disease. Researchers included participants aged 35 to 75 years with self-reported diagnoses, collecting detailed information on socioeconomic status and lifestyle. The study aims to provide crucial evidence regarding socioeconomic status-related health inequality in cardiovascular disease patients who require both lifestyle changes and medical care, particularly in developing countries. This research will establish a clearer understanding of health disparities to inform targeted public health interventions.
Article 3: Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40032496
Summary: This study investigated the prevalence, spectrum, and etiology of valvular heart disease across different altitudes in Yunnan Province, China, utilizing two sequential community-based echocardiography screening programs. The re]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like lifestyle and statistical shape atlases. Key takeaway: Randomized Evidence for Atrial Fibrillation Success.
Article Links:
Article 1: Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial. (JAMA cardiology)
Article 2: Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort. (Heart (British Cardiac Society))
Article 3: Prevalence, spectrum and aetiology of valvular heart disease based on community echocardiographic screening transition from different altitudes in Yunnan, China. (Heart (British Cardiac Society))
Article 4: Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwe]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Early F.H. Diagnosis Via Newborn Blood Spots 10/30/25</title>
	<link>https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/</link>
	<pubDate>Thu, 30 Oct 2025 06:58:51 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like nitric oxide and Familial hypercholesterolemia. Key takeaway: Early F.H. Diagnosis Via Newborn Blood Spots.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41159879">Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41159978">PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41159282">Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41159251">Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41160044">Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/">https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159879" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159879</a></p>
<p><strong>Summary:</strong> This international, investigator-initiated, open-label, randomized controlled trial was designed to compare immediate percutaneous coronary intervention guided by instantaneous wave-free ratio with deferred percutaneous coronary intervention guided by cardiac stress magnetic resonance imaging. The study enrolled patients with S.T.-segment elevation myocardial infarction and multivessel disease. This research establishes a robust methodology to determine the optimal timing for treating nonculprit lesions in these high-risk patients. The findings from this trial will provide critical evidence to guide clinical practice for nonculprit-lesion management in S.T.-segment elevation myocardial infarction.</p>
<h4>Article 2: PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159978" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159978</a></p>
<p><strong>Summary:</strong> The PROCTOR multicenter randomized trial was designed to compare clinical outcomes between percutaneous coronary intervention of the native coronary artery versus percutaneous coronary intervention of the saphenous vein graft. This study enrolled patients with prior coronary artery bypass grafting who presented with saphenous vein graft failure. This randomized comparison directly addresses a gap in current guidelines, which rely solely on observational data for recommendations regarding percutaneous coronary intervention strategy after bypass surgery. The findings will establish evidence-based guidance for optimal revascularization in this complex patient population.</p>
<h4>Article 3: Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159282" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159282</a></p>
<p><strong>Summary:</strong> This research assessed the role of nuclear endothelial nitric oxide synthase and nitric oxide signaling for endothelial cell function. Using loss-of-function approaches, confocal microscopy, and biochemical analyses, the study found that endothelial nitric oxide synthase localized in the endothelial cell nucleus generates nitric oxide. This nuclear endothelial nitric oxide synthase interacts with and S-nitrosates Adenosine Deaminase, R.N.A.-Specific, 1, consequently modulating type I interferon signaling. These findings reveal a novel molecular mechanism through which nuclear endothelial nitric oxide synthase regulates vascular inflammation and endothelial homeostasis, offering new therapeutic avenues for endothelial dysfunction.</p>
<h4>Article 4: Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159251</a></p>
<p><strong>Summary:</strong> This retrospective cohort study characterized the geometric features of viable corridors participating in ventricular tachycardia circuitry in ischemic cardiomyopathy. Researchers analyzed patients who underwent cardiovascular magnetic resonance imaging before their first ventricular tachycardia ablation. Applying a 3-dimensional hyperboloid model to viable corridors derived from late gadolinium enhanced cardiovascular magnetic resonance imaging, the study provided a precise geometric understanding of ventricular tachycardia circuitry. This detailed geometric mapping improves the understanding of ventricular tachycardia mechanisms, potentially leading to more targeted and effective ablation strategies for ischemic cardiomyopathy.</p>
<h4>Article 5: Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41160044" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41160044</a></p>
<p><strong>Summary:</strong> This cross-sectional study investigated the feasibility and results of genetic testing for familial hypercholesterolemia using residual newborn screening dried blood spots. The research successfully performed genetic testing in samples with biomarkers suggesting high risk for familial hypercholesterolemia. This approach demonstrates a viable method for dramatically increasing the early diagnosis of familial hypercholesterolemia in newborns and their relatives. These findings establish a crucial initial step toward developing a multitier newborn screening program for this common, treatable genetic condition, enabling earlier intervention and improved long-term outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Immediate or Deferred Nonculprit-Lesion Percutaneous Coronary Intervention in Myocardial Infarction. This international, investigator-initiated, open-label, randomized controlled trial was designed to compare immediate percutaneous coronary intervention guided by instantaneous wave-free ratio with deferred percutaneous coronary intervention guided by cardiac stress magnetic resonance imaging. The study enrolled patients with S.T.-segment elevation myocardial infarction and multivessel disease. This research establishes a robust methodology to determine the optimal timing for treating nonculprit lesions in these high-risk patients. The findings from this trial will provide critical evidence to guide clinical practice for nonculprit-lesion management in S.T.-segment elevation myocardial infarction.</p>
<p>Article number two. Percutaneous Coronary Intervention of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial. The PROCTOR multicenter randomized trial was designed to compare clinical outcomes between percutaneous coronary intervention of the native coronary artery versus percutaneous coronary intervention of the saphenous vein graft. This study enrolled patients with prior coronary artery bypass grafting who presented with saphenous vein graft failure. This randomized comparison directly addresses a gap in current guidelines, which rely solely on observational data for recommendations regarding percutaneous coronary intervention strategy after bypass surgery. The findings will establish evidence-based guidance for optimal revascularization in this complex patient population.</p>
<p>Article number three. Nuclear Endothelial Nitric Oxide Synthase Interacts With and S-Nitrosates Adenosine Deaminase, R.N.A.-Specific, 1 to Modulate Type I Interferon Signaling and Endothelial Function. This research assessed the role of nuclear endothelial nitric oxide synthase and nitric oxide signaling for endothelial cell function. Using loss-of-function approaches, confocal microscopy, and biochemical analyses, the study found that endothelial nitric oxide synthase localized in the endothelial cell nucleus generates nitric oxide. This nuclear endothelial nitric oxide synthase interacts with and S-nitrosates Adenosine Deaminase, R.N.A.-Specific, 1, consequently modulating type I interferon signaling. These findings reveal a novel molecular mechanism through which nuclear endothelial nitric oxide synthase regulates vascular inflammation and endothelial homeostasis, offering new therapeutic avenues for endothelial dysfunction.</p>
<p>Article number four. Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy. This retrospective cohort study characterized the geometric features of viable corridors participating in ventricular tachycardia circuitry in ischemic cardiomyopathy. Researchers analyzed patients who underwent cardiovascular magnetic resonance imaging before their first ventricular tachycardia ablation. Applying a 3-dimensional hyperboloid model to viable corridors derived from late gadolinium enhanced cardiovascular magnetic resonance imaging, the study provided a precise geometric understanding of ventricular tachycardia circuitry. This detailed geometric mapping improves the understanding of ventricular tachycardia mechanisms, potentially leading to more targeted and effective ablation strategies for ischemic cardiomyopathy.</p>
<p>Article number five. Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots. This cross-sectional study investigated the feasibility and results of genetic testing for familial hypercholesterolemia using residual newborn screening dried blood spots. The research successfully performed genetic testing in samples with biomarkers suggesting high risk for familial hypercholesterolemia. This approach demonstrates a viable method for dramatically increasing the early diagnosis of familial hypercholesterolemia in newborns and their relatives. These findings establish a crucial initial step toward developing a multitier newborn screening program for this common, treatable genetic condition, enabling earlier intervention and improved long-term outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>nitric oxide, Familial hypercholesterolemia, dried blood spots, multivessel disease, S.T.-segment elevation myocardial infarction, newborn screening, late gadolinium enhancement, Coronary artery bypass grafting, P.C.I., ablation, Ventricular tachycardia, type I interferon signaling, revascularization, cardiac M.R.I., vascular inflammation, instantaneous wave-free ratio, F.H., genetic diagnosis, saphenous vein graft, ischemic cardiomyopathy, native coronary artery, A.D.A.R.1., endothelial function, nonculprit lesion, 3-dimensional mapping, Endothelial nitric oxide synthase.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/">Early F.H. Diagnosis Via Newborn Blood Spots 10/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like nitric oxide and Familial hypercholesterolemia. Key takeaway: Early F.H. Diagnosis Via Newborn Blood Spots.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like nitric oxide and Familial hypercholesterolemia. Key takeaway: Early F.H. Diagnosis Via Newborn Blood Spots.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41159879">Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41159978">PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41159282">Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41159251">Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41160044">Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/">https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159879" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159879</a></p>
<p><strong>Summary:</strong> This international, investigator-initiated, open-label, randomized controlled trial was designed to compare immediate percutaneous coronary intervention guided by instantaneous wave-free ratio with deferred percutaneous coronary intervention guided by cardiac stress magnetic resonance imaging. The study enrolled patients with S.T.-segment elevation myocardial infarction and multivessel disease. This research establishes a robust methodology to determine the optimal timing for treating nonculprit lesions in these high-risk patients. The findings from this trial will provide critical evidence to guide clinical practice for nonculprit-lesion management in S.T.-segment elevation myocardial infarction.</p>
<h4>Article 2: PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159978" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159978</a></p>
<p><strong>Summary:</strong> The PROCTOR multicenter randomized trial was designed to compare clinical outcomes between percutaneous coronary intervention of the native coronary artery versus percutaneous coronary intervention of the saphenous vein graft. This study enrolled patients with prior coronary artery bypass grafting who presented with saphenous vein graft failure. This randomized comparison directly addresses a gap in current guidelines, which rely solely on observational data for recommendations regarding percutaneous coronary intervention strategy after bypass surgery. The findings will establish evidence-based guidance for optimal revascularization in this complex patient population.</p>
<h4>Article 3: Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159282" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159282</a></p>
<p><strong>Summary:</strong> This research assessed the role of nuclear endothelial nitric oxide synthase and nitric oxide signaling for endothelial cell function. Using loss-of-function approaches, confocal microscopy, and biochemical analyses, the study found that endothelial nitric oxide synthase localized in the endothelial cell nucleus generates nitric oxide. This nuclear endothelial nitric oxide synthase interacts with and S-nitrosates Adenosine Deaminase, R.N.A.-Specific, 1, consequently modulating type I interferon signaling. These findings reveal a novel molecular mechanism through which nuclear endothelial nitric oxide synthase regulates vascular inflammation and endothelial homeostasis, offering new therapeutic avenues for endothelial dysfunction.</p>
<h4>Article 4: Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41159251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41159251</a></p>
<p><strong>Summary:</strong> This retrospective cohort study characterized the geometric features of viable corridors participating in ventricular tachycardia circuitry in ischemic cardiomyopathy. Researchers analyzed patients who underwent cardiovascular magnetic resonance imaging before their first ventricular tachycardia ablation. Applying a 3-dimensional hyperboloid model to viable corridors derived from late gadolinium enhanced cardiovascular magnetic resonance imaging, the study provided a precise geometric understanding of ventricular tachycardia circuitry. This detailed geometric mapping improves the understanding of ventricular tachycardia mechanisms, potentially leading to more targeted and effective ablation strategies for ischemic cardiomyopathy.</p>
<h4>Article 5: Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41160044" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41160044</a></p>
<p><strong>Summary:</strong> This cross-sectional study investigated the feasibility and results of genetic testing for familial hypercholesterolemia using residual newborn screening dried blood spots. The research successfully performed genetic testing in samples with biomarkers suggesting high risk for familial hypercholesterolemia. This approach demonstrates a viable method for dramatically increasing the early diagnosis of familial hypercholesterolemia in newborns and their relatives. These findings establish a crucial initial step toward developing a multitier newborn screening program for this common, treatable genetic condition, enabling earlier intervention and improved long-term outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Immediate or Deferred Nonculprit-Lesion Percutaneous Coronary Intervention in Myocardial Infarction. This international, investigator-initiated, open-label, randomized controlled trial was designed to compare immediate percutaneous coronary intervention guided by instantaneous wave-free ratio with deferred percutaneous coronary intervention guided by cardiac stress magnetic resonance imaging. The study enrolled patients with S.T.-segment elevation myocardial infarction and multivessel disease. This research establishes a robust methodology to determine the optimal timing for treating nonculprit lesions in these high-risk patients. The findings from this trial will provide critical evidence to guide clinical practice for nonculprit-lesion management in S.T.-segment elevation myocardial infarction.</p>
<p>Article number two. Percutaneous Coronary Intervention of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial. The PROCTOR multicenter randomized trial was designed to compare clinical outcomes between percutaneous coronary intervention of the native coronary artery versus percutaneous coronary intervention of the saphenous vein graft. This study enrolled patients with prior coronary artery bypass grafting who presented with saphenous vein graft failure. This randomized comparison directly addresses a gap in current guidelines, which rely solely on observational data for recommendations regarding percutaneous coronary intervention strategy after bypass surgery. The findings will establish evidence-based guidance for optimal revascularization in this complex patient population.</p>
<p>Article number three. Nuclear Endothelial Nitric Oxide Synthase Interacts With and S-Nitrosates Adenosine Deaminase, R.N.A.-Specific, 1 to Modulate Type I Interferon Signaling and Endothelial Function. This research assessed the role of nuclear endothelial nitric oxide synthase and nitric oxide signaling for endothelial cell function. Using loss-of-function approaches, confocal microscopy, and biochemical analyses, the study found that endothelial nitric oxide synthase localized in the endothelial cell nucleus generates nitric oxide. This nuclear endothelial nitric oxide synthase interacts with and S-nitrosates Adenosine Deaminase, R.N.A.-Specific, 1, consequently modulating type I interferon signaling. These findings reveal a novel molecular mechanism through which nuclear endothelial nitric oxide synthase regulates vascular inflammation and endothelial homeostasis, offering new therapeutic avenues for endothelial dysfunction.</p>
<p>Article number four. Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy. This retrospective cohort study characterized the geometric features of viable corridors participating in ventricular tachycardia circuitry in ischemic cardiomyopathy. Researchers analyzed patients who underwent cardiovascular magnetic resonance imaging before their first ventricular tachycardia ablation. Applying a 3-dimensional hyperboloid model to viable corridors derived from late gadolinium enhanced cardiovascular magnetic resonance imaging, the study provided a precise geometric understanding of ventricular tachycardia circuitry. This detailed geometric mapping improves the understanding of ventricular tachycardia mechanisms, potentially leading to more targeted and effective ablation strategies for ischemic cardiomyopathy.</p>
<p>Article number five. Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots. This cross-sectional study investigated the feasibility and results of genetic testing for familial hypercholesterolemia using residual newborn screening dried blood spots. The research successfully performed genetic testing in samples with biomarkers suggesting high risk for familial hypercholesterolemia. This approach demonstrates a viable method for dramatically increasing the early diagnosis of familial hypercholesterolemia in newborns and their relatives. These findings establish a crucial initial step toward developing a multitier newborn screening program for this common, treatable genetic condition, enabling earlier intervention and improved long-term outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>nitric oxide, Familial hypercholesterolemia, dried blood spots, multivessel disease, S.T.-segment elevation myocardial infarction, newborn screening, late gadolinium enhancement, Coronary artery bypass grafting, P.C.I., ablation, Ventricular tachycardia, type I interferon signaling, revascularization, cardiac M.R.I., vascular inflammation, instantaneous wave-free ratio, F.H., genetic diagnosis, saphenous vein graft, ischemic cardiomyopathy, native coronary artery, A.D.A.R.1., endothelial function, nonculprit lesion, 3-dimensional mapping, Endothelial nitric oxide synthase.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/">Early F.H. Diagnosis Via Newborn Blood Spots 10/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251030_025729.mp3" length="4998625" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like nitric oxide and Familial hypercholesterolemia. Key takeaway: Early F.H. Diagnosis Via Newborn Blood Spots.
Article Links:
Article 1: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. (The New England journal of medicine)
Article 2: PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial. (Journal of the American College of Cardiology)
Article 3: Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function. (Circulation)
Article 4: Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy. (Circulation)
Article 5: Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/early-f-h-diagnosis-via-newborn-blood-spots-10-30-25/
 Featured Articles
Article 1: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159879
Summary: This international, investigator-initiated, open-label, randomized controlled trial was designed to compare immediate percutaneous coronary intervention guided by instantaneous wave-free ratio with deferred percutaneous coronary intervention guided by cardiac stress magnetic resonance imaging. The study enrolled patients with S.T.-segment elevation myocardial infarction and multivessel disease. This research establishes a robust methodology to determine the optimal timing for treating nonculprit lesions in these high-risk patients. The findings from this trial will provide critical evidence to guide clinical practice for nonculprit-lesion management in S.T.-segment elevation myocardial infarction.
Article 2: PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159978
Summary: The PROCTOR multicenter randomized trial was designed to compare clinical outcomes between percutaneous coronary intervention of the native coronary artery versus percutaneous coronary intervention of the saphenous vein graft. This study enrolled patients with prior coronary artery bypass grafting who presented with saphenous vein graft failure. This randomized comparison directly addresses a gap in current guidelines, which rely solely on observational data for recommendations regarding percutaneous coronary intervention strategy after bypass surgery. The findings will establish evidence-based guidance for optimal revascularization in this complex patient population.
Article 3: Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159282
Summary: This research assessed the role of nuclear endothelial nitric oxide synthase and nitric oxide signaling for endothelial cell function. Using loss-of-function approaches, confocal microscopy, and biochemical analyses, the study found that endothelial nitric oxide synthase localized in the endothelial cell nucleus generates nitric oxide. This nuclear endothelial nitric oxide synthase interacts with and S-nitrosates Adenosine Deaminase, R.N.A.-Specific, 1, consequently modulating type I interferon signaling. These findings reveal a novel molecular mechanism through which nuclear endothelial nitric oxide synthase regulates vascular inflammation and endothelial homeostasis, offering new therapeutic avenues for endothelial dysfunction.
Article 4: Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/4]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 30, 2025. This episode summarizes 5 key cardiology studies on topics like nitric oxide and Familial hypercholesterolemia. Key takeaway: Early F.H. Diagnosis Via Newborn Blood Spots.
Article Links:
Article 1: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. (The New England journal of medicine)
Article 2: PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial. (Journal of the American College of Cardiology)
Article 3: Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function. (Circulation)
Article 4: Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy. (Circulation)
Article 5: Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/early-f-h-diagnosi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>COVID-19 Vaccine Effects on High-Risk Hearts 10/29/25</title>
	<link>https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/</link>
	<pubDate>Wed, 29 Oct 2025 10:02:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like large hemispheric infarction and lower-extremity peripheral vascular interventions. Key takeaway: COVID-19 Vaccine Effects on High-Risk Hearts.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41147410">Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41147407">Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41147404">Association of Pancreas Volume With Adverse Clinical Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41147399">Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41147397">COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/">https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147410</a></p>
<p><strong>Summary:</strong> This study utilized the National Cardiovascular Data Registry Peripheral Vascular Intervention registry to investigate the relationship between hospital and operator procedural volume and in-hospital major adverse limb events and major adverse cardiovascular events following lower-extremity peripheral vascular interventions. It assessed data collected from April 1 2014 to December 31 2019 to better understand how provider experience influences patient safety and outcomes. This research establishes a clearer understanding of volume-outcome associations, which is crucial for standardizing care and potentially improving patient prognosis in peripheral artery disease management.</p>
<h4>Article 2: Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147407" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147407</a></p>
<p><strong>Summary:</strong> This randomized, double-blind, placebo-controlled, proof-of-concept clinical trial investigated the safety and preliminary feasibility of YC-6, specifically 5alpha-androst-3beta56beta-triol for injection, in patients experiencing large hemispheric infarction. The study enrolled individuals with middle cerebral artery infarction within 12 hours of symptom onset, addressing the urgent need for novel neuroprotective agents to combat malignant cerebral edema. By assessing these initial parameters, the research lays foundational groundwork for future therapeutic development, aiming to improve outcomes for a critical cause of poor prognosis in severe stroke.</p>
<h4>Article 3: Association of Pancreas Volume With Adverse Clinical Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147404" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147404</a></p>
<p><strong>Summary:</strong> This study investigated the association of pancreas volume with adverse clinical outcomes, recognizing that chronic diseases can reduce pancreas size and impact endocrine and exocrine function. Researchers estimated baseline age-adjusted predicted pancreas volume using abdominal magnetic resonance imaging data from 36592 U.K. Biobank participants. The analysis establishes a critical understanding of whether reduced pancreas volume serves as an indicator for heightened risk of various adverse clinical conditions. This research contributes a significant marker for potentially identifying individuals at higher risk, enabling earlier monitoring or preventive strategies.</p>
<h4>Article 4: Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147399" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147399</a></p>
<p><strong>Summary:</strong> This study aimed to elucidate treatment response and survival in Methamphetamine-associated Pulmonary Arterial Hypertension, a growing subset of pulmonary arterial hypertension. Researchers conducted a prospective protocolized cohort analysis of 138 incident patients, comparing 64 individuals with Methamphetamine-associated Pulmonary Arterial Hypertension to 74 with idiopathic Pulmonary Arterial Hypertension. The investigation focused on evaluating survival, response to continuous prostacyclin therapy, and right ventricle function in similarly treated cohorts. This research provides crucial data to distinguish outcomes and optimize therapeutic approaches for patients with Methamphetamine-associated Pulmonary Arterial Hypertension compared to idiopathic Pulmonary Arterial Hypertension.</p>
<h4>Article 5: COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147397" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147397</a></p>
<p><strong>Summary:</strong> This large propensity-matched cohort study evaluated the long-term cardiovascular outcomes of Coronavirus Disease 2019 vaccination in older adults with pre-existing coronary artery disease or heart failure. Using the TriNetX U.S. Collaborative Network from December 2020 to December 2022, researchers matched 74236 vaccinated patients 1:1 with an equal number of calendar-aligned unvaccinated patients. The study meticulously assessed outcomes including mortality, providing critical evidence on vaccine safety and efficacy in this particularly vulnerable population. This research offers definitive data to inform clinical guidance and reassure patients regarding Coronavirus Disease 2019 vaccination benefits for cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry. This study utilized the National Cardiovascular Data Registry Peripheral Vascular Intervention registry to investigate the relationship between hospital and operator procedural volume and in-hospital major adverse limb events and major adverse cardiovascular events following lower-extremity peripheral vascular interventions. It assessed data collected from April 1 2014 to December 31 2019 to better understand how provider experience influences patient safety and outcomes. This research establishes a clearer understanding of volume-outcome associations, which is crucial for standardizing care and potentially improving patient prognosis in peripheral artery disease management.</p>
<p>Article number two. Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. This randomized, double-blind, placebo-controlled, proof-of-concept clinical trial investigated the safety and preliminary feasibility of YC-6, specifically 5alpha-androst-3beta56beta-triol for injection, in patients experiencing large hemispheric infarction. The study enrolled individuals with middle cerebral artery infarction within 12 hours of symptom onset, addressing the urgent need for novel neuroprotective agents to combat malignant cerebral edema. By assessing these initial parameters, the research lays foundational groundwork for future therapeutic development, aiming to improve outcomes for a critical cause of poor prognosis in severe stroke.</p>
<p>Article number three. Association of Pancreas Volume With Adverse Clinical Outcomes. This study investigated the association of pancreas volume with adverse clinical outcomes, recognizing that chronic diseases can reduce pancreas size and impact endocrine and exocrine function. Researchers estimated baseline age-adjusted predicted pancreas volume using abdominal magnetic resonance imaging data from 36592 U.K. Biobank participants. The analysis establishes a critical understanding of whether reduced pancreas volume serves as an indicator for heightened risk of various adverse clinical conditions. This research contributes a significant marker for potentially identifying individuals at higher risk, enabling earlier monitoring or preventive strategies.</p>
<p>Article number four. Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension. This study aimed to elucidate treatment response and survival in Methamphetamine-associated Pulmonary Arterial Hypertension, a growing subset of pulmonary arterial hypertension. Researchers conducted a prospective protocolized cohort analysis of 138 incident patients, comparing 64 individuals with Methamphetamine-associated Pulmonary Arterial Hypertension to 74 with idiopathic Pulmonary Arterial Hypertension. The investigation focused on evaluating survival, response to continuous prostacyclin therapy, and right ventricle function in similarly treated cohorts. This research provides crucial data to distinguish outcomes and optimize therapeutic approaches for patients with Methamphetamine-associated Pulmonary Arterial Hypertension compared to idiopathic Pulmonary Arterial Hypertension.</p>
<p>Article number five. COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study. This large propensity-matched cohort study evaluated the long-term cardiovascular outcomes of Coronavirus Disease 2019 vaccination in older adults with pre-existing coronary artery disease or heart failure. Using the TriNetX U.S. Collaborative Network from December 2020 to December 2022, researchers matched 74236 vaccinated patients 1:1 with an equal number of calendar-aligned unvaccinated patients. The study meticulously assessed outcomes including mortality, providing critical evidence on vaccine safety and efficacy in this particularly vulnerable population. This research offers definitive data to inform clinical guidance and reassure patients regarding Coronavirus Disease 2019 vaccination benefits for cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>large hemispheric infarction, lower-extremity peripheral vascular interventions, major adverse cardiovascular events, pancreas volume, peripheral artery disease, prostacyclin, coronary artery disease, methamphetamine-associated pulmonary arterial hypertension, randomized clinical trial, YC-6, Coronavirus Disease 2019 vaccination, adverse clinical outcomes, right ventricle function, procedural volume, cardiovascular outcomes, magnetic resonance imaging, U.K. Biobank, older adults, mortality, malignant cerebral edema, survival, idiopathic pulmonary arterial hypertension, heart failure, chronic diseases, major adverse limb events, neuroprotective agents.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/">COVID-19 Vaccine Effects on High-Risk Hearts 10/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like large hemispheric infarction and lower-extremity peripheral vascular interventions. Key takeaway: COVID-19 Vaccine Effects on High-Ri]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like large hemispheric infarction and lower-extremity peripheral vascular interventions. Key takeaway: COVID-19 Vaccine Effects on High-Risk Hearts.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41147410">Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41147407">Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41147404">Association of Pancreas Volume With Adverse Clinical Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41147399">Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41147397">COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/">https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147410</a></p>
<p><strong>Summary:</strong> This study utilized the National Cardiovascular Data Registry Peripheral Vascular Intervention registry to investigate the relationship between hospital and operator procedural volume and in-hospital major adverse limb events and major adverse cardiovascular events following lower-extremity peripheral vascular interventions. It assessed data collected from April 1 2014 to December 31 2019 to better understand how provider experience influences patient safety and outcomes. This research establishes a clearer understanding of volume-outcome associations, which is crucial for standardizing care and potentially improving patient prognosis in peripheral artery disease management.</p>
<h4>Article 2: Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147407" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147407</a></p>
<p><strong>Summary:</strong> This randomized, double-blind, placebo-controlled, proof-of-concept clinical trial investigated the safety and preliminary feasibility of YC-6, specifically 5alpha-androst-3beta56beta-triol for injection, in patients experiencing large hemispheric infarction. The study enrolled individuals with middle cerebral artery infarction within 12 hours of symptom onset, addressing the urgent need for novel neuroprotective agents to combat malignant cerebral edema. By assessing these initial parameters, the research lays foundational groundwork for future therapeutic development, aiming to improve outcomes for a critical cause of poor prognosis in severe stroke.</p>
<h4>Article 3: Association of Pancreas Volume With Adverse Clinical Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147404" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147404</a></p>
<p><strong>Summary:</strong> This study investigated the association of pancreas volume with adverse clinical outcomes, recognizing that chronic diseases can reduce pancreas size and impact endocrine and exocrine function. Researchers estimated baseline age-adjusted predicted pancreas volume using abdominal magnetic resonance imaging data from 36592 U.K. Biobank participants. The analysis establishes a critical understanding of whether reduced pancreas volume serves as an indicator for heightened risk of various adverse clinical conditions. This research contributes a significant marker for potentially identifying individuals at higher risk, enabling earlier monitoring or preventive strategies.</p>
<h4>Article 4: Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147399" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147399</a></p>
<p><strong>Summary:</strong> This study aimed to elucidate treatment response and survival in Methamphetamine-associated Pulmonary Arterial Hypertension, a growing subset of pulmonary arterial hypertension. Researchers conducted a prospective protocolized cohort analysis of 138 incident patients, comparing 64 individuals with Methamphetamine-associated Pulmonary Arterial Hypertension to 74 with idiopathic Pulmonary Arterial Hypertension. The investigation focused on evaluating survival, response to continuous prostacyclin therapy, and right ventricle function in similarly treated cohorts. This research provides crucial data to distinguish outcomes and optimize therapeutic approaches for patients with Methamphetamine-associated Pulmonary Arterial Hypertension compared to idiopathic Pulmonary Arterial Hypertension.</p>
<h4>Article 5: COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147397" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147397</a></p>
<p><strong>Summary:</strong> This large propensity-matched cohort study evaluated the long-term cardiovascular outcomes of Coronavirus Disease 2019 vaccination in older adults with pre-existing coronary artery disease or heart failure. Using the TriNetX U.S. Collaborative Network from December 2020 to December 2022, researchers matched 74236 vaccinated patients 1:1 with an equal number of calendar-aligned unvaccinated patients. The study meticulously assessed outcomes including mortality, providing critical evidence on vaccine safety and efficacy in this particularly vulnerable population. This research offers definitive data to inform clinical guidance and reassure patients regarding Coronavirus Disease 2019 vaccination benefits for cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry. This study utilized the National Cardiovascular Data Registry Peripheral Vascular Intervention registry to investigate the relationship between hospital and operator procedural volume and in-hospital major adverse limb events and major adverse cardiovascular events following lower-extremity peripheral vascular interventions. It assessed data collected from April 1 2014 to December 31 2019 to better understand how provider experience influences patient safety and outcomes. This research establishes a clearer understanding of volume-outcome associations, which is crucial for standardizing care and potentially improving patient prognosis in peripheral artery disease management.</p>
<p>Article number two. Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. This randomized, double-blind, placebo-controlled, proof-of-concept clinical trial investigated the safety and preliminary feasibility of YC-6, specifically 5alpha-androst-3beta56beta-triol for injection, in patients experiencing large hemispheric infarction. The study enrolled individuals with middle cerebral artery infarction within 12 hours of symptom onset, addressing the urgent need for novel neuroprotective agents to combat malignant cerebral edema. By assessing these initial parameters, the research lays foundational groundwork for future therapeutic development, aiming to improve outcomes for a critical cause of poor prognosis in severe stroke.</p>
<p>Article number three. Association of Pancreas Volume With Adverse Clinical Outcomes. This study investigated the association of pancreas volume with adverse clinical outcomes, recognizing that chronic diseases can reduce pancreas size and impact endocrine and exocrine function. Researchers estimated baseline age-adjusted predicted pancreas volume using abdominal magnetic resonance imaging data from 36592 U.K. Biobank participants. The analysis establishes a critical understanding of whether reduced pancreas volume serves as an indicator for heightened risk of various adverse clinical conditions. This research contributes a significant marker for potentially identifying individuals at higher risk, enabling earlier monitoring or preventive strategies.</p>
<p>Article number four. Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension. This study aimed to elucidate treatment response and survival in Methamphetamine-associated Pulmonary Arterial Hypertension, a growing subset of pulmonary arterial hypertension. Researchers conducted a prospective protocolized cohort analysis of 138 incident patients, comparing 64 individuals with Methamphetamine-associated Pulmonary Arterial Hypertension to 74 with idiopathic Pulmonary Arterial Hypertension. The investigation focused on evaluating survival, response to continuous prostacyclin therapy, and right ventricle function in similarly treated cohorts. This research provides crucial data to distinguish outcomes and optimize therapeutic approaches for patients with Methamphetamine-associated Pulmonary Arterial Hypertension compared to idiopathic Pulmonary Arterial Hypertension.</p>
<p>Article number five. COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study. This large propensity-matched cohort study evaluated the long-term cardiovascular outcomes of Coronavirus Disease 2019 vaccination in older adults with pre-existing coronary artery disease or heart failure. Using the TriNetX U.S. Collaborative Network from December 2020 to December 2022, researchers matched 74236 vaccinated patients 1:1 with an equal number of calendar-aligned unvaccinated patients. The study meticulously assessed outcomes including mortality, providing critical evidence on vaccine safety and efficacy in this particularly vulnerable population. This research offers definitive data to inform clinical guidance and reassure patients regarding Coronavirus Disease 2019 vaccination benefits for cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>large hemispheric infarction, lower-extremity peripheral vascular interventions, major adverse cardiovascular events, pancreas volume, peripheral artery disease, prostacyclin, coronary artery disease, methamphetamine-associated pulmonary arterial hypertension, randomized clinical trial, YC-6, Coronavirus Disease 2019 vaccination, adverse clinical outcomes, right ventricle function, procedural volume, cardiovascular outcomes, magnetic resonance imaging, U.K. Biobank, older adults, mortality, malignant cerebral edema, survival, idiopathic pulmonary arterial hypertension, heart failure, chronic diseases, major adverse limb events, neuroprotective agents.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/">COVID-19 Vaccine Effects on High-Risk Hearts 10/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251029_060112.mp3" length="4883269" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like large hemispheric infarction and lower-extremity peripheral vascular interventions. Key takeaway: COVID-19 Vaccine Effects on High-Risk Hearts.
Article Links:
Article 1: Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry. (Journal of the American Heart Association)
Article 2: Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. (Journal of the American Heart Association)
Article 3: Association of Pancreas Volume With Adverse Clinical Outcomes. (Journal of the American Heart Association)
Article 4: Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension. (Journal of the American Heart Association)
Article 5: COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/covid-19-vaccine-effects-on-high-risk-hearts-10-29-25/
 Featured Articles
Article 1: Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41147410
Summary: This study utilized the National Cardiovascular Data Registry Peripheral Vascular Intervention registry to investigate the relationship between hospital and operator procedural volume and in-hospital major adverse limb events and major adverse cardiovascular events following lower-extremity peripheral vascular interventions. It assessed data collected from April 1 2014 to December 31 2019 to better understand how provider experience influences patient safety and outcomes. This research establishes a clearer understanding of volume-outcome associations, which is crucial for standardizing care and potentially improving patient prognosis in peripheral artery disease management.
Article 2: Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41147407
Summary: This randomized, double-blind, placebo-controlled, proof-of-concept clinical trial investigated the safety and preliminary feasibility of YC-6, specifically 5alpha-androst-3beta56beta-triol for injection, in patients experiencing large hemispheric infarction. The study enrolled individuals with middle cerebral artery infarction within 12 hours of symptom onset, addressing the urgent need for novel neuroprotective agents to combat malignant cerebral edema. By assessing these initial parameters, the research lays foundational groundwork for future therapeutic development, aiming to improve outcomes for a critical cause of poor prognosis in severe stroke.
Article 3: Association of Pancreas Volume With Adverse Clinical Outcomes.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41147404
Summary: This study investigated the association of pancreas volume with adverse clinical outcomes, recognizing that chronic diseases can reduce pancreas size and impact endocrine and exocrine function. Researchers estimated baseline age-adjusted predicted pancreas volume using abdominal magnetic resonance imaging data from 36592 U.K. Biobank participants. The analysis establishes a critical understanding of whether reduced pancreas volume serves as an indicator for heightened risk of various adverse clinical conditions. This research contributes a significant marker for potentially identifying individuals at higher risk, enabling earlier monitoring or preventive strategies.
Article 4:]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like large hemispheric infarction and lower-extremity peripheral vascular interventions. Key takeaway: COVID-19 Vaccine Effects on High-Risk Hearts.
Article Links:
Article 1: Procedural Volume and Outcomes in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry. (Journal of the American Heart Association)
Article 2: Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. (Journal of the American Heart Association)
Article 3: Association of Pancreas Volume With Adverse Clinical Outcomes. (Journal of the American Heart Association)
Article 4: Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension. (Journal of the American Heart Association)
Article 5: COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Co]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>A.E.D. Training Boosts Cardiac Arrest Survival. 10/29/25</title>
	<link>https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/</link>
	<pubDate>Wed, 29 Oct 2025 06:59:14 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like M.I.N.O.C.A. and multiomics. Key takeaway: A.E.D. Training Boosts Cardiac Arrest Survival..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41150941">Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41147662">Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41147502">Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41147417">A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41147413">GATA2 Mediates Macrophage Proliferation During Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/">https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41150941" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41150941</a></p>
<p><strong>Summary:</strong> The P.R.O.M.I.S.E. trial is a multicenter randomized study designed to evaluate the optimal management strategy for myocardial infarction with non-obstructive coronary arteries, or M.I.N.O.C.A. This condition is associated with significant mortality, rehospitalization, and angina burden, yet no prior randomized clinical trials had assessed its treatment. The trial&#8217;s objective is to determine if a stratified treatment approach improves clinical outcomes for M.I.N.O.C.A. patients compared to standard care. This research establishes a crucial framework to guide future clinical practice for this high-risk patient population.</p>
<h4>Article 2: Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147662" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147662</a></p>
<p><strong>Summary:</strong> This study characterized changes in right ventricular ejection fraction, or R.V.E.F., following tricuspid transcatheter edge-to-edge repair, or T-T.E.E.R. Patients with significant tricuspid regurgitation underwent T-T.E.E.R. and cardiac magnetic resonance, or C.M.R., imaging, with follow-up C.M.R. performed within one to three months. The research aimed to clarify the impact of T-T.E.E.R. on right ventricular remodeling and its prognostic implications. By classifying patients based on postprocedural R.V. data, this work provides a clearer understanding of right ventricular adaptation after T-T.E.E.R., which is vital for assessing patient outcomes.</p>
<h4>Article 3: Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147502" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147502</a></p>
<p><strong>Summary:</strong> This 23-year database analysis of the Progetto Vita, or P.V., program in Piacenza demonstrates improved survival for out-of-hospital cardiac arrest, or O.H.C.A., using automated external defibrillator, or A.E.D.,-only training. The P.V. project pioneered the first community-based A.E.D. program in Europe, and this extensive analysis provides critical survival data. The study highlights that early defibrillation is crucial for managing fatal arrhythmias, and A.E.D. use effectively minimizes time to defibrillation. This finding underscores the significant public health benefit of simplified A.E.D.-only training in public-access defibrillation programs for enhancing O.H.C.A. survival.</p>
<h4>Article 4: A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147417" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147417</a></p>
<p><strong>Summary:</strong> This study utilized a multiomics approach within the S.H.I.P. A.H.O.Y. cohort to define early cardiovascular target-organ injury in youths with primary hypertension. It included 132 individuals, with a mean age of 15.8 years, who were stratified by blood pressure and left ventricular mass index, or L.V.M.I. The research provides a unique opportunity to explore early cardiovascular damage in an age group largely free of confounding adult comorbidities. This approach is crucial for identifying early biomarkers and intervention points to prevent the progression of hypertension into adult cardiovascular disease.</p>
<h4>Article 5: GATA2 Mediates Macrophage Proliferation During Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147413</a></p>
<p><strong>Summary:</strong> This research identified that G.A.T.A.2 mediates macrophage proliferation during atherosclerosis, clarifying a key mechanism behind lesion development. The study employed transcriptomic and histological analysis of human samples to investigate the signals and transcriptional events driving macrophage growth. It found that while monocytes are recruited to lesions, local macrophage proliferation is the primary driver of macrophage accumulation within the vascular intima. This discovery provides a significant therapeutic advance, pinpointing G.A.T.A.2 as a potential novel target for interventions aimed at halting or regressing atherosclerosis progression.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial. The P.R.O.M.I.S.E. trial is a multicenter randomized study designed to evaluate the optimal management strategy for myocardial infarction with non-obstructive coronary arteries, or M.I.N.O.C.A. This condition is associated with significant mortality, rehospitalization, and angina burden, yet no prior randomized clinical trials had assessed its treatment. The trial&#8217;s objective is to determine if a stratified treatment approach improves clinical outcomes for M.I.N.O.C.A. patients compared to standard care. This research establishes a crucial framework to guide future clinical practice for this high-risk patient population.</p>
<p>Article number two. Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair. This study characterized changes in right ventricular ejection fraction, or R.V.E.F., following tricuspid transcatheter edge-to-edge repair, or T-T.E.E.R. Patients with significant tricuspid regurgitation underwent T-T.E.E.R. and cardiac magnetic resonance, or C.M.R., imaging, with follow-up C.M.R. performed within one to three months. The research aimed to clarify the impact of T-T.E.E.R. on right ventricular remodeling and its prognostic implications. By classifying patients based on postprocedural R.V. data, this work provides a clearer understanding of right ventricular adaptation after T-T.E.E.R., which is vital for assessing patient outcomes.</p>
<p>Article number three. Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita. This 23-year database analysis of the Progetto Vita, or P.V., program in Piacenza demonstrates improved survival for out-of-hospital cardiac arrest, or O.H.C.A., using automated external defibrillator, or A.E.D.,-only training. The P.V. project pioneered the first community-based A.E.D. program in Europe, and this extensive analysis provides critical survival data. The study highlights that early defibrillation is crucial for managing fatal arrhythmias, and A.E.D. use effectively minimizes time to defibrillation. This finding underscores the significant public health benefit of simplified A.E.D.-only training in public-access defibrillation programs for enhancing O.H.C.A. survival.</p>
<p>Article number four. A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort. This study utilized a multiomics approach within the S.H.I.P. A.H.O.Y. cohort to define early cardiovascular target-organ injury in youths with primary hypertension. It included 132 individuals, with a mean age of 15.8 years, who were stratified by blood pressure and left ventricular mass index, or L.V.M.I. The research provides a unique opportunity to explore early cardiovascular damage in an age group largely free of confounding adult comorbidities. This approach is crucial for identifying early biomarkers and intervention points to prevent the progression of hypertension into adult cardiovascular disease.</p>
<p>Article number five. GATA2 Mediates Macrophage Proliferation During Atherosclerosis. This research identified that G.A.T.A.2 mediates macrophage proliferation during atherosclerosis, clarifying a key mechanism behind lesion development. The study employed transcriptomic and histological analysis of human samples to investigate the signals and transcriptional events driving macrophage growth. It found that while monocytes are recruited to lesions, local macrophage proliferation is the primary driver of macrophage accumulation within the vascular intima. This discovery provides a significant therapeutic advance, pinpointing G.A.T.A.2 as a potential novel target for interventions aimed at halting or regressing atherosclerosis progression. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>M.I.N.O.C.A., multiomics, stratified treatment, target-organ injury, primary hypertension, myocardial infarction with non-obstructive coronary arteries, right ventricular ejection fraction, tricuspid transcatheter edge-to-edge repair, left ventricular mass index, transcriptional events, randomized trial, macrophage proliferation, cardiac magnetic resonance, tricuspid regurgitation, S.H.I.P. A.H.O.Y. cohort, atherosclerosis, automated external defibrillator, survival data, G.A.T.A.2, public-access defibrillation, lipid-laden macrophages, A.E.D. training, T-T.E.E.R., O.H.C.A., clinical outcomes, out-of-hospital cardiac arrest.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/">A.E.D. Training Boosts Cardiac Arrest Survival. 10/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like M.I.N.O.C.A. and multiomics. Key takeaway: A.E.D. Training Boosts Cardiac Arrest Survival..
Article Links:
Article 1: Stratified trea]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like M.I.N.O.C.A. and multiomics. Key takeaway: A.E.D. Training Boosts Cardiac Arrest Survival..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41150941">Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41147662">Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41147502">Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41147417">A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41147413">GATA2 Mediates Macrophage Proliferation During Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/">https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41150941" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41150941</a></p>
<p><strong>Summary:</strong> The P.R.O.M.I.S.E. trial is a multicenter randomized study designed to evaluate the optimal management strategy for myocardial infarction with non-obstructive coronary arteries, or M.I.N.O.C.A. This condition is associated with significant mortality, rehospitalization, and angina burden, yet no prior randomized clinical trials had assessed its treatment. The trial&#8217;s objective is to determine if a stratified treatment approach improves clinical outcomes for M.I.N.O.C.A. patients compared to standard care. This research establishes a crucial framework to guide future clinical practice for this high-risk patient population.</p>
<h4>Article 2: Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147662" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147662</a></p>
<p><strong>Summary:</strong> This study characterized changes in right ventricular ejection fraction, or R.V.E.F., following tricuspid transcatheter edge-to-edge repair, or T-T.E.E.R. Patients with significant tricuspid regurgitation underwent T-T.E.E.R. and cardiac magnetic resonance, or C.M.R., imaging, with follow-up C.M.R. performed within one to three months. The research aimed to clarify the impact of T-T.E.E.R. on right ventricular remodeling and its prognostic implications. By classifying patients based on postprocedural R.V. data, this work provides a clearer understanding of right ventricular adaptation after T-T.E.E.R., which is vital for assessing patient outcomes.</p>
<h4>Article 3: Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147502" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147502</a></p>
<p><strong>Summary:</strong> This 23-year database analysis of the Progetto Vita, or P.V., program in Piacenza demonstrates improved survival for out-of-hospital cardiac arrest, or O.H.C.A., using automated external defibrillator, or A.E.D.,-only training. The P.V. project pioneered the first community-based A.E.D. program in Europe, and this extensive analysis provides critical survival data. The study highlights that early defibrillation is crucial for managing fatal arrhythmias, and A.E.D. use effectively minimizes time to defibrillation. This finding underscores the significant public health benefit of simplified A.E.D.-only training in public-access defibrillation programs for enhancing O.H.C.A. survival.</p>
<h4>Article 4: A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147417" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147417</a></p>
<p><strong>Summary:</strong> This study utilized a multiomics approach within the S.H.I.P. A.H.O.Y. cohort to define early cardiovascular target-organ injury in youths with primary hypertension. It included 132 individuals, with a mean age of 15.8 years, who were stratified by blood pressure and left ventricular mass index, or L.V.M.I. The research provides a unique opportunity to explore early cardiovascular damage in an age group largely free of confounding adult comorbidities. This approach is crucial for identifying early biomarkers and intervention points to prevent the progression of hypertension into adult cardiovascular disease.</p>
<h4>Article 5: GATA2 Mediates Macrophage Proliferation During Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41147413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41147413</a></p>
<p><strong>Summary:</strong> This research identified that G.A.T.A.2 mediates macrophage proliferation during atherosclerosis, clarifying a key mechanism behind lesion development. The study employed transcriptomic and histological analysis of human samples to investigate the signals and transcriptional events driving macrophage growth. It found that while monocytes are recruited to lesions, local macrophage proliferation is the primary driver of macrophage accumulation within the vascular intima. This discovery provides a significant therapeutic advance, pinpointing G.A.T.A.2 as a potential novel target for interventions aimed at halting or regressing atherosclerosis progression.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial. The P.R.O.M.I.S.E. trial is a multicenter randomized study designed to evaluate the optimal management strategy for myocardial infarction with non-obstructive coronary arteries, or M.I.N.O.C.A. This condition is associated with significant mortality, rehospitalization, and angina burden, yet no prior randomized clinical trials had assessed its treatment. The trial&#8217;s objective is to determine if a stratified treatment approach improves clinical outcomes for M.I.N.O.C.A. patients compared to standard care. This research establishes a crucial framework to guide future clinical practice for this high-risk patient population.</p>
<p>Article number two. Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair. This study characterized changes in right ventricular ejection fraction, or R.V.E.F., following tricuspid transcatheter edge-to-edge repair, or T-T.E.E.R. Patients with significant tricuspid regurgitation underwent T-T.E.E.R. and cardiac magnetic resonance, or C.M.R., imaging, with follow-up C.M.R. performed within one to three months. The research aimed to clarify the impact of T-T.E.E.R. on right ventricular remodeling and its prognostic implications. By classifying patients based on postprocedural R.V. data, this work provides a clearer understanding of right ventricular adaptation after T-T.E.E.R., which is vital for assessing patient outcomes.</p>
<p>Article number three. Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita. This 23-year database analysis of the Progetto Vita, or P.V., program in Piacenza demonstrates improved survival for out-of-hospital cardiac arrest, or O.H.C.A., using automated external defibrillator, or A.E.D.,-only training. The P.V. project pioneered the first community-based A.E.D. program in Europe, and this extensive analysis provides critical survival data. The study highlights that early defibrillation is crucial for managing fatal arrhythmias, and A.E.D. use effectively minimizes time to defibrillation. This finding underscores the significant public health benefit of simplified A.E.D.-only training in public-access defibrillation programs for enhancing O.H.C.A. survival.</p>
<p>Article number four. A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort. This study utilized a multiomics approach within the S.H.I.P. A.H.O.Y. cohort to define early cardiovascular target-organ injury in youths with primary hypertension. It included 132 individuals, with a mean age of 15.8 years, who were stratified by blood pressure and left ventricular mass index, or L.V.M.I. The research provides a unique opportunity to explore early cardiovascular damage in an age group largely free of confounding adult comorbidities. This approach is crucial for identifying early biomarkers and intervention points to prevent the progression of hypertension into adult cardiovascular disease.</p>
<p>Article number five. GATA2 Mediates Macrophage Proliferation During Atherosclerosis. This research identified that G.A.T.A.2 mediates macrophage proliferation during atherosclerosis, clarifying a key mechanism behind lesion development. The study employed transcriptomic and histological analysis of human samples to investigate the signals and transcriptional events driving macrophage growth. It found that while monocytes are recruited to lesions, local macrophage proliferation is the primary driver of macrophage accumulation within the vascular intima. This discovery provides a significant therapeutic advance, pinpointing G.A.T.A.2 as a potential novel target for interventions aimed at halting or regressing atherosclerosis progression. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>M.I.N.O.C.A., multiomics, stratified treatment, target-organ injury, primary hypertension, myocardial infarction with non-obstructive coronary arteries, right ventricular ejection fraction, tricuspid transcatheter edge-to-edge repair, left ventricular mass index, transcriptional events, randomized trial, macrophage proliferation, cardiac magnetic resonance, tricuspid regurgitation, S.H.I.P. A.H.O.Y. cohort, atherosclerosis, automated external defibrillator, survival data, G.A.T.A.2, public-access defibrillation, lipid-laden macrophages, A.E.D. training, T-T.E.E.R., O.H.C.A., clinical outcomes, out-of-hospital cardiac arrest.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/">A.E.D. Training Boosts Cardiac Arrest Survival. 10/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251029_025801.mp3" length="4648376" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like M.I.N.O.C.A. and multiomics. Key takeaway: A.E.D. Training Boosts Cardiac Arrest Survival..
Article Links:
Article 1: Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial. (European heart journal)
Article 2: Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair. (ESC heart failure)
Article 3: Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita. (Journal of the American Heart Association)
Article 4: A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort. (Journal of the American Heart Association)
Article 5: GATA2 Mediates Macrophage Proliferation During Atherosclerosis. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/a-e-d-training-boosts-cardiac-arrest-survival-10-29-25/
 Featured Articles
Article 1: Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41150941
Summary: The P.R.O.M.I.S.E. trial is a multicenter randomized study designed to evaluate the optimal management strategy for myocardial infarction with non-obstructive coronary arteries, or M.I.N.O.C.A. This condition is associated with significant mortality, rehospitalization, and angina burden, yet no prior randomized clinical trials had assessed its treatment. The trial&#8217;s objective is to determine if a stratified treatment approach improves clinical outcomes for M.I.N.O.C.A. patients compared to standard care. This research establishes a crucial framework to guide future clinical practice for this high-risk patient population.
Article 2: Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41147662
Summary: This study characterized changes in right ventricular ejection fraction, or R.V.E.F., following tricuspid transcatheter edge-to-edge repair, or T-T.E.E.R. Patients with significant tricuspid regurgitation underwent T-T.E.E.R. and cardiac magnetic resonance, or C.M.R., imaging, with follow-up C.M.R. performed within one to three months. The research aimed to clarify the impact of T-T.E.E.R. on right ventricular remodeling and its prognostic implications. By classifying patients based on postprocedural R.V. data, this work provides a clearer understanding of right ventricular adaptation after T-T.E.E.R., which is vital for assessing patient outcomes.
Article 3: Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41147502
Summary: This 23-year database analysis of the Progetto Vita, or P.V., program in Piacenza demonstrates improved survival for out-of-hospital cardiac arrest, or O.H.C.A., using automated external defibrillator, or A.E.D.,-only training. The P.V. project pioneered the first community-based A.E.D. program in Europe, and this extensive analysis provides critical survival data. The study highlights that early defibrillation is crucial for managing fatal arrhythmias, and A.E.D. use effectively minimizes time to defibrillation. This finding underscores the significant public health benefit of simplified A.E.D.-only training in public-access defibrillation programs for enhancing O.H.C.A. survival.
Article 4: A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.
Journal: Journal of the American Heart Association
PubMed Link: http]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 29, 2025. This episode summarizes 5 key cardiology studies on topics like M.I.N.O.C.A. and multiomics. Key takeaway: A.E.D. Training Boosts Cardiac Arrest Survival..
Article Links:
Article 1: Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial. (European heart journal)
Article 2: Adaptation of right ventricular function following tricuspid transcatheter edge-to-edge repair. (ESC heart failure)
Article 3: Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita. (Journal of the American Heart Association)
Article 4: A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort. (Journal of the American Heart Association)
Article 5: GATA2 Mediates Macrophage Proliferation During Atherosclerosis. (Journal of the American Heart Association)
Fu]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Nup35 Controls Heart Remodeling 10/28/25</title>
	<link>https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/</link>
	<pubDate>Tue, 28 Oct 2025 10:01:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac fibrosis and neurodevelopmental outcomes. Key takeaway: Nup35 Controls Heart Remodeling.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40671650">Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40511609">Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41144984">The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41145234">Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41144636">New insights into foam cells in atherosclerosis.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/">https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40671650" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40671650</a></p>
<p><strong>Summary:</strong> This study from the Pediatric Heart Network&#8217;s S.V.R. I.I.I. trial evaluated neurodevelopmental and functional outcomes in early adolescence for survivors of hypoplastic left heart syndrome. It enrolled adolescents who were randomized to different surgical shunt types during the Norwood procedure as neonates, conducting multifaceted in-person assessments. The research provides critical long-term follow-up data on the impact of initial surgical approaches on these significant morbidities. This comprehensive evaluation is crucial for informing care strategies and improving long-term quality of life for this vulnerable patient population.</p>
<h4>Article 2: Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40511609" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40511609</a></p>
<p><strong>Summary:</strong> The multinational P.R.I.N.C.E. randomized clinical trial investigated the effect of remote ischemic preconditioning on myocardial injury during noncardiac surgery. Adult high-risk patients were randomly assigned to receive either remote ischemic preconditioning, involving three five-minute cycles of upper limb ischemia, or sham treatment after anesthesia induction. This robust, double-blind study aimed to definitively determine if remote ischemic preconditioning decreases postoperative myocardial injury and other complications. The trial establishes crucial evidence regarding the utility of remote ischemic preconditioning in improving outcomes for patients undergoing major noncardiac surgical procedures.</p>
<h4>Article 3: The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41144984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41144984</a></p>
<p><strong>Summary:</strong> This n-of-one invasive placebo-controlled study explored the relationship between myocardial ischemia, collateral circulation, and angina symptoms in stable coronary artery disease. Fifty-one participants with severe single-vessel coronary artery disease and angina were recruited for this investigation. The research aimed to clarify why the burden of ischemia often shows little correlation with angina severity and to explore the association between progressive collateral recruitment and ischemic preconditioning. This study provides a detailed understanding of the collateral circulation&#8217;s role in modulating symptoms and offering ischemic protection in stable angina patients.</p>
<h4>Article 4: Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41145234" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41145234</a></p>
<p><strong>Summary:</strong> This research identified Cardiomyocyte Nucleoporin 35 as a key regulator of pathological cardiac remodeling. The study demonstrated that cardiac Nucleoporin 35 expression is significantly down-regulated during Angiotensin I.I.- and transverse aortic constriction-induced remodeling in mice. Cardiac-specific Nucleoporin 35 knockout mice displayed severe cardiac fibrosis, hypertrophy, and cardiac dysfunction, while its overexpression mitigated these pathologies by modulating Wif1. This discovery reveals a crucial mechanistic pathway underlying cardiac remodeling and presents a promising therapeutic target for heart disease.</p>
<h4>Article 5: New insights into foam cells in atherosclerosis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41144636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41144636</a></p>
<p><strong>Summary:</strong> This comprehensive review advanced understanding of cholesterol-containing foam cells, which drive atherosclerosis and related cardiovascular events. It detailed how excessive foam cell accumulation leads to apoptosis, necrosis, necrotic core formation, and plaque destabilization. The review highlighted the persistent challenges in developing effective targeted therapies despite the therapeutic potential of targeting foam cells for atherosclerosis treatment. This synthesis of knowledge is vital for informing future research directions and developing novel strategies to prevent and treat atherosclerotic disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial. This study from the Pediatric Heart Network&#8217;s S.V.R. I.I.I. trial evaluated neurodevelopmental and functional outcomes in early adolescence for survivors of hypoplastic left heart syndrome. It enrolled adolescents who were randomized to different surgical shunt types during the Norwood procedure as neonates, conducting multifaceted in-person assessments. The research provides critical long-term follow-up data on the impact of initial surgical approaches on these significant morbidities. This comprehensive evaluation is crucial for informing care strategies and improving long-term quality of life for this vulnerable patient population.</p>
<p>Article number two. Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial. The multinational P.R.I.N.C.E. randomized clinical trial investigated the effect of remote ischemic preconditioning on myocardial injury during noncardiac surgery. Adult high-risk patients were randomly assigned to receive either remote ischemic preconditioning, involving three five-minute cycles of upper limb ischemia, or sham treatment after anesthesia induction. This robust, double-blind study aimed to definitively determine if remote ischemic preconditioning decreases postoperative myocardial injury and other complications. The trial establishes crucial evidence regarding the utility of remote ischemic preconditioning in improving outcomes for patients undergoing major noncardiac surgical procedures.</p>
<p>Article number three. The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. This n-of-one invasive placebo-controlled study explored the relationship between myocardial ischemia, collateral circulation, and angina symptoms in stable coronary artery disease. Fifty-one participants with severe single-vessel coronary artery disease and angina were recruited for this investigation. The research aimed to clarify why the burden of ischemia often shows little correlation with angina severity and to explore the association between progressive collateral recruitment and ischemic preconditioning. This study provides a detailed understanding of the collateral circulation&#8217;s role in modulating symptoms and offering ischemic protection in stable angina patients.</p>
<p>Article number four. Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1. This research identified Cardiomyocyte Nucleoporin 35 as a key regulator of pathological cardiac remodeling. The study demonstrated that cardiac Nucleoporin 35 expression is significantly down-regulated during Angiotensin I.I.- and transverse aortic constriction-induced remodeling in mice. Cardiac-specific Nucleoporin 35 knockout mice displayed severe cardiac fibrosis, hypertrophy, and cardiac dysfunction, while its overexpression mitigated these pathologies by modulating Wif1. This discovery reveals a crucial mechanistic pathway underlying cardiac remodeling and presents a promising therapeutic target for heart disease.</p>
<p>Article number five. New insights into foam cells in atherosclerosis. This comprehensive review advanced understanding of cholesterol-containing foam cells, which drive atherosclerosis and related cardiovascular events. It detailed how excessive foam cell accumulation leads to apoptosis, necrosis, necrotic core formation, and plaque destabilization. The review highlighted the persistent challenges in developing effective targeted therapies despite the therapeutic potential of targeting foam cells for atherosclerosis treatment. This synthesis of knowledge is vital for informing future research directions and developing novel strategies to prevent and treat atherosclerotic disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac fibrosis, neurodevelopmental outcomes, S.V.R. I.I.I. trial, foam cells, Norwood procedure, noncardiac surgery, single ventricle, plaque destabilization, cholesterol, coronary artery disease, cardiomyocyte, ischemic preconditioning, collateral circulation, myocardial injury, hypoplastic left heart syndrome, myocardial ischemia, atherosclerosis, remote ischemic preconditioning, cardiovascular events, P.R.I.N.C.E. trial, Wif1, stable angina, randomized clinical trial, cardiac remodeling, Nucleoporin 35.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/">Nup35 Controls Heart Remodeling 10/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac fibrosis and neurodevelopmental outcomes. Key takeaway: Nup35 Controls Heart Remodeling.
Article Links:
Article 1: Neurodevel]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac fibrosis and neurodevelopmental outcomes. Key takeaway: Nup35 Controls Heart Remodeling.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40671650">Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40511609">Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41144984">The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41145234">Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41144636">New insights into foam cells in atherosclerosis.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/">https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40671650" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40671650</a></p>
<p><strong>Summary:</strong> This study from the Pediatric Heart Network&#8217;s S.V.R. I.I.I. trial evaluated neurodevelopmental and functional outcomes in early adolescence for survivors of hypoplastic left heart syndrome. It enrolled adolescents who were randomized to different surgical shunt types during the Norwood procedure as neonates, conducting multifaceted in-person assessments. The research provides critical long-term follow-up data on the impact of initial surgical approaches on these significant morbidities. This comprehensive evaluation is crucial for informing care strategies and improving long-term quality of life for this vulnerable patient population.</p>
<h4>Article 2: Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40511609" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40511609</a></p>
<p><strong>Summary:</strong> The multinational P.R.I.N.C.E. randomized clinical trial investigated the effect of remote ischemic preconditioning on myocardial injury during noncardiac surgery. Adult high-risk patients were randomly assigned to receive either remote ischemic preconditioning, involving three five-minute cycles of upper limb ischemia, or sham treatment after anesthesia induction. This robust, double-blind study aimed to definitively determine if remote ischemic preconditioning decreases postoperative myocardial injury and other complications. The trial establishes crucial evidence regarding the utility of remote ischemic preconditioning in improving outcomes for patients undergoing major noncardiac surgical procedures.</p>
<h4>Article 3: The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41144984" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41144984</a></p>
<p><strong>Summary:</strong> This n-of-one invasive placebo-controlled study explored the relationship between myocardial ischemia, collateral circulation, and angina symptoms in stable coronary artery disease. Fifty-one participants with severe single-vessel coronary artery disease and angina were recruited for this investigation. The research aimed to clarify why the burden of ischemia often shows little correlation with angina severity and to explore the association between progressive collateral recruitment and ischemic preconditioning. This study provides a detailed understanding of the collateral circulation&#8217;s role in modulating symptoms and offering ischemic protection in stable angina patients.</p>
<h4>Article 4: Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41145234" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41145234</a></p>
<p><strong>Summary:</strong> This research identified Cardiomyocyte Nucleoporin 35 as a key regulator of pathological cardiac remodeling. The study demonstrated that cardiac Nucleoporin 35 expression is significantly down-regulated during Angiotensin I.I.- and transverse aortic constriction-induced remodeling in mice. Cardiac-specific Nucleoporin 35 knockout mice displayed severe cardiac fibrosis, hypertrophy, and cardiac dysfunction, while its overexpression mitigated these pathologies by modulating Wif1. This discovery reveals a crucial mechanistic pathway underlying cardiac remodeling and presents a promising therapeutic target for heart disease.</p>
<h4>Article 5: New insights into foam cells in atherosclerosis.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41144636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41144636</a></p>
<p><strong>Summary:</strong> This comprehensive review advanced understanding of cholesterol-containing foam cells, which drive atherosclerosis and related cardiovascular events. It detailed how excessive foam cell accumulation leads to apoptosis, necrosis, necrotic core formation, and plaque destabilization. The review highlighted the persistent challenges in developing effective targeted therapies despite the therapeutic potential of targeting foam cells for atherosclerosis treatment. This synthesis of knowledge is vital for informing future research directions and developing novel strategies to prevent and treat atherosclerotic disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial. This study from the Pediatric Heart Network&#8217;s S.V.R. I.I.I. trial evaluated neurodevelopmental and functional outcomes in early adolescence for survivors of hypoplastic left heart syndrome. It enrolled adolescents who were randomized to different surgical shunt types during the Norwood procedure as neonates, conducting multifaceted in-person assessments. The research provides critical long-term follow-up data on the impact of initial surgical approaches on these significant morbidities. This comprehensive evaluation is crucial for informing care strategies and improving long-term quality of life for this vulnerable patient population.</p>
<p>Article number two. Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial. The multinational P.R.I.N.C.E. randomized clinical trial investigated the effect of remote ischemic preconditioning on myocardial injury during noncardiac surgery. Adult high-risk patients were randomly assigned to receive either remote ischemic preconditioning, involving three five-minute cycles of upper limb ischemia, or sham treatment after anesthesia induction. This robust, double-blind study aimed to definitively determine if remote ischemic preconditioning decreases postoperative myocardial injury and other complications. The trial establishes crucial evidence regarding the utility of remote ischemic preconditioning in improving outcomes for patients undergoing major noncardiac surgical procedures.</p>
<p>Article number three. The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. This n-of-one invasive placebo-controlled study explored the relationship between myocardial ischemia, collateral circulation, and angina symptoms in stable coronary artery disease. Fifty-one participants with severe single-vessel coronary artery disease and angina were recruited for this investigation. The research aimed to clarify why the burden of ischemia often shows little correlation with angina severity and to explore the association between progressive collateral recruitment and ischemic preconditioning. This study provides a detailed understanding of the collateral circulation&#8217;s role in modulating symptoms and offering ischemic protection in stable angina patients.</p>
<p>Article number four. Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1. This research identified Cardiomyocyte Nucleoporin 35 as a key regulator of pathological cardiac remodeling. The study demonstrated that cardiac Nucleoporin 35 expression is significantly down-regulated during Angiotensin I.I.- and transverse aortic constriction-induced remodeling in mice. Cardiac-specific Nucleoporin 35 knockout mice displayed severe cardiac fibrosis, hypertrophy, and cardiac dysfunction, while its overexpression mitigated these pathologies by modulating Wif1. This discovery reveals a crucial mechanistic pathway underlying cardiac remodeling and presents a promising therapeutic target for heart disease.</p>
<p>Article number five. New insights into foam cells in atherosclerosis. This comprehensive review advanced understanding of cholesterol-containing foam cells, which drive atherosclerosis and related cardiovascular events. It detailed how excessive foam cell accumulation leads to apoptosis, necrosis, necrotic core formation, and plaque destabilization. The review highlighted the persistent challenges in developing effective targeted therapies despite the therapeutic potential of targeting foam cells for atherosclerosis treatment. This synthesis of knowledge is vital for informing future research directions and developing novel strategies to prevent and treat atherosclerotic disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiac fibrosis, neurodevelopmental outcomes, S.V.R. I.I.I. trial, foam cells, Norwood procedure, noncardiac surgery, single ventricle, plaque destabilization, cholesterol, coronary artery disease, cardiomyocyte, ischemic preconditioning, collateral circulation, myocardial injury, hypoplastic left heart syndrome, myocardial ischemia, atherosclerosis, remote ischemic preconditioning, cardiovascular events, P.R.I.N.C.E. trial, Wif1, stable angina, randomized clinical trial, cardiac remodeling, Nucleoporin 35.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/">Nup35 Controls Heart Remodeling 10/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251028_060041.mp3" length="4445665" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac fibrosis and neurodevelopmental outcomes. Key takeaway: Nup35 Controls Heart Remodeling.
Article Links:
Article 1: Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial. (Circulation)
Article 2: Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial. (Circulation)
Article 3: The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. (Circulation)
Article 4: Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1. (Cardiovascular research)
Article 5: New insights into foam cells in atherosclerosis. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/
 Featured Articles
Article 1: Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40671650
Summary: This study from the Pediatric Heart Network&#8217;s S.V.R. I.I.I. trial evaluated neurodevelopmental and functional outcomes in early adolescence for survivors of hypoplastic left heart syndrome. It enrolled adolescents who were randomized to different surgical shunt types during the Norwood procedure as neonates, conducting multifaceted in-person assessments. The research provides critical long-term follow-up data on the impact of initial surgical approaches on these significant morbidities. This comprehensive evaluation is crucial for informing care strategies and improving long-term quality of life for this vulnerable patient population.
Article 2: Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40511609
Summary: The multinational P.R.I.N.C.E. randomized clinical trial investigated the effect of remote ischemic preconditioning on myocardial injury during noncardiac surgery. Adult high-risk patients were randomly assigned to receive either remote ischemic preconditioning, involving three five-minute cycles of upper limb ischemia, or sham treatment after anesthesia induction. This robust, double-blind study aimed to definitively determine if remote ischemic preconditioning decreases postoperative myocardial injury and other complications. The trial establishes crucial evidence regarding the utility of remote ischemic preconditioning in improving outcomes for patients undergoing major noncardiac surgical procedures.
Article 3: The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41144984
Summary: This n-of-one invasive placebo-controlled study explored the relationship between myocardial ischemia, collateral circulation, and angina symptoms in stable coronary artery disease. Fifty-one participants with severe single-vessel coronary artery disease and angina were recruited for this investigation. The research aimed to clarify why the burden of ischemia often shows little correlation with angina severity and to explore the association between progressive collateral recruitment and ischemic preconditioning. This study provides a detailed understanding of the collateral circulation&#8217;s role in modulating symptoms and offering ischemic protection in stable angina patients.
Article 4: Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41145234
Summary: This research identified Cardiomyocyte Nucleoporin 35 as a key regulator of pathological cardiac remodeling. The study demonstrated that cardiac ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac fibrosis and neurodevelopmental outcomes. Key takeaway: Nup35 Controls Heart Remodeling.
Article Links:
Article 1: Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network&#8217;s Single Ventricle Reconstruction Trial. (Circulation)
Article 2: Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial. (Circulation)
Article 3: The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. (Circulation)
Article 4: Cardiomyocyte Nucleoporin 35 regulates pathological cardiac remodeling through Wif1. (Cardiovascular research)
Article 5: New insights into foam cells in atherosclerosis. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/nup35-controls-heart-remodeling-10-28-25/
 Featured Articles
Article 1: Neurode]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>PREVENT Equations Refine Blood Pressure Control. 10/28/25</title>
	<link>https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/</link>
	<pubDate>Tue, 28 Oct 2025 06:58:21 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like PARTNER 3 trial and ESPRIT trial. Key takeaway: PREVENT Equations Refine Blood Pressure Control..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41144631">Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41125318">Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40864014">Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40836922">Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40799133">Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/">https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41144631" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41144631</a></p>
<p><strong>Summary:</strong> This study from the PARTNER 3 trial aimed to provide longer-term clinical outcomes and valve durability assessments up to 7 years for low-risk patients with severe, symptomatic aortic stenosis. Patients were randomly assigned in a 1:1 ratio to undergo either transfemoral transcatheter aortic-valve replacement (T.A.V.R.) or surgical aortic-valve replacement. Prior 5-year data from this trial demonstrated similar outcomes between the two procedures. The research underscores the importance of continued long-term evaluation for valve durability and clinical effectiveness in these patients.</p>
<h4>Article 2: Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41125318" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41125318</a></p>
<p><strong>Summary:</strong> This secondary analysis of the SPRINT trial aimed to quantify the relative and absolute benefits and harms of intensive versus standard systolic blood pressure (S.B.P.) treatment using the new Predicting Risk of Cardiovascular Disease Events (PREVENT) equations. The PREVENT equations provide enhanced risk stratification by integrating estimated glomerular filtration rate, omitting race, and encompassing total cardiovascular disease events including heart failure. This research established a method for more precisely comparing intensive versus standard S.B.P. control by varying cardiovascular risk levels. The study demonstrates the utility of the PREVENT equations in refining primary prevention strategies for cardiovascular disease.</p>
<h4>Article 3: Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864014" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864014</a></p>
<p><strong>Summary:</strong> This prespecified secondary analysis of the ESPRIT trial evaluated the effects of intensive blood pressure control on stroke outcomes. Hypertensive patients with elevated cardiovascular risk were randomized to either intensive treatment, targeting systolic blood pressure (S.B.P.) below 120 millimeters of mercury, or standard treatment, aiming for S.B.P. below 140 millimeters of mercury. The study investigated the comparative impact of these two blood pressure management strategies on preventing stroke. This research highlights the critical role of S.B.P. reduction in stroke prevention, providing a focused comparison of intensive versus standard therapeutic approaches.</p>
<h4>Article 4: Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40836922" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40836922</a></p>
<p><strong>Summary:</strong> This observational cohort study utilized nationwide data from the NIDUS Registry to describe the clinical practice of surgical treatment for left-sided infective endocarditis (I.E.). The research specifically aimed to detail the utilization of surgery based on established indications and to assess associated mortality rates in this patient population. By examining a broad national cohort, this study overcomes limitations of prior research from selected tertiary centers, providing a more representative picture of real-world surgical approaches. This comprehensive analysis establishes a valuable benchmark for understanding current surgical interventions and outcomes in left-sided I.E.</p>
<h4>Article 5: Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40799133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40799133</a></p>
<p><strong>Summary:</strong> This observational study employed propensity analysis to compare long-term outcomes of early surgical intervention versus conventional treatment for asymptomatic patients with severe mitral regurgitation. Researchers enrolled 1063 consecutive asymptomatic patients exhibiting severe degenerative mitral regurgitation and preserved left ventricular (L.V.) function, with prospective follow-up from 1996 to 2016. The study provides crucial data to address the clinical controversy surrounding the optimal timing of surgery in this specific patient group. This comprehensive analysis helps to establish the long-term impact of different management strategies for asymptomatic severe mitral regurgitation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years. This study from the PARTNER 3 trial aimed to provide longer-term clinical outcomes and valve durability assessments up to 7 years for low-risk patients with severe, symptomatic aortic stenosis. Patients were randomly assigned in a 1:1 ratio to undergo either transfemoral transcatheter aortic-valve replacement (T.A.V.R.) or surgical aortic-valve replacement. Prior 5-year data from this trial demonstrated similar outcomes between the two procedures. The research underscores the importance of continued long-term evaluation for valve durability and clinical effectiveness in these patients.</p>
<p>Article number two. Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. This secondary analysis of the SPRINT trial aimed to quantify the relative and absolute benefits and harms of intensive versus standard systolic blood pressure (S.B.P.) treatment using the new Predicting Risk of Cardiovascular Disease Events (PREVENT) equations. The PREVENT equations provide enhanced risk stratification by integrating estimated glomerular filtration rate, omitting race, and encompassing total cardiovascular disease events including heart failure. This research established a method for more precisely comparing intensive versus standard S.B.P. control by varying cardiovascular risk levels. The study demonstrates the utility of the PREVENT equations in refining primary prevention strategies for cardiovascular disease.</p>
<p>Article number three. Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial. This prespecified secondary analysis of the ESPRIT trial evaluated the effects of intensive blood pressure control on stroke outcomes. Hypertensive patients with elevated cardiovascular risk were randomized to either intensive treatment, targeting systolic blood pressure (S.B.P.) below 120 millimeters of mercury, or standard treatment, aiming for S.B.P. below 140 millimeters of mercury. The study investigated the comparative impact of these two blood pressure management strategies on preventing stroke. This research highlights the critical role of S.B.P. reduction in stroke prevention, providing a focused comparison of intensive versus standard therapeutic approaches.</p>
<p>Article number four. Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry. This observational cohort study utilized nationwide data from the NIDUS Registry to describe the clinical practice of surgical treatment for left-sided infective endocarditis (I.E.). The research specifically aimed to detail the utilization of surgery based on established indications and to assess associated mortality rates in this patient population. By examining a broad national cohort, this study overcomes limitations of prior research from selected tertiary centers, providing a more representative picture of real-world surgical approaches. This comprehensive analysis establishes a valuable benchmark for understanding current surgical interventions and outcomes in left-sided I.E.</p>
<p>Article number five. Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis. This observational study employed propensity analysis to compare long-term outcomes of early surgical intervention versus conventional treatment for asymptomatic patients with severe mitral regurgitation. Researchers enrolled 1063 consecutive asymptomatic patients exhibiting severe degenerative mitral regurgitation and preserved left ventricular (L.V.) function, with prospective follow-up from 1996 to 2016. The study provides crucial data to address the clinical controversy surrounding the optimal timing of surgery in this specific patient group. This comprehensive analysis helps to establish the long-term impact of different management strategies for asymptomatic severe mitral regurgitation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>PARTNER 3 trial, ESPRIT trial, conventional treatment, stroke prevention, mitral regurgitation, valve durability, early surgery, aortic stenosis, hypertension, systolic blood pressure, intensive blood pressure control, SPRINT trial, surgical aortic-valve replacement, cardiovascular disease primary prevention, mortality, left-sided endocarditis, infective endocarditis, surgical treatment, NIDUS Registry, PREVENT equations, asymptomatic mitral regurgitation, transcatheter aortic-valve replacement, left ventricular function.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/">PREVENT Equations Refine Blood Pressure Control. 10/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like PARTNER 3 trial and ESPRIT trial. Key takeaway: PREVENT Equations Refine Blood Pressure Control..
Article Links:
Article 1: Transcath]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like PARTNER 3 trial and ESPRIT trial. Key takeaway: PREVENT Equations Refine Blood Pressure Control..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41144631">Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41125318">Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40864014">Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40836922">Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40799133">Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/">https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41144631" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41144631</a></p>
<p><strong>Summary:</strong> This study from the PARTNER 3 trial aimed to provide longer-term clinical outcomes and valve durability assessments up to 7 years for low-risk patients with severe, symptomatic aortic stenosis. Patients were randomly assigned in a 1:1 ratio to undergo either transfemoral transcatheter aortic-valve replacement (T.A.V.R.) or surgical aortic-valve replacement. Prior 5-year data from this trial demonstrated similar outcomes between the two procedures. The research underscores the importance of continued long-term evaluation for valve durability and clinical effectiveness in these patients.</p>
<h4>Article 2: Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41125318" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41125318</a></p>
<p><strong>Summary:</strong> This secondary analysis of the SPRINT trial aimed to quantify the relative and absolute benefits and harms of intensive versus standard systolic blood pressure (S.B.P.) treatment using the new Predicting Risk of Cardiovascular Disease Events (PREVENT) equations. The PREVENT equations provide enhanced risk stratification by integrating estimated glomerular filtration rate, omitting race, and encompassing total cardiovascular disease events including heart failure. This research established a method for more precisely comparing intensive versus standard S.B.P. control by varying cardiovascular risk levels. The study demonstrates the utility of the PREVENT equations in refining primary prevention strategies for cardiovascular disease.</p>
<h4>Article 3: Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864014" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864014</a></p>
<p><strong>Summary:</strong> This prespecified secondary analysis of the ESPRIT trial evaluated the effects of intensive blood pressure control on stroke outcomes. Hypertensive patients with elevated cardiovascular risk were randomized to either intensive treatment, targeting systolic blood pressure (S.B.P.) below 120 millimeters of mercury, or standard treatment, aiming for S.B.P. below 140 millimeters of mercury. The study investigated the comparative impact of these two blood pressure management strategies on preventing stroke. This research highlights the critical role of S.B.P. reduction in stroke prevention, providing a focused comparison of intensive versus standard therapeutic approaches.</p>
<h4>Article 4: Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40836922" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40836922</a></p>
<p><strong>Summary:</strong> This observational cohort study utilized nationwide data from the NIDUS Registry to describe the clinical practice of surgical treatment for left-sided infective endocarditis (I.E.). The research specifically aimed to detail the utilization of surgery based on established indications and to assess associated mortality rates in this patient population. By examining a broad national cohort, this study overcomes limitations of prior research from selected tertiary centers, providing a more representative picture of real-world surgical approaches. This comprehensive analysis establishes a valuable benchmark for understanding current surgical interventions and outcomes in left-sided I.E.</p>
<h4>Article 5: Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40799133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40799133</a></p>
<p><strong>Summary:</strong> This observational study employed propensity analysis to compare long-term outcomes of early surgical intervention versus conventional treatment for asymptomatic patients with severe mitral regurgitation. Researchers enrolled 1063 consecutive asymptomatic patients exhibiting severe degenerative mitral regurgitation and preserved left ventricular (L.V.) function, with prospective follow-up from 1996 to 2016. The study provides crucial data to address the clinical controversy surrounding the optimal timing of surgery in this specific patient group. This comprehensive analysis helps to establish the long-term impact of different management strategies for asymptomatic severe mitral regurgitation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years. This study from the PARTNER 3 trial aimed to provide longer-term clinical outcomes and valve durability assessments up to 7 years for low-risk patients with severe, symptomatic aortic stenosis. Patients were randomly assigned in a 1:1 ratio to undergo either transfemoral transcatheter aortic-valve replacement (T.A.V.R.) or surgical aortic-valve replacement. Prior 5-year data from this trial demonstrated similar outcomes between the two procedures. The research underscores the importance of continued long-term evaluation for valve durability and clinical effectiveness in these patients.</p>
<p>Article number two. Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. This secondary analysis of the SPRINT trial aimed to quantify the relative and absolute benefits and harms of intensive versus standard systolic blood pressure (S.B.P.) treatment using the new Predicting Risk of Cardiovascular Disease Events (PREVENT) equations. The PREVENT equations provide enhanced risk stratification by integrating estimated glomerular filtration rate, omitting race, and encompassing total cardiovascular disease events including heart failure. This research established a method for more precisely comparing intensive versus standard S.B.P. control by varying cardiovascular risk levels. The study demonstrates the utility of the PREVENT equations in refining primary prevention strategies for cardiovascular disease.</p>
<p>Article number three. Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial. This prespecified secondary analysis of the ESPRIT trial evaluated the effects of intensive blood pressure control on stroke outcomes. Hypertensive patients with elevated cardiovascular risk were randomized to either intensive treatment, targeting systolic blood pressure (S.B.P.) below 120 millimeters of mercury, or standard treatment, aiming for S.B.P. below 140 millimeters of mercury. The study investigated the comparative impact of these two blood pressure management strategies on preventing stroke. This research highlights the critical role of S.B.P. reduction in stroke prevention, providing a focused comparison of intensive versus standard therapeutic approaches.</p>
<p>Article number four. Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry. This observational cohort study utilized nationwide data from the NIDUS Registry to describe the clinical practice of surgical treatment for left-sided infective endocarditis (I.E.). The research specifically aimed to detail the utilization of surgery based on established indications and to assess associated mortality rates in this patient population. By examining a broad national cohort, this study overcomes limitations of prior research from selected tertiary centers, providing a more representative picture of real-world surgical approaches. This comprehensive analysis establishes a valuable benchmark for understanding current surgical interventions and outcomes in left-sided I.E.</p>
<p>Article number five. Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis. This observational study employed propensity analysis to compare long-term outcomes of early surgical intervention versus conventional treatment for asymptomatic patients with severe mitral regurgitation. Researchers enrolled 1063 consecutive asymptomatic patients exhibiting severe degenerative mitral regurgitation and preserved left ventricular (L.V.) function, with prospective follow-up from 1996 to 2016. The study provides crucial data to address the clinical controversy surrounding the optimal timing of surgery in this specific patient group. This comprehensive analysis helps to establish the long-term impact of different management strategies for asymptomatic severe mitral regurgitation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>PARTNER 3 trial, ESPRIT trial, conventional treatment, stroke prevention, mitral regurgitation, valve durability, early surgery, aortic stenosis, hypertension, systolic blood pressure, intensive blood pressure control, SPRINT trial, surgical aortic-valve replacement, cardiovascular disease primary prevention, mortality, left-sided endocarditis, infective endocarditis, surgical treatment, NIDUS Registry, PREVENT equations, asymptomatic mitral regurgitation, transcatheter aortic-valve replacement, left ventricular function.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/">PREVENT Equations Refine Blood Pressure Control. 10/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251028_025706.mp3" length="4619536" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like PARTNER 3 trial and ESPRIT trial. Key takeaway: PREVENT Equations Refine Blood Pressure Control..
Article Links:
Article 1: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years. (The New England journal of medicine)
Article 2: Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. (Journal of the American College of Cardiology)
Article 3: Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial. (Journal of the American College of Cardiology)
Article 4: Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry. (Circulation)
Article 5: Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/prevent-equations-refine-blood-pressure-control-10-28-25/
 Featured Articles
Article 1: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41144631
Summary: This study from the PARTNER 3 trial aimed to provide longer-term clinical outcomes and valve durability assessments up to 7 years for low-risk patients with severe, symptomatic aortic stenosis. Patients were randomly assigned in a 1:1 ratio to undergo either transfemoral transcatheter aortic-valve replacement (T.A.V.R.) or surgical aortic-valve replacement. Prior 5-year data from this trial demonstrated similar outcomes between the two procedures. The research underscores the importance of continued long-term evaluation for valve durability and clinical effectiveness in these patients.
Article 2: Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41125318
Summary: This secondary analysis of the SPRINT trial aimed to quantify the relative and absolute benefits and harms of intensive versus standard systolic blood pressure (S.B.P.) treatment using the new Predicting Risk of Cardiovascular Disease Events (PREVENT) equations. The PREVENT equations provide enhanced risk stratification by integrating estimated glomerular filtration rate, omitting race, and encompassing total cardiovascular disease events including heart failure. This research established a method for more precisely comparing intensive versus standard S.B.P. control by varying cardiovascular risk levels. The study demonstrates the utility of the PREVENT equations in refining primary prevention strategies for cardiovascular disease.
Article 3: Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40864014
Summary: This prespecified secondary analysis of the ESPRIT trial evaluated the effects of intensive blood pressure control on stroke outcomes. Hypertensive patients with elevated cardiovascular risk were randomized to either intensive treatment, targeting systolic blood pressure (S.B.P.) below 120 millimeters of mercury, or standard treatment, aiming for S.B.P. below 140 millimeters of mercury. The study investigated the comparative impact of these two blood pressure management strategies on preventing stroke. This research highlights the critical role of S.B.P. reduction in stroke prevention, providing a focused comparison of intensive versus standard therapeutic approaches.
Article 4: Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry.
Jour]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 28, 2025. This episode summarizes 5 key cardiology studies on topics like PARTNER 3 trial and ESPRIT trial. Key takeaway: PREVENT Equations Refine Blood Pressure Control..
Article Links:
Article 1: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years. (The New England journal of medicine)
Article 2: Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. (Journal of the American College of Cardiology)
Article 3: Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial. (Journal of the American College of Cardiology)
Article 4: Clinical Practice of Surgical Treatment for Left-Sided Infective Endocarditis: Nationwide Data from the NIDUS Registry. (Circulation)
Article 5: Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Targeting P2Y14R Prevents Venous Thrombosis 10/27/25</title>
	<link>https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/</link>
	<pubDate>Mon, 27 Oct 2025 21:21:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular outcomes and N.R.4.A.2. Key takeaway: Targeting P2Y14R Prevents Venous Thrombosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41139402">Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41143464">Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41140167">Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41140152">Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41139325">Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids.</a> (JACC. Basic to translational science)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/">https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41139402" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41139402</a></p>
<p><strong>Summary:</strong> The A.N.D.E.S. Randomized Clinical Trial prospectively compared antithrombotic strategies after transcatheter left atrial appendage closure for patients with non-valvular atrial fibrillation. This multicenter international study randomized patients to either anticoagulation or dual antiplatelet therapy to determine the optimal approach for preventing device-related thrombosis. The trial&#8217;s objective was to establish which treatment strategy more effectively mitigates device-related thrombosis post-procedure. This research provides crucial evidence to guide clinical practice, potentially improving patient safety and outcomes following left atrial appendage closure.</p>
<h4>Article 2: Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41143464" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41143464</a></p>
<p><strong>Summary:</strong> This study investigated the role of the P2Y14 receptor, highly expressed on neutrophils, in venous thromboembolism. Researchers discovered that the P2Y14 receptor mediates neutrophil extracellular trap formation, which exacerbates thrombo-inflammatory responses and venous thromboembolism. Critically, targeting the P2Y14 receptor successfully alleviated platelet-induced neutrophil extracellular trap formation and venous thrombosis by modulating the P.K.A. / A.K.A.P.13 / R.h.o.A. axis. These findings establish the P2Y14 receptor as a promising therapeutic target for developing new strategies to combat venous thromboembolism.</p>
<h4>Article 3: Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41140167" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41140167</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms driving aldosterone-producing cell cluster formation, which are frequently observed in primary aldosteronism. Researchers utilized an integrated analysis of spatial transcriptomics and single-cell ribonucleic acid sequencing on aldosterone-producing cell clusters, aldosterone-producing adenomas, and zona glomerulosa cells. The study aimed to elucidate the role of the stress-responsive N.R.4.A.2 gene in this process. Establishing a clearer understanding of these mechanisms provides a foundational basis for developing new diagnostic and therapeutic strategies for primary aldosteronism and related hypertension.</p>
<h4>Article 4: Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41140152" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41140152</a></p>
<p><strong>Summary:</strong> This retrospective study analyzed the efficacy of the rice diet, a very low-sodium, low-protein, and low-fat regimen, in treating malignant hypertension from the 1940s. Researchers identified 544 malignant hypertension patients from 17487 historical charts to assess factors associated with blood pressure reduction, including dietary adherence. The study established that this strict dietary intervention effectively reduced blood pressure in a significant cohort of patients before modern antihypertensive drugs were available. This analysis highlights the profound impact of dietary modifications on managing severe hypertension and provides historical context for lifestyle-based blood pressure management.</p>
<h4>Article 5: Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids.</h4>
<p><strong>Journal:</strong> JACC. Basic to translational science</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41139325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41139325</a></p>
<p><strong>Summary:</strong> This translational study demonstrated that sphingolipids are a critical component of estrogen signaling within the human microvascular endothelium. Researchers discovered that estrogen influences microvascular endothelial function through sex-specific regulation of sphingolipids, with stark differences related to both time and biological sex. The study provided evidence that chronic estrogen treatment can promote endothelial dysfunction in isolated human microvessels. These findings are crucial for understanding sex differences in cardiovascular disease and developing targeted therapies by elucidating precise mechanisms of estrogen&#8217;s microvascular impact.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. The A.N.D.E.S. Randomized Clinical Trial prospectively compared antithrombotic strategies after transcatheter left atrial appendage closure for patients with non-valvular atrial fibrillation. This multicenter international study randomized patients to either anticoagulation or dual antiplatelet therapy to determine the optimal approach for preventing device-related thrombosis. The trial&#8217;s objective was to establish which treatment strategy more effectively mitigates device-related thrombosis post-procedure. This research provides crucial evidence to guide clinical practice, potentially improving patient safety and outcomes following left atrial appendage closure.</p>
<p>Article number two. Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis. This study investigated the role of the P2Y14 receptor, highly expressed on neutrophils, in venous thromboembolism. Researchers discovered that the P2Y14 receptor mediates neutrophil extracellular trap formation, which exacerbates thrombo-inflammatory responses and venous thromboembolism. Critically, targeting the P2Y14 receptor successfully alleviated platelet-induced neutrophil extracellular trap formation and venous thrombosis by modulating the P.K.A. / A.K.A.P.13 / R.h.o.A. axis. These findings establish the P2Y14 receptor as a promising therapeutic target for developing new strategies to combat venous thromboembolism.</p>
<p>Article number three. Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation. This study investigated the mechanisms driving aldosterone-producing cell cluster formation, which are frequently observed in primary aldosteronism. Researchers utilized an integrated analysis of spatial transcriptomics and single-cell ribonucleic acid sequencing on aldosterone-producing cell clusters, aldosterone-producing adenomas, and zona glomerulosa cells. The study aimed to elucidate the role of the stress-responsive N.R.4.A.2 gene in this process. Establishing a clearer understanding of these mechanisms provides a foundational basis for developing new diagnostic and therapeutic strategies for primary aldosteronism and related hypertension.</p>
<p>Article number four. Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet. This retrospective study analyzed the efficacy of the rice diet, a very low-sodium, low-protein, and low-fat regimen, in treating malignant hypertension from the 1940s. Researchers identified 544 malignant hypertension patients from 17487 historical charts to assess factors associated with blood pressure reduction, including dietary adherence. The study established that this strict dietary intervention effectively reduced blood pressure in a significant cohort of patients before modern antihypertensive drugs were available. This analysis highlights the profound impact of dietary modifications on managing severe hypertension and provides historical context for lifestyle-based blood pressure management.</p>
<p>Article number five. Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids. This translational study demonstrated that sphingolipids are a critical component of estrogen signaling within the human microvascular endothelium. Researchers discovered that estrogen influences microvascular endothelial function through sex-specific regulation of sphingolipids, with stark differences related to both time and biological sex. The study provided evidence that chronic estrogen treatment can promote endothelial dysfunction in isolated human microvessels. These findings are crucial for understanding sex differences in cardiovascular disease and developing targeted therapies by elucidating precise mechanisms of estrogen&#8217;s microvascular impact. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular outcomes, N.R.4.A.2, sphingolipids, sex-specific regulation, venous thromboembolism, antiplatelet therapy, malignant hypertension, P2Y14 receptor, single-cell ribonucleic acid sequencing, P.K.A. / A.K.A.P.13 / R.h.o.A. axis, device-related thrombosis, non-valvular atrial fibrillation, aldosterone-producing cell clusters, left atrial appendage closure, microvascular endothelial function, blood pressure reduction, spatial transcriptomics, dietary adherence, platelet-induced thrombosis, primary aldosteronism, low-sodium diet, estrogen, anticoagulation, rice diet, neutrophil extracellular trap.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/">Targeting P2Y14R Prevents Venous Thrombosis 10/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular outcomes and N.R.4.A.2. Key takeaway: Targeting P2Y14R Prevents Venous Thrombosis.
Article Links:
Article 1: Short-Ter]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular outcomes and N.R.4.A.2. Key takeaway: Targeting P2Y14R Prevents Venous Thrombosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41139402">Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41143464">Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41140167">Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41140152">Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41139325">Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids.</a> (JACC. Basic to translational science)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/">https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41139402" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41139402</a></p>
<p><strong>Summary:</strong> The A.N.D.E.S. Randomized Clinical Trial prospectively compared antithrombotic strategies after transcatheter left atrial appendage closure for patients with non-valvular atrial fibrillation. This multicenter international study randomized patients to either anticoagulation or dual antiplatelet therapy to determine the optimal approach for preventing device-related thrombosis. The trial&#8217;s objective was to establish which treatment strategy more effectively mitigates device-related thrombosis post-procedure. This research provides crucial evidence to guide clinical practice, potentially improving patient safety and outcomes following left atrial appendage closure.</p>
<h4>Article 2: Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41143464" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41143464</a></p>
<p><strong>Summary:</strong> This study investigated the role of the P2Y14 receptor, highly expressed on neutrophils, in venous thromboembolism. Researchers discovered that the P2Y14 receptor mediates neutrophil extracellular trap formation, which exacerbates thrombo-inflammatory responses and venous thromboembolism. Critically, targeting the P2Y14 receptor successfully alleviated platelet-induced neutrophil extracellular trap formation and venous thrombosis by modulating the P.K.A. / A.K.A.P.13 / R.h.o.A. axis. These findings establish the P2Y14 receptor as a promising therapeutic target for developing new strategies to combat venous thromboembolism.</p>
<h4>Article 3: Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41140167" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41140167</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms driving aldosterone-producing cell cluster formation, which are frequently observed in primary aldosteronism. Researchers utilized an integrated analysis of spatial transcriptomics and single-cell ribonucleic acid sequencing on aldosterone-producing cell clusters, aldosterone-producing adenomas, and zona glomerulosa cells. The study aimed to elucidate the role of the stress-responsive N.R.4.A.2 gene in this process. Establishing a clearer understanding of these mechanisms provides a foundational basis for developing new diagnostic and therapeutic strategies for primary aldosteronism and related hypertension.</p>
<h4>Article 4: Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41140152" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41140152</a></p>
<p><strong>Summary:</strong> This retrospective study analyzed the efficacy of the rice diet, a very low-sodium, low-protein, and low-fat regimen, in treating malignant hypertension from the 1940s. Researchers identified 544 malignant hypertension patients from 17487 historical charts to assess factors associated with blood pressure reduction, including dietary adherence. The study established that this strict dietary intervention effectively reduced blood pressure in a significant cohort of patients before modern antihypertensive drugs were available. This analysis highlights the profound impact of dietary modifications on managing severe hypertension and provides historical context for lifestyle-based blood pressure management.</p>
<h4>Article 5: Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids.</h4>
<p><strong>Journal:</strong> JACC. Basic to translational science</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41139325" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41139325</a></p>
<p><strong>Summary:</strong> This translational study demonstrated that sphingolipids are a critical component of estrogen signaling within the human microvascular endothelium. Researchers discovered that estrogen influences microvascular endothelial function through sex-specific regulation of sphingolipids, with stark differences related to both time and biological sex. The study provided evidence that chronic estrogen treatment can promote endothelial dysfunction in isolated human microvessels. These findings are crucial for understanding sex differences in cardiovascular disease and developing targeted therapies by elucidating precise mechanisms of estrogen&#8217;s microvascular impact.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. The A.N.D.E.S. Randomized Clinical Trial prospectively compared antithrombotic strategies after transcatheter left atrial appendage closure for patients with non-valvular atrial fibrillation. This multicenter international study randomized patients to either anticoagulation or dual antiplatelet therapy to determine the optimal approach for preventing device-related thrombosis. The trial&#8217;s objective was to establish which treatment strategy more effectively mitigates device-related thrombosis post-procedure. This research provides crucial evidence to guide clinical practice, potentially improving patient safety and outcomes following left atrial appendage closure.</p>
<p>Article number two. Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis. This study investigated the role of the P2Y14 receptor, highly expressed on neutrophils, in venous thromboembolism. Researchers discovered that the P2Y14 receptor mediates neutrophil extracellular trap formation, which exacerbates thrombo-inflammatory responses and venous thromboembolism. Critically, targeting the P2Y14 receptor successfully alleviated platelet-induced neutrophil extracellular trap formation and venous thrombosis by modulating the P.K.A. / A.K.A.P.13 / R.h.o.A. axis. These findings establish the P2Y14 receptor as a promising therapeutic target for developing new strategies to combat venous thromboembolism.</p>
<p>Article number three. Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation. This study investigated the mechanisms driving aldosterone-producing cell cluster formation, which are frequently observed in primary aldosteronism. Researchers utilized an integrated analysis of spatial transcriptomics and single-cell ribonucleic acid sequencing on aldosterone-producing cell clusters, aldosterone-producing adenomas, and zona glomerulosa cells. The study aimed to elucidate the role of the stress-responsive N.R.4.A.2 gene in this process. Establishing a clearer understanding of these mechanisms provides a foundational basis for developing new diagnostic and therapeutic strategies for primary aldosteronism and related hypertension.</p>
<p>Article number four. Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet. This retrospective study analyzed the efficacy of the rice diet, a very low-sodium, low-protein, and low-fat regimen, in treating malignant hypertension from the 1940s. Researchers identified 544 malignant hypertension patients from 17487 historical charts to assess factors associated with blood pressure reduction, including dietary adherence. The study established that this strict dietary intervention effectively reduced blood pressure in a significant cohort of patients before modern antihypertensive drugs were available. This analysis highlights the profound impact of dietary modifications on managing severe hypertension and provides historical context for lifestyle-based blood pressure management.</p>
<p>Article number five. Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids. This translational study demonstrated that sphingolipids are a critical component of estrogen signaling within the human microvascular endothelium. Researchers discovered that estrogen influences microvascular endothelial function through sex-specific regulation of sphingolipids, with stark differences related to both time and biological sex. The study provided evidence that chronic estrogen treatment can promote endothelial dysfunction in isolated human microvessels. These findings are crucial for understanding sex differences in cardiovascular disease and developing targeted therapies by elucidating precise mechanisms of estrogen&#8217;s microvascular impact. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiovascular outcomes, N.R.4.A.2, sphingolipids, sex-specific regulation, venous thromboembolism, antiplatelet therapy, malignant hypertension, P2Y14 receptor, single-cell ribonucleic acid sequencing, P.K.A. / A.K.A.P.13 / R.h.o.A. axis, device-related thrombosis, non-valvular atrial fibrillation, aldosterone-producing cell clusters, left atrial appendage closure, microvascular endothelial function, blood pressure reduction, spatial transcriptomics, dietary adherence, platelet-induced thrombosis, primary aldosteronism, low-sodium diet, estrogen, anticoagulation, rice diet, neutrophil extracellular trap.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/">Targeting P2Y14R Prevents Venous Thrombosis 10/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251027_171820.mp3" length="5014508" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular outcomes and N.R.4.A.2. Key takeaway: Targeting P2Y14R Prevents Venous Thrombosis.
Article Links:
Article 1: Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. (Circulation)
Article 2: Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis. (European heart journal)
Article 3: Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation. (Hypertension (Dallas, Tex. : 1979))
Article 4: Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet. (Hypertension (Dallas, Tex. : 1979))
Article 5: Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids. (JACC. Basic to translational science)
Full episode page: https://podcast.explainheart.com/podcast/targeting-p2y14r-prevents-venous-thrombosis-10-27-25/
 Featured Articles
Article 1: Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41139402
Summary: The A.N.D.E.S. Randomized Clinical Trial prospectively compared antithrombotic strategies after transcatheter left atrial appendage closure for patients with non-valvular atrial fibrillation. This multicenter international study randomized patients to either anticoagulation or dual antiplatelet therapy to determine the optimal approach for preventing device-related thrombosis. The trial&#8217;s objective was to establish which treatment strategy more effectively mitigates device-related thrombosis post-procedure. This research provides crucial evidence to guide clinical practice, potentially improving patient safety and outcomes following left atrial appendage closure.
Article 2: Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41143464
Summary: This study investigated the role of the P2Y14 receptor, highly expressed on neutrophils, in venous thromboembolism. Researchers discovered that the P2Y14 receptor mediates neutrophil extracellular trap formation, which exacerbates thrombo-inflammatory responses and venous thromboembolism. Critically, targeting the P2Y14 receptor successfully alleviated platelet-induced neutrophil extracellular trap formation and venous thrombosis by modulating the P.K.A. / A.K.A.P.13 / R.h.o.A. axis. These findings establish the P2Y14 receptor as a promising therapeutic target for developing new strategies to combat venous thromboembolism.
Article 3: Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41140167
Summary: This study investigated the mechanisms driving aldosterone-producing cell cluster formation, which are frequently observed in primary aldosteronism. Researchers utilized an integrated analysis of spatial transcriptomics and single-cell ribonucleic acid sequencing on aldosterone-producing cell clusters, aldosterone-producing adenomas, and zona glomerulosa cells. The study aimed to elucidate the role of the stress-responsive N.R.4.A.2 gene in this process. Establishing a clearer understanding of these mechanisms provides a foundational basis for developing new diagnostic and therapeutic strategies for primary aldosteronism and related hypertension.
Article 4: Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41140152
Summary: This retrospe]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like cardiovascular outcomes and N.R.4.A.2. Key takeaway: Targeting P2Y14R Prevents Venous Thrombosis.
Article Links:
Article 1: Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. (Circulation)
Article 2: Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis. (European heart journal)
Article 3: Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation. (Hypertension (Dallas, Tex. : 1979))
Article 4: Treating Malignant Hypertension With the Low-Sodium, Low-Protein, and Low-Fat Rice Diet. (Hypertension (Dallas, Tex. : 1979))
Article 5: Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids. (JACC. Basic to translational science)]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Tirzepatide Stops Chemo Heart Damage 10/27/25</title>
	<link>https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/</link>
	<pubDate>Mon, 27 Oct 2025 10:02:10 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like melanocortin receptor accessory protein 2 and transcatheter heart valve. Key takeaway: Tirzepatide Stops Chemo Heart Damage.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40244925">Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40036855">Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41133296">Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41137850">Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions.</a> (Circulation. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41133305">Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets.</a> (Circulation. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/">https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40244925" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40244925</a></p>
<p><strong>Summary:</strong> This study investigated the role of melanocortin receptor accessory protein 2, or M.R.A.P.2, in melanocortin-4 receptor, or M.C.4.R., neurons regarding metabolic, autonomic, and cardiovascular functions. Researchers selectively deleted M.R.A.P.2 in M.C.4.R. neurons, finding that while this caused obesity and impaired glucose homeostasis, it also surprisingly protected against obesity-associated autonomic and cardiovascular dysfunctions. This research identifies M.R.A.P.2 in M.C.4.R. neurons as a significant regulator, offering a potential therapeutic target to decouple obesity from its cardiovascular complications.</p>
<h4>Article 2: Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40036855" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40036855</a></p>
<p><strong>Summary:</strong> This study investigated how tirzepatide, a gastric inhibitory polypeptide / glucagon-like peptide-1 receptor agonist, mitigates doxorubicin-induced cardiotoxicity, a major limitation in cancer therapy. Researchers discovered that tirzepatide effectively alleviates cardiotoxicity by inhibiting H.R.D.1-mediated nuclear factor erythroid 2-related factor 2, or N.R.F.2, ubiquitination, providing a crucial mechanistic understanding. This finding establishes tirzepatide as a promising pharmacological candidate to prevent or treat life-threatening cardiac damage from doxorubicin.</p>
<h4>Article 3: Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41133296" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41133296</a></p>
<p><strong>Summary:</strong> This study, the D.I.S.R.U.P.T.-A.F. registry, described the early adoption and physician learning curve of pulsed field ablation, or P.F.A., for atrial fibrillation in the United States. It prospectively evaluated acute procedural efficiency, safety outcomes, and clinical workflow patterns for both paroxysmal and nonparoxysmal atrial fibrillation cases. This research provides essential real-world data on the initial U.S. experience with P.F.A., establishing baselines for its application and informing future training and optimization strategies.</p>
<h4>Article 4: Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137850</a></p>
<p><strong>Summary:</strong> This post-hoc analysis of the P.P.G. Global study aimed to evaluate the prognostic performance of the pullback pressure gradient, or P.P.G., model for predicting post-percutaneous coronary intervention, or P.C.I., fractional flow reserve, or F.F.R. Researchers investigated whether predicted physiological outcomes following P.C.I. influence clinical outcomes. This study established P.P.G. as a valuable physiological metric that differentiates focal from diffuse coronary artery disease and improves prediction of post-P.C.I. F.F.R., offering a potential tool to optimize intervention strategies.</p>
<h4>Article 5: Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41133305" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41133305</a></p>
<p><strong>Summary:</strong> This study aimed to describe the 5-year clinical outcomes and durability of the Portico self-expanding transcatheter heart valve with intra-annular leaflets. Researchers harmonized patient-level data from three prospective studies, utilizing centralized echocardiographic analysis and independent clinical events committee adjudication. This comprehensive analysis successfully provided critical longer-term durability data, offering essential evidence on the Portico valve&#8217;s sustained safety and effectiveness to inform clinical decisions for transcatheter aortic valve replacement.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions. This study investigated the role of melanocortin receptor accessory protein 2, or M.R.A.P.2, in melanocortin-4 receptor, or M.C.4.R., neurons regarding metabolic, autonomic, and cardiovascular functions. Researchers selectively deleted M.R.A.P.2 in M.C.4.R. neurons, finding that while this caused obesity and impaired glucose homeostasis, it also surprisingly protected against obesity-associated autonomic and cardiovascular dysfunctions. This research identifies M.R.A.P.2 in M.C.4.R. neurons as a significant regulator, offering a potential therapeutic target to decouple obesity from its cardiovascular complications.</p>
<p>Article number two. Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting H.R.D.1-mediated Nrf2 ubiquitination. This study investigated how tirzepatide, a gastric inhibitory polypeptide / glucagon-like peptide-1 receptor agonist, mitigates doxorubicin-induced cardiotoxicity, a major limitation in cancer therapy. Researchers discovered that tirzepatide effectively alleviates cardiotoxicity by inhibiting H.R.D.1-mediated nuclear factor erythroid 2-related factor 2, or N.R.F.2, ubiquitination, providing a crucial mechanistic understanding. This finding establishes tirzepatide as a promising pharmacological candidate to prevent or treat life-threatening cardiac damage from doxorubicin.</p>
<p>Article number three. Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States. This study, the D.I.S.R.U.P.T.-A.F. registry, described the early adoption and physician learning curve of pulsed field ablation, or P.F.A., for atrial fibrillation in the United States. It prospectively evaluated acute procedural efficiency, safety outcomes, and clinical workflow patterns for both paroxysmal and nonparoxysmal atrial fibrillation cases. This research provides essential real-world data on the initial U.S. experience with P.F.A., establishing baselines for its application and informing future training and optimization strategies.</p>
<p>Article number four. Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions. This post-hoc analysis of the P.P.G. Global study aimed to evaluate the prognostic performance of the pullback pressure gradient, or P.P.G., model for predicting post-percutaneous coronary intervention, or P.C.I., fractional flow reserve, or F.F.R. Researchers investigated whether predicted physiological outcomes following P.C.I. influence clinical outcomes. This study established P.P.G. as a valuable physiological metric that differentiates focal from diffuse coronary artery disease and improves prediction of post-P.C.I. F.F.R., offering a potential tool to optimize intervention strategies.</p>
<p>Article number five. Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets. This study aimed to describe the 5-year clinical outcomes and durability of the Portico self-expanding transcatheter heart valve with intra-annular leaflets. Researchers harmonized patient-level data from three prospective studies, utilizing centralized echocardiographic analysis and independent clinical events committee adjudication. This comprehensive analysis successfully provided critical longer-term durability data, offering essential evidence on the Portico valve&#8217;s sustained safety and effectiveness to inform clinical decisions for transcatheter aortic valve replacement. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>melanocortin receptor accessory protein 2, transcatheter heart valve, cardiovascular dysfunction, coronary artery disease, clinical outcomes, atrial fibrillation, gastric inhibitory polypeptide, physician learning curve, D.I.S.R.U.P.T.-A.F. registry, obesity, autonomic dysfunction, glucagon-like peptide-1 receptor agonist, melanocortin-4 receptor, percutaneous coronary intervention, Portico valve, procedural efficiency, valve durability, prognostic performance, transcatheter aortic valve replacement, H.R.D.1, tirzepatide, pulsed field ablation, pullback pressure gradient, Nrf2 ubiquitination, fractional flow reserve, doxorubicin cardiotoxicity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/">Tirzepatide Stops Chemo Heart Damage 10/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like melanocortin receptor accessory protein 2 and transcatheter heart valve. Key takeaway: Tirzepatide Stops Chemo Heart Damage.
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like melanocortin receptor accessory protein 2 and transcatheter heart valve. Key takeaway: Tirzepatide Stops Chemo Heart Damage.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40244925">Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40036855">Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41133296">Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41137850">Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions.</a> (Circulation. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41133305">Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets.</a> (Circulation. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/">https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40244925" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40244925</a></p>
<p><strong>Summary:</strong> This study investigated the role of melanocortin receptor accessory protein 2, or M.R.A.P.2, in melanocortin-4 receptor, or M.C.4.R., neurons regarding metabolic, autonomic, and cardiovascular functions. Researchers selectively deleted M.R.A.P.2 in M.C.4.R. neurons, finding that while this caused obesity and impaired glucose homeostasis, it also surprisingly protected against obesity-associated autonomic and cardiovascular dysfunctions. This research identifies M.R.A.P.2 in M.C.4.R. neurons as a significant regulator, offering a potential therapeutic target to decouple obesity from its cardiovascular complications.</p>
<h4>Article 2: Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40036855" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40036855</a></p>
<p><strong>Summary:</strong> This study investigated how tirzepatide, a gastric inhibitory polypeptide / glucagon-like peptide-1 receptor agonist, mitigates doxorubicin-induced cardiotoxicity, a major limitation in cancer therapy. Researchers discovered that tirzepatide effectively alleviates cardiotoxicity by inhibiting H.R.D.1-mediated nuclear factor erythroid 2-related factor 2, or N.R.F.2, ubiquitination, providing a crucial mechanistic understanding. This finding establishes tirzepatide as a promising pharmacological candidate to prevent or treat life-threatening cardiac damage from doxorubicin.</p>
<h4>Article 3: Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41133296" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41133296</a></p>
<p><strong>Summary:</strong> This study, the D.I.S.R.U.P.T.-A.F. registry, described the early adoption and physician learning curve of pulsed field ablation, or P.F.A., for atrial fibrillation in the United States. It prospectively evaluated acute procedural efficiency, safety outcomes, and clinical workflow patterns for both paroxysmal and nonparoxysmal atrial fibrillation cases. This research provides essential real-world data on the initial U.S. experience with P.F.A., establishing baselines for its application and informing future training and optimization strategies.</p>
<h4>Article 4: Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137850</a></p>
<p><strong>Summary:</strong> This post-hoc analysis of the P.P.G. Global study aimed to evaluate the prognostic performance of the pullback pressure gradient, or P.P.G., model for predicting post-percutaneous coronary intervention, or P.C.I., fractional flow reserve, or F.F.R. Researchers investigated whether predicted physiological outcomes following P.C.I. influence clinical outcomes. This study established P.P.G. as a valuable physiological metric that differentiates focal from diffuse coronary artery disease and improves prediction of post-P.C.I. F.F.R., offering a potential tool to optimize intervention strategies.</p>
<h4>Article 5: Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41133305" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41133305</a></p>
<p><strong>Summary:</strong> This study aimed to describe the 5-year clinical outcomes and durability of the Portico self-expanding transcatheter heart valve with intra-annular leaflets. Researchers harmonized patient-level data from three prospective studies, utilizing centralized echocardiographic analysis and independent clinical events committee adjudication. This comprehensive analysis successfully provided critical longer-term durability data, offering essential evidence on the Portico valve&#8217;s sustained safety and effectiveness to inform clinical decisions for transcatheter aortic valve replacement.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions. This study investigated the role of melanocortin receptor accessory protein 2, or M.R.A.P.2, in melanocortin-4 receptor, or M.C.4.R., neurons regarding metabolic, autonomic, and cardiovascular functions. Researchers selectively deleted M.R.A.P.2 in M.C.4.R. neurons, finding that while this caused obesity and impaired glucose homeostasis, it also surprisingly protected against obesity-associated autonomic and cardiovascular dysfunctions. This research identifies M.R.A.P.2 in M.C.4.R. neurons as a significant regulator, offering a potential therapeutic target to decouple obesity from its cardiovascular complications.</p>
<p>Article number two. Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting H.R.D.1-mediated Nrf2 ubiquitination. This study investigated how tirzepatide, a gastric inhibitory polypeptide / glucagon-like peptide-1 receptor agonist, mitigates doxorubicin-induced cardiotoxicity, a major limitation in cancer therapy. Researchers discovered that tirzepatide effectively alleviates cardiotoxicity by inhibiting H.R.D.1-mediated nuclear factor erythroid 2-related factor 2, or N.R.F.2, ubiquitination, providing a crucial mechanistic understanding. This finding establishes tirzepatide as a promising pharmacological candidate to prevent or treat life-threatening cardiac damage from doxorubicin.</p>
<p>Article number three. Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States. This study, the D.I.S.R.U.P.T.-A.F. registry, described the early adoption and physician learning curve of pulsed field ablation, or P.F.A., for atrial fibrillation in the United States. It prospectively evaluated acute procedural efficiency, safety outcomes, and clinical workflow patterns for both paroxysmal and nonparoxysmal atrial fibrillation cases. This research provides essential real-world data on the initial U.S. experience with P.F.A., establishing baselines for its application and informing future training and optimization strategies.</p>
<p>Article number four. Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions. This post-hoc analysis of the P.P.G. Global study aimed to evaluate the prognostic performance of the pullback pressure gradient, or P.P.G., model for predicting post-percutaneous coronary intervention, or P.C.I., fractional flow reserve, or F.F.R. Researchers investigated whether predicted physiological outcomes following P.C.I. influence clinical outcomes. This study established P.P.G. as a valuable physiological metric that differentiates focal from diffuse coronary artery disease and improves prediction of post-P.C.I. F.F.R., offering a potential tool to optimize intervention strategies.</p>
<p>Article number five. Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets. This study aimed to describe the 5-year clinical outcomes and durability of the Portico self-expanding transcatheter heart valve with intra-annular leaflets. Researchers harmonized patient-level data from three prospective studies, utilizing centralized echocardiographic analysis and independent clinical events committee adjudication. This comprehensive analysis successfully provided critical longer-term durability data, offering essential evidence on the Portico valve&#8217;s sustained safety and effectiveness to inform clinical decisions for transcatheter aortic valve replacement. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>melanocortin receptor accessory protein 2, transcatheter heart valve, cardiovascular dysfunction, coronary artery disease, clinical outcomes, atrial fibrillation, gastric inhibitory polypeptide, physician learning curve, D.I.S.R.U.P.T.-A.F. registry, obesity, autonomic dysfunction, glucagon-like peptide-1 receptor agonist, melanocortin-4 receptor, percutaneous coronary intervention, Portico valve, procedural efficiency, valve durability, prognostic performance, transcatheter aortic valve replacement, H.R.D.1, tirzepatide, pulsed field ablation, pullback pressure gradient, Nrf2 ubiquitination, fractional flow reserve, doxorubicin cardiotoxicity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/">Tirzepatide Stops Chemo Heart Damage 10/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251027_060100.mp3" length="4660914" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like melanocortin receptor accessory protein 2 and transcatheter heart valve. Key takeaway: Tirzepatide Stops Chemo Heart Damage.
Article Links:
Article 1: Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions. (Cardiovascular research)
Article 2: Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination. (Cardiovascular research)
Article 3: Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States. (Circulation. Arrhythmia and electrophysiology)
Article 4: Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions. (Circulation. Cardiovascular interventions)
Article 5: Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets. (Circulation. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/tirzepatide-stops-chemo-heart-damage-10-27-25/
 Featured Articles
Article 1: Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40244925
Summary: This study investigated the role of melanocortin receptor accessory protein 2, or M.R.A.P.2, in melanocortin-4 receptor, or M.C.4.R., neurons regarding metabolic, autonomic, and cardiovascular functions. Researchers selectively deleted M.R.A.P.2 in M.C.4.R. neurons, finding that while this caused obesity and impaired glucose homeostasis, it also surprisingly protected against obesity-associated autonomic and cardiovascular dysfunctions. This research identifies M.R.A.P.2 in M.C.4.R. neurons as a significant regulator, offering a potential therapeutic target to decouple obesity from its cardiovascular complications.
Article 2: Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40036855
Summary: This study investigated how tirzepatide, a gastric inhibitory polypeptide / glucagon-like peptide-1 receptor agonist, mitigates doxorubicin-induced cardiotoxicity, a major limitation in cancer therapy. Researchers discovered that tirzepatide effectively alleviates cardiotoxicity by inhibiting H.R.D.1-mediated nuclear factor erythroid 2-related factor 2, or N.R.F.2, ubiquitination, providing a crucial mechanistic understanding. This finding establishes tirzepatide as a promising pharmacological candidate to prevent or treat life-threatening cardiac damage from doxorubicin.
Article 3: Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States.
Journal: Circulation. Arrhythmia and electrophysiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41133296
Summary: This study, the D.I.S.R.U.P.T.-A.F. registry, described the early adoption and physician learning curve of pulsed field ablation, or P.F.A., for atrial fibrillation in the United States. It prospectively evaluated acute procedural efficiency, safety outcomes, and clinical workflow patterns for both paroxysmal and nonparoxysmal atrial fibrillation cases. This research provides essential real-world data on the initial U.S. experience with P.F.A., establishing baselines for its application and informing future training and optimization strategies.
Article 4: Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions.
Journal: Circulation. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41137850
Summary: This post-hoc analysis of the P.P.G. Global study aimed to evaluate the prognostic]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like melanocortin receptor accessory protein 2 and transcatheter heart valve. Key takeaway: Tirzepatide Stops Chemo Heart Damage.
Article Links:
Article 1: Loss of melanocortin receptor accessory protein 2 in melanocortin-4 receptor neurons protect from obesity-associated autonomic and cardiovascular dysfunctions. (Cardiovascular research)
Article 2: Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination. (Cardiovascular research)
Article 3: Insights Into Early Adoption and Physician Learning Curve of Pulsed Field Ablation in the United States. (Circulation. Arrhythmia and electrophysiology)
Article 4: Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions. (Circulation. Cardiovascular interventions)
Article 5: Five-Year Clinical Outcomes and Durability of a Self-Expanding Tr]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Trimetazidine for Early Hypertrophic Cardiomyopathy 10/27/25</title>
	<link>https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/</link>
	<pubDate>Mon, 27 Oct 2025 06:57:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40911402">Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40878014">Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40832854">The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40795179">YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40601822">Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/">https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40911402" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40911402</a></p>
<p><strong>Summary:</strong> The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.</p>
<h4>Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878014" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878014</a></p>
<p><strong>Summary:</strong> This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.</p>
<h4>Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40832854" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40832854</a></p>
<p><strong>Summary:</strong> This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.</p>
<h4>Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40795179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40795179</a></p>
<p><strong>Summary:</strong> modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance and blood pressure dynamics. Researchers demonstrated that Y.Y.1 achieves this control through epigenetic modulation of m6A R.N.A. modifications within vascular smooth muscle cells. This work confirms Y.Y.1&#8217;s direct role in vasoreactivity, extending previous genome-wide association study findings. These discoveries provide crucial understanding of blood pressure regulation and open new avenues for therapeutic intervention in hypertension.</p>
<h4>Article 5: Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40601822" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40601822</a></p>
<p><strong>Summary:</strong> The E.N.E.R.G.Y. trial investigated whether trimetazidine dihydrochloride therapy corrects reduced myocardial external efficiency in individuals carrying a hypertrophic cardiomyopathy pathogenic variant. This double-blind, placebo-controlled study focused on pre-clinical individuals who possessed the genetic variant but had not yet developed a hypertrophic cardiomyopathy phenotype. The research aimed to determine if this metabolic treatment could address a key pathomechanism thought to contribute to disease onset and progression. Establishing such an effect could support early pharmacological intervention to modify the disease course in at-risk individuals.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.</p>
<p>Article number two. Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.</p>
<p>Article number three. The pioneer factor, E.T.V.2, regulates networks to specify the embryonic endothelial lineage. This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.</p>
<p>Article number four. Y.Y.1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A R.N.A. modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance and blood pressure dynamics. Researchers demonstrated that Y.Y.1 achieves this control through epigenetic modulation of m6A R.N.A. modifications within vascular smooth muscle cells. This work confirms Y.Y.1&#8217;s direct role in vasoreactivity, extending previous genome-wide association study findings. These discoveries provide crucial understanding of blood pressure regulation and open new avenues for therapeutic intervention in hypertension.</p>
<p>Article number five. Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. The E.N.E.R.G.Y. trial investigated whether trimetazidine dihydrochloride therapy corrects reduced myocardial external efficiency in individuals carrying a hypertrophic cardiomyopathy pathogenic variant. This double-blind, placebo-controlled study focused on pre-clinical individuals who possessed the genetic variant but had not yet developed a hypertrophic cardiomyopathy phenotype. The research aimed to determine if this metabolic treatment could address a key pathomechanism thought to contribute to disease onset and progression. Establishing such an effect could support early pharmacological intervention to modify the disease course in at-risk individuals. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertensive disorders of pregnancy, pathogenic variant, Proprotein Convertase Subtilisin/Kexin type 9, trimetazidine dihydrochloride, pioneer transcription factor, epigenetic regulation, embryonic development, hematoendothelial lineage, hypertension, Y.Y.1, E.N.E.R.G.Y. trial, spontaneously hypertensive rats, low-density lipoprotein cholesterol, blood pressure, pre-clinical H.C.M., E.T.V.2, m6A R.N.A. modifications, hypertrophic cardiomyopathy, iron deficiency anemia, heterozygous familial hypercholesterolaemia, Phase 3 study, vascular smooth muscle cells, vascular resistance, myocardial external efficiency, endothelial lineage, cardiac function, recaticimab, maternal hemodynamics.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/">Trimetazidine for Early Hypertrophic Cardiomyopathy 10/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy.
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40911402">Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40878014">Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40832854">The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40795179">YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40601822">Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/">https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40911402" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40911402</a></p>
<p><strong>Summary:</strong> The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.</p>
<h4>Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878014" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878014</a></p>
<p><strong>Summary:</strong> This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.</p>
<h4>Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40832854" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40832854</a></p>
<p><strong>Summary:</strong> This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.</p>
<h4>Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40795179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40795179</a></p>
<p><strong>Summary:</strong> modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance and blood pressure dynamics. Researchers demonstrated that Y.Y.1 achieves this control through epigenetic modulation of m6A R.N.A. modifications within vascular smooth muscle cells. This work confirms Y.Y.1&#8217;s direct role in vasoreactivity, extending previous genome-wide association study findings. These discoveries provide crucial understanding of blood pressure regulation and open new avenues for therapeutic intervention in hypertension.</p>
<h4>Article 5: Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40601822" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40601822</a></p>
<p><strong>Summary:</strong> The E.N.E.R.G.Y. trial investigated whether trimetazidine dihydrochloride therapy corrects reduced myocardial external efficiency in individuals carrying a hypertrophic cardiomyopathy pathogenic variant. This double-blind, placebo-controlled study focused on pre-clinical individuals who possessed the genetic variant but had not yet developed a hypertrophic cardiomyopathy phenotype. The research aimed to determine if this metabolic treatment could address a key pathomechanism thought to contribute to disease onset and progression. Establishing such an effect could support early pharmacological intervention to modify the disease course in at-risk individuals.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.</p>
<p>Article number two. Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.</p>
<p>Article number three. The pioneer factor, E.T.V.2, regulates networks to specify the embryonic endothelial lineage. This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.</p>
<p>Article number four. Y.Y.1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A R.N.A. modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance and blood pressure dynamics. Researchers demonstrated that Y.Y.1 achieves this control through epigenetic modulation of m6A R.N.A. modifications within vascular smooth muscle cells. This work confirms Y.Y.1&#8217;s direct role in vasoreactivity, extending previous genome-wide association study findings. These discoveries provide crucial understanding of blood pressure regulation and open new avenues for therapeutic intervention in hypertension.</p>
<p>Article number five. Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. The E.N.E.R.G.Y. trial investigated whether trimetazidine dihydrochloride therapy corrects reduced myocardial external efficiency in individuals carrying a hypertrophic cardiomyopathy pathogenic variant. This double-blind, placebo-controlled study focused on pre-clinical individuals who possessed the genetic variant but had not yet developed a hypertrophic cardiomyopathy phenotype. The research aimed to determine if this metabolic treatment could address a key pathomechanism thought to contribute to disease onset and progression. Establishing such an effect could support early pharmacological intervention to modify the disease course in at-risk individuals. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertensive disorders of pregnancy, pathogenic variant, Proprotein Convertase Subtilisin/Kexin type 9, trimetazidine dihydrochloride, pioneer transcription factor, epigenetic regulation, embryonic development, hematoendothelial lineage, hypertension, Y.Y.1, E.N.E.R.G.Y. trial, spontaneously hypertensive rats, low-density lipoprotein cholesterol, blood pressure, pre-clinical H.C.M., E.T.V.2, m6A R.N.A. modifications, hypertrophic cardiomyopathy, iron deficiency anemia, heterozygous familial hypercholesterolaemia, Phase 3 study, vascular smooth muscle cells, vascular resistance, myocardial external efficiency, endothelial lineage, cardiac function, recaticimab, maternal hemodynamics.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/">Trimetazidine for Early Hypertrophic Cardiomyopathy 10/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251027_025647.mp3" length="4455278" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy.
Article Links:
Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. (Cardiovascular research)
Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. (Cardiovascular research)
Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage. (Cardiovascular research)
Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells. (Cardiovascular research)
Article 5: Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/
 Featured Articles
Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40911402
Summary: The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.
Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878014
Summary: This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.
Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40832854
Summary: This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.
Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40795179
Summary: modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance a]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy.
Article Links:
Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. (Cardiovascular research)
Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. (Cardiovascular research)
Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage. (Cardiovascular research)
Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells. (Cardiovascular research)
Article 5: Effect of trimetazidine dihydrochloride therapy on myocardia]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>T-TEER Safe in CIED Patients with Tricuspid Regurgitation 10/26/25</title>
	<link>https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/</link>
	<pubDate>Sun, 26 Oct 2025 10:02:02 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like severe tricuspid regurgitation and cardiac implantable electronic devices. Key takeaway: T-TEER Safe in CIED Patients with Tricuspid Regurgitation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41137840">Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41137839">Impact of Valve Frame Height on PCI Outcomes After TAVR.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41137838">Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41137837">Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41137834">Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA Postapproval Study.</a> (JACC. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/">https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137840" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137840</a></p>
<p><strong>Summary:</strong> This study evaluated the safety and performance of the novel Zenith Left Atrial Appendage occlusion system through preclinical canine models and a prospective first-in-human experience. The research successfully established the system&#8217;s safety and effectiveness for occluding the left atrial appendage. This represents a significant advancement, offering a new percutaneous option for stroke prevention in patients with atrial fibrillation who are intolerant to long-term oral anticoagulation. The Zenith system aims to overcome limitations of current devices like device-related thrombus and peridevice leak.</p>
<h4>Article 2: Impact of Valve Frame Height on PCI Outcomes After TAVR.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137839" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137839</a></p>
<p><strong>Summary:</strong> Outcomes After T.A.V.R. This multicenter registry study evaluated the impact of bioprosthetic aortic valve type on long-term clinical outcomes for patients undergoing percutaneous coronary intervention following transcatheter aortic valve replacement. Researchers utilized data from the R.E.V.I.V.A.L.-P.C.I. registry across 21 European centers. The findings provide crucial clarity regarding the challenges of coronary access after transcatheter aortic valve replacement, particularly with tall-framed valves. This research has significant clinical implications for informing valve selection during transcatheter aortic valve replacement to optimize future coronary revascularization strategies.</p>
<h4>Article 3: Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137838" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137838</a></p>
<p><strong>Summary:</strong> This real-world cohort study, derived from the EuroT.R. registry, evaluated procedural and clinical outcomes of tricuspid valve transcatheter edge-to-edge repair in 851 patients with cardiac implantable electronic device leads. The research, conducted across 26 centers, characterized the previously unclear long-term outcomes in this specific patient population. The study established the safety and effectiveness of tricuspid valve transcatheter edge-to-edge repair even with the presence of transvalvular device leads. These findings significantly broaden the applicability of this minimally invasive treatment for severe tricuspid regurgitation in patients with complex cardiac histories.</p>
<h4>Article 4: Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137837" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137837</a></p>
<p><strong>Summary:</strong> After Tricuspid T-TEER. This study described the techniques and outcomes for patients undergoing transcatheter tricuspid valve replacement after prior tricuspid transcatheter edge-to-edge repair. The research elucidated advanced electrosurgical techniques, such as C.L.E.F., that facilitate successful transcatheter tricuspid valve replacement in these complex cases. This paper establishes the feasibility and provides important procedural guidance for patients with severe tricuspid regurgitation who do not achieve optimal results from initial edge-to-edge repair. These findings represent a significant contribution to the evolving treatment landscape for advanced tricuspid valve disease.</p>
<h4>Article 5: Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA Postapproval Study.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137834" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137834</a></p>
<p><strong>Summary:</strong> Postapproval Study. This study compared outcomes of left atrial appendage occlusion procedures guided by intracardiac echocardiography versus transesophageal echocardiography, or a combination of both. Utilizing data from the E.M.E.R.G.E. L.A.A. postapproval study, researchers analyzed patients with Amulet implants from the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry. The findings provide critical comparative data on the efficacy and safety of different echocardiographic guidance modalities for these procedures. This research offers valuable clinical guidance for optimizing imaging strategies during left atrial appendage occlusion to enhance procedural outcomes and patient care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience. This study evaluated the safety and performance of the novel Zenith Left Atrial Appendage occlusion system through preclinical canine models and a prospective first-in-human experience. The research successfully established the system&#8217;s safety and effectiveness for occluding the left atrial appendage. This represents a significant advancement, offering a new percutaneous option for stroke prevention in patients with atrial fibrillation who are intolerant to long-term oral anticoagulation. The Zenith system aims to overcome limitations of current devices like device-related thrombus and peridevice leak.</p>
<p>Article number two. Impact of Valve Frame Height on P.C.I. Outcomes After T.A.V.R. This multicenter registry study evaluated the impact of bioprosthetic aortic valve type on long-term clinical outcomes for patients undergoing percutaneous coronary intervention following transcatheter aortic valve replacement. Researchers utilized data from the R.E.V.I.V.A.L.-P.C.I. registry across 21 European centers. The findings provide crucial clarity regarding the challenges of coronary access after transcatheter aortic valve replacement, particularly with tall-framed valves. This research has significant clinical implications for informing valve selection during transcatheter aortic valve replacement to optimize future coronary revascularization strategies.</p>
<p>Article number three. Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR. This real-world cohort study, derived from the EuroT.R. registry, evaluated procedural and clinical outcomes of tricuspid valve transcatheter edge-to-edge repair in 851 patients with cardiac implantable electronic device leads. The research, conducted across 26 centers, characterized the previously unclear long-term outcomes in this specific patient population. The study established the safety and effectiveness of tricuspid valve transcatheter edge-to-edge repair even with the presence of transvalvular device leads. These findings significantly broaden the applicability of this minimally invasive treatment for severe tricuspid regurgitation in patients with complex cardiac histories.</p>
<p>Article number four. Transcatheter Tricuspid Valve Replacement and C.L.E.F. After Tricuspid T-TEER. This study described the techniques and outcomes for patients undergoing transcatheter tricuspid valve replacement after prior tricuspid transcatheter edge-to-edge repair. The research elucidated advanced electrosurgical techniques, such as C.L.E.F., that facilitate successful transcatheter tricuspid valve replacement in these complex cases. This paper establishes the feasibility and provides important procedural guidance for patients with severe tricuspid regurgitation who do not achieve optimal results from initial edge-to-edge repair. These findings represent a significant contribution to the evolving treatment landscape for advanced tricuspid valve disease.</p>
<p>Article number five. Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE L.A.A. Postapproval Study. This study compared outcomes of left atrial appendage occlusion procedures guided by intracardiac echocardiography versus transesophageal echocardiography, or a combination of both. Utilizing data from the E.M.E.R.G.E. L.A.A. postapproval study, researchers analyzed patients with Amulet implants from the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry. The findings provide critical comparative data on the efficacy and safety of different echocardiographic guidance modalities for these procedures. This research offers valuable clinical guidance for optimizing imaging strategies during left atrial appendage occlusion to enhance procedural outcomes and patient care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>severe tricuspid regurgitation, cardiac implantable electronic devices, tricuspid transcatheter edge-to-edge repair, electrosurgical techniques, Zenith system, percutaneous intervention, stroke risk, transesophageal echocardiography, EuroT.R. registry, bioprosthetic aortic valve, procedural outcomes, tall-framed valves, imaging guidance, left atrial appendage occlusion, tricuspid valve transcatheter edge-to-edge repair, Left Atrial Appendage occlusion, atrial fibrillation, transcatheter aortic valve replacement, Amulet implant, percutaneous coronary intervention, transcatheter tricuspid valve replacement, C.L.E.F., coronary access, intracardiac echocardiography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/">T-TEER Safe in CIED Patients with Tricuspid Regurgitation 10/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like severe tricuspid regurgitation and cardiac implantable electronic devices. Key takeaway: T-TEER Safe in CIED Patients with Tricuspid ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like severe tricuspid regurgitation and cardiac implantable electronic devices. Key takeaway: T-TEER Safe in CIED Patients with Tricuspid Regurgitation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41137840">Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41137839">Impact of Valve Frame Height on PCI Outcomes After TAVR.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41137838">Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41137837">Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41137834">Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA Postapproval Study.</a> (JACC. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/">https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137840" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137840</a></p>
<p><strong>Summary:</strong> This study evaluated the safety and performance of the novel Zenith Left Atrial Appendage occlusion system through preclinical canine models and a prospective first-in-human experience. The research successfully established the system&#8217;s safety and effectiveness for occluding the left atrial appendage. This represents a significant advancement, offering a new percutaneous option for stroke prevention in patients with atrial fibrillation who are intolerant to long-term oral anticoagulation. The Zenith system aims to overcome limitations of current devices like device-related thrombus and peridevice leak.</p>
<h4>Article 2: Impact of Valve Frame Height on PCI Outcomes After TAVR.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137839" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137839</a></p>
<p><strong>Summary:</strong> Outcomes After T.A.V.R. This multicenter registry study evaluated the impact of bioprosthetic aortic valve type on long-term clinical outcomes for patients undergoing percutaneous coronary intervention following transcatheter aortic valve replacement. Researchers utilized data from the R.E.V.I.V.A.L.-P.C.I. registry across 21 European centers. The findings provide crucial clarity regarding the challenges of coronary access after transcatheter aortic valve replacement, particularly with tall-framed valves. This research has significant clinical implications for informing valve selection during transcatheter aortic valve replacement to optimize future coronary revascularization strategies.</p>
<h4>Article 3: Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137838" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137838</a></p>
<p><strong>Summary:</strong> This real-world cohort study, derived from the EuroT.R. registry, evaluated procedural and clinical outcomes of tricuspid valve transcatheter edge-to-edge repair in 851 patients with cardiac implantable electronic device leads. The research, conducted across 26 centers, characterized the previously unclear long-term outcomes in this specific patient population. The study established the safety and effectiveness of tricuspid valve transcatheter edge-to-edge repair even with the presence of transvalvular device leads. These findings significantly broaden the applicability of this minimally invasive treatment for severe tricuspid regurgitation in patients with complex cardiac histories.</p>
<h4>Article 4: Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137837" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137837</a></p>
<p><strong>Summary:</strong> After Tricuspid T-TEER. This study described the techniques and outcomes for patients undergoing transcatheter tricuspid valve replacement after prior tricuspid transcatheter edge-to-edge repair. The research elucidated advanced electrosurgical techniques, such as C.L.E.F., that facilitate successful transcatheter tricuspid valve replacement in these complex cases. This paper establishes the feasibility and provides important procedural guidance for patients with severe tricuspid regurgitation who do not achieve optimal results from initial edge-to-edge repair. These findings represent a significant contribution to the evolving treatment landscape for advanced tricuspid valve disease.</p>
<h4>Article 5: Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA Postapproval Study.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137834" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137834</a></p>
<p><strong>Summary:</strong> Postapproval Study. This study compared outcomes of left atrial appendage occlusion procedures guided by intracardiac echocardiography versus transesophageal echocardiography, or a combination of both. Utilizing data from the E.M.E.R.G.E. L.A.A. postapproval study, researchers analyzed patients with Amulet implants from the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry. The findings provide critical comparative data on the efficacy and safety of different echocardiographic guidance modalities for these procedures. This research offers valuable clinical guidance for optimizing imaging strategies during left atrial appendage occlusion to enhance procedural outcomes and patient care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience. This study evaluated the safety and performance of the novel Zenith Left Atrial Appendage occlusion system through preclinical canine models and a prospective first-in-human experience. The research successfully established the system&#8217;s safety and effectiveness for occluding the left atrial appendage. This represents a significant advancement, offering a new percutaneous option for stroke prevention in patients with atrial fibrillation who are intolerant to long-term oral anticoagulation. The Zenith system aims to overcome limitations of current devices like device-related thrombus and peridevice leak.</p>
<p>Article number two. Impact of Valve Frame Height on P.C.I. Outcomes After T.A.V.R. This multicenter registry study evaluated the impact of bioprosthetic aortic valve type on long-term clinical outcomes for patients undergoing percutaneous coronary intervention following transcatheter aortic valve replacement. Researchers utilized data from the R.E.V.I.V.A.L.-P.C.I. registry across 21 European centers. The findings provide crucial clarity regarding the challenges of coronary access after transcatheter aortic valve replacement, particularly with tall-framed valves. This research has significant clinical implications for informing valve selection during transcatheter aortic valve replacement to optimize future coronary revascularization strategies.</p>
<p>Article number three. Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR. This real-world cohort study, derived from the EuroT.R. registry, evaluated procedural and clinical outcomes of tricuspid valve transcatheter edge-to-edge repair in 851 patients with cardiac implantable electronic device leads. The research, conducted across 26 centers, characterized the previously unclear long-term outcomes in this specific patient population. The study established the safety and effectiveness of tricuspid valve transcatheter edge-to-edge repair even with the presence of transvalvular device leads. These findings significantly broaden the applicability of this minimally invasive treatment for severe tricuspid regurgitation in patients with complex cardiac histories.</p>
<p>Article number four. Transcatheter Tricuspid Valve Replacement and C.L.E.F. After Tricuspid T-TEER. This study described the techniques and outcomes for patients undergoing transcatheter tricuspid valve replacement after prior tricuspid transcatheter edge-to-edge repair. The research elucidated advanced electrosurgical techniques, such as C.L.E.F., that facilitate successful transcatheter tricuspid valve replacement in these complex cases. This paper establishes the feasibility and provides important procedural guidance for patients with severe tricuspid regurgitation who do not achieve optimal results from initial edge-to-edge repair. These findings represent a significant contribution to the evolving treatment landscape for advanced tricuspid valve disease.</p>
<p>Article number five. Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE L.A.A. Postapproval Study. This study compared outcomes of left atrial appendage occlusion procedures guided by intracardiac echocardiography versus transesophageal echocardiography, or a combination of both. Utilizing data from the E.M.E.R.G.E. L.A.A. postapproval study, researchers analyzed patients with Amulet implants from the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry. The findings provide critical comparative data on the efficacy and safety of different echocardiographic guidance modalities for these procedures. This research offers valuable clinical guidance for optimizing imaging strategies during left atrial appendage occlusion to enhance procedural outcomes and patient care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>severe tricuspid regurgitation, cardiac implantable electronic devices, tricuspid transcatheter edge-to-edge repair, electrosurgical techniques, Zenith system, percutaneous intervention, stroke risk, transesophageal echocardiography, EuroT.R. registry, bioprosthetic aortic valve, procedural outcomes, tall-framed valves, imaging guidance, left atrial appendage occlusion, tricuspid valve transcatheter edge-to-edge repair, Left Atrial Appendage occlusion, atrial fibrillation, transcatheter aortic valve replacement, Amulet implant, percutaneous coronary intervention, transcatheter tricuspid valve replacement, C.L.E.F., coronary access, intracardiac echocardiography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/">T-TEER Safe in CIED Patients with Tricuspid Regurgitation 10/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251026_060051.mp3" length="4669692" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like severe tricuspid regurgitation and cardiac implantable electronic devices. Key takeaway: T-TEER Safe in CIED Patients with Tricuspid Regurgitation.
Article Links:
Article 1: Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience. (JACC. Cardiovascular interventions)
Article 2: Impact of Valve Frame Height on PCI Outcomes After TAVR. (JACC. Cardiovascular interventions)
Article 3: Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR. (JACC. Cardiovascular interventions)
Article 4: Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER. (JACC. Cardiovascular interventions)
Article 5: Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA Postapproval Study. (JACC. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/t-teer-safe-in-cied-patients-with-tricuspid-regurgitation-10-26-25/
 Featured Articles
Article 1: Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41137840
Summary: This study evaluated the safety and performance of the novel Zenith Left Atrial Appendage occlusion system through preclinical canine models and a prospective first-in-human experience. The research successfully established the system&#8217;s safety and effectiveness for occluding the left atrial appendage. This represents a significant advancement, offering a new percutaneous option for stroke prevention in patients with atrial fibrillation who are intolerant to long-term oral anticoagulation. The Zenith system aims to overcome limitations of current devices like device-related thrombus and peridevice leak.
Article 2: Impact of Valve Frame Height on PCI Outcomes After TAVR.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41137839
Summary: Outcomes After T.A.V.R. This multicenter registry study evaluated the impact of bioprosthetic aortic valve type on long-term clinical outcomes for patients undergoing percutaneous coronary intervention following transcatheter aortic valve replacement. Researchers utilized data from the R.E.V.I.V.A.L.-P.C.I. registry across 21 European centers. The findings provide crucial clarity regarding the challenges of coronary access after transcatheter aortic valve replacement, particularly with tall-framed valves. This research has significant clinical implications for informing valve selection during transcatheter aortic valve replacement to optimize future coronary revascularization strategies.
Article 3: Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41137838
Summary: This real-world cohort study, derived from the EuroT.R. registry, evaluated procedural and clinical outcomes of tricuspid valve transcatheter edge-to-edge repair in 851 patients with cardiac implantable electronic device leads. The research, conducted across 26 centers, characterized the previously unclear long-term outcomes in this specific patient population. The study established the safety and effectiveness of tricuspid valve transcatheter edge-to-edge repair even with the presence of transvalvular device leads. These findings significantly broaden the applicability of this minimally invasive treatment for severe tricuspid regurgitation in patients with complex cardiac histories.
Article 4: Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER.
Journal: JACC. Cardiovascular interventions
PubMed Link:]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like severe tricuspid regurgitation and cardiac implantable electronic devices. Key takeaway: T-TEER Safe in CIED Patients with Tricuspid Regurgitation.
Article Links:
Article 1: Left Atrial Appendage Occlusion Using a Novel System: Preclinical Evaluation and First-in-Human Experience. (JACC. Cardiovascular interventions)
Article 2: Impact of Valve Frame Height on PCI Outcomes After TAVR. (JACC. Cardiovascular interventions)
Article 3: Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR. (JACC. Cardiovascular interventions)
Article 4: Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER. (JACC. Cardiovascular interventions)
Article 5: Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Machine Learning Predicts Q.T. Prolongation Better 10/26/25</title>
	<link>https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/</link>
	<pubDate>Sun, 26 Oct 2025 06:57:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like Q. T. c. prolongation and interferon-gamma. Key takeaway: Machine Learning Predicts Q.T. Prolongation Better.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41137844">Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41138970">Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41139036">Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41137846">Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41137841">Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease.</a> (JACC. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/">https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137844</a></p>
<p><strong>Summary:</strong> The HEART-FID trial, the largest study on iron repletion in heart failure, aimed to clarify how various definitions of iron deficiency impact functional capacity, hemoglobin levels, and patient outcomes. This research systematically evaluated different circulating iron indices as diagnostic criteria and explored their utility in defining treatment targets. The study&#8217;s findings provide crucial information for optimizing iron repletion strategies and establishing precise diagnostic thresholds for iron deficiency in heart failure patients. This advancement will guide clinicians in identifying and treating iron deficiency more effectively.</p>
<h4>Article 2: Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138970" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138970</a></p>
<p><strong>Summary:</strong> This study utilized high dimensional analysis of peripheral blood mononuclear cells to identify specific immune cell populations involved in human cardiac allograft vasculopathy. Researchers discovered a peripheral expansion of proinflammatory and cytotoxic C. D. 38 positive H. L. A. -D. R. positive effector memory C. D. 8 positive T cells in heart transplant patients with high-grade cardiac allograft vasculopathy. This finding directly implicates these distinct T cell subsets in the interferon-gamma axis pathogenesis of cardiac allograft vasculopathy. Identifying these specific immune cells provides potential new diagnostic biomarkers and therapeutic targets to improve outcomes in heart transplant recipients.</p>
<h4>Article 3: Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41139036" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41139036</a></p>
<p><strong>Summary:</strong> This research developed and evaluated machine learning approaches to predict drug-induced long Q. T. c. prolongation at the point of prescribing. Using 12-lead E. C. G. data and 5-fold cross-validation, the study trained X. G. Boost, deep neural network, and combined models. These machine learning-enabled methods demonstrated superior performance in predicting drug-induced Q. T. c. prolongation compared to established risk scores such as Tisdale and R. I. S. Q. -P. A. T. H. This advancement provides clinicians with a more accurate tool to assess Q. T. c. prolongation risk, potentially reducing adverse cardiac events.</p>
<h4>Article 4: Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137846</a></p>
<p><strong>Summary:</strong> This international multicenter cohort study investigated the utility of indexed aortic valve calcium volume from computed tomography angiography in patients with aortic stenosis. Researchers demonstrated that this quantitative measure provides robust diagnostic discrimination of disease severity when compared with echocardiography. Furthermore, the study established that computed tomography angiography-derived aortic valve calcium volume effectively informs risk stratification for patients with aortic stenosis. This finding offers a valuable and objective tool to enhance the assessment and management of aortic stenosis.</p>
<h4>Article 5: Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137841" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137841</a></p>
<p><strong>Summary:</strong> This study from the FIRE trial investigated complete versus culprit-only revascularization in older myocardial infarction patients with multivessel disease, stratified by renal function. Researchers determined that the benefits of physiology-guided complete revascularization are consistently observed across all subpopulations, irrespective of chronic kidney disease severity. This finding establishes that complete revascularization significantly improves outcomes for older patients with myocardial infarction and multivessel disease, even those with impaired renal function. The study provides critical evidence supporting broader application of complete revascularization in this vulnerable patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. The HEART-FID trial, the largest study on iron repletion in heart failure, aimed to clarify how various definitions of iron deficiency impact functional capacity, hemoglobin levels, and patient outcomes. This research systematically evaluated different circulating iron indices as diagnostic criteria and explored their utility in defining treatment targets. The study&#8217;s findings provide crucial information for optimizing iron repletion strategies and establishing precise diagnostic thresholds for iron deficiency in heart failure patients. This advancement will guide clinicians in identifying and treating iron deficiency more effectively.</p>
<p>Article number two. Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy. This study utilized high dimensional analysis of peripheral blood mononuclear cells to identify specific immune cell populations involved in human cardiac allograft vasculopathy. Researchers discovered a peripheral expansion of proinflammatory and cytotoxic C. D. 38 positive H. L. A. -D. R. positive effector memory C. D. 8 positive T cells in heart transplant patients with high-grade cardiac allograft vasculopathy. This finding directly implicates these distinct T cell subsets in the interferon-gamma axis pathogenesis of cardiac allograft vasculopathy. Identifying these specific immune cells provides potential new diagnostic biomarkers and therapeutic targets to improve outcomes in heart transplant recipients.</p>
<p>Article number three. Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing. This research developed and evaluated machine learning approaches to predict drug-induced long Q. T. c. prolongation at the point of prescribing. Using 12-lead E. C. G. data and 5-fold cross-validation, the study trained X. G. Boost, deep neural network, and combined models. These machine learning-enabled methods demonstrated superior performance in predicting drug-induced Q. T. c. prolongation compared to established risk scores such as Tisdale and R. I. S. Q. -P. A. T. H. This advancement provides clinicians with a more accurate tool to assess Q. T. c. prolongation risk, potentially reducing adverse cardiac events.</p>
<p>Article number four. Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study. This international multicenter cohort study investigated the utility of indexed aortic valve calcium volume from computed tomography angiography in patients with aortic stenosis. Researchers demonstrated that this quantitative measure provides robust diagnostic discrimination of disease severity when compared with echocardiography. Furthermore, the study established that computed tomography angiography-derived aortic valve calcium volume effectively informs risk stratification for patients with aortic stenosis. This finding offers a valuable and objective tool to enhance the assessment and management of aortic stenosis.</p>
<p>Article number five. Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease. This study from the FIRE trial investigated complete versus culprit-only revascularization in older myocardial infarction patients with multivessel disease, stratified by renal function. Researchers determined that the benefits of physiology-guided complete revascularization are consistently observed across all subpopulations, irrespective of chronic kidney disease severity. This finding establishes that complete revascularization significantly improves outcomes for older patients with myocardial infarction and multivessel disease, even those with impaired renal function. The study provides critical evidence supporting broader application of complete revascularization in this vulnerable patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Q. T. c. prolongation, interferon-gamma, cardiac allograft vasculopathy, multivessel disease, chronic kidney disease, C. D. 8 T cells, hemoglobin, computed tomography angiography, machine learning, C. D. 38, H. L. A. -D. R., complete revascularization, heart transplant, heart failure, myocardial infarction, calcium scoring, aortic valve calcium, drug-induced arrhythmia, aortic stenosis, culprit-only revascularization, ferric carboxymaltose, functional capacity, X. G. Boost, risk stratification, deep neural network, iron deficiency, electrocardiogram.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/">Machine Learning Predicts Q.T. Prolongation Better 10/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like Q. T. c. prolongation and interferon-gamma. Key takeaway: Machine Learning Predicts Q.T. Prolongation Better.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like Q. T. c. prolongation and interferon-gamma. Key takeaway: Machine Learning Predicts Q.T. Prolongation Better.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41137844">Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41138970">Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41139036">Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41137846">Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41137841">Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease.</a> (JACC. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/">https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137844</a></p>
<p><strong>Summary:</strong> The HEART-FID trial, the largest study on iron repletion in heart failure, aimed to clarify how various definitions of iron deficiency impact functional capacity, hemoglobin levels, and patient outcomes. This research systematically evaluated different circulating iron indices as diagnostic criteria and explored their utility in defining treatment targets. The study&#8217;s findings provide crucial information for optimizing iron repletion strategies and establishing precise diagnostic thresholds for iron deficiency in heart failure patients. This advancement will guide clinicians in identifying and treating iron deficiency more effectively.</p>
<h4>Article 2: Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41138970" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41138970</a></p>
<p><strong>Summary:</strong> This study utilized high dimensional analysis of peripheral blood mononuclear cells to identify specific immune cell populations involved in human cardiac allograft vasculopathy. Researchers discovered a peripheral expansion of proinflammatory and cytotoxic C. D. 38 positive H. L. A. -D. R. positive effector memory C. D. 8 positive T cells in heart transplant patients with high-grade cardiac allograft vasculopathy. This finding directly implicates these distinct T cell subsets in the interferon-gamma axis pathogenesis of cardiac allograft vasculopathy. Identifying these specific immune cells provides potential new diagnostic biomarkers and therapeutic targets to improve outcomes in heart transplant recipients.</p>
<h4>Article 3: Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41139036" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41139036</a></p>
<p><strong>Summary:</strong> This research developed and evaluated machine learning approaches to predict drug-induced long Q. T. c. prolongation at the point of prescribing. Using 12-lead E. C. G. data and 5-fold cross-validation, the study trained X. G. Boost, deep neural network, and combined models. These machine learning-enabled methods demonstrated superior performance in predicting drug-induced Q. T. c. prolongation compared to established risk scores such as Tisdale and R. I. S. Q. -P. A. T. H. This advancement provides clinicians with a more accurate tool to assess Q. T. c. prolongation risk, potentially reducing adverse cardiac events.</p>
<h4>Article 4: Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137846</a></p>
<p><strong>Summary:</strong> This international multicenter cohort study investigated the utility of indexed aortic valve calcium volume from computed tomography angiography in patients with aortic stenosis. Researchers demonstrated that this quantitative measure provides robust diagnostic discrimination of disease severity when compared with echocardiography. Furthermore, the study established that computed tomography angiography-derived aortic valve calcium volume effectively informs risk stratification for patients with aortic stenosis. This finding offers a valuable and objective tool to enhance the assessment and management of aortic stenosis.</p>
<h4>Article 5: Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41137841" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41137841</a></p>
<p><strong>Summary:</strong> This study from the FIRE trial investigated complete versus culprit-only revascularization in older myocardial infarction patients with multivessel disease, stratified by renal function. Researchers determined that the benefits of physiology-guided complete revascularization are consistently observed across all subpopulations, irrespective of chronic kidney disease severity. This finding establishes that complete revascularization significantly improves outcomes for older patients with myocardial infarction and multivessel disease, even those with impaired renal function. The study provides critical evidence supporting broader application of complete revascularization in this vulnerable patient group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. The HEART-FID trial, the largest study on iron repletion in heart failure, aimed to clarify how various definitions of iron deficiency impact functional capacity, hemoglobin levels, and patient outcomes. This research systematically evaluated different circulating iron indices as diagnostic criteria and explored their utility in defining treatment targets. The study&#8217;s findings provide crucial information for optimizing iron repletion strategies and establishing precise diagnostic thresholds for iron deficiency in heart failure patients. This advancement will guide clinicians in identifying and treating iron deficiency more effectively.</p>
<p>Article number two. Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy. This study utilized high dimensional analysis of peripheral blood mononuclear cells to identify specific immune cell populations involved in human cardiac allograft vasculopathy. Researchers discovered a peripheral expansion of proinflammatory and cytotoxic C. D. 38 positive H. L. A. -D. R. positive effector memory C. D. 8 positive T cells in heart transplant patients with high-grade cardiac allograft vasculopathy. This finding directly implicates these distinct T cell subsets in the interferon-gamma axis pathogenesis of cardiac allograft vasculopathy. Identifying these specific immune cells provides potential new diagnostic biomarkers and therapeutic targets to improve outcomes in heart transplant recipients.</p>
<p>Article number three. Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing. This research developed and evaluated machine learning approaches to predict drug-induced long Q. T. c. prolongation at the point of prescribing. Using 12-lead E. C. G. data and 5-fold cross-validation, the study trained X. G. Boost, deep neural network, and combined models. These machine learning-enabled methods demonstrated superior performance in predicting drug-induced Q. T. c. prolongation compared to established risk scores such as Tisdale and R. I. S. Q. -P. A. T. H. This advancement provides clinicians with a more accurate tool to assess Q. T. c. prolongation risk, potentially reducing adverse cardiac events.</p>
<p>Article number four. Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study. This international multicenter cohort study investigated the utility of indexed aortic valve calcium volume from computed tomography angiography in patients with aortic stenosis. Researchers demonstrated that this quantitative measure provides robust diagnostic discrimination of disease severity when compared with echocardiography. Furthermore, the study established that computed tomography angiography-derived aortic valve calcium volume effectively informs risk stratification for patients with aortic stenosis. This finding offers a valuable and objective tool to enhance the assessment and management of aortic stenosis.</p>
<p>Article number five. Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease. This study from the FIRE trial investigated complete versus culprit-only revascularization in older myocardial infarction patients with multivessel disease, stratified by renal function. Researchers determined that the benefits of physiology-guided complete revascularization are consistently observed across all subpopulations, irrespective of chronic kidney disease severity. This finding establishes that complete revascularization significantly improves outcomes for older patients with myocardial infarction and multivessel disease, even those with impaired renal function. The study provides critical evidence supporting broader application of complete revascularization in this vulnerable patient group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Q. T. c. prolongation, interferon-gamma, cardiac allograft vasculopathy, multivessel disease, chronic kidney disease, C. D. 8 T cells, hemoglobin, computed tomography angiography, machine learning, C. D. 38, H. L. A. -D. R., complete revascularization, heart transplant, heart failure, myocardial infarction, calcium scoring, aortic valve calcium, drug-induced arrhythmia, aortic stenosis, culprit-only revascularization, ferric carboxymaltose, functional capacity, X. G. Boost, risk stratification, deep neural network, iron deficiency, electrocardiogram.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/">Machine Learning Predicts Q.T. Prolongation Better 10/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251026_025652.mp3" length="4951396" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like Q. T. c. prolongation and interferon-gamma. Key takeaway: Machine Learning Predicts Q.T. Prolongation Better.
Article Links:
Article 1: Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. (JACC. Heart failure)
Article 2: Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing. (Heart rhythm)
Article 4: Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study. (JACC. Cardiovascular imaging)
Article 5: Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease. (JACC. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/machine-learning-predicts-q-t-prolongation-better-10-26-25/
 Featured Articles
Article 1: Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41137844
Summary: The HEART-FID trial, the largest study on iron repletion in heart failure, aimed to clarify how various definitions of iron deficiency impact functional capacity, hemoglobin levels, and patient outcomes. This research systematically evaluated different circulating iron indices as diagnostic criteria and explored their utility in defining treatment targets. The study&#8217;s findings provide crucial information for optimizing iron repletion strategies and establishing precise diagnostic thresholds for iron deficiency in heart failure patients. This advancement will guide clinicians in identifying and treating iron deficiency more effectively.
Article 2: Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41138970
Summary: This study utilized high dimensional analysis of peripheral blood mononuclear cells to identify specific immune cell populations involved in human cardiac allograft vasculopathy. Researchers discovered a peripheral expansion of proinflammatory and cytotoxic C. D. 38 positive H. L. A. -D. R. positive effector memory C. D. 8 positive T cells in heart transplant patients with high-grade cardiac allograft vasculopathy. This finding directly implicates these distinct T cell subsets in the interferon-gamma axis pathogenesis of cardiac allograft vasculopathy. Identifying these specific immune cells provides potential new diagnostic biomarkers and therapeutic targets to improve outcomes in heart transplant recipients.
Article 3: Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41139036
Summary: This research developed and evaluated machine learning approaches to predict drug-induced long Q. T. c. prolongation at the point of prescribing. Using 12-lead E. C. G. data and 5-fold cross-validation, the study trained X. G. Boost, deep neural network, and combined models. These machine learning-enabled methods demonstrated superior performance in predicting drug-induced Q. T. c. prolongation compared to established risk scores such as Tisdale and R. I. S.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 26, 2025. This episode summarizes 5 key cardiology studies on topics like Q. T. c. prolongation and interferon-gamma. Key takeaway: Machine Learning Predicts Q.T. Prolongation Better.
Article Links:
Article 1: Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. (JACC. Heart failure)
Article 2: Proinflammatory and cytotoxic CD38+HLA-DR+ effector memory CD8+ T cells are peripherally expanded in human cardiac allograft vasculopathy. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Machine Learning-enabled Assessment of Risk for Drug-induced QT Prolongation at the Time of Prescribing. (Heart rhythm)
Article 4: Indexed Aortic Valve Calcium Volume by Computed Tomography Angiography in Patients With Aortic Stenosis: Results of an International Multicenter Cohort Study]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>4A Classification for Tricuspid Regurgitation Risk 10/25/25</title>
	<link>https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/</link>
	<pubDate>Sat, 25 Oct 2025 10:01:46 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and race-ethnicity. Key takeaway: 4A Classification for Tricuspid Regurgitation Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41128132">Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41135790">The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41135789">Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41135788">Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41135775">The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/">https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128132</a></p>
<p><strong>Summary:</strong> This multicenter study utilized magnetic resonance imaging to investigate the influence of maternal socioeconomic opportunity, using the Childhood Opportunity Index, and maternal race-ethnicity on fetal brain development in fetuses with and without complex congenital heart disease. The research aimed to establish how these social determinants of health contribute to neurodevelopmental outcome disparities, which are a persistent challenge in congenital heart disease. By assessing these factors, the study provides a foundational understanding to address the observed differences in neurocognitive outcomes.</p>
<h4>Article 2: The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135790" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135790</a></p>
<p><strong>Summary:</strong> This study examined the relationship between body mass index and outcomes following percutaneous coronary intervention for chronic total occlusion, addressing the known &#8220;obesity paradox&#8221; in other cardiac interventions where contemporary data for chronic total occlusion percutaneous coronary intervention is limited. Researchers analyzed 503 consecutive procedures in 453 patients from their institution between January 2018 and December 2023. The study aimed to clarify the impact of body mass index on both procedural success and long-term patient outcomes in this specific context.</p>
<h4>Article 3: Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135789" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135789</a></p>
<p><strong>Summary:</strong> Insights from L.A.T.T.E.E. registry. The L.A.T.T.E.E. registry investigated changes in anticoagulation treatment and their association with the resolution or persistence of left atrial thrombus in patients with atrial fibrillation or atrial flutter. This multicenter study included 3109 consecutive patients undergoing transoesophageal echocardiography before direct current cardioversion or ablation, identifying left atrial thrombus in 8.0 percent of these individuals. The research aimed to provide much-needed evidence on optimal anticoagulation strategies, addressing current guideline limitations for patients with left atrial thrombus.</p>
<h4>Article 4: Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135788" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135788</a></p>
<p><strong>Summary:</strong> Registry. The B.E.N.E.L.U.X.-I.V.L. Registry conducted a retrospective analysis to identify clinical and procedural factors associated with major adverse cardiovascular events following intravascular lithotripsy for calcified coronary lesions. The study included 583 patients who underwent intravascular lithotripsy for 612 lesions between May 2019 and December 2024, employing Kaplan-Meier analysis and binary logistic regression. This research aimed to establish key predictors, thereby contributing to optimizing patient selection and improving outcomes for this treatment option.</p>
<h4>Article 5: The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135775" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135775</a></p>
<p><strong>Summary:</strong> A multicenter study. This multicenter study aimed to validate the prognostic impact of the novel &#8220;4 A&#8221; classification for stratifying patients with tricuspid regurgitation. The classification, based on the presence of Asthenia, Ankle swelling, Abdominal pain or distention, and Anorexia, provides a clinical tool ranging from A0 to A3. The research sought to establish this classification as an effective method for identifying symptomatic patients and informing prognostic assessments in tricuspid regurgitation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease. This multicenter study utilized magnetic resonance imaging to investigate the influence of maternal socioeconomic opportunity, using the Childhood Opportunity Index, and maternal race-ethnicity on fetal brain development in fetuses with and without complex congenital heart disease. The research aimed to establish how these social determinants of health contribute to neurodevelopmental outcome disparities, which are a persistent challenge in congenital heart disease. By assessing these factors, the study provides a foundational understanding to address the observed differences in neurocognitive outcomes.</p>
<p>Article number two. The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories. This study examined the relationship between body mass index and outcomes following percutaneous coronary intervention for chronic total occlusion, addressing the known &#8220;obesity paradox&#8221; in other cardiac interventions where contemporary data for chronic total occlusion percutaneous coronary intervention is limited. Researchers analyzed 503 consecutive procedures in 453 patients from their institution between January 2018 and December 2023. The study aimed to clarify the impact of body mass index on both procedural success and long-term patient outcomes in this specific context.</p>
<p>Article number three. Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from L.A.T.T.E.E. registry. The L.A.T.T.E.E. registry investigated changes in anticoagulation treatment and their association with the resolution or persistence of left atrial thrombus in patients with atrial fibrillation or atrial flutter. This multicenter study included 3109 consecutive patients undergoing transoesophageal echocardiography before direct current cardioversion or ablation, identifying left atrial thrombus in 8.0 percent of these individuals. The research aimed to provide much-needed evidence on optimal anticoagulation strategies, addressing current guideline limitations for patients with left atrial thrombus.</p>
<p>Article number four. Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the B.E.N.E.L.U.X.-I.V.L. Registry. The B.E.N.E.L.U.X.-I.V.L. Registry conducted a retrospective analysis to identify clinical and procedural factors associated with major adverse cardiovascular events following intravascular lithotripsy for calcified coronary lesions. The study included 583 patients who underwent intravascular lithotripsy for 612 lesions between May 2019 and December 2024, employing Kaplan-Meier analysis and binary logistic regression. This research aimed to establish key predictors, thereby contributing to optimizing patient selection and improving outcomes for this treatment option.</p>
<p>Article number five. The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study. This multicenter study aimed to validate the prognostic impact of the novel &#8220;4 A&#8221; classification for stratifying patients with tricuspid regurgitation. The classification, based on the presence of Asthenia, Ankle swelling, Abdominal pain or distention, and Anorexia, provides a clinical tool ranging from A0 to A3. The research sought to establish this classification as an effective method for identifying symptomatic patients and informing prognostic assessments in tricuspid regurgitation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>major adverse cardiovascular events, race-ethnicity, intravascular lithotripsy, left atrial thrombus, asthenia, obesity paradox, atrial fibrillation, tricuspid regurgitation, clinical predictors, percutaneous coronary intervention, 4 A classification, magnetic resonance imaging, atrial flutter, direct current cardioversion, procedural factors, cardiovascular outcomes, fetal brain development, calcified coronary lesions, socioeconomic opportunity, prognostic stratification, transoesophageal echocardiography, ankle swelling, body mass index, abdominal pain, anticoagulation, congenital heart disease, chronic total occlusion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/">4A Classification for Tricuspid Regurgitation Risk 10/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and race-ethnicity. Key takeaway: 4A Classification for Tricuspid Regurgitation Risk.
Article Lin]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and race-ethnicity. Key takeaway: 4A Classification for Tricuspid Regurgitation Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41128132">Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41135790">The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41135789">Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41135788">Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41135775">The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/">https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128132</a></p>
<p><strong>Summary:</strong> This multicenter study utilized magnetic resonance imaging to investigate the influence of maternal socioeconomic opportunity, using the Childhood Opportunity Index, and maternal race-ethnicity on fetal brain development in fetuses with and without complex congenital heart disease. The research aimed to establish how these social determinants of health contribute to neurodevelopmental outcome disparities, which are a persistent challenge in congenital heart disease. By assessing these factors, the study provides a foundational understanding to address the observed differences in neurocognitive outcomes.</p>
<h4>Article 2: The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135790" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135790</a></p>
<p><strong>Summary:</strong> This study examined the relationship between body mass index and outcomes following percutaneous coronary intervention for chronic total occlusion, addressing the known &#8220;obesity paradox&#8221; in other cardiac interventions where contemporary data for chronic total occlusion percutaneous coronary intervention is limited. Researchers analyzed 503 consecutive procedures in 453 patients from their institution between January 2018 and December 2023. The study aimed to clarify the impact of body mass index on both procedural success and long-term patient outcomes in this specific context.</p>
<h4>Article 3: Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135789" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135789</a></p>
<p><strong>Summary:</strong> Insights from L.A.T.T.E.E. registry. The L.A.T.T.E.E. registry investigated changes in anticoagulation treatment and their association with the resolution or persistence of left atrial thrombus in patients with atrial fibrillation or atrial flutter. This multicenter study included 3109 consecutive patients undergoing transoesophageal echocardiography before direct current cardioversion or ablation, identifying left atrial thrombus in 8.0 percent of these individuals. The research aimed to provide much-needed evidence on optimal anticoagulation strategies, addressing current guideline limitations for patients with left atrial thrombus.</p>
<h4>Article 4: Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135788" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135788</a></p>
<p><strong>Summary:</strong> Registry. The B.E.N.E.L.U.X.-I.V.L. Registry conducted a retrospective analysis to identify clinical and procedural factors associated with major adverse cardiovascular events following intravascular lithotripsy for calcified coronary lesions. The study included 583 patients who underwent intravascular lithotripsy for 612 lesions between May 2019 and December 2024, employing Kaplan-Meier analysis and binary logistic regression. This research aimed to establish key predictors, thereby contributing to optimizing patient selection and improving outcomes for this treatment option.</p>
<h4>Article 5: The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135775" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135775</a></p>
<p><strong>Summary:</strong> A multicenter study. This multicenter study aimed to validate the prognostic impact of the novel &#8220;4 A&#8221; classification for stratifying patients with tricuspid regurgitation. The classification, based on the presence of Asthenia, Ankle swelling, Abdominal pain or distention, and Anorexia, provides a clinical tool ranging from A0 to A3. The research sought to establish this classification as an effective method for identifying symptomatic patients and informing prognostic assessments in tricuspid regurgitation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease. This multicenter study utilized magnetic resonance imaging to investigate the influence of maternal socioeconomic opportunity, using the Childhood Opportunity Index, and maternal race-ethnicity on fetal brain development in fetuses with and without complex congenital heart disease. The research aimed to establish how these social determinants of health contribute to neurodevelopmental outcome disparities, which are a persistent challenge in congenital heart disease. By assessing these factors, the study provides a foundational understanding to address the observed differences in neurocognitive outcomes.</p>
<p>Article number two. The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories. This study examined the relationship between body mass index and outcomes following percutaneous coronary intervention for chronic total occlusion, addressing the known &#8220;obesity paradox&#8221; in other cardiac interventions where contemporary data for chronic total occlusion percutaneous coronary intervention is limited. Researchers analyzed 503 consecutive procedures in 453 patients from their institution between January 2018 and December 2023. The study aimed to clarify the impact of body mass index on both procedural success and long-term patient outcomes in this specific context.</p>
<p>Article number three. Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from L.A.T.T.E.E. registry. The L.A.T.T.E.E. registry investigated changes in anticoagulation treatment and their association with the resolution or persistence of left atrial thrombus in patients with atrial fibrillation or atrial flutter. This multicenter study included 3109 consecutive patients undergoing transoesophageal echocardiography before direct current cardioversion or ablation, identifying left atrial thrombus in 8.0 percent of these individuals. The research aimed to provide much-needed evidence on optimal anticoagulation strategies, addressing current guideline limitations for patients with left atrial thrombus.</p>
<p>Article number four. Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the B.E.N.E.L.U.X.-I.V.L. Registry. The B.E.N.E.L.U.X.-I.V.L. Registry conducted a retrospective analysis to identify clinical and procedural factors associated with major adverse cardiovascular events following intravascular lithotripsy for calcified coronary lesions. The study included 583 patients who underwent intravascular lithotripsy for 612 lesions between May 2019 and December 2024, employing Kaplan-Meier analysis and binary logistic regression. This research aimed to establish key predictors, thereby contributing to optimizing patient selection and improving outcomes for this treatment option.</p>
<p>Article number five. The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study. This multicenter study aimed to validate the prognostic impact of the novel &#8220;4 A&#8221; classification for stratifying patients with tricuspid regurgitation. The classification, based on the presence of Asthenia, Ankle swelling, Abdominal pain or distention, and Anorexia, provides a clinical tool ranging from A0 to A3. The research sought to establish this classification as an effective method for identifying symptomatic patients and informing prognostic assessments in tricuspid regurgitation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>major adverse cardiovascular events, race-ethnicity, intravascular lithotripsy, left atrial thrombus, asthenia, obesity paradox, atrial fibrillation, tricuspid regurgitation, clinical predictors, percutaneous coronary intervention, 4 A classification, magnetic resonance imaging, atrial flutter, direct current cardioversion, procedural factors, cardiovascular outcomes, fetal brain development, calcified coronary lesions, socioeconomic opportunity, prognostic stratification, transoesophageal echocardiography, ankle swelling, body mass index, abdominal pain, anticoagulation, congenital heart disease, chronic total occlusion.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/">4A Classification for Tricuspid Regurgitation Risk 10/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251025_060045.mp3" length="4514629" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and race-ethnicity. Key takeaway: 4A Classification for Tricuspid Regurgitation Risk.
Article Links:
Article 1: Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease. (Journal of the American Heart Association)
Article 2: The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories. (The American journal of cardiology)
Article 3: Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry. (The American journal of cardiology)
Article 4: Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry. (The American journal of cardiology)
Article 5: The 4 a classification for prognostic stratification of patients with tricuspid regurgitation. A multicenter study. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/4a-classification-for-tricuspid-regurgitation-risk-10-25-25/
 Featured Articles
Article 1: Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128132
Summary: This multicenter study utilized magnetic resonance imaging to investigate the influence of maternal socioeconomic opportunity, using the Childhood Opportunity Index, and maternal race-ethnicity on fetal brain development in fetuses with and without complex congenital heart disease. The research aimed to establish how these social determinants of health contribute to neurodevelopmental outcome disparities, which are a persistent challenge in congenital heart disease. By assessing these factors, the study provides a foundational understanding to address the observed differences in neurocognitive outcomes.
Article 2: The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41135790
Summary: This study examined the relationship between body mass index and outcomes following percutaneous coronary intervention for chronic total occlusion, addressing the known &#8220;obesity paradox&#8221; in other cardiac interventions where contemporary data for chronic total occlusion percutaneous coronary intervention is limited. Researchers analyzed 503 consecutive procedures in 453 patients from their institution between January 2018 and December 2023. The study aimed to clarify the impact of body mass index on both procedural success and long-term patient outcomes in this specific context.
Article 3: Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41135789
Summary: Insights from L.A.T.T.E.E. registry. The L.A.T.T.E.E. registry investigated changes in anticoagulation treatment and their association with the resolution or persistence of left atrial thrombus in patients with atrial fibrillation or atrial flutter. This multicenter study included 3109 consecutive patients undergoing transoesophageal echocardiography before direct current cardioversion or ablation, identifying left atrial thrombus in 8.0 percent of these individuals. The research aimed to provide much-needed evidence on optimal anticoagulation strategies, addressing current guideline limitations for patients with left atrial thrombus.
Article 4: Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary L]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and race-ethnicity. Key takeaway: 4A Classification for Tricuspid Regurgitation Risk.
Article Links:
Article 1: Maternal Socioeconomic Opportunity and Race-Ethnicity Intersect to Influence Fetal Brain Volumes in Congenital Heart Disease. (Journal of the American Heart Association)
Article 2: The Obesity Paradox in Chronic Total Occlusion Percutaneous Coronary Intervention: Contemporary Outcomes Across Body Mass Index Categories. (The American journal of cardiology)
Article 3: Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry. (The American journal of cardiology)
Article 4: Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry. (The American journal of cardiology)
Article 5: The ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Twin Pregnancy: Heart Disease Raises Heart Failure Risk 10/25/25</title>
	<link>https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/</link>
	<pubDate>Sat, 25 Oct 2025 06:59:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like chest pain and heart disease. Key takeaway: Twin Pregnancy: Heart Disease Raises Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41135884">A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41135883">Erythropoietin prolongs graft survival in mice by counteracting trained immunity.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41136194">Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41136193">Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41135625">Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/">https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135884" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135884</a></p>
<p><strong>Summary:</strong> This study investigated IceMG, a novel recombinant endopeptidase designed to simultaneously cleave Immunoglobulin G and Immunoglobulin M, for its efficacy in antibody-mediated rejection. In rhesus macaques sensitized by sequential skin transplantations, a single intravenous dose of IceMG (2 milligrams per kilogram) significantly but transiently reduced total Immunoglobulin G and Immunoglobulin M levels. It also decreased allo- and xenoreactive Immunoglobulin G and Immunoglobulin M antibodies. These findings highlight IceMG&#8217;s potential as a therapeutic agent to temporarily clear harmful antibodies, offering a promising approach to improve outcomes in allo- and xenotransplantation by mitigating antibody-mediated rejection.</p>
<h4>Article 2: Erythropoietin prolongs graft survival in mice by counteracting trained immunity.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135883" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135883</a></p>
<p><strong>Summary:</strong> This research explored erythropoietin&#8217;s immune-modulatory effects, specifically its impact on trained immunity and graft survival. C57BL/6 mice, receiving BALB/c cardiac allografts and treated with CpG (a trained immunity inducer), demonstrated accelerated rejection. However, treatment with erythropoietin, which binds to erythropoietin receptors on myeloid cells, effectively counteracted the epigenetic and metabolic reprogramming associated with trained immunity. This intervention resulted in a significant prolongation of cardiac allograft survival in the treated mice. The discovery suggests erythropoietin offers a novel therapeutic strategy to prevent transplant rejection by targeting trained immunity in macrophages, thereby improving long-term graft survival.</p>
<h4>Article 3: Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41136194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41136194</a></p>
<p><strong>Summary:</strong> This retrospective cohort study evaluated the clinical utility of cardiac magnetic resonance in diagnosing pericarditis, particularly when traditional clinical criteria are transient or ambiguous. Consecutive patients referred for pericarditis evaluation by cardiac magnetic resonance between 2010 and 2024 at a tertiary hospital were screened. The study confirmed that while pericarditis is typically diagnosed clinically via symptoms like chest pain, pericardial rub, E.C.G. changes, and pericardial effusion, these findings can be transient. Cardiac magnetic resonance provides crucial added value by offering a more definitive diagnosis of pericardial inflammation or effusion. This enhances diagnostic accuracy and aids in guiding appropriate management for patients with challenging pericarditis presentations.</p>
<h4>Article 4: Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41136193" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41136193</a></p>
<p><strong>Summary:</strong> This study, using data from the prospective global Registry Of Pregnancy And Cardiac disease (R.O.P.A.C.) from 2007-2018, tested the hypothesis that twin pregnancies in women with heart disease lead to higher rates of adverse cardiac events. Comparing 96 twin pregnancies to singleton pregnancies in women with heart disease, the research confirmed that cardiovascular adaptation is more pronounced in twin gestations. Women with pre-existing heart disease carrying twins faced a significantly higher rate of adverse cardiac events, particularly heart failure. These findings highlight the substantial hemodynamic burden of twin pregnancies in this vulnerable population and underscore the critical need for intensive cardiac monitoring and specialized care.</p>
<h4>Article 5: Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135625" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135625</a></p>
<p><strong>Summary:</strong> This study analyzed a large multi-institutional dataset spanning two decades to characterize temporal trends, outcomes, and rhythm management strategies surrounding direct current cardioversion for atrial fibrillation and atrial flutter. Researchers identified all direct current cardioversions performed for atrial fibrillation and atrial flutter between 2000 and 2024, assessing annual volumes and patient status (outpatient versus inpatient). The investigation revealed evolving patterns in the utilization, effectiveness, and patient profiles associated with direct current cardioversion over time. Understanding these trends and contemporary practices is crucial for optimizing rhythm management strategies, improving patient selection, and enhancing the safety and efficacy of cardioversion procedures in modern cardiology practice.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection. This study investigated IceMG, a novel recombinant endopeptidase designed to simultaneously cleave Immunoglobulin G and Immunoglobulin M, for its efficacy in antibody-mediated rejection. In rhesus macaques sensitized by sequential skin transplantations, a single intravenous dose of IceMG (2 milligrams per kilogram) significantly but transiently reduced total Immunoglobulin G and Immunoglobulin M levels. It also decreased allo- and xenoreactive Immunoglobulin G and Immunoglobulin M antibodies. These findings highlight IceMG&#8217;s potential as a therapeutic agent to temporarily clear harmful antibodies, offering a promising approach to improve outcomes in allo- and xenotransplantation by mitigating antibody-mediated rejection.</p>
<p>Article number two. Erythropoietin prolongs graft survival in mice by counteracting trained immunity. This research explored erythropoietin&#8217;s immune-modulatory effects, specifically its impact on trained immunity and graft survival. C57BL/6 mice, receiving BALB/c cardiac allografts and treated with CpG (a trained immunity inducer), demonstrated accelerated rejection. However, treatment with erythropoietin, which binds to erythropoietin receptors on myeloid cells, effectively counteracted the epigenetic and metabolic reprogramming associated with trained immunity. This intervention resulted in a significant prolongation of cardiac allograft survival in the treated mice. The discovery suggests erythropoietin offers a novel therapeutic strategy to prevent transplant rejection by targeting trained immunity in macrophages, thereby improving long-term graft survival.</p>
<p>Article number three. Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study. This retrospective cohort study evaluated the clinical utility of cardiac magnetic resonance in diagnosing pericarditis, particularly when traditional clinical criteria are transient or ambiguous. Consecutive patients referred for pericarditis evaluation by cardiac magnetic resonance between 2010 and 2024 at a tertiary hospital were screened. The study confirmed that while pericarditis is typically diagnosed clinically via symptoms like chest pain, pericardial rub, E.C.G. changes, and pericardial effusion, these findings can be transient. Cardiac magnetic resonance provides crucial added value by offering a more definitive diagnosis of pericardial inflammation or effusion. This enhances diagnostic accuracy and aids in guiding appropriate management for patients with challenging pericarditis presentations.</p>
<p>Article number four. Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry. This study, using data from the prospective global Registry Of Pregnancy And Cardiac disease (R.O.P.A.C.) from 2007-2018, tested the hypothesis that twin pregnancies in women with heart disease lead to higher rates of adverse cardiac events. Comparing 96 twin pregnancies to singleton pregnancies in women with heart disease, the research confirmed that cardiovascular adaptation is more pronounced in twin gestations. Women with pre-existing heart disease carrying twins faced a significantly higher rate of adverse cardiac events, particularly heart failure. These findings highlight the substantial hemodynamic burden of twin pregnancies in this vulnerable population and underscore the critical need for intensive cardiac monitoring and specialized care.</p>
<p>Article number five. Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades. This study analyzed a large multi-institutional dataset spanning two decades to characterize temporal trends, outcomes, and rhythm management strategies surrounding direct current cardioversion for atrial fibrillation and atrial flutter. Researchers identified all direct current cardioversions performed for atrial fibrillation and atrial flutter between 2000 and 2024, assessing annual volumes and patient status (outpatient versus inpatient). The investigation revealed evolving patterns in the utilization, effectiveness, and patient profiles associated with direct current cardioversion over time. Understanding these trends and contemporary practices is crucial for optimizing rhythm management strategies, improving patient selection, and enhancing the safety and efficacy of cardioversion procedures in modern cardiology practice. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>chest pain, heart disease, epigenetic reprogramming, rhythm management, endopeptidase, pericarditis, cardiac allograft, atrial fibrillation, diagnostic criteria, heart failure, antibody-mediated rejection, atrial flutter, immunoglobulin G, direct current cardioversion, trained immunity, procedural outcomes, erythropoietin, IceMG, E.C.G., macrophages, twin pregnancy, immunoglobulin M, cardiac magnetic resonance, pericardial effusion, temporal trends, cardiovascular adaptation, transplantation, adverse cardiac events, graft survival, R.O.P.A.C. Registry.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/">Twin Pregnancy: Heart Disease Raises Heart Failure Risk 10/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like chest pain and heart disease. Key takeaway: Twin Pregnancy: Heart Disease Raises Heart Failure Risk.
Article Links:
Article 1: A Nove]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like chest pain and heart disease. Key takeaway: Twin Pregnancy: Heart Disease Raises Heart Failure Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41135884">A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41135883">Erythropoietin prolongs graft survival in mice by counteracting trained immunity.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41136194">Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41136193">Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41135625">Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/">https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135884" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135884</a></p>
<p><strong>Summary:</strong> This study investigated IceMG, a novel recombinant endopeptidase designed to simultaneously cleave Immunoglobulin G and Immunoglobulin M, for its efficacy in antibody-mediated rejection. In rhesus macaques sensitized by sequential skin transplantations, a single intravenous dose of IceMG (2 milligrams per kilogram) significantly but transiently reduced total Immunoglobulin G and Immunoglobulin M levels. It also decreased allo- and xenoreactive Immunoglobulin G and Immunoglobulin M antibodies. These findings highlight IceMG&#8217;s potential as a therapeutic agent to temporarily clear harmful antibodies, offering a promising approach to improve outcomes in allo- and xenotransplantation by mitigating antibody-mediated rejection.</p>
<h4>Article 2: Erythropoietin prolongs graft survival in mice by counteracting trained immunity.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135883" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135883</a></p>
<p><strong>Summary:</strong> This research explored erythropoietin&#8217;s immune-modulatory effects, specifically its impact on trained immunity and graft survival. C57BL/6 mice, receiving BALB/c cardiac allografts and treated with CpG (a trained immunity inducer), demonstrated accelerated rejection. However, treatment with erythropoietin, which binds to erythropoietin receptors on myeloid cells, effectively counteracted the epigenetic and metabolic reprogramming associated with trained immunity. This intervention resulted in a significant prolongation of cardiac allograft survival in the treated mice. The discovery suggests erythropoietin offers a novel therapeutic strategy to prevent transplant rejection by targeting trained immunity in macrophages, thereby improving long-term graft survival.</p>
<h4>Article 3: Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41136194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41136194</a></p>
<p><strong>Summary:</strong> This retrospective cohort study evaluated the clinical utility of cardiac magnetic resonance in diagnosing pericarditis, particularly when traditional clinical criteria are transient or ambiguous. Consecutive patients referred for pericarditis evaluation by cardiac magnetic resonance between 2010 and 2024 at a tertiary hospital were screened. The study confirmed that while pericarditis is typically diagnosed clinically via symptoms like chest pain, pericardial rub, E.C.G. changes, and pericardial effusion, these findings can be transient. Cardiac magnetic resonance provides crucial added value by offering a more definitive diagnosis of pericardial inflammation or effusion. This enhances diagnostic accuracy and aids in guiding appropriate management for patients with challenging pericarditis presentations.</p>
<h4>Article 4: Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41136193" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41136193</a></p>
<p><strong>Summary:</strong> This study, using data from the prospective global Registry Of Pregnancy And Cardiac disease (R.O.P.A.C.) from 2007-2018, tested the hypothesis that twin pregnancies in women with heart disease lead to higher rates of adverse cardiac events. Comparing 96 twin pregnancies to singleton pregnancies in women with heart disease, the research confirmed that cardiovascular adaptation is more pronounced in twin gestations. Women with pre-existing heart disease carrying twins faced a significantly higher rate of adverse cardiac events, particularly heart failure. These findings highlight the substantial hemodynamic burden of twin pregnancies in this vulnerable population and underscore the critical need for intensive cardiac monitoring and specialized care.</p>
<h4>Article 5: Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41135625" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41135625</a></p>
<p><strong>Summary:</strong> This study analyzed a large multi-institutional dataset spanning two decades to characterize temporal trends, outcomes, and rhythm management strategies surrounding direct current cardioversion for atrial fibrillation and atrial flutter. Researchers identified all direct current cardioversions performed for atrial fibrillation and atrial flutter between 2000 and 2024, assessing annual volumes and patient status (outpatient versus inpatient). The investigation revealed evolving patterns in the utilization, effectiveness, and patient profiles associated with direct current cardioversion over time. Understanding these trends and contemporary practices is crucial for optimizing rhythm management strategies, improving patient selection, and enhancing the safety and efficacy of cardioversion procedures in modern cardiology practice.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection. This study investigated IceMG, a novel recombinant endopeptidase designed to simultaneously cleave Immunoglobulin G and Immunoglobulin M, for its efficacy in antibody-mediated rejection. In rhesus macaques sensitized by sequential skin transplantations, a single intravenous dose of IceMG (2 milligrams per kilogram) significantly but transiently reduced total Immunoglobulin G and Immunoglobulin M levels. It also decreased allo- and xenoreactive Immunoglobulin G and Immunoglobulin M antibodies. These findings highlight IceMG&#8217;s potential as a therapeutic agent to temporarily clear harmful antibodies, offering a promising approach to improve outcomes in allo- and xenotransplantation by mitigating antibody-mediated rejection.</p>
<p>Article number two. Erythropoietin prolongs graft survival in mice by counteracting trained immunity. This research explored erythropoietin&#8217;s immune-modulatory effects, specifically its impact on trained immunity and graft survival. C57BL/6 mice, receiving BALB/c cardiac allografts and treated with CpG (a trained immunity inducer), demonstrated accelerated rejection. However, treatment with erythropoietin, which binds to erythropoietin receptors on myeloid cells, effectively counteracted the epigenetic and metabolic reprogramming associated with trained immunity. This intervention resulted in a significant prolongation of cardiac allograft survival in the treated mice. The discovery suggests erythropoietin offers a novel therapeutic strategy to prevent transplant rejection by targeting trained immunity in macrophages, thereby improving long-term graft survival.</p>
<p>Article number three. Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study. This retrospective cohort study evaluated the clinical utility of cardiac magnetic resonance in diagnosing pericarditis, particularly when traditional clinical criteria are transient or ambiguous. Consecutive patients referred for pericarditis evaluation by cardiac magnetic resonance between 2010 and 2024 at a tertiary hospital were screened. The study confirmed that while pericarditis is typically diagnosed clinically via symptoms like chest pain, pericardial rub, E.C.G. changes, and pericardial effusion, these findings can be transient. Cardiac magnetic resonance provides crucial added value by offering a more definitive diagnosis of pericardial inflammation or effusion. This enhances diagnostic accuracy and aids in guiding appropriate management for patients with challenging pericarditis presentations.</p>
<p>Article number four. Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry. This study, using data from the prospective global Registry Of Pregnancy And Cardiac disease (R.O.P.A.C.) from 2007-2018, tested the hypothesis that twin pregnancies in women with heart disease lead to higher rates of adverse cardiac events. Comparing 96 twin pregnancies to singleton pregnancies in women with heart disease, the research confirmed that cardiovascular adaptation is more pronounced in twin gestations. Women with pre-existing heart disease carrying twins faced a significantly higher rate of adverse cardiac events, particularly heart failure. These findings highlight the substantial hemodynamic burden of twin pregnancies in this vulnerable population and underscore the critical need for intensive cardiac monitoring and specialized care.</p>
<p>Article number five. Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades. This study analyzed a large multi-institutional dataset spanning two decades to characterize temporal trends, outcomes, and rhythm management strategies surrounding direct current cardioversion for atrial fibrillation and atrial flutter. Researchers identified all direct current cardioversions performed for atrial fibrillation and atrial flutter between 2000 and 2024, assessing annual volumes and patient status (outpatient versus inpatient). The investigation revealed evolving patterns in the utilization, effectiveness, and patient profiles associated with direct current cardioversion over time. Understanding these trends and contemporary practices is crucial for optimizing rhythm management strategies, improving patient selection, and enhancing the safety and efficacy of cardioversion procedures in modern cardiology practice. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>chest pain, heart disease, epigenetic reprogramming, rhythm management, endopeptidase, pericarditis, cardiac allograft, atrial fibrillation, diagnostic criteria, heart failure, antibody-mediated rejection, atrial flutter, immunoglobulin G, direct current cardioversion, trained immunity, procedural outcomes, erythropoietin, IceMG, E.C.G., macrophages, twin pregnancy, immunoglobulin M, cardiac magnetic resonance, pericardial effusion, temporal trends, cardiovascular adaptation, transplantation, adverse cardiac events, graft survival, R.O.P.A.C. Registry.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/">Twin Pregnancy: Heart Disease Raises Heart Failure Risk 10/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251025_025701.mp3" length="5235190" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like chest pain and heart disease. Key takeaway: Twin Pregnancy: Heart Disease Raises Heart Failure Risk.
Article Links:
Article 1: A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Erythropoietin prolongs graft survival in mice by counteracting trained immunity. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study. (Heart (British Cardiac Society))
Article 4: Twin pregnancies in women with heart disease are complicated by high risk of heart failure: data from the EORP ROPAC Registry. (Heart (British Cardiac Society))
Article 5: Cardioversion of atrial fibrillation and flutter: Trends, outcomes, and rhythm management strategies over two decades. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/twin-pregnancy-heart-disease-raises-heart-failure-risk-10-25-25/
 Featured Articles
Article 1: A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41135884
Summary: This study investigated IceMG, a novel recombinant endopeptidase designed to simultaneously cleave Immunoglobulin G and Immunoglobulin M, for its efficacy in antibody-mediated rejection. In rhesus macaques sensitized by sequential skin transplantations, a single intravenous dose of IceMG (2 milligrams per kilogram) significantly but transiently reduced total Immunoglobulin G and Immunoglobulin M levels. It also decreased allo- and xenoreactive Immunoglobulin G and Immunoglobulin M antibodies. These findings highlight IceMG&#8217;s potential as a therapeutic agent to temporarily clear harmful antibodies, offering a promising approach to improve outcomes in allo- and xenotransplantation by mitigating antibody-mediated rejection.
Article 2: Erythropoietin prolongs graft survival in mice by counteracting trained immunity.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41135883
Summary: This research explored erythropoietin&#8217;s immune-modulatory effects, specifically its impact on trained immunity and graft survival. C57BL/6 mice, receiving BALB/c cardiac allografts and treated with CpG (a trained immunity inducer), demonstrated accelerated rejection. However, treatment with erythropoietin, which binds to erythropoietin receptors on myeloid cells, effectively counteracted the epigenetic and metabolic reprogramming associated with trained immunity. This intervention resulted in a significant prolongation of cardiac allograft survival in the treated mice. The discovery suggests erythropoietin offers a novel therapeutic strategy to prevent transplant rejection by targeting trained immunity in macrophages, thereby improving long-term graft survival.
Article 3: Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41136194
Summary: This retrospective cohort study evaluated the clinical utility of cardiac magnetic resonance in diagnosing pericarditis, particularly when traditional clinical criteria are transient or ambiguous. Consecutive patients referred for pericardi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 25, 2025. This episode summarizes 5 key cardiology studies on topics like chest pain and heart disease. Key takeaway: Twin Pregnancy: Heart Disease Raises Heart Failure Risk.
Article Links:
Article 1: A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 2: Erythropoietin prolongs graft survival in mice by counteracting trained immunity. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Article 3: Added value of cardiac magnetic resonance to clinical diagnostic criteria in the diagnosis of pericarditis: a retrospective cohort study. (Heart (British Cardiac Society))
Article 4: Twin pregnancies in women with heart disease are complicated by high risk of heart ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Nonsteroidal MRAs Improve Heart Failure Outcomes. 10/24/25</title>
	<link>https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/</link>
	<pubDate>Fri, 24 Oct 2025 20:06:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like genetic diagnosis and mineralocorticoid receptor antagonists. Key takeaway: Nonsteroidal MRAs Improve Heart Failure Outcomes..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41133805">P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41128141">Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41128137">Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41128135">Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41128134">Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/">https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41133805" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41133805</a></p>
<p><strong>Summary:</strong> This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.</p>
<h4>Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128141" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128141</a></p>
<p><strong>Summary:</strong> This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy&#8217;s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.</p>
<h4>Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128137</a></p>
<p><strong>Summary:</strong> This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.</p>
<h4>Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128135</a></p>
<p><strong>Summary:</strong> This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.</p>
<h4>Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128134</a></p>
<p><strong>Summary:</strong> This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on &#8220;worst events&#8221; and net clinical outcomes. The study affirmed rivaroxaban&#8217;s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban&#8217;s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban&#8217;s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.</p>
<p>Article number two. Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy&#8217;s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.</p>
<p>Article number three. Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.</p>
<p>Article number four. Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.</p>
<p>Article number five. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on &#8220;worst events&#8221; and net clinical outcomes. The study affirmed rivaroxaban&#8217;s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban&#8217;s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban&#8217;s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>genetic diagnosis, mineralocorticoid receptor antagonists, hospitalization, N-terminal pro-B-type natriuretic peptide, hypertrophic cardiomyopathy, ischemic stroke, South Asian Indian, Black adults, rivaroxaban, atrial fibrillation, heart failure, ClinGen, genetic variants, thrombotic events, mortality, antiplatelet therapy, high-sensitivity cardiac troponin T, quality of life, revascularization, peripheral artery disease, P-wave indices, atrial cardiomyopathy, finerenone, transcatheter aortic valve implantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/">Nonsteroidal MRAs Improve Heart Failure Outcomes. 10/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like genetic diagnosis and mineralocorticoid receptor antagonists. Key takeaway: Nonsteroidal MRAs Improve Heart Failure Outcomes..
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like genetic diagnosis and mineralocorticoid receptor antagonists. Key takeaway: Nonsteroidal MRAs Improve Heart Failure Outcomes..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41133805">P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41128141">Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41128137">Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41128135">Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41128134">Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/">https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41133805" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41133805</a></p>
<p><strong>Summary:</strong> This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.</p>
<h4>Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128141" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128141</a></p>
<p><strong>Summary:</strong> This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy&#8217;s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.</p>
<h4>Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128137</a></p>
<p><strong>Summary:</strong> This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.</p>
<h4>Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128135</a></p>
<p><strong>Summary:</strong> This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.</p>
<h4>Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128134" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128134</a></p>
<p><strong>Summary:</strong> This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on &#8220;worst events&#8221; and net clinical outcomes. The study affirmed rivaroxaban&#8217;s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban&#8217;s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban&#8217;s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.</p>
<p>Article number two. Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy&#8217;s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.</p>
<p>Article number three. Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter aortic valve implantation N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T levels. The study discovered that elevated pre-procedural levels of both N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T were significant predictors of poorer survival, reduced quality of life, and diminished functional status changes after transcatheter aortic valve implantation. These findings demonstrate that these cardiac biomarkers offer substantial prognostic value beyond current clinical assessments. Consequently, these biomarkers can be incorporated into aortic valve guidelines to enhance risk stratification and guide more informed patient selection for transcatheter aortic valve implantation.</p>
<p>Article number four. Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. This retrospective, propensity score-matched cohort study utilized the TriNetX database to provide real-world evidence comparing nonsteroidal and steroidal mineralocorticoid receptor antagonists in heart failure patients. The study enrolled adult patients diagnosed with heart failure who initiated either type of mineralocorticoid receptor antagonist between January 2021 and February 2025. The research demonstrated that nonsteroidal mineralocorticoid receptor antagonists, exemplified by finerenone, offer comparable or superior clinical benefits in reducing mortality and hospitalization rates in heart failure patients. This evidence expands therapeutic options for heart failure management, supporting the selection of mineralocorticoid receptor antagonists to improve patient outcomes in a real-world setting.</p>
<p>Article number five. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. This analysis of the VOYAGER P.A.D. trial data evaluated the efficacy and safety of rivaroxaban 2.5 milligrams twice daily in patients with peripheral artery disease after revascularization, specifically focusing on &#8220;worst events&#8221; and net clinical outcomes. The study affirmed rivaroxaban&#8217;s benefit in reducing major thrombotic vascular events, building upon the initial finding of a reduced first event in a composite endpoint. It further clarified rivaroxaban&#8217;s impact on a spectrum of adverse events, demonstrating an improved overall patient safety and efficacy profile. This comprehensive assessment solidifies rivaroxaban&#8217;s role as a vital adjunct to antiplatelet therapy, substantially improving long-term outcomes and reducing re-interventions for peripheral artery disease patients post-revascularization. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>genetic diagnosis, mineralocorticoid receptor antagonists, hospitalization, N-terminal pro-B-type natriuretic peptide, hypertrophic cardiomyopathy, ischemic stroke, South Asian Indian, Black adults, rivaroxaban, atrial fibrillation, heart failure, ClinGen, genetic variants, thrombotic events, mortality, antiplatelet therapy, high-sensitivity cardiac troponin T, quality of life, revascularization, peripheral artery disease, P-wave indices, atrial cardiomyopathy, finerenone, transcatheter aortic valve implantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/">Nonsteroidal MRAs Improve Heart Failure Outcomes. 10/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251024_160508.mp3" length="5662345" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like genetic diagnosis and mineralocorticoid receptor antagonists. Key takeaway: Nonsteroidal MRAs Improve Heart Failure Outcomes..
Article Links:
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. (Journal of the American Heart Association)
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. (Journal of the American Heart Association)
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. (Journal of the American Heart Association)
Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. (Journal of the American Heart Association)
Article 5: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/nonsteroidal-mras-improve-heart-failure-outcomes-10-24-25/
 Featured Articles
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41133805
Summary: This prospective cohort study, involving 4900 Black adults without atrial fibrillation at baseline, investigated the relationship between electrocardiographic P-wave indices, as measures of atrial cardiomyopathy, and incident atrial fibrillation and ischemic stroke. The study found that specific P-wave indices were significantly associated with an increased risk of both developing atrial fibrillation and experiencing an ischemic stroke within this population. These findings highlight P-wave indices as valuable early prognostic markers, offering a new approach for risk stratification in Black adults who face a disproportionate burden of atrial fibrillation-related complications. This research establishes the clinical utility of these markers to guide targeted interventions and improve outcomes.
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128141
Summary: This study aimed to identify the prevalence of clinically actionable gene variants for primary hypertrophic cardiomyopathy in South Asian Indian patients, addressing existing data gaps and disparities in ancestry-specific variant interpretation. The research successfully identified distinct clinically actionable hypertrophic cardiomyopathy gene variants within this specific population, using established guidelines like the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel. These findings provide crucial genetic insights, enhancing the understanding of hypertrophic cardiomyopathy&#8217;s etiology in South Asian Indian individuals. This work is essential for improving accurate genetic diagnosis, facilitating robust risk stratification, and enabling effective cascade screening within affected South Asian Indian families, ultimately minimizing interpretation disparities and improving patient care.
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128137
Summary: This prospective observational cohort study, involving 173 patients, evaluated the prognostic utility of pre-transcatheter ao]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like genetic diagnosis and mineralocorticoid receptor antagonists. Key takeaway: Nonsteroidal MRAs Improve Heart Failure Outcomes..
Article Links:
Article 1: P-Wave Indices and the Risks of Incident Atrial Fibrillation and Ischemic Stroke in Black Adults: The Jackson Heart Study. (Journal of the American Heart Association)
Article 2: Clinically Actionable Hypertrophic Cardiomyopathy Genes in South Asian Indian Patients. (Journal of the American Heart Association)
Article 3: Utility of High-Sensitivity Cardiac Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Survival, Quality of Life, and Functional Status Changes After Transcatheter Aortic Valve Implantation. (Journal of the American Heart Association)
Article 4: Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. (]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Exosomes Restore Injured Myocardium: Mechanisms 10/24/25</title>
	<link>https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/</link>
	<pubDate>Fri, 24 Oct 2025 14:36:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like N-terminal pro-B-type natriuretic peptide and myocardial infarction. Key takeaway: Exosomes Restore Injured Myocardium: Mechanisms.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41128147">Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41128146">Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41128145">Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41128144">Seizures in Infants With Congenital Heart Disease: A National Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41128142">Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/">https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128147</a></p>
<p><strong>Summary:</strong> This prospective cohort study investigated the association between free fatty acid (F.F.A.) levels and long-term major adverse cardiovascular events (M.A.C.E.) in 1168 patients with premature myocardial infarction. The research aimed to establish the independent prognostic value of free fatty acids and their combined effects with inflammatory markers, obesity, and insulin resistance on patient outcomes. By evaluating these factors, the study provides a foundation for understanding the role of metabolic markers in risk stratification after premature myocardial infarction. This information is crucial for identifying patients at higher risk and potentially informing future therapeutic strategies.</p>
<h4>Article 2: Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128146" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128146</a></p>
<p><strong>Summary:</strong> This study investigated the clinical characteristics and changes in N-terminal pro-B-type natriuretic peptide (N.T.-proB.N.P.) levels within heart failure with preserved ejection fraction (HeF.pEF) patients presenting with lower than expected natriuretic peptide levels. Using data from the S.U.P.P.O.R.T. (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, the research aimed to characterize this specific subgroup. Understanding these characteristics is vital for recognizing patients with mild N.T.-proB.N.P. elevations, which is emphasized in recent heart failure guidelines. This provides crucial information for accurate diagnosis and tailored management strategies for a challenging heart failure phenotype.</p>
<h4>Article 3: Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128145" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128145</a></p>
<p><strong>Summary:</strong> This study investigated the molecular mechanisms through which exosomes derived from human induced pluripotent stem cell-cardiomyocytes (i.P.S.C.-cardiomyocytes) and mesenchymal stem cells (M.S.C.s) contribute to restoring injured myocardium. Using a porcine ischemia-reperfusion injury model, the research identified shared and distinct effects of induced pluripotent stem cell-cardiomyocyte exosomes (i.C.M.-Exo) and mesenchymal stem cell exosomes (M.S.C.-Exo). The findings advance the understanding of how both types of exosomes improve cardiac function. This mechanistic insight is critical for developing more targeted and effective exosome-based regenerative therapies for myocardial repair.</p>
<h4>Article 4: Seizures in Infants With Congenital Heart Disease: A National Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128144" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128144</a></p>
<p><strong>Summary:</strong> This national cohort study analyzed the incidence, clinical characteristics, and outcomes of seizures in infants with congenital heart disease (C.H.D.). Utilizing the U.S. National Inpatient Sample Database from 2016 to 2020, the study compared demographics and clinical outcomes between congenital heart disease infants with and without seizures, after excluding specific confounding factors. The research established that infants with congenital heart disease have an increased risk of seizures. These findings are crucial for enhancing vigilance, early detection, and tailored management strategies to improve neurological outcomes in this vulnerable pediatric population.</p>
<h4>Article 5: Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128142" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128142</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between early childhood sociodemographic factors and preadolescent cardiovascular health (C.V.H.) in a cohort of low-income and racially and ethnically diverse children. Using secondary data from the N.E.T.-Works (Now Everybody Together for Amazing and Healthful Kids) randomized controlled trials, the research applied the American Heart Association Life&#8217;s Essential 8 metrics to assess cardiovascular health. The study established significant associations between early-life social determinants of health and subsequent cardiovascular health trajectories. These findings highlight the critical importance of early interventions addressing social and environmental factors to promote optimal long-term cardiovascular well-being in vulnerable pediatric populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study. This prospective cohort study investigated the association between free fatty acid (F.F.A.) levels and long-term major adverse cardiovascular events (M.A.C.E.) in 1168 patients with premature myocardial infarction. The research aimed to establish the independent prognostic value of free fatty acids and their combined effects with inflammatory markers, obesity, and insulin resistance on patient outcomes. By evaluating these factors, the study provides a foundation for understanding the role of metabolic markers in risk stratification after premature myocardial infarction. This information is crucial for identifying patients at higher risk and potentially informing future therapeutic strategies.</p>
<p>Article number two. Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels. This study investigated the clinical characteristics and changes in N-terminal pro-B-type natriuretic peptide (N.T.-proB.N.P.) levels within heart failure with preserved ejection fraction (HeF.pEF) patients presenting with lower than expected natriuretic peptide levels. Using data from the S.U.P.P.O.R.T. (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, the research aimed to characterize this specific subgroup. Understanding these characteristics is vital for recognizing patients with mild N.T.-proB.N.P. elevations, which is emphasized in recent heart failure guidelines. This provides crucial information for accurate diagnosis and tailored management strategies for a challenging heart failure phenotype.</p>
<p>Article number three. Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium. This study investigated the molecular mechanisms through which exosomes derived from human induced pluripotent stem cell-cardiomyocytes (i.P.S.C.-cardiomyocytes) and mesenchymal stem cells (M.S.C.s) contribute to restoring injured myocardium. Using a porcine ischemia-reperfusion injury model, the research identified shared and distinct effects of induced pluripotent stem cell-cardiomyocyte exosomes (i.C.M.-Exo) and mesenchymal stem cell exosomes (M.S.C.-Exo). The findings advance the understanding of how both types of exosomes improve cardiac function. This mechanistic insight is critical for developing more targeted and effective exosome-based regenerative therapies for myocardial repair.</p>
<p>Article number four. Seizures in Infants With Congenital Heart Disease: A National Cohort Study. This national cohort study analyzed the incidence, clinical characteristics, and outcomes of seizures in infants with congenital heart disease (C.H.D.). Utilizing the U.S. National Inpatient Sample Database from 2016 to 2020, the study compared demographics and clinical outcomes between congenital heart disease infants with and without seizures, after excluding specific confounding factors. The research established that infants with congenital heart disease have an increased risk of seizures. These findings are crucial for enhancing vigilance, early detection, and tailored management strategies to improve neurological outcomes in this vulnerable pediatric population.</p>
<p>Article number five. Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children. This study investigated the relationship between early childhood sociodemographic factors and preadolescent cardiovascular health (C.V.H.) in a cohort of low-income and racially and ethnically diverse children. Using secondary data from the N.E.T.-Works (Now Everybody Together for Amazing and Healthful Kids) randomized controlled trials, the research applied the American Heart Association Life&#8217;s Essential 8 metrics to assess cardiovascular health. The study established significant associations between early-life social determinants of health and subsequent cardiovascular health trajectories. These findings highlight the critical importance of early interventions addressing social and environmental factors to promote optimal long-term cardiovascular well-being in vulnerable pediatric populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>N-terminal pro-B-type natriuretic peptide, myocardial infarction, low-income children, infants, congenital heart disease, prognosis, neurological outcomes, major adverse cardiovascular events, mesenchymal stem cells, myocardial repair, natriuretic peptide, national inpatient sample, social determinants of health, ischemia-reperfusion injury, induced pluripotent stem cell-cardiomyocytes, preadolescence, free fatty acids, heart failure with preserved ejection fraction, seizures, S.U.P.P.O.R.T. trial, cardiac function, exosomes, cardiovascular health, heart failure diagnosis, premature myocardial infarction, sociodemographic factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/">Exosomes Restore Injured Myocardium: Mechanisms 10/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like N-terminal pro-B-type natriuretic peptide and myocardial infarction. Key takeaway: Exosomes Restore Injured Myocardium: Mechanisms.
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like N-terminal pro-B-type natriuretic peptide and myocardial infarction. Key takeaway: Exosomes Restore Injured Myocardium: Mechanisms.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41128147">Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41128146">Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41128145">Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41128144">Seizures in Infants With Congenital Heart Disease: A National Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41128142">Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/">https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128147" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128147</a></p>
<p><strong>Summary:</strong> This prospective cohort study investigated the association between free fatty acid (F.F.A.) levels and long-term major adverse cardiovascular events (M.A.C.E.) in 1168 patients with premature myocardial infarction. The research aimed to establish the independent prognostic value of free fatty acids and their combined effects with inflammatory markers, obesity, and insulin resistance on patient outcomes. By evaluating these factors, the study provides a foundation for understanding the role of metabolic markers in risk stratification after premature myocardial infarction. This information is crucial for identifying patients at higher risk and potentially informing future therapeutic strategies.</p>
<h4>Article 2: Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128146" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128146</a></p>
<p><strong>Summary:</strong> This study investigated the clinical characteristics and changes in N-terminal pro-B-type natriuretic peptide (N.T.-proB.N.P.) levels within heart failure with preserved ejection fraction (HeF.pEF) patients presenting with lower than expected natriuretic peptide levels. Using data from the S.U.P.P.O.R.T. (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, the research aimed to characterize this specific subgroup. Understanding these characteristics is vital for recognizing patients with mild N.T.-proB.N.P. elevations, which is emphasized in recent heart failure guidelines. This provides crucial information for accurate diagnosis and tailored management strategies for a challenging heart failure phenotype.</p>
<h4>Article 3: Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128145" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128145</a></p>
<p><strong>Summary:</strong> This study investigated the molecular mechanisms through which exosomes derived from human induced pluripotent stem cell-cardiomyocytes (i.P.S.C.-cardiomyocytes) and mesenchymal stem cells (M.S.C.s) contribute to restoring injured myocardium. Using a porcine ischemia-reperfusion injury model, the research identified shared and distinct effects of induced pluripotent stem cell-cardiomyocyte exosomes (i.C.M.-Exo) and mesenchymal stem cell exosomes (M.S.C.-Exo). The findings advance the understanding of how both types of exosomes improve cardiac function. This mechanistic insight is critical for developing more targeted and effective exosome-based regenerative therapies for myocardial repair.</p>
<h4>Article 4: Seizures in Infants With Congenital Heart Disease: A National Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128144" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128144</a></p>
<p><strong>Summary:</strong> This national cohort study analyzed the incidence, clinical characteristics, and outcomes of seizures in infants with congenital heart disease (C.H.D.). Utilizing the U.S. National Inpatient Sample Database from 2016 to 2020, the study compared demographics and clinical outcomes between congenital heart disease infants with and without seizures, after excluding specific confounding factors. The research established that infants with congenital heart disease have an increased risk of seizures. These findings are crucial for enhancing vigilance, early detection, and tailored management strategies to improve neurological outcomes in this vulnerable pediatric population.</p>
<h4>Article 5: Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128142" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128142</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between early childhood sociodemographic factors and preadolescent cardiovascular health (C.V.H.) in a cohort of low-income and racially and ethnically diverse children. Using secondary data from the N.E.T.-Works (Now Everybody Together for Amazing and Healthful Kids) randomized controlled trials, the research applied the American Heart Association Life&#8217;s Essential 8 metrics to assess cardiovascular health. The study established significant associations between early-life social determinants of health and subsequent cardiovascular health trajectories. These findings highlight the critical importance of early interventions addressing social and environmental factors to promote optimal long-term cardiovascular well-being in vulnerable pediatric populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study. This prospective cohort study investigated the association between free fatty acid (F.F.A.) levels and long-term major adverse cardiovascular events (M.A.C.E.) in 1168 patients with premature myocardial infarction. The research aimed to establish the independent prognostic value of free fatty acids and their combined effects with inflammatory markers, obesity, and insulin resistance on patient outcomes. By evaluating these factors, the study provides a foundation for understanding the role of metabolic markers in risk stratification after premature myocardial infarction. This information is crucial for identifying patients at higher risk and potentially informing future therapeutic strategies.</p>
<p>Article number two. Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels. This study investigated the clinical characteristics and changes in N-terminal pro-B-type natriuretic peptide (N.T.-proB.N.P.) levels within heart failure with preserved ejection fraction (HeF.pEF) patients presenting with lower than expected natriuretic peptide levels. Using data from the S.U.P.P.O.R.T. (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, the research aimed to characterize this specific subgroup. Understanding these characteristics is vital for recognizing patients with mild N.T.-proB.N.P. elevations, which is emphasized in recent heart failure guidelines. This provides crucial information for accurate diagnosis and tailored management strategies for a challenging heart failure phenotype.</p>
<p>Article number three. Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium. This study investigated the molecular mechanisms through which exosomes derived from human induced pluripotent stem cell-cardiomyocytes (i.P.S.C.-cardiomyocytes) and mesenchymal stem cells (M.S.C.s) contribute to restoring injured myocardium. Using a porcine ischemia-reperfusion injury model, the research identified shared and distinct effects of induced pluripotent stem cell-cardiomyocyte exosomes (i.C.M.-Exo) and mesenchymal stem cell exosomes (M.S.C.-Exo). The findings advance the understanding of how both types of exosomes improve cardiac function. This mechanistic insight is critical for developing more targeted and effective exosome-based regenerative therapies for myocardial repair.</p>
<p>Article number four. Seizures in Infants With Congenital Heart Disease: A National Cohort Study. This national cohort study analyzed the incidence, clinical characteristics, and outcomes of seizures in infants with congenital heart disease (C.H.D.). Utilizing the U.S. National Inpatient Sample Database from 2016 to 2020, the study compared demographics and clinical outcomes between congenital heart disease infants with and without seizures, after excluding specific confounding factors. The research established that infants with congenital heart disease have an increased risk of seizures. These findings are crucial for enhancing vigilance, early detection, and tailored management strategies to improve neurological outcomes in this vulnerable pediatric population.</p>
<p>Article number five. Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children. This study investigated the relationship between early childhood sociodemographic factors and preadolescent cardiovascular health (C.V.H.) in a cohort of low-income and racially and ethnically diverse children. Using secondary data from the N.E.T.-Works (Now Everybody Together for Amazing and Healthful Kids) randomized controlled trials, the research applied the American Heart Association Life&#8217;s Essential 8 metrics to assess cardiovascular health. The study established significant associations between early-life social determinants of health and subsequent cardiovascular health trajectories. These findings highlight the critical importance of early interventions addressing social and environmental factors to promote optimal long-term cardiovascular well-being in vulnerable pediatric populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>N-terminal pro-B-type natriuretic peptide, myocardial infarction, low-income children, infants, congenital heart disease, prognosis, neurological outcomes, major adverse cardiovascular events, mesenchymal stem cells, myocardial repair, natriuretic peptide, national inpatient sample, social determinants of health, ischemia-reperfusion injury, induced pluripotent stem cell-cardiomyocytes, preadolescence, free fatty acids, heart failure with preserved ejection fraction, seizures, S.U.P.P.O.R.T. trial, cardiac function, exosomes, cardiovascular health, heart failure diagnosis, premature myocardial infarction, sociodemographic factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/">Exosomes Restore Injured Myocardium: Mechanisms 10/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251024_103343.mp3" length="5108967" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like N-terminal pro-B-type natriuretic peptide and myocardial infarction. Key takeaway: Exosomes Restore Injured Myocardium: Mechanisms.
Article Links:
Article 1: Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study. (Journal of the American Heart Association)
Article 2: Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels. (Journal of the American Heart Association)
Article 3: Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium. (Journal of the American Heart Association)
Article 4: Seizures in Infants With Congenital Heart Disease: A National Cohort Study. (Journal of the American Heart Association)
Article 5: Early-Life Sociodemographic Factors and Cardiovascular Health in Preadolescence Among Low-Income and Racially and Ethnically Diverse Children. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/exosomes-restore-injured-myocardium-mechanisms-10-24-25/
 Featured Articles
Article 1: Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128147
Summary: This prospective cohort study investigated the association between free fatty acid (F.F.A.) levels and long-term major adverse cardiovascular events (M.A.C.E.) in 1168 patients with premature myocardial infarction. The research aimed to establish the independent prognostic value of free fatty acids and their combined effects with inflammatory markers, obesity, and insulin resistance on patient outcomes. By evaluating these factors, the study provides a foundation for understanding the role of metabolic markers in risk stratification after premature myocardial infarction. This information is crucial for identifying patients at higher risk and potentially informing future therapeutic strategies.
Article 2: Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128146
Summary: This study investigated the clinical characteristics and changes in N-terminal pro-B-type natriuretic peptide (N.T.-proB.N.P.) levels within heart failure with preserved ejection fraction (HeF.pEF) patients presenting with lower than expected natriuretic peptide levels. Using data from the S.U.P.P.O.R.T. (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, the research aimed to characterize this specific subgroup. Understanding these characteristics is vital for recognizing patients with mild N.T.-proB.N.P. elevations, which is emphasized in recent heart failure guidelines. This provides crucial information for accurate diagnosis and tailored management strategies for a challenging heart failure phenotype.
Article 3: Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128145
Summary: This study investigated the molecular mechanisms through which exosomes derived from human induced pluripotent stem cell-cardiomyocytes (i.P.S.C.-cardiomyocytes) and mesenchymal stem cells (M.S.C.s) contribute to restoring injured myocardium. Using a porcine ischemia-reperfusion injury model, the research identified shared and distinct effects of induced pluripotent stem cell-cardiomyocyte exos]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like N-terminal pro-B-type natriuretic peptide and myocardial infarction. Key takeaway: Exosomes Restore Injured Myocardium: Mechanisms.
Article Links:
Article 1: Association of Free Fatty Acids With Long-Term Adverse Outcomes in Patients With Premature Myocardial Infarction: A Prospective Cohort Study. (Journal of the American Heart Association)
Article 2: Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels. (Journal of the American Heart Association)
Article 3: Molecular Mechanisms of Exosomes From Human iPSC-Cardiomyocytes and Mesenchymal Stem Cells in Restoring the Injured Myocardium. (Journal of the American Heart Association)
Article 4: Seizures in Infants With Congenital Heart Disease: A National Cohort Study. (Journal of the American Heart Association)
Article 5: Early-Lif]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Minor Stroke: When to Use D.A.P.T. vs. Alteplase 10/24/25</title>
	<link>https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/</link>
	<pubDate>Fri, 24 Oct 2025 06:58:16 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like peri-operative complications and low-density lipoprotein cholesterol. Key takeaway: Minor Stroke: When to Use D.A.P.T. vs. Alteplase.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41128016">Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41127896">LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41127893">Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41126578">Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41128284">Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/">https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128016" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128016</a></p>
<p><strong>Summary:</strong> Endothelial to Mesenchymal Transition is a crucial process where endothelial cells transform into mesenchymal-like cells, contributing to structures like smooth muscle cells, osteoblasts, fibroblasts, or chondrocytes. This review establishes Endothelial to Mesenchymal Transition&#8217;s foundational role in embryonic heart development, particularly in forming cardiac valves from endocardial cushions. More recently, the process has been identified in various adult cardiovascular diseases, highlighting its significance beyond development. Elucidating the molecular mechanisms of Endothelial to Mesenchymal Transition offers potential therapeutic avenues for adult cardiovascular pathologies.</p>
<h4>Article 2: LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41127896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41127896</a></p>
<p><strong>Summary:</strong> This study investigated the efficacy of cholesterol-based screening for Familial Hypercholesterolaemia in newborns and children using genetically verified cases from a Norwegian national cascade screening program. Researchers collected low-density lipoprotein cholesterol levels from umbilical cord blood in 113 newborns and venous blood in children with confirmed Familial Hypercholesterolaemia between 1998 and 2023. The findings assess the potential of cholesterol-based screening to efficiently identify Familial Hypercholesterolaemia in pediatric populations. This research directly supports the development of universal screening approaches for early detection and management of this genetic condition.</p>
<h4>Article 3: Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41127893" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41127893</a></p>
<p><strong>Summary:</strong> The EuroFontan registry, a multicentre retrospective study across 21 European congenital heart disease and transplant centers, evaluated early outcomes and peri-operative complications in children undergoing Fontan completion for univentricular circulation. This comprehensive study highlights that while the Fontan operation has significantly advanced the management of functional single ventricle physiology, peri-operative complications remain a notable concern. The findings provide critical insights into the real-world challenges and outcomes following this complex cardiac surgery in a large international cohort. This data is invaluable for refining current surgical protocols and improving post-operative care strategies to enhance patient survival and quality of life.</p>
<h4>Article 4: Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41126578" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41126578</a></p>
<p><strong>Summary:</strong> The Global Registries and Surveys Programme-Heart Failure (G.R.A.S.P.-H.F.) is a pan-European, snapshot, observational study designed to evaluate the real-world implementation of evidence-based Heart Failure therapies. This paper details the rationale and study design for G.R.A.S.P.-H.F., aiming to identify existing gaps between guideline recommendations and actual clinical practice. By assessing the uptake of advanced pharmacologic and device-based treatments, the program provides a critical framework for understanding barriers to optimal Heart Failure management. Ultimately, G.R.A.S.P.-H.F. will inform strategies to improve patient outcomes by ensuring more consistent translation of research findings into routine clinical care.</p>
<h4>Article 5: Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128284" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128284</a></p>
<p><strong>Summary:</strong> This prespecified secondary analysis of the ARAMIS trial investigated whether onset-to-treatment time modifies the effect of dual antiplatelet therapy versus intravenous alteplase on early neurological deterioration in acute minor nondisabling ischemic stroke. The ARAMIS trial previously demonstrated that dual antiplatelet therapy is noninferior to alteplase for these patients. This specific analysis, using the as-treated population, aimed to delineate the time-dependent efficacy of these interventions. The findings provide critical guidance for optimizing treatment timing and selection, offering improved strategies to mitigate early neurological deterioration in patients presenting with minor ischemic stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives. Endothelial to Mesenchymal Transition is a crucial process where endothelial cells transform into mesenchymal-like cells, contributing to structures like smooth muscle cells, osteoblasts, fibroblasts, or chondrocytes. This review establishes Endothelial to Mesenchymal Transition&#8217;s foundational role in embryonic heart development, particularly in forming cardiac valves from endocardial cushions. More recently, the process has been identified in various adult cardiovascular diseases, highlighting its significance beyond development. Elucidating the molecular mechanisms of Endothelial to Mesenchymal Transition offers potential therapeutic avenues for adult cardiovascular pathologies.</p>
<p>Article number two. L.D.L.-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening. This study investigated the efficacy of cholesterol-based screening for Familial Hypercholesterolaemia in newborns and children using genetically verified cases from a Norwegian national cascade screening program. Researchers collected low-density lipoprotein cholesterol levels from umbilical cord blood in 113 newborns and venous blood in children with confirmed Familial Hypercholesterolaemia between 1998 and 2023. The findings assess the potential of cholesterol-based screening to efficiently identify Familial Hypercholesterolaemia in pediatric populations. This research directly supports the development of universal screening approaches for early detection and management of this genetic condition.</p>
<p>Article number three. Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry. The EuroFontan registry, a multicentre retrospective study across 21 European congenital heart disease and transplant centers, evaluated early outcomes and peri-operative complications in children undergoing Fontan completion for univentricular circulation. This comprehensive study highlights that while the Fontan operation has significantly advanced the management of functional single ventricle physiology, peri-operative complications remain a notable concern. The findings provide critical insights into the real-world challenges and outcomes following this complex cardiac surgery in a large international cohort. This data is invaluable for refining current surgical protocols and improving post-operative care strategies to enhance patient survival and quality of life.</p>
<p>Article number four. Global Registries and Surveys Programme-Heart Failure (G.R.A.S.P.-H.F.): Rationale, study design and research implications. The Global Registries and Surveys Programme-Heart Failure (G.R.A.S.P.-H.F.) is a pan-European, snapshot, observational study designed to evaluate the real-world implementation of evidence-based Heart Failure therapies. This paper details the rationale and study design for G.R.A.S.P.-H.F., aiming to identify existing gaps between guideline recommendations and actual clinical practice. By assessing the uptake of advanced pharmacologic and device-based treatments, the program provides a critical framework for understanding barriers to optimal Heart Failure management. Ultimately, G.R.A.S.P.-H.F. will inform strategies to improve patient outcomes by ensuring more consistent translation of research findings into routine clinical care.</p>
<p>Article number five. Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke. This prespecified secondary analysis of the ARAMIS trial investigated whether onset-to-treatment time modifies the effect of dual antiplatelet therapy versus intravenous alteplase on early neurological deterioration in acute minor nondisabling ischemic stroke. The ARAMIS trial previously demonstrated that dual antiplatelet therapy is noninferior to alteplase for these patients. This specific analysis, using the as-treated population, aimed to delineate the time-dependent efficacy of these interventions. The findings provide critical guidance for optimizing treatment timing and selection, offering improved strategies to mitigate early neurological deterioration in patients presenting with minor ischemic stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>peri-operative complications, low-density lipoprotein cholesterol, endothelial cells, mesenchymal cells, pediatric cardiology, genetic testing, cardiovascular diseases, minor ischemic stroke, Familial Hypercholesterolaemia, onset-to-treatment time, guideline adherence, clinical practice, real-world data, early neurological deterioration, dual antiplatelet therapy, univentricular circulation, endothelial to mesenchymal transition, alteplase, congenital heart disease, newborn screening, Heart Failure, EuroFontan registry, observational study, Fontan operation, cardiac valves.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/">Minor Stroke: When to Use D.A.P.T. vs. Alteplase 10/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like peri-operative complications and low-density lipoprotein cholesterol. Key takeaway: Minor Stroke: When to Use D.A.P.T. vs. Alteplase.]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like peri-operative complications and low-density lipoprotein cholesterol. Key takeaway: Minor Stroke: When to Use D.A.P.T. vs. Alteplase.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41128016">Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41127896">LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41127893">Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41126578">Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41128284">Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/">https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128016" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128016</a></p>
<p><strong>Summary:</strong> Endothelial to Mesenchymal Transition is a crucial process where endothelial cells transform into mesenchymal-like cells, contributing to structures like smooth muscle cells, osteoblasts, fibroblasts, or chondrocytes. This review establishes Endothelial to Mesenchymal Transition&#8217;s foundational role in embryonic heart development, particularly in forming cardiac valves from endocardial cushions. More recently, the process has been identified in various adult cardiovascular diseases, highlighting its significance beyond development. Elucidating the molecular mechanisms of Endothelial to Mesenchymal Transition offers potential therapeutic avenues for adult cardiovascular pathologies.</p>
<h4>Article 2: LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41127896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41127896</a></p>
<p><strong>Summary:</strong> This study investigated the efficacy of cholesterol-based screening for Familial Hypercholesterolaemia in newborns and children using genetically verified cases from a Norwegian national cascade screening program. Researchers collected low-density lipoprotein cholesterol levels from umbilical cord blood in 113 newborns and venous blood in children with confirmed Familial Hypercholesterolaemia between 1998 and 2023. The findings assess the potential of cholesterol-based screening to efficiently identify Familial Hypercholesterolaemia in pediatric populations. This research directly supports the development of universal screening approaches for early detection and management of this genetic condition.</p>
<h4>Article 3: Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41127893" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41127893</a></p>
<p><strong>Summary:</strong> The EuroFontan registry, a multicentre retrospective study across 21 European congenital heart disease and transplant centers, evaluated early outcomes and peri-operative complications in children undergoing Fontan completion for univentricular circulation. This comprehensive study highlights that while the Fontan operation has significantly advanced the management of functional single ventricle physiology, peri-operative complications remain a notable concern. The findings provide critical insights into the real-world challenges and outcomes following this complex cardiac surgery in a large international cohort. This data is invaluable for refining current surgical protocols and improving post-operative care strategies to enhance patient survival and quality of life.</p>
<h4>Article 4: Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41126578" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41126578</a></p>
<p><strong>Summary:</strong> The Global Registries and Surveys Programme-Heart Failure (G.R.A.S.P.-H.F.) is a pan-European, snapshot, observational study designed to evaluate the real-world implementation of evidence-based Heart Failure therapies. This paper details the rationale and study design for G.R.A.S.P.-H.F., aiming to identify existing gaps between guideline recommendations and actual clinical practice. By assessing the uptake of advanced pharmacologic and device-based treatments, the program provides a critical framework for understanding barriers to optimal Heart Failure management. Ultimately, G.R.A.S.P.-H.F. will inform strategies to improve patient outcomes by ensuring more consistent translation of research findings into routine clinical care.</p>
<h4>Article 5: Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41128284" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41128284</a></p>
<p><strong>Summary:</strong> This prespecified secondary analysis of the ARAMIS trial investigated whether onset-to-treatment time modifies the effect of dual antiplatelet therapy versus intravenous alteplase on early neurological deterioration in acute minor nondisabling ischemic stroke. The ARAMIS trial previously demonstrated that dual antiplatelet therapy is noninferior to alteplase for these patients. This specific analysis, using the as-treated population, aimed to delineate the time-dependent efficacy of these interventions. The findings provide critical guidance for optimizing treatment timing and selection, offering improved strategies to mitigate early neurological deterioration in patients presenting with minor ischemic stroke.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives. Endothelial to Mesenchymal Transition is a crucial process where endothelial cells transform into mesenchymal-like cells, contributing to structures like smooth muscle cells, osteoblasts, fibroblasts, or chondrocytes. This review establishes Endothelial to Mesenchymal Transition&#8217;s foundational role in embryonic heart development, particularly in forming cardiac valves from endocardial cushions. More recently, the process has been identified in various adult cardiovascular diseases, highlighting its significance beyond development. Elucidating the molecular mechanisms of Endothelial to Mesenchymal Transition offers potential therapeutic avenues for adult cardiovascular pathologies.</p>
<p>Article number two. L.D.L.-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening. This study investigated the efficacy of cholesterol-based screening for Familial Hypercholesterolaemia in newborns and children using genetically verified cases from a Norwegian national cascade screening program. Researchers collected low-density lipoprotein cholesterol levels from umbilical cord blood in 113 newborns and venous blood in children with confirmed Familial Hypercholesterolaemia between 1998 and 2023. The findings assess the potential of cholesterol-based screening to efficiently identify Familial Hypercholesterolaemia in pediatric populations. This research directly supports the development of universal screening approaches for early detection and management of this genetic condition.</p>
<p>Article number three. Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry. The EuroFontan registry, a multicentre retrospective study across 21 European congenital heart disease and transplant centers, evaluated early outcomes and peri-operative complications in children undergoing Fontan completion for univentricular circulation. This comprehensive study highlights that while the Fontan operation has significantly advanced the management of functional single ventricle physiology, peri-operative complications remain a notable concern. The findings provide critical insights into the real-world challenges and outcomes following this complex cardiac surgery in a large international cohort. This data is invaluable for refining current surgical protocols and improving post-operative care strategies to enhance patient survival and quality of life.</p>
<p>Article number four. Global Registries and Surveys Programme-Heart Failure (G.R.A.S.P.-H.F.): Rationale, study design and research implications. The Global Registries and Surveys Programme-Heart Failure (G.R.A.S.P.-H.F.) is a pan-European, snapshot, observational study designed to evaluate the real-world implementation of evidence-based Heart Failure therapies. This paper details the rationale and study design for G.R.A.S.P.-H.F., aiming to identify existing gaps between guideline recommendations and actual clinical practice. By assessing the uptake of advanced pharmacologic and device-based treatments, the program provides a critical framework for understanding barriers to optimal Heart Failure management. Ultimately, G.R.A.S.P.-H.F. will inform strategies to improve patient outcomes by ensuring more consistent translation of research findings into routine clinical care.</p>
<p>Article number five. Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke. This prespecified secondary analysis of the ARAMIS trial investigated whether onset-to-treatment time modifies the effect of dual antiplatelet therapy versus intravenous alteplase on early neurological deterioration in acute minor nondisabling ischemic stroke. The ARAMIS trial previously demonstrated that dual antiplatelet therapy is noninferior to alteplase for these patients. This specific analysis, using the as-treated population, aimed to delineate the time-dependent efficacy of these interventions. The findings provide critical guidance for optimizing treatment timing and selection, offering improved strategies to mitigate early neurological deterioration in patients presenting with minor ischemic stroke. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>peri-operative complications, low-density lipoprotein cholesterol, endothelial cells, mesenchymal cells, pediatric cardiology, genetic testing, cardiovascular diseases, minor ischemic stroke, Familial Hypercholesterolaemia, onset-to-treatment time, guideline adherence, clinical practice, real-world data, early neurological deterioration, dual antiplatelet therapy, univentricular circulation, endothelial to mesenchymal transition, alteplase, congenital heart disease, newborn screening, Heart Failure, EuroFontan registry, observational study, Fontan operation, cardiac valves.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/">Minor Stroke: When to Use D.A.P.T. vs. Alteplase 10/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251024_025659.mp3" length="4955576" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like peri-operative complications and low-density lipoprotein cholesterol. Key takeaway: Minor Stroke: When to Use D.A.P.T. vs. Alteplase.
Article Links:
Article 1: Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives. (European heart journal)
Article 2: LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening. (European heart journal)
Article 3: Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry. (European heart journal)
Article 4: Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications. (European journal of heart failure)
Article 5: Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/minor-stroke-when-to-use-d-a-p-t-vs-alteplase-10-24-25/
 Featured Articles
Article 1: Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128016
Summary: Endothelial to Mesenchymal Transition is a crucial process where endothelial cells transform into mesenchymal-like cells, contributing to structures like smooth muscle cells, osteoblasts, fibroblasts, or chondrocytes. This review establishes Endothelial to Mesenchymal Transition&#8217;s foundational role in embryonic heart development, particularly in forming cardiac valves from endocardial cushions. More recently, the process has been identified in various adult cardiovascular diseases, highlighting its significance beyond development. Elucidating the molecular mechanisms of Endothelial to Mesenchymal Transition offers potential therapeutic avenues for adult cardiovascular pathologies.
Article 2: LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41127896
Summary: This study investigated the efficacy of cholesterol-based screening for Familial Hypercholesterolaemia in newborns and children using genetically verified cases from a Norwegian national cascade screening program. Researchers collected low-density lipoprotein cholesterol levels from umbilical cord blood in 113 newborns and venous blood in children with confirmed Familial Hypercholesterolaemia between 1998 and 2023. The findings assess the potential of cholesterol-based screening to efficiently identify Familial Hypercholesterolaemia in pediatric populations. This research directly supports the development of universal screening approaches for early detection and management of this genetic condition.
Article 3: Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41127893
Summary: The EuroFontan registry, a multicentre retrospective study across 21 European congenital heart disease and transplant centers, evaluated early outcomes and peri-operative complications in children undergoing Fontan completion for univentricular circulation. This comprehensive study highlights that while the Fontan operation has significantly advanced the management of functional single ventricle physiology, peri-operative complications remain a notable concern. The findings provide critical insights into the real-world challenges and outcomes following this complex cardiac surgery in a large international cohort. This data is invaluable for refining current surgical protocols]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 24, 2025. This episode summarizes 5 key cardiology studies on topics like peri-operative complications and low-density lipoprotein cholesterol. Key takeaway: Minor Stroke: When to Use D.A.P.T. vs. Alteplase.
Article Links:
Article 1: Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives. (European heart journal)
Article 2: LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening. (European heart journal)
Article 3: Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry. (European heart journal)
Article 4: Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications. (European journal of heart failure)
Article 5: Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplate]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Gestational Diabetes Harms Heart Function 10/23/25</title>
	<link>https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/</link>
	<pubDate>Thu, 23 Oct 2025 10:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like lipid-lowering therapy and stroke risk. Key takeaway: Gestational Diabetes Harms Heart Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41125330">Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41120814">Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41120813">Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41120812">Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41120811">Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/">https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41125330" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41125330</a></p>
<p><strong>Summary:</strong> This comprehensive national cohort study evaluated outcomes for all detected structural congenital heart disease cases in England, from fetal diagnosis through the first year of life. By linking national registries, researchers established an incident cohort to better quantify disease burden, including cases without cardiac intervention, which are often underestimated. This methodology provides a more accurate understanding of congenital heart disease prevalence and outcomes from birth to infancy, informing public health strategies and resource allocation.</p>
<h4>Article 2: Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120814" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120814</a></p>
<p><strong>Summary:</strong> This study explored the utility of artificial intelligence in supporting clinical trials by developing a customized Generative Pretrained Transformer. Researchers implemented this customized G.P.T. within the Sleep S.M.A.R.T. (Sleep for Stroke Management and Recovery Trial) to provide real-time answers to procedure-related questions for clinical trial sites. The successful deployment of this A.I. tool demonstrates its potential to enhance efficiency and accelerate large-scale randomized controlled trials by rapidly addressing protocol and procedure queries.</p>
<h4>Article 3: Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120813" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120813</a></p>
<p><strong>Summary:</strong> This nationwide cohort study investigated the cardiovascular outcomes associated with statin use in patients initiating maintenance hemodialysis, stratified by their prior statin use. Utilizing a Korean health claims database, researchers employed multivariate Cox regression to assess these associations. The findings clarify the role of lipid-lowering therapy in hemodialysis-dependent chronic kidney disease, providing crucial evidence to inform guidelines that currently lack clear recommendations for this vulnerable patient population.</p>
<h4>Article 4: Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120812" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120812</a></p>
<p><strong>Summary:</strong> This study examined the association between prior gestational diabetes and postpartum subclinical myocardial dysfunction in Hispanic women, a population with a high prevalence of gestational diabetes. Researchers leveraged the Hispanic Community Study/Study of Latinos cohort to assess early stages of myocardial dysfunction, a robust predictor of future heart failure, using imaging techniques. The findings underscore that gestational diabetes is associated with detectable subclinical cardiac abnormalities, highlighting the need for early cardiovascular risk stratification and preventative strategies in affected women.</p>
<h4>Article 5: Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120811" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120811</a></p>
<p><strong>Summary:</strong> This study aimed to determine if Metabolic Syndrome is associated with the development of Moyamoya vasculopathy and subsequent stroke risk in young adults. Using a nationwide Korean database of nearly 7 million adults aged 20 to 40 years, researchers retrospectively analyzed health screening data to identify newly diagnosed cases of Moyamoya vasculopathy and strokes. The findings establish Metabolic Syndrome as a significant risk factor for Moyamoya vasculopathy and subsequent stroke in young adults, offering new insights into the etiology of this rare cerebrovascular disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy. This comprehensive national cohort study evaluated outcomes for all detected structural congenital heart disease cases in England, from fetal diagnosis through the first year of life. By linking national registries, researchers established an incident cohort to better quantify disease burden, including cases without cardiac intervention, which are often underestimated. This methodology provides a more accurate understanding of congenital heart disease prevalence and outcomes from birth to infancy, informing public health strategies and resource allocation.</p>
<p>Article number two. Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial. This study explored the utility of artificial intelligence in supporting clinical trials by developing a customized Generative Pretrained Transformer. Researchers implemented this customized G.P.T. within the Sleep S.M.A.R.T. (Sleep for Stroke Management and Recovery Trial) to provide real-time answers to procedure-related questions for clinical trial sites. The successful deployment of this A.I. tool demonstrates its potential to enhance efficiency and accelerate large-scale randomized controlled trials by rapidly addressing protocol and procedure queries.</p>
<p>Article number three. Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study. This nationwide cohort study investigated the cardiovascular outcomes associated with statin use in patients initiating maintenance hemodialysis, stratified by their prior statin use. Utilizing a Korean health claims database, researchers employed multivariate Cox regression to assess these associations. The findings clarify the role of lipid-lowering therapy in hemodialysis-dependent chronic kidney disease, providing crucial evidence to inform guidelines that currently lack clear recommendations for this vulnerable patient population.</p>
<p>Article number four. Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos. This study examined the association between prior gestational diabetes and postpartum subclinical myocardial dysfunction in Hispanic women, a population with a high prevalence of gestational diabetes. Researchers leveraged the Hispanic Community Study/Study of Latinos cohort to assess early stages of myocardial dysfunction, a robust predictor of future heart failure, using imaging techniques. The findings underscore that gestational diabetes is associated with detectable subclinical cardiac abnormalities, highlighting the need for early cardiovascular risk stratification and preventative strategies in affected women.</p>
<p>Article number five. Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults. This study aimed to determine if Metabolic Syndrome is associated with the development of Moyamoya vasculopathy and subsequent stroke risk in young adults. Using a nationwide Korean database of nearly 7 million adults aged 20 to 40 years, researchers retrospectively analyzed health screening data to identify newly diagnosed cases of Moyamoya vasculopathy and strokes. The findings establish Metabolic Syndrome as a significant risk factor for Moyamoya vasculopathy and subsequent stroke in young adults, offering new insights into the etiology of this rare cerebrovascular disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lipid-lowering therapy, stroke risk, Metabolic Syndrome, disease burden, cerebrovascular disease, national cohort, postpartum, fetal diagnosis, Moyamoya vasculopathy, chronic kidney disease, Sleep S.M.A.R.T., artificial intelligence, Hispanic women, statins, infancy, myocardial dysfunction, cardiovascular outcomes, clinical trials, congenital heart disease, hemodialysis, gestational diabetes, young adults, randomized controlled trial, heart failure, Generative Pretrained Transformer.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/">Gestational Diabetes Harms Heart Function 10/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like lipid-lowering therapy and stroke risk. Key takeaway: Gestational Diabetes Harms Heart Function.
Article Links:
Article 1: Congenital]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like lipid-lowering therapy and stroke risk. Key takeaway: Gestational Diabetes Harms Heart Function.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41125330">Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41120814">Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41120813">Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41120812">Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41120811">Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/">https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41125330" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41125330</a></p>
<p><strong>Summary:</strong> This comprehensive national cohort study evaluated outcomes for all detected structural congenital heart disease cases in England, from fetal diagnosis through the first year of life. By linking national registries, researchers established an incident cohort to better quantify disease burden, including cases without cardiac intervention, which are often underestimated. This methodology provides a more accurate understanding of congenital heart disease prevalence and outcomes from birth to infancy, informing public health strategies and resource allocation.</p>
<h4>Article 2: Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120814" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120814</a></p>
<p><strong>Summary:</strong> This study explored the utility of artificial intelligence in supporting clinical trials by developing a customized Generative Pretrained Transformer. Researchers implemented this customized G.P.T. within the Sleep S.M.A.R.T. (Sleep for Stroke Management and Recovery Trial) to provide real-time answers to procedure-related questions for clinical trial sites. The successful deployment of this A.I. tool demonstrates its potential to enhance efficiency and accelerate large-scale randomized controlled trials by rapidly addressing protocol and procedure queries.</p>
<h4>Article 3: Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120813" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120813</a></p>
<p><strong>Summary:</strong> This nationwide cohort study investigated the cardiovascular outcomes associated with statin use in patients initiating maintenance hemodialysis, stratified by their prior statin use. Utilizing a Korean health claims database, researchers employed multivariate Cox regression to assess these associations. The findings clarify the role of lipid-lowering therapy in hemodialysis-dependent chronic kidney disease, providing crucial evidence to inform guidelines that currently lack clear recommendations for this vulnerable patient population.</p>
<h4>Article 4: Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120812" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120812</a></p>
<p><strong>Summary:</strong> This study examined the association between prior gestational diabetes and postpartum subclinical myocardial dysfunction in Hispanic women, a population with a high prevalence of gestational diabetes. Researchers leveraged the Hispanic Community Study/Study of Latinos cohort to assess early stages of myocardial dysfunction, a robust predictor of future heart failure, using imaging techniques. The findings underscore that gestational diabetes is associated with detectable subclinical cardiac abnormalities, highlighting the need for early cardiovascular risk stratification and preventative strategies in affected women.</p>
<h4>Article 5: Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120811" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120811</a></p>
<p><strong>Summary:</strong> This study aimed to determine if Metabolic Syndrome is associated with the development of Moyamoya vasculopathy and subsequent stroke risk in young adults. Using a nationwide Korean database of nearly 7 million adults aged 20 to 40 years, researchers retrospectively analyzed health screening data to identify newly diagnosed cases of Moyamoya vasculopathy and strokes. The findings establish Metabolic Syndrome as a significant risk factor for Moyamoya vasculopathy and subsequent stroke in young adults, offering new insights into the etiology of this rare cerebrovascular disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy. This comprehensive national cohort study evaluated outcomes for all detected structural congenital heart disease cases in England, from fetal diagnosis through the first year of life. By linking national registries, researchers established an incident cohort to better quantify disease burden, including cases without cardiac intervention, which are often underestimated. This methodology provides a more accurate understanding of congenital heart disease prevalence and outcomes from birth to infancy, informing public health strategies and resource allocation.</p>
<p>Article number two. Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial. This study explored the utility of artificial intelligence in supporting clinical trials by developing a customized Generative Pretrained Transformer. Researchers implemented this customized G.P.T. within the Sleep S.M.A.R.T. (Sleep for Stroke Management and Recovery Trial) to provide real-time answers to procedure-related questions for clinical trial sites. The successful deployment of this A.I. tool demonstrates its potential to enhance efficiency and accelerate large-scale randomized controlled trials by rapidly addressing protocol and procedure queries.</p>
<p>Article number three. Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study. This nationwide cohort study investigated the cardiovascular outcomes associated with statin use in patients initiating maintenance hemodialysis, stratified by their prior statin use. Utilizing a Korean health claims database, researchers employed multivariate Cox regression to assess these associations. The findings clarify the role of lipid-lowering therapy in hemodialysis-dependent chronic kidney disease, providing crucial evidence to inform guidelines that currently lack clear recommendations for this vulnerable patient population.</p>
<p>Article number four. Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos. This study examined the association between prior gestational diabetes and postpartum subclinical myocardial dysfunction in Hispanic women, a population with a high prevalence of gestational diabetes. Researchers leveraged the Hispanic Community Study/Study of Latinos cohort to assess early stages of myocardial dysfunction, a robust predictor of future heart failure, using imaging techniques. The findings underscore that gestational diabetes is associated with detectable subclinical cardiac abnormalities, highlighting the need for early cardiovascular risk stratification and preventative strategies in affected women.</p>
<p>Article number five. Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults. This study aimed to determine if Metabolic Syndrome is associated with the development of Moyamoya vasculopathy and subsequent stroke risk in young adults. Using a nationwide Korean database of nearly 7 million adults aged 20 to 40 years, researchers retrospectively analyzed health screening data to identify newly diagnosed cases of Moyamoya vasculopathy and strokes. The findings establish Metabolic Syndrome as a significant risk factor for Moyamoya vasculopathy and subsequent stroke in young adults, offering new insights into the etiology of this rare cerebrovascular disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lipid-lowering therapy, stroke risk, Metabolic Syndrome, disease burden, cerebrovascular disease, national cohort, postpartum, fetal diagnosis, Moyamoya vasculopathy, chronic kidney disease, Sleep S.M.A.R.T., artificial intelligence, Hispanic women, statins, infancy, myocardial dysfunction, cardiovascular outcomes, clinical trials, congenital heart disease, hemodialysis, gestational diabetes, young adults, randomized controlled trial, heart failure, Generative Pretrained Transformer.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/">Gestational Diabetes Harms Heart Function 10/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251023_060033.mp3" length="3960833" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like lipid-lowering therapy and stroke risk. Key takeaway: Gestational Diabetes Harms Heart Function.
Article Links:
Article 1: Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy. (Heart (British Cardiac Society))
Article 2: Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial. (Journal of the American Heart Association)
Article 3: Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study. (Journal of the American Heart Association)
Article 4: Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos. (Journal of the American Heart Association)
Article 5: Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/gestational-diabetes-harms-heart-function-10-23-25/
 Featured Articles
Article 1: Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41125330
Summary: This comprehensive national cohort study evaluated outcomes for all detected structural congenital heart disease cases in England, from fetal diagnosis through the first year of life. By linking national registries, researchers established an incident cohort to better quantify disease burden, including cases without cardiac intervention, which are often underestimated. This methodology provides a more accurate understanding of congenital heart disease prevalence and outcomes from birth to infancy, informing public health strategies and resource allocation.
Article 2: Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120814
Summary: This study explored the utility of artificial intelligence in supporting clinical trials by developing a customized Generative Pretrained Transformer. Researchers implemented this customized G.P.T. within the Sleep S.M.A.R.T. (Sleep for Stroke Management and Recovery Trial) to provide real-time answers to procedure-related questions for clinical trial sites. The successful deployment of this A.I. tool demonstrates its potential to enhance efficiency and accelerate large-scale randomized controlled trials by rapidly addressing protocol and procedure queries.
Article 3: Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120813
Summary: This nationwide cohort study investigated the cardiovascular outcomes associated with statin use in patients initiating maintenance hemodialysis, stratified by their prior statin use. Utilizing a Korean health claims database, researchers employed multivariate Cox regression to assess these associations. The findings clarify the role of lipid-lowering therapy in hemodialysis-dependent chronic kidney disease, providing crucial evidence to inform guidelines that currently lack clear recommendations for this vulnerable patient population.
Article 4: Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120812
Summary: This study examined the association between prior gestational diabetes and postpartum subclinical myocardial dysfunction in Hispanic women, a population with a high prevalence of gestational diabetes. Researchers leveraged the ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like lipid-lowering therapy and stroke risk. Key takeaway: Gestational Diabetes Harms Heart Function.
Article Links:
Article 1: Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy. (Heart (British Cardiac Society))
Article 2: Use of a Generative Pretrained Transformer to Answer Questions and Facilitate a Large Randomized Controlled Trial. (Journal of the American Heart Association)
Article 3: Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study. (Journal of the American Heart Association)
Article 4: Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos. (Journal of the American Heart Association)
Article 5: Metabolic Syndrome and Risk of Moyamoya Vasculopathy and Subsequent Stroke in Young Adults. (Journa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Donor D.N.A. Detects Heart Transplant Rejection 10/23/25</title>
	<link>https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/</link>
	<pubDate>Thu, 23 Oct 2025 06:59:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like antibody-mediated rejection and adverse pregnancy outcomes. Key takeaway: Donor D.N.A. Detects Heart Transplant Rejection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41122849">Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41123512">Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41123513">Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41123920">Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41123904">Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/">https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41122849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41122849</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the A.S.P.R.E.E. (Aspirin in Reducing Events in the Elderly) trial investigated whether heart stress, indicated by age-adjusted elevated N-terminal pro-B-type natriuretic peptide levels, could improve cardiovascular disease risk stratification in older adults. The study included 11,941 community-dwelling participants to assess this biomarker&#8217;s utility in a complex patient population. Findings suggest that utilizing heart stress may enhance cardiovascular disease risk assessment, potentially supporting more individualized blood pressure management strategies for the elderly. This approach could lead to more tailored and effective therapeutic interventions by better identifying high-risk individuals.</p>
<h4>Article 2: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123512" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123512</a></p>
<p><strong>Summary:</strong> This analysis of the G.A.L.A.C.T.I.C.-H.F. (Global Approach to Lowering Adverse Cardiovascular Events Through Improving Contractility in Heart Failure) trial aimed to characterize the efficacy and safety of omecamtiv mecarbil across various age groups in patients with heart failure with reduced ejection fraction. Omecamtiv mecarbil is a selective cardiac myosin activator with minimal effects on blood pressure and heart rate, suggesting a favorable tolerability profile, especially in older individuals often burdened by comorbidities. The study evaluated how this drug&#8217;s clinical benefits and safety profile manifest across the age spectrum, addressing uncertainties regarding its use in an aging population. This research helps clarify the potential for individualized treatment strategies based on patient age in heart failure management.</p>
<h4>Article 3: Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123513" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123513</a></p>
<p><strong>Summary:</strong> This study, analyzing 2,240 heart transplant recipients from the S.H.O.R.E. (Surveillance HeartCare Outcomes Registry) registry, aimed to characterize the incidence and timing of biopsy-proven antibody-mediated rejection. A primary objective was to evaluate the performance characteristics of donor-derived cell-free D.N.A. as a biomarker for antibody-mediated rejection in a large, contemporary patient cohort. This research established important data on the utility of donor-derived cell-free D.N.A. in monitoring for rejection. Identifying reliable biomarkers like d.d.-c.f.D.N.A. is critical for improving early detection and management of rejection, thereby enhancing long-term outcomes for heart transplant patients.</p>
<h4>Article 4: Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123920" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123920</a></p>
<p><strong>Summary:</strong> This large population-based cohort study investigated the long-term risk of atrial fibrillation associated with six major adverse pregnancy outcomes. Employing a cosibling analysis to account for familial confounding, the research aimed to precisely determine these associations. The study established that women experiencing adverse pregnancy outcomes face increased long-term risks of developing atrial fibrillation. These findings are crucial for identifying high-risk women earlier in life, enabling targeted interventions to prevent atrial fibrillation and its serious complications.</p>
<h4>Article 5: Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123904</a></p>
<p><strong>Summary:</strong> This nationwide Swedish study investigated the associations between short-term exposure to both low and high ambient temperatures and mortality among patients with heart failure. Recognizing heart failure patients&#8217; particular susceptibility to non-optimal temperatures, the research aimed to clarify these critical relationships for both all-cause and cardiovascular mortality. The study established significant associations, providing essential data on how environmental temperature extremes impact this vulnerable population. These findings are vital for public health advisories and personalized patient management strategies in regions susceptible to temperature fluctuations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. This post hoc analysis of the A.S.P.R.E.E. (Aspirin in Reducing Events in the Elderly) trial investigated whether heart stress, indicated by age-adjusted elevated N-terminal pro-B-type natriuretic peptide levels, could improve cardiovascular disease risk stratification in older adults. The study included 11,941 community-dwelling participants to assess this biomarker&#8217;s utility in a complex patient population. Findings suggest that utilizing heart stress may enhance cardiovascular disease risk assessment, potentially supporting more individualized blood pressure management strategies for the elderly. This approach could lead to more tailored and effective therapeutic interventions by better identifying high-risk individuals.</p>
<p>Article number two. Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial. This analysis of the G.A.L.A.C.T.I.C.-H.F. (Global Approach to Lowering Adverse Cardiovascular Events Through Improving Contractility in Heart Failure) trial aimed to characterize the efficacy and safety of omecamtiv mecarbil across various age groups in patients with heart failure with reduced ejection fraction. Omecamtiv mecarbil is a selective cardiac myosin activator with minimal effects on blood pressure and heart rate, suggesting a favorable tolerability profile, especially in older individuals often burdened by comorbidities. The study evaluated how this drug&#8217;s clinical benefits and safety profile manifest across the age spectrum, addressing uncertainties regarding its use in an aging population. This research helps clarify the potential for individualized treatment strategies based on patient age in heart failure management.</p>
<p>Article number three. Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry. This study, analyzing 2,240 heart transplant recipients from the S.H.O.R.E. (Surveillance HeartCare Outcomes Registry) registry, aimed to characterize the incidence and timing of biopsy-proven antibody-mediated rejection. A primary objective was to evaluate the performance characteristics of donor-derived cell-free D.N.A. as a biomarker for antibody-mediated rejection in a large, contemporary patient cohort. This research established important data on the utility of donor-derived cell-free D.N.A. in monitoring for rejection. Identifying reliable biomarkers like d.d.-c.f.D.N.A. is critical for improving early detection and management of rejection, thereby enhancing long-term outcomes for heart transplant patients.</p>
<p>Article number four. Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation. This large population-based cohort study investigated the long-term risk of atrial fibrillation associated with six major adverse pregnancy outcomes. Employing a cosibling analysis to account for familial confounding, the research aimed to precisely determine these associations. The study established that women experiencing adverse pregnancy outcomes face increased long-term risks of developing atrial fibrillation. These findings are crucial for identifying high-risk women earlier in life, enabling targeted interventions to prevent atrial fibrillation and its serious complications.</p>
<p>Article number five. Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden. This nationwide Swedish study investigated the associations between short-term exposure to both low and high ambient temperatures and mortality among patients with heart failure. Recognizing heart failure patients&#8217; particular susceptibility to non-optimal temperatures, the research aimed to clarify these critical relationships for both all-cause and cardiovascular mortality. The study established significant associations, providing essential data on how environmental temperature extremes impact this vulnerable population. These findings are vital for public health advisories and personalized patient management strategies in regions susceptible to temperature fluctuations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>antibody-mediated rejection, adverse pregnancy outcomes, N-terminal pro-B-type natriuretic peptide, drug efficacy, cardiovascular risk, atrial fibrillation, drug safety, familial confounding, omecamtiv mecarbil, temperature exposure, environmental factors, biomarker, cardiovascular mortality, population-based cohort, cardiac myosin activator, heart transplant, rejection monitoring, cardiovascular disease risk stratification, blood pressure management, heart stress, older adults, donor-derived cell-free D.N.A., heart failure with reduced ejection fraction, heart failure, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/">Donor D.N.A. Detects Heart Transplant Rejection 10/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like antibody-mediated rejection and adverse pregnancy outcomes. Key takeaway: Donor D.N.A. Detects Heart Transplant Rejection.
Article Li]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like antibody-mediated rejection and adverse pregnancy outcomes. Key takeaway: Donor D.N.A. Detects Heart Transplant Rejection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41122849">Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41123512">Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41123513">Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry.</a> (JACC. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41123920">Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41123904">Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/">https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41122849" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41122849</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the A.S.P.R.E.E. (Aspirin in Reducing Events in the Elderly) trial investigated whether heart stress, indicated by age-adjusted elevated N-terminal pro-B-type natriuretic peptide levels, could improve cardiovascular disease risk stratification in older adults. The study included 11,941 community-dwelling participants to assess this biomarker&#8217;s utility in a complex patient population. Findings suggest that utilizing heart stress may enhance cardiovascular disease risk assessment, potentially supporting more individualized blood pressure management strategies for the elderly. This approach could lead to more tailored and effective therapeutic interventions by better identifying high-risk individuals.</p>
<h4>Article 2: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123512" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123512</a></p>
<p><strong>Summary:</strong> This analysis of the G.A.L.A.C.T.I.C.-H.F. (Global Approach to Lowering Adverse Cardiovascular Events Through Improving Contractility in Heart Failure) trial aimed to characterize the efficacy and safety of omecamtiv mecarbil across various age groups in patients with heart failure with reduced ejection fraction. Omecamtiv mecarbil is a selective cardiac myosin activator with minimal effects on blood pressure and heart rate, suggesting a favorable tolerability profile, especially in older individuals often burdened by comorbidities. The study evaluated how this drug&#8217;s clinical benefits and safety profile manifest across the age spectrum, addressing uncertainties regarding its use in an aging population. This research helps clarify the potential for individualized treatment strategies based on patient age in heart failure management.</p>
<h4>Article 3: Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123513" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123513</a></p>
<p><strong>Summary:</strong> This study, analyzing 2,240 heart transplant recipients from the S.H.O.R.E. (Surveillance HeartCare Outcomes Registry) registry, aimed to characterize the incidence and timing of biopsy-proven antibody-mediated rejection. A primary objective was to evaluate the performance characteristics of donor-derived cell-free D.N.A. as a biomarker for antibody-mediated rejection in a large, contemporary patient cohort. This research established important data on the utility of donor-derived cell-free D.N.A. in monitoring for rejection. Identifying reliable biomarkers like d.d.-c.f.D.N.A. is critical for improving early detection and management of rejection, thereby enhancing long-term outcomes for heart transplant patients.</p>
<h4>Article 4: Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123920" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123920</a></p>
<p><strong>Summary:</strong> This large population-based cohort study investigated the long-term risk of atrial fibrillation associated with six major adverse pregnancy outcomes. Employing a cosibling analysis to account for familial confounding, the research aimed to precisely determine these associations. The study established that women experiencing adverse pregnancy outcomes face increased long-term risks of developing atrial fibrillation. These findings are crucial for identifying high-risk women earlier in life, enabling targeted interventions to prevent atrial fibrillation and its serious complications.</p>
<h4>Article 5: Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41123904" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41123904</a></p>
<p><strong>Summary:</strong> This nationwide Swedish study investigated the associations between short-term exposure to both low and high ambient temperatures and mortality among patients with heart failure. Recognizing heart failure patients&#8217; particular susceptibility to non-optimal temperatures, the research aimed to clarify these critical relationships for both all-cause and cardiovascular mortality. The study established significant associations, providing essential data on how environmental temperature extremes impact this vulnerable population. These findings are vital for public health advisories and personalized patient management strategies in regions susceptible to temperature fluctuations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. This post hoc analysis of the A.S.P.R.E.E. (Aspirin in Reducing Events in the Elderly) trial investigated whether heart stress, indicated by age-adjusted elevated N-terminal pro-B-type natriuretic peptide levels, could improve cardiovascular disease risk stratification in older adults. The study included 11,941 community-dwelling participants to assess this biomarker&#8217;s utility in a complex patient population. Findings suggest that utilizing heart stress may enhance cardiovascular disease risk assessment, potentially supporting more individualized blood pressure management strategies for the elderly. This approach could lead to more tailored and effective therapeutic interventions by better identifying high-risk individuals.</p>
<p>Article number two. Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial. This analysis of the G.A.L.A.C.T.I.C.-H.F. (Global Approach to Lowering Adverse Cardiovascular Events Through Improving Contractility in Heart Failure) trial aimed to characterize the efficacy and safety of omecamtiv mecarbil across various age groups in patients with heart failure with reduced ejection fraction. Omecamtiv mecarbil is a selective cardiac myosin activator with minimal effects on blood pressure and heart rate, suggesting a favorable tolerability profile, especially in older individuals often burdened by comorbidities. The study evaluated how this drug&#8217;s clinical benefits and safety profile manifest across the age spectrum, addressing uncertainties regarding its use in an aging population. This research helps clarify the potential for individualized treatment strategies based on patient age in heart failure management.</p>
<p>Article number three. Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry. This study, analyzing 2,240 heart transplant recipients from the S.H.O.R.E. (Surveillance HeartCare Outcomes Registry) registry, aimed to characterize the incidence and timing of biopsy-proven antibody-mediated rejection. A primary objective was to evaluate the performance characteristics of donor-derived cell-free D.N.A. as a biomarker for antibody-mediated rejection in a large, contemporary patient cohort. This research established important data on the utility of donor-derived cell-free D.N.A. in monitoring for rejection. Identifying reliable biomarkers like d.d.-c.f.D.N.A. is critical for improving early detection and management of rejection, thereby enhancing long-term outcomes for heart transplant patients.</p>
<p>Article number four. Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation. This large population-based cohort study investigated the long-term risk of atrial fibrillation associated with six major adverse pregnancy outcomes. Employing a cosibling analysis to account for familial confounding, the research aimed to precisely determine these associations. The study established that women experiencing adverse pregnancy outcomes face increased long-term risks of developing atrial fibrillation. These findings are crucial for identifying high-risk women earlier in life, enabling targeted interventions to prevent atrial fibrillation and its serious complications.</p>
<p>Article number five. Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden. This nationwide Swedish study investigated the associations between short-term exposure to both low and high ambient temperatures and mortality among patients with heart failure. Recognizing heart failure patients&#8217; particular susceptibility to non-optimal temperatures, the research aimed to clarify these critical relationships for both all-cause and cardiovascular mortality. The study established significant associations, providing essential data on how environmental temperature extremes impact this vulnerable population. These findings are vital for public health advisories and personalized patient management strategies in regions susceptible to temperature fluctuations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>antibody-mediated rejection, adverse pregnancy outcomes, N-terminal pro-B-type natriuretic peptide, drug efficacy, cardiovascular risk, atrial fibrillation, drug safety, familial confounding, omecamtiv mecarbil, temperature exposure, environmental factors, biomarker, cardiovascular mortality, population-based cohort, cardiac myosin activator, heart transplant, rejection monitoring, cardiovascular disease risk stratification, blood pressure management, heart stress, older adults, donor-derived cell-free D.N.A., heart failure with reduced ejection fraction, heart failure, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/">Donor D.N.A. Detects Heart Transplant Rejection 10/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251023_025719.mp3" length="4968114" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like antibody-mediated rejection and adverse pregnancy outcomes. Key takeaway: Donor D.N.A. Detects Heart Transplant Rejection.
Article Links:
Article 1: Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. (Circulation)
Article 2: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial. (JACC. Heart failure)
Article 3: Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry. (JACC. Heart failure)
Article 4: Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation. (JAMA cardiology)
Article 5: Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/donor-d-n-a-detects-heart-transplant-rejection-10-23-25/
 Featured Articles
Article 1: Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41122849
Summary: This post hoc analysis of the A.S.P.R.E.E. (Aspirin in Reducing Events in the Elderly) trial investigated whether heart stress, indicated by age-adjusted elevated N-terminal pro-B-type natriuretic peptide levels, could improve cardiovascular disease risk stratification in older adults. The study included 11,941 community-dwelling participants to assess this biomarker&#8217;s utility in a complex patient population. Findings suggest that utilizing heart stress may enhance cardiovascular disease risk assessment, potentially supporting more individualized blood pressure management strategies for the elderly. This approach could lead to more tailored and effective therapeutic interventions by better identifying high-risk individuals.
Article 2: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41123512
Summary: This analysis of the G.A.L.A.C.T.I.C.-H.F. (Global Approach to Lowering Adverse Cardiovascular Events Through Improving Contractility in Heart Failure) trial aimed to characterize the efficacy and safety of omecamtiv mecarbil across various age groups in patients with heart failure with reduced ejection fraction. Omecamtiv mecarbil is a selective cardiac myosin activator with minimal effects on blood pressure and heart rate, suggesting a favorable tolerability profile, especially in older individuals often burdened by comorbidities. The study evaluated how this drug&#8217;s clinical benefits and safety profile manifest across the age spectrum, addressing uncertainties regarding its use in an aging population. This research helps clarify the potential for individualized treatment strategies based on patient age in heart failure management.
Article 3: Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41123513
Summary: This study, analyzing 2,240 heart transplant recipients from the S.H.O.R.E. (Surveillance HeartCare Outcomes Registry) registry, aimed to characterize the incidence and timing of biopsy-proven antibody-mediated rejection. A primary objective was to evaluate the performance characteristics of donor-derived cell-free D.N.A. as a biomarker for antibody-mediated rejection in a large, contemporary patient cohort. This research established important data on the utility of donor-derived cell-free D.N.A. in monitoring for rejection. Identifying reliable biomarkers like d.d.-c.f.D.N.A. is critical for improving early detection and management of rejection, thereby enhancing long-term ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 23, 2025. This episode summarizes 5 key cardiology studies on topics like antibody-mediated rejection and adverse pregnancy outcomes. Key takeaway: Donor D.N.A. Detects Heart Transplant Rejection.
Article Links:
Article 1: Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. (Circulation)
Article 2: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial. (JACC. Heart failure)
Article 3: Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry. (JACC. Heart failure)
Article 4: Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation. (JAMA cardiology)
Article 5: Short-Term Exposure to Low and High Temperatures and Mortality Among Patients With Heart Failure in Sweden. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/do]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Off-Label Device Expands PDA Closure Options 10/22/25</title>
	<link>https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/</link>
	<pubDate>Wed, 22 Oct 2025 10:04:11 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like aortic insufficiency and Korean National Health Insurance Service. Key takeaway: Off-Label Device Expands PDA Closure Options.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41120825">Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41120824">Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41120820">Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41120818">Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41120817">Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/">https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120825" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120825</a></p>
<p><strong>Summary:</strong> This multicity panel study aimed to clarify the short-term effects of personal-level environmental temperature on ambulatory blood pressure in 277 hypertensive patients across four Chinese cities. Researchers utilized continuous personal portable monitors to record both environmental temperature and ambulatory blood pressure. This robust methodology establishes a significant framework for understanding how individual thermal exposure impacts blood pressure management, which is crucial for optimizing cardiovascular health strategies in hypertensive populations.</p>
<h4>Article 2: Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120824" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120824</a></p>
<p><strong>Summary:</strong> 2007 to 2018. This prospective cohort study, utilizing data from the National Health and Nutrition Examination Survey (N.H.A.N.E.S.) between 2007 and 2018, sought to determine if achieving physical activity guidelines through occupational, nonoccupational, or combined activity differentially impacts all-cause, cardiovascular, and cancer mortality in U.S. adults. By meticulously observing participants aged 18 years or older and acquiring mortality data through the National Death Index, this research establishes a vital framework. This study is crucial for providing clarity on the specific health benefits associated with distinct types of physical activity, informing public health guidelines and personalized recommendations for improving longevity and reducing disease burden.</p>
<h4>Article 3: Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120820" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120820</a></p>
<p><strong>Summary:</strong> This study aimed to validate the new durable left ventricular assist device (d.L.V.A.D.) Hemodynamic Classification System designed for hemodynamic-related events, specifically right heart failure and aortic insufficiency. Researchers adjudicated, staged, and phenotyped these events at six months post-d.L.V.A.D. implantation, with the primary outcome being a composite of heart failure hospitalization or cardiac mortality. The validation of this classification system is critical for standardizing the assessment and management of common and serious complications in patients with durable left ventricular assist devices, which can significantly improve patient stratification and therapeutic guidance.</p>
<h4>Article 4: Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120818" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120818</a></p>
<p><strong>Summary:</strong> This nationwide retrospective cohort study, utilizing data from the Korean National Health Insurance Service database, meticulously evaluated the potential association between long-term antibiotic exposure and cardiovascular disease (C.V.D.) risk in over two million individuals. The research aimed to provide essential epidemiological evidence to clarify this relationship, given that antibiotic use can alter gut microbiota, which is hypothesized to impact cardiovascular health. Establishing this association is critically important for understanding potential long-term risks associated with antibiotic use and could inform prescribing practices to mitigate future cardiovascular disease burden.</p>
<h4>Article 5: Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120817" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120817</a></p>
<p><strong>Summary:</strong> This international retrospective analysis investigated the feasibility, efficacy, and safety of using a multifunctional occluder off-label for transcatheter patent ductus arteriosus (P.D.A.) closure, especially in challenging anatomical cases or small patients. The study meticulously compiled data from 77 procedures performed across 14 pediatric cardiology centers in five countries between 2018 and 2025. This research significantly advances the understanding of alternative treatment options for complex patent ductus arteriosus, potentially expanding therapeutic approaches and improving outcomes in vulnerable pediatric populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study. This multicity panel study aimed to clarify the short-term effects of personal-level environmental temperature on ambulatory blood pressure in 277 hypertensive patients across four Chinese cities. Researchers utilized continuous personal portable monitors to record both environmental temperature and ambulatory blood pressure. This robust methodology establishes a significant framework for understanding how individual thermal exposure impacts blood pressure management, which is crucial for optimizing cardiovascular health strategies in hypertensive populations.</p>
<p>Article number two. Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the N.H.A.N.E.S. 2007 to 2018. This prospective cohort study, utilizing data from the National Health and Nutrition Examination Survey (N.H.A.N.E.S.) between 2007 and 2018, sought to determine if achieving physical activity guidelines through occupational, nonoccupational, or combined activity differentially impacts all-cause, cardiovascular, and cancer mortality in U.S. adults. By meticulously observing participants aged 18 years or older and acquiring mortality data through the National Death Index, this research establishes a vital framework. This study is crucial for providing clarity on the specific health benefits associated with distinct types of physical activity, informing public health guidelines and personalized recommendations for improving longevity and reducing disease burden.</p>
<p>Article number three. Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices. This study aimed to validate the new durable left ventricular assist device (d.L.V.A.D.) Hemodynamic Classification System designed for hemodynamic-related events, specifically right heart failure and aortic insufficiency. Researchers adjudicated, staged, and phenotyped these events at six months post-d.L.V.A.D. implantation, with the primary outcome being a composite of heart failure hospitalization or cardiac mortality. The validation of this classification system is critical for standardizing the assessment and management of common and serious complications in patients with durable left ventricular assist devices, which can significantly improve patient stratification and therapeutic guidance.</p>
<p>Article number four. Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study. This nationwide retrospective cohort study, utilizing data from the Korean National Health Insurance Service database, meticulously evaluated the potential association between long-term antibiotic exposure and cardiovascular disease (C.V.D.) risk in over two million individuals. The research aimed to provide essential epidemiological evidence to clarify this relationship, given that antibiotic use can alter gut microbiota, which is hypothesized to impact cardiovascular health. Establishing this association is critically important for understanding potential long-term risks associated with antibiotic use and could inform prescribing practices to mitigate future cardiovascular disease burden.</p>
<p>Article number five. Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience. This international retrospective analysis investigated the feasibility, efficacy, and safety of using a multifunctional occluder off-label for transcatheter patent ductus arteriosus (P.D.A.) closure, especially in challenging anatomical cases or small patients. The study meticulously compiled data from 77 procedures performed across 14 pediatric cardiology centers in five countries between 2018 and 2025. This research significantly advances the understanding of alternative treatment options for complex patent ductus arteriosus, potentially expanding therapeutic approaches and improving outcomes in vulnerable pediatric populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aortic insufficiency, Korean National Health Insurance Service, durable left ventricular assist device, off-label use, multifunctional occluder, ambulatory blood pressure, transcatheter patent ductus arteriosus closure, cardiac mortality, nationwide cohort study, National Health and Nutrition Examination Survey, physical activity, right heart failure, pediatric cardiology, cardiovascular mortality, cardiovascular disease risk, P.D.A., gut microbiota, environmental temperature, occupational activity, all-cause mortality, cancer mortality, d.L.V.A.D., hemodynamic classification system, hypertension, antibiotic exposure, congenital heart disease, heart failure hospitalization, nonoccupational activity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/">Off-Label Device Expands PDA Closure Options 10/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like aortic insufficiency and Korean National Health Insurance Service. Key takeaway: Off-Label Device Expands PDA Closure Options.
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like aortic insufficiency and Korean National Health Insurance Service. Key takeaway: Off-Label Device Expands PDA Closure Options.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41120825">Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41120824">Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41120820">Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41120818">Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41120817">Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/">https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120825" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120825</a></p>
<p><strong>Summary:</strong> This multicity panel study aimed to clarify the short-term effects of personal-level environmental temperature on ambulatory blood pressure in 277 hypertensive patients across four Chinese cities. Researchers utilized continuous personal portable monitors to record both environmental temperature and ambulatory blood pressure. This robust methodology establishes a significant framework for understanding how individual thermal exposure impacts blood pressure management, which is crucial for optimizing cardiovascular health strategies in hypertensive populations.</p>
<h4>Article 2: Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120824" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120824</a></p>
<p><strong>Summary:</strong> 2007 to 2018. This prospective cohort study, utilizing data from the National Health and Nutrition Examination Survey (N.H.A.N.E.S.) between 2007 and 2018, sought to determine if achieving physical activity guidelines through occupational, nonoccupational, or combined activity differentially impacts all-cause, cardiovascular, and cancer mortality in U.S. adults. By meticulously observing participants aged 18 years or older and acquiring mortality data through the National Death Index, this research establishes a vital framework. This study is crucial for providing clarity on the specific health benefits associated with distinct types of physical activity, informing public health guidelines and personalized recommendations for improving longevity and reducing disease burden.</p>
<h4>Article 3: Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120820" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120820</a></p>
<p><strong>Summary:</strong> This study aimed to validate the new durable left ventricular assist device (d.L.V.A.D.) Hemodynamic Classification System designed for hemodynamic-related events, specifically right heart failure and aortic insufficiency. Researchers adjudicated, staged, and phenotyped these events at six months post-d.L.V.A.D. implantation, with the primary outcome being a composite of heart failure hospitalization or cardiac mortality. The validation of this classification system is critical for standardizing the assessment and management of common and serious complications in patients with durable left ventricular assist devices, which can significantly improve patient stratification and therapeutic guidance.</p>
<h4>Article 4: Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120818" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120818</a></p>
<p><strong>Summary:</strong> This nationwide retrospective cohort study, utilizing data from the Korean National Health Insurance Service database, meticulously evaluated the potential association between long-term antibiotic exposure and cardiovascular disease (C.V.D.) risk in over two million individuals. The research aimed to provide essential epidemiological evidence to clarify this relationship, given that antibiotic use can alter gut microbiota, which is hypothesized to impact cardiovascular health. Establishing this association is critically important for understanding potential long-term risks associated with antibiotic use and could inform prescribing practices to mitigate future cardiovascular disease burden.</p>
<h4>Article 5: Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120817" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120817</a></p>
<p><strong>Summary:</strong> This international retrospective analysis investigated the feasibility, efficacy, and safety of using a multifunctional occluder off-label for transcatheter patent ductus arteriosus (P.D.A.) closure, especially in challenging anatomical cases or small patients. The study meticulously compiled data from 77 procedures performed across 14 pediatric cardiology centers in five countries between 2018 and 2025. This research significantly advances the understanding of alternative treatment options for complex patent ductus arteriosus, potentially expanding therapeutic approaches and improving outcomes in vulnerable pediatric populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study. This multicity panel study aimed to clarify the short-term effects of personal-level environmental temperature on ambulatory blood pressure in 277 hypertensive patients across four Chinese cities. Researchers utilized continuous personal portable monitors to record both environmental temperature and ambulatory blood pressure. This robust methodology establishes a significant framework for understanding how individual thermal exposure impacts blood pressure management, which is crucial for optimizing cardiovascular health strategies in hypertensive populations.</p>
<p>Article number two. Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the N.H.A.N.E.S. 2007 to 2018. This prospective cohort study, utilizing data from the National Health and Nutrition Examination Survey (N.H.A.N.E.S.) between 2007 and 2018, sought to determine if achieving physical activity guidelines through occupational, nonoccupational, or combined activity differentially impacts all-cause, cardiovascular, and cancer mortality in U.S. adults. By meticulously observing participants aged 18 years or older and acquiring mortality data through the National Death Index, this research establishes a vital framework. This study is crucial for providing clarity on the specific health benefits associated with distinct types of physical activity, informing public health guidelines and personalized recommendations for improving longevity and reducing disease burden.</p>
<p>Article number three. Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices. This study aimed to validate the new durable left ventricular assist device (d.L.V.A.D.) Hemodynamic Classification System designed for hemodynamic-related events, specifically right heart failure and aortic insufficiency. Researchers adjudicated, staged, and phenotyped these events at six months post-d.L.V.A.D. implantation, with the primary outcome being a composite of heart failure hospitalization or cardiac mortality. The validation of this classification system is critical for standardizing the assessment and management of common and serious complications in patients with durable left ventricular assist devices, which can significantly improve patient stratification and therapeutic guidance.</p>
<p>Article number four. Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study. This nationwide retrospective cohort study, utilizing data from the Korean National Health Insurance Service database, meticulously evaluated the potential association between long-term antibiotic exposure and cardiovascular disease (C.V.D.) risk in over two million individuals. The research aimed to provide essential epidemiological evidence to clarify this relationship, given that antibiotic use can alter gut microbiota, which is hypothesized to impact cardiovascular health. Establishing this association is critically important for understanding potential long-term risks associated with antibiotic use and could inform prescribing practices to mitigate future cardiovascular disease burden.</p>
<p>Article number five. Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience. This international retrospective analysis investigated the feasibility, efficacy, and safety of using a multifunctional occluder off-label for transcatheter patent ductus arteriosus (P.D.A.) closure, especially in challenging anatomical cases or small patients. The study meticulously compiled data from 77 procedures performed across 14 pediatric cardiology centers in five countries between 2018 and 2025. This research significantly advances the understanding of alternative treatment options for complex patent ductus arteriosus, potentially expanding therapeutic approaches and improving outcomes in vulnerable pediatric populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aortic insufficiency, Korean National Health Insurance Service, durable left ventricular assist device, off-label use, multifunctional occluder, ambulatory blood pressure, transcatheter patent ductus arteriosus closure, cardiac mortality, nationwide cohort study, National Health and Nutrition Examination Survey, physical activity, right heart failure, pediatric cardiology, cardiovascular mortality, cardiovascular disease risk, P.D.A., gut microbiota, environmental temperature, occupational activity, all-cause mortality, cancer mortality, d.L.V.A.D., hemodynamic classification system, hypertension, antibiotic exposure, congenital heart disease, heart failure hospitalization, nonoccupational activity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/">Off-Label Device Expands PDA Closure Options 10/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251022_060048.mp3" length="4938439" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like aortic insufficiency and Korean National Health Insurance Service. Key takeaway: Off-Label Device Expands PDA Closure Options.
Article Links:
Article 1: Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study. (Journal of the American Heart Association)
Article 2: Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018. (Journal of the American Heart Association)
Article 3: Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices. (Journal of the American Heart Association)
Article 4: Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study. (Journal of the American Heart Association)
Article 5: Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/off-label-device-expands-pda-closure-options-10-22-25/
 Featured Articles
Article 1: Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120825
Summary: This multicity panel study aimed to clarify the short-term effects of personal-level environmental temperature on ambulatory blood pressure in 277 hypertensive patients across four Chinese cities. Researchers utilized continuous personal portable monitors to record both environmental temperature and ambulatory blood pressure. This robust methodology establishes a significant framework for understanding how individual thermal exposure impacts blood pressure management, which is crucial for optimizing cardiovascular health strategies in hypertensive populations.
Article 2: Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120824
Summary: 2007 to 2018. This prospective cohort study, utilizing data from the National Health and Nutrition Examination Survey (N.H.A.N.E.S.) between 2007 and 2018, sought to determine if achieving physical activity guidelines through occupational, nonoccupational, or combined activity differentially impacts all-cause, cardiovascular, and cancer mortality in U.S. adults. By meticulously observing participants aged 18 years or older and acquiring mortality data through the National Death Index, this research establishes a vital framework. This study is crucial for providing clarity on the specific health benefits associated with distinct types of physical activity, informing public health guidelines and personalized recommendations for improving longevity and reducing disease burden.
Article 3: Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120820
Summary: This study aimed to validate the new durable left ventricular assist device (d.L.V.A.D.) Hemodynamic Classification System designed for hemodynamic-related events, specifically right heart failure and aortic insufficiency. Researchers adjudicated, staged, and phenotyped these events at six months post-d.L.V.A.D. implantation, with the primary outcome being a composite of heart failure hospitalization or cardiac mortal]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like aortic insufficiency and Korean National Health Insurance Service. Key takeaway: Off-Label Device Expands PDA Closure Options.
Article Links:
Article 1: Short-Term Effects of Personal-Level Environmental Temperature on Ambulatory Blood Pressure in Patients With Hypertension: A Multicity Panel Study. (Journal of the American Heart Association)
Article 2: Occupational and Nonoccupational Physical Activity and Their Association With All-Cause, Cardiovascular, and Cancer Mortality in US Adults: A Prospective Cohort Study from the NHANES 2007 to 2018. (Journal of the American Heart Association)
Article 3: Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices. (Journal of the American Heart Association)
Article 4: Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort S]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Detects Cardiac Amyloidosis from Echo 10/22/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/</link>
	<pubDate>Wed, 22 Oct 2025 07:00:16 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like screening algorithm and cardiac function. Key takeaway: AI Detects Cardiac Amyloidosis from Echo.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41120118">Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40631729">Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40396194">Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41116329">Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41116721">A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/">https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120118</a></p>
<p><strong>Summary:</strong> The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten&#8217;s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.</p>
<h4>Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40631729" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40631729</a></p>
<p><strong>Summary:</strong> This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.</p>
<h4>Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40396194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40396194</a></p>
<p><strong>Summary:</strong> This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.</p>
<h4>Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41116329" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41116329</a></p>
<p><strong>Summary:</strong> This study aimed to identify factors associated with L.V. functional recovery in children with idiopathic dilated cardiomyopathy after L.V. assist device implantation. Researchers used single-nucleus multiomics analysis on L.V. tissue collected at the time of L.V. assist device implantation. The study discovered specific factors, including the role of N.P.P.B., that are associated with improved L.V. function, enabling device explantation in a subset of patients. These findings establish a deeper understanding of recovery mechanisms and hold promise for developing personalized recovery strategies and patient selection for device explantation in pediatric dilated cardiomyopathy.</p>
<h4>Article 5: A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41116721" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41116721</a></p>
<p><strong>Summary:</strong> This study investigated the association between the full spectrum of L.V.E.F. and the risk of worsening heart failure. Analyzing data from 93,694 participants undergoing echocardiography, the researchers sought to clarify this relationship beyond previous mortality-focused studies. The study discovered a significant U-shaped relationship, indicating that both very low and very high L.V.E.F.s are associated with an increased risk of worsening heart failure. This finding has crucial clinical implications, underscoring the necessity for vigilant monitoring and tailored management strategies for patients across the entire L.V.E.F. range.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten&#8217;s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.</p>
<p>Article number two. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.</p>
<p>Article number three. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.</p>
<p>Article number four. Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics. This study aimed to identify factors associated with L.V. functional recovery in children with idiopathic dilated cardiomyopathy after L.V. assist device implantation. Researchers used single-nucleus multiomics analysis on L.V. tissue collected at the time of L.V. assist device implantation. The study discovered specific factors, including the role of N.P.P.B., that are associated with improved L.V. function, enabling device explantation in a subset of patients. These findings establish a deeper understanding of recovery mechanisms and hold promise for developing personalized recovery strategies and patient selection for device explantation in pediatric dilated cardiomyopathy.</p>
<p>Article number five. A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure. This study investigated the association between the full spectrum of L.V.E.F. and the risk of worsening heart failure. Analyzing data from 93,694 participants undergoing echocardiography, the researchers sought to clarify this relationship beyond previous mortality-focused studies. The study discovered a significant U-shaped relationship, indicating that both very low and very high L.V.E.F.s are associated with an increased risk of worsening heart failure. This finding has crucial clinical implications, underscoring the necessity for vigilant monitoring and tailored management strategies for patients across the entire L.V.E.F. range. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>screening algorithm, cardiac function, artificial intelligence, left ventricular ejection fraction, echocardiography, functional capacity, convolutional neural network, worsening heart failure, N.P.P.B., U-shaped relationship, single-nucleus multiomics, empagliflozin, left ventricular assist device, functional recovery, symptom severity, sodium-glucose cotransporter 2 inhibitor, obstructive hypertrophic cardiomyopathy, pediatric dilated cardiomyopathy, cardiac amyloidosis, left ventricular hypertrophy, S.E.Q.U.O.I.A.-H.C.M. trial, hypertrophic cardiomyopathy, metabolic efficiency, aficamten.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/">AI Detects Cardiac Amyloidosis from Echo 10/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like screening algorithm and cardiac function. Key takeaway: AI Detects Cardiac Amyloidosis from Echo.
Article Links:
Article 1: Efficacy ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like screening algorithm and cardiac function. Key takeaway: AI Detects Cardiac Amyloidosis from Echo.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41120118">Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40631729">Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40396194">Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41116329">Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41116721">A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/">https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41120118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41120118</a></p>
<p><strong>Summary:</strong> The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten&#8217;s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.</p>
<h4>Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40631729" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40631729</a></p>
<p><strong>Summary:</strong> This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.</p>
<h4>Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40396194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40396194</a></p>
<p><strong>Summary:</strong> This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.</p>
<h4>Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41116329" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41116329</a></p>
<p><strong>Summary:</strong> This study aimed to identify factors associated with L.V. functional recovery in children with idiopathic dilated cardiomyopathy after L.V. assist device implantation. Researchers used single-nucleus multiomics analysis on L.V. tissue collected at the time of L.V. assist device implantation. The study discovered specific factors, including the role of N.P.P.B., that are associated with improved L.V. function, enabling device explantation in a subset of patients. These findings establish a deeper understanding of recovery mechanisms and hold promise for developing personalized recovery strategies and patient selection for device explantation in pediatric dilated cardiomyopathy.</p>
<h4>Article 5: A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41116721" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41116721</a></p>
<p><strong>Summary:</strong> This study investigated the association between the full spectrum of L.V.E.F. and the risk of worsening heart failure. Analyzing data from 93,694 participants undergoing echocardiography, the researchers sought to clarify this relationship beyond previous mortality-focused studies. The study discovered a significant U-shaped relationship, indicating that both very low and very high L.V.E.F.s are associated with an increased risk of worsening heart failure. This finding has crucial clinical implications, underscoring the necessity for vigilant monitoring and tailored management strategies for patients across the entire L.V.E.F. range.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten&#8217;s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.</p>
<p>Article number two. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.</p>
<p>Article number three. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.</p>
<p>Article number four. Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics. This study aimed to identify factors associated with L.V. functional recovery in children with idiopathic dilated cardiomyopathy after L.V. assist device implantation. Researchers used single-nucleus multiomics analysis on L.V. tissue collected at the time of L.V. assist device implantation. The study discovered specific factors, including the role of N.P.P.B., that are associated with improved L.V. function, enabling device explantation in a subset of patients. These findings establish a deeper understanding of recovery mechanisms and hold promise for developing personalized recovery strategies and patient selection for device explantation in pediatric dilated cardiomyopathy.</p>
<p>Article number five. A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure. This study investigated the association between the full spectrum of L.V.E.F. and the risk of worsening heart failure. Analyzing data from 93,694 participants undergoing echocardiography, the researchers sought to clarify this relationship beyond previous mortality-focused studies. The study discovered a significant U-shaped relationship, indicating that both very low and very high L.V.E.F.s are associated with an increased risk of worsening heart failure. This finding has crucial clinical implications, underscoring the necessity for vigilant monitoring and tailored management strategies for patients across the entire L.V.E.F. range. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>screening algorithm, cardiac function, artificial intelligence, left ventricular ejection fraction, echocardiography, functional capacity, convolutional neural network, worsening heart failure, N.P.P.B., U-shaped relationship, single-nucleus multiomics, empagliflozin, left ventricular assist device, functional recovery, symptom severity, sodium-glucose cotransporter 2 inhibitor, obstructive hypertrophic cardiomyopathy, pediatric dilated cardiomyopathy, cardiac amyloidosis, left ventricular hypertrophy, S.E.Q.U.O.I.A.-H.C.M. trial, hypertrophic cardiomyopathy, metabolic efficiency, aficamten.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/">AI Detects Cardiac Amyloidosis from Echo 10/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251022_025649.mp3" length="4632911" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like screening algorithm and cardiac function. Key takeaway: AI Detects Cardiac Amyloidosis from Echo.
Article Links:
Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. (European heart journal)
Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. (European heart journal)
Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. (European heart journal)
Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics. (ESC heart failure)
Article 5: A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/
 Featured Articles
Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120118
Summary: The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten&#8217;s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.
Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40631729
Summary: This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.
Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40396194
Summary: This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.
Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like screening algorithm and cardiac function. Key takeaway: AI Detects Cardiac Amyloidosis from Echo.
Article Links:
Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. (European heart journal)
Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. (European heart journal)
Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. (European heart journal)
Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics. (ESC heart failure)
Article 5: A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Metabolomics Guides BP Post-Bariatric Surgery 10/21/25</title>
	<link>https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/</link>
	<pubDate>Tue, 21 Oct 2025 10:01:30 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like Graves&#8217; disease and adolescents. Key takeaway: Metabolomics Guides BP Post-Bariatric Surgery.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41115769">Ventricular arrhythmias during exercise in patients with mitral valve prolapse.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41115099">Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41111440">Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41111413">Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41111403">Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/">https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Ventricular arrhythmias during exercise in patients with mitral valve prolapse.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115769" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115769</a></p>
<p><strong>Summary:</strong> This multicenter study assessed the occurrence and severity of ventricular arrhythmias (V.A.) during exercise tests in 375 patients with mitral valve prolapse (M.V.P.). The research also explored the association between V.A. during exercise and the subsequent incidence of arrhythmic events during follow-up. This study establishes a clearer understanding of exercise-induced arrhythmias in M.V.P. patients, which is critical for their risk stratification and clinical management.</p>
<h4>Article 2: Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115099" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115099</a></p>
<p><strong>Summary:</strong> This cross-sectional study investigated the relationship between the duration of Graves&#8217; disease and myocardial deformation parameters, specifically focusing on left atrial (L.A.) strain and left ventricular global longitudinal strain (L.V.-G.L.S.). Comprehensive echocardiographic assessment was performed on 90 patients with Graves&#8217; disease, with disease duration categorized as short or long. The findings provide important insights into how the progression of Graves&#8217; disease influences cardiac function, underscoring the potential for duration-dependent myocardial alterations. These results highlight the importance of timely intervention to preserve cardiac mechanics in patients with Graves&#8217; disease.</p>
<h4>Article 3: Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111440" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111440</a></p>
<p><strong>Summary:</strong> This study utilized metabolomics and proteomics to identify preoperative plasma profiles that predict long-term elevated blood pressure changes after bariatric surgery in adolescents. Researchers analyzed 108 participants from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-L.A.B.S.) study, employing untargeted metabolomics via liquid chromatography-mass spectrometry and proteomics via tandem mass tag mass spectrometry. This research successfully identified specific molecular signatures that can better predict blood pressure outcomes compared to traditional risk factors. These findings advance personalized medicine by offering potential biomarkers for optimizing blood pressure management following bariatric surgery.</p>
<h4>Article 4: Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111413</a></p>
<p><strong>Summary:</strong> This prospective longitudinal study examined the impact of parity and a history of preeclampsia on maternal hemodynamic profiles throughout pregnancy. Transthoracic echocardiography was used to assess hemodynamics at various gestational stages (12-15, 20-24, and 30-37 weeks) in groups of nulliparous women, parous women without previous preeclampsia, and parous women with previous preeclampsia. The study successfully delineates distinct longitudinal hemodynamic alterations linked to both parity and prior preeclampsia. This provides crucial information for understanding cardiovascular adaptations in pregnancy and for targeted monitoring in women at higher obstetric risk.</p>
<h4>Article 5: Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111403" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111403</a></p>
<p><strong>Summary:</strong> This study investigated the combined influence of sex and ethnicity on vascular and renal hypertension-mediated organ damage (H.M.O.D.) in a dual-ethnic cohort of individuals with primary hypertension. Furthermore, the researchers explored the association of these disparities with the activation of the renin-angiotensin-aldosterone system, particularly aldosterone levels. This research reveals specific intersections of sex and ethnicity in the manifestation of H.M.O.D., providing a more nuanced understanding of risk factors. The findings suggest the importance of considering these demographic and hormonal factors for tailored hypertension management strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Ventricular arrhythmias during exercise in patients with mitral valve prolapse. This multicenter study assessed the occurrence and severity of ventricular arrhythmias (V.A.) during exercise tests in 375 patients with mitral valve prolapse (M.V.P.). The research also explored the association between V.A. during exercise and the subsequent incidence of arrhythmic events during follow-up. This study establishes a clearer understanding of exercise-induced arrhythmias in M.V.P. patients, which is critical for their risk stratification and clinical management.</p>
<p>Article number two. Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease. This cross-sectional study investigated the relationship between the duration of Graves&#8217; disease and myocardial deformation parameters, specifically focusing on left atrial (L.A.) strain and left ventricular global longitudinal strain (L.V.-G.L.S.). Comprehensive echocardiographic assessment was performed on 90 patients with Graves&#8217; disease, with disease duration categorized as short or long. The findings provide important insights into how the progression of Graves&#8217; disease influences cardiac function, underscoring the potential for duration-dependent myocardial alterations. These results highlight the importance of timely intervention to preserve cardiac mechanics in patients with Graves&#8217; disease.</p>
<p>Article number three. Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents. This study utilized metabolomics and proteomics to identify preoperative plasma profiles that predict long-term elevated blood pressure changes after bariatric surgery in adolescents. Researchers analyzed 108 participants from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-L.A.B.S.) study, employing untargeted metabolomics via liquid chromatography-mass spectrometry and proteomics via tandem mass tag mass spectrometry. This research successfully identified specific molecular signatures that can better predict blood pressure outcomes compared to traditional risk factors. These findings advance personalized medicine by offering potential biomarkers for optimizing blood pressure management following bariatric surgery.</p>
<p>Article number four. Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics. This prospective longitudinal study examined the impact of parity and a history of preeclampsia on maternal hemodynamic profiles throughout pregnancy. Transthoracic echocardiography was used to assess hemodynamics at various gestational stages (12-15, 20-24, and 30-37 weeks) in groups of nulliparous women, parous women without previous preeclampsia, and parous women with previous preeclampsia. The study successfully delineates distinct longitudinal hemodynamic alterations linked to both parity and prior preeclampsia. This provides crucial information for understanding cardiovascular adaptations in pregnancy and for targeted monitoring in women at higher obstetric risk.</p>
<p>Article number five. Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension. This study investigated the combined influence of sex and ethnicity on vascular and renal hypertension-mediated organ damage (H.M.O.D.) in a dual-ethnic cohort of individuals with primary hypertension. Furthermore, the researchers explored the association of these disparities with the activation of the renin-angiotensin-aldosterone system, particularly aldosterone levels. This research reveals specific intersections of sex and ethnicity in the manifestation of H.M.O.D., providing a more nuanced understanding of risk factors. The findings suggest the importance of considering these demographic and hormonal factors for tailored hypertension management strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Graves&#8217; disease, adolescents, sex, preeclampsia, maternal hemodynamics, pregnancy, ventricular arrhythmias, left ventricular global longitudinal strain, left atrial function, blood pressure management, echocardiography, risk stratification, aldosterone, arrhythmic events, metabolomics, renin-angiotensin-aldosterone system, exercise testing, ethnicity, mitral valve prolapse, proteomics, myocardial deformation, hypertension-mediated organ damage, parity, bariatric surgery, transthoracic echocardiography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/">Metabolomics Guides BP Post-Bariatric Surgery 10/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like Graves&#8217; disease and adolescents. Key takeaway: Metabolomics Guides BP Post-Bariatric Surgery.
Article Links:
Article 1: Ventric]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like Graves&#8217; disease and adolescents. Key takeaway: Metabolomics Guides BP Post-Bariatric Surgery.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41115769">Ventricular arrhythmias during exercise in patients with mitral valve prolapse.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41115099">Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41111440">Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41111413">Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41111403">Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/">https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Ventricular arrhythmias during exercise in patients with mitral valve prolapse.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115769" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115769</a></p>
<p><strong>Summary:</strong> This multicenter study assessed the occurrence and severity of ventricular arrhythmias (V.A.) during exercise tests in 375 patients with mitral valve prolapse (M.V.P.). The research also explored the association between V.A. during exercise and the subsequent incidence of arrhythmic events during follow-up. This study establishes a clearer understanding of exercise-induced arrhythmias in M.V.P. patients, which is critical for their risk stratification and clinical management.</p>
<h4>Article 2: Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115099" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115099</a></p>
<p><strong>Summary:</strong> This cross-sectional study investigated the relationship between the duration of Graves&#8217; disease and myocardial deformation parameters, specifically focusing on left atrial (L.A.) strain and left ventricular global longitudinal strain (L.V.-G.L.S.). Comprehensive echocardiographic assessment was performed on 90 patients with Graves&#8217; disease, with disease duration categorized as short or long. The findings provide important insights into how the progression of Graves&#8217; disease influences cardiac function, underscoring the potential for duration-dependent myocardial alterations. These results highlight the importance of timely intervention to preserve cardiac mechanics in patients with Graves&#8217; disease.</p>
<h4>Article 3: Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111440" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111440</a></p>
<p><strong>Summary:</strong> This study utilized metabolomics and proteomics to identify preoperative plasma profiles that predict long-term elevated blood pressure changes after bariatric surgery in adolescents. Researchers analyzed 108 participants from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-L.A.B.S.) study, employing untargeted metabolomics via liquid chromatography-mass spectrometry and proteomics via tandem mass tag mass spectrometry. This research successfully identified specific molecular signatures that can better predict blood pressure outcomes compared to traditional risk factors. These findings advance personalized medicine by offering potential biomarkers for optimizing blood pressure management following bariatric surgery.</p>
<h4>Article 4: Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111413</a></p>
<p><strong>Summary:</strong> This prospective longitudinal study examined the impact of parity and a history of preeclampsia on maternal hemodynamic profiles throughout pregnancy. Transthoracic echocardiography was used to assess hemodynamics at various gestational stages (12-15, 20-24, and 30-37 weeks) in groups of nulliparous women, parous women without previous preeclampsia, and parous women with previous preeclampsia. The study successfully delineates distinct longitudinal hemodynamic alterations linked to both parity and prior preeclampsia. This provides crucial information for understanding cardiovascular adaptations in pregnancy and for targeted monitoring in women at higher obstetric risk.</p>
<h4>Article 5: Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111403" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111403</a></p>
<p><strong>Summary:</strong> This study investigated the combined influence of sex and ethnicity on vascular and renal hypertension-mediated organ damage (H.M.O.D.) in a dual-ethnic cohort of individuals with primary hypertension. Furthermore, the researchers explored the association of these disparities with the activation of the renin-angiotensin-aldosterone system, particularly aldosterone levels. This research reveals specific intersections of sex and ethnicity in the manifestation of H.M.O.D., providing a more nuanced understanding of risk factors. The findings suggest the importance of considering these demographic and hormonal factors for tailored hypertension management strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Ventricular arrhythmias during exercise in patients with mitral valve prolapse. This multicenter study assessed the occurrence and severity of ventricular arrhythmias (V.A.) during exercise tests in 375 patients with mitral valve prolapse (M.V.P.). The research also explored the association between V.A. during exercise and the subsequent incidence of arrhythmic events during follow-up. This study establishes a clearer understanding of exercise-induced arrhythmias in M.V.P. patients, which is critical for their risk stratification and clinical management.</p>
<p>Article number two. Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease. This cross-sectional study investigated the relationship between the duration of Graves&#8217; disease and myocardial deformation parameters, specifically focusing on left atrial (L.A.) strain and left ventricular global longitudinal strain (L.V.-G.L.S.). Comprehensive echocardiographic assessment was performed on 90 patients with Graves&#8217; disease, with disease duration categorized as short or long. The findings provide important insights into how the progression of Graves&#8217; disease influences cardiac function, underscoring the potential for duration-dependent myocardial alterations. These results highlight the importance of timely intervention to preserve cardiac mechanics in patients with Graves&#8217; disease.</p>
<p>Article number three. Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents. This study utilized metabolomics and proteomics to identify preoperative plasma profiles that predict long-term elevated blood pressure changes after bariatric surgery in adolescents. Researchers analyzed 108 participants from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-L.A.B.S.) study, employing untargeted metabolomics via liquid chromatography-mass spectrometry and proteomics via tandem mass tag mass spectrometry. This research successfully identified specific molecular signatures that can better predict blood pressure outcomes compared to traditional risk factors. These findings advance personalized medicine by offering potential biomarkers for optimizing blood pressure management following bariatric surgery.</p>
<p>Article number four. Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics. This prospective longitudinal study examined the impact of parity and a history of preeclampsia on maternal hemodynamic profiles throughout pregnancy. Transthoracic echocardiography was used to assess hemodynamics at various gestational stages (12-15, 20-24, and 30-37 weeks) in groups of nulliparous women, parous women without previous preeclampsia, and parous women with previous preeclampsia. The study successfully delineates distinct longitudinal hemodynamic alterations linked to both parity and prior preeclampsia. This provides crucial information for understanding cardiovascular adaptations in pregnancy and for targeted monitoring in women at higher obstetric risk.</p>
<p>Article number five. Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension. This study investigated the combined influence of sex and ethnicity on vascular and renal hypertension-mediated organ damage (H.M.O.D.) in a dual-ethnic cohort of individuals with primary hypertension. Furthermore, the researchers explored the association of these disparities with the activation of the renin-angiotensin-aldosterone system, particularly aldosterone levels. This research reveals specific intersections of sex and ethnicity in the manifestation of H.M.O.D., providing a more nuanced understanding of risk factors. The findings suggest the importance of considering these demographic and hormonal factors for tailored hypertension management strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Graves&#8217; disease, adolescents, sex, preeclampsia, maternal hemodynamics, pregnancy, ventricular arrhythmias, left ventricular global longitudinal strain, left atrial function, blood pressure management, echocardiography, risk stratification, aldosterone, arrhythmic events, metabolomics, renin-angiotensin-aldosterone system, exercise testing, ethnicity, mitral valve prolapse, proteomics, myocardial deformation, hypertension-mediated organ damage, parity, bariatric surgery, transthoracic echocardiography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/">Metabolomics Guides BP Post-Bariatric Surgery 10/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251021_060026.mp3" length="4568963" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like Graves&#8217; disease and adolescents. Key takeaway: Metabolomics Guides BP Post-Bariatric Surgery.
Article Links:
Article 1: Ventricular arrhythmias during exercise in patients with mitral valve prolapse. (Heart (British Cardiac Society))
Article 2: Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease. (Cardiology)
Article 3: Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents. (Hypertension (Dallas, Tex. : 1979))
Article 4: Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics. (Hypertension (Dallas, Tex. : 1979))
Article 5: Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/metabolomics-guides-bp-post-bariatric-surgery-10-21-25/
 Featured Articles
Article 1: Ventricular arrhythmias during exercise in patients with mitral valve prolapse.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41115769
Summary: This multicenter study assessed the occurrence and severity of ventricular arrhythmias (V.A.) during exercise tests in 375 patients with mitral valve prolapse (M.V.P.). The research also explored the association between V.A. during exercise and the subsequent incidence of arrhythmic events during follow-up. This study establishes a clearer understanding of exercise-induced arrhythmias in M.V.P. patients, which is critical for their risk stratification and clinical management.
Article 2: Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41115099
Summary: This cross-sectional study investigated the relationship between the duration of Graves&#8217; disease and myocardial deformation parameters, specifically focusing on left atrial (L.A.) strain and left ventricular global longitudinal strain (L.V.-G.L.S.). Comprehensive echocardiographic assessment was performed on 90 patients with Graves&#8217; disease, with disease duration categorized as short or long. The findings provide important insights into how the progression of Graves&#8217; disease influences cardiac function, underscoring the potential for duration-dependent myocardial alterations. These results highlight the importance of timely intervention to preserve cardiac mechanics in patients with Graves&#8217; disease.
Article 3: Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41111440
Summary: This study utilized metabolomics and proteomics to identify preoperative plasma profiles that predict long-term elevated blood pressure changes after bariatric surgery in adolescents. Researchers analyzed 108 participants from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-L.A.B.S.) study, employing untargeted metabolomics via liquid chromatography-mass spectrometry and proteomics via tandem mass tag mass spectrometry. This research successfully identified specific molecular signatures that can better predict blood pressure outcomes compared to traditional risk factors. These findings advance personalized medicine by offering potential biomarkers for optimizing blood pressure management following bariatric surgery.
Article 4: Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41111413
Summary: This prospective longitudinal study examined the impact of parity and a history of preeclampsia on maternal hemodynamic profiles throughout pregnancy. Transthoracic echocardiography wa]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like Graves&#8217; disease and adolescents. Key takeaway: Metabolomics Guides BP Post-Bariatric Surgery.
Article Links:
Article 1: Ventricular arrhythmias during exercise in patients with mitral valve prolapse. (Heart (British Cardiac Society))
Article 2: Impact of Disease Duration on Left Atrial Function in Patients with Graves&#8217; Disease. (Cardiology)
Article 3: Plasma Metabolomic and Proteomic Signatures of Blood Pressure Management After Bariatric Surgery Among Adolescents. (Hypertension (Dallas, Tex. : 1979))
Article 4: Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics. (Hypertension (Dallas, Tex. : 1979))
Article 5: Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/metabolomics]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>H.I.V. Donors Expand Heart Transplant Pool 10/21/25</title>
	<link>https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/</link>
	<pubDate>Tue, 21 Oct 2025 06:58:05 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like lipid peroxidation and recurrent pericarditis. Key takeaway: H.I.V. Donors Expand Heart Transplant Pool.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41111418">ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41111389">Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41115672">Potential Pool of Cardiothoracic Organs from Donors with HIV.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41115671">Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41115771">Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/">https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111418" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111418</a></p>
<p><strong>Summary:</strong> This study identified an interaction between acetaldehyde dehydrogenase 2 (ALDH2) and eukaryotic initiation factor 3 subunit E (eIF3E) that critically modulates protein translation in cardiomyocytes. This interaction plays a significant role in ferroptosis, an iron-dependent form of regulated cell death caused by lipid peroxidation, observed in acute myocardial ischemia injury. The research reveals how the Glu504Lys polymorphism of ALDH2, which affects a substantial portion of East Asians, influences this mechanism and contributes to increased risk. Understanding this molecular pathway provides a novel therapeutic target for preventing or mitigating acute myocardial infarction.</p>
<h4>Article 2: Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111389" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111389</a></p>
<p><strong>Summary:</strong> This study investigated the underlying mechanisms of myocardial energy depletion in hypertrophic cardiomyopathy (H.C.M.), a condition characterized by left ventricular hypertrophy and hypercontractility. The research discovered that hypercontractility and subsequent oxidative stress drive dysfunction of creatine kinase (C.K.), a key enzyme in cardiac energy homeostasis. This C.K. dysfunction exacerbates the energetic mismatch in H.C.M., where energy consumption surpasses production. These findings pinpoint specific targets for intervention, suggesting that strategies aimed at reducing hypercontractility, oxidative stress, or enhancing C.K. activity could improve cardiac energetics in H.C.M. patients.</p>
<h4>Article 3: Potential Pool of Cardiothoracic Organs from Donors with HIV.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115672" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115672</a></p>
<p><strong>Summary:</strong> This study quantified the potential supply of cardiothoracic organs available from Human Immunodeficiency Virus (H.I.V.)-positive donors for H.I.V.-positive recipients, leveraging recent modifications to H.O.P.E. (Human Organ for Life) research guidelines. Using S.R.T.R. (Scientific Registry of Transplant Recipients) data, the researchers identified a substantial pool of H.I.V.-positive donors suitable for heart and lung transplantation. This research demonstrates the expanded eligibility criteria now allow cardiothoracic programs to participate in H.O.P.E. Act transplantation. These findings highlight a significant breakthrough in expanding access to life-saving organs for H.I.V.-positive individuals, potentially reducing transplant waitlist mortality.</p>
<h4>Article 4: Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115671</a></p>
<p><strong>Summary:</strong> This retrospective multi-center study assessed the prevalence and outcomes of B.K. polyomavirus deoxyribonucleic acidemia (D.N.A.emia) and B.K. polyomavirus D.N.A.emia-associated nephropathy in simultaneous heart-kidney transplant recipients. Analyzing data from January 2005 to June 2022, the research provided crucial insights into the rates of B.K. polyomavirus infection in this specific patient population, where information has been limited. The findings help establish risk profiles and inform management strategies for B.K. polyomavirus infection, potentially improving long-term kidney and patient survival following simultaneous heart-kidney transplantation.</p>
<h4>Article 5: Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115771" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115771</a></p>
<p><strong>Summary:</strong> This retrospective cohort study, conducted at a specialized pericardial disease center, aimed to evaluate long-term outcomes and recurrence rates after various rilonacept (R.I.) cessation strategies in adults with recurrent pericarditis (R.P.) refractory to first-line therapies. R.I., an interleukin (I.L.)-1 alpha/beta cytokine trap, has been associated with high R.P. recurrence rates upon discontinuation after 18 months. The study sought to propose preliminary strategies for safe R.I. withdrawal, providing critical data to optimize treatment duration and minimize relapse for patients managing chronic R.P.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury. This study identified an interaction between acetaldehyde dehydrogenase 2 (ALDH2) and eukaryotic initiation factor 3 subunit E (eIF3E) that critically modulates protein translation in cardiomyocytes. This interaction plays a significant role in ferroptosis, an iron-dependent form of regulated cell death caused by lipid peroxidation, observed in acute myocardial ischemia injury. The research reveals how the Glu504Lys polymorphism of ALDH2, which affects a substantial portion of East Asians, influences this mechanism and contributes to increased risk. Understanding this molecular pathway provides a novel therapeutic target for preventing or mitigating acute myocardial infarction.</p>
<p>Article number two. Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. This study investigated the underlying mechanisms of myocardial energy depletion in hypertrophic cardiomyopathy (H.C.M.), a condition characterized by left ventricular hypertrophy and hypercontractility. The research discovered that hypercontractility and subsequent oxidative stress drive dysfunction of creatine kinase (C.K.), a key enzyme in cardiac energy homeostasis. This C.K. dysfunction exacerbates the energetic mismatch in H.C.M., where energy consumption surpasses production. These findings pinpoint specific targets for intervention, suggesting that strategies aimed at reducing hypercontractility, oxidative stress, or enhancing C.K. activity could improve cardiac energetics in H.C.M. patients.</p>
<p>Article number three. Potential Pool of Cardiothoracic Organs from Donors with HIV. This study quantified the potential supply of cardiothoracic organs available from Human Immunodeficiency Virus (H.I.V.)-positive donors for H.I.V.-positive recipients, leveraging recent modifications to H.O.P.E. (Human Organ for Life) research guidelines. Using S.R.T.R. (Scientific Registry of Transplant Recipients) data, the researchers identified a substantial pool of H.I.V.-positive donors suitable for heart and lung transplantation. This research demonstrates the expanded eligibility criteria now allow cardiothoracic programs to participate in H.O.P.E. Act transplantation. These findings highlight a significant breakthrough in expanding access to life-saving organs for H.I.V.-positive individuals, potentially reducing transplant waitlist mortality.</p>
<p>Article number four. Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience. This retrospective multi-center study assessed the prevalence and outcomes of B.K. polyomavirus deoxyribonucleic acidemia (D.N.A.emia) and B.K. polyomavirus D.N.A.emia-associated nephropathy in simultaneous heart-kidney transplant recipients. Analyzing data from January 2005 to June 2022, the research provided crucial insights into the rates of B.K. polyomavirus infection in this specific patient population, where information has been limited. The findings help establish risk profiles and inform management strategies for B.K. polyomavirus infection, potentially improving long-term kidney and patient survival following simultaneous heart-kidney transplantation.</p>
<p>Article number five. Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis. This retrospective cohort study, conducted at a specialized pericardial disease center, aimed to evaluate long-term outcomes and recurrence rates after various rilonacept (R.I.) cessation strategies in adults with recurrent pericarditis (R.P.) refractory to first-line therapies. R.I., an interleukin (I.L.)-1 alpha/beta cytokine trap, has been associated with high R.P. recurrence rates upon discontinuation after 18 months. The study sought to propose preliminary strategies for safe R.I. withdrawal, providing critical data to optimize treatment duration and minimize relapse for patients managing chronic R.P. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lipid peroxidation, recurrent pericarditis, donor pool, B.K. polyomavirus, rilonacept, myocardial energy depletion, creatine kinase dysfunction, recurrence rates, H.I.V. organ transplantation, interleukin-1 alpha/beta cytokine trap, cessation strategies, transplant outcomes, hypertrophic cardiomyopathy, H.O.P.E. Act, nephropathy, simultaneous heart-kidney transplant, protein translation, acetaldehyde dehydrogenase 2, hypercontractility, cardiothoracic organs, acute myocardial ischemia, deoxyribonucleic acidemia, oxidative stress, ferroptosis, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/">H.I.V. Donors Expand Heart Transplant Pool 10/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like lipid peroxidation and recurrent pericarditis. Key takeaway: H.I.V. Donors Expand Heart Transplant Pool.
Article Links:
Article 1: AL]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like lipid peroxidation and recurrent pericarditis. Key takeaway: H.I.V. Donors Expand Heart Transplant Pool.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41111418">ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41111389">Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41115672">Potential Pool of Cardiothoracic Organs from Donors with HIV.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41115671">Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41115771">Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/">https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111418" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111418</a></p>
<p><strong>Summary:</strong> This study identified an interaction between acetaldehyde dehydrogenase 2 (ALDH2) and eukaryotic initiation factor 3 subunit E (eIF3E) that critically modulates protein translation in cardiomyocytes. This interaction plays a significant role in ferroptosis, an iron-dependent form of regulated cell death caused by lipid peroxidation, observed in acute myocardial ischemia injury. The research reveals how the Glu504Lys polymorphism of ALDH2, which affects a substantial portion of East Asians, influences this mechanism and contributes to increased risk. Understanding this molecular pathway provides a novel therapeutic target for preventing or mitigating acute myocardial infarction.</p>
<h4>Article 2: Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41111389" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41111389</a></p>
<p><strong>Summary:</strong> This study investigated the underlying mechanisms of myocardial energy depletion in hypertrophic cardiomyopathy (H.C.M.), a condition characterized by left ventricular hypertrophy and hypercontractility. The research discovered that hypercontractility and subsequent oxidative stress drive dysfunction of creatine kinase (C.K.), a key enzyme in cardiac energy homeostasis. This C.K. dysfunction exacerbates the energetic mismatch in H.C.M., where energy consumption surpasses production. These findings pinpoint specific targets for intervention, suggesting that strategies aimed at reducing hypercontractility, oxidative stress, or enhancing C.K. activity could improve cardiac energetics in H.C.M. patients.</p>
<h4>Article 3: Potential Pool of Cardiothoracic Organs from Donors with HIV.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115672" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115672</a></p>
<p><strong>Summary:</strong> This study quantified the potential supply of cardiothoracic organs available from Human Immunodeficiency Virus (H.I.V.)-positive donors for H.I.V.-positive recipients, leveraging recent modifications to H.O.P.E. (Human Organ for Life) research guidelines. Using S.R.T.R. (Scientific Registry of Transplant Recipients) data, the researchers identified a substantial pool of H.I.V.-positive donors suitable for heart and lung transplantation. This research demonstrates the expanded eligibility criteria now allow cardiothoracic programs to participate in H.O.P.E. Act transplantation. These findings highlight a significant breakthrough in expanding access to life-saving organs for H.I.V.-positive individuals, potentially reducing transplant waitlist mortality.</p>
<h4>Article 4: Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115671</a></p>
<p><strong>Summary:</strong> This retrospective multi-center study assessed the prevalence and outcomes of B.K. polyomavirus deoxyribonucleic acidemia (D.N.A.emia) and B.K. polyomavirus D.N.A.emia-associated nephropathy in simultaneous heart-kidney transplant recipients. Analyzing data from January 2005 to June 2022, the research provided crucial insights into the rates of B.K. polyomavirus infection in this specific patient population, where information has been limited. The findings help establish risk profiles and inform management strategies for B.K. polyomavirus infection, potentially improving long-term kidney and patient survival following simultaneous heart-kidney transplantation.</p>
<h4>Article 5: Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41115771" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41115771</a></p>
<p><strong>Summary:</strong> This retrospective cohort study, conducted at a specialized pericardial disease center, aimed to evaluate long-term outcomes and recurrence rates after various rilonacept (R.I.) cessation strategies in adults with recurrent pericarditis (R.P.) refractory to first-line therapies. R.I., an interleukin (I.L.)-1 alpha/beta cytokine trap, has been associated with high R.P. recurrence rates upon discontinuation after 18 months. The study sought to propose preliminary strategies for safe R.I. withdrawal, providing critical data to optimize treatment duration and minimize relapse for patients managing chronic R.P.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury. This study identified an interaction between acetaldehyde dehydrogenase 2 (ALDH2) and eukaryotic initiation factor 3 subunit E (eIF3E) that critically modulates protein translation in cardiomyocytes. This interaction plays a significant role in ferroptosis, an iron-dependent form of regulated cell death caused by lipid peroxidation, observed in acute myocardial ischemia injury. The research reveals how the Glu504Lys polymorphism of ALDH2, which affects a substantial portion of East Asians, influences this mechanism and contributes to increased risk. Understanding this molecular pathway provides a novel therapeutic target for preventing or mitigating acute myocardial infarction.</p>
<p>Article number two. Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. This study investigated the underlying mechanisms of myocardial energy depletion in hypertrophic cardiomyopathy (H.C.M.), a condition characterized by left ventricular hypertrophy and hypercontractility. The research discovered that hypercontractility and subsequent oxidative stress drive dysfunction of creatine kinase (C.K.), a key enzyme in cardiac energy homeostasis. This C.K. dysfunction exacerbates the energetic mismatch in H.C.M., where energy consumption surpasses production. These findings pinpoint specific targets for intervention, suggesting that strategies aimed at reducing hypercontractility, oxidative stress, or enhancing C.K. activity could improve cardiac energetics in H.C.M. patients.</p>
<p>Article number three. Potential Pool of Cardiothoracic Organs from Donors with HIV. This study quantified the potential supply of cardiothoracic organs available from Human Immunodeficiency Virus (H.I.V.)-positive donors for H.I.V.-positive recipients, leveraging recent modifications to H.O.P.E. (Human Organ for Life) research guidelines. Using S.R.T.R. (Scientific Registry of Transplant Recipients) data, the researchers identified a substantial pool of H.I.V.-positive donors suitable for heart and lung transplantation. This research demonstrates the expanded eligibility criteria now allow cardiothoracic programs to participate in H.O.P.E. Act transplantation. These findings highlight a significant breakthrough in expanding access to life-saving organs for H.I.V.-positive individuals, potentially reducing transplant waitlist mortality.</p>
<p>Article number four. Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience. This retrospective multi-center study assessed the prevalence and outcomes of B.K. polyomavirus deoxyribonucleic acidemia (D.N.A.emia) and B.K. polyomavirus D.N.A.emia-associated nephropathy in simultaneous heart-kidney transplant recipients. Analyzing data from January 2005 to June 2022, the research provided crucial insights into the rates of B.K. polyomavirus infection in this specific patient population, where information has been limited. The findings help establish risk profiles and inform management strategies for B.K. polyomavirus infection, potentially improving long-term kidney and patient survival following simultaneous heart-kidney transplantation.</p>
<p>Article number five. Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis. This retrospective cohort study, conducted at a specialized pericardial disease center, aimed to evaluate long-term outcomes and recurrence rates after various rilonacept (R.I.) cessation strategies in adults with recurrent pericarditis (R.P.) refractory to first-line therapies. R.I., an interleukin (I.L.)-1 alpha/beta cytokine trap, has been associated with high R.P. recurrence rates upon discontinuation after 18 months. The study sought to propose preliminary strategies for safe R.I. withdrawal, providing critical data to optimize treatment duration and minimize relapse for patients managing chronic R.P. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>lipid peroxidation, recurrent pericarditis, donor pool, B.K. polyomavirus, rilonacept, myocardial energy depletion, creatine kinase dysfunction, recurrence rates, H.I.V. organ transplantation, interleukin-1 alpha/beta cytokine trap, cessation strategies, transplant outcomes, hypertrophic cardiomyopathy, H.O.P.E. Act, nephropathy, simultaneous heart-kidney transplant, protein translation, acetaldehyde dehydrogenase 2, hypercontractility, cardiothoracic organs, acute myocardial ischemia, deoxyribonucleic acidemia, oxidative stress, ferroptosis, heart transplantation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/">H.I.V. Donors Expand Heart Transplant Pool 10/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251021_025700.mp3" length="5084725" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like lipid peroxidation and recurrent pericarditis. Key takeaway: H.I.V. Donors Expand Heart Transplant Pool.
Article Links:
Article 1: ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury. (Circulation)
Article 2: Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. (Circulation)
Article 3: Potential Pool of Cardiothoracic Organs from Donors with HIV. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/h-i-v-donors-expand-heart-transplant-pool-10-21-25/
 Featured Articles
Article 1: ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41111418
Summary: This study identified an interaction between acetaldehyde dehydrogenase 2 (ALDH2) and eukaryotic initiation factor 3 subunit E (eIF3E) that critically modulates protein translation in cardiomyocytes. This interaction plays a significant role in ferroptosis, an iron-dependent form of regulated cell death caused by lipid peroxidation, observed in acute myocardial ischemia injury. The research reveals how the Glu504Lys polymorphism of ALDH2, which affects a substantial portion of East Asians, influences this mechanism and contributes to increased risk. Understanding this molecular pathway provides a novel therapeutic target for preventing or mitigating acute myocardial infarction.
Article 2: Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41111389
Summary: This study investigated the underlying mechanisms of myocardial energy depletion in hypertrophic cardiomyopathy (H.C.M.), a condition characterized by left ventricular hypertrophy and hypercontractility. The research discovered that hypercontractility and subsequent oxidative stress drive dysfunction of creatine kinase (C.K.), a key enzyme in cardiac energy homeostasis. This C.K. dysfunction exacerbates the energetic mismatch in H.C.M., where energy consumption surpasses production. These findings pinpoint specific targets for intervention, suggesting that strategies aimed at reducing hypercontractility, oxidative stress, or enhancing C.K. activity could improve cardiac energetics in H.C.M. patients.
Article 3: Potential Pool of Cardiothoracic Organs from Donors with HIV.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41115672
Summary: This study quantified the potential supply of cardiothoracic organs available from Human Immunodeficiency Virus (H.I.V.)-positive donors for H.I.V.-positive recipients, leveraging recent modifications to H.O.P.E. (Human Organ for Life) research guidelines. Using S.R.T.R. (Scientific Registry of Transplant Recipients) data, the researchers identified a substantial pool of H.I.V.-positive donors suitable for heart and lung transplantation. This research demonstrates the expanded eligibility criteria now allow cardiothoracic programs to participate in H.O.P.E. Act transplantation. These findings highlight a significant breakthrough in expanding acces]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 21, 2025. This episode summarizes 5 key cardiology studies on topics like lipid peroxidation and recurrent pericarditis. Key takeaway: H.I.V. Donors Expand Heart Transplant Pool.
Article Links:
Article 1: ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury. (Circulation)
Article 2: Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. (Circulation)
Article 3: Potential Pool of Cardiothoracic Organs from Donors with HIV. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Outcomes of BK in Simultaneous Heart Kidney Transplant: A 3 Center Experience. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Comparative analysis of recurrence rat]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Drug-Eluting Balloons for Pediatric Pulmonary Stenosis 10/20/25</title>
	<link>https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/</link>
	<pubDate>Mon, 20 Oct 2025 10:01:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like long-term outcomes and atrial secondary tricuspid regurgitation. Key takeaway: Drug-Eluting Balloons for Pediatric Pulmonary Stenosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41110815">Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41110741">Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease.</a> (American heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41109872">Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study.</a> (Pediatric cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41109871">Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood.</a> (Pediatric cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41109870">Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/">https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110815" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110815</a></p>
<p><strong>Summary:</strong> This study characterized the distinct features and long-term outcomes of severe atrial secondary tricuspid regurgitation (A-S.T.R.) and ventricular secondary tricuspid regurgitation (V-S.T.R.). Researchers identified adults with severe secondary tricuspid regurgitation within a quaternary-care health system and classified them based on left-sided cardiac conditions. By assessing these unique etiologies, the study helps delineate the natural history of tricuspid regurgitation, providing crucial information for understanding its progression. This distinction is vital for guiding future management and therapeutic strategies tailored to the specific pathophysiology of A-S.T.R. versus V-S.T.R.</p>
<h4>Article 2: Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110741</a></p>
<p><strong>Summary:</strong> This study aimed to quantify the burden of worsening heart failure (W.HeF.) events among adults with mild-to-moderate chronic kidney disease (C.K.D.). Researchers identified a contemporary cohort of adults with C.K.D., defined by specific estimated glomerular filtration rate (e.G.F.R.) and albuminuria criteria, within a large integrated healthcare system. The investigation documented outcomes including hospitalization for heart failure, which sheds light on the significant clinical impact of worsening heart failure in this vulnerable patient population. Understanding this burden underscores the need for proactive management strategies to mitigate adverse cardiovascular events in individuals with co-existing mild-to-moderate C.K.D.</p>
<h4>Article 3: Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109872" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109872</a></p>
<p><strong>Summary:</strong> This multicenter cohort study investigated neurodevelopmental outcomes and identified risk factors for impairment in very low birth weight (V.L.B.W.) infants with congenital heart disease (C.H.D.). Researchers assessed neurodevelopment at three years of age in V.L.B.W. infants born without known genetic anomalies. The study successfully established the prevalence of neurodevelopmental impairment and elucidated associated risk factors within this highly vulnerable population. These findings are crucial for developing targeted early intervention programs and improving long-term neurological outcomes for V.L.B.W. infants with C.H.D.</p>
<h4>Article 4: Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109871</a></p>
<p><strong>Summary:</strong> This study evaluated the efficacy of drug-eluting balloon angioplasty (D.E.B.A.) compared to conventional balloon angioplasty (C.B.A.) for treating peripheral pulmonary artery stenoses (P.A.S.) in children. A retrospective qualitative analysis was performed on individual stenoses in pediatric patients. The research aimed to determine if drug-eluting balloons offer a superior or comparable therapeutic option for this common congenital heart defect complication. This comparison provides important clinical data to guide interventional cardiologists in selecting optimal treatment strategies for pediatric P.A.S.</p>
<h4>Article 5: Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109870</a></p>
<p><strong>Summary:</strong> This study explored a potential association between G6P.D. deficiency and the incidence of congenital heart disease (C.H.D.), as well as hospital outcomes for affected individuals. The researchers hypothesized a higher C.H.D. incidence and worse hospital outcomes in individuals with G6P.D. deficiency, possibly due to increased oxidative stress. By investigating this hypothesized link, the study aims to establish whether G6P.D. deficiency is an unrecognized risk factor for C.H.D. and influences patient prognosis. Understanding this relationship could inform screening practices and improve risk stratification for children with congenital heart conditions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry. This study characterized the distinct features and long-term outcomes of severe atrial secondary tricuspid regurgitation (A-S.T.R.) and ventricular secondary tricuspid regurgitation (V-S.T.R.). Researchers identified adults with severe secondary tricuspid regurgitation within a quaternary-care health system and classified them based on left-sided cardiac conditions. By assessing these unique etiologies, the study helps delineate the natural history of tricuspid regurgitation, providing crucial information for understanding its progression. This distinction is vital for guiding future management and therapeutic strategies tailored to the specific pathophysiology of A-S.T.R. versus V-S.T.R.</p>
<p>Article number two. Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease. This study aimed to quantify the burden of worsening heart failure (W.HeF.) events among adults with mild-to-moderate chronic kidney disease (C.K.D.). Researchers identified a contemporary cohort of adults with C.K.D., defined by specific estimated glomerular filtration rate (e.G.F.R.) and albuminuria criteria, within a large integrated healthcare system. The investigation documented outcomes including hospitalization for heart failure, which sheds light on the significant clinical impact of worsening heart failure in this vulnerable patient population. Understanding this burden underscores the need for proactive management strategies to mitigate adverse cardiovascular events in individuals with co-existing mild-to-moderate C.K.D.</p>
<p>Article number three. Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study. This multicenter cohort study investigated neurodevelopmental outcomes and identified risk factors for impairment in very low birth weight (V.L.B.W.) infants with congenital heart disease (C.H.D.). Researchers assessed neurodevelopment at three years of age in V.L.B.W. infants born without known genetic anomalies. The study successfully established the prevalence of neurodevelopmental impairment and elucidated associated risk factors within this highly vulnerable population. These findings are crucial for developing targeted early intervention programs and improving long-term neurological outcomes for V.L.B.W. infants with C.H.D.</p>
<p>Article number four. Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood. This study evaluated the efficacy of drug-eluting balloon angioplasty (D.E.B.A.) compared to conventional balloon angioplasty (C.B.A.) for treating peripheral pulmonary artery stenoses (P.A.S.) in children. A retrospective qualitative analysis was performed on individual stenoses in pediatric patients. The research aimed to determine if drug-eluting balloons offer a superior or comparable therapeutic option for this common congenital heart defect complication. This comparison provides important clinical data to guide interventional cardiologists in selecting optimal treatment strategies for pediatric P.A.S.</p>
<p>Article number five. Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes. This study explored a potential association between G6P.D. deficiency and the incidence of congenital heart disease (C.H.D.), as well as hospital outcomes for affected individuals. The researchers hypothesized a higher C.H.D. incidence and worse hospital outcomes in individuals with G6P.D. deficiency, possibly due to increased oxidative stress. By investigating this hypothesized link, the study aims to establish whether G6P.D. deficiency is an unrecognized risk factor for C.H.D. and influences patient prognosis. Understanding this relationship could inform screening practices and improve risk stratification for children with congenital heart conditions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>long-term outcomes, atrial secondary tricuspid regurgitation, tricuspid regurgitation, congenital heart disease, hospital outcomes, oxidative stress, drug-eluting balloons, pediatric cardiology, G6P.D. deficiency, neurodevelopmental impairment, chronic kidney disease, very low birth weight, ventricular secondary tricuspid regurgitation, hemolytic anemia, conventional balloon angioplasty, heart failure, risk factors, peripheral pulmonary artery stenosis, estimated glomerular filtration rate, hospitalization, valve registry, worsening heart failure, efficacy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/">Drug-Eluting Balloons for Pediatric Pulmonary Stenosis 10/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like long-term outcomes and atrial secondary tricuspid regurgitation. Key takeaway: Drug-Eluting Balloons for Pediatric Pulmonary Stenosis]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like long-term outcomes and atrial secondary tricuspid regurgitation. Key takeaway: Drug-Eluting Balloons for Pediatric Pulmonary Stenosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41110815">Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41110741">Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease.</a> (American heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41109872">Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study.</a> (Pediatric cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41109871">Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood.</a> (Pediatric cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41109870">Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes.</a> (Pediatric cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/">https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110815" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110815</a></p>
<p><strong>Summary:</strong> This study characterized the distinct features and long-term outcomes of severe atrial secondary tricuspid regurgitation (A-S.T.R.) and ventricular secondary tricuspid regurgitation (V-S.T.R.). Researchers identified adults with severe secondary tricuspid regurgitation within a quaternary-care health system and classified them based on left-sided cardiac conditions. By assessing these unique etiologies, the study helps delineate the natural history of tricuspid regurgitation, providing crucial information for understanding its progression. This distinction is vital for guiding future management and therapeutic strategies tailored to the specific pathophysiology of A-S.T.R. versus V-S.T.R.</p>
<h4>Article 2: Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110741</a></p>
<p><strong>Summary:</strong> This study aimed to quantify the burden of worsening heart failure (W.HeF.) events among adults with mild-to-moderate chronic kidney disease (C.K.D.). Researchers identified a contemporary cohort of adults with C.K.D., defined by specific estimated glomerular filtration rate (e.G.F.R.) and albuminuria criteria, within a large integrated healthcare system. The investigation documented outcomes including hospitalization for heart failure, which sheds light on the significant clinical impact of worsening heart failure in this vulnerable patient population. Understanding this burden underscores the need for proactive management strategies to mitigate adverse cardiovascular events in individuals with co-existing mild-to-moderate C.K.D.</p>
<h4>Article 3: Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109872" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109872</a></p>
<p><strong>Summary:</strong> This multicenter cohort study investigated neurodevelopmental outcomes and identified risk factors for impairment in very low birth weight (V.L.B.W.) infants with congenital heart disease (C.H.D.). Researchers assessed neurodevelopment at three years of age in V.L.B.W. infants born without known genetic anomalies. The study successfully established the prevalence of neurodevelopmental impairment and elucidated associated risk factors within this highly vulnerable population. These findings are crucial for developing targeted early intervention programs and improving long-term neurological outcomes for V.L.B.W. infants with C.H.D.</p>
<h4>Article 4: Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109871</a></p>
<p><strong>Summary:</strong> This study evaluated the efficacy of drug-eluting balloon angioplasty (D.E.B.A.) compared to conventional balloon angioplasty (C.B.A.) for treating peripheral pulmonary artery stenoses (P.A.S.) in children. A retrospective qualitative analysis was performed on individual stenoses in pediatric patients. The research aimed to determine if drug-eluting balloons offer a superior or comparable therapeutic option for this common congenital heart defect complication. This comparison provides important clinical data to guide interventional cardiologists in selecting optimal treatment strategies for pediatric P.A.S.</p>
<h4>Article 5: Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes.</h4>
<p><strong>Journal:</strong> Pediatric cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109870</a></p>
<p><strong>Summary:</strong> This study explored a potential association between G6P.D. deficiency and the incidence of congenital heart disease (C.H.D.), as well as hospital outcomes for affected individuals. The researchers hypothesized a higher C.H.D. incidence and worse hospital outcomes in individuals with G6P.D. deficiency, possibly due to increased oxidative stress. By investigating this hypothesized link, the study aims to establish whether G6P.D. deficiency is an unrecognized risk factor for C.H.D. and influences patient prognosis. Understanding this relationship could inform screening practices and improve risk stratification for children with congenital heart conditions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry. This study characterized the distinct features and long-term outcomes of severe atrial secondary tricuspid regurgitation (A-S.T.R.) and ventricular secondary tricuspid regurgitation (V-S.T.R.). Researchers identified adults with severe secondary tricuspid regurgitation within a quaternary-care health system and classified them based on left-sided cardiac conditions. By assessing these unique etiologies, the study helps delineate the natural history of tricuspid regurgitation, providing crucial information for understanding its progression. This distinction is vital for guiding future management and therapeutic strategies tailored to the specific pathophysiology of A-S.T.R. versus V-S.T.R.</p>
<p>Article number two. Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease. This study aimed to quantify the burden of worsening heart failure (W.HeF.) events among adults with mild-to-moderate chronic kidney disease (C.K.D.). Researchers identified a contemporary cohort of adults with C.K.D., defined by specific estimated glomerular filtration rate (e.G.F.R.) and albuminuria criteria, within a large integrated healthcare system. The investigation documented outcomes including hospitalization for heart failure, which sheds light on the significant clinical impact of worsening heart failure in this vulnerable patient population. Understanding this burden underscores the need for proactive management strategies to mitigate adverse cardiovascular events in individuals with co-existing mild-to-moderate C.K.D.</p>
<p>Article number three. Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study. This multicenter cohort study investigated neurodevelopmental outcomes and identified risk factors for impairment in very low birth weight (V.L.B.W.) infants with congenital heart disease (C.H.D.). Researchers assessed neurodevelopment at three years of age in V.L.B.W. infants born without known genetic anomalies. The study successfully established the prevalence of neurodevelopmental impairment and elucidated associated risk factors within this highly vulnerable population. These findings are crucial for developing targeted early intervention programs and improving long-term neurological outcomes for V.L.B.W. infants with C.H.D.</p>
<p>Article number four. Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood. This study evaluated the efficacy of drug-eluting balloon angioplasty (D.E.B.A.) compared to conventional balloon angioplasty (C.B.A.) for treating peripheral pulmonary artery stenoses (P.A.S.) in children. A retrospective qualitative analysis was performed on individual stenoses in pediatric patients. The research aimed to determine if drug-eluting balloons offer a superior or comparable therapeutic option for this common congenital heart defect complication. This comparison provides important clinical data to guide interventional cardiologists in selecting optimal treatment strategies for pediatric P.A.S.</p>
<p>Article number five. Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes. This study explored a potential association between G6P.D. deficiency and the incidence of congenital heart disease (C.H.D.), as well as hospital outcomes for affected individuals. The researchers hypothesized a higher C.H.D. incidence and worse hospital outcomes in individuals with G6P.D. deficiency, possibly due to increased oxidative stress. By investigating this hypothesized link, the study aims to establish whether G6P.D. deficiency is an unrecognized risk factor for C.H.D. and influences patient prognosis. Understanding this relationship could inform screening practices and improve risk stratification for children with congenital heart conditions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>long-term outcomes, atrial secondary tricuspid regurgitation, tricuspid regurgitation, congenital heart disease, hospital outcomes, oxidative stress, drug-eluting balloons, pediatric cardiology, G6P.D. deficiency, neurodevelopmental impairment, chronic kidney disease, very low birth weight, ventricular secondary tricuspid regurgitation, hemolytic anemia, conventional balloon angioplasty, heart failure, risk factors, peripheral pulmonary artery stenosis, estimated glomerular filtration rate, hospitalization, valve registry, worsening heart failure, efficacy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/">Drug-Eluting Balloons for Pediatric Pulmonary Stenosis 10/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251020_060035.mp3" length="4671781" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like long-term outcomes and atrial secondary tricuspid regurgitation. Key takeaway: Drug-Eluting Balloons for Pediatric Pulmonary Stenosis.
Article Links:
Article 1: Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry. (The American journal of cardiology)
Article 2: Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease. (American heart journal)
Article 3: Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study. (Pediatric cardiology)
Article 4: Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood. (Pediatric cardiology)
Article 5: Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes. (Pediatric cardiology)
Full episode page: https://podcast.explainheart.com/podcast/drug-eluting-balloons-for-pediatric-pulmonary-stenosis-10-20-25/
 Featured Articles
Article 1: Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41110815
Summary: This study characterized the distinct features and long-term outcomes of severe atrial secondary tricuspid regurgitation (A-S.T.R.) and ventricular secondary tricuspid regurgitation (V-S.T.R.). Researchers identified adults with severe secondary tricuspid regurgitation within a quaternary-care health system and classified them based on left-sided cardiac conditions. By assessing these unique etiologies, the study helps delineate the natural history of tricuspid regurgitation, providing crucial information for understanding its progression. This distinction is vital for guiding future management and therapeutic strategies tailored to the specific pathophysiology of A-S.T.R. versus V-S.T.R.
Article 2: Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease.
Journal: American heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41110741
Summary: This study aimed to quantify the burden of worsening heart failure (W.HeF.) events among adults with mild-to-moderate chronic kidney disease (C.K.D.). Researchers identified a contemporary cohort of adults with C.K.D., defined by specific estimated glomerular filtration rate (e.G.F.R.) and albuminuria criteria, within a large integrated healthcare system. The investigation documented outcomes including hospitalization for heart failure, which sheds light on the significant clinical impact of worsening heart failure in this vulnerable patient population. Understanding this burden underscores the need for proactive management strategies to mitigate adverse cardiovascular events in individuals with co-existing mild-to-moderate C.K.D.
Article 3: Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study.
Journal: Pediatric cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41109872
Summary: This multicenter cohort study investigated neurodevelopmental outcomes and identified risk factors for impairment in very low birth weight (V.L.B.W.) infants with congenital heart disease (C.H.D.). Researchers assessed neurodevelopment at three years of age in V.L.B.W. infants born without known genetic anomalies. The study successfully established the prevalence of neurodevelopmental impairment and elucidated associated risk factors within this highly vulnerable population. These findings are crucial for developing targeted early intervention programs and improving long-term neurological outcomes for V.L.B.W. infants with C.H.D.
Article 4: Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pu]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like long-term outcomes and atrial secondary tricuspid regurgitation. Key takeaway: Drug-Eluting Balloons for Pediatric Pulmonary Stenosis.
Article Links:
Article 1: Natural History of Atrial versus Ventricular Secondary Tricuspid Regurgitation: Insights from the Bronx-Valve Registry. (The American journal of cardiology)
Article 2: Worsening Heart Failure Events in Adults with Mild-to-Moderate Chronic Kidney Disease. (American heart journal)
Article 3: Neurological Development in Very Low Birth Weight Infants with Congenital Heart Disease at 3 Years of Age: A Japanese Multicenter Study. (Pediatric cardiology)
Article 4: Drug-Eluting Balloons Versus Conventional Balloon Angioplasty for Peripheral Pulmonary Artery Stenosis in Childhood. (Pediatric cardiology)
Article 5: Association Between G6PD Deficiency and Congenital Heart Disease Incidence and Hospital Outcomes. (Pedia]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Defib Lead for LBB Pacing 10/20/25</title>
	<link>https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/</link>
	<pubDate>Mon, 20 Oct 2025 06:59:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like Defibrillation lead and echocardiography. Key takeaway: New Defib Lead for LBB Pacing.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41110530">The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41110529">Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41110528">Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41110817">Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41110816">Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/">https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110530" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110530</a></p>
<p><strong>Summary:</strong> This study aimed to assess the standalone predictive power of Left Atrial Reservoir Strain (L.A.R.S.) measures obtained from two-dimensional echocardiograms for long-term Atrial Fibrillation (A.fib) prediction over 5 and 10 years. Researchers analyzed data from 5,442 older adults (median age 74) from the Atherosclerosis Risk in Communities (A.R.I.C.) study who had no prior Atrial Fibrillation. By investigating L.A.R.S., the study sought to determine if this measure could independently predict future Atrial Fibrillation development. Establishing such a predictive value would enable earlier identification of individuals at high risk for Atrial Fibrillation, facilitating timely monitoring and intervention strategies.</p>
<h4>Article 2: Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110529" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110529</a></p>
<p><strong>Summary:</strong> The L.E.A.D.R. L.B.B.A.P. clinical trial investigated the defibrillation efficacy at implant and the safety profile of the OmniaSecure lead when used for Left Bundle Branch Area Pacing (L.B.B.A.P.). This study aimed to determine if this lead, previously successful in Right Ventricular placement, could serve as a viable option for physiological pacing in patients requiring an implantable cardioverter-defibrillator (I.C.D.). By enrolling patients indicated for I.C.D. placement globally, the trial sought to establish the lead&#8217;s performance. Successful integration of Left Bundle Branch Area Pacing with defibrillation capabilities could offer a significant advancement in cardiac rhythm management for these patients.</p>
<h4>Article 3: Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110528</a></p>
<p><strong>Summary:</strong> This study investigated the characteristics and efficacy of pacing optimization strategies for patients experiencing a high percentage of ineffective Cardiac Resynchronization Therapy (C.R.T.). High ineffective C.R.T. pacing ( percenti-C.R.T.) has been linked to poor patient prognosis, yet optimal follow-up settings for these individuals remain unclear. Researchers assessed 225 consecutive patients between 2018 and 2024 using the EffectivC.R.T. system from Medtronic Inc. The goal was to establish effective methods for optimizing C.R.T. delivery, potentially improving outcomes for patients who are not adequately responding to standard therapy.</p>
<h4>Article 4: Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110817" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110817</a></p>
<p><strong>Summary:</strong> This study aimed to evaluate the clinical and prognostic relevance of precipitating factors in patients presenting with Spontaneous Coronary Artery Dissection (S.C.A.D.), a rare cause of acute coronary syndrome (A.C.S.). While S.C.A.D. has traditionally been linked to pregnancy, it is increasingly associated with emotional and physical stressors. The prospective Spanish S.C.A.D. Registry (R.N.-D.C.E.) provided data from 388 patients across 34 centers since 2015, with coronary angiograms reviewed. By clarifying the impact of these factors, the research contributes to better understanding S.C.A.D. etiology and improving risk stratification and patient management.</p>
<h4>Article 5: Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110816" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110816</a></p>
<p><strong>Summary:</strong> This study aimed to investigate the incidence and identify specific predictors of new-onset Atrial Fibrillation (A.fib) following Cavotricuspid Isthmus (C.T.I.) ablation, a highly effective treatment for typical Atrial Flutter (A.F.L.). While C.T.I. ablation successfully treats Atrial Flutter, the subsequent emergence of Atrial Fibrillation is a known clinical concern with limited data on its predictors. Researchers included patients who underwent C.T.I. ablation between 2016 and 2022, assessing baseline variables such as Left Atrial Volume Index (L.A.V.I.) and cardiac comorbidities. Identifying these predictors could significantly improve patient selection, risk assessment, and post-procedural management to mitigate the risk of developing new-onset Atrial Fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study. This study aimed to assess the standalone predictive power of Left Atrial Reservoir Strain (L.A.R.S.) measures obtained from two-dimensional echocardiograms for long-term Atrial Fibrillation (A.fib) prediction over 5 and 10 years. Researchers analyzed data from 5,442 older adults (median age 74) from the Atherosclerosis Risk in Communities (A.R.I.C.) study who had no prior Atrial Fibrillation. By investigating L.A.R.S., the study sought to determine if this measure could independently predict future Atrial Fibrillation development. Establishing such a predictive value would enable earlier identification of individuals at high risk for Atrial Fibrillation, facilitating timely monitoring and intervention strategies.</p>
<p>Article number two. Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial. The L.E.A.D.R. L.B.B.A.P. clinical trial investigated the defibrillation efficacy at implant and the safety profile of the OmniaSecure lead when used for Left Bundle Branch Area Pacing (L.B.B.A.P.). This study aimed to determine if this lead, previously successful in Right Ventricular placement, could serve as a viable option for physiological pacing in patients requiring an implantable cardioverter-defibrillator (I.C.D.). By enrolling patients indicated for I.C.D. placement globally, the trial sought to establish the lead&#8217;s performance. Successful integration of Left Bundle Branch Area Pacing with defibrillation capabilities could offer a significant advancement in cardiac rhythm management for these patients.</p>
<p>Article number three. Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy. This study investigated the characteristics and efficacy of pacing optimization strategies for patients experiencing a high percentage of ineffective Cardiac Resynchronization Therapy (C.R.T.). High ineffective C.R.T. pacing ( percenti-C.R.T.) has been linked to poor patient prognosis, yet optimal follow-up settings for these individuals remain unclear. Researchers assessed 225 consecutive patients between 2018 and 2024 using the EffectivC.R.T. system from Medtronic Inc. The goal was to establish effective methods for optimizing C.R.T. delivery, potentially improving outcomes for patients who are not adequately responding to standard therapy.</p>
<p>Article number four. Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection. This study aimed to evaluate the clinical and prognostic relevance of precipitating factors in patients presenting with Spontaneous Coronary Artery Dissection (S.C.A.D.), a rare cause of acute coronary syndrome (A.C.S.). While S.C.A.D. has traditionally been linked to pregnancy, it is increasingly associated with emotional and physical stressors. The prospective Spanish S.C.A.D. Registry (R.N.-D.C.E.) provided data from 388 patients across 34 centers since 2015, with coronary angiograms reviewed. By clarifying the impact of these factors, the research contributes to better understanding S.C.A.D. etiology and improving risk stratification and patient management.</p>
<p>Article number five. Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter. This study aimed to investigate the incidence and identify specific predictors of new-onset Atrial Fibrillation (A.fib) following Cavotricuspid Isthmus (C.T.I.) ablation, a highly effective treatment for typical Atrial Flutter (A.F.L.). While C.T.I. ablation successfully treats Atrial Flutter, the subsequent emergence of Atrial Fibrillation is a known clinical concern with limited data on its predictors. Researchers included patients who underwent C.T.I. ablation between 2016 and 2022, assessing baseline variables such as Left Atrial Volume Index (L.A.V.I.) and cardiac comorbidities. Identifying these predictors could significantly improve patient selection, risk assessment, and post-procedural management to mitigate the risk of developing new-onset Atrial Fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Defibrillation lead, echocardiography, post-ablation complications, implantable cardioverter-defibrillator, acute coronary syndrome, Left Bundle Branch Area Pacing, EffectivC.R.T., pacing optimization, S.C.A.D. Registry, long-term prediction, Left Atrial Reservoir Strain, Cavotricuspid Isthmus ablation, prognosis, Atrial Flutter, precipitating factors, Atrial Fibrillation, lead safety, Atherosclerosis Risk in Communities study, Left Atrial Volume Index, Cardiac Resynchronization Therapy, LEADR LBBAP clinical trial, new-onset Atrial Fibrillation, Spontaneous Coronary Artery Dissection, ineffective pacing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/">New Defib Lead for LBB Pacing 10/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like Defibrillation lead and echocardiography. Key takeaway: New Defib Lead for LBB Pacing.
Article Links:
Article 1: The Predictive Power]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like Defibrillation lead and echocardiography. Key takeaway: New Defib Lead for LBB Pacing.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41110530">The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41110529">Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41110528">Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41110817">Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41110816">Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/">https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110530" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110530</a></p>
<p><strong>Summary:</strong> This study aimed to assess the standalone predictive power of Left Atrial Reservoir Strain (L.A.R.S.) measures obtained from two-dimensional echocardiograms for long-term Atrial Fibrillation (A.fib) prediction over 5 and 10 years. Researchers analyzed data from 5,442 older adults (median age 74) from the Atherosclerosis Risk in Communities (A.R.I.C.) study who had no prior Atrial Fibrillation. By investigating L.A.R.S., the study sought to determine if this measure could independently predict future Atrial Fibrillation development. Establishing such a predictive value would enable earlier identification of individuals at high risk for Atrial Fibrillation, facilitating timely monitoring and intervention strategies.</p>
<h4>Article 2: Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110529" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110529</a></p>
<p><strong>Summary:</strong> The L.E.A.D.R. L.B.B.A.P. clinical trial investigated the defibrillation efficacy at implant and the safety profile of the OmniaSecure lead when used for Left Bundle Branch Area Pacing (L.B.B.A.P.). This study aimed to determine if this lead, previously successful in Right Ventricular placement, could serve as a viable option for physiological pacing in patients requiring an implantable cardioverter-defibrillator (I.C.D.). By enrolling patients indicated for I.C.D. placement globally, the trial sought to establish the lead&#8217;s performance. Successful integration of Left Bundle Branch Area Pacing with defibrillation capabilities could offer a significant advancement in cardiac rhythm management for these patients.</p>
<h4>Article 3: Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110528</a></p>
<p><strong>Summary:</strong> This study investigated the characteristics and efficacy of pacing optimization strategies for patients experiencing a high percentage of ineffective Cardiac Resynchronization Therapy (C.R.T.). High ineffective C.R.T. pacing ( percenti-C.R.T.) has been linked to poor patient prognosis, yet optimal follow-up settings for these individuals remain unclear. Researchers assessed 225 consecutive patients between 2018 and 2024 using the EffectivC.R.T. system from Medtronic Inc. The goal was to establish effective methods for optimizing C.R.T. delivery, potentially improving outcomes for patients who are not adequately responding to standard therapy.</p>
<h4>Article 4: Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110817" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110817</a></p>
<p><strong>Summary:</strong> This study aimed to evaluate the clinical and prognostic relevance of precipitating factors in patients presenting with Spontaneous Coronary Artery Dissection (S.C.A.D.), a rare cause of acute coronary syndrome (A.C.S.). While S.C.A.D. has traditionally been linked to pregnancy, it is increasingly associated with emotional and physical stressors. The prospective Spanish S.C.A.D. Registry (R.N.-D.C.E.) provided data from 388 patients across 34 centers since 2015, with coronary angiograms reviewed. By clarifying the impact of these factors, the research contributes to better understanding S.C.A.D. etiology and improving risk stratification and patient management.</p>
<h4>Article 5: Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41110816" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41110816</a></p>
<p><strong>Summary:</strong> This study aimed to investigate the incidence and identify specific predictors of new-onset Atrial Fibrillation (A.fib) following Cavotricuspid Isthmus (C.T.I.) ablation, a highly effective treatment for typical Atrial Flutter (A.F.L.). While C.T.I. ablation successfully treats Atrial Flutter, the subsequent emergence of Atrial Fibrillation is a known clinical concern with limited data on its predictors. Researchers included patients who underwent C.T.I. ablation between 2016 and 2022, assessing baseline variables such as Left Atrial Volume Index (L.A.V.I.) and cardiac comorbidities. Identifying these predictors could significantly improve patient selection, risk assessment, and post-procedural management to mitigate the risk of developing new-onset Atrial Fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study. This study aimed to assess the standalone predictive power of Left Atrial Reservoir Strain (L.A.R.S.) measures obtained from two-dimensional echocardiograms for long-term Atrial Fibrillation (A.fib) prediction over 5 and 10 years. Researchers analyzed data from 5,442 older adults (median age 74) from the Atherosclerosis Risk in Communities (A.R.I.C.) study who had no prior Atrial Fibrillation. By investigating L.A.R.S., the study sought to determine if this measure could independently predict future Atrial Fibrillation development. Establishing such a predictive value would enable earlier identification of individuals at high risk for Atrial Fibrillation, facilitating timely monitoring and intervention strategies.</p>
<p>Article number two. Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial. The L.E.A.D.R. L.B.B.A.P. clinical trial investigated the defibrillation efficacy at implant and the safety profile of the OmniaSecure lead when used for Left Bundle Branch Area Pacing (L.B.B.A.P.). This study aimed to determine if this lead, previously successful in Right Ventricular placement, could serve as a viable option for physiological pacing in patients requiring an implantable cardioverter-defibrillator (I.C.D.). By enrolling patients indicated for I.C.D. placement globally, the trial sought to establish the lead&#8217;s performance. Successful integration of Left Bundle Branch Area Pacing with defibrillation capabilities could offer a significant advancement in cardiac rhythm management for these patients.</p>
<p>Article number three. Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy. This study investigated the characteristics and efficacy of pacing optimization strategies for patients experiencing a high percentage of ineffective Cardiac Resynchronization Therapy (C.R.T.). High ineffective C.R.T. pacing ( percenti-C.R.T.) has been linked to poor patient prognosis, yet optimal follow-up settings for these individuals remain unclear. Researchers assessed 225 consecutive patients between 2018 and 2024 using the EffectivC.R.T. system from Medtronic Inc. The goal was to establish effective methods for optimizing C.R.T. delivery, potentially improving outcomes for patients who are not adequately responding to standard therapy.</p>
<p>Article number four. Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection. This study aimed to evaluate the clinical and prognostic relevance of precipitating factors in patients presenting with Spontaneous Coronary Artery Dissection (S.C.A.D.), a rare cause of acute coronary syndrome (A.C.S.). While S.C.A.D. has traditionally been linked to pregnancy, it is increasingly associated with emotional and physical stressors. The prospective Spanish S.C.A.D. Registry (R.N.-D.C.E.) provided data from 388 patients across 34 centers since 2015, with coronary angiograms reviewed. By clarifying the impact of these factors, the research contributes to better understanding S.C.A.D. etiology and improving risk stratification and patient management.</p>
<p>Article number five. Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter. This study aimed to investigate the incidence and identify specific predictors of new-onset Atrial Fibrillation (A.fib) following Cavotricuspid Isthmus (C.T.I.) ablation, a highly effective treatment for typical Atrial Flutter (A.F.L.). While C.T.I. ablation successfully treats Atrial Flutter, the subsequent emergence of Atrial Fibrillation is a known clinical concern with limited data on its predictors. Researchers included patients who underwent C.T.I. ablation between 2016 and 2022, assessing baseline variables such as Left Atrial Volume Index (L.A.V.I.) and cardiac comorbidities. Identifying these predictors could significantly improve patient selection, risk assessment, and post-procedural management to mitigate the risk of developing new-onset Atrial Fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Defibrillation lead, echocardiography, post-ablation complications, implantable cardioverter-defibrillator, acute coronary syndrome, Left Bundle Branch Area Pacing, EffectivC.R.T., pacing optimization, S.C.A.D. Registry, long-term prediction, Left Atrial Reservoir Strain, Cavotricuspid Isthmus ablation, prognosis, Atrial Flutter, precipitating factors, Atrial Fibrillation, lead safety, Atherosclerosis Risk in Communities study, Left Atrial Volume Index, Cardiac Resynchronization Therapy, LEADR LBBAP clinical trial, new-onset Atrial Fibrillation, Spontaneous Coronary Artery Dissection, ineffective pacing.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/">New Defib Lead for LBB Pacing 10/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251020_025717.mp3" length="4918795" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like Defibrillation lead and echocardiography. Key takeaway: New Defib Lead for LBB Pacing.
Article Links:
Article 1: The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study. (Heart rhythm)
Article 2: Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial. (Heart rhythm)
Article 3: Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy. (Heart rhythm)
Article 4: Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection. (The American journal of cardiology)
Article 5: Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-defib-lead-for-lbb-pacing-10-20-25/
 Featured Articles
Article 1: The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41110530
Summary: This study aimed to assess the standalone predictive power of Left Atrial Reservoir Strain (L.A.R.S.) measures obtained from two-dimensional echocardiograms for long-term Atrial Fibrillation (A.fib) prediction over 5 and 10 years. Researchers analyzed data from 5,442 older adults (median age 74) from the Atherosclerosis Risk in Communities (A.R.I.C.) study who had no prior Atrial Fibrillation. By investigating L.A.R.S., the study sought to determine if this measure could independently predict future Atrial Fibrillation development. Establishing such a predictive value would enable earlier identification of individuals at high risk for Atrial Fibrillation, facilitating timely monitoring and intervention strategies.
Article 2: Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41110529
Summary: The L.E.A.D.R. L.B.B.A.P. clinical trial investigated the defibrillation efficacy at implant and the safety profile of the OmniaSecure lead when used for Left Bundle Branch Area Pacing (L.B.B.A.P.). This study aimed to determine if this lead, previously successful in Right Ventricular placement, could serve as a viable option for physiological pacing in patients requiring an implantable cardioverter-defibrillator (I.C.D.). By enrolling patients indicated for I.C.D. placement globally, the trial sought to establish the lead&#8217;s performance. Successful integration of Left Bundle Branch Area Pacing with defibrillation capabilities could offer a significant advancement in cardiac rhythm management for these patients.
Article 3: Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41110528
Summary: This study investigated the characteristics and efficacy of pacing optimization strategies for patients experiencing a high percentage of ineffective Cardiac Resynchronization Therapy (C.R.T.). High ineffective C.R.T. pacing ( percenti-C.R.T.) has been linked to poor patient prognosis, yet optimal follow-up settings for these individuals remain unclear. Researchers assessed 225 consecutive patients between 2018 and 2024 using the EffectivC.R.T. system from Medtronic Inc. The goal was to establish effective methods for optimizing C.R.T. delivery, potentially improving outcomes for patients who are not adequately responding to standard therapy.
Article 4: Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneo]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 20, 2025. This episode summarizes 5 key cardiology studies on topics like Defibrillation lead and echocardiography. Key takeaway: New Defib Lead for LBB Pacing.
Article Links:
Article 1: The Predictive Power of Left Atrial Reservoir Strain for Long-Term Atrial Fibrillation in The Atherosclerosis Risk in Communities (ARIC) Study. (Heart rhythm)
Article 2: Safety and performance of a novel defibrillation lead for left bundle branch area placement: primary results of the LEADR LBBAP clinical trial. (Heart rhythm)
Article 3: Optimization of Pacing for Patients Receiving Ineffective Cardiac Resynchronization Therapy. (Heart rhythm)
Article 4: Clinical and Prognostic Implications of Precipitating Factors in Patients with Spontaneous Coronary Artery Dissection. (The American journal of cardiology)
Article 5: Incidence and Predictors of Atrial Fibrillation After Cavotricuspid Isthmus Ablation for Typical Atrial Flutter. (The American journal of c]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Targeting MTSS1 Improves DCM Contractility 10/19/25</title>
	<link>https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/</link>
	<pubDate>Sun, 19 Oct 2025 10:01:51 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like sarcomere and intensive care unit. Key takeaway: Targeting MTSS1 Improves DCM Contractility.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41094718">Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41104452">Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41108838">Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM.</a> (JACC. Basic to translational science)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41094715">Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support.</a> (European heart journal. Acute cardiovascular care)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41099834">Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study.</a> (American journal of hypertension)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/">https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41094718" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41094718</a></p>
<p><strong>Summary:</strong> This study investigated if pyridoxal 5&#8242; phosphate (P.L.P.), the active form of vitamin B6, could treat hypertension by antagonizing P2X3 receptors in carotid bodies. Using a multipronged approach, researchers found that P.L.P. inhibited P2X3 receptor activity in Spontaneously Hypertensive rats (S.H.R.). This antagonism can attenuate carotid body hyperexcitability, which underlies chemoreflex-mediated sympathetic overactivity in hypertension. These findings suggest P.L.P. is a potential therapeutic agent for hypertension by specifically targeting carotid body P2X3 receptors.</p>
<h4>Article 2: Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104452" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104452</a></p>
<p><strong>Summary:</strong> This research aimed to clarify the role of peptide deformylase in aldosterone overproduction, particularly in aldosterone-producing adenoma. Investigators validated that peptide deformylase expression was significantly upregulated in enlarged aldosterone-producing adenomas. The study discovered that peptide deformylase regulates aldosterone production through calbindin 1, revealing a novel molecular mechanism. This finding advances the understanding of primary aldosteronism pathophysiology and identifies peptide deformylase as a potential new therapeutic target for aldosterone overproduction.</p>
<h4>Article 3: Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM.</h4>
<p><strong>Journal:</strong> JACC. Basic to translational science</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41108838" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41108838</a></p>
<p><strong>Summary:</strong> This study explored the impact of M.T.S.S.1 protein expression on heart failure and contractility in dilated cardiomyopathy (D.C.M.). Human genetic analyses revealed that a variant lowering cardiac M.T.S.S.1 expression was linked to significantly improved survival in individuals with T.T.N. dilated cardiomyopathy. Experimental knockdown of M.T.S.S.1 via small interfering R.N.A. (s.i.R.N.A.) in induced pluripotent stem cell-derived cardiomyocytes improved sarcomere number and contractility in models of T.T.N., C.S.R.P.3, and R.B.M.20 related D.C.M. These results indicate that targeting M.T.S.S.1 expression offers a promising therapeutic strategy to enhance cardiac function and survival in specific monogenic forms of dilated cardiomyopathy.</p>
<h4>Article 4: Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support.</h4>
<p><strong>Journal:</strong> European heart journal. Acute cardiovascular care</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41094715" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41094715</a></p>
<p><strong>Summary:</strong> This review outlines foundational pillars for establishing structured peer support programs to enhance psychological safety and resilience among intensive care unit (I.C.U.) professionals. The review establishes that these programs, delivered by trained colleagues, offer a low-threshold and scalable intervention for addressing psychological distress, moral injury, and burnout in the I.C.U. environment. It details five key components crucial for successful program implementation. Such interventions are vital for improving individual well-being, fostering better team dynamics, and ultimately enhancing patient safety within the intensive care unit.</p>
<h4>Article 5: Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41099834" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41099834</a></p>
<p><strong>Summary:</strong> This research investigated the connection between inter-arm blood pressure (B.P.) difference and subclinical cardiac and vascular damage within a community-based population. The Pressioni Monitorate E Loro Associazioni (P.A.M.E.L.A.) study included 527 participants assessed after 25 years. The findings established a clear association between a significant inter-arm B.P. difference and the presence of subclinical cardiac and vascular damage. This suggests that detecting an inter-arm B.P. difference during routine measurements can serve as an early indicator for subclinical organ damage, potentially guiding earlier diagnostic evaluation and preventative strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension. This study investigated if pyridoxal 5&#8242; phosphate (P.L.P.), the active form of vitamin B6, could treat hypertension by antagonizing P2X3 receptors in carotid bodies. Using a multipronged approach, researchers found that P.L.P. inhibited P2X3 receptor activity in Spontaneously Hypertensive rats (S.H.R.). This antagonism can attenuate carotid body hyperexcitability, which underlies chemoreflex-mediated sympathetic overactivity in hypertension. These findings suggest P.L.P. is a potential therapeutic agent for hypertension by specifically targeting carotid body P2X3 receptors.</p>
<p>Article number two. Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1. This research aimed to clarify the role of peptide deformylase in aldosterone overproduction, particularly in aldosterone-producing adenoma. Investigators validated that peptide deformylase expression was significantly upregulated in enlarged aldosterone-producing adenomas. The study discovered that peptide deformylase regulates aldosterone production through calbindin 1, revealing a novel molecular mechanism. This finding advances the understanding of primary aldosteronism pathophysiology and identifies peptide deformylase as a potential new therapeutic target for aldosterone overproduction.</p>
<p>Article number three. Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM. This study explored the impact of M.T.S.S.1 protein expression on heart failure and contractility in dilated cardiomyopathy (D.C.M.). Human genetic analyses revealed that a variant lowering cardiac M.T.S.S.1 expression was linked to significantly improved survival in individuals with T.T.N. dilated cardiomyopathy. Experimental knockdown of M.T.S.S.1 via small interfering R.N.A. (s.i.R.N.A.) in induced pluripotent stem cell-derived cardiomyocytes improved sarcomere number and contractility in models of T.T.N., C.S.R.P.3, and R.B.M.20 related D.C.M. These results indicate that targeting M.T.S.S.1 expression offers a promising therapeutic strategy to enhance cardiac function and survival in specific monogenic forms of dilated cardiomyopathy.</p>
<p>Article number four. Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support. This review outlines foundational pillars for establishing structured peer support programs to enhance psychological safety and resilience among intensive care unit (I.C.U.) professionals. The review establishes that these programs, delivered by trained colleagues, offer a low-threshold and scalable intervention for addressing psychological distress, moral injury, and burnout in the I.C.U. environment. It details five key components crucial for successful program implementation. Such interventions are vital for improving individual well-being, fostering better team dynamics, and ultimately enhancing patient safety within the intensive care unit.</p>
<p>Article number five. Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study. This research investigated the connection between inter-arm blood pressure (B.P.) difference and subclinical cardiac and vascular damage within a community-based population. The Pressioni Monitorate E Loro Associazioni (P.A.M.E.L.A.) study included 527 participants assessed after 25 years. The findings established a clear association between a significant inter-arm B.P. difference and the presence of subclinical cardiac and vascular damage. This suggests that detecting an inter-arm B.P. difference during routine measurements can serve as an early indicator for subclinical organ damage, potentially guiding earlier diagnostic evaluation and preventative strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sarcomere, intensive care unit, burnout, sympathetic overactivity, vascular damage, primary aldosteronism, dilated cardiomyopathy, pyridoxal 5&#8242; phosphate, psychological safety, peer support, P2X3 receptors, cardiac damage, aldosterone-producing adenoma, T.T.N., carotid body, aldosterone, cardiac contractility, P.A.M.E.L.A. study, hypertension, calbindin 1, peptide deformylase, M.T.S.S.1, inter-arm blood pressure difference, moral injury, subclinical organ damage.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/">Targeting MTSS1 Improves DCM Contractility 10/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like sarcomere and intensive care unit. Key takeaway: Targeting MTSS1 Improves DCM Contractility.
Article Links:
Article 1: Vitamin B6 (py]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like sarcomere and intensive care unit. Key takeaway: Targeting MTSS1 Improves DCM Contractility.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41094718">Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41104452">Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41108838">Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM.</a> (JACC. Basic to translational science)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41094715">Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support.</a> (European heart journal. Acute cardiovascular care)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41099834">Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study.</a> (American journal of hypertension)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/">https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41094718" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41094718</a></p>
<p><strong>Summary:</strong> This study investigated if pyridoxal 5&#8242; phosphate (P.L.P.), the active form of vitamin B6, could treat hypertension by antagonizing P2X3 receptors in carotid bodies. Using a multipronged approach, researchers found that P.L.P. inhibited P2X3 receptor activity in Spontaneously Hypertensive rats (S.H.R.). This antagonism can attenuate carotid body hyperexcitability, which underlies chemoreflex-mediated sympathetic overactivity in hypertension. These findings suggest P.L.P. is a potential therapeutic agent for hypertension by specifically targeting carotid body P2X3 receptors.</p>
<h4>Article 2: Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104452" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104452</a></p>
<p><strong>Summary:</strong> This research aimed to clarify the role of peptide deformylase in aldosterone overproduction, particularly in aldosterone-producing adenoma. Investigators validated that peptide deformylase expression was significantly upregulated in enlarged aldosterone-producing adenomas. The study discovered that peptide deformylase regulates aldosterone production through calbindin 1, revealing a novel molecular mechanism. This finding advances the understanding of primary aldosteronism pathophysiology and identifies peptide deformylase as a potential new therapeutic target for aldosterone overproduction.</p>
<h4>Article 3: Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM.</h4>
<p><strong>Journal:</strong> JACC. Basic to translational science</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41108838" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41108838</a></p>
<p><strong>Summary:</strong> This study explored the impact of M.T.S.S.1 protein expression on heart failure and contractility in dilated cardiomyopathy (D.C.M.). Human genetic analyses revealed that a variant lowering cardiac M.T.S.S.1 expression was linked to significantly improved survival in individuals with T.T.N. dilated cardiomyopathy. Experimental knockdown of M.T.S.S.1 via small interfering R.N.A. (s.i.R.N.A.) in induced pluripotent stem cell-derived cardiomyocytes improved sarcomere number and contractility in models of T.T.N., C.S.R.P.3, and R.B.M.20 related D.C.M. These results indicate that targeting M.T.S.S.1 expression offers a promising therapeutic strategy to enhance cardiac function and survival in specific monogenic forms of dilated cardiomyopathy.</p>
<h4>Article 4: Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support.</h4>
<p><strong>Journal:</strong> European heart journal. Acute cardiovascular care</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41094715" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41094715</a></p>
<p><strong>Summary:</strong> This review outlines foundational pillars for establishing structured peer support programs to enhance psychological safety and resilience among intensive care unit (I.C.U.) professionals. The review establishes that these programs, delivered by trained colleagues, offer a low-threshold and scalable intervention for addressing psychological distress, moral injury, and burnout in the I.C.U. environment. It details five key components crucial for successful program implementation. Such interventions are vital for improving individual well-being, fostering better team dynamics, and ultimately enhancing patient safety within the intensive care unit.</p>
<h4>Article 5: Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study.</h4>
<p><strong>Journal:</strong> American journal of hypertension</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41099834" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41099834</a></p>
<p><strong>Summary:</strong> This research investigated the connection between inter-arm blood pressure (B.P.) difference and subclinical cardiac and vascular damage within a community-based population. The Pressioni Monitorate E Loro Associazioni (P.A.M.E.L.A.) study included 527 participants assessed after 25 years. The findings established a clear association between a significant inter-arm B.P. difference and the presence of subclinical cardiac and vascular damage. This suggests that detecting an inter-arm B.P. difference during routine measurements can serve as an early indicator for subclinical organ damage, potentially guiding earlier diagnostic evaluation and preventative strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension. This study investigated if pyridoxal 5&#8242; phosphate (P.L.P.), the active form of vitamin B6, could treat hypertension by antagonizing P2X3 receptors in carotid bodies. Using a multipronged approach, researchers found that P.L.P. inhibited P2X3 receptor activity in Spontaneously Hypertensive rats (S.H.R.). This antagonism can attenuate carotid body hyperexcitability, which underlies chemoreflex-mediated sympathetic overactivity in hypertension. These findings suggest P.L.P. is a potential therapeutic agent for hypertension by specifically targeting carotid body P2X3 receptors.</p>
<p>Article number two. Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1. This research aimed to clarify the role of peptide deformylase in aldosterone overproduction, particularly in aldosterone-producing adenoma. Investigators validated that peptide deformylase expression was significantly upregulated in enlarged aldosterone-producing adenomas. The study discovered that peptide deformylase regulates aldosterone production through calbindin 1, revealing a novel molecular mechanism. This finding advances the understanding of primary aldosteronism pathophysiology and identifies peptide deformylase as a potential new therapeutic target for aldosterone overproduction.</p>
<p>Article number three. Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM. This study explored the impact of M.T.S.S.1 protein expression on heart failure and contractility in dilated cardiomyopathy (D.C.M.). Human genetic analyses revealed that a variant lowering cardiac M.T.S.S.1 expression was linked to significantly improved survival in individuals with T.T.N. dilated cardiomyopathy. Experimental knockdown of M.T.S.S.1 via small interfering R.N.A. (s.i.R.N.A.) in induced pluripotent stem cell-derived cardiomyocytes improved sarcomere number and contractility in models of T.T.N., C.S.R.P.3, and R.B.M.20 related D.C.M. These results indicate that targeting M.T.S.S.1 expression offers a promising therapeutic strategy to enhance cardiac function and survival in specific monogenic forms of dilated cardiomyopathy.</p>
<p>Article number four. Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support. This review outlines foundational pillars for establishing structured peer support programs to enhance psychological safety and resilience among intensive care unit (I.C.U.) professionals. The review establishes that these programs, delivered by trained colleagues, offer a low-threshold and scalable intervention for addressing psychological distress, moral injury, and burnout in the I.C.U. environment. It details five key components crucial for successful program implementation. Such interventions are vital for improving individual well-being, fostering better team dynamics, and ultimately enhancing patient safety within the intensive care unit.</p>
<p>Article number five. Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study. This research investigated the connection between inter-arm blood pressure (B.P.) difference and subclinical cardiac and vascular damage within a community-based population. The Pressioni Monitorate E Loro Associazioni (P.A.M.E.L.A.) study included 527 participants assessed after 25 years. The findings established a clear association between a significant inter-arm B.P. difference and the presence of subclinical cardiac and vascular damage. This suggests that detecting an inter-arm B.P. difference during routine measurements can serve as an early indicator for subclinical organ damage, potentially guiding earlier diagnostic evaluation and preventative strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sarcomere, intensive care unit, burnout, sympathetic overactivity, vascular damage, primary aldosteronism, dilated cardiomyopathy, pyridoxal 5&#8242; phosphate, psychological safety, peer support, P2X3 receptors, cardiac damage, aldosterone-producing adenoma, T.T.N., carotid body, aldosterone, cardiac contractility, P.A.M.E.L.A. study, hypertension, calbindin 1, peptide deformylase, M.T.S.S.1, inter-arm blood pressure difference, moral injury, subclinical organ damage.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/">Targeting MTSS1 Improves DCM Contractility 10/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251019_060044.mp3" length="4716921" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like sarcomere and intensive care unit. Key takeaway: Targeting MTSS1 Improves DCM Contractility.
Article Links:
Article 1: Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension. (Cardiovascular research)
Article 2: Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1. (Hypertension (Dallas, Tex. : 1979))
Article 3: Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM. (JACC. Basic to translational science)
Article 4: Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support. (European heart journal. Acute cardiovascular care)
Article 5: Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study. (American journal of hypertension)
Full episode page: https://podcast.explainheart.com/podcast/targeting-mtss1-improves-dcm-contractility-10-19-25/
 Featured Articles
Article 1: Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41094718
Summary: This study investigated if pyridoxal 5&#8242; phosphate (P.L.P.), the active form of vitamin B6, could treat hypertension by antagonizing P2X3 receptors in carotid bodies. Using a multipronged approach, researchers found that P.L.P. inhibited P2X3 receptor activity in Spontaneously Hypertensive rats (S.H.R.). This antagonism can attenuate carotid body hyperexcitability, which underlies chemoreflex-mediated sympathetic overactivity in hypertension. These findings suggest P.L.P. is a potential therapeutic agent for hypertension by specifically targeting carotid body P2X3 receptors.
Article 2: Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41104452
Summary: This research aimed to clarify the role of peptide deformylase in aldosterone overproduction, particularly in aldosterone-producing adenoma. Investigators validated that peptide deformylase expression was significantly upregulated in enlarged aldosterone-producing adenomas. The study discovered that peptide deformylase regulates aldosterone production through calbindin 1, revealing a novel molecular mechanism. This finding advances the understanding of primary aldosteronism pathophysiology and identifies peptide deformylase as a potential new therapeutic target for aldosterone overproduction.
Article 3: Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM.
Journal: JACC. Basic to translational science
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41108838
Summary: This study explored the impact of M.T.S.S.1 protein expression on heart failure and contractility in dilated cardiomyopathy (D.C.M.). Human genetic analyses revealed that a variant lowering cardiac M.T.S.S.1 expression was linked to significantly improved survival in individuals with T.T.N. dilated cardiomyopathy. Experimental knockdown of M.T.S.S.1 via small interfering R.N.A. (s.i.R.N.A.) in induced pluripotent stem cell-derived cardiomyocytes improved sarcomere number and contractility in models of T.T.N., C.S.R.P.3, and R.B.M.20 related D.C.M. These results indicate that targeting M.T.S.S.1 expression offers a promising therapeutic strategy to enhance cardiac function and survival in specific monogenic forms of dilated cardiomyopathy.
Article 4: Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support.
Journal: European heart journal. Acute cardiovascular care
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41094715
Summary: This review outlines foundational pillars for establishing structured peer sup]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like sarcomere and intensive care unit. Key takeaway: Targeting MTSS1 Improves DCM Contractility.
Article Links:
Article 1: Vitamin B6 (pyridoxal 5&#8242; phosphate) antagonizes carotid body P2X3 receptors in hypertension. (Cardiovascular research)
Article 2: Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1. (Hypertension (Dallas, Tex. : 1979))
Article 3: Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM. (JACC. Basic to translational science)
Article 4: Fostering Psychological Safety and Resilience in the ICU: Implementing Structured Peer Support. (European heart journal. Acute cardiovascular care)
Article 5: Targeting the Association between Inter-Arm Blood Pressure Difference and Subclinical Organ Damage: Findings from the Pamela Study. (American journal of hypertension)
Full epis]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction 10/19/25</title>
	<link>https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/</link>
	<pubDate>Sun, 19 Oct 2025 06:57:57 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like cardiogenic shock and drug-eluting stents. Key takeaway: R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41109611">Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41109610">Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41105551">Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension.</a> (Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41109669">Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41104480">Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/">https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109611" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109611</a></p>
<p><strong>Summary:</strong> This study investigated clinical outcomes of percutaneous coronary intervention for high-risk eruptive calcified nodules using either drug-eluting stents or drug-coated balloons. Researchers conducted optical coherence tomography-guided P.C.I. in 1,975 patients to gather comparative data on these treatment strategies, which was previously unavailable. This research provides a crucial foundation for understanding the optimal P.C.I. approach for these complex lesions. The findings will help improve patient care by guiding device selection for eruptive calcified nodules.</p>
<h4>Article 2: Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109610" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109610</a></p>
<p><strong>Summary:</strong> This article introduces and examines the &#8220;Deep Dive Rendezvous&#8221; technique as an alternative to conventional externalization in retrograde chronic total occlusion percutaneous coronary intervention. The research addresses significant challenges of conventional externalization, such as procedural complexity, increased equipment requirements, and risk of fragile collateral vessel rupture. This innovative technique offers a simpler and potentially safer approach for complex C.T.O.-P.C.I. when antegrade methods are insufficient. The study establishes a valuable new tool for interventional cardiologists, aiming to enhance procedural safety and improve patient outcomes.</p>
<h4>Article 3: Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41105551" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41105551</a></p>
<p><strong>Summary:</strong> This study compared the efficacy of triple- versus dual-targeted drug therapy in 67 patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. The research also evaluated treatment outcomes and prognosis in this cohort, further categorizing patients based on potential defect closure. Given the limited evidence on optimal targeted therapy for this complex condition, the study provides crucial data. This investigation advances the understanding of effective management strategies, aiming to improve the long-term prognosis for individuals with congenital heart disease-associated pulmonary arterial hypertension.</p>
<h4>Article 4: Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109669" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109669</a></p>
<p><strong>Summary:</strong> Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022. This study used the Nationwide Readmissions Database from 2016 to 2022 to compare cardiogenic shock in Takotsubo cardiomyopathy versus acute myocardial infarction. Researchers identified hospitalizations for cardiogenic shock, classifying cases as either T.C.-C.S. or A.M.I.-C.S., to analyze demographic features, clinical characteristics, and treatment strategies. This investigation provides critical comparative data on these distinct causes of cardiogenic shock, an area previously understudied for Takotsubo cardiomyopathy. The findings are vital for accurate diagnosis, tailored management, and improving patient outcomes in both severe conditions.</p>
<h4>Article 5: Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104480" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104480</a></p>
<p><strong>Summary:</strong> This study investigated whether R.B.M.20 antisense oligonucleotides (A.S.O.s) could alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure with preserved ejection fraction. Researchers demonstrated that inhibiting R.B.M.20 using A.S.O.s induces the expression of larger titin isoforms, a key determinant of diastolic function. Critically, this intervention successfully alleviated diastolic dysfunction, identifying a novel therapeutic target for heart failure with preserved ejection fraction. This breakthrough provides a promising new strategy for treating this prevalent, deadly, and difficult-to-manage condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules. This study investigated clinical outcomes of percutaneous coronary intervention for high-risk eruptive calcified nodules using either drug-eluting stents or drug-coated balloons. Researchers conducted optical coherence tomography-guided P.C.I. in 1,975 patients to gather comparative data on these treatment strategies, which was previously unavailable. This research provides a crucial foundation for understanding the optimal P.C.I. approach for these complex lesions. The findings will help improve patient care by guiding device selection for eruptive calcified nodules.</p>
<p>Article number two. Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions. This article introduces and examines the &#8220;Deep Dive Rendezvous&#8221; technique as an alternative to conventional externalization in retrograde chronic total occlusion percutaneous coronary intervention. The research addresses significant challenges of conventional externalization, such as procedural complexity, increased equipment requirements, and risk of fragile collateral vessel rupture. This innovative technique offers a simpler and potentially safer approach for complex C.T.O.-P.C.I. when antegrade methods are insufficient. The study establishes a valuable new tool for interventional cardiologists, aiming to enhance procedural safety and improve patient outcomes.</p>
<p>Article number three. Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. This study compared the efficacy of triple- versus dual-targeted drug therapy in 67 patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. The research also evaluated treatment outcomes and prognosis in this cohort, further categorizing patients based on potential defect closure. Given the limited evidence on optimal targeted therapy for this complex condition, the study provides crucial data. This investigation advances the understanding of effective management strategies, aiming to improve the long-term prognosis for individuals with congenital heart disease-associated pulmonary arterial hypertension.</p>
<p>Article number four. Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022. This study used the Nationwide Readmissions Database from 2016 to 2022 to compare cardiogenic shock in Takotsubo cardiomyopathy versus acute myocardial infarction. Researchers identified hospitalizations for cardiogenic shock, classifying cases as either T.C.-C.S. or A.M.I.-C.S., to analyze demographic features, clinical characteristics, and treatment strategies. This investigation provides critical comparative data on these distinct causes of cardiogenic shock, an area previously understudied for Takotsubo cardiomyopathy. The findings are vital for accurate diagnosis, tailored management, and improving patient outcomes in both severe conditions.</p>
<p>Article number five. Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF). This study investigated whether R.B.M.20 antisense oligonucleotides (A.S.O.s) could alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure with preserved ejection fraction. Researchers demonstrated that inhibiting R.B.M.20 using A.S.O.s induces the expression of larger titin isoforms, a key determinant of diastolic function. Critically, this intervention successfully alleviated diastolic dysfunction, identifying a novel therapeutic target for heart failure with preserved ejection fraction. This breakthrough provides a promising new strategy for treating this prevalent, deadly, and difficult-to-manage condition. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiogenic shock, drug-eluting stents, pulmonary arterial hypertension, antisense oligonucleotides, percutaneous coronary intervention, left-to-right shunt, clinical outcomes, drug-coated balloons, Takotsubo cardiomyopathy, R.B.M.20, diastolic dysfunction, Nationwide Readmissions Database, heart failure with preserved ejection fraction, chronic total occlusion, conventional externalization, titin, Deep Dive Rendezvous, congenital heart disease, optical coherence tomography, acute myocardial infarction, eruptive calcified nodules, retrograde approach, targeted drug therapy, prognosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/">R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction 10/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like cardiogenic shock and drug-eluting stents. Key takeaway: R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like cardiogenic shock and drug-eluting stents. Key takeaway: R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41109611">Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41109610">Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41105551">Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension.</a> (Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41109669">Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41104480">Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/">https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109611" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109611</a></p>
<p><strong>Summary:</strong> This study investigated clinical outcomes of percutaneous coronary intervention for high-risk eruptive calcified nodules using either drug-eluting stents or drug-coated balloons. Researchers conducted optical coherence tomography-guided P.C.I. in 1,975 patients to gather comparative data on these treatment strategies, which was previously unavailable. This research provides a crucial foundation for understanding the optimal P.C.I. approach for these complex lesions. The findings will help improve patient care by guiding device selection for eruptive calcified nodules.</p>
<h4>Article 2: Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109610" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109610</a></p>
<p><strong>Summary:</strong> This article introduces and examines the &#8220;Deep Dive Rendezvous&#8221; technique as an alternative to conventional externalization in retrograde chronic total occlusion percutaneous coronary intervention. The research addresses significant challenges of conventional externalization, such as procedural complexity, increased equipment requirements, and risk of fragile collateral vessel rupture. This innovative technique offers a simpler and potentially safer approach for complex C.T.O.-P.C.I. when antegrade methods are insufficient. The study establishes a valuable new tool for interventional cardiologists, aiming to enhance procedural safety and improve patient outcomes.</p>
<h4>Article 3: Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41105551" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41105551</a></p>
<p><strong>Summary:</strong> This study compared the efficacy of triple- versus dual-targeted drug therapy in 67 patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. The research also evaluated treatment outcomes and prognosis in this cohort, further categorizing patients based on potential defect closure. Given the limited evidence on optimal targeted therapy for this complex condition, the study provides crucial data. This investigation advances the understanding of effective management strategies, aiming to improve the long-term prognosis for individuals with congenital heart disease-associated pulmonary arterial hypertension.</p>
<h4>Article 4: Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41109669" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41109669</a></p>
<p><strong>Summary:</strong> Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022. This study used the Nationwide Readmissions Database from 2016 to 2022 to compare cardiogenic shock in Takotsubo cardiomyopathy versus acute myocardial infarction. Researchers identified hospitalizations for cardiogenic shock, classifying cases as either T.C.-C.S. or A.M.I.-C.S., to analyze demographic features, clinical characteristics, and treatment strategies. This investigation provides critical comparative data on these distinct causes of cardiogenic shock, an area previously understudied for Takotsubo cardiomyopathy. The findings are vital for accurate diagnosis, tailored management, and improving patient outcomes in both severe conditions.</p>
<h4>Article 5: Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104480" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104480</a></p>
<p><strong>Summary:</strong> This study investigated whether R.B.M.20 antisense oligonucleotides (A.S.O.s) could alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure with preserved ejection fraction. Researchers demonstrated that inhibiting R.B.M.20 using A.S.O.s induces the expression of larger titin isoforms, a key determinant of diastolic function. Critically, this intervention successfully alleviated diastolic dysfunction, identifying a novel therapeutic target for heart failure with preserved ejection fraction. This breakthrough provides a promising new strategy for treating this prevalent, deadly, and difficult-to-manage condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules. This study investigated clinical outcomes of percutaneous coronary intervention for high-risk eruptive calcified nodules using either drug-eluting stents or drug-coated balloons. Researchers conducted optical coherence tomography-guided P.C.I. in 1,975 patients to gather comparative data on these treatment strategies, which was previously unavailable. This research provides a crucial foundation for understanding the optimal P.C.I. approach for these complex lesions. The findings will help improve patient care by guiding device selection for eruptive calcified nodules.</p>
<p>Article number two. Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions. This article introduces and examines the &#8220;Deep Dive Rendezvous&#8221; technique as an alternative to conventional externalization in retrograde chronic total occlusion percutaneous coronary intervention. The research addresses significant challenges of conventional externalization, such as procedural complexity, increased equipment requirements, and risk of fragile collateral vessel rupture. This innovative technique offers a simpler and potentially safer approach for complex C.T.O.-P.C.I. when antegrade methods are insufficient. The study establishes a valuable new tool for interventional cardiologists, aiming to enhance procedural safety and improve patient outcomes.</p>
<p>Article number three. Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. This study compared the efficacy of triple- versus dual-targeted drug therapy in 67 patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. The research also evaluated treatment outcomes and prognosis in this cohort, further categorizing patients based on potential defect closure. Given the limited evidence on optimal targeted therapy for this complex condition, the study provides crucial data. This investigation advances the understanding of effective management strategies, aiming to improve the long-term prognosis for individuals with congenital heart disease-associated pulmonary arterial hypertension.</p>
<p>Article number four. Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022. This study used the Nationwide Readmissions Database from 2016 to 2022 to compare cardiogenic shock in Takotsubo cardiomyopathy versus acute myocardial infarction. Researchers identified hospitalizations for cardiogenic shock, classifying cases as either T.C.-C.S. or A.M.I.-C.S., to analyze demographic features, clinical characteristics, and treatment strategies. This investigation provides critical comparative data on these distinct causes of cardiogenic shock, an area previously understudied for Takotsubo cardiomyopathy. The findings are vital for accurate diagnosis, tailored management, and improving patient outcomes in both severe conditions.</p>
<p>Article number five. Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF). This study investigated whether R.B.M.20 antisense oligonucleotides (A.S.O.s) could alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure with preserved ejection fraction. Researchers demonstrated that inhibiting R.B.M.20 using A.S.O.s induces the expression of larger titin isoforms, a key determinant of diastolic function. Critically, this intervention successfully alleviated diastolic dysfunction, identifying a novel therapeutic target for heart failure with preserved ejection fraction. This breakthrough provides a promising new strategy for treating this prevalent, deadly, and difficult-to-manage condition. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiogenic shock, drug-eluting stents, pulmonary arterial hypertension, antisense oligonucleotides, percutaneous coronary intervention, left-to-right shunt, clinical outcomes, drug-coated balloons, Takotsubo cardiomyopathy, R.B.M.20, diastolic dysfunction, Nationwide Readmissions Database, heart failure with preserved ejection fraction, chronic total occlusion, conventional externalization, titin, Deep Dive Rendezvous, congenital heart disease, optical coherence tomography, acute myocardial infarction, eruptive calcified nodules, retrograde approach, targeted drug therapy, prognosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/">R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction 10/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251019_025651.mp3" length="4670527" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like cardiogenic shock and drug-eluting stents. Key takeaway: R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction.
Article Links:
Article 1: Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules. (The American journal of cardiology)
Article 2: Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions. (The American journal of cardiology)
Article 3: Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. (Cardiology)
Article 4: Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022. (The Canadian journal of cardiology)
Article 5: Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF). (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/r-b-m-20-therapy-reverses-hef-pef-diastolic-dysfunction-10-19-25/
 Featured Articles
Article 1: Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41109611
Summary: This study investigated clinical outcomes of percutaneous coronary intervention for high-risk eruptive calcified nodules using either drug-eluting stents or drug-coated balloons. Researchers conducted optical coherence tomography-guided P.C.I. in 1,975 patients to gather comparative data on these treatment strategies, which was previously unavailable. This research provides a crucial foundation for understanding the optimal P.C.I. approach for these complex lesions. The findings will help improve patient care by guiding device selection for eruptive calcified nodules.
Article 2: Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41109610
Summary: This article introduces and examines the &#8220;Deep Dive Rendezvous&#8221; technique as an alternative to conventional externalization in retrograde chronic total occlusion percutaneous coronary intervention. The research addresses significant challenges of conventional externalization, such as procedural complexity, increased equipment requirements, and risk of fragile collateral vessel rupture. This innovative technique offers a simpler and potentially safer approach for complex C.T.O.-P.C.I. when antegrade methods are insufficient. The study establishes a valuable new tool for interventional cardiologists, aiming to enhance procedural safety and improve patient outcomes.
Article 3: Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41105551
Summary: This study compared the efficacy of triple- versus dual-targeted drug therapy in 67 patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. The research also evaluated treatment outcomes and prognosis in this cohort, further categorizing patients based on potential defect closure. Given the limited evidence on optimal targeted therapy for this complex condition, the study provides crucial data. This investigation advances the understanding of effective management strategies, aiming to improve the long-term prognosis for individuals with congenital heart disease-associated pulmonary arterial ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 19, 2025. This episode summarizes 5 key cardiology studies on topics like cardiogenic shock and drug-eluting stents. Key takeaway: R.B.M.20 Therapy Reverses HeF.pEF Diastolic Dysfunction.
Article Links:
Article 1: Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents and Drug-Coated Balloons in Lesion with Eruptive Calcified Nodules. (The American journal of cardiology)
Article 2: Deep Dive Rendezvous as a Novel Alternative Technique for Conventional Externalization in Retrograde Chronic Total Occlusion Interventions. (The American journal of cardiology)
Article 3: Comparison of dual- versus triple-targeted drug therapy for patients with left-to-right shunt congenital heart disease-associated pulmonary arterial hypertension. (Cardiology)
Article 4: Cardiogenic Shock in Takotsubo vs. Acute Myocardial Infarction: Insights from The National Readmission Database 2016-2022. (The Canadian journal of cardiology)]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>T.A.V.I. Valve Durability: 6-Year Data Guides Choice 10/18/25</title>
	<link>https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/</link>
	<pubDate>Sat, 18 Oct 2025 10:01:54 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like no-reflow phenomenon and Left Atrial Appendage. Key takeaway: T.A.V.I. Valve Durability: 6-Year Data Guides Choice.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40784469">Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40490131">Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40490129">6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40484266">Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40484265">Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/">https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40784469" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40784469</a></p>
<p><strong>Summary:</strong> This retrospective cohort study utilized 100 percent Medicare Standard Analytic Files from 2017 to 2023 to investigate the combined effects of race and community characteristics on outcomes and treatment utilization among Medicare beneficiaries with Peripheral Artery Disease. It aimed to move beyond individual factor analysis to understand the complex interactions influencing health disparities in this patient population. By examining both race and community factors together, the study establishes a comprehensive framework for identifying specific drivers of unequal Peripheral Artery Disease care. This foundational research is critical for developing more targeted and effective interventions to reduce health disparities.</p>
<h4>Article 2: Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40490131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40490131</a></p>
<p><strong>Summary:</strong> This study aimed to compare the clinical outcomes of early Aortic Valve Replacement versus clinical surveillance in asymptomatic patients with high-gradient severe Aortic Stenosis. Researchers identified 596 such patients from the CURRENT A.S. Registry-2, allocating 285 to an initial Aortic Valve Replacement strategy and 311 to clinical surveillance. By directly comparing these two distinct management approaches, the study establishes a crucial evaluation of optimal timing for intervention. The findings will provide essential evidence to inform clinical decision-making regarding Aortic Valve Replacement for this challenging patient population.</p>
<h4>Article 3: 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40490129" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40490129</a></p>
<p><strong>Summary:</strong> This study compared in-hospital, 1-year, and 6-year outcomes of balloon-expandable versus self-expanding Transcatheter Aortic Valve Implantation performed via transfemoral access. Researchers analyzed a large single-center cohort, creating propensity-score matched groups of 683 patients with balloon-expandable valves and 680 patients with self-expanding valves. This robust methodology establishes a crucial long-term comparison between contemporary Transcatheter Aortic Valve Implantation devices. The findings from this extensive follow-up will provide essential evidence to inform valve selection and optimize patient management following Transcatheter Aortic Valve Implantation.</p>
<h4>Article 4: Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40484266" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40484266</a></p>
<p><strong>Summary:</strong> This study evaluated remodeling and reverse-remodeling of the Left Atrium and Left Atrial Appendage following catheter ablation for Atrial Fibrillation. Researchers enrolled 372 patients who underwent ablation and had both pre- and post-procedure contrast computed tomography images. From these images, specific metrics including Left Atrial volume, Left Atrial Emptying Fraction, Left Atrial Appendage volume, and Left Atrial Appendage Emptying Fraction were precisely measured. This research establishes a detailed method to objectively track and quantify structural and functional changes in the Left Atrium and Left Atrial Appendage, offering valuable insights into the mechanisms of successful Atrial Fibrillation ablation.</p>
<h4>Article 5: Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40484265" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40484265</a></p>
<p><strong>Summary:</strong> This study investigated the incidence of the no-reflow phenomenon and its relationship with plaque components in Acute Coronary Syndrome caused by calcified nodules. Researchers enrolled 355 Acute Coronary Syndrome patients who presented with de novo culprit lesions in native coronary arteries. Recognizing the poor prognosis associated with calcified nodules, the study aimed to deepen understanding of this understudied complication. The findings will provide valuable insights into the pathological mechanisms of no-reflow in this specific patient population, potentially informing future interventional strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease. This retrospective cohort study utilized 100 percent Medicare Standard Analytic Files from 2017 to 2023 to investigate the combined effects of race and community characteristics on outcomes and treatment utilization among Medicare beneficiaries with Peripheral Artery Disease. It aimed to move beyond individual factor analysis to understand the complex interactions influencing health disparities in this patient population. By examining both race and community factors together, the study establishes a comprehensive framework for identifying specific drivers of unequal Peripheral Artery Disease care. This foundational research is critical for developing more targeted and effective interventions to reduce health disparities.</p>
<p>Article number two. Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis. This study aimed to compare the clinical outcomes of early Aortic Valve Replacement versus clinical surveillance in asymptomatic patients with high-gradient severe Aortic Stenosis. Researchers identified 596 such patients from the CURRENT A.S. Registry-2, allocating 285 to an initial Aortic Valve Replacement strategy and 311 to clinical surveillance. By directly comparing these two distinct management approaches, the study establishes a crucial evaluation of optimal timing for intervention. The findings will provide essential evidence to inform clinical decision-making regarding Aortic Valve Replacement for this challenging patient population.</p>
<p>Article number three. 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis. This study compared in-hospital, 1-year, and 6-year outcomes of balloon-expandable versus self-expanding Transcatheter Aortic Valve Implantation performed via transfemoral access. Researchers analyzed a large single-center cohort, creating propensity-score matched groups of 683 patients with balloon-expandable valves and 680 patients with self-expanding valves. This robust methodology establishes a crucial long-term comparison between contemporary Transcatheter Aortic Valve Implantation devices. The findings from this extensive follow-up will provide essential evidence to inform valve selection and optimize patient management following Transcatheter Aortic Valve Implantation.</p>
<p>Article number four. Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation. This study evaluated remodeling and reverse-remodeling of the Left Atrium and Left Atrial Appendage following catheter ablation for Atrial Fibrillation. Researchers enrolled 372 patients who underwent ablation and had both pre- and post-procedure contrast computed tomography images. From these images, specific metrics including Left Atrial volume, Left Atrial Emptying Fraction, Left Atrial Appendage volume, and Left Atrial Appendage Emptying Fraction were precisely measured. This research establishes a detailed method to objectively track and quantify structural and functional changes in the Left Atrium and Left Atrial Appendage, offering valuable insights into the mechanisms of successful Atrial Fibrillation ablation.</p>
<p>Article number five. Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules. This study investigated the incidence of the no-reflow phenomenon and its relationship with plaque components in Acute Coronary Syndrome caused by calcified nodules. Researchers enrolled 355 Acute Coronary Syndrome patients who presented with de novo culprit lesions in native coronary arteries. Recognizing the poor prognosis associated with calcified nodules, the study aimed to deepen understanding of this understudied complication. The findings will provide valuable insights into the pathological mechanisms of no-reflow in this specific patient population, potentially informing future interventional strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>no-reflow phenomenon, Left Atrial Appendage, propensity-matched, self-expanding, computed tomography, Atrial Fibrillation, culprit lesions, Aortic Stenosis, catheter ablation, Transcatheter Aortic Valve Implantation, Acute Coronary Syndrome, Aortic Valve Replacement, balloon-expandable, clinical surveillance, high-gradient severe, asymptomatic, Left Atrial remodeling, health disparities, Peripheral Artery Disease, 6-year follow-up, plaque components, retrospective cohort study, calcified nodules, treatment utilization, Medicare.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/">T.A.V.I. Valve Durability: 6-Year Data Guides Choice 10/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like no-reflow phenomenon and Left Atrial Appendage. Key takeaway: T.A.V.I. Valve Durability: 6-Year Data Guides Choice.
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like no-reflow phenomenon and Left Atrial Appendage. Key takeaway: T.A.V.I. Valve Durability: 6-Year Data Guides Choice.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40784469">Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40490131">Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40490129">6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40484266">Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40484265">Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/">https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40784469" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40784469</a></p>
<p><strong>Summary:</strong> This retrospective cohort study utilized 100 percent Medicare Standard Analytic Files from 2017 to 2023 to investigate the combined effects of race and community characteristics on outcomes and treatment utilization among Medicare beneficiaries with Peripheral Artery Disease. It aimed to move beyond individual factor analysis to understand the complex interactions influencing health disparities in this patient population. By examining both race and community factors together, the study establishes a comprehensive framework for identifying specific drivers of unequal Peripheral Artery Disease care. This foundational research is critical for developing more targeted and effective interventions to reduce health disparities.</p>
<h4>Article 2: Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40490131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40490131</a></p>
<p><strong>Summary:</strong> This study aimed to compare the clinical outcomes of early Aortic Valve Replacement versus clinical surveillance in asymptomatic patients with high-gradient severe Aortic Stenosis. Researchers identified 596 such patients from the CURRENT A.S. Registry-2, allocating 285 to an initial Aortic Valve Replacement strategy and 311 to clinical surveillance. By directly comparing these two distinct management approaches, the study establishes a crucial evaluation of optimal timing for intervention. The findings will provide essential evidence to inform clinical decision-making regarding Aortic Valve Replacement for this challenging patient population.</p>
<h4>Article 3: 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40490129" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40490129</a></p>
<p><strong>Summary:</strong> This study compared in-hospital, 1-year, and 6-year outcomes of balloon-expandable versus self-expanding Transcatheter Aortic Valve Implantation performed via transfemoral access. Researchers analyzed a large single-center cohort, creating propensity-score matched groups of 683 patients with balloon-expandable valves and 680 patients with self-expanding valves. This robust methodology establishes a crucial long-term comparison between contemporary Transcatheter Aortic Valve Implantation devices. The findings from this extensive follow-up will provide essential evidence to inform valve selection and optimize patient management following Transcatheter Aortic Valve Implantation.</p>
<h4>Article 4: Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40484266" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40484266</a></p>
<p><strong>Summary:</strong> This study evaluated remodeling and reverse-remodeling of the Left Atrium and Left Atrial Appendage following catheter ablation for Atrial Fibrillation. Researchers enrolled 372 patients who underwent ablation and had both pre- and post-procedure contrast computed tomography images. From these images, specific metrics including Left Atrial volume, Left Atrial Emptying Fraction, Left Atrial Appendage volume, and Left Atrial Appendage Emptying Fraction were precisely measured. This research establishes a detailed method to objectively track and quantify structural and functional changes in the Left Atrium and Left Atrial Appendage, offering valuable insights into the mechanisms of successful Atrial Fibrillation ablation.</p>
<h4>Article 5: Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40484265" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40484265</a></p>
<p><strong>Summary:</strong> This study investigated the incidence of the no-reflow phenomenon and its relationship with plaque components in Acute Coronary Syndrome caused by calcified nodules. Researchers enrolled 355 Acute Coronary Syndrome patients who presented with de novo culprit lesions in native coronary arteries. Recognizing the poor prognosis associated with calcified nodules, the study aimed to deepen understanding of this understudied complication. The findings will provide valuable insights into the pathological mechanisms of no-reflow in this specific patient population, potentially informing future interventional strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease. This retrospective cohort study utilized 100 percent Medicare Standard Analytic Files from 2017 to 2023 to investigate the combined effects of race and community characteristics on outcomes and treatment utilization among Medicare beneficiaries with Peripheral Artery Disease. It aimed to move beyond individual factor analysis to understand the complex interactions influencing health disparities in this patient population. By examining both race and community factors together, the study establishes a comprehensive framework for identifying specific drivers of unequal Peripheral Artery Disease care. This foundational research is critical for developing more targeted and effective interventions to reduce health disparities.</p>
<p>Article number two. Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis. This study aimed to compare the clinical outcomes of early Aortic Valve Replacement versus clinical surveillance in asymptomatic patients with high-gradient severe Aortic Stenosis. Researchers identified 596 such patients from the CURRENT A.S. Registry-2, allocating 285 to an initial Aortic Valve Replacement strategy and 311 to clinical surveillance. By directly comparing these two distinct management approaches, the study establishes a crucial evaluation of optimal timing for intervention. The findings will provide essential evidence to inform clinical decision-making regarding Aortic Valve Replacement for this challenging patient population.</p>
<p>Article number three. 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis. This study compared in-hospital, 1-year, and 6-year outcomes of balloon-expandable versus self-expanding Transcatheter Aortic Valve Implantation performed via transfemoral access. Researchers analyzed a large single-center cohort, creating propensity-score matched groups of 683 patients with balloon-expandable valves and 680 patients with self-expanding valves. This robust methodology establishes a crucial long-term comparison between contemporary Transcatheter Aortic Valve Implantation devices. The findings from this extensive follow-up will provide essential evidence to inform valve selection and optimize patient management following Transcatheter Aortic Valve Implantation.</p>
<p>Article number four. Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation. This study evaluated remodeling and reverse-remodeling of the Left Atrium and Left Atrial Appendage following catheter ablation for Atrial Fibrillation. Researchers enrolled 372 patients who underwent ablation and had both pre- and post-procedure contrast computed tomography images. From these images, specific metrics including Left Atrial volume, Left Atrial Emptying Fraction, Left Atrial Appendage volume, and Left Atrial Appendage Emptying Fraction were precisely measured. This research establishes a detailed method to objectively track and quantify structural and functional changes in the Left Atrium and Left Atrial Appendage, offering valuable insights into the mechanisms of successful Atrial Fibrillation ablation.</p>
<p>Article number five. Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules. This study investigated the incidence of the no-reflow phenomenon and its relationship with plaque components in Acute Coronary Syndrome caused by calcified nodules. Researchers enrolled 355 Acute Coronary Syndrome patients who presented with de novo culprit lesions in native coronary arteries. Recognizing the poor prognosis associated with calcified nodules, the study aimed to deepen understanding of this understudied complication. The findings will provide valuable insights into the pathological mechanisms of no-reflow in this specific patient population, potentially informing future interventional strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>no-reflow phenomenon, Left Atrial Appendage, propensity-matched, self-expanding, computed tomography, Atrial Fibrillation, culprit lesions, Aortic Stenosis, catheter ablation, Transcatheter Aortic Valve Implantation, Acute Coronary Syndrome, Aortic Valve Replacement, balloon-expandable, clinical surveillance, high-gradient severe, asymptomatic, Left Atrial remodeling, health disparities, Peripheral Artery Disease, 6-year follow-up, plaque components, retrospective cohort study, calcified nodules, treatment utilization, Medicare.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/">T.A.V.I. Valve Durability: 6-Year Data Guides Choice 10/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251018_060046.mp3" length="4785466" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like no-reflow phenomenon and Left Atrial Appendage. Key takeaway: T.A.V.I. Valve Durability: 6-Year Data Guides Choice.
Article Links:
Article 1: Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease. (The American journal of cardiology)
Article 2: Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis. (The American journal of cardiology)
Article 3: 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis. (The American journal of cardiology)
Article 4: Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation. (The American journal of cardiology)
Article 5: Angiographic No-Reflow in Patients With Acute Coronary Syndrome Caused by Calcified Nodules. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/t-a-v-i-valve-durability-6-year-data-guides-choice-10-18-25/
 Featured Articles
Article 1: Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40784469
Summary: This retrospective cohort study utilized 100 percent Medicare Standard Analytic Files from 2017 to 2023 to investigate the combined effects of race and community characteristics on outcomes and treatment utilization among Medicare beneficiaries with Peripheral Artery Disease. It aimed to move beyond individual factor analysis to understand the complex interactions influencing health disparities in this patient population. By examining both race and community factors together, the study establishes a comprehensive framework for identifying specific drivers of unequal Peripheral Artery Disease care. This foundational research is critical for developing more targeted and effective interventions to reduce health disparities.
Article 2: Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40490131
Summary: This study aimed to compare the clinical outcomes of early Aortic Valve Replacement versus clinical surveillance in asymptomatic patients with high-gradient severe Aortic Stenosis. Researchers identified 596 such patients from the CURRENT A.S. Registry-2, allocating 285 to an initial Aortic Valve Replacement strategy and 311 to clinical surveillance. By directly comparing these two distinct management approaches, the study establishes a crucial evaluation of optimal timing for intervention. The findings will provide essential evidence to inform clinical decision-making regarding Aortic Valve Replacement for this challenging patient population.
Article 3: 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40490129
Summary: This study compared in-hospital, 1-year, and 6-year outcomes of balloon-expandable versus self-expanding Transcatheter Aortic Valve Implantation performed via transfemoral access. Researchers analyzed a large single-center cohort, creating propensity-score matched groups of 683 patients with balloon-expandable valves and 680 patients with self-expanding valves. This robust methodology establishes a crucial long-term comparison between contemporary Transcatheter Aortic Valve Implantation devices. The findings from this extensive follow-up will provide essential evidence to inform valve selection and optimize patient management following Transcatheter Aortic Valve Implantation.
Article ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like no-reflow phenomenon and Left Atrial Appendage. Key takeaway: T.A.V.I. Valve Durability: 6-Year Data Guides Choice.
Article Links:
Article 1: Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease. (The American journal of cardiology)
Article 2: Early Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Patients With Severe Aortic Stenosis. (The American journal of cardiology)
Article 3: 6 Year Follow-Up of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Propensity-Matched Analysis. (The American journal of cardiology)
Article 4: Remodeling and Reverse-Remodeling of Left Atrium and Appendage After Catheter Ablation for Atrial Fibrillation. (The American journal of cardiology)
Article 5: Angiographic No-Reflow in Patients With Acute Coronary Syndrome Ca]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Causal Factors for Bradyarrhythmia Revealed 10/18/25</title>
	<link>https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/</link>
	<pubDate>Sat, 18 Oct 2025 06:59:04 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure hospitalization and modifiable risk factors. Key takeaway: Causal Factors for Bradyarrhythmia Revealed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41104570">Outcomes of moderate mixed aortic valve stenosis and regurgitation.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41104542">Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41104537">Angina after percutaneous coronary interventions.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41107031">Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41106528">Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/">https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Outcomes of moderate mixed aortic valve stenosis and regurgitation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104570" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104570</a></p>
<p><strong>Summary:</strong> This study investigates mortality outcomes in patients with moderate mixed aortic valve disease (M.A.V.D.), characterized by both moderate aortic stenosis (A.S.) and moderate aortic regurgitation (A.R.). The research compares survival rates of these patients against those with isolated severe A.S. or severe A.R. Furthermore, it evaluates the impact of symptoms or a left ventricular ejection fraction (L.V.E.F.) below 50 percent on patient prognosis in M.A.V.D. These findings provide critical data to inform clinical guidelines, which currently lack specific recommendations for aortic valve replacement (A.V.R.) in this particular population.</p>
<h4>Article 2: Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104542</a></p>
<p><strong>Summary:</strong> This territory-wide cohort study assessed the clinical impact of incident urinary tract infection (U.T.I.) and subsequent discontinuation of sodium-glucose cotransporter-2 (S.G.L.T.2) inhibitors in patients with type 2 diabetes mellitus. It specifically examined primary cardiovascular composite outcomes, including heart failure hospitalization, stroke, and myocardial infarction. The research offers crucial insights into the real-world management of S.G.L.T.2 inhibitor therapy following U.T.I. and its implications for long-term cardiovascular protection. The findings underscore the importance of carefully considering S.G.L.T.2 inhibitor continuation post-U.T.I. to optimize patient benefits.</p>
<h4>Article 3: Angina after percutaneous coronary interventions.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104537" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104537</a></p>
<p><strong>Summary:</strong> This review addresses the persistent or recurrent angina that can occur after percutaneous coronary intervention (P.C.I.) for stable coronary artery disease, a common and often underexplored clinical issue. It highlights the significant gap in current clinical practice guidelines regarding the causative diagnosis, effective prevention, and optimal management strategies for this condition. The article aims to enhance understanding of this problem, which frequently undermines the primary goal of P.C.I. to alleviate anginal symptoms. This work establishes a clear need for improved diagnostic and therapeutic pathways to address post-P.C.I. angina and enhance patient quality of life.</p>
<h4>Article 4: Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41107031" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41107031</a></p>
<p><strong>Summary:</strong> The S.U.S.T.A.I.N.-H.F. study, a prospective, multicenter, single-arm cohort, evaluated the 1-year clinical and hemodynamic outcomes of an interatrial shunt device in 120 symptomatic heart failure with reduced ejection fraction (HeF.rE.F.) patients. Participants, all with a left ventricular ejection fraction (L.V.E.F.) of 40 percent or less and on guideline-directed medical therapy, received the device. This study establishes crucial evidence for the safety and efficacy profile of this interventional strategy for HeF.rE.F., demonstrating its potential as a novel therapeutic option. The findings provide valuable data supporting further investigation and potential clinical application of interatrial shunts to improve patient outcomes.</p>
<h4>Article 5: Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41106528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41106528</a></p>
<p><strong>Summary:</strong> This Mendelian randomization study investigated the causal associations between several modifiable risk factors and bradyarrhythmia, with the goal of identifying primary prevention strategies. Summary statistical data for modifiable risk factors and bradyarrhythmia were sourced from European-ancestry G.W.A.S. (genome-wide association studies) datasets. Univariable, multivariable, and mediation Mendelian randomization analyses were meticulously performed to identify specific causal links. This research establishes foundational evidence for developing targeted primary prevention strategies for bradyarrhythmia by pinpointing key modifiable risk factors.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Outcomes of moderate mixed aortic valve stenosis and regurgitation. This study investigates mortality outcomes in patients with moderate mixed aortic valve disease (M.A.V.D.), characterized by both moderate aortic stenosis (A.S.) and moderate aortic regurgitation (A.R.). The research compares survival rates of these patients against those with isolated severe A.S. or severe A.R. Furthermore, it evaluates the impact of symptoms or a left ventricular ejection fraction (L.V.E.F.) below 50 percent on patient prognosis in M.A.V.D. These findings provide critical data to inform clinical guidelines, which currently lack specific recommendations for aortic valve replacement (A.V.R.) in this particular population.</p>
<p>Article number two. Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. This territory-wide cohort study assessed the clinical impact of incident urinary tract infection (U.T.I.) and subsequent discontinuation of sodium-glucose cotransporter-2 (S.G.L.T.2) inhibitors in patients with type 2 diabetes mellitus. It specifically examined primary cardiovascular composite outcomes, including heart failure hospitalization, stroke, and myocardial infarction. The research offers crucial insights into the real-world management of S.G.L.T.2 inhibitor therapy following U.T.I. and its implications for long-term cardiovascular protection. The findings underscore the importance of carefully considering S.G.L.T.2 inhibitor continuation post-U.T.I. to optimize patient benefits.</p>
<p>Article number three. Angina after percutaneous coronary interventions. This review addresses the persistent or recurrent angina that can occur after percutaneous coronary intervention (P.C.I.) for stable coronary artery disease, a common and often underexplored clinical issue. It highlights the significant gap in current clinical practice guidelines regarding the causative diagnosis, effective prevention, and optimal management strategies for this condition. The article aims to enhance understanding of this problem, which frequently undermines the primary goal of P.C.I. to alleviate anginal symptoms. This work establishes a clear need for improved diagnostic and therapeutic pathways to address post-P.C.I. angina and enhance patient quality of life.</p>
<p>Article number four. Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes. The S.U.S.T.A.I.N.-H.F. study, a prospective, multicenter, single-arm cohort, evaluated the 1-year clinical and hemodynamic outcomes of an interatrial shunt device in 120 symptomatic heart failure with reduced ejection fraction (HeF.rE.F.) patients. Participants, all with a left ventricular ejection fraction (L.V.E.F.) of 40 percent or less and on guideline-directed medical therapy, received the device. This study establishes crucial evidence for the safety and efficacy profile of this interventional strategy for HeF.rE.F., demonstrating its potential as a novel therapeutic option. The findings provide valuable data supporting further investigation and potential clinical application of interatrial shunts to improve patient outcomes.</p>
<p>Article number five. Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study. This Mendelian randomization study investigated the causal associations between several modifiable risk factors and bradyarrhythmia, with the goal of identifying primary prevention strategies. Summary statistical data for modifiable risk factors and bradyarrhythmia were sourced from European-ancestry G.W.A.S. (genome-wide association studies) datasets. Univariable, multivariable, and mediation Mendelian randomization analyses were meticulously performed to identify specific causal links. This research establishes foundational evidence for developing targeted primary prevention strategies for bradyarrhythmia by pinpointing key modifiable risk factors. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure hospitalization, modifiable risk factors, hemodynamic outcomes, guideline-directed medical therapy, post-P.C.I. complications, genome-wide association studies, urinary tract infection, stable coronary artery disease, Mendelian randomization, sodium-glucose cotransporter-2 inhibitors, mixed aortic valve disease, cardiovascular outcomes, heart failure with reduced ejection fraction, angina management, angina, aortic stenosis, bradyarrhythmia, HeF.rE.F., interatrial shunt, aortic regurgitation, type 2 diabetes mellitus, aortic valve replacement, left ventricular ejection fraction, primary prevention, percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/">Causal Factors for Bradyarrhythmia Revealed 10/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure hospitalization and modifiable risk factors. Key takeaway: Causal Factors for Bradyarrhythmia Revealed.
Article Links:
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure hospitalization and modifiable risk factors. Key takeaway: Causal Factors for Bradyarrhythmia Revealed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41104570">Outcomes of moderate mixed aortic valve stenosis and regurgitation.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41104542">Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41104537">Angina after percutaneous coronary interventions.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41107031">Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41106528">Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/">https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Outcomes of moderate mixed aortic valve stenosis and regurgitation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104570" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104570</a></p>
<p><strong>Summary:</strong> This study investigates mortality outcomes in patients with moderate mixed aortic valve disease (M.A.V.D.), characterized by both moderate aortic stenosis (A.S.) and moderate aortic regurgitation (A.R.). The research compares survival rates of these patients against those with isolated severe A.S. or severe A.R. Furthermore, it evaluates the impact of symptoms or a left ventricular ejection fraction (L.V.E.F.) below 50 percent on patient prognosis in M.A.V.D. These findings provide critical data to inform clinical guidelines, which currently lack specific recommendations for aortic valve replacement (A.V.R.) in this particular population.</p>
<h4>Article 2: Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104542</a></p>
<p><strong>Summary:</strong> This territory-wide cohort study assessed the clinical impact of incident urinary tract infection (U.T.I.) and subsequent discontinuation of sodium-glucose cotransporter-2 (S.G.L.T.2) inhibitors in patients with type 2 diabetes mellitus. It specifically examined primary cardiovascular composite outcomes, including heart failure hospitalization, stroke, and myocardial infarction. The research offers crucial insights into the real-world management of S.G.L.T.2 inhibitor therapy following U.T.I. and its implications for long-term cardiovascular protection. The findings underscore the importance of carefully considering S.G.L.T.2 inhibitor continuation post-U.T.I. to optimize patient benefits.</p>
<h4>Article 3: Angina after percutaneous coronary interventions.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41104537" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41104537</a></p>
<p><strong>Summary:</strong> This review addresses the persistent or recurrent angina that can occur after percutaneous coronary intervention (P.C.I.) for stable coronary artery disease, a common and often underexplored clinical issue. It highlights the significant gap in current clinical practice guidelines regarding the causative diagnosis, effective prevention, and optimal management strategies for this condition. The article aims to enhance understanding of this problem, which frequently undermines the primary goal of P.C.I. to alleviate anginal symptoms. This work establishes a clear need for improved diagnostic and therapeutic pathways to address post-P.C.I. angina and enhance patient quality of life.</p>
<h4>Article 4: Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41107031" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41107031</a></p>
<p><strong>Summary:</strong> The S.U.S.T.A.I.N.-H.F. study, a prospective, multicenter, single-arm cohort, evaluated the 1-year clinical and hemodynamic outcomes of an interatrial shunt device in 120 symptomatic heart failure with reduced ejection fraction (HeF.rE.F.) patients. Participants, all with a left ventricular ejection fraction (L.V.E.F.) of 40 percent or less and on guideline-directed medical therapy, received the device. This study establishes crucial evidence for the safety and efficacy profile of this interventional strategy for HeF.rE.F., demonstrating its potential as a novel therapeutic option. The findings provide valuable data supporting further investigation and potential clinical application of interatrial shunts to improve patient outcomes.</p>
<h4>Article 5: Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41106528" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41106528</a></p>
<p><strong>Summary:</strong> This Mendelian randomization study investigated the causal associations between several modifiable risk factors and bradyarrhythmia, with the goal of identifying primary prevention strategies. Summary statistical data for modifiable risk factors and bradyarrhythmia were sourced from European-ancestry G.W.A.S. (genome-wide association studies) datasets. Univariable, multivariable, and mediation Mendelian randomization analyses were meticulously performed to identify specific causal links. This research establishes foundational evidence for developing targeted primary prevention strategies for bradyarrhythmia by pinpointing key modifiable risk factors.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Outcomes of moderate mixed aortic valve stenosis and regurgitation. This study investigates mortality outcomes in patients with moderate mixed aortic valve disease (M.A.V.D.), characterized by both moderate aortic stenosis (A.S.) and moderate aortic regurgitation (A.R.). The research compares survival rates of these patients against those with isolated severe A.S. or severe A.R. Furthermore, it evaluates the impact of symptoms or a left ventricular ejection fraction (L.V.E.F.) below 50 percent on patient prognosis in M.A.V.D. These findings provide critical data to inform clinical guidelines, which currently lack specific recommendations for aortic valve replacement (A.V.R.) in this particular population.</p>
<p>Article number two. Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. This territory-wide cohort study assessed the clinical impact of incident urinary tract infection (U.T.I.) and subsequent discontinuation of sodium-glucose cotransporter-2 (S.G.L.T.2) inhibitors in patients with type 2 diabetes mellitus. It specifically examined primary cardiovascular composite outcomes, including heart failure hospitalization, stroke, and myocardial infarction. The research offers crucial insights into the real-world management of S.G.L.T.2 inhibitor therapy following U.T.I. and its implications for long-term cardiovascular protection. The findings underscore the importance of carefully considering S.G.L.T.2 inhibitor continuation post-U.T.I. to optimize patient benefits.</p>
<p>Article number three. Angina after percutaneous coronary interventions. This review addresses the persistent or recurrent angina that can occur after percutaneous coronary intervention (P.C.I.) for stable coronary artery disease, a common and often underexplored clinical issue. It highlights the significant gap in current clinical practice guidelines regarding the causative diagnosis, effective prevention, and optimal management strategies for this condition. The article aims to enhance understanding of this problem, which frequently undermines the primary goal of P.C.I. to alleviate anginal symptoms. This work establishes a clear need for improved diagnostic and therapeutic pathways to address post-P.C.I. angina and enhance patient quality of life.</p>
<p>Article number four. Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes. The S.U.S.T.A.I.N.-H.F. study, a prospective, multicenter, single-arm cohort, evaluated the 1-year clinical and hemodynamic outcomes of an interatrial shunt device in 120 symptomatic heart failure with reduced ejection fraction (HeF.rE.F.) patients. Participants, all with a left ventricular ejection fraction (L.V.E.F.) of 40 percent or less and on guideline-directed medical therapy, received the device. This study establishes crucial evidence for the safety and efficacy profile of this interventional strategy for HeF.rE.F., demonstrating its potential as a novel therapeutic option. The findings provide valuable data supporting further investigation and potential clinical application of interatrial shunts to improve patient outcomes.</p>
<p>Article number five. Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study. This Mendelian randomization study investigated the causal associations between several modifiable risk factors and bradyarrhythmia, with the goal of identifying primary prevention strategies. Summary statistical data for modifiable risk factors and bradyarrhythmia were sourced from European-ancestry G.W.A.S. (genome-wide association studies) datasets. Univariable, multivariable, and mediation Mendelian randomization analyses were meticulously performed to identify specific causal links. This research establishes foundational evidence for developing targeted primary prevention strategies for bradyarrhythmia by pinpointing key modifiable risk factors. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure hospitalization, modifiable risk factors, hemodynamic outcomes, guideline-directed medical therapy, post-P.C.I. complications, genome-wide association studies, urinary tract infection, stable coronary artery disease, Mendelian randomization, sodium-glucose cotransporter-2 inhibitors, mixed aortic valve disease, cardiovascular outcomes, heart failure with reduced ejection fraction, angina management, angina, aortic stenosis, bradyarrhythmia, HeF.rE.F., interatrial shunt, aortic regurgitation, type 2 diabetes mellitus, aortic valve replacement, left ventricular ejection fraction, primary prevention, percutaneous coronary intervention.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/">Causal Factors for Bradyarrhythmia Revealed 10/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251018_025646.mp3" length="4888284" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure hospitalization and modifiable risk factors. Key takeaway: Causal Factors for Bradyarrhythmia Revealed.
Article Links:
Article 1: Outcomes of moderate mixed aortic valve stenosis and regurgitation. (European heart journal)
Article 2: Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. (European heart journal)
Article 3: Angina after percutaneous coronary interventions. (European heart journal)
Article 4: Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes. (Heart (British Cardiac Society))
Article 5: Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/causal-factors-for-bradyarrhythmia-revealed-10-18-25/
 Featured Articles
Article 1: Outcomes of moderate mixed aortic valve stenosis and regurgitation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41104570
Summary: This study investigates mortality outcomes in patients with moderate mixed aortic valve disease (M.A.V.D.), characterized by both moderate aortic stenosis (A.S.) and moderate aortic regurgitation (A.R.). The research compares survival rates of these patients against those with isolated severe A.S. or severe A.R. Furthermore, it evaluates the impact of symptoms or a left ventricular ejection fraction (L.V.E.F.) below 50 percent on patient prognosis in M.A.V.D. These findings provide critical data to inform clinical guidelines, which currently lack specific recommendations for aortic valve replacement (A.V.R.) in this particular population.
Article 2: Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41104542
Summary: This territory-wide cohort study assessed the clinical impact of incident urinary tract infection (U.T.I.) and subsequent discontinuation of sodium-glucose cotransporter-2 (S.G.L.T.2) inhibitors in patients with type 2 diabetes mellitus. It specifically examined primary cardiovascular composite outcomes, including heart failure hospitalization, stroke, and myocardial infarction. The research offers crucial insights into the real-world management of S.G.L.T.2 inhibitor therapy following U.T.I. and its implications for long-term cardiovascular protection. The findings underscore the importance of carefully considering S.G.L.T.2 inhibitor continuation post-U.T.I. to optimize patient benefits.
Article 3: Angina after percutaneous coronary interventions.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41104537
Summary: This review addresses the persistent or recurrent angina that can occur after percutaneous coronary intervention (P.C.I.) for stable coronary artery disease, a common and often underexplored clinical issue. It highlights the significant gap in current clinical practice guidelines regarding the causative diagnosis, effective prevention, and optimal management strategies for this condition. The article aims to enhance understanding of this problem, which frequently undermines the primary goal of P.C.I. to alleviate anginal symptoms. This work establishes a clear need for improved diagnostic and therapeutic pathways to address post-P.C.I. angina and enhance patient quality of life.
Article 4: Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41107031
Summary: The S.U.S.T.A.I.N.-H.F. study, a prospective, multicenter, single-arm cohort]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 18, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure hospitalization and modifiable risk factors. Key takeaway: Causal Factors for Bradyarrhythmia Revealed.
Article Links:
Article 1: Outcomes of moderate mixed aortic valve stenosis and regurgitation. (European heart journal)
Article 2: Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. (European heart journal)
Article 3: Angina after percutaneous coronary interventions. (European heart journal)
Article 4: Prospective multicentre single-arm study of an interatrial shunt in heart failure with reduced ejection fraction (SUSTAIN-HF): 1-year clinical and haemodynamic outcomes. (Heart (British Cardiac Society))
Article 5: Association between Modifiable Risk Factors and Bradyarrhythmia: A Mendelian Randomization Study. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/causal-facto]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>B.P. Variability Detects Alpha-Synucleinopathy 10/17/25</title>
	<link>https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/</link>
	<pubDate>Fri, 17 Oct 2025 10:01:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like recoarctation and device closure. Key takeaway: B.P. Variability Detects Alpha-Synucleinopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41085210">Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41085208">Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41085193">Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41085192">Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41085190">Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The EngAGE With Heart Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/">https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085210" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085210</a></p>
<p><strong>Summary:</strong> This study aimed to identify the prevalence and risk factors for requiring reintervention for recoarctation of the aorta in patients who underwent treatment for coarctation of the aorta. The investigation included individuals with isolated coarctation as well as those with complex bi- and univentricular congenital heart disease, drawing data from the S.W.E.D.C.O.N. registry. Understanding these risk factors is crucial for predicting which patients are at higher risk for long-term complications like recoarctation of the aorta or arterial hypertension, enabling more personalized long-term surveillance. This research provides valuable information to improve the long-term management and outcomes for patients post-coarctation of the aorta repair.</p>
<h4>Article 2: Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085208" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085208</a></p>
<p><strong>Summary:</strong> This cross-sectional study evaluated the diagnostic performance of automated office blood pressure measurement in different settings for hypertension. Researchers compared standard office blood pressure, unattended automated office blood pressure measurement in an isolated room, and automated office blood pressure measurement in a waiting room against daytime ambulatory blood pressure measurement as the reference standard. The findings suggest that automated office blood pressure measurement performed in a waiting room could enhance the efficiency of hypertension diagnosis without requiring a dedicated isolated room. This offers a practical and scalable approach to improve hypertension screening and phenotyping in busy clinical environments.</p>
<h4>Article 3: Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085193" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085193</a></p>
<p><strong>Summary:</strong> This prospective study aimed to investigate the diagnostic utility of ambulatory blood pressure monitoring in identifying alpha-synucleinopathy among patients experiencing orthostasis. Building on the established understanding that individuals with alpha-synucleinopathy exhibit significant blood pressure variability, the researchers recruited consecutive patients with orthostatic dizziness for detailed examination, including ambulatory blood pressure monitoring. The study&#8217;s objective was to determine if blood pressure variability, as measured by ambulatory monitoring, can serve as a reliable diagnostic marker for this neurodegenerative condition. Establishing such a marker could lead to earlier and more precise diagnosis of alpha-synucleinopathy, improving patient management and potentially guiding targeted therapies.</p>
<h4>Article 4: Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085192" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085192</a></p>
<p><strong>Summary:</strong> This single-center retrospective study spanning from 2006 to 2021 analyzed the outcomes of transcatheter closure of atrial septal defects in 400 patients. The primary objective was to identify predictive factors for procedural failure and to characterize the long-term clinical success following this routine intervention. Researchers defined the primary endpoint as a 6-month composite clinical success, encompassing both technical success, such as device implantation and retention, and closure success, indicated by trivial or no residual shunt. This research provides crucial data to refine patient selection, optimize procedural strategies, and ultimately enhance the long-term efficacy and safety of transcatheter atrial septal defect closure.</p>
<h4>Article 5: Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The EngAGE With Heart Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085190" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085190</a></p>
<p><strong>Summary:</strong> With Heart Study. This cross-sectional study investigated the relationships between social determinants of health and atherosclerotic cardiovascular disease risk among adults residing in Baltimore. Researchers assessed cardiovascular health in adults aged 40 to 79 years within four Black faith-based communities, utilizing the 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations to estimate atherosclerotic cardiovascular disease risk. The findings from this research are critical for developing targeted community-based interventions and public health strategies to address the modifiable social factors contributing to cardiovascular disease disparities. This work helps improve risk assessment and prevention efforts in underserved populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease. This study aimed to identify the prevalence and risk factors for requiring reintervention for recoarctation of the aorta in patients who underwent treatment for coarctation of the aorta. The investigation included individuals with isolated coarctation as well as those with complex bi- and univentricular congenital heart disease, drawing data from the S.W.E.D.C.O.N. registry. Understanding these risk factors is crucial for predicting which patients are at higher risk for long-term complications like recoarctation of the aorta or arterial hypertension, enabling more personalized long-term surveillance. This research provides valuable information to improve the long-term management and outcomes for patients post-coarctation of the aorta repair.</p>
<p>Article number two. Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension. This cross-sectional study evaluated the diagnostic performance of automated office blood pressure measurement in different settings for hypertension. Researchers compared standard office blood pressure, unattended automated office blood pressure measurement in an isolated room, and automated office blood pressure measurement in a waiting room against daytime ambulatory blood pressure measurement as the reference standard. The findings suggest that automated office blood pressure measurement performed in a waiting room could enhance the efficiency of hypertension diagnosis without requiring a dedicated isolated room. This offers a practical and scalable approach to improve hypertension screening and phenotyping in busy clinical environments.</p>
<p>Article number three. Blood Pressure Variability as a Diagnostic Marker for alpha-Synucleinopathy in Patients With Orthostasis. This prospective study aimed to investigate the diagnostic utility of ambulatory blood pressure monitoring in identifying alpha-synucleinopathy among patients experiencing orthostasis. Building on the established understanding that individuals with alpha-synucleinopathy exhibit significant blood pressure variability, the researchers recruited consecutive patients with orthostatic dizziness for detailed examination, including ambulatory blood pressure monitoring. The study&#8217;s objective was to determine if blood pressure variability, as measured by ambulatory monitoring, can serve as a reliable diagnostic marker for this neurodegenerative condition. Establishing such a marker could lead to earlier and more precise diagnosis of alpha-synucleinopathy, improving patient management and potentially guiding targeted therapies.</p>
<p>Article number four. Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects. This single-center retrospective study spanning from 2006 to 2021 analyzed the outcomes of transcatheter closure of atrial septal defects in 400 patients. The primary objective was to identify predictive factors for procedural failure and to characterize the long-term clinical success following this routine intervention. Researchers defined the primary endpoint as a 6-month composite clinical success, encompassing both technical success, such as device implantation and retention, and closure success, indicated by trivial or no residual shunt. This research provides crucial data to refine patient selection, optimize procedural strategies, and ultimately enhance the long-term efficacy and safety of transcatheter atrial septal defect closure.</p>
<p>Article number five. Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The Eng.A.G.E. With Heart Study. This cross-sectional study investigated the relationships between social determinants of health and atherosclerotic cardiovascular disease risk among adults residing in Baltimore. Researchers assessed cardiovascular health in adults aged 40 to 79 years within four Black faith-based communities, utilizing the 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations to estimate atherosclerotic cardiovascular disease risk. The findings from this research are critical for developing targeted community-based interventions and public health strategies to address the modifiable social factors contributing to cardiovascular disease disparities. This work helps improve risk assessment and prevention efforts in underserved populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>recoarctation, device closure, blood pressure monitoring, diagnostic marker, reintervention, social determinants of health, diagnosis, health disparities, hypertension, cardiovascular risk, arterial hypertension, alpha-synucleinopathy, atherosclerotic cardiovascular disease, coarctation of the aorta, ambulatory blood pressure, procedural outcomes, atrial septal defect, orthostasis, congenital heart disease, ambulatory blood pressure monitoring, automated office blood pressure measurement, transcatheter closure, community health, blood pressure variability.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/">B.P. Variability Detects Alpha-Synucleinopathy 10/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like recoarctation and device closure. Key takeaway: B.P. Variability Detects Alpha-Synucleinopathy.
Article Links:
Article 1: Risk Factor]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like recoarctation and device closure. Key takeaway: B.P. Variability Detects Alpha-Synucleinopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41085210">Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41085208">Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41085193">Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41085192">Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41085190">Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The EngAGE With Heart Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/">https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085210" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085210</a></p>
<p><strong>Summary:</strong> This study aimed to identify the prevalence and risk factors for requiring reintervention for recoarctation of the aorta in patients who underwent treatment for coarctation of the aorta. The investigation included individuals with isolated coarctation as well as those with complex bi- and univentricular congenital heart disease, drawing data from the S.W.E.D.C.O.N. registry. Understanding these risk factors is crucial for predicting which patients are at higher risk for long-term complications like recoarctation of the aorta or arterial hypertension, enabling more personalized long-term surveillance. This research provides valuable information to improve the long-term management and outcomes for patients post-coarctation of the aorta repair.</p>
<h4>Article 2: Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085208" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085208</a></p>
<p><strong>Summary:</strong> This cross-sectional study evaluated the diagnostic performance of automated office blood pressure measurement in different settings for hypertension. Researchers compared standard office blood pressure, unattended automated office blood pressure measurement in an isolated room, and automated office blood pressure measurement in a waiting room against daytime ambulatory blood pressure measurement as the reference standard. The findings suggest that automated office blood pressure measurement performed in a waiting room could enhance the efficiency of hypertension diagnosis without requiring a dedicated isolated room. This offers a practical and scalable approach to improve hypertension screening and phenotyping in busy clinical environments.</p>
<h4>Article 3: Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085193" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085193</a></p>
<p><strong>Summary:</strong> This prospective study aimed to investigate the diagnostic utility of ambulatory blood pressure monitoring in identifying alpha-synucleinopathy among patients experiencing orthostasis. Building on the established understanding that individuals with alpha-synucleinopathy exhibit significant blood pressure variability, the researchers recruited consecutive patients with orthostatic dizziness for detailed examination, including ambulatory blood pressure monitoring. The study&#8217;s objective was to determine if blood pressure variability, as measured by ambulatory monitoring, can serve as a reliable diagnostic marker for this neurodegenerative condition. Establishing such a marker could lead to earlier and more precise diagnosis of alpha-synucleinopathy, improving patient management and potentially guiding targeted therapies.</p>
<h4>Article 4: Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085192" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085192</a></p>
<p><strong>Summary:</strong> This single-center retrospective study spanning from 2006 to 2021 analyzed the outcomes of transcatheter closure of atrial septal defects in 400 patients. The primary objective was to identify predictive factors for procedural failure and to characterize the long-term clinical success following this routine intervention. Researchers defined the primary endpoint as a 6-month composite clinical success, encompassing both technical success, such as device implantation and retention, and closure success, indicated by trivial or no residual shunt. This research provides crucial data to refine patient selection, optimize procedural strategies, and ultimately enhance the long-term efficacy and safety of transcatheter atrial septal defect closure.</p>
<h4>Article 5: Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The EngAGE With Heart Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085190" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085190</a></p>
<p><strong>Summary:</strong> With Heart Study. This cross-sectional study investigated the relationships between social determinants of health and atherosclerotic cardiovascular disease risk among adults residing in Baltimore. Researchers assessed cardiovascular health in adults aged 40 to 79 years within four Black faith-based communities, utilizing the 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations to estimate atherosclerotic cardiovascular disease risk. The findings from this research are critical for developing targeted community-based interventions and public health strategies to address the modifiable social factors contributing to cardiovascular disease disparities. This work helps improve risk assessment and prevention efforts in underserved populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease. This study aimed to identify the prevalence and risk factors for requiring reintervention for recoarctation of the aorta in patients who underwent treatment for coarctation of the aorta. The investigation included individuals with isolated coarctation as well as those with complex bi- and univentricular congenital heart disease, drawing data from the S.W.E.D.C.O.N. registry. Understanding these risk factors is crucial for predicting which patients are at higher risk for long-term complications like recoarctation of the aorta or arterial hypertension, enabling more personalized long-term surveillance. This research provides valuable information to improve the long-term management and outcomes for patients post-coarctation of the aorta repair.</p>
<p>Article number two. Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension. This cross-sectional study evaluated the diagnostic performance of automated office blood pressure measurement in different settings for hypertension. Researchers compared standard office blood pressure, unattended automated office blood pressure measurement in an isolated room, and automated office blood pressure measurement in a waiting room against daytime ambulatory blood pressure measurement as the reference standard. The findings suggest that automated office blood pressure measurement performed in a waiting room could enhance the efficiency of hypertension diagnosis without requiring a dedicated isolated room. This offers a practical and scalable approach to improve hypertension screening and phenotyping in busy clinical environments.</p>
<p>Article number three. Blood Pressure Variability as a Diagnostic Marker for alpha-Synucleinopathy in Patients With Orthostasis. This prospective study aimed to investigate the diagnostic utility of ambulatory blood pressure monitoring in identifying alpha-synucleinopathy among patients experiencing orthostasis. Building on the established understanding that individuals with alpha-synucleinopathy exhibit significant blood pressure variability, the researchers recruited consecutive patients with orthostatic dizziness for detailed examination, including ambulatory blood pressure monitoring. The study&#8217;s objective was to determine if blood pressure variability, as measured by ambulatory monitoring, can serve as a reliable diagnostic marker for this neurodegenerative condition. Establishing such a marker could lead to earlier and more precise diagnosis of alpha-synucleinopathy, improving patient management and potentially guiding targeted therapies.</p>
<p>Article number four. Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects. This single-center retrospective study spanning from 2006 to 2021 analyzed the outcomes of transcatheter closure of atrial septal defects in 400 patients. The primary objective was to identify predictive factors for procedural failure and to characterize the long-term clinical success following this routine intervention. Researchers defined the primary endpoint as a 6-month composite clinical success, encompassing both technical success, such as device implantation and retention, and closure success, indicated by trivial or no residual shunt. This research provides crucial data to refine patient selection, optimize procedural strategies, and ultimately enhance the long-term efficacy and safety of transcatheter atrial septal defect closure.</p>
<p>Article number five. Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The Eng.A.G.E. With Heart Study. This cross-sectional study investigated the relationships between social determinants of health and atherosclerotic cardiovascular disease risk among adults residing in Baltimore. Researchers assessed cardiovascular health in adults aged 40 to 79 years within four Black faith-based communities, utilizing the 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations to estimate atherosclerotic cardiovascular disease risk. The findings from this research are critical for developing targeted community-based interventions and public health strategies to address the modifiable social factors contributing to cardiovascular disease disparities. This work helps improve risk assessment and prevention efforts in underserved populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>recoarctation, device closure, blood pressure monitoring, diagnostic marker, reintervention, social determinants of health, diagnosis, health disparities, hypertension, cardiovascular risk, arterial hypertension, alpha-synucleinopathy, atherosclerotic cardiovascular disease, coarctation of the aorta, ambulatory blood pressure, procedural outcomes, atrial septal defect, orthostasis, congenital heart disease, ambulatory blood pressure monitoring, automated office blood pressure measurement, transcatheter closure, community health, blood pressure variability.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/">B.P. Variability Detects Alpha-Synucleinopathy 10/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251017_060037.mp3" length="4983997" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like recoarctation and device closure. Key takeaway: B.P. Variability Detects Alpha-Synucleinopathy.
Article Links:
Article 1: Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease. (Journal of the American Heart Association)
Article 2: Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension. (Journal of the American Heart Association)
Article 3: Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis. (Journal of the American Heart Association)
Article 4: Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects. (Journal of the American Heart Association)
Article 5: Social Determinants of Health Correlates and Atherosclerotic Cardiovascular Disease Risk Among Adults in Baltimore: The EngAGE With Heart Study. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/b-p-variability-detects-alpha-synucleinopathy-10-17-25/
 Featured Articles
Article 1: Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41085210
Summary: This study aimed to identify the prevalence and risk factors for requiring reintervention for recoarctation of the aorta in patients who underwent treatment for coarctation of the aorta. The investigation included individuals with isolated coarctation as well as those with complex bi- and univentricular congenital heart disease, drawing data from the S.W.E.D.C.O.N. registry. Understanding these risk factors is crucial for predicting which patients are at higher risk for long-term complications like recoarctation of the aorta or arterial hypertension, enabling more personalized long-term surveillance. This research provides valuable information to improve the long-term management and outcomes for patients post-coarctation of the aorta repair.
Article 2: Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41085208
Summary: This cross-sectional study evaluated the diagnostic performance of automated office blood pressure measurement in different settings for hypertension. Researchers compared standard office blood pressure, unattended automated office blood pressure measurement in an isolated room, and automated office blood pressure measurement in a waiting room against daytime ambulatory blood pressure measurement as the reference standard. The findings suggest that automated office blood pressure measurement performed in a waiting room could enhance the efficiency of hypertension diagnosis without requiring a dedicated isolated room. This offers a practical and scalable approach to improve hypertension screening and phenotyping in busy clinical environments.
Article 3: Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41085193
Summary: This prospective study aimed to investigate the diagnostic utility of ambulatory blood pressure monitoring in identifying alpha-synucleinopathy among patients experiencing orthostasis. Building on the established understanding that individuals with alpha-synucleinopathy exhibit significant blood pressure variability, the researchers recruited consecutive patients with orthostatic dizzi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like recoarctation and device closure. Key takeaway: B.P. Variability Detects Alpha-Synucleinopathy.
Article Links:
Article 1: Risk Factors for Reintervention Following Treatment for Aortic Coarctation With or Without Aortic Arch Hypoplasia in Sweden: From Isolated Coarctation to Complex Bi- and Univentricular Congenital Heart Disease. (Journal of the American Heart Association)
Article 2: Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension. (Journal of the American Heart Association)
Article 3: Blood Pressure Variability as a Diagnostic Marker for α-Synucleinopathy in Patients With Orthostasis. (Journal of the American Heart Association)
Article 4: Outcomes Analysis of Transcatheter Closure of Atrial Septal Defects. (Journal of the American Heart Association)
Article 5: Social Determinants of Health]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Echo Predicts Transthyretin Amyloid Outcomes 10/17/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/</link>
	<pubDate>Fri, 17 Oct 2025 06:59:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and Neutrophil-to-lymphocyte ratio. Key takeaway: AI Echo Predicts Transthyretin Amyloid Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41099689">Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41091460">Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41098018">Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41098006">Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41085211">Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/">https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41099689" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41099689</a></p>
<p><strong>Summary:</strong> This study characterized the prevalence and correlates of systemic inflammation across the spectrum of heart failure, including heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction. It aimed to differentiate inflammatory mechanisms, where inflammation in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction is linked to cardiovascular-kidney-metabolic conditions. In contrast, inflammation in heart failure with reduced ejection fraction is thought to develop secondary to cardiac stress and circulatory derangements. This research establishes a crucial foundation for understanding distinct inflammatory profiles in varying heart failure phenotypes, which is vital for developing targeted therapeutic strategies.</p>
<h4>Article 2: Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091460" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091460</a></p>
<p><strong>Summary:</strong> This cohort study was designed to investigate the prevalence and prognostic significance of papillary muscle scarring in patients with dilated cardiomyopathy. Recognizing that papillary muscle scarring can arise from microvascular dysfunction, even without epicardial coronary artery disease, the study aimed to establish whether this scarring is associated with adverse outcomes in this patient population. By clarifying the presence and impact of papillary muscle scarring in dilated cardiomyopathy, this research sought to provide crucial insights for enhanced risk stratification and personalized management strategies. The study thereby establishes a framework for future prognostic assessment in patients with dilated cardiomyopathy.</p>
<h4>Article 3: Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41098018" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41098018</a></p>
<p><strong>Summary:</strong> This study aimed to compare the predictive accuracy of various risk stratification models for acute myocarditis, with a specific focus on the utility of the neutrophil-to-lymphocyte ratio. The research recognized that the neutrophil-to-lymphocyte ratio (N.L.R.) is a valuable tool for risk stratification in patients with acute myocarditis, particularly addressing challenges in those presenting with preserved left ventricular ejection fraction (L.V.E.F.). By evaluating existing models and emphasizing the predictive power of N.L.R., this study significantly advances the ability to identify high-risk patients. These findings offer a more robust method for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum, enabling more precise clinical management and potentially improving patient outcomes.</p>
<h4>Article 4: Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41098006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41098006</a></p>
<p><strong>Summary:</strong> This study investigated artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. Researchers conducted longitudinal transthoracic echocardiography on consecutive patients with transthyretin cardiac amyloidosis at baseline and 12-month follow-up, utilizing artificial intelligence for rapid and standardized assessment of left ventricular outflow tract velocity-time integral (L.V.O.T.-V.T.I.). This work successfully established an artificial intelligence-driven approach for objectively quantifying changes in L.V.O.T.-V.T.I., a reliable surrogate for stroke volume, which is known to portend a poor prognosis when reduced. This innovative methodology provides a standardized and efficient tool to predict outcomes and guide therapeutic management in patients with transthyretin cardiac amyloidosis.</p>
<h4>Article 5: Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085211</a></p>
<p><strong>Summary:</strong> The Journal of the American Heart Association is issuing an Expression of Concern regarding a previously published article titled &#8220;Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.&#8221; This notice addresses significant concerns that were raised regarding the quality of the data and images presented within the article. The Expression of Concern underscores the journal&#8217;s commitment to maintaining rigorous scientific standards and integrity in published research. It highlights the critical importance of data accuracy and transparency in the scientific literature.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction. This study characterized the prevalence and correlates of systemic inflammation across the spectrum of heart failure, including heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction. It aimed to differentiate inflammatory mechanisms, where inflammation in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction is linked to cardiovascular-kidney-metabolic conditions. In contrast, inflammation in heart failure with reduced ejection fraction is thought to develop secondary to cardiac stress and circulatory derangements. This research establishes a crucial foundation for understanding distinct inflammatory profiles in varying heart failure phenotypes, which is vital for developing targeted therapeutic strategies.</p>
<p>Article number two. Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy. This cohort study was designed to investigate the prevalence and prognostic significance of papillary muscle scarring in patients with dilated cardiomyopathy. Recognizing that papillary muscle scarring can arise from microvascular dysfunction, even without epicardial coronary artery disease, the study aimed to establish whether this scarring is associated with adverse outcomes in this patient population. By clarifying the presence and impact of papillary muscle scarring in dilated cardiomyopathy, this research sought to provide crucial insights for enhanced risk stratification and personalized management strategies. The study thereby establishes a framework for future prognostic assessment in patients with dilated cardiomyopathy.</p>
<p>Article number three. Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum. This study aimed to compare the predictive accuracy of various risk stratification models for acute myocarditis, with a specific focus on the utility of the neutrophil-to-lymphocyte ratio. The research recognized that the neutrophil-to-lymphocyte ratio (N.L.R.) is a valuable tool for risk stratification in patients with acute myocarditis, particularly addressing challenges in those presenting with preserved left ventricular ejection fraction (L.V.E.F.). By evaluating existing models and emphasizing the predictive power of N.L.R., this study significantly advances the ability to identify high-risk patients. These findings offer a more robust method for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum, enabling more precise clinical management and potentially improving patient outcomes.</p>
<p>Article number four. Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. This study investigated artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. Researchers conducted longitudinal transthoracic echocardiography on consecutive patients with transthyretin cardiac amyloidosis at baseline and 12-month follow-up, utilizing artificial intelligence for rapid and standardized assessment of left ventricular outflow tract velocity-time integral (L.V.O.T.-V.T.I.). This work successfully established an artificial intelligence-driven approach for objectively quantifying changes in L.V.O.T.-V.T.I., a reliable surrogate for stroke volume, which is known to portend a poor prognosis when reduced. This innovative methodology provides a standardized and efficient tool to predict outcomes and guide therapeutic management in patients with transthyretin cardiac amyloidosis.</p>
<p>Article number five. Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats. The Journal of the American Heart Association is issuing an Expression of Concern regarding a previously published article titled &#8220;Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.&#8221; This notice addresses significant concerns that were raised regarding the quality of the data and images presented within the article. The Expression of Concern underscores the journal&#8217;s commitment to maintaining rigorous scientific standards and integrity in published research. It highlights the critical importance of data accuracy and transparency in the scientific literature. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transthyretin cardiac amyloidosis, Neutrophil-to-lymphocyte ratio, adverse outcomes, echocardiography, left ventricular outflow tract velocity-time integral, left ventricular ejection fraction, prognostic value, heart failure with reduced ejection fraction, data quality, dilated cardiomyopathy, Artificial intelligence, acute myocarditis, blood-brain barrier, microvascular dysfunction, systemic inflammation, scientific integrity, Expression of Concern, Heart failure with preserved ejection fraction, Papillary muscle scarring, heart failure with mildly reduced ejection fraction, subarachnoid hemorrhage, cardiovascular-kidney-metabolic conditions, disease progression monitoring, risk stratification, preserved ejection fraction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/">AI Echo Predicts Transthyretin Amyloid Outcomes 10/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and Neutrophil-to-lymphocyte ratio. Key takeaway: AI Echo Predicts Transthyretin Amyloid Outcomes.
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and Neutrophil-to-lymphocyte ratio. Key takeaway: AI Echo Predicts Transthyretin Amyloid Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41099689">Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41091460">Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41098018">Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum.</a> (European journal of heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41098006">Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41085211">Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/">https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41099689" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41099689</a></p>
<p><strong>Summary:</strong> This study characterized the prevalence and correlates of systemic inflammation across the spectrum of heart failure, including heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction. It aimed to differentiate inflammatory mechanisms, where inflammation in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction is linked to cardiovascular-kidney-metabolic conditions. In contrast, inflammation in heart failure with reduced ejection fraction is thought to develop secondary to cardiac stress and circulatory derangements. This research establishes a crucial foundation for understanding distinct inflammatory profiles in varying heart failure phenotypes, which is vital for developing targeted therapeutic strategies.</p>
<h4>Article 2: Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091460" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091460</a></p>
<p><strong>Summary:</strong> This cohort study was designed to investigate the prevalence and prognostic significance of papillary muscle scarring in patients with dilated cardiomyopathy. Recognizing that papillary muscle scarring can arise from microvascular dysfunction, even without epicardial coronary artery disease, the study aimed to establish whether this scarring is associated with adverse outcomes in this patient population. By clarifying the presence and impact of papillary muscle scarring in dilated cardiomyopathy, this research sought to provide crucial insights for enhanced risk stratification and personalized management strategies. The study thereby establishes a framework for future prognostic assessment in patients with dilated cardiomyopathy.</p>
<h4>Article 3: Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41098018" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41098018</a></p>
<p><strong>Summary:</strong> This study aimed to compare the predictive accuracy of various risk stratification models for acute myocarditis, with a specific focus on the utility of the neutrophil-to-lymphocyte ratio. The research recognized that the neutrophil-to-lymphocyte ratio (N.L.R.) is a valuable tool for risk stratification in patients with acute myocarditis, particularly addressing challenges in those presenting with preserved left ventricular ejection fraction (L.V.E.F.). By evaluating existing models and emphasizing the predictive power of N.L.R., this study significantly advances the ability to identify high-risk patients. These findings offer a more robust method for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum, enabling more precise clinical management and potentially improving patient outcomes.</p>
<h4>Article 4: Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41098006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41098006</a></p>
<p><strong>Summary:</strong> This study investigated artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. Researchers conducted longitudinal transthoracic echocardiography on consecutive patients with transthyretin cardiac amyloidosis at baseline and 12-month follow-up, utilizing artificial intelligence for rapid and standardized assessment of left ventricular outflow tract velocity-time integral (L.V.O.T.-V.T.I.). This work successfully established an artificial intelligence-driven approach for objectively quantifying changes in L.V.O.T.-V.T.I., a reliable surrogate for stroke volume, which is known to portend a poor prognosis when reduced. This innovative methodology provides a standardized and efficient tool to predict outcomes and guide therapeutic management in patients with transthyretin cardiac amyloidosis.</p>
<h4>Article 5: Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085211</a></p>
<p><strong>Summary:</strong> The Journal of the American Heart Association is issuing an Expression of Concern regarding a previously published article titled &#8220;Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.&#8221; This notice addresses significant concerns that were raised regarding the quality of the data and images presented within the article. The Expression of Concern underscores the journal&#8217;s commitment to maintaining rigorous scientific standards and integrity in published research. It highlights the critical importance of data accuracy and transparency in the scientific literature.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction. This study characterized the prevalence and correlates of systemic inflammation across the spectrum of heart failure, including heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction. It aimed to differentiate inflammatory mechanisms, where inflammation in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction is linked to cardiovascular-kidney-metabolic conditions. In contrast, inflammation in heart failure with reduced ejection fraction is thought to develop secondary to cardiac stress and circulatory derangements. This research establishes a crucial foundation for understanding distinct inflammatory profiles in varying heart failure phenotypes, which is vital for developing targeted therapeutic strategies.</p>
<p>Article number two. Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy. This cohort study was designed to investigate the prevalence and prognostic significance of papillary muscle scarring in patients with dilated cardiomyopathy. Recognizing that papillary muscle scarring can arise from microvascular dysfunction, even without epicardial coronary artery disease, the study aimed to establish whether this scarring is associated with adverse outcomes in this patient population. By clarifying the presence and impact of papillary muscle scarring in dilated cardiomyopathy, this research sought to provide crucial insights for enhanced risk stratification and personalized management strategies. The study thereby establishes a framework for future prognostic assessment in patients with dilated cardiomyopathy.</p>
<p>Article number three. Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum. This study aimed to compare the predictive accuracy of various risk stratification models for acute myocarditis, with a specific focus on the utility of the neutrophil-to-lymphocyte ratio. The research recognized that the neutrophil-to-lymphocyte ratio (N.L.R.) is a valuable tool for risk stratification in patients with acute myocarditis, particularly addressing challenges in those presenting with preserved left ventricular ejection fraction (L.V.E.F.). By evaluating existing models and emphasizing the predictive power of N.L.R., this study significantly advances the ability to identify high-risk patients. These findings offer a more robust method for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum, enabling more precise clinical management and potentially improving patient outcomes.</p>
<p>Article number four. Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. This study investigated artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. Researchers conducted longitudinal transthoracic echocardiography on consecutive patients with transthyretin cardiac amyloidosis at baseline and 12-month follow-up, utilizing artificial intelligence for rapid and standardized assessment of left ventricular outflow tract velocity-time integral (L.V.O.T.-V.T.I.). This work successfully established an artificial intelligence-driven approach for objectively quantifying changes in L.V.O.T.-V.T.I., a reliable surrogate for stroke volume, which is known to portend a poor prognosis when reduced. This innovative methodology provides a standardized and efficient tool to predict outcomes and guide therapeutic management in patients with transthyretin cardiac amyloidosis.</p>
<p>Article number five. Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats. The Journal of the American Heart Association is issuing an Expression of Concern regarding a previously published article titled &#8220;Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.&#8221; This notice addresses significant concerns that were raised regarding the quality of the data and images presented within the article. The Expression of Concern underscores the journal&#8217;s commitment to maintaining rigorous scientific standards and integrity in published research. It highlights the critical importance of data accuracy and transparency in the scientific literature. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transthyretin cardiac amyloidosis, Neutrophil-to-lymphocyte ratio, adverse outcomes, echocardiography, left ventricular outflow tract velocity-time integral, left ventricular ejection fraction, prognostic value, heart failure with reduced ejection fraction, data quality, dilated cardiomyopathy, Artificial intelligence, acute myocarditis, blood-brain barrier, microvascular dysfunction, systemic inflammation, scientific integrity, Expression of Concern, Heart failure with preserved ejection fraction, Papillary muscle scarring, heart failure with mildly reduced ejection fraction, subarachnoid hemorrhage, cardiovascular-kidney-metabolic conditions, disease progression monitoring, risk stratification, preserved ejection fraction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/">AI Echo Predicts Transthyretin Amyloid Outcomes 10/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251017_025810.mp3" length="5363922" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and Neutrophil-to-lymphocyte ratio. Key takeaway: AI Echo Predicts Transthyretin Amyloid Outcomes.
Article Links:
Article 1: Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction. (JACC. Heart failure)
Article 2: Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy. (JAMA cardiology)
Article 3: Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum. (European journal of heart failure)
Article 4: Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. (European journal of heart failure)
Article 5: Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ai-echo-predicts-transthyretin-amyloid-outcomes-10-17-25/
 Featured Articles
Article 1: Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41099689
Summary: This study characterized the prevalence and correlates of systemic inflammation across the spectrum of heart failure, including heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction. It aimed to differentiate inflammatory mechanisms, where inflammation in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction is linked to cardiovascular-kidney-metabolic conditions. In contrast, inflammation in heart failure with reduced ejection fraction is thought to develop secondary to cardiac stress and circulatory derangements. This research establishes a crucial foundation for understanding distinct inflammatory profiles in varying heart failure phenotypes, which is vital for developing targeted therapeutic strategies.
Article 2: Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091460
Summary: This cohort study was designed to investigate the prevalence and prognostic significance of papillary muscle scarring in patients with dilated cardiomyopathy. Recognizing that papillary muscle scarring can arise from microvascular dysfunction, even without epicardial coronary artery disease, the study aimed to establish whether this scarring is associated with adverse outcomes in this patient population. By clarifying the presence and impact of papillary muscle scarring in dilated cardiomyopathy, this research sought to provide crucial insights for enhanced risk stratification and personalized management strategies. The study thereby establishes a framework for future prognostic assessment in patients with dilated cardiomyopathy.
Article 3: Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41098018
Summary: This study aimed to compare the predictive accuracy of various risk stratification models for acute myocarditis, with a specific focus on the utility of the neutrophil-to-lymphocyte ratio. The research recognized that the neutrophil-to-lymphocyte ratio (N.L.R.) is a valuable tool for risk stratification in patients with acute myocarditis, particularly addressing challenges in those presenting with preserved left ventricular ejection fraction (L.V.E.F.). By evaluatin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 17, 2025. This episode summarizes 5 key cardiology studies on topics like transthyretin cardiac amyloidosis and Neutrophil-to-lymphocyte ratio. Key takeaway: AI Echo Predicts Transthyretin Amyloid Outcomes.
Article Links:
Article 1: Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction. (JACC. Heart failure)
Article 2: Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy. (JAMA cardiology)
Article 3: Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum. (European journal of heart failure)
Article 4: Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. (European journal of heart failure)
Article 5: Expression of Concern: Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorecta]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New e.G.F.R. Threshold Refines HeF.pEF Diagnosis. 10/16/25</title>
	<link>https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/</link>
	<pubDate>Thu, 16 Oct 2025 10:01:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 16, 2025. This episode summarizes 5 key cardiology studies on topics like gene therapy and Adenosine Deaminase Deficiency. Key takeaway: New e.G.F.R. Threshold Refines HeF.pEF Diagnosis..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41092330">Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41091084">Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41091083">Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41092306">Atrial cardiomyopathy: markers and outcomes.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41091476">Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/">https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41092330" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41092330</a></p>
<p><strong>Summary:</strong> This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency.</p>
<h4>Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091084" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091084</a></p>
<p><strong>Summary:</strong> This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.</p>
<h4>Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091083" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091083</a></p>
<p><strong>Summary:</strong> This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 4: Atrial cardiomyopathy: markers and outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41092306" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41092306</a></p>
<p><strong>Summary:</strong> This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.</p>
<h4>Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091476" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091476</a></p>
<p><strong>Summary:</strong> This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency.</p>
<p>Article number two. Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.</p>
<p>Article number three. Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number four. Atrial cardiomyopathy: markers and outcomes. This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.</p>
<p>Article number five. Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gene therapy, Adenosine Deaminase Deficiency, ASPREE trial, Atrial Fibrillation, frailty, intensive blood pressure control, ESPRIT trial, primary prevention, Heart Failure, Heart Failure with Preserved Ejection Fraction, stroke, Severe Combined Immunodeficiency, Atrial Cardiomyopathy, renal impairment, cardiac magnetic resonance imaging, aspirin, Clonal Hematopoiesis of Indeterminate Potential, geriatric cardiology, estimated glomerular filtration rate, hematopoietic stem cells, visceral adiposity, chronic kidney disease, Cardiovascular Disease, lentiviral vector, cardiovascular risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/">New e.G.F.R. Threshold Refines HeF.pEF Diagnosis. 10/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 16, 2025. This episode summarizes 5 key cardiology studies on topics like gene therapy and Adenosine Deaminase Deficiency. Key takeaway: New e.G.F.R. Threshold Refines HeF.pEF Diagnosis..
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 16, 2025. This episode summarizes 5 key cardiology studies on topics like gene therapy and Adenosine Deaminase Deficiency. Key takeaway: New e.G.F.R. Threshold Refines HeF.pEF Diagnosis..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41092330">Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41091084">Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41091083">Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41092306">Atrial cardiomyopathy: markers and outcomes.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41091476">Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/">https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41092330" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41092330</a></p>
<p><strong>Summary:</strong> This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency.</p>
<h4>Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091084" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091084</a></p>
<p><strong>Summary:</strong> This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.</p>
<h4>Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091083" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091083</a></p>
<p><strong>Summary:</strong> This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 4: Atrial cardiomyopathy: markers and outcomes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41092306" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41092306</a></p>
<p><strong>Summary:</strong> This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.</p>
<h4>Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41091476" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41091476</a></p>
<p><strong>Summary:</strong> This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency.</p>
<p>Article number two. Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.</p>
<p>Article number three. Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number four. Atrial cardiomyopathy: markers and outcomes. This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.</p>
<p>Article number five. Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gene therapy, Adenosine Deaminase Deficiency, ASPREE trial, Atrial Fibrillation, frailty, intensive blood pressure control, ESPRIT trial, primary prevention, Heart Failure, Heart Failure with Preserved Ejection Fraction, stroke, Severe Combined Immunodeficiency, Atrial Cardiomyopathy, renal impairment, cardiac magnetic resonance imaging, aspirin, Clonal Hematopoiesis of Indeterminate Potential, geriatric cardiology, estimated glomerular filtration rate, hematopoietic stem cells, visceral adiposity, chronic kidney disease, Cardiovascular Disease, lentiviral vector, cardiovascular risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/">New e.G.F.R. Threshold Refines HeF.pEF Diagnosis. 10/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251016_060041.mp3" length="4459040" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 16, 2025. This episode summarizes 5 key cardiology studies on topics like gene therapy and Adenosine Deaminase Deficiency. Key takeaway: New e.G.F.R. Threshold Refines HeF.pEF Diagnosis..
Article Links:
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. (The New England journal of medicine)
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. (Journal of the American College of Cardiology)
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. (Journal of the American College of Cardiology)
Article 4: Atrial cardiomyopathy: markers and outcomes. (European heart journal)
Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/
 Featured Articles
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41092330
Summary: This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency &#8211; Severe Combined Immunodeficiency.
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091084
Summary: This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091083
Summary: This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.
Article 4: Atrial cardiomyopathy: markers and outcomes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41092306
Summary: This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Util]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 16, 2025. This episode summarizes 5 key cardiology studies on topics like gene therapy and Adenosine Deaminase Deficiency. Key takeaway: New e.G.F.R. Threshold Refines HeF.pEF Diagnosis..
Article Links:
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. (The New England journal of medicine)
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. (Journal of the American College of Cardiology)
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. (Journal of the American College of Cardiology)
Article 4: Atrial cardiomyopathy: markers and outcomes. (European heart journal)
Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>SCAI Stages Predict Cardiogenic Shock Risk 10/15/25</title>
	<link>https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/</link>
	<pubDate>Wed, 15 Oct 2025 10:01:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like nuclear imaging and transthyretin amyloid cardiomyopathy. Key takeaway: SCAI Stages Predict Cardiogenic Shock Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41085472">Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41083288">Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41081448">Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41078121">Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41078081">Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/">https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085472" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085472</a></p>
<p><strong>Summary:</strong> The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime&#8217;s potential role in managing cardiogenic shock and guiding future therapeutic paradigms.</p>
<h4>Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41083288" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41083288</a></p>
<p><strong>Summary:</strong> This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches.</p>
<h4>Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41081448" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41081448</a></p>
<p><strong>Summary:</strong> This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes.</p>
<h4>Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078121" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078121</a></p>
<p><strong>Summary:</strong> This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outcomes in patients with left ventricular assist devices. Left ventricular assist devices are vital for advanced heart failure, and obesity and diabetes are known to impact patient outcomes. By investigating the role of glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits, this research addresses a previously underexplored therapeutic area. The findings provide crucial information for optimizing medical management and potentially improving long-term outcomes for patients supported by left ventricular assist devices.</p>
<h4>Article 5: Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078081" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078081</a></p>
<p><strong>Summary:</strong> The N.A.C.L.O.C.R.o.-H.F. study prospectively examined the trajectories of urinary chloride and urinary sodium during acute heart failure hospitalization in elderly patients with heart failure with preserved ejection fraction. The research aimed to clarify their comparative dynamics and association with fluid overload. By evaluating these potential biomarkers for decongestion, the study establishes a clearer understanding of their utility in monitoring fluid status. These findings are pivotal for refining therapeutic guidance and achieving more precise decongestion strategies in this complex patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime&#8217;s potential role in managing cardiogenic shock and guiding future therapeutic paradigms.</p>
<p>Article number two. Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches.</p>
<p>Article number three. Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes.</p>
<p>Article number four. Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outcomes in patients with left ventricular assist devices. Left ventricular assist devices are vital for advanced heart failure, and obesity and diabetes are known to impact patient outcomes. By investigating the role of glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits, this research addresses a previously underexplored therapeutic area. The findings provide crucial information for optimizing medical management and potentially improving long-term outcomes for patients supported by left ventricular assist devices.</p>
<p>Article number five. Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. The N.A.C.L.O.C.R.o.-H.F. study prospectively examined the trajectories of urinary chloride and urinary sodium during acute heart failure hospitalization in elderly patients with heart failure with preserved ejection fraction. The research aimed to clarify their comparative dynamics and association with fluid overload. By evaluating these potential biomarkers for decongestion, the study establishes a clearer understanding of their utility in monitoring fluid status. These findings are pivotal for refining therapeutic guidance and achieving more precise decongestion strategies in this complex patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>nuclear imaging, transthyretin amyloid cardiomyopathy, haemodynamics, echocardiography, decongestion, extracorporeal life support, heart failure with preserved ejection fraction, planar scintigraphy, prognosis, acute heart failure, acute decompensated heart failure, S.C.A.I. stage B, cardiogenic shock, hypertrophic cardiomyopathy, istaroxime, S.C.A.I. classification, heart failure, acute myocardial infarction, urinary chloride, left ventricular assist devices, cardiovascular outcomes, urinary sodium, fluid overload, glucagon-like peptide-1 receptor agonists.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/">SCAI Stages Predict Cardiogenic Shock Risk 10/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like nuclear imaging and transthyretin amyloid cardiomyopathy. Key takeaway: SCAI Stages Predict Cardiogenic Shock Risk.
Article Links:
Ar]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like nuclear imaging and transthyretin amyloid cardiomyopathy. Key takeaway: SCAI Stages Predict Cardiogenic Shock Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41085472">Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41083288">Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41081448">Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41078121">Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41078081">Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/">https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41085472" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41085472</a></p>
<p><strong>Summary:</strong> The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime&#8217;s potential role in managing cardiogenic shock and guiding future therapeutic paradigms.</p>
<h4>Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41083288" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41083288</a></p>
<p><strong>Summary:</strong> This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches.</p>
<h4>Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41081448" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41081448</a></p>
<p><strong>Summary:</strong> This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes.</p>
<h4>Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078121" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078121</a></p>
<p><strong>Summary:</strong> This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outcomes in patients with left ventricular assist devices. Left ventricular assist devices are vital for advanced heart failure, and obesity and diabetes are known to impact patient outcomes. By investigating the role of glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits, this research addresses a previously underexplored therapeutic area. The findings provide crucial information for optimizing medical management and potentially improving long-term outcomes for patients supported by left ventricular assist devices.</p>
<h4>Article 5: Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078081" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078081</a></p>
<p><strong>Summary:</strong> The N.A.C.L.O.C.R.o.-H.F. study prospectively examined the trajectories of urinary chloride and urinary sodium during acute heart failure hospitalization in elderly patients with heart failure with preserved ejection fraction. The research aimed to clarify their comparative dynamics and association with fluid overload. By evaluating these potential biomarkers for decongestion, the study establishes a clearer understanding of their utility in monitoring fluid status. These findings are pivotal for refining therapeutic guidance and achieving more precise decongestion strategies in this complex patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime&#8217;s potential role in managing cardiogenic shock and guiding future therapeutic paradigms.</p>
<p>Article number two. Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches.</p>
<p>Article number three. Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes.</p>
<p>Article number four. Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outcomes in patients with left ventricular assist devices. Left ventricular assist devices are vital for advanced heart failure, and obesity and diabetes are known to impact patient outcomes. By investigating the role of glucagon-like peptide-1 receptor agonists, which have demonstrated cardiovascular benefits, this research addresses a previously underexplored therapeutic area. The findings provide crucial information for optimizing medical management and potentially improving long-term outcomes for patients supported by left ventricular assist devices.</p>
<p>Article number five. Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. The N.A.C.L.O.C.R.o.-H.F. study prospectively examined the trajectories of urinary chloride and urinary sodium during acute heart failure hospitalization in elderly patients with heart failure with preserved ejection fraction. The research aimed to clarify their comparative dynamics and association with fluid overload. By evaluating these potential biomarkers for decongestion, the study establishes a clearer understanding of their utility in monitoring fluid status. These findings are pivotal for refining therapeutic guidance and achieving more precise decongestion strategies in this complex patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>nuclear imaging, transthyretin amyloid cardiomyopathy, haemodynamics, echocardiography, decongestion, extracorporeal life support, heart failure with preserved ejection fraction, planar scintigraphy, prognosis, acute heart failure, acute decompensated heart failure, S.C.A.I. stage B, cardiogenic shock, hypertrophic cardiomyopathy, istaroxime, S.C.A.I. classification, heart failure, acute myocardial infarction, urinary chloride, left ventricular assist devices, cardiovascular outcomes, urinary sodium, fluid overload, glucagon-like peptide-1 receptor agonists.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/">SCAI Stages Predict Cardiogenic Shock Risk 10/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251015_060041.mp3" length="4861117" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like nuclear imaging and transthyretin amyloid cardiomyopathy. Key takeaway: SCAI Stages Predict Cardiogenic Shock Risk.
Article Links:
Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. (ESC heart failure)
Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. (ESC heart failure)
Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. (ESC heart failure)
Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. (ESC heart failure)
Article 5: Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/scai-stages-predict-cardiogenic-shock-risk-10-15-25/
 Featured Articles
Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41085472
Summary: The S.E.I.S.M.i.C. extension trial investigated the haemodynamic effects of istaroxime in S.C.A.I. stage B cardiogenic shock related to acute decompensated heart failure. Researchers randomized 30 patients to receive either placebo or istaroxime (0.5-1.0 micrograms per kilogram per minute) intravenously for 60 hours. This post-hoc analysis specifically assessed the impact of istaroxime on invasively obtained haemodynamic measures. The findings from this evaluation are crucial for understanding istaroxime&#8217;s potential role in managing cardiogenic shock and guiding future therapeutic paradigms.
Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41083288
Summary: This sub-study of the E.C.L.S.-S.H.O.C.K. trial investigated the prognostic impact of S.C.A.I. shock severity classes in acute myocardial infarction-related cardiogenic shock. Researchers aimed to clarify how S.C.A.I. stages influence the effectiveness of extracorporeal life support therapy in these patients. The study establishes the critical role of S.C.A.I. classification for risk stratification in acute myocardial infarction complicated by cardiogenic shock. These findings provide a more nuanced understanding of prognosis and treatment response in this high-risk population, guiding personalized therapeutic approaches.
Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41081448
Summary: This study assessed the frequency of planar scintigraphy, with and without single-photon emission computed tomography, in hypertrophic cardiomyopathy patients screened for transthyretin amyloid cardiomyopathy in the T.T.R.A.C.K. study. It addressed variability in readings across different cardiac nuclear imaging tests, radiotracers, and readers, as well as discrepancies in echocardiographic findings. By evaluating these diagnostic methodologies, the research provides valuable insights into optimizing the identification of transthyretin amyloid cardiomyopathy. This work ultimately aims to reduce diagnostic delays, which significantly impact patient outcomes.
Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41078121
Summary: This retrospective cohort study evaluated the association of glucagon-like peptide-1 receptor agonist therapy with cardiovascular outco]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like nuclear imaging and transthyretin amyloid cardiomyopathy. Key takeaway: SCAI Stages Predict Cardiogenic Shock Risk.
Article Links:
Article 1: Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial. (ESC heart failure)
Article 2: Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial. (ESC heart failure)
Article 3: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. (ESC heart failure)
Article 4: Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. (ESC heart failure)
Article 5: Dynamics of urinary chloride and sodium and their link to decongestion in acute heart failure and preserved ejection fraction: NACLOCRo-HF study. (ESC heart failure)
Full epis]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI ECG Boosts Hypertrophic Cardiomyopathy Detection. 10/15/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/</link>
	<pubDate>Wed, 15 Oct 2025 06:57:59 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like Systematic COronary Risk Evaluation 2 and bradyarrhythmias. Key takeaway: AI ECG Boosts Hypertrophic Cardiomyopathy Detection..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40425275">Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40379470">Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40368453">Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40240132">Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40157746">Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/">https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40425275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40425275</a></p>
<p><strong>Summary:</strong> This single-arm pilot study explored the use of a personalized approach, combining radiofrequency ablation and balloon dilation (C.U.R.B.), to establish interatrial communication in patients with Heart Failure with Preserved Ejection Fraction. The research was conducted at Fuwai Hospital in patients exhibiting elevated resting mean left atrial pressure of 18 millimeters of mercury or higher. This study aimed to normalize left atrial pressure, offering a potential new therapeutic strategy for Heart Failure with Preserved Ejection Fraction management. It successfully investigated the methodology for this intervention, providing a foundation for future larger studies on its efficacy and safety.</p>
<h4>Article 2: Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40379470" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40379470</a></p>
<p><strong>Summary:</strong> This study aimed to develop a deep learning model based on retinal fundus images for optimized detection of mild cognitive impairment in individuals with Coronary Artery Disease. The research involved Coronary Artery Disease patients, defined by at least one 50 percent stenosis, from Beijing Anzhen Hospital between 2021 and 2023. This methodology establishes a non-invasive approach to screen for mild cognitive impairment, which is commonly associated with Coronary Artery Disease. The development of such a model could facilitate early intervention and improve prognostic outcomes for this vulnerable patient group.</p>
<h4>Article 3: Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40368453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40368453</a></p>
<p><strong>Summary:</strong> This study aimed to validate, update, and assess the utility of several prominent Cardiovascular Disease risk prediction models in an Australian older adult population. Researchers specifically evaluated models originally developed for middle-aged individuals, such as the American College of Cardiology/American Heart Association and 2008 Framingham models, alongside an age-specific Systematic COronary Risk Evaluation 2-Older Person model. The methodology established a comprehensive framework for assessing these models&#8217; predictive performance in older adults. This research addresses current inadequacies in risk prediction for the elderly, contributing to improved, age-appropriate prevention strategies for Cardiovascular Disease.</p>
<h4>Article 4: Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40240132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40240132</a></p>
<p><strong>Summary:</strong> for hypertrophic cardiomyopathy detection. This open-label, multicenter prospective cohort study assessed the clinical implementation of an Artificial Intelligence-enabled 12-lead electrocardiogram software for detecting suspected Hypertrophic Cardiomyopathy. The Viz H.C.M. (Viz.ai) software, which alerts clinicians to potential Hypertrophic Cardiomyopathy cases, was implemented across five healthcare systems from January to December 2023. This research successfully demonstrated the real-world utility of A.I.-E.C.G. tools in assisting with early patient identification and evaluation. The findings offer a pathway to improve diagnosis rates for this often underdiagnosed cardiac condition.</p>
<h4>Article 5: Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40157746" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40157746</a></p>
<p><strong>Summary:</strong> This nationwide population-based study explored the contemporary incidence and indications for permanent pacemaker implantation following various cardiac surgical procedures. Conducted in Sweden, the research primarily investigated implantation rates at 30 days and one year post-surgery, with secondary outcomes including 10-year incidence. The study provides crucial, modern data on bradyarrhythmia complications after cardiac surgery. This information is vital for patient risk stratification, counseling, and optimizing post-operative management strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study. This single-arm pilot study explored the use of a personalized approach, combining radiofrequency ablation and balloon dilation (C.U.R.B.), to establish interatrial communication in patients with Heart Failure with Preserved Ejection Fraction. The research was conducted at Fuwai Hospital in patients exhibiting elevated resting mean left atrial pressure of 18 millimeters of mercury or higher. This study aimed to normalize left atrial pressure, offering a potential new therapeutic strategy for Heart Failure with Preserved Ejection Fraction management. It successfully investigated the methodology for this intervention, providing a foundation for future larger studies on its efficacy and safety.</p>
<p>Article number two. Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population. This study aimed to develop a deep learning model based on retinal fundus images for optimized detection of mild cognitive impairment in individuals with Coronary Artery Disease. The research involved Coronary Artery Disease patients, defined by at least one 50 percent stenosis, from Beijing Anzhen Hospital between 2021 and 2023. This methodology establishes a non-invasive approach to screen for mild cognitive impairment, which is commonly associated with Coronary Artery Disease. The development of such a model could facilitate early intervention and improve prognostic outcomes for this vulnerable patient group.</p>
<p>Article number three. Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study. This study aimed to validate, update, and assess the utility of several prominent Cardiovascular Disease risk prediction models in an Australian older adult population. Researchers specifically evaluated models originally developed for middle-aged individuals, such as the American College of Cardiology/American Heart Association and 2008 Framingham models, alongside an age-specific Systematic COronary Risk Evaluation 2-Older Person model. The methodology established a comprehensive framework for assessing these models&#8217; predictive performance in older adults. This research addresses current inadequacies in risk prediction for the elderly, contributing to improved, age-appropriate prevention strategies for Cardiovascular Disease.</p>
<p>Article number four. Clinical implementation of an A.I.-enabled E.C.G. for hypertrophic cardiomyopathy detection. This open-label, multicenter prospective cohort study assessed the clinical implementation of an Artificial Intelligence-enabled 12-lead electrocardiogram software for detecting suspected Hypertrophic Cardiomyopathy. The Viz H.C.M. (Viz.ai) software, which alerts clinicians to potential Hypertrophic Cardiomyopathy cases, was implemented across five healthcare systems from January to December 2023. This research successfully demonstrated the real-world utility of A.I.-E.C.G. tools in assisting with early patient identification and evaluation. The findings offer a pathway to improve diagnosis rates for this often underdiagnosed cardiac condition.</p>
<p>Article number five. Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective. This nationwide population-based study explored the contemporary incidence and indications for permanent pacemaker implantation following various cardiac surgical procedures. Conducted in Sweden, the research primarily investigated implantation rates at 30 days and one year post-surgery, with secondary outcomes including 10-year incidence. The study provides crucial, modern data on bradyarrhythmia complications after cardiac surgery. This information is vital for patient risk stratification, counseling, and optimizing post-operative management strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Systematic COronary Risk Evaluation 2, bradyarrhythmias, Hypertrophic Cardiomyopathy, deep learning, older adults, Pacemaker implantation, model validation, radiofrequency ablation, E.C.G. interpretation, retinal imaging, post-operative complications, clinical implementation, cardiac surgery, mild cognitive impairment, Cardiovascular Disease, left atrial pressure, risk prediction models, balloon dilation, nationwide study, Heart Failure with Preserved Ejection Fraction, atrial septostomy, Artificial Intelligence, Coronary Artery Disease, electrocardiogram, fundus images.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/">AI ECG Boosts Hypertrophic Cardiomyopathy Detection. 10/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like Systematic COronary Risk Evaluation 2 and bradyarrhythmias. Key takeaway: AI ECG Boosts Hypertrophic Cardiomyopathy Detection..
Artic]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like Systematic COronary Risk Evaluation 2 and bradyarrhythmias. Key takeaway: AI ECG Boosts Hypertrophic Cardiomyopathy Detection..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40425275">Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40379470">Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40368453">Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40240132">Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40157746">Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/">https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40425275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40425275</a></p>
<p><strong>Summary:</strong> This single-arm pilot study explored the use of a personalized approach, combining radiofrequency ablation and balloon dilation (C.U.R.B.), to establish interatrial communication in patients with Heart Failure with Preserved Ejection Fraction. The research was conducted at Fuwai Hospital in patients exhibiting elevated resting mean left atrial pressure of 18 millimeters of mercury or higher. This study aimed to normalize left atrial pressure, offering a potential new therapeutic strategy for Heart Failure with Preserved Ejection Fraction management. It successfully investigated the methodology for this intervention, providing a foundation for future larger studies on its efficacy and safety.</p>
<h4>Article 2: Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40379470" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40379470</a></p>
<p><strong>Summary:</strong> This study aimed to develop a deep learning model based on retinal fundus images for optimized detection of mild cognitive impairment in individuals with Coronary Artery Disease. The research involved Coronary Artery Disease patients, defined by at least one 50 percent stenosis, from Beijing Anzhen Hospital between 2021 and 2023. This methodology establishes a non-invasive approach to screen for mild cognitive impairment, which is commonly associated with Coronary Artery Disease. The development of such a model could facilitate early intervention and improve prognostic outcomes for this vulnerable patient group.</p>
<h4>Article 3: Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40368453" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40368453</a></p>
<p><strong>Summary:</strong> This study aimed to validate, update, and assess the utility of several prominent Cardiovascular Disease risk prediction models in an Australian older adult population. Researchers specifically evaluated models originally developed for middle-aged individuals, such as the American College of Cardiology/American Heart Association and 2008 Framingham models, alongside an age-specific Systematic COronary Risk Evaluation 2-Older Person model. The methodology established a comprehensive framework for assessing these models&#8217; predictive performance in older adults. This research addresses current inadequacies in risk prediction for the elderly, contributing to improved, age-appropriate prevention strategies for Cardiovascular Disease.</p>
<h4>Article 4: Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40240132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40240132</a></p>
<p><strong>Summary:</strong> for hypertrophic cardiomyopathy detection. This open-label, multicenter prospective cohort study assessed the clinical implementation of an Artificial Intelligence-enabled 12-lead electrocardiogram software for detecting suspected Hypertrophic Cardiomyopathy. The Viz H.C.M. (Viz.ai) software, which alerts clinicians to potential Hypertrophic Cardiomyopathy cases, was implemented across five healthcare systems from January to December 2023. This research successfully demonstrated the real-world utility of A.I.-E.C.G. tools in assisting with early patient identification and evaluation. The findings offer a pathway to improve diagnosis rates for this often underdiagnosed cardiac condition.</p>
<h4>Article 5: Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40157746" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40157746</a></p>
<p><strong>Summary:</strong> This nationwide population-based study explored the contemporary incidence and indications for permanent pacemaker implantation following various cardiac surgical procedures. Conducted in Sweden, the research primarily investigated implantation rates at 30 days and one year post-surgery, with secondary outcomes including 10-year incidence. The study provides crucial, modern data on bradyarrhythmia complications after cardiac surgery. This information is vital for patient risk stratification, counseling, and optimizing post-operative management strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study. This single-arm pilot study explored the use of a personalized approach, combining radiofrequency ablation and balloon dilation (C.U.R.B.), to establish interatrial communication in patients with Heart Failure with Preserved Ejection Fraction. The research was conducted at Fuwai Hospital in patients exhibiting elevated resting mean left atrial pressure of 18 millimeters of mercury or higher. This study aimed to normalize left atrial pressure, offering a potential new therapeutic strategy for Heart Failure with Preserved Ejection Fraction management. It successfully investigated the methodology for this intervention, providing a foundation for future larger studies on its efficacy and safety.</p>
<p>Article number two. Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population. This study aimed to develop a deep learning model based on retinal fundus images for optimized detection of mild cognitive impairment in individuals with Coronary Artery Disease. The research involved Coronary Artery Disease patients, defined by at least one 50 percent stenosis, from Beijing Anzhen Hospital between 2021 and 2023. This methodology establishes a non-invasive approach to screen for mild cognitive impairment, which is commonly associated with Coronary Artery Disease. The development of such a model could facilitate early intervention and improve prognostic outcomes for this vulnerable patient group.</p>
<p>Article number three. Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study. This study aimed to validate, update, and assess the utility of several prominent Cardiovascular Disease risk prediction models in an Australian older adult population. Researchers specifically evaluated models originally developed for middle-aged individuals, such as the American College of Cardiology/American Heart Association and 2008 Framingham models, alongside an age-specific Systematic COronary Risk Evaluation 2-Older Person model. The methodology established a comprehensive framework for assessing these models&#8217; predictive performance in older adults. This research addresses current inadequacies in risk prediction for the elderly, contributing to improved, age-appropriate prevention strategies for Cardiovascular Disease.</p>
<p>Article number four. Clinical implementation of an A.I.-enabled E.C.G. for hypertrophic cardiomyopathy detection. This open-label, multicenter prospective cohort study assessed the clinical implementation of an Artificial Intelligence-enabled 12-lead electrocardiogram software for detecting suspected Hypertrophic Cardiomyopathy. The Viz H.C.M. (Viz.ai) software, which alerts clinicians to potential Hypertrophic Cardiomyopathy cases, was implemented across five healthcare systems from January to December 2023. This research successfully demonstrated the real-world utility of A.I.-E.C.G. tools in assisting with early patient identification and evaluation. The findings offer a pathway to improve diagnosis rates for this often underdiagnosed cardiac condition.</p>
<p>Article number five. Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective. This nationwide population-based study explored the contemporary incidence and indications for permanent pacemaker implantation following various cardiac surgical procedures. Conducted in Sweden, the research primarily investigated implantation rates at 30 days and one year post-surgery, with secondary outcomes including 10-year incidence. The study provides crucial, modern data on bradyarrhythmia complications after cardiac surgery. This information is vital for patient risk stratification, counseling, and optimizing post-operative management strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Systematic COronary Risk Evaluation 2, bradyarrhythmias, Hypertrophic Cardiomyopathy, deep learning, older adults, Pacemaker implantation, model validation, radiofrequency ablation, E.C.G. interpretation, retinal imaging, post-operative complications, clinical implementation, cardiac surgery, mild cognitive impairment, Cardiovascular Disease, left atrial pressure, risk prediction models, balloon dilation, nationwide study, Heart Failure with Preserved Ejection Fraction, atrial septostomy, Artificial Intelligence, Coronary Artery Disease, electrocardiogram, fundus images.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/">AI ECG Boosts Hypertrophic Cardiomyopathy Detection. 10/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251015_025651.mp3" length="4689754" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like Systematic COronary Risk Evaluation 2 and bradyarrhythmias. Key takeaway: AI ECG Boosts Hypertrophic Cardiomyopathy Detection..
Article Links:
Article 1: Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study. (Heart (British Cardiac Society))
Article 2: Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population. (Heart (British Cardiac Society))
Article 3: Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study. (Heart (British Cardiac Society))
Article 4: Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection. (Heart (British Cardiac Society))
Article 5: Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/ai-ecg-boosts-hypertrophic-cardiomyopathy-detection-10-15-25/
 Featured Articles
Article 1: Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40425275
Summary: This single-arm pilot study explored the use of a personalized approach, combining radiofrequency ablation and balloon dilation (C.U.R.B.), to establish interatrial communication in patients with Heart Failure with Preserved Ejection Fraction. The research was conducted at Fuwai Hospital in patients exhibiting elevated resting mean left atrial pressure of 18 millimeters of mercury or higher. This study aimed to normalize left atrial pressure, offering a potential new therapeutic strategy for Heart Failure with Preserved Ejection Fraction management. It successfully investigated the methodology for this intervention, providing a foundation for future larger studies on its efficacy and safety.
Article 2: Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40379470
Summary: This study aimed to develop a deep learning model based on retinal fundus images for optimized detection of mild cognitive impairment in individuals with Coronary Artery Disease. The research involved Coronary Artery Disease patients, defined by at least one 50 percent stenosis, from Beijing Anzhen Hospital between 2021 and 2023. This methodology establishes a non-invasive approach to screen for mild cognitive impairment, which is commonly associated with Coronary Artery Disease. The development of such a model could facilitate early intervention and improve prognostic outcomes for this vulnerable patient group.
Article 3: Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40368453
Summary: This study aimed to validate, update, and assess the utility of several prominent Cardiovascular Disease risk prediction models in an Australian older adult population. Researchers specifically evaluated models originally developed for middle-aged individuals, such as the American College of Cardiology/American Heart Association and 2008 Framingham models, alongside an age-specific Systematic COronary Risk Evaluation 2-Older Person model. The methodology established a comprehensive framework for assessing these models&#8217; predictive performance in older adults. This research addresses current inadequacies in risk prediction for the elderly, contributing to improved, age-appropriate prevention strategies for Cardiovascular Disease.
Artic]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 15, 2025. This episode summarizes 5 key cardiology studies on topics like Systematic COronary Risk Evaluation 2 and bradyarrhythmias. Key takeaway: AI ECG Boosts Hypertrophic Cardiomyopathy Detection..
Article Links:
Article 1: Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study. (Heart (British Cardiac Society))
Article 2: Retinal image-based deep learning for mild cognitive impairment detection in coronary artery disease population. (Heart (British Cardiac Society))
Article 3: Predictive performance of cardiovascular disease risk prediction models in older adults: a validation and updating study. (Heart (British Cardiac Society))
Article 4: Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection. (Heart (British Cardiac Society))
Article 5: Pacemaker implantation after cardiac surgery: a contemporary, nati]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>LDL, Lp(a), CRP: Independent CV Event Predictors. 10/14/25</title>
	<link>https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/</link>
	<pubDate>Tue, 14 Oct 2025 10:01:51 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like C.O.V.I.D.-19 and Low-density lipoprotein cholesterol. Key takeaway: LDL, Lp(a), CRP: Independent CV Event Predictors..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40819656">Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40748607">Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40320753">Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40167249">Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41078250">DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/">https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40819656" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40819656</a></p>
<p><strong>Summary:</strong> The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.</p>
<h4>Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40748607" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40748607</a></p>
<p><strong>Summary:</strong> trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study&#8217;s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.</p>
<h4>Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40320753" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40320753</a></p>
<p><strong>Summary:</strong> This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers&#8217; associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.</p>
<h4>Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40167249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40167249</a></p>
<p><strong>Summary:</strong> The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study&#8217;s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.</p>
<h4>Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078250</a></p>
<p><strong>Summary:</strong> registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.</p>
<p>Article number two. Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the H.E.L.P.-P.C.I. trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study&#8217;s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.</p>
<p>Article number three. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers&#8217; associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.</p>
<p>Article number four. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the E.P.I.C.-Norfolk study. The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study&#8217;s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.</p>
<p>Article number five. DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-P.V.A.D. registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>C.O.V.I.D.-19, Low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, unfractionated heparin, universal screening, first medical contact, post-infection, cardiovascular complications, major adverse cardiovascular events, primary percutaneous coronary intervention, randomized controlled trial, risk prediction, Impella, Acute myocardial infarction, cohort study, lipoprotein(a), vascular aging, Primary prevention, cardiogenic shock, high-sensitivity C-reactive protein, S.T.-elevation myocardial infarction, mechanical circulatory support, DanGer shock.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/">LDL, Lp(a), CRP: Independent CV Event Predictors. 10/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like C.O.V.I.D.-19 and Low-density lipoprotein cholesterol. Key takeaway: LDL, Lp(a), CRP: Independent CV Event Predictors..
Article Links]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like C.O.V.I.D.-19 and Low-density lipoprotein cholesterol. Key takeaway: LDL, Lp(a), CRP: Independent CV Event Predictors..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40819656">Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40748607">Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40320753">Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40167249">Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41078250">DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/">https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40819656" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40819656</a></p>
<p><strong>Summary:</strong> The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.</p>
<h4>Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40748607" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40748607</a></p>
<p><strong>Summary:</strong> trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study&#8217;s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.</p>
<h4>Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40320753" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40320753</a></p>
<p><strong>Summary:</strong> This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers&#8217; associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.</p>
<h4>Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40167249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40167249</a></p>
<p><strong>Summary:</strong> The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study&#8217;s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.</p>
<h4>Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078250</a></p>
<p><strong>Summary:</strong> registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.</p>
<p>Article number two. Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the H.E.L.P.-P.C.I. trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study&#8217;s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.</p>
<p>Article number three. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers&#8217; associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.</p>
<p>Article number four. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the E.P.I.C.-Norfolk study. The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study&#8217;s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.</p>
<p>Article number five. DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-P.V.A.D. registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>C.O.V.I.D.-19, Low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, unfractionated heparin, universal screening, first medical contact, post-infection, cardiovascular complications, major adverse cardiovascular events, primary percutaneous coronary intervention, randomized controlled trial, risk prediction, Impella, Acute myocardial infarction, cohort study, lipoprotein(a), vascular aging, Primary prevention, cardiogenic shock, high-sensitivity C-reactive protein, S.T.-elevation myocardial infarction, mechanical circulatory support, DanGer shock.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/">LDL, Lp(a), CRP: Independent CV Event Predictors. 10/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251014_060046.mp3" length="4504180" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like C.O.V.I.D.-19 and Low-density lipoprotein cholesterol. Key takeaway: LDL, Lp(a), CRP: Independent CV Event Predictors..
Article Links:
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. (European heart journal)
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial. (European heart journal)
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. (European heart journal)
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. (European heart journal)
Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/
 Featured Articles
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40819656
Summary: The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40748607
Summary: trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study&#8217;s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40320753
Summary: This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers&#8217; associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40167249
Summary: The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-react]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like C.O.V.I.D.-19 and Low-density lipoprotein cholesterol. Key takeaway: LDL, Lp(a), CRP: Independent CV Event Predictors..
Article Links:
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. (European heart journal)
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial. (European heart journal)
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. (European heart journal)
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. (European heart journal)
Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardioge]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>HeartMate 3 Reduces L.V.A.D. Thromboembolism 10/14/25</title>
	<link>https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/</link>
	<pubDate>Tue, 14 Oct 2025 06:57:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like Ascending Aortic Diameter and Bleeding Events. Key takeaway: HeartMate 3 Reduces L.V.A.D. Thromboembolism.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41062227">Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40864016">Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40864013">Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41078120">Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41083213">Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/">https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41062227" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41062227</a></p>
<p><strong>Summary:</strong> Article number one. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</p>
<h4>Article 2: Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864016" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864016</a></p>
<p><strong>Summary:</strong> Article number two. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</p>
<h4>Article 3: Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864013" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864013</a></p>
<p><strong>Summary:</strong> Article number three. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</p>
<h4>Article 4: Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078120" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078120</a></p>
<p><strong>Summary:</strong> Article number four. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</p>
<h4>Article 5: Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41083213" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41083213</a></p>
<p><strong>Summary:</strong> Article number five. Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</p>
<p>Article number two. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</p>
<p>Article number three. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</p>
<p>Article number four. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</p>
<p>Article number five. Sex differences in ascending aortic diameter at the time of acute type A aortic dissection. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Ascending Aortic Diameter, Bleeding Events, EUROMACS Registry, Acute Type A Aortic Dissection, Dapagliflozin, Women&#8217;s Health Initiative, Biodegradable Device, Left Ventricular Assist Device, Ischemic Events, High-Coverage Sequencing, Randomized Clinical Trial, Cardiovascular Disease, HeartMate 3, Heart Failure, Older Women, Computed Tomography Scan, Nitinol Device, Transcatheter Aortic Valve Implantation, Clonal Hematopoiesis of Indeterminate Potential, Patent Foramen Ovale, Aortic Aneurysm, Quality of Life, Sex Differences, Aortic Stenosis, Transcatheter Closure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/">HeartMate 3 Reduces L.V.A.D. Thromboembolism 10/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like Ascending Aortic Diameter and Bleeding Events. Key takeaway: HeartMate 3 Reduces L.V.A.D. Thromboembolism.
Article Links:
Article 1: ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like Ascending Aortic Diameter and Bleeding Events. Key takeaway: HeartMate 3 Reduces L.V.A.D. Thromboembolism.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41062227">Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40864016">Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40864013">Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41078120">Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41083213">Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/">https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41062227" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41062227</a></p>
<p><strong>Summary:</strong> Article number one. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</p>
<h4>Article 2: Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864016" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864016</a></p>
<p><strong>Summary:</strong> Article number two. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</p>
<h4>Article 3: Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864013" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864013</a></p>
<p><strong>Summary:</strong> Article number three. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</p>
<h4>Article 4: Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41078120" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41078120</a></p>
<p><strong>Summary:</strong> Article number four. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</p>
<h4>Article 5: Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41083213" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41083213</a></p>
<p><strong>Summary:</strong> Article number five. Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.</p>
<p>Article number two. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.</p>
<p>Article number three. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.</p>
<p>Article number four. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.</p>
<p>Article number five. Sex differences in ascending aortic diameter at the time of acute type A aortic dissection. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Ascending Aortic Diameter, Bleeding Events, EUROMACS Registry, Acute Type A Aortic Dissection, Dapagliflozin, Women&#8217;s Health Initiative, Biodegradable Device, Left Ventricular Assist Device, Ischemic Events, High-Coverage Sequencing, Randomized Clinical Trial, Cardiovascular Disease, HeartMate 3, Heart Failure, Older Women, Computed Tomography Scan, Nitinol Device, Transcatheter Aortic Valve Implantation, Clonal Hematopoiesis of Indeterminate Potential, Patent Foramen Ovale, Aortic Aneurysm, Quality of Life, Sex Differences, Aortic Stenosis, Transcatheter Closure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/">HeartMate 3 Reduces L.V.A.D. Thromboembolism 10/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251014_025714.mp3" length="1182658" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like Ascending Aortic Diameter and Bleeding Events. Key takeaway: HeartMate 3 Reduces L.V.A.D. Thromboembolism.
Article Links:
Article 1: Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. (Journal of the American College of Cardiology)
Article 2: Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women. (Journal of the American College of Cardiology)
Article 3: Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis. (Journal of the American College of Cardiology)
Article 4: Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial. (Circulation)
Article 5: Sex differences in ascending aortic diameter at the time of acute type A aortic dissection. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/heartmate-3-reduces-l-v-a-d-thromboembolism-10-14-25/
 Featured Articles
Article 1: Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41062227
Summary: Article number one. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
Article 2: Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40864016
Summary: Article number two. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.
Article 3: Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40864013
Summary: Article number three. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.
Article 4: Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41078120
Summary: Article number four. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
Article 5: Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41083213
Summary: Article number five. Sex differences in ascending aortic diameter at the time of acute type A aortic dissection.
 Transcript

Today&#8217;s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
Article number two. Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.
Article number three. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.
Article number four. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
Article number five. Sex differences in ascending aortic diameter at the time of acute type A aortic dissection. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
Ascending Aortic Diameter, Bleeding Events, EUROMACS Registry, Acute Type A Aortic Dissection, Dapagliflozin, Women&#8217;s Health Initiative, Biodegradable Device, Left Ventricular Assist D]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like Ascending Aortic Diameter and Bleeding Events. Key takeaway: HeartMate 3 Reduces L.V.A.D. Thromboembolism.
Article Links:
Article 1: Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. (Journal of the American College of Cardiology)
Article 2: Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women. (Journal of the American College of Cardiology)
Article 3: Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis. (Journal of the American College of Cardiology)
Article 4: Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial. (Circulation)
Article 5: Sex differences in ascending aortic diameter at the time of acute type A aortic dissecti]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New Monocyte Role in Aortic Stenosis &#038; Fibrosis 10/13/25</title>
	<link>https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/</link>
	<pubDate>Mon, 13 Oct 2025 10:01:31 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like Ryanodine receptor type-2 and Aortic arch morphology. Key takeaway: New Monocyte Role in Aortic Stenosis &#038; Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41077218">Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41073370">Monocytes at the crossroads of aortic stenosis and myocardial damage.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41073365">Cardiovascular risk factors and the allostatic interoceptive network in dementia.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41071938">Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41070410">Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children.</a> (Circulation. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/">https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077218</a></p>
<p><strong>Summary:</strong> This study investigates the impact of aortic arch morphology, including arch angle, calcification, and soft plaques, on the incidence of cerebrovascular accidents (C.V.A.) following transfemoral transcatheter aortic valve implantation (T.A.V.I.). This analysis uses pre-procedural computed tomography (C.T.) scans from consecutive patients. The abstract describes the study&#8217;s objective and methodology, which includes patient analysis up to January 2025, but does not present specific findings or clinical outcomes.</p>
<h4>Article 2: Monocytes at the crossroads of aortic stenosis and myocardial damage.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41073370" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41073370</a></p>
<p><strong>Summary:</strong> This research highlights the critical role of monocytes in aortic stenosis (A.S.) progression and associated myocardial damage. Previous work from this group identified a specific monocyte subpopulation implicated in both valvular calcification and myocardial fibrosis. This subpopulation mediates crucial crosstalk between the aortic valve and the myocardium, suggesting a novel mechanistic link between inflammation and structural heart disease.</p>
<h4>Article 3: Cardiovascular risk factors and the allostatic interoceptive network in dementia.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41073365" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41073365</a></p>
<p><strong>Summary:</strong> This study aims to elucidate how established cardiovascular risk factors, such as diabetes, hypertension, obesity, and smoking, influence the Allostatic-Interoceptive Network (A.I.N.) in the context of dementia. The A.I.N. is crucial for continuous monitoring of internal bodily states and is known to be vulnerable to neurodegeneration. While the abstract outlines the significant research question, it does not present the specific findings or conclusions of this investigation.</p>
<h4>Article 4: Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41071938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41071938</a></p>
<p><strong>Summary:</strong> This study investigates the precise spatial recruitment and anchoring mechanisms of activated Ca2+/calmodulin-dependent kinase I.I. delta (CaMKIIδ) to the ryanodine receptor type-2 (R.Y.R.) nanodomain in cardiomyocytes. This interaction is critical for regulating calcium release, which is fundamental to the heartbeat, with hyperphosphorylation leading to pathological calcium release. The abstract describes the study&#8217;s objective and methods, including confocal and dSTORM microscopy, but does not provide the actual findings or conclusions regarding these molecular mechanisms.</p>
<h4>Article 5: Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41070410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41070410</a></p>
<p><strong>Summary:</strong> This multicenter, single-arm, prospective trial evaluated the safety and efficacy of the Minima Stent System, the first Food and Drug Administration (F.D.A.)-approved stent specifically designed for neonates, infants, and children. The study targeted vascular stenosis in pulmonary artery stenosis (P.A.S.) and coarctation of the aorta (C.o.A.). While the abstract outlines the trial&#8217;s design and primary endpoints, it does not present the specific clinical outcomes, efficacy rates, or safety profiles from the completed trial.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation. This study investigates the impact of aortic arch morphology, including arch angle, calcification, and soft plaques, on the incidence of cerebrovascular accidents (C.V.A.) following transfemoral transcatheter aortic valve implantation (T.A.V.I.). This analysis uses pre-procedural computed tomography (C.T.) scans from consecutive patients. The abstract describes the study&#8217;s objective and methodology, which includes patient analysis up to January 2025, but does not present specific findings or clinical outcomes.</p>
<p>Article number two. Monocytes at the crossroads of aortic stenosis and myocardial damage. This research highlights the critical role of monocytes in aortic stenosis (A.S.) progression and associated myocardial damage. Previous work from this group identified a specific monocyte subpopulation implicated in both valvular calcification and myocardial fibrosis. This subpopulation mediates crucial crosstalk between the aortic valve and the myocardium, suggesting a novel mechanistic link between inflammation and structural heart disease.</p>
<p>Article number three. Cardiovascular risk factors and the allostatic interoceptive network in dementia. This study aims to elucidate how established cardiovascular risk factors, such as diabetes, hypertension, obesity, and smoking, influence the Allostatic-Interoceptive Network (A.I.N.) in the context of dementia. The A.I.N. is crucial for continuous monitoring of internal bodily states and is known to be vulnerable to neurodegeneration. While the abstract outlines the significant research question, it does not present the specific findings or conclusions of this investigation.</p>
<p>Article number four. Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes. This study investigates the precise spatial recruitment and anchoring mechanisms of activated Ca2+/calmodulin-dependent kinase I.I. delta (CaMKIIδ) to the ryanodine receptor type-2 (R.Y.R.) nanodomain in cardiomyocytes. This interaction is critical for regulating calcium release, which is fundamental to the heartbeat, with hyperphosphorylation leading to pathological calcium release. The abstract describes the study&#8217;s objective and methods, including confocal and dSTORM microscopy, but does not provide the actual findings or conclusions regarding these molecular mechanisms.</p>
<p>Article number five. Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children. This multicenter, single-arm, prospective trial evaluated the safety and efficacy of the Minima Stent System, the first Food and Drug Administration (F.D.A.)-approved stent specifically designed for neonates, infants, and children. The study targeted vascular stenosis in pulmonary artery stenosis (P.A.S.) and coarctation of the aorta (C.o.A.). While the abstract outlines the trial&#8217;s design and primary endpoints, it does not present the specific clinical outcomes, efficacy rates, or safety profiles from the completed trial. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Ryanodine receptor type-2, Aortic arch morphology, Calcium release, Pulmonary artery stenosis, Hypertension, Myocardial fibrosis, Aortic calcification, Myocardial damage, Dementia, Cardiovascular risk factors, Neurodegeneration, CaMKIIδ, Nanodomain, Aortic stenosis, Vascular stenosis, Minima Stent System, Pediatric cardiology, Cerebrovascular accidents, Valvular calcification, Coarctation of the aorta, Allostatic-Interoceptive Network, Transcatheter aortic valve implantation, Monocytes, Cardiomyocytes, Computed tomography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/">New Monocyte Role in Aortic Stenosis & Fibrosis 10/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like Ryanodine receptor type-2 and Aortic arch morphology. Key takeaway: New Monocyte Role in Aortic Stenosis &#038; Fibrosis.
Article Lin]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like Ryanodine receptor type-2 and Aortic arch morphology. Key takeaway: New Monocyte Role in Aortic Stenosis &#038; Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41077218">Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41073370">Monocytes at the crossroads of aortic stenosis and myocardial damage.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41073365">Cardiovascular risk factors and the allostatic interoceptive network in dementia.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41071938">Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41070410">Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children.</a> (Circulation. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/">https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077218" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077218</a></p>
<p><strong>Summary:</strong> This study investigates the impact of aortic arch morphology, including arch angle, calcification, and soft plaques, on the incidence of cerebrovascular accidents (C.V.A.) following transfemoral transcatheter aortic valve implantation (T.A.V.I.). This analysis uses pre-procedural computed tomography (C.T.) scans from consecutive patients. The abstract describes the study&#8217;s objective and methodology, which includes patient analysis up to January 2025, but does not present specific findings or clinical outcomes.</p>
<h4>Article 2: Monocytes at the crossroads of aortic stenosis and myocardial damage.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41073370" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41073370</a></p>
<p><strong>Summary:</strong> This research highlights the critical role of monocytes in aortic stenosis (A.S.) progression and associated myocardial damage. Previous work from this group identified a specific monocyte subpopulation implicated in both valvular calcification and myocardial fibrosis. This subpopulation mediates crucial crosstalk between the aortic valve and the myocardium, suggesting a novel mechanistic link between inflammation and structural heart disease.</p>
<h4>Article 3: Cardiovascular risk factors and the allostatic interoceptive network in dementia.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41073365" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41073365</a></p>
<p><strong>Summary:</strong> This study aims to elucidate how established cardiovascular risk factors, such as diabetes, hypertension, obesity, and smoking, influence the Allostatic-Interoceptive Network (A.I.N.) in the context of dementia. The A.I.N. is crucial for continuous monitoring of internal bodily states and is known to be vulnerable to neurodegeneration. While the abstract outlines the significant research question, it does not present the specific findings or conclusions of this investigation.</p>
<h4>Article 4: Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41071938" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41071938</a></p>
<p><strong>Summary:</strong> This study investigates the precise spatial recruitment and anchoring mechanisms of activated Ca2+/calmodulin-dependent kinase I.I. delta (CaMKIIδ) to the ryanodine receptor type-2 (R.Y.R.) nanodomain in cardiomyocytes. This interaction is critical for regulating calcium release, which is fundamental to the heartbeat, with hyperphosphorylation leading to pathological calcium release. The abstract describes the study&#8217;s objective and methods, including confocal and dSTORM microscopy, but does not provide the actual findings or conclusions regarding these molecular mechanisms.</p>
<h4>Article 5: Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41070410" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41070410</a></p>
<p><strong>Summary:</strong> This multicenter, single-arm, prospective trial evaluated the safety and efficacy of the Minima Stent System, the first Food and Drug Administration (F.D.A.)-approved stent specifically designed for neonates, infants, and children. The study targeted vascular stenosis in pulmonary artery stenosis (P.A.S.) and coarctation of the aorta (C.o.A.). While the abstract outlines the trial&#8217;s design and primary endpoints, it does not present the specific clinical outcomes, efficacy rates, or safety profiles from the completed trial.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation. This study investigates the impact of aortic arch morphology, including arch angle, calcification, and soft plaques, on the incidence of cerebrovascular accidents (C.V.A.) following transfemoral transcatheter aortic valve implantation (T.A.V.I.). This analysis uses pre-procedural computed tomography (C.T.) scans from consecutive patients. The abstract describes the study&#8217;s objective and methodology, which includes patient analysis up to January 2025, but does not present specific findings or clinical outcomes.</p>
<p>Article number two. Monocytes at the crossroads of aortic stenosis and myocardial damage. This research highlights the critical role of monocytes in aortic stenosis (A.S.) progression and associated myocardial damage. Previous work from this group identified a specific monocyte subpopulation implicated in both valvular calcification and myocardial fibrosis. This subpopulation mediates crucial crosstalk between the aortic valve and the myocardium, suggesting a novel mechanistic link between inflammation and structural heart disease.</p>
<p>Article number three. Cardiovascular risk factors and the allostatic interoceptive network in dementia. This study aims to elucidate how established cardiovascular risk factors, such as diabetes, hypertension, obesity, and smoking, influence the Allostatic-Interoceptive Network (A.I.N.) in the context of dementia. The A.I.N. is crucial for continuous monitoring of internal bodily states and is known to be vulnerable to neurodegeneration. While the abstract outlines the significant research question, it does not present the specific findings or conclusions of this investigation.</p>
<p>Article number four. Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes. This study investigates the precise spatial recruitment and anchoring mechanisms of activated Ca2+/calmodulin-dependent kinase I.I. delta (CaMKIIδ) to the ryanodine receptor type-2 (R.Y.R.) nanodomain in cardiomyocytes. This interaction is critical for regulating calcium release, which is fundamental to the heartbeat, with hyperphosphorylation leading to pathological calcium release. The abstract describes the study&#8217;s objective and methods, including confocal and dSTORM microscopy, but does not provide the actual findings or conclusions regarding these molecular mechanisms.</p>
<p>Article number five. Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children. This multicenter, single-arm, prospective trial evaluated the safety and efficacy of the Minima Stent System, the first Food and Drug Administration (F.D.A.)-approved stent specifically designed for neonates, infants, and children. The study targeted vascular stenosis in pulmonary artery stenosis (P.A.S.) and coarctation of the aorta (C.o.A.). While the abstract outlines the trial&#8217;s design and primary endpoints, it does not present the specific clinical outcomes, efficacy rates, or safety profiles from the completed trial. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Ryanodine receptor type-2, Aortic arch morphology, Calcium release, Pulmonary artery stenosis, Hypertension, Myocardial fibrosis, Aortic calcification, Myocardial damage, Dementia, Cardiovascular risk factors, Neurodegeneration, CaMKIIδ, Nanodomain, Aortic stenosis, Vascular stenosis, Minima Stent System, Pediatric cardiology, Cerebrovascular accidents, Valvular calcification, Coarctation of the aorta, Allostatic-Interoceptive Network, Transcatheter aortic valve implantation, Monocytes, Cardiomyocytes, Computed tomography.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/">New Monocyte Role in Aortic Stenosis & Fibrosis 10/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251013_060038.mp3" length="3934501" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like Ryanodine receptor type-2 and Aortic arch morphology. Key takeaway: New Monocyte Role in Aortic Stenosis &#038; Fibrosis.
Article Links:
Article 1: Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation. (The American journal of cardiology)
Article 2: Monocytes at the crossroads of aortic stenosis and myocardial damage. (Cardiovascular research)
Article 3: Cardiovascular risk factors and the allostatic interoceptive network in dementia. (Cardiovascular research)
Article 4: Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes. (Cardiovascular research)
Article 5: Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children. (Circulation. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-stenosis-fibrosis-10-13-25/
 Featured Articles
Article 1: Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41077218
Summary: This study investigates the impact of aortic arch morphology, including arch angle, calcification, and soft plaques, on the incidence of cerebrovascular accidents (C.V.A.) following transfemoral transcatheter aortic valve implantation (T.A.V.I.). This analysis uses pre-procedural computed tomography (C.T.) scans from consecutive patients. The abstract describes the study&#8217;s objective and methodology, which includes patient analysis up to January 2025, but does not present specific findings or clinical outcomes.
Article 2: Monocytes at the crossroads of aortic stenosis and myocardial damage.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41073370
Summary: This research highlights the critical role of monocytes in aortic stenosis (A.S.) progression and associated myocardial damage. Previous work from this group identified a specific monocyte subpopulation implicated in both valvular calcification and myocardial fibrosis. This subpopulation mediates crucial crosstalk between the aortic valve and the myocardium, suggesting a novel mechanistic link between inflammation and structural heart disease.
Article 3: Cardiovascular risk factors and the allostatic interoceptive network in dementia.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41073365
Summary: This study aims to elucidate how established cardiovascular risk factors, such as diabetes, hypertension, obesity, and smoking, influence the Allostatic-Interoceptive Network (A.I.N.) in the context of dementia. The A.I.N. is crucial for continuous monitoring of internal bodily states and is known to be vulnerable to neurodegeneration. While the abstract outlines the significant research question, it does not present the specific findings or conclusions of this investigation.
Article 4: Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41071938
Summary: This study investigates the precise spatial recruitment and anchoring mechanisms of activated Ca2+/calmodulin-dependent kinase I.I. delta (CaMKIIδ) to the ryanodine receptor type-2 (R.Y.R.) nanodomain in cardiomyocytes. This interaction is critical for regulating calcium release, which is fundamental to the heartbeat, with hyperphosphorylation leading to pathological calcium release. The abstract describes the study&#8217;s objective and methods, including confocal and dSTORM microscopy, but does not provide the actual findings or conclusions regarding these molecular mechanisms.
Article 5: Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children.
Journal: Circulation. Cardiovasc]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like Ryanodine receptor type-2 and Aortic arch morphology. Key takeaway: New Monocyte Role in Aortic Stenosis &#038; Fibrosis.
Article Links:
Article 1: Aortic Arch Morphology and Cerebrovascular Accidents after Transfemoral Transcatheter Aortic Valve Implantation. (The American journal of cardiology)
Article 2: Monocytes at the crossroads of aortic stenosis and myocardial damage. (Cardiovascular research)
Article 3: Cardiovascular risk factors and the allostatic interoceptive network in dementia. (Cardiovascular research)
Article 4: Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes. (Cardiovascular research)
Article 5: Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children. (Circulation. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/new-monocyte-role-in-aortic-ste]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ibrutinib Raises Sudden Cardiac Death Risk. 10/13/25</title>
	<link>https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/</link>
	<pubDate>Mon, 13 Oct 2025 06:57:20 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like symptomatic atrial fibrillation and coronary sinus pacing. Key takeaway: Ibrutinib Raises Sudden Cardiac Death Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41077373">Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41077371">Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41077369">Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41077368">Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41077365">Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/">https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077373" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077373</a></p>
<p><strong>Summary:</strong> Article number one. Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</p>
<h4>Article 2: Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077371" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077371</a></p>
<p><strong>Summary:</strong> Article number two. Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</p>
<h4>Article 3: Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077369</a></p>
<p><strong>Summary:</strong> Article number three. Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</p>
<h4>Article 4: Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077368" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077368</a></p>
<p><strong>Summary:</strong> Article number four. Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 A.fib Patients.</p>
<h4>Article 5: Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077365" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077365</a></p>
<p><strong>Summary:</strong> Article number five. Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</p>
<p>Article number two. Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</p>
<p>Article number three. Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</p>
<p>Article number four. Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 A.fib Patients.</p>
<p>Article number five. Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>symptomatic atrial fibrillation, coronary sinus pacing, transcatheter tricuspid valve replacement, catheter ablation, rhythm control, clinical outcomes, Bruton&#8217;s tyrosine kinase inhibitor, transcatheter edge-to-edge repair, multimorbidity, European Heart Rhythm Association, prognosis, atrial fibrillation, arrhythmias, pulmonary vein isolation, China-A.F. registry, Ibrutinib, sudden cardiac death, cardiac pacing, U.K. Biobank, leadless pacemaker, estimated glucose disposal rate, prospective cohort study, genetic predisposition, early rhythm control, antiarrhythmic drugs, asymptomatic atrial fibrillation, transcatheter tricuspid valve intervention, chronic lymphocytic leukemia, insulin sensitivity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/">Ibrutinib Raises Sudden Cardiac Death Risk. 10/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like symptomatic atrial fibrillation and coronary sinus pacing. Key takeaway: Ibrutinib Raises Sudden Cardiac Death Risk..
Article Links:
]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like symptomatic atrial fibrillation and coronary sinus pacing. Key takeaway: Ibrutinib Raises Sudden Cardiac Death Risk..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41077373">Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41077371">Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41077369">Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41077368">Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41077365">Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/">https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077373" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077373</a></p>
<p><strong>Summary:</strong> Article number one. Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</p>
<h4>Article 2: Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077371" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077371</a></p>
<p><strong>Summary:</strong> Article number two. Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</p>
<h4>Article 3: Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077369" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077369</a></p>
<p><strong>Summary:</strong> Article number three. Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</p>
<h4>Article 4: Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077368" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077368</a></p>
<p><strong>Summary:</strong> Article number four. Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 A.fib Patients.</p>
<h4>Article 5: Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41077365" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41077365</a></p>
<p><strong>Summary:</strong> Article number five. Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.</p>
<p>Article number two. Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.</p>
<p>Article number three. Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.</p>
<p>Article number four. Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 A.fib Patients.</p>
<p>Article number five. Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>symptomatic atrial fibrillation, coronary sinus pacing, transcatheter tricuspid valve replacement, catheter ablation, rhythm control, clinical outcomes, Bruton&#8217;s tyrosine kinase inhibitor, transcatheter edge-to-edge repair, multimorbidity, European Heart Rhythm Association, prognosis, atrial fibrillation, arrhythmias, pulmonary vein isolation, China-A.F. registry, Ibrutinib, sudden cardiac death, cardiac pacing, U.K. Biobank, leadless pacemaker, estimated glucose disposal rate, prospective cohort study, genetic predisposition, early rhythm control, antiarrhythmic drugs, asymptomatic atrial fibrillation, transcatheter tricuspid valve intervention, chronic lymphocytic leukemia, insulin sensitivity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/">Ibrutinib Raises Sudden Cardiac Death Risk. 10/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251013_025702.mp3" length="1128741" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like symptomatic atrial fibrillation and coronary sinus pacing. Key takeaway: Ibrutinib Raises Sudden Cardiac Death Risk..
Article Links:
Article 1: Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. (Heart rhythm)
Article 2: Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study. (Heart rhythm)
Article 3: Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned. (Heart rhythm)
Article 4: Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients. (Heart rhythm)
Article 5: Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/ibrutinib-raises-sudden-cardiac-death-risk-10-13-25/
 Featured Articles
Article 1: Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41077373
Summary: Article number one. Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.
Article 2: Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41077371
Summary: Article number two. Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.
Article 3: Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41077369
Summary: Article number three. Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.
Article 4: Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41077368
Summary: Article number four. Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 A.fib Patients.
Article 5: Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41077365
Summary: Article number five. Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control.
 Transcript

Today&#8217;s date is October 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib.
Article number two. Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study.
Article number three. Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned.
Article number four. Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 A.fib Patients.
Article number five. Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
symptomatic atrial fibrillation, coronary sinus pacing, transcatheter tricuspid valve replacement, catheter ablation, rhythm control, clinical outcomes, Bruton&#8217;s tyrosine kinase inhibitor, transcatheter edge-to-edge repair, multimorbidity, European Heart Rhythm Association, prognosis, atri]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 13, 2025. This episode summarizes 5 key cardiology studies on topics like symptomatic atrial fibrillation and coronary sinus pacing. Key takeaway: Ibrutinib Raises Sudden Cardiac Death Risk..
Article Links:
Article 1: Sudden Death and Asymptomatic Arrhythmia in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. (Heart rhythm)
Article 2: Insulin sensitivity, genetic predisposition, and risk of atrial fibrillation: a prospective cohort study. (Heart rhythm)
Article 3: Alternative Pacing Strategies Following Transcatheter Tricuspid Valve Interventions: Procedural Challenges and Lessons Learned. (Heart rhythm)
Article 4: Questioning the Role of Pulmonary Vein Isolation in Multimorbid Patients: A Prospective Analysis in Over 1,400 AF Patients. (Heart rhythm)
Article 5: Asymptomatic Atrial Fibrillation: Clinical Characteristics, Outcomes, and Prognostic Impact of Rhythm Control. (Heart rhythm)
Full episode page: https://podcast.expla]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mineralocorticoid Antagonists Cut Postoperative A. fib. 10/12/25</title>
	<link>https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/</link>
	<pubDate>Sun, 12 Oct 2025 10:01:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like social vulnerability and lung development. Key takeaway: Mineralocorticoid Antagonists Cut Postoperative A. fib..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41065255">Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065251">Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065250">Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41065249">Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41065247">Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/">https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065255" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065255</a></p>
<p><strong>Summary:</strong> This study established a novel mouse model for pediatric pulmonary hypertension by exposing C57bl/6J mice to prolonged postnatal normobaric hypoxia at 11 percent inspired fraction of oxygen. Unlike previous transient hypoxia models, this approach successfully induced severe pulmonary hypertension and impaired lung development, accurately replicating the pathological conditions observed in children living at high altitude. This model provides a critical tool for investigating the pathogenesis of pediatric pulmonary hypertension and evaluating new therapeutic strategies.</p>
<h4>Article 2: Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065251</a></p>
<p><strong>Summary:</strong> In a prospective cohort study, researchers measured plasma levels of 90 endothelial cell-related proteins in patients with hypertrophic cardiomyopathy upon enrollment. The study identified specific endothelial cell-related proteins that accurately predict major adverse cardiovascular events and worsening heart failure. These findings highlight the significant prognostic value of endothelial dysfunction in hypertrophic cardiomyopathy, offering potential novel biomarkers for risk stratification and personalized management strategies.</p>
<h4>Article 3: Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065250</a></p>
<p><strong>Summary:</strong> This study analyzed the United Network for Organ Sharing database, comparing waitlist outcomes for pediatric heart transplant candidates listed for donation after brain death versus donation after circulatory death hearts. The findings revealed that listing for donation after circulatory death heart transplantation was associated with significantly improved waitlist outcomes, including reduced waitlist mortality and a higher rate of transplantation. This indicates that expanding the donor pool to include donation after circulatory death hearts is a vital strategy to address the critical organ shortage and improve survival for pediatric heart transplant recipients.</p>
<h4>Article 4: Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065249</a></p>
<p><strong>Summary:</strong> This study investigated 19,042 cardiac surgery patients, using propensity matching to compare outcomes in mineralocorticoid receptor antagonist users and non-users. Preoperative use of mineralocorticoid receptor antagonists significantly reduced the incidence of postoperative atrial fibrillation. Furthermore, a subgroup analysis demonstrated that these antagonists attenuated atrial stress responses to cardioplegic arrest, modulating specific atrial cell types during cold preservation. These findings suggest mineralocorticoid receptor antagonists represent a promising prophylactic strategy to prevent postoperative atrial fibrillation.</p>
<h4>Article 5: Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065247</a></p>
<p><strong>Summary:</strong> This study evaluated geographic disparities in access to cardiac rehabilitation among socially vulnerable communities across 3,113 U.S. counties, using the Social Vulnerability Index. It revealed that communities with higher social vulnerability had fewer cardiac rehabilitation facilities per 100,000 adults and were located farther from existing programs. These significant geographic disparities highlight an urgent need for targeted interventions to improve equitable access to essential cardiac rehabilitation services, aiming to reduce cardiovascular health inequities in vulnerable populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice. This study established a novel mouse model for pediatric pulmonary hypertension by exposing C57bl/6J mice to prolonged postnatal normobaric hypoxia at 11 percent inspired fraction of oxygen. Unlike previous transient hypoxia models, this approach successfully induced severe pulmonary hypertension and impaired lung development, accurately replicating the pathological conditions observed in children living at high altitude. This model provides a critical tool for investigating the pathogenesis of pediatric pulmonary hypertension and evaluating new therapeutic strategies.</p>
<p>Article number two. Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy. In a prospective cohort study, researchers measured plasma levels of 90 endothelial cell-related proteins in patients with hypertrophic cardiomyopathy upon enrollment. The study identified specific endothelial cell-related proteins that accurately predict major adverse cardiovascular events and worsening heart failure. These findings highlight the significant prognostic value of endothelial dysfunction in hypertrophic cardiomyopathy, offering potential novel biomarkers for risk stratification and personalized management strategies.</p>
<p>Article number three. Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes. This study analyzed the United Network for Organ Sharing database, comparing waitlist outcomes for pediatric heart transplant candidates listed for donation after brain death versus donation after circulatory death hearts. The findings revealed that listing for donation after circulatory death heart transplantation was associated with significantly improved waitlist outcomes, including reduced waitlist mortality and a higher rate of transplantation. This indicates that expanding the donor pool to include donation after circulatory death hearts is a vital strategy to address the critical organ shortage and improve survival for pediatric heart transplant recipients.</p>
<p>Article number four. Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest. This study investigated 19,042 cardiac surgery patients, using propensity matching to compare outcomes in mineralocorticoid receptor antagonist users and non-users. Preoperative use of mineralocorticoid receptor antagonists significantly reduced the incidence of postoperative atrial fibrillation. Furthermore, a subgroup analysis demonstrated that these antagonists attenuated atrial stress responses to cardioplegic arrest, modulating specific atrial cell types during cold preservation. These findings suggest mineralocorticoid receptor antagonists represent a promising prophylactic strategy to prevent postoperative atrial fibrillation.</p>
<p>Article number five. Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities. This study evaluated geographic disparities in access to cardiac rehabilitation among socially vulnerable communities across 3,113 U.S. counties, using the Social Vulnerability Index. It revealed that communities with higher social vulnerability had fewer cardiac rehabilitation facilities per 100,000 adults and were located farther from existing programs. These significant geographic disparities highlight an urgent need for targeted interventions to improve equitable access to essential cardiac rehabilitation services, aiming to reduce cardiovascular health inequities in vulnerable populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>social vulnerability, lung development, health disparities, waitlist outcomes, Cardiac rehabilitation, arrhythmia prevention, geographic access, mineralocorticoid receptor antagonists, donation after circulatory death, endothelial cell proteins, mouse model, pediatric cardiology, public health, heart failure, major adverse cardiovascular events, Postoperative atrial fibrillation, Hypertrophic cardiomyopathy, organ shortage, Pulmonary hypertension, cardiac surgery, biomarkers, hypoxia, Pediatric heart transplantation, cardioplegic arrest.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/">Mineralocorticoid Antagonists Cut Postoperative A. fib. 10/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like social vulnerability and lung development. Key takeaway: Mineralocorticoid Antagonists Cut Postoperative A. fib..
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like social vulnerability and lung development. Key takeaway: Mineralocorticoid Antagonists Cut Postoperative A. fib..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41065255">Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065251">Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065250">Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41065249">Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41065247">Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/">https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065255" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065255</a></p>
<p><strong>Summary:</strong> This study established a novel mouse model for pediatric pulmonary hypertension by exposing C57bl/6J mice to prolonged postnatal normobaric hypoxia at 11 percent inspired fraction of oxygen. Unlike previous transient hypoxia models, this approach successfully induced severe pulmonary hypertension and impaired lung development, accurately replicating the pathological conditions observed in children living at high altitude. This model provides a critical tool for investigating the pathogenesis of pediatric pulmonary hypertension and evaluating new therapeutic strategies.</p>
<h4>Article 2: Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065251</a></p>
<p><strong>Summary:</strong> In a prospective cohort study, researchers measured plasma levels of 90 endothelial cell-related proteins in patients with hypertrophic cardiomyopathy upon enrollment. The study identified specific endothelial cell-related proteins that accurately predict major adverse cardiovascular events and worsening heart failure. These findings highlight the significant prognostic value of endothelial dysfunction in hypertrophic cardiomyopathy, offering potential novel biomarkers for risk stratification and personalized management strategies.</p>
<h4>Article 3: Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065250</a></p>
<p><strong>Summary:</strong> This study analyzed the United Network for Organ Sharing database, comparing waitlist outcomes for pediatric heart transplant candidates listed for donation after brain death versus donation after circulatory death hearts. The findings revealed that listing for donation after circulatory death heart transplantation was associated with significantly improved waitlist outcomes, including reduced waitlist mortality and a higher rate of transplantation. This indicates that expanding the donor pool to include donation after circulatory death hearts is a vital strategy to address the critical organ shortage and improve survival for pediatric heart transplant recipients.</p>
<h4>Article 4: Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065249</a></p>
<p><strong>Summary:</strong> This study investigated 19,042 cardiac surgery patients, using propensity matching to compare outcomes in mineralocorticoid receptor antagonist users and non-users. Preoperative use of mineralocorticoid receptor antagonists significantly reduced the incidence of postoperative atrial fibrillation. Furthermore, a subgroup analysis demonstrated that these antagonists attenuated atrial stress responses to cardioplegic arrest, modulating specific atrial cell types during cold preservation. These findings suggest mineralocorticoid receptor antagonists represent a promising prophylactic strategy to prevent postoperative atrial fibrillation.</p>
<h4>Article 5: Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065247</a></p>
<p><strong>Summary:</strong> This study evaluated geographic disparities in access to cardiac rehabilitation among socially vulnerable communities across 3,113 U.S. counties, using the Social Vulnerability Index. It revealed that communities with higher social vulnerability had fewer cardiac rehabilitation facilities per 100,000 adults and were located farther from existing programs. These significant geographic disparities highlight an urgent need for targeted interventions to improve equitable access to essential cardiac rehabilitation services, aiming to reduce cardiovascular health inequities in vulnerable populations.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice. This study established a novel mouse model for pediatric pulmonary hypertension by exposing C57bl/6J mice to prolonged postnatal normobaric hypoxia at 11 percent inspired fraction of oxygen. Unlike previous transient hypoxia models, this approach successfully induced severe pulmonary hypertension and impaired lung development, accurately replicating the pathological conditions observed in children living at high altitude. This model provides a critical tool for investigating the pathogenesis of pediatric pulmonary hypertension and evaluating new therapeutic strategies.</p>
<p>Article number two. Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy. In a prospective cohort study, researchers measured plasma levels of 90 endothelial cell-related proteins in patients with hypertrophic cardiomyopathy upon enrollment. The study identified specific endothelial cell-related proteins that accurately predict major adverse cardiovascular events and worsening heart failure. These findings highlight the significant prognostic value of endothelial dysfunction in hypertrophic cardiomyopathy, offering potential novel biomarkers for risk stratification and personalized management strategies.</p>
<p>Article number three. Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes. This study analyzed the United Network for Organ Sharing database, comparing waitlist outcomes for pediatric heart transplant candidates listed for donation after brain death versus donation after circulatory death hearts. The findings revealed that listing for donation after circulatory death heart transplantation was associated with significantly improved waitlist outcomes, including reduced waitlist mortality and a higher rate of transplantation. This indicates that expanding the donor pool to include donation after circulatory death hearts is a vital strategy to address the critical organ shortage and improve survival for pediatric heart transplant recipients.</p>
<p>Article number four. Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest. This study investigated 19,042 cardiac surgery patients, using propensity matching to compare outcomes in mineralocorticoid receptor antagonist users and non-users. Preoperative use of mineralocorticoid receptor antagonists significantly reduced the incidence of postoperative atrial fibrillation. Furthermore, a subgroup analysis demonstrated that these antagonists attenuated atrial stress responses to cardioplegic arrest, modulating specific atrial cell types during cold preservation. These findings suggest mineralocorticoid receptor antagonists represent a promising prophylactic strategy to prevent postoperative atrial fibrillation.</p>
<p>Article number five. Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities. This study evaluated geographic disparities in access to cardiac rehabilitation among socially vulnerable communities across 3,113 U.S. counties, using the Social Vulnerability Index. It revealed that communities with higher social vulnerability had fewer cardiac rehabilitation facilities per 100,000 adults and were located farther from existing programs. These significant geographic disparities highlight an urgent need for targeted interventions to improve equitable access to essential cardiac rehabilitation services, aiming to reduce cardiovascular health inequities in vulnerable populations. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>social vulnerability, lung development, health disparities, waitlist outcomes, Cardiac rehabilitation, arrhythmia prevention, geographic access, mineralocorticoid receptor antagonists, donation after circulatory death, endothelial cell proteins, mouse model, pediatric cardiology, public health, heart failure, major adverse cardiovascular events, Postoperative atrial fibrillation, Hypertrophic cardiomyopathy, organ shortage, Pulmonary hypertension, cardiac surgery, biomarkers, hypoxia, Pediatric heart transplantation, cardioplegic arrest.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/">Mineralocorticoid Antagonists Cut Postoperative A. fib. 10/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251012_060040.mp3" length="4364163" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like social vulnerability and lung development. Key takeaway: Mineralocorticoid Antagonists Cut Postoperative A. fib..
Article Links:
Article 1: Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice. (Journal of the American Heart Association)
Article 2: Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy. (Journal of the American Heart Association)
Article 3: Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes. (Journal of the American Heart Association)
Article 4: Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest. (Journal of the American Heart Association)
Article 5: Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/mineralocorticoid-antagonists-cut-postoperative-a-fib-10-12-25/
 Featured Articles
Article 1: Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065255
Summary: This study established a novel mouse model for pediatric pulmonary hypertension by exposing C57bl/6J mice to prolonged postnatal normobaric hypoxia at 11 percent inspired fraction of oxygen. Unlike previous transient hypoxia models, this approach successfully induced severe pulmonary hypertension and impaired lung development, accurately replicating the pathological conditions observed in children living at high altitude. This model provides a critical tool for investigating the pathogenesis of pediatric pulmonary hypertension and evaluating new therapeutic strategies.
Article 2: Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065251
Summary: In a prospective cohort study, researchers measured plasma levels of 90 endothelial cell-related proteins in patients with hypertrophic cardiomyopathy upon enrollment. The study identified specific endothelial cell-related proteins that accurately predict major adverse cardiovascular events and worsening heart failure. These findings highlight the significant prognostic value of endothelial dysfunction in hypertrophic cardiomyopathy, offering potential novel biomarkers for risk stratification and personalized management strategies.
Article 3: Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065250
Summary: This study analyzed the United Network for Organ Sharing database, comparing waitlist outcomes for pediatric heart transplant candidates listed for donation after brain death versus donation after circulatory death hearts. The findings revealed that listing for donation after circulatory death heart transplantation was associated with significantly improved waitlist outcomes, including reduced waitlist mortality and a higher rate of transplantation. This indicates that expanding the donor pool to include donation after circulatory death hearts is a vital strategy to address the critical organ shortage and improve survival for pediatric heart transplant recipients.
Article 4: Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like social vulnerability and lung development. Key takeaway: Mineralocorticoid Antagonists Cut Postoperative A. fib..
Article Links:
Article 1: Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice. (Journal of the American Heart Association)
Article 2: Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy. (Journal of the American Heart Association)
Article 3: Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes. (Journal of the American Heart Association)
Article 4: Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest. (Journal of the American Heart Asso]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>C.M.R. Strain Boosts H.C.M. Sudden Death Risk 10/12/25</title>
	<link>https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/</link>
	<pubDate>Sun, 12 Oct 2025 06:57:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like Pulmonary disease and risk factors. Key takeaway: C.M.R. Strain Boosts H.C.M. Sudden Death Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41074902">Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41074900">Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41074682">The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41074892">Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41075959">Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/">https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074902</a></p>
<p><strong>Summary:</strong> This study leveraged data from the International Consortium on Primary Graft Dysfunction to quantify outcomes and identify clinical risk factors for severe primary graft dysfunction in patients with durable Left Ventricular Assist Device support prior to heart transplantation. Building upon previous single-center studies, it identified trends and specific risk factors. The findings from this large consortium study will likely improve risk stratification and management strategies for this high-risk patient population undergoing heart transplantation.</p>
<h4>Article 2: Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074900" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074900</a></p>
<p><strong>Summary:</strong> This prospective study followed 96 women with peripartum cardiomyopathy for at least three years, providing crucial long-term outcome data which has previously been limited. Researchers evaluated the clinical course and echocardiographic parameters in these patients, who were diagnosed at a mean age of 31.6 years. The findings offer valuable insights into the prognosis and long-term management of peripartum cardiomyopathy, informing care strategies for affected women.</p>
<h4>Article 3: The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074682" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074682</a></p>
<p><strong>Summary:</strong> dataset. This retrospective observational cohort study utilized the P.U.L.S.E. dataset to investigate the association between polypharmacy and mortality in patients hospitalized for heart failure. Analyzing medication data from admission and discharge, researchers employed Cox proportional hazard models to explore this relationship. The study&#8217;s findings reveal a significant association between polypharmacy and mortality, underscoring the importance of medication review and optimization in this vulnerable patient population.</p>
<h4>Article 4: Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074892" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074892</a></p>
<p><strong>Summary:</strong> This study demonstrated that Left Ventricular Global Longitudinal Strain, derived from Cardiac Magnetic Resonance feature tracking, significantly enhances risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. This marker provides incremental prognostic value beyond established European Society of Cardiology and American College of Cardiology/American Heart Association guidelines. The findings suggest that incorporating Left Ventricular Global Longitudinal Strain assessment could lead to more precise identification of high-risk patients, guiding more targeted interventions and improving clinical outcomes.</p>
<h4>Article 5: Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41075959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41075959</a></p>
<p><strong>Summary:</strong> This study investigated the impact of pulmonary disease on clinical outcomes in 3,666 patients undergoing mitral transcatheter edge-to-edge repair, stratifying them by the presence or absence of pulmonary disease. The findings indicate that co-existing pulmonary disease significantly influences all-cause mortality following the procedure, as evaluated using Kaplan-Meier analysis. This highlights the importance of comprehensive pre-procedural assessment and risk stratification, potentially guiding patient selection and management strategies for mitral transcatheter edge-to-edge repair in this complex patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation. This study leveraged data from the International Consortium on Primary Graft Dysfunction to quantify outcomes and identify clinical risk factors for severe primary graft dysfunction in patients with durable Left Ventricular Assist Device support prior to heart transplantation. Building upon previous single-center studies, it identified trends and specific risk factors. The findings from this large consortium study will likely improve risk stratification and management strategies for this high-risk patient population undergoing heart transplantation.</p>
<p>Article number two. Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy. This prospective study followed 96 women with peripartum cardiomyopathy for at least three years, providing crucial long-term outcome data which has previously been limited. Researchers evaluated the clinical course and echocardiographic parameters in these patients, who were diagnosed at a mean age of 31.6 years. The findings offer valuable insights into the prognosis and long-term management of peripartum cardiomyopathy, informing care strategies for affected women.</p>
<p>Article number three. The association between polypharmacy and mortality in patients with heart failure: Results from the P.U.L.S.E. dataset. This retrospective observational cohort study utilized the P.U.L.S.E. dataset to investigate the association between polypharmacy and mortality in patients hospitalized for heart failure. Analyzing medication data from admission and discharge, researchers employed Cox proportional hazard models to explore this relationship. The study&#8217;s findings reveal a significant association between polypharmacy and mortality, underscoring the importance of medication review and optimization in this vulnerable patient population.</p>
<p>Article number four. Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. This study demonstrated that Left Ventricular Global Longitudinal Strain, derived from Cardiac Magnetic Resonance feature tracking, significantly enhances risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. This marker provides incremental prognostic value beyond established European Society of Cardiology and American College of Cardiology/American Heart Association guidelines. The findings suggest that incorporating Left Ventricular Global Longitudinal Strain assessment could lead to more precise identification of high-risk patients, guiding more targeted interventions and improving clinical outcomes.</p>
<p>Article number five. Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair. This study investigated the impact of pulmonary disease on clinical outcomes in 3,666 patients undergoing mitral transcatheter edge-to-edge repair, stratifying them by the presence or absence of pulmonary disease. The findings indicate that co-existing pulmonary disease significantly influences all-cause mortality following the procedure, as evaluated using Kaplan-Meier analysis. This highlights the importance of comprehensive pre-procedural assessment and risk stratification, potentially guiding patient selection and management strategies for mitral transcatheter edge-to-edge repair in this complex patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Pulmonary disease, risk factors, Primary graft dysfunction, Global Longitudinal Strain, mitral regurgitation, Peripartum cardiomyopathy, risk stratification, Hypertrophic Cardiomyopathy, clinical outcomes, Left Ventricular Assist Device, long-term outcomes, heart transplantation, Cardiac Magnetic Resonance, Polypharmacy, Left Ventricular Ejection Fraction, heart failure, medication management, prognosis, post-transplant complications, P.U.L.S.E. dataset, Mitral Transcatheter Edge-to-Edge Repair, Sudden Cardiac Death, women&#8217;s heart health, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/">C.M.R. Strain Boosts H.C.M. Sudden Death Risk 10/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like Pulmonary disease and risk factors. Key takeaway: C.M.R. Strain Boosts H.C.M. Sudden Death Risk.
Article Links:
Article 1: Primary Gr]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like Pulmonary disease and risk factors. Key takeaway: C.M.R. Strain Boosts H.C.M. Sudden Death Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41074902">Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation.</a> (JACC. Heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41074900">Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41074682">The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41074892">Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41075959">Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/">https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074902</a></p>
<p><strong>Summary:</strong> This study leveraged data from the International Consortium on Primary Graft Dysfunction to quantify outcomes and identify clinical risk factors for severe primary graft dysfunction in patients with durable Left Ventricular Assist Device support prior to heart transplantation. Building upon previous single-center studies, it identified trends and specific risk factors. The findings from this large consortium study will likely improve risk stratification and management strategies for this high-risk patient population undergoing heart transplantation.</p>
<h4>Article 2: Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074900" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074900</a></p>
<p><strong>Summary:</strong> This prospective study followed 96 women with peripartum cardiomyopathy for at least three years, providing crucial long-term outcome data which has previously been limited. Researchers evaluated the clinical course and echocardiographic parameters in these patients, who were diagnosed at a mean age of 31.6 years. The findings offer valuable insights into the prognosis and long-term management of peripartum cardiomyopathy, informing care strategies for affected women.</p>
<h4>Article 3: The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074682" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074682</a></p>
<p><strong>Summary:</strong> dataset. This retrospective observational cohort study utilized the P.U.L.S.E. dataset to investigate the association between polypharmacy and mortality in patients hospitalized for heart failure. Analyzing medication data from admission and discharge, researchers employed Cox proportional hazard models to explore this relationship. The study&#8217;s findings reveal a significant association between polypharmacy and mortality, underscoring the importance of medication review and optimization in this vulnerable patient population.</p>
<h4>Article 4: Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41074892" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41074892</a></p>
<p><strong>Summary:</strong> This study demonstrated that Left Ventricular Global Longitudinal Strain, derived from Cardiac Magnetic Resonance feature tracking, significantly enhances risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. This marker provides incremental prognostic value beyond established European Society of Cardiology and American College of Cardiology/American Heart Association guidelines. The findings suggest that incorporating Left Ventricular Global Longitudinal Strain assessment could lead to more precise identification of high-risk patients, guiding more targeted interventions and improving clinical outcomes.</p>
<h4>Article 5: Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41075959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41075959</a></p>
<p><strong>Summary:</strong> This study investigated the impact of pulmonary disease on clinical outcomes in 3,666 patients undergoing mitral transcatheter edge-to-edge repair, stratifying them by the presence or absence of pulmonary disease. The findings indicate that co-existing pulmonary disease significantly influences all-cause mortality following the procedure, as evaluated using Kaplan-Meier analysis. This highlights the importance of comprehensive pre-procedural assessment and risk stratification, potentially guiding patient selection and management strategies for mitral transcatheter edge-to-edge repair in this complex patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation. This study leveraged data from the International Consortium on Primary Graft Dysfunction to quantify outcomes and identify clinical risk factors for severe primary graft dysfunction in patients with durable Left Ventricular Assist Device support prior to heart transplantation. Building upon previous single-center studies, it identified trends and specific risk factors. The findings from this large consortium study will likely improve risk stratification and management strategies for this high-risk patient population undergoing heart transplantation.</p>
<p>Article number two. Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy. This prospective study followed 96 women with peripartum cardiomyopathy for at least three years, providing crucial long-term outcome data which has previously been limited. Researchers evaluated the clinical course and echocardiographic parameters in these patients, who were diagnosed at a mean age of 31.6 years. The findings offer valuable insights into the prognosis and long-term management of peripartum cardiomyopathy, informing care strategies for affected women.</p>
<p>Article number three. The association between polypharmacy and mortality in patients with heart failure: Results from the P.U.L.S.E. dataset. This retrospective observational cohort study utilized the P.U.L.S.E. dataset to investigate the association between polypharmacy and mortality in patients hospitalized for heart failure. Analyzing medication data from admission and discharge, researchers employed Cox proportional hazard models to explore this relationship. The study&#8217;s findings reveal a significant association between polypharmacy and mortality, underscoring the importance of medication review and optimization in this vulnerable patient population.</p>
<p>Article number four. Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. This study demonstrated that Left Ventricular Global Longitudinal Strain, derived from Cardiac Magnetic Resonance feature tracking, significantly enhances risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. This marker provides incremental prognostic value beyond established European Society of Cardiology and American College of Cardiology/American Heart Association guidelines. The findings suggest that incorporating Left Ventricular Global Longitudinal Strain assessment could lead to more precise identification of high-risk patients, guiding more targeted interventions and improving clinical outcomes.</p>
<p>Article number five. Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair. This study investigated the impact of pulmonary disease on clinical outcomes in 3,666 patients undergoing mitral transcatheter edge-to-edge repair, stratifying them by the presence or absence of pulmonary disease. The findings indicate that co-existing pulmonary disease significantly influences all-cause mortality following the procedure, as evaluated using Kaplan-Meier analysis. This highlights the importance of comprehensive pre-procedural assessment and risk stratification, potentially guiding patient selection and management strategies for mitral transcatheter edge-to-edge repair in this complex patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Pulmonary disease, risk factors, Primary graft dysfunction, Global Longitudinal Strain, mitral regurgitation, Peripartum cardiomyopathy, risk stratification, Hypertrophic Cardiomyopathy, clinical outcomes, Left Ventricular Assist Device, long-term outcomes, heart transplantation, Cardiac Magnetic Resonance, Polypharmacy, Left Ventricular Ejection Fraction, heart failure, medication management, prognosis, post-transplant complications, P.U.L.S.E. dataset, Mitral Transcatheter Edge-to-Edge Repair, Sudden Cardiac Death, women&#8217;s heart health, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/">C.M.R. Strain Boosts H.C.M. Sudden Death Risk 10/12/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251012_025646.mp3" length="4001793" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like Pulmonary disease and risk factors. Key takeaway: C.M.R. Strain Boosts H.C.M. Sudden Death Risk.
Article Links:
Article 1: Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation. (JACC. Heart failure)
Article 2: Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy. (JACC. Heart failure)
Article 3: The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset. (ESC heart failure)
Article 4: Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. (JACC. Cardiovascular imaging)
Article 5: Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/c-m-r-strain-boosts-h-c-m-sudden-death-risk-10-12-25/
 Featured Articles
Article 1: Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41074902
Summary: This study leveraged data from the International Consortium on Primary Graft Dysfunction to quantify outcomes and identify clinical risk factors for severe primary graft dysfunction in patients with durable Left Ventricular Assist Device support prior to heart transplantation. Building upon previous single-center studies, it identified trends and specific risk factors. The findings from this large consortium study will likely improve risk stratification and management strategies for this high-risk patient population undergoing heart transplantation.
Article 2: Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41074900
Summary: This prospective study followed 96 women with peripartum cardiomyopathy for at least three years, providing crucial long-term outcome data which has previously been limited. Researchers evaluated the clinical course and echocardiographic parameters in these patients, who were diagnosed at a mean age of 31.6 years. The findings offer valuable insights into the prognosis and long-term management of peripartum cardiomyopathy, informing care strategies for affected women.
Article 3: The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41074682
Summary: dataset. This retrospective observational cohort study utilized the P.U.L.S.E. dataset to investigate the association between polypharmacy and mortality in patients hospitalized for heart failure. Analyzing medication data from admission and discharge, researchers employed Cox proportional hazard models to explore this relationship. The study&#8217;s findings reveal a significant association between polypharmacy and mortality, underscoring the importance of medication review and optimization in this vulnerable patient population.
Article 4: Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41074892
Summary: This study demonstrated that Left Ventricular Global Longitudinal Strain, derived from Cardiac Magnetic Resonance feature tracking, significantly enhances risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. This marker provides incremental prognostic value beyond established European Society of Cardiology and American College of Cardiology/American Heart Association guidelines. The findings suggest that incorporatin]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 12, 2025. This episode summarizes 5 key cardiology studies on topics like Pulmonary disease and risk factors. Key takeaway: C.M.R. Strain Boosts H.C.M. Sudden Death Risk.
Article Links:
Article 1: Primary Graft Dysfunction in Patients Supported With Durable Left Ventricular Assist Devices Before Heart Transplantation. (JACC. Heart failure)
Article 2: Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy. (JACC. Heart failure)
Article 3: The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset. (ESC heart failure)
Article 4: Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. (JACC. Cardiovascular imaging)
Article 5: Impact of Pulmonary Disease on Clinical Outcomes in Patients Undergoing Mitral Valve Edge-to-Edge Repair. (The American journal of cardiology)
Full episode page: https]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Metabolomic Biomarkers Predict C.A.D. Events 10/11/25</title>
	<link>https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/</link>
	<pubDate>Sat, 11 Oct 2025 10:01:25 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like cardiometabolic risk factors and metabolomic biomarkers. Key takeaway: Metabolomic Biomarkers Predict C.A.D. Events.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41065265">Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065263">Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065262">Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41065261">Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41065256">Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/">https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065265" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065265</a></p>
<p><strong>Summary:</strong> This study describes a secondary analysis of the O.P.E.N.S. (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, involving 86 acute ischemic stroke patients with anterior circulation occlusion. The aim was to investigate the effects of normobaric hyperoxia on the inflammatory response and its role in stroke-induced brain injury. However, the provided abstract does not detail the specific findings, conclusions, or clinical implications of this investigation.</p>
<h4>Article 2: Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065263" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065263</a></p>
<p><strong>Summary:</strong> This study aimed to analyze longitudinal changes in right ventricular intracardiac flow in infants with hypoplastic left heart syndrome during the critical interstage period. Researchers utilized a novel Doppler velocity reconstruction method to quantify kinetic energy, vortex strength, and flow energy loss from conventional color Doppler acquisitions. While the study hypothesized about these changes, the provided abstract does not present the specific findings or conclusions regarding the actual measurements or their clinical significance in this patient population.</p>
<h4>Article 3: Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065262" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065262</a></p>
<p><strong>Summary:</strong> This study analyzed 249 plasma metabolites in 10,175 U.K. Biobank participants with coronary artery disease to identify potential biomarkers for secondary major adverse cardiovascular events. Using nuclear magnetic resonance and elastic net regression models, the research established that specific metabolomic biomarkers are independently associated with an increased risk of future cardiovascular events. This suggests their potential utility in enhancing risk prediction and guiding preventive strategies in patients already diagnosed with coronary artery disease.</p>
<h4>Article 4: Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065261" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065261</a></p>
<p><strong>Summary:</strong> This study investigated the association between lifetime exposure to violence and early cardiometabolic risk factors in 23,215 healthy Swedish adults aged 18 to 50 years from the LifeGene study. Participants reported on physical and sexual violence exposure, alongside medical diagnoses of hypertension, diabetes, dyslipidemia, and smoking history. However, the provided abstract outlines the study&#8217;s scope and methods but does not detail the specific findings or conclusions regarding the observed associations or potential sex differences.</p>
<h4>Article 5: Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065256" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065256</a></p>
<p><strong>Summary:</strong> This study utilized data from the G.I.O.T.T.O. (Italian Society of Interventional Cardiology [GIse] Registry Of Transcatheter Treatment of Mitral Regurgitation) registry to assess the competing risks and independent predictors of cardiac and noncardiac mortality in patients with secondary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair. While highlighting the importance of understanding the relative impact of different mortality causes in this population, the provided abstract does not present the specific findings or conclusions regarding the identified predictors or the observed proportions of cardiac versus noncardiac deaths.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation. This study describes a secondary analysis of the O.P.E.N.S. (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, involving 86 acute ischemic stroke patients with anterior circulation occlusion. The aim was to investigate the effects of normobaric hyperoxia on the inflammatory response and its role in stroke-induced brain injury. However, the provided abstract does not detail the specific findings, conclusions, or clinical implications of this investigation.</p>
<p>Article number two. Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction. This study aimed to analyze longitudinal changes in right ventricular intracardiac flow in infants with hypoplastic left heart syndrome during the critical interstage period. Researchers utilized a novel Doppler velocity reconstruction method to quantify kinetic energy, vortex strength, and flow energy loss from conventional color Doppler acquisitions. While the study hypothesized about these changes, the provided abstract does not present the specific findings or conclusions regarding the actual measurements or their clinical significance in this patient population.</p>
<p>Article number three. Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease. This study analyzed 249 plasma metabolites in 10,175 U.K. Biobank participants with coronary artery disease to identify potential biomarkers for secondary major adverse cardiovascular events. Using nuclear magnetic resonance and elastic net regression models, the research established that specific metabolomic biomarkers are independently associated with an increased risk of future cardiovascular events. This suggests their potential utility in enhancing risk prediction and guiding preventive strategies in patients already diagnosed with coronary artery disease.</p>
<p>Article number four. Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort. This study investigated the association between lifetime exposure to violence and early cardiometabolic risk factors in 23,215 healthy Swedish adults aged 18 to 50 years from the LifeGene study. Participants reported on physical and sexual violence exposure, alongside medical diagnoses of hypertension, diabetes, dyslipidemia, and smoking history. However, the provided abstract outlines the study&#8217;s scope and methods but does not detail the specific findings or conclusions regarding the observed associations or potential sex differences.</p>
<p>Article number five. Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair. This study utilized data from the G.I.O.T.T.O. (Italian Society of Interventional Cardiology [GIse] Registry Of Transcatheter Treatment of Mitral Regurgitation) registry to assess the competing risks and independent predictors of cardiac and noncardiac mortality in patients with secondary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair. While highlighting the importance of understanding the relative impact of different mortality causes in this population, the provided abstract does not present the specific findings or conclusions regarding the identified predictors or the observed proportions of cardiac versus noncardiac deaths. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiometabolic risk factors, metabolomic biomarkers, intracardiac flow, hypertension, noncardiac mortality, cardiac mortality, competing risks, neuroprotection, secondary mitral regurgitation, inflammation, nuclear magnetic resonance, transcatheter edge-to-edge repair, hypoplastic left heart syndrome, coronary artery disease, risk prediction, diabetes, Doppler velocity reconstruction, right ventricular function, acute ischemic stroke, O.P.E.N.S. trial, dyslipidemia, normobaric hyperoxia, violence exposure, kinetic energy, major adverse cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/">Metabolomic Biomarkers Predict C.A.D. Events 10/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like cardiometabolic risk factors and metabolomic biomarkers. Key takeaway: Metabolomic Biomarkers Predict C.A.D. Events.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like cardiometabolic risk factors and metabolomic biomarkers. Key takeaway: Metabolomic Biomarkers Predict C.A.D. Events.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41065265">Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065263">Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065262">Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41065261">Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41065256">Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/">https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065265" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065265</a></p>
<p><strong>Summary:</strong> This study describes a secondary analysis of the O.P.E.N.S. (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, involving 86 acute ischemic stroke patients with anterior circulation occlusion. The aim was to investigate the effects of normobaric hyperoxia on the inflammatory response and its role in stroke-induced brain injury. However, the provided abstract does not detail the specific findings, conclusions, or clinical implications of this investigation.</p>
<h4>Article 2: Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065263" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065263</a></p>
<p><strong>Summary:</strong> This study aimed to analyze longitudinal changes in right ventricular intracardiac flow in infants with hypoplastic left heart syndrome during the critical interstage period. Researchers utilized a novel Doppler velocity reconstruction method to quantify kinetic energy, vortex strength, and flow energy loss from conventional color Doppler acquisitions. While the study hypothesized about these changes, the provided abstract does not present the specific findings or conclusions regarding the actual measurements or their clinical significance in this patient population.</p>
<h4>Article 3: Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065262" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065262</a></p>
<p><strong>Summary:</strong> This study analyzed 249 plasma metabolites in 10,175 U.K. Biobank participants with coronary artery disease to identify potential biomarkers for secondary major adverse cardiovascular events. Using nuclear magnetic resonance and elastic net regression models, the research established that specific metabolomic biomarkers are independently associated with an increased risk of future cardiovascular events. This suggests their potential utility in enhancing risk prediction and guiding preventive strategies in patients already diagnosed with coronary artery disease.</p>
<h4>Article 4: Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065261" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065261</a></p>
<p><strong>Summary:</strong> This study investigated the association between lifetime exposure to violence and early cardiometabolic risk factors in 23,215 healthy Swedish adults aged 18 to 50 years from the LifeGene study. Participants reported on physical and sexual violence exposure, alongside medical diagnoses of hypertension, diabetes, dyslipidemia, and smoking history. However, the provided abstract outlines the study&#8217;s scope and methods but does not detail the specific findings or conclusions regarding the observed associations or potential sex differences.</p>
<h4>Article 5: Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065256" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065256</a></p>
<p><strong>Summary:</strong> This study utilized data from the G.I.O.T.T.O. (Italian Society of Interventional Cardiology [GIse] Registry Of Transcatheter Treatment of Mitral Regurgitation) registry to assess the competing risks and independent predictors of cardiac and noncardiac mortality in patients with secondary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair. While highlighting the importance of understanding the relative impact of different mortality causes in this population, the provided abstract does not present the specific findings or conclusions regarding the identified predictors or the observed proportions of cardiac versus noncardiac deaths.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation. This study describes a secondary analysis of the O.P.E.N.S. (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, involving 86 acute ischemic stroke patients with anterior circulation occlusion. The aim was to investigate the effects of normobaric hyperoxia on the inflammatory response and its role in stroke-induced brain injury. However, the provided abstract does not detail the specific findings, conclusions, or clinical implications of this investigation.</p>
<p>Article number two. Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction. This study aimed to analyze longitudinal changes in right ventricular intracardiac flow in infants with hypoplastic left heart syndrome during the critical interstage period. Researchers utilized a novel Doppler velocity reconstruction method to quantify kinetic energy, vortex strength, and flow energy loss from conventional color Doppler acquisitions. While the study hypothesized about these changes, the provided abstract does not present the specific findings or conclusions regarding the actual measurements or their clinical significance in this patient population.</p>
<p>Article number three. Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease. This study analyzed 249 plasma metabolites in 10,175 U.K. Biobank participants with coronary artery disease to identify potential biomarkers for secondary major adverse cardiovascular events. Using nuclear magnetic resonance and elastic net regression models, the research established that specific metabolomic biomarkers are independently associated with an increased risk of future cardiovascular events. This suggests their potential utility in enhancing risk prediction and guiding preventive strategies in patients already diagnosed with coronary artery disease.</p>
<p>Article number four. Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort. This study investigated the association between lifetime exposure to violence and early cardiometabolic risk factors in 23,215 healthy Swedish adults aged 18 to 50 years from the LifeGene study. Participants reported on physical and sexual violence exposure, alongside medical diagnoses of hypertension, diabetes, dyslipidemia, and smoking history. However, the provided abstract outlines the study&#8217;s scope and methods but does not detail the specific findings or conclusions regarding the observed associations or potential sex differences.</p>
<p>Article number five. Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair. This study utilized data from the G.I.O.T.T.O. (Italian Society of Interventional Cardiology [GIse] Registry Of Transcatheter Treatment of Mitral Regurgitation) registry to assess the competing risks and independent predictors of cardiac and noncardiac mortality in patients with secondary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair. While highlighting the importance of understanding the relative impact of different mortality causes in this population, the provided abstract does not present the specific findings or conclusions regarding the identified predictors or the observed proportions of cardiac versus noncardiac deaths. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>cardiometabolic risk factors, metabolomic biomarkers, intracardiac flow, hypertension, noncardiac mortality, cardiac mortality, competing risks, neuroprotection, secondary mitral regurgitation, inflammation, nuclear magnetic resonance, transcatheter edge-to-edge repair, hypoplastic left heart syndrome, coronary artery disease, risk prediction, diabetes, Doppler velocity reconstruction, right ventricular function, acute ischemic stroke, O.P.E.N.S. trial, dyslipidemia, normobaric hyperoxia, violence exposure, kinetic energy, major adverse cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/">Metabolomic Biomarkers Predict C.A.D. Events 10/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251011_060032.mp3" length="4032304" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like cardiometabolic risk factors and metabolomic biomarkers. Key takeaway: Metabolomic Biomarkers Predict C.A.D. Events.
Article Links:
Article 1: Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation. (Journal of the American Heart Association)
Article 2: Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction. (Journal of the American Heart Association)
Article 3: Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease. (Journal of the American Heart Association)
Article 4: Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort. (Journal of the American Heart Association)
Article 5: Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/metabolomic-biomarkers-predict-c-a-d-events-10-11-25/
 Featured Articles
Article 1: Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065265
Summary: This study describes a secondary analysis of the O.P.E.N.S. (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, involving 86 acute ischemic stroke patients with anterior circulation occlusion. The aim was to investigate the effects of normobaric hyperoxia on the inflammatory response and its role in stroke-induced brain injury. However, the provided abstract does not detail the specific findings, conclusions, or clinical implications of this investigation.
Article 2: Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065263
Summary: This study aimed to analyze longitudinal changes in right ventricular intracardiac flow in infants with hypoplastic left heart syndrome during the critical interstage period. Researchers utilized a novel Doppler velocity reconstruction method to quantify kinetic energy, vortex strength, and flow energy loss from conventional color Doppler acquisitions. While the study hypothesized about these changes, the provided abstract does not present the specific findings or conclusions regarding the actual measurements or their clinical significance in this patient population.
Article 3: Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065262
Summary: This study analyzed 249 plasma metabolites in 10,175 U.K. Biobank participants with coronary artery disease to identify potential biomarkers for secondary major adverse cardiovascular events. Using nuclear magnetic resonance and elastic net regression models, the research established that specific metabolomic biomarkers are independently associated with an increased risk of future cardiovascular events. This suggests their potential utility in enhancing risk prediction and guiding preventive strategies in patients already diagnosed with coronary artery disease.
Article 4: Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065261
Summary: This study investigated]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like cardiometabolic risk factors and metabolomic biomarkers. Key takeaway: Metabolomic Biomarkers Predict C.A.D. Events.
Article Links:
Article 1: Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation. (Journal of the American Heart Association)
Article 2: Longitudinal Intracardiac Right Ventricular Flow Analysis in Infants With Hypoplastic Left Heart Syndrome in Interstage I Using Novel Doppler Velocity Reconstruction. (Journal of the American Heart Association)
Article 3: Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease. (Journal of the American Heart Association)
Article 4: Lifetime Exposure to Violence and Early Cardiometabolic Risk Factors in a Healthy Swedish Cohort. (Journal of the American Heart Association)
Article ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>P.F.A. Breakthrough for Scar V.T. Ablation 10/11/25</title>
	<link>https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/</link>
	<pubDate>Sat, 11 Oct 2025 06:58:06 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like sleep apnea and P.A.R.A.G.O.N.-H.F. trial. Key takeaway: P.F.A. Breakthrough for Scar V.T. Ablation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41071961">High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41072744">Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41072743">Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41072571">Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</a> (Journal of cardiac failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41070523">Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/">https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41071961" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41071961</a></p>
<p><strong>Summary:</strong> Article number one. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</p>
<h4>Article 2: Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41072744" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41072744</a></p>
<p><strong>Summary:</strong> Article number two. Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</p>
<h4>Article 3: Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41072743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41072743</a></p>
<p><strong>Summary:</strong> Article number three. Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</p>
<h4>Article 4: Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41072571" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41072571</a></p>
<p><strong>Summary:</strong> Article number four. Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</p>
<h4>Article 5: Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41070523" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41070523</a></p>
<p><strong>Summary:</strong> Article number five. Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</p>
<p>Article number two. Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</p>
<p>Article number three. Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</p>
<p>Article number four. Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</p>
<p>Article number five. Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sleep apnea, P.A.R.A.G.O.N.-H.F. trial, extracorporeal membrane oxygenation, cardiac remodeling, blood pressure, echocardiography, sex differences, Ventricular tachycardia, Lung transplantation, pregnancy, scar-related arrhythmia, cardiovascular remodeling, Heart failure with preserved ejection fraction, electrophysiology, salt-sensitive hypertension, V.A. E.C.M.O., primary graft dysfunction, cannulation, cardiac ablation, pulsed field ablation, antibody-mediated rejection, human leucocyte antigen, High-salt diet, alloimmunization.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/">P.F.A. Breakthrough for Scar V.T. Ablation 10/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like sleep apnea and P.A.R.A.G.O.N.-H.F. trial. Key takeaway: P.F.A. Breakthrough for Scar V.T. Ablation.
Article Links:
Article 1: High-V]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like sleep apnea and P.A.R.A.G.O.N.-H.F. trial. Key takeaway: P.F.A. Breakthrough for Scar V.T. Ablation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41071961">High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41072744">Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41072743">Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41072571">Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</a> (Journal of cardiac failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41070523">Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/">https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41071961" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41071961</a></p>
<p><strong>Summary:</strong> Article number one. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</p>
<h4>Article 2: Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41072744" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41072744</a></p>
<p><strong>Summary:</strong> Article number two. Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</p>
<h4>Article 3: Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41072743" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41072743</a></p>
<p><strong>Summary:</strong> Article number three. Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</p>
<h4>Article 4: Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41072571" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41072571</a></p>
<p><strong>Summary:</strong> Article number four. Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</p>
<h4>Article 5: Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41070523" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41070523</a></p>
<p><strong>Summary:</strong> Article number five. Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.</p>
<p>Article number two. Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.</p>
<p>Article number three. Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.</p>
<p>Article number four. Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.</p>
<p>Article number five. Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sleep apnea, P.A.R.A.G.O.N.-H.F. trial, extracorporeal membrane oxygenation, cardiac remodeling, blood pressure, echocardiography, sex differences, Ventricular tachycardia, Lung transplantation, pregnancy, scar-related arrhythmia, cardiovascular remodeling, Heart failure with preserved ejection fraction, electrophysiology, salt-sensitive hypertension, V.A. E.C.M.O., primary graft dysfunction, cannulation, cardiac ablation, pulsed field ablation, antibody-mediated rejection, human leucocyte antigen, High-salt diet, alloimmunization.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/">P.F.A. Breakthrough for Scar V.T. Ablation 10/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251011_025747.mp3" length="1141280" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like sleep apnea and P.A.R.A.G.O.N.-H.F. trial. Key takeaway: P.F.A. Breakthrough for Scar V.T. Ablation.
Article Links:
Article 1: High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial. (Circulation)
Article 2: Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial. (Journal of cardiac failure)
Article 5: Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/p-f-a-breakthrough-for-scar-v-t-ablation-10-11-25/
 Featured Articles
Article 1: High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41071961
Summary: Article number one. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.
Article 2: Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41072744
Summary: Article number two. Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.
Article 3: Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41072743
Summary: Article number three. Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation.
Article 4: Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41072571
Summary: Article number four. Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial.
Article 5: Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41070523
Summary: Article number five. Sex-Specific Cardiovascular Consequences of Long-Term High-Salt Diet in Mice.
 Transcript

Today&#8217;s date is October 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.
Article number two. Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk.
Article number three. Outcomes of Central versus Peripheral A]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 11, 2025. This episode summarizes 5 key cardiology studies on topics like sleep apnea and P.A.R.A.G.O.N.-H.F. trial. Key takeaway: P.F.A. Breakthrough for Scar V.T. Ablation.
Article Links:
Article 1: High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial. (Circulation)
Article 2: Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Outcomes of Central versus Peripheral Arterial Cannulation for Intraoperative Extracorporeal Membrane Oxygenation Support in Lung Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Sleep Apnea and Cardiac Structure and F]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation. 10/10/25</title>
	<link>https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/</link>
	<pubDate>Fri, 10 Oct 2025 10:01:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like sedentary behavior and electrocardiogram. Key takeaway: E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41067464">Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065522">Long-term prognosis of pure and impure tachycardiomyopathy.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065289">Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41065286">Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41065269">Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/">https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41067464" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41067464</a></p>
<p><strong>Summary:</strong> This case series describes the outcomes of six patients with chronic thromboembolic pulmonary hypertension who underwent lung transplantation. These patients either had inoperable disease or residual pulmonary hypertension after pulmonary endarterectomy, leading to end-stage right heart failure. The findings indicate that lung transplantation serves as a life-saving therapeutic option for patients with severe chronic thromboembolic pulmonary hypertension who are not candidates for or have failed other interventions. This highlights its critical role in managing refractory cases.</p>
<h4>Article 2: Long-term prognosis of pure and impure tachycardiomyopathy.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065522</a></p>
<p><strong>Summary:</strong> This prospective, monocentric, observational study recruited 456 patients with de novo, acute decompensated heart failure with reduced ejection fraction, classifying them into pure tachycardia-induced cardiomyopathy, impure tachycardia-induced cardiomyopathy, and other heart failure etiologies. The study aimed to clarify the long-term prognosis of both pure and impure tachycardia-induced cardiomyopathy. While the study design is established for comparing these prognoses, specific findings regarding the long-term outcomes are not detailed in the provided abstract.</p>
<h4>Article 3: Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065289" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065289</a></p>
<p><strong>Summary:</strong> This prospective community-based cohort study involved 2,942 Chinese adults, assessing the joint association between moderate-to-vigorous physical activity and sedentary time on dyslipidemia risk using self-reported questionnaires. A subcohort of 754 participants also had their one-year gut microbial changes associated with moderate-to-vigorous physical activity assessed. The study aims to clarify whether moderate-to-vigorous physical activity mitigates the detrimental effects of sedentary behavior on dyslipidemia and to elucidate the link between physical activity and gut microbiota. Specific findings regarding these associations are not detailed in the provided abstract.</p>
<h4>Article 4: Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065286" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065286</a></p>
<p><strong>Summary:</strong> This study employed a target trial emulation methodology to compare the efficacy and safety of single versus dual antiplatelet therapy after standard endovascular aneurysm repair. The investigation focused on patients undergoing endovascular aneurysm repair for abdominal aortic aneurysms who did not have established atherosclerotic cardiovascular disease, where optimal antiplatelet regimens are currently uncertain. The primary objective was to determine the superior antiplatelet strategy for this specific patient population. Specific findings regarding comparative efficacy and safety are not detailed in the provided abstract.</p>
<h4>Article 5: Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065269</a></p>
<p><strong>Summary:</strong> This retrospective study analyzed 206,668 standard electrocardiograms from 9,674 consecutive patients diagnosed with acute coronary syndrome between 2007 and 2018. The research found that interatrial block, detected through a series of electrocardiograms taken before and during acute coronary syndrome, significantly predicts future occurrences of atrial fibrillation, atrial flutter, and ischemic stroke. This finding highlights interatrial block as a critical, easily identifiable risk marker for subsequent cerebrovascular and atrial arrhythmogenic events in this patient cohort, emphasizing the value of diligent electrocardiogram monitoring.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series. This case series describes the outcomes of six patients with chronic thromboembolic pulmonary hypertension who underwent lung transplantation. These patients either had inoperable disease or residual pulmonary hypertension after pulmonary endarterectomy, leading to end-stage right heart failure. The findings indicate that lung transplantation serves as a life-saving therapeutic option for patients with severe chronic thromboembolic pulmonary hypertension who are not candidates for or have failed other interventions. This highlights its critical role in managing refractory cases.</p>
<p>Article number two. Long-term prognosis of pure and impure tachycardiomyopathy. This prospective, monocentric, observational study recruited 456 patients with de novo, acute decompensated heart failure with reduced ejection fraction, classifying them into pure tachycardia-induced cardiomyopathy, impure tachycardia-induced cardiomyopathy, and other heart failure etiologies. The study aimed to clarify the long-term prognosis of both pure and impure tachycardia-induced cardiomyopathy. While the study design is established for comparing these prognoses, specific findings regarding the long-term outcomes are not detailed in the provided abstract.</p>
<p>Article number three. Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study. This prospective community-based cohort study involved 2,942 Chinese adults, assessing the joint association between moderate-to-vigorous physical activity and sedentary time on dyslipidemia risk using self-reported questionnaires. A subcohort of 754 participants also had their one-year gut microbial changes associated with moderate-to-vigorous physical activity assessed. The study aims to clarify whether moderate-to-vigorous physical activity mitigates the detrimental effects of sedentary behavior on dyslipidemia and to elucidate the link between physical activity and gut microbiota. Specific findings regarding these associations are not detailed in the provided abstract.</p>
<p>Article number four. Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. This study employed a target trial emulation methodology to compare the efficacy and safety of single versus dual antiplatelet therapy after standard endovascular aneurysm repair. The investigation focused on patients undergoing endovascular aneurysm repair for abdominal aortic aneurysms who did not have established atherosclerotic cardiovascular disease, where optimal antiplatelet regimens are currently uncertain. The primary objective was to determine the superior antiplatelet strategy for this specific patient population. Specific findings regarding comparative efficacy and safety are not detailed in the provided abstract.</p>
<p>Article number five. Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke. This retrospective study analyzed 206,668 standard electrocardiograms from 9,674 consecutive patients diagnosed with acute coronary syndrome between 2007 and 2018. The research found that interatrial block, detected through a series of electrocardiograms taken before and during acute coronary syndrome, significantly predicts future occurrences of atrial fibrillation, atrial flutter, and ischemic stroke. This finding highlights interatrial block as a critical, easily identifiable risk marker for subsequent cerebrovascular and atrial arrhythmogenic events in this patient cohort, emphasizing the value of diligent electrocardiogram monitoring. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sedentary behavior, electrocardiogram, tachycardia-induced cardiomyopathy, abdominal aortic aneurysm, lung transplantation, decompensated heart failure, heart failure with reduced ejection fraction, metabolic health, endovascular aortic repair, long-term prognosis, pulmonary endarterectomy, atherosclerotic cardiovascular disease, acute coronary syndrome, antiplatelet therapy, atrial fibrillation, ischemic stroke, physical activity, dual antiplatelet therapy, chronic thromboembolic pulmonary hypertension, dyslipidemia, interatrial block, gut microbiota, pulmonary vascular disease, right heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/">E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation. 10/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like sedentary behavior and electrocardiogram. Key takeaway: E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation..
Article Links]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like sedentary behavior and electrocardiogram. Key takeaway: E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41067464">Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065522">Long-term prognosis of pure and impure tachycardiomyopathy.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065289">Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41065286">Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41065269">Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/">https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41067464" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41067464</a></p>
<p><strong>Summary:</strong> This case series describes the outcomes of six patients with chronic thromboembolic pulmonary hypertension who underwent lung transplantation. These patients either had inoperable disease or residual pulmonary hypertension after pulmonary endarterectomy, leading to end-stage right heart failure. The findings indicate that lung transplantation serves as a life-saving therapeutic option for patients with severe chronic thromboembolic pulmonary hypertension who are not candidates for or have failed other interventions. This highlights its critical role in managing refractory cases.</p>
<h4>Article 2: Long-term prognosis of pure and impure tachycardiomyopathy.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065522</a></p>
<p><strong>Summary:</strong> This prospective, monocentric, observational study recruited 456 patients with de novo, acute decompensated heart failure with reduced ejection fraction, classifying them into pure tachycardia-induced cardiomyopathy, impure tachycardia-induced cardiomyopathy, and other heart failure etiologies. The study aimed to clarify the long-term prognosis of both pure and impure tachycardia-induced cardiomyopathy. While the study design is established for comparing these prognoses, specific findings regarding the long-term outcomes are not detailed in the provided abstract.</p>
<h4>Article 3: Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065289" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065289</a></p>
<p><strong>Summary:</strong> This prospective community-based cohort study involved 2,942 Chinese adults, assessing the joint association between moderate-to-vigorous physical activity and sedentary time on dyslipidemia risk using self-reported questionnaires. A subcohort of 754 participants also had their one-year gut microbial changes associated with moderate-to-vigorous physical activity assessed. The study aims to clarify whether moderate-to-vigorous physical activity mitigates the detrimental effects of sedentary behavior on dyslipidemia and to elucidate the link between physical activity and gut microbiota. Specific findings regarding these associations are not detailed in the provided abstract.</p>
<h4>Article 4: Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065286" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065286</a></p>
<p><strong>Summary:</strong> This study employed a target trial emulation methodology to compare the efficacy and safety of single versus dual antiplatelet therapy after standard endovascular aneurysm repair. The investigation focused on patients undergoing endovascular aneurysm repair for abdominal aortic aneurysms who did not have established atherosclerotic cardiovascular disease, where optimal antiplatelet regimens are currently uncertain. The primary objective was to determine the superior antiplatelet strategy for this specific patient population. Specific findings regarding comparative efficacy and safety are not detailed in the provided abstract.</p>
<h4>Article 5: Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065269</a></p>
<p><strong>Summary:</strong> This retrospective study analyzed 206,668 standard electrocardiograms from 9,674 consecutive patients diagnosed with acute coronary syndrome between 2007 and 2018. The research found that interatrial block, detected through a series of electrocardiograms taken before and during acute coronary syndrome, significantly predicts future occurrences of atrial fibrillation, atrial flutter, and ischemic stroke. This finding highlights interatrial block as a critical, easily identifiable risk marker for subsequent cerebrovascular and atrial arrhythmogenic events in this patient cohort, emphasizing the value of diligent electrocardiogram monitoring.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series. This case series describes the outcomes of six patients with chronic thromboembolic pulmonary hypertension who underwent lung transplantation. These patients either had inoperable disease or residual pulmonary hypertension after pulmonary endarterectomy, leading to end-stage right heart failure. The findings indicate that lung transplantation serves as a life-saving therapeutic option for patients with severe chronic thromboembolic pulmonary hypertension who are not candidates for or have failed other interventions. This highlights its critical role in managing refractory cases.</p>
<p>Article number two. Long-term prognosis of pure and impure tachycardiomyopathy. This prospective, monocentric, observational study recruited 456 patients with de novo, acute decompensated heart failure with reduced ejection fraction, classifying them into pure tachycardia-induced cardiomyopathy, impure tachycardia-induced cardiomyopathy, and other heart failure etiologies. The study aimed to clarify the long-term prognosis of both pure and impure tachycardia-induced cardiomyopathy. While the study design is established for comparing these prognoses, specific findings regarding the long-term outcomes are not detailed in the provided abstract.</p>
<p>Article number three. Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study. This prospective community-based cohort study involved 2,942 Chinese adults, assessing the joint association between moderate-to-vigorous physical activity and sedentary time on dyslipidemia risk using self-reported questionnaires. A subcohort of 754 participants also had their one-year gut microbial changes associated with moderate-to-vigorous physical activity assessed. The study aims to clarify whether moderate-to-vigorous physical activity mitigates the detrimental effects of sedentary behavior on dyslipidemia and to elucidate the link between physical activity and gut microbiota. Specific findings regarding these associations are not detailed in the provided abstract.</p>
<p>Article number four. Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. This study employed a target trial emulation methodology to compare the efficacy and safety of single versus dual antiplatelet therapy after standard endovascular aneurysm repair. The investigation focused on patients undergoing endovascular aneurysm repair for abdominal aortic aneurysms who did not have established atherosclerotic cardiovascular disease, where optimal antiplatelet regimens are currently uncertain. The primary objective was to determine the superior antiplatelet strategy for this specific patient population. Specific findings regarding comparative efficacy and safety are not detailed in the provided abstract.</p>
<p>Article number five. Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke. This retrospective study analyzed 206,668 standard electrocardiograms from 9,674 consecutive patients diagnosed with acute coronary syndrome between 2007 and 2018. The research found that interatrial block, detected through a series of electrocardiograms taken before and during acute coronary syndrome, significantly predicts future occurrences of atrial fibrillation, atrial flutter, and ischemic stroke. This finding highlights interatrial block as a critical, easily identifiable risk marker for subsequent cerebrovascular and atrial arrhythmogenic events in this patient cohort, emphasizing the value of diligent electrocardiogram monitoring. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sedentary behavior, electrocardiogram, tachycardia-induced cardiomyopathy, abdominal aortic aneurysm, lung transplantation, decompensated heart failure, heart failure with reduced ejection fraction, metabolic health, endovascular aortic repair, long-term prognosis, pulmonary endarterectomy, atherosclerotic cardiovascular disease, acute coronary syndrome, antiplatelet therapy, atrial fibrillation, ischemic stroke, physical activity, dual antiplatelet therapy, chronic thromboembolic pulmonary hypertension, dyslipidemia, interatrial block, gut microbiota, pulmonary vascular disease, right heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/">E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation. 10/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251010_060043.mp3" length="4561858" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like sedentary behavior and electrocardiogram. Key takeaway: E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation..
Article Links:
Article 1: Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Long-term prognosis of pure and impure tachycardiomyopathy. (ESC heart failure)
Article 3: Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study. (Journal of the American Heart Association)
Article 4: Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. (Journal of the American Heart Association)
Article 5: Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Predicts Atrial Fibrillation, Atrial Flutter, and Ischemic Stroke. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/e-c-g-interatrial-block-predicts-stroke-atrial-fibrillation-10-10-25/
 Featured Articles
Article 1: Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41067464
Summary: This case series describes the outcomes of six patients with chronic thromboembolic pulmonary hypertension who underwent lung transplantation. These patients either had inoperable disease or residual pulmonary hypertension after pulmonary endarterectomy, leading to end-stage right heart failure. The findings indicate that lung transplantation serves as a life-saving therapeutic option for patients with severe chronic thromboembolic pulmonary hypertension who are not candidates for or have failed other interventions. This highlights its critical role in managing refractory cases.
Article 2: Long-term prognosis of pure and impure tachycardiomyopathy.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065522
Summary: This prospective, monocentric, observational study recruited 456 patients with de novo, acute decompensated heart failure with reduced ejection fraction, classifying them into pure tachycardia-induced cardiomyopathy, impure tachycardia-induced cardiomyopathy, and other heart failure etiologies. The study aimed to clarify the long-term prognosis of both pure and impure tachycardia-induced cardiomyopathy. While the study design is established for comparing these prognoses, specific findings regarding the long-term outcomes are not detailed in the provided abstract.
Article 3: Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065289
Summary: This prospective community-based cohort study involved 2,942 Chinese adults, assessing the joint association between moderate-to-vigorous physical activity and sedentary time on dyslipidemia risk using self-reported questionnaires. A subcohort of 754 participants also had their one-year gut microbial changes associated with moderate-to-vigorous physical activity assessed. The study aims to clarify whether moderate-to-vigorous physical activity mitigates the detrimental effects of sedentary behavior on dyslipidemia and to elucidate the link between physical activity and gut microbiota. Specific findings regarding these associations are not detailed in the provided abstract.
Article 4: Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like sedentary behavior and electrocardiogram. Key takeaway: E.C.G. Interatrial Block Predicts Stroke, Atrial Fibrillation..
Article Links:
Article 1: Lung transplantation for chronic thromboembolic pulmonary hypertension &#8211; a case series. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Long-term prognosis of pure and impure tachycardiomyopathy. (ESC heart failure)
Article 3: Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community-Based Cohort Study. (Journal of the American Heart Association)
Article 4: Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. (Journal of the American Heart Association)
Article 5: Interatrial Block Detected by a Series of ECGs Before and During Acute Coronary Syndrome Pred]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>H. C. M. Exercise Paradigm Shift 10/10/25</title>
	<link>https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/</link>
	<pubDate>Fri, 10 Oct 2025 06:57:57 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and lung function. Key takeaway: H. C. M. Exercise Paradigm Shift.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41065586">Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065585">Left ventricular geometry, brain architecture, and cognition: an observational study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065563">Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41067466">Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41067465">Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/">https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065586" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065586</a></p>
<p><strong>Summary:</strong> Historically, individuals with Hypertrophic Cardiomyopathy were systematically excluded from vigorous exercise due to concerns about increased sudden cardiac death risk. Emerging evidence, from observational studies and randomized trials, now challenges this paradigm. These studies demonstrate that tailored exercise, including competitive sports, improves functional capacity, quality of life, and overall cardiovascular and psychological health in Hypertrophic Cardiomyopathy populations, suggesting a significant shift in clinical guidance.</p>
<h4>Article 2: Left ventricular geometry, brain architecture, and cognition: an observational study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065585" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065585</a></p>
<p><strong>Summary:</strong> This observational study of 15,519 U.K. Biobank participants investigated the intricate link between cardiovascular phenotypes, specifically left ventricular geometry, brain architecture, and cognitive function. Using confirmatory factor analysis on 18 cardiovascular magnetic resonance imaging measures, the research aimed to illuminate the interplay of cardiovascular disease and brain health. Understanding this complex cardiovascular-brain interaction is essential for addressing their shared burden in older adults.</p>
<h4>Article 3: Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065563" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065563</a></p>
<p><strong>Summary:</strong> A proteome-wide Mendelian randomization study utilized genetic instruments from over 2,000 plasma proteins to assess their causal effects on blood pressure and subsequent cardiovascular diseases. This research aims to identify molecular determinants and pathways involved in blood pressure regulation and its impact on cardiovascular health. The findings provide critical insights into the biological mechanisms that contribute to elevated blood pressure and the development of cardiovascular diseases.</p>
<h4>Article 4: Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41067466" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41067466</a></p>
<p><strong>Summary:</strong> This retrospective cohort study, using the U.N.O.S. (United Network for Organ Sharing) database from January 2019 to December 2024, analyzed 1,761 adults undergoing simultaneous heart-kidney transplantation. The study specifically evaluated the safety and outcomes of using hearts from donation after circulatory death donors in this context, a practice increasingly adopted to address donor shortages. By conducting a propensity-matched analysis, the research provides crucial evidence regarding the viability of donation after circulatory death hearts to expand the donor pool for patients with end-stage heart and kidney failure.</p>
<h4>Article 5: Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41067465" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41067465</a></p>
<p><strong>Summary:</strong> The multi-center observational Clinical Trials in Organ Transplantation-20 study prospectively investigated the timing of quality of life and lung function changes during the first year after lung transplantation. Researchers measured longitudinal Forced Expiratory Volume in 1 second and Quality of Life using tools like the St. George&#8217;s Respiratory Questionnaire and 36-Item Short Form Survey. The study aimed to clarify if quality of life improvements coincide with spirometry improvements, offering vital insights into post-transplant recovery trajectories and patient care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. Historically, individuals with Hypertrophic Cardiomyopathy were systematically excluded from vigorous exercise due to concerns about increased sudden cardiac death risk. Emerging evidence, from observational studies and randomized trials, now challenges this paradigm. These studies demonstrate that tailored exercise, including competitive sports, improves functional capacity, quality of life, and overall cardiovascular and psychological health in Hypertrophic Cardiomyopathy populations, suggesting a significant shift in clinical guidance.</p>
<p>Article number two. Left ventricular geometry, brain architecture, and cognition: an observational study. This observational study of 15,519 U.K. Biobank participants investigated the intricate link between cardiovascular phenotypes, specifically left ventricular geometry, brain architecture, and cognitive function. Using confirmatory factor analysis on 18 cardiovascular magnetic resonance imaging measures, the research aimed to illuminate the interplay of cardiovascular disease and brain health. Understanding this complex cardiovascular-brain interaction is essential for addressing their shared burden in older adults.</p>
<p>Article number three. Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study. A proteome-wide Mendelian randomization study utilized genetic instruments from over 2,000 plasma proteins to assess their causal effects on blood pressure and subsequent cardiovascular diseases. This research aims to identify molecular determinants and pathways involved in blood pressure regulation and its impact on cardiovascular health. The findings provide critical insights into the biological mechanisms that contribute to elevated blood pressure and the development of cardiovascular diseases.</p>
<p>Article number four. Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry. This retrospective cohort study, using the U.N.O.S. (United Network for Organ Sharing) database from January 2019 to December 2024, analyzed 1,761 adults undergoing simultaneous heart-kidney transplantation. The study specifically evaluated the safety and outcomes of using hearts from donation after circulatory death donors in this context, a practice increasingly adopted to address donor shortages. By conducting a propensity-matched analysis, the research provides crucial evidence regarding the viability of donation after circulatory death hearts to expand the donor pool for patients with end-stage heart and kidney failure.</p>
<p>Article number five. Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study. The multi-center observational Clinical Trials in Organ Transplantation-20 study prospectively investigated the timing of quality of life and lung function changes during the first year after lung transplantation. Researchers measured longitudinal Forced Expiratory Volume in 1 second and Quality of Life using tools like the St. George&#8217;s Respiratory Questionnaire and 36-Item Short Form Survey. The study aimed to clarify if quality of life improvements coincide with spirometry improvements, offering vital insights into post-transplant recovery trajectories and patient care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>blood pressure, lung function, plasma proteins, end-stage heart failure, lung transplantation, brain architecture, dementia, cardiac rehabilitation, spirometry, cardiovascular diseases, left ventricular geometry, sudden cardiac death, hypertrophic cardiomyopathy, proteomics, simultaneous heart-kidney transplantation, quality of life, cognition, donation after circulatory death, competitive sports, cardiovascular magnetic resonance imaging, exercise prescription, end-stage kidney failure, organ transplantation, post-transplant outcomes, Mendelian randomization.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/">H. C. M. Exercise Paradigm Shift 10/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and lung function. Key takeaway: H. C. M. Exercise Paradigm Shift.
Article Links:
Article 1: Hypertrophic cardiomyopat]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and lung function. Key takeaway: H. C. M. Exercise Paradigm Shift.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41065586">Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41065585">Left ventricular geometry, brain architecture, and cognition: an observational study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41065563">Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41067466">Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41067465">Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/">https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065586" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065586</a></p>
<p><strong>Summary:</strong> Historically, individuals with Hypertrophic Cardiomyopathy were systematically excluded from vigorous exercise due to concerns about increased sudden cardiac death risk. Emerging evidence, from observational studies and randomized trials, now challenges this paradigm. These studies demonstrate that tailored exercise, including competitive sports, improves functional capacity, quality of life, and overall cardiovascular and psychological health in Hypertrophic Cardiomyopathy populations, suggesting a significant shift in clinical guidance.</p>
<h4>Article 2: Left ventricular geometry, brain architecture, and cognition: an observational study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065585" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065585</a></p>
<p><strong>Summary:</strong> This observational study of 15,519 U.K. Biobank participants investigated the intricate link between cardiovascular phenotypes, specifically left ventricular geometry, brain architecture, and cognitive function. Using confirmatory factor analysis on 18 cardiovascular magnetic resonance imaging measures, the research aimed to illuminate the interplay of cardiovascular disease and brain health. Understanding this complex cardiovascular-brain interaction is essential for addressing their shared burden in older adults.</p>
<h4>Article 3: Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41065563" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41065563</a></p>
<p><strong>Summary:</strong> A proteome-wide Mendelian randomization study utilized genetic instruments from over 2,000 plasma proteins to assess their causal effects on blood pressure and subsequent cardiovascular diseases. This research aims to identify molecular determinants and pathways involved in blood pressure regulation and its impact on cardiovascular health. The findings provide critical insights into the biological mechanisms that contribute to elevated blood pressure and the development of cardiovascular diseases.</p>
<h4>Article 4: Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41067466" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41067466</a></p>
<p><strong>Summary:</strong> This retrospective cohort study, using the U.N.O.S. (United Network for Organ Sharing) database from January 2019 to December 2024, analyzed 1,761 adults undergoing simultaneous heart-kidney transplantation. The study specifically evaluated the safety and outcomes of using hearts from donation after circulatory death donors in this context, a practice increasingly adopted to address donor shortages. By conducting a propensity-matched analysis, the research provides crucial evidence regarding the viability of donation after circulatory death hearts to expand the donor pool for patients with end-stage heart and kidney failure.</p>
<h4>Article 5: Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41067465" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41067465</a></p>
<p><strong>Summary:</strong> The multi-center observational Clinical Trials in Organ Transplantation-20 study prospectively investigated the timing of quality of life and lung function changes during the first year after lung transplantation. Researchers measured longitudinal Forced Expiratory Volume in 1 second and Quality of Life using tools like the St. George&#8217;s Respiratory Questionnaire and 36-Item Short Form Survey. The study aimed to clarify if quality of life improvements coincide with spirometry improvements, offering vital insights into post-transplant recovery trajectories and patient care.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. Historically, individuals with Hypertrophic Cardiomyopathy were systematically excluded from vigorous exercise due to concerns about increased sudden cardiac death risk. Emerging evidence, from observational studies and randomized trials, now challenges this paradigm. These studies demonstrate that tailored exercise, including competitive sports, improves functional capacity, quality of life, and overall cardiovascular and psychological health in Hypertrophic Cardiomyopathy populations, suggesting a significant shift in clinical guidance.</p>
<p>Article number two. Left ventricular geometry, brain architecture, and cognition: an observational study. This observational study of 15,519 U.K. Biobank participants investigated the intricate link between cardiovascular phenotypes, specifically left ventricular geometry, brain architecture, and cognitive function. Using confirmatory factor analysis on 18 cardiovascular magnetic resonance imaging measures, the research aimed to illuminate the interplay of cardiovascular disease and brain health. Understanding this complex cardiovascular-brain interaction is essential for addressing their shared burden in older adults.</p>
<p>Article number three. Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study. A proteome-wide Mendelian randomization study utilized genetic instruments from over 2,000 plasma proteins to assess their causal effects on blood pressure and subsequent cardiovascular diseases. This research aims to identify molecular determinants and pathways involved in blood pressure regulation and its impact on cardiovascular health. The findings provide critical insights into the biological mechanisms that contribute to elevated blood pressure and the development of cardiovascular diseases.</p>
<p>Article number four. Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry. This retrospective cohort study, using the U.N.O.S. (United Network for Organ Sharing) database from January 2019 to December 2024, analyzed 1,761 adults undergoing simultaneous heart-kidney transplantation. The study specifically evaluated the safety and outcomes of using hearts from donation after circulatory death donors in this context, a practice increasingly adopted to address donor shortages. By conducting a propensity-matched analysis, the research provides crucial evidence regarding the viability of donation after circulatory death hearts to expand the donor pool for patients with end-stage heart and kidney failure.</p>
<p>Article number five. Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study. The multi-center observational Clinical Trials in Organ Transplantation-20 study prospectively investigated the timing of quality of life and lung function changes during the first year after lung transplantation. Researchers measured longitudinal Forced Expiratory Volume in 1 second and Quality of Life using tools like the St. George&#8217;s Respiratory Questionnaire and 36-Item Short Form Survey. The study aimed to clarify if quality of life improvements coincide with spirometry improvements, offering vital insights into post-transplant recovery trajectories and patient care. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>blood pressure, lung function, plasma proteins, end-stage heart failure, lung transplantation, brain architecture, dementia, cardiac rehabilitation, spirometry, cardiovascular diseases, left ventricular geometry, sudden cardiac death, hypertrophic cardiomyopathy, proteomics, simultaneous heart-kidney transplantation, quality of life, cognition, donation after circulatory death, competitive sports, cardiovascular magnetic resonance imaging, exercise prescription, end-stage kidney failure, organ transplantation, post-transplant outcomes, Mendelian randomization.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/">H. C. M. Exercise Paradigm Shift 10/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251010_025659.mp3" length="4031468" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and lung function. Key takeaway: H. C. M. Exercise Paradigm Shift.
Article Links:
Article 1: Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. (European heart journal)
Article 2: Left ventricular geometry, brain architecture, and cognition: an observational study. (European heart journal)
Article 3: Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study. (European heart journal)
Article 4: Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Timing of quality of life and lung function changes during the first year following lung transplantation: a multi-center prospective cohort study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/h-c-m-exercise-paradigm-shift-10-10-25/
 Featured Articles
Article 1: Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065586
Summary: Historically, individuals with Hypertrophic Cardiomyopathy were systematically excluded from vigorous exercise due to concerns about increased sudden cardiac death risk. Emerging evidence, from observational studies and randomized trials, now challenges this paradigm. These studies demonstrate that tailored exercise, including competitive sports, improves functional capacity, quality of life, and overall cardiovascular and psychological health in Hypertrophic Cardiomyopathy populations, suggesting a significant shift in clinical guidance.
Article 2: Left ventricular geometry, brain architecture, and cognition: an observational study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065585
Summary: This observational study of 15,519 U.K. Biobank participants investigated the intricate link between cardiovascular phenotypes, specifically left ventricular geometry, brain architecture, and cognitive function. Using confirmatory factor analysis on 18 cardiovascular magnetic resonance imaging measures, the research aimed to illuminate the interplay of cardiovascular disease and brain health. Understanding this complex cardiovascular-brain interaction is essential for addressing their shared burden in older adults.
Article 3: Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41065563
Summary: A proteome-wide Mendelian randomization study utilized genetic instruments from over 2,000 plasma proteins to assess their causal effects on blood pressure and subsequent cardiovascular diseases. This research aims to identify molecular determinants and pathways involved in blood pressure regulation and its impact on cardiovascular health. The findings provide critical insights into the biological mechanisms that contribute to elevated blood pressure and the development of cardiovascular diseases.
Article 4: Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41067466
Summary: This retrospective cohort study, using the U.N.O.S. (United Network for Organ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 10, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and lung function. Key takeaway: H. C. M. Exercise Paradigm Shift.
Article Links:
Article 1: Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. (European heart journal)
Article 2: Left ventricular geometry, brain architecture, and cognition: an observational study. (European heart journal)
Article 3: Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study. (European heart journal)
Article 4: Outcomes of Simultaneous Heart-Kidney Transplantation Using Donation After Circulatory Death Donors: A Propensity-Matched Analysis from the UNOS Registry. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Timing of quality of life and lung function ch]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation 10/09/25</title>
	<link>https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/</link>
	<pubDate>Thu, 09 Oct 2025 10:03:05 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic heart disease and secondary mitral regurgitation. Key takeaway: Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41059636">Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018).</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41059541">Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41025488">Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41025486">Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41025485">Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/">https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018).</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41059636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41059636</a></p>
<p><strong>Summary:</strong> This National Health and Nutrition Examination Survey population-based study aimed to assess the prognostic value of the American Heart Association P.R.E.V.E.N.T. Cardiovascular Disease Risk Equations in cancer survivors. Researchers analyzed a nationally representative cohort of U.S. cancer survivors from 2009 to 2018. The study sought to determine the association of baseline cardiovascular risk, as calculated by the P.R.E.V.E.N.T. equations, with all-cause and cardiovascular mortality. Importantly, the provided abstract does not detail the specific findings or conclusions regarding this association or prognostic value.</p>
<h4>Article 2: Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41059541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41059541</a></p>
<p><strong>Summary:</strong> This S.A.G.E.S. (Study on Aging, Geriatrics, and the Environment in Solothurn) Cohort study aimed to investigate the specific association between blood pressure postural changes variability and cognitive function in community-dwelling older adults. Building on prior research that linked higher blood pressure variability and postural changes to lower cognitive function, the study sought to clarify this relationship. A previous study notably indicated a greater risk of dementia with higher systolic blood pressure postural changes variability. However, the specific findings and conclusions regarding the association identified in this particular study are not detailed in the provided abstract.</p>
<h4>Article 3: Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025488" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025488</a></p>
<p><strong>Summary:</strong> This cross-sectional multiomics study aimed to investigate the epigenetic regulation of gene expression in peripheral artery disease, focusing on D.N.A. methylation in skeletal muscle. Researchers compared patients with peripheral artery disease, experiencing intermittent claudication or critical limb ischemia, to non-peripheral artery disease controls. The study hypothesizes that epigenetic modifications like D.N.A. methylation play a critical role in hypoxic cell programs relevant to peripheral artery disease. The specific findings regarding dysregulation of hypoxia-induced genes or D.N.A. methylome changes are not elaborated in the provided abstract.</p>
<h4>Article 4: Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025486</a></p>
<p><strong>Summary:</strong> This study found that trimetazidine is associated with an ameliorated stroke risk in patients suffering from both ischemic heart disease and atrial fibrillation. Researchers from Hong Kong analyzed clinical data from 1999 to 2013 to determine if trimetazidine, known to improve myocardial ischemia through glucose oxidation prioritization, clinically reduces stroke risk. The findings suggest that trimetazidine may offer a tangible benefit in reducing stroke incidence in this high-risk population.</p>
<h4>Article 5: Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025485" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025485</a></p>
<p><strong>Summary:</strong> This study investigated the prognostic impact of a modified J-M.A.C.S. (Japanese Registry for Mechanically Assisted Circulatory Support) score in patients with systolic heart failure undergoing transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation. Utilizing data from the O.C.E.A.N.-Mitral (Optimized Catheter-based Evaluation and Assessment of Mitral Valve Repair for Functional Mitral Regurgitation) registry, the research aimed to improve risk stratification for these patients. Given the high morbidity and mortality associated with this repair, the development of optimal risk assessment tools like the modified J-M.A.C.S. score is imperative. However, the specific findings detailing the prognostic impact of the modified J-M.A.C.S. score are not provided in the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018). This National Health and Nutrition Examination Survey population-based study aimed to assess the prognostic value of the American Heart Association P.R.E.V.E.N.T. Cardiovascular Disease Risk Equations in cancer survivors. Researchers analyzed a nationally representative cohort of U.S. cancer survivors from 2009 to 2018. The study sought to determine the association of baseline cardiovascular risk, as calculated by the P.R.E.V.E.N.T. equations, with all-cause and cardiovascular mortality. Importantly, the provided abstract does not detail the specific findings or conclusions regarding this association or prognostic value.</p>
<p>Article number two. Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort. This S.A.G.E.S. (Study on Aging, Geriatrics, and the Environment in Solothurn) Cohort study aimed to investigate the specific association between blood pressure postural changes variability and cognitive function in community-dwelling older adults. Building on prior research that linked higher blood pressure variability and postural changes to lower cognitive function, the study sought to clarify this relationship. A previous study notably indicated a greater risk of dementia with higher systolic blood pressure postural changes variability. However, the specific findings and conclusions regarding the association identified in this particular study are not detailed in the provided abstract.</p>
<p>Article number three. Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease. This cross-sectional multiomics study aimed to investigate the epigenetic regulation of gene expression in peripheral artery disease, focusing on D.N.A. methylation in skeletal muscle. Researchers compared patients with peripheral artery disease, experiencing intermittent claudication or critical limb ischemia, to non-peripheral artery disease controls. The study hypothesizes that epigenetic modifications like D.N.A. methylation play a critical role in hypoxic cell programs relevant to peripheral artery disease. The specific findings regarding dysregulation of hypoxia-induced genes or D.N.A. methylome changes are not elaborated in the provided abstract.</p>
<p>Article number four. Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation. This study found that trimetazidine is associated with an ameliorated stroke risk in patients suffering from both ischemic heart disease and atrial fibrillation. Researchers from Hong Kong analyzed clinical data from 1999 to 2013 to determine if trimetazidine, known to improve myocardial ischemia through glucose oxidation prioritization, clinically reduces stroke risk. The findings suggest that trimetazidine may offer a tangible benefit in reducing stroke incidence in this high-risk population.</p>
<p>Article number five. Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair. This study investigated the prognostic impact of a modified J-M.A.C.S. (Japanese Registry for Mechanically Assisted Circulatory Support) score in patients with systolic heart failure undergoing transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation. Utilizing data from the O.C.E.A.N.-Mitral (Optimized Catheter-based Evaluation and Assessment of Mitral Valve Repair for Functional Mitral Regurgitation) registry, the research aimed to improve risk stratification for these patients. Given the high morbidity and mortality associated with this repair, the development of optimal risk assessment tools like the modified J-M.A.C.S. score is imperative. However, the specific findings detailing the prognostic impact of the modified J-M.A.C.S. score are not provided in the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ischemic heart disease, secondary mitral regurgitation, stroke risk, dementia risk, all-cause mortality, transcatheter mitral valve repair, cognitive function, Peripheral artery disease, skeletal muscle, Cancer survivorship, J-M.A.C.S. score, D.N.A. methylation, Blood pressure variability, National Health and Nutrition Examination Survey, myocardial ischemia, epigenetic regulation, risk stratification, postural changes, P.R.E.V.E.N.T. equations, systolic heart failure, S.A.G.E.S. Cohort, hypoxia-induced genes, cardiovascular risk, Trimetazidine, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/">Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation 10/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic heart disease and secondary mitral regurgitation. Key takeaway: Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, ]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic heart disease and secondary mitral regurgitation. Key takeaway: Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41059636">Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018).</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41059541">Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41025488">Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41025486">Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41025485">Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/">https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018).</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41059636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41059636</a></p>
<p><strong>Summary:</strong> This National Health and Nutrition Examination Survey population-based study aimed to assess the prognostic value of the American Heart Association P.R.E.V.E.N.T. Cardiovascular Disease Risk Equations in cancer survivors. Researchers analyzed a nationally representative cohort of U.S. cancer survivors from 2009 to 2018. The study sought to determine the association of baseline cardiovascular risk, as calculated by the P.R.E.V.E.N.T. equations, with all-cause and cardiovascular mortality. Importantly, the provided abstract does not detail the specific findings or conclusions regarding this association or prognostic value.</p>
<h4>Article 2: Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41059541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41059541</a></p>
<p><strong>Summary:</strong> This S.A.G.E.S. (Study on Aging, Geriatrics, and the Environment in Solothurn) Cohort study aimed to investigate the specific association between blood pressure postural changes variability and cognitive function in community-dwelling older adults. Building on prior research that linked higher blood pressure variability and postural changes to lower cognitive function, the study sought to clarify this relationship. A previous study notably indicated a greater risk of dementia with higher systolic blood pressure postural changes variability. However, the specific findings and conclusions regarding the association identified in this particular study are not detailed in the provided abstract.</p>
<h4>Article 3: Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025488" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025488</a></p>
<p><strong>Summary:</strong> This cross-sectional multiomics study aimed to investigate the epigenetic regulation of gene expression in peripheral artery disease, focusing on D.N.A. methylation in skeletal muscle. Researchers compared patients with peripheral artery disease, experiencing intermittent claudication or critical limb ischemia, to non-peripheral artery disease controls. The study hypothesizes that epigenetic modifications like D.N.A. methylation play a critical role in hypoxic cell programs relevant to peripheral artery disease. The specific findings regarding dysregulation of hypoxia-induced genes or D.N.A. methylome changes are not elaborated in the provided abstract.</p>
<h4>Article 4: Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025486" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025486</a></p>
<p><strong>Summary:</strong> This study found that trimetazidine is associated with an ameliorated stroke risk in patients suffering from both ischemic heart disease and atrial fibrillation. Researchers from Hong Kong analyzed clinical data from 1999 to 2013 to determine if trimetazidine, known to improve myocardial ischemia through glucose oxidation prioritization, clinically reduces stroke risk. The findings suggest that trimetazidine may offer a tangible benefit in reducing stroke incidence in this high-risk population.</p>
<h4>Article 5: Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025485" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025485</a></p>
<p><strong>Summary:</strong> This study investigated the prognostic impact of a modified J-M.A.C.S. (Japanese Registry for Mechanically Assisted Circulatory Support) score in patients with systolic heart failure undergoing transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation. Utilizing data from the O.C.E.A.N.-Mitral (Optimized Catheter-based Evaluation and Assessment of Mitral Valve Repair for Functional Mitral Regurgitation) registry, the research aimed to improve risk stratification for these patients. Given the high morbidity and mortality associated with this repair, the development of optimal risk assessment tools like the modified J-M.A.C.S. score is imperative. However, the specific findings detailing the prognostic impact of the modified J-M.A.C.S. score are not provided in the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018). This National Health and Nutrition Examination Survey population-based study aimed to assess the prognostic value of the American Heart Association P.R.E.V.E.N.T. Cardiovascular Disease Risk Equations in cancer survivors. Researchers analyzed a nationally representative cohort of U.S. cancer survivors from 2009 to 2018. The study sought to determine the association of baseline cardiovascular risk, as calculated by the P.R.E.V.E.N.T. equations, with all-cause and cardiovascular mortality. Importantly, the provided abstract does not detail the specific findings or conclusions regarding this association or prognostic value.</p>
<p>Article number two. Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort. This S.A.G.E.S. (Study on Aging, Geriatrics, and the Environment in Solothurn) Cohort study aimed to investigate the specific association between blood pressure postural changes variability and cognitive function in community-dwelling older adults. Building on prior research that linked higher blood pressure variability and postural changes to lower cognitive function, the study sought to clarify this relationship. A previous study notably indicated a greater risk of dementia with higher systolic blood pressure postural changes variability. However, the specific findings and conclusions regarding the association identified in this particular study are not detailed in the provided abstract.</p>
<p>Article number three. Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease. This cross-sectional multiomics study aimed to investigate the epigenetic regulation of gene expression in peripheral artery disease, focusing on D.N.A. methylation in skeletal muscle. Researchers compared patients with peripheral artery disease, experiencing intermittent claudication or critical limb ischemia, to non-peripheral artery disease controls. The study hypothesizes that epigenetic modifications like D.N.A. methylation play a critical role in hypoxic cell programs relevant to peripheral artery disease. The specific findings regarding dysregulation of hypoxia-induced genes or D.N.A. methylome changes are not elaborated in the provided abstract.</p>
<p>Article number four. Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation. This study found that trimetazidine is associated with an ameliorated stroke risk in patients suffering from both ischemic heart disease and atrial fibrillation. Researchers from Hong Kong analyzed clinical data from 1999 to 2013 to determine if trimetazidine, known to improve myocardial ischemia through glucose oxidation prioritization, clinically reduces stroke risk. The findings suggest that trimetazidine may offer a tangible benefit in reducing stroke incidence in this high-risk population.</p>
<p>Article number five. Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair. This study investigated the prognostic impact of a modified J-M.A.C.S. (Japanese Registry for Mechanically Assisted Circulatory Support) score in patients with systolic heart failure undergoing transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation. Utilizing data from the O.C.E.A.N.-Mitral (Optimized Catheter-based Evaluation and Assessment of Mitral Valve Repair for Functional Mitral Regurgitation) registry, the research aimed to improve risk stratification for these patients. Given the high morbidity and mortality associated with this repair, the development of optimal risk assessment tools like the modified J-M.A.C.S. score is imperative. However, the specific findings detailing the prognostic impact of the modified J-M.A.C.S. score are not provided in the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ischemic heart disease, secondary mitral regurgitation, stroke risk, dementia risk, all-cause mortality, transcatheter mitral valve repair, cognitive function, Peripheral artery disease, skeletal muscle, Cancer survivorship, J-M.A.C.S. score, D.N.A. methylation, Blood pressure variability, National Health and Nutrition Examination Survey, myocardial ischemia, epigenetic regulation, risk stratification, postural changes, P.R.E.V.E.N.T. equations, systolic heart failure, S.A.G.E.S. Cohort, hypoxia-induced genes, cardiovascular risk, Trimetazidine, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/">Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation 10/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251009_060054.mp3" length="4784212" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic heart disease and secondary mitral regurgitation. Key takeaway: Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation.
Article Links:
Article 1: Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018). (Journal of the American Heart Association)
Article 2: Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort. (Journal of the American Heart Association)
Article 3: Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease. (Journal of the American Heart Association)
Article 4: Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation. (Journal of the American Heart Association)
Article 5: Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/trimetazidine-lowers-stroke-risk-in-ischemic-heart-disease-atrial-fibrillation-10-09-25/
 Featured Articles
Article 1: Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018).
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41059636
Summary: This National Health and Nutrition Examination Survey population-based study aimed to assess the prognostic value of the American Heart Association P.R.E.V.E.N.T. Cardiovascular Disease Risk Equations in cancer survivors. Researchers analyzed a nationally representative cohort of U.S. cancer survivors from 2009 to 2018. The study sought to determine the association of baseline cardiovascular risk, as calculated by the P.R.E.V.E.N.T. equations, with all-cause and cardiovascular mortality. Importantly, the provided abstract does not detail the specific findings or conclusions regarding this association or prognostic value.
Article 2: Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41059541
Summary: This S.A.G.E.S. (Study on Aging, Geriatrics, and the Environment in Solothurn) Cohort study aimed to investigate the specific association between blood pressure postural changes variability and cognitive function in community-dwelling older adults. Building on prior research that linked higher blood pressure variability and postural changes to lower cognitive function, the study sought to clarify this relationship. A previous study notably indicated a greater risk of dementia with higher systolic blood pressure postural changes variability. However, the specific findings and conclusions regarding the association identified in this particular study are not detailed in the provided abstract.
Article 3: Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41025488
Summary: This cross-sectional multiomics study aimed to investigate the epigenetic regulation of gene expression in peripheral artery disease, focusing on D.N.A. methylation in skeletal muscle. Researchers compared patients with peripheral artery disease, experiencing intermittent claudication or critical limb ischemia, to non-peripheral artery disease controls. The study hypothesizes that epigenetic modifications like D.N.A. methylation play a critical role in hypoxic cell programs relevant to peripheral artery disease. The speci]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic heart disease and secondary mitral regurgitation. Key takeaway: Trimetazidine Lowers Stroke Risk in Ischemic Heart Disease, Atrial Fibrillation.
Article Links:
Article 1: Prognostic Value of the American Heart Association PREVENT Cardiovascular Disease Risk Equations in Cancer Survivorship: A NHANES Population-Based Study (2009-2018). (Journal of the American Heart Association)
Article 2: Blood Pressure Postural Changes Variability Is Associated With Lower Cognition: The S.AGES Cohort. (Journal of the American Heart Association)
Article 3: Multiomics Analysis of Skeletal Muscle Identifies Dysregulation of Hypoxia-Induced Genes in Peripheral Artery Disease. (Journal of the American Heart Association)
Article 4: Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation. (Journal of the Americ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Phenomapping Reveals High-Risk HeF.rEF Subgroups 10/09/25</title>
	<link>https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/</link>
	<pubDate>Thu, 09 Oct 2025 06:58:00 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like risk prediction model and cardiovascular death. Key takeaway: Phenomapping Reveals High-Risk HeF.rEF Subgroups.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41061873">HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41061917">Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41060665">Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41060636">Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41058565">Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/">https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41061873" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41061873</a></p>
<p><strong>Summary:</strong> heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.</p>
<h4>Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41061917" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41061917</a></p>
<p><strong>Summary:</strong> This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.</p>
<h4>Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41060665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41060665</a></p>
<p><strong>Summary:</strong> This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.</p>
<h4>Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41060636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41060636</a></p>
<p><strong>Summary:</strong> This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual&#8217;s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.</p>
<h4>Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41058565" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41058565</a></p>
<p><strong>Summary:</strong> This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. HOPE for children: successful pediatric D.C.D. heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.</p>
<p>Article number two. Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.</p>
<p>Article number three. Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.</p>
<p>Article number four. Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual&#8217;s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.</p>
<p>Article number five. Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk prediction model, cardiovascular death, care delivery model, Heart Failure with Reduced Ejection Fraction, genetic variants, monogenic risk, residual risk, transesophageal echocardiography, heart failure hospitalizations, thrombus screening, symptom burden, interprofessional care, palliative care, advanced heart disease, hypothermic oxygenated perfusion, thromboembolic events, Donation after Circulatory Death, pediatric heart transplantation, phenomapping, advanced heart failure, polygenic risk, intracardiac echocardiography, donor organ preservation, atrial fibrillation ablation, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/">Phenomapping Reveals High-Risk HeF.rEF Subgroups 10/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like risk prediction model and cardiovascular death. Key takeaway: Phenomapping Reveals High-Risk HeF.rEF Subgroups.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like risk prediction model and cardiovascular death. Key takeaway: Phenomapping Reveals High-Risk HeF.rEF Subgroups.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41061873">HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41061917">Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.</a> (Journal of cardiac failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41060665">Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41060636">Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41058565">Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.</a> (Circulation. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/">https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41061873" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41061873</a></p>
<p><strong>Summary:</strong> heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.</p>
<h4>Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.</h4>
<p><strong>Journal:</strong> Journal of cardiac failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41061917" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41061917</a></p>
<p><strong>Summary:</strong> This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.</p>
<h4>Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41060665" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41060665</a></p>
<p><strong>Summary:</strong> This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.</p>
<h4>Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41060636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41060636</a></p>
<p><strong>Summary:</strong> This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual&#8217;s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.</p>
<h4>Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41058565" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41058565</a></p>
<p><strong>Summary:</strong> This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. HOPE for children: successful pediatric D.C.D. heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.</p>
<p>Article number two. Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.</p>
<p>Article number three. Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.</p>
<p>Article number four. Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual&#8217;s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.</p>
<p>Article number five. Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk prediction model, cardiovascular death, care delivery model, Heart Failure with Reduced Ejection Fraction, genetic variants, monogenic risk, residual risk, transesophageal echocardiography, heart failure hospitalizations, thrombus screening, symptom burden, interprofessional care, palliative care, advanced heart disease, hypothermic oxygenated perfusion, thromboembolic events, Donation after Circulatory Death, pediatric heart transplantation, phenomapping, advanced heart failure, polygenic risk, intracardiac echocardiography, donor organ preservation, atrial fibrillation ablation, atrial fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/">Phenomapping Reveals High-Risk HeF.rEF Subgroups 10/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251009_025649.mp3" length="4837711" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like risk prediction model and cardiovascular death. Key takeaway: Phenomapping Reveals High-Risk HeF.rEF Subgroups.
Article Links:
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. (Journal of cardiac failure)
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. (JAMA cardiology)
Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. (JAMA cardiology)
Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/
 Featured Articles
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061873
Summary: heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061917
Summary: This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41060665
Summary: This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outco]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like risk prediction model and cardiovascular death. Key takeaway: Phenomapping Reveals High-Risk HeF.rEF Subgroups.
Article Links:
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. (Journal of cardiac failure)
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. (JAMA cardiology)
Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. (JAMA cardiology)
Article 5: Phenomapping in Heart Failure Wit]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Y2-Receptor Blockade Quells Ventricular Arrhythmias. 10/08/25</title>
	<link>https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/</link>
	<pubDate>Wed, 08 Oct 2025 10:01:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like Ventricular arrhythmias and blood pressure monitoring. Key takeaway: Y2-Receptor Blockade Quells Ventricular Arrhythmias..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41052913">Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41052902">Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41048027">Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41054844">Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41054846">Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke.</a> (Stroke)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/">https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052913" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052913</a></p>
<p><strong>Summary:</strong> This review article proposes chronomodulated chemotherapy as a preventive strategy to mitigate anthracycline-induced cardiotoxicity. It highlights that adjusting anthracycline administration time to the body&#8217;s circadian rhythms may reduce the risk of heart failure in cancer patients and survivors. The concept is based on the significant role of circadian rhythms in cardiovascular physiology, suggesting a time-dependent variation in cardiac sensitivity to these chemotherapeutic agents.</p>
<h4>Article 2: Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052902</a></p>
<p><strong>Summary:</strong> This study investigates the intricate sympathovagal crosstalk involved in ventricular arrhythmias, focusing on the role of neuropeptide Y. Researchers found that vagal nerve stimulation reduces neuropeptide Y levels through a muscarinic receptor-mediated mechanism. Crucially, blockade of presynaptic Y2-receptors was shown to further enhance these vagal effects, leading to a reduction in neuropeptide Y. This discovery elucidates a novel therapeutic target to modulate autonomic balance and potentially mitigate ventricular arrhythmia risk.</p>
<h4>Article 3: Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41048027" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41048027</a></p>
<p><strong>Summary:</strong> This retrospective cohort study investigated the association between postpartum blood pressure and the development of later hypertension following a hypertensive disorder of pregnancy. Researchers identified that blood pressure measurements taken 15 to 90 days after delivery are significantly associated with incident hypertension in women without pre-existing conditions. This finding emphasizes the critical importance of timely blood pressure monitoring during the early postpartum period for cardiovascular disease prevention strategies.</p>
<h4>Article 4: Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41054844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41054844</a></p>
<p><strong>Summary:</strong> This study explored the role of mitochondrial calcium in cardiomyocyte function, specifically focusing on the mitochondrial calcium uniporter complex and its subunit M.I.C.U.1, which regulates mitochondrial calcium uptake. Researchers discovered that the left and right ventricles exhibit distinct adaptive mechanisms to elevated mitochondrial calcium levels. This fundamental difference in ventricular calcium handling provides critical insights into the pathophysiology of heart failure and may inform ventricle-specific therapeutic strategies.</p>
<h4>Article 5: Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41054846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41054846</a></p>
<p><strong>Summary:</strong> This study introduces a miniaturized, closed-loop vagus nerve stimulation system designed to enhance recovery in individuals with chronic stroke. Building on the established benefits of vagus nerve stimulation combined with task-oriented training for upper limb recovery, this new system demonstrated significant and lasting improvements. The development offers a more refined and potentially less invasive approach compared to conventional devices, addressing a critical need in long-term stroke rehabilitation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity. This review article proposes chronomodulated chemotherapy as a preventive strategy to mitigate anthracycline-induced cardiotoxicity. It highlights that adjusting anthracycline administration time to the body&#8217;s circadian rhythms may reduce the risk of heart failure in cancer patients and survivors. The concept is based on the significant role of circadian rhythms in cardiovascular physiology, suggesting a time-dependent variation in cardiac sensitivity to these chemotherapeutic agents.</p>
<p>Article number two. Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation. This study investigates the intricate sympathovagal crosstalk involved in ventricular arrhythmias, focusing on the role of neuropeptide Y. Researchers found that vagal nerve stimulation reduces neuropeptide Y levels through a muscarinic receptor-mediated mechanism. Crucially, blockade of presynaptic Y2-receptors was shown to further enhance these vagal effects, leading to a reduction in neuropeptide Y. This discovery elucidates a novel therapeutic target to modulate autonomic balance and potentially mitigate ventricular arrhythmia risk.</p>
<p>Article number three. Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension. This retrospective cohort study investigated the association between postpartum blood pressure and the development of later hypertension following a hypertensive disorder of pregnancy. Researchers identified that blood pressure measurements taken 15 to 90 days after delivery are significantly associated with incident hypertension in women without pre-existing conditions. This finding emphasizes the critical importance of timely blood pressure monitoring during the early postpartum period for cardiovascular disease prevention strategies.</p>
<p>Article number four. Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles. This study explored the role of mitochondrial calcium in cardiomyocyte function, specifically focusing on the mitochondrial calcium uniporter complex and its subunit M.I.C.U.1, which regulates mitochondrial calcium uptake. Researchers discovered that the left and right ventricles exhibit distinct adaptive mechanisms to elevated mitochondrial calcium levels. This fundamental difference in ventricular calcium handling provides critical insights into the pathophysiology of heart failure and may inform ventricle-specific therapeutic strategies.</p>
<p>Article number five. Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke. This study introduces a miniaturized, closed-loop vagus nerve stimulation system designed to enhance recovery in individuals with chronic stroke. Building on the established benefits of vagus nerve stimulation combined with task-oriented training for upper limb recovery, this new system demonstrated significant and lasting improvements. The development offers a more refined and potentially less invasive approach compared to conventional devices, addressing a critical need in long-term stroke rehabilitation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Ventricular arrhythmias, blood pressure monitoring, sympathoexcitation, cardiomyocyte function, M.I.C.U.1, Anthracycline cardiotoxicity, heart failure, muscarinic receptors, vagal nerve stimulation, postpartum hypertension, chronic stroke, chronotherapy, upper limb recovery, circadian rhythms, chemotherapy, Mitochondrial calcium, Vagus nerve stimulation, cardiovascular disease prevention, left ventricle, Y2-receptor blockade, neurorehabilitation, neuropeptide Y, incident hypertension, right ventricle, Hypertensive disorder of pregnancy, miniaturized device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/">Y2-Receptor Blockade Quells Ventricular Arrhythmias. 10/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like Ventricular arrhythmias and blood pressure monitoring. Key takeaway: Y2-Receptor Blockade Quells Ventricular Arrhythmias..
Article Li]]></itunes:subtitle>
	<itunes:episode>101</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like Ventricular arrhythmias and blood pressure monitoring. Key takeaway: Y2-Receptor Blockade Quells Ventricular Arrhythmias..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41052913">Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity.</a> (Cardiovascular research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41052902">Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation.</a> (Cardiovascular research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41048027">Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41054844">Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41054846">Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke.</a> (Stroke)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/">https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052913" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052913</a></p>
<p><strong>Summary:</strong> This review article proposes chronomodulated chemotherapy as a preventive strategy to mitigate anthracycline-induced cardiotoxicity. It highlights that adjusting anthracycline administration time to the body&#8217;s circadian rhythms may reduce the risk of heart failure in cancer patients and survivors. The concept is based on the significant role of circadian rhythms in cardiovascular physiology, suggesting a time-dependent variation in cardiac sensitivity to these chemotherapeutic agents.</p>
<h4>Article 2: Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052902" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052902</a></p>
<p><strong>Summary:</strong> This study investigates the intricate sympathovagal crosstalk involved in ventricular arrhythmias, focusing on the role of neuropeptide Y. Researchers found that vagal nerve stimulation reduces neuropeptide Y levels through a muscarinic receptor-mediated mechanism. Crucially, blockade of presynaptic Y2-receptors was shown to further enhance these vagal effects, leading to a reduction in neuropeptide Y. This discovery elucidates a novel therapeutic target to modulate autonomic balance and potentially mitigate ventricular arrhythmia risk.</p>
<h4>Article 3: Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41048027" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41048027</a></p>
<p><strong>Summary:</strong> This retrospective cohort study investigated the association between postpartum blood pressure and the development of later hypertension following a hypertensive disorder of pregnancy. Researchers identified that blood pressure measurements taken 15 to 90 days after delivery are significantly associated with incident hypertension in women without pre-existing conditions. This finding emphasizes the critical importance of timely blood pressure monitoring during the early postpartum period for cardiovascular disease prevention strategies.</p>
<h4>Article 4: Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41054844" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41054844</a></p>
<p><strong>Summary:</strong> This study explored the role of mitochondrial calcium in cardiomyocyte function, specifically focusing on the mitochondrial calcium uniporter complex and its subunit M.I.C.U.1, which regulates mitochondrial calcium uptake. Researchers discovered that the left and right ventricles exhibit distinct adaptive mechanisms to elevated mitochondrial calcium levels. This fundamental difference in ventricular calcium handling provides critical insights into the pathophysiology of heart failure and may inform ventricle-specific therapeutic strategies.</p>
<h4>Article 5: Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41054846" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41054846</a></p>
<p><strong>Summary:</strong> This study introduces a miniaturized, closed-loop vagus nerve stimulation system designed to enhance recovery in individuals with chronic stroke. Building on the established benefits of vagus nerve stimulation combined with task-oriented training for upper limb recovery, this new system demonstrated significant and lasting improvements. The development offers a more refined and potentially less invasive approach compared to conventional devices, addressing a critical need in long-term stroke rehabilitation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity. This review article proposes chronomodulated chemotherapy as a preventive strategy to mitigate anthracycline-induced cardiotoxicity. It highlights that adjusting anthracycline administration time to the body&#8217;s circadian rhythms may reduce the risk of heart failure in cancer patients and survivors. The concept is based on the significant role of circadian rhythms in cardiovascular physiology, suggesting a time-dependent variation in cardiac sensitivity to these chemotherapeutic agents.</p>
<p>Article number two. Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation. This study investigates the intricate sympathovagal crosstalk involved in ventricular arrhythmias, focusing on the role of neuropeptide Y. Researchers found that vagal nerve stimulation reduces neuropeptide Y levels through a muscarinic receptor-mediated mechanism. Crucially, blockade of presynaptic Y2-receptors was shown to further enhance these vagal effects, leading to a reduction in neuropeptide Y. This discovery elucidates a novel therapeutic target to modulate autonomic balance and potentially mitigate ventricular arrhythmia risk.</p>
<p>Article number three. Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension. This retrospective cohort study investigated the association between postpartum blood pressure and the development of later hypertension following a hypertensive disorder of pregnancy. Researchers identified that blood pressure measurements taken 15 to 90 days after delivery are significantly associated with incident hypertension in women without pre-existing conditions. This finding emphasizes the critical importance of timely blood pressure monitoring during the early postpartum period for cardiovascular disease prevention strategies.</p>
<p>Article number four. Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles. This study explored the role of mitochondrial calcium in cardiomyocyte function, specifically focusing on the mitochondrial calcium uniporter complex and its subunit M.I.C.U.1, which regulates mitochondrial calcium uptake. Researchers discovered that the left and right ventricles exhibit distinct adaptive mechanisms to elevated mitochondrial calcium levels. This fundamental difference in ventricular calcium handling provides critical insights into the pathophysiology of heart failure and may inform ventricle-specific therapeutic strategies.</p>
<p>Article number five. Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke. This study introduces a miniaturized, closed-loop vagus nerve stimulation system designed to enhance recovery in individuals with chronic stroke. Building on the established benefits of vagus nerve stimulation combined with task-oriented training for upper limb recovery, this new system demonstrated significant and lasting improvements. The development offers a more refined and potentially less invasive approach compared to conventional devices, addressing a critical need in long-term stroke rehabilitation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Ventricular arrhythmias, blood pressure monitoring, sympathoexcitation, cardiomyocyte function, M.I.C.U.1, Anthracycline cardiotoxicity, heart failure, muscarinic receptors, vagal nerve stimulation, postpartum hypertension, chronic stroke, chronotherapy, upper limb recovery, circadian rhythms, chemotherapy, Mitochondrial calcium, Vagus nerve stimulation, cardiovascular disease prevention, left ventricle, Y2-receptor blockade, neurorehabilitation, neuropeptide Y, incident hypertension, right ventricle, Hypertensive disorder of pregnancy, miniaturized device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/">Y2-Receptor Blockade Quells Ventricular Arrhythmias. 10/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251008_060043.mp3" length="3764810" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like Ventricular arrhythmias and blood pressure monitoring. Key takeaway: Y2-Receptor Blockade Quells Ventricular Arrhythmias..
Article Links:
Article 1: Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity. (Cardiovascular research)
Article 2: Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation. (Cardiovascular research)
Article 3: Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension. (Hypertension (Dallas, Tex. : 1979))
Article 4: Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles. (Circulation research)
Article 5: Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke. (Stroke)
Full episode page: https://podcast.explainheart.com/podcast/y2-receptor-blockade-quells-ventricular-arrhythmias-10-08-25/
 Featured Articles
Article 1: Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41052913
Summary: This review article proposes chronomodulated chemotherapy as a preventive strategy to mitigate anthracycline-induced cardiotoxicity. It highlights that adjusting anthracycline administration time to the body&#8217;s circadian rhythms may reduce the risk of heart failure in cancer patients and survivors. The concept is based on the significant role of circadian rhythms in cardiovascular physiology, suggesting a time-dependent variation in cardiac sensitivity to these chemotherapeutic agents.
Article 2: Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41052902
Summary: This study investigates the intricate sympathovagal crosstalk involved in ventricular arrhythmias, focusing on the role of neuropeptide Y. Researchers found that vagal nerve stimulation reduces neuropeptide Y levels through a muscarinic receptor-mediated mechanism. Crucially, blockade of presynaptic Y2-receptors was shown to further enhance these vagal effects, leading to a reduction in neuropeptide Y. This discovery elucidates a novel therapeutic target to modulate autonomic balance and potentially mitigate ventricular arrhythmia risk.
Article 3: Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41048027
Summary: This retrospective cohort study investigated the association between postpartum blood pressure and the development of later hypertension following a hypertensive disorder of pregnancy. Researchers identified that blood pressure measurements taken 15 to 90 days after delivery are significantly associated with incident hypertension in women without pre-existing conditions. This finding emphasizes the critical importance of timely blood pressure monitoring during the early postpartum period for cardiovascular disease prevention strategies.
Article 4: Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41054844
Summary: This study explored the role of mitochondrial calcium in cardiomyocyte function, specifically focusing on the mitochondrial calcium uniporter complex and its subunit M.I.C.U.1, which regulates mitochondrial calcium uptake. Researchers discovered that the left and right ventricles exhibit distinct adaptive mechanisms to elevated mitochondrial calcium levels. This fundamental difference in ventricular calcium handling provides critical insights into the path]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like Ventricular arrhythmias and blood pressure monitoring. Key takeaway: Y2-Receptor Blockade Quells Ventricular Arrhythmias..
Article Links:
Article 1: Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity. (Cardiovascular research)
Article 2: Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn Reduce NPY levels via muscarinic receptor activation. (Cardiovascular research)
Article 3: Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension. (Hypertension (Dallas, Tex. : 1979))
Article 4: Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles. (Circulation research)
Article 5: Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke. (Stroke)
Full episode page: https]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ischemic Heart Disease Rising in Young Women 10/08/25</title>
	<link>https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/</link>
	<pubDate>Wed, 08 Oct 2025 06:58:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like undiagnosed heart failure and fractional flow reserve. Key takeaway: Ischemic Heart Disease Rising in Young Women.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41056188">Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41056187">Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41055899">Stable angina in young women.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41057251">Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41055670">Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/">https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41056188" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41056188</a></p>
<p><strong>Summary:</strong> The FAIR randomized trial aims to compare Fractional Flow Reserve (F.F.R.)-guided renal artery revascularization with traditional angiography-guided revascularization for atherosclerotic renovascular hypertension. This ongoing study enrolled 101 patients with atherosclerotic renal artery stenosis (A.R.A.S.) and hypertension, randomizing them to F.F.R.-guided or angiography-guided groups. In the angiography group, stenting was performed irrespective of F.F.R. values, but specific outcomes or findings are not yet reported.</p>
<h4>Article 2: Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41056187" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41056187</a></p>
<p><strong>Summary:</strong> This study investigates whether genetically proxied body weight reduction through the Glucose-Dependent Insulinotropic Polypeptide (G.I.P.) receptor pathway can lower cardiovascular disease risk. It also aims to compare this effect with polygenic weight reduction pathways. The abstract describes the study&#8217;s objectives and methodology, but it does not present specific findings or conclusions regarding cardiovascular outcomes.</p>
<h4>Article 3: Stable angina in young women.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41055899" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41055899</a></p>
<p><strong>Summary:</strong> Ischemic Heart Disease (I.H.D.) prevalence is concerningly rising in younger women, with a 3 percent increase between 1990 and 2019, and I.H.D. mortality in this demographic is increasing in some high-income countries. Angina serves as the primary presenting symptom for suspected I.H.D. and coronary artery disease. This article highlights critical epidemiological trends emphasizing the increasing burden of Ischemic Heart Disease in young women globally, warranting heightened clinical attention.</p>
<h4>Article 4: Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41057251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41057251</a></p>
<p><strong>Summary:</strong> This retrospective cohort study aimed to characterize twelve-lead Electrocardiogram (E.C.G.) findings and identify potential E.C.G. predictors of Major Adverse Cardiovascular Events (M.A.C.E.) in children with RASopathy-associated hypertrophic cardiomyopathy (H.C.M.). Major Adverse Cardiovascular Events included cardiovascular mortality, resuscitated cardiac arrest, ventricular arrhythmias, appropriate implantable cardioverter defibrillator therapy, or heart failure. While the study design and its objectives are detailed, the abstract does not report specific E.C.G. characteristics or identified prognostic implications.</p>
<h4>Article 5: Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41055670" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41055670</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of the Systolic Blood Pressure Intervention Trial (S.P.R.I.N.T.) evaluated the Heart Failure with Preserved Ejection Fraction (H.F.pEF)-A.B.A. score&#8217;s utility in identifying high-risk, undiagnosed H.F.pEF subgroups with elevated cardiovascular event rates. The H.F.pEF-A.B.A. score successfully identified these high-risk individuals with undiagnosed H.F.pEF. While the analysis aimed to assess intensive blood pressure control&#8217;s impact, specific cardiovascular benefits or outcomes related to this intervention are not detailed in the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial. The FAIR randomized trial aims to compare Fractional Flow Reserve (F.F.R.)-guided renal artery revascularization with traditional angiography-guided revascularization for atherosclerotic renovascular hypertension. This ongoing study enrolled 101 patients with atherosclerotic renal artery stenosis (A.R.A.S.) and hypertension, randomizing them to F.F.R.-guided or angiography-guided groups. In the angiography group, stenting was performed irrespective of F.F.R. values, but specific outcomes or findings are not yet reported.</p>
<p>Article number two. Genetic variants of glucose-dependent insulinotropic polypeptide (G.I.P.) signalling as proxy for body weight reduction and cardiovascular risk. This study investigates whether genetically proxied body weight reduction through the Glucose-Dependent Insulinotropic Polypeptide (G.I.P.) receptor pathway can lower cardiovascular disease risk. It also aims to compare this effect with polygenic weight reduction pathways. The abstract describes the study&#8217;s objectives and methodology, but it does not present specific findings or conclusions regarding cardiovascular outcomes.</p>
<p>Article number three. Stable angina in young women. Ischemic Heart Disease (I.H.D.) prevalence is concerningly rising in younger women, with a 3 percent increase between 1990 and 2019, and I.H.D. mortality in this demographic is increasing in some high-income countries. Angina serves as the primary presenting symptom for suspected I.H.D. and coronary artery disease. This article highlights critical epidemiological trends emphasizing the increasing burden of Ischemic Heart Disease in young women globally, warranting heightened clinical attention.</p>
<p>Article number four. Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy. This retrospective cohort study aimed to characterize twelve-lead Electrocardiogram (E.C.G.) findings and identify potential E.C.G. predictors of Major Adverse Cardiovascular Events (M.A.C.E.) in children with RASopathy-associated hypertrophic cardiomyopathy (H.C.M.). Major Adverse Cardiovascular Events included cardiovascular mortality, resuscitated cardiac arrest, ventricular arrhythmias, appropriate implantable cardioverter defibrillator therapy, or heart failure. While the study design and its objectives are detailed, the abstract does not report specific E.C.G. characteristics or identified prognostic implications.</p>
<p>Article number five. Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed H.F.pEF patients. A post-hoc analysis of the Systolic Blood Pressure Intervention Trial (S.P.R.I.N.T.) evaluated the Heart Failure with Preserved Ejection Fraction (H.F.pEF)-A.B.A. score&#8217;s utility in identifying high-risk, undiagnosed H.F.pEF subgroups with elevated cardiovascular event rates. The H.F.pEF-A.B.A. score successfully identified these high-risk individuals with undiagnosed H.F.pEF. While the analysis aimed to assess intensive blood pressure control&#8217;s impact, specific cardiovascular benefits or outcomes related to this intervention are not detailed in the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>undiagnosed heart failure, fractional flow reserve, genetic variants, pediatric cardiology, revascularization, Ischemic heart disease, epidemiology, body weight reduction, intensive blood pressure control, young women, G.I.P. receptor, stable angina, renal artery stenting, RASopathy, Renal artery stenosis, electrocardiogram, Hypertrophic cardiomyopathy, H.F.pEF-A.B.A. score, S.P.R.I.N.T. trial, Glucose-dependent insulinotropic polypeptide, major adverse cardiovascular events, atherosclerotic renovascular hypertension, Heart failure with preserved ejection fraction, cardiovascular mortality, cardiovascular risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/">Ischemic Heart Disease Rising in Young Women 10/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like undiagnosed heart failure and fractional flow reserve. Key takeaway: Ischemic Heart Disease Rising in Young Women.
Article Links:
Art]]></itunes:subtitle>
	<itunes:episode>100</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like undiagnosed heart failure and fractional flow reserve. Key takeaway: Ischemic Heart Disease Rising in Young Women.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41056188">Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41056187">Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41055899">Stable angina in young women.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41057251">Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41055670">Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/">https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41056188" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41056188</a></p>
<p><strong>Summary:</strong> The FAIR randomized trial aims to compare Fractional Flow Reserve (F.F.R.)-guided renal artery revascularization with traditional angiography-guided revascularization for atherosclerotic renovascular hypertension. This ongoing study enrolled 101 patients with atherosclerotic renal artery stenosis (A.R.A.S.) and hypertension, randomizing them to F.F.R.-guided or angiography-guided groups. In the angiography group, stenting was performed irrespective of F.F.R. values, but specific outcomes or findings are not yet reported.</p>
<h4>Article 2: Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41056187" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41056187</a></p>
<p><strong>Summary:</strong> This study investigates whether genetically proxied body weight reduction through the Glucose-Dependent Insulinotropic Polypeptide (G.I.P.) receptor pathway can lower cardiovascular disease risk. It also aims to compare this effect with polygenic weight reduction pathways. The abstract describes the study&#8217;s objectives and methodology, but it does not present specific findings or conclusions regarding cardiovascular outcomes.</p>
<h4>Article 3: Stable angina in young women.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41055899" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41055899</a></p>
<p><strong>Summary:</strong> Ischemic Heart Disease (I.H.D.) prevalence is concerningly rising in younger women, with a 3 percent increase between 1990 and 2019, and I.H.D. mortality in this demographic is increasing in some high-income countries. Angina serves as the primary presenting symptom for suspected I.H.D. and coronary artery disease. This article highlights critical epidemiological trends emphasizing the increasing burden of Ischemic Heart Disease in young women globally, warranting heightened clinical attention.</p>
<h4>Article 4: Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41057251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41057251</a></p>
<p><strong>Summary:</strong> This retrospective cohort study aimed to characterize twelve-lead Electrocardiogram (E.C.G.) findings and identify potential E.C.G. predictors of Major Adverse Cardiovascular Events (M.A.C.E.) in children with RASopathy-associated hypertrophic cardiomyopathy (H.C.M.). Major Adverse Cardiovascular Events included cardiovascular mortality, resuscitated cardiac arrest, ventricular arrhythmias, appropriate implantable cardioverter defibrillator therapy, or heart failure. While the study design and its objectives are detailed, the abstract does not report specific E.C.G. characteristics or identified prognostic implications.</p>
<h4>Article 5: Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41055670" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41055670</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of the Systolic Blood Pressure Intervention Trial (S.P.R.I.N.T.) evaluated the Heart Failure with Preserved Ejection Fraction (H.F.pEF)-A.B.A. score&#8217;s utility in identifying high-risk, undiagnosed H.F.pEF subgroups with elevated cardiovascular event rates. The H.F.pEF-A.B.A. score successfully identified these high-risk individuals with undiagnosed H.F.pEF. While the analysis aimed to assess intensive blood pressure control&#8217;s impact, specific cardiovascular benefits or outcomes related to this intervention are not detailed in the abstract.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial. The FAIR randomized trial aims to compare Fractional Flow Reserve (F.F.R.)-guided renal artery revascularization with traditional angiography-guided revascularization for atherosclerotic renovascular hypertension. This ongoing study enrolled 101 patients with atherosclerotic renal artery stenosis (A.R.A.S.) and hypertension, randomizing them to F.F.R.-guided or angiography-guided groups. In the angiography group, stenting was performed irrespective of F.F.R. values, but specific outcomes or findings are not yet reported.</p>
<p>Article number two. Genetic variants of glucose-dependent insulinotropic polypeptide (G.I.P.) signalling as proxy for body weight reduction and cardiovascular risk. This study investigates whether genetically proxied body weight reduction through the Glucose-Dependent Insulinotropic Polypeptide (G.I.P.) receptor pathway can lower cardiovascular disease risk. It also aims to compare this effect with polygenic weight reduction pathways. The abstract describes the study&#8217;s objectives and methodology, but it does not present specific findings or conclusions regarding cardiovascular outcomes.</p>
<p>Article number three. Stable angina in young women. Ischemic Heart Disease (I.H.D.) prevalence is concerningly rising in younger women, with a 3 percent increase between 1990 and 2019, and I.H.D. mortality in this demographic is increasing in some high-income countries. Angina serves as the primary presenting symptom for suspected I.H.D. and coronary artery disease. This article highlights critical epidemiological trends emphasizing the increasing burden of Ischemic Heart Disease in young women globally, warranting heightened clinical attention.</p>
<p>Article number four. Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy. This retrospective cohort study aimed to characterize twelve-lead Electrocardiogram (E.C.G.) findings and identify potential E.C.G. predictors of Major Adverse Cardiovascular Events (M.A.C.E.) in children with RASopathy-associated hypertrophic cardiomyopathy (H.C.M.). Major Adverse Cardiovascular Events included cardiovascular mortality, resuscitated cardiac arrest, ventricular arrhythmias, appropriate implantable cardioverter defibrillator therapy, or heart failure. While the study design and its objectives are detailed, the abstract does not report specific E.C.G. characteristics or identified prognostic implications.</p>
<p>Article number five. Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed H.F.pEF patients. A post-hoc analysis of the Systolic Blood Pressure Intervention Trial (S.P.R.I.N.T.) evaluated the Heart Failure with Preserved Ejection Fraction (H.F.pEF)-A.B.A. score&#8217;s utility in identifying high-risk, undiagnosed H.F.pEF subgroups with elevated cardiovascular event rates. The H.F.pEF-A.B.A. score successfully identified these high-risk individuals with undiagnosed H.F.pEF. While the analysis aimed to assess intensive blood pressure control&#8217;s impact, specific cardiovascular benefits or outcomes related to this intervention are not detailed in the abstract. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>undiagnosed heart failure, fractional flow reserve, genetic variants, pediatric cardiology, revascularization, Ischemic heart disease, epidemiology, body weight reduction, intensive blood pressure control, young women, G.I.P. receptor, stable angina, renal artery stenting, RASopathy, Renal artery stenosis, electrocardiogram, Hypertrophic cardiomyopathy, H.F.pEF-A.B.A. score, S.P.R.I.N.T. trial, Glucose-dependent insulinotropic polypeptide, major adverse cardiovascular events, atherosclerotic renovascular hypertension, Heart failure with preserved ejection fraction, cardiovascular mortality, cardiovascular risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/">Ischemic Heart Disease Rising in Young Women 10/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251008_025655.mp3" length="4186531" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like undiagnosed heart failure and fractional flow reserve. Key takeaway: Ischemic Heart Disease Rising in Young Women.
Article Links:
Article 1: Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial. (European heart journal)
Article 2: Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk. (European heart journal)
Article 3: Stable angina in young women. (European heart journal)
Article 4: Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy. (Heart (British Cardiac Society))
Article 5: Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/ischemic-heart-disease-rising-in-young-women-10-08-25/
 Featured Articles
Article 1: Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41056188
Summary: The FAIR randomized trial aims to compare Fractional Flow Reserve (F.F.R.)-guided renal artery revascularization with traditional angiography-guided revascularization for atherosclerotic renovascular hypertension. This ongoing study enrolled 101 patients with atherosclerotic renal artery stenosis (A.R.A.S.) and hypertension, randomizing them to F.F.R.-guided or angiography-guided groups. In the angiography group, stenting was performed irrespective of F.F.R. values, but specific outcomes or findings are not yet reported.
Article 2: Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41056187
Summary: This study investigates whether genetically proxied body weight reduction through the Glucose-Dependent Insulinotropic Polypeptide (G.I.P.) receptor pathway can lower cardiovascular disease risk. It also aims to compare this effect with polygenic weight reduction pathways. The abstract describes the study&#8217;s objectives and methodology, but it does not present specific findings or conclusions regarding cardiovascular outcomes.
Article 3: Stable angina in young women.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41055899
Summary: Ischemic Heart Disease (I.H.D.) prevalence is concerningly rising in younger women, with a 3 percent increase between 1990 and 2019, and I.H.D. mortality in this demographic is increasing in some high-income countries. Angina serves as the primary presenting symptom for suspected I.H.D. and coronary artery disease. This article highlights critical epidemiological trends emphasizing the increasing burden of Ischemic Heart Disease in young women globally, warranting heightened clinical attention.
Article 4: Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41057251
Summary: This retrospective cohort study aimed to characterize twelve-lead Electrocardiogram (E.C.G.) findings and identify potential E.C.G. predictors of Major Adverse Cardiovascular Events (M.A.C.E.) in children with RASopathy-associated hypertrophic cardiomyopathy (H.C.M.). Major Adverse Cardiovascular Events included cardiovascular mortality, resuscitated cardiac arrest, ventricular arrhythmias, appropriate implantable cardioverter defibrillator therapy, or heart failure. While the study design and its objectives are detailed, the abstr]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 08, 2025. This episode summarizes 5 key cardiology studies on topics like undiagnosed heart failure and fractional flow reserve. Key takeaway: Ischemic Heart Disease Rising in Young Women.
Article Links:
Article 1: Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial. (European heart journal)
Article 2: Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk. (European heart journal)
Article 3: Stable angina in young women. (European heart journal)
Article 4: Characterisation and prognostic implications of the 12-lead electrocardiogram in children with RASopathy-associated hypertrophic cardiomyopathy. (Heart (British Cardiac Society))
Article 5: Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients. (ESC heart failure)
Full epis]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Predicting Cardiac Events in Adult Type 1 Diabetes 10/07/25</title>
	<link>https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/</link>
	<pubDate>Tue, 07 Oct 2025 10:01:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like preventive therapy and molecular classifiers. Key takeaway: Predicting Cardiac Events in Adult Type 1 Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41048030">Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40742158">Standards for cardiac telerehabilitation.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40605456">First myocardial infarction: risk factors, symptoms, and medical therapy.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40364641">Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41052637">Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/">https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41048030" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41048030</a></p>
<p><strong>Summary:</strong> The Contemporary Burden of Cardiovascular Disease in Pregnancy study aims to comprehensively characterize the contemporary prevalence and secular trends of maternal cardiovascular comorbidities and pregnancy-related cardiovascular disease in a real-world electronic health record cohort. This multi-institutional effort seeks to provide critical insights into cardiovascular complications, which are the leading causes of maternal mortality and morbidity. The study&#8217;s findings are expected to inform clinical practice and public health strategies for pregnant individuals.</p>
<h4>Article 2: Standards for cardiac telerehabilitation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40742158" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40742158</a></p>
<p><strong>Summary:</strong> Participation in recommended comprehensive cardiac rehabilitation programs remains low, at only 30 to 40 percent of eligible patients in Europe, largely due to practical barriers such as transport and scheduling. This article establishes standards for cardiac telerehabilitation, proposing it as an essential strategy to overcome these barriers and significantly improve patient access and uptake of secondary prevention programs. Implementing these standards for remote delivery of multidisciplinary care is crucial for enhancing cardiovascular disease management.</p>
<h4>Article 3: First myocardial infarction: risk factors, symptoms, and medical therapy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40605456" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40605456</a></p>
<p><strong>Summary:</strong> This real-world study aims to investigate the prevalence of documented coronary artery disease risk factors, symptoms, physician visits, and preventive therapy uptake prior to a patient&#8217;s first myocardial infarction. Despite existing clinical risk algorithms, the global burden of atherosclerotic cardiovascular disease continues to rise, underscoring the need for better insights into pre-myocardial infarction presentation. The study&#8217;s anticipated findings will provide valuable data to improve early identification and preventive strategies for acute coronary events.</p>
<h4>Article 4: Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40364641" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40364641</a></p>
<p><strong>Summary:</strong> A large-scale registry study utilizing the Swedish National Diabetes Register and Total Population Register assessed mortality and major adverse cardiovascular events in over 10,000 adult-onset Type 1 Diabetes patients, comparing them to Type 2 Diabetes patients and population controls. This research identified crucial prognostic factors, particularly in those diagnosed at age 40 or older, providing robust data on an under-investigated population. The findings offer significant implications for refined risk stratification and targeted management strategies to improve cardiovascular outcomes in adult-onset Type 1 Diabetes.</p>
<h4>Article 5: Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052637" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052637</a></p>
<p><strong>Summary:</strong> This prospective, single-center study employed microarray analysis of procurement biopsies from 276 deceased donor kidneys to identify molecular phenotypes predictive of post-transplant outcomes. Leveraging machine learning classifiers, researchers demonstrated that donor kidney tissue transcriptomics, combined with clinical variables like age and body mass index, offers a novel dimension for predicting transplant success. This molecular approach represents a breakthrough for optimizing donor kidney assessment and improving long-term patient and graft outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort. The Contemporary Burden of Cardiovascular Disease in Pregnancy study aims to comprehensively characterize the contemporary prevalence and secular trends of maternal cardiovascular comorbidities and pregnancy-related cardiovascular disease in a real-world electronic health record cohort. This multi-institutional effort seeks to provide critical insights into cardiovascular complications, which are the leading causes of maternal mortality and morbidity. The study&#8217;s findings are expected to inform clinical practice and public health strategies for pregnant individuals.</p>
<p>Article number two. Standards for cardiac telerehabilitation. Participation in recommended comprehensive cardiac rehabilitation programs remains low, at only 30 to 40 percent of eligible patients in Europe, largely due to practical barriers such as transport and scheduling. This article establishes standards for cardiac telerehabilitation, proposing it as an essential strategy to overcome these barriers and significantly improve patient access and uptake of secondary prevention programs. Implementing these standards for remote delivery of multidisciplinary care is crucial for enhancing cardiovascular disease management.</p>
<p>Article number three. First myocardial infarction: risk factors, symptoms, and medical therapy. This real-world study aims to investigate the prevalence of documented coronary artery disease risk factors, symptoms, physician visits, and preventive therapy uptake prior to a patient&#8217;s first myocardial infarction. Despite existing clinical risk algorithms, the global burden of atherosclerotic cardiovascular disease continues to rise, underscoring the need for better insights into pre-myocardial infarction presentation. The study&#8217;s anticipated findings will provide valuable data to improve early identification and preventive strategies for acute coronary events.</p>
<p>Article number four. Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. A large-scale registry study utilizing the Swedish National Diabetes Register and Total Population Register assessed mortality and major adverse cardiovascular events in over 10,000 adult-onset Type 1 Diabetes patients, comparing them to Type 2 Diabetes patients and population controls. This research identified crucial prognostic factors, particularly in those diagnosed at age 40 or older, providing robust data on an under-investigated population. The findings offer significant implications for refined risk stratification and targeted management strategies to improve cardiovascular outcomes in adult-onset Type 1 Diabetes.</p>
<p>Article number five. Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes. This prospective, single-center study employed microarray analysis of procurement biopsies from 276 deceased donor kidneys to identify molecular phenotypes predictive of post-transplant outcomes. Leveraging machine learning classifiers, researchers demonstrated that donor kidney tissue transcriptomics, combined with clinical variables like age and body mass index, offers a novel dimension for predicting transplant success. This molecular approach represents a breakthrough for optimizing donor kidney assessment and improving long-term patient and graft outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preventive therapy, molecular classifiers, post-transplant outcomes, cardiovascular disease, deceased donors, myocardial infarction, acute coronary events, cardiovascular disease management, major adverse cardiovascular events, Type 1 Diabetes, mortality, transcriptomics, kidney transplantation, risk stratification, electronic health record, secondary prevention, cardiac rehabilitation, pregnancy, telerehabilitation, prognostic factors, risk factors, cardiovascular complications, maternal mortality, patient participation, atherosclerotic cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/">Predicting Cardiac Events in Adult Type 1 Diabetes 10/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like preventive therapy and molecular classifiers. Key takeaway: Predicting Cardiac Events in Adult Type 1 Diabetes.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>99</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like preventive therapy and molecular classifiers. Key takeaway: Predicting Cardiac Events in Adult Type 1 Diabetes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41048030">Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40742158">Standards for cardiac telerehabilitation.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40605456">First myocardial infarction: risk factors, symptoms, and medical therapy.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40364641">Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41052637">Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes.</a> (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/">https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41048030" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41048030</a></p>
<p><strong>Summary:</strong> The Contemporary Burden of Cardiovascular Disease in Pregnancy study aims to comprehensively characterize the contemporary prevalence and secular trends of maternal cardiovascular comorbidities and pregnancy-related cardiovascular disease in a real-world electronic health record cohort. This multi-institutional effort seeks to provide critical insights into cardiovascular complications, which are the leading causes of maternal mortality and morbidity. The study&#8217;s findings are expected to inform clinical practice and public health strategies for pregnant individuals.</p>
<h4>Article 2: Standards for cardiac telerehabilitation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40742158" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40742158</a></p>
<p><strong>Summary:</strong> Participation in recommended comprehensive cardiac rehabilitation programs remains low, at only 30 to 40 percent of eligible patients in Europe, largely due to practical barriers such as transport and scheduling. This article establishes standards for cardiac telerehabilitation, proposing it as an essential strategy to overcome these barriers and significantly improve patient access and uptake of secondary prevention programs. Implementing these standards for remote delivery of multidisciplinary care is crucial for enhancing cardiovascular disease management.</p>
<h4>Article 3: First myocardial infarction: risk factors, symptoms, and medical therapy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40605456" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40605456</a></p>
<p><strong>Summary:</strong> This real-world study aims to investigate the prevalence of documented coronary artery disease risk factors, symptoms, physician visits, and preventive therapy uptake prior to a patient&#8217;s first myocardial infarction. Despite existing clinical risk algorithms, the global burden of atherosclerotic cardiovascular disease continues to rise, underscoring the need for better insights into pre-myocardial infarction presentation. The study&#8217;s anticipated findings will provide valuable data to improve early identification and preventive strategies for acute coronary events.</p>
<h4>Article 4: Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40364641" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40364641</a></p>
<p><strong>Summary:</strong> A large-scale registry study utilizing the Swedish National Diabetes Register and Total Population Register assessed mortality and major adverse cardiovascular events in over 10,000 adult-onset Type 1 Diabetes patients, comparing them to Type 2 Diabetes patients and population controls. This research identified crucial prognostic factors, particularly in those diagnosed at age 40 or older, providing robust data on an under-investigated population. The findings offer significant implications for refined risk stratification and targeted management strategies to improve cardiovascular outcomes in adult-onset Type 1 Diabetes.</p>
<h4>Article 5: Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes.</h4>
<p><strong>Journal:</strong> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41052637" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41052637</a></p>
<p><strong>Summary:</strong> This prospective, single-center study employed microarray analysis of procurement biopsies from 276 deceased donor kidneys to identify molecular phenotypes predictive of post-transplant outcomes. Leveraging machine learning classifiers, researchers demonstrated that donor kidney tissue transcriptomics, combined with clinical variables like age and body mass index, offers a novel dimension for predicting transplant success. This molecular approach represents a breakthrough for optimizing donor kidney assessment and improving long-term patient and graft outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort. The Contemporary Burden of Cardiovascular Disease in Pregnancy study aims to comprehensively characterize the contemporary prevalence and secular trends of maternal cardiovascular comorbidities and pregnancy-related cardiovascular disease in a real-world electronic health record cohort. This multi-institutional effort seeks to provide critical insights into cardiovascular complications, which are the leading causes of maternal mortality and morbidity. The study&#8217;s findings are expected to inform clinical practice and public health strategies for pregnant individuals.</p>
<p>Article number two. Standards for cardiac telerehabilitation. Participation in recommended comprehensive cardiac rehabilitation programs remains low, at only 30 to 40 percent of eligible patients in Europe, largely due to practical barriers such as transport and scheduling. This article establishes standards for cardiac telerehabilitation, proposing it as an essential strategy to overcome these barriers and significantly improve patient access and uptake of secondary prevention programs. Implementing these standards for remote delivery of multidisciplinary care is crucial for enhancing cardiovascular disease management.</p>
<p>Article number three. First myocardial infarction: risk factors, symptoms, and medical therapy. This real-world study aims to investigate the prevalence of documented coronary artery disease risk factors, symptoms, physician visits, and preventive therapy uptake prior to a patient&#8217;s first myocardial infarction. Despite existing clinical risk algorithms, the global burden of atherosclerotic cardiovascular disease continues to rise, underscoring the need for better insights into pre-myocardial infarction presentation. The study&#8217;s anticipated findings will provide valuable data to improve early identification and preventive strategies for acute coronary events.</p>
<p>Article number four. Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. A large-scale registry study utilizing the Swedish National Diabetes Register and Total Population Register assessed mortality and major adverse cardiovascular events in over 10,000 adult-onset Type 1 Diabetes patients, comparing them to Type 2 Diabetes patients and population controls. This research identified crucial prognostic factors, particularly in those diagnosed at age 40 or older, providing robust data on an under-investigated population. The findings offer significant implications for refined risk stratification and targeted management strategies to improve cardiovascular outcomes in adult-onset Type 1 Diabetes.</p>
<p>Article number five. Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes. This prospective, single-center study employed microarray analysis of procurement biopsies from 276 deceased donor kidneys to identify molecular phenotypes predictive of post-transplant outcomes. Leveraging machine learning classifiers, researchers demonstrated that donor kidney tissue transcriptomics, combined with clinical variables like age and body mass index, offers a novel dimension for predicting transplant success. This molecular approach represents a breakthrough for optimizing donor kidney assessment and improving long-term patient and graft outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preventive therapy, molecular classifiers, post-transplant outcomes, cardiovascular disease, deceased donors, myocardial infarction, acute coronary events, cardiovascular disease management, major adverse cardiovascular events, Type 1 Diabetes, mortality, transcriptomics, kidney transplantation, risk stratification, electronic health record, secondary prevention, cardiac rehabilitation, pregnancy, telerehabilitation, prognostic factors, risk factors, cardiovascular complications, maternal mortality, patient participation, atherosclerotic cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/">Predicting Cardiac Events in Adult Type 1 Diabetes 10/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251007_060036.mp3" length="3903154" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like preventive therapy and molecular classifiers. Key takeaway: Predicting Cardiac Events in Adult Type 1 Diabetes.
Article Links:
Article 1: Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort. (Circulation)
Article 2: Standards for cardiac telerehabilitation. (European heart journal)
Article 3: First myocardial infarction: risk factors, symptoms, and medical therapy. (European heart journal)
Article 4: Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. (European heart journal)
Article 5: Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Full episode page: https://podcast.explainheart.com/podcast/predicting-cardiac-events-in-adult-type-1-diabetes-10-07-25/
 Featured Articles
Article 1: Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41048030
Summary: The Contemporary Burden of Cardiovascular Disease in Pregnancy study aims to comprehensively characterize the contemporary prevalence and secular trends of maternal cardiovascular comorbidities and pregnancy-related cardiovascular disease in a real-world electronic health record cohort. This multi-institutional effort seeks to provide critical insights into cardiovascular complications, which are the leading causes of maternal mortality and morbidity. The study&#8217;s findings are expected to inform clinical practice and public health strategies for pregnant individuals.
Article 2: Standards for cardiac telerehabilitation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40742158
Summary: Participation in recommended comprehensive cardiac rehabilitation programs remains low, at only 30 to 40 percent of eligible patients in Europe, largely due to practical barriers such as transport and scheduling. This article establishes standards for cardiac telerehabilitation, proposing it as an essential strategy to overcome these barriers and significantly improve patient access and uptake of secondary prevention programs. Implementing these standards for remote delivery of multidisciplinary care is crucial for enhancing cardiovascular disease management.
Article 3: First myocardial infarction: risk factors, symptoms, and medical therapy.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40605456
Summary: This real-world study aims to investigate the prevalence of documented coronary artery disease risk factors, symptoms, physician visits, and preventive therapy uptake prior to a patient&#8217;s first myocardial infarction. Despite existing clinical risk algorithms, the global burden of atherosclerotic cardiovascular disease continues to rise, underscoring the need for better insights into pre-myocardial infarction presentation. The study&#8217;s anticipated findings will provide valuable data to improve early identification and preventive strategies for acute coronary events.
Article 4: Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40364641
Summary: A large-scale registry study utilizing the Swedish National Diabetes Register and Total Population Register assessed mortality and major adverse cardiovascular events in over 10,000 adult-onset Type 1 Diabetes patients, comparing them to Type 2 Diabetes patients and population controls. This research identified crucial prognostic factors, particularly in those diagnosed at age 40 or older, providing robust data on]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like preventive therapy and molecular classifiers. Key takeaway: Predicting Cardiac Events in Adult Type 1 Diabetes.
Article Links:
Article 1: Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort. (Circulation)
Article 2: Standards for cardiac telerehabilitation. (European heart journal)
Article 3: First myocardial infarction: risk factors, symptoms, and medical therapy. (European heart journal)
Article 4: Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. (European heart journal)
Article 5: Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
Full episode page: https://pod]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Obicetrapib Cuts M.A.C.E. in High-Risk Patients 10/07/25</title>
	<link>https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/</link>
	<pubDate>Tue, 07 Oct 2025 06:57:54 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like Obicetrapib and cholesteryl ester transfer protein inhibitor. Key takeaway: Obicetrapib Cuts M.A.C.E. in High-Risk Patients.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41033741">Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41033739">Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888776">Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40832715">Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40762079">Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/">https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033741</a></p>
<p><strong>Summary:</strong> This retrospective study evaluated percutaneous mechanical debulking with a manual vacuum aspiration device during Cardiac Implantable Electronic Device (C.I.E.D.) extraction for large lead-related vegetations. The technique offers a less invasive alternative to surgical removal, which traditionally carries high morbidity and mortality risks in these complex patients. Findings suggest this approach can improve outcomes, demonstrating its potential as a safer management strategy for C.I.E.D. infections.</p>
<h4>Article 2: Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033739" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033739</a></p>
<p><strong>Summary:</strong> This study investigated the antecedent prevalence of nonoptimally controlled traditional risk factors, including blood pressure, cholesterol, glucose, and body mass index, prior to the onset of cardiovascular disease. Findings revealed a very high prevalence of these nonoptimal risk factors at the time of Coronary Heart Disease, Heart Failure, or stroke diagnosis. This suggests that &#8220;risk factor-free&#8221; cardiovascular disease may often be attributed to subthreshold or unrecognised nonoptimal control, underscoring the critical need for proactive risk factor management.</p>
<h4>Article 3: Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888776" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888776</a></p>
<p><strong>Summary:</strong> This pooled analysis evaluated the effect of the cholesteryl ester transfer protein (C.E.T.P.) inhibitor obicetrapib on major adverse cardiovascular events in high-risk patients. The study compared 10 milligrams of obicetrapib daily versus placebo in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Obicetrapib significantly reduced atherogenic lipids, increased high-density lipoprotein cholesterol, and demonstrated a favorable impact on major adverse cardiovascular event rates, highlighting its potential as a new therapeutic strategy.</p>
<h4>Article 4: Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40832715" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40832715</a></p>
<p><strong>Summary:</strong> This study assessed the prognostic impact of myocarditis-like episodes and their treatment in patients carrying pathogenic or likely pathogenic desmoplakin (D.S.P.) variants. It confirmed that recurrent myocarditis-like episodes are associated with a higher risk of sustained ventricular arrhythmias and progression to Heart Failure in this population. Crucially, the study determined that specific treatments for these inflammatory episodes can modify disease progression and improve long-term outcomes, emphasizing the need for active management.</p>
<h4>Article 5: Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40762079" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40762079</a></p>
<p><strong>Summary:</strong> This single-cell multi-omics study investigated the underlying mechanisms of acute myocarditis by analyzing peripheral blood mononuclear cells from 40 patients. Researchers identified distinct populations of specialized cytotoxic and migratory C.D.8. positive effector T cells unique to acute myocarditis, particularly in its fulminant form. These findings provide critical insights into the immune pathology of this life-threatening cardiac inflammation, paving the way for the development of novel, precision-targeted therapeutic strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction. This retrospective study evaluated percutaneous mechanical debulking with a manual vacuum aspiration device during Cardiac Implantable Electronic Device (C.I.E.D.) extraction for large lead-related vegetations. The technique offers a less invasive alternative to surgical removal, which traditionally carries high morbidity and mortality risks in these complex patients. Findings suggest this approach can improve outcomes, demonstrating its potential as a safer management strategy for C.I.E.D. infections.</p>
<p>Article number two. Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. This study investigated the antecedent prevalence of nonoptimally controlled traditional risk factors, including blood pressure, cholesterol, glucose, and body mass index, prior to the onset of cardiovascular disease. Findings revealed a very high prevalence of these nonoptimal risk factors at the time of Coronary Heart Disease, Heart Failure, or stroke diagnosis. This suggests that &#8220;risk factor-free&#8221; cardiovascular disease may often be attributed to subthreshold or unrecognised nonoptimal control, underscoring the critical need for proactive risk factor management.</p>
<p>Article number three. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. This pooled analysis evaluated the effect of the cholesteryl ester transfer protein (C.E.T.P.) inhibitor obicetrapib on major adverse cardiovascular events in high-risk patients. The study compared 10 milligrams of obicetrapib daily versus placebo in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Obicetrapib significantly reduced atherogenic lipids, increased high-density lipoprotein cholesterol, and demonstrated a favorable impact on major adverse cardiovascular event rates, highlighting its potential as a new therapeutic strategy.</p>
<p>Article number four. Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. This study assessed the prognostic impact of myocarditis-like episodes and their treatment in patients carrying pathogenic or likely pathogenic desmoplakin (D.S.P.) variants. It confirmed that recurrent myocarditis-like episodes are associated with a higher risk of sustained ventricular arrhythmias and progression to Heart Failure in this population. Crucially, the study determined that specific treatments for these inflammatory episodes can modify disease progression and improve long-term outcomes, emphasizing the need for active management.</p>
<p>Article number five. Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis. This single-cell multi-omics study investigated the underlying mechanisms of acute myocarditis by analyzing peripheral blood mononuclear cells from 40 patients. Researchers identified distinct populations of specialized cytotoxic and migratory C.D.8. positive effector T cells unique to acute myocarditis, particularly in its fulminant form. These findings provide critical insights into the immune pathology of this life-threatening cardiac inflammation, paving the way for the development of novel, precision-targeted therapeutic strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Obicetrapib, cholesteryl ester transfer protein inhibitor, percutaneous mechanical debulking, body mass index, major adverse cardiovascular events, endocarditis, desmoplakin variants, single-cell multi-omics, ventricular arrhythmias, prognosis, heart failure, Cardiac Implantable Electronic Device extraction, Heart Failure, C.D.8. positive T cells, fulminant myocarditis, blood pressure, cholesterol, lipid modification, Cardiovascular disease, Acute myocarditis, Coronary Heart Disease, stroke, risk factors, immune pathology, vacuum aspiration, cytotoxic T cells, lead vegetations, glucose, genetic cardiomyopathy, heterozygous familial hypercholesterolemia, Myocarditis, atherosclerotic cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/">Obicetrapib Cuts M.A.C.E. in High-Risk Patients 10/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like Obicetrapib and cholesteryl ester transfer protein inhibitor. Key takeaway: Obicetrapib Cuts M.A.C.E. in High-Risk Patients.
Article ]]></itunes:subtitle>
	<itunes:episode>98</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like Obicetrapib and cholesteryl ester transfer protein inhibitor. Key takeaway: Obicetrapib Cuts M.A.C.E. in High-Risk Patients.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41033741">Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41033739">Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888776">Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40832715">Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40762079">Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/">https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033741</a></p>
<p><strong>Summary:</strong> This retrospective study evaluated percutaneous mechanical debulking with a manual vacuum aspiration device during Cardiac Implantable Electronic Device (C.I.E.D.) extraction for large lead-related vegetations. The technique offers a less invasive alternative to surgical removal, which traditionally carries high morbidity and mortality risks in these complex patients. Findings suggest this approach can improve outcomes, demonstrating its potential as a safer management strategy for C.I.E.D. infections.</p>
<h4>Article 2: Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033739" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033739</a></p>
<p><strong>Summary:</strong> This study investigated the antecedent prevalence of nonoptimally controlled traditional risk factors, including blood pressure, cholesterol, glucose, and body mass index, prior to the onset of cardiovascular disease. Findings revealed a very high prevalence of these nonoptimal risk factors at the time of Coronary Heart Disease, Heart Failure, or stroke diagnosis. This suggests that &#8220;risk factor-free&#8221; cardiovascular disease may often be attributed to subthreshold or unrecognised nonoptimal control, underscoring the critical need for proactive risk factor management.</p>
<h4>Article 3: Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888776" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888776</a></p>
<p><strong>Summary:</strong> This pooled analysis evaluated the effect of the cholesteryl ester transfer protein (C.E.T.P.) inhibitor obicetrapib on major adverse cardiovascular events in high-risk patients. The study compared 10 milligrams of obicetrapib daily versus placebo in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Obicetrapib significantly reduced atherogenic lipids, increased high-density lipoprotein cholesterol, and demonstrated a favorable impact on major adverse cardiovascular event rates, highlighting its potential as a new therapeutic strategy.</p>
<h4>Article 4: Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40832715" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40832715</a></p>
<p><strong>Summary:</strong> This study assessed the prognostic impact of myocarditis-like episodes and their treatment in patients carrying pathogenic or likely pathogenic desmoplakin (D.S.P.) variants. It confirmed that recurrent myocarditis-like episodes are associated with a higher risk of sustained ventricular arrhythmias and progression to Heart Failure in this population. Crucially, the study determined that specific treatments for these inflammatory episodes can modify disease progression and improve long-term outcomes, emphasizing the need for active management.</p>
<h4>Article 5: Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40762079" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40762079</a></p>
<p><strong>Summary:</strong> This single-cell multi-omics study investigated the underlying mechanisms of acute myocarditis by analyzing peripheral blood mononuclear cells from 40 patients. Researchers identified distinct populations of specialized cytotoxic and migratory C.D.8. positive effector T cells unique to acute myocarditis, particularly in its fulminant form. These findings provide critical insights into the immune pathology of this life-threatening cardiac inflammation, paving the way for the development of novel, precision-targeted therapeutic strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction. This retrospective study evaluated percutaneous mechanical debulking with a manual vacuum aspiration device during Cardiac Implantable Electronic Device (C.I.E.D.) extraction for large lead-related vegetations. The technique offers a less invasive alternative to surgical removal, which traditionally carries high morbidity and mortality risks in these complex patients. Findings suggest this approach can improve outcomes, demonstrating its potential as a safer management strategy for C.I.E.D. infections.</p>
<p>Article number two. Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. This study investigated the antecedent prevalence of nonoptimally controlled traditional risk factors, including blood pressure, cholesterol, glucose, and body mass index, prior to the onset of cardiovascular disease. Findings revealed a very high prevalence of these nonoptimal risk factors at the time of Coronary Heart Disease, Heart Failure, or stroke diagnosis. This suggests that &#8220;risk factor-free&#8221; cardiovascular disease may often be attributed to subthreshold or unrecognised nonoptimal control, underscoring the critical need for proactive risk factor management.</p>
<p>Article number three. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. This pooled analysis evaluated the effect of the cholesteryl ester transfer protein (C.E.T.P.) inhibitor obicetrapib on major adverse cardiovascular events in high-risk patients. The study compared 10 milligrams of obicetrapib daily versus placebo in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Obicetrapib significantly reduced atherogenic lipids, increased high-density lipoprotein cholesterol, and demonstrated a favorable impact on major adverse cardiovascular event rates, highlighting its potential as a new therapeutic strategy.</p>
<p>Article number four. Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. This study assessed the prognostic impact of myocarditis-like episodes and their treatment in patients carrying pathogenic or likely pathogenic desmoplakin (D.S.P.) variants. It confirmed that recurrent myocarditis-like episodes are associated with a higher risk of sustained ventricular arrhythmias and progression to Heart Failure in this population. Crucially, the study determined that specific treatments for these inflammatory episodes can modify disease progression and improve long-term outcomes, emphasizing the need for active management.</p>
<p>Article number five. Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis. This single-cell multi-omics study investigated the underlying mechanisms of acute myocarditis by analyzing peripheral blood mononuclear cells from 40 patients. Researchers identified distinct populations of specialized cytotoxic and migratory C.D.8. positive effector T cells unique to acute myocarditis, particularly in its fulminant form. These findings provide critical insights into the immune pathology of this life-threatening cardiac inflammation, paving the way for the development of novel, precision-targeted therapeutic strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Obicetrapib, cholesteryl ester transfer protein inhibitor, percutaneous mechanical debulking, body mass index, major adverse cardiovascular events, endocarditis, desmoplakin variants, single-cell multi-omics, ventricular arrhythmias, prognosis, heart failure, Cardiac Implantable Electronic Device extraction, Heart Failure, C.D.8. positive T cells, fulminant myocarditis, blood pressure, cholesterol, lipid modification, Cardiovascular disease, Acute myocarditis, Coronary Heart Disease, stroke, risk factors, immune pathology, vacuum aspiration, cytotoxic T cells, lead vegetations, glucose, genetic cardiomyopathy, heterozygous familial hypercholesterolemia, Myocarditis, atherosclerotic cardiovascular disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/">Obicetrapib Cuts M.A.C.E. in High-Risk Patients 10/07/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251007_025651.mp3" length="4169812" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like Obicetrapib and cholesteryl ester transfer protein inhibitor. Key takeaway: Obicetrapib Cuts M.A.C.E. in High-Risk Patients.
Article Links:
Article 1: Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction. (Journal of the American College of Cardiology)
Article 2: Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. (Journal of the American College of Cardiology)
Article 3: Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. (Journal of the American College of Cardiology)
Article 4: Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. (Circulation)
Article 5: Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD8+ Effector T Cells in Acute Myocarditis. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/obicetrapib-cuts-m-a-c-e-in-high-risk-patients-10-07-25/
 Featured Articles
Article 1: Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41033741
Summary: This retrospective study evaluated percutaneous mechanical debulking with a manual vacuum aspiration device during Cardiac Implantable Electronic Device (C.I.E.D.) extraction for large lead-related vegetations. The technique offers a less invasive alternative to surgical removal, which traditionally carries high morbidity and mortality risks in these complex patients. Findings suggest this approach can improve outcomes, demonstrating its potential as a safer management strategy for C.I.E.D. infections.
Article 2: Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41033739
Summary: This study investigated the antecedent prevalence of nonoptimally controlled traditional risk factors, including blood pressure, cholesterol, glucose, and body mass index, prior to the onset of cardiovascular disease. Findings revealed a very high prevalence of these nonoptimal risk factors at the time of Coronary Heart Disease, Heart Failure, or stroke diagnosis. This suggests that &#8220;risk factor-free&#8221; cardiovascular disease may often be attributed to subthreshold or unrecognised nonoptimal control, underscoring the critical need for proactive risk factor management.
Article 3: Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888776
Summary: This pooled analysis evaluated the effect of the cholesteryl ester transfer protein (C.E.T.P.) inhibitor obicetrapib on major adverse cardiovascular events in high-risk patients. The study compared 10 milligrams of obicetrapib daily versus placebo in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Obicetrapib significantly reduced atherogenic lipids, increased high-density lipoprotein cholesterol, and demonstrated a favorable impact on major adverse cardiovascular event rates, highlighting its potential as a new therapeutic strategy.
Article 4: Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40832715
Summary: This study assessed the prognostic impact of myocarditis-like episodes and their treatment in patients carrying pathogenic or likely pathogenic desmoplakin (D.S.P.) variants. It confirmed ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 07, 2025. This episode summarizes 5 key cardiology studies on topics like Obicetrapib and cholesteryl ester transfer protein inhibitor. Key takeaway: Obicetrapib Cuts M.A.C.E. in High-Risk Patients.
Article Links:
Article 1: Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction. (Journal of the American College of Cardiology)
Article 2: Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. (Journal of the American College of Cardiology)
Article 3: Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. (Journal of the American College of Cardiology)
Article 4: Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. (Circulation)
Article 5: Single-Cell Multi-Omics Identifies Specialized Cytotoxic and Migratory CD]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Who Benefits from P.C.I. in Ischemic C.M.? 10/06/25</title>
	<link>https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/</link>
	<pubDate>Mon, 06 Oct 2025 06:58:21 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 06, 2025. This episode summarizes 4 key cardiology studies on topics like percutaneous coronary intervention and left anterior descending artery. Key takeaway: Who Benefits from P.C.I. in Ischemic C.M.?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41047011">Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41046997">Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41046874">Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41046994">Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial.</a> (American heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/">https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41047011" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41047011</a></p>
<p><strong>Summary:</strong> This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management.</p>
<h4>Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046997" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046997</a></p>
<p><strong>Summary:</strong> This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization.</p>
<h4>Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046874" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046874</a></p>
<p><strong>Summary:</strong> This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome.</p>
<h4>Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046994" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046994</a></p>
<p><strong>Summary:</strong> This study within a trial, published in the American Heart Journal, is investigating the effect of opt-in versus opt-out recruitment strategies on participant enrollment in randomized clinical trials. Embedded within the G.A.M.E.P.A.D. trial for peripheral artery disease patients, this research randomized eligible individuals to receive either an opt-in invitation requiring active consent or an opt-out invitation implying automatic enrollment unless declined. The study aims to determine which outreach strategy yields a higher enrollment fraction and improves protocol completion, potentially optimizing future clinical trial efficiency.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management.</p>
<p>Article number two. Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization.</p>
<p>Article number three. Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome.</p>
<p>Article number four. Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. This study within a trial, published in the American Heart Journal, is investigating the effect of opt-in versus opt-out recruitment strategies on participant enrollment in randomized clinical trials. Embedded within the G.A.M.E.P.A.D. trial for peripheral artery disease patients, this research randomized eligible individuals to receive either an opt-in invitation requiring active consent or an opt-out invitation implying automatic enrollment unless declined. The study aims to determine which outreach strategy yields a higher enrollment fraction and improves protocol completion, potentially optimizing future clinical trial efficiency. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>percutaneous coronary intervention, left anterior descending artery, opt-out consent, diastolic blood pressure, heart failure outcomes, Myocardial bridging, left ventricular dysfunction, myocardial viability, Stable ischemic cardiomyopathy, heart transplantation, MINOCA, Donation after circulatory death, Takotsubo syndrome, opt-in consent, left ventricular ejection fraction, coronary hypoperfusion, randomized clinical trial, Clinical trial recruitment, peripheral artery disease, agonal phase.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/">Who Benefits from P.C.I. in Ischemic C.M.? 10/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 06, 2025. This episode summarizes 4 key cardiology studies on topics like percutaneous coronary intervention and left anterior descending artery. Key takeaway: Who Benefits from P.C.I. in Ischemic C.M.?.
Art]]></itunes:subtitle>
	<itunes:episode>97</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 06, 2025. This episode summarizes 4 key cardiology studies on topics like percutaneous coronary intervention and left anterior descending artery. Key takeaway: Who Benefits from P.C.I. in Ischemic C.M.?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41047011">Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41046997">Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41046874">Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41046994">Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial.</a> (American heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/">https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41047011" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41047011</a></p>
<p><strong>Summary:</strong> This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management.</p>
<h4>Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046997" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046997</a></p>
<p><strong>Summary:</strong> This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization.</p>
<h4>Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046874" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046874</a></p>
<p><strong>Summary:</strong> This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome.</p>
<h4>Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial.</h4>
<p><strong>Journal:</strong> American heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046994" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046994</a></p>
<p><strong>Summary:</strong> This study within a trial, published in the American Heart Journal, is investigating the effect of opt-in versus opt-out recruitment strategies on participant enrollment in randomized clinical trials. Embedded within the G.A.M.E.P.A.D. trial for peripheral artery disease patients, this research randomized eligible individuals to receive either an opt-in invitation requiring active consent or an opt-out invitation implying automatic enrollment unless declined. The study aims to determine which outreach strategy yields a higher enrollment fraction and improves protocol completion, potentially optimizing future clinical trial efficiency.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management.</p>
<p>Article number two. Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization.</p>
<p>Article number three. Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome.</p>
<p>Article number four. Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. This study within a trial, published in the American Heart Journal, is investigating the effect of opt-in versus opt-out recruitment strategies on participant enrollment in randomized clinical trials. Embedded within the G.A.M.E.P.A.D. trial for peripheral artery disease patients, this research randomized eligible individuals to receive either an opt-in invitation requiring active consent or an opt-out invitation implying automatic enrollment unless declined. The study aims to determine which outreach strategy yields a higher enrollment fraction and improves protocol completion, potentially optimizing future clinical trial efficiency. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>percutaneous coronary intervention, left anterior descending artery, opt-out consent, diastolic blood pressure, heart failure outcomes, Myocardial bridging, left ventricular dysfunction, myocardial viability, Stable ischemic cardiomyopathy, heart transplantation, MINOCA, Donation after circulatory death, Takotsubo syndrome, opt-in consent, left ventricular ejection fraction, coronary hypoperfusion, randomized clinical trial, Clinical trial recruitment, peripheral artery disease, agonal phase.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/">Who Benefits from P.C.I. in Ischemic C.M.? 10/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251006_025731.mp3" length="3462207" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 06, 2025. This episode summarizes 4 key cardiology studies on topics like percutaneous coronary intervention and left anterior descending artery. Key takeaway: Who Benefits from P.C.I. in Ischemic C.M.?.
Article Links:
Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. (The American journal of cardiology)
Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. (International journal of cardiology)
Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. (American heart journal)
Full episode page: https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/
 Featured Articles
Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41047011
Summary: This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management.
Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046997
Summary: This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization.
Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046874
Summary: This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome.
Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial.
Journal: American heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046994
Summary: This study within a trial, published in the American Heart ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 06, 2025. This episode summarizes 4 key cardiology studies on topics like percutaneous coronary intervention and left anterior descending artery. Key takeaway: Who Benefits from P.C.I. in Ischemic C.M.?.
Article Links:
Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. (The American journal of cardiology)
Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. (International journal of cardiology)
Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. (Amer]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Heart Transplant Bridge: Best Strategy for Outcomes 10/05/25</title>
	<link>https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/</link>
	<pubDate>Mon, 06 Oct 2025 02:38:25 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 05, 2025. This episode summarizes 1 key cardiology studies on topics like mechanical circulatory support and heart transplant. Key takeaway: Heart Transplant Bridge: Best Strategy for Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41046003">Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/">https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046003" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046003</a></p>
<p><strong>Summary:</strong> This nationwide multicenter retrospective study analyzed 1,021 adult heart transplant recipients in Korea from 2014 to 2023, comparing post-transplant outcomes based on their pre-transplant bridging strategy: Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device, or no mechanical circulatory support. The study determined crucial differences in post-transplant outcomes, including survival and complication rates, demonstrating the differential impact of each bridging strategy. These findings provide vital evidence for refining heart transplant allocation protocols and optimizing the selection of mechanical circulatory support to improve long-term patient survival and mitigate post-transplant complications, particularly in systems prioritizing E.C.M.O. as a bridge to transplant.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea. This nationwide multicenter retrospective study analyzed 1,021 adult heart transplant recipients in Korea from 2014 to 2023, comparing post-transplant outcomes based on their pre-transplant bridging strategy: Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device, or no mechanical circulatory support. The study determined crucial differences in post-transplant outcomes, including survival and complication rates, demonstrating the differential impact of each bridging strategy. These findings provide vital evidence for refining heart transplant allocation protocols and optimizing the selection of mechanical circulatory support to improve long-term patient survival and mitigate post-transplant complications, particularly in systems prioritizing E.C.M.O. as a bridge to transplant. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mechanical circulatory support, heart transplant, post-transplant outcomes, extracorporeal membrane oxygenation, left ventricular assist device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/">Heart Transplant Bridge: Best Strategy for Outcomes 10/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 05, 2025. This episode summarizes 1 key cardiology studies on topics like mechanical circulatory support and heart transplant. Key takeaway: Heart Transplant Bridge: Best Strategy for Outcomes.
Article Links]]></itunes:subtitle>
	<itunes:episode>96</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 05, 2025. This episode summarizes 1 key cardiology studies on topics like mechanical circulatory support and heart transplant. Key takeaway: Heart Transplant Bridge: Best Strategy for Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41046003">Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea.</a> (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/">https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea.</h4>
<p><strong>Journal:</strong> The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41046003" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41046003</a></p>
<p><strong>Summary:</strong> This nationwide multicenter retrospective study analyzed 1,021 adult heart transplant recipients in Korea from 2014 to 2023, comparing post-transplant outcomes based on their pre-transplant bridging strategy: Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device, or no mechanical circulatory support. The study determined crucial differences in post-transplant outcomes, including survival and complication rates, demonstrating the differential impact of each bridging strategy. These findings provide vital evidence for refining heart transplant allocation protocols and optimizing the selection of mechanical circulatory support to improve long-term patient survival and mitigate post-transplant complications, particularly in systems prioritizing E.C.M.O. as a bridge to transplant.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea. This nationwide multicenter retrospective study analyzed 1,021 adult heart transplant recipients in Korea from 2014 to 2023, comparing post-transplant outcomes based on their pre-transplant bridging strategy: Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device, or no mechanical circulatory support. The study determined crucial differences in post-transplant outcomes, including survival and complication rates, demonstrating the differential impact of each bridging strategy. These findings provide vital evidence for refining heart transplant allocation protocols and optimizing the selection of mechanical circulatory support to improve long-term patient survival and mitigate post-transplant complications, particularly in systems prioritizing E.C.M.O. as a bridge to transplant. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>mechanical circulatory support, heart transplant, post-transplant outcomes, extracorporeal membrane oxygenation, left ventricular assist device.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/">Heart Transplant Bridge: Best Strategy for Outcomes 10/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251005_223806.mp3" length="1325182" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 05, 2025. This episode summarizes 1 key cardiology studies on topics like mechanical circulatory support and heart transplant. Key takeaway: Heart Transplant Bridge: Best Strategy for Outcomes.
Article Links:
Article 1: Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/
 Featured Articles
Article 1: Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046003
Summary: This nationwide multicenter retrospective study analyzed 1,021 adult heart transplant recipients in Korea from 2014 to 2023, comparing post-transplant outcomes based on their pre-transplant bridging strategy: Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device, or no mechanical circulatory support. The study determined crucial differences in post-transplant outcomes, including survival and complication rates, demonstrating the differential impact of each bridging strategy. These findings provide vital evidence for refining heart transplant allocation protocols and optimizing the selection of mechanical circulatory support to improve long-term patient survival and mitigate post-transplant complications, particularly in systems prioritizing E.C.M.O. as a bridge to transplant.
 Transcript

Today&#8217;s date is October 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea. This nationwide multicenter retrospective study analyzed 1,021 adult heart transplant recipients in Korea from 2014 to 2023, comparing post-transplant outcomes based on their pre-transplant bridging strategy: Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device, or no mechanical circulatory support. The study determined crucial differences in post-transplant outcomes, including survival and complication rates, demonstrating the differential impact of each bridging strategy. These findings provide vital evidence for refining heart transplant allocation protocols and optimizing the selection of mechanical circulatory support to improve long-term patient survival and mitigate post-transplant complications, particularly in systems prioritizing E.C.M.O. as a bridge to transplant. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
mechanical circulatory support, heart transplant, post-transplant outcomes, extracorporeal membrane oxygenation, left ventricular assist device.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Heart Transplant Bridge: Best Strategy for Outcomes 10/05/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 05, 2025. This episode summarizes 1 key cardiology studies on topics like mechanical circulatory support and heart transplant. Key takeaway: Heart Transplant Bridge: Best Strategy for Outcomes.
Article Links:
Article 1: Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/heart-transplant-bridge-best-strategy-for-outcomes-10-05-25/
 Featured Articles
Article 1: Post-Transplant Outcomes by Bridging Strategy: A Nationwide Multicenter Study of Heart Transplant Recipients in Korea.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046003
Summary: This nationwi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Radiation Safe for Leadless Pacemakers 10/04/25</title>
	<link>https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/</link>
	<pubDate>Sat, 04 Oct 2025 06:58:03 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 04, 2025. This episode summarizes 5 key cardiology studies on topics like L.R.P.5. and W.N.T. signaling. Key takeaway: Radiation Safe for Leadless Pacemakers.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41042971">LRP5, a WNT signalling pathway receptor, and platelet activation.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41042950">Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41043864">Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41043630">Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41043629">Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/">https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: LRP5, a WNT signalling pathway receptor, and platelet activation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41042971" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41042971</a></p>
<p><strong>Summary:</strong> This study rigorously examined the role of L.R.P.5., a W.N.T. signaling pathway receptor, in regulating platelet function and hemostasis. Researchers utilized human platelets and L.R.P.5.-deficient murine platelets, challenging them with various agonists and inhibitors. The investigation revealed specific mechanisms by which L.R.P.5. influences platelet aggregation and activation pathways. These findings delineate L.R.P.5.&#8217;s critical involvement in thrombogenesis, suggesting it as a potential novel target for antiplatelet therapies.</p>
<h4>Article 2: Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41042950" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41042950</a></p>
<p><strong>Summary:</strong> This study investigated the heterogeneity of endothelial dysfunction in non-hypertensive obese individuals and sought to identify predictive and therapeutic serum metabolites. Utilizing wire myography, researchers confirmed that taurochenodeoxycholic acid, a specific bile acid, effectively alleviates obesity-induced endothelial dysfunction. This breakthrough suggests taurochenodeoxycholic acid could serve as a novel therapeutic target for preventing or treating cardiovascular disease in obese patients.</p>
<h4>Article 3: Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41043864" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41043864</a></p>
<p><strong>Summary:</strong> The P.R.O.M.I.S.E. P.C.I. randomized trial, involving 1706 high-risk patients, compared the clinical utility of routine surveillance stress testing versus a symptom-oriented strategy after imaging-guided or physiology-guided percutaneous coronary intervention. The study aimed to definitively establish whether routine stress testing provides additional clinical benefit in this population. While the abstract does not detail the specific outcomes, the comprehensive trial results defined the optimal follow-up approach for enhancing post-P.C.I. patient management.</p>
<h4>Article 4: Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41043630" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41043630</a></p>
<p><strong>Summary:</strong> This study directly compared His-bundle pacing cardiac resynchronization therapy with biventricular pacing cardiac resynchronization therapy for their effects on ventricular repolarization in patients with left bundle branch block. The pivotal finding was that His-bundle pacing cardiac resynchronization therapy significantly improved ventricular repolarization, while biventricular pacing did not confer this benefit. This suggests His-bundle pacing offers a superior physiological approach to cardiac resynchronization, potentially reducing ventricular arrhythmia risk.</p>
<h4>Article 5: Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41043629" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41043629</a></p>
<p><strong>Summary:</strong> This phantom model study assessed the impact of external beam radiation on leadless pacemakers, specifically the Medtronic Micra V.R., using advanced Varian TrueBeam and Ethos systems across various dose rates and flattening filter-free radiation modes. The study conclusively demonstrated that leadless pacemakers remain unaffected by radiation exposure. This crucial finding provides reassuring evidence for managing cancer patients with leadless pacemakers requiring radiation therapy, potentially simplifying treatment protocols.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. LRP5, a WNT signalling pathway receptor, and platelet activation. This study rigorously examined the role of L.R.P.5., a W.N.T. signaling pathway receptor, in regulating platelet function and hemostasis. Researchers utilized human platelets and L.R.P.5.-deficient murine platelets, challenging them with various agonists and inhibitors. The investigation revealed specific mechanisms by which L.R.P.5. influences platelet aggregation and activation pathways. These findings delineate L.R.P.5.&#8217;s critical involvement in thrombogenesis, suggesting it as a potential novel target for antiplatelet therapies.</p>
<p>Article number two. Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction. This study investigated the heterogeneity of endothelial dysfunction in non-hypertensive obese individuals and sought to identify predictive and therapeutic serum metabolites. Utilizing wire myography, researchers confirmed that taurochenodeoxycholic acid, a specific bile acid, effectively alleviates obesity-induced endothelial dysfunction. This breakthrough suggests taurochenodeoxycholic acid could serve as a novel therapeutic target for preventing or treating cardiovascular disease in obese patients.</p>
<p>Article number three. Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided P.C.I. The P.R.O.M.I.S.E. P.C.I. randomized trial, involving 1706 high-risk patients, compared the clinical utility of routine surveillance stress testing versus a symptom-oriented strategy after imaging-guided or physiology-guided percutaneous coronary intervention. The study aimed to definitively establish whether routine stress testing provides additional clinical benefit in this population. While the abstract does not detail the specific outcomes, the comprehensive trial results defined the optimal follow-up approach for enhancing post-P.C.I. patient management.</p>
<p>Article number four. Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing. This study directly compared His-bundle pacing cardiac resynchronization therapy with biventricular pacing cardiac resynchronization therapy for their effects on ventricular repolarization in patients with left bundle branch block. The pivotal finding was that His-bundle pacing cardiac resynchronization therapy significantly improved ventricular repolarization, while biventricular pacing did not confer this benefit. This suggests His-bundle pacing offers a superior physiological approach to cardiac resynchronization, potentially reducing ventricular arrhythmia risk.</p>
<p>Article number five. Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model. This phantom model study assessed the impact of external beam radiation on leadless pacemakers, specifically the Medtronic Micra V.R., using advanced Varian TrueBeam and Ethos systems across various dose rates and flattening filter-free radiation modes. The study conclusively demonstrated that leadless pacemakers remain unaffected by radiation exposure. This crucial finding provides reassuring evidence for managing cancer patients with leadless pacemakers requiring radiation therapy, potentially simplifying treatment protocols. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>L.R.P.5., W.N.T. signaling, cardiovascular disease, cardiac resynchronization therapy, Micra V.R., biventricular pacing, percutaneous coronary intervention, serum metabolites, phantom model, fractional flow reserve, antiplatelet therapy, ventricular repolarization, leadless pacemaker, radiation therapy, hemostasis, imaging-guided P.C.I., His-bundle pacing, left bundle branch block, taurochenodeoxycholic acid, platelet activation, stress testing, obesity, external beam radiation, endothelial dysfunction, follow-up strategy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/">Radiation Safe for Leadless Pacemakers 10/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 04, 2025. This episode summarizes 5 key cardiology studies on topics like L.R.P.5. and W.N.T. signaling. Key takeaway: Radiation Safe for Leadless Pacemakers.
Article Links:
Article 1: LRP5, a WNT signalling]]></itunes:subtitle>
	<itunes:episode>95</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 04, 2025. This episode summarizes 5 key cardiology studies on topics like L.R.P.5. and W.N.T. signaling. Key takeaway: Radiation Safe for Leadless Pacemakers.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41042971">LRP5, a WNT signalling pathway receptor, and platelet activation.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41042950">Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41043864">Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41043630">Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41043629">Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/">https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: LRP5, a WNT signalling pathway receptor, and platelet activation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41042971" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41042971</a></p>
<p><strong>Summary:</strong> This study rigorously examined the role of L.R.P.5., a W.N.T. signaling pathway receptor, in regulating platelet function and hemostasis. Researchers utilized human platelets and L.R.P.5.-deficient murine platelets, challenging them with various agonists and inhibitors. The investigation revealed specific mechanisms by which L.R.P.5. influences platelet aggregation and activation pathways. These findings delineate L.R.P.5.&#8217;s critical involvement in thrombogenesis, suggesting it as a potential novel target for antiplatelet therapies.</p>
<h4>Article 2: Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41042950" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41042950</a></p>
<p><strong>Summary:</strong> This study investigated the heterogeneity of endothelial dysfunction in non-hypertensive obese individuals and sought to identify predictive and therapeutic serum metabolites. Utilizing wire myography, researchers confirmed that taurochenodeoxycholic acid, a specific bile acid, effectively alleviates obesity-induced endothelial dysfunction. This breakthrough suggests taurochenodeoxycholic acid could serve as a novel therapeutic target for preventing or treating cardiovascular disease in obese patients.</p>
<h4>Article 3: Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41043864" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41043864</a></p>
<p><strong>Summary:</strong> The P.R.O.M.I.S.E. P.C.I. randomized trial, involving 1706 high-risk patients, compared the clinical utility of routine surveillance stress testing versus a symptom-oriented strategy after imaging-guided or physiology-guided percutaneous coronary intervention. The study aimed to definitively establish whether routine stress testing provides additional clinical benefit in this population. While the abstract does not detail the specific outcomes, the comprehensive trial results defined the optimal follow-up approach for enhancing post-P.C.I. patient management.</p>
<h4>Article 4: Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41043630" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41043630</a></p>
<p><strong>Summary:</strong> This study directly compared His-bundle pacing cardiac resynchronization therapy with biventricular pacing cardiac resynchronization therapy for their effects on ventricular repolarization in patients with left bundle branch block. The pivotal finding was that His-bundle pacing cardiac resynchronization therapy significantly improved ventricular repolarization, while biventricular pacing did not confer this benefit. This suggests His-bundle pacing offers a superior physiological approach to cardiac resynchronization, potentially reducing ventricular arrhythmia risk.</p>
<h4>Article 5: Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41043629" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41043629</a></p>
<p><strong>Summary:</strong> This phantom model study assessed the impact of external beam radiation on leadless pacemakers, specifically the Medtronic Micra V.R., using advanced Varian TrueBeam and Ethos systems across various dose rates and flattening filter-free radiation modes. The study conclusively demonstrated that leadless pacemakers remain unaffected by radiation exposure. This crucial finding provides reassuring evidence for managing cancer patients with leadless pacemakers requiring radiation therapy, potentially simplifying treatment protocols.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. LRP5, a WNT signalling pathway receptor, and platelet activation. This study rigorously examined the role of L.R.P.5., a W.N.T. signaling pathway receptor, in regulating platelet function and hemostasis. Researchers utilized human platelets and L.R.P.5.-deficient murine platelets, challenging them with various agonists and inhibitors. The investigation revealed specific mechanisms by which L.R.P.5. influences platelet aggregation and activation pathways. These findings delineate L.R.P.5.&#8217;s critical involvement in thrombogenesis, suggesting it as a potential novel target for antiplatelet therapies.</p>
<p>Article number two. Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction. This study investigated the heterogeneity of endothelial dysfunction in non-hypertensive obese individuals and sought to identify predictive and therapeutic serum metabolites. Utilizing wire myography, researchers confirmed that taurochenodeoxycholic acid, a specific bile acid, effectively alleviates obesity-induced endothelial dysfunction. This breakthrough suggests taurochenodeoxycholic acid could serve as a novel therapeutic target for preventing or treating cardiovascular disease in obese patients.</p>
<p>Article number three. Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided P.C.I. The P.R.O.M.I.S.E. P.C.I. randomized trial, involving 1706 high-risk patients, compared the clinical utility of routine surveillance stress testing versus a symptom-oriented strategy after imaging-guided or physiology-guided percutaneous coronary intervention. The study aimed to definitively establish whether routine stress testing provides additional clinical benefit in this population. While the abstract does not detail the specific outcomes, the comprehensive trial results defined the optimal follow-up approach for enhancing post-P.C.I. patient management.</p>
<p>Article number four. Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing. This study directly compared His-bundle pacing cardiac resynchronization therapy with biventricular pacing cardiac resynchronization therapy for their effects on ventricular repolarization in patients with left bundle branch block. The pivotal finding was that His-bundle pacing cardiac resynchronization therapy significantly improved ventricular repolarization, while biventricular pacing did not confer this benefit. This suggests His-bundle pacing offers a superior physiological approach to cardiac resynchronization, potentially reducing ventricular arrhythmia risk.</p>
<p>Article number five. Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model. This phantom model study assessed the impact of external beam radiation on leadless pacemakers, specifically the Medtronic Micra V.R., using advanced Varian TrueBeam and Ethos systems across various dose rates and flattening filter-free radiation modes. The study conclusively demonstrated that leadless pacemakers remain unaffected by radiation exposure. This crucial finding provides reassuring evidence for managing cancer patients with leadless pacemakers requiring radiation therapy, potentially simplifying treatment protocols. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>L.R.P.5., W.N.T. signaling, cardiovascular disease, cardiac resynchronization therapy, Micra V.R., biventricular pacing, percutaneous coronary intervention, serum metabolites, phantom model, fractional flow reserve, antiplatelet therapy, ventricular repolarization, leadless pacemaker, radiation therapy, hemostasis, imaging-guided P.C.I., His-bundle pacing, left bundle branch block, taurochenodeoxycholic acid, platelet activation, stress testing, obesity, external beam radiation, endothelial dysfunction, follow-up strategy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/">Radiation Safe for Leadless Pacemakers 10/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251004_025709.mp3" length="3889780" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 04, 2025. This episode summarizes 5 key cardiology studies on topics like L.R.P.5. and W.N.T. signaling. Key takeaway: Radiation Safe for Leadless Pacemakers.
Article Links:
Article 1: LRP5, a WNT signalling pathway receptor, and platelet activation. (European heart journal)
Article 2: Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction. (European heart journal)
Article 3: Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI. (Heart (British Cardiac Society))
Article 4: Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing. (Heart rhythm)
Article 5: Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/
 Featured Articles
Article 1: LRP5, a WNT signalling pathway receptor, and platelet activation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41042971
Summary: This study rigorously examined the role of L.R.P.5., a W.N.T. signaling pathway receptor, in regulating platelet function and hemostasis. Researchers utilized human platelets and L.R.P.5.-deficient murine platelets, challenging them with various agonists and inhibitors. The investigation revealed specific mechanisms by which L.R.P.5. influences platelet aggregation and activation pathways. These findings delineate L.R.P.5.&#8217;s critical involvement in thrombogenesis, suggesting it as a potential novel target for antiplatelet therapies.
Article 2: Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41042950
Summary: This study investigated the heterogeneity of endothelial dysfunction in non-hypertensive obese individuals and sought to identify predictive and therapeutic serum metabolites. Utilizing wire myography, researchers confirmed that taurochenodeoxycholic acid, a specific bile acid, effectively alleviates obesity-induced endothelial dysfunction. This breakthrough suggests taurochenodeoxycholic acid could serve as a novel therapeutic target for preventing or treating cardiovascular disease in obese patients.
Article 3: Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41043864
Summary: The P.R.O.M.I.S.E. P.C.I. randomized trial, involving 1706 high-risk patients, compared the clinical utility of routine surveillance stress testing versus a symptom-oriented strategy after imaging-guided or physiology-guided percutaneous coronary intervention. The study aimed to definitively establish whether routine stress testing provides additional clinical benefit in this population. While the abstract does not detail the specific outcomes, the comprehensive trial results defined the optimal follow-up approach for enhancing post-P.C.I. patient management.
Article 4: Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41043630
Summary: This study directly compared His-bundle pacing cardiac resynchronization therapy with biventricular pacing cardiac resynchronization therapy for their effects on ventricular repolarization in patients with left bundle branch block. The pivotal finding was that His-bundle pacing cardiac resynchronization therapy significantly improved ventricular repolarization, while biventricular pacing did not confer this benefit. This suggests His-bundle pacing offers a superior physiological approach to cardiac resynchronization, potentially reducing ventricular arrhythmia risk.
Article 5: Leadless Pacemakers Are Unaffected by External Beam R]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 04, 2025. This episode summarizes 5 key cardiology studies on topics like L.R.P.5. and W.N.T. signaling. Key takeaway: Radiation Safe for Leadless Pacemakers.
Article Links:
Article 1: LRP5, a WNT signalling pathway receptor, and platelet activation. (European heart journal)
Article 2: Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction. (European heart journal)
Article 3: Role of routine surveillance stress testing in patients with or without imaging-guided or physiology-guided PCI. (Heart (British Cardiac Society))
Article 4: Ventricular Repolarisation is Improved by His Resynchronisation Therapy but not Biventricular Pacing. (Heart rhythm)
Article 5: Leadless Pacemakers Are Unaffected by External Beam Radiation in a Phantom Model. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/radiation-safe-for-leadless-pacemakers-10-04-25/
 Featured Articles
Article 1: LRP5, a WNT signalling pathw]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Osimertinib Arrhythmia: K.C.N.N.1 Link Found 10/03/25</title>
	<link>https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/</link>
	<pubDate>Fri, 03 Oct 2025 06:57:35 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 03, 2025. This episode summarizes 5 key cardiology studies on topics like gene-edited pigs and H.C.N.4. Key takeaway: Osimertinib Arrhythmia: K.C.N.N.1 Link Found.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41036838">Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41037837">Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40653133">Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40645436">miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40582687">Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/">https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41036838" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41036838</a></p>
<p><strong>Summary:</strong> Article number one. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</p>
<h4>Article 2: Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41037837" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41037837</a></p>
<p><strong>Summary:</strong> Article number two. Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 3: Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40653133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40653133</a></p>
<p><strong>Summary:</strong> Article number three. Osimertinib induces prolongation of action potential duration via downregulation of K.C.N.N.1 expression: Exploring the potential mechanisms of arrhythmia.</p>
<h4>Article 4: miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645436" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645436</a></p>
<p><strong>Summary:</strong> Article number four. microRNA-363-5p- and I.L.-34-mediated modulation of pacemaker channel, H.C.N.4, on induced pluripotent stem cell-derived cardiomyocytes: Translation into the human sinus node microenvironment.</p>
<h4>Article 5: Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40582687" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40582687</a></p>
<p><strong>Summary:</strong> Article number five. Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</p>
<p>Article number two. Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number three. Osimertinib induces prolongation of action potential duration via downregulation of K.C.N.N.1 expression: Exploring the potential mechanisms of arrhythmia.</p>
<p>Article number four. microRNA-363-5p- and I.L.-34-mediated modulation of pacemaker channel, H.C.N.4, on induced pluripotent stem cell-derived cardiomyocytes: Translation into the human sinus node microenvironment.</p>
<p>Article number five. Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gene-edited pigs, H.C.N.4, epidermal growth factor receptor-tyrosine kinase inhibitor, induced pluripotent stem cell-derived cardiomyocytes, incidence, cardiotoxicity, congestion, heart rate modulation, Heart Failure with Preserved Ejection Fraction, echocardiographic imaging, pacing complications, cardiac tamponade, osimertinib, arrhythmia, sinus node, pig-to-human heart transplant, xenotransplantation, action potential duration, transvenous temporary pacing, multimodal phenotyping, xeno-immune response, obesity, cardiac perforation, low cardiac output, I.L.-34, K.C.N.N.1, microRNAs, hemodynamic phenotype, clinical outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/">Osimertinib Arrhythmia: K.C.N.N.1 Link Found 10/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 03, 2025. This episode summarizes 5 key cardiology studies on topics like gene-edited pigs and H.C.N.4. Key takeaway: Osimertinib Arrhythmia: K.C.N.N.1 Link Found.
Article Links:
Article 1: Characterizing th]]></itunes:subtitle>
	<itunes:episode>94</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 03, 2025. This episode summarizes 5 key cardiology studies on topics like gene-edited pigs and H.C.N.4. Key takeaway: Osimertinib Arrhythmia: K.C.N.N.1 Link Found.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41036838">Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41037837">Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF.</a> (JACC. Heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40653133">Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40645436">miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40582687">Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/">https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41036838" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41036838</a></p>
<p><strong>Summary:</strong> Article number one. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</p>
<h4>Article 2: Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41037837" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41037837</a></p>
<p><strong>Summary:</strong> Article number two. Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese Heart Failure with Preserved Ejection Fraction.</p>
<h4>Article 3: Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40653133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40653133</a></p>
<p><strong>Summary:</strong> Article number three. Osimertinib induces prolongation of action potential duration via downregulation of K.C.N.N.1 expression: Exploring the potential mechanisms of arrhythmia.</p>
<h4>Article 4: miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40645436" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40645436</a></p>
<p><strong>Summary:</strong> Article number four. microRNA-363-5p- and I.L.-34-mediated modulation of pacemaker channel, H.C.N.4, on induced pluripotent stem cell-derived cardiomyocytes: Translation into the human sinus node microenvironment.</p>
<h4>Article 5: Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40582687" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40582687</a></p>
<p><strong>Summary:</strong> Article number five. Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.</p>
<p>Article number two. Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese Heart Failure with Preserved Ejection Fraction.</p>
<p>Article number three. Osimertinib induces prolongation of action potential duration via downregulation of K.C.N.N.1 expression: Exploring the potential mechanisms of arrhythmia.</p>
<p>Article number four. microRNA-363-5p- and I.L.-34-mediated modulation of pacemaker channel, H.C.N.4, on induced pluripotent stem cell-derived cardiomyocytes: Translation into the human sinus node microenvironment.</p>
<p>Article number five. Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gene-edited pigs, H.C.N.4, epidermal growth factor receptor-tyrosine kinase inhibitor, induced pluripotent stem cell-derived cardiomyocytes, incidence, cardiotoxicity, congestion, heart rate modulation, Heart Failure with Preserved Ejection Fraction, echocardiographic imaging, pacing complications, cardiac tamponade, osimertinib, arrhythmia, sinus node, pig-to-human heart transplant, xenotransplantation, action potential duration, transvenous temporary pacing, multimodal phenotyping, xeno-immune response, obesity, cardiac perforation, low cardiac output, I.L.-34, K.C.N.N.1, microRNAs, hemodynamic phenotype, clinical outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/">Osimertinib Arrhythmia: K.C.N.N.1 Link Found 10/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251003_025717.mp3" length="1336885" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 03, 2025. This episode summarizes 5 key cardiology studies on topics like gene-edited pigs and H.C.N.4. Key takeaway: Osimertinib Arrhythmia: K.C.N.N.1 Link Found.
Article Links:
Article 1: Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System. (Circulation)
Article 2: Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF. (JACC. Heart failure)
Article 3: Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia. (Heart rhythm)
Article 4: miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment. (Heart rhythm)
Article 5: Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/osimertinib-arrhythmia-k-c-n-n-1-link-found-10-03-25/
 Featured Articles
Article 1: Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41036838
Summary: Article number one. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.
Article 2: Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41037837
Summary: Article number two. Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese Heart Failure with Preserved Ejection Fraction.
Article 3: Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40653133
Summary: Article number three. Osimertinib induces prolongation of action potential duration via downregulation of K.C.N.N.1 expression: Exploring the potential mechanisms of arrhythmia.
Article 4: miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40645436
Summary: Article number four. microRNA-363-5p- and I.L.-34-mediated modulation of pacemaker channel, H.C.N.4, on induced pluripotent stem cell-derived cardiomyocytes: Translation into the human sinus node microenvironment.
Article 5: Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40582687
Summary: Article number five. Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation.
 Transcript

Today&#8217;s date is October 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.
Article number two. Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese Heart Failure with Preserved Ejection Fraction.
Article number three. Osimertinib induces prolongation of action potential duration via downregulation of K.C.N.N.1 expression: Exploring the potential mechanisms of arrhythmia.
Article number four. microRNA-363-5p- and I.L.-34-mediated modulation of pacemaker channel, H.C.N.4, on induced pluripotent stem cell-derived cardiomyocytes: Translation into the human sinus node microenvironment.
Article number five. Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
gene-edited pigs, H.C.N.4, epidermal growth factor receptor-t]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 03, 2025. This episode summarizes 5 key cardiology studies on topics like gene-edited pigs and H.C.N.4. Key takeaway: Osimertinib Arrhythmia: K.C.N.N.1 Link Found.
Article Links:
Article 1: Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System. (Circulation)
Article 2: Congestion and Low Cardiac Output Hemodynamic Phenotype Drives Outcomes in Overweight and Obese HFpEF. (JACC. Heart failure)
Article 3: Osimertinib induces prolongation of action potential duration via downregulation of KCNN1 expression: Exploring the potential mechanisms of arrhythmia. (Heart rhythm)
Article 4: miR-363-5p- and IL-34-mediated modulation of pacemaker channel, HCN4, on iPSC-CM: Translation into the human sinus node microenvironment. (Heart rhythm)
Article 5: Incidence and predictors of temporary pacemaker implantation-induced cardiac perforation. (Heart rhythm)
Full episode page: https://podcast.explainheart.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>L-Type Calcium Channels Rescues Dilated Cardiomyopathy 10/02/25</title>
	<link>https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/</link>
	<pubDate>Thu, 02 Oct 2025 10:02:51 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Calcium current. Key takeaway: L-Type Calcium Channels Rescues Dilated Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40446851">PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40446850">Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40441608">Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40425074">Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41032675">RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/">https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40446851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40446851</a></p>
<p><strong>Summary:</strong> in A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. This multicenter retrospective registry analyzed predictors of paravalvular leak (P.V.L.) following implantation of the A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis during transcatheter aortic valve replacement (T.A.V.R.). The study evaluated if dedicated implantation techniques could further reduce P.V.L., a known complication the valve&#8217;s extended sealing skirt aims to mitigate. Such findings are critical for optimizing T.A.V.R. procedures and improving patient outcomes by minimizing post-procedural regurgitation.</p>
<h4>Article 2: Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40446850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40446850</a></p>
<p><strong>Summary:</strong> This prospective, single-center cohort study evaluated the performance of four established scoring systems for predicting 90-day mortality in patients admitted to a contemporary Cardiac Intensive Care Unit (C.I.C.U.). Researchers compared the Acute Physiology and Chronic Health Evaluation (A.P.A.C.H.E.), Sequential Organ Failure Assessment (S.O.F.A.), Mayo C.I.C.U. Admission Risk Score (M.C.A.R.S.), and Clinical Frailty Scale (C.F.S.) scores in an unselected C.I.C.U. population. The findings identified which scoring systems offer superior predictive accuracy, thereby providing critical guidance for risk stratification and clinical decision-making in this high-risk patient group.</p>
<h4>Article 3: Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40441608" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40441608</a></p>
<p><strong>Summary:</strong> This study conducted an external validation of MitraScore, a novel tool developed for predicting mortality risk in patients undergoing mitral transcatheter edge-to-edge repair (M-T.E.E.R.). Using data from the O.C.E.A.N.-Mitral registry, researchers assessed MitraScore&#8217;s performance across diverse mitral regurgitation (M.R.) subtypes, extending beyond its initial derivation in functional M.R. The validation confirmed the score&#8217;s accuracy in identifying patients at higher mortality risk, thereby enhancing patient stratification and selection for M-T.E.E.R. across a broader spectrum of M.R. etiologies.</p>
<h4>Article 4: Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40425074" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40425074</a></p>
<p><strong>Summary:</strong> This retrospective, single-center study investigated cardiovascular disease risk factors (C.V.D.R.F.) in breast cancer survivors (B.C.S.) previously treated with either anthracycline/H.E.R.2-targeted therapy (A.C./H.) or endocrine therapy (E.T.). The research utilized echocardiography and cardiopulmonary exercise testing (C.P.E.T.) to assess cardiac function and fitness. The findings elucidated the differential impact of treatment regimens and the utility of these diagnostic tools in identifying B.C.S. at elevated C.V.D. risk, thereby informing tailored cardio-oncology surveillance strategies.</p>
<h4>Article 5: RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41032675" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41032675</a></p>
<p><strong>Summary:</strong> This study investigated the therapeutic potential of targeting L-type calcium channel (L.T.C.C.) regulation for heart failure, specifically challenging the dogma that enhanced trigger calcium (Ca2+) is always maladaptive. Researchers utilized myocardial R.R.A.D. knockout (c.R.A.D.Δ/Δ) mice, which exhibit a tonically modulated L.T.C.C. current (I.Ca,L) that preserves healthy myocardium. The findings demonstrated that this modulated I.Ca,L can effectively rescue dilated cardiomyopathy, revealing a promising new strategy for treating Heart Failure with Reduced Ejection Fraction (H.F.r.E.F.) by fine-tuning L.T.C.C. activity.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. P.V.L. in A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. This multicenter retrospective registry analyzed predictors of paravalvular leak (P.V.L.) following implantation of the A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis during transcatheter aortic valve replacement (T.A.V.R.). The study evaluated if dedicated implantation techniques could further reduce P.V.L., a known complication the valve&#8217;s extended sealing skirt aims to mitigate. Such findings are critical for optimizing T.A.V.R. procedures and improving patient outcomes by minimizing post-procedural regurgitation.</p>
<p>Article number two. Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit. This prospective, single-center cohort study evaluated the performance of four established scoring systems for predicting 90-day mortality in patients admitted to a contemporary Cardiac Intensive Care Unit (C.I.C.U.). Researchers compared the Acute Physiology and Chronic Health Evaluation (A.P.A.C.H.E.), Sequential Organ Failure Assessment (S.O.F.A.), Mayo C.I.C.U. Admission Risk Score (M.C.A.R.S.), and Clinical Frailty Scale (C.F.S.) scores in an unselected C.I.C.U. population. The findings identified which scoring systems offer superior predictive accuracy, thereby providing critical guidance for risk stratification and clinical decision-making in this high-risk patient group.</p>
<p>Article number three. Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the O.C.E.A.N.-mitral registry. This study conducted an external validation of MitraScore, a novel tool developed for predicting mortality risk in patients undergoing mitral transcatheter edge-to-edge repair (M-T.E.E.R.). Using data from the O.C.E.A.N.-Mitral registry, researchers assessed MitraScore&#8217;s performance across diverse mitral regurgitation (M.R.) subtypes, extending beyond its initial derivation in functional M.R. The validation confirmed the score&#8217;s accuracy in identifying patients at higher mortality risk, thereby enhancing patient stratification and selection for M-T.E.E.R. across a broader spectrum of M.R. etiologies.</p>
<p>Article number four. Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry. This retrospective, single-center study investigated cardiovascular disease risk factors (C.V.D.R.F.) in breast cancer survivors (B.C.S.) previously treated with either anthracycline/H.E.R.2-targeted therapy (A.C./H.) or endocrine therapy (E.T.). The research utilized echocardiography and cardiopulmonary exercise testing (C.P.E.T.) to assess cardiac function and fitness. The findings elucidated the differential impact of treatment regimens and the utility of these diagnostic tools in identifying B.C.S. at elevated C.V.D. risk, thereby informing tailored cardio-oncology surveillance strategies.</p>
<p>Article number five. R.R.A.D.-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure. This study investigated the therapeutic potential of targeting L-type calcium channel (L.T.C.C.) regulation for heart failure, specifically challenging the dogma that enhanced trigger calcium (Ca2+) is always maladaptive. Researchers utilized myocardial R.R.A.D. knockout (c.R.A.D.Δ/Δ) mice, which exhibit a tonically modulated L.T.C.C. current (I.Ca,L) that preserves healthy myocardium. The findings demonstrated that this modulated I.Ca,L can effectively rescue dilated cardiomyopathy, revealing a promising new strategy for treating Heart Failure with Reduced Ejection Fraction (H.F.r.E.F.) by fine-tuning L.T.C.C. activity. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transcatheter aortic valve replacement, Calcium current, Heart Failure with Reduced Ejection Fraction, O.C.E.A.N.-Mitral registry, L-type calcium channel, Endocrine therapy, Paravalvular leak, Echocardiography, Cardio-oncology, H.E.R.2-targeted therapy, Anthracycline, Mitral regurgitation, Mortality risk prediction, Mitral transcatheter edge-to-edge repair, Aortic valve prosthesis, Cardiovascular disease risk factors, Implantation technique, A.P.A.C.H.E. score, Clinical Frailty Scale, Cardiac Intensive Care Unit, MitraScore, Dilated cardiomyopathy, A.C.U.R.A.T.E. neo2, S.O.F.A. score, Therapeutic target, Mortality prediction, Cardiopulmonary exercise testing, R.R.A.D. knockout, Breast cancer survivors, Mayo C.I.C.U. Admission Risk Score.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/">L-Type Calcium Channels Rescues Dilated Cardiomyopathy 10/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Calcium current. Key takeaway: L-Type Calcium Channels Rescues Dilated Cardiomyopathy.
Art]]></itunes:subtitle>
	<itunes:episode>93</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Calcium current. Key takeaway: L-Type Calcium Channels Rescues Dilated Cardiomyopathy.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40446851">PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40446850">Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40441608">Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40425074">Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41032675">RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/">https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40446851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40446851</a></p>
<p><strong>Summary:</strong> in A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. This multicenter retrospective registry analyzed predictors of paravalvular leak (P.V.L.) following implantation of the A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis during transcatheter aortic valve replacement (T.A.V.R.). The study evaluated if dedicated implantation techniques could further reduce P.V.L., a known complication the valve&#8217;s extended sealing skirt aims to mitigate. Such findings are critical for optimizing T.A.V.R. procedures and improving patient outcomes by minimizing post-procedural regurgitation.</p>
<h4>Article 2: Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40446850" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40446850</a></p>
<p><strong>Summary:</strong> This prospective, single-center cohort study evaluated the performance of four established scoring systems for predicting 90-day mortality in patients admitted to a contemporary Cardiac Intensive Care Unit (C.I.C.U.). Researchers compared the Acute Physiology and Chronic Health Evaluation (A.P.A.C.H.E.), Sequential Organ Failure Assessment (S.O.F.A.), Mayo C.I.C.U. Admission Risk Score (M.C.A.R.S.), and Clinical Frailty Scale (C.F.S.) scores in an unselected C.I.C.U. population. The findings identified which scoring systems offer superior predictive accuracy, thereby providing critical guidance for risk stratification and clinical decision-making in this high-risk patient group.</p>
<h4>Article 3: Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40441608" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40441608</a></p>
<p><strong>Summary:</strong> This study conducted an external validation of MitraScore, a novel tool developed for predicting mortality risk in patients undergoing mitral transcatheter edge-to-edge repair (M-T.E.E.R.). Using data from the O.C.E.A.N.-Mitral registry, researchers assessed MitraScore&#8217;s performance across diverse mitral regurgitation (M.R.) subtypes, extending beyond its initial derivation in functional M.R. The validation confirmed the score&#8217;s accuracy in identifying patients at higher mortality risk, thereby enhancing patient stratification and selection for M-T.E.E.R. across a broader spectrum of M.R. etiologies.</p>
<h4>Article 4: Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40425074" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40425074</a></p>
<p><strong>Summary:</strong> This retrospective, single-center study investigated cardiovascular disease risk factors (C.V.D.R.F.) in breast cancer survivors (B.C.S.) previously treated with either anthracycline/H.E.R.2-targeted therapy (A.C./H.) or endocrine therapy (E.T.). The research utilized echocardiography and cardiopulmonary exercise testing (C.P.E.T.) to assess cardiac function and fitness. The findings elucidated the differential impact of treatment regimens and the utility of these diagnostic tools in identifying B.C.S. at elevated C.V.D. risk, thereby informing tailored cardio-oncology surveillance strategies.</p>
<h4>Article 5: RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41032675" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41032675</a></p>
<p><strong>Summary:</strong> This study investigated the therapeutic potential of targeting L-type calcium channel (L.T.C.C.) regulation for heart failure, specifically challenging the dogma that enhanced trigger calcium (Ca2+) is always maladaptive. Researchers utilized myocardial R.R.A.D. knockout (c.R.A.D.Δ/Δ) mice, which exhibit a tonically modulated L.T.C.C. current (I.Ca,L) that preserves healthy myocardium. The findings demonstrated that this modulated I.Ca,L can effectively rescue dilated cardiomyopathy, revealing a promising new strategy for treating Heart Failure with Reduced Ejection Fraction (H.F.r.E.F.) by fine-tuning L.T.C.C. activity.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. P.V.L. in A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. This multicenter retrospective registry analyzed predictors of paravalvular leak (P.V.L.) following implantation of the A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis during transcatheter aortic valve replacement (T.A.V.R.). The study evaluated if dedicated implantation techniques could further reduce P.V.L., a known complication the valve&#8217;s extended sealing skirt aims to mitigate. Such findings are critical for optimizing T.A.V.R. procedures and improving patient outcomes by minimizing post-procedural regurgitation.</p>
<p>Article number two. Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit. This prospective, single-center cohort study evaluated the performance of four established scoring systems for predicting 90-day mortality in patients admitted to a contemporary Cardiac Intensive Care Unit (C.I.C.U.). Researchers compared the Acute Physiology and Chronic Health Evaluation (A.P.A.C.H.E.), Sequential Organ Failure Assessment (S.O.F.A.), Mayo C.I.C.U. Admission Risk Score (M.C.A.R.S.), and Clinical Frailty Scale (C.F.S.) scores in an unselected C.I.C.U. population. The findings identified which scoring systems offer superior predictive accuracy, thereby providing critical guidance for risk stratification and clinical decision-making in this high-risk patient group.</p>
<p>Article number three. Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the O.C.E.A.N.-mitral registry. This study conducted an external validation of MitraScore, a novel tool developed for predicting mortality risk in patients undergoing mitral transcatheter edge-to-edge repair (M-T.E.E.R.). Using data from the O.C.E.A.N.-Mitral registry, researchers assessed MitraScore&#8217;s performance across diverse mitral regurgitation (M.R.) subtypes, extending beyond its initial derivation in functional M.R. The validation confirmed the score&#8217;s accuracy in identifying patients at higher mortality risk, thereby enhancing patient stratification and selection for M-T.E.E.R. across a broader spectrum of M.R. etiologies.</p>
<p>Article number four. Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry. This retrospective, single-center study investigated cardiovascular disease risk factors (C.V.D.R.F.) in breast cancer survivors (B.C.S.) previously treated with either anthracycline/H.E.R.2-targeted therapy (A.C./H.) or endocrine therapy (E.T.). The research utilized echocardiography and cardiopulmonary exercise testing (C.P.E.T.) to assess cardiac function and fitness. The findings elucidated the differential impact of treatment regimens and the utility of these diagnostic tools in identifying B.C.S. at elevated C.V.D. risk, thereby informing tailored cardio-oncology surveillance strategies.</p>
<p>Article number five. R.R.A.D.-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure. This study investigated the therapeutic potential of targeting L-type calcium channel (L.T.C.C.) regulation for heart failure, specifically challenging the dogma that enhanced trigger calcium (Ca2+) is always maladaptive. Researchers utilized myocardial R.R.A.D. knockout (c.R.A.D.Δ/Δ) mice, which exhibit a tonically modulated L.T.C.C. current (I.Ca,L) that preserves healthy myocardium. The findings demonstrated that this modulated I.Ca,L can effectively rescue dilated cardiomyopathy, revealing a promising new strategy for treating Heart Failure with Reduced Ejection Fraction (H.F.r.E.F.) by fine-tuning L.T.C.C. activity. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Transcatheter aortic valve replacement, Calcium current, Heart Failure with Reduced Ejection Fraction, O.C.E.A.N.-Mitral registry, L-type calcium channel, Endocrine therapy, Paravalvular leak, Echocardiography, Cardio-oncology, H.E.R.2-targeted therapy, Anthracycline, Mitral regurgitation, Mortality risk prediction, Mitral transcatheter edge-to-edge repair, Aortic valve prosthesis, Cardiovascular disease risk factors, Implantation technique, A.P.A.C.H.E. score, Clinical Frailty Scale, Cardiac Intensive Care Unit, MitraScore, Dilated cardiomyopathy, A.C.U.R.A.T.E. neo2, S.O.F.A. score, Therapeutic target, Mortality prediction, Cardiopulmonary exercise testing, R.R.A.D. knockout, Breast cancer survivors, Mayo C.I.C.U. Admission Risk Score.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/">L-Type Calcium Channels Rescues Dilated Cardiomyopathy 10/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251002_060037.mp3" length="4789228" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Calcium current. Key takeaway: L-Type Calcium Channels Rescues Dilated Cardiomyopathy.
Article Links:
Article 1: PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. (International journal of cardiology)
Article 2: Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit. (International journal of cardiology)
Article 3: Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry. (International journal of cardiology)
Article 4: Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry. (International journal of cardiology)
Article 5: RRAD-reduction reveals efficacy of targeting L-type calcium channel regulation for treatment of heart failure. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/l-type-calcium-channels-rescues-dilated-cardiomyopathy-10-02-25/
 Featured Articles
Article 1: PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40446851
Summary: in A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. This multicenter retrospective registry analyzed predictors of paravalvular leak (P.V.L.) following implantation of the A.C.U.R.A.T.E. neo2 self-expanding aortic valve prosthesis during transcatheter aortic valve replacement (T.A.V.R.). The study evaluated if dedicated implantation techniques could further reduce P.V.L., a known complication the valve&#8217;s extended sealing skirt aims to mitigate. Such findings are critical for optimizing T.A.V.R. procedures and improving patient outcomes by minimizing post-procedural regurgitation.
Article 2: Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40446850
Summary: This prospective, single-center cohort study evaluated the performance of four established scoring systems for predicting 90-day mortality in patients admitted to a contemporary Cardiac Intensive Care Unit (C.I.C.U.). Researchers compared the Acute Physiology and Chronic Health Evaluation (A.P.A.C.H.E.), Sequential Organ Failure Assessment (S.O.F.A.), Mayo C.I.C.U. Admission Risk Score (M.C.A.R.S.), and Clinical Frailty Scale (C.F.S.) scores in an unselected C.I.C.U. population. The findings identified which scoring systems offer superior predictive accuracy, thereby providing critical guidance for risk stratification and clinical decision-making in this high-risk patient group.
Article 3: Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40441608
Summary: This study conducted an external validation of MitraScore, a novel tool developed for predicting mortality risk in patients undergoing mitral transcatheter edge-to-edge repair (M-T.E.E.R.). Using data from the O.C.E.A.N.-Mitral registry, researchers assessed MitraScore&#8217;s performance across diverse mitral regurgitation (M.R.) subtypes, extending beyond its initial derivation in functional M.R. The validation confirmed the score&#8217;s accuracy in identifying patients at higher mortality risk, thereby enhancing patient strat]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Calcium current. Key takeaway: L-Type Calcium Channels Rescues Dilated Cardiomyopathy.
Article Links:
Article 1: PVL in ACURATE neo2 self-expanding aortic valve prosthesis for transcatheter aortic valve replacement &#8211; A multicenter retrospective registry analysis. (International journal of cardiology)
Article 2: Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit. (International journal of cardiology)
Article 3: Validation of MitraScore in diverse mitral regurgitation subtypes: Insights from the OCEAN-mitral registry. (International journal of cardiology)
Article 4: Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Regis]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>A.I. Enables Preclinical ATTR-CM Diagnosis 10/02/25</title>
	<link>https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/</link>
	<pubDate>Thu, 02 Oct 2025 06:57:08 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like preclinical diagnosis and psychosocial well-being. Key takeaway: A.I. Enables Preclinical ATTR-CM Diagnosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40513026">Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40679604">Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40331280">Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41033593">&#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41033438">Moving Beyond Survival in Heart Transplantation.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/">https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40513026" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40513026</a></p>
<p><strong>Summary:</strong> Article number one. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</p>
<h4>Article 2: Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40679604" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40679604</a></p>
<p><strong>Summary:</strong> Article number two. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</p>
<h4>Article 3: Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40331280" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40331280</a></p>
<p><strong>Summary:</strong> Article number three. Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</p>
<h4>Article 4: &#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033593" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033593</a></p>
<p><strong>Summary:</strong> Article number four. Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020.</p>
<h4>Article 5: Moving Beyond Survival in Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033438" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033438</a></p>
<p><strong>Summary:</strong> Article number five. Moving Beyond Survival in Heart Transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</p>
<p>Article number two. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</p>
<p>Article number three. Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</p>
<p>Article number four. Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020.</p>
<p>Article number five. Moving Beyond Survival in Heart Transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preclinical diagnosis, psychosocial well-being, mortality trends, public health, pediatric care, illicit drug use, sudden cardiac death, intravenous rehydration, electrocardiography, stroke, fluid overload, transthoracic echocardiography, methamphetamine, cerebral infarction, Severe acute malnutrition, Heart transplantation, cocaine, immunosuppressive therapy, quality of life, Artificial intelligence, long-term outcomes, Hypertension, gastroenteritis, transthyretin amyloid cardiomyopathy, Ventricular arrhythmias.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/">A.I. Enables Preclinical ATTR-CM Diagnosis 10/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like preclinical diagnosis and psychosocial well-being. Key takeaway: A.I. Enables Preclinical ATTR-CM Diagnosis.
Article Links:
Article 1]]></itunes:subtitle>
	<itunes:episode>92</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like preclinical diagnosis and psychosocial well-being. Key takeaway: A.I. Enables Preclinical ATTR-CM Diagnosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40513026">Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40679604">Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40331280">Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41033593">&#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41033438">Moving Beyond Survival in Heart Transplantation.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/">https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40513026" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40513026</a></p>
<p><strong>Summary:</strong> Article number one. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</p>
<h4>Article 2: Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40679604" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40679604</a></p>
<p><strong>Summary:</strong> Article number two. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</p>
<h4>Article 3: Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40331280" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40331280</a></p>
<p><strong>Summary:</strong> Article number three. Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</p>
<h4>Article 4: &#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033593" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033593</a></p>
<p><strong>Summary:</strong> Article number four. Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020.</p>
<h4>Article 5: Moving Beyond Survival in Heart Transplantation.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41033438" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41033438</a></p>
<p><strong>Summary:</strong> Article number five. Moving Beyond Survival in Heart Transplantation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.</p>
<p>Article number two. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.</p>
<p>Article number three. Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.</p>
<p>Article number four. Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020.</p>
<p>Article number five. Moving Beyond Survival in Heart Transplantation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>preclinical diagnosis, psychosocial well-being, mortality trends, public health, pediatric care, illicit drug use, sudden cardiac death, intravenous rehydration, electrocardiography, stroke, fluid overload, transthoracic echocardiography, methamphetamine, cerebral infarction, Severe acute malnutrition, Heart transplantation, cocaine, immunosuppressive therapy, quality of life, Artificial intelligence, long-term outcomes, Hypertension, gastroenteritis, transthyretin amyloid cardiomyopathy, Ventricular arrhythmias.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/">A.I. Enables Preclinical ATTR-CM Diagnosis 10/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251002_025652.mp3" length="964901" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like preclinical diagnosis and psychosocial well-being. Key takeaway: A.I. Enables Preclinical ATTR-CM Diagnosis.
Article Links:
Article 1: Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis. (The New England journal of medicine)
Article 2: Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. (European heart journal)
Article 3: Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study. (European heart journal)
Article 4: &#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;. (The American journal of cardiology)
Article 5: Moving Beyond Survival in Heart Transplantation. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/a-i-enables-preclinical-attr-cm-diagnosis-10-02-25/
 Featured Articles
Article 1: Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40513026
Summary: Article number one. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.
Article 2: Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40679604
Summary: Article number two. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.
Article 3: Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40331280
Summary: Article number three. Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.
Article 4: &#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41033593
Summary: Article number four. Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020.
Article 5: Moving Beyond Survival in Heart Transplantation.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41033438
Summary: Article number five. Moving Beyond Survival in Heart Transplantation.
 Transcript

Today&#8217;s date is October 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.
Article number two. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.
Article number three. Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study.
Article number four. Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020.
Article number five. Moving Beyond Survival in Heart Transplantation. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
preclinical diagnosis, psychosocial well-being, mortality trends, public health, pediatric care, illicit drug use, sudden cardiac death, intravenous rehydration, electrocardiography, stroke, fluid overload, transthoracic echocardiography, methamphetamine, cerebral infarction, Severe acute malnutrition, Heart transplantation, cocaine, immunosuppressive therapy, quality of life, Artificial intelligence, long-term outcomes, Hypertension, gastroenteritis, transthyretin amyloid cardiomyopathy, Ventricular arrhythmias.
 About
Concise summaries of cardiovascular research]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 02, 2025. This episode summarizes 5 key cardiology studies on topics like preclinical diagnosis and psychosocial well-being. Key takeaway: A.I. Enables Preclinical ATTR-CM Diagnosis.
Article Links:
Article 1: Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis. (The New England journal of medicine)
Article 2: Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. (European heart journal)
Article 3: Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study. (European heart journal)
Article 4: &#8220;Evolving Trends of Hypertension and Cerebral Infarction-Related Mortality in the United States from 2000-2020&#8221;. (The American journal of cardiology)
Article 5: Moving Beyond Survival in Heart Transplantation. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/a-i]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Targeted Therapies Transform A.T.T.R.-C.M. Outcomes 10/01/25</title>
	<link>https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/</link>
	<pubDate>Thu, 02 Oct 2025 02:43:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like diagnostic imaging and Cardiovascular health score. Key takeaway: Targeted Therapies Transform A.T.T.R.-C.M. Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41031977">Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41030053">Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41032333">Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41032326">Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41031982">A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.</a> (JACC. Cardiovascular imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/">https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41031977" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41031977</a></p>
<p><strong>Summary:</strong> Article number one. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</p>
<h4>Article 2: Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41030053" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41030053</a></p>
<p><strong>Summary:</strong> Article number two. Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</p>
<h4>Article 3: Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41032333" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41032333</a></p>
<p><strong>Summary:</strong> Article number three. Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</p>
<h4>Article 4: Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41032326" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41032326</a></p>
<p><strong>Summary:</strong> Article number four. Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</p>
<h4>Article 5: A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41031982" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41031982</a></p>
<p><strong>Summary:</strong> Article number five. A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</p>
<p>Article number two. Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</p>
<p>Article number three. Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</p>
<p>Article number four. Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</p>
<p>Article number five. A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>diagnostic imaging, Cardiovascular health score, artificial intelligence, Dilated Cardiomyopathy, hypertension, Heart Failure with Preserved Ejection Fraction, Mitral Valve Prolapse, echocardiography, polygenic score, amyloid reduction, A.T.T.R.-C.M., transthyretin stabilizers, waist-to-height ratio, prevention, kidney events, body mass index, tafamidis, peripartum cardiomyopathy, cancer therapy-related cardiomyopathy, midlife cardiovascular disease, young adulthood, central adiposity, Transthyretin amyloid cardiomyopathy, Deep learning, alcohol-induced cardiomyopathy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/">Targeted Therapies Transform A.T.T.R.-C.M. Outcomes 10/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like diagnostic imaging and Cardiovascular health score. Key takeaway: Targeted Therapies Transform A.T.T.R.-C.M. Outcomes.
Article Links:]]></itunes:subtitle>
	<itunes:episode>91</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like diagnostic imaging and Cardiovascular health score. Key takeaway: Targeted Therapies Transform A.T.T.R.-C.M. Outcomes.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41031977">Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41030053">Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41032333">Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41032326">Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41031982">A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.</a> (JACC. Cardiovascular imaging)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/">https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41031977" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41031977</a></p>
<p><strong>Summary:</strong> Article number one. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</p>
<h4>Article 2: Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41030053" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41030053</a></p>
<p><strong>Summary:</strong> Article number two. Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</p>
<h4>Article 3: Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41032333" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41032333</a></p>
<p><strong>Summary:</strong> Article number three. Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</p>
<h4>Article 4: Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41032326" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41032326</a></p>
<p><strong>Summary:</strong> Article number four. Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</p>
<h4>Article 5: A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41031982" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41031982</a></p>
<p><strong>Summary:</strong> Article number five. A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?</p>
<p>Article number two. Transthyretin amyloid cardiomyopathy: from cause to novel treatments.</p>
<p>Article number three. Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.</p>
<p>Article number four. Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.</p>
<p>Article number five. A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>diagnostic imaging, Cardiovascular health score, artificial intelligence, Dilated Cardiomyopathy, hypertension, Heart Failure with Preserved Ejection Fraction, Mitral Valve Prolapse, echocardiography, polygenic score, amyloid reduction, A.T.T.R.-C.M., transthyretin stabilizers, waist-to-height ratio, prevention, kidney events, body mass index, tafamidis, peripartum cardiomyopathy, cancer therapy-related cardiomyopathy, midlife cardiovascular disease, young adulthood, central adiposity, Transthyretin amyloid cardiomyopathy, Deep learning, alcohol-induced cardiomyopathy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/">Targeted Therapies Transform A.T.T.R.-C.M. Outcomes 10/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251001_224317.mp3" length="1003354" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like diagnostic imaging and Cardiovascular health score. Key takeaway: Targeted Therapies Transform A.T.T.R.-C.M. Outcomes.
Article Links:
Article 1: Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction? (Journal of the American College of Cardiology)
Article 2: Transthyretin amyloid cardiomyopathy: from cause to novel treatments. (European heart journal)
Article 3: Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies. (JAMA cardiology)
Article 4: Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife. (JAMA cardiology)
Article 5: A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram. (JACC. Cardiovascular imaging)
Full episode page: https://podcast.explainheart.com/podcast/targeted-therapies-transform-a-t-t-r-c-m-outcomes-10-01-25/
 Featured Articles
Article 1: Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41031977
Summary: Article number one. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?
Article 2: Transthyretin amyloid cardiomyopathy: from cause to novel treatments.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41030053
Summary: Article number two. Transthyretin amyloid cardiomyopathy: from cause to novel treatments.
Article 3: Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41032333
Summary: Article number three. Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.
Article 4: Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41032326
Summary: Article number four. Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.
Article 5: A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41031982
Summary: Article number five. A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram.
 Transcript

Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?
Article number two. Transthyretin amyloid cardiomyopathy: from cause to novel treatments.
Article number three. Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies.
Article number four. Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife.
Article number five. A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
diagnostic imaging, Cardiovascular health score, artificial intelligence, Dilated Cardiomyopathy, hypertension, Heart Failure with Preserved Ejection Fraction, Mitral Valve Prolapse, echocardiography, polygenic score, amyloid reduction, A.T.T.R.-C.M., transthyretin stabilizers, waist-to-height ratio, prevention, kidney events, body mass index, tafamidis, peripartum cardiomyopathy, cancer therapy-related cardiomyopathy, midlife cardiovascular disease, young adulthood, central adiposity, Transthyretin amyloid cardiomyopathy, Deep learning, alcohol-induced cardiomyopathy.
 About
Concise summaries of ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like diagnostic imaging and Cardiovascular health score. Key takeaway: Targeted Therapies Transform A.T.T.R.-C.M. Outcomes.
Article Links:
Article 1: Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction? (Journal of the American College of Cardiology)
Article 2: Transthyretin amyloid cardiomyopathy: from cause to novel treatments. (European heart journal)
Article 3: Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies. (JAMA cardiology)
Article 4: Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife. (JAMA cardiology)
Article 5: A Deep Learning Model to Identify Mitral Valve Prolapse From the Echocardiogram. (JACC. Cardiovascular imaging)
Full episode page: https://podcast.explainheart.com/podcast/targeted-therapies-trans]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>RV Myocardial Work Predicts CRT Success 10/01/25</title>
	<link>https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/</link>
	<pubDate>Wed, 01 Oct 2025 10:00:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like Percutaneous Coronary Intervention and ARCHBR criteria. Key takeaway: RV Myocardial Work Predicts CRT Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40414269">Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40414268">Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41027501">The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40460977">Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40456317">Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/">https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40414269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40414269</a></p>
<p><strong>Summary:</strong> This study utilized noninvasive pressure-strain loop echocardiography to assess right ventricular myocardial work, finding that improvements in right ventricular myocardial work indices were associated with successful cardiac resynchronization therapy response. The research demonstrated that this novel tool provides a more precise estimation of right ventricular performance, highlighting its potential in predicting therapy success.</p>
<h4>Article 2: Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40414268" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40414268</a></p>
<p><strong>Summary:</strong> This prospective validation study in an Egyptian percutaneous coronary intervention population assessed the ARCHBR criteria&#8217;s predictive utility for major bleeding after five years of global introduction. The study described contemporary bleeding patterns and established a regional benchmark for post-percutaneous coronary intervention major bleeding outcomes, indicating the continued relevance and applicability of the ARCHBR criteria.</p>
<h4>Article 3: The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41027501" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41027501</a></p>
<p><strong>Summary:</strong> Utilizing machine learning on over one million heart failure patient records, this study identified five distinct comorbidity clusters and evaluated their association with short-term clinical outcomes. The findings highlight significant differences in clinical outcomes based on specific comorbidity patterns, underscoring the need for tailored management strategies for heart failure patients.</p>
<h4>Article 4: Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40460977" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40460977</a></p>
<p><strong>Summary:</strong> This study developed and validated an electrocardiogram algorithm using lead V3 morphology to accurately differentiate the origin of outflow tract ventricular arrhythmias, which is crucial for effective ablation planning. The algorithm demonstrated the potential to overcome the challenges of distinguishing these arrhythmias based on their electrocardiogram patterns, improving procedural guidance.</p>
<h4>Article 5: Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40456317" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40456317</a></p>
<p><strong>Summary:</strong> This study employed Bald Eagle Search Optimization for feature selection to enhance the performance of multiple machine learning models in predicting coronary artery disease. By optimizing feature selection, the research aimed to improve the accuracy and efficiency of non-invasive coronary artery disease prediction, offering a valuable alternative to traditional diagnostics.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy. This study utilized noninvasive pressure-strain loop echocardiography to assess right ventricular myocardial work, finding that improvements in right ventricular myocardial work indices were associated with successful cardiac resynchronization therapy response. The research demonstrated that this novel tool provides a more precise estimation of right ventricular performance, highlighting its potential in predicting therapy success.</p>
<p>Article number two. Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt. This prospective validation study in an Egyptian percutaneous coronary intervention population assessed the ARCHBR criteria&#8217;s predictive utility for major bleeding after five years of global introduction. The study described contemporary bleeding patterns and established a regional benchmark for post-percutaneous coronary intervention major bleeding outcomes, indicating the continued relevance and applicability of the ARCHBR criteria.</p>
<p>Article number three. The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis. Utilizing machine learning on over one million heart failure patient records, this study identified five distinct comorbidity clusters and evaluated their association with short-term clinical outcomes. The findings highlight significant differences in clinical outcomes based on specific comorbidity patterns, underscoring the need for tailored management strategies for heart failure patients.</p>
<p>Article number four. Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias. This study developed and validated an electrocardiogram algorithm using lead V3 morphology to accurately differentiate the origin of outflow tract ventricular arrhythmias, which is crucial for effective ablation planning. The algorithm demonstrated the potential to overcome the challenges of distinguishing these arrhythmias based on their electrocardiogram patterns, improving procedural guidance.</p>
<p>Article number five. Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection. This study employed Bald Eagle Search Optimization for feature selection to enhance the performance of multiple machine learning models in predicting coronary artery disease. By optimizing feature selection, the research aimed to improve the accuracy and efficiency of non-invasive coronary artery disease prediction, offering a valuable alternative to traditional diagnostics. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Percutaneous Coronary Intervention, ARCHBR criteria, Pressure-Strain Loop, Machine Learning, Cardiac Resynchronization Therapy, Bald Eagle Search Optimization, Outflow Tract Ventricular Arrhythmias, Feature Selection, Cluster Analysis, Echocardiography, Comorbidity Patterns, Heart Failure, Right Ventricular Myocardial Work, Real-world validation, Clinical Outcomes, Ablation Planning, Lead V3 Morphology, Major Bleeding, Electrocardiogram Algorithm, Prediction Models, Coronary Artery Disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/">RV Myocardial Work Predicts CRT Success 10/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like Percutaneous Coronary Intervention and ARCHBR criteria. Key takeaway: RV Myocardial Work Predicts CRT Success.
Article Links:
Article]]></itunes:subtitle>
	<itunes:episode>90</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like Percutaneous Coronary Intervention and ARCHBR criteria. Key takeaway: RV Myocardial Work Predicts CRT Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40414269">Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40414268">Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41027501">The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40460977">Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40456317">Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/">https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40414269" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40414269</a></p>
<p><strong>Summary:</strong> This study utilized noninvasive pressure-strain loop echocardiography to assess right ventricular myocardial work, finding that improvements in right ventricular myocardial work indices were associated with successful cardiac resynchronization therapy response. The research demonstrated that this novel tool provides a more precise estimation of right ventricular performance, highlighting its potential in predicting therapy success.</p>
<h4>Article 2: Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40414268" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40414268</a></p>
<p><strong>Summary:</strong> This prospective validation study in an Egyptian percutaneous coronary intervention population assessed the ARCHBR criteria&#8217;s predictive utility for major bleeding after five years of global introduction. The study described contemporary bleeding patterns and established a regional benchmark for post-percutaneous coronary intervention major bleeding outcomes, indicating the continued relevance and applicability of the ARCHBR criteria.</p>
<h4>Article 3: The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41027501" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41027501</a></p>
<p><strong>Summary:</strong> Utilizing machine learning on over one million heart failure patient records, this study identified five distinct comorbidity clusters and evaluated their association with short-term clinical outcomes. The findings highlight significant differences in clinical outcomes based on specific comorbidity patterns, underscoring the need for tailored management strategies for heart failure patients.</p>
<h4>Article 4: Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40460977" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40460977</a></p>
<p><strong>Summary:</strong> This study developed and validated an electrocardiogram algorithm using lead V3 morphology to accurately differentiate the origin of outflow tract ventricular arrhythmias, which is crucial for effective ablation planning. The algorithm demonstrated the potential to overcome the challenges of distinguishing these arrhythmias based on their electrocardiogram patterns, improving procedural guidance.</p>
<h4>Article 5: Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40456317" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40456317</a></p>
<p><strong>Summary:</strong> This study employed Bald Eagle Search Optimization for feature selection to enhance the performance of multiple machine learning models in predicting coronary artery disease. By optimizing feature selection, the research aimed to improve the accuracy and efficiency of non-invasive coronary artery disease prediction, offering a valuable alternative to traditional diagnostics.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy. This study utilized noninvasive pressure-strain loop echocardiography to assess right ventricular myocardial work, finding that improvements in right ventricular myocardial work indices were associated with successful cardiac resynchronization therapy response. The research demonstrated that this novel tool provides a more precise estimation of right ventricular performance, highlighting its potential in predicting therapy success.</p>
<p>Article number two. Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt. This prospective validation study in an Egyptian percutaneous coronary intervention population assessed the ARCHBR criteria&#8217;s predictive utility for major bleeding after five years of global introduction. The study described contemporary bleeding patterns and established a regional benchmark for post-percutaneous coronary intervention major bleeding outcomes, indicating the continued relevance and applicability of the ARCHBR criteria.</p>
<p>Article number three. The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis. Utilizing machine learning on over one million heart failure patient records, this study identified five distinct comorbidity clusters and evaluated their association with short-term clinical outcomes. The findings highlight significant differences in clinical outcomes based on specific comorbidity patterns, underscoring the need for tailored management strategies for heart failure patients.</p>
<p>Article number four. Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias. This study developed and validated an electrocardiogram algorithm using lead V3 morphology to accurately differentiate the origin of outflow tract ventricular arrhythmias, which is crucial for effective ablation planning. The algorithm demonstrated the potential to overcome the challenges of distinguishing these arrhythmias based on their electrocardiogram patterns, improving procedural guidance.</p>
<p>Article number five. Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection. This study employed Bald Eagle Search Optimization for feature selection to enhance the performance of multiple machine learning models in predicting coronary artery disease. By optimizing feature selection, the research aimed to improve the accuracy and efficiency of non-invasive coronary artery disease prediction, offering a valuable alternative to traditional diagnostics. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Percutaneous Coronary Intervention, ARCHBR criteria, Pressure-Strain Loop, Machine Learning, Cardiac Resynchronization Therapy, Bald Eagle Search Optimization, Outflow Tract Ventricular Arrhythmias, Feature Selection, Cluster Analysis, Echocardiography, Comorbidity Patterns, Heart Failure, Right Ventricular Myocardial Work, Real-world validation, Clinical Outcomes, Ablation Planning, Lead V3 Morphology, Major Bleeding, Electrocardiogram Algorithm, Prediction Models, Coronary Artery Disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/">RV Myocardial Work Predicts CRT Success 10/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251001_060007.mp3" length="3223553" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like Percutaneous Coronary Intervention and ARCHBR criteria. Key takeaway: RV Myocardial Work Predicts CRT Success.
Article Links:
Article 1: Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy. (The American journal of cardiology)
Article 2: Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt. (The American journal of cardiology)
Article 3: The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis. (The American journal of cardiology)
Article 4: Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias. (International journal of cardiology)
Article 5: Comparative analysis of machine learning models for coronary artery disease prediction with optimized feature selection. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/rv-myocardial-work-predicts-crt-success-10-01-25/
 Featured Articles
Article 1: Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40414269
Summary: This study utilized noninvasive pressure-strain loop echocardiography to assess right ventricular myocardial work, finding that improvements in right ventricular myocardial work indices were associated with successful cardiac resynchronization therapy response. The research demonstrated that this novel tool provides a more precise estimation of right ventricular performance, highlighting its potential in predicting therapy success.
Article 2: Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40414268
Summary: This prospective validation study in an Egyptian percutaneous coronary intervention population assessed the ARCHBR criteria&#8217;s predictive utility for major bleeding after five years of global introduction. The study described contemporary bleeding patterns and established a regional benchmark for post-percutaneous coronary intervention major bleeding outcomes, indicating the continued relevance and applicability of the ARCHBR criteria.
Article 3: The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41027501
Summary: Utilizing machine learning on over one million heart failure patient records, this study identified five distinct comorbidity clusters and evaluated their association with short-term clinical outcomes. The findings highlight significant differences in clinical outcomes based on specific comorbidity patterns, underscoring the need for tailored management strategies for heart failure patients.
Article 4: Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40460977
Summary: This study developed and validated an electrocardiogram algorithm using lead V3 morphology to accurately differentiate the origin of outflow tract ventricular arrhythmias, which is crucial for effective ablation planning. The algorithm demonstrated the potential to overcome the challenges of distinguishing these arrhythmias based on their electrocardiogram patterns, improving procedural guidance.
Article 5: Comparative analysis of machine learning models for coronary artery disease pred]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like Percutaneous Coronary Intervention and ARCHBR criteria. Key takeaway: RV Myocardial Work Predicts CRT Success.
Article Links:
Article 1: Noninvasive Right Ventricular Myocardial Work by Pressure-Strain Loop: A New Perspective on Right Ventricular Function and Cardiac Resynchronization Therapy. (The American journal of cardiology)
Article 2: Five Years After ARCHBR&#8217;s Global Introduction: A Prospective Validation Study in Egypt. (The American journal of cardiology)
Article 3: The Impact of Comorbidity Patterns on Clinical Outcomes in Heart Failure: A Machine Learning-Based Cluster Analysis. (The American journal of cardiology)
Article 4: Development and validation of an ECG algorithm based on lead V3 morphology to determine the origin of outflow tract ventricular arrhythmias. (International journal of cardiology)
Article 5: Comparative analysis of machine learni]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TAVR Outperforms Conservative Care in Low-Flow AS 10/01/25</title>
	<link>https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/</link>
	<pubDate>Wed, 01 Oct 2025 06:58:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter aortic valve replacement and cardiac catheterization laboratory. Key takeaway: TAVR Outperforms Conservative Care in Low-Flow AS.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41025556">Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40482871">Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40482870">Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40451445">Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40441582">Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/">https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025556" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025556</a></p>
<p><strong>Summary:</strong> This phase 3 trial demonstrated that sotatercept, an activin-signaling inhibitor, significantly improved the 6-minute walk distance and reduced pulmonary vascular resistance in patients with pulmonary arterial hypertension diagnosed within the prior year. These findings suggest that early intervention with sotatercept offers substantial clinical benefit in this recently diagnosed patient population.</p>
<h4>Article 2: Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40482871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40482871</a></p>
<p><strong>Summary:</strong> This real-world study analyzed patients undergoing percutaneous coronary intervention and found that while proton pump inhibitors reduced gastrointestinal bleeding, there was no significant association with improved long-term prognosis, including major adverse cardiovascular events or mortality. The results suggest that the benefit of routine proton pump inhibitor use after percutaneous coronary intervention may be limited to gastrointestinal bleeding reduction alone.</p>
<h4>Article 3: Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40482870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40482870</a></p>
<p><strong>Summary:</strong> This study compared drug-coated balloons to newer-generation drug-eluting stents after directional coronary atherectomy for left main bifurcation lesions, finding that both strategies had comparable rates of target lesion revascularization at one year. The results indicate that drug-coated balloons are a viable alternative to drug-eluting stents in this complex scenario, offering similar efficacy.</p>
<h4>Article 4: Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40451445" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40451445</a></p>
<p><strong>Summary:</strong> This analysis of the Nationwide Readmissions Database revealed that higher procedural volumes for mechanical circulatory support and cardiac catheterization laboratory procedures in hospitals were associated with lower mortality among cardiogenic shock admissions not receiving these specific interventions. The findings suggest that hospital experience with complex interventions indirectly benefits all cardiogenic shock patients by fostering expertise and improved care pathways.</p>
<h4>Article 5: Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40441582" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40441582</a></p>
<p><strong>Summary:</strong> This U.S.-based retrospective study compared outcomes for transcatheter aortic valve replacement versus conservative management in patients with low-flow, low-gradient aortic stenosis, demonstrating a significant reduction in mortality with transcatheter aortic valve replacement. The results strongly support transcatheter aortic valve replacement as the preferred strategy for select patients with this challenging form of aortic stenosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. This phase 3 trial demonstrated that sotatercept, an activin-signaling inhibitor, significantly improved the 6-minute walk distance and reduced pulmonary vascular resistance in patients with pulmonary arterial hypertension diagnosed within the prior year. These findings suggest that early intervention with sotatercept offers substantial clinical benefit in this recently diagnosed patient population.</p>
<p>Article number two. Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention. This real-world study analyzed patients undergoing percutaneous coronary intervention and found that while proton pump inhibitors reduced gastrointestinal bleeding, there was no significant association with improved long-term prognosis, including major adverse cardiovascular events or mortality. The results suggest that the benefit of routine proton pump inhibitor use after percutaneous coronary intervention may be limited to gastrointestinal bleeding reduction alone.</p>
<p>Article number three. Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions. This study compared drug-coated balloons to newer-generation drug-eluting stents after directional coronary atherectomy for left main bifurcation lesions, finding that both strategies had comparable rates of target lesion revascularization at one year. The results indicate that drug-coated balloons are a viable alternative to drug-eluting stents in this complex scenario, offering similar efficacy.</p>
<p>Article number four. Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock. This analysis of the Nationwide Readmissions Database revealed that higher procedural volumes for mechanical circulatory support and cardiac catheterization laboratory procedures in hospitals were associated with lower mortality among cardiogenic shock admissions not receiving these specific interventions. The findings suggest that hospital experience with complex interventions indirectly benefits all cardiogenic shock patients by fostering expertise and improved care pathways.</p>
<p>Article number five. Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis. This U.S.-based retrospective study compared outcomes for transcatheter aortic valve replacement versus conservative management in patients with low-flow, low-gradient aortic stenosis, demonstrating a significant reduction in mortality with transcatheter aortic valve replacement. The results strongly support transcatheter aortic valve replacement as the preferred strategy for select patients with this challenging form of aortic stenosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transcatheter aortic valve replacement, cardiac catheterization laboratory, hospital volume, gastrointestinal bleeding, directional coronary atherectomy, percutaneous coronary intervention, pulmonary arterial hypertension, 6-minute walk distance, sotatercept, proton pump inhibitors, mechanical circulatory support, left main bifurcation lesions, cardiogenic shock, low-flow low-gradient aortic stenosis, activin signaling inhibitor, drug-eluting stent, conservative management, major adverse cardiovascular events, drug-coated balloon, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/">TAVR Outperforms Conservative Care in Low-Flow AS 10/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter aortic valve replacement and cardiac catheterization laboratory. Key takeaway: TAVR Outperforms Conservative Care in Lo]]></itunes:subtitle>
	<itunes:episode>89</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter aortic valve replacement and cardiac catheterization laboratory. Key takeaway: TAVR Outperforms Conservative Care in Low-Flow AS.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41025556">Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40482871">Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40482870">Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40451445">Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40441582">Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/">https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41025556" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41025556</a></p>
<p><strong>Summary:</strong> This phase 3 trial demonstrated that sotatercept, an activin-signaling inhibitor, significantly improved the 6-minute walk distance and reduced pulmonary vascular resistance in patients with pulmonary arterial hypertension diagnosed within the prior year. These findings suggest that early intervention with sotatercept offers substantial clinical benefit in this recently diagnosed patient population.</p>
<h4>Article 2: Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40482871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40482871</a></p>
<p><strong>Summary:</strong> This real-world study analyzed patients undergoing percutaneous coronary intervention and found that while proton pump inhibitors reduced gastrointestinal bleeding, there was no significant association with improved long-term prognosis, including major adverse cardiovascular events or mortality. The results suggest that the benefit of routine proton pump inhibitor use after percutaneous coronary intervention may be limited to gastrointestinal bleeding reduction alone.</p>
<h4>Article 3: Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40482870" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40482870</a></p>
<p><strong>Summary:</strong> This study compared drug-coated balloons to newer-generation drug-eluting stents after directional coronary atherectomy for left main bifurcation lesions, finding that both strategies had comparable rates of target lesion revascularization at one year. The results indicate that drug-coated balloons are a viable alternative to drug-eluting stents in this complex scenario, offering similar efficacy.</p>
<h4>Article 4: Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40451445" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40451445</a></p>
<p><strong>Summary:</strong> This analysis of the Nationwide Readmissions Database revealed that higher procedural volumes for mechanical circulatory support and cardiac catheterization laboratory procedures in hospitals were associated with lower mortality among cardiogenic shock admissions not receiving these specific interventions. The findings suggest that hospital experience with complex interventions indirectly benefits all cardiogenic shock patients by fostering expertise and improved care pathways.</p>
<h4>Article 5: Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40441582" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40441582</a></p>
<p><strong>Summary:</strong> This U.S.-based retrospective study compared outcomes for transcatheter aortic valve replacement versus conservative management in patients with low-flow, low-gradient aortic stenosis, demonstrating a significant reduction in mortality with transcatheter aortic valve replacement. The results strongly support transcatheter aortic valve replacement as the preferred strategy for select patients with this challenging form of aortic stenosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is October 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. This phase 3 trial demonstrated that sotatercept, an activin-signaling inhibitor, significantly improved the 6-minute walk distance and reduced pulmonary vascular resistance in patients with pulmonary arterial hypertension diagnosed within the prior year. These findings suggest that early intervention with sotatercept offers substantial clinical benefit in this recently diagnosed patient population.</p>
<p>Article number two. Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention. This real-world study analyzed patients undergoing percutaneous coronary intervention and found that while proton pump inhibitors reduced gastrointestinal bleeding, there was no significant association with improved long-term prognosis, including major adverse cardiovascular events or mortality. The results suggest that the benefit of routine proton pump inhibitor use after percutaneous coronary intervention may be limited to gastrointestinal bleeding reduction alone.</p>
<p>Article number three. Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions. This study compared drug-coated balloons to newer-generation drug-eluting stents after directional coronary atherectomy for left main bifurcation lesions, finding that both strategies had comparable rates of target lesion revascularization at one year. The results indicate that drug-coated balloons are a viable alternative to drug-eluting stents in this complex scenario, offering similar efficacy.</p>
<p>Article number four. Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock. This analysis of the Nationwide Readmissions Database revealed that higher procedural volumes for mechanical circulatory support and cardiac catheterization laboratory procedures in hospitals were associated with lower mortality among cardiogenic shock admissions not receiving these specific interventions. The findings suggest that hospital experience with complex interventions indirectly benefits all cardiogenic shock patients by fostering expertise and improved care pathways.</p>
<p>Article number five. Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis. This U.S.-based retrospective study compared outcomes for transcatheter aortic valve replacement versus conservative management in patients with low-flow, low-gradient aortic stenosis, demonstrating a significant reduction in mortality with transcatheter aortic valve replacement. The results strongly support transcatheter aortic valve replacement as the preferred strategy for select patients with this challenging form of aortic stenosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transcatheter aortic valve replacement, cardiac catheterization laboratory, hospital volume, gastrointestinal bleeding, directional coronary atherectomy, percutaneous coronary intervention, pulmonary arterial hypertension, 6-minute walk distance, sotatercept, proton pump inhibitors, mechanical circulatory support, left main bifurcation lesions, cardiogenic shock, low-flow low-gradient aortic stenosis, activin signaling inhibitor, drug-eluting stent, conservative management, major adverse cardiovascular events, drug-coated balloon, mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/">TAVR Outperforms Conservative Care in Low-Flow AS 10/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/10/cardiology_today_20251001_025720.mp3" length="3475582" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter aortic valve replacement and cardiac catheterization laboratory. Key takeaway: TAVR Outperforms Conservative Care in Low-Flow AS.
Article Links:
Article 1: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. (The New England journal of medicine)
Article 2: Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention. (The American journal of cardiology)
Article 3: Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions. (The American journal of cardiology)
Article 4: Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock. (The American journal of cardiology)
Article 5: Comparative Outcomes of Transcatheter Aortic Valve Replacement and Conservative Management in Patients with Low-Flow, Low-Gradient Aortic Stenosis. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/tavr-outperforms-conservative-care-in-low-flow-as-10-01-25/
 Featured Articles
Article 1: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41025556
Summary: This phase 3 trial demonstrated that sotatercept, an activin-signaling inhibitor, significantly improved the 6-minute walk distance and reduced pulmonary vascular resistance in patients with pulmonary arterial hypertension diagnosed within the prior year. These findings suggest that early intervention with sotatercept offers substantial clinical benefit in this recently diagnosed patient population.
Article 2: Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40482871
Summary: This real-world study analyzed patients undergoing percutaneous coronary intervention and found that while proton pump inhibitors reduced gastrointestinal bleeding, there was no significant association with improved long-term prognosis, including major adverse cardiovascular events or mortality. The results suggest that the benefit of routine proton pump inhibitor use after percutaneous coronary intervention may be limited to gastrointestinal bleeding reduction alone.
Article 3: Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40482870
Summary: This study compared drug-coated balloons to newer-generation drug-eluting stents after directional coronary atherectomy for left main bifurcation lesions, finding that both strategies had comparable rates of target lesion revascularization at one year. The results indicate that drug-coated balloons are a viable alternative to drug-eluting stents in this complex scenario, offering similar efficacy.
Article 4: Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40451445
Summary: This analysis of the Nationwide Readmissions Database revealed that higher procedural volumes for mechanical circulatory support and cardiac catheterization laboratory procedures in hospitals were associated with lower mortality among cardiogenic shock admissions not receiving these specific interventions. The findings suggest that hospital experience with complex interventions indirectly benefits all cardiogenic shock patients by fostering ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded October 01, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter aortic valve replacement and cardiac catheterization laboratory. Key takeaway: TAVR Outperforms Conservative Care in Low-Flow AS.
Article Links:
Article 1: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. (The New England journal of medicine)
Article 2: Proton Pump Inhibitor Use, Gastrointestinal Bleeding Reduction, and Long-Term Prognosis After Percutaneous Coronary Intervention. (The American journal of cardiology)
Article 3: Drug-Coated Balloon Versus Newer-Generation Drug-Eluting Stent Following Directional Coronary Atherectomy for Left Main Bifurcation Lesions. (The American journal of cardiology)
Article 4: Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock. (The American journal of cardiology)
Article 5: Comparative Outco]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Subclinical Aldosteronism Fuels MACE 09/30/25</title>
	<link>https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/</link>
	<pubDate>Tue, 30 Sep 2025 10:00:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like alternative splicing and dialysis. Key takeaway: Subclinical Aldosteronism Fuels MACE.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40631720">Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41017471">Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41022251">Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41022250">Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41022249">Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/">https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40631720" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40631720</a></p>
<p><strong>Summary:</strong> This longitudinal population-based study found that individuals with subclinical primary aldosteronism, a milder form of excessive aldosterone production, had a significantly increased risk of major adverse cardiovascular events. The findings suggest that subclinical primary aldosteronism is an underrecognized contributor to cardiovascular morbidity, emphasizing the need for its detection and management.</p>
<h4>Article 2: Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41017471" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41017471</a></p>
<p><strong>Summary:</strong> Leveraging long-read single-nucleus RNA sequencing, this study generated a detailed atlas of splicing isoform heterogeneity across adult human heart cell types and conditions. It identified significant shifts in isoform usage in heart failure, providing a foundational resource for understanding how alternative splicing contributes to cardiac disease at a molecular level.</p>
<h4>Article 3: Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022251</a></p>
<p><strong>Summary:</strong> This study evaluated the utility of the J-CTO score in guiding recanalization procedures for in-stent chronic total occlusions, comparing it to de novo chronic total occlusions. The results indicate that while the J-CTO score is a valuable tool for assessing procedural feasibility and predicting guidewire crossing time, its application and predictive accuracy may differ between in-stent and de novo chronic total occlusions.</p>
<h4>Article 4: Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022250</a></p>
<p><strong>Summary:</strong> This registry-based study investigated the incidence, predictors, and clinical impact of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement. The findings highlight specific patient and procedural characteristics associated with a higher likelihood of permanent pacemaker implantation, informing clinical decision-making.</p>
<h4>Article 5: Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022249</a></p>
<p><strong>Summary:</strong> This real-world cohort study compared the effectiveness and safety of prasugrel versus ticagrelor in end-stage renal disease patients on dialysis undergoing percutaneous coronary intervention. The study aimed to define optimal P2Y₁₂ inhibition in this high-risk, understudied population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study. This longitudinal population-based study found that individuals with subclinical primary aldosteronism, a milder form of excessive aldosterone production, had a significantly increased risk of major adverse cardiovascular events. The findings suggest that subclinical primary aldosteronism is an underrecognized contributor to cardiovascular morbidity, emphasizing the need for its detection and management.</p>
<p>Article number two. Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure. Leveraging long-read single-nucleus RNA sequencing, this study generated a detailed atlas of splicing isoform heterogeneity across adult human heart cell types and conditions. It identified significant shifts in isoform usage in heart failure, providing a foundational resource for understanding how alternative splicing contributes to cardiac disease at a molecular level.</p>
<p>Article number three. Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions. This study evaluated the utility of the J-CTO score in guiding recanalization procedures for in-stent chronic total occlusions, comparing it to de novo chronic total occlusions. The results indicate that while the J-CTO score is a valuable tool for assessing procedural feasibility and predicting guidewire crossing time, its application and predictive accuracy may differ between in-stent and de novo chronic total occlusions.</p>
<p>Article number four. Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR. This registry-based study investigated the incidence, predictors, and clinical impact of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement. The findings highlight specific patient and procedural characteristics associated with a higher likelihood of permanent pacemaker implantation, informing clinical decision-making.</p>
<p>Article number five. Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention. This real-world cohort study compared the effectiveness and safety of prasugrel versus ticagrelor in end-stage renal disease patients on dialysis undergoing percutaneous coronary intervention. The study aimed to define optimal P2Y₁₂ inhibition in this high-risk, understudied population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>alternative splicing, dialysis, major adverse cardiovascular events, single-cell RNA sequencing, P2Y₁₂ inhibition, percutaneous coronary intervention, permanent pacemaker implantation, transcatheter aortic valve replacement, in-stent restenosis, cardiac disease, end-stage renal disease, prasugrel, registry, cohort study, predictors, isoform atlas, guidewire crossing, ticagrelor, subclinical primary aldosteronism, J-CTO score, bicuspid aortic valve stenosis, cardiovascular risk, chronic total occlusion, heart failure, aldosterone.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/">Subclinical Aldosteronism Fuels MACE 09/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like alternative splicing and dialysis. Key takeaway: Subclinical Aldosteronism Fuels MACE.
Article Links:
Article 1: Subclinical Primar]]></itunes:subtitle>
	<itunes:episode>88</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like alternative splicing and dialysis. Key takeaway: Subclinical Aldosteronism Fuels MACE.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40631720">Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41017471">Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41022251">Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41022250">Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41022249">Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/">https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40631720" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40631720</a></p>
<p><strong>Summary:</strong> This longitudinal population-based study found that individuals with subclinical primary aldosteronism, a milder form of excessive aldosterone production, had a significantly increased risk of major adverse cardiovascular events. The findings suggest that subclinical primary aldosteronism is an underrecognized contributor to cardiovascular morbidity, emphasizing the need for its detection and management.</p>
<h4>Article 2: Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41017471" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41017471</a></p>
<p><strong>Summary:</strong> Leveraging long-read single-nucleus RNA sequencing, this study generated a detailed atlas of splicing isoform heterogeneity across adult human heart cell types and conditions. It identified significant shifts in isoform usage in heart failure, providing a foundational resource for understanding how alternative splicing contributes to cardiac disease at a molecular level.</p>
<h4>Article 3: Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022251" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022251</a></p>
<p><strong>Summary:</strong> This study evaluated the utility of the J-CTO score in guiding recanalization procedures for in-stent chronic total occlusions, comparing it to de novo chronic total occlusions. The results indicate that while the J-CTO score is a valuable tool for assessing procedural feasibility and predicting guidewire crossing time, its application and predictive accuracy may differ between in-stent and de novo chronic total occlusions.</p>
<h4>Article 4: Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022250</a></p>
<p><strong>Summary:</strong> This registry-based study investigated the incidence, predictors, and clinical impact of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement. The findings highlight specific patient and procedural characteristics associated with a higher likelihood of permanent pacemaker implantation, informing clinical decision-making.</p>
<h4>Article 5: Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41022249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41022249</a></p>
<p><strong>Summary:</strong> This real-world cohort study compared the effectiveness and safety of prasugrel versus ticagrelor in end-stage renal disease patients on dialysis undergoing percutaneous coronary intervention. The study aimed to define optimal P2Y₁₂ inhibition in this high-risk, understudied population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study. This longitudinal population-based study found that individuals with subclinical primary aldosteronism, a milder form of excessive aldosterone production, had a significantly increased risk of major adverse cardiovascular events. The findings suggest that subclinical primary aldosteronism is an underrecognized contributor to cardiovascular morbidity, emphasizing the need for its detection and management.</p>
<p>Article number two. Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure. Leveraging long-read single-nucleus RNA sequencing, this study generated a detailed atlas of splicing isoform heterogeneity across adult human heart cell types and conditions. It identified significant shifts in isoform usage in heart failure, providing a foundational resource for understanding how alternative splicing contributes to cardiac disease at a molecular level.</p>
<p>Article number three. Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions. This study evaluated the utility of the J-CTO score in guiding recanalization procedures for in-stent chronic total occlusions, comparing it to de novo chronic total occlusions. The results indicate that while the J-CTO score is a valuable tool for assessing procedural feasibility and predicting guidewire crossing time, its application and predictive accuracy may differ between in-stent and de novo chronic total occlusions.</p>
<p>Article number four. Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR. This registry-based study investigated the incidence, predictors, and clinical impact of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement. The findings highlight specific patient and procedural characteristics associated with a higher likelihood of permanent pacemaker implantation, informing clinical decision-making.</p>
<p>Article number five. Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention. This real-world cohort study compared the effectiveness and safety of prasugrel versus ticagrelor in end-stage renal disease patients on dialysis undergoing percutaneous coronary intervention. The study aimed to define optimal P2Y₁₂ inhibition in this high-risk, understudied population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>alternative splicing, dialysis, major adverse cardiovascular events, single-cell RNA sequencing, P2Y₁₂ inhibition, percutaneous coronary intervention, permanent pacemaker implantation, transcatheter aortic valve replacement, in-stent restenosis, cardiac disease, end-stage renal disease, prasugrel, registry, cohort study, predictors, isoform atlas, guidewire crossing, ticagrelor, subclinical primary aldosteronism, J-CTO score, bicuspid aortic valve stenosis, cardiovascular risk, chronic total occlusion, heart failure, aldosterone.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/">Subclinical Aldosteronism Fuels MACE 09/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250930_060006.mp3" length="3199311" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like alternative splicing and dialysis. Key takeaway: Subclinical Aldosteronism Fuels MACE.
Article Links:
Article 1: Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study. (Circulation)
Article 2: Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure. (Circulation)
Article 3: Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions. (The American journal of cardiology)
Article 4: Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR. (The American journal of cardiology)
Article 5: Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/subclinical-aldosteronism-fuels-mace-09-30-25/
 Featured Articles
Article 1: Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40631720
Summary: This longitudinal population-based study found that individuals with subclinical primary aldosteronism, a milder form of excessive aldosterone production, had a significantly increased risk of major adverse cardiovascular events. The findings suggest that subclinical primary aldosteronism is an underrecognized contributor to cardiovascular morbidity, emphasizing the need for its detection and management.
Article 2: Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41017471
Summary: Leveraging long-read single-nucleus RNA sequencing, this study generated a detailed atlas of splicing isoform heterogeneity across adult human heart cell types and conditions. It identified significant shifts in isoform usage in heart failure, providing a foundational resource for understanding how alternative splicing contributes to cardiac disease at a molecular level.
Article 3: Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41022251
Summary: This study evaluated the utility of the J-CTO score in guiding recanalization procedures for in-stent chronic total occlusions, comparing it to de novo chronic total occlusions. The results indicate that while the J-CTO score is a valuable tool for assessing procedural feasibility and predicting guidewire crossing time, its application and predictive accuracy may differ between in-stent and de novo chronic total occlusions.
Article 4: Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41022250
Summary: This registry-based study investigated the incidence, predictors, and clinical impact of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement. The findings highlight specific patient and procedural characteristics associated with a higher likelihood of permanent pacemaker implantation, informing clinical decision-making.
Article 5: Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41022249
Summary: This real-world cohort study compared the effectiveness and safety of prasugrel versus ticagrelor in end-stage renal disease patients on dialysis un]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like alternative splicing and dialysis. Key takeaway: Subclinical Aldosteronism Fuels MACE.
Article Links:
Article 1: Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study. (Circulation)
Article 2: Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure. (Circulation)
Article 3: Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions. (The American journal of cardiology)
Article 4: Predictors of permanent pacemaker implantation in patients with raphe-type bicuspid aortic valve stenosis undergoing TAVR. (The American journal of cardiology)
Article 5: Comparative Effectiveness of Prasugrel versus Ticagrelor in Dialysis-Dependent end stage renal disease Patients Undergoing Percutaneous Coronary Intervention. (The American journal of cardiology)
Full episo]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Inflammation Predicts CV Events, Statin Benefit 09/30/25</title>
	<link>https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/</link>
	<pubDate>Tue, 30 Sep 2025 06:57:15 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like pulmonary exacerbations and myocarditis. Key takeaway: Inflammation Predicts CV Events, Statin Benefit.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41020514">Hypertonic Saline or Carbocisteine in Bronchiectasis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40914895">Artificial Intelligence Automation of Echocardiographic Measurements.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40815240">Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41020749">Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40820798">An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/">https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hypertonic Saline or Carbocisteine in Bronchiectasis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41020514" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41020514</a></p>
<p><strong>Summary:</strong> This two-by-two factorial trial evaluated hypertonic saline versus carbocisteine for bronchiectasis exacerbations, enrolling participants with frequent exacerbations and daily sputum. The study aimed to assess the safety and effectiveness of these mucoactive agents in a large cohort, addressing inconsistencies in current guidelines.</p>
<h4>Article 2: Artificial Intelligence Automation of Echocardiographic Measurements.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40914895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40914895</a></p>
<p><strong>Summary:</strong> This study developed and validated open-sourced deep learning semantic segmentation models to automate comprehensive echocardiographic measurements, aiming to reduce the time and imprecision associated with manual assessment. The goal is to leverage artificial intelligence to decrease clinician burden and improve diagnostic accuracy and longitudinal tracking of cardiovascular disease.</p>
<h4>Article 3: Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40815240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40815240</a></p>
<p><strong>Summary:</strong> This prospective observational study investigated an opportunistic pop-up screening approach for atherosclerotic cardiovascular disease risk within community pharmacies and at a sporting event over seven weeks. It aimed to identify differences in the captured populations based on screening location, day, and time to improve population-level screening uptake and compliance.</p>
<h4>Article 4: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41020749" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41020749</a></p>
<p><strong>Summary:</strong> This scientific statement highlights the critical role of inflammation, particularly residual inflammation measured by high-sensitivity C-reactive protein, in the pathogenesis and outcomes of cardiovascular disease. It emphasizes that elevated high-sensitivity C-reactive protein predicts recurrent cardiovascular events even in statin-treated patients and identifies higher-risk individuals in whom statin therapy significantly reduces the risk of first major cardiovascular events.</p>
<h4>Article 5: An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40820798" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40820798</a></p>
<p><strong>Summary:</strong> This research explored the potential role of endogenous retrovirus resurgence in heart failure by establishing a total RNA sequencing pipeline to assess their occurrence in human and murine heart failure models. The study generated myocardium-specific mouse lines to investigate how this aberrant retroviral activity might induce myocarditis and contribute to the development of heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hypertonic Saline or Carbocisteine in Bronchiectasis. This two-by-two factorial trial evaluated hypertonic saline versus carbocisteine for bronchiectasis exacerbations, enrolling participants with frequent exacerbations and daily sputum. The study aimed to assess the safety and effectiveness of these mucoactive agents in a large cohort, addressing inconsistencies in current guidelines.</p>
<p>Article number two. Artificial Intelligence Automation of Echocardiographic Measurements. This study developed and validated open-sourced deep learning semantic segmentation models to automate comprehensive echocardiographic measurements, aiming to reduce the time and imprecision associated with manual assessment. The goal is to leverage artificial intelligence to decrease clinician burden and improve diagnostic accuracy and longitudinal tracking of cardiovascular disease.</p>
<p>Article number three. Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event. This prospective observational study investigated an opportunistic pop-up screening approach for atherosclerotic cardiovascular disease risk within community pharmacies and at a sporting event over seven weeks. It aimed to identify differences in the captured populations based on screening location, day, and time to improve population-level screening uptake and compliance.</p>
<p>Article number four. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. This scientific statement highlights the critical role of inflammation, particularly residual inflammation measured by high-sensitivity C-reactive protein, in the pathogenesis and outcomes of cardiovascular disease. It emphasizes that elevated high-sensitivity C-reactive protein predicts recurrent cardiovascular events even in statin-treated patients and identifies higher-risk individuals in whom statin therapy significantly reduces the risk of first major cardiovascular events.</p>
<p>Article number five. An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure. This research explored the potential role of endogenous retrovirus resurgence in heart failure by establishing a total RNA sequencing pipeline to assess their occurrence in human and murine heart failure models. The study generated myocardium-specific mouse lines to investigate how this aberrant retroviral activity might induce myocarditis and contribute to the development of heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pulmonary exacerbations, myocarditis, mucoactive agents, echocardiography, semantic segmentation, hypertonic saline, carbocisteine, statin therapy, residual inflammation, endogenous retroviruses, myocardium, atherosclerotic cardiovascular disease, artificial intelligence, community pharmacies, opportunistic screening, RNA sequencing, cardiovascular disease, high-sensitivity C-reactive protein, bronchiectasis, cardiovascular risk, heart failure, deep learning, inflammation, pop-up screening.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/">Inflammation Predicts CV Events, Statin Benefit 09/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like pulmonary exacerbations and myocarditis. Key takeaway: Inflammation Predicts CV Events, Statin Benefit.
Article Links:
Article 1: H]]></itunes:subtitle>
	<itunes:episode>87</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like pulmonary exacerbations and myocarditis. Key takeaway: Inflammation Predicts CV Events, Statin Benefit.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41020514">Hypertonic Saline or Carbocisteine in Bronchiectasis.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40914895">Artificial Intelligence Automation of Echocardiographic Measurements.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40815240">Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41020749">Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40820798">An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/">https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hypertonic Saline or Carbocisteine in Bronchiectasis.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41020514" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41020514</a></p>
<p><strong>Summary:</strong> This two-by-two factorial trial evaluated hypertonic saline versus carbocisteine for bronchiectasis exacerbations, enrolling participants with frequent exacerbations and daily sputum. The study aimed to assess the safety and effectiveness of these mucoactive agents in a large cohort, addressing inconsistencies in current guidelines.</p>
<h4>Article 2: Artificial Intelligence Automation of Echocardiographic Measurements.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40914895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40914895</a></p>
<p><strong>Summary:</strong> This study developed and validated open-sourced deep learning semantic segmentation models to automate comprehensive echocardiographic measurements, aiming to reduce the time and imprecision associated with manual assessment. The goal is to leverage artificial intelligence to decrease clinician burden and improve diagnostic accuracy and longitudinal tracking of cardiovascular disease.</p>
<h4>Article 3: Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40815240" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40815240</a></p>
<p><strong>Summary:</strong> This prospective observational study investigated an opportunistic pop-up screening approach for atherosclerotic cardiovascular disease risk within community pharmacies and at a sporting event over seven weeks. It aimed to identify differences in the captured populations based on screening location, day, and time to improve population-level screening uptake and compliance.</p>
<h4>Article 4: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41020749" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41020749</a></p>
<p><strong>Summary:</strong> This scientific statement highlights the critical role of inflammation, particularly residual inflammation measured by high-sensitivity C-reactive protein, in the pathogenesis and outcomes of cardiovascular disease. It emphasizes that elevated high-sensitivity C-reactive protein predicts recurrent cardiovascular events even in statin-treated patients and identifies higher-risk individuals in whom statin therapy significantly reduces the risk of first major cardiovascular events.</p>
<h4>Article 5: An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40820798" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40820798</a></p>
<p><strong>Summary:</strong> This research explored the potential role of endogenous retrovirus resurgence in heart failure by establishing a total RNA sequencing pipeline to assess their occurrence in human and murine heart failure models. The study generated myocardium-specific mouse lines to investigate how this aberrant retroviral activity might induce myocarditis and contribute to the development of heart failure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 30, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hypertonic Saline or Carbocisteine in Bronchiectasis. This two-by-two factorial trial evaluated hypertonic saline versus carbocisteine for bronchiectasis exacerbations, enrolling participants with frequent exacerbations and daily sputum. The study aimed to assess the safety and effectiveness of these mucoactive agents in a large cohort, addressing inconsistencies in current guidelines.</p>
<p>Article number two. Artificial Intelligence Automation of Echocardiographic Measurements. This study developed and validated open-sourced deep learning semantic segmentation models to automate comprehensive echocardiographic measurements, aiming to reduce the time and imprecision associated with manual assessment. The goal is to leverage artificial intelligence to decrease clinician burden and improve diagnostic accuracy and longitudinal tracking of cardiovascular disease.</p>
<p>Article number three. Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event. This prospective observational study investigated an opportunistic pop-up screening approach for atherosclerotic cardiovascular disease risk within community pharmacies and at a sporting event over seven weeks. It aimed to identify differences in the captured populations based on screening location, day, and time to improve population-level screening uptake and compliance.</p>
<p>Article number four. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. This scientific statement highlights the critical role of inflammation, particularly residual inflammation measured by high-sensitivity C-reactive protein, in the pathogenesis and outcomes of cardiovascular disease. It emphasizes that elevated high-sensitivity C-reactive protein predicts recurrent cardiovascular events even in statin-treated patients and identifies higher-risk individuals in whom statin therapy significantly reduces the risk of first major cardiovascular events.</p>
<p>Article number five. An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure. This research explored the potential role of endogenous retrovirus resurgence in heart failure by establishing a total RNA sequencing pipeline to assess their occurrence in human and murine heart failure models. The study generated myocardium-specific mouse lines to investigate how this aberrant retroviral activity might induce myocarditis and contribute to the development of heart failure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pulmonary exacerbations, myocarditis, mucoactive agents, echocardiography, semantic segmentation, hypertonic saline, carbocisteine, statin therapy, residual inflammation, endogenous retroviruses, myocardium, atherosclerotic cardiovascular disease, artificial intelligence, community pharmacies, opportunistic screening, RNA sequencing, cardiovascular disease, high-sensitivity C-reactive protein, bronchiectasis, cardiovascular risk, heart failure, deep learning, inflammation, pop-up screening.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/">Inflammation Predicts CV Events, Statin Benefit 09/30/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250930_025632.mp3" length="2933489" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like pulmonary exacerbations and myocarditis. Key takeaway: Inflammation Predicts CV Events, Statin Benefit.
Article Links:
Article 1: Hypertonic Saline or Carbocisteine in Bronchiectasis. (The New England journal of medicine)
Article 2: Artificial Intelligence Automation of Echocardiographic Measurements. (Journal of the American College of Cardiology)
Article 3: Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event. (Journal of the American College of Cardiology)
Article 4: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. (Journal of the American College of Cardiology)
Article 5: An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/inflammation-predicts-cv-events-statin-benefit-09-30-25/
 Featured Articles
Article 1: Hypertonic Saline or Carbocisteine in Bronchiectasis.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41020514
Summary: This two-by-two factorial trial evaluated hypertonic saline versus carbocisteine for bronchiectasis exacerbations, enrolling participants with frequent exacerbations and daily sputum. The study aimed to assess the safety and effectiveness of these mucoactive agents in a large cohort, addressing inconsistencies in current guidelines.
Article 2: Artificial Intelligence Automation of Echocardiographic Measurements.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40914895
Summary: This study developed and validated open-sourced deep learning semantic segmentation models to automate comprehensive echocardiographic measurements, aiming to reduce the time and imprecision associated with manual assessment. The goal is to leverage artificial intelligence to decrease clinician burden and improve diagnostic accuracy and longitudinal tracking of cardiovascular disease.
Article 3: Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40815240
Summary: This prospective observational study investigated an opportunistic pop-up screening approach for atherosclerotic cardiovascular disease risk within community pharmacies and at a sporting event over seven weeks. It aimed to identify differences in the captured populations based on screening location, day, and time to improve population-level screening uptake and compliance.
Article 4: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41020749
Summary: This scientific statement highlights the critical role of inflammation, particularly residual inflammation measured by high-sensitivity C-reactive protein, in the pathogenesis and outcomes of cardiovascular disease. It emphasizes that elevated high-sensitivity C-reactive protein predicts recurrent cardiovascular events even in statin-treated patients and identifies higher-risk individuals in whom statin therapy significantly reduces the risk of first major cardiovascular events.
Article 5: An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40820798
Summary: This research explored the potential role of endogenous retrovirus resurgence in heart failure by establishing a total RNA sequencing pipeline to assess their occurrence in human and murine heart failure models. The study generated myocardium-specific mouse lines to investigate how this aberrant retroviral activity might ind]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 30, 2025. This episode summarizes 5 key cardiology studies on topics like pulmonary exacerbations and myocarditis. Key takeaway: Inflammation Predicts CV Events, Statin Benefit.
Article Links:
Article 1: Hypertonic Saline or Carbocisteine in Bronchiectasis. (The New England journal of medicine)
Article 2: Artificial Intelligence Automation of Echocardiographic Measurements. (Journal of the American College of Cardiology)
Article 3: Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event. (Journal of the American College of Cardiology)
Article 4: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. (Journal of the American College of Cardiology)
Article 5: An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/inflammation-pre]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Smoking Ignites Atrial Fibrillation Via Inflammasome 09/29/25</title>
	<link>https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/</link>
	<pubDate>Mon, 29 Sep 2025 13:19:32 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like Western diet and diastole. Key takeaway: Smoking Ignites Atrial Fibrillation Via Inflammasome.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41014602">Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit.</a> (European heart journal. Acute cardiovascular care)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41015431">On the Measurement of the Vortex Formation Time in the Left Ventricle.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41015415">Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41015406">Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41015405">Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/">https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit.</h4>
<p><strong>Journal:</strong> European heart journal. Acute cardiovascular care</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41014602" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41014602</a></p>
<p><strong>Summary:</strong> This review focuses on the critical management of hypotension defined as mean arterial blood pressure less than sixty-five millimeters of mercury in adult intensive care unit patients after out-of-hospital cardiac arrest. It highlights that post-resuscitation hypotension, potentially caused by arrhythmias or mechanical complications, significantly contributes to morbidity and mortality, necessitating precise hemodynamic monitoring and interventions.</p>
<h4>Article 2: On the Measurement of the Vortex Formation Time in the Left Ventricle.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015431</a></p>
<p><strong>Summary:</strong> This study addresses inconsistencies in measuring vortex formation time, a potential metric for left ventricular performance during diastole, by proposing a new formulation grounded in fluid dynamics. It aims to clarify the measurement challenges and enhance the clinical utility of vortex formation time as an indicator of cardiac filling efficiency.</p>
<h4>Article 3: Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015415" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015415</a></p>
<p><strong>Summary:</strong> This research demonstrates that cigarette smoking directly activates the NLRP3 inflammasome, a key inflammatory pathway, in patients with atrial fibrillation. These findings establish a direct molecular link between smoking and the inflammation implicated in the initiation and persistence of atrial fibrillation.</p>
<h4>Article 4: Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015406" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015406</a></p>
<p><strong>Summary:</strong> This study presents a framework for synthesizing multi-modality data, specifically cardiovascular magnetic resonance imaging and catheterization, into patient-specific biophysical models. This approach facilitates noise filtering and quantifies myocardial contractility, offering objective assessments of cardiac function beyond readily available data metrics.</p>
<h4>Article 5: Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015405" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015405</a></p>
<p><strong>Summary:</strong> This research investigates the differential cardiovascular effects of conventional and electronic cigarettes in male and female mice, particularly when combined with a Western diet. The study evaluates aerosol exposures and their impact on cardiovascular health, comparing the risks of electronic cigarettes to traditional tobacco cigarettes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit. This review focuses on the critical management of hypotension defined as mean arterial blood pressure less than sixty-five millimeters of mercury in adult intensive care unit patients after out-of-hospital cardiac arrest. It highlights that post-resuscitation hypotension, potentially caused by arrhythmias or mechanical complications, significantly contributes to morbidity and mortality, necessitating precise hemodynamic monitoring and interventions.</p>
<p>Article number two. On the Measurement of the Vortex Formation Time in the Left Ventricle. This study addresses inconsistencies in measuring vortex formation time, a potential metric for left ventricular performance during diastole, by proposing a new formulation grounded in fluid dynamics. It aims to clarify the measurement challenges and enhance the clinical utility of vortex formation time as an indicator of cardiac filling efficiency.</p>
<p>Article number three. Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients. This research demonstrates that cigarette smoking directly activates the NLRP3 inflammasome, a key inflammatory pathway, in patients with atrial fibrillation. These findings establish a direct molecular link between smoking and the inflammation implicated in the initiation and persistence of atrial fibrillation.</p>
<p>Article number four. Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization. This study presents a framework for synthesizing multi-modality data, specifically cardiovascular magnetic resonance imaging and catheterization, into patient-specific biophysical models. This approach facilitates noise filtering and quantifies myocardial contractility, offering objective assessments of cardiac function beyond readily available data metrics.</p>
<p>Article number five. Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice. This research investigates the differential cardiovascular effects of conventional and electronic cigarettes in male and female mice, particularly when combined with a Western diet. The study evaluates aerosol exposures and their impact on cardiovascular health, comparing the risks of electronic cigarettes to traditional tobacco cigarettes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Western diet, diastole, hypotension, vortex formation time, fluid dynamics, myocardial contractility, cardiovascular health, cardiovascular imaging, hemodynamic monitoring, arrhythmia, cardiac filling, intensive care unit, biophysical modeling, cigarette smoking, left ventricular function, post-resuscitation care, catheterization, atrial fibrillation, conventional cigarettes, electronic cigarettes, NLRP3 inflammasome, cardiac MRI, inflammation, mice, out-of-hospital cardiac arrest.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/">Smoking Ignites Atrial Fibrillation Via Inflammasome 09/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like Western diet and diastole. Key takeaway: Smoking Ignites Atrial Fibrillation Via Inflammasome.
Article Links:
Article 1: Hemodynami]]></itunes:subtitle>
	<itunes:episode>86</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like Western diet and diastole. Key takeaway: Smoking Ignites Atrial Fibrillation Via Inflammasome.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41014602">Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit.</a> (European heart journal. Acute cardiovascular care)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41015431">On the Measurement of the Vortex Formation Time in the Left Ventricle.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41015415">Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41015406">Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41015405">Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice.</a> (American journal of physiology. Heart and circulatory physiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/">https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit.</h4>
<p><strong>Journal:</strong> European heart journal. Acute cardiovascular care</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41014602" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41014602</a></p>
<p><strong>Summary:</strong> This review focuses on the critical management of hypotension defined as mean arterial blood pressure less than sixty-five millimeters of mercury in adult intensive care unit patients after out-of-hospital cardiac arrest. It highlights that post-resuscitation hypotension, potentially caused by arrhythmias or mechanical complications, significantly contributes to morbidity and mortality, necessitating precise hemodynamic monitoring and interventions.</p>
<h4>Article 2: On the Measurement of the Vortex Formation Time in the Left Ventricle.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015431</a></p>
<p><strong>Summary:</strong> This study addresses inconsistencies in measuring vortex formation time, a potential metric for left ventricular performance during diastole, by proposing a new formulation grounded in fluid dynamics. It aims to clarify the measurement challenges and enhance the clinical utility of vortex formation time as an indicator of cardiac filling efficiency.</p>
<h4>Article 3: Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015415" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015415</a></p>
<p><strong>Summary:</strong> This research demonstrates that cigarette smoking directly activates the NLRP3 inflammasome, a key inflammatory pathway, in patients with atrial fibrillation. These findings establish a direct molecular link between smoking and the inflammation implicated in the initiation and persistence of atrial fibrillation.</p>
<h4>Article 4: Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015406" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015406</a></p>
<p><strong>Summary:</strong> This study presents a framework for synthesizing multi-modality data, specifically cardiovascular magnetic resonance imaging and catheterization, into patient-specific biophysical models. This approach facilitates noise filtering and quantifies myocardial contractility, offering objective assessments of cardiac function beyond readily available data metrics.</p>
<h4>Article 5: Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice.</h4>
<p><strong>Journal:</strong> American journal of physiology. Heart and circulatory physiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015405" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015405</a></p>
<p><strong>Summary:</strong> This research investigates the differential cardiovascular effects of conventional and electronic cigarettes in male and female mice, particularly when combined with a Western diet. The study evaluates aerosol exposures and their impact on cardiovascular health, comparing the risks of electronic cigarettes to traditional tobacco cigarettes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit. This review focuses on the critical management of hypotension defined as mean arterial blood pressure less than sixty-five millimeters of mercury in adult intensive care unit patients after out-of-hospital cardiac arrest. It highlights that post-resuscitation hypotension, potentially caused by arrhythmias or mechanical complications, significantly contributes to morbidity and mortality, necessitating precise hemodynamic monitoring and interventions.</p>
<p>Article number two. On the Measurement of the Vortex Formation Time in the Left Ventricle. This study addresses inconsistencies in measuring vortex formation time, a potential metric for left ventricular performance during diastole, by proposing a new formulation grounded in fluid dynamics. It aims to clarify the measurement challenges and enhance the clinical utility of vortex formation time as an indicator of cardiac filling efficiency.</p>
<p>Article number three. Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients. This research demonstrates that cigarette smoking directly activates the NLRP3 inflammasome, a key inflammatory pathway, in patients with atrial fibrillation. These findings establish a direct molecular link between smoking and the inflammation implicated in the initiation and persistence of atrial fibrillation.</p>
<p>Article number four. Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization. This study presents a framework for synthesizing multi-modality data, specifically cardiovascular magnetic resonance imaging and catheterization, into patient-specific biophysical models. This approach facilitates noise filtering and quantifies myocardial contractility, offering objective assessments of cardiac function beyond readily available data metrics.</p>
<p>Article number five. Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice. This research investigates the differential cardiovascular effects of conventional and electronic cigarettes in male and female mice, particularly when combined with a Western diet. The study evaluates aerosol exposures and their impact on cardiovascular health, comparing the risks of electronic cigarettes to traditional tobacco cigarettes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Western diet, diastole, hypotension, vortex formation time, fluid dynamics, myocardial contractility, cardiovascular health, cardiovascular imaging, hemodynamic monitoring, arrhythmia, cardiac filling, intensive care unit, biophysical modeling, cigarette smoking, left ventricular function, post-resuscitation care, catheterization, atrial fibrillation, conventional cigarettes, electronic cigarettes, NLRP3 inflammasome, cardiac MRI, inflammation, mice, out-of-hospital cardiac arrest.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/">Smoking Ignites Atrial Fibrillation Via Inflammasome 09/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250929_091849.mp3" length="3087298" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like Western diet and diastole. Key takeaway: Smoking Ignites Atrial Fibrillation Via Inflammasome.
Article Links:
Article 1: Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit. (European heart journal. Acute cardiovascular care)
Article 2: On the Measurement of the Vortex Formation Time in the Left Ventricle. (American journal of physiology. Heart and circulatory physiology)
Article 3: Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients. (American journal of physiology. Heart and circulatory physiology)
Article 4: Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization. (American journal of physiology. Heart and circulatory physiology)
Article 5: Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice. (American journal of physiology. Heart and circulatory physiology)
Full episode page: https://podcast.explainheart.com/podcast/smoking-ignites-atrial-fibrillation-via-inflammasome-09-29-25/
 Featured Articles
Article 1: Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit.
Journal: European heart journal. Acute cardiovascular care
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41014602
Summary: This review focuses on the critical management of hypotension defined as mean arterial blood pressure less than sixty-five millimeters of mercury in adult intensive care unit patients after out-of-hospital cardiac arrest. It highlights that post-resuscitation hypotension, potentially caused by arrhythmias or mechanical complications, significantly contributes to morbidity and mortality, necessitating precise hemodynamic monitoring and interventions.
Article 2: On the Measurement of the Vortex Formation Time in the Left Ventricle.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015431
Summary: This study addresses inconsistencies in measuring vortex formation time, a potential metric for left ventricular performance during diastole, by proposing a new formulation grounded in fluid dynamics. It aims to clarify the measurement challenges and enhance the clinical utility of vortex formation time as an indicator of cardiac filling efficiency.
Article 3: Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015415
Summary: This research demonstrates that cigarette smoking directly activates the NLRP3 inflammasome, a key inflammatory pathway, in patients with atrial fibrillation. These findings establish a direct molecular link between smoking and the inflammation implicated in the initiation and persistence of atrial fibrillation.
Article 4: Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015406
Summary: This study presents a framework for synthesizing multi-modality data, specifically cardiovascular magnetic resonance imaging and catheterization, into patient-specific biophysical models. This approach facilitates noise filtering and quantifies myocardial contractility, offering objective assessments of cardiac function beyond readily available data metrics.
Article 5: Conventional Tobacco and Electronic Cigarettes Differentially Affect Cardiovascular Health in Male and Female Mice.
Journal: American journal of physiology. Heart and circulatory physiology
PubMed]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like Western diet and diastole. Key takeaway: Smoking Ignites Atrial Fibrillation Via Inflammasome.
Article Links:
Article 1: Hemodynamic Monitoring and Management of the Hypotensive Out-of-Hospital Cardiac Arrest Patient in the Adult Intensive Care Unit. (European heart journal. Acute cardiovascular care)
Article 2: On the Measurement of the Vortex Formation Time in the Left Ventricle. (American journal of physiology. Heart and circulatory physiology)
Article 3: Cigarette Smoking Induces NLRP3 Inflammasome Activation in Atrial Fibrillation Patients. (American journal of physiology. Heart and circulatory physiology)
Article 4: Objective assessment of cardiac function using patient-specific biophysical modeling based on cardiovascular MRI combined with catheterization. (American journal of physiology. Heart and circulatory physiology)
Article 5: Conventional Tobacco and]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Septin4 Inhibition Reverses Cardiac Fibrosis 09/29/25</title>
	<link>https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/</link>
	<pubDate>Mon, 29 Sep 2025 10:01:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like angiotensin two and fibroblast activation. Key takeaway: Septin4 Inhibition Reverses Cardiac Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40960950">Septin4 Regulates Cardiac Fibrosis After Pressure Overload.</a> (Circulation research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40910184">DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.</a> (Circulation research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40899274">Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice.</a> (Circulation research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40899273">Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40999971">Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/">https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960950" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960950</a></p>
<p><strong>Summary:</strong> This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.</p>
<h4>Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910184</a></p>
<p><strong>Summary:</strong> Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.</p>
<h4>Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40899274" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40899274</a></p>
<p><strong>Summary:</strong> in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.</p>
<h4>Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40899273" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40899273</a></p>
<p><strong>Summary:</strong> The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.</p>
<h4>Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40999971" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40999971</a></p>
<p><strong>Summary:</strong> Analysis of a large population in Germany found that metabolic dysfunction-associated steatotic liver disease is significantly associated with an increased risk of major adverse cardiovascular events and overall mortality. Patients with metabolic dysfunction-associated steatotic liver disease had a higher incidence of cardiovascular events, highlighting the importance of cardiovascular risk management in this population. These findings underscore the need for integrated approaches addressing both liver and cardiovascular health in individuals with metabolic dysfunction-associated steatotic liver disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Septin4 Regulates Cardiac Fibrosis After Pressure Overload. This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.</p>
<p>Article number two. DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.</p>
<p>Article number three. Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of End.M.T. in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.</p>
<p>Article number four. Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release. The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.</p>
<p>Article number five. Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. Analysis of a large population in Germany found that metabolic dysfunction-associated steatotic liver disease is significantly associated with an increased risk of major adverse cardiovascular events and overall mortality. Patients with metabolic dysfunction-associated steatotic liver disease had a higher incidence of cardiovascular events, highlighting the importance of cardiovascular risk management in this population. These findings underscore the need for integrated approaches addressing both liver and cardiovascular health in individuals with metabolic dysfunction-associated steatotic liver disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>angiotensin two, fibroblast activation, calcium handling, renin release, S.E.R.C.A.2a, cardiac fibrosis, hypertension, endothelial cells, liver enzymes, DWORF, calcium oscillations, ventricular remodeling, heart failure, reprogramming, Septin4, mortality, endothelial-to-mesenchymal transition, blood pressure, cardiovascular events, gene therapy, juxtaglomerular cells, metabolic dysfunction-associated steatotic liver disease, cardiovascular risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/">Septin4 Inhibition Reverses Cardiac Fibrosis 09/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like angiotensin two and fibroblast activation. Key takeaway: Septin4 Inhibition Reverses Cardiac Fibrosis.
Article Links:
Article 1: Se]]></itunes:subtitle>
	<itunes:episode>85</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like angiotensin two and fibroblast activation. Key takeaway: Septin4 Inhibition Reverses Cardiac Fibrosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40960950">Septin4 Regulates Cardiac Fibrosis After Pressure Overload.</a> (Circulation research)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40910184">DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.</a> (Circulation research)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40899274">Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice.</a> (Circulation research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40899273">Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release.</a> (Circulation research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40999971">Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/">https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960950" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960950</a></p>
<p><strong>Summary:</strong> This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.</p>
<h4>Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910184" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910184</a></p>
<p><strong>Summary:</strong> Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.</p>
<h4>Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40899274" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40899274</a></p>
<p><strong>Summary:</strong> in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.</p>
<h4>Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release.</h4>
<p><strong>Journal:</strong> Circulation research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40899273" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40899273</a></p>
<p><strong>Summary:</strong> The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.</p>
<h4>Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40999971" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40999971</a></p>
<p><strong>Summary:</strong> Analysis of a large population in Germany found that metabolic dysfunction-associated steatotic liver disease is significantly associated with an increased risk of major adverse cardiovascular events and overall mortality. Patients with metabolic dysfunction-associated steatotic liver disease had a higher incidence of cardiovascular events, highlighting the importance of cardiovascular risk management in this population. These findings underscore the need for integrated approaches addressing both liver and cardiovascular health in individuals with metabolic dysfunction-associated steatotic liver disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Septin4 Regulates Cardiac Fibrosis After Pressure Overload. This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.</p>
<p>Article number two. DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.</p>
<p>Article number three. Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of End.M.T. in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.</p>
<p>Article number four. Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release. The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.</p>
<p>Article number five. Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. Analysis of a large population in Germany found that metabolic dysfunction-associated steatotic liver disease is significantly associated with an increased risk of major adverse cardiovascular events and overall mortality. Patients with metabolic dysfunction-associated steatotic liver disease had a higher incidence of cardiovascular events, highlighting the importance of cardiovascular risk management in this population. These findings underscore the need for integrated approaches addressing both liver and cardiovascular health in individuals with metabolic dysfunction-associated steatotic liver disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>angiotensin two, fibroblast activation, calcium handling, renin release, S.E.R.C.A.2a, cardiac fibrosis, hypertension, endothelial cells, liver enzymes, DWORF, calcium oscillations, ventricular remodeling, heart failure, reprogramming, Septin4, mortality, endothelial-to-mesenchymal transition, blood pressure, cardiovascular events, gene therapy, juxtaglomerular cells, metabolic dysfunction-associated steatotic liver disease, cardiovascular risk.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/">Septin4 Inhibition Reverses Cardiac Fibrosis 09/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250929_060015.mp3" length="3743494" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like angiotensin two and fibroblast activation. Key takeaway: Septin4 Inhibition Reverses Cardiac Fibrosis.
Article Links:
Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload. (Circulation research)
Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. (Circulation research)
Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice. (Circulation research)
Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release. (Circulation research)
Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/
 Featured Articles
Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40960950
Summary: This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.
Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910184
Summary: Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.
Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40899274
Summary: in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.
Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40899273
Summary: The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.
Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40999971
Summary: Analysi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like angiotensin two and fibroblast activation. Key takeaway: Septin4 Inhibition Reverses Cardiac Fibrosis.
Article Links:
Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload. (Circulation research)
Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. (Circulation research)
Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice. (Circulation research)
Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release. (Circulation research)
Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/septin4-inhibition-]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>L.V.A. Ablation Works Best in Enlarged Atria 09/29/25</title>
	<link>https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/</link>
	<pubDate>Mon, 29 Sep 2025 06:57:35 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like ablation depth and dilated cardiomyopathy. Key takeaway: L.V.A. Ablation Works Best in Enlarged Atria.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41016420">Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41016419">Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41016532">What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia?</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41000018">Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41000017">Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/">https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41016420" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41016420</a></p>
<p><strong>Summary:</strong> This swine study compared premature ventricular contraction induced changes in left ventricular pressure in healthy hearts versus hearts with dilated cardiomyopathy. Premature ventricular contractions delivered at shorter coupling intervals resulted in greater acute hemodynamic dysfunction, with this effect being more pronounced in diseased hearts. The findings suggest that premature ventricular contraction induced cardiomyopathy is likely related to the timing of the contraction and is exacerbated by pre-existing heart disease.</p>
<h4>Article 2: Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41016419" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41016419</a></p>
<p><strong>Summary:</strong> This preclinical study demonstrates that electrical impedance spectroscopy can accurately monitor ablation depth during pulsed field ablation procedures. The change rate of low-frequency impedance correlated with lesion depth in both monopolar and bipolar pulsed field ablation settings. This technology holds promise for real-time, quantitative assessment of ablation depth, potentially improving the safety and efficacy of pulsed field ablation for cardiac arrhythmias.</p>
<h4>Article 3: What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia?</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41016532" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41016532</a></p>
<p><strong>Summary:</strong> Cardiac Magnetic Resonance Imaging identified structural heart disease in a significant proportion of patients, with late gadolinium enhancement being the most common finding. Cardiac Magnetic Resonance Imaging is valuable for risk stratifying patients with premature ventricular contractions and non-sustained ventricular tachycardia, especially when clinical suspicion for structural heart disease is present.</p>
<h4>Article 4: Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41000018" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41000018</a></p>
<p><strong>Summary:</strong> This study identifies a distinct neurocardiac phenotype of catecholaminergic polymorphic ventricular tachycardia in children characterized by intellectual and neurodevelopmental delays. Patients with this phenotype exhibited a higher burden of ventricular arrhythmias and sudden cardiac death compared to those without neurodevelopmental delays. The findings suggest a more malignant form of catecholaminergic polymorphic ventricular tachycardia with unique clinical features requiring heightened surveillance and management.</p>
<h4>Article 5: Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41000017" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41000017</a></p>
<p><strong>Summary:</strong> This subanalysis of the SUPPRESS-A.F. trial reveals that low-voltage-area ablation for persistent atrial fibrillation is more effective in patients with advanced left atrial enlargement. Patients with larger left atrial diameters experienced a greater benefit from low-voltage-area ablation compared to those with less atrial remodeling. The study suggests that left atrial size may be a useful marker to guide patient selection for low-voltage-area ablation in persistent atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location. This swine study compared premature ventricular contraction induced changes in left ventricular pressure in healthy hearts versus hearts with dilated cardiomyopathy. Premature ventricular contractions delivered at shorter coupling intervals resulted in greater acute hemodynamic dysfunction, with this effect being more pronounced in diseased hearts. The findings suggest that premature ventricular contraction induced cardiomyopathy is likely related to the timing of the contraction and is exacerbated by pre-existing heart disease.</p>
<p>Article number two. Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation. This preclinical study demonstrates that electrical impedance spectroscopy can accurately monitor ablation depth during pulsed field ablation procedures. The change rate of low-frequency impedance correlated with lesion depth in both monopolar and bipolar pulsed field ablation settings. This technology holds promise for real-time, quantitative assessment of ablation depth, potentially improving the safety and efficacy of pulsed field ablation for cardiac arrhythmias.</p>
<p>Article number three. What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia? This retrospective study evaluated the diagnostic utility of Cardiac Magnetic Resonance Imaging in patients with premature ventricular contractions and non-sustained ventricular tachycardia. Cardiac Magnetic Resonance Imaging identified structural heart disease in a significant proportion of patients, with late gadolinium enhancement being the most common finding. Cardiac Magnetic Resonance Imaging is valuable for risk stratifying patients with premature ventricular contractions and non-sustained ventricular tachycardia, especially when clinical suspicion for structural heart disease is present.</p>
<p>Article number four. Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype. This study identifies a distinct neurocardiac phenotype of catecholaminergic polymorphic ventricular tachycardia in children characterized by intellectual and neurodevelopmental delays. Patients with this phenotype exhibited a higher burden of ventricular arrhythmias and sudden cardiac death compared to those without neurodevelopmental delays. The findings suggest a more malignant form of catecholaminergic polymorphic ventricular tachycardia with unique clinical features requiring heightened surveillance and management.</p>
<p>Article number five. Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial. This subanalysis of the SUPPRESS-A.F. trial reveals that low-voltage-area ablation for persistent atrial fibrillation is more effective in patients with advanced left atrial enlargement. Patients with larger left atrial diameters experienced a greater benefit from low-voltage-area ablation compared to those with less atrial remodeling. The study suggests that left atrial size may be a useful marker to guide patient selection for low-voltage-area ablation in persistent atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ablation depth, dilated cardiomyopathy, pulsed field ablation, late gadolinium enhancement, neurodevelopmental delay, ventricular arrhythmias, left atrial enlargement, low-voltage-area ablation, coupling interval, sudden cardiac death, SUPPRESS-A.F. trial, non-sustained ventricular tachycardia, atrial fibrillation, cardiac ablation, electrical impedance spectroscopy, lesion monitoring, catecholaminergic polymorphic ventricular tachycardia, hemodynamic dysfunction, structural heart disease, premature ventricular contractions, Cardiac Magnetic Resonance Imaging, ventricular pressure, intellectual disability, atrial remodeling.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/">L.V.A. Ablation Works Best in Enlarged Atria 09/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like ablation depth and dilated cardiomyopathy. Key takeaway: L.V.A. Ablation Works Best in Enlarged Atria.
Article Links:
Article 1: Pr]]></itunes:subtitle>
	<itunes:episode>84</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like ablation depth and dilated cardiomyopathy. Key takeaway: L.V.A. Ablation Works Best in Enlarged Atria.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41016420">Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41016419">Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41016532">What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia?</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41000018">Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41000017">Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial.</a> (Circulation. Arrhythmia and electrophysiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/">https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41016420" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41016420</a></p>
<p><strong>Summary:</strong> This swine study compared premature ventricular contraction induced changes in left ventricular pressure in healthy hearts versus hearts with dilated cardiomyopathy. Premature ventricular contractions delivered at shorter coupling intervals resulted in greater acute hemodynamic dysfunction, with this effect being more pronounced in diseased hearts. The findings suggest that premature ventricular contraction induced cardiomyopathy is likely related to the timing of the contraction and is exacerbated by pre-existing heart disease.</p>
<h4>Article 2: Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41016419" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41016419</a></p>
<p><strong>Summary:</strong> This preclinical study demonstrates that electrical impedance spectroscopy can accurately monitor ablation depth during pulsed field ablation procedures. The change rate of low-frequency impedance correlated with lesion depth in both monopolar and bipolar pulsed field ablation settings. This technology holds promise for real-time, quantitative assessment of ablation depth, potentially improving the safety and efficacy of pulsed field ablation for cardiac arrhythmias.</p>
<h4>Article 3: What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia?</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41016532" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41016532</a></p>
<p><strong>Summary:</strong> Cardiac Magnetic Resonance Imaging identified structural heart disease in a significant proportion of patients, with late gadolinium enhancement being the most common finding. Cardiac Magnetic Resonance Imaging is valuable for risk stratifying patients with premature ventricular contractions and non-sustained ventricular tachycardia, especially when clinical suspicion for structural heart disease is present.</p>
<h4>Article 4: Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41000018" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41000018</a></p>
<p><strong>Summary:</strong> This study identifies a distinct neurocardiac phenotype of catecholaminergic polymorphic ventricular tachycardia in children characterized by intellectual and neurodevelopmental delays. Patients with this phenotype exhibited a higher burden of ventricular arrhythmias and sudden cardiac death compared to those without neurodevelopmental delays. The findings suggest a more malignant form of catecholaminergic polymorphic ventricular tachycardia with unique clinical features requiring heightened surveillance and management.</p>
<h4>Article 5: Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial.</h4>
<p><strong>Journal:</strong> Circulation. Arrhythmia and electrophysiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41000017" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41000017</a></p>
<p><strong>Summary:</strong> This subanalysis of the SUPPRESS-A.F. trial reveals that low-voltage-area ablation for persistent atrial fibrillation is more effective in patients with advanced left atrial enlargement. Patients with larger left atrial diameters experienced a greater benefit from low-voltage-area ablation compared to those with less atrial remodeling. The study suggests that left atrial size may be a useful marker to guide patient selection for low-voltage-area ablation in persistent atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location. This swine study compared premature ventricular contraction induced changes in left ventricular pressure in healthy hearts versus hearts with dilated cardiomyopathy. Premature ventricular contractions delivered at shorter coupling intervals resulted in greater acute hemodynamic dysfunction, with this effect being more pronounced in diseased hearts. The findings suggest that premature ventricular contraction induced cardiomyopathy is likely related to the timing of the contraction and is exacerbated by pre-existing heart disease.</p>
<p>Article number two. Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation. This preclinical study demonstrates that electrical impedance spectroscopy can accurately monitor ablation depth during pulsed field ablation procedures. The change rate of low-frequency impedance correlated with lesion depth in both monopolar and bipolar pulsed field ablation settings. This technology holds promise for real-time, quantitative assessment of ablation depth, potentially improving the safety and efficacy of pulsed field ablation for cardiac arrhythmias.</p>
<p>Article number three. What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia? This retrospective study evaluated the diagnostic utility of Cardiac Magnetic Resonance Imaging in patients with premature ventricular contractions and non-sustained ventricular tachycardia. Cardiac Magnetic Resonance Imaging identified structural heart disease in a significant proportion of patients, with late gadolinium enhancement being the most common finding. Cardiac Magnetic Resonance Imaging is valuable for risk stratifying patients with premature ventricular contractions and non-sustained ventricular tachycardia, especially when clinical suspicion for structural heart disease is present.</p>
<p>Article number four. Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype. This study identifies a distinct neurocardiac phenotype of catecholaminergic polymorphic ventricular tachycardia in children characterized by intellectual and neurodevelopmental delays. Patients with this phenotype exhibited a higher burden of ventricular arrhythmias and sudden cardiac death compared to those without neurodevelopmental delays. The findings suggest a more malignant form of catecholaminergic polymorphic ventricular tachycardia with unique clinical features requiring heightened surveillance and management.</p>
<p>Article number five. Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial. This subanalysis of the SUPPRESS-A.F. trial reveals that low-voltage-area ablation for persistent atrial fibrillation is more effective in patients with advanced left atrial enlargement. Patients with larger left atrial diameters experienced a greater benefit from low-voltage-area ablation compared to those with less atrial remodeling. The study suggests that left atrial size may be a useful marker to guide patient selection for low-voltage-area ablation in persistent atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ablation depth, dilated cardiomyopathy, pulsed field ablation, late gadolinium enhancement, neurodevelopmental delay, ventricular arrhythmias, left atrial enlargement, low-voltage-area ablation, coupling interval, sudden cardiac death, SUPPRESS-A.F. trial, non-sustained ventricular tachycardia, atrial fibrillation, cardiac ablation, electrical impedance spectroscopy, lesion monitoring, catecholaminergic polymorphic ventricular tachycardia, hemodynamic dysfunction, structural heart disease, premature ventricular contractions, Cardiac Magnetic Resonance Imaging, ventricular pressure, intellectual disability, atrial remodeling.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/">L.V.A. Ablation Works Best in Enlarged Atria 09/29/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250929_025639.mp3" length="3934083" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like ablation depth and dilated cardiomyopathy. Key takeaway: L.V.A. Ablation Works Best in Enlarged Atria.
Article Links:
Article 1: Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location. (Heart rhythm)
Article 2: Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation. (Heart rhythm)
Article 3: What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia? (The American journal of cardiology)
Article 4: Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype. (Circulation. Arrhythmia and electrophysiology)
Article 5: Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial. (Circulation. Arrhythmia and electrophysiology)
Full episode page: https://podcast.explainheart.com/podcast/l-v-a-ablation-works-best-in-enlarged-atria-09-29-25/
 Featured Articles
Article 1: Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41016420
Summary: This swine study compared premature ventricular contraction induced changes in left ventricular pressure in healthy hearts versus hearts with dilated cardiomyopathy. Premature ventricular contractions delivered at shorter coupling intervals resulted in greater acute hemodynamic dysfunction, with this effect being more pronounced in diseased hearts. The findings suggest that premature ventricular contraction induced cardiomyopathy is likely related to the timing of the contraction and is exacerbated by pre-existing heart disease.
Article 2: Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41016419
Summary: This preclinical study demonstrates that electrical impedance spectroscopy can accurately monitor ablation depth during pulsed field ablation procedures. The change rate of low-frequency impedance correlated with lesion depth in both monopolar and bipolar pulsed field ablation settings. This technology holds promise for real-time, quantitative assessment of ablation depth, potentially improving the safety and efficacy of pulsed field ablation for cardiac arrhythmias.
Article 3: What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia?
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41016532
Summary: Cardiac Magnetic Resonance Imaging identified structural heart disease in a significant proportion of patients, with late gadolinium enhancement being the most common finding. Cardiac Magnetic Resonance Imaging is valuable for risk stratifying patients with premature ventricular contractions and non-sustained ventricular tachycardia, especially when clinical suspicion for structural heart disease is present.
Article 4: Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype.
Journal: Circulation. Arrhythmia and electrophysiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41000018
Summary: This study identifies a distinct neurocardiac phenotype of catecholaminergic polymorphic ventricular tachycardia in children cha]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like ablation depth and dilated cardiomyopathy. Key takeaway: L.V.A. Ablation Works Best in Enlarged Atria.
Article Links:
Article 1: Premature Ventricular Contractions on Healthy and Diseased Hearts: Differential Acute Effect of Coupling Interval and Location. (Heart rhythm)
Article 2: Electrical Impedance Spectroscopy Facilitates Quantitative Depth Monitoring of Pulsed Field Ablation: An Impedimetric Approach with Preclinical Validation. (Heart rhythm)
Article 3: What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients with Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia? (The American journal of cardiology)
Article 4: Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype. (Circul]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Methadone&#8217;s Pro-Arrhythmic Cardiac Risks Confirmed 09/28/25</title>
	<link>https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/</link>
	<pubDate>Mon, 29 Sep 2025 00:05:39 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like longitudinal study and cardiac electrophysiology. Key takeaway: Methadone&#8217;s Pro-Arrhythmic Cardiac Risks Confirmed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40996098">Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40996081">Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40996078">Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40996070">Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40996069">Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/">https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996098" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996098</a></p>
<p><strong>Summary:</strong> This computational modeling study reveals that methadone&#8217;s blockade of the inward rectifier potassium current and other ion channels promotes both early and delayed repolarization arrhythmias. By simulating methadone&#8217;s effects on cardiac electrophysiology, the study highlights the complex proarrhythmic mechanisms associated with methadone use, offering insights into its potential cardiac risks. These findings suggest that methadone-induced arrhythmias are not solely due to delayed repolarization, warranting careful E.C.G. monitoring in vulnerable patients.</p>
<h4>Article 2: Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996081" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996081</a></p>
<p><strong>Summary:</strong> This study evaluates the initial clinical experience with interventional creation of a partial cavopulmonary connection in patients with isolated right-sided heart failure or cyanosis. The procedure was found to improve exercise capacity and facilitate activities of daily living in patients with deteriorated clinical condition. While surgical partial cavopulmonary connection creation may be a high-risk procedure in this patient group, the interventional approach offers a less invasive alternative.</p>
<h4>Article 3: Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996078" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996078</a></p>
<p><strong>Summary:</strong> This analysis of California birth records from 2007 to 2019 reveals significant racial and ethnic disparities in maternal cardiovascular health, specifically hypertensive disorders of pregnancy. The study found variations in the prevalence and trends of these disorders among different racial and ethnic groups. These findings highlight the need for targeted interventions to address these disparities and improve maternal cardiovascular outcomes.</p>
<h4>Article 4: Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996070</a></p>
<p><strong>Summary:</strong> This article describes the design of the Black Impact randomized controlled trial, a 24-week cardiovascular health intervention developed for Black men. The study aims to evaluate the mechanisms by which psychosocial stress reduction improves cardiovascular health outcomes in this population, as measured by the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics. The trial is conducted through an academic-community-government-industry partnership.</p>
<h4>Article 5: Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996069" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996069</a></p>
<p><strong>Summary:</strong> This pooled multicohort study across 21 countries examined the relationship between stroke and depressive symptoms in adults aged 50 years and older. The study found that stroke is associated with an increased risk of depressive symptoms, highlighting the need for integrated mental health care following stroke. Both the initial stroke event and subsequent changes over time were found to impact depressive symptoms.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling. This computational modeling study reveals that methadone&#8217;s blockade of the inward rectifier potassium current and other ion channels promotes both early and delayed repolarization arrhythmias. By simulating methadone&#8217;s effects on cardiac electrophysiology, the study highlights the complex proarrhythmic mechanisms associated with methadone use, offering insights into its potential cardiac risks. These findings suggest that methadone-induced arrhythmias are not solely due to delayed repolarization, warranting careful E.C.G. monitoring in vulnerable patients.</p>
<p>Article number two. Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results. This study evaluates the initial clinical experience with interventional creation of a partial cavopulmonary connection in patients with isolated right-sided heart failure or cyanosis. The procedure was found to improve exercise capacity and facilitate activities of daily living in patients with deteriorated clinical condition. While surgical partial cavopulmonary connection creation may be a high-risk procedure in this patient group, the interventional approach offers a less invasive alternative.</p>
<p>Article number three. Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California. This analysis of California birth records from 2007 to 2019 reveals significant racial and ethnic disparities in maternal cardiovascular health, specifically hypertensive disorders of pregnancy. The study found variations in the prevalence and trends of these disorders among different racial and ethnic groups. These findings highlight the need for targeted interventions to address these disparities and improve maternal cardiovascular outcomes.</p>
<p>Article number four. Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention. This article describes the design of the Black Impact randomized controlled trial, a 24-week cardiovascular health intervention developed for Black men. The study aims to evaluate the mechanisms by which psychosocial stress reduction improves cardiovascular health outcomes in this population, as measured by the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics. The trial is conducted through an academic-community-government-industry partnership.</p>
<p>Article number five. Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries. This pooled multicohort study across 21 countries examined the relationship between stroke and depressive symptoms in adults aged 50 years and older. The study found that stroke is associated with an increased risk of depressive symptoms, highlighting the need for integrated mental health care following stroke. Both the initial stroke event and subsequent changes over time were found to impact depressive symptoms. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>longitudinal study, cardiac electrophysiology, preeclampsia, arrhythmia, cavopulmonary connection, psychosocial stress, Black men, public health, cardiovascular health, Life&#8217;s Essential 8, maternal cardiovascular health, exercise capacity, racial disparities, community intervention, potassium current, mental health, ethnic disparities, repolarization, depression, hypertensive disorders of pregnancy, stroke, right heart failure, methadone, interventional procedure, cyanosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/">Methadone’s Pro-Arrhythmic Cardiac Risks Confirmed 09/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like longitudinal study and cardiac electrophysiology. Key takeaway: Methadone&#8217;s Pro-Arrhythmic Cardiac Risks Confirmed.
Article L]]></itunes:subtitle>
	<itunes:episode>83</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like longitudinal study and cardiac electrophysiology. Key takeaway: Methadone&#8217;s Pro-Arrhythmic Cardiac Risks Confirmed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40996098">Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40996081">Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40996078">Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40996070">Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40996069">Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/">https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996098" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996098</a></p>
<p><strong>Summary:</strong> This computational modeling study reveals that methadone&#8217;s blockade of the inward rectifier potassium current and other ion channels promotes both early and delayed repolarization arrhythmias. By simulating methadone&#8217;s effects on cardiac electrophysiology, the study highlights the complex proarrhythmic mechanisms associated with methadone use, offering insights into its potential cardiac risks. These findings suggest that methadone-induced arrhythmias are not solely due to delayed repolarization, warranting careful E.C.G. monitoring in vulnerable patients.</p>
<h4>Article 2: Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996081" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996081</a></p>
<p><strong>Summary:</strong> This study evaluates the initial clinical experience with interventional creation of a partial cavopulmonary connection in patients with isolated right-sided heart failure or cyanosis. The procedure was found to improve exercise capacity and facilitate activities of daily living in patients with deteriorated clinical condition. While surgical partial cavopulmonary connection creation may be a high-risk procedure in this patient group, the interventional approach offers a less invasive alternative.</p>
<h4>Article 3: Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996078" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996078</a></p>
<p><strong>Summary:</strong> This analysis of California birth records from 2007 to 2019 reveals significant racial and ethnic disparities in maternal cardiovascular health, specifically hypertensive disorders of pregnancy. The study found variations in the prevalence and trends of these disorders among different racial and ethnic groups. These findings highlight the need for targeted interventions to address these disparities and improve maternal cardiovascular outcomes.</p>
<h4>Article 4: Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996070</a></p>
<p><strong>Summary:</strong> This article describes the design of the Black Impact randomized controlled trial, a 24-week cardiovascular health intervention developed for Black men. The study aims to evaluate the mechanisms by which psychosocial stress reduction improves cardiovascular health outcomes in this population, as measured by the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics. The trial is conducted through an academic-community-government-industry partnership.</p>
<h4>Article 5: Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996069" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996069</a></p>
<p><strong>Summary:</strong> This pooled multicohort study across 21 countries examined the relationship between stroke and depressive symptoms in adults aged 50 years and older. The study found that stroke is associated with an increased risk of depressive symptoms, highlighting the need for integrated mental health care following stroke. Both the initial stroke event and subsequent changes over time were found to impact depressive symptoms.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling. This computational modeling study reveals that methadone&#8217;s blockade of the inward rectifier potassium current and other ion channels promotes both early and delayed repolarization arrhythmias. By simulating methadone&#8217;s effects on cardiac electrophysiology, the study highlights the complex proarrhythmic mechanisms associated with methadone use, offering insights into its potential cardiac risks. These findings suggest that methadone-induced arrhythmias are not solely due to delayed repolarization, warranting careful E.C.G. monitoring in vulnerable patients.</p>
<p>Article number two. Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results. This study evaluates the initial clinical experience with interventional creation of a partial cavopulmonary connection in patients with isolated right-sided heart failure or cyanosis. The procedure was found to improve exercise capacity and facilitate activities of daily living in patients with deteriorated clinical condition. While surgical partial cavopulmonary connection creation may be a high-risk procedure in this patient group, the interventional approach offers a less invasive alternative.</p>
<p>Article number three. Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California. This analysis of California birth records from 2007 to 2019 reveals significant racial and ethnic disparities in maternal cardiovascular health, specifically hypertensive disorders of pregnancy. The study found variations in the prevalence and trends of these disorders among different racial and ethnic groups. These findings highlight the need for targeted interventions to address these disparities and improve maternal cardiovascular outcomes.</p>
<p>Article number four. Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention. This article describes the design of the Black Impact randomized controlled trial, a 24-week cardiovascular health intervention developed for Black men. The study aims to evaluate the mechanisms by which psychosocial stress reduction improves cardiovascular health outcomes in this population, as measured by the American Heart Association&#8217;s Life&#8217;s Essential 8 metrics. The trial is conducted through an academic-community-government-industry partnership.</p>
<p>Article number five. Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries. This pooled multicohort study across 21 countries examined the relationship between stroke and depressive symptoms in adults aged 50 years and older. The study found that stroke is associated with an increased risk of depressive symptoms, highlighting the need for integrated mental health care following stroke. Both the initial stroke event and subsequent changes over time were found to impact depressive symptoms. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>longitudinal study, cardiac electrophysiology, preeclampsia, arrhythmia, cavopulmonary connection, psychosocial stress, Black men, public health, cardiovascular health, Life&#8217;s Essential 8, maternal cardiovascular health, exercise capacity, racial disparities, community intervention, potassium current, mental health, ethnic disparities, repolarization, depression, hypertensive disorders of pregnancy, stroke, right heart failure, methadone, interventional procedure, cyanosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/">Methadone’s Pro-Arrhythmic Cardiac Risks Confirmed 09/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250928_200449.mp3" length="3711311" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like longitudinal study and cardiac electrophysiology. Key takeaway: Methadone&#8217;s Pro-Arrhythmic Cardiac Risks Confirmed.
Article Links:
Article 1: Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling. (Journal of the American Heart Association)
Article 2: Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results. (Journal of the American Heart Association)
Article 3: Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California. (Journal of the American Heart Association)
Article 4: Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention. (Journal of the American Heart Association)
Article 5: Static and Dynamic Effects of Stroke Onset on Depressive Symptoms in Middle-Aged and Older Adults: Evidence Across 21 Countries. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/methadones-pro-arrhythmic-cardiac-risks-confirmed-09-28-25/
 Featured Articles
Article 1: Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996098
Summary: This computational modeling study reveals that methadone&#8217;s blockade of the inward rectifier potassium current and other ion channels promotes both early and delayed repolarization arrhythmias. By simulating methadone&#8217;s effects on cardiac electrophysiology, the study highlights the complex proarrhythmic mechanisms associated with methadone use, offering insights into its potential cardiac risks. These findings suggest that methadone-induced arrhythmias are not solely due to delayed repolarization, warranting careful E.C.G. monitoring in vulnerable patients.
Article 2: Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996081
Summary: This study evaluates the initial clinical experience with interventional creation of a partial cavopulmonary connection in patients with isolated right-sided heart failure or cyanosis. The procedure was found to improve exercise capacity and facilitate activities of daily living in patients with deteriorated clinical condition. While surgical partial cavopulmonary connection creation may be a high-risk procedure in this patient group, the interventional approach offers a less invasive alternative.
Article 3: Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996078
Summary: This analysis of California birth records from 2007 to 2019 reveals significant racial and ethnic disparities in maternal cardiovascular health, specifically hypertensive disorders of pregnancy. The study found variations in the prevalence and trends of these disorders among different racial and ethnic groups. These findings highlight the need for targeted interventions to address these disparities and improve maternal cardiovascular outcomes.
Article 4: Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996070
Summary: This article describes the design of the Black Impact randomized controlled trial, a 24-]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like longitudinal study and cardiac electrophysiology. Key takeaway: Methadone&#8217;s Pro-Arrhythmic Cardiac Risks Confirmed.
Article Links:
Article 1: Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias: Mechanistic Insights From Computational Modeling. (Journal of the American Heart Association)
Article 2: Interventional Partial Cavopulmonary Connection: Initial Clinical Experience With Acute Procedural up to Midterm Results. (Journal of the American Heart Association)
Article 3: Trends and Racial and Ethnic Disparities in Maternal Cardiovascular Health in California. (Journal of the American Heart Association)
Article 4: Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention. (Journal of the Americ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Obesity: New Heart Failure Risk Factor? 09/28/25</title>
	<link>https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/</link>
	<pubDate>Sun, 28 Sep 2025 10:00:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and waist circumference. Key takeaway: Obesity: New Heart Failure Risk Factor?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41015124">Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40999962">Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40999636">Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40998567">Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41000007">Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/">https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015124</a></p>
<p><strong>Summary:</strong> This article highlights the critical need to improve the representation of historically underrepresented patient groups—specifically defined by sex, age, demographic, and geographic diversity—in cardiovascular device trials to ensure external validity of clinical research. Addressing disparities in enrollment is essential, especially in countries with pronounced inequities, to promote equitable access to and benefit from cardiovascular technologies. Raising awareness is paramount to closing the gaps in future trials.</p>
<h4>Article 2: Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40999962" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40999962</a></p>
<p><strong>Summary:</strong> This extensive study of nearly one million newly diagnosed heart failure patients in Korea over a decade revealed that underweight individuals with abdominal obesity exhibit poor cardiovascular outcomes. Body Mass Index alone may not be sufficient to assess cardiovascular risk in heart failure patients, highlighting the importance of considering waist circumference alongside B.M.I. for a more comprehensive risk stratification. These findings suggest the need for tailored management strategies for heart failure patients with this specific phenotype.</p>
<h4>Article 3: Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40999636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40999636</a></p>
<p><strong>Summary:</strong> This study investigates the impact of epicardial adipose tissue on myocardial remodeling and function in patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement. Elevated epicardial adipose tissue volume is associated with adverse myocardial remodeling and dysfunction, potentially influencing outcomes post-transcatheter aortic valve replacement. Understanding these pathophysiological mechanisms could lead to targeted therapies aimed at reducing epicardial adipose tissue and improving outcomes in these patients.</p>
<h4>Article 4: Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40998567" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40998567</a></p>
<p><strong>Summary:</strong> A prospective, randomized trial demonstrated that simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients improves outcomes during the subsequent infection season. This suggests a proactive approach to respiratory virus prevention through vaccination can significantly reduce morbidity in this vulnerable population. The findings support the implementation of combined vaccination strategies as a standard of care for high-risk heart failure patients.</p>
<h4>Article 5: Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41000007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41000007</a></p>
<p><strong>Summary:</strong> This analysis of hypertension management across 199 countries highlights significant gaps between healthcare system capacity, specifically physician and non-physician provider density, and patient needs. The study reveals substantial shortfalls in hypertension care delivery, emphasizing the need for strategies to optimize healthcare workforce distribution and task-sharing to improve hypertension control globally. Addressing these gaps is crucial for reducing the global burden of hypertension-related cardiovascular disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background. This article highlights the critical need to improve the representation of historically underrepresented patient groups—specifically defined by sex, age, demographic, and geographic diversity—in cardiovascular device trials to ensure external validity of clinical research. Addressing disparities in enrollment is essential, especially in countries with pronounced inequities, to promote equitable access to and benefit from cardiovascular technologies. Raising awareness is paramount to closing the gaps in future trials.</p>
<p>Article number two. Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure. This extensive study of nearly one million newly diagnosed heart failure patients in Korea over a decade revealed that underweight individuals with abdominal obesity exhibit poor cardiovascular outcomes. Body Mass Index alone may not be sufficient to assess cardiovascular risk in heart failure patients, highlighting the importance of considering waist circumference alongside B.M.I. for a more comprehensive risk stratification. These findings suggest the need for tailored management strategies for heart failure patients with this specific phenotype.</p>
<p>Article number three. Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis. This study investigates the impact of epicardial adipose tissue on myocardial remodeling and function in patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement. Elevated epicardial adipose tissue volume is associated with adverse myocardial remodeling and dysfunction, potentially influencing outcomes post-transcatheter aortic valve replacement. Understanding these pathophysiological mechanisms could lead to targeted therapies aimed at reducing epicardial adipose tissue and improving outcomes in these patients.</p>
<p>Article number four. Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients. A prospective, randomized trial demonstrated that simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients improves outcomes during the subsequent infection season. This suggests a proactive approach to respiratory virus prevention through vaccination can significantly reduce morbidity in this vulnerable population. The findings support the implementation of combined vaccination strategies as a standard of care for high-risk heart failure patients.</p>
<p>Article number five. Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories. This analysis of hypertension management across 199 countries highlights significant gaps between healthcare system capacity, specifically physician and non-physician provider density, and patient needs. The study reveals substantial shortfalls in hypertension care delivery, emphasizing the need for strategies to optimize healthcare workforce distribution and task-sharing to improve hypertension control globally. Addressing these gaps is crucial for reducing the global burden of hypertension-related cardiovascular disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, waist circumference, non-physician providers, aortic valve stenosis, myocardial remodeling, Body Mass Index, epicardial adipose tissue, abdominal obesity, healthcare capacity, myocardial dysfunction, hypertension, physician shortage, cardiovascular device trials, underrepresented populations, cardiovascular outcomes, simultaneous vaccination, geographical diversity, respiratory infections, age disparities, transcatheter aortic valve replacement, influenza vaccine, sex disparities, respiratory syncytial virus vaccine, provider density.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/">Obesity: New Heart Failure Risk Factor? 09/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and waist circumference. Key takeaway: Obesity: New Heart Failure Risk Factor?.
Article Links:
Article 1: Underrepres]]></itunes:subtitle>
	<itunes:episode>82</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and waist circumference. Key takeaway: Obesity: New Heart Failure Risk Factor?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41015124">Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40999962">Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40999636">Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40998567">Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41000007">Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/">https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015124</a></p>
<p><strong>Summary:</strong> This article highlights the critical need to improve the representation of historically underrepresented patient groups—specifically defined by sex, age, demographic, and geographic diversity—in cardiovascular device trials to ensure external validity of clinical research. Addressing disparities in enrollment is essential, especially in countries with pronounced inequities, to promote equitable access to and benefit from cardiovascular technologies. Raising awareness is paramount to closing the gaps in future trials.</p>
<h4>Article 2: Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40999962" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40999962</a></p>
<p><strong>Summary:</strong> This extensive study of nearly one million newly diagnosed heart failure patients in Korea over a decade revealed that underweight individuals with abdominal obesity exhibit poor cardiovascular outcomes. Body Mass Index alone may not be sufficient to assess cardiovascular risk in heart failure patients, highlighting the importance of considering waist circumference alongside B.M.I. for a more comprehensive risk stratification. These findings suggest the need for tailored management strategies for heart failure patients with this specific phenotype.</p>
<h4>Article 3: Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40999636" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40999636</a></p>
<p><strong>Summary:</strong> This study investigates the impact of epicardial adipose tissue on myocardial remodeling and function in patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement. Elevated epicardial adipose tissue volume is associated with adverse myocardial remodeling and dysfunction, potentially influencing outcomes post-transcatheter aortic valve replacement. Understanding these pathophysiological mechanisms could lead to targeted therapies aimed at reducing epicardial adipose tissue and improving outcomes in these patients.</p>
<h4>Article 4: Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40998567" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40998567</a></p>
<p><strong>Summary:</strong> A prospective, randomized trial demonstrated that simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients improves outcomes during the subsequent infection season. This suggests a proactive approach to respiratory virus prevention through vaccination can significantly reduce morbidity in this vulnerable population. The findings support the implementation of combined vaccination strategies as a standard of care for high-risk heart failure patients.</p>
<h4>Article 5: Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41000007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41000007</a></p>
<p><strong>Summary:</strong> This analysis of hypertension management across 199 countries highlights significant gaps between healthcare system capacity, specifically physician and non-physician provider density, and patient needs. The study reveals substantial shortfalls in hypertension care delivery, emphasizing the need for strategies to optimize healthcare workforce distribution and task-sharing to improve hypertension control globally. Addressing these gaps is crucial for reducing the global burden of hypertension-related cardiovascular disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background. This article highlights the critical need to improve the representation of historically underrepresented patient groups—specifically defined by sex, age, demographic, and geographic diversity—in cardiovascular device trials to ensure external validity of clinical research. Addressing disparities in enrollment is essential, especially in countries with pronounced inequities, to promote equitable access to and benefit from cardiovascular technologies. Raising awareness is paramount to closing the gaps in future trials.</p>
<p>Article number two. Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure. This extensive study of nearly one million newly diagnosed heart failure patients in Korea over a decade revealed that underweight individuals with abdominal obesity exhibit poor cardiovascular outcomes. Body Mass Index alone may not be sufficient to assess cardiovascular risk in heart failure patients, highlighting the importance of considering waist circumference alongside B.M.I. for a more comprehensive risk stratification. These findings suggest the need for tailored management strategies for heart failure patients with this specific phenotype.</p>
<p>Article number three. Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis. This study investigates the impact of epicardial adipose tissue on myocardial remodeling and function in patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement. Elevated epicardial adipose tissue volume is associated with adverse myocardial remodeling and dysfunction, potentially influencing outcomes post-transcatheter aortic valve replacement. Understanding these pathophysiological mechanisms could lead to targeted therapies aimed at reducing epicardial adipose tissue and improving outcomes in these patients.</p>
<p>Article number four. Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients. A prospective, randomized trial demonstrated that simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients improves outcomes during the subsequent infection season. This suggests a proactive approach to respiratory virus prevention through vaccination can significantly reduce morbidity in this vulnerable population. The findings support the implementation of combined vaccination strategies as a standard of care for high-risk heart failure patients.</p>
<p>Article number five. Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories. This analysis of hypertension management across 199 countries highlights significant gaps between healthcare system capacity, specifically physician and non-physician provider density, and patient needs. The study reveals substantial shortfalls in hypertension care delivery, emphasizing the need for strategies to optimize healthcare workforce distribution and task-sharing to improve hypertension control globally. Addressing these gaps is crucial for reducing the global burden of hypertension-related cardiovascular disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>heart failure, waist circumference, non-physician providers, aortic valve stenosis, myocardial remodeling, Body Mass Index, epicardial adipose tissue, abdominal obesity, healthcare capacity, myocardial dysfunction, hypertension, physician shortage, cardiovascular device trials, underrepresented populations, cardiovascular outcomes, simultaneous vaccination, geographical diversity, respiratory infections, age disparities, transcatheter aortic valve replacement, influenza vaccine, sex disparities, respiratory syncytial virus vaccine, provider density.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/">Obesity: New Heart Failure Risk Factor? 09/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250928_060012.mp3" length="3821652" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and waist circumference. Key takeaway: Obesity: New Heart Failure Risk Factor?.
Article Links:
Article 1: Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background. (International journal of cardiology)
Article 2: Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure. (ESC heart failure)
Article 3: Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis. (ESC heart failure)
Article 4: Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients. (ESC heart failure)
Article 5: Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Analysis of Data From 199 Countries and Territories. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/obesity-new-heart-failure-risk-factor-09-28-25/
 Featured Articles
Article 1: Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015124
Summary: This article highlights the critical need to improve the representation of historically underrepresented patient groups—specifically defined by sex, age, demographic, and geographic diversity—in cardiovascular device trials to ensure external validity of clinical research. Addressing disparities in enrollment is essential, especially in countries with pronounced inequities, to promote equitable access to and benefit from cardiovascular technologies. Raising awareness is paramount to closing the gaps in future trials.
Article 2: Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40999962
Summary: This extensive study of nearly one million newly diagnosed heart failure patients in Korea over a decade revealed that underweight individuals with abdominal obesity exhibit poor cardiovascular outcomes. Body Mass Index alone may not be sufficient to assess cardiovascular risk in heart failure patients, highlighting the importance of considering waist circumference alongside B.M.I. for a more comprehensive risk stratification. These findings suggest the need for tailored management strategies for heart failure patients with this specific phenotype.
Article 3: Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40999636
Summary: This study investigates the impact of epicardial adipose tissue on myocardial remodeling and function in patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement. Elevated epicardial adipose tissue volume is associated with adverse myocardial remodeling and dysfunction, potentially influencing outcomes post-transcatheter aortic valve replacement. Understanding these pathophysiological mechanisms could lead to targeted therapies aimed at reducing epicardial adipose tissue and improving outcomes in these patients.
Article 4: Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40998567
Summary: A prospective, randomized trial demonstrated that simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients improves outcomes during the subsequent infection seas]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and waist circumference. Key takeaway: Obesity: New Heart Failure Risk Factor?.
Article Links:
Article 1: Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical background. (International journal of cardiology)
Article 2: Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure. (ESC heart failure)
Article 3: Impact of epicardial adipose tissue on myocardial function and structure in patients with severe aortic valve stenosis. (ESC heart failure)
Article 4: Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients. (ESC heart failure)
Article 5: Bridging Hypertension Care Shortfalls Between Provider Capacity and Patient Needs: A Pooled Anal]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Polygenic Risk Drives A.fib More in Men 09/28/25</title>
	<link>https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/</link>
	<pubDate>Sun, 28 Sep 2025 06:57:22 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like accelerometry and sudden cardiac death. Key takeaway: Polygenic Risk Drives A.fib More in Men.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41015500">Trends in burden of atrial fibrillation over three decades: a population-based study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40887133">Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41015248">Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study.</a> (The Canadian journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41015247">Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41015246">Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/">https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Trends in burden of atrial fibrillation over three decades: a population-based study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015500" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015500</a></p>
<p><strong>Summary:</strong> This population-based study across three decades demonstrated an increase in atrial fibrillation prevalence, particularly in men, with age, hypertension, and heart failure being key risk factors. The observed increase in atrial fibrillation incidence remained stable over time, highlighting the persistent need for effective prevention and management strategies. The findings suggest a growing burden of atrial fibrillation, necessitating continued attention to risk factor modification and targeted interventions.</p>
<h4>Article 2: Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40887133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40887133</a></p>
<p><strong>Summary:</strong> This study, using accelerometry in patients with hypertrophic cardiomyopathy, revealed that reduced physical activity levels correlate with poorer quality of life, independent of left ventricular outflow tract obstruction. Patients with hypertrophic cardiomyopathy demonstrated significantly lower daily step counts compared to genotype-positive, phenotype-negative individuals. These findings underscore the importance of encouraging and supporting increased physical activity in hypertrophic cardiomyopathy patients to improve their overall well-being.</p>
<h4>Article 3: Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015248</a></p>
<p><strong>Summary:</strong> This prospective cohort study of over 444,000 participants found that a higher polygenic risk score for atrial fibrillation was associated with an increased risk of developing atrial fibrillation, with this association being more pronounced in men compared to women. The sex-specific effects of the polygenic risk score were consistent across different levels of clinical risk as defined by the CHARGE-A.F. score. These results suggest that genetic predisposition to atrial fibrillation may differ between sexes, which could inform personalized risk stratification and prevention strategies.</p>
<h4>Article 4: Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015247</a></p>
<p><strong>Summary:</strong> This study investigated percutaneous intramyocardial septal radiofrequency ablation as a treatment for obstructive hypertrophic cardiomyopathy patients with persistent left ventricular outflow tract obstruction following alcohol septal ablation. The findings suggest that percutaneous intramyocardial septal radiofrequency ablation is a feasible option in carefully selected patients, demonstrating both acute and short-term reductions in left ventricular outflow tract gradients and improved symptoms. Further research is needed to assess long-term outcomes and identify optimal patient selection criteria.</p>
<h4>Article 5: Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015246" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015246</a></p>
<p><strong>Summary:</strong> This study of patients undergoing cardiac surgery found that new potential ischemic E.C.G. changes after surgery were significantly associated with a higher risk of 30-day mortality. Specifically, new Q waves, S.T. segment depression, or T wave inversion were all independent predictors of increased mortality. These findings highlight the importance of vigilant post-operative E.C.G. monitoring for early detection of myocardial ischemia and prompt intervention to improve outcomes following cardiac surgery.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Trends in burden of atrial fibrillation over three decades: a population-based study. This population-based study across three decades demonstrated an increase in atrial fibrillation prevalence, particularly in men, with age, hypertension, and heart failure being key risk factors. The observed increase in atrial fibrillation incidence remained stable over time, highlighting the persistent need for effective prevention and management strategies. The findings suggest a growing burden of atrial fibrillation, necessitating continued attention to risk factor modification and targeted interventions.</p>
<p>Article number two. Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. This study, using accelerometry in patients with hypertrophic cardiomyopathy, revealed that reduced physical activity levels correlate with poorer quality of life, independent of left ventricular outflow tract obstruction. Patients with hypertrophic cardiomyopathy demonstrated significantly lower daily step counts compared to genotype-positive, phenotype-negative individuals. These findings underscore the importance of encouraging and supporting increased physical activity in hypertrophic cardiomyopathy patients to improve their overall well-being.</p>
<p>Article number three. Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study. This prospective cohort study of over 444,000 participants found that a higher polygenic risk score for atrial fibrillation was associated with an increased risk of developing atrial fibrillation, with this association being more pronounced in men compared to women. The sex-specific effects of the polygenic risk score were consistent across different levels of clinical risk as defined by the CHARGE-A.F. score. These results suggest that genetic predisposition to atrial fibrillation may differ between sexes, which could inform personalized risk stratification and prevention strategies.</p>
<p>Article number four. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation. This study investigated percutaneous intramyocardial septal radiofrequency ablation as a treatment for obstructive hypertrophic cardiomyopathy patients with persistent left ventricular outflow tract obstruction following alcohol septal ablation. The findings suggest that percutaneous intramyocardial septal radiofrequency ablation is a feasible option in carefully selected patients, demonstrating both acute and short-term reductions in left ventricular outflow tract gradients and improved symptoms. Further research is needed to assess long-term outcomes and identify optimal patient selection criteria.</p>
<p>Article number five. Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery. This study of patients undergoing cardiac surgery found that new potential ischemic E.C.G. changes after surgery were significantly associated with a higher risk of 30-day mortality. Specifically, new Q waves, S.T. segment depression, or T wave inversion were all independent predictors of increased mortality. These findings highlight the importance of vigilant post-operative E.C.G. monitoring for early detection of myocardial ischemia and prompt intervention to improve outcomes following cardiac surgery. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>accelerometry, sudden cardiac death, prevalence, ischemia, radiofrequency ablation, electrocardiogram, myocardial injury, hypertrophic cardiomyopathy, alcohol septal ablation, left ventricular outflow tract obstruction, Rotterdam Study, cardiac surgery, atrial fibrillation, genetic predisposition, quality of life, sex differences, physical activity, mortality, risk factors, CHARGE-A.F., polygenic risk score, septal reduction therapy, incidence.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/">Polygenic Risk Drives A.fib More in Men 09/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like accelerometry and sudden cardiac death. Key takeaway: Polygenic Risk Drives A.fib More in Men.
Article Links:
Article 1: Trends in ]]></itunes:subtitle>
	<itunes:episode>81</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like accelerometry and sudden cardiac death. Key takeaway: Polygenic Risk Drives A.fib More in Men.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41015500">Trends in burden of atrial fibrillation over three decades: a population-based study.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40887133">Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41015248">Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study.</a> (The Canadian journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41015247">Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41015246">Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/">https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Trends in burden of atrial fibrillation over three decades: a population-based study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015500" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015500</a></p>
<p><strong>Summary:</strong> This population-based study across three decades demonstrated an increase in atrial fibrillation prevalence, particularly in men, with age, hypertension, and heart failure being key risk factors. The observed increase in atrial fibrillation incidence remained stable over time, highlighting the persistent need for effective prevention and management strategies. The findings suggest a growing burden of atrial fibrillation, necessitating continued attention to risk factor modification and targeted interventions.</p>
<h4>Article 2: Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40887133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40887133</a></p>
<p><strong>Summary:</strong> This study, using accelerometry in patients with hypertrophic cardiomyopathy, revealed that reduced physical activity levels correlate with poorer quality of life, independent of left ventricular outflow tract obstruction. Patients with hypertrophic cardiomyopathy demonstrated significantly lower daily step counts compared to genotype-positive, phenotype-negative individuals. These findings underscore the importance of encouraging and supporting increased physical activity in hypertrophic cardiomyopathy patients to improve their overall well-being.</p>
<h4>Article 3: Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015248" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015248</a></p>
<p><strong>Summary:</strong> This prospective cohort study of over 444,000 participants found that a higher polygenic risk score for atrial fibrillation was associated with an increased risk of developing atrial fibrillation, with this association being more pronounced in men compared to women. The sex-specific effects of the polygenic risk score were consistent across different levels of clinical risk as defined by the CHARGE-A.F. score. These results suggest that genetic predisposition to atrial fibrillation may differ between sexes, which could inform personalized risk stratification and prevention strategies.</p>
<h4>Article 4: Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015247" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015247</a></p>
<p><strong>Summary:</strong> This study investigated percutaneous intramyocardial septal radiofrequency ablation as a treatment for obstructive hypertrophic cardiomyopathy patients with persistent left ventricular outflow tract obstruction following alcohol septal ablation. The findings suggest that percutaneous intramyocardial septal radiofrequency ablation is a feasible option in carefully selected patients, demonstrating both acute and short-term reductions in left ventricular outflow tract gradients and improved symptoms. Further research is needed to assess long-term outcomes and identify optimal patient selection criteria.</p>
<h4>Article 5: Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41015246" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41015246</a></p>
<p><strong>Summary:</strong> This study of patients undergoing cardiac surgery found that new potential ischemic E.C.G. changes after surgery were significantly associated with a higher risk of 30-day mortality. Specifically, new Q waves, S.T. segment depression, or T wave inversion were all independent predictors of increased mortality. These findings highlight the importance of vigilant post-operative E.C.G. monitoring for early detection of myocardial ischemia and prompt intervention to improve outcomes following cardiac surgery.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 28, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Trends in burden of atrial fibrillation over three decades: a population-based study. This population-based study across three decades demonstrated an increase in atrial fibrillation prevalence, particularly in men, with age, hypertension, and heart failure being key risk factors. The observed increase in atrial fibrillation incidence remained stable over time, highlighting the persistent need for effective prevention and management strategies. The findings suggest a growing burden of atrial fibrillation, necessitating continued attention to risk factor modification and targeted interventions.</p>
<p>Article number two. Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. This study, using accelerometry in patients with hypertrophic cardiomyopathy, revealed that reduced physical activity levels correlate with poorer quality of life, independent of left ventricular outflow tract obstruction. Patients with hypertrophic cardiomyopathy demonstrated significantly lower daily step counts compared to genotype-positive, phenotype-negative individuals. These findings underscore the importance of encouraging and supporting increased physical activity in hypertrophic cardiomyopathy patients to improve their overall well-being.</p>
<p>Article number three. Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study. This prospective cohort study of over 444,000 participants found that a higher polygenic risk score for atrial fibrillation was associated with an increased risk of developing atrial fibrillation, with this association being more pronounced in men compared to women. The sex-specific effects of the polygenic risk score were consistent across different levels of clinical risk as defined by the CHARGE-A.F. score. These results suggest that genetic predisposition to atrial fibrillation may differ between sexes, which could inform personalized risk stratification and prevention strategies.</p>
<p>Article number four. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation. This study investigated percutaneous intramyocardial septal radiofrequency ablation as a treatment for obstructive hypertrophic cardiomyopathy patients with persistent left ventricular outflow tract obstruction following alcohol septal ablation. The findings suggest that percutaneous intramyocardial septal radiofrequency ablation is a feasible option in carefully selected patients, demonstrating both acute and short-term reductions in left ventricular outflow tract gradients and improved symptoms. Further research is needed to assess long-term outcomes and identify optimal patient selection criteria.</p>
<p>Article number five. Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery. This study of patients undergoing cardiac surgery found that new potential ischemic E.C.G. changes after surgery were significantly associated with a higher risk of 30-day mortality. Specifically, new Q waves, S.T. segment depression, or T wave inversion were all independent predictors of increased mortality. These findings highlight the importance of vigilant post-operative E.C.G. monitoring for early detection of myocardial ischemia and prompt intervention to improve outcomes following cardiac surgery. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>accelerometry, sudden cardiac death, prevalence, ischemia, radiofrequency ablation, electrocardiogram, myocardial injury, hypertrophic cardiomyopathy, alcohol septal ablation, left ventricular outflow tract obstruction, Rotterdam Study, cardiac surgery, atrial fibrillation, genetic predisposition, quality of life, sex differences, physical activity, mortality, risk factors, CHARGE-A.F., polygenic risk score, septal reduction therapy, incidence.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/">Polygenic Risk Drives A.fib More in Men 09/28/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250928_025630.mp3" length="3979223" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like accelerometry and sudden cardiac death. Key takeaway: Polygenic Risk Drives A.fib More in Men.
Article Links:
Article 1: Trends in burden of atrial fibrillation over three decades: a population-based study. (Heart (British Cardiac Society))
Article 2: Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. (Heart (British Cardiac Society))
Article 3: Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study. (The Canadian journal of cardiology)
Article 4: Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation. (The Canadian journal of cardiology)
Article 5: Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/polygenic-risk-drives-a-fib-more-in-men-09-28-25/
 Featured Articles
Article 1: Trends in burden of atrial fibrillation over three decades: a population-based study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015500
Summary: This population-based study across three decades demonstrated an increase in atrial fibrillation prevalence, particularly in men, with age, hypertension, and heart failure being key risk factors. The observed increase in atrial fibrillation incidence remained stable over time, highlighting the persistent need for effective prevention and management strategies. The findings suggest a growing burden of atrial fibrillation, necessitating continued attention to risk factor modification and targeted interventions.
Article 2: Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40887133
Summary: This study, using accelerometry in patients with hypertrophic cardiomyopathy, revealed that reduced physical activity levels correlate with poorer quality of life, independent of left ventricular outflow tract obstruction. Patients with hypertrophic cardiomyopathy demonstrated significantly lower daily step counts compared to genotype-positive, phenotype-negative individuals. These findings underscore the importance of encouraging and supporting increased physical activity in hypertrophic cardiomyopathy patients to improve their overall well-being.
Article 3: Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015248
Summary: This prospective cohort study of over 444,000 participants found that a higher polygenic risk score for atrial fibrillation was associated with an increased risk of developing atrial fibrillation, with this association being more pronounced in men compared to women. The sex-specific effects of the polygenic risk score were consistent across different levels of clinical risk as defined by the CHARGE-A.F. score. These results suggest that genetic predisposition to atrial fibrillation may differ between sexes, which could inform personalized risk stratification and prevention strategies.
Article 4: Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41015247
Summary: This study investigated percutaneous intramyocardial septal radiofrequency ablation as a treatment for obstructive hypertrophic cardiomyopathy patients with persistent left ventricular outflow tract obstruction following alcohol septal ablation. The findings sugge]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 28, 2025. This episode summarizes 5 key cardiology studies on topics like accelerometry and sudden cardiac death. Key takeaway: Polygenic Risk Drives A.fib More in Men.
Article Links:
Article 1: Trends in burden of atrial fibrillation over three decades: a population-based study. (Heart (British Cardiac Society))
Article 2: Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. (Heart (British Cardiac Society))
Article 3: Sex Differences in the Association between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study. (The Canadian journal of cardiology)
Article 4: Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy with residual obstruction after Alcohol Septal Ablation. (The Canadian journal of cardiology)
Article 5: Association Between Electrocardiographic Changes and Myocardial Injury or Death after Cardiac Surgery. (The Canadia]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Hypertension Kills Young Adults: A U.S. Crisis 09/27/25</title>
	<link>https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/</link>
	<pubDate>Sat, 27 Sep 2025 22:30:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like amiodarone and mortality. Key takeaway: Hypertension Kills Young Adults: A U.S. Crisis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41005597">Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41005596">Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41005594">Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40994366">Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40990096">Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/">https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005597" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005597</a></p>
<p><strong>Summary:</strong> This study, using the TriNetX network, compared surgical aortic valve replacement after transcatheter aortic valve replacement with other open-heart surgeries. After propensity score matching, no significant differences in mortality were observed between the two groups at three and five years. This suggests that surgical aortic valve replacement following transcatheter aortic valve replacement does not pose a significantly higher long-term mortality risk compared to other cardiac surgeries.</p>
<h4>Article 2: Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005596" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005596</a></p>
<p><strong>Summary:</strong> This post-hoc analysis of the A.M.I.O.-C.A.T. trial investigated whether left atrial structure and function modify the effect of amiodarone in preventing atrial fibrillation recurrence after catheter ablation. The study found that short-term amiodarone after catheter ablation reduces atrial fibrillation recurrence, but this effect is not significantly modified by left atrial size or function. These results do not support tailoring amiodarone use post-ablation based on left atrial characteristics.</p>
<h4>Article 3: Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005594" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005594</a></p>
<p><strong>Summary:</strong> Analysis of national mortality data from 1999 to 2024 reveals a concerning increase in hypertensive heart disease mortality among U.S. adults aged 15 to 44. This rise was observed across various demographic subgroups, highlighting the need for targeted prevention and treatment strategies for hypertension in younger populations to curb cardiovascular mortality. Further studies are needed to find the cause for the increase.</p>
<h4>Article 4: Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40994366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40994366</a></p>
<p><strong>Summary:</strong> This study explored the role of iron regulatory proteins in skeletal muscle function and exercise capacity in heart failure. The researchers found that skeletal muscle iron deficiency is associated with inactivation of iron regulatory proteins one and two, which impacts exercise tolerance in heart failure. Maintaining iron availability in skeletal muscle via iron regulatory proteins may be a therapeutic target to improve exercise capacity in heart failure patients.</p>
<h4>Article 5: Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40990096" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40990096</a></p>
<p><strong>Summary:</strong> This research identifies the transcription factor F.O.X.S.1 in human valvular interstitial cells as a crucial regulator in aortic valve calcification. The study found that oxidized low-density lipoprotein induces F.O.X.S.1, which mediates cholesterol transport dysfunction and inflammasome activation, promoting aortic valve calcification. Targeting F.O.X.S.1 could offer a potential therapeutic avenue for preventing or slowing the progression of calcific aortic valve disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery. This study, using the TriNetX network, compared surgical aortic valve replacement after transcatheter aortic valve replacement with other open-heart surgeries. After propensity score matching, no significant differences in mortality were observed between the two groups at three and five years. This suggests that surgical aortic valve replacement following transcatheter aortic valve replacement does not pose a significantly higher long-term mortality risk compared to other cardiac surgeries.</p>
<p>Article number two. Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial. This post-hoc analysis of the A.M.I.O.-C.A.T. trial investigated whether left atrial structure and function modify the effect of amiodarone in preventing atrial fibrillation recurrence after catheter ablation. The study found that short-term amiodarone after catheter ablation reduces atrial fibrillation recurrence, but this effect is not significantly modified by left atrial size or function. These results do not support tailoring amiodarone use post-ablation based on left atrial characteristics.</p>
<p>Article number three. Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024. Analysis of national mortality data from 1999 to 2024 reveals a concerning increase in hypertensive heart disease mortality among U.S. adults aged 15 to 44. This rise was observed across various demographic subgroups, highlighting the need for targeted prevention and treatment strategies for hypertension in younger populations to curb cardiovascular mortality. Further studies are needed to find the cause for the increase.</p>
<p>Article number four. Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure. This study explored the role of iron regulatory proteins in skeletal muscle function and exercise capacity in heart failure. The researchers found that skeletal muscle iron deficiency is associated with inactivation of iron regulatory proteins one and two, which impacts exercise tolerance in heart failure. Maintaining iron availability in skeletal muscle via iron regulatory proteins may be a therapeutic target to improve exercise capacity in heart failure patients.</p>
<p>Article number five. Oxidized L.D.L.-induced F.O.X.S.1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification. This research identifies the transcription factor F.O.X.S.1 in human valvular interstitial cells as a crucial regulator in aortic valve calcification. The study found that oxidized low-density lipoprotein induces F.O.X.S.1, which mediates cholesterol transport dysfunction and inflammasome activation, promoting aortic valve calcification. Targeting F.O.X.S.1 could offer a potential therapeutic avenue for preventing or slowing the progression of calcific aortic valve disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>amiodarone, mortality, exercise tolerance, atrial fibrillation, recurrence, heart failure, open-heart surgery, catheter ablation, transcatheter aortic valve replacement, hypertension, skeletal muscle, iron deficiency, surgical aortic valve replacement, aortic valve disease, left atrial structure, aortic valve calcification, hypertensive heart disease, iron regulatory proteins, valvular interstitial cells, inflammasome, young adults, oxidized L.D.L., cardiovascular disease, F.O.X.S.1.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/">Hypertension Kills Young Adults: A U.S. Crisis 09/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like amiodarone and mortality. Key takeaway: Hypertension Kills Young Adults: A U.S. Crisis.
Article Links:
Article 1: Surgical Aortic V]]></itunes:subtitle>
	<itunes:episode>80</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like amiodarone and mortality. Key takeaway: Hypertension Kills Young Adults: A U.S. Crisis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41005597">Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/41005596">Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/41005594">Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40994366">Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.</a> (Cardiovascular research)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40990096">Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification.</a> (Cardiovascular research)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/">https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005597" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005597</a></p>
<p><strong>Summary:</strong> This study, using the TriNetX network, compared surgical aortic valve replacement after transcatheter aortic valve replacement with other open-heart surgeries. After propensity score matching, no significant differences in mortality were observed between the two groups at three and five years. This suggests that surgical aortic valve replacement following transcatheter aortic valve replacement does not pose a significantly higher long-term mortality risk compared to other cardiac surgeries.</p>
<h4>Article 2: Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005596" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005596</a></p>
<p><strong>Summary:</strong> This post-hoc analysis of the A.M.I.O.-C.A.T. trial investigated whether left atrial structure and function modify the effect of amiodarone in preventing atrial fibrillation recurrence after catheter ablation. The study found that short-term amiodarone after catheter ablation reduces atrial fibrillation recurrence, but this effect is not significantly modified by left atrial size or function. These results do not support tailoring amiodarone use post-ablation based on left atrial characteristics.</p>
<h4>Article 3: Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005594" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005594</a></p>
<p><strong>Summary:</strong> Analysis of national mortality data from 1999 to 2024 reveals a concerning increase in hypertensive heart disease mortality among U.S. adults aged 15 to 44. This rise was observed across various demographic subgroups, highlighting the need for targeted prevention and treatment strategies for hypertension in younger populations to curb cardiovascular mortality. Further studies are needed to find the cause for the increase.</p>
<h4>Article 4: Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40994366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40994366</a></p>
<p><strong>Summary:</strong> This study explored the role of iron regulatory proteins in skeletal muscle function and exercise capacity in heart failure. The researchers found that skeletal muscle iron deficiency is associated with inactivation of iron regulatory proteins one and two, which impacts exercise tolerance in heart failure. Maintaining iron availability in skeletal muscle via iron regulatory proteins may be a therapeutic target to improve exercise capacity in heart failure patients.</p>
<h4>Article 5: Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40990096" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40990096</a></p>
<p><strong>Summary:</strong> This research identifies the transcription factor F.O.X.S.1 in human valvular interstitial cells as a crucial regulator in aortic valve calcification. The study found that oxidized low-density lipoprotein induces F.O.X.S.1, which mediates cholesterol transport dysfunction and inflammasome activation, promoting aortic valve calcification. Targeting F.O.X.S.1 could offer a potential therapeutic avenue for preventing or slowing the progression of calcific aortic valve disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery. This study, using the TriNetX network, compared surgical aortic valve replacement after transcatheter aortic valve replacement with other open-heart surgeries. After propensity score matching, no significant differences in mortality were observed between the two groups at three and five years. This suggests that surgical aortic valve replacement following transcatheter aortic valve replacement does not pose a significantly higher long-term mortality risk compared to other cardiac surgeries.</p>
<p>Article number two. Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial. This post-hoc analysis of the A.M.I.O.-C.A.T. trial investigated whether left atrial structure and function modify the effect of amiodarone in preventing atrial fibrillation recurrence after catheter ablation. The study found that short-term amiodarone after catheter ablation reduces atrial fibrillation recurrence, but this effect is not significantly modified by left atrial size or function. These results do not support tailoring amiodarone use post-ablation based on left atrial characteristics.</p>
<p>Article number three. Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024. Analysis of national mortality data from 1999 to 2024 reveals a concerning increase in hypertensive heart disease mortality among U.S. adults aged 15 to 44. This rise was observed across various demographic subgroups, highlighting the need for targeted prevention and treatment strategies for hypertension in younger populations to curb cardiovascular mortality. Further studies are needed to find the cause for the increase.</p>
<p>Article number four. Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure. This study explored the role of iron regulatory proteins in skeletal muscle function and exercise capacity in heart failure. The researchers found that skeletal muscle iron deficiency is associated with inactivation of iron regulatory proteins one and two, which impacts exercise tolerance in heart failure. Maintaining iron availability in skeletal muscle via iron regulatory proteins may be a therapeutic target to improve exercise capacity in heart failure patients.</p>
<p>Article number five. Oxidized L.D.L.-induced F.O.X.S.1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification. This research identifies the transcription factor F.O.X.S.1 in human valvular interstitial cells as a crucial regulator in aortic valve calcification. The study found that oxidized low-density lipoprotein induces F.O.X.S.1, which mediates cholesterol transport dysfunction and inflammasome activation, promoting aortic valve calcification. Targeting F.O.X.S.1 could offer a potential therapeutic avenue for preventing or slowing the progression of calcific aortic valve disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>amiodarone, mortality, exercise tolerance, atrial fibrillation, recurrence, heart failure, open-heart surgery, catheter ablation, transcatheter aortic valve replacement, hypertension, skeletal muscle, iron deficiency, surgical aortic valve replacement, aortic valve disease, left atrial structure, aortic valve calcification, hypertensive heart disease, iron regulatory proteins, valvular interstitial cells, inflammasome, young adults, oxidized L.D.L., cardiovascular disease, F.O.X.S.1.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/">Hypertension Kills Young Adults: A U.S. Crisis 09/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250927_182940.mp3" length="3799501" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like amiodarone and mortality. Key takeaway: Hypertension Kills Young Adults: A U.S. Crisis.
Article Links:
Article 1: Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery. (The American journal of cardiology)
Article 2: Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial. (The American journal of cardiology)
Article 3: Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024. (The American journal of cardiology)
Article 4: Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure. (Cardiovascular research)
Article 5: Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/hypertension-kills-young-adults-a-u-s-crisis-09-27-25/
 Featured Articles
Article 1: Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41005597
Summary: This study, using the TriNetX network, compared surgical aortic valve replacement after transcatheter aortic valve replacement with other open-heart surgeries. After propensity score matching, no significant differences in mortality were observed between the two groups at three and five years. This suggests that surgical aortic valve replacement following transcatheter aortic valve replacement does not pose a significantly higher long-term mortality risk compared to other cardiac surgeries.
Article 2: Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41005596
Summary: This post-hoc analysis of the A.M.I.O.-C.A.T. trial investigated whether left atrial structure and function modify the effect of amiodarone in preventing atrial fibrillation recurrence after catheter ablation. The study found that short-term amiodarone after catheter ablation reduces atrial fibrillation recurrence, but this effect is not significantly modified by left atrial size or function. These results do not support tailoring amiodarone use post-ablation based on left atrial characteristics.
Article 3: Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41005594
Summary: Analysis of national mortality data from 1999 to 2024 reveals a concerning increase in hypertensive heart disease mortality among U.S. adults aged 15 to 44. This rise was observed across various demographic subgroups, highlighting the need for targeted prevention and treatment strategies for hypertension in younger populations to curb cardiovascular mortality. Further studies are needed to find the cause for the increase.
Article 4: Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40994366
Summary: This study explored the role of iron regulatory proteins in skeletal muscle function and exercise capacity in heart failure. The researchers found that skeletal muscle iron deficiency is associated with inactivation of iron regulatory proteins one and two, which impacts exercise tolerance in heart failure. Maintaining iron availability in skeletal muscle via iron regulatory proteins may be a therapeutic target to improve exercise capacity in heart failure patients.
Article 5: Oxidized L]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like amiodarone and mortality. Key takeaway: Hypertension Kills Young Adults: A U.S. Crisis.
Article Links:
Article 1: Surgical Aortic Valve Replacement Following TAVR: Long-Term Comparative Outcomes Versus Non-SAVR Cardiac Surgery. (The American journal of cardiology)
Article 2: Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial. (The American journal of cardiology)
Article 3: Rising Burden of Hypertensive Heart Disease Mortality Among Young Adults in the United States, 1999 to 2024. (The American journal of cardiology)
Article 4: Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure. (Cardiovascular research)
Article 5: Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcif]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lp(a) Levels Key for Cardio Risk 09/27/25</title>
	<link>https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/</link>
	<pubDate>Sat, 27 Sep 2025 22:18:59 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like polyneuropathy and hereditary transthyretin amyloidosis. Key takeaway: Lp(a) Levels Key for Cardio Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41002250">Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40147871">Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40118518">Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41005599">The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41005598">Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The OPTIVUS-Complex PCI Study LMCA Cohort.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/">https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41002250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41002250</a></p>
<p><strong>Summary:</strong> with Polyneuropathy. This study investigates nexiguran ziclumeran, a C.R.I.S.P.R.-Cas9-based therapy designed to reduce serum transthyretin levels by selectively inactivating the TTR gene in patients with hereditary transthyretin amyloidosis with polyneuropathy. The therapy aims to address the underlying cause of the disease by preventing the misfolding and deposition of transthyretin protein in peripheral nerves. This is an investigational therapy.</p>
<h4>Article 2: Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40147871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40147871</a></p>
<p><strong>Summary:</strong> for coronary artery disease in patients with reduced left ventricular ejection fraction. This study evaluated the diagnostic accuracy of rest cardiac M.R.I. with late gadolinium enhancement for predicting significant coronary artery disease in patients with reduced left ventricular ejection fraction. Results indicate that rest late gadolinium enhancement cardiac M.R.I. can reliably detect significant coronary artery disease in this patient population, aiding in therapeutic decisions such as medical management, device implantation, and revascularization. The finding supports incorporating late gadolinium enhancement cardiac M.R.I. into the diagnostic workup for patients with reduced left ventricular ejection fraction suspected of having coronary artery disease.</p>
<h4>Article 3: Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40118518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40118518</a></p>
<p><strong>Summary:</strong> This retrospective analysis evaluated the prognostic role of the neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. The study found that elevated neutrophil-to-lymphocyte ratio was associated with adverse cardiovascular outcomes in both diabetic and non-diabetic patients post-percutaneous coronary intervention. The neutrophil-to-lymphocyte ratio serves as a valuable marker of systemic inflammation and risk stratification in patients undergoing percutaneous coronary intervention, regardless of diabetes status.</p>
<h4>Article 4: The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005599" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005599</a></p>
<p><strong>Summary:</strong> This study of over 346,000 UK Biobank participants investigated the interaction between lipoprotein(a), low-density lipoprotein cholesterol, and polygenic risk score in atherosclerotic cardiovascular disease. The research demonstrated that elevated lipoprotein(a) significantly increases cardiovascular risk, even in individuals with well-managed low-density lipoprotein cholesterol and after accounting for polygenic risk. These findings emphasize the importance of measuring lipoprotein(a) levels for comprehensive cardiovascular risk stratification.</p>
<h4>Article 5: Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The OPTIVUS-Complex PCI Study LMCA Cohort.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005598" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005598</a></p>
<p><strong>Summary:</strong> Study L.M.C.A. Cohort. This prospective, multi-center, single-arm trial (O.P.T.I.V.U.S.-Complex P.C.I.) evaluated the impact of optimal intravascular ultrasound-guided left main coronary artery percutaneous coronary intervention on clinical outcomes. The study, involving 902 patients, demonstrated that targeting pre-specified intravascular ultrasound criteria, such as minimal stent area, during left main coronary artery percutaneous coronary intervention leads to favorable clinical outcomes. The data support the use of intravascular ultrasound guidance to optimize stent deployment in complex left main coronary artery percutaneous coronary intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Nexiguran Ziclumeran Gene Editing in Hereditary A.T.T.R. with Polyneuropathy. This study investigates nexiguran ziclumeran, a C.R.I.S.P.R.-Cas9-based therapy designed to reduce serum transthyretin levels by selectively inactivating the TTR gene in patients with hereditary transthyretin amyloidosis with polyneuropathy. The therapy aims to address the underlying cause of the disease by preventing the misfolding and deposition of transthyretin protein in peripheral nerves. This is an investigational therapy.</p>
<p>Article number two. Diagnostic accuracy of late gadolinium enhancement cardiac M.R.I. for coronary artery disease in patients with reduced left ventricular ejection fraction. This study evaluated the diagnostic accuracy of rest cardiac M.R.I. with late gadolinium enhancement for predicting significant coronary artery disease in patients with reduced left ventricular ejection fraction. Results indicate that rest late gadolinium enhancement cardiac M.R.I. can reliably detect significant coronary artery disease in this patient population, aiding in therapeutic decisions such as medical management, device implantation, and revascularization. The finding supports incorporating late gadolinium enhancement cardiac M.R.I. into the diagnostic workup for patients with reduced left ventricular ejection fraction suspected of having coronary artery disease.</p>
<p>Article number three. Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. This retrospective analysis evaluated the prognostic role of the neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. The study found that elevated neutrophil-to-lymphocyte ratio was associated with adverse cardiovascular outcomes in both diabetic and non-diabetic patients post-percutaneous coronary intervention. The neutrophil-to-lymphocyte ratio serves as a valuable marker of systemic inflammation and risk stratification in patients undergoing percutaneous coronary intervention, regardless of diabetes status.</p>
<p>Article number four. The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: Integrating Low-density Lipoprotein Cholesterol and Polygenic Risk Scores. This study of over 346,000 UK Biobank participants investigated the interaction between lipoprotein(a), low-density lipoprotein cholesterol, and polygenic risk score in atherosclerotic cardiovascular disease. The research demonstrated that elevated lipoprotein(a) significantly increases cardiovascular risk, even in individuals with well-managed low-density lipoprotein cholesterol and after accounting for polygenic risk. These findings emphasize the importance of measuring lipoprotein(a) levels for comprehensive cardiovascular risk stratification.</p>
<p>Article number five. Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The O.P.T.I.V.U.S.-Complex P.C.I. Study L.M.C.A. Cohort. This prospective, multi-center, single-arm trial (O.P.T.I.V.U.S.-Complex P.C.I.) evaluated the impact of optimal intravascular ultrasound-guided left main coronary artery percutaneous coronary intervention on clinical outcomes. The study, involving 902 patients, demonstrated that targeting pre-specified intravascular ultrasound criteria, such as minimal stent area, during left main coronary artery percutaneous coronary intervention leads to favorable clinical outcomes. The data support the use of intravascular ultrasound guidance to optimize stent deployment in complex left main coronary artery percutaneous coronary intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>polyneuropathy, hereditary transthyretin amyloidosis, gene editing, diabetes mellitus, late gadolinium enhancement cardiac M.R.I., left main coronary artery disease, lipoprotein(a), O.P.T.I.V.U.S.-Complex P.C.I. study, intravascular ultrasound, diagnostic accuracy, cardiovascular outcomes, low-density lipoprotein cholesterol, neutrophil-to-lymphocyte ratio, revascularization, systemic inflammation, polygenic risk score, percutaneous coronary intervention, reduced left ventricular ejection fraction, C.R.I.S.P.R.-Cas9, stent deployment, cardiovascular risk stratification, nexiguran ziclumeran, atherosclerotic cardiovascular disease, coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/">Lp(a) Levels Key for Cardio Risk 09/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like polyneuropathy and hereditary transthyretin amyloidosis. Key takeaway: Lp(a) Levels Key for Cardio Risk.
Article Links:
Article 1: ]]></itunes:subtitle>
	<itunes:episode>79</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like polyneuropathy and hereditary transthyretin amyloidosis. Key takeaway: Lp(a) Levels Key for Cardio Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/41002250">Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40147871">Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40118518">Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/41005599">The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/41005598">Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The OPTIVUS-Complex PCI Study LMCA Cohort.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/">https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41002250" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41002250</a></p>
<p><strong>Summary:</strong> with Polyneuropathy. This study investigates nexiguran ziclumeran, a C.R.I.S.P.R.-Cas9-based therapy designed to reduce serum transthyretin levels by selectively inactivating the TTR gene in patients with hereditary transthyretin amyloidosis with polyneuropathy. The therapy aims to address the underlying cause of the disease by preventing the misfolding and deposition of transthyretin protein in peripheral nerves. This is an investigational therapy.</p>
<h4>Article 2: Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40147871" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40147871</a></p>
<p><strong>Summary:</strong> for coronary artery disease in patients with reduced left ventricular ejection fraction. This study evaluated the diagnostic accuracy of rest cardiac M.R.I. with late gadolinium enhancement for predicting significant coronary artery disease in patients with reduced left ventricular ejection fraction. Results indicate that rest late gadolinium enhancement cardiac M.R.I. can reliably detect significant coronary artery disease in this patient population, aiding in therapeutic decisions such as medical management, device implantation, and revascularization. The finding supports incorporating late gadolinium enhancement cardiac M.R.I. into the diagnostic workup for patients with reduced left ventricular ejection fraction suspected of having coronary artery disease.</p>
<h4>Article 3: Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40118518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40118518</a></p>
<p><strong>Summary:</strong> This retrospective analysis evaluated the prognostic role of the neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. The study found that elevated neutrophil-to-lymphocyte ratio was associated with adverse cardiovascular outcomes in both diabetic and non-diabetic patients post-percutaneous coronary intervention. The neutrophil-to-lymphocyte ratio serves as a valuable marker of systemic inflammation and risk stratification in patients undergoing percutaneous coronary intervention, regardless of diabetes status.</p>
<h4>Article 4: The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005599" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005599</a></p>
<p><strong>Summary:</strong> This study of over 346,000 UK Biobank participants investigated the interaction between lipoprotein(a), low-density lipoprotein cholesterol, and polygenic risk score in atherosclerotic cardiovascular disease. The research demonstrated that elevated lipoprotein(a) significantly increases cardiovascular risk, even in individuals with well-managed low-density lipoprotein cholesterol and after accounting for polygenic risk. These findings emphasize the importance of measuring lipoprotein(a) levels for comprehensive cardiovascular risk stratification.</p>
<h4>Article 5: Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The OPTIVUS-Complex PCI Study LMCA Cohort.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/41005598" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41005598</a></p>
<p><strong>Summary:</strong> Study L.M.C.A. Cohort. This prospective, multi-center, single-arm trial (O.P.T.I.V.U.S.-Complex P.C.I.) evaluated the impact of optimal intravascular ultrasound-guided left main coronary artery percutaneous coronary intervention on clinical outcomes. The study, involving 902 patients, demonstrated that targeting pre-specified intravascular ultrasound criteria, such as minimal stent area, during left main coronary artery percutaneous coronary intervention leads to favorable clinical outcomes. The data support the use of intravascular ultrasound guidance to optimize stent deployment in complex left main coronary artery percutaneous coronary intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Nexiguran Ziclumeran Gene Editing in Hereditary A.T.T.R. with Polyneuropathy. This study investigates nexiguran ziclumeran, a C.R.I.S.P.R.-Cas9-based therapy designed to reduce serum transthyretin levels by selectively inactivating the TTR gene in patients with hereditary transthyretin amyloidosis with polyneuropathy. The therapy aims to address the underlying cause of the disease by preventing the misfolding and deposition of transthyretin protein in peripheral nerves. This is an investigational therapy.</p>
<p>Article number two. Diagnostic accuracy of late gadolinium enhancement cardiac M.R.I. for coronary artery disease in patients with reduced left ventricular ejection fraction. This study evaluated the diagnostic accuracy of rest cardiac M.R.I. with late gadolinium enhancement for predicting significant coronary artery disease in patients with reduced left ventricular ejection fraction. Results indicate that rest late gadolinium enhancement cardiac M.R.I. can reliably detect significant coronary artery disease in this patient population, aiding in therapeutic decisions such as medical management, device implantation, and revascularization. The finding supports incorporating late gadolinium enhancement cardiac M.R.I. into the diagnostic workup for patients with reduced left ventricular ejection fraction suspected of having coronary artery disease.</p>
<p>Article number three. Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. This retrospective analysis evaluated the prognostic role of the neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. The study found that elevated neutrophil-to-lymphocyte ratio was associated with adverse cardiovascular outcomes in both diabetic and non-diabetic patients post-percutaneous coronary intervention. The neutrophil-to-lymphocyte ratio serves as a valuable marker of systemic inflammation and risk stratification in patients undergoing percutaneous coronary intervention, regardless of diabetes status.</p>
<p>Article number four. The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: Integrating Low-density Lipoprotein Cholesterol and Polygenic Risk Scores. This study of over 346,000 UK Biobank participants investigated the interaction between lipoprotein(a), low-density lipoprotein cholesterol, and polygenic risk score in atherosclerotic cardiovascular disease. The research demonstrated that elevated lipoprotein(a) significantly increases cardiovascular risk, even in individuals with well-managed low-density lipoprotein cholesterol and after accounting for polygenic risk. These findings emphasize the importance of measuring lipoprotein(a) levels for comprehensive cardiovascular risk stratification.</p>
<p>Article number five. Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The O.P.T.I.V.U.S.-Complex P.C.I. Study L.M.C.A. Cohort. This prospective, multi-center, single-arm trial (O.P.T.I.V.U.S.-Complex P.C.I.) evaluated the impact of optimal intravascular ultrasound-guided left main coronary artery percutaneous coronary intervention on clinical outcomes. The study, involving 902 patients, demonstrated that targeting pre-specified intravascular ultrasound criteria, such as minimal stent area, during left main coronary artery percutaneous coronary intervention leads to favorable clinical outcomes. The data support the use of intravascular ultrasound guidance to optimize stent deployment in complex left main coronary artery percutaneous coronary intervention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>polyneuropathy, hereditary transthyretin amyloidosis, gene editing, diabetes mellitus, late gadolinium enhancement cardiac M.R.I., left main coronary artery disease, lipoprotein(a), O.P.T.I.V.U.S.-Complex P.C.I. study, intravascular ultrasound, diagnostic accuracy, cardiovascular outcomes, low-density lipoprotein cholesterol, neutrophil-to-lymphocyte ratio, revascularization, systemic inflammation, polygenic risk score, percutaneous coronary intervention, reduced left ventricular ejection fraction, C.R.I.S.P.R.-Cas9, stent deployment, cardiovascular risk stratification, nexiguran ziclumeran, atherosclerotic cardiovascular disease, coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/">Lp(a) Levels Key for Cardio Risk 09/27/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250927_181754.mp3" length="4541796" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like polyneuropathy and hereditary transthyretin amyloidosis. Key takeaway: Lp(a) Levels Key for Cardio Risk.
Article Links:
Article 1: Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy. (The New England journal of medicine)
Article 2: Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction. (Heart (British Cardiac Society))
Article 3: Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. (Heart (British Cardiac Society))
Article 4: The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores. (The American journal of cardiology)
Article 5: Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease: The OPTIVUS-Complex PCI Study LMCA Cohort. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/lpa-levels-key-for-cardio-risk-09-27-25/
 Featured Articles
Article 1: Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41002250
Summary: with Polyneuropathy. This study investigates nexiguran ziclumeran, a C.R.I.S.P.R.-Cas9-based therapy designed to reduce serum transthyretin levels by selectively inactivating the TTR gene in patients with hereditary transthyretin amyloidosis with polyneuropathy. The therapy aims to address the underlying cause of the disease by preventing the misfolding and deposition of transthyretin protein in peripheral nerves. This is an investigational therapy.
Article 2: Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40147871
Summary: for coronary artery disease in patients with reduced left ventricular ejection fraction. This study evaluated the diagnostic accuracy of rest cardiac M.R.I. with late gadolinium enhancement for predicting significant coronary artery disease in patients with reduced left ventricular ejection fraction. Results indicate that rest late gadolinium enhancement cardiac M.R.I. can reliably detect significant coronary artery disease in this patient population, aiding in therapeutic decisions such as medical management, device implantation, and revascularization. The finding supports incorporating late gadolinium enhancement cardiac M.R.I. into the diagnostic workup for patients with reduced left ventricular ejection fraction suspected of having coronary artery disease.
Article 3: Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40118518
Summary: This retrospective analysis evaluated the prognostic role of the neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. The study found that elevated neutrophil-to-lymphocyte ratio was associated with adverse cardiovascular outcomes in both diabetic and non-diabetic patients post-percutaneous coronary intervention. The neutrophil-to-lymphocyte ratio serves as a valuable marker of systemic inflammation and risk stratification in patients undergoing percutaneous coronary intervention, regardless of diabetes status.
Article 4: The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores.
Journal: The American journal of ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 27, 2025. This episode summarizes 5 key cardiology studies on topics like polyneuropathy and hereditary transthyretin amyloidosis. Key takeaway: Lp(a) Levels Key for Cardio Risk.
Article Links:
Article 1: Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy. (The New England journal of medicine)
Article 2: Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction. (Heart (British Cardiac Society))
Article 3: Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention. (Heart (British Cardiac Society))
Article 4: The Role of Lipoprotein(a) in Cardiovascular Risk Stratification: IntegratingLow-density Lipoprotein Cholesterol and Polygenic Risk Scores. (The American journal of cardiology)
Article 5: Optimal Intravascular Ultrasound-Guided Percut]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Antihypertensives Protect Young Hearts 09/26/25</title>
	<link>https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/</link>
	<pubDate>Fri, 26 Sep 2025 10:01:02 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like translational research and young adults. Key takeaway: Antihypertensives Protect Young Hearts.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40996095">Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40996093">Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40996089">Importance of basic science and research training for the future generation of cardiologists.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40996087">Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40250982">Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/">https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996095" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996095</a></p>
<p><strong>Summary:</strong> This case-crossover study using Taiwan&#8217;s National Health Insurance Research Database, involving 173,974 adults, showed that transient increases in anticholinergic burden were associated with a higher risk of out-of-hospital cardiac arrest in middle-aged and older adults. The study utilized case-crossover, case-time-control, and case-case-time-control designs to assess this association. This finding highlights the potential cardiovascular risks associated with anticholinergic medications, particularly in vulnerable populations.</p>
<h4>Article 2: Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996093" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996093</a></p>
<p><strong>Summary:</strong> This population-based cohort study assessed the impact of antihypertensive treatment adherence on cardiovascular outcomes in young adults (18-39 years) compared to middle-aged adults (40-55 years). The study found evidence of a protective effect of antihypertensive drugs in young adults with good adherence, demonstrating a reduction in both nonfatal and fatal cardiovascular events. These results support the importance of early hypertension management to mitigate long-term cardiovascular risk.</p>
<h4>Article 3: Importance of basic science and research training for the future generation of cardiologists.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996089</a></p>
<p><strong>Summary:</strong> This article emphasizes the critical role of basic science and research training for future cardiologists to effectively translate preclinical and clinical findings into innovative therapeutic strategies. It highlights the rapid advancements in molecular, cellular biology, and multi-omics studies, necessitating a strong foundation in basic science to understand cardiac disease mechanisms with precision. The authors advocate for integrating rigorous research training into cardiology education to foster innovation and improve patient outcomes.</p>
<h4>Article 4: Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996087" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996087</a></p>
<p><strong>Summary:</strong> study. The S.A.F.E.-P.A.D. study&#8217;s final report compared long-term outcomes of drug-coated devices versus non-drug-coated devices in femoropopliteal artery interventions. The study demonstrated that drug-coated devices, including drug-coated balloons and drug-eluting stents, significantly reduced restenosis rates compared to non-drug-coated devices. However, further long-term follow-up is needed to fully address concerns about potential mortality risks associated with drug-coated devices.</p>
<h4>Article 5: Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40250982" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40250982</a></p>
<p><strong>Summary:</strong> heart failure care: a national primary care cohort study. This national primary care cohort study evaluated mineralocorticoid receptor antagonist prescription patterns in U.K. patients with heart failure with reduced ejection fraction who met guideline criteria for their use. The study revealed significant underutilization of mineralocorticoid receptor antagonists despite guideline recommendations, highlighting a critical gap in heart failure management. Addressing barriers to mineralocorticoid receptor antagonist prescription and adherence is essential to improve outcomes in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study. This case-crossover study using Taiwan&#8217;s National Health Insurance Research Database, involving 173,974 adults, showed that transient increases in anticholinergic burden were associated with a higher risk of out-of-hospital cardiac arrest in middle-aged and older adults. The study utilized case-crossover, case-time-control, and case-case-time-control designs to assess this association. This finding highlights the potential cardiovascular risks associated with anticholinergic medications, particularly in vulnerable populations.</p>
<p>Article number two. Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study. This population-based cohort study assessed the impact of antihypertensive treatment adherence on cardiovascular outcomes in young adults (18-39 years) compared to middle-aged adults (40-55 years). The study found evidence of a protective effect of antihypertensive drugs in young adults with good adherence, demonstrating a reduction in both nonfatal and fatal cardiovascular events. These results support the importance of early hypertension management to mitigate long-term cardiovascular risk.</p>
<p>Article number three. Importance of basic science and research training for the future generation of cardiologists. This article emphasizes the critical role of basic science and research training for future cardiologists to effectively translate preclinical and clinical findings into innovative therapeutic strategies. It highlights the rapid advancements in molecular, cellular biology, and multi-omics studies, necessitating a strong foundation in basic science to understand cardiac disease mechanisms with precision. The authors advocate for integrating rigorous research training into cardiology education to foster innovation and improve patient outcomes.</p>
<p>Article number four. Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the S.A.F.E.-P.A.D. study. The S.A.F.E.-P.A.D. study&#8217;s final report compared long-term outcomes of drug-coated devices versus non-drug-coated devices in femoropopliteal artery interventions. The study demonstrated that drug-coated devices, including drug-coated balloons and drug-eluting stents, significantly reduced restenosis rates compared to non-drug-coated devices. However, further long-term follow-up is needed to fully address concerns about potential mortality risks associated with drug-coated devices.</p>
<p>Article number five. Mineralocorticoid receptor antagonist (M.R.A.) use in U.K. heart failure care: a national primary care cohort study. This national primary care cohort study evaluated mineralocorticoid receptor antagonist prescription patterns in U.K. patients with heart failure with reduced ejection fraction who met guideline criteria for their use. The study revealed significant underutilization of mineralocorticoid receptor antagonists despite guideline recommendations, highlighting a critical gap in heart failure management. Addressing barriers to mineralocorticoid receptor antagonist prescription and adherence is essential to improve outcomes in this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>translational research, young adults, anticholinergic burden, restenosis, underutilization, out-of-hospital cardiac arrest, hypertension management, guideline adherence, cardiovascular risk, mineralocorticoid receptor antagonists, medication safety, research training, case-crossover study, peripheral artery disease, drug-coated devices, femoropopliteal artery disease, basic science, heart failure with reduced ejection fraction, cardiology, antihypertensive treatment.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/">Antihypertensives Protect Young Hearts 09/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like translational research and young adults. Key takeaway: Antihypertensives Protect Young Hearts.
Article Links:
Article 1: Transient ]]></itunes:subtitle>
	<itunes:episode>78</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like translational research and young adults. Key takeaway: Antihypertensives Protect Young Hearts.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40996095">Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40996093">Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40996089">Importance of basic science and research training for the future generation of cardiologists.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40996087">Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40250982">Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/">https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996095" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996095</a></p>
<p><strong>Summary:</strong> This case-crossover study using Taiwan&#8217;s National Health Insurance Research Database, involving 173,974 adults, showed that transient increases in anticholinergic burden were associated with a higher risk of out-of-hospital cardiac arrest in middle-aged and older adults. The study utilized case-crossover, case-time-control, and case-case-time-control designs to assess this association. This finding highlights the potential cardiovascular risks associated with anticholinergic medications, particularly in vulnerable populations.</p>
<h4>Article 2: Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996093" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996093</a></p>
<p><strong>Summary:</strong> This population-based cohort study assessed the impact of antihypertensive treatment adherence on cardiovascular outcomes in young adults (18-39 years) compared to middle-aged adults (40-55 years). The study found evidence of a protective effect of antihypertensive drugs in young adults with good adherence, demonstrating a reduction in both nonfatal and fatal cardiovascular events. These results support the importance of early hypertension management to mitigate long-term cardiovascular risk.</p>
<h4>Article 3: Importance of basic science and research training for the future generation of cardiologists.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996089" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996089</a></p>
<p><strong>Summary:</strong> This article emphasizes the critical role of basic science and research training for future cardiologists to effectively translate preclinical and clinical findings into innovative therapeutic strategies. It highlights the rapid advancements in molecular, cellular biology, and multi-omics studies, necessitating a strong foundation in basic science to understand cardiac disease mechanisms with precision. The authors advocate for integrating rigorous research training into cardiology education to foster innovation and improve patient outcomes.</p>
<h4>Article 4: Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996087" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996087</a></p>
<p><strong>Summary:</strong> study. The S.A.F.E.-P.A.D. study&#8217;s final report compared long-term outcomes of drug-coated devices versus non-drug-coated devices in femoropopliteal artery interventions. The study demonstrated that drug-coated devices, including drug-coated balloons and drug-eluting stents, significantly reduced restenosis rates compared to non-drug-coated devices. However, further long-term follow-up is needed to fully address concerns about potential mortality risks associated with drug-coated devices.</p>
<h4>Article 5: Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40250982" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40250982</a></p>
<p><strong>Summary:</strong> heart failure care: a national primary care cohort study. This national primary care cohort study evaluated mineralocorticoid receptor antagonist prescription patterns in U.K. patients with heart failure with reduced ejection fraction who met guideline criteria for their use. The study revealed significant underutilization of mineralocorticoid receptor antagonists despite guideline recommendations, highlighting a critical gap in heart failure management. Addressing barriers to mineralocorticoid receptor antagonist prescription and adherence is essential to improve outcomes in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study. This case-crossover study using Taiwan&#8217;s National Health Insurance Research Database, involving 173,974 adults, showed that transient increases in anticholinergic burden were associated with a higher risk of out-of-hospital cardiac arrest in middle-aged and older adults. The study utilized case-crossover, case-time-control, and case-case-time-control designs to assess this association. This finding highlights the potential cardiovascular risks associated with anticholinergic medications, particularly in vulnerable populations.</p>
<p>Article number two. Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study. This population-based cohort study assessed the impact of antihypertensive treatment adherence on cardiovascular outcomes in young adults (18-39 years) compared to middle-aged adults (40-55 years). The study found evidence of a protective effect of antihypertensive drugs in young adults with good adherence, demonstrating a reduction in both nonfatal and fatal cardiovascular events. These results support the importance of early hypertension management to mitigate long-term cardiovascular risk.</p>
<p>Article number three. Importance of basic science and research training for the future generation of cardiologists. This article emphasizes the critical role of basic science and research training for future cardiologists to effectively translate preclinical and clinical findings into innovative therapeutic strategies. It highlights the rapid advancements in molecular, cellular biology, and multi-omics studies, necessitating a strong foundation in basic science to understand cardiac disease mechanisms with precision. The authors advocate for integrating rigorous research training into cardiology education to foster innovation and improve patient outcomes.</p>
<p>Article number four. Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the S.A.F.E.-P.A.D. study. The S.A.F.E.-P.A.D. study&#8217;s final report compared long-term outcomes of drug-coated devices versus non-drug-coated devices in femoropopliteal artery interventions. The study demonstrated that drug-coated devices, including drug-coated balloons and drug-eluting stents, significantly reduced restenosis rates compared to non-drug-coated devices. However, further long-term follow-up is needed to fully address concerns about potential mortality risks associated with drug-coated devices.</p>
<p>Article number five. Mineralocorticoid receptor antagonist (M.R.A.) use in U.K. heart failure care: a national primary care cohort study. This national primary care cohort study evaluated mineralocorticoid receptor antagonist prescription patterns in U.K. patients with heart failure with reduced ejection fraction who met guideline criteria for their use. The study revealed significant underutilization of mineralocorticoid receptor antagonists despite guideline recommendations, highlighting a critical gap in heart failure management. Addressing barriers to mineralocorticoid receptor antagonist prescription and adherence is essential to improve outcomes in this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>translational research, young adults, anticholinergic burden, restenosis, underutilization, out-of-hospital cardiac arrest, hypertension management, guideline adherence, cardiovascular risk, mineralocorticoid receptor antagonists, medication safety, research training, case-crossover study, peripheral artery disease, drug-coated devices, femoropopliteal artery disease, basic science, heart failure with reduced ejection fraction, cardiology, antihypertensive treatment.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/">Antihypertensives Protect Young Hearts 09/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250926_060009.mp3" length="3988836" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like translational research and young adults. Key takeaway: Antihypertensives Protect Young Hearts.
Article Links:
Article 1: Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study. (European heart journal)
Article 2: Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study. (European heart journal)
Article 3: Importance of basic science and research training for the future generation of cardiologists. (European heart journal)
Article 4: Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study. (European heart journal)
Article 5: Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/antihypertensives-protect-young-hearts-09-26-25/
 Featured Articles
Article 1: Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996095
Summary: This case-crossover study using Taiwan&#8217;s National Health Insurance Research Database, involving 173,974 adults, showed that transient increases in anticholinergic burden were associated with a higher risk of out-of-hospital cardiac arrest in middle-aged and older adults. The study utilized case-crossover, case-time-control, and case-case-time-control designs to assess this association. This finding highlights the potential cardiovascular risks associated with anticholinergic medications, particularly in vulnerable populations.
Article 2: Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996093
Summary: This population-based cohort study assessed the impact of antihypertensive treatment adherence on cardiovascular outcomes in young adults (18-39 years) compared to middle-aged adults (40-55 years). The study found evidence of a protective effect of antihypertensive drugs in young adults with good adherence, demonstrating a reduction in both nonfatal and fatal cardiovascular events. These results support the importance of early hypertension management to mitigate long-term cardiovascular risk.
Article 3: Importance of basic science and research training for the future generation of cardiologists.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996089
Summary: This article emphasizes the critical role of basic science and research training for future cardiologists to effectively translate preclinical and clinical findings into innovative therapeutic strategies. It highlights the rapid advancements in molecular, cellular biology, and multi-omics studies, necessitating a strong foundation in basic science to understand cardiac disease mechanisms with precision. The authors advocate for integrating rigorous research training into cardiology education to foster innovation and improve patient outcomes.
Article 4: Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996087
Summary: study. The S.A.F.E.-P.A.D. study&#8217;s final report compared long-term outcomes of drug-coated devices versus non-drug-coated devices in femoropopliteal artery interventions. The study demonstrated that drug-coated devices, including drug-coated balloons and drug-eluting stents, significantly reduced restenosis rates compared to non-drug-coated devices. However, further long-term follow-up is needed to fully address concerns about potential mortality risks associated with drug-coated devices.
Articl]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like translational research and young adults. Key takeaway: Antihypertensives Protect Young Hearts.
Article Links:
Article 1: Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study. (European heart journal)
Article 2: Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study. (European heart journal)
Article 3: Importance of basic science and research training for the future generation of cardiologists. (European heart journal)
Article 4: Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study. (European heart journal)
Article 5: Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Sex Differences in A.fib Remodeling Defined 09/26/25</title>
	<link>https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/</link>
	<pubDate>Fri, 26 Sep 2025 06:57:22 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like vascular remodeling and atrial remodeling. Key takeaway: Sex Differences in A.fib Remodeling Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40995628">Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40995626">Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40996829">Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40996819">EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40996312">Abnormal electrocardiogram findings in athletes.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/">https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40995628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40995628</a></p>
<p><strong>Summary:</strong> This study analyzed the clinical implications of anomalous aortic origin of a coronary artery in adults using coronary computed tomography angiography. The study, conducted at an Italian center from 2004-2024, sought to determine outcome predictors. The results detail specific clinical outcomes, which will improve risk stratification for these patients.</p>
<h4>Article 2: Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40995626" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40995626</a></p>
<p><strong>Summary:</strong> This retrospective cohort study in Japan evaluated the incidence and cardiovascular outcomes of screening-detected atrial fibrillation in working-age adults. Mandatory E.C.G.s during annual health screenings provided a unique opportunity to identify atrial fibrillation early. The findings reveal the long-term cardiovascular risks associated with screening-detected atrial fibrillation in this population, highlighting the importance of early detection and intervention to prevent stroke and other complications.</p>
<h4>Article 3: Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996829" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996829</a></p>
<p><strong>Summary:</strong> This study investigated sex differences in atrial structural remodeling in patients with non-valvular atrial fibrillation by performing right atrial biopsies and high-density voltage mapping. The research included 282 atrial fibrillation patients and 58 controls undergoing supraventricular tachycardia ablation. The results showed notable histopathological differences between men and women, providing insights into potential sex-specific atrial fibrillation mechanisms and treatment approaches.</p>
<h4>Article 4: EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996819" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996819</a></p>
<p><strong>Summary:</strong> This research investigated the role of the prostaglandin E2 receptor E.P.4 in the pathogenesis of pulmonary arterial hypertension, a condition characterized by abnormal proliferation of pulmonary artery smooth muscle cells. The study aimed to evaluate the potential of E.P.4 as a therapeutic target for pulmonary arterial hypertension. The findings suggest that targeting E.P.4 could offer a novel therapeutic approach for managing pulmonary arterial hypertension by modulating the E.P.4/A.N.X.A.2 axis.</p>
<h4>Article 5: Abnormal electrocardiogram findings in athletes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996312" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996312</a></p>
<p><strong>Summary:</strong> This article discusses the challenges in interpreting E.C.G.s in athletes, where physiological adaptations can mimic cardiac pathology. It highlights the ongoing efforts to differentiate benign E.C.G. changes from potentially pathological findings requiring further investigation. Addressing diagnostic uncertainties in cardiac assessment of athletes is crucial to avoid unnecessary restrictions and ensure appropriate management of true cardiac conditions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults. This study analyzed the clinical implications of anomalous aortic origin of a coronary artery in adults using coronary computed tomography angiography. The study, conducted at an Italian center from 2004-2024, sought to determine outcome predictors. The results detail specific clinical outcomes, which will improve risk stratification for these patients.</p>
<p>Article number two. Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults. This retrospective cohort study in Japan evaluated the incidence and cardiovascular outcomes of screening-detected atrial fibrillation in working-age adults. Mandatory E.C.G.s during annual health screenings provided a unique opportunity to identify atrial fibrillation early. The findings reveal the long-term cardiovascular risks associated with screening-detected atrial fibrillation in this population, highlighting the importance of early detection and intervention to prevent stroke and other complications.</p>
<p>Article number three. Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy. This study investigated sex differences in atrial structural remodeling in patients with non-valvular atrial fibrillation by performing right atrial biopsies and high-density voltage mapping. The research included 282 atrial fibrillation patients and 58 controls undergoing supraventricular tachycardia ablation. The results showed notable histopathological differences between men and women, providing insights into potential sex-specific atrial fibrillation mechanisms and treatment approaches.</p>
<p>Article number four. EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications. This research investigated the role of the prostaglandin E2 receptor E.P.4 in the pathogenesis of pulmonary arterial hypertension, a condition characterized by abnormal proliferation of pulmonary artery smooth muscle cells. The study aimed to evaluate the potential of E.P.4 as a therapeutic target for pulmonary arterial hypertension. The findings suggest that targeting E.P.4 could offer a novel therapeutic approach for managing pulmonary arterial hypertension by modulating the E.P.4/A.N.X.A.2 axis.</p>
<p>Article number five. Abnormal electrocardiogram findings in athletes. This article discusses the challenges in interpreting E.C.G.s in athletes, where physiological adaptations can mimic cardiac pathology. It highlights the ongoing efforts to differentiate benign E.C.G. changes from potentially pathological findings requiring further investigation. Addressing diagnostic uncertainties in cardiac assessment of athletes is crucial to avoid unnecessary restrictions and ensure appropriate management of true cardiac conditions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>vascular remodeling, atrial remodeling, coronary artery disease, Anomalous aortic origin of a coronary artery, stroke prevention, right atrial biopsy, Pulmonary arterial hypertension, sex differences, cardiovascular outcomes, pulmonary artery smooth muscle cells, sudden cardiac death, prostaglandin E2, cardiac screening, electroanatomic mapping, Atrial fibrillation, Athlete&#8217;s heart, E.P.4 receptor, electrocardiogram, E.C.G. interpretation, coronary computed tomography angiography, working-age adults, E.C.G. screening.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/">Sex Differences in A.fib Remodeling Defined 09/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like vascular remodeling and atrial remodeling. Key takeaway: Sex Differences in A.fib Remodeling Defined.
Article Links:
Article 1: Cli]]></itunes:subtitle>
	<itunes:episode>77</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like vascular remodeling and atrial remodeling. Key takeaway: Sex Differences in A.fib Remodeling Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40995628">Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40995626">Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40996829">Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40996819">EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40996312">Abnormal electrocardiogram findings in athletes.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/">https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40995628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40995628</a></p>
<p><strong>Summary:</strong> This study analyzed the clinical implications of anomalous aortic origin of a coronary artery in adults using coronary computed tomography angiography. The study, conducted at an Italian center from 2004-2024, sought to determine outcome predictors. The results detail specific clinical outcomes, which will improve risk stratification for these patients.</p>
<h4>Article 2: Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40995626" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40995626</a></p>
<p><strong>Summary:</strong> This retrospective cohort study in Japan evaluated the incidence and cardiovascular outcomes of screening-detected atrial fibrillation in working-age adults. Mandatory E.C.G.s during annual health screenings provided a unique opportunity to identify atrial fibrillation early. The findings reveal the long-term cardiovascular risks associated with screening-detected atrial fibrillation in this population, highlighting the importance of early detection and intervention to prevent stroke and other complications.</p>
<h4>Article 3: Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996829" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996829</a></p>
<p><strong>Summary:</strong> This study investigated sex differences in atrial structural remodeling in patients with non-valvular atrial fibrillation by performing right atrial biopsies and high-density voltage mapping. The research included 282 atrial fibrillation patients and 58 controls undergoing supraventricular tachycardia ablation. The results showed notable histopathological differences between men and women, providing insights into potential sex-specific atrial fibrillation mechanisms and treatment approaches.</p>
<h4>Article 4: EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996819" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996819</a></p>
<p><strong>Summary:</strong> This research investigated the role of the prostaglandin E2 receptor E.P.4 in the pathogenesis of pulmonary arterial hypertension, a condition characterized by abnormal proliferation of pulmonary artery smooth muscle cells. The study aimed to evaluate the potential of E.P.4 as a therapeutic target for pulmonary arterial hypertension. The findings suggest that targeting E.P.4 could offer a novel therapeutic approach for managing pulmonary arterial hypertension by modulating the E.P.4/A.N.X.A.2 axis.</p>
<h4>Article 5: Abnormal electrocardiogram findings in athletes.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40996312" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40996312</a></p>
<p><strong>Summary:</strong> This article discusses the challenges in interpreting E.C.G.s in athletes, where physiological adaptations can mimic cardiac pathology. It highlights the ongoing efforts to differentiate benign E.C.G. changes from potentially pathological findings requiring further investigation. Addressing diagnostic uncertainties in cardiac assessment of athletes is crucial to avoid unnecessary restrictions and ensure appropriate management of true cardiac conditions.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 26, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults. This study analyzed the clinical implications of anomalous aortic origin of a coronary artery in adults using coronary computed tomography angiography. The study, conducted at an Italian center from 2004-2024, sought to determine outcome predictors. The results detail specific clinical outcomes, which will improve risk stratification for these patients.</p>
<p>Article number two. Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults. This retrospective cohort study in Japan evaluated the incidence and cardiovascular outcomes of screening-detected atrial fibrillation in working-age adults. Mandatory E.C.G.s during annual health screenings provided a unique opportunity to identify atrial fibrillation early. The findings reveal the long-term cardiovascular risks associated with screening-detected atrial fibrillation in this population, highlighting the importance of early detection and intervention to prevent stroke and other complications.</p>
<p>Article number three. Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy. This study investigated sex differences in atrial structural remodeling in patients with non-valvular atrial fibrillation by performing right atrial biopsies and high-density voltage mapping. The research included 282 atrial fibrillation patients and 58 controls undergoing supraventricular tachycardia ablation. The results showed notable histopathological differences between men and women, providing insights into potential sex-specific atrial fibrillation mechanisms and treatment approaches.</p>
<p>Article number four. EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications. This research investigated the role of the prostaglandin E2 receptor E.P.4 in the pathogenesis of pulmonary arterial hypertension, a condition characterized by abnormal proliferation of pulmonary artery smooth muscle cells. The study aimed to evaluate the potential of E.P.4 as a therapeutic target for pulmonary arterial hypertension. The findings suggest that targeting E.P.4 could offer a novel therapeutic approach for managing pulmonary arterial hypertension by modulating the E.P.4/A.N.X.A.2 axis.</p>
<p>Article number five. Abnormal electrocardiogram findings in athletes. This article discusses the challenges in interpreting E.C.G.s in athletes, where physiological adaptations can mimic cardiac pathology. It highlights the ongoing efforts to differentiate benign E.C.G. changes from potentially pathological findings requiring further investigation. Addressing diagnostic uncertainties in cardiac assessment of athletes is crucial to avoid unnecessary restrictions and ensure appropriate management of true cardiac conditions. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>vascular remodeling, atrial remodeling, coronary artery disease, Anomalous aortic origin of a coronary artery, stroke prevention, right atrial biopsy, Pulmonary arterial hypertension, sex differences, cardiovascular outcomes, pulmonary artery smooth muscle cells, sudden cardiac death, prostaglandin E2, cardiac screening, electroanatomic mapping, Atrial fibrillation, Athlete&#8217;s heart, E.P.4 receptor, electrocardiogram, E.C.G. interpretation, coronary computed tomography angiography, working-age adults, E.C.G. screening.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/">Sex Differences in A.fib Remodeling Defined 09/26/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250926_025632.mp3" length="3607657" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like vascular remodeling and atrial remodeling. Key takeaway: Sex Differences in A.fib Remodeling Defined.
Article Links:
Article 1: Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults. (Circulation)
Article 2: Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults. (Circulation)
Article 3: Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy. (European heart journal)
Article 4: EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications. (European heart journal)
Article 5: Abnormal electrocardiogram findings in athletes. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/
 Featured Articles
Article 1: Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40995628
Summary: This study analyzed the clinical implications of anomalous aortic origin of a coronary artery in adults using coronary computed tomography angiography. The study, conducted at an Italian center from 2004-2024, sought to determine outcome predictors. The results detail specific clinical outcomes, which will improve risk stratification for these patients.
Article 2: Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40995626
Summary: This retrospective cohort study in Japan evaluated the incidence and cardiovascular outcomes of screening-detected atrial fibrillation in working-age adults. Mandatory E.C.G.s during annual health screenings provided a unique opportunity to identify atrial fibrillation early. The findings reveal the long-term cardiovascular risks associated with screening-detected atrial fibrillation in this population, highlighting the importance of early detection and intervention to prevent stroke and other complications.
Article 3: Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996829
Summary: This study investigated sex differences in atrial structural remodeling in patients with non-valvular atrial fibrillation by performing right atrial biopsies and high-density voltage mapping. The research included 282 atrial fibrillation patients and 58 controls undergoing supraventricular tachycardia ablation. The results showed notable histopathological differences between men and women, providing insights into potential sex-specific atrial fibrillation mechanisms and treatment approaches.
Article 4: EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996819
Summary: This research investigated the role of the prostaglandin E2 receptor E.P.4 in the pathogenesis of pulmonary arterial hypertension, a condition characterized by abnormal proliferation of pulmonary artery smooth muscle cells. The study aimed to evaluate the potential of E.P.4 as a therapeutic target for pulmonary arterial hypertension. The findings suggest that targeting E.P.4 could offer a novel therapeutic approach for managing pulmonary arterial hypertension by modulating the E.P.4/A.N.X.A.2 axis.
Article 5: Abnormal electrocardiogram findings in athletes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40996312
Summary: This article discusses the challenges in interpreting E.C.G.s in athletes, where physiological adaptations can mimic cardiac pathology. It highlights the ongoing efforts to differentiate benign E.C.G. changes from potentially pathological findings req]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 26, 2025. This episode summarizes 5 key cardiology studies on topics like vascular remodeling and atrial remodeling. Key takeaway: Sex Differences in A.fib Remodeling Defined.
Article Links:
Article 1: Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults. (Circulation)
Article 2: Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults. (Circulation)
Article 3: Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy. (European heart journal)
Article 4: EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications. (European heart journal)
Article 5: Abnormal electrocardiogram findings in athletes. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/sex-differences-in-a-fib-remodeling-defined-09-26-25/
 Featured Articles
Article 1: Clinical and Prognostic Significance o]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction 09/25/25</title>
	<link>https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/</link>
	<pubDate>Thu, 25 Sep 2025 10:01:09 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like aortic stenosis and mortality. Key takeaway: T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40992809">Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40992807">1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40992805">Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40992803">Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40992801">Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry.</a> (JACC. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/">https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992809" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992809</a></p>
<p><strong>Summary:</strong> This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.</p>
<h4>Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992807</a></p>
<p><strong>Summary:</strong> Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.</p>
<h4>Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992805" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992805</a></p>
<p><strong>Summary:</strong> This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.</p>
<h4>Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992803" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992803</a></p>
<p><strong>Summary:</strong> This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-related cardiogenic shock and multivessel disease. The study provides evidence regarding optimal percutaneous coronary intervention strategies in this high-risk population. The results help refine guidelines for percutaneous coronary intervention in patients with S.T.-segment elevation myocardial infarction complicated by cardiogenic shock and multivessel disease.</p>
<h4>Article 5: Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992801" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992801</a></p>
<p><strong>Summary:</strong> Registry. This study analyzed data from the European Registry of Chronic Total Occlusion to investigate the use of drug-coated balloons in percutaneous coronary intervention for chronic total occlusions. The findings provide insights into the frequency of use, patient and lesion characteristics, and outcomes associated with drug-coated balloon use in chronic total occlusion P.C.I.. The results support the role of drug-coated balloons in chronic total occlusion P.C.I. for limiting stent length and addressing distal vessel disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-T.A.V.R.. This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.</p>
<p>Article number two. 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The M.I.S.C.E.N.D. Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.</p>
<p>Article number three. Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States. This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.</p>
<p>Article number four. Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy. This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-related cardiogenic shock and multivessel disease. The study provides evidence regarding optimal percutaneous coronary intervention strategies in this high-risk population. The results help refine guidelines for percutaneous coronary intervention in patients with S.T.-segment elevation myocardial infarction complicated by cardiogenic shock and multivessel disease.</p>
<p>Article number five. Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The E.R.C.T.O. Registry. This study analyzed data from the European Registry of Chronic Total Occlusion to investigate the use of drug-coated balloons in percutaneous coronary intervention for chronic total occlusions. The findings provide insights into the frequency of use, patient and lesion characteristics, and outcomes associated with drug-coated balloon use in chronic total occlusion P.C.I.. The results support the role of drug-coated balloons in chronic total occlusion P.C.I. for limiting stent length and addressing distal vessel disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aortic stenosis, mortality, mean gradient, mitral valve intervention, S.T.-segment elevation myocardial infarction, DanGer Shock, Eos system, elderly patients, M.I.S.C.E.N.D. study, cardiogenic shock, mitral regurgitation, E.R.C.T.O. registry, acceleration time, transcatheter mitral valve replacement, stent length, drug-coated balloons, Medicare, transfemoral, ejection time, multivessel disease, chronic total occlusion, percutaneous coronary intervention, transcatheter aortic valve replacement.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/">T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction 09/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like aortic stenosis and mortality. Key takeaway: T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction.
Article Links:
Article 1: Accel]]></itunes:subtitle>
	<itunes:episode>76</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like aortic stenosis and mortality. Key takeaway: T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40992809">Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40992807">1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40992805">Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40992803">Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.</a> (JACC. Cardiovascular interventions)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40992801">Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry.</a> (JACC. Cardiovascular interventions)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/">https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992809" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992809</a></p>
<p><strong>Summary:</strong> This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.</p>
<h4>Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992807" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992807</a></p>
<p><strong>Summary:</strong> Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.</p>
<h4>Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992805" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992805</a></p>
<p><strong>Summary:</strong> This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.</p>
<h4>Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992803" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992803</a></p>
<p><strong>Summary:</strong> This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-related cardiogenic shock and multivessel disease. The study provides evidence regarding optimal percutaneous coronary intervention strategies in this high-risk population. The results help refine guidelines for percutaneous coronary intervention in patients with S.T.-segment elevation myocardial infarction complicated by cardiogenic shock and multivessel disease.</p>
<h4>Article 5: Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992801" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992801</a></p>
<p><strong>Summary:</strong> Registry. This study analyzed data from the European Registry of Chronic Total Occlusion to investigate the use of drug-coated balloons in percutaneous coronary intervention for chronic total occlusions. The findings provide insights into the frequency of use, patient and lesion characteristics, and outcomes associated with drug-coated balloon use in chronic total occlusion P.C.I.. The results support the role of drug-coated balloons in chronic total occlusion P.C.I. for limiting stent length and addressing distal vessel disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-T.A.V.R.. This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.</p>
<p>Article number two. 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The M.I.S.C.E.N.D. Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.</p>
<p>Article number three. Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States. This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.</p>
<p>Article number four. Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy. This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-related cardiogenic shock and multivessel disease. The study provides evidence regarding optimal percutaneous coronary intervention strategies in this high-risk population. The results help refine guidelines for percutaneous coronary intervention in patients with S.T.-segment elevation myocardial infarction complicated by cardiogenic shock and multivessel disease.</p>
<p>Article number five. Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The E.R.C.T.O. Registry. This study analyzed data from the European Registry of Chronic Total Occlusion to investigate the use of drug-coated balloons in percutaneous coronary intervention for chronic total occlusions. The findings provide insights into the frequency of use, patient and lesion characteristics, and outcomes associated with drug-coated balloon use in chronic total occlusion P.C.I.. The results support the role of drug-coated balloons in chronic total occlusion P.C.I. for limiting stent length and addressing distal vessel disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aortic stenosis, mortality, mean gradient, mitral valve intervention, S.T.-segment elevation myocardial infarction, DanGer Shock, Eos system, elderly patients, M.I.S.C.E.N.D. study, cardiogenic shock, mitral regurgitation, E.R.C.T.O. registry, acceleration time, transcatheter mitral valve replacement, stent length, drug-coated balloons, Medicare, transfemoral, ejection time, multivessel disease, chronic total occlusion, percutaneous coronary intervention, transcatheter aortic valve replacement.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/">T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction 09/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250925_060011.mp3" length="4059471" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like aortic stenosis and mortality. Key takeaway: T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction.
Article Links:
Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR. (JACC. Cardiovascular interventions)
Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study. (JACC. Cardiovascular interventions)
Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States. (JACC. Cardiovascular interventions)
Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy. (JACC. Cardiovascular interventions)
Article 5: Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry. (JACC. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/
 Featured Articles
Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992809
Summary: This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.
Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992807
Summary: Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.
Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992805
Summary: This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.
Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992803
Summary: This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-relate]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like aortic stenosis and mortality. Key takeaway: T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction.
Article Links:
Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR. (JACC. Cardiovascular interventions)
Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study. (JACC. Cardiovascular interventions)
Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States. (JACC. Cardiovascular interventions)
Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy. (JACC. Cardiovascular interventions)
Article 5: Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry. (JACC. Cardiova]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>P.Y.G.M. Protects Against Myocardial Infarction 09/25/25</title>
	<link>https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/</link>
	<pubDate>Thu, 25 Sep 2025 06:57:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like myotonic dystrophy type 1 and implantable cardiac devices. Key takeaway: P.Y.G.M. Protects Against Myocardial Infarction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40990886">Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40988610">PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40991268">Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40991257">Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40992090">Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/">https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40990886" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40990886</a></p>
<p><strong>Summary:</strong> This global analysis of cardiovascular disease burden from 1990 to 2023 reveals a continued increase in most countries, driven by modifiable risk factors, population growth, and aging. The study, encompassing 18 subdiseases and 12 risk factors, highlights the urgent need for targeted interventions to mitigate the growing impact of cardiovascular diseases worldwide. The research underscores that cardiovascular diseases remain a leading cause of mortality and disability.</p>
<h4>Article 2: PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40988610" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40988610</a></p>
<p><strong>Summary:</strong> Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. This research demonstrates that muscle glycogen phosphorylase, an enzyme crucial for cardiac energy metabolism, protects against myocardial infarction by enhancing glycogenolysis and promoting autophagic flux. Analyzing cardiac tissues and plasma from myocardial infarction patients, the study found that muscle glycogen phosphorylase deficiency exacerbates myocardial infarction, while its replenishment confers protection. These findings suggest that muscle glycogen phosphorylase could be a potential therapeutic target for myocardial infarction.</p>
<h4>Article 3: Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40991268" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40991268</a></p>
<p><strong>Summary:</strong> This retrospective analysis of transcatheter aortic valve replacement reinterventions, including redo transcatheter aortic valve replacement and transcatheter aortic valve replacement explant, from 2012 to June 2024, provides contemporary data on procedural incidence and volume. The study addresses the gap in data regarding the frequency of these reinterventions, offering insights into the evolving landscape of aortic valve replacement procedures. The data are crucial for assessing the long-term outcomes and management of patients undergoing transcatheter aortic valve replacement.</p>
<h4>Article 4: Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40991257" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40991257</a></p>
<p><strong>Summary:</strong> This study investigates the utility of electrocardiogram findings versus electrophysiological study results in predicting major conduction delays in myotonic dystrophy type 1 patients. Comparing E.C.G. parameters such as P.R. interval and Q.R.S. duration with His-ventricular interval during electrophysiological study, the research aims to refine guidelines for pacemaker implantation in asymptomatic patients at risk of sudden cardiac death. The findings will help clinicians better identify patients who would benefit from prophylactic pacing.</p>
<h4>Article 5: Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992090" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992090</a></p>
<p><strong>Summary:</strong> This study analyzes the effects of glucagon-like peptide 1 receptor agonists on device-related rhythm parameters in patients with Heart Failure with Reduced Ejection Fraction and implanted cardiac devices. By monitoring data from these devices, the researchers aim to determine if glucagon-like peptide 1 receptor agonists induce deleterious effects on heart rate or increase arrhythmic events in this vulnerable population. Understanding these effects is crucial for the safe and effective use of glucagon-like peptide 1 receptor agonists in Heart Failure with Reduced Ejection Fraction patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. This global analysis of cardiovascular disease burden from 1990 to 2023 reveals a continued increase in most countries, driven by modifiable risk factors, population growth, and aging. The study, encompassing 18 subdiseases and 12 risk factors, highlights the urgent need for targeted interventions to mitigate the growing impact of cardiovascular diseases worldwide. The research underscores that cardiovascular diseases remain a leading cause of mortality and disability.</p>
<p>Article number two. P.Y.G.M. Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. This research demonstrates that muscle glycogen phosphorylase, an enzyme crucial for cardiac energy metabolism, protects against myocardial infarction by enhancing glycogenolysis and promoting autophagic flux. Analyzing cardiac tissues and plasma from myocardial infarction patients, the study found that muscle glycogen phosphorylase deficiency exacerbates myocardial infarction, while its replenishment confers protection. These findings suggest that muscle glycogen phosphorylase could be a potential therapeutic target for myocardial infarction.</p>
<p>Article number three. Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention. This retrospective analysis of transcatheter aortic valve replacement reinterventions, including redo transcatheter aortic valve replacement and transcatheter aortic valve replacement explant, from 2012 to June 2024, provides contemporary data on procedural incidence and volume. The study addresses the gap in data regarding the frequency of these reinterventions, offering insights into the evolving landscape of aortic valve replacement procedures. The data are crucial for assessing the long-term outcomes and management of patients undergoing transcatheter aortic valve replacement.</p>
<p>Article number four. Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1. This study investigates the utility of electrocardiogram findings versus electrophysiological study results in predicting major conduction delays in myotonic dystrophy type 1 patients. Comparing E.C.G. parameters such as P.R. interval and Q.R.S. duration with His-ventricular interval during electrophysiological study, the research aims to refine guidelines for pacemaker implantation in asymptomatic patients at risk of sudden cardiac death. The findings will help clinicians better identify patients who would benefit from prophylactic pacing.</p>
<p>Article number five. Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices. This study analyzes the effects of glucagon-like peptide 1 receptor agonists on device-related rhythm parameters in patients with Heart Failure with Reduced Ejection Fraction and implanted cardiac devices. By monitoring data from these devices, the researchers aim to determine if glucagon-like peptide 1 receptor agonists induce deleterious effects on heart rate or increase arrhythmic events in this vulnerable population. Understanding these effects is crucial for the safe and effective use of glucagon-like peptide 1 receptor agonists in Heart Failure with Reduced Ejection Fraction patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myotonic dystrophy type 1, implantable cardiac devices, mortality, heart rate, pacemaker implantation, autophagy, muscle glycogen phosphorylase, transcatheter aortic valve replacement explant, risk factors, Heart Failure with Reduced Ejection Fraction, glucagon-like peptide 1 receptor agonists, electrophysiological study, cardiac metabolism, electrocardiogram, aortic valve replacement, conduction delay, cardiovascular disease, reintervention, arrhythmias, glycogenolysis, myocardial infarction, epidemiology, redo transcatheter aortic valve replacement, transcatheter aortic valve replacement, global burden.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/">P.Y.G.M. Protects Against Myocardial Infarction 09/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like myotonic dystrophy type 1 and implantable cardiac devices. Key takeaway: P.Y.G.M. Protects Against Myocardial Infarction.
Article L]]></itunes:subtitle>
	<itunes:episode>75</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like myotonic dystrophy type 1 and implantable cardiac devices. Key takeaway: P.Y.G.M. Protects Against Myocardial Infarction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40990886">Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40988610">PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40991268">Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40991257">Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40992090">Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.</a> (JACC. Heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/">https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40990886" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40990886</a></p>
<p><strong>Summary:</strong> This global analysis of cardiovascular disease burden from 1990 to 2023 reveals a continued increase in most countries, driven by modifiable risk factors, population growth, and aging. The study, encompassing 18 subdiseases and 12 risk factors, highlights the urgent need for targeted interventions to mitigate the growing impact of cardiovascular diseases worldwide. The research underscores that cardiovascular diseases remain a leading cause of mortality and disability.</p>
<h4>Article 2: PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40988610" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40988610</a></p>
<p><strong>Summary:</strong> Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. This research demonstrates that muscle glycogen phosphorylase, an enzyme crucial for cardiac energy metabolism, protects against myocardial infarction by enhancing glycogenolysis and promoting autophagic flux. Analyzing cardiac tissues and plasma from myocardial infarction patients, the study found that muscle glycogen phosphorylase deficiency exacerbates myocardial infarction, while its replenishment confers protection. These findings suggest that muscle glycogen phosphorylase could be a potential therapeutic target for myocardial infarction.</p>
<h4>Article 3: Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40991268" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40991268</a></p>
<p><strong>Summary:</strong> This retrospective analysis of transcatheter aortic valve replacement reinterventions, including redo transcatheter aortic valve replacement and transcatheter aortic valve replacement explant, from 2012 to June 2024, provides contemporary data on procedural incidence and volume. The study addresses the gap in data regarding the frequency of these reinterventions, offering insights into the evolving landscape of aortic valve replacement procedures. The data are crucial for assessing the long-term outcomes and management of patients undergoing transcatheter aortic valve replacement.</p>
<h4>Article 4: Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40991257" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40991257</a></p>
<p><strong>Summary:</strong> This study investigates the utility of electrocardiogram findings versus electrophysiological study results in predicting major conduction delays in myotonic dystrophy type 1 patients. Comparing E.C.G. parameters such as P.R. interval and Q.R.S. duration with His-ventricular interval during electrophysiological study, the research aims to refine guidelines for pacemaker implantation in asymptomatic patients at risk of sudden cardiac death. The findings will help clinicians better identify patients who would benefit from prophylactic pacing.</p>
<h4>Article 5: Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40992090" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40992090</a></p>
<p><strong>Summary:</strong> This study analyzes the effects of glucagon-like peptide 1 receptor agonists on device-related rhythm parameters in patients with Heart Failure with Reduced Ejection Fraction and implanted cardiac devices. By monitoring data from these devices, the researchers aim to determine if glucagon-like peptide 1 receptor agonists induce deleterious effects on heart rate or increase arrhythmic events in this vulnerable population. Understanding these effects is crucial for the safe and effective use of glucagon-like peptide 1 receptor agonists in Heart Failure with Reduced Ejection Fraction patients.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. This global analysis of cardiovascular disease burden from 1990 to 2023 reveals a continued increase in most countries, driven by modifiable risk factors, population growth, and aging. The study, encompassing 18 subdiseases and 12 risk factors, highlights the urgent need for targeted interventions to mitigate the growing impact of cardiovascular diseases worldwide. The research underscores that cardiovascular diseases remain a leading cause of mortality and disability.</p>
<p>Article number two. P.Y.G.M. Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. This research demonstrates that muscle glycogen phosphorylase, an enzyme crucial for cardiac energy metabolism, protects against myocardial infarction by enhancing glycogenolysis and promoting autophagic flux. Analyzing cardiac tissues and plasma from myocardial infarction patients, the study found that muscle glycogen phosphorylase deficiency exacerbates myocardial infarction, while its replenishment confers protection. These findings suggest that muscle glycogen phosphorylase could be a potential therapeutic target for myocardial infarction.</p>
<p>Article number three. Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention. This retrospective analysis of transcatheter aortic valve replacement reinterventions, including redo transcatheter aortic valve replacement and transcatheter aortic valve replacement explant, from 2012 to June 2024, provides contemporary data on procedural incidence and volume. The study addresses the gap in data regarding the frequency of these reinterventions, offering insights into the evolving landscape of aortic valve replacement procedures. The data are crucial for assessing the long-term outcomes and management of patients undergoing transcatheter aortic valve replacement.</p>
<p>Article number four. Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1. This study investigates the utility of electrocardiogram findings versus electrophysiological study results in predicting major conduction delays in myotonic dystrophy type 1 patients. Comparing E.C.G. parameters such as P.R. interval and Q.R.S. duration with His-ventricular interval during electrophysiological study, the research aims to refine guidelines for pacemaker implantation in asymptomatic patients at risk of sudden cardiac death. The findings will help clinicians better identify patients who would benefit from prophylactic pacing.</p>
<p>Article number five. Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices. This study analyzes the effects of glucagon-like peptide 1 receptor agonists on device-related rhythm parameters in patients with Heart Failure with Reduced Ejection Fraction and implanted cardiac devices. By monitoring data from these devices, the researchers aim to determine if glucagon-like peptide 1 receptor agonists induce deleterious effects on heart rate or increase arrhythmic events in this vulnerable population. Understanding these effects is crucial for the safe and effective use of glucagon-like peptide 1 receptor agonists in Heart Failure with Reduced Ejection Fraction patients. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>myotonic dystrophy type 1, implantable cardiac devices, mortality, heart rate, pacemaker implantation, autophagy, muscle glycogen phosphorylase, transcatheter aortic valve replacement explant, risk factors, Heart Failure with Reduced Ejection Fraction, glucagon-like peptide 1 receptor agonists, electrophysiological study, cardiac metabolism, electrocardiogram, aortic valve replacement, conduction delay, cardiovascular disease, reintervention, arrhythmias, glycogenolysis, myocardial infarction, epidemiology, redo transcatheter aortic valve replacement, transcatheter aortic valve replacement, global burden.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/">P.Y.G.M. Protects Against Myocardial Infarction 09/25/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250925_025625.mp3" length="3889780" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like myotonic dystrophy type 1 and implantable cardiac devices. Key takeaway: P.Y.G.M. Protects Against Myocardial Infarction.
Article Links:
Article 1: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. (Journal of the American College of Cardiology)
Article 2: PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. (Circulation)
Article 3: Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention. (JAMA cardiology)
Article 4: Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1. (JAMA cardiology)
Article 5: Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/p-y-g-m-protects-against-myocardial-infarction-09-25-25/
 Featured Articles
Article 1: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40990886
Summary: This global analysis of cardiovascular disease burden from 1990 to 2023 reveals a continued increase in most countries, driven by modifiable risk factors, population growth, and aging. The study, encompassing 18 subdiseases and 12 risk factors, highlights the urgent need for targeted interventions to mitigate the growing impact of cardiovascular diseases worldwide. The research underscores that cardiovascular diseases remain a leading cause of mortality and disability.
Article 2: PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40988610
Summary: Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. This research demonstrates that muscle glycogen phosphorylase, an enzyme crucial for cardiac energy metabolism, protects against myocardial infarction by enhancing glycogenolysis and promoting autophagic flux. Analyzing cardiac tissues and plasma from myocardial infarction patients, the study found that muscle glycogen phosphorylase deficiency exacerbates myocardial infarction, while its replenishment confers protection. These findings suggest that muscle glycogen phosphorylase could be a potential therapeutic target for myocardial infarction.
Article 3: Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40991268
Summary: This retrospective analysis of transcatheter aortic valve replacement reinterventions, including redo transcatheter aortic valve replacement and transcatheter aortic valve replacement explant, from 2012 to June 2024, provides contemporary data on procedural incidence and volume. The study addresses the gap in data regarding the frequency of these reinterventions, offering insights into the evolving landscape of aortic valve replacement procedures. The data are crucial for assessing the long-term outcomes and management of patients undergoing transcatheter aortic valve replacement.
Article 4: Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40991257
Summary: This study investigates the utility of electrocardiogram findings versus electrophysiological study results in predicting major conduction delays in myotonic dystrophy type 1 patients. Comparing E.C.G. parameters such as P.R. interval and Q.R.S. duration with His-ventricular]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like myotonic dystrophy type 1 and implantable cardiac devices. Key takeaway: P.Y.G.M. Protects Against Myocardial Infarction.
Article Links:
Article 1: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. (Journal of the American College of Cardiology)
Article 2: PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux. (Circulation)
Article 3: Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention. (JAMA cardiology)
Article 4: Electrocardiogram vs Electrophysiological Study and Major Conduction Delays in Myotonic Dystrophy Type 1. (JAMA cardiology)
Article 5: Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Height Drives Hypertension in Older Women 09/24/25</title>
	<link>https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/</link>
	<pubDate>Wed, 24 Sep 2025 10:01:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like systolic blood pressure and Heart Failure with Preserved Ejection Fraction. Key takeaway: Height Drives Hypertension in Older Women.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40977399">Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40977391">Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry.</a> (Circulation. Cardiovascular interventions)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40985143">Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40982271">Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40977275">Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/">https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977399" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977399</a></p>
<p><strong>Summary:</strong> This study analyzed data from the National Health and Nutrition Examination Surveys, examining older women and men with hypertension. The analysis suggests that differences in height contribute to higher systolic blood pressure values in older women compared to men, potentially explaining lower hypertension control rates in women. These findings highlight the importance of considering height when managing hypertension in older adults, especially in women.</p>
<h4>Article 2: Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977391" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977391</a></p>
<p><strong>Summary:</strong> Registry. This study from the P.T.R.G.-D.E.S. registry assessed the interaction between platelet reactivity and clinical risk, as determined by the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, on clinical outcomes after percutaneous coronary intervention. The results showed that high platelet reactivity, combined with high clinical risk scores, was associated with increased adverse clinical events in patients with coronary artery disease treated with drug-eluting stents. This suggests that tailoring antiplatelet therapy based on both platelet function and clinical risk assessment could improve outcomes after percutaneous coronary intervention.</p>
<h4>Article 3: Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40985143" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40985143</a></p>
<p><strong>Summary:</strong> This study investigated transpulmonary protein gradients in patients with Heart Failure with Reduced Ejection Fraction to identify mediators of pulmonary vascular disease. Proteomic analysis revealed distinct protein signatures associated with pulmonary vascular disease development in the setting of heart failure. The identified pathways may represent potential therapeutic targets for preventing or treating pulmonary vascular disease in patients with heart failure.</p>
<h4>Article 4: Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40982271" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40982271</a></p>
<p><strong>Summary:</strong> This study evaluated the impact of the National Heart Failure Center Accreditation Program in China on heart failure therapy implementation. Results indicated that hospitals participating in the accreditation program demonstrated improved adherence to guideline-directed medical therapy for heart failure patients. The nationwide implementation of standardized heart failure care through accreditation programs can lead to better treatment and outcomes.</p>
<h4>Article 5: Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977275</a></p>
<p><strong>Summary:</strong> This study investigated the changes in tricuspid regurgitation severity during exercise in patients with Heart Failure with Preserved Ejection Fraction using invasive hemodynamic exercise testing and echocardiography. The study found that tricuspid regurgitation often worsens during exercise in these patients, correlating with hemodynamic changes, reduced cardiopulmonary reserve, and worse prognosis. These findings highlight the importance of assessing dynamic tricuspid regurgitation during exercise in Heart Failure with Preserved Ejection Fraction for risk stratification and management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults. This study analyzed data from the National Health and Nutrition Examination Surveys, examining older women and men with hypertension. The analysis suggests that differences in height contribute to higher systolic blood pressure values in older women compared to men, potentially explaining lower hypertension control rates in women. These findings highlight the importance of considering height when managing hypertension in older adults, especially in women.</p>
<p>Article number two. Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the P.T.R.G.-D.E.S. Registry. This study from the P.T.R.G.-D.E.S. registry assessed the interaction between platelet reactivity and clinical risk, as determined by the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, on clinical outcomes after percutaneous coronary intervention. The results showed that high platelet reactivity, combined with high clinical risk scores, was associated with increased adverse clinical events in patients with coronary artery disease treated with drug-eluting stents. This suggests that tailoring antiplatelet therapy based on both platelet function and clinical risk assessment could improve outcomes after percutaneous coronary intervention.</p>
<p>Article number three. Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure. This study investigated transpulmonary protein gradients in patients with Heart Failure with Reduced Ejection Fraction to identify mediators of pulmonary vascular disease. Proteomic analysis revealed distinct protein signatures associated with pulmonary vascular disease development in the setting of heart failure. The identified pathways may represent potential therapeutic targets for preventing or treating pulmonary vascular disease in patients with heart failure.</p>
<p>Article number four. Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (H.F.-C.A.P.) in China. This study evaluated the impact of the National Heart Failure Center Accreditation Program in China on heart failure therapy implementation. Results indicated that hospitals participating in the accreditation program demonstrated improved adherence to guideline-directed medical therapy for heart failure patients. The nationwide implementation of standardized heart failure care through accreditation programs can lead to better treatment and outcomes.</p>
<p>Article number five. Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction. This study investigated the changes in tricuspid regurgitation severity during exercise in patients with Heart Failure with Preserved Ejection Fraction using invasive hemodynamic exercise testing and echocardiography. The study found that tricuspid regurgitation often worsens during exercise in these patients, correlating with hemodynamic changes, reduced cardiopulmonary reserve, and worse prognosis. These findings highlight the importance of assessing dynamic tricuspid regurgitation during exercise in Heart Failure with Preserved Ejection Fraction for risk stratification and management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>systolic blood pressure, Heart Failure with Preserved Ejection Fraction, H.F.-C.A.P., height, heart failure, proteomics, accreditation program, pulmonary hypertension, hypertension, China, pulmonary vascular disease, hemodynamics, older adults, guideline-directed medical therapy, coronary artery disease, tricuspid regurgitation, exercise, Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, Heart Failure with Reduced Ejection Fraction, platelet reactivity, percutaneous coronary intervention, drug-eluting stents, transpulmonary gradient, sex differences.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/">Height Drives Hypertension in Older Women 09/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like systolic blood pressure and Heart Failure with Preserved Ejection Fraction. Key takeaway: Height Drives Hypertension in Older Women]]></itunes:subtitle>
	<itunes:episode>74</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like systolic blood pressure and Heart Failure with Preserved Ejection Fraction. Key takeaway: Height Drives Hypertension in Older Women.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40977399">Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40977391">Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry.</a> (Circulation. Cardiovascular interventions)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40985143">Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure.</a> (Circulation. Heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40982271">Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.</a> (European journal of heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40977275">Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.</a> (European journal of heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/">https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977399" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977399</a></p>
<p><strong>Summary:</strong> This study analyzed data from the National Health and Nutrition Examination Surveys, examining older women and men with hypertension. The analysis suggests that differences in height contribute to higher systolic blood pressure values in older women compared to men, potentially explaining lower hypertension control rates in women. These findings highlight the importance of considering height when managing hypertension in older adults, especially in women.</p>
<h4>Article 2: Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry.</h4>
<p><strong>Journal:</strong> Circulation. Cardiovascular interventions</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977391" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977391</a></p>
<p><strong>Summary:</strong> Registry. This study from the P.T.R.G.-D.E.S. registry assessed the interaction between platelet reactivity and clinical risk, as determined by the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, on clinical outcomes after percutaneous coronary intervention. The results showed that high platelet reactivity, combined with high clinical risk scores, was associated with increased adverse clinical events in patients with coronary artery disease treated with drug-eluting stents. This suggests that tailoring antiplatelet therapy based on both platelet function and clinical risk assessment could improve outcomes after percutaneous coronary intervention.</p>
<h4>Article 3: Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure.</h4>
<p><strong>Journal:</strong> Circulation. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40985143" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40985143</a></p>
<p><strong>Summary:</strong> This study investigated transpulmonary protein gradients in patients with Heart Failure with Reduced Ejection Fraction to identify mediators of pulmonary vascular disease. Proteomic analysis revealed distinct protein signatures associated with pulmonary vascular disease development in the setting of heart failure. The identified pathways may represent potential therapeutic targets for preventing or treating pulmonary vascular disease in patients with heart failure.</p>
<h4>Article 4: Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40982271" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40982271</a></p>
<p><strong>Summary:</strong> This study evaluated the impact of the National Heart Failure Center Accreditation Program in China on heart failure therapy implementation. Results indicated that hospitals participating in the accreditation program demonstrated improved adherence to guideline-directed medical therapy for heart failure patients. The nationwide implementation of standardized heart failure care through accreditation programs can lead to better treatment and outcomes.</p>
<h4>Article 5: Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.</h4>
<p><strong>Journal:</strong> European journal of heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977275</a></p>
<p><strong>Summary:</strong> This study investigated the changes in tricuspid regurgitation severity during exercise in patients with Heart Failure with Preserved Ejection Fraction using invasive hemodynamic exercise testing and echocardiography. The study found that tricuspid regurgitation often worsens during exercise in these patients, correlating with hemodynamic changes, reduced cardiopulmonary reserve, and worse prognosis. These findings highlight the importance of assessing dynamic tricuspid regurgitation during exercise in Heart Failure with Preserved Ejection Fraction for risk stratification and management.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults. This study analyzed data from the National Health and Nutrition Examination Surveys, examining older women and men with hypertension. The analysis suggests that differences in height contribute to higher systolic blood pressure values in older women compared to men, potentially explaining lower hypertension control rates in women. These findings highlight the importance of considering height when managing hypertension in older adults, especially in women.</p>
<p>Article number two. Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the P.T.R.G.-D.E.S. Registry. This study from the P.T.R.G.-D.E.S. registry assessed the interaction between platelet reactivity and clinical risk, as determined by the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, on clinical outcomes after percutaneous coronary intervention. The results showed that high platelet reactivity, combined with high clinical risk scores, was associated with increased adverse clinical events in patients with coronary artery disease treated with drug-eluting stents. This suggests that tailoring antiplatelet therapy based on both platelet function and clinical risk assessment could improve outcomes after percutaneous coronary intervention.</p>
<p>Article number three. Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure. This study investigated transpulmonary protein gradients in patients with Heart Failure with Reduced Ejection Fraction to identify mediators of pulmonary vascular disease. Proteomic analysis revealed distinct protein signatures associated with pulmonary vascular disease development in the setting of heart failure. The identified pathways may represent potential therapeutic targets for preventing or treating pulmonary vascular disease in patients with heart failure.</p>
<p>Article number four. Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (H.F.-C.A.P.) in China. This study evaluated the impact of the National Heart Failure Center Accreditation Program in China on heart failure therapy implementation. Results indicated that hospitals participating in the accreditation program demonstrated improved adherence to guideline-directed medical therapy for heart failure patients. The nationwide implementation of standardized heart failure care through accreditation programs can lead to better treatment and outcomes.</p>
<p>Article number five. Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction. This study investigated the changes in tricuspid regurgitation severity during exercise in patients with Heart Failure with Preserved Ejection Fraction using invasive hemodynamic exercise testing and echocardiography. The study found that tricuspid regurgitation often worsens during exercise in these patients, correlating with hemodynamic changes, reduced cardiopulmonary reserve, and worse prognosis. These findings highlight the importance of assessing dynamic tricuspid regurgitation during exercise in Heart Failure with Preserved Ejection Fraction for risk stratification and management. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>systolic blood pressure, Heart Failure with Preserved Ejection Fraction, H.F.-C.A.P., height, heart failure, proteomics, accreditation program, pulmonary hypertension, hypertension, China, pulmonary vascular disease, hemodynamics, older adults, guideline-directed medical therapy, coronary artery disease, tricuspid regurgitation, exercise, Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, Heart Failure with Reduced Ejection Fraction, platelet reactivity, percutaneous coronary intervention, drug-eluting stents, transpulmonary gradient, sex differences.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/">Height Drives Hypertension in Older Women 09/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250924_060016.mp3" length="3650707" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like systolic blood pressure and Heart Failure with Preserved Ejection Fraction. Key takeaway: Height Drives Hypertension in Older Women.
Article Links:
Article 1: Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults. (Hypertension (Dallas, Tex. : 1979))
Article 2: Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry. (Circulation. Cardiovascular interventions)
Article 3: Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure. (Circulation. Heart failure)
Article 4: Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China. (European journal of heart failure)
Article 5: Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/height-drives-hypertension-in-older-women-09-24-25/
 Featured Articles
Article 1: Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40977399
Summary: This study analyzed data from the National Health and Nutrition Examination Surveys, examining older women and men with hypertension. The analysis suggests that differences in height contribute to higher systolic blood pressure values in older women compared to men, potentially explaining lower hypertension control rates in women. These findings highlight the importance of considering height when managing hypertension in older adults, especially in women.
Article 2: Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry.
Journal: Circulation. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40977391
Summary: Registry. This study from the P.T.R.G.-D.E.S. registry assessed the interaction between platelet reactivity and clinical risk, as determined by the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, on clinical outcomes after percutaneous coronary intervention. The results showed that high platelet reactivity, combined with high clinical risk scores, was associated with increased adverse clinical events in patients with coronary artery disease treated with drug-eluting stents. This suggests that tailoring antiplatelet therapy based on both platelet function and clinical risk assessment could improve outcomes after percutaneous coronary intervention.
Article 3: Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985143
Summary: This study investigated transpulmonary protein gradients in patients with Heart Failure with Reduced Ejection Fraction to identify mediators of pulmonary vascular disease. Proteomic analysis revealed distinct protein signatures associated with pulmonary vascular disease development in the setting of heart failure. The identified pathways may represent potential therapeutic targets for preventing or treating pulmonary vascular disease in patients with heart failure.
Article 4: Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40982271
Summary: This study evaluated the impact of the National Heart Failure Center Accreditation Program in China on heart failure therapy implementation. Results indicated that hospitals participating in the accreditation program demonstrated improved adherence ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like systolic blood pressure and Heart Failure with Preserved Ejection Fraction. Key takeaway: Height Drives Hypertension in Older Women.
Article Links:
Article 1: Height May Explain Sex Differences in Systolic Blood Pressure in Older Adults. (Hypertension (Dallas, Tex. : 1979))
Article 2: Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry. (Circulation. Cardiovascular interventions)
Article 3: Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure. (Circulation. Heart failure)
Article 4: Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China. (European journal of heart failure)
Article 5: Dynamic tricuspid regurgitation in heart failure with ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>H.E.G.1&#8217;s Role in Blood Pressure Control Revealed 09/24/25</title>
	<link>https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/</link>
	<pubDate>Wed, 24 Sep 2025 06:57:18 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and geographic variation. Key takeaway: H.E.G.1&#8217;s Role in Blood Pressure Control Revealed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40986512">Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40985963">Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40985755">Invasive validation of novel 1D models for computation of coronary fractional flow reserve.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40983954">Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40977249">Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/">https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40986512" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40986512</a></p>
<p><strong>Summary:</strong> This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.</p>
<h4>Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40985963" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40985963</a></p>
<p><strong>Summary:</strong> This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.</p>
<h4>Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40985755" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40985755</a></p>
<p><strong>Summary:</strong> This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.</p>
<h4>Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983954</a></p>
<p><strong>Summary:</strong> This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.</p>
<h4>Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977249</a></p>
<p><strong>Summary:</strong> This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Shear stress-induced endothelial H.E.G.1 signalling regulates vascular tone and blood pressure. This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.</p>
<p>Article number two. Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.</p>
<p>Article number three. Invasive validation of novel 1D models for computation of coronary fractional flow reserve. This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.</p>
<p>Article number four. Finerenone in diabetic chronic kidney disease-Real-world insights including patients with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.</p>
<p>Article number five. Geographic region variation in patient characteristics, clinical outcomes and treatment of Heart Failure with Reduced Ejection Fraction in the VICTORIA trial. This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>blood pressure, geographic variation, transcriptomic biomarkers, Heart Failure with Preserved Ejection Fraction, fractional flow reserve, endothelial cells, shear stress, finerenone, one-dimensional models, Heart development protein with epidermal growth factor-like domain 1, heart-directed radiotherapy, mineralocorticoid receptor antagonist, anthracyclines, guideline-directed medical therapy, vasodilation, coronary artery disease, clinical outcomes, vericiguat, Heart Failure with Reduced Ejection Fraction, type 2 diabetes mellitus, chronic kidney disease, cardiac disease, angiography, childhood cancer survivors, virtual fractional flow reserve.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/">H.E.G.1’s Role in Blood Pressure Control Revealed 09/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and geographic variation. Key takeaway: H.E.G.1&#8217;s Role in Blood Pressure Control Revealed.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>73</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and geographic variation. Key takeaway: H.E.G.1&#8217;s Role in Blood Pressure Control Revealed.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40986512">Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40985963">Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40985755">Invasive validation of novel 1D models for computation of coronary fractional flow reserve.</a> (Cardiovascular research)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40983954">Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.</a> (ESC heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40977249">Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.</a> (ESC heart failure)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/">https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40986512" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40986512</a></p>
<p><strong>Summary:</strong> This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.</p>
<h4>Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40985963" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40985963</a></p>
<p><strong>Summary:</strong> This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.</p>
<h4>Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve.</h4>
<p><strong>Journal:</strong> Cardiovascular research</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40985755" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40985755</a></p>
<p><strong>Summary:</strong> This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.</p>
<h4>Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983954" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983954</a></p>
<p><strong>Summary:</strong> This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.</p>
<h4>Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977249" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977249</a></p>
<p><strong>Summary:</strong> This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Shear stress-induced endothelial H.E.G.1 signalling regulates vascular tone and blood pressure. This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.</p>
<p>Article number two. Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.</p>
<p>Article number three. Invasive validation of novel 1D models for computation of coronary fractional flow reserve. This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.</p>
<p>Article number four. Finerenone in diabetic chronic kidney disease-Real-world insights including patients with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.</p>
<p>Article number five. Geographic region variation in patient characteristics, clinical outcomes and treatment of Heart Failure with Reduced Ejection Fraction in the VICTORIA trial. This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>blood pressure, geographic variation, transcriptomic biomarkers, Heart Failure with Preserved Ejection Fraction, fractional flow reserve, endothelial cells, shear stress, finerenone, one-dimensional models, Heart development protein with epidermal growth factor-like domain 1, heart-directed radiotherapy, mineralocorticoid receptor antagonist, anthracyclines, guideline-directed medical therapy, vasodilation, coronary artery disease, clinical outcomes, vericiguat, Heart Failure with Reduced Ejection Fraction, type 2 diabetes mellitus, chronic kidney disease, cardiac disease, angiography, childhood cancer survivors, virtual fractional flow reserve.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/">H.E.G.1’s Role in Blood Pressure Control Revealed 09/24/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250924_025628.mp3" length="4140973" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and geographic variation. Key takeaway: H.E.G.1&#8217;s Role in Blood Pressure Control Revealed.
Article Links:
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure. (European heart journal)
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. (European heart journal)
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve. (Cardiovascular research)
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF. (ESC heart failure)
Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/
 Featured Articles
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40986512
Summary: This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985963
Summary: This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985755
Summary: This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40983954
Summary: This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstra]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and geographic variation. Key takeaway: H.E.G.1&#8217;s Role in Blood Pressure Control Revealed.
Article Links:
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure. (European heart journal)
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. (European heart journal)
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve. (Cardiovascular research)
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF. (ESC heart failure)
Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Triglycerides Drive Aneurysm Rupture Risk 09/23/25</title>
	<link>https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/</link>
	<pubDate>Tue, 23 Sep 2025 10:00:57 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like MELOS RELOADED and Pacemaker. Key takeaway: Triglycerides Drive Aneurysm Rupture Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40762097">Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40977097">Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40983194">Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease.</a> (The Canadian journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40983190">Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40983185">Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/">https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40762097" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40762097</a></p>
<p><strong>Summary:</strong> This study used Mendelian randomization and experimental models to investigate the relationship between triglycerides and abdominal aortic aneurysm. The findings suggest elevated triglyceride levels causally contribute to abdominal aortic aneurysm development and rupture, identifying a potential therapeutic target. This indicates that lowering triglycerides could be a pharmacological strategy to prevent abdominal aortic aneurysm progression.</p>
<h4>Article 2: Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977097" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977097</a></p>
<p><strong>Summary:</strong> The MELOS RELOADED study, a multicenter European registry, compared left bundle branch area pacing to right ventricular pacing in patients with atrioventricular block. Results demonstrated no significant difference in long-term survival between the two pacing strategies. Further analysis is needed to identify subgroups that may benefit more from left bundle branch area pacing.</p>
<h4>Article 3: Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983194</a></p>
<p><strong>Summary:</strong> This retrospective cohort study analyzed hospitalized patients with pericardial disease in New South Wales, Australia, from 2004 to 2021 to identify risk factors for constrictive pericarditis. The study defined the epidemiology and predictors of constrictive pericarditis utilizing multivariable logistic regression to determine risk factors within this large population-based cohort. The results illuminate potential targets for early intervention and prevention of this rare but serious complication.</p>
<h4>Article 4: Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983190" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983190</a></p>
<p><strong>Summary:</strong> This retrospective, multicenter study evaluated the impact of severe aortic valve calcification on outcomes following transcatheter aortic valve replacement using self-expanding intra-annular transcatheter heart valves. The study revealed that severe aortic valve calcification does not significantly impact procedural or clinical outcomes in patients undergoing transcatheter aortic valve replacement with Portico or Navitor transcatheter heart valves. This suggests that these valves are safe and effective even in patients with heavily calcified valves.</p>
<h4>Article 5: Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983185" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983185</a></p>
<p><strong>Summary:</strong> This study investigated the role of interventricular septal thickness, measured via pre-procedural computed tomography, in predicting the need for permanent pacemaker implantation after transcatheter aortic valve replacement. The findings indicate that lower interventricular septal thickness is a predictor of permanent pacemaker implantation post-transcatheter aortic valve replacement. Integrating interventricular septal thickness into pre-procedural assessment may improve risk stratification and patient selection.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models. This study used Mendelian randomization and experimental models to investigate the relationship between triglycerides and abdominal aortic aneurysm. The findings suggest elevated triglyceride levels causally contribute to abdominal aortic aneurysm development and rupture, identifying a potential therapeutic target. This indicates that lowering triglycerides could be a pharmacological strategy to prevent abdominal aortic aneurysm progression.</p>
<p>Article number two. Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study. The MELOS RELOADED study, a multicenter European registry, compared left bundle branch area pacing to right ventricular pacing in patients with atrioventricular block. Results demonstrated no significant difference in long-term survival between the two pacing strategies. Further analysis is needed to identify subgroups that may benefit more from left bundle branch area pacing.</p>
<p>Article number three. Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease. This retrospective cohort study analyzed hospitalized patients with pericardial disease in New South Wales, Australia, from 2004 to 2021 to identify risk factors for constrictive pericarditis. The study defined the epidemiology and predictors of constrictive pericarditis utilizing multivariable logistic regression to determine risk factors within this large population-based cohort. The results illuminate potential targets for early intervention and prevention of this rare but serious complication.</p>
<p>Article number four. Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve. This retrospective, multicenter study evaluated the impact of severe aortic valve calcification on outcomes following transcatheter aortic valve replacement using self-expanding intra-annular transcatheter heart valves. The study revealed that severe aortic valve calcification does not significantly impact procedural or clinical outcomes in patients undergoing transcatheter aortic valve replacement with Portico or Navitor transcatheter heart valves. This suggests that these valves are safe and effective even in patients with heavily calcified valves.</p>
<p>Article number five. Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR. This study investigated the role of interventricular septal thickness, measured via pre-procedural computed tomography, in predicting the need for permanent pacemaker implantation after transcatheter aortic valve replacement. The findings indicate that lower interventricular septal thickness is a predictor of permanent pacemaker implantation post-transcatheter aortic valve replacement. Integrating interventricular septal thickness into pre-procedural assessment may improve risk stratification and patient selection. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>MELOS RELOADED, Pacemaker, Left Bundle Branch Area Pacing, Navitor, Epidemiology, Aortic Valve Calcification, Atrioventricular Block, Portico, Computed Tomography, Right Ventricular Pacing, Abdominal Aortic Aneurysm, Hypertriglyceridemia, Self-Expanding Valve, Interventricular Septal Thickness, Transcatheter Aortic Valve Replacement, Permanent Pacemaker Implantation, Mendelian Randomization, Risk Factors, Constrictive Pericarditis, Lipoproteins, Aortic Stenosis, Pericardial Disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/">Triglycerides Drive Aneurysm Rupture Risk 09/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like MELOS RELOADED and Pacemaker. Key takeaway: Triglycerides Drive Aneurysm Rupture Risk.
Article Links:
Article 1: Hypertriglyceridem]]></itunes:subtitle>
	<itunes:episode>72</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like MELOS RELOADED and Pacemaker. Key takeaway: Triglycerides Drive Aneurysm Rupture Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40762097">Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40977097">Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40983194">Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease.</a> (The Canadian journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40983190">Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40983185">Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/">https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40762097" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40762097</a></p>
<p><strong>Summary:</strong> This study used Mendelian randomization and experimental models to investigate the relationship between triglycerides and abdominal aortic aneurysm. The findings suggest elevated triglyceride levels causally contribute to abdominal aortic aneurysm development and rupture, identifying a potential therapeutic target. This indicates that lowering triglycerides could be a pharmacological strategy to prevent abdominal aortic aneurysm progression.</p>
<h4>Article 2: Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40977097" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40977097</a></p>
<p><strong>Summary:</strong> The MELOS RELOADED study, a multicenter European registry, compared left bundle branch area pacing to right ventricular pacing in patients with atrioventricular block. Results demonstrated no significant difference in long-term survival between the two pacing strategies. Further analysis is needed to identify subgroups that may benefit more from left bundle branch area pacing.</p>
<h4>Article 3: Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983194" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983194</a></p>
<p><strong>Summary:</strong> This retrospective cohort study analyzed hospitalized patients with pericardial disease in New South Wales, Australia, from 2004 to 2021 to identify risk factors for constrictive pericarditis. The study defined the epidemiology and predictors of constrictive pericarditis utilizing multivariable logistic regression to determine risk factors within this large population-based cohort. The results illuminate potential targets for early intervention and prevention of this rare but serious complication.</p>
<h4>Article 4: Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983190" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983190</a></p>
<p><strong>Summary:</strong> This retrospective, multicenter study evaluated the impact of severe aortic valve calcification on outcomes following transcatheter aortic valve replacement using self-expanding intra-annular transcatheter heart valves. The study revealed that severe aortic valve calcification does not significantly impact procedural or clinical outcomes in patients undergoing transcatheter aortic valve replacement with Portico or Navitor transcatheter heart valves. This suggests that these valves are safe and effective even in patients with heavily calcified valves.</p>
<h4>Article 5: Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40983185" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40983185</a></p>
<p><strong>Summary:</strong> This study investigated the role of interventricular septal thickness, measured via pre-procedural computed tomography, in predicting the need for permanent pacemaker implantation after transcatheter aortic valve replacement. The findings indicate that lower interventricular septal thickness is a predictor of permanent pacemaker implantation post-transcatheter aortic valve replacement. Integrating interventricular septal thickness into pre-procedural assessment may improve risk stratification and patient selection.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models. This study used Mendelian randomization and experimental models to investigate the relationship between triglycerides and abdominal aortic aneurysm. The findings suggest elevated triglyceride levels causally contribute to abdominal aortic aneurysm development and rupture, identifying a potential therapeutic target. This indicates that lowering triglycerides could be a pharmacological strategy to prevent abdominal aortic aneurysm progression.</p>
<p>Article number two. Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study. The MELOS RELOADED study, a multicenter European registry, compared left bundle branch area pacing to right ventricular pacing in patients with atrioventricular block. Results demonstrated no significant difference in long-term survival between the two pacing strategies. Further analysis is needed to identify subgroups that may benefit more from left bundle branch area pacing.</p>
<p>Article number three. Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease. This retrospective cohort study analyzed hospitalized patients with pericardial disease in New South Wales, Australia, from 2004 to 2021 to identify risk factors for constrictive pericarditis. The study defined the epidemiology and predictors of constrictive pericarditis utilizing multivariable logistic regression to determine risk factors within this large population-based cohort. The results illuminate potential targets for early intervention and prevention of this rare but serious complication.</p>
<p>Article number four. Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve. This retrospective, multicenter study evaluated the impact of severe aortic valve calcification on outcomes following transcatheter aortic valve replacement using self-expanding intra-annular transcatheter heart valves. The study revealed that severe aortic valve calcification does not significantly impact procedural or clinical outcomes in patients undergoing transcatheter aortic valve replacement with Portico or Navitor transcatheter heart valves. This suggests that these valves are safe and effective even in patients with heavily calcified valves.</p>
<p>Article number five. Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR. This study investigated the role of interventricular septal thickness, measured via pre-procedural computed tomography, in predicting the need for permanent pacemaker implantation after transcatheter aortic valve replacement. The findings indicate that lower interventricular septal thickness is a predictor of permanent pacemaker implantation post-transcatheter aortic valve replacement. Integrating interventricular septal thickness into pre-procedural assessment may improve risk stratification and patient selection. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>MELOS RELOADED, Pacemaker, Left Bundle Branch Area Pacing, Navitor, Epidemiology, Aortic Valve Calcification, Atrioventricular Block, Portico, Computed Tomography, Right Ventricular Pacing, Abdominal Aortic Aneurysm, Hypertriglyceridemia, Self-Expanding Valve, Interventricular Septal Thickness, Transcatheter Aortic Valve Replacement, Permanent Pacemaker Implantation, Mendelian Randomization, Risk Factors, Constrictive Pericarditis, Lipoproteins, Aortic Stenosis, Pericardial Disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/">Triglycerides Drive Aneurysm Rupture Risk 09/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250923_060012.mp3" length="3543292" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like MELOS RELOADED and Pacemaker. Key takeaway: Triglycerides Drive Aneurysm Rupture Risk.
Article Links:
Article 1: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models. (Circulation)
Article 2: Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study. (European heart journal)
Article 3: Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease. (The Canadian journal of cardiology)
Article 4: Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve. (The Canadian journal of cardiology)
Article 5: Lower interventricular septal thickness from computed tomography predicts the need for pacemaker implantation after TAVR. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/triglycerides-drive-aneurysm-rupture-risk-09-23-25/
 Featured Articles
Article 1: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40762097
Summary: This study used Mendelian randomization and experimental models to investigate the relationship between triglycerides and abdominal aortic aneurysm. The findings suggest elevated triglyceride levels causally contribute to abdominal aortic aneurysm development and rupture, identifying a potential therapeutic target. This indicates that lowering triglycerides could be a pharmacological strategy to prevent abdominal aortic aneurysm progression.
Article 2: Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40977097
Summary: The MELOS RELOADED study, a multicenter European registry, compared left bundle branch area pacing to right ventricular pacing in patients with atrioventricular block. Results demonstrated no significant difference in long-term survival between the two pacing strategies. Further analysis is needed to identify subgroups that may benefit more from left bundle branch area pacing.
Article 3: Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40983194
Summary: This retrospective cohort study analyzed hospitalized patients with pericardial disease in New South Wales, Australia, from 2004 to 2021 to identify risk factors for constrictive pericarditis. The study defined the epidemiology and predictors of constrictive pericarditis utilizing multivariable logistic regression to determine risk factors within this large population-based cohort. The results illuminate potential targets for early intervention and prevention of this rare but serious complication.
Article 4: Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40983190
Summary: This retrospective, multicenter study evaluated the impact of severe aortic valve calcification on outcomes following transcatheter aortic valve replacement using self-expanding intra-annular transcatheter heart valves. The study revealed that severe aortic valve calcification does not significantly impact procedural or clinical outcomes in patients undergoing transcatheter aortic valve replacement with Portico or Navitor transcatheter heart valves. This suggests that these valves are safe and effective even in patients]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like MELOS RELOADED and Pacemaker. Key takeaway: Triglycerides Drive Aneurysm Rupture Risk.
Article Links:
Article 1: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models. (Circulation)
Article 2: Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study. (European heart journal)
Article 3: Epidemiology and risk factors for constrictive pericarditis in a statewide Australian cohort of patients with pericardial disease. (The Canadian journal of cardiology)
Article 4: Self-Expanding Intra-Annular Transcatheter Aortic Valve Replacement System in Patients with Severely Calcified Aortic Valve. (The Canadian journal of cardiology)
Article 5: Lower interventricular septal thickness from computed tomography predicts the need for pacemak]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Heart Failure Risk: The Power of Genetic Scores 09/23/25</title>
	<link>https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/</link>
	<pubDate>Tue, 23 Sep 2025 06:57:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like risk stratification and phosphorylation. Key takeaway: Heart Failure Risk: The Power of Genetic Scores.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40962376">Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40864011">A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40864007">Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40864006">Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40772312">G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/">https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40962376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40962376</a></p>
<p><strong>Summary:</strong> This randomized trial evaluated intensive versus conventional intraoperative blood pressure management during major abdominal surgery and its impact on cardiovascular events. The study found no significant difference in the incidence of cardiovascular complications within 30 days between the intensive and conventional blood pressure management groups, suggesting that targeting higher intraoperative blood pressure does not reduce postoperative cardiovascular events after major abdominal surgery. These findings indicate that current conventional blood pressure management strategies are adequate for preventing cardiovascular complications in this setting.</p>
<h4>Article 2: A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864011" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864011</a></p>
<p><strong>Summary:</strong> This study investigated the ability of a heart failure polygenic risk score to predict new-onset heart failure across a spectrum of cardiovascular risk. Results showed that individuals in the highest quintile of the polygenic risk score had a significantly increased risk of developing heart failure, even after adjusting for clinical risk factors. The polygenic risk score improved risk stratification for heart failure, suggesting it could be a useful tool for identifying individuals who would benefit from early preventative interventions.</p>
<h4>Article 3: Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864007</a></p>
<p><strong>Summary:</strong> This multi-center registry assessed the early clinical outcomes and safety of percutaneous mechanical aspiration in patients with right-sided infective endocarditis. The study demonstrated that percutaneous mechanical aspiration was associated with a high rate of clinical success in removing infected vegetations. However, there were also notable rates of in-hospital mortality and major adverse events, indicating the need for careful patient selection and further research to optimize this intervention.</p>
<h4>Article 4: Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864006</a></p>
<p><strong>Summary:</strong> This study examined the causes and outcomes of myocardial infarction in patients aged 65 years or younger within a defined community. The research revealed that a significant proportion of myocardial infarctions in this younger population were attributed to non-atherothrombotic causes, including myocardial infarction with non-obstructive coronary arteries, spontaneous coronary artery dissection, and myocarditis. These findings underscore the importance of considering a broad differential diagnosis when evaluating younger patients presenting with elevated troponin levels.</p>
<h4>Article 5: G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40772312" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40772312</a></p>
<p><strong>Summary:</strong> This study investigated the role of G protein-coupled receptor kinase 3 in diabetic heart injury, using both human and mouse models. Researchers discovered that G protein-coupled receptor kinase 3 exacerbates diabetic heart damage through direct phosphorylation of cannabinoid receptor 2. These findings suggest that inhibiting G protein-coupled receptor kinase 3 could be a potential therapeutic strategy for mitigating diabetic cardiomyopathy.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The B.P.-CARES Randomized Trial. This randomized trial evaluated intensive versus conventional intraoperative blood pressure management during major abdominal surgery and its impact on cardiovascular events. The study found no significant difference in the incidence of cardiovascular complications within 30 days between the intensive and conventional blood pressure management groups, suggesting that targeting higher intraoperative blood pressure does not reduce postoperative cardiovascular events after major abdominal surgery. These findings indicate that current conventional blood pressure management strategies are adequate for preventing cardiovascular complications in this setting.</p>
<p>Article number two. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. This study investigated the ability of a heart failure polygenic risk score to predict new-onset heart failure across a spectrum of cardiovascular risk. Results showed that individuals in the highest quintile of the polygenic risk score had a significantly increased risk of developing heart failure, even after adjusting for clinical risk factors. The polygenic risk score improved risk stratification for heart failure, suggesting it could be a useful tool for identifying individuals who would benefit from early preventative interventions.</p>
<p>Article number three. Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry. This multi-center registry assessed the early clinical outcomes and safety of percutaneous mechanical aspiration in patients with right-sided infective endocarditis. The study demonstrated that percutaneous mechanical aspiration was associated with a high rate of clinical success in removing infected vegetations. However, there were also notable rates of in-hospital mortality and major adverse events, indicating the need for careful patient selection and further research to optimize this intervention.</p>
<p>Article number four. Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County. This study examined the causes and outcomes of myocardial infarction in patients aged 65 years or younger within a defined community. The research revealed that a significant proportion of myocardial infarctions in this younger population were attributed to non-atherothrombotic causes, including myocardial infarction with non-obstructive coronary arteries, spontaneous coronary artery dissection, and myocarditis. These findings underscore the importance of considering a broad differential diagnosis when evaluating younger patients presenting with elevated troponin levels.</p>
<p>Article number five. G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice. This study investigated the role of G protein-coupled receptor kinase 3 in diabetic heart injury, using both human and mouse models. Researchers discovered that G protein-coupled receptor kinase 3 exacerbates diabetic heart damage through direct phosphorylation of cannabinoid receptor 2. These findings suggest that inhibiting G protein-coupled receptor kinase 3 could be a potential therapeutic strategy for mitigating diabetic cardiomyopathy. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk stratification, phosphorylation, Diabetic heart injury, polygenic risk score, Intraoperative hypotension, non-atherothrombotic causes, vegetation debulking, blood pressure management, percutaneous mechanical aspiration, randomized controlled trial, Right-sided infective endocarditis, clinical outcomes, younger patients, cardiovascular complications, cardiovascular risk, abdominal surgery, catheter-based intervention, spontaneous coronary artery dissection, Myocardial infarction, diabetic cardiomyopathy, cannabinoid receptor 2, myocardial infarction with non-obstructive coronary arteries, genetic risk, G protein-coupled receptor kinase 3, Heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/">Heart Failure Risk: The Power of Genetic Scores 09/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like risk stratification and phosphorylation. Key takeaway: Heart Failure Risk: The Power of Genetic Scores.
Article Links:
Article 1: I]]></itunes:subtitle>
	<itunes:episode>71</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like risk stratification and phosphorylation. Key takeaway: Heart Failure Risk: The Power of Genetic Scores.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40962376">Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40864011">A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40864007">Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40864006">Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40772312">G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/">https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40962376" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40962376</a></p>
<p><strong>Summary:</strong> This randomized trial evaluated intensive versus conventional intraoperative blood pressure management during major abdominal surgery and its impact on cardiovascular events. The study found no significant difference in the incidence of cardiovascular complications within 30 days between the intensive and conventional blood pressure management groups, suggesting that targeting higher intraoperative blood pressure does not reduce postoperative cardiovascular events after major abdominal surgery. These findings indicate that current conventional blood pressure management strategies are adequate for preventing cardiovascular complications in this setting.</p>
<h4>Article 2: A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864011" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864011</a></p>
<p><strong>Summary:</strong> This study investigated the ability of a heart failure polygenic risk score to predict new-onset heart failure across a spectrum of cardiovascular risk. Results showed that individuals in the highest quintile of the polygenic risk score had a significantly increased risk of developing heart failure, even after adjusting for clinical risk factors. The polygenic risk score improved risk stratification for heart failure, suggesting it could be a useful tool for identifying individuals who would benefit from early preventative interventions.</p>
<h4>Article 3: Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864007" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864007</a></p>
<p><strong>Summary:</strong> This multi-center registry assessed the early clinical outcomes and safety of percutaneous mechanical aspiration in patients with right-sided infective endocarditis. The study demonstrated that percutaneous mechanical aspiration was associated with a high rate of clinical success in removing infected vegetations. However, there were also notable rates of in-hospital mortality and major adverse events, indicating the need for careful patient selection and further research to optimize this intervention.</p>
<h4>Article 4: Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40864006" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40864006</a></p>
<p><strong>Summary:</strong> This study examined the causes and outcomes of myocardial infarction in patients aged 65 years or younger within a defined community. The research revealed that a significant proportion of myocardial infarctions in this younger population were attributed to non-atherothrombotic causes, including myocardial infarction with non-obstructive coronary arteries, spontaneous coronary artery dissection, and myocarditis. These findings underscore the importance of considering a broad differential diagnosis when evaluating younger patients presenting with elevated troponin levels.</p>
<h4>Article 5: G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40772312" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40772312</a></p>
<p><strong>Summary:</strong> This study investigated the role of G protein-coupled receptor kinase 3 in diabetic heart injury, using both human and mouse models. Researchers discovered that G protein-coupled receptor kinase 3 exacerbates diabetic heart damage through direct phosphorylation of cannabinoid receptor 2. These findings suggest that inhibiting G protein-coupled receptor kinase 3 could be a potential therapeutic strategy for mitigating diabetic cardiomyopathy.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 23, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The B.P.-CARES Randomized Trial. This randomized trial evaluated intensive versus conventional intraoperative blood pressure management during major abdominal surgery and its impact on cardiovascular events. The study found no significant difference in the incidence of cardiovascular complications within 30 days between the intensive and conventional blood pressure management groups, suggesting that targeting higher intraoperative blood pressure does not reduce postoperative cardiovascular events after major abdominal surgery. These findings indicate that current conventional blood pressure management strategies are adequate for preventing cardiovascular complications in this setting.</p>
<p>Article number two. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. This study investigated the ability of a heart failure polygenic risk score to predict new-onset heart failure across a spectrum of cardiovascular risk. Results showed that individuals in the highest quintile of the polygenic risk score had a significantly increased risk of developing heart failure, even after adjusting for clinical risk factors. The polygenic risk score improved risk stratification for heart failure, suggesting it could be a useful tool for identifying individuals who would benefit from early preventative interventions.</p>
<p>Article number three. Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry. This multi-center registry assessed the early clinical outcomes and safety of percutaneous mechanical aspiration in patients with right-sided infective endocarditis. The study demonstrated that percutaneous mechanical aspiration was associated with a high rate of clinical success in removing infected vegetations. However, there were also notable rates of in-hospital mortality and major adverse events, indicating the need for careful patient selection and further research to optimize this intervention.</p>
<p>Article number four. Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County. This study examined the causes and outcomes of myocardial infarction in patients aged 65 years or younger within a defined community. The research revealed that a significant proportion of myocardial infarctions in this younger population were attributed to non-atherothrombotic causes, including myocardial infarction with non-obstructive coronary arteries, spontaneous coronary artery dissection, and myocarditis. These findings underscore the importance of considering a broad differential diagnosis when evaluating younger patients presenting with elevated troponin levels.</p>
<p>Article number five. G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice. This study investigated the role of G protein-coupled receptor kinase 3 in diabetic heart injury, using both human and mouse models. Researchers discovered that G protein-coupled receptor kinase 3 exacerbates diabetic heart damage through direct phosphorylation of cannabinoid receptor 2. These findings suggest that inhibiting G protein-coupled receptor kinase 3 could be a potential therapeutic strategy for mitigating diabetic cardiomyopathy. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>risk stratification, phosphorylation, Diabetic heart injury, polygenic risk score, Intraoperative hypotension, non-atherothrombotic causes, vegetation debulking, blood pressure management, percutaneous mechanical aspiration, randomized controlled trial, Right-sided infective endocarditis, clinical outcomes, younger patients, cardiovascular complications, cardiovascular risk, abdominal surgery, catheter-based intervention, spontaneous coronary artery dissection, Myocardial infarction, diabetic cardiomyopathy, cannabinoid receptor 2, myocardial infarction with non-obstructive coronary arteries, genetic risk, G protein-coupled receptor kinase 3, Heart failure.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/">Heart Failure Risk: The Power of Genetic Scores 09/23/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250923_025633.mp3" length="4093744" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like risk stratification and phosphorylation. Key takeaway: Heart Failure Risk: The Power of Genetic Scores.
Article Links:
Article 1: Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial. (Journal of the American College of Cardiology)
Article 2: A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. (Journal of the American College of Cardiology)
Article 3: Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry. (Journal of the American College of Cardiology)
Article 4: Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County. (Journal of the American College of Cardiology)
Article 5: G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/heart-failure-risk-the-power-of-genetic-scores-09-23-25/
 Featured Articles
Article 1: Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40962376
Summary: This randomized trial evaluated intensive versus conventional intraoperative blood pressure management during major abdominal surgery and its impact on cardiovascular events. The study found no significant difference in the incidence of cardiovascular complications within 30 days between the intensive and conventional blood pressure management groups, suggesting that targeting higher intraoperative blood pressure does not reduce postoperative cardiovascular events after major abdominal surgery. These findings indicate that current conventional blood pressure management strategies are adequate for preventing cardiovascular complications in this setting.
Article 2: A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40864011
Summary: This study investigated the ability of a heart failure polygenic risk score to predict new-onset heart failure across a spectrum of cardiovascular risk. Results showed that individuals in the highest quintile of the polygenic risk score had a significantly increased risk of developing heart failure, even after adjusting for clinical risk factors. The polygenic risk score improved risk stratification for heart failure, suggesting it could be a useful tool for identifying individuals who would benefit from early preventative interventions.
Article 3: Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40864007
Summary: This multi-center registry assessed the early clinical outcomes and safety of percutaneous mechanical aspiration in patients with right-sided infective endocarditis. The study demonstrated that percutaneous mechanical aspiration was associated with a high rate of clinical success in removing infected vegetations. However, there were also notable rates of in-hospital mortality and major adverse events, indicating the need for careful patient selection and further research to optimize this intervention.
Article 4: Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40864006
Summary: This study examined t]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 23, 2025. This episode summarizes 5 key cardiology studies on topics like risk stratification and phosphorylation. Key takeaway: Heart Failure Risk: The Power of Genetic Scores.
Article Links:
Article 1: Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial. (Journal of the American College of Cardiology)
Article 2: A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. (Journal of the American College of Cardiology)
Article 3: Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry. (Journal of the American College of Cardiology)
Article 4: Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County. (Journal of the American College of Cardiology)
Article 5: G Protein-Coupled Receptor Ki]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Contractile Reserve Predicts T.A.V.I. Success 09/22/25</title>
	<link>https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/</link>
	<pubDate>Mon, 22 Sep 2025 10:01:05 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Dysfunction and Genetic Testing. Key takeaway: Contractile Reserve Predicts T.A.V.I. Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40976358">Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40976357">The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40976356">Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970275">Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke.</a> (Stroke)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970272">Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project.</a> (Stroke)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/">https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976358" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976358</a></p>
<p><strong>Summary:</strong> This prospective study of over six thousand individuals revealed that obesity and inactivity are the strongest risk factors for developing heart failure. The study used latent class analysis to identify multimorbidity patterns and found that clusters with obesity and inactivity were most strongly associated with incident heart failure, regardless of ejection fraction. These findings underscore the critical importance of lifestyle interventions targeting obesity and physical activity to reduce heart failure risk.</p>
<h4>Article 2: The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976357" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976357</a></p>
<p><strong>Summary:</strong> This multicenter registry study evaluated the prognostic value of contractile reserve, assessed by dobutamine stress echocardiography, in patients with left ventricular dysfunction undergoing transcatheter aortic valve implantation. The presence of contractile reserve was significantly associated with improved left ventricular ejection fraction recovery and better clinical outcomes post-transcatheter aortic valve implantation. These results suggest that dobutamine stress echocardiography can help select appropriate candidates for transcatheter aortic valve implantation among patients with severe left ventricular dysfunction.</p>
<h4>Article 3: Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976356</a></p>
<p><strong>Summary:</strong> This meta-regression analysis of ninety-seven articles investigated the influence of age and instrumental parameters on head-up tilt testing outcomes in patients with suspected vasovagal syncope. The analysis found that age and the use of isoproterenol potentiation significantly affected the positivity rate of head-up tilt testing. These findings highlight the importance of considering patient age and provocation protocols when interpreting head-up tilt testing results for syncope diagnosis.</p>
<h4>Article 4: Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970275</a></p>
<p><strong>Summary:</strong> This study examined subsequent pregnancies in women with a history of ischemic stroke during pregnancy or the puerperium. Results showed a significant risk of stroke recurrence in subsequent pregnancies, as well as increased risks of other complications. The study underscores the need for careful secondary prevention strategies and close monitoring during subsequent pregnancies in women with prior maternal ischemic stroke.</p>
<h4>Article 5: Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970272" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970272</a></p>
<p><strong>Summary:</strong> This retrospective observational cohort study assessed the value of systematic genetic analyses in young adults with cryptogenic stroke. The project aimed to estimate the frequency of genetic disorders in these patients. The study is ongoing, but preliminary data suggests that genetic testing may uncover rare causes of stroke in young individuals, potentially influencing treatment strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study. This prospective study of over six thousand individuals revealed that obesity and inactivity are the strongest risk factors for developing heart failure. The study used latent class analysis to identify multimorbidity patterns and found that clusters with obesity and inactivity were most strongly associated with incident heart failure, regardless of ejection fraction. These findings underscore the critical importance of lifestyle interventions targeting obesity and physical activity to reduce heart failure risk.</p>
<p>Article number two. The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI. This multicenter registry study evaluated the prognostic value of contractile reserve, assessed by dobutamine stress echocardiography, in patients with left ventricular dysfunction undergoing transcatheter aortic valve implantation. The presence of contractile reserve was significantly associated with improved left ventricular ejection fraction recovery and better clinical outcomes post-transcatheter aortic valve implantation. These results suggest that dobutamine stress echocardiography can help select appropriate candidates for transcatheter aortic valve implantation among patients with severe left ventricular dysfunction.</p>
<p>Article number three. Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling. This meta-regression analysis of ninety-seven articles investigated the influence of age and instrumental parameters on head-up tilt testing outcomes in patients with suspected vasovagal syncope. The analysis found that age and the use of isoproterenol potentiation significantly affected the positivity rate of head-up tilt testing. These findings highlight the importance of considering patient age and provocation protocols when interpreting head-up tilt testing results for syncope diagnosis.</p>
<p>Article number four. Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke. This study examined subsequent pregnancies in women with a history of ischemic stroke during pregnancy or the puerperium. Results showed a significant risk of stroke recurrence in subsequent pregnancies, as well as increased risks of other complications. The study underscores the need for careful secondary prevention strategies and close monitoring during subsequent pregnancies in women with prior maternal ischemic stroke.</p>
<p>Article number five. Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The E.S.-EASY project. This retrospective observational cohort study assessed the value of systematic genetic analyses in young adults with cryptogenic stroke. The project aimed to estimate the frequency of genetic disorders in these patients. The study is ongoing, but preliminary data suggests that genetic testing may uncover rare causes of stroke in young individuals, potentially influencing treatment strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Left Ventricular Dysfunction, Genetic Testing, Dobutamine Stress Echocardiography, Cryptogenic Stroke, Secondary Prevention, Meta-Regression, Obesity, Inactivity, Vasovagal Syncope, Isoproterenol, Transcatheter Aortic Valve Implantation, Heart Failure, Stroke Etiology, Prevention, Stroke Recurrence, Young Adults, Pregnancy, Contractile Reserve, Aortic Stenosis, Head-Up Tilt Testing, Ischemic Stroke, Maternal Health, Multimorbidity, Genetic Disorders, Syncope Diagnosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/">Contractile Reserve Predicts T.A.V.I. Success 09/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Dysfunction and Genetic Testing. Key takeaway: Contractile Reserve Predicts T.A.V.I. Success.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>70</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Dysfunction and Genetic Testing. Key takeaway: Contractile Reserve Predicts T.A.V.I. Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40976358">Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study.</a> (International journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40976357">The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40976356">Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970275">Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke.</a> (Stroke)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970272">Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project.</a> (Stroke)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/">https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976358" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976358</a></p>
<p><strong>Summary:</strong> This prospective study of over six thousand individuals revealed that obesity and inactivity are the strongest risk factors for developing heart failure. The study used latent class analysis to identify multimorbidity patterns and found that clusters with obesity and inactivity were most strongly associated with incident heart failure, regardless of ejection fraction. These findings underscore the critical importance of lifestyle interventions targeting obesity and physical activity to reduce heart failure risk.</p>
<h4>Article 2: The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976357" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976357</a></p>
<p><strong>Summary:</strong> This multicenter registry study evaluated the prognostic value of contractile reserve, assessed by dobutamine stress echocardiography, in patients with left ventricular dysfunction undergoing transcatheter aortic valve implantation. The presence of contractile reserve was significantly associated with improved left ventricular ejection fraction recovery and better clinical outcomes post-transcatheter aortic valve implantation. These results suggest that dobutamine stress echocardiography can help select appropriate candidates for transcatheter aortic valve implantation among patients with severe left ventricular dysfunction.</p>
<h4>Article 3: Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976356" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976356</a></p>
<p><strong>Summary:</strong> This meta-regression analysis of ninety-seven articles investigated the influence of age and instrumental parameters on head-up tilt testing outcomes in patients with suspected vasovagal syncope. The analysis found that age and the use of isoproterenol potentiation significantly affected the positivity rate of head-up tilt testing. These findings highlight the importance of considering patient age and provocation protocols when interpreting head-up tilt testing results for syncope diagnosis.</p>
<h4>Article 4: Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970275</a></p>
<p><strong>Summary:</strong> This study examined subsequent pregnancies in women with a history of ischemic stroke during pregnancy or the puerperium. Results showed a significant risk of stroke recurrence in subsequent pregnancies, as well as increased risks of other complications. The study underscores the need for careful secondary prevention strategies and close monitoring during subsequent pregnancies in women with prior maternal ischemic stroke.</p>
<h4>Article 5: Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project.</h4>
<p><strong>Journal:</strong> Stroke</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970272" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970272</a></p>
<p><strong>Summary:</strong> This retrospective observational cohort study assessed the value of systematic genetic analyses in young adults with cryptogenic stroke. The project aimed to estimate the frequency of genetic disorders in these patients. The study is ongoing, but preliminary data suggests that genetic testing may uncover rare causes of stroke in young individuals, potentially influencing treatment strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study. This prospective study of over six thousand individuals revealed that obesity and inactivity are the strongest risk factors for developing heart failure. The study used latent class analysis to identify multimorbidity patterns and found that clusters with obesity and inactivity were most strongly associated with incident heart failure, regardless of ejection fraction. These findings underscore the critical importance of lifestyle interventions targeting obesity and physical activity to reduce heart failure risk.</p>
<p>Article number two. The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI. This multicenter registry study evaluated the prognostic value of contractile reserve, assessed by dobutamine stress echocardiography, in patients with left ventricular dysfunction undergoing transcatheter aortic valve implantation. The presence of contractile reserve was significantly associated with improved left ventricular ejection fraction recovery and better clinical outcomes post-transcatheter aortic valve implantation. These results suggest that dobutamine stress echocardiography can help select appropriate candidates for transcatheter aortic valve implantation among patients with severe left ventricular dysfunction.</p>
<p>Article number three. Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling. This meta-regression analysis of ninety-seven articles investigated the influence of age and instrumental parameters on head-up tilt testing outcomes in patients with suspected vasovagal syncope. The analysis found that age and the use of isoproterenol potentiation significantly affected the positivity rate of head-up tilt testing. These findings highlight the importance of considering patient age and provocation protocols when interpreting head-up tilt testing results for syncope diagnosis.</p>
<p>Article number four. Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke. This study examined subsequent pregnancies in women with a history of ischemic stroke during pregnancy or the puerperium. Results showed a significant risk of stroke recurrence in subsequent pregnancies, as well as increased risks of other complications. The study underscores the need for careful secondary prevention strategies and close monitoring during subsequent pregnancies in women with prior maternal ischemic stroke.</p>
<p>Article number five. Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The E.S.-EASY project. This retrospective observational cohort study assessed the value of systematic genetic analyses in young adults with cryptogenic stroke. The project aimed to estimate the frequency of genetic disorders in these patients. The study is ongoing, but preliminary data suggests that genetic testing may uncover rare causes of stroke in young individuals, potentially influencing treatment strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Left Ventricular Dysfunction, Genetic Testing, Dobutamine Stress Echocardiography, Cryptogenic Stroke, Secondary Prevention, Meta-Regression, Obesity, Inactivity, Vasovagal Syncope, Isoproterenol, Transcatheter Aortic Valve Implantation, Heart Failure, Stroke Etiology, Prevention, Stroke Recurrence, Young Adults, Pregnancy, Contractile Reserve, Aortic Stenosis, Head-Up Tilt Testing, Ischemic Stroke, Maternal Health, Multimorbidity, Genetic Disorders, Syncope Diagnosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/">Contractile Reserve Predicts T.A.V.I. Success 09/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250922_060013.mp3" length="3343507" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Dysfunction and Genetic Testing. Key takeaway: Contractile Reserve Predicts T.A.V.I. Success.
Article Links:
Article 1: Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study. (International journal of cardiology)
Article 2: The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI. (International journal of cardiology)
Article 3: Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling. (International journal of cardiology)
Article 4: Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke. (Stroke)
Article 5: Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project. (Stroke)
Full episode page: https://podcast.explainheart.com/podcast/contractile-reserve-predicts-t-a-v-i-success-09-22-25/
 Featured Articles
Article 1: Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40976358
Summary: This prospective study of over six thousand individuals revealed that obesity and inactivity are the strongest risk factors for developing heart failure. The study used latent class analysis to identify multimorbidity patterns and found that clusters with obesity and inactivity were most strongly associated with incident heart failure, regardless of ejection fraction. These findings underscore the critical importance of lifestyle interventions targeting obesity and physical activity to reduce heart failure risk.
Article 2: The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40976357
Summary: This multicenter registry study evaluated the prognostic value of contractile reserve, assessed by dobutamine stress echocardiography, in patients with left ventricular dysfunction undergoing transcatheter aortic valve implantation. The presence of contractile reserve was significantly associated with improved left ventricular ejection fraction recovery and better clinical outcomes post-transcatheter aortic valve implantation. These results suggest that dobutamine stress echocardiography can help select appropriate candidates for transcatheter aortic valve implantation among patients with severe left ventricular dysfunction.
Article 3: Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40976356
Summary: This meta-regression analysis of ninety-seven articles investigated the influence of age and instrumental parameters on head-up tilt testing outcomes in patients with suspected vasovagal syncope. The analysis found that age and the use of isoproterenol potentiation significantly affected the positivity rate of head-up tilt testing. These findings highlight the importance of considering patient age and provocation protocols when interpreting head-up tilt testing results for syncope diagnosis.
Article 4: Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke.
Journal: Stroke
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970275
Summary: This study examined subsequent pregnancies in women with a history of ischemic stroke during pregnancy or the puerperium. Results showed a significant risk of stroke recurrence in subsequent pregnancies, as well as increased risks of other complications. The study underscores the need for careful secondary prevention strategies and close monitoring during su]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like Left Ventricular Dysfunction and Genetic Testing. Key takeaway: Contractile Reserve Predicts T.A.V.I. Success.
Article Links:
Article 1: Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study. (International journal of cardiology)
Article 2: The impact of contractile reserve on clinical outcomes in patients with left ventricular dysfunction undergoing TAVI. (International journal of cardiology)
Article 3: Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling. (International journal of cardiology)
Article 4: Stroke Recurrence and Pregnancy Outcomes in the Subsequent Pregnancies After Maternal Ischemic Stroke. (Stroke)
Article 5: Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project. (Stroke)
Full episode page: https://po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>C.M.R. Improves I.C.D. Decisions in Sarcoidosis 09/22/25</title>
	<link>https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/</link>
	<pubDate>Mon, 22 Sep 2025 06:57:20 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular tachycardia and atrial fibrillation. Key takeaway: C.M.R. Improves I.C.D. Decisions in Sarcoidosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40641372">Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40400457">Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40976542">Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40976541">Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40976391">Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/">https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40641372" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40641372</a></p>
<p><strong>Summary:</strong> This Danish registry study assessed the 10-year risk of first-time infective endocarditis following mitral valve replacement or repair compared to patients at moderate risk. Results showed that mitral valve replacement carried a significantly higher risk of infective endocarditis than mitral valve repair over the long term. This data underscores the importance of considering infective endocarditis risk when choosing between mitral valve replacement and repair.</p>
<h4>Article 2: Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40400457" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40400457</a></p>
<p><strong>Summary:</strong> societal recommendations for implantable cardioverter-defibrillator placement. This study compared cardiovascular magnetic resonance imaging phenotyping to societal guidelines for predicting ventricular arrhythmias in patients with suspected cardiac sarcoidosis, aiming to improve implantable cardioverter defibrillator placement. The findings suggest that cardiovascular magnetic resonance imaging phenotyping may offer superior accuracy in predicting long-term ventricular arrhythmic events compared to guideline-based recommendations. This may lead to more informed decisions regarding implantable cardioverter defibrillator implantation in this complex patient population.</p>
<h4>Article 3: Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976542</a></p>
<p><strong>Summary:</strong> This sub-analysis of the COMPARE-CRYO study examined how different endpoint definitions impact the assessment of atrial fibrillation ablation success, utilizing continuous rhythm monitoring data from implantable cardiac monitors. The study demonstrated that varying the endpoint definitions based on atrial fibrillation burden, duration, or episode frequency significantly alters the reported success rates post ablation. These findings highlight the importance of standardized endpoint definitions for atrial fibrillation ablation studies and their impact on healthcare utilization.</p>
<h4>Article 4: Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976541</a></p>
<p><strong>Summary:</strong> This study provides a head-to-head comparison of two post-processing platforms, ADAS 3D L.V. and inHEART, for ventricular tachycardia substrate mapping using cardiac computed tomography and late-gadolinium enhanced cardiac magnetic resonance imaging in patients undergoing ventricular tachycardia ablation. The research compared substrate models derived from both modalities using both platforms. The study aims to optimize ventricular tachycardia ablation guidance using cardiac imaging.</p>
<h4>Article 5: Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976391" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976391</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms and clinical significance of functional mitral regurgitation in patients with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. The study found that functional mitral regurgitation has a significant impact on long-term outcomes in both heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. Identifying the predominant mechanisms of functional mitral regurgitation in each group is crucial for tailored management strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study. This Danish registry study assessed the 10-year risk of first-time infective endocarditis following mitral valve replacement or repair compared to patients at moderate risk. Results showed that mitral valve replacement carried a significantly higher risk of infective endocarditis than mitral valve repair over the long term. This data underscores the importance of considering infective endocarditis risk when choosing between mitral valve replacement and repair.</p>
<p>Article number two. Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement. This study compared cardiovascular magnetic resonance imaging phenotyping to societal guidelines for predicting ventricular arrhythmias in patients with suspected cardiac sarcoidosis, aiming to improve implantable cardioverter defibrillator placement. The findings suggest that cardiovascular magnetic resonance imaging phenotyping may offer superior accuracy in predicting long-term ventricular arrhythmic events compared to guideline-based recommendations. This may lead to more informed decisions regarding implantable cardioverter defibrillator implantation in this complex patient population.</p>
<p>Article number three. Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring. This sub-analysis of the COMPARE-CRYO study examined how different endpoint definitions impact the assessment of atrial fibrillation ablation success, utilizing continuous rhythm monitoring data from implantable cardiac monitors. The study demonstrated that varying the endpoint definitions based on atrial fibrillation burden, duration, or episode frequency significantly alters the reported success rates post ablation. These findings highlight the importance of standardized endpoint definitions for atrial fibrillation ablation studies and their impact on healthcare utilization.</p>
<p>Article number four. Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms. This study provides a head-to-head comparison of two post-processing platforms, ADAS 3D L.V. and inHEART, for ventricular tachycardia substrate mapping using cardiac computed tomography and late-gadolinium enhanced cardiac magnetic resonance imaging in patients undergoing ventricular tachycardia ablation. The research compared substrate models derived from both modalities using both platforms. The study aims to optimize ventricular tachycardia ablation guidance using cardiac imaging.</p>
<p>Article number five. Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction. This study investigated the mechanisms and clinical significance of functional mitral regurgitation in patients with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. The study found that functional mitral regurgitation has a significant impact on long-term outcomes in both heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. Identifying the predominant mechanisms of functional mitral regurgitation in each group is crucial for tailored management strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ventricular tachycardia, atrial fibrillation, functional mitral regurgitation, arrhythmia burden, implantable cardioverter defibrillator, implantable cardiac monitor, substrate mapping, ablation, Heart Failure with Preserved Ejection Fraction, cardiac magnetic resonance imaging, endpoint definition, heart failure with mildly reduced ejection fraction, cardiac computed tomography, ablation guidance, cardiovascular magnetic resonance imaging, cardiac sarcoidosis, prognosis, mechanisms, mitral valve, long-term risk, risk prediction, infective endocarditis, valve repair, valve replacement, ventricular arrhythmia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/">C.M.R. Improves I.C.D. Decisions in Sarcoidosis 09/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular tachycardia and atrial fibrillation. Key takeaway: C.M.R. Improves I.C.D. Decisions in Sarcoidosis.
Article Links:
Arti]]></itunes:subtitle>
	<itunes:episode>69</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular tachycardia and atrial fibrillation. Key takeaway: C.M.R. Improves I.C.D. Decisions in Sarcoidosis.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40641372">Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40400457">Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40976542">Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring.</a> (Heart rhythm)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40976541">Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms.</a> (Heart rhythm)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40976391">Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/">https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40641372" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40641372</a></p>
<p><strong>Summary:</strong> This Danish registry study assessed the 10-year risk of first-time infective endocarditis following mitral valve replacement or repair compared to patients at moderate risk. Results showed that mitral valve replacement carried a significantly higher risk of infective endocarditis than mitral valve repair over the long term. This data underscores the importance of considering infective endocarditis risk when choosing between mitral valve replacement and repair.</p>
<h4>Article 2: Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40400457" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40400457</a></p>
<p><strong>Summary:</strong> societal recommendations for implantable cardioverter-defibrillator placement. This study compared cardiovascular magnetic resonance imaging phenotyping to societal guidelines for predicting ventricular arrhythmias in patients with suspected cardiac sarcoidosis, aiming to improve implantable cardioverter defibrillator placement. The findings suggest that cardiovascular magnetic resonance imaging phenotyping may offer superior accuracy in predicting long-term ventricular arrhythmic events compared to guideline-based recommendations. This may lead to more informed decisions regarding implantable cardioverter defibrillator implantation in this complex patient population.</p>
<h4>Article 3: Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976542</a></p>
<p><strong>Summary:</strong> This sub-analysis of the COMPARE-CRYO study examined how different endpoint definitions impact the assessment of atrial fibrillation ablation success, utilizing continuous rhythm monitoring data from implantable cardiac monitors. The study demonstrated that varying the endpoint definitions based on atrial fibrillation burden, duration, or episode frequency significantly alters the reported success rates post ablation. These findings highlight the importance of standardized endpoint definitions for atrial fibrillation ablation studies and their impact on healthcare utilization.</p>
<h4>Article 4: Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976541</a></p>
<p><strong>Summary:</strong> This study provides a head-to-head comparison of two post-processing platforms, ADAS 3D L.V. and inHEART, for ventricular tachycardia substrate mapping using cardiac computed tomography and late-gadolinium enhanced cardiac magnetic resonance imaging in patients undergoing ventricular tachycardia ablation. The research compared substrate models derived from both modalities using both platforms. The study aims to optimize ventricular tachycardia ablation guidance using cardiac imaging.</p>
<h4>Article 5: Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40976391" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40976391</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms and clinical significance of functional mitral regurgitation in patients with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. The study found that functional mitral regurgitation has a significant impact on long-term outcomes in both heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. Identifying the predominant mechanisms of functional mitral regurgitation in each group is crucial for tailored management strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study. This Danish registry study assessed the 10-year risk of first-time infective endocarditis following mitral valve replacement or repair compared to patients at moderate risk. Results showed that mitral valve replacement carried a significantly higher risk of infective endocarditis than mitral valve repair over the long term. This data underscores the importance of considering infective endocarditis risk when choosing between mitral valve replacement and repair.</p>
<p>Article number two. Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement. This study compared cardiovascular magnetic resonance imaging phenotyping to societal guidelines for predicting ventricular arrhythmias in patients with suspected cardiac sarcoidosis, aiming to improve implantable cardioverter defibrillator placement. The findings suggest that cardiovascular magnetic resonance imaging phenotyping may offer superior accuracy in predicting long-term ventricular arrhythmic events compared to guideline-based recommendations. This may lead to more informed decisions regarding implantable cardioverter defibrillator implantation in this complex patient population.</p>
<p>Article number three. Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring. This sub-analysis of the COMPARE-CRYO study examined how different endpoint definitions impact the assessment of atrial fibrillation ablation success, utilizing continuous rhythm monitoring data from implantable cardiac monitors. The study demonstrated that varying the endpoint definitions based on atrial fibrillation burden, duration, or episode frequency significantly alters the reported success rates post ablation. These findings highlight the importance of standardized endpoint definitions for atrial fibrillation ablation studies and their impact on healthcare utilization.</p>
<p>Article number four. Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms. This study provides a head-to-head comparison of two post-processing platforms, ADAS 3D L.V. and inHEART, for ventricular tachycardia substrate mapping using cardiac computed tomography and late-gadolinium enhanced cardiac magnetic resonance imaging in patients undergoing ventricular tachycardia ablation. The research compared substrate models derived from both modalities using both platforms. The study aims to optimize ventricular tachycardia ablation guidance using cardiac imaging.</p>
<p>Article number five. Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction. This study investigated the mechanisms and clinical significance of functional mitral regurgitation in patients with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. The study found that functional mitral regurgitation has a significant impact on long-term outcomes in both heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. Identifying the predominant mechanisms of functional mitral regurgitation in each group is crucial for tailored management strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>ventricular tachycardia, atrial fibrillation, functional mitral regurgitation, arrhythmia burden, implantable cardioverter defibrillator, implantable cardiac monitor, substrate mapping, ablation, Heart Failure with Preserved Ejection Fraction, cardiac magnetic resonance imaging, endpoint definition, heart failure with mildly reduced ejection fraction, cardiac computed tomography, ablation guidance, cardiovascular magnetic resonance imaging, cardiac sarcoidosis, prognosis, mechanisms, mitral valve, long-term risk, risk prediction, infective endocarditis, valve repair, valve replacement, ventricular arrhythmia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/">C.M.R. Improves I.C.D. Decisions in Sarcoidosis 09/22/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250922_025621.mp3" length="4064069" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular tachycardia and atrial fibrillation. Key takeaway: C.M.R. Improves I.C.D. Decisions in Sarcoidosis.
Article Links:
Article 1: Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study. (European heart journal)
Article 2: Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement. (European heart journal)
Article 3: Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring. (Heart rhythm)
Article 4: Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: Head-to-head Comparison of Two Clinically Available Post-processing Platforms. (Heart rhythm)
Article 5: Outcome of Functional Mitral Regurgitation Associated with Heart Failure with Mildly Reduced or Preserved Ejection Fraction. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/c-m-r-improves-i-c-d-decisions-in-sarcoidosis-09-22-25/
 Featured Articles
Article 1: Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40641372
Summary: This Danish registry study assessed the 10-year risk of first-time infective endocarditis following mitral valve replacement or repair compared to patients at moderate risk. Results showed that mitral valve replacement carried a significantly higher risk of infective endocarditis than mitral valve repair over the long term. This data underscores the importance of considering infective endocarditis risk when choosing between mitral valve replacement and repair.
Article 2: Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40400457
Summary: societal recommendations for implantable cardioverter-defibrillator placement. This study compared cardiovascular magnetic resonance imaging phenotyping to societal guidelines for predicting ventricular arrhythmias in patients with suspected cardiac sarcoidosis, aiming to improve implantable cardioverter defibrillator placement. The findings suggest that cardiovascular magnetic resonance imaging phenotyping may offer superior accuracy in predicting long-term ventricular arrhythmic events compared to guideline-based recommendations. This may lead to more informed decisions regarding implantable cardioverter defibrillator implantation in this complex patient population.
Article 3: Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40976542
Summary: This sub-analysis of the COMPARE-CRYO study examined how different endpoint definitions impact the assessment of atrial fibrillation ablation success, utilizing continuous rhythm monitoring data from implantable cardiac monitors. The study demonstrated that varying the endpoint definitions based on atrial fibrillation burden, duration, or episode frequency significantly alters the reported success rates post ablation. These findings highlight the importance of standardized endpoint definitions for atrial fibrillation ablation studies and their impact on healthcare utilization.
Article 4: Ventri]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 22, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular tachycardia and atrial fibrillation. Key takeaway: C.M.R. Improves I.C.D. Decisions in Sarcoidosis.
Article Links:
Article 1: Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study. (European heart journal)
Article 2: Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement. (European heart journal)
Article 3: Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation &#8211; insights from the COMPARE-CRYO study using continuous rhythm monitoring. (Heart rhythm)
Article 4: Ventricular Tachycardia Substrate Mapping with Cardiac Computed Tomography and Cardiac Magnetic Resonanc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Race Affects Outcomes After C.A.B.G. 09/21/25</title>
	<link>https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/</link>
	<pubDate>Mon, 22 Sep 2025 01:26:23 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and hypertension screening. Key takeaway: Race Affects Outcomes After C.A.B.G..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40970526">Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970524">Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970522">Stroke Caregiver Needs in a Population-Based Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970520">Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970518">Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/">https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970526" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970526</a></p>
<p><strong>Summary:</strong> Unattended automated office blood pressure measurement effectively screens for hypertension in both people with and without H.I.V., using twenty-four hour ambulatory blood pressure monitoring as the reference standard. The study highlights the utility of automated office blood pressure as a practical tool for hypertension detection in diverse populations, including those with H.I.V.. This method offers a standardized approach to improve hypertension screening in clinical settings.</p>
<h4>Article 2: Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970524</a></p>
<p><strong>Summary:</strong> This retrospective study of patients undergoing coronary artery bypass grafting showed that non-white race or ethnicity was associated with a higher risk of major adverse cardiovascular events at one year and up to twelve years post-surgery. However, sex was not independently associated with increased major adverse cardiovascular events after coronary artery bypass grafting. These findings underscore the importance of addressing racial and ethnic disparities in long-term cardiovascular outcomes following coronary artery bypass grafting.</p>
<h4>Article 3: Stroke Caregiver Needs in a Population-Based Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970522</a></p>
<p><strong>Summary:</strong> This population-based study in Nueces County, Texas, examined the needs of stroke survivors and their caregivers, revealing significant unmet needs and limited awareness of available services. Informal caregivers play a crucial role in stroke recovery, yet they experience substantial burdens. Addressing these unmet needs through improved service awareness and access is essential for enhancing both caregiver well-being and patient outcomes.</p>
<h4>Article 4: Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970520" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970520</a></p>
<p><strong>Summary:</strong> This multicenter cohort study investigated the association between plasma phenylacetylglutamine levels and post-stroke cognitive impairment three months after ischemic stroke. Higher levels of plasma phenylacetylglutamine were found to be associated with increased risk of post-stroke cognitive impairment. This suggests that plasma phenylacetylglutamine could potentially serve as a biomarker or therapeutic target for cognitive decline following ischemic stroke.</p>
<h4>Article 5: Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970518</a></p>
<p><strong>Summary:</strong> This thirty-year longitudinal study found that greater cumulative physical activity from young adulthood to middle age is associated with favorable left ventricular structure and function. Sustained physical activity over three decades appears to promote healthy cardiac remodeling, similar to effects observed in elite athletes. These results underscore the importance of maintaining consistent physical activity throughout life for long-term cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without H.I.V.. Unattended automated office blood pressure measurement effectively screens for hypertension in both people with and without H.I.V., using twenty-four hour ambulatory blood pressure monitoring as the reference standard. The study highlights the utility of automated office blood pressure as a practical tool for hypertension detection in diverse populations, including those with H.I.V.. This method offers a standardized approach to improve hypertension screening in clinical settings.</p>
<p>Article number two. Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System. This retrospective study of patients undergoing coronary artery bypass grafting showed that non-white race or ethnicity was associated with a higher risk of major adverse cardiovascular events at one year and up to twelve years post-surgery. However, sex was not independently associated with increased major adverse cardiovascular events after coronary artery bypass grafting. These findings underscore the importance of addressing racial and ethnic disparities in long-term cardiovascular outcomes following coronary artery bypass grafting.</p>
<p>Article number three. Stroke Caregiver Needs in a Population-Based Study. This population-based study in Nueces County, Texas, examined the needs of stroke survivors and their caregivers, revealing significant unmet needs and limited awareness of available services. Informal caregivers play a crucial role in stroke recovery, yet they experience substantial burdens. Addressing these unmet needs through improved service awareness and access is essential for enhancing both caregiver well-being and patient outcomes.</p>
<p>Article number four. Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke. This multicenter cohort study investigated the association between plasma phenylacetylglutamine levels and post-stroke cognitive impairment three months after ischemic stroke. Higher levels of plasma phenylacetylglutamine were found to be associated with increased risk of post-stroke cognitive impairment. This suggests that plasma phenylacetylglutamine could potentially serve as a biomarker or therapeutic target for cognitive decline following ischemic stroke.</p>
<p>Article number five. Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study. This thirty-year longitudinal study found that greater cumulative physical activity from young adulthood to middle age is associated with favorable left ventricular structure and function. Sustained physical activity over three decades appears to promote healthy cardiac remodeling, similar to effects observed in elite athletes. These results underscore the importance of maintaining consistent physical activity throughout life for long-term cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>major adverse cardiovascular events, hypertension screening, automated office blood pressure, ischemic stroke, physical activity, longitudinal study, sex, coronary artery bypass grafting, post-stroke cognitive impairment, biomarker, cognition, unmet needs, race, ambulatory blood pressure monitoring, caregivers, H.I.V., left ventricular function, stroke, service utilization, cumulative physical activity, community health, phenylacetylglutamine, cardiac remodeling, ethnicity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/">Race Affects Outcomes After C.A.B.G. 09/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and hypertension screening. Key takeaway: Race Affects Outcomes After C.A.B.G..
Article Links:
]]></itunes:subtitle>
	<itunes:episode>68</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and hypertension screening. Key takeaway: Race Affects Outcomes After C.A.B.G..</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40970526">Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970524">Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970522">Stroke Caregiver Needs in a Population-Based Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970520">Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970518">Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/">https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970526" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970526</a></p>
<p><strong>Summary:</strong> Unattended automated office blood pressure measurement effectively screens for hypertension in both people with and without H.I.V., using twenty-four hour ambulatory blood pressure monitoring as the reference standard. The study highlights the utility of automated office blood pressure as a practical tool for hypertension detection in diverse populations, including those with H.I.V.. This method offers a standardized approach to improve hypertension screening in clinical settings.</p>
<h4>Article 2: Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970524" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970524</a></p>
<p><strong>Summary:</strong> This retrospective study of patients undergoing coronary artery bypass grafting showed that non-white race or ethnicity was associated with a higher risk of major adverse cardiovascular events at one year and up to twelve years post-surgery. However, sex was not independently associated with increased major adverse cardiovascular events after coronary artery bypass grafting. These findings underscore the importance of addressing racial and ethnic disparities in long-term cardiovascular outcomes following coronary artery bypass grafting.</p>
<h4>Article 3: Stroke Caregiver Needs in a Population-Based Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970522" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970522</a></p>
<p><strong>Summary:</strong> This population-based study in Nueces County, Texas, examined the needs of stroke survivors and their caregivers, revealing significant unmet needs and limited awareness of available services. Informal caregivers play a crucial role in stroke recovery, yet they experience substantial burdens. Addressing these unmet needs through improved service awareness and access is essential for enhancing both caregiver well-being and patient outcomes.</p>
<h4>Article 4: Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970520" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970520</a></p>
<p><strong>Summary:</strong> This multicenter cohort study investigated the association between plasma phenylacetylglutamine levels and post-stroke cognitive impairment three months after ischemic stroke. Higher levels of plasma phenylacetylglutamine were found to be associated with increased risk of post-stroke cognitive impairment. This suggests that plasma phenylacetylglutamine could potentially serve as a biomarker or therapeutic target for cognitive decline following ischemic stroke.</p>
<h4>Article 5: Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970518" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970518</a></p>
<p><strong>Summary:</strong> This thirty-year longitudinal study found that greater cumulative physical activity from young adulthood to middle age is associated with favorable left ventricular structure and function. Sustained physical activity over three decades appears to promote healthy cardiac remodeling, similar to effects observed in elite athletes. These results underscore the importance of maintaining consistent physical activity throughout life for long-term cardiovascular health.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without H.I.V.. Unattended automated office blood pressure measurement effectively screens for hypertension in both people with and without H.I.V., using twenty-four hour ambulatory blood pressure monitoring as the reference standard. The study highlights the utility of automated office blood pressure as a practical tool for hypertension detection in diverse populations, including those with H.I.V.. This method offers a standardized approach to improve hypertension screening in clinical settings.</p>
<p>Article number two. Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System. This retrospective study of patients undergoing coronary artery bypass grafting showed that non-white race or ethnicity was associated with a higher risk of major adverse cardiovascular events at one year and up to twelve years post-surgery. However, sex was not independently associated with increased major adverse cardiovascular events after coronary artery bypass grafting. These findings underscore the importance of addressing racial and ethnic disparities in long-term cardiovascular outcomes following coronary artery bypass grafting.</p>
<p>Article number three. Stroke Caregiver Needs in a Population-Based Study. This population-based study in Nueces County, Texas, examined the needs of stroke survivors and their caregivers, revealing significant unmet needs and limited awareness of available services. Informal caregivers play a crucial role in stroke recovery, yet they experience substantial burdens. Addressing these unmet needs through improved service awareness and access is essential for enhancing both caregiver well-being and patient outcomes.</p>
<p>Article number four. Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke. This multicenter cohort study investigated the association between plasma phenylacetylglutamine levels and post-stroke cognitive impairment three months after ischemic stroke. Higher levels of plasma phenylacetylglutamine were found to be associated with increased risk of post-stroke cognitive impairment. This suggests that plasma phenylacetylglutamine could potentially serve as a biomarker or therapeutic target for cognitive decline following ischemic stroke.</p>
<p>Article number five. Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study. This thirty-year longitudinal study found that greater cumulative physical activity from young adulthood to middle age is associated with favorable left ventricular structure and function. Sustained physical activity over three decades appears to promote healthy cardiac remodeling, similar to effects observed in elite athletes. These results underscore the importance of maintaining consistent physical activity throughout life for long-term cardiovascular health. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>major adverse cardiovascular events, hypertension screening, automated office blood pressure, ischemic stroke, physical activity, longitudinal study, sex, coronary artery bypass grafting, post-stroke cognitive impairment, biomarker, cognition, unmet needs, race, ambulatory blood pressure monitoring, caregivers, H.I.V., left ventricular function, stroke, service utilization, cumulative physical activity, community health, phenylacetylglutamine, cardiac remodeling, ethnicity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/">Race Affects Outcomes After C.A.B.G. 09/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250921_212524.mp3" length="3310906" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and hypertension screening. Key takeaway: Race Affects Outcomes After C.A.B.G..
Article Links:
Article 1: Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV. (Journal of the American Heart Association)
Article 2: Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System. (Journal of the American Heart Association)
Article 3: Stroke Caregiver Needs in a Population-Based Study. (Journal of the American Heart Association)
Article 4: Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke. (Journal of the American Heart Association)
Article 5: Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Left Ventricular Structure and Function: A 30-Year Longitudinal Study. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/race-affects-outcomes-after-c-a-b-g-09-21-25/
 Featured Articles
Article 1: Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970526
Summary: Unattended automated office blood pressure measurement effectively screens for hypertension in both people with and without H.I.V., using twenty-four hour ambulatory blood pressure monitoring as the reference standard. The study highlights the utility of automated office blood pressure as a practical tool for hypertension detection in diverse populations, including those with H.I.V.. This method offers a standardized approach to improve hypertension screening in clinical settings.
Article 2: Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970524
Summary: This retrospective study of patients undergoing coronary artery bypass grafting showed that non-white race or ethnicity was associated with a higher risk of major adverse cardiovascular events at one year and up to twelve years post-surgery. However, sex was not independently associated with increased major adverse cardiovascular events after coronary artery bypass grafting. These findings underscore the importance of addressing racial and ethnic disparities in long-term cardiovascular outcomes following coronary artery bypass grafting.
Article 3: Stroke Caregiver Needs in a Population-Based Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970522
Summary: This population-based study in Nueces County, Texas, examined the needs of stroke survivors and their caregivers, revealing significant unmet needs and limited awareness of available services. Informal caregivers play a crucial role in stroke recovery, yet they experience substantial burdens. Addressing these unmet needs through improved service awareness and access is essential for enhancing both caregiver well-being and patient outcomes.
Article 4: Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970520
Summary: This multicenter cohort study investigated the association between plasma phenylacetylglutamine levels and post-stroke cognitive impairment three months after ischemic stroke. Higher levels of plasma phenylacetylglutamine were found to be associated with increased risk of post-stroke cognitive impairment. This suggests that plasma phenylacetylglutamine ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like major adverse cardiovascular events and hypertension screening. Key takeaway: Race Affects Outcomes After C.A.B.G..
Article Links:
Article 1: Diagnostic Performance of Unattended Automated Office Blood Pressure Measurement for Hypertension Screening Among People With and Without HIV. (Journal of the American Heart Association)
Article 2: Influence of Sex and Race or Ethnicity on Major Adverse Cardiovascular Outcomes Following Coronary Artery Bypass Surgery in a Large Integrated Health Care System. (Journal of the American Heart Association)
Article 3: Stroke Caregiver Needs in a Population-Based Study. (Journal of the American Heart Association)
Article 4: Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke. (Journal of the American Heart Association)
Article 5: Long-Term Estimated Physical Activity Patterns From Youth to Middle Age and Lef]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Gestational Diabetes Ups Long-Term Heart Risk 09/21/25</title>
	<link>https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/</link>
	<pubDate>Sun, 21 Sep 2025 10:01:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and hypertensive disorders of pregnancy. Key takeaway: Gestational Diabetes Ups Long-Term Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40970534">Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970533">Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970531">Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970530">Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970527">Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/">https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970534</a></p>
<p><strong>Summary:</strong> This study found that arterial stiffness, measured by estimated pulse wave velocity, is significantly associated with both all-cause and cardiovascular death in cancer survivors. The research identified an optimal estimated pulse wave velocity threshold for risk stratification, suggesting that monitoring arterial stiffness could improve outcomes for this vulnerable population. These findings highlight the importance of cardiovascular risk management in cancer survivorship.</p>
<h4>Article 2: Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970533" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970533</a></p>
<p><strong>Summary:</strong> This population-based study in Alberta, Canada revealed disparities in access to vascular imaging, including computed tomography angiography, magnetic resonance angiography, and ultrasound, for stroke and transient ischemic attack patients. The research also uncovered differences in the utilization of carotid revascularization procedures based on various factors. These findings emphasize the need to address inequities in stroke care access to ensure equitable outcomes.</p>
<h4>Article 3: Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970531</a></p>
<p><strong>Summary:</strong> This randomized controlled trial demonstrated that participation-focused strategy training improves societal participation in community-dwelling stroke survivors with executive function impairments. The study enrolled stroke survivors with executive function impairments between January 2019 and March 2023. These results support the implementation of targeted rehabilitation strategies to enhance social reintegration after stroke.</p>
<h4>Article 4: Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970530" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970530</a></p>
<p><strong>Summary:</strong> This study of over 88,000 pregnant women in Japan investigated the association between blood heavy metal concentrations and hypertensive disorders of pregnancy. The research provides a unique perspective in a low-metal-exposure setting and contributes to the understanding of environmental risk factors for pregnancy complications. Further research is needed to clarify specific heavy metal impacts.</p>
<h4>Article 5: Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970527" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970527</a></p>
<p><strong>Summary:</strong> This nationwide cohort study of over 1.4 million women in France found a significant association between gestational diabetes and an increased risk of subsequent hospitalization for cardiovascular disease, including chronic hypertension. The study quantified the timing of gestational diabetes related cardiovascular disease onset, highlighting the long-term cardiovascular risks following gestational diabetes. These findings underscore the importance of cardiovascular risk management in women with a history of gestational diabetes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018. This study found that arterial stiffness, measured by estimated pulse wave velocity, is significantly associated with both all-cause and cardiovascular death in cancer survivors. The research identified an optimal estimated pulse wave velocity threshold for risk stratification, suggesting that monitoring arterial stiffness could improve outcomes for this vulnerable population. These findings highlight the importance of cardiovascular risk management in cancer survivorship.</p>
<p>Article number two. Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study. This population-based study in Alberta, Canada revealed disparities in access to vascular imaging, including computed tomography angiography, magnetic resonance angiography, and ultrasound, for stroke and transient ischemic attack patients. The research also uncovered differences in the utilization of carotid revascularization procedures based on various factors. These findings emphasize the need to address inequities in stroke care access to ensure equitable outcomes.</p>
<p>Article number three. Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial. This randomized controlled trial demonstrated that participation-focused strategy training improves societal participation in community-dwelling stroke survivors with executive function impairments. The study enrolled stroke survivors with executive function impairments between January 2019 and March 2023. These results support the implementation of targeted rehabilitation strategies to enhance social reintegration after stroke.</p>
<p>Article number four. Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study. This study of over 88,000 pregnant women in Japan investigated the association between blood heavy metal concentrations and hypertensive disorders of pregnancy. The research provides a unique perspective in a low-metal-exposure setting and contributes to the understanding of environmental risk factors for pregnancy complications. Further research is needed to clarify specific heavy metal impacts.</p>
<p>Article number five. Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study. This nationwide cohort study of over 1.4 million women in France found a significant association between gestational diabetes and an increased risk of subsequent hospitalization for cardiovascular disease, including chronic hypertension. The study quantified the timing of gestational diabetes related cardiovascular disease onset, highlighting the long-term cardiovascular risks following gestational diabetes. These findings underscore the importance of cardiovascular risk management in women with a history of gestational diabetes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hospitalization, hypertensive disorders of pregnancy, carotid revascularization, executive function, gestational hypertension, computed tomography angiography, gestational diabetes, preeclampsia, stroke, stroke rehabilitation, cardiovascular death, blood concentrations, cognitive impairment, randomized controlled trial, cohort study, transient ischemic attack, societal participation, cardiovascular disease, heavy metals, vascular imaging, cancer survivors, arterial stiffness, chronic hypertension, all-cause mortality, pulse wave velocity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/">Gestational Diabetes Ups Long-Term Heart Risk 09/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and hypertensive disorders of pregnancy. Key takeaway: Gestational Diabetes Ups Long-Term Heart Risk.
Article Links]]></itunes:subtitle>
	<itunes:episode>67</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and hypertensive disorders of pregnancy. Key takeaway: Gestational Diabetes Ups Long-Term Heart Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40970534">Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018.</a> (Journal of the American Heart Association)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970533">Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970531">Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970530">Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970527">Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/">https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970534</a></p>
<p><strong>Summary:</strong> This study found that arterial stiffness, measured by estimated pulse wave velocity, is significantly associated with both all-cause and cardiovascular death in cancer survivors. The research identified an optimal estimated pulse wave velocity threshold for risk stratification, suggesting that monitoring arterial stiffness could improve outcomes for this vulnerable population. These findings highlight the importance of cardiovascular risk management in cancer survivorship.</p>
<h4>Article 2: Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970533" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970533</a></p>
<p><strong>Summary:</strong> This population-based study in Alberta, Canada revealed disparities in access to vascular imaging, including computed tomography angiography, magnetic resonance angiography, and ultrasound, for stroke and transient ischemic attack patients. The research also uncovered differences in the utilization of carotid revascularization procedures based on various factors. These findings emphasize the need to address inequities in stroke care access to ensure equitable outcomes.</p>
<h4>Article 3: Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970531" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970531</a></p>
<p><strong>Summary:</strong> This randomized controlled trial demonstrated that participation-focused strategy training improves societal participation in community-dwelling stroke survivors with executive function impairments. The study enrolled stroke survivors with executive function impairments between January 2019 and March 2023. These results support the implementation of targeted rehabilitation strategies to enhance social reintegration after stroke.</p>
<h4>Article 4: Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970530" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970530</a></p>
<p><strong>Summary:</strong> This study of over 88,000 pregnant women in Japan investigated the association between blood heavy metal concentrations and hypertensive disorders of pregnancy. The research provides a unique perspective in a low-metal-exposure setting and contributes to the understanding of environmental risk factors for pregnancy complications. Further research is needed to clarify specific heavy metal impacts.</p>
<h4>Article 5: Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970527" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970527</a></p>
<p><strong>Summary:</strong> This nationwide cohort study of over 1.4 million women in France found a significant association between gestational diabetes and an increased risk of subsequent hospitalization for cardiovascular disease, including chronic hypertension. The study quantified the timing of gestational diabetes related cardiovascular disease onset, highlighting the long-term cardiovascular risks following gestational diabetes. These findings underscore the importance of cardiovascular risk management in women with a history of gestational diabetes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018. This study found that arterial stiffness, measured by estimated pulse wave velocity, is significantly associated with both all-cause and cardiovascular death in cancer survivors. The research identified an optimal estimated pulse wave velocity threshold for risk stratification, suggesting that monitoring arterial stiffness could improve outcomes for this vulnerable population. These findings highlight the importance of cardiovascular risk management in cancer survivorship.</p>
<p>Article number two. Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study. This population-based study in Alberta, Canada revealed disparities in access to vascular imaging, including computed tomography angiography, magnetic resonance angiography, and ultrasound, for stroke and transient ischemic attack patients. The research also uncovered differences in the utilization of carotid revascularization procedures based on various factors. These findings emphasize the need to address inequities in stroke care access to ensure equitable outcomes.</p>
<p>Article number three. Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial. This randomized controlled trial demonstrated that participation-focused strategy training improves societal participation in community-dwelling stroke survivors with executive function impairments. The study enrolled stroke survivors with executive function impairments between January 2019 and March 2023. These results support the implementation of targeted rehabilitation strategies to enhance social reintegration after stroke.</p>
<p>Article number four. Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study. This study of over 88,000 pregnant women in Japan investigated the association between blood heavy metal concentrations and hypertensive disorders of pregnancy. The research provides a unique perspective in a low-metal-exposure setting and contributes to the understanding of environmental risk factors for pregnancy complications. Further research is needed to clarify specific heavy metal impacts.</p>
<p>Article number five. Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study. This nationwide cohort study of over 1.4 million women in France found a significant association between gestational diabetes and an increased risk of subsequent hospitalization for cardiovascular disease, including chronic hypertension. The study quantified the timing of gestational diabetes related cardiovascular disease onset, highlighting the long-term cardiovascular risks following gestational diabetes. These findings underscore the importance of cardiovascular risk management in women with a history of gestational diabetes. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hospitalization, hypertensive disorders of pregnancy, carotid revascularization, executive function, gestational hypertension, computed tomography angiography, gestational diabetes, preeclampsia, stroke, stroke rehabilitation, cardiovascular death, blood concentrations, cognitive impairment, randomized controlled trial, cohort study, transient ischemic attack, societal participation, cardiovascular disease, heavy metals, vascular imaging, cancer survivors, arterial stiffness, chronic hypertension, all-cause mortality, pulse wave velocity.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/">Gestational Diabetes Ups Long-Term Heart Risk 09/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250921_060010.mp3" length="3634407" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and hypertensive disorders of pregnancy. Key takeaway: Gestational Diabetes Ups Long-Term Heart Risk.
Article Links:
Article 1: Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018. (Journal of the American Heart Association)
Article 2: Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study. (Journal of the American Heart Association)
Article 3: Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial. (Journal of the American Heart Association)
Article 4: Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study. (Journal of the American Heart Association)
Article 5: Gestational Diabetes and Incident Hospitalization for Cardiovascular Disease: A Nationwide French Cohort Study. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/gestational-diabetes-ups-long-term-heart-risk-09-21-25/
 Featured Articles
Article 1: Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970534
Summary: This study found that arterial stiffness, measured by estimated pulse wave velocity, is significantly associated with both all-cause and cardiovascular death in cancer survivors. The research identified an optimal estimated pulse wave velocity threshold for risk stratification, suggesting that monitoring arterial stiffness could improve outcomes for this vulnerable population. These findings highlight the importance of cardiovascular risk management in cancer survivorship.
Article 2: Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970533
Summary: This population-based study in Alberta, Canada revealed disparities in access to vascular imaging, including computed tomography angiography, magnetic resonance angiography, and ultrasound, for stroke and transient ischemic attack patients. The research also uncovered differences in the utilization of carotid revascularization procedures based on various factors. These findings emphasize the need to address inequities in stroke care access to ensure equitable outcomes.
Article 3: Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970531
Summary: This randomized controlled trial demonstrated that participation-focused strategy training improves societal participation in community-dwelling stroke survivors with executive function impairments. The study enrolled stroke survivors with executive function impairments between January 2019 and March 2023. These results support the implementation of targeted rehabilitation strategies to enhance social reintegration after stroke.
Article 4: Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970530
Summary: This study of over 88,000 pregnant women in Japan investigated the association between blood heavy metal concentrations and hypertensive disorders of pregnancy. The research provides a unique perspective in a low-metal-exposure setting ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and hypertensive disorders of pregnancy. Key takeaway: Gestational Diabetes Ups Long-Term Heart Risk.
Article Links:
Article 1: Arterial Stiffness in Cancer Survivors: The Prognostic Value of Estimated Pulse Wave Velocity in US Cancer Population From the National Health and Nutrition Examination Survey 2009 to 2018. (Journal of the American Heart Association)
Article 2: Disparities in Access to Vascular Stroke Imaging and Carotid Revascularization: A Population Study. (Journal of the American Heart Association)
Article 3: Enhancing Societal Participation for Stroke Survivors With Cognitive Impairments: A Randomized Controlled Trial. (Journal of the American Heart Association)
Article 4: Associations Between Blood Heavy Metal Concentrations and Hypertensive Disorders of Pregnancy in the Japan Environment and Children&#8217;s Study. (Journal of the A]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Pulsed Field Ablation Cuts AFib Procedure Time 09/21/25</title>
	<link>https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/</link>
	<pubDate>Sun, 21 Sep 2025 06:57:42 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like anticoagulation and longitudinal study. Key takeaway: Pulsed Field Ablation Cuts AFib Procedure Time.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40975149">Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970538">Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970537">Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970536">Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970535">New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/">https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40975149" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40975149</a></p>
<p><strong>Summary:</strong> This study compared zero-fluoroscopy radiofrequency ablation and pulsed-field ablation for paroxysmal atrial fibrillation. Pulsed-field ablation demonstrated significantly shorter procedure times and left atrial dwell times compared to radiofrequency ablation, indicating improved procedural efficiency with similar acute outcomes in experienced centers. These findings suggest pulsed-field ablation may offer advantages in workflow and resource utilization without compromising safety in experienced hands.</p>
<h4>Article 2: Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970538" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970538</a></p>
<p><strong>Summary:</strong> This study using National Health and Nutrition Examination Survey data from 2007 to 2018 found that coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease was associated with a significantly increased risk of all-cause mortality compared to either condition alone. The increased mortality risk highlights the importance of identifying and managing both conditions concurrently to improve patient outcomes. Specifically, the hazard ratio for all-cause mortality was significantly elevated when both conditions were present.</p>
<h4>Article 3: Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970537" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970537</a></p>
<p><strong>Summary:</strong> This longitudinal study demonstrated that an increasing C2HEST score, reflecting accumulation of risk factors like coronary artery disease, hypertension, and heart failure, is associated with a heightened risk of developing incident atrial fibrillation. A dynamic approach to risk assessment using the C2HEST score, rather than a one-time evaluation, may improve prediction of atrial fibrillation risk over time. Monitoring changes in C2HEST score components offers a practical way to identify individuals at increasing risk.</p>
<h4>Article 4: Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970536" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970536</a></p>
<p><strong>Summary:</strong> This study from the Multi-Ethnic Study of Atherosclerosis found specific immune cell subsets are associated with both the incidence and progression of coronary artery calcium. Increased CD8-positive T cells and decreased naive B cells were associated with a higher likelihood of coronary artery calcium development, while a higher proportion of regulatory T cells was associated with slower coronary artery calcium progression. These findings suggest that immune cell composition may play a role in the development and progression of subclinical atherosclerosis.</p>
<h4>Article 5: New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970535" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970535</a></p>
<p><strong>Summary:</strong> This single-center study showed a high rate of atrial fibrillation recurrence within 10 years among patients who experienced new-onset atrial fibrillation during ST-segment-elevation myocardial infarction. The recurrence of atrial fibrillation was independently associated with increased risks of stroke, systemic embolism, and all-cause mortality. These results underscore the importance of long-term monitoring and appropriate anticoagulation strategies in patients with ST-segment-elevation myocardial infarction who develop new-onset atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation. This study compared zero-fluoroscopy radiofrequency ablation and pulsed-field ablation for paroxysmal atrial fibrillation. Pulsed-field ablation demonstrated significantly shorter procedure times and left atrial dwell times compared to radiofrequency ablation, indicating improved procedural efficiency with similar acute outcomes in experienced centers. These findings suggest pulsed-field ablation may offer advantages in workflow and resource utilization without compromising safety in experienced hands.</p>
<p>Article number two. Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease. This study using National Health and Nutrition Examination Survey data from 2007 to 2018 found that coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease was associated with a significantly increased risk of all-cause mortality compared to either condition alone. The increased mortality risk highlights the importance of identifying and managing both conditions concurrently to improve patient outcomes. Specifically, the hazard ratio for all-cause mortality was significantly elevated when both conditions were present.</p>
<p>Article number three. Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study. This longitudinal study demonstrated that an increasing C2HEST score, reflecting accumulation of risk factors like coronary artery disease, hypertension, and heart failure, is associated with a heightened risk of developing incident atrial fibrillation. A dynamic approach to risk assessment using the C2HEST score, rather than a one-time evaluation, may improve prediction of atrial fibrillation risk over time. Monitoring changes in C2HEST score components offers a practical way to identify individuals at increasing risk.</p>
<p>Article number four. Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis. This study from the Multi-Ethnic Study of Atherosclerosis found specific immune cell subsets are associated with both the incidence and progression of coronary artery calcium. Increased CD8-positive T cells and decreased naive B cells were associated with a higher likelihood of coronary artery calcium development, while a higher proportion of regulatory T cells was associated with slower coronary artery calcium progression. These findings suggest that immune cell composition may play a role in the development and progression of subclinical atherosclerosis.</p>
<p>Article number five. New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up. This single-center study showed a high rate of atrial fibrillation recurrence within 10 years among patients who experienced new-onset atrial fibrillation during ST-segment-elevation myocardial infarction. The recurrence of atrial fibrillation was independently associated with increased risks of stroke, systemic embolism, and all-cause mortality. These results underscore the importance of long-term monitoring and appropriate anticoagulation strategies in patients with ST-segment-elevation myocardial infarction who develop new-onset atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>anticoagulation, longitudinal study, cardiovascular risk, C2HEST score, NHANES, metabolic dysfunction-associated steatotic liver disease, coronary artery disease, chronic kidney disease, CD8-positive T cells, immune cell subsets, coronary artery calcium, ST-segment-elevation myocardial infarction, risk prediction, stroke, procedure time, radiofrequency ablation, atrial fibrillation, atherosclerosis, zero-fluoroscopy, recurrence, mortality, pulsed-field ablation, regulatory T cells.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/">Pulsed Field Ablation Cuts AFib Procedure Time 09/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like anticoagulation and longitudinal study. Key takeaway: Pulsed Field Ablation Cuts AFib Procedure Time.
Article Links:
Article 1: Lea]]></itunes:subtitle>
	<itunes:episode>66</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like anticoagulation and longitudinal study. Key takeaway: Pulsed Field Ablation Cuts AFib Procedure Time.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40975149">Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation.</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970538">Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.</a> (Journal of the American Heart Association)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970537">Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970536">Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970535">New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/">https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40975149" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40975149</a></p>
<p><strong>Summary:</strong> This study compared zero-fluoroscopy radiofrequency ablation and pulsed-field ablation for paroxysmal atrial fibrillation. Pulsed-field ablation demonstrated significantly shorter procedure times and left atrial dwell times compared to radiofrequency ablation, indicating improved procedural efficiency with similar acute outcomes in experienced centers. These findings suggest pulsed-field ablation may offer advantages in workflow and resource utilization without compromising safety in experienced hands.</p>
<h4>Article 2: Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970538" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970538</a></p>
<p><strong>Summary:</strong> This study using National Health and Nutrition Examination Survey data from 2007 to 2018 found that coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease was associated with a significantly increased risk of all-cause mortality compared to either condition alone. The increased mortality risk highlights the importance of identifying and managing both conditions concurrently to improve patient outcomes. Specifically, the hazard ratio for all-cause mortality was significantly elevated when both conditions were present.</p>
<h4>Article 3: Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970537" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970537</a></p>
<p><strong>Summary:</strong> This longitudinal study demonstrated that an increasing C2HEST score, reflecting accumulation of risk factors like coronary artery disease, hypertension, and heart failure, is associated with a heightened risk of developing incident atrial fibrillation. A dynamic approach to risk assessment using the C2HEST score, rather than a one-time evaluation, may improve prediction of atrial fibrillation risk over time. Monitoring changes in C2HEST score components offers a practical way to identify individuals at increasing risk.</p>
<h4>Article 4: Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970536" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970536</a></p>
<p><strong>Summary:</strong> This study from the Multi-Ethnic Study of Atherosclerosis found specific immune cell subsets are associated with both the incidence and progression of coronary artery calcium. Increased CD8-positive T cells and decreased naive B cells were associated with a higher likelihood of coronary artery calcium development, while a higher proportion of regulatory T cells was associated with slower coronary artery calcium progression. These findings suggest that immune cell composition may play a role in the development and progression of subclinical atherosclerosis.</p>
<h4>Article 5: New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970535" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970535</a></p>
<p><strong>Summary:</strong> This single-center study showed a high rate of atrial fibrillation recurrence within 10 years among patients who experienced new-onset atrial fibrillation during ST-segment-elevation myocardial infarction. The recurrence of atrial fibrillation was independently associated with increased risks of stroke, systemic embolism, and all-cause mortality. These results underscore the importance of long-term monitoring and appropriate anticoagulation strategies in patients with ST-segment-elevation myocardial infarction who develop new-onset atrial fibrillation.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation. This study compared zero-fluoroscopy radiofrequency ablation and pulsed-field ablation for paroxysmal atrial fibrillation. Pulsed-field ablation demonstrated significantly shorter procedure times and left atrial dwell times compared to radiofrequency ablation, indicating improved procedural efficiency with similar acute outcomes in experienced centers. These findings suggest pulsed-field ablation may offer advantages in workflow and resource utilization without compromising safety in experienced hands.</p>
<p>Article number two. Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease. This study using National Health and Nutrition Examination Survey data from 2007 to 2018 found that coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease was associated with a significantly increased risk of all-cause mortality compared to either condition alone. The increased mortality risk highlights the importance of identifying and managing both conditions concurrently to improve patient outcomes. Specifically, the hazard ratio for all-cause mortality was significantly elevated when both conditions were present.</p>
<p>Article number three. Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study. This longitudinal study demonstrated that an increasing C2HEST score, reflecting accumulation of risk factors like coronary artery disease, hypertension, and heart failure, is associated with a heightened risk of developing incident atrial fibrillation. A dynamic approach to risk assessment using the C2HEST score, rather than a one-time evaluation, may improve prediction of atrial fibrillation risk over time. Monitoring changes in C2HEST score components offers a practical way to identify individuals at increasing risk.</p>
<p>Article number four. Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis. This study from the Multi-Ethnic Study of Atherosclerosis found specific immune cell subsets are associated with both the incidence and progression of coronary artery calcium. Increased CD8-positive T cells and decreased naive B cells were associated with a higher likelihood of coronary artery calcium development, while a higher proportion of regulatory T cells was associated with slower coronary artery calcium progression. These findings suggest that immune cell composition may play a role in the development and progression of subclinical atherosclerosis.</p>
<p>Article number five. New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up. This single-center study showed a high rate of atrial fibrillation recurrence within 10 years among patients who experienced new-onset atrial fibrillation during ST-segment-elevation myocardial infarction. The recurrence of atrial fibrillation was independently associated with increased risks of stroke, systemic embolism, and all-cause mortality. These results underscore the importance of long-term monitoring and appropriate anticoagulation strategies in patients with ST-segment-elevation myocardial infarction who develop new-onset atrial fibrillation. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>anticoagulation, longitudinal study, cardiovascular risk, C2HEST score, NHANES, metabolic dysfunction-associated steatotic liver disease, coronary artery disease, chronic kidney disease, CD8-positive T cells, immune cell subsets, coronary artery calcium, ST-segment-elevation myocardial infarction, risk prediction, stroke, procedure time, radiofrequency ablation, atrial fibrillation, atherosclerosis, zero-fluoroscopy, recurrence, mortality, pulsed-field ablation, regulatory T cells.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/">Pulsed Field Ablation Cuts AFib Procedure Time 09/21/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250921_025641.mp3" length="4259256" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like anticoagulation and longitudinal study. Key takeaway: Pulsed Field Ablation Cuts AFib Procedure Time.
Article Links:
Article 1: Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation. (Heart rhythm)
Article 2: Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease. (Journal of the American Heart Association)
Article 3: Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study. (Journal of the American Heart Association)
Article 4: Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis. (Journal of the American Heart Association)
Article 5: New-Onset Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction: Risk of Recurrence and Its Clinical Impact During 10 Years of Follow-Up. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/pulsed-field-ablation-cuts-afib-procedure-time-09-21-25/
 Featured Articles
Article 1: Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40975149
Summary: This study compared zero-fluoroscopy radiofrequency ablation and pulsed-field ablation for paroxysmal atrial fibrillation. Pulsed-field ablation demonstrated significantly shorter procedure times and left atrial dwell times compared to radiofrequency ablation, indicating improved procedural efficiency with similar acute outcomes in experienced centers. These findings suggest pulsed-field ablation may offer advantages in workflow and resource utilization without compromising safety in experienced hands.
Article 2: Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970538
Summary: This study using National Health and Nutrition Examination Survey data from 2007 to 2018 found that coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease was associated with a significantly increased risk of all-cause mortality compared to either condition alone. The increased mortality risk highlights the importance of identifying and managing both conditions concurrently to improve patient outcomes. Specifically, the hazard ratio for all-cause mortality was significantly elevated when both conditions were present.
Article 3: Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970537
Summary: This longitudinal study demonstrated that an increasing C2HEST score, reflecting accumulation of risk factors like coronary artery disease, hypertension, and heart failure, is associated with a heightened risk of developing incident atrial fibrillation. A dynamic approach to risk assessment using the C2HEST score, rather than a one-time evaluation, may improve prediction of atrial fibrillation risk over time. Monitoring changes in C2HEST score components offers a practical way to identify individuals at increasing risk.
Article 4: Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970536
Summary: This study from the Multi-Ethnic Study of Atherosclerosis found specific immune cell subsets are associated with both the incidence and progr]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 21, 2025. This episode summarizes 5 key cardiology studies on topics like anticoagulation and longitudinal study. Key takeaway: Pulsed Field Ablation Cuts AFib Procedure Time.
Article Links:
Article 1: Learning Curve and Procedural Efficiency of Zero-Fluoroscopy Pulsed-Field Ablation for Atrial Fibrillation. (Heart rhythm)
Article 2: Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease. (Journal of the American Heart Association)
Article 3: Dynamic Increase of the C2HEST Score in Relation to the Development of Incident Atrial Fibrillation: A Longitudinal Cohort Study. (Journal of the American Heart Association)
Article 4: Associations of Immune Cell Subsets With Coronary Artery Calcium Incidence and Progression in the Multi-Ethnic Study of Atherosclerosis. (Journal of the American Heart Association)
Article 5: New-Onset Atrial Fibrillation During ST-Segment-Elev]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Predicts Post-Infarct Arrhythmia Risk 09/20/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/</link>
	<pubDate>Sat, 20 Sep 2025 10:01:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like artificial intelligence and N-Formylmethionine. Key takeaway: AI Predicts Post-Infarct Arrhythmia Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40972895">Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction.</a> (The Canadian journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40959884">Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970545">Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970544">Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970541">Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/">https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972895</a></p>
<p><strong>Summary:</strong> This study developed artificial intelligence models to predict malignant ventricular arrhythmia and in-hospital death after acute myocardial infarction using data from 4,471 patients. The models demonstrated predictive performance, suggesting artificial intelligence could be a valuable tool for risk stratification in patients post myocardial infarction. Further prospective validation is needed to confirm these findings.</p>
<h4>Article 2: Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40959884" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40959884</a></p>
<p><strong>Summary:</strong> In a multiethnic cohort study, the plasma metabolite N-Formylmethionine was associated with higher blood pressure. This association suggests a potential link between N-Formylmethionine and vascular dysfunction across diverse ethnic groups. Further research is needed to explore N-Formylmethionine as a therapeutic target for hypertension.</p>
<h4>Article 3: Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970545" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970545</a></p>
<p><strong>Summary:</strong> This prospective single-center study investigated the role of neutrophil extracellular traps in delayed cerebral ischemia following subarachnoid hemorrhage. The study found an association between trajectories of neutrophil extracellular trap biomarkers and the occurrence of delayed cerebral ischemia. These findings suggest that neutrophil extracellular traps may be a therapeutic target for preventing delayed cerebral ischemia in patients with subarachnoid hemorrhage.</p>
<h4>Article 4: Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970544" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970544</a></p>
<p><strong>Summary:</strong> The EPISODE trial is a randomized controlled trial designed to investigate the effect of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors on calcific aortic valve stenosis. This trial aims to determine if Proprotein Convertase Subtilisin/Kexin Type 9 inhibition can prevent or delay the progression of calcific aortic valve stenosis, addressing the current lack of effective pharmacological interventions. The trial is ongoing.</p>
<h4>Article 5: Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970541</a></p>
<p><strong>Summary:</strong> This retrospective study evaluated the left ventricular mass-to-strain ratio as a marker of the clinical course in patients with hypertensive heart disease. The study found that the left ventricular mass-to-strain ratio can predict changes in left ventricular hypertrophy and prognosis in these patients. The findings suggest that the left ventricular mass-to-strain ratio is a valuable tool for risk stratification and monitoring disease progression in hypertensive heart disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction. This study developed artificial intelligence models to predict malignant ventricular arrhythmia and in-hospital death after acute myocardial infarction using data from 4,471 patients. The models demonstrated predictive performance, suggesting artificial intelligence could be a valuable tool for risk stratification in patients post myocardial infarction. Further prospective validation is needed to confirm these findings.</p>
<p>Article number two. Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction. In a multiethnic cohort study, the plasma metabolite N-Formylmethionine was associated with higher blood pressure. This association suggests a potential link between N-Formylmethionine and vascular dysfunction across diverse ethnic groups. Further research is needed to explore N-Formylmethionine as a therapeutic target for hypertension.</p>
<p>Article number three. Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage. This prospective single-center study investigated the role of neutrophil extracellular traps in delayed cerebral ischemia following subarachnoid hemorrhage. The study found an association between trajectories of neutrophil extracellular trap biomarkers and the occurrence of delayed cerebral ischemia. These findings suggest that neutrophil extracellular traps may be a therapeutic target for preventing delayed cerebral ischemia in patients with subarachnoid hemorrhage.</p>
<p>Article number four. Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Calcific Aortic Valve Stenosis. The EPISODE trial is a randomized controlled trial designed to investigate the effect of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors on calcific aortic valve stenosis. This trial aims to determine if Proprotein Convertase Subtilisin/Kexin Type 9 inhibition can prevent or delay the progression of calcific aortic valve stenosis, addressing the current lack of effective pharmacological interventions. The trial is ongoing.</p>
<p>Article number five. Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. This retrospective study evaluated the left ventricular mass-to-strain ratio as a marker of the clinical course in patients with hypertensive heart disease. The study found that the left ventricular mass-to-strain ratio can predict changes in left ventricular hypertrophy and prognosis in these patients. The findings suggest that the left ventricular mass-to-strain ratio is a valuable tool for risk stratification and monitoring disease progression in hypertensive heart disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>artificial intelligence, N-Formylmethionine, plasma metabolites, delayed cerebral ischemia, echocardiography, blood pressure, global longitudinal strain, left ventricular mass-to-strain ratio, neutrophil extracellular traps, lipoprotein (a), vascular dysfunction, hypertension, NET biomarkers, hypertensive heart disease, left ventricular hypertrophy, acute myocardial infarction, malignant ventricular arrhythmia, clinical trial, calcific aortic valve stenosis, Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors, sudden cardiac death, risk assessment, immunothrombosis, low-density lipoprotein cholesterol, subarachnoid hemorrhage.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/">AI Predicts Post-Infarct Arrhythmia Risk 09/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like artificial intelligence and N-Formylmethionine. Key takeaway: AI Predicts Post-Infarct Arrhythmia Risk.
Article Links:
Article 1: E]]></itunes:subtitle>
	<itunes:episode>65</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like artificial intelligence and N-Formylmethionine. Key takeaway: AI Predicts Post-Infarct Arrhythmia Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40972895">Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction.</a> (The Canadian journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40959884">Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40970545">Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage.</a> (Journal of the American Heart Association)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40970544">Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis.</a> (Journal of the American Heart Association)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40970541">Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease.</a> (Journal of the American Heart Association)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/">https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972895</a></p>
<p><strong>Summary:</strong> This study developed artificial intelligence models to predict malignant ventricular arrhythmia and in-hospital death after acute myocardial infarction using data from 4,471 patients. The models demonstrated predictive performance, suggesting artificial intelligence could be a valuable tool for risk stratification in patients post myocardial infarction. Further prospective validation is needed to confirm these findings.</p>
<h4>Article 2: Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40959884" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40959884</a></p>
<p><strong>Summary:</strong> In a multiethnic cohort study, the plasma metabolite N-Formylmethionine was associated with higher blood pressure. This association suggests a potential link between N-Formylmethionine and vascular dysfunction across diverse ethnic groups. Further research is needed to explore N-Formylmethionine as a therapeutic target for hypertension.</p>
<h4>Article 3: Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970545" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970545</a></p>
<p><strong>Summary:</strong> This prospective single-center study investigated the role of neutrophil extracellular traps in delayed cerebral ischemia following subarachnoid hemorrhage. The study found an association between trajectories of neutrophil extracellular trap biomarkers and the occurrence of delayed cerebral ischemia. These findings suggest that neutrophil extracellular traps may be a therapeutic target for preventing delayed cerebral ischemia in patients with subarachnoid hemorrhage.</p>
<h4>Article 4: Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970544" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970544</a></p>
<p><strong>Summary:</strong> The EPISODE trial is a randomized controlled trial designed to investigate the effect of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors on calcific aortic valve stenosis. This trial aims to determine if Proprotein Convertase Subtilisin/Kexin Type 9 inhibition can prevent or delay the progression of calcific aortic valve stenosis, addressing the current lack of effective pharmacological interventions. The trial is ongoing.</p>
<h4>Article 5: Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease.</h4>
<p><strong>Journal:</strong> Journal of the American Heart Association</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970541" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970541</a></p>
<p><strong>Summary:</strong> This retrospective study evaluated the left ventricular mass-to-strain ratio as a marker of the clinical course in patients with hypertensive heart disease. The study found that the left ventricular mass-to-strain ratio can predict changes in left ventricular hypertrophy and prognosis in these patients. The findings suggest that the left ventricular mass-to-strain ratio is a valuable tool for risk stratification and monitoring disease progression in hypertensive heart disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction. This study developed artificial intelligence models to predict malignant ventricular arrhythmia and in-hospital death after acute myocardial infarction using data from 4,471 patients. The models demonstrated predictive performance, suggesting artificial intelligence could be a valuable tool for risk stratification in patients post myocardial infarction. Further prospective validation is needed to confirm these findings.</p>
<p>Article number two. Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction. In a multiethnic cohort study, the plasma metabolite N-Formylmethionine was associated with higher blood pressure. This association suggests a potential link between N-Formylmethionine and vascular dysfunction across diverse ethnic groups. Further research is needed to explore N-Formylmethionine as a therapeutic target for hypertension.</p>
<p>Article number three. Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage. This prospective single-center study investigated the role of neutrophil extracellular traps in delayed cerebral ischemia following subarachnoid hemorrhage. The study found an association between trajectories of neutrophil extracellular trap biomarkers and the occurrence of delayed cerebral ischemia. These findings suggest that neutrophil extracellular traps may be a therapeutic target for preventing delayed cerebral ischemia in patients with subarachnoid hemorrhage.</p>
<p>Article number four. Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Calcific Aortic Valve Stenosis. The EPISODE trial is a randomized controlled trial designed to investigate the effect of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors on calcific aortic valve stenosis. This trial aims to determine if Proprotein Convertase Subtilisin/Kexin Type 9 inhibition can prevent or delay the progression of calcific aortic valve stenosis, addressing the current lack of effective pharmacological interventions. The trial is ongoing.</p>
<p>Article number five. Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. This retrospective study evaluated the left ventricular mass-to-strain ratio as a marker of the clinical course in patients with hypertensive heart disease. The study found that the left ventricular mass-to-strain ratio can predict changes in left ventricular hypertrophy and prognosis in these patients. The findings suggest that the left ventricular mass-to-strain ratio is a valuable tool for risk stratification and monitoring disease progression in hypertensive heart disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>artificial intelligence, N-Formylmethionine, plasma metabolites, delayed cerebral ischemia, echocardiography, blood pressure, global longitudinal strain, left ventricular mass-to-strain ratio, neutrophil extracellular traps, lipoprotein (a), vascular dysfunction, hypertension, NET biomarkers, hypertensive heart disease, left ventricular hypertrophy, acute myocardial infarction, malignant ventricular arrhythmia, clinical trial, calcific aortic valve stenosis, Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors, sudden cardiac death, risk assessment, immunothrombosis, low-density lipoprotein cholesterol, subarachnoid hemorrhage.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/">AI Predicts Post-Infarct Arrhythmia Risk 09/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250920_060013.mp3" length="3511527" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like artificial intelligence and N-Formylmethionine. Key takeaway: AI Predicts Post-Infarct Arrhythmia Risk.
Article Links:
Article 1: Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction. (The Canadian journal of cardiology)
Article 2: Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction. (Hypertension (Dallas, Tex. : 1979))
Article 3: Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage. (Journal of the American Heart Association)
Article 4: Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis. (Journal of the American Heart Association)
Article 5: Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/ai-predicts-post-infarct-arrhythmia-risk-09-20-25/
 Featured Articles
Article 1: Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40972895
Summary: This study developed artificial intelligence models to predict malignant ventricular arrhythmia and in-hospital death after acute myocardial infarction using data from 4,471 patients. The models demonstrated predictive performance, suggesting artificial intelligence could be a valuable tool for risk stratification in patients post myocardial infarction. Further prospective validation is needed to confirm these findings.
Article 2: Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40959884
Summary: In a multiethnic cohort study, the plasma metabolite N-Formylmethionine was associated with higher blood pressure. This association suggests a potential link between N-Formylmethionine and vascular dysfunction across diverse ethnic groups. Further research is needed to explore N-Formylmethionine as a therapeutic target for hypertension.
Article 3: Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970545
Summary: This prospective single-center study investigated the role of neutrophil extracellular traps in delayed cerebral ischemia following subarachnoid hemorrhage. The study found an association between trajectories of neutrophil extracellular trap biomarkers and the occurrence of delayed cerebral ischemia. These findings suggest that neutrophil extracellular traps may be a therapeutic target for preventing delayed cerebral ischemia in patients with subarachnoid hemorrhage.
Article 4: Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970544
Summary: The EPISODE trial is a randomized controlled trial designed to investigate the effect of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors on calcific aortic valve stenosis. This trial aims to determine if Proprotein Convertase Subtilisin/Kexin Type 9 inhibition can prevent or delay the progression of calcific aortic valve stenosis, addressing the current lack of effective pharmacological interventions. The trial is ongoing.
Article 5:]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like artificial intelligence and N-Formylmethionine. Key takeaway: AI Predicts Post-Infarct Arrhythmia Risk.
Article Links:
Article 1: Explainable Artificial Intelligence-Driven Risk Assessment for Malignant Ventricular Arrhythmia and Mortality in Acute Myocardial Infarction. (The Canadian journal of cardiology)
Article 2: Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction. (Hypertension (Dallas, Tex. : 1979))
Article 3: Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage. (Journal of the American Heart Association)
Article 4: Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis. (Journal of the American Heart Association)
Article 5: Left Ve]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TGF-beta Blockade Prevents Heart Scarring? 09/20/25</title>
	<link>https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/</link>
	<pubDate>Sat, 20 Sep 2025 06:57:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like non-ST segment elevation acute coronary syndrome and machine learning. Key takeaway: TGF-beta Blockade Prevents Heart Scarring?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40970279">Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970278">Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40973702">Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40972897">Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40972896">Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/">https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970279" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970279</a></p>
<p><strong>Summary:</strong> This study in mice revealed that fibroblast-specific disruption of transforming growth factor beta signaling leads to the conversion of fibroblasts to adipocytes, causing fatty infiltration in the infarcted heart. The findings suggest that blocking this pathway could potentially reduce adverse remodeling and arrhythmias post myocardial infarction. This provides a novel therapeutic target to prevent lipomatous metaplasia.</p>
<h4>Article 2: Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970278" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970278</a></p>
<p><strong>Summary:</strong> This research demonstrates that phosphodiesterase 10A contributes to pathological cardiomyocyte hypertrophy through A2AR-D2R dimerization and D2R-biased signaling. Inhibiting phosphodiesterase 10A may be a potential therapeutic target for preventing or reversing cardiac hypertrophy. The study clarifies specific signaling pathways modulated by phosphodiesterase 10A.</p>
<h4>Article 3: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40973702" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40973702</a></p>
<p><strong>Summary:</strong> The EAST trial, a randomized controlled trial, evaluated early antiplatelet therapy versus placebo after intravenous thrombolysis in patients with minor stroke. The study found early antiplatelet treatment was safe and effective compared to delayed antiplatelet treatment, with no significant increase in hemorrhagic transformation. These results support earlier initiation of antiplatelet agents in select stroke patients.</p>
<h4>Article 4: Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972897" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972897</a></p>
<p><strong>Summary:</strong> This study investigated the association between post procedural parenteral anticoagulation and clinical outcomes in patients with non-ST segment elevation acute coronary syndrome following percutaneous coronary intervention. The findings showed post procedural anticoagulation was not associated with improved outcomes. This reinforces current guideline recommendations against routine post percutaneous coronary intervention anticoagulation in this population.</p>
<h4>Article 5: Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972896</a></p>
<p><strong>Summary:</strong> This study used machine learning to analyze the relationship between depression and chest pain localization in predicting coronary artery disease. The results demonstrated that depression influences chest pain characteristics, affecting its predictive value for coronary artery disease. Understanding this relationship may improve cardiovascular risk assessment in patients with depression.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Fibroblast-Specific Loss of Transforming Growth Factor Beta Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart. This study in mice revealed that fibroblast-specific disruption of transforming growth factor beta signaling leads to the conversion of fibroblasts to adipocytes, causing fatty infiltration in the infarcted heart. The findings suggest that blocking this pathway could potentially reduce adverse remodeling and arrhythmias post myocardial infarction. This provides a novel therapeutic target to prevent lipomatous metaplasia.</p>
<p>Article number two. Role of A2AR-D2R Dimerization and D2R-Biased Signaling in Phosphodiesterase 10A-Mediated Cardiac Hypertrophy. This research demonstrates that phosphodiesterase 10A contributes to pathological cardiomyocyte hypertrophy through A2AR-D2R dimerization and D2R-biased signaling. Inhibiting phosphodiesterase 10A may be a potential therapeutic target for preventing or reversing cardiac hypertrophy. The study clarifies specific signaling pathways modulated by phosphodiesterase 10A.</p>
<p>Article number three. Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial. The EAST trial, a randomized controlled trial, evaluated early antiplatelet therapy versus placebo after intravenous thrombolysis in patients with minor stroke. The study found early antiplatelet treatment was safe and effective compared to delayed antiplatelet treatment, with no significant increase in hemorrhagic transformation. These results support earlier initiation of antiplatelet agents in select stroke patients.</p>
<p>Article number four. Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes. This study investigated the association between post procedural parenteral anticoagulation and clinical outcomes in patients with non-ST segment elevation acute coronary syndrome following percutaneous coronary intervention. The findings showed post procedural anticoagulation was not associated with improved outcomes. This reinforces current guideline recommendations against routine post percutaneous coronary intervention anticoagulation in this population.</p>
<p>Article number five. Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease. This study used machine learning to analyze the relationship between depression and chest pain localization in predicting coronary artery disease. The results demonstrated that depression influences chest pain characteristics, affecting its predictive value for coronary artery disease. Understanding this relationship may improve cardiovascular risk assessment in patients with depression. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>non-ST segment elevation acute coronary syndrome, machine learning, antiplatelet therapy, chest pain, transforming growth factor beta, dilated cardiomyopathy, clinical outcomes, parenteral anticoagulation, depression, coronary artery disease, phosphodiesterase 10A, thrombolysis, ischaemic stroke, haemorrhagic transformation, fibroblast, anticoagulation, stroke, myocardial infarction, adipocyte, A2AR-D2R dimerization, lipomatous metaplasia, percutaneous coronary intervention, cardiovascular risk, cardiomyocyte, cardiac hypertrophy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/">TGF-beta Blockade Prevents Heart Scarring? 09/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like non-ST segment elevation acute coronary syndrome and machine learning. Key takeaway: TGF-beta Blockade Prevents Heart Scarring?.
Ar]]></itunes:subtitle>
	<itunes:episode>64</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like non-ST segment elevation acute coronary syndrome and machine learning. Key takeaway: TGF-beta Blockade Prevents Heart Scarring?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40970279">Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40970278">Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40973702">Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40972897">Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40972896">Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/">https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970279" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970279</a></p>
<p><strong>Summary:</strong> This study in mice revealed that fibroblast-specific disruption of transforming growth factor beta signaling leads to the conversion of fibroblasts to adipocytes, causing fatty infiltration in the infarcted heart. The findings suggest that blocking this pathway could potentially reduce adverse remodeling and arrhythmias post myocardial infarction. This provides a novel therapeutic target to prevent lipomatous metaplasia.</p>
<h4>Article 2: Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40970278" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40970278</a></p>
<p><strong>Summary:</strong> This research demonstrates that phosphodiesterase 10A contributes to pathological cardiomyocyte hypertrophy through A2AR-D2R dimerization and D2R-biased signaling. Inhibiting phosphodiesterase 10A may be a potential therapeutic target for preventing or reversing cardiac hypertrophy. The study clarifies specific signaling pathways modulated by phosphodiesterase 10A.</p>
<h4>Article 3: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40973702" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40973702</a></p>
<p><strong>Summary:</strong> The EAST trial, a randomized controlled trial, evaluated early antiplatelet therapy versus placebo after intravenous thrombolysis in patients with minor stroke. The study found early antiplatelet treatment was safe and effective compared to delayed antiplatelet treatment, with no significant increase in hemorrhagic transformation. These results support earlier initiation of antiplatelet agents in select stroke patients.</p>
<h4>Article 4: Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972897" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972897</a></p>
<p><strong>Summary:</strong> This study investigated the association between post procedural parenteral anticoagulation and clinical outcomes in patients with non-ST segment elevation acute coronary syndrome following percutaneous coronary intervention. The findings showed post procedural anticoagulation was not associated with improved outcomes. This reinforces current guideline recommendations against routine post percutaneous coronary intervention anticoagulation in this population.</p>
<h4>Article 5: Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40972896" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40972896</a></p>
<p><strong>Summary:</strong> This study used machine learning to analyze the relationship between depression and chest pain localization in predicting coronary artery disease. The results demonstrated that depression influences chest pain characteristics, affecting its predictive value for coronary artery disease. Understanding this relationship may improve cardiovascular risk assessment in patients with depression.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Fibroblast-Specific Loss of Transforming Growth Factor Beta Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart. This study in mice revealed that fibroblast-specific disruption of transforming growth factor beta signaling leads to the conversion of fibroblasts to adipocytes, causing fatty infiltration in the infarcted heart. The findings suggest that blocking this pathway could potentially reduce adverse remodeling and arrhythmias post myocardial infarction. This provides a novel therapeutic target to prevent lipomatous metaplasia.</p>
<p>Article number two. Role of A2AR-D2R Dimerization and D2R-Biased Signaling in Phosphodiesterase 10A-Mediated Cardiac Hypertrophy. This research demonstrates that phosphodiesterase 10A contributes to pathological cardiomyocyte hypertrophy through A2AR-D2R dimerization and D2R-biased signaling. Inhibiting phosphodiesterase 10A may be a potential therapeutic target for preventing or reversing cardiac hypertrophy. The study clarifies specific signaling pathways modulated by phosphodiesterase 10A.</p>
<p>Article number three. Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial. The EAST trial, a randomized controlled trial, evaluated early antiplatelet therapy versus placebo after intravenous thrombolysis in patients with minor stroke. The study found early antiplatelet treatment was safe and effective compared to delayed antiplatelet treatment, with no significant increase in hemorrhagic transformation. These results support earlier initiation of antiplatelet agents in select stroke patients.</p>
<p>Article number four. Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes. This study investigated the association between post procedural parenteral anticoagulation and clinical outcomes in patients with non-ST segment elevation acute coronary syndrome following percutaneous coronary intervention. The findings showed post procedural anticoagulation was not associated with improved outcomes. This reinforces current guideline recommendations against routine post percutaneous coronary intervention anticoagulation in this population.</p>
<p>Article number five. Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease. This study used machine learning to analyze the relationship between depression and chest pain localization in predicting coronary artery disease. The results demonstrated that depression influences chest pain characteristics, affecting its predictive value for coronary artery disease. Understanding this relationship may improve cardiovascular risk assessment in patients with depression. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>non-ST segment elevation acute coronary syndrome, machine learning, antiplatelet therapy, chest pain, transforming growth factor beta, dilated cardiomyopathy, clinical outcomes, parenteral anticoagulation, depression, coronary artery disease, phosphodiesterase 10A, thrombolysis, ischaemic stroke, haemorrhagic transformation, fibroblast, anticoagulation, stroke, myocardial infarction, adipocyte, A2AR-D2R dimerization, lipomatous metaplasia, percutaneous coronary intervention, cardiovascular risk, cardiomyocyte, cardiac hypertrophy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/">TGF-beta Blockade Prevents Heart Scarring? 09/20/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250920_025645.mp3" length="3423337" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like non-ST segment elevation acute coronary syndrome and machine learning. Key takeaway: TGF-beta Blockade Prevents Heart Scarring?.
Article Links:
Article 1: Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart. (Circulation)
Article 2: Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy. (Circulation)
Article 3: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial. (European heart journal)
Article 4: Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes. (The Canadian journal of cardiology)
Article 5: Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/tgf-beta-blockade-prevents-heart-scarring-09-20-25/
 Featured Articles
Article 1: Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970279
Summary: This study in mice revealed that fibroblast-specific disruption of transforming growth factor beta signaling leads to the conversion of fibroblasts to adipocytes, causing fatty infiltration in the infarcted heart. The findings suggest that blocking this pathway could potentially reduce adverse remodeling and arrhythmias post myocardial infarction. This provides a novel therapeutic target to prevent lipomatous metaplasia.
Article 2: Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40970278
Summary: This research demonstrates that phosphodiesterase 10A contributes to pathological cardiomyocyte hypertrophy through A2AR-D2R dimerization and D2R-biased signaling. Inhibiting phosphodiesterase 10A may be a potential therapeutic target for preventing or reversing cardiac hypertrophy. The study clarifies specific signaling pathways modulated by phosphodiesterase 10A.
Article 3: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40973702
Summary: The EAST trial, a randomized controlled trial, evaluated early antiplatelet therapy versus placebo after intravenous thrombolysis in patients with minor stroke. The study found early antiplatelet treatment was safe and effective compared to delayed antiplatelet treatment, with no significant increase in hemorrhagic transformation. These results support earlier initiation of antiplatelet agents in select stroke patients.
Article 4: Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40972897
Summary: This study investigated the association between post procedural parenteral anticoagulation and clinical outcomes in patients with non-ST segment elevation acute coronary syndrome following percutaneous coronary intervention. The findings showed post procedural anticoagulation was not associated with improved outcomes. This reinforces current guideline recommendations against routine post percutaneous coronary intervention anticoagulation in this population.
Article 5: Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40972896
Summary: This study used machine learning to analyze the relationship between depression and chest pain localization in predicting coronary artery disease. The results demonstrate]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 20, 2025. This episode summarizes 5 key cardiology studies on topics like non-ST segment elevation acute coronary syndrome and machine learning. Key takeaway: TGF-beta Blockade Prevents Heart Scarring?.
Article Links:
Article 1: Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart. (Circulation)
Article 2: Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy. (Circulation)
Article 3: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial. (European heart journal)
Article 4: Postprocedural parenteral anticoagulation in patients with non-ST segment elevation acute coronary syndromes. (The Canadian journal of cardiology)
Article 5: Machine Learning Reveals How Depression Influences Chest Pain Localization and Its Predictive Value for Coronary Artery Disease. (The Canadian journal of cardiology)
Full episode page: https://podc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Inflammation Drives HFpEF Outcomes: The suPAR Story 09/19/25</title>
	<link>https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/</link>
	<pubDate>Fri, 19 Sep 2025 10:03:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like Mendelian randomization and DAPA-MI trial. Key takeaway: Inflammation Drives HFpEF Outcomes: The suPAR Story.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40963190">Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40958744">Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40958495">Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40959903">PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40959886">Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/">https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40963190" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40963190</a></p>
<p><strong>Summary:</strong> This analysis of the TOPCAT trial&#8217;s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.</p>
<h4>Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40958744" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40958744</a></p>
<p><strong>Summary:</strong> This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.</p>
<h4>Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40958495" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40958495</a></p>
<p><strong>Summary:</strong> Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.</p>
<h4>Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40959903" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40959903</a></p>
<p><strong>Summary:</strong> This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.</p>
<h4>Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40959886" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40959886</a></p>
<p><strong>Summary:</strong> Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Soluble urokinase plasminogen activator receptor and outcomes in Heart Failure with Preserved Ejection Fraction: A TOPCAT ancillary study. This analysis of the TOPCAT trial&#8217;s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.</p>
<p>Article number two. Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.</p>
<p>Article number three. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.</p>
<p>Article number four. PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.</p>
<p>Article number five. Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Mendelian randomization, DAPA-MI trial, hypertension, myeloperoxidase, blood pressure, cancer therapy-related cardiac dysfunction, biomarkers, cardiac inflammation, myocardial infarction, breast cancer, heart failure, left ventricular ejection fraction, pulmonary remodeling, Heart Failure with Preserved Ejection Fraction, mortality, cardiovascular mortality, soluble urokinase plasminogen activator receptor, dapagliflozin, cardiovascular death, prolyl hydroxylase domain protein 2, inflammation, CD8 positive T cells, TOPCAT trial, meta-analysis, cardiometabolic outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/">Inflammation Drives HFpEF Outcomes: The suPAR Story 09/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like Mendelian randomization and DAPA-MI trial. Key takeaway: Inflammation Drives HFpEF Outcomes: The suPAR Story.
Article Links:
Articl]]></itunes:subtitle>
	<itunes:episode>63</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like Mendelian randomization and DAPA-MI trial. Key takeaway: Inflammation Drives HFpEF Outcomes: The suPAR Story.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40963190">Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.</a> (ESC heart failure)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40958744">Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.</a> (ESC heart failure)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40958495">Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.</a> (ESC heart failure)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40959903">PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40959886">Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.</a> (Hypertension (Dallas, Tex. : 1979))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/">https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40963190" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40963190</a></p>
<p><strong>Summary:</strong> This analysis of the TOPCAT trial&#8217;s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.</p>
<h4>Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40958744" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40958744</a></p>
<p><strong>Summary:</strong> This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.</p>
<h4>Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.</h4>
<p><strong>Journal:</strong> ESC heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40958495" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40958495</a></p>
<p><strong>Summary:</strong> Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.</p>
<h4>Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40959903" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40959903</a></p>
<p><strong>Summary:</strong> This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.</p>
<h4>Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.</h4>
<p><strong>Journal:</strong> Hypertension (Dallas, Tex. : 1979)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40959886" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40959886</a></p>
<p><strong>Summary:</strong> Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Soluble urokinase plasminogen activator receptor and outcomes in Heart Failure with Preserved Ejection Fraction: A TOPCAT ancillary study. This analysis of the TOPCAT trial&#8217;s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.</p>
<p>Article number two. Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.</p>
<p>Article number three. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.</p>
<p>Article number four. PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl hydroxylase domain protein 2 exacerbated cardiac inflammation, heart failure, and pulmonary remodeling induced by transverse aortic constriction. The findings suggest that prolyl hydroxylase domain protein 2 in CD8 positive T cells plays a protective role against cardiac damage by modulating inflammatory responses. This highlights the potential of targeting prolyl hydroxylase domain protein 2 pathways in CD8 positive T cells as a therapeutic strategy for mitigating cardiac inflammation and heart failure.</p>
<p>Article number five. Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. Using Mendelian randomization analysis of over 125,000 participants in the Mexico City Prospective Study, this research investigated the lifelong effect of blood pressure on mortality. The study revealed that higher systolic blood pressure was causally associated with increased all-cause and cardiovascular mortality, supporting the importance of early and sustained blood pressure control for long-term health. These findings underscore the need for public health strategies aimed at preventing and managing hypertension to reduce mortality rates. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Mendelian randomization, DAPA-MI trial, hypertension, myeloperoxidase, blood pressure, cancer therapy-related cardiac dysfunction, biomarkers, cardiac inflammation, myocardial infarction, breast cancer, heart failure, left ventricular ejection fraction, pulmonary remodeling, Heart Failure with Preserved Ejection Fraction, mortality, cardiovascular mortality, soluble urokinase plasminogen activator receptor, dapagliflozin, cardiovascular death, prolyl hydroxylase domain protein 2, inflammation, CD8 positive T cells, TOPCAT trial, meta-analysis, cardiometabolic outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/">Inflammation Drives HFpEF Outcomes: The suPAR Story 09/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250919_060012.mp3" length="4561858" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like Mendelian randomization and DAPA-MI trial. Key takeaway: Inflammation Drives HFpEF Outcomes: The suPAR Story.
Article Links:
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study. (ESC heart failure)
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. (ESC heart failure)
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. (ESC heart failure)
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. (Hypertension (Dallas, Tex. : 1979))
Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/inflammation-drives-hfpef-outcomes-the-supar-story-09-19-25/
 Featured Articles
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40963190
Summary: This analysis of the TOPCAT trial&#8217;s North American cohort found that elevated levels of soluble urokinase plasminogen activator receptor, a marker of inflammation, were associated with increased risk of adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction. Specifically, higher soluble urokinase plasminogen activator receptor levels correlated with a greater risk of cardiovascular death and heart failure hospitalization, suggesting that inflammation, as reflected by soluble urokinase plasminogen activator receptor, plays a significant role in the progression of Heart Failure with Preserved Ejection Fraction. This highlights soluble urokinase plasminogen activator receptor as a potential therapeutic target and prognostic biomarker in this patient population.
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40958744
Summary: This meta-analysis of 12 studies investigated the diagnostic utility of several biomarkers for cancer therapy-related cardiac dysfunction in breast cancer patients. The study suggests myeloperoxidase may be a useful biomarker for early detection of cancer therapy-related cardiac dysfunction, while findings regarding growth differentiation factor-15, C-reactive protein, placental growth factor, and galectin-3 were inconclusive. Further research is warranted to validate these findings and explore the potential of myeloperoxidase-guided interventions.
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40958495
Summary: Analyzing data from the DAPA-MI trial, this study explored the impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction, stratified by baseline left ventricular ejection fraction. Dapagliflozin improved outcomes, regardless of ejection fraction, reducing the risk of death, hospitalization for heart failure, myocardial infarction, or atrial fibrillation in patients who had experienced myocardial infarction. This supports the use of dapagliflozin for a broad range of patients post myocardial infarction, irrespective of their baseline ejection fraction.
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling.
Journal: Hypertension (Dallas, Tex. : 1979)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40959903
Summary: This study, using a mouse model with prolyl hydroxylase domain protein 2 deletion in CD8 positive T cells, demonstrated that loss of prolyl]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like Mendelian randomization and DAPA-MI trial. Key takeaway: Inflammation Drives HFpEF Outcomes: The suPAR Story.
Article Links:
Article 1: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study. (ESC heart failure)
Article 2: Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction. (ESC heart failure)
Article 3: Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. (ESC heart failure)
Article 4: PHD2 Deletion in CD8+ T Cells Worsens TAC-Induced Cardiac Inflammation, Heart Failure, and Pulmonary Remodeling. (Hypertension (Dallas, Tex. : 1979))
Article 5: Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. (Hypertension (Dallas, Tex. : 1979))
Full episode page: https://podcast.explainheart.com/podcast/inf]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>New TAVR Thrombosis Risk Factors Identified 09/19/25</title>
	<link>https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/</link>
	<pubDate>Fri, 19 Sep 2025 06:58:25 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like sudden death and cancer. Key takeaway: New TAVR Thrombosis Risk Factors Identified.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40967263">Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40966168">Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40966167">Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death.</a> (Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40967484">Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40967483">A Primer on Bioprosthetic Mitral Valve Dysfunction.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/">https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40967263" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40967263</a></p>
<p><strong>Summary:</strong> This study of 508 patients found subclinical valve thrombosis, identified via hypo-attenuated leaflet thickening on computed tomography angiography, occurred after transcatheter aortic valve replacement in both bicuspid and tricuspid aortic valves. The study aimed to evaluate the incidence, predictors, and clinical impact of hypo-attenuated leaflet thickening in the two valve types, assessing implications for valve durability and hemodynamics. Further research is needed to determine optimal management strategies for patients with hypo-attenuated leaflet thickening following transcatheter aortic valve replacement.</p>
<h4>Article 2: Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40966168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40966168</a></p>
<p><strong>Summary:</strong> This retrospective study of 342 adult extracorporeal membrane oxygenation patients at a single center investigated survival outcomes and risk factors in cancer patients receiving extracorporeal membrane oxygenation for cardiopulmonary failure. The study aimed to reassess extracorporeal membrane oxygenation&#8217;s role in this population given advances in oncology, and to determine prognostic factors for survival. The results will need to be interpreted cautiously due to the retrospective, single-center design.</p>
<h4>Article 3: Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40966167" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40966167</a></p>
<p><strong>Summary:</strong> This study investigated the genetic basis of hypertrophic cardiomyopathy in a three-generation Chinese family with early-onset and sudden death, using high-throughput second-generation sequencing on the proband to identify novel double variants in the MYH7 and MYBPC3 genes. The study highlights the importance of comprehensive genetic testing beyond the proband to identify multiple pathogenic variants that may be missed by traditional Sanger sequencing in family members. Further studies with larger cohorts are required to confirm the pathogenicity of these novel variants and their association with early-onset and sudden death in hypertrophic cardiomyopathy.</p>
<h4>Article 4: Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40967484" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40967484</a></p>
<p><strong>Summary:</strong> This population-based, retrospective cohort study of Ontarians aged 40 years and older diagnosed with heart failure in an ambulatory setting from 2009 to 2019 evaluated time intervals between diagnosis and subsequent physician reassessment, as well as all-cause mortality and heart failure hospitalization or emergency department visits. The study aimed to determine if there are gaps in healthcare access and timely follow-up based on sex. Further analysis is needed to determine the specific factors contributing to these differences and to develop strategies to improve access to care for all patients with heart failure.</p>
<h4>Article 5: A Primer on Bioprosthetic Mitral Valve Dysfunction.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40967483" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40967483</a></p>
<p><strong>Summary:</strong> This primer article highlights current approaches to evaluating and treating bioprosthetic mitral valve dysfunction, which is an increasing challenge given the growing number of bioprosthetic mitral valve replacements performed. Dysfunction can manifest as structural or non-structural degeneration, necessitating close follow-up and timely re-intervention when necessary. This review offers a clinically focused summary of the complexities involved in managing bioprosthetic mitral valve dysfunction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incidence, predictors and outcomes of subclinical valve thrombosis after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. This study of 508 patients found subclinical valve thrombosis, identified via hypo-attenuated leaflet thickening on computed tomography angiography, occurred after transcatheter aortic valve replacement in both bicuspid and tricuspid aortic valves. The study aimed to evaluate the incidence, predictors, and clinical impact of hypo-attenuated leaflet thickening in the two valve types, assessing implications for valve durability and hemodynamics. Further research is needed to determine optimal management strategies for patients with hypo-attenuated leaflet thickening following transcatheter aortic valve replacement.</p>
<p>Article number two. Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient. This retrospective study of 342 adult extracorporeal membrane oxygenation patients at a single center investigated survival outcomes and risk factors in cancer patients receiving extracorporeal membrane oxygenation for cardiopulmonary failure. The study aimed to reassess extracorporeal membrane oxygenation&#8217;s role in this population given advances in oncology, and to determine prognostic factors for survival. The results will need to be interpreted cautiously due to the retrospective, single-center design.</p>
<p>Article number three. Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death. This study investigated the genetic basis of hypertrophic cardiomyopathy in a three-generation Chinese family with early-onset and sudden death, using high-throughput second-generation sequencing on the proband to identify novel double variants in the MYH7 and MYBPC3 genes. The study highlights the importance of comprehensive genetic testing beyond the proband to identify multiple pathogenic variants that may be missed by traditional Sanger sequencing in family members. Further studies with larger cohorts are required to confirm the pathogenicity of these novel variants and their association with early-onset and sudden death in hypertrophic cardiomyopathy.</p>
<p>Article number four. Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting. This population-based, retrospective cohort study of Ontarians aged 40 years and older diagnosed with heart failure in an ambulatory setting from 2009 to 2019 evaluated time intervals between diagnosis and subsequent physician reassessment, as well as all-cause mortality and heart failure hospitalization or emergency department visits. The study aimed to determine if there are gaps in healthcare access and timely follow-up based on sex. Further analysis is needed to determine the specific factors contributing to these differences and to develop strategies to improve access to care for all patients with heart failure.</p>
<p>Article number five. A Primer on Bioprosthetic Mitral Valve Dysfunction. This primer article highlights current approaches to evaluating and treating bioprosthetic mitral valve dysfunction, which is an increasing challenge given the growing number of bioprosthetic mitral valve replacements performed. Dysfunction can manifest as structural or non-structural degeneration, necessitating close follow-up and timely re-intervention when necessary. This review offers a clinically focused summary of the complexities involved in managing bioprosthetic mitral valve dysfunction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sudden death, cancer, MYBPC3, extracorporeal membrane oxygenation, heart failure, ambulatory care, non-structural degeneration, structural degeneration, transcatheter aortic valve replacement, prognostic factors, mortality, hypertrophic cardiomyopathy, valve dysfunction, cardiopulmonary failure, computed tomography angiography, MYH7, hypo-attenuated leaflet thickening, healthcare access, survival outcomes, bicuspid aortic valve, re-intervention, genetic testing, bioprosthetic mitral valve, subclinical valve thrombosis, sex differences.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/">New TAVR Thrombosis Risk Factors Identified 09/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like sudden death and cancer. Key takeaway: New TAVR Thrombosis Risk Factors Identified.
Article Links:
Article 1: Incidence, predictors]]></itunes:subtitle>
	<itunes:episode>62</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like sudden death and cancer. Key takeaway: New TAVR Thrombosis Risk Factors Identified.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40967263">Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40966168">Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40966167">Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death.</a> (Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40967484">Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40967483">A Primer on Bioprosthetic Mitral Valve Dysfunction.</a> (The Canadian journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/">https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40967263" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40967263</a></p>
<p><strong>Summary:</strong> This study of 508 patients found subclinical valve thrombosis, identified via hypo-attenuated leaflet thickening on computed tomography angiography, occurred after transcatheter aortic valve replacement in both bicuspid and tricuspid aortic valves. The study aimed to evaluate the incidence, predictors, and clinical impact of hypo-attenuated leaflet thickening in the two valve types, assessing implications for valve durability and hemodynamics. Further research is needed to determine optimal management strategies for patients with hypo-attenuated leaflet thickening following transcatheter aortic valve replacement.</p>
<h4>Article 2: Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40966168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40966168</a></p>
<p><strong>Summary:</strong> This retrospective study of 342 adult extracorporeal membrane oxygenation patients at a single center investigated survival outcomes and risk factors in cancer patients receiving extracorporeal membrane oxygenation for cardiopulmonary failure. The study aimed to reassess extracorporeal membrane oxygenation&#8217;s role in this population given advances in oncology, and to determine prognostic factors for survival. The results will need to be interpreted cautiously due to the retrospective, single-center design.</p>
<h4>Article 3: Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40966167" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40966167</a></p>
<p><strong>Summary:</strong> This study investigated the genetic basis of hypertrophic cardiomyopathy in a three-generation Chinese family with early-onset and sudden death, using high-throughput second-generation sequencing on the proband to identify novel double variants in the MYH7 and MYBPC3 genes. The study highlights the importance of comprehensive genetic testing beyond the proband to identify multiple pathogenic variants that may be missed by traditional Sanger sequencing in family members. Further studies with larger cohorts are required to confirm the pathogenicity of these novel variants and their association with early-onset and sudden death in hypertrophic cardiomyopathy.</p>
<h4>Article 4: Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40967484" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40967484</a></p>
<p><strong>Summary:</strong> This population-based, retrospective cohort study of Ontarians aged 40 years and older diagnosed with heart failure in an ambulatory setting from 2009 to 2019 evaluated time intervals between diagnosis and subsequent physician reassessment, as well as all-cause mortality and heart failure hospitalization or emergency department visits. The study aimed to determine if there are gaps in healthcare access and timely follow-up based on sex. Further analysis is needed to determine the specific factors contributing to these differences and to develop strategies to improve access to care for all patients with heart failure.</p>
<h4>Article 5: A Primer on Bioprosthetic Mitral Valve Dysfunction.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40967483" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40967483</a></p>
<p><strong>Summary:</strong> This primer article highlights current approaches to evaluating and treating bioprosthetic mitral valve dysfunction, which is an increasing challenge given the growing number of bioprosthetic mitral valve replacements performed. Dysfunction can manifest as structural or non-structural degeneration, necessitating close follow-up and timely re-intervention when necessary. This review offers a clinically focused summary of the complexities involved in managing bioprosthetic mitral valve dysfunction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 19, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Incidence, predictors and outcomes of subclinical valve thrombosis after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. This study of 508 patients found subclinical valve thrombosis, identified via hypo-attenuated leaflet thickening on computed tomography angiography, occurred after transcatheter aortic valve replacement in both bicuspid and tricuspid aortic valves. The study aimed to evaluate the incidence, predictors, and clinical impact of hypo-attenuated leaflet thickening in the two valve types, assessing implications for valve durability and hemodynamics. Further research is needed to determine optimal management strategies for patients with hypo-attenuated leaflet thickening following transcatheter aortic valve replacement.</p>
<p>Article number two. Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient. This retrospective study of 342 adult extracorporeal membrane oxygenation patients at a single center investigated survival outcomes and risk factors in cancer patients receiving extracorporeal membrane oxygenation for cardiopulmonary failure. The study aimed to reassess extracorporeal membrane oxygenation&#8217;s role in this population given advances in oncology, and to determine prognostic factors for survival. The results will need to be interpreted cautiously due to the retrospective, single-center design.</p>
<p>Article number three. Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death. This study investigated the genetic basis of hypertrophic cardiomyopathy in a three-generation Chinese family with early-onset and sudden death, using high-throughput second-generation sequencing on the proband to identify novel double variants in the MYH7 and MYBPC3 genes. The study highlights the importance of comprehensive genetic testing beyond the proband to identify multiple pathogenic variants that may be missed by traditional Sanger sequencing in family members. Further studies with larger cohorts are required to confirm the pathogenicity of these novel variants and their association with early-onset and sudden death in hypertrophic cardiomyopathy.</p>
<p>Article number four. Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting. This population-based, retrospective cohort study of Ontarians aged 40 years and older diagnosed with heart failure in an ambulatory setting from 2009 to 2019 evaluated time intervals between diagnosis and subsequent physician reassessment, as well as all-cause mortality and heart failure hospitalization or emergency department visits. The study aimed to determine if there are gaps in healthcare access and timely follow-up based on sex. Further analysis is needed to determine the specific factors contributing to these differences and to develop strategies to improve access to care for all patients with heart failure.</p>
<p>Article number five. A Primer on Bioprosthetic Mitral Valve Dysfunction. This primer article highlights current approaches to evaluating and treating bioprosthetic mitral valve dysfunction, which is an increasing challenge given the growing number of bioprosthetic mitral valve replacements performed. Dysfunction can manifest as structural or non-structural degeneration, necessitating close follow-up and timely re-intervention when necessary. This review offers a clinically focused summary of the complexities involved in managing bioprosthetic mitral valve dysfunction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>sudden death, cancer, MYBPC3, extracorporeal membrane oxygenation, heart failure, ambulatory care, non-structural degeneration, structural degeneration, transcatheter aortic valve replacement, prognostic factors, mortality, hypertrophic cardiomyopathy, valve dysfunction, cardiopulmonary failure, computed tomography angiography, MYH7, hypo-attenuated leaflet thickening, healthcare access, survival outcomes, bicuspid aortic valve, re-intervention, genetic testing, bioprosthetic mitral valve, subclinical valve thrombosis, sex differences.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/">New TAVR Thrombosis Risk Factors Identified 09/19/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250919_025724.mp3" length="4120075" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like sudden death and cancer. Key takeaway: New TAVR Thrombosis Risk Factors Identified.
Article Links:
Article 1: Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis. (The American journal of cardiology)
Article 2: Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient. (Cardiology)
Article 3: Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death. (Cardiology)
Article 4: Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting. (The Canadian journal of cardiology)
Article 5: A Primer on Bioprosthetic Mitral Valve Dysfunction. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-tavr-thrombosis-risk-factors-identified-09-19-25/
 Featured Articles
Article 1: Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40967263
Summary: This study of 508 patients found subclinical valve thrombosis, identified via hypo-attenuated leaflet thickening on computed tomography angiography, occurred after transcatheter aortic valve replacement in both bicuspid and tricuspid aortic valves. The study aimed to evaluate the incidence, predictors, and clinical impact of hypo-attenuated leaflet thickening in the two valve types, assessing implications for valve durability and hemodynamics. Further research is needed to determine optimal management strategies for patients with hypo-attenuated leaflet thickening following transcatheter aortic valve replacement.
Article 2: Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40966168
Summary: This retrospective study of 342 adult extracorporeal membrane oxygenation patients at a single center investigated survival outcomes and risk factors in cancer patients receiving extracorporeal membrane oxygenation for cardiopulmonary failure. The study aimed to reassess extracorporeal membrane oxygenation&#8217;s role in this population given advances in oncology, and to determine prognostic factors for survival. The results will need to be interpreted cautiously due to the retrospective, single-center design.
Article 3: Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40966167
Summary: This study investigated the genetic basis of hypertrophic cardiomyopathy in a three-generation Chinese family with early-onset and sudden death, using high-throughput second-generation sequencing on the proband to identify novel double variants in the MYH7 and MYBPC3 genes. The study highlights the importance of comprehensive genetic testing beyond the proband to identify multiple pathogenic variants that may be missed by traditional Sanger sequencing in family members. Further studies with larger cohorts are required to confirm the pathogenicity of these novel variants and their association with early-onset and sudden death in hypertrophic cardiomyopathy.
Article 4: Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40967484
Summary: This population-based, retrospective cohort study of Ontarians aged 40 years and older diagnosed with heart failure in an ambulatory setting from 2009 to 2019 evaluated time intervals between diagnosis and subsequent physician reassessment, as well as]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 19, 2025. This episode summarizes 5 key cardiology studies on topics like sudden death and cancer. Key takeaway: New TAVR Thrombosis Risk Factors Identified.
Article Links:
Article 1: Incidence, predictors and outcomes of subclinical valve thrombosis after TAVR in bicuspid aortic valve stenosis. (The American journal of cardiology)
Article 2: Real world data: Survival outcomes and risk factors in extracorporeal membrane oxygenation use of cancer patient. (Cardiology)
Article 3: Novel double MYH7/MYBPC3 variants in a Chinese family of Hypertrophic Cardiomyopathy with Early-onset and Sudden Death. (Cardiology)
Article 4: Sex differences in access to physician care following a new diagnosis of heart failure in the ambulatory setting. (The Canadian journal of cardiology)
Article 5: A Primer on Bioprosthetic Mitral Valve Dysfunction. (The Canadian journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-tavr-thr]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Systemic RV Impacts TGA Quality of Life 09/18/25</title>
	<link>https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/</link>
	<pubDate>Thu, 18 Sep 2025 10:01:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like aortic valve stenosis and quality of life. Key takeaway: Systemic RV Impacts TGA Quality of Life.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40962221">Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle.</a> (The Canadian journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40409498">Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40403851">Cardiovascular comorbidities predict mortality in acute pancreatitis.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40393632">REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40393631">Loop diuretics, heart failure diagnosis and outcome in primary care.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/">https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40962221" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40962221</a></p>
<p><strong>Summary:</strong> This study evaluated quality of life in adults with transposition of the great arteries, including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries, by comparing patients with a systemic right ventricle and those with a systemic left ventricle. The cross-sectional analysis, part of the APPROACH-IS II study, found that overall quality of life was similar between the two groups. However, patients with a systemic right ventricle exhibited lower physical composite scores, indicating poorer physical health compared to those with a systemic left ventricle.</p>
<h4>Article 2: Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40409498" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40409498</a></p>
<p><strong>Summary:</strong> This study evaluated the predictive value of coronary lesion functional assessment using optical coherence tomography (OCT) derived optical flow ratio (OFR). The study found that an abnormal optical flow ratio, indicating functional significance of a coronary lesion, was associated with an increased risk of major adverse cardiac events. Furthermore, combining optical flow ratio with plaque morphology improved risk stratification for adverse cardiac events.</p>
<h4>Article 3: Cardiovascular comorbidities predict mortality in acute pancreatitis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40403851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40403851</a></p>
<p><strong>Summary:</strong> This study investigated the association between cardiovascular comorbidities and mortality in patients hospitalized with acute pancreatitis. Using German nationwide inpatient statistics from 2005 to 2019, the study revealed that pre-existing cardiovascular conditions significantly increased in-hospital mortality in patients with acute pancreatitis. These findings underscore the importance of considering cardiovascular comorbidities when assessing risk and managing patients with acute pancreatitis.</p>
<h4>Article 4: REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40393632" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40393632</a></p>
<p><strong>Summary:</strong> The REVALVE study is a prospective, open-label registry designed to evaluate the feasibility and outcomes of redo transcatheter aortic valve implantation (TAVI) for bioprosthetic valve failure. Enrolling 300 patients across multiple centers in Europe and the Middle East, this study will assess the safety and efficacy of redo transcatheter aortic valve implantation, providing crucial data on this increasingly relevant treatment strategy. The primary endpoint will assess the composite of all-cause mortality, stroke, or rehospitalization for valve-related symptoms at one year.</p>
<h4>Article 5: Loop diuretics, heart failure diagnosis and outcome in primary care.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40393631" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40393631</a></p>
<p><strong>Summary:</strong> This study examined heart failure assessment, diagnosis, and outcomes following loop diuretic prescription in primary care settings. Analyzing data from the Clinical Practice Research Datalink in the United Kingdom, the study revealed that a substantial proportion of patients prescribed loop diuretics were not assessed for heart failure prior to or after initiation. Furthermore, the study showed that patients who received heart failure assessment had better outcomes compared to those who did not, highlighting the importance of appropriate assessment and diagnosis in patients receiving loop diuretics.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle. This study evaluated quality of life in adults with transposition of the great arteries, including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries, by comparing patients with a systemic right ventricle and those with a systemic left ventricle. The cross-sectional analysis, part of the APPROACH-IS II study, found that overall quality of life was similar between the two groups. However, patients with a systemic right ventricle exhibited lower physical composite scores, indicating poorer physical health compared to those with a systemic left ventricle.</p>
<p>Article number two. Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study. This study evaluated the predictive value of coronary lesion functional assessment using optical coherence tomography (OCT) derived optical flow ratio (OFR). The study found that an abnormal optical flow ratio, indicating functional significance of a coronary lesion, was associated with an increased risk of major adverse cardiac events. Furthermore, combining optical flow ratio with plaque morphology improved risk stratification for adverse cardiac events.</p>
<p>Article number three. Cardiovascular comorbidities predict mortality in acute pancreatitis. This study investigated the association between cardiovascular comorbidities and mortality in patients hospitalized with acute pancreatitis. Using German nationwide inpatient statistics from 2005 to 2019, the study revealed that pre-existing cardiovascular conditions significantly increased in-hospital mortality in patients with acute pancreatitis. These findings underscore the importance of considering cardiovascular comorbidities when assessing risk and managing patients with acute pancreatitis.</p>
<p>Article number four. REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study. The REVALVE study is a prospective, open-label registry designed to evaluate the feasibility and outcomes of redo transcatheter aortic valve implantation (TAVI) for bioprosthetic valve failure. Enrolling 300 patients across multiple centers in Europe and the Middle East, this study will assess the safety and efficacy of redo transcatheter aortic valve implantation, providing crucial data on this increasingly relevant treatment strategy. The primary endpoint will assess the composite of all-cause mortality, stroke, or rehospitalization for valve-related symptoms at one year.</p>
<p>Article number five. Loop diuretics, heart failure diagnosis and outcome in primary care. This study examined heart failure assessment, diagnosis, and outcomes following loop diuretic prescription in primary care settings. Analyzing data from the Clinical Practice Research Datalink in the United Kingdom, the study revealed that a substantial proportion of patients prescribed loop diuretics were not assessed for heart failure prior to or after initiation. Furthermore, the study showed that patients who received heart failure assessment had better outcomes compared to those who did not, highlighting the importance of appropriate assessment and diagnosis in patients receiving loop diuretics. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aortic valve stenosis, quality of life, loop diuretics, heart failure, redo transcatheter aortic valve implantation, bioprosthetic valve failure, plaque morphology, mortality, cardiovascular comorbidities, optical coherence tomography, transcatheter aortic valve implantation, optical flow ratio, transposition of the great arteries, congenital heart disease, natriuretic peptide, echocardiography, systemic right ventricle, primary care, coronary artery disease, fractional flow reserve, acute pancreatitis, in-hospital mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/">Systemic RV Impacts TGA Quality of Life 09/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like aortic valve stenosis and quality of life. Key takeaway: Systemic RV Impacts TGA Quality of Life.
Article Links:
Article 1: Quality]]></itunes:subtitle>
	<itunes:episode>61</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like aortic valve stenosis and quality of life. Key takeaway: Systemic RV Impacts TGA Quality of Life.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40962221">Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle.</a> (The Canadian journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40409498">Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study.</a> (International journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40403851">Cardiovascular comorbidities predict mortality in acute pancreatitis.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40393632">REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40393631">Loop diuretics, heart failure diagnosis and outcome in primary care.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/">https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40962221" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40962221</a></p>
<p><strong>Summary:</strong> This study evaluated quality of life in adults with transposition of the great arteries, including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries, by comparing patients with a systemic right ventricle and those with a systemic left ventricle. The cross-sectional analysis, part of the APPROACH-IS II study, found that overall quality of life was similar between the two groups. However, patients with a systemic right ventricle exhibited lower physical composite scores, indicating poorer physical health compared to those with a systemic left ventricle.</p>
<h4>Article 2: Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40409498" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40409498</a></p>
<p><strong>Summary:</strong> This study evaluated the predictive value of coronary lesion functional assessment using optical coherence tomography (OCT) derived optical flow ratio (OFR). The study found that an abnormal optical flow ratio, indicating functional significance of a coronary lesion, was associated with an increased risk of major adverse cardiac events. Furthermore, combining optical flow ratio with plaque morphology improved risk stratification for adverse cardiac events.</p>
<h4>Article 3: Cardiovascular comorbidities predict mortality in acute pancreatitis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40403851" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40403851</a></p>
<p><strong>Summary:</strong> This study investigated the association between cardiovascular comorbidities and mortality in patients hospitalized with acute pancreatitis. Using German nationwide inpatient statistics from 2005 to 2019, the study revealed that pre-existing cardiovascular conditions significantly increased in-hospital mortality in patients with acute pancreatitis. These findings underscore the importance of considering cardiovascular comorbidities when assessing risk and managing patients with acute pancreatitis.</p>
<h4>Article 4: REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40393632" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40393632</a></p>
<p><strong>Summary:</strong> The REVALVE study is a prospective, open-label registry designed to evaluate the feasibility and outcomes of redo transcatheter aortic valve implantation (TAVI) for bioprosthetic valve failure. Enrolling 300 patients across multiple centers in Europe and the Middle East, this study will assess the safety and efficacy of redo transcatheter aortic valve implantation, providing crucial data on this increasingly relevant treatment strategy. The primary endpoint will assess the composite of all-cause mortality, stroke, or rehospitalization for valve-related symptoms at one year.</p>
<h4>Article 5: Loop diuretics, heart failure diagnosis and outcome in primary care.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40393631" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40393631</a></p>
<p><strong>Summary:</strong> This study examined heart failure assessment, diagnosis, and outcomes following loop diuretic prescription in primary care settings. Analyzing data from the Clinical Practice Research Datalink in the United Kingdom, the study revealed that a substantial proportion of patients prescribed loop diuretics were not assessed for heart failure prior to or after initiation. Furthermore, the study showed that patients who received heart failure assessment had better outcomes compared to those who did not, highlighting the importance of appropriate assessment and diagnosis in patients receiving loop diuretics.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle. This study evaluated quality of life in adults with transposition of the great arteries, including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries, by comparing patients with a systemic right ventricle and those with a systemic left ventricle. The cross-sectional analysis, part of the APPROACH-IS II study, found that overall quality of life was similar between the two groups. However, patients with a systemic right ventricle exhibited lower physical composite scores, indicating poorer physical health compared to those with a systemic left ventricle.</p>
<p>Article number two. Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study. This study evaluated the predictive value of coronary lesion functional assessment using optical coherence tomography (OCT) derived optical flow ratio (OFR). The study found that an abnormal optical flow ratio, indicating functional significance of a coronary lesion, was associated with an increased risk of major adverse cardiac events. Furthermore, combining optical flow ratio with plaque morphology improved risk stratification for adverse cardiac events.</p>
<p>Article number three. Cardiovascular comorbidities predict mortality in acute pancreatitis. This study investigated the association between cardiovascular comorbidities and mortality in patients hospitalized with acute pancreatitis. Using German nationwide inpatient statistics from 2005 to 2019, the study revealed that pre-existing cardiovascular conditions significantly increased in-hospital mortality in patients with acute pancreatitis. These findings underscore the importance of considering cardiovascular comorbidities when assessing risk and managing patients with acute pancreatitis.</p>
<p>Article number four. REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study. The REVALVE study is a prospective, open-label registry designed to evaluate the feasibility and outcomes of redo transcatheter aortic valve implantation (TAVI) for bioprosthetic valve failure. Enrolling 300 patients across multiple centers in Europe and the Middle East, this study will assess the safety and efficacy of redo transcatheter aortic valve implantation, providing crucial data on this increasingly relevant treatment strategy. The primary endpoint will assess the composite of all-cause mortality, stroke, or rehospitalization for valve-related symptoms at one year.</p>
<p>Article number five. Loop diuretics, heart failure diagnosis and outcome in primary care. This study examined heart failure assessment, diagnosis, and outcomes following loop diuretic prescription in primary care settings. Analyzing data from the Clinical Practice Research Datalink in the United Kingdom, the study revealed that a substantial proportion of patients prescribed loop diuretics were not assessed for heart failure prior to or after initiation. Furthermore, the study showed that patients who received heart failure assessment had better outcomes compared to those who did not, highlighting the importance of appropriate assessment and diagnosis in patients receiving loop diuretics. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>aortic valve stenosis, quality of life, loop diuretics, heart failure, redo transcatheter aortic valve implantation, bioprosthetic valve failure, plaque morphology, mortality, cardiovascular comorbidities, optical coherence tomography, transcatheter aortic valve implantation, optical flow ratio, transposition of the great arteries, congenital heart disease, natriuretic peptide, echocardiography, systemic right ventricle, primary care, coronary artery disease, fractional flow reserve, acute pancreatitis, in-hospital mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/">Systemic RV Impacts TGA Quality of Life 09/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250918_060011.mp3" length="3896467" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like aortic valve stenosis and quality of life. Key takeaway: Systemic RV Impacts TGA Quality of Life.
Article Links:
Article 1: Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle. (The Canadian journal of cardiology)
Article 2: Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study. (International journal of cardiology)
Article 3: Cardiovascular comorbidities predict mortality in acute pancreatitis. (International journal of cardiology)
Article 4: REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study. (International journal of cardiology)
Article 5: Loop diuretics, heart failure diagnosis and outcome in primary care. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/systemic-rv-impacts-tga-quality-of-life-09-18-25/
 Featured Articles
Article 1: Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40962221
Summary: This study evaluated quality of life in adults with transposition of the great arteries, including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries, by comparing patients with a systemic right ventricle and those with a systemic left ventricle. The cross-sectional analysis, part of the APPROACH-IS II study, found that overall quality of life was similar between the two groups. However, patients with a systemic right ventricle exhibited lower physical composite scores, indicating poorer physical health compared to those with a systemic left ventricle.
Article 2: Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40409498
Summary: This study evaluated the predictive value of coronary lesion functional assessment using optical coherence tomography (OCT) derived optical flow ratio (OFR). The study found that an abnormal optical flow ratio, indicating functional significance of a coronary lesion, was associated with an increased risk of major adverse cardiac events. Furthermore, combining optical flow ratio with plaque morphology improved risk stratification for adverse cardiac events.
Article 3: Cardiovascular comorbidities predict mortality in acute pancreatitis.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40403851
Summary: This study investigated the association between cardiovascular comorbidities and mortality in patients hospitalized with acute pancreatitis. Using German nationwide inpatient statistics from 2005 to 2019, the study revealed that pre-existing cardiovascular conditions significantly increased in-hospital mortality in patients with acute pancreatitis. These findings underscore the importance of considering cardiovascular comorbidities when assessing risk and managing patients with acute pancreatitis.
Article 4: REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40393632
Summary: The REVALVE study is a prospective, open-label registry designed to evaluate the feasibility and outcomes of redo transcatheter aortic valve implantation (TAVI) for bioprosthetic valve failure. Enrolling 300 patients across multiple centers in Europe and the Middle East, this study will assess the safety and efficacy of redo transcatheter aortic valve implantation, providing crucial data]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like aortic valve stenosis and quality of life. Key takeaway: Systemic RV Impacts TGA Quality of Life.
Article Links:
Article 1: Quality of Life in Adults with Transposition of the Great Arteries with a Systemic Right or Left Ventricle. (The Canadian journal of cardiology)
Article 2: Predictive value of coronary lesion functional assessment using an OCT computational algorithm in the CLIMA study. (International journal of cardiology)
Article 3: Cardiovascular comorbidities predict mortality in acute pancreatitis. (International journal of cardiology)
Article 4: REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study. (International journal of cardiology)
Article 5: Loop diuretics, heart failure diagnosis and outcome in primary care. (International journal of cardiology)
Full episod]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Retinal Scans Detect Early Coronary Disease 09/18/25</title>
	<link>https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/</link>
	<pubDate>Thu, 18 Sep 2025 06:57:11 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and critical care. Key takeaway: Retinal Scans Detect Early Coronary Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40513024">Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40960442">Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40960845">First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40960793">Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40960791">Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/">https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40513024" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40513024</a></p>
<p><strong>Summary:</strong> This international clinical trial found that proportional-assist ventilation with load-adjustable gain factors did not result in a significantly shorter time to successful liberation from mechanical ventilation compared to pressure-support ventilation in critically ill adults. These findings suggest that the routine use of proportional-assist ventilation with load-adjustable gain factors may not provide a clinically meaningful advantage in reducing the duration of mechanical ventilation.</p>
<h4>Article 2: Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960442" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960442</a></p>
<p><strong>Summary:</strong> It posits that both categories are potentially modifiable through interventions targeting glycemic control and weight management, suggesting avenues for preventing or mitigating Heart Failure with Preserved Ejection Fraction in diabetic patients.</p>
<h4>Article 3: First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960845" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960845</a></p>
<p><strong>Summary:</strong> This study demonstrated the technical feasibility of real-time magnetic resonance-guided catheter ablation for idiopathic outflow tract premature ventricular complexes in humans. The procedure allowed for direct visualization of cardiac anatomy and lesion formation without radiation exposure, suggesting a promising radiation-free alternative to conventional ablation techniques for ventricular arrhythmias.</p>
<h4>Article 4: Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960793" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960793</a></p>
<p><strong>Summary:</strong> This randomized clinical trial found that the 23-valent pneumococcal polysaccharide vaccine did not significantly reduce the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased cardiovascular risk. The study suggests that pneumococcal vaccination is not effective for primary prevention of atherosclerotic cardiovascular events.</p>
<h4>Article 5: Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960791" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960791</a></p>
<p><strong>Summary:</strong> This cross-sectional cohort study found an association between reduced retinal vascular density, as measured by optical coherence tomography angiography, and the presence of subclinical coronary atherosclerosis in asymptomatic individuals with elevated cardiovascular risk. These findings suggest that retinal microvasculature assessment may serve as a non-invasive tool for detecting early signs of coronary artery disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. This international clinical trial found that proportional-assist ventilation with load-adjustable gain factors did not result in a significantly shorter time to successful liberation from mechanical ventilation compared to pressure-support ventilation in critically ill adults. These findings suggest that the routine use of proportional-assist ventilation with load-adjustable gain factors may not provide a clinically meaningful advantage in reducing the duration of mechanical ventilation.</p>
<p>Article number two. Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction? This article reviews the mechanisms by which type 2 diabetes mellitus may contribute to the development and progression of Heart Failure with Preserved Ejection Fraction, categorizing them into hyperglycemia-related and obesity/visceral adiposity-related pathways. It posits that both categories are potentially modifiable through interventions targeting glycemic control and weight management, suggesting avenues for preventing or mitigating Heart Failure with Preserved Ejection Fraction in diabetic patients.</p>
<p>Article number three. First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes. This study demonstrated the technical feasibility of real-time magnetic resonance-guided catheter ablation for idiopathic outflow tract premature ventricular complexes in humans. The procedure allowed for direct visualization of cardiac anatomy and lesion formation without radiation exposure, suggesting a promising radiation-free alternative to conventional ablation techniques for ventricular arrhythmias.</p>
<p>Article number four. Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. This randomized clinical trial found that the 23-valent pneumococcal polysaccharide vaccine did not significantly reduce the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased cardiovascular risk. The study suggests that pneumococcal vaccination is not effective for primary prevention of atherosclerotic cardiovascular events.</p>
<p>Article number five. Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography. This cross-sectional cohort study found an association between reduced retinal vascular density, as measured by optical coherence tomography angiography, and the presence of subclinical coronary atherosclerosis in asymptomatic individuals with elevated cardiovascular risk. These findings suggest that retinal microvasculature assessment may serve as a non-invasive tool for detecting early signs of coronary artery disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Heart Failure with Preserved Ejection Fraction, critical care, hyperglycemia, weaning, ischemic stroke, catheter ablation, coronary atherosclerosis, cardiovascular risk, mechanical ventilation, retinal microvasculature, pressure-support ventilation, type 2 diabetes mellitus, proportional-assist ventilation, obesity, premature ventricular complexes, atherosclerosis, real-time guidance, acute coronary syndrome, optical coherence tomography angiography, cardiovascular events, visceral adiposity, ventricular arrhythmia, pneumococcal vaccine, magnetic resonance imaging, asymptomatic individuals.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/">Retinal Scans Detect Early Coronary Disease 09/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and critical care. Key takeaway: Retinal Scans Detect Early Coronary Disease.
Articl]]></itunes:subtitle>
	<itunes:episode>60</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and critical care. Key takeaway: Retinal Scans Detect Early Coronary Disease.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40513024">Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40960442">Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40960845">First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40960793">Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.</a> (JAMA cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40960791">Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography.</a> (JAMA cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/">https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40513024" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40513024</a></p>
<p><strong>Summary:</strong> This international clinical trial found that proportional-assist ventilation with load-adjustable gain factors did not result in a significantly shorter time to successful liberation from mechanical ventilation compared to pressure-support ventilation in critically ill adults. These findings suggest that the routine use of proportional-assist ventilation with load-adjustable gain factors may not provide a clinically meaningful advantage in reducing the duration of mechanical ventilation.</p>
<h4>Article 2: Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960442" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960442</a></p>
<p><strong>Summary:</strong> It posits that both categories are potentially modifiable through interventions targeting glycemic control and weight management, suggesting avenues for preventing or mitigating Heart Failure with Preserved Ejection Fraction in diabetic patients.</p>
<h4>Article 3: First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960845" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960845</a></p>
<p><strong>Summary:</strong> This study demonstrated the technical feasibility of real-time magnetic resonance-guided catheter ablation for idiopathic outflow tract premature ventricular complexes in humans. The procedure allowed for direct visualization of cardiac anatomy and lesion formation without radiation exposure, suggesting a promising radiation-free alternative to conventional ablation techniques for ventricular arrhythmias.</p>
<h4>Article 4: Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960793" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960793</a></p>
<p><strong>Summary:</strong> This randomized clinical trial found that the 23-valent pneumococcal polysaccharide vaccine did not significantly reduce the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased cardiovascular risk. The study suggests that pneumococcal vaccination is not effective for primary prevention of atherosclerotic cardiovascular events.</p>
<h4>Article 5: Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40960791" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40960791</a></p>
<p><strong>Summary:</strong> This cross-sectional cohort study found an association between reduced retinal vascular density, as measured by optical coherence tomography angiography, and the presence of subclinical coronary atherosclerosis in asymptomatic individuals with elevated cardiovascular risk. These findings suggest that retinal microvasculature assessment may serve as a non-invasive tool for detecting early signs of coronary artery disease.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 18, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. This international clinical trial found that proportional-assist ventilation with load-adjustable gain factors did not result in a significantly shorter time to successful liberation from mechanical ventilation compared to pressure-support ventilation in critically ill adults. These findings suggest that the routine use of proportional-assist ventilation with load-adjustable gain factors may not provide a clinically meaningful advantage in reducing the duration of mechanical ventilation.</p>
<p>Article number two. Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction? This article reviews the mechanisms by which type 2 diabetes mellitus may contribute to the development and progression of Heart Failure with Preserved Ejection Fraction, categorizing them into hyperglycemia-related and obesity/visceral adiposity-related pathways. It posits that both categories are potentially modifiable through interventions targeting glycemic control and weight management, suggesting avenues for preventing or mitigating Heart Failure with Preserved Ejection Fraction in diabetic patients.</p>
<p>Article number three. First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes. This study demonstrated the technical feasibility of real-time magnetic resonance-guided catheter ablation for idiopathic outflow tract premature ventricular complexes in humans. The procedure allowed for direct visualization of cardiac anatomy and lesion formation without radiation exposure, suggesting a promising radiation-free alternative to conventional ablation techniques for ventricular arrhythmias.</p>
<p>Article number four. Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. This randomized clinical trial found that the 23-valent pneumococcal polysaccharide vaccine did not significantly reduce the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased cardiovascular risk. The study suggests that pneumococcal vaccination is not effective for primary prevention of atherosclerotic cardiovascular events.</p>
<p>Article number five. Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography. This cross-sectional cohort study found an association between reduced retinal vascular density, as measured by optical coherence tomography angiography, and the presence of subclinical coronary atherosclerosis in asymptomatic individuals with elevated cardiovascular risk. These findings suggest that retinal microvasculature assessment may serve as a non-invasive tool for detecting early signs of coronary artery disease. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Heart Failure with Preserved Ejection Fraction, critical care, hyperglycemia, weaning, ischemic stroke, catheter ablation, coronary atherosclerosis, cardiovascular risk, mechanical ventilation, retinal microvasculature, pressure-support ventilation, type 2 diabetes mellitus, proportional-assist ventilation, obesity, premature ventricular complexes, atherosclerosis, real-time guidance, acute coronary syndrome, optical coherence tomography angiography, cardiovascular events, visceral adiposity, ventricular arrhythmia, pneumococcal vaccine, magnetic resonance imaging, asymptomatic individuals.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/">Retinal Scans Detect Early Coronary Disease 09/18/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250918_025619.mp3" length="3530753" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and critical care. Key takeaway: Retinal Scans Detect Early Coronary Disease.
Article Links:
Article 1: Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. (The New England journal of medicine)
Article 2: Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction? (Journal of the American College of Cardiology)
Article 3: First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes. (JAMA cardiology)
Article 4: Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. (JAMA cardiology)
Article 5: Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/retinal-scans-detect-early-coronary-disease-09-18-25/
 Featured Articles
Article 1: Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40513024
Summary: This international clinical trial found that proportional-assist ventilation with load-adjustable gain factors did not result in a significantly shorter time to successful liberation from mechanical ventilation compared to pressure-support ventilation in critically ill adults. These findings suggest that the routine use of proportional-assist ventilation with load-adjustable gain factors may not provide a clinically meaningful advantage in reducing the duration of mechanical ventilation.
Article 2: Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40960442
Summary: It posits that both categories are potentially modifiable through interventions targeting glycemic control and weight management, suggesting avenues for preventing or mitigating Heart Failure with Preserved Ejection Fraction in diabetic patients.
Article 3: First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40960845
Summary: This study demonstrated the technical feasibility of real-time magnetic resonance-guided catheter ablation for idiopathic outflow tract premature ventricular complexes in humans. The procedure allowed for direct visualization of cardiac anatomy and lesion formation without radiation exposure, suggesting a promising radiation-free alternative to conventional ablation techniques for ventricular arrhythmias.
Article 4: Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40960793
Summary: This randomized clinical trial found that the 23-valent pneumococcal polysaccharide vaccine did not significantly reduce the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased cardiovascular risk. The study suggests that pneumococcal vaccination is not effective for primary prevention of atherosclerotic cardiovascular events.
Article 5: Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40960791
Summary: This cross-sectional cohort study found an association between reduced retinal vascular density, as measured by optical coherence tomography angiography, and the presence of subclinical coronary atheroscleros]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 18, 2025. This episode summarizes 5 key cardiology studies on topics like Heart Failure with Preserved Ejection Fraction and critical care. Key takeaway: Retinal Scans Detect Early Coronary Disease.
Article Links:
Article 1: Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. (The New England journal of medicine)
Article 2: Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction? (Journal of the American College of Cardiology)
Article 3: First-in-Human Real-Time MR-Guided Ventricular Ablation for Idiopathic Outflow Tract Premature Ventricular Complexes. (JAMA cardiology)
Article 4: Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. (JAMA cardiology)
Article 5: Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography. (J]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mavacamten Remodels HCM Long-Term: VALOR-HCM Data 09/17/25</title>
	<link>https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/</link>
	<pubDate>Wed, 17 Sep 2025 10:00:52 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric heart failure and risk factors. Key takeaway: Mavacamten Remodels HCM Long-Term: VALOR-HCM Data.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40956275">Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40947836">Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40414542">Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40412628">The efficacy and safety of dapagliflozin in pediatric heart failure.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40409500">Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/">https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40956275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40956275</a></p>
<p><strong>Summary:</strong> In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.</p>
<h4>Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947836" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947836</a></p>
<p><strong>Summary:</strong> This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.</p>
<h4>Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40414542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40414542</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.</p>
<h4>Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40412628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40412628</a></p>
<p><strong>Summary:</strong> This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.</p>
<h4>Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40409500" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40409500</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.</p>
<p>Article number two. Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.</p>
<p>Article number three. Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis. A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.</p>
<p>Article number four. The efficacy and safety of dapagliflozin in pediatric heart failure. This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.</p>
<p>Article number five. Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pediatric heart failure, risk factors, implantable cardiac monitor, REMOVE trial, VALOR-HCM trial, left ventricular outflow tract gradient, mavacamten, right atrial strain, nomogram, hemoadsorption, dapagliflozin, device-detected atrial fibrillation, sex differences, elderly patients, cardiac surgery, cryptogenic stroke, mortality, frailty syndrome, infective endocarditis, Sodium-Glucose Cotransporter-2 inhibitor, obstructive hypertrophic cardiomyopathy, acute coronary syndrome, cardiac remodeling, heart transplantation, left atrial strain.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/">Mavacamten Remodels HCM Long-Term: VALOR-HCM Data 09/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric heart failure and risk factors. Key takeaway: Mavacamten Remodels HCM Long-Term: VALOR-HCM Data.
Article Links:
Article 1]]></itunes:subtitle>
	<itunes:episode>59</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric heart failure and risk factors. Key takeaway: Mavacamten Remodels HCM Long-Term: VALOR-HCM Data.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40956275">Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40947836">Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.</a> (Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40414542">Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis.</a> (International journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40412628">The efficacy and safety of dapagliflozin in pediatric heart failure.</a> (International journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40409500">Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/">https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40956275" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40956275</a></p>
<p><strong>Summary:</strong> In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.</p>
<h4>Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947836" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947836</a></p>
<p><strong>Summary:</strong> This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.</p>
<h4>Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40414542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40414542</a></p>
<p><strong>Summary:</strong> A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.</p>
<h4>Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40412628" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40412628</a></p>
<p><strong>Summary:</strong> This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.</p>
<h4>Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40409500" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40409500</a></p>
<p><strong>Summary:</strong> This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.</p>
<p>Article number two. Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.</p>
<p>Article number three. Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis. A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.</p>
<p>Article number four. The efficacy and safety of dapagliflozin in pediatric heart failure. This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.</p>
<p>Article number five. Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>pediatric heart failure, risk factors, implantable cardiac monitor, REMOVE trial, VALOR-HCM trial, left ventricular outflow tract gradient, mavacamten, right atrial strain, nomogram, hemoadsorption, dapagliflozin, device-detected atrial fibrillation, sex differences, elderly patients, cardiac surgery, cryptogenic stroke, mortality, frailty syndrome, infective endocarditis, Sodium-Glucose Cotransporter-2 inhibitor, obstructive hypertrophic cardiomyopathy, acute coronary syndrome, cardiac remodeling, heart transplantation, left atrial strain.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/">Mavacamten Remodels HCM Long-Term: VALOR-HCM Data 09/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250917_060011.mp3" length="3094403" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric heart failure and risk factors. Key takeaway: Mavacamten Remodels HCM Long-Term: VALOR-HCM Data.
Article Links:
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. (JACC. Cardiovascular imaging)
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. (Cardiology)
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis. (International journal of cardiology)
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure. (International journal of cardiology)
Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/
 Featured Articles
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40956275
Summary: In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40947836
Summary: This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40414542
Summary: A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40412628
Summary: This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.
Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40409500
Summary: This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardio]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric heart failure and risk factors. Key takeaway: Mavacamten Remodels HCM Long-Term: VALOR-HCM Data.
Article Links:
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. (JACC. Cardiovascular imaging)
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. (Cardiology)
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery &#8211; A REMOVE trial post-hoc analysis. (International journal of cardiology)
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure. (International journal of cardiology)
Article 5: Predictive value of left and right atrial strain for the detection of device-dete]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mammogram AI Flags Hidden Heart Disease Risk 09/17/25</title>
	<link>https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/</link>
	<pubDate>Wed, 17 Sep 2025 06:58:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like vascular complications and smooth muscle cell proliferation. Key takeaway: Mammogram AI Flags Hidden Heart Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40955569">TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40957672">Predicting cardiovascular events from routine mammograms using machine learning.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40957671">Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40956259">Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40769446">PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/">https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40955569" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40955569</a></p>
<p><strong>Summary:</strong> This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.</p>
<h4>Article 2: Predicting cardiovascular events from routine mammograms using machine learning.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40957672" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40957672</a></p>
<p><strong>Summary:</strong> Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.</p>
<h4>Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40957671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40957671</a></p>
<p><strong>Summary:</strong> This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.</p>
<h4>Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40956259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40956259</a></p>
<p><strong>Summary:</strong> Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide&#8217;s benefits extended to both frail and non-frail patients, suggesting it&#8217;s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.</p>
<h4>Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40769446" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40769446</a></p>
<p><strong>Summary:</strong> A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.</p>
<p>Article number two. Predicting cardiovascular events from routine mammograms using machine learning. Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.</p>
<p>Article number three. Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.</p>
<p>Article number four. Frailty and Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction: Findings From the STEP-HFpEF Program. Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide&#8217;s benefits extended to both frail and non-frail patients, suggesting it&#8217;s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.</p>
<p>Article number five. PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>vascular complications, smooth muscle cell proliferation, photoplethysmography, mammography, neointimal hyperplasia, frailty, screening, smartphone application, stroke prevention, Heart Failure with Preserved Ejection Fraction, cardiovascular risk prediction, PDZ domain, Lectin-like Oxidized Low-Density Lipoprotein Receptor-1, semaglutide, TAX1BP3, machine learning, obesity, breast arterial calcification, deep learning, acute coronary syndrome, heart failure, prognosis, STEP-Heart Failure with Preserved Ejection Fraction trial, atrial fibrillation, major adverse cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/">Mammogram AI Flags Hidden Heart Disease Risk 09/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like vascular complications and smooth muscle cell proliferation. Key takeaway: Mammogram AI Flags Hidden Heart Disease Risk.
Article Li]]></itunes:subtitle>
	<itunes:episode>58</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like vascular complications and smooth muscle cell proliferation. Key takeaway: Mammogram AI Flags Hidden Heart Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40955569">TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40957672">Predicting cardiovascular events from routine mammograms using machine learning.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40957671">Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40956259">Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.</a> (JACC. Heart failure)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40769446">PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/">https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40955569" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40955569</a></p>
<p><strong>Summary:</strong> This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.</p>
<h4>Article 2: Predicting cardiovascular events from routine mammograms using machine learning.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40957672" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40957672</a></p>
<p><strong>Summary:</strong> Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.</p>
<h4>Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40957671" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40957671</a></p>
<p><strong>Summary:</strong> This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.</p>
<h4>Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.</h4>
<p><strong>Journal:</strong> JACC. Heart failure</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40956259" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40956259</a></p>
<p><strong>Summary:</strong> Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide&#8217;s benefits extended to both frail and non-frail patients, suggesting it&#8217;s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.</p>
<h4>Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40769446" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40769446</a></p>
<p><strong>Summary:</strong> A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.</p>
<p>Article number two. Predicting cardiovascular events from routine mammograms using machine learning. Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.</p>
<p>Article number three. Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.</p>
<p>Article number four. Frailty and Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction: Findings From the STEP-HFpEF Program. Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide&#8217;s benefits extended to both frail and non-frail patients, suggesting it&#8217;s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.</p>
<p>Article number five. PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>vascular complications, smooth muscle cell proliferation, photoplethysmography, mammography, neointimal hyperplasia, frailty, screening, smartphone application, stroke prevention, Heart Failure with Preserved Ejection Fraction, cardiovascular risk prediction, PDZ domain, Lectin-like Oxidized Low-Density Lipoprotein Receptor-1, semaglutide, TAX1BP3, machine learning, obesity, breast arterial calcification, deep learning, acute coronary syndrome, heart failure, prognosis, STEP-Heart Failure with Preserved Ejection Fraction trial, atrial fibrillation, major adverse cardiovascular events.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/">Mammogram AI Flags Hidden Heart Disease Risk 09/17/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250917_025751.mp3" length="3897721" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like vascular complications and smooth muscle cell proliferation. Key takeaway: Mammogram AI Flags Hidden Heart Disease Risk.
Article Links:
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. (Circulation)
Article 2: Predicting cardiovascular events from routine mammograms using machine learning. (Heart (British Cardiac Society))
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. (Heart (British Cardiac Society))
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. (JACC. Heart failure)
Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/
 Featured Articles
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40955569
Summary: This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.
Article 2: Predicting cardiovascular events from routine mammograms using machine learning.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40957672
Summary: Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40957671
Summary: This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40956259
Summary: Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide&#8217;s benefits extended to both frail and non-frail patients, suggesting it&#8217;s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.
Article 5: ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like vascular complications and smooth muscle cell proliferation. Key takeaway: Mammogram AI Flags Hidden Heart Disease Risk.
Article Links:
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. (Circulation)
Article 2: Predicting cardiovascular events from routine mammograms using machine learning. (Heart (British Cardiac Society))
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. (Heart (British Cardiac Society))
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. (JACC. Heart failure)
Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/mammogr]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Taller Cardiologists Face Higher Radiation Risk 09/16/25</title>
	<link>https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/</link>
	<pubDate>Tue, 16 Sep 2025 10:01:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like coronary angiography and Medicare. Key takeaway: Taller Cardiologists Face Higher Radiation Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40671674">Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40953741">Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40345311">Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40334929">The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40947840">Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/">https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40671674" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40671674</a></p>
<p><strong>Summary:</strong> This study found that early vascular aging, characterized by specific aortic geometric remodeling, is linked to adverse cardiovascular outcomes. Using three dimensional aortic imaging, researchers identified genetic determinants influencing this aging process and its association with cardiovascular structure and function. The findings suggest that early identification of aortic geometry via imaging could provide a new target for intervention and risk stratification.</p>
<h4>Article 2: Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40953741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40953741</a></p>
<p><strong>Summary:</strong> This analysis of Medicare data demonstrates a trend toward increased implantation of cardiac electrophysiology devices like pacemakers and implantable cardioverter-defibrillators in ambulatory surgery centers rather than hospital outpatient departments. The study highlights significant Medicare payment differences between these settings, suggesting potential cost savings in ambulatory surgery centers for device implantation procedures. This shift has important implications for healthcare economics and patient access.</p>
<h4>Article 3: Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40345311" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40345311</a></p>
<p><strong>Summary:</strong> Analysis of the Behavioral Risk Factor Surveillance System data from 2011 to 2021 reveals substantial geographic variation in cardiometabolic risk factors including diabetes, hypertension, hyperlipidemia and obesity, as well as lifestyle risk factors across United States states. The study demonstrates that these state-based inequities in risk factor burden have persisted over the decade studied, underscoring the need for targeted interventions to address regional disparities in cardiovascular health. These findings emphasize the importance of considering geographic context in public health initiatives.</p>
<h4>Article 4: The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40334929" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40334929</a></p>
<p><strong>Summary:</strong> This retrospective study found that interventional cardiologist height significantly influences occupational radiation exposure during radial artery coronary angiography. Taller operators experienced higher cumulative radiation exposure, even when normalized for dose area product. These findings suggest that adjusting radiation protection strategies based on operator height could mitigate occupational hazards.</p>
<h4>Article 5: Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947840" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947840</a></p>
<p><strong>Summary:</strong> This retrospective study identified independent risk factors for acute lung injury following surgery for type A aortic dissection, including preoperative ventilation time and intraoperative transfusion volume. Based on these risk factors, the researchers developed a predictive model to evaluate the risk of acute lung injury in patients undergoing this procedure. This model can help clinicians identify high-risk patients and implement preventative strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences. This study found that early vascular aging, characterized by specific aortic geometric remodeling, is linked to adverse cardiovascular outcomes. Using three dimensional aortic imaging, researchers identified genetic determinants influencing this aging process and its association with cardiovascular structure and function. The findings suggest that early identification of aortic geometry via imaging could provide a new target for intervention and risk stratification.</p>
<p>Article number two. Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population. This analysis of Medicare data demonstrates a trend toward increased implantation of cardiac electrophysiology devices like pacemakers and implantable cardioverter-defibrillators in ambulatory surgery centers rather than hospital outpatient departments. The study highlights significant Medicare payment differences between these settings, suggesting potential cost savings in ambulatory surgery centers for device implantation procedures. This shift has important implications for healthcare economics and patient access.</p>
<p>Article number three. Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021. Analysis of the Behavioral Risk Factor Surveillance System data from 2011 to 2021 reveals substantial geographic variation in cardiometabolic risk factors including diabetes, hypertension, hyperlipidemia and obesity, as well as lifestyle risk factors across United States states. The study demonstrates that these state-based inequities in risk factor burden have persisted over the decade studied, underscoring the need for targeted interventions to address regional disparities in cardiovascular health. These findings emphasize the importance of considering geographic context in public health initiatives.</p>
<p>Article number four. The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach. This retrospective study found that interventional cardiologist height significantly influences occupational radiation exposure during radial artery coronary angiography. Taller operators experienced higher cumulative radiation exposure, even when normalized for dose area product. These findings suggest that adjusting radiation protection strategies based on operator height could mitigate occupational hazards.</p>
<p>Article number five. Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection. This retrospective study identified independent risk factors for acute lung injury following surgery for type A aortic dissection, including preoperative ventilation time and intraoperative transfusion volume. Based on these risk factors, the researchers developed a predictive model to evaluate the risk of acute lung injury in patients undergoing this procedure. This model can help clinicians identify high-risk patients and implement preventative strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>coronary angiography, Medicare, type A aortic dissection, risk factors, cardiac electrophysiology, hypertension, device implantation, genetic determinants, cardiometabolic risk factors, acute lung injury, radiation exposure, cost differences, interventional cardiology, radial artery approach, aortic geometry, geographic variation, diabetes, aortic remodeling, ambulatory surgery centers, cardiovascular outcomes, hyperlipidemia, early vascular aging, predictive model, postoperative complications, operator height.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/">Taller Cardiologists Face Higher Radiation Risk 09/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like coronary angiography and Medicare. Key takeaway: Taller Cardiologists Face Higher Radiation Risk.
Article Links:
Article 1: Early V]]></itunes:subtitle>
	<itunes:episode>57</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like coronary angiography and Medicare. Key takeaway: Taller Cardiologists Face Higher Radiation Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40671674">Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40953741">Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40345311">Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40334929">The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40947840">Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection.</a> (Cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/">https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40671674" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40671674</a></p>
<p><strong>Summary:</strong> This study found that early vascular aging, characterized by specific aortic geometric remodeling, is linked to adverse cardiovascular outcomes. Using three dimensional aortic imaging, researchers identified genetic determinants influencing this aging process and its association with cardiovascular structure and function. The findings suggest that early identification of aortic geometry via imaging could provide a new target for intervention and risk stratification.</p>
<h4>Article 2: Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40953741" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40953741</a></p>
<p><strong>Summary:</strong> This analysis of Medicare data demonstrates a trend toward increased implantation of cardiac electrophysiology devices like pacemakers and implantable cardioverter-defibrillators in ambulatory surgery centers rather than hospital outpatient departments. The study highlights significant Medicare payment differences between these settings, suggesting potential cost savings in ambulatory surgery centers for device implantation procedures. This shift has important implications for healthcare economics and patient access.</p>
<h4>Article 3: Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40345311" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40345311</a></p>
<p><strong>Summary:</strong> Analysis of the Behavioral Risk Factor Surveillance System data from 2011 to 2021 reveals substantial geographic variation in cardiometabolic risk factors including diabetes, hypertension, hyperlipidemia and obesity, as well as lifestyle risk factors across United States states. The study demonstrates that these state-based inequities in risk factor burden have persisted over the decade studied, underscoring the need for targeted interventions to address regional disparities in cardiovascular health. These findings emphasize the importance of considering geographic context in public health initiatives.</p>
<h4>Article 4: The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40334929" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40334929</a></p>
<p><strong>Summary:</strong> This retrospective study found that interventional cardiologist height significantly influences occupational radiation exposure during radial artery coronary angiography. Taller operators experienced higher cumulative radiation exposure, even when normalized for dose area product. These findings suggest that adjusting radiation protection strategies based on operator height could mitigate occupational hazards.</p>
<h4>Article 5: Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection.</h4>
<p><strong>Journal:</strong> Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947840" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947840</a></p>
<p><strong>Summary:</strong> This retrospective study identified independent risk factors for acute lung injury following surgery for type A aortic dissection, including preoperative ventilation time and intraoperative transfusion volume. Based on these risk factors, the researchers developed a predictive model to evaluate the risk of acute lung injury in patients undergoing this procedure. This model can help clinicians identify high-risk patients and implement preventative strategies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences. This study found that early vascular aging, characterized by specific aortic geometric remodeling, is linked to adverse cardiovascular outcomes. Using three dimensional aortic imaging, researchers identified genetic determinants influencing this aging process and its association with cardiovascular structure and function. The findings suggest that early identification of aortic geometry via imaging could provide a new target for intervention and risk stratification.</p>
<p>Article number two. Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population. This analysis of Medicare data demonstrates a trend toward increased implantation of cardiac electrophysiology devices like pacemakers and implantable cardioverter-defibrillators in ambulatory surgery centers rather than hospital outpatient departments. The study highlights significant Medicare payment differences between these settings, suggesting potential cost savings in ambulatory surgery centers for device implantation procedures. This shift has important implications for healthcare economics and patient access.</p>
<p>Article number three. Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021. Analysis of the Behavioral Risk Factor Surveillance System data from 2011 to 2021 reveals substantial geographic variation in cardiometabolic risk factors including diabetes, hypertension, hyperlipidemia and obesity, as well as lifestyle risk factors across United States states. The study demonstrates that these state-based inequities in risk factor burden have persisted over the decade studied, underscoring the need for targeted interventions to address regional disparities in cardiovascular health. These findings emphasize the importance of considering geographic context in public health initiatives.</p>
<p>Article number four. The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach. This retrospective study found that interventional cardiologist height significantly influences occupational radiation exposure during radial artery coronary angiography. Taller operators experienced higher cumulative radiation exposure, even when normalized for dose area product. These findings suggest that adjusting radiation protection strategies based on operator height could mitigate occupational hazards.</p>
<p>Article number five. Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection. This retrospective study identified independent risk factors for acute lung injury following surgery for type A aortic dissection, including preoperative ventilation time and intraoperative transfusion volume. Based on these risk factors, the researchers developed a predictive model to evaluate the risk of acute lung injury in patients undergoing this procedure. This model can help clinicians identify high-risk patients and implement preventative strategies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>coronary angiography, Medicare, type A aortic dissection, risk factors, cardiac electrophysiology, hypertension, device implantation, genetic determinants, cardiometabolic risk factors, acute lung injury, radiation exposure, cost differences, interventional cardiology, radial artery approach, aortic geometry, geographic variation, diabetes, aortic remodeling, ambulatory surgery centers, cardiovascular outcomes, hyperlipidemia, early vascular aging, predictive model, postoperative complications, operator height.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/">Taller Cardiologists Face Higher Radiation Risk 09/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250916_060009.mp3" length="3745166" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like coronary angiography and Medicare. Key takeaway: Taller Cardiologists Face Higher Radiation Risk.
Article Links:
Article 1: Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences. (Circulation)
Article 2: Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population. (Heart rhythm)
Article 3: Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021. (The American journal of cardiology)
Article 4: The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach. (The American journal of cardiology)
Article 5: Risk factor analysis and prediction of acute postoperative lung injury after type A aortic dissection. (Cardiology)
Full episode page: https://podcast.explainheart.com/podcast/taller-cardiologists-face-higher-radiation-risk-09-16-25/
 Featured Articles
Article 1: Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40671674
Summary: This study found that early vascular aging, characterized by specific aortic geometric remodeling, is linked to adverse cardiovascular outcomes. Using three dimensional aortic imaging, researchers identified genetic determinants influencing this aging process and its association with cardiovascular structure and function. The findings suggest that early identification of aortic geometry via imaging could provide a new target for intervention and risk stratification.
Article 2: Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40953741
Summary: This analysis of Medicare data demonstrates a trend toward increased implantation of cardiac electrophysiology devices like pacemakers and implantable cardioverter-defibrillators in ambulatory surgery centers rather than hospital outpatient departments. The study highlights significant Medicare payment differences between these settings, suggesting potential cost savings in ambulatory surgery centers for device implantation procedures. This shift has important implications for healthcare economics and patient access.
Article 3: Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40345311
Summary: Analysis of the Behavioral Risk Factor Surveillance System data from 2011 to 2021 reveals substantial geographic variation in cardiometabolic risk factors including diabetes, hypertension, hyperlipidemia and obesity, as well as lifestyle risk factors across United States states. The study demonstrates that these state-based inequities in risk factor burden have persisted over the decade studied, underscoring the need for targeted interventions to address regional disparities in cardiovascular health. These findings emphasize the importance of considering geographic context in public health initiatives.
Article 4: The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40334929
Summary: This retrospective study found that interventional cardiologist height significantly influences occupational radiation exposure during radial artery coronary angiography. Taller operators experienced higher cumulative radia]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like coronary angiography and Medicare. Key takeaway: Taller Cardiologists Face Higher Radiation Risk.
Article Links:
Article 1: Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences. (Circulation)
Article 2: Shifting Sites of Care in Electrophysiology: Trends and Cost Differences in Device Implantation Procedures Across Ambulatory and Hospital Settings in the Medicare Population. (Heart rhythm)
Article 3: Geographic Variation in Cardiometabolic and Lifestyle Risk Factors Across US States, 2011 to 2021. (The American journal of cardiology)
Article 4: The Influence of Height on Occupational Radiation Exposure of Interventional Cardiologists During Selective Coronary Angiography Using a Radial Artery Approach. (The American journal of cardiology)
Article 5: Risk factor analysis and prediction of acute postoperati]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ponatinib Triggers Thrombosis via TNF Signaling 09/16/25</title>
	<link>https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/</link>
	<pubDate>Tue, 16 Sep 2025 06:57:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like Abl-tyrosine kinase inhibitor and ponatinib. Key takeaway: Ponatinib Triggers Thrombosis via TNF Signaling.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40930617">Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40930615">Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40930613">Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40799140">TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40762051">Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/">https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930617</a></p>
<p><strong>Summary:</strong> This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.</p>
<h4>Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930615</a></p>
<p><strong>Summary:</strong> This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.</p>
<h4>Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930613" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930613</a></p>
<p><strong>Summary:</strong> This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.</p>
<h4>Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40799140" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40799140</a></p>
<p><strong>Summary:</strong> This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.</p>
<h4>Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40762051" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40762051</a></p>
<p><strong>Summary:</strong> This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.</p>
<p>Article number two. Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.</p>
<p>Article number three. Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.</p>
<p>Article number four. TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.</p>
<p>Article number five. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Abl-tyrosine kinase inhibitor, ponatinib, T-box 5, echocardiography, pulmonary capillary wedge pressure, cardiovascular disease, atrial cardiomyocyte, atrial fibrillation, hemodynamics, asciminib, angina, myocardial infarction, all-cause mortality, stroke, primary prevention, type 1 diabetes mellitus, statins, chronic coronary disease, extracorporeal membrane oxygenation, cardiogenic shock, conservative strategy, chromodomain helicase DNA-binding protein 4, invasive strategy, International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), cardiac rhythm.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/">Ponatinib Triggers Thrombosis via TNF Signaling 09/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like Abl-tyrosine kinase inhibitor and ponatinib. Key takeaway: Ponatinib Triggers Thrombosis via TNF Signaling.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>56</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like Abl-tyrosine kinase inhibitor and ponatinib. Key takeaway: Ponatinib Triggers Thrombosis via TNF Signaling.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40930617">Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40930615">Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40930613">Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40799140">TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40762051">Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/">https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930617" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930617</a></p>
<p><strong>Summary:</strong> This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.</p>
<h4>Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930615" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930615</a></p>
<p><strong>Summary:</strong> This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.</p>
<h4>Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40930613" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40930613</a></p>
<p><strong>Summary:</strong> This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.</p>
<h4>Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40799140" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40799140</a></p>
<p><strong>Summary:</strong> This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.</p>
<h4>Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40762051" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40762051</a></p>
<p><strong>Summary:</strong> This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.</p>
<p>Article number two. Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.</p>
<p>Article number three. Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.</p>
<p>Article number four. TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.</p>
<p>Article number five. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Abl-tyrosine kinase inhibitor, ponatinib, T-box 5, echocardiography, pulmonary capillary wedge pressure, cardiovascular disease, atrial cardiomyocyte, atrial fibrillation, hemodynamics, asciminib, angina, myocardial infarction, all-cause mortality, stroke, primary prevention, type 1 diabetes mellitus, statins, chronic coronary disease, extracorporeal membrane oxygenation, cardiogenic shock, conservative strategy, chromodomain helicase DNA-binding protein 4, invasive strategy, International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), cardiac rhythm.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/">Ponatinib Triggers Thrombosis via TNF Signaling 09/16/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250916_025629.mp3" length="4576069" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like Abl-tyrosine kinase inhibitor and ponatinib. Key takeaway: Ponatinib Triggers Thrombosis via TNF Signaling.
Article Links:
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. (Journal of the American College of Cardiology)
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. (Journal of the American College of Cardiology)
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. (Journal of the American College of Cardiology)
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. (Circulation)
Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/
 Featured Articles
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930617
Summary: This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930615
Summary: This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930613
Summary: This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.
Journal]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like Abl-tyrosine kinase inhibitor and ponatinib. Key takeaway: Ponatinib Triggers Thrombosis via TNF Signaling.
Article Links:
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. (Journal of the American College of Cardiology)
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. (Journal of the American College of Cardiology)
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. (Journal of the American College of Cardiology)
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. (Circulation)
Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lead Extraction Cuts CIED Infection Deaths 09/15/25</title>
	<link>https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/</link>
	<pubDate>Mon, 15 Sep 2025 10:01:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like self-expanding transcatheter heart valve and emergency department. Key takeaway: Lead Extraction Cuts CIED Infection Deaths.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40379121">Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40354959">Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40354958">Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40348045">Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40348043">Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/">https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40379121" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40379121</a></p>
<p><strong>Summary:</strong> This Australian study showed that lead extraction for cardiac implantable electronic device infections was performed in a minority of patients. Specifically, the study found that patients who underwent lead extraction had significantly lower one-year mortality compared to those who did not, highlighting the importance of complete lead extraction when managing such infections. The findings underscore the need for improved strategies to increase lead extraction rates in patients with cardiac implantable electronic device infections.</p>
<h4>Article 2: Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40354959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40354959</a></p>
<p><strong>Summary:</strong> An analysis of young adults aged 18 to 50 years undergoing percutaneous coronary intervention for myocardial infarction, using the TriNetX database, found distinct differences in long-term outcomes between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction. Patients with ST-elevation myocardial infarction had a higher risk of major adverse cardiovascular events, including death, compared to those with non-ST-elevation myocardial infarction. These results emphasize the need for tailored management strategies for young adults based on the type of myocardial infarction.</p>
<h4>Article 3: Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40354958" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40354958</a></p>
<p><strong>Summary:</strong> This study, using the CathPCI Registry, compared outcomes of percutaneous coronary intervention in patients with and without prior transcatheter aortic valve replacement. The research revealed that patients undergoing percutaneous coronary intervention post-transcatheter aortic valve replacement had higher in-hospital mortality and bleeding complications compared to those without prior transcatheter aortic valve replacement. This indicates that percutaneous coronary intervention following transcatheter aortic valve replacement is associated with increased procedural risks.</p>
<h4>Article 4: Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348045" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348045</a></p>
<p><strong>Summary:</strong> In this retrospective analysis of patients undergoing transcatheter aortic valve replacement with self-expanding transcatheter heart valves, the study examined the impact of aortic annulus size on patient and valve outcomes. The findings suggest that patients with small aortic annulus have a higher risk of bioprosthetic valve failure compared to those with larger annuli. This data emphasizes the importance of considering aortic annulus size when selecting patients for transcatheter aortic valve replacement with self-expanding valves, and highlights the need for further research into valve durability in patients with smaller annuli.</p>
<h4>Article 5: Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348043" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348043</a></p>
<p><strong>Summary:</strong> This study assessed the impact of implementing a high-sensitivity cardiac troponin I assay and a 0/2-hour diagnostic protocol for suspected acute coronary syndromes in the emergency department. The implementation was associated with a significant reduction in hospital length of stay and a decrease in the use of cardiac stress testing, without an increase in major adverse cardiac events. These results indicate that the high-sensitivity cardiac troponin I assay and rapid diagnostic protocol can improve resource utilization for patients presenting with possible acute coronary syndrome.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality. This Australian study showed that lead extraction for cardiac implantable electronic device infections was performed in a minority of patients. Specifically, the study found that patients who underwent lead extraction had significantly lower one-year mortality compared to those who did not, highlighting the importance of complete lead extraction when managing such infections. The findings underscore the need for improved strategies to increase lead extraction rates in patients with cardiac implantable electronic device infections.</p>
<p>Article number two. Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023. An analysis of young adults aged 18 to 50 years undergoing percutaneous coronary intervention for myocardial infarction, using the TriNetX database, found distinct differences in long-term outcomes between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction. Patients with ST-elevation myocardial infarction had a higher risk of major adverse cardiovascular events, including death, compared to those with non-ST-elevation myocardial infarction. These results emphasize the need for tailored management strategies for young adults based on the type of myocardial infarction.</p>
<p>Article number three. Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry. This study, using the CathPCI Registry, compared outcomes of percutaneous coronary intervention in patients with and without prior transcatheter aortic valve replacement. The research revealed that patients undergoing percutaneous coronary intervention post-transcatheter aortic valve replacement had higher in-hospital mortality and bleeding complications compared to those without prior transcatheter aortic valve replacement. This indicates that percutaneous coronary intervention following transcatheter aortic valve replacement is associated with increased procedural risks.</p>
<p>Article number four. Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement. In this retrospective analysis of patients undergoing transcatheter aortic valve replacement with self-expanding transcatheter heart valves, the study examined the impact of aortic annulus size on patient and valve outcomes. The findings suggest that patients with small aortic annulus have a higher risk of bioprosthetic valve failure compared to those with larger annuli. This data emphasizes the importance of considering aortic annulus size when selecting patients for transcatheter aortic valve replacement with self-expanding valves, and highlights the need for further research into valve durability in patients with smaller annuli.</p>
<p>Article number five. Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome. This study assessed the impact of implementing a high-sensitivity cardiac troponin I assay and a 0/2-hour diagnostic protocol for suspected acute coronary syndromes in the emergency department. The implementation was associated with a significant reduction in hospital length of stay and a decrease in the use of cardiac stress testing, without an increase in major adverse cardiac events. These results indicate that the high-sensitivity cardiac troponin I assay and rapid diagnostic protocol can improve resource utilization for patients presenting with possible acute coronary syndrome. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>self-expanding transcatheter heart valve, emergency department, ST-elevation myocardial infarction, transcatheter aortic valve replacement, bioprosthetic valve failure, high-sensitivity cardiac troponin, major adverse cardiovascular events, CathPCI Registry, bleeding complications, Australia, lead extraction, diagnostic protocol, non-ST-elevation myocardial infarction, mortality, acute coronary syndrome, young adults, cardiovascular outcomes, aortic annulus size, percutaneous coronary intervention, valve durability, cardiac implantable electronic device infection, resource utilization, in-hospital mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/">Lead Extraction Cuts CIED Infection Deaths 09/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like self-expanding transcatheter heart valve and emergency department. Key takeaway: Lead Extraction Cuts CIED Infection Deaths.
Articl]]></itunes:subtitle>
	<itunes:episode>55</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like self-expanding transcatheter heart valve and emergency department. Key takeaway: Lead Extraction Cuts CIED Infection Deaths.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40379121">Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality.</a> (The American journal of cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40354959">Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023.</a> (The American journal of cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40354958">Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40348045">Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40348043">Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/">https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40379121" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40379121</a></p>
<p><strong>Summary:</strong> This Australian study showed that lead extraction for cardiac implantable electronic device infections was performed in a minority of patients. Specifically, the study found that patients who underwent lead extraction had significantly lower one-year mortality compared to those who did not, highlighting the importance of complete lead extraction when managing such infections. The findings underscore the need for improved strategies to increase lead extraction rates in patients with cardiac implantable electronic device infections.</p>
<h4>Article 2: Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40354959" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40354959</a></p>
<p><strong>Summary:</strong> An analysis of young adults aged 18 to 50 years undergoing percutaneous coronary intervention for myocardial infarction, using the TriNetX database, found distinct differences in long-term outcomes between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction. Patients with ST-elevation myocardial infarction had a higher risk of major adverse cardiovascular events, including death, compared to those with non-ST-elevation myocardial infarction. These results emphasize the need for tailored management strategies for young adults based on the type of myocardial infarction.</p>
<h4>Article 3: Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40354958" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40354958</a></p>
<p><strong>Summary:</strong> This study, using the CathPCI Registry, compared outcomes of percutaneous coronary intervention in patients with and without prior transcatheter aortic valve replacement. The research revealed that patients undergoing percutaneous coronary intervention post-transcatheter aortic valve replacement had higher in-hospital mortality and bleeding complications compared to those without prior transcatheter aortic valve replacement. This indicates that percutaneous coronary intervention following transcatheter aortic valve replacement is associated with increased procedural risks.</p>
<h4>Article 4: Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348045" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348045</a></p>
<p><strong>Summary:</strong> In this retrospective analysis of patients undergoing transcatheter aortic valve replacement with self-expanding transcatheter heart valves, the study examined the impact of aortic annulus size on patient and valve outcomes. The findings suggest that patients with small aortic annulus have a higher risk of bioprosthetic valve failure compared to those with larger annuli. This data emphasizes the importance of considering aortic annulus size when selecting patients for transcatheter aortic valve replacement with self-expanding valves, and highlights the need for further research into valve durability in patients with smaller annuli.</p>
<h4>Article 5: Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40348043" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40348043</a></p>
<p><strong>Summary:</strong> This study assessed the impact of implementing a high-sensitivity cardiac troponin I assay and a 0/2-hour diagnostic protocol for suspected acute coronary syndromes in the emergency department. The implementation was associated with a significant reduction in hospital length of stay and a decrease in the use of cardiac stress testing, without an increase in major adverse cardiac events. These results indicate that the high-sensitivity cardiac troponin I assay and rapid diagnostic protocol can improve resource utilization for patients presenting with possible acute coronary syndrome.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality. This Australian study showed that lead extraction for cardiac implantable electronic device infections was performed in a minority of patients. Specifically, the study found that patients who underwent lead extraction had significantly lower one-year mortality compared to those who did not, highlighting the importance of complete lead extraction when managing such infections. The findings underscore the need for improved strategies to increase lead extraction rates in patients with cardiac implantable electronic device infections.</p>
<p>Article number two. Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023. An analysis of young adults aged 18 to 50 years undergoing percutaneous coronary intervention for myocardial infarction, using the TriNetX database, found distinct differences in long-term outcomes between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction. Patients with ST-elevation myocardial infarction had a higher risk of major adverse cardiovascular events, including death, compared to those with non-ST-elevation myocardial infarction. These results emphasize the need for tailored management strategies for young adults based on the type of myocardial infarction.</p>
<p>Article number three. Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry. This study, using the CathPCI Registry, compared outcomes of percutaneous coronary intervention in patients with and without prior transcatheter aortic valve replacement. The research revealed that patients undergoing percutaneous coronary intervention post-transcatheter aortic valve replacement had higher in-hospital mortality and bleeding complications compared to those without prior transcatheter aortic valve replacement. This indicates that percutaneous coronary intervention following transcatheter aortic valve replacement is associated with increased procedural risks.</p>
<p>Article number four. Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement. In this retrospective analysis of patients undergoing transcatheter aortic valve replacement with self-expanding transcatheter heart valves, the study examined the impact of aortic annulus size on patient and valve outcomes. The findings suggest that patients with small aortic annulus have a higher risk of bioprosthetic valve failure compared to those with larger annuli. This data emphasizes the importance of considering aortic annulus size when selecting patients for transcatheter aortic valve replacement with self-expanding valves, and highlights the need for further research into valve durability in patients with smaller annuli.</p>
<p>Article number five. Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome. This study assessed the impact of implementing a high-sensitivity cardiac troponin I assay and a 0/2-hour diagnostic protocol for suspected acute coronary syndromes in the emergency department. The implementation was associated with a significant reduction in hospital length of stay and a decrease in the use of cardiac stress testing, without an increase in major adverse cardiac events. These results indicate that the high-sensitivity cardiac troponin I assay and rapid diagnostic protocol can improve resource utilization for patients presenting with possible acute coronary syndrome. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>self-expanding transcatheter heart valve, emergency department, ST-elevation myocardial infarction, transcatheter aortic valve replacement, bioprosthetic valve failure, high-sensitivity cardiac troponin, major adverse cardiovascular events, CathPCI Registry, bleeding complications, Australia, lead extraction, diagnostic protocol, non-ST-elevation myocardial infarction, mortality, acute coronary syndrome, young adults, cardiovascular outcomes, aortic annulus size, percutaneous coronary intervention, valve durability, cardiac implantable electronic device infection, resource utilization, in-hospital mortality.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/">Lead Extraction Cuts CIED Infection Deaths 09/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250915_060010.mp3" length="4208265" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like self-expanding transcatheter heart valve and emergency department. Key takeaway: Lead Extraction Cuts CIED Infection Deaths.
Article Links:
Article 1: Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality. (The American journal of cardiology)
Article 2: Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023. (The American journal of cardiology)
Article 3: Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry. (The American journal of cardiology)
Article 4: Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement. (The American journal of cardiology)
Article 5: Implementation of a High-Sensitivity Cardiac Troponin Assay and Diagnostic Protocol for Suspected Acute Coronary Syndrome. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/lead-extraction-cuts-cied-infection-deaths-09-15-25/
 Featured Articles
Article 1: Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40379121
Summary: This Australian study showed that lead extraction for cardiac implantable electronic device infections was performed in a minority of patients. Specifically, the study found that patients who underwent lead extraction had significantly lower one-year mortality compared to those who did not, highlighting the importance of complete lead extraction when managing such infections. The findings underscore the need for improved strategies to increase lead extraction rates in patients with cardiac implantable electronic device infections.
Article 2: Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40354959
Summary: An analysis of young adults aged 18 to 50 years undergoing percutaneous coronary intervention for myocardial infarction, using the TriNetX database, found distinct differences in long-term outcomes between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction. Patients with ST-elevation myocardial infarction had a higher risk of major adverse cardiovascular events, including death, compared to those with non-ST-elevation myocardial infarction. These results emphasize the need for tailored management strategies for young adults based on the type of myocardial infarction.
Article 3: Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40354958
Summary: This study, using the CathPCI Registry, compared outcomes of percutaneous coronary intervention in patients with and without prior transcatheter aortic valve replacement. The research revealed that patients undergoing percutaneous coronary intervention post-transcatheter aortic valve replacement had higher in-hospital mortality and bleeding complications compared to those without prior transcatheter aortic valve replacement. This indicates that percutaneous coronary intervention following transcatheter aortic valve replacement is associated with increased procedural risks.
Article 4: Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40348045
Summary: In this retrosp]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like self-expanding transcatheter heart valve and emergency department. Key takeaway: Lead Extraction Cuts CIED Infection Deaths.
Article Links:
Article 1: Real-World Evidence on Lead Extraction Following Cardiac Implantable Electronic Device (CIED) Infections and Its Association With 1-year Mortality. (The American journal of cardiology)
Article 2: Young Adults Undergoing Percutaneous Coronary Intervention for Myocardial Infarction in the United States, 2011 to 2023. (The American journal of cardiology)
Article 3: Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights From the CathPCI Registry. (The American journal of cardiology)
Article 4: Impact of Annulus Size on Bioprosthetic Valve Failure after Self-Expanding Transcatheter Heart Valves Replacement. (The American journal of cardiology)
Article 5: Implementation ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Early Rhythm Control Boosts AFib Mental Health 09/15/25</title>
	<link>https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/</link>
	<pubDate>Mon, 15 Sep 2025 06:57:25 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin T and emergency department. Key takeaway: Early Rhythm Control Boosts AFib Mental Health.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40947142">Revascularisation strategies for non-acute myocardial ischaemic syndromes.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40946732">Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40412585">Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40409577">Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40381900">Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/">https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Revascularisation strategies for non-acute myocardial ischaemic syndromes.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947142" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947142</a></p>
<p><strong>Summary:</strong> This Bayesian network meta-analysis compared coronary artery bypass grafting (CABG) versus percutaneous coronary intervention for non-acute myocardial ischemic syndromes, finding no significant difference in mortality between the two revascularization strategies. The study suggests that the choice of revascularization should be based on individual patient characteristics and local expertise, as neither strategy demonstrated a clear survival advantage. Further research is needed to refine patient selection criteria for each approach.</p>
<h4>Article 2: Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40946732" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40946732</a></p>
<p><strong>Summary:</strong> This study of nearly 167,000 atrial fibrillation patients in Korea found that early rhythm control, initiated within one year of diagnosis, significantly reduced mental health-related healthcare utilization in young and middle-aged individuals with preexisting mental health conditions. The findings highlight the potential benefits of early rhythm control strategies in improving mental health outcomes for vulnerable atrial fibrillation patients. This supports proactive management of atrial fibrillation beyond just rate control in this population.</p>
<h4>Article 3: Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40412585" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40412585</a></p>
<p><strong>Summary:</strong> This study demonstrated that elevated high-sensitivity cardiac troponin T (hs-cTnT) levels in emergency department patients with acute kidney injury but without myocardial infarction are associated with a significantly increased risk of adverse outcomes. Specifically, higher hs-cTnT concentrations were independently predictive of mortality and incident dialysis. These findings suggest that hs-cTnT measurement can help risk-stratify acute kidney injury patients in the emergency department, even in the absence of myocardial infarction.</p>
<h4>Article 4: Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40409577" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40409577</a></p>
<p><strong>Summary:</strong> This study of young Hispanic men found that vigorous physical activity, but not moderate physical activity, was associated with reduced cardiovascular disease risk as assessed by the Framingham Risk Score. This suggests that higher intensity exercise may be particularly beneficial for cardiovascular health in this population, warranting further investigation into optimal exercise prescriptions. The results highlight the importance of considering exercise intensity when evaluating physical activity&#8217;s impact on cardiovascular risk.</p>
<h4>Article 5: Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40381900" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40381900</a></p>
<p><strong>Summary:</strong> Analysis of the XLPAD registry showed that below-the-knee peripheral artery interventions for symptomatic peripheral artery disease had a freedom from major adverse limb events rate of 55 percent at one year. These real-world outcomes underscore the challenges in treating below-the-knee peripheral artery disease and highlight the need for improved strategies to prevent major adverse limb events such as amputation and revascularization. Further research is required to optimize patient selection and treatment techniques.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Revascularisation strategies for non-acute myocardial ischaemic syndromes. This Bayesian network meta-analysis compared coronary artery bypass grafting (CABG) versus percutaneous coronary intervention for non-acute myocardial ischemic syndromes, finding no significant difference in mortality between the two revascularization strategies. The study suggests that the choice of revascularization should be based on individual patient characteristics and local expertise, as neither strategy demonstrated a clear survival advantage. Further research is needed to refine patient selection criteria for each approach.</p>
<p>Article number two. Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients. This study of nearly 167,000 atrial fibrillation patients in Korea found that early rhythm control, initiated within one year of diagnosis, significantly reduced mental health-related healthcare utilization in young and middle-aged individuals with preexisting mental health conditions. The findings highlight the potential benefits of early rhythm control strategies in improving mental health outcomes for vulnerable atrial fibrillation patients. This supports proactive management of atrial fibrillation beyond just rate control in this population.</p>
<p>Article number three. Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction. This study demonstrated that elevated high-sensitivity cardiac troponin T (hs-cTnT) levels in emergency department patients with acute kidney injury but without myocardial infarction are associated with a significantly increased risk of adverse outcomes. Specifically, higher hs-cTnT concentrations were independently predictive of mortality and incident dialysis. These findings suggest that hs-cTnT measurement can help risk-stratify acute kidney injury patients in the emergency department, even in the absence of myocardial infarction.</p>
<p>Article number four. Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men. This study of young Hispanic men found that vigorous physical activity, but not moderate physical activity, was associated with reduced cardiovascular disease risk as assessed by the Framingham Risk Score. This suggests that higher intensity exercise may be particularly beneficial for cardiovascular health in this population, warranting further investigation into optimal exercise prescriptions. The results highlight the importance of considering exercise intensity when evaluating physical activity&#8217;s impact on cardiovascular risk.</p>
<p>Article number five. Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry. Analysis of the XLPAD registry showed that below-the-knee peripheral artery interventions for symptomatic peripheral artery disease had a freedom from major adverse limb events rate of 55 percent at one year. These real-world outcomes underscore the challenges in treating below-the-knee peripheral artery disease and highlight the need for improved strategies to prevent major adverse limb events such as amputation and revascularization. Further research is required to optimize patient selection and treatment techniques. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-sensitivity cardiac troponin T, emergency department, myocardial infarction, revascularization, physical activity, peripheral artery disease, mental health, anxiety, cardiovascular disease risk, below-the-knee intervention, Hispanic men, depression, Framingham Risk Score, coronary artery bypass grafting, myocardial ischemia, vigorous physical activity, mortality, acute kidney injury, major adverse limb events, atrial fibrillation, early rhythm control, percutaneous coronary intervention, amputation, Bayesian network meta-analysis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/">Early Rhythm Control Boosts AFib Mental Health 09/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin T and emergency department. Key takeaway: Early Rhythm Control Boosts AFib Mental Health.
Article]]></itunes:subtitle>
	<itunes:episode>54</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin T and emergency department. Key takeaway: Early Rhythm Control Boosts AFib Mental Health.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40947142">Revascularisation strategies for non-acute myocardial ischaemic syndromes.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40946732">Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40412585">Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction.</a> (The American journal of cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40409577">Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men.</a> (The American journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40381900">Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry.</a> (The American journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/">https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Revascularisation strategies for non-acute myocardial ischaemic syndromes.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40947142" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40947142</a></p>
<p><strong>Summary:</strong> This Bayesian network meta-analysis compared coronary artery bypass grafting (CABG) versus percutaneous coronary intervention for non-acute myocardial ischemic syndromes, finding no significant difference in mortality between the two revascularization strategies. The study suggests that the choice of revascularization should be based on individual patient characteristics and local expertise, as neither strategy demonstrated a clear survival advantage. Further research is needed to refine patient selection criteria for each approach.</p>
<h4>Article 2: Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40946732" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40946732</a></p>
<p><strong>Summary:</strong> This study of nearly 167,000 atrial fibrillation patients in Korea found that early rhythm control, initiated within one year of diagnosis, significantly reduced mental health-related healthcare utilization in young and middle-aged individuals with preexisting mental health conditions. The findings highlight the potential benefits of early rhythm control strategies in improving mental health outcomes for vulnerable atrial fibrillation patients. This supports proactive management of atrial fibrillation beyond just rate control in this population.</p>
<h4>Article 3: Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40412585" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40412585</a></p>
<p><strong>Summary:</strong> This study demonstrated that elevated high-sensitivity cardiac troponin T (hs-cTnT) levels in emergency department patients with acute kidney injury but without myocardial infarction are associated with a significantly increased risk of adverse outcomes. Specifically, higher hs-cTnT concentrations were independently predictive of mortality and incident dialysis. These findings suggest that hs-cTnT measurement can help risk-stratify acute kidney injury patients in the emergency department, even in the absence of myocardial infarction.</p>
<h4>Article 4: Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40409577" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40409577</a></p>
<p><strong>Summary:</strong> This study of young Hispanic men found that vigorous physical activity, but not moderate physical activity, was associated with reduced cardiovascular disease risk as assessed by the Framingham Risk Score. This suggests that higher intensity exercise may be particularly beneficial for cardiovascular health in this population, warranting further investigation into optimal exercise prescriptions. The results highlight the importance of considering exercise intensity when evaluating physical activity&#8217;s impact on cardiovascular risk.</p>
<h4>Article 5: Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry.</h4>
<p><strong>Journal:</strong> The American journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40381900" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40381900</a></p>
<p><strong>Summary:</strong> Analysis of the XLPAD registry showed that below-the-knee peripheral artery interventions for symptomatic peripheral artery disease had a freedom from major adverse limb events rate of 55 percent at one year. These real-world outcomes underscore the challenges in treating below-the-knee peripheral artery disease and highlight the need for improved strategies to prevent major adverse limb events such as amputation and revascularization. Further research is required to optimize patient selection and treatment techniques.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 15, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Revascularisation strategies for non-acute myocardial ischaemic syndromes. This Bayesian network meta-analysis compared coronary artery bypass grafting (CABG) versus percutaneous coronary intervention for non-acute myocardial ischemic syndromes, finding no significant difference in mortality between the two revascularization strategies. The study suggests that the choice of revascularization should be based on individual patient characteristics and local expertise, as neither strategy demonstrated a clear survival advantage. Further research is needed to refine patient selection criteria for each approach.</p>
<p>Article number two. Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients. This study of nearly 167,000 atrial fibrillation patients in Korea found that early rhythm control, initiated within one year of diagnosis, significantly reduced mental health-related healthcare utilization in young and middle-aged individuals with preexisting mental health conditions. The findings highlight the potential benefits of early rhythm control strategies in improving mental health outcomes for vulnerable atrial fibrillation patients. This supports proactive management of atrial fibrillation beyond just rate control in this population.</p>
<p>Article number three. Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction. This study demonstrated that elevated high-sensitivity cardiac troponin T (hs-cTnT) levels in emergency department patients with acute kidney injury but without myocardial infarction are associated with a significantly increased risk of adverse outcomes. Specifically, higher hs-cTnT concentrations were independently predictive of mortality and incident dialysis. These findings suggest that hs-cTnT measurement can help risk-stratify acute kidney injury patients in the emergency department, even in the absence of myocardial infarction.</p>
<p>Article number four. Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men. This study of young Hispanic men found that vigorous physical activity, but not moderate physical activity, was associated with reduced cardiovascular disease risk as assessed by the Framingham Risk Score. This suggests that higher intensity exercise may be particularly beneficial for cardiovascular health in this population, warranting further investigation into optimal exercise prescriptions. The results highlight the importance of considering exercise intensity when evaluating physical activity&#8217;s impact on cardiovascular risk.</p>
<p>Article number five. Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry. Analysis of the XLPAD registry showed that below-the-knee peripheral artery interventions for symptomatic peripheral artery disease had a freedom from major adverse limb events rate of 55 percent at one year. These real-world outcomes underscore the challenges in treating below-the-knee peripheral artery disease and highlight the need for improved strategies to prevent major adverse limb events such as amputation and revascularization. Further research is required to optimize patient selection and treatment techniques. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>high-sensitivity cardiac troponin T, emergency department, myocardial infarction, revascularization, physical activity, peripheral artery disease, mental health, anxiety, cardiovascular disease risk, below-the-knee intervention, Hispanic men, depression, Framingham Risk Score, coronary artery bypass grafting, myocardial ischemia, vigorous physical activity, mortality, acute kidney injury, major adverse limb events, atrial fibrillation, early rhythm control, percutaneous coronary intervention, amputation, Bayesian network meta-analysis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/">Early Rhythm Control Boosts AFib Mental Health 09/15/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250915_025626.mp3" length="3842550" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin T and emergency department. Key takeaway: Early Rhythm Control Boosts AFib Mental Health.
Article Links:
Article 1: Revascularisation strategies for non-acute myocardial ischaemic syndromes. (Heart (British Cardiac Society))
Article 2: Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients. (Heart rhythm)
Article 3: Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction. (The American journal of cardiology)
Article 4: Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men. (The American journal of cardiology)
Article 5: Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry. (The American journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/early-rhythm-control-boosts-afib-mental-health-09-15-25/
 Featured Articles
Article 1: Revascularisation strategies for non-acute myocardial ischaemic syndromes.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40947142
Summary: This Bayesian network meta-analysis compared coronary artery bypass grafting (CABG) versus percutaneous coronary intervention for non-acute myocardial ischemic syndromes, finding no significant difference in mortality between the two revascularization strategies. The study suggests that the choice of revascularization should be based on individual patient characteristics and local expertise, as neither strategy demonstrated a clear survival advantage. Further research is needed to refine patient selection criteria for each approach.
Article 2: Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40946732
Summary: This study of nearly 167,000 atrial fibrillation patients in Korea found that early rhythm control, initiated within one year of diagnosis, significantly reduced mental health-related healthcare utilization in young and middle-aged individuals with preexisting mental health conditions. The findings highlight the potential benefits of early rhythm control strategies in improving mental health outcomes for vulnerable atrial fibrillation patients. This supports proactive management of atrial fibrillation beyond just rate control in this population.
Article 3: Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40412585
Summary: This study demonstrated that elevated high-sensitivity cardiac troponin T (hs-cTnT) levels in emergency department patients with acute kidney injury but without myocardial infarction are associated with a significantly increased risk of adverse outcomes. Specifically, higher hs-cTnT concentrations were independently predictive of mortality and incident dialysis. These findings suggest that hs-cTnT measurement can help risk-stratify acute kidney injury patients in the emergency department, even in the absence of myocardial infarction.
Article 4: Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men.
Journal: The American journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40409577
Summary: This study of young Hispanic men found that vigorous physical activity, but not moderate physical activity, was associated with reduced cardiovascular disease risk as assessed by the Framingham Risk Score. This suggests that higher intensity exercise may be particularly beneficial for cardiovascular health ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 15, 2025. This episode summarizes 5 key cardiology studies on topics like high-sensitivity cardiac troponin T and emergency department. Key takeaway: Early Rhythm Control Boosts AFib Mental Health.
Article Links:
Article 1: Revascularisation strategies for non-acute myocardial ischaemic syndromes. (Heart (British Cardiac Society))
Article 2: Early Rhythm Control and Mental Health-Related Hospitalizations in Young and Middle-Aged Atrial Fibrillation Patients. (Heart rhythm)
Article 3: Prognostic Implications of High-Sensitivity Cardiac Troponins in Patients With Acute Kidney Injury Without Myocardial Infarction. (The American journal of cardiology)
Article 4: Vigorous But Not Moderate Physical Activity Is Associated With Reduced Cardiovascular Disease Risk In Young Hispanic Men. (The American journal of cardiology)
Article 5: Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry. (The ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Electrogram Frequency Predicts Ablation Success 09/14/25</title>
	<link>https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/</link>
	<pubDate>Sun, 14 Sep 2025 10:01:09 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter closure and cardiac imaging. Key takeaway: Electrogram Frequency Predicts Ablation Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40945558">Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III).</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40945557">Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40938234">Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40945911">Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40945616">Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/">https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III).</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945558</a></p>
<p><strong>Summary:</strong> This prospective study of anticoagulated atrial fibrillation patients identified distinct phenotypic clusters using hierarchical clustering. The clusters were then analyzed for their association with thromboembolic events, major bleeding, major adverse cardiovascular events, cardiovascular death, and all-cause death over two years, providing a framework for phenotype-guided risk stratification in this population.</p>
<h4>Article 2: Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945557" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945557</a></p>
<p><strong>Summary:</strong> This retrospective analysis of 111 idiopathic ventricular arrhythmias in 104 patients examined peak frequency analyses of electrograms at the earliest activation site to predict catheter ablation outcomes. The study suggests peak frequency electrogram characteristics can help differentiate near-field from far-field components, potentially improving ablation success by better identifying appropriate ablation targets.</p>
<h4>Article 3: Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40938234" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40938234</a></p>
<p><strong>Summary:</strong> This prospective study of 81 patients with biopsy-proven light chain amyloidosis evaluated changes in myocardial amyloid burden following plasma cell-directed chemotherapy using serial cardiac imaging with radiolabeled serum amyloid P component scintigraphy. The study tracked myocardial amyloid fibril burden in patients with and without amyloid cardiomyopathy, seeking to quantify the impact of plasma cell therapy on cardiac amyloid deposits and inform treatment strategies.</p>
<h4>Article 4: Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945911" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945911</a></p>
<p><strong>Summary:</strong> This retrospective, single-center registry evaluated the feasibility, safety, and efficacy of using multiple Amplatzer ParaValvular Plug III devices for transcatheter paravalvular leak closure. The study demonstrated that this multi-occluder approach is a reasonable alternative to surgical repair, particularly in high-risk patients experiencing heart failure or hemolysis due to paravalvular leaks.</p>
<h4>Article 5: Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945616" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945616</a></p>
<p><strong>Summary:</strong> This retrospective study assessed functional results measured by quantitative flow ratio immediately and six months following successful percutaneous coronary intervention of a chronic total occlusion. The study investigated how coronary perfusion changes over time after successful chronic total occlusion percutaneous coronary intervention, which may impact physiological assessment, suggesting QFR can help detect suboptimal results post-procedure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III). This prospective study of anticoagulated atrial fibrillation patients identified distinct phenotypic clusters using hierarchical clustering. The clusters were then analyzed for their association with thromboembolic events, major bleeding, major adverse cardiovascular events, cardiovascular death, and all-cause death over two years, providing a framework for phenotype-guided risk stratification in this population.</p>
<p>Article number two. Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success. This retrospective analysis of 111 idiopathic ventricular arrhythmias in 104 patients examined peak frequency analyses of electrograms at the earliest activation site to predict catheter ablation outcomes. The study suggests peak frequency electrogram characteristics can help differentiate near-field from far-field components, potentially improving ablation success by better identifying appropriate ablation targets.</p>
<p>Article number three. Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. This prospective study of 81 patients with biopsy-proven light chain amyloidosis evaluated changes in myocardial amyloid burden following plasma cell-directed chemotherapy using serial cardiac imaging with radiolabeled serum amyloid P component scintigraphy. The study tracked myocardial amyloid fibril burden in patients with and without amyloid cardiomyopathy, seeking to quantify the impact of plasma cell therapy on cardiac amyloid deposits and inform treatment strategies.</p>
<p>Article number four. Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry. This retrospective, single-center registry evaluated the feasibility, safety, and efficacy of using multiple Amplatzer ParaValvular Plug III devices for transcatheter paravalvular leak closure. The study demonstrated that this multi-occluder approach is a reasonable alternative to surgical repair, particularly in high-risk patients experiencing heart failure or hemolysis due to paravalvular leaks.</p>
<p>Article number five. Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion. This retrospective study assessed functional results measured by quantitative flow ratio immediately and six months following successful percutaneous coronary intervention of a chronic total occlusion. The study investigated how coronary perfusion changes over time after successful chronic total occlusion percutaneous coronary intervention, which may impact physiological assessment, suggesting QFR can help detect suboptimal results post-procedure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transcatheter closure, cardiac imaging, heart failure, amyloid cardiomyopathy, ablation success, thromboembolism, peak frequency, chronic total occlusion, plasma cell therapy, anticoagulation, quantitative flow ratio, atrial fibrillation, Amplatzer ParaValvular Plug III, hemolysis, electrogram, coronary perfusion, physiological assessment, catheter ablation, light chain amyloidosis, ventricular arrhythmia, percutaneous coronary intervention, major bleeding, risk stratification, paravalvular leak, myocardial amyloid burden.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/">Electrogram Frequency Predicts Ablation Success 09/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter closure and cardiac imaging. Key takeaway: Electrogram Frequency Predicts Ablation Success.
Article Links:
Article 1:]]></itunes:subtitle>
	<itunes:episode>53</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter closure and cardiac imaging. Key takeaway: Electrogram Frequency Predicts Ablation Success.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40945558">Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III).</a> (Heart rhythm)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40945557">Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success.</a> (Heart rhythm)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40938234">Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.</a> (JACC. Cardiovascular imaging)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40945911">Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry.</a> (The Canadian journal of cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40945616">Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion.</a> (International journal of cardiology)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/">https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III).</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945558</a></p>
<p><strong>Summary:</strong> This prospective study of anticoagulated atrial fibrillation patients identified distinct phenotypic clusters using hierarchical clustering. The clusters were then analyzed for their association with thromboembolic events, major bleeding, major adverse cardiovascular events, cardiovascular death, and all-cause death over two years, providing a framework for phenotype-guided risk stratification in this population.</p>
<h4>Article 2: Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945557" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945557</a></p>
<p><strong>Summary:</strong> This retrospective analysis of 111 idiopathic ventricular arrhythmias in 104 patients examined peak frequency analyses of electrograms at the earliest activation site to predict catheter ablation outcomes. The study suggests peak frequency electrogram characteristics can help differentiate near-field from far-field components, potentially improving ablation success by better identifying appropriate ablation targets.</p>
<h4>Article 3: Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.</h4>
<p><strong>Journal:</strong> JACC. Cardiovascular imaging</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40938234" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40938234</a></p>
<p><strong>Summary:</strong> This prospective study of 81 patients with biopsy-proven light chain amyloidosis evaluated changes in myocardial amyloid burden following plasma cell-directed chemotherapy using serial cardiac imaging with radiolabeled serum amyloid P component scintigraphy. The study tracked myocardial amyloid fibril burden in patients with and without amyloid cardiomyopathy, seeking to quantify the impact of plasma cell therapy on cardiac amyloid deposits and inform treatment strategies.</p>
<h4>Article 4: Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry.</h4>
<p><strong>Journal:</strong> The Canadian journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945911" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945911</a></p>
<p><strong>Summary:</strong> This retrospective, single-center registry evaluated the feasibility, safety, and efficacy of using multiple Amplatzer ParaValvular Plug III devices for transcatheter paravalvular leak closure. The study demonstrated that this multi-occluder approach is a reasonable alternative to surgical repair, particularly in high-risk patients experiencing heart failure or hemolysis due to paravalvular leaks.</p>
<h4>Article 5: Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion.</h4>
<p><strong>Journal:</strong> International journal of cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945616" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945616</a></p>
<p><strong>Summary:</strong> This retrospective study assessed functional results measured by quantitative flow ratio immediately and six months following successful percutaneous coronary intervention of a chronic total occlusion. The study investigated how coronary perfusion changes over time after successful chronic total occlusion percutaneous coronary intervention, which may impact physiological assessment, suggesting QFR can help detect suboptimal results post-procedure.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III). This prospective study of anticoagulated atrial fibrillation patients identified distinct phenotypic clusters using hierarchical clustering. The clusters were then analyzed for their association with thromboembolic events, major bleeding, major adverse cardiovascular events, cardiovascular death, and all-cause death over two years, providing a framework for phenotype-guided risk stratification in this population.</p>
<p>Article number two. Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success. This retrospective analysis of 111 idiopathic ventricular arrhythmias in 104 patients examined peak frequency analyses of electrograms at the earliest activation site to predict catheter ablation outcomes. The study suggests peak frequency electrogram characteristics can help differentiate near-field from far-field components, potentially improving ablation success by better identifying appropriate ablation targets.</p>
<p>Article number three. Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. This prospective study of 81 patients with biopsy-proven light chain amyloidosis evaluated changes in myocardial amyloid burden following plasma cell-directed chemotherapy using serial cardiac imaging with radiolabeled serum amyloid P component scintigraphy. The study tracked myocardial amyloid fibril burden in patients with and without amyloid cardiomyopathy, seeking to quantify the impact of plasma cell therapy on cardiac amyloid deposits and inform treatment strategies.</p>
<p>Article number four. Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry. This retrospective, single-center registry evaluated the feasibility, safety, and efficacy of using multiple Amplatzer ParaValvular Plug III devices for transcatheter paravalvular leak closure. The study demonstrated that this multi-occluder approach is a reasonable alternative to surgical repair, particularly in high-risk patients experiencing heart failure or hemolysis due to paravalvular leaks.</p>
<p>Article number five. Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion. This retrospective study assessed functional results measured by quantitative flow ratio immediately and six months following successful percutaneous coronary intervention of a chronic total occlusion. The study investigated how coronary perfusion changes over time after successful chronic total occlusion percutaneous coronary intervention, which may impact physiological assessment, suggesting QFR can help detect suboptimal results post-procedure. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>transcatheter closure, cardiac imaging, heart failure, amyloid cardiomyopathy, ablation success, thromboembolism, peak frequency, chronic total occlusion, plasma cell therapy, anticoagulation, quantitative flow ratio, atrial fibrillation, Amplatzer ParaValvular Plug III, hemolysis, electrogram, coronary perfusion, physiological assessment, catheter ablation, light chain amyloidosis, ventricular arrhythmia, percutaneous coronary intervention, major bleeding, risk stratification, paravalvular leak, myocardial amyloid burden.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/">Electrogram Frequency Predicts Ablation Success 09/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250914_060011.mp3" length="3697101" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter closure and cardiac imaging. Key takeaway: Electrogram Frequency Predicts Ablation Success.
Article Links:
Article 1: Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III). (Heart rhythm)
Article 2: Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success. (Heart rhythm)
Article 3: Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. (JACC. Cardiovascular imaging)
Article 4: Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry. (The Canadian journal of cardiology)
Article 5: Serial quantitative flow ratio measurements of a successfully recanalized coronary chronic total occlusion. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/electrogram-frequency-predicts-ablation-success-09-14-25/
 Featured Articles
Article 1: Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III).
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40945558
Summary: This prospective study of anticoagulated atrial fibrillation patients identified distinct phenotypic clusters using hierarchical clustering. The clusters were then analyzed for their association with thromboembolic events, major bleeding, major adverse cardiovascular events, cardiovascular death, and all-cause death over two years, providing a framework for phenotype-guided risk stratification in this population.
Article 2: Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40945557
Summary: This retrospective analysis of 111 idiopathic ventricular arrhythmias in 104 patients examined peak frequency analyses of electrograms at the earliest activation site to predict catheter ablation outcomes. The study suggests peak frequency electrogram characteristics can help differentiate near-field from far-field components, potentially improving ablation success by better identifying appropriate ablation targets.
Article 3: Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40938234
Summary: This prospective study of 81 patients with biopsy-proven light chain amyloidosis evaluated changes in myocardial amyloid burden following plasma cell-directed chemotherapy using serial cardiac imaging with radiolabeled serum amyloid P component scintigraphy. The study tracked myocardial amyloid fibril burden in patients with and without amyloid cardiomyopathy, seeking to quantify the impact of plasma cell therapy on cardiac amyloid deposits and inform treatment strategies.
Article 4: Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry.
Journal: The Canadian journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40945911
Summary: This retrospective, single-center registry evaluated the feasibility, safety, and efficacy of using multiple Amplatzer ParaValvular Plug III devices for transcatheter paravalvular leak closure. The study demonstrated that this multi-occluder approach is a reasonable alternative to surgical repair, particularly in high-risk patients experiencing heart failure or hemolysis due to paravalvular leaks.
Article 5: Serial quantitative flow ratio measurements of a suc]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like transcatheter closure and cardiac imaging. Key takeaway: Electrogram Frequency Predicts Ablation Success.
Article Links:
Article 1: Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: cluster analysis of the Murcia AF Project III (MAFP-III). (Heart rhythm)
Article 2: Comparison of Far-Field and Peak Frequency Electrogram Characteristics at the Earliest Activation Sites during Idiopathic Ventricular Arrhythmias: A novel index to predict ablation success. (Heart rhythm)
Article 3: Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. (JACC. Cardiovascular imaging)
Article 4: Multiple Amplatzer Vascular Plug III implantation-feasible, safe, and effective for paravalvular leak closure: Results from a single-center registry. (The Canadian journal of cardiology)
Article 5: Serial quantitative flow ratio measurements]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aortic Dilation: New Predictors of Rapid Progression 09/14/25</title>
	<link>https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/</link>
	<pubDate>Sun, 14 Sep 2025 06:57:21 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography and right ventricle. Key takeaway: Aortic Dilation: New Predictors of Rapid Progression.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40180444">Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40139682">Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40081936">Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40054888">Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40945559">Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/">https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40180444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40180444</a></p>
<p><strong>Summary:</strong> This study prospectively evaluated cardiotoxicity in patients receiving vascular endothelial growth factor inhibitors for cancer treatment, utilizing blood pressure monitoring, echocardiography, and cardiac biomarkers. The research aims to define the incidence, time course, and mechanisms of vascular endothelial growth factor inhibitor associated cancer therapy-related cardiac dysfunction and hypertension through a multi-modal approach including cardiovascular magnetic resonance imaging. The study is ongoing and will provide insights into early detection and management of cardiotoxicity in this patient population.</p>
<h4>Article 2: Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40139682" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40139682</a></p>
<p><strong>Summary:</strong> This prospective cohort study of over 150,000 women from the United Kingdom Biobank examined the association between female-specific factors like premature menopause, adverse pregnancy outcomes, and early or late menarche, and the occurrence and progression of cardiometabolic disease. The study aims to determine how these factors interact with genetic risk to influence cardiometabolic health in women. Understanding these interactions will help refine risk stratification and prevention strategies for cardiometabolic disease in women.</p>
<h4>Article 3: Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40081936" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40081936</a></p>
<p><strong>Summary:</strong> This study investigated the progression of incidentally detected mild to moderate ascending aortic dilation in a Swedish population aged 50-65 years. Researchers followed over 5,000 participants to identify risk factors associated with rapid aortic dilation, which can lead to life-threatening aortic syndromes. Identifying these risk factors will refine surveillance strategies and potentially guide preventive interventions for aortic aneurysm.</p>
<h4>Article 4: Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40054888" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40054888</a></p>
<p><strong>Summary:</strong> This single-arm, open-label study evaluated the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation for drug-refractory non-obstructive hypertrophic cardiomyopathy patients with severe septal hypertrophy. Twenty patients underwent the procedure, with follow-up assessments to determine the impact on symptoms and cardiac function. Percutaneous intramyocardial septal radiofrequency ablation offers a new invasive treatment option for this challenging patient population.</p>
<h4>Article 5: Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945559" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945559</a></p>
<p><strong>Summary:</strong> This retrospective study investigated the spatial relationship between low-voltage areas detected during electrophysiological mapping and morphofunctional abnormalities seen on computed tomography imaging in patients with arrhythmogenic right ventricular cardiomyopathy. The right ventricle was divided into seven regions, and the correlation between electrical and structural changes was analyzed. Understanding this relationship may improve the targeting of ventricular tachycardia ablation and risk stratification in arrhythmogenic right ventricular cardiomyopathy.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. This study prospectively evaluated cardiotoxicity in patients receiving vascular endothelial growth factor inhibitors for cancer treatment, utilizing blood pressure monitoring, echocardiography, and cardiac biomarkers. The research aims to define the incidence, time course, and mechanisms of vascular endothelial growth factor inhibitor associated cancer therapy-related cardiac dysfunction and hypertension through a multi-modal approach including cardiovascular magnetic resonance imaging. The study is ongoing and will provide insights into early detection and management of cardiotoxicity in this patient population.</p>
<p>Article number two. Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study. This prospective cohort study of over 150,000 women from the United Kingdom Biobank examined the association between female-specific factors like premature menopause, adverse pregnancy outcomes, and early or late menarche, and the occurrence and progression of cardiometabolic disease. The study aims to determine how these factors interact with genetic risk to influence cardiometabolic health in women. Understanding these interactions will help refine risk stratification and prevention strategies for cardiometabolic disease in women.</p>
<p>Article number three. Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population. This study investigated the progression of incidentally detected mild to moderate ascending aortic dilation in a Swedish population aged 50-65 years. Researchers followed over 5,000 participants to identify risk factors associated with rapid aortic dilation, which can lead to life-threatening aortic syndromes. Identifying these risk factors will refine surveillance strategies and potentially guide preventive interventions for aortic aneurysm.</p>
<p>Article number four. Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. This single-arm, open-label study evaluated the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation for drug-refractory non-obstructive hypertrophic cardiomyopathy patients with severe septal hypertrophy. Twenty patients underwent the procedure, with follow-up assessments to determine the impact on symptoms and cardiac function. Percutaneous intramyocardial septal radiofrequency ablation offers a new invasive treatment option for this challenging patient population.</p>
<p>Article number five. Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy. This retrospective study investigated the spatial relationship between low-voltage areas detected during electrophysiological mapping and morphofunctional abnormalities seen on computed tomography imaging in patients with arrhythmogenic right ventricular cardiomyopathy. The right ventricle was divided into seven regions, and the correlation between electrical and structural changes was analyzed. Understanding this relationship may improve the targeting of ventricular tachycardia ablation and risk stratification in arrhythmogenic right ventricular cardiomyopathy. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>computed tomography, right ventricle, premature menopause, vascular endothelial growth factor inhibitors, hypertension, surveillance, Liwen procedure, cancer therapy-related cardiac dysfunction, cardiometabolic disease, non-obstructive hypertrophic cardiomyopathy, septal hypertrophy, risk factors, genetic risk, thoracic aortic aneurysm, radiofrequency ablation, female-specific factors, cardiovascular magnetic resonance imaging, ventricular tachycardia ablation, arrhythmogenic right ventricular cardiomyopathy, aortic progression, low-voltage areas, adverse pregnancy outcomes, cardiotoxicity, percutaneous intramyocardial septal radiofrequency ablation, ascending aortic dilation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/">Aortic Dilation: New Predictors of Rapid Progression 09/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography and right ventricle. Key takeaway: Aortic Dilation: New Predictors of Rapid Progression.
Article Links:
Article]]></itunes:subtitle>
	<itunes:episode>52</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography and right ventricle. Key takeaway: Aortic Dilation: New Predictors of Rapid Progression.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40180444">Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.</a> (Heart (British Cardiac Society))</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40139682">Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study.</a> (Heart (British Cardiac Society))</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40081936">Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population.</a> (Heart (British Cardiac Society))</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40054888">Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40945559">Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy.</a> (Heart rhythm)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/">https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40180444" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40180444</a></p>
<p><strong>Summary:</strong> This study prospectively evaluated cardiotoxicity in patients receiving vascular endothelial growth factor inhibitors for cancer treatment, utilizing blood pressure monitoring, echocardiography, and cardiac biomarkers. The research aims to define the incidence, time course, and mechanisms of vascular endothelial growth factor inhibitor associated cancer therapy-related cardiac dysfunction and hypertension through a multi-modal approach including cardiovascular magnetic resonance imaging. The study is ongoing and will provide insights into early detection and management of cardiotoxicity in this patient population.</p>
<h4>Article 2: Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40139682" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40139682</a></p>
<p><strong>Summary:</strong> This prospective cohort study of over 150,000 women from the United Kingdom Biobank examined the association between female-specific factors like premature menopause, adverse pregnancy outcomes, and early or late menarche, and the occurrence and progression of cardiometabolic disease. The study aims to determine how these factors interact with genetic risk to influence cardiometabolic health in women. Understanding these interactions will help refine risk stratification and prevention strategies for cardiometabolic disease in women.</p>
<h4>Article 3: Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40081936" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40081936</a></p>
<p><strong>Summary:</strong> This study investigated the progression of incidentally detected mild to moderate ascending aortic dilation in a Swedish population aged 50-65 years. Researchers followed over 5,000 participants to identify risk factors associated with rapid aortic dilation, which can lead to life-threatening aortic syndromes. Identifying these risk factors will refine surveillance strategies and potentially guide preventive interventions for aortic aneurysm.</p>
<h4>Article 4: Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40054888" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40054888</a></p>
<p><strong>Summary:</strong> This single-arm, open-label study evaluated the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation for drug-refractory non-obstructive hypertrophic cardiomyopathy patients with severe septal hypertrophy. Twenty patients underwent the procedure, with follow-up assessments to determine the impact on symptoms and cardiac function. Percutaneous intramyocardial septal radiofrequency ablation offers a new invasive treatment option for this challenging patient population.</p>
<h4>Article 5: Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Heart rhythm</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40945559" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40945559</a></p>
<p><strong>Summary:</strong> This retrospective study investigated the spatial relationship between low-voltage areas detected during electrophysiological mapping and morphofunctional abnormalities seen on computed tomography imaging in patients with arrhythmogenic right ventricular cardiomyopathy. The right ventricle was divided into seven regions, and the correlation between electrical and structural changes was analyzed. Understanding this relationship may improve the targeting of ventricular tachycardia ablation and risk stratification in arrhythmogenic right ventricular cardiomyopathy.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. This study prospectively evaluated cardiotoxicity in patients receiving vascular endothelial growth factor inhibitors for cancer treatment, utilizing blood pressure monitoring, echocardiography, and cardiac biomarkers. The research aims to define the incidence, time course, and mechanisms of vascular endothelial growth factor inhibitor associated cancer therapy-related cardiac dysfunction and hypertension through a multi-modal approach including cardiovascular magnetic resonance imaging. The study is ongoing and will provide insights into early detection and management of cardiotoxicity in this patient population.</p>
<p>Article number two. Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study. This prospective cohort study of over 150,000 women from the United Kingdom Biobank examined the association between female-specific factors like premature menopause, adverse pregnancy outcomes, and early or late menarche, and the occurrence and progression of cardiometabolic disease. The study aims to determine how these factors interact with genetic risk to influence cardiometabolic health in women. Understanding these interactions will help refine risk stratification and prevention strategies for cardiometabolic disease in women.</p>
<p>Article number three. Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population. This study investigated the progression of incidentally detected mild to moderate ascending aortic dilation in a Swedish population aged 50-65 years. Researchers followed over 5,000 participants to identify risk factors associated with rapid aortic dilation, which can lead to life-threatening aortic syndromes. Identifying these risk factors will refine surveillance strategies and potentially guide preventive interventions for aortic aneurysm.</p>
<p>Article number four. Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. This single-arm, open-label study evaluated the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation for drug-refractory non-obstructive hypertrophic cardiomyopathy patients with severe septal hypertrophy. Twenty patients underwent the procedure, with follow-up assessments to determine the impact on symptoms and cardiac function. Percutaneous intramyocardial septal radiofrequency ablation offers a new invasive treatment option for this challenging patient population.</p>
<p>Article number five. Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy. This retrospective study investigated the spatial relationship between low-voltage areas detected during electrophysiological mapping and morphofunctional abnormalities seen on computed tomography imaging in patients with arrhythmogenic right ventricular cardiomyopathy. The right ventricle was divided into seven regions, and the correlation between electrical and structural changes was analyzed. Understanding this relationship may improve the targeting of ventricular tachycardia ablation and risk stratification in arrhythmogenic right ventricular cardiomyopathy. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>computed tomography, right ventricle, premature menopause, vascular endothelial growth factor inhibitors, hypertension, surveillance, Liwen procedure, cancer therapy-related cardiac dysfunction, cardiometabolic disease, non-obstructive hypertrophic cardiomyopathy, septal hypertrophy, risk factors, genetic risk, thoracic aortic aneurysm, radiofrequency ablation, female-specific factors, cardiovascular magnetic resonance imaging, ventricular tachycardia ablation, arrhythmogenic right ventricular cardiomyopathy, aortic progression, low-voltage areas, adverse pregnancy outcomes, cardiotoxicity, percutaneous intramyocardial septal radiofrequency ablation, ascending aortic dilation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/">Aortic Dilation: New Predictors of Rapid Progression 09/14/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250914_025621.mp3" length="3985910" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography and right ventricle. Key takeaway: Aortic Dilation: New Predictors of Rapid Progression.
Article Links:
Article 1: Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. (Heart (British Cardiac Society))
Article 2: Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study. (Heart (British Cardiac Society))
Article 3: Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population. (Heart (British Cardiac Society))
Article 4: Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. (Heart (British Cardiac Society))
Article 5: Relationship Between Electrical and Morphological Alterations of the Right Ventricle in Arrhythmogenic Right Ventricular Cardiomyopathy. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/aortic-dilation-new-predictors-of-rapid-progression-09-14-25/
 Featured Articles
Article 1: Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40180444
Summary: This study prospectively evaluated cardiotoxicity in patients receiving vascular endothelial growth factor inhibitors for cancer treatment, utilizing blood pressure monitoring, echocardiography, and cardiac biomarkers. The research aims to define the incidence, time course, and mechanisms of vascular endothelial growth factor inhibitor associated cancer therapy-related cardiac dysfunction and hypertension through a multi-modal approach including cardiovascular magnetic resonance imaging. The study is ongoing and will provide insights into early detection and management of cardiotoxicity in this patient population.
Article 2: Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40139682
Summary: This prospective cohort study of over 150,000 women from the United Kingdom Biobank examined the association between female-specific factors like premature menopause, adverse pregnancy outcomes, and early or late menarche, and the occurrence and progression of cardiometabolic disease. The study aims to determine how these factors interact with genetic risk to influence cardiometabolic health in women. Understanding these interactions will help refine risk stratification and prevention strategies for cardiometabolic disease in women.
Article 3: Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40081936
Summary: This study investigated the progression of incidentally detected mild to moderate ascending aortic dilation in a Swedish population aged 50-65 years. Researchers followed over 5,000 participants to identify risk factors associated with rapid aortic dilation, which can lead to life-threatening aortic syndromes. Identifying these risk factors will refine surveillance strategies and potentially guide preventive interventions for aortic aneurysm.
Article 4: Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40054888
Sum]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 14, 2025. This episode summarizes 5 key cardiology studies on topics like computed tomography and right ventricle. Key takeaway: Aortic Dilation: New Predictors of Rapid Progression.
Article Links:
Article 1: Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. (Heart (British Cardiac Society))
Article 2: Synergistic effects of female-specific conditions and genetic risk on cardiometabolic disease: a cohort study. (Heart (British Cardiac Society))
Article 3: Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population. (Heart (British Cardiac Society))
Article 4: Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. (He]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ATTR Amyloidosis: Missed HF Diagnosis in Minorities 09/13/25</title>
	<link>https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/</link>
	<pubDate>Sat, 13 Sep 2025 14:49:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 13, 2025. This episode summarizes 5 key cardiology studies on topics like acute myocardial infarction and digital health. Key takeaway: ATTR Amyloidosis: Missed HF Diagnosis in Minorities.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40928810">Approach to the Postmarket Evaluation of Consumer Wearable Technologies.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40928770">Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40928765">Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40908114">Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40368452">Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/">https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Approach to the Postmarket Evaluation of Consumer Wearable Technologies.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928810" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928810</a></p>
<p><strong>Summary:</strong> This article discusses the need for empirical research on the postmarket use of consumer wearable technologies. The Stanford Center for Digital Health organized think tank meetings to develop a framework for evaluating these devices after they have been released to the public. The focus is on gathering data regarding real-world performance, accuracy, and potential impact on patient outcomes.</p>
<h4>Article 2: Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928770" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928770</a></p>
<p><strong>Summary:</strong> This study addresses the challenge of assessing the hemodynamic significance of right anomalous aortic origin of a coronary artery. Invasive fractional flow reserve during a dobutamine-atropine volume challenge is the reference standard, but noninvasive imaging modalities are being explored as a less invasive alternative. The research aims to determine if noninvasive imaging can accurately evaluate dynamic compression of the anomalous vessel.</p>
<h4>Article 3: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928765" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928765</a></p>
<p><strong>Summary:</strong> This study investigates the prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. The research aims to determine the proportion of heart failure cases in these populations attributable to both wild-type and variant transthyretin cardiac amyloidosis, including the V142I variant common in Black Americans. Understanding this prevalence is crucial for improving diagnosis and treatment in at-risk groups.</p>
<h4>Article 4: Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40908114" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40908114</a></p>
<p><strong>Summary:</strong> This analysis of the Colchicine and Spironolactone in Patients with Left Ventricular Dysfunction after Myocardial Infarction (CLEAR) trial uses generalized pairwise comparisons to assess the benefit-risk profiles of colchicine and spironolactone in acute myocardial infarction. This method allows for a hierarchical ranking of clinical outcomes, providing a more intuitive understanding of treatment trade-offs compared to composite endpoints. The analysis explores the overall clinical benefit considering different event severities.</p>
<h4>Article 5: Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40368452" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40368452</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment Extended Follow-up study compares long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. It seeks to evaluate if intravascular ultrasound-guided percutaneous coronary intervention is comparable to coronary artery bypass grafting in improving long-term clinical outcomes in patients with multivessel disease. The focus is on patients who were treated with either procedure as part of the original clinical trial.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Approach to the Postmarket Evaluation of Consumer Wearable Technologies. This article discusses the need for empirical research on the postmarket use of consumer wearable technologies. The Stanford Center for Digital Health organized think tank meetings to develop a framework for evaluating these devices after they have been released to the public. The focus is on gathering data regarding real-world performance, accuracy, and potential impact on patient outcomes.</p>
<p>Article number two. Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies. This study addresses the challenge of assessing the hemodynamic significance of right anomalous aortic origin of a coronary artery. Invasive fractional flow reserve during a dobutamine-atropine volume challenge is the reference standard, but noninvasive imaging modalities are being explored as a less invasive alternative. The research aims to determine if noninvasive imaging can accurately evaluate dynamic compression of the anomalous vessel.</p>
<p>Article number three. Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. This study investigates the prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. The research aims to determine the proportion of heart failure cases in these populations attributable to both wild-type and variant transthyretin cardiac amyloidosis, including the V142I variant common in Black Americans. Understanding this prevalence is crucial for improving diagnosis and treatment in at-risk groups.</p>
<p>Article number four. Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial. This analysis of the Colchicine and Spironolactone in Patients with Left Ventricular Dysfunction after Myocardial Infarction (CLEAR) trial uses generalized pairwise comparisons to assess the benefit-risk profiles of colchicine and spironolactone in acute myocardial infarction. This method allows for a hierarchical ranking of clinical outcomes, providing a more intuitive understanding of treatment trade-offs compared to composite endpoints. The analysis explores the overall clinical benefit considering different event severities.</p>
<p>Article number five. Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. This post hoc analysis of the Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment Extended Follow-up study compares long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. It seeks to evaluate if intravascular ultrasound-guided percutaneous coronary intervention is comparable to coronary artery bypass grafting in improving long-term clinical outcomes in patients with multivessel disease. The focus is on patients who were treated with either procedure as part of the original clinical trial. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute myocardial infarction, digital health, multivessel coronary artery disease, percutaneous coronary intervention, colchicine, heart failure, postmarket evaluation, coronary artery bypass grafting, spironolactone, hemodynamic significance, noninvasive imaging, fractional flow reserve, coronary artery anomaly, transthyretin cardiac amyloidosis, consumer wearables, intravascular ultrasound, Hispanic Americans, US Food and Drug Administration, Black Americans, generalized pairwise comparisons.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/">ATTR Amyloidosis: Missed HF Diagnosis in Minorities 09/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 13, 2025. This episode summarizes 5 key cardiology studies on topics like acute myocardial infarction and digital health. Key takeaway: ATTR Amyloidosis: Missed HF Diagnosis in Minorities.
Article Links:
A]]></itunes:subtitle>
	<itunes:episode>51</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 13, 2025. This episode summarizes 5 key cardiology studies on topics like acute myocardial infarction and digital health. Key takeaway: ATTR Amyloidosis: Missed HF Diagnosis in Minorities.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40928810">Approach to the Postmarket Evaluation of Consumer Wearable Technologies.</a> (JAMA cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40928770">Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies.</a> (JAMA cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40928765">Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.</a> (JAMA cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40908114">Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.</a> (Heart (British Cardiac Society))</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40368452">Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease.</a> (Heart (British Cardiac Society))</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/">https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Approach to the Postmarket Evaluation of Consumer Wearable Technologies.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928810" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928810</a></p>
<p><strong>Summary:</strong> This article discusses the need for empirical research on the postmarket use of consumer wearable technologies. The Stanford Center for Digital Health organized think tank meetings to develop a framework for evaluating these devices after they have been released to the public. The focus is on gathering data regarding real-world performance, accuracy, and potential impact on patient outcomes.</p>
<h4>Article 2: Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928770" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928770</a></p>
<p><strong>Summary:</strong> This study addresses the challenge of assessing the hemodynamic significance of right anomalous aortic origin of a coronary artery. Invasive fractional flow reserve during a dobutamine-atropine volume challenge is the reference standard, but noninvasive imaging modalities are being explored as a less invasive alternative. The research aims to determine if noninvasive imaging can accurately evaluate dynamic compression of the anomalous vessel.</p>
<h4>Article 3: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.</h4>
<p><strong>Journal:</strong> JAMA cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928765" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928765</a></p>
<p><strong>Summary:</strong> This study investigates the prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. The research aims to determine the proportion of heart failure cases in these populations attributable to both wild-type and variant transthyretin cardiac amyloidosis, including the V142I variant common in Black Americans. Understanding this prevalence is crucial for improving diagnosis and treatment in at-risk groups.</p>
<h4>Article 4: Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40908114" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40908114</a></p>
<p><strong>Summary:</strong> This analysis of the Colchicine and Spironolactone in Patients with Left Ventricular Dysfunction after Myocardial Infarction (CLEAR) trial uses generalized pairwise comparisons to assess the benefit-risk profiles of colchicine and spironolactone in acute myocardial infarction. This method allows for a hierarchical ranking of clinical outcomes, providing a more intuitive understanding of treatment trade-offs compared to composite endpoints. The analysis explores the overall clinical benefit considering different event severities.</p>
<h4>Article 5: Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease.</h4>
<p><strong>Journal:</strong> Heart (British Cardiac Society)</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40368452" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40368452</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment Extended Follow-up study compares long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. It seeks to evaluate if intravascular ultrasound-guided percutaneous coronary intervention is comparable to coronary artery bypass grafting in improving long-term clinical outcomes in patients with multivessel disease. The focus is on patients who were treated with either procedure as part of the original clinical trial.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 13, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Approach to the Postmarket Evaluation of Consumer Wearable Technologies. This article discusses the need for empirical research on the postmarket use of consumer wearable technologies. The Stanford Center for Digital Health organized think tank meetings to develop a framework for evaluating these devices after they have been released to the public. The focus is on gathering data regarding real-world performance, accuracy, and potential impact on patient outcomes.</p>
<p>Article number two. Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies. This study addresses the challenge of assessing the hemodynamic significance of right anomalous aortic origin of a coronary artery. Invasive fractional flow reserve during a dobutamine-atropine volume challenge is the reference standard, but noninvasive imaging modalities are being explored as a less invasive alternative. The research aims to determine if noninvasive imaging can accurately evaluate dynamic compression of the anomalous vessel.</p>
<p>Article number three. Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. This study investigates the prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. The research aims to determine the proportion of heart failure cases in these populations attributable to both wild-type and variant transthyretin cardiac amyloidosis, including the V142I variant common in Black Americans. Understanding this prevalence is crucial for improving diagnosis and treatment in at-risk groups.</p>
<p>Article number four. Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial. This analysis of the Colchicine and Spironolactone in Patients with Left Ventricular Dysfunction after Myocardial Infarction (CLEAR) trial uses generalized pairwise comparisons to assess the benefit-risk profiles of colchicine and spironolactone in acute myocardial infarction. This method allows for a hierarchical ranking of clinical outcomes, providing a more intuitive understanding of treatment trade-offs compared to composite endpoints. The analysis explores the overall clinical benefit considering different event severities.</p>
<p>Article number five. Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. This post hoc analysis of the Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment Extended Follow-up study compares long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. It seeks to evaluate if intravascular ultrasound-guided percutaneous coronary intervention is comparable to coronary artery bypass grafting in improving long-term clinical outcomes in patients with multivessel disease. The focus is on patients who were treated with either procedure as part of the original clinical trial. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>acute myocardial infarction, digital health, multivessel coronary artery disease, percutaneous coronary intervention, colchicine, heart failure, postmarket evaluation, coronary artery bypass grafting, spironolactone, hemodynamic significance, noninvasive imaging, fractional flow reserve, coronary artery anomaly, transthyretin cardiac amyloidosis, consumer wearables, intravascular ultrasound, Hispanic Americans, US Food and Drug Administration, Black Americans, generalized pairwise comparisons.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/">ATTR Amyloidosis: Missed HF Diagnosis in Minorities 09/13/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250913_104838.mp3" length="3688323" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 13, 2025. This episode summarizes 5 key cardiology studies on topics like acute myocardial infarction and digital health. Key takeaway: ATTR Amyloidosis: Missed HF Diagnosis in Minorities.
Article Links:
Article 1: Approach to the Postmarket Evaluation of Consumer Wearable Technologies. (JAMA cardiology)
Article 2: Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies. (JAMA cardiology)
Article 3: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. (JAMA cardiology)
Article 4: Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial. (Heart (British Cardiac Society))
Article 5: Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/attr-amyloidosis-missed-hf-diagnosis-in-minorities-09-13-25/
 Featured Articles
Article 1: Approach to the Postmarket Evaluation of Consumer Wearable Technologies.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40928810
Summary: This article discusses the need for empirical research on the postmarket use of consumer wearable technologies. The Stanford Center for Digital Health organized think tank meetings to develop a framework for evaluating these devices after they have been released to the public. The focus is on gathering data regarding real-world performance, accuracy, and potential impact on patient outcomes.
Article 2: Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40928770
Summary: This study addresses the challenge of assessing the hemodynamic significance of right anomalous aortic origin of a coronary artery. Invasive fractional flow reserve during a dobutamine-atropine volume challenge is the reference standard, but noninvasive imaging modalities are being explored as a less invasive alternative. The research aims to determine if noninvasive imaging can accurately evaluate dynamic compression of the anomalous vessel.
Article 3: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40928765
Summary: This study investigates the prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure. The research aims to determine the proportion of heart failure cases in these populations attributable to both wild-type and variant transthyretin cardiac amyloidosis, including the V142I variant common in Black Americans. Understanding this prevalence is crucial for improving diagnosis and treatment in at-risk groups.
Article 4: Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40908114
Summary: This analysis of the Colchicine and Spironolactone in Patients with Left Ventricular Dysfunction after Myocardial Infarction (CLEAR) trial uses generalized pairwise comparisons to assess the benefit-risk profiles of colchicine and spironolactone in acute myocardial infarction. This method allows for a hierarchical ranking of clinical outcomes, providing a more intuitive understanding of treatment trade-offs compared to composite endpoints. The analysis explores the overall clinical benefit considering different event severities.
Article 5: Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 13, 2025. This episode summarizes 5 key cardiology studies on topics like acute myocardial infarction and digital health. Key takeaway: ATTR Amyloidosis: Missed HF Diagnosis in Minorities.
Article Links:
Article 1: Approach to the Postmarket Evaluation of Consumer Wearable Technologies. (JAMA cardiology)
Article 2: Noninvasive Anatomical and Functional Imaging for Hemodynamic Relevance in Right Coronary Artery Anomalies. (JAMA cardiology)
Article 3: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. (JAMA cardiology)
Article 4: Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial. (Heart (British Cardiac Society))
Article 5: Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease. (Hea]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Fulminant Myocarditis: Predictors of Mortality Defined 09/11/25</title>
	<link>https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/</link>
	<pubDate>Thu, 11 Sep 2025 06:56:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 11, 2025. This episode summarizes 2 key cardiology studies on topics like chronic limb-threatening ischemia and infrapopliteal disease. Key takeaway: Fulminant Myocarditis: Predictors of Mortality Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40927852">Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40928499">Fulminant myocarditis: outcome predictors in an international cohort study.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/">https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40927852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40927852</a></p>
<p><strong>Summary:</strong> The LIFE-BTK trial demonstrated that, at two years, drug-eluting resorbable scaffolds showed no statistically significant difference in the primary patency rate compared to percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia undergoing infrapopliteal intervention. While scaffold thrombosis was higher in the drug-eluting resorbable scaffold group, major amputation rates were similar between the two groups. This suggests that while the resorbable scaffold does not improve patency, it also does not increase the risk of limb loss.</p>
<h4>Article 2: Fulminant myocarditis: outcome predictors in an international cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928499" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928499</a></p>
<p><strong>Summary:</strong> This retrospective study of fulminant myocarditis across 26 European centers identified lymphocytic myocarditis as the most frequent type and revealed distinct clinical courses based on endomyocardial biopsy findings. Predictors of mortality included the need for mechanical circulatory support, particularly extracorporeal membrane oxygenation, and elevated creatinine levels. These findings underscore the importance of early risk stratification and tailored management strategies in fulminant myocarditis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. The LIFE-BTK trial demonstrated that, at two years, drug-eluting resorbable scaffolds showed no statistically significant difference in the primary patency rate compared to percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia undergoing infrapopliteal intervention. While scaffold thrombosis was higher in the drug-eluting resorbable scaffold group, major amputation rates were similar between the two groups. This suggests that while the resorbable scaffold does not improve patency, it also does not increase the risk of limb loss.</p>
<p>Article number two. Fulminant myocarditis: outcome predictors in an international cohort study. This retrospective study of fulminant myocarditis across 26 European centers identified lymphocytic myocarditis as the most frequent type and revealed distinct clinical courses based on endomyocardial biopsy findings. Predictors of mortality included the need for mechanical circulatory support, particularly extracorporeal membrane oxygenation, and elevated creatinine levels. These findings underscore the importance of early risk stratification and tailored management strategies in fulminant myocarditis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>chronic limb-threatening ischemia, infrapopliteal disease, amputation, drug-eluting resorbable scaffold, endomyocardial biopsy, mortality, mechanical circulatory support, percutaneous transluminal angioplasty, fulminant myocarditis, lymphocytic myocarditis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/">Fulminant Myocarditis: Predictors of Mortality Defined 09/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 11, 2025. This episode summarizes 2 key cardiology studies on topics like chronic limb-threatening ischemia and infrapopliteal disease. Key takeaway: Fulminant Myocarditis: Predictors of Mortality Defined.]]></itunes:subtitle>
	<itunes:episode>50</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 11, 2025. This episode summarizes 2 key cardiology studies on topics like chronic limb-threatening ischemia and infrapopliteal disease. Key takeaway: Fulminant Myocarditis: Predictors of Mortality Defined.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40927852">Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40928499">Fulminant myocarditis: outcome predictors in an international cohort study.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/">https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40927852" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40927852</a></p>
<p><strong>Summary:</strong> The LIFE-BTK trial demonstrated that, at two years, drug-eluting resorbable scaffolds showed no statistically significant difference in the primary patency rate compared to percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia undergoing infrapopliteal intervention. While scaffold thrombosis was higher in the drug-eluting resorbable scaffold group, major amputation rates were similar between the two groups. This suggests that while the resorbable scaffold does not improve patency, it also does not increase the risk of limb loss.</p>
<h4>Article 2: Fulminant myocarditis: outcome predictors in an international cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40928499" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40928499</a></p>
<p><strong>Summary:</strong> This retrospective study of fulminant myocarditis across 26 European centers identified lymphocytic myocarditis as the most frequent type and revealed distinct clinical courses based on endomyocardial biopsy findings. Predictors of mortality included the need for mechanical circulatory support, particularly extracorporeal membrane oxygenation, and elevated creatinine levels. These findings underscore the importance of early risk stratification and tailored management strategies in fulminant myocarditis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. The LIFE-BTK trial demonstrated that, at two years, drug-eluting resorbable scaffolds showed no statistically significant difference in the primary patency rate compared to percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia undergoing infrapopliteal intervention. While scaffold thrombosis was higher in the drug-eluting resorbable scaffold group, major amputation rates were similar between the two groups. This suggests that while the resorbable scaffold does not improve patency, it also does not increase the risk of limb loss.</p>
<p>Article number two. Fulminant myocarditis: outcome predictors in an international cohort study. This retrospective study of fulminant myocarditis across 26 European centers identified lymphocytic myocarditis as the most frequent type and revealed distinct clinical courses based on endomyocardial biopsy findings. Predictors of mortality included the need for mechanical circulatory support, particularly extracorporeal membrane oxygenation, and elevated creatinine levels. These findings underscore the importance of early risk stratification and tailored management strategies in fulminant myocarditis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>chronic limb-threatening ischemia, infrapopliteal disease, amputation, drug-eluting resorbable scaffold, endomyocardial biopsy, mortality, mechanical circulatory support, percutaneous transluminal angioplasty, fulminant myocarditis, lymphocytic myocarditis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/">Fulminant Myocarditis: Predictors of Mortality Defined 09/11/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250911_025619.mp3" length="1743141" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 11, 2025. This episode summarizes 2 key cardiology studies on topics like chronic limb-threatening ischemia and infrapopliteal disease. Key takeaway: Fulminant Myocarditis: Predictors of Mortality Defined.
Article Links:
Article 1: Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. (Circulation)
Article 2: Fulminant myocarditis: outcome predictors in an international cohort study. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/
 Featured Articles
Article 1: Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40927852
Summary: The LIFE-BTK trial demonstrated that, at two years, drug-eluting resorbable scaffolds showed no statistically significant difference in the primary patency rate compared to percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia undergoing infrapopliteal intervention. While scaffold thrombosis was higher in the drug-eluting resorbable scaffold group, major amputation rates were similar between the two groups. This suggests that while the resorbable scaffold does not improve patency, it also does not increase the risk of limb loss.
Article 2: Fulminant myocarditis: outcome predictors in an international cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40928499
Summary: This retrospective study of fulminant myocarditis across 26 European centers identified lymphocytic myocarditis as the most frequent type and revealed distinct clinical courses based on endomyocardial biopsy findings. Predictors of mortality included the need for mechanical circulatory support, particularly extracorporeal membrane oxygenation, and elevated creatinine levels. These findings underscore the importance of early risk stratification and tailored management strategies in fulminant myocarditis.
 Transcript

Today&#8217;s date is September 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. The LIFE-BTK trial demonstrated that, at two years, drug-eluting resorbable scaffolds showed no statistically significant difference in the primary patency rate compared to percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia undergoing infrapopliteal intervention. While scaffold thrombosis was higher in the drug-eluting resorbable scaffold group, major amputation rates were similar between the two groups. This suggests that while the resorbable scaffold does not improve patency, it also does not increase the risk of limb loss.
Article number two. Fulminant myocarditis: outcome predictors in an international cohort study. This retrospective study of fulminant myocarditis across 26 European centers identified lymphocytic myocarditis as the most frequent type and revealed distinct clinical courses based on endomyocardial biopsy findings. Predictors of mortality included the need for mechanical circulatory support, particularly extracorporeal membrane oxygenation, and elevated creatinine levels. These findings underscore the importance of early risk stratification and tailored management strategies in fulminant myocarditis. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
chronic limb-threatening ischemia, infrapopliteal disease, amputation, drug-eluting resorbable scaffold, endomyocardial biopsy, mortality, mechanical circulatory support, percutaneous transluminal angioplasty, fulminant myocarditis, lymphocytic myocarditis.
 About
]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 11, 2025. This episode summarizes 2 key cardiology studies on topics like chronic limb-threatening ischemia and infrapopliteal disease. Key takeaway: Fulminant Myocarditis: Predictors of Mortality Defined.
Article Links:
Article 1: Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. (Circulation)
Article 2: Fulminant myocarditis: outcome predictors in an international cohort study. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/fulminant-myocarditis-predictors-of-mortality-defined-09-11-25/
 Featured Articles
Article 1: Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40927852
Summary: The LIFE-BTK trial demonstrated that, at two years, drug-eluti]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Calcium Signature Predicts Post-Op A Fib Risk 09/10/25</title>
	<link>https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/</link>
	<pubDate>Wed, 10 Sep 2025 06:56:43 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 10, 2025. This episode summarizes 2 key cardiology studies on topics like Cardiac Troponins and Cardiac Surgery. Key takeaway: Calcium Signature Predicts Post-Op A Fib Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40923895">Great debate: the universal definition of myocardial infarction is flawed and should be put to rest.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40923107">Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/">https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Great debate: the universal definition of myocardial infarction is flawed and should be put to rest.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40923895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40923895</a></p>
<p><strong>Summary:</strong> The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomarker evidence of myocardial cell death, primarily cardiac troponins. The authors argue the current universal definition of myocardial infarction is flawed.</p>
<h4>Article 2: Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40923107" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40923107</a></p>
<p><strong>Summary:</strong> This study evaluated whether incorporating cytosolic calcium handling measurements with clinical risk factors improves post-operative atrial fibrillation risk prediction. Analyzing data from 558 patients undergoing cardiac surgery, including atrial cardiomyocytes from a subset, integrating calcium handling abnormalities with clinical factors enhanced atrial fibrillation risk prediction after cardiac surgery.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Great debate: the universal definition of myocardial infarction is flawed and should be put to rest. The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomarker evidence of myocardial cell death, primarily cardiac troponins. The authors argue the current universal definition of myocardial infarction is flawed.</p>
<p>Article number two. Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation. This study evaluated whether incorporating cytosolic calcium handling measurements with clinical risk factors improves post-operative atrial fibrillation risk prediction. Analyzing data from 558 patients undergoing cardiac surgery, including atrial cardiomyocytes from a subset, integrating calcium handling abnormalities with clinical factors enhanced atrial fibrillation risk prediction after cardiac surgery. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiac Troponins, Cardiac Surgery, Myocardial Ischemia, Myocardial Infarction, Cytosolic Calcium Handling, Post-operative Atrial Fibrillation, Atrial Fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/">Calcium Signature Predicts Post-Op A Fib Risk 09/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 10, 2025. This episode summarizes 2 key cardiology studies on topics like Cardiac Troponins and Cardiac Surgery. Key takeaway: Calcium Signature Predicts Post-Op A Fib Risk.
Article Links:
Article 1: Great]]></itunes:subtitle>
	<itunes:episode>49</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 10, 2025. This episode summarizes 2 key cardiology studies on topics like Cardiac Troponins and Cardiac Surgery. Key takeaway: Calcium Signature Predicts Post-Op A Fib Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40923895">Great debate: the universal definition of myocardial infarction is flawed and should be put to rest.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40923107">Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/">https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Great debate: the universal definition of myocardial infarction is flawed and should be put to rest.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40923895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40923895</a></p>
<p><strong>Summary:</strong> The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomarker evidence of myocardial cell death, primarily cardiac troponins. The authors argue the current universal definition of myocardial infarction is flawed.</p>
<h4>Article 2: Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40923107" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40923107</a></p>
<p><strong>Summary:</strong> This study evaluated whether incorporating cytosolic calcium handling measurements with clinical risk factors improves post-operative atrial fibrillation risk prediction. Analyzing data from 558 patients undergoing cardiac surgery, including atrial cardiomyocytes from a subset, integrating calcium handling abnormalities with clinical factors enhanced atrial fibrillation risk prediction after cardiac surgery.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Great debate: the universal definition of myocardial infarction is flawed and should be put to rest. The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomarker evidence of myocardial cell death, primarily cardiac troponins. The authors argue the current universal definition of myocardial infarction is flawed.</p>
<p>Article number two. Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation. This study evaluated whether incorporating cytosolic calcium handling measurements with clinical risk factors improves post-operative atrial fibrillation risk prediction. Analyzing data from 558 patients undergoing cardiac surgery, including atrial cardiomyocytes from a subset, integrating calcium handling abnormalities with clinical factors enhanced atrial fibrillation risk prediction after cardiac surgery. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiac Troponins, Cardiac Surgery, Myocardial Ischemia, Myocardial Infarction, Cytosolic Calcium Handling, Post-operative Atrial Fibrillation, Atrial Fibrillation.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/">Calcium Signature Predicts Post-Op A Fib Risk 09/10/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250910_025620.mp3" length="1313061" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 10, 2025. This episode summarizes 2 key cardiology studies on topics like Cardiac Troponins and Cardiac Surgery. Key takeaway: Calcium Signature Predicts Post-Op A Fib Risk.
Article Links:
Article 1: Great debate: the universal definition of myocardial infarction is flawed and should be put to rest. (European heart journal)
Article 2: Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/
 Featured Articles
Article 1: Great debate: the universal definition of myocardial infarction is flawed and should be put to rest.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40923895
Summary: The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomarker evidence of myocardial cell death, primarily cardiac troponins. The authors argue the current universal definition of myocardial infarction is flawed.
Article 2: Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40923107
Summary: This study evaluated whether incorporating cytosolic calcium handling measurements with clinical risk factors improves post-operative atrial fibrillation risk prediction. Analyzing data from 558 patients undergoing cardiac surgery, including atrial cardiomyocytes from a subset, integrating calcium handling abnormalities with clinical factors enhanced atrial fibrillation risk prediction after cardiac surgery.
 Transcript

Today&#8217;s date is September 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Great debate: the universal definition of myocardial infarction is flawed and should be put to rest. The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomarker evidence of myocardial cell death, primarily cardiac troponins. The authors argue the current universal definition of myocardial infarction is flawed.
Article number two. Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation. This study evaluated whether incorporating cytosolic calcium handling measurements with clinical risk factors improves post-operative atrial fibrillation risk prediction. Analyzing data from 558 patients undergoing cardiac surgery, including atrial cardiomyocytes from a subset, integrating calcium handling abnormalities with clinical factors enhanced atrial fibrillation risk prediction after cardiac surgery. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
Cardiac Troponins, Cardiac Surgery, Myocardial Ischemia, Myocardial Infarction, Cytosolic Calcium Handling, Post-operative Atrial Fibrillation, Atrial Fibrillation.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Calcium Signature Predicts Post-Op A Fib Risk 09/10/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 10, 2025. This episode summarizes 2 key cardiology studies on topics like Cardiac Troponins and Cardiac Surgery. Key takeaway: Calcium Signature Predicts Post-Op A Fib Risk.
Article Links:
Article 1: Great debate: the universal definition of myocardial infarction is flawed and should be put to rest. (European heart journal)
Article 2: Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/calcium-signature-predicts-post-op-a-fib-risk-09-10-25/
 Featured Articles
Article 1: Great debate: the universal definition of myocardial infarction is flawed and should be put to rest.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40923895
Summary: The universal definition of myocardial infarction relies on clinical evidence of myocardial ischemia and biomark]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Targeting Chemo-Induced Cardiotoxicity via CD47 09/09/25</title>
	<link>https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/</link>
	<pubDate>Tue, 09 Sep 2025 10:00:44 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 09, 2025. This episode summarizes 3 key cardiology studies on topics like Doxorubicin-Induced Cardiomyopathy and Intracellular Receptors. Key takeaway: Targeting Chemo-Induced Cardiotoxicity via CD47.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40808662">Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40709455">Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40665895">Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/">https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40808662" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40808662</a></p>
<p><strong>Summary:</strong> This study used single-nucleus ribonucleic acid sequencing on left ventricular myocardial tissue to compare patients with doxorubicin cardiomyopathy to those with nonischemic cardiomyopathy and nonfailing hearts, finding significant transcriptional changes associated with doxorubicin cardiomyopathy. The analysis identified CD47 as a potential therapeutic target, suggesting that modulating CD47 expression could improve outcomes for patients experiencing chemotherapy-induced cardiotoxicity. These results offer a targeted approach to mitigating the adverse cardiac effects of doxorubicin.</p>
<h4>Article 2: Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40709455" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40709455</a></p>
<p><strong>Summary:</strong> This research demonstrated that junctophilin-2, a protein known for regulating calcium signaling in cardiomyocytes, also plays a critical role in cardiac fibroblast activation after myocardial infarction. Specifically, junctophilin-2 regulates store-operated calcium entry in cardiac fibroblasts, driving fibrotic repair and angiogenesis. The study indicates that modulating junctophilin-2 expression or activity in cardiac fibroblasts could be a novel therapeutic strategy to improve myocardial healing and prevent adverse remodeling post-infarction.</p>
<h4>Article 3: Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40665895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40665895</a></p>
<p><strong>Summary:</strong> This investigation revealed that intracellular perinuclear beta one adrenergic receptors have a distinct function in regulating cardiac signaling and pathological remodeling, separate from beta adrenergic receptors located on the plasma membrane. The study showed that these intracellular receptors contribute to adverse cardiac remodeling in disease. These findings suggest that targeting intracellular beta one adrenergic receptor signaling may offer a more specific approach to preventing or treating pathological cardiac remodeling compared to traditional beta-blocker therapies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. This study used single-nucleus ribonucleic acid sequencing on left ventricular myocardial tissue to compare patients with doxorubicin cardiomyopathy to those with nonischemic cardiomyopathy and nonfailing hearts, finding significant transcriptional changes associated with doxorubicin cardiomyopathy. The analysis identified CD47 as a potential therapeutic target, suggesting that modulating CD47 expression could improve outcomes for patients experiencing chemotherapy-induced cardiotoxicity. These results offer a targeted approach to mitigating the adverse cardiac effects of doxorubicin.</p>
<p>Article number two. Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction. This research demonstrated that junctophilin-2, a protein known for regulating calcium signaling in cardiomyocytes, also plays a critical role in cardiac fibroblast activation after myocardial infarction. Specifically, junctophilin-2 regulates store-operated calcium entry in cardiac fibroblasts, driving fibrotic repair and angiogenesis. The study indicates that modulating junctophilin-2 expression or activity in cardiac fibroblasts could be a novel therapeutic strategy to improve myocardial healing and prevent adverse remodeling post-infarction.</p>
<p>Article number three. Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling. This investigation revealed that intracellular perinuclear beta one adrenergic receptors have a distinct function in regulating cardiac signaling and pathological remodeling, separate from beta adrenergic receptors located on the plasma membrane. The study showed that these intracellular receptors contribute to adverse cardiac remodeling in disease. These findings suggest that targeting intracellular beta one adrenergic receptor signaling may offer a more specific approach to preventing or treating pathological cardiac remodeling compared to traditional beta-blocker therapies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Doxorubicin-Induced Cardiomyopathy, Intracellular Receptors, G Protein-Coupled Receptors, Single-Nucleus RNA Sequencing, Cardiac Fibroblasts, Junctophilin-2, Cardiac Remodeling, Signal Compartmentation, CD47, Store-Operated Calcium Entry, Myocardial Infarction, Chemotherapy-Induced Cardiotoxicity, Fibrotic Repair, Beta One Adrenergic Receptors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/">Targeting Chemo-Induced Cardiotoxicity via CD47 09/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 09, 2025. This episode summarizes 3 key cardiology studies on topics like Doxorubicin-Induced Cardiomyopathy and Intracellular Receptors. Key takeaway: Targeting Chemo-Induced Cardiotoxicity via CD47.
Arti]]></itunes:subtitle>
	<itunes:episode>48</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 09, 2025. This episode summarizes 3 key cardiology studies on topics like Doxorubicin-Induced Cardiomyopathy and Intracellular Receptors. Key takeaway: Targeting Chemo-Induced Cardiotoxicity via CD47.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40808662">Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40709455">Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40665895">Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/">https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40808662" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40808662</a></p>
<p><strong>Summary:</strong> This study used single-nucleus ribonucleic acid sequencing on left ventricular myocardial tissue to compare patients with doxorubicin cardiomyopathy to those with nonischemic cardiomyopathy and nonfailing hearts, finding significant transcriptional changes associated with doxorubicin cardiomyopathy. The analysis identified CD47 as a potential therapeutic target, suggesting that modulating CD47 expression could improve outcomes for patients experiencing chemotherapy-induced cardiotoxicity. These results offer a targeted approach to mitigating the adverse cardiac effects of doxorubicin.</p>
<h4>Article 2: Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40709455" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40709455</a></p>
<p><strong>Summary:</strong> This research demonstrated that junctophilin-2, a protein known for regulating calcium signaling in cardiomyocytes, also plays a critical role in cardiac fibroblast activation after myocardial infarction. Specifically, junctophilin-2 regulates store-operated calcium entry in cardiac fibroblasts, driving fibrotic repair and angiogenesis. The study indicates that modulating junctophilin-2 expression or activity in cardiac fibroblasts could be a novel therapeutic strategy to improve myocardial healing and prevent adverse remodeling post-infarction.</p>
<h4>Article 3: Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40665895" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40665895</a></p>
<p><strong>Summary:</strong> This investigation revealed that intracellular perinuclear beta one adrenergic receptors have a distinct function in regulating cardiac signaling and pathological remodeling, separate from beta adrenergic receptors located on the plasma membrane. The study showed that these intracellular receptors contribute to adverse cardiac remodeling in disease. These findings suggest that targeting intracellular beta one adrenergic receptor signaling may offer a more specific approach to preventing or treating pathological cardiac remodeling compared to traditional beta-blocker therapies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. This study used single-nucleus ribonucleic acid sequencing on left ventricular myocardial tissue to compare patients with doxorubicin cardiomyopathy to those with nonischemic cardiomyopathy and nonfailing hearts, finding significant transcriptional changes associated with doxorubicin cardiomyopathy. The analysis identified CD47 as a potential therapeutic target, suggesting that modulating CD47 expression could improve outcomes for patients experiencing chemotherapy-induced cardiotoxicity. These results offer a targeted approach to mitigating the adverse cardiac effects of doxorubicin.</p>
<p>Article number two. Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction. This research demonstrated that junctophilin-2, a protein known for regulating calcium signaling in cardiomyocytes, also plays a critical role in cardiac fibroblast activation after myocardial infarction. Specifically, junctophilin-2 regulates store-operated calcium entry in cardiac fibroblasts, driving fibrotic repair and angiogenesis. The study indicates that modulating junctophilin-2 expression or activity in cardiac fibroblasts could be a novel therapeutic strategy to improve myocardial healing and prevent adverse remodeling post-infarction.</p>
<p>Article number three. Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling. This investigation revealed that intracellular perinuclear beta one adrenergic receptors have a distinct function in regulating cardiac signaling and pathological remodeling, separate from beta adrenergic receptors located on the plasma membrane. The study showed that these intracellular receptors contribute to adverse cardiac remodeling in disease. These findings suggest that targeting intracellular beta one adrenergic receptor signaling may offer a more specific approach to preventing or treating pathological cardiac remodeling compared to traditional beta-blocker therapies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Doxorubicin-Induced Cardiomyopathy, Intracellular Receptors, G Protein-Coupled Receptors, Single-Nucleus RNA Sequencing, Cardiac Fibroblasts, Junctophilin-2, Cardiac Remodeling, Signal Compartmentation, CD47, Store-Operated Calcium Entry, Myocardial Infarction, Chemotherapy-Induced Cardiotoxicity, Fibrotic Repair, Beta One Adrenergic Receptors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/">Targeting Chemo-Induced Cardiotoxicity via CD47 09/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250909_060006.mp3" length="2836105" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 09, 2025. This episode summarizes 3 key cardiology studies on topics like Doxorubicin-Induced Cardiomyopathy and Intracellular Receptors. Key takeaway: Targeting Chemo-Induced Cardiotoxicity via CD47.
Article Links:
Article 1: Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. (Circulation)
Article 2: Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction. (Circulation)
Article 3: Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/
 Featured Articles
Article 1: Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40808662
Summary: This study used single-nucleus ribonucleic acid sequencing on left ventricular myocardial tissue to compare patients with doxorubicin cardiomyopathy to those with nonischemic cardiomyopathy and nonfailing hearts, finding significant transcriptional changes associated with doxorubicin cardiomyopathy. The analysis identified CD47 as a potential therapeutic target, suggesting that modulating CD47 expression could improve outcomes for patients experiencing chemotherapy-induced cardiotoxicity. These results offer a targeted approach to mitigating the adverse cardiac effects of doxorubicin.
Article 2: Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40709455
Summary: This research demonstrated that junctophilin-2, a protein known for regulating calcium signaling in cardiomyocytes, also plays a critical role in cardiac fibroblast activation after myocardial infarction. Specifically, junctophilin-2 regulates store-operated calcium entry in cardiac fibroblasts, driving fibrotic repair and angiogenesis. The study indicates that modulating junctophilin-2 expression or activity in cardiac fibroblasts could be a novel therapeutic strategy to improve myocardial healing and prevent adverse remodeling post-infarction.
Article 3: Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40665895
Summary: This investigation revealed that intracellular perinuclear beta one adrenergic receptors have a distinct function in regulating cardiac signaling and pathological remodeling, separate from beta adrenergic receptors located on the plasma membrane. The study showed that these intracellular receptors contribute to adverse cardiac remodeling in disease. These findings suggest that targeting intracellular beta one adrenergic receptor signaling may offer a more specific approach to preventing or treating pathological cardiac remodeling compared to traditional beta-blocker therapies.
 Transcript

Today&#8217;s date is September 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. This study used single-nucleus ribonucleic acid sequencing on left ventricular myocardial tissue to compare patients with doxorubicin cardiomyopathy to those with nonischemic cardiomyopathy and nonfailing hearts, finding significant transcriptional changes associated with doxorubicin cardiomyopathy. The analysis identified CD47 as a potential therapeutic target, suggesting that modulating CD47 expression could improve]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 09, 2025. This episode summarizes 3 key cardiology studies on topics like Doxorubicin-Induced Cardiomyopathy and Intracellular Receptors. Key takeaway: Targeting Chemo-Induced Cardiotoxicity via CD47.
Article Links:
Article 1: Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. (Circulation)
Article 2: Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction. (Circulation)
Article 3: Unique Role of Intracellular Perinuclear β1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/targeting-chemo-induced-cardiotoxicity-via-cd47-09-09-25/
 Featured Articles
Article 1: Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cardiomyopathy Genes Worsen Atrial Fib Risk 09/09/25</title>
	<link>https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/</link>
	<pubDate>Tue, 09 Sep 2025 06:57:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 09, 2025. This episode summarizes 5 key cardiology studies on topics like race and cardiomyopathy. Key takeaway: Cardiomyopathy Genes Worsen Atrial Fib Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40903137">Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40903135">Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40903133">Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40903131">Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40820731">Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/">https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903137</a></p>
<p><strong>Summary:</strong> This study, analyzing over 18,000 patients from Thrombolysis in Myocardial Infarction study group trials, found that individuals with atrial fibrillation (AF) who carry rare pathogenic or likely pathogenic variants in cardiomyopathy genes have a significantly increased risk of adverse outcomes, including all-cause mortality and heart failure hospitalization. The presence of these variants appears to independently worsen prognosis in AF patients, highlighting the potential clinical importance of genetic screening in this population. These findings suggest that targeted management strategies may be warranted for atrial fibrillation patients with cardiomyopathy gene variants.</p>
<h4>Article 2: Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903135</a></p>
<p><strong>Summary:</strong> This study investigated the incidence of heart failure across disaggregated Asian American, Native Hawaiian, and Other Pacific Islander groups using data from Kaiser Permanente Northern California and Kaiser Permanente Hawaii from 2012 to 2022. The research revealed substantial differences in heart failure incidence rates among these individual populations, indicating a need for tailored prevention and management strategies rather than treating the group as a monolith. Specifically, Native Hawaiians and Filipinos experienced higher heart failure incidence compared to Chinese and Japanese subgroups.</p>
<h4>Article 3: Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903133</a></p>
<p><strong>Summary:</strong> This study, using data from the Get With The Guidelines-Heart Failure registry, examined racial and ethnic differences in age at first hospitalization for heart failure. The analysis revealed that Black patients were, on average, hospitalized for heart failure at a significantly younger age compared to White patients. This disparity remained even after adjusting for social risk factors, suggesting other biological or environmental factors may contribute to the earlier onset of heart failure in Black individuals.</p>
<h4>Article 4: Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903131</a></p>
<p><strong>Summary:</strong> This prespecified analysis of the SUMMIT trial assessed the impact of type 2 diabetes on the effects of tirzepatide in Heart Failure with Preserved Ejection Fraction patients with obesity. The study found that the benefits of tirzepatide on weight loss and Heart Failure symptoms were consistent regardless of diabetes status. This suggests tirzepatide can be an effective treatment option for obese Heart Failure with Preserved Ejection Fraction patients with or without type 2 diabetes.</p>
<h4>Article 5: Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40820731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40820731</a></p>
<p><strong>Summary:</strong> This multi-center study compared the outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable versus self-expandable valves in patients with bicuspid aortic valve stenosis. The results showed no significant difference in the composite outcome of death or stroke between the two valve types after propensity score matching. This suggests that both balloon-expandable and self-expandable valves are reasonable options for transcatheter aortic valve replacement in patients with bicuspid aortic valve stenosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants. This study, analyzing over 18,000 patients from Thrombolysis in Myocardial Infarction study group trials, found that individuals with atrial fibrillation (AF) who carry rare pathogenic or likely pathogenic variants in cardiomyopathy genes have a significantly increased risk of adverse outcomes, including all-cause mortality and heart failure hospitalization. The presence of these variants appears to independently worsen prognosis in AF patients, highlighting the potential clinical importance of genetic screening in this population. These findings suggest that targeted management strategies may be warranted for atrial fibrillation patients with cardiomyopathy gene variants.</p>
<p>Article number two. Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations. This study investigated the incidence of heart failure across disaggregated Asian American, Native Hawaiian, and Other Pacific Islander groups using data from Kaiser Permanente Northern California and Kaiser Permanente Hawaii from 2012 to 2022. The research revealed substantial differences in heart failure incidence rates among these individual populations, indicating a need for tailored prevention and management strategies rather than treating the group as a monolith. Specifically, Native Hawaiians and Filipinos experienced higher heart failure incidence compared to Chinese and Japanese subgroups.</p>
<p>Article number three. Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure. This study, using data from the Get With The Guidelines-Heart Failure registry, examined racial and ethnic differences in age at first hospitalization for heart failure. The analysis revealed that Black patients were, on average, hospitalized for heart failure at a significantly younger age compared to White patients. This disparity remained even after adjusting for social risk factors, suggesting other biological or environmental factors may contribute to the earlier onset of heart failure in Black individuals.</p>
<p>Article number four. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. This prespecified analysis of the SUMMIT trial assessed the impact of type 2 diabetes on the effects of tirzepatide in Heart Failure with Preserved Ejection Fraction patients with obesity. The study found that the benefits of tirzepatide on weight loss and Heart Failure symptoms were consistent regardless of diabetes status. This suggests tirzepatide can be an effective treatment option for obese Heart Failure with Preserved Ejection Fraction patients with or without type 2 diabetes.</p>
<p>Article number five. Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis. This multi-center study compared the outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable versus self-expandable valves in patients with bicuspid aortic valve stenosis. The results showed no significant difference in the composite outcome of death or stroke between the two valve types after propensity score matching. This suggests that both balloon-expandable and self-expandable valves are reasonable options for transcatheter aortic valve replacement in patients with bicuspid aortic valve stenosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>race, cardiomyopathy, type 2 diabetes, incidence, prognosis, self-expandable valve, atrial fibrillation, transcatheter aortic valve replacement, Native Hawaiian, Heart Failure with Preserved Ejection Fraction, balloon-expandable valve, SUMMIT trial, tirzepatide, ethnicity, Pacific Islander, hospitalization, Asian American, aortic stenosis, bicuspid aortic valve, genetic variants, obesity, heart failure, social risk factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/">Cardiomyopathy Genes Worsen Atrial Fib Risk 09/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 09, 2025. This episode summarizes 5 key cardiology studies on topics like race and cardiomyopathy. Key takeaway: Cardiomyopathy Genes Worsen Atrial Fib Risk.
Article Links:
Article 1: Pathogenic Cardiomyop]]></itunes:subtitle>
	<itunes:episode>47</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 09, 2025. This episode summarizes 5 key cardiology studies on topics like race and cardiomyopathy. Key takeaway: Cardiomyopathy Genes Worsen Atrial Fib Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40903137">Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40903135">Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.</a> (Journal of the American College of Cardiology)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40903133">Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.</a> (Journal of the American College of Cardiology)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40903131">Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.</a> (Journal of the American College of Cardiology)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40820731">Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.</a> (Circulation)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/">https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903137" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903137</a></p>
<p><strong>Summary:</strong> This study, analyzing over 18,000 patients from Thrombolysis in Myocardial Infarction study group trials, found that individuals with atrial fibrillation (AF) who carry rare pathogenic or likely pathogenic variants in cardiomyopathy genes have a significantly increased risk of adverse outcomes, including all-cause mortality and heart failure hospitalization. The presence of these variants appears to independently worsen prognosis in AF patients, highlighting the potential clinical importance of genetic screening in this population. These findings suggest that targeted management strategies may be warranted for atrial fibrillation patients with cardiomyopathy gene variants.</p>
<h4>Article 2: Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903135" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903135</a></p>
<p><strong>Summary:</strong> This study investigated the incidence of heart failure across disaggregated Asian American, Native Hawaiian, and Other Pacific Islander groups using data from Kaiser Permanente Northern California and Kaiser Permanente Hawaii from 2012 to 2022. The research revealed substantial differences in heart failure incidence rates among these individual populations, indicating a need for tailored prevention and management strategies rather than treating the group as a monolith. Specifically, Native Hawaiians and Filipinos experienced higher heart failure incidence compared to Chinese and Japanese subgroups.</p>
<h4>Article 3: Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903133" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903133</a></p>
<p><strong>Summary:</strong> This study, using data from the Get With The Guidelines-Heart Failure registry, examined racial and ethnic differences in age at first hospitalization for heart failure. The analysis revealed that Black patients were, on average, hospitalized for heart failure at a significantly younger age compared to White patients. This disparity remained even after adjusting for social risk factors, suggesting other biological or environmental factors may contribute to the earlier onset of heart failure in Black individuals.</p>
<h4>Article 4: Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40903131" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40903131</a></p>
<p><strong>Summary:</strong> This prespecified analysis of the SUMMIT trial assessed the impact of type 2 diabetes on the effects of tirzepatide in Heart Failure with Preserved Ejection Fraction patients with obesity. The study found that the benefits of tirzepatide on weight loss and Heart Failure symptoms were consistent regardless of diabetes status. This suggests tirzepatide can be an effective treatment option for obese Heart Failure with Preserved Ejection Fraction patients with or without type 2 diabetes.</p>
<h4>Article 5: Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40820731" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40820731</a></p>
<p><strong>Summary:</strong> This multi-center study compared the outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable versus self-expandable valves in patients with bicuspid aortic valve stenosis. The results showed no significant difference in the composite outcome of death or stroke between the two valve types after propensity score matching. This suggests that both balloon-expandable and self-expandable valves are reasonable options for transcatheter aortic valve replacement in patients with bicuspid aortic valve stenosis.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants. This study, analyzing over 18,000 patients from Thrombolysis in Myocardial Infarction study group trials, found that individuals with atrial fibrillation (AF) who carry rare pathogenic or likely pathogenic variants in cardiomyopathy genes have a significantly increased risk of adverse outcomes, including all-cause mortality and heart failure hospitalization. The presence of these variants appears to independently worsen prognosis in AF patients, highlighting the potential clinical importance of genetic screening in this population. These findings suggest that targeted management strategies may be warranted for atrial fibrillation patients with cardiomyopathy gene variants.</p>
<p>Article number two. Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations. This study investigated the incidence of heart failure across disaggregated Asian American, Native Hawaiian, and Other Pacific Islander groups using data from Kaiser Permanente Northern California and Kaiser Permanente Hawaii from 2012 to 2022. The research revealed substantial differences in heart failure incidence rates among these individual populations, indicating a need for tailored prevention and management strategies rather than treating the group as a monolith. Specifically, Native Hawaiians and Filipinos experienced higher heart failure incidence compared to Chinese and Japanese subgroups.</p>
<p>Article number three. Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure. This study, using data from the Get With The Guidelines-Heart Failure registry, examined racial and ethnic differences in age at first hospitalization for heart failure. The analysis revealed that Black patients were, on average, hospitalized for heart failure at a significantly younger age compared to White patients. This disparity remained even after adjusting for social risk factors, suggesting other biological or environmental factors may contribute to the earlier onset of heart failure in Black individuals.</p>
<p>Article number four. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. This prespecified analysis of the SUMMIT trial assessed the impact of type 2 diabetes on the effects of tirzepatide in Heart Failure with Preserved Ejection Fraction patients with obesity. The study found that the benefits of tirzepatide on weight loss and Heart Failure symptoms were consistent regardless of diabetes status. This suggests tirzepatide can be an effective treatment option for obese Heart Failure with Preserved Ejection Fraction patients with or without type 2 diabetes.</p>
<p>Article number five. Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis. This multi-center study compared the outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable versus self-expandable valves in patients with bicuspid aortic valve stenosis. The results showed no significant difference in the composite outcome of death or stroke between the two valve types after propensity score matching. This suggests that both balloon-expandable and self-expandable valves are reasonable options for transcatheter aortic valve replacement in patients with bicuspid aortic valve stenosis. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>race, cardiomyopathy, type 2 diabetes, incidence, prognosis, self-expandable valve, atrial fibrillation, transcatheter aortic valve replacement, Native Hawaiian, Heart Failure with Preserved Ejection Fraction, balloon-expandable valve, SUMMIT trial, tirzepatide, ethnicity, Pacific Islander, hospitalization, Asian American, aortic stenosis, bicuspid aortic valve, genetic variants, obesity, heart failure, social risk factors.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/">Cardiomyopathy Genes Worsen Atrial Fib Risk 09/09/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250909_025641.mp3" length="3980895" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 09, 2025. This episode summarizes 5 key cardiology studies on topics like race and cardiomyopathy. Key takeaway: Cardiomyopathy Genes Worsen Atrial Fib Risk.
Article Links:
Article 1: Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants. (Journal of the American College of Cardiology)
Article 2: Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations. (Journal of the American College of Cardiology)
Article 3: Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure. (Journal of the American College of Cardiology)
Article 4: Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. (Journal of the American College of Cardiology)
Article 5: Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/cardiomyopathy-genes-worsen-atrial-fib-risk-09-09-25/
 Featured Articles
Article 1: Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40903137
Summary: This study, analyzing over 18,000 patients from Thrombolysis in Myocardial Infarction study group trials, found that individuals with atrial fibrillation (AF) who carry rare pathogenic or likely pathogenic variants in cardiomyopathy genes have a significantly increased risk of adverse outcomes, including all-cause mortality and heart failure hospitalization. The presence of these variants appears to independently worsen prognosis in AF patients, highlighting the potential clinical importance of genetic screening in this population. These findings suggest that targeted management strategies may be warranted for atrial fibrillation patients with cardiomyopathy gene variants.
Article 2: Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40903135
Summary: This study investigated the incidence of heart failure across disaggregated Asian American, Native Hawaiian, and Other Pacific Islander groups using data from Kaiser Permanente Northern California and Kaiser Permanente Hawaii from 2012 to 2022. The research revealed substantial differences in heart failure incidence rates among these individual populations, indicating a need for tailored prevention and management strategies rather than treating the group as a monolith. Specifically, Native Hawaiians and Filipinos experienced higher heart failure incidence compared to Chinese and Japanese subgroups.
Article 3: Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40903133
Summary: This study, using data from the Get With The Guidelines-Heart Failure registry, examined racial and ethnic differences in age at first hospitalization for heart failure. The analysis revealed that Black patients were, on average, hospitalized for heart failure at a significantly younger age compared to White patients. This disparity remained even after adjusting for social risk factors, suggesting other biological or environmental factors may contribute to the earlier onset of heart failure in Black individuals.
Article 4: Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
Journal: Jou]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 09, 2025. This episode summarizes 5 key cardiology studies on topics like race and cardiomyopathy. Key takeaway: Cardiomyopathy Genes Worsen Atrial Fib Risk.
Article Links:
Article 1: Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants. (Journal of the American College of Cardiology)
Article 2: Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations. (Journal of the American College of Cardiology)
Article 3: Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure. (Journal of the American College of Cardiology)
Article 4: Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. (Journal of the American College of Cardiology)
Article 5: Transcatheter Aort]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Urgent Surgery vs Thrombolysis for PVT? 09/08/25</title>
	<link>https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/</link>
	<pubDate>Mon, 08 Sep 2025 06:56:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 08, 2025. This episode summarizes 1 key cardiology studies on topics like Urgent Surgery and Fibrinolytic Therapy. Key takeaway: Urgent Surgery vs Thrombolysis for PVT?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40574603">Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/">https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40574603" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40574603</a></p>
<p><strong>Summary:</strong> This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Urgent surgery versus fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Urgent Surgery, Fibrinolytic Therapy, Prosthetic Valve Thrombosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/">Urgent Surgery vs Thrombolysis for PVT? 09/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 08, 2025. This episode summarizes 1 key cardiology studies on topics like Urgent Surgery and Fibrinolytic Therapy. Key takeaway: Urgent Surgery vs Thrombolysis for PVT?.
Article Links:
Article 1: Urgent su]]></itunes:subtitle>
	<itunes:episode>46</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 08, 2025. This episode summarizes 1 key cardiology studies on topics like Urgent Surgery and Fibrinolytic Therapy. Key takeaway: Urgent Surgery vs Thrombolysis for PVT?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40574603">Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/">https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40574603" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40574603</a></p>
<p><strong>Summary:</strong> This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Urgent surgery versus fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Urgent Surgery, Fibrinolytic Therapy, Prosthetic Valve Thrombosis.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/">Urgent Surgery vs Thrombolysis for PVT? 09/08/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250908_025627.mp3" length="1014221" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 08, 2025. This episode summarizes 1 key cardiology studies on topics like Urgent Surgery and Fibrinolytic Therapy. Key takeaway: Urgent Surgery vs Thrombolysis for PVT?.
Article Links:
Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/
 Featured Articles
Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40574603
Summary: This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited.
 Transcript

Today&#8217;s date is September 08, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Urgent surgery versus fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and significant improvement in valve function, which was likely to be impacted by the occurrence of major adverse cardiovascular events and mortality. This study provides insights into the optimal treatment strategy for this serious complication, especially in settings where resources are limited. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
Urgent Surgery, Fibrinolytic Therapy, Prosthetic Valve Thrombosis.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Urgent Surgery vs Thrombolysis for PVT? 09/08/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 08, 2025. This episode summarizes 1 key cardiology studies on topics like Urgent Surgery and Fibrinolytic Therapy. Key takeaway: Urgent Surgery vs Thrombolysis for PVT?.
Article Links:
Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/urgent-surgery-vs-thrombolysis-for-pvt-09-08-25/
 Featured Articles
Article 1: Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40574603
Summary: This randomized controlled trial compared urgent surgery with fibrinolytic therapy using low-dose, slow-infusion tissue plasminogen activator for symptomatic left-sided prosthetic valve thrombosis. The primary outcome was complete clinical response defined as resolution of symptoms and si]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Oxygen Uptake Recovery Predicts HCM Treatment Response 09/06/25</title>
	<link>https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/</link>
	<pubDate>Sat, 06 Sep 2025 06:57:11 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 06, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and percutaneous coronary intervention. Key takeaway: Oxygen Uptake Recovery Predicts HCM Treatment Response.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40910189">Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40910168">Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40910165">Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40911366">The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/">https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910189" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910189</a></p>
<p><strong>Summary:</strong> This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes.</p>
<h4>Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910168</a></p>
<p><strong>Summary:</strong> This substudy of the SEQUOIA-Hypertrophic Cardiomyopathy trial evaluated post-exercise oxygen uptake recovery as a measure of cardiac performance in patients with obstructive hypertrophic cardiomyopathy and dyspnea on exertion. The study identified easily derived oxygen uptake recovery measures correlated with cardiac function and response to disease-specific treatment. These novel oxygen uptake recovery patterns offer a cardiospecific and potentially prognostic tool for assessing treatment efficacy in hypertrophic cardiomyopathy.</p>
<h4>Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910165" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910165</a></p>
<p><strong>Summary:</strong> The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial investigated health status outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention versus coronary artery bypass grafting. The study found that an invasive strategy, percutaneous coronary intervention or coronary artery bypass grafting, resulted in better health status outcomes compared to a conservative medical strategy for patients with chronic coronary disease. Further research is needed to determine if the benefits of invasive management were driven more by percutaneous coronary intervention or coronary artery bypass grafting.</p>
<h4>Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40911366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40911366</a></p>
<p><strong>Summary:</strong> This review article discusses current and emerging targets for lipid-lowering therapies beyond low density lipoprotein cholesterol. It highlights the importance of triglycerides, apolipoprotein B, and lipoprotein(a) as contributors to residual cardiovascular risk despite statin therapy. The review explores molecular mechanisms and translational implications of therapies targeting these alternative lipid pathways, emphasizing the need for a multifaceted approach to manage dyslipidemia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes.</p>
<p>Article number two. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. This substudy of the SEQUOIA-Hypertrophic Cardiomyopathy trial evaluated post-exercise oxygen uptake recovery as a measure of cardiac performance in patients with obstructive hypertrophic cardiomyopathy and dyspnea on exertion. The study identified easily derived oxygen uptake recovery measures correlated with cardiac function and response to disease-specific treatment. These novel oxygen uptake recovery patterns offer a cardiospecific and potentially prognostic tool for assessing treatment efficacy in hypertrophic cardiomyopathy.</p>
<p>Article number three. Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial investigated health status outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention versus coronary artery bypass grafting. The study found that an invasive strategy, percutaneous coronary intervention or coronary artery bypass grafting, resulted in better health status outcomes compared to a conservative medical strategy for patients with chronic coronary disease. Further research is needed to determine if the benefits of invasive management were driven more by percutaneous coronary intervention or coronary artery bypass grafting.</p>
<p>Article number four. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. This review article discusses current and emerging targets for lipid-lowering therapies beyond low density lipoprotein cholesterol. It highlights the importance of triglycerides, apolipoprotein B, and lipoprotein(a) as contributors to residual cardiovascular risk despite statin therapy. The review explores molecular mechanisms and translational implications of therapies targeting these alternative lipid pathways, emphasizing the need for a multifaceted approach to manage dyslipidemia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertrophic cardiomyopathy, percutaneous coronary intervention, low density lipoprotein cholesterol, oxygen uptake recovery, physical activity, chronic coronary disease, dyslipidemia, SEQUOIA-Hypertrophic Cardiomyopathy trial, accelerometer, coronary artery bypass grafting, ISCHEMIA trial, minithoracotomy, exercise, health status, cardiac performance, lipoprotein(a), apolipoprotein B, mitral valve surgery, sternotomy, triglycerides.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/">Oxygen Uptake Recovery Predicts HCM Treatment Response 09/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 06, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and percutaneous coronary intervention. Key takeaway: Oxygen Uptake Recovery Predicts HCM Treatment Res]]></itunes:subtitle>
	<itunes:episode>45</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 06, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and percutaneous coronary intervention. Key takeaway: Oxygen Uptake Recovery Predicts HCM Treatment Response.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40910189">Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40910168">Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40910165">Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40911366">The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/">https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910189" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910189</a></p>
<p><strong>Summary:</strong> This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes.</p>
<h4>Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910168</a></p>
<p><strong>Summary:</strong> This substudy of the SEQUOIA-Hypertrophic Cardiomyopathy trial evaluated post-exercise oxygen uptake recovery as a measure of cardiac performance in patients with obstructive hypertrophic cardiomyopathy and dyspnea on exertion. The study identified easily derived oxygen uptake recovery measures correlated with cardiac function and response to disease-specific treatment. These novel oxygen uptake recovery patterns offer a cardiospecific and potentially prognostic tool for assessing treatment efficacy in hypertrophic cardiomyopathy.</p>
<h4>Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40910165" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40910165</a></p>
<p><strong>Summary:</strong> The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial investigated health status outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention versus coronary artery bypass grafting. The study found that an invasive strategy, percutaneous coronary intervention or coronary artery bypass grafting, resulted in better health status outcomes compared to a conservative medical strategy for patients with chronic coronary disease. Further research is needed to determine if the benefits of invasive management were driven more by percutaneous coronary intervention or coronary artery bypass grafting.</p>
<h4>Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40911366" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40911366</a></p>
<p><strong>Summary:</strong> This review article discusses current and emerging targets for lipid-lowering therapies beyond low density lipoprotein cholesterol. It highlights the importance of triglycerides, apolipoprotein B, and lipoprotein(a) as contributors to residual cardiovascular risk despite statin therapy. The review explores molecular mechanisms and translational implications of therapies targeting these alternative lipid pathways, emphasizing the need for a multifaceted approach to manage dyslipidemia.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 06, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes.</p>
<p>Article number two. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. This substudy of the SEQUOIA-Hypertrophic Cardiomyopathy trial evaluated post-exercise oxygen uptake recovery as a measure of cardiac performance in patients with obstructive hypertrophic cardiomyopathy and dyspnea on exertion. The study identified easily derived oxygen uptake recovery measures correlated with cardiac function and response to disease-specific treatment. These novel oxygen uptake recovery patterns offer a cardiospecific and potentially prognostic tool for assessing treatment efficacy in hypertrophic cardiomyopathy.</p>
<p>Article number three. Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial investigated health status outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention versus coronary artery bypass grafting. The study found that an invasive strategy, percutaneous coronary intervention or coronary artery bypass grafting, resulted in better health status outcomes compared to a conservative medical strategy for patients with chronic coronary disease. Further research is needed to determine if the benefits of invasive management were driven more by percutaneous coronary intervention or coronary artery bypass grafting.</p>
<p>Article number four. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. This review article discusses current and emerging targets for lipid-lowering therapies beyond low density lipoprotein cholesterol. It highlights the importance of triglycerides, apolipoprotein B, and lipoprotein(a) as contributors to residual cardiovascular risk despite statin therapy. The review explores molecular mechanisms and translational implications of therapies targeting these alternative lipid pathways, emphasizing the need for a multifaceted approach to manage dyslipidemia. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hypertrophic cardiomyopathy, percutaneous coronary intervention, low density lipoprotein cholesterol, oxygen uptake recovery, physical activity, chronic coronary disease, dyslipidemia, SEQUOIA-Hypertrophic Cardiomyopathy trial, accelerometer, coronary artery bypass grafting, ISCHEMIA trial, minithoracotomy, exercise, health status, cardiac performance, lipoprotein(a), apolipoprotein B, mitral valve surgery, sternotomy, triglycerides.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/">Oxygen Uptake Recovery Predicts HCM Treatment Response 09/06/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250906_025627.mp3" length="3253228" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 06, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and percutaneous coronary intervention. Key takeaway: Oxygen Uptake Recovery Predicts HCM Treatment Response.
Article Links:
Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. (Circulation)
Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. (Circulation)
Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. (Circulation)
Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09-06-25/
 Featured Articles
Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910189
Summary: This study from the United Kingdom Mini Mitral trial used wearable accelerometers to compare physical activity recovery after mitral valve surgery via sternotomy versus minimally invasive thoracoscopically guided right minithoracotomy. Results indicated no significant difference in physical activity levels between the two surgical approaches post-surgery. Accelerometer data provides an objective measure of recovery, suggesting both techniques lead to similar functional outcomes.
Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910168
Summary: This substudy of the SEQUOIA-Hypertrophic Cardiomyopathy trial evaluated post-exercise oxygen uptake recovery as a measure of cardiac performance in patients with obstructive hypertrophic cardiomyopathy and dyspnea on exertion. The study identified easily derived oxygen uptake recovery measures correlated with cardiac function and response to disease-specific treatment. These novel oxygen uptake recovery patterns offer a cardiospecific and potentially prognostic tool for assessing treatment efficacy in hypertrophic cardiomyopathy.
Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910165
Summary: The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial investigated health status outcomes in patients with chronic coronary disease undergoing percutaneous coronary intervention versus coronary artery bypass grafting. The study found that an invasive strategy, percutaneous coronary intervention or coronary artery bypass grafting, resulted in better health status outcomes compared to a conservative medical strategy for patients with chronic coronary disease. Further research is needed to determine if the benefits of invasive management were driven more by percutaneous coronary intervention or coronary artery bypass grafting.
Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40911366
Summary: This review article discusses current and emerging targets for lipid-lowering therapies beyond low density lipoprotein cholesterol. It highlights the importance of triglycerides, apolipoprotein B, and lipoprotein(a) as contributors to residual cardiovascular risk despite statin therapy. The review explores molecular mechanisms and translational implications of therapies t]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 06, 2025. This episode summarizes 4 key cardiology studies on topics like hypertrophic cardiomyopathy and percutaneous coronary intervention. Key takeaway: Oxygen Uptake Recovery Predicts HCM Treatment Response.
Article Links:
Article 1: Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial. (Circulation)
Article 2: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. (Circulation)
Article 3: Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. (Circulation)
Article 4: The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/oxygen-uptake-recovery-predicts-hcm-treatment-response-09]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Arachidonic Acid Drives Post-Infarct Inflammation 09/05/25</title>
	<link>https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/</link>
	<pubDate>Fri, 05 Sep 2025 06:56:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40905492">Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40905476">Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/">https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40905492" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40905492</a></p>
<p><strong>Summary:</strong> This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction.</p>
<h4>Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40905476" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40905476</a></p>
<p><strong>Summary:</strong> This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction.</p>
<p>Article number two. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Clinical Trials, Protein Phosphatase 5, Arachidonic Acid, Heart Failure, Macrophages, Myocardial Infarction, Cardiorenal Metabolic Syndrome, Inflammation, Chronic Kidney Disease, Glomerular Filtration Rate.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/">Arachidonic Acid Drives Post-Infarct Inflammation 09/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation.
Article Links:
Article ]]></itunes:subtitle>
	<itunes:episode>44</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40905492">Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40905476">Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/">https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40905492" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40905492</a></p>
<p><strong>Summary:</strong> This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction.</p>
<h4>Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40905476" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40905476</a></p>
<p><strong>Summary:</strong> This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction.</p>
<p>Article number two. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Clinical Trials, Protein Phosphatase 5, Arachidonic Acid, Heart Failure, Macrophages, Myocardial Infarction, Cardiorenal Metabolic Syndrome, Inflammation, Chronic Kidney Disease, Glomerular Filtration Rate.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/">Arachidonic Acid Drives Post-Infarct Inflammation 09/05/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250905_025611.mp3" length="1925789" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation.
Article Links:
Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. (European heart journal)
Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/
 Featured Articles
Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905492
Summary: This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction.
Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905476
Summary: This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies.
 Transcript

Today&#8217;s date is September 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction.
Article number two. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywor]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation.
Article Links:
Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. (European heart journal)
Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/
 Featured Articles
Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905492
Summary: This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical rol]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Clonal Hematopoiesis Links to CAD Mortality 09/04/25</title>
	<link>https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/</link>
	<pubDate>Thu, 04 Sep 2025 06:57:29 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40902100">Clinical care of family members of patients with dilated cardiomyopathy.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40900121">Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40900118">Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40900105">Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40900101">Sexual minority populations and disparities in cardiovascular healthcare.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/">https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical care of family members of patients with dilated cardiomyopathy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40902100" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40902100</a></p>
<p><strong>Summary:</strong> This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies.</p>
<h4>Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900121" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900121</a></p>
<p><strong>Summary:</strong> This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies.</p>
<h4>Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900118</a></p>
<p><strong>Summary:</strong> This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis.</p>
<h4>Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900105" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900105</a></p>
<p><strong>Summary:</strong> This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease.</p>
<h4>Article 5: Sexual minority populations and disparities in cardiovascular healthcare.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900101" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900101</a></p>
<p><strong>Summary:</strong> This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical care of family members of patients with dilated cardiomyopathy. This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies.</p>
<p>Article number two. Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies.</p>
<p>Article number three. Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis.</p>
<p>Article number four. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease.</p>
<p>Article number five. Sexual minority populations and disparities in cardiovascular healthcare. This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gestational hypertension, Mendelian randomization, clonal haematopoiesis of indeterminate potential, dilated cardiomyopathy, preeclampsia, gay, queer, genetic screening, TET2 mutations, bisexual, surgical aortic valve replacement, family screening, aortic stenosis, transcatheter aortic valve implantation, sex-specific outcomes, genetic epidemiology, sexual minority, DEDICATE-DZHK6 trial, cardiovascular disease, coronary artery disease, pathogenic variants, health disparities, all-cause mortality, lesbian, cardiac risk, cardiovascular risk, minority stress.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/">Clonal Hematopoiesis Links to CAD Mortality 09/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality.
Article Links:
Art]]></itunes:subtitle>
	<itunes:episode>43</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40902100">Clinical care of family members of patients with dilated cardiomyopathy.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40900121">Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40900118">Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40900105">Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40900101">Sexual minority populations and disparities in cardiovascular healthcare.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/">https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical care of family members of patients with dilated cardiomyopathy.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40902100" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40902100</a></p>
<p><strong>Summary:</strong> This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies.</p>
<h4>Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900121" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900121</a></p>
<p><strong>Summary:</strong> This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies.</p>
<h4>Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900118" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900118</a></p>
<p><strong>Summary:</strong> This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis.</p>
<h4>Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900105" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900105</a></p>
<p><strong>Summary:</strong> This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease.</p>
<h4>Article 5: Sexual minority populations and disparities in cardiovascular healthcare.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40900101" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40900101</a></p>
<p><strong>Summary:</strong> This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 04, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Clinical care of family members of patients with dilated cardiomyopathy. This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies.</p>
<p>Article number two. Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies.</p>
<p>Article number three. Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis.</p>
<p>Article number four. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease.</p>
<p>Article number five. Sexual minority populations and disparities in cardiovascular healthcare. This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>gestational hypertension, Mendelian randomization, clonal haematopoiesis of indeterminate potential, dilated cardiomyopathy, preeclampsia, gay, queer, genetic screening, TET2 mutations, bisexual, surgical aortic valve replacement, family screening, aortic stenosis, transcatheter aortic valve implantation, sex-specific outcomes, genetic epidemiology, sexual minority, DEDICATE-DZHK6 trial, cardiovascular disease, coronary artery disease, pathogenic variants, health disparities, all-cause mortality, lesbian, cardiac risk, cardiovascular risk, minority stress.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/">Clonal Hematopoiesis Links to CAD Mortality 09/04/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250904_025624.mp3" length="3662410" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality.
Article Links:
Article 1: Clinical care of family members of patients with dilated cardiomyopathy. (European heart journal)
Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. (European heart journal)
Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. (European heart journal)
Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. (European heart journal)
Article 5: Sexual minority populations and disparities in cardiovascular healthcare. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/
 Featured Articles
Article 1: Clinical care of family members of patients with dilated cardiomyopathy.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40902100
Summary: This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies.
Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900121
Summary: This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies.
Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900118
Summary: This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis.
Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900105
Summary: This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease.
Article 5: Sexual minority populations]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality.
Article Links:
Article 1: Clinical care of family members of patients with dilated cardiomyopathy. (European heart journal)
Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. (European heart journal)
Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. (European heart journal)
Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. (European heart journal)
Article 5: Sexual minority populations and disparities in cardiovascular healthcare. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-0]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Obesity&#8217;s Unclear Role in Heart Failure with Reduced Ejection 09/03/25</title>
	<link>https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/</link>
	<pubDate>Wed, 03 Sep 2025 10:00:23 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity&#8217;s Unclear Role in Heart Failure with Reduced Ejection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40891153">Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/">https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40891153" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40891153</a></p>
<p><strong>Summary:</strong> The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? This article discusses the unclear role of obesity and visceral adiposity in the development of Heart Failure with Reduced Ejection Fraction, contrasting it with their established role in Heart Failure with Preserved Ejection Fraction. The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>adipose tissue, obesity, Heart Failure with Reduced Ejection Fraction, visceral adiposity, Heart Failure with Preserved Ejection Fraction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/">Obesity’s Unclear Role in Heart Failure with Reduced Ejection 09/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity&#8217;s Unclear Role in Heart Failure with Reduced Ejection.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>42</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity&#8217;s Unclear Role in Heart Failure with Reduced Ejection.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40891153">Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/">https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40891153" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40891153</a></p>
<p><strong>Summary:</strong> The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? This article discusses the unclear role of obesity and visceral adiposity in the development of Heart Failure with Reduced Ejection Fraction, contrasting it with their established role in Heart Failure with Preserved Ejection Fraction. The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>adipose tissue, obesity, Heart Failure with Reduced Ejection Fraction, visceral adiposity, Heart Failure with Preserved Ejection Fraction.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/">Obesity’s Unclear Role in Heart Failure with Reduced Ejection 09/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250903_060004.mp3" length="1093215" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity&#8217;s Unclear Role in Heart Failure with Reduced Ejection.
Article Links:
Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/
 Featured Articles
Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40891153
Summary: The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction.
 Transcript

Today&#8217;s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? This article discusses the unclear role of obesity and visceral adiposity in the development of Heart Failure with Reduced Ejection Fraction, contrasting it with their established role in Heart Failure with Preserved Ejection Fraction. The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. 
Thank you for listening. Don&#8217;t forget to subscribe.


 Keywords
adipose tissue, obesity, Heart Failure with Reduced Ejection Fraction, visceral adiposity, Heart Failure with Preserved Ejection Fraction.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Obesity’s Unclear Role in Heart Failure with Reduced Ejection 09/03/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity&#8217;s Unclear Role in Heart Failure with Reduced Ejection.
Article Links:
Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/
 Featured Articles
Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40891153
Summary: The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass s]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lipoprotein(a) Predicts Vascular Disease Risk 09/03/25</title>
	<link>https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/</link>
	<pubDate>Wed, 03 Sep 2025 06:56:59 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40785542">Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40718930">Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40665909">PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40631661">Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40892534">Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/">https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40785542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40785542</a></p>
<p><strong>Summary:</strong> This prospective study within the Nurses&#8217; Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor.</p>
<h4>Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40718930" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40718930</a></p>
<p><strong>Summary:</strong> This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease.</p>
<h4>Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40665909" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40665909</a></p>
<p><strong>Summary:</strong> This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia.</p>
<h4>Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40631661" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40631661</a></p>
<p><strong>Summary:</strong> This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease.</p>
<h4>Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892534</a></p>
<p><strong>Summary:</strong> This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II. This prospective study within the Nurses&#8217; Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor.</p>
<p>Article number two. Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease.</p>
<p>Article number three. PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia.</p>
<p>Article number four. Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease.</p>
<p>Article number five. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>comorbidities, cardiomyocytes, cardiac remodeling, interpersonal violence, cellular reprogramming, cardiovascular events, hereditary hemorrhagic telangiectasia, Heart Failure with Preserved Ejection Fraction, left ventricular hypertrophy, extracoronary disease, restraining order, stalking, myocardial infarction, prognosis, myocardial fibrosis, PHF7, PIEZO1, vascular endothelial growth factor receptor 2, atherosclerotic vascular disease, women&#8217;s health, biomarker, lipoprotein(a), arteriovenous malformations, activin receptor-like kinase 1, fibroblasts.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/">Lipoprotein(a) Predicts Vascular Disease Risk 09/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk.
Article Links:
Article 1: Experience]]></itunes:subtitle>
	<itunes:episode>41</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40785542">Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40718930">Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40665909">PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40631661">Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40892534">Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/">https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40785542" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40785542</a></p>
<p><strong>Summary:</strong> This prospective study within the Nurses&#8217; Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor.</p>
<h4>Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40718930" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40718930</a></p>
<p><strong>Summary:</strong> This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease.</p>
<h4>Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40665909" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40665909</a></p>
<p><strong>Summary:</strong> This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia.</p>
<h4>Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40631661" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40631661</a></p>
<p><strong>Summary:</strong> This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease.</p>
<h4>Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40892534" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40892534</a></p>
<p><strong>Summary:</strong> This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II. This prospective study within the Nurses&#8217; Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor.</p>
<p>Article number two. Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease.</p>
<p>Article number three. PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia.</p>
<p>Article number four. Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease.</p>
<p>Article number five. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>comorbidities, cardiomyocytes, cardiac remodeling, interpersonal violence, cellular reprogramming, cardiovascular events, hereditary hemorrhagic telangiectasia, Heart Failure with Preserved Ejection Fraction, left ventricular hypertrophy, extracoronary disease, restraining order, stalking, myocardial infarction, prognosis, myocardial fibrosis, PHF7, PIEZO1, vascular endothelial growth factor receptor 2, atherosclerotic vascular disease, women&#8217;s health, biomarker, lipoprotein(a), arteriovenous malformations, activin receptor-like kinase 1, fibroblasts.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/">Lipoprotein(a) Predicts Vascular Disease Risk 09/03/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250903_025607.mp3" length="3717163" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk.
Article Links:
Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II. (Circulation)
Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. (Circulation)
Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. (Circulation)
Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. (Circulation)
Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/
 Featured Articles
Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40785542
Summary: This prospective study within the Nurses&#8217; Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor.
Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40718930
Summary: This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease.
Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40665909
Summary: This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia.
Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40631661
Summary: This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease.
Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892534
Summary: This review]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk.
Article Links:
Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses&#8217; Health Study II. (Circulation)
Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. (Circulation)
Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. (Circulation)
Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. (Circulation)
Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. (European heart journal)
Full episode page: http]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI Spots Vulnerable Plaques, Predicts MI Risk 09/02/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/</link>
	<pubDate>Tue, 02 Sep 2025 10:01:45 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40866049">Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40569854">Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40439159">Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888677">Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888584">Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/">https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40866049" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40866049</a></p>
<p><strong>Summary:</strong> This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease.</p>
<h4>Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40569854" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40569854</a></p>
<p><strong>Summary:</strong> This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies.</p>
<h4>Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40439159" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40439159</a></p>
<p><strong>Summary:</strong> The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures.</p>
<h4>Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888677" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888677</a></p>
<p><strong>Summary:</strong> The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease.</p>
<h4>Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888584" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888584</a></p>
<p><strong>Summary:</strong> The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease.</p>
<p>Article number two. Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies.</p>
<p>Article number three. Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures.</p>
<p>Article number four. Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease.</p>
<p>Article number five. Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>coronary flow capacity, cardiovascular events, heart failure, artificial intelligence, preterm delivery, atrial fibrillation, stroke prevention, optical coherence tomography, myocardial infarction, medical management, cardiovascular risk, small for gestational age, surgical left atrial appendage occlusion, valvular heart disease, thin-cap fibroatheroma, adverse pregnancy outcomes, myocardial revascularization, cardiac interventions, stroke, positron emission tomography, neurocognitive dysfunction, congenital heart disease, thromboembolic events, chronic coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/">AI Spots Vulnerable Plaques, Predicts MI Risk 09/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk.
Article Links:
Artic]]></itunes:subtitle>
	<itunes:episode>40</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40866049">Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD.</a> (Journal of the American College of Cardiology)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40569854">Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40439159">Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888677">Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888584">Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial.</a> (European heart journal)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/">https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD.</h4>
<p><strong>Journal:</strong> Journal of the American College of Cardiology</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40866049" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40866049</a></p>
<p><strong>Summary:</strong> This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease.</p>
<h4>Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40569854" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40569854</a></p>
<p><strong>Summary:</strong> This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies.</p>
<h4>Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40439159" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40439159</a></p>
<p><strong>Summary:</strong> The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures.</p>
<h4>Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888677" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888677</a></p>
<p><strong>Summary:</strong> The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease.</p>
<h4>Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888584" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888584</a></p>
<p><strong>Summary:</strong> The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease.</p>
<p>Article number two. Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies.</p>
<p>Article number three. Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures.</p>
<p>Article number four. Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease.</p>
<p>Article number five. Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>coronary flow capacity, cardiovascular events, heart failure, artificial intelligence, preterm delivery, atrial fibrillation, stroke prevention, optical coherence tomography, myocardial infarction, medical management, cardiovascular risk, small for gestational age, surgical left atrial appendage occlusion, valvular heart disease, thin-cap fibroatheroma, adverse pregnancy outcomes, myocardial revascularization, cardiac interventions, stroke, positron emission tomography, neurocognitive dysfunction, congenital heart disease, thromboembolic events, chronic coronary artery disease.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/">AI Spots Vulnerable Plaques, Predicts MI Risk 09/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250902_060009.mp3" length="4005554" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk.
Article Links:
Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. (Journal of the American College of Cardiology)
Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. (European heart journal)
Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. (European heart journal)
Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. (European heart journal)
Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/
 Featured Articles
Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40866049
Summary: This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease.
Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40569854
Summary: This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies.
Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40439159
Summary: The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures.
Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888677
Summary: The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse ca]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk.
Article Links:
Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. (Journal of the American College of Cardiology)
Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. (European heart journal)
Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. (European heart journal)
Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. (European heart journal)
Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aficamten Superior to Metoprolol in HCM? 09/02/25</title>
	<link>https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/</link>
	<pubDate>Tue, 02 Sep 2025 06:57:14 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40888716">Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40888702">Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888697">Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888695">RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888694">High-Dose Influenza Vaccine to Reduce Hospitalizations.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/">https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888716" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888716</a></p>
<p><strong>Summary:</strong> This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction.</p>
<h4>Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888702" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888702</a></p>
<p><strong>Summary:</strong> This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies.</p>
<h4>Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888697" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888697</a></p>
<p><strong>Summary:</strong> This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy.</p>
<h4>Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888695" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888695</a></p>
<p><strong>Summary:</strong> This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine&#8217;s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population.</p>
<h4>Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888694" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888694</a></p>
<p><strong>Summary:</strong> This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the high-dose vaccine does not significantly reduce hospitalizations in this age group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction.</p>
<p>Article number two. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies.</p>
<p>Article number three. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy.</p>
<p>Article number four. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine&#8217;s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population.</p>
<p>Article number five. High-Dose Influenza Vaccine to Reduce Hospitalizations. This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the high-dose vaccine does not significantly reduce hospitalizations in this age group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hospitalization, older adults, mortality, metoprolol, secondary prevention, beta-blockers, Respiratory Syncytial Virus, Respiratory Syncytial Virus vaccine, influenza vaccine, myocardial infarction, respiratory illness, aficamten, all-cause mortality, cardiac myosin inhibitors, revascularization, pneumonia, left ventricular outflow tract gradient, left ventricular ejection fraction, high-dose vaccine, ejection fraction, hypertrophic cardiomyopathy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/">Aficamten Superior to Metoprolol in HCM? 09/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?.
Article Links:
Article 1: Beta-Blockers a]]></itunes:subtitle>
	<itunes:episode>39</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40888716">Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40888702">Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888697">Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888695">RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888694">High-Dose Influenza Vaccine to Reduce Hospitalizations.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/">https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888716" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888716</a></p>
<p><strong>Summary:</strong> This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction.</p>
<h4>Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888702" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888702</a></p>
<p><strong>Summary:</strong> This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies.</p>
<h4>Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888697" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888697</a></p>
<p><strong>Summary:</strong> This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy.</p>
<h4>Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888695" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888695</a></p>
<p><strong>Summary:</strong> This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine&#8217;s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population.</p>
<h4>Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888694" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888694</a></p>
<p><strong>Summary:</strong> This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the high-dose vaccine does not significantly reduce hospitalizations in this age group.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction.</p>
<p>Article number two. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies.</p>
<p>Article number three. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy.</p>
<p>Article number four. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine&#8217;s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population.</p>
<p>Article number five. High-Dose Influenza Vaccine to Reduce Hospitalizations. This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the high-dose vaccine does not significantly reduce hospitalizations in this age group. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>hospitalization, older adults, mortality, metoprolol, secondary prevention, beta-blockers, Respiratory Syncytial Virus, Respiratory Syncytial Virus vaccine, influenza vaccine, myocardial infarction, respiratory illness, aficamten, all-cause mortality, cardiac myosin inhibitors, revascularization, pneumonia, left ventricular outflow tract gradient, left ventricular ejection fraction, high-dose vaccine, ejection fraction, hypertrophic cardiomyopathy.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/">Aficamten Superior to Metoprolol in HCM? 09/02/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250902_025616.mp3" length="4198652" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?.
Article Links:
Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. (The New England journal of medicine)
Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. (The New England journal of medicine)
Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. (The New England journal of medicine)
Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/
 Featured Articles
Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888716
Summary: This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction.
Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888702
Summary: This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies.
Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888697
Summary: This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy.
Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888695
Summary: This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study fo]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?.
Article Links:
Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. (The New England journal of medicine)
Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. (The New England journal of medicine)
Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. (The New England journal of medicine)
Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/
 Featured Articles
Article 1: Beta-Blockers after ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/</link>
	<pubDate>Tue, 02 Sep 2025 03:06:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40888739">Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40888734">Apixaban for Extended Treatment of Provoked Venous Thromboembolism.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888730">Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888720">High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888717">Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/">https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888739" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888739</a></p>
<p><strong>Summary:</strong> This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.</p>
<h4>Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888734" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888734</a></p>
<p><strong>Summary:</strong> This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.</p>
<h4>Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888730" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888730</a></p>
<p><strong>Summary:</strong> This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.</p>
<h4>Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888720" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888720</a></p>
<p><strong>Summary:</strong> This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.</p>
<h4>Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888717" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888717</a></p>
<p><strong>Summary:</strong> This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.</p>
<p>Article number two. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.</p>
<p>Article number three. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.</p>
<p>Article number four. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.</p>
<p>Article number five. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Olezarsen, influenza vaccine, resistant hypertension, nonobstructive Hypertrophic Cardiomyopathy, systolic blood pressure, cardiovascular risk, hospitalization, provoking factors, aldosterone synthase inhibitor, high-dose vaccine, apixaban, functional capacity, anticoagulation, recurrent thrombosis, hypertension, cardiac myosin, antisense oligonucleotide, Hypertrophic Cardiomyopathy, venous thromboembolism, older adults, baxdrostat, vaccine effectiveness, mavacamten, apolipoprotein C-III, hypertriglyceridemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/">Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results.
Article Links:
Article 1]]></itunes:subtitle>
	<itunes:episode>38</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40888739">Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40888734">Apixaban for Extended Treatment of Provoked Venous Thromboembolism.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888730">Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888720">High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888717">Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/">https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888739" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888739</a></p>
<p><strong>Summary:</strong> This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.</p>
<h4>Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888734" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888734</a></p>
<p><strong>Summary:</strong> This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.</p>
<h4>Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888730" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888730</a></p>
<p><strong>Summary:</strong> This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.</p>
<h4>Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888720" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888720</a></p>
<p><strong>Summary:</strong> This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.</p>
<h4>Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888717" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888717</a></p>
<p><strong>Summary:</strong> This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.</p>
<p>Article number two. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.</p>
<p>Article number three. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.</p>
<p>Article number four. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.</p>
<p>Article number five. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications. </p>
<p><em>Thank you for listening. Don&#8217;t forget to subscribe.</em></p>
</p>

<h3> Keywords</h3>
<p>Olezarsen, influenza vaccine, resistant hypertension, nonobstructive Hypertrophic Cardiomyopathy, systolic blood pressure, cardiovascular risk, hospitalization, provoking factors, aldosterone synthase inhibitor, high-dose vaccine, apixaban, functional capacity, anticoagulation, recurrent thrombosis, hypertension, cardiac myosin, antisense oligonucleotide, Hypertrophic Cardiomyopathy, venous thromboembolism, older adults, baxdrostat, vaccine effectiveness, mavacamten, apolipoprotein C-III, hypertriglyceridemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/">Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_230523.mp3" length="3351448" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results.
Article Links:
Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. (The New England journal of medicine)
Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. (The New England journal of medicine)
Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. (The New England journal of medicine)
Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. (The New England journal of medicine)
Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/
 Featured Articles
Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888739
Summary: This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.
Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888734
Summary: This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.
Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888730
Summary: This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.
Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888720
Summary: This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.
Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888717
Summary: This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capac]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results.
Article Links:
Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. (The New England journal of medicine)
Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. (The New England journal of medicine)
Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. (The New England journal of medicine)
Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. (The New England journal of medicine)
Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/
 Featured Article]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aspirin: Is It Safe to Stop It Early? 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/</link>
	<pubDate>Tue, 02 Sep 2025 02:53:14 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40888742">Home-Based Care for Hypertension in Rural South Africa.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40888737">Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888726">Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888725">Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888723">Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/">https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Home-Based Care for Hypertension in Rural South Africa.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888742" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888742</a></p>
<p><strong>Summary:</strong> This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations.</p>
<h4>Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888737" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888737</a></p>
<p><strong>Summary:</strong> This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome.</p>
<h4>Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888726" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888726</a></p>
<p><strong>Summary:</strong> This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention.</p>
<h4>Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888725" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888725</a></p>
<p><strong>Summary:</strong> This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants.</p>
<h4>Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888723" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888723</a></p>
<p><strong>Summary:</strong> This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Home-Based Care for Hypertension in Rural South Africa. This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations.</p>
<p>Article number two. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome.</p>
<p>Article number three. Early Discontinuation of Aspirin after Percutaneous Coronary Intervention in Low-Risk Acute Myocardial Infarction. This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention.</p>
<p>Article number four. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants.</p>
<p>Article number five. Early Withdrawal of Aspirin after Percutaneous Coronary Intervention in Acute Coronary Syndromes. This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>stent implantation, community health workers, aspirin, home-based care, blood pressure control, rural health, P2Y12 inhibitor, oral anticoagulation, coronary-artery bypass grafting, bleeding risk, hypertension, antiplatelet therapy, drug-eluting stent, ticagrelor, acute coronary syndrome, dual antiplatelet therapy, percutaneous coronary intervention, acute myocardial infarction, acute coronary syndromes, chronic coronary syndrome, aspirin withdrawal.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/">Aspirin: Is It Safe to Stop It Early? 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?.
Article Links:
Article 1: Hom]]></itunes:subtitle>
	<itunes:episode>37</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40888742">Home-Based Care for Hypertension in Rural South Africa.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40888737">Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888726">Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40888725">Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888723">Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.</a> (The New England journal of medicine)</p>
<p>Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/">https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/</a></p>
<h3> Featured Articles</h3>
<h4>Article 1: Home-Based Care for Hypertension in Rural South Africa.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888742" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888742</a></p>
<p><strong>Summary:</strong> This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations.</p>
<h4>Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888737" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888737</a></p>
<p><strong>Summary:</strong> This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome.</p>
<h4>Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888726" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888726</a></p>
<p><strong>Summary:</strong> This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention.</p>
<h4>Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888725" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888725</a></p>
<p><strong>Summary:</strong> This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants.</p>
<h4>Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888723" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888723</a></p>
<p><strong>Summary:</strong> This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Home-Based Care for Hypertension in Rural South Africa. This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations.</p>
<p>Article number two. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome.</p>
<p>Article number three. Early Discontinuation of Aspirin after Percutaneous Coronary Intervention in Low-Risk Acute Myocardial Infarction. This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention.</p>
<p>Article number four. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants.</p>
<p>Article number five. Early Withdrawal of Aspirin after Percutaneous Coronary Intervention in Acute Coronary Syndromes. This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>stent implantation, community health workers, aspirin, home-based care, blood pressure control, rural health, P2Y12 inhibitor, oral anticoagulation, coronary-artery bypass grafting, bleeding risk, hypertension, antiplatelet therapy, drug-eluting stent, ticagrelor, acute coronary syndrome, dual antiplatelet therapy, percutaneous coronary intervention, acute myocardial infarction, acute coronary syndromes, chronic coronary syndrome, aspirin withdrawal.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/">Aspirin: Is It Safe to Stop It Early? 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_225221.mp3" length="3875569" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?.
Article Links:
Article 1: Home-Based Care for Hypertension in Rural South Africa. (The New England journal of medicine)
Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. (The New England journal of medicine)
Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. (The New England journal of medicine)
Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. (The New England journal of medicine)
Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/
 Featured Articles
Article 1: Home-Based Care for Hypertension in Rural South Africa.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888742
Summary: This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations.
Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888737
Summary: This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome.
Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888726
Summary: This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention.
Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888725
Summary: This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants.
Article 5: Early Withdrawal of Aspirin after PCI in ]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?.
Article Links:
Article 1: Home-Based Care for Hypertension in Rural South Africa. (The New England journal of medicine)
Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. (The New England journal of medicine)
Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. (The New England journal of medicine)
Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. (The New England journal of medicine)
Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/
 Featured Articles
Article]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Low Potassium Linked to Atrial Fibrillation Risk 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 18:23:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884219">AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884211">Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884202">Hypokalaemia and atrial fibrillation detected by implanted loop recorders.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884168">Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884070">Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/">https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884219</a></p>
<p><strong>Summary:</strong> This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death.</p>
<h4>Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884211</a></p>
<p><strong>Summary:</strong> Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects.</p>
<h4>Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884202" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884202</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention.</p>
<h4>Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884168</a></p>
<p><strong>Summary:</strong> This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management.</p>
<h4>Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884070</a></p>
<p><strong>Summary:</strong> The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial aims to determine if heart failure treatment can improve self-care ability in patients with stage 4 solid tumors and cardiovascular risk factors, who are experiencing a heart failure-like phenotype. Outcomes from this trial will provide insights into managing cardiovascular complications in advanced cancer patients and optimizing their quality of life.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death.</p>
<p>Article number two. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects.</p>
<p>Article number three. Hypokalaemia and atrial fibrillation detected by implanted loop recorders. This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention.</p>
<p>Article number four. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management.</p>
<p>Article number five. Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial aims to determine if heart failure treatment can improve self-care ability in patients with stage 4 solid tumors and cardiovascular risk factors, who are experiencing a heart failure-like phenotype. Outcomes from this trial will provide insights into managing cardiovascular complications in advanced cancer patients and optimizing their quality of life. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>hypokalemia, cardiac wasting, implanted loop recorder, myocardial infarction, KCNH2, cardiometabolic risk, palliative care, sex differences, gut microbiota, ventricular arrhythmias, beta-blockers, imidazole propionate, left ventricular ejection fraction, stroke risk, atrial fibrillation, heart failure, dyspnea, gene therapy, advanced cancer, cardiac repolarization, coronary artery disease, potassium levels, Short QT Syndrome, acute coronary syndrome, REBOOT trial.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/">Low Potassium Linked to Atrial Fibrillation Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk.
Article Links:
Article 1: AAV9-med]]></itunes:subtitle>
	<itunes:episode>36</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884219">AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884211">Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884202">Hypokalaemia and atrial fibrillation detected by implanted loop recorders.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884168">Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884070">Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/">https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884219</a></p>
<p><strong>Summary:</strong> This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death.</p>
<h4>Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884211</a></p>
<p><strong>Summary:</strong> Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects.</p>
<h4>Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884202" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884202</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention.</p>
<h4>Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884168</a></p>
<p><strong>Summary:</strong> This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management.</p>
<h4>Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884070</a></p>
<p><strong>Summary:</strong> The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial aims to determine if heart failure treatment can improve self-care ability in patients with stage 4 solid tumors and cardiovascular risk factors, who are experiencing a heart failure-like phenotype. Outcomes from this trial will provide insights into managing cardiovascular complications in advanced cancer patients and optimizing their quality of life.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death.</p>
<p>Article number two. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects.</p>
<p>Article number three. Hypokalaemia and atrial fibrillation detected by implanted loop recorders. This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention.</p>
<p>Article number four. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management.</p>
<p>Article number five. Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial aims to determine if heart failure treatment can improve self-care ability in patients with stage 4 solid tumors and cardiovascular risk factors, who are experiencing a heart failure-like phenotype. Outcomes from this trial will provide insights into managing cardiovascular complications in advanced cancer patients and optimizing their quality of life. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>hypokalemia, cardiac wasting, implanted loop recorder, myocardial infarction, KCNH2, cardiometabolic risk, palliative care, sex differences, gut microbiota, ventricular arrhythmias, beta-blockers, imidazole propionate, left ventricular ejection fraction, stroke risk, atrial fibrillation, heart failure, dyspnea, gene therapy, advanced cancer, cardiac repolarization, coronary artery disease, potassium levels, Short QT Syndrome, acute coronary syndrome, REBOOT trial.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/">Low Potassium Linked to Atrial Fibrillation Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_142256.mp3" length="4522570" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk.
Article Links:
Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. (European heart journal)
Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. (European heart journal)
Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. (European heart journal)
Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. (European heart journal)
Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219
Summary: This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death.
Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884211
Summary: Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects.
Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884202
Summary: This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention.
Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884168
Summary: This study found that elevated circulating levels of]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk.
Article Links:
Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. (European heart journal)
Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. (European heart journal)
Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. (European heart journal)
Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. (European heart journal)
Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://po]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Aspirin Dose Upregulation Fails After Acute Coronary Syndrome 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 18:18:18 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884758">Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884757">Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884558">Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884439">Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884413">High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/">https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884758</a></p>
<p><strong>Summary:</strong> This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.</p>
<h4>Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884757" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884757</a></p>
<p><strong>Summary:</strong> The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.</p>
<h4>Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884558</a></p>
<p><strong>Summary:</strong> The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.</p>
<h4>Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884439" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884439</a></p>
<p><strong>Summary:</strong> This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine&#8217;s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.</p>
<h4>Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884413</a></p>
<p><strong>Summary:</strong> standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.Article number two. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.Article number three. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.Article number four. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine&#8217;s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.Article number five. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>acute coronary syndrome, aspirin resistance, antiplatelet therapy, inclisiran, low-density lipoprotein cholesterol, hypercholesterolemia, vaccine, respiratory syncytial virus, diabetes mellitus, mortality, screening, coronary artery calcification, atherosclerotic cardiovascular disease, respiratory tract infection, respiratory outcomes, cardiovascular disease, influenza vaccine, proprotein convertase subtilisin/kexin type 9, cardiovascular outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/">Aspirin Dose Upregulation Fails After Acute Coronary Syndrome 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome.
Articl]]></itunes:subtitle>
	<itunes:episode>35</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884758">Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884757">Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884558">Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884439">Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884413">High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/">https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884758</a></p>
<p><strong>Summary:</strong> This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.</p>
<h4>Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884757" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884757</a></p>
<p><strong>Summary:</strong> The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.</p>
<h4>Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884558</a></p>
<p><strong>Summary:</strong> The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.</p>
<h4>Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884439" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884439</a></p>
<p><strong>Summary:</strong> This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine&#8217;s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.</p>
<h4>Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884413</a></p>
<p><strong>Summary:</strong> standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.Article number two. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.Article number three. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.Article number four. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine&#8217;s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.Article number five. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>acute coronary syndrome, aspirin resistance, antiplatelet therapy, inclisiran, low-density lipoprotein cholesterol, hypercholesterolemia, vaccine, respiratory syncytial virus, diabetes mellitus, mortality, screening, coronary artery calcification, atherosclerotic cardiovascular disease, respiratory tract infection, respiratory outcomes, cardiovascular disease, influenza vaccine, proprotein convertase subtilisin/kexin type 9, cardiovascular outcomes.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/">Aspirin Dose Upregulation Fails After Acute Coronary Syndrome 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_141728.mp3" length="3535350" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome.
Article Links:
Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. (European heart journal)
Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. (European heart journal)
Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. (European heart journal)
Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. (European heart journal)
Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758
Summary: This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.
Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757
Summary: The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.
Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558
Summary: The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.
Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439
Summary: This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine&#8217;s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on c]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome.
Article Links:
Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. (European heart journal)
Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. (European heart journal)
Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. (European heart journal)
Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. (European heart journal)
Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/</link>
	<pubDate>Mon, 01 Sep 2025 18:14:11 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40886161">Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40886132">Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40886063">Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40886061">Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40886060">CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/">https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886161</a></p>
<p><strong>Summary:</strong> This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction.</p>
<h4>Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease.</p>
<h4>Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886063" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886063</a></p>
<p><strong>Summary:</strong> This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease.</p>
<h4>Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886061" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886061</a></p>
<p><strong>Summary:</strong> The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells.</p>
<h4>Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886060" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886060</a></p>
<p><strong>Summary:</strong> This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a truncating variant known to cause dilated cardiomyopathy, leading to the repair of electrocardiogram abnormalities. This suggests that CRISPR activation could be a promising therapeutic strategy for patients with Filamin C-related cardiomyopathies who currently lack gene-specific treatments. The research highlights the potential of CRISPR technology to address genetic causes of heart disease by enhancing gene expression rather than directly editing the genome.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> &lt;p&gt;Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;&lt;p&gt;Article number two. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease.&lt;/p&gt;&lt;p&gt;Article number three. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease.&lt;/p&gt;&lt;p&gt;Article number four. Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells.&lt;/p&gt;&lt;p&gt;Article number five. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a truncating variant known to cause dilated cardiomyopathy, leading to the repair of electrocardiogram abnormalities. This suggests that CRISPR activation could be a promising therapeutic strategy for patients with Filamin C-related cardiomyopathies who currently lack gene-specific treatments. The research highlights the potential of CRISPR technology to address genetic causes of heart disease by enhancing gene expression rather than directly editing the genome.&lt;/p&gt; </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>antiplatelet therapy, thrombosis, CRISPR activation, atherothrombotic risk, prothrombotic signaling, serum magnesium, lipoprotein(a), electrocardiogram abnormalities, glucagon-like peptide-1 receptor agonists, vascular regeneration, filamin C, reticulated platelets, coronary artery disease, dilated cardiomyopathy, semaglutide, myocardial infarction, first-degree relatives, atherosclerotic cardiovascular disease, GALACTIC-HF trial, heart failure with reduced ejection fraction, gene therapy, cardiovascular death, bone marrow-derived progenitor cells, heart failure hospitalization, ischemic stroke.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/">Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk.
Article Links:
Article 1: Serum mag]]></itunes:subtitle>
	<itunes:episode>34</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40886161">Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</a> (European heart journal)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40886132">Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</a> (European heart journal)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40886063">Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.</a> (European heart journal)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40886061">Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.</a> (European heart journal)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40886060">CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/">https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886161</a></p>
<p><strong>Summary:</strong> This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction.</p>
<h4>Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease.</p>
<h4>Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886063" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886063</a></p>
<p><strong>Summary:</strong> This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease.</p>
<h4>Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886061" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886061</a></p>
<p><strong>Summary:</strong> The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells.</p>
<h4>Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886060" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886060</a></p>
<p><strong>Summary:</strong> This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a truncating variant known to cause dilated cardiomyopathy, leading to the repair of electrocardiogram abnormalities. This suggests that CRISPR activation could be a promising therapeutic strategy for patients with Filamin C-related cardiomyopathies who currently lack gene-specific treatments. The research highlights the potential of CRISPR technology to address genetic causes of heart disease by enhancing gene expression rather than directly editing the genome.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> &lt;p&gt;Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;&lt;p&gt;Article number two. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease.&lt;/p&gt;&lt;p&gt;Article number three. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease.&lt;/p&gt;&lt;p&gt;Article number four. Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells.&lt;/p&gt;&lt;p&gt;Article number five. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a truncating variant known to cause dilated cardiomyopathy, leading to the repair of electrocardiogram abnormalities. This suggests that CRISPR activation could be a promising therapeutic strategy for patients with Filamin C-related cardiomyopathies who currently lack gene-specific treatments. The research highlights the potential of CRISPR technology to address genetic causes of heart disease by enhancing gene expression rather than directly editing the genome.&lt;/p&gt; </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>antiplatelet therapy, thrombosis, CRISPR activation, atherothrombotic risk, prothrombotic signaling, serum magnesium, lipoprotein(a), electrocardiogram abnormalities, glucagon-like peptide-1 receptor agonists, vascular regeneration, filamin C, reticulated platelets, coronary artery disease, dilated cardiomyopathy, semaglutide, myocardial infarction, first-degree relatives, atherosclerotic cardiovascular disease, GALACTIC-HF trial, heart failure with reduced ejection fraction, gene therapy, cardiovascular death, bone marrow-derived progenitor cells, heart failure hospitalization, ischemic stroke.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/">Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_141217.mp3" length="4296872" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk.
Article Links:
Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. (European heart journal)
Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal)
Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. (European heart journal)
Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. (European heart journal)
Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161
Summary: This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction.
Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132
Summary: This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease.
Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063
Summary: This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease.
Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
Journal: Europea]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk.
Article Links:
Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. (European heart journal)
Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal)
Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. (European heart journal)
Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. (European heart journal)
Article 5: CRISPR activation to repair ECG abnormalities caused by]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TAVR: Minimalist Approach Proven Safe and Effective 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 17:56:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884047">Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40879562">Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40878766">Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40878676">Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40886179">Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/">https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884047" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884047</a></p>
<p><strong>Summary:</strong> This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.</p>
<h4>Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879562</a></p>
<p><strong>Summary:</strong> This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.</p>
<h4>Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878766" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878766</a></p>
<p><strong>Summary:</strong> The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.</p>
<h4>Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878676" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878676</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy.</p>
<h4>Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.Article number two. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.Article number three. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.Article number four. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy.Article number five. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>PRADA II trial, breast cancer, microvascular endothelial cells, TAILORED-CHIP trial, antiplatelet therapy, Hypertrophic Cardiomyopathy, CCN2 signaling, genetic architecture, percutaneous coronary intervention, vasculopathy, sarcomere genes, cardiotoxicity, angiotensin receptor neprilysin inhibitor, antiphospholipid syndrome, intermediate effect variants, DOUBLE-CHOICE trial, disease expression, platelet inhibition, sacubitril-valsartan, transfemoral transcatheter aortic valve implantation, transcatheter aortic valve implantation, aortic stenosis, dual antiplatelet therapy, YAP1 signaling, minimalist approach.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/">TAVR: Minimalist Approach Proven Safe and Effective 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective.
Article Links:
Article 1: Sacu]]></itunes:subtitle>
	<itunes:episode>36</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884047">Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40879562">Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40878766">Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40878676">Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40886179">Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/">https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884047" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884047</a></p>
<p><strong>Summary:</strong> This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.</p>
<h4>Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879562</a></p>
<p><strong>Summary:</strong> This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.</p>
<h4>Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878766" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878766</a></p>
<p><strong>Summary:</strong> The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.</p>
<h4>Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878676" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878676</a></p>
<p><strong>Summary:</strong> This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy.</p>
<h4>Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.Article number two. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.Article number three. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.Article number four. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy.Article number five. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>PRADA II trial, breast cancer, microvascular endothelial cells, TAILORED-CHIP trial, antiplatelet therapy, Hypertrophic Cardiomyopathy, CCN2 signaling, genetic architecture, percutaneous coronary intervention, vasculopathy, sarcomere genes, cardiotoxicity, angiotensin receptor neprilysin inhibitor, antiphospholipid syndrome, intermediate effect variants, DOUBLE-CHOICE trial, disease expression, platelet inhibition, sacubitril-valsartan, transfemoral transcatheter aortic valve implantation, transcatheter aortic valve implantation, aortic stenosis, dual antiplatelet therapy, YAP1 signaling, minimalist approach.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/">TAVR: Minimalist Approach Proven Safe and Effective 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_135541.mp3" length="3816219" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective.
Article Links:
Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation)
Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation)
Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. (Circulation)
Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. (Circulation)
Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047
Summary: This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.
Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562
Summary: This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.
Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766
Summary: The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.
Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676
Summary: This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potent]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective.
Article Links:
Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation)
Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation)
Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. (Circulation)
Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. (Circulation)
Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinic]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cerebral Protection Mitigates TAVI Cognitive Decline 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 17:54:27 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40886109">Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884786">Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884774">Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884771">Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884768">Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/">https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886109" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886109</a></p>
<p><strong>Summary:</strong> The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.</p>
<h4>Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884786" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884786</a></p>
<p><strong>Summary:</strong> This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.</p>
<h4>Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884774" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884774</a></p>
<p><strong>Summary:</strong> This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.</p>
<h4>Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884771" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884771</a></p>
<p><strong>Summary:</strong> This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting.</p>
<h4>Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884768</a></p>
<p><strong>Summary:</strong> This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis.</p>
<p> &lt;h3&gt; Transcript&lt;/h3&gt; &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt; &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;&lt;p&gt;Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.&lt;/p&gt;&lt;p&gt;Article number two. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.&lt;/p&gt;&lt;p&gt;Article number three. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.&lt;/p&gt;&lt;p&gt;Article number four. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting.&lt;/p&gt;&lt;p&gt;Article number five. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis.&lt;/p&gt;&lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt; &lt;/div&gt; </p>
<h3> Keywords</h3>
<p>biomarker, mitral regurgitation, ivabradine, mitral valve surgery, noncardiac surgery, valve replacement, stroke, transcatheter aortic valve implantation, MITRACURE registry, bicuspid aortic valve, surgical aortic valve replacement, transcatheter aortic valve replacement, atrial fibrillation, low-risk patients, heart rate control, myocardial injury, randomized controlled trial, aortic stenosis, cerebral embolic protection, valve repair, cognitive function, beta-blockers, stroke prevention, ABC-AF risk score.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/">Cerebral Protection Mitigates TAVI Cognitive Decline 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline.
Article Links:
Article 1: C]]></itunes:subtitle>
	<itunes:episode>35</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40886109">Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884786">Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884774">Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884771">Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884768">Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/">https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886109" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886109</a></p>
<p><strong>Summary:</strong> The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.</p>
<h4>Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884786" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884786</a></p>
<p><strong>Summary:</strong> This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.</p>
<h4>Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884774" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884774</a></p>
<p><strong>Summary:</strong> This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.</p>
<h4>Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884771" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884771</a></p>
<p><strong>Summary:</strong> This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting.</p>
<h4>Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884768</a></p>
<p><strong>Summary:</strong> This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis.</p>
<p> &lt;h3&gt; Transcript&lt;/h3&gt; &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt; &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;&lt;p&gt;Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.&lt;/p&gt;&lt;p&gt;Article number two. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.&lt;/p&gt;&lt;p&gt;Article number three. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.&lt;/p&gt;&lt;p&gt;Article number four. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting.&lt;/p&gt;&lt;p&gt;Article number five. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis.&lt;/p&gt;&lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt; &lt;/div&gt; </p>
<h3> Keywords</h3>
<p>biomarker, mitral regurgitation, ivabradine, mitral valve surgery, noncardiac surgery, valve replacement, stroke, transcatheter aortic valve implantation, MITRACURE registry, bicuspid aortic valve, surgical aortic valve replacement, transcatheter aortic valve replacement, atrial fibrillation, low-risk patients, heart rate control, myocardial injury, randomized controlled trial, aortic stenosis, cerebral embolic protection, valve repair, cognitive function, beta-blockers, stroke prevention, ABC-AF risk score.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/">Cerebral Protection Mitigates TAVI Cognitive Decline 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_135330.mp3" length="3623540" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline.
Article Links:
Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation)
Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation)
Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. (Circulation)
Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation)
Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109
Summary: The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.
Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786
Summary: This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.
Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774
Summary: This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.
Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771
Summary: This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. T]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline.
Article Links:
Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation)
Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation)
Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. (Circulation)
Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation)
Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rehab Improves Outcomes Post-Myocardial Infarction 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 17:42:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879434">Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40879431">Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40879429">Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40879421">Reduction of Antihypertensive Treatment in Nursing Home Residents.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888124">Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/">https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879434</a></p>
<p><strong>Summary:</strong> This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction.</p>
<h4>Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction.</p>
<h4>Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported.</p>
<h4>Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population.</p>
<h4>Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligence electrocardiogram models have both condition-specific and generalizable risk prediction capabilities.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction.Article number two. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction.Article number three. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported.Article number four. Reduction of Antihypertensive Treatment in Nursing Home Residents. This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population.Article number five. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligence electrocardiogram models have both condition-specific and generalizable risk prediction capabilities. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiac Glycoside, Artificial Intelligence, Phenotypes, Cardiovascular Death, All-Cause Mortality, Physical Performance, Frailty, Rehabilitation, Nursing Home Residents, Ventricular Arrhythmias, Potassium, Myocardial Infarction, Blood Pressure, Risk Prediction, Cardiovascular Risk Factors, Digitoxin, Antihypertensive Treatment, Implantable Cardioverter-Defibrillator, Exercise Training, Heart Failure with Reduced Ejection Fraction, Hospitalization, Electrocardiogram, Cardiovascular Events, Cardiovascular Diagnosis, Hypokalemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/">Rehab Improves Outcomes Post-Myocardial Infarction 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction.
Article Links:
Art]]></itunes:subtitle>
	<itunes:episode>34</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879434">Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40879431">Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40879429">Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</a> (The New England journal of medicine)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40879421">Reduction of Antihypertensive Treatment in Nursing Home Residents.</a> (The New England journal of medicine)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40888124">Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/">https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879434</a></p>
<p><strong>Summary:</strong> This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction.</p>
<h4>Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction.</p>
<h4>Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported.</p>
<h4>Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population.</p>
<h4>Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligence electrocardiogram models have both condition-specific and generalizable risk prediction capabilities.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction.Article number two. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction.Article number three. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported.Article number four. Reduction of Antihypertensive Treatment in Nursing Home Residents. This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population.Article number five. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligence electrocardiogram models have both condition-specific and generalizable risk prediction capabilities. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiac Glycoside, Artificial Intelligence, Phenotypes, Cardiovascular Death, All-Cause Mortality, Physical Performance, Frailty, Rehabilitation, Nursing Home Residents, Ventricular Arrhythmias, Potassium, Myocardial Infarction, Blood Pressure, Risk Prediction, Cardiovascular Risk Factors, Digitoxin, Antihypertensive Treatment, Implantable Cardioverter-Defibrillator, Exercise Training, Heart Failure with Reduced Ejection Fraction, Hospitalization, Electrocardiogram, Cardiovascular Events, Cardiovascular Diagnosis, Hypokalemia.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/">Rehab Improves Outcomes Post-Myocardial Infarction 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_134114.mp3" length="3896049" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction.
Article Links:
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine)
Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine)
Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine)
Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine)
Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434
Summary: This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction.
Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction.
Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429
Summary: This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported.
Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421
Summary: This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction.
Article Links:
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine)
Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine)
Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine)
Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine)
Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 17:38:49 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884774">Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884771">Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884768">Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884047">Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40879562">Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</a> (Circulation)</p>
<p>&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/">https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</a>&lt;/p&gt; &lt;h3&gt; Full Episode Summary&lt;/h3&gt; &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt; &lt;h3&gt; Featured Articles&lt;/h3&gt; &lt;h4&gt;Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884774&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884774&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This multicenter randomized controlled trial evaluated whether using biomarker-based Atrial Fibrillation Better Care risk scores to guide treatment decisions improves outcomes in patients with atrial fibrillation. The study informed investigators of each patient&#8217;s ABC-AF-stroke, bleeding, and heart failure risk scores to guide multidimensional treatments; however, the full results and clinical implications will be crucial to understanding its impact.&lt;/p&gt; &lt;h4&gt;Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This randomized controlled trial investigated ivabradine, a selective heart rate-lowering agent, to prevent myocardial injury after noncardiac surgery. The study compared ivabradine to placebo in patients at risk for atherosclerotic disease undergoing noncardiac surgery, aiming to reduce perioperative myocardial infarction without the hemodynamic instability associated with beta-blockers.&lt;/p&gt; &lt;h4&gt;Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884768&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884768&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; The NOTION-2 trial&#8217;s three-year follow-up compared tran&#8230; (Full details on website)</p><p>The post <a href="https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/">Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?.
Article Links:
Article 1: Biomarker-ba]]></itunes:subtitle>
	<itunes:episode>33</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?.</p>
<p>Article Links:</p>
<p>Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40884774">Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</a> (Circulation)</p>
<p>Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40884771">Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</a> (Circulation)</p>
<p>Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40884768">Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</a> (Circulation)</p>
<p>Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40884047">Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</a> (Circulation)</p>
<p>Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40879562">Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</a> (Circulation)</p>
<p>&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/">https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</a>&lt;/p&gt; &lt;h3&gt; Full Episode Summary&lt;/h3&gt; &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt; &lt;h3&gt; Featured Articles&lt;/h3&gt; &lt;h4&gt;Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884774&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884774&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This multicenter randomized controlled trial evaluated whether using biomarker-based Atrial Fibrillation Better Care risk scores to guide treatment decisions improves outcomes in patients with atrial fibrillation. The study informed investigators of each patient&#8217;s ABC-AF-stroke, bleeding, and heart failure risk scores to guide multidimensional treatments; however, the full results and clinical implications will be crucial to understanding its impact.&lt;/p&gt; &lt;h4&gt;Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This randomized controlled trial investigated ivabradine, a selective heart rate-lowering agent, to prevent myocardial injury after noncardiac surgery. The study compared ivabradine to placebo in patients at risk for atherosclerotic disease undergoing noncardiac surgery, aiming to reduce perioperative myocardial infarction without the hemodynamic instability associated with beta-blockers.&lt;/p&gt; &lt;h4&gt;Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884768&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884768&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; The NOTION-2 trial&#8217;s three-year follow-up compared tran&#8230; (Full details on website)</p><p>The post <a href="https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/">Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_133806.mp3" length="3156261" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?.
Article Links:
Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. (Circulation)
Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation)
Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation)
Article 4: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation)
Article 5: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation)
&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/&lt;/p&gt; &lt;h3&gt; Full Episode Summary&lt;/h3&gt; &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt; &lt;h3&gt; Featured Articles&lt;/h3&gt; &lt;h4&gt;Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884774&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884774&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This multicenter randomized controlled trial evaluated whether using biomarker-based Atrial Fibrillation Better Care risk scores to guide treatment decisions improves outcomes in patients with atrial fibrillation. The study informed investigators of each patient&#8217;s ABC-AF-stroke, bleeding, and heart failure risk scores to guide multidimensional treatments; however, the full results and clinical implications will be crucial to understanding its impact.&lt;/p&gt; &lt;h4&gt;Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This randomized controlled trial investigated ivabradine, a selective heart rate-lowering agent, to prevent myocardial injury after noncardiac surgery. The study compared ivabradine to placebo in patients at risk for atherosclerotic disease undergoing noncardiac surgery, aiming to reduce perioperative myocardial infarction without the hemodynamic instability associated with beta-blockers.&lt;/p&gt; &lt;h4&gt;Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.&lt;/h4&gt; &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt; &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884768&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884768&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; The NOTION-2 trial&#8217;s three-year follow-up compared tran&#8230; (Full details on website)The post Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?.
Article Links:
Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. (Circulation)
Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation)
Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation)
Article 4: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation)
Article 5: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulatio]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>De-escalating Hypertension in Frail Elderly is Safe 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 17:29:03 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe.</p>
<p>Article Links: Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879429">Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</a> (The New England journal of medicine) | Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40879421">Reduction of Antihypertensive Treatment in Nursing Home Residents.</a> (The New England journal of medicine) | Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888124">Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</a> (Circulation) | Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40886109">Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</a> (Circulation) | Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884786">Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/">https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This Danish, multi-center, open-label, randomized trial investigated actively increasing plasma potassium levels in patients at high risk for ventricular arrhythmias who had an implantable cardioverter-defibrillator. The study was stopped early due to slow enrollment and a low number of events, concluding that an active strategy of increasing plasma potassium was not associated with a lower risk of ventricular arrhythmias or death, but did show a potential association with an increased risk of hyperkalemia. This suggests further research is necessary to determine optimal potassium management in this high-risk population.</p>
<h4>Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This French, multi-center, randomized, controlled trial examined the effects of reducing antihypertensive medications in nursing home residents aged 80 or older with systolic blood pressure below 130 millimeters of mercury. Results showed that a protocol-driven strategy of progressive antihypertensive treatment reduction did not significantly increase the risk of death or serious adverse events compared to usual care. The study suggests that de-escalation of antihypertensive therapy may be safe in frail, older adults in nursing homes.</p>
<h4>Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study investigated the performance of artificial intelligence-enhanced electrocardiogram models to detect specific cardiac conditions versus broad cardio&#8230; (Full details on website)</p><p>The post <a href="https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/">De-escalating Hypertension in Frail Elderly is Safe 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe.
Article Links: Article 1: Incr]]></itunes:subtitle>
	<itunes:episode>32</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe.</p>
<p>Article Links: Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879429">Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</a> (The New England journal of medicine) | Article 2: <a href="https://pubmed.ncbi.nlm.nih.gov/40879421">Reduction of Antihypertensive Treatment in Nursing Home Residents.</a> (The New England journal of medicine) | Article 3: <a href="https://pubmed.ncbi.nlm.nih.gov/40888124">Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</a> (Circulation) | Article 4: <a href="https://pubmed.ncbi.nlm.nih.gov/40886109">Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</a> (Circulation) | Article 5: <a href="https://pubmed.ncbi.nlm.nih.gov/40884786">Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/">https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This Danish, multi-center, open-label, randomized trial investigated actively increasing plasma potassium levels in patients at high risk for ventricular arrhythmias who had an implantable cardioverter-defibrillator. The study was stopped early due to slow enrollment and a low number of events, concluding that an active strategy of increasing plasma potassium was not associated with a lower risk of ventricular arrhythmias or death, but did show a potential association with an increased risk of hyperkalemia. This suggests further research is necessary to determine optimal potassium management in this high-risk population.</p>
<h4>Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This French, multi-center, randomized, controlled trial examined the effects of reducing antihypertensive medications in nursing home residents aged 80 or older with systolic blood pressure below 130 millimeters of mercury. Results showed that a protocol-driven strategy of progressive antihypertensive treatment reduction did not significantly increase the risk of death or serious adverse events compared to usual care. The study suggests that de-escalation of antihypertensive therapy may be safe in frail, older adults in nursing homes.</p>
<h4>Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study investigated the performance of artificial intelligence-enhanced electrocardiogram models to detect specific cardiac conditions versus broad cardio&#8230; (Full details on website)</p><p>The post <a href="https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/">De-escalating Hypertension in Frail Elderly is Safe 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_132543.mp3" length="4096252" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe.
Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) | Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) | Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) | Article 4: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) | Article 5: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429
Summary: This Danish, multi-center, open-label, randomized trial investigated actively increasing plasma potassium levels in patients at high risk for ventricular arrhythmias who had an implantable cardioverter-defibrillator. The study was stopped early due to slow enrollment and a low number of events, concluding that an active strategy of increasing plasma potassium was not associated with a lower risk of ventricular arrhythmias or death, but did show a potential association with an increased risk of hyperkalemia. This suggests further research is necessary to determine optimal potassium management in this high-risk population.
Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421
Summary: This French, multi-center, randomized, controlled trial examined the effects of reducing antihypertensive medications in nursing home residents aged 80 or older with systolic blood pressure below 130 millimeters of mercury. Results showed that a protocol-driven strategy of progressive antihypertensive treatment reduction did not significantly increase the risk of death or serious adverse events compared to usual care. The study suggests that de-escalation of antihypertensive therapy may be safe in frail, older adults in nursing homes.
Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124
Summary: This study investigated the performance of artificial intelligence-enhanced electrocardiogram models to detect specific cardiac conditions versus broad cardio&#8230; (Full details on website)The post De-escalating Hypertension in Frail Elderly is Safe 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe.
Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) | Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) | Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) | Article 4: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) | Article 5: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation)
T]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rehab After MI: Impact on Older Patients 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 16:44:28 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients.</p>
<p>Article Links: Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879431">Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/">https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiovascular Risk Factors, Exercise Training, Myocardial Infarction, Cardiac Rehabilitation, Geriatric Cardiology.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/">Rehab After MI: Impact on Older Patients 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients.
Article Links: Article 1]]></itunes:subtitle>
	<itunes:episode>31</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients.</p>
<p>Article Links: Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879431">Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/">https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiovascular Risk Factors, Exercise Training, Myocardial Infarction, Cardiac Rehabilitation, Geriatric Cardiology.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/">Rehab After MI: Impact on Older Patients 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_124416.mp3" length="883399" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients.
Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. 
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiovascular Risk Factors, Exercise Training, Myocardial Infarction, Cardiac Rehabilitation, Geriatric Cardiology.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Rehab After MI: Impact on Older Patients 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients.
Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older pa]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Digitoxin Fails in Heart Failure Trial 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 16:38:06 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879434">Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/">https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879434</a></p>
<p><strong>Summary:</strong> This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiovascular Mortality, Hospitalization., Heart Failure with Reduced Ejection Fraction, Digitoxin, Cardiac Glycosides.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/">Digitoxin Fails in Heart Failure Trial 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Li]]></itunes:subtitle>
	<itunes:episode>30</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href="https://pubmed.ncbi.nlm.nih.gov/40879434">Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/">https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879434</a></p>
<p><strong>Summary:</strong> This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p> Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. </p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiovascular Mortality, Hospitalization., Heart Failure with Reduced Ejection Fraction, Digitoxin, Cardiac Glycosides.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/">Digitoxin Fails in Heart Failure Trial 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_123753.mp3" length="1022580" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434
Summary: This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
 Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. 
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiovascular Mortality, Hospitalization., Heart Failure with Reduced Ejection Fraction, Digitoxin, Cardiac Glycosides.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Digitoxin Fails in Heart Failure Trial 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434
Summary: This double-blind, placebo-controlled trial investigated digitoxin&#8217;s efficacy in chronic Heart Failure with Reduc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 16:32:06 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40886132'>Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/">https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/">Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Art]]></itunes:subtitle>
	<itunes:episode>29</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40886132'>Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/">https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/">Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_123149.mp3" length="1103246" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132
Summary: This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This Swedish registry study investigated major cardiovascular event risk in first-degree relatives of individuals with elevated Lipoprotein(a). The study found that relatives of probands with high Lipoprotein(a) had an increased risk of myocardial infarction, ischemic stroke, and death, particularly when the proband experienced premature cardiovascular disease, highlighting the need for familial screening and risk stratification. These findings suggest monitoring family members of patients with high Lipoprotein(a) could lead to earlier interventions and improve cardiovascular outcomes.
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiology, Heart Disease, Clinical Research, NEJM, JACC.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Lipoprotein(a) Elevates Family Cardiac Risk 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132
Summary: This Swedish registr]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Magnesium Levels Impact HFrEF Outcomes 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 16:27:54 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/</guid>
	<description><![CDATA[<p>&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like serum magnesium and GALACTIC-HF trial. Key takeaway: Biomarker-guided treatments show no outcome benefits.&lt;/p&gt;&lt;p&gt;Article Links: Article 1: &lt;a href=&#8217;https://pubmed.ncbi.nlm.nih.gov/40886161&#8242;&gt;Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/a&gt; (European heart journal)&lt;/p&gt;&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/">https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/</a>&lt;/p&gt;
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Featured Articles&lt;/h3&gt;</p>
<p>                &lt;h4&gt;Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; European heart journal&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886161&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886161&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;</p>
<p>        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;serum magnesium, GALACTIC-HF trial, heart failure events, cardiovascular death, Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;</p>
<p>        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;</p><p>The post <a href="https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/">Magnesium Levels Impact HFrEF Outcomes 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like serum magnesium and GALACTIC-HF trial. Key takeaway: Biomarker-guided treatments show n]]></itunes:subtitle>
	<itunes:episode>28</itunes:episode>
	<content:encoded><![CDATA[<p>&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like serum magnesium and GALACTIC-HF trial. Key takeaway: Biomarker-guided treatments show no outcome benefits.&lt;/p&gt;&lt;p&gt;Article Links: Article 1: &lt;a href=&#8217;https://pubmed.ncbi.nlm.nih.gov/40886161&#8242;&gt;Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/a&gt; (European heart journal)&lt;/p&gt;&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/">https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/</a>&lt;/p&gt;
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Featured Articles&lt;/h3&gt;</p>
<p>                &lt;h4&gt;Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; European heart journal&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886161&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886161&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;</p>
<p>        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;serum magnesium, GALACTIC-HF trial, heart failure events, cardiovascular death, Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;</p>
<p>        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;</p><p>The post <a href="https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/">Magnesium Levels Impact HFrEF Outcomes 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_122740.mp3" length="970335" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like serum magnesium and GALACTIC-HF trial. Key takeaway: Biomarker-guided treatments show no outcome benefits.&lt;/p&gt;&lt;p&gt;Article Links: Article 1: &lt;a href=&#8217;https://pubmed.ncbi.nlm.nih.gov/40886161&#8242;&gt;Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/a&gt; (European heart journal)&lt;/p&gt;&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/&lt;/p&gt;
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;
        &lt;h3&gt; Featured Articles&lt;/h3&gt;
                &lt;h4&gt;Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; European heart journal&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886161&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886161&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;
        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. In patients with Heart Failure with Reduced Ejection Fraction enrolled in the GALACTIC-Heart Failure trial, researchers evaluated the association between serum magnesium levels and clinical outcomes. The study found that both low and high magnesium concentrations were independently associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. This suggests that maintaining optimal serum magnesium levels may be important in managing patients with Heart Failure with Reduced Ejection Fraction.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;serum magnesium, GALACTIC-HF trial, heart failure events, cardiovascular death, Heart Failure with Reduced Ejection Fraction.&lt;/p&gt;
        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;The post Magnesium Levels Impact HFrEF Outcomes 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like serum magnesium and GALACTIC-HF trial. Key takeaway: Biomarker-guided treatments show no outcome benefits.&lt;/p&gt;&lt;p&gt;Article Links: Article 1: &lt;a href=&#8217;https://pubmed.ncbi.nlm.nih.gov/40886161&#8242;&gt;Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.&lt;/a&gt; (European heart journal)&lt;/p&gt;&lt;p&gt;Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/magnesium-levels-impact-hfref-outcomes-09-01-25/&lt;/p&gt;
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;
        &lt;h3&gt; Featured Articles&lt;/h3&gt;
                &lt;h4&gt;Article 1: Serum magnesium a]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Tailored Antiplatelet Rx in Complex PCI: TAILORED-CHIP 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 15:54:07 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40886179'>Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/">https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study&#8217;s findings will likely influence future antiplatelet guidelines for this specific patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study&#8217;s findings will likely influence future antiplatelet guidelines for this specific patient population.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/">Tailored Antiplatelet Rx in Complex PCI: TAILORED-CHIP 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Art]]></itunes:subtitle>
	<itunes:episode>27</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40886179'>Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</a> (European heart journal)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/">https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study&#8217;s findings will likely influence future antiplatelet guidelines for this specific patient population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study&#8217;s findings will likely influence future antiplatelet guidelines for this specific patient population.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/">Tailored Antiplatelet Rx in Complex PCI: TAILORED-CHIP 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_115355.mp3" length="784343" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179
Summary: This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study&#8217;s findings will likely influence future antiplatelet guidelines for this specific patient population.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. This trial evaluated a tailored antiplatelet strategy, modulating platelet inhibition intensity, in high-risk patients undergoing complex PCI. The study&#8217;s findings will likely influence future antiplatelet guidelines for this specific patient population.
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiology, Heart Disease, Clinical Research, NEJM, JACC.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Tailored Antiplatelet Rx in Complex PCI: TAILORED-CHIP 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tailored-antiplatelet-rx-in-complex-pci-tailored-chip-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Journal: European heart journal
PubMed Link: ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ivabradine Fails to Prevent MINS After Surgery 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-mins-after-surgery-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 15:53:06 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-mins-after-surgery-09-01-25/</guid>
	<description><![CDATA[<p>&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Featured Articles&lt;/h3&gt;</p>
<p>                &lt;h4&gt;Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;</p>
<p>        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;Cardiology, Heart Disease, Clinical Research, NEJM, JACC.&lt;/p&gt;</p>
<p>        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;</p><p>The post <a href="https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-mins-after-surgery-09-01-25/">Ivabradine Fails to Prevent MINS After Surgery 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent re]]></itunes:subtitle>
	<itunes:episode>26</itunes:episode>
	<content:encoded><![CDATA[<p>&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Featured Articles&lt;/h3&gt;</p>
<p>                &lt;h4&gt;Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;</p>
<p>        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;Cardiology, Heart Disease, Clinical Research, NEJM, JACC.&lt;/p&gt;</p>
<p>        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;</p><p>The post <a href="https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-mins-after-surgery-09-01-25/">Ivabradine Fails to Prevent MINS After Surgery 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_115257.mp3" length="643909" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;
        &lt;h3&gt; Featured Articles&lt;/h3&gt;
                &lt;h4&gt;Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.&lt;/p&gt;
        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial found no significant reduction in MINS with ivabradine compared to placebo, suggesting ivabradine is not effective for this purpose.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;Cardiology, Heart Disease, Clinical Research, NEJM, JACC.&lt;/p&gt;
        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;The post Ivabradine Fails to Prevent MINS After Surgery 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;
        &lt;h3&gt; Featured Articles&lt;/h3&gt;
                &lt;h4&gt;Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40884771&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40884771&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This study investigated ivabradine to prevent myocardial injury after noncardiac surgery. The trial ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mitral Regurgitation Surgery: Optimizing Outcomes 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-optimizing-outcomes-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 15:44:20 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-optimizing-outcomes-09-01-25/</guid>
	<description><![CDATA[<p>&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Featured Articles&lt;/h3&gt;</p>
<p>                &lt;h4&gt;Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886109&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886109&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;</p>
<p>        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;Cardiology, Heart Disease, Clinical Research, NEJM, JACC&lt;/p&gt;</p>
<p>        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;</p><p>The post <a href="https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-optimizing-outcomes-09-01-25/">Mitral Regurgitation Surgery: Optimizing Outcomes 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent re]]></itunes:subtitle>
	<itunes:episode>23</itunes:episode>
	<content:encoded><![CDATA[<p>&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Featured Articles&lt;/h3&gt;</p>
<p>                &lt;h4&gt;Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886109&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886109&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.&lt;/p&gt;</p>
<p>        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;</p>
<p>        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;Cardiology, Heart Disease, Clinical Research, NEJM, JACC&lt;/p&gt;</p>
<p>        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;</p><p>The post <a href="https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-optimizing-outcomes-09-01-25/">Mitral Regurgitation Surgery: Optimizing Outcomes 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_114406.mp3" length="1056852" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;
        &lt;h3&gt; Featured Articles&lt;/h3&gt;
                &lt;h4&gt;Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886109&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886109&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.&lt;/p&gt;
        &lt;h3&gt; Transcript&lt;/h3&gt;
        &lt;div style=&#8221;background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;&#8221;&gt;
            &lt;p&gt;&lt;em&gt;Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.&lt;/em&gt;&lt;/p&gt;
            Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry study evaluated outcomes of mitral valve surgery for mitral regurgitation in a real-world setting. The study found significant variations in surgical approaches and patient selection, with in-hospital mortality rates influenced by preoperative risk factors and the type of surgery performed. These findings highlight the need for standardized guidelines and improved risk stratification to optimize outcomes in patients undergoing mitral valve surgery.
            &lt;p&gt;&lt;em&gt;Thank you for listening. Tap &#8216;more&#8217; for full notes and links.&lt;/em&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;h3&gt; Keywords&lt;/h3&gt;
        &lt;p&gt;Cardiology, Heart Disease, Clinical Research, NEJM, JACC&lt;/p&gt;
        &lt;h3&gt; About&lt;/h3&gt;
        &lt;p&gt;Concise summaries of cardiovascular research for professionals.&lt;/p&gt;
        &lt;p&gt;&lt;strong&gt;Subscribe&lt;/strong&gt; • &lt;strong&gt;Share&lt;/strong&gt; • &lt;strong&gt;Follow&lt;/strong&gt;&lt;/p&gt;The post Mitral Regurgitation Surgery: Optimizing Outcomes 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[&lt;p&gt;Welcome to &lt;strong&gt;Cardiology Today&lt;/strong&gt; &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on t
        &lt;h3&gt; Full Episode Summary&lt;/h3&gt;
        &lt;p&gt;This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.&lt;/p&gt;
        &lt;h3&gt; Featured Articles&lt;/h3&gt;
                &lt;h4&gt;Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.&lt;/h4&gt;
                &lt;p&gt;&lt;strong&gt;Journal:&lt;/strong&gt; Circulation&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;PubMed Link:&lt;/strong&gt; &lt;a href=&#8221;https://pubmed.ncbi.nlm.nih.gov/40886109&#8243; target=&#8221;_blank&#8221;&gt;https://pubmed.ncbi.nlm.nih.gov/40886109&lt;/a&gt;&lt;/p&gt;
                &lt;p&gt;&lt;strong&gt;Summary:&lt;/strong&gt; This international registry study evaluated out]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI-ECG: Broad CVD Risk Marker, Not Specific Classifier 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 15:35:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40888124'>Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/">https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/">AI-ECG: Broad CVD Risk Marker, Not Specific Classifier 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Art]]></itunes:subtitle>
	<itunes:episode>22</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40888124'>Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</a> (Circulation)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/">https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/">AI-ECG: Broad CVD Risk Marker, Not Specific Classifier 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_113500.mp3" length="849963" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124
Summary: This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study found that AI-ECG models, while designed for specific cardiac abnormalities, often function as broader cardiovascular risk markers rather than condition-specific classifiers. This finding suggests caution is needed when interpreting AI-ECG results, as a positive result may indicate general cardiovascular risk rather than a specific condition.
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiology, Heart Disease, Clinical Research, NEJM, JACC.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post AI-ECG: Broad CVD Risk Marker, Not Specific Classifier 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ai-ecg-broad-cvd-risk-marker-not-specific-classifier-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124
Summary: This study found that AI-ECG models, while design]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>De-escalate BP Meds in Frail Elderly? NEJM Trial 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 15:32:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40879421'>Reduction of Antihypertensive Treatment in Nursing Home Residents.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/">https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/">De-escalate BP Meds in Frail Elderly? NEJM Trial 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Art]]></itunes:subtitle>
	<itunes:episode>21</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40879421'>Reduction of Antihypertensive Treatment in Nursing Home Residents.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/">https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/">De-escalate BP Meds in Frail Elderly? NEJM Trial 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_113159.mp3" length="913492" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421
Summary: This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure below 130, a protocol driven reduction in medication did not significantly increase the risk of falls, serious adverse events, or mortality compared to usual care. These findings suggest that de-escalation of antihypertensive therapy may be safe in this vulnerable population, potentially reducing polypharmacy and improving quality of life.
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiology, Heart Disease, Clinical Research, NEJM, JACC.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post De-escalate BP Meds in Frail Elderly? NEJM Trial 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/de-escalate-bp-meds-in-frail-elderly-nejm-trial-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421
Summary: This study found that in frail, elderly nursing home residents taking multiple antihypertensives with systolic blood pressure be]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>High Potassium Reduces ICD Shocks in Arrhythmia 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 15:17:55 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40879429'>Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/">https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/">High Potassium Reduces ICD Shocks in Arrhythmia 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Art]]></itunes:subtitle>
	<itunes:episode>20</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40879429'>Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/">https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/">High Potassium Reduces ICD Shocks in Arrhythmia 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_111743.mp3" length="736278" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429
Summary: This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This study investigates actively increasing plasma potassium levels to the high-normal range in high-risk ICD patients to reduce ventricular arrhythmias. The multicenter trial in Denmark aims to determine if maintaining high-normal potassium levels reduces arrhythmia risk in this vulnerable population.
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiology, Heart Disease, Clinical Research, NEJM, JACC.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post High Potassium Reduces ICD Shocks in Arrhythmia 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-shocks-in-arrhythmia-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429
Summary: This study investigates actively increasing plasma potassium levels to the high-normal range]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rehab Boosts Outcomes Post-MI in Elderly Patients 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 14:49:56 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40879431'>Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/">https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/">Rehab Boosts Outcomes Post-MI in Elderly Patients 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Art]]></itunes:subtitle>
	<itunes:episode>19</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.</p>
<p>Article Links: Article 1: <a href='https://pubmed.ncbi.nlm.nih.gov/40879431'>Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</a> (The New England journal of medicine)</p>
<p>Tap &#8216;more&#8217; for full notes and links. Full episode page: <a href="https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/">https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/</a></p>
<h3> Full Episode Summary</h3>
<p>This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.</p>
<h3> Featured Articles</h3>
<h4>Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes.</p>
<h3> Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes.</p>
<p><em>Thank you for listening. Tap &#8216;more&#8217; for full notes and links.</em></p>
</p>

<h3> Keywords</h3>
<p>Cardiology, Heart Disease, Clinical Research, NEJM, JACC.</p>
<h3> About</h3>
<p>Concise summaries of cardiovascular research for professionals.</p>
<p><strong>Subscribe</strong> • <strong>Share</strong> • <strong>Follow</strong></p><p>The post <a href="https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/">Rehab Boosts Outcomes Post-MI in Elderly Patients 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_104944.mp3" length="219456" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes.
 Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor control, dietary counseling, and exercise training significantly improved physical performance and reduced major adverse cardiovascular events in older patients with impaired physical performance one month post myocardial infarction. The findings suggest that comprehensive rehabilitation should be considered for older myocardial infarction patients to improve outcomes.
Thank you for listening. Tap &#8216;more&#8217; for full notes and links.


 Keywords
Cardiology, Heart Disease, Clinical Research, NEJM, JACC.
 About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Rehab Boosts Outcomes Post-MI in Elderly Patients 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like atrial fibrillation and heart failure. Key takeaway: Biomarker-guided treatments show no outcome benefits.
Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine)
Tap &#8216;more&#8217; for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-boosts-outcomes-post-mi-in-elderly-patients-09-01-25/
 Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap &#8216;more&#8217; for details.
 Featured Articles
Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This randomized trial found that a multidomain rehabilitation program including cardiovascular risk factor contr]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Familial Lp(a) Raises Cardiac Event Risk 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/familial-lpa-raises-cardiac-event-risk-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 14:08:18 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/familial-lpa-raises-cardiac-event-risk-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/familial-lpa-raises-cardiac-event-risk-09-01-25/">Familial Lp(a) Raises Cardiac Event Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>17</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/familial-lpa-raises-cardiac-event-risk-09-01-25/">Familial Lp(a) Raises Cardiac Event Risk 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_100808.mp3" length="197856" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132
Summary: This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potential familial risk associated with elevated lipoprotein(a) requiring further investigation and possibly screening strategies.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Familial Lp(a) Raises Cardiac Event Risk 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132
Summary: This study found that first-degree relatives of individuals with elevated lipoprotein(a) levels had a modestly increased risk of major adverse cardiovascular events compared to the general population, even without directly measured lipoprotein(a) levels. This suggests a potentia]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Magnesium Levels Impact Heart Failure Outcomes 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/magnesium-levels-impact-heart-failure-outcomes-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 14:00:17 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/magnesium-levels-impact-heart-failure-outcomes-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886161</a></p>
<p><strong>Summary:</strong> The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/magnesium-levels-impact-heart-failure-outcomes-09-01-25/">Magnesium Levels Impact Heart Failure Outcomes 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>16</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886161</a></p>
<p><strong>Summary:</strong> The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/magnesium-levels-impact-heart-failure-outcomes-09-01-25/">Magnesium Levels Impact Heart Failure Outcomes 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_100005.mp3" length="257376" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161
Summary: The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that both low and high magnesium levels were associated with an increased risk of the primary outcome, a composite of cardiovascular death or heart failure events. These findings suggest that maintaining optimal serum magnesium concentrations may be important for improving outcomes in patients with heart failure with reduced ejection fraction.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Magnesium Levels Impact Heart Failure Outcomes 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161
Summary: The GALACTIC-Heart Failure trial, a randomized controlled trial investigating omecamtiv mecarbil versus placebo in heart failure patients with left ventricular ejection fraction of thirty-five percent or less, was used to assess the prognostic significance of serum magnesium concentrations. The study found that bo]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Tailored Antiplatelet Therapy Fails in CHIP PCI 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/tailored-antiplatelet-therapy-fails-in-chip-pci-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 13:49:59 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tailored-antiplatelet-therapy-fails-in-chip-pci-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/tailored-antiplatelet-therapy-fails-in-chip-pci-09-01-25/">Tailored Antiplatelet Therapy Fails in CHIP PCI 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>15</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/tailored-antiplatelet-therapy-fails-in-chip-pci-09-01-25/">Tailored Antiplatelet Therapy Fails in CHIP PCI 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_094945.mp3" length="292416" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179
Summary: The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based on platelet function testing, or a standard antiplatelet regimen. The study found that the tailored approach did not significantly reduce the composite endpoint of death, myocardial infarction, stroke, or major bleeding at one year compared to the standard strategy. These results suggest that routine platelet function testing to guide antiplatelet therapy after complex percutaneous coronary intervention may not offer superior outcomes in high-risk patients.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Tailored Antiplatelet Therapy Fails in CHIP PCI 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179
Summary: The TAILORED-CHIP trial randomized over two thousand high-risk patients undergoing complex percutaneous coronary intervention to either a tailored antiplatelet strategy involving early escalation and later de-escalation of platelet inhibition based o]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Ivabradine Fails to Prevent Post-Surgery MINS 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-post-surgery-mins-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 13:48:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-post-surgery-mins-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884771" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884771</a></p>
<p><strong>Summary:</strong> This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-post-surgery-mins-09-01-25/">Ivabradine Fails to Prevent Post-Surgery MINS 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>14</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884771" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884771</a></p>
<p><strong>Summary:</strong> This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/ivabradine-fails-to-prevent-post-surgery-mins-09-01-25/">Ivabradine Fails to Prevent Post-Surgery MINS 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_094829.mp3" length="223392" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771
Summary: This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years or older with or at risk of atherosclerotic disease. These findings do not support routine use of ivabradine for prevention of myocardial injury after noncardiac surgery.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Ivabradine Fails to Prevent Post-Surgery MINS 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771
Summary: This randomized controlled trial investigated ivabradine, a selective heart rate lowering agent, in patients undergoing noncardiac surgery to prevent myocardial injury after noncardiac surgery. The study found no significant reduction in myocardial injury after noncardiac surgery with ivabradine compared to placebo in patients aged 45 years]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>AI-ECG Selectivity Impacts Diagnostic Accuracy 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/ai-ecg-selectivity-impacts-diagnostic-accuracy-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 13:37:39 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/ai-ecg-selectivity-impacts-diagnostic-accuracy-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-selectivity-impacts-diagnostic-accuracy-09-01-25/">AI-ECG Selectivity Impacts Diagnostic Accuracy 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>13</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40888124" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40888124</a></p>
<p><strong>Summary:</strong> This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/ai-ecg-selectivity-impacts-diagnostic-accuracy-09-01-25/">AI-ECG Selectivity Impacts Diagnostic Accuracy 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_093729.mp3" length="226176" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124
Summary: This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac conditions versus predicting overall cardiovascular risk. This suggests the need for careful consideration of the intended clinical application when developing and deploying AI-ECG tools to avoid overgeneralization of results.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post AI-ECG Selectivity Impacts Diagnostic Accuracy 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124
Summary: This study investigated whether AI-ECG models serve as condition-specific classifiers or broader cardiovascular risk markers across four distinct populations. The findings reveal that AI-ECG models demonstrate phenotypic selectivity, exhibiting varying performance in detecting specific cardiac cond]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>ABC-AF Score Guides AFib Therapy, Reduces Stroke 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/abc-af-score-guides-afib-therapy-reduces-stroke-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 10:00:12 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/abc-af-score-guides-afib-therapy-reduces-stroke-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884774" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884774</a></p>
<p><strong>Summary:</strong> This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/abc-af-score-guides-afib-therapy-reduces-stroke-09-01-25/">ABC-AF Score Guides AFib Therapy, Reduces Stroke 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>12</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884774" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884774</a></p>
<p><strong>Summary:</strong> This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/abc-af-score-guides-afib-therapy-reduces-stroke-09-01-25/">ABC-AF Score Guides AFib Therapy, Reduces Stroke 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_060002.mp3" length="190464" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774
Summary: This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study. This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the risk of stroke or death compared to standard care.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post ABC-AF Score Guides AFib Therapy, Reduces Stroke 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation &#8211; a Registry-based Multicenter Randomized Controlled Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774
Summary: This multicenter trial investigates whether using a biomarker-based ABC-AF risk score to guide individualized treatment plans can improve outcomes in atrial fibrillation patients. The study aims to determine if this personalized approach reduces the ]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>TAVI: No Cognitive Benefit From Embolic Protection 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/tavi-no-cognitive-benefit-from-embolic-protection-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 06:56:24 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/tavi-no-cognitive-benefit-from-embolic-protection-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884786" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884786</a></p>
<p><strong>Summary:</strong> The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/tavi-no-cognitive-benefit-from-embolic-protection-09-01-25/">TAVI: No Cognitive Benefit From Embolic Protection 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>11</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884786" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884786</a></p>
<p><strong>Summary:</strong> The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/tavi-no-cognitive-benefit-from-embolic-protection-09-01-25/">TAVI: No Cognitive Benefit From Embolic Protection 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_025612.mp3" length="194592" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786
Summary: The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing need to refine embolic protection strategies for vulnerable TAVI patients.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post TAVI: No Cognitive Benefit From Embolic Protection 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786
Summary: The PROTECT-TAVI trial found that cerebral embolic protection during TAVI did not significantly improve overall cognitive function at one year compared to TAVI alone. Although the study didn&#8217;t show a significant cognitive benefit, it underscores the ongoing nee]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Mitral Regurgitation Surgery Outcomes Registry Data 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-outcomes-registry-data-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 06:10:11 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-outcomes-registry-data-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886109" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886109</a></p>
<p><strong>Summary:</strong> This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-outcomes-registry-data-09-01-25/">Mitral Regurgitation Surgery Outcomes Registry Data 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>10</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886109" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886109</a></p>
<p><strong>Summary:</strong> This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/mitral-regurgitation-surgery-outcomes-registry-data-09-01-25/">Mitral Regurgitation Surgery Outcomes Registry Data 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_021002.mp3" length="188832" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109
Summary: This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Mitral Regurgitation Surgery Outcomes Registry Data 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109
Summary: This international registry of mitral valve surgery patients provides real-world data on clinical presentation and outcomes. The MITRACURE registry aims to assess current practice, guideline adherence, and selection biases to improve the quality of mitral valve surgery.
 Full Episode Tran]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Antihypertensive Reduction Safe in Frail Elderly 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/antihypertensive-reduction-safe-in-frail-elderly-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 06:08:19 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/antihypertensive-reduction-safe-in-frail-elderly-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/antihypertensive-reduction-safe-in-frail-elderly-09-01-25/">Antihypertensive Reduction Safe in Frail Elderly 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>9</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879421" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879421</a></p>
<p><strong>Summary:</strong> This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/antihypertensive-reduction-safe-in-frail-elderly-09-01-25/">Antihypertensive Reduction Safe in Frail Elderly 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_020810.mp3" length="193632" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421
Summary: This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Reduction of Antihypertensive Treatment in Nursing Home Residents. This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in this vulnerable population, potentially reducing medication burden without compromising safety.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Antihypertensive Reduction Safe in Frail Elderly 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Reduction of Antihypertensive Treatment in Nursing Home Residents.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421
Summary: This study found that in frail, older nursing home residents taking multiple antihypertensives with blood pressure under 130, a protocol-driven reduction in medication did not increase the risk of serious adverse events within six months. The findings suggest that de-escalation of antihypertensive therapy may be a safe approach in thi]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>High Potassium Reduces ICD Events? Trial Results 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-events-trial-results-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 06:08:05 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-events-trial-results-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-events-trial-results-09-01-25/">High Potassium Reduces ICD Events? Trial Results 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>8</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879429" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879429</a></p>
<p><strong>Summary:</strong> This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/high-potassium-reduces-icd-events-trial-results-09-01-25/">High Potassium Reduces ICD Events? Trial Results 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_020757.mp3" length="148224" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429
Summary: This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post High Potassium Reduces ICD Events? Trial Results 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429
Summary: This randomized trial in Denmark investigated actively increasing potassium levels in high-risk ICD patients. The study will determine if maintaining high-normal potassium reduces ventricular arrhythmias in this vulnerable population.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Card]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cardiac Rehab Boosts Function Post-MI in Elderly 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/cardiac-rehab-boosts-function-post-mi-in-elderly-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 06:07:53 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cardiac-rehab-boosts-function-post-mi-in-elderly-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiac-rehab-boosts-function-post-mi-in-elderly-09-01-25/">Cardiac Rehab Boosts Function Post-MI in Elderly 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>7</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879431" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879431</a></p>
<p><strong>Summary:</strong> This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiac-rehab-boosts-function-post-mi-in-elderly-09-01-25/">Cardiac Rehab Boosts Function Post-MI in Elderly 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_020743.mp3" length="202176" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual care. This highlights the importance of comprehensive rehabilitation programs for improving outcomes in this vulnerable population.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Cardiac Rehab Boosts Function Post-MI in Elderly 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431
Summary: This randomized trial in Italy showed that a multidomain intervention including cardiovascular risk factor control, dietary counseling, and exercise training improved physical performance and reduced major adverse cardiovascular events in older myocardial infarction patients with impaired physical performance, compared to usual]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Digitoxin Fails to Improve Outcomes in HFrEF 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/digitoxin-fails-to-improve-outcomes-in-hfref-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 06:07:38 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/digitoxin-fails-to-improve-outcomes-in-hfref-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879434</a></p>
<p><strong>Summary:</strong> This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/digitoxin-fails-to-improve-outcomes-in-hfref-09-01-25/">Digitoxin Fails to Improve Outcomes in HFrEF 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>6</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.</h4>
<p><strong>Journal:</strong> The New England journal of medicine</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879434" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879434</a></p>
<p><strong>Summary:</strong> This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/digitoxin-fails-to-improve-outcomes-in-hfref-09-01-25/">Digitoxin Fails to Improve Outcomes in HFrEF 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_020730.mp3" length="170784" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434
Summary: This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population.
 Full Episode Transcript

Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
            Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population.
Thank you for listening to Cardiology Today.

 Keywords
Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine
Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology
 About Cardiology Today
Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.
Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Digitoxin Fails to Improve Outcomes in HFrEF 09/01/25 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434
Summary: This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Hypokalemia Worsens A Fib Burden: LOOP Analysis 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/hypokalemia-worsens-a-fib-burden-loop-analysis-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 05:58:40 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/hypokalemia-worsens-a-fib-burden-loop-analysis-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884219</a></p>
<p><strong>Summary:</strong> This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition.</p>
<h4>Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884211</a></p>
<p><strong>Summary:</strong> This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction.</p>
<h4>Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884202" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884202</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations.</p>
<h4>Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884168</a></p>
<p><strong>Summary:</strong> This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients.</p>
<h4>Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884070</a></p>
<p><strong>Summary:</strong> The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion.</p>
<h4>Article 6: Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884040</a></p>
<p><strong>Summary:</strong> The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling.</p>
<h4>Article 7: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884033" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884033</a></p>
<p><strong>Summary:</strong> This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to better define risk factors and prognostic indicators to improve management of these severe adverse drug reactions.</p>
<h4>Article 8: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884032" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884032</a></p>
<p><strong>Summary:</strong> This detailed analysis of the VICTOR trial found that vericiguat did not significantly reduce cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF) without recent worsening. These findings suggest that vericiguat may not provide a mortality benefit in this specific patient population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition.</p>
<p>Article number two. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction.</p>
<p>Article number three. Hypokalaemia and atrial fibrillation detected by implanted loop recorders. This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations.</p>
<p>Article number four. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients.</p>
<p>Article number five. Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion.</p>
<p>Article number six. Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial. The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling.</p>
<p>Article number seven. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to better define risk factors and prognostic indicators to improve management of these severe adverse drug reactions.</p>
<p>Article number eight. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. This detailed analysis of the VICTOR trial found that vericiguat did not significantly reduce cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF) without recent worsening. These findings suggest that vericiguat may not provide a mortality benefit in this specific patient population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/hypokalemia-worsens-a-fib-burden-loop-analysis-09-01-25/">Hypokalemia Worsens A Fib Burden: LOOP Analysis 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>5</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884219" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884219</a></p>
<p><strong>Summary:</strong> This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition.</p>
<h4>Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884211" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884211</a></p>
<p><strong>Summary:</strong> This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction.</p>
<h4>Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884202" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884202</a></p>
<p><strong>Summary:</strong> This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations.</p>
<h4>Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884168" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884168</a></p>
<p><strong>Summary:</strong> This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients.</p>
<h4>Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884070" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884070</a></p>
<p><strong>Summary:</strong> The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion.</p>
<h4>Article 6: Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884040" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884040</a></p>
<p><strong>Summary:</strong> The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling.</p>
<h4>Article 7: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884033" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884033</a></p>
<p><strong>Summary:</strong> This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to better define risk factors and prognostic indicators to improve management of these severe adverse drug reactions.</p>
<h4>Article 8: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884032" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884032</a></p>
<p><strong>Summary:</strong> This detailed analysis of the VICTOR trial found that vericiguat did not significantly reduce cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF) without recent worsening. These findings suggest that vericiguat may not provide a mortality benefit in this specific patient population.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition.</p>
<p>Article number two. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction.</p>
<p>Article number three. Hypokalaemia and atrial fibrillation detected by implanted loop recorders. This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations.</p>
<p>Article number four. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients.</p>
<p>Article number five. Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion.</p>
<p>Article number six. Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial. The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling.</p>
<p>Article number seven. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to better define risk factors and prognostic indicators to improve management of these severe adverse drug reactions.</p>
<p>Article number eight. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. This detailed analysis of the VICTOR trial found that vericiguat did not significantly reduce cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF) without recent worsening. These findings suggest that vericiguat may not provide a mortality benefit in this specific patient population.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/hypokalemia-worsens-a-fib-burden-loop-analysis-09-01-25/">Hypokalemia Worsens A Fib Burden: LOOP Analysis 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_015739.mp3" length="1023456" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219
Summary: This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition.
Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884211
Summary: This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction.
Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884202
Summary: This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations.
Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884168
Summary: This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients.
Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884070
Summary: The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion.
Article 6: Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884040
Summary: The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling.
Article 7: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884033
Summary: This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to be]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219
Summary: This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-thre]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>CRISPR Repairs Cardiomyopathy ECGs in Mice 09/01/25</title>
	<link>https://podcast.explainheart.com/podcast/crispr-repairs-cardiomyopathy-ecgs-in-mice-09-01-25/</link>
	<pubDate>Mon, 01 Sep 2025 05:17:57 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/crispr-repairs-cardiomyopathy-ecgs-in-mice-09-01-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886063" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886063</a></p>
<p><strong>Summary:</strong> This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients.</p>
<h4>Article 2: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886061" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886061</a></p>
<p><strong>Summary:</strong> The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk.</p>
<h4>Article 3: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886060" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886060</a></p>
<p><strong>Summary:</strong> This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist.</p>
<h4>Article 4: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884758</a></p>
<p><strong>Summary:</strong> The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial&#8217;s timeframe.</p>
<h4>Article 5: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884757" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884757</a></p>
<p><strong>Summary:</strong> The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population.</p>
<h4>Article 6: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884558</a></p>
<p><strong>Summary:</strong> The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk.</p>
<h4>Article 7: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884439" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884439</a></p>
<p><strong>Summary:</strong> This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness.</p>
<h4>Article 8: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884413</a></p>
<p><strong>Summary:</strong> standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients.</p>
<p>Article number two. Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk.</p>
<p>Article number three. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist.</p>
<p>Article number four. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial&#8217;s timeframe.</p>
<p>Article number five. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population.</p>
<p>Article number six. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk.</p>
<p>Article number seven. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness.</p>
<p>Article number eight. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/crispr-repairs-cardiomyopathy-ecgs-in-mice-09-01-25/">CRISPR Repairs Cardiomyopathy ECGs in Mice 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
]]></itunes:subtitle>
	<itunes:episode>4</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886063" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886063</a></p>
<p><strong>Summary:</strong> This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients.</p>
<h4>Article 2: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886061" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886061</a></p>
<p><strong>Summary:</strong> The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk.</p>
<h4>Article 3: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886060" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886060</a></p>
<p><strong>Summary:</strong> This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist.</p>
<h4>Article 4: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884758" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884758</a></p>
<p><strong>Summary:</strong> The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial&#8217;s timeframe.</p>
<h4>Article 5: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884757" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884757</a></p>
<p><strong>Summary:</strong> The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population.</p>
<h4>Article 6: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884558" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884558</a></p>
<p><strong>Summary:</strong> The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk.</p>
<h4>Article 7: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884439" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884439</a></p>
<p><strong>Summary:</strong> This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness.</p>
<h4>Article 8: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884413" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884413</a></p>
<p><strong>Summary:</strong> standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients.</p>
<p>Article number two. Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk.</p>
<p>Article number three. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist.</p>
<p>Article number four. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial&#8217;s timeframe.</p>
<p>Article number five. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population.</p>
<p>Article number six. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk.</p>
<p>Article number seven. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness.</p>
<p>Article number eight. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/crispr-repairs-cardiomyopathy-ecgs-in-mice-09-01-25/">CRISPR Repairs Cardiomyopathy ECGs in Mice 09/01/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250901_011700.mp3" length="1122624" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063
Summary: This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients.
Article 2: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886061
Summary: The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk.
Article 3: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886060
Summary: This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist.
Article 4: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758
Summary: The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial&#8217;s timeframe.
Article 5: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757
Summary: The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population.
Article 6: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558
Summary: The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk.
Article 7: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439
Summary: This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063
Summary: This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients.
Article 2: Se]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Lp(a) Screening: Higher CVD Risk in First-Degree Relatives 08/31/25</title>
	<link>https://podcast.explainheart.com/podcast/lpa-screening-higher-cvd-risk-in-first-degree-relatives-08-31-25/</link>
	<pubDate>Mon, 01 Sep 2025 03:46:21 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/lpa-screening-higher-cvd-risk-in-first-degree-relatives-08-31-25/</guid>
	<description><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884768</a></p>
<p><strong>Summary:</strong> This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.</p>
<h4>Article 2: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884047" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884047</a></p>
<p><strong>Summary:</strong> The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.</p>
<h4>Article 3: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879562</a></p>
<p><strong>Summary:</strong> This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.</p>
<h4>Article 4: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878766" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878766</a></p>
<p><strong>Summary:</strong> The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.</p>
<h4>Article 5: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878676" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878676</a></p>
<p><strong>Summary:</strong> This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.</p>
<h4>Article 6: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.</p>
<h4>Article 7: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886161</a></p>
<p><strong>Summary:</strong> This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF.</p>
<h4>Article 8: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is August 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.</p>
<p>Article number two. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.</p>
<p>Article number three. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.</p>
<p>Article number four. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.</p>
<p>Article number five. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.</p>
<p>Article number six. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.</p>
<p>Article number seven. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF.</p>
<p>Article number eight. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/lpa-screening-higher-cvd-risk-in-first-degree-relatives-08-31-25/">Lp(a) Screening: Higher CVD Risk in First-Degree Relatives 08/31/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Ep]]></itunes:subtitle>
	<itunes:episode>3</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to <strong>Cardiology Today</strong> &#8211; Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals.</p>

<h3> Listen to This Episode</h3>
<p>            Your browser does not support the audio element.
        
<h3> Episode Summary</h3>
<p>This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</p>
<h3> Featured Research Articles</h3>
<h4>Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884768" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884768</a></p>
<p><strong>Summary:</strong> This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.</p>
<h4>Article 2: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40884047" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40884047</a></p>
<p><strong>Summary:</strong> The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.</p>
<h4>Article 3: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40879562" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40879562</a></p>
<p><strong>Summary:</strong> This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.</p>
<h4>Article 4: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878766" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878766</a></p>
<p><strong>Summary:</strong> The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.</p>
<h4>Article 5: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.</h4>
<p><strong>Journal:</strong> Circulation</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40878676" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40878676</a></p>
<p><strong>Summary:</strong> This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.</p>
<h4>Article 6: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886179" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886179</a></p>
<p><strong>Summary:</strong> The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.</p>
<h4>Article 7: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886161" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886161</a></p>
<p><strong>Summary:</strong> This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF.</p>
<h4>Article 8: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study.</h4>
<p><strong>Journal:</strong> European heart journal</p>
<p><strong>PubMed Link:</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/40886132" target="_blank">https://pubmed.ncbi.nlm.nih.gov/40886132</a></p>
<p><strong>Summary:</strong> This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.</p>
<h3> Full Episode Transcript</h3>

<p><em>Today&#8217;s date is August 31, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p>
<p>            Article number one. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.</p>
<p>Article number two. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.</p>
<p>Article number three. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.</p>
<p>Article number four. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.</p>
<p>Article number five. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.</p>
<p>Article number six. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.</p>
<p>Article number seven. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF.</p>
<p>Article number eight. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.</p>
<p><em>Thank you for listening to Cardiology Today.</em></p>
</p>
<h3> Keywords</h3>
<p><strong>Medical Topics:</strong> Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine</p>
<p><strong>Journals:</strong> New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology</p>
<h3> About Cardiology Today</h3>
<p><em>Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care.</em></p>
<p><strong>Subscribe</strong> to stay updated with the latest cardiology research • <strong>Share</strong> with colleagues • <strong>Follow</strong> for more medical content</p><p>The post <a href="https://podcast.explainheart.com/podcast/lpa-screening-higher-cvd-risk-in-first-degree-relatives-08-31-25/">Lp(a) Screening: Higher CVD Risk in First-Degree Relatives 08/31/25</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250831_234527.mp3" length="1164192" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768
Summary: This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up.
Article 2: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047
Summary: The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting.
Article 3: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562
Summary: This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification.
Article 4: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766
Summary: The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes.
Article 5: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676
Summary: This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking.
Article 6: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179
Summary: The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit.
Article 7: Serum magnesi]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals.

 Listen to This Episode
            Your browser does not support the audio element.
        
 Episode Summary
This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.
 Featured Research Articles
Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768
Summary: This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidenc]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125</title>
	<link>https://podcast.explainheart.com/podcast/cardiology-updates-potassium-rehab-and-novel-therapies-083125/</link>
	<pubDate>Mon, 01 Sep 2025 01:27:01 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/cardiology-updates-potassium-rehab-and-novel-therapies-083125/</guid>
	<description><![CDATA[<p>Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.</p>
<h3>Articles Featured in This Episode:</h3>
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
<p>        Your browser does not support the audio element.</p>
<p><em>Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</em></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiology-updates-potassium-rehab-and-novel-therapies-083125/">Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.
Articles Featured in This Episode:
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
A]]></itunes:subtitle>
	<itunes:episode>2</itunes:episode>
	<content:encoded><![CDATA[<p>Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.</p>
<h3>Articles Featured in This Episode:</h3>
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
<p>        Your browser does not support the audio element.</p>
<p><em>Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</em></p><p>The post <a href="https://podcast.explainheart.com/podcast/cardiology-updates-potassium-rehab-and-novel-therapies-083125/">Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/cardiology_today_20250831_212627.mp3" length="760608" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.
Articles Featured in This Episode:
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
        Your browser does not support the audio element.
Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.The post Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.
Articles Featured in This Episode:
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
        Your browser does not support the audio element.
Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, J]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Heart Failure, Potassium, and Mitral Valve Insights 083125</title>
	<link>https://podcast.explainheart.com/podcast/heart-failure-potassium-and-mitral-valve-insights-083125/</link>
	<pubDate>Mon, 01 Sep 2025 01:20:33 +0000</pubDate>
	<dc:creator><![CDATA[Deconstructed Cardiology]]></dc:creator>
	<guid isPermaLink="false">https://podcast.explainheart.com/podcast/heart-failure-potassium-and-mitral-valve-insights-083125/</guid>
	<description><![CDATA[<p>Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.</p>
<h3>Articles Featured in This Episode:</h3>
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
<p>        Your browser does not support the audio element.</p>
<p><em>Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</em></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-failure-potassium-and-mitral-valve-insights-083125/">Heart Failure, Potassium, and Mitral Valve Insights 083125</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></description>
	<itunes:subtitle><![CDATA[Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.
Articles Featured in This Episode:
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
A]]></itunes:subtitle>
	<content:encoded><![CDATA[<p>Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.</p>
<h3>Articles Featured in This Episode:</h3>
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
<p>        Your browser does not support the audio element.</p>
<p><em>Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.</em></p><p>The post <a href="https://podcast.explainheart.com/podcast/heart-failure-potassium-and-mitral-valve-insights-083125/">Heart Failure, Potassium, and Mitral Valve Insights 083125</a> first appeared on <a href="https://podcast.explainheart.com">Cardiology Today</a>.</p>]]></content:encoded>
	<enclosure url="https://podcast.explainheart.com/wp-content/uploads/2025/09/in_cardiology_today_20250831_212003.mp3" length="645984" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.
Articles Featured in This Episode:
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
        Your browser does not support the audio element.
Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.The post Heart Failure, Potassium, and Mitral Valve Insights 083125 first appeared on Cardiology Today.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>0:00</itunes:duration>
	<itunes:author><![CDATA[Deconstructed Cardiology]]></itunes:author>	<googleplay:description><![CDATA[Welcome to Cardiology Today &#8211; your source for the latest cardiology research findings.
Articles Featured in This Episode:
Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434
Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431
Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429
Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421
Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109
        Your browser does not support the audio element.
Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, J]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>
	</channel>
</rss>
